PMID,NCTID,Trial_Type,protocol,population,Trial_Inclusion,Trial_Exclusion,DLT_EVA,comments
30278378,NCT02020577,Combination,No,"The trial is divided in two parts, Part A and Part B. Part A will involve dose-finding of dose-limiting toxicity (DLT) and MTD in patients with advanced solid tumours. Part B will involve expansion of the MTD to 3 cohorts including non-small cell lung cancer squamous histology, recurrent/ metastatic squamous cell carcinoma of head and neck and other advanced solid tumours (except sarcomas).","Inclusion criteria:Part A onlyPatients must have advanced malignant solid tumours that are metastatic or unresectableAt least one measurable or evaluable (non-measurable) lesion per RECIST 1.1 Part B onlyPatients must have:measurable disease per RECIST 1.1diagnosis of one of the followingAdvanced Non-Small Cell Lung Cancer -Squamous Histology (NSCLC-SQ) with no more than 2 lines of chemotherapy for advanced/metastatic disease ( prior EGFR directed treatment is permitted) orRecurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (R/M SCCHN) no more than 2 lines of chemotherapy for advanced disease and no more than 1 line of prior cetuximab permitted.orOther malignant solid tumours except sarcomas (for metastatic colorectal cancer, only wild type KRAS are permitted) Part A and BAge 18 years or olderWritten informed consent that is consistent with ICH-GCP guidelines and local law.Histological/Cytological confirmed diagnosis of malignant solid tumours (exclusion of sarcomas)Advanced disease for whom standard treatment is ineffective or no longer effectiveRecovered from previous therapy related AE to </= Grade 1 at the study entry (except, for stable sensory neuropathy </= Grade 2 and alopecia)Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.Adequate organ function as defined by the following criteria:LVEF >50% or within institutional valuesAbsolute neutrophil count (ANC) >1500/ mm3Platelet count >75.000/ mm3Estimated creatinine clearance > 45ml/ minTotal bilirubin<1.5 times upper limit of institutional normalAspartate amino transferase (AST) or alanine amino transferase (ALT) <3 x upper limit of institutional normal (ULN) (if related to liver metastases< 5xULN)Patients entering Part A were required to have 1measurable or evaluable (non-measurable) lesion according to Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1. Patients entering Part Bwere required to have measurable disease per RECIST,version 1.1, and diagnosis of advanced squamousNSCLC (2 lines of chemotherapy for advanced disease; prior EGFR-directed treatment permitted), R/MHNSCC (2 lines of chemotherapy for advanced disease; 1 line of cetuximab therapy) or other solid tumours, except sarcomas (for metastatic colorectalcancer, only wild-type KRAS tumours were permitted).","Chemotherapy, biological therapy or investigational agents within 4 weeks prior to the start of study treatment.Hormonal anti-cancer treatment within 2 weeks prior to the start of study treatment (continued use of anti-androgens and/or gonadorelin analogues [LHRH] is permitted)Radiotherapy within 4 weeks prior to the start of study treatment, except as follows:Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to study treatment, andSingle dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.Major surgery (as judged by the investigator) within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the studyKnown hypersensitivity to afatinib or the excipients of any of the trial drugsHistory or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior start treatment.Female patients of childbearing potential who:are nursing orare pregnant orare not using an acceptable method of birth control or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drugPrevious or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.Requiring treatment with any of the prohibited concomitant medications listed in the protocol that can not be stopped for the duration of trial participationKnown pre-existing interstitial lung diseaseAny history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption)Active hepatitis B infection (defined as presence of HepB sAg and/ or Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier.Prior participation in an afatinib clinical study, even if not assigned to afatinib treatment.Meningeal carcinomatosisPatients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids or have been on stable dose of corticosteroids for at least 4 weeks before starting study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment.Any SPC listed contra-indications for cetuximabUse of alcohol or drugs incompatible with patient participation in the study in the investigator's opinion.",DLTs were assessed over the first 21-day cycle todetermine the MTD and were also recorded across alltreatment cycles.,NA
28280091,NCT00501410,Combination,No,Patients with MetastaticColorectal Cancer,"Eligible patients were required to have histologically or cytologically confirmed colorectal adenocarcinoma with metastaticdisease documented on diagnostic imaging studies, mass spectroscopy genotyping confirmed KRAS mutation status (exon 1,codon 12, 13), evaluable or measurable disease by ResponseEvaluation Guide for Solid Tumors (RECIST) version 1.0 andEastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1. Patients also had to be 18 years of age withadequate hematopoietic, hepatic, and kidney function and a lifeexpectancy  3 months. Each patient must have had previouslyprogressed, either clinically or radiographically, on systemic therapy for mCRC, with no limit on the number of prior regimens.Patients in the phase II cohort must have progressed on fluorouracil (5-FU) or capecitabine and oxaliplatin if KRAS-mutant andeither cetuximab or panitumumab if KRAS wild-type. ","Key exclusion criteria included recent (within 4 weeks of the first infusion ofstudy drugs on this study) or planned participation in anotherexperimental therapeutic drug study; systemic chemotherapy,radiotherapy, or major surgery within 21 days prior to the firstinfusion of study drugs; radiographic evidence of pleural effusionsin the last 30 days prior to enrollment; known brain metastases;known dihydropyrimidine dehydrogenase deficiency; long QTsyndrome; history of clinically significant ventricular arrhythmias;concurrent severe and/or uncontrolledmedical conditions including uncontrolled high blood pressure (140/90), unstable anginaor stable angina markedly limiting ordinary physical activity, NewYork Heart Association (NYHA)  grade 2 congestive heart failure,myocardial infarction within 6 months of study enrollment,history of stroke within 6 months of study enrollment, unstablesymptomatic arrhythmia requiring medication, clinically significant peripheral vascular disease, uncontrolled diabetes, and serious active or uncontrolled infection.",NA,NA
32053229,NCT01962792,Combination,No,patients with RRMM whohad received at least two previous lines of therapy,"Key patient inclusion criteria were age ≥18 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2; measurable MM with at least two prior lines of therapy includingbortezomib and an IMID and no response or disease progression tothe most recent treatment regimen. Permitted laboratory parametersincluded adequate hematologic function without transfusion orgrowth factor support, including absolute neutrophil count ≥1000/mm3 and platelet counts ≥75 000/mm3, and adequate hepatic andrenal function (including estimated creatinine clearance ≥30 mL/min).","Key exclusion criteria included primary refractory disease defined asnonresponsive in patients who had never achieved a minimalresponse or better with any therapy, recent prior chemotherapy, priortreatment with ibrutinib or any other BTK inhibitor, prior carfilzomibtreatment if patients were refractory or nonresponsive, requirementof strong CYP3A inhibitors or vitamin K antagonists (other anticoagulant and antiplatelet agent use was allowed on study), left ventricularejection fraction <40%, and uncontrolled or symptomatic arrhythmias",not provided,NA
28422758,NCT02095054,Combination,No,advanced cancer patients,"Patients were eligible if they were aged 12 years or older, had evaluable or measurable advanced or metastatic cancer refractory to standard therapies, and had significant organ function reserve, defined as leukocyte count (WBC) greater than or equal to 3,000/ml, absolute neutrophil count (ANC) greater than or equal to 1,000/ml, platelets greater than or equal to 100,000/ml, creatinine less than or equal to 2 times the upper limit of normal (ULN), total bilirubin less than or equal to 2 times ULN, alanine aminotransferase (ALT, formerly serum glutamic pyruvic transaminase [SGPT]) less than or equal to 3 times ULN, and the ECOG performance status less than or equal to 2. For patients with liver metastases, total bilirubin less than or equal to 3 times the ULN, ALT or aspartate aminotransferase (AST, formerly serum glutamic oxaloacetic transaminase [SGOT]) less than or equal to 5 times the ULN were allowed. ","Patients with KRAS-mutated CRC, recent history of major surgery, hemoptysis or uncontrolled bleed, uncontrolled hypertension, clinically significant cardiovascular disease, or untreated or uncontrolled brain metastases were excluded.",during the first cycle of treatment ,NA
30327312,NCT02350712,Combination,No,Recurrent or MetastaticSquamous Cell Carcinoma of the Head and Neck,"Adults (age 18 years) with Eastern Cooperative OncologyGroup (ECOG) performance status of 0 or 1; histologically orcytologically confirmed recurrent disease or metastatic SCCHNoriginating from the oral cavity, oropharynx, hypopharynx, orlarynx; and with adequate hematologic, renal, and hepatic function were eligible for inclusion in this study.Adequate hematologic function was defined as having anabsolute neutrophil count 1.5  109/L, platelet count 100 109/L, and hemoglobin 10 g/dL. Adequate renal function wasdefined as having a calculated creatinine clearance 60 mL/minute. Adequate hepatic function was defined as having anaspartate aminotransferase and alanine aminotransferase2.5  upper limit of normal (ULN; <5  ULN if liver metastasesare present), alkaline phosphatase2.0 ULN (<5 ULN if boneor liver metastases are present), and bilirubin 1.5  ULN.Patients also had prothrombin time or partial thromboplastintime 1.5  ULN. Patients were to comply with the contraceptionrequirements as specified in the study protocol or be of nonchildbearing potential.","Patients were excluded if they had prior anti-EGFR, anti-HER2,anti-HER3, or anti-HER4 targeted therapy, prior treatment forrecurrent and/or metastatic disease, history of other malignancies,except adequately treated nonmelanoma skin cancer, curativelytreated in situ disease, or other solid tumors curatively treated withno evidence of disease for 5 years, history of active brainmetastases, left ventricular ejection fraction <50%, or uncontrolled hypertension (systolic blood pressure >160 mm Hg ordiastolic blood pressure >100 mm Hg).",the DLT observation period (days 1–21),NA
30941307,NCT02429089,Combination,No,Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck,Eligible patients had to have R/M HPV-negative SCCHN not amenable to curative treatment with surgery and/or chemotherapy and/or radiation; progressive disease (PD) within 1 year of first-line platinum-based chemotherapy given either as part of multimodal curative treatment or in the palliative setting; Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1; at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST); and the ability to swallow ribociclib tablets. Previous treatment with cetuximab was allowed either in the metastatic or curative setting (with radiation). ,"Patients needed to have adequate organ function, absolute neutrophil count (ANC) >1,500/mm3, hemoglobin ≥9 g/dl, platelet count >100,000/mm3, serum creatinine ≤1.5 the upper limit of normal (ULN), total bilirubin ≤1 ULN, and alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) <1.5 ULN. HPV-negative tumor was defined by the absence of p16INK4A staining.",DLTs were evaluated during cycle 1 (4 weeks) ,NA
32545260,NCT02277197,Combination,No,"Cetuximab-Resistant, Recurrent/Metastatic Headand Neck Cancer","Primary inclusion criteria included recurrent/metastatic HNSCC from any primarysite (except for Epstein–Barr virus-positive nasopharynx); known HPV status in the case of anoropharynx primary site as determined by p16 immunohistochemistry; measurable disease inaccordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 ; age ≥ 18;Eastern Cooperative Oncology Group (ECOG) performance status 0–1; adequate end organ function andelectrolytes; albumin ≥ 3 mg/dL; willingness to undergo baseline research biopsy. Clinical cetuximabresistance was required during cohort expansion, and was defined as either disease recurrence within6 months of completing definitive cetuximab-radiation therapy or disease progression during or within6 months of cetuximab in the recurrent/metastatic setting . Cetuximab was not required to be themost recent systemic therapy received.",Primary exclusion criteria included prior treatment with anHGF/cMet inhibitor; peripheral edema ≥ Grade 2; interstitial lung disease; any medical comorbiditythat would interfere with the subject’s safety or compliance.,the first cycle (4 weeks),NA
27311401,NA,Combination,No,in patientswith recurrent/metastatic head and neck squamous cell carcinoma,"Eligibility required RM HNSCC, defined as distant metastases orunresectable, previously irradiated local/regional recurrence. Priorcetuximab or platin for RM disease was allowed. Prior cytotoxicchemotherapy for RM disease was not required because somepatients are poor candidates for or decline such therapy. Patientswere P18 years, had Eastern Cooperative Oncology Group performance status of 62, adequate marrow/organ function (absoluteneutrophil count P1500/mm3, platelet count P100,000/mm3, creatinine and bilirubin <1.5 upper limits of normal [ULN], andaspartate transaminase, alanine transaminase, and alkaline phosphatase <2.5 ULN), and QTc < 480 ms",Exclusion criteria included inability to swallowand concurrent use of CYP3A4 inhibitors/inducers,. DLT and MTD were assessed during cycle one,NA
27729313,NCT01787500,Combination,No,in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation,"including metastatic colorectal cancer, with BRAFV600E mutation and KRAS wild-type at codons 12 and 13 as confi rmed with tissue biopsy in a CLIA-certifi ed laboratory. For most patients, screening for BRAF and KRAS mutations was performed using NGS at a minimum of 250x, with additional profi ling for genes including NRAS, PIK3CA, AKT , and TP53 . Prior exposure to irinotecan and to anti-EGFR therapies was allowed, as was prior treatment with a BRAF inhibitor or MEK inhibitor. Additional eligibility criteria were Eastern Cooperative Oncology Group performance status of 0 to 2, normal organ and bone marrow function, and life expectancy greater than 3 months",NA,were used to assess for dose-limiting toxic effects during the fi rst 28 days and for new and ongoing adverse events until 30 days after the last dose of study treatment ,NA
34251048,NCT01755975,Combination,No,required to have histologically confirmedrelapsed/refractory non-Hodgkin lymphoma or Hodgkin lymphomaafter at least one prior systemic therapy,"For both studies, patientswere required to be at least 18 years old; have ECOG performancestatus ≤2 and those in the expansion cohort had measurable disease.Prior romidepsin, lenalidomide, or carfilzomib exposure was not exclusionary unless patients discontinued these agents due to toxicit absoluteneutrophil count of greater than 1000/μl, total bilirubin ≤1.5 timesupper institutional limit of normal (ULN), AST/ALT ≤3 times ULN(or five times ULN if liver involvement) and creatinine clearance of≥50 ml/min in the phase I portion. Entry criteria that differedbetween studies included: creatinine clearance in the cohort expansion portion (≥30 ml/min for regimen A, ≥40 ml/min for regimen B);platelet count (≥70 000/μl for regimen A, ≥80 000/μl for regimen B).In both studies, patients with platelet counts >50 000/μl were permitted if thrombocytopenia was due to bone marrow involvementby lymphoma.",NA,Dose limiting toxicities (DLT)were defined in cycle one,NA
32335709,NA,Combination,No,in Japanese patientswith relapsed or refractory multiple myeloma:,"The inclusion criteria were as follows: age ≥20 years; Eastern Cooperative Oncology Group Performance Status of 0‐2; symptomaticMM with measurable disease (serum M‐protein level ≥0.5 g/dL orurine M‐protein level ≥200 mg/24 hours); at least 2 previous treatments for MM, including bortezomib and immunomodulatory agents(both refractory and non‐refractory patients could be enrolled);response to at least 1 previous MM treatment (≥25% reduction inM‐protein); and adequate hematologic, hepatic and renal function atscreening, evidenced by absolute white blood cell count of ≥2000/mm3, neutrophil count of ≥1000/mm3, platelet count of ≥50 000/mm3, hemoglobin of ≥8.0 g/dL, aspartate aminotransferase andalanine aminotransferase of less than 3 times the upper limits of thenormal values, serum bilirubin of less than 2 times the upper limit ofthe normal value, estimated creatinine clearance value by the Cockcroft–Gault formula of ≥30 mL/min, and serum creatinine of≤2.0 mg/dL","The major exclusion criteria were as follows: patients previouslytreated with carfilzomib, those with grade 3‐4 neuropathy or grade≥2 neuropathy accompanied by neuropathic pain; a history of interstitial lung disease, New York Heart Association class III or IV congestive heart failure, symptomatic myocardial ischemia oruncontrolled conduction abnormalities; serious amyloidosis or suspicion of serious amyloidosis such as cardiac or intestinal amyloidosis;or poorly controlled hypertension or diabetes",cycle 1,NA
28054329,NA,Single Drug,No,in patients with advanced or recurrentsolid tumors,"The major inclusion criteria were: (i) histologically or cytologically confirmed advanced or recurrent malignant solid tumors refractory to standard therapy or with no viable treatmentoptions, (ii) age 20 to 75 years, (iii) life expectancy of 12 ormore weeks from the first administration of study medication,(iv) adequate organ function, and (v) Eastern CooperativeOncology Group (ECOG) performance status of 0 or 1 atbaseline.",Major exclusion criteria were: (i) past or currenthistory of anthracycline use and (ii) clinically significant echocardiogram abnormalities or clinically significant heartdisease,NA,NA
32122924,NCT02889523,Combination,No,Patients with Newly Diagnosed Diffuse LargeB-Cell Lymphoma (DLBCL) with Poor Prognosis Features,"Eligible patients were aged between 60 and 80 years and had beendiagnosed with an untreated high-risk DLBCL (aaIPI 2-3). Othereligible criteria wereas follows: ECOG performance status of 0–1,adequate renal function (creatinine clearance > 40 mL/min), bonemarrow function (ANC ≥ 1,500/mm3, platelets ≥ 75,000/mm3, hemoglobin ≥ 9 g/dL), liver function, left ventricular ejection fraction > 50%","Patients were excluded if they presented a central nervous system ormeningeal involvement, had received prior treatment with anyEZH2 inhibitor, any previous lymphoma treatment, or had anyconditions that might compromise their safety or the study accordingto the investigator. A full list of inclusion/exclusion criteria is providedin the Supplementary Appendix.",the first twocycles (DLT period).Toxicities assigned as DLT were assessed during C1 and C2 (42 days). ,NA
32381487, NCT03168061,Single Drug,No,"in Patients with AdvancedSolid Tumors or Advanced, Metastatic, orUnresectable Soft-tissue Sarcoma","Adult subjects (age ≥ 18 years) that met the following criteria wererecruited: a histologically or cytologically confirmed diagnosis ofadvanced solid tumor, including soft-tissue sarcoma, that had relapsedor was refractory to standard therapy; Eastern Cooperative OncologyGroup (ECOG) performance status, defined as 0 or 1; adequate bonemarrow reserve (absolute neutrophil count ≥1.5  109/L; plateletcount ≥100  109/L; and hemoglobin level ≥10 g/dL), cardiac function[left ventricular ejection fraction (LVEF) ≥50%; QTcF ≤470 ms; nohistory of uncontrolled cardiac dysrhythmia, hepatic dysfunction, orrenal dysfunction]","Subjects who had been treated previously with an anthracyclinewere eligible if cumulative exposure had not exceeded acceptablelimits, defined as ≤375 mg/m2 doxorubicin or liposomal doxorubicin,or ≤675 mg/m2 epirubicin. Subjects who had palliative surgery and/orradiation treatment within 30 days prior to screening, or had activecentral nervous system or brain metastasis at the time of screeningwere excluded.",during the first treatment cycle,NA
31675535,NCT00856037,Combination,No,patients withrelapsed or refractory small cell lung cancer (SCLC):,"Eligible patients were older than 19 years of age; had pathologicallyproven diagnosis of SCLC; at least one prior chemotherapy regimen forSCLC; primary refractory or relapsed disease; Eastern CooperativeOncology Group (ECOG) performance status ≤ 2; measurable or nonmeasurable disease by Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1; and adequate hematologic, hepatic, and renalfunction","Exclusion criteria included known hypersensitivity to any component of topotecan or doxorubicin; ejection fraction <50%; pregnant orbreast-feeding women; uncontrolled intercurrent illnesses including,but not limited to unstable angina or uncontrolled cardiac arrhythmia,chronic liver disease, complete left bundle branch block, obligate use ofa cardiac pacemaker, ST depression of >1 mm in two or more leadsand/or T wave inversions in two or more contiguous leads, congenitallong QT syndrome, history of or presence of significant ventricular oratrial tachyarrhythmias, clinically significant resting bradycardia (<50beats per minute), and QTc >480 milliseconds on a screening electrocardiogram",during the first 2 cycles,NA
26903311,NCT00878904,Combination,No,in solidtumors with a dose expansion in patients with sarcoma,"Eligible patients had metastatic solid tumor malignancies and any numberof prior therapies with adequate organ function and normal cardiac output[left ventricular ejection fraction (LVEF) >55%]. Prior anthracycline exposure was limited to 300 mg/m2 of doxorubicin and 480 mg/m2 of epirubicin(refer to supplementary Data, available at Annals of Oncology online forfurther criteria)",NA,Toxicities were assessed by CTCAE 4.0 criteria weekly in cycle 1,NA
33219014,NCT02779855,Combination,No,Nonmetastatic Triple-Negative BreastCancer,"To be eligible for the study, patients had to be female, 18 to 70 yearsof age, diagnosed with their first case of clinical stage T2-3N0-2M0triple-negative invasive breast cancer as defined by College of American Pathologists criteria, and eligible for neoadjuvant chemotherapy.Patients must also have had an Eastern Cooperative Group performance status of 0–1, adequate organ function/hematologiccounts, and an echocardiogram within institutional normal limits","Patients were excluded if they presented with inflammatory, bilateral, or multicentric breast cancers, active herpes simplex virusinfections, immunodeficiency, autoimmune disease, or were takinganticoagulation medicine",during the first 5 weeks of study treatment ,NA
29856514,NA,Combination,No,relapsedrefractory acute lymphoblastic leukemia,"Patients of age 1–30 years at the time of initial diagnosis withrefractory or recurrent ALL or lymphoblastic lymphoma were eligible. Patients must have had a Karnofsky / Lansky score above 50 andless than 350 mg/m2 lifetime exposure of anthracycline chemotherapy.A 6-month interval must have elapsed since the last treatment withan induction/reinduction type regimen containing an anthracycline,steroid, asparaginase and vincristine. Patients must have had adequateorgan function defined by serum creatinine ≤1.5 × upper limit of normal (ULN) for age, total bilirubin ≤ 1.5 × ULN for age, ALT ≤ 5 × ULNfor age, unless the elevation is disease-related, adequate cardiac function as defined as shortening fraction of ≥ 27% by echocardiogram orejection fraction ≥ 45% by gated radionuclide study","Patients were excluded if they planned on receiving other investigational agents while on this study, had contraindications to receiving intended therapies (e.g., anaphylaxis or pancreatitis with asparaginase), had an active infection defined as positive blood culture within48 hr of study registration, or required supplemental oxygen or vasopressors within 48 hr of study entry. Use of corticosteroids was notpermitted aside from dexamethasone treatment as part of the studytreatment regimen. Patients also may have been on hydroxyurea untilthe first dose of metformin. Patients must have recovered from the acute side effects of all prior anticancer therapy as defined by at least1 week from prior cytotoxic chemotherapy, 4 weeks from craniospinalirradiation, and at least 4 months since hematopoetic stem cell transplantation without evidence of active graft versus host disease. Pregnant or lactating women were also excluded. ",during the first course of therapy,NA
27403082,NCT00878800,Combination,No,Patients with Soft Tissue Sarcomas,"Eligibility criteria were as follows:patients 18 years or older and giving informed consent;performance status (ECOG) ≤2; life expectancy of at least3 months; acceptable liver, renal, coagulation, and bonemarrow function; serum potassium within normal range; andacceptable coagulation status. Eligibility criteria for doseescalation phase I part: patients with histological or cytological confirmed solid tumours (including sarcomas), with noknown curative therapy. Eligibility criteria for MTD expansion phase II part: patients with an established diagnosis ofSTS in need of first-line chemotherapy and with measurabledisease",Main exclusion criteria wereinvestigational treatment within 4 weeks prior to studytreatment; prior anticancer therapy within the last 3 weeks;coexisting significant medical condition or active infection;concurrent second malignancy; history of hypersensitivityto doxorubicin; pregnancy. Main exclusion criteria for doseescalation phase I part: more than two prior doses ofanthracycline or more than three prior lines of chemotherapygiven for metastatic disease. Main exclusion criteria for MTDexpansion phase II part: prior chemotherapy and LVEF belownormal range (45% by MUGA),during the first cycle of treatment,NA
33093947,EudraCT Number: 2015-003213-18; ISRCTN13626902 ,Combination,Yes,Diffuse Large B-cell Lymphoma (DLBCL),"Inclusion criteriaParticipants should fulfil the following criteria:Histologically confirmed DLBCL, expressing CD20; sufficient tumour block should be available to forward to a central laboratory for gene expression profiling and pathology review; at a minimum, participants should have sufficient tumour material to test for: H/E morphological check of compatibility of DLBCL diagnosis, immunophenotyping and RNA for gene expression profilingMeasurable disease of at least 15mmNot previously treated for lymphoma and fit enough to receive combination chemoimmunotherapy with curative intentStage IAX (bulk defined as lymph node diameter >10cm) to stage IV disease and deemed to require a full course of chemotherapy. Patients with non-bulky IE disease will not be eligibleECOG performance status 0–2 or 3 if this is directly attributable to lymphomaAdequate bone marrow function with platelets > 100×109/L; neutrophils > 1.0×109/L at study entry, unless lower figures are attributable to lymphomaMeasured or calculated creatinine clearance > 30mls/min, (calculated using the formula of Cockcroft and Gault [(140-Age) × Mass (kg) × (1.04 (for women) or 1.23 (for men))/Serum Creatinine (µmolL)]Serum bilirubin < 35μmol/L and transaminases < 2.5× upper limit of normal at time of study entryCardiac function sufficient to tolerate 300mg/m2 of doxorubicin. A pre-treatment echocardiogram or MUGA is required to establish baseline LVEF equal to or greater than institutional normal range.No concurrent uncontrolled medical conditionLife expectancy > 3 monthsAged 16 years and aboveWilling and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficultyAbility to understand the purpose and risks of the study and provide signed and dated informed consent","Exclusion criteriaPatients will be excluded from the study entry if any of the following criteria are met:Previous history of treated or untreated indolent lymphoma; however newly diagnosed patients with DLBCL who are found to also have small cell infiltration of the bone marrow or other diagnostic material (discordant lymphoma) will be eligiblePatients who have received immunisation with a live vaccine within four weeks prior to enrolment will be ineligibleDiagnosis of primary mediastinal lymphomaDiagnosis of primary Central Nervous System lymphomaHistory of stroke or intracranial haemorrhage in preceding 6 monthsHistory of bleeding diathesis (e.g., haemophilia, von Willebrand disease)Requires or receiving anticoagulation with warfarin or equivalent antagonists (e.g. phenprocoumon) within 7 days of first dose of acalabrutinib; however, patients using therapeutic low molecule weight heparin or low dose aspirin will be eligiblePrior exposure to a BCR inhibitor (e.g. Btk inhibitors, phosphoinositide-3 kinase (PI3K), or Syk inhibitors) or BCL-2 inhibitor (e.g. ABT-199)Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer.Requires treatment with proton pump inhibitors (e.g. omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole)○ Patients receiving proton pump inhibitors should switch to short-acting H2-receptor antagonists or antacids prior to study entry to be eligible for enrolment into this studyUncontrolled systemic infection.Major surgery in the preceding 4 weeks of first dose of study drug. If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drugSignificant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or corrected QT interval (QTc) > 480 msec at screening. QTc interval should be calculated using Fridericia’s formulaSerological positivity for Hepatitis B (HBV), C (HCV), or known HIV infection. As per standard of care, prior to initiation of immunochemotherapy, the results of hepatitis serology should be known prior to commencement of therapy.- Positive test results for chronic HBV infection (defined as positive HBsAg serology) will not be eligible. Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) will not be eligible. Patients who have protective titres of hepatitis B surface antibody (HBsAb) after vaccination will be eligible- Positive test results for HCV (HCV antibody serology testing) will not be eligibleWomen who can bear children must agree to use two highly effective forms of contraception or abstinence during the study and for 12 months after the last treatment dose (contraception is discussed under ‘5. Relevant concomitant care permitted or prohibited during the trial’)Breastfeeding or pregnant womenMen who can father children must agree to use two highly effective forms of contraception with additional barrier or abstinence during the study and for 12 months after the last treatment dose (contraception is discussed under ‘Relevant concomitant care permitted or prohibited during the trial’)Men must agree to refrain from sperm donation during the study and for 12 months after the last treatment doseSerious medical or psychiatric illness likely to affect participation or that may compromise the ability to give informed consentPrior malignancy (other than DLBCL), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to < 2 years. Note: these cases must be discussed with Southampton Clinical Trials Unit (SCTU)Malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, gastric bypass, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction or gastric restrictions and bariatric surgery, such as gastric bypassAny immunotherapy within 4 weeks of 1st dose of the studyConcurrent participation in another therapeutic clinical trial",The DLT reporting period is from the start of treatment until the end of cycle 3. Events meeting the below criteria following the end of cycle 3 will not be recorded as DLTs.,NA
33602316,NCT01839097,Combination,No,"patients with newly diagnosed peripheral T-cell lymphoma.in patients with newly diagnosed PTCL, who were candidates for frst-line chemotherapy with CHOP","Eligible patients were≥18  years of age with histologically confrmed PTCL or transformed CTCL, an Eastern Cooperative Oncology Group (ECOG) performance status of≤2, and a life expectancy of≥3  months. Patients must have had measurable disease based on Cheson criteria  and been eligible for frst-line CHOP therapy. Patients must have had adequate hematologic, hepatic, and renal function, including absolute neutrophil count (ANC)≥1.5×109, platelets≥100,000/mm3, alanine and aspartate aminotransferases (AST and ALT)≤3×the upper limit of normal (ULN), total bilirubin≤2.0  mg/dL, calculated creatinine clearance≥50  mL/min , and prothrombin time or international normalized ratio<1.5×ULN (or in the therapeutic range of anticoagulation therapy). ","Prohibited prior therapy included HDAC inhibitors (except for CTCL), extensive radiotherapy, severely myelotoxic regimens, and stem celltransplantation. Patients with≥Grade 3 neuropathy, cardiovascular disease (including prolonged QT), and active infections requiring therapy were also excluded.",during Cycle 1 to inform dose-escalation/reduction decisions,NA
29055839,NA,Single Drug,No,in patientswith advanced or metastatic solid tumours,"This phase I trial included adult patients with solid tumours whose disease had progressed on standardtherapy, with a World Health Organisation performancestatus of 0 or 1, who had received a maximum of threelines of chemotherapy for locally advanced or metastaticdisease, with absolute neutrophil and platelet counts1500/mL and 100,000/mL respectively, normal serumalbumin and creatinine, AST/ALT and alkaline phosphatase <2.5 of the upper limit of normal. Patients hadnormal cardiac function and a normal left ventricularejection fraction (LVEF) at study entry. ","Exclusioncriteria included prior anthracycline exposure of morethan 300 mg/m2 of cumulative total equivalent of Doxor a failure of previous anthracycline-based chemotherapy within 6 months after adjuvant therapy or 3months after discontinuation of treatment in the metastatic setting, serious concomitant illness, prior radiation therapy or systemic anticancer therapy within 4weeks (6 weeks for mitomycin C and nitrosoureas),symptomatic brain metastasis and prior radiation therapy to more than 30% of the bone marrow",the first treatment cycle (3weeks).,NA
33474828,NCT02677116,Combination,No,in pediatric patients with relapsed/refractory solid and central nervous system tumors,"Eligible patients were <18 years of age and had relapsed or refractory solid or CNS tumors, not amenable to curative treatment and for which chemotherapy with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide was deemed appropriate by the treating investigator. Patients had measurable and/or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria In Solid Tumors (RECIST version 1.1),13 or by the Response Assessment in NeuroOncology (RANO) criteria for CNS tumors,14 and adequate hematologic, organ, and coagulation function ≤2 weeks prior to first dose of the study drug. In addition, patients had a Lansky (<16  years of age)15 or Karnofsky (≥16  years of age)16 performance score ≥50; were fully recovered from the acute effects of all prior anticancer therapies; were able (patient or patient's parent/guardian) to provide informed consent and comply with study procedures; and, if of childbearing potential, had agreed to use adequate contraception if sexually active prior to study entry and for the duration of study participation. Patients with no prior history of anthracycline exposure were able to enroll on the doxorubicin combination arm and had to have a left ventricular ejection fraction ≥50% or shortening fraction ≥27% at baseline, and a corrected QT interval of <480 msec on screening.","Patients were excluded if they had undergone a bone marrow or solid organ transplant (prior autologous stem cell infusion was allowed), or if they had an uncontrolled intercurrent illness including, but not limited to, an ongoing/active infection requiring parenteral antibiotics, symptomatic congestive heart failure, severe myocardial insufficiency, cardiac arrhythmia, cardiomyopathy, or psychiatric illness/social situation that would limit compliance with study requirements. Patients could not concurrently be enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study or have received an investigational agent or non-approved use of a drug or device within 21 days of the initial dose of study drug.",A DLT was defined as an adverse event (AE) during the first 21  days of monotherapy or combination therapy. Part A and B patients who completed Cycle 1 or discontinued treatment due to an AE during Cycle 1 were considered DLT-evaluable for olaratumab monotherapy. Part A and B patients who completed Cycle 2 or discontinued treatment due to an AE during Cycle 2 and Part C patients who completed Cycle 1 or discontinued treatment due to an AE during Cycle 1 were considered DLT-evaluable for combination treatment,"Parts A, B, C"
32055930,NCT01145430,Combination,Yes,recurrent gynecologic cancer and triple negative breast cancer,"This study sought to enroll patients with a histologically confrmed diagnosis of recurrent or residual epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma (referred to as ovarian cancer) OR histologically confrmed metastatic breast cancer, that is ERnegative, PR-negative, and HER2/neu less than 3+and/or not amplifed by FISH. These patients were included since high grade serous ovarian cancers have a high proportion of homologous recombination defciencies and triple negative breast cancers respond to platinum agents.Patients with ovarian cancer already on PLD were eligible if they were receiving PLD beyond three cycles without prohibitive (i.e. no grade 3 or 4) skin or mucosal toxicities and with no disease progression (stratum A). Ovarian cancer patients with no prior PLD exposure were eligible if they recurred after platinum-containing chemotherapy; no more than 2 prior platinum containing regimens were permitted (stratum B). Both platinum sensitive and -resistant patients could be enrolled. Breast cancer eligibility was confned to triple-negative patients with no more than two prior chemotherapy regimens for metastatic disease, and no prior PLD, however treatment with doxorubicin was acceptable (stratum B)Histologically confirmed* diagnosis of recurrent or residual epithelial ovarian cancer, primary peritoneal carcinoma or Fallopian tube carcinoma, OR histologically confirmed metastatic breast cancer, that is ER-negative, PR-negative, and HER2/neu negative (as determined by local pathology laboratory). 3.1.2 Prior chemotherapy: Ovarian cancer: Patients with no prior PLD exposure are eligible after failure of platinum-containing chemotherapy; no more than 2 prior platinum containing regimens is permitted. (b) Dose Escalating Cohorts Only: Patients already on PLD are also eligible if they are receiving PLD beyond 3 cycles without prohibitive (i.e. no grade 3 or 4) skin or mucosal toxicities, and showing no progressive disease compared to a CT scan obtained 2 or more months earlier. These patients are eligible in spite of any progression from baseline determined prematurely (i.e., applicable to those patients who are deemed in their best interest to continue to receive PLD after a CT obtained at 2 or 3 months has shown progression from baseline).• Breast cancer: Patients may have received 0-2 prior chemotherapy regimens for metastatic disease. Breast cancer patients may not have received prior PLD, and will not be eligible for the expanded cohort A. • Interval between prior chemotherapy and registration for breast and ovarian cancer. There should be at least a 3 week interval between the last chemotherapy regimen and registration, and the patient should have recovered from acute toxicity related to prior therapy (6 weeks if the last regiment included BCNU or mitomycin C).• Dose Escalating Cohorts Only: Patients will be categorized in the following strata based upon prior PLD exposure: (A) Stratum A –Patients with ovarian cancer who have had prior PLD exposure and received at least 3 cycles of PLD without prohibitive (i.e. no grade 3 or 4 skin toxicity) and have not had progressive disease. (B) Stratum B: Patients with ovarian or breast cancer who have had no prior PLD exposure. ECOG performance score 0-2 (see Appendix A).3.1.4 All potential subjects should be evaluated for whether BRCA1-2 testing is medically appropriate. Individuals who have a 10% or higher risk of having a BRCA1-2 mutation (Myriad tables at www.myriad.com) are encouraged (but not required) to have mutation testing and results known. Information regarding mutation status (positive [including specific mutation], negative, or unknown) and projected risk of having a mutation (as determined by Myriad tables) will be collected at the time of diagnosis. 3.1.5 Non-measurable and/or measurable disease by RECIST criteria, or abnormal CA-125 to levels (in patients with ovarian cancer) at least 1.5x normal documented by two independent measurements at least 4 weeks apart.3.1.6 Ability to give voluntary informed consent and to comply with treatment and required tests.3.1.7 Ability to tolerate oral medications.3.1.8 Female subjects age > 18 years (males with breast cancer are eligible).3.1.9 Patients must have adequate:a. Hematologic function – DEVROXWH QHXWURSKLO FRXQW  P/ DQG SODWHOHWV  P/b. Renal function – &UHDWLQLQH  .PJG/c. Hepatic function – 7RWDO ELOLUXELQ  .[ LQVWLWXWLRQDO XSSHU OLPLW RI QRUPDO $67 DQG $/7  [ LQVWLWXWLRQDO XSSHU OLPLW RI QRUPDO  [ institutional upper limit of normal if evidence of liver metastasis)d. Cardiac function – Left ventricular ejection fraction at or above institutional lower limit of normal (obtained within 8 weeks of registration by MUGA scan or echocardiogram; the same test performed at baseline should be repeated after every 3 cycles of therapy as shown in the study calendar, section 10).3.1.10 The effects of ABT-888 on the developing human fetus are unknown. For this reason and because other therapeutic agents or modalities used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately","Known CNS metastases with active symptoms, or requiring anticonvulsive medications, or steroids.3.2.2 Prior chemotherapy (except PLD in Dose Escalation Cohorts only) or any investigational agent within 3 weeks prior to registration.3.2.3 Prior radiation therapy to whole pelvis or greater amount of marrow-forming bone.3.2.4 Prior or current non-gynecologic or non-breast malignancy within 5 years except nonmelanoma skin cancer.3.2.5 Patients with active severe infection; known infection with HIV, Hepatitis B virus, Hepatitis C virus, or severe concurrent illness.3.2.6 Patients with any non-malignant intercurrent illness (e.g. cardiovascular, pulmonary, central nervous system disease) which is either poorly controlled with currently available treatment, or which is of such severity that the investigators deem it unwise to enter the patient on protocol.3.2.7 Patients with history of seizure disorder requiring antiepeleptics who have had a seizure episode within the last 6 months.3.2.8 Pregnant (positive pregnancy test) or lactating. Unwillingness to use effective means of contraception in subjects with child-bearing potential.3.2.9 Evidence of complete or partial bowel obstruction or other unable to take oral medications.3.3 Inclusion of Women and MinoritiesThis study will be available to all female eligible patients, regardless of race or ethnic origin. The geographical region served by N01 consortia, has a population mirrors of general U.S. population. This includes approximately 25% minorities. Based on prior NCCTG studies involving similar disease sites, we expect about 25% of patients will be classified as minorities by race.",The dose limiting toxicity (DLT) was defned as the dose level that caused a protocol-defned DLT according to guidelines outlined in the NCI–CTCAE version 4.0 during the frst treatment cycle,NA
27255289,NA,Combination,No,"in patients with advanced solidtumors and chemotherapy-naı¨ve advanced or metastaticesophagogastric cancer.. The first two cohorts (1 and 2)enrolled patients with an advanced or metastatic solidtumor, regardless of the number of prior therapies receivedfor this tumor. Following a protocol modification, enrollment to cohort 3 was restricted to patients with previouslyuntreated advanced or metastatic esophagogastric cancer.","For cohorts 1 and 2 (planned S-1 dose levels of 20 and25 mg/m2, respectively), patients aged C18 years of agewith an advanced or metastatic solid tumor for which noestablished curative therapy was available, who could takeoral medication, and who had an Eastern CooperativeOncology Group performance status at baseline of 0 or 1, alife expectancy of at least 3 months, and a left ventricularejection fraction greater than the lower limit of normalwere eligible. Patients were also required to have serumtroponin T and CPK-MB values Bupper limit of normal(ULN) for the institution and adequate organ function, asdefined by aspartate aminotransferase (AST) and alanineaminotransferase (ALT) B2.5 9 ULN; or if liver functionabnormalities were due to underlying liver metastasis, ASTand ALT B 5 9 ULN; total serum bilirubin ofB1.5 9 ULN; absolute neutrophil count of C1500/mm3;platelet count C100,000/mm3; and a hemoglobin value ofC9.0 g/dL and creatinine clearance C60 mL/min based oncalculated creatinine clearance or 24-h urine collection.Enrollment in cohort 3 (planned S-1 dose level of 25 mg/m2) was additionally restricted to patients who hadadvanced or metastatic esophagogastric adenocarcinomaand who had received no previous chemotherapy foradvanced or metastatic disease.","Key exclusion criteria included major surgery orradiotherapy in the 4 weeks prior to enrollment, receipt ofany investigational agent concurrently or within the previous 30 days, and current enrollment in another interventional trial. For cohorts 1 and 2, patients should nothave had [25 % of marrow-bearing bone irradiatedreceived any chemotherapy within the prior 3 weeks, havepreviously received oxaliplatin or S-1, have previouslyreceived epirubicin at a cumulative dose [350 mg/m2,have extensive prior exposure to other anthracycline oranthracenedione agents, or have received trastuzumabwithin the prior 24 weeks. Patients were excluded from allcohorts if they had another serious illness or medicalcondition, were receiving concomitant treatment withparticular drugs which might interact with S-1 or epirubicin, if they were pregnant, or if they had a knownhypersensitivity to 5-FU, epirubicin, oxaliplatin, or otherplatinum compounds","dose-limiting toxicity (DLT), as assessedduring the first 21-day treatment cycle",NA
29174203,NA,Combination,No,in MetastaticBreast Cancer,"Eligible patients were adults (> 18 years old) with MBC,measurable disease by Response Evaluation Criteria in Solid Tumors(RECIST) criteria, Eastern Cooperative Oncology Group performance status equal or less than 2, adequate bone marrow reserve, andintact renal and hepatic function (creatinine < 2.5 mg/dL and liverfunction tests < 2-3 upper limit of normal). Baseline cardiacfunction > 50% by multigated acquisition scan or 2D-echocardiography within 42 days prior to the first dose of study drug wasrequired. Patients were enrolled between the years 2006 and 2009.","Pregnant or lactating woman were excluded from participation.Patients were also excluded if they had a history of hypersensitivityreactions to doxorubicin or PLD, active cardiac disease (use ofantianginal medication, cardiac arrhythmia requiring medications,severe conduction abnormality, clinically significant valvular disease,ventricular hypertrophy, uncontrolled hypertension, pericardialeffusion, use of digitalis or beta-blocker for congestive heart failure),history of significant cardiac disease (history of myocardial infarction, congestive heart failure, cardiomegaly, arrhythmia), presence ofother life threatening illness other than malignancy, mental illnessprecluding them from informed consent, and life expectancy lessthan 4 months",NA,NA
27577069,NCT01176799,Combination,No,in the pre-operative treatment of breast cancer,"Eligibility criteria included female patients aged ≥18 years with histologically confirmed treatment-naïve breast cancer planned for surgery, measurable primary tumor ≥2.0 cm, Karnofsky performance score ≥70, absolute neutrophil count ≥1.5x109/l, platelets ≥100x109/l, serum total bilirubin ≤1.5x upper limit of normal (ULN), alanine aminotransferase and aspartate aminotransferase ≤2.5xULN, serum creatinine ≤1.5xULN and left ventricular ejection fraction ≥50%. ",Significant exclusions were central nervous system metastases and clinically detectable second malignancies,NA,NA
31772119,NCT01902225,Combination,No,Patients with Relapsed or Refractory T-CellLymphoma inrelapsed/refractory CTCL and PTCL,"Eligible patientswere 18 years of age or older with relapsed or refractory (i) CTCL(limited to stage IB-IVB mycosis fungoides or Sezary syndrome) after 1or more prior systemic therapies or more than 2 prior skin-directedtherapies, or (ii) PTCL of any stage and subtype after 1 or more priorsystemic therapies. Eligible patients had an Eastern CooperativeOncology Group (ECOG) performance status  2 with adequatehepatic, hematologic, and renal function: aspartate transaminase(AST) and alanine transaminase (ALT)  3  upper limit of normal(ULN), total bilirubin  2  ULN, absolute neutrophil count 750/mm3, platelet count  75,000/mm3, and creatinine clearance 30 mL/minute. Prior autologous stem cell transplant (ASCT) and priorexposure to HDAC inhibitors, doxorubicin, and/or LD were permitted.","Key exclusion criteria included the following: active centralnervous system or leptomeningeal lymphoma, HIV infection, hepatitisB/C infection, prior allogeneic hematopoietic cell transplant, priorcumulative anthracycline exposure > 450 mg/m2 doxorubicin equivalents, and any significant cardiac abnormalities including baseline QTcinterval  480 milliseconds. During the study, medications leading tosignificant QTc prolongation or known to be strong cytochrome P450(CYP3A4) inhibitors or inducers were prohibited. All prior therapies,including radiation and chemotherapy, had to be discontinued for atleast one week or three half-lives, whichever was longest, prior to studydrug treatment.",Dose-limiting toxicities (DLT) were monitored during the first 28 daysof treatment ,NA
29104762,NCT01655693,Single Drug,No,in hepatocellular carcinoma,"HCC ineligible for curative options (surgical resection, liver transplantation, radiofrequency ablation) according to international guidelines,21 and absence of objective response to TACE when applicable; (2) absence of decompensated cirrhosis; (3) Eastern Cooperative Oncology Group ≤2; and (4) 18–80 years of age. ","(1) HCC invasion >50%liver parenchyma; (2) HCC occurring on a transplanted liver; (3) impaired clotting tests (platelet count <100 × 109/L or prothrombin activity <60%); (4) contraindication to doxorubicin (neutrophils <1.500/mm3, cardiac left ventricular ejection fraction <50%, previous cumulative dose of doxorubicin ≥550mg/m²); (5) respiratory insufficiency (forced vital capacity (FVC) <80%, total lung capacity <80%, carbon monoxide diffusing capacity (or transfer factor) <80%, forced expiratory volume/FVC <65%, PaO2<75mm Hg); (6) presence of high risk bleeding of oesophageal varices; and (7) anticancer therapy within 6 weeks prior to inclusion",within the 4 weeks after injection,NA
32601796,NA,Combination,No,relapse and refractorymantle cell lymphoma,"Only patients ≥ 18 years with histologically or cytologically confirmed refractory or relapsed MCL (at initial diagnosisor relapse) and who had received at least one prior therapy, butno more than three line therapies were eligible for inclusion.Ann Arbor Stage II-IV with at least one tumor site measurablewas required. Patients should have adequate hepatic and renalfunction (defined by AST or ALT ≤ 3.0 × upper limit of normal (ULN); serum total bilirubin ≤ 1.5 mg/dL (26 μmol/L)except in case of hemolytic anemia, serum creatinine ≤2 mg/dL, or calculated creatinine clearance (Cockcroft-Gaultformula) of ≥ 50 mL /min) and adequate bone marrow reserve(absolute neutrophil count (ANC) ≥ 1 G/L (1000 cells/mm3);platelet count ≥ 50 G/L; hemoglobin ≥ 9.0 g/dL).",NA,DLT was defined as one or more of the following adverseevents occurring during the first two cycles:,NA
30361524,NCT01304797,Combination,No,in patients withadvanced HER2-positive breast cancer:,"Key inclusion criteria were: histologically or cytologically confirmed HER2-positive locally advanced/metastatic breast cancer;tumor amenable to biopsy; measurable disease per ResponseEvaluation Criteria in Solid Tumors (RECIST) version 1·1; age ≥ 18years; Eastern Cooperative Oncology Group (ECOG) performancestatus 0 or 1; left ventricular ejection fraction (LVEF) ≥ 50%;adequate renal/hepatic function and bone marrow reserves.Patients with stable, treated central nervous system metastaseswere allowed.",Key exclusion criteria were: previous cumulative anthracyclinetotal dose of > 300 mg/m2 doxorubicin equivalent; significantcardiovascular problems,DLTs were evaluated during cycle 1 of treatment,NA
28718812,NCT02562378,Combination,No,HER2-positive (HER2+) metastatic breast cancer (MBC).,"Eligible patients were age ≥18 years with HER2+ (according to 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines), unresectable, locally advanced or MBC by local testing. Patients could have previously received up to two prior chemotherapy regimens in an advanced setting, and the disease had to have progressed or relapsed during or after taxane—and trastuzumab—based therapy. Other inclusion criteria were ECOG performance status ≤1 and adequate bone marrow, renal, hepatic, and cardiovascular function (LVEF ≥55%). Patients were required to have evaluable or measurable disease according to RECIST v.1.1.","The major exclusion criteria included previous treatment with T-DM1 or anthracyclines, either in a (neo)adjuvant or metastatic setting; central nervous system involvement (except if the patient was >4 weeks from radiotherapy completion, clinically stable, and not receiving steroids at study entry); cardiopulmonary dysfunction; history of a LVEF decline to <40.0% or symptomatic heart failure with previous trastuzumab-based treatment; and peripheral neuropathy of grade 3 or higher according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.",during the first two cycles of study treatment,NA
29903707,NCT01622439,Combination,No,first-line therapy in diffuse large B-cell lymphoma (VALFRID),"Patients aged 18 to 80 years with histologically confirmed DLBCL according to the World Health Organization (WHO) Classification and clinical stages II to IV were eligible. WHO performance status 0 to 2, and adequate organ function (international normalized ratio, bilirubin, ASAT, ALAT, pancreatic amylase, p-creatinine within normal limits, neutrophils $1.0 3109/L, platelets $60 3 109) were required for study inclusion.","Exclusion criteria were HIV positivity and seropositivity for hepatitis C virus, hepatitis B surface antigen, anti–hepatitis B core total antibodies, or other active infection, including a history of hepatitis or porphyria. Patients with psychiatric or neurological diseases or a hearing impairment .grade 2 were excluded from the study. Prior exposure to anthracyclins was an exclusion criterion, but corticosteroids for alleviation of lymphoma symptoms were allowed.",during the first treatment cycle,NA
30850381,NCT02055820,Combination,No,non-Hodgkin lymphoma (NHL),"Eligible patients were aged 18 years or older, with histologically confirmed B-cell NHL (transformed lymphomas, including Richter syndrome cases, were considered following discussion with the Medical Monitor); untreated or with 1 prior therapy (excluding R-CHOP); 1 or more bidimensionally measurable lesions >1.5 cm; Eastern Cooperative Oncology Group (ECOG) performance status <=2; and adequate organ and hematologic function, defined as hemoglobin >= 9 g/dL, absolute neutrophil count $1.5 3 109/L, and platelet count >=75 3 109/L (unless due to underlying disease, as evidenced by extensive bone marrow [BM] involvement).",Exclusion criteria included mantle cell lymphoma or small lymphocytic lymphoma histology; primary mediastinal DLBCL; primary central nervous system lymphoma or secondary involvement; chemotherapy or other investigational therapy within 28 days prior to start of cycle 1; significant cardiovascular or liver disease that could affect compliance with the protocol or interpretation of results or that could increase risk to the patient; or known HIV infection. A full list of inclusion/exclusion criteria is provided in the supplemental Appendix.,"The DLT window was defined as the first 2 cycles, because venetoclax administration started on day 4 of cycle 1.",NA
16870542,NA,Combination,No,first-line treatment ol'advanced non small cell lung cancer,"Patients recruited into this study were required to have histologically confirmed non small cell lung cancer (NSCLC). All patients were to have measura ble disease target lesions on physical examination (photographs), or computed tomography (CT). Other eligibility criteria were age > 18 years, World Health Organization (WHO) performance status (PS) _ 2 with a life eKpectancy > 5 months, adequate bone marrow reserve (absolute granulocyte count, > 1.500 t~l; platelet count, > 100.000 1~1; hemoglobin level > 10 g/dl), as well as adequate renal and hepatic function (serum creatinine, AST, ALT and bilirubin levels < 1.25 times the upper lhnit of norulal).","Exclusion criteria were the presence of other concomitant or metaehronous cancers, brain or leptomeningeal metastases, radiation to the only measurable disease or within 4 weeks of starting chemotherapy, a previous chemotherapy regimen, simultaneous infection disease or polyneu ropathy, severe cardiac arrhythmia or heart failure, pregnancy or breast feeding.",NA,NA
16179099,NA,Single Drug,No,Advanced Non–Small-Cell Lung Cancer,"Patients recruited into this study were required to have histologically confirmed NSCLC and to have had vinorelbine proposed as first-line therapy for advanced disease. All patients were to have measurable disease target lesions on physical examination (photographs) or computed tomography (CT). Other eligibility criteria were age > 18 years, World Health Organization (WHO) performance status (PS) ≤ 2 with a life expectancy > 3 months, adequate bone marrow reserve (absolute granulocyte count, > 1500/μL; platelet count, > 100,000/μL; hemoglobin level, > 10 g/dL), as well as adequate renal and hepatic function (serum creatinine, aspartate aminotransferase, alanine aminotransferase, and bilirubin levels < 1.25 times the upper limit of normal).","Exclusion criteria were the presence of other concomitant or metachronous cancers, brain or leptomeningeal metastases, radiation to the only measurable disease or within 4 weeks of starting chemotherapy, a previous chemotherapy regimen, simultaneous infection disease or polyneuropathy, severe cardiac arrhythmia or heart failure, and pregnancy or breast feeding.",NA,NA
12655441,NA,Single Drug,No,patients with refractory solid tumors,"Patients with histologically documented, advanced solid malignancies refractory to conventional therapy or for whom no effective therapy existed were entered. Inclusion criteria included: age ‡18 years, an Eastern Cooperative Oncology Group performance status of 0–2, and a life expectancy of ‡12 weeks; no chemotherapy or radiotherapy in the 4 weeks prior to entering the study (6 weeks for nitrosoureas, mitomycin C or radiotherapy to more than 20% of bone marrow); ANC ‡1500/ll, platelet count ‡100,000/ll, total serum bilirubin £ 1.3 mg/dl, AST and ALT £ 2.5 times the upper limit of the institutional normal, and serum creatinine £ 1.5 mg/dl or creatinine clearance ‡60 ml/min; no uncontrolled brain metastases or general medical problems, and no neurotoxicity from previous therapy greater than National Cancer Institute Common Toxicity Criteria (NCI CTC) grade 2. All patients gave written informed consent according to federal and institutional guidelines before treatment.",NA,DLT was defined on the first cycle only for dose escalation to the next level.,NA
12649112,NA,Single Drug,No,patients with advanced solid tumours,"Patients were candidates for the study if they had solid tumours for which effective standard therapy was not available or if they had progressive disease after standard therapeutic modalities and had received no more than two prior regimens for advanced or metastatic disease. The interval between completion of the last chemotherapy and/or immunotherapy and/or radiotherapy and enrolment in the trial had to be at least 4 weeks. Recruited patients were between 18 and 75 years old, with World Health Organization (WHO) performance status (PS) score of 0–2 and an estimated life expectancy of at least 12 weeks. The biological criteria for eligibility were defined by laboratory tests of adequate haematological function: white blood cell (WBC) count ≥4.0 × 109/l, neutrophils ≥2.0 × 109/l, platelets ≥100 × 109/l, haemoglobin ≥9 g/dl. Biochemistry: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.6 × the upper normal limits (UNL), serum bilirubin ≤UNL and serum creatinine ≤UNL. At least one measurable or evaluable lesion outside of a previous radiation field was required. Measurable lesions were identified as those with a diameter ≥20 mm on computed tomography (CT) scan.","Patients were excluded if they had clinical evidence of brain or leptomeningeal metastasis, symptomatic peripheral neuropathy grade ≥2 [according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) scale], uncontrolled hypercalcaemia or unstable cardiovascular conditions (heart failure, uncontrolled angina, uncontrolled hypertension, myocardial infarction within 6 months).Concurrent treatment with other experimental drugs or participation in another clinical trial within the 30-day period prior to study entry were not permitted.",during cycle 1,NA
15809877,NA,Combination,No,Patients with advanced solid tumours,"Eligible criteria for this trial were: age ‡18 years; histologically or cytologically confirmed diagnosis of inoperable metastatic or locally advanced solid cancer and not eligible for curative surgery or radiotherapy; Eastern Cooperative Oncology Group (ECOG) performance status £ 2; use of adequate birth control; previous treatment with no more than two chemotherapy regimens (including adjuvant therapy); no previous exposure to vinca alkaloids or MDR/MRP modulator treatment; and absolute granulocytes ‡1.5·109 l1, platelets ‡100·109 l1, serum creatinine less than 1.5 times the upper limit of normal (ULN) or creatinine clearance >50 ml/min, bilirubin not more than 1.5 times the ULN and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) not more than 2.5 times the ULN.","Patients were ineligible if they had a haematologic malignancy not in remission, were pregnant or lactating, had a systemic infection requiring parenteral antibiotics, had a serious concomitant illness, had a prior history of seizure disorders, had unstable CNS metastases (previously treated patients with stable brain metastases for 3 months were eligible), were on concurrent treatment with other investigational or conventional anticancer therapies, or had grade 2 or worse peripheral neuropathy. All chemotherapy, radiotherapy or surgery had to be completed at least 3 weeks prior to registration (6 weeks if treated with nitrosourea or mitomycin C).",occur in the first cycle of treatment,NA
16211365,NA,Single Drug,No,solid tumours,"Patients were eligible for the study if they had solid tumours for which effective standard therapy was not available or if they had developed progressive disease after standard treatment. No patient had received more than 2 prior chemotherapeutic regimens for advanced or metastatic disease. All patients had completed prior anticancer therapy at least 4 weeks prior to enrolment in the trial. Patients were aged between 18 and 75 years old, with World Health Organization (WHO) Performance Status (PS) score of 0 to 2 and an estimated life expectancy of at least 12 weeks.All patients had adequate haematological, hepatic and renal function as indicated by the following laboratory tests: Haematology; total white blood cell count (WBC) ≥4.0 × 109/L, absolute neutrophil count ≥ 2.0 × 109/L, platelet count ≥100 × 109/L, haemoglobin ≥9 g/dL; Biochemistry; AST and ALT ≤2.6 times the upper limit of normal (UNL), serum bilirubin ≤ UNL and serum creatinine ≤UNL. All patients had at least one measurable or evaluable lesion outside a previous radiation field. Measurable lesions were identified as those with at least one diameter of 20 mm on computed tomography (CT) scan. ","Patients were excluded if they had clinical evidence of brain or leptomeningeal metastasis, symptomatic peripheral neuropathy of grade 2 or greater (NCIC-CTC scale: version 2) , uncontrolled hypercalcaemia or unstable cardiovascular conditions (heart failure, uncontrolled angina, uncontrolled hypertension and/or myocardial infarction within previous 6 months). Concurrent treatment with other experimental drugs or participation in other clinical trials within the 30-day period prior to study entry was not permitted.",during the first treatment cycle,NA
16937306,NA,Combination,No,patients with locally advanced non-small-cell lung cancer,"Patients with histologically or cytologically confirmed locally advanced NSCLC were enrolled in this study. All patients were deemed suitable for definitive TRT by a radiation oncologist (T.T.). Other eligibility criteria included the following: age, 20 years or older; Eastern Cooperative Oncology Group (ECOG) performance status, 0 or 1; unresectable stage IIIA or IIIB; absence of malignant pleural or pericardial effusion; absence of involvement of contralateral hilar lymph nodes; no prior chemotherapy or TRT; adequate bone marrow function (leukocyte count ≥4000/μl, neutrophil count ≥2000/μl, hemoglobin level ≥10 g/dl, and platelet count ≥100 000/μl), renal function (creatinine level ≤ upper limit of normal and creatinine clearance ≥50 ml/min), hepatic function (aspartate aminotransferase/alanine aminotransferase [AST/ALT] ≤ twice upper limit of normal and bilirubin level ≤ upper limit of normal), and pulmonary function (arterial partial pressure of oxygen [PaO2] ≥70 mmHg); absence of interstitial pneumonitis or pulmonary fibrosis, or other serious illnesses; and no pregnancy or lactation.",NA,NA,NA
14984944,NA,Combination,No,cervical carcinoma and other advanced pelvic malignancies,"Patients with locally advanced pelvic malignancies for which pelvic RT was planned were eligible. No patients could have received chemotherapy before RT. A performance status of 2 or less (GOG scale) and informed consent were required. Laboratory criteria included a white blood cell (WBC) count z 3500/Al, platelet count z 100,000/Al, creatinine V 1.5 mg%, and a calculated creatinine clearance of z 50 ml/min. Pretreatment evaluation included a physical examination including a pelvic examination, complete blood count, and differential, platelets, serum electrolytes, liver function tests and magnesium level. All patients also underwent a chest X-ray, electrocardiogram, and abdominopelvic CT scan.",NA,NA,NA
15122074,NA,Combination,No,patients with refractory carcinoma,"Patients with histologically proven metastatic or surgically unresectable solid tumors who have failed conventional therapy or for whom no standard therapy exists were eligible for enrollment. All patients were between 18 and 65 years of age; had bi-dimensionally measurable or evaluable disease; had a life expectancy of ≥3 months; had a performance status (ECOG) of ≤2; had complete recovery from toxicity related to prior hormonal, radiation, or biologic therapy; had pretreatment laboratory values above stated minimum values (WBC ≥ 3.0 × 109/L, ANC ≥ 1.5 × 109/L, platelets ≥ 100 × 109/L, hemoglobin ≥ 9.0 gm/dl, serum creatinine ≤ 1.8 mg/dl, and bilirubin (total) ≤ 1.5 ml/dl); had absence of significant effusions or ascites; had no major surgery requiring general anesthesia within the preceding 28 days; and, had received ≤2 prior systemic regimens.","Exclusion criteria included history or evidence of cardiac arrhythmia or congestive heart failure (New York Heart Association Class III or IV); women of childbearing age unless surgically sterile or using effective contraception; pregnant or lactating women; known CNS metastasis as determined by imaging studies (i.e. CT scan of brain) or neurological exam; or history of a seizure disorder. In addition, patients were ineligible if they had a history of another malignancy within the past 3 years excluding basal cell carcinoma of the skin or carcinoma in-situ of the uterine cervix; had organ allografts; required ongoing therapy with DPH; required concomitant therapy with agents known to modulate MDR (i.e. phenothiazines, cyclosporin A, tamoxifen, progesterone, verapimil and quinidine); required ongoing therapy with agents known to modify DPH pharmacokinetics (i.e. antacids, sucralfate, theophylline, heparin, nonsteroidal anti-inflammatory agents, corticosteroids, coumadin, allopurinol, omeprazole, and H2-blockers); had received chemotherapy, immunotherapy and/or radiotherapy within the past 28 days; or had received local or systemic antibiotics for infections within the past 28 days.",During cycle one of treatment,NA
31959492,NA,Combination,No,Newly diagnosed ovarian cancer,"Eligible patients had non-mucinous subtypes of invasive epithelial OC pathologically confirmed at MSK, a Karnofsky performance status (KPS) of ≥70%, and adequate organ function, including adequate mar- row (absolute neutrophil count [ANC] ≥1500/μL, platelets ≥100,000/μL, hemoglobin ≥10 g/dL), renal (creatinine ≤1.5 mg/dL), and hepatic (bili- rubin ≤1.5× upper limit of normal [ULN], aspartate transaminase [AST] and alanine transaminase [ALT] ≤3× ULN) function. Eligibility criteria also included baseline sensory neuropathy ≤ grade 2 (CTCAE v. 4.0) and excreted urine protein  <1 g in 24 h. Patients were required to either have, or agree to undergo, insertion of an IP port. Germline BRCA testing was required. ","Key exclusion criteria included the following: prior ab- dominal chemotherapy or radiation therapy, poorly controlled hyper- tension, or a non-healing wound. Additional eligibility criteria are listed in the protocol.",during Cycle 1 or 2,NA
24493831,NA,Combination,No,Patients with Advanced Solid Malignancies,"Key inclusion criteria were adults with histologically confirmed solid malignancy that was incurable, locally advanced, or metastatic and that had failed to respond to at least one prior regimen or for which standard of care therapy did not exist; measurable or evaluable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST;); Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2; adequate renal (creatinine <= 1.5 mg/dL or creatinine clearance >= 50 mL/min), hematologic (granulocytes>= 1,500/uL, platelets >= 100,000/uL, hemoglobin >= 10 g/dL), and hepatic function [aspartate aminotransferase, alanine aminotransferase, and total bilirubin within normal limits or National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade 1 or less if liver had tumor involvement].","Patients were generally excluded if they had received antitumor therapies or undergone a major surgical procedure within 4 weeks of the start of the study. Patients were excluded from the bevacizumab cohort in phase Ib if they had inadequately controlled hypertension as defined by systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg, a history of cardiovascular disease or significant vascular disease within 6 months before enrollment, or major surgery within 28 days before start of dosing.",cycle 1,NA
24649202,NA,Combination,No,Japanese patients with locally advanced rectal cancer,"Eligible patients had previously untreated stage T3 or T4 locally advanced rectal cancer, as determined by computed tomography (CT), magnetic resonance imaging (MRI) or endoscopic ultrasound criteria and had histologically confirmed adenocarcinoma prior to surgery. Eligible patients also had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and a survival expectation of >3 months. Additional eligibility criteria included: age 20‑80 years at enroll ment; no severe compromise of main organ functions (including bone marrow, lung, liver and kidney) or blood biochemistry (leukocyte count 4,000‑12,000/mm3; platelet count ≥100x10^3/̸μl; hemoglobin concentration>=9.0g/dl; total bilirubin concentration ≤1.5 *upper limit of normal; serum aspartate aminotransferase and alanine aminotransferase levels <2.5 * upper limit of normal; and serum creatinine concentration <1.5 *upper limit of normal).","patients with potential risk factors for bevacizumab, 5-FU and LV-related adverse events. The risk factors included: patients with child-bearing potential or lactation; clinical evidence of thrombosis, requiring medication; uncontrolled hypertension; clinically significant cardiovascular or pulmonary disease; clinical evidence of gastrointestinal bleeding; bowel obstruction and perforation; active inflammatory bowel disease; active infection; brain metastasis; synchronous or metachronous malignancy; major surgical procedure within 28 days of study enrollment; and any other cases regarded as inadequate for enrollment by the investogator.",NA,NA
24770667,NCT00633529,Combination,No,patients with advanced or metastatic NSCLC who progressed during or after first-line therapy," Patients ≥18 years old with histologically proven stage 3 or 4 NSCLC according to American Joint Committee on Cancer Classification (AJCC 6th ed) whose disease was not amenable to curative therapy and for whom erlotinib and bevacizumab therapy was appropriate were eligible. Patients were also required to have received at least one standard platinum-containing chemotherapy regimen prior to enrollment, a radiologic assessment within 21 days prior to inclusion if measurable disease was present, an Eastern Cooperative Oncology group (ECOG) performance status of 0 or 1, and adequate bone marrow, liver, and renal function.","Main exclusion criteria were as follows: presence of squamous cell carcinoma, except for patients with no or well-controlled intrathoracic disease or small peripheral lesions only and no cavitating lesions; known metastases of the central nervous system; <4 weeks between registration and last receipt of nSClC-related treatment; or concurrent or planned use of hormonal agents. EGFR mutation status of tumors was not determined; at the time of study initiation, routine testing was neither common nor required according to erlotinib’s label. ",cycle 1,"On day 1 of cycle 1, bevacizumab was administered simultaneously with erlotinib, followed by IMO-2055 administered 90 min later.On day 1 of cycle 2 and all subsequent cycles, all three drugs could be administered simultaneously. On days 8 and 15 of cycle 1 and all subsequent cycles, IMO-2055 and erlotinib could be given simultaneously."
24752867,NA,Combination,No,advanced solid tumors,"Patients had histologically confirmed malignancies refractory to standard therapies or had no available standard therapies; were aged >= 15 years; had an Eastern Cooperative Oncology Group performance status (ECOG PS) of <= 2; and had adequate bone marrow, hepatic, and renal function (absolute neutrophil count >= 1500/uL, platelet count >= 100,000/uL, bilirubin <= 2mg/dL [except among those with Gilbert syndrome], aspartate aminotransferase or alanine transaminase < 2.5 times the upper limit of normal without liver involvement [5 times the upper limit of normal with liver involvement], and creatinine < 2 mg=dL). Prior therapy ending >= 28 days before study entry was allowed. Patients with stable brain metastases documented by magnetic resonance imaging 4 weeks after the completion of whole-brain radiotherapy were eligible.","Patients with squamous non-small cell lung carcinoma, uncontrolled medical conditions, or hemoptysis were excluded. Another exclusion criteria was uncontrolled systemic vascular hypertension (systolic blood pressure > 140 mm Hg and diastolic blood pressure > 90 mm Hg). Patients were also excluded if they had clinically significant cardiovascular disease, such as history of myocardial infarction or unstable angina within 6 months, New York Heart Association class II or higher congestive heart failure, serious cardiac arrhythmia requiring medication, unstable angina pectoris, clinically significant peripheral vascular disease, QTc prolongation > 500 milliseconds or another significant electrocardiography abnormality noted within 14 days of registration, or conditions requiring the concurrent use of drugs or biologics with proarrhythmic potential (because drugs with proarrhythmic potential are prohibited during studies with AZD2171). Urine protein was screened by dipstick or urine analysis. For proteinuria > 1+ or a urine protein:creatinine ratio of > 1.0, 24-hour urine protein was obtained and the level had to be < 1000 mg for patient enrollment.",for 4 weeks after the first administration of bevacizumab and cediranib,NA
32847973,NCT00572078,Combination,No,Advanced Refractory Solid Tumors,"Eligible patients were ≥18 years, with histologically proven advanced solid malignancies, Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy ≥12 weeks, and adequate organ function. Patients may have received prior taxanes including paclitaxel, or antiangiogenic therapies, and had prior disease progression on either taxanes or anti-angiogenic therapy, but not both.","Exclusion criteria included brain metastases, squamous cell lung cancer, peripheral neuropathy grade ≥2, unstable angina, myocardial infarction or thrombotic or embolic events within 6 months, congestive heart failure NYHA grade ≥1, uncontrolled hypertension (HTN), symptomatic peripheral vascular disease, impairment of gastrointestinal function, which could affect sorafenib absorption, need for therapeutic warfarin, and known hypersensitivity to paclitaxel.",cycle 1,NA
33159605,UMIN000006254,Combination,No,previously treated advanced non‑squamous non‑small‑cell lung cancer,"Each patient had to meet the following eligibility criteria: histology- or cytology-confirmed non-squamous NSCLC; stage IIIB, IV, or postoperative recurrence; an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0–1; age ≥ 20 years; progression during or after prior platinum-based chemotherapy; with or without anti-VEGF/VEGFR antibody treatment; and measurable lesions (based on the response evaluation criteria in solid tumors (RECIST), version 1.1 ); adequate organ function, defined as adequate bone marrow function (white blood cell count ≥ 3000/mm3 or neutrophil count ≥ 1500/ mm3, hemoglobin ≥ 9.0 g/dL, and platelet count ≥ 100,000/ mm3); adequate hepatic function (aspartate aminotransferase [AST], alanine aminotransferase [ALT] levels ≤ 2.5 times the upper limit of normal [ULN]) and total bilirubin ≤ 1.5 mg/ dL); renal function (serum creatinine ≤ 1.5 times ULN, creatinine clearance [Ccr] level ≥ 30 mL/min [calculated using the Cockcroft–Gault formula], and urine protein < 2 + ; coagulation function (prothrombin time [PT] ≤ ULN and PTinternational normalized ratio ≤ 1.5); and pulmonary function (SpO2 ≥ 95% or PaO2 ≥ 60 torr on room air); life expectancy of at least 12 weeks; and written informed consent. ","The exclusion criteria were as follows: interstitial lung disease on chest radiography; serious or uncontrolled concomitant systemic disorders; active systemic infections that require systemic administration of antibacterial and antifungal agents; active concomitant malignancy (disease-free period within 5 years); administration of chronic systemic corticosteroids; previous treatment with fluoropyrimidines; brain metastases showing symptoms or requiring treatment; uncontrolled pleural effusion and ascites; history of high risk of bleeding such as hemoptysis (> 2.5 mL) for ≤ 3 months, major blood-vessel invasion, significant intratumor cavitation, bleeding and coagulation abnormalities; uncontrolled hypertension; pregnancy, lactation, and possibility of being pregnant; uncontrollable peptic ulcer within 1 year; symptomatic congestive heart failure, unstable angina, arrhythmia requiring treatment, and myocardial infarction within 1 year; cerebrovascular disorder with symptoms or within 1 year; and ingestion impossible.",the first 21 days of the treatment,NA
32522887,NCT02030561,Combination,No,HER2-positive Cancers,"Age 18-75; histologically confirmed diagnosis of HER2-positive breast or gastric cancer or other refractory HER2-positive solid tumors (defined as IHC 3+ or HER2 FISH amplification ratio >2.2); metastatic disease with presence of measurable or non-measurable tumour by RECIST 1.1 criteria; for HER2-positive breast cancer, patient must have failed at least two lines of anti-HER2 based therapy (documented relapse while receiving adjuvant or neoadjuvant trastuzumab for HER2 positive breast cancer is considered one prior line). For HER2-positive gastric cancer, patient must have failed at least one line of anti-HER2 based therapy, or have failed standard therapies for other refractory HER2 positive solid tumors (non-breast, non-gastric); at least two weeks since receipt of any biological therapy, chemotherapy, and/or radiation therapy; left ventricular ejection fraction ≥50%; adequate organ function (ANC ≥1500/µL, platelet count ≥100,000/µL, creatinine clearance ≥60 ml/minute, total bilirubin ≤1.5x upper limit normal (ULN) AST ≤ 2 x ULN, ALT ≤ 2 x ULN, ECOG performance status of 0-1); life expectancy of at least 60 days; negative serum or urine pregnancy test result within 14 days prior to enrolment for women who are of childbearing potential; ability to provide informed consent. Otherwise, a legally authorized representative must be present throughout the consent process and is allowed to give consent on the patient’s behalf; patients with reproductive potential must agree to use an approved contraceptive method; ability to comply with study procedures","Treatment within the last 30 days with any investigational drug; concurrent administration of any other anti-cancer therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy; major surgery within 28 days of study drug administration; active infection that in the opinion of the investigator would compromise the patient’s ability to tolerate therapy; lactating or pregnant; serious concomitant disorders that would compromise the safety of the patient or compromise the patient’s ability to complete the study, at the discretion of the investigator; serious cardiac illness or medical conditions including but not limited to patients with dyspnea at rest, history of documented congestive heart failure, high risk uncontrolled arrhythmias, angina pectoris requiring a medicinal product, clinically significant valvular disease, evidence of transmural infarction on ECG, poorly controlled hypertension; second primary malignancy that is clinically detectable at the time of consideration for study enrolment; symptomatic brain metastases; receipt of steroids during time period of 3 days prior to expanded NK cell infusion to 30 days after infusion (i.e. day -3 to day +30). ",NA,NA
32490554,UMIN000016094,Combination,No,Colorectal cancer; Metastatic/advanced,NA,NA,the first and second cycles (14 days/cycle),NA
31932108,NCT02055690,Combination,No,recurrent ovarian cancer,"Eligible patients had recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. All eligible patients had received ≥1 prior lines of platinum chemotherapy and had progressive evaluable disease according to RECIST v1.1 and/or GCIG CA-125 criteria within 3 to 12 months of a platinum-based regimen. Eligible patients were aged 18 years or older; had a WHO performance status 0–1; adequate bone marrow function (haemoglobin ≥90 g/L, neutrophil count ≥1.5 × 10^9/L, platelet count ≥100 × 10^9/L); adequate renal function (either an uncorrected calculated CrCl [CockcroftGault equation] or corrected isotopic clearance measurement ≥40 mL/ min); adequate liver function (bilirubin ≤1.5 × ULN, ALT or AST ≤2.5 × ULN); adequate blood coagulation parameters (PT or INR ≤1.3 × ULN and aPPT ≤1.2 × ULN); urine protein level ≤ 2+ or < 2g over 24 h and were clinically euthyroid. Eligible patients could have received bevacizumab prior to trial entry providing the last dose was administered ≥6 months before the first dose of pazopanib/fosbretabulin.","Patients were excluded if they had undergone radiotherapy, surgery or tumor embolization within 28 days of the first dose of pazopanib/ fosbretabulin; had endocrine therapy, immunotherapy or chemotherapy during the previous 4 weeks before the first dose of pazopanib/ fosbretabulin; had ongoing grade ≥ 2 toxic manifestations of previous treatments; were known to be serologically positive for HBV, HCV or HIV; were pregnant or breast feeding; had major thoracic/abdominal surgery from which they had not yet recovered prior to trial entry; had a history of cardiovascular disease within 6 months of trial entry including coronary revascularisation, acute coronary syndrome, symptomatic peripheral vascular disease or congestive heart failure (NYHA class III/IV); had sustained hypertension defined as a 3 or more readings of systolic blood pressure (BP) N140 mmHg or a diastolic BP N90 mmHg during screening; had clinically significant abnormalities on a screening EKG; had a history of cerebrovascular disease (including transient ischaemia attack), pulmonary embolism or untreated deep vein thrombosis within 6 months of trial entry; had clinical evidence of, or, symptomatic CNS metastases/leptomeningeal carcinomatosis; had clinically significant abnormalities that could increase the risk of gastrointestinal bleeding or perforation; had evidence of active bleeding; were known to have endobronchial lesions or lesions infiltrating major pulmonary vessels; had clinically significant haemoptysis within 8 weeks of starting pazopanib/fosbretabulin; had been previously treated with pazopanib and/or fosbretabulin; had concurrent malignancies other than adequately treated cone-biopsied carcinoma in situ of the cervix or basal/squamous cell carcinoma of the skin.",cycle 1 (28 days),phase 1b
31924737,NCT01916447,Combination,No,Advanced Gastrointestinal Tumors,"Patients with histologically confirmed advanced gastrointestinal tumors (malignancy of gastrointestinal origin or an adenocarcinoma of unknown primary, likely to be of gastrointestinal origin) were eligible for enrollment in the dose-escalation phase. Eligibility for the triplet combination in the expansion phase was restricted to those with histologically confirmed mCRC. Patients aged >= 18 years with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at baseline who were refractory to at least one line of chemotherapy for metastatic disease and had no curative treatment options were enrolled. ","Key exclusion criteria included recent major surgery or extended-field radiotherapy (within 4 weeks prior to starting therapy), recent anticancer therapy (within 3 weeks prior to initiating therapy), any unresolved grade >= 1 toxicities from prior therapies, partial or total gastrectomy, a serious illness or medical condition that precluded safe participation, or active central nervous system metastases.",cycles 1 or 2 (14 days circle),NA
31375879,NCT02354131,Combination,No,platinum‑sensitive epithelial ovarian cancer,"Eligible patients had recurrent platinum-sensitive epithelial ovarian cancer with high-grade serous or high-grade endometrioid histology. Other histologic types were allowed providing there was evidence of a BRCA mutation. Platinum sensitivity was defined as the absence of progression or recurrence within 6 months of the last dose of platinumbased chemotherapy. Patients must have received platinumcontaining therapy for primary disease. There was no upper limit to the number of prior platinum-based therapies, but only one non-platinum-based line of therapy for recurrent disease was permitted.",Not available,the first 21 days,NA
31194228,NCT02657889,Combination,Yes,Patients With Recurrent Platinum-Resistant Ovarian Carcinoma or metastatic triple-negative breast cancer,"Patient is male or female, at least 18 years of age. not OC. Male patients are only for TNBC and 2. Patient has histologically proven advanced (unresectable) or metastatic cancer as outlined below according to study phase and disease type: a. Phase 1 patients (breast or ovarian cancer) Patients with advanced or metastatic breast cancer must have disease that is HER2-negative, estrogen receptor-negative, and progesterone receptornegative (ie, TNBC). Patients with disease recurrence or progression following neoadjuvant or adjuvant therapy are eligible. Patients with advanced or metastatic disease may have up to 4 lines of cytotoxic therapy. Neoadjuvant and adjuvant therapies are not counted towards lines of therapy. Targeted small molecules (eg, tyrosine kinase inhibitors), hormonal agents and monoclonal antibodies that inhibit angiogenesis (eg, bevacizumab, afilbercept) are not counted in the number of lines of therapy. Patients must have any epithelial (ie , serous, endometroid, mucinous, clear cell) ovarian, fallopian tube, or primary peritoneal cancer. Patients must have experienced a response lasting at least 6 months to first-line platinum-based therapy but currently considered to have platinum-resistant disease per investigator’s assessment (e.g, patient is not eligible for further platinum containing treatment). Patients may have received up to 5 lines of cytotoxic therapy for advanced or metastatic cancer. Neoadjuvant and adjuvant therapies are not counted towards lines of therapy. Treatment with small molecules (eg tyrosine kinase inhibitors), hormonal agents and monoclonal antibodies that inhibit angiogenesis (eg, bevacizumab, aflibercept) are not counted in the number of lines of therapy.  Patient has archival tumor tissue available that is formalin-fixed and paraffinembedded.  a. For patients who do not have archival tissue, tissue from a fresh biopsy must be obtained prior to study treatment initiation.  b. Serial fresh tumor tissue samples will be collected in patients with lesions amenable for a biopsy who consent to such a procedure. 4. Patient has measurable lesions by RECIST v1.1. 5. Patient has an ECOG performance status of 0 to 1. 6. Patient has adequate organ function, defined as (Note: complete blood count [CBC] should be obtained without transfusion or receipt of colony stimulating factors weeks of obtaining sample): a. Absolute neutrophil count (ANC) ≥ 1500/μL b. Platelets ≥ 100,000/μL c. Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L d. Serum creatinine ≤ 1.5× upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min using Cockcrofttest before 2 Gault equation for patients with creatinine levels > 1.5× institutional ULN e. Total bilirubin ≤ 1.5× ULN OR direct bilirubin ≤ 1× ULN f. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× unless liver metastases are present, in which case they must be ≤ 5× ULN g. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5× ULN ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants h. Activated partial thromboplastin time (aPTT) ≤ 1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants 7. Patient is able to take oral medications. 8. Female patient has a negative serum pregnancy test within 72 hours prior to taking study medication if of childbearing potential, or agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment, or be of non-childbearing potential. Nonchildbearing potential is defined as (by other than medical reasons): a. ≥45 years of age and has not had menses for >1 year b. Amenorrheic for < 2 years without a hysterectomy and oophorectomy and a folliclestimulating hormone (FSH) value in the postmenopausal range upon pre-study (screening) evaluation c. Post hysterectomy, bilateral oophorectomy or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 120 days after the last dose of study therapy. See Section 5.7.2 of acceptable birth control methods. for a list Information must be captured appropriately within the site's source documents. Note: Abstinence is acceptable if this is the established and for the patient. preferred contraception 9. Male patient agrees to use an adequate method of contraception (please see Section 5.7.2 for a list of accep table birth control methods) starting with the first dose of study therapy through 120 days after the last dose of study therapy.Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.   10. Patient agrees to blood samples during screening and at the end of treatment for cytogenetic analysis. ","1. Patients with primary platinum refractory ovarian cancer (ie, progressive disease on or within 6 months of first-line platinum therapy) are not eligible in Phase 1 or Phase 2 this study.  2. Patient has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.   of Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes from study participation regardless of clinical stability. 3. a patient Patient has a known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer. 4. Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active infection that requires systemic therapy. Specific examples include, but are not limited to, history of (non-infectious) pneumonitis that required steroids or current pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere w ith cooperation with the requirements of the study (including obtaining informed consent).  5. Patient has a condition (such as transfusion dependent anemia or thrombocytopenia) therapy, or laboratory abnormality that might confound the study results, or int , erfere with the patient’s participation for the full duration of the study treatment. Patients who received colony-stimulating factors (eg, granulocyte colony stimulating factor [GCSF], granulocyte macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 2 weeks prior to the first dose of study treatment are not eligible. 6. Patient is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through 12 0 days after the last dose of study treatment. 7. Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.  8. Patient has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies). 9. Patient has known active hepatitis B (eg, hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid [HCV RNA] [qualitative] is detected). 10. Patient has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, the thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 11. Patient has not recovered (ie, to ≤Grade 1 or to baseline) from cytotoxic therapyinduced AEs. Note: Patient with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia is this criterion and may qualify for the study. 12. an exception to Patient is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.  13. Patient has had a prior cytotoxic therapy, anticancer targeted small molecules (eg, tyrosine kinase inhibitors), hormonal agents within 5 half-lives, or monoclonal antibodies (mAb) within 5 half-lives or 4 weeks (whichever is sh orter) of that treatment prior to study Day 1 or radiation therapy encompassing > 20% of the bone marrow within 2 weeks or any radiation therapy within 1 week prior to study Day 1. 14. Patient has not recovered adequately from AEs surgery prior to starting therapy. and/or complications from any major 15. Patient has received prior therapy with an anti-programmed death-1 (anti-PD-1), PD-1-ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD-L2) antiagent or the patient has previously participated in Merck MK-3475 (pembrolizumab) clinical studies. 16. Patient has received a live vaccine within 30 days of planned start of study therapy. 17. Patient has undergone prior treatment with a known poly(ADP-ribose) polymerase (PARP) inhibitor. 18. Patient has a heart-rate corrected QT interval (QTc) prolongation > 470 msec at screening. Note: If a patient has a prolonged QT interval and the prolongation is deemed to be due to a pacemaker upon Investigator evalu ation (ie, the patient otherwise has no cardiac abnormalities), the patient may be eligible to participate in the study following discussion with the Medical Monitor. 19. Patient has a known hypersensitivity to niraparib or pembrolizumab components or excipients. 20. Known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).",cycle 1 (21 days),NA
30302599,NCT01047293,Combination,No,first–line treatment of metastatic colorectal cancer,"Eligible patients were ≥ 18 years old with histologically or cytologically confirmed and previously untreated metastatic colorectal cancer (mCRC). Patients were allowed to have received cytotoxic chemotherapy in the adjuvant setting for non-metastatic colorectal cancer. Patients were required to have ECOG performance status of 0 or 1, adequate bone marrow function (absolute neutrophil count ≥1500/mm3,hemoglobin ≥9 mg/dL, platelets ≥100,000/μl), adequate hepatic function (AST and ALT ≤2.5 x upper limit of normal, unless there were liver metastasis in which case AST and ALT ≤5.0 * ULN, serum bilirubin <1.5* ULN), adequate renal function (serum creatinine ≤1.5 x ULN or calculated creatinine of ≥50 mL/min), and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).",NA,the first 28 days,NA
30185228,NCT00960960,Combination,No,locally recurrent or metastatic adenocarcinoma of the breast,"Eligible patients were ≥ 18 years with histologically or cytologically confirmed locally recurrent or metastatic adenocarcinoma of the breast. Inclusion criteria specified that patients had HER2-negative tumors, unless in the cohort that received trastuzumab, where all patients were required to have HER2-positive tumors and an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. Patients who received letrozole were postmenopausal and required to have hormone receptor-positive disease. Adequate hematologic and end-organ function was required, in addition to disease measurable by Response Evaluation Criteria In Solid Tumors (RECIST) v1.0. Patients were eligible for enrollment in the pictilisib + letrozole arm part 3) if they were currently receiving letrozole for the treatment of advanced or metastatic breast cancer.","Patients who had received more than two prior chemotherapy regimens for locally recurrent or metastatic breast cancer were not eligible for inclusion in the arms that received pictilisib + paclitaxel ± bevacizumab or trastuzumab treatment (parts 1 and 2). Patients were eligible for enrollment in the pictilisib + letrozole arm part 3) if they were currently receiving letrozole for the treatment of advanced or metastatic breast cancer, but they were excluded if they had received more than one prior chemotherapy regimen or more than two prior endocrine therapy regimens for locally recurrent or metastatic breast cancer. Patients with known hypersensitivity to paclitaxel were excluded. Patients were not eligible for bevacizumab treatment if they had inadequately controlled hypertension, significant vascular disease within 6 months prior to the first dose of study treatment, history of hemoptysis within 1 month prior to the first dose of study treatment, or evidence of bleeding diathesis or significant coagulopathy. Patients were not eligible for trastuzumab treatment if they had a history of grade ≥ 3 hypersensitivity to the antibody, or grade ≥ 1 with the most recent trastuzumab infusion before study entry, or continued requirement for prolonged trastuzumab infusions (> 30 minutes) to prevent infusion-related reactions. Patients with a history of exposure to anthracyclines (cumulative doses > 500 mg doxorubicin, > 900 mg liposomal doxorubicin, > 900 mg epirubicin, > 120 mg mitoxantrone, and > 90 mg idarubicin; if another anthracycline or more than one anthracycline was used, the cumulative dose could not exceed the equivalent of 500 mg doxorubicin) and cardiopulmonary dysfunction were also excluded.",the first dose of pictilisib and including evaluations prior to dosing on day 1 of cycle 2,NA
30603797,NCT02835833,Combination,No,"an advanced tumor for which bevacizumab has an indication (renal cell carcinoma, colorectal adenocarcinoma, non-squamous non-small cell lung cancer, platinum-refractory ovarian carcinoma, and cervical carcinoma)","Adult patients (≥ 18 years of age) with a histologically confirmed diagnosis of an advanced tumor for which bevacizumab has an indication (renal cell carcinoma, colorectal adenocarcinoma, non-squamous non-small cell lung cancer, platinum-refractory ovarian carcinoma, and cervical carcinoma) were eligible. Eligible patients had: (1) progressed on at least one line of standard systemic therapy; (2) Eastern Cooperative Oncology Group (ECOG) performance status of 0–1; (3) adequate organ function as defined by adequate organ function as defined by normal serum bilirubin, AST/ALT ≤ 2.5× upper limit of normal (ULN), serum creatinine < 1.5× ULN, absolute neutrophil count (ANC) > 1500, platelets > 100 k and hemoglobin > 9.0 without transfusion support in the past 28 days, urinalysis ≤ 1 + protein and (4) no contra-indications to antiangiogenic therapy.","Patients were ineligible if they had: (1) previously experienced serious toxicities while on bevacizumab therapy; and (2) hypersensitivity to nintedanib. Patients with a history of prior brain metastasis were eligible provided the lesions were fully treated, asymptomatic, and stable as evidenced by repeat MRI brain imaging within 2 weeks prior to starting study treatment. Patients were also excluded if they: (1) required therapeutic anti-coagulation; (2) had a history of clinically significant hemorrhagic or thromboembolic event(s) in the past 6 months and/or surgery within the past 4 weeks, prior to start of study treatment; (3) had significant cerebrovascular and cardiovascular events within the past 6 months; (4) had proteinuria of ≥ grade 2; and (5) had pulmonary hemorrhage or hemoptysis within 6 months of starting study treatment.",during the first cycle,NA
29695765,NCT01113476,Combination,No,"advsnced cancer;The most common tumour types enrolled were ovarian (n = 21), pancreatic (n = 19), sarcoma (n = 10), urothelial (n = 7), gastroesophageal junction (n = 7), gastric (n = 5), and small cell lung cancer (n = 4).","Eligible patients had disease that had progressed despite standard therapy or for whom no available therapy would likely increase survival by at least 3 months. Patients were required to be off systemic therapy for at least 4 weeks (or for the time of 5 half-lives, in the case of biologic or targeted agents). Other inclusion criteria included an Eastern Cooperative Oncology Group performance status of 0–2, absolute neutrophil count ≥1000/μl, platelet count ≥50,000/μl, total bilirubin level ≤3 mg/dl, alanine aminotransferase level <5 times the institutional upper limit of normal, creatinine level <3 times the institutional upper limit of normal, and the use of contraception during the study.","Patients were excluded if they had a history of myocardial infarction within 6 months prior to starting the treatment, were pregnant or breastfeeding, had uncontrolled hypertension (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg on medication), had any unhealed wounds, and/or had undergone a major surgical procedure and/or had clinically significant, unexplained bleeding within 28 days prior to starting the treatment. Patients with any prior hypersensitivity reaction to bevacizumab, gemcitabine, paclitaxel, and/or nab-paclitaxel were also excluded. Patients were allowed to receive palliative radiation therapy but not allowed to use other standard or investigational anti-cancer agents during the study period.",the first 28 days,NA
29290249,UMIN000015944,Combination,No,chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations,"Those patients who met the following criteria were eligible: histologically or cytologically confirmed stage IIIB/IV or postoperative recurrent non-squamous NSCLC with activating EGFR mutations (either exon 19 deletion or Leu858Arg), age ≥20 years, Eastern Cooperative Oncology Group performance status of 0 or 1, adequate organ function, and life expectancy of 3 months or more.  Tumor samples were screened by PCR-based hypersensitive EGFR mutation testing in local laboratories, according to standard testing practices. ","Those who received previous EGFR-TKI therapy or radiation therapy for lung tumors were excluded. Major exclusion criteria included confirmation of the Thr790Met mutation, presence of symptomatic brain metastasis or leptomeningeal carcinomatosis, history or presence of hemoptysis, bloody sputum or a coagulation disorder, tumor invading or abutting major blood vessels, tumor cavitation, or coexisting or previous interstitial lung disease.",first 28 days from initiation of the combination therapy,NA
29264836,NA,Combination,No,recurrent malignant gliomas,"Adult subjects aged 18 and older were eligible if they had a histologically confirmed diagnosis of HGG with radiographic evidence of recurrence or disease progression (defined as either a > 25% increase in the largest bi-dimensional product of enhancement or a new enhancing lesion) following prior therapy. In Phase I, subjects could have had either World Health Organization (WHO) Grade 3 or 4 malignant glioma. Other key eligibility criteria included a KPS of 70% or greater; adequate hematologic, renal, and liver function and subjects must have signed the informed consent approved by the Duke Institutional Review Board (IRB).","Subjects were excluded from both phases of the study if they had received prior therapy with histone deacetylase inhibitors (including valproic acid), but prior BEV was allowed as long as there was no history of progression while taking BEV. Moreover, prior 5-day regimen TMZ was allowed, but subjects receiving prior daily metronomic TMZ were excluded from participation.",during cycle 1,NA
28810837,NCT01202032,Combination,No,metastatic renal cell carcinoma or other advanced tumors (inclduing melanoma; pancreatic cancer; head and neck and cervix cancer,"Adult patients with histologically confirmed diagnosis of solid tumor excluding squamous non-small-cell lung cancer because of an increased bleeding risk, and refractory to a maximum of two lines of standard treatments, or without prior treatment for renal cell carcinoma were eligible. Additional inclusion criteria were Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 or 1, adequate vital functions defined as absolute neutrophil count ≥1500 cells/μL, hemoglobin ≥9.0 g/dL, and platelets ≥100,000 cells/μL, PT ≤1.2*upper limit of normal [ULN] and APTT ≤1.2*ULN, hepatic aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤2.5*ULN, total bilirubin ≤1.5*ULN, and serum creatinine ≤1.5 mg/dL or creatinine clearance ≥50 mL/min. ","Patients with insufficiently controlled blood pressure, increased proteinuria (>1.0 g/L), history of acute cardiac event, coronary disease or stroke in the previous 6 months, or corrected QT (QTc) interval prolongation (>480 ms using Bazett’s formula), and patients with history of brain metastases were excluded.",first 8 weeks,NA
29101518,UMIN000012536,Combination,No,chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations,"The inclusion criteria were as follows: (1) histologically or cytologically confirmed non-SQ NSCLC; (2) activating EGFR mutations (exon 19 deletion or point mutations, such as L858R); (3) clinical stage IIIB or IV, or postoperative recurrent disease; (4) lesions not amenable to curative radiotherapy; (5) no prior chemotherapy; (6) age 20 years or older; (7) Eastern Cooperative Oncology Group performance status (PS) of 0 or 1; (8) measurable disease as per the Response Evaluated Criteria in Solid Tumors (RECIST, version 1.1); (9) adequate organ function, as indicated by: peripheral capillary oxygen saturation (SpO2) ≥90%, hemoglobin ≥9.0 g/ dL, white blood cell count ≥4000/mm3, neutrophil count ≥1500/mm3,plateletcount≥100,000/mm3, aspartate aminotransferase (AST)/alanine transaminase (ALT) ≤2.5 times the upper limit of normal, total bilirubin ≤1.5 mg/dL, serum creatinine ≤1.2 mg/dL, and predicted or 24-h creatinine clearance ≥60 mL/min, as estimated by the Cockcroft–Gault formula; and (10) a life expectancy of at least 3 months.","Exclusion criteria were history of gross hemoptysis (>2.5 mL), history of coagulation disorders or therapeutic anticoagulation, medically uncontrolled hypertension, pregnancy or lactation, clinically significant cardiovascular disease, radiation therapy outside the chest field within 2 weeks or inside the chest field within 12 weeks before enrollment, and major surgery within 4 weeks before enrollment.",cycle 1,21 day circle
28760399,UMIN000012883,Combination,Yes,patients with metastatic colorectal cancer refractory to standard therapies,"patients aged 20 years or older; had histologically confirmed unresectable, metastatic colorectal adenocarcinoma; had a treatment history of one or more regimens of standard chemotherapy; and were refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF therapy, and anti-EGFR therapy (for tumours with wild-type KRAS). A patient was deemed refractory to a chemotherapy if they had confirmed tumour progression based on imaging during or within 3 months after the last administration of the chemotherapy in a metastatic setting. Refractoriness could also apply to an adjuvant chemotherapy if a tumour had recurred within 6 months after the last administration; and intolerance to a chemotherapy was defined as the patient having experienced clinically significant adverse events from chemotherapy that precluded the re-administration of that same chemotherapy. Eligible patients had no previous treatment with regorafenib, were able to take oral drugs, had measurable or non-measurable lesions, based on the Response Evaluation Criteria In Solid Tumors (RECIST version 1.1), and had Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Adequate bone marrow, hepatic, and renal functions were required by blood testing within the 7 days before enrolment, and patients who had thromboembolic events within the 6 months before enrolment were excluded.","Patients could not have any of the following serious comorbidities: existing uncontrolled hypertension or diabetes; an unhealed wound or traumatic fracture; thromboembolism and a history or complication of severe lung disease within the past 6 months; tendency of haemorrhage and undergoing treatment with an antithrombotic drug (including a daily dose of 325 mg or more of oral aspirin); serious renal dysfunction including urine test with +2 protein or higher within the 7 days before enrollment; and heart disease within the past 12 months. Patients who had received the following treatments were not eligible: extensive surgery during the 4 weeks before enrolment; anticancer therapies during the 3 weeks before enrolment; extensive exposure to radiation during the 4 weeks before enrolment, or limited exposure during the 2 weeks before enrolment; any investigational drugs administered during the 4 weeks before enrolment; blood transfusions or haemopoetic factors within the 14 days before enrolment; and any previous treatment with TAS-102, which could include participation in placebo-controlled studies such as J003-10040030 or RECOURSE trials if patients had not been assigned to the placebo arm. Eligible patients could not have active infections, require immunosuppressive treatment due to an autoimmune disorder or history of organ transplantation, or have unresolved adverse events of grade 2 or higher (classified with the National Cancer Institute Common Terminology Criteria for Adverse Events [CTCAE] version 4.03) from previous treatment. The study was done in accordance with the Declaration of Helsinki and the Japanese Good Clinical Practice guidelines.",cycle 1,NA
28391576,NCT01660360,Single Drug,No,Rectal cancer;Colon cancer; Head and neck squamous cell carcinoma; Gastric cancer ;Non-small cell lung cancer; Esophageal cancer; Adenoid cystic carcinoma ; Malignant fibrous histiocytoma,"Eligibility criteria for study entry were as follows: histologically confirmed, advanced cancers that failed to respond to at least one prior regimen or for which there is no standard therapy; evaluable disease (measurable or non-measurable based on RECIST criteria v 1.1); age > 20 years; ECOG (Eastern Cooperative Oncology Group) performance status 0–2; life expectancy of greater than 12 weeks; hemoglobin ≥9.0 g/dL, absolute neutrophil count ≥1500/μL, platelets ≥100,000/μL, total bilirubin ≤1.5 times the upper limit of normal, AST/ALT ≤2.5 times the upper limit of normal, serum creatinine ≤1.5 mg/dL, PT-INR ≤1.3 times the upper limit of normal, aPTT ≤1.5 times the upper limit of normal and Bazett’scorrection QTc < 450 msec in ECG. ","Patients were excluded from the study if they had undergone radiotherapy, last chemotherapy, or major surgery within the 4 weeks prior to entering the study, had pleural effusion, ascites or leptomeningeal disease as the only manifestation of the current malignancy, had uncontrolled intercurrent illness, active serious infection, the presence of gastrointestinal perforation, tracheoesophageal fistula, grade IV proteinuria, arterial thromboembolic events, hypersensitivity to CHO cell products or other recombined human or humanized antibodies.",during the first cycle of therapy,NA
27943153,NCT00867321,Combination,No,Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma,"Patients ≥ 18 years of age with locally advanced or metastatic HCC not candidates for surgery or liver transplant were eligible for enrollment. Inclusion criteria for the trial included: no prior systemic chemotherapy or external beam radiation therapy for HCC, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, measurable disease, total bilirubin ≤ 1.5 x upper limit of normal (ULN), AST ≤ 5x ULN, alkaline phosphatase ≤ 5 x ULN, and adequate bone marrow and renal function. Patients with Child Pugh A or B7 liver disease were allowed in the study. Patients must have had ≥ 3 months life expectancy to participate in the trial.","Patients who had chemoembolization, radioembolization, radiofrequency ablation (RFA), or other local ablative therapies < 6 weeks prior to registration were excluded. Patients who had treatment of known or clinically suspected esophageal varices ≤6 months prior to registration were not eligible. Patients with bleeding diathesis or on chronic anticoagulation were ineligible. Patients with brain metastases, uncontrolled hypertension (defined as systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg), class III or IV congestive heart failure, ventricular arrhythmia or arterial thrombotic event in the previous 6 months, non-healing wound, major surgery or trauma within 4 weeks, and any other illness which the investigator felt would make the patient inappropriate for study entry were excluded.",the first 28-day cycle,NA
27765756,132071,Combination,No,patients with advanced non-small-cell lung cancer,"Patients who met the following criteria were eligible: had histologically or cytologically confirmed NSCLC; had chemotherapy-naïve NSCLC for arm A, chemotherapy-naïve non-squamous NSCLC for arm B and C, one prior chemotherapy including platinum-doublet or two prior chemotherapies including platinum-doublet, and an EGFR or ALK tyrosine kinase inhibitor for arm D; had stage IIIB without indication for definitive thoracic radiotherapy, stage IV, or recurrent NSCLC; age ≥20 years; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; had measurable lesions as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; had adequate hematological, hepatic, and renal function. ","Patients who had a history of infusion reaction with other antibody therapies, history of interstitial lung disease (ILD) or pulmonary fibrosis, coexisting autoimmune disease, who were receiving systemic corticosteroids or immune suppressants, who had symptomatic central nerve system metastasis were excluded.",the first treatment cycle,phase 1b
27872953,NA,Combination,No,NSCLC; esophageal cancer;Ovarian; Biliary tree; Cervical; Kidney; bladder; breast,"Eligible patients were aged ≥18 years with advanced, recurrent or metastatic solid malignancies. Patients were also required to have adequate organ function, Eastern Cooperative Oncology Group performance status of 0 or 1, and life expectancy of at least 3 months. ","Exclusion criteria included gastrointestinal dysfunction that could impair oral absorption; significant cardiovascular disease, use of full-dose anticoagulation medication; persistent grade ≥2 (Common Terminology Criteria for Adverse Events [CTCAE] version 3.0) neurotoxicity or neuropathy; treatment with chemotherapy, immunotherapy, radiotherapy, hormone therapy, EGFR- or HER2-targeting drugs or other investigational agents within 4 weeks prior to start of therapy; known preexisting interstitial lung disease; active infectious disease; untreated or symptomatic brain metastases; intra-abdominal inflammation or major surgery within 4 weeks of treatment start. Patients with conditions contraindicating the use of bevacizumab (significant hypertension or hemoptysis, thrombotic or hemorrhagic disorders, international normalized ratio ≥1.5 or squamous NSCLC) were excluded.",the first 4 weeks of treatment,NA
27507617,NCT01183494,Combination,No,mCRC with UGT *1/*1 and *1/*28,"Patients with histologically or cytologically confirmed diagnosis of mCRC were enrolled. Eligibility criteria included UGT1A1 *1/*1 and *1/*28 genotypes, no prior chemotherapy for metastatic disease, age >=18 years, absolute neutrophil count (ANC) >=1,500/ mL, platelets >=100,000/uL, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, creatinine clearance <1.58 the upper limit of normal (ULN), ALT and AST <2.5* the ULN (< 5* the ULN in the presence of liver metastases), and total serum bilirubin <1.6 mg/dL. ","Patients with the UGT1A1 *28/*28 genotype or carriers of other UGT1A1 alleles [86, *36 (TA5), *37 (TA8)] were not eligible.",NA,"Before starting irinotecan, patients were pretreated with atropine 0.5 mg, dexamethasone 20 mg, and ondansetron 8 mg (all given intravenously).28 days cycle"
27457310,NA,Combination,No,metastatic renal cell carcinoma,"Eligible patients 18 years and older and with ECOG performance status 0 or 1 had histologically confirmed metastatic or locally advanced unresectable RCC. Tumors needed to be measurable by the Response Evaluation Criteria in Solid Tumors guidelines (RECIST) v1.1 with disease sites assessed within 4 weeks of study entry. No prior bevacizumab or topoisomerase-1 inhibitor was allowed and patients must have received at least one prior conventional therapy (defined as pazopanib, sorafenib, sunitinib, temsirolimus, axitinib, or everolimus) in a non-adjuvant setting. A 2-week washout period was required between the last dose of prior therapy and baseline correlative studies (including bone marrow biopsy as applicable) and toxicities from prior therapy must have declined to ≤grade 1 before initiation of study therapy. Prior treatment with surgery, radiation, conventional chemotherapy, or cytokine therapy was allowed. Patients with treated brain or spinalassociated metastases were eligible but must have had their disease controlled, off steroids, and be neurologically stable.",No prior bevacizumab or topoisomerase-1 inhibitor was allowed,NA,NA
27085994,NCT01183663,Combination,No,colorectal carcinoma; melanoma; and other advance tumor.,"Patients with histologically confirmed advanced or metastatic cancer that was refractory to standard therapy, had recurred after standard therapy, or for which there was no standard therapy available were eligible for the protocol. Participants had to have completed their previous anticancer therapy (cytotoxic chemotherapy, major surgery, or radiation therapy) ≥3 weeks prior to study entry (or ≥5 half-lives prior, if they had received targeted or biologic therapy). Participants were also required to have an Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and adequate renal (creatinine clearance ≥50 mL/ min by Cockcroft-Gault formula), hepatic (total bilirubin <2.0 mg/dL or alanine aminotransferase ≤5 × upper normal reference value), and bone marrow (absolute neutrophil count ≥1000 cells/μL and platelet count ≥100,000 cells/ μL) function. Female patients of childbearing potential were eligible if they had a negative urine or human chorionic gonadotropin serum test and agreed to use effective contraception throughout study participation.","Patients were ineligible if they were pregnant or breastfeeding or had any of the following conditions: serious uncontrolled medical illness, psychiatric illness that limited their capacity to sign the consent documents, uncontrolled hypertension (systolic blood pressure >140 mm Hg and diastolic blood pressure >90 mm Hg on medication), history of deep vein thrombosis or pulmonary embolism, significant cardiovascular disease (history of myocardial infarction or history of cerebrovascular accident or unstable angina pectoris within the past 6 months), or known hypersensitivity to thalidomide.",during the first cycle,NA
27198170,NCT01283048,Combination,No,Metastatic Renal Cell Carcinoma Progressing on Vascular Endothelial Growth Factor-Targeted Therapies,"Patients with mRCC with a clear cell component or papillary or chromophobe histologies were eligible. Participants must have received at least 1 prior anti-VEGF systemic therapy for mRCC (excluding bevacizumab and a PI3K inhibitor). Prior treatment with everolimus or temsirolimus was allowed. Other eligibility criteria included age >= 18 years; an Eastern Cooperative Oncology Group performance status <= 2; absolute neutrophil count >= 1.5 * 10^9/L; platelet count >= 100 * 10^9/L; hemoglobin >= 9 g/dL; serum creatinine <= 1.5 the upper limit of normal (ULN); fasting glucose <= 120 mg/dL or hemoglobin A1c <= 6.7%; a urine protein/creatinine ratio <1.5 or 1 + protein on urinalysis; and amylase, lipase, aspartate aminotransferase (AST) (or <= 3 times the ULN if liver metastases were present), alanine aminotransferase (ALT) (or <= 3 times the ULN if liver metastases were present), bilirubin (or <= 1.5 times the ULN if liver metastases were present), calcium (corrected for serum albumin), potassium, and magnesium within the institutional normal range. ","Patients with untreated brain metastases, active liver disease, active pancreatic disease including poorly controlled diabetes, cardiac disease, and poorly controlled hypertension (defined as a systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) were excluded. Patients with Common Terminology Criteria for Adverse Events (version 4.0) anxiety or active psychiatric illness were excluded unless disease was stable without modifications to medical therapy within 6 weeks of therapy initiation.",NA,NA
26933802,NA,Combination,No,advanced cancer(HNSCC;Chondrosarcoma;Adenocarcinoma of the tongue;Colorectal;Squamous cell carcinoma head & neck;Melanoma ;Chondrosarcoma ; Cholangiocarcinoma ;Mesothelioma ; Cervical adenoma ; Adenocarcinoma of tongue ;Adenocarcinoma of Gastroesophageal Junction ;Gastric adenocarcinoma; Adnexal carcinoma;Urethral carcinoma),"Key inclusion criteria were histologicallydocumented, advanced or metastatic solid tumors refractory to standard treatment or for which no standard therapy was available; Eastern Cooperative Oncology Group (ECOG) performance status ≤ two; absolute neutrophil count ≥ 1 x 10^9/L; platelet count ≥ 50.0 x 10^9/L; serum creatinine < 3.0 mg/dL, aspartate transferase (AST), alanine transferase (ALT) ≤ five times the upper limit of normal (ULN); bilirubin ≤ 3.0 mg/dL, total fasting cholesterol ≤ 350 mg/dL; and triglyceride ≤ 400 mg/dL. Patients with prior exposure to bevacizumab, cetuximab or mTOR inhibitors were not excluded from the study, nor were patients with a history of venous thromboembolism excluded.","Key exclusion criteria were clinically significant, unexplained bleeding or hemoptysis within 28 days prior to study entry; poorly controlled hypertension (systolic blood pressure > 140 mm Hg, diastolic pressure > 90 mm Hg on medication); patients with clinically significant cardiovascular disease; KRAS mutated colorectal cancer patients; history of hypersensitivity to any of the three drugs; patients who had major surgery within 6 weeks of enrollment in the study; and pregnancy. ",first cycle(28 days),NA
26581401,NA,Combination,No,advanced gastrointestinal malignancies:mCRC; metastatic esophageal adenocarcinoma; metastatic gall bladder adenocarcinoma,"Patients ≥18 years of age with metastatic and/or unresectable gastrointestinal malignancies who were candidates for irinotecan-based therapy were eligible for this study. Patients must have met the following criteria: ECOG Performance Status (PS) 0 or 1, able to provide informed consent, willing to return to Mayo Clinic for follow up, life expectancy ≥84 days (3 months), and women of child bearing potential must have had a negative pregnancy test ≤7 days prior to registration. Measurable disease was required. Patients who had received irinotecan previously were allowed if the treating physician felt further treatment with irinotecan-based therapy was appropriate.   ","Prior treatment with sorafenib was not allowed. Patients with inadequately controlled hypertension, recent cardiovascular or thrombotic events, bleeding diathesis, brain metastasis, history of abdominal fistula, recent gastrointestinal perforation or intra-abdominal abscess, and other active malignancies were excluded. Patients could not have received chemotherapy ≤14 days prior to registration, immunotherapy ≤28 days prior to registration, radiation therapy ≤28 days prior to registration, or radiation to >25 % of bone marrow. Patients who had not fully recovered from reversible effects of prior chemotherapy were ineligible. Women who are pregnant or nursing and persons of childbearing potential who are unwilling to employ adequate contraception were not allowed on the study.",a minimum of 28 days (two full cycles),14-day cycle
26272806,NCT00904839,Combination,No,first-line metastatic colorectal cancer patients,"Age ≥18 years; Histologically proven colorectal adenocarcinoma; Metastatic disease, not amenable to potentially curative treatment; At least 1 measurable lesion (according to RECIST criteria); No previous oxaliplatin based chemotherapy unless disease-free survival after the end of chemotherapy was ≥12 months; No previous adjuvant therapy with fluoropyrimidines unless disease-free survival after the end of chemotherapy was >6 months; ECOG performance status ≤2; Adequate hepatic, renal, and bone marrow functions: Total bilirubin normal; ALT and AST ≤2 x the upper limit of the normal range (ULN). If there was liver metastasis: total bilirubin ≤1.5 x ULN, ALT and AST ≤3 x ULN, Serum creatinine ≤1.5 x ULN International normalised ratio <2.5 x ULN, Absolute neutrophil count ≥1.5 x 10^9/L, Platelets ≥100 x 109/L","History of other malignancies in the last 5 years; Serious concomitant disease affecting compliance with trial requirements or which were considered relevant for the evaluation of the efficacy or safety of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract or skin); Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within the past 6 months, congestive heart failure greater than New York Heart Association stage II); History of severe haemorrhagic or thromboembolic event in the past 12 months; Symptomatic brain metastases or brain metastases requiring therapy",first two cycles,NA
25990659,NA,Combination,No,advanced cancers metastatic to the liver:CRC and others.,"Patients enrolled in this trial had histologically confirmed metastatic advanced cancers with liver involvement that were refractory to standard therapy or for which no available standard therapy improved survival by at least 3 months. Inclusion criteria included adequate renal (serum creatinine≤ 2.5 times the upper limit of normal [ULN]), liver (total bilirubin≤3mg/dLandALT≤5X ULN), and bone marrow (absolute neutrophil count≥1000 cells/μL and platelet count≥100, 000 cells/μL) function. Additionally, patients had been off previous chemotherapy or radiotherapy for at least 3 weeks.",Exclusion criteria included pregnancy or lactation; abdominal fistula; gastrointestinal perforation or intra-abdominal abscess within 28 days; invasive procedures including major surgical procedures within 28 days or anticipation of need for such procedures during the study; bleeding diathesis; active gastric or duodenal ulcer; hypersensitivity to any drug in the regimen; heparin-induced thrombocytopenia; or uncontrolled systemic vascular hypertension. Patients with colorectal cancer and KRAS mutation were excluded from the cetuximab arm.,first cycle,NA
25525888,NA,Combination,No,Breast cancer; Prostate cancer; Uterine cancer; Ovarian cancer; Head and neck squamous cell cancer; Oesophageal cancer; pancreatic cancer;Small cell lung cancer; Testicular cancer; Ureteral cancer; Melanoma; Non-small cell lung cancer;soft-tissue sarcoma ,"Key eligibility criteria included age ≥18 years; a diagnosis of advanced solid tumors refractory to standard treatment; measurable or evaluable (nonmeasurable) disease per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (v.1.0); an Eastern Cooperative Oncology Group (ECOG) performance status ≤2; and adequate hematological, renal, and hepatic function. ","Excluded were patients with a prior bleeding diathesis, gastrointestinal surgery or disease, thrombosis or pulmonary embolism or cardiovascular events during the past year; a diagnosis of ovarian cancer while receiving bevacizumab; a diagnosis of lung cancer with tumor lesions ≥3 cm; or chronic uncontrolled hypertension, chronic hepatitis, or symptomatic or untreated central nervous system metastases; a treatment history with angiopoietin or VEGF inhibitors or radiation therapy to the abdomen; recent treatment with anticancer or palliative radiation; or current treatment regimens containing strong CYP 3A inhibitors, immune modulators, St. John’s wort, or coumarin anticoagulants ≥2 mg/day. Because two patients with squamous cell head and neck cancer developed grade 5 hemorrhage, the protocol was amended to exclude patients with head and neck cancer or lung squamous cell tumors.",the initial 28 study days,NA
25363205,NA,Combination,No,advanced solid tumors:Ovarian/Fallopian Tube; Hepatocellular; Colorectal; Thyroid; Melanoma; Cholangiocarcinoma; bladder; renal cell; adrenocortical; breast; gallbladder,"Patients had metastatic or advanced cancer not amenable to standard therapy, an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, and adequate hematologic, hepatic, and renal function. ","Exclusion criteria included hemoptysis, unexplained bleeding, significant cardiovascular isease, intercurrent uncontrolled illness, significant gastrointestinal bleeding within 28 days, hemorrhagic brain metastases, prior abdominal surgery within 30 days, pregnancy, and a history of hypersensitivity to bevacizumab and/or sorafenib.",NA,NA
25080061,UMIN000006937,Combination,No,ocally advanced lower rectal cancer,"Histologically confirmed diagnosis of rectal cancer (adenocarcinoma); All of the following conditions satisfied on imaging studies within 4 weeks before enrollment: The site of the primary lesion is either the lower rectum (Rb) or anal canal (P), A diagnosis of resectable disease with a clinical stage of T2–T4, as well as N0–N3 lymph node metastasis, The lower tumor margin is located on the anal side of the peritoneal reflection; No hepatic metastasis, peritoneal metastasis, or distant metastasis; Age 20–75 years at the time of registration Performance status (PS) of 0–2 No severe disturbances of main organ functions (including bone marrow, heart, lung, and kidney); No severe disturbances of blood biochemistry (absolute white blood cell count [4,000/mm3, neutrophil count [2,000/mm3, platelets [100,000/mm3,Hb[9.0 g/dL, AST and ALT within 2.5 times the upper limit of normal for the institution, serum bilirubin level below 1.5 mg/dL, serum creatinine level below 1.5 mg/dL and BUN under 25 mg/dL), an estimated creatinine clearance of 60 mL/min or higher (calculated according to the Cockcroft–Gault formula); No previous treatment; Ability to ingest solid foods and drugs orally",NA,"within 1 week after the completion of chemo radiotherapy;DLT was considered to have occurred if S-1 was given on less than two-thirds of the days specified in the protocol (13 days or less), if oxaliplatin was not given on days 8, 15, and 22, or if radiotherapy was stopped five times or more.",NA
24875133,NA,Combination,No,advanced melanoma,"Patients eligible for this study were required to have pathologically confirmed, unresectable stage III or stage IV malignant melanoma. Prior therapy was limited to one prior cytotoxic regimen. Measurable disease as defined by RECIST 1.0 was required. Other key inclusion criteria included age > 18 years, ECOG performance status 0 or 1, and adequate organ and marrow function defined by absolute neutrophil count > 1500 μL, platelets > 100,000 μL, creatinine (serum) < 2.0 mg/dL, total bilirubin < 1.5 mg/dL, and AST/ALT < 2.5 × institutional upper limit of normal. ","Key exclusion criteria included active autoimmune disorders, previous treatment with adjuvant high-dose interferon, and known brain metastases.",NA,NA
24413064,ACTRN12610000924055,Combination,No,acute myeloid leukemia and high-risk myelodysplastic syndrome,"Eligible patients were previously untreated AML (X20% blasts) or poor-risk MDS patients (intermediate-2 or high risk as per the International Prognostic Scoring System (IPSS)), not suitable for intensive therapy as per the physician’s discretion. Patients were required to have Eastern Cooperative Oncology Group performance status <3, bilirubin <= 2 * the upper limit of normal (ULN), AST or ALT<= 3 *ULN, serum creatinine <= 1.5 * ULN, life expectancy of at least 3 months and no uncontrolled infection. ","Exclusion criteria included the presence of serious medical or psychiatric conditions, CNS leukemia, uncontrolled hepatitis B or C infection, HIV infection or other clinically significant medical co-morbidities.",cycle 1,NA
24138944,NCT00861874,Combination,No,relapsed/refractory AML,"Patients greater than or equal to 18 years of age with a diagnosis of AML according to World Health Organization criteria with refractory or relapsed leukemia were eligible for the study. Refractory AML was defined as failure to achieve CR after 2 cycles of induction chemotherapy or persistence of >40% marrow blasts after one cycle of chemotherapy induction, and relapsed AML was defined as any evidence of disease recurrence after achieving a documented first or greater complete remission, including relapse after allogeneic stem cell transplant >100 days post-stem cell infusion. Those with ECOG performance status <3 were allowed, and patients had to have acceptable renal and hepatic function (creatinine clearance ≥ 30 mL/min and bilirubin ≤ 2.0 mg/dL and transaminases ≤ to 2.5 times the upper limits of normal). Those who were post-allogeneic transplantation could not have active GHVD greater than grade 1 of skin, and if relapse had been treated with donor leukocyte infusions, at least 4 weeks had to have elapsed since the last infusion.",Acute promyelocytic leukemia was excluded. Patients could not have active systemic infection or be pregnant or breastfeeding.,cycle 1,"Hydroxyurea could be given before and during the first cycle for white cell count reduction to <30,000/L, but no other antileukemia therapies were allowed."
23798029,NCT01130662,Combination,No,Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia,"The study enrolled adult patients (age 18 or older) with relapsed/refractory AML and those patients 60 years or older with previously untreated AML who were not candidates for ntensive cytarabine/anthracycline-based induction therapy. Patients were required to have a total bilirubin of 1.5 mg/dl or less, creatinine 3 mg/dl or less, alanine aminotransferase/aspartate aminotransferase 1.5 or less times the upper limit of normal, a left ventricular ejection fraction of 50% or more, a baseline QTc less than 450 msec, and a Karnofsky Performance Status of 70 or more.",No other prior therapies were allowed within 30 days of starting study treatment.,cycle 1,"hydroxyurea was permitted before enrollment and for the first 7 days of treatment to maintain a WBC count lower than 50,000/ll."
23789936,NA,Single Drug,No,myelodysplastic syndromes,"Patients >=18 years of age with an Eastern Cooperative Oncology Group (ECOG) Performance Status <=2 and a diagnosis of MDS according to the World Health Organization (WHO) Criteria  with Low, Intermediate 1 or -2 or High Risk IPSS scores and with cytopenia of at least one lineage (absolute neutrophil count <1.8 * 10^9/l, platelet count <100 * 10^9/l or haemoglobin <100 g/l) were eligible for the trial. At least 4 weeks [only 2 weeks if an erythrocyte stimulating agent (ESA) was used] had to have elapsed from prior MDS treatment. Patients had to have failed to respond to or have an inadequate response to azacitidine, decitabine, lenalidomide, or to an ESA, or had to have failed to respond to, relapsed following, or opted not to undergo a HSCT. ","Key exclusion criteria included anaemia due to factors other than MDS, bone marrow cellularity <10%, any active malignancy within the past year, human immunodeficiency virus 1 (HIV-1) seropositivity, uncontrolled intercurrent illness, total bilirubin ≥25.6 mmol/l not related to haemolysis or Gilbert disease, aspartate aminotransferase/alanine transaminase ≥29 upper limit of normal (ULN), serum creatinine ≥1.5 * ULN, ascites, hyponatraemia, uncontrolled hypertension, new onset seizures, psychiatric illness/social situations that would limit the patient’s ability to tolerate and/or comply with study requirements, or concurrent treatment with an investigational agent or with chemotherapy, radiotherapy or immunotherapy. ",within 28 d of the first dose,"This phase I trial was conducted in three consecutive parts: In Part I, the bioavailability and tolerability of oral rigosertib administered as single weekly escalating doses in a fasting state were determined in three patients. In Part II, we determined the MTD of oral rigosertib administered in a fasting state twice a day for 14 consecutive days of each 21-d cycle using an adaptive design. In Part 3, an expansion cohort, comprising an additional 22 patients, was enrolled at the MTD dose level."
21901396,NA,Combination,No,advanced solid tumor malignancies.,"All patients were required to have a histologic diagnosis of a solid tumor malignancy that was either locally advanced and incurable or metastatic. All were required to have disease which had been previously treated and/or for which there was no acceptable standard treatment regimen. All were appropriate candidates for treatment, with an Eastern Cooperative Oncology Group (ECOG) performance status of ·2 at the time of the initiation of therapy, adequate endorgan function, no severe co-morbidity, and ability to provide informed consent.  All patients were required to sign an informed consent.",Patients were excluded if they were pregnant or lactating women; had a myocardial infarction or unstable angina within 6 months; had uncontrolled‘ clinically signiWcant dysrhythmia; had evidence of uncontrolled metastatic disease of the central nervous system; and had received either radiotherapy or surgery within 2 weeks.,first cycle,NA
21576646,NA,Single Drug,No,"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia","Eligible patients were >= 18 years, had an Eastern Cooperative Oncology Group performance status score of 0 to 2, and a diagnosis of MDSs, CMML, or AML according to WHO classification.6,7 For patients with AML, eligibility was limited to those for whom standard curative measures did not exist or were no longer effective. ","Exclusion criteria included a diagnosis of acute promyelocytic leukemia, previous treatment with hypomethylating agents within 4 weeks before cycle 1, and anticancer therapy within 21 days before the first dose of study drug, or less than full recovery from any significant toxic effects of prior treatments.",during the first oral azacitidine cycle (cycle 2),NA
21278245,NA,Combination,No,Advanced Solid Tumors and Non-Hodgkin's Lymphomas: Colorectal; NHL; Breast; Melanoma; Cholangiocarcinoma; NSCLC; Duodenal; Mesothelioma; Appendix; Uterine (adenocarcinoma and sarcoma); Stomach; Pancreas (mucinous cystic carcinoma and neuroendocrine); Fallopian tube; Thymus; Liver; Ovarian (Sertoli-Leyding cell); Parotid (Non–small-cell and adenoid cystic); Sweat gland adenocarcinoma; Lacrimal gland (adenoid cystic); Submandibolar gland (adenoid cystic); Nasal cavity (adenoid cystic); Oral cavity (adenoid cystic),"Patients were eligible if they had a histologically or cytologically documented advanced solid malignancy or NHL, refractory to standard therapy or for which no standard therapy existed. Other key eligibility criteria included: Eastern Cooperative Oncology Group performance status 0 to 2; adequate hematologic, hepatic, and renal functions [white blood cell count >= 3*10^9/L, absolute neutrophil count (ANC) >= 1.5 * 10^9/L, platelets >= 100 * 10^9/L, AST (aspartate aminotransferase)/ALT (alanine aminotransferase) <= 2.5 times upper limit of normal, bilirubin within normal limits, creatinine <= 150 mmol/L and creatinine clearance >= 60 mL/minute]; unlimited prior chemotherapy, radiotherapy or targeted agents with at least 3-week interval (6-week interval if prior nitrosoureas or mitomycin C) between study entry and any prior treatment; no valproic acid or other HDACi for at least 2 weeks before study entry; no prior decitabine; and no known brain metastases.",NA,the first cycle,NA
23172636,NCT00715793,Combination,No,metastatic melanoma,"The eligible patients had non-resectable stage IIIB/C or stage IV metastatic melanoma; either no prior therapy or have progressed despite prior therapies. Prior biological therapy was allowed, and one line of prior chemotherapy was allowed if it did not include TMZ or DTIC. Patients had to have an Eastern Cooperative Oncology Group performance status (ECOG PS) ≤2, adequate bone marrow, renal, and hepatic function. Patients with treated brain metastases were allowed if stable for >4 weeks or >2 weeks if treated with stereotactic radiosurgery.",NA,NA,NA
22033493,NCT00890929,Combination,No,elderly patients with acute myeloid leukemia,"All had World Health Organizationconfirmed diagnoses of AML other than acute promyelocytic leukemia, were X60 years, not eligible for or not interested in conventional therapies, and had not received lenalidomide or prior AML treatment. Patients had an Eastern Cooperative Oncology Group performance status of <=2, creatinine <=1.5 mg/dl, total bilirubin <=1.5 times the upper limit of normal and transaminase levels <=2.5 times the upper limit of normal. White blood cell count was required to be <=10 000 K/ul at the initiation of treatment, but use of hydroxyurea to attain this was permitted;","Patients were excluded for advanced hepatic tumors, active opportunistic infections or concomitant chemotherapy.","during the first cycle or for patients in the first cohort, during the zero or first cycle",NA
20456354,NA,Single Drug,No,patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma,"Patients with relapsed or refractory CLL by 1996 National Cancer Institute (NCI) Working Group Criteria or diffuse large B-cell, transformed, or mantle cell NHL by 1999 World Health Organization Criteria after at least one prior therapy were enrolled to OSU 0336 and OSU 0475, respectively. Patients with aggressive NHL eligible for autologous stem cell transplantation were not enrolled; however, prior stem cell transplantation was permitted. Eligibility requirements included age >= 18 years, Eastern Cooperative Oncology Group (ECOG) performance status 0–2, creatinine <= 176.8 lmol/l, total bilirubin £ 25.5 lmol/l, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.0 * the upper limit of normal. For NHL patients, an absolute neutrophil count (ANC) >= 1.5*10^9/l and a total platelet count >= 75*10^9/l were also required. There were no restrictions on pre-treatment ANC or platelet counts for patients with CLL. ","Patients with aggressive NHL eligible for autologous stem cell transplantation were not enrolled;Patients with active infections including human immunodeficiency virus (HIV), central nervous system involvement, uncontrolled medical conditions, or autoimmune haemolytic anaemia or idiopathic thrombocytopenia were not eligible.",first cycle,NA
14604977,NA,Single Drug,No,hematopoietic malignancies: AML; MDS; ALL; CML,"Patients entered in the study were required to have a diagnosis of AML, acute lymphocytic leukemia (ALL), MDS or myeloproliferative disease, or CML. All patients with CML or ALL had to have failed at least one prior regimen. Patients with AML and MDS were eligible if they had relapsed after induction chemotherapy, or if such therapy was felt to offer little potential benefit. Other eligibility criteria were adequate performance status (Eastern Cooperative Oncology Group 2 or better), and adequate cardiac (New York Heart Association Classes II-IV excluded) and hepatorenal functions (creatinine level, < 176.8 uM; bilirubin level, <34.2 uM; and hepatic enzymes less than twice the upper limit of normal). ",NA,NA,NA
10830142,NA,Combination,No,advanced solid tumors: NSCLC; Colorectal; Renal; Cervical; Esophageal; Pancreas; adenocarcinoma of unknown primary,"For the phase I trial, 3–5 patients with advanced refractory solid tumors, including NSCLC were accrued sequentially, with a minimum interval of one week between patients, at each dose escalation level, regardless of prior exposure to cytotoxic therapy. Patients 18 years-old or older who had histopathologically confirmed diagnosis of malignancy, progressive disease, adequate hematopoietic ANC of >1500/ul, platelet count of >100,000/ul), renal (serum creatinine of < 1.5 mg/dl) and hepatic function (serum bilirubin of < 1.5 mg/dl), who had given an oral witnessed informed consent. The presence of a bidimensionally measurable lesion was not a requirement for entering the study. Good-risk patients were those having WHO performance status of 0–1, minimal or no involvement by bone metastases, prior irradiation to less than 30% of the skeletum, as well as minimum or no prior myelosuppressive cytotoxic therapy.","The evidence of coexisting medical conditions that might compromise compliance with the study, such as active infection, severe organ dysfunction, mental illness or pregnancy were considered as exclusion criteria.",NA,NA
10492074,NA,Single Drug,No,Adult Acute Leukemia and Chronic Myelogenous Leukemia in Blastic Phase,"Adults with a diagnosis of acute leukemia or blastic phase CML who were refractory or had relapsed on salvage chemotherapy were entered on study. All patients signed an informed consent according to institutional guidelines. Eligibility criteria required: (1) a performance status of 3 or better on Zubrod scale, and (2) a bilirubin level of 1.5 mg% or less and a creatinine level of 1.5mg% or less. Pretreatment evaluation included a history and physical examination; complete blood counts (CBC), differentialand platelet counts; SMAl2with liver and renal function tests; coagulation profile; bone marrow aspirate, biopsy, chemical and enzymatic stains, and cytogenetic studies. Diagnosis was confirmed by morphology and histochemical stains and categorized according to the French-American-British criteria (14). Follow-up studies included CBC, differential and platelet counts twice weekly and SMA 12 at least weekly; as well as bone marrow aspiration on day 14 and 21 from start of therapy, then every 3 to 7 days as indicated until remission, and before each maintenance course.",NA,NA,NA
20564122,NA,Combination,No,"Patients With Recurrent, PlatinumResistant, Epithelial Ovarian Cancer","Patients with advanced, histologically documented EOC or primary peritoneal carcinomatosis who progressed during or recurred within 6 months after platinum-based chemotherapy were eligible. Eligibility included both measurable and detectable disease. Measurable disease was defined according to Response Evaluation Criteria in Solid Tumors (RECIST). Patients with nonmeasurable disease could enroll if they had clinically or radiologically detectable disease and a pretreatment serum CA 125 level at least twice the upper limit of normal. All patients were at least 18 years old with an Eastern Cooperative Oncology Group performance status of 0 to 1 and life expectancy of at least 3 months. Eligibility criteria allowed an unlimited number of prior cytotoxic therapies, and required adequate hematologic, hepatic, and renal function. ","Key exclusion criteria included prior history of allergic reaction to carboplatin, history of brain metastases, grade 2 or higher neuropathy, or ongoing uncontrolled medical problems.",first 4 weeks,Each cycle was 4 weeks; Growth factor support was not permitted during Cycle 1
17679729,NA,Combination,No,Acute Myeloid Leukemia,"This study enrolled patients (age >= 18 years) with relapsed AML and those older than 60 years with previously untreated AML who were not candidates for intensive cytarabine/anthracycline-based induction therapy. Patients were required to have a stable WBC count (WBC < 40,000/uL for 1 week) before initiation of therapy, total bilirubin <= 1.5 mg/dL, creatinine <= 2.0 mg/dL, ALT/AST <= 2* upper limit of normal, and Eastern Cooperative Oncology Group performance status <= 2.",NA,first cycle,"There were two steps of the study. In step A, decitabine as a single agent was escalated in approximately 25% increments from 15 mg/m2/d to determine an optimal biologic dose (OBD; defined as the dose at which mRNA expression of ER and/or p15, genes frequently methylated in AML, increased  100% compared with pretreatment in at least five of six patients at a single dose level). In step B, decitabine (at the OBD) was combined with escalating doses of VA to determine the MTD of the combination. "
33963476,"EudraCT 2009-016080-11, Dutch Trial Register NTR2391",Combination,No,children with progressive diffuse intrinsic pontine glioma,"Children aged 3–18 years with progressive DIPG were eligible for this study. The following patients were eligible for inclusion: (i) patients with clinical or radiological disease progression after initial therapy, (ii) patients who participated in the first phase of this trial experiencing progressive disease, (iii) patients with progressive disease who did not participate in the first phase of this trial but underwent at least radiotherapy (conventional or hypo-fractionated) at diagnosis, (iv) written informed consent, (v) transfusionindependent platelet count ≥ 75 × 109/L, (vi) peripheral absolute neutrophil count (ANC) ≥ 0.75 × 109/L, (vii) adequate liver function, defined as direct bilirubin ≤ 1.5 × upper limit of normal (ULN) for age and alanine aminotransferase (ALAT) < 5 × upper limit of normal (ULN) for age, (viii) adequate renal function, defined as serum creatinine ≤ 1.5 × upper limit of normal (ULN) for age, (ix) willingness to perform a pregnancy test and apply contraceptives in females of child-bearing age. Biopsy was offered as an option, but was not mandatory. ","Exclusion criteria were: (i) patients who received radiotherapy or chemotherapy in the past 2 weeks, (ii) pregnant or breastfeeding, (iii) contra-indications for chemotherapy or targeted therapy, (iv) clinically-diagnosed neurofibromatosis type I (DNA-diagnostics not mandatory), (v) performance status (Lansky or Karnofsky score) of ≤ 40.",during the first two treatment courses (i.e. over the first 4 weeks of the total treatment period),NA
33777754,ChiCTR1900021555,Single Drug,No,Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy,"Gynecological cancer patients who fulfilled the indication of HIPEC according to CACA guidelines were eligible if they met all the following criteria: age between 18 and 65 years; adequate renal function (blood creatinine: 58–96 μmol/L), bone marrow function (hemoglobin ≥ 110 g/L, white cell count ≥ 4.0 × 10^9/L, neutrophil count ≥ 2.0 × 10^9/L, platelet count ≥ 100 × 10^9/L) and hepatic function [bilirubin 3.4–22.2 μmol/L, alanine aminotransferase (ALT) 7–40 U/L, aspartate aminotransferase (AST) 13–35 U/L, AST/ALT≤ 1.5]. ",Patients were excluded if they had been treated with cisplatin for any reason within 3 weeks prior to HIPEC.,within 3 weeks following HIPEC,NA
33616416,NCT01852409,Single Drug,No,refractory malignant ascites,"Patients with refractory malignant ascites admitted to Department of Gastrointestinal Oncology in Peking University Cancer Hospital were enrolled in this study. The eligibility criteria included histologically or cytologically confirmed non-squamous cell carcinoma that did not respond to standard systemic therapy. Malignant ascites was diagnosed via cytology and imaging (ultrasound or computed tomography). The eligibility criteria were as follows: age of 18 to 75 years, Eastern Cooperative Oncology Group performance status of 0 to 2, and expected survival of more than 8 weeks. The requirements included normal hematologic function, as demonstrated by an absolute neutrophil count >=1500 cells/mL, hemoglobin >=9g/dL (transfusion allowed), and platelet count >=100,000/ mL,aswellasnormalrenal(creatinine <1.5 mg/dL) and hepatic function (bilirubin < 1.5* the upper limit of normal).","Patients were excluded if they received chemotherapy, radiation therapy, immunotherapy, or targeted therapy (tyrosine kinase inhibitors or VEGF monoclonal antibodies) within the prior 4 weeks before study entry; underwent major surgery within 4 weeks without complete recovery; had concurrent gastrointestinal obstruction, peptic ulcer, Crohn’s disease, ulcerative colitis, and other gastrointestinal diseases that may cause gastrointestinal bleeding or perforation; had uncontrolled hypertension and active bleeding, hemoptysis, or bloody ascites; had thrombosis within 12 months or any psychiatric conditions; or had symptomatic brain metastasis. Patients who were pregnant or lactating were also excluded. Informed consent was obtained from all individual participants included in the study.",NA,NA
34164713,NCT01749384,Combination,No,"adult patient with advanced solid tumors: Colorectal adenocarcinoma; Mesothelioma; Non-small cell lung; Renal cell carcinoma, papillary; Alveolar soft part sarcoma; Myxofibrosarcoma; Leiomyosarcoma; Paraganglioma","Eligible patients were ≥ 18 years old with histologically confirmed solid tumor malignancy (excluding squamous cell carcinoma of the lung) that was metastatic or unresectable and for which standard curative or palliative measures did not exist or where no longer effective. Other key eligibility criteria included: measurable or evaluable disease by the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1; ECOG performance status 0 to 2; life expectancy greater than 3 months; ability to swallow pills; and no significant impairment in gastrointestinal absorption. Patients were required to have adequate hematologic (hemoglobin ≥ 9.0 g/dL, leukocytes ≥ 3000/μL and absolute neutrophil count ≥ 1500/μL, platelets ≥ 100,000/ μL), hepatic (total bilirubin ≤ 5 × institutional Upper Limit of Normal (ULN), AST (SGOT) ≤ 2.5× institutional ULN, ALT (SGPT) ≤ 2.5× institutional ULN), and renal (serum or plasma creatinine ≤ 1.5× institutional ULN or creatinine clearance ≥ 60 mL/min) function. Patients were assessed for proteinuria at baseline and during treatment; urine protein was required to be ≤ + 1 on spot urinalysis/urine dipstick, and if the value was > + 1 then a 24-h urine for protein was required to be ≤ 1 g/24h. There were no restrictions regarding prior lines of therapy, and prior treatment with bevacizumab and inhibitors of MET or HGF was specifically allowed.","Key exclusion criteria included: treatment with chemotherapy, monoclonal antibody therapy, or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the start of study treatment; major hemorrhagic or thrombotic events within 3 months of the start of protocol therapy, or major surgery within 6 weeks or non-healing wounds; untreated brain metastases; uncontrolled intercurrent illnesses, including inadequately controlled hypertension, defined as systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 90 mmHg despite antihypertensive medication; and pregnant or nursing mothers. Investigators were cautioned to consider potential interactions with inhibitors and/or inducers of CYP2C19 and CYP3A4, although these medications were not strictly prohibited.",cycle 1,NA
33215270,NA,Combination,No,"advanced solid tumors or lymphoma including :breast (3), colon (2), lung (2), ovarian/endometrial (2), pancreatic (2), lymphoma (1) for Gemcitabine arm; esophageal (2), lung (2), unknown primary (2), gastric (1), melanoma (1), pancreatic (1) for Docetaxel arm; breast, cholangio-carcinoma, sarcoma for Sunitinib arm; colorectal (20), lung (5), breast (3), unknown primary (3), pancreatic (1), head & neck (1), ovarian (1) for Bevacizumab arm; pancreatic (14), lung (6), colorectal (5), head & neck (3), breast (2), unknown primary (2), squamous cell skin (1), biliary (1) for Erlotinib arm; lung (14), colorectal (5), head & neck (5), pancreatic (5), melanoma (4), sarcoma (3), ovarian (2), prostate (2), squamous cell skin (2), gallbladder (1), gastric (1), hepatoma (1), renal cell (1), ureter (1), unknown primary (1) for Cisplatin arm; colorectal (22), unknown primary (4), cholangiocarcinoma (2), pancreatic (2), gastric (1), non-melanoma skin (1) for 5-Fluorouracil + Leucovorin arm.","Patients at least 18 years of age who had a histologically or cytologically confirmed non-hematological advanced solid tumor malignancy or lymphoma for which no curative therapy exists and for which monotherapy with the oncolytic drugs of the treatment arms would be warranted were eligible for enrollment. Other study entrance criteria included measurable disease (by radiographic evaluation or elevated tumor markers), Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, life expectancy greater than 3 months, ability to understand and willingness to provide written informed consent, and acceptable organ and marrow function during the screening period (absolute neutrophil count ≥ 1500 cells/mm^3; hemoglobin ≥ 9g/dL; platelets ≥ 100,000 cells/mm^3; total bilirubin < 1.5* upper limit of normal; AST (SGOT) < 2.5X institutional upper limit of normal (ULN) or ≤ 5* ULN for patients with liver metastasis; ALT (SGPT) < 2.5*ULN or ≤ 5*ULN for patients with liver metastasis; creatinine within normal limits or creatinine clearance ≥ 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal limits. ","Exclusion criteria included patients who had received chemotherapy within 21 days (or 6 weeks for nitrosoureas or mitomycin C) prior to day 1 of cycle 1 or had not recovered from AEs) from agents administered more than 21 days prior, and those who had received radiotherapy or an investigational agent within 4 weeks prior to Day 1. Also excluded were patients with known active brain metastases or leptomeningeal carcinomatosis; peripheral neuropathy ≥ grade 2 (NCI CTC version 3 AE scale); a history of allergic reactions to compounds of similar chemical or biological composition to PG-11047; or uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Immune deficiency or HIV-positive patients receiving combination antiretroviral therapy were excluded, as were those with a history of myocardial infarction or hospitalization for decompensated congestive heart failure within the 6 months prior to cycle 1, day 1, or who are actively being treatment for uncontrolled cardiac arrhythmias on the basis of pretreatment ECG monitoring. Also excluded were patients with clinically significant gastrointestinal tract hemorrhage that had required transfusion therapy within the 3 months prior to study commencement and women who were pregnant, breast-feeding, or of childbearing age and unwilling to use approved, effective means of contraception.",the first dosing cycle,NA
15205668,NA,Combination,No,"multiple myeloma/primary amyloidosis, nonHodgkin lymphoma/Hodgkin lymphoma; Breast cancer; acute myelogenous leukemia; Ovarian cancer","Inclusion criteria were as follows: (1) age 14 to 70 years; (2) confirmation of primary malignant diagnosis, recurrence, or both (diagnoses included malignancies commonly treated by AHSCT regimens); (3) disease status with low curative potential with other AHSCT regimens; (4) absence of a higher-priority intrainstitutional AHSCT protocol; (5) Eastern Cooperative Oncology Group performance status <= 2; (6) full recovery from acute toxic effects of prior therapy; (7) acceptable hematologic function and marrow cellularity >= 20%; (8) acceptable critical organ status, defined as measured creatinine clearance >= 60 mL/ min, left ventricular ejection fraction >= 45% (by multiple-gated acquisition scan or echocardiogram), diffusion capacity for carbon monoxide >= 50% and forced vital capacity (forced expiratory volume in 1 second) >= 60% of predicted, and liver function studies <= 2times normal; (9) cumulative anthracycline dose or dose equivalent <= 450 mg/m2 of doxorubicin; (10) human immunodeficiency virus seronegativity; (11) first or second AHSCT; and (12) informed consent.","Exclusion criteria were (1) active solid brain metastases or malignant meningitis; (2) inability to discontinue antihypertensive drugs for 24 hours before the administration of amifostine; and (3) presence of any comorbid condition that, in the view of the attending physician, rendered the patient at excessive risk from anticipated treatment complications.",NA,NA
8855989,NA,Combination,No,small-cell lung cancer,"Previously untreated patients with histologically or cytologically proven small-cell lung cancer, WHO performance status <3, age <70 years and normal renal, hepatic and cardiac function were eligible for the study. Other eligibility criteria included: no previous or concurrent malignancy; no other serious medical or psychiatric illness which would preclude informed consent or prevent the administration of an intensive treatment. All patients gave their informed consent according to national and institutional guidelines. The prestudy work-up included complete history, physical examination and recording of weight, height, performance status and tumour stage. Computed tomography (CT) scan of the thorax and brain, bone marrow biopsy, fibreoptic bronchoscopy with biopsy, bone nuclear scan, upper abdomen CT scan or echography and ECG were performed in all patients. Initial laboratory data obtained included complete blood chemistries and blood cell count with differential, NSE and CEA test. ","Patients with brain metastasis, those under steroid treatment, those with fever >38°C or infection were not eligible for the study.",NA,NA
8519675,NA,Combination,No,previously untreated non-small-cell lung cancer stage IIIB -IV,"Eligibility criteria were histologically proven NSCLC with disseminated or unresectable disease not amenable to surgery. Patients who had received prior radiotherapy had to have finished treatment at least 4 weeks before entry. Additional inclusion criterion were age between 18 and 75 years, Eastern Cooperation Oncology Group (ECOG) performance score (PS) <= 2, white blood count (WBC) >= 4.0 x 10^9 /l , neutrophils >= 2.0 x 1091-, platelets > 100 x 10^9 /l , bilirubin< 35 umol/l and creatinine < 120 umol/l.","No prior chemotherapy was allowed. Patients wtih symptomatic brain metastases, myocardial infarction within the last 12 months, left ventricular ejection fraction (LVEF) less than 90% of lower normal institutional limit as measured by multiple ECG-gated radionuclide study (MUGA scan), arrhythmias requiring permanent medication, uncontrolled hypertension or ischaemic heart disease were ineligible.",first cycle,NA
8652277,NA,Combination,No,Metastatic Breast Cancer,Those eligible for treatment were ambulant patients not more than 70 years old with measurable or evaluable progressing metastases from histologically proven breast cancer.,NA,NA,NA
8261569,NA,Single Drug,No,"Colorectal carcinoma; Squamoushead and neck carcinoma; Hepatocellular carcinoma; Mesothelioma; cervicalcarcinoma, osteosarcoma, adenocarcinoma of unknown primary, non-small-cell lung carcinoma, endometrial carcinoma, adenocarcinoma of the esophagus","Patients eligible for study had to have histological proof of a malignant solid tumor for which conventional therapy had either failed or was unavailable. Patients had to have recovered from all toxicities of prior treatment and were required to have received no radiation or chemotherapy within 4 weeks of entry (8 weeks for drugs with delayed toxicity such as nitrosoureas or mitomycin C). A minimal life expectancy of 12 weeks and an ECOG performance status of <= 2 were required. Patients must have had adequate bone marrow function (WBC, >= 3,500 cells/ul; PLT, >= 100,000/ul), adequate liver function (bilirubin, <= 1.5 mg/dl), and adequate renal function (serum creatinine, <= 1.5 mg/dl). All patients signed an informed consent form approved by the Institutional Review Boards of the University of Maryland and the National Cancer Institute. Sexually active fertile patients must have consented to the use of effective birth control, and sexually active fertile women must have had a negative serum pregnancy test prior to drug administration.","Patients with evidence of congestive heart failure or a prior history of life-threatening cardiac arrhythmia, prior anthracycline treatment, or treatment with > 100 mg/m2 mitoxantrone and evidence of congestive heart failure were excluded. Pregnant patients and patients with an allergy to eggs were excluded. ",NA,NA
2313718,NA,Single Drug,No,NA,"Main criteria for patient eligibility were: performance status of 70 or greater (Karnofsky scale); age between 16 and 65 years; histologic proof of solid tumors usually refractory to chemotherapy; and normal liver, kidney, and heart function. Patients who had been previously treated with anthracyclines were eligible only if they had not received a cumulative dose larger than 300 mg of DOX/m2. ","After the first occurrence of grade 3 toxicity of any type in the study, patients who had been previously treated with anthracyclines were no longer eligible.",NA,NA
7691117,NA,Combination,No,Non-small Cell Lung Cancer,"Eligibility criteria included histologically proven stage IIIB-IV NSCLC, performance status (ECOG) 2 or less, age 70 years or less, no previous chemotherapy, white blood cells (WBC) > 4000/mm^3, platelets > 120000/mm^3, bilirubin <= 1 mg/ 100 ml, creatinine <= 1.2 mg/lOO ml, normal cardiac, hepatic and renal functions.",NA,NA,NA
8612318,NA,Combination,No,Advanced non-small-cell lung cancer,"Eligibility criteria included histologically proven stage IIIB – IV NSCLC, an Eastern Cooperative Oncology Group (ECOG) performance status of <= 2, an age of <= 70 years, no previous chemotherapy, a WBC of > 4,000/mm3, a platelet count of > 120,000/mm3, a bilirubin level of <= 1 mg/100 ml, a creatinine value of <= 1.2 mg/100 ml, and normal cardiac, hepatic, and renal function.",NA,NA,NA
7529516,NA,Combination,No,METASTATIC BREAST CARCINOMA,"All patients had to fulfil the following criteria: histological diagnosis of advanced breast carcinoma: age <= 70 years; Karnofsky index >= 60; life expectancy > 2 months; measurable disease according to WHO criteria: adequate bone marrow function (WBC>4*10^9/l; platelet >= 120*10^9/l); serum bilirubin <= 12 mg/l; serum creatinine <= 12 mg/l, BUN <= 0.5 g/l; absence of brain metastases; no other malignant neoplasm with exception of cutaneous basalioma and in situ carcinoma of the uterus; no previous radiotherapy including the heart area; no severe cardiovascular. respiratory, neurological, or metabolic disease; geographical accessibility in order to assure a close follow-up. All patients had to give their written informed consent.",NA,NA,NA
8392903,NA,Combination,No,small cell lung cancer,"Eligible patients were required to have histologically proven SCLC, a Karnofsky performance status (PS) >= 5O%, age 70 years or younger, no previous cytotoxic treatment, and no prior malignancies. Patients had to have evidence of adequate renal, hepatic, cardiac, and hematologic functions. Pretreatment laboratory parameters included the following: serum creatinine < 122 umol/l, bilirubin < 17 umol/l, leukocytes > 4.0 * 10^9/l, platelets > 100 * 10^9/l, and hemoglobin > 10 g/dl. All patients gave informed consent, indicating they were aware of the investigational nature of the treatment.",Patients were excluded if they had evidence of continuing infections.,first cycle,NA
7954234,NA,Combination,No,colorectal cancers metastatic to the liver,"All patients were treated on the inpatient medical service of Memorial Sloan-Kettering Cancer Center. All patients had biopsy-proven adenocarcinoma of the colon or rectum, and all had received prior intrahepatic chemotherapy, and thus had hepatic artery catheters in place. In patients who had implantable infusion pumps (13 of the 14), the side port of the pump was accessed and used for verapamil and doxorubicin therapy. One patient had an angiographically placed hepatic artery catheter that was attached to a subcutaneous, surgically placed, infusion port. Pretreatment evaluation of all patients consisted of a full history and physical examination, computed tomography scan of the abdomen, chest X-ray, and a Tc99macroaggregated albumin flow study of the hepatic artery access device to assure proper distribution of flow throughout the liver. Patients were required to have a leukocyte count of 3500 cells/mm3 or greater, platelet count of 150,000/mm3 or greater, creatinine of < 1.5 mg/dl, and total bilirubin of < 1.5 mg/ dl. Patients were required to have a normal cardiac ejection fraction, as demonstrated by radionuclide cineangiography. ","Patients receiving digoxin, beta blockers, calcium channel blockers, or other cardiac or antihypertensive medications were excluded.",NA,NA
8070013,NA,Combination,No,metastatic breast cancer,"For inclusion in the study, patients were required to (1) be under 70 years of age, (2) have a performance status of <= 2 according to WHO guidelines, and (3) have experienced a first recurrence after primary therapy for carcinoma of the breast. Furthermore, the patients could have no history of cardiac disease. Cardiac function was evaluated using ECG and multiple ECG-gated radionuclide cineangiocardiography (MUGA) scans, requiring a left ventricular ejection fraction (LVEF) of >= 50%. Finally, patients were required to have normal bone marrow function (WBC, >= 3.0 * 10^9/l; platelets, >= 100 x 10^9/l) as well as adequate hepatic and renal function (bilirubin, <= 35 mmol/l; creatinine, <= 130 umol/l).",NA,first course,NA
8453681,NA,Combination,No,"breast, colon, nsclc, pancreas, mesothelioma",only patients with tumor accessible for repetitive analysis (pleural effusion) were included.,NA,NA,NA
7987997,NA,Combination,No,advanced breast cancer,"To be eligible for this study, patients were required to have histologically proven ABC. Further eligibility requirements included the presence of progressive measurable and/or evaluable disease (objective measurable disease was mandatory for the phase II trial), an age <= 70 years, an ECOG performance status <= 2, a white blood cell count of >= 3500/mm3, a platelet count of >=100,000/ram3, adequate liver and renal function, and a normal left ventricular ejection fraction (LVEF). ","Previous chemotherapy for metastatic disease excluded patients from participation whereas adjuvant cytotoxic therapy did not, provided that the therapy had been stopped for a minimum of 12 months before entry.",first six courses,NA
1768677,NA,Combination,No,Refractory Malignancies,"Patients (>= 18 years) with histologically proven refractory malignancy, who had either measurable or evaluable disease and had not received rIL-2 or doxorubicin, were eligible. A performance status (PS) of <= 2 (Eastern Cooperative Oncology Group), a life expectancy >= 3 months, and a period of >20 days from recent major surgical procedures werealso required.  a carbon monoxide diffusing capacity (DLco ) >= 50% of predicted value, and a left ventricular ejection fraction (LEVF) >= 50% were required.",Radiotherapy or chemotherapy within 28 days of study entry (42 days for nitrosoureas or mitomycin C) were not allowed. Exclusion criteria were identical to our previous trials. ,NA,NA
7636539,NA,Combination,No,Non-Hodgkin's lymphoma; Hodgkin's disease; Sarcoma,"Entry criteria for the study were histologically confirmed diagnosis of lymphoma or sarcoma, EPOCH-refractory disease, a nonreactive test for human immunodeficiency virus (HIV), radionuclide ejection fraction >= 40%, and adequate renal (creatinine < 1.5 mg/dL or creatinine clearance >= 40 mL/min), hepatic (bilirubin < 2.5 mg/dL), and hematopoietic (absolute neutrophil count [ANC] >= 1,000/uL and platelet count >= 100,000/uL) function, unless there was respective organ involvement by tumor. ",Patients with heart block or cardiac arrhythmias requiring medical intervention and those taking antihypertensive and/or calcium channel blockers were ineligible.,NA,NA
7913721,NA,Single Drug,No,"refractory lymphoma, non-small-cell lung cancer, and doxorubicin/mitoxantrone-refractory metastatic breast cancer","patients with a normal ECG; cardiac ejection fraction >= 40%; serum creatinine level less than 1.5 mg/dL or creatinine clearance more than 50 mL/ min; serum aspartate aminotransferase (AST; normal range, 9 to 34 U/L), alkaline phosphatase (normal range, 37 to 116 U/L), and bilirubin (normal range, 0.1 to 1.0 mg/dL) levels - two times normal; an absolute granulocyte count (AGC) - 1,500/ML; and a platelet count R 100,000/ptL (unless due to tumor involvement).",NA,cycle 1,NA
8622073,NA,Combination,No,breast cancer,"Patients with adenocarcinoma of the breast pathologically confirmed as T1-3NIMO were eligible. Entry requirements included the following: no prior treatment with cytotoxic or hormone therapy for breast cancer, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, WBC count >= 4,000/uL, platelet count >= 100,000/uL, bilirubin level <= 1.5 mg/dL, normal renal function, and cardiac ejection fraction greater than 50%. ","Patients were ineligible if they had a previous malignancy (except for cured nonmelanoma skin cancer and cervical carcinoma-in-situ), a history of congestive heart failure or myocardial infarction, angina, poorly controlled hypertension, any condition that required chronic glucocorticoid therapy, known hypersensitivity to Escherichia coli-derived drug preparations, or known bladder disease.",NA,NA
8622080,NA,Combination,No,Hormone-Resistant Prostate Cancer,"Eligibility criteria included histologic proof of adenocarcinoma of the prostate with distant metastases, refractory to hormonal therapy with combined androgen blockade. Simultaneous antiandrogen withdrawal was undertaken only in the first four patients treated. All subsequent patients either never received antiandrogen, were never removed from antiandrogen therapy, or had previously undergone (and ultimately failed to respond) antiandrogen withdrawal. While there was no minimum prostate-specific antigen (PSA) level required for inclusion in the study for patients who lacked measurable disease, only two of 20 such patients had a PSA less than 20 ng/ mL (3.4 ng/mL and 4.3 ng/mL, respectively). Patients were eligible if they had a Karnofsky performance status (KPS) > 60%, estimated life expectancy greater than 12 weeks, adequate hematologic parameters (granulocyte count >= 1,500/uL and platelet count >= 125,000/ uL), and adequate renal and hepatic function (total bilirubin level <= 2 mg/dL, AST <= twice the upper limit of normal, and serum creatinine concentration <= 2 mg/dL). Prior XRT was permitted provided it had been concluded at least 4 weeks before protocol registration. Prior strontium 89 therapy was permitted provided it was completed more than 8 weeks before protocol registration. ",Patients who had received prior chemotherapy were excluded. Patients with clinically significant heart disease were excluded from the study and a cardiac ejection fraction greater than 40% was required.,the first cycle,NA
8523055,NA,Combination,No,Poor-Prognosis Aggressive Non-Hodgkin's Lymphoma,"Patients with aggressive NHL (diffuse mixed, diffuse largecell, or large-cell immunoblastic lymphoma [Rappaport classification]) were enrolled onto the pilot study. Eligible patients were required to have high-risk disease as defined by the clinical prognostic criteria in use at the DanaFarber Cancer Institute and Brigham and Women's Hospital in 1991. Specifically, patients were required to have both advancedstage disease (Ann Arbor III or IV) and at least one area of tumor involvement >= 10 cm. Protocol patients were also required to have normal complete blood cell (CBC) counts (WBC count > 3,000/uL, hematocrit > 25%, and platelet count > 100,000/uL), cardiac ejection fractions of >= 50%, and no significant hepatic or renal dysfunction (total bilirubin level < 1.5 mg/dL, AST < 90 IU, serum creatinine level < 2.0 mg/dL) or evidence of lymphomatous CNS involvement.",NA,first cycle,NA
7680373,NA,Combination,No,Advanced Urothelial Cancer,"Patients with urothelial tract tumors, T3b or T4, N+, or M+ were considered eligible for the study protocol, provided that they satisfied the following requirements: Karnofsky performance status (KPS) >= 60%, life expectancy greater than 4 months, no prior systemic chemotherapy, no prior pelvic irradiation, no evidence of active ischemic heart disease (New York Heart Association functional class III/IV), no evidence of brain metastasis, adequate bone marrow reserve (peripheral WBC count > 3500 cells/uL, platelet count > 150,000 cells/uL), creatinine clearance greater than 55 mL/min/1.73 m2, serum bilirubin less than 1.5 mg/dL, and clinically normal auditory function. All patients required histologic confirmation of the diagnosis of urothelial tract cancer by the Department of Pathology at Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY. Written informed consent was provided by all patients.",NA,NA,NA
7689093,NA,Combination,No,Breast; Colon; Pancreas; Kidney; Esophagus; Adrenal cortex,"Patients age 18 years or older with advanced histologically or cytologically proven malignancy refractory to standard therapy were eligible for this clinical study. All patients, including those with prior anthracycline exposure, were required to have baseline left ventricular ejection fraction (LVEF) more than 45% and an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at study entry. Laboratory requirements included adequate bone marrow reserve with an absolute granulocyte count (AGC) >= 2,000/uL, platelets> 100,000/uL, serum bilirubin less than 1.5 mg/dL, ALT and AST less than two or more times the upper limit of normal, and serum creatinine less than 1.5 mg/dL. ","Patients were excluded if they had CNS metastases, exposure to hematopoietic stem-cell toxins (such as melphalan or mitomycin) within the 6 months preceding enrollment, or a history of cardiac disease. Prior irradiation of either the mediastinum, more than 25% of the bone marrow, more than 50% of the left ventricle volume, or of the internal mammary nodes, or concurrent radiation therapy was not allowed.",first two cycles,NA
8664188,NA,Combination,No,locally-advanced or metastatic breast cancer,"Patients younger than 66 years of age with locally-advanced or metastatic breast cancer were eligible for the study.  Prior hormonal treatment was accepted. The following conditions had to be met ECOG performance status of 0-1, normal left ventricular ejection fraction (as assessed by MUGA scan) combined with a normal cardiac history, serum bilirubin <30 umol/L, serum creatinine <120 umol/L, absolute neutrophil count >= 2.0 x 10^9/L, platelet count >= 100 x 10^9/L, and an absence of bone marrow involvement documented by iliac crest bone marrow histology. ","Prior chemotherapy (including adjuvant chemotherapy), prior palliative radiotherapy, prior cytokines and X-ray-documented bone metastases were exclusion criteria. ",first 2 cycles of chemotherapy,NA
29850984,NA,Combination,No,HER2-positive inop-erable locally advanced or MBC (metastatic breast cancer),"Patients had histologically confirmed HER2-positive inop-erable locally advanced or MBC. Locally advanced disease must be inoperable and have progressed within 6 months of trastuzumab and/or taxane treatment and MBC must have progressed during or after trastuzumab and taxane therapy. Other key inclusion criteria included ECOG performance status ≤ 2 and adequate bone marrow, renal, and hepatic functions. Patients were not required to have measurable dis-ease. ","Key exclusion criteria included clinically manifested diabetes (fasting plasma glucose >   140 mg/dL or a history of steroid-induced diabetes), known history of liver disease, or other active medical problems.",<= 21 days following the first dose of alpelisib,NA
1453205,NA,Single Drug,No,"ovarian cancer (five), head and neck cancer (four), esophageal cancer (four), non-small-cell lung cancer (six), adenocarcinoma of unknown origin (two), colorectal cancer (one), bladder cancer (one), and malignant melanoma (one).",NA,NA,NA,NA
1310105,NA,Single Drug,No,previously untreated patients with advanced NSCLC (stages III and IV),"Patients with either measurable or assessable disease were eligible for treatment during this phase of the trial. Patients with unresectable, limited disease that was nonamenable to potentially curative radiotherapy were eligible also, although only a very small number of such patients were entered. Patients greater than 18 years of age with an expected survival of at least 12 weeks were eligible for the trial. Eligible patients had to have an Eastern Cooperative Oncology Group (ECOG) performance status <= 2.  A WBC count of 4.0 x 10^9 /L with an absolute granulocyte count (AGC) >= 2.0 x 10^9/L and a platelet count of >= 100 x 10^9/L were required for study entry. In addition, patients were required to have adequate liver function (serum bilirubin level <= 35 umol/L) and adequate renal function (serum creatinine level <= 220 umol/L).   The patients had to be willing to comply with the scheduled follow-up visits and investigations, and had to be willing to give signed, informed consent, according to individual institutional requirements.","Patients who had received prior radiotherapy to 25% or more of the bone marrow were ineligible for treatment. Because of the potential cardiotoxicity of epirubicin, patients with a baseline left ventricular ejection fraction (LVEF), as measured by multiple-gated angiogram (MUGA) scan, greater than 10% below the normal institutional lower limit were ineligible. Patients with active angina or myocardial infarction within the last 6 months or with a significant arrhythmia requiring ongoing medication were excluded, as were patients with a history of prior malignancies other than nonmelanoma skin cancer.",NA,NA
8622023,NA,Combination,No,Metastatic Breast Cancer,"All patients gave informed consent according to National Institutes of Health (NIH) guidelines. All patients had histologically proven adenocarcinoma of the breast with evidence of metastatic disease. Bidimensionally measurable disease was required for entry and patients must have received no prior chemotherapy for metastatic disease. Patients who developed metastatic disease within 12 months of their initial diagnosis were eligible for study, as were patients with longer disease-free intervals. Prior hormonal therapy or radiotherapy did not exclude patients from entry provided the radiation did not exceed 25% of the total bone marrow. Other requirements were Karnofsky performance status greater than 70%, WBC count greater than 3,500/uL and platelet count >= 100,000/uL, hepatic transaminase and bilirubin levels no greater than two times normal unless there was evidence of metastatic liver disease, serum creatinine concentration <= 1.5 mg/dL or creatinine clearance greater than 50 mL/min, no prior history of cardiac disease including arrhythmias or conduction system abnormalities, and a baseline gated blood pool scan (MUGA) and ECG that were normal for age. ","No patient had been previously treated with paclitaxel or doxorubicin in the adjuvant setting. Concurrent chemotherapy, radiotherapy, or immunotherapy was prohibited.",on cycle 1,NA
7595726,NA,Combination,No,Women With Untreated Metastatic Breast Cancer,"From June 1993 to October 1994, 35 patients with metastatic breast cancer were accrued into this open-label dose-finding study in which therapeutic doses of DOX and paclitaxel were used. The trial was approved by the ethical committee of the Istituto Nazionale Tumori. All patients provided witnessed, informed consent. Criteria for inclusion were as follows: histologic proof of breast cancer; age 18 to 70 years; performance status 0 to 2 (Eastern Cooperative Oncology Group [ECOG] scale), absolute neutrophil count (ANC) >= 2,000/uL and platelet count >= 100,000/uL; normal function tests for liver bilirubinn level <= 1.25 times upper normal limit) and kidneys (creatinine concentration <= 1.25 times upper normal limit); left ventricular ejection fraction (LVEF) -normal limit of 50% by echocardiograph or radionuclide cineangiography; presence of at least one neoplastic lesion bidimensionally measurable by physical examination or instrumental studies (central CNS or bone metastases as the only site of disease were excluded); and no prior chemotherapy.",NA,NA,NA
8620409,NA,Combination,No,advanced pancreatic adenocarcinoma,"Patients eligible for this study had histologically or cytologically confirmed advanced pancreatic adenocarcinoma. All had bidimensionally measurable disease and had not received previous chemotherapy or radiation therapy. Patients were required to be aged 70 years or younger and have an anticipated life expectancy of 3 months. Patients were required to have a World Health Organization (WHO) performance status of 0 or 1, and to have adequate kidney (serum creatinine level < 1.5 mg/dl), liver (total bilirubin level < 1.5 mg/dl, transaminase levels < two times the upper limits of normal), and bone marrow functions (leukocyte count > 4000/ pL, platelet count > lOO,OOO/uL). All patients had normal pretreatment electrocardiograms and echocardiograms (left ventricular ejection fraction of more than 50% and no wall motion abnormalities), and resting systolic blood pressure greater than 110 mmHg. ","Patients with a history of cardiovascular disease, active systemic infections, coagulation disorders, active central nervous system metastatic disease, and pregnant or lactating females were not eligible for treatment. Also excluded were patients who were receiving antiarrhythmic agents, beta blockers, calcium channel blockers, or other antihypertensive medications.",first two treatment courses,NA
8246030,NA,Combination,No,breast cancer,"Eligible patients had a histologic diagnosis of invasive breast cancer: they had either recurrent breast cancer or were new patients eligible for adjuvant chemotherapy postmastectomy or postlumpectomy, in whom five or more axillary nodes were positive for adenocarcinoma. Patients had no previous treatment with CAF, although previous systemic antineoplastic chemotherapy more than 4 weeks before enrollment was permitted. All were aged 18 years or older and had a WBC count greater than 4.0 x 10^9/L, hematocrit greater than 30%, platelet count greater than 100 * 10^9/L, serum albumin greater than 33 g/L, and serum creatinine less than 160 mmol/L. Patients had no history of myocardial infarction in the previous 6 months, congestive heart failure, medically significant cardiac arrhythmia, hemodynamically significant valvular disease, uncontrolled angina pectoris, or uncontrolled hypertension. Each patient had a normal cardiac ejection fraction at baseline determined by a nuclear, multiple-gated angiogram (Muga) scan. The disease-related performance status was equal to or better than Eastern Cooperative Oncology Group (ECOG) grade 2. All patients had a life expectancy of at least 3 months and had provided written, informed consent. Concurrent serious infection was not present and women of childbearing age needed to practice effective contraception.","Patients were excluded based on the following criteria: they had received previous therapy with CAF; there was a concomitant malignancy, except basal cell carcinoma or carcinoma in situ of the cervix; the serum bilirubin was greater than 17 umol/L; or the patient required pharmacologic doses of corticosteroids.",NA,NA
1525387,NA,Single Drug,No,primary hepatocellular carcinoma or with hepatic metastases from primary gastric or colorectal adenocarcinoma.,Life expectancy of greater than 2 months. Karnofski status of 50% or greater. Serum bilirubin 40 μmol/l or less. White cells greater than 4 x 10^9/l. Platelets greater than 100 x 10^9 /l. Identifiable marker lesion(s) on computed tomography (CT) or ultrasound scans.,Prior chemotherapy. Radiotherapy with past 4 months. Significant cardiac disease. Pregnancy. Breast feeding.,NA,NA
12056705,NA,Combination,No,patients with advanced or metastatic pancreatic cancer,"Patients with locally advanced pancreatic adenocarcinoma (ACA), not amenable to treatment with combined radiation and chemotherapy, or metastatic pancreatic ACA were eligible for entry into this trial. Prior chemotherapy, when used as a radiosensitizer in the adjuvant setting or for local disease, was permitted. The patients had Eastern Cooperative Oncology Group (ECOG) performance scores of ≤2 and life expectancies of ≥12 weeks. The inclusion criteria included: absolute neutrophil count of ≥1500/mm^3; bilirubin ≤1.5 mg/dl; AST and alkaline phosphatase levels ≤3 times the institutional upper limits of normal; creatinine ≤2 mg/dl; and negative pregnancy test for women with childbearing potential. ",Exclusion criteria included: chemotherapy or radiotherapy for metastatic disease; radiation to >25% of the bone marrow; pregnancy or lactation; uncontrolled infections; chronic debilitating diseases; New York Heart Association class 3 or 4 heart disease; and central nervous system metastases.,a minimum of 6 weeks,NA
15937714,NA,Combination,No,non small-cell lung cancer,"Chemotherapy-naive patients with histologically or cytologically confirmed, inoperable, locally advanced or metastatic NSCLC, performance status <= 2 (ECOG scale) and life expectancy of at least 12 weeks, were eligible for the study. Patients were also required to have adequate bone marrow function (absolute neutrophil count >= 1.5·10^9/l, platelet count >=100·10^9/l and hemoglobin >= 100 gr/l), adequate liver function (total bilirubin <= 1.5 time the upper normal limit, AST and/or ALT <= 3 times the upper normal limit) and a creatinine clearance rate of >= 60 ml/min. Patients with asymptomatic brain metastases were eligible. ","Patients with cardiac arrhythmias, heart failure, AV block or acute myocardial infarction within 4 months before study entry, as well as those with concurrent or previous malignancies, (except adequately treated squamous-cell carcinoma of the skin), were excluded. No prior irradiation was allowed within the 4 weeks preceding treatment.",the first two cycles,NA
32147669,NCT02039336,Combination,No,"patients with KRASmutation-positive colorectal, non-small-cell lung and pancreatic cancer","This investigator-initiated, multicentre, open-label, Phase 1 doseescalation study enrolled patients at three sites in The Netherlands. Adult patients with histologically or cytologically confirmed advanced CRC, NSCLC or pancreatic cancer were enrolled on the basis of documented KRAS mutations in exons 2, 3 or 4, and PIK3CA wild-type status. Eligibility criteria included Eastern Cooperative Oncology Group (ECOG) performance status of <2, life expectancy of ≥3 months, measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, adequate bone marrow (absolute neutrophil count ≥1.5 × 10^9/L, platelets ≥100 × 10^9/L and haemoglobin ≥6.0 mmol/L), hepati(total bilirubin ≤1.5 × upper limit of normal [ULN], aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN) and renal (serum creatinine ≤1.5 × ULN) functions.","Radiotherapy, immunotherapy, chemotherapy or any treatment with investigational medication within 4 weeks prior to study treatment were not allowed, and patients with a history of other primary malignancies were excluded with the exception of patients who had been disease-free for ≥3 years, or with completely resected non-melanoma skin cancer. Additional exclusion criteria included symptomatic or untreated leptomeningeal disease, symptomatic brain metastasis, history of interstitial lung disease or pneumonitis, history of retinal vein occlusion and prior therapy containing targeted drug combinations known to interfere with EGFR, HER2, HER3, HER4 or MAPK- and PI3Kpathway components, including PI3K, AKT, mTOR, BRAF, MEK and ERK. ",first cycle,NA
29067643,NCT01347866,Combination,No,Colorectal cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Breast cancer; Gastrointestinal stromal tumor; Gastric cancer; Cholangiocarcinoma; Esophageal carcinoma; Endometrial cancer; Liposarcoma; Cancer of the appendix; Prostate cancer,"Patients 18 years of age or older with a histologic or cytologic diagnosis of advanced/metastatic solid tumor for which there was no current clinically effective treatment were included in the study. Patients had to have adequate bone marrow, renal, liver and cardiac functions, and adequate glucose control (including no previous diagnosis of diabetes mellitus and hemoglobin A1C <7%). Only patients with Eastern Cooperative Oncology Group performance status 0 or 1 were eligible. Patients enrolled in stage 2 (expansion cohort) of arm C were required to have metastatic CRC (regardless of KRAS mutation status), which had progressed on irinotecan-based regimens, or pancreatic ductal adenocarcinoma after progression on first-line treatment for advanced disease. Patients enrolled in stage 1 (dose escalation) of arm D were required to have tumors with KRAS or BRAF mutation (archived or fresh biopsy).","Patients with known active brain metastases, clinically decompensated cardiovascular disease, impaired pulmonary function, or surgery within 4 weeks prior to the start of study treatment were not eligible. Additionally, chemotherapy, radiotherapy and biologic or investigational anticancer therapy within 4 weeks prior to the start of study treatment were not allowed. Use of or anticipated need for cytochrome P450 3A4 inhibitors/inducers or drugs known to be UGT1A9 substrates, and concurrent administration of herbal preparations were also not permitted.",the first cycle (28 days of treatment),NA
20215549,NA,Single Drug,No,Melanoma; Breast cancer; NSCLC; Colorectal cancer,"Eligibility criteria included adult patients with histologically or cytologically documented advanced breast cancer, colorectal cancer, non–small cell lung cancer (NSCLC), or nonocular melanoma refractory to standard therapy or for whom no standard therapy existed. RAS-MAPK pathway is constitutively active in a proportion of these tumor types, giving a more homogenous population for interpretation of biomarkers and mutation analysis. Initially, all participants enrolled were required to provide one pretreatment and one posttreatment tumor biopsy. Following implementation of a protocol amendment, patients were recommended to provide tumor biopsies. Participants were required to have an Eastern Cooperative Oncology Group performance status of ≤2 and adequate bone marrow (absolute neutrophil count ≥1,500/μL, platelets ≥100,000/μL, hemoglobin ≥9 g/dL), hepatic [bilirubin ≤2× upper limit of normal ULN), aspartate aminotransferase or alanine aminotransferase <3 ULN, or <5 ULN if liver metastases], and renal (creatinine ≤1.5× ULN) functions. Participants were required to have a left ventricular ejection fraction ≥50% as assessed by multigated acquisition scan.","Radiation or cytotoxic therapy within 4 wk of study entry was not permitted. Patients with a history of congestive heart failure, active brain metastases, or other seriousmedical conditions were excluded. After two cases of retinal vein occlusion (RVO), a protocol amendment also excluded patients with glaucoma, intraocular pressure >21mmHg, or any other significant abnormality on ophthalmic examination (by an ophthalmologist). Pregnant women were not eligible for enrollment, and patients of reproductive age were requested to practice birth control while on treatment.",cycle 1 (28 days),NA
11937310,NA,Combination,No,patients with metastatic breast cancer,"Patients with histologically-confirmed adencarcinoma of the breast and evidence of metastatic disease were eligible for this phase I study, provided that they were anthracycline resistant or pretreated with both anthracyclines and taxanes in either the adjuvant or metastatic settings (or both). Anthracycline resistance was defined as either a disease-free interval from the end of adjuvant anthracyclines of < 12 months, or a disease stabilisation of < 6 months or disease progression as the best response to anthracycline treatment for metastatic disease. Other eligibility criteria included a Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2,age> 18 years, a maximum of two prior lines of chemotherapy for metastatic disease, adequate haematological function (granulocyte count > 2*10^9 cells/l, and platelet count > 100*10^9 cells/l), adequate renal function (serum creatinine <= 1.5 times the upper limit of normal (ULN)), adequate hepatic function (bilirubin <= 2 itmes the ULN and transaminases <= 2 times the ULN). ","Patients who were pregnant or breast feeding, had had a myocardial infarction or angina pectoris within the previous 6 months, or who had prior therapy with continuous infusion 5-FU or gemcitabine were not eligible.",first cycle,NA
14739041,NA,Combination,No,non-small cell lung cancer,Patients with histologically or cytologically-proven recurrent or metastatic NSCLC were eligible for the trial when they met all of the following criteria: presence of measurable or evaluable disease; not more than two previous chemotherapy regimens; prior chemotherapy ended at least 4 weeks previously; 18 years ≥ age ≤ 75 years; eastern cooperative oncology group (ECOG) performance status ≤2; adequate bone marrow reserve (absolute neutrophil count [ANC] ≥ 1.500 mm^−3; platelet count [PLT] ≥ 120.000 mm^−3); adequate hepatic and renal function; absence of brain metastases; estimated life expectancy ≥12 weeks; and no neuropathy caused by previous treatment. ,NA,NA,NA
11728688,NA,Combination,No,LOCALLY ADVANCED NON–SMALL-CELL LUNG CANCER,"Patients with histologically or cytologically confirmed Stage IIIa (T1–3N2 M0) or IIIb (T4N1–3M0 or T1– 4N3 M0) NSCLC were eligible for enrollment. Tumor–nodemetastasis (TNM) staging designations were made in accordance with the International Staging System. Further eligibility requirements included an Eastern Cooperative Oncology Group (ECOG) performance status 0 –2, age 18 years or greater, adequate hematologic function (granulocytes > 1500/mm3, hemoglobin > 10 gm/dL, platelet count > 100,000/mm3), adequate renal function (serum creatinine <= 2.0 mg/dL), and a life expectancy greater than 6 months. ","Patients with involvement of the supraclavicular lymph nodes, positive pleural effusions, or who had received prior chemotherapy or radiation for NSCLC were not eligible. ",the 6 weeks of concurrent chemoradiation therapy.,NA
14758140,NA,Combination,No,Non–Small-Cell Lung Carcinoma,"Eligible patients had previously untreated and histologically confirmed stage IV or inoperable stage III NSCLC or were in relapse after surgery either alone or in combination with thoracic irradiation; Eastern Cooperative Oncology Group performance status of 0 to 2; no prior chemotherapy; aged at least 18 years; life expectancy more than 3 months; and bidimensional measurable lesion(s) of greater than 20 mm * 20 mm. Patients with asymptomatic brain metastases without corticosteroid therapy could also be included; absolute neutrophil count and platelet count of greater than 1,500/ul and 100,000/ul, respectively; calculated or actual creatinine clearance more than 60 ml/min; AST or ALT less than or equal to three times the upper limit of normal. ",NA,first cycle,NA
12504047,NA,Combination,No,LOCALLY ADVANCED PANCREATIC CANCER,"For primary pancreatic carcinoma, the helical CT criteria used to determine unresectability included infiltration of peripancreatic organs, except the duodenum or into the retroperitoneal soft tissues; vessel involvement of >90° of their circumference (portal vein, confluens, superior mesenteric artery, celiac trunk, including hepatic artery and splenic artery, and superior mesenteric vein); and vessel stenosis/obstruction. Patients were required to have a Karnofsky performance score >60%. The initial laboratory requirements included white blood cell (WBC) count >=4000/uL, platelet count >=100,000/uL, bilirubin <=2.0 mg/dL, and a creatinine clearance >=70 mL/min. In the case of jaundice before CRT, endoscopic retrograde cholangiopancreatography with bile duct stenting was performed. Cardiac ultrasonography was performed to ensure that a volume load of 2.5 L/d was tolerable. A port-a-cath was implanted for chemotherapy and for sufficient nutrition. Weight loss before or during therapy was treated by outpatient temporary supplemental parenteral feeding. Patients had to be chemotherapy and RT naive. ",Tumors requiring resection of the superior mesenteric vein or portal vein were not considered for primary resection because of the bad prognosis of such patients in our experience.,during treatment or within 4 weeks after completion,NA
15484216,NA,Combination,No,Advanced Soft Tissue Sarcoma,"Eligible patients had histologically diagnosed advanced soft tissue sarcoma (ASTS) that was refractory to treatment with doxorubicin and ifosfamide; patients who were ineligible to receive either of these agents also were eligible for the study. All patients had unresectable progressive disease, World Health Organization (WHO) performance status <= 2, adequate bone marrow reserves (leukocyte count >= 3.5 * 10^9/L, granulocyte count >= 1.5 *10^9/L, and platelet count >= 100 * 10^9/L), and adequate liver and renal functioning (serum bilirubin concentration <= 1.6 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels < 2 times the upper limit of normal, and serum creatinine concentration <= 1.6 mg/dL). The presence of measurable disease was not an eligibility requirement. Before enrollment, all patients had their clinical histories recorded; underwent physical examination and assessment of performance status; and had complete blood cell counts, serum chemistry assays, urinalysis, electrocardiography, and chest X-rays performed. When present, measurable lesions were assessed via computed tomography or chest X-ray. ","Patients younger than age 18 years, patients with severe associated diseases, patients with central nervous system metastases, and patients for whom follow-up was not possible were excluded from the study.",the first 4 weeks,NA
12702534,NA,Combination,No,"Non-small-cell lung cancer, Head and neck, Ovarian, Pancreas","Patients were eligible if they had an advanced or refractory histologically or cytologically confirmed malignant solid tumor, for which no standard therapy was available. This included, but was not limited to, metastatic cancer of unknown primary origin. Other eligibility criteria included the following: age 18–70 years; Eastern Cooperative Oncology Group (ECOG) performance status ≤2; no previous anticancer therapy for at least 4 weeks (6 weeks for nitrosoureas or mitomycin); no previous radiotherapy for at least 4 weeks; no treatment with more than two prior chemotherapy combination regimens; and adequate hematopoietic (absolute neutrophil count ≥2 × 10^9/l and platelet count ≥100 × 10^9/l), renal (serum creatinine concentration ≤135 μmol/l or creatinine clearance ≥60 ml/min) and hepatic [total serum bilirubin level ≤1.25× upper normal limit (UNL) and serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤3× UNL; in case of liver metastasis, total serum bilirubin level ≤1.5× UNL and serum AST and ALT levels ≤5× UNL] function. Other eligibility criteria included measurable or assessable disease. All patients gave written informed consent before they were entered into the study.",NA,NA,NA
12140144,NA,Combination,No,unresectable non-small cell lung cancer,"Performance status 0-1 (according to Eastern Cooperative Oncology Group -ECOG); Age range 18 -75 years; No pulmonary or cardiovascular contraindications; NSCLC histo- or cytologically proven; Stage IIIa, IIIb, IV (single completely treated metastasis), no neoplastic pleural effusion; Life expectancy over 3 months; Informed consent",NA,NA,NA
16150481,NA,Combination,No,"women with previously treated epithelial ovarian, peritoneal, or fallopian tube cancer.","To be eligible for this study, patients had documented epithelial ovarian, fallopian tube, or peritoneal cancer. Patients must have received one prior treatment with a platinum and paclitaxel-based regimen and could not have received radiotherapy to more than 10% of the bone marrow. Also required was a GOG performance status of 0-2 and adequate hematologic, renal, and hepatocellular functions, defined as granulocytes—1500/ul and platelets—100,000/ul; creatinine—1.5 mg%; and SGOT—3 times upper limit of normal; and bilirubin—1.5 mg/dl.","Patients with tumors of low malignant potential or those treated previously with either gemcitabine or topotecan were ineligible, as were those with any other malignancy (except non-melanoma skin cancer) within the previous 5 years. ",NA,NA
12540024,NA,Combination,No,Patients with Unresectable Adenocarcinoma of the Pancreatic Head,"Only patients with locally advanced (unresectable) pancreatic adenocarcinoma were eligible. Locally advanced disease was defined as involvement of the celiac axis or superior mesenteric artery (SMA), or occlusion of the superior mesenteric vein (SMV)-portal venous confluence, and absence of metastatic disease. Metastatic disease was defined as the presence of any extrapancreatic visceral or bony metastatic disease (i.e., regional nodal disease was not considered metastatic). Cytologic or histologic proof of adenocarcinoma of the pancreatic head prior to treatment was required. Patients unable to undergo resection because of underlying medical problems and inoperable patients who had undergone prior operative staging were eligible. There was no upper age restriction, but patients had to have a Karnofsky performance status >70 and had to be able to maintain adequate oral nutrition (90–100% of the estimated required calories and protein).Also, an absolute granulocyte count (AGC) >1500 cells/mL, platelet count >100,000 cells/mL,serum creatinine level <1.5 mg/dL, serum bilirubin <2 mg/dL, and alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) <5 times the upper limit of normal were required prior to the start of therapy. Patients were also required to have adequate bilateral renal function demonstrated by contrast filtration on abdominal CT scan and normal serum creatinine. ","Patients with fever, evidence of infection, or other coexisting medical condition that would preclude protocol therapy were not eligible.",NA,NA
14533441,NA,Combination,No,Patients with Inoperable or Metastatic Non-small Cell Lung Cancer,"Patients were deemed eligible for entry into this study if they met the following criteria: (a) a histologically confirmed diagnosis of NSCLC; (b) stage IV disease or stage IIIb disease that was not a candidate for curative radiation; (c) had no prior systemic therapy for lung cancer; (d) a bidimensional measurable non-central nervous system (CNS) lesion; (e) a performance status of 0, 1, 2 on the Eastern Cooperative Oncology Group, (ECOG) (Zubrod) scale; (f) adequate bone marrow function (neutrophil count >= 1500 ul, platelet count >= 100,000/ul, hemoglobin>= 9.0 g/dL after transfusion, if required), adequate hepatic function aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels < 2 times the upper limit of normal or ,< 5 times upper limit normal (ULN) if liver mets present, bilirubin <= the upper limit of normal), adequate renal function (creatinine ,2.0 mg/dL or creatinine clearance >= 50 ml/min); (g) at least 4 weeks from last surgery (lesser period is acceptable if deemed in the best interest of the patient) at least 24 hours since last radiation treatment; (h) age greater than 18 years; and (i) written informed consent by the patient. ","Patients were ineligible if they had acute intercurrent illness such as infection; previous chemotherapy; clinical signs or symptoms of brain/leptomeningeal metastases confirmed by CT/MRI—patient may be included if CNS metastases are asymptomatic on neurologic examination and is not receiving glucocorticoids to control symptoms; concurrent malignancies or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell cancer of the skin or carcinoma in situ of the cervix.",NA,NA
11157033,NA,Combination,No,Locally Advanced Head and Neck Cancer,"Patients eligible for the study had locally or regionally advanced cancer of the extracranial head and neck without evidence of distant metastases. Patients were judged to be unresectable by the referring surgeon, found to be unresectable at surgery, or had advanced disease (T3/4 or N3 according to the American Joint Committee on Cancer staging) and were medically inoperable or refused surgery. Eligibility criteria included Karnofsky performance status score >= 60, age >= 18 years, estimated life expectancy of at least 16 weeks, adequate bone marrow reserve (hemoglobin > 9 g/dL, platelet count > 100 *10^9/L, granulocyte count > 1.5*10^9/L), adequate renal function (serum creatinine <= 2.0 mg/dL and blood urea nitrogen <= 40 mg/dL), and adequate liver function (bilirubin < 2.0 mg/dL, prothrombin and activated partial thromboplastine times <= 1.5 times control, and ALT and AST elevated to no more than three times normal range). A complete history and physical examination were performed before treatment, including height, weight, performance status, head and neck computed tomography (CT) and/or magnetic resonance imaging scans, and direct endoscopy under anesthesia to assess tumor extent and determine stage. All patients signed an informed consent approved by the institutional review board and were treated at the University of Michigan Hospital (Ann Arbor, MI) and the Ann Arbor Veterans Affairs Research Service.",Patients who had experienced prior chemotherapy or radiation were not allowed to participate in the study.,NA,NA
12003196,NA,Combination,No,non-small cell lung cancer,"To be eligible for the study, patients must have had histologically confirmed NSCLC, measurable or assessable disease, clinical or pathological stage IIIB-IV or inoperable disease. Patients were also required to be ≤75 years, have a Karnofsky performance status (KPS) ≥60, have a life expectancy >12 weeks, and be in close proximity to the hospital to ensure treatment compliance. Patients could not have received prior chemotherapy or radiation treatment. Also required were adequate bone marrow reserve (neutrophils ≥2 × 10^9/L, platelets ≥100 × 10^9/L, hemoglobin ≥10 g/dL, hematocrit ≥30%), adequate liver function (total bilirubin level ≤1.5 mg/dL and alanine aminotransferase [ALT] and aspartate aminotransferase [AST] levels <3 times the upper limit of normal, including patients with liver metastasis), and adequate renal function (serum creatinine level ≤2 mg/dL), no severe uncontrolled comorbidity, and no second malignancies. ",Patients were excluded if they had brain metastases or peripheral neuropathy >grade 2. ,first treatment cycle,NA
12201494,NA,Combination,No,non-small cell lung cancer,"histologically confirmed stage IIIA, IIIB, or IV NSCLC; age up to 75 years; Karnofsky performance status ≥60; life expectancy >12 weeks; no previous radiotherapy or chemotherapy; measurable or evaluable disease; adequate bone marrow reserve (neutrophil count ≥2 × 10^9/L, platelet count ≥100 × 10^9/L, hemoglobin ≥10 g/dL, and hematocrit ≥30%); normal liver function (bilirubin ≤1.5 mg/dL, aspartate aminotransferase [AST] and alanine aminotransferase [ALT] up to 1.5 times the upper limit of normal [ULN] including patients with liver metastases); adequate renal function (creatinine ≤1.4 mg/dL); and residency in the same area to ensure study compliance. ","Patients were excluded for the presence of severe uncontrolled co morbidity and second malignancies, or brain metastases or peripheral neuropathy World Health Organization (WHO) >grade 1.",first cycle,NA
12419757,NA,Combination,No,"Ovary; Lung; Sarcoma; Breast; Colorectal; cervix, endometrium, kidney, hepatoma, melanoma, peritoneum","Eligibility criteria included presence of a pathologically confirmed malignancy refractory to standard treatment or for which no standard treatment exists, evaluable disease (by tumor markers, physical exam or radiology), age ≥18 years, life expectancy of ≥2 months, and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2. Required laboratory parameters were hemoglobin ≥9 g/dl, neutrophil count ≥1500/mm^3, platelet count ≥100000/mm^3, creatinine ≤2 mg/dl, bilirubin ≤1.5 times the institutional upper limit of normal (ULN), and AST and ALT ≤2 times the institutional ULN. ","Patients with prior exposure to rubitecan or gemcitabine were excluded. No treatment with chemotherapy, radiation therapy or immunotherapy was allowed 3 weeks prior to enrollment. Other exclusion criteria included pregnancy or breast feeding and active or uncontrolled central nervous system metastases. All patients provided written informed consent.",NA,NA
11810040,NA,Combination,No,Anthracycline- and Taxane-Refractory Breast Cancer Patients,"The eligibility criteria for patients entering this study included: histologically/cytologically proven metastatic breast cancer, previous exposure to both anthracyclines and taxanes, no prior chemotherapy with gemcitabine or with the combination of 5-FU/LFA (previous CTX exposure was permitted only for the adjuvant setting), any radiotherapy or chemotherapy completed at least 4 weeks prior to entry into the trial, age <= 70 years, ECOG performance status 0–2, absence of CNS involvement, bidimensionally measurable disease, life expectancy of at least 12 weeks, adequate renal, hepatic and hematologic function, written signed informed consent. ",NA,the first cycle,NA
33052756,2018-000482-36,Single Drug,Yes,Relapsed or Refractory Acute Myeloid Leukemia,"Patients aged 16 and above; Relapsed or refractory AL (excluding promyelocytic leukaemia) considered by the investigator ineligible for intensive chemotherapy regimen at that time; ECOG Performance Status (PS) of 0-2; Women of child-bearing potential must have negative serum or urine pregnancy test within two weeks prior treatment start; Fertile male or female patients must use highly efficient contraception for the duration of the study and 6 months after the last ORY-1001 dose; Male patients must use condoms to avoid drug exposure of their partner; Patients must be capable of understanding and complying with protocol requirements, and they must be able and willing to sign a written informed consent; Life expectancy of at least 2 months ","Cancer history that according to the investigator might confound the assessment of the study endpoints; Patients with uncontrolled hypertension or diabetes, hepatitis or HIV; Intercurrent illness or social situation that will limit compliance with study requirements; Pregnancy or breast feeding patient; Any medical condition which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities if entered into the clinical study; Acute myeloid leukaemia treatment within the previous 14 days. Hydroxyurea or 6mercaptopurine are allowed until 12 hours prior study treatment start and after the first treatment block (day 1-5) in case of hyperleucocytosis; Patients medicated with anti-depressants reported to have KDM1A/LSD1 inhibitory activity: Tranylcypromine or Phenelzine; Radiotherapy less than 2 weeks prior to the start of the study.",NA,NA
25977344,NCT01295827,Single Drug,No,Adenocarcinoma; Carcinoid/neuroendocrine; Colorectal; Melanoma; Merkelcellcarcinoma; Non–smallcelllungcancer; Prostate; Kaposisarcoma; Softmmtissue sarcoma; Peripheral nerve sheath tumor; Pancreatic adenocarcinoma; Squamouscell lung cancer,"Patients were eligible for enrollment if they were 18 years or older, had a histologically or cytologically confirmed advanced solid tumor, experienced disease progression on or were intolerant of or not eligible for standard therapy, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and had adequate organ function. All patients provided written informed consent.","Key exclusion criteria included previous treatment with a PD-1, PD-L1, or cytotoxic T-lymphocyte–associated protein 4 inhibitor, requirement for chronic systemic steroid therapy, and presence of active autoimmunedisease orinfections. Patients with previously treated brain metastases were eligible if they were clinically stable for at least 8 weeks before enrollment (the first 7 patients enrolled were eligible if they were clinically stable for at least 4 weeks). ",during the first 28-day treatment cycle,NA
12562660,NA,Combination,No,Adenocarcinoma; breast cancer; Non-small-cell lung cancer; Transitional cell carcinoma;Soft tissue sarcoma; Soft tissue sarcoma; others,"Patients were eligible if they were 18–75 years of age and had histologically or cytologically confirmed advanced or metastatic solid tumors refractory to conventional therapy. Chemonaive patients with advanced tumors for whom no effective treatment existed were also eligible. Prior surgery, radiotherapy (to <25% of marrow-containing bones), or chemotherapy (maximum two prior regimens) was allowed, but a treatment-free interval of at least 4 weeks was required before study entry. Other inclusion criteria were as follows: WHO performance status of two or less; adequate blood counts (absolute neutrophil count >1500/μl, hemoglobin >10 g/dl and platelets >100 000/μl); adequate renal function (serum creatinine <2 mg/dl); adequate hepatic function (total bilirubin <1.5 mg/dl and alanine aminotransferase/aspartate aminotransferase <3 × upper normal limit); pre-existing peripheral neuropathy up to National Cancer Institute grade 1; and a life expectancy of at least 3 months. All patients signed a written informed consent before study entry.",NA,during the first chemotherapy cycle.,NA
15125746,NA,Combination,No,unresectable local-regional recurrence of breast cancer,"Histopathologic confirmation of a chest wall recurrence with at least 1 cm of gross unresectable disease with or without nodal involvement was required. Patients with synchronous distant metastases were eligible as long as their life expectancy was at least 4 months. No concurrent chemotherapy other than gemcitabine was allowed, with a mandatory washout time of at least 4 weeks from any previous chemotherapy or hormonal therapy. Additional eligibility criteria included age ≥18 years, Karnofsky performance score of 60 or greater, freedom from any medical comorbidity that would limit survival to less than 2 years, and adequate organ function as demonstrated by a white blood cell count greater than 3000/mm3, absolute neutrophil count ≥1500/mm3, platelet count ≥100,000/ mm3, hemoglobin ≥10 μg/dl, creatinine less than 2.0 mg/dl, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than three times the upper limits of normal, total bilirubin less than 2.0 mg / dl, prothrombin time (PT) less than 14, and partial thromboplastin time (PTT) less than 40.",any regional node involvement in the absence of chest wall failure and a history of any prior irradiation to the chest wall and /or supraclavicular fossa regions.,a minimum of 4 weeks after completion of their treatments.,NA
14533444,NA,Combination,No,"Melanoma, NSCLC, Squamous cell cancer, Colon cancer, Lymphoma, Ocular melanoma, Renal cell cancer, ","All patients were required to be either males or females of at least 18 years of age with a histologic or cytologic diagnosis of a metastatic or locally advanced malignancy that is either refractory to standard therapy or for which no standard therapy exists. Prior radiation therapy was allowed (except to the whole pelvis) but must have been completed at least 4 weeks prior to study entry. Prior chemotherapy was also allowed providing that it was completed at least 4 weeks prior to entry into the study and that the patient had recovered from the acute toxicities of that therapy. However, for nitrosoureas or mitomycin C therapy, this treatment must have been completed at least 6 weeks prior to study entry. All patients were also required to have a performance status of 0 to 2 on the Southwest Oncology Group/Eastern Cooperative Oncology Group (SWOG/ECOG) scale and to have a life expectancy of at least 12 weeks. Participants were also required to have adequately functioning organs <= 15 days prior to registration, as indicated by the following laboratory values: serum creatinine < 2.0 mg/dL or calculated creatinine clearance > 60 ml/min, and serum bilirubin <= 1.5 mg/dL, regardless of whether or not their cancer had liver involvement. Also, the SGOT/SGPT of each patient was required to be < 3 * the institutional upper limit of normal values, unless the liver was involved with the tumor, in which case the SGOT/SGPT had to be < 5 * the institutional upper limit of normal. In addition, every participant’s absolute neutrophil count (ANC) had to be greater than 1.5 * 10^9/L and platelets had to be greater than 100 * 10^9/L. All female patients with childbearing potential were required to have a negative serum pregnancy test within 7 days of their study enrollment, and all men and women of reproductive potential were required to use an effective form of contraception while enrolled in this study. Each patient also had to give written informed consent to participate in this study.","Patients could not have a known hypersensitivity to the study drugs or analogs or could not have used any prior investigational agent within 21 days of study enrollment. No participants were allowed to have any active or uncontrolled infection or any psychiatric disorders that would interfere with their consent or with following up. Pregnant or lactating females were excluded from the study. Patients could not have an active second malignancy with the exception of nonmetastatic, nonmelanoma skin cancer, not requiring chemotherapy or radiation. The presence of symptomatic, uncontrolled central nervous system metastasis, carcinomatous meningitis, or any other concurrent diseases that, in the judgment of the investigator, would make the patient inappropriate for entry into this study were also not allowed. In addition, those with a history of significant myocardial disease (functional class III –IV, unstable angina, recent MI) were kept out of this study. Also, because the combination of mitoguazone, diflornithine, and tegretol produce hepatic necrosis and hepatic failure, patients receiving tegretol had to be off the drug 14 days prior to the study. Finally, in the case of undergoing major surgery, patients were required to wait 21 days after the surgery before enrolling in the study.",during cycle 1.,NA
15349753,NA,Combination,No,advanced hematologic malignant diseases,"Patients were eligible for this study if they had histologically confirmed malignant hematologic disease that was refractory to standard therapy or for which no standard therapy existed. Patients had to be 18 years of age or older and have a performance status of 0, 1 or 2 (Cancer and Leukemia Group B, CALGB, criteria). ","Patients were ineligible if they had a serum creatinine 1.5 mg/dl or greater (or calculated creatinine clearance of less than 60 ml/min) or serum total bilirubin 2.0 mg/ dl or greater (unless due to Gilbert’s syndrome). Patients were also excluded if they had significant local or systemic infection at the onset of the study, bleeding requiring platelet transfusions, symptomatic CNS disease, pregnancy, or any other significant underlying medical condition that would make administration of either gemcitabine or 2CdA unusually hazardous. In addition, no cytotoxic therapy or radiotherapy was permitted within 2 weeks (6 weeks for mitomycin C and nitrosoureas) of starting therapy with the exception of hydroxyurea, which could be administered up to 72 h prior to the proposed treatment. Patients could not receive warfarin, or steroids (for tumor treatment).",NA,NA
12881394,NA,Combination,No,locally advanced cervical carcinoma,"Women with untreated invasive squamous-cell carcinoma of the cervix of International Federation of Gynecology and Obstetrics (FIGO) stages IIB (local-zed disease with parametrial involvement), stage III (extension of the tumor to the pelvic wall) or stage IVA (involvement of the bladder or rectal mucosa) were enrolled in the study from July 1999 to March 2001. All cancers were histologically confirmed. Patients with disease outside the pelvis and para-aorticlymph nodes metastases were not eligible. This was determined by non-invasive methods. An Eastern Cooperative Oncology Group performance status 0, 1 or 2 and no history of previous cancers were required. Other eligibility criteria were as follows: leukocyte count >3.0 × 10^9/l; platelet count >100 × 10^9/l; hemoglobin ≥10 g/dl (after transfusion if necessary); serum creatinine level <2.0 mg/dl (177 μmol/l); serum bilirubin level <1.5 × upper normal limit at the institution where it was measured; and serum aspartate aminotransferase level <3 × upper normal limit at the institute where it was measured. All patients gave their written informed consent.",NA,NA,NA
11458814,NA,Combination,No,"Previously Treated, Advanced Nonsmall Cell Lung Cancer","All patients underwent a complete history, physical examination, and laboratory evaluation. Eligibility criteria included (i) histologic or cytologic evidence of unresectable NSCLC; (ii) age at least 18 years; (iii) Eastern Cooperative Oncology Group (ECOG) performance status <= 2; (iv) life expectancy >=12 weeks; (v) previous treatment with at least one chemotherapeutic regimen; (vi) at least a 3-week period since previous chemotherapy or radiotherapy (at least 6 weeks for nitrosoureas or mitomycin C) and recovery from any significant toxicity associated with the most recent therapy; (vii) adequate bone marrow function (white blood cell count [WBC] >=3500/ mm3 or granulocytes >=1500/mm3, platelets >=100,000/ mm3, hemoglobin [Hgb] >=9g/dl), hepatic function (bilirubin <= 1.5 times the upper limit of normal), aspartate transaminase [AST] or alanine transaminase [ALT] <= 3.0 times normal (AST or ALT <= 5 times normal if due to malignancy), renal function (creatinine <= 2.0 mg/dl or Clcreat >= 60 ml/min); and (viii) written, informed consent. ","Exclusion criteria included (i) clinical evidence of active brain metastases; (ii) serious pre-existing medical conditions, which would prevent full compliance with the study; (iii) pregnancy; or (iv) prior topotecan or gemcitabine treatment.",NA,NA
16327288,NA,Combination,No,Pancreatic Carcinoma,"The entry criteria included patients with locally nonresectable pancreatic carcinoma with no evidence of distant metastases. Patients with limited para-aortic lymph node involvement at a level as low as the left renal vein were regarded as eligible. Postoperative patients with a positive surgical margin or with local recurrence after resection were also eligible, but only if they were to be treated exactly as the new cases. Further eligibility included age between 20 and 75 years, ECOG performance status of 0–2, without preceding chemotherapy or radiotherapy, and without a history of another malignancy. Adequate bone marrow (white blood cell count 3,000–12,000/mm3, platelet count > 75,000/mm3, and hemoglobin level > 10 g/dl), renal function (blood urea nitrogen and creatinine within the normal limits), and hepatic function (aspartate aminotransferase (AST) and alanine aminotransferase (ALT) three times below the upper limit of normal) were also required. Written informed consent was provided by all patients.",NA,2 months after the end of radiotherapy,NA
11172947,NA,Combination,No,locally advanced pancreatic cancer,"Patients with histologically or cytologically confirmed locally advanced unresectable adenocarcinoma of the pancreas were enrolled onto this trial between January 1997 and August 1998. They were required to have a World Health Organization (WHO) performance status of 0 –2, age between 18 and 75 years, life expectancy of at least 3 months, and adequate bone marrow (WBC count >= 4000/uL, platelet count >= 100,000/uL), renal (serum creatinine concentration < 1.5 mg/dL), and hepatic function (serum bilirubin < 1.5 mg/dL, serum transaminase level <2 * the upper normal range). Patients were diagnosed/staged by laparotomy and open biopsy, or by fine-needle aspiration cytology following computed tomographic scanning +- angiography as needed to document unresectable disease. Endoscopic ultrasonography was also used in the more recent cases. Staging followed the American Joint Committee (AJCC) tumor-node-metastasis system. All patients had to have bidimensionally measurable disease that could be assessed by radiographic procedures.  Written informed consent was obtained from all patients according to institutional regulations.","Patients were excluded if they had distant metastases, serious or uncontrolled concurrent medical illness, or a history of other malignancies. No prior chemotherapy or radiation therapy was allowed.the first two treatment courses",the first two treatment courses,NA
15226322,NA,Combination,No,muscleinvasive transitional cell carcinoma that was clinical stage T2 or T3 and amenable to transurethral resectionEligible patients had histologically confirmed muscleinvasive transitional cell carcinoma that was clinical stage T2 or T3,"Eligible patients had histologically confirmed muscleinvasive transitional cell carcinoma that was clinical stage T2 or T3 and amenable to transurethral resection. All patients were candidates for cystectomy and had absolute neutrophil count (ANC) >= 1,500/uL, platelets >= 100,000/uL; creatinine <-= 2.0, bilirubin <= 3 times the institutional upper limit of normal, AST <= 4 institutional upper limit of normal, Eastern Cooperative Oncology Group performance status <= 1, and no prior radiotherapy or systemic therapy for transitional cell carcinoma. Patients with adenomatous or squamous differentiation of their tumors were eligible. Imaging studies (abdominal/pelvic computed tomography [CT] scan and chest radiograph) were performed before initiation of therapy in order to rule out any evidence of locally advanced or metastatic disease. All patients were assessed by the senior urologic, medical, and radiation oncologist before participation to ensure compliance with the eligibility criteria. ",NA,at least 3 months following the completion of therapy before patients were enrolled at the next dose level,NA
12394252,NA,Combination,No,"pancreatic, ovarian, renal, NSCLC","All patients had to have a histologic or cytologic diagnosis of locally advanced or metastatic NSCLC, ovarian, pancreatic or renal cancer. Patients from 18 to 80 years of age with a predicted life expectancy of at least 3 months and a Karnofsky performance status of at least 60 were included. Patients were allowed to have had up to two previous chemotherapy regimens, provided they discontinued previous therapy at least 3 weeks prior to study start and recovered from the toxic effects of the treatment. No other form of therapy, such as radiotherapy, was allowed for at least 3 weeks before enrollment in the study. Adequate bone marrow reserve [white blood cell (WBC) count 3.5 * 10^9/l, platelets 90 * 10^9/l, hemoglobin 100 g/l], liver function [bilirubin 1.5 imes the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 times the ULN or 5 times the ULN in patients with metastatic liver disease] and renal function (serum creatinine within 1.5 times the ULN) were required. Patient compliance and geographic proximity had to allow for adequate follow-up. In females, the child-bearing potential had to be either terminated by surgery, radiotherapy or menopause, or attenuated by use of an approved contraceptive method during and for 3 months after the trial.","Patients were excluded from the trial if they were receiving concomitant cytotoxic therapy, hormonal treatment, immunotherapy or an experimental agent. Further exclusion criteria included active central nervous system metastases, active infection, serious concomitant systemic disorders, congestive heart failure [New York Heart Association (NYHA) class III and IV], uncontrolled hypertension, unstable angina, severe arrhythmias and intolerance to human protein.",first cycle of therapy,NA
16012794,NA,Combination,No,metastatic breast cancer,"Patients aged 18 to 75 years with histologically confirmed metastatic breast cancer were included in the trial. Patients were required to have adequate hematological, renal, hepatic and cardiac function (ANC >1.5 × 10^9/l; platelets >100 × 10^9/l; hemoglobin >10 g/dl; serum bilirubin <1.5 × ULN, serum transaminase levels <2.5 × ULN in patients without liver involvement or <5.0 × ULN in patients with liver metastases; serum creatinine level within normal range; left ventricular ejection fraction of at least 50%), a Karnofsky performance status of at least 60, an estimated life expectancy of at least 12 weeks, a negative pregnancy test and appropriate contraception throughout the study (in premenopausal women only). Written, informed consent was required.","Exclusion criteria included brain metastases, pretreatment with the study medication, radiotherapy within 4 weeks prior to study entry, extensive radiotherapy (more than 30% of bone marrow involved), a history of other prior malignancies (except for curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix), severe cardiac arrhythmias, congestive heart failure, myocardial infarction within 6 months prior to study start, active infection or other serious underlying medical or psychiatric conditions which would impair the ability of the patient to receive protocol treatment. Pregnant or lactating women were ineligible.",Cycle 1,NA
15714201,NA,Combination,No,patients with carcinoma,"Patients with histologically or cytologically confirmed carcinoma and BM were eligible for the study provided that surgery was not an option. Eligibility criteria also included an Eastern Cooperative Oncology Group performance status of 0 – 2 and age >=18 years. Adequate haematologic function was required: a white blood count of >=3500 cells/ul, a platelet count of >=100 000/ul, and a haemoglobin level of >=10 g/dl. Also, serum bilirubin needed to be below two times the upper limit of normal (ULN), ALT and AST below three times ULN – ALT and AST could be elevated to five times ULN in patients with known metastatic disease in the liver and creatinine below two times ULN. Previous chemotherapy was allowed up to second line as long as gemcitabine had not been used. Patients had to be stable on steroids. For female subjects of childbearing potential, adequate contraception during and 3 months post-treatment was required. ","Patients with seizures who were not stable on antiepileptic medication were excluded. No previous radiotherapy to the brain of any form was allowed. No surgical procedure to the brain and no confusion was allowed (correctable confusion (hypercalcaemia, hyponatremia) with time to correct it and documented adequate mini-mental test scoring was allowed). Patients with haemorrhagic metastases were excluded and patients allergic to contrast material either underwent MRI as baseline study or were excluded.",NA,NA
12182983,NA,Combination,No,LOCALLY ADVANCED PANCREATIC CANCER,"Patients with histologically documented adenocarcinoma of the pancreas were enrolled onto this study between December 1999 and July 2001. Eligible patients included those with locally unresectable disease, because of vascular invasion or extensive regional adenopathy. Required laboratory parameters included granulocyte count >= 1,800 cells/uL, platelet count >= 100,000 cells/uL, bilirubin <= 3 mg/dL, and creatinine <= 3 mg/dL. Patients with biliary or gastroduodenal obstruction must have had prior drainage before starting chemoradiation. A complete history and physical examination were performed on all patients before treatment. Height, weight, performance status, and tumor stage were recorded. Required staging studies included a chest radiograph and abdominal computed tomographic (CT) scan. Laparoscopy was not required. ","Patients with known metastatic disease to other organs, ascites, or peritoneal implants and those who had received prior irradiation to the planned field were ineligible.",NA,NA
16251868,NA,Combination,No,Pancreatic; adenocarcinoma of unknown primary; Ovary; Colorectal; Gastric; Anal canal; Bile duct carcinoma; Head and neck; Mesothelioma; Sarcoma; Oesophagus,"Patients were eligible if they had a histologically or cytologically confirmed advanced solid tumour for which no curative therapy exists. Other eligibility criteria included a WHO performance status of 0 – 2 and age >= 18 years. Previous radiotherapy or anticancer chemotherapy had to be discontinued for >= 4 weeks before entry into the study, or 6 weeks in case of nitrosourea or mitomycin C. All patients had to have acceptable bone marrow function, defined by neutrophil counts (ANC) >= 1500/ul, platelets >= 100 000/ul and Hgb >= 5.6 mmol/l; and adequate hepatic and renal function defined as creatinine clearance >=50 ml/min, total bilirubin <= 1.5*upper limit of normal and ASAT and ALAT <= 2.5 times the normal upper limit (or <=5 times the normal upper limit in case of hepatic metastases). The study protocol was approved by the Medical Ethics Committee of the hospital and all patients had to give written informed consent.",NA,cycle 1,NA
12481889,NA,Single Drug,No,Children with Relapsed or Refractory Leukemia,"Between February 1997 and October 1998 we enrolled patients with relapsed or refractory leukemia who were under 21 years old, for whom conventional therapy had failed, and for whom no effective therapy was known. The protocol was approved by the individual institutional review boards (IRBs) of participating institutions. Informed consent was obtained from each patient or their guardians. Patients were required to have fully recovered from effects of prior therapy before entry (2 – 4 weeks from prior chemotherapy) and to have near normal organ function (hepatic, renal, etc.) with the exception of cytopenias. Patients who had prior bone marrow transplant were eligible.",Patients with central nervous system (CNS) disease (> 5% cells/mm^3 with blasts on cytospin) were not eligible.,NA,NA
15165093,NA,Single Drug,No,non-small cell lung cancer,"Inclusion criteria required all patients to sign a consent form and have a confirmed histologic diagnosis of NSCLC. Patients who had prior radiation therapy were eligible as long as the irradiated area was not the only source of measurable disease. All patients were required to have measurable disease (minimum 1cm × 1 cm by computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound) and adequate bone marrow reserve (white blood cell count (WBC) 3500 mm^3, platelets 100,000 mm^3, hemoglobin 10 gm%, and hematocrit 30%).  The protocol was approved by the Institutional Review Board of the University of Pittsburgh.","No prior systemic chemotherapy or biotherapy was permitted; any other form of therapy, such as radiation or steroids, was not permitted for at least 3 weeks prior to enrollment. Patients were excluded if they had central nervous system metastases, active infection, inadequate liver function (bilirubin >1.5 mg/dl, prothrombin or partial thromboplastin time = 1.5 times control, asparate aminotransferase (AST) and alanine aminotransferase (ALT) = 3 times normal (or five times normal for patients with liver metastases), inadequate renal function (creatinine >1.5 mg/dl), elevated calcium level (calcium >10.5 mg/dl), active cardiac disease (decompensated heart failure, angina, and/or arrhythmias), severe pulmonary disease, significant peripheral vascular disease, and neurologic (such as seizures) or psychiatric disorders.",during the first cycle of treatment,NA
12394268,NA,Combination,No,patients with advanced esophageal cancer,"Patients were eligible for entry if they had histologically confirmed non-resectable, stage II (proximally located tumor), III or IV SCC or adenocarcinoma of the esophagus, had not received prior chemotherapy, were >18 years of age, had a Karnofsky performance status >= 60% as well as adequate bone marrow, liver and renal function. Patients may have had a prior malignancy if they had been curatively treated and had been relapse free for >3 years.","Patients were excluded if they had an active infection, liver enzymes (ALT/AST) > 3 times the upper reference value (URV), bilirubin >= 1.5 times the URV or if their creatinine clearance was < 60 ml/ min. Increased calcium levels, pregnancy or breastfeeding and complications that needed acute intervention were also reasons for exclusion.",first 2 cycles of therapy (3 months),NA
14760128,NA,Combination,No,non-small-cell lung cancer,"Patients with histologically-proven stage IIIB–IV NSCLC who were suitable for cisplatin and gemcitabine chemotherapy were eligible for entry onto the study. Other eligibility criteria were as follows: age ≥18 years; World Health Organization (WHO) performance status <2; life expectancy ≥3 months; no chemotherapy or investigational agent administered during the previous 28 days (40 days for mitomycin C, nitrosoureas or immunotherapy); no major surgery or radiotherapy during the previous 28 days; no evidence of brain metastases; no concurrent malignancy (except basal cell carcinoma and in situ cervical cancer); no active infection and no other severe concomitant illness. An effective contraception method was recommended for the overall duration of treatment and for at least 6 months post-treatment. Eligible patients fulfilled the following criteria for study entry: neutrophil count, ≥1.5 × 10^9/l; hemoglobin ≥10 g/dl; platelet count ≥100 × 10^9/l; serum creatinine <1.5 × upper limit of normal (ULN); and total bilirubin <1.5 × ULN with serum aspartate aminotransferase and alanine aminotransferase levels <2.0 × ULN. All patients gave their written informed consent before treatment according to institutional and national guidelines. The study was performed according to French and Swedish drug regulations and complied with the principles of the Helsinki Declaration. ","Women who were pregnant, breast feeding, or adults of reproductive potential without an effective birth control method at least 1 week prior to treatment were excluded; ",during cycle 1,NA
12499100,NA,Combination,No,previously untreated advanced non-small cell lung cancer,"Patients with histologically or cytologically proven stage IIIB or IV NSCLC who had not previously received chemotherapy or radiotherapy were eligible for this study. Other eligibility criteria were: (1) age between 20 and 75 years; (2) Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less; (3) a measurable lesion; (4) life expectancy of 3 months or more; (5) adequate bone marrow function (white blood cell (WBC) count from 4000 to 12 000/ml, neutrophil count of 2000/ul or more, platelet count of 100 000/ul or more, and hemoglobin level of 9.0 g/dl or more), renal function (serum creatinine levels less than 1.5 mg/dl and creatinine clearance rate of 50 ml/min or more), and hepatic function (total serum bilirubin level less than the upper limit of the normal range, AST and ALT levels less than or equal to twice the upper limits of the normal ranges), and arterial oxygen pressure of 70 mmHg or more. Written informed consent was obtained from all patients.","Patients were excluded if they had active infections, severe heart disease, interstitial pneumonia or lung fibrosis, peripheral neuropathy, pleural effusion or pericardial effusion that required drainage, symptomatic brain metastasis, or an active second malignancy.",during the first cycle of chemotherapy,NA
12643004,NA,Combination,No,Lung; Colorectal; Unknown primary; Head and neck; Esophagus; Bladder/transitional cell CA; Kidney; Breast; Anal; Others,"Patients with histologically or cytologically confirmed cancer not curable by standard means and have measurable/assessable disease were eligible. Prior chemo- or radiation therapy was allowed as long as patients had completely recovered from all treatmentrelated toxicities. Patients were required to have adequate performance status (SWOG 0–2) with a life expectancy greater than 12 weeks. Patients must have adequate hematological (absolute neutrophil count >= 1500/uL, platelet count >100,000/uL), renal (serum creatinine <=1.5), and hepatic (serum bilirubin and AST within twice institutional limits) parameters.  ",Patients who were pregnant or with unstable medical conditions (such as uncontrolled congestive heart failure and unstable angina) were excluded. ,during cycle 1,NA
12393998,NA,Combination,No,Breast; NSCLC; Bladder/ureter; Colorectal; Sarcoma; Small-cell lung cancer;  Unknown primary;Other,"All patients underwent a complete history, physical examination, and laboratory evaluation. Eligibility criteria included: 1) histologic evidence of a solid tumor refractory to conventional therapy; 2) at least 18 years of age; 3) ECOG performance status <=2; 4) life expectancy >=12 weeks; 5) off previous anticancer therapy for at least 3 weeks (at least 6 weeks for nitrosoureas or mitomycin C); 6) adequate bone marrow function (WBC >=3500/mm^3 or granulocytes >=1500/mm^3, platelets >=100,000/mm^3, Hgb >=9 gm%), hepatic function (bilirubin <=1.5 mg/dl, serum aspartate transaminase (AST) or serum alanine transaminase (ALT) <=2.5 times normal (AST or ALT <=5 times normal if due to malignancy), renal function (creatinine <=2.0 mg/dl or Clcreat >= 60 ml/min); and 7) written, informed consent. ","Exclusion criteria included: 1) serious preexisting medical conditions that would prevent full compliance with the study, 2) pregnancy, and 3) clinical evidence of active brain metastases.",NA,NA
15493356,NA,Combination,No,Gastric; Esophogeal; Prostate; Gall bladder; Renal Cell; Fibrous histiocytoma; Lung; Adrenal cortical; Colon; Rectal; ,"Patients with histologically confirmed advancedstage solid tumors for whom no conventional therapy existed were eligible. Patients had to be at least 18 years of age and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 prior to treatment. Demonstration of measurable or evaluable disease and adequate renal, liver, and bone marrow function [serum creatinine <= 1.5 times the upper limit of normal (ULN), and creatinine clearance >50 cc/min, total bilirubin <= 1.5 mg/dL, absolute neutrophil count (ANC) >= 1500/uL, platelet count >= 100,000/mL, and hemoglobin >= 9 g/dL were required. Patients were not permitted to have treatment with prior topotecan/gemcitabine or prior chemotherapy involving > 6 courses with alkalating agents or >4 courses of carboplatin or any prior nitrosourea or Mitomycin C. Patients also were required to have a survival expectancy of > 3 months. Signed informed consent approved by our Institutional Review Board was required.","Major exclusion criteria included women of childbearing potential not using contraceptives, who were pregnant or who received radiation therapy involving >25% of marrow-productive bone or >30% pelvic irradiation. Patients were excluded if any radiation therapy, hormone therapy, or immunotherapy was given within three weeks prior to treatment. Clinical evidence suggestive of brain metastases was an exclusion if it occurred within three weeks prior to treatment, and concurrent serious infection or lifethreatening illness was an exclusion.",cycles 1 or 2,NA
11821464,NA,Combination,No,Patients With Inoperable Non–Small-Cell Lung Cancer,"Patients with histologically or cytologically confirmed, locally advanced, unresectable NSCLC who had not undergone any previous oncologic treatment were enrolled in a phase I trial of combined radiotherapy and weekly GEM. Specific eligibility criteria were as follows: Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; age range 18 to 75 years; no pulmonary or cardiovascular contraindications; adequate hematologic function (WBCs >=4,000/uL, neutrophil count >= 2,000/uL, platelet count >= 100,000/uL, and hemoglobin level >=11 g/dL); adequate hepatic function (AST and ALT < three times normal values, total bilirubin < 1.5 times normal values, and prothrombin time and activated partial thromboplastin time < 1.5 times normal values); adequate renal function (creatinine serum concentration < 1.5 times normal values); and life expectancy longer than 3 months. Generic eligibility criteria for oncologic treatment were applied as well. All patients gave written informed consent in conformity with European Community regulations governing good clinical practice.",NA,NA,NA
11593051,NA,Single Drug,No,squamous head and neck; sarcoma; squamous esophageal; non-small cell lung cancer; ovarian,"Patients with advanced, previously treated, solid tumors who fulfilled all the following criteria were eligible for the study: 18-75 years of age, Eastern Cooperative Oncology Group performance status (PS) of 0-2, estimated life expectancy of >12 weeks, prior treatment with at least one chemotherapy schedule (including 30-min gemcitabine infusion) and no radiotherapy for at least 3 weeks prior to protocol entry. We defined as refractory those patients with progressive disease during or within 6 months of adjuvant therapy or during or within 3 months of chemotherapy in advanced disease. ","Exclusion criteria included: active infection, prior central nervous system metastases, significant renal, hepatic or bone marrow impairment, active cardiac disease requiring therapy for failure, angina, arrhytmias and/or myocardial infarction in the preceding 6 months.",during the first cycle.,NA
16222156,NA,Combination,No,non-small cell lung cancer,"Chemonaive patients were eligible for this trial if they had histologic or cytologic diagnosis of NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–2, stage IIIB with cytologically positive pleural effusion or stage IV, measurable and previously unirradiated lesion, no clinical evidence of brain metastases, and adequate hematopoietic, liver and kidney function.",NA,NA,NA
15380578,NA,Combination,No,PATIENTS UNDERGOING PANCREATICODUODENECTOMY WITH EXTENDED LYMPHADENECTOMY FOR LOCALLY ADVANCED PANCREATIC CANCER,"Eligible patients were required to be >18 years and a performance status <=2, based on World Health Organization (WHO) criteria, and have radiologic malignant or cytologically defined adenocarcinoma (<=5cm in diameter) in either the caput or ampullar region of the pancreas considered resectable with curative intent. On the basis of radiologic imaging, the tumor should have been local or locally advanced T1–T3. ","Patients were excluded for any other concomitant cancers or serious illnesses and for metastatic disease. Patients with lymph node–positive disease based on CT, MRI, or US or a performance status >2 were also excluded from the study. Patients were excluded if the absolute neutrofil count was <1.5 *10^9/L, platelets <150 * 10^9/L serum bilirubin >1.5 times the upper limit of the reference range (ULRR), ALT/aspartate aminotransferase >2.5 times the ULRR, or serum creatinine >1.5 times the ULRR.",NA,NA
11804180,NA,Combination,No,metastatic breast cancer,"Eligibility criteria were histologically confirmed metastatic breast cancer with evidence of disease progression; age 18–70 years; WHO performance status of 0–2; adequate bone marrow reserve (WBC count ≥3.5 × 10^9/l, neutrophils ≥2 × 10^9/l, platelets ≥100 × 10^9/l, hemoglobin ≥9 g/l); adequate organ function (bilirubin <1.5 mg/dl, AST or ALT < 3 times upper limit of normal range, and creatinine ≤2 mg/dl); life expectancy of at least 12 weeks; no severe uncontrolled co-morbidity, no second malignancies and no central nervous system (CNS) metastases.",NA,NA,NA
11899362,NA,Combination,No,Patients with Metastatic Breast Carcinoma Previously Treated with Taxanes,"Patients were required to have histologically confirmed, locally advanced or metastatic breast cancer, which was measurable or evaluable, and must have failed at least 1 prior chemotherapy regimen for metastatic disease. Other requirements included Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 and adequate organ function (neutrophil count ≥ 1500/μL and platelet count ≥ 100,000/μL, serum creatinine within normal limits or calculated creatinine clearance ≥ 60 mL/minute, and aspartate aminotransferase and total bilirubin < 2-fold elevated). Preor perimenopausal women were required to have a negative pregnancy test within 7 days of registration. All patients were required to provide written informed consent. The research protocol and consent were approved by the Institutional Review Board at Montefiore Medical Center.",NA,during the standard dose escalation portion of the study,NA
15245938,NA,Combination,No,bladder cancer,"Patients were required to have an Eastern Cooperative Oncology Group performance status of 0 or 1 and to have a histologic diagnosis of urothelial carcinoma of the bladder. All patients had clinical Stage T2-T3 lesions and were cystectomy candidates. Before study entry, all patients underwent maximal transurethral resection with bladder mapping. ",NA,NA,NA
11704320,NA,Combination,No,ADVANCED PANCREATIC CANCER,"Patients with histologically confirmed adenocarcinoma of the pancreas were enrolled onto this study from November 1998 to May 2000. Eligible patients included those with medically inoperable or surgically unresectable locally advanced disease, encompassable within a single tolerable radiation treatment portal with acceptable doses to liver and kidney. Resected patients with residual disease were also eligible. Patients with asymptomatic pulmonary or liver metastases were also eligible if they had an estimated life expectancy greater than 3 months. Eligibility criteria also included an ECOG performance status of 0 to 2, age > 18 years, adequate bone marrow function (absolute neutrophil count > 1500/uL, platelet count > 100,000/uL, hemoglobin level > 10 g/dL), adequate renal function (blood urea nitrogen < 30 mg/dL, creatinine < 2.0 mg/dL), adequate liver function (alanine aminotransferase [ALT] less than 2 *normal; patients with a bilirubin level greater than 2 mg/dL caused by biliary obstruction from tumor were allowed if biliary stenting or surgical bypass was performed and the bilirubin level did not increase in the 2 weeks before treatment), and life expectancy greater than 12 weeks. Patients had to maintain adequate oral intake of 1500 calories per day and adequate hydration or had the placement of a supplemental feeding tube.","However, patients with peritoneal seeding or ascites and those who had received prior chemotherapy or irradiation to the planned field were not allowed.",occurring during treatment or within 4 months after completing treatment.,NA
25854284,NCT00839982,Combination,No,previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age,"Patients aged 60 years or older with AML or high-risk MDS (10–19% bone marrow blasts) and first remission less than 1 year were eligible if: (i) they had had primary refractory disease [had never achieved a morphological complete remission (CR)] or disease in first relapse with a remission duration of less than 1 year, (ii) they had not previously received treatment with cytarabine or clofarabine, and (iii) they were not candidates for intensive chemotherapy or haematopoietic stem-cell transplantation. ",NA,NA,NA
32009149,NCT01514201,Combination,No,newly diagnosed diffuse pontine glioma Pediatric,"Children ≤21 years of age with newly diagnosed diffuse intrinsic pontine glioma, defined as tumors with a pontine epicenter and diffuse intrinsic involvement of the pons, were eligible without biopsy. Patients with atypical tumors were only eligible if a biopsy showed histology consistent with fibrillary astrocytoma, anaplastic astrocytoma, GBM, gliosarcoma, or anaplastic mixed glioma. Patients were required to have a Karnofsky or Lansky performance status ≥50. Patients must not have received prior therapy for their DIPG; had to be able to swallow oral medications; and have adequate baseline renal, hepatic, and hematologic functions. Patients were excluded if they were receiving other anticancer or experimental therapy; had systemic illness, uncontrolled infection, or seizures; or were pregnant or lactating.","Patients were excluded if they were receiving other anticancer or experimental therapy; had systemic illness, uncontrolled infection, or seizures; or were pregnant or lactating.",during the first 10 weeks of therapy,NA
32002547,NCT01120639,Combination,No,newly diagnosed glioblastoma,"Patients older than 18 years with newly diagnosed, pathologically confirmed, supratentorial newly diagnosed glioblastoma (GBM) were candidates for this institutional review board–approved prospective trial (clinicaltrials.gov: NCT01120639). Eligibility criteria included an expected survival of more than 12 weeks, adequate organ function to receive TMZ, ability to give informed consent, and a maximum final planning target volume (PTV) of 150 cm3. ","Patients were excluded if they had previous cranial irradiation, infratentorial tumor extension, or multifocal or leptomeningeal disease or were pregnant or unable to have MRI or CT scans or give informed consent.","within 30 days of stereotactic radiosurgery (SRS), with lifelong assessment for late (defined as after 30 days) SRS-related adverse radiation effect (ARE).",NA
26333381,NCT00993239,Single Drug,No,Gastrointestinal; Endocrine; Genitourinary; Gynecologic; Head and Neck; Lung; Musculoskeletal; Skin; Lymphoma,"Patients were >= 18 years with advanced treatment-refractory malignancies (or for which no effective therapy existed). Included patients had measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) or Revised Response Criteria for Malignant Lymphoma, were Eastern Cooperative Oncology Group (ECOG) performance status (PS) <= 2, and had adequate renal [<= 1.5* upper limit of normal (ULN)], hepatic (<=3* ULN) and bone marrow function [defined as absolute neutrophil (ANC) >=1,500/mm3 (>=1.5 *10^6/L), platelet count >=75,000/mm3 (>=75 * 10^6/L), and hemoglobin >=10 g/dL (in the absence of transfusion within 24 hours prior to dosing)]. Patients were ineligible if they had a history of autoimmune disease within the previous 5 years, or any immunosuppressive therapy 4 weeks prior to study.",NA,in the first cycle,NA
28434648,NCT01658878,Single Drug,No,patients with advanced hepatocellular carcinoma,"Eligible patients were at least 18 years old with histologically confirmed advanced hepatocellular carcinoma (not amenable to curative surgery or local treatment); use of archival tissue samples was allowed. Fresh tumour biopsy was required at baseline if no other record of histological diagnosis was available. Patients in the dose-escalation phase and patients in the HCV-infected and HBV-infected cohorts of the expansion phase included those whose disease progressed while receiving at least one previous line of systemic therapy, including sorafenib, or who were intolerant of or refused sorafenib treatment. Patients were also required to have Child-Pugh scores of 7 or less (Child-Pugh A or B7) for the dose-escalation phase and 6 or less (Child-Pugh A) for the dose-expansion phase at screening, and an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less. Patients with HBV infection were required to be receiving effective antiviral therapy and have a viral load less than 100 IU/mL at screening; antiviral therapy was not required for patients with HCV infection. ","Patients who had previously been treated with an agent targeting T-cell costimulation or checkpoint pathways (including those targeting PD-1, PD-L1 or PD-L2, CD137, or cytotoxic T-lymphocyte antigen [CTLA-4]) were excluded.",Dose-limiting toxicities were determined on the basis of the incidence and intensity of adverse events occurring up to 2 weeks after the third nivolumab dose.,NA
22648179,NCT00932373,Single Drug,Yes,patients with advanced human epidermal growth factor 2–positive breast cancer,"Eligible patients had HER2-positive (fluorescence in situ hybridization–positive or immunohistochemistry 3+), histologically documented, incurable, locally advanced, or metastatic breast cancer that had been previously treated with chemotherapy (in the metastatic setting) and trastuzumab (in any setting). Progression no later than 60 days after treatment with any prior trastuzumab-containing regimen was required, as was adequate organ function and limited prior exposure to anthracyclines (≤360 mg/m2 of doxorubicin or equivalent).",NA,21 days DLT observation period,NA
27932068,NCT01901653,Single Drug,No,small-cell lung cancer; large-cell neuroendocrine carcinoma,"Eligible patients were aged 18 years or older and had histologically or cytologically confirmed small-cell lung cancer or large-cell neuroendocrine tumours with progressive measurable disease (according to Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1) previously treated with one or two chemotherapeutic regimens, including a platinum-based regimen. Further inclusion criteria were: Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; minimum life expectancy of 12 weeks; and adequate haematological counts and hepatic and renal function. ",Key exclusion criteria included: presence of active CNS metastases; administration of previous chemotherapy within 21 days; any concurrent anticancer treatment; and uncontrolled infection or systemic disease or clinically significant cardiac disease.,cycle 1,NA
21069335,NCT00684099,Combination,No,patients with advanced unresectable or metastatic non-small-cell lung cancer (NSCLC).,"Patients aged >18 years with a pathologically or cytolog- ically confirmed, unresectable locally advanced (stage IIIB with pleural infusion) or metastatic NSCLC who had received prior chemotherapy (maximum one prior chemo- therapy regimen) as well as chemotherapy-na ̈ıve patients were eligible for the study; in addition, patients with CNS disease were also eligible if they had been irradiated and were clinically stable.Prior surgery or radiotherapy (to less than 25% of bone marrow) was allowed. However, a treatment-free interval of at least 4 weeks was required before study enrollment.Other inclusion criteria were as follows: performance status 0–2 (ECOG); adequate blood counts (absolute neutrophil count [1,500>ll, hemoglobin <10/ll and platelets>100,000/ll); adequate renal function (serum creatinine <2 mg/dl); adequate hepatic function (total bilirubin <2 mg/dl and transaminases <3 times the upper normal limit); adequate cardiac function without unstable angina or myocardial infarction within the last 6 months; no history of other primary cancer; and life expectancy of at least 3 months. ",NA,first chemotherapy cycle,NA
21481618,NA,Combination,No,patients with advanced solid tumors and metastatic castrate-resistant prostate cancermen with chemotherapy naïve metastatic castrate-resistant prostate cancer (CRPC).,"All patients were over 18 years of age withan Eastern Cooperative Oncology Group (ECOG) performance status of 0–2 and at least a 3-month life expectancy.Patients in phase 1 had a histologically confirmed solid malignancy that was refractory to standard therapy or for which no curative standard therapy was available.Measurable or evaluable disease, and adequate organ function defined as absolute neutrophil count (ANC) >=1,500/mm3, platelet count >=100,000/mm3, total bilirubin  upper limit of normal (ULN), and serum creatinine  1.7 mg/dl and creatinine clearance >50 ml/min, using the Cockcroft Gault equation.A serum aspartate aminotransferase and alanine aminotransferase of <5*ULN was permitted provided they were associated with a predefined level of alkaline phosphatase.Patients in the 1b portion of the study included men with histologically confirmed adenocarcinoma of the prostate who were surgically castrate or medically castrate with the use of hormonal therapy (estrogen therapy, luteinizing hormone receptor antagonist  casodex) and documented to have a serum testosterone <50 ng/ml.Adequate organ function as defined above for the first cohort, along with progressive disease defined by new lesions on bone scan or new/enlarging lesions on CT scan, or metastatic disease and rising prostate specific antigen (PSA) within 4 weeks prior to registration.Treatment with flutamide must have been discontinued >=4 weeks prior toregistration with continued evidence of progressio.For bicalutamide or nilutamide, patients must have discontinued the drug >=6 weeks prior to registration with evidence of progression.","Prior treatment with docetaxel or a platinum agent <3 months from the time of enrollment or <4 weeks since any other prior chemotherapy. <4 weeks since prior radiotherapy, evidence of concurrent second malignancy, greater than grade 1 pre-existing peripheral neuropathy, edema, or ototoxicity, concurrent use of medications that inhibit cytochrome P450 3A4, untreated brain metastases, or any condition that would place the patient at excessive or unacceptable risk of toxicity.no prior cytotoxic chemotherapeutic treatment was allowed, however, up to 1 prior experimental therapy (non-cytoxic) was permitted as long as it was given >4 weeks prior to study entry, radiation therapy performed<4 weeks prior to study as long as it involved less than 25% of the bone marrow, treatment with strontium 89, samarium 152, or other radioisotope, concurrent use of estrogen, or estrogen-like agents.","phase 1 portion:the first,must have been considered at least possibly related to the study drugs. phase 1b: was at least possibly attributable to the combination of docetaxel and satraplatin.",NA
23942080,NA,Combination,No,patients with advanced solid tumours,"incurable, locally advanced, or metastatic cancer for which docetaxel administered at a dose of 75 mg m^(-2) IV every 21 days is approved,considered standard of care, or is compendia listed; measurable disease per RECIST 1.1 or, for metastatic castrate resistant prostate cancer (mCRPC), evaluable for response or progression based on prostate-specific antigen (PSA) or bone scan; life expectancy >3 months; adequate hepatic, haematological, and renal function; Eastern Cooperative Oncology Group performance status of <=1; and completed previous treatment >4 weeks.",presence of any medical/social factors impacting patient safety; pregnancy or breastfeeding; previous treatment with docetaxel (except in CRPC) or a PI3K inhibitor; known human immunodeficiency virus; known or suspected clinically active brain metastases; grade >=2 peripheral neuropathy; and/or history of hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate.,cycle 1 ,NA
22828917,NA,Combination,No,patients with metastatic castration-resistant prostate cancer,"Eligible adult males had documented metastatic CRPC that was chemo-naive and progressive despite orchiectomy or gonadotropin-releasing hormone analog.Patients must have had Karnofsky performance status ≥60 and adequate bone marrow, liver, and renal function. ",Patients were excluded for central nervous system metastases; HIV-positive or hepatitis B or C infection; peripheral neuropathy ≥Grade 2; or significant comorbidity that may interfere with study conduct. ,Cycle 1,NA
21792569,NA,Combination,No,Men with histologically confirmed prostate adenocarcinoma metastatic to bone.,"Men with histologically confirmed prostate adenocarcinoma metastatic to bone were eligible if they had rising PSA levels despite castrate levels of testosterone.Bone metastases needed to show uptake of Tc-hydroxymethylene diphosphonate (HDP) on bone scintigraphy.All patients had a WHO performance status of 0 or 1 and a life expectancy of at least 3 months.Patients were required to have a haemoglobin ≥11 g/dl, an ANC of ≥1.5 × 10^9 /l and a platelet count of ≥100 × 10^9 /l.Adequate renal function, defined as a serum creatinine <130 μmol/l, was required.Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were both ≤2.5 × upper limit of normal.",if they had extensive soft tissue disease and/or lymphadenopathy.,NA,NA
23553066,NCT00732745,Combination,No,Patients with advanced gastroesophageal cancer.,"Patients must have had histologically confirmed advanced adenocarcinoma or squamous cell cancer of the esophagus or the GE junction; must have been >18 years of age with an anticipated life expectancy of >12 weeks and an ECOG performance statu of 0–1.Patients must have had at least one measurable lesion as per RECIST criteria.Normal organ and marrow function was required based on ANC >1500/μl, platelets > 100,000/μl, total bilirubin < = institutional upper limit of normal (ULN), creatinine < 1.5 × ULN as well as liver enzyme criteria as followd in the paper.","if they had received any prior systemic therapy for metastatic disease.Patients with active CNS metastases were excluded and patients must have completed major surgery, chemotherapy, radiation therapy, investigational agents or other cancer therapy within 4 weeks of treatment day 1.Prior anti-VEGF or EGFR therapy, including bevacizumab was not permitted.Patients with the following conditions were also excluded: prolonged baseline QTc >480 msec, significant cardiovascularevents within 3 months prior to study entry, history of arrhythmia (but atrial fibrillation, controlled on medication was allowed), congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age, QT prolongation with other medications that required discontinuation of that medication, presence of left bundle branch block (LBBB), QTc with Bazett’s correction that was immeasurable, or ≥480 msec on screening ECG.Patients with a potassium <4.0 mmol/L despite supplementation, or above the CTCAE grade 1 upper limit.; serum calcium (ionized or adjusted for albumin), or magnesium out of normal range despite supplementation, or above the CTCAE grade 1 upper limit, hypertension not controlled by medical therapy (SBP> 160 mmHg or DBP>100 mmHg), concomitant medications that are potent inducers (rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital and St. John’s Wort) of CYP3A4 function, currently active diarrhea greater than CTC grade 1 were excluded.",cycle 1 of therapy.,NA
22124669,NCT00058253,Combination,No,Adult patients with solid tumors.,"All patients signed written informed consent.Patients were required to have a histologically conWrmed malignancy that was metastatic or unresectable and for which curative or palliative measures did not exist or were no longer effective. Patients were required to be over 18 years of age, have a Karnofsky Performance Status ¸70%, and a life expectancy >6 months. Intact hepatic, renal, and bone marrow function as deWned by speciWc laboratory ranges was a prerequisite for enrollment.","Exclusion criteria included prior chemotherapy, radiotherapy, or other investigational therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C); active brain metastases or epidural disease; symptomatic peripheral neuropathy ¸Grade 2; a history of severe hypersensitivity reaction to paclitaxel, docetaxel, or polysorbate 80; and allergy to egg or egg products (because of its inclusion in the EPL diluent vehicle).Cardiac-speciWc exclusion criteria were altered during the course of the trial. The initial 43 patients enrolled required screening radionuclide angiography or echocardiogram for suspected or documented congestive heart failure with a depressed ejection fraction, coronary artery disease, or arrhythmia other than atrial Wbrillation. Following reports of prolonged QTc intervals on other 17-AAG trials, we also excluded from this study patients with signiWcant cardiac disease including heart failure that met New York Heart Association (NYHA) class III or IV deWnitions, a history of myocardial infarction or active ischemic heart disease within 12 months of study entry, uncontrolled dysrhythmias, and individuals requiring antiarrhythmic drugs. Patients with the following were also excluded: history of serious ventricular arrhythmia (VT or VF lasting ¸ 3 consecutive beats); QTc > 450 ms for men and >470 ms for women; congenital long QT syndrome; left bundle branch block; history of prior radiation that potentially included the heart in the Weld (e.g., mantle); or LVEF · 40% by multi-gated acquisition scan or echocardiography. Medications previously shown to prolong the QTc interval were restricted.",during cycle 1 of treatment,NA
23712328,NA,Combination,No,All patients participating in this study had histologically or cytologically confirmed metastatic or recurrent malignant solid tumors that did not respond to standard therapy and/or for which no known curative or standard palliative therapy was available.,"Patients were at least 18 years of age with a life expectancy of at least 12 weeks and a Southwest Oncology Group performance status of 0–2.In addition, patients were required to have adequate organ and marrow function determined by leukocytes >=3,000/ul, absolute neutrophil count >=1,500/ul, platelets >=100,000/ll, total bilirubin within 1.5 times the normal institutional limits, AST (SGOT)/ALT (SGPT) within 2.5 times the normal institutional limits, creatinine within 1.25 times the normal institutional limits and baseline serum calcium <=12 mg/dl.Patients must have recovered from previous therapy, and the last treatment must have been completed 30 days prior to entry into the study.Prior therapy with 5-FU and/or cisplatin was allowed. Patients who had received mitomycin C and nitrosourea must have completed therapy 6 weeks prior to entry.","Patients with HIV or receiving anti-retroviral therapy (HAART) were excluded due to possible pharmacokinetic interactions.Patients who did not recover from surgery or previous therapy-related toxicity were excluded. Pregnant or nursing women were not eligible, and adequate contraception was required for men or women of childbearing age prior to study entry and for the duration of study participation.Additionally, patients with central nervous system metastases, history of allergy to platinum compounds or to antiemetics, uncontrolled intercurrent illness and neuropathy were also not eligible",first course of treatment,NA
22042372,NA,Combination,No,phase 1 portion.,"Patients C18 years of age with histologically confirmed, measurable, or evaluable, stage IV HER-2 overexpressing MBC were eligible.Patients had to have tumors with 3+HER-2 expression as determined by immunohistochemistry, or HER-2 amplification determined by fluorescence in situ hybridization (FISH).Prior adjuvant chemotherapy and trastuzumab were allowed unless disease had recurred within 6 months of receiving that therapy. Previous treatment with chemotherapy or trastuzumab in the metastatic setting was not permitted.absolute granulocyte count >=1,500/ml; platelet count >=100,000/ml; creatinine level<1.6 mg/dl; total bilirubin level<1.5 *the upper limit of normal; aspartate aminotransferase and alanine aminotransferase levels<2.5*the upper limit of normal without demonstrable liver metastases, or<5.0*the upper limit of normal with liver metastases; ECOG performance status <=2; and left ventricular ejection fraction>55%.",NA,in the first three subjects,NA
22999386,NA,Combination,No,"female, aged 18–70 years with histologically confirmed locally-advanced/inflammatory breast cancer (T4 a–d, any N or any T, N2 or N3) or large operable breast cancer (T3N0 any oestrogen receptor (ER) or T2N1 any ER or T2N0 ER negative) which had been shown to be HER2 positive (IHC 3+ and/or FISH +).",NA,NA,during cycle 1,NA
20878160,NA,Combination,No,"patients had to be at least 18 years of age at the time of registration and have histologically or cytologically confirmed squamous cell carcinoma (SCC), which was surgically unresectable or recurrent.","They also had to have an EOCG performance status of 0, 1, or 2, a life expectancy of>12 weeks, and adequate liver, bone marrow, renal and cardiovascular function (serum bilirubin <=1.5 mg/dl; neutrophil count >=1,500/mm3 ; serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) B twice the upper limit of normal range; platelet count >10 *10^4/mm3 ; hemoglobin >8.0 g/dl; and creatinine <=1.2 mg/dl (or creatinine clearance >60 ml/min).","serious concomitant illness, symptomatic infectious disease, severe drug allergy, symptomatic peripheral neuropathy, or uncontrolled diabetes mellitus.",NA,NA
20085867,NA,Combination,No,Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer,"Patients had to present with an assessable stage IIIB (excluding malignant pleural effusion) or inoperable stage IIIA tumor, based primarily on computed tomography (CT) and bronchoscopy.Patients were required to have adequate physiologic, hematologic (hemoglobin [Hb] ≥ 12 mg/dL), renal, and hepatic function, as well as a forced expiratory volume (FEV) in 1 second of > 1.5 L.Age between 18 and 75 years and a life expectancy ≥ 12 weeks.","Patients with distant metastases or previous or concomitant malignancies (staging was performed by positron emission tomography scan, abdominal CT, body scintigraphy, and liver sonography), a Karnofsky performance score of < 70, severe motor or sensory neuropathy (World Health Organization [WHO] grade ≥ 2), cardiac arrhythmias, congestive heart failure (New York Heart Association classes III or IV), recent myocardial infarction, complete intestinal obstruction, acute infections, or psychiatric disorders were excluded.",Both Chemoradiation Therapy(CRT) and Docetaxel Consolidation Therapy(DCT) phases,NA
20087171,NA,Combination,No,Patients with a histologically confirmed advanced stage malignant solid tumour.,"which was either known to be sensitive to these agents or refractory to conventional effective therapy, or for whom no standard therapy existed, were eligible.Earlier chemotherapy and radiotherapy were allowed, provided they had been discontinued for more than 4 weeks.The required treatment-free interval was 6 weeks for earlier use of nitrosurea, mitomycin C and carboplatin, and 8 weeks if granulocyte-colonystimulating factor (CSF) or granulocyte macrophageCSF had been used.age above 18 years, performance status 0–2 according to the World Health Organization scale, life expectancy of greater than 12 weeks, and adequate organ function, defined as white blood cells greater than 4*10^9 /l, absolute neutrophil count greater than 2*10^9 /l, platelets greater than 100*10^9 , serum creatinine less than 1.25*upper normal limit, creatinine clearance greater than 60 ml/min, transaminases less than 3*upper normal limit, alkaline phosphatase less than six times upper normal limit.","Patients with a combination of an elevated transaminases level greater than 1.5*upper normal limit and alkaline phophatase greater than 2.5*upper normal limit, and with a history of significant neurological or psychiatric disorders, active infection, congestive heart failure, uncontrolled hypertension or serious arrhythmia requiring medication, known brain or leptomeningeal involvement, symptomatic peripheral neuropathy greater than two by National Cancer Institute Canada-Common Toxicity Criteria 2, and earlier irradiation of more than 30% of bone marrow were excluded.",first treatment cycle,NA
22989664,NA,Combination,No,patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma,NA,NA,with 4 cycles of TPF for induction,NA
20530449,NA,Combination,Yes,Gastric Cancer with Peritoneal Dissemination,age: 20-75 years; no prior chemotherapy; ECOG performance status 1-2; adequate function of major organs; no other active malignancy; estimated life expectancy of more than 3 months; provision of written informed consent.,"Patients ineligible for inclusion were those with severe comorbid conditions, infectious diseases, brain metastasis, severe pleural effusion, severe pericardial effusion, peripheral neuropathy or a past history of drug allergy. Pregnant and breast-feeding women were also excluded.",NA,NA
21892109,NA,Combination,No,patients with advanced solid tumors ,"Patients with histologically or cytologically confirmed advanced solid tumors treated with any number of prior chemotherapy regimens were eligible for the phase I portion of the trial.Eligibility for the phase II portion consisted of cytologically or histologically confirmed NSCLC, treated with no greater than one previous treatment for metastatic disease. Prior chemotherapy or radiotherapy must have been completed at least 4 or 2 weeks, respectively, before study entry, and all significant previous treatment-related toxicities had to be resolved.Adequate hematologic (absolute neutrophil count>=1500/ul and platelet count >=100,000/ul), renal (serum creatinine<=1.5 mg/dl or a calculated creatinine clearance >=50 ml/min), and hepatic function (serum bilirubin less than or equal to the institutional upper limit of normal and aspartate aminotransferases within 2.5 times the upper limit of normal) were required.Patients with asymptomatic treated brain metastasis (surgical resection or radiotherapy) were eligible if they were neurologically stable and had stopped taking steroids and/or anticonvulsants for a minimum of 4 weeks. Patients of childbearing potential were required to use a medically acceptable contraceptive.",Patients who had previously received EGFRtargeted therapy or docetaxel were excluded. Patients with clinically significant ophthalmologic abnormalities or other disorders that might increase the risk of corneal epithelial injury were excluded. Patients with preexisting peripheral neuropathy >=grade 2 or who were pregnant were not eligible.,first cycle of treatment,NA
21075438,NA,Combination,No,Women with recurrent epithelial ovarian cancer,"Patients ≥18 years of age were eligible if they had persistent or recurrent histologically or cytologically confirmed diagnosis of advanced epithelial ovarian carcinoma, peritoneal carcinoma, or fallopian tube carcinoma following first or subsequent relapse after taxane and platinum-based chemotherapy. All patients had a GOG performance status of 0 or 1, and measurable disease was not required. Laboratory criteria for eligibility included an absolute neutrophil count (ANC)≥1500/μL, platelet count≥100,000/μL, white blood count≥3000/μL, creatinine≤1.5 times upper limit of normal (ULN), bilirubin≤1.5 times ULN, alanine transaminase and aspartate transaminase≤2.5 times ULN, and neuropathy (sensory and motor)≤grade 1 using the National Cancer Institute Common Toxicity Criteria version 2.0 (NCI CTC v2).Patients with ureteral obstruction were eligible if a stent or nephrostomy tube was placed prior to study entry. Women of child-bearing potential could not be nursing or pregnant and had to be using an acceptable method of contraception.",Patients were ineligible if they received prior radiation to the pelvis or abdomen.,NA,NA
20564143,NA,Combination,No,Patients with advanced stage NSCLC and progression after prior platinum-based chemotherapy,"Eligible patients had histological or cytological confirmation of NSCLC that was advanced stage and progressed after at least 1 prior chemotherapy regimen.Other pertinent eligibility criteria were an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2, age >18 years, and life expectancy >12 weeks. Qualifying laboratory criteria were leukocytes >=3000/lL, absolute neutrophil count>=1500/lL, platelet count>=100,000/ lL, serum total bilirubin<=1.5*institutional upper limit of normal (ULN), serum transaminases<=2.5*ULN, and serum creatinine<=1.5*ULN.Patients had to have recovered from toxicities related to prior therapies to grade <2, and at least 3 weeks should have elapsed since prior chemotherapy or radiotherapy.","Patients with untreated or symptomatic brain metastasis were excluded.Patients who had received prior therapy with a known mTOR inhibitor, were on full dose anticoagulation therapy with warfarin, had known human immunodeficiency virus seropositivity, or were unable to take oral medications on a regular basis were excluded.Pregnant or lactating women were not allowed in the study because of the potential for teratogenic effects with the combination regimen. Patients with a serious comorbid illness, known hypersensitivity to docetaxel, or other active malignancies were also excluded.",during Cycle 1 of therapy,NA
21327495,NA,Combination,No,Patients were eligible if they had advanced non-small cell lung cancer that had progressed after treatment with at least one chemotherapy regimen or another metastatic malignancy.,"were ≥18 years of age,with Eastern Cooperative Oncology Group performance status ≤1 with adequate hematopoietic,electrolyte, hepatic, renal, coagulation and cardiac laboratory findings and had signed informed consent. ","Patients were excluded if they had specified oncology therapies within 3–12 weeks (depending on the therapy) prior to study entry, significant cardiac history, requirement for anti-coagulant or anticonvulsant use, history of VDA or docetaxel treatment, seizure disorder, brain metastases, specified gastrointestinal bleeding disorders and vascular disorders, a history of whole abdomen or perioperative pelvic radiotherapy, or were pregnant, breast feeding, or had a significant active infection or second malignancy.",during Cycle 1.,NA
22872523,NA,Combination,No,Female patients >=18 years old were eligible if they had confirmed measurable or nonmeasurable [per Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 [12]] adenocarcinoma of the breast with locally recurrent or metastatic disease.,"Eastern Cooperative Oncology Group performance status of 0/1, and adequate organ function.","included[1 prior chemotherapy regimen for MBC; taxane-containing treatment within 6 months, bevacizumab within 3 months, or VEGFR-targeted therapy within 1 month before enrollment; uncontrolled hypertension; prior malignancy (except in situ cervical cancer or nonmelanoma skin cancer); radiation therapy to[25 % of bone marrow; radiation therapy for peripheral lesions within 14 days of enrollment; central nervous system metastases; arterial or venous thrombosis within 12 months before enrollment; bleeding diathesis or bleeding within 14 days or major surgery within 28 days before enrollment; clinically significant cardiac disease; and prior episodes of cholecystitis.",during cycle 1,NA
20142723,NA,Combination,No,"Patients With Advanced Solid Tumors:Lung,Esophagus, Thyroid, Breast,Colorectal, Kidney, Nasopharynx,Stomach,Sarcoma.","Patients were required to have a histologic diagnosis of cancer,which was advanced or recurrent and had failed prior therapy, or for which no effective therapy was available. Prior treatment with PLD and/or weekly T was not allowed. Prior T administered every 3 weeks and prior doxorubicin was allowed. Participating patients were required to have adequate bone marrow (absolute granulocytes>=1500/uL and platelets >=100,000/uL), and hepatic (bilirubin  the upper limit of normal (ULN), serum glutamic oxaloacetic transaminase<=2.5 times ULN and alkaline phosphatase<=times the upper limit of normal) functions.A baseline cardiac ejection fraction 50% was required as assessed by nucleotide scan or echocardiography.SWOG performance status of 0–2 was required.Women of child bearing potential were required to use an adequate method of birth control and a negative serum pregnancy test. Patients who completed 2 cycles of treatment were considered evaluable for response and patients who received at least one cycle of therapy and who are followed a minimum of 4 weeks after completion of the first cycle or who experience DLT were evaluable for toxicity.",NA,during the first cycle of chemotherapy,NA
21439816,NA,Combination,No,"Patients with a cytologically or histologically confirmed diagnosis of an advanced and measurable or evaluable solid tumour:GIST,Melanoma,Miscellaneous.","age>=18 years; ECOG performance status 0 or 1; an adequate bone marrow function (haemoglobin >= 10 g/dL, platelet count >= 100*10^9 /L, absolute neutrophil count >=1.5*10^9 /L), liver function (bilirubin<=1.5 the upper limit of normal (ULN), alanine aminotransferase and aspartate aminotransferase<=2.5*ULN (5*ULN in case of liver metastasis in the presence of a normal alkaline phosphatase), alkaline phosphatase <=2.5*ULN (5*ULN in case of bone or liver metastasis in the presence of a normal ALT/AST)) and renal function (serum creatinine<= 1.5*ULN) and a serum albumin >=3.0 g/dL.","Specific exclusion criteria included but were not limited to prior treatment with high-dose chemotherapy requiring stem cell rescue; prior treatment with docetaxel; prior irradiation to >25% of the bone marrow reserve; uncontrolled hypertension; presence of malabsorption due to prior surgery, gastrointestinal disease or an unknown reason or inability to take oral medication and/or CTCAE grade >2 neuropathy or oedema from any cause. ",both the first and second cycle,NA
23016517,NCT00225420,Combination,No,Eligible subjects were aged ≥ 18 years with histologically confi rmed adenocarcinoma of the prostate and had locally advanced (clinical T3 or T4) or high-risk localised (Gleason 8 – 10 or PSA level of ≥ 20 ng/mL) disease.,"All patients had a chest X-ray, bone scan, and CT of the abdomen/pelvis to exclude nodal and distant metastasis. Other eligibility criteria included Eastern Cooperative Oncology Group performance status 0 – 1, no prior pelvic or prostate RT or chemotherapy for prostate cancer, adequate haematological [ absolute neutrophil count ≥ 1500/mm 3  , haemoglobin ≥ 8.0 g/dL, platelets ≥ 100 000/mm 3 ] , hepatic [ total bilirubin ≤ 1.2 mg/dL, transaminases(alanine transaminase and aspartate transaminase) ≤ 1.5 × the upper limit of normal (ULN), alkaline phosphatase≤ 2.5 × ULN ] , and renal (creatinine≤ 1.5 × ULN) function. ","Patients were excluded if they had documented metastases, a life expectancy of < 10 years secondary to comorbid illness,myocardial infarction or a signifi cant change in anginal pattern of chest pain within 1 year prior to study entry, congestive heart failure (New York Heart Association Class ≥ 2), a hypersensitivity reaction to docetaxel,or a history of invasive malignancy within the last 5 years before study entry (except for carcinoma in situ or non-melanoma skin cancer). ",NA,NA
22870147,NA,Combination,No,Patients with recurrent non-small cell lung cancer.age 20-74 years,"histologically or cytologically proven NSCLC; measurable or evaluable lesions; prior administration of first-line platinum-based chemotherapy, with or without second-line gefitinib, and iv) an interval of at least 4 weeks following the last administration of prior chemotherapy. an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, iii) adequate hematopoietic function (white blood cells, ≥4,000/mm3 ; neutrocytes, ≥2,000/mm3 ; platelets, ≥10x104/mm3 and hemoglobin, ≥9.5 g/dl), iv) adequate hepatic function (total bilirubin ≤1.5 mg/dl and transaminase ≤2 times institutional normal upper limit), v) serum creatinine ≤1.5 mg/dl, vi) adequate pulmonary function (PaO2 >60 Torr or SpO2 >90%), vii) adequate cardiac function without treatment, viii) anticipated survival ≥12 weeks, and ix) written informed consent prior to treatment. ","i) massive plural effusion or pericardial effusion, ii) superior vena cava syndrome, iii) serious concomitant systemic disorders, including active infection, uncontrollable diabetes mellitus, hypertension, uncontrollable angina, severe heart failure, active ulcer or another primary malignancy, iv) active interstitial pneumonia, v) coagulation system disorder, vi) history of drug allergy, including allergy to polysorbate 80, vii) pregnancy or breastfeeding, and viii) other concomitant anticancer drug administration, including flucytosine.",first treatment cycle,NA
20407240,NA,Combination,No,patients with unresectable locally advanced gastric adenocarcinoma,N/A,N/A,N/A,NA
24018362,NA,Combination,No,"Adult patients with refractory solid tumor malignancies:Lung Cancer;NSCLC;SCLC;Sarcoma;Pancreatic/Biliary;Mesothelioma;Bladder;Other (colon, Breast, Cervical, Melanoma).","ECOG performance status 0–2, estimated survival >3 months, measurable or evaluable disease, intact GI absorption; total leukocytes>3500/μl; neutrophil count>1,500/μl; platelet count > 125,000/μl; prothrombin time and partial prothromboplatin time within institutional upper normal limits (ULN), serum creatinine<1.5 mg/dl, total bilirubin<1.5 mg/dl; ALT, AST and alkaline phosphatase<2.5x the institutional ULN. Patients were also required to have had their last chemotherapy or radiotherapy at least 4 weeks prior to start of the trial and to have recovered from the toxicities of previous chemotherapy or radiotherapy. Prior therapy with gemcitabine and/or docetaxel was allowed.",Patients were excluded if they had more than 12 months of continuous cytotoxic therapy; more than 2 prior cytotoxic regimens for metastatic disease; history of bone marrow transplantation; radiation to more than 25% of bone marrow; known or suspected bone marrow infiltration by cancer; newly diagnosed or uncontrolled brain metastasis; chronic uncontrolled diarrhea and/or daily emesis; Grade 2 or higher neuropathy; or significant peripheral edema. Patients were instructed to not use acetaminophen or grapefruit juice during the trial.,The first cycle of therapy.,NA
22752248,NA,Combination,Yes,men with metastatic castration-resistant prostate cancer (mCRPC).,"Eligible men had histologically confirmed metastatic prostate adenocarcinoma with disease progression despite well-conducted castration (serum testosterone <50 ng/dl).Radiological evidence of disease progression according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 or serum prostate-specific antigen (PSA) ascension defined as C2 consecutive rises over a baseline value taken at least 1 week apart was required.No prior chemotherapy was allowed.Patients previously treated with antiandrogens had to comply with a withdrawal period of C6 weeks and had to demonstrate progression despite antiandrogen withdrawal. Prior treatment with corticosteroids or radiotherapy to B25 % of the bone marrow was allowed.Other requirements included: Eastern Cooperative Oncology Group (ECOG) performance status 0–2, hemoglobin >9 g/dL, platelets>100*10^9/L, neutrophils > 1.5*10^9 /L, total bilirubin\the institution’s upper normal limit (UNL), SGPT and SGOT<2.5 times the UNL, serum creatinine <1.5 times the UNL, creatinine clearance >50 mL/min, absence of uncontrolled medical conditions or other malignant diseases within 5 years of inclusion.","the inability to swallow oral medication, gastrointestinal disorders, prior therapy using isotopes or other targeted agents, grade C2 sensory neuropathy according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0, and comedication with drugs metabolized by cytochrome P450.",during cycle 1.,NA
20686817,NA,Combination,No,"Enrollment was limited to only patients with diseases where docetaxel has demonstrated clinical activity as monotherapy: non-small cell lung, prostate, and bladder cancer.","There was no limit on prior courses of chemotherapy as long as the prior regimens did not contain docetaxel.Prior use of paclitaxel or other taxanes was permitted.Other requirements included age ≥18, Zubrod performance status (PS) of 0–2, absolute neutrophil count (ANC) ≥1500/mm3 , platelet count ≥100,000/mm3 , serum creatinine ≤2.0 mg/dl or creatinine clearance ≥60 ml/min per the Cockcroft-Gault equation , total bilirubin ≤ the institutional upper limit of normal, and SGOT/SGPT ≤2.5X the upper limit of normal. ","Patients were ineligible if they had peripheral neuropathy of grade ≥2, congestive heart failure (New York Heart Association Class III or IV), active angina pectoris or a myocardial infarction within the last 6 months, were on anti-androgen therapy, or were unable to take oral medication on a routine basis.Exclusion criteria also included symptomatic, uncontrolled brain or leptomeningeal disease. ",first cycle of therapy,NA
23482452,NA,Combination,No,All patients had histological proven and unresectable Stage III NSCLC.,All patients had histological proven and unresectable Stage III NSCLC without previous RT.Other eligibility criteria included: (a)Age ≥18 years; (b) Performance Status of 0 or 1 by the Eastern Cooperative Oncology Group (ECOG) scale in patients ≤70 years old; (c) Negative head computed tomography and bone scan; (d)Weight loss < 10% within the past 6 months of diagnosis; (e) Adequate end organ function as defined by Granulocyte count≥1. 5×109/L; (f)Platelet count ≥100×109/L; (g) Serum bilirubin level ≤1. 5 × the upper limit of normal; (h) Calculated creatinine clearance ≥30 ml/min; (i) AST and ALT level≤2× the upper limit of normal; alkaline phosphatase level ≤2 ×the upper limit of normal; (j) Forced expiratory volume in 1 second ≥1. 5 L or >50% of the predictive value; (k) No other treatment for cancer in the last month. Women were required to have childbearing potential terminated previously by surgery or menopause or attenuated by the use of an approved contraceptive method. ,"Patients were excluded from the study if they had documented distant metastases; malignant pleural effusion; preexisting cardiac, pulmonary, neurological, or other diseases that the investigator judged to be clinically significant; active infectious processes; severe malnutrition or intractable emesis; previous or concurrent malignancy except inactive non-melanoma skin cancer, in-situ carcinoma of the cervix. Pregnant and/or lactating women were also excluded from participation.",NA,NA
20530200,NA,Combination,No,patients with locally advanced or recurrent/metastatic head and neck cancer;Site of primary tumor:Hypopharynx;Oral cavity;Oropharynx;Salivary gland;Nasopharynx;Nasal cavity,"All patients had a histologically or cytologically confirmed diagnosis of HNC with recurrent/metastatic or unresectable locally advanced disease. Eligibility also required an Eastern Cooperative Oncology Group performance status of zero or one, age 20–75 years, and adequate organ function. ","history of prior chemotherapy; concurrent active malignancy except excised intramucosal gastric or esophageal cancer, which could be removed by endoscopic mucosal resection; pharyngeal fistula; active bleeding from the GI tract; active infection; serious medical problem that might interfere with the achievement of study objectives; pregnancy or lactation; or expected survival of <3 months.",events occurring within 30 days after completion of the first cycle of TPS,NA
21157450,NA,Combination,No,patients with  locally advanced oesophageal cancer,"Patients were eligible if they met the following criteria: (1) histologically proven squamous cell carcinoma or adenocarcinoma ofthe oesophagus; (2) considered unsuitable for surgical resection(due to advanced T or N stage, or patient medically unsuitablefor surgery) based on multidisciplinary opinion; (3) no previoustherapy for oesophageal cancer; (4) ECOG performance status (PS)of zero or one; (5) life expectancy >3 months; (6) adequate organ function – (i) hepatic: serum bilirubin <=1.0*upper limit normal(ULN), AST and/or ALT <=2.0  ULN, ALP<=2.5  ULN, (ii) bonemarrow: haemoglobin>=100gl^(-1), neutrophil count>=1.5 109 per l,platelet count >=100*10^9 per l, (iii) renal: creatinine clearance>=55 ml min^(-1) (using radioisotope renal scan or derived from serum creatinine using the Cockroft-Gault formula); (7) agreed compliance to adequate contraception; (8) written informed consent.",The following patients were ineligible: (1) resectable oesophageal carcinoma; (2) carcinoma of the cervical oesophagus; (3) tumour predominantly in the stomach; (4) metastatic oesophageal carcinoma; (5) medical comorbidities which would compromise the delivery of therapy or which may be exacerbated by the planned treatment; (6) receiving treatment with another investigational agent; (7) pregnant or lactating females.,occurring during or up to 2 weeks after chemoradiotherapy,NA
20107799,NA,Combination,No,patients with non-small cell lung cancer.,"Patients with histologically conWrmed advanced NSCLC (stage IIIB with malignant pleural eVusion or stage IV) who had progressed on a platinum-containing regimen were eligible for this study.Up to two prior chemotherapy regimens were allowed, with a washout period of 28 days.No prior docetaxel or gemcitabine was allowed. Prior suramin, epidermal growth factor receptor (EGFR)-targeted therapy, and radiation therapy were permitted. Additional eligibility criteria included age ¸18 years; Eastern Cooperative Oncology Group performance status of 0–2; a life expectancy ¸12 weeks; and adequate hematopoietic, hepatic, and renal function. ","Patients were excluded from participation if they had untreated brain metastases or leptomeningeal involvement; a history of myocardial infarction within the previous six months, congestive heart failure requiring therapy, or unstable angina; any known active serious infectious process or current treatment for human immunodeWciency virus type 1 infection; uncontrolled diabetes mellitus; grade ¸2 neuropathy; any history of hypersensitivity to suramin; or if they were pregnant or  lactating.",NA,NA
21493186,NA,Combination,No,locally advanced unresectable head and neck cancer,"The tumour needed to be considered as unresectable by a multidisciplinary team that included members of the medical oncology, radiation oncology and H&N surgery teams. Tumours needed to have at least one measurable lesion. signed written informed consent; age 18–75 years; Eastern Cooperative Oncology Group (ECOG) performance status 0–1; expected survival >3 months; adequate haematological function (neutrophil count>=2.0*109/l, platelet count >=100*109/l,haemoglobin>=10 g/l); adequate hepatobiliary function (serum aspartate aminotransferase and alanine aminotransferase<=2.5 times the upper limit of the normal range (ULN), serum bilirubin<=1*ULN, alkaline phosphatase <=5*ULN); adequate renal function (creatinine <=1.25 mg/ dl or 120 µmol/l, or calculated clearance >=60 ml/min); and adequate nutritional status (weight loss <20%, albumin >35 g/l). No previous chemotherapy or radiotherapy for the disease was permitted in the study protocol.Patients should not have been prescribed corticosteroids in the previous 6 months except if prescribed at low doses (20 mg prednisone or equivalent). ","Cancers of the nasopharynx, nasal cavity and paranasal sinus sites were excluded. ",NA,NA
23423490,NA,Combination,No,gastric cancer patients with peritoneal carcinomatosis,"The patients enrolled in this study had histologically confirmed with PC,PC was confirmed by either laparoscopy or laparotomy. PC was classified according to the criteria of the Japanese Research Society for Gastric Cancer  as follows: P1, cancerous implants to the region directly adjacent to the stomach peritoneum (cranial to the transverse colon) including the great omentum; P2, several scattered metastases to the distant peritoneum and ovarian metastasis alone and P3,numerous metastases to the distant peritoneum. Photographs of peritoneal lesions were taken before and after treatment to estimate an objective response. (1) Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; (2) age ranged between 20 and 75 years old; (3) adequate bone marrow, liver, and renal functions as defined by WBC>4,000, <12,000/mm3 , PLT >100,000/mm3, Hb >8.0 g/dl, AST/ ALT \2 times institutional upper limit, total bilirubin \1.5 mg/dl, creatinine\1.5 mg/dl and creatinine clearance >60 mL/min; (4) no significant cardiac disease evident on electrocardiogram; and (5) expected survival period >3 months.",(1) previous treatment for gastric cancer; (2) coexistence of another malignant neoplasm; (3) a history of reactions to drugs; (4) massive ascites and/or pleural effusion; and (5) brain metastasis.,during the first two treatment cycles,NA
23033004,NA,Combination,No,patients with previously treated non-small cell lung cancer,"(1) histologically or cytologically confirmed NSCLC; (2) stages IIIB–IV that is inadequate for curative-intent thoracic radiotherapy, or relapse after surgery; (3) measurable lesions using Response Evaluation Criteria In Solid Tumours (RECIST); (4) previously received cytotoxic chemotherapy; (5) at least 4 weeks had to have elapsed from completion of prior chemotherapy; (6) Eastern Cooperative Oncology Group performance status of 0–2; (7) age 20 years or more; (8) adequate organ functions (white blood cell count of 4000–12 000 per ml, neutrophil count of 2000 per ml or more, platelet count of 100 000 per ml or more, haemoglobin level of 9 g dl  1 or more, levels of aspartate aminotransferase and alanine aminotransferase less than or equal to 2.5-fold of the upper limits of the normal ranges, total serum bilirubin level less than 1.5 mg dl  1 , total serum creatinine level less than the upper limit of the normal range, creatinine clearance rate of 50 ml min  1 or more); (9) life expectancy exceeding 3 months; (10) capable of oral intake; and (11) written informed consent provided.",NA,NA,NA
23098625,NA,Combination,No,"The PR-104 dose-level was escalated or de-escalated by 0.5-, 1.25-, 1.5- or 2.0-times according to the number of subjects with DLT at the previous dose-level. The safety committee could modify the dose-escalation plan by adding patients, intermediate dose-levels and supportive care therapies or by adjusting the combination agent dose, as appropriate according to the accruing safety data.","Selection criteria for patient enrolment into this study included age 18 years or more; histologically-confirmed malignancy for which treatment with gemcitabine or docetaxel in combination with an investigational agent was considered clinically appropriate; measurable or evaluable disease; ECOG Performance Status of 0 or 1; ability to provide written informed consent; no or stable dose of systemic steroid for at least two weeks; adequate bone marrow function (absolute neutrophil count ≥ 1.5 x 109/L, platelet count ≥ 100 x 109/L, haemoglobin level≥ 90 g/L not maintained by red blood cell transfusion,prothrombin and activated partial thromboplastin times≤ 1.1 x upper limit of normal (ULN)); adequate liverfunction (serum bilirubin within normal limits, ALT andAST ≤ 2.5 x ULN), and serum creatinine ≤ 1.5 x ULN.","Exclusion criteria included: licensed or investigational anti-cancer therapy (including radiotherapy but excluding androgen deprivation therapy) within four weeks; nitrosoureas or mitomycin C within six weeks; prior radiotherapy to more than 25% of bone marrow; prior high-dose chemotherapy; prior receipt of more than three chemotherapy regimens; pregnancy, breast feeding or plans for becoming pregnant during the study; unwillingness to use effective contraception during the study and for 30 days following the last dose of study medication; other medical disorder or laboratory finding that in the opinion of the investigator compromised subject safety; less than four weeks since major surgery, or; HIV, hepatitis B surface antigen or hepatitis C positivity with abnormal liver function tests.",first three weeks following day one of cycle one,NA
23394629,NCT00374985,Combination,No,patients with adenocarcinoma of the oesophagogastric junction.,"Patients with histologically proven adenocarcinoma of the oesophagogastric junction (AEG II–III, according to the Siewert classification) with stage I–III disease (T3 N0–N3 to T4 N0–N3) and at least one measurable lesion according to RECIST criteria were eligible.Cancer of the oesophagogastric junction was defined according to the Siewert classification  whereas AEG type I is defined as adenocarcinoma of the distal oesophagus, AEG type II is defined as adenocarcinoma of the cardia and AEG type III is defined as subcardial adenocarcinoma with infiltration of the oesophagogastric junction.Only patients with AEG type II and type III were included into this study.Patients were required to be between 18 and 75 years of age with adequate organ function and a Karnofsky performance status of ≥ 70% at study entry.","Patients with distant metastases and any previous palliative, adjuvant or neoadjuvant chemotherapy and/or radiotherapy or previous surgery of the primary tumour were excluded.Patients with any other tumour type (except basal skin cell carcinoma or in situ cervical carcinoma that had been successfully treated), symptomatic peripheral neuropathy as determined by the National Cancer Institute common toxicity criteria (NCI-CTC) grade ≥ 2, or other serious medical conditions, known hypersensitivity to platinumbased substances or pregnant or breast-feeding patients were also ineligible.Women of child-bearing potential were advised on contraception.",NA,NA
21821830,NCT00137436,Combination,No,"metastatic, castration-resistant prostate cancer","Chemotherapy-naı¨ve patients with confirmed progressive mCRPC were enrolled. Progression was defined by either nonmeasurable disease plus elevated prostate-specific antigen (PSA) levels or measurable disease alone (as shown by transaxial imaging with computed tomography or magnetic resonance imaging scans according to RECIST v1.0.Other key eligibility criteria included Eastern Cooperative Oncology Group (ECOG) performance status of zero to one, testosterone <50 ng/dl and adequate cardiac, renal, hepatic and bone marrow function.","Patients were ineligible if previously treated with an antiangiogenic agent, chemotherapy, radioisotope or radiotherapy to ‡25% of bone marrow. Additionally, brain metastases, uncontrolled hypertension or pain, severe hemorrhage <4 weeks before commencing treatment, impending complication from bone metastases, unresolved urinary obstruction or clinically significant cardiovascular event/ disease during the preceding 6 months were exclusionary.","the lead-in period plus the first combination cycle, totaling 9 weeks.",NA
20628389,NA,Combination,No,patients with advanced solid tumours:castration-resistant prostate cancer;Oesophageal;gastro-oesophageal junction;Sarcoma;Gastric;Cervix;nonsmall cell lung cancer;Vulva;Ovarian,"Patients with histologic or cytologic confirmation of advanced solid tumours refractory to standard therapy were eligible. Other inclusion criteria included: age X18 years; Eastern Cooperative Oncology Group performance status of 0 or 1; adequate bone count>=1500 ml^(–1), haemoglobin>=10 g per 100 ml, platelets >100 000 ml^(–1), creatinine clearance>=30 ml min^(–1), and total bilirubin equal to or less than the institution upper limit ofnormal (ULN), AST, and alanine aminotransferase (ALT)<=1.5  ULN); and use of adequate contraception in patients with reproductive potential.","Exclusion criteria included: anticancer therapy or surgery within 4 weeks, excluding luteinising hormonereleasing hormone (LHRH) analogues in prostate cancer patients; severe hypersensitivity reaction to docetaxel or drugs formulated in polysorbate 80; neuropathy of grade>=1; symptomatic or untreated brain metastases; pregnancy or lactation; significant active cardiac disease; concomitant high-dose corticosteroids (>=100 mg prednisone per day or equivalent); serious active infection; and other uncontrolled significant medical illness.",during cycle 1,NA
34070561,2604784,Combination,No,"Patients with Peritoneal Metastases from ovarian, gastric, intestinal and appendiceal cancer.","Unresectable peritoneal metastasis on peritoneal cytology/histology;Age between 18 and 80 years;Eastern Cooperative Oncology Group (ECOG) performance status ≤2;Adequate liver function [AST/SGOT and/or ALT/SGPT ≤2.5 × ULN (upper limit of the normal range) or ≤5 × ULN if liver metastases are present, serum bilirubin≤1.5 × ULN];Adequate renal function (serum creatinine ≤ 1.5 × ULN or creatinine clearance>50 mL/min);Cardiac and pulmonary function preserved;Adequate bone marrow function [absolute neutrophil count (ANC) ≥ 1.5 × 109/L,hemoglobin (Hb) ≥9 g/dL, platelets (PLT) ≥100 × 109/L];Total recovery or a CTCAE grade ≤1 from all adverse clinical events of previous chemotherapy, including surgery and radiotherapy, except for alopecia;No chemotherapy/major surgery in the last four weeks prior to the PIPAC procedure;Written informed consent signed.","Extra abdominal metastatic disease (withthe exception of isolated pleural carcinomatosis);Bowel obstruction;History of allergic reactions to cisplatin/doxorubicin/oxaliplatin or their derivatives;Severe renal failure, myelosuppression, severe hepatic failure, severe heart failure, recent myocardial infarction, severe arrhythmia;Immunosuppressed patients, undergoing immunosuppressive therapy;Previous treatment with reaching the maximum cumulative dose of doxorubicin, daunorubicin, epirubicin, idarubicin and/or other anthracyclines and anthracenedions;Pregnancy;Patients of both sexes with reproductive potential who refuse to use an adequate method of contraception;Major surgery or systemic chemotherap less than four weeks prior to PIPAC procedure.",NA,NA
33755379,2987244,Combination,No,patients with peripheral T-cell lymphoma,The diagnosis of PTCL was confirmed according to the 2016 WHO classification10.,"ALCL (ALK+), NK/T-cell lymphoma, and primary cutaneous lymphoma were excluded.",first 2 cycles,NA
11408509,NA,Combination,No,breast cancer,"Patients were required to have histologically confirmed adenocarcinoma of the breast with manifestations of progressive regional or metastatic disease that was measurable or assessable. Other requirements included an Eastern Cooperative Oncology Group performance status of 0, 1, or 2; normal organ function (ie, normal total bilirubin and AST <= 2.5-fold the upper limits of normal, neutrophil count >=1,500/uL, and platelet count >=100,000/uL); a normal left ventricular ejection fraction (LVEF) as measured by radionuclide angiography; and no symptomatic or untreated brain metastases. Patients were allowed to receive up to one prior regimen for metastatic disease as long as it did not contain an anthracycline or taxane. Prior adjuvant doxorubicin (up to 400 mg/m2 ) or taxane therapy was permitted, as was prior hormonal therapy. All patients were required to provide written informed consent, and the protocol was approved by the institutional review boards at each participating institution. ",NA,cycle 1.,NA
9053501,NA,Combination,No,Advanced Non-Small-Cell Lung Cancer,"Patients were required to have histologically or cytologically proven metastatic, locally recurrent, or unresectable locally advanced NSCLC. No prior chemotherapy, including neoadjuvant chemotherapy or concurrent chemoradiotherapy, was permitted. Prior radiation therapy was permitted provided it had been completed at least 4 weeks before study entry (6 weeks for extensive radiation therapy).Other eligibility criteria were age 18 to 75 years, performance status (World Health Organization [WHO]) 0 to 2, absolute neutrophil count >= 2.0 x 10^9 /L, platelet count>=100 X 10^9/L, serum bilirubin level <= 1.25 times upper limit of normal for the institution, AST<=two times upper limit of normal for the institution, serum creatinine concentration <=120 /.mol/L, and measured 24-hour creatinine clearance >= 60 mL/min. Written informed consent was obtained from all patients and the protocol was approved by the institutional ethics committees of the participating centers.","Patients were excluded from the trial for any of the following: known brain or meningeal metastases; preexisting symptomatic peripheral neuropathy 2 grade I by the common toxicity criteria of the National Cancer Institute (NCI-CTC); preexisting significant neurologic or psychiatric disease, including psychosis, dementia,and seizures; unstable cardiac disease that required treatment; active uncontrolled infection; and pregnancy or lactation. Concomitant other anticancer therapy or experimental drug treatment of any type was not permitted. Patients were not permitted to receive corticosteroid medication while on study, except as outlined later.",in the first cycle,NA
9440738,NA,Combination,No,Patients with intrathoracic neoplasm.,"Patient eligibility was determined at a multidisciplinary chest oncology conference. Eligibility criteria included a pathologically documented intrathoracic neoplasm for which chest radiotherapy was considered standard therapy. Indications for standard chest radiotherapy included either as adjuvant therapy following local surgical resection in patients with poor prognosis, as definitive therapy, or as palliative therapy. Previous chemotherapy more than 4 weeks before study entry was allowed.A Cancer and Leukemia Group B (CALGB) performance status of 0 to 2 was necessary. Laboratory measures required at study entry included the following: neutrophils>=2.0 X 10^9/L, platelet count>=100 x 10^9/L, aspartate aminotransferase level<=2.5 times the institutional upper limit of normal, and bilirubin level within the institutional upper limit of normal. Written informed consent was obtained from all patients before protocol treatment was begun.",prior treatment with taxanes was not permitted.Patients were ineligible if they had received prior radiation therapy to the chest or to 25% of the bone marrow. Patients with symptomatic peripheral neuropathy (grade > 1 according to the National Cancer Institute common toxicity criteria) or CNS metastases were excluded. ,each 3-week cycle of treatment. ,NA
9459161,NA,Combination,No,advanced solid tumours: Head and neck cancer 5;Non-small cell lung cancer 5;Malignant melanoma 5;Soft tissue sarcoma 3;Malignant mesothelioma 3;Primary unknown 2;Colon cancer 2 ;Miscellaneous 9,"Only patients with a histologically confirmed solid tumour for which no therapies with greater potential benefit than docetaxel and ifosfamide existed were candidates for this study.(a) age>= 18 years and < 75 years; (b) WHO performance status 0-2; (c) no more than one line of previous chemotherapy for advanced disease, previous (neo) adjuvant chemotherapy was allowed provided that this chemotherapy had ended at least 6 months before study entry; (d) no previous anticancer therapy for more than 4 weeks (6 weeks in cases of nitrosureas, mitomycin C and carboplatin); (e) no previous treatment with docetaxel, ifosfamide or paclitaxel; (f) no previous radiotherapy for at least 4 weeks (8 weeks in cases of extensive previous radiotherapy); (g) adequate bone marrow (neutrophils>=2 x 10^9 1^(-1), platelets>=100 x 10^9 1^(-1)', hepatic (total bilirubin <= 1.25 times the upper-normal limits, ASAT (SGOT) < 2 times and in case of proven liver metastases <=3 times the upper-normal limits) and renal function (serum creatinine<=120umol 1^(-1)); (h) absence of symptomatic peripheral neuropathy>= grade 2 according to NCI Common Toxicity Criteria (CTC) (Brundage et al, 1993); and (i) no peptic ulcer, unstable diabetes mellitus or other contraindications for the use of corticosteroids.",NA,cycle 1 ,NA
9193350,NA,Combination,No,children with refractory solid tumors:Osteosarcoma;Ewing's sarcoma/PPNET;Rhabdomyosarcoma;Wilms' tumor;Hepatoblastoma,"Patients >= 1 year and < 21 years of age with a histologically confirmed solid tumor refractory to standard therapy were eligible for this trial.Other eligibility criteria included: (1) an Eastern Cooperative Oncology Group (ECOG) performance status < 2; (2) a life expectancy greater than 8 weeks; (3) adequate bone marrow function (an absolute neutrophil count [ANC] > 1,500/gLL, hemoglobin level > 9.0 g/dL; and platelet count > 100,000/puL); (4) adequate liver function (serum bilirubin level < 1.5 mg/dL; ALT < 2 x normal); (5) adequate renal function (serum creatinine level < 1.5 mg% or creatinine clearance > 60 mL/min/1.73 m2); (6) recovery from the toxicity of prior therapy; (7) no other chemotherapy within 2 weeks (6 weeks for prior nitrosourea therapy) of entery onto this protocol; and (8) no prior extensive radiotherapy (eg, pelvic or craniospinal) or bone marrow transplantation (BMT) with total-body irradiation.After determination of the maximum-tolerated dose (MTD) in this heavily pretreated patient population, the eligibility criteria were revised to study a less heavily pretreated patient population, because the MTD identified in the heavily pretreated patients (65 mg/m2 ) was much lower than the adult MTD (100 mg/m2).","The revised eligibility criteria excluded patients who had received more than two prior chemotherapy treatment regimens and patients who had received any prior central axis radiation (skull, spine, pelvis, or ribs) or a BMT.",NA,NA
9850032,NA,Combination,No,Patients with refractory solid tumors:Non-Small-cell lung cancer;Breast;Small-cell lung cancer;Ovarian;Bladder;Esophageal adenocarcinoma;Squamous anal;Squamous skin metastatic;Colon,"Eligible patients had measurable or assessable advanced carcinomas that had progressed during or after standard chemotherapy or for which no standard therapy existed.They also had adequate marrow, hepatic, and renal function, with an absolute neutrophil count (ANC) of 1,500/tL or greater, platelet count of 100,000/4L or greater, total bilirubin level equal to the institutional upper limits of normal (ULN) or less, transaminase levels (AST and ALT ) 1.5-fold or less than ULN, alkaline phosphatase level 2.5-fold of ULN or less, serum creatinine level 1.5 mg/dL or less, and a Southwest Oncology Group (SWOG) performance status of 0 to 2.",Patients were ineligible if they had received prior gemcitabine or docetaxel or if they had peripheral neuropathy greater than grade 1.,first cycle of chemotherapy,NA
11138457,NA,Combination,No,"solid tumor:Ovary;Breast;Colorectal;Adenocarcinoma, unknown origin;Non-small-cell lung;Miscellaneous","Inpatients at the Institut Jules Bordet were eligible for entry onto the study if they met the following criteria: (1) histologically confirmed diagnosis of a solid tumor; (2) advanced disease refractory to conventional effective therapy or for which no standard therapy exists; (3) age between 18 and 75 years; (4) life expectancy>=12 weeks; (5) World Health Organization (WHO) performance status (PS) <= 2; (6) no chemotherapy or radiotherapy within 4 weeks before entry (within 6 weeks for nitrosoureas, mitomycin, or extensive radiotherapy); and (7) adequate bone marrow (leukocyte count>=4,000/uL, granulocyte count>=1,500/uL, platelet count >100,000/uL), hepatic (serum bilirubin<=1.25 and AST<=two times the upper limit of normal values), and renal (serum creatinine<=1.35 mg/dL) functions.","Patients were not eligible if they had symptomatic peripheral neuropathy of any origin (WHO grade <=1), or evidence of brain metastases.",NA,NA
10678557,NA,Combination,No,metastatic non-small cell lung cancer (NSCLC),"The eligibility criteria for this trial required a histologically or cytologically proven diagnosis of metastatic NSCLC.No previous chemotherapy was permitted and no radiation therapy within 4 weeks prior to the study.Other criteria included measurable disease, age 20-75 years, performance status (ECOG) 0 or 1, leukocyte count <12,000/mm3 and >=4000/mm3, absolute neutrophil count>=2000/mm3, platelet count >=100xI0^3/mm3, hemoglobin>=9.5 g/dl, serum GOT and serum GPT level <2 times the upper limit of the normal range, serum bilirubin level <upper limit of normal range, serum creatinine <upper limit of normal range, 24 h creatinine clearance>=60 ml/min, O2 pressure of arterial blood>=70 mmHg and written informed consent.",NA,first cycle,NA
10811508,NA,Combination,No,refractory advanced breast cancer patients,"Candidates for this study were women with histologicaHy/cytologically-proven locally-advanced or metastatic breast cancer who had not responded to, or had relapsed after, anthracycline-based chemotherapy for advanced disease.Other requirements included measurable or assessable disease, age<=70 years, ECOG performance status<=2, and adequate hematologdc, renal and hepatic functions.",NA,first chemotherapy cycle,NA
11147602,NA,Combination,No,Patients with Solid Tumors:Prostate;Pancreatic;Gynecologic;Gastric;Lung;Unknown primary;Renal;Hepatocellular,"All patients had biopsy proven advanced malignancy and informed consent was obtained from all patients.Entry criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of<=2, a life expectancy of at least 3 months, a leukocyte count of>3000 cells/mL, and a platelet count>150,000 cells/mL; normal liver function tests and a serum creatinine concentration <1.5 mg/dL also were required.",NA,NA,NA
10944133,NA,Combination,No,advanced non–small-cell lung cancer (NSCLC) patients.,"Patients were enrolled onto this study if they met the following criteria: a histologic or cytologic diagnosis of lung cancer; a stage IV disease, or stage IIIB disease that was not a candidate for curative radiation therapy; a measurable or assessable lesion; no prior therapy; a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) scale; a life expectancy of at least 3 months; adequate bone marrow function (leukocyte count >= 4,000/mL, neutrophil count >= 12,000/mL, platelet count >=100,000/mL, and hemoglobin level >= 9.5 g/dL), adequate hepatic function (AST and ALT levels <=2.0 times the upper limit of normal, and bilirubin level<= the upper limit of normal), adequate renal function (creatinine level<=the upper limit of normal, 24-hour creatinine clearance>=50 mL/min), and arterial oxygen partial pressure of 70 torr or greater; age between 20 and 74 years; and written informed consent to the study.","Patients were ineligible if they experienced the following: had serious infectious diseases or other severe complications (heart diseases, pulmonary fibrosis/interstitial pneumonia, bleeding, uncontrollable diabetes, or pseudomembranous colitis); had symptomatic peripheral neuropathy; had watery diarrhea, paralytic ileus, or intestinal obstruction; had massive pleural effusion or ascitic fluid; had symptomatic brain metastases; had active concurrent malignancies; were lactating or pregnant women, or were willing to be pregnant; had a history of a drug allergy; had a history of acute myocardial infarction within the previous 6 months; had superior vena caval syndrome, which required urgent radiotherapy; or had other medical problems severe enough to prevent compliance with the protocol. Patients currently being treated with calcium channel blockers, ketoconazol, erythromycin, or systemic corticosteroid therapy were also ineligible. ",First Cycle,NA
9060547,NA,Combination,No,Patients With Advanced Solid Tumors:Colon or rectal cancer 23;Unknown primary cancer 13;Breast cancer 5;Head and neck cancer 5;Soft tissue sarcoma 2;Ewing sarcoma 2;Stomach cancer 5;Lung (non-small-cell) cancer 3;Melanoma 2;Pancreatic cancer 1;Peritoneal cancer 1;Urothelial cell cancer 1;Renal 1,"Only patients with histologically documented solid tumors for which no therapies with greater potential benefit than docetaxel and cisplatin existed were candidates for this study.(1) age>=18 and <= 75 years;(2) World Health Organization (WHO) performance status 0 to 2;(3) life expectancy of at least 12 weeks;(4) no more than one prior combination regimen or more than two single-agent regimens;(5) off previous anticancer therapy for at least 4 weeks;(6 weeks in case of mitomycin, nitrosoureas, or extensive radiotherapy); (6) no prior treatment with cisplatin derivatives or taxoid drugs;(7) adequate bone marrow (neutrophil count>=2 x 10^9/L and platelet count >= 100 X 10^9 /L),hepatic (total bilirubin level<=1.25 times and AST c two times the upper normal limits), and renal (creatinine concentration<=120 pmol/L or creatinine clearance >=60 mL/min) functions;(8) absence of symptomatic peripheral neuropathy greater than grade 0 according to the National Cancer Institute (NCI) common toxicity criteria (CTC).",NA,cycle 1,NA
11032597,NA,Combination,No,Patients With Advanced Solid Tumors:NSCLC 8;Pancreatic carcinoma 8;Mesothelioma 4;Gastric carcinoma 4;Bladder carcinoma 3;Cholangiocarcinoma 2;UCNT 2;Oesophageous 1;Others 8,"Patients were eligible if they had advanced or metastatic solid tumors refractory to conventional therapy or tumors for which no effective therapy existed, they were aged 18 to 75 years, and their World Health Organization performance status was # 1. Their life expectancy should be at least 12 weeks. Only one prior chemotherapy regimen for advanced or metastatic disease, with no taxanes or topoisomerase I inhibitors, was allowed. Patients had to have discontinued previous chemotherapy for at least 4 weeks (6 weeks in case of nitrosourea, mitomycin, and carboplatin). Prior radiotherapy to pelvis or abdomen was not allowed because of the increased risk of diarrhea induced by irinotecan. Adequate hematologic function (absolute neutrophil count>=2,000/uL and platelet count>=100,000/uL), hepatic function(total bilirubin<= 1.25 times the upper limit of normal, AST<= two times the upper limit of normal), and renal function (serum creatinine level <=120 umol/L) were required. No clinical significant neuropathy>=grade 2, according to the National Cancer Institute criteria, was allowed. All patients signed a written informed consent before study entry.",NA,All cycles,NA
10963645,NA,Combination,No,Patients With Advanced Solid Tumors:Non–small-cell lung 8;Breast 2;Head and neck 2;Colorectal 2;Gastric 1;Thyroid 1;Esophageal 1;Uterus 1;Pancreas 1,"Patients with histologically or cytologically proven solid tumors that were refractory to standard therapy or for which there was no effective therapy were eligible. It was preferable that patients had measurable or assessable lesions. Eligibility criteria included the following: age of 20 to 74 years, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, life expectancy of greater than 3 months, adequate organ function (WBC count >= 4,000/uL, neutrophil count >= 2,000/mL, platelet count >= 100,000/mL, total bilirubin level <= 1.5 mg/dL, AST and ALT levels <= 2.5 times upper normal limits, serum creatinine <= 1.5 mg/dL, creatinine clearance >= 60 mL/min), normal coagulation tests, and a normal ECG. At least 4 weeks (6 weeks in the case of nitrosourea, mitomycin, and radiation therapy against more than 20% of all the bones in the body) must have elapsed since the completion of previous therapy. Also, patients must have recovered from the toxic effects of the previous therapy.","Exclusion criteria included heart failure, infection with fever, uncontrollable diabetes mellitus, obstruction or paralysis of the bowel, peripheral neuropathy, massive pleural effusion or ascites, peripheral edema, severe mental disease, active concurrent malignancies, hepatitis B or C virus infection, human immunodeficiency virus or T-cell lymphotropic virus type I infection, brain metastases, pregnancy, lactation, and the use of corticosteroids (except in patients who were taking corticosteroids less than 20 mg/d for more than 6 months). Patients who had prior paclitaxel- or docetaxel-containing chemotherapy or who had intensive chemotherapy or radiation therapy with autologous bone marrow transplantation were excluded. Patients who had a history of hypersensitivity to any drugs were also ineligible.",first course,NA
33856277,NCT02142049,Combination,No,patients with relapsed/refractory diffuse large B-cell lymphoma,"Adults 18 years of age with pathologically confirmed, measurable DLBCL were eligible for the study. Part 1 enrolled patients with all subtypes of DLBCL; part 2 enrolled patients with the non-GCB subtype as determined by immunohistochemistry (IHC) using the Hans criteria.Patients had R/R disease defined as recurrence of disease after CR or disease progression, an Eastern Cooperative Oncology Group performance status of<=2, and left ventricular ejection fraction >45%. Patients with transformed DLBCL, coexisting histologies, or primary mediastinal lymphoma were eligible for part 1 only. Patients did not receive prophylactic antibiotics.",Patients with an allogeneic stem cell transplant within 6 months of study start were ineligible.,first treatment cycle,NA
34474927,NCT03639246,Combination,No,platinum-resistant ovarian cancer (PROC),"Key eligibility criteria included age ≥ 18 years; ovarian, fallopian tube, or primary peritoneal platinum-resistant cancer including adenocarcinoma not otherwise specified (NOS), grade 3 endometrioid adenocarcinoma, mixed epithelial carcinoma with at least an 80% high grade serous component, high-grade serous adenocarcinoma, and undifferentiated carcinoma; measurable disease as assessed by Response Evaluation Criteria in Advanced Solid Tumors (RECIST 1.1), Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate organ function. All patients were required to provide tumor tissue from a newly obtained biopsy sample or an archived tumor sample.","Patients were excluded if they received more than 3 prior treatment regimens, not including maintenance, hormonal, or other adjuvant therapy; received prior therapy with Pac in the recurrent setting (if physicianchosen chemotherapy in this study was Pac) or PLD (if physicianchosen chemotherapy in this study was PLD); if they were platinum refractory (defined as progression during or within 4 weeks after completion of first platinum regimen); or if they received an anticancer or hormonal therapy within 4 weeks of the first dose of study treatment.",at least 28 days,NA
11181674,NA,Combination,No,Locally Advanced Squamous Cell Cancer of the Head and Neck,"Patients were eligible if they had histologically or cytologically confirmed SCCHN, at least one unidimensionally measurable lesion, and stage III or IV disease without evidence of distant metastases. Patients with primary sites in the larynx,hypopharynx, oropharynx, or oral cavity were eligible，Patients were required to be 18 years of age or older and have an Eastern Cooperative Oncology Group performance status of 1 or better.Patients were required to have adequate nutritional intake.","Patients with unknown primary cancers, nasopharynx cancer, salivary gland cancer, and cancers arising in the paranasal sinuses were specifically excluded from the study. Patients who had received previous chemotherapy were specifically excluded, and patients who had been treated with definitive surgery or any radiotherapy for a previous SCCHN were excluded.Patients were ineligible if they had another cancer, other then basal or squamous cancer of the skin or carcinoma-in-situ of the uterine cervix,within 5 years of study entry.Patients were excluded if they required intravenous (IV) alimentation to maintain adequate nutrition.Patients were excluded if they had a serious concomitant illness or medical condition, including chronic obstructive pulmonary disease requiring hospitalization within the last year; myocardial infarction within 6 months; symptomatic angina pectoris; arrhythmias other then stable atrial fibrillation; uncontrolled hypertension; active infection; active neurologic or psychiatric disorder; concurrent treatment with corticosteroids, unless chronic, for greater then 1 month and at low dose, equivalent to less than 20 mg/d of methylprednisolone; active peptic ulcer disease; uncontrolled diabetes mellitus; or pregnancy.",at least three of six patients at that dose level,NA
9552034,NA,Combination,No,patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).Primary tumor site：Unknown1；Hypopharynx 2；Larynx2；Tonsil2；Base of tongue9；Oral cavity4；Nasopharynx4,"Patients with locally advanced nonmetastatic SCCHN or its histologic variants (eg, lymphoepithelioma, undifferentiated epidermoid carcinoma) were enrolled onto an institutional review board-approved phase I/II study of TPFL5 followed by definitive radiation therapy. All patients signed informed consent statements approved by our institution's human protection committee before enrollment. All subjects were required to have an Eastern Cooperative Oncology Group performance status of 2 or less, estimated enteral intake of greater than 1,800 kcal/day, stable weight, life expectancy of greater than 3 months, WBC count 4,000 cells/pL or greater, platelet count 100,000/pL or greater, hemoglobin level 10 gm/dL or greater, AST level less than 1.5 times upper limit of normal (ULN), alkaline phosphatase level less than 2.5 times ULN, total bilirubin level 2 times ULN or less, creatinine level 1.5 mg/dL or less or 24-hour creatinine clearance value greater than 50 mL/min, peripheral neuropathy less than grade 2 by National Cancer Institute Common Toxicity Criteria (NCI CTC), and be able to tolerate 3 L of intravenous normal saline per day.","Enrollment was limited to patients with assessable previously untreated stage III or IVdisease, which excluded those with metastatic disease, tumor, node,metastatic (TNM) stage T3NO exophytic tumors, or TINI lesions.Patients with previous head and neck cancers or any non-SCCHN malignancy except curatively treated skin or cervical cancers were excluded.",NA,NA
10416004,NA,Combination,No,metastatic breast cancer ,"Further eligibility criteria were: a cumulative doxorubicin dose received in prior adjuvant treatment of less than 300 mg/m2  or equivalent; a life expectancy of more than three months; adequate hematologic parameters (absolute neutropenia count > 1500/mm3, hemoglobin 3* lOg/dl, platelets 5 100 x 103) as well as renal (serum creatinine < 1.5 mg/dl) and hepatic (serum bilirubin s£ 1.5 mg/dl, SGPT, SGOT =g 3 x normal values) function tests; normal cardiac function with left ventricular ejection fraction (LVEF) > 50%; an interval of more than four weeks since the last radiation course; irradiation of less than 25% of bone marrow-containing bones.",NA,first chemotherapy course,NA
10416003,NA,Combination,No,patients with advanced breast cancer,"Patients with histologically or cytologically documented raetastatic or locally advanced breast cancer who had received no prior chemotherapy for metastatic disease were eligible. Neoadjuvant chemotherapy completed at least six months prior to study entry and not containing anthracyclines was allowed. Prior hormonal therapy for advanced disease was allowed.Criteria for inclusion were as follows: adequate hematologic (ANC >=2.0 x 1O^9 /1, platelet count>=100 x 10^9 /l) renal, hepatic (liver function tests currently recommended for treatment with docetaxel) (and cardiac function (LVEF > 50% by echocardiography), measurable or evaluable disease, written informed consent.",NA,first cycle,NA
10416005,NA,Combination,No,patients with metastatic breast cancer,"Eligible patients had to satisfy the following criteria: age 18 to 75 years, histologically proven metastatic breast cancer (histological or cytological proof of metastasis was required for patients with a single metastatic target lesion), WHO performance status <=2, measurable and/or evaluable disease. Normal hematologic and blood chemistry values were mandatory: adequate bone marrow (absolute neutrophil count (ANC)>= 2000/ul, platelet count>= 100 000/ul), hemoglobin (>= 10 g/dl), liver function (serum bilirubin level <= 1.25 times the upper limit of normal value (LNV), AST or ALT <=2 times the upper LNV, alkaline phosphatase <=6 times the upper LNV) and renal function (serum creatinine <= 140 umol/1), and normal baseline left ventricular ejection fraction (LVEF). ","Patients were excluded if they had received prior chemotherapy for metastatic disease, although neoadjuvant and/or adjuvant treatment were permitted provided there had been a chemotherapy-free interval of at least 12 months before study entry. Patients were ineligible if they had received prior therapy with taxoids. With respect to prior adjuvant anthracyclines, the maximum permitted cumulative doses prior to study entry were doxorubicin<= 300 mg/m2 or epirubicin<=500 mg/m2 or pirarubicin <=500 mg/m2, with the exception of patients who were to receive the highest planned dose of doxorubicin (60 mg/m2), in whom the total prior doses were<=200, <=300 and <=300 mg/m2.Patients were excluded for the following reasons: history of prior malignancies (excluding non-melanoma skin cancer or excised cervical carcinoma), known CNS metastases, symptomatic peripheral neuropathy grade>= 2 and other coexisting medical problems that were not adequately controlled. Concurrent treatment with other anticancer or experimental drugs was prohibited. Patients with impaired liver function (AST and/or ALT > 1.5 times upper LNV associated with alkaline phosphatase > 2.5 times upper LNV) were also excluded from the study.",NA,NA
11137204,NA,Combination,No,patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.,"Patients with histologically or cytologically confirmed NSCLC, aged B75 years, who had failed front-line chemotherapy with taxotere in combination with either gemcitabine (n=14) or cisplatin (n=8) were enrolled.Other eligibility criteria were, performance status (World Health Organization (WHO)) 0–2; a life expectancy of at least 3 months; inoperable stage IIIB or IV disease; adequate hematologic parameters (absolute granulocyte count >1500/dL, hemoglobin level>9 gr/dL, and platelet count >100 000/dL), adequate hepatic (serum bilirubin <1.5 mg/dL, transaminases less than twice the upper limit of normal), and renal (serum creatinine <1.5 mg/ dL) function. Patients with brain metastases were eligible if they had been irradiated, the brain lesions were radiographically stable, and clinical improvement was evident.","Patients with malnutrition (more than 20% loss of body weight), active infection, massive liver metastases covering more than 50% of the liver surface, or a second primary tumor except from squamous skin carcinoma or in situ cervical carcinoma, were excluded from the study.",the first chemotherapy course,NA
9989521,NA,Combination,No,cancer patients:Brain glioblastoma 9;Nonsmall cell lung cancer (stage IIIb) 9 ;Cervical cancer (squamous; stage IVa) 3;Endometrial adenocarcinoma (stage IVa) 2;Endometrial adenocarcinoma (pelvic recurrence) 1;Bladder cancer (transitional; stage IVa) 2;Unknown primary pelvic adenocarcinoma 1,Patients recruited in the study had a performance status equal or less than 2 (World Health Organization). Written informed consent was obtained from all patients. ,"Patients previously treated with radiotherapy or chemotherapy or with white blood cells<2500/ul and platelets<100,000/mlwere excluded. Patients with hemoglobin < 10 g/dl were transfused until hemoglobin levels were raised above 11 g/dl. Pregnant women or patients with major heart, lung, liver, renal, psychiatric disease, or hematological malignancies were also excluded. Patients known to present severe allergic response to any drug or substance were excluded.",NA,NA
34189636,NA,Combination,No,advanced relapsed ovarian cancer,"Eligible patients were aged≥20 years, had an Eastern Cooperative Oncology Group performance status of 0 or 1, and had a histologically confrmed diagnosis of epithelial ovarian, primary peritoneal, or fallopian tube cancer that had relapsed following treatment with platinum-based chemotherapy.Only patients not expected to beneft from retreatment with platinum-based chemotherapy were included. ",Patients were excluded if they had received a cumulative dose of doxorubicin (or other anthracycline)>300mg/m^2.,cycle 1 in the DEP,NA
11429197,NA,Combination,No,Patients with stage IIIB or IV non-small cell lung cancer (NSCLC).,"Eligible patients were required to have histologically or cytologically confirmed NSCLC of unresectable stage IIIB or IV; be between 20 and 69 years of age; had no previous chemotherapy or radiotherapy; have a performance status (PS) of 0–2 on the Eastern Cooperative Oncology Group (ECOG) scale; have a life expectancy of >=12 weeks; adequate bone marrow (a leukocyte count of >=4000 mm−3 , neutrophile count of >=2000 mm−3 , platelet count of >=100 000 mm−3 , and hemoglobin >=10.0 g dl−1), and a normal liver (total serum bilirubin <=1.5 mg dl−1 , and AST and ALT less than twice the upper limit of the normal range) and renal function (serum creatinine<=1.5 mg dl−1 and creatinine clearance >=60 ml min−1 ).",Patients with concomitant malignancy were excluded. Patients with central nervous system metastases were ineligible. Patients with active infectious diseases or other serious medical problems were also ineligible.,first two courses,NA
34669023,NA,Combination,No,advanced malignancies:Breast 59;Ovary 9;Prostate 2;Colon 2;Blood (angioimmunoblastic T-cell NHL)1;Rectum1;Bladder1;Ampulla of vater1; Appendiceal1 ;Parotid gland1;Testes1;Lung1.,"Adult patients were eligible with histologically confirmed metastatic malignancy for which no standard therapy was available. They were required to have an Eastern Coopera- tive Oncology Group Performance Status (ECOG PS) of ≤ 2, adequate organ function, and evaluable or measurable dis- ease by RECIST 1.1. Patients enrolled to treatment with AC required a pre-treatment ejection fraction ≥ 50% and could not have had prior doxorubicin exposure of > 300 mg/m2. Only metastatic breast cancer patients were enrolled onto the schedules of veliparib for 7 days and 14 days with AC (Groups 3 and 4).Eligible patients had adequate bone marrow (absolute neutrophil count ≥ 1500/mL; platelet count ≥ 100,000/mL; hemoglobin ≥ 9 g/dL), liver function (total bilirubin within normal institutional limits; ALT and AST≤2.5×ULN or ≤ 5 × with liver metastases, renal function (serum cre- atinine within normal institutional limits or ≥ 60 mL/min for with creatinine levels above institutional normal), and adequate coagulation status (international normalized ratio or prothrombin time or activated partial thromboplastin time ≤ 1.2 × ULN). Previous anticancer treatment had to be completed at least 4 weeks before study entry. There was no limit on prior cytotoxic chemotherapy regimens.Patients with CNS metastases were also allowed if treated, off steroid treatment for > 3 months, and asymptomatic.","Medications or substances that were strong inhibitors or strong inducers of CYP3A4, CYP2B6, CYP2C9, or CYP2C19 were not allowed.Other exclusion criteria included history of active seizures, active systemic infections, symptomatic congestive heart failure, and any impairment to swallow capsules.",during the frst cycle and second cycle,NA
12954580,NA,Combination,No,refractory or resistant epithelial ovarian cancer,Eligibility criteria were: (i) a cytologically or histologically proven epithelial ovarian cancer resistant (i.e. relapsed <1 year from completion of platinumbased treatment) or refractory (i.e. progressed during platinum-based treatment or within 3 months from treatment completion) to previous platinum– paclitaxel-containing chemotherapy; (ii) age ≤70 years; (iii) Eastern Cooperative Oncology Group (ECOG) performance status ≤3 ; (iv) white blood count ≥4000/mm3;(v) platelet count ≥100 000/mm3; (vi) serum creatinine ≤1.5 mg/dl; (vii) AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ≤1.25× upper normal value; and (viii) bilirubin ≤1.25× upper normal value.,Patients previously treated with anthracyclines were not eligible.,during cycles 1 to 4,NA
15292922,NA,Combination,No,patients with advanced and metastatic bladder cancer,"Patients with histologically confirmed muscle invasive primary transitional cell carcinoma of the bladder and with locally relapsed, locally advanced or metastatic disease were eligible for the study. No more than one prior systemic chemotherapy regimen for primary radical treatment at the time of disease presentation was permissible. Patients previously treated with radiotherapy were eligible 3 months post-treatment and after having recovered from any radiation-related toxicity.The presence of one or more clinically or radiologically bidimensionally measurable lesion with one diameter of at least 2 cm was required.","Other criteria for patient entry into this trial were: age greater than 18 years; life expectancy X12 weeks; WHO performance status 0 –2; adequate haematological function (Hb >=10.0 g dl^(-1),neutrophils >=2.0  10^9 l^(-1),platelets >=100*10^9 l^(-1)); adequate renal function (glomerular filtration rate (GFR) >40 ml min^(-1) calculated using Cockcroft formula); and adequate liver function (serum bilirubin within normal limits, AST, ALT, ALP <1.5 times upper limit of normal (ULN), or up to 2.5 times ULN in patients with liver metastases and ALP allowed to 2.5 times for bone metastases). Women of child-bearing potential required a negative pregnancy test prior to entry and both men and women were required to use an adequate contraceptive method, to be continued for 3 months after the study.",NA,NA
11925133,NA,Combination,No,"Ovarian, Peritoneal, and Tubal Carcinoma","To be eligible, patients had to have a diagnosis of adenocarcinoma of the ovary, peritoneum, or fallopian tube confirmed histologically by GOG Pathology Committee review.Eligible patients had to demonstrate persistent or recurrent measurable or evaluable disease and must have received at least one platinum- and paclitaxel-based regimen. They were not eligible for any other GOG phase II trials. Patients could have no history of other malignancy within the past 5 years, no prior anthracycline-containing chemotherapy, and no radiation therapy to more than 10% of the bone marrow. Additional eligibility requirements included a GOG performance status of 0–2 and left ventricular ejection fraction within the institutional normal range as determined by gated cardiac radionuclide scan (MUGA). Pretreatment laboratory eligibility requirements included leukocytes >=3000/l, platelets >=100,000/l, and granulocytes >=1500/l, as well as creatinine<=2.0 mg%, bilirubin<=1.5 times institutional normal, and SGOT and alkaline phosphatase <=2.5 times institutional normal. Pretreatment evaluation included a physical examination with assessment of performance status; chest radiograph; measurement of the indicator lesion/s; complete blood count and differential; and measurement of serum CA-125, electrolytes, and glutamic oxaloacetic transaminase, along with bilirubin, alkaline phosphatase, creatinine, and blood urea nitrogen.","We excluded patients with tumors of low malignant potential (borderline tumors), active infection, hepatitis, gastrointestinal bleeding, a history of myocardial infarction, abnormal cardiac conduction diagnosed within 6 months, or unstable angina.",first course of treatment,NA
11557123,NA,Combination,No,patients with small-cell lung cancer,"Patients 18–75 years old with cytologically or histologically confirmed SCLC and measurable or assessable disease, who progressed or failed frontline treatment, were enrolled. Other eligibility criteria included performance status (WHO) 0–2, life expectancy of at least 3 months, and at least 4 weeks from prior cytotoxic chemotherapy. Prior radiotherapy (to<25% of marrow containingbones) was allowed, but a treatment-free interval of at least 4 weeks was required before study entry. Adequate blood counts (absolute neutrophil count 1500/dl, hemoglobin 10 g/dl, and platelets 100 000/dl), adequate renal (serum creatinine <1.5 mg/dl), and hepatic function (total bilirubin <1.5 mg/dl and serum transaminase values <3 times normal values) were required. Patients with brain metastases were allowed provided that they had been irradiated and had clinical and radiological improvement.","Patients with active infection, malnutrition or concurrent active malignancy were ineligible.",first cycle,NA
12452452,NA,Combination,No,high-risk primary breast cancer,"Eligible patients had histologically documented Stage IIIB or Stage II/IIIA breast cancer, ≥4 involved regional lymph nodes, and no evidence of metastatic disease by CT scan of the chest and abdomen and nuclear medicine bone scan. They also underwent therapy with either modified radical mastectomy (MRM) or lumpectomy and axillary lymph node dissection followed by local radiation. Other eligibility requirements included LVEF by MUGA of ≥50%; serum creatinine ≤2.0 mg/dl, SGOT/SGPT <2 × normal, alkaline phosphatase <1.2× normal, total and direct bilirubin <1.2× normal; white blood count ≥3000, absolute neutrophil count (ANC) ≥1500, and a platelet count of ≥100,000. All patients gave informed consent. Eligible patients were as described above and must have initiated adjuvant therapy with either A-T-F or ≥4 cycles of a conventional doxorubicin-based regimen within 12 weeks of definitive surgery. In addition to the eligibility criteria described above, patients were required to have bone marrow reserve adequate for harvest and morphologically negative for carcinoma. They also had to have pulmonary function tests documenting both FVC and FEV1 of ≥65% predicted, and adequate cardiac function with an LVEF by MUGA of ≥45%.","Patients were excluded if they were pregnant or lactating, had known heart disease (including angina pectoris, arrhythmia, myocardial infarction within the preceding 12 months, and congestive heart failure), active infection, or other co-morbid conditions that would increase the risk/benefit ratio of the protocol.Exclusion criteria were as listed above for the Phase I study; additional exclusion criteria included active hepatitis B infection, documented evidence of HIV, prior systemic chemotherapy (except as described above), or history of other malignancy (other than a history skin cancer or carcinoma in situ of the cervix).",NA,NA
11466671,NA,Combination,No,Patients with Diffuse Lymphoma,"Eligible patients included those with previously untreated, bulky Stage II (. 10 cm mass) or Stage III or IV aggressive lymphomas, specifically, diffuse small cleaved cell, diffuse mixed, diffuse large cell, and immunoblastic histologies (International Working Formulation stages E–H).The studies required a performance status of 0 –1 and a life expectancy >2 months. ",Patients with central nervous system involvement or acquired immunodeficiency syndrome were excluded.,one cycle at the current level,NA
12782942,NA,Combination,No,advanced ovarian epithelial carcinoma,"written informed consent; histologically proven diagnosis of advanced, stage III–IV ovarian epithelial carcinoma; age 18–65 years; ECOG performance status 0–1; life expectancy of at least 3 months; adequate bone marrow function [white blood cells <=4000/mm3 , platelets (PTL)<= 120 000/mm3,hemoglobim <= 9 g%]; adequate liver (serum bilirubin >=1.2 mg%, serum transaminases < 2*the normal value) and renal functions (serum creatinine >=1.2 mg%, BUN >= 50 mg%); normal cardiac function as evaluated by ECG and echocardiography; no signs of CNS metastases; and absence of severe, uncontrolled metabolic, respiratory, cardiovascular or neurological diseases. Other prerequisites necessary for eligibility included: absence of second malignancy with the exception of adequately managed in situ uterine carcinoma or cutaneous basal cell carcinoma; and geographical accessibility to the oncological centers in order to guarantee correct follow-up.Patients had not to have previously received chemotherapy and/or radiotherapy for any reason. The presence of bidimensionally measurable disease according to WHO criteria was not a necessary prerequisite due to the phase I nature of the first part of the study. On the other hand,measurable disease was mandatory for patients enrolled in the phase II part of the study.",NA,first three cycles of chemotherapy,NA
12419750,NA,Combination,No,patients with advanced hepatocellular carcinoma,"Chemonaïve (no intra-arterial or systemic chemotherapy) patients with a histological diagnosis of inoperable HCC not amenable to curative surgery (TNM stage IVA/IVB) were enrolled.  Unidimensionally and/or bidimensionally measurable Okuda stage I/II disease was required. Lesions were either pathologically proven or measurable lesions, as demonstrated by imaging studies, that were highly suggestive of HCC, with elevated α-fetoprotein (α-FP) levels >400 ng/ml.Patients were to have received no other form of therapy, such as radiation, transcatheter arterial chemoembolization (TACE) or percutaneous ethanol injection (PEI), for at least 3 weeks prior to enrollment; prior radiation was allowed provided that the irradiated area was not the only source of measurable disease.Patients were also required to be between 18 and 70 years of age and have a Zubrod performance status of 0 to 2 and an anticipated life expectancy of at least 8 weeks. Additional eligibility criteria included adequate renal (serum creatinine level ≤2.0 mg/dl) and bone marrow function (leukocyte count >3500/µl, platelet count >100 000/µl).Patients with liver dysfunction were enrolled based on the clinical judgement of whether they could tolerate the therapy, but the serum level of total bilirubin for inclusion was set as ≤3.0 mg/dl.No patients were on anti-viral treatment although this was not specifically prohibited.","Patients with other serious or uncontrolled concurrent medical conditions or with brain metastases were excluded from the study, as were patients with active, or history of, second malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin), peripheral neuropathy or significant neurological/psychiatric disorders.",NA,NA
12621462,NA,Combination,No,metastatic breast cancer,"Women <60 years old, performance status 0–1 (ECOG scale) with histologically confirmed metastatic breast cancer with stable disease or in partial remission (WHO criteria) following induction chemotherapy with GETwere eligible for HDC treatment with peripheral blood progenitor cell (PBPC) support.Other eligibility criteria included left ventricular ejection fraction (L-VEF) 450%, as determined by bidimensional echocardiography, no history of cardiac abnormality, negative HBsAg, HCV and HIV. Prior hormone therapy and/or prior adjuvant chemotherapy were permitted.Patients were required to sign an informed consent and the Ethics Committee of St Chiara University Hospital approved the study.",Patients with bone disease only were excluded. ,NA,NA
15218308,NA,Combination,No,metastatic breast cancer,"Patients aged 18–70 years with histologically proven metastatic breast cancer were eligible for the study. Other eligibility criteria included: bidimensionally measurable lesions (other than bone metastases), Eastern Cooperative Oncology Group (ECOG) performance status 0–2; life expectancy >12 weeks; absolute neutrophil count (ANC) >=2,000 cells/Ìl, platelet count >=100,000 cells/Ìl, adequate renal (serum creatinine <=1.25*upper normal limit) and hepatic (total bilirubin, SGOT and SGPT <=1.5*upper normal limit) function, and left ventricular ejection fraction (LVEF) >=50% by isotopic cardiac scan.patients could not have received any prior chemotherapy for metastatic disease. Patients were required to have a disease-free interval of at least 6 months between completion of initial treatment (surgery, radiotherapy or chemotherapy) and diagnosis of metastatic disease.An interval of 4 weeks must have elapsed from the last radiation course; patients must have discontinued hormonal therapy before commencing the study regimen.","Patients were excluded from the study for any of the following: local relapse after prior initial treatment, symptomatic brain metastasis, history of another neoplasm (except for nonmelanoma skin carcinoma or curatively treated carcinoma in situ of the cervix), history of atrial or ventricular arrhythmias or congestive heart failure, or second- or third-degree heart block, or documented myocardial infarction within the previous 6 months, motor or sensory neuropathy 6 WHO grade 2, psychiatric disorder, or active infection. Pregnant or lactating women were excluded; patients of childbearing potential were required to use adequate contraception and have a negative pregnancy test at study onset. ",first course,NA
12196358,NA,Combination,No,aggressive lymphomas,"The inclusion criteria were age ≤65 years, ECOG performance status ≤2 (or higher if related to the underlying disease) and absence of severe concomitant illnesses or previous neoplastic disease.",NA,Ninety courses,NA
11870176,NA,Single Drug,No,Advanced Soft Tissue Sarcomas,"Patients between the ages of 14 and 75 years with histologically confirmed locally advanced STS, metastatic STS, or both were eligible for this study. They were required to have bidimensionally measurable disease; World Health Organization performance status <= 2; no prior chemotherapy; no history of active cardiac disease, including myocardial infarction, congestive heart failure, or angina pectoris; and a resting left-ventricular ejection fraction (LVEF)  45%. No concurrent therapy was allowed. Other baseline eligibility criteria were adequate renal (serum creatinine <=1.5 mg/dL), liver (serum bilirubin <=1.5 mg/dL), and bone marrow (absolute WBC>=4,000/L, platelet count 100,000 uL) functions.","Exclusion criteria were a history of other malignancies (except adequately treated carcinoma in situ of the cervix or basal cell carcinoma), CNS involvement, and prior radiotherapy on parameter lesions. Patients with mesothelioma, neuroblastoma, Ewing’s sarcoma, chondrosarcoma, osteosarcoma, embryonal rhabdomyosarcoma, and dermatofibrosarcoma were excluded.",NA,NA
11900234,NA,Combination,No,patients with peritoneal carcinomatosis or sarcomatosis (PCS),"1. Histologically confirmed PCS originating from: ovarian carcinoma (not pretreated with anthracyclins), peritoneal mesothelioma, and multiple or recurrent visceral/retroperitoneal sarcoma;2. After CS residual disease absent or less than or equal to 3 mm3. Age between 18 and 72 years4. Satisfactory cardiovascular, respiratory, hepatic and renal functions (ASA score 1–2)5. Leukocyte greater than or equal to 4000 mm3, platelet count normal6. Eastern Cooperative Oncology Group performance status 0, 1, or 2.7. Patient’s fully informed consent obtained.",NA,30 days from CS and HIIC,NA
15166622,NA,Combination,No,metastatic carcinoma of the head and neck,"Patients with histologically proven, recurrent and/or metastatic carcinoma of the head and neck, not curable by surgery or radiotherapy, were enrolled. Patients aged>=18 years with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) <= 2 and a life expectancy of >= 3 months were eligible for the study. Patients with squamous cell carcinoma as well as undifferentiated or non-keratinizing carcinoma of the nasopharynx were included. Measurable disease outside of pre-irradiated areas was required for inclusion.The disease could be located in previously irradiated areas provided that subsequent progression was documented.Previous chemotherapy prior to or concomitant with radiation as a locoregional modality was allowed, if administered >= 1 year before entry. All patients gave an informed consent.",Patients with prior chemotherapy for recurrent or metastatic disease were excluded.,the first cycle,NA
15138468,NA,Combination,No,patients with upper gastrointestinal cancer：Primary 19 (70)；Liver 17 (63)；Lymph nodes 6 (22)；Peritoneal carcinomatosis 10 (37)；Other 2 (7),"Patients with histologically confirmed gastrointestinal cancer refractory to at least one chemotherapy regimen were eligible. They should have been off previous anticancer therapy for at least 4 weeks.Patients with chemotherapy-naı¨ve gastric cancer were eligible for inclusion at the recommended dose.Other eligibility criteria were an ECOG performance status p2, age p75 years, a life expectancy of at least 3 months and adequate bone marrow function (leucocyte count >3000 ul^(-1) , platelet count >100 000 ul^(-1)).Adequate renal (serum creatinine <=1.4 mg dl^(-1) or creatinine clearance >60 ml min^(-1) ) and hepatic function (bilirubin <=2 mg dl^(-1)) were required.Left ventricular ejection fraction (LVEF), assessed by echocardiography, was at least 50% in eligible patients. Appropriate contraception was required in fertile patients. All patients provided written informed consent. ",NA,first cycle within the first 57 days,NA
14998859,NA,Combination,No,patients with metastatic stomach cancer.,"Patients with cytologically or histologically confirmed advanced or recurrent gastric cancer refractory to conventional therapy were eligible for entry in thisstudy.Eligibility criteria also included the following: (i) World Health Organization performance status ≤2; (ii) age ≥20 and <75 years; (iii) normal hematological (white blood cell count ≥4000/µl, platelet count ≥100 000/µl), hepatic [total bilirubin level ≤1.5 mg/dl; aspartate aminotransferase and alanine aminotransferase ≤2.5× the upper limit of normal (ULN), unless the elevation was a result of hepatic metastasis, in which case elevations ≤3× ULN were permitted], renal (serum creatinine within normal range), cardiac (classification of New York Heart Association ≤I) and pulmonary (PaO2 ≥60 mmHg) function; (iv) no chemotherapy within 4 weeks (6 weeks for nitrosourea and mitomycin C) before administration of MCC-465; (v) a lifetime cumulative dose of DXR <100 mg/m2 or that of epirubicin and pirarubicin <200 mg/m2; (vi) no radiotherapy within 4 weeks before treatment; (vii) life expectancy >3 months; and (viii) full recovery from toxicity caused by any other test drug previously administered.","Patients with any serious infection, including hepatitis B and C viruses, and HIV, uncontrollable hypertension, symptomatic brain metastasis, allergy to anthracycline-type drugs, pre-existing cardiac disease including congestive heart failure, arrhythmia requiring treatment and myocardial infarction, vascular disordesr including a history of pulmonary embolism, deep venous thrombosis, and peripheral artery occlusive disease, were excluded.Patients were also excluded if they were pregnant or lactating, or showing gastrointestinal bleeding. In addition, any patient who the principal investigator or investigator considered ineligible was excluded.",first cycle,NA
11387367,NA,Single Drug,No,"Tumor types:Colorectal 12;Ovary 8;Kidney 3;Lung, non–small-cell 5;Breast 5;Soft tissues sarcoma 3;Endometrium 2;Hepatocellular 2;Carcinoma of the pancreas, adrenal gland 5;salivary gland, cervix, and mesothelioma(one patient each).","Patients with histologically or cytologically confirmed solid malignancies refractory to standard therapy or for whom no standard therapy existed were eligible.Patient entry criteria also included age >= 18 years old; life-expectancy of at least 12 weeks; a Southwest Oncology Group performance status of 0 to 2; no prior chemotherapy within 4 weeks (6 weeks for prior mitomycin C or a nitrosourea); adequate hematopoietic (hemoglobin >= 9 g/dL, absolute neutrophil count [ANC] >= 1,500/uL, platelet count >=100,000/uL), hepatic (bilirubin , 1.5 mg/dL, AST, ALT, and alkaline phosphatase <= two times the upper limit of normal, or , five times the institutional upper limit of normal if the elevation was caused by hepatic metastases), and renal (serum creatinine <=1.5 mg/dL) functions; measurable or assessable disease; no evidence of brain metastases; and no coexisting medical problem of sufficient severity to limit compliance with the study.",NA,All courses,NA
11408511,NA,Combination,No,Patients with histologically documented assessable or measurable tumors:Kidney 6;Colorectal 6;Non–small-cell lung cancer 4;Small-cell lung cancer 2;Sarcoma 2;Bladder 2;Esophageal 1;Ovarian 1;Gallbladder 1;Pancreatic 1;Mesothelioma 1;Unknown 1,"Patients with histologically documented assessable or measurable tumors who previously failed to respond to or were not candidates for standard therapy were eligible for this study. In addition, subjects were required to be 18 years of age or older; to have a confirmed diagnosis of incurable malignancy; a Karnofsky performance status score of 70% or more; to have adequate hepatic, renal, and hematologic function; to have left ventricular ejection fraction within the normal range; to have no significant laboratory abnormalities; and to have a life expectancy of at least 12 weeks. Patients who had received prior therapy were required to have recovered from reversible toxicities associated with that therapy.",Patients were not considered eligible who had had treatment under another investigational protocol within 28 days; who had significant EEG abnormalities or history of seizures; who had active concomitant malignancies; or who had other serious comorbid illness.Subjects may have had prior doxorubicin therapy but must not have received cumulative exposure of more than 325 mg/m2. Pregnant or lactating women were not eligible. ,Cycle 1,NA
15150584,NA,Combination,No,"patients with advanced cancer:Colorectal 5;Oesophagus 5 ;Soft-tissue sarcoma 4 ;Lung 3 ;Mesothelioma 2;Others:Ewing’s sarcoma (one), ovary (one), kidney (one), cholangiocarcinoma (one), liver (one), neuroblastoma (one), unknown primary (one).","Patients with histologically proven cancer refractory to conventional treatment or for which no suitable conventional therapy existed were considered for entry into this study.Patients were required to be >=18 years of age with a Karnofsky Performance Status of 80 or greater and an expected survival of 12 weeks or more. They needed adequate haematological and biochemical function with haemoglobin >=10.0 g dl^(-1), total white blood cells (WBC) >=3.0*10^9 l^(-1) , absolute neutrophil count (ANC) >=2.0*10^9 l^(-1) and platelets >=100*10^9 l^(-1) , and serum creatinine <=130 umoll^(-1) (if >130 umol l^(-1) then creatinine clearance must be >50 ml min^(-1)),serum bilirubin <=20 umoll^(-1), serum AST or ALT p2  upperlimit of the normal. A left ventricular ejection fraction (LVEF)>=55% by multinucleated gated angiography (MUGA) was also required.","Patients were excluded if they fulfilled any of the following: major thoracic or abdominal surgery in the preceding 4 weeks; chemotherapeutic agents, experimental drugs or radiation therapy (other than local radiotherapy not involving bone marrow reserves) within the 4 weeks prior to therapy; mitomycin C or nitrosoureas within the previous 6 weeks; any persistent toxic manifestations of previous treatments (except alopecia) must have resolved, or be no greater than Grade 1 and have been stable for over 4 weeks prior to entry; active uncontrolled infection, or other significant nonmalignant intercurrent illness; pregnant or lactating women (negative serum pregnancy test prior to enrolment in those women with child-bearing potential and all patients were required to use medically approved contraceptive precautions during the study and for 4 weeks afterwards); known or suggested central nervous system metastases; known hypersensitivity to anthracycline therapy; prior radiotherapy to more than one-third of haemopoietic sites; clinically significant hepatic disease other than involvement by tumour; history of cardiac disease with New York State Heart Association Class II level or greater or myocardial infarction within the past year; any other condition which in the Investigator’s opinion would not make the patient a good candidate for the study.",NA,NA
11432625,NA,Single Drug,No,advanced or refractory non-Hodgkin's lymphoma,"Eligible patients had measurable and active advanced or refractory NHL not amendable for conventional chemotherapy including the following entities according to the REAL classification, Eligible patients had measurable and active advanced or refractory NHL not amendable for conventional chemotherapy including the following entities according to the REAL classification. chronic lymphocytic leukemia (CLL) pretreated with chlorambucil and fludarabine,mantle-cell lymphoma in first relapse, follicular NHL in second or subsequent relapse and aggressive NHL of any histology in second or subsequent relapse. Pretreatment with anthracychnes and radiotherapy was allowed. Prior chemotherapy had to be completed four weeks before study drug administration. Prior radiotherapy had to be ceased six weeks before study entry. Other inclusion criteria were World Health Organization (WHO) performance status of 2 or less, age between 18 and 75 years, white blood cell count greater than 2.5 x 10^9/l.platelet count greater than 80 x 10^9 /l, hemoglobin level greater than 10 g/dl, bilimbin levels less than two times and liver enzyme level less than three times above the upper normal limit, creatinine clearance greater than 65 ml/min, normal cardiac function as measured by echocardiography with a baseline left ventricular ejection fraction (LVEF) greater than 50%. no history of myocardial infarction or current history of angina, no cardiac arrhythmia and no other major medical problems.No new administration of a corticosteroid regimen during the study was allowed.",NA,NA,NA
11914595,NA,Combination,No,Relapsed Ovarian Cancer,"Patients with progressing/recurring epithelial ovarian cancer and radiological evidence of bidimensional, measurable (11 cm) lesions were eligible for the study. Further entry criteria were: age over 18 years; Eastern Cooperative Oncology Group (ECOG ) performance status <=2; life expectancy >12 weeks; absolute neutrophil count >=1.5 * 10^9/l; platelet count >150*10^9/l; bilirubin and creatinine levels<1.5 times the upper limit of normal; normal cardiac function defined as left ventricular ejection fraction >50%.","Patients were ineligible in the case of: previous or current malignancies at other sites, with the exception of basal or squamous cell carcinoma of the skin and cone-biopsied carcinoma in situ of the uterine cervix; Brenner’s and borderline ovarian tumors; prior anthracycline therapy with a cumulative doxorubicin dose exceeding 300 mg/m2 or a cumulative epirubicin dose exceeding 540 mg/m2; significant heart disease including any history of ischemic heart disease, any history of arrhythmia requiring treatment, or clinically significant valvular disease; other investigational cytotoxic drugs given within 30 days prior to entry into the study; symptomatic CNS metastases; uncontrolled severe infection and/or medical problems unrelated to malignancy which would limit full compliance with the study, or expose the patient to extreme risks. ",first course,NA
14501385,NA,Combination,No,advanced ovarian cancer,"Eligibility criteria included patients aged 18 years of age or older with histologically or cytologically confirmed advanced ovarian cancer, recurrent after, or failing to achieve an objective response to paclitaxel/carboplatin chemotherapy or to a cisplatin or non-platinum-based second-line chemotherapy. Other eligibility criteria included: bidimensionally measurable or assessable disease,age <= 75 years, a performance status <= 3 (ECOG scale) and an anticipated life expectancy of at least 3 months.The patients were required to have an adequate hematological (WBC > 4000/ml, platelets > 100 000/ ml), hepatic [bilirubin level < 1.5 mg/dl and alanine aminotransferase (AST) <= 2  the upper limit of normal], renal (creatinine concentration <= 1.5 mg/dl) and cardiac function.Patients with a performance status of 3 and a life expectancy longer than 3 months were included in this trial in order to make the results more applicable to a broader population of previously treated ovarian cancer patients.","Patients with additional malignancies, other than curatively treated skin and cervical cancer or with active cardiovascular disease, were excluded.",first treatment cycle and second cycle,NA
11996468,NA,Single Drug,No,patients with solid tumours：Stomach 5；Lung 3；Head and neck 3；Pancreas 3；Kidney 2；Colon/rectum 2；Thyroid 2；Breast 1；Cervix 1；Eye melanoma 1；Oesophagus 1；Primary unknown 1,"All patients had a pathologically confirmed diagnosis of a solid tumour not amenable to standard treatment and had evaluable or measurable disease. They were older than 18 years, had a good performance status ≤2 [World Health Organization (WHO)] , a life expectancy of at least 3 months, and adequate renal (creatinine <1.4 mg/dl), liver (bilirubin ≤1.5 mg/dl, other liver function tests equal or less than twice the upper limit of normal, unless liver metastases were present), bone marrow (neutrophils ≥1500/mm3, platelets ≥100 000/mm3) and cardiac function (left ventricular ejection fraction measured by multiple gated acquisition (MUGA) scan ≥50%). Patients had no other significant medical conditions affecting compliance with the protocol. Prior radiotherapy, immunotherapy or chemotherapy was discontinued for at least 4 weeks prior to the start of the study, and 6 weeks in the case of extensive radiotherapy, mitomycin or nitrosourea treatment.","Patients who were pregnant, breast-feeding or fertile without adequate contraceptives were excluded, as were those who had acute infections, severe psychological disorders, or clinical signs of brain or meningeal metastases.Prior use of anthracyclines or anthracenediones was not allowed.",cycle 1,NA
12065868,NA,Combination,No,Patients with Advanced Solid Tumors:Breast adenocarcinoma 12 46;Gastric adenocarcinoma 4 15;Adenocarcinoma of unknown primary 3 12;Carcinoid tumor 1;Ovarian carcinoma 1;Head and neck carcinoma 1;Pancreatic carcinoma 1;Penile carcinoma 1;Cervical carcinoma 1;Hepatocellular carcinoma 1,"Patients (age: 18–75 years) with histologically or cytologically confirmed advanced stage solid tumors, for which there is no effective therapy or who have relapsed after receiving the ‘standard’ firstline treatment, were entered into the study.Prior surgery, radiotherapy (to less than 25% of bone marrow containing bones) or chemotherapy (maximum 2 prior regimens) were allowed but with a treatment-free interval of at least 4 weeks before entering the study.Other inclusion criteria were: World Health Organization (WHO) performance status 0–2, life expectancy of at least 3 months, adequate blood counts (absolute neutrophil count >1,500/dl, Hb >10 g/dl, platelets >100,000/dl), and normal renal (serum creatinine <2 mg/ dl), hepatic (total bilirubin <1.5 mg/dl, SGPT/SGOT <2 times normal values) and cardiac function (normal baseline LVEF by multiple gated acquistion, MUGA, scan or echocardiogram) as well as preexisting peripheral neuropathy below WHO grade 1. Patients with brain metastases were allowed to participate if they had been irradiated with clinical and/or radiographic improvement.",Patients with active infection or malnutrition (>20% weight loss during the last 3 months) or prior history of congestive heart failure or coronary artery disease were not eligible. The presence of bidimensionally measurable disease was not required. ,first cycle of treatment,NA
22918789,NA,Combination,No,recurrent malignant gliomas,"Eligible patients were C18 years of age with recurrent malignant gliomas (pathologically confirmed WHO grade III or IV). Patients must have unequivocal radiographic evidence of disease recurrence by Macdonald criteria and evaluable or measureable disease on either magnetic resonance imaging (MRI) or computed tomography (CT). There were no restrictions on the number of previous recurrences and treatments, but patients must have failed treatment with radiation therapy.Eligibility criteria also included KPS C60 and adequate hematologic and organ function. ","Patients were excluded if they received previous treatments with EGFRinhibitors or mTOR inhibitors, were receiving enzymeinducing antiepileptic drugs, were diagnosed with psychiatric disorders, or were pregnant or breastfeeding.",first 28 days of treatments,NA
11251001,NA,Combination,No,Patients With Metastatic Breast Cancer,"Patients were eligible for the study if they had histologic proof of metastatic breast carcinoma with evidence of progression of their disease.There was no limit on the prior number of chemotherapy regimens. Patients could have either measurable or assessable disease but bone marrow metastases, pleural effusions, or ascites could not be the only sites of disease.Patients were required to have a life expectancy of at least 12 weeks, to have a performance status of <=2 on the Zubrod scale,and to be at least 18 years of age.Other eligibility criteria included adequate bone marrow function, defined as an absolute granulocyte count of >= 1,500/mL and a platelet count of >= 100,000/mL; adequate liver and renal function, defined as a bilirubin concentration less than 1.2 mg/dL and serum creatinine concentration less than 2.0 mg/dL; and a cardiac ejection fraction >= 50% without evidence of congestive heart failure. All participants signed an informed consent form. Patients must have been off all previous systemic therapy, except hormone therapy, for 3 weeks before entering this study and must have recovered from the toxic effects of prior therapy.","Patients were not eligible for this study if they had received prior therapy with liposomal doxorubicin and/or gemcitabine.The simultaneous administration of other chemotherapy, hormone therapy, immunotherapy, or radiotherapy was not allowed.Patients were not eligible for the study if they had evidence of uncontrolled brain metastases or depletion of bone marrow reserves secondary to tumor involvement, irradiation or high dose chemotherapy followed by bone marrow transplant. Patients were not allowed to enter the study if they had evidence of other serious uncontrolled illnesses or if the control of an illness may have been jeopardized by the complications of this therapy.",First Course,NA
12376203,NA,Combination,No,patients with advanced solid tumours:Type of tumour;Breast cancer 5;Ovarian cancer 3;Gastric cancer 2;Cancer of unknown primary 2;Head and neck tumours 2;Other 5,"Patients with histologically- or cytologically-confirmed advanced stage solid tumours who had disease progression after one or two chemotherapy regimens were enrolled onto the study. Prior radiotherapy (to less than 20% of bone marrow-containing bones) or chemotherapy were allowed, but a treatment-free interval of at least 4 weeks was required before entering the study.Other inclusion criteria were: age 18–75 years, performance status World Health Organization (WHO) 0-2, life expectancy of at least 3 months, adequate blood counts (absolute neutrophil count >=1500*10^6 cells/l, platelets >=100 000*10^6 cells/l), renal (serum creatinine<=132.6 mg/dl), liver aspartate aminotransferase(SGOT), alanine aminotransferase (SGPT), alkalinephospatase, bilirubin <=2 times upper normal limit) andcardiac function, absence of active infection or severemalnutrition (loss of more than 20% of the bodyweight) and absence of any psychological or geographical condition potentially hampering compliance with the study protocol. Patients who had received prior doxorubicin-based chemotherapy had to have a LVEF > 50% evaluated by multigated (MUGA) scan. The presence of measurable disease was not required. All patients were required to provide written informed consent before entering the study.",NA,cycle 1,NA
15196868,NA,Combination,No,women with mu¨llerian malignancies,"Patients had to have a histologically confirmed diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, primary peritoneal carcinoma, or other tumor of mu¨llerian origin, such as papillary serous carcinoma of the endometrium or clear cell carcinoma of the cervix.Evidence of recurrent disease by any one, or any combination of the following was required: (1) CA-125 confirmed to be greater than 35 and rising on two sequential samples, (2) recurrent disease documented by CXR, CT scan or physical exam, and CA-125 > 35, (3) biopsy documented disease that was evaluable by radiological or clinical parameters. All patients had to have a previous attempt at surgical debulking, platinum-based chemotherapy, and an Eastern Cooperative Oncology Group performance status of <=2. Patients had to have adequate hepatic, renal, and hematological function determined by a serum glutamate-oxaloacetate transaminase <5 *upper limit of normal (ULN), bilirubin <1.5*ULN, calculated (Jellife) creatinine clearance > 50 ml/min, an absolute neutrophil count (ANC) > 1500/Al, and platelets > 150,000/Al. Patients had to be more than 4 weeks from last chemotherapy, radiotherapy or investigational agent, and at least 2 weeks from surgery. Gated blood pool scan or cardiac ultrasound estimation of ejection fraction had to be more than 50% and patients could not have evidence of serious comorbid illness, a history of congestive cardiac failure, or an electrocardiogram (EKG), suggesting significant conduction defect or myocardial ischemia. Additional inclusion criteria included age >18 years, central venous access, and an anticipated life expectancy in excess of 2 months. Eligibility tests had to be performed within 21 days of commencing therapy.","Previous treatment with either topotecan or Doxil was not an exclusion criteria; however, patients with progressive disease on either agent or who had been treated with more than 300 mg/m2 of Doxil were excluded.Patients who had received more than four prior lines of chemotherapy were also excluded.Active psychiatric disease or neurologic symptoms requiring treatment (Grade I sensory neuropathy allowed) were also reasons for exclusion. ",first two cycles,NA
11458813,NA,Combination,No,Patients with Metastatic Breast Cancer,"Patients were considered to be eligible if they had microscopically confirmed carcinoma of the breast that had metastasized.All patients were required to have an adequate bone marrow reserve as reflected by a granulocyte count >1500/µl and a platelet count >100,000/µl. In addition, they were required to have normal results of renal function tests, a bilirubin level 1.5 mg/m2, and a serum alanine aminotransferase  4 times the upper limit of normal. Eligible patients had to be older than 18 years with a life expectancy >=12 weeks and a Zubrod performance status <=2. ",Patients were not allowed in the study if they had received more than three prior chemotherapy regimens for their metastatic breast cancer.,NA,NA
11408493,NA,Combination,No,epithelial ovarian cancer,"Patients were eligible for enrollment onto the study if they had a histologically confirmed diagnosis of epithelial ovarian cancer, refractory to previous combination treatment with cisplatin and an anthracycline. Patients were between 18 and 70 years old and had measurable disease, a World Health Organization performance status of less than two, and a life expectancy of at least 3 months.The refractory state was defined as either progressive disease during treatment with cisplatin and an anthracycline, or stable disease for at least three cycles of this therapy or a relapse within 6 months after discontinuing it.No routine determination of MDR1 or Pgp expression status was performed.","Patients with abnormal left ventricular function (ejection fraction , 40%), significant cardiac disease within the previous 12 months, or impaired gastrointestinal, hepatic, renal, hematologic, or neurologic function were excluded, as were patients who had received MDRmodifying agents together with chemotherapy or myelosuppressive cytotoxic agents within 14 days of study entry.Patients who had had other malignancies (with exception of nonmelanoma skin cancer or in situ cervical carcinoma) within the previous 5 years were not included.Medications known to alter cyclosporine pharmacokinetics were not allowed. Laboratory exclusion criteria included a WBC count of less than 3.0*10^9/L, an absolute neutrophil count (ANC) of less than 1.0*10^9 /L, a platelet count of less than 100*10^9/L, serum creatinine and total bilirubin more than 1.5 times the institutional upper limit of normal range, and liver enzymes (AST, ALT, g-glutamyltransferase, and alkaline phosphatase) more than three times institutional upper limit of normal. ",two treatment cycles,NA
14962724,NA,Combination,No,Tumour type:Miscellaneaous;NSCLC;Breast cancer,"age >=18 years;Eastern Cooperative Oncology Group (ECOG) performance status 41; normal bone marrow, renal and liver function; left ventricular ejection fraction (LVEF) 55% by echocardiography; a maximum of one prior chemotherapy regimen and no prior anthracyclines.  ",Patients refractory to paclitaxel/docetaxel (defined as progression on therapy or within 6 months from last dose) were excluded.,First-cycle,NA
23099006,NA,Combination,No,advanced solid malignancy:Primary tumour:Colorectal 8 (38%);Renal 3 (14%);Non-small cell lung 2 (10%);Gastric 2 (10%);Othera 6 (29%),"Eligible patients had a pathologically confirmed advanced solid malignancy, refractory to conventional therapy; age >=18; life expectancy P12 weeks; Eastern Cooperative Oncology Group (ECOG) performance status <=2; and adequate organ function. Prior chemotherapy and/or targeted therapy was permitted, provided the patient had recovered from treatment-related toxicity, and at least 3 weeks had elapsed between end of treatment and enrolment in the study.","Exclusion criteria included significant uncontrolled cardiovascular disorders, unstable brain metastases, significant ophthalmologic abnormalities or previous unacceptable toxicity with an EGFR inhibitor. Current or former smokers were ineligible unless they had stopped smoking >3 months prior to registration.Prohibited medications included any CYP3A4 or CYP1A2 inducers during the 14 d prior to study entry, and during the initial 28-d treatment period. No concomitant anticancer therapy was permitted.",during the first 28-d cycle,NA
26886016,NCT01010945,Combination,No,patients with previously untreated advanced pancreatic cancer,"Adult patients with histologically or cytologically confirmed measurable locally advanced, unresectable or metastatic adenocarcinoma of the pancreas were included in the trial. Patients could not have received any prior therapy for pancreatic cancer and had to have an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–1 and a life expectancy of at least 12 weeks. Eligible patients had adequate liver [total bilirubin at or below the institutional upper limit of normal (ULN), aspartate transaminase (AST), and alanine transaminase (ALT) ≤2 × ULN], marrow [absolute neutrophil count (ANC) ≥1500/μL, platelets ≥100,000/ μL], and kidney function (creatinine ≤1.5 × ULN).","Patients were excluded if they had active uncontrolled cardiac disease, a psychiatric condition, infection, or any serious medical condition that would interfere with their study participation. Patients could not smoke within 14 days of enrollment or have a positive cotinine test at baseline. Other exclusion criteria included pregnant or breastfeeding women, symptomatic brain metastases that were unstable, or history of allergic reactions to compounds similar to those of the study drugs.",during the first treatment cycle (28 days),NA
29801474,UMIN000010150,Combination,No,unresectable locally advanced pancreatic cancer,"The following inclusion criteria were used for the selection of the patients: 1) Patients diagnosed with pancreatic cancer histopathologically through EUS-guided fine needle aspiration (EUS-FNA) and considered as locally advanced unresectable without distant metastasis (including non-regional lymph node metastasis) after discussion with surgical department based on NCCN Clinical Practice Guidelines in Oncology  (Additional file 1: Table S1); 2) Accessible for injection of HF10 under EUS-guidance; 3) At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria; 4) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2; 5) Estimated life expectancy of more than 3 months; 6) Older than 20 years and younger than 80 years of age; 7) adequate bone marrow function (white blood cell count≧4000/mm3 , neutrophil count≧2000/mm3 , platelet count≧100,000/mm3 ); 8) Adequate renal function (creatinine clearance (Cockroft-Gault Equation)≧60 ml/ min); 9) Adequate liver function (serum total bilirubin≦2 times the upper limits of normal (ULN), transaminases≦1. 5 times ULN); 10) Patients who provided written informed consent; 11) Positive HSV-1 antibody.","The exclusion criteria were as follows: Bleeding diathesis; Ascites, pleural effusion, cardiac effusion to be treated; Active infection; Duplicated active cancers (synchronous duplicated cancer or metachronous cancer with less than 5 years of disease free period); Increased intracranial pressure to be treated due to brain metastases; pregnant or lactating women; Allergic to live vaccine; Use of anti HSV drugs; Implementation of immunotherapy for cancer; Positive HBs antigen, HCV antibody or HIV antibody; Adrenal insufficiency, hemodialysis, unilateral kidney.",NA,NA
28424891,NCT00600496,Combination,No,"patients with advanced solid tumors：Primary tumor site：Colorectal 21；Lung 12；Pancreas 5；Renal 2；Skin/soft tissue 2 ；Liver 2 ；Thyroid ；Other：Breast, bladder, and in two patients unknown site of primary tumor","Patients eligible for the study were those with advanced solid tumors for whom erlotinib or temsirolimus would be an appropriate standard of care, or those who might benefit from rlotinib or temsirolimus combined with a novel agent such as selumetinib. Other eligibility criteria included: aged ≥18 years; measurable and/or non-measurable disease lacking curative options; World Health Organization (WHO) performance status 0–1; evidence of post-menopausal status or negative urine/ serum pregnancy test for pre-menopausal female patients; and calculated creatinine clearance >50 mL/min.","Patients with any of the following were excluded from the study: prior treatment with a MEK inhibitor; received an investigational drug within 30 days of entering the study, or had not recovered from the AEs of an investigational study drug; received radiotherapy or standard chemotherapy within 21 days of study entry; use of strong cytochrome 1A2 or 3A4 inducers and/or inhibitors; brain metastases or spinal cord compression unless treated and stable (>1 month) and off steroids; factors that increased the risk of QT prolongation or arrhythmic events or QTc interval of >450 ms for males or >470 ms for females; inadequate bone marrow, hepatic, cardiac, or renal function; current smoker or user of any tobacco (erlotinib arm only).",within the first 28 days of therapy from cycle 1/day1,NA
28798270,NCT00975182,Combination,No,locally advanced or metastatic solid tumors：Primary cancer diagnosis：Colorectal 13 (22.8)；Non-small cell lung 11 (19.3)；Mesothelioma 5 (8.8)；Head and neck 4 (7.0)；Pancreatic 3 (5.3)；Ovarian 3 (5.3)；Synovial sarcoma 2 (3.5)；Melanoma 2 (3.5)；Parotid gland 2 (3.5)；Renal cell 2 (3.5)；Bladder 1 (1.8)；Gastric 1 (1.8)；Prostate 1 (1.8)；Ileocecum adenocarcinoma 1 (1.8)；Basal cell carcinoma (right nostril) 1 (1.8)；Cholangiocarcinoma 1 (1.8)；Duodenum 1 (1.8)；Ewing sarcoma 1 (1.8)；Neuroendocrine carcinoid 1 (1.8)；Unknown 1 (1.8),"Eligible patients aged 18 years had locally advanced or metastatic solid tumors for which there is no standard therapy, or standard therapy had proven ineffective or intolerable for the patient. An Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, adequate hematologic and end organ function, evaluable disease or measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.0, and a baseline diffusing capacity of the lungs for carbon monoxide (DLCO) 50% of the predicted value corrected for hemoglobin and alveolar volume were required.Patients with a history of smoking must have stopped 2 weeks before the start of treatment.",Major exclusion criteria were prior PI3K-inhibitor treatment and diabetes requiring daily medication.,cycle 1,NA
29050231,NA,Combination,No,advanced non-small cell lung cancer,Patients with advanced non-small cell lung cancer were eligible to participate in the trial if they had: (1) histologically or cytologically confirmed NSCLC; (2) one prior regimen of chemotherapy for advanced disease that had failed and were eligible to receive erlotinib; (3) positive or unknown tumor EGFR protein expression (per product label); (4) archival tissue available for analysis (including repeat sampling prior to registration); (5) had measurable disease by RECIST 1.1; (6) had an Eastern Cooperative Group performance status (ECOG PS) of ≤ 2; (7) had adequate renal (serum creatinine < 1.5 times the upper institutional limit) and hepatic (serum alanine aminotransferase or aspartate aminotransferase < 2 times the upper institutional limit) function; and (8) the ability to provide written informed consent. ,"if they had: (1) untreated or uncontrolled cardiovascular conditions including resting systolic blood pressure >150 mm Hg and/or diastolic pressure > 100 mm Hg; (2) more than two prior chemotherapy regimens for metastatic disease; (3) prior treatment with anti-EGFR agents; (4) symptomatic or untreated brain metastasis.exclude patients with pre-existing thromboembolic disease, based on data from other studies suggesting a potential increase in risk with foretinib.",cycle 1 ,NA
27036206,NCT00966472,Combination,No,patients with advanced solid malignancies:Primary tumour NSCLC;Esophageal;Pancreas;GU;Colon;Breast;Unknow,"Eligible adult patients had a diagnosis of advanced/metastatic (stage IIIB/IV) incurable solid malignancies. Patients received therapy until evidence of disease progression, the development of serious or unmanageable adverse events (SAE), or until study withdrawal. Clinically or radiological documented disease and an ECOG performance status of 0, 1 or 2 was also required. All study patients had adequate hematogical, hepatic and renal functions at baseline. Adequate hematological function was defined as hemoglobin  ≥90  g/L, absolute granulocyte count ≥1.5 ×  10^9 /L and platelet counts ≥100 ×  10^9 /L. Biochemical parameters for hepatic function included; total bilirubin  <1.5× the upper limit of normal (ULN) and ALT/AST  <1.5× ULN. Adequate renal function was defined as a creatinine clearance  >60  ml/min as measured by 24  h urine collection. Any anticholesterol agents were discontinued at least 7 days prior to starting the trial.","Other exclusion criteria included known brain or leptomeningeal metastases, no prior EGFR inhibitor therapy, no known neuromuscular disorders as well as known hypersensitivity or allergy to HMG-CoA reductase inhibitors including rosuvastatin in Asian populations which were also excluded",first-course,NA
27853997,NCT00987766,Combination,No,advanced biliary tract cancers,"Adult patients with unresectable or metastatic cancers that were histologically or cytologically confirmed to be biliary tract, pancreas, duodenal, or ampullary carcinomas were included. Patients must not have had prior chemotherapy or prior EGFR-targeted therapy for their disease. Patients were required to have an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2 with adequate bone marrow, renal, and hepatic function defined as pretreatment bilirubin less than 2.5 times the upper limit of normal (ULN) and hepatic transaminases less than 2.5 times ULN or less than 5 times ULN if liver metastases were present.","Patients with central nervous system metastases or other recent cancers were excluded. Additionally, patients with uncontrolled infection, significant neuropathy, or any other concurrent medical condition that would make the patient an inappropriate candidate for study enrollment were not included.",Course 1 (two 14-day cycles),NA
22271880,NA,Combination,No,Squamous Cell Carcinoma of the Head and Neck,"Eligibility requirements included a new diagnosis of histologically confirmed AJCC Stage III (T3N0–1) or IV (T1–4N2–3M0, T4N0M0) squamous cell carcinoma of the oral cavity or oropharynx. Other criteria included the following: no prior therapy for the SCCHN; no diagnosis of other malignancy within the prior 3 years; age 18 years or more; ECOG PS 0–2; adequate organ and marrow function as denoted by ANC 1,500/mm3 or more, platelets 100,000/ mm3 or more, total bilirubin within institutional upper limit of normal (ULN), transaminases less than 2.5 * ULN, creatinine within ULN or creatinine  1.73 m2 or more.",NA,NA,NA
33159216,NCT00770263,Combination,No,"Disease type, N (%):Non-small cell lung cancera 10 24.4; Pancreatic cancer 9 22.0;Adenoid cystic 4 9.8;Breast cancer 2 4.9;Gastric cancer 2 4.9;Cancer of unknown primary 2 4.9;Small cell lung cancer 1 2.4;Papillary thyroid cancer 1 2.4;Colon cancer 1 2.4;Cholangiocarcinoma 1 2.4;Ampullary adenocarcinoma 1 2.4;Sarcoma 1 2.4;Thymic cancer 1 2.4;Anal cancer 1 2.4;Mesothelioma 1 2.4;Vulvar cancer 1 2.4;Hepatocellular carcinoma 1 2.4;Head and neck squamous cell cancer 1 2.4","Patients with histologically confrmed solid tumor who were resistant to standard treatments were enrolled. Patients without measurable disease were allowed to participate. Patients were required to ECOG performance status of 0–1, aged 18 or older, and have preserved organ functions including absolute neutrophil count of 1500/mm3 or greater, platelets 100,000/mm3 or greater, hemoglobin 9.0 g/dL or greater, total bilirubin of 1.5×upper limit of normal (ULN) or less, transaminases of 3×ULN or less, creatinine of 2×ULN or less or creatinine clearance 60 mL/min or greater, and fasting serum cholesterol 350 mg/dL or less. Additional eligibility requirements for the expansion cohort included (1) available archival tissue; (2) known tumor mutational status including PTEN loss, PIK3CA mutation, and/or EGFR mutation, without KRAS or BRAF mutations as determined by next generation sequencing performed at the Genomic and Pathology Services at Washington University or other CLIA-certifed laboratories; (3) squamous carcinoma histology, papillary thyroid carcinoma, and adenoid cystic carcinoma regardless of genetic alterations based on durable stable disease seen during dose escalation phase in these histology types; and (4) consent to mandatory post-cycle 1 biopsy.",Patients who were concomitantly on CYP3A4 inducers were not allowed as temsirolimus is primarily metabolized by CYP3A4. Other exclusions included known hypersensitivity to macrolide antibiotics; active anti-retroviral therapy for HIV infection; active central nervous system disease; or uncontrolled intercurrent illness.,first cycle,NA
24429877,NCT00738751,Combination,No,Patients with Advanced Aerodigestive Tract Tumors,"Eligible patients included those >=18 years of age with advanced/metastatic NSCLC or head and neck cancer who had failed at least one line of systemic therapy. Participants had measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST; version 1.0), an Eastern Cooperative Oncology Group Performance Status<=1, no prior systemic chemotherapy within 14 days, no cardiac dysfunction, and a baseline multi-gated acquisition scan or echocardiogram demonstrating a left ventricular institutionally normal value (50%). Patients with stable, asymptomatic pretreated brain metastases no longer requiring steroids were allowed. Potentially fertile participants had to agree to use an approved contraceptive method. There were no limits to number of prior therapies. Prior EGFR-TKI therapy was permitted.",Patients with significant laboratory abnormalities were excluded.,within cycle 1,NA
25170013,NCT00826449,Combination,No,Non-Small Cell Lung Cancer,NA,NA,NA,NA
22237261,NA,Combination,No,Patients with Advanced Non-small Cell Lung Cancer,"Patients with histologically or cytologically documented locally advanced or metastatic NSCLC, age older than or equal to 18 years, and those who had progressed on or after receiving platinum-containing chemotherapy were eligible. A later amendment allowed the enrollment of patients with EGFR-MTs who were untreated. Other criteria included Eastern Cooperative Oncology Group performance status<=2; life expectancy >=3 months; presence of evaluable or measurable disease as defined by the RECIST (version 1.0); fasting serum glucose less than 120 mg/dL; and adequate hematopoietic, hepatic, and renal function.",Exclusion criteria included previous exposure to other EGFR or IGF-1R inhibitors; chemotherapy within five half-lives of the agent or 28 days if the half-life was unknown or was a monoclonal antibody; radiotherapy within 28 days; major surgery within 4 months of the study; ongoing previous treatment-related side effects/AEs that were grade 2; known brain metastases unless adequately treated and stable off anticonvulsants and steroids; pregnancy; and poorly controlled diabetes mellitus or other uncontrolled intercurrent illness.,within cycle 1,NA
22547007,NCT00266097,Combination,No,unresectable pancreatic carcinoma,"Eligible patients had biopsy proven unresectable locally advanced or metastatic (at the discretion of the treating team) pancreatic carcinoma, ECOG performance status 0–2, a life expectancy greater than 2 months, adequate hematologic, renal and hepatic function, and a washout period of at least 3 weeks after previous anticancer therapy.During the second phase of the study (erlotinib phase), patients taking strong inducers or inhibitors of CYP3A were required to stop the medication to enter the study. The human subjects committees at each participating center approved this study and all patients provided written informed consent prior to participation. All trial procedures were conducted in accordance with the principles established by the Helsinki Declaration.",NA,NA,NA
21791058,NCT01235416,Combination,No,solid tumors:Colon;Pancreatic;Breast;Melanoma;Non—small cell lung;Squamous cell head/neck;Medullary thyroid;Carcinoma unknown origin;Ovarian;Prostate;Stomach;Other:Includes tumor types occurring in ≤ 2% of patients.,"Eligible patients (aged > 18 years) had histologically or cytologically documented solid tumors, had an Eastern Cooperative Oncology Group performance status ≤ 2, and were candidates for treatment with erlotinib or with the combination of gemcitabine and erlotinib in the opinion of the investigator.","Key exclusion criteria were: squamous cell NSCLC; hematologic malignancies; large central thoracic tumor lesions; direct bowel wall invasion (except for primary tumors of the bowel); untreated or symptomatic brain metastases; primary solid cancers with no known active disease present and no curative treatment administered for the last 3 years (except for curatively treated nonmelanoma skin cancer); history of bleeding or bleeding diathesis, or arterial or deep vein thrombosis; myocardial infarction within 1 year of study enrollment; uncontrolled hypertension (systolic blood pressure > 145 mmHg and diastolic blood pressure > 85 mmHg); inadequate cardiac, hepatic, renal or hematologic function; prior treatment with VEGF/VEGFR inhibitors, erlotinib, or gemcitabine; and systemic chemotherapy (within 21 days of study enrollment) or radiation therapy (within 14 days of study enrollment).",first 5 weeks of treatment.,NA
25521398,NA,Single Drug,No,Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer,"Eligible patients were more than or equal to 18 years with histologically or cytologically confirmed metastatic (stage 3B/4) adenocarcinoma NSCLC, which was KRAS wild type.Patients had received more than or equal to one regimen of chemotherapy (including ≥1 platinum-based therapy) and erlotinib or gefitinib with evidence of PD less than or equal to 6 months after treatment.Patients had Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1 (phase I cohort) and 0–2 (phase II cohort); ",those with known active brain metastases were excluded,during the first 21 days of cycle 1,NA
28761738,NA,Combination,No,patients with stage IV non-small-cell lung cancer,"Study entry was limited to patients aged >18 years with histologically or cytologically confirmed NSCLC previously treated, with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1. Oxygen saturation >93% and adequate bone marrow, renal and liver function were required. Patients with asymptomatic, stable, treated brain metastases were eligible for trial participation. A non-platinum-based first-line therapy was allowed.","Main exclusion criteria were: EGFR/ALK (anaplastic lymphoma kinase)-mutated histologically proven NSCLC, diabetes mellitus, clinically significant cardiovascular disease, previous exposure to EGFR TKIs, immunotherapy, hormonal therapy and radiotherapy within 2 weeks before entering the study.",first 2 weeks of combined treatment of metformin and erlotinib,NA
29843755,NCT00769483,Combination,No,advanced pancreatic adenocarcinoma,The eligibility criteria included treatment naïve metastatic PCA; age > 18 years; Eastern Cooperative Oncology Group (ECOG) ≤ 1; adequate organ function; had measurable disease as defined by the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1; ≥ 6 months elapsed since completion of previous therapy; and patients who enrolled in phase II cohorts were required to had biopsies for correlative studies.,"We excluded patients who had prior systemic therapy, had brain metastases, were pregnant or nursing, had uncontrolled illness that would limit study compliance, and had another cancer, except treated basal or squamous cell skin carcinoma or cervical carcinoma in situ, or if patient had been disease-free for > 2 years.",after the first cycle,NA
23135778,NCT00619424,Combination,No,"Primary tumor type, n (%): Non-small-cell lung 13 (39);Non-squamous 11 (33);Squamous 2 (6);Colorectal 4 (12);Mesothelioma 2 (6);Melanoma 2 (6);Thyroid 2 (6);Ovary 2 (6);Other 8 (24)[includes 1 patient each for the following tumor types: gastroesophageal, small-cell lung, neuroendocrine, liver, oral, endometrium/uterus,cervix, and sarcoma]","Inclusion criteria included age at least 18 years; histologically or cytologically confirmed diagnosis of advanced solid tumor that had failed standard therapy, for which no standard therapy existed, or for which erlotinib was considered standard therapy; Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; adequate hematologic, hepatic, and renal function; and measurable disease on a computed tomography scan. Prior treatment with bevacizumab was allowed. At least 28 days or 5 half-lives of a drug, whichever was longer, must have elapsed from the last administration of any antecedent systemic therapy or investigational agent before initiation of protocol treatment. Determination of EGFR mutation status was not required for study enrollment.","Exclusion criteria included central nervous system metastases (unless treated and stable without medication); hypertension (≥140/90 mmHg); evidence of active bleeding, including hemoptysis, or bleeding diathesis; gastrointestinal abnormalities that might interfere with oral dosing; any surgery or trauma within the 4 weeks before study treatment initiation; and cardiovascular or cerebrovascular events in the 6 months before enrollment in the study.",within the first 21 consecutive days of observation,NA
32943457,NA,Combination,No,Patients with Advanced Premalignant Lesions (APL) of the Head and Neck,"The key eligibility criteria included: documented histology of premalignant lesions of the oral cavity or larynx including APL [mild dysplasia, moderate dysplasia, severe dysplasia, or carcinoma in situ (CIS)]; definitively treated T1–2N0 with OPLs; Eastern Cooperative Oncology Group performance status of 0 or 1; at least 18 years of age; normal bone marrow, renal, and hepatic functions; ability to swallow the pills of green tea PPE and erlotinib; adequate contraception and negative pregnancy test for women of child-bearing potential; consent to have rebiopsy for pathologic responses and biomarker studies using tissue; cytobrushed or blood samples; and signed written informed consent form. For biomarker studies, we recruited nonsmoking normal individuals as controls.",NA,NA,NA
28971268,NCT01839955,Combination,No,locally advanced or metastatic non small cell lung cancer,"The eligibility criteria included histologically or cytologically confirmed locally advanced, recurrent or metastatic NSCLC (with subtypes of adenocarcinoma, squamous cell carcinoma, large cell and sarcomatoid carcinoma being eligible). EGFR wild type NSCLC patients were eligible after progression on at least one platinum-containing regimen for the treatment of advanced or metastatic disease. Prior maintenance therapy was allowed and was considered as the same line of therapy when continued without discontinuation after initiation of a treatment regimen. NSCLC patients with documented EGFR exon 19 deletion or exon 21 point mutation were eligible after progression on an EGFR-TKI alone. NSCLC with other molecular targets, such as fusion gene involving the anaplastic lymphoma kinase (ALK) gene (such as EML4-ALK) or ROS − 1, were eligible if they had progressed on targeted agents (ALK inhibitor) and chemotherapy or were not a candidate for chemotherapy. The study required known EGFR mutation status for patients with adenocarcinoma histology.The patients must have been >18 years of age with anticipated life expectancy of >12 weeks, ECOG performance status of 0–2, atleast one measurable lesion per RECIST criteria (version 1.1). Adequate hematologic, hepatic and renal function defined as hemoglobin > 9 /dl, ANC > 1500/μl, platelets >100,000/μl, AST, ALT, Alkaline phosphatase <2.5 x upper limits of normal (ULN) in subjects with no liver metastasis or <5 x ULN in subjects with liver metastasis, serum creatinine ≤1.5 x ULN.Patients with stable brain lesions confirmed by MRI within 4 weeks of first day of study were eligible.","Patients with previous anti-cancer chemotherapy, immunotherapy or investigational agent ≤3 weeks prior to the first day of study defined treatment were excluded. NSCLC patients with EGFR mutation were permitted within 7 days of discontinuing EGFR-TKI. Patients needing gamma knife radiosurgery for brain metastases or palliative radiation less than 1 week before the start of treatment were also excluded. Patients with history of myocardial infarction within 6 months prior to study entry, NYHA class II to IV congestive heart failure, previously diagnosed bradycardia or other cardiac arrhythmia defined as ≥ Grade 2 CTCAE, Version 4.0 were excluded. ",during Cycle 1 of therapy,NA
24496004,NCT00777699,Combination,No,"Patients with Advanced Solid Tumors：including 37 cases of lung cancer patients, other cancer types were not listed","Patients aged 18 years or older with Eastern Cooperative Oncology Group performance status 1 or less, acceptable organ function, and a histologically or cytologically confirmed solid tumor that was metastatic or unresectable and was no longer responding to therapies or for which no standard treatment exists were eligible. Patients with lung cancer must have received an EGFR inhibitor before study entry. ",Patients who were intolerant to erlotinib or who had received previous treatment with a PI3K inhibitor were not eligible.,during cycle 1 ,NA
27697581,NCT00965731,Combination,No,Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer,"Patients with histologically proven, locally advanced/ metastatic (stage IIIB/IV) nonsquamous NSCLC who were aged 18 years or older, had progressed after one or two chemotherapy regimens for advanced disease, had an Eastern Cooperative Oncology Group performance status of 0 to 2, had measurable disease (defined by Response Evaluation Criteria in Solid Tumors, version 1.1), and had adequate organ function were eligible for  nclusion in this study.Patients with brain metastasis were eligible if appropriately treated and neurologically stable for at least 4 weeks. No prior crizotinib or EGFR TKIs were allowed. A subsequent protocol amendment allowed patients with prior EGFR TKIs onto the phase I portion of the trial.",Patients with interstitial lung fibrosis or interstitial lung disease were also excluded.,during cycle 1 (28-day DLT evaluation period),NA
24901237,NCT00725634,Combination,No,refractory advanced solid tumours and multiple myeloma,"All patients were aged >=18 years and signed an institutional review board–approved consent form before starting the clinical trial.Eligible patients had advanced refractory solid tumour malignancies. Patients with multiple myeloma must have satisfied standard published requirements.Pertinent eligibility included written informed consent before study entry, Eastern Cooperative Oncology Group performance status of 0 or 1, and no radiotherapy within 3 weeks before the first study drug infusion. All patients were required to have adequate blood, kidney and liver laboratory parameters.","Other than patients with GBM, who could enrol in the safety expansion cohort or in the erlotinib combination cohort, patients with central nervous system disease were excluded.Patients with grade X2 diarrhoea at baseline, inflammatory bowel disease, or acute onset of new or progressive pulmonary symptoms within 4 weeks before first study treatment were not eligible for the erlotinib combination cohort.",first two cycles of treatment,NA
21778302,NA,Combination,No,patients with surgically resected locally advanced squamous cell carcinoma of the head and neck,"Patients with histological or cytological diagnosis of squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx who had been treated with surgical resection with curative intent were eligible.Patients were required to have at least one of the following criteria: pT3–4 tumor stage (except T3N0 of the larynx with negative margins); pN2–3 nodal stage; or unfavorable pathological findings such as extranodal extension, positive resection margins, and perineural and/or vascular involvement. Other eligibility criteria included the following: age 18–70 years old; life expectancy ‡ 12 months; Eastern Cooperative Oncology Group (ECOG) performance status of zero to one; adequate bone marrow (absolute neutrophil count > 1.5*109^/l, platelets > 100*10^9/l and hemoglobin > 9 g/dl), liver [bilirubin < 1.5*upper limit of normal (ULN), alkaline phosphatase, aspartate transaminase and alanine transaminase < 3.0*ULN], and renal function (calculated creatinine clearance > 60 ml/min or serum creatinine < 1.5*ULN).Women of childbearing potential were required to have a negative pregnancy test within 48 h of study enrollment. In addition, fertile male and female patients were required to use appropriate contraceptive methods. Patients needed to be able to swallow pills or have a functioning gastrostomy tube. ","Patients with gastrointestinal disorders that could interfere with drug absorption were excluded. Patients with prior chemotherapy, radiation therapy, or treatment with inhibitors of the EGFR were excluded as well as patients with incomplete surgical resection. Other exclusion criteria included prior history of cancer (except nonmelanoma skin cancer or resected cervical cancer), pregnancy or lactation, active infection or any other concomitant disease that in the investigators’ criteria could negatively interfere with study treatment, increase the toxicity of study agents or limit treatment administration. Patients with significant ophthalmologic problems such as dry eye, queratoconjuntivitis sica and Sjo¨gren’s syndrome or other disorders that could increase the risk of corneal damage were excluded.",NA,NA
25441058,NCT00761345,Combination,No,patients with locally advanced or limited metastatic pancreatic cancer,"Patients P18 years of age able to provide written informed consent with locally advanced or minimally metastatic adenocarcinoma of the pancreas with ECOG performance status of 0–1 were eligible for this study. Minimally metastatic was defined as having limited metastatic disease in the upper abdomen or liver that could be included in the upper abdominal radiation port. Patients recurring after pancreatectomy were eligible if adjuvant chemotherapy was completed >1 year prior to study entry.Patients were required to have adequate hematologic and organ function as measured by an absolute neutrophil count of P1000/ lL, platelets >=100,000/lL, hemoglobin>=9.0/dL, bilirubin <=1.5*the upper limit of institutional normal and an ALT/AST <=3.0*the upper limit of institutional normal. In addition, the serum creatinine was required to be <1.5*the upper limit of institutional normal and the serum albumin needed to be >2.5 g/dL.",Patients with prior chemotherapy for metastatic pancreatic cancer were initially ineligible but the study was subsequently amended to include patients who had received one prior non-gemcitabine containing regimen.Patients with prior radiotherapy were ineligible.Patients were ineligible if they had any other active illnesses that would preclude safe therapy in the judgment of the treating physicians. Pregnant or breast feeding women were ineligible.Patients with a concurrent malignancy requiring therapy were not eligible but patients with a prior malignancy not on current therapy were eligible.,during cycle 1,NA
31570268,NCT01650506,Combination,No,Metastatic Triple-Negative Breast Cancer,"Patients between 18 and 80 years of age with a confirmed diagnosis of mTNBC were eligible. Patients with human epidermal growth factor receptor 2 (HER2)-negative disease by American Society of Clinical Oncology/College of American Pathologists guidelines and estrogen receptor (ER)-positive disease with immunohistochemical (IHC) staining of 1% to 9% were eligible regardless of progesterone receptor (PgR) status.Prior diagnosis of ER-positive, HER2-negative disease was allowed, provided that ER expression on the patient’s most recent biopsy result was < 10%.  Patients must have received at least one prior treatment for metastatic disease. Measurable or nonmeasurable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria was allowed. Participation required an Eastern Cooperative Oncology Group performance status between 0 and 2, life expectancy > 12 weeks, absolute neutrophil count>= 1250/mm3,platelets>=75,000/mm3, hemoglobin >=8.5 g/dL, total bilirubin<=1.5 times the upper limit of normal (ULN), aspartate aminotransferase and alanine aminotransferase levels <=3.0 times ULN, alkaline phosphatase <=2.5 ULN, and estimated creatinine clearance >=60 mL/min (Cockcroft-Gault formula). Patients with a history of central nervous system metastases or cord compression must have remained clinically stable and not receiving corticosteroids for at least 6 weeks since completion of definitive treatment.","Concomitant use of medications known to be inducers or inhibitors of CYP3A4 was not permitted. Patients with diabetes or fasting blood glucose level  126 mg/dL were ineligible. Patients who had previously received metformin or EGFRtargeted therapy were ineligible. Patients who had used tobacco or nicotine products or medications during the previous 3 months were ineligible, given the potential effects on erlotinib drug levels.19 Patients with a condition thought to increase the risk of metformin-associated acidosis were ineligible; examples of such conditions included New York Heart Association class III or IV congestive heart failure, history of acidosis of any type, or regular intake of 3 or more alcoholic beverages per day.",during the first 5 weeks of therapy,NA
21220471,NCT00225121,Combination,No,"Primary tumor, n (%);NSCLC 50 (45) 7 (70);Colorectal 24 (22) 0;Breast 7 (6) 1 (10);Ovarian 5 (5) 0;Biliary 4 (4) 1 (10);Other 21 (19) 1 (10)","Adults >=18 years of age with histologically or cytologically confirmed malignant solid tumors unresponsive tovcurrently available therapies and for which there is no currently approved treatment likely to be tolerated or acceptable were included in this study. Additional inclusion criteria included Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 and adequate cardiac, renal and hepatic functions.","Exclusion criteria included prior chemotherapy, radiotherapy, biological or investigational agents 4 weeks before starting study treatment, apart from EGFR-inhibitors which could be taken until up to 2 weeks before starting PF299804; history of grade 3 or 4 toxicity related to treatment with an inhibitor of EGFR (apart from grade 3 skin rash); or requirement for treatment with drugs highly dependent on CYP2D6 for metabolism.",first 21 days of treatment (cycle 1),NA
19786667,NCT00153933,Combination,No,"Relapsed and Relapsed/Refractory Multiple Myeloma","Eligible patients were age 18 years or older; had relapsed or relapsed/ refractory MM after one or more prior therapies (including lenalidomide, bortezomib, or thalidomide); and had an Eastern Cooperative Oncology Group performance status of 0 to 2. Patients were considered refractory if they had progressive disease (PD;  25% increase in serum and/or urine Mprotein; absolute increases of5 g/L in serum or200mg/24 hours in urine) on prior therapy or within 60 days of salvage treatment, subsequent to relapse","Patients were excluded if they had grade 3 or greater or had painful grade 2 peripheral neuropathy (PNY); serum creatinine greater than 2.0 mg/dL; evidence of mucosal or internal bleeding; platelets less than 50,000/L; absolute neutrophil count less than 1,000/L; hemoglobin less than 8.0 g/dL; AST or ALT at least twice the upper limit of normal; prior chemotherapy within 3 weeks or nitrosoureas within 6 weeks of day 1, cycle 1; previous intolerance to lenalidomide or bortezomib; or known hypersensitivity to thalidomide. Con comitant radiation therapy, anti-MM chemotherapy, and corticosteroids (ex cept as indicatedfor other conditions to amaximum of prednisone 10mg/d or equivalent, or as premedicationfor othermedications or blood products)were not permitted.","during the first treatment cycle",NA
20150632,NA,Combination,No,Advanced Solid Tumors,"Patients were eligible if they had histologically or cytologically confirmed metastatic solid tumors for which standard curative measures were no longer effective, age ≥18 years, Karnofsky performance status ≥60, organ and marrow functions within 14 days of receiving the first study drug dose must have been adequately defined as: absolute neutrophil count (ANC) ≥1,500/mm3, platelet count ≥100,000/mm3, hemoglobin ≥8 g/dl, serum creatinine ≤1.5 units, total bilirubin ≤2 mg/dl, aspartate transaminase (AST) ≤3× upper limit of normal values. Patients must not have received a previous chemotherapy, immunotherapy, or radiotherapy within 4 weeks of enrolling. Because of the unknown risks to a developing fetus, patients were required to use an acceptable method of birth control if they were of child-bearing age. Prior treatment with gemcitabine was allowed.","Patients were excluded if they had ≥grade 2 peripheral neuropathy within 14 days before enrollment; uncontrolled intercurrent illness; uncontrolled brain metastases; were HIV-positive; or were hypersensitive to bortezomib, boron, mannitol, or gemcitabine.",the first course of treatment,NA
20378507,NA,Combination,No,Locally Advanced or Metastatic Rectal Cancer,"Eligibility criteria included patients who had histopathologically confirmed rectal carcinoma, clinically staged II or III (T3, T4, and/or node-positive disease). Patients with known distant metastasis who, according to the treating physician, required local therapy for palliative reasons or in whom potentially curative resection of metastatic disease would be attempted were also eligible. Patients who developed local recurrence of rectal cancer following surgery alone and who were felt to require radiation therapy, regardless of clinical stage, were eligible for this study. An Eastern Cooperative Oncology Group performance status of 0-2, a life expectancy > 3 months, and the following laboratory requirements at entry were also required: white blood cell count ≥ 4000/µL; absolute neutrophil count > 2 × 109/L; platelet count ≥ 100,000/µL; serum creatinine ≤ 1.5 mg/dL; and total bilirubin ≤ 1.5 mg/dL within 14 days of the start of therapy","Pregnant women were excluded, as were patients who had previous pelvic radiation therapy. Patients with the following conditions were also ineligible: a serious medical or psychiatric illness that would prevent informed consent or limit survival to < 2 years, a history of refractory congestive heart failure or cardiomyopathy, active coronary artery disease or a history of myocardial infarction within 3 months of treatment, or a history of stroke within 3 months of treatment.",NA,NA
19774377,NA,Combination,No,advanced solid tumors,"Eligibility criteria included histologically confirmed met astatic or locally advanced solid tumors and the following: age[18 years; ECOG performance status B 2; adequate organ function as defined by leukocytes [3,000/ll; abso lute neutrophil count [1,500/ll; platelets[100,000/ll; total bilirubin within normal limits; AST/ALT \2.5 9 upper limit institutional normal (ULIN); creati nine \ULIN; and left ventricular ejection frac tion [lower limit of institutional normal. Prior paclitaxel was permitted.","Patients with known central nervous system metastases, recent thrombotic events, orthostatic hypotension (clinically euvolemic) uncontrolled intercurrent illness, and known immune deficiency were excluded from the study. Patients who received chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who had not recovered from adverse events due to previous chemotherapy were also excluded.",during the first treatment cycle,NA
21447728,NA,Combination,No,Recurrent or Refractory B-Cell Neoplasms,"The eligibility criteria were as follows: (a) recurrent or refractory B-cell neoplasms include follicle center lymphoma, follicular or diffuse; mantle cell lymphoma; marginal zone B-cell lymphoma, splenic, nodal or extranodal; lymphoplasmacytoid lymphoma/immunocytoma; plasma cell myeloma; plasmacytoma; plasma cell leukemia; or Waldenstrom’s macroglobulinemia; (b) age 18 years or older; (c) ECOG performance status of 1 or less; (d) no neuropathy grade 2 or more; (e) hemoglobin level of 8 g/dL or more; (f) absolute neutrophil count (ANC) of 1.5  109/L or more; (g) platelet count of 100 X 109/L or; (h) preserved kidney and liver function; (i) prior autologous stem cell transplantation was allowed",but prior allogeneic stem cell transplantation was not; and (j) patients with history of central nervous system neoplasm or a primary central nervous system neoplasm were not eligible.,during the first course of treatment,NA
21596852,NCT00724568,Combination,No,Multiple Myeloma,"Eligible patients had to be >= 18 years of age, have newly diagnosed MM requiring first-line therapy according to the International Myeloma Foundation diagnostic criteria,19 have measurable disease per International Myeloma Working Group criteria,20 have an adequate Karnofsky performance status score (>= 60) or an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2, and have either a left ventricular ejection fraction (LVEF) of >= 50% by multigated acquisition scan or an echocardiography with an LVEF >= the lower limit of normal for the testing facilit","Patients were excluded if they had: grade >= 2 peripheral neuropathy,absolute neutrophil count (ANC) of < 1000 cells/mm3, hemoglobin levelof < 8.0 g/dL, platelet count of > 50 000 (or unable to maintain plateletcount of > 50 000 with platelet transfusions), creatinine level of > 2.5 mg/dL,aspartate aminotransferase of >= 2.5 X the upper limit of normal, totalbilirubin level of >= 1.5 X the upper limit of normal, or serious comorbidities (eg, myocardial infarction < 6 months before enrollment, clinically relevant and active infection, severe chronic obstructive or chronic restrictive pulmonary disease, or documented hepatic cirrhosi",during cycle 1,NA
21680752,NA,Combination,No,Solid Tumors,"Patients were eligible if older than 18, with Eastern Cooperative Oncology Group (ECOG) performance status 0–2 and histologically confirmed malignancy that was metastatic or unresectable and for which no standard or palliative measures existed. Entry was restricted to patients with solid tumors commonly exhibiting RAS/RAF/MAPK pathway activation, that is, pancreas, non–small-cell lung carcinoma (NSCLC), melanoma, colon, breast, prostate, ovary, and papillary thyroid cancer (6, 7). Unlimited number of prior chemotherapies and past paclitaxel or bortezomib treatment were also allowed. Adequate organ function was required: white blood cell >= 3,500/mL and absolute neutrophil count >= 1,500/mL, platelets >= 100,000/mL, creatinine <= 2 X the upper limit of normal (ULN), total bilirubin <=  1.5 X ULN, aspartate, and alanine aminotrasnferases <= 2.5 X ULN (or <= 5 X ULN, if tumor-involved liver).","Patients with untreated or uncontrolled brain metastases, active infections, significant comorbid cardiac disease, neuropathy common terminology criteria for adverse events grade 1 or above with pain within 14 days, or having received other anticancer treatment within 4 weeks before enrollment were excluded.",NA,NA
21911830, NCT00431990,Combination,No,relapsed or refractory multiple myeloma,"Eligible patients were 18 years of age or more, had at least 1 previous therapy for MM, and required further treatment because of relapsed or refractory disease. Patients were required to have measurable disease, which was defined as one of either serum monoclonal protein of >= 5 g/L, urine Bence Jones protein of >= 200 mg/24 hours, serum-free light chain of > 100 mg/L, or a measureable soft tissue plasmacytoma. Patients previously treated with bortezomib were eligible if the response to bortezomib was > 6 months. Patients were not selected on the basis of cytogenetic or other clinical risk–based criteria. Additional eligibility criteria included a Karnofsky performance status of 80% or greater; anticipated life expectancy of at least 3 months; adequate BM reserve (a minimum peripheral absolute neutrophil count of 0.75 X 109/L, platelet count of 50 X 109/L, and hemoglobin of 75 g/L); adequate liver function (aspartase aminotransferase and alanine aminotransferase of up to 2.5 times the upper limit of normal, bilirubin up 1.5 times the upper limit of normal); adequate cardiac function (ventricular ejection fraction of at least 45% by gated radionuclide study); creatinine clearance of at least 20 mL/min; and normal serum calcium, potassium, and magnesium levels (state supplements allowed).","Patients on drugs that could cause prolongation of the QTc interval or inhibit CYP3A4 or those with National Cancer Institute-Common Terminology Criteria for Adverse Events (CTCAE) >= grade 3 neuropathy, congestive heart failure, uncontrolled ischemic heart disease, cardiac arrhythmias requiring antiarrhythmic medications other than calcium channel or beta-blockers, QTc interval of 480 milliseconds or above, any past history of sustained ventricular tachyarrhythmia, or pregnant or lactating women were excluded.",during cycle 1,NA
21812533,NA,Combination,No,relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma ,"Patients with a recurrent histologically proven low-grade B-cell or mantle cell non-Hodgkin lymphoma were eligible for enrollment on this trial. Inclusion criteria included: age >= 18 years, Eastern Cooperative Oncology Group performance status of 0 – 2, calculated creatinine clearance >= 50 mL/min using the Cockcroft – Gault formula, liver function tests including bilirubin, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 times the upper limit of normal (ULN), absolute neutrophil count (ANC) >= 1.5 X 10 9 /L and platelets >= 100 000 X 10 9 /L. ","Patients who had previously received radioimmunotherapy were excluded, but there was no limit to the number of prior therapies. Prior exposure to bortezomib was not an exclusion criterion. Other exclusion criteria included: grade 2 or worse neuropathy (based on the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v. 3.0), >= 25% bone marrow involvement by lymphoma, active central nervous system (CNS) involvement, use of granulocytic growth factor within the 14 days prior to initiating protocol, psychiatric conditions that could interfere with compliance, New York Heart Association class III or IV heart failure, current hepatitis B infection, HIV infection, treatment with other investigational agents within the past 14 days or any chemotherapy, radiation or surgical resection within the past 3 weeks. Pregnant and breast-feeding subjects were also excluded.",one cycle of therapy,NA
22479278,NCT00379574,Combination,No,advanced-stage diffuse large B-cell lymphomas,"Patients aged ＜70 years with histologically confirmed DLBCL and no prior history of any anti-cancer treatment, including chemotherapy or radiotherapy, were eligible. All patients had the following characteristics: an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; at least 1 unidimensionally measurable lesion; and adequate organ functions, defined as absolute neutrophil count (ANC) of ≥1,500/mm3, platelet count of ≥75,000/mm3, serum creatinine level of ≤2.0 mg/dL, estimated creatinine clearance of ≥50 mL/min, bilirubin level of ＜1.25× the upper limit of normal (ULN), and serum aminotransferase level ≤2.5 ×ULN. ","Patients with any of the following characteristics were excluded: grade 2 or higher peripheral neuropathy; a history of hypersensitivity to bortezomib, boron, or mannitol; or a serious medical or psychiatric illness. Women who were pregnant or breast-feeding were also excluded from the study.",during the first treatment cycle,NA
22534815,NA,Combination,No,Advanced Non–Small-Cell Lung Cancer,"Adult patients with inoperable, locally advanced, or metastatic NSCLC (stage IIIB with pleural effusion or stage IV disease, based on the 6th edition of the American Joint Committee on Cancer) were eligible for this study. Tumors were cytologically or histologically confirmed. As a result of safety concerns with bevacizumab, the study initially included only nonsquamous NSCLC patients. However, the study was subsequently amended to include patients with squamous cell histology if they met the following criteria: (1) extra-thoracic disease only (2) peripheral lung lesions only (peripheral lesion is defined as a lesion in which epicenter of tumor is less than 2 cm from costal or diaphragmatic pleura and is more than 2 cm from trachea, main and lobar bronchi). No squamous cell patients were accrued on the study at the time of study closure.Other key eligibility criteria included measurable disease, age 18 years or more, ECOG performance status of 2 or lesser, no gross hemoptysis (defined as bright red blood of half-teaspoon or more), no history of thrombotic, hemorrhagic, or coagulopathy disorders, free of active infection, and availability for active follow-up. Patients also had to meet the key laboratory criteria, including a white blood cell count of more than 3500/mm3 and absolute neutrophil count more than 1500/mm3 and a platelet count of more than 100,000/mm3; total bilirubin less than 1.5 mg/dl, creatinine less than 1.5 mg/dl, or calculated creatinine clearance more than 45 ml/min; international normalized ratio less than 1.5, and a partial thromboplastin time no greater than upper limits of normal within 1 week before registration. Patients with lung cancer, who were placed on anticoagulant therapy for a thrombotic event were not eligible for this study.Patients must have received no prior chemotherapy for metastatic disease. Patient may have received chemotherapy in adjuvant setting or with radiation for stage-III disease. However, the disease-free interval from last chemotherapy had to be more than 6 months. Patients must be disease free for more than 5 years if they had a prior second malignancy, and had to agree to use an acceptable method of contraception for the duration of the study.","Patients meeting any of the following exclusion criteria were not enrolled in the study: untreated central nervous system disease with the exception of treated brain metastasis; a history of grade-2 or higher peripheral neuropathy within 14 days before enrollment; known previous sensitivity reactions to boron, or mannitol; known HIV positivity; myocardial infarction within 6 months before enrollment or New York Hospital Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure of >100 mmHg); history of stroke or transient ischemia attack or significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months before day 1; major surgical procedure, open biopsy, or significant traumatic injury within 28 days before day 1, anticipation of the need for major surgical procedure during the course of the study; minor surgical procedure such as fine-needle aspirations or core biopsies (excluding the placement of vascular access device) within 7 days before day 1; proteinuria as demonstrated by urine protein: creatinine ratio more than 1.0 at screening; history of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months before day 1; serious, nonhealing wound, ulcer, or bone fracture; receipt of other investigational drugs by the patient within 14 days before enrollment or expected participation in an experimental drug study during this study treatment; or serious medical or psychiatric illness likely to interfere with participation in this clinical study.",during the first cycle of treatment,NA
22291084,NCT00726869,Combination,No,Relapsed/Refractory Multiple Myeloma,"Men and women age >= 18 years with confirmed MM and one to three prior MM therapies were eligible. Other inclusion criteria were measurable serum and/or urine M-protein, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, adequate liver function (ALT/AST 3 <= upper limit of normal), adequate bone marrow (BM) function (absolute neutrophil count > 1.0 X 109 /L, platelet count >= 75 X 109/L, and hemoglobin >= 8 g/dL), and serum calcium less than or equal to the upper limit of normal.","Exclusion criteria were life expectancy less than 3 months; prior malignancy (except for adequately treated basal cell carcinoma/squamous cell carcinoma, cervical cancer in situ, or other malignancies from which the patient had been disease-freefor > 2 years); uncontrolledmedical problem(s); stem-cell or BM transplantation less than 12 weeks before the first dose; neuropathy grade >= 2 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v3.0); and thalidomide, lenalidomide, or corticosteroid therapy or radiotherapy less than 2 weeks before screening",at the end of cycle 1,NA
22677155, NCT00294632,Combination,No,relapsed or refractory mantle-cell lymphoma,"Patients with relapsed or refractory MCL who met the following criteria were eligible for this study: confi rmed tissue diagnosis of MCL with CD20 and cyclin D1 positivity; had undergone one to four previous lines of treatment; had received no treatment in the month before study entry; and had an Eastern Cooperative Oncology Group performance status score of 2 or less. Additional inclusion criteria were a serum creatinine concentration of 1·8 μmol/L or less, aspartate aminotransferase and alanine aminotransferase concentrations of less than two times the upper limit of normal, a platelet count of at least 50×10⁹ cells per L, and an absolute neutrophil count of at least 1×10⁹ cells per L. Previous treatment with rituximab or bortezomib was permitted, regardless of sensitivity. ",NA,during the fi rst cycle,NA
22535574,NA,Combination,No,Untreated Follicular Lymphoma and Other Low-Grade B-Cell Lymphomas,"Patients who satisfied all the following criteria were enrolled into the study: 1) histologically confirmed diagnosis of a previously untreated FL (grade 1, 2, 3a, or 3b), small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), or lymphoplasmacytic lymphoma; 2) an indication for treatment based on modified French Follicular Lymphoma Study Group criteria20 or a Follicular Lymphoma International Prognostic Index score >= 3; 3) an Eastern Cooperative Oncology Group (ECOG) performance status <= 2; 4) aged >= 18 years at the time of registration; 5) at least 1 measurable tumor mass (>1.5 cm in greatest dimension and >1.0 cm in the short axis) on a computed tomography (CT) scan or physical examination; 6) adequate renal function demonstrated by a serum creatinine level <1.5 mg/dL; 7) alanine and aspartate aminotransferase levels <= 3.5 the upper limit of normal and a total bilirubin level <= 2.0 mg/dL unless secondary to lymphoma; 8) cardiac left ventricular ejection fraction >= 50%; and 10) no previous treatment of the disease other than external-beam radiation (<= 2 sites of therapy) or steroids (<2 months of therap).","Patients with any other malignancies within the past 5 years except basal carcinoma of the skin or carcinoma in situ of the cervix were excluded from the study. Patients were excluded for pregnancy, central nervous system lymphoma, hypersensitivity to boron or mannitol, human immunodeficiency virus, or active hepatitis B or C.",during cycle 1,NA
23150919,NA,Combination,No,relapsed or refractory multiple myeloma,"Eligible patients, per protocol, were aged >= 18 years and had R/R MM, a serum monoclonal protein >= 10 g/l and/or urine monoclonal protein spike >= 200 mg/24 h and PD from prior MM treatment (excluding bendamustine). Eastern Cooperative Oncology Group (ECOG) performance status was <= 2 and International Staging System scores were I (30%), II (43%), III (25%), and missing (3%) at the time of enrolment on the study (Table I). Patients had a life expectancy >3 months; platelets >= 75 X 109/l and absolute neutrophil count (ANC) >= 1.5 X 109/l (platelets >= 50 X 109/l and ANC >= 1X0 9 109/l with extensive bone marrow infiltration); hepatic aminotransferase levels <= 3 times upper limit of normal (ULN); serum bilirubin <= 2 times ULN; and creatinine clearance >= 30 ml/min ( >= 10 ml/min if due to myeloma-related involvement of the kidneys).","Exclusion criteria included plasma cell leukaemia or another type of malignancy besides nonmelanomatous skin cancer within 5 years; grade >= 2 PN; other severe and/or uncontrolled medical or psychiatric conditions, including abnormal laboratory values; treatment with corticosteroids (>10 mg/d prednisone or equivalent) or chemotherapy within 3 weeks before enrolment (nitrosoureas within 6 weeks) or immunotherapy, antibody, or radiation therapy within 4 weeks; and use of any investigational drug within 1 month before screening. Supportive therapy (e.g. administration of bisphosphonates, erythropoietin, and immunoglobulins) was permitted during study treatment.",NA,NA
22906230,NA,Combination,No,relapsed/refractory follicular non-Hodgkin lymphoma,"Eligible patients were aged > 18 years, with histologically confi rmed FL (Revised European-American Lymphoma classifi cation: follicular lymphoma grade 1, 2, 3a or World Health Organization [WHO]: 1, 2, 3a) that had relapsed or transformed and had been treated with at least one prior therapy. When Food and Drug Administration (FDA) approval for the treatment of transformed lymphoma with Y-90-ibritumomab tiuxetan was withdrawn, the eligibility criteria were amended to make patients with transformation ineligible. Patients were required to have stage 2, 3 or 4 disease and to have had complete staging that included computed tomography (CT) scans of the chest, abdomen and pelvis and bilateral bone marrow examination within 6 weeks of study registration. Measurable disease defi ned as at least one lesion >= 10 mm with CT scan or >= 20 mm with conventional techniques was required. Other inclusion criteria included CD20-positivity at the time of diagnosis or on subsequent biopsy and an Eastern Cooperative Oncology Group performance status of 0 – 2. Patients were required to have a platelet count >= 150 000/ μ L and an ANC >= 1000/ μ L within 14 days of enrollment, an aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than two times the upper limit of normal, and a creatinine clearance of >= 30 mL/min. ","Patients with bone marrow involvement of >= 25% of the cellular elements by lymphoma or with marrow cellularity of less than 15% and patients who had had prior external beam radiation to greater than 25% of the active bone marrow were excluded. Other exclusion criteria included prior autologous or allogeneic stem cell transplant, pregnancy or breast-feeding, known human immunodefi ciency virus or acquired immune defi -ciency syndrome-related lymphoma, anti-cancer therapy within 3 weeks, major surgery within 4 weeks, history of or evidence of central nervous system (CNS) involvement, > grade 2 peripheral neuropathy within 14 days of enrollment, New York Heart Association class III or IV congestive heart failure, uncontrolled angina or ventricular arrhythmias, and patients with hypersensitivity to rituximab, bortezomib, boron or mannitol.",NA,NA
23322195,NCT00720148,Combination,No,refractory solid tumor malignancies,"Patients with confirmed solid organ malignancies refractory to standard therapy, or for whom no standard therapy existed, and measurable disease by RECIST criteria (version 1.0) were eligible. Other eligibility criteria included age X18 years; Eastern Cooperative Group (ECOG) performance status p2; adequate bone marrow reserve, renal and hepatic function.","Patients were excluded if they had prior radiation to 430% of bone marrow volume; ejection fraction of p45%; uncontrolled cardiovascular disease; peripheral neuropathy of Xgrade 2 by NCI Common Toxicity Criteria for Adverse Events (CTCAE), version 4; and/or recent (within 30 days) history of venous thromboembolism.",during the first cycle,NA
23243282,NCT00833833,Single Drug,No,refractory multiple myeloma ,"Patients aged >18 years, with RRMM and an Eastern Cooperative Oncology Group performance status score of ,2 were eligible. All patients had to have received prior treatment that included >2 cycles of lenalidomide and >2 cycles of bortezomib (in separate regimens or within the same combination regimen). Patients must have received >2 prior therapies, and have relapsed after having achieved at least stable disease (SD) for a minimum of one treatment cycle of a prior regimen before developing progressive disease (PD). Patients must have progressed on or within 60 days of the last treatment regimen used before enrollment (to define occurrence of refractory disease). Eligible patients had measurable levels of M-protein in the serum (>0.5 g/dL) or urine (>0.2 g/day) at study entry.","Patients were excluded if they had an absolute neutrophil count (ANC) of ,1000/mL; platelet counts of ,75 000/mL (in patients in whom ,50% of bone marrow nucleated cells were plasma cells) or ,30 000/mL (in patients in whom >50% of bone marrow nucleated cells were plasma cells); a serum creatinine level of >3.0 mg/dL; serum transaminase levels .3 times the upper limit of normal (ULN); and a serum total bilirubin level of .2.0 mg/dL. Patients were also excluded if they had grade >2 peripheral neuropathy (PN) or known hypersensitivity to lenalidomide, thalidomide, or dexamethasone",within the first cycle,NA
23256542, NCT00103272,Combination,No,relapsed or refractory acute myeloid leukemia,"Patients (aged >= 18 years) with relapsed or refractory non-M3 AML, not candidates for curative therapy with stem cell transplant, were eligible. Patients were required to have a stable white blood cell (WBC) count <= 40 X 10 9 /L for 5 days prior to initiation of therapy, total bilirubin <= 1.5 mg/dL, aspartate aminotransferase/alanine aminotransferase (AST/ALT) <=2.5 X upper limit of normal (ULN), creatinine <= 2.0 mg/dL, Eastern Cooperative Oncology Group performance status of <= 2, and life expectancy of at least 12 weeks. Initially, a resting ejection fraction (EF) >= 50% on a pretreatment echocardiogram (ECHO) or multigated acquisition (MUGA) and a QTc of <= 500 ms on an electrocardiogram (ECG) were the only eligibility criteria used to defi ne adequate cardiac function. Th ree months after the trial opened these criteria were modifi ed because of observed cardiac toxicities that were possibly associated with 17-AAG administration in this and other trials sponsored by the National Cancer Institute (NCI) Cancer Th erapy Evaluation Program (CTEP). ","As a result, patients with signifi cant heart disease, including heart failure that met New York Heart Association (NYHA) class III and IV defi nitions, myocardial infarction within 1 year of entry, uncontrolled dysrhythmias, a history of serious ventricular arrhythmias or poorly controlled angina, were now excluded. Th e QTc requirement was also changed. Men were required to have a baseline QTc <= 450 ms and women <= 470 ms. At trial opening, the use of concomitant medications that could prolong the QTc was not prohibited; however, with the change in eligibility requirements, all ancillary medications known to prolong the QTc were excluded. Adequate pulmonary function with a pretreatment diffusion lung carbon monoxide (DLCO) >= 60% and an exercise oxygen saturation by pulse oximetry of >= 90% were required. Patients with symptomatic pulmonary disease were not eligible. Patients with a pre-existing >= grade 2 sensory or motor peripheral neuropathy, history of allergic reaction to eggs (17-AAG is formulated using egg phospholipids), or active or untreated central nervous system (CNS) leukemia were not eligible. Concurrent treatment with hydroxyurea (maximum dose 1 g TID) was allowed during cycle 1 only. No other chemotherapy, radiation therapy or other investigational agents were allowed within 14 days of initiation of therapy. ",during cycle 1 of treatment,NA
23887852,NCT00303797,Combination,No,advanced malignancies,"Patients over 18 years of age, with cytologic or histologic proof of unresectable cancer without curative treatment options, were enrolled provided they had adequate hematological (neutrophils≥1,500/μL; hemoglobin≥9 g/dl; platelets≥100,000/μL) and organ function (total bilirubin≤1.5 x upper limit of normal (ULN), AST≤3×ULN or AST≤5×ULN if liver involvement, creatinine≤1.5×ULN). Inclusion on the study required an ECOG performance status<= 2, no residual adverse effects from preceding therapy, and no active infection. A New York Heart Association classification III or IV, presence of uncontrolled hypertension, more than grade 1 sensory peripheral neuropathy of any etiology or neuropathic pain of any etiology, need for therapeutic anticoagulation or active HIV infection requiring therapy excluded patients from participating.",NA,NA,NA
23543109,NA,Combination,No,advanced solid malignancies,"Patients with histologic proof of malignancy that was refractory to standard treatment for which no other curative or life extending therapy was available were eligible for the trial. Patients were ≥ 18 years old, had a life expectancy ≥ 12 weeks, an Eastern Cooperative Oncology Group performance status ≤ 2, and were willing to return for follow up care and monitoring. Adequate hematologic, renal, and hepatic function was demonstrated by hemoglobin ≥ 9 g/dL, absolute neutrophil count ≥ 1500/μL, platelets ≥ 100,000/μL, creatinine ≤ 2 × upper limit of normal (ULN), total bilirubin ≤ 2 × ULN, aspartate aminotransferase (AST) ≤ 2.5 × ULN, and alkaline phosphatase ≤ 2 × ULN or ≤ 5 × ULN if liver involvement.","Exclusion criteria included any chemotherapy, radiationtherapy, immunotherapy, or biologic therapy ≤ 4 weeksprior to study entry (≤ 6 weeks with mitomycin C ornitrosoureas). Patients who received radiation to > 25 % ofbone marrow, radiopharmaceuticals, chest radiation, orthose who had failed to fully recover from toxicities of priortherapy were also excluded. Patients with significant cardiacdisease including New York Heart Association III or IVheart failure, left ventricular ejection fraction ≤ 40 %, historyof serious left ventricular tachycardia or fibrillation, history ofmyocardial infarction or active ischemic heart disease ≤ 1 year prior to study entry, uncontrolled dysrhythmias, antiarrhythmic therapy, current warfarin therapy that could not be switched to low molecular weight heparin, poorly controlled angina, congenital long QT syndrome, QTc > 500 msec, left bundle branch block, or a prior history of cardiac toxicity after receiving anthracyclines were also excluded from the study. Patients with significant pulmonary disease including diseases that require supplemental oxygen, severely limit activity, require medication for dyspnea, pulse oximetry ≤ 88 % at rest or with exercise, or a prior history of pulmonary toxicity after receiving anthracyclines were also excluded from the study. Other exclusion criteria included uncontrolled infections, CNS metastases, seizure disorder, peripheral neuropathy ≥ grade 1, neuropathic pain of any etiology, history of serious allergic reaction to eggs, or use of concomitant medications that are known or suspected to prolong QTc. Patients were excluded if receiving other investigational therapies while on study. Pregnant women, nursing women, and patients of childbearing potential who were unwilling to employ adequate contraception, were excluded.",during cycle 1,NA
24019544,NCT00532389,Combination,No,Relapsed or Relapsed and Refractory Multiple Myeloma,"Key inclusion criteria were creatinine clearance >= 30 mL/min, platelets >= 100 X 109/L, absolute neutrophil count >= 1.5 X 109/L, and left ventricular ejectionfractionwithin normallimits. ","Patientswith severe cardiac disease, long QT syndrome, or >= grade 1 peripheral neuropathy; patients taking medications inducing QT prolongation or CYP3A4 inhibitors; or patients with prior deacetylase inhibitor (DACi) therapy were excluded. The inclusion and exclusion criteria were amended for patients enrolled onto the dose expansion phase, requiring patients to have measurable disease at study entry per IMWG criteria and narrowing exclusion for peripheral neuropathy to grade 1 with pain or >= grade 2.",occurred <= 21 days after the first dose of study treatment,NA
24075534,NCT00382954,Combination,No,acute myeloid leukemia,"Eligible patients were treated at either the University of Kentucky or the University of Rochester and provided written informed consent according to the respective Institutional Review Board guidelines and in agreement with the Declaration of Helsinki. Eligibility criteria included: diagnosis of AML as defined by the World Health Organization classification  and meeting one of two entry criteria:(1) newly diagnosed and age ≥60 years unsuitable for intensive chemotherapy induction – antecedent hematologic disorders, pre-existing MDS, unfavorable cytogenetics, or unacceptable comorbidities; or, (2) age ≥18 with relapsed disease occurring after at least one successful complete remission. Other requirements included Karnofsky performance status >60, cardiac ejection fraction >40% by multiple-gate acquisition scan, and no symptomatic cardiac disease.","Exclusion criteria included: prior induction chemotherapy for newly diagnosed AML with the exception of hydroxyurea within the preceding 14 days; prior anthracycline dose of ≥150 mg/m2 of doxorubicin or >36 mg/m2 of idarubicin [34,35]; AML-M3; active central nervous system leukemia; or uncontrolled bacterial, fungal, or viral (including HIV) infection",4 weeks,NA
24114121,NA,Combination,No,advanced malignancies,"Eligible patients had a histologically documented, advanced solid malignancy refractory to standard therapy or for which no curative therapy existed. Other inclusion criteria included: age ≥ 18 years; Eastern Cooperative Oncology Group performance status 0 to 2; adequate hematologic, hepatic and renal functions (WBC ≥ 3,000/μl, absolute neutrophil count ≥ 1,500/μl, platelets ≥ 100,000/μl, total bilirubin within institutional normal limit, AST/ALT ≤ 2.5 × the institutional upper limit of normal, creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 60 ml/min/1.73 m2 for patients with creatinine levels above institutional normal); and life expectancy greater than 12 weeks.",Exclusion criteria included untreated brain metastasis; chemotherapy or radiation therapy within 4 weeks; history of myocardial infarction; severe pulmonary disease requiring oxygen supplementation; active infection; and any serious concomitant conditions that would place the patient at excessive or unacceptable risk of toxicity. Patients were required to practice effective birth control.,During cycle 1,NA
24114123,NA,Combination,No,advanced solid tumors,"Patients with histologically documented, advanced solid malignancy refractory to standard therapy or for which no curative standard therapy was available were considered eligible. Other key eligibility criteria included: ≥ 18 years, Eastern Cooperative Oncology Group performance status of 0 to 2, adequate hematologic, hepatic and renal functions (WBC≥3,000/μl, absolute neutrophil count≥1, 500/μl, platelets≥100,000/μl, total bilirubin within institutional normal limit, AST/ALT≤2.5 × the institutional upper limit of normal, creatinine≤1.5 mg/dl or measured creatinine clearance≥60 ml/min/1.73 m2 for patients with creatinine levels about institutional normal); and life expectancy greater than 12 weeks.","Patients were excluded if they had untreated brain metastasis, were treated within 4 weeks with chemotherapy or radiation therapy, had a history of myocardial infarction or had severe pulmonary disease requiring oxygen. All patients were required to practice effective birth control.",during the first cycle,NA
23665866,NA,Combination,No,advanced oesophagogastric adenocarcinoma,"Adult patients (≥18 years of age) with histologically proven adenocarcinoma of the stomach, gastro-oesophageal junction or lower third of the oesophagus suitable for treatment with the combination of epirubicin, carboplatin and capecitabine were eligible. Patients were required to have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy >12 weeks.","Patients were excluded if they had a haemoglobin ≤10 gdl−1, inadequate haematopoeitic function (absolute neutrophil count (ANC) ≤1.5×109 per liter, platelet count ≤100×109 per liter), inadequate liver function (serum bilirubin, aspartate (AST) or alanine transferase (ALT) ≥1.5 times the upper limit of normal (ULN)), measured glomerular filtration rate (GFR) <50 mlmin-1 or previous chemotherapy for advanced gastro-oesophageal cancer with the exception of peri-operative, neoadjuvant or adjuvant chemotherapy therapy where more than 12 months had elapsed between its completion and the first dose of study treatment. Further key exclusion criteria included symptoms and signs of ≥NCI CTCAE grade 2 peripheral neuropathy, any concomitant active serious disease or infection, pregnant or nursing mothers, a history of any other previous malignancy (other than adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer), or any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow up schedule.","during the 2nd cycle and subsequent cycles, for a maximum of eight cycles of treatment.",NA
24434781,NA,Combination,No,"Relapsed Indolent Non-Hodgkin Lymphoma, Transformed, or Mantle Cell Lymphoma","Inclusion criteria included age 19 years or older and persistent, relapsed, or refractory indolent NHL including FL, composite lymphomas with >=50% of tumor showing follicular histology, transformed follicular, lymphoplasmacytic, marginal zone lymphoma, small lymphocytic lymphoma (including T cell subtypes), MCL (MCL were included only if they were in first CR), or any peripheral T cell lymphoma that was relapsed, refractory, or in first CR or PR. We included heterogeneous group of patients with NHL in whom HDT followed by ASCT is considered to be the standard of care and who have a disease that has been historically associated with a high risk of relapse after HDT and ASCT. Additional inclusion criteria were expected survival duration of 6 months or more, Karnofsky performance status of 70% or higher, liver functions <3 times upper limits of normal unless due to disease, serum creatinine <2.5 mg/dL or calculated creatinine clearance >50 mL/min, absolute neutrophil count >500 cells/mm3, and platelet count >50 mm3. Patients older than 60 years or with clinical signs of heart disease must have had an ejection fraction >= 45%. Patients with clinical signs of pulmonary insufficiency must have had diffusion capacity of carbon monoxide higher than 50% of predicted value. Patient must have been able to collect more than 1.2 X 106/kg CD34þ cell for transplantation. All patients signed a written informed consent. Male and female patients of reproductive potential were required to follow accepted birth control measures.","Exclusion criteria included human immunodeficiency virus seropositivity; active infection at the time of transplantation; myocardial infarction within 6 months before enrollment; New York Hospital Association class III or IV heart failure; uncontrolled angina; severe uncontrolled ventricular arrhythmias; electrocardiographic evidence of acute ischemia or active conduction system abnormalities; a serious disease or condition that, in the opinion of the investigators, would compromise the patient’s ability to participate in the study; pregnant or lactating females; or hypersensitivity to bortezomib, boron, or mannitol.",between day -11 and engraftment,NA
24429497,NCT01365559,Combination,No,multiple myeloma,"MM patients X18 years old with measurable and progressive disease and who had progressed while on or within 12 weeks of receiving the last dose of their most recent bortezomib-containing regimen were eligible. All patients must have received four doses of bortezomib (X1.0 mg/m2) in 21 or 28 days per cycle for at least one cycle. In addition to bortezomib, a patient’s most recent bortezomib-containing regimen must have contained an alkylating agent (for example, melphalan, cyclophosphamide or bendamustine), anthracycline (for example, doxorubicin or pegylated liposomal doxorubicin), IMiD (thalidomide and/or lenalidomide) and/or glucocorticosteroid (prednisone, dexamethasone or methylprednisolone). Patients were required to have not received any anti-MM therapy for X3 weeks before enrollment to ensure that there was adequate washout of the prior anti-myeloma regimen (see below). Patients must have had a life expectancy of X3 months and an Eastern Cooperative Oncology Group performance status of 0–2. Laboratory entry criteria included an absolute neutrophil count of >= 1.5X 109/l (>= 1.0 X 109/l if the bone marrow was extensively infiltrated); hemoglobin count of >= 8 g/dl; platelet count of >= 75 X 109/l (>= 50 X 109/l if the bone marrow was extensively infiltrated); creatinine clearance X30 ml/min; aspartate transaminase (serum glutamic oxaloacetic transaminase) and ALT (serum glutamic-pyruvic transaminase) <= 3 X upper limit of normal or <= 5 X upper limit of normal if hepatic metastases were present; serum total bilirubin <= 1.5 X upper limit of normal and serum potassium >=3 and <=5. Men were required to use contraception; women of childbearing potential were also required to use contraception and receive pregnancy tests throughout the study.","Patients were excluded if they had peripheral neuropathy (grades 3 or 4 or grade 2 with pain) within 14 days before enrollment; impaired cardiac function or clinically significant cardiac disease (for example, unstable angina or myocardial infarction within 4 months before enrollment; New York Heart Association Class III or IV congestive heart failure (CHF); uncontrolled angina; clinically significant pericardial disease or arrhythmias); gastrointestinal disease or impaired gastrointestinal function; plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes syndrome; plasma cell leukemia; a prior malignancy within 5 years except non-melanomatous skin cancer; major surgery within 28 days before enrollment or severe hypercalcemia (corrected serum calcium X12 mg/dl). Patients were also excluded if they received prior therapy with carfilzomib or chemotherapy, corticosteroids (410 mg per day prednisone or equivalent), immunotherapy, antibody therapy, thalidomide, lenalidomide, arsenic trioxide, bortezomib or radiation therapy within 21 days of enrollment; other experimental drug or therapy within 28 days of enrollment or concurrent use of any other anticancer agents or treatments. In addition, patients were excluded if they had experienced an acute active infection that required treatment, known human immunodeficiency virus infection or active hepatitis B, or C infection. Pregnant or lactating females were also excluded.",during any of the first four dose escalation cycles,NA
25248382,NCT00082784,Combination,No,Recurrent or Refractory Indolent B-cell Neoplasms,"Patients must have had a diagnosis of relapsed or refractory follicle center lymphoma (follicular or diffuse), MCL, marginal zone B-cell lymphoma (splenic, nodal, or extranodal), lymphoplasmacytoid lymphoma/immunocytoma, plasma cell myeloma, plasmacytoma, plasma cell leukemia, or Waldenstrom macroglobulinemia with no potential curative therapeutic options. Patients with a history of a central nervous system involvement were ineligible. Prior autologous SCT, but not prior allogeneic SCT, was allowed. Prior bortezomib was also allowed. Additional eligibility criteria included being at least 18 years of age, an Eastern Cooperative Oncology Group performance status (ECOG) score of 1 or less, no grade 2 or greater neuropathy, preserved kidney and liver function, hemoglobin levels of 8 g/dL or higher, an absolute neutrophil count of 1.5 X 109/L or greater, and platelet counts of 100 X 109/L or greater.",NA,during the first cycle,NA
25373733,NA,Combination,No,"advanced, refractory malignancies","Patient eligibility criteria included patients with advanced or metastatic cancer, who progressed following standard therapy or for whom no standard effective therapy is available; Eastern Cooperative Oncology Group (ECOG) performance status of ≤2; adequate bone marrow function (leukocytes ≥3,000/ml, absolute neutrophil count ≥1,500/ml, platelet count ≥75,000/ml), liver (bilirubin ≤2.0 mg/dL, alanine aminotransferase (ALT) ≤3x upper limit of normal (patients with liver metastases allowed bilirubin ≤3xULN, ALT ≤5xULN)), and kidney (creatinine ≤2xULN); and were at least 4 weeks beyond other chemotherapy or radiotherapy (at least 1 week if palliative low dose radiotherapy given to the limbs, at least 6 weeks with nitrosourea or mitomycin-C, or at least 5 half-lives or 4 weeks, whichever is shorter, for patients who received non-chemotherapeutic biologic agents) and recovered to Grade ≤1 toxicity.","Patients with hemoptysis or clinically significant unexplained bleeding within 28 days of entering study, uncontrolled hypertension, clinically significant cardiovascular disease, uncontrolled intercurrent illness, hypersensitivity to study drug components, and pregnant/lactating women were excluded.",NA,NA
25247339,NA,Combination,No,Non–Small-Cell Lung Cancer,Patients with histologic or cytologic confirmed inoperable nonmetastatic (stage IIIA or IIIB according to American Joint Committee on Cancer staging system 6th edition) non–small-cell lung carcinoma (NSCLC) requiring RT were eligible for the study. Other eligibility criteria included the following: aged 18 years or older; Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1; life expectancy of 12 weeks or longer; absolute neutrophil count ≥1.5×109/liter; platelet count ≥100×109/liter; total serum bilirubin ≤1.5mg/dl or direct bilirubin ≤1.5 × upper limits of normal (ULN); and aspartate transaminase ≤3 ×ULN and creatinine ≤1.5 ×ULN. ,"Patients with weight loss of 10% or greater in past 3 months, forced expiratory volume in 1 second less than 1 liter or 35% of predicted forced expiratory volume in 1 second, history of before RT to the chest and systemic chemotherapy for NSCLC, major surgery or unhealed wound ≤2 weeks before registration, New York Heart Association classification III or IV, uncontrolled infection, and peripheral neuropathy ≥ grade 2 were excluded.","over the 6 weeks of combined chemotherapy/RT, including a 4-week observation",NA
24730538,NCT00777114,Single Drug,No,relapsed non-Hodgkin lymphoma,"Patients must have histologically proven relapsed or refractory MCL, DLBCL including subtypes mediastinal large B cell, centroblastic, immunoblastic, T cell rich B cell and anaplastic large B cell lymphoma, or low grade B cell NHL. Patients must have received prior systemic therapy for their lymphoma. Age >18 years. Life expectancy of greater than 12 week.s Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Ability to understand and the willingness to sign a written informed consent document","Patients may not be receiving any other investigational agents. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. History of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib or boron. Previous radiation therapy to the maximum tissue tolerance at any site. Previous autologous or allogeneic stem cell transplantation. Involvement of the bone marrow of >25% by lymphoma. Known involvement of the central nervous system by lymphoma. 17 Significant organ dysfunction, including hematologic (absolute neutrophil count <1500, platelets <150,000). ECOG performance status >2. Uncontrolled illness including, but not limited to, ongoing or active infection,symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. HIV infection. Patient has a calculated or measured creatinine clearance of <20 mL/minute within 14 days before enrollment. Patient has ≥Grade 2 peripheral neuropathy within 14 days before enrollment. Myocardial infarction within 3 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant. Patient has hypersensitivity to bortezomib, boron or mannitol. Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.",NA,NA
25655379,NCT01309412,Combination,No,relapsed/refractory multiple myeloma,"Eligible patients had to be 20 years of age or older, have symptomatic or nonsecretory multiple myeloma according to the International Myeloma Working Group criteria, have previously received 1–3 treatments for multiple myeloma and had relapsed or been refractory (less than minimal response, or disease progression within 2 months of last dose) after the most recent regimen. Patients were also included if they had a measurable lesion (generally, serum immunoglobulin G [IgG] or serum immunoglobulin M [IgM] M-protein ≥1.0 g/dL; serum immunoglobulin A [IgA] M-protein ≥0.5 g/dL; serum immunoglobulin D [IgD] M-protein ≥0.05 g/dL; or serum immunoglobulin E [IgE] M-protein ≥50 IU/mL). For nonsecretory multiple myeloma, measurable lesions were defined as patients with a soft tissue mass (plasmacytoma) that could be measured in two dimensions as longest diameter ≥2 cm with an appropriate diagnostic imaging technique (computed tomography or magnetic resonance imaging). Additionally, patients were eligible if they had an Eastern Cooperative Oncology Group performance status of 0–2; adequate hematologic function (absolute neutrophil count ≥1,000/mm3, hemoglobin ≥8 g/dL, platelet count ≥50,000/mm3); adequate hepatic function (aspartate aminotransferase and alanine aminotransferase ≤2.5 times the upper limit of normal, total bilirubin ≤1.5 mg/dL); corrected serum calcium <12.5 mg/dL; and adequate renal function (creatinine clearance [CrCL] ≥20 mL/min).","Patients were excluded if they had a condition in which M-protein was present in the absence of a clonal plasma cell infiltration with lytic bone lesions; peripheral neuropathy (grade 1 with pain or ≥ grade 2); previous IL-6 therapy; previous poor response to bortezomib due to its toxicity; an allogeneic stem cell transplantation within 28 days prior to study treatment; or major surgery, chemotherapy, plasmapheresis, or radiation therapy within 21 days before study treatment. Patients who had significant respiratory illnesses (pneumonitis, interstitial pneumonia, or pulmonary fibrosis); significant cardiac disease; significant concomitant illnesses (including human immunodeficiency virus); or any condition that the investigators found inappropriate were also excluded. Concomitant therapy with other anticancer therapies, live attenuated vaccines, systemic corticosteroids, or other therapies the investigators found unsuitable were not allowed. ",21 days after the first administration of siltuximab ,NA
25986244,NCT01078961,Combination,No,Advanced Malignant Melanoma,"Histological or cytological confirmation of malignant melanoma that is metastatic or unresectable. Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as 10mm or greater with spiral CT scan. Patients may have received up to 4 prior treatments for their disease including immunotherapies such as high-dose interleukin 2 and antibodies directed against the human cytotoxic T-lymphocyte antigen 4. 18 years of age or older. Life expectancy of greater than three months. ECOG Performance status of 0 or 1. Adequate organ and marrow function as outlined in the protocol. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment. INT < 1.5 or a PT/PTT within normal limits. Patients receiving anti-coagulation treatment wih an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable. Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.","Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events dur to agents administered more than 4 weeks earlier. Participants may not be receiving any other study agents. Known, active CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any unstable or untreated brain metastasis, or history of stroke within the past 12 months. Prior therapy with bortezomib, sorafenib, or other proteasome inhibitor. History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib and bortezomib. Participants receiving any medications or substances that are inducers of CYP3A4. Known cardiac disease including congestive heart failure > class II NHYA, unstable angina or new onset angina, myocardial infarction within the past 6 months, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. Uncontrolled intercurrent illness. Pregnant women. Individuals with a history of a different malignancy are ineligible except for the circumstances outlined in the protocol. HIV-positive individuals on combination antiretroviral therapy. Uncontrolled hypertension despite optimal medical management. Thrombolic or embolic events. Pulmonary hemorrhage/bleeding event CTCAE Grade 2 or greater within 4 weeks of first dose of study drug. Any other hemorrhage/bleeding event CTCAE Grade 3 or greater within 4 weeks of first dose of study drug. Serious non-healing wound, ulcer or bone fracture. Evidence or history of bleeding diathesis or coagulopathy. Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug. Any condition that impairs patient's ability to swallow whole pills. Any malabsorption problem. Known hypersensitivity to boron or mannitol. Grade 2 or greater peripheral neuropathy within 14 days before enrollment",during cycle 1,NA
25749662,NCT01371227,Combination,No,relapsed or refractory multiple myeloma,"Eligible patients were to be ≥20 years of age with MM whose disease had either progressed after ≥1 line of prior therapy or was refractory to initial treatment. The criteria to determine the progressive disease were: ≥25 % increase in M-protein; development of new or worsening lytic bone lesions, plasmacytoma, and/or hypercalcemia (>11.5 mg/dL or 2.8 mmol/L corrected) which is not attributable to any other cause. Other key inclusion criteria included Eastern Cooperative Oncology Group performance status score of 0 or 1; absolute paraprotein of >1 g/dL in serum or >200 mg/day in urine; adequate hematological parameters such as absolute neutrophil count ≥1000/mm3, platelet count ≥75,000/mm3 and hemoglobin ≥8.0 g/dL; adequate hepatic function, total bilirubin ≤1.5 × upper limit of normal (ULN), aspartate aminotransferase and alanine aminotransferase ≤2.5 × ULN; adequate renal function, creatinine clearance ≥30 mL/min; normal cardia unction, left ventricular ejection fraction within institutional normal limits","Patients were excluded if they had prior treatment with doxorubicin (>240 mg/m2), or an equivalent amount of another anthracycline (1 mg doxorubicin = 1.8 mg epirubicin = 0.3 mg mitoxantrone = 0.25 mg idarubicin); history of treatment with bortezomib; progressive disease while receiving anthracycline-containing regimen; no change in disease status during initial therapy; Grade 1 peripheral neuropathy with pain or Grade 2 or higher peripheral neuropathy as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0; myocardial infarct within 6 months; congestive heart failure NYHA Class II–IV; clinically significant conduction system abnormalities; chemotherapy (within 21 days prior to study); treatment with nitrosoureas (within 42 days), plasmapheresis (within 30 days), major surgery or radiation therapy (within 30 days); positive for hepatitis B surface antigen or hepatitis C antibody; or human immunodeficiency virus (HIV) antibody positive.",during cycle 1 ,NA
25809731,NCT00708292,Combination,No,Relapsed or Refractory Multiple Myeloma,"Adult patients with relapsed or refractory MM who had progressed after 2 to 4 prior antimyeloma regimens, including at least bortezomib, lenalidomide, or thalidomide, were included in phase 1. Patients with relapsed or refractory MM who progressed after 2 or fewer prior antimyeloma regimens (excluding bortezomib or dexamethasone monotherapy) were eligible for phase 1B. Induction therapy followed by any kind of stem cell transplantation and/or maintenance therapy was considered to be regimen 1. Other key inclusion criteria were a diagnosis of active MM (according to the International Myeloma Working Group criteria),17 suitability for treatment with bortezomib (phase 1B), the presence of measurable disease, and an Eastern Cooperative Oncology Group performance status <= 2","Key exclusion criteria were unresolved diarrhea >= grade 2 according to the Common Terminology Criteria for Adverse Events (CTCAE), acute or chronic liver disease, peripheral neuropathy > CTCAE grade 1 (phase 1B), impaired cardiac function or clinically significant cardiac diseases, known disorders due to a deficiency in bilirubin glucuronidation, a history of another malignancy within the past 5 years except for adequately treated basal cell skin cancer or carcinoma in situ of the cervix, prior treatment with any HSP90 or histone deacetylase inhibitor, and treatment with therapeutic doses of coumarin-based anticoagulants. All patients provided written informed consent",in the first treatment cycle,NA
26298823,UMIN000001347,Combination,No,relapsed and/or refractory multiple myeloma,"Patients aged 20–69 years, diagnosed with multiple myeloma and with an Eastern Cooperative Oncology Group performance status of 0–1, were eligible for enrollment. All patients had to have relapsed disease or disease refractory to no more than two prior regimens of standard therapies that had not included bortezomib. Scheduled therapies related to ASCT were considered as one regimen. Major inclusion criteria included the following: no chemotherapy for at least 3 weeks since the last standard-dose chemotherapy or for 3 months after ASCT, WBC count ≥3000/mm3, neutrophil count ≥1500/mm3, platelet count ≥75,000/mm3, ALT ≤2.5 × upper limit of normal (ULN), total bilirubin ≤1.5 × ULN, creatinine ≤2 × ULN, left ventricular ejection fraction ≥50 %, SpO2 ≥92 %, and measurable disease of serum M-protein ≥1 g/dL and/or urine M-protein ≥200 mg/24 h. A patient with non-secretary disease was eligible when clonal plasma cell percentage in bone marrow was 50 % or more","Major exclusion criteria were as follows: cardiovascular disease (such as angina pectoris acute myocardial infarction within the recent 6 months, or congestive heart failure or arrhythmia requiring treatment), pulmonary disease (interstitial pneumonitis, COPD and infections more than twice in the preceding year), viral infection (HIV infection, HBsAg positivity, HBsAb and/or HBcAb positivity, or anti-HCV positivity), neuropathy [peripheral neuropathy (PN) ≥grade 2, neurologic pain due to PN], uncontrolled diabetes mellitus, allergy to CPM, the diagnosis of an active second primary cancer, and subjects not willing to participate in the study for any reason or those identified as ineligible by the investigator.",during the first treatment cycle.,NA
26331432,NCT01049945,Combination,No,relapsed multiple myeloma,"Patients were eligible to participate in the study if they had relapsed MM following at least 1 prior therapy, and had no more than four lines of prior therapy and an adequate performance status (ECOG < 2 OR Karnofsky >= 60%). Patients previously refractory to lenalidomide were also eligible. Patients were required to have measurable or evaluable disease, defined by conventional criteria, as any of the following: (i) serum monoclonal protein >= 1.0 g/dl, (ii) >= 200 mg/dl of urinary monoclonal protein, (iii) serum immunoglobulin free light chain >= 10 mg/dl and abnormal serum immunoglobulin kappa to lambda free lightchain ratio, or (iv) monoclonal bone marrow plasmacytosis >=30% (evaluable disease). Adequate hematological function was defined by an absolute neutrophil count (ANC) >= 1.0 3 109/l) in the absence of any growth factor support, hemoglobin >=8.0 g/dl, and an untransfused platelet count >= 75 3 109/l. A platelet count >= 50 3 109/l was allowed in patients with > 50% of bone marrow plasma cells. Adequate organ function was defined by an AST and ALT <= 3.0 times upper limit of normal (ULN), total Bilirubin <= 1.5 mg/dl, an estimated creatinine clearance >= 60 ml/min (Cockcroft-Gault calculation) for patients in phase 1 and estimated creatinine clearance >= 30 ml/min for patients in phase 2",NA,during cycle 1;,NA
26619834,NCT00858234,Combination,No,relapsed or refractory multiple myeloma,"Japanese patients at least 20 years of age with an established diagnosis of MM were enrolled in the study. A protocol amendment after study initiation restricted the study population to those not considered to be refractory to bortezomib therapy. Patients were considered refractory to bortezomib if they did not respond to prior bortezomib-containing regimens or had disease progression on or within 60 days of a bortezomib-containing regimen. Patients must have had an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 and clinically measurable disease previously treated with 1–3 anti-myeloma regimens, with progressive disease after the most recent treatment based on European Group for Blood and Marrow Transplantation (EBMT) criteria.","Patients who had had any prior allogeneic or planned hematopoietic stem cell transplant were excluded from the study. Patients were also excluded if they had an active systemic infection requiring treatment or were receiving >10 mg/day prednisone or equivalent corticosteroid treatment. Prior treatment with vorinostat or other HDAC inhibitor drugs, inability to tolerate prior bortezomib treatment, or known hypersensitivity to bortezomib or vorinostat were also criteria for exclusion",during the first cycle,NA
26494130,NCT00532389,Combination,No,relapsed and relapsed/refractory multiple myeloma,Patient has a previous diagnosis of multiple myeloma.nPatient requires retreatment for multiple myeloma. Patient has measurable M component in serum or urine at study screening,"Patient who has progressed under all prior lines of anti MM therapy. Patient who has been treated by bortezomib before, and did not reach at least a minor response under this therapy, or progressed under it or within 60 days of last dose. Patient has shown intolerance to bortezomib or to dexamethasone or components of these drugs or has any contraindication to one or the other drug , following locally applicable prescribing information. Patient received prior treatment with DAC inhibitors including panobinostat. Patient has impaired cardiac function, or a prolonged QTc interval at screening ECG. Patient taking medications with relative risk of prolonging the QT interval or inducing Torsade de pointes. Female patient who is pregnant or breast feeding or with childbearing potential and not willing to use a double method of contraception up to 3 months after the end of study treatment. Male patient who is not willing to use a barrier method of contraception up to 3 months after the end of study treatment.",NA,NA
26871714, NCT01531998,Combination,No,multiple myeloma,"Patients with a confirmed diagnosis of MM by the IMWG (International Myeloma Working Group) Criteria19 were eligible for the study if they had received no prior systemic myeloma therapy. Prior local radiotherapy, with or without concomitant exposure to steroids for pain control or management of cord/nerve root compression, was allowed, and patients were required to register into, and comply with the RevAssist program. Additional key inclusion criteria included: (1) Eastern Cooperative Oncology Group performance status of 0–2 and (2) age418. Key exclusion criteria included: (1) patients with greater than grade 2 peripheral neuropathy; (2) renal insufficiency (creatinine clearance o30 ml/min by the Cockroft-Gault formula); (3) mucosal or internal bleeding and/or inability to maintain a platelet count of ⩾ 50 000 cells/mm3; (4) absolute neutrophil count o1000 cells/mm3 without growth factors; (5) bilirubin 41.5 mg/dl; (6) hemoglobin o8.0 g/dl, with transfusions permitted; (7) aspartate and alanine aminotransferase ⩾2 × the upper limit of normal; (8) myocardial infarction within 6 months before enrollment, New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia or active conduction system abnormalities (any electrocardiographic abnormality at screening or Cycle 1 Day 1 had to be documented by the investigator as not medically relevant); (9) clinically relevant active infection requiring intravenous antibiotics; (10) serious comorbid medical conditions such as uncontrolled chronic obstructive or chronic restrictive pulmonary disease, cirrhosis, uncontrolled diabetes mellitus (fasting blood sugar 4400 mg/dl despite medical treatment); (11) known history of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome; and (12) active human immunodeficiency virus, hepatitis B or hepatitis C infection.","Those vaccinated with any live, attenuated vaccine within 4 weeks of the first dose of study treatment, and pregnant or breast-feeding female subjects were also excluded",during the first cycle,NA
26758913,NA,Combination,No,relapsed multiple myeloma,"Men or women (>= 18 years) with MM diagnosis, who had received prior therapy for MM and had evidence of relapse or progression since their previous therapy or measurable, secretory disease, were enrolled in this study. Patients were required to have Eastern Cooperative Oncology Group Performance Status score of 0–2, electrolytes (Ca, K, and Mg) within normal limits, LVEF WNL and adequate cardiovascular, renal, bone marrow, and hepatic function. Bortezomib relapsed and refractory patients were allowed","Exclusionary criteria included prior HDACi therapy; >= three previous lines of cancer therapy; history of other malignancies within past 5 years; peripheral neuropathy or grade >= 2 neuralgia as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03; and presence of cardiovascular risk factors (including New York Heart Association class II–IV, cardiomyopathy, unstable angina, or myocardial infarction within 12 months, QTcF4450 ms in men or4470 ms in women, any history of clinically significant rhythm or conduction abnormalities)",during cycle 1.,NA
27647864,NCT01352338,Combination,No,lenalidomide-refractory multiple myeloma,"Patients were eligible to participate in the study if they had lenalidomide-refractory MM following at least 1 prior therapy. Lenalidomide-refractory MM was defined as progressive disease during therapy, no response (< PR) to prior lenalidomide-containing therapy, or within 60 days of discontinuation from lenalidomide-containing regimens, according to the International Myeloma Working Group criteria.3 Similar criteria were used for the definition of bortezomib-refractory myeloma.3 Patients were required to have measurable disease, defined by conventional criteria, as any of the following: (1) serum monoclonal protein >=10 g/L, (2) urine M-protein >= 200 mg/24 hours, or (3) serum immunoglobulin free light chain >= 100 mg/L and abnormal serum immunoglobulin k to l free light-chain ratio. Furthermore, a World Health Organization (WHO) performance status of 0 to 3, a platelet count of >=75 X 109/L, an absolute neutrophil count of >= 1.0 X 109/L, and serum hepatic aminotransferases and bilirubin levels ,threefold the upper limit of normal were required. Patients were required to have an estimated creatinine clearance of >= 50 mL/min (Cockcroft-Gault calculation) in phase 1 and >= 30 mL/min in phase 2. Patients had to agree to use contraception in this trial.",Exclusion criteria included clinically relevant active comorbid medical or psychiatric conditions or a history of malignancy within the last 5 years.,during the first treatment cycle,NA
28341300,NCT01074411,Combination,No,persistent or recurrent ovarian cancer,"Eligible patients must have had recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Either measurable disease (as defined by RECIST 1.121) or detectable disease (e.g., ascites, pleural effusion, non-measurable disease, or a baseline values of CA-125 at least twice the upper limit of normal) was required. Tumor debulking prior to protocol entry was not required. All patients must have had a GOG Performance Status of 0 to 2.Patients must have had at least two and were allowed up to four prior regimens (inclusive of the primary treatment). Prior treatment with biologic (non-cytotoxic) therapy either alone or as part of the cytotoxic regimens for management of recurrent or persistent disease was allowed, but prior treatment with bortezomib was not allowed. All prior anti-cancer treatment must have been discontinued three weeks prior to registration. Laboratory criteria for eligibility included an absolute neutrophil count (ANC) ≥ 1500/mcl, platelets ≥ 100,000/mcl, creatinine ≤ 1.5 times the institutional upper limit of normal (ULN), bilirubin <1.2 times the ULN, alanine transaminase and aspartate transaminase ≤ 3.0 times the ULN, and alkaline phosphatase ≤ 2.5 times the ULN. Patients must have had a baseline neuropathy (sensory and motor) ≤ Grade 1 (NCI CTCAE Version 4.",NA,during first cycle of treatment,NA
28103725,NCT00963274,Combination,No,"chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma","Eligible patients were at least 18 years old, with anEastern Cooperative Oncology Group performance status of 0 or 1, and a diagnosis of relapsed or refractoryCLL/SLL, indolent B-cell lymphoma (including FL, marginal zone B-cell lymphoma, and lymphoplasmacyticlymphoma), PTCL (including anaplastic large celllymphoma [ALK positive or negative], angioimmunoblastic T-cell lymphoma, enteropathy-associated T-celllymphoma, extranodal NK/T-cell lymphoma [nasal type], hepatosplenic T-cell lymphoma, PTCL not otherwise specified, and subcutaneous panniculitis-like T-cell lymphoma), or CTCL (with subtypes of mycosis fungoides Stage IB or higher, Sezary syndrome, or primary cutaneous anaplastic large cell lymphoma with failure on a previous systemic treatment). Patients with mantle cell lymphoma were not included in this study due to competing studies with ibrutinib. Prior allogeneic stem cell transplant was allowed provided that at least 6 months had elapsed since allogeneic transplant, no graft-versus-host disease was present, and no immunosuppressive therapy was currently being administered. Additional eligibility criteria included normal to near-normal kidney (serum creatinine <= 1.2 mg/dL or actual or calculated creatinine clearance >= 60 mL/min) and liver (AST, ALT <= 2.5 x upper limit of normal; bilirubin <= ULN) function, absolute neutrophil count greater than 1.5 X 109 /L, hemoglobin greater than 7.5 g/L (transfusion was permissible), platelets greater than 75 X 109/L, serum potassium greater than or equal to 3.5 mEq/L, and serum magnesium greater than or equal to 1.7 mg/dL","Patients were excluded if they had persistent blood pressure of greater than or equal to 160/95; current or history of CNS malignant disease; grade 1 or higher neuralgia if due to peripheral neuropathy of greater than or equal to grade 2 paresthesias, peripheral motor neuropathy, or peripheral sensory neuropathy within 14 days prior to enrollment; clinically significant active infection; or were less than 3 weeks from prior cancer treatment. Other exclusion criteria included risks related to torsades de pointes and heart disease, including heart-related arrhythmias and concomitant treatment with and anti-arrhythmic agents. Patients were excluded from the study if they had an ejection fraction of less than 40% by MUGA scan or less than 50% by echocardiogram. Patients with other malignancies and current or ongoing treatment with chemotherapy or investigational agents were also excluded. Patients with CTCL were excluded if they received extracorporeal photopheresis, phototherapy with PUVA, or UV therapy within 2 weeks prior to study treatment; or systemic corticosteroids within 3 weeks of study treatment.",During cycle 1,NA
28550039,NCT01659658,Single Drug,No,relapsed or refractory AL amyloidosis,"Patients aged 18 years or older with biopsy-proven RRAL after 1 or more prior line of therapy, and requiring further treatment as assessed by the investigator, were enrolled. Other eligibility criteria included measurable major organ (heart/kidney) involvement, Eastern Cooperative Oncology Group performance status 0 to 2, and AL amyloidosis risk stage I/II. Patients who had received prior bortezomib were eligible for the study. ","Exclusion criteria included treatment with any investigational product within 28 days of the first dose of study drug, failure to fully recover from the effects of prior chemotherapy, New York Heart Association classification III/IV, grade 3 or worse diarrhea, grade 2 or worse or painful peripheral neuropathy (PN), systemic infections, or other malignant disease.",in cycle 1 ,NA
28873084,NCT01063907,Combination,No,relapsed/refractory multiple myeloma,"Adults (X18 years) with a confirmed diagnosis of MM by International Myeloma Working Group (IMWG) criteria (Durie et al, 2006; Kyle and Rajkumar, 2009), who had relapsed or failed to respond at least one prior MM regimens with an Eastern Cooperative Oncology Group (ECOG) performance status p2 and a life expectancy >= 3 months were eligible for the trial. Patients had to have disease that could be evaluated by serum or urinary M protein (>= 1 g dl-1 or >= 200 mg 24 h -1 , respectively), or serum-free light chains (>=10 mg dl-1 with abnormal k/l ratio (normal range, 0.26–1.65)) in the absence of measurable M protein in serum or urine. Patients could not have progressed while receiving BTZ or another proteasome inhibitor alone or in combination, and 460 days must have elapsed since that treatment. Prior therapy had to be completed 44 weeks (46 weeks for nitrosoureas) previously and monoclonal antibody therapy 46 weeks prior to entry. A stable dose of bisphosphonate treatment for 43 months prior to entry was permitted. Patients had to have adequate haematological (absolute neutrophil count >= 1 X 109 l-1, haemoglobin >= 9 g dl-1, and platelets >= 75 X109 l-1), hepatic (total bilirubin o1.5 times the institutional upper limit of normal (ULN) excluding Gilbert’s syndrome, and aspartate aminotransferase and alanine aminotransferase < 2.5 times ULN), and renal function (serum creatinine <= 2 mg dl-1 or calculated creatinine clearance > 30 ml min-1 1.73 m-2 if serum creatinine 42 mg dl-1). Excluding these specifications, patients had to have resolution of any significant toxicity from prior anticancer therapy to grade p1 according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, 2009. Women of child-bearing potential and men with female partners of child-bearing potential had to agree to use a highly effective method of birth control (i.e., condom or diaphragm plus spermicide, some intrauterine devices, hormonal devices, hormonal contraceptive, true sexual abstinence, or male vasectomy) during study drug treatment and until 3 months after last BTZ administration.","Patient exclusion criteria were significant uncontrolled intercurrent illness, intracranial or epidural disease, history of macular degeneration or blindness in one eye, or any other ocular diagnosis where the benefit-risk ratio would favour exclusion from the trial; non-secretory or biclonal MM; known hypersensitivity to boron or mannitol; prior treatment with any Hsp90 inhibitor; grade 41 sensory and/or motor neuropathy; known HIV infection or AIDS-related illness, known hepatitis B or C or other active liver disease, and active herpes zoster infection (those with a prior history of herpes zoster infection were permitted entry into the trial if treated with prophylactic acyclovir unless contraindicated); pregnancy or breast-feeding; use of immunosuppressive therapy other than corticosteroids at a dose equivalent to dexamethasone <= 2.5 mg d -1 ; use of medication known to commonly cause QTc interval prolongation; Fridericia-correct QTc >= 480 ms on screening; inability or unwillingness to receive blood or platelet transfusion that might be indicated to manage haematological complication; major surgery < 6 weeks prior to screening; receipt of allogeneic stem cell transplantation; other malignant conditions unless disease-free for > 5 years, except for adequately treated basal or squamous cell cutaneous carcinoma or cervical carcinoma in situ; clinically significant findings on screening slit-lamp retinal examination (phase I only) or any change in visual acuity or other ocular symptoms at screening or prior to the first dose (phases I and II); and requirement to use potent cytochrome P450 isoenzyme 3A4 (CYP3A4) or CYP2C19 inhibitors or inducers.",during the first cycle of treatment,NA
28436582,NA,Combination,No,relapsed/refractory high-risk neuroblastoma,"Patients with histologically proven HR-NBL who were 30 years or younger at diagnosis were eligible if they had either recurrent/progressive disease or refractory disease after front-line therapy with a minimum of four cycles of multiagent chemotherapy. Patients were required to have either measurable disease (>10 mm in one dimension) on computed tomography (CT) or magnetic resonance imaging (MRI) or evaluable disease with uptake in at least one abnormal site by metaiodobenzylguanidine (MIBG) scintigraphy, with or without bone marrow (BM) involvement. However, those patients whose only known site of disease was BM involvement were not eligible for the study. Other eligibility criteria included Karnofsky or Lansky scores of 60 or more, recovery from acute toxic effects of prior therapies, negative pregnancy test for women of child-bearing potential, absolute neutrophil count 1,000 per 𝜇l, platelet count 100,000 or more per DL, and adequate renal and hepatic function as defined by serum creatinine less than or equal to 1.5× normal serum creatinine as adjusted for age, alanine amino transferase (ALT) less than or equal to 2.5× upper limit of normal (ULN) for age, and bilirubin less than 1.5× upper limit of normal for age. Patients with BM involvement at the study entry were eligible irrespective of hematologic parameters, but they were not eligible for evaluation for hematologic toxicities. More than 3, 6, or 8 weeks must have elapsed from prior cytotoxic chemotherapy, high-dose MIBG therapy, or autologous stem cell transplantation, respectively","Exclusion criteria included use of enzyme-inducing anticonvulsants, active infection, or grade 2 or higher diarrhea (Common Toxicity Criteria for Adverse Events [CTCAE] v3.0).",during first two treatment cycles,NA
28642620,NCT01497093,Combination,No,myeloma,Patients enrolled into the study were aged ⩾ 18 years with an Eastern Cooperative Oncology Group performance status of ⩽2 and were required to have a documented diagnosis of MM with measurable disease by serum (⩾0.5 g/dl) and/or urine protein (⩾200 mg/24 h) electrophoresis. All patients must have received 1–4 prior antimyeloma therapies. Prior treatment must have included ⩾2 consecutive cycles of lenalidomide and ⩾2 consecutive cycles of a PI. Patients were required to be refractory to the last lenalidomide containing regimen but were not allowed to be refractory to bortezomib < 1.3 mg/m2 twice weekly either as a single agent or in combination. Refractory status/disease was defined as documented disease progression during treatment or within 60 days after the last dose of either agent given as monotherapy or with combination treatment.,"Patients were ineligible if they had previously received pomalidomide; had hypersensitivity to thalidomide, lenalidomide, bortezomib or dexamethasone; or had grade ⩾ 3 rash during prior therapy with thalidomide or lenalidomide. Patients with grade ⩾ 2 peripheral neuropathy or a history of congestive heart failure, myocardial infarction within 12 months of starting the study or unstable or poorly controlled angina pectoris were excluded. Patients with any of the following laboratory abnormalities were also ineligible for study participation: absolute neutrophil count of o1000/μl; platelet count of o75 000/μl for patients in whom o50% of bone marrow nucleated cells were plasma cells or o30 000/μl for patients in whom ⩾ 50% of bone marrow cellularity were plasma cells; creatinine clearance of o45 ml/min according to the Cockcroft-Gault formula or on collection of 24-h urine; hemoglobin of o8 g/dl; corrected serum calcium of 43.4 mmol/l; total bilirubin level of 41.5 × upper limit of normal; or liver enzyme levels of 43 × upper limit of normal. Additional exclusion criteria included other malignancies unless the patient was disease free for ⩾ 5 years or the malignancy included basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer (T1a or T1b or otherwise considered curable); gastrointestinal disease that may interfere with pomalidomide absorption; plasmapheresis, major surgery, radiation therapy or any antimyeloma treatment for ⩽ 14 days of therapy; other conditions that require chronic steroids or immunosuppression; or known infection with human immunodeficiency virus or hepatitis B or C virus.",during cycle 1,NA
28696812, NCT00671112,Combination,No,relapsed/refractory non-Hodgkin lymphoma,"Adult (age >= 18) patients were eligible if they had a diagnosis of relapsed or r/r NHL. There was no limit on prior therapy. Subjects were required to have measurable disease by standard radiographic findings (or monoclonal protein assessment for patients with lymphoplasmacytic lymphoma), and ECOG performance status of <=2. Laboratory requirements included serum bilirubin levels <= 1.5 times the upper limit of the normal (ULN) range for the laboratory, AST and ALT levels <= 2.5 X ULN, creatinine <= 1.5 X ULN, absolute neutrophil count (ANC) >= 1000/lL, and hemoglobin >= 9.0 g/dL. Platelet count was initially mandated to be >100,000/lL but subsequent amendments permitted >75,000/l","Exclusion criteria were prior treatment with any investigational drug, chemotherapy, or monoclonal antibody within the preceding 1 month prior to enrollment, chronic treatment with systemic steroids or another immunosuppressive agent, and history of allogeneic stem cell transplantation. In addition, any patient with known diabetes mellitus currently requiring insulin therapy, or any patient with preexisting diabetes mellitus in poor control, defined as a hemoglobin A1C (HbA1C) value of over 9% within 4 weeks of starting therapy was excluded as well as subjects with fasting serum cholesterol >300 mg/dL OR >7.75 mmol/L or fasting triglycerides >2.5 X ULN. Patients were excluded if they had uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases. Patients could also be excluded by any other severe and/or uncontrolled medical conditions or other conditions that could affect the participation in the stud",during cycle 1,NA
30061664, NCT01864018.,Combination,No,previously untreated symptomatic multiple myeloma,"The study enrolled patients, 18 years of age or older, with newly diagnosed MM fulfilling the IMWG criteria for symptomatic MM and who have not received any prior therapy for myeloma. Patients were required to have measurable disease (serum M-protein ≥ 1 g/dL or urine M-protein ≥ 200 mg/24 h or involved free light chain level ≥ 10 mg/dL provided the serum free light chain ratio was abnormal), Eastern Cooperative Oncology Group performance status of 0–2, adequate hematologic (absolute neutrophil count ≥ 1000/mm3, platelets ≥ 75,000/mm3), hepatic (total bilirubin ≤ 1.5 × upper limit of normal [ULN], alanine/aspartate aminotransferase ≤ 3 ×ULN), and renal (creatinine clearance ≥ 30 mL/min) function.","Patients with grade ≥ 3 peripheral neuropathy or grade 2 with pain, grade > 1 diarrhea, or who had major surgery or serious infection within 14 days prior to start of therapy were excluded. Patients receiving systemic treatment with strong CYP1A2 inhibitors or strong inhibitors/ inducers of CYP3A within 14 days were excluded. Other factors that precluded participation in the trial included uncontrolled cardiovascular conditions (including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months), known human immunodeficiency virus infection, known hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection, and known allergy to any of the study medications, their analogs, or excipients in the various formulations. Other comorbidities or severe pre-existing illness that in the treating physician’s opinion could interfere with oral absorption and/or tolerance of ixazomib citrate excluded patients from participation. Patients were characterized as having high-risk genetics if they had one of the following abnormalities on FISH testing: t(4;14), t(14;16), t(14;20) or del17p",during the first cycle,NA
30058108,JapicCTI‐122020,Combination,No,relapsed or refractory multiple myeloma,"The inclusion criteria were as follows: age ≥20 years; Eastern Cooperative Oncology Group Performance Status of 0‐2; symptomatic MM with measurable disease (serum M‐protein level ≥0.5 g/dL or urine M‐protein level ≥200 mg/24 hours); at least 2 previous treatments for MM, including bortezomib and immunomodulatory agents (both refractory and non‐refractory patients could be enrolled); response to at least 1 previous MM treatment (≥25% reduction in M‐protein); and adequate hematologic, hepatic and renal function at screening, evidenced by absolute white blood cell count of ≥2000/mm3, neutrophil count of ≥1000/mm3, platelet count of ≥50 000/mm3, hemoglobin of ≥8.0 g/dL, aspartate aminotransferase and alanine aminotransferase of less than 3 times the upper limits of the normal values, serum bilirubin of less than 2 times the upper limit of the normal value, estimated creatinine clearance value by the Cockcroft–Gault formula of ≥30 mL/min, and serum creatinine of ≤2.0 mg/dL.","The major exclusion criteria were as follows: patients previously treated with carfilzomib, those with grade 3‐4 neuropathy or grade ≥2 neuropathy accompanied by neuropathic pain; a history of interstitial lung disease, New York Heart Association class III or IV congestive heart failure, symptomatic myocardial ischemia or uncontrolled conduction abnormalities; serious amyloidosis or suspicion of serious amyloidosis such as cardiac or intestinal amyloidosis; or poorly controlled hypertension or diabetes",during Cycle 1,NA
30400780,NCT02993094,Combination,No,advanced triple-negative breast cancer,"Patients with metastatic histologically confirmed triple-negative adenocarcinoma of the breast will be assessed for eligibility. Detailed inclusion and exclusion criteria are listed in Table 2. Patients with locally advanced disease are eligible provided they cannot be offered a potentially curative loco-regional treatment option. TNBC is defined by the absence of staining for estrogen receptor (IHC < 1%), progesterone receptor (IHC < 1%) and HER2/neu (IHC 1+ or ISH ratio of < 2.0 between HER2 gene copy number and centromere of chromosome 17 or a copy number of 4 or less ). A signed informed consent, with the understanding that consent may be withdrawn at any time without prejudice to future medical care, have to be provided prior to any study-specific procedure. All patients must be female and aged 18 or older with a performance status of ECOG 0–2 and a life expectancy of at least 12 weeks. A disease progression with at least one measurable lesion according to RECIST 1.1 criteria must be documented. Patients must be pretreated with at least one prior line of chemotherapy for advanced disease or a progression must have occurred within 12 months of completion of adjuvant chemotherapy. Women of childbearing potential must have a negative pregnancy test at screening and agree to practice 2 effective methods of contraception, at the same time. An adequate left ventricular ejection fraction at baseline, defined as LVEF ≥50% by either echocardiogram or MUGA and adequate hematological, liver and renal function (absolute neutrophil count ≥1.5 × 109/L, hemoglobin ≥8 g/dL, platelets ≥100 × 109/L, albumin ≥2.5 g/dL, serum bilirubin ≤2 mg/dL, aspartate transaminase and alanine transaminase ≤3 x ULN without liver metastases and ≤ 5 x ULN with documented liver metastases, and serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥50 ml/min) is required. If present, a peripheral neuropathy must be less or equal to grade 1 or grade 2 without pain.","Patients with at least one of the following conditions or pretreatments are excluded from trial participation: serious medical or psychiatric disorders interfering with patient’s safety or informed consent, lactating patients, radiation of the target lesion within the last 4 weeks before enrollment, prior radiation to ≥30% of bone marrow, active bacterial, viral or fungal infections, known HIV infection, major surgery within 14 days before enrollment, clinically apparent brain metastases or evidence of a spinal cord compression, systemic treatment with strong CYP3A inducers or use of Ginkgo biloba or St. John’s wort within 14 days before the first dose of ixazomib, previous treatment with a proteasome inhibitor or with a platinum derivative unless applied in the (neo-)adjuvant setting if breast cancer recurred later than 12 months after (neo-)adjuvant chemotherapy completion, participation in other clinical trials, application of any investigational agents within 30 days of the start and throughout the duration of this trial, history of another malignancy unless disease-free for ≥5 years or with a history of completely resected non-melanoma skin cancer or a successfully treated in situ carcinoma.",during the first treatment cycle,NA
30352784,NCT02343042,Combination,No,relapsed or refractory multiple myeloma,"Written informed consent signed in accordance with federal, local, and institutional guidelines. Age greater than or equal to (≥) 18 years at the time of informed consent. Histologically confirmed diagnosis with measurable disease for relapsed/refractory myeloma. Symptomatic MM, based on IMWG guidelines. Patients must have measurable disease as defined by at least one of the following: Serum M-protein ≥ 0.5 gram per deciliter (g/dL) by serum protein electrophoresis (SPEP) or, for immunoglobulin A (IgA) myeloma, by quantitative IgA Urinary M-protein excretion at least 200 mg/24 hours Serum free light chain (FLC) ≥ 100 milligram per liter (mg/L), provided that FLC ratio is abnormal If SPEP is felt to be unreliable for routine M-protein measurement (example, for IgA MM), then quantitative immunoglobulin (Ig) levels by nephelometry or turbidometry are acceptable Any non-hematological toxicities (except for peripheral neuropathy as described in exclusion criterion #22) that patients had from treatments in previous clinical studies must have resolved to less than or equal (≤) Grade 2 by C1D1. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2. Adequate hepatic function within 28 days prior to C1D1: For SPd, SRd, and SPEd: Total bilirubin < 2* upper limit of normal (ULN) (except patients with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3* ULN) and both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5* ULN For SVd, SPVd, SDd, SNd, SBd and SDPd: Total bilirubin of < 1.5* ULN (except patients with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3* ULN) and both AST and ALT < 2.0* ULN For SKd: Total bilirubin < 2* ULN (except patients with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3* ULN) and both AST and ALT < 3.0* ULN Adequate renal function within 28 days prior to C1D1. Estimated creatinine clearance (CrCl) calculated using the formula of Cockroft and Gault (1976): ≥ 20 milliliter per minute (mL/min) for SVd, SDd, and SKd arms ≥ 30 mL/min for SNd and SBd arms ≥ 45 mL/min for SPd, SPVd, SPEd and SDPd arms > 60 mL/min for SRd arm Adequate hematopoietic function within 28 days prior to C1D1: total white blood cell (WBC) count ≥ 1,500/millimeter cube (mm^3), absolute neutrophil count (ANC) ≥ 1,000/mm^3, hemoglobin (Hb) ≥ 8.0 g/dL, and platelet count ≥ 100,000/mm^3. SPVd (Arm 4) and SKd (Arm 6) only: platelet count ≥150,000. Female patients of childbearing potential must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients must use highly effective methods of contraception throughout the study and for 1 week following the last dose of study treatment. SPd (Arm 1) Only: Relapsed or refractory MM with: Documented evidence of progressive disease (PD) after achieving at least stable disease (SD) for ≥ 1 cycle during a previous MM regimen (i.e., relapsed MM) ≤ 25 percent (%) response (i.e., patients never achieved ≥ MR) or PD during or within 60 days from the end of the most recent MM regimen (i.e., refractory MM) Previously undergone ≥ 2 cycles of lenalidomide and a PI (in separate therapeutic regimens [not for maintenance] or in combination) In the expansion arm at RP2D, patients must not be pomalidomide refractory SVd (Arm 2) Only: Relapsed or refractory MM with: Documented evidence of relapse after ≥ 1 previous line of therapy Not refractory to bortezomib in their most recent line of therapy SRd in RRMM (Arm 3) Only: Patients who received ≥ 1 prior therapeutic regimen (prior lenalidomide is allowed as long as patient's MM was not refractory to prior lenalidomide; patients whose MM was refractory to lenalidomide maintenance regimens will be allowed in this cohort). SPVd (Arm 4) Only: Patients who received 1- 3 prior lines of therapy, including ≥ 2 cycles of lenalidomide and have demonstrated disease progression on their last therapy (may include prior bortezomib, as long as the patient's MM was not refractory to bortezomib therapy), but patients must be pomalidomide-naïve in the Dose Expansion at RP2D (Cohort 4.3 ONLY). SDd (Arm 5) Only:Patients who received ≥ 3 prior lines of therapy, including a PI and an immunomodulatory agent (IMiD), or patients with MM refractory to both a PI and an IMiD. Patients must not have received prior anti-cluster of differentiation 38 (anti-CD38) monoclonal antibodies (Cohort 5.3 ONLY - Dose Expansion at RP2D). SKd (Arm 6) Only: Patients may have received prior PIs; however, their MM must NOT be refractory to carfilzomib. SRd in NDMM (Arm 7) Only: Patients must have symptomatic myeloma per IMWG guidelines with either CRAB criteria (calcium elevation, renal failure, anemia, lytic bone lesions) or myeloma-defining events and need systemic therapy. No prior systemic therapy for NDMM is permitted other than pulse dose dexamethasone (maximum dose of 160 mg) or corticosteroid equivalent. SNd (Arm 8) Only: Patients must have MM that relapsed after 1 - 3 prior lines of therapy (may not include those with MM refractory to bortezomib or carfilzomib but patients must be ixazomib-naïve). SPEd (Arm 9) Only: Patients who received ≥ 2 prior therapies, including lenalidomide and a proteasome inhibitor (in separate or the same regimens), but patients must be pomalidomide-naive and elotuzumab-naive in the Dose Expansion at RP2D (Cohort 9.3 ONLY). SBd (Arm 10) Only: Patients who have MM that was refractory to an IMiD, a proteasome inhibitor, and refractory or intolerant (or both) to an anti-CD38 monoclonal antibody. Patients must be belantamab mafodotin-naive in the Dose Expansion cohort at RP2D (Cohort 10.3 ONLY).","Smoldering MM. MM that does not express M-protein or FLC (i.e., non-secretory MM is excluded), and quantitative immunoglobulin levels cannot be used instead. Documented active systemic amyloid light chain amyloidosis. Active plasma cell leukemia. Red Blood Cell (RBC) and platelet transfusions and blood growth factors within 14 days of C1D1. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks prior to C1D1, and radio-immunotherapy within 6 weeks prior to C1D1. Patients on long-term glucocorticoids during Screening do not require a washout period. Prior radiation is permitted for treatment of fractures or to prevent fractures as well as for pain management. Patients with history of spinal cord compression with residual paraplegia (Dose Escalation Phase only). Treatment with an investigational anti-cancer therapy within 3 weeks prior to C1D1. Prior autologous stem cell transplantation < 1 month, or allogeneic stem cell transplantation < 3 months prior to C1D1. Active graft versus host disease after allogeneic stem cell transplantation. Life expectancy < 3 months. Major surgery within 4 weeks prior to C1D1. Active, unstable cardiovascular function: Symptomatic ischemia, or Uncontrolled clinically-significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded), or Congestive heart failure (CHF) of New York Heart Association (NYHA) Class ≥ 3, or Myocardial infarction (MI) within 3 months prior to C1D1 Ejection fraction (EF) < 50% at Screening Uncontrolled active hypertension. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose. Known active hepatitis A, B or C. Known human immunodeficiency virus (HIV) infection or HIV seropositivity. Any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment. Currently pregnant or breastfeeding. A serious active psychiatric or active medical condition which, in the opinion of the Investigator, could interfere with treatment. Hypersensitivity to any of the treatments for the arm in which the patient is enrolled. SVd Arm (Arm 2), SPVd (Arm 4), and SNd Arm (Arm 8) only: Prior history of neuropathy Grade > 2, or Grade ≥ 2 neuropathy with pain at Screening (within 28 days prior to C1D1). Patients who are eligible for the selinexor PK Run-in only: Treatment with moderate or strong inhibitors/inducers of CYP3A within 7 days prior to Day 1 of the PK Run-in period. Patients who are eligible for the selinexor PK Run-in only: Not able to receive a strong CYP3A4 inhibitor due to concomitant medications. SKd arm only: HBs Ag + plus HBc Ab + even though no active hepatitis B virus (HBV) hepatitis. If HBs Ag - plus HBc Ab +, treating physician needs to contact the medical monitor. Prior exposure to a selective inhibitor of nuclear export (SINE) compound, including selinexor. SBd (Arm 10): Only: Current corneal epithelial disease except mild punctate keratopathy.",in the first cycle,NA
30297385,NCT00923247,Combination,No,Locally Advanced or Metastatic Medullary Thyroid Cancer,"Patients 18 years of age and older with solid tumors that cannot be surgically removed and have either recurred or shown further growth. The tumor(s) must be able to be evaluated by X-ray, MRI (magnetic resonance imaging), and CT (computerized tomography) scanning. Patients who have been diagnosed with medullary thyroid cancer will participate in Phase II of the study.",NA,NA,NA
30610196, NCT01549431,Combination,No,relapsed/refractory multiple myeloma,Key inclusion criteria were: age ≥ 18 years; measurable disease; Eastern Cooperative Oncology Group performance status of 0 to 2; adequate bone marrow reserves; serum creatinine clearance ≥ 30 mL per minute; adequate hepatic function (alanine aminotransferase up to 2.5 times and bilirubin up to 1.5 times of the upper normal limit). ,"Exclusion criteria were history or presence of ventricular arrhythmias; a baseline electrocardiogram (EKG) with a QTc interval > 450 msec, uncontrolled hypertension; unstable angina or myocardial infarction within 6 months prior to enrollment, NYHA Class III or IV heart failure; impairment of GI function or GI disease that may significantly alter the absorption of panobinostat.",during cycle 1,NA
30279233,NCT01522872,Combination,No,Relapsed/Refractory Multiple Myeloma,"This trial included patients who had relapsed/refractory multiple myeloma for which no standard therapies were anticipated to result in a durable response. These patients were also relapsed/ refractory to a bortezomib-containing regimen and/or an iMID-containing regimen. Eligible patients were required to have measurable disease as defined by the International Myeloma Working Group (IMWG) Criteria (24, 25) with the only exception being that measurable serum paraprotein was defined as >= 0.5 g/dL. Other eligibility criteria included age 18 years or older, Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, and adequate hepatic and renal functions. ","Exclusion criteria included New York Heart Association class III or IV, POEMS syndrome, symptomatic brain metastases, severe chronic obstructive pulmonary disease, active uncontrolled infection, or a washout period of less than 3 weeks for cytotoxic agents and less than 2 weeks for noncytotoxic agents from prior treatment to the time of entry on study",during the first cycle,NA
31124580,NCT02199665,Combination,No,relapsed/refractory multiple myeloma,"Patients aged ≥18 years with progressive RRMM were enrolled at five Multiple Myeloma Research Consortium sites in North America. Patients were eligible provided they had been previously treated with at least two anti-myeloma therapies, including a PI and an IMiD, had an absolute neutrophil count ≥1.0 X 109/l, a haemoglobin concentration ≥80 g/l, a platelet count ≥50 X 109/l and adequate hepatic (total bilirubin ≤2 times the upper limit of normal and alanine aminotransferase ≤2.5 times the upper limit of normal) and renal function (creatinine clearance ≥30 ml/min) within 14 days of treatment initiation.","Patients were excluded if they had received prior selinexor or any other anticancer therapy within 2 weeks of treatment initiation. Concurrent anticancer therapy other than steroids was not allowed. Other exclusion criteria included unstable angina or myocardial infarction within 4 months of treatment initiation, New York Heart Association Class III/IV congestive heart failure, left ventricular ejection fraction <40%, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias or uncontrolled hypertension or uncontrolled diabetes within 14 days of treatment initiation. Patients with plasma cell leukaemia, Waldenstrom macroglobulinaemia, POEMS € (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome or amyloidosis were also excluded",first cycle of treatment,NA
31120355,NCT01111188,Combination,No,mantle cell lymphoma,"Adult patients with previously treated MCL and a performance status of <= 2 were eligible for this study. Patients that had received prior bortezomib were eligible if they had not experienced significant hematologic or neuropathic toxicities due to prior bortezomib therapy. Patients were required to have an absolute neutrophil count of at least 750 cells/lL and a platelet count of at least 75,000 cells/lL within 14 days of study entry. ","Patients with peripheral neuropathy >= grade 2, known HIV infection, known or suspected CNS involvement by MCL, or other uncontrolled illness were not eligible",during cycle 1,NA
10531568,NA,Combination,No,Children With Disseminated Solid Tumors,"Patients younger than 17 years of age with disseminated or relapsed solid tumors were eligible for the present study. Parents were required to give informed consent for transplantation and associated procedures. Children were eligible for this protocol if they had adequate cardiac (ejection fraction >45% by echocardiogram), hepatic (total plasma bilirubin <= 2 mg/dl and transaminases <2 times normal), renal (plasma creatinine <= 1.5 mg/dl), and pulmonary (forced vital capacity and forced expiratory volume >= 70% of predicted) function.",NA,NA,NA
11025470,NA,Combination,No,Children With Acute Myelogenous Leukemia,NA,NA,NA,NA
12420202,NA,Combination,No,haematological malignancies,"1 Poor risk hematologic disease: CML beyond CP1, AML in CR1 (autografts) or beyond CR1 (autografts or allografts), Ph+ ALL in CR1 or ALL beyond CR1, HD or NHL beyond CR1 or failure to achieve CR1. 2 No previous or existing liver dysfunction. 3 Negative hepatitis serology. 4 KCO or FEV1/VC >75% predicted. 5 Cardiac ejection fraction >45%. 6 Creatinine clearance at or above lower limit of predicted normal. 7 No previous mediastinal radiotherapy (added after first six autograft patients).","In general, patients with recurrent disease were transplanted in untreated relapse or chemosensitive relapse; multiply relapsed chemorefractory patients were not eligible. Prior mediastinal radiotherapy was added as an exclusion criterion in autograft recipients following reports of increased pulmonary toxicity in that patient group",NA,NA
12431963,NA,Single Drug,No,Refractory Hematologic Malignancies,"Patients with a histologically confirmed hematologic malignancy refractory to standard therapy, or for whom no standard therapy was available,were eligible for enrollment. Inclusion criteria included the following: (1) Eastern Cooperative Oncology Group performance status of 0 to 2; (2) age >= 18 years; (3) expected survival >= 6 weeks; (4) no radiation/chemotherapy/immunotherapy in the previous 4 weeks, and no major surgery in the previous 2 weeks; (5) absence of active infection; (6) adequate cardiovascular function without ischemia, conduction abnormalities, or myocardial infarction in the previous 6 months; and (7) adequate hepatic function, with bilirubin less than 1.5 times the upper limit of normal, and AST and ALT of less than 2.5 times the upper limit of normal. A total WBC count >=2,000/mm3, absolute neutrophil count >= 1,000/mm3, hemoglobin >= 8.0g/dL, and a platelet count >= 50,000/mm3 were required. Patients receiving supportive care could continue to do so, but had to be transfusion independent. An estimated creatinine clearance of >= 50 mL/min was required, and was calculated using the formula of Cockroft and Gault.21 When the activity of PS-341 against multiple myeloma was identified, because renal function had been noted to be a common reason for such patients to be excluded, this was subsequently amended to allow a serum creatinine of <= 2.5 mg/dL",Exclusion criteria included (1) pregnancy or breast-feeding; (2) New York Heart Association class III to IV congestive heart failure; and (3) serious medical/psychiatric conditions that could interfere with treatment. All patients had to practice effective birth control and gave written informed consent in accordance with federal and institutional guidelines before treatment.,during first cycle ,NA
15286694,NA,Single Drug,No,relapsed or refractory high-grade lymphoma,The study was open to adults up to 60 years of age with relapsed or refractory high-grade lymphoma who had received chemotherapy with or without radiotherapy for their primary lymphoma manifestation. Patients were considered refractory to the primary treatment if they never achieved at least PR. Early or late relapse was defined as relapse within or beyond 1 year after primary diagnosis,Patients with antecedent or concurrent neoplastic disease were excluded.,NA,NA
15570082,NA,Single Drug,No,Pediatric Patients With Refractory Solid Tumors,"Patients younger than 22 years of age with a histologically confirmed solid tumor refractory to standard therapy were eligible for this trial. Other eligibility criteria included: a Karnofsky or Lansky performance score of >= 50; a life expectancy of greater than 8 weeks; adequate bone marrow function [absolute neutrophil count >= 1,500/uL, platelet count >= 75,000 uL (transfusion independent), and hemoglobin >= 8 gm/dL]; adequate liver function (serum bilirubin < 1.5 mg/dL, ALT < 5 Xthe upper limit of normal for age, and albumin >= 2 g/dL); adequate renal function (serum creatinine below the upper limits or normal for age or a radioisotope glomerular filtration rate >= 70/mL/min/1.73 m2b); recovery from the toxic effects of prior chemotherapy, radiotherapy, and immunotherapy with a minimum elapsed period of at least 3 months for prior allogeneic stem-cell transplant and of at least 6 months for prior craniospinal or hemipelvic radiation.","Patients with intrinsic brainstem gliomas or optic pathway tumors were excluded from the requirement for histologic verification. Study exclusion criteria included pregnancy or lactation in women of child bearing age, uncontrolled infection, receipt of concomitant anticonvulsants, or prior receipt of study drug.",during the first course,NA
15626743,NA,Combination,No,advanced hematologic malignancies,"Patients with a confirmed hematologic malignancy who had relapsed orbeen refractory to at least 1 standard therapy, or who could not receiveconventional therapy, or for whom no standard was available werecandidates for this study. Inclusion criteria were as follows: (a) Karnofskyperformance status of at least 60%; (b) age 18 years or older; (c) expectedsurvival 2 months or longer; (d) no major surgery, radiation, or chemotherapy in the previous 3 weeks and no immunotherapy in the previous 4weeks; (e) absence of active infection; (f) adequate hepatic function, withtotal bilirubin level less than 1.2 times the upper limit of normal (ULN) andaspartate and alanine aminotransferase levels less than 2.5 times the ULN;and (g) adequate coagulation function, with a prothrombin time andactivated partial thromboplastin time of less than 1.5 times the ULN.Adequate bone marrow function was a white blood cell count of at least 2 X 109/L (2000/uL), absolute neutrophil count of at least 1 X 109/L (1000/uL), hemoglobin level of at least 80 g/L (8.0 g/dL), and a platelet count of at least 50 X 109/L (50 000/uL). Patients who were transfusion- or growth factor–dependent were allowed, provided these values could be achieved with transfusion. A prior doxorubicin exposure of 400 mg/m2 or less was required, and adequate cardiovascular function was defined as no ischemia, new conduction system abnormalities, class 3 or 4 New York Heart Association congestive heart failure, or myocardial infarction in the previous 6 months. A 50% left ventricular ejection fraction (LVEF) was initially required but later amended to 45%. Initially, the required serum creatinine level was 132.6 uM (1.5 mg/dL) or less but this was later amended to 221.0 uM (2.5 mg/dL) or less, or an estimated creatinine clearance level of at least 0.50 mL/s (30 mL/min).",Exclusion criteria included the following: (a) pregnancy or breast feeding; (b) known human immunodeficiency virus seropositivity or active viral hepatitis; (c) known hypersensitivity to standard or liposomal doxorubicin preparations or boron-containing compounds; and (d) serious medical or psychiatric conditions that could interfere with treatment. All patients practiced effective birth control and gave written informed consent in accordance with federal and institutional guidelines before treatment.,during cycle 1,NA
16135477,NA,Combination,No,solid tumors or lymphomas,"Patients 18 years old or older with histologically confirmed cancers were eligible after failure of standard therapy or if no other known effective treatment was available. Eastern Cooperative Oncolgoy Group (ECOG) performance status <= 2, hematologic parameters including absolute neutrophil count (ANC) >= 1,500/mm3 and platelets >= 100,000/mm3 ; adequate liver function defined as AST <= 2.5 X upper limit of normal, total bilirubin <= 1.5 mg/dL, and serum creatinine <= 1.5 mg/dL were required.","Surgery within 2 weeks, chemotherapy or radiation therapy within 4 weeks, or chemotherapy with nitrosourea-containing regimens within 6 weeks of study entry were not allowed. Due to cardiovascular toxicities in animals, patients with electrocardiographic evidence of acute ischemia or significant conduction abnormality (bifascicular block, defined as left anterior hemiblock in the presence of right bunder branch block; second or third degree atrio-ventricular blocks) were excluded.",during the first 2 cycles,NA
17409841,NA,Combination,No,Advanced Non-small Cell Lung Cancer and Other Solid Tumors,"Patients with histologically confirmed locally advanced or metastatic NSCLC as well as other solid tumors, who were treatment-naı¨ve or had previously received up to two chemotherapy regimens, were enrolled subject to the following main inclusion criteria: (1): age >= 8 years; (2) measurable or evaluable disease; (3) Karnofsky Performance Status (KPS) >= 60; (4) life expectancy >=3 months; and (5) adequate hematologic, renal, and hepatic end-organ function","Patients were excluded if they had: (1) previously received docetaxel, cisplatin (at a cumulative dose >350 mg/m2), or radiation therapy to >25% of bone marrow; (2) grade 2 or higher peripheral neuropathy; (3) electrocardiographic evidence of acute ischemia or new conduction system abnormalities; or (4) uncontrolled brain metastases or central nervous system disease",in cycle 1,NA
16489083,NA,Combination,No,Advanced Solid Tumors,"Patients with histologically confirmed advanced solid malignancies without conventional treatment options were eligible for the trial. Inclusion criteria included age >= 18 years; Eastern Cooperative Oncology Groupperformance status of 0, 1, or 2 (Karnofsky performance status z 50%); life expectancy >12 weeks; at least 4 weeks elapsed since prior chemotherapy or radiation therapy [6 weeks if the regimen included 1,3-bis(2-chloroethyl)-1-nitrosourea or mitomycin C, without receiving >3 cycles of mitomycin C total]; at least 6 months elapsed since previous weekly docetaxel treatment; adequate organ function [leukocytes >= 3,000/AL, hemoglobin >= 8 mg/dL, absolute neutrophil count >= 1,500/AL, platelets >= 100,000/AL, total bilirubin within normal institutional limits (WNL), creatinine WNL or creatinine clearance >= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal].","Patients were excluded if they had known brain metastases, hypersensitivity to taxanes or corticosteroids, intolerance of corticosteroids, peripheral neuropathy >grade 1 (Common Toxicity Criteria version 2), pregnancy, HIV infection, or within 14 days of study drug administration total bilirubin above institutional normal limits, alanine aminotransferase/aspartate aminotransferase >1.5 upper limit of normal, alkaline phosphatase > 2.5 upper limit of normal (unless shown to be bone-derived whereas alanine aminotransferase/aspartate aminotransferase < 1.5 X upper limit of normal)",during cycles 1 and 2,NA
16418495,NA,Combination,No,Relapsed or Refractory Multiple Myeloma,"Patients with relapsed or refractory MM with active progression after receiving >= two prior treatment regimens were eligible for enrollment. Inclusion criteria included age >= 18 years, measurable disease, Karnofsky performance status >= 60%, creatinine clearance >= 30 mL/min, and a life expectancy >= 3 months","Patients were excluded if they had received chemotherapy <= 3 weeks before enrollment, had a baseline platelet count<=50,000/uL (or<=30,000/uL if thrombocytopenia was disease related), hemoglobin <= 8 g/dL, absolute neutrophil count <= 1,000/uL, serum hepatic aminotransferase levels >= 3 X the upper limit of normal or a total serum bilirubin >= 2 X the upper limit of normal, or any other serious medical illness that could potentially interfere with the completion of treatment",during the first cycle,NA
16533779,PBTC-004,Combination,No,Children withNeoplastic Meningitis,"Eligibility criteria for this study were (a) age >=2 and <=21 years; (b) presence of a primary malignant brain tumor refractory to standard therapy and metastatic to CSF and/or leptomeningeal subarachnoid space as determined by CSF cytology and/or neuroimaging evidence of leptomeningeal disease; (c) Karnofsky or Lansky status of >= 50% and life expectancy of at least 8 weeks; (d) evidence of recovery from prior therapy 3 weeks from prior systemic chemotherapy (6 weeks for nitrosoureas), 1 week from prior intrathecal chemotherapy (2 weeks for liposomal cytarabine), 1 week from prior focal radiotherapy, and 8 weeks from prior craniospinal irradiation; (e) adequate organ function, including an absolute neutrophil count >1,000/mm3, platelets >= 75,000/mm3, serum creatinine <1.5 times normal for age, serum bilirubin within normal limits for age, serum transaminases (alanine aminotransferase/ aspartate aminotransferase) <5 times normal for age, and no overt evidence of cardiac, pulmonary, or renal disease; (f) adequate CSF circulation as shown by a 111Indium-labeled or 99Technetium-labeled diethylenetriaminepentaacetic acid CSF flow study obtained following a lumbar puncture; and (g) signed informed consent according to institutional guidelines","Patients excluded from this study were those with CSF obstruction or compartmentalization, concomitant bone marrow disease, and uncontrolled infection. Focal radiotherapy was allowed within 2 weeks of treatment to improve CSF flow in those with CSF obstruction, but a repeat CSF flow study was required to confirm adequate CSF circulation before enrollment. Patients who were pregnant or breastfeeding were also excluded from the study.",first two weeks,NA
17036355,NA,Combination,No,Advanced Solid Tumors,"Patients age >= 18 years with advanced solid tumors that had progressed after receiving at least 2 prior regimens of chemotherapy were eligible for this study. Patients were required to have measurable or evaluable disease measured radiographically by computed tomography. A Karnofsky performance status >= 60%, and life expectancy >3 months were required. An absolute neutrophil count >= 1500/mm3, a platelet count >= 100,000/mm3, a total bilirubin level <= 1.5 times the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels <= 2.5 times ULN (<= 5 times ULN for patients with liver metastases), and a serum creatinine concentration <= 1.5 mg/dL were required within 14 days of starting treatment. ","Patients who had received chemotherapy within 4 weeks, nitrosoureas within 6 weeks, antibody therapy within 8 weeks, or radiation therapy to more than 35% of the bone marrow within 4 weeks of enrollment were ineligible. Other exclusion criteria included the presence of malignant lymphoma, leukemia, residual toxicity from previous treatment, uncontrolled brain metastases or nonneoplastic central nervous system disease, active hepatitis B or C infection, human immunodeficiency virus infection, electrocardiographic evidence of acute ischemia or new conduction system abnormalities, myocardial infarction within 6 months of enrollment, major surgery within 4 weeks of enrollment, or any other intercurrent illness that could potentially interfere with completion of the study protocol. Patients who had been previously treated with gemcitabine and required a dose reduction because of drug-related toxicity were excluded. Use of acceptable birth control for all fertile participants was required, and women who were pregnant or breast feeding were excluded.",in cycle 1,NA
17575229,NA,Combination,No,Advanced Solid Tumors,"Chemonaive adult patients with inoperable, locally advanced, or metastatic cancer, for whom gemcitabine and cisplatin therapy was an acceptable therapeutic option, were eligible for this study.Tumors were cytologically or histologically confirmed.Other eligibility criteria included: Karnofsky performance status >=70; life expectancy >3 months; measurable or evaluable disease.An adequate method of birth control had to be used, and women of childbearing potential had to have a negative urine pregnancy test","Patients were excluded if they had received prior treatment with chemotherapy or bortezomib; had received treatment with monoclonal antibodies, other biological therapies, or investigational agents V4 weeks before enrollment; underwent major surgery V4 weeks before enrollment; underwent prior extensive radiation therapy (>25% of bone marrow reserve); underwent radiation therapy within 4 weeks before enrollment (except for limited radiation of bone metastases with 1-2 fractions); had inadequate bone marrow and/or organ function, defined as creatinine clearance <60 mL/min (calculated according to Cockcroft-Gault formula), total bilirubin >=2 times the upper limits of normal, aspartate transaminase >=3 times the upper limits of normal, alanine transaminase z3 times the upper limits of normal, hemoglobin <= 9.0 g/dL, platelet count <100 X 109/L, absolute neutrophils count <1.5 X 109/L; had grade >=2 peripheral neuropathy or grade >=3 hearing loss as defined by National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0; had symptomatic central nervous system metastases (corticosteroid use was allowed to suppress symptoms); were hypersensitive for boron or mannitol; had serious uncontrolled medical disease, active infection, significant cardiovascular disorder, or any psychiatric illness or other disorders that could potentially impair compliance",in cycle 1,NA
18432260,NA,Combination,No,advanced and refractory multiple myeloma,"Patients over the age of 17 years with MM that had relapsed after or had proven refractory to at least 2 lines of prior therapy were candidates for this study. Serum M-protein level > 1.0 g/100 ml measured by serum protein electrophoresis or urinary M-protein excretion > 200 mg/24 h or bone marrow plasmacytosis of > 30% was required for enrollment. Patients had to have a performance status of <= 2 as per Southwest Oncology Group (SWOG) criteria, unless a higher scale was due to MM-related bone destruction","Except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, patients had to be cancer-free for at least 3 years. Hematopoietic function had to be preserved as defined by levels of neutrophils exceeding 750/mm3 and platelets exceeding 25 000/mm3. Preexisting > 2 grade neurotoxicity as well as active infection requiring antibiotics, serious and interfering medical or psychiatric conditions, pregnancy or breast-feeding were exclusion criteria",during the first 2 cycles,NA
18640031,NA,Combination,No,advanced solid tumours,"Eligibility criteria were a histologically or cytologically confirmed diagnosis of solid tumours, progressive disease, ECOG performance status <= 1, age >= 18 and <= 70 years, adequate haematological, liver and renal function (bilirubin within UNL; alkaline phosphatase <= 1.5 X UNL; ALT, AST <= UNL or <= 2.5 X UNL in case of liver metastases; albumin >= 2.5 mg/dl; creatinine <= UNL), life expectancy of P 3 months. A maximum of two prior chemotherapy regimens for advanced disease was allowed in the dose escalation phase, one in the expansion phase. Disease measurability according to Response Evaluation Criteria in Solid Tumours (RECIST 6) was required only for patients in the expansion phas","Distinctive exclusion criteria of the study were resistance to taxane (defined as progression of diseasewhile on treatment or within 6 months from the end of treatment), pre-existing peripheral neuropathy > grade 1, prior radiation to > 35% of bone marrow, presence of cirrhosis or active or chronic hepatitis, known history of allergy to cremophor, mannitol or boron",in the first cycle,NA
18645194,NA,Combination,No,Relapsed and Refractory Multiple Myeloma,"The eligibility criteria included: confirmed diagnosis of relapsed/refractoryMM; age>=18 years;>= one prior chemotherapy regimen; Eastern Cooperative Oncology Group performance status 0 to 2; serum creatinine level <= 186 umol/L; hemoglobin >= 80 g/L, absolute neutrophil count (ANC) >= 1.0 X 109/L, and the ability to maintain a platelet count >= 50 X 109/L; no serious comorbid illness or other malignancy within 3 years (excluding skin cancer or cervical cancer in situ); and informed consent. After one patient who was given granulocyte colonystimulating factor (G-CSF) to bring up his ANC to be eligible for the trial developed grade 3 neutropenia during cycle 1, the protocol was modified to exclude the use of G-CSF within 2 weeks of study entry.",NA,during cycle 1,NA
18327587,NA,Combination,No,refractory solid tumors,"Patients with histologically or cytologically conWrmed solid tumor malignancies refractory to at least one conventional therapy, or for whom no standard therapy existed, were candidates for this study. Eligibility criteria included age >18 years; Karnofsky performance status >60%; a life expectancy of ¸8 weeks; no major surgery, radiotherapy, or chemotherapy within 21 days of study entry; adequate hematopoietic (hemoglobin >8.0 g/dL, ANC >1,500/uL, and platelets >50,000/uL), hepatic (total bilirubin <1.2 mg/dL and transaminases <2.5 times the upper limits of normal), and renal function (creatinine ·2.5 mg/dL); adequate cardiovascular function as deWned by no evidence of ischemia on electrocardiography (ECG) and a left ventricular ejection fraction (LVEF) >45%; not pregnant or nursing and amenable to use appropriate contraception; and no other coexisting medical problems of suYcient severity to limit full compliance with the study or which could cause undue risk. ","Patients were ineligible if they had a prior cumulative exposure to doxorubicin >400 mg/m2, or hyper-sensitivity to PLD, or had uncontrolled active infections, or were known to be human immunodeWciency virus seropositive, or have active viral hepatitis.",on the first cycle,NA
18322686,NA,Combination,No,advanced cancer,"Inclusion criteria included Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, age greater than or equal to 18 years and presence of measurable or evaluable disease by the response evaluation criteria in solid tumors (RECIST) criteria . Patients had no signs of brain metastases, preexisting grade 2 or higher peripheral neuropathy, serious active infection, or prior cumulative doxorubicin exceeding 280 mg/m2. Patients had not received any chemotherapy or radiation therapy within 4 weeks prior to entering this study. Patients had adequate organ function defined as an absolute neutrophil count of at least 1,500/mm2, platelets of at least 100,000/mm3, total serum bilirubin within normal limits, serum creatinine less than 1.5 mg/dl or creatinine clearance greater than 60 ml/min and left ventricular ejection fraction (LVEF) greater than or equal to 45%.",NA,during cycle 1,NA
18809314,NA,Combination,No,advanced colorectal cancer,"Patients aged P18 years with histologically proven advanced/metastatic colorectal cancer, amenable to the first-line treatment with oxaliplatin and 5-FU/LV, were eligible for the study. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and an adequate bone marrow, hepatic and renal function defined as absolute neutrophil count (ANC) >= 2000 X 109/l, platelets >= 100,000 X 109/l, bilirubin <= 1.5 mg/dl, alkaline phosphatase and serum transaminases <= 2.5 times the upper limit of reference range (ULRR) in the absence of liver metastases or <5 times the ULRR in the presence of liver metastases, serum creatinine <= 150 lmol/l (1.7 mg/dl). ","Patients were ineligible if having received prior chemotherapy for advanced disease; non-oxaliplatin-based adjuvant chemotherapy was allowed if completed more than 6 months before registration.  Additional exclusion criteria included the presence of pre-existing neuropathy Pgrade 1; evidence of brain metastases; prior radiotherapy or major surgery (within prior 4 and 2 weeks, respectively); history or the presence of malignancies at other sites (with the exception of cone biopsied carcinoma of the cervix and adequately treated basal or squamous cell skin carcinoma); unstable systemic diseases; active uncontrolled infections and electrocardiogram (ECG) changes with the history of ischemic heart disease in the past 6 months",at cycle 1,NA
19183191,NA,Combination,No,relapsed multiple myeloma,"Patients with relapsed MM after >= 1 prior treatment and a minimal response of >= 3 months after their last line of therapy were eligible for enrollment. Additional eligibility criteria included an Eastern Cooperative Oncology Group performance status of <3, measurable serum or urinary paraprotein, platelet count >100 · 109/l, absolute neutrophil count >1.5 X 109/l, and serum creatinine <170 lmol/l.",Patients with peripheral neuropathy grade ‡2 or patients receiving any investigational drugs within 14-d of enrollment were not eligible for this trial.,during the first cycle of therapy,NA
19401697, NCT00622674,Combination,No,solid tumours,"All patients were X18 years old with histologically confirmed advanced solid cancer refractory to standard treatment and at least one EGFR-positive tumour specimen determined by immunohistochemical staining. Expression of EGFR was assessed by pathologists at the University of Minnesota. An ECOG performance status of 0 –1 and a life expectancy of at least 12 weeks were required. Earlier systemic chemotherapy, immunotherapy or biological therapy was allowed, except for earlier treatment with bortezomib and/or cetuximab. Patients were required to complete earlier radiation or systemic therapy at least 14 days before study entry and at least 30 days for investigational agents. Any grade 41 toxicity had to be resolved before study enrolment. Adequate organ function within 14 days of study enrolment was required, including adequate bone marrow reserve: absolute neutrophil count (ANC) X1.5 X 109 l -1, platelets >100 X 109 l -1 and haemoglobin >9 g per 100 ml, and hepatic function: bilirubin <1.5 time the upper limit of normal ( X ULN), alkaline phosphatase (ALP), aspartate transaminase (AST) and alanine transaminase (ALT) <3.0 X ULN (ALP, AST and ALT <5 X ULN was acceptable if liver had tumour involvement). A calculated or measured creatinine clearance of >30 ml min-1 was required within 14 days before enrolment. Disease status had to be that of measurable or nonmeasurable disease, as defined by RECIST criter",NA,in cycle 1,NA
21252987, NCT00477542,Combination,No,high-risk and refractory acute leukemia,"Patients were eligible if they had acute myeloid leukemia or acute lymphoblastic leukemia that was primary refractory, relapsed and refractory (>5% bone marrow blasts or extramedullary disease), or who were in second or subsequent complete remission (CR). Patients also had to be 18–60 years old, have a Karnofsky performance status >=70%, a left ventricular ejection fraction >45%, DLCO >50%, creatinine clearance >60 ml/min/1.73 m2, and serum bilirubin, aspartate aminotransferase and alanine aminotransferase (ALT) levels <2 X upper limits of normal. Donors were eligible if they were related and matched at 5 or 6 of the 6 human leukocyte antigen-matched loci (human leukocyte antigen-A, -B and -DRB1), or unrelated and 10 of 10 antigenmatched (human leukocyte antigen-A, -B, -C, -DRB1 and-DQB1) by high-resolution typing.","Patients were excluded if they had a previous HSCT, central nervous system leukemia, or if they were seropositive for HIV.",until day +30,NA
22080439,NA,Single Drug,No,Relapsed/Refractory CD30-Positive Hematologic Malignancies,"Eligible patients were 12 or more years of age and had relapsed or refractory, histologically confirmed CD30-positive hematologic malignancies with bi-dimensional measurable disease of at least 1.5 cm by radiographic evaluation. Patients with Hodgkin lymphoma had received systemic chemotherapy as induction therapy for advanced-stage disease or salvage therapy after initial radiotherapy for early-stage disease and had previously undergone ASCT unless they were ineligible for or had declined treatment. Patients with other CD30-positive malignancies had previously failed or were refractory to front-line chemotherapy.","Patients were excluded if they had a current diagnosis of primary cutaneous ALCL; however, patients who had transformed to systemic ALCL were eligible. Furthermore, patients with a history of alloSCT or prior treatment with any anti-CD30 antibody were also ineligible.",during cycle 1,NA
22179664,NCT00195260,Single Drug,No,Advanced Solid Tumors,"Patients with advanced histologically or cytologically confirmed solid tumor malignancies were eligible for this study. Patients had to be at least 18 years of age and have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to1 or Karnofsky performance status of at last 80 (amendment 5), measurable disease as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST, version 1.0; ref. 16), and adequate organ function","Patients were excluded if they could not swallow the bosutinib capsules or had impaired lung, liver, or central nervous system function; a major cardiac condition; or left ventricular ejection fraction <=50%. After the first 25 patients in part 1 were treated with bosutinib, patients who were on warfarin were excluded because of elevated coagulation tests (increased international normalized ratio) for 2 of 3 patients on warfarin. In part 2 of the study, patients on warfarin were required to reduce their warfarin dose by 50%, initially, and further dose modifications were made as required after the first 2 weeks of bosutinib treatment",in the first cycle,NA
22198540,NA,Combination,No,hematologic malignancy or myeloproliferative disorder,"Patients were eligible if they had a diagnosis of hematologic malignancy or myeloproliferative disorder, were between the ages of 16 and 65, had a related or unrelated donor compatible for 10/10 or 9/10 HLA A, B, or C, DRB1, and DQB1 alleles (the protocol was later amended to allow donors compatible for 8/8 or 7/8 HLA A, B, or C, and DRB1 loci, given the reported lack of correlation between DQ mismatches and adverse outcomes) , Karnofsky performance status 70% to 100%, diffusing capacity of the lung for carbon monoxide (DLCO) greater than 50% of predicted values, left ventricular ejection fraction greater than 45%, creatinine clearance greater than or equal to 50 mL/min, total bilirubin less than or equal to 2 mg/dL, and serum transaminases less than two times the institutional upper limit of normal.","Excluded were patients with active infection, central nervous system (CNS) malignancy, human immunodeficiency virus or hepatitis seropositivity, history of chronic hepatitis, pregnancy or lactation, current use of metronidazole or acetaminophen, prior treatment with gemtuzumab ozogamicin, prior HCT (either allogeneic or autologous), prior chest or abdominal irradiation with greater than 1,800 cGy, history of myocardial infarction or coronary artery disease less than 6 months before enrollment, congestive heart failure, peripheral vascular disease, untreated thoracic or abdominal aneurysm, history of cerebrovascular accident, dementia, connective tissue/rheumatologic disorders, uncontrolled diabetes, history of prior malignancy (excluding nonmelanoma skin or cervical carcinoma after curative resection) less than 5 years from enrollment, or history of renal failure requiring renal replacement therapy.",within 100 days posttransplantation,NA
24239220,NCT01060904,Combination,No,newly diagnosed Hodgkin’s lymphoma,"Eligibility criteria for patients included being newly diagnosed with Hodgkin’s lymphoma, treatment-naive, CD30-positive with histologically confi rmed stage IIA bulky disease or stage IIB–IV disease, having adequate organ function and an Eastern Cooperative Oncology Group performance status of two or less. Patients must be adults (18–60 years old) who had bidimensional, measurable disease of at least 1·5 cm at the longest axis  by radiographic technique.","Exclusion factors included  known cerebral or meningeal disease, symptomatic  cardiac, pulmonary, and neurological diseases, or known  hypersensitivity to any ingredient in the drug formulation  of brentuximab vedotin or ABVD.",during the first treatment cycle of 28 days,NA
25776193,NA,Combination,No,Autologous Stem Cell Transplantation in Acute Myeloid Leukemia,"Eligible patients included adults aged 18 to 69 years deemed appropriate candidates for postremission consolidation with high-dose chemotherapy and autologous stem cell rescue per our institutional standards, including Eastern Cooperative Oncology Group performance status <= 2 and normal organ function (serum creatinine < 2.0 mg/dL, total bilirubin < 2.0 mg/dL, aspartate aminotransferase and alkaline phosphatase < 3 times the upper limit of normal, cardiac ejection fraction >= 40%, and DLCO >= 40% of predicted).","Exclusion criteria included acute promyelocytic leukemia, previous myeloproliferative neoplasm, active central nervous system leukemia, and uncontrolled intercurrent illness including active infections requiring antimicrobial therapy.",NA,NA
26210442,NCT00448357,Combination,No,"advanced, refractory, or high-risk hematologic cancers","Histologically confirmed diagnosis of any of the following:Chronic lymphocytic leukemia or prolymphocytic leukemia Chemotherapy-refractory or advanced disease after ≥ 3 prior treatments Chronic myelogenous leukemia Diagnosis based on t(9;22) or related t(9;12) cytogenetic abnormalities AND characterized by elevated white blood counts (WBC) in peripheral blood or marrow Patients with progressive disease on imatinib mesylate or other protein tyrosine kinase inhibitors; less than a major cytogenetic or fluorescent in situ hybridization (FISH) complete response (CR) after a minimum of 6 months of targeted therapy; or less than a complete FISH or cytogenetic response after 12 months of targeted therapy are eligible Patients with other cytogenetic abnormalities, such as t(9;12), that are associated with an aggressive clinical course are eligible Non-Hodgkin's lymphoma (NHL) or Hodgkin's lymphoma Any World Health Organization (WHO) classification histologic subtype allowed Must have advanced disease as defined by relapse after initial CR or failure to achieve CR OR deemed to have less than a 30% likelihood of durable response with an autologous stem cell transplant Refractory low-grade NHL histologies or any intermediate or aggressive large cell or mantle cell lymphoma allowed Acute myeloid leukemia (AML) High-risk disease in first CR (CR1) OR evidence of any recurrent disease beyond CR1 High-risk individuals are those requiring more than 1 course of induction therapy to achieve remission; those with extra-medullary disease at presentation; or those with high-risk cytogenetic abnormalities (abnormalities of chromosomes 5, 7, 2, trisomy 8, or 3) or > 2 cytogenetic abnormalities. Multiple myeloma. Myelodysplastic syndromes (MDS) Must have MDS defined by WHO criteria with > 5% blasts or high-risk cytogenetic abnormalities (abnormalities of chromosomes 5, 7, 2, trisomy 8, or 3). Acute lymphoblastic leukemia (ALL) High-risk disease in CR1 OR beyond CR1 High-risk disease includes the following: t(9;22) or t(4;11); WBC > 30,000/mm³ at presentation; non-T-cell phenotype; or more than 30 years of age. Myelofibrosis/agnogenic myeloid metaplasia. Patients must be transfusion dependant or have evidence of evolving AML as evidenced by an excess of blasts or a state of marrow failure/fibrosis. Myeloproliferative disorders with advanced disease (e.g., progressive or spent phase polycythemia vera, myelofibrosis, or essential thrombocythemia). Any of the following categories of donors are acceptable*: Human Leucocyte Antigen (HLA)-identical or 1 antigen-mismatched sibling (5/6, 6/6, or 8/10) donor. Minimal serologic typing required for class I (A, B); molecular typing required for class II (DRB1). 8/10 matched unrelated donor (MUD). Molecular analysis at HLA-A, -B, -C, -DRB1 and -DQB1 (8/10 match) by high resolution typing is required 5/6 MUD. Molecular analysis at HLA-A, -B, and -DRB1 required Note: *No syngeneic donors. PATIENT CHARACTERISTICS: Performance status 0-2. Bilirubin ≤ 2 times upper limit of normal (ULN). Aspartate aminotransferase (AST) ≤ 2 times ULN. Creatinine clearance ≥ 50 mL/min. Not pregnant or nursing. Negative pregnancy test. Fertile patients must use effective contraception. Diffusing capacity of the lungs for carbon monoxide (DLCO) > 60% with no symptomatic pulmonary disease. Left ventricular ejection fraction (LVEF) ≥ 50% by multigated acquisition (MUGA) scan","Uncontrolled or severe cardiovascular disease, pulmonary disease, or infection that, in the opinion of the treating physician, would make this study unreasonably hazardous to the patient Other serious illness that would limit survival to < 2 years Psychiatric condition that would preclude study compliance Uncontrolled diabetes mellitus or active serious infection Active second malignancy except for nonmelanomatous skin cancer Known hypersensitivity to E. coli-derived products HIV positivity",NA,NA
28473406,NCT01940796,Single Drug,No,steroid-refractory acute graft-versus-host disease (SR-aGVHD),"Patients were thus eligible if they failed steroids plus an additional agent usedin sequence or startedtogether as initial therapy. Agents used for GVHD prophylaxis were allowed to be continued and increased to target trough levels. Use of topical creams, oral nonabsorbable steroids and ursodiol were all permitted. For patients who met eligibility for recurrent GVHD upon tapering of steroids,steroids were allowed to be increased to a maximum of their initial baseline starting dose","Exclusion criteria included the presence of acute/chronic GVHD overlap syndrome, significant organ dysfunction, and use of .1 systemic agent beyond corticosteroids for treatment of aGVHD",NA,NA
31619057,NA,Combination,No,Multiple Myeloma,"Patients aged 65 years or older irrespective of renal function with SWOG performance of 0–2 and symptomatic MM at the time of initial clinic visit at the Huntsman Cancer Institute requiring treatment were enrolled into the study. Patients needed to demonstrate adequate lung function defined as >= 50% on FEV1, FVC, and DLCO and adequate cardiac function >= 40% LVEF on Echo or MUGA scan to be eligible for the study.",Patients with a history of chronic obstructive or restrictive pulmonary disease were excluded from the study. Patients were excluded if they had transaminases >1.5 times the upper limit of normal and/or direct bilirubin >1.5 times the upper limit of normal; were HIV positive or had active Hepatitis B or Hepatitis C infection; had a prior autologous or allogeneic bone marrow transplantation; had < 3 million CD34 cells/kg stored; were pregnant or nursing; had a prior malignancy that affects their life expectancy,within 30 days after infusion of the last dose of busulfan,NA
33991360,NCT02311998,Combination,No,relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia,"Patients needed to be older than 18 years, have Eastern Cooperative Oncology Group performances status ≤2, CD22 expression ≥20% on blasts, adequate end organ function with serum alanine (ALT) and aspartate aminotransferase (AST) ≤3x upper limit of normal, serum bilirubin ≤2.0 mg/dL and serum creatinine ≤2.0 mg/dL","Patients were excluded if they had T315I mutation, prior exposure to anti-CD22 directed therapy, active liver disease, hepatitis, or cirrhosis, allogeneic stem-cell transplantation (allo-SCT) within prior 100 days, active graft-versus-host disease (GvHD), active central nervous system (CNS) involvement by leukemia, or uncontrolled comorbidities or infections.",NA,NA
34614506,NCT03613532,Combination,No,"high risk acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and MDS/myeloproliferative neoplasms (MPN) undergoing transplant","Eligible patients were at least 18 years old and had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2, adequate organ function, an available 8 of 8 HLA-matched related or unrelated donor with peripheral blood stem cells (PBSC) as source, and a diagnosis of one of the following: (1) high risk AML defined as adverse risk per European LeukemiaNet12, secondary (history of antecedent hematologic malignancy or therapy-related) or secondary-type ontogeny13, or persistent measurable residual disease by multiparameter flow cytometry (>= 0.1%) despite morphologic remission14,15; (2) high risk MDS defined as IPSS intermediate-2 or higher at diagnosis, therapy related, or mutation in TP53 or in the RAS pathway2; or (3) high risk chronic myelomonocytic leukemia or MDS/MPN-unclassifiable defined by the presence of trisomy 8, chromosome 7 abnormalities, or complex karyotype16 or a mutation in ASXL1. Due to recent frontline venetoclax-combination therapy approval in elderly AML, the protocol was subsequently amended to allow prior venetoclax exposure.Patients with MDS or MDS/MPN were required to enter study with 10% marrow blasts and those with AML were required to be in CR/CRi (<5% marrow blasts) by morphological exam. Persistent flow or NGS MRD on screening marrow was allowed but not required. ",Patients with a history of prior allo-HCT or eligible to receive a myeloablative transplant were excluded. ,from the first dose of venetoclax (day -8) to day +28 post-transplant (37 days),NA
9537208,NA,Combination,No,Refractory Malignancies,"Patients were required to have advanced, histologically confirmed urothelial, lung, or breast carcinoma or lymphoma, with manifestations of progressive disease despite therapy. The protocol was subsequently modified to accept all histologically confirmed malignancies refractory to curative therapy. Patients must have received no more than one prior systemic chemotherapy for metastatic disease. Patients who had breast cancer could have received one adjuvant regimen and one regimen for metastatic disease. Patients could not have received prior treatment with paclitaxel or gallium nitrate. Their last major surgery, chemotherapy, or radiotherapy had to have occurred more than 4 weeks earlier and they had to be recovered from all toxicity. Patients must have been at least 6 weeks from treatment with mitomycin C or nitrosoureas. All patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. Patients must have had adequate measurements for hematologic (granulocytes ≥ 1500 mm3 and platelets ≥ 100,000 mm3); hepatic (aspartate aminotransferase ≤ 3 × normal and bilirubin ≤ 1.6 mg/dL); and renal function (serum creatinine ≤ 1.6 mg/dL). They were also required to be without brain metastases. Women of childbearing potential were required to use an appropriate form of contraception during the period of study. ",Pregnant and lactating patients were ineligible,during first treatment cycle,NA
17317832,NA,Combination,No,Advanced Solid Tumors,"Patients with histologically or cytologically confirmed solid tumors that were metastatic or unresectable and for which standard curative or palliative measures did not exist were eligible for the trial. The last chemotherapeutic or radiation treatment was at least 4 weeks (6 weeks for nitrosoureas or mitomycin C) before trial enrollment. Other criteria included age >= 18 years, Eastern Cooperative Oncology Group performance status <= 2, estimated life expectancy >12 weeks, no central nervous system involvement, adequate bone marrow function (neutrophils >= 1,500/AL, hemoglobin >= 8.0 g/dL, and platelets >= 100,000/AL), adequate hepatic function (serum bilirubin V upper limit of the reference range; serum aspartate aminotransferase and alanine aminotransferase <= 2.5 X upper limit of the reference range), and adequate renal function (creatinine <= 1.5 upper limit of the reference range or creatinine clearance >=60 mL/min).","The study excluded patients unable to receive oral medications; patients with brain metastases; patients with history of hypercalcemia or genitourinary stones; patients on digoxin, thiazide, calcium supplements, and supraphysiologic doses of glucocorticoids (exceeding the equivalent of 15 mg of hydrocortisone per day); and patients with prior allergic reaction to calcitriol or gefitinib. HIV-positive patients were not eligible because of possible pharmacokinetic interaction with antiretroviral drugs.",During cycle 1 (first 4 weeks of treatment),NA
17066293,NA,Combination,No,solid tumors,"Eligible patients had advanced solid tumors that had failed at least one prior therapy. Patients with prostate cancer with a rising PSA after therapy with curative intent or failing hormonal therapy were also eligible. For patients with tumors other than prostate cancer, the intent was to enroll patients for whom standard therapies were no longer available. Because the number of standard therapies varies considerably among tumor types, the number of prior therapies required beyond one was not speciWed. The more liberal entry criteria for prostate cancer patients reXected the more extensive prior experience with high-dose calcitriol in this disease. Other inclusion criteria included: ECOG performance status <= 2, life expectancy >=3 months, white blood cell count >= 3,000/mm3, neutrophil count >= 1,500/mm3, platelet count >= 100,000/mm3, serum creatinine <1.5 mg/dL, albumin >3.0 gm/dL, serum calcium <upper limit of normal (ULN).","Patients were excluded for uncontrolled heart failure, a history of cancer-related hypercalcemia, known hypercalcemia, or vitamin D toxicity, known hypersensitivity to calcitriol, kidney stones within 5 years, or any signiWcant active medical illness that would preclude protocol treatment in the opinion of the investigator. Additionally, patients were not eligible if they had investigational therapy within the past 30 days, calcitrio within 3 months, or concurrent active treatment for cancer (except for androgen deprivation for prostate cancer). The following concomitant medications were excluded: calcium- or magnesium-containing antacids, bile-resin binders, calcium supplements, and ketoconazole or related compounds.",within 7 days,NA
19396601,NA,Combination,No,advanced solid tumors,"Only patients with histologically conWrmed metastatic or unresectable solid tumors for which there was no standard curative or palliative treatment were enrolled in the study. Patients had to be over 18 years of age, with Eastern Cooperative Oncology Group performance status ·2, estimated life expectancy >12 weeks, and oV-cancer chemotherapeutic or radiation treatment for at least 4 weeks (6 weeks for nitrosoureas or mitomycin C). Adequate bone marrow (neutrophils >= 1,500/ul, hemoglobin ¸8.0 g/dL, and platelets >= 100,000/ul), hepatic function (serum bilirubin ·upper limit of the reference range, serum AST and ALT <= 2.5 X upper limit of the reference range), and renal function (creatinine <= 1.5 upper limit of the reference range or creatinine clearance >= 60 ml/min) were a prerequisite for enrollment in the study.","Patients unable to take oral medications; with brain metastases; history of hypercalcemia or genitourinary stones; patients on digoxin, thiazide, calcium supplements, supra-physiologic doses of glucocorticoids (exceeding the equivalent of 15 mg of hydrocortisone/day), and/or allergic to calcitriol or geWtinib were excluded from study. HIV-positive patients were not eligible because of possible pharmacokinetic interaction with antiretroviral drugs. ",on cycle 1 (first 4 weeks of treatment),NA
21606412,NCT00215605,Single Drug,No,Medullary Thyroid Cancer,"The study enrolled adult patients with histologically confirmed solid tumors or lymphomas that were metastatic or unresectable who were no longer responding to conventional therapies or who had disease for which no standard therapy exists. All patients had an Eastern Cooperative Oncology Group performance status score of 0 to 2 and life expectancy longer than 3 months. Additional parameters for study entry included adequate neutrophil counts (>= 1,500/uL), platelets (>= 100,000/uL), hemoglobin (>= 9g/dL), bilirubin (>= 1.5 mg/dL), serum creatinine (< 1.5 mg/dL), and ALT and AST (<=2.5 X upper limit of normal with no liver involvement or <= 5 X upper limit of normal with liver involvement).","Patients were ineligible if they had received chemotherapy or immunotherapy within 4 weeks, nitrosourea therapy within 6 weeks, or radiotherapy or investigational agents within 30 days of the first dose of cabozantinib. Patients with brain metastases, uncontrolled intercurrent illness, or known HIV infection were ineligible.",NA,NA
22975213,NA,Single Drug,No,advanced solid tumours,"Patients (18–70 years of age) with histologically proven cancer at first diagnosis were eligible, provided that the neoplastic disease was advanced and either refractory to conventional treatment or for which no standard therapy existed. Patients were required to have a life expectancy of at least 12 weeks, an Eastern Cooperative Oncology Group performance status of 0–2 and not to have received previous anticancer therapy (radiotherapy or chemotherapy) for at least 4 weeks. Prior paclitaxel or docetaxel therapy was allowed. Patients were required to have recovered from the toxic effects of any previous treatment (current grade 61, except for alopecia, for which any grade was permitted). Patients were also required to have adequate organ function, which was indicated by neutrophils >= 2.0 X 109/l; platelets >= 100 X 109/l, serum creatinine <120 lmol/l (if values were borderline, the creatinine clearance [CL] had to be P60 ml/min), total bilirubin within the normal limits, and alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase <= 2.5 times the upper limit of normal for the treating institution.","Patients with haematologic malignancies or symptomatic brain metastases, patients receiving concurrent treatment with other experimental drugs, any anticancer therapy or corticosteroids (with the exception of chronic treatment), patients with prior extensive radiotherapy (>20% of bone marrow area) and pregnant or breastfeeding women were ineligible. Patients were also ineligible if they had another serious medical condition that could hamper participation in the study. A further exclusion criterion was receipt of more than two prior chemotherapy regimens for advanced disease, more than two regimens containing mitomycin C or nitrosoureas or any prior intensive therapy with autologous stem cell rescue.",during the first cycle,NA
23435876,NA,Combination,No,advanced non-small-cell lung cancer,"Key inclusion criteria included histologically or cytologically confirmed metastatic (pleural metastasis or IV) nonsmall-cell lung cancer (NSCLC) in patients[18 years who were chemotherapy naı¨ve with evaluable or measurable disease (for phase II) defined by the Response Evaluation Criteria in Solid Tumors (RECIST), Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1, with adequate bone marrow function (neutrophils >1,500/lL, hemoglobin > 10 g/dL and platelets[100,000/lL), adequate hepatic function (total bilirubin within the upper limit of the institutional normal range, transaminases (SGOT or SGPT) <= 1.5 times the upper limit of the institutional normal range), adequate renal function (creatinine within the upper limit of the institutional normal range; creatinine clearance >= 50 mL/min). Patients had to have normal cardiac function or compensated heart disease with no history of unstable angina or CHF in the 6 weeks prior to study entry. Palliative radiation was permitted as long as the amount of bone marrow exposed was not >10 %. Palliative radiation to brain metastasis was allowed as long as 2 weeks had elapsed following whole brain radiation; no wait was required for stereotactic radiosurgery. Women could not be pregnant or lactating. The expected life expectancy at study enrollment of least 3 months was required. Prior adjuvant chemotherapy use was permitted.","Key exclusion criteria included presence of any grade >= 2 peripheral neuropathy or history of severe hypersensitivity reaction to 1,25-D3, cisplatin or docetaxel or other drugs formulated with polysorbate 80, hypercalcemia (serum albumin corrected calcium > 10.7 mg/dL), history of renal/bladder stones in the previous 10 years, single kidney or uncontrolled heart disease. Concurrent use of calcium supplements, thiazides, digoxin, glucocorticoids, phenytoin, barbiturates, rifampin, carbamazepine, phenobarbital or St John’s Wort was not permitted.",during the first treatment cycle,NA
24099585, NCT01755390,Single Drug,No,advanced solid tumours,"The study included patients (18–70 years of age) with progressive, histologically proven, advanced neoplastic disease that was either refractory to conventional treatment or for which no standard therapy existed. Patients were required to have adequate organ function, a life expectancy of ≥ 12 weeks and Eastern Cooperative Oncology Group performance status 0–2. Prior therapies were permitted providing they had been terminated a minimum of 4 weeks prior to the start of the study (depending on the therapy), and the patient had fully recovered from any toxic effects of treatment. Prior paclitaxel and/or docetaxel treatment was permitted providing there was no residual evidence of taxane toxicity (exceptions included alopecia [any grade] or peripheral neuropathy [not exceeding Grade 1]).","Patients with haematological malignancies or symptomatic brain metastases were ineligible, as were pregnant or lactating women and those receiving concurrent treatment with other experimental drugs, any anticancer therapy or corticosteroids (unless as chronic treatment). Patients were also ineligible if they had another serious medical condition, current peripheral neuropathy of any origin or a history of severe allergic reaction to docetaxel or paclitaxel. Patients who had received previous extensive radiotherapy (> 20% of bone marrow area), prior intensive therapy with autologous stem cell rescue, more than two prior chemotherapy regimens for advanced disease or more than two regimens containing mitomycin C or nitrosoureas were also excluded from the study.",at the first cycle,NA
24488323,NA,Combination,No,castration‑resistant prostate cancer,"Patients who had not undergone surgery for >4 weeks prior to registration for the study and fulfilled the following eligibility criteria were included: histologically or cytologically proven prostate adenocarcinoma was refractory to hormone therapy (prior castration by orchiectomy and/or chemical castration and documented progression of disease or relapse) or docetaxel, age between 20 and 74 years, a life expectancy of ≥12 weeks, and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0–2. ","Patients with a serum creatinine level of >1.5 mg/dL, compromised liver function (serum bilirubin/alanine transaminase [ALT]/aspartate transaminase [AST] level of >1.5 times the upper normal limit of the institutional norm), neutrophil count of <2.0 × 109/L, platelet count of <100 × 109/L, or hemoglobin level of <9.0 g/dLwere not eligible. Patients were excluded if they had known brain or leptomeningeal involvement, previously undergone extensive radiotherapy, peripheral neuropathy of ≥grade 2 according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 , other serious diseases including congestive heart failure, angina pectoris, myocardial infarction within 1 year from the time of study registration, uncontrolled hypertension or arrhythmias, significant neurologic or psychiatric disorders such as dementia and seizures, active infections, uncontrolled peptic ulcer, unstable diabetic mellitus, or other contraindications for the use of corticosteroids. Patients with active secondary cancer, those undergoing concurrent treatment with another anticancer chemotherapeutic regimen, or those receiving radiotherapy within 28 days prior to patient registration were also excluded. Patients previously treated with a cumulative docetaxel dose of <225 mg/m2 were also excluded. Patients with a severe immune deficiency, including an AIDS-related illness or active varicella zoster infection, or who were positive for the anti-HCV antibody were not eligible. Patients with a history of a severe hypersensitivity reaction or intolerance to prednisolone, a severe allergic reaction to a taxane, a severe hypersensitivity reaction (≥grade 3) to drugs containing polysorbate 80, or alcoholic hypersensitivity were ineligible",in Cycle 1,NA
25013124,NA,Combination,No,Metastatic Castration Resistant Prostate Cancer,NA,NA,during the 3 weeks following the initial administration,NA
25486878,NCT01497964,Single Drug,No,advanced gastric cancer,"Eligible patients were 18–85 years of age, with histologically and cytologically confirmed unresectable or metastatic gastric adenocarcinoma, including adenocarcinoma of the gastro-esophageal junction, that had failed two prior chemotherapy regimens. Prior chemotherapy with at least one of the following was required: 5-fluorouracil or derivatives, taxanes, platinum compounds or irinotecan. Patients were required to have an Eastern Cooperative Oncology Group performance status ≤1, a life expectancy ≥2 months and adequate hematologic and organ function. ","Patients were excluded if they had received prior cabazitaxel treatment, any anticancer therapy (surgery, chemotherapy, targeted agents, investigational agents) within 4 weeks prior to enrollment in the study (6 weeks for mitomycin-containing regimens), prior radiation therapy within 6 weeks prior to enrollment (except for palliative radiation for local pain control) or treatment with hematopoietic growth factors including granulocyte colony-stimulating factor (G-CSF) within 2 weeks prior to enrollment.",in Cycle 1,NA
26020806,NCT01001221,Combination,No,metastatic or unresectable advanced solid malignancies,"Adult patients with a histologically or cytologically confirmed advanced, refractory solid malignancy that was metastatic or unresectable, and for which standard treatment did not exist, were eligible for this study. ","Exclusion criteria included: Eastern Cooperative Oncology Group (ECOG) performance status (PS) of at least 2, anticipated need for a major surgical procedure or radiation therapy during the study, prior cabazitaxel treatment within 2 years, or a history of grade 3–4 hypersensitivity to taxanes, polysorbate-80, or their derivatives. Patients with any clinically significant toxic effect (excluding alopecia) of prior therapy that had not resolved to grade 1 or lower according to NCI-CTCAE version 3.0 , those who had not completed prior chemotherapy, biologic therapy, targeted noncytotoxic therapy for at least 3 weeks, or radiotherapy for at least 4 weeks before registration; and those who had inadequate organ function (bone marrow, hepatic, renal) were also excluded.",during cycle 1,NA
27439894,NCT01663272,Combination,No,advanced pancreatic cancer,"Patients 18 years and older with pathologically confirmed, locally advanced or metastatic PDAC were eligible. Study participants were required to have good performance status (ECOG 0 or 1) and adequate organ function [absolute neutrophil count ≥1500/mm3, platelets ≥100,000/mm3, hemoglobin≥9 g/dL, serum creatinine ≤1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥60 mL/min, total serum bilirubin ≤1.5 x ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN if no disease involvement of the liver, or ≤5 x ULN with liver involvement]. ","Patients were excluded if they had received more than one prior systemic treatment regimen for locally advanced or metastatic PDAC. Prior gemcitabine was allowed only if received as neoadjuvant or adjuvant therapy and provided that at least 6 months had elapsed from the completion of that therapy to study treatment. Other exclusion criteria included brain metastases, major bleeding event within 3 months of study initiation, active treatment with therapeutic doses of anticoagulants, or uncontrolled significant illness including active cardiac disease or gastrointestinal disorders associated with high risk for perforation or fistula formation",within the first 35 days of therapy,NA
28039155,NCT01511536,Combination,No,metastatic castration-resistant prostate cancer (mCRPC) progressing ,"Diagnosis of prostate adenocarcinoma proven histologically or cytologically, resistant to hormone therapy and previously treated with a docetaxel-containing regimen. In Phase 2 part, participants should have been treated with abiraterone acetate for at least 3 months and should continue treatment with abiraterone acetate before study entry Presence of metastatic prostate cancer. Participant must had progressive disease documented by rising PSA defined as 2 sequential increases above a previous lowest reference value (each PSA value must be obtained at least 1 week apart. A PSA value of at least 6 ng/mL was required at study entry). In Phase 1 part, in addition to rising PSA, progressive disease must be documented by: Increase in non-measureable or measurable disease, and/or Appearance of new lesions, including those on bone scan (≥2 new lesions on 2 consecutive bone scans if progressive disease diagnosed on bone scan only) consistent with progressive prostate cancer Effective castration (serum testosterone levels ≤0.50 ng/mL) by orchiectomy and/or luteinizing hormone-releasing hormone agonists /antagonist. If the participant had been treated with luteinizing hormone-releasing hormone agonists/antagonist (i.e., without orchiectomy), then this therapy had been initiated at least 4 weeks prior to cycle 1 day 1 and should be continued throughout the study. Prior anti-androgen therapy should be stopped before enrollment Eastern Cooperative Oncology Group performance status: 0 - 1.","Previous treatment with mitoxantrone or cabazitaxel. Prior bone-seeking radio-isotope therapy (participants treated with Radium223 were not excluded from the study). Radiotherapy to ≥30% of bone marrow. Adverse events from any prior anticancer therapy of grade >1 at the time of enrollment. Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment in the study (except luteinizing hormone-releasing hormone agonist /antagonist and abiraterone acetate in the Phase 2 part of the study); small field single fraction palliative radiation within 1 week. Prior malignancy. Curatively treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer were allowed, as well as any other cancer for which chemotherapy had been completed ≥ 3 years ago and from which the participant had been disease-free for ≥ 3 years. Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to enrollment. Known brain or leptomeningeal metastases. Any severe acute or chronic medical condition which could impair the ability of the participant to participate to the study or to comply with the study procedures or interfere with interpretation of study results. Other concurrent serious illness or medical conditions Absence of signed and dated participant informed consent form prior to enrollment into the study. History of hypersensitivity to docetaxel, polysorbate 80 Known allergies, hypersensitivity or intolerance to prednisone or excipients of abiraterone acetate Known history of mineralocorticoid excess or deficiency Inadequate organ and bone marrow function Contraindications to the use of corticosteroid treatment. Symptomatic peripheral neuropathy grade > 1 Concurrent treatment with strong inducers or strong inhibitors of cytochrome P450 (CYP450) 3A4 Concurrent treatment with medications metabolized by cytochrome P2D6 (CYP2D6), particularly for those with a small therapeutic window History of cardiac arrhythmias requiring medical therapy such as atrial fibrillation requiring anticoagulation or digoxin/digitalis; uncontrolled angina pectoris. History of congestive heart failure or myocardial infarction within last 6 months was also not allowed. Uncontrolled hypertension (systolic BP ≥160 mmHg or diastolic BP ≥ 95 mmHg). Participants with a history of hypertension were allowed, provided that blood pressure was controlled to within these limits by anti-hypertensive treatment Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 12 months, severe or unstable angina, or New York Heart Association Class III or IV heart disease or cardiac left ventricular ejection fraction measurement of <50% at baseline Participants with reproductive potential who did not agree to use accepted and effective method of contraception in conjunction with their partner(s) during the study treatment period. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",during Cycles 1 and 2,NA
28058445,NCT01140607,Single Drug,No,"advanced, non-hematologic cancer","Eligible patients were aged ≥18 years with a life expectancy of >3 months, diagnosed with metastatic or locally advanced non-hematologic cancer for which no effective curative therapy was available, had refractory or progressive disease following standard therapies, and had normal hepatic function or chronic hepatic impairment. Patients were enrolled into one of four cohorts based on their degree of hepatic function, defined using National Cancer Institute (NCI) criteria . Cohort 1 had normal hepatic function, defined as total bilirubin and aspartate aminotransferase (AST) ≤ institutional upper limit of normal (ULN); Cohort 2 had mild hepatic impairment, defined as total bilirubin >1.0 to ≤1.5 × ULN or AST >1.5 × ULN; Cohort 3 had moderate hepatic impairment, defined as total bilirubin >1.5 to ≤3.0 × ULN; and Cohort 4 had severe hepatic impairment, defined as total bilirubin >3.0 to 10.0 × ULN. Stable liver function or dysfunction was required.","Key exclusion criteria included Eastern Cooperative Oncology Group (ECOG) performance status >2, prior bone marrow transplant or cabazitaxel, known brain metastases, history of Gilbert’s syndrome or grade ≥3 hypersensitivity to taxanes, polysorbate 80or similar compounds, prior anticancer therapy <3 weeks before study initiation, concurrent or planned participation in another clinical trial, expected need for major surgery or radiation therapy during the study, other concurrent serious illness, acute or chronic medical illness or psychiatric condition that might affect the trial results or the patients’ ability to participate. Patients with significant laboratory abnormalities requiring further investigation, unresolved significant toxicity from prior therapy, or inadequate organ function were also excluded.",during cycle 1,NA
27862097,NCT01513733,Combination,No,Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC),"Eligible men had be 18 years of age or older and have confirmed prostate adenocarcinoma without small cell features, ongoing ADT with a baseline serum testosterone of less than 50 ng/dl, and castrate resistant disease progression defined by having at least 1 of 3 criteria: (i) PSA progression defined by consecutive PSA rise with a minimum of three rising PSA levels with an interval of >=1 week between each determination and a screening PSA of >= 2 ng/ml; (ii) soft tissue disease progression defined by RECIST1.1 ; and (iii) bone metastatic disease progression defined by one or more new lesions on bone scan that are not clinically consistent with tumor flare. Patients were required to have radiographic evidence of metastatic disease and have a KPS of 70 or higher. Patients could have no more than three prior chemotherapy regimens with at least one regimen having docetaxel, or be intolerant of docetaxel.Patients were required to be <80 years of age in the phase I dose escalation phase, but the dose expansion phase did not have age limits. All patients were required to have a life expectancy of at least 3 months, and patients could not have major infectious co-morbidities, untreated brain or epidural metastases, significant renal, hepatic, cardiac or bone marrow dysfunction, or grade 3 or more neuropathy judged by NCI Common Toxicity Criteria v4.0. Patients had to have been able to swallow the study drug and comply with study requirements.",NA,"prolonged DLT observation period of 6 weeks (dose level 1), 9 weeks (dose level 2), and 12 weeks (dose level 3)",NA
28352985,NCT00596648,Combination,No,non-small cell lung cancer,"Eligible patients had histologically confrmed Stage IIIb or IV NSCLC. Patients were at least 18 years old, had adequate organ and marrow function with an absolute neutrophil count ≥1500/mm3, platelets ≥100,000/mm3, hemoglobin ≥9  g/dL, bilirubin ≤1.5 times the upper limit of normal (ULN), serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥60 mL/min, and alanine aminotransferase and aspartate aminotransferase ≤2.5 times ULN. In addition to these eligibility criteria, patients enrolled in phase I must have failed prior treatment with erlotinib but tolerated erlotinib at a dose greater than or equal to the dose of the cohort in which they were assigned. Patients had to have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.","Patients with uncontrolled brain metastases, clinically signifcant hemoptysis, and hematemesis were excluded. Patients were also excluded for the presence of cavitary pulmonary lesion(s), endobronchial lesion or a lesion abutting a major blood vessel, pregnancy or lactation, serious intercurrent illness, uncontrolled hypertension [sustained blood pressure (BP) readings of >140  mmHg systolic or >90  mmHg diastolic], unhealed wounds from recent surgery, or congestive heart failure, unstable angina, or clinically signifcant cardiac arrhythmias within 3  months, or transient ischemic attack, stroke, or myocardial infarction within 6 months. Anti-cancer therapy, other than erlotinib (or geftinib in phase II), was not allowed within 4 weeks prior to entry.",during the frst 28  days of treatment,NA
28263212,NA,Combination,No,Metastatic Castration-Resistant Prostate Cancer,"Men with histologically confirmed prostate carcinoma were eligible if they had bone metastatic disease and evidence of disease progression despite serum testosterone of less than 50 ng/dL. Minimum evidence of prostate-specific antigen (PSA) progression was defined as a 25% increase in PSA over a reference value of PSA, provided that the increase was more than 2 ng/mL. Radiological progression was assessed using the RECIST 1.1 criteria. Bone metastases had to show uptake of 99mTc–hydroxymethylene diphosphonate at bone scintigraphy. All patients were pretreated with docetaxel. Previous exposure to 188Re-HEDP or 223Ra-chloride was not allowed within 2 months prior to inclusion. Other inclusion criteria were World Health Organization performance status 0 or 1, age older than 18 years, and life expectancy of at least 3 months. Patients were required to have an absolute neutrophil count (ANC) 1.5 X 109/L or greater, a platelet count 100 X 109/L or greater, a hemoglobin 9.0 g/dL or greater, and adequate renal and liver function",NA,The first 7 weeks after administration of 188Re-HEDP ,NA
28688700,NA,Combination,No,locally advanced squamous cell carcinoma of head and neck (LA-SCCHN),"Eligible patients with histologically confirmed stage IV SCC of the oral cavity, oropharynx, nasopharynx, larynx, hypopharynx and unknown primary were enrolled into the escalation cohort regardless of HPV status. HPV positive patients with SCC of the oropharynx or unknown primary were allowed in the expansion cohort if they were current smokers, where current smoking was defined as either active smoking within the past 20 years with a cumulative pack-year history of >20 pack-years, or active smoking (>1 cigarette per day) within the last 5 years. HPV status was determined before enrollment by p16 immunohistochemistry (IHC) with confirmatory HPV testing by PCR. Patients with metastatic SCCHN (except for symptomatic, unstable brain metastases) were allowed in the escalation cohort, but not in the expansion cohort. Patients had measurable disease of the primary tumor, lymph nodes or both by clinical and radiographic methods per Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. No prior therapy or any other investigational agents were allowed. ECOG performance status of 0 or 1 and normal hepatic, renal and bone marrow function were required.","Exclusion criteria included grade 2 or greater peripheral neuropathy by the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 3.0, other serious comorbid illness, and involuntary weight loss of more than 20% of body weight in the 3 months preceding study entry.",NA,NA
28960265,NCT01961765,Single Drug,No,Acute Myeloid Leukemia,"Patients were eligible for enrollment if they were 18 years or older with relapsed/refractory AML or if they were 70 years old or older with newly diagnosed disease. Participants were required to have an Eastern Cooperative Oncology Group performance status of 0 or 1; a cardiac ejection fraction greater than or equal to 50%; and intact organ function, as manifested by aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels less than 3 times the upper limit of normal, a direct bilirubin level less than 1.5 mg/dL, a lipase level less than 2.0 times the upper limit of normal, and a creatinine clearance greater than or equal to 50 mL/min. ","but were ineligible for or declined conventional therapy. In addition, because of the range of enzymes inhibited by cabozantinib, which includes VEGFR2, patients with severe hypertension, cavitary lung lesions or significant hemoptysis, active peptic ulcer disease, bowel inflammation, an obstruction or perforation, or recent major surgeries were excluded",during cycle 1 of the treatment,NA
29750396,NCT01751308,Single Drug,No,pediatric patients with refractory solid tumors including tumors of the central nervous system,"Eligible patients were 2–18 years old, had acceptable performance status (Lansky ≥60 for patients ≤10 years of age; Karnofsky ≥60% for patients >10 years of age), adequate organ function and a body surface area (BSA) <2.1 m2. Patients must have recovered from acute toxic effects of all prior therapy to grade ≤1 before study entry","Patients were excluded if they had systemic anticancer therapy within ≤3 weeks of study entry; investigational agents or small field radiotherapy ≤4 weeks; craniospinal (or other large-field) radiation therapy ≤6 months prior to the first cabazitaxel dose; prior systemic radioisotope therapy or total body irradiation; prior bone marrow or stem cell transplant; or any clinically significant illness that could not be controlled with appropriate therapy, would compromise cabazitaxel tolerability, or result in an inability to assess toxicity. Patients requiring concomitant treatment with strong inhibitors/inducers of CYP3A4 or enzyme-inducing anti-epileptic drugs 14 days prior to the first cabazitaxel dose were excluded",during cycle 1,NA
31765988,NA,Combination,EudraCT2011-003169-13,oesophagogastric adenocarcinoma,"Age ≥ 18 years. WHO performance status 0-1. Adequate respiratory and cardiac function. Able to give informed consent and be capable of co-operating with protocol. Haematological and biochemical indices within the ranges shown below: Haemoglobin (Hb) ≥10g/dl, Neutrophils≥ 2000/µl, Platelet count ≥ 100.000/µl, AST or ALT ≤ 3 ULN, alkaline phosphatase ≤ 2x ULN, Serum Bilirubin ≤ 1.5 ULN, Creatinine Clearance ≥ 50ml/min (Calculated by Cockcroft Gault equation, or by EDTA). Able to swallow oral medication. Male patients must use a barrier method of contraception (female condom or diaphragm are not acceptable) during the study and after cessation of therapy for 6 months. Patients with locally advanced or metastatic gastro-oesophageal adenocarcinoma, i.e. inoperable. Women of child bearing potential must use an acceptable method of contraception during the study and after cessation of therapy for 4 months, and have a negative pregnancy test","Previous chemotherapy for oesophago-gastric adenocarcinoma. Squamous cell pathology. Uncontrolled angina, myocardial infarction within 6 months, heart failure or impaired LV function on echocardiogram/MUGA, uncontrolled arrhythmias. History of interstitial lung disease. Known peripheral neuropathy >Grade 1. Other experimental treatment ≤ 4 weeks prior to this study (including chemotherapy and immunotherapy). Known or expected dihydropyridime dehydrogenase deficiency. Resting ECG with QTc >480msec at 2 or more time points within a 24h period. Requirement for medication known to inhibit or induce CYP3A4 or 2D6, or medication known to prolong QT interval. History of other malignancy less than 5 years before the diagnosis of oesophageal cancer, EXCLUDING the following: Non-melanoma skin cancer, in situ carcinoma of the cervix treated surgically with curative intent, other malignant tumours that have been treated curatively and patient is deemed disease-free. Active infections (including chronic hepatitis type B or C and HIV infection if status known), severe immunologic defect, compromised bone marrow function. Prior diagnosis of dry eye syndrome or eye-lid/eye-lash abnormalities. History of eye injury, corneal surgery, orbital irradiation, collagen vascular, chronic inflammatory or denegerative disease with eye involvement, clinically significant ocular surface disease. Known hypersensitivity to any component of chemotherapy. Pregnancy, inadequate or unreliable contraceptive measures during participation in the trial; breast feeding. Other psychological, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results.",during cycle 1,NA
32175106,NA,Combination,No,advanced pancreatic adenocarcinoma,"Patients eligible for enrollment were at least 18 years of age, had histologically or cytologically proven metastatic or unresectable PDAC, and had progressed on or were intolerant of prior gemcitabine-based therapy. Inclusion criteria required ECOG performance status of 0–2, and adequate bone marrow and organ function [ANC >1,000/µL, platelets >100,000/µL, total bilirubin ≤2 mg/dL, creatinine ≤2 mg/dL, AST or ALT ≤2.5× ULN (≤5× ULN in the setting of liver metastases)].","Exclusion criteria included prior chemotherapy or radiotherapy within two weeks of study entry, known brain metastases, prior treatment with aminopeptidase inhibitor, known dihydropyrimidine dehydrogenase deficiency (DPD), significant cardiovascular disease or known HIV positivity on combination antiretroviral therapy.",during cycle 1,NA
33206291,NCT01588522,Combination,No,solid tumor,"Patients enrolled in the trial must be at least 18 years of age and able to provide informed consent for participation in the trial. In addition, patients were required to be scheduled to receive a weekly taxane-based regimen for a pathologically confrmed solid tumor. Patients should have no evidence of alopecia or mild alopecia, categorized using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 4.0. Patients with female/male-pattern baldness or age-related alopecia were allowed if not> Grade 1 (hair loss of<50% of normal for that individual that was not obvious from a distance but only on close inspection; a diferent hair style could be required to cover the alopecia but it does not require a wig or hair piece to camoufage) per NCI-CTCAE v4.0 and patients who had previously lost their hair could enroll if they had Grade 0 or 1 alopecia. Additional criteria included Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1 within 14 days prior to registration, baseline neutrophil counts o f>1500 cells/mm3 within 72 h prior to registration, and serum calcium≤upper limit of normal, and ULN (for patients with an albumin <3.0, a corrected serum calcium=serum calcium+[0.8] [3.5- serum albumin]) within 72 h prior to registration.","Patients were excluded if they met any of the following criteria: receiving calcium-lowering therapy or drugs that may afect calcium levels (e.g., calcitonin, mithramycin, phosphate, or denosumab) within 4 weeks of initiation of topical calcitriol or receiving bisphosphonates or calcium-lowering therapy for 3 months or greater prior to the start of the trial. Additional exclusion criteria included a history of drug or alcohol abuse within 1 year of study enrollment, patients who elected to shave the scalp hair prior to the initiation of chemotherapy or planning to do so during the chemotherapy treatment, and any dermatological condition that, in the opinion of the investigator, would impact the absorption of the study medication, e.g., atopic dermatitis, etc. Patients were excluded if they received an investigational agent within 30 days or six half-lives of its biologic activity (whichever is shorter) before the start of study drug, had a history of hypercalcemia or Vitamin D toxicity, or hospitalization for treatment of angina, myocardial infarction, or congestive heart failure or psychiatric illness currently or within 30 days of study entry as determined by the investigator. Patients could take vitamin D supplements if they had been on them for 30 days or more prior to the initiation of the study, and the dose of the Vitamin D supplement had to remain the same throughout the study, received medications known to afect calcium levels within 4 weeks of initiation of topical therapy (>500 international unit, IU, Vitamin A, calcium supplements, fuoride, or antiepileptics), with the exception of patients on stable therapy for>6 months, or a history of hypercalcemia or kidney stones. There also could be no self-report of signifcant hair breakage or hair damage and associated alopecia from hair over processing within the last 30 days due to peroxide applications, permanent hair coloring, bleaches, streaking, perms, relaxers, and/or hair oxidative dyes, current alopecia Grade 2 or greater (as per NCI-CTCAE v4.0), or signifcant alopecia or hair breakage, or prior radiation to the cranium. Finally, patients could not be pregnant or breastfeeding.",during the frst 28 days of topical application and subsequently every 4 weeks by a study clinician,NA
32969563,NCT01683994,Combination,No,metastatic castration-resistant prostate cancer,"Eligible patients had a confirmed history of mCRPC with radiographically measurable disease by Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 or nonmeasurable disease on Tc99 bone scan. Key inclusion criteria included Eastern Cooperative Oncology Group performance status 0–2, and adequate bone marrow/organ function","Key exclusion criteria included tumour invading major blood vessels, brain metastases/epidural disease, clinically significant bleeding within 3 months, previous chemotherapy for mCRPC and progression of metastatic castration-sensitive prostate cancer on docetaxel",in the first two (3-week) cycles,NA
32253554,NA,Combination,No,advanced neuroendocrine tumors,Patients with histologically or cytologically confirmed unresectable or metastatic neuroendocrine tumors of any grade or primary site were eligible for enrollment. Concurrent somatostatin analogue use was allowed provided that the dose has been stable (± 10 mg) for at least 8 weeks. Eastern Cooperative Oncology Group (ECOG) performance status of 0–2 was required at the time of enrolment. Adequate organ function was required as outlined in the protocol.,"Patients with prior radiation therapy irradiating more than 10% of total bone marrow were excluded. Patients who were previously treated with TAS-102 or TMZ were not allowed to participate. Patients with history of partial or total gastrectomy were excluded due to concerns about their ability to absorb the medications. Patients with symptomatic brain metastases requiring treatment, active infection requiring treatment, uncontrolled diabetes, significant cardiac comorbidities, or with known history of pulmonary fibrosis were not eligible for participation",during cycle 1,NA
32382808,NTR4639,Single Drug,No,advanced solid tumours,"Patients aged ≥18 years, with advanced solid tumours potentially benefiting from capecitabine treatment and adequate bone marrow, hepatic and renal function were eligible for enrolment.",Patients with known DPD deficiency caused by genetic polymorphisms in DPYD (DPYD*2A or c.2846A > T) were excluded.,the first three weeks of treatment,NA
32915679,NCT02496208,Combination,No,Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,"Patients in the phase I portion must have: Histologically confirmed diagnosis of metastatic, genitourinary solid tumor Metastatic disease defined as new or progressive lesions on cross-sectional imaging; patients must have at least: One evaluable site of disease Or, appearance of one new bone lesion. ","The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 3 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatment. Patients who have been previously treated with MET or vascular endothelial growth factor receptor (VEGFR) inhibitors (except for patients on renal cell cancer [RCC] cohort) are not eligible for the expansion cohorts but can enroll in the phase I portion. Prior treatment with any therapy on the programmed cell death 1 (PD-1)/PD-L1 axis or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors unless enrolling the urothelial carcinoma with previous checkpoint inhibition therapy expansion cohort. The subject has received radiation therapy: To the thoracic cavity or abdomen within 3 months before the first dose of study treatment, or has ongoing complications, or is without complete recovery and healing from prior radiation therapy. To bone or brain metastasis within 3 weeks before the first dose of study treatment. To any other site(s) within 28 days before the first dose of study treatment. The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment. The subject has received prior treatment with a small molecule kinase inhibitor within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment. The subject has received prior treatment with hormonal therapy within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment; subjects receiving gonadotropin-releasing hormone (GnRH) agonists and antagonists are allowed to participate. The subject has received any other type of investigational agent within 28 days before the first dose of study treatment. The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs) defined as lab elevation with no associated symptoms or sequelae. The subject has active brain metastases or epidural disease; subjects with brain metastases previously treated with whole brain radiation or radiosurgery or subjects with epidural disease previously treated with radiation or surgery who are asymptomatic and do not require steroid treatment for at least 2 weeks before starting study treatment are eligible; neurosurgical resection of brain metastases or brain biopsy is permitted if completed at least 3 months before starting study treatment; baseline brain imaging with contrast-enhanced CT or magnetic resonance imaging (MRI) scans for subjects with known brain metastases is required to confirm eligibility. The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= 1.5 x the laboratory ULN within 7 days before the first dose of study treatment. No concomitant treatment with warfarin is permitted. Aspirin (up to 325 mg/day), thrombin or factor Xa inhibitors, low-dose warfarin (=<1 mg/day), prophylactic and therapeutic low molecular weight heparin (LMWH) are permitted. The subject requires chronic concomitant treatment of strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's wort); Because the lists of these agents are constantly changing, it is important to regularly consult medical reference texts such as the Physicians' Desk Reference may also provide this information; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product. The subject has experienced any of the following: Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment. Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment. Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment. The subject has tumor invading any major blood vessels. The subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: Cardiovascular disorders including: Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening. Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mmHg systolic, or > 90 mmHg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment. The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms within 28 days before randomization; Note: if initial QTcF is found to be > 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed; if the average of these three consecutive results for QTcF is =< 500 ms, the subject meets eligibility in this regard. Any history of congenital long QT syndrome. Any of the following within 6 months before the first dose of study treatment: Unstable angina pectoris. Clinically-significant cardiac arrhythmias. Stroke (including transient ischemic attack [TIA], or other ischemic event). Myocardial infarction. Cardiomyopathy. Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including: Any of the following that have not resolved within 28 days before the first dose of study treatment. Intra-abdominal tumor/metastases invading GI mucosa. Active peptic ulcer disease. Diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis. Malabsorption syndrome. Any of the following within 6 months before the first dose of study treatment: Abdominal fistula. Gastrointestinal perforation. Bowel obstruction or gastric outlet obstruction. Intra-abdominal abscess; Note: complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 6 months before the first dose of study treatment. Other disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement within 3 months before the first dose of study therapy. Other clinically significant disorders such as: Severe active infection requiring systemic treatment within 14 days before the first dose of study treatment. Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment. History of organ transplant. Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid stimulating hormone [TSH], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment). History of major surgery as follows: Major surgery within 3 months of the first dose of cabozantinib; however, if there were no wound healing complications, patients with rapidly growing aggressive cancers, may start as soon as 6 weeks if wound has completely healed post-surgery. Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications excluding core biopsies and Mediport placement. In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery. The subject is unable to swallow tablets. History of severe hypersensitivity reaction to any monoclonal antibody. The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee. For disease specific studies: the subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment. History of allergic reactions attributed to compounds of similar chemical or biolo",the first 4 weeks for CaboNivo and the first 6 weeks for CaboNivoIpi,NA
33452614,NA,Single Drug,No,Advanced Solid Tumors,"Patients with advanced NET were eligible as TrkB (NTRK2) signaling pathway is considered to be involved in the proliferation, tumorigenesis, and invasive nature of NET (6). In addition, patients with tumor-induced pain from advanced solid tumors, and patients with ROS1/NRTK1-3 rearranged tumors were eligible. Other major eligibility criteria included age > 18 years old, ECOG PS of 0-1, at least one extracranial RECIST (1.1) measurable lesion, adequate organ function [platelet count ≥100 X109/L; hemoglobin ≥9.0 g/dL; absolute neutrophil count ≥1.5X 109/L; calculated CrCl ≥60 mL/minute or serum creatinine ≤1.5X upper limited normal (ULN); AST/ALT levels ≤3  ULN (≤5XULN if liver metastases are present) and bilirubin ≤1.5  ULN].","Major exclusion criteria included untreated and symptomatic central nervous system (CNS) metastases, active HIV, Hepatitis B or C infection, QTcF > 450 ms at baseline, history of myocardial infraction within 6 months of enrollment, or New York class III/IV congestive heart failure.",during cycle 1 ,NA
25318436,NA,Single,No,refractory solid tumors,"Eligible patients had a histologically documented, advanced solid malignancy refractory to standard therapy or for which no curative therapy existed. Other inclusion criteria included: age of at least 18 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; adequate hematologic, hepatic and renal functions (total white blood cell count ≥3,000/μl, absolute neutrophil count ≥1,500/μl, platelets ≥100,000/μl, total bilirubin within institutional normal limit, aspartate transaminase/alanine transaminase ≤2.5 x the institutional upper limit of normal, creatinine ≤1.5 mg/dl or creatinine clearance ≥60 ml/min/1.73 m2 for patients with creatinine levels above institutional normal); and life expectancy greater than 12 weeks","Exclusion criteria included untreated brain metastasis; chemotherapy or radiation therapy within 4 weeks; anti-epileptics metabolized by cytochrome P450 history of cirrhosis or uncontrolled electrolyte abnormalities; active infection; HIV, baseline prolonged corrected QT interval on ECG (defined as baseline QTcF (QT interval using Fridericia’s formula) >450 msec [male] or QTcF >470 msec [female]), and known dihydropyrimidine dehydrogenase (DPD) deficiency. Patients were required to practice effective birth control.",during the first cycle,NA
29725881,NCT01129310,Combination,No,metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma,"Eligibility criteria included age ≥ 18 years old, histologically documented metastatic HER2/neu unamplified or unknown gastric or GEJ adenocarcinoma, no previous palliative systemic chemotherapy, and Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1. Other eligibility criteria include life expectancy of at least 3 months, adequate hematologic function (hemoglobin >100 g/L, platelet count of >100 109/L and absolute granulocyte count of >1.5 109/L) and hepatic function (AST and ALT <2.5 times the upper limit of normal (<5 times if with liver metastases), bilirubin ≤ upper limit of normal), and calculated creatinine clearance of ≥50 mL/min. Prior chemotherapy or radiation therapy, delivered as part of initial curative therapy, was permitted as long as treatment was completed at least 6 months prior to IXO start date. ","Exclusion criteria included lack of physical integrity of the upper gastrointestinal tract (malabsorption syndrome or history of bowel obstruction due to peritoneal metastases), concurrent malignancies, Gilbert’s disease, known dihydropyrimidine dehydrogenase deficiency, known HER2-positive disease, preexisting neuropathy of ≥ grade 2 based on the National Cancer Institute Common Terminology Criteria of Adverse Events Version 3.0 (NCI-CTCAE v3.0), unstable brain metastasis, pregnancy, and lactation",within the first 2 cycles,NA
28973403,NCT01791374,Combination,No,gastric cancer,Eligible patients were Japanese men and women ≥20 years of age with an Eastern Cooperative Oncology Group performance status of 0 or 1; evaluable (measurable or nonmeasurable) disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; and adequate hematologic and organ function,"Patients were excluded if they had central nervous system metastases; Grade >1 peripheral edema or peripheral neuropathy; and arterial thrombosis, vascular ischemic events, or venous thromboembolic events within 6 months before enrollment.",NA,NA
26706729,NA,Combination,No,advanced non‑small cell lung cancer,"Patients were considered eligible for the study if they had a diagnosis of NSCLC, with adenocarcinoma histology (mixed histology was excluded), ≥18 years old, and not suitable for radical treatment. They had to have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2 and a predicted life expectancy of ≥12 weeks. All patients had to have adequate organ function, defined as an absolute neutrophil count ≥1.5 × 109/L, platelet count ≥100 × 109/L, bilirubin ≤1.5 × upper limit of normal (ULN), alanine transaminase ≤2.5 × ULN (≤5 × ULN in the presence of liver metastases) and creatinine clearance ≥50 mL/min (calculated by Cockcroft-Gault equation). Concomitant use of CYP3A4 or CYP1A2 inducers or inhibitors was prohibited, and prior treatment with an EGFR inhibitor was not allowed. Patients must have ceased prior active cancer treatment, with a 28-day washout period.  Corticosteroid use was allowed on study, provided the dose had been stable in the 3 weeks preceding entry onto the study.","Patients were excluded if they had another active malignancy in the last 3 years, active or uncontrolled infections or serious medical conditions that could interfere with the patients’ participation in the study, including psychiatric conditions that may interfere with compliance. Any gastrointestinal abnormalities that could interfere with drug absorption were excluded.",the first 2 cycles,NA
30783204, NCT01323530,Combination,No,"advanced, treatment-refractory, solid tumours","Key eligibility criteria included patients aged ≥18 years with histologically or cytologically confirmed advanced or metastatic cancer resistant or refractory to approved therapies. Resistant/refractory to approved therapies (defined as progressive disease during or within 6 months after the last anticancer therapy) or for whom single-agent capecitabine at this dose level and schedule were a reasonable treatment option in the opinion of the investigator. For patients who had received capecitabine, all of its related toxicities must have been completely resolved. An ECOG PS of ≤ 2. Males who were not abstinent or had not undergone a successful vasectomy, who were partners of women of childbearing potential, must have used, or their partners must have used, a highly effective method of contraception (e.g., condom + spermicide, condom + diaphragm with spermicide, IUD) for at least 1 menstrual cycle prior to starting study drug and throughout the entire study period, and for 30 days (longer, if appropriate) after the last dose of study drug. Those with partners using hormonal contraceptives must also have been using an additional approved method of contraception (as described previously). Adequate bone marrow function: Absolute neutrophil count ≥1.5 x 109/L; Haemoglobin ≥10.0 g/dL; Platelet count ≥100 x 109/L. Adequate liver function: Bilirubin ≤1.5 times the upper limit of normal. Alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase ≤3 times the upper limit of normal (≤5 times the upper limit of normal for patients with liver metastases). Adequate renal function: Creatinine clearance ≥50 mL/min as per the Cockcroft–Gault formula or radioisotope measurement.	Life expectancy of >3 months. Females of childbearing potential must have had a negative urine or serum ßhCG result at visit 1 (screening) and prior to starting study drugs on day 1. Women of childbearing potential must have agreed to be abstinent or to use highly effective methods of contraception (e.g., condom + spermicide, condom + diaphragm with spermicide, IUD, or have a vasectomised partner) for at least 1 menstrual cycle prior to starting study drugs and throughout the entire study period, and for 30 days (longer, if appropriate) after the last dose of study drugs. Women using hormonal contraceptives must also have been using an additional approved method of contraception (as described previously). Perimenopausal women must have been amenorrhoeic for at least 12 months to be considered of nonchildbearing potential","Significant cardiovascular impairment (history of congestive heart failure >NYHA grade II, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia). Electrocardiogram with QTc interval >470 msec (as measured either by Bazett’s or Fridericia’s formula)",during treatment or up to 30 days following the last dose of study treatment,NA
24820348,NA,Combination,No,Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes,"Patients with MBC that had been histopathologically confirmed as HER2-negative and had received pretreatment with anthracyclines and taxanes in either adjuvant or metastatic settings were eligible for this study. Additional eligibility criteria included measurable lesions defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0  , an Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0–2, adequate organ functions and an estimated life expectancy of >2 months. All patients had undergone prior chemotherapy including treatment with anthracyclines and taxanes. Adjuvant and/or first-line metastatic hormone therapy was authorized with a washout period of ≥ 4 weeks prior to study entry. Immunohistochemical examinations of primary tumors were performed by SRL Japan (Hachioji, Tokyo, Japan) and estrogen receptor (ER) and progesterone receptor (PgR) statuses were determined, taking a finding of >10% as positive. HER2 testing was performed using the HercepTest (DacoCytomation, Carpinteria, Calif., USA) and was scored from 0 to 3+, with a finding of 3+ defined as HER2-positive. Fluorescence in situ hybridization was also performed using PathVysion HER2 (Vysis; Abbott Laboratories, Abbott Park, Ill., USA) to determine the HER2/17q centromere ratio, with values of >2.0 defined as positive if immunohistochemistry showed a HER2 result of 2+. ",NA,during the first 2 cycles,NA
29330005,NA,Combination,No,Advanced Colorectal Cancer,"Eligible patients were aged  18 years and had an Eastern Cooperative Oncology Group performance status of  2, measurable disease using the Response Evaluation Criteria in Solid Tumors, version 1.0,8 and histologically documented locally advanced CRC or mCRC, which had been evaluated as unresectable. The surgical unresectability was established through a multidisciplinary evaluation, performed by medical and radiation oncologists and colorectal and hepatobiliary surgeons. No previous chemotherapy for advanced disease was allowed. Previous adjuvant therapy with fluoropyrimidines, but not irinotecan or oxaliplatin, was permitted. Adequate hematologic, renal, and hepatic function was required.",NA,the first cycle (3 weeks) of treatment,NA
31266024,NA,Combination,No,Locally Advanced Rectal Cancer ,"Patients were recruited from one site in Japan. Eligibility criteria were ( 1) age over 20 years; ( 2) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; ( 3) histologically proven adenocarcinoma of the rectum; ( 4) resectable clinical stage T3 or T4, N0–2 disease with the primary tumor located either above or below the peritoneal reflection, and the inferior tumor margin located within 12 cm of the anal verge; and ( 5) adequate organ function defined by a white blood cell count ≥4,000 × 109/L, hemoglobin ≥9.0 g/dL, platelet count ≥100 × 109/L, total bilirubin ≤1.5 mg/dL, serum transaminases ≤150 IU/L, and serum creatinine ≤1.5 mg/dL. ","Exclusion criteria were ( 1) major surgery, radiation therapy, and prior chemotherapy within 4 weeks of trial inclusion; ( 2) history of interstitial pneumonia, watery diarrhea, concurrent active infections (including hepatitis B surface antigen positive), or other current, severe, systemic disease (e.g., heart failure, hepatic failure, ulcers, uncontrolled diabetes mellitus, etc.); ( 4) history of other malignancies in the last 5 years; ( 5) pregnancy or breast-feeding; ( 6) a genotype of UGT1A1*6/*6, UGT1A1*28/*28, or heterozygous for both (UGT1A1*6/*28); and ( 7) peripheral neuropathy grade ≥2 per National Cancer Institute-Common Toxicity Criteria (NCI-CTC) v. 4.0. All patients were required to provide written informed consent before entering the study. ",during the first cycle of treatment,NA
26460795,NCT01226732,Combination,No,Advanced Solid Tumors,"Adult patients were required to have histologicallyconfirmed metastatic or unresectable solid tumor malignancy that is incurable, and for which capecitabine is clinically appropriate. The following are additional inclusion criteria: Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (5); adequate bone marrow function (absolute neutrophil count (ANC) ≥ 1500/μL; hemoglobin (Hgb) ≥ 9 g/dL; Platelets ≥ 100,000/μL), hepatic function (aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) ≤ 3 x the upper limit of normal (ULN), or ≤ 5 x ULN in patients with liver metastases; total bilirubin ≤ 1.5 x the institutional ULN, renal function (serum creatinine ≤ 1.5 x ULN or 24-hour creatinine clearance ≥ 40 mL/min), and normal electrolytes (phosphorous and magnesium ≥ the lower limit of normal); written informed consent.","Patients were considered ineligible for any of the following: receiving treatment with therapeutic doses of coumarintype anticoagulants; untreated central nervous system (CNS) metastases; history of or current cardiac abnormalities including, but not limited to, a mean QTc ≥ 450 msec on baseline ECG, history of clinically manifested ischemic heart disease (i.e. myocardial infarction and/or unstable angina) ≤ 6 months prior to study start, and/or history of heart failure or left ventricular (LV) dysfunction (LVEF ≤ 45%) by MUGA or ECHO.",During the first cycle of treatment,NA
29153866,NCT01300962,Combination,No,Metastatic Breast Cancer,"Patients with a histologic diagnosis of metastatic breast cancer for which capecitabine was deemed a reasonable treatment option were eligible for enrollment. The eligibility criteria also included age >= 18 years, Eastern Cooperative Oncology Group performance status of 0 to 2, and life expectancy of >= 12 weeks. The patients were required to have either measurable or nonmeasurable, but evaluable, disease as defined using Response Evaluation Criteria In Solid Tumors, version 1.1. Normal bone marrow function was defined as follows: absolute neutrophil count >= 1500/mL, platelet count >= 100,000/mL, and hemoglobin >= 8.5 g/dL. Organ function was required to be within normal limits, with the following caveats: total bilirubin <= 1.5 times the upper limit of normal and aspartate aminotransferase (AST)/alanine transaminase (ALT) <= 3 times the upper limit of normal, if liver metastases were present. The fasting plasma glucose level was required to be < 120 mg/dL. The patients had to have recovered from all toxicities related to their previous treatment (other than alopecia) to grade <= 1 or baseline. Brain metastases were allowed if central nervous system-directed treatment had been given >= 3 months before enrollment with clinically and radiographically stable disease for  8 weeks.","The pertinent exclusion criteria included previous treatment with capecitabine or a PI3K inhibitor; concurrent use of an endocrine, a cytotoxic, or a biologic agent; major surgery <= 2 weeks before starting buparlisib; and chronic systemic treatment with steroids or other immunosuppressive agents. Patients with known dihydropyrimidine dehydrogenase deficiency were excluded, as were patients with known coagulopathies resulting from warfarin-derived anticoagulant agents. Other comorbid conditions that prohibited enrollment included acute or chronic liver disease, renal disease, pancreatitis, poorly controlled diabetes mellitus, a known diagnosis of human immunodeficiency virus infection, inadequately controlled hypertension, and clinically significant active cardiac disease. Patients with documented mood or anxiety disorders and those with gastrointestinal dysfunction resulting in impaired absorption were also excluded.",within the first 3 weeks,NA
30418178,NA,Combination,No,advanced solid tumor and pancreatic cancer ,"The eligibility criteria included patients with histologically or cytologically confirmed advanced or metastatic solid malignancies where the gemcitabine combination was considered standard therapy or a rational option; patients eligible for the expansion cohort would have locally advanced or metastatic pancreas or biliary tract adenocarcinoma; age ≥ 18 years; Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1; adequate bone marrow, renal and liver function defined by absolute neutrophil count (ANC) ≥ 1,500 cells/mm3, platelets ≥ 100,000 cells/mm3, hemoglobin ≥ 9.0 g/dL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × upper limit of normal (ULN), total bilirubin ≤ 1.5 × ULN, serum creatinine ≤ 1.5 × ULN, international normalized ratio (INR) ≤ 1.5 (anti-coagulation is allowed if target INR ≤ 1.5 on a stable dose of warfarin or on a stable dose of low molecular weight heparin for > 2 weeks at the first dose of study agent), 24-hour urine protein < 2 grams if urinalysis showed proteinuria. Patients should have completed any anti-cancer therapy ≥ 4 weeks (≥ 2 weeks for targeted therapy; e.g., sunitinib, sorafenib, pazopanib) prior to initiation of study drug and without residual toxicity.","Patients with active, clinically significant and/or uncontrolled medical conditions were excluded",occurring during cycle 1,NA
29573846,NA,Combination,Yes,Advanced Oesophago-Gastric Cancer,"Patients were at least 18 years of age with histologically verified adenocarcinoma, squamous cell carcinoma or undifferentiated carcinoma of the oesophagus, oesophagogastric junction or stomach, which was deemed ineligible for curative treatment because of locally advanced or metastatic disease on staging, including computerised tomography of thorax, abdomen and pelvis. Patients with recurrent disease were eligible if they had had no previous systemic anticancer therapy. Those who had had previous radiotherapy needed to have evidence of relapse outside of the radiotherapy field. Further eligibility criteria included: measurable disease according to RECIST; World Health Organisation performance scale 0e2; predicted life expectancy of at least 3 months; adequate renal function (creatinine clearance  60 ml/min as measured by EDTA clearance or 24 h urinary creatinine clearance); adequate hepatic function (bilirubin 22 mmol/l, serum transaminase <= 2.5X upper limit of normal and alkaline phosphatase <= 5Xupper limit of normal except in the presence of bone metastases and absence of liver disorder); adequate bone marrow function (white blood cells >= 3 X 109/l, neutrophils > 1.5 X 109/l, platelets > 100 X 109/l).","Patients were excluded from the study for the following reasons: a history of malignant disease other than adequately treated non-melanotic skin cancer or in situ carcinoma of the uterine cervix, a medical or psychiatric condition that impaired their ability to give informed consent, pregnant or lactating women, planned radiotherapy to a target lesion or >= grade 2 oto-/neurotoxicity.",within the first two cycles,NA
30949758,NCT03295084,Combination,No,metastatic or unresectable solid tumors,"Signed written Informed Consent. 18 years of age or older. Capable of understanding the protocol requirements and risk associated with the study. Patients must have histological confirmed malignancy (solid tumor) that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. Patients with either measurable disease according to RECIST 1.1 or non-measurable disease. Performance status 0-1 (ECOG). Life expectancy ≥ 3 months. Coagulation INR < 1.3 and APTT within normal limits. WBC ≥ 3000/mm3. Absolute neutrophil count ≥ 1500/mm3. Hemoglobin ≥ 6.0 mmol/L. Platelet count ≥ 100.000/mm3. Bilirubin ≤ 1.5 times upper limit of normal (ULN). AST and ALT ≤ 2.5 times ULN AST and ALT ≤ 2.5 times ULN. For patients with liver metastasis adequate hepatic function is defined by aspartate aminotransferase (AST) ≤ 5 x ULN and alanine aminotransferase ALT ≤ 5 x ULN. No severe or uncontrolled renal condition (creatinine ≤ than 1.5 ULN). No significant cardiovascular disease (New York Heart Association Class III and IV). No other severe cardiac condition not defined above. No significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year prior for patients to be enrolled and treated in combination with oral capecitabine. No severe or uncontrolled pulmonary condition. No known prior hypersensitivity reaction to irinotecan. No known prior hypersensitivity to capecitabine or 5-fluorouracil for patients to be enrolled and treated in combination with oral capecitabine. No chronic enteropathy (e.g. active inflammatory bowel disease, extensive intestinal resection or chronic diarrhea). No bowel obstruction or sub-obstruction. No prior history of intestinal malabsorption. Patients have to be able to swallow normally and have to be willing to comply with the intake of tablets. No psychiatric condition that would preclude study participation. No co-existing active infection requiring antibiotics or any co-existing medical conditions likely to interfere with study procedures. No other condition that will preclude study participation. A negative pregnancy test for women of childbearing potential. For men and women of child-producing potential, the use of effective contraceptives methods during the study and at least 3 months after discontinuations of the study drug is required. Not pregnant or nursing. Peripheral neuropathy NCI CTCAE grade less than 2 for patients to be enrolled and treated in combination with oral capecitabine. The patient is willing and able to comply with hospitalization for treatment and scheduled follow-up visits and examinations",Simultaneous participation in any other study involving investigational drugs or having participated in a study within 4 weeks prior to start of study treatment Symptomatic brain metastases Intake of any prohibited concomitant medication Known Dihydropyrimidine dehydrogenase (DPD) deficiency for patients to be enrolled and treated in combination with oral capecitabine.,"two consecutive treatment cycles ",NA
29707156,NA,Combination,No,locally advanced rectal cancer,"Patients were eligible if they had histologically confirmed diagnosis of measurable LARC, clinically staged as cT3/T4 any cN or any cT cN1/N2; age 18- 75 years; World Health Organization (WHO) PS ≤ 2; adequate hematological, renal and hepatic functions; life expectancy more than 3 months.","Patients with secondary CIRS stage, consisting of ≥ 3 comorbidities or a severe comorbidity, with or without dependent IADL, were not enrolled. Criteria to define patients unfit for the proposed treatment strategy were: uncontrolled severe diseases; cardiovascular disease (uncontrolled hypertension, uncontrolled arrhythmia, ischemic cardiac diseases in the last year); thromboembolic disease, coagulopathy, preexisting bleeding diatheses.",NA,NA
28894576,NA,Combination,No,advanced gastric cancer,"The eligibility criteria for inclusion in the present study were as follows: Age ≥20 years; histologically confirmed human epidermal growth factor receptor type 2-negative unresectable or recurrent gastric cancer; Eastern Cooperative Oncology Group (ECOG) performance status <2; estimated life expectancy ≥3 months; and adequate organ function, as defined by hemoglobin (Hb) ≥8 g/dl, absolute neutrophil count (ANC) ≥1,500/mm3, platelet count ≥100,000/mm3, total bilirubin ≤1.5 mg/dl, serum transaminase level ≤100 U/l and creatinine clearance ≥40 ml/min.",The exclusion criteria were as follows: Contraindication to either drug included in the chemotherapy regimen; evidence of prior history of platinum administration; insufficient oral intake; synchronous or previous malignancy other than carcinoma in situ; or severe comorbidities.,in the first cycle,NA
29273261,NCT01474187,Combination,No,locally advanced rectal cancer,"Patients with histologically confirmed, non-metastatic, locally advanced rectal adenocarcinoma (cT3/4, and/or N+) located within 12 cm of the anal verge were screened for the UGT1A1⁄28 genotype. Eligibility criteria included the ⁄1⁄1 and ⁄1⁄28 genotypes, age 18–75 years, Karnofsky performance status >= 60, adequate bone marrow function (leukocyte count >4000/mL, platelet count >1,00,000/mL), adequate renal function (creatinine clearance >50 mL/min) and hepatic function (ALT and AST <= 2X the upper limit of normal), and total serum bilirubin <= 1.25X the upper limit of normal. ","Patients were excluded if they carried the ⁄28⁄28 genotype, had previously received pelvic RT or systematic chemotherapy, had other previous malignant tumors, or had ischemic heart disease, inflammatory bowel disease, malabsorption syndrome, or any other condition not suitable for CRT",during the first 7 weeks,NA
27473815,NCT01781403,Combination,No,Locally Advanced Rectal Cancer,"Patients with locally advanced, nonmetastatic, histologically confirmed adenocarcinoma of the rectum were enrolled. To be eligible, patients were required to have: (1) histologically confirmed adenocarcinoma of the rectum; (2) a distal tumor margin located 0 to 12 cm from the anal verge; (3) a clinically confirmed T3 to 4 lesion or involvement of regional nodes (Nþ) as determined by magnetic resonance imaging (MRI); (4) available tumor samples collected before treatment to enable the investigation of MGMT hypermethylation; (5) age older than 20 years; (6) Eastern Cooperative Oncology Group performance status of 1 or lower; (7) no prior history of chemotherapy, immunotherapy, or radiation therapy; and (8) adequate hematologic, hepatic, and renal function.","The exclusion criteria were as follows: histology other than adenocarcinoma or tumor arising from inflammatory bowel disease; any evidence of systemic metastasis; unresected synchronous colon cancer; current or impending obstructive symptoms; and prior history of another malignancy within 5 years of study entry, except for basal cell carcinoma of the skin or carcinoma in situ of the uterine cervix. Patients with organ allografts requiring immunosuppressive therapy, known dihydropyrimidine dehydrogenase deficiency, or any condition indicating unsuitability for CRT were also excluded.",During study treatment 6±2 weeks before surgery,NA
26499900,NA,Combination,No,advanced cancer of the stomach or the gastroesophageal junction,"Patients were eligible if they had histologically or cytologically confirmed, irresectable, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. Further inclusion criteria were as follows: no adjuvant chemotherapy within 12 months before study registration; measurable or non-measurable, evaluable disease; age 18 years or older; WHO performance status of ≤ 2; adequate bone marrow function (i.e., absolute neutrophile count ≥ 1.5 × 109/L, platelets ≥ 100 × 109/L and hemoglobin ≥6 mmol/L); and adequate hepatic and renal function defined as serum creatinine ≤ 1.5 × upper limit of normal (ULN), serum bilirubin ≤ 1.5 × ULN and ALAT/ASAT ≤ 2.5 × ULN","Patients were excluded if they were known to have central nervous system or leptomeningeal metastases; history of another primary cancer except curatively treated in situ cervical cancer or resected nonmelanoma skin cancer; mental disorders not suitable for follow-up; known positive HIV, active hepatitis B or C; and women who were pregnant or lactating, or able to conceive but unwilling to practice effective anticonception.",during the first cycle,NA
27404453,NCT01730222,Combination,No,unresectable or borderline resectable pancreatic adenocarcinoma,"Pathologic diagnosis of pancreatic adenocarcinoma; Stage III or IV disease; Age > 17 < 76 years; Karnofsky Performance Status > 50; Measurable disease (only for phase II part); Adequate bone marrow (GB > 3500/mm3, neutrophils > 1500/mm3; platelets > 100000/mm3; hemoglobin > 10 g/dl), liver (total bilirubin < 2 mg/dL; SGOT e SGPT < 3 UNL) and kidney function (serum creatinin < 1.5 mg/dL;); Written informed consent","previous chemotherapy; concurrent treatment with other experimental drugs; previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the skin and of other neoplasms without evidence of disease at least from 5 years; symptomatic brain metastases; history of interstitial lung disease; presence of serious disease which can compromise safety (cardiac failure, previous myocardial infarction within the prior 6 months, cardiac arrhythmia, history of psychiatric disabilities); pregnancy and lactating; History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa).",during the first cycle,NA
31207904,NCT02273713,Combination,No,Metastatic Esophagogastric Adenocarcinoma,"Patients must provide written informed consent according to ICH/GCP, and national/local regulations prior to any screening procedures. Patients with histologically confirmed diagnosis of metastatic or irresectable carcinoma of the stomach or oesophagus; Patients with metastatic or irresectable carcinoma of the stomach or oesophagus not pre-treated with chemotherapy or radiotherapy for irresectable or metastatic disease.; Measurable disease as assessed by RECIST 1.1; ECOG (WHO) performance status 0-2; Patient has adequate bone marrow and organ function; If a female patient is of child-bearing potential: negative serum pregnancy test, If sexually active, the patient must agree to use contraception. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial","Prior systemic treatment for metastatic or irresectable stomach or oesophageal cancer. Evidence of disease progression within 3 months after completion of adjuvant or neoadjuvant treatment containing capecitabine and/or oxaliplatin. History of hypersensitivity to nab-paclitaxel, capecitabine or oxaliplatin. All target lesions in a radiation field without documented disease progression. WHO 2-4. Use of other investigational drugs within 30 days of enrollment. Patient has known brain metastases, unless previously treated and well-controlled for at least 3 months (defined as clinically stable, no oedema, no steroids and stable in 2 scans at least 4 weeks apart). History of malignancy in the last 5 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Patients with other malignancies are eligible if they were cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years. Patients who are not willing to avoid consumption of Seville oranges, grapefruit or grapefruit juice grapefruit hybrids, pomelos and exotic citrus fruits during the entire study. Patient is currently being treated with drugs known to be strong inhibitors or inducers of CYP3A4 or CYP2C8, which cannot be discontinued or switched to a different medication 7 days prior to starting study treatment and for the duration of the study. Patient has active, uncontrolled bacterial, viral or fungal infection(s) requiring systemic therapy. Patient has known historical or active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment contraindicate patient participation in the clinical study (e.g. hematological, cardiovascular, lung disease etc). Patient is enrolled in any other clinical protocol or investigational trial with the same primary endpoint. Patients who in the investigators' opinion may be unwilling, unable or unlikely to comply with requirements of the study protocol.",the first cycle,NA
25687867,NCT00842244,Combination,No,Previously Untreated Advanced Gastric Cancer,"Patients aged ! 20 years at Japanese sites or ! 18 years at Korean sites with stage IV gastric or gastroesophageal junction adenocarcinoma (type II or III tumors) for which curative intent was not possible, and at least one unidimensionally measureable lesion using a modified Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.0 were eligible. Patients were required to have Eastern Cooperative Oncology Group performance status of 0 or 1; adequate bone marrow, renal, and hepatic function; and blood pressure (BP) <= 130/80 mm Hg. Antihypertensive medications were permitted.","Patients who had undergone radiation therapy or surgery within 4 weeks prior to study entry or prior treatment with a systemic anticancer agent for advanced gastric cancer were excluded. Palliative radiation therapy to non-target lesions within 2 weeks prior to study entry was allowed. Patients with disease progression while on prior adjuvant treatment or progression-free interval < 6 months after completion of adjuvant therapy were not permitted. Because the trastuzumab trial  results were unknown when this trial was designed, HER2 status was not assessed",during cycle 1,NA
24983373,NCT00604409,Combination,No,advanced cancer,"Adult patients with histologically or cytologically confirmed incurable solid tumours that were predominantly or exclusively involving the liver were included in the trial. Patients who had received any number of prior regimens were permitted provided they had an Eastern Cooperative Oncology Group performance status of 0-1 and a life expectancy of at least 12 weeks. Eligible patients had adequate liver (total bilirubin pupper limit of normal (ULN), aspartate transaminase and alanine transaminase <= 1.5 ULN and without clinical evidence of ascites or decompensated cirrhosis), marrow (leukocytes >= 3000/ml, absolute neutrophil count >= 1000/ml and platelets >= 75 000/ml), and kidney function (creatinine pULN or estimated glomerular filtration rate >= 60 ml min  1). Upon pretreatment work-up (Coldwell et al, 2011), patients were required to have a patent portal vein and liver-to-lung shunting < 20% as measured by technetium-99m-macroaggregated albumin (99mTc-MAA) on single photon emission computed tomography (CT).","Patients were excluded if they had a history of allergic reactions or hyperbilirubinemia X2 mg/dl attributed to prior capecitabine, had not recovered from adverse events due to agents administered > 4 weeks earlier (excluding chronic neuropathy or alopecia), or had received any chemotherapy, radiotherapy or investigational agent <= 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to screening. Pregnant/nursing women, those using insufficient birth control methods (where appropriate), or any patient who had an uncontrolled or intercurrent illness that would limit compliance with study requirements or effect the interpretation of the results were excluded.",within the first 8 weeks of therapy,NA
25750312,NCT00478634,Combination,No,Metastatic Colorectal Cancer,"Inclusion criteria were age 18 to 65 years, histopathologically or cytologically-confirmed mCRC, progressive disease despite previous therapy with FOLFOX (5-fluorouracil and oxaliplatin) or XELOX (capecitabine and oxaliplatin) plus bevacizumab (if given as part of local standard practice), one or more measurable lesions per the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0 (25), World Health Organization performance status 0 or 1, and adequate organ function","Exclusion criteria included Gilbert’s syndrome or other conditions associated with deficient bilirubin glucuronidation, homozygosity for the UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) *28 allele, previous irinotecan or mTOR inhibitor treatment, long-term immunosuppressive therapy, any severe or uncontrolled medical conditions, and untreated or unstable central nervous system metastases.",in the first two cycles,NA
30988080,NCT02650752,Combination,No,Central Nervous System Metastases,"The study included patients with HER2þ breast cancer as defined by IHC with the score of 3þ, or if 2þ with confirmatory FISH ratio of 2.0. Radiologic evidence of new or progressive parenchymal brain metastasis or leptomeningeal disease by MRI of the brain or spine or CSF cytology evidence of new or persistent leptomeningeal disease was required. The study was later amended to include new or progressive intramedullary spinal cord metastases, as this diagnosis was considered as CNS metastases. Prior lapatinib at a standard FDA-approved dose and capecitabine were allowed as long as capecitabine exposure was more than 6 months prior to the study enrollment. Patients must have received prior trastuzumab or chemotherapy for MBC unless the CNS was the only site of metastasis. Measurable disease was not required. Performance status between 0–2 on Eastern Cooperative Oncology Group (ECOG) scale was allowed. Patients must have had adequate organ function. Prior CNS-targeted therapies (including radiotherapy, surgery, or intrathecal therapy) were allowed.",NA,during cycle 1,NA
25142843,EudraCT: 2007-001021-10,Combination,No,Metastatic or Unresectable Renal Cell Carcinoma,NA,NA,NA,NA
26715573,NCT00551096,Combination,No,advanced solid tumors,"Patients were ≥18 years old, with an Eastern Cooperative Oncology Group (ECOG) status of ≤1, and ≥3 month life expectancy. Patients were required to have adequate hematologic function (ANC >1500/mm3, platelet >100, 000 mm3, hemoglobin >9.0 g/dL), liver function (transaminases <2.5 times the upper limit of normal [ULN], or <5 times ULN if known liver metastasis; and bilirubin <1.5 times the ULN), and renal function (creatinine <1.5 times the ULN). Eligible patients also had evaluable disease based on the Response Evaluation Criteria in Solid Tumors (RECIST v1.0)","Study specific exclusion criteria included therapeutic anticoagulation, uncontrolled hypertension, symptomatic central nervous system involvement, abnormal electrolytes despite therapy, or a significant recent cardiac event. Additionally, patients with refractory or active gastrointestinal symptoms were excluded. Once the MTD was established, the cohort was expanded to include patients with advanced biliary or pancreatic malignancies who had not previously received systemic chemotherapy.",the first 28-day cycle,NA
27106554,NA,Combination,No,pancreatic cancer,"Eligible patients had histologically confirmed non-metastatic pancreatic cancer and were treatment naïve. Resectability was determined by a surgical oncologist using the Intergroup definition of borderline resectable pancreatic cancer. Patients had to be >= 18 years old, be able to provide written informed consent, have an Eastern Cooperative Oncology Group performance status of 0–2, and have adequate hematologic, renal and hepatic function, normal magnesium levels.","Ineligibility criteria included prior radiation to any area within the planned radiation field, history of hypersensitivity to fluoropyrimidines or HDACs, Dihydropyrimidine dehydrogenase deficiency, any significant uncontrolled medical conditions, coumadin, pregnancy or breast feeding.",during the first 4 weeks,NA
25267761,NA,Single Drug,No,Locally Advanced or Metastatic Breast Cancer,"The study was open to women at least 18 years of age, with pathologically confirmed locally advanced or metastatic carcinoma of the breast, progressive within 6months of last therapy. Eligible patients had received at least two prior chemotherapeutic regimens for breast cancer, with at least one given in the locally advanced or metastatic setting. Unless the patient was not eligible or intolerant to any of these agents, prior treatments must have included an anthracycline, a taxane, and capecitabine, as well as trastuzumab for patients with HER2-overexpressing tumors. There were no restrictions regarding the number of prior treatments with hormonal, biologic, or immunotherapeutic agents. A wash-out of at least 2 weeks was required for most anticancer therapies (including chemotherapy, radiation, and hormonal therapy). HER2-targeted agents and investigational therapy were to be discontinued at least 3 weeks before initiation of study treatment. Additional eligibility requirements included measurable or evaluable disease,20 Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, life expectancy of at least 3 months, and adequate renal, hepatic, and bone marrow function","Patients who were pregnant, breast-feeding, or had active brain metastases or any other significant, active, concurrent medical illness that would have precluded study treatment were ineligible. The study was revised during dose escalation to exclude patients with persistent residual neuropathy more than grade 1.",in cycle 1,NA
30858085,NCT02010567,Combination,No,locally advanced rectal cancer,"Adult patients with clinical T3-4 N0 or clinical T1-4 N+, pathologically-confirmed rectal cancer and ECOG performance status of ≤2 were eligible. During the phase Ib dose-finding portion, patients with metastatic rectal cancer were permitted if their primary site met eligibility requirements and CRT was recommended as initial therapy for palliation by the multidisciplinary tumor board.","Exclusion criteria included patients with baseline ≥ grade 2 diarrhea, prior pelvic RT, or prior treatment with a topoisomerase I inhibitor. Patients whose laboratory values did not meet the following criteria were also excluded: Hemoglobin ≥10 g/dL (male); ≥9 g/dL (female); absolute neutrophil count ≥1500/mm3 ; platelets ≥100,000/mm3 ; alanine aminotransferase and aspartate aminotransferase <2.5 upper limit of normal; total bilirubin <1.5 upper limit of normal; creatinine clearance ≥50 mL/min; INR ≤2. ",12 weeks,NA
25287822,NCT00741260,Combination,No,Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer,"In part one, eligible patients had a confirmed diagnosis of a solid tumor not curable with available therapies. In part two, women with confirmed HER2-amplified metastatic or locally advanced breast cancer were eligible. HER2 statuswas documented locally byfluorescent (FISH) or chromogenicin situ hybridization (CISH), immunohistochemistry (IHC) 3+, or IHC 2+ confirmed by FISH or CISH. Patients were required to have experienced disease progression during or after  one prior trastuzumab-containing regimen administered for  6 weeks for metastatic or locally advanced disease and received prior taxane treatment. All patients were required to be age >= 18 years, with an Eastern Cooperative Oncology Group performance status <= 2, and to have adequate hematologic, renal, and hepatic function.","Patients were excluded if they had received prior treatment with capecitabine, lapatinib (excluding preplanned patients enrolled with prior lapatinib treatment), any other HER2-targeted agent, or anthracyclines (cumulative dose of doxorubicin > 400 mg/m2 orepirubicin 800mg/m2or equivalent dosefor other anthracyclines).",From first dose date to day 21,NA
31138588,NCT02361112,Combination,No,HER2-Positive Metastatic Breast Cancer,"Patients were eligible if they (i) had a confirmed histologic/cytologic diagnosis of MBC for which standard therapy failed or for which standard treatment was not available, (ii) are HER2 positive (IHC 3þ, or IHC2þ confirmed by FISH), (iii) aged between 18 and 70 years, (iv) had a measurable lesion defined by revised Response Evaluation Criteria in Solid Tumors guidelines version 1.1 (RECIST 1.1), (v) had an Eastern Cooperative Oncology Group performance status < 2, and (vi) had adequate hematologic, hepatic, and renal function","Patients were excluded if they had received capecitabine within 1 year before study entry, or if they had received prior treatment with small-molecule anti-HER2 TKIs. Other exclusive criteria included: chemotherapy, radiotherapy, hormone therapy, immunotherapy, or investigational agents within 4 weeks before treatment day 1; resistant (disease progression within 12 weeks after initiation of capecitabine) or intolerable to prior capecitabine exposure; intracranial lesions or history of brain metastases; a history of clinically significant cardiac disease, including congestive heart failure, myocardial infarction, and significant arrhythmia; and evidence of significant medical illness including severe/uncontrolled hypertension, diabetes, or thyroid disease. No limits on number of prior cytotoxic regimens for metastatic disease were required",within the first cycle,NA
28413680,"ChiCTR‑ONRC‑13,004,023",Combination,No,advanced gastric cancer,"i) Advanced gastric cancer confirmed histologically or cytologically; ii) no previous treatment with docetaxel, oxaliplatin or capecitabine, and the last chemotherapy cycle completed at least 4 weeks prior to enrollment; iii) an age of 18‑70 years; iv) an Eastern Cooperative Oncology Group Performance Status (ECOG‑PS) ≤1; v) estimated survival of at least 3 months; vi) blood parameters as follows: White blood cells ≥4.0x109/l, absolute neutrophil count ≥2.0x109/l, hemoglobin ≥100 g/l, platelets ≥100.0x1012/l; vii) aspartate aminotransferase and alanine aminotransferase ≤2.5 times the upper limit of normal levels in liver function tests, and normal renal function; and viii) written informed consent","i) Allergies to docetaxel, oxaliplatin or capecitabine; ii) inability to receive oral capecitabine; iii) malabsorption syndromes; iv) serious heart and liver dysfunction; v) brain metastases; and vii) any other factor rendering the subject unsuitable for the trial",during the first cycle,NA
30893699,UMIN000018383,Combination,No,Advanced or Metastatic Breast Cancer,"Eligible patients must have had histologically proven HER2- positive advanced or metastatic breast cancer that had been treated previously with systemic chemotherapy including trastuzumab, whether it was in neoadjuvant, adjuvant, or in an advanced or metastatic setting, be aged 20 years or older, and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2. A history of treatment with T-DM1 monotherapy was allowed. To assess efficacy, at least one assessable (measurability was not indispensable) lesion by RECIST guidelines v.1.1 was required. Other eligibility criteria were as follows: absolute neutrophil count (ANC) ≥1,500/mm3; hemoglobin ≥8.0 g/dL; platelets ≥100,000/mm3; serum total bilirubin ≤1.5 mg/dL; hepatic transaminases and alkaline phosphatase ≤100 IU/L (≤150 IU/L with liver metastasis); serum albumin ≥2.5 g/dL; serum creatinine ≤1.5 mg/dL or creatinine clearance ≥50 mL/min; non-pregnant, and no persisting grade ≥2 adverse events induced by previous chemotherapy (except for stable adverse events such as alopecia, peripheral neuropathy, skin pigmentation, and dysgeusia). ","The exclusion criteria were: any endocrine therapy, chemotherapy (including trastuzumab, T-DM1), or radiotherapy within 2 weeks prior to the start of the study; major surgery within 4 weeks of study enrollment; symptomatic brain metastasis; history of multiple cancers; discontinuation of pretreatment with trastuzumab, T-DM1, or S-1 due to adverse events; a grade 3 infusion reaction induced by HER2-directed therapies; pretreatment with a cumulative dose of epirubicin ≥500 mg/m2; pre-existing peripheral neuropathy of grade >2, and severe and/or uncontrolled medical conditions or other conditions that could affect a patient’s treatment in the study, such as active hepatic disease, uncontrolled hypertension, unstable angina, or congestive heart failure such as the presence of left ventricular ejection fraction <50%",the first cycle,NA
19839918,NA,Combination,No,advanced solid tumors,"Patients with histologically or cytologically confirmed advanced solid tumors who had failed to respond to standard therapy or for which no standard or effective treatment was available were eligible for the trial. Eligibility criteria included age < 75 years, a life expectancy of at least three months, adequate P.S (WHO scale 0-2), adequate renal (creatinine clearance > 60 ml/min) and hepatic function (serum bilirubin < 1.5 the upper limit of the reference range; transaminases < 5 the upper limit of the reference range), adequate hematological function (hemoglobin > 10 gr/dl; neutrophil count > 1.5 X 10 9/l; PLT > 100 X 10 9/l) and adequate cardiac function (LVEF > 50% and no history of myocardial infarction in the past six months). Patients with brain metastases were eligible if they had been irradiated, the brain lesions were radiographically stable and clinical improvement was evident. Patients should be off previous anticancer therapy for at least four weeks (six weeks for nitrosureas or mitomycin C).","The study excluded patients unable to receive oral medications, those with a history of allergic reaction to any of the study agents or peripheral neuropathy, or patients receiving other investigational agents. Patients were also excluded if they demonstrated evidence of any other medical problems severe enough to affect their compliance to the protocol.",on the first chemotherapy cycle,NA
19657639,NA,Combination,No,gastrointestinal malignancies,"Patients were required to have histologically conWrmed gastrointestinal solid tumor malignancy (with the exclusion of lymphomas and sarcomas). Up to two prior chemotherapy regimens in the metastatic setting were allowed. At least 4 weeks from the end of any chemo- or radiotherapy to the start of the study was required. Exclusion criteria included the following: age less than 18 years and pregnant or lactating women; psychiatric disorders that would interfere with consent of follow up; uncontrolled intercurrent illness including, but not limited to, clinically signiWcant cardiac disease not well-controlled with medication (e.g., congestive heart failure, symptomatic coronary artery disease, and cardiac arrhythmias) or myocardial infarction within the last 12 months, and serious concurrent infections; patients being anticoagulated with warfarin-based medications; patient with a known history of severe hypersensitivity reaction to Xuoropyrimidines; and patients with previous exposure to MMC or capecitabine. All women of childbearing capacity were required to have a negative pregnancy test prior to study entry, and both men and women of childbearing capacity were required to utilize an eVective contraceptive method, while on the study and for 3 months thereafter, if applicable. Patients were required to have an ECOG performance status of 0–2, as well as a life expectancy of at least 12 weeks. Patients were required to have adequate organ function deWned as follows: absolute neutrophil count (ANC) greater than 1,500/mm3; hemoglobin >9 g/dl; platelet count >= 1,00,000/mm3; creatinine <1.5 upper limit normal (ULN); serum bilirubin <= ULN; and AST/ALT <= 2.5 ULN (<5 ULN if due to liver metastases).","Patients were to have no evidence of any active serious infection, and they were to be free of other malignancies for >= 5 years (except basal and squamous cell skin cancers and carcinoma in situ of the cervix). Other exclusionary criteria included lack of physical integrity of the upper gastrointestinal tract, inability to swallow tablets or malabsorption syndrome, and patients who have an organ allograft.",in the Wrst two cycles of therapy,NA
20839949,NA,Combination,No,Locally Advanced or Metastatic Adenocarcinoma of Stomach and GE Junction,"To be eligible for the study, patients were required to have a histological diagnosis of adenocarcinoma of stomach or GE junction with evidence of locally advanced or metastatic disease. Patients with prior chemoradiation for localized disease were also eligible as long as treatment had finished at least six months before initiation of study drugs and patients had fully recovered from all treatment-related acute and late toxicities with clear evidence of disease progression or development of metastases. Eligible patients should not have received any prior chemotherapy for advanced disease. They were also required to have ECOG performance status 0–2, age ≥ 18 years, adequate bone marrow, liver, and renal function, and a measurable disease as defined by RECIST criteria. Female patients of childbearing potential were required to be neither pregnant nor breastfeeding. Postmenopausal women were required to be amenorrheic for at least 12 months. Men and women of childbearing potential were required to consent to using effective contraception while on treatment and for at least three months thereafter","We excluded patients with known allergy to any one of the study drugs, life expectancy of less than three months, and concurrent or previous invasive malignancy. Patients with lack of physical integrity of the upper gastrointestinal tract, inability to swallow tablets, or those having malabsorption syndrome were also excluded. Other exclusion criteria included concurrent infections, any serious medical illness such as significant cardiac disease, or myocardial infarction within the last 12 months, uncontrolled diabetes, peripheral neuropathy > grade 1, known DPD deficiency, evidence of CNS metastases, major surgery within four weeks of the start of study treatment, existing uncontrolled coagulopathy, unwillingness to give a written informed consent, unwillingness to participate, or inability to comply with the protocol for the duration of the study.",during the first 2 cycles,NA
23263993,NA,Combination,No,advanced pancreatic and biliary tract cancer,"To be eligible for participation in this study, patients were required to have histologically or cytologically confirmed adenocarcinoma of the pancreas or biliary tract without more than one prior systemic treatment for his or her disease. Eligible patients were required to have at least one measurable lesion as defined by RECISTv1.0 . All participating patients had to be at least 18 years of age, have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and have adequate organ and marrow function (including leukocytes≥3,000/μl, absolute neutrophil count ≥1,500/μl, platelets ≥100,000/μl, total bilirubin ≤ 2.5 x institutional upper limit of normal (ULN), AST (SGOT)/ALT (SGPT)≤5 X ULN, creatinine clearance ≥50 mL/min as calculated by the Cockcroft-Gault formula).","Exclusion criteria included concomitant radiation therapy, or other systemic cancer therapies, known brain metastases, allergy to any of the study drugs, pregnancy or nursing, HIV, second malignancy within three years, gastrointestinal malabsorption or uncontrolled intercurrent illness. Patients were also excluded if he or she had a grade 2 or greater peripheral neuropathy (as defined in the Common Toxicity Criteria, version 3.0) . In addition, the protocol required that prior systemic therapy, radiotherapy, major surgery, open biopsy or significant traumatic injury be completed more than 4 weeks from first dose of study drug. Because of drug interactions with sorafenib, use of St. John’s Wort or rifampin (rifampicin) was contraindicated. Patients were allowed to discontinue the use of these drugs to become eligible.",days 1 through 28 ,NA
20461379,NCT00320749,Combination,No,metastatic adenocarcinoma of the pancreas,"Patients were required to have histologically or cytologically conWrmed metastatic pancreatic adenocarcinoma and measurable disease per RECIST criteria . No prior chemotherapy or radiation therapy was allowed within the previous 5 years unless it was given as adjuvant treatment for pancreas cancer, in which case 4 weeks had to have elapsed from the end of the prior treatment to the beginning of this study. Patients were required to have an ECOG performance status of 0 or 1, as well as a life expectancy of at least 12 weeks. Additional eligibility criteria included adequate organ function, deWned as follows: absolute neutrophil count (ANC) greater than 1,500/mm3; hemoglobin > 9 g/dL; platelet count >= 100,000/mm3; creatinine <1.5 upper limit normal (ULN); serum bilirubin <= ULN; AST/ALT < 1.5 ULN. Patients were to have no evidence of any active infection, and they were to be free of other malignancies for >= 5 years (except basal and squamous cell skin cancers and carcinoma in situ of the cervix). Any preexisting peripheral neuropathy was required to be ·grade 1, as deWned by the NCI Common Toxicity Criteria version 3.0. All women of childbearing capacity were required to have a negative pregnancy test prior to study entry, and both men and women of childbearing capacity were required to utilize an eVective contraceptive method while on the study and for 3 months thereafter, if applicable","Exclusion criteria included the following: Age less than 18 years and pregnant or lactating women; psychiatric disorders that would interfere with consent or follow-up; uncontrolled diabetes mellitus, deWned as random blood sugar of > 250 mg/dL; patients with a history of myocardial infarction within the previous 6 months, congestive heart failure requiring therapy, or unstable angina; patients being anticoagulated with coumadin-based medications; and patients with a known history of severe hypersensitivity reaction to either docetaxel, gemcitabine, or capecitabine.",in the Wrst 2 cycles of therapy,NA
21184645,NA,Combination,No,advanced solid malignancies,"Eligibility criteria included diagnosis of solid tumors for which treatment with C or platinum containing regimens could be of benefi t,  two previous lines of chemotherapy for advanced disease. ECOG PS two, adequate hematological (ANC >= 1500/ μl, Platelet >= 100 000/ μl) renal (serum creatinine  1.5 mg/dl) and liver function (total bilirubin  ULN, AST, ALT and alkaline phosphatase (AP) <= 5 X ULN). In case of AP value between 2.5 and 5 X ULN, the hepatic isoenzyme of AP had to be  2.5 <= ULN","Exclusion criteria were resistance to fl uoropyrimidine or platinum defi ned as disease progression < six months from the last treatment with each agent, prior radiotherapy involving > 30% of active bone marrow, persisting > G1 toxicity due to previous treatment, > G1 neuropathy, > G1 hearing loss and > G2 tinnitus, impaired oral intake or abnormal absorption, symptomatic brain metastases, uncontrolled intercurrent illness, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness. The concurrent use of cytochrome P450 3A4 inhibitors was not allowed",at cycle 1,NA
22045498,NA,Combination,No,metastatic breast cancer,"Patients were required to have histologically proven metastatic breast carcinoma with documented progressive disease, to have received prior anthracycline and taxane-based therapy in the neo/adjuvant setting and/or in the Wrst-line treatment of MBC. Patients who progressed during or within 12 months of completing neo/adjuvant chemotherapy that contained an anthracycline and a taxane were also eligible. Until RD, patients with non-measurable disease according to RECIST were allowed; however, at the RD, only patients with at least one measurable lesion were to enter the study. Other requirements included age >= 18 years and <=75 years; predicted life expectancy >= 3 months; a WHO performance status (PS) of 0, 1 or 2; no severe or uncontrolled medical conditions; no symptomatic peripheral neuropathy grade >= 2 according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) (version 2.0); an ECG without clinically signiWcant abnormality; adequate haematologic (absolute neutrophil count >=2.0 X 109/L, platelets >= 100 X 109/L), liver (bilirubin <= 1.5 X upper normal limit UNL, transaminases <= 2.5, UNL unless due to liver involvement) and renal functions within 7 days before study drug administration.",NA,during the Wrst cycle,NA
23053263,NA,Combination,No,metastatic pancreatic cancer,"Patients with histologically confirmed pancreatic adenocarcinoma and documented extrapancreatic metastases were eligible for the study; those with locally advanced unresectable disease were not included. Patients were required to have either radiographically measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors) criteria or an elevated serum CA19-9 at baseline [C29 upper limit of normal (ULN)]. Prior therapy for their cancer diagnosis was not permitted unless administered in the adjuvant setting more than 6 months prior to study enrollment. Additional eligibility requirements included the following: Eastern Cooperative Oncology performance score of 0–1; age of 18 or older; life expectancy of at least 12 weeks; adequate bone marrow, hepatic, and renal function as defined by: absolute neutrophil count C1,500/lL, platelet count >= 100,000/lL, hemoglobin >= 9.0 g/dL, total bilirubin <= 1.5 X ULN, AST (SGOT) <= 2.5X ULN, ALT (SGPT) <= 2.5 X ULN, creatinine clearance >= 40 mL/min, or serum creatinine <= 1.5 X ULN; and the ability to tolerate, swallow, and absorb oral medications. ","The presence of central nervous system metastases, a positive pregnancy test, clinically significant cardiac disease, uncontrolled coagulopathy, preexisting sensory neuropathy [grade 1, recent surgery during the previous 4 weeks, prior malignancy within the past 5 years (except for basal cell skin cancer, in situ cervical cancer, and adequately treated stage I or II cancer), or any other comorbid medical conditions that would render the patient at high risk for treatment-related complications represented exclusion criteria. Patients who were on coumadin were also excluded, unless they were able to switch to an alternative form of anticoagulation (e.g., low molecular weight heparin) at least 1 week prior to starting study treatment.",during the initial 4 weeks of treatment,NA
21590447,NCT00705375,Combination,No,metastatic breast cancer,"Patients with HER2-negative, histologically conWrmed MBC were eligible for the study. It was recommended that women should have been pretreated with an anthracycline and a taxane in the neo-adjuvant, adjuvant, or metastatic settings. However, women who had a contraindication for these drugs or wished to receive an all-oral therapy were eligible for this study. Other eligibility criteria were as follows: age >18 years, performance status (ECOG) 0–2; adequate bone marrow (absolute neutrophil count >= 1.5 X 109/L and platelets >= 100 X 109/L), renal (creatinine <= 1.25 times the upper limit of normal and creatinine clearance > 50 ml/min) and liver (total bilirubin <= 1.25 times and aspartate and alanine aminotransferases <= 3.0 times the upper limit of normal, respectively) function; absence of active infection and malnutrition (loss of more than 20% of the body weight). ","Patients with brain metastases, severe cardiac dysfunction, chronic diarrhea, incomplete obstruction of the gastrointestinal tract, total colectomy, and patients unable to receive and/or comply with oral medications were excluded from the study.",during the Wrst cycle of chemotherapy,NA
20881475,NCT00121251,Combination,No,Advanced Renal Cell Carcinoma,"Adult subjects with advanced RCC with measurable disease by response evaluation criteria in solid tumors (RECIST)16 were eligible for enrollment. Histologic or cytologic confirmation of RCC (primary site or metastatic site) was required. Sarcomatoid differentiation was allowed, but pure sarcomas, collecting duct carcinomas, oncocytomas, and transitional cell carcinomas were excluded. Prior chemotherapy or sorafenib was not allowed, but subjects could have received up to 1 prior systemic therapy regimen. Additional eligibility criteria included eastern cooperative oncology group (ECOG) performance status 0 to 2, white blood cell count >= 3000 cells/mm3 , absolute neutrophil count >= 1000/mm3 , platelet count >= 100,000, serum bilirubin <= 1.5 mg/dL, asparate aminotransferase, and alanine aminotransferase (ALT) <= 2.5 X upper limit of normal, and serum creatinine <= 1.5 mg/dL or creatinine clearance > 60 mL per minute.","Exclusion criteria included known brain metastases, other active cancers, or clinically significant cardiac, renal, hepatic, pulmonary, thyroid, or psychiatric disease. Concurrent megestrol, enzyme-inducing antiepileptic drugs, rifampin, and St. John’s Wort were not allowed. ",during the first 2 cycles of therapy,NA
21404105,NA,Combination,No,metastatic colorectal cancer,"Patients were recruited at the Stanford Cancer Center in Stanford, CA. Individuals over the age of 18 with stage 4 histologically confirmed colorectal cancer, life expectancy of at least 3 months, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 were eligible for the study. Laboratory parameters for eligibility were AST or ALT levels 2.5 times ≤ upper normal limit (ULN), total bilirubin levels 1.5 times ≤ ULN, serum creatinine 1.5 times ≤ ULN, absolute neutrophil count of 1,500/mm3 and platelet count of 100,000/mm3.","Patients were excluded if they had recent major thoracic or abdominal surgery; prior chemotherapeutic or investigational agents, or radiotherapy in the preceding 4 weeks; significant non-malignant intercurrent illness; known central nervous system metastases; a history of seizures; unresolved gastrointestinal symptoms; were pregnant or lactating; serologically positive for hepatitis B, hepatitis C or HIV; or were unable to swallow capsules. Patients with any prior history of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which was symptomatic or required treatment or asymptomatic sustained ventricular tachycardia; any history of QTc prolongation (or QTc ≥ 480 msec); or presence of left bundle branch block were disqualified from the trial. However, atrial fibrillation, controlled on medication, was not excluded. A negative serum pregnancy test was required in women with childbearing potential, and all patients were required to use medically approved contraceptive precautions during the study and for 4 weeks afterwards.",during the first 2 cycles of treatment,NA
22367239,NCT01077986,Combination,No,advanced pancreatic cancer,"Patients with cytological or histological confirmed locally advanced or metastatic adenocarcinoma of the pancreas were eligible. Further inclusion criteria comprised an Eastern cooperative oncology group/World health organization (ECOG/WHO) performance status of 0, 1 or 2, measurable lesions on CT according to RECIST 1.0 criteria (for the phase II part of the study), age eighteen years of age or older and a life-expectancy of at least three months. Patients had to be mentally, physically and geographically able to undergo treatment and follow-up. Adequate renal, liver and bone marrow function was necessary. Laboratory values accompanied hereby were serum creatinine <150 μmol/L, bilirubin 1.5x upper limit of laboratory normal (ULN), aspartate aminotransferase and alanine aminotransferase <2.5x ULN or <5.0x in case of liver metastasis, white blood cell count >3.0x109, platelets >100x109, respectively.","Patients were not eligible if they had previous treatment with an mTOR inhibitor. Other exclusion criteria included pregnancy and lactation, clinical or radiological evidence of central nervous system metastasis at time of enrollment, known hypersensitivity to everolimus or other rapamycins or to its excipients, any severe and/or uncontrolled medical conditions, such as clinically significant heart conditions or myocardial infarction in 6 months prior to randomization, uncontrolled diabetes as defined by fasting glucose above 1.5x ULN, active or uncontrolled infection, serious liver disease and severely impaired lung function, or a serious concomitant systemic disorder that would compromise the safety of the patient, at the discretion of the investigator",in the first two cycles,NA
19693503,NA,Combination,No,metastatic breast cancer,"Eligibility criteria included histologically proven metastatic breast carcinoma, pretreatment with at least one line of chemotherapy for metastatic disease, age >= 18 years, ECOG performance status >2, absolute neutrophil count (ANC) >1.5 X 109/L, platelets >100 X 109/L, bilirubin <= 1.5 times the upper limits of normal (ULN), ALT <= 2.5 times the ULN, creatinine <= 1.5 times the ULN, left ventricular ejection fraction (LVEF) >= 50%, and life expectancy >12 weeks. ","Exclusion criteria included the presence of active brain metastases, a history of cardiac disease, and pretreatment with a cumulative dose of doxorubici>300 mg/m2 or of epirubicin >600 mg/m2.",during the Wrst cycle of treatment,NA
NA,NA,NA,NA,NA,NA,NA,NA,NA
20397772,NA,Combination,No,pancreatic carcinoma,"Patients with resected pancreatic adenocarcinoma were eligible for this trial. Eligibility criteria for adjuvant radiotherapy included nonmetastatic pancreatic adenocarcinoma, age younger than 75 years, 0–2 Eastern Cooperative Oncology Group performance score, granulocyte count greater than 3 000 granulocytes/ml, platelet count greater than 100 000 platelets/ml, and hemoglobin level greater than 10 g/dl. Before starting chemoradiotherapy, the following tests were performed in all patients: physical examination, complete blood count, blood chemistry, chest radiography. Abdominal computed tomography (CT) with intravenous contrast medium was always performed after surgery. Cancer staging was performed according to the Union Internationale Contre le Cancer 1997 classifi cation . Prior chemotherapy administration was allowed.",Patients with a history of prior upper abdominal radiotherapy were ineligible for this trial. ,NA,NA
24661655,NCT00858429,Combination,No,Hepatic Malignancies,"DISEASE CHARACTERISTICS: Histologically confirmed diagnosis of 1 of the following: Intrahepatic cholangiocarcinoma. Metastatic cancer confined to the liver. Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension as ≥ 20 mm by conventional techniques or as ≥ 10 mm by spiral CT scan. Must have tumor volume ≤ 50% of total liver volume based on visual estimation. PATIENT CHARACTERISTICS: ECOG performance status 0-2. ANC ≥ 1,500/mm^3. Platelet count ≥ 75,000/mm^3. Serum creatinine ≤ 2.0 mg/dL. Serum bilirubin ≤ 1.5 times upper limit of normal. Albumin ≥ 2.0 g/dL. No baseline symptoms or laboratory values > grade 2 in severity by NCI CTCAE v 3.0 criteria. Not pregnant or nursing. Fertile patients must use effective contraception. No malabsorption syndrome. No severe liver dysfunction or pulmonary insufficiency. No complete occlusion of the main portal vein. No contraindication to iodine-based contrast agents. No contraindication to hepatic artery catheterization (e.g., vascular abnormalities or bleeding diathesis). No prior unanticipated severe reaction to fluoropyrimidine therapy, known hypersensitivity to fluorouracil, or known dihydropyrimidine dehydrogenase deficiency. PRIOR CONCURRENT THERAPY: No prior radiotherapy to the liver. No more than 2 prior therapies for metastatic disease to the liver. No prior intervention to or compromise of the Ampulla of Vater. At least 4 weeks since prior and no concurrent sorivudine or brivudine. No concurrent cimetidine",NA,During treatment (3 cycles) and up to 30 days post-treatment,NA
22681700,NA,Combination,No,oligometastatic colorectal cancer,"The eligibility criteria included histopathologically confirmed oligometastatic colorectal cancer (1–3 metastases with largest diameter 5 cm or local recurrens of rectal cancer plus 1–2 metastases of ≤ 5 cm in technically or clinically irresectable disease, extention to the recruitment of patients in a neoadjuvant situation (before planned resection). Patients with first-, second- or third-line therapy of oligometastatic colorectal cancer were eligible for this study in adequate renal, hepatic and hematologic function. Additional inclusion criteria were age ≥ 18 years, Karnofsky performance status ≥ 70%, creatinin clearance > 30 mL/min calculated according to Cockroft and Gault, total bilirubin concentration less than 2.5 and transaminases less than 2.5 times the upper normal limit with hepatic metastases after image-guided exclusion of intra- or extrahepatic cholestasis and transaminases less than 5.0 times the upper normal limit, neutrophils > 2.5 x 109/L, platelet count > 125 x 109/L, estimated life expectancy of more than 3 months, written informed consent and tumor assessment analyzed according to “Response Evaluation Criteria in Solid Tumors” (RECIST).","Key exclusion criteria included previously administered radiotherapy not allowing the required dose, significant cardiac disease (heart failure NYHA III-IV, myocardial infarction within the last three months or symptomatic heart disease) and cerebrovascular disorders thought to adverse-affects treatment compliance. Patients with the following conditions were also ineligible: serious, uncontrolled infections, malabsorption syndrome, known sensitivity to fluoropyrimidines and dihydropyrimidine dehydrogenase deficiency, allergy to platin derivative, peripheral neuropathy, current treatment with sorivudin or bivudin and treatment history of other cancer or participation in another clinical trial within 4 weeks of the start of treatment. Pregnant or lactating patients and women with childbearing potential who lacked a reliable contraceptive method were also excluded.",NA,NA
23403636,NCT00452673,Combination,No,Advanced Breast Cancer,"Women aged 18 years or more with a prior histologic diagnosis of invasive metastatic breast cancer who had received prior taxane and/or anthracycline therapy (either in the adjuvant or metastatic setting) were eligible. Performance status of 0–1 (Eastern Cooperative Oncology Group scale) was required. Patients were required to have a paraffin-embedded tumor sample available for analysis and presence of unresectable metastatic and/or locally advanced breast cancer. For the expansion cohort, measurable tumor [using Response Evaluation Criteria in Solid Tumors (RECIST)] was also required. Local (chest wall) relapse, if unresectable, was considered eligible for enrollment in this trial. Patients were permitted to have received up to 2 prior chemotherapy-containing regimens in the advanced setting (no limit on hormonal therapies). No prior capecitabine or Src inhibitor therapy was allowed, no antitumor therapy was allowed within 21 days before study entry (7 days for hormonal therapy), and no prior intravenous bisphosphonates were allowed within 7 days before study entry. Women of childbearing potential were eligible provided that adequate contraception was used during study","Patients with symptomatic central nervous system metastases were excluded as were those with significant cardiovascular disease (left ventricular ejection fraction of <40%, congestive heart failure deemed as New York Heart Association Class III or IV), recent myocardial infarction (within 6 months), major conduction abnormality (unless pacemaker is in place), grade >= 1 pleural or pericardial effusion, creatinine >= upper limit of normal, grade >= 1 hepatic abnormalities (grade 2 permitted if due to liver metastasis), grade >= 2 hematologic abnormalities, calcium < lower limit of normal, and grade >= 2 other electrolyte abnormalities. Patients on therapeutic doses of coumadin or strong inhibitors of CYP3A4 were excluded. ",during the first cycle,NA
19858399,NA,Combination,No,Advanced Pancreatic Cancer,"Eligible patients had inoperable histologically/cytologically proven locally advanced or metastatic pancreatic ductal adenocarcinoma/undifferentiated carcinoma. Patients were older than 18 years; had Eastern Cooperative Oncology Group performance status (PS) <= 2; and had adequate renal (creatinine clearance  50 mL/min), bone marrow (platelets > 100 X 109/L, leukocytes > 3.0 X 109/L, and absolute neutrophil count [ANC] > 1.5 X 109/L), and liver (total bilirubin < 2 X the upper limit of normal) function, a serum albumin  26 g/L, and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST).28 ","Exclusion criteria included any prior chemotherapy, radiotherapy, or investigational agents; intracerebral/meningeal metastases; uncontrolled hypertension; significant cardiovascular comorbidity; major bleeding diathesis; full-dose anticoagulation before study; aspirin use (>= 325 mg/d); major surgery/traumatic injury within 28 days; nonhealingwound/fracture; secondmalignancy; uncontrolled comorbid conditions; and pregnancy/lactation. After a protocol amendment, patients with duodenal invasion were permitted.",first-cycle,NA
24551455,NA,Combination,No,Advanced or Metastatic Breast Cancer Patients,"Patients aged 18 years or more, with histological proven locally advanced (inoperable) or metastatic breast cancer with the following characteristics were eligible: pre- or postmenopausal, pretreated with anthracyclines and taxanes or not suitable for each of these drugs or both due to clinical conditions, HER2-negative or HER2-positive not suitable or no longer suitable to antiHER2 agents due to cardiac impairment, measurable or evaluable disease, life-expectancy > 12 weeks, ECOG PS ≤ 2, adequate (bone) marrow, liver, and renal function (absolute neutrophil count > 1.5 × 109/L, platelets > 100 × 109/L, haemoglobin > 10 g/dL; total bilirubin within the normal institutional limits, AST/ALT < 2.5 × UNL, or < 5 × UNL in the case of liver involvement, creatinine within normal institutional limits, or creatinine clearance ≥ 50 mL/min, according to Cockroft-Gault formula), INR < 3 at the screening for patients taking warfarin, and absence of cerebral or leptomeningeal metastases. Written informed consent was required",NA,the 1st cycle,NA
22037922,NCT 00544063,Combination,No,metastatic solid tumors,"Patients with histologic confirmation of metastatic carcinoma, independently the site of primary tumor, evaluable or not according to RECIST criteria were eligible. Main additional inclusion criteria were age between 18 and 75 years, WHO performance status <= 2, life expectancy >= 16 weeks, adequate hematological, liver, and renal functions, rest period of at least 4 weeks in case of prior myelosuppressive chemotherapy, and no previous treatment with irinotecan or oxaliplatin or capecitabine.","Patients who presented with symptomatic brain metastases or carcinomatous meningitis, concurrent severe infection or major organ failure, malabsorption syndrome or dysphagia, prior history of major gastrointestinal resection, bowel obstruction, or uncontrolled epilepsy were not eligible",during the first three cycles,NA
20215798,NA,Combination,No,Advanced Colorectal Cancer ,"Patients with histologically confirmed aCRC after failure of a 1st-line therapy were eligible for study entry. Additionally, patients had to meet the following criteria: measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST), WHO performance status ≤ 2, age ≥ 18 years, adequate bone marrow function (absolute neutrophil count (ANC) ≥ 1,500/ml, platelet count ≥ 100,000/ml), adequate hepatic function (bilirubin ≤ 1.25 times the upper limit of reference range (ULRR); alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 times the ULRR or ≤ 5 times the ULRR in the case of liver metastases), adequate renal function (calculated creatinine clearance ≥ 30 ml/min). ","Exclusion criteria were: life expectancy of less than 12 weeks, use of sorivudine or brivudine, phenytoin, carbamazepine, barbiturates, rifampicin, or St John’s Wort, prior treatment with gefitinib or capecitabine, no appropriate contraception in fertile patients.",during the first 6 weeks of treatment,NA
19443364,NA,Combination,No,Pretreated Pancreatic Cancer,"Patients were eligible if their disease was in progression after at least one line of chemotherapy or chemo/radiotherapy. They had to have histologically or cytologically proven, surgically unresectable, locally advanced or metastatic pancreatic adenocarcinoma. Other inclusion criteria were age 18 to 80 years, ECOG performance status ≤1 and adequate organ function (leukocyte count >3,500/μL, haemoglobin >10.0 g/dL, serum creatinine <1.25 times upper limit of normal (ULN), transaminases and alkaline phosphatase <2.5 times ULN, bilirubin <1.5 times ULN).",NA,during the first two treatment courses,NA
21552099,NA,Combination,No,Advanced Pancreatic and Biliary Carcinomas,"Patients with histologically confirmed pancreatic adenocarcinoma or biliary tract carcinoma (including cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma) not amenable to surgical resection were eligible for enrollment on the dose-finding portion of the study. An expanded cohort specifically for advanced pancreatic cancer patients was enrolled at MTD. Patients were required to have either radiographically measurable disease based on criteria as defined by the Response Evaluation Criteria in Solid Tumors Committee, and/or an elevated baseline serum CA 19-9 >= 2 X upper limit of normal (ULN). Prior therapy for their cancer diagnosis was not permitted unless administered in the adjuvant setting more than 6 months before study enrollment. Additional eligibility requirements included the following: Eastern Cooperative Oncology Group performance status of 0 or 1; adequate bone marrow, hepatic, and renal function as defined by absolute neutrophil count Z1500/mL, platelet count >= 100,000/mL, hemoglobin >= 9.0 g/dL, total bilirubin <= 1.5 x ULN, aspartate aminotransferase and alanine aminotranferease <= 2.5 ULN, and creatinine clearance >= 40 mL/min and/or serum creatinine <=1.5 x ULN; ability to tolerate and absorb oral medications; no concurrent use of warfarin; no central nervous system metastases; no prior malignancy except for basal cell skin cancer, in-situ cervical cancer, or treated stage 1 or 2 cancer from which the patient was in complete remission for at least 5 years; and no other medical conditions that, in the opinion of the investigator, would render the patient at high risk of treatment-related complications.",NA,during the first 4 weeks of treatment,NA
20216541,NA,Combination,No,metastatic colorectal cancer,"All eligible patients had histologically confirmed mCRC not amenable to curative surgery, age between 18 and 75 years, an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 –2 and a life expectancy > 12 weeks. In addition, adequate organ function was required as indicated by an absolute neutrophil count > 1.5 x 109/l, a platelet count > 75 X 109/l, serum creatinine < 1.3 mg dl, serum bilirubin < 1.25 times the normal upper limit (UNL) and serum transaminases < 3.0 times UNL. ","The exclusion criteria included active second malignancy (except for non-melanoma skin cancer or in situ cervical cancer), symptomatic metastases in the central nervous system or carcinomatous leptomeningitis, uncontrolled severe infection, major organic failure, ischemic cardiopathy, active inflammatory bowel disease or chronic diarrhoea syndrome, bowel obstruction or prior extensive pelvic radiotherapy.",NA,NA
21931969,NA,Combination,No,advanced malignancies,"Eligible patients were ≥18 years old with metastatic or unresectable malignancy refractory to standard therapy or for which a capecitabine-based regimen was appropriate, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, had recovered from the acute toxicity of prior therapies and had adequate hematologic, renal and hepatic function. ","Patients with prior exposure to trabectedin or known hypersensitivity to dexamethasone, capecitabine or any of the components of the trabectedin formulation and those who were pregnant, lactating or of childbearing potential and not using adequate contraception were excluded. Patients also were excluded if they had grade ≥2 peripheral neuropathy, pre-existing grade >1 nausea and/or vomiting, clinically significant gastrointestinal disorders that could prevent absorption of capecitabine, known central nervous system metastases or other uncontrolled or serious medical conditions. Patients <4 weeks from radiation, hormonal and biological treatment or chemotherapy (<6 weeks for nitrosoureas or mitomycin C) or therapy with another investigational agent were excluded.",in cycle 1,NA
20839031,NA,Combination,No,advanced gastric cancer,"Patients 18–75 years of age with pathologically documented gastric or gastroesophageal junction adenocarcinoma were eligible for inclusion in this study. They were required to have metastatic or unresectable disease, either initially diagnosed or relapsed after surgery, with no history of chemotherapy or radiotherapy. Measurable or evaluable lesions according to Response Evaluation Criteria in Solid Tumours (RECIST) were required for enrollment. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and adequate organ function defined as: Hemoglobin ≥8.0 g/dL, absolute neutrophil count (ANC) ≥1,500/mm3, platelet count ≥100,000/mm3, total bilirubin ≤2.0 mg/dL, alanine aminotransferase (ALT) and aspartate aminotranferase (AST) ≤ three times the upper limit of normal (ULN) or ≤ five times the ULN in the case of liver metastasis, prothrombin time (international normalized ratio) ≤1.5, partial thromboplastin time ≤1.5×ULN, and serum creatinine ≤1.5 mg/dL.","Patients with a history of or concurrent malignancies other than gastric cancer (except for curatively treated nonmelanoma skin cancer or in situ carcinoma of the cervix uteri), obvious peritoneal seeding with bowel obstruction, serious gastrointestinal bleeding, peripheral neuropathy, significant neurologic or psychiatric disorders, seizure disorder requiring medication, clinically active serious infection, or other serious illness were excluded. Patients were excluded if they had cardiac diseases such as congestive heart failure (> New York Heart Association class 2), active coronary artery disease within 6 months, arrhythmias requiring antiarrhythmic therapy except beta blockers or digoxin, and uncontrolled hypertension. Pregnant or lactating women and women of child-bearing potential not employing adequate contraception were also excluded.",in the first cycle of treatment,NA
22648745,NA,Combination,No,metastatic colorectal cancer,"Patients aged more than 18 years with histologically proven mCRC who had received no more than one line of treatment in the metastatic setting were eligible. Patients had to have radiologically measurable disease, Eastern Cooperative Oncology Group (ECOG) performance status 0–2, and adequate end organ function (stable electrocardiogram, creatinine clearance >= 50 mL/min, bilirubin, aspartate aminotransferase (AST) and alanine transaminase (ALT) concentrations <=3 X the institutional upper limit of normal, alkaline phosphatase (ALP) <= 5 X the institutional upper limit of normal, hemoglobin >= 10 g/dL, absolute neutrophil count (ANC) >= 1.5 x 109/L, platelets >= 100 x 109/L), with estimated life expectancy of 6 months or more.","Patients were excluded if they had prior exposure to oxaliplatin, were pregnant or lactating, or had unacceptable comorbidities that could result in excessive toxicity (unstable cardiac disease, active infection, active or extensive brain metastases, uncontrolled diarrhea, moderate to severe renal failure, moderate or severe neuropathy).",within the first 2 cycles,NA
19936751,NA,Combination,No,advanced gastric cancer,"All patients entered into this study were aged between 18 and 70 years and had histologically or cytologically conWrmed unresectable or metastatic gastric adenocarcinoma. Eligibility criteria also included estimated life expectancy >= 12 weeks; adequate bone marrow function (absolute neutrophil count [ANC] >= 1.5 x 109/L and platelet count >= 100 X 109/L); adequate renal function (serum creatinine < 1.5 mg/dl or calculated creatinine clearance >= 60 ml/min by the Cockcroft and Gault formula); adequate hepatic function (total bilirubin level ·2 times institutional upper limit of normal [ULN], and serum transaminases levels <= 3 times institutional ULN).","Patients who had received prior chemotherapy were excluded. Patient’s performance status was assessed using the Eastern Cooperative Oncology Group (ECOG) criteria, and those patients with performance status <= 2 were considered eligible. Eligibility also included the ability to reliably tolerate and to comply with oral medication, and patients with gastro-intestinal obstruction or evidence of ongoing serious gastro-intestinal bleeding were excluded. Patients also were excluded if they had evidence of central nervous system metastasis, peripheral neuropathy >= grade 2, serious uncontrolled concomitant disease, other primary malignancy (except squamous or basal cell skin caner or cervical carcinoma in situ) within 5 years, or if they were pregnant or breastfeeding.",during the Wrst two cycles of treatment,NA
19596976,NA,Combination,No,Head and Neck Cancer,"The study was open to non-pregnant patients over 17 years of age with previously untreated and measurable locally advanced stage III or IV squamous cell carcinoma of the oral cavity, oropharynx, or hypopharynx (T2-4, N-0-3, M0), ECOG performance status ≤2, no significant co-morbidities, and a signed study-specific written informed consent approved by the University of Virginia Protocol Review and Human Investigation Committees. ",NA,NA,NA
21853311,NCT00960349,Combination,No,advanced gastric cancer,Japanese patients >= 20 years of age with histologically or cytologically confirmed previously untreated recurrent or metastatic unresectable gastric adenocarcinoma were eligible for inclusion. Patients were required to have a life expectancy >= 12 weeks and a World Health Organization performance status of 0 or 1.,"The main exclusion criteria were as follows: significant respiratory, cardiac, hepatic or renal dysfunction; unstable brain metastases; poorly controlled hypertension; significant haemorrhage (>30 ml bleeding/episode in the previous 3 months) or haemoptysis (>5 ml fresh blood in the previous 4 weeks); arterial thromboembolic events in the previous 12 months; history of other malignancies within the previous 5 years; any unresolved toxicity according to Common Terminology Criteria for Adverse Events (CTCAE) from prior radiotherapy; recent (<14 days) major thoracic or abdominal surgery; and incomplete recovery from prior surgery",within the first 21 days of cycle 1 ,NA
24173967,NCT00920868,Combination,No,metastatic colorectal cancer,"Eligibility in part 1 (dose escalation) required a histologically confirmed metastatic or unresectable solid tumor malignancy. No prior treatment for metastatic disease was permitted in the colorectal expansion cohort. Prior adjuvant treatment with a 5-FU/LV or capecitabine based regimen was allowed if it was completed at least 6 months before study registration. Prior adjuvant therapy can have included oxaliplatin and/or bevacizumab only if completed at least 12 months before study registration. Inclusion criteria for all subjects included age ≥18, Karnofsky performance status (KPS) ≥70 %, life expectancy of at least 3 months, adequate organ and marrow function, and negative pregnancy test in women of child-bearing age.","Exclusion criteria for all subjects included anti-cancer therapy within 28 days prior to start of treatment, systolic blood pressure >150 and/or diastolic blood pressure > 100 mmHg, significant cardiovascular disease, history of fistula, history of gastrointestinal perforation, serious non-healing wound, proteinuria at the time of screening, and any other concurrent severe and/or poorly controlled medical condition that could compromise safety of treatment. Patients with known central nervous system (CNS) metastases were excluded.",in the first 21-day cycle,NA
20429725,NA,Combination,No,advanced gastro-oesophageal cancer,"Patients were required to have histologically confi rmed adenocarcinoma of the lower oesophagus, gastro-oesophageal junction or stomach not amenable to surgical resection. Eligibility criteria included measurable or non-measurable disease; estimated life expectancy > 12 weeks; World Health Organisation performance status 0 – 1; age > 18 years; no prior chemotherapy other than adjuvant chemotherapy completed at least six months before inclusion; adequate bone marrow function (neutrophil count > 1.5 x 10 9 /l; platelets > 100 x 10 9 /l); adequate hepatic function (serum bilirubin <= 1, 5 x upper normal limit (UNL); transaminase <= 3 X UNL, however in cases of liver metastases, there were no upper limit for transaminases); adequate renal function (calculated creatinine clearance >= 60 ml min –1 by the Cockroft and Gault formula). Other inclusion criteria were treatment start within eight days after inclusion, ability to tolerate oral medication, no peripheral neuropathy, no co-existent severe medical illness, no sign of brain metastases and no concomitant treatment with other anticancer drugs",Females were not included if they were pregnant or lactating,the first cycle,NA
20857171,NA,Combination,No,advanced solid tumors,"Adult patients, at least 18 years of age, who had radiographic or clinical evidence of an active solid tumor malignancy for which no curative therapy was available were eligible for this study. Patients were required to have an Eastern Cooperative Oncology Group performance status of 0, 1 or 2, absolute neutrophil count (ANC) ≥2000/mm3 , platelets ≥150,000/mm3 , hemoglobin ≥9.0 gm/dL, serum creatinine ≤2.0 mg/dL, bilirubin within the institutional upper limit of normal (IULN) regardless of liver involvement secondary to tumor. Serum glutamate-oxaloacetate transaminase (SGOT) was to be ≤3 times the IULN, but SGOT ≤5 times the IULN was allowed if there was liver involvement by tumor. Additionally, patients were required to be positive for a tumor marker if appropriate based on the type of cancer. ","Patients previously treated with irinotecan, capecitabine, infusional 5-fluorouracil (5-FU), mitomycin C, or nitrosureas were excluded from participation in the study as were patients who had been treated previously with more than 2 chemotherapy regimens or who had undergone progenitor cell transplantation. Other exclusions were concomitant diagnoses of coronary artery disease, cerebrovascular disease, active inflammatory bowel disease, or chronic diarrhea.",during the first treatment cycle,NA
24574780,NA,Combination,No,gastric cancer,"The eligibility criteria included the following: (1) pathologically confirmed adenocarcinoma; (2) postoperative classification of anyTN + M0 according to the 7th edition of the American Joint Committee on Cancer TNM Classification; (3) World Health Organization performance status of ≤ 1 and age ≤ 70 years; (4) no prior or concurrent malignancy (except non-melanoma skin cancers or in situ carcinoma of the cervix); (5) no history of abdominal radiation; and (6) hemoglobin level ≥ 10.0 g/L, leukocyte count ≥ 3.5 × 109/L, neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L and normal liver and kidney function",NA,During the five-week treatment,NA
20421151,NA,Combination,No,RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA OF THE HEAD,"Patients with resectable pancreatic cancer were prospectively enrolled on a clinical trial approved by the Dana-Farber/Harvard Cancer Center institutional review board. Patients were required to have biopsy-proven adenocarcinoma of the pancreatic head or neck amenable to surgical resection with a pancreaticoduodenectomy. Patients with ampullary cancer, biliary cancer, or duodenal cancer were excluded. Also, patients with distal tumors of the body or tail of the pancreas requiring a distal pancreatectomy were excluded. Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1 was required. Patients were required to have a pancreatic protocol computed tomography (CT) scan that, in the judgment of the surgeon and the rest of the multidisciplinary team, showed a resectable tumor. Patients were also required to have no evidence of metastatic disease based on CT of the chest/abdomen/pelvis and diagnostic laparoscopy (including cytology). Laboratory evaluation included CA 19-9, electrolytes (Na, K, Cl, CO2, Ca, Mg, Phos), complete blood count (CBC), liver function tests (SGOT, SGPT, alkaline phosphatase, total bilirubin, direct bilirubin), and renal function tests (BUN, creatinine). Patients were required to have ANC >= 1,500 cells/mm3,platelet count >= 100,000 cells/mm3, AST and ALT <= 2.5 times the upper limit of normal, total bilirubin <= 2.5 times the upper limit of normal if patient had recent biliary stenting, total bilirubin <= 1.5 times the upper limit of normal if no biliary stenting was done serum creatinine within normal range (0.6–1.5 mg/dl) with a creatinine clearance >= 30 ml/min (as estimated by Cockroft Gault equation).","Patients were not permitted to have any prior therapy for pancreatic cancer, radiation therapy or chemotherapy in the last 5 years, any prior radiation therapy to the upper abdomen, any invasive cancer in the last 5 years, and any known dihydropyrimidine dehydrogenase (DPD) deficiency.",within 3 weeks of the start of radiation therapy,NA
24091982,NCT00555620,Combination,No,advanced gastric cancer,"The study population comprised patients aged ≥18 years with histologically or cytologically confirmed stage IV gastric or gastro-esophageal junction adenocarcinoma (type II or type III tumors) that was measurable using Response Evaluation Criteria in Solid Tumors (RECIST v1.0 ). Additional inclusion criteria were: no prior systemic therapy for metastatic disease, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ function","Patients were excluded if they had received radiation therapy or surgery within 4 weeks of enrollment, except palliative radiotherapy to non-target lesions within the previous 2 weeks. Additional exclusion criteria were: recurrent disease while receiving adjuvant therapy or a recurrence-free interval <6 months after completing adjuvant therapy, brain metastases, carcinomatous meningitis, or uncontrolled hypertension. Patients with clinically significant cardiovascular events or pulmonary embolism ≤12 months prior to starting study treatment were also excluded",during the first 3-week cycle of therapy,NA
20092990,NA,Combination,No,advanced pancreatic and other gastrointestinal malignancies,"Entry criteria included patients with histologic or cytologic diagnosis of locally advanced or metastatic pancreatic adenocarcinoma and other GI cancers, who had failed prior chemotherapy. All patients must have had at least one previously unirradiated unidimensionally measureable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) scan of >= 20 mm (by conventional CT) or Z10 mm (by spiral CT). Other eligibility criteria included the following: age 18 years or older, Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower, and adequate bone marrow (absolute neutrophil count [ANC] >= 1500/ml, and platelets > 100,000/ml), kidney (creatinine <= 1.5 mg/dl), and liver function (bilirubin <= 2 mg/dl, transaminase levels <= 2.5 times the upper limit normal (ULN), alkaline phosphatase <= 2.5 times ULN or 5 times ULN for patients with liver metastasis). Prior 5-FU or capecitabine was permitted in this Phase I study. Patients were required to provide written informed consent.","Patients were excluded if they had brain or meningeal metastasis, were taking herbal medicines or supplements r7 days prior to study entry, had known hypersensitivity or intolerance to either PHY906 or capecitabine, or had any preexisting medical condition of sufficient severity to prevent full compliance with the study.",first cycle,NA
22669361,NA,Combination,No,gastric cancer,"Eligibility criteria were: histologically or cytologically confirmed adenocarcinoma of the stomach or lower third of the esophagus; inoperability determined by clinical evaluation, radiological imaging, or during laparotomy; age C18 years; estimated life expectancy >12 weeks; clinical stage T4N-/?M0 or TxNxM1; local relapse not deemed amenable to curative surgery; no prior chemotherapy for advanced or locally relapsed disease; previous adjuvant chemotherapy completed at least 6 months before registration; measurable/evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 3.0 ; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; and signed informed consent. Required baseline laboratory values included: absolute neutrophil count (ANC) >=2,000/mm3; hemoglobin >10.0 g/dL; platelet count >=100,000/mm3; creatinine <1.5 times the upper limit of normal (ULN) (if the threshold value was given, creatinine clearance would be evaluated according to the Cockroft–Gault formula, and it should be >= 60 ml/min); transaminases <2.5 times the ULN; alkaline phosphatase<=2.5 times the ULN; and total bilirubin<1.0 times the ULN","Exclusion criteria were: prior chemotherapy for metastatic or relapsed disease; New York Heart Association Class 3 or 4 heart disease; clinically significant heart disease, including but not limited to myocardial infarction within the past 6 months, congestive heart failure, unstable angina, clinically significant pericardial effusion, or serious arrhythmia; peripheral neuropathy grade >=2 ; any serious (uncontrolled or requiring treatment) active infection; any history or evidence of central nervous system (CNS) disease, e.g., brain metastases; any known hypersensitivity to the study drug components; lack of physical integrity of the upper gastrointestinal tract; malabsorption syndrome, or inability to take oral medication; pregnant or lactating women; and fertile patients (male and female) unwilling to use effective means of contraception during the study",the first 2 cycles (6 weeks),NA
23235319,NA,Combination,No,Advanced Pancreatic Cancer,"Eligible patients were aged between 18 and 75 years with a confirmed histological or cytological diagnosis of pancreatic carcinoma. Additional inclusion criteria were: advanced disease in patients not responding to primary treatment and/or having no other effective treatment available, Eastern Cooperative Oncology Group performance status <= 2, no other serious disease, estimated life expectancy 1 8 weeks, acceptable bone marrow function (absolute neutrophil count >= 1,500/ml, platelet count >= 100,000/ml), adequate hepatic function [bilirubin <= 1.5 times the institutional upper limit of normal (ULN) and liver enzymes <= 1.5 times the ULN ( <= 5 times the ULN in patients with known liver metastasis)] and adequate renal function (serum creatinine <= 130 mol/l or creatinine clearance > 30 ml/min).","Exclusion criteria included: prior treatment with erlotinib, known intracerebral metastasis, history of pulmonary interstitial disease, history of significant uncontrolled cardiac disease, intolerance to any product in the study, galactosemia, lactase deficiency and malabsorption of glucose or galactose. Coadministration of CYP3A4 modulators was not authorized. Pretreatment evaluations included a complete medical history, physical examination, complete blood count and chemistry panel, serum creatinine and liver enzymes.",during the first treatment cycle,NA
23647753,NA,Combination,No,locally advanced rectal cancer,The aim of this phase I study was to define the RP2D of nelfinavir in combination with capecitabine 825 mg/m2 and radiotherapy in patients with cT3-4N0-2M0 (staging based on MRI) rectal cancer,NA,within 30 days post-surgery,NA
24315563,NA,Combination,No,Rectal Cancer,"The study included patients with stage II to III (T3-T4 and/or node-positive) rectal adenocarcinoma, based on endorectal ultrasound (EUS) and/or pelvic magnetic resonance imaging (MRI). The tumor had to be within 12 cm of the anal verge, and there had to be no evidence of distant metastasis on chest CT, and abdominal-pelvic computed tomography (CT) or MRI. The study included patients >= 18 years of age, and Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. Other inclusion criteria were hemoglobin >= 9 g/dL, absolute neutrophil count >= 1500/mL, platelet count >= 100,000/mL, total bilirubin <2 mg/dL, blood urea nitrogen <= 30 mg/dL, creatinine <= 1.5 mg/dL, and creatinine clearance >= 30 mL/min.","Exclusion criteria were inadequately controlled hypertension, recent history of myocardial infarction or unstable angina, class II or greater congestive heart failure, unstable symptomatic arrhythmia, class II or greater peripheral vascular disease, history of stroke or transient ischemic attack, history of hypertensive crisis or hypertensive encephalopathy, history of aortic aneurysm or aortic dissection, recent history of peripheral arterial thrombosis, proteinuria or significantly impaired renal function, impaired hepatic function, coagulopathy, serious and uncontrolled infection, nonhealing wound, ulcer or bone fracture, and recent abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess. Patients with prior pelvic radiation therapy, chemotherapy, VEGF- or EGFR-directed therapy, or recent surgical procedures were also excluded.",during and within 4 weeks after chemoradiation,NA
23517808,NA,Combination,No,Locally Advanced Anal Carcinoma,"Patients with histologically confirmed primary squamous cell carcinoma of the anal canal stage T2-4 (with T2 > 4 cm), N0-1, M0 or T2-4, N2-3, M0 were included. Disease staging was performed according to the American Joint Committee on Cancer (AJCC), version 6, and the International Union Against Cancer (IUCC) system. Other inclusion criteria included age 18 years or more, World Health Organization (WHO) performance status of 0-2, absolute neutrophile count >= 1.5 x 109/L, platelets >= 100 x 109/L, hemoglobin 6 mmol/L, serum creatinine <= 1.5 times the upper limit of normal (ULN), serum bilirubin <= 1.5 x ULN, and ALAT/ ASAT <= 2.5 x ULN.","Exclusion criteria were known distant metastases, history of another metastasized cancer less than 5 years before inclusion, uncontrolled infectious disease, known hepatitis B or C, or human immunodeficiency virus infection, previous radiation therapy to the pelvic or inguinal region, uncontrolled cardiovascular disease, DPYD*2A polymorphism, or psychiatric disorders not enabling adequate follow-up. ",until 2 weeks after end of treatment,NA
21547572,NA,Combination,No,advanced solid tumors,"Men or women who were at least 18 years of age and of any racial or ethnic group and had a histologically or cytologically confirmed locally advanced or metastatic solid tumor were eligible for enrollment. Patients were to be minimally pretreated, which was defined as <6 cycles of alkylating agent-containing chemotherapy, <=6 cycles of carboplatin, < 2 cycles of mitomycin C or a nitrosourea as a part of a single regimen, no prior bone marrow transplantation, and radiation therapy to <= 25% of hematopoietic reserves. Other eligibility criteria included a life expectancy of >= 3 months; full recovery from previous surgery (>= 4 weeks since major surgery); recovery from prior chemotherapy or radiation therapy (>= 4 weeks since prior myelosuppressive therapy); Eastern Cooperative Oncology Group (ECOG) performance status of <= 2; adequate bone marrow function (absolute neutrophil count [ANC] >= 1,500/ll and platelet count >= 100,000/ll), adequate kidney function (serum creatinine level <= 1.5 x upper limit of normal [ULN]), and adequate liver function (total bilirubin level <= 1.5 x ULN and serum glutamic oxaloacetic transaminase [SGOT] and serum glutamic pyruvic transaminase [SGPT] levels <= 2.5 x ULN or <= 5 x ULN when liver metastases were present). Before enrollment, patients with reproductive potential were to agree to practice approved methods of birth control, and women of childbearing potential had to have a negative pregnancy test documented during screening","Patients were disqualified from entering the study if they had a history of other prior malignancy (except nonmelanoma skin cancer or in situ carcinoma of the uterine cervix), unless complete remission had been apparent and therapy discontinued for >= 2 years; major surgery of the stomach or small intestine; chronic diarrhea; severe or lifethreatening hypersensitivity reaction to a taxane or capecitabine; or positive serology for human immunodeficiency virus. Pregnant or lactating women and patients who were receiving any cancer chemotherapy or radiotherapy or who had received any investigational drug within 28 days before tesetaxel administration also were excluded from the study. Additional exclusion criteria included concurrent serious infection; symptomatic brain metastases; neuropathy >= Grade 2 at baseline; swallowing difficulties or malabsorption disorder; diarrhea (i.e., more than 2–3 stools per day above the normal frequency during the previous month); psychiatric disorder that precluded informed consent or prevented patient compliance; and severe or uncontrolled underlying nononcologic medical condition that could compromise patient safety or affect study outcome.",during Cycle 1,NA
19294501,NA,Combination,No,metastatic breast cancer,"Patients age 18 years or older with histologically or cytologically confirmed locally advanced or metastatic breast cancer (MBC) were eligible for study. Patients had an Eastern Cooperative Oncology Group (ECOG) performance status 0–2; normal renal, hepatic, and hematologic function on prestudy evaluation.","Patients were ineligible if they had more than four prior chemotherapeutic regimens for MBC, prior progression of disease on capecitabine treatment, or if they had HER2- overexpressing tumors (positive by fluorescent in situ hybridization or 3+ by immunohistochemistry) and had not received trastuzumab.",during the first cycle of treatment,NA
24114122,NCT00433550,Combination,No,metastatic or locally advanced cancer,"Patients with histologic or cytologic confirmed measurable or assessable metastatic or locally advanced cancer for which no established life-prolonging therapy was available or patients unresponsive to conventional therapy were eligible for this study. Other eligibility criteria included the following: age ≥18 years; Eastern Cooperative Oncology Group performance status ≤2; estimated life expectancy of ≥12 weeks; completion of chemotherapy, biologic therapy, or immunotherapy ≥4 weeks prior to study entry (≥6 weeks in patients treated with mitomycin or nitrosoureas) and recovery from any toxic effects of prior treatment; ≤ three prior chemotherapy regimens; completion of radiation therapy ≥4 weeks before enrollment; radiation therapy to ≤25 % of bone marrow; neutrophil count ≥1,500/μL; platelet count ≥100,000/μL; hemoglobin ≥9.0 g/dL; serum creatinine ≤1.5 times the upper limit of normal. AST ≤3 times upper limit of normal or AST ≤5 times upper limit of normal if liver involvement with malignancy; total bilirubin ≤ upper limit of normal in patients with wild-type UGT1A1 genotype, and total bilirubin ≤1.5 times upper limit of normal for patients heterozygous or homozygous for UGT1A1*28 genotype; no active or uncontrolled infection; absence of pregnancy or lactation and willingness to use adequate contraception; no untreated CNS metastases; no uncontrolled seizure disorder; no uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure (New York Heart Association classification III or IV); no evident peripheral neuropathy ≥ grade 2; absence of any history of allergy to platinum compounds, irinotecan, or to antiemetics or antidiarrheals appropriate for administration in conjunction with chemotherapy as directed by this protocol; and absence of concomitant antiretroviral therapy. Patients at the MTD were required to participate in pharmacokinetic studies. All patients gave written informed consent according to institutional and federal guidelines.",NA,during cycle one,NA
17998790,NA,Combination,No,Advanced Solid Tumors,"Patients with histologically or cytologically confirmed solid tumors for whom there was no other proven effective treatment option were eligible for the study. Other eligibility criteria were: age > 18 years, ECOG performance status (PS) 0–2; adequate bone marrow (absolute neutrophil count > 1.5 x 10 9/l and platelets >= 100 x 10 9/l), renal (creatinine <= 1.25 x the upper limit of normal and creatinine clearance > 50 ml/min) and liver function (total bilirubin ^ 1.25 ! and aspartate and alanine aminotransferases <= 3.0 x the upper limit of normal, respectively), and absence of active infection and malnutrition (body weight loss > 20%).","Patients with chronic diarrhea, incomplete obstruction of the gastrointestinal tract, total colectomy, neoplastic infiltration of > 50% of the hepatic parenchyma, severe cardiac dysfunction and peripheral neuropathy >= grade 2 were excluded from the study",during the first cycle of chemotherapy,NA
17628744,NA,Combination,No,advanced solid tumors,"Patients with histologically or cytologically confirmed advanced or metastatic malignant solid tumors were eligible for inclusion if, in the investigator’s opinion, they could benefit from irofulven/capecitabine combination therapy (e.g., chemotherapy naive patients with hepatocarcinoma, prostate, unknown primary carcinoma (UPC); fluoropyrimidine-naive patients with hepatocarcinoma, head and neck, prostate, pancreatic previously treated with single agent gemcitabine, and unknown primary carcinoma; patients previously treated by bolus 5-FU including breast cancer patients previously treated by anthracyclines and taxanes, and colorectal cancer patients previously treated by 5-FU bolus ± oxaliplatin or irinotecan). Patients with other pretreated tumors, even if pretreated by infusional fluoropyrimidines, could be included, provided they had a maximum of one previous combination regimen for advanced disease, there was a treatment free interval ≥6 months and no proven clinical resistance to fluoropyrimidines had been documented. Patients were also required to be ≥18 years old; have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1; life expectancy >3 months; previous anticancer treatment discontinued at least 4 weeks prior to treatment initiation (6 weeks for mitomycin C); adequate organ function (white blood cell count (WBC) ≥3.0×109/l, absolute neutrophil count (ANC) ≥1.5×109/l, platelet count ≥150×109/l, hemoglobin ≥9 g/dl; bilirubin ≤1.25 times the upper limit of normal (ULN), alkaline phosphatase, aspartate transaminases (AST) and alanine transaminases (ALT) ≤2.5×ULN (≤5×ULN in case of liver metastases), prothrombin time ≥50% of control, serum albumin >25 g/l; creatinine clearance (calculated according to the Cockroft and Gault formula ) ≥60 ml/min); patients of reproductive age had to be using effective contraceptive methods and have a negative pregnancy test.","Patients were ineligible in the following cases: prior radiation therapy to more than 35% of the bone marrow; prior therapy with nitrosoureas, high dose carboplatin (AUC>6), bone marrow transplant or intensive chemotherapy with stem cell support; prior mitomycin C cumulative dose ≥25 mg/m2; presence of any serious concomitant systemic disorders incompatible with the study; presence of any significant central nervous system or psychiatric disorder(s) that would affect patient compliance; presence of symptomatic or uncontrolled brain or leptomeningeal metastases; history of significant gastric or small bowel resection, malabsorption syndrome or other lack of integrity of the upper gastrointestinal tract that might compromise absorption of capecitabine; unavailability of the oral route; treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to study entry; breastfeeding patients; prior treatment with coumarin derivatives and/or phenytoin within 14 days prior to receiving the first dose of study drug, or during the study period. Patients with retinopathy were to be enrolled on a case-by-case basis according to the expected risk/benefit ratio, taking into account the malignant disease and the existence of objectively assessed decreased visual acuity and its degree. ",during the first two cycles,NA
17426973,NA,Combination,No,metastatic breast cancer,"Patients with metastatic breast cancer who progressed on at least one prior chemotherapy regimen (not including adjuvant therapy) were eligible for study entry. Additional inclusion criteria were as follows: Eastern Cooperative Oncology Group performance score <2 and expected survival >3 months, adequate bone marrow function (absolute neutrophil count >1.5x 109/l, platelet count >10 12/l, hemoglobin >9.0 g/dl); and adequate renal (serum creatinine <1.5 x ULN or creatinine clearance >50 ml/min) and hepatic function (serum bilirubin <1.5£ ULN, AST <2 x ULN). Patients of childbearing potential were required to use appropriate contraception. Patients could not have had chemotherapy in the previous 3 weeks or major surgery or radiation in the prior 4 weeks (except small port radiotherapy for symptom control).",Patients were excluded for uncontrolled infection or other uncontrolled medical illness. Patients who had tumor accessible to biopsy were asked to consent for serial biopsies.,during the Wrst cycle of therapy,NA
18765554,NA,Combination,No,Advanced Colorectal Cancer,"Eligible patients were required to have histologic/cytologic diagnosis of metastatic, relapsed, or advanced-stage CRC not amenable to curative treatment. Eligibility criteria also included (a) life expectancy of at least 3 mo; (b) age of z18 y; (c) measurable or evaluable disease; (d) Eastern Cooperative Oncology Group performance status of 0 to 2 (not declining within past 2 wk); and (d) adequate hepatic, renal, and bone marrow function including aspartate aminotransferase/alanine aminotransferase of <= 3 x institutional upper limit of normal or <= 5 x upper limit of normal if liver metastases, total bilirubin of <= 1.5 x upper limit of normal, creatinine of <= 1.25 x upper limit of normal, or <= 1.5 x upper limit of normal and calculated creatinine clearance of >= 60 mL/min, hemoglobin of >= 8.5 mg/dL, absolute neutrophil count of >=1,500/mm3, and platelets >= 100,000/mm3.","Patients were excluded if they had chemotherapy; radiotherapy; or investigative agents within 4 wk before study entry; prior treatment with EGFR inhibitors; prior treatment with capecitabine; more than four prior chemotherapy treatment regimens for relapsed/metastatic disease, hypersensitivity, or severe toxicity with prior 5-FU; surgery within 2 wk before study entry; or active central nervous system metastases (as indicated by clinical symptoms, cerebral edema, required use of corticosteroids, and/or progressive growth). Pregnant or nursing women were excluded. The prophylactic use of hematopoietic growth factors was not permitted in the first cycle but was allowed thereafter and for the treatment of febrile neutropenia",the first treatment cycle,NA
19074845,NA,Combination,No,advanced solid tumors,"Eligible patients had a confirmed pathologic diagnosis of a nonhematologic malignancy refractory to standard treatment or for which there was no standard therapy. Additional inclusion criteria included age >= 18 years; life expectancy >= 12 weeks; Eastern Cooperative Oncology Group performance status of 0 to 2; discontinuation of previous chemotherapy for at least 4 weeks (6 weeks for nitrosureas or mitomycin C), recovery from any toxic effects of prior treatment; and adequate bone marrow, liver, and renal function. Women of childbearing potential must have had a negative urine pregnancy test before study entry, and men and women agreed to use adequate contraception. The study was approved by the local institutional review board and conducted in accordance with the guidelines of the Declaration of Helsinki. Each patient was informed of the investigational nature of this study and signed a written institutional review boardapproved consent before registration and enrollment into the study.","Patients were excluded from this study for active infection, any serious concomitant systemic disorder (including other malignancy), uncontrolled brain metastases, history of hypersensitivity to 5-FU, or documented dihydropyrimidine dehydrogenase deficiency. Patients who were taking cytochrome P450 3A4 inducers, including rifampin, phenytoin, carbamazapine, and barbiturates, were required to discontinue these agents before entering the trial",the first 2 cycles,NA
17582215,NA,Combination,No,Advanced Cancer,"Eligible patients had to have previous histologic or cytologic diagnosis of malignancy that was metastatic or unresectable and for which standard curative measures did not exist or were no longer effective, or were refractory or recurrent after conventional treatment. Patients were required to be at least 18 years of age; sign an informed consent; have a life expectancy of at least three months; an Eastern Cooperative Oncology Group performance status (PS) of 0 to 2; and adequate hepatic, renal, and bone marrow function (AST/ALT ≤2.5x the institutional upper limit of normal [ULN]; total bilirubin ≤2x ULN; creatinine ≤2 mg/dL, or a calculated creatinine clearance >30 mL/min; absolute neutrophil count ≥1,500/mL; platelet count ≥100,000/mL). Prior treatments were allowed","Patients were excluded if they could not swallow the medications, had chemotherapy or radiotherapy within two weeks prior to entering the study, had not recovered from adverse events due to agents administered more than two weeks earlier; were receiving other investigational agent(s) for treatment of the cancer; had growing or uncontrolled brain metastases; history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide, capecitabine or thalidomide; pregnancy; uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",within the first cycle,NA
16750332,NA,Combination,No,RECTAL ADENOCARCINOMA,"Patients with a histologically confirmed rectal adenocarcinoma that involved the distal 12 cm of the rectum without evidence of distant metastases were eligible. Patients must have been staged within 6 weeks before initiation of study by endoscopic ultrasound (US) with evidence of T3 to T4 tumor or evidence of lymph node involvement defined by the presence of at least one enlarged perirectal lymph node (>5 mm in size and suspicious for metastasis) (13, 14). No prior RT to the pelvis and no prior chemotherapy for rectal cancer were allowed. Age restriction was between 18 and 75 years. All patients should have had an Eastern Cooperative Oncology Group (ECOG) performance of 0 to 2 and should have been able to take oral medications. Life expectancy of participants should have been >1 year. Fertile participants should have agreed to appropriate methods of contraception or abstinence. Patients should have had good renal function (creatinine within normal limits or creatinine clearance >60 cc/min), hepatic function (AST and ALT ,2.5 x upper limit of normal and a normal bilirubin), and bone marrow function (WBC >=3000/L, ANC >=1500/L, platelets >=100,000/L). All patients should have agreed and signed an informed consent before participating.","Patients were excluded if they had other concurrent malignancies within 5 years from study screening. Other exclusion criteria included concurrent nonstudy investigational drugs, Grade 2 and above neuropathy, history of allergic reaction to any of the study drugs, significant concurrent systemic illnesses, and pregnancy or lactation",starting Day 1 of treatment and up to 2 weeks after last RT,NA
17158771,NA,Combination,No,metastatic cancer,"All patients had a baseline history and full physical examination with radiologic and laboratory evaluation. Patients with measurable or clinically assessable histologically confirmed advanced solid tumors were eligible for this study. An age between 18 and 80 years, an Eastern Cooperative Oncology Group (ECOG) performance status of one or less, and a life expectancy >3 months were required. Bone marrow function requirements included an absolute neutrophil count >= 1500/mm3, a platelet count >=100 000/mm3, and hemoglobin >= 10.0 g/100 ml. Preserved renal function (serum creatinine <=1.6 mg/dl, normal creatinine clearance), hepatic function (total bilirubin <=1.5 mg/dl, aspartate aminotransferase and alanine aminotransferase <=2.5 x normal without hepatic metastasis, and <=4 x normal with hepatic metastasis; serum alkaline phosphatase <2.5 x the upper limit of normal or <5 x the upper limit of normal if liver metastases were present or <10 x the upper limit of normal if bone metastases were present), and cardiac function were required","Major exclusion criteria included cytotoxic or radiotherapy treatment within the previous 4 weeks (6 weeks if the previous therapy included a nitrosourea or mitomycin C). Concomitant use of amiodarone, ketoconazole, itraconazole, diltiazem, verapamil, barbiturates, and warfarin was not permitted. Pregnant or breast-feeding woman or patients with uncontrolled severe disease were excluded. Patients with significant stomach, small intestine, liver, or kidney disease likely to affect drug absorption or metabolism were excluded from the study. Patients with history of coagulopathy or with central nervous system tumor or metastasis were excluded too",during the first two cycles of therapy,NA
18209010,NA,Combination,No,metastatic breast cancer,"Eligible patients had to have histologically confirmed MBC and one or two prior lines of chemotherapies for metastatic disease including anthracyclines and/or taxanes. Patients were required to have measurable disease. All patients had to have adequate haematological, renal and hepatic function [haemoglobin > 8 g/dl; absolute neutrophil count (ANC) > 1.5 x 109/l; platelets > 75 x 109/l; serum bilirubin level < 1.5 x upper limit of normal (ULN) and serum creatinine level <= ULN], a Karnofsky performance status >=60 and an estimated life expectancy ‡12 weeks. Written informed consent was required before enrolment.","Exclusion criteria included brain metastases, bone metastases as the only site of metastases, radiotherapy within 4 weeks before study entry, a history of other prior malignancies (except for curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix), significant cardiac disease or any other serious medical or psychiatric conditions which would impair the ability of the patient to receive protocol treatment. Pregnant or lactating women were ineligible.",during the first cycle,NA
17641893,NA,Combination,No,Breast Cancer,"Female patients with histologically or cytologically conWrmed breast cancer and evidence of measurable metastatic disease using Response Evaluation Criteria in Solid Tumors (RECIST) were eligible for this study. Main inclusion criteria were: age 20–75 years, ECOG performance status 0 or 1, normal renal, hepatic, and hematologic function conWrmed by a prestudy examination (white blood cell count >= 4,000/mm3 and <= 12,000/mm3, neutrophil count >= 2,000/mm3, platelet count >= 100,000/mm3, hemoglobin >= 9.0 g/dl, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 x upper limit of clinic normal (ULN), total bilirubin < 1.25 x ULN, serum creatinine < 1.5 x ULN, creatinine clearance > 50ml/min), and no prior radiotherapy to the target lesion. At least 2 weeks must have elapsed since completing previous endocrine therapy and 4 weeks must have elapsed since completion of previous chemotherapy, radiotherapy, surgery, or treatment with an investigational new drug.",Patients were ineligible if they had previously received a taxane or capecitabine.,during the Wrst two cycles,NA
18000507,NA,Combination,No,pre-treated tumours,"Patients with histological confirmed locally advanced or metastatic cancer refractory to or relapsed after at least one palliative chemotherapy regimen were eligible for entry into the study. Additional inclusion criteria comprised: Eastern Cooperative Oncology Group (ECOG) performance status <=2, age >=18 years, life expectancy >=3 months, measurable disease, left ventricular ejection fraction (LVEF) >50%, cardiac insufficiency NYHA <2, adequate bone marrow function (leucocyte count >=3000 ml-1, platelet count >=100 000 ml-1), and adequate renal (serum creatinine <=1.4 mg dl-1 or creatinine clearance 460 ml min-1) and hepatic function (bilirubin p2 mg dl-1).",NA,during the first two cycles of chemotherapy,NA
17465235,NA,Combination,No,Metastatic Breast Cancer,"Eligibility criteria included: histologically or cytologically confirmed MBC; age 20 to 74 years; ECOG Performance Status 0 to 2; at least one prior chemotherapy regimen in the adjuvant or metastatic setting; resolution of all toxicities from prior therapy; adequate vital organ functions (serum haemoglobin concentration ≥9.0 g/dl, neutrophil count ≥2,000/mm3, platelet count ≥100,000/mm3, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <1.5 x upper normal limit (UNL) of range set by the institution (in cases of hepatic metastasis, ≤3 x UNL, alkaline phosphatase ≤2.5 x UNL, serum creatinine <1.5 x UNL, serum total bilirubin <1.25 x UNL, and normal electrocardiogram)); creatinine clearance >50 ml/min; life expectancy ≥3 months; no symptomatic central nervous system metastases and no infectious complications. All patients provided written informed consent.",NA,during the first two cycles of therapy,NA
18936940,NA,Combination,No,advanced colorectal cancer,"The eligibility criteria included histologically or cytologically proven diagnosis of colorectal carcinoma with metastatic measurable and/or evaluable lesions, aged between 18 and 65 years, ECOG performance status (PS) 0–2, neutrophils count >= 2 x 109/L, platelets count >= 100 x 109/L, total bilirubin <= 1.5 time the upper-normal limits (UNL) of the Institutional normal values, aspartate aminotransferase/alanine aminotransferase <= 2 x UNL (<= five times the UNL for patients with liver metastasis), alkaline phosphatase <=2.5 x UNL (unless bone metastasis are present in the absence of any liver disorders), serum creatinine <140 umol/L (1.6 mg/dL). Patients may have had only one previous chemotherapy treatment including oxaliplatin regimen for metastatic disease, other than adjuvant Xuoropyrimidines in combination with leucovorin.","Exclusion criteria included congestive hearth failure or angina pectoris even if medically controlled, previous history of myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia, history of signiWcant neurologic or psychiatric disorders including dementia or seizures, active infection, concurrent treatment with other experimental drugs, pregnant or lactating women or women of childbearing potential (e.g. not using adequate contraception), past or current history of neoplasm other than curatively treated non-melanoma skin cancer or carcinoma in situ of the uterine cervix. A malabsorption syndrome or any other disorder that would aVect gastrointestinal absorption was also included in exclusion criteria.",during a minimum of 3 weeks follows the first cycle,NA
18841362,NA,Combination,No,advanced solid malignancies,"Eligible patients were, at baseline, >= 18 years old; had an Eastern Cooperative Oncology Group performance status (PS) <= 2 ; had biopsy-conWrmed locally advanced, unresectable or metastatic solid malignancy; had adequate major organ function [absolute neutrophil count (ANC) >1,500/uL, hemoglobin ¸10 g/dL, platelet count >100,000/uL, estimated creatinine clearance >50 mL/min, total bilirubin <1.5 times the upper limit of normal (ULN), aminotransferases <2.5 times the ULN (or <5 times the ULN in the case of liver metastasis), alkaline phosphatase <2.5 times the ULN (or <5 times the ULN in the case of liver metastasis or <10 times the ULN in the case of bone metastasis)]; had received ·3 chemotherapy regimens; had >=1 non-irradiated measurable lesion; and had a life expectancy >= 12 weeks. At least 4 weeks had passed from prior treatment (6 weeks in the case of prior mitomycin C or nitrosoureas)","Exclusion criteria included pregnancy or breastfeeding, brain metastasis, other malignancy within 5 years, severe allergic reaction to 5-FU or gemcitabine, intestinal malabsorption, surgery within 4 weeks, need to continue warfarin therapy, unstable coronary artery disease, uncontrolled cardiac arrhythmias and myocardial infarction within the previous year",cycle 1 ,NA
18187954,NA,Combination,No,Inoperable or Metastatic Breast Cancer ,"Eligible patients were female, 20–74 years old, with histologically confirmed inoperable or metastatic breast cancer, ECOG performance status <= 1, measurable and evaluable disease according to Response Evaluation Criteria in Solid Tumors, life expectancy >= 12 weeks, capability of taking oral therapy, and adequate bone marrow function (white blood cell count <= 12,000/ul; absolute neutrophil count >= 2,000/ul; platelet count >= 100,000/ul; hemoglobin >= 9.0 g/dl), hepatic function (total bilirubin < 1.25 times upper normal limit; aspartate aminotransferase and alanine aminotransferase <= 2.5 times upper normal limit; alkaline phosphatase < 2.5 times upper normal limit) and renal function (serum creatinine < 1.5 times upper normal limit; creatinine clearance > 50 ml/min). If a patient had previously received anthracycline-containing chemotherapy, left ventricular fraction measured either by echocardiography or by radionuclide angiocardiography had to be >= 50%, and total doses of epirubicin or doxorubicin had to be < 500 and 278 mg/m 2 , respectively. Patients had to have completed previous chemotherapy, radiotherapy, surgery and investigational therapies >= 4 weeks before starting study treatment, and had to have recovered from all previous treatmentrelated toxicities. Informed consent was obtained from all patients enrolled in this study",NA,within the first or second cycle of treatment ,NA
16778105,NA,Combination,No,Advanced Solid Tumors,"Patients with pathologically proven locallyadvanced or metastatic solid tumors without available standard therapyor for whom irinotecan and/or capecitabine was considered adequatetreatment were eligible for enrollment. Other inclusion criteria were patients ages >= 18 years,WHO performance status <= 2,and a life expectancy >= 3 months. The presence of measurable disease according to response evaluation criteria in solid tumors criteria was preferred but not required. Furthermore,biological values had to be adequate: bone marrow,absolute neutrophil count >= 2.0 x 109/L; platelets >= 100 x 109/L; hemoglobin >= 10 g/dL; adequate hepatic function defined as serum total bilirubin within the reference ranges; aspartate aminotransferase,alanine aminotransferase,alkaline phosphatase <= 3x upper normal limit or <= 5 x upper normal limit in case of liver metastases; serum creatinine <= 1.5 mg/dL (<= 135 Amol/L) or a measured creatinine clearance z60 mL/min. Previous chemotherapy had to be discontinued for at least 4 weeks; in case of nitrosoureas or mitomycin C, chemotherapy had to be discontinued for at least 6 weeks. Patients should have recovered from toxicities from previous therapy to grade <2 (except alopecia),and patients had to be able to swallow normally, have a normal gastrointestinal absorption,and had to comply to intake of capsules according to treatment plan with scheduled visits and laboratory tests","Exclusion criteria included leukemia,prior high-dose chemotherapy with progenitor blood cells transplantation,symptomatic brain metastases or leptomeningeal involvement,concomitant severe infection or major organ failure,and chronic diarrhea. Furthermore,no concomitant treatment with cytochrome P450 3A inhibitors or inducers and no prior treatment with irinotecan, capecitabine,or 5-fluorouracil infusion were allowed,except for 5-fluorouracil bolus injection. Patients with known dihydropyrimidine dehydrogenase deficiency,surgery in the previous 4 weeks,prior extensive pelvic irradiation,and concurrent radiotherapy in case >25% of the bone marrow was involved in the irradiated field were excluded. In addition,pregnant or breast-feeding patients and patients with alcohol or drug addiction were excluded. ",During the first cycle,NA
17600871,NA,Combination,No,metastatic breast cancer,"Eligible patients were females ≥ 18 years old with histologically proven MBC who had previously received adjuvant or fi rst-line anthracycline-containing therapy, had received no more than one prior line of chemotherapy, and had received the last dose of chemotherapy at least 12 weeks prior to enrollment. Previous capecitabine or taxane therapy was not permitted, but endocrine therapy for metastatic disease was allowed. Other eligibility criteria were: Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, presence of at least one measurable lesion, and normal hematologic (absolute neutrophil count [ANC] ≥ 2.0×109/L and platelets ≥ 100×109/L), hepatic (total bilirubin < 1.5×upper normal limit [UNL] and/or aspartate aminotransferase [AST] and alanine aminotransferase [ALT] < 2.5×UNL), renal (serum creatinine < 1.5×UNL; if serum creatinine concentration was > 1.25×UNL, creatinine clearance had to be ≥ 60 ml/min) and cardiac function (ejection fraction ≥ 50% measured by MUGA scan or ultrasound).",NA,the fi rst 2 cycles of therapy (6 weeks) ,NA
16821609,NA,Combination,No,Locally Advanced Squamous Cell Carcinoma of the Head and Neck,"To be eligible for the study, patients had to be 18 years of age or older, with histologically confirmed A-SCCHN, which was deemed unsuitable for radical surgery and/or radiotherapy. Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status ≤2, a life expectancy greater than 3 months, and adequate liver, bone marrow, renal and cardiovascular functions (bilirubin <34 Mol/l; WBC count ≥3x109/l; platelet count ≥100x109/l; creatinine clearance >60 ml per minute). ",Patients previously treated with systemic chemotherapy for recurrent disease or irradiation to major bone areas were excluded from the study. Patients were also excluded if they had any serious concomitant illness or medical condition,NA,NA
18249110,NA,Combination,No,metastatic breast cancer,"Eligible patients were female, >=18 years, with histologically confirmed, incurable, locally advanced breast cancer or MBC. Key inclusion criteria included measurable disease, <=1 previous chemotherapy regimen for advanced/metastatic disease (patients may also have had adjuvant chemotherapy), Eastern Cooperative Oncology Group (ECOG) performance status 0–1, and adequate haematologic, hepatic and renal function","Patients were ineligible if they had received prior docetaxel or HER-targeted therapy; radio-, immuno- or chemotherapy within the previous 28 days, or if they had any unresolved treatment-related toxicities. Other exclusion criteria included pregnancy; life expectancy <12 weeks; central nervous system disorders; unstable systemic disease; cardiac disease or other primary malignancies.",during cycle 1 ,NA
18539404,NA,Combination,No,GASTRIC CANCER,"Patients with histologically confirmed resected adenocarcinoma of the stomach or the gastro-esophageal junction were eligible for entry into the study if their tumor characteristics were pT3-4 N0 M0 or pT1-4 N1-3 M0. Patients with R1 resections were allowed to participate in the study. The tumors had to be resected at least by a D1 resection. An additional inclusion criteria was a time interval between surgery and inclusion into the study 6 weeks or less. Eastern Cooperative Oncology Group performance status of 2 or less, age 18 years or more, cardiac insufficiency less than New York Heart Association Class 2, adequate bone marrow function (hemoglobin >= 10 g/dl, leukocyte count >=3,500 ml-1, platelet count >= 100,000 ml-1), and adequate renal (serum creatinine <= 1.4 mgdl-1 or creatinine clearance >60 ml min-1) and hepatic function (bilirubin <=2 mg dl-1). Effective contraception was required in fertile patients.",NA,during radiochemotherapy,NA
17195945,NA,Combination,No,advanced solid cancers,"Eligible patients were required to have an advanced solid malignancy confirmed on histology and refractory to standard treatment; age greater than or equal to 18 years; measurable or evaluable disease; ECOG performance status (PS) ≤ 2; and adequate organ function as defined by absolute neutrophil count (ANC) ≥ 1500/µl, platelet count ≥ 100,000/µl, hemoglobin ≥ 9 gm/dl; creatinine clearance ≥ 50 ml/min; serum bilirubin within 1.5 times the institutional normal limits (INL); and ALT and AST ≤ 3 times INL","Pregnant or nursing women were excluded and patients of childbearing age were required to practice contraception. Patients were required to have at least a 4-week interval from all previous surgery, chemotherapy, and radiotherapy, prior to study initiation",in cycle 1 ,NA
18414865,NA,Combination,No,solid tumors,"Patients were required to have measurable or evaluable metastatic solid tumors for which there was no curative treatment. Eligibility criteria included age >= 18 years; ECOG performance status <= 2; no large-Weld radiation therapy within 4 weeks; no anti-cancer therapy within 3 weeks; and adequate end-organ function (WBC >= 4,000/uL, neutrophils >= 1,500/uL, platelets >= 100,000/uL, hemoglobin > 10.0 g/dL), hepatic function (bilirubin <= 1.5 mg/dL, AST and ALT < 2 times upper limit of normal), and renal function (serum creatinine <= 1.5 mg/dL and/or serum creatinine clearance >60 mL/min/1.73 m2). Signed informed consent was required.","Patients with New York Heart Association classiWcation III or IV heart disease, brain metastases or primary brain tumors, and those who were pregnant or lactating were excluded.",during the Wrst cycle,NA
18525298,NA,Combination,No,Solid Malignancies,"Patients eligible for this trial were required to have a cytologic or histologic diagnosis of adenocarcinomas of the gastrointestinal tract, lung or breast, have measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, be able to take oral medication, have an ECOG performance status of 0 to 2, have adequate organ function as determined by the following: absolute neutrophil count >= 1.5 x 109/L, platelets >= 100 x 109/L, hemoglobin >= 9 mg/dL, serum creatinine <= 1 mg/dL, or calculated creatinine clearance >= 50 mL/min, total bilirubin < 1.5 times upper limit of normal, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x upper limit of normal (< 5 times upper limit of normal if liver metastasis were present) and no signs or symptoms of gastrointestinal obstruction. Up to 3 prior chemotherapy regimens were allowed except for prior doxorubicin at a total cumulative dose of greater than 300 mg/m2. Any prior chemotherapy, radiotherapy, surgery, hormonal therapy, investigational agents, or immunotherapy was discontinued at least 4 weeks (6 weeks for Mitomycin C and nitrosoureas) before enrollment and patients had to be fully recovered from toxicity associated with the prior treatment","Patients were excluded from the study if they had active uncontrolled infections; a history of coronary disease that included unstable angina, myocardial infarction or congestive heart failure, pregnant, had overt psychosis, were mentally disabled, or were unable to give an informed consent; had second active malignancies; had a history of prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity reaction to 5-FU; lacked a physical integrity of the upper gastrointestinal tract, were unable to swallow tablets, or had malabsorption syndromes; had a history of organ allografts; or were known to be human immunodeficiency virus-positive.",the first cycle,NA
18398145,NA,Single Drug,No,Metastatic Breast Cancer,"Patients enrolled in this study were more than 18 years of age with histologically confirmed metastatic breast carcinoma that was measurable by Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines criteria. Patients could have received any number of prior endocrine, biologic, or chemotherapy regimens except fluoropyrimidine-containing therapy for the treatment of metastatic breast cancer or as adjuvant therapy within 6 months of enrollment. At least 3 weeks were elapsed from last cytotoxic or biologic therapy. Patients with breast cancer amplified for human epidermal growth factor receptor 2 (HER-2) by fluorescence in-situ hybridization or overexpressed by immunohistochemistry (3+) could not have been candidates for trastuzumab therapy. Patients were required to have an Eastern Cooperative Oncology Group performance status <= 2, absolute neutrophil count more than 1.5 x 109/L, platelets more than 100 x 109/L, creatinine clearance >= 50 mL/min by the Cockcroft-Gault equation, bilirubin less than 1.5 times the upper limit of normal, and AST/ALT/alkaline phosphatase less than 2.5 times the upper limit of normal.","Pregnant or lactating patients were excluded. Patients could not have had a life expectancy less than 3 months, known dihydropyrimidine dehydrogenase deficiency, untreated symptomatic brain metastases, or uncontrolled gastrointestinal malabsorption.",during the first cycle (28 days),NA
18534963,NA,Combination,No,advanced upper gastrointestinal malignancies,"Eligibility criteria included patients 18 years or older with pathologically confirmed advanced gastrointestinal malignancy; presence of measurable or evaluable disease (by physical examination, radiology or tumor marker); a life expectancy of >= 8 weeks, and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of zero to two. Patients must have recovered from the acute toxic effects of all prior chemotherapy, radiotherapy or other targeted anticancer therapy. Patients must have received <= 2 prior chemotherapy regimens (0–2) with no chemotherapy or radiotherapy given within 3 weeks before the start of protocol treatment. Other requirements included adequate bone marrow function [peripheral absolute neutrophil count (ANC) >= 1500 cells/mm3, platelet count >=100 000 cells/mm3 and hemoglobin >= 9 g/dl]; adequate hepatic and renal functions (total serum bilirubin less than or equal to the institutional upper limit of normal, serum transaminases less than or equal to four times the institutional upper limit of normal and serum creatinine of <= 2.0 mg/dl or creatinine clearance of >= 60 ml/min/1.73 m2 for patients with creatinine levels >2.0 mg/dl).","Other exclusion criteria include presence of active central nervous system metastases; grade 2 or higher peripheral neuropathy; known hypersensitivity to oxaliplatin, gemcitabine or capecitabine and uncontrolled intercurrent illness. Pregnant and lactating patients were excluded from the study",during the first cycle,NA
18773144,NA,Combination,No,advanced solid malignancies,"The study protocol was approved by the institutional review board of the University of New Mexico and conducted in accordance with the 1996 Declaration of Helsinki. Informed consent was obtained according to federal and institutional guidelines. Male or female patients ≥18 years old who had histologically confirmed locally advanced or metastatic cancer were eligible for this study, provided that they met the following criteria: (1) Eastern Cooperative Oncology Group performance status of 0–2 and a life expectancy of at least 12 weeks; (2) absolute neutrophil count greater or equal to 1.5×103/mm3, platelet count greater or equal to 100×103/mm3; (3) a serum creatinine and a total bilirubin level up to 1.5 times upper limit of normal and a transaminase level up to 2.5 times the upper limit of normal; and (4) at least 4 weeks since prior surgery, radiation or chemotherapy.","Exclusion criteria were (1) disease progression during earlier treatment with irinotecan, 5-FU, or platinum; (2) concurrent radiotherapy, surgery or chemotherapy; (3) women with a potential of becoming pregnant, unless utilizing birth control; (4) symptomatic brain metastasis; (5) previous or current other malignancies (except in situ carcinoma of the cervix or non-melanoma cancer of the skin); (6) concurrent life threatening illness; mental disability or incompetence to give informed consent; (7) administration of any investigational drug within 28 days prior to enrollment in the study; and (8) history of hypersensitivity to platinum agents or irinotecan.",during the course of the second cycle,NA
16909414,NA,Combination,No,Brain Metastases From Breast Carcinoma,"Patients were eligible for this study if they had bidimensionally measurable supratentorial or infratentorial brain metastasis from histologically confirmed breast carcinoma. Patients with newly diagnosed brain metastases who had declined radiation therapy and were neurologically stable or had tumor recurrence or progression after WBRT or stereotactic radiotherapy (SRT) were eligible. Patients could have received up to 3 prior chemotherapy regimens for systemic metastatic disease but prior treatment with temozolomide or capecitabine was not permitted unless there was no evidence of disease progression while using capecitabine. Patients were required to have a life expectancy of at least 8 weeks and to have a performance status <= 2 on the Zubrod scale. Other eligibility criteria included adequate renal function with a creatinine level <2.0 mg/dL, adequate liver function with an aspartate aminotransferase (AST) <1.5 upper limit of normal, bilirubin <1.2 mg/dL, adequate bone marrow function with platelets >100,000 mm3, hemoglobin >8 g/dL, and absolute neutrophil count >1,500 cells/mm3.",Patients were not eligible if they had rapidly progressing visceral disease or other serious medical conditions.,in Cycle 1,NA
19238629,NA,Combination,No,advanced oesophagogastric cancer,"Eligibility requirements included histologically confirmed adenocarcinoma of the stomach or lower third of the oesophagus, locally advanced, metastatic or recurrent disease, measurable disease by computed tomography (CT), EGFR expression in tumour tissue, normal cardiac function defined by left ventricular ejection fraction, Karnofsky performance status (KPS) X60%, life expectancy > 12 weeks, no prior chemotherapy at all, no radiotherapy or major surgery within 4 weeks before the first study treatment, adequate baseline bone marrow and liver function, a glomerular filtration rate > 60 ml min-1, no severe uncontrolled comorbidities and signed informed consent.",NA,during the first two cycles,NA
18455328,NA,Combination,No,Stage II or III rectal adenocarcinoma,"Male or female patients aged 18 –75 years with histologically confirmed Stage II and III rectal adenocarcinoma scheduled for postoperative conventional RT of the pelvic region were eligible for this study. The tumor had to have been at least grossly removed. Further inclusion criteria were Karnofsky performance status >= 70, no prior RT or no chemotherapy in the past 6 months, adequate hematologic parameters (hemoglobin >= 12 g/dL, white blood cell count >= 4.0 x 109/L; and platelet count >= 100 x 109/L), creatinine and total bilirubin levels <= 1.0 times the upper limit of normal, aspartate and alanine aminotransferase levels <= 2.5 times the upper limit of normal, and enrollment within 3 months from the date of surgery.Only patients who hadundergone radical resection of rectal cancer were enrolled in thisstudy. The primary objective of the study was to determine a suitable","Patients who were excluded included pregnant or lactating women, women of childbearing age who lacked a reliable contra- ceptive method, patients with significant cardiac disease or uncon- trolled diabetes, patients with central nervous system disorders or psychological disability thought to preclude providing informed consent or adversely affecting patient compliance, and patients with a second primary tumor other than nonmelanoma skin cancer or in situ cervical carcinoma. Patients were also excluded if they had serious, uncontrolled infections, were sensitive to fluoropyri- midines, or had participated in another clinical trial within 4 weeks before the start of treatment",during the radiotherapy (5 weeks),NA
17450468,NA,Combination,No,non-resectable gastric cancer,"Patients were eligible if they had histologically confirmed non-resectable adenocarcinoma of the stomach or gastrooesophageal junction. Eligibility criteria included estimated life expectancy>12weeks; measurable or non-measurable disease; adequate renal function (calculated creatinineclearance>30 ml/min by the Cockroft and Gault formula); adequate hepatic function (serum bilirubinB/1.5/upper normal limit (UNL); transaminasesB/3/UNL, however in cases of liver metastases, there were no upper limit for transaminases); adequate hematological function (neutrophil count>1.5/109/l; platelets>100/109/l); no prior chemotherapy; WHO performance status 0 to 2, and age between 18 and 75 years. Other inclusion criterias were ability to tolerate and comply with oral medication, no signs of intestinal obstruction or malabsorption, no peripheral neuropathy, no co-existent severe medical illness, no sign of brain metastases and no concomitant treatment with other anticancer therapy.",NA,the first cycle,NA
19219674,NA,Combination,No,Advanced Solid Tumors,"Eligibility criteria included documentation of incurable solid tumor malignancy, with histology confirmed at Memorial SloanKettering Cancer Center (MSKCC). All patients were ≥18 years old and were required to have essentially normal bone marrow, renal and hepatic function, with a white blood cell count≥3,000/μL, absolute neutrophil count (ANC)≥1,500/μL, platelets ≥100,000/μL, serum creatinine ≤1.5 mg/dl, serum bilirubin ≤1.5 mg/dl, and aspartamine transaminase (AST or SGOT) ≤3 times the upper limit of normal (or 5 times the upper limit of normal in the case of hepatic metastases). A Karnofsky performance status ≥70% was required. No more than one prior chemotherapy regimen was permitted. Prior radiotherapy administered more than 4 weeks before enrollment was allowed but mantle radiation, hemi-body radiation or radiation to the pelvis or lumbar spine were not permitted.",NA,first-cycle,NA
18208793,NA,Combination,No,colorectal cancer,"Eligible patients were required to have histologic or cytologic diagnosis of metastatic, relapsed or advanced-stage CRC not amenable to curative treatment and refractory to at least one prior regimen of systemic therapy. Eligibility criteria also included (a) life expectancy of at least 3 months, (b) age ≥18 years, (c) measurable or evaluable disease, (d) Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, (d) adequate hepatic, renal and bone marrow function including prothrombin time ≥70% of the reference, AST/ALT ≤2.5×institutional upper limit of normal (ULN) or ≤5×ULN if liver metastases, alkaline phosphatase ≤5×ULN (or ≤20×ULN if liver metastases), total bilirubin ≤1.5×ULN, creatinine ≤1.25×ULN, or ≤1.5×ULN and calculated creatinine clearance ≥30mL/min, haemoglobin ≥10 g/dL, absolute neutrophil count (ANC) ≥1500/mm3 and platelets ≥100 000/mm3","Patients were excluded if they had had chemotherapy, radiotherapy or investigative agents within 4 weeks before study entry, prior treatment with EGFR inhibitors, prior treatment with capecitabine, more than 4 prior chemotherapy treatment regimens for relapsed/metastatic disease, hypersensitivity or severe toxicity with prior 5-FU, active central nervous system (CNS) metastases (as indicated by clinical symptoms, cerebral oedema, required use of corticosteroids and/or progressive growth), any uncontrolled medical condition, or concomitant use of phenytoin, carbamazepine, rifampim or barbiturates. Pregnant or nursing women were excluded. The prophylactic use of haematopoietic growth factors was not permitted in the first cycle but was allowed thereafter and for the treatment of febrile neutropenia",the first cycle ,NA
18650153,NA,Combination,No,Metastatic Breast Cancer,"Eligible patients were aged ≥ 18 years with histologically confirmed locally advanced or MBC previously treated with an anthracycline and a taxane. Measurable disease was not required for the phase I (dose-escalation) portion of the study but was required for the phase 2 (response evaluation) portion. Additional eligibility criteria included adequate bone marrow, hepatic, and renal function; an Eastern Cooperative Oncology Group performance status of 0/1; life expectancy ≥ 3 months; and an interval of ≥ 3 weeks since the end of previous treatment. Up to 3 previous chemotherapy regimens for MBC were allowed. ","Exclusion criteria included previous exposure to epothilones, concurrent hormonal or biologic (eg, trastuzumab or lapatinib) therapies, other concurrent investigational treatments for MBC, and grade ≥ 2 motor/sensory neuropathy. ",during the first 2 treatment cycles ,NA
17848909,NA,Combination,No,gastric cancer,"Patients with histologically proven adenocarcinoma of stomach or gastro-oesophageal junction in AJCC stage Ib-IV (M0) were eligible for this study (Greene, 2002). All patients were asked to participate in this study after macroscopically radical gastric surgery was performed. Patients had to be > 18 years old, with a WHO performance status of <= 2. Haematology: haemoglobin >= 6.5 mmol l-1; leucocytes >= 3.5 x 109 l-1; neutrophils >= 1.5 x 109 l-1 and thrombocytes >= 100 x 109 l-1. Renal function: serum creatinine <= 1.25 x ULN and creatinine clearance >= 60 ml min-1 as assessed by 24 h urine collection or calculated by Cockroft and Gault formula. Liver function: total bilirubin <=1.5 x ULN; alkaline phosphatase and ASAT/ALAT <= 3 x ULN. Before treatment, a baseline Tc99mthiatide renogram was performed to evaluate the relative function of the left and right kidney. All patients underwent physical examination, chest X-ray, chest and abdominal CT scans, ECG and evaluation of caloric intake by a dietitian at baseline. A caloric intake of at least 1500 kcal day-1 had to be established",Patients with previousmalignancies or comorbidity that might compromise delivery ofthe planned treatment were excluded,up to 4 weeks after treatment,NA
17653805,NA,Combination,No,Dutch Colorectal Cancer,"Eligibility criteria included histologically documented adenocarcinoma of the rectum within 15 cm from the anal sphincter, locally advanced stage T3 (distance to the endopelvic fascia < 2 mm) or T4 tumors based on computed tomography (CT) or magnetic resonance imaging (MRI) findings, performance status (Eastern Cooperative Oncology Group) 0–2, age >18 years old, adequate hematological, liver function, and other laboratory parameters (white blood cells 3.0 x 109/L, platelets >100 x 109/L, creatinin clearance > 50 mL/min, bilirubin < 1.5 times the upper limit of the normal range (ULN), and written informed consent. Patients with reproductive potential should use adequate contraceptive measures","Patients were excluded in case of prior chemotherapy and/or pelvic radiotherapy, acute bowel obstruction without colostomy, uncontrolled ischemic heart disease, peripheral neuropathy, or any uncontrolled serious systemic disease",NA,NA
17415843,NA,Combination,No,stage II and III rectal cancer,"1. Age 18 to 80 years; 2. Histologically confirmed rectal adenocarcinoma after potentially curative resection of the primary tumor and regional lymph nodes with neither gross nor microscopic residual disease; 3. Tumor with either extension through the bowel wall or positive lymph nodes without evidence of distant metastatic disease (T3-T4, or N1-N3 and M0). A tumor was considered to be rectal cancer if a portion of the tumor was located below the peritoneal reflection or if the lower margin of the tumor was within 12 cm of the anal verge on endoscopy; 4. Pathological stage II (T3-4N0M0) or III (anyTN1-2M0) rectal adenocarcinoma; 5. No prior treatment other than curative resection, and no history of inflammatory bowel disease, malabsorption syndrome and peripheral neuropathy; 6. ECOG performance status 0-2; 7. Estimated life expectancy more than 3 months; 8. Female patients were not pregnant or lactating; 9. Adequate hematologic, liver, and renal function (neutrophils ≥ 2.5 × 109/L, platelet count ≥ 125 × 109/L, creatinine clearance ≥ 50 mL/min, total serum bilirubin < 1.5 times the upper limit of normal, and serum transaminases or alkaline phosphatase concentrations < 2 times the upper limit of normal).","Exclusion criteria included previous RT to the pelvis, or a planned course of RT with a total dose of less than 45 Gy or a high dose (more than 2 Gy) per fraction, previous CT or immunotherapy, other malignancy within the last 5 years, other serious medical illnesses that would limit the patientís ability to receive protocol therapy. Patients with known sensitivity to fluoropyrimidines and patients who participated in another clinical trial within 4 weeks from the start of treatment were ineligible. Patients began therapy between 3 and 10 weeks post-surgery.",at least 2 weeks after the end of treatment,NA
17333194,NA,Single Drug,No,advanced solid tumours refractory to standard therapy,"All patients enrolled in the study had histologically or cytologically conWrmed inoperable malignant solid tumours refractory to standard palliative treatment. Eligibility criteria included ECOG performance status 0–2, estimated life expectancy >12 weeks and adequate bone marrow(absolute neutrophil count ANC >= 1.5 x 109/l, platelet count PLT >= 100 x 109/l), hepatic (AST, ALT, Alkaline phosphatase < 2.5 x upper limit of normal, bilirubin < 1.5 x upper limit of normal) and renal (glomerular Wltration rate GFR >= 50 ml/min as measured by the Cockroft-Gault formula) function",NA,during the Wrst 6 weeks of therapy only,NA
16374040,NA,Combination,No,Refractory Solid Tumors,"Patients enrolled in this study suffered from histologically confi rmed inoperable solid neoplasms. They had received at least one previous chemotherapy regimen or they had refractory tumors for which no standard therapy was available. Eligibility criteria included age < 75 years and a life expectancy of at least 3 months, adequate performance status (WHO scale scores 0–2), adequate renal function (creatinine clearance 6 60 ml/min), adequate hepatic function (serum bilirubin <= 1.5 x the upper limit of the reference range; transaminases < 5 x the upper limit of the reference range), adequate hematological function (hemoglobin > 10 g/dl; neutrophil count > 1.5 x 109 /l; platelets > 100 x 109 /l) and adequate cardiac function [left ventricular ejection fraction (LVEF) > 50% and no history of myocardial infarction]. Patients with brain metastases were eligible if they had been irradiated, the brain lesions were radiographically stable and clinical improvement was evident. Patients should be off previous anticancer therapy for at least 4 weeks. ","Patients who had received prior anthracycline/anthracenedione therapy with a cumulative total dose of epirubicin > 480 mg/m2 , doxorubicin 1 240 mg/m2 , or mitoxantrone > 70 mg/m2 , or prior anthracycline-containing adjuvant therapy completed < 6 months prior to the study entry were excluded. Patients were also excluded if they demonstrated evidence of any other medical problems severe enough to affect their compliance to the protocol",on the first chemotherapy cycle,NA
15729602,NA,Single Drug,No,malignant solid tumors,"Eligible patients had histologically confirmed tumors that were unresponsive to standard therapies or for which there were no other standard treatments. Patients were between 15 and 75 years of age, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, and had received no cytotoxic or radiation therapy within 4 weeks prior to study treatment (2 weeks for prior antimetabolites, immunotherapy, and hormonal therapy). Patients were to have adequate hematologic (hemoglobin, >= 9g/dl, leukocyte count, >=4.0 x 109/l, platelet count, >= 100 x 109/l), hepatic (total bilirubin, <1.5mg/dl, serum transaminases and alkaline phosphatase, <2.5 times upper normal limit), and renal (serum creatinine, <1.5mg/dl) function","Patients with central nervous system metastases or serious concomitant disease, or those with a life expectancy of less than 3 months were excluded",a 6-week period,NA
14739668,NA,Combination,No,advanced cancer,"Patients with a histological or cytological diagnosis os advanced cancer were eligible. Patients were required to have measurable or evaluable disease. other eligibility criteria included: age between 18 and 75 years; World Health organization (WHO) performance status 0-2; predicted like expectancy>=12 weeks; no exposure to topoisomerase I inhibitors within the preceding 3 months; no more than one prior chemotherapy regimen for advanced disease or inthe neoadjuvant or adjuvant setting, and adepquate hematopoietic (hemoglobin>90 g/L, neutrophil count >=1.5X10 9/L, platelet count >=100x10 9/L). hepatic (serum bilirubin<=1.0 x the upper limit of normal (ULN), AST and/or ALT<=5.0 x ULN) and renal function (creatinine clearance >= 50 ml/min calculated using the Cockcroft-Gault formular). Patients with stable cerebral metastases were allowed.","Specific exclusion criteria included: previous cumulative cisplatin dose >= 200 mg/m2; radiotherapy within the preceding 4 weeks or to >= 30% of bone marrow; lack of physical integrity of the upper gastrointestinal tract, or known malaborption syndrome that may affect absorption of oral capecitabine, and hearing impairment or neuropathy of greater than grade 1 accoreding to the national Cancer Institute common toxicity criteria (NCI-CTC) version 2. ",during the cycle 1,NA
16622464,NA,Combination,No,advanced gastroesophageal adenocarcinoma,"To be eligible for either phase, patients had to have histologically confirmed locally advanced or metastatic adenocarcinoma of the oesophagus or stomach, unsuitable for curative surgery or chemoradiotherapy; age >18 years; WHO performance status 0, 1 or 2; adequate haematological and biochemical parameters (white blood cells >= 4, platelets >= 150, bilirubin <= 1.5 x upper limit of normal (ULN), alkaline phosphatase <5 x ULN, aspartate aminotransferase and alanine aminotransferase <2.5 x ULN and creatinine clearance 450 ml min-1); and written, informed consent. ","Main exclusion criteria were as follows: prior radical chemoradiotherapy; treatment with radiotherapy or any investigational drug within the preceding 4 weeks; a prior severe reaction to fluoropyrimidine therapy; concurrent uncontrolled medical condition (e.g. angina and cardiac failure), infection or diarrhoea; requirement for a contraindicated medication; history of epilepsy; any condition that may impair oral self-medication; pregnant or lactating women, or inadequate contraception in women of childbearing potential.",during the first three cycles,NA
12196374,NA,Combination,No,inoperable oesophago-gastric adenocarcinoma,"All patients entered into this study had histologically or cytologically confirmed adenocarcinoma of the stomach, oesophagus or gastrooesophageal junction. Inoperability was determined on the basis of clinical evaluation, radiological imaging, laparoscopy or at laparotomy with failed resection. Eligibility criteria included estimated life expectancy ≥12 weeks; adequate renal function (calculated creatinine clearance ≥60 ml/min by the Cockcroft and Gault formula), adequate hepatic function (serum bilirubin ≤1.5 × the upper limit of the reference range; transaminases <5 × the upper limit of the reference range) and adequate haematological function (haemoglobin ≥10 g/dl; neutrophil count ≤1.5 × 109/l; platelets ≥100 × 109/l). These patients were considered eligible if the investigator considered that there was no malabsorption syndrome and no gastro-intestinal obstruction that would impair administration of oral therapy.","Patients who had received prior chemotherapy for advanced disease were excluded. Patient performance status was assessed using the Eastern Cooperative Oncology Group (ECOG) criteria, and those patients with performance status ≤2 were considered eligible. Eligibility also included the ability to reliably tolerate and comply with oral medication, and patients with a lack of physical integrity of the gastro-intestinal tract leading to intestinal obstruction or a malabsorption syndrome were excluded. Similarly, patients were excluded if they had severity of dysphagia such that compliance and tolerance of oral medication would have been compromised. However, it was anticipated that all potential patients would have either a history of oesophago-gastric surgery for carcinoma or have an on-going primary oesophago-gastric or locally recurrent cancer",the first cycle of chemotherapy,NA
10883663,NA,Combination,No,advanced solid tumours,"Patients with histologically confirmed solid tumours for whom no other therapy with greater potential benefit existed than the combination of capecitabine with docetaxel, were entered into this study. The study was approved by the institutional ethics committee. Eligibility criteria included: age 18 years and older; Karnofsky performance status ≥ 70; no more than two prior single-agent chemotherapy regimens or one prior combination chemotherapy regimen; no prior treatment with docetaxel and/or capecitabine; normal bone marrow (haemoglobin > 9.0 g dl–1, granulocytes > 1.5 × 109 l–1, platelet count > 100 × 109 l –1), renal (serum creatinine < 1.5 × upper normal limit) and hepatic function (bilirubin < 1.25 × upper normal limit, alkaline phosphatase < 2.5 × upper normal limit, and transaminases < 1.5 × upper normal limit); uric acid < 1.25 × upper normal limit, calcium < 2.88 mmol l–1, no clinically significant cardiac disease or myocardial infarction within the last 12 months; no radiation therapy within 4 weeks of treatment start; no major surgery to the gastrointestinal tract, the liver or kidney within 4 weeks of study entry which may impact on the pharmacokinetics of capecitabine or docetaxel; no participation in any investigational drug study within 4 weeks preceding treatment start; no history of peptic ulcer, ulcerative colitis, ulcerative stomatitis and/or lack of physical integrity of the upper intestinal tract. ",NA,in the first 2 cycles of treatment,NA
11432617,NA,Combination,No,breast cancer ,"Patients with histologically confirmed regionally advanced and/or metastatic breast cancer who had not previously received paclitaxel or capecitabine were candidates for this study. Eligibility criteria also included- 1) age > 18 years; 2) Karnofsky performance status > 70% (ambulatory and capable of self-care); 3) a life expectancy > 3 months; 4) no major surgery, radiotherapy, or chemotherapy within 28 days of study entry: 5) no gastrointestinal disorder that might affect the gastrointestinal absorption of capecitabine, 6) adequate hematopoietic (white blood cell count (WBC) Jt 3000/ul, absolute neutrophil count (ANC) of ^1500/ul, platelets > 100,000/ul, and hemoglobin (Hgb) level of >9.0 g/dl); hepatic (total serum bilirubin level < 1.25 times institutional upper normal limits, aspartate amino transaminase (AST) and alanine amino transaminase (ALT) < 1.5 times institutional upper normal limits, and alkaline phosphatase < 2 5 times institutional upper normal limits); renal (serum creatinine < 1.5 times institutional upper normal limits) functions, 7) no clinically significant cardiac disease (New York Heart Association Class 3 or 4) or myocardial infarction within the last 12 months, 8) no history of seizures, central nervous system, or psychiatric disorder that might alter study compliance; 9) no brain metastases, unless the lesions had been previously irradiated, stable and asymptomatic; 10) absence of organ allografts or serious uncontrolled infections; and 11) no prior documentation of human immunodeficiency virus type 1 antibodies, although screening for such antibodies was not performed. ",NA,in the first course,NA
16284060,NA,Combination,No,locally advanced rectal cancer,"Patients with biopsy-proven LARC were included in the study. Patients were selected either on the basis of tumour fixity on digital rectal examination or a high likelihood of CRM involvement, as indicated by MRI. Tumours were classified as rectal if the lower limit was located within 12 cm of the anaverge on rigid sigmoidoscopy. Clinical staging was based on the criteria from the American Joint Committee on Cancer (2002) . Patients were aged between 18 and 75 years and had Eastern Cooperative Oncology Group performance status 0 to <= 1. Adequate haematological and renal function (absolute neutrophil count >= 1500/l, platelet count >= 100 000/l, and serum creatinine <= 1.25 upper normal limit) were also required. Patients should have no evidence of metastatic disease based on computed tomography scanning or chest X-ray and liver ultrasound.","Exclusion criteria included prior chemotherapy and/or pelvic radiation, tumour recurrence after primary surgery, or evidence of metastatic disease. Patients with more than six stools per day were also excluded, as it was felt that this would preclude accurate grading of toxicity. Patients were ineligible if there was a large amount of small bowel in the radiation field (>500 ml in the high-dose volume). In addition, sexually active patients unwilling to practice effective contraception were also excluded. Other exclusion criteria were pregnancy, inflammatory bowel disease and cardiac conditions that would compromise the safe delivery of capecitabine.",NA,NA
12491516,NA,Combination,No,"Refractory, Metastatic Solid Tumors","This study included adults age > 18 years with histologically confirmed, metastatic carcinoma that either had no standard curative therapy or had progressed despite standard therapy. Patients must have had a life expectancy of at least 2 months and an Eastern Cooperative Oncology Group performance status <= 2. Prior chemotherapy other than capecitabine was permitted provided that 1) no chemotherapy or radiotherapy had been received within the past 3 weeks, 2) no mitomycin C or nitrosoureas had been received within the past 6 weeks, 3) toxicities from prior chemotherapy or radiotherapy must have resolved to Grade 0 or 1, and 4) there was no documented history of intolerance to 5-FU. Patients must not have undergone major surgery within the preceding 2 weeks, and no other uncontrolled, serious medical or psychiatric illnesses were permitted. Adequate contraception was required of both males and females, and women could not be pregnant or lactating. The following laboratory values were necessary: absolute neutrophil count >= 1500/mm3, platelets >= 100,000/mm3, aspartate aminotransferase (AST) and alkaline phosphatase levels <= 3 timesthe upper limit of normal, total bilirubin <= 1.5 timesthe upper limit or normal, and creatinine <= 2.0 mg/dL",NA,NA,NA
12864942,NA,Combination,No,Advanced Breast Cancer ,"All patients were required to have histologically confirmed metastatic breast cancer, and must not have had any anticancer therapy for the past 4 weeks. Moreover, first-line chemotherapy for metastatic disease with anthracyclines and/or taxanes was required. Other eligibility criteria included a World Health Organization (WHO) performance status of 0-2, aged < 75 years, a life expectancy of ≥ 3 months, adequate hematologic parameters (absolute granulocyte count [AGC] > l500/μL, hemoglobin level > 9 g/dL, and platelet count > 100,000/μL), adequate hepatic (serum bilirubin < 1.5 mg/dL, transaminases < 2 times the upper limit of normal) and renal function (serum creatinine < 1.5mg/dL); preexisting peripheral neuropathy up to Eastern Cooperative Oncology Group grade 1, and no other medical problems severe enough to affect patient compliance to the protocol. Patients with brain metastases were eligible if they had been irradiated, the brain lesions were radiographically stable, and clinical improvement was evident.","Patients with malnutrition (> 20% loss of body weight), active infection, or a second primary tumor other than skin squamous cell carcinoma or in situ cervical carcinoma, were not eligible. ",during the first chemotherapy course,NA
16242260,NA,Combination,No,OPERABLE RECTAL CANCER,"Male or female patients aged 18–75 years with histologically confirmed Stage II and III rectal adenocarcinoma scheduled for postoperative conventional RT of the pelvic region were eligible for this study. The tumor had to have been at least grossly removed. Further inclusion criteria were Karnofsky performance status >= 70, no prior RT or no chemotherapy in the past 6 months, adequate hematologic parameters (hemoglobin >= 12 g/dL, white blood cell count >=4.0 x 109/L; and platelet count >= 100 x 109/L), creatinine and total bilirubin levels <= 1.0 times the upper limit of normal, aspartate and alanine aminotransferase levels <= 2.5 times the upper limit of normal, and enrollment within 3 months from the date of surgery","Patients who were excluded included pregnant or lactating women, women of childbearing age who lacked a reliable contraceptive method, patients with significant cardiac disease or uncontrolled diabetes, patients with central nervous system disorders or psychological disability thought to preclude providing informed consent or adversely affecting patient compliance, and patients with a second primary tumor other than nonmelanoma skin cancer or in situ cervical carcinoma. Patients were also excluded if they had serious, uncontrolled infections, were sensitive to fluoropyrimidines, or had participated in another clinical trial within 4 weeks before the start of treatment",NA,NA
15827767,NA,Combination,No,metastatic gastric cancer,"All patients had to fulfill the following eligibility criteria: (1) histological confirmation of gastric adenocarcinoma; (2) inoperable metastatic disease or recurrent metastatic disease after surgery; (3) measurable or evaluable lesions; (4) aged from 20 to 75 years; (5) performance status (PS) <= 2 on the Eastern Cooperative Oncology Group (ECOG) scale; (6) a maximum of one prior chemotherapy other than paclitaxel or doxifluridine for advanced disease (prior chemotherapy for advanced disease must have been completed at least 4 weeks prior to enrollment); (7) adequate bone marrow function (absolute granulocyte count >= 1500/mm3 and platelet count >= 100,000/mm3 ; (8) adequate liver function (serum bilirubin <1.5 mg/dl and serum transaminase <100 U/l); (9) adequate renal function (serum creatinine <1.2 mg/dl); (10) no other severe medical conditions; (11) no other active malignancies; (12) no pregnant or lactating patients; (13) no peripheral neuropathy; and (14) provision of written informed consent.",NA,during the first treatment cycle,NA
15520075,NA,Combination,No,advanced solid malignancy,"Patients with a histological diagnosis of advanced solid malignancy for which no known effective therapy is available, and for which capecitabine is a reasonable treatment option, were eligible for this study. Other eligibility criteria included age >=18 years, Eastern Cooperative Oncology Group (ECOG) performance status <=1 and life expectancy >=8 weeks. Patients may not have received radiation therapy or chemotherapy within 3 weeks (6 weeks for mitomycin C and nitrosurea), or hormone therapy, immunotherapy, or other biological therapy within 2 weeks of first treatment. Patients needed to be capable of swallowing intact capecitabine tablets and CI-994 capsules and to not have previously received treatment with either drug. Required laboratory values included the following: absolute neutrophil count _>1500/ml; platelet count >=100 000/ml; total bilirubin <1.5= times upper limit of normal; and serum creatinine <=1.5 times the upper limit of normal","Patients were excluded for new brain metastases diagnosed within 3 weeks of first study treatment, myocardial infarction within 6 months of study entry, unstable angina, second- or third- degree heart block, and other non-tumor-related life-threatening illnesses. Pregnant or lactating patients were ineligible for this study. There were no limits on the number of previous treatment regimens. Concurrent leucovorin administration was not allowed.",in the first treatment cycle,NA
15612026,NA,Combination,No,Metastatic Renal Cell Carcinoma,"Eligible patients had histologically or cytologically confirmed Stage IV RCC of any histologic subtype. Patients had measurable disease defined by response evaluation criteria in solid tumors (RECIST) criteria.22 A life expectancy > 3 months and an Eastern Cooperative Oncology Group performance status <= 2 were required. Patients had normal organ and bone marrow function as defined by the following characteristics: leukocyte count >= 3000 cells per microliter, absolute neutrophil count >= 1500 cells per microliter, platelet count >= 100,000 cells per microliter, total bilirubin level <= 1.5 x the institutional upper limit of normal (ULN), aspartate aminotransferase/alanine aminotransferase levels <= 2.5 x the institutional ULN, and creatinine clearance >= 60 mL/1.73 m2 per minute (calculated by the Cockcroft–Gault formula).","Previous gemcitabine or fluoropyrimidine (capecitabine, 5-FU, or fluorodeoxyuridine ) for the treatment of metastatic RCC was not permitted. There was neither an exclusion of patients based on the number of previous therapies received nor were patients required to have received any previous systemic therapy for RCC. Patients who had received previous systemic therapy for RCC, surgery, or radiotherapy within 4 weeks before entering the study or those who had not recovered from adverse events due to previously administered agents were excluded. Concurrent antineoplastic therapy including investigational agents was prohibited. Other exclusion criteria were any history of significant gastric or small bowel resection, malabsorption syndrome or other lack of integrity of the upper gastrointestinal tract that might compromise absorption of capecitabine, previous severe reaction to fluoropyrimidine therapy, or known hypersensitivity to 5-FU.",during the first cycle of therapy,NA
15305186,NA,Combination,No,"locally advanced, potentially resectable rectal cancer","For this trial, eligible patients were required to have a pathologically documented adenocarcinoma of the rectum with the lower limit within 12 cm from the anal verge. Patients were 18–75 years old, although patients over the age of 75 years were eligible if in the opinion of the investigators they were fit and well for the purposes of the trial. Patients had to be considered suitable for curative resection by the participating surgeon at the time of study entry. Tumours were clinical stage T3 –T4 tethered, or with radiological (ultrasound or CT) evidence of perirectal fat infiltration or nodal involvement. Examples of resectable T4 lesions were a rectovaginal or rectovesical fistula. The patient had to have a World Health Organisation (WHO) performance status of 0, 1 or 2.","Patients with recurrent rectal cancer were not eligible. The exclusion criteria were previous pelvic or abdominal radiotherapy or a scheduled dose of less than 50 Gy or treatment with high-dose per fraction (>2 Gy). Patients with evidence of metastatic disease, history of seizures, central nervous system disorders, clinically significant psychiatric disability, dementia, altered mental status or psychosis were not eligible. Patients with a history of severe and unexpected reaction to fluoropyrimidine therapy possibly related to DPD deficiency, or known hypersensitivity to 5FU were excluded. Patients with <1.5 x 109 l-1, platelet count <100 x 109 l-1, Hb <9 g dl-1) or moderate to severe renal impairment, that is, creatinine clearance <= 50 ml min-1, as calculated by the Crockroft Gault formula were not eligible. The use of blood transfusions to render patients eligible was allowed, but the use of growth factors to aid haematologic recovery was not allowed within 2 weeks before the start of or during the course of treatment. Pregnant or lactating women, women of child-bearing potential with either a positive pregnancy test at baseline or not using a reliable and appropriate contraceptive method were not eligible. Other exclusion criteria were autologous or allogeneic organ grafts, lack of physical integrity of the upper gastrointestinal tract, malabsorption syndromes, inability to tolerate or absorb oral medication or positive hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus type 1 or 2 antibodies.",during and up to 6 weeks after treatment,NA
15939714,NA,Combination,No,advanced colorectal cancer,"Between May 2000 and December 2003, patients were recruited from three centres to the phase I component and subsequently from nine centres to the phase II component. The main eligibility criteria were: histologically proven metastatic adenocarcinoma of the colon or rectum with measurable disease, no prior chemotherapy for metastatic disease, age >_ 18 and <_ 75 years, WHO performance status 0, 1 or 2, life expectancy >3 months, adequate haematological and biochemical parameters [haemaglobin >_ 10 g/dl, neutrophils >_ 2 x 109/l, platelets >_ 100 x 109/l, bilirubin <_1.2 5x institutional upper limit of normal range (ULN), aspartate aminotransferase and alanine aminotransferase <_ 5 times ULN, serum creatinine <_1.25 ULN or creatinine clearance >50 ml/min], and written informed consent.","Main exclusion criteria were: pregnant or lactating women, inadequate contraception in women with childbearing potential, prior exposure to irinotecan and/or exposure to more than one thymidine synthetase inhibitor regimen, severe concomitant conditions, inflammatory bowel disease or malabsorption.",in the first cycle,NA
16601432,NA,Combination,No,Locally Advanced or Metastatic Nonsmall Cell Lung Cancer,"Eligibility criteria included pathologically confirmed locally advanced or metastatic stage IIIB or IV NSCLC; aged 18 to 75; ECOG performance status 0 to 2; no previous chemotherapy or radiotherapy; one or more bi-dimensionally measurable lesion(s), defined as at least 1 cm x 1 cm by computed tomography (CT) scan; and adequate hematologic, renal, and hepatic functions, defined as white blood cell count >= 4000/L, absolute neutrophil count >= 2000/L, hemoglobin >= 10 g/dL, platelet count >= 100,000/L, serum creatinine >= 1.5 mg/dL, serum bilirubin <= 1.2 mg/dL, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) up to 2.5 times the upper limit of normal.","Patients were excluded if there was severe uncontrolled comorbidity. Patients who had history of significant gastric or small bowel resection, or malabsorption syndrome, or other lack of integrity of the upper gastrointestinal tract that might compromise the absorption of capecitabine were also excluded. The presence of CNS metastases, however, was not considered as an exclusion criterion, provided that CNS symptoms had been well controlled with corticosteroids",in the first cycle of treatment,NA
12763217,NA,Combination,No,large operable or locally advanced/inflammatory breast cancer,"Patients eligible for the study were female, aged 18–70 years, with a histological or cytological (fine needle aspiration (FNA), incisional biopsy or Trucut biopsy) diagnosis of locally-advanced/inflammatory breast cancer (T4, any N or any T, N2 or N3 or T4d) or large operable breast cancer (large T2 or T3 breast cancers for which a tumour shrinkage was needed before consideringbreast-conservative surgery as a valid treatment option). Other requirements were a World Health Organization (WHO) Performance Status of 0-1, adequate marrow function (absolute neutrophil count >= 1.5x109/l, platelets >= 100x109/l), renal function (serum creatinine <= 1.5xupper normal limit) and hepatic function (total bilirubin <= 1.25xupper normal limit, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)<=2xupper normal limit) and left ventricular fraction (LVEF) measured either by echocardiography or by radionuclide angiocardiography (MUGA) within normal institutional limits",Distant metastasis other than ipsilateral supraclavicular nodes and previous chemotherapy or radiation therapy were exclusion criteria,minimum of four cycles,NA
12954586,NA,Combination,No,metastatic colorectal cancer,"The eligibility criteria for the phase I trial were as follows: age ≥18 years; histological confirmed colorectal cancer; measurable, metastatic disease; no previous chemo- or radiotherapy for metastatic disease; interval between the end of previous adjuvant radio- and/or chemotherapy and study entry at least 6 months; predicted life expectancy ≥3 months; World Health Organization (WHO) performance status ≤2; ability to take oral medication; adequate baseline organ functions, defined as neutrophile count ≥2000/µl, platelet count ≥100 000/µl, hemoglobin ≥10.0 g/dl; serum bilirubin level ≤1.25 times, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 times (in case of liver metastases ≤5 times) the upper limit of the institutional reference range (UNL); serum creatinine ≤140 µmol/l or a creatinine clearance ≥60 ml/min; no chronic diarrhea or unresolved bowel obstruction; no severe uncontrolled co-morbidities or medical conditions (e.g. myocardial infarction within the last 12 months); no brain metastases; no concurrent treatment with other commercial or experimental antineoplastic drugs; no second malignancies; and signed informed consent",NA,during the first treatment cycle,NA
11843252,NA,Combination,No,advanced colorectal cancer,"Patients with histologically-proven advanced adenocarcinotna of the colon or rectum were eligible for this study They had to be pretreated with no more than two CT lines for advanced disease or relapsed within six months after the end of adjuvant 5-FU-based adjuvant therapy. Measurable disease was not required. All patients were required to have World Health Organization (WHO) performance status (PS) ^2 . age between 18 and 75 years, life expectancy greater than 12 weeks, WBC count 4 x 109 cells/1, absolute neutrophil count (ANC) of 2.0 x 109 neutrophils/l, platelet count 100 x 109 platelets/1, hemoglobin level 10 g/dl, serum creatinine level within normal values, totalbilirubin level 1.5 times the upper limit of normal (ULN). alkaline phosphatases less than five times ULN. AST and ALT 1.5 times ULN (or <5 x ULN if hepatic metastases were present). ","Exclusion criteria were: CTor radiotherapy within four weeks before study entry, prior CT with capecilabine or oxaliplatin, history of other malignancies (except excised in situ cervical carcinoma or basal/squamous cell skin carcinoma), peripheral neuropathy of National Cancer Institute (NCI) grade 2, symptomatic brain metastases and concurrent treatment with other experimental drugs or participation in another clinical trial within 30 days prior to study screening Written informed consent was required for each patient.",during a first cycle (three-week observation period),NA
15550580,NA,Combination,No,metastatic breast cancer,"Patients >_65 years with histologically or cytologically documented metastatic or locally advanced breast cancer without prior chemotherapy for metastatic disease were eligible. Two strata, for patients with and for patients without bone involvement, were run. Adjuvant chemotherapy had to be completed at least 6 months prior to trial entry. Prior hormonal treatment for advanced disease was permitted. Eligibility criteria included WHO performance status <_2, normal peripheral blood count, aspartate aminotransferase and alanine aminotransferase <_2 the upper normal limit (UNL), and creatinine <_ 1.5 UNL. In March 2001 an amendment was added requesting that patients with a calculated creatinine clearance (Cockroft–Gault formula) between 30 and 50 ml/min should receive 75% of the capecitabine dose. Bisphosphonates were allowed if at least one extraskeletal indicator lesion was present. All patients signed written informed consent forms.","Exclusion criteria were known or suspected central nervous system metastases, pre-existent peripheral neuropathy grade >_ 2, concomitant steroids and previous or present malignant disease other than adequately treated in situ carcinoma of the cervix or basal or squamous cell carcinoma of the skin. Patients with radiotherapy involving >30% of bone marrow or mucosa or administered to indicator lesions were not eligible.",during the first cycle of chemotherapy,NA
15238990,NA,Combination,No,gastrointestinal cancer,"Patients with histologically confirmed gastrointestinal cancer refractory to or relapsed after at least one chemotherapy regimen for metastatic disease were eligible for entry into the study. Previous anticancer therapy was not permitted within the 4-week period immediately prior to study commencement. Other eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) performance status <= 2, age >= 18 years, a life expectancy of X3 months, and adequate bone marrow function (leucocyte count >3000 ml-1, platelet count >100 000 ml-1). Patients were also required to have adequate renal (serum creatinine <= 1.4 mg dl-1 or creatinine clearance > 60 ml min-1) and hepatic function (bilirubin <= 2 mg dl-1). Left ventricular ejection fraction (LVEF) had to be X50%. Patients of childbearing potential were required to be using appropriate contraception.",NA,during the first two cycles of chemotherapy,NA
16462509,NA,Combination,No,Gastrointestinal Tumors,"Patients aged 75 years or less with a histologic diagnosis of metastatic or not operable, locally advanced abdominal neoplasm (colon or rectal cancer, pancreatic, gastric, gallbladder or bile duct cancer, or peritoneal mesothelioma) were eligible for the study. Other entry criteria were: performance status <= 1, according to the WHO scale;12 life expectancy > 3 months; hematological values within normal ranges (absolute neutrophil count ANC >= 2000/mm3, platelets >= 100,000/mm3; hemoglobin level >= 10); serum creatinine <= 1.6 mg/dL; bilirubin <= 1.25 times normal value; ALT and AST <= 2.5 times normal value. Previous treatment of adjuvant or metastatic disease was permitted","Patients were excluded if they had myocardial infarction during the previous 12 months, congestive heart failure, uncontrolled arrhythmias, or active infection.",in the first 2 cycles of chemotherapy,NA
15539915,NA,Combination,No,Advanced Breast Cancer,"Patients between 18 and 64 years of age with histologically or cytologically confirmed adenocarcinoma of the breast and evidence of metastatic disease were eligible for this phase I trial. Patients had to have evaluable or measurable lesions. Further eligibility criteria included adequate peripheral blood counts (hemoglobin > 100 g/l, WBC > 13.5 x 109/l, thrombocyte count > 100 x 109/l), adequate liver and renal function (ASAT/ALAT <2 x upper limit of normal, in the case of liver metastases <3 x upper limit of normal, creatinine < 1.5 x upper limit of normal and a creatinine clearance > 50 ml/min as calculated according to Cockroft and Gault), Eastern Cooperative Oncology Group performance status of 0–2, and an interval of more than 6 months since the end of adjuvant chemotherapy. One prior chemotherapy regimen for metastatic or locally advanced disease, but no prior weekly taxane or capecitabine treatment was allowed. Prior 3-weekly taxane or continuous-infusion fluorouracil treatment was allowed if terminated more than 1 year before trial entry. Prior hormonal treatment for metastatic disease was allowed, and bisphosphonates were allowed if the indicator lesion was a non-bone lesion. Local ethics committees approved the trial protocol, and all trial procedures were in accordance with the Helsinki declaration of the World Medical Association. All patients provided written informed consent to participate in the trial",NA,during the first cycle of chemotherapy,NA
34301752,NCT02264678,Combination,No,Advanced Solid Tumors,"Aged at least 18. The presence of a solid malignant tumour that is not considered appropriate for further standard treatment. Module 1 and 2 Part B study expansions, and Module 3: patients must have a tumour at least 1 cm in size that can be measured using a CT or MRI scan. Module 1 Part B Study expansion: second line lung adenocarcinoma with ATM deficient tumours.. Module 2 Part B All - No previous treatment with PARP inhibitor.. Module 2 Part B1 Study expansion: advanced gastric adenocarcinoma (including GEJ) patients with ATM deficient tumours. Module 2 Part B2 Study expansion: advanced gastric adenocarcinoma (including GEJ) patients with ATM proficient tumours. Module2 Part B3 Study expansion: Second or thrid line HER2 negative breast cancer. Module 2 Part B4 Study expansion: Second or third line triple negative breast cancer (TNBC). Module 2 Part B5 Study expansion: BRCA mutant or RAD51C/D mutant or HRD positive status ovarian cancer patient who are Platinum sensitive and have previously progressed on a licensed PARPi. Module 3: advanced recurrent or metastatic non-small cell lung cancer, or head and neck squamous cell carcinoma",A diagnosis of ataxia telangiectasia. Prior exposure to an ATR inhibitor. Bad reaction to ceralasertib. Module 1: Contra-indicated for treatment with carboplatin. Module 2: Contra-indicated for treatment with olaparib. Module 3: Contra-indicated for treatment with durvalumab,during the periods of cycle 0 (monotherapy) and cycle 1 (combination),NA
16283312,NA,Combination,No,metastatic breast cancer,"Eligible patients had metastatic breast cancer, with measurable or evaluable disease by RECIST criteria","Karnofsky performance status was >70, and patients had normal hematologic, renal, and hepatic function defined as ANC>1500, platelet count>100 K, calculated creatinine clearance>60 ml/min, AST/ALTPatients were excluded if they had previous treatment with continuous infusion or daily oral administration of fluorouracil, capecitabine, or vinca alkaloids and if they had baseline Grade 2 or greater peripheral neuropathy, or if they were pregnant or nursing. Patients who required concurrent treatment within 7 days prior to initial vinorelbine with drugs known to induce or inhibit CYP3A activity were also ineligible. Excluded drugs included midazolam, anti-mycotic agents (ketoconazole and related compounds), macrolide antibiotics (erythromycin and related compounds), nifedipine, anti-seizure drugs, H2 blockers, grapefruit juice, and rifampin",during the first cycle,NA
12506172,NA,Combination,No,Advanced Pancreatic Carcinoma,"Patients were eligible if they were naı¨ve to chemotherapy and had histologically or cytologically proven, surgically unresectable, locally advanced or metastatic adenocarcinoma of the pancreas. Additional inclusion criteria were age 18 to 80 years, Karnofsky performance status >= 60%, life expectancy >3 months, and adequate organ functions (leukocyte count > 3,500/L, platelet count > 100,000/L, hemoglobin > 10.0g/dL, serum creatinine < 1.25 times upper limit of normal [ULN], transaminases and alkaline phosphatase < 2.5 times ULN or < 5 times ULN in patients with liver metastasis, bilirubin < 1.5 times ULN, prothrombin time < 12.0 seconds, and calcium < 2.88 mmol/L). Written informed consent was obtained from each patient.",Patients with central nervous system involvement or other significant medical conditions were excluded.,during the first two treatment courses,NA
15218291,NA,Combination,No,Advanced Solid Tumors,"All patients had to have histologically confirmed inoperable neoplasm and should have been off previous anticancer therapy for at least 4 weeks. Other eligibility criteria were: WHO performance status 0–2; age <75 years; a life expectancy of at least 3 months; adequate hematologic parameters (absolute granulocyte count >1,500/ul, hemoglobin level >9 g/dl, platelet count >100,000/ul), adequate hepatic (serum bilirubin >1.5 mg/dl, transaminases <2 x the upper limit of normal), and renal function (serum creatinine <1.5 mg/dl); preexisting peripheral neuropathy up to National Cancer Institute grade 1 and no other medical problems severe enough to affect patient’s compliance with the protocol. Patients with brain metastases were eligible if they had been irradiated, the brain lesions were radiographically stable, and clinical improvement was evident","Patients with malnutrition (120% loss of body weight), active infection, or a second primary tumor other than skin squamous cell carcinoma or in situ cervical carcinoma, were not eligible",on the first chemotherapy cycle,NA
11786589,NA,Combination,No,Advanced Cancer,"Patients with histologically confirmed advanced solid tumors that had failed to respond to standard therapy or for which no standard therapy was available were eligible to participate in this study. Other eligibility criteria included measurable or assessable disease by computed tomography, magnetic resonance imaging, radiograph, or physical examination; age at least 18 years; Karnofsky performance status of at least 70% (ambulatory and capable of self-care); life expectancy of at least 3 months; and adequate organ function defined as absolute neutrophil count of at least 1,500/uL, platelet count of at least 100,000/uL, hemoglobin at least 9.0 g/dL, serum creatinine level < 1.6 mg/dL, total bilirubin < 2.0 mg/dL, serum albumin > 2.5 g/dL, prothrombin time < 1.5 times control level, AST and ALT levels < 2.5 times the upper limit of normal or < five times the upper limit of normal if liver metastases were present, and serum alkaline phosphatase < 2.5 times the upper limit of normal or < five times the upper limit of normal if liver metastases were present or < 10 times the upper limit of normal if bone metastases were present. Patients must have been off previous anticancer therapy, including radiation therapy, for at least 4 weeks (6 weeks if the previous therapy included a nitrosourea or mitomycin) and must have recovered from the toxic effects of any previous therapy","Patients were excluded from the study if they had any unstable, pre-existing medical condition, prior unanticipated severe reaction to fluoropyrimidine therapy, organ allograft, evidence of CNS metastases, or history of significant gastric or small bowel resection, malabsorption syndrome, or other lack of integrity of the upper gastrointestinal tract that might compromise absorption of capecitabine. Pregnant and lactating women were also excluded from participation, and all patients with reproductive potential were required to use an effective contraceptive method if they were sexually active",during the first cycle of therapy,NA
16446337,NA,Combination,No,Pancreatic and Rectal Cancer,"Patients with histologically/cytologically confirmed resectable or locally advanced adenocarcinoma of the pancreas or stages II-IV rectal cancer were eligible. Patients with pelvic recurrence of colorectal cancer were also eligible. Additional eligibility criteria included: age > 18 years, Karnofsky performance status >= 80%, and adequate bone marrow function (leukocytes > 2,000/mm3, platelets > 100,000/mm3, hemoglobin > 9.0). Adequate renal (creatinine clearance > 50 mL/min) and hepatic function (bilirubin < 1.5 x upper normal limit; AST, ALT, and alkaline phosphatase < 3 x upper normal limit or < 5 x upper normal limit, if known hepatic metastases) was required. Patients were not allowed to use medications that could potentially interfere with the metabolism of capecitabine or gefitinib",NA,during the radiation course,NA
12377646,NA,Combination,No,advanced colorectal cancer,"Eligible patients had histologically-confirmed, nonresectable metastatic or locally recurrent colorectal cancer and bidimensionally measurable disease (defined as presence of at least one index lesion capable of twodimensional measurement by computed tomographic (CT) scan outside any irradiated zone and >2 cm in diameter). Other eligibility criteria included age between 19 and 75 years, a World Health Organization (WHO) performance status of 0 or 1, a life expectancy of at least 3 months, adequate bone marrow reserve [absolute neutrophil count (ANC) > 1500/µl, platelet count >100 000/µl), adequate renal (serum creatinine concentration <132 µmol) and hepatic function (serum bilirubin level <34 µmol/l and serum transaminase level <2 × upper limit of normal). Patients may have received adjuvant fluoropyrimidine-based chemotherapy and/or radiation therapy, which must have been completed at least 6 months before study entry. Similarly, palliative radiotherapy was allowed, provided that less than 20% of the bone marrow was involved, presence of a target lesion outside the radiation port and full resolution of toxicities","Exclusion criteria included the presence of CNS metastases, serious or uncontrolled concurrent medical illness, peripheral neuropathy and a history of other malignancies, with the exception of excised cervical or basal skin/squamous cell carcinoma",the first two treatment cycles,NA
10561233,NA,Combination,No,Advanced Solid Malignancies,"Patients with histologically confirmed solid malignancies refractory to conventional therapy or for whom no effective therapy existed were candidates for this study. Eligibility criteria also included the following: age >= 18 years; Karnofsky performance status >= 70% (ambulatory and capable of self-care); a life expectancy >= 3 months; no major surgery, radiotherapy, or chemotherapy within 28 days (42 days for mitomycin or nitrosourea); no history of major disorders or surgery involving the stomach, small intestines, liver, or kidney that might affect the gastrointestinal absorption or clearance of capecitabine; adequate hematopoietic (WBC count >= 3,000/µL, absolute neutrophil count [ANC] >=  1,500/µL, platelet count >= 100,000/µL, and hemoglobin level $ 9.0 g/dL), hepatic (total bilirubin level < 1.5 times the upper normal limits; AST, ALT, and alkaline phosphatase< 2.5 times the upper normal limits), and renal (serum creatinine < 1.5 times the upper normal limits) functions; no clinically significant cardiac disease (New York Heart Association class III or IV); no history of seizures, CNS disorders, or psychiatric disease that might affect study compliance; no evidence of brain metastases; no history of hypersensitivity to paclitaxel or other drugs formulated in Cremophor EL (polyoxyethylated castor oil); no requirement for chronic corticosteroids except for inhalation therapy; and no prior documentation of hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus type 1 antibodies, although such viral evaluations were not required for eligibility. All patients gave informed written consent before treatment.",NA,during their first cycle of therapy,NA
12393999,NA,Combination,No,Gastrointestinal and Other Solid Malignancies,"Trial eligibility included adult patients (>=18 years) with histologically confirmed diagnosis of solid tumors, an absolute neutrophil count (ANC) >=1,500/l or leukocytes >=3,500/l and platelets >=100,000/l; serum creatinine <=1.5 mg/dl; and total bilirubin <=  1.5 mg/dl. Patients must not have received radiotherapy or chemotherapy within 4 weeks of beginning of treatment. At least 6 weeks must have elapsed if prior therapy included mitomycin C or nitrosoureas. All patients were required to give a signed informed consent before participation in this Montefiore Institutional Review Board approved trial.","Patients with a history of significant hepatic, bone marrow, and/or cardiac disease requiring active medical treatment or total gastrectomy or ileocolectomy were excluded",during their first treatment course,NA
15312392,NA,Combination,No,early-stage nasopharyngeal carcinoma,经病理学证实的初诊鼻咽癌 患者，临床分期(1992福州分期)为 T2N Mo；年龄 l8～ 65岁；预计生存期 >6个月；全身功能状态评分 (ECOG)≤2分；外周血白细胞计数 >3．5×lo9／L， 中性粒细胞计数 >1．5×lO9／L，血小板计数 >100× 109／L；心电图基本正常；肝肾功能正常；以往未接受 过化疗；填写患者知情同意书。治疗前常规行胸部 x线、腹部 B超和全身骨扫描检查以排除远处转移,NA,NA,NA
16504126,NA,Single Drug,No,advanced and/or metastatic cancer,"All patients had a baseline history and full physical examination with radiologic and laboratory evaluation. Patients with measurable or clinically assessable histologically confirmed advanced solid tumours who hade failed to response to standard therapy or for whom no standard therapy was available were elegible for this study. An age between 18 and 80 years, an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 and a life expectance > 3 months were required. Bone marrow function requirements included an absolute neutrophil count ≥ 1500/mm3, a platelet count ≥ 100000/mm3 and hemoglobin ≥ 10.0 g/100 ml. Preserved renal function (serum creatinine ≤ 1.6 mg/dL, normal creatinine clearance), hepatic function (total bilirubin ≤ 1.5 mg/dL, AST and ALT ≤ 2,5 times normal without hepatic metastasis and ≤4 times normal with hepatic metastasis; serum alkaline phosphatase < 2.5 times the upper limit of normal or < five times the upper limit of normal if liver metastases were present or < 10 times the upper limit of normal if bone metastases were present) and cardiac function were required.","Major exclusion criteria included cytotoxic or radiotherapy treatment within the previous 4 weeks (6 weeks if the previous therapy included a nitrosourea or mitomycin). Concomitant use of amiodarone, ketoconazole, itraconazole, diltiazem, verapamil, barbiturates, warfarin was not permitted. Pregnant or breast feeding woman or patients with uncontrolled severe disease were excluded. Patients with significant stomach, small intestine, liver, or kidney disease likely to affect drug absorption or metabolism were excluded from the study. Patients with history of coagulopathy or with nervous central system tumour or metastasis were excluded too. All patients were required to provide written informed consent prior to initiation of treatment, after a complete and opportune explanation. Local ethics committee approval was obtained. Women in fertile age had to be informed about risks incurring in case of pregnancy",occurring during the first two cycles of therapy,NA
12351595,NA,Combination,No,Rectal Cancer,"Male or female patients between 18 and 80 years of age with histologically confirmed rectal adenocarcinoma scheduled for conventional radiotherapy (>= 45 Gy) of the pelvic region in the adjuvant, neoadjuvant, or palliative setting were eligible for this study (the trial was extended to the recruitment of patients in a neoadjuvant situation by a protocol amendment implemented in February 2000). Further inclusion criteria were Karnofsky performance status >= 70% and an estimated life expectancy of more than 3 months in the palliative setting and M= 10 years in the adjuvant or neoadjuvant settings.","Exclusion criteria included previous radiotherapy of the pelvic region or a planned course of radiotherapy with a total dose of less than 45 Gy or a high dose (more than 2 Gy) per fraction. The following patients were also excluded: pregnant or lactating patients; women with childbearing potential who lacked a reliable contraceptive method; patients with organ allografts; patients with significant cardiac disease; and patients with CNS metastases or a history of uncontrolled seizures, CNS disorders, or psychological disability thought to be clinically significant, precluding informed consent, or adversely affecting patient compliance. Patients were also excluded if they had serious, uncontrolled infections, malabsorption syndrome, or if they lacked physical integrity of the upper gastrointestinal tract ensuring rapid and reproducible absorption of the drug. Patients with known sensitivity to fluoropyrimidines and patients who had received cytotoxic chemotherapy (except for one or two previous cycles of 5-FU/leucovorin immediately before recruitment onto the trial) or participated in another clinical trial within 4 weeks of the start of treatment were ineligible. Patients with hemoglobin less than 9 g/dL, absolute neutrophil count less than 2.5 x 109/L, and platelet count less than 125 x 109/L were excluded, as were those with creatinine concentrations more than 1.5 times the upper limit of normal, total bilirubin concentrations more than 2.0 times the upper limit of normal, calcium concentrations more than 11.5 mg/dL, or transaminase or alkaline phosphatase concentrations more than 2.5 times the upper limit of normal or, in patients with liver or bone metastases, more than 5 times the upper limit of normal.",the entire treatment period,NA
15894361,NA,Combination,No,locally advanced squamous cervical cancer,"Patients eligible for the study were suffering with squamous carcinoma of cervix and had locally advanced disease (FIGO Stage 1b to Stage 4a). Staging was based on both clinical assessment supplemented by imaging either by CT scan of chest, pelvis and abdomen or MRI scan of pelvis and abdomen plus a chest X-ray. No patients had extra pelvic metastases. All patients were considered fit for radiotherapy and chemotherapy and had adequate bone marrow reserves (haemoglobin > 10 g after blood transfusion if necessary, neutrophil count > 1.5 x 10/l, platelet count > 100 x 10/l). All patients had a creatinine clearance > 50 ml/min and normal or mildly abnormal liver function tests only (serum bilirubin < 1.5, transaminase < 2.5, alkaline phosphatase < 2.5 than normal upper limits).",Patients who had received previous pelvic radiotherapy or had a history of malignancy in the last 5 years were excluded from the study. No patients had received prior chemotherapy,during chemoradiotherapy and for 4 weeks after completing treatment.,NA
34562230,NCT02419495,Combination,No,advanced solid tumors,"Adult (age≥18 years) patients with histologically documented, advanced or metastatic solid tumors (excluding brain tumors) whose tumors were unresponsive or had relapsed following prior systemic therapy or where the addition of selinexor to standard chemotherapy deemed appropriate and acceptable were eligible. Other key inclusion criteria included Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and adequate organ function. The number of prior treatments was not limited. Patients in the study had to have at least one measurable target lesion as defned by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) [19, 20] criteria for solid tumors, except for patients with castrate resistant prostate cancer(CRPC) where prostate cancer working group 2 (PCWG2) criteria was utilized ","Key exclusions were patients with primary CNS tumor or active CNS tumor involvement, evidence of complete or partial bowel obstruction or needing total parenteral nutrition, prior treatment with an agent targeting the exportin, and unstable cardiovascular functions.",during cycle 1,NA
34607210,NCT02944396,Combination,No,metastatic or advanced non-small cell lung cancer,"Patients were at least 18 years of age with a life expectancy >12 weeks and cytologically or histologically confirmed unresectable advanced/metastatic (stage IIIB/IV) NSCLC not amenable to radiation or chemoradiation with curative intent at screening. Eligible patients had ≥1 unidimensional measurable NSCLC lesion on a computed tomography scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and resolution to ≤grade 1 AEs (except alopecia) of the most recent therapy prior to Cycle 1 Day 2. Recruitment was restricted to patients with an Eastern Cooperative Oncology Group performance score (ECOG-PS) of 0–1, and adequate bone marrow, renal, and hepatic function. ","Exclusion criteria included untreated central nervous system metastases; prior cytotoxic CT or chemoradiotherapy for NSCLC (except for adjuvant or neoadjuvant therapy accompanied by surgery with curative intent that was completed 1 year prior to Cycle 1 Day –2); prior therapy with a PARP inhibitor, any anti-PD-1, PD-L1, or PD-L2 agent, or an antibody targeting other immunoregulatory receptors or mechanisms; and lung radiotherapy (>30 Gy) within 6 months, antineoplastic biologic therapy within 21 days, major surgery within 21 days, tyrosine kinase inhibitor therapy within 7 days, or palliative radiation within 7 days of the first dose of study medication.","from the first three or six patients enrolled in each dosing cohort, and were determined from the start of veliparib dosing (Cycle 1 Day –2) to pre-dose Cycle 3 Day 1",NA
34311345,NCT02412371,Combination,No,stage III non-small cell lung cancer ,"Patients aged ≥18 years with histologically or cytologically confirmed unresectable stage III NSCLC were enrolled. Eligible patients were required to have a lung V20 (volume of lung to receive ≥20 Gy radiotherapy according to simulation) <35%, an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, adequate bone marrow, renal, and hepatic function, and pulmonary function tests within 12 weeks prior to randomization with forced expiratory volume in one second (FEV1) ≥1.2 L/second and/or ≥50% predicted","Patients were excluded if they had prior chemotherapy or RT for their NSCLC, received previous treatment with PARP inhibitors, had a known hypersensitivity to carboplatin, paclitaxel, or formulations containing polyethoxylated castor oil (Cremophor® EL), sensory peripheral neuropathy grade ≥2 at baseline, an inability to swallow medication, or history of seizure within the prior 12 months. ",from the start of veliparib dosing through 28 days following completion of RT or until consolidation chemotherapy was initiated for the CRT period; and from Cycle 1 Day 1 to the end of Cycle 1 for the consolidation period,NA
16284056,NA,Combination,No,advanced breast cancer ,"Thirty-two patients with histologically or cytologically proven progressive MBC entered into this dose finding trial. Eligibility criteria included: treatment with one or more lines of CT, treatment with taxanes in adjuvant setting stopped at least 12 months before, Eastern Cooperative Oncology Group performance status <= 2, life expectancy >3 months, normal hepatic and renal function, normal cardiac function and written informed consent","Patients were ineligible if they were pregnant or lactating, had received prior treatment with taxanes and/or continuous infusion of 5-FU and/or capecitabine as advanced disease, had experienced previous or concurrent second malignant disease(except superficial squamous or basal-cell carcinoma of the skin or in situ carcinoma of the cervix) or non-malignant systemic disease such as congestive heart failure, angina pectoris, previous  history of myocardial infarction, history of significant neurological or psychiatric disorders including dementia or seizures, active infection, peptic ulcer, or unstable diabetes mellitus precluding administration of CT. An history of prior allergic reactions to drugs containing Cremophor EL (teniposide, K vitamin, cyclosporine) was an exclusion criteria. Patients with neutrophil count <2 x 109/l and/or platelet count <100 000/ml were not included.",during the first cycle of CT,NA
31174889,NCT02092363,Combination,No,recurrent platinum-sensitive ovarian cancer,"Eligible patients were ≥18 years, with histologically documented EOC, recurrent disease deemed appropriate for retreatment with platinum (N6 months from last platinum therapy), Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, evaluable or measurable disease per RECIST 1.1, and adequate organ function. Archival tumor was required for all patients and fresh tumor biopsy during study was optional during dose escalation but mandatory during dose expansion.","Osteoporosis based on the total femur and L1–L4 T scores (≤−2.5) on screening bone density scan was exclusionary. T scores had to be obtained for either the right or left hip or right or left femoral neck and lumbar spine (L1–L4). History of bone metastases with a prior history of a pathologic fracture, or with a lytic lesion requiring an orthopedic intervention, or not receiving a bisphosphonate or denosumab as per institutional guidelines were exclusionary. Patients were excluded if they were on glucocorticoid therapy at the equivalent of ≥7.5 mg/day of oral prednisone for ≥4 weeks within the last 8 weeks; fasting β-Cterminal telopeptide (β-CTX) N 1000 pg/ml; metabolic bone disease; or history of a symptomatic vertebral fragility fracture or any fragility fracture of hip, pelvis, wrist or other location; or a history of moderate morphometric fractures, for a 10 year fracture risk of N20% for any bone or N3% for the hip as determined by the US FRAX calculation tool.",during the first 21 days (cohorts 1 and 2) or 28 (cohorts 3+) days of treatment,NA
31190276,NCT00268905,Combination,No,advanced solid tumors and  non‑small cell lung cancer,"Patients enrolled in this study had to be at least 18 years of age with pathologically confrmed advanced solid tumors that progressed following standard therapy, or for which no standard therapy existed. They were also required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; life expectancy of at least 3 months; adequate renal, bone marrow, and liver function; and grade 2 or lower chemotherapy or radiation-related toxicities, except alopecia. Specifcally, for the expansion cohort, patients were required to have pathologically confrmed advanced NSCLC (Stage IIIB or IV) with measurable disease, not amenable to curative surgical or radiation treatment, and to have received no prior chemotherapy for NSCLC. Informed consent was obtained from all individual participants included in the study","For all patient cohorts, key exclusion criteria included: (1) anticancer therapy (investigational drugs, immunotherapy, gene therapy, hormone therapy, biological therapy, chemotherapy, or radiation) within 3 weeks before study treatment; (2) prior high-dose chemotherapy with hematopoietic stem cell rescue, or stem cell or bone marrow transplant in the past 2 years; (3) pulmonary lymphangitic involvement requiring active treatment; and (4) active symptomatic brain metastases or meningeal carcinomatosis. Other criteria for ineligibility included signifcant cardiovascular impairment (history of congestive heart failure of greater than grade II severity by New York Heart Association classifcation, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia); preexisting neuropathy of greater than grade 2 severity; prior use of anticoagulants; HIV-positivity; or active hepatitis B or C at study entry. For patients with NSCLC, a prior malignancy (other than carcinoma in situ of the cervix or nonmelanoma skin cancer) was not allowed, unless the prior malignancy was diagnosed and treated at least 5 years previously",in cycle 1,NA
33539540,NCT02418624,Combination,No,advanced cancer,"Histological or cytological proof of advanced cancer pre-treated with maximally one line of systemic chemotherapy in the advanced setting and any line of hormonal therapy for advanced disease, and potentially benefitting from olaparib-carboplatin combination therapy (prior (neo-)adjuvant chemotherapy is accepted and does not count as one line, since administered in early stage disease); Age ≥ 18 years; Able and willing to give written informed consent; WHO performance status of 0, 1 or 2; Able and willing to undergo blood sampling for PK and PD analysis; Life expectancy ≥ 3 months, allowing adequate follow up of toxicity evaluation and antitumor activity; Evaluable disease according to RECIST 1.1 criteria; Minimal acceptable safety laboratory values ANC of ≥ 1.5 x 10^9 /L; Hemoglobin of at least 6.2 mM and no transfusions in the last 28 days. Platelet count of ≥ 100 x 10^9 /L Hepatic function as defined by serum bilirubin ≤ 1.5 x ULN (or < 3 x ULN in case of known Gilbert syndrome), ASAT and ALAT 2.5 x ULN (or <5 x ULN in case of liver metastasis) Renal function as defined by serum creatinine ≤1.5 x ULN or creatinine clearance ≥ 50 mL/min (by Cockcroft-Gault formula); Negative pregnancy test (urine/serum) for female patients with childbearing potential;","Any treatment with investigational drugs within 28 days prior to receiving the first dose of investigational treatment; or 21 days for standard (neo-)adjuvant chemotherapy, hormonal and immunotherapy; Patients who have received high dose alkylating agents, a PARP1 inhibitor or carboplatin pretreatment; unless no progression on carboplatin had been observed during earlier treatment and the last carboplatin administration had been longer than 6 months ago; Any current treatment with drugs that induce or inhibit the CYP3A4 system : http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#inVivo or APPENDIX IX. Women who have a positive pregnancy test (urine/serum) and/or who are breast feeding; Unreliable contraceptive methods. Women and men enrolled in this trial must agree to use a reliable contraceptive method throughout the study (adequate contraceptive methods are: oral, injected or implanted hormonal methods, intra-uterine devices or systems, condom or other barrier contraceptive measures, sterilization and true abstinence); Radiotherapy within the last four weeks prior to receiving the first dose of investigational treatment; except 1x8 Gy for pain palliation then a seven days interval should be maintained; Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients; Patients with known active hepatitis B or C; Recent myocardial infarction (< six months) or unstable angina; Symptomatic brain metastases. If adequately treated with resection and/or irradiation and patients are at least four weeks completely free of symptoms of these metastases and without medication related to these metastases patients could be eligible if all other in- and exclusion criteria are obeyed. Known leptomeningeal metastases. Patients with myelodysplastic syndrome or acute myeloid leukemia. Any medical condition not yet specified above that is considered to possibly, probably or definitely interfere with study procedures, including adequate follow-up and compliance and/or would jeopardize safe treatment.",in the first cycle,NA
30327308,NCT02289690,Combination,No,Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors,"Patients with histologically or cytologically confirmed advanced or metastatic solid tumors for which carboplatin and etoposide treatment was considered appropriate were included. Eligible patients were 18 years of age, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and had adequate hematology, blood chemistry, bone marrow, liver, and renal functions.","Patients were not eligible if they received prior anticancer therapy other than: hormonal, nonmyelosuppressive, biological, targeted, or immune therapy (completed >= 4 weeks prior to cycle 1 day - 2); 1 line of cytotoxic chemotherapy (including carboplatin, cisplatin, etoposide, paclitaxel, doxorubicin, cyclophosphamide, methotrexate; completed >= 4 weeks prior to cycle 1 day -2); adjuvant/neoadjuvant radiotherapy (completed >= 12 months prior to cycle 1 day -2, with field not involving >10% of bone marrow reserve). Patients with central nervous system or leptomeningeal metastases were not eligible (brain imaging was performed if brain metastases were suspected), nor were patients with a history of seizures within 12 months of cycle 1 day - 2 or at increased risk of seizures.",during the first 21 days in the current cohort,NA
31231786,NCT03201146,Combination,No,stage IV non-squamous NSCLC,"1. Signed the informed consent form prior to patient entry. 2. ≥ 18 and ≤ 70 years of age. 3. Histologically or pathologically confirmed non-squamous EGFR wild-type, ALK-rearrangement negative, stage IV non-small cell lung cancer(NSCLC). 4. Must have at least one measurable lesion as per RECIST 1.1 defined as a lesion that is 10mm in longest diameter or lymph node that is 15mm in short axis imaged by CT scan, prior topical treatment, such as radiotherapy or cryosurgery to the lesions is not allowed. 5. No prior systemic chemotherapy for advanced or metastatic NSCLC. 6. Eastern Cooperative Oncology Group(ECOG) performance status 0 or 1. 7. Life expectancy of more than 3 months. 8. Adequate bone marrow function : WBC ≥ 3.0 ×10 E+9/L, neutrophil ≥ 1.5 × 10 E+9/L, platelets ≥ 80 × 10E+9/L,Hb ≥ 10.0g/dL. 9. Adequate hepatic and renal functions: a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL), a alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL or ≤5 UNL in case of liver metastasis, a creatinine (Cr) of ≤ 1.5 UNL; a creatinine clearance rate ≥ 50ml/min (Cockcroft-Gault). 10. With normal coagulation function: INR and PTT, each ≤ 1.5 x ULN. 11. Adequate cardiovascular function: left ventricular ejection fraction (LVEF) ≥ 50%, QTcF ≤ 450 msec. 12. Alkaline phosphatase ≤ 2.5 x ULN. 13. The subjects are willing to coordinate with the follow-up with good compliance. 14. Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of apatinib until 8 weeks after discontinuing study drug. Male subjects must agree to use contraceptive measures during the study and 8 weeks after last dose of study drug.","1. Patients with active brain metastasis, carcinomatous meningitis, or spinal compression, or disease of brain or pia mater according to the screening test, imaging, CT or MRI tests (patients who have completed the treatment and in a stable condition 21 days before screening could be included, but brain MRI, CT or venography is required to confirm that there are no brain hemorrhage symptoms). 2. Patients with uncontrollable hypertension (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg, despite optimal drug therapy). 3. Patients with with grade Ⅱ myocardial ischemia or myocardial infarction, poor control of arrhythmias (including QTc interval male ≥ 450 ms, female ≥470 ms). 4. According to NYHA standard, grade Ⅲ ~ Ⅳ heart failure, or cardiac color Doppler ultrasound examination showed left ventricular ejection fraction (LVEF) <50%. 5. Coagulation dysfunction (INR> 1.5, PT> ULN +4s or APTT> 1.5 ULN), with bleeding tendency or ongoing thrombolysis or anti-blood coagulation treatment. 6. Patients treated with anticoagulation agents or Vitamin K antagonist such as Warfarin, heparin, or other similar drugs. 7. Patients who had obvious hemoptysis within 2 months before screening, or experienced daily hemoptysis with a volume more than half a tea spoon (2.5ml) or above. 8. Patients who experienced bleeding symptoms of clinical significance within 3 months before screening, or with confirmed bleeding tendency such as hemorrhage of digestive tract, hemorrhagic gastric ulcer, baseline occult blood in stool ++ and above, or vasculitis, etc. 9. Patients who manifested arterial/venous thrombus events, e.g. cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism, etc., within 12 months before screening. 10. Known genetic or acquired bleeding or bleeding tendency (such as hemophilia, blood coagulation dysfunction, thrombocytopenia, and hypersplenism, etc.). 11. Patients who have unhealed wounds or fractures for a long time. 12. Patients who received major surgical operations or experienced severe traumatic injuries, bone fracture, or ulcers within 4 weeks before screening. 13. Patients with obvious factors affecting absorption of oral drugs, such as difficulties in swallowing, chronic diarrhea and intestinal obstruction, etc. 14. Occurrence of abdominal fistula, gastrointestinal perforation, or intraperitoneal abscess within 6 months before screening. 15. Patients whose routine urine tests indicate that urine protein ≥ ++ or verifies that the 24-h urine protein quantitation ≥ 1.0 g. 16. Patients with active hepatitis B virus or hepatitis c virus infection. 17. Active infection requiring antimicrobial treatment, such as antibacterial, antifungal, or antiviral therapy. 18. Patients with clinical symptoms, or dropsy of serous cavity requiring surgical treatment (including hydrothorax, ascites, and hydropericardium). 19. Patients who have a history of psychotropic drug abuse and are unable to break the habit, or who have a psychogeny. 20. Patients who have taken part in other drug clinical tests within 4 weeks before screening. 21. Prior VEGFR inhibitor treatment. 22. Patients who formerly suffered from or currently are complicated with other uncured malignant tumors, except basal cell carcinoma, carcinoma in situ of cervix and superficial bladder cancer that have been cured. 23. Patients who received the treatment with potent CYP3A4 inhibitors within 7 days before screening, or potent CYP3A4 inducers within 12 days before being included. 24. Pregnant or lactating women, fertile patients who are unwilling or unable to take effective contraceptive measures. 25. Conditions determined by investigators to possibly affect the clinical study or determination of the study results.",during the first cycle of the combined treatment,NA
30174176,NA,Combination,No,Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes,"Women with histologically confirmed cervical cancer (squamous, adenocarcinoma, or adenosquamous) including those FIGO clinical stages IB-IVA were eligible. All participants underwent clinical staging as permitted by FIGO rules. An abdominal and pelvic CT scan with intravenous contrast was required, as was radiologic assessment of the chest with either chest CT or chest x-ray. All patients were required to undergo PET/CT, fine needle aspiration (FNA), or surgical assessment of the para-aortic nodes for confirmation of involvement. Patients were required to have GOG performance status of 0–2; adequate bone marrow function (absolute neutrophil count (ANC) ≥1500/μl, and platelets ≥100,000/μl); renal function (creatinine ≤1.5 × institutional upper limit of normal (ULN) of if ≥ULN, creatinine clearance had to be N50 ml/min); hepatic function (bilirubin ≤1.5 × institutional ULN, and AST, ALT and alkaline phosphatase ≤2.5 × institutional ULN); and neurologic function (baseline sensory and/or motor neuropathy) ≤ Common Toxicity Criteria grade 1). HIV status was not specifically determined at enrollment. Patients with ureteral obstruction were allowed but required to undergo stent or nephrostomy tube placement prior to study entry. All patients were required to have an audiogram at baseline, and patients with pre-existing hearing loss or hearing loss during treatment required frequent assessment.",Patients were not allowed to receive any previous pelvic or abdominal radiation or any cytotoxic chemotherapy. Patients must have been enrolled prior to chemoRT and were not allowed to enroll in the study for the adjuvant chemotherapy portion only,in the first cycle of adjuvant chemotherapy,NA
33634324,NCT01304303,Combination,No,advanced solid malignancies and biliary tract cancers,"Patients were eligible for the study if they were 18 years old and above, with histologically or cytologically confrmed diagnosis of advanced-stage solid tumors for which rational treatment options include taxane-based therapy in Part A1, and platinum plus taxane-based therapy in Part B. To be eligible for the A2 expansion cohort, patients were to have histologically or cytologically confrmed biliary tract carcinoma. Other inclusion criteria included Eastern Cooperative Oncology Group (ECOG) performance status 0–1, estimated life expectancy≥12 weeks, measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, adequate bone marrow [absolute neutrophil count (ANC)≥1.5× 109/L, hemoglobin≥9.0 g/dL, and platelet count≥100 × 109/L], liver [total bilirubin≤1.5 mg/dL (or≤2 mg/dL for liver metastases), aspartate transaminase (AST)≤2.5×upper limit of normal (ULN; or≤5 × ULN for liver metastases), alanine transaminase (ALT)≤2.5×ULN (or≤5×ULN for liver metastases), and alkaline phosphatase (ALP)≤5×ULN)], and renal functions [creatinine≤2.0 mg/dL in Part A and≤1.5×ULN or creatinine clearance (CrCl)>50 mL/min in Part B] within 2 weeks of initiation of treatment. Patients must have completed radiotherapy, chemotherapy and/or major surgery≥4 weeks prior to study enrollment without residual toxicity with the exception of alopecia","Patients were excluded if they had known hypersensitivity to the study drug, active central nervous system metastases, pre-existing clinically signifcant peripheral neuropathy [grade≥2 per Common Terminology Criteria of Adverse Events (CTCAE) version 4.0], severe concurrent disease per investigator assessment, and clinically signifcant pleural and/or ascitic fuid.",in Cycle 1 treatment,NA
31953695,NA,Combination,No,triple negative breast cancer,"Eligible patients were those with histologically proven TNM AJCC 7th edition stage II-III invasive, HER-2 and hormone receptor negative breast cancer who were candidates for neoadjuvant chemotherapy. Hormone receptor negative breast cancer was defined as the presence of estrogen receptor and progesterone receptor in less than 10% of invasive cancer cells based on immunohistochemistry (IHC) staining. Negative HER2 status was defined as 0 or 1+ IHC staining or 2+ IHC staining and negative fluorescence in-situ hybridization (FISH) for amplification of the HER2 gene (based on HER2/CEP17 ratio of <2.0). The participants were required to have clinically or radiographically measurable primary breast cancer, with tumor size ≥2.0 cm. Other eligibility criteria included: ECOG Performance Status ≤1, age ≥ 18 years, absolute neutrophil count (ANC) >1500/dL, hemoglobin >9 g/dL, platelet count >100,000/ dL, creatinine: < 1.5 × upper limit of normal (ULN), an adequate liver function: AST and ALT <2.5 × ULN, alkaline phosphatase <2.5 × ULN, and bilirubin <ULN. Women of childbearing potential and men had to use two forms of contraception at least 4 weeks prior to study entry, for the duration of study participation, and for at least 12 months post-treatment",NA,during the first 21-day treatment cycle,NA
31388792,NCT00891072,Combination,No,solid tumors,"Eligible patients were > 18 years of age with histologically or cytologically confirmed metastatic and/or unresectable malignancies, and for which standard curative or palliative measures no longer exist or are no longer effective. Other inclusion criteria included: an ECOG performance status ≤2, life expectancy of ≥3 months, and adequate organ function including: absolute neutrophil count of >1500/μL and platelets >100,000/μL without hematopoietic growth factor support (such as granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, or interleukin-11), or platelet transfusions, creatinine within normal institutional limits (or a measured, 24 h, creatinine clearance greater than 60 mL/min), total bilirubin within normal limits, and aspartate transaminase and alanine transaminase ≤2.5 times the upper limit of normal)","Patients were excluded if they received more than nine months of previous marrow damaging cytotoxic chemotherapy, or if they received prior racemic gossypol or AT-101 treatment. Patients with clinically and radiographically stable, previously treated, brain metastases, or those who clinically improved at least four weeks after completion of radiation therapy and were off steroids were considered eligible",during the first cycle,NA
34052705,NCT02185690,Combination,No,non-squamous non-small cell lung cancer ,"Subjects eligible for enrolment on the study must meet all of the following criteria: Patients with histologically confirmed non-squamous EGFR wild-type, ALK-rearrangement negative carcinoma of lung. Patients with neuroendocrine carcinoma, mixed small and non-small cell carcinoma or squamous carcinoma are not eligible. Tissue available for KRAS mutation status analysis. Patients must have metastatic disease (Incurable stage IIIB/stage IV). Patients must have clinically and/or radiographically documented measurable disease. At least one site of disease must be unidimensionally measurable by RECIST v1.1 as follows (Eisenhauer et al.): CT-scan, physical exam ≥10 mm Chest X-ray ≥20 mm Lymph node short axis ≥15 mm. All radiology studies must be performed within 28 days prior to registration (35 days if negative). Lesions in previously irradiated areas should not be selected unless there is clear evidence of progression in such lesions. Patients may not have received any prior systemic treatment for metastatic NSCLC. Patients who have received adjuvant treatment or chemoradiation for stage III disease should have completed this ≥12 months prior to study enrollment. Patients with stable CNS metastases are permitted if stability of disease is documented with imaging ≥28 days after treatment completion, are and off corticosteroids by day 1 of study treatment. Patients may have had prior malignancy if definitively treated and/or, in the opinion of the investigator, the only active malignancy is NSCLC. Patients with mixed small cell lung cancer histology are excluded. Patients who have received radiotherapy to >30% bone marrow are excluded. Consult PI if unsure whether second malignancies meet requirements specified above. In patients treated for other malignancy, all prior treatment-related toxicities must be CTCAE v4.0 ≤ Grade 1 (except alopecia) at the time of enrollment. Able to swallow and retain oral medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels. Patients receiving medications or substances that are inhibitors or inducers of CYP1A2, CYP2A19, CYP2B6, CYP3A4 and/or UGT1A1 and UGT1A9 are eligible but these drugs must be used with caution (Appendix C). Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http://medicine.iupui.edu/clinpharm/ddis/table.aspx; Patients must be aged ≥18 years. Eastern Cooperative Oncology Group (ECOG) performance status ≤1; Adequate organ and laboratory parameters, defined below. Laboratory Requirements - within 7 days prior to enrollment: Haematology: absolute granulocytes ≥1.5 × 109/L platelets ≥100 × 109/L Biochemistry: bilirubin ≤1.25 × institutional upper limit of normal AST(SGOT) ≤2.5 × institutional upper limit of normal /ALT(SGPT) or ≤5 × institutional upper limit of normal in the presence of liver metastases; creatinine clearance ≥45 mL/min/1.73 m2. -Patients must be able to provide Informed Consent based on the details below: absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial; before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.","History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR): History of RVO or CSR, or predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease such as hypertension, diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes). Patients with prior deep venous thrombosis or pulmonary embolism are permitted. Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk factor for RVO or CSR such as: Evidence of new optic disc cupping; Evidence of new visual field defects on automated perimetry; Intraocular pressure >21mmHg as measured by tonography. Any serious and/or unstable pre-existing medical (aside from malignancy exception), psychiatric disorder, or other conditions that could interfere with subjects' safety, obtaining informed consent or compliance to the study procedures, in the opinion of the PI. History of interstitial lung disease or pneumonitis. Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal metabolic or cardiac disease). Any factors that increase the risk of QTc prolongation or risk of arrhythmic events (e.g. congenital long QT syndrome, family history of long QT syndrome, hypokalemia) or baseline QTcB interval ≥480 msec. History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within the past 6 months or cardiac metastases. History or evidence of current clinically significant uncontrolled arrhythmias. History or evidence of current ≥Class II congestive heart failure as defined by New York Heart Association (NYHA). Known positivity for Hepatitis B surface antigen or Hepatitis C antibody. Known Human Immunodeficiency Virus (HIV) infection. Treatment refractory hypertension defined as a blood pressure systolic >140 mmHg and/or diastolic >90 mmHg which cannot be controlled by anti-hypertensive therapy. Subjects with intra-cardiac defibrillators or permanent pacemakers. Pregnant or nursing (lactating) women are excluded. Female patient of child bearing potential must have a negative serum or urine pregnancy test. Women of child-bearing potential must agree to use of appropriate contraceptive methods throughout the study and for 120 days after, These methods include: Total abstinence or 2 barrier methods or a barrier method plus hormonal method from visit 1 to 120 days after the last dose of treatment. Men must agree to use an appropriate method of contraception starting with first dose of study drug through 120 days after the last dose of treatment (see above). Whilst not excluded, patients with significant impaired hearing must be made aware of potential ototoxicity and may choose not to be included. If included, baseline audiograms are recommended and should be followed by repeat audiograms prior to cycle 2.",during cycle 1,NA
31708167,NCT00989651,Combination,No,"newly diagnosed ovarian, primary peritoneal and fallopian tube cancer","Patients with a histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, or carcinosarcoma stage II, III, or IV with either optimal (=< 1 cm residual disease) or suboptimal residual disease. All patients must have a procedure for determining diagnosis of epithelial ovarian, fallopian tube, primary peritoneal, or carcinosarcoma with appropriate tissue for histologic evaluation. Patients with the following histologic cell types are eligible: Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial adenocarcinoma, transitional cell carcinoma, malignant Brenner's tumor, adenocarcinoma not otherwise specified (N.O.S.) or carcinosarcoma. Absolute neutrophil count (ANC) greater than or equal to 1,500/mm^3, equivalent to CTEP Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, grade 1; this ANC cannot have been induced or supported by granulocyte colony stimulating factors. Platelets greater than or equal to 100,000/mm^3. Regimens I and II: Creatinine =< 1.5 x institutional upper limit normal (ULN), CTCAE grade 1. Regimen III: Creatinine no greater than the institutional upper limits of normal. Bilirubin less than or equal to 1.5 x ULN (CTEP CTCAE version 4.0, grade 1). Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) less than or equal to 3 x ULN (CTEP CTCAE version 4.0, grade 1). Alkaline phosphatase less than or equal to 2.5 x ULN (CTEP CTCAE version 4.0, grade 1). Albumin greater than or equal to 3.0 g/dL. Neuropathy (sensory and motor) less than or equal to CTEP CTCAE version 4.0, grade 1. Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) < 1.5 x ULN. Patients must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2. Patients must be entered between 1 and 12 weeks after initial surgery performed for the combined purpose of diagnosis, staging and cytoreduction. Patients who have met the pre-entry requirements specified. Patients must have signed an approved informed consent and authorization permitting release of personal health information","Patients with a current diagnosis of borderline epithelial ovarian tumor (formerly ""tumors of low malignant potential"") or recurrent invasive epithelial ovarian, primary peritoneal or fallopian tube cancer treated with surgery only (such as patients with stage IA or IB low-grade epithelial ovarian or fallopian tube cancers) are not eligible; NOTE: Patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently develop an unrelated, new invasive epithelial ovarian, peritoneal primary or fallopian tube cancer are eligible, provided that they have not received prior chemotherapy for any ovarian tumor. Patients with synchronous primary endometrial cancer or a past history of endometrial cancer, unless all of the following conditions are met: Stage not greater than IB; No more than superficial myometrial invasion; No vascular or lymphatic invasion; No poorly differentiated subtypes, including papillary serous, clear cell, or other International Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions. Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer and other specific malignancies as noted, are excluded if there is any evidence of other malignancy being present within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy. Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease. Patients who have received prior chemotherapy for any abdominal or pelvic tumor within the last five years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease. Patients with acute hepatitis or active infection that requires parenteral antibiotics. Patients with serious non-healing wound, ulcer, or bone fracture; this includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations. Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels. Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures or history of seizures, and/or any CNS metastases are ineligible. Patients with history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study are ineligible. Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg. Myocardial infarction or unstable angina < 6 months prior to registration. New York Heart Association (NYHA) class II or higher congestive heart failure. Serious cardiac arrhythmia requiring medication. CTEP CTCAE version 4.0, grade 2 or higher peripheral ischemia (brief [< 24 hours (hrs)] episode of ischemia managed non-surgically and without permanent deficit). Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies. Patients with clinically significant proteinuria (urine protein creatinine ratio greater or equal to 1.0). Patients with invasive procedures or anticipation of invasive procedures within the following timeframes as defined below: Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of bevacizumab therapy (cycle 2); Major surgical procedure anticipated during the course of the study; Core biopsy within 7 days prior to the first date of bevacizumab therapy (cycle 2). Patients who are pregnant or nursing. Patients with clinical symptoms or signs of gastrointestinal obstruction and who require parenteral hydration or nutrition. Patients with GOG performance status of 3 or 4",first or second-cycle ,NA
30088048,NCT00809133,Combination,No,advanced solid tumors,"Male or female patients (patients) with a histologically confirmed diagnosis of malignancy that is now advanced, non-resectable and / or metastatic. Age 18 years old or older. Life expectancy of at least 3 months. Written informed consent that is consistent with ICH-GCP guidelines. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1. Patients must have recovered from any previous surgery. Adequate organ function including the following: Cardiac left ventricular function with resting ejection fraction greater than or equal to 50%; Absolute neutrophil count of greater than or equal to 1,500/microlitres; greater than 2000/microlitres for carboplatin; Platelets greater than or equal to 100,000/microlitres; Total bilirubin less than or equal to 1.5 mg/dl (<26 micromol /L, SI unit equivalent). AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional upper limit of normal. Creatinine less than or equal to 1.5 mg/dl (less than or equal to 132 micromol per liter, SI unit equivalent). Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) for the duration of trial participation. Female patients with reproductive potential must have a negative serum pregnancy test within 7 days of trial enrolment. Breast feeding mothers will be excluded since these agents may be toxic to infants.","Active infectious disease. Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol. GI tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease. Significant cardiovascular disease (a history of congestive heart failure requiring therapy, a need for anti-arrhythmic therapy for a ventricular arrhythmia, unstable angina pectoris or myocardial infarction within 6 months prior to trial entry). Patients who require full-dose anticoagulation. Patients not completely recovered from any therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies to CTC less than or equal to Grade 1. Prior chemotherapy is allowed if completed at least 4 weeks prior to 1st trial treatment (6 weeks for mitomycin C or nitrosoureas) and the patient has recovered from the acute toxicities of that therapy. Patients with untreated or symptomatic brain metastases. Patients with treated, asymptomatic brain metastases are eligible if there has been no change in brain disease status for at least 8 weeks, no history of cerebral oedema or bleeding in the past 8 weeks and no requirement for steroids or anti-epileptic therapy. Persistent Grade 2 or greater neurotoxicity / neuropathy from any cause. Patients on immunosuppressant therapy or with known HIV infection. Treatment with any of the following within 4 weeks of starting trial medication, or during the trial, is not permitted: chemo-, immuno-, radio- (small field palliative radiotherapy is allowed provided this does not represent clear disease progression), biological therapies (including trastuzumab), hormone therapy (excluding LHRH agonists in prostate cancer, or bisphosphonates), or treatment with other investigational drugs. Participation in another clinical trial within the past 4 weeks before start of therapy or concomitantly with this trial. Prior treatment with EGFR targeting therapies or treatment with EGFR- or HER2 inhibiting drugs within the past 4 weeks before start of therapy or concomitantly with this trial. Patients with known or suspected hypersensitivity to any of the trial drugs, their excipients or similar compounds. Patients unable to comply with the protocol. Active alcohol or drug abuse. Patients with known pre-existing interstitial lung disease. Additional exclusion criteria for patients recruited to cohorts B: Patients with known or suspected hypersensitivity to bevacizumab, its excipients or Chinese hamster ovary cell products or other recombinant human or humanised antibodies. Patients with brain metastases (a brain scan is not required unless the patient shows signs and symptoms of brain metastases and a brain scan is performed to rule out the presence of brain metastases). Patients with intra-abdominal inflammation . Major surgery within 4 weeks of starting treatment or any wound(s) deemed by the investigator to pose a significant risk to the patient in the event of delayed healing. Prior treatment with anthracycline and/or prior radiation to the chest wall ( patients in these categories will only be entered into the study where the investigator deems the benefit to the patient to outweigh the risk). Patients with any of the following conditions: significant hypertension, significant haemoptysis, known brian metastases, thrombotic or haemorrhagic disorders, INR greater than or equal to 1.5 abnormal PTT, therapeutic anti-coagulation, squamous non small cell lung cancer Additional exclusion criteria for patients recruited to cohorts C and D: Patients with severe myelosuppression; i.e. absolute neutrophil count less than 2000/microlitres; Patients with renal impairment (creatinine clearance less than 60ml per minute by Cockcroft-Gault equation)",during Cycle 1,NA
33513474,NCT01711541,Combination,No,head and neck squamous cell carcinom,"Patients who are treatment naïve, high risk, stage IVa/IVb (all other sites) and histologically proven squamous cell carcinoma of the head and neck (SCCHN) with no definitive evidence of metastatic disease, excluding patients with oropharynx human papillomavirus (HPV)-positive tumors; in summary, those patients eligible are newly diagnosed and treatment naive: Stage IVa-b squamous cell carcinoma other than oropharyngeal cancer (OPC), or Oropharyngeal cancer (OPC) HPV-negative, stage IVa-b. Patients must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria; i.e., patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan magnetic resonance imaging (MRI), or calipers by clinical exam. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Patients must be able to swallow the drug. Ability to understand and the willingness to sign a written informed consent document. Leukocytes >= 3,000/mm^3. Absolute neutrophil count >= 1,500/mm^3. Platelets >= 100,000/mm^3. Total bilirubin =< 1.5 institutional upper limit of normal (ULN). Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x institutional ULN as calculated by Cockcroft-Gault. Creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above ULN as calculated by Cockcroft-Gault. Patients who are receiving any other investigational agents are not eligible. Patients with active seizure or a history of seizure are not eligible. Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study, including Cremophor, carboplatin, paclitaxel, cisplatin, 5-fluorouracil, hydroxyurea, or any compounds of similar chemical or biologic composition are not eligible. Patients with impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of ABT-888 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection) are not eligible to participate in this study. Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements are not eligible to participate in the study. Pregnant women are not eligible to participate in this study; NOTE: women of child bearing potential must have a negative serum or urine pregnancy test within 7 days prior to treatment. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; Breastfeeding should be discontinued if the mother is treated with ABT-888. Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are not eligible. Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent are not eligible to participate in this study; topical or inhaled corticosteroids are allowed. Patients with other malignancies within the past 2 years, except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin or surgically treated early stage solid tumors are ineligible to participate in this study","Exclusion criteria included M1 disease, impaired gastrointestinal function interfering with absorption, inability to swallow pills, co-morbidities interfering with therapy or survival, pregnancy, and malignancy within the past 3 years.",in the first induction cycle,NA
31791552,NCT01663857,Combination,No,recurrent platinum-sensitive ovarian cancer,"Have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer. Have been treated one time with a platinum-based chemotherapy and your disease has come back at least six months after you completed treatment. Are able to swallow tablets. Have given written informed consent prior to any study procedures. Have adequate blood counts, hepatic and renal function. Have performance status equal to or less than 2 on Eastern Cooperative Oncology Group (ECOG) scale. Have negative pregnancy test, and if participant is of child bearing potential must use birth control while on study and for three months after stopping study drug","Have been previously treated with Gemcitabine for ovarian, fallopian tube or primary peritoneal cancer. Are currently enrolled or discontinued less than 14 days from another clinical trial. Have a history of inflammatory bowel disease (Crohn's disease or ulcerative colitis). Have taken certain medications or had grapefruit juice within 7 days of initial dose of study drug, as levels of the study drug may be affected. Must not be pregnant or breastfeeding.. Have malignancy or metastasis of the central nervous system. Have borderline malignancy",during Cycle 1 ,NA
31446228,NCT01868022,Combination,No,FGFR1-amplified non-small cell lung cancer,"Signed written informed consent. Histologically or cytologically confirmed diagnosis: Arm A and B- stage IV recurrent metastatic squamous NSCLC with Fibroblast growth factor receptor 1 (FGFR1) gene amplification by central laboratory testing. Arm C- recurrent after local therapy or unresectable MPM with measurable lesions. For specific arms the following requirements: Arm A: Subjects who have received no prior therapy for Stage IIIB or Stage IV or recurrent metastatic disease. Note, to avoid any undue delay of initiating systemic chemotherapy for these subjects with newly diagnosed metastatic disease, it is allowed to initiate the first cycle of chemotherapy while eligibility for the study is still being determined, as long as the first dose of GSK3052230 is given no later than Cycle 2 Day 1 of chemotherapy. In addition, subjects with Stage IIIB or Stage IV disease and recurrence after previous NSCLC that has been treated with surgery and adjuvant chemotherapy or a radio- chemotherapy regimen with curative intent are eligible, provided 6 months has passed since this treatment ended. Arm B: Subjects who have documented tumor progression (based on radiological imaging) or intolerability after receiving at least one prior line of platinum containing combination chemotherapy for Stage IIIB or Stage IV or recurrent metastatic disease. Note: Prior treatment should not include docetaxel but may have included paclitaxel. Arm C: Subjects who have received no prior systemic therapy for MPM. - Availability of archival tumor tissue required for assessment of deregulated FGF pathway signalling, but not limited to, FGFR1 amplification or FGF2 or FGFR1 expression. If archival tissue is not available, a fresh biopsy is required. In Arms A and B, subjects will be prospectively screened for FGFR1 gene amplification using a Fluorescence in situ hybridization (FISH) assay for the dose expansion and the MTD/MFD cohorts only. For inclusion in this study, based on the central laboratory testing, FGFR1 gene amplification must meet one of the following criteria: a ratio of FGFR1/CEN 8 of >=2; or average number of FGFR1 signals per tumor nucleus of >=6; or the percentage of tumor nuclei containing >=5 FGFR1 signals is >=50%. In Arm C, FGF2 expression by IHC will be evaluated retrospectively in tissue samples by a central laboratory and is not a requirement for study entry. Measurable disease per RECIST version 1.1 (Arm A and B) and modified RECIST for Arm C. Male or female >=18 years of age. Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception, from 14 days prior to the first dose of study treatment, throughout the study, and for 6 months following the last dose of chemotherapy or 4 weeks after the last dose of GSK3052230, whichever is latest. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception for at least 2 weeks prior to administration of the first dose of study treatment and for at least 6 months after the last dose of chemotherapy to allow for clearance of any altered sperm. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 for Arm A and C subjects and 0-2 for Arm B. French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category. Must have adequate organ function as defined by the following baseline values: Absolute neutrophil count >=1.5 x 10^9/Liter, Hemoglobin >=9 gram (g)/decilitre(dL), Platelets >=100 x 10^9/L, Partial thromboplastin time (PTT) <=1.25 x upper limit of normal (ULN), Albumin >=2.5 g/dL, Serum total bilirubin <=1.25 times ULN (for Arm B: <=ULN ), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) <=2.5 times ULN (for Arm B: <=1.5 times ULN), Serum Creatinine <=1.5 x ULN, Or Measured or Calculated Creatinine Clearance >=45 mL/min (Arm A or B), >=65 mL/min (Arm C), Left ventricular ejection fraction >=50% by ECHO.","For Arms A and C: Treatment with any FGFR inhibitor. For Arm B: Treatment with any anti-cancer therapy (for biological anti-cancer therapies see criteria below) during the preceding 4 weeks or within 4 half-lives of the therapy, whichever is longer. Receipt of any biological therapy within 6 weeks of the first dose of GSK3052230 Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03 (NCI CTCAE version 4.03) Grade 2 or higher from previous anti-cancer therapy, except alopecia. Active malignancy other than the cancer under study. Subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible. Presence of uncontrolled infection. Prior major surgery or trauma within 28 days before first dose of study drug. Presence of any non-healing wound, fracture, or ulcer. Any prohibited medication(s) as described in protocol. Conditions likely to increase the potential for abdominal perforation or fistula formation, including but not limited to: Luminal intestinal cancers or bulky abdominal disease. Presence or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease or intra-abdominal abscess within the six months prior to the first dose of GSK3052230. Other risk factors for perforation, such as acute diverticulitis, obstruction or previous abdominal or pelvic radiation. Symptomatic leptomeningeal or brain metastases or spinal cord compression Note: Subjects previously treated for these conditions are eligible if they meet both of the criteria below: (1) have had stable CNS disease for at least 4 weeks after local therapy as assessed by imaging (contrast enhanced magnetic resonance imaging [MRI] or computed tomography [CT]) prior to Day 1, and (2) are asymptomatic and off corticosteroids, or are on stable dose of corticosteroids for at least 4 weeks prior to Day 1. Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drugs (GSK3052230, docetaxel, paclitaxel, carboplatin, pemetrexed, cisplatin) and or their excipients that contraindicate their participation. Known human immunodeficiency virus-positive serology, acquired immunodeficiency syndrome (AIDS), or an AIDS-related illness. Prior organ or allogeneic stem cell transplant. The following cardiac abnormalities: Corrected QT (QTc) interval >=480 millisecond. History of acute coronary syndromes (including unstable angina) within the past 24 weeks Coronary angioplasty or stenting within the past 24 weeks. Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system. Abnormal cardiac valve morphology (>= Grade 2) documented by echocardiogram (subjects with Grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). History of known arrhythmias (except sinus arrhythmia and atrial fibrillation that is controlled) within the past 24 weeks. Presence or history of hemoptysis (>1/2 teaspoon of red blood) 2 weeks prior to the first dose of GSK3052230. Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures. Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease per investigator's assessment). Pregnant, lactating or actively breast feeding females. French subjects: The French subject has participated in any study using an investigational study treatment(s) during the previous 30 days.",in the first 21 days,NA
30596402,NCT01165112,Combination,No,relapsed or refractory aggressive lymphoma,"Eligible patients had histologically-confirmed relapsed or refractory DLBCL or HL. Patients with other lymphoid malignancies were eligible for the dose escalation portion of the study with protocol chair review and approval. Patients were required to have measurable disease, age ≥18 years, an Eastern Cooperative Oncology Group (ECOG) performance status score ≤2, absolute neutrophil count (ANC) ≥1.5 x 109/l, platelet count ≥100 x 109/l, serum creatinine ≤132.6 lmol/l or creatinine clearance ≥50 ml/min, total bilirubin ≤1.5 times upper limit of normal (ULN), aspartate transaminase and alanine transaminase <2.5 times ULN.","Patients were excluded if they had known human immunodeficiency virus or active Hepatitis B virus infection, active central nervous system disease, were pregnant or nursing, had prior malignancies within 5 years, had lymphoma refractory to a regimen containing carboplatin, cisplatin, ifosfamide or etoposide, had prior treatment with bendamustine, had pelvic radiation within 12 months or received more than 2 prior therapies with myelotoxic regimens, active infection, active cardiac disease, a left ventricular ejection fraction <50%, autologous or allogeneic transplantation within 12 months, or radioimmunotherapy within 6 months.",NA,NA
32665311,NCT01934361,Combination,No,recurrent glioblastoma,"Eligible patients were aged 18 years or older with rGBM pretreated with RT and TMZ SoC. Patients must have had at least one measurable and/or non-measurable lesion as per the Response Assessment in Neuro-Oncology (RANO) criteria,25 must have recovered (to grade ≤1) from all clinically significant toxicities related to prior antineoplastic therapies, must have had a Karnofsky Performance Status (KPS) ≥70%, and must have had adequate organ and bone marrow functions. PI3K expression status was not an inclusion criterion and testing isocitrate dehydrogenase (IDH) mutations or O6-methylguanine-DNA methyltransferase (MGMT) methylation status was not planned.","Patients were excluded if they had received previous treatment with PI3K pathway inhibitors: lomustine or carboplatin for newly diagnosed GBM or rGBM, or antineoplastic treatment for rGBM. Patients who had received more than one line of cytotoxic CT, patients with a history of or having an active cardiac disease, patients with grade ≥3 anxiety, patients with a Generalized Anxiety Disorder-7 (GAD-7) mood scale score ≥15, and patients with a score ≥12 on the Patient Health Questionnaire-9 (PHQ-9) were not permitted",during cycle 1 f,NA
30842183,NA,Combination,No,Advanced Non-small-cell Lung Cancer,"1) age 20 years or older; 2) histologically- or cytologically-confirmed cytotoxic chemotherapy-naive advanced (Stage IIIB, IV, postoperative recurrence, or recurrence after radiotherapy) NSCLC; 3) ECOG PS 2 (PS was assessed by more than 2 doctors); 4) evaluable lesions and adequate organ function; and 5) life expectancy of more than 12 weeks. All patients provided written informed consent","Patients were excluded if they had 1) symptomatic brain metastasis; 2) interstitial pneumonia with usual interstitial pneumonia pattern on chest computed tomography; 3) uncontrolled pleural effusion, ascites or pericardial effusion; 4) received palliative radiotherapy within the past two weeks; 5) active concomitant malignancy; 6) severe complication; 7) positivity for hepatitis B surface antigen; 8) a history of previous severe drug allergy; 9) receiving continuous systemic administration of steroid; and 10) were pregnant or breastfeeding.",during cycle 1,NA
28790114,NCT02358200,Combination,No,Advanced Solid Tumors,"Men and women, 18 years or older with advanced malignancies for which no standard therapy is available. Dose Escalation: Patients with any solid tumor malignancies Does Expansion: Patients with advanced malignancies that have germline and/or somatic BRCA mutations (cohort gBRCA) Or Triple negative (TN) metastatic breast cancer without known BRCA mutation (cohort TNBC). Tumors will be considered TN when: Estrogen receptor (ER) expression <1%; Progesterone receptor (PR) expression <1%; Her2 negative as per the American Society of Clinical Oncology (ASCO) guidelines; Paclitaxel expansion: any solid tumor malignancy with potential benefit from this combination and paclitaxel (ASP). Dose expansion cohort only: Histological or cytological confirmation of advanced unresectable solid tumors for which no standard therapy is available in patients with a known BRCA germline mutation or those with metastatic triple negative breast cancer without known BRCA mutation (see inclusion criteria one for definition of triple negative breast cancer).. For the paclitaxel cohorts, any solid tumors with potential benefit from this combination and paclitaxel. Consent to screening tumor biopsy (for accessible tumors when appropriate) [optional in dose escalation, mandatory in dose expansion] Part 2 only: Measureable tumor (RECIST1.1). Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2. Adequate organ function:nAbsolute neutrophil count (ANC) ≥ 1.5 X 109/L; Hemoglobin (Hgb) ≥9.5 g/dL(transfusion before treatment is allowable if more than 3 days prior to study start); Platelets (plt) ≥ 100 x 109/L; Potassium within normal range, or correctable with supplements; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x Upper Limit Normal (ULN); Serum total bilirubin ≤ 1.5 x ULN Serum creatinine ≤ 1.5 x ULN, or calculated creatinine clearance ≥ 60ml/min. Females of child-bearing potential (FCBP) must have negative serum pregnancy test within 7 days before starting study treatment and willingness to adhere to acceptable forms of birth control (a physician-approved contraceptive method: oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) for a minimum of 4 weeks following the discontinuation of study treatment.","Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half-lives or 4 weeks, whichever is shorter, prior to starting study treatment. Patients must have recovered from side effects from prior cancer-directed therapy to grade 1 or less (unless deemed not clinically significant by study investigator). Major surgery ≤ 4 weeks prior to starting study regimen or who have not recovered from surgery. Any known unstable angina, significant cardiac arrhythmia, or New York Heart Association (NYHA) class 3 or 4 congestive heart failure. History of myocardial infraction (MI) within 6 month prior to starting study treatment. Any significant medical condition, laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. Any condition that confounds the ability to interpret data from the study. Symptomatic central nervous system metastases. Subjects with brain metastases that have been previously treated and are stable for 4 weeks are allowed. Malabsorption or uncontrolled peptic ulcer disease. Grade 2 or higher peripheral neuropathy (paclitaxel arm only). Known allergic reaction or poor tolerability to PARP inhibitors, carboplatin, or paclitaxel. Pregnant or breastfeeding. Known active human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV)",in cycle 1,NA
28356425,NCT01149083,Combination,No,Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer,"Patients must be female, and must have histologically confirmed breast cancer that is metastatic or locally advanced, unresectable and for which standard curative measures do not exist or are no longer effective. Patient must have a known deleterious BRCA mutation confirmed by report from a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory (generally Myriad Genetics Laboratory). It is expected that BRCA testing will be covered as medically necessary care by the patient's insurance carrier. Measurable disease by RECIST criteria; (evaluable disease is allowed only for the safety lead-in phase). Prior chemotherapy regimens for metastatic disease are completed, at least 3 weeks prior to starting therapy; prior radiation and hormonal treatment must be completed at least 1 week prior to starting therapy. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Life expectancy greater than four months. Absolute neutrophil count (ANC) >= 1,500/mcL. Platelets >= 100,000/mcL. Total bilirubin =< 1.5 times institutional upper limit of normal. Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamate pyruvate transaminase (SGPT) =< 2.5 times institutional upper limit of normal unless there is evidence of liver metastasis, in which case the AST (SGOT)/ALT (SGPT) must be =< 5 times institutional upper limit of normal. Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal. If a woman is of child-bearing potential, a negative serum or urine pregnancy test is required; (The effects of ABT-888 [NSC 737664] on the developing human fetus are unknown; for this reason and because PARP Inhibitor agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; participants should agree to use contraception for at least 3 months after the completion of study therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.) Ability to understand and the willingness to sign a written informed consent document","Prior therapy with platinum agents (adjuvant therapy with platinum agents is allowed, if completed >= 12 months prior to relapse), or PARP inhibitors (prior iniparib, since it is no longer considered a PARP inhibitor, is allowed). Patients may not be receiving any other investigational agents. Patients with known central nervous system (CNS) metastases requiring anticonvulsive medications, or steroids or with active symptomatology; patients on anticonvulsant medications prescribed for reasons other than CNS metastases, not on steroids and without active symptomatology are eligible; patients must be off anti-seizure medications and steroids for 3 months or more before enrollment. Patients with active seizure or a history of seizure; patients with CNS metastases must be stable after therapy for > 3 months and off steroid treatment prior to study enrollment. History of allergic reactions attributed to compounds of similar chemical or biological composition to ABT-888 (NSC 737664) or PARP Inhibitors. Patients with contraindications to platinum agents are excluded. Prior or current non-breast malignancy within 5 years except non-melanoma skin cancer or resected stage I ovarian cancer. Patients with any non-malignant intercurrent illness (e.g., cardiovascular, pulmonary, or central nervous system disease) which is either poorly controlled with currently available treatment or which is of such severity that the investigators deem it unwise to enter the patient on protocol. Pregnant women are excluded from this study because ABT-888 (NSC 737664) has the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ABT-888 (NSC 737664), breastfeeding should be discontinued. Patients unable to swallow the ABT-888 tablets whole are ineligible; (the tablets cannot be crushed or broken). Patients with an active severe infection; known infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus; HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ABT-888 (NSC 737664); in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated",NA,NA
32669375,NCT01590160,Combination,No,Pleural Mesothelioma,"	Histopathological confirmation of malignant pleural mesothelioma.	Measurable disease using meso-modified RECIST criteria (CT scan must be within 28 days of registration/randomisation).	Performance status ECOG 0-1.	Age at least 18 years.	Adequate haematological status:	Haemoglobin 100g/L or greater;	Neutrophil count ≥2.0 x 109/L;	Platelets ≥100 x 109 /L;	Adequate organ function:	Bilirubin ≤1.5x ULN, ALP ≤2.5x ULN, ALT or AST ≤1.5x ULN.	Serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥ 60ml/min (C&G or EDTA) (appendix 4).	Chemotherapy naïve.	Negative serum pregnancy test for female patients of child-bearing potential. 	Male subjects and women of child-bearing potential must agree to use an acceptable method of birth control for the duration of the trial and for 6. months after the last trial treatment cycle has finished. 	Ability to understand and willing to sign the written informed consent to participate (including donation of diagnostic biopsy tissue for research).	Ability to comply with the requirements of the protocol","Prior exposure to other investigational or commercial agents or therapies administered with the intent of treating the patient's malignancy. This includes crizotinib, other ALK-targeted agents, and any Hsp90 inhibitor (e.g. ganetespib). Prior valproic acid is acceptable but only if there has been at least 30 days wash-out period. Evidence of CNS metastases that in the opinion of the investigator should receive local treatment prior to systemic cytotoxic chemotherapy. Uncontrolled intercurrent illness including but not limited to: Symptomatic neurological illness; Active uncontrolled systemic infection considered opportunistic, life threatening or clinically significant at the time of treatment; Significant pulmonary disease or hypoxia; Psychiatric illness/social situations that would limit compliance with trial requirements; Human immunodeficiency virus (HIV)-positive patients; Known hepatitis B or C infection; Uncontrolled diabetes mellitus. Serum potassium, magnesium, and calcium levels no more than 10% outside the Sites normal reference ranges. Known serious cardiac illness including but not confined to: Clinically unstable cardiac disease, including unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, active myocardial ischemia, or indwelling temporary pacemaker; Ventricular tachycardia or a supraventricular tachycardia that requires treatment with a Class Ia anti-arrhythmic drug (e.g., quinidine, procainamide, disopyramide) or Class III anti-arrhythmic drug (e.g., sotalol, amiodarone, dofetilide). Use of other anti-arrhythmic drugs is permitted; Use of medications that have been linked to the occurrence of torsades de pointes; Second- or third-degree atrioventricular (AV) block unless treated with a permanent pacemaker; Complete left bundle branch block (LBBB); History of long QT Syndrome or a family member with this condition; QTc >470ms (average of triplicate ECG recordings); a consistent method of QTc calculation must be used for each patient's QTc measurements. QTcF (Fridericia's formula) is preferred. The patient has a history of prior malignant tumour, unless the patient has been without evidence of disease for at least three years, or the tumour was a non-melanoma skin tumour or in situ cervix carcinoma. Pregnant women or those who are lactating. Pre-planned surgery or procedures that would interfere with the conduct of the trial. Patients who have had surgery (does not include pleurodesis or pleurectomy) within 28 days of randomisation should not be included. Previous treatment of mesothelioma with systemic chemotherapy. Receipt of extensive radiation therapy, systemic chemotherapy, or other anti-neoplastic therapy within 4 weeks before enrolment is not allowed. However, drain site radiotherapy is allowed. Significant weight loss (≥10% body weight) within the 4 weeks prior to Cycle 1 Day 1. Patients who have had a yellow fever vaccination in the previous 30 days. Other medications, severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.","cycles 1 and 2 only for patients in the cisplatin cohort, and cycle 1 only for the carboplatin cohort",NA
30383888,NCT01636622,Combination,No,BRAF-Mutated Melanoma and Other Advanced Malignancies,"Patient must be age >/= 12 years. Patient must have histologically or cytologically confirmed diagnosis of advanced solid tumor or lymphoma harboring a BRAF mutation, for which no standard therapy is available, is resistant/refractory to standard therapy, has relapsed after standard therapy, or has no standard therapy that improves survival by at least three months. Patient with QTc interval must be less than 500 msec. Patient must have completed any prior cytotoxic chemotherapy or radiation therapy at least 21 days prior to starting the study drug(s), except selective RAF inhibitors (vemurafenib, dabrafenib or LGX818). There is no washout period for prior selective RAF inhibitors. Patients must be at least 5 half-lives or 3 weeks, whichever is shorter, from their previous targeted or biologic therapy. Local palliative radiation therapy that is not delivered to all target lesions is allowed immediately before or during treatment. Patients must have evaluable disease for response. Patient must have an ECOG performance status of 0 to 2. Patient must have adequate liver and renal function as documented by the following laboratory test results within 14 days prior to starting therapy: total bilirubin less than or equal to 2 x upper limit of normal (ULN) (exceptions may apply to benign non-malignant indirect hyperbilirubinemia such as Gilbert syndrome); AST (SGOT) and ALT (SGPT) less than or equal to 2.5 X ULN or less than or equal to 5 X ULN if liver metastasis is present; serum creatinine less than or equal to 2 X ULN. Patient must have adequate bone marrow function as documented by the following laboratory test results within 14 days prior to starting therapy: platelets greater than 75,000/mm^3;absolute neutrophil count (ANC) greater than 1000/mm^3; hemoglobin greater than 8.0 g/dL. Patient (man or woman) must agree to practice effective contraception during the entire study period, unless documentation of infertility exists, and for at least 4 weeks after the last dose of the study drug(s).Patient must be willing and able to sign the informed consent form.","Patients with clinically significant illnesses which could compromise participation in the study, including, but not limited to: active or uncontrolled infection; or unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled cardiac arrhythmia. Patients with an inability to swallow tablets or capsules. Patients with leptomeningeal disease; Patients who are pregnant or breastfeeding",during the first 21 days of therapy,NA
31549216,NCT00535119,Combination,No,advanced solid malignancies,"Histologically or cytologically confirmed advanced solid malignancy. Patients enrolled in stratum II of the study must have BRCA1/2 mutation (added 04/07/09). Patients with CNS metastases must be stable after therapy for CNS metastases (such as surgery, radiotherapy or stereotactic radiosurgery) for > 3 months and must be off steroid treatment prior to study enrollment. ECOG performance status 0-2. Life expectancy > 12 weeks. ANC ≥ 1,500/μL. Platelet count ≥ 100,000/μL. Total bilirubin ≤ 1.5 times upper limit of normal (ULN). AST and ALT ≤ 2.5 times ULN. Creatinine normal OR creatinine clearance ≥ 60 mL/min. Not pregnant or nursing. Negative pregnancy test. Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment. More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C). More than 3 weeks since prior radiotherapy. Prior veliparib allowed","Known history of allergic reactions to veliparib, carboplatin, or Cremophor-paclitaxel. Uncontrolled intercurrent illness, including, but not limited to, any of the following: Ongoing or active infection; Symptomatic congestive heart failure; Unstable angina pectoris; Cardiac arrhythmia. Psychiatric illness or social situations that would preclude compliance with study requirements. Peripheral neuropathy > grade 1. Inability to take oral medications on a continuous basis. Active seizure or history of seizure disorder. Evidence of bleeding diathesis. Received > 3 prior chemotherapy regimens for advanced stage disease for patients enrolled in stratum I (there is no upper limit on the number of prior regimens for patients enrolled in stratum II) (added 04/07/09). Adjuvant chemotherapy administered ≥ 2 years prior to enrollment to the study does not count as a prior chemotherapy regimen. Other concurrent investigational agents. Concurrent combination antiretroviral therapy for HIV-positive patients",during cycle 2,NA
29352572,NCT01063816,Combination,No,advanced ovarian cancer and other solid malignancies,"Histologically or cytologically confirmed solid tumors that are metastatic or unrespectable for which carboplatin/gemcitabine is a treatment option. Eastern Cooperative Group performance score of 0 to 2. Adequate hematologic, hepatic and renal function. Subject has received up to 2 DNA damaging or cytotoxic regimens in the past five years","Subject has received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy within 28 days prior to study administration. Subjects with known history of brain metastases and primary CNS tumors. Hypersensitivity reactions to platinum compounds or gemcitabine. Clinically significant and uncontrolled major medical conditions. Active malignancy within the past 5 years except for any cancer in situ cured or non-melanoma carcinoma of the skin.",during the second 21-day cycle of treatment,NA
32146550,NCT02312661,Combination,No,advanced epithelial ovarian cancer,"Patients with advanced stage (FIGO III-IV), histologically confirmed and documented epithelial ovarian carcinoma. Patients eligible for neo-adjuvant carboplatin/paclitaxel chemotherapy prior to surgical debulking OR patients with relapsed or progressive ovarian cancer after initial treatment eligible for palliative carboplatin/paclitaxel chemotherapy. Eastern Cooperative Oncology Group-performance status (ECOG-PS) of 0-2. Age ≥ 18 years. Laboratory Requirements - within 7 days prior to enrolment: absolute neutrophil count (ANC) ≥1.5 x 109/L; platelets > 100 x 109/L; hemoglobin >9g/dl. Patients may be transfused or use erythropoietin to maintain hemoglobin values ≥ 9 g/dl.. hepatic function: bilirubin ≤1.5×upper limit of normal (ULN), aspartate aminotransferase (AST)/ALT≤2.5×ULN. estimated creatinine clearance ≥ 60ml/min. Before patient registration/randomization, written informed consent for the trial must be given according to International Conference on Harmonisation (ICH)/ good clinical practice (GCP), and national/local regulations.","Current or recent (within 30 days of first study dosing) treatment with another investigational drug or participation in another investigational study. Metformin within 4 weeks prior to enrolment. Symptomatic central nervous system (CNS) metastasis. Pre-existing peripheral neuropathy ≥ Common toxicity criteria (CTC) grade 2. Pregnant or lactating females. Serum pregnancy test to be assessed within 7 days prior to study treatment start, or within 14 days with a confirmatory urine pregnancy test within 7 days prior to study treatment start. Women of childbearing potential (defined as <2 years after last menstruation and not surgically sterile) not using effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly) during the study and for 6 months after the last study medication. Known hypersensitivity to any of the study drugs or excipients. Serious active infection requiring i.v. antibiotics at enrolment. Unstable medical conditions. Evidence of any other medical conditions, physical examination or laboratory findings that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications.",until the end of cycle 2,NA
28413662,UMIN000007600,Combination,No,human epidermal growth factor receptor 2-overexpressing breast cancer,"In general, non-treated female patients with primary breast cancer who satisfied the following inclusion criteria were selected for enrollment in the study: i) Histologically confirmed invasive ductal carcinoma, regardless of the hormonal status, ii) stage IIIB or IIIC disease, iii) patient age 20-70 years, iv) patients with at least one measurable lesion, v) cancer tissue specimens were evaluated for HER2 overexpression by immunohistochemistry (IHC; Hercep Test©; Dako, Carpinteria, CA, USA) with an IHC score of 3+ or demonstrated fluorescence in situ hybridization (FISH) positive (>2.2) for HER2 gene amplification, and patients with tumors testing 2+ by IHC were required to have a positive FISH test, vi) patients with a normal left ventricular ejection fraction (≥55% measured by echocardiography or multiple‑gated acquisition scan), vii) no abnormal findings on electrocardiography, viii) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1, ix) absence of severe dysfunction of major organs (white blood cell count ≥3,000/mm3; neutrophil count ≥2,000/mm3; platelet count ≥100,000/mm3; hemoglobin level ≥9.0 g/dl; aspartate aminotransferase ≤100 IU/l; alanine aminotransferase ≤100 IU/l; total bilirubin ≤1.5 mg/dl; serum creatinine ≤1.5 mg/dl; serum albumin ≥3.0 mg/dl), and x) all patients provided written informed consent","The exclusion criteria included the following: i) History of severe drug hypersensitivity, ii) inflammatory breast cancer (T4d), iii) active double cancer, iv) infection, diarrhea, ileus, poorly controlled diabetes and severe complications, v) uncontrollable pleural effusion or ascites, vi) peripheral neuropathy, vii) gastrointestinal ulcer or bleeding, viii) severe psychiatric disorder, ix) pregnancy or the possibility of pregnancy, x) hepatitis B surface antigen positivity or patients who required nucleoside analogue treatment, or xi) any other reason for which the investigator deemed the patient to be unsuitable for inclusion in this study",during the first cycle,NA
28595616,NCT01256268,Combination,No,solid tumor cancers,"Must have measurable disease or evaluable disease. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must be a minimum size of 10 mm by CT scan (CT scan slice thickness no greater than 5 mm), 10 mm caliper measurement by clinical exam or 20 mm by chest X-ray. Lymph node must be ≥ 15 mm in short axis when assessed by CT scan. Evaluable disease is disease evident on imaging that does not meet Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1, however, meets tumor marker evaluation, e.g., Gynecologic Cancer Intergroup (GCIG) criteria. Notes: i) If the patient's only disease is confined to a solitary lesion, its neoplastic nature must be confirmed by histology or cytology unless it is accompanied by GCIG criteria or can be clearly be shown as new disease when compared to prior imaging. ii) Disease in a previously irradiated field is acceptable as the only site of measurable disease only if there has been clear progression since completion of radiotherapy. Age > 18 years and competent to give informed consent. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 and a life expectancy of at least 60 days. Patients must have adequate: Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1,500/ul, equivalent to Common Toxicity Criteria (CTCAE v4.0) grade 1. Platelets greater than or equal to 100,000/ul.; Renal function: creatinine less than or equal to 1.5 x institutional upper limit normal (ULN), CTCAE v4.0 grade 1.; Hepatic function: Bilirubin less than or equal to 1.5 x ULN (CTCAE v4.0 grade 1). serum glutamic oxaloacetic transaminase (SGOT) and alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v4.0 grade 1).; Neurologic function: Neuropathy (sensory and motor) less than or equal to CTCAE v4.0 grade 1.; No chemotherapy, radiotherapy, biologic, hormonal, or investigational drug therapy within 28 days prior to start of treatment on study. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to the study entry and be practicing an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized. Prior to study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an intentional pregnancy. Phase 1A - Additional criteria applicable to phase 1A. Must have pathologically confirmed solid cancer that is locally advanced or metastatic cancer. Patient's physician believes that the cancer is advanced, recurrent or metastatic and not curable by local measures (i.e., surgery, radiation, other drugs). Patient's physician believes the patient may potentially benefit from this combination of therapy. Patients may have had up to three (3) prior cytotoxic chemotherapeutic regimens including prior treatment with carboplatin and paclitaxel. Chemotherapy drug changes and modifications made for reasons other than progression are not considered a separate regimen. Examples would be drug changes for toxicity or consolidation chemotherapy after adjuvant treatment. Patients may have received any number of prior non-cytotoxic regimens such as monoclonal antibodies, cytokines, signal transduction inhibitors, or hormonal therapy. Previous radiation therapy is allowed. Phase 1B - Endometrial: Additional Inclusion Criteria: Epithelial endometrial cancer. (i.e. carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma are excluded). May have had up to one prior chemotherapy for endometrial cancer. Prior taxane or platinum therapy is allowed as long as it was received either as adjuvant therapy or if there were a response to prior therapy and at least 6 months have elapsed since platinum treatment. Radiation sensitizing chemotherapy will not count as a prior regimen. Must have measurable disease. Phase 1B - Ovarian: Additional Inclusion Criteria: Recurrent epithelial ovarian cancer (no stromal or germ cell ovarian cancers); Platinum-sensitive defined as a recurrence at least 6 months (180 days) after the last day of primary adjuvant chemotherapy. Patients may have been retreated with a salvage line of chemotherapy but there must be a platinum-free interval of 6 or more months. Two (2) or less prior therapies including adjuvant chemotherapy; Measurable or evaluable disease","An upper gastrointestinal or other condition that would impair swallowing or absorption of oral medication. Any serious illness or medical condition that would not permit the patient to be managed according to the protocol, including, but not limited to, any the following: History of significant neurologic or psychiatric disorder (e.g., uncontrolled psychiatric disorders) that would impair the ability to obtain consent or limit compliance with study requirement. Active uncontrolled or serious infection. Active peptic ulcer disease. Patients who have the following cardiac conditions: Uncontrolled angina or myocardial infarction with the past six months; Diagnosed or suspected congenital long QT syndrome; Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes); Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec) on both the Fridericia and Bazett's correction. Uncontrolled hypertension defined as systolic greater than 180 and diastolic greater than 100. History of other invasive malignancies in the last 3 years, with the exception of non-melanoma skin cancer, unless they have had no evidence of recurrence from that cancer for last two years. Serum creatinine >1.5 times the institutional upper limits of normal. Patients taking certain concomitant medications (see below). Patients can enroll on protocol if they stop these medications and a wash-out period of ≥14 days, unless otherwise noted, is done prior to starting ridaforolimus. There must be at least 14 days since prior (and no current expectations to receive) CYP3A4 inhibitors including, but not limited to, any of the following: Azole antifungals ( i.e., ketoconazole, itraconazole, miconazole, fluconazole); HIV protease inhibitors (i.e., indinavir, saquinavir, ritonavir, atazanavir, nelfinavir); Clarithromycin; Verapamil; Erythromycin; Delavirdine; Diltiazem; Nefazodone; Telithromycin. There must be at least 14 days since prior (and no current expectations to receive) CYP3A4 inducers including, but not limited to, any of the following: Rifampin, Phenytoin, Rifabutin, St.John's wort, Carbamazepine, Efavirenz, Phenobarbital, Tipranavir. Full dose anticoagulation with warfarin (coumadin) or other vitamin K dependent anticoagulant. Low-dose prophylactic warfarin (i.e. 1mg per day port prophylaxis) is allowable. Low molecular heparin (e.g., danaparoid, dalteparin, tinzaparin, enoxaparin) is allowable if patient has been established on therapy. Have received an estimated dose of radiation therapy to >35% of the bone marrow. Patients previously exposed to mTOR inhibitors are permitted in phase 1A but not allowed in phase 1B. History of grade 3 hypersensitivity to paclitaxel. However, if after prior hypersensitivity the patient was subsequently successfully rechallenged without incident, the patient may be eligible at investigator's discretion. Known hypersensitivity to the study drug ridaforolimus or its components. Ridaforolimus should be administered with caution to patients known to be hypersensitive to macrolide antibiotics, Tween80 (polysorbate 80), or any other excipient in the product formulation. Significant lipid abnormalities: Serum cholesterol > 350mg/dL; Triglycerides > 400mg/dL",during the first cycle of treatment,NA
33147935,NCT03212937,Combination,No,relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma ,"Patients must have histologically confirmed T or NK/T-cell lymphomas including the following histologies: Peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS); Angioimmunoblastic T-cell lymphomas (AITL); Anaplastic large cell lymphoma (ALCL); Natural-killer/T-cell lymphoma (NKTL). Patients must have received at least two cycles of one prior regimen administered with curative intent and one of the following: failed to have achieve at least a partial response after 2 or more cycles; failed to achieve a complete response after 6 or more cycles; progressed after an initial response; For patients who have CD30+ anaplastic large cell lymphoma, they must have failed or are ineligible or intolerant of brentuximab vedotin. Patients must be age >18 years. Patients must have at least one site of measurable disease, 1.5 cm in diameter or greater. Patients must have ECOG performance status of 0-2. Patients must have laboratory test results within these ranges: Absolute neutrophil count ≥1500/mm³; Platelet count ≥75,000/mm³; Creatinine clearance ≥40ml/min; Total bilirubin ≤1.5x ULN. Higher levels are acceptable if these can be attributed to active haemolysis or ineffective erythropoiesis. AST (SGOT) and ALT (SGPT) ≤2x ULN. Women of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test prior to KPT-330 treatment. Male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. For both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose. As the effects of selinexor on the developing human fetus at the recommended therapeutic dose are unknown, women of childbearing potential should be advised to avoid becoming pregnant and men should be advised to not father a child while receiving treatment with selinexor. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Women that are pregnant or breastfeeding are excluded from the study because the risks to an unborn fetus or potential risks in nursing infants are unknown. Patients must be able to understand and willing to sign a written informed consent document. Patients must be able to adhere to the study visit schedule and other protocol requirements. Patients must not have any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. Patients must not have any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.","Patients who have had prior malignancies (other than T and NK/T-cell lymphomas) for ≤5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma ""in situ"" of the cervix or breast. Patients who have had other anti-cancer therapy, including radiation or experimental drug or therapy, within 28 days of enrollment. Patients with known HIV, active hepatitis B, active hepatitis C. Patients with known central nervous system involvement by lymphoma. Patients with known or suspected hypersensitivity to selinexor.",during the first cycle of treatment,NA
32452601,NCT01251874,Combination,No,Metastatic Breast Cancer,"Patients eligible for the trial were adult women with metastatic or locally advanced inoperable breast cancer that fulfilled one of the three criteria: (a) negative for estrogen, progesterone, and HER2 receptors (based on American Society of Clinical Oncology/College of American Pathologists guidelines); (b) HR-positive (defined as ER and/or progesterone receptor positive), HER2-negative breast cancer that is deficient for the FA pathway based on the FATSI test (i.e., no FANCD2 foci in nuclei of 100 proliferating tumor cells); or (c) HER2-negative breast cancer with known germline BRCA1/2 mutation. HR-positive/HER2-negative patients without known germline BRCA 1 or 2 mutation initially signed a screening consent for testing their archival tumors for FATSI and only proceeded with the therapeutic portion of the study if testing showed deficiency in FA pathway. Other eligibility criteria requirements included no more than three prior chemotherapy regimens for metastatic disease, at least 4 weeks from prior chemotherapy or radiation therapy, an Eastern Cooperative Oncology Group performance status of 0–2, and adequate bone marrow, renal, and hepatic function. Patients with treated central nervous system (CNS) metastasis were eligible. Prior platinum exposure was allowed.","Exclusion criteria included prior therapy with veliparib or other PARP inhibitors for metastatic disease, uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness/social situations that would limit compliance with study requirements, known human immunodeficiency virus infection, seizures, and uncontrolled CNS metastasis.",in the first cycle,NA
32568634,NCT02157792,Combination,Yes,Advanced Solid Tumors,"Male and female patients aged ≥18 years • Disease status Parts A1, A2, and B1: Patients with histologically or cytologically confirmed malignant advanced solid tumors refractory to standard therapy or for which no suitable effective standard therapy exists o Parts A1 and A2: Patients will preferentially have mutations known to be involved in the DDR, (eg, ATM or TP53 genes) identified by sequencing of tumor tissue derived DNA, using a platform such as the Illumina MiSeq o Part B1: In the MTD expansion cohort, ≥6 patients must have disease sites amenable for paired biopsies • Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 • ECOG performance status of 0 or 1 • Life expectancy of ≥12 weeks • Hematologic and biochemical indices within the ranges shown below at screening. These values must be confirmed at the first day of dosing, before study drug administration o Hemoglobin: ≥9.0g/dL o Absolute neutrophil count: ≥2.0×109/L o Platelet count: ≥150×109/L o Serum bilirubin: ≤1.5×ULN, unless the patient has known or suspected Gilbert syndrome o ALT and AST: ≤2.5×ULN or ≤5×ULN in presence of liver metastases o Estimated glomerular filtration rate: ≥50mL/min o Prothrombin time: <1.5×ULN o In addition, the patient should not have other clinically significant metabolic or hematologic abnormalities that are uncorrectable or that require ongoing, recurrent pharmacological management • Signed and dated informed consent document • Willingness and ability to comply with scheduled visits, treatment plan, lifestyle, laboratory tests, contraceptive guidelines, and other study procedures","Radiotherapy unless brief course for palliative therapy, endocrine therapy (except for ongoing luteinizing hormone–releasing hormone–agonist therapy for patients with prostate cancer that has progressed), immunotherapy, or chemotherapy during the 4 weeks (6 weeks for nitrosoureas and mitomycin C and 4 weeks for investigational medicinal products) or 4 drug half-lives before the first dose of study drug, whichever is longer • Ongoing toxic manifestations of previous treatments including any known history of grade 4 thrombocytopenia with any prior chemotherapy regimen, unless approved by the Vertex medical monitor. Exceptions to this are alopecia or certain grade 1 toxicities, which in the opinion of the investigator should not exclude the patient • Spinal cord compression or brain metastases unless asymptomatic, treated, stable, and not requiring steroids for ≥4 weeks before first dose of study drug. Any history of leptomeningeal metastases • Female patients who are already pregnant or lactating or plan to become pregnant within 6 months of the last dose of study drug are excluded. Female patients of childbearing potential must adhere to contraception guidelines as outlined in study protocol section 11.6.5.1. Female patients will be considered to be of nonchildbearing potential if they have undergone surgical hysterectomy or bilateral oophorectomy or have been amenorrheic for over 2 years with a screening serum follicle-stimulating hormone level within the laboratory’s reference range for postmenopausal women • Male patients with partners of childbearing potential must agree to adhere to contraception guidelines in study protocol section 11.6.5.1. Men with pregnant or lactating partners or partners who plan to become pregnant during the study or within 6 months of the last dose of study drug are excluded • Major surgery ≤4 weeks before the first dose of study drug or incomplete recovery from a prior major surgical procedure • Cardiac conditions as follows: o Clinically significant cardiovascular event within 6 months before study entry: Congestive heart failure requiring therapy; Unstable angina pectoris; Myocardial infarction;  Class II/III/IV cardiac disease (New York Heart Association); Presence of severe valvular heart disease; Presence of ventricular arrhythmia requiring treatment o History of arrhythmia that is symptomatic or requires treatment (CTCAE3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Patients with atrial fibrillation controlled by medication are permitted o Uncontrolled hypertension (blood pressure ≥160/100 despite optimal therapy) o Second- or third-degree heart block with or without symptoms o QTc >470ms (by either Fridericia or Bazett correction) not due to electrolyte abnormality and that does not resolve with correction of electrolytes o History of congenital long QT syndrome o History of torsades de pointes (or any concurrent medication with a known risk of inducing torsades de pointes) o Clinically significant abnormality, including ejection fraction below normal institutional limits or presence on transthoracic echocardiogram performed at screening for parts A1, A2, and B1. • Prior bone marrow transplant or extensive radiotherapy to >15% of bone marrow • Participation or plan of participation in another interventional clinical study while taking part in this phase I study of M6620. Participation in an observational study would be acceptable • Any other condition which in the investigator’s opinion would not make the patient a good candidate for the clinical study, including: o History of HIV-1, HIV-2, hepatitis C virus, or unresolved hepatitis B infection o High medical risk because of nonmalignant systemic disease, including active uncontrolled infection o History of serious allergy or autoimmune disease o Patients who have been diagnosed with Li-Fraumeni syndrome or ataxia telangiectasia • Current therapy o Patients receiving treatment with medications that are known to be strong inhibitors or inducers of cytochrome P450 3A that cannot be discontinued ≥1 week before first dose of study drug and for the duration of the study o For part B1: patients receiving treatment with ototoxic or nephrotoxic medications that cannot be discontinued ≥7 days before the first dose of study drug and through the safety follow-up visit. Inadvertent or shortterm use on study will not cause a patient to be ineligible. If a short course of therapy with nephrotoxic or ototoxic medication is anticipated and required, carboplatin should be discontinued until 7 days after this course is completed",NA,NA
33373402,NCT01644955,Single Drug,Yes,recurrent high-grade gliomas,"Patients must have progressive disease for which craniotomy and tumor resection is recommended as treatment. Patients must sign a consent form indicating that they are aware of the investigational nature of the study; the informed consent form will indicate that the patient has been made aware of all other appropriate therapies. Patients with histologically confirmed grade III or IV astrocytoma, oligoastrocytoma, and oligodendroglioma who are at first or second recurrence. Patients require an initial diagnosis of a malignant glioma as outlined in the inclusion criteria which must be confirmed at the treating facility. Patients must have unequivocal evidence of tumor progression by magnetic resonance imaging (MRI) performed no longer than 28 days prior to study registration. Patients must have pathologically confirmed recurrence at the time of catheter placement. Patients must be on a stable or decreasing dexamethasone dosage for at least 1 week prior to baseline MRI. Patients must have been treated previously with radiation therapy and treatment must have been completed at least 8 weeks prior to surgery for catheter implantation. Last dose of cytotoxic chemotherapy must have been at least 4 weeks (6 weeks for nitrosoureas) prior to catheter placement; patients are eligible if they received bevacizumab or other anti-vascular endothelial growth factor (VEGF) therapies, although the most recent dose must be at least 6 weeks prior to catheter placement. Patients previously treated with stereotactic radiosurgery, stereotactic radiotherapy, brachytherapy, Gliadel wafers or other intratumoral chemotherapy are eligible. Patients must have recovered from all prior therapy. Patients must have a life expectancy of >= 3 months and a Karnofsky performance status >= 60 Leukocytes >= 3,000/mcL Absolute neutrophil count >= 1,500/mcL Platelets >= 100,000/mcL Hemoglobin >= 9 g/dL Serum calcium =< 12.0 mg/dL Total serum bilirubin < institutional upper limit of normal (ULN) Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional ULN Creatinine < 1.5 X institutional ULN. Women of child bearing years must have a negative pregnancy test (serum or urine) within 1 week of study entry; men and women of reproductive potential must agree to use an effective contraceptive method including one of the following: surgical sterilization (tubal ligation for women or vasectomy for men); approved hormonal contraceptives (such as birth control pills, Depo-Provera or Lupron Depro); barrier methods (such as condom or diaphragm) used with a spermicide cream or an intrauterine device (IUD). Patient or designated individuals with durable medical power of attorney must give written informed consent prior to any study-specific procedures being implemented. Both men and women and members of all races and ethnic groups are eligible for this trial","Patients with infratentorial, multifocal, or pathologically confirmed cerebrospinal fluid (CSF) disseminated tumor. Patients that have been treated with > 3 prior chemotherapy regimens. Pregnant or lactating women or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception. Patients who have a history of bleeding disorders including congenital or acquired coagulopathies. Known acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition or other acquired or congenital disorder of the immune system. Patients with unstable or serious concurrent illness including, but not limited to, ongoing or active infections requiring IV antibiotics or psychiatric illness/social situations that would limit compliance with study requirements are ineligible; (if patient has a stable chronic infection requiring oral antibiotics, the patient may be treated at the investigators discretion; however a clinical note must include the justification regarding the safety of treating the patient). Patients who have received any other investigational agent in a 28-day period prior to enrollment in this study. Patients whose tumors are located less than 2 cm from the ventricles. Patients taking greater than 12 mg daily of dexamethasone. Prior invasive malignancy that is not low-grade glioma, glioblastoma or gliosarcoma (except non-melanomatous skin cancer or carcinoma in situ of the cervix) unless the patient has been disease free and off therapy for that disease for a minimum of 3 years",at least 28 days,NA
31080557,NCT01445418,Combination,No,heavily pretreated recurrent high-grade serous ovarian cancer ,"Patients must have breast and/or epithelial ovarian cancer, primary peritoneal cancer, and/or fallopian tube cancer histologically or cytologically confirmed at the NCI that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective. All patients in cohort 1 must have measurable and/or evaluable disease. Patients in the expansion cohort 2 must have safely biopsible disease as determine by an interventional radiologist and must agree to the first mandatory biopsy (the other two biopsies optional). Breast cancer patients with locally advanced, unresectable disease must have been previously treated with standard therapy. There is no limit on number of prior therapy. Patients must be at least 6 months from their last platinum exposure. Platinum-resistant patients may participate. Patients with allergic reaction to platinums (up to and including grade 3 without a reaction protocol, and up to and including grade 2 in the face of pretrement, but not graduated treatment exposure) are still eligible. Age greater than or equal to 18 years. ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60%). Life expectancy greater than 3 months. Patients must have normal organ and marrow function as defined below: hemoglobin greater than or equal to 10g/dL, leukocytesgreater than or equal to 3,000/mcL, absolute neutrophil count greater than or equal to 1,500/mcL, platelets greater than or equal to 100,000/mcL, total bilirubin less than or equal to upper limit of normal (ULN) in the absence of Gilbert s syndrome, AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X ULN, creatinine clearance greater than or equal to 60 mL/min by 24-hour urine OR serum creatinine less than or equal to 1.5 mg/dl, corrected or Ionized Calcium less than or equal to ULN, potassium within normal limits. A documented deleterious BRCA 1/2 germline mutation or BRCAPRO score of greater than or equal to 30% for patients enrolling in Group A. For patients enrolling in the sporadic serous epithelial ovarian cancer group, Group B, a negative family history (BRCAPRO score less than or equal to 20% or negative BRCA1/2 mutation test). For patients enrolling in the triple negative breast cancer (ER-/PR- /Her2-) group, Group B, a negative family history and /or BRCAPRO score less than or equal to 10% or negative BRCA1/2 mutation test). The effects of AZD on the developing human fetus are unknown. For this reason and because platinum agents are known to be teratogenic, men and women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately, Patients of child-bearing potential should continue on contraception for at least three months following the last dose of therapy on study. Toxicities from previous cancer therapies must have recovered to grade 1 (defined by CTC 3.0). Chronic stable grade 2 peripheral neuropathy secondary to neurotoxicity from prior therapies may be considered on a case by case basis by the Principal Investigator. No patients with functional impairment due to neuropathy will be eligible for the study. Hypomagnesemia will not be considered an exclusion criteria. Magnesium levels will be monitored and replaced as clinically indicated. Ability to understand and the willingness to sign a written informed consent document. Female patients with reproductive potential must have a negative urine or serum pregnancy test within 4 days prior to the start of the study.","Patients who have had chemotherapy, biological therapy, hormonal therapy (with the exception of raloxifene or others approved for bone health) or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Patients may not be receiving any other investigational agents or had them in the previous 28 days. Patients with known brain metastases diagnosed within 1 year should be excluded from this clinical trail because of their poor prognosis and because they often develop progressive neurological dysfunction that would confound the evaluation of neurologic and other adverse events. ---Patients with brain metastases diagnosed greater than 1 year prior to study entry are eligible if they received sterilizing therapy to the CNS (resection or radiation) and have been CNS recurrence-free for a full 1-year period. Clinically significant bleeding. Inability to swallow pills. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Pregnant and breast-feeding women. HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AZD2281. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy such as carboplatin. Previous treatment with PARP inhibitor. Major surgery within the past 28 days. Patients with locally advanced breast tumors presenting for their initial therapy, or patients with local (only in breast or chest wall) recurrence only will not be eligible for this trial. For subjects in the dose-expansion cohorts, history of prior invasive malignancies within the past 5 years (with the exception of non-melanomatous skin cancers, non-invasive bladder cancer, stage I endometrial cancer or cervical cancer cured by surgical resection). Patients with a history of grade 4 allergic reaction to platinums",during the first two cycles of therapy,NA
32559454,UMIN000011216,Combination,No,squamous-cell lung cancer,"Patients were considered eligible if they were aged 75 years or older and had histologically or cytologically confirmed advanced SqCLC and an ECOG PS of 0 or 1. All the patients had stage III or IV or postoperative recurrent disease without pretreatment. Other eligibility criteria included: (1) at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; (2) adequate organ functions (i.e., total bilirubin ≤1.5 mg/dL, AST and ALT ≤ 100 U/L, serum creatinine ≤1.5 mg/dL, leukocyte count 3000–12,000/mm3, neutrophil count ≥1500/mm3, hemoglobin ≥9.0g/dL, platelet count ≥100,000/mm3, and PaO2 on room air ≥70 mmHg or SpO2 on room air ≥95%); (3) no grade 2 (Common Terminology Criteria for Adverse Events version 4.0) or higher peripheral neuropathy; (4) no interstitial pneumonia or pulmonary fibrosis, as determined by chest X-ray; (5 no symptomatic brain metastases; (6) no pleural effusion, ascites, or pericardial effusion requiring drainage or other treatment (patients with pleural effusions controlled with picibanil, minocycline, or other drugs were allowed); (7) no active infection; (8) no multiple active cancers; (9) no unwillingness to avoid pregnancy; and (10) a life expectancy ≥12 weeks after the start of treatment.",NA,during cycle 1,NA
30563934,NCT01653912,Combination,No,Recurrent Platinum-resistant Ovarian Cancer,"Female, 18 years of age as of signing the informed consent form, capable of giving/complying with written informed consent. Histologically or cytologically confirmed serous ovarian cancer (includes primary peritoneal and Fallopian tube). Negative serum pregnancy test in women of childbearing potential within 14 days of first dose of treatment, agree to use effective contraception during/after (6 months post dose of paclitaxel or 30 days post dose GSK2110183 whichever is longer). Performance Status score of 0-2 according to the ECOG scale. Able to swallow and retain oral medication. Subjects diagnosed previously with Type 2 diabetes must have been diagnosed ≥ 6 months prior to enrollment. Prior treatment-related toxicities (except for alopecia) must be ≤ Grade 1 according to NCI-CTCAE (Version 4.0 [NCI, 2009]) at the time of treatment allocation OR ≤ Grade 2 and stable for 4 weeks or longer at the time of screening evaluation. Exception: Subjects with peripheral neuropathy >/= Grade 2 will NOT be eligible Adequate organ system function","History of another malignancy (some exceptions may apply). Serious and/or unstable pre-existing medical or psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures. Current use of prohibited medication during treatment.Chemotherapy, immunotherapy, or other anti-cancer therapy within 14 days prior to the first dose study drug. Radiotherapy prior to initiation of therapy (some exceptions may apply). Contraindications (identified by the investigator) to the doses of carboplatin and/or paclitaxel. History of reduction in standard of care paclitaxel dose for peripheral neuropathy. No known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs similar or related to GSK2110183. No known delayed hypersensitivity reaction or idiosyncratic reaction to drugs similar to carboplatin or paclitaxel (some exceptions may apply). Prior use of a drug that targets AKT including perifosine. History of Type 1 diabetes. Gastrointestinal disease or other condition that could affect absorption or predispose subject to gastrointestinal ulceration. Mucosal or internal bleeding. Major surgery within the last four weeks. Infection requiring parenteral or oral anti-infective treatment. Severe or uncontrolled systemic diseases. Brain metastases and/or leptomeningeal disease. QTcF interval ≥ 470 msecs. Bundle branch block, pacemaker or clinically significant ECG abnormalities including 2nd degree (Type II) or 3rd degree atrioventricular (AV) block. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty,stenting or bypass grafting within six months of Screening. Class II, III or IV heart failure as defined by the NYHA functional classification system. Pregnant or lactating female. Malignancies related to HIV or solid organ transplant; history of known HIV, history of know HBV surface antigen positivity (subjects with documented laboratory evidence of HBV clearance may be enrolled) or positive HCV antibody",within first 3 weeks of therapy,NA
29781056,NCT01862328,Combination,No,advanced solid tumors,"18 years of age or older. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. Have a histologically or cytologically confirmed metastatic or locally advanced and incurable solid tumor that is felt to be appropriate for treatment with 1 of the 3 chemotherapy regimens in this study, or have progressed despite standard therapy, or for whom conventional therapy is not considered effective. The tumor must be radiographically or clinically evaluable and/or measurable. Recovered (that is, <=Grade 1 toxicity) from the effects of prior antineoplastic therapy. Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to practice true abstinence. Male participants who agree to practice effective barrier contraception or agree to practice true abstinence. Voluntary written consent must be given before performance of any study-related procedure. Suitable venous access for the study-required blood sampling. Adequate clinical laboratory values during the screening period as specified in the protocol. Participants who are willing to refrain from donating blood for at least 90 days after their final dose of MLN4924 and (for male participants) willing to refrain from donating semen for at least 4 months after their final dose of MLN4924. Availability of fixed tumor specimen (block or slides) for exploratory biomarker analysis. If no slides or block are available, fresh tumor biopsies should be obtained and used for these assessments","Major surgery within 14 days before the first dose of study drug. Female participants who are lactating or pregnant. Active uncontrolled infection or severe infectious disease. Receiving antibiotic therapy within 14 days before the first dose of study treatment. Life-threatening illness unrelated to cancer. Known hypersensitivity to study-assigned chemotherapy. Prior treatment with MLN4924; however, prior treatment with docetaxel, paclitaxel,carboplatin, and gemcitabine is allowed. History of severe hypersensitivity reactions to docetaxel (polysorbate 80-based formulations) for participants to be enrolled in Arm 1 (MLN4924 + docetaxel), history of hypersensitivity to carboplatin for participants to be enrolled in Arm 2 (MLN4924 + paclitaxel + carboplatin), or history of severe hypersensitivity to paclitaxel (cremophor-based formulations) for participants to be enrolled in Arm 2. Persistent diarrhea (greater than Grade 2) lasting >3 days within 2 weeks before the first dose of study treatment. Systemic antineoplastic therapy within 21 days before the first dose of study drug. Radiotherapy within 14 days preceding the first dose of study treatment. Prior treatment with radiation therapy involving greater than or equal to (>=) 25% of the hematopoietically active bone marrow. Treatment with cytochrome P450 3A (CYP3A) inducers within 14 days before the first dose of MLN4924.",cycle 1,NA
30089585,NCT01573338,Combination,No,extensive-disease smallcell lung cancer,"Male or female subjects aged >/=18 years. Histologically or cytologically confirmed, extensive disease SCLC. At least 1 solid tumor lesion measurable by computer tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST 1.1. Subjects with non-measurable disease according to RECIST 1.1 can be included in the Phase Ib part of the study. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1. Life expectancy of at least 12 weeks. Serum sodium >/=130 mmol/L","Exclusion criteria included: any prior systemic anticancer therapy or radiotherapy, or anticoagulation therapy; hepatic impairment of ChildPugh class B or C; a history of cardiac disease or organ allograft; human immunodeficiency virus infection or chronic hepatitis B or C virus; symptomatic metastatic brain or meningeal tumors; or previous or coexisting cancer distinct in primary site or histology from the cancer evaluated in this study (excluding cervical cancer in situ, treated basal cell carcinoma, superficial bladder tumors, or any cancer curatively treated more than 3 years before study entry).",during cycle 1,NA
28792260,NCT01169636,Combination,No,relapsed or refractory classical Hodgkin lymphoma,"Histologically confirmed classical Hodgkin lymphoma (nodular sclerosis, mixed cellularity, or lymphocyte-rich classical HL). Patients must have failed (relapsed or refractory) front-line standard anthracycline-containing regimen, such as ABVD, Stanford V, or BEACOPP.Bidimensionally measurable disease with at least 1 lesion >/= 2.0 cm in a single dimension. Acceptable hematologic status:Hemoglobin >/= 9.0 g/dL, Absolute neutrophil count >/= 1500 cells/mm3, Platelet count >/= 100,000 cells/mm3. Normal serum K+, Mg+, PO4, and total Ca++ (pre-treatment abnormal values may be therapeutically corrected before starting therapy and must be documented as normal or if abnormal values persist must be documented as clinically insignificant). Albumin should be >/= 3. Pre-study World Health Organization (WHO) performance status of 0, 1, or 2. Age >/= 16 years. Voluntary signed Institutional Review Board (IRB) approved consent informed before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. Patients of reproductive potential (female of child bearing potential has not been postmenopausal for at least 12 consecutive months or not surgically sterile; male of child bearing potential has not been surgically sterile)must follow accepted birth control methods (e.g. barrier method) during treatment. Clinically euthyroid. Note: Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism. Baseline Multiple Gated Acquisition (MUGA) or ECHO must demonstrate left ventricular ejection fraction (LVEF) >/= 50%.","Lymphocyte predominant histology. More than one prior chemotherapy regimens. Prior therapy with other HDAC inhibitors, including valproic acid. Prior therapy with heat shock protein (HSP)-90 inhibitors. Prior stem cell transplant. Abnormal liver function: Bilirubin > 2.0 mg/dL (26 µmol/L), Alkaline phosphatase > 2 x upper limits of normal (ULN), aspartate aminotransferase AST (SGOT) and/or alanine aminotransferase ALT > 2 x ULN. Serum creatinine >1.5 mg/dl. Presence of Central Nervous System (CNS) involvement with Hodgkin lymphoma. Presence of Human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS). Another primary malignancy (other than squamous cell and basal cell carcinoma of the skin, in situ carcinoma of the cervix, or treated prostate cancer with a stable Prostate Specific Antigen PSA) for which the patient has not been disease free for at least 3 years. Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions which would compromise protocol objectives in the opinion of the investigator. Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:History or presence of sustained ventricular tachyarrhythmia, Any history of ventricular fibrillation or torsade de pointes, Bradycardia defined as HR< 50 bpm, Patients with pacemakers are eligible if HR >/= 50 bpm, Screening ECG with a corrected QT interval (QTc) > 450 msec, Right bundle branch block + left anterior hemiblock (bifascicular block), Patients with myocardial infarction or unstable angina </= 6 months prior to starting study drug, Other clinically significant heart disease (e.g., congestive heart failure (CHF) New York Heart Association class III or IV , uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen). Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum Beta-human chorionic gonadotropin (Beta-hCG) pregnancy test result obtained during screening, unless the female has recently (within 8 weeks) undergone egg harvest, which would result in the (Beta-hCG) test to be elevated without pregnancy. Pregnancy testing is not required for post-menopausal or surgically sterilized women. Patient has received other investigational drugs within 14 days before enrollment or who have not recovered from side effects of those therapies. Serious medical or psychiatric illness likely to interfere with participation in this clinical study. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat. Patients with diarrhea > Common Terminology Criteria for Adverse Events Version 4 (CTCAE V.4) grade 2. Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug. Patients who have received either immunotherapy within </= 8 weeks; chemotherapy within </= 3 weeks; or radiation therapy to > 30% of marrow-bearing bone within </= 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies. Patients who have undergone major surgery </= 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy.","from first dose of panobinostat (or chemotherapy, in the arm of ICE alone) until 30 days after last dose",NA
30552156,NCT01844947,Combination,No,Post-Platinum Metastatic Urothelial Carcinoma,"signed informed consent; histologically confirmed transitional cell (pure or mixed histology including transitional cell carcinoma are allowed) carcinoma of the urothelial tract; patients who have received neoadjuvant or adjuvant platinum-containing chemotherapy and who are diagnosed with locoregional recurrent or metastatic disease prior to or at the 6-months"" visit , are eligible or patients who have received palliative platinum-containing chemotherapy and who are diagnosed with progression prior to or at the 6-months"" visit, are eligible or patients who have contraindication to platinum-containing chemotherapy; previous systemic chemotherapy must have been stopped 14 days before the inclusion with recovery (G1 or less) from any treatment related toxicity; measurable and/or non-measurable disease using RECIST and defined as: Measurable disease: lesions that can be measured in at least one dimension and which have not been previously irradiated. Longest diameter 20 mm with conventional techniques or 10 mm with spiral CT scan or MRI. Non-measurable disease: lesions which have not been previously irradiated, or longest diameter <20 mm with conventional techniques or <10 mm with spiral CT scan or MRI, or truly non measurable lesions including bone lesions, ascites, pleural/pericardial effusion, and lymphangitis cutis/pulmonitis; age 18 up to 80 years; ECOG / WHO Performance Status (PS) ≤1; haematological function: haemoglobin ≥100 g/L absolute neutrophil count 1.0 x LL (lower limit of normal value) platelets 100 x 109/L; hepatic function: bilirubin <1.5 x ULN*, transaminases <2.5 x ULN* *ULN = upper limit of normal value; renal function: creatinine clearance 40 ml/min (measured by either iohexol clearance or Cr-EDTA technique); Clinically normal cardiac function based on ejection fraction (LVEF assessed by MUGA or ECHO, LVEF ≥50%); able to swallow and retain oral medication; previous treatment related toxicity must be grade ≤1 at time of inclusion and no presence of asthenia, hand-foot skin reaction or rash grade >1 (NCI CTCAE v4.0) at enrolment; no known or suspected allergy to the investigational agent or any agents given in association with this trial;","non-transitional cell carcinoma of the urothelial tract (e.g. pure adenocarcinoma or squamous cell carcinoma); prior treatment with vinflunine; diagnosed brain metastases or leptomeningeal involvement. Brain CT-scans or MRI are not required unless there is clinical suspicion of central nervous system involvement. peripheral neuropathy G3 (NCI CTCAE v4.0); history of serious or concurrent illness or uncontrolled medical disorder; any medical condition that might be aggravated by treatment or which could not be controlled: active infection requiring antibiotics within 2 weeks before the study inclusion, unstable diabetes mellitus, uncontrolled hypercalcaemia >2.9 mmol/L (or >G2 NCI CTCAE v4.0), concurrent congestive heart failure NYHA (class III-IV) or any type of angina pectoris and/or a diagnosis of myocardial infarction during the previous 6 months and/or poorly controlled hypertension will be excluded, QTc >450 ms at baseline, additional risk factors for Torsade de Pointes (heart failure and hypokalemia (≥G1, i.e. P-K <LLN-2.5 mM) or family history of long QT-syndrome), cardiac arrhythmias requiring anti-arrhythmics (excluding beta-blockers or digoxin for chronic atrial fibrillation); patients having received more than one previous systemic chemotherapy for advanced or metastatic disease; patients who have received any other investigational or anti-cancer therapy 14 days before the inclusion; other malignancies, except adequately treated basal carcinoma of the skin or in-situ cervix carcinoma or incidental prostate cancer (T1a, Gleason score ≤6, PSA <0.5 ng/ml), or any other tumour with a disease free survival of ≥5 years; pregnant or lactating women; men or women of childbearing potential not employing adequate contraception; any psychological, familial, sociological, or geographical condition which does not permit protocol compliance and medical follow-up. poorly controlled hypertension. At baseline, blood pressure >150/90 is defined as poorly controlled. renal dysfunction: creatinine clearance <40 ml/min measured by either iohexol clearance or Cr-EDTA technique. ECOG / WHO Performance Status ≥2; presence of hand-foot skin reaction or rash >G1 at enrolment; known or suspected allergy to the investigational agent or any agents given in association with this trial;  current medical treatment with any compound that prolongs QTc",during cycle 1 and 2,NA
26403509,NCT01287520,Combination,No,advanced/metastatic solid tumor,"Have a performance status of less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) scale. Have a life expectancy of greater than or equal to 12 weeks. Males and females with reproductive potential agree to use medically approved contraceptive precautions during the trial and for 3 months following the last dose of study drug. Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic disease for which no proven effective therapy exists. Have the presence of measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST). Have adequate hematologic, hepatic, and renal function. Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy, or other investigational therapy for at least 30 days (6 weeks for mitomycin-C or nitrosoureas) prior to study enrollment and recovered from the acute effects of therapy.","Have received treatment within 30 days of the initial dose of study drug with a drug that has not received regulatory approval for any indication. Have serious preexisting medical conditions (left to discretion of investigator). Have one of the following conduction abnormalities: Corrected time between start of Q wave and end of T wave (QTc) prolongation >450 millisecond (msec) on screening electrocardiogram (ECG), previous history of QTc prolongation with another medication that required discontinuation, congenital long-QT-syndrome, or left bundle branch block (LBBB). Are taking any concomitant medication that may cause QTc prolongation, or induce Torsades de Pointes. Have systolic blood pressure greater than or equal to 140 millimeters of Mercury (mm Hg), and diastolic blood pressure greater than or equal to 90 mm Hg that is not controlled by medical therapy. Have serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class II or higher; have history of arrhythmia that is symptomatic or requires treatment. Have chronic atrial fibrillation and/or bradycardia. Have uncorrected electrolyte disorders including potassium <3.4 molar equivalent per liter (mEq/L) (<3.4 millimole per liter [mmol/l]), calcium <8.4 milligram per deciliter (mg/dL) (2.1 mmol/L), or magnesium <1.2 mg/dL (<0.62 mmol/L). Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required). Have a hematologic malignancy. Females who are pregnant or lactating",during Cycle 1 and 2 (cohorts 1–3) or Cycle 1 (cohort 4 and beyond),NA
22988282,NA,Combination,No,non-small-cell lung cancer,"The eligibility criteria for study entry were: cytological or histological confirmation of a previously untreated NSCLC evaluable lesion and no other severe internal diseases that required patient hospitalisation. Only patients with Stage III–IV (UICC, 1997) disease or a medically unresectable tumour of any stage, or those who had refused surgery for personal reasons, were included in the study. Stage IV patients were recruited because, for cultural and economic reasons, there are few patients in China who are willing to accept concurrent chemoradiotherapy and who can afford it. Some patients with relatively mild disease, who met the conditions for chemoradiotherapy for Stage IV disease, were also included to accelerate completion of the Phase I trial. The literature contains similar reports of Phase I trials of concurrent chemoradiotherapy in which patients with Stage IV disease were recruited [9, 10]. Additional inclusion criteria were: age ≥18 years and ≤75 years, Karnofsky performance status ≥70, and a life expectancy >3 months. The required laboratory findings were: 2.0 × 109 neutrophils/l; ≥100 × 109 platelets/l; ≥100 g haemoglobin/l; and serum creatinine, aspartate aminotransferase, alanine aminotransferase, and total serum bilirubin levels below the upper limits of normal.","Patients with any of the following conditions were excluded: Stage IIIb disease with effusion; multiple metastatic lesions in the brain or bones; interstitial pneumonia; superior vena cava syndrome; pregnancy or lactation; a history of other malignancies, with the exception of carcinoma in situ of the cervix, non-melanomatous skin cancer, and cancer from which the patient had been disease-free for 5 years; or a general medical condition that prevented combined modality therapy. Patients being treated with another concurrent antineoplastic therapy (such as cancer immunotherapy, targeted therapy, etc. during concurrent chemoradiotherapy rather than cytotoxic drug therapy) were also excluded.",during the first 90 days after the start of radiotherapy,NA
27323902, NCT02418624,Combination,Yes,BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer,"Patients are eligible for this study if they are ≥18 years old, have histological or cytological proven metastatic cancer, with a life expectancy ≥3 months, a World Health Organization (WHO) performance status of 0, 1, or 2, and a negative pregnancy test. Minimal acceptable safety laboratory values include ANC ≥1.5 × 109/L, hemoglobin ≥6.2 mM (with no transfusions in the last 28 days), platelet count ≥100 × 109/L, serum bilirubin ≤1.5 × upper limit of normal (ULN) (or <3 × ULN in case of known Gilbert’s syndrome), ASAT and ALAT 2.5 × ULN (or <5 × ULN in case of liver metastasis), and serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min (by the Cockcroft-Gault formula). Patients should be able and willing to give informed consent. In Part 1, all patients with tumors who may benefit from carboplatin-olaparib therapy and who did not receive more than one line of systemic chemotherapy in the advanced setting and any line of hormonal therapy for advanced disease may be included. Prior (neo-)adjuvant chemotherapy is accepted and does not count as one line, because it was administered for early stage disease. The tumor must be evaluable according to RECIST 1.1. Patients must consent to undergo blood sampling for pharmacokinetics and pharmacodynamics analyses.","Patients are excluded from this study if they are pregnant or breastfeeding, use unreliable contraceptive methods, are treated with cytochrome P450 3A4 (CYP3A4) inducers or inhibitors, or previously received a PARP1 inhibitor or high-dose alkylating agent. Radiotherapy and treatment with investigational drugs are prohibited within 28 days prior to receiving the first dose of investigational treatment; exceptions are 1 × 8 Gray (Gy) for pain palliation and standard (neo-)adjuvant chemo-, hormonal- and immunotherapy. Then 7- and 21-day intervals should be maintained, respectively. Other conditions excluding a patient from participating in this part of the study are uncontrolled infectious diseases, known human immunodeficiency virus (HIV)-1 or −2 infections, active hepatitis B or C, myocardial infarction (<6 months) or unstable angina, myelodysplastic syndrome, acute myeloid leukemia, symptomatic brain metastases, leptomeningeal metastases, or any other medical condition that interferes with study procedures or compliance and/or jeopardizes safe treatment. In Part 1 patients are excluded if they previously received carboplatin, unless no progression on carboplatin was observed during earlier treatment and the last carboplatin administration was longer than 6 months ago.",during cycle 1,NA
26705063,NCT01732640,Combination,No,HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma,"Patients must have a histologically confirmed diagnosis of squamous cell carcinoma, operable or inoperable tumors, stage III (T3N0-1) and IVA-B (T1-4 N2-3M0 or T4N0-1M0) of oral cavity, oropharynx, hypopharynx and larynx. For patients with oropharynx primary, either HPV negative or HPV positive with a > 10 pack year tobacco history or current smokers are eligible. HPV status should be determined before the enrollment in only non-smokers with oropharynx primary by HPV in-situ hybridization and/or p16 immunostain. Patients must have measurable disease of primary, nodes or both by clinical and radiographic methods per RECIST v1.1.. No prior therapy, including surgery with curative intent, chemotherapy, radiation therapy, immunotherapy, EGFR targeted therapies, or any other investigational agents. Age >= 18 years. ECOG performance status 0-1. Patients must have normal hepatic, renal and bone marrow function: Absolute neutrophil count >=1,000/ mm3 Count; Platelets >= 100,000/mm3 Count; Total serum bilirubin =< 1.5mg/dL Level: AST and ALT =< 2.5 X ULN; Alkaline Phosphatase =< 2.5 X ULN; Total calculated creatinine clearance >= 60 mL/min. Patients with a history of a curatively treated malignancy must be disease-free for at least two years except for carcinoma in situ of cervix and/or non-melanomatous skin cancer. Patients with the following within the last 6 months prior to pre-registration must be evaluated by a cardiologist and/or neurologist prior to entry into the study: Congestive heart failure > NYHA Class II; CVA/TIA; Unstable angina; Myocardial infarction (with or without ST elevation). Ability to understand and the willingness to sign a written informed consent document.","Any prior radiation above the clavicles. Any prior invasive malignancy (unless non-melanomatous resectable skin or the DFS is 2 years or more). History of allergic reactions attributed to compounds of similar chemical or biological composition to afatinib, or other agents used in study. Cardiac left ventricular dysfunction with resting ejection fraction of less than institutional lower limit of normal ( if no lower limit of normal is defined in the institution, the lower limit is 50%) Gastrointestinal tract disease resulting in an inability to take or absorb oral or enteral medication. Baseline significant gastrointestinal symptoms with diarrhoea as a major symptom or a CTCAE Grade >1 diarrhoea of any etiology. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception. Known pre-existing interstitial lung disease (ILD). Pregnant women are excluded.",during the 2 cycles of IC,NA
23835505,NA,Combination,No,Early-Stage Cervical Cancer Patients With Positive Pelvic Lymph Nodes,"Patients were considered to be eligible if they fulfilled the following criteria: having undergone a type 3 radical hysterectomy with pelvic lymphadenectomy for clinical stage IA2-IIB uterine cervical cancer, being younger than 75 years, having an Eastern Cooperative Oncology Group performance status of 1 or less, having no history of chemotherapy or radiotherapy, displaying any tumor cell type except for small cell carcinoma, and having histologically confirmed positive pelvic lymph nodes. In addition, the patients had to display adequate bone marrow, renal, and hepatic function, which were defined as an absolute neutrophil count of 1500/KL or greater; a platelet count of 100,000/KL or greater; and a creatinine level of less than 2.0 mg/dL, a bilirubin level of 1.5 times normal or less, and a liver enzyme level of 3 times normal or less. ","Patients who displayed evidence of disease outside the pelvis, known hypersensitivity to carboplatin or paclitaxel, poorly controlled medical conditions, or renal abnormalities that would require radiation field modification, such as pelvic kidney or renal transplantation, as well as patients whose circumstances did not permit them to complete the study or the required follow-up period, were excluded",within 30 days of the completion of radiation therapy,NA
22644799,NCT01016769,Combination,No,recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC),"Key inclusion criteria were Karnofsky performance status >= 70 % and measurable disease by RECIST criteria. Patients were required to have adequate bone marrow function: absolute neutrophil count >= 1.5 x 109/L, platelets >= 100 x 109/L, and hemoglobin > 9 g/dL. Other required laboratory parameters were as follows: serum bilirubin within normal limits, serum transaminases (alanine aminotransferase, ALT; aspartate aminotransferase, AST) and alkaline phosphatase <= 1.5 x the upper limit of normal, and serum creatinine <= 1.3 mg/dL. Patients with serum creatinine > 1.3 mg/dL may be eligible if creatinine clearance (CrCl) >= 45 mL/min based on the standard Cockcroft and Gault formula. For women of child-bearing potential, a negative urine or serum pregnancy test was required within 14 days of first study treatment","Patients with any prior treatment with temsirolimus or other mTOR inhibitor were excluded. Patients who had received more than 2 prior cytotoxic chemotherapy regimens in the R/M disease setting were also excluded. Other exclusion criteria included: history of any brain metastases, known active interstitial pneumonitis, oxygen saturation < 88 % on room air by pulse oximetry, hypertriglyceridemia Cgrade 2 (CTCAE version 3.0), prior treatment with temsirolimus or other mTOR inhibitor, other active malignancy (other than indolent malignancies which the investigator determines are unlikely to interfere with treatment and safety analysis), hypertriglyceridemia >= grade 2, multifocal sensory alterations or paresthesias interfering with function, therapeutic anticoagulation with coumadin, need for concomitant medications excluded per protocol due to hepatic CYP3A4 metabolism, active infection or serious underlying medical condition, pregnancy or lactation.",during cycle 1,NA
27551000,NA,Combination,No,"Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia","Patients over the age of 18 years with pathologically confirmed relapsed or refractory AMLs, newly diagnosed aggressive MPN, or aggressive CMML were eligible. Consistent with our previous study (29), for aggressive MPNs (primary myelofibrosis, agnogenic myeloid metaplasia, polycythemia vera, essential thrombocythemia, Ph-negative atypical CML) or CMML, one or more of the following disease acceleration criteria had to be present (30): marrow blasts >5%, peripheral blood blasts + promonocytes >10%, new onset or increasing myelofibrosis, new onset or >25% increase in hepatomegaly or splenomegaly, or new onset constitutional symptoms (fever, weight loss, splenic pain, bone pain). Patients were required to have: an Eastern Cooperative Oncology Group performance status of 0–2; left ventricular ejection fraction of ≥45%; hepatic enzymes ≤ 5x upper limit of normal; bilirubin ≤ 2.0 mg/dL unless due to Gilbert syndrome; interval of >4 weeks since allogeneic bone marrow transplantation (BMT) if performed; and absence of active GVHD, active CNS leukemia, and active uncontrolled infection. All patients gave informed consent to participate in the IRB-approved protocol according to the Declaration of Helsinki.",NA,NA,NA
22943879,NA,Combination,No,"patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma","Patients with a histologic diagnosis of stage II–IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, or ovari- an carcinosarcoma, with optimal (≤ 1 cm residual disease) or suboptimal disease following surgery were eligible. Patients with a GOG performance status of 0–2 were entered and treatment begun within 12 weeks of surgery. Laboratory criteria for eligibility included an absolute neutrophil count (ANC) ≥ 1,500/mcl, platelet count ≥ 100,000/mcl, white blood count ≥ 3,000/mcl, creatinine ≤ 1.5 times upper limit of normal (ULN), bilirubin ≤ 1.5 times ULN, alanine transaminase and aspartate transaminase ≤ 2.5 times ULN, and neu- ropathy (sensory and motor) ≤ grade 1 using the National Cancer Institute Common Toxicity Criteria version 3.0 (NCI CTCAE v3).",NA,during the first cycle of therapy,NA
23468081,NCT00420186,Combination,No,advanced or metastatic solid malignancies,"Eligible participants included male or female patients, 18 years or older, with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and advanced or metastatic tumors for which PC would be considered an appropriate therapy. Eligibility criteria included adequate organ function, including bone marrow, kidney, and liver; life expectancy of >= 12 weeks; normal electrolytes, calcium, magnesium, and acceptable coagulation profiles (<1.5 times the institutional normal limits); and no proteinuria (proteinuria <1 g/24 h). Both previously treated or treatment-naive patients were eligible, including those who had surgery, chemotherapy, prior antiangiogenics, prior hormonal or immunotherapy, and/or radiotherapy, provided that toxicity from prior therapy had resolved, returned to baseline, or been deemed irreversible and a 4-week period between initiation of study therapy and surgery had elapsed. Patients with stable brain metastases (off steroid therapy for at least 4 weeks) or centrally located squamous cell carcinoma of the lung were allowed to enroll. Available archival tissue for predictive marker analyses was required, and patients were required to have evaluable progressive disease. Female patients were required to have a negative pregnancy test, to not be breast-feeding, and to use contraception during and up to 3 months after the study","Patients were excluded for uncontrolled or symptomatic brain metastases, thromboembolic disease, bleeding diatheses within the last 6 months (including subjects with tumors that were known to have spontaneously bled C10 mL of blood), gastrointestinal disease that would impact drug absorption, inability to swallow tablets, peripheral neuropathy Cgrade 1, uncontrolled or significant cardiovascular disease including myocardial infarction within 12 months, uncontrolled angina within 6 months and congestive heart failure within 6 months (LVEF <= 50 % at baseline), uncontrolled hypertension (>= 150/100 mmHg), clinically significant ventricular arrhythmia (atrial fibrillation was not an exclusion), ECG abnormalities of QRS > 120 ms, PR >220 ms, HR < 50 beats per minute, second- or third-degree heart block, or prolongation of the QTc interval (>= 450 ms via Bazett’s or Fridericia’s correction) . Due to the metabolism of BMS-690514 via multiple oxidative reactions involving cytochrome P450 (CYP) enzymes CYP3A4, CYP2D6, and CYP2C9 [39, 40], the use of concurrent administration of a strong P450 enzyme inhibiting drug was an exclusion criterion. Patients with prior exposure or allergy to BMS-690514 or its components or prior allergy to Cremophor EL [BASF SE, Limburgerhof] were also excluded.",the first cyle of therapy,NA
28028994,NA,Combination,No,Korean patients with advanced ovarian cancer,"This study was performed at the Seoul National University Hospital (Seoul, Korea), Asan Medical Center (Seoul, Korea), and Severance Hospital (Seoul, Korea). Patients were eligible for the trial when they satisfied the following inclusion criteria: (1) 18 years or older; (2) written informed consent provided before study participation; (3) histologically diagnosed with an advanced epithelial ovarian cancer, classified as IIIB-IV according to International Federation of Gynecology and Obstetrics (FIGO) classifications; (4) disease measurable with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 , and no experience with chemotherapy; (5) appropriate for paclitaxel and carboplatin combination therapy; (6) Eastern Cooperative Oncology Group (ECOG) performance grade 0–2; (7) life expectancy more than 6 months; and (8) proper blood, kidney, and liver function upon screening, within 14 days before administration of the test drugs; indicators of proper function were defined as follows: hemoglobin (Hb) level ≥10 g/dL, absolute neutrophil count (ANC) ≥1.5×109/L, platelet count ≥100×109/L, serum total bilirubin ≤1.5 times the upper limit of normal (×ULN), serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5×ULN, serum alkaline phosphatase (ALP) ≤2.5×ULN, and serum creatinine ≤1.5×ULN.","The study exclusion criteria were: (1) received chemotherapy other than debulking surgery; (2) received radiotherapy in the abdominal cavity or pelvis; (3) received immunotherapy or hormone therapy for ovarian cancer; (4) history of carcinoma in the past 5 years; (5) received a major surgery other than debulking surgery within 2 weeks before the screening; (6) past or present medical history of metastasis in the central nervous system (CNS); (7) grade 1 or higher level of sensory or motor neuropathy, based on the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) V3.0; (8) severe comorbidities, including a medical or mental condition that prevented understanding the clinical trial and providing written informed consent, severe cardiovascular disease, uncontrolled active infectious disease, or hypersensitivity to the test drugs or the vehicle; and (9) participated in another study within 4 weeks before the screening.",during the first treatment cycle,NA
22610355,NA,Combination,No,Japanese patients with gynecologic malignancies,"Patients were required to have an Eastern Cooperative Oncology Group performance status of 0–2. The number of prior chemotherapy regimens was not limited. An interval greater than 4 weeks after the previous chemotherapy was necessary. Additional criteria included adequate bone marrow function [platelets >= 100,000 platelets/mm3, hemoglobin levels >=9.0 g/dL, absolute neutrophil count (ANC) >= 1,500 neutrophils/mm3], both serum aspartate aminotransferase and alanine aminotransferase levels <= 100 U/mL, total bilirubin levels <= 1.5 mg/dL, serum creatinine levels B1.2 mg/dL, creatinine clearance (Ccr) levels, which were calculated by the Cockloft–Gault formula >= 50 mL/min, and normal or minor electrocardiographic changes without symptoms that required any therapeutic interventions. In addition, patients received an explanation of this study from the physicians through written informed consent forms and other relevant information, and they freely provided informed consent before this study. This protocol was approved by the Institutional Review Board for Research at both Tottori University and Jichi Medical College. Written informed consent was obtained from all patients entered onto this trial","Patients who had any of the following exclusion criteria were excluded from this study: typical infections, severe complications, including myocardial infarction or angina within 6 months before the study, uncontrolled diabetes, uncontrolled hypertension, double invasive cancer within 5 years of the disease-free interval, need for continuous drainage of pleural effusion, ascites, or pericardial fluid, prior chemotherapy with anthracycline, gastrointestinal obstruction, severe diarrhea, known hypersensitivity to CPT-11 or NDP, and any determination by a physician that a patient was ineligible for this study. When patients met any of the following exclusion criteria conditions, which included platelets <100,000 platelets/mm3, absolute neutrophil count <1,000 neutrophils/mm3, or a greater than grade 1 infection, fever, or diarrhea, they were prohibited from receiving CPT-11 chemotherapy on day 8.",during the first cycle of treatment,NA
23957889,NA,Combination,No,unresectable stage III non-small-cell lung cancer,"Patients with previously untreated unresectable stage IIIA or stage IIIB NSCLC (as defined by the 2009 staging standards of the International Union Against Cancer (UICC)) were recruited, who were confirmed pathologically or cytologically. The patients had to be older than 18 years of age and no more than 75 years of age. The Karnofsky performance status (KPS) scores of these patients were at least 70, and the patients were expected to survive for at least 3 months. With respect to laboratory test results, the patients possessed absolute neutrophil counts (ANCs) of at least 2.0×109/L; haemoglobin levels of at least 100 g/L; platelet counts (PLTs) of at least100×109/L; and serum creatinine, alanine aminotransferase, aspartate aminotransferase, and total bilirubin levels that were below the upper limit of the normal range. No significant electrocardiography (ECG) abnormalities and no requirement hospitalisation for diseases other than NSCLC.","Exclusion criteria: pregnant or breastfeeding; with malignancies other than NSCLC, with the exception of cases of cervical carcinoma in situ or non-malignant melanoma skin cancer that had been clinically cured for at least five years; who could not undergo concurrent chemoradiotherapy for medical reasons; or suffered from either superior vena cava syndrome or severe lung disorders that affected lung function.",after the completion of full-dose radiotherapy and at least concurrent one cycle chemotherapy,NA
22665539,NA,Combination,No,Children With Metastatic Medulloblastoma,"Patients between the ages of 3 and 21 years with newly diagnosed highrisk PNET were eligible for enrollment. High-risk PNET was defined as those with M + MB, more than 1.5 cm3 postoperative residual tumor, or supratentorial PNET, regardless of M stage or resection. Patients were classified as M1 when they had positive CSF cytology without other evidence of metastatic disease, as M2 when they had supratentorial without spinal metastases, and M3 when they had spinal metastases with (M3b) or without (M3a) supratentorial disease. Patients underwent a complete staging evaluation, including pre- and postoperative brain magnetic resonance imaging scans, spinal magnetic resonance imaging scans, and CSF cytology. All patients began therapy within 31 days of definitive surgery. Eligibility criteria also included normal renal function (creatinine < 1.5 x normal for age), bone marrow function (absolute neutrophil count [ANC] > 1,500/uL, platelet count > 100,000/uL, hemoglobin > 10 g/dL), and liver function (bilirubin < 1.5 mg/dL, ALT < 2.5 x normal).",Patients with extraneural metastases were excluded.,during the 12-week evaluation period,NA
27421044,NA,Combination,No,"Patients with Recurrent Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Cancer","Eligible patients were > 18 years of age and diagnosed with histologically confirmed recurrent ovarian, fallopian tube, or peritoneal cancer, with disease progression > 6months following completion of platinum-based chemotherapy. Patients were required to have at least one measurable lesion according to RECIST criteria, version 1.1 and an Eastern Cooperative Oncology Group performance status of 0-2, life expectancy of >12 weeks, and adequate organ function, defined as absolute neutrophil count (ANC) > 1500/mm3, platelet count >100,000/µL, total bilirubin < 1.5X institutional upper limit of normal (ULN), ALT and AST < 3X ULN, and creatinine < 1.5X ULN.19,20 Patients were allowed receipt of up to 2 prior lines of chemotherapy in the recurrent cancer setting","Exclusion criteria included CNS metastases, signs of intestinal obstruction that would interfere with bowel function and/or nutrition.",during the cycle 1,NA
25103371,NA,Combination,No,Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck,"Patients with histologically or cytologically confirmed diagnoses of RMSCCHN who were not considered viable candidates for curative surgery or other therapy modalities were enrolled. Patients had a performance status estimated to be 0 to 2 on the Eastern Cooperative Oncology Group scale, and they had adequate bone marrow liver and renal function.","Patients with active concomitant malignancies other than basal cell carcinoma of the skin were excluded. Other grounds for exclusion included prior chemotherapy for recurrent or metastatic disease, brain metastases, a known history of viral hepatitis B or C, radiation therapy within 2 weeks of the initiation of the study treatment, steroid therapy within the month before enrollment, and the use of a medication known to be a cytochrome P450 3A4 inhibitor. Patients who had prior cetuximab exposure as part of curative therapy were not excluded from study participation.",during the first cycle of therapy ,NA
23860537, NCT00832819,Combination,No,non-small-cell lung cancer,"Patients aged 20–74 years with a histologically or cytologically confirmed diagnosis of NSCLC (stage IIIB/IV), at least 1 measurable tumour lesion by Response Evaluation Criteria in Solid Tumours (RECIST) version 1.0 (Therasse et al, 2000), and an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1 were eligible for the study. Patients were required to have adequate organ function and were excluded from the study if they had received previous therapy for NSCLC, including prior chemotherapy, and surgery and radiotherapy for the primary site.","Patients who had hemoptysis of more than 1/2 teaspoon, clinically significant haemorrhagic or thrombotic events within 4 weeks of enrollment or hypertension X150/90 mm Hg at screening (one antihypertensive medication was permitted) were excluded. Other key exclusion criteria included the presence of clinically significant pulmonary or cardiovascular disease, symptomatic brain metastasis, or brain metastasis requiring treatment. Concomitant use of antiplatelet and anticoagulant drugs such as aspirin, warfarin, and ticlopidine was prohibited throughout the study.",during cycle 1,NA
24387695,NCT00848718,Combination,No,patients with advanced solid tumors,"Patients 18 years or older with confirmed advanced solid tumors were eligible if they had progressed after standard therapy, or if no standard therapy was available for them; had Eastern Cooperative Oncology Group performance status ≤1; surgery or chemotherapy within the previous 4 weeks; ≤3 prior lines of cytotoxic therapies (arms 1 and 2 only); residual toxicity from prior treatment grade ≤1; adequate bone marrow, renal, and hepatic function; and fasting serum glucose ≤1.1× the upper limit of normal and hemoglobin A1c (HbA1c) ≤8%.","Patients were excluded if they were diabetic and on antidiabetic therapy, pregnant or breastfeeding, receiving oral corticosteroids, had any condition(s) that would impede drug ingestion or absorption, or had other significant coexisting medical conditions.",during the first cycle of treatment,NA
24849582,NCT00881166,Combination,No,adults with advanced solid tumors,"Malignant disease appropriate for initiating treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel, or erlotinib. Must be able to read, understand, and sign the IRB approved Informed Consent Form. At least 18 years old. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Adequate bone marrow function; normal renal and hepatic function, normal cardiac function.","Any other active invasive malignancy except non-melanoma skin cancers or cervical carcinoma in situ. History of significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure and/or myocardial infarction. Received any anticancer agent(s) within the past 3 weeks, including investigational agents, chemotherapy (6 weeks for nitrosoureas or mitomycin), immunotherapy, biologic or hormonal therapy other than LHRH agonists. Received prior radiation therapy within the past 4 weeks. Any serious, uncontrolled active infection that requires systemic treatment or known infection with HIV, HCV or HBV. Patient requires treatment with immunosuppressive agents other than corticosteroids appropriate for the SOC chemotherapy regimen or those at stable doses for at least 2 weeks.",the first treatment cycle,NA
23267154,UMIN 000005263,Combination,No,Elderly Patients with Advanced Non-small Cell Lung Cancer,"Patients with histologically- or cytologically-proven NSCLC, aged 70 years or older, and with disease unsuitable for complete resection or concurrent chemoradiotherapy were eligible for the study. Other criteria included naïve to chemotherapy; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2; adequate bone marrow, hepatic, and renal function; and normal blood coagulation parameters.","Exclusion criteria included serious infections, clinically active brain metastasis or pleural effusion, or inability to metabolize alcohol.",in the first cycle,NA
24942022,NCT00101205,Combination,No,Pediatric Patients with Refractory Solid Tumors,"Patients ≤21 years of age with recurrent solid tumors unresponsive to therapy or without known effective therapy were eligible if they met the following criteria: Karnofsky/Lansky score >50%; CNS tumor–related neurologic deficits stable for ≥2 weeks; life expectancy >8 weeks; recovery from acute effects of previous treatment; no myelosuppressive chemotherapy for ≥3 weeks (6 weeks if nitrosurea); no biologic agent(s) for ≥7 days; no craniospinal, whole pelvis, or total body irradiation for ≥3 months; no substantial bone marrow radiation for >6 weeks; no focal radiation for metastases for >2 weeks; no allogeneic stem cell transplantation for ≥6 months; no active graft vs. host disease; and no growth factors for >1 week. Indicators of adequate organ function were also required: absolute neutrophil count (ANC) >1000/μL; hemoglobin >8 g/dl; platelets >100,000/μL (transfusion-independent); hyperbilirubinemia grade ≤1; ALT elevation and hypoalbuminemia grade ≤2; normal serum creatinine or GFR ≥80 ml/min/1.73m2; <50 urine RBCs/HPF; normal magnesium and calcium; potassium, sodium, and phosphate abnormalities grade ≤1 (supplements permitted); normal electrocardiogram with SF >27%; EF >50% on echocardiogram; no resting dyspnea or exercise intolerance; room air O2 saturation >94%; no seizures or seizures controlled by non-enzyme-inducing anticonvulsants; and peripheral neuropathy grade ≤1.",Patients were excluded if they were receiving anticancer/experimental therapy; had uncontrolled infection; had previously received oxaliplatin; had life-threatening platinum hypersensitivity; or were pregnant or breastfeeding.,during course 1,NA
23609829,NA,Combination,No,patients with solid tumors,"Patients had to be ≥18 years old and have histologically- or cytologically-confirmed diagnosis of a solid tumor, evidence of disease recurrence or metastatic disease, an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, and adequate hematologic, hepatic, and renal function. Patients were excluded from the study if they had a known hypersensitivity to carboplatin; radiological or clinical evidence of brain involvement or leptomeningeal disease; clinically evident human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection; ≥ grade 2 peripheral neuropathy; or serious illness or medical conditions (e.g., congestive heart failure, previous history of myocardial infarction within 1 year from study entry, active infection, unstable diabetes, or psychiatric disorder that could interfere with consent).","Women who were pregnant or breast feeding were excluded from the study. Patients were also excluded if they received concurrent chemotherapy, investigational agents, radiotherapy, or surgery; had previously received radiation therapy to >30 % of bone marrow, or received any investigational drug within the prior 30 days. Patients of reproductive capacity who refused to use appropriate pregnancy-prevention methods during the study were also excluded.",occurring during treatment Cycle 1,NA
28275119,NCT00756847,Combination,No,Patients with Solid Tumors,Confirmed diagnosis of: Advanced solid tumor that is no longer responding to therapies OR Advanced or recurrent endometrial carcinoma OR Advanced or recurrent ovarian carcinoma OR Unresectable (Stage IIIB or IV) NSCLC. ECOG Performance Status 0-1 (ECOG status of 2 may be considered following discussion and agreement with sponsor). Adequate organ and bone marrow function as defined by hematological and serum chemistry limits. At least 18 years old. Both men and women must practice adequate contraception. Informed consent,"Restriction of some therapies/medications within specific timeframes prior to enrollment and during the study including prior therapy with PI3K, AKT, or mTOR inhibitors, cytotoxic chemotherapy, biologic agents, nitrosoureas or mitomycin C, small-molecule kinase inhibitors, non-cytotoxic hormonal agents. Known allergy or hypersensitivity to any of the components of the treatment formulations. Taking oral corticosteroids chronically or > 1 mg/day warfarin. Not recovered from the toxic effects of prior therapy. History of diabetes mellitus. Uncontrolled intercurrent illness. Pregnant or breastfeeding. Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study. HIV positive. Diagnosis of another malignancy may exclude subject from study",NA,NA
26119093,NA,Combination,No,"women with recurrent, platinum‑sensitive epithelial ovarian, fallopian tube, or peritoneal cancer","Eligibility for this phase I study included the following: a diagnosis of recurrent epithelial ovarian, fallopian tube or peritoneal cancer of any histology or grade, primary platinum sensitive (defined as a cancer initially platinum sensitive followed by a progression-free interval from first exposure to platinum of ≥6 months), RECIST 1.0  measureable cancer, life expectancy >4 months, 18 years of age or older, Eastern Cooperative Oncology Group (ECOG) performance status ≤2, receipt of a maximum of two prior platinum chemotherapy regimens (one at initial diagnosis and one for recurrence) and one non-platinum chemotherapy regimen in the recurrent setting, normal blood counts and organ function, normal QTc interval (QTc ≤ 470 ms) and no history of QTc, able to take oral medications, and no evidence of active or impending malignant bowel obstruction.",Exclusion criteria included receipt of radiation therapy to >25 % of bone marrow-bearing areas and current use of valproic acid (another HDAC inhibitor).,during first cycle of treatment,NA
27995307,"UMIN 000,020,359",Combination,No,Jananese patients with locally advanced non‑small cell lung cancer,"Eligible patients were required to have the following criteria: histologically or cytologically proven unresectable stage IIIA or IIIB NSCLC; no previous chemotherapy or radiotherapy; a performance status of 0–1 on the Eastern Cooperative Oncology Group (ECOG) scale; an age between 20 and 74 years; a life expectancy of 3 months or more; adequate bone marrow reserve (leukocyte count ≥4000 mm−3, neutrophil count ≥2000 mm−3, platelet count ≥100,000 mm−3, and hemoglobin ≥9.0 g/dL); normal liver function (total serum bilirubin ≤1.5 mg/dL; asparate transaminase [AST] and alanine transaminase [ALT] <2.5 times the upper limit of the normal range); normal renal function (normal serum creatinine and blood ureanitrogen levels); and arterial oxygen pressure ≥70 torr","Patients were excluded if they had any of the following: malignant pericardial or pleural effusions; active double cancer; a concomitant serious illness such as myocardial infarction in the previous 3 months, uncontrolled angina pectoris, heart failure, uncontrolled diabetes mellitus, uncontrolled hypertension, interstitial pneumonia, or lung disease; infection or other diseases contraindicating chemotherapy or radiotherapy; pregnancy; or breast-feeding.",during concurrent chemotherapy and thoracic radiation,NA
23483678,NCT00607048,Combination,No,patients with advanced solid tumors,"Patients were at least 18 years of age with an ECOG performance status of 0 or 1. Patients with brain metastases (unless treated and clinically stable), autoimmune disorders, coagulopathies or major co-morbidities or who were pregnant or lactating were excluded from this study.",There were no exclusion criteria regarding prior cancer therapies.,First Cycle,NA
27016411,NA,Combination,No,cervical cancer patients,"Patients, aged between 18 and 70 years, were eligible for inclusion if they had histologically confirmed squamous cell carcinoma or adenocarcinoma FIGO stage IB2 (> 4 cm), II, III or IVA, regardless of the pelvic lymph node status (surgical exploration was optional), but without para-aortic metastasis. Additional inclusion criteria were: detection of the HPV genome in the initial tumor (Hybrid Capture II assay; Roche, France); life expectancy > 3 months; a negative β HCG test for premenopausal women; Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1 at trial entry; adequate hematologic, hepatic, and renal functions","Exclusion criteria comprised: a history of cancer other than basal cell carcinoma; prior radiotherapy or chemotherapy; pregnancy; prior or current psychiatric illness; active infection or another serious underlying pathology that could prevent the patient from receiving the treatment (especially liver, nephrological, or heart conditions); inclusion in another clinical trial with an experimental compound (during this study or one month prior to enrollment); inability to adhere to study followup requirements for geographical; social or psychological reasons.",during treatment until week 10,NA
26072101,NA,Combination,No,relapsed or refractory germ cell tumors,"Eligible patients included men and women  18 years of age with GCTs of any primary site (including the central nervous system) that was histologically confirmed at Memorial Sloan Kettering Cancer Center (MSKCC) and progressive disease (PD) after  1 cisplatin-based chemotherapy regimen. Evidence of PD included worsening radiographic findings, increase in serum tumor marker (STM) levels, or pathologically-confirmed residual disease following chemotherapy. Adequate bone marrow (white blood cells  3000/mL, platelets  100,000/mL), and organ function (12-hour urine creatinine clearance > 50 cc/min, aspartate transaminase/alanine transaminase < 2 times the upper limit of normal [ULN] and bilirubin < 1.5 times ULN) was also required.",Exclusion criteria included previous HDCT or positive HIV or human T-lymphotropic virus serology. All patients provided informed consent.,within 21 days of initiation of HD cycle 1,NA
26395450,NA,Combination,No,untreated patients with extensive disease small cell lung cancer,"Eligible patients had histologically confirmed measurable/evaluable EDSCLC, ECOG performance status 0–2, and adequate bone marrow, renal, and hepatic reserve. Patients with brain metastases were permitted provided that they had not received radiotherapy or stereotactic radiosurgery and that they were no longer symptomatic. For those without brain metastases, prophylactic cranial irradiation was permitted at the discretion of the investigator and the patient.","Exclusion criteria included concurrent cancer chemotherapy, biologic therapy, radiotherapy, concurrent serious/ uncontrolled comorbidities, preexisting grade 2 or higher neuropathy, and chronic diarrhea",in cycle 1 of regiment A,NA
27663600,NCT01237067,Combination,No,metastatic or recurrent women's cancer,"Patients must have confirmed at the NCI, histologically or cytologically recurrent/refractory gynecologic cancers such as but not restricted to epithelial ovarian, fallopian, primary peritoneal, uterine papillary serous cancer, cervix cancer, malignant mixed mullerian tumors, or any type of breast cancer that is metastatic or unresectable and for whom curative therapies do not exist. All patients must have measurable and/or evaluable disease; biomarker-only disease is not considered measurable or evaluable; eligibility of bone only disease is a PI decision on an individual patient basis. Breast cancer patients with locally advanced, unresectable disease must have been previously treated with standard therapy. Breast cancer patients with deleterious mutation in DNA repair enzymes with locally advanced or metastatic disease do not have to have had prior therapy for their progressive disease. Men with BRCA1/2 mutation and metastatic breast cancer will be eligible for study. Ovarian or endometrial cancer patients with deleterious mutation in DNA repair enzymes may be treated in first recurrence independent of platinum-sensitivity history. There is no limit on number of prior therapies. Patients must be at least 6 months from their last platinum exposure and platinum-resistant patients may participate. Age greater than or equal to 18 years. ECOG performance status less than or equal to 2. Patients must have normal organ and marrow function as defined below: Absolute neutrophil count greater than or equal to 1,500/mm3; Platelets greater than or equal to 100,000/mm3; Serum Creatinine less or than or equal to 1.5 mg/dL or if low, Cr Cl greater than 60 mL/min; Total bilirubin less than or equal to 1.5 times the limit of normal (ULN) in the absence of Gilbert s syndrome; AST(SGOT0/ALT(SGPT) less than or equal to 3 times the ULN (CTCAE4.0 grade 2). Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least three months following the last dose of experimental therapy. Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to the start of the study. Ability to understand and the willingness to sign a written informed consent document. Inclusion of Women and Minorities: Women and members of all races and ethnic groups are eligible for this trial.","Patients who have had treatment for their disease, such as chemotherapy, biological therapy, radiotherapy, surgery, or complementary and alternative therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Patients who were treated with other PARP inhibitors greater than 28 days prior to study are eligible. Must be at least 2 weeks from the last phase 0 intervention (longer at the discretion of the PI) and at least 1 day from non-cancer-related complementary and alternative medicine prior to entering the study. Previous treatment with olaparib (AZD2281). Invasive cancer, other than co-existent breast/gynecologic cancers, within the past 2 years. Noninvasive nonmelanoma skin cancers are not exclusions. Patients with known brain metastases diagnosed within 1 year will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with brain metastases diagnosed greater than 1 year prior to study entry may be considered if they received sterilizing therapy to the CNS (resection or radiation) and have been CNS recurrence-free for a full 1-year period. History of grade 4 allergic reactions to platinums: Patients with allergic reaction to platinums (up to and including grade 3 without a reaction protocol, and up to and including grade 2 in the face of aggressive pre-treatment) may be eligible pending review of experience, and PI approval. Patients who have not been rechallenged after a severe reaction may be eligible on a case-by-case basis. Clinically significant GI bleeding or hemoptysis within 28 days prior to the start of the study. Inability to swallow pills. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (no antibiotics prior to entering the study within 7 days), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Pregnant and breast-feeding women: If a woman becomes pregnant or suspects she is pregnant while participating in this study, she should inform her treating physician immediately. HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AZD2281. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy such as carboplatin. HIV- positive patients who are not on combination antiretroviral therapy but with CD4 counts >500, eligibility is a PI decision on an individual patient basis. Major surgery within the past 28 days",during the first two cycles of therapy,NA
23963796,NCT00528619,Combination,No,patients with advanced solid malignancies,"Patients aged 18 years or older with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 were enrolled. Patients had a histologic or cytopathologic diagnosis of solid malignancy refractory to standard therapy or for which no standard therapy existed, adequate organ function (including bone marrow, kidney, and liver), and a life expectancy of ≥12 weeks. In the expansion cohort, previously treated and/or platinum- refractory/-intolerant patients with recurrent or advanced NSCLC of any histologic subtype and patients with advanced unresectable mesothelioma (pleural or peritoneal; stage 3 or 4) were eligible for enrollment.","Patients were excluded if they had uncontrolled or symptomatic brain metastases; gross hemoptysis (≥5 ml per episode or ≥10 ml per day) within 4 weeks of study start; uncontrolled hypertension (>150/100 mmHg) despite standard antihypertensive agents; or cardiac disease, cerebrovascular accident or pulmonary embolism within 12 months of starting the study. Other exclusion criteria included: National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 3 hemorrhage within 4 weeks of treatment; ongoing cardiac dysrhythmias of grade ≥2; atrial fibrillation of any grade; prolongation of the QTc interval (>450 ms for males or >470 ms for females); chemotherapy, surgery or radiation therapy less than 4 weeks before study start (except palliative radiotherapy to non-target lesions); known hypersensitivity to carboplatin; or prior treatment with pemetrexed, carboplatin, or sunitinib.",during the first 22 days of treatment,NA
22843927,NCT00930475,Combination,No,Metastatic Breast Cancer,"Eligible patients were aged ≥18 years, with histologically or cytologically confirmed metastatic breast cancer and at least two prior chemotherapy lines, including anthracyclines and taxanes, in the adjuvant or metastatic setting. All patients had to have adequate hematological, renal and hepatic function [white blood cells (WBC) >2.5×109/l, absolute neutrophil count (ANC) >1.5×109/l, platelets >80×109/l, and hemoglobin >8 g/dl; serum bilirubin levels ≤1× upper limit of normal (ULN), albumin >3g/dl, serum transaminase activity <2.5×ULN, alkaline phosphatase <2.5×ULN, serum creatinine level <2×ULN], a Karnofsky performance status ≥60%, and had to provide their written informed consent (Table I).","Exclusion criteria included prior treatment with mTOR inhibitors or carboplatin, cisplatin or oxaliplatin, inability to discontinue therapy with potent CytochromeP4503A4 (CYP3A4) inhibitors or inducers, uncontrolled central nervous system metastases, unresolved hepatitis B or C infection, known HIV infection, or prevalence of a hypercholesterolemia or hypertriglyceridemia (>CTC grade 3). Patients were not eligible if they had other severe disorders or had received an investigational drug within the previous 30 days.",during the first cycle,NA
26100175,NA,Combination,No,patients with small-cell lung cancer,"The eligibility criteria were as follows: o75 years old, histologically confirmed SCLC, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2. The laboratory requirements included hemoglobin 410 g/dL, a white blood cell count 44000/mm3, an absolute neutrophil count 42000/mm3, platelet count 4100,000/mm3, serum bilirubin o1.5 mg/dL, alanine/aspartate aminotransferase o1.5  the institutional upper limit of normal, and creatinine clearance 440 mL/min",Patients with symptomatic brain metastasis or severe comorbidity were excluded.,during cycle 1,NA
21826439,NA,Combination,No,patients with advanced solid tumors,"Patients with histologically confirmed advanced solid malignancies refractory to standard therapy or for whom no effective therapy existed were candidates for this study. Other eligibility criteria included: Age ≥18 years, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, adequate hematopoietic (ANC≥ 1.5×109/L, HGB ≥8.0 g/dL, Platelet count ≥75×109/L), hepatic {Aspartate aminotransferase (AST)≤2.5 × upper limit of normal (ULN) (<5 × ULN if liver metastases)}and renal (serum creatinine ≤2.0 mg/dL) functions, a minimum of 3 weeks must have elapsed between last receipt of chemotherapy,surgery, or radiotherapy and the first administration of KOS862 and carboplatin;","Patients were excluded if they had: pre-existing neuropathy of Common Terminology Criteria for Adverse Events of the National Cancer Institute version 3 (CTCAE)Grade ≥2 due to any cause; prior significant toxicity to carboplatin therapy that would preclude retreatment with this agent (such as clinically symptomatic Grade 4 myelosuppression); documented hypersensitivity reaction of CTCAE Grade ≥3 to prior therapy containing Cremophor®; pregnant or breast-feeding women; known central nervous system (CNS) metastases requiring corticosteroids; patients with personal or family history of congenital long QT syndrome, or patients with mean QTc interval >450 msec (males) or >470 msec (females) identified on screening electrocardiograms (ECGs); prior malignancies unless free of recurrence for at least 5 years, except cured basal cell carcinoma of the skin, carcinoma-in-situ of either the cervix, breast or urinary bladder or stage T1 or T2 prostate cancer in patients whose prostate-specific antigen (PSA) level was <2 ng/mL.",during the first treatment cycle,NA
19088046,NA,Combination,No,Patients with Advanced Solid Malignancies,"All patients gave written informed consent before any study-specific procedures were done. Adults (z18 y) with histologically or cytologically proven advanced solid tumors refractory to conventional treatment or for whom no standard treatment existed were recruited. Additional inclusion criteria were Eastern Cooperative Oncology Group performance status 0 to 1; adequate hematologic function (absolute neutrophil count z2,000 cells/mm3, platelet count z125,000 cells/mm3, hemoglobin z9 g/dL) and hepatorenal function (bilirubin V1.5 mg/dL; transaminases V2.5 times the upper limit of normal and serum creatinine V1.5 times the upper limit of normal); and at least 4 wk since last chemotherapy or radiation therapy (6 wk for nitrosureas or mitomycin C). Women of child-bearing potential were required to have a negative serum or urine pregnancy test within 72 h before starting the study drug.",Exclusion criteria included prior treatment with more than two chemotherapy regimens for metastatic disease or in the adjuvant setting or any platinum-containing treatment; preexisting peripheral neuropathy Common Toxicity Criteria (CTC) grade >1; brain metastases; or a documented history of hypersensitivity to paclitaxel or other therapies containing Cremophor EL.,during cycle 1,NA
19889612,NA,Combination,No,patients with advanced gynecological malignancies,"Patients with a histologically confirmed diagnosis of an advanced or recurrent gynecological malignancy (epithelial ovarian cancer, endometrial carcinoma, mixed mesenchymal tumor or cervical carcinoma) with an indication for paclitaxel and carboplatin combination therapy were eligible for this trial. Patients were aged ‡18 years with an Eastern Cooperative Oncology Group  performance status of zero or one and must have provided written informed consent.","Patients who had received radiotherapy, chemotherapy, immunotherapy or hormonal therapy within 4 weeks before the start of therapy were excluded",in the first treatment period,NA
19404211,NA,Combination,No,Patients with Extensive-Disease Small Cell Lung Cancer,"Eligibility criteria for patients in this study included the following: a histologically and/or cytologically confirmed diagnosis of SCLC; extensive stage disease19; no prior chemotherapy or radiotherapy; age <=75 years; Eastern Cooperative Oncology Group performance status <=1; life expectancy greater than 12 weeks; adequate bone marrow function (leukocyte count >= 4000/l, platelet count >= 10.0 x 104/l, and hemoglobin level .= 10.0 g/dl); serum bilirubin level <= 1.5 mg/dl; alanine aminotransferase (ALT) and aspartate transaminase (AST) levels <= 2 times the normal upper limit; serum creatinine level less than the normal upper limit; and no medical problems severe enough to prevent compliance with the protocol",NA,the first cycle,NA
18618082,NA,Combination,No,advanced solid tumors refractory to standard therapy,"Patients with pathologically confirmed advanced solid malignancies with measurable or non-measurable disease without curative options were enrolled in this study. Patients could not have received chemotherapy, radiation, or any other investigational agent for at least 4 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C) and must have recovered from any toxic effects of previous therapy. Palliative radiation therapy was allowed two or more weeks prior to enrollment. Patients may have received carboplatin and/or etoposide chemotherapy in the past. Patients with a known history of intracranial metastases could be included, provided that they were clinically stable, had no active seizures, and were on stable anti-epileptic or steroid medications for at least 7 days prior to study enrollment. Patients must not have had wide-field radiation therapy to more than 35% of their bone marrow reserve, any pelvic radiation, greater than two courses of mitomycin C, or have undergone stem cell transplant. Additional eligibility criteria included: age≥16 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, and life expectancy of greater than 12 weeks. Study candidates were required to have adequate hematopoietic (ANC≥1,500/μl, hemoglobin≥9 g/dl, platelets≥100,000/μl), hepatic (total serum bilirubin≤1.5 times upper limits of normal; SGOT and SGPT≤2.5 times upper normal limits or lesser or equal to five times upper normal limits for patients with hepatic metastases), and renal (serum creatinine≤ 1.5 mg/dl or creatinine clearance of at least 60 ml/min) function.",Pregnant or nursing women were excluded,in the first course,NA
19520688,NA,Combination,No,Advanced Non-small Cell Lung Cancer and a Performance Status of 2,"Patients with histologically or cytologically proven advanced NSCLC were eligible for the study. Each patient was required to meet the following criteria: (i) clinical stage IIIB or IV; (ii) ECOG PS of 2; (iii) aged 20 – 75 years; (iv) measurable lesion; (v) no prior chemotherapy; (vi) adequate hematological function (white blood cell 3500/mm3, hemoglobin 9.5 g/dl and platelets 100 000/mm3); (vii) adequate hepatic and renal function (total bilirubin 1.5 mg/dl, AST and ALT,100 IU/l and creatinine 1.5 mg/dl); (viii) PaO2 60 mmHg; and (ix) written informed consent.","Patients with active concomitant malignancy, radiologically apparent interstitial pneumonia or pulmonary fibrosis, serious concurrent illness (e.g. uncontrolled diabetes mellitus, hypertension, angina pectoris, myocardial infarction within 3 months after onset or severe infection), history of severe drug allergy or pregnant/lactating women were excluded.",in the first course of chemotherapy,NA
18692224,NA,Combination,No,in women with platinum sensitive recurrent ovarian carcinoma,"Patients with a measurable platinum sensitive (defined as recurrence ≥6 months from completing primary therapy) first recurrence of epithelial ovarian cancer or primary peritoneal cancer were eligible for the study. Patients had to be ≥18 years of age; have adequate organ function including a normal left ventricular ejection fraction; normal hematopoietic reserve, including white blood cell count > 3000/uL, a platelet count > 100,000/uL, serum creatinine b2.0, total bilirubin < 1.5× institutional upper limit of normal, and AST, ALT, and alkaline phosphatase < 2.5× the institutional upper limits of normal; GOG performance status of ≤2; life expectancy > 12 weeks; and have provided informed consent.","Patients were excluded if they had known brain metastases, were pregnant, had known HIV infection, or were unable to effectively utilize oral medications or used medications known to interfere with the metabolism of lapatinib.",NA,NA
19479255,NA,Combination,No,chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer,"Chemotherapy-naïve patients between 18 and 75 years of age with histologically or cytologically proven non-irradiable stage IIIB or stage IV NSCLC with a life expectancy of at least 12 weeks and an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2 were eligible. Adequate organ function was necessary, including: neutrophils >= 2.0 x 109/L; platelets >=100 x 109/L; creatinine within upper normal limits (if borderline, creatinine clearance of >=60 mL/min was needed); total bilirubin within normal limits and alanine aminotransferase/aspartate aminotransferase (ALT/AST) and alkaline phosphatase (AP) <= .5 times the upper limit of the institutional norms or ALT/AST <= 1.5 times and AP <= 5 times the upper limit of the institutional norms. The presence of at least one measurable lesion, according to RECIST guidelines, was recommended, but not required; patients with non-measurable disease were eligible . ","Principal exclusion criteria were: hypercalcemia (>2.8 mM/L); prior chemotherapy, radiotherapy (to a major bone marrow area within 4 weeks prior to study entry or to >10% of bone marrow area) or surgery for NSCLC; symptomatic brain or leptomeningeal metastases; peripheral neuropathy >grade 1; another serious comorbid condition; a prior history of cancer (excluding basal cell skin or in situ disease); concomitant treatment with other experimental drugs, other anticancer therapy or corticosteroids (with the exception of chronic treatment); or pregnancy.",during the first 3-week cycle of treatment,NA
19843663,NA,Combination,No,Relapsed and Refractory Acute Myelogenous Leukemia,"Subjects were recruited from the clinical practices of the University of Pennsylvania between May 2004 and January 2007. Eligible subjects were ages 18 to 65 with non-M3 AML that either had relapsed following prior chemotherapy or was refractory to induction chemotherapy. Primary refractory leukemia was defined as persistent disease (>5% marrow blasts) following two induction cycles or recurrent leukemia following a single induction cycle that had resulted in a nadir marrow biopsy with no leukemia. Patients with untreated secondary leukemia—defined as AML arising out of an antecedent hematologic disorder or following chemotherapy or radiation therapy—were also eligible. Patients with accelerated or myeloid blast phase chronic myelogenous leukemia could participate provided they had progressive disease despite treatment with BCR-ABL kinase inhibitors. Pathology review at the Hospital of the University of Pennsylvania was done to confirm diagnoses in all cases. All subjects were required to have an Eastern Cooperative Oncology Group performance status of 0 to 1 and resolution of prior treatmentrelated toxicities. Required baseline organ function studies specified an ejection fraction >45%, creatinine ≤2.0 mg/dL, total bilirubin ≤1.5 mg/dL, hepatic transaminases ≤3× upper level of normal, no uncontrolled infections, and no unstable baseline comorbidities that would jeopardize toxicity assessment. Due to significant drug-drug interactions between sirolimus and systemic imidazole or triazole antifungals, these medications were prohibited for 1 wk prior to enrollment.",NA,N/A,NA
20588278,NA,Combination,No,patients with solid tumours,"Patients with histological or cytological confirmation of advanced solid malignancy refractory to standard therapy were eligible, provided that they met the following criteria: age >=18 years; Eastern Co-operative Oncology Group performance status <=2; adequate bone marrow, hepatic and renal function (neutrophils >1.0 x 109 l-1, platelets >100 x 109 l-1, total bilirubin <=1.5 x upper limit of normal, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase <=3 x upper limit of normal (or <=5 x upper limit of normal if liver metastases) and calculated creatinine clearance >=45 ml min-1); female patients of reproductive potential were required to have a negativepregnancy test.",Patients were excluded if they had co-existing significant medical conditions including prolonged QTc > 500 ms; use of concomitant medication that may cause torsade de Pointes; neuropathy >=grade II because of previous treatment; or had received >3 previous lines of chemotherapy for metastatic disease,NA,NA
19297278,NA,Combination,No,Patients with Advanced Non-Small-Cell Lung Cancer,"Eligible patients had to meet the following criteria: histologically and/or cytologically proven nsCLC; stage iiiB without any indication for radiotherapy or stage iV; an age range from 20 to 75 years; a performance status (Ps) of 0-2 on the Eastern Cooperative Oncology Group; a projected life expectancy of at least 3 months; measurable disease; no previous chemotherapy or radiotherapy, and written informed consent. Other eligibility criteria for an organ function were as follows: a leukocyte count >4,000/ml; neutrophil count >2,000/ml ; platelet count >100,000/ml; hemoglobin level >9.0 g/dl; total serum bilirubin <1.5 mg/dl; transaminase <2.5 times institutional normal upper limit; normal creatinine level; creatinine clearance >50 ml/min; partial pressure of arterial oxygen >70 mmHg.","Any patients who had interstitial pneumonitis, pleural effusion and/or ascites and/or pericardial effusion requiring drainage, concomitant malignancy, active infectious disease, other serious medical problem, or brain metastases were excluded.",during the first one cycle,NA
21277623,NA,Combination,No,"untreated ovarian, fallopian tube, and primary peritoneal carcinoma","Eligible patients had to be ≥18 years of age and have previously untreated stage II, III or IV, epithelial ovarian, primary peritoneal or fallopian tube carcinoma regardless of residual disease following surgery. A GOG Performance Status of ≤2 was required, and patients were entered within 12 weeks of surgery. Patients had to have adequate bone marrow function (absolute neutrophil count (ANC) ≥1.5×109/L, platelets ≥100×109/L), renal function (creatinine ≤1.5×institutional upper limit normal (ULN)), hepatic function (bilirubin ≤1.5×ULN, ALT, AST, and alkaline phosphatase ≤2.5×ULN) and neurologic function (sensory or motor neuropathy ≤grade 1). After Institutional Review Board approval, written informed consent consistent with all federal, state and local requirements was obtained from all patients before study entry.",NA,in the first cycle during the dose-seeking phase (or in the first 4 cycles in the expanded phase),NA
22155262,NA,Combination,No,"untreated ovarian, fallopian tube or primary peritoneal carcinoma:","Patients with a histologic diagnosis of Stages II–IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma were eligible. Patients with a GOG performance status of 0–2 were entered within 12 weeks of surgery. Laboratory criteria included an absolute neutrophil count (ANC)≥1500/mcL, platelet count≥100,000/mcL, white blood count≥3000/mcL, creatinine≤1.5 times upper limit of normal (ULN), bilirubin≤1.5 times ULN, alanine transaminase and aspartate transaminase≤2.5 times ULN, and neuropathy (sensory and motor)≤grade 1 using the National Cancer Institute Common Toxicity Criteria version 3.0 (NCI CTCAE v3).",NA,within the first 4 treatment cycles,NA
20580118,NCT00573690,Combination,No,refractory solid tumor patients,"1. Histologically or cytologically confirmed metastatic solid tumor. 2. Measurable disease by RECIST criteria. 3. Progressed on at least one standard therapy or who have a disease for which there is no standard therapy. 4. Age ≥ 18 years old. 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 6. Adequate organ function defined as: - Bone marrow: hemoglobin ≥ 9.0 g/dL, ANC ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L - Hepatic: total bilirubin ≤ 1.5 × ULN, ALT and AST ≤ 2.5 × ULN, INR < 1.5 or a PT/PTT within normal limits. Patients receiving warfarin or heparin were allowed to participate. For patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable - Renal: Cockcroft calculated creatinine clearance (CrCL) ≥45 mL/min. 7. Asymptomatic brain metastases were permitted if treated ≥6 months before study entry, and clinically stable without steroid treatment for 1 week. 8. Women of childbearing potential: negative serum pregnancy test performed within 7 days prior to the start of treatment. 9. Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men and women should use adequate birth control for at least 2 weeks after the last administration of sorafenib. 10. Able and willing to provide written informed consent","1. Histological or cytological diagnosis of squamous cell carcinoma of the lung. 2. Congestive heart failure > class II NYHA; unstable angina, new onset angina (began within the last 3 months), or myocardial infarction within the past 6 months. 3. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. 4. Uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic > 90 mmHg) despite optimal medical management. 5. Known severe hypersensitivity to sorafenib or any of the excipients, etoposide, pemetrexed, cisplatin, or carboplatin. 6. Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C. 7. Active clinically serious infection > CTCAE grade 2. 8. Thrombolic or embolic events within the past 6 months. 9. Pulmonary hemorrhage/bleeding event > CTCAE grade 2 or any other hemorrhage/bleeding event > CTCAE grade 3 within the past 4 weeks. 10. Serious non-healing wound, ulcer, or bone fracture. 11. Evidence or history of bleeding diathesis or coagulopathy. 12. Major surgery, open biopsy or significant traumatic injury within the past 4 weeks. 13. Use of St. John’s Wort or rifampin. 14. Any condition that impairs patient’s ability to swallow whole pills. 15. Any malabsorption problem or uncontrolled inflammatory bowel disease or gastrointestinal disorder causing ≥5 bowel movements in 24 h period at baseline. 16. For Arms B/C (carboplatin/pemetrexed): - Clinically relevant pleural effusions or ascites which cannot be controlled by drainage - Non-compliance or inability to take vitamin B12 and folic acid supplementation - Inability to discontinue non-steroidal anti-inflammatory drugs (NSAIDs) for 2 days before (5 days for long-acting NSAIDs), the day of, and the 2 days after pemetrexed administration. 17. Prior exposure to >3 cytotoxic therapies for metastatic disease",in cycle 1,NA
22345119,NA,Combination,No,advanced non-small-cell lung cancer,"Adult patients with pathologically confirmed stage IIIB (including malignant pleural effusion) or stage IV NSCLC of all histologies, with a life expectancy of at least 3 months, an ECOG performance status of zero or one and measurable disease were eligible for this study. Patients who had received prior therapy for NSCLC, including chemotherapy, biological/targeted therapy or any investigational drug, were excluded from the trial.","Those with active brain metastases were excluded, as were patients with gastrointestinal disorders that could interfere with the absorption of the study drug. Patients who had experienced a hemorrhagic or thromboembolic event in the past 12 months, or clinically significant hemoptysis in the past 3 months, and those with centrally located tumors with radiological evidence (computed tomography or magnetic resonance imaging) of local invasion of major blood vessels or who had significant cardiovascular disease were excluded. In addition, patients with total bilirubin > 1.5 mg/dl, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 1.5 × upper limit of normal or serum creatinine > 1.5 mg/dl were excluded.",in treatment cycle 1,NA
22306126,NA,Combination,No,advanced non-small cell lung cancer,"Patients with histologically or cytologically confirmed NSCLC who had received no previous chemotherapy were eligible. The eligibility criteria were as follows: (1) stage IV or stage III lung cancer not amenable to surgery and curative radiotherapy;(2)measurable lesions; (3) age 70 years or older; (4) Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–1; (5) adequate organ function [absolute neutrophil count (ANC) ≥ 2000/L, platelet count ≥ 100,000/L, hemoglobin count ≥ 9.5 g/dL, serum total bilirubin ≤ 1.5 mg/dL, serum transaminase ≤ 100 IU/L, serum creatinine ≤ 1.5 mg/dL, SpO2 ≥ 90%]. Surgery and prior radiotherapy except for the primary tumors and evaluable lesions were allowed. At least two weeks had to have passed after completion of the previous radiotherapy. ","The exclusion criteria were as follows: (1) pulmonary fibrosis or interstitial pneumonitis with symptoms or apparent abnormalities on the chest X-ray; (2) massive pleural effusion, pericardial effusion, or ascites; (3) symptomatic brain metastases; (4) active concurrent malignancies; (5) patients who had received a bone marrow transplantation or peripheral blood stem cell transplantation; (6) severe drug allergies; (7) severe infections requiring antibiotics or severe comorbidities such as gastrointestinal bleeding and heart disease; (8) poorly controlled diabetes.",NA,NA
18506181,NA,Combination,No,"ovarian, fallopian tube and primary peritoneal cancers","Eligible patients were women aged X18 years of age with histologically confirmed epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Additional inclusion criteria were as follows: International Federation of Gynecologic Oncology (FIGO) stage III – IV disease; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 –2; no prior exposure to chemo- or radiotherapy; p8 weeks following surgery (debulking surgery was not an entry requirement; however, patients not considered operable must have had appropriate pathology on biopsy).","Key exclusion criteria included symptomatic peripheral neuropathy; inadequate renal, hepatic, cardiopulmonary or haematologic function; severe and/or uncontrolled comorbidity; and prior sensitivity to docetaxel.",during the first cycle with erlotinib,NA
20054549,NA,Combination,No,recurrent ovarian cancer,"Women >= 18 years of age were eligible who had platinum-sensitive recurrent cancer of the ovary, fallopian tube, or peritoneum, at least 6 months after completion of primary standard therapy with surgery and first-line combination therapy with platinum and paclitaxel. Patients were required to have measurable lesions or non-measurable disease as defined by Response Criteria in Solid Tumors (RECIST)  or had to be evaluable for CA-125 response evaluation according to the GCIG-criteria . Eastern Cooperative Oncology Group (ECOG) performance status had to be <=2, patients were required to have normal hematologic, liver, and renal function with laboratory parameters within the normal range, including a glomerular filtration rate >= 45 ml/min based on the standard Cockcroft and Gault formula or on measured GFR using an appropriate radiolabeled method (51-CrEDTA or Tc99 m-DTPA), serum creatinine levels <= 1.5 mg/dl, and an adequate bone marrow function (absolute neutrophil count [ANC] >= 1.5 x 109/l and platelets >=100 x 109/l).","Patients suffering from a secondary malignancy or serious concomitant systemic disorders or psychiatric disease were excluded from the study, as were subjects receiving other cytotoxic, immunological, hormonal, or targeted therapy. All patients provided written informed consent. Patients were excluded if they had more than two previous lines of therapy for ovarian cancer or a serious concomitant systemic disorder that would compromise the ability to complete the study",during cycle 1 of treatment,NA
19404408,NA,Combination,No,advanced solid tumor not curable by standard therapies,"Eligibility criteria included patients with a diagnosis of advanced solid tumor not curable by standard therapies; measurable disease; Zubrod performance status of 0–2; age >18 years; prior chemotherapy was allowed except irinotecan or carboplatin; adequate hematologic (ANC >1500 and platelets >100 000/mL), hepatic (total bilirubin and SGOT <2× upper limit of normal), and renal (serum creatinine <1.5 mg/dl) functions. All patients signed informed consent in accordance with guidelines of the institutional review board",NA,NA,NA
19520687,NA,Combination,No,Inoperable Non-small Cell Lung Cancer,Patients eligibility requirements for entering into this study included the following criteria: histologically or cytologically confirmed NSCLC; measurable or assessable disease at stages IV and IIIB without curative radiotherapy; age 75 years or younger; no prior chemotherapy or radiotherapy; and Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 – 1. Additional criteria were: expected survival >= 3 months; adequate organ functions; leukocyte count >= 4000/mm3; neutrophil count >= 2000/mm3; platelet count >= 100 000/mm3; hemoglobin level >= 9.5 g/dl; total bilirubin within upper limit of normal range; AST/ALT <= 2 x upper limit of normal range; creatinine <=1.5 x upper limit of normal range; 24 h creatinine clearance (CCR) >= 30 ml/min; and PaO2 >= 70 mmHg.,"Exclusion criteria included other active malignancy, pleural effusion or pericardial effusion requiring medical treatment, symptomatic brain metastases, superior vena cava syndrome requiring radiotherapy, history of myocardial infarction within 3 months, serious medical illness, history of severe anaphylaxis, history of anaphylaxis to castor oil, pregnancy or lactation",during the first three administrations of the drugs,NA
19800673,NA,Combination,No,"relapsed, platinum-sensitive ovarian cancer patients","Women ≥18 years of age with a documented pathologic diagnosis of ovarian, primary peritoneal, or fallopian tube carcinomas and relapsing N6 months since last platinum treatment were eligible. One additional treatment with platinum and/or paclitaxel regimen was permitted. The presence of measurable disease by physical exam or imaging was required. Ascites of proven malignant nature or rising CA-125 were acceptable for enrollment, but response assessment was not made in the absence of measurable disease. Other enrollment criteria were the Karnofsky Performance Status ≥70, an estimated life expectancy of ≥16 weeks, and an adequate bone marrow function. Patients receiving prior treatment for brain metastases were eligible if they remained stable for ≥6 months after treatment without requiring corticosteroids.","Exclusion criteria included inadequate liver and renal function, prior gemcitabine therapy, concurrent use of tamoxifen, patients receiving investigational drugs 4 weeks prior to study participation, uncontrolled infection, serious uncontrolled concomitant disorders, second primary malignancy, or another malignancy for which the patient has been disease free for ≤3 years.","For Arms 1 and 2, DLTs were based on the first cycle of treatment only and for Arm 3, four cycles of treatment determined DLTs.",NA
19652058,NA,Combination,No,Advanced Solid Malignancies,"Patients with histologically or cytologically documented solid malignancies refractory to standard therapy, for which no standard exists, or for which the combination of paclitaxel and carboplatin was considered an appropriate standard treatment were eligible. Other key eligibility criteria included age >= 18 years; Eastern Cooperative Oncology Group performance status <= 1; presence of evaluable or measurable disease as defined by the Response Evaluation Criteria in Solid Tumors; and adequate hematopoietic, hepatic, and renal function","Exclusion criteria included chemotherapy, radiotherapy, or anticancer hormone therapy within 3 weeks; persistent grade  2 toxicity related to prior therapies except alopecia; systemic corticosteroids within 1 week of starting, unless used as part of an antiemetic regimen or maintenance corticosteroids for noncancerous disease; known brain metastases, unless adequately treated and stable off anticonvulsants and steroids; and known chronic or acute hepatitis or HIV infection",during the first 21 days of treatment,NA
20049927,NA,Combination,No,Advanced Stage Neuroblastoma,"Patients age 1–21 years with newly diagnosed Stage 4 or surgery-only treated low stage disease that progressed to Stage 4 at >=1 year of age with weight >=10 kg were diagnosed by tumor histology or presence of tumor in bone marrow with elevated catecholamines  at eight Childrens Cancer Group approved hematopoietic cell transplant centers (listed in Appendix I) between May 1996 and October 2001. Patients had normal renal, cardiac, liver function and bone marrow function and no prior systemic chemotherapy or non-emergent radiation therapy. Written informed consent of parent/guardian was obtained according to National Cancer Institute and institutional IRB guidelines.",NA,by dat 28,NA
19090012,NA,Combination,No,Subjects Aged 1 to 21 Years With Refractory Solid Tumors,"Patients ages 1 to 21 years with a histologically or cytologically confirmed diagnosis of a solid malignancy that had progressed on standard therapy or for which no standard effective therapy was known were eligible to enroll after written and voluntary informed consent from patients or their legal guardians. Patient assent was obtained if appropriate. The study was approved by each institution’s institutional review board. Other criteria included: measurable or nonmeasurable disease; adequate bone marrow function (absolute neutrophil count [ANC] >1.0 x 109/L and platelet count >100,000 x 106/L); adequate hepatic function (total bilirubin <= 1.5 mg/dL and alanine transaminase <= 2.5 times the institutional upper limit of normal); adequate renal function (glomerular filtration rate [GFR] >30 mL/min/m2 as measured by creatinine clearance or radionuclide scan); at least a 4-week interval since the last immunotherapy, radiotherapy, or chemotherapy; life expectancy of at least 8 weeks; recovery to baseline or grade 1 from toxicities resulting from prior therapy; Karnofsky score or Lansky play scale 50; and a negative pregnancy test.","Patients were ineligible or excluded for any of the following reasons: >3 prior chemotherapy regimens; serious uncontrolled medical disorder or infection; symptomatic brain metastases; receiving phenytoin, phenobarbitol, primidone, carbamazepine, or valproic acid; and having previously underwent bone marrow transplantation.",the first cycle of treatment,NA
20159815,NA,Combination,No,Advanced Non-Squamous Non–Small-Cell Lung Cancer,"Institutional review board approval and signed informed consents were obtained before study-related procedures were started. Inclusion criteria included histologically or cytologically confirmed nonsquamous NSCLC (stage IIIb with malignant pleural effusion, stage IV, or recurrent disease); planning to receive 6 cycles of chemotherapy; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; absolute neutrophil count >= 1.5 x 109/L; platelet count >= 100  109/L; AST or ALT <= 2.5 x upper limits of normal (ULN); alkaline phosphatase <= 2.5 x ULN (<= 5 x ULN in the presence of bone or liver metastasis); total bilirubin <= 1.5 x ULN; and creatinine clearance >= 50 mL/min","Exclusion criteria included CNS metastases; myocardial infarction or unstable or uncontrolled disease or condition related to or impacting cardiac function; uncontrolled hypertension; history of arterial thrombosis, pulmonary embolus, deep vein thrombosis, or hemorrhagic disorders within 1 year of enrollment; prior chemotherapy (except for adjuvant chemotherapy, provided the last dose was received at least 1 year before enrollment); and anticoagulation treatment.",time to complete the first cycle of treatment and follow-up [21 days]),NA
20028752,NCT00094835,Combination,No,Advanced Non–Small Cell Lung Cancer,"Eligible adult (≥18 y) patients had histologically confirmed, unresectable stage IIIB or stage IV NSCLC with measurable or evaluable (nonmeasurable) disease per Response Evaluation Criteria in Solid Tumors (RECIST; ref. 31). Patients either were chemotherapy-naïve (arm A and C) or had received no more than one prior chemotherapy regimen for NSCLC (arm B). Other key inclusion criteria were Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of ≥3 mo, and adequate hematologic, renal, and hepatic function","Key exclusion criteria were symptomatic or untreated central nervous system metastases requiring concurrent treatment; large (≥3 cm) central tumor lesions (located adjacent to or within the hilum or mediastinum) of squamous cell histology unless treated by central irradiation; uncontrolled hypertension; history of arterial or venous thrombosis, bleeding diathesis, pulmonary hemorrhage, gross hemoptysis, or ischemic heart disease; systemic chemotherapy, radiation therapy, or antibody therapy within 14, 21 d, or 6 wk of study enrollment, respectively; or treatment with any anti-VEGF or anti-EGFR therapy.",NA,NA
20927639,NA,Combination,No,advanced solid tumors,"Patients were required to have measurable and histologically confirmed solid tumors; age ≥18 years; life expectancy ≥3 months; Eastern Cooperative Oncology Group (ECOG) performance status score ≤1; adequate hematological function (absolute neutrophil count [ANC] ≥1.5×109/l, platelet count ≥100×109/l and hemoglobin ≥10 g/dl); adequate hepatic function (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ≤2.5 × the upper limit of normal [ULN]; total bilirubin ≤ ULN, alkaline phosphatase [AP] ≤ ULN [if total AP > ULN, the AP liver fraction and/or 5′-nucleotidase and/or gamma glutamyltransferase were required to be within normal limits] and albumin ≥2.5 g/dl); and adequate renal function (creatinine ≤1.2 mg/dl or creatinine clearance ≥50 ml/min).","Patients were excluded if they had received any chemotherapy, radiotherapy (wide-field with >25% bone marrow reserve) or any other pharmacological treatment within 4 weeks prior to inclusion (within 6 weeks if the regimen contained mitomycin C or nitrosurea); were pregnant or lactating women, fertile patients not using effective contraceptive methods; had serious non-malignant medical condition (i.e., active uncontrolled infection, hearing problems, significant liver, cardiac or renal impairment, presence of neurological or psychiatric disorders, or brain or leptomeningeal involvement); received previous treatment with trabectedin; or had peripheral neuropathyexceeding National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade 1.",during the first cycle of treatment,NA
21035955,NCT00721292,Combination,No,RECURRENT MALIGNANT GLIOMAS,"Patients were eligible for the study if they were adults (>18 years) with histopathologically confirmed malignant gliomas (World Health Organization Grade 3 or 4) with radiographic evidence of recurrence on post-contrast magnetic resonance imaging (MRI) after initial surgery, chemotherapy, and radiation therapy. An interval of >=3 months was required since prior radiation therapy. Prior chemotherapy was allowed, except with anti-VEGFR and/or anti-EGFR agents. At the time of recurrence, reresection was recommended if it was feasible. Contrast-enhancing tumor had to be #6 cm in largest diameter without abutment of the brainstem, optic chiasm or optic nerves. Patients had to have a Karnofsky performance score of >= 60, and have an estimated survival of at least 3 months. Patients were required to have normal bone marrow and organ function (hemoglobin >=10 g/dL, absolute neutrophil count >=1500/uL, platelets >= 100,000/uL, blood urea nitrogen <= 25 mg/dL, bilirubin <=2.0 mg/dL, and AST and ALT <= twice the upper limit of normal).","The use of any concomitant medication that may cause QTc prolongation, induce Torsades de Pointes or induce CYP3A4 function was not allowed. Patients who were taking enzyme-inducing anticonvulsant drugs were asked to consult their neuro-oncologist and switch to non-enzyme-inducing anticonvulsant drugs at least 7 days before enrollment. Patients with severe or uncontrolled systemic disease, a history of prolonged QTc interval, clinically significant cardiac disease, or clinically active interstitial lung disease were excluded. Patients were excluded if they had any major surgery or wound healing complication within the previous 4 weeks.",NA,NA
19531625,NA,Combination,No,Malignant SolidTumors,"Patients were eligible if they had a histologically or cytologically confirmed solid tumor and a metastatic tumor accessible for biopsy. Other eligibility criteria included age >= 18 y, WHO performance status <= 2, and an estimated life expectancy z3 mo. Previous chemotherapy had to be discontinued for at least 4 wk before entry into the study or 6 wk in the case of mitomycin C or nitrosourea. Patients had to have acceptable hematologic blood values (WBC >=3.5 x 109/L, absolute neutrophil count >= 1.5 x 109/L, platelets >= 100 x 109/L, hemoglobin level >= 9.0 g/dL), as well as acceptable renal and hepatic functions [creatinine clearance >= 60 mL/min, serum bilirubin <= 1.5 times the normal upper limit, and aspartate aminotransferase and alanine aminotransferase <= 2 times the normal upper limit (or <= 5 times the normal upper limit in the presence of hepatic metastases)]. The study protocol was approved by the Medical Ethics Committee of the hospital and all patients had to give written informed consent",NA,during the first treatment cycle,NA
19390943,NA,Combination,No,non-small cell lung cancer previously treated with platinum-based chemotherapy,"The ethics review boards at the Hokkaido University School of Medicine and KKR Sapporo Medical Center approved this study. Eligibility criteria were: (1) histological or cytological evidence of NSCLC; (2) prior administration of fi rstline platinum-based chemotherapy; (3) an interval of at least 4 weeks after the last administration of agents from the prior chemotherapy; (4) no prior administration of amrubicin or vinorelbine; (5) stage IIIB or IV disease; (6) measurable or assessable disease; (7) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; (8) age 20 to 75 years, with white blood cell (WBC) counts of more than 4 × 109/l, hemoglobin (Hb), more than 9.5 g/dl, platelet (PLT) counts of more than 100 × 109/l, bilirubin less than 1.5 mg/dl, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than twice upper limits of normal, creatinine less than 1.5 mg/dl, and PaO2 more than 70 Torr; (9) anticipated survival 3 months or more; and (10) provision of written informed consent","Exclusion criteria were: (1) serious concomitant systemic disorders including severe heart failure, uncontrollable angina, hypertension, diabetes mellitus, interstitial pneumonia, active infection, ulcer, or another primary malignancy; (2) history of severe hypersensitivity; and (3) pregnancy.",NA,NA
21397973,NA,Combination,No,locally advanced non-small cell lung cancer,"Previously untreated patients with histologically confirmed locally unresectable stage IIB, IIIA or IIIB NSCLC were eligible. Patients were ≤75 years old and had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1 and measurable or assessable disease. Patients were required to have adequate bone marrow function (white blood cell count ≥4000/mm3, hemoglobin count ≥9.5 g/dl, platelet count ≥100,000/mm3), renal function (serum creatinine ≤2 times upper limit of institutional normal), liver function (aspartate aminotransferase and alanine aminotransferase ≤2 times upper limit of institutional normal, total bilirubin ≤1.5 mg/dl) and pulmonary function (arterial blood gases PaO2 ≥70 Torr).","Exclusion criteria were any of the following: (i) poorly controlled medical conditions, (ii) a history of other active malignancies, (iii) severe drug allergy, (iv) known hypersensitivity to the study drug or polioxyethilene, or (v) pregnancy or lactation",NA,NA
18621626,NA,Combination,No,Patients with Non–Small-Cell Lung Cancer,"Patients naive to chemotherapy aged 18-75 years with histologically or cytologically confirmed metastatic (excluding metastases to the brain or meninges), locally recurrent, or unresectable locally advanced NSCLC (stage IIIB/IV) were eligible for this study. Patients were required to have an Eastern Cooperative Oncology Group performance status (PS) of 0/1, a life expectancy of ≥ 15 weeks, and could not have received radiation therapy within 4 weeks of study entry. Patients were also required to have normal electrocardiogram (ECG), blood pressure, and heart rate and no serious or concurrent diseases or active, uncontrolled infection. Those with unstable cardiac disease were excluded from enrollment.",Excluded from study entry were patients receiving investigational drugs or a drug known to cause major organ toxicity or liver enzyme abnormalities within the past 3 months. Patients with preexisting peripheral neuropathy grade ≥ 1 (National Cancer Institute Common Toxicity Criteria [NCI-CTC]) were excluded,from the first 2 weeks of the first cycle,NA
18166842,NA,Combination,No,Stage III Non-small Cell Lung Cancer,"Eligibility criteria included previously untreated, histologically or cytologically confirmed stage IIIA or IIIB NSCLC (1997 American Joint Committee on Cancer). Additional eligibility requirements included Cancer and Leukemia Group B (CALGB) performance status (PS) of 0, 1, or 2 and measurable or evaluable disease. Pretreatment staging evaluation included a complete history and physical examination, complete blood count, and complete metabolic panel. Prestudy radiographs included posterior-anterior (PA) and lateral chest x-rays, a chest computed tomography (CT) scan including the liver and adrenal glands, a head CT, and a bone scan. Surgical resectability was determined by thoracic surgeons before registration. Laboratory measures required at study entry included white blood count >3500/l; absolute neutrophil count (ANC)>= 1500/l; hemoglobin > 10 g/dl; platelet count > 100,000/l; blood urea nitrogen < 1.5 times the institutional limit of normal; creatinine <=1.5mg/dl or creatinine clearance >= 50 ml/min[Cockcroft]; bilirubin <= 1.5 times the institutional limit of normal; and serum glutamicoxaloacetic transaminase < 2 times the institutional limit of normal.","Patients were excluded if they had a pleural effusion involving more than one third of the respective hemithorax or was cytologically positive. Patients were excluded if they had a serious medical or psychiatric illness which might complicate or interfere with chemotherapy or radiation administration, were taking phenytoin, phenobarbital, or other antiepileptic prophylaxis, or were pregnant or lactating. Patients could not have any additional active malignancy or malignancy within 3 years excluding nonmelanoma skin cancer. Patients were not permitted to have undergone previous chemotherapy or radiotherapy for NSCLC. Patients with a known history of Gilbert syndrome were excluded because these individuals may experience excessive irinotecan-induced toxicity.","when administered in combination with paclitaxel, carboplatin, and concomitant chest radiotherapy",NA
18802151,NA,Single Drug,No,Relapsed or Refractory Pediatric Solid Malignancies,"Eligibility criteriaincluded patient age of 6months to 21 years; histologic or cytologic diagnosis of solid malignancy; two or more previous lines of chemotherapy and/or no effective treatment available; life expectancy>=6 weeks; no concomitant anticancer or investigational drug;Eastern Cooperative Oncology Group performance status <= 2 or Lansky play score more than 50%; completion of anticancer therapy >= 4 weeks before study entry; no clinical evidence of peripheral sensory or motor neuropathies; adequate bone marrow; AST/ALT <= 2.5x the upper limit of normal (ULN); bilirubin <= 1.5x the ULN; creatinine less than 3x the ULN for age; no organ toxicity, including ototoxicity grade >= 2; and informed consent signed. The protocol was approved by institutional review board/independent ethics committee.",NA,during cycle 1,NA
20623160,NA,Combination,No,advanced solid tumors or lymphomas,"Patients were adults diagnosed with metastatic or unresectable malignant solid tumors or lymphomas for which no standard therapy would reasonably be expected to result in cure or palliation; recovered from any toxicity derived from previous treatments (except for alopecia or grade <2 symptomatic peripheral neuropathy); performance status (ECOG) score ≤2; life expectancy ≥3 months; adequate organ function [platelet count ≥100×109/l, hemoglobin ≥9.5 g/dl and absolute neutrophil count (ANC)≥1.5×109/l; aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤2.5× the upper limit of normal (ULN) (5×ULN in the event of extensive liver metastases); total bilirubin≤1.5×ULN; alkaline phosphatase (AP)≤2.5×ULN; creatinine clearance ≥40 ml/min or creatinine ≤1.4 mg/dl; creatine phosphokinase (CPK)≤2.5×ULN; albumin ≥2.5 g/dl; partial thromboplastin time ≤1.1×ULN; international normalized ratio ≤1.1 (unless due to oral anticoagulants)], and left ventricular ejection fraction (LVEF) within normal limits.","Patients were excluded if they had received prior therapy with plitidepsin, with any investigational product within 30 days prior to inclusion, or any antitumor therapy within 4 weeks prior to inclusion (8 weeks in case of extensive radiotherapy, or 6 weeks in case of mitomycin C or highdose chemotherapy); if their disease had progressed while on a prior carboplatin-based chemotherapy; if they had evidence of progressive central nervous system (CNS) metastases or any symptomatic brain or leptomeningeal metastases; were pregnant or lactating women, or men and women not using effective contraceptive methods; had a history of other relevant disease or adverse clinical conditions, or known hypersensitivity to plitidepsin, carboplatin, or excipients.",during the first cycle,NA
20647930,ACTRN12609000790246,Combination,No,Patients with advanced cancer,"Patients with advanced cancer, refractory to standard chemotherapy regimens, were eligible for participation in this trial if they fulfilled the inclusion/exclusion criteria and signed a written informed consent. Key inclusion criteria included age between 19 and 75 years, performance status 0–2 on the WHO scale, a life expectancy of at least 12 weeks, and no residual toxicity from earlier therapy. Adequate reserves of bone marrow, hepatic, and renal functions were also required, as documented by a white blood cell count of greater than or equal to 3.5 x 109/l, an absolute neutrophil count of greater than or equal to 1.5 x 109/l, platelet count of greater than or equal to 150 x 109/l, total serum bilirubin of less than or equal to 1.5 mg/dl, serum transaminases of less than or equal to 2 x upper normal limit unless attributed to liver metastases, and serum creatinine no greater than 1.4 mg/dl","Exclusion criteria were serious chronic illnesses, such as congestive heart failure, unstable angina pectoris, chronic bowel disease, and significant neurologic or psychiatric disease, symptomatic peripheral neuropathy, active or uncontrolled infection, pregnant or nursing women, and earlier abdominal or pelvic radiotherapy.",NA,NA
20107803,NA,Combination,No,recurrent or refractory brain or spinal cord tumors,"Between June, 1999, and September, 2001, 17 patients with advanced or recurrent histologically proven primary or metastatic central nervous system malignancies were entered on this phase I trial. The tumor must have been unresponsive to previous chemo- or radiotherapeutic regimens, or have no deWned “standard” chemotherapeutic regimen. Patients were required to have a Karnofsky performance status of greater than or equal to 50% and age greater than or equal to 18 years, and an expected survival of at least 1 month. Adequate renal function was deWned as serum creatinine <=1.5 mg/dl. Adequate bone marrow function for enrollment was deWned as a total white count >= 4,000/l or absolute neutrophil count >= 2,000/dl, and platelet count >= 150,000/l. Adequate hepatic function was deWned as serum bilirubin > 1.5 mg/dl, and SGOT and SGPT within twice the institutional upper limit of normal. Prior radiation or chemotherapy must have been completed at least 4 weeks prior to beginning treatment on this protocol. Ongoing steroid or anti-convulsant therapy was not an exclusion for entry on this study; however, patients must have been on a stable dose for 2 weeks prior to beginning therapy. There was no limit on the number of prior courses of chemotherapy or radiotherapy. Female patients could not be pregnant. All patients gave their voluntary informed consent and signed a consent document that had been reviewed and approved by the City of Hope National Medical Center Clinical Protocol Review Monitoring Committee and Institutional Review Board.",NA,NA,NA
19096311,NA,Combination,No,Patients with Favorable Prognosis Inoperable Stage IIIA/B Non-small Cell Lung Cancer,"The detailed patient characteristics are listed in Table 1. Eligibility stipulated unresectable loco-regionally advanced NSCLC without evidence of hematogenous metastases, Stages IIIA, or IIIB, Zubrod performance status 0 –1, and weight loss < 10% in the 3 months before diagnosis. Additional eligibility criteria included forced expiratory volume in 1 second (forced expiratory volume in the 1 second >= 1000 ml); no pleural effusion on chest radiograph unless it appeared only after a thoracotomy or other invasive procedure thoracic procedure; serum creatinine level <= 1.5 mg/dl, hemoglobin >= 8.0 g/dl, absolute granulocyte count >= 2000/l, platelets >= 100,000/l, serum bilirubin 1.5 mg/dl and SGOT >= 1.5 times the upper limits of normal (unless caused by documented benign disease). All patients signed a studyspecific consent form in accordance with local institutional review board and national regulatory guidelines.","Ineligibility criteria included evidence of small cell histology; Stage I, II, or IV NSCLC; complete or subtotal tumor resection; any synchronous or prior invasive malignancy (except nonmelanomatous skin cancer) unless disease free for >=3 years; prior chemotherapy or thoracic/neck radiation therapy; patients with myocardial infarction within 6 months or symptomatic heart disease; and pregnant status for women.",NA,NA
21140147,NA,Combination,No,advanced solid tumors,Patients C18 years with advanced solid tumors refractory to standard therapy or for which no curative therapy exists were eligible if they were considered suitable for treatment with standard doses of carboplatin and paclitaxel and had a life expectancy of >=12 weeks. A maximum of two prior chemotherapy regimens was permitted. Additional inclusion criteria included an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 and adequate organ function.,"Exclusion criteria included prior treatment with high-dose chemotherapy requiring stem cell rescue or prior irradiation to >= 25% of bone marrow; and surgery, systemic therapy, or any investigational agent within 4 weeks prior to starting study treatment (except palliative radiotherapy). Other exclusion criteria included history of untreated brain metastases and severe acute or chronic cardiovascular abnormalities.",during the first cycle,NA
21447615,NA,Combination,No,advanced solid tumors,"Eligibility criteria for admission to the study included the following: histologically confirmed solid tumor not curable by standard therapies, for which treatment with CP was a reasonable therapeutic option; age ‡18 years; written informed consent; Eastern Cooperative Oncology Group (ECOG) performance status of one or less; two or less prior chemotherapy regimens; absolute granulocytes >=1.5 x 109/l, platelets >= 100 x 109/l, bilirubin <1.5 x upper normal limit (UNL), alanine aminotransferase/ aspartate aminotransferase (AST) <3 x UNL (<5 x UNL if liver metastases present); creatinine clearance >50 ml/min (Cockcroft–Gault formula).",NA,in cycle 1,NA
17278895,NA,Combination,No,Nonsmall Cell Lung Cancer,"Eligible patients were required to have: histologically and/or cytologically proven unresectable stage IIIB or IV NSCLC; no previous chemotherapy or radiotherapy; a performance status (PS) of 0 –2 on the ECOG scale if they were between 70 and 79 years, or a PS of 0 –1 on the ECOG if they were>=80 years; a life expectancy of >=12 weeks; adequate bone marrow reserve (leukocyte count >= 4000/mm3, neutrophil count >= 2000/mm3, platelet count >= 100,000/mm3, and hemoglobin >= 10 g/dL); normal liver function total serum bilirubin <= 1.5 mg/dL, and aspartate transaminase (AST), alanine transaminase (ALT) less than twice the upper limit of the normal range and normal renal function (serum creatinine <= 1.5 mg/dL and creatinine clearance >= 60 mL/min).","Patients with concomitant malignancy, central nervous system metastases, active infectious diseases, or other serious medical problems were ineligible. ",during the first chemotherapy cycle,NA
16047343,NA,Combination,No,Patients with Advanced Ovarian Carcinoma who Previously Received Platinum-Containing Chemotherapy,"Patients were enrolled in the study if they fulfilled the following eligibility criteria: 1) histologically proven ovarian carcinoma; 2) prior platinum-containing chemotherapy, whether in platinum-sensitive or platinum-resistant patients19; 3) life expectancy >= 3 months; 4) age 15 years or older but younger than 75 years; 5) an Eastern Cooperative Oncology Group performance status < 2; 6) adequate bone marrow and organ function (leukocytes >= 4000/L, neutrophils >= 2000/L, platelets >= 100,000/L, total bilirubin >= 1.5 mg/dL, serum transaminase levels not more than 2.5 times the upper limit of normal, serum creatinine >= 1.5 mg/dL); 7) having measurable lesions was not required; and 8) written informed consent. This study was approved by the Institutional Review Board of the National Cancer Center Hospital.","Patients who had active infection, bowel obstruction, interstitial pneumonitis, severe heart disease, or a past history of hypersensitivity to antitumor drugs were excluded from the study. Patients who had pleural effusion or ascites that required drainage, brain metastasis, or active concomitant malignancy also were excluded.",in the first cycle,NA
17409916,NA,Combination,No,Elderly Patients with Small-Cell Lung Cancer,"Patients aged 70 years or older with histologically confirmed SCLC who had never received chemotherapy or radiotherapy were enrolled in this study. Other eligibility criteria included Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1, and estimated life expectancy >= 12 weeks. Laboratory requirements included hemoglobin >=9 g/dL, white blood cell count >=4,000/mm3, absolute neutrophil count >=2000/mm3, platelets >100,000/mm3, serum bilirubin >= 1.5 times the institutional upper limit of normal, aspartate transaminase (AST) and alanine aminotransferase (ALT) 100 international unit (IU)/L, and creatinine clearance >= 40 mL/min.",Patients with symptomatic brain metastasis or severe comorbidity were excluded.,during the first cycle,NA
15737558,NA,Combination,No,advanced ovarian cancer,"Women with histologically proven International Federation of Gynecology and Obstetrics (FIGO) stage IIB-IV epithelial ovarian carcinoma were eligible. Other inclusion criteria were: no prior chemotherapy, no concurrent other anti-tumour or investigational therapy; Eastern Cooperative Oncology Group (ECOG) performance status less than 3; age over 18 years; life-expectancy more than 6 months; adequate bone marrow function with an absolute neutrophil count (ANC) > 1.5 x 109/l or leukocyte count > 3.0 · 109/l and platelet count >100 · 109/l; serum bilirubin < 1.5 x upper normal limit (UNL); alkaline phosphatase and alanine aminotransferase (ALAT) < 2 x UNL; serum creatinine < 1.5 x UNL and a creatinine clearance > 1 ml/s.","Patients were excluded with previous or concomitant malignancies, bowel obstruction or massive ascites. Patients with peritoneal adhesions, which prevented homogeneous distribution of i.p. fluid, were excluded.",during the first cycle,NA
17881149,NA,Combination,No,ADVANCED ESOPHAGEAL CARCINOMA,"Eligible patients were 18 years or older with previously untreated histologically confirmed adenocarcinoma or squamous cell carcinoma of the thoracic esophagus or GE junction, for which chemotherapy and RT were indicated. Patients were required to have bidimensionally measurable disease, Karnofsky performance status of 70 or higher, and life expectancy of 3 months or longer. Baseline laboratory requirements were as follows: absolute neutrophil count of 1,500/ml or greater, platelets of 100,000/ml or greater, total bilirubin level of 1.5 mg/dl or less, serum creatinine level 1.5 times the upper limit of normal or less, and aspartate/alanine aminotransferase levels 2.5 times the upper limit of normal or less.","Patients with distant metastases were eligible, with the exception of brain metastases, carcinomatous meningitis, or lymphangitic lung metastases. Other exclusion criteria were radiographic or bronchoscopic evidence of esophageal perforation, serious underlying medical conditions that would impair the ability to receive protocol treatment, tumor extension above the thoracic inlet or 4 cm distal to the GE junction, or previous chemotherapy or RT.",during or up to 2 weeks after completion of chemoradiotherapy,NA
16203659,NA,Combination,No,Extensive Stage Small Cell Lung Cancer,"Eligible patients had histologically or cytologically confirmed SCLC and evidence of extensive-stage disease defined as either disease not encompassed in a reasonable radiation port or extrathoracic disease. Patients could have either measurable or evaluable disease, and had to meet the following criteria: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–2; no prior chemotherapy; absolute neutrophil count >1500/mm3; hemoglobin >9 gm/dl; platelet count >100,000/mm3; total bilirubin; AST and ALT each <3 times the upper limits of normal; and serum creatinine <1.6 gm/dl or calculated (i.e., Cockcroft-Gault) creatinine clearance >40 ml/min.","Exclusion criteria were: previous or concurrent malignancy (except nonmelanoma skin cancer, in situ carcinoma of the cervix or breast, or other cancer if the patient has been disease-free for 5 five years); a serious medical or psychiatric illness preventing informed consent; or survival limited to less than 2 months. Prior radiation was allowed at the discretion of treating physician",during Cycle 1 ,NA
16463061,NA,Combination,No,elderly (‡75 year-old) patients with small-cell lung cancer,"Patients, 75 years or older, with any stage of SCLC were enrolled. Tumor staging was performed on the basis of a complete medical history and physical examination, routine chest radiography, bone scintiscanning, computed tomography (CT) of the chest and abdomen, magnetic resonance imaging or CT of the head, and bronchoscopy. Staging was performed according to the tumor node metastasis system . Eligibility criteria included the following: histologically or cytologically confirmed SCLC; no previous chemotherapy; measurable or assessable disease; age >= 75 years with a performance status (PS) of the Eastern Cooperative Oncology Group (ECOG) of 0–2; adequate hematologic function (leukocyte >= 3,500/ll, hemoglobin >= 9.0 g/dl, platelet count >= 100,000/ll), hepatic function (total bilirubin <= 1.5 mg/dl, ALT, and AST levels £ double the normal upper limit) and renal function (serum creatinine <= 1.5 mg/dl); no serious cardiac or pulmonary dysfunction (PaO2 >=70 torr); no other serious illness; no concomitant malignancies; and the ability to provide informed consent.",NA,NA,NA
17882655,NCT00117572,Combination,No,Locally Advanced Head and Neck Cancer,"Eligible patients were ≥18 years old, with a previously untreated, pathologically confirmed diagnosis of squamous cell or poorly differentiated carcinoma. Only patients with AJCC (6th edition) Stage IV (a/b) oral cavity, pharynx, and larynx; Stage III or IV (a /b) cancer of the nasopharynx, base of the tongue, and hypopharynx; and Stage IV (a/b) HNC presenting with cervical lymph node metastasis of an unknown primary were eligible.  Screening was performed by CT scan of the head and neck, the chest, and the upper abdomen. Equivocal lesions were biopsied when feasible. PET scans were not routinely performed. Prior surgical therapy was allowed as long as it consisted only of a biopsy or organ-sparing procedure. An ECOG performance status ≤2, no existing peripheral neuropathy >Grade 1, and normal organ and marrow function as defined by hemoglobin >8.0 g/dl, absolute neutrophil count ≥1.500/µl, platelet count ≥100,000/µl, albumin >2.9 g/dl, and creatinine and liver enzymes within the normal range were required. ",Patients with unequivocal metastatic disease were ineligible although patients with Mx disease were eligible.,NA,NA
16622691,NA,Combination,No,non-small cell lung cancer after prior taxane + platinum-based regimens,"Patients with histologically conWrmed advanced NSCLC, stages IIIA/IIIB and IV, that had relapsed after or progressed on a taxane + platinum-based combination chemotherapy regimen and had never received GEM and camptothecin analogues (CPT-11 or topotecan) were candidates for the present study. Eligibility included: (1) histologically conWrmed NSCLC in relapse not potentially curable by surgery and or radiotherapy, (2) WHO performance status (PS) · 2, (3) life expectancy ¸ 3 months, (4) adequate hematopoietic [absolute neutrophil count (ANC) > 1,500/ul, platelet count (PLT) > 100,000/ul], liver [bilirubin < 1.5 mg/dl, AST/ALT < 2£ upper normal limit (nl), unless caused by tumor and serum albumin > 3.0 g/dl] and renal function (BUN and creatinine < 1.5 nl; nl=1.5 mg/dl in our laboratory or creatinine clearance > 50 ml/min), (5) progression after or during prior chemotherapy with a taxane + platinum analogue-based regimen; docetaxel–ifosfamide–cisplatin (DIP) , docetaxel–ifosfamide–carboplatin (DICb) , docetaxel–carboplatin, paclitaxel–carboplatin, and paclitaxel–ifosfamide–cisplatin (PIC) , (6) absence of active coronary artery disease (in the form of unstable angina or myocardial infarction over the last 12 months), unstable diabetes mellitus, or peripheral neuropathy¸ grade 2 by the NCI-common toxicity criteria (CTC), (7) no prior irradiation to areas encompassing > 30% of marrow-bearing bone, apart for emergency radiotherapy for superior vena cava obstruction, imminent vertebral or weight-bearing long bone fracture as a result of metastatic involvement, or symptomatic rapidly progressive brain metastases and (8) presence of bi-dimensionally measurable with or without evaluable disease sites (however, all patients had to have at least one bi-dimentionally measurable lesion) located outside a previously irradiated Weld, unless deWnite evidence of progression at this site was documented.",NA,during the first chemotherapy cycle,NA
16193241,NA,Combination,No,limited-stage small cell lung cancer,"All patients had histologically or cytologically confirmed LS-SCLC. LS disease was defined as disease that could be entirely encompassed within a tolerable, single radiation port. Patients had to have measurable or evaluable disease, a performance status (PS) of 0–2, and adequate bone marrow, renal, cardiac, and liver function. Patients could not have received prior chemotherapy or biological therapy. All patients gave written informed consent in accordance with institutional and federal regulations.","Patients with extrathoracic metastases, pleural effusions or severe emphysema defined as an FEV 1 < 1.0 liters were excluded.",during cycle 1,NA
15246197,NA,Combination,No,patients with stage III non-small cell lung cancer,"Eligibilitycriteria were as follows: (1) stage IIIA or IIIB non-small cell lung cancer (without a malignant pleural effusion) as defined bythe current AJCC staging system; (2) histologic or cytologic documentation of non-small cell lung cancer, pathologic staging of mediastinal lymph nodes (N2—N3) was required; (3) measurable disease (a lesion which can be clearlymeasured in two dimensions on X-ray, CT scan or MRI) or evaluable disease (such as a pulmonaryinfiltrate which can be followed on X-ray); (4) Eastern Oncology Cooperative Group (EOCG) performance status 0—2; (5) laboratoryparameters: absolute neutrophil count ≥1500/mm3, platelet count ≥100,000/mm3, total bilirubin ≤1.5 × upper limit of normal (ULN), SGOT ≤3 × ULN, creatinine ≥1.5 × ULN, and creatinine clearance ≥50 ml/min; (6) no prior pelvic or thoracic radiation or chemotherapywas permitted; (7) no active infection or other severe complicating medical illness (such as active cardiac ischemia, congestive heart failure, or severe neurologic or psychiatric disease which could interfere with compliance to the treatment regimen); (8) patients were of age ≥18 years; (9) no pregnant or lactating women were allowed to participate; (10) women of child-bearing age and men were advised to use a standard form of contraception; (11) no concurrent malignancy except cervical carcinoma in situ or non-melanoma skin cancer was allowed for studyparticipants; and (12) signed informed consent.",NA,during  during all 6 weeks of concurrent chemoradiotherapy,NA
17634546,NA,Combination,No,Patients with Advanced Cancer,"Patients with advanced cancer who would normally be considered for carboplatin-based chemotherapy were eligible for this study. Patients were permitted to have received up to two prior chemotherapy regimens, including one with carboplatin. Men and women aged >= 18 years were required to have evaluable disease that had been histologically or cytologically confirmed, WHO performance score <= 2, estimated life expectancy >= 3 months, and adequate bone marrow, liver, and renal function, defined as a neutrophil count >1.5 x 109/L, platelet count >= 100 x 109/L, serum alanine aminotransferase or aspartate aminotransferase <2.5 x the upper limit of normal (ULN), serum total bilirubin <1.5 x ULN, serum creatinine <1.5 x ULN, and a glomerular filtration rate >=60 mL/min. All patients were required to give written informed consent","Patients were excluded if they had undergone major surgery <4 weeks before study entry, received any chemotherapy or investigational agent <= 30 days before study entry, received radiotherapy <4 weeks before the start of the study (except for palliative therapy of distant metastases), received radiotherapy to >= 25% of the bone marrow, or had clinical signs of symptomatic brain metastases or leptomeningeal disease. Additional exclusion criteria were previous malignancy <= 5 years from study entry, treatment with warfarin or other agents containing warfarin in doses >= 1 mg/day, and the presence of cardiac disease (New York Heart Association class III or IV), grade >1 unresolved diarrhea, grade >1 neuropathy, acute or chronic uncontrolled infection, hepatitis B or C, or HIV infection.",during the first cycle,NA
15690136,NA,Combination,No,peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors,"Children and young adults 25 years or younger were eligible at diagnosis with glioblastoma multiforme, unresectable anaplastic astrocytoma, metastatic PNETs, and resistant brain tumors with no recognized standard therapy. Relapsed tumors involving the central nervous system of any histology were eligible, with the exception of brain stem gliomas for which high dose therapy has been shown to be ineffectual .","Exclusion criteria included a life expectancy of less than 6 weeks, a Lansky or Karnosky score of less than 50, mediastinal radiation in the prior 3 months and/or a cumulative anthracycline dose of more 350 mg/m2. All patients had a glomerular filtration rate of greater than 70 ml/min/1.73 m2",NA,NA
17523723,NA,Combination,No,Previously Untreated Patients with Extensive-Stage Small Cell Lung Cancer (SCLC),"Patients eligible for inclusion in this study had histologically or cytologically proven extensive stage SCLC, and were chemotherapy- and radio-therapy-naive. Male and female patients, aged between 18 and 75 years, with a WHO-performance status ≤2 and a life-expectancy of ≥3 months could be included. Patients were required to have adequate bone marrow function (leucocyte count ≥4000/mm3 and platelet count ≥120 000/mm3, with the exception of cytopenia in case of bone marrow infiltration). Patients were also required to have renal (serum creatinine) and hepatic function (aspartate aminotransferase [AST], serum alanine aminotransferase [ALT], and bilirubin, with the exception of increased liver enzymes due to liver metastases within the normal range. ","Patients with an additional malignant tumour (with the exception of in situ cervical cancer and basalioma), clinical signs of congestive heart failure and/or acute febrile infections were excluded from the trial. Pregnant or breast-feeding women and women of childbearing age without adequate contraception were also excluded",within 6 weeks after the start of treatment.,NA
15150564,NA,Combination,No,advanced non-small-cell lung cancer,"Patients with histologic or cytologic confirmation of locally advanced or metastatic NSCLC who received either no prior chemotherapy or one previous chemotherapy regimen were eligible. The eligibility criteria were as follows; (1) measurable lesions; (2) age <= 75 years; (3) Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 –1; (4) adequate organ function (a white blood count (WBC) >= 4000 ul-1, a neutrophil count >=2000 ul-1, a platelet count >= 100 000 ul-1, a haemoglobin count >= 9.5 g dl-1, serum total bilirubin <= 1.5 mg dl-1, serum transaminase p2  upper normal limits, a serum creatinine p upper normal limits, blood urea nitrogen (BUN) <= 25 mg dl-1, PaO2 >= 60 mmHg or SpO2 >= 90%]; and (5) normal electrocardiogram (ECG). At least 4 weeks must have passed after the completion of previous therapy and the patients had to have recovered from the toxic effects of previous therapy.","The exclusion criteria consisted of pulmonary fibrosis or interstitial pneumonitis with symptoms or apparent abnormalities on chest X-ray, massive pleural effusion or ascites, acute inflammation, pregnancy, lactation, symptomatic brain metastases, active concurrent malignancies, severe drug allergies, severe heart disease, cerebrovascular disease, uncontrollable diabetes mellitus or hypertension, severe infection, active peptic ulcer, ileus, paralysis intestinal, diarrhoea and jaundice. ",in the first cycle,NA
15007250,NA,Combination,No,Patients with Recurrent Ovarian Cancer after Failure of First-Line Chemotherapy with Paclitaxel and Platinum,"Patients with advanced ovarian cancer who had relapsed after platinumand paclitaxel-containing therapy were eligible for this study. All patients were required to have adequate hepatic, renal, and bone marrow function, with a whole blood count (WBC) ≥4.0 × 109/l; granulocytes ≥2.0 × 109/l; platelets ≥100 × 109/l; hemoglobin ≥9 g/dl, serum bilirubin ≤2.0 mg/dl; SGOT, SGPT and alkaline phosphatase ≤2× the upper limit of the normal range if no liver metastases, ≤3× the normal range if liver metastases were present, serum creatinine ≤15 µmol/l or calculated creatinine clearance ≥60 ml/min. Other inclusion criteria were ≥18 years of age, ECOG performance status ≤2, no known hypersensitivity to compounds chemically related to topotecan or gemcitabine, no presence of any disease capable of modifying the prognosis or likely to require procedures altering the schedule of this trial, and a life-expectancy of at least 3 months. The number of the prior chemotherapy regimens was not limited. ",NA,during the first 4 courses of therapy,NA
15054448,NA,Combination,No,advanced epithelial ovarian cancer,"In all, 17 patients were enrolled into the study between February 2000 and June 2002. All had histologically proven EOC, were aged 18 –65 years, performance status 0 –2, with a life expectancy of > 3 months. Other eligibility criteria were measurable or evaluable disease by RECIST criteria, normal haematological function, adequate renal function (GFR >60 ml min-1 ) and hepatic function (LFTs <2 x ULN). Patients were either previously untreated with stage IV or bulky unresectable stage III disease (10), or had relapsed with a treatment-free interval of > 1 year (7)","Patients were excluded if there was a concurrent malignancy (other than nonmelanoma skin cancer), central nervous system metastases, presence of atypical red blood cell antibodies, hepatitis B surface antigen or anti-hepatitis C antibodies, HIV 1 and 2 antibodies, a previous adverse reaction to carboplatin or paclitaxel or contraindication to the use of platinum",the full cycle of treatment,NA
17498782,NA,Single Drug,No,ovarian carcinoma,"This phase I study performed at the Wake Forest University Baptist Medical Center recruited patients with presumed stage III ovarian carcinoma and was approved by the institutional review board. After informed consent, seventeen patients were enrolled to determine the maximum tolerated dose (MTD) of carboplatin administered intraoperatively as intraperitoneal hyperthermic chemotherapy. The group included both those scheduled for initial cytoreductive surgery as well as second look reassessment surgery. Six patients evaluated for the MTD at second look laparotomy only had previously received standard platinum-based systemic chemotherapy. Eleven newly diagnosed patients undergoing IPHC with initial cytoreductive surgery were also evaluated for tolerability of post-IPHC standard systemic chemotherapy with a taxane and platinum drug combination. Eight patients that received initial IPHC and subsequent systemic chemotherapy underwent second look laparotomy and repeat IPHC. The average patient age was 53 years with all patients having stage III disease. The majority of patients had poorly differentiated serous histology.",NA,during the immediate treatment period,"Using the ThermoChem™ HT System, carboplatin were administered intraoperatively as IPHC with a perfusion time of 90 min at the initial cytoreductive procedure"
16959305,NA,Combination,No,ovarian and peritoneal carcinoma,"Eligible patients had adenocarcinoma of the ovary, peritoneum or fallopian tube diagnosed within 12 weeks and confirmed histologically on GOG Pathology Committee central review. All stages of disease were eligible. Patients could not have had a history of other malignancy, chemotherapy or radiation therapy and were to have a GOG performance status of 2 or better, left ventricular ejection fraction (LVEF) within institutional normal range as determined by gated cardiac radionuclide scan (MUGA) and were to have recovered from prior surgery. Ineligible patients were those having tumors of low malignant potential (borderline tumors), active infection, hepatitis, gastrointestinal bleeding, a history of a myocardial infarction or abnormal cardiac conduction diagnosed within 6 months or unstable angina. All patients provided written informed consent meeting all federal, state and local requirements prior to receiving protocol therapy. Pretreatment laboratory eligibility requirements included the following: leukocyte count ≥3000/μl, platelet count ≥100,000/μl and granulocyte count ≥1500/μl, creatinine ≤2.0 mg%, bilirubin ≤1.5 times the institutional upper limit of normal and SGOT and alkaline phosphatase ≤3 times the institutional upper limit of normal.",NA,the first cycle of chemotherapy,NA
16282248,NA,Combination,No,advanced gynecologic tumors,"Women enrolled in the study had a histological diagnosis of malignancy originating from the ovaries, the Fallopian tube or the uterus. Patients with epithelial ovarian cancer must have completed a platinum-containing chemotherapy regimen for first-line treatment at least 6 months prior to study entry. Women with other malignancies could be either chemotherapynaı¨ve or suffering from relapsed disease after receiving at most one prior treatment. Prior radiation therapy to £25% of the hematopoietic system was permitted, but must have been completed at least 6 weeks before study entry. Hormonal therapy must have been stopped within 10 days of study entry and immunotherapy at least 4 weeks prior to study entry. Enrollment required an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2 or Karnofsky score >60, age ‡18 years, estimated life expectancy >12 weeks, and normal hematologic, renal and hepatic function.","Preexisting National Cancer Institute (NCI) grade 2 motor or sensory neurotoxicity, active infection or other serious medical infection, history of heart disease, or pregnancy were cause for exclusion.",during the first three chemotherapy courses,NA
16115936,NA,Combination,No,Patients with Advanced Malignancies,"Requirements for enrollment in the trial included histologic proof of advanced solid tumor malignancy with no hope of curative, or clearly established life-prolonging, therapy; age >18 years; performance status 0 to 2; life expectancy >3 months; ability to accomplish informed consent; WBC >3,500; ANC >1,700; PLT >100,000; normal direct bilirubin; and creatinine, alkaline phosphotase, aspartate aminotransferase, and alanine aminotransferase <2.5 x UNL","Exclusion criteria included radiation to >25% bone marrow, prior cisplatin or carboplatin therapy; chemotherapy, biological, immunotherapy, or radiotherapy within the past 4 weeks (6 weeks for mitomycin C/nitrosoureas); New York Heart Association class III or IV or history of angina; central nervous system metastases or seizure disorder; pregnancy/lactation; and grade >1 peripheral neuropathy.",NA,NA
15812395,NA,Combination,No,Advanced Refractory Malignancies,"Eligibility was restricted to patients with advanced refractory tumors. Breast cancer patients met >= 1 of the following criteria: tumor progression while receiving chemotherapy, no response after >= 2 lines of chemotherapy for metastatic disease, unresponsive liver metastases, asymptomatic central nervous system (CNS) disease, relapse within an irradiated field, or prior HDC. Patients with ovarian carcinoma had large-volume disease after second-line chemotherapy, >= 3 prior chemotherapy regimens, chemorefractory disease, or unresponsive parenchymal liver disease. Patients with non-Hodgkin lymphoma (NHL), Hodgkin disease (HD), or germ cell tumors (GCTs) were eligible if they had experienced no response or progression after second-line chemotherapy. Chemorefractory patients with other diagnoses were eligible. General physical criteria included full recovery from the acute toxic effects of prior therapy, a performance status of 0 or 1, and acceptable end-organ performance: creatinine clearance > 60 mL/min, left ventricular ejection fraction >45%, diffusion capacity of carbon monoxide and forced expiratory volume in 1 second >60% of predicted, liver function tests (aspartate aminotransferase, alanine aminotransferase, and bilirubin) < 2 times their upper normal limits, and acceptable bone marrow function, with a white blood cell count of >3000/mm3, absolute neutrophil count > 1000/mm3, and platelet count >100 000/mm3. Previous cumulative doxorubicin exposure was limited to 450 mg/m2. Prior treatment with docetaxel, melphalan, or platinum compounds was allowed.",NA,NA,NA
17950919,NA,Combination,No,Patients with Advanced Refractory Tumors,"Eligibility was restricted to patients with advanced cancers refractory to standard chemotherapy. Patients with breast cancer met at least 1 of the following criteria: tumor progression while on chemotherapy, no response after 2 or more chemotherapy regimens for metastatic disease, unresponsive liver metastases, relapse within an irradiated field, or prior HDC. Patients with non-Hodgkin lymphoma (NHL) or germcell tumors were eligible if their disease was refractory to first-line or salvage chemotherapy. Patients with Hodgkin disease were required to be in refractory relapse. Patients with other chemorefractory diseases were also eligible. Pretransplant staging tests included chest, abdomen, and pelvis CT scans, head MRI, bone scan, and bilateral bone marrow aspirate and biopsies. In addition, a positron emission tomography (PET)/CT was performed in HL and NHL patients. General physical inclusion criteria were full recovery from acute toxic effects of prior therapy, performance status of 0 to 1, and acceptable end-organ performance, defined as the following: creatinine clearance >= 60 mL/min, left ventricular ejection fraction (LVEF) >= 45%, diffusion capacity of carbon monoxide (DLCO) and forced expiratory volume 1.0, >= 60% of predicted, liver function tests (aspartate transaminase, alanine transaminase and bilirubin levels) 2 times their upper normal limits, and acceptable bone marrow function (white blood cell count >= 3000/mm3 with absolute neutrophil count >= 1000/mm3 , and platelet count >= 100,000/mm3). The previous cumulative doxorubicin dose was limited to 450 mg/m2. Any prior treatment with docetaxel, gemcitabine, melphalan, or carboplatin was allowed. Apheresis of a minimum of 1 million CD34 cells/kg after peripheral blood progenitor cell (PBPC) mobilization with granulocytecolony stimulating factor (G-CSF), with or without chemotherapy, was required.",NA,NA,NA
17285317,NA,Combination,No,patients with solid tumors,"Adults with advanced solid tumors, which had progressed on standard therapy or for which there was no standard therapy, were eligible for inclusion in this study. Eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of zero to two, an absolute neutrophil count (ANC) >= 1.5 x 109 L-1, platelet count ¸100 £ 109 L¡1, and hemoglobin concentration >= 8.0 g/dL. Adequate renal function, deWned as a serum creatinine in the normal range or a Cockcroft-Gault calculated creatinine clearance of ¸60 mL/min, and hepatic function, deWned as hepatic transaminases <= 2.5 upper limit of normal and total bilirubin within the normal range, were required","Patients were not eligible if they had received chemotherapy, radiation therapy, or immunotherapy for treatment of malignancy within 3 weeks. No limit was set on the number of previous therapies, and patients with previous exposure to taxanes were eligible for the study. Patients were required to have evaluable disease by RECIST  or disease that was evaluable by tumor markers.",during the first cycle,NA
17049403,NA,Combination,No,patients with extensive stage small cell lung cancer,"The eligibility criteria included: age ≥18 years; Eastern Cooperative Oncology Group (ECOG) performance status 0—2; and life expectancy >2 months. Females had to be non-pregnant and non-nursing because of significant risks to the fetus or infant. No prior chemotherapy was allowed. Prior radiation was only allowed for brain metastasis, but patients had to be neurologically stable. The required laboratory values at entry included: absolute neutrophil count (ANC) ≥1500/l; platelet count ≥100,000/l; serum creatinine ≤1.5 mg/dl; and total bilirubin ≤1.5 mg/dl. Patients had to be able to swallow capsules because treatment depended on their compliance with oral topotecan and etoposide. Other serious medical or psychiatric illness precluded participation in this trial.",NA,in the first treatment course,NA
15589596,NA,Combination,No,primary cervical cancer,"Patients were considered eligible for this study if they were 18 years of age or older with primary, previously untreated, histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous of the uterine cervix, FIGO clinical stage IB2 to IVA, and had negative paraaortic nodes determined by lymphangiogram, CT/MRI or staging lymphadenectomy, adequate bone marrow, renal and hepatic function, a GOG Performance Status of <= 2, and life expectancy of >= 3 months. In addition, laboratory criteria for entry included white blood cell count >= 3000/mm3, absolute granulocyte count >= 1500 mm3, platelets >= 100,000 mm3, total bilirubin <= 1.5 times upper normal limit, serum creatinine < 1.5 times upper normal limit, AST or ALT <= 2.5 times upper normal limit, serum calcium <= 1.3 times upper normal limit, and alkaline phosphatase <= 2.5 times upper normal limit. Patients with Stage IB1 disease were allowed to participate if they had histologically metastatic pelvic nodal disease, negative para-aortic nodes, and did not undergo hysterectomy. Patients with enlarged para-aortic nodes were required to have biopsy-documented negative histology before entry.","Patients who were pregnant or lactating, had a concurrent invasive malignancy, with the exception of nonmelanomatous skin cancer, or who had a previous history of hysterectomy, cervical cancer, pelvic radiotherapy, or cytotoxic chemotherapy were excluded from participation in this study.",during treatment and at 30 days postchemotherapy,NA
16421427,NA,Combination,No,Refractory Neuroblastoma,"Patients with high-risk neuroblastoma who were age 1 to 21 years at diagnosis were eligible if they had poorly responding neuroblastoma, defined as stable disease or partial response at the end of at least 12 weeks of any induction therapy; bone marrow containing greater than 100 tumor cells per 105 mononuclear cells by immunocytology after 12 weeks of induction therapy,2 or progressive disease at any time. All patients were required to have demonstrated MIBG uptake in the skeleton or soft tissue tumor. Patients were required to have hematopoietic stem cells without detectable tumor by immunocytology, or to have no tumor in bone marrow by routine morphology before peripheral-blood stem-cell (PBSC) collection. Patients had normal organ function and glomerular filtration rate (GFR) of >= 60 mL/min/1.73 m2.",Patients who had undergone prior myeloablative therapy were excluded.,NA,NA
15249718,NA,Combination,No,Small Cell Lung Cancer,"Patients with histologically or cytologically confirmed SCLC (extensive disease) were eligible for treatment within this trial. Eligibility criteria included no prior chemotherapy, life expectancy of >3 months, age ≤75 years, Karnofsky index ≥60%, measurable lesions, adequate hematologic function (leucocyte count > 4,000/mm3, platelet count > 100,000/mm3, hemoglobine > 9 g/dl), no severe hepatic or cardiac dysfunction. A decreased renal function was allowed, if serum creatinine was ≤2.0 mg/dl. The trial was approved by the local ethics committee",NA,NA,NA
17921708,NA,Combination,No,Frail Patients With Advanced Non-Small Cell Lung Cancer,"Patients with unresectable clinical stage IIIB or IV NSCLC, no prior chemotherapy, an EGOG performance status (PS) of 0 to 2, and have a life expectancy of >= 12 weeks, and age of 20 years or more, were enrolled in this study (Table 1a). We defined the eligibility criteria for frail patients in this study (Table 1b). The criteria were as follows: (A) age > 80 years with PS 0 or 1 and adequate organ function; (B) < age 80 years with PS 2 and adequate organ function; and (C) < age 80 years with PS 0 or 1 and one inadequate organ function of bone marrow, liver or kidney. Adequate bone marrow reserve (leukocyte count > 4000/L, neutrophil count > 2000/L, platelet count > 100,000/L, and hemoglobin > 10 g/dL); normal liver function (total serum bilirubin < 1.5 mg/dL, and aspartate transaminase AST, alanine transaminase ALT: less than the upper limit of the normal range) and normal renal function (serum creatinine < 1.5 mg/dL and creatinine clearance (CCr) > 60 mL/min).","Inadequate organ functions were as follows: inadequate bone marrow reserve (leukocyte count > 3000/L, neutrophil count > 1500/L, platelet count >75,000/L, and hemoglobin > 8 g/dL; inadequate liver function (total serum bilirubin less than 1.5 times normal and AST, ALT: less than 2.5 times normal), inadequate total bilirubin: < 1.5 times normal, inadequate albumin: > normal-1.5 g/dL, inadequate renal function serum creatinine: < 1.7 mg/dL and CCr > 30 mL/min. Patients with concomitant malignancy, central nervous system metastases, active infections disease, or other serious medical problems were ineligible.",in the first cycle,NA
17326096,NA,Combination,No,Patients With Solid Tumors,"Patients with a histologically or cytologically confirmed diagnosis of a malignant solid tumor that was refractory to standard chemotherapy or patients for whom no established standard chemotherapy existed were eligible to participate in the current study. Less than or equal to 2 prior chemotherapy regimens were allowed, and prior adjuvant or neoadjuvant therapy counted as 1 of those regimens. Additionaleligibility criteria included the following: age >= 18 years, an Eastern Cooperative Oncology Group performance status of 0 or 1; an estimated life expectancy >= 2 weeks; the ability to comply with study treatment and follow-up; adequate hematopoietic function (absolute neutrophil count >= 1.5 x 109/L, platelet count >= 100,000 x 106 /L, and hemoglobin >= 9 g/L), hepatic function (total bilirubin <1.5, alanine transaminase [ALT] or aspartate transaminase [AST] <3 times normal [ALT and AST could be elevated up to 5 times normal in patients with known metastatic disease in the liver]), and renal function (creatinine <= 2.0 mg/dL); childbearing potential either terminated by surgery, radiation, or menopause or attenuated by use of an approved contraceptive method (intrauterine device, birth control pills, or barrier device) during and for 3 months after the trial; negative urine pregnancy tests in women; no known central nervous system metastasis or uncontrolled seizure disorder; no intercurrent illness; no active infection; and no second primary malignancy within the past 5 years (except for carcinoma in situ of the cervix or adequately treated basal cell carcinoma of the skin).",NA,during the first cycle,NA
16377585,NA,Combination,No,Patients with Advanced Solid Tumors,"Patients with histologically proven solid tumors refractory to conventional treatment and for whom no conventional therapy was available were eligible for this Phase I, single-center study. Additional eligibility criteria include: age 18 or older;ECOG performance status 0–2; and acceptable bone marrow, renal, hepatic, and neurologic function.","Patients were excluded for active brain metastasis, infection, and organ malfunction. Patients were required to be without any anticancer treatment for at least 4 weeks from initiation of study treatment",NA,NA
17917089,NA,Combination,No,chemo-naive patients with advanced non-small cell lung cancer (NSCLC),"Selection criteria included: (a) previously untreated and histologically proven NSCLC (stage 3B or 4), relapsing or metastatic (local or distant) disease with either clinically or radiologically measurable lesion; (b) viable organ function, defined as bone marrow function: WBC > 4,000/mm3, PLT > 100,000/mm3, Hb > 9 g/dl; hepatic function: AST and ALT < twice the upper normal level, total bilirubin < 1.5 mg/dl; renal function: serum creatinine < 1.5 mg/dl, Ccr (24 h) > 60 ml/min; (c) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2; (d) age 20– 75 years; and (e) inpatient status. Exclusion criteria included: (a) presence of severe complications; (b) history of drug hypersensitivity; (c) pregnant or lactating women or women who might or intended to become pregnant; and (d) judgment by the investigator that the patient was unsuitable for the study",NA,during the first course of chemotherapy,NA
17103043,NA,Combination,No,patients with advanced solid tumors,"Patients were enrolled at the Taussig Cancer Center, Cleveland Clinic Foundation from September 2004 to May 2005. Patients diagnosed with pathologically proven advanced nsolid tumors with measurable disease as per the Response Evaluation Criteria in Solid Tumors (RECIST) Committee criteria were eligible to participate in the study. Additional inclusion criteria included age ≥ 18 years, the ability to give written informed consent, and ECOG performance status of ≤ 2. All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 28 days prior to treatment in this study, and the patient should not have received more than 2 prior chemotherapy regimens. Women of childbearing potential were required to have a negative serum or urine pregnancy test within 7 days of starting the study drug, and sexually active men and women were required to use adequate contraceptive methods while on the study drug and for 4 weeks following the last dose.","Exclusion criteria included pregnant or lactating females, erythema nodosum, prior use of lenalidomide, failure of prior docetaxel/carboplatin regimen (except in the adjuvant setting), active metastatic brain disease, known HIV or infectious hepatitis, and pre-existing peripheral neuropathy ≥ grade 2. Patients were not eligible if they had laboratory criteria of absolute neutrophil count ≤ 1.5 × 109 /L, serum creatinine ≥ 1.5 mg/dl, elevated bilirubin ≥ 1.5 mg/dl, AST (SGOT) and ALT (SGPT) ≥ 2 × upper limit of normal (ULN) or ≥ 5 × ULN if hepatic metastases were present and alkaline phosphatase of ≥ 3 × ULN.",during the first cycle of therapy,NA
15494716,NA,Combination,No,patients with advanced malignant solid tumours,"Patients were eligible for study entry if they fulfilled the following criteria: a histological diagnosis of an advanced solid tumour; had received conventional treatment for the disease; platinum-based therapy was considered appropriate; at least 4 weeks and recovery from previous antitumour therapy (6 weeks for Mitomycin-C and nitrosoureas); age418 years; performance status 0, 1 or 2; neutrophil count >= 1.5 x 109 l; platelet count >= 100 x 109 l;adequate liver function (total bilirubin levels no greater than 1.5 times the normal limits and transaminases no higher than 2.5 times the normal limits); adequate renal function (glomerular filtration rate (GFR)>60 ml min-1, as measured using 51CrEDTA) and ability to give informed consent.","Exclusion criteria included prior therapy with any taxane; a past or current history of other cancer (except for curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix or other cancers if no current evidence of active disease was present); known or clinical evidence of central nervous system (CNS) metastases; peripheral neuropathy (of any aetiology, which was greater than grade 1); an unstable or serious concurrent medical condition.",in treatment course 1,NA
16445611,NA,Combination,No,women with advanced ovarian cancer,"Patients with persistent or recurrent, histologically confirmed disease or radiologic evidence of recurrence with cancer antigen 125 (CA125) > 100 U/mL after >= 3 cycles of standard first-line platinum-based therapy were enrolled. Patients who had stage IV disease at study entry and a clinical or pathologic complete response (CR) after standard platinum-based therapy were also eligible. All patients had an Eastern Cooperative Oncology Group performance status of 0 or 1 and a life expectancy of > 2 months. All patients had an adequate hematopoietic (absolute neutrophil count >1.5 x 109 cells/L and platelet count > 100 x 109/L), hepatic (bilirubin < 1.5 times the upper limit of normal [ULN] and liver transaminases ,1.5 times ULN), renal (serum creatinine < 1.5 times ULN and glomerular filtration rate >55 mL/min), and cardiac (left ventricular ejection fraction >= 45%) function.",NA,NA,tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support
15856233,NA,Combination,No,non-small-cell lung cancer patients,"Patients were required to have histologically or cytologically proven stage IV or unresectable stage III nonsmall-cell lung cancer. No prior chemotherapy was permitted. Patients who had been previously treated with radiation therapy were eligible if it had been completed at least 4 weeks before entering the study. Other eligibility criteria were age 20–74 years of age, performance status (World Health Organization)  of 2 or better, life expectancy of at least 12 weeks, adequate bone marrow function (leukocyte count >= 4000/ll, absolute neutrophil count >= 2000/ll, and platelet count >= 100,000/ll), aspartate transaminase (AST) not more than twice the upper limit of normal for the institution, alanine transaminase (ALT) not more than twice the upper limit of normal for the institution, serum creatinine level <= 1.5 mg/dl (enzymatic methods), and PaO2 >= 60 mmHg or SaO2 (arterial hemoglobin oxygen saturation) >= 90%.","Exclusion criteria included: malignant pleural or pericardial effusions that required treatment; uncontrolled serious medical illnesses such as cardiac disease, hypertension, diabetes mellitus and active infection; hypertension being treated with any calcium channel blockers; concurrent malignancy; preexisting malignancy within 5 years; and pregnancy or lactation",the first cycle,NA
17922272,NA,Combination,No,patients with platinum-sensitive recurrent ovarian cancer,"Women >= 18 years of age with platinum-sensitive recurrent ovarian cancer, fallopian tube carcinoma or primary peritoneal cancer, relapsed at least 6 months after completion of primary standard therapy with surgery and Wrst-line combination therapy with platinum and paclitaxel were eligible for study enrolment. Patients were required to have measurable or assessable lesions, an Eastern Cooperative Oncology Group (ECOG) performance status <= 2, normal hematological, liver and renal function with laboratory  parameters within the normal range, including a glomerular Wltration rate >= 60 ml/min, serum creatinine levels <= 1.5 mg/dl and an adequate bone marrow function (absolute neutrophil count, ANC >= 1.5 x 109 /l and platelets >= 100 x 109/l). ","Patients suVering from a secondary malignancy or serious concomitant systemic disorders or psychiatric disease were excluded from the study, as were subjects receiving other cytotoxic, immunological, hormonal or targeted therapy. ",during any of the Wrst four cycles of treatment,NA
12120886,NA,Combination,No,Advanced Non-Small Cell Lung Cancer,"Eligibility criteria for patients entering the trial included: histologically confirmed stage IIIB or stage IV NSCLC; age up to 75 years; no prior chemotherapy or radiotherapy; performance status grade 1-2 (ECOG scale); a baseline bilirubin serum level of <1.2 mg/dL and creatinine serum level of <1.2 mg/dL; normal cardiac function; baseline normal marrow function defined as a WBC count of at least 3000/µL, a platelet count of 100,000/ µL.",NA,NA,NA
14612900,NA,Combination,No,patients with advanced melanoma,"Patients with histologically confirmed, unresectable or metastatic, malignant melanoma, with measurable or assessable lesions, were eligible for the study. Patients were required to be over 18 years, have a life expectancy of at least 3 months and have an Eastern Cooperative Oncology Group (ECOG) performance status of < 2. No prior chemotherapy was allowed, but radiotherapy was permissible to nonindicator lesions completed at least 3 weeks prior to entry. Eligibility criteria included Hb >10 g dl-1, WBC >3 x 109 l-1, platelets >100  109 l-1, serum creatinine of <120 mmol l-1 or creatinine clearance of >50 ml min-1, bilirubin <30 mmol l-1, AST <3 x upper limit of normal (ULN) and alkaline phosphatase <3 x ULN.",NA,NA,NA
12201492,NA,Combination,No,patients with advanced cancer,"Patients with histologic or cytologic evidence of metastatic or locally advanced cancer for which there was no established curative or life-prolonging therapy, were eligible for this study. Written informed consent was obtained before enrollment. Eligibility criteria also included age ≥ 18 years; Eastern Cooperative Oncology Group performance status ≤ 2; prior radiation to ≤ 25% of bone marrow, and completed at least 4 weeks prior to study enrollment; life expectancy of at least 12 weeks; adequate bone marrow (platelets ≥ 150 × 109/L, absolute neutrophil count [ANC] > 1.7 × 109/L), hepatic (total bilirubin ≤ 1.3 times the upper limit of normal, aspartate transaminase ≤ 1.5 times upper limit of normal, alkaline phosphatase ≤ 1.5 times upper limit of normal) and renal (normal serum creatinine) functions",NA,NA,NA
12404295,NA,Combination,No,Patients with Advanced Carcinoma,"Patients with histologically documented advanced malignancy, age 18 years and older, Eastern Cooperative Oncology Group performance status 0–2, and patients with less than 50% irradiated marrow space were eligible for this dose-finding study. Laboratory eligibility criteria included adequate bone marrow (neutrophil count >= 1800/uL, platelet count >= 100,000/uL), liver (bilirubin level < 1.5 times the upper limit of normal), and renal (calculated creatinine clearance >= 30 mL/min) function. ","Patients with significant preexisting neuropathy, another medical illness limiting survival to less than 2 years, or an inability to give informed consent were ineligible for the study.",during the first cycle,NA
11127946,NA,Combination,No,patients with advanced gynecologic malignancies,"All subjects were required to have histologic proof of advanced-stage malignant solid tumor or soft tissue sarcoma not curable with surgery, radiation therapy or standard chemotherapy. In addition, all participants had to have a performance status of 2 or less (ECOG), to be greater than 18 years of age, and to have an anticipated life expectancy of at least 12 weeks. Measurable disease, while desired, was not required. Patients were required to have adequate bone marrow function (total white cell count greater than 4000/ul and platelets greater than 100,000/ul), liver function (total serum bilirubin less than 2.0mg/dl), and renal function (serum creatinine less than 2.0 mg/dl). ","Patients who had received prior doxorubicin therapy were excluded, as were those with previous myocardial infarction. ",NA,NA
14733637,NA,Combination,No,Stage III Unresectable Non–Small-Cell Lung Cancer,"To be eligible for this study patients had to be ≥ 18 years of age and have histologically documented, unresectable stage IIIA/B NSCLC. They had measurable/evaluable disease and no prior chemotherapy or radiation. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and weight loss < 15% in the 3 months prior to diagnosis. Adequate pulmonary, hematologic, renal, and hepatic function was required. ",NA,NA,NA
11733958,NA,Combination,No,Recurrent Epithelial Ovarian Cancer,"This was an open, nonrandomized trial. Women with relapsing ovarian cancer more than 6 months after first-line treatment, observed between March 1998 and May 1999 at the collaborating Centres (Gynecological Departments, University of Varese, Tourin, Pavia, Milan) were eligible for the study. At entry, all woman had Karnofsky performance status .580 and normal hematological measurable diseases. Written informed consent was obtained.",NA,NA,NA
11506300,NA,Combination,No,elderly Patients with Small-Cell Lung Cancer,"Patient selection was restricted to those over 70 years of age with no prior chemotherapy or radiotherapy, with histologically or cytologically proven SCLC. Eligibility stipulated measurable or evaluable disease, performance status of 0-3 on the ECOGscale, adequate hepatic function with serum transaminases <2 times upper limit of normal and normal total bilirubin, adequate renal function with normal serum creatinine, adequate pretreatment bone marrowreserve (leukocyte count >4,000/|ll1, and adequate cardiac functions.",NA,during the first cycle of chemotherapy,NA
14984965,NA,Combination,No,advanced gynecological tumors,"Patients were required to have a histologically or cytologically confirmed advanced gynecological malignancy excluding squamous cell carcinoma of the cervix uteri. Previous chemotherapy was not allowed but patients could have received previous immunotherapy until at least 4 weeks before study entry or hormonal therapy that had to be discontinued immediately before the first administration of the study drugs. Eligibility criteria were also: a performance status of 0 – 2 according to Eastern Cooperative Oncology Group (ECOG) or World Health Organizati (WHO), or of >= 60% according to Karnofsky; age >= 18 years; minimum life expectancy of 12 weeks; normal cardiac function; adequate hematological, renal and hepatic function, defined as hemoglobin >= 10 mg/dl, absolute neutrophil count >= 1.5 x 109/l, platelet count >= 100 x 109/l, total serum bilirubin <= 1.25 times the upper limit of normal (ULN), and serum creatinine <= 1.25 times ULN. All women of childbearing potential were required to have a negative pregnancy test and to use an adequate contraceptive method throughout the study period",Patients were ineligible for study entry if they had clinical evidence of brain metastases; prior radiation therapy that extended beyond true pelvis; motor or sensory neurotoxicity zgrade 2 according to NCI CTC criteria at baseline; active infection or any other medical condition making implementation of the study protocol or interpretation of study results difficult.,during the first treatment cycle,NA
11398884,NA,Combination,No,breast cancer patients,Stage IIIB and IV breast cancer patients were eligibl,NA,NA,"Induction chemotherapy consisted of three cycles of CEF (cyclophosphamide 600 mg/m , epirubicin 100 mg/m . 5-fluorouracil 600 mg/m2) plus G-CSF (Filgrastim, 300 |jg/day subcutaneously) fromdays 3-10"
11828945,NA,Combination,No,ovarian cancer,"Patients with histologically confirmed epithelial ovarian cancer were enrolled if they fulfilled all of the following criteria: (1) able to be hospitalized for treatment; (2) clinical stage International Federation of Gynecology and Obstetrics (FIGO) stage III/IV disease; (3) treated previously with no more than one regimen of chemotherapy; (4) age between 20 and 75 years; (5) World Health Organization (WHO) performance status of 0 to 2; and (6) adequate bone marrow and organ function (hemoglobin, > 9.0 g/dl; white blood cell count [WBC], > 4000/l; platelet count, > 10 x 104/l; total bilirubin, < 1.5mg/dl; and aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatases within twice the treating institution’s range of normal values).","Exclusion criteria included the following: (1) treatment with two previous chemotherapy regimens; (2) severe concomitant illness, such as obvious infection, ischemic heart disease, arrhythmia, or liver function disorder; (3) low blood pressure (systolic pressure, < 90mm/Hg); (4) a second malignancy; (5) hypersensitivity to agents containing polyoxyethylene castor oil or preparations containing sclerosing castor oil, or a history of hypersensitivity to either agent; (6) possibility of being pregnant or desire to become pregnant; (7) massive fluid retention; (8) brain metastasis; and (9) other conditions as judged by the attending physician",NA,NA
11142482,NA,Combination,No,advanced non-small-cell lung cancer,"Eligibility criteria were identical for the two portions of the study. Patients were required to have histologically or cytologically proven stage IIIB, or unresectable IIIA with bulky N2 disease, or stage IV NSCLC, with measurable disease. Patients with recurrent metastatic disease following surgery were eligible for the study; prior radiotherapy or chemotherapy was not allowed. Patients with brain metastases could be enrolled only if they had no neurological symptom and had another measurable site of disease. Patients were eligible if they were between 18 and 70 years of age and had a performance status (PS) of 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale. Normal hepatic, renal and hematological parameters (absolute neutrophil count > 2000/ul, platelet count>100,000/ul, creatinine <1.5 mg/dl, bilirubin <l.5 mg/dl) were required",Patients with a history of acute myocardial infarction within the last six months or with arrhythmias or chronic heart failure requiring permanent medication were excluded from the study. Patients treated for any other type of cancer during the previous five years and patients with serious co-existing medical illnesses were also excluded. A negative pregnancy test was needed for women of childbearing potential. ,during the first cycle,NA
11134194,NA,Combination,No,Advanced Prostate Cancer,"Patients with histologically confirmed androgen-dependent or androgen-independent prostate cancer were considered for the study. Patientswith androgen-dependent disease included patients with locally advanced adenocarcinoma of the prostate and an estimated 3-year relapse-free survival rate of less than 25% (T3/T4N0/1M0 or Gleason score >= 7 and serum PSA levels >= 20 ng/mL)15; patients with local relapse after radiation therapy or radical prostatectomy, with measurable disease on a computed tomography (CT) scan or magnetic resonance image; and patients with poor-risk metastatic disease (bone scan showing $ 20 osseous lesions or visceral metastatic disease). Patients with small-cell or neuroendocrine carcinoma of the prostate were also eligible. Patients with androgen-dependent disease who met one of the inclusion criteria were eligible for the study if they had been undergoing androgen ablation for less than 3 months. Patients with androgen-independent disease were required to have documentation of progressive disease after discontinuation of treatment with an antiandrogen,16 castrate levels of testosterone (< 30 ng/mL), and a life expectancy of more than 3 months and to have had no more than one prior course of chemotherapy (patients could have been treated with one previous estramustine- or taxane-based regimen), palliative radiotherapy, or radioisotope therapy. Disease progression was considered to have occurred if at least one of the following criteria was met: an increase in PSA level of >= 50%, compared with baseline, on three successive occasions; new metastatic lesions seen on a bone scan; and an increase of more than 25% of a bidimensionally measurable tumor mass. In patients who had not undergone surgical castration, treatment with luteinizing hormone-releasing hormone (LHRH) agonists was continued. Each patient had a Karnofsky performance status (KPS) score >= 70, WBC count >= 3,500/mm3, granulocyte count >= 1,500/mm3, platelet count >= 120,000/mm3, hemoglobin level >= 8.0 g/dL, serum creatinine level >= 2.0 mg/dL, and a baseline AST level less than two times the institutional normal. Eligible patients had not undergone major surgery, radiation therapy, chemotherapy, or immunotherapy within 4 weeks of study entry nor radioisotope therapy within 8 weeks of entry.","Individuals were excluded if they had New York Heart Association class III or IV heart disease, histories of ventricular arrhythmias, histories of bleeding disorder, peripheral neuropathy (grade 3 or 4), CNS disease, active infection, insulin-dependent diabetes mellitus, or brain metastases. Written informed consent was required",during the first 4 weeks of therapy,NA
14613998,NA,Single Drug,No,Advanced Malignancies,"Patients were eligible if they had pathological confirmation of a malignancy that was unresponsive to <= 3 standard therapies or for which there was no known effective treatment. Treatment with a prior taxane (paclitaxel or docetaxel) was permitted. Patients were required to have measurable disease, an Eastern Cooperative Oncology Group performance status of 0–2, and anticipated survival of >3 months. No chemotherapy, immunotherapy, wide-field radiotherapy (>=30% of the bone marrow), or major surgery for 4 weeks before study entry was permitted. In addition, patients must have recovered to <= grade 1 from toxicities of previous therapies. Laboratory parameters for inclusion were serum creatinine < 1.5 mg/dl, bilirubin  1 mg/dl, aspartate aminotransferase < 3 x upper limit of normal, WBC count > 3,500/mm3, and platelet count > 100,000/mm3. Appropriate imaging studies performed < 4 weeks before study entry were accepted for baseline tumor measurements. ","Exclusion criteria included active central nervous system metastasis, prior history of hypersensitivity to Cremophor EL, or pre-existing neurotoxicity. Female patients were required to be nonpregnant and nonlactating.",in the first or second course,NA
12743738,NA,Combination,No,advanced non-small-cell lung cancer,"Patients with stage IIIb and IV NSCLC, no prior treatment, an ECOG performance status of 0 to 2, and a life expectancy greater than 12 weeks, were enrolled in the study (Table 1). The patients were aged between 18 and 75 years, had measurable or evaluable disease, and were required to have adequate bone marrow, hepatic, and renal functions, defined as a white blood cell count of >=4,000/ll, hemoglobin >= 9.5 g/ll, a platelet count of ‡100,000/ll, bilirubin <= 1.5 mg/dl, aspartate aminotransferase not more than twice the upper limit of normal, and serum creatinine <= 1.5 mg/dl.","Patients were excluded if they had significant cardiac disease, active infection, symptoms of brain metastases, diarrhea, pulmonary fibrosis, massive pleural effusion, a past or current history of other malignancy, or were pregnant.",during the first four cycles of treatment ,NA
12177114,NA,Combination,No,Malignant Pleural Mesothelioma,"Patients were required to have a histologic diagnosis of MPM with no prior chemotherapy treatment. Prior radiation therapy was permitted as long as the patient had recovered from the acute toxic effects and it involved less than 30% of the bone marrow. Only patients with measurable disease and a World Health Organization performance status of 0 to 2 were eligible. Bone marrow reserve had to be adequate with an absolute neutrophil count >= 1.5 x 109/L, platelet count >= 100 x 109/L, and hemoglobin >= 9 g/dL. Measured creatinine clearance had to be >= 40 mL/min, as assessed by 51Cr-EDTA. Hepatic function was required to be adequate with a bilirubin <= 1.5 times the upper limit of normal, and AST and ALT were <= three times normal (higher levels were acceptable if liver metastases were present).","In addition to the common exclusion criteria used in clinical trials, patients on this study were excluded if they were unable to discontinue administration of aspirin and other nonsteroidal anti-inflammatory agents for 2 days before, the day of, and 2 days after the dose of pemetrexed (5 days for long-acting agents). Evidence of nutritional deficiency or an albumin level less than 2.5 g/dL were also considered exclusion criteria. The latter patients were required to have a plasma homocysteine level less than 12 umol/L because during the course of the trial, data were generated from other trials of pemetrexed that demonstrated that a raised pretreatment homocysteine level was associated with a significantly increased risk of hematologic toxicity. In fact, no patient who was recruited after this protocol modification needed to be excluded on this account.",during cycles 1 and 2,NA
11398891,NA,Combination,No,advanced solid tumors,"Eligible patients had biopsy proven incurable malignancy They had either failed prior standard therapy or had tumors for which standard therapy was ineffective Other eligibility criteria included age greater than 16. Eastern Cooperative Oncology Group performance status 2 or less, estimated life expectancy at least 12 weeks, and measurable or cvaluable disease Adequate hematological, hepatic, and renal function were required and were defined respectively as neutrophil count greater than or equal to 1500/ul, platelets greater or equal to 100,000/ul, serum bihrubin less than or equal to 1 25 times upper limit normal (ULN). SGOT less than or equal to 2 5 times ULN, and serum creatinine less than or equal to 1 5 times ULN Patients were required to be greater than four weeks from prior radiotherapy or chemotherapy There were no limits on amount of prior chemotherapy",lnehgibility criteria included peripheral neuropathy greater than or equal to grade 3 ,during the first course of treatment,NA
11142689,NA,Combination,No,advanced non-small cell lung cancer,"Patients were enrolled in the study if they met the following eligibility criteria: histologically or cytologically confirmed advanced NSCLC (stage IIIB or IV), no prior chemotherapy or no therapy for at least 4 weeks before study entry, a life expectancy of at least 3 months, a performance status of 0±2 on the Eastern Cooperative Oncology Group (ECOG) scale, between 15 and 75 years of age, adequate bone marrow function (hemoglobin >= 9 g/dl, leukocyte count >= 4000/mm3, platelet count >= 100 000/mm3), adequate renal function (serum creatinine <1.5 mg/dl) and adequate liver function (asparatate aminotransferase and alanine aminotransferase < 2 times the upper limit of normal). All patients provided written informed consent.","Exclusion criteria were as follows: sever concurrent medical conditions, pregnant or nursing mothers, active concomitant malignancy, active uncontrolled infection, intestinal paralysis and obstruction, interstitial pneumonia or pulmonary fibrosis, and/or large amount of ascites and/or pleural effusion.",during two courses,NA
12649113,NA,Combination,No,advanced ovarian carcinoma,"Patients naïve to chemotherapy with histologically confirmed advanced (stage IC–IV) epithelial carcinoma of the ovary or fallopian tube, primary peritoneal carcinoma or patients with intra-abdominal carcinoma of unknown origin thought to originate in the genital tract were eligible for this study. Other inclusion criteria were: good performance status, World Health Organization (WHO) grade 0–2; measurable or evaluable disease; life expectancy ≥3 months; age 18–70 years; normal cardiac ejection fraction, as estimated by a baseline MUGA (multigated acquisition) scan; neutrophil count ≥1.5 × 109/l; platelet count ≥100 × 109/l; haemoglobin ≥10 g/dl; glomerular filtration rate (GFR; measured by 51Cr-EDTA or creatinine clearance) ≥60 ml/min; and total bilirubin and transaminases <2 × upper limit of normal range (ULN), <3 × ULN in the presence of liver metastasis.","Exclusion criteria were: previous pelvic irradiation (limited prior radiotherapy, for example a single fraction for bone pain, was allowed); borderline histology; central or peripheral neuropathy, common toxicity criteria (CTC) grade ≥2; undrained ascites; bowel obstruction; significant comorbidities; history of a second malignancy, unless disease-free for ≥3 years; cerebral metastases; allergy to any study medication or to cremophor-containing drugs; and pregnancy or lactation",NA,NA
12045462,NA,Combination,No,stage IIIB or IV non-small cell lung cancer,"Patients were enrolled onto the study if they met the following eligibility criteria: histologically or cytologically proven advanced NSCLC (stage IIIB or IV); no prior chemotherapy or no therapy for at least 4 weeks before study entry; a life expectancy of at least 3 months; a performance status of 0–2 on the Eastern Cooperative Oncology Group (ECOG) scale; between 15 and 75 years of age; adequate bone marrow function (hemoglobin 9 g/dl, neutrophil count 2000/mm3, platelet count 100 000/mm3); adequate renal function (serum creatinine <1.5 mg/dl); adequate liver function (asparatate aminotransferase and alanine aminotransferase <2 x normal upper limit); written informed consent was obtained from all patients.",Exclusion criteria were as follows: severe concurrent medical conditions; pregnant or nursing mothers; active concomitant malignancy; active uncontrolled infection; intestinal paralysis and obstruction; interstitial pneumonia or pulmonary fibrosis; and/or large amount of ascites and/or pleural effusion.,during two courses,NA
11325490,NA,Combination,No,advanced non-small cell lung carcinoma,"Eligible patients included those with pathologically documented NSCLC with advanced disease or recurrent or progressive disease after prior radiation therapy or surgery or both. Advanced disease included patients with metastatic disease (M1) or patients with malignant pleural effusion or positive supraclavicular lymph nodes. Patients with brain metastases were eligible if stable after treatment with radiation therapy. Only patients receiving no prior chemotherapy or immunotherapy were included. Other criteria for eligibility included an ECOG performance status (PS) of 0–2, age > 18 years, recovery from previous surgery or radiation therapy; no previous or concomitant malignancy; no serious medical or psychiatric illness; normal hematologic (neutrophils >= 1.5×109/l, platelets 100×109/l, hemoglobin >6.2 mmol/l), renal (creatinine no greater than twice the upper limit of normal) and liver (bilirubin <= 25.7 umol/l) function. Patients could have either measurable or evaluable disease.",NA,during the first cycle of chemotherapy only,NA
11800024,NA,Combination,No,advanced non-small-cell lung cancer,"Eligibility criteria included the following: (a) a histologically or cytologically confirmed diagnosis of NSCLC; (b) previous treatment with anticancer drugs; (c) age<= 75 years; (d) Eastern Cooperative Oncology Group (ECOG) performance status (PS) <= 2; (e) life expectancy greater than 12 weeks; (f) adequate bone marrow function (leukocyte count >= 4000/ul, platelet count >= 100,000/ul and hemoglobin level >= 9 g'dl); (g) serum bilirubin level <= 1.5 mg/dl; (h) s-AST and s-ALT levels no more than twice the normal upper limit; (i) serum creatinine level <= 1.2 mg/dl; (j) no medical problems severe enough to prevent compliance with the protocol; and (k) provision of written informed consent.",NA,during the first cycle of each dose level,NA
11914594,NA,Combination,No,Patients with Taxane and Anthracycline Pretreated Advanced Breast Cancer,"Patients with histologically confirmed metastatic breast cancer pretreated with taxane- and anthracycline-containing chemotherapy were enrolled. Other inclusion criteria were as follows: age 18–75 years; a World Health Organization (WHO) performance status (PS) of 0 to 2; life expectancy of at least 3 months; adequate hematopoietic (ANC > 1,500/ul, PLT > 100,000/ul), liver (bilirubin < 1.5 mg/dl, AST/ALT <2 x upper normal limit, unless caused by tumor and serum albumin > 3.0 g/dl) and renal function (BUN and creatinine <1.5 x upper normal limit; and creatinine clearance > 50 ml/min), and cardiac function [left-ventricular ejection fraction (LVEF) > 50%]. Patients with brain metastases were eligible provided that they had been irradiated and had clinical and radiological improvement. ","Other exclusion criteria were radiation therapy within 4 weeks from treatment initiation, irradiation of more than 25% of the bone marrow-containing bones, severe infection or malnutrition. The study was approved by the Ethics and Scientific Committees of the participating institutions. ",during the first chemotherapy cycle,NA
11550166,NA,Combination,No,Children with Refractory Carcinoma,"To be eligible for our study, patients had to be younger than 21 years old, with a Karnofsky score of greater than 50% and a life expectancy of more than 3 months. Their nutritional status had to be greater than the third percentile for weight and height, and their albumin concentration had to be greater than 3 g/dL. Evidence of recovery from prior chemotherapy was required, and patients could not have been treated with prior radiation to the pelvis or spine for at least 6 weeks before entry into the study or with total-body irradiation for 6 months before entry. Patients had to have adequate hematopoietic function (absolute neutrophil count [ANC] > 1500/mL, platelet count > 100/mL, renal function [normal creatinine for age or glomerular filtration rate > 70 mL/minute per 1.73 m2], hepatic function [bilirubin < 1.5 mg/dL, aspartate transaminase {AST} < 2 x upper limit of normal for age], and cardiac function [> 27% shortening fraction, > 50% ejection fraction]). Before study entry, all patients, parents or guardians, as appropriate, gave written informed consent according to the institutional guidelines.",NA,Dose-limiting toxicities were evaluated for all treatment cycles,NA
12750842,NA,Combination,No,chemonaive advanced non-small-cell lung cancer,"Eligibility criteria for study entry included histologically or cytologically confirmed stage IIIB or stage IV NSCLC. Patients wererequired to have measurable or evaluable disease and to have received one or no prior chemotherapy for advanced disease. Previous neoadjuvant or adjuvant chemotherapy, or chemotherapy given concurrently with radiotherapy for non-metastatic disease was allowed if the last dose had been administered 6 months or more before study entry. Patients who had received prior platinum and/or gemcitabine were excluded. Patients with symptomatic central nervous system metastases requiring steroid were excluded. Prior radiotherapy was allowed as long as the indicator lesion(s) was not within the previous radiation field and the last dose of radiotherapy had been completed at least 3 weeks before study entry. Patients were required to have a Karnofsky performance status of >=70%, WBC count >=3500/ll, neutrophils >=2000/ll, platelet count >=100,000/ll, hemoglobin >=9 g/dl, serum creatinine <133 lmol/l or creatinine clearance >30 ml/min (based on the Cockcroft formula), serum bilirubin not more than 1.5 times the upper limit of normal (ULN), serum transaminase levels not morethan twice ULN (not more than five times ULN if liver metastases were present), life expectancy >3 months, and age >=18 years",NA,during the first cycle of chemotherapy,NA
11955654,NA,Combination,No,metastatic non-small-cell lung cancer,"Eligible patients were aged between 18 and 70, with an Eastern Cooperative Oncology Group (ECOG) score <= 2 and a life expectancy>= 12 weeks. They were required to have histologically or cytologically proven NSCLC, with no previous chemotherapy. They had to have a metastatic disease or a stage IIIB disease with pleural involvement, but without brain metastase. The following laboratory values were required: white blood cells >= 4×109 per l with neutrophils >= 2×109 per l, platelets >=150×109 per l, hemoglobin >=10 g/dl, total bilirubin <=1.25 times theupper limit of the institutional normal range, and creatinine concentration <=180 umol/l. In addition, patients were required to have at least one uni-dimensionally measurable target lesion, >=2 cm on a computed tomographic (CT) scan. Bone metastases and pleural or peritoneal effusions were not considered to be measurable lesions. ","Patients were excluded from the trial for any of the following reasons: an active uncontrolled infection or fever >38.3 °C, unstable coronary cardiac disease, psychiatric disorders, previous malignant disease (except in-situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin), brain metastasis, superior cava syndrome.",NA,NA
11710627,NA,Combination,No,children with brain tumors,"patients<= 21 years of age with histologically confirmed primary brain tumors refractory to stantand therapy were eligible for this trial. Histological confirmation was not required for brain stem gliomas. Patients had to have recovered from the toxic effects of prior therapy and have an ECOG performance score of <=2. All patients were required to have a serum bilirubin and SGPT no more than twice the upper limit of normal. Normal renal function was not required for study entry because carboplatin was adaptively dose based on renal function, but patients were required to have a serum creatinine of <= 1.2 mg/dl if aged under 5 years, <= 1.5 mg/dl if aged 5-10 years, <= 1.8 mg/dl if aged 10-15 years, and <=2.4 mg/dl if aged over 15 years. Patients who had not previously received craniospinal irradiation or myeloablative therapy with bone marrow ro stem cell rescue were considered to be evaluable for hematological toxicity and were required to have a granulocyte count> 1500/u;, hemoglobin >8.0g%, and a platelet count >100,000/ul.",Patients treated with carboplatin within the 6 months prior to study entry were ineligible. Patients who were pregnant or breastfeeding or who had a significant systemic illness were also excluded from the study.,during the first cycle,NA
11714542,NA,Combination,No,stage III unresectable non-small-cell lung cancer,"Previously untreated patients with histologically documented stage IIIA or stage IIIB NSCLC which was medically inoperable due to COPD, cardiac, or other comorbid disease were eligible for this study. Patients with direct vertebral body invasion or a malignant or exudative pleural effusion were not eligible. All patients had measurable or assessable disease. Further eligibility criteria included: age greater than 18 years; ECOG performance status <= 2; weight loss less than 15% during the 3 months preceding diagnosis; no prior chemotherapy; no prior lung radiation therapy; platelet count >= 100 000/ul; absolute neutrophil count (ANC) >=1800/ul; hemoglobin >=9 g/dl; BUN < 1.5 times normal; creatinine level < 1.5mg/dl; bilirubin < 1.5 times the upper limit of normal; Transaminases (SGOT and/or SGPT) up to 2.5× institutional upper limit of normal (ULN) if alkaline phosphatase was < ULN, or alkaline phosphatase up to 4× ULN if transaminases  ULN. ","However, patients who had both transaminase elevation >1.5× ULN and alkaline phosphatase >2.5× ULN were not eligible for this study (due to decreased clearance of docetaxel and increased risk of toxicity); PO2 >50 mmHg, PCO2 <50 mmHg in a sample of arterial blood; forced expiratory volume in1s(FEV1) >800 ml; and no other serious medical or psychiatric illness",NA,NA
11800029,NA,Combination,No,lung cancer,"Patients were enrolled in the study if they met the following criteria: (1) histologic or cytologic confirmation of lung cancer; (2) stage IV disease or stage III disease not amenable to concurrent chemoradiotherapy; (3) no prior chemotherapy and radiotherapy; (4) life expectancy at least 8 weeks; (50 age not more than 75 years; (6) performance status <= 2 on the World Health Organization (WHO) scale; (7) adequate bone marrow function (leukocyte count >=4000/ul, neutrophil count >=2000/ul, platelet count>=100,000/ul), adequate hepatic function (bilirubin level <= 1.5 mg/dl, transaminase level not more than twice the upper limit of normal), and adequate renal function(serum creatinine level <=1.5 mg/dl); (8) no concurrent malignancy; (9) no medical complications which prevented compliance with the protocol and (10) no history of drug allergy. Patients with postoperative relapse or non-symptomatic brain metastasis were eligible. ",NA,NA,NA
12702526,NA,Combination,No,advanced non-small-cell lung cancer,"Eligibility criteria included a histologically or cytologically confirmed diagnosis of stage IIIB (with pleural effusion) or stage IV NSCLC. Measurable or evaluable disease was required. Prior treatment with a single chemotherapy regimen was allowed, if it included a single investigational agent. Prior radiation therapy to 40% or less of the bone marrow was also permitted. Patients with brain metastases were eligible following cranial irradiation if they were without neurological symptoms. A CALGB performance status of 0, 1 or 2 was necessary. Laboratory measures required at study entry included: white blood cell count (WBC) ≥3500/µl; absolute neutrophil count ≥1500/µl; hemoglobin ≥10 g/dl; platelet count ≥100000/µl; creatinine ≤1.5 times the institutional upper limit of normal or creatinine clearance ≥50 ml/min ; bilirubin ≤1.5 mg/dl; and glutamic-oxaloacetic transaminase <2 times the institutional limit of normal. ","Patients with second- or third-degree heart block, bundle branch block, or supraventricular arrhythmia noted on electrocardiogram were excluded.",during cycle 1 of therapy,NA
12942108,NA,Combination,No,locally advanced non-small-cell lung cancer,Previously untreated patients with histologically documented inoperable stage IIIA or stage IIIB NSCLC were eligible for this study. All patients had measurable or assessable disease. Further eligibility criteria included: age greater than 20 and less than 75 years; ECOG performance status <=2; no prior chemotherapy; no prior lung radiation therapy; platelet count >=100 000 ml-1; white blood cell (WBC) count 3000 ml-1; haemoglobin >10 g dl-1;BUN o1.5-fold the upper limit of normal (ULN); creatinine level <1.1 mg dl-1; bilirubin o1.5-fold the upper limit of normal (ULN); AST otwo-fold the ULN; 24-h creatinine clearance >= 60 ml min-1; PaO2>65 mmHg in a sample of arterial blood; and no other serious medical or psychiatric illness.,Patients with a malignant or exudative pleural effusion were not eligible.,NA,NA
11330952,NA,Combination,No,Previously Untreated Ovarian Cancer,"Patients between 18 and 65 years were eligible if they had histologically proven stage IIIC or IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma which was either suboptimally debulked or optimally debulked (<1 cm) with macroscopically visible residual disease. Patients with clear cell histology were not required to have macroscopically visible disease. Patients were required to have an ECOG performance status <3, life expectancy of at least 2 months, adequate bone marrow function with an absolute neutrophil count (ANC) >= 1.5 x 109/L and platelet count >= 100 x 109/L, adequate liver function with bilirubin upper limit of normal and aspartate transaminase <= 2 times upper limit of normal, adequate renal function with serum urea and creatinine <= 1.5 x upper limit of normal, and glomerular filtration rate (GFR) of >=60 ml/min",NA,during the first cycle,"Patients received d two cycles of carboplatin AUC 5 5 and 175 mg/m2 of paclitaxel with Peripheral Blood Progenitor Cell Support after the second cycle, and subsequently received three cycles of high-dose therapy (HDT) with topotecan on a daily 35 schedule, paclitaxel (250 mg/m2 over 24 h), and carboplatin (AUC 5 12–16)."
11583193,NA,Combination,No,platinum sensitive ovarian cancer,"Inclusion criteria included histologically confirmed epithelial ovarian cancer or primary peritoneal adenocarcinoma recurring after a minimum of a six-month treatment free interval following one prior platinum-containing chemotherapy. Other inclusion criteria were standard for phase I — II studies and included Eastern Cooperative Oncology Group performance status of 0-2, an adequate bone-marrow function (absolute neutrophil count > 1.49 x IO9/1 and platelet count > 99 x 109/l), and an adequate renal and hepatic function (creatinine and bihrubin < 1.51 x upper limit of normal)","Patients were ineligible if they had prior malignancies (excluding non-melanomatous skin cancer), more than one prior chemotherapy, prior gemcitabine exposure, active infection, bowel obstruction, or mental disorder.",in all of the first three courses,NA
11325487,NA,Combination,No,stage III inoperable non small cell lung cancer,"Thirty-eight patients with inoperable NSCLC stage UICC III (IIIA: n=14, IIIB: n=24, Karnofsky-Index >=70%) were entered into this prospective trial between March 1995 and March 1997. Informed consent was obtained from each patient before entering the study.",NA,NA,NA
12468349,NA,Combination,No,Locally Advanced Primary and Recurrent Cervical Cancer,"Chemotherapy-naive patients with histologically confirmed advanced cervical cancer (FIGO stage IIB–IVA) qualified for study entry, as did those with local recurrences or metastatic disease (FIGO stage IVB). Additional eligibility criteria were as follows: age 18–65 years; WHO performance status 0–2; no previous systemic anticancer therapy; adequate function of bone marrow (white blood cell [WBC] count >= 4 x 109/L and platelet count >100 x 109/L), liver (total bilirubin and aspartate aminotransferase (AST) level <3 times upper limit of normal), and kidneys (glomerular filtration rate >=30 mL/min). The study was approved by the local and regional ethical committees. Written informed consent was required from each patient prior to study entry.",NA,NA,NA
11066051,NA,Combination,No,Locally Advanced Head and Neck Carcinoma,"1. Histologic type was squamous cell carcinoma. 2. Age did not exceed 75 years. 3. Performance status was 0 –2 by Eastern Cooperative Oncology Group criteria. 4. No active synchronous carcinoma was present. 5. Liver function tests showed glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, and bilirubin within 2 times the normal ranges and a 24-hour creatinine clearance of 60 mL/minute or higher. Pretreatment cellleukocyte count was greater than 4 x 103/mL, platelet count was 1 x 105/mL or higher, and hemoglobin was 10g/dL or higher. No severe impairment of cardiopulmonary function was present. 6. No distant metastasis was detected by plain chest X-P, abdominal ultrasonography, and bone scintigraphy. A survival period of at least 6 months was expected if the primary lesion was controlled. 7. In case of treated cases, the previous treatment should have been performed at least 4 weeks before the study, and it did not interfere with the current study. 8. The local control probability by conventional radiotherapy alone would have been very low. 9. The patient understood fully the risks and benefitsof the study treatment and consented",NA,NA,NA
10997810,NA,Combination,No,previously untreated patients with small-cell lung cancer,"Patients with histologically verified SCLC (WHO type II) or mixed histology (WHO type V) regardless of disease extent were candidates for the trial provided that they had measurable or evaluable disease, age between 18 and 70 years, WHO performance status of 0-2, and had not received prior radio- or chemotherapy. The following laboratory values were required at entry: hemoglobin level >= 6.0 mmol/1 (9.6 g/dl), white blood cell count >=3OOOO/ul, neutrophil count >= 1500/ul, platelet count >= 100,000/ul, serum creatinine level <= 133 mmol/1 (1.5 mg/dl), slCr-EDTA clearance >=60 ml/min, serum bilirubin level <= 34 mmol/1 (1.4 mg/dl), transaminases and alkaline phosphatase <= 2 times the upper limit of normal or <= 3 times the upper limit of normal in the presence of liver metastases. The protocol was approved by the local ethical committee. All patients gave written informed consent. ","Patients were ineligible if they had a history of prior or present malignancies other than SCLC except for carcinoma of the skin or CIS of the cervix, active non-controlled infection, a concurrent medical problem unrelated to their lung cancer which could significantly limit full compliance with the study or expose the patient to an undue risk of decreased life expectancy. Further, treatment with an investigational drug within 30 days prior to study entry was not allowed. No concurrent chemotherapy, immunotherapy, or investigational therapy for the treatment of SCLC were allowed. Radiotherapy could be administered if the clinical condition demanded it. Pregnant or lactating females were not allowed to enter the study.",in the first cycles A,NA
9610696,NA,Combination,No,Advanced Nonsmall Cell Lung Carcinoma,"Patients with histologically or cytologically confirmed advanced NSCLC were eligible for this Phase I study. Eligibility criteria included an expected survival of >= 3 months, age < 75 years, an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 –2, measurable or evaluable lesions, no chemotherapy or radiotherapy within 4 weeks of entering this study, no previous platinum-based chemotherapy, adequate hematologic function (a leukocyte count of >= 4,000/mm3, a platelet count of >= 10 x 104/mm3, and hemoglobin >= 10.0 g/dL), renal function (serum creatinine <=1.5 mg/dL and creatinine clearance [Ccr] >= 60 mL/min), and hepatic function (total serum bilirubin < 1.5 mg/dL, and glutamic oxaloacetic transaminase and glutamic pyruvic transaminase less than twice the upper limit of the normal range). Patients who had experienced postoperative recurrence and those who had received radiotherapy to metastatic sites were eligible for the current study. Written informed consent was obtained from all patients.",NA,NA,NA
10654007,NA,Combination,No,small cell lung cancer,"Patients with histologically or cytologically documented, SCLC without prior therapy were eligible for the study. Each patient was required to meet the following criteria: World Health Organization (WHO) performance status (PS) of 0, 1, or 2; < 70 years of age; the presence of measurable disease; adequate renal function (creatinine clearance >60 ml/min); adequate hepatic reserve (total bilirubin, serum AST and ALT < 2.5 times normal), normal bone marrow function (WBC count >=3.5 x 109/l, platelet count >100 3 109/l, hemoglobin level >=10 g/dl)","Patients with active concomitant malignancy, liver cirrhosis, active infection and severe heart disease were excluded. Bone marrow aspirates were obtained before beginning the therapy and patients with bone marrow involvement were excluded.",on the first course of the regimen and on the rest of the regimen separately,"A phase I dose-escalation study of multicyclic, ifosfamide, carboplatin, and etoposide (ICE) with sequential reinfusion of peripheral blood stem cells (PBSCs)"
11127945,NA,Combination,No,neooplastic disease,"Eligible patients included those with histological or cytological documentation of neoplastic disease considered refractory to standard therapy or for whom no standard therapy existed. Patients were required to have a Karnofsky performance status of at least 60%, and estimated survival of at least 2 months. a hemoglobin greater than 10g%, a leukocyte count of more than 3500/ul, and a platelet count of more than 150,000/ul. Total serum bilirubin could not eceed 1.5 mg/dl and serum transaminases were required to be less than 1.5 mg/dl or creatinine clearance more than 60 ml/min. In patients with a history of pulmonary disease, the FEV1 had to exceed 21 and oxygen saturation had to exceed 92% with the patient breathing room air. Patients with measurable lesions were required to have baseline determinations performed with appropriate radiographic studies within 4 weeks of entry into the trial; pleural effusions, ascites, and bone metastases were not considered measurable. There were no limitations on the extent of exposure to prior radiotherapy or no limitations on the extent of exposure to prior radiotherapy or on the types and numbers of previously admiistered chemotherapies except that prior cisplatin exposure could not have exceeded 300 mg/m2 (1200 mg/m2 for CBDCA). All prior therapy had to have been completed at least 4 weeks before study entry.","Protocol exclusion criteria included pregnancy or the presence of concomitant nonmalignant disease that was either poorly controlled by therapy or of such severity that it was considered potentially unsafe for the patient to participate in the trial. Also excluded were patients with narrow angle glaucoma, Parkinson's disease, extrapyramidal disorders, seizure disorders, known hypersensitivity or neurological intolerance of phenothiazines or diphenhydramine, or who required chronic antipsychotic medication. Patients with symptomatic coronary artery disease, cardiac arrhythmias, venous thrombosis undergoing anticoagulant therapy, bronchodilator-dependent asthma, or chronic obstructive pulmonary disease were not  eligible. Additionally, patients undergoing therapy with calcium channel blocking agents were ineligible unless these drugs could be withheld for at least 72 h prior to protocol treatment.",NA,NA
9486605,NA,Combination,No,REGIONALLY INOPERABLE NON-SMALL CELL LUNG CANCER ,"Patients with histologically or cytologically confirmed inoperable NSCLC Stage IIIB, medically inoperable stage I-IIIA, or patients with local-regional recurrence following surgery were eligible to participate in this trial if they had measurable or evaluable disease. Normal organ function, as defined in the protocol, and an SWOG performance status of 12 were required. Patients could not have received prior chemotherapy or radiotherapy. ",Patients with cytology positive pleural effusions were excluded.Patients with a prior history of malignancy other than nonmelanoma skin cancer or cervical carcinoma in situ were excluded if their disease free interval was less than 5 years,NA,NA
9404925,NA,Combination,No,advanced ovarian or breast carcinoma,"Patients were eligible for the study if they had stage 4 ability that the incidence of unresolved grade 4 RRT would breast cancer, relapsed ovarian carcinoma or stage 3–4 not exceed 20%. ovarian carcinoma who failed to achieve a CR to initial chemotherapy. Additional inclusion criteria included: age of 70 years or less, ECOG performance status of 0–2 and evidence of adequate hepatic, renal and cardiac function. Table 1 Phase I dose escalation trial Patients were treated on an FDA-registered protocol approved by the institutional review board of the hospital Patient characteristics n = 14 (%) where the therapy was administered and all gave informed consent.",NA,from day −5 to day 28 post-PBSC infusion,high-dose utility of dose-escalation of chemotherapeutic agents withchemotherapy (HDC) and peripheral blood stem cell out hematopoietic stem cell support in patients with (PBSC) regimen for treatment of patients with ovarian advanced ovarian cancer have produced conflicting carcinoma
10491535,NA,Combination,No,Brainstem Gliomas,"Patients with pontine tumors were eligible without histologic confirmation if they were age >3 years and < 21 years at the time of radiologic diagnosis with a clinical syndrome comprised of a brief history (< 3 months) of progressive brainstem dysfunction (characterized by diplopia, facial weakness, and/or dysphagia) combined with ataxia or hemiparesis. Patients with an atypical history, neurofibromatosis, or a primary brainstem tumor arising outside the pons required histologic confirmation of a high grade glioma.",NA,NA,NA
9000605,NA,Combination,No,carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas,"Forty patients with histologically proven CUPS or inoperable pancreatic/oesophagogastric adenocarcinoma were recruited at the Royal Marsden Hospital. Patients were required to be of ECOG performance status (PS) 0-2 (Oken et al, 1982), with a minimum life expectancy of 3 months and have bidimensionally measurable disease.",Patients in whom tumour markers and imaging techniques revealed a primary tumour were ineligible for the trial (other than inoperable oesophagogastric and pancreatic adenocarcinomas).,for all cycles,NA
8656258,NA,Combination,No,primary epithelial ovarian carcinoma,"Eligibility for both studies was restricted to patients with a GOG performance status <= 2 (Karnofsky >= 50%) with adequate bone marrow (WBC count >= 4,000 cells/uL and platelet count >= 100,000/uL), renal (creatinine concentration <= 1.5 mg/dL), and hepatic (bilirubin level <= 1.5 times normal and AST <= 3 times normal) function. Patients were required to have a pathologic diagnosis of invasive epithelial ovarian or peritoneal carcinoma; patients with borderline tumors of low malignant potential were excluded.",NA,during the first cycle of therapy,NA
9001351,NA,Combination,No,Relapsed or Refractory Non-Hodgkin's Lymphoma,"Patients with relapsed or refractory lymphoma who had received standard chemotherapeutic regimens were eligible if they met the following criteria: (1) histologic and/or cytologic confirmation of non-Hodgkin's lymphoma excluding adult T-cell leukemia-lymphoma; (2) 5% or less lymphoma cells in peripheral blood and bone marrow; (3) patients with lymphoma refractory to standard chemotherapy, those with relapse after attaining CR, or those showing disease progression after attaining PR; (4) presence of measurable disease; (5) no chemotherapy or irradiation within two weeks prior to the study, and no prior chemotherapy including platinum compounds; (6) life expectancy of at least two months; (7) 15 years of age or older, and younger than 75 years; (8) performance status two or better on the Eastern Cooperative Oncology Group Scale; (9) adequate bone marrow function (leukocyte count >= 3000/ul, platelet count >= 100,000/ul, hemoglobin >= 8.0 g/dl), adequate hepatic function (bilirubin <= 1.5 mg/dl, transaminases <= 2.5 times the upper limits of normal), adequate renal function (creatinine <= 1.5 mg/ul, creatinine clearance >= 50 ml/min), and adequate pulmonary function (PaO2 >= 70 mmHg); (10) no severe complication; (11) no active double cancer; (12) written informed consent",NA,NA,NA
9514802,NA,Combination,No,Advanced Ovarian Carcinoma,"Eligibility criteria included biopsy-proven epithelial ovarian carcinoma, FIGO stage III or IV, life expectancy > 3 months, no prior radiation or chemotherapy, WBC > 3000/ul, platelet count > 100,000/ul, creatinine level > 2 mg/dl, liver function tests > 2 x normal, no prior malignancy, and informed consent. All patients were subjected to primary surgery in an attempt to reduce residual disease to < 5 mm (optimal debulking), that is, hysterectomy, oophorectomy, and omentectomy, and removal of as many intestinal metastases as possible.",NA,NA,NA
10762746,NA,Combination,No,advanced non-small cell lung carcinoma,"Previously untreated patients with histologically or cytologically proven NSCLC, and inoperable stage IIIB or IV disease, were enrolled into the study. Other inclusion criteria were: age 18±75 years; performance status (World Health Organization (WHO)) 0±2; no prior radiotherapy of the primary tumour; life expectancy of, at least, 3 months; no active central nervous system (CNS) metastatic disease unless previously irradiated with clinical and radiological improvement; adequate haematological parameters (absolute neutrophil count >1500 cells/dl and platelet count >120 000 cells/dl), normal renal (serum creatinine <1.5 mg/dl), and liver (bilirubin <1.5 mg/dl) function tests; absence of congestive heart failure or unstable angina pectoris; absence of infection or malnutrition (loss of more than 25% of the body weight), and a written informed consent signed by the patient. ",NA,during the ®rst chemotherapy cycle,NA
11036956,NA,Combination,No,advanced non-small cell lung cancer,"Eligibility for entering this study required previously untreated, histologically proven NSCLC (stage IIIB or IV), relapsing or metastatic (local or distant) disease with at least one clinically and/or radiologically measurable lesion. Additional patient eligibility criteria included age of 18-75 years inclusive, WHO performance status 42, life expectancy <= 2 weeks, adequate bone marrow function (absolute neutrophil count >= 1500/ml, platelet count >= 100 000/ml), adequate liver function (total bilirubin level <= 1.25 times normal), and adequate renal function (serum creatinine <= normal upper limit). Patients with a psychiatric condition, a history of cardiac disease (arrhythmias, congestive heart failure, myocardial infarction in previous 6 months, second- or thirddegree heart block), motor or sensory neurotoxicity (WHO grade 2 or greater) were not eligible. Further criteria for exclusion were an additional malignant disease during the previous 5 years, a documented gastrointestinal ulcer in the previous 6 months, any active infection or a co-existing medical condition. During the study other anticancer drugs, hormonal agents, corticosteroids or immunotherapy were prohibited. Women of childbearing potential had to use adequate contraception during treatment and those who were pregnant or lactating were excluded. Investigations before treatment included a medical history, physical examination, electrocardiogram (ECG), laboratory data (including white blood cell count with differential and platelet count, electrolytes, liver function tests and serum creatinine), radiological disease assessment (chest X-ray and, according to sites, site-specific X-ray, ultrasound, computed tomography or magnetic resonance imaging) and bronchoscopy.",NA,in the first cycle ,NA
9508176,NA,Combination,No,Pediatric Solid Tumors,"Eligibility criteria for transplantation included age less than 21 years and histologic verification of the malignancy. This study was mainly designed as a consolidation regimen for patients with pediatric solid tumors in first or subsequent relapses. Relapsed patients were reinduced according to the institutional regimens with chemotherapy, surgery, and/or local radiotherapy. After achieving a CR or a partial response (PR), patients were eligible for this study. Patients with progressive disease during reinduction were ineligible. Patients who achieved a CR or PR then underwent hematopoietic stem-cell harvesting. Although designed mainly for relapsed patients, patients with high-risk Ewing's sarcoma, metastatic peripheral primitive neuroectodermal tumor (PNET), metastatic rhabdomyosarcoma, and rhabdoid tumor were eligible during the first CR. High-risk Ewing's sarcoma was defined as metastatic disease with bone and/or bone marrow (BM) involvement.",Patients who had BM metastases at the time of hematopoietic stem-cell harvesting were ineligible.,NA,Double-Alkylator Non-Total-Body Irradiation Regimen With Autologous Hematopoietic Stem-Cell Transplantation. autologous BM or autologous BM plus PBSC were infused on day 0
8151314,NA,Combination,No,Recurrent Ovarian Cancer,"Patients with recurrent ovarian carcinoma who were suitable for remission reinduction with a platinum-based regimen were eligible for entry onto this study. In general, patients were considered to be platinum-responsive if they have had platinum-free interval of at least 6 months. Patients were required to have adequate performance status (PS) (Karnofsky PS >= 60%), renal function (serum creatinine level <= 2.0 mg/dL and creatine clearance >= 60 mL/min), and hepatic function (bilirubin level <= 1.5 mg/dL and prothrombin time <= 1.3 times control values), and a life expectancy of at least 3 months",NA,from prechemo cycle to the end of cycle 2,NA
8201386,NA,Combination,No,in Non-Small-Cell Lung Cancer,"Patients were eligible if they had a histologically confirmed solid malignancy or NHL either refractory to standard therapy or for which there was no generally accepted standard therapy. Patients were required to have measurable or assessable disease, Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2, adequate bone marrow function (neutrophil count > 1,500/uL, platelet count > 100.000/uL). creatinine level <= 1.5 mg/dL, and total bilirubin level <= 2 mg/dL","Patients were ineligible if they had received prior cisplatin, melphalan, mitomycin, nitrosoureas, or radiation therapy to more than 20% of the marrow-bearing bone. Patients with solid tumor malignancies were excluded if overt marrow involvement by tumor was present.",during the first cycle,NA
7620926,NA,Combination,No,recurrent malignant solid tumors of childhood,"<= 21 years of old; histologically proven recurrent disease resistant to conventional therapy; Exposure to no more than two out of three of the drugs used in ICE; No prior theatment with phase I agents; Evidence of recovery from all prior therapy, with normal renal function and normal bone marrow unless tumor involvement; A life expectancy of 6 weeks; Informed consent accordiing to institutional guidelines",NA,NA,NA
7844593,NA,Combination,No,poor-prognosis malignancies,"Patients 1 to 65 years of age with pathologically documented disease were eligible for study. Before entry onto the study, all patients underwent thorough evaluation to assess disease extent and physiologic function. Disease staging was tailored to individual diseases and included computed tomographic (CT) scans of the head, chest, abdomen, and pelvis; bone scans in patients with solid tumors; serum chemistries and complete blood cell counts; disease-related tumor markers such as lactic dehydrogenase, carcinoembryonic antigen, CA-15-3, CA-125, etc; and bilateral bone marrow (BM) aspirates and biopsies. Adequate physiologic function was required, with a pulmonary diffusion capacity ! 60% of predicted, a left ventricular ejection fraction - 50% (by multiple-gated angiogram [MUGA]), a measured creatinine clearance >= 60 mL/min, serum total bilirubin level <= 2 mg/dL, AST and ALT <= 2.5 times normal, and a Karnofsky performance status >= 80%. All patients were evaluated by an oral surgeon before HDCT to exclude active dental infections. All patients underwent psychosocial evaluation before HDCT","Patients with brain metastases, human immunodeficiency virus-positive patients, and patients with a previous history of malignancy were excluded",NA,Stem cells were reinfused on day 0
9440750,NA,Combination,No,Advanced Carcinoma of the Urothelium,"Patients were enrolled at the University of Pennsylvania Cancer Center and affiliated community institutions of the Penn Cancer Clinical Trials Group. Patients with histologically or cytologically documented metastatic or locally advanced (incurable by surgery or radiation) carcinoma of the urothelium (renal pelvis, ureter, bladder, or urethra) were eligible. All histologic subtypes were allowed, including transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, or mixed cancers. Patients could not have received chemotherapy for metastatic disease, but adjuvant chemotherapy or prior pelvic radiation therapy at least 6 months before enrollment was allowed. All patients had bidimensionally measurable disease in a nonradiated field. Patients needed a life expectancy of 2 months and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Initial laboratory requirements included an absolute granulocyte count >= 2 ,000/uL, platelet count >= 100,000/uL, and bilirubin level <= 1.5 mg/dL. No restrictions were made with respect to renal function, except that patients could not be dialysis-dependent.","Patients with active cardiac disease and those with any evidence of a significant conduction system abnormality (second- or third-degree heart block, bundle branch block, or other arrhythmia requiring medication) were ineligible",during the first and second cycle of treatment.,NA
11095134,NA,Combination,No,solid tumor,"Patients with histologically or cytologically proven solid tumors that were regractory to standard therapy or for whom there was no effective therapy were enrolled. Eligibility criteria included age 20-74 years, ECOG performance status (PS) 0-2, life expectancy > 2 months, adequate organ function (4000/mm3 <= white blood cell (WBC) counts <1000/mm3, platelet counts (plt) >=100000/mm3, hemoglobin level >= 9.5 g/dl, total bilirubin level <= 1.5 mg/dl, aspartaet aminotransferase (AST) and alanine aminotransferase (ALT) level <=2.5 times their upper normal limit, serum creatinine <= 1.3 mg/dl, blood urea nitrogen <=25 mg/dl and creatinine clearnce >= 60 ml/min). Patients were treated on an inpatient basis. Alt leat 4 weeks (6 weeks in the case of nitrosourea, CBDCA and mitomycin) must have passed after the completion of previous therapy and the patients had to have recovered from the toxic effects of previous therapy.","Exclusion criteria consisted of severe heart disease, cerebrovascular disease, uncontrollable diabetes mellitus, uncontrollable hypertension, severe infection, massive pleural effusion or ascites, active peptic ulcer, active concurrent malignancies, brain metastasis, pregnancy, lactation and use of corticosteroids. Patients who had a history of gastrointestinal disorders that might affect absorption (e.g. total gastrectomy) or who had experienced severe uncontrollable emesis from previous platinum-vased chemotherapy were excluded. Prior wide-field irradiation, e.g. greater than half of the pelvic bone, also made patients ineligible. ",during the first course,NA
11054441,NA,Combination,No,Advanced Solid Tumors,"Patients with solid tumors refractory to conventional chemotherapy or for whom no effective therapy existed, were eligible for this study. Patients were required to have at least one nonirradiated site of disease (or progressive disease since completion of radiation therapy) or an elevated tumor marker. Patients entered onto stage I of the study could have had up to a maximum of two prior chemotherapy regimens. Patients entered onto stage II of the study were required to be chemotherapy-naı¨ve. Eligibility criteria included the following: age >= 18 years old; Eastern Cooperative Oncology Group performance status <= 2 (ambulatory and capable of self-care); and ability to give written informed consent before study entry.","Patients were excluded from study participation for any of the following reasons: investigational therapy within 30 days of study entry; radiation therapy within 4 weeks of treatment; major surgery within 2 weeks; known metastases to the brain or leptomeninges; concurrent severe and/or uncontrolled medical disease; impairment of gastrointestinal function that might significantly alter absorption of valspodar (ie, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or previous small bowel resection); a history of chronic active hepatitis or cirrhosis; known seropositivity for human immunodeficiency virus; impairment of hepatic, renal, or hematologic function (ALT > 2.5 times normal, bilirubin >= 1.5 times normal, serum creatinine >= 1.5 times normal unless creatinine clearance > 50 mL/min, platelets < 100,000/mL, and absolute neutrophil count [ANC] < 1,500/mL); impairment of neuro-cerebellar function corresponding to toxicity >= grade 1 according to National Cancer Institute expanded common toxicity criteria; patients receiving treatment with any of the following agents if the drug could not be discontinued at the specified time relative to valspodar administration: (1) drugs that increase CsA concentrations (excluded 48 hours before to 48 hours after valspodar dosing): diltiazem, nicardipine, verapamil, fluconazole (>= 200 mg/d), itraconazole, ketoconazole, clarithromycin, erythromycin, bromocriptine, and danazol; and (B) drugs that decrease CsA concentration d(excluded 14 days before to end of valspodar dosing): nafcillin, rifampin, carbamazepine, phenobarbital, and phenytoin.",during the first treatment cycle,NA
7790322,NA,Combination,No,lung cancer,"Eligible patients had histologically or cytologically confirmed lung cancer. Those with small-cell lung cancer were eligible if their disease was refractory or resistant to standard chemotherapy and radiotherapy regimens. All patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of <= 2. Prior to starting the protocol, at least 4 weeks had to have elapsed since the last course of chemotherapy or radiotherapy, and in the case of a mitomycin C-, and nitrosourea-containing regimen, at least 8 weeks had to have elapsed since the last course of chemotherapy. The patients were also required to have adequate bone marrow, hepatic and renal function, manifested as a white blood cell (WBC) count of >= 4,000/µI, platelet count of >= 100,000/µl, hemoglobin of >= 10 g/dl, total serum bilirubin of <= 1.5 mg/di, serum transaminases <= 2 X normal limit and serum creatinine <= 1.2 mg/di. Measurable disease was not a prerequisite for entry into this study. ","Patients with massive pleural effusion, ascites and/or pericardia} effusion were con­sidered ineligible, and those with another concomitant malignancy and/or other serious medical or psychiatric disease were excluded. ",NA,NA
8931678,NA,Combination,No,Extensive Small Cell Lung Cancer,"Eligibility criteria included histologically proven extensive SCLC, performance status (PS) (ECOG) of ≤2, age ≤70 years, no previous chemotherapy, white blood cells (WBC) > 4,000/mm3 , platelets > 100,000/mm3, and normal cardiac, hepatic, and renal functions.",NA,NA,NA
9220292,NA,Combination,No,stage IV non-small cell lung cancer,"The eligibility criteria included: 1) measurable or evaluable, histologically-documented, stage IV NSCLC; (2) age >= 18 years; (3) an ECOG performance status <= 2; (4) no prior chemotherapy; (5) no prior radiotherapy to > 25% of hematopoietic reserves; (6) adequate hematopoietic (absolute neutrophil count [ANC] >= 1500/uL and platelet count >= 100,000/uL), hepatic (total bilirubin <= 2.0 mg/dL), and renal (creatinine <= 2.0 mg/dL) functions; (7) no prior hypersensitivity reactions to drugs formulated in polyoxyethylated castor oil (Cremophor EL) or products derived from E. coli for patients treated at dose levels requiring G-CSF; (8) no brain metastases that have not been previously treated with radiation; and (9) no other co-existing medical problems of sufficient severity to prevent full compliance with the study. All patients gave written informed consent according to federal and institutional guidelines prior to treatment.",NA,in courses 1 and 2,NA
10944128,NA,Combination,No,"Ovarian, Peritoneal, and Tubal Carcinoma","Patients were entered onto this Gynecologic Oncology Group study between August 1996 and August 1998. All patients had adenocarcinoma of the ovary, peritoneum, or fallopian tube diagnosed within 12 weeks and confirmed histologically by review of the GOG Pathology Committee. All stages of disease were eligible. Patients were required to have no history of other malignancy, chemotherapy, or radiation therapy; to have GOG performance status of 2 or better; and to have had recovered from prior surgery. In view of the limitations of commercially available oral dosing of etoposide, the patient was required to have at least 1 m2 of body-surface area and adequate intestinal function (ie, the patient could not require intravenous hydration or nutritional support). Pretreatment laboratory eligibility requirements included the following: leukocyte count >= 3,000/mL, platelet count >= 100,000/mL, granulocyte count >= 1,500/mL, creatinine <= 2.0 mg/100 mL, bilirubin <= 1.5 times the institutional upper limit of normal, and AST and alkaline phosphatase # three times the institutional upper limit of normal.","Excluded were patients with a GOG performance status of 3 or 4, tumors of low malignant potential (borderline tumors), active infection, hepatitis, gastrointestinal bleeding, a history of a myocardial infarction, abnormal cardiac conduction diagnosed within 6 months, or unstable angina.",the first cycle of chemotherapy,NA
7666081,NA,Combination,No,Advanced Malignancy,"Eligibility requirements included the following: histologically confirmed cancer unresponsive to previous chemotherapeutic regimens or for which no standard chemotherapeutic regimen existed; Karnofsky performance status 2- 60%; and adequate renal and bone marrow function, defined as a creatinine level <= 1.5 mg/dL or creatinine clearance >= 60 mL/min, and hemoglobin level >= 10 g/dL, platelet count >= 150,000/uL, and total WBC count >= 4,000/uL. In addition, bilirubin level was required to be <= 1.5mg/dL and hepatic transaminase levels were required to be less than three times the upper limit of normal. Patients must have recovered from the toxicity of any previous chemotherapy or radiotherapy. All patients provided voluntary, informed consent and signed an informed-consent document approved by the City of Hope National Medical Center Institutional Review Board.",NA,during the first 2 cycles,NA
10785477,NA,Combination,No,Advanced Epithelial Ovarian Cancer,"Patients with histologically confirmed stage IV epithelial ovarian carcinoma (EOC) or with stage III EOC and any amount of gross residual disease after surgical debulking were eligible for the study. Other eligibility criteria included age at least 18 years; Eastern Cooperative Oncology Group (ECOG) performance status 0–2; white blood cell (WBC) count >= 3000/uL and platelet count >= 100,000/uL; serum bilirubin, ALT, and alkaline phosphatase <= the upper limit of normal; and calculated creatinine clearance >= 30 mL/min as determined by the Jelliffe formula (using ideal body surface area of 1.73 m2 as previously described)",Patients were not eligible if they had received previous chemotherapy or radiation for ovarian cancer. Patients with borderline tumors of low malignant potential were excluded.,during the first treatment cycle,NA
9740546,NA,Combination,No,advanced solid tumors,"Criteria for study entry consisted of histologically or cryotologically demonstrated advanced solid tumors not previously treated with chemotherapy. Patients were required to have measurable or assessable disease, a performance status of 0–2, a life expectancy > 8 weeks, a pretreatment white blood count ≥ 4,000/µl, platelet count ≥ 150,000/µl, serum creatinine ≤ 1.5 mg/minute, and a serum bilirubin and SGOT within 1–1/2 times institutional normal limits.",Patients with known brain metastasis or clinically significant third space fluid accumulation were not eligible. ,during the first cycle of therapy,NA
9020283,NA,Combination,No,Extensive Small-Cell Lung Cancer,"Patients with extensive histologically or cytologically documented SCLC were eligible for study. Staging evaluation included a complete physical examination, blood counts, electrolytes, liver function tests, creatinine clearance, chest x-ray, isotopic bone scan, bone marrow aspirate and biopsy, and computed tomography (CT) scans of the brain, chest, and abdomen. Extensive disease was defined as tumor spread beyond the confines of one lung, the mediastinum, contralateral hilar nodes, or ipsi- or contralateral supraclavicular nodes. A malignant pleural effusion was considered extensive disease. Also required were a performance status of ≥2 (CALGB criteria), a life expectancy of at least 2 months, no previous or concomitant malignancy, and no prior chemotherapy or radiotherapy. The required pretreatment peripheral blood granulocyte count was >1,800/μl, platelet count >100,000/μl, and serum creatinine, BUN, and bilirubin <1.5 × normal. All patients gave informed consent.",NA,during cycle one,NA
9143391,NA,Combination,No,Children With Malignant Solid Tumors,"Between June 1991 and July 1993, 28 children (<= 21 years of age) with refractory solid tumors or tumors for which no standard therapy was available were entered on a clinical trial of chemotherapy with ifosfamide, carboplatin, and etoposide (ICE), preceded by escalating doses of rhuIL-1a. Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status of at least 2, a life expectancy of at least 8 weeks, adequate renal and liver function (serum creatinine <2.0 mg/dl;bilirubin <2.0 mg/dl; alkaline phosphatase #3 times normal), absolute neutrophil count (ANC) >= 1,000/ml, packed red cell volume >29%, and platelet count >=100,000/ml.",NA,NA,NA
10071285,NA,Combination,No,Stage IIIB-IV Non–Small-Cell Lung Cancer,"Eligibility criteria for study entry included histologically or cytologically confirmed stage IIIB or IV NSCLC; age 18 to 75 years; no prior chemotherapy; an Eastern Cooperative Oncology Group performance status of 0 to 2; adequate baseline organ function, defined as a WBC count of at least 3,000/µL, a platelet count of at least 100,000/µL, a bilirubin level of less than 1.5 mg/dL, serum transaminase levels of less than 2 times the upper limit of normal, and a creatinine value of less than 1.4 mg/dL; and a life expectancy of at least 12 weeks. Prior palliative radiotherapy to symptomatic metastases was allowed, provided that these lesions were not monitored for tumor response",NA,during the first cycle,NA
10466861,NA,Combination,No,advanced non-small cell lung cancer,"Patients were required to have cyto- or histologically proven NSCLC, clinically staged as IIIb or IV, without previous radio- and/or chemotherapeutic treatments. Patients were also required to have objective measurable (bidimensionally) or evaluable (unidimensionally) disease, a life expectancy of at least 12 weeks, an ECOG performance status <=2, age between 18 and 75 years old, adequate bone marrow function (white blood cell count ]3000/mmc, platelet count >= 100 000/mmc), hepatic and renal function. Patients with previous cancer, except adequately treated basal cell carcinoma of the skin or carcinoma of the cervix, patients with a history of serious cardiac disease, unless adequately controlled, those with pre-existing motor or sensory neuropathy \WHO grade I and patients with active infections were excluded from the study.All patients signed a written informed consent for treatment according to the protocol submitted and approved by regional ethical committees.",NA,during cycle 1,NA
8882989,NA,Combination,No,small cell lung cancer,"(1) Diagnosed as having SCLC by cytological or histologic study. (2) Age <= 75 years. (3) Performance status O-2. When patients received prior chemotherapy, a washout period of at least 4 weeks was required, with no residual effect of the treatment. (4) Satisfactory organ function (leukocyte count >= 3000/mm3, platelet count >= 100000/mm3, GOT and GPT less than twice the upper limit of normal range, total bilirubin <= 1.5 mg/dl, and creatinine <= 1.4 mg/dl). ",NA,during the first two courses,NA
9209665,NA,Combination,No,advanced epithelial ovarian cancer,"Inclusion criteria were histologically confirmed epithelial ovanan cancer, age > 18 and <= 75 years, Eastern Cooperative Oncology Group performance status of 2 or better, and adequate bone-marrow function (absolute neutrophil count >= 2 x 1O9/1 and platelet count >= 100 x 1O9/1), adequate renal and hepatic function (creatinine and bilirubine <= 1.25 x upper limit of normal). ","Patients were ineligible, if they had prior malignancies excluding non-melanomatous skin cancer, prior chemo- or radiotherapy, a history of atnal or ventricular arrhythmias, congestive heart failure or a history of myocardial infarction, pre-existing motor or sensory neurotoxicity of WHO grade 2 or greater, active infection, bowel obstruction, and mental disorders.",the first four consecutive courses,NA
10231137,NA,Combination,No,advanced ovarian cancer,All patients were FIGO stage III and IV. Stage III patients had either tumor residue .2 cm in diameter or prior extensive infiltration of the intestine or upper abdomen,NA,NA,Chemotherapy was started 3 to 4 weeks after debulking surgery. The first cycle of therapy was supported by PBPCs collected after a minimum of 4 days of filgrastim (5 or 10 mg/kg/day s.c.) priming. 
8398708,NA,Combination,No,cancer that was refractory to or relapsed,"Patients were eligible for participation in this trial if they were 18 years of age or older and had a histologically proven diagnosis of cancer that was refractory to or relapsed after conventional modes of therapy or for which no effective chemotherapy exists. All patients were fully ambulatory and had a life expectancy of at least eight weeks. Patients had to have recovered from the toxic effects of prior therapy and have normal renal (creatinine < 1.5 mg dl-') and hepatic function (bilirubin <1.5 mg%, SGOT less than three times the upper limit of normal). Hematologic parameters required a granulocyte count greater than 1,500 mm-3 and platelet count greater than 100,000 mm-3. Written informed consent was obtained prior to entry on the study.",NA,NA,High risk - more than six prior cycles of chemotherapy or age greater than 70.Low risk - less than six prior cycles of chemotherapy and age less than 70.
2651580,NA,Combination,No,unresectable or metastatic malignancy ,"Patients with histologically confirmed, unresectable or metastatic malignancy for whom curative or standard palliative therapy was unavailable were eligible for the study. Initial evaluation included a history and physical examination, chest x-ray, and audiogram. Patients undergoing ABMT were further required to have a histologically tumor-free bone marrow aspirate and biopsy, no evidence for CNS tumor on computerized tomography, and normal pulmonary function tests.","Patients were excluded from the study if they had abnormal hepatic or renal serum chemistries, a WBC count < 3 ,000/ul, a platelet count < 100,000/ul, or a 24-hour urinary creatinine clearance < 60 mL/min",NA,"autologous bone marrow reinfusion was added to the regimen at doses of 1,600 mg/m' and above"
32590047,NCT02442531,Combination,No,advanced solid tumours,"Eligible patients had a pathologically confirmed diagnosis of an advanced solid tumour with no standard therapy options, with measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. Eligible patients were ≥ 18 years of age, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and had adequate haematological, liver and renal function. Eligible patients had to have a haemoglobin > 9.6 g/dL, absolute neutrophil count (ANC >1,500 / mm3, platelet count >100,000 /mm3, serum bilirubin < 1.5 x upper limit of normal (ULN), serum creatinine < 1.5 x ULN and a calculated Glomerular Filtration Rate of >50 mL/min","Patients with symptomatic brain metastases and/or toxicities resulting from previous anticancer therapy (radiation therapy, chemotherapy or surgery) that had not resolved to ≤ grade 2 (according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03) were not eligible.",during treatment cycle 1,NA
25762000,NCT00566410,Single Drug,No,advanced solid tumors,"Patients with histologically or cytologically confirmed, treatment-refractory advanced solid tumors were eligible. Prior chemotherapy or radiotherapy must have been completed at least 4 weeks before study entry and all significant previous treatment-related toxicities must have resolved to grade≤1. Additional eligibility criteria included: age≥18 years; ECOG performance status≤2; left ventricular ejection fraction> 50 %; life expectancy>12 weeks; adequate hematologic (absolute neutrophil count≥1500/μL, platelet count≥100,000/ μL), adequate renal (serum creatinine≤1.5 mg/dL or a calculated creatinine clearance≥50 mL/min), and hepatic function (serum bilirubin≤upper limit of normal (ULN) and aspartate aminotransferase within 2.5X ULN). ","Patients were ineligible if they had any of the following criteria: brain metastases; grade≥2 peripheral neuropathy; allergy to compounds similar to DCA; malabsorption syndrome; taking coumadin, oral hypoglycemics and/or insulin use; known infection with HIV or significant intercurrent illness.",during the first cycle,NA
1846407,NA,Combination,No,malignancy and had failed any curative regimen available,"Eligible patients had histologically documented malignancy and had failed any curative regimen available. Patients with advanced metastatic sarcoma or relapsed germ cell carcinoma could be treated during response to standarddose regimens; other patients had progressive disease. A Cancer and Leukemic Group B performance status 0 to 1, WBC >= 3,000/LL, platelets >= 100,000/iL, normal renal and hepatic function (creatinine, SGOT, bilirubin <= 1.5 x normal, creatinine clearance >= 60 cc/min) and written informed consent were required.",NA,NA,NA
23335436,CCI-06-00092,Combination,No,Relapsed or Refractory Extracranial Non-Hematopoietic Solid Tumors,"Patients <= 21 years of age with a histologically confirmed extra-cranial solid tumor which was refractory to conventional therapy, body weight >= 10 kg, a Karnofsky or Lansky performance score of >50%, and with an expected life expectancy of >= 8 weeks were eligible. Organ function requirements were as follows: peripheral blood neutrophil count (ANC) >= 750/ul, platelet count >= 75,000/ul (transfusion-independent), Hemoglobin >= 8 g/dl; ANC >= 500/ul, platelet count >= 50,000/ul (transfusion-independent) in patients with bone marrow involvement; normal serum creatinine for age or a glomerular filtration rate of >= 70 ml/min/m2; left ventricular shortening fraction of >= 28% by echocardiogram or ejection fraction of >= 55% by MUGA scan; bilirubin level <= 1.5  upper limit for age, alanine aminotransferase <= grade 2. Patients must have recovered from toxic effects of prior therapy; and not received (1) myelosuppressive therapy within 2 weeks (6 weeks if nitrosurea); (2) biological agent within 2 weeks; (3) small-port palliative radiotherapy within 2 weeks; (4) total body, craniospinal or hemi-pelvic radiation within 6 months; (5) autologous or allogeneic stem cell transplant in the previous 6 months; (6) hematopoietic growth factors within 1 week.","Patients who had previously received oxaliplatin or cumulative anthracycline (doxorubicin equivalent) dose of >450 mg/m2 were ineligible. Pregnant or breast feeding females, and patients with uncontrolled infection were excluded.",during the first course,NA
1698110,NA,Combination,No,Advanced Malignant Tumors,"Patient eligibility requirements included: a Karnofsky performance status of 2 60%; a life expectancy of at least 6 weeks; serum bilirubin < 2 mg%; white blood cells > 4000/ul and platelets > 150,OOO/pl; blood urea nitrogen (BUN) < 30 mg%, creatinine < 1.5 mg%, and/or creatinine clearance of at least 50 cc/min/l.73 m2; maximum of one prior chemotherapeutic regimen (multidrug regimen permissible). No chemotherapy could have been given within 4 weeks of carboplatin therapy (6 weeks for mitomycin C and nitrosoureas). Patients must have given signed informed consent. Measurable disease was desired but not required. ",NA,NA,NA
2162912,NA,Combination,No,Solid Tumor Patients,"Patients aged less than 20 to 55 years with metastatic or unresectable cancer, for whom no additional chemotherapy with established benefit existed, were evaluated by history, physical examination, pathologic review, hepatic and renal chemistries, ECG, chest roentgenogram, pulmonary function testing, computed tomography (CT) of the head, and bilateral posterior iliac crest biopsies","Patients with bone marrow or CNS metastases, significant hepatic, renal or cardiopulmonary impairment, performance status greater than 1, or prior pelvic radiation were excluded.",NA,With Autologous Bone Marrow Transplantation (day 0)
2072142,NA,Combination,No,Locally Advanced Head and Neck Squamous Cell Carcinoma,"Eligible patients had a locally advanced (stage III or IV), histologically confirmed squamous cell carcinoma of the larynx, hypopharynx, oropharynx, or oral cavity without previous surgery, radiotherapy, or chemotherapy. Other eligible criteria included good Karnofsky performance status (> 70), no previous malignancy except cured basal cell carcinoma or stage Ia squamous cell carcinoma of the cervix, creatinine level <= 1.2 mg/dL or creatinine clearance >= 70 mL/min, granulocyte count >= 2,000/uL, and platelet count > 150,000/uL.",NA,NA,NA
33144248,NA,Combination,No,inoperable esophageal squamous cell carcinoma,"Study subjects were recruited between November 2016 and October 2019. All eligible patients were: (1) histologically confirmed ESCC; (2) inoperable stage II-IVB disease based on the TNM staging system proposed by the American Joint Committee on Cancer (8th edition) ; (3) aged from 18 to 70 years; (4) Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1–2. The main exclusion criteria included: (1) contraindication for chemotherapy or radiotherapy; (2) prior malignancy, except for non-melanoma or cervical carcinoma in situ.",NA,NA,NA
33870151,NCT02223247,Combination,No,in advanced tumors,"Adult men and women with histologically- or cytologically- confirmed metastatic or advanced solid malignant tumors refractory to standard therapy were eligible. Patients may have received up to 4 prior cytotoxic chemotherapy regimens for metastatic disease as well as prior endocrine therapy and/or non-myelosuppressive therapy. Patients were required to have adequate renal, hepatic, and bone marrow function and performance status (Eastern Cooperative Oncology Group [ECOG] performance status [PS] of 0 or 1).",NA,within the first treatment cycle (Days 1 to 21 of cycle 1 for monotherapy cohort(s); Days 1 to 28 of cycle 1 for combination with anti-cancer agent cohort(s)),NA
8281628,NA,Combination,No,solid tumors refractory ,"Patients were being treated as the three participating cancer centers (Wayne State University, University of New Mexico and University of Arizona); they had documented solid tumors refractory to standard therapy or no standard therapy existed for them. Further inclusion criteria were: measurable or evaluable disease, Southwest Oncology Group performance status of 0-1, granulocyte count >= 1500/ul, platelet count >= 100,000/ul, creatinine clearance (calculated or measured) of >= 60 ml/min, and serum bilirubin <= 2.0 mg/dl. The results of all blood work and scans for disease measurement were obtained within 14 days of treatment registration. All patients were required to have signed an informed consent form reviewed and previously approved by the institutional investigational review board.","Patients were not included if they had a history of myocardial infarction or congestive heart failure, and had to have had a MMGA scan demonstrating an ejection fraction >= 50%. Patients were excluded if they had had prior chemotherapy with anthracyclines. Patients could have received prior cisplatin. Patients with concomitant serious medical illnesses and those who were pregnant were excluded.",during the first cycle,NA
1403054,NA,Combination,No,Lymphomas and Solid Tumors,"Eligible patients were 18 years of age or older with documented breast cancer, testicular cancer, or lymphoma (Hodgkin's and non-Hodgkin's) after standard therapy and for whom conventional therapy had no curative potential. Patients with breast and testicular cancers received aggressive chemotherapy immediately before ICE/autologous bone marrow transplantation (AuBMT), and all had persistent disease despite this therapy. All of the patients with lymphoma had relapsed after primary induction treatment or did not achieve an initial remission, and were treated with combination chemotherapy until they achieved minimal residual disease or CR immediately before ICE and AuBMT. Before study entry, all patients were evaluated to determine the extent of disease and physiologic reserve. Routine disease evaluation included physical examination, blood chemistries, complete blood cell count, serum p-HCG and AFP levels, computed tomography (CT) of the chest and abdomen, lymphangiogram in patients with lymphoma, bone scan in patients with breast cancer and bilateral bone marrow biopsies. Adequate physiologic reserve was required with cardiac ejection fraction >= 40%, creatinine clearance >= 50 mL/min, bilirubin <= 1.5 mg/dL, SGOT less than two times normal, pulmonary forced expiratory volume in 1 second more than 55%, and Karnofsky performance status >= 60. ","Patients at risk or with signs of CNS disease underwent a lumbar puncture and a head CT scan, and were ineligible if there was evidence of disease. Patients with bone marrow disease at the time of ICE and AuBMT were ineligible unless they had a low-grade non-Hodgkin's lymphoma that was positive for the CD20 cell-surface marker, which involved less than 25% of the bone marrow; the harvested marrow of these patients underwent purging with monoclonal anti-B1 antibody and complement.",NA,a single course of ICE with autologous bone marrow rescue
8270975,NA,Combination,No,Refractory Ovarian Carcinoma,"Patients with histologically confirmed advanced malignancies were eligible if 4 weeks had elapsed since prior chemotherapy and 6 weeks since prior nitrosurea or radiation therapy. Eligibility criteria included adequate end organ function: renal (measured or calculated creatinine clearance > 60 mL/min), hepatic (serum transaminases < twice normal), cardiac (left ventricular ejection fraction > 0.45 by multiple-gated angiogram scan), and hematologic (WBC count > 3,500/uL, hemoglobin level > 10 g/dL, platelet count > 100,000/uL). Patients had to be younger than 65 years of age, human immunodeficiency virus-negative, and free of active infections at time of bone marrow harvesting. Tumor-free bone marrow was assessed by bilateral bone marrow aspirates and biopsy, bone scan, and pelvic radiographs.","Exclusion criteria included pregnancy, prior hemorrhagic cystitis, hearing loss in the voice tones, and Southwest Oncology Group performance status >= 2",NA,NA
8422699,NA,Single Drug,No,metastatic solid tumors ,"The inclusion criteria included a life expectancy of 12 weeks, a performance status of at least 2 Zubrod , an age of between 18 and 80 years, adequate bone marrow function (an absolute granulocyte count of > 1500/ul and a platelet count of > 100,000/ul); adequate hepatic function (bilimbin values of <1.5 rag/100 ml and alkaline phosphatase and transaminase levels of less than twice the normal values), and adequate renal function (creatinine clearance of >60 mil/min as determined by 24-h collection). ","Excluded from the study were patients who had received cytotoxic chemotherapy or radiation therapy during 3 weeks prior to enrollment (6 weeks for mitomycin or nitrosonreas); those who had received more than one prior chemotherapy regimen containing a platinum compound, who had undergone major surgery within 2 weeks of study entry, or who had comorbid medical conditions; those with a clinical hearing deficit or a history of peripheral neuropathy or myopathy; those who had received aminoglycoside antibiotics within 4 weeks of enrollment; mad those with brain metastases. ",NA,NA
21152384,NA,Combination,No,Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas,"Patients were eligible if they had a histologically or cytologically documented advanced solid malignancy or NHL, refractory to standard therapy or for which no standard therapy existed. Other key eligibility criteria included: Eastern Cooperative Oncology Group performance status 0 to 2; adequate hematologic, hepatic, and renal functions [white blood cell count >= 3 x 109/L, absolute neutrophil count (ANC) >= 1.5 x 109/L, platelets >= 100 x 109/L, AST(aspartate aminotransferase)/ALT (alanine aminotransferase) <= 2.5 times upper limit of normal, bilirubin within normal limits, creatinine <= 150 mmol/L and creatinine clearance >= 60 mL/minute]; unlimited prior chemotherapy, radiotherapy or targeted agents with at least 3-week interval (6-week interval if prior nitrosoureas or mitomycin C) between study entry and any prior treatment; no valproic acid or other HDACi for at least 2 weeks before study entry; no prior decitabine; and no known brain metastases",NA,during the first cycle of treatment,NA
34310349,NA,Combination,No,Refractory Solid Tumors,"Eligible patients met the following inclusion criteria: (1) Histologic or cytologic diagnosis of a refractory solid malignancy or a solid malignancy that had no remaining effective therapy. (2) Patients may have received no >2 prior chemotherapy regimens in the metastatic setting. (3) Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. (4) Age 18 years old and above. (5) Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. (6) Life expectancy ≥ 8 weeks. (7) Adequate organ function defined for: (a) bone marrow: absolute neutrophil count ≥1500/mm3, platelets ≥ 100,000/mm3, and hemoglobin ≥9 g/dL; (b) liver function: bilirubin ≤1.5×institutional normal, alanine aminotransferase/serum glutamicpyruvic transaminase, aspartate aminotransferase/serum glutamic-oxaloacetic transaminase, and alkaline phosphatase ≤2.5×institutional normal; (c) kidney function: creatinine ≤ 2.0 mg/dL or creatinine clearance ≥ 60 mL/min.","Exclusion criteria included: (1) Active central nervous system metastases or spinal cord compression. (2) Last dose of chemotherapy or radiotherapy received within 4 weeks before the start of protocol treatment including palliative radiotherapy. (4) Patients with known hypersensitivity reactions to macrolide antibiotics (such as erythromycin, clarithromycin, and azithromycin). (5) Coadministration of potent cytochrome CYP3A4 or CYP2D6 inducers or inhibitors",during the first cycle,NA
2258073,NA,Single,No,Early Ovarian Cancer ,"Patients with histologically verified epithelial ovarian cancer FIG0 stage IB low and intermediate grade plus all stage II entered the study. Additional inclusion criteria were radical primary surgery with no evidence of residual tumor, WBC count >= 3.0 x log/liter, platelet count >= 100 X log/liter, creatinine clearance >= 55 ml/min, normal hepatic function, Karnofsky performance status >= 60, and oral informed consent according to the local committee of research ethics. ",Patients previously treated with chemo- or radiotherapy were not eligible. ,NA,NA
9427692,NA,Single,No,relapsed cutaneous T-cell lymphoma (CTCL),"Patients of legal consenting age of either sex were eligible for treatment if they had CTCL, other NHL, or HD disease. Pathologic confirmation and determination of IL-2R expression on malignant cells was required within 6 months of enrollment or after most recent therapy. Patients were required to have an evaluable tumor burden, a performance status of .70% (Karnofsky), and preserved organ function.",NA,NA,NA
34263358,NA,Combination,No,locally advanced squamous cell carcinoma of the external auditory canal,"Eligibility criteria were as follows: (1) newly diagnosed, previously untreated, histologically confrmed squamous cell carcinoma arising from the external or middle auditory canal; (2) T3 or T4 disease and any N stage according to the modifed Pittsburgh classifcation; (3) no distant metastatic disease; (4) age ranging from 20 to 75 years; (5) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, (6) no previous history of radiotherapy in the head and neck lesion, (7) no chemotherapy for other carcinomas within 3 years, and (8) retention of major organ function and laboratory test values meeting the following criteria at least within 14 days before enrollment: white blood cell≥3000/mm3, neutrophils ≥ 1500/mm3, platelet ≥ 10 × 104/mm3, hemoglobin≥9.0 g/dL, total-bilirubin≤1.5 mg/dL, creatinine≤1.2 mg/dL or creatinine clearance≥60 ml/min.","Exclusion criteria were as follows: (1) severe uncontrolled intercurrent illness including symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, uncontrollable hypertension, or any other condition or circumstance that could interfere with adherence to the study’s procedures; (2) prior treatment with any of the chemotherapy medications; (3) prior bone marrow transplant or history of organ transplant requiring the need for any chronic immunosuppressive medications; (4) major psychiatric disorders that would limit compliance; (5) active infection requiring systemic antibiotic therapy; (6) pregnant or breast-feeding females; (7) known prior severe allergy or hypersensitivity to the chemotherapy or any of the components of the study treatment.",from day 1 to day 50,NA
32600929,NCT00916123,Combination,No,metastatic castration resistant prostate cancer,Subjects with histologically or cytologically confirmed prostate cancer with castration-resistant progression per Prostate Cancer Working Group 2 were eligible to enroll. Subjects with prior docetaxel therapy were eligible for the study provided that they did not have disease progression while receiving chemotherapy and all docetaxel-related toxicities had resolved to grade 1 or less (with the exception of alopecia). No selection for PSMA-positivity was used.,"Exclusion criteria included ECOG Performance Status >2, platelet count <150,000/mm3, absolute neutrophil count <2,000/mm3, need for platelet transfusions or hematopoietic growth factors, and cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment. Subjects with prior radiation therapy encompassing >25% of skeleton, prior treatment with bone-targeted beta-emitters (such as strontium-89 or samarium-153) were excluded.",NA,NA
10071279,NA,Combination,No,Advanced Breast Cancer,"Patients were required to have histologically confirmed adenocarcinoma of the breast that was either locally advanced (stage IIIB) or metastatic (stage IV) and to have disease that was measurable or assessable. Other requirements included (1) age at least 18 years and less than 70 years; (2) Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2; (3) normal organ function (ie, normal total bilirubin and AST , two fold the upper limit of normal, neutrophil count > 1,500/µL, platelets > 100,000/µL); (4) no prior chemotherapy for metastases; (5) no prior adjuvant doxorubicin or taxane; (6) no adjuvant chemotherapy within 6 months of registration; (7) normal LVEF as measured by radionuclide angiography or echocardiography within 4 weeks of registration; (8) no risk factors of doxorubicinassociated cardiomyopathy (ie, no atherosclerotic heart disease, no hypertension requiring therapy within 3 months of registration, no irradiation to the mediastinum or left chest wall after mastectomy, and age < 70 years); (9) not taking drugs known to alter cardiac conduction (ie, digoxin, beta blockers, or calcium channel blockers); (10) no history of irradiation to a field encompassing more than 25% of bone marrow; and (11) no symptomatic or untreated brain metastases",NA,during cycles 1 and 2,NA
17442993,NA,Combination,No,Children With Relapsed Solid Tumors,"Eligibility criteria included age older than 1 year and younger than 22 years; a diagnosis of a malignant solid tumor (excluding lymphoma and CNS tumors) refractory to conventional therapy; Karnofsky (children older than 10 years) or Lansky (children <= 10 years) score >= 50; life expectancy >= 8 weeks; recovery from prior therapy; no chemotherapy within 2 weeks (6 weeks for prior nitrosourea therapy) and no biologic agent or growth factor therapy within 1 week of study entry; no substantial radiotherapy to the bone marrow within 6 weeks of study entry; no allogeneic stem-cell transplantation within 6 months of study entry and no active graft-versus-host disease; normal ageadjusted serum creatinine or glomerular filtration rate >= 70 mL/min/1.73 m2; serum bilirubin concentration <= 1.5 x and serum ALT <= 3 x the upper limit of the normal for age; and a cardiac shortening fraction >= 28% or an ejection fraction >= 45%. Initially, patients were allowed to enroll onto the study with the following hematologic requirements: an absolute neutrophil count >= 500/uL, a platelet count >= 50,000/uL, and a hemoglobin concentration >= 8 g/dL. Once the initial DLT was found to be myelosuppression, patients had to have an absolute neutrophil count >= 1,000/uL, a platelet count <= 100,000/uL, and a hemoglobin concentration  >= 8 g/dL. No limitation was placed on the number of prior chemotherapy regimens","Study exclusion criteria were uncontrolled infection or systemic illness, total lifetime anthracycline dose more than 450 mg/m2, and pregnancy or lactation.",NA,NA
8383914,NA,Combination,No,extensive small-cell lung cancer,"Patients with extensive histologically or cytologically documented SCLC were eligible for study. Staging evaluation included a commplete physical examination, blood cell counts, electrolytes, liver function tests, creatinine clearance, chest x-ray, isotopic bone scan, bone marrow aspirate and biopsy, and computed tomography (CT) scans of the brain, chest, and abdomen.Extensive disease was defined as tumor not confined to a lung, mediastinum, contralateral hilar nodes. A malignant pleural effusion was considered extensive disease. Also required were measurable disease, a performance status of 2 or better (CALGB criteria), a life expectancy of at least 2 months, weight loss of less than 10% in the previous 6 months, and no previous or concomitatnt malignancy. Pretreatment peripheral blood granulocyte count required was > 1,800/ul, platelet count > 100,000/ul, and serum creatinine, BUN, and bilirubin <1.5 X normal. All patients gave informed consent. ",NA,NA,NA
29463550,NCT01546038,Combination,No,Patients with AML or High-Risk MDS,"Adult patients (18 and older) were included in this study if they had newly diagnosed and previously untreated AML (de novo AML, AML evolving from MDS or other prior hematologic malignancy, or AML secondary to previous cytotoxic or radiotherapy) or refractory anemia with excess blast 2 high-risk MDS by the World Health Organization 2008 classification. Patients were allowed 1 prior regimen with a commercially available agent for prior hematologic disease, but no prior therapy for their AML. Patients had to have adequate hepatic function [aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3 x upper limit of normal (ULN), or AST and ALT <= 5 x ULN if liver function abnormalities were due to underlying malignancy] and renal function (serum creatinine <= 1.5 x ULN or estimated creatinine clearance >= 60 mL/min), and Eastern Cooperative Oncology Group performance status (ECOG PS) 0–2.","Patients were excluded if they had t(9;22), acute promyelocytic leukemia; hyperleukocytosis (leukocytes >= 30 x 109/L) at screening (hydroxyurea or leukopheresis were allowed before and up to  1 week after first dose of glasdegib for control of rapidly progressing leukemia); known active leukemia in the central nervous system; received prior treatment with an Hh inhibitor or other investigational agents for hematologic malignancies; ongoing or recent cardiac disease [i.e., myocardial infarction, congenital long QT syndrome, torsades de pointes, clinically significant ventricular arrhythmia, or QTc interval > 470 msec using the Fridericia (QTcF) correction formula].",during the first-cycle,NA
15113758,NA,Single Drug,No,patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation,"Informed consent was obtained from patients before they enrolled. Diagnosis of acute GVHD was made clinically and supported with biopsies in most cases. Steroidrefractory GVHD was defined as no improvement in GVHD after 2 weeks on corticosteroids (>= 1 mg/kg methylprednisolone), progression of GVHD after 1 week on corticosteroids, or GVHD flare after taper that was nunresponsive to corticosteroid rechallenge. ","Mechanical ventilation, serum creatinine level 3 mg/dL or higher, dialysis, vasopressor requirement, Eastern Cooperative Oncology Group (ECOG) performance status more than 3, alanine aminotransaminase (ALT) or aspartate aminotransaminase (AST) level equal to or more than 5 x upper limits of normal (ULN), and serum albumin level 1.5 g/dL or less were exclusion criteria. Patients were excluded if they received daclizumab within 7 days or had other immune suppressive agents added within 3 days of enrollment.",NA,NA
18719348,NA,Combination,No,Advanced Gastric Cancer,"Eligible patients had to meet the following criteria: (1) a histopathologically confirmed diagnosis of adenocarcinoma of the stomach that was unresectable or recurrent; (2) an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; (3) only measurable or assessable lesions; (4) no prior treatment (e.g. radiotherapy, chemotherapy and hormone therapy); (5) age between 20 and 80 years; (6) no serious organ dysfunction, i.e. a leukocyte count >= 3 x 10 3 /ul, a platelet count >= 100 x 10 3 /ul, a serum total bilirubin level <= 1.5 mg/dl, serum concentrations of aspartate (AST) and alanine aminotransferase (ALT) not exceeding 2.5 times the upper limit of normal (in patients with liver metastasis, serum concentrations of AST and ALT not exceeding 5 times the upper limit of normal at the institution performing the test), a serum creatinine concentration <= 1.5 mg/dl and a creatinine clearance >= 50 ml/min in a 24-hour urine specimen; (7) a normal electrocardiogram (no electrocardiographic abnormalities requiring treatment); (8) the ability to take oral medication; (9) an expected survival of at least 8 weeks, and (10) no serious complications or other active cancers. All patients gave written informed consent to participate in the study.","Exclusion criteria were: (1) serious complications, e.g. ischemic heart disease requiring treatment and heart disease with arrhythmias (except for conditions such as left ventricular hypertrophy associated with hypertension; mild left ventricular volume overload, or mild right bundle-branch block), myocardial infarction within the past 6 months, liver cirrhosis, dyspnea associated with conditions such as interstitial pneumonia and pulmonary fibrosis requiring oxygen administration, fresh gastrointestinal bleeding requiring repeated transfusions, psychiatric disorders being treated with or thought to require psychotropic agents, diabetes mellitus that was difficult to control, clinical evidence of ileus or subileus; (2) a history of serious drug hypersensitivity; (3) acute inflammatory diseases; (4) pregnancy, breast-feeding and the risk (intention) of pregnancy in females; (5) prospective family planning in males; (6) other active malignant diseases that might influence survival or adverse events; (7) symptomatic cerebral metastasis; (8) massive ascites or retention of pleural effusion; (9) extensive bone metastasis; (10) diarrhea (4 times or more a day or watery stools), and (11) ineligibility according to the attending physician.",NA,NA
17519066,NA,Combination,No,advanced solid malignancies,"Patients 18 years of age or older were eligible to participate in the study if they had a pathological confirmation of solid cancer for which docetaxel was a viable therapeutic option or for whom other treatment options were not available, an Eastern Cooperative Oncology Group (ECOG) performance status21 of 0–2, a life expectancy of ≥ 3 months, and had received no more than one prior chemotherapy regimen for advanced disease. Patients were required to have fully recovered from side effects of prior systemic therapy, with no ongoing neurotoxicity. Adequate organ function – defined as white blood cell (WBC) count ≥ 3500/µL, neutrophil count ≥ 2000/μL, platelet count ≥ 100 000/µL, serum creatinine, serum glutamic oxaloacetic transaminase (SGOT), and serum glutamic pyruvic transaminase (SGPT) ≤ 1.5 × upper limit of normal (ULN), alkaline phosphatase less than 2.5 × ULN, and a normal bilirubin concentration – was required for inclusion in the study. Those patients who were treated with radiotherapy must have received their last dose of small field radiation at least 2 weeks prior to study entry or 4 weeks prior to study entry for large field. A negative pregnancy test was required for female patients with reproductive potential","Patients were not eligible to participate in the study if they had prior bone marrow transplantation or highdose chemotherapy with marrow or stem cell rescue, prior extensive radiation therapy to greater than 25% of bone marrow, or concurrent radiation therapy, chemotherapy, hormonal therapy, or immunotherapy. Patients were excluded if they had participated in another investigational study within 30 days of the current study registration.",during the first cycle,NA
19251309,NA,Combination,No,locally advanced squamous cell cervical cancer,"Eligible patients were 18 years old or greater, had biopsy-proven and untreated squamous cell carcinoma of the cervix, stages IIB through IVA, had negative para-aortic lymph nodes as determined by lymphadenectomy, CT scan or PET scan, were scheduled for definitive chemo-radiation, had adequate bone marrow, renal and hepatic function, and a GOG Performance Status of 2 or less. Additionally, laboratory criteria for entry included white blood cell count ≥3000/mm3, absolute granulocyte count ≥1500 mm3, platelets ≥100,000 mm3, total bilirubin ≤1.5 times upper normal limit, serum creatinine ≤1.5 times upper normal limit, and AST or ALT≤2.5 times upper normal limit. Patients with enlarged para-aortic nodes were required to have biopsy-documented negative histology before entry",NA,NA,NA
17909805,NA,Combination,No,patients with advanced cancers,"Patients with histologically or cytologically proven metastatic or unresectable solid cancers refractory to standard treatment or for which docetaxel was indicated were eligible for this study. Additional eligibility criteria include the following: (1) the presence of measurable or evaluable disease, (2) life expectancy more than 3 months, (3) Karnofsky performance status (KPS) >= 70%, (4) adequate renal and liver functions (serum creatinine and bilirubin within normal institutional limits, AST (SGOT) and ALT (SGPT) <= 1.5 x upper limit of normal), (5) adequate marrow function (WBC >= 3,000 ul¡1, ANC >= 1,800 ul¡1, platelets >= 100,000 ul¡1), (6) adequate contraception for men and women of child-bearing potential, and (7) more than 4 weeks since surgery, radiotherapy, or chemotherapy with resolution of all acute toxic eVects of grade <= 1 with the exception of alopecia, fatigue, nausea, and asthenia","Patients were excluded from this study if they were concurrently on antacid, proton pump inhibitors, H2-blockers, any other investigational agents, or medications that are inducers, inhibitors, or substrates of CYP3A4, had malabsorption syndromes, a known history of allergic reaction attributed to compounds of similar chemical or biological composition to agents used in this study, active central nervous system disease or severe intercurrent systemic disease",in the Wrst cycle,NA
18405987,NA,Combination,No,advanced esophageal carcinoma,"Eligible patients had to have histologically confirmed squamous-cell carcinoma or adenocarcinoma of the thoracic esophagus with clinically confirmed T4 tumors and/or M1 LYM according to the Tumor-Node-Metastasis classification of the UICC International Union Against Cancer. Patients were excluded if they had esophagotracheal or esophagobronchial fistulas or if they had metastases to distant organs. All areas of nodal disease had to be able to be contained in the radiation field. Patients were also excluded if they had metastases to lymph nodes distal to the celiac lymph nodes. No prior treatment was allowed. Eligibility required that subjects be 20–75 years of age with an Eastern Cooperative Oncology Group performance status 0–2, a white-cell count of at least 3000/uL, a hemoglobin concentration of at least 10.0 mg/dL, a platelet count of at least 100,000/uL, aspartate aminotransferase and alanine aminotransferase levels of within 2 times the upper limit of normal, a serum bilirubin level of 1.5 mg/dL or less, a creatinine level of 1.1 mg/dL or less, a creatinine clearance of at least 50 mL/min, and a normal electrocardiogram.","Patients were excluded from the study if they had any of the following conditions: (1) serious complications such as ischemic heart disease, arrhythmias, or other types of heart disease requiring treatment; liver cirrhosis; interstitial pneumonia or pulmonary fibrosis; active gastrointestinal bleeding; mental disorders being treated with antipsychotic agents or requiring treatment; poorly controlled diabetes mellitus; (2) a history of serious drug hypersensitivity; (3) acute inflammatory disease; (4) pregnancy, possible pregnancy, or breast-feeding; (5) active malignancy at another site; or (6) any other conditions considered by the attending physician to make the patient ineligible.",during chemoradiotherapy,NA
18172649,NA,Combination,No,patients with advanced solid tumors,"Eligible patients had, (a) histologically conWrmed, incurable malignancy refractory to standard therapy or for which no standard therapy exists, (b) an ECOG performance status of 0, 1, or 2, (c) preserved organ function as demonstrated by platelet count >= 100,000 mm-3, ANC >= 1,500 mm-3, hemoglobin >= 10 g/dl, bilirubin <= 1.5 mg/dl, serum creatinine <= 1.5 mg/dl, (d) sensory neuropathy <= grade 1, (e) diarrhea <= grade 1 and (f) age >= 18 years. Pregnant and lactating females were not eligible. In addition, 4 weeks must have elapsed since prior chemotherapy or radiotherapy, and patients must have recovered fully from toxicity.",NA,in cycle 1,NA
19499186,NA,Combination,No,"patients with advanced breast, non-small cell lung and prostate cancer","The study was conducted in compliance with Good Clinical Practice guidelines of the International Conference on Harmonization and the Declaration of Helsinki. All patients gave written informed consent in keeping with the policies of the Surveillance (Human Subjects) Committee of the M. D. Anderson Cancer Center (Houston, TX). Patients were eligible if they were 18 years of age or older and had pathologically confirmed non-small cell lung cancer (NSCLC), breast cancer or hormone-refractory prostate cancer (HRPC). Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2 at study entry, and preserved hepatic function (bilirubin < upper limit of normal) and renal function (creatinine ≤ 1.5 mg/dL).","Patients with an unstable medical condition or intercurrent illness, including uncontrolled diabetes mellitus or hypertension; active infections requiring systemic antibiotics, congestive heart failure; uncontrolled arrhythmias; active coagulation disorders; brain metastases; or uncontrolled seizure disorder were excluded. Pregnant women and those who were breast feeding were excluded as were individuals less than four weeks from prior radiation or chemotherapy. Patients were screened for glucose-6-phosphate dehydrogenase deficiency prior to study enrollment and were excluded if deficient in this enzyme.",during administration of the first cycle of therapy,NA
18319713,NA,Combination,No,advanced solid tumours,"Patients with histologically confirmed locally advanced or metastatic solid tumours, refractory to conventional therapy or for which no standard therapy exists, were eligible provided they met the following criteria: age >=18; Eastern Co-operative Oncology Group (ECOG) performance status (PS) 0 –1; life expectancy of >= 12 weeks; adequate haematopoietic (absolute neutrophil count (ANC) >= 1.5 x 109 l-1, platelet count >= 100 x 109 l-1, haemoglobin >= 9 g dl-1), hepatic (transaminases <2 x upper limit of normal (ULN) or < 1.5 x ULN if alkaline phosphatase >= 3 x ULN, bilirubin pULN) and renal function (creatinine clearance 》40 ml min-1 (calculated by the Cockroft –Gault Formula)) (Drinka and Langer, 1989); and a negative pregnancy test for females of child-bearing potential.",Exclusion criteria included the following: pre-existing neuropathy >= grade 2; unstable or pre-existing major medical conditions; evidence of symptomatic or uncontrolled brain metastases or leptomeningeal disease; major surgery or any anticancer therapy within the previous 4 weeks; lactating females; and unwillingness to use barrier contraception throughout the trial,during cycle 1 of treatment,NA
17896192,NA,Combination,No,solid tumors,"Patients with histologically or cytologically proven malignancy with no curative therapy available were enrolled. Other eligibility criteria were:>= 18 years old; ECOG performance status 0-2 with a life expectancy >= 3 months; no more than 2 prior chemotherapy regimens (exclusive of any chemotherapy received in the adjuvant setting); absolute neutrophil count >= 1 500/mm3, Hb > 8 g/dl, and platelet count >= 100 000/mm3; adequate liver function defined as bilirubin < upper limit of institutional normal and SGOT <= 2 x institutional normal, and serum creatinine <= 2.0 mg/dl. Patients with brain metastases were eligible if they had completed and recovered from radiation therapy. ",Patients who had peripheral neuropathy grade 2 or more and those who were on anticonvulsant therapy were excluded. Previous history of severe hypersensitivity reaction to docetaxel or other drug formulated with Polysorbate 80 was exclusion criteria,during the first cycle,NA
17940076,NA,Combination,No,Cancer of the Larynx/hypopharynx,"The study population consisted of patients with T2N0-1M0, T3N0M0 hypopharyngeal cancer or T2N0-1M0, T3N0-1M0 laryngeal cancer, who met the protocol conditions. Inclusion criteria specified that patients should be aged 20 – 75 years and have a definitive pathological diagnosis of cancer of the head and neck, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, no previous radiotherapy, lesion(s) evaluated by imaging, provided informed consent and a life expectancy of at least 3 months. If the patients had previously received treatment, there had to be a minimum period of 1 month since the last treatment. Adequate hematological function (white blood cell count >= 4000/mm3, neutrophil count >= 2000/mm3, platelet count >= 100000/mm3 and hemoglobin level >= 9.5 g/dl). Adequate hepatic function (aspartate aminotransferase and alanine aminotransferase <= 1.5 times the normal upper limit, total bilirubin <= 1.5 mg/dl and alkaline phosphatase <= 2.5 times the normal upper limit), and adequate renal function (creatinine serum <1.2 mg/dl). ","Excluded patients were those with a history of hypersensitivity to the test drug or preparations containing Polysorbate 80, serious concurrent disease or apparent infection with fever, pregnant or lactating women or women who may possibly be pregnant, and other patients considered by the attending physician to be unsuitable for participation in the study",NA,NA
19704337,NA,Combination,No,Advanced Non-small Cell Lung Cancer,"For the phase I dose escalation portion of the study, patients with histologic or cytologic confirmation of advanced solid malignancies were eligible to participate if they had received up to one line of prior chemotherapy for advanced disease. Prior endothelial growth factor receptor inhibitor therapy, endocrine therapy if appropriate (phase I), radiotherapy, and surgery were permitted, but therapy must have been discontinued at least 4 weeks before study entry. Prior docetaxel therapy was not permitted. Patients were required to have measurable disease, Eastern Cooperative Oncology Group performance status <= 2, age >= 18 years, life expectancy > 3 months, adequate hematopoietic (neutrophils >= 1.5 x 109/L, platelets >= 100 x 109/L), hepatic and renal function, and normal coagulation parameters.","Patients with symptomatic or progressive brain metastases, coagulopathy or therapeutic anticoagulation, pre-existing neuropathy  NCI common toxicity criteria grade 2, uncontrolled comorbid illness, contraindication or allergy to study treatment, HIV infection receiving antiretroviral therapy, and pregnant or lactating women were excluded.",during the first 21-day cycle,NA
19066894,NA,Combination,No,advanced gastric cancer,"Patients with a histopathologically or cytologically conWrmed diagnosis of unresectable or metastatic gastric adenocarcinoma, who had never been previously treated, were eligible for the study. Other inclusion criteria were: age >= 18 years; ECOG performance status 0–2; unidimensionally measurable disease (i.e., a diameter ¸1 cm on spiral CT scan); adequate liver (aspartate aminotransferase (ASAT) and/or [alanine aminotransferase (ALAT) <= 3 upper limit of normal (ULN)], renal (serum creatinine <= 1.5 ULN), bone marrow function (absolute neutrophil count >= 1.5 x 109/L; platelets >= 100 x 109/L); and written informed consent","Patients were excluded if they had any other malignancy in the past 5 years with the exception of skin basal cell carcinoma or CIS of cervix, serious comorbid diseases, or were pregnant or breast-feeding.",during the Wrst cycle of treatment,NA
18000498,NA,Combination,No,advanced solid tumours,"Patients with histologically confirmed advanced solid tumours that had progressed during or after standard therapy or for which no standard therapy was available were eligible for this study. A minimum of 4 weeks had to have passed from prior treatment with chemotherapy or radiotherapy. Patients were also required to have a life expectancy of at least 12 weeks and a Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1. Other eligibility criteria included adequate bone marrow (absolute neutrophil count >= 1500 m-3, platelet count X100 000 m-3, and haemoglobin (Hgb) >= 9 g dl-1), renal (creatinine <= upper normal limit or creatinine clearance of >= 60 ml min-1), hepatic (bilirubin <= upper normal limit and aspartate aminotransferase [AST], and alanine aminotransferase [ALT] <= 2.5 times the upper limits of normal) and cardiac (baseline left ventricular ejection fraction [LVEF] of >= 50%) function and a serum calcium within normal limits.","Similarly, patients were excluded from the study if they had uncontrolled hypertension, symptomatic CNS metastasis or neuropathy >+ grade 2 according to NCI-CTC version 3.0, or any prior malignancy, cardiac condition or serious medical illness that would affect their management according to the study protocol. Patients were also excluded if they had received a prior cumulative doxorubicin dose greater than 360 mg m-2 or equivalent or had a prior history of severe hypersensitivity reactions to polysorbate 80. ",during cycle 1 ,NA
17826308,NA,Combination,No,oral squamous cell carcinoma,"Selected patients had histologically proven squamous cell carcinoma of the oral cavity (stage II/III/IVA), were previously untreated, had objectively measurable disease, were from 20–75 years old, had a performance status of 0 or 1 using Eastern Cooperative Oncology Group criteria, had acceptable cardiac function based on electrocardiogram results, had adequate renal function with a serum creatinine level <= 1.2 mg/dl and a creatinine clearance level >= 60 ml/min, had adequate hepatic function with a total bilirubin level <= 1.5 mg/dl and a serum transaminase level less than two times the normal value, and had adequate bone marrow reserves (leukocytes >= 4000/mm3, platelets >= 100 000/mm3 and hemoglobin >= 10.0 g/dl).",NA,NA,"Four weeks after the initial chemotherapy course, patients had definitive surgery"
18493840,NA,Combination,No,node-positive or high-risk breast cancer patients,"In principle, patients who satisfied the following inclusion criteria were selected for enrollment in the study: (1)histologically confirmed breast cancer, (2) histologically node-positive or tumor diameter over 2 cm, (3) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1, (4) patients capable of principle and outpatient management between the ages of 20 and 70, (5) absence of severe dysfunction of major organs (white blood cell count, >3,500/mm3; neutrophil count >2,000/mm3; platelet count > 100,000/mm3; hemoglobin > 8.5 g/dl; transaminases <= 2.5 times the upper normal limit in the institution; alkaline phosphatase <= 2.5 times the upper normal limit in the institution; total bilirubin < 1.5 mg/dl, and serum creatinine < 1.5 mg/dl), and (6) all patients provided written informed consent","Patients were excluded from the study if any of the following criteria applied: (1) presence of infection, (2) presence of severe complications, such as pulmonary fibrosis, interstitial pneumonia, or hemorrhagic tendency, (3) presence of peripheral neuropathy or edema, (4) presence of an active double cancer, (5) pregnancy or breast-feeding or the possibility of pregnancy, (6) presence of serious complications of the heart, lung, or kidney, and presence of pleural effusion, ascites, or pericardial effusion, (7) a history of drug allergy, (8) long-term administration of corticosteroid before the start of the examination, (9) recurrence of permeation cancer less than 5 years since treatment ended, (10) non-synchronous or bilateral breast cancer, and (11) any other reason for which the investigator judged the patient to be unsuitable for inclusion in this study.",during the first cycle,NA
17594929,NA,Combination,No,Patients with Advanced Breast Cancer Failing Prior AnthracyclineBased Regimens,"Patients with histologically confirmed metastatic breast cancer pretreated with anthracycline-based chemotherapy were enrolled; (i) patients progressing on anthracycline-based therapy or within 4 months after the end of such a treatment, (ii) or patients treated with neoadjuvant and adjuvant anthracyclines who progressed within 12 months after the end of adjuvant chemotherapy were deemed anthracyclinerefractory, (iii) while all other patients were considered potentially anthracycline-sensitive. Patients had to have bi-dimensionally measurable lesions with at least one outside a previously irradiated field, unless definite evidence of progression at this site was observed during a minimum 3-month period. No prior taxanes or ifosfamide were allowed. Patients identified in retrospect (on archive or new biopsy material) to have HER2 (c-erbB2) overexpressing tumors by immunohistochemistry and/or FISH analysis, as this became available after the end of 2000, were not offered trastuzumab therapy in combination with the study regimen of docetaxel-ifosfamide until disease progression. Other inclusion criteria were as follows: age 18 to 72 years; a World Health Organization (WHO) performance status (PS) of 0 to 2; life expectancy of at least 3 months; adequate hematopoietic (ANC≥1500/µL, PLT≥100,000/µL), liver [bilirubin <1.5 mg/dl, AST/ALT <2 x upper normal limit, unless caused by tumor and serum albumin >3.0 g/dl] and renal function (BUN and creatinine <1.5x upper normal limit; and creatinine clearance >50 ml/min), and cardiac function (left ventricular ejection fraction [LVEF]≥50%). Patients with brain metastases were eligible, provided that they had been irradiated and had clinical and radiological improvement and were off steroids or receiving tapering doses of steroids.","Other exclusion criteria were radiation therapy within 4 weeks from treatment initiation, irradiation of more than 25% of the bone marrow-bearing skeleton, severe infection or malnutrition",during the first chemotherapy cycle,NA
18758179,NA,Combination,No,Advanced or Recurrent Breast Cancer,"The study included women between 20 and 75 years of age with histologically or cytologically documented advanced or recurrent breast cancer who had received prior chemotherapy for metastatic disease. Other criteria for inclusion were as follows: performance status of 0, 1 or 2; adequate bone marrow reserve, white blood cell count >= 4.0 x 10 9 /l, neutrophil count >= 2.0 x 10 9/ l, platelet count >= 100 x 10 9/l, hemoglobin >= 9.5 g/dl; acceptable hepatic function, i.e. normal total bilirubin, alanine aminotransferase and aspartate aminotransferase <= 2-fold the upper limits of normal; normal renal function, i.e. serum creatinine level within normal limit; normal electrocardiogram and cardiac function with a left ventricular ejection fraction of > 50% by echocardiography; measurable or evaluable disease. Prior adjuvant EPI (up to 450 mg/m 2 ) or doxorubicin therapy (up to 300 mg/m 2 ) was permitted, as were prior hormonal and radiation therapy",NA,during the first cycle,NA
19190908,NA,Combination,No,advanced gastric cancer,"Patients were eligible if they met all of the following criteria: presence of unresectable, locally advanced or metastatic, and histologically conWrmed adenocarcinoma of the stomach; age range, 18–70 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; estimated life expectancy of more than 3 months; and adequate hematological, renal, and hepatic functions as deWned by a white blood cell count >= 4.0 x 109/L or an absolute granulocyte count ¸>= 1.5 x 109/L, a platelet count >= 100 x 109/L, hemoglobin level >= 9.0 g/dL, serum creatinine level <= 1.4 mg/dL, serum bilirubin level <=1.8 mg/dL, and aspartate transaminase/alanine transaminase (AST/ALT) levels less than or equal to twofold the upper limit of normal.","Patients were excluded if they had a previous history of chemotherapy (excluding adjuvant chemotherapy), central nervous system metastasis, obvious bowel obstruction, serous gastrointestinal bleeding, or other serious comorbid condition. Each patient provided written informed consent before entering the study. ",during the Wrst two cycles,NA
18425392,NA,Single Drug,No,advanced gastric cancer patients with peritoneal carcinomatosis,"The patients with cytologically or histologically confirmed peritoneal carcinomatosis were eligible for this study. Other eligibility criteria were: age 18-75 years, Eastern Cooperative Oncology Group (ECOG) performance status 0-2, no history of previous chemo- or radiotherapy, adequate bone marrow function (<3000/mm3 white cell count or <1500/mm3 neutrophil count, platelet count >80,000/mm3 and hemoglobin >8.0 g/dl), adequate liver function (bilirubin level <1.5 mg/dl, and aspartate and alanine aminotransferase within twice the upper limit of the normal). All of the patients gave written informed consent, conforming to institutional guidelines.",NA,in the first treatment cycle,NA
19543076,NA,Combination,No,gastric cancer patients with para-aortic lymph node metastases,"Patients fulfilling the following criteria were enrolled in this study: (i) histologically confirmed gastric adenocarcinoma; (ii) presence of para-aortic lymph node metastases [detection of two or more enlarged lymph nodes > 10 mm by computed tomography (CT)]; (iii) absence of peritoneal metastasis confirmed by staging laparoscopy; (iv) age of 18–75 years; (v) Eastern Cooperative Oncology Group performance status of 0–1; (vi) no prior chemotherapy or radiotherapy; (vii) normal organ functions, including bone marrow, heart, lung, liver and kidney; (viii) no other malignancies; and (ix) written informed consent. The study protocol was approved by the Institutional Review Board of Kanazawa University Hospital, Kanazawa, Japan",NA,in the first treatment cycle,NA
18477581,NA,Combination,No,primary breast cancer,"Patient eligibility criteria included histologically confirmed previously untreated PBC T2–4a–c N0–3 M0, age >= 18 years, Karnofsky performance status >+ 80%, adequate hematologic (absolute neutrophil count >= 1.5 x 109/l, platelet count >100 x 109/l), hepatic, renal and cardiac function. Patients were excluded if they had inflammatory breast cancer, any prior treatment for breast cancer or simultaneous concurrence of all of the following factors: age > 35 years, tumor size < 5 cm, estrogen receptor (ER) and progesterone receptor (PgR) positivity, no suggestion of axillary lymph node involvement by palpation or ultrasound and grading 1–2 because patients with a concomitance of these factors may not require (neo-)adjuvant chemotherapy ",NA,At cycle 1,NA
19415031,NA,Combination,No,IN HIGH RISK HEAD AND NECK CANCER,"Patients with histologically proven and completely resected squamous cell carcinoma of the oral cavity, oropharynx or larynx, with histologically involved regional lymph nodes and/or extra nodal disease and/or positive surgical margins were eligible to participate. Other inclusion criteria included: a Southwest Oncology Group performance status, (SWOG PS) of 0 or 1, age ≥ 18 years, absolute neutrophil count ≥ 1500/mm3 , hemoglobin >8.0g/dL, platelet count ≥ 100,000/dL, and adequate renal and liver function. Patients were required to register within six weeks of surgery, by signed and witnessed informed consent describing the investigational nature of this study.","Patients who had prior chemotherapy or radiation therapy to the head and neck, evidence of distant metastasis, synchronous or concurrent head and neck primary tumors, peripheral neuropathy greater than grade 1, or other malignancies within the last five years were excluded. ",NA,NA
18824702,NA,Combination,No,Patients with advanced solid malignancies or lymphoma,"Eligible patients had pathologically confirmed solid malignancies refractory to standard therapy or for whom no standard therapy existed; age >= 18 years; life expectancy >= 12 weeks; an Eastern Cooperative Oncology Group performance status of 0 to 2; previous chemotherapy >= 4 weeks (6 weeks for prior mitomycin or a nitrosourea); hemoglobin >= 9 g/dL; absolute neutrophil count (ANC) >= 1,500/uL; platelets >= 100,000/uL; creatinine  upper limit of normal (ULN) and calculated creatinine clearance more than 60 mL/min, bilirubin <= 1.5 x ULN; AST and ALT <= 2.5 x ULN; absence of pregnancy, HIV and hepatitis B/C sero-positivity, or brain metastases; and no coexisting severe medical conditions. Patients gave written informed consent according to federal and institutional guidelines before treatment.",NA,during cycle 1,NA
19074216,NA,Combination,No,"in stages II and IIIA, HER2-overexpressing breast cancer patients","Patients were enrolled in this trial from April 2004 to March 2006 in six centers in Spain. The inclusion criteria the patients eligible had to meet were histologically proven (breast core biopsy) stages II and IIIA breast cancer-overexpressing HER-2, confirmed by FISH carried out at a central reference laboratory; absence of systemic disease measured by bilateral mammogram, chest X-ray, abdominal computed tomography scan or ultrasound, and bone scintigraphy; a Karnofsky performance status of 80 or higher; hemoglobin >= 10 g/dl, absolute neutrophil count >= 2 x 109/l, and platelet count >= 100 x 109/l; adequate hepatic and renal functions; left ventricular ejection fraction (LVEF) >= 50%; no previous chemotherapy treatment (including anthracyclines or taxanes) for any previous malignancy; and no previous radiotherapy treatment for breast cancer; all patients were females at least 18 years of age considered to be fit to receive combination chemotherapy. Patients were required to provide written informed consent before inclusion in the study.",Patients with bilateral invasive breast cancer or preexisting motor or sensorial neurotoxicity grade ‡2 on the basis of the National Cancer Institute—Common Toxicity Criteria version 2.0 (NCI-CTC v2.0) score system were excluded.,in the first two cycles,NA
18493761,NA,Combination,No,advanced gastric cancer,"Patients with histologically proven metastatic or locally advanced inoperable gastric carcinoma were eligible. Patients were required to be older than 20 years with a life expectancy of >3 months and to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1. All patients were required to have at least one target lesion according to RECIST criteria and/or assessable metastatic disease according to World Health Organization criteria [20, 21]. Failure of one line of prior palliative chemotherapy was allowed except for prior taxane or S-1 (considering that patients receive one palliative chemotherapy if recurrence occurs within 6 months of adjuvant chemotherapy), and patients should not be under the inXuence of the eVects or side eVects of previous treatments; at least 4 weeks must have passed since the last drug administration. All eligible patients were also required to have adequate hematologic counts [a white blood cell count of >= 4,000/ul, an absolute neutrophil count (ANC) of >= 2,000/ul, a platelet count of >= 100,000/ul, and hemoglobin >= 8.0 g/dl], laboratory results within the following limits [serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase <2.5 £ UNL, serum bilirubin <= 1.5 mg/dl], and renal function within the following limits (creatinine <1.25 £ UNL or <=120 umol/L).","Exclusion criteria were as follows: pregnant or nursing women; sexually active males/females unwilling to use contraception during the study; gastric cancer other than adenocarcinoma; within the previous 5 years, malignancies other than gastric carcinoma except for adequately treated in situ carcinoma of the cervix, or non-melanoma skin cancer; known brain or leptomeningeal metastasis; a history of hypersensitivity to the treatment drugs or preparations containing polysorvate 80, taxotere, or Xuoropyrimidine derivatives; obvious corticosteroid contraindication; simultaneous administration of other anticancer drug; peripheral sensory neuropathy of >= Grade 2 according to National Cancer Institute—Common Toxicity Criteria Adverse Event (NCI-CTCAE) version 3.0; or other medically important illnesses or medical conditions as determined by the treating physician. ",at the Wrst cycle,NA
19636016,NA,Combination,No,Advanced Non–Small-Cell Lung Cancer,"Eligible patients had histologically or cytologically confirmed refractory non–small-cell lung cancer (NSCLC), renal cell cancer (RCC) and pancreatic cancer (PC; MONO study) or NSCLC with progression on first-line platinbased therapy or had failed or declined other regimens (COMBO study). Tumor types for the trials were based on our own data showing expression of 5T4 in the majority (> 95%) of these tumor types. Other criteria included age >= 18 years; Eastern Cooperative Oncology Group performance status1; prior radiation completed  3 weeks earlier; and adequate bone marrow (platelets >= 100 x 109/L, absolute neutrophil count > 1.5 x 109/L, hemoglobin >= 10 g/dL), hepatic function (MONO study: total bilirubin <+ 2 times the upper limit of normal (ULN), AST <= 2.5 times ULN; COMBO study: consistent with docetaxel labeling and renal [serum creatinine <= than 1.5 times ULN] function)","Exclusions included active infections, active cardiac disease, other active, invasive malignancies, allergy or hypersensitivity to kanamycin, or current use of any corticosteroids",during treatment cycle 1,NA
18343924,NA,Combination,No,patients with advanced gastric cancer,"Patients with histologically conWrmed, unresectable, recurrent and/or metastatic gastric adenocarcinoma were eligible for inclusion in this study. Additional inclusion criteria included: age 18–70; ECOG performance status <=2; adequate bone marrow function (absolute neutrophil count and platelet count >= 1.5 x 109 and 75 x 109 L-1, respectively); hepatic function (total serum bilirubin <= 1.5 mg/dL, transaminases <= 1.5 times upper normal limit) and adequate renal function (calculated creatinine clearance >= 60 mL/min). Measurable disease was not mandatory for inclusion in the study. Patients who had previously received chemotherapy were also eligible, except those with prior regimens that contained taxanes, or those who had received a 24-h continuous infusion of 5-FU. Patients were required to have fully recovered from the toxicity of previous chemotherapy treatments except alopecia.",NA,the first cycle of treatment,NA
18751437,NA,Combination,No,Advanced Gastric Cancer,"Patients who had histologically proven advanced gastric cancer (inoperable or recurrent) were enrolled in this study. The inclusion criteria in terms of the disease characteristics were atleast one measurable lesion and no prior chemotherapy. The inclusion criteria in terms of the patient characteristics were as follows: 20-75 years of age; Eastern Cooperative Oncology Group (ECOG) performance status <2; estimated life expectancy ≥3 months; adequate liver function (total serum bilirubin <1.5 mg/dl and transaminase ≤2 times the normal upper limit for our institution); adequate renal function (serum creatinine within the normal upper limit for our institution, blood urea nitrogen ≤25 mg/dl and 24 h creatinine clearance >50 ml/min); adequate haematopoietic function (4,000/mm3 ≤ WBC count ≤12,000/mm3, absolute neutrophil count >2,000/mm3, platelet count ≥10×104/mm3 and haemoglobin level ≥9.5 g/dl); adequate cardiac function; adequate pulmonary function; written informed consent provided by the patient.","The major exclusion criteria were as follows: brain metastasis, symptomatic infectious disease, past history of drug allergy, symptomatic peripheral neuropathy or oedema, other active malignancies, pregnancy or breast feeding, uncontrolled diabetes mellitus, uncontrolled mental illness and gastrointestinal haemorrhage",over two courses,NA
19704061,NA,Combination,No,Locally Advanced Squamous Cell Carcinoma of the Head and Neck,"Patients with stage III or IV, previously untreated, locally advanced SCCHN were eligible for participation in this phase I study. Primary sites allowed included the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, and unknown primary. Additional eligibility criteria included measurable disease based on Response Evaluation Criteria in Solid Tumors guidelines, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and normal hematologic, renal, and liver function.","Exclusion criteria included >= grade 2 peripheral neuropathy by National Cancer Institute Common Toxicity Criteria for Adverse Events version 3.0, other serious comorbid illness, and involuntary weight loss of more than 20% of body weight in the 3 months preceding study entry.",the first 3-week cycle ,NA
17695429,NA,Combination,No,Advanced Gastric Cancer,"Patients, aged 20 to 75 years, with at least one measurable lesion of pathologically proven inoperable or recurrent gastric cancer were enrolled. Inoperability was determined on the basis of clinical evaluation, radiological imaging, laparoscopy or laparotomy with failed resection. Patients who had no more than two previous treatment regimens not including taxanes (docetaxel or paclitaxel) or S-1 were eligible. Other eligibility criteria were: Eastern Cooperative Oncology Group performance status 0 or 1; estimated life expectancy of at least 3 months; adequate renal function (serum creatinine <1.5x upper limit of the reference range (ULN)), adequate hepatic function (serum bilirubin <1.5x ULN; transaminases <2.5x ULN) and adequate hematological function (hemoglobin >8 g/dl, leukocytes >4,000/ÌL and thrombocytes >100,000/ÌL). No other anti-tumor therapy was allowed 28 days prior to treatment. Eligibility also included the ability to reliably tolerate and comply with oral medication. Patient compliance was recorded using chemotherapy diary cards. Pre-treatment evaluation included a complete medical history and physical examination, basic laboratory evaluation and staging of the underlying malignancy with either ultrasound, chest radiograph or computed tomography (CT) scan","Main exclusion criteria were follows: pregnancy or breast feeding, symptomatic infectious disease, pulmonary fibrosis or interstitial pneumonia, grade 3 or severe hemorrhage/bleeding, grade 2 or severe peripheral neuropathy, symptomatic peripheral effusion or ascites, past history or allergic reaction to polysorbate 80, obstructive bowel disease or severe diarrhea, congestive heart failure, uncontrolled angina pectoris, or arrhythmia, uncontrolled diabetes or hypertension, symptomatic brain metastasis and active concomitant malignancy",in the first treatment cycle,NA
19768460,NA,Combination,No,advanced or recurrent breast cancer,"Women aged 20–75 years with either advanced breast cancer defined as stage IIIA–B or axillary lymph nodes metastases C4, or recurrent breast cancer were eligible for enrollment. Invasive ductal carcinoma was definitively diagnosed on the basis of histological examination of surgical specimens. The main inclusion criteria were ECOG performance status 0–1; normal cardiac (absence of serious arrhythmia and serious ischemic change on ECG), renal (serum creatinine < 1.5 mg/dL), hepatic (aspartate aminotransferase and alanine aminotransferase <= 100 IU/L; bilirubin < 1.5 mg/dL), and hematologic (white blood cell count >= 3,000/mm3; neutrophils >= 1,500/mm3; platelets >= 100,000/mm3; hemoglobin >= 8.0 g/dL) function confirmed by prestudy examination; and, for recurrent breast cancer patients, life expectancy >= 3 months. Inclusion was not dependent on the presence or absence of measurable lesions.",NA,During the first course,NA
17695421,NA,Combination,No,Patients with Advanced Esophageal Cancer,"Patients were considered eligible for this study based on the following criteria: a histologically confirmed diagnosis of unresectable malignant neoplasm of the esophagus; prior chemotherapy was permitted, provided it had been completed at least 4 weeks earlier; prior esophageal bypass operation was permitted if performed at least 2 weeks before the study; no prior radiotherapy to the sites planned for irradiation in the present study; evaluable or measurable disease; age 18 to 75 years; a performance status under 2 according to the World Health Organization (WHO) scale; life expectancy of 3 months or more; adequate bone marrow function (white blood cell (WBC) count between 3000/mm3 and 12000/mm3, absolute neutrophil count of >2000/mm3, platelet count of >100000/mm3, Hb >9.5 g/dl) adequate renal function (serum creatinine <1.5 mg/dl); adequate liver function (serum bilirubin level <1.5 mg/dl, serum AST and ALT within 1.5 times the upper limit of normal for the institution, serum alkaline phosphatase within 2.5 times the upper limit of normal for the institution). Written informed consent was obtained from each patient.","Patients were excluded from the trial if any of the following exclusion criteria were fulfilled: symptomatic infectious disease, pulmonary fibrosis, interstitial pneumonia, malignant hypertension, congestive heart failure, severe coronary artery disease, severe liver cirrhosis, uncontrolled diabetes mellitus, bleeding tendency, preexisting symptomatic peripheral neuropathy or edema of more than grade 2 severity according to the common toxicity criteria of the National Cancer Institute (NCI-CTC), active double cancer, symptomatic pleural effusion or pericardial effusion, past history of allergic reaction to polysorbate 80, and pregnancy or breast feeding",NA,NA
19437020,NA,Single Drug,No,Japanese patients with advanced solid tumours,"Patients aged 20–74 years of age with a histologically or cytologically proven diagnosis of metastatic or advanced solid tumour malignancy with no available standard curative measures were eligible. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and life expectancy of at least 12 weeks and were to have recovered to grade ·1 (according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 [CTCAE v.3.0]) from all clinically signiWcant toxic eVects (excluding alopecia) of any prior surgery, radiotherapy, hormonal therapy, immunotherapy, therapeutic antibody or other molecularly targeted non-cytotoxic therapy, or chemotherapy. Prior hormonal or molecularly targeted non-cytotoxic therapy should have been completed >= 3 weeks before Wrst administration of the study treatment dose and all prior chemotherapy, immunotherapy, antibody therapy and radiotherapy should have been completed >= 4 weeks before the Wrst administration of study drug. Patients were also required to have adequate organ function as follows: absolute neutrophil count >= 1.5 x 109 L-1 ; platelet count >100 x 109 L-1 ; haemoglobin >= 9.0 g/dL; albumin >= 3.5 g/dL; creatinine <1.5 x upper limit of normal (ULN); total bilirubin within normal limits, serum aspartate aminotransferase/alanine aminotransferase (AST/ ALT) <= 2.5 x ULN (if alkaline phosphatase was <= 2.5 x ULN) or <= 1.5 £ ULN (if alkaline phosphates was >2.5 to <= 5.0 x ULN).","Patients were ineligible if they were breastfeeding or if they had received more than two prior chemotherapy regimens for advanced disease, radiation therapy to >25% bone marrow area, or if they had a history of hypersensitivity to taxanes, polysorbate-80 or alcohols. They were also excluded if they had brain or leptomeningeal disease, interstitial pneumonitis, peripheral neuropathy grade >= 2 or a serious illness or medical condition that could deter participation in the study.",over the first treatment cycle,NA
17848958,NA,Combination,No,patients with unresectable metastatic gastric cancer,"Patients were entered into the study if they fulfilled the following eligibility criteria: (1) histologic confirmation of gastric cancer; (2) unresectable distant metastatic disease (M1 stage according to the Japanese Classification of Gastric Carcinoma; Nishi et al, 1999); (3) measurable lesion(s) or evaluable disease; (4) agep75 years; (5)performance status (PS) <= 2 on the Eastern Cooperative Oncology Group (ECOG) scale; (6) no prior chemotherapy; (7) adequate bone marrow function (WBC count >= 4000 ml-1 and platelet count >= 100 000 ml-1); (8) adequate liver function (serum bilirubin level <= 1.5 mg dl-1 and serum transaminase levels <= three times the upper limit of normal); (9) adequate renal function (serum creatinine level <= 1.5 mg dl-1, blood urea nitrogen level<= 25 mg dl-1 and creatinine clearance >= 50 ml min-1.); (10) no other severe medical conditions; (11) not pregnant or lactating and (12) provision of written informed consent in accordance with government guidelines (Good Clinical Practice, by the Ministry of Health and Welfare of Japan) and guidelines of each institution or hospital.",NA,during the first course of treatment,NA
19002462,NA,Combination,No,metastatic melanoma,"To be eligible for the study, patients had to have a histologically conWrmed diagnosis of advanced or inoperable melanoma and clinically measurable metastases. Other inclusion criteria were a Zubrod performance status score of 2 or less and adequate hematologic (absolute neutrophil count >= 1,500/uL; platelet count >= 100,000/uL) and renal functions (serum creatinine level within the normal limit). Patients must have had adequate hepatic function with a normal serum bilirubin level. Patients with increased serum transaminases levels up to 2.5 times the upper limit of normal were allowed to enter the study if their serum alkaline phosphatase level was normal. Those with an increased serum alkaline phosphatase level up to four times the upper limit of normal were also allowed if their serum transaminases levels were normal. Both chemo-naive and previously-treated patients were enrolled.","However, patients who had previously received all three study drugs or related drugs (taxanes, temozolomide, and platinums) were excluded. Patients with uncontrolled brain metastases (symptoms due to brain metastases or who required steroidal or anticonvulsant drugs for the management of brain metastases) were ineligible, but those with controlled, asymptomatic brain metastases (no evidence of progression in brain metastases for at least 3 months after complete surgical tumor resection, stereotactic radiosurgery, or wholebrain irradiation) were allowed to participate. Patients with clinically symptomatic cardiac or pulmonary disease were excluded.",during the Wrst cycle ,NA
19237630,NA,Single Drug,No,Advanced Refractory Cancer,"Eligible patients had solid, histologically proven malignant tumors that were refractory to conventional treatment, or for which the investigator believed no standard treatment existed. Further requirements were age  18 years, WHO performance status of 0 or 1, life expectancy more than 12 weeks, and adequate bone marrow and biochemical function within 1 week before commencing treatment (hemoglobin >= 10g/dL, absolute neutrophil count >= 1.5 x 109/L, platelets >= 100 x 109/L, prothrombin time and activated partial thromboplastin time within normal range, serum bilirubin within normal limit, ALT <= 2.5 x upper limit of normal, AST <=  2.5 x upper limit of normal, creatinine clearance >= 50 mL/min)","Treatment with radiotherapy (except palliative), endocrine therapy, or chemotherapy must have ceased at least 4 weeks before starting treatment. Further patient exclusions were known bleeding diathesis; treatment with anticoagulants (including aspirin); major surgery within 4 weeks; significant comorbidity; unstable symptoms from brain metastases; pregnant or nursing; serologically positivefor hepatitis B, hepatitis C, or HIV; or history of allergy to antisense agents. All toxic manifestations of previous treatment had to be resolved (with the exception of certain grade 1 toxicities). Treatment required placement of a central venous or peripherally inserted central catheter line for drug administration.",in the first cycle,NA
18470481,NA,Combination,No,advanced solid tumors,"Patients with histologically confirmed solid tumors not amenable to standard therapy were eligible. Other inclusion criteria included age ≥18years, life expectancy of at least four months, ECOG performance status 0 or 1, and measurable or evaluable disease. At least four weeks must have elapsed since prior large-field radiation therapy. Patients must have discontinued previous anti-cancer therapy for at least three weeks and recovered from all treatment-related toxicity. Peripheral neuropathy had to be less than or equal to grade 1 prior to study enrollment. Sexually active patients were required to use contraception, patients had to comply with the FDA-mandated thalidomide STEPS program, and women of child-bearing age had to have a negative pregnancy test.","Exclusion criteria included white blood cell count < 4,000/μl or ANC <1,500/μl, platelets <100,000/μl, hemoglobin <10gm/dL, impaired hepatic function (total bilirubin > upper limit of normal [ULN], transaminases > 2.5 × ULN if alkaline phosphatase was <ULN, or alkaline phosphatase up to 4xULN if transaminases were normal), renal dysfunction (creatinine > 1.5mg/dl or creatinine clearance <60ml/min/ 1.73m2), New York Heart Association classification III or IV heart disease, pregnant or lactating patients, and patients with a history of a hypersensitivity reaction to docetaxel. Patients with a prior exposure to thalidomide and docetaxel were allowed to enroll.",cycle 1,NA
19011760,NA,Combination,No,advanced solid tumors,"Patients with histologically confirmed solid tumors not amenable to standard therapy were eligible. Other inclusion criteria included age ≥18 years, life expectancy of at least 4 months, ability to complete 6 weeks of therapy, ECOG performance status 0–2, and measurable or evaluable disease. Patients must have discontinued prior anti-cancer therapy (chemotherapy or radiation) for at least 4 weeks and recovered from all significant treatment-related toxicity. Patients may have not received more than one prior cytotoxic regimen, but unlimited prior non-myelosuppressive targeted regimens (i.e. tyrosine kinase inhibitors, anti-angiogenic agents, vascular targeting agents) were allowed. Peripheral neuropathy had to be ≤grade 1 prior to study enrollment. Sexually active patients were required to use contraception, and women of child-bearing potential were required to haveserial negative pregnancy tests.","Exclusion criteria included ANC <1,500/μL, platelet count <100,000/μL, hemoglobin <8 g/dL, impaired hepatic function (total bilirubin higher than upper limit of normal or liver function tests defined in Table 1), renal dysfunction (creatinine <2 mg/dL), New York Heart Association classification III or IV heart disease, pregnant or lactating patients, history of a hypersensitivity reaction to docetaxel or other drugs formulated in polysorbate-80, concurrent use of investigational drugs or anti-cancer agents besides bisphosphonates, brain metastases (unless treated beforehand with no active brain lesions confirmed by imaging for at least 6 months), prior desquamating rash or ≥grade 2 allergic reaction related to thalidomide, prior radiation to the pelvis or to >25% of the bone marrow containing compartment, patients requiring coumadin for anti-coagulation (switching to heparin was allowed), and other uncontrolled disease or illness.",cycle 1,NA
18626572,NA,Combination,No,metastatic disease,"The eligibility criteria included an informed consent, age of 18 or older, a minimum life expectancy of four months and an ECOG performance status of 0–2. In addition patients were required to have a histologically or cytologically confirmed diagnosis of a nonhematological malignancy refractory to standard therapy (or for which no standard therapy was available) and have measurable disease as defined by RECIST criteria. Prior therapy was permitted, and could include 3 or more regimes of either immunotherapy or chemotherapy (except adjuvant IFN alpha). Adequate pretreatment bone marrow function was required and was defined as granulocyte count of 1500/μl or more, platelets of 100,000/ μl or more, and total hemoglobin of 8.0gm/dl or more (erythropoetin or transfusions were permitted). Additional entry criteria included adequate organ function defined as a normal sodium and potassium, a creatinine 2 mg/dl or less, bilirubin within normal limits and prothrombin time within normal institutional limits unless the patient was on coumadin therapy. If present pretreatment peripheral neuropathy, had to be grade 1 or less. Patients with CNS metastases were eligible if they weren’t being actively treated with dexamethasone, had stable brain metastasis status post external beam radiation therapy, gamma knife or surgical resection confirmed with a MRI or a CT scan four weeks after therapy completion.","Patients with refractory cardiac arrhythmias or stage 3 or 4 cardiac failure, active untreated CNS metastasis, history of pulmonary embolism within three weeks, a history of stem cell or organ transplantation or a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 were excluded. Patients with an AST level more than 1.5 times the upper limit of normal with an alkaline phosphatase more than 2.5 times normal were also excluded. Other exclusion criteria were history of infection requiring intravenous antibiotics within the past 14 days, immunotherapy or chemotherapy within the past 21 days, hormonal therapy (except luteinizing hormone-releasing hormone (LHRH) agonists), radiation therapy within 21 days, surgery within 21 days requiring general anesthesia or a history of positivity for HIV, hepatitis B (HbsAg) or hepatitis C (anti-HCV).",during the first 4 week treatment period,NA
19434371,NA,Combination,No,advanced malignancies,"Patients with a pathologically or cytologically confirmed diagnosis of a non-hematologic, distantly metastatic or locally advanced or recurrent malignancy (UICC stage IIIB-IV), which was either refractory to standard therapy or which had been reported to respond to either cyclophosphamide, doxorubicin or docetaxel were allowed to enroll in the study. Prior adjuvant or neoadjuvant chemotherapy was allowed as were additional 0–1 regimens for advanced disease. Prior treatment with doxorubicin was permitted only if the cumulative dose of the drug did not exceed 360 mg/m2. Any number of prior biologic or hormonal regimens was allowed as well. At least one site of evaluable or bidimensionally measurable disease was required. In addition, patients had to be at least 18 years of age, have ECOG performance status of 0–2, WBC ≥3500/μL, absolute neutrophil count (ANC) ≥1250/ μL, Platelet count of ≥100,000/μL, hemoglobin of ≥8.0 gm/dL serum creatinine ≤ institutional upper limits of normal or 24 h creatinine clearance of ≥60 ml/min, and bilirubin ≤ institutional upper limit of normal. Elevated ALT or AST was allowed only if it was ≤2.5 × upper limit of normal and alkaline phosphatase was within normal limit. A left ventricular Ejection fraction (LVEF) of ≥50% by MUGA scan or echocardiogram was required.","Patients were excluded from the study if their estimated life expectancy was less than 3 months, if they had known hypersensitivity to docetaxel or polysorbate 80 (Tween 80), were concurrently receiving radiotherapy, reversible hormonal therapy for malignancy or other chemotherapy while on this protocol, (except for patients with prostate cancer, who were permitted to continue hormonal therapy). Patients were also excluded from the study if they had laboratory abnormalities that did not satisfy the above inclusion criteria, and were physically, mentally or emotionally unable to give informed consent. Patients who had symptomatic, New York Heart Association (NYHA) class II or higher congestive heart failure (regardless of EF) or patients who were previously treated with high dose chemotherapy requiring a bone marrow or peripheral blood stem cell transplant were excluded as well. Pregnant or lactating patients were ineligible. Men or women of reproductive potential were not allowed to participate unless they agreed to use an effective contraceptive method",during the first 6 weeks of therapy,NA
19740565,C000000281,Combination,No,untreated advanced non-small cell lung cancer,"Patients meeting all the following criteria were enrolled in this multicenter trial: (i) confirmed untreated NSCLC of clinical stage IIIB or IV that is inadequate for curative-intent thoracic radiotherapy, (ii) a performance status (PS) (Eastern Cooperative Oncology Group) of 0–2, (iii) age ranging from 20 to 75 years, (iv) adequate organ functions (neutrophils ≥ 2000/mm3, platelets ≥ 100,000/mm3, total bilirubin ≤ 1.5 g/dl, AST/ALT ≤ 2.5-fold of the normal value, creatinine ≤ the normal value, creatinine clearance ≥ 50 ml/min, and PaO2 ≥ 70 Torr), (v) measurable lesions using response evaluation criteria in solid tumours (RECIST), (vi) life expectancy exceeding 3 months, and (vii) written informed consent.","Patients with any of the following conditions were ineligible: (i) fever suggesting infectious diseases, (ii) past treatment with flucytosine, (iii) interstitial lung disease, (iv) history of hypersensitivity to any component of S-1 or docetaxel, (v) edema, pleural or pericardial effusion requiring treatment, (vi) requirement for continuous or intermittent oxygen therapy, (vii) any serious complications (e.g., liver cirrhosis, uncontrolled diabetes mellitus, heart disease, and myocardial infarction within 6 months interval before enrollment), (viii) superior vena cava syndrome, (ix) pregnancy or feeding, (x) symptomatic brain metastasis, or (xi) other inadequate conditions.",in the first course ,NA
18362939,NA,Combination,No,metastatic gastric carcinoma,"Patients were eligible for this trial if they were over 18 years of age with histologically proven MGC, unidimensionally measurable disease, an ECOG (Eastern Cooperative Oncology Group) performance status of 0 –2, and possessed adequate baseline haematological function (ANC (absolute neutrophil count) >= 1.5 x 109 l-1, platelet count >= 100 x 109 l-1), hepatic function (serum aspartate aminotransferase and alanine aminotransferase <= 2.5 times ULN (upper limit of normal) and serum bilirubin <<= ULN), and renal function (serum creatinine <= ULN). Patients in the phase II part had received no prior chemotherapy, including adjuvant chemotherapy, whereas patients in the phase I part were permitted up to two previous chemotherapy regimens, except for prior taxane or S-1, and were required to have discontinued chemotherapy for at least 4 weeks before participating in this study.","Patients were excluded if they had a history of other malignancies within the previous 3 years, had severe comorbid conditions, or lacked the ability to comply with the requirements of the protocol. Patients receiving drugs with potential interactions with S-1 (e.g., flucytosine, allopurinol, and phenytoin) were also excluded",during the first cycle,NA
18481067,NA,Combination,No,patients with advanced or recurrent gastric cancer with consideration to age,"Patients were eligible if they met all the following criteria: presence of unresectable, locally advanced or metastatic, histologically conWrmed adenocarcinoma of the stomach; age range 18–70 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; estimated life expectancy of more than 3 months; and adequate hematological, renal and hepatic functions as deWned by white blood cell count >= 4.0 x 109 per L or absolute granulocyte count >= 1.5 x 109 per L, platelet count >= 100 x 109 per L, hemoglobin level >= 9.0 g/dL, serum creatinine level <= 1.4 mg/dL, serum bilirubin level <= 1.8 mg/dL and AST/ ALT <= two times the upper limit of normal","Patients were excluded if they had previous history of chemotherapy (but adjuvant chemotherapy was allowed), central nervous system metastasis, obvious bowel obstruction, serous gastrointestinal bleeding or serious comorbid conditions.",during the first two cycles,NA
20043166,NA,Combination,No,patients with advanced solid tumors,"Male and female patients who were 18 years of age or older, had histologically proven advanced solid tumors for which curative therapy was not available, and were considered eligible for treatment with standard doses of singleagent docetaxel were recruited. All patients provided written and informed consent. Other key inclusion criteria included (a) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; (b) resolution of all acute toxic effects of prior chemotherapy, radiotherapy, or surgical procedure to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grade <= 1; (c) adequate hematologic parameters (absolute neutrophil count [ANC] >= 1,500/uL; platelets >= 100,000/uL; hemoglobin >= 9 g/dL) and hepatic, renal, and cardiac function, including left ventricular ejection fraction (LVEF) >= 50% without the support of cardiotropic agents.","Exclusion criteria included (a) prior treatment with highdose chemotherapy requiring stem cell rescue or prior irradiation to >= 25% of the bone marrow; (b) surgery, systemic therapy or any investigational agent within 4 weeks prior to starting study treatment; (c) extensive prior anthracycline or anthracenedione exposure (i.e. cumulative doxorubicin exposure > 300 mg/m2, epirubicin exposure > 900 mg/m2, mitoxanthrone exposure >=120 mg/m2, doxorubicin liposome injection exposure >= 550 mg/m2); (d) centrally located lung lesions (unless irradiated with >= 30 Gy >= 2 weeks prior to starting study treatment); (e) NCI CTCAE grade 3 hemorrhage within 4 weeks of study entry, significant hemoptysis, or grade >=  2 neuropathy or edema; (f) diagnosis of a second malignancy within the last 5 years, except for adequately treated basal or squamous cell skin cancer, localized prostate cancer, or in situ bladder or cervical cancer; (g) known brain metastases, spinal cord compression or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease; (h) severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack within 12 months of study entry or ongoing cardiac dysrhythmias (grade >= 2), atrial fibrillation or QTc interval prolongation; (i) history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. Patients who were pregnant or breastfeeding were also excluded.",during the first 31 or 21 days of cycle 1,NA
17569044,NA,Combination,No,metastatic breast cancer,"The criteria for enrolment in the trial included histological or cytological proven breast cancer at Wrst diagnosis, evidence of progressive metastatic disease, age between 18 and 70, Karnofsky performance status >=70%, life expectancy >=12 weeks, adequate bone marrow, hepatic and renal functions characterized as follows: neutrophils >=2.0 x 109 l-1, platelets >=100 x 109 l-1, haemoglobin >=10 g dl-1 or 6.2 mmol l-1, total bilirubin x ULN (according to each centre), transaminases (ALAT, ASAT) <= 2.5 ULN, alkaline phosphatase <= 5 x ULN and serum creatinine <= 1.5 x ULN.","Non-inclusion criteria included prior adjuvant chemotherapy with vinca derivatives or taxanes, concurrent treatment with any other cancer chemotherapy, participation in any other clinical trial within 30 days prior to study screening, poorly controlled medical disorder (diabetes, hypertension, infection), active CNS disorder and brain or leptomenigeal metastasis.",in the first treatment cycle,NA
16683205,NA,Combination,No,advanced solid cancers,"Eligible patients were required to have had the diagnosis of advanced solid malignancy confirmed on histology and to have been refractory to standard treatment or for which there was no current standard therapy; age greater than or equal to 18 years; measurable or evaluable disease; performance status (PS) ≤ 2; and adequate organ function as defined by absolute neutrophil count (ANC) ≥1500/μl, platelet count ≥100,000/μ1, hemoglobin >8.5 gm/dl, prothrombin time (PT)/activated partial thromboplastin time (aPTT) within institutional normal limits (INL); serum creatinine ≤1.25 times INL, serum bilirubin within INL; and ALT and AST ≤3 times INL. Patients of childbearing age were required to practice contraception. Patients were required to have recovered from all previous surgery, chemotherapy, and radiotherapy prior to study initiation. All patients gave written informed consent approved by the Institutional Review Board at Montefiore Medical Center.",Exclusion criteria included renal tubular dysfunction (≥2 + proteinuria on urine dipstick); known hypersensitivity to docetaxel or oligonucleotides; progressive central nervous system metastases requiring medical or surgical intervention; or grade 2 or greater clinical neuropathy. Pregnant or nursing women were excluded; as were patients on anticoagulation therapy,in cycle 1,NA
16619558,NA,Combination,No,Advanced or Recurrent Gastric Cancer,"The subjects of the study were patients who were able to be administered a medicine orally and who had histologically or cytologically proven metastatic, recurrent, or unresectable locally advanced gastric cancer. The inclusion criteria were: age 20 to 75 years, performance status (World Health Organization: WHO) 0 to 2 and an estimated life expectancy of more than 3 months. Prior chemotherapy or adjuvant chemotherapy was permitted, provided that it had been completed at least 4 or 2 weeks, respectively, prior to the start of the study. Other eligibility criteria included white blood cell count between 4,000/mm3 and 12,000/mm3, absolute neutrophil count more than 2,000/mm3, platelet count more than 100,000/mm3, Hb more than 9.0g/dl, AST and ALT within 2 times the upper limit of normal for the institution, serum bilirubin level below 1.5 mg/dl, BUN under 25 mg/dl and a serum creatinine level below 1.5 mg/dl. Written informed consent was obtained from all patients and the protocol was approved by the institutional ethics committee. ","Patients were excluded from the trial if any of the following exclusion criteria were extant: symptomatic infectious disease, pulmonary fibrosis, interstitial pneumonia, bleeding tendency, severe heart disease, pre-existing symptomatic peripheral neuropathy or edema of more than grade 2 severity according to the common toxicity criteria of the National Cancer Institute (NCICTC), active double cancer, symptomatic pleural effusion or ascites, past history of allergic reaction to polysorbate 80, pregnancy or breast feeding, obstructive bowel disease, other concomitant anticancer therapy administration, including flucytocine or phenytoin, severe diabetes mellitus requiring insulin, or past history of drug allergy. Patients were not permitted to receive granulocyte colony-stimulating factor (G-CSF) during the study period, except as outlined later",the first cycle,NA
16683073,NA,Combination,No,non-hematologic cancer ,"Patients were eligible for the study if they had a confirmed pathologic diagnosis of a nonhematologic malignancy for which no standard curative or palliative therapy was available. Patients were also required to have a Eastern Cooperative Oncology Group (ECOG) performance status of ≤2, a life expectancy of at least 12 weeks, and adequate hematologic, renal and hepatic function defined by the following parameters: neutrophil count ≥1,500/ µL, platelet count ≥ 100,000/µL, serum creatinine ≤1.5 mg/dL, total serum bilirubin within the institution’s normal limits and serum aminotransferases less than 2.5 times upper limit of the institutional normal range. Patients were required to have bidimesionally measurable disease. Irradiated tumors with no evidence of progression after radiation therapy were not considered measurable. Prior chemotherapy, surgery, or radiation therapy was permitted as long as the patients had recovered adequately from these procedures. At least 6 months must have elapsed from completion of prior taxane-based therapy to be eligible for the study. Female patients of childbearing potential must have had a negative serum pregnancy test prior to enrolment, and all fertile patients must have agreed to use contraception during the study. All patients provided a signed informed consent in accordance with the Wayne State University Human Investigation Committee guidelines prior to enrolment on the study.","Patients were excluded from study participation if they had uncontrolled brain metastases. Other exclusion criteria included uncontrolled intercurrent illness such as active infection, symptomatic congestive heart failure, or unstable angina.",the first cycle of therapy,NA
15277270,NA,Combination,No,patients with advanced breast cancer and other solid tumors,"Eligible patients had histologically confirmed measurable or evaluable advanced solid tumors for which treatment with docetaxel was appropriate. Priority was given to patients with breast cancer, but tumors of all histology could be included. To be eligible, patients’ tumors must have exhibited Bcl-2 overexpression defined by immunohistochemical staining of the Bcl-2 protein in >= 20% of tumor cells using anti-Bcl-2 antibody M887 (DAKO, Inc., Carpenteria, CA) . Bcl-2 expression was measured on previously obtained tumor specimens in the majority of cases. There was no restriction of the number of previous therapies, and previous exposure to paclitaxel or docetaxel was permitted. Eligibility criteria also included age >= 18 years, Eastern Cooperative Oncology Group (ECOG) performance status <=2, and life-expectancy >= 12 weeks. Adequate organ functions were required using standard criteria","Patients were excluded if they had active tumor metastasis in the central nervous system, had previous myeloablative chemotherapy requiring stem cell support, or had grade >2 peripheral neuropathy",within the first cycle,NA
17009034,NA,Combination,No,patients with advanced non-small-cell lung cancer,"Eligibility requirements for entry into the study were as follows: (1) histologically or cytologically proven NSCLC, (2) no prior chemotherapy, radiotherapy or surgery, (3) age of 75 years or less, (4) clinical stage of IIIB with malignant pleural eVusion or IV, (5) performance status (PS) of 0–2 on the Eastern Cooperative Oncology Group (ECOG) scale , (6) presence of measurable disease, (7) adequate functional reserves of the kidney (creatinine clearance >= 60 ml/min), liver (ALT, AST <twice the upper limit of normal), and bone marrow (a leukocyte count >= 4,000/cmm and a platelet count >= 100,000/cmm), (8) no concomitant malignancies, and (9) receipt of a written form of informed consent.",NA,NA,NA
15494635,NA,Combination,No,locally advanced or metastatic solid tumors,"Eligibility criteria for all patients included age higher than 17 years, performance status 0–2 on the WHO scale, life expectancy of at least 12 weeks, adequate bone marrow [white blood cell count (WBC) > 3.5 x 109/l, absolute neutrophil count (ANC) > 1.5 x 109/l, platelet count > 100 x 109/l], renal [serum creatinine < 1.5 x upper limit of normal (ULN)] and hepatic (serum bilirubin < 1.25 x ULN, serum transaminases < 2 x ULN or < 5 x ULN in the presence of liver metastases) function, and absence of clinically relevant neuropathy, psychiatric illness, pregnancy or lactation. Patients were to have histologically or cytologically proven locally advanced or metastatic solid tumors. Any previous chemotherapy should have been discontinued at least 4 weeks (6 weeks for nitrosoureas, melphalan and mitomycin C) before enrollment. Extended field radiotherapy should have been stopped at least 6 weeks prior to study entry, whereas concurrent limited field radiotherapy was allowed. Before enrollment in the trial, all patients provided written informed consent",the first two cycles (four courses) of treatment ,NA,NA
17357187,NA,Combination,No,patients with advanced breast cancer failing prior anthracyclines,"Patients with histologically confirmed metastatic breast cancer pretreated with anthracycline-based chemotherapy were enrolled. The following patient categories were formed: (i) patients progressing on anthracycline-based therapy or within 4 months after the end of such a treatment, (ii) or patients treated with neoadjuvant and adjuvant anthracyclines that progressed within 12 months after the end of adjuvant chemotherapy were deemed anthracycline-refractory, (iii) while all other patients were considered potentially anthracycline-sensitive. Patients had to have bi-dimensionally measurable lesions with at least one outside a previously irradiated fieldunless definite evidence of progression at this site was observed during a minimum 3-month period. No prior taxanes or ifosfamide were allowed. Patients identified in retrospect (on archive or new biopsy material) to have HER2 (c-erbB2) overexpressing tumors by immunohistochemistry and/or FISH analysis, as this became available after the end of 2000, were not offered trastuzumab therapy in combination with the study regimen of docetaxel-ifosfamide until disease progression. Other inclusion criteria were as follows: age 18 to 72 years; a WHO PS of 0 to 2; life expectancy of at least 3 months; adequate hematopoietic (absolute neutrophil count–ANC ≥ 1500/µL, platelets–PLT ≥ 100.000/µL), liver (bilirubin < 1.5 mg/dl, AST/ALT < 2 × upper normal limit, unless caused by tumor, and serum albumin > 3.0 g/dl), renal (BUN and creatinine < 1.5 × upper normal limit; and creatinine clearance > 50 ml/min), andcardiac function (left ventricular ejection fraction [LVEF] ≥ 50%).Patients with brain metastases were eligible, provided they had been irradiated and had clinical and radiological improvement and were off steroids or receiving tapering doses of steroids","Other exclusioncriteria were radiation therapy within 4 weeks from treatment initiation, irradiation of more than 25% of the bone marrow-bearingskeleton, severe infection or malnutrition.",during the first chemotherapy cycle,NA
17180514,NA,Combination,No,"patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation","Eligible patients with metastatic, or locally recurrent, or residual disease not curable with surgery had been previously treated with CDDP, 5FU, and radiation, with total dosages of more than 160mg/m2 of CDDP, more than 8g/m2 of 5FU, and more than 50 gray (Gy) of radiation. Other eligibility criteria included an Eastern Clinical Oncology Group (ECOG) scale performance status of 2 or less; age between 20 and 79 years; life expectancy of at least 3 months; provision of written informed consent in accordance with government and institutional guidelines; and adequate organ functions, with a WBC count of more than 3000/mm3; absolute neutrophil count of more than 1500/mm3; platelet count of more than 10 × 104/mm3; aspartate aminotransferase (AST) and alanine aminotransferase (ALT levels) within three times the upper limit of normal (ULN) or five times the ULN in the presence of liver metastasis; total bilirubin less than 1.5mg/dl; serum creatinine less than 1.5mg/dl and/or creatine clearance more than 50ml/min. ","Exclusion criteria included the following: concomitant uncontrolled, nonmalignant disease (malignant hypertension; cardiac, pulmonary, renal, or hepatic disease; active infection), neuropathy of more than grade 2, active double cancer, pregnant women, brain metastases with any symptoms, or a prior history of treatment for psychiatric diseases. Patients with active interstitial pneumonitis or severe pulmonary fibrosis on chest X-rays or computed tomography (CT) were also excluded. ",during the first cycle of therapy,NA
16162980,NA,Combination,No,early breast cancer,"Patients aged 18–65 years were eligible to enter the study if they had histologically confirmed, untreated T2–4 N0– 2 M0 monocentric breast cancer with a bidimensionally measurable breast tumor > 2.0 (pre-menopausal patients) or > 2.4 cm (post-menopausal patients), no distant metastases as assessed by physical examination, abdominal ultrasound, chest X-ray and bone scan, an ECOG performance status r 2 and adequate hematologic (absolute neutrophil count >= 1.5 x 109/l and platelet count > 100 x109/l), hepatic and renal function. ","Patients were excluded if they were pregnant or lactating, receiving immunosuppressive therapy, had a history of malignancies (except for basal squamous skin cell carcinoma, in situ cervical carcinoma or any other tumor that was cured and had not recurred for at least 10 years), active infections, significant neurologic or psychiatric illness, or other disorders that might interfere with therapy or put the patients at additional risk.",during the first 3 cycles of gemcitabine plus epirubicin and the first 2 cycles of docetaxel,NA
15519516,NA,Combination,No,patients with early breast cancer,"Women with newly diagnosed non-metastatic breast cancer presenting at the Universities of Heidelberg or Tuebingen or the community hospital of Weinheim were invited to participate in this study if they met the following eligibility criteria: histologically-confirmed, unilateral large (P 2.5 cm in diameter in postmenopausal or P 2.1 cm in premenopausal women) or inflammatory BC ; no evidence of distant metastatic disease as assessed by physical examination, chest X-ray, liver ultrasound, bone scan, and full blood count; Eastern Cooperative Oncology Group (ECOG) performance status of 6 2; adequate bone marrow function (absolute neutrophil count (ANC) >= 1.5 x 109 cells/L, platelet count > 100 x 109 cells/L); adequate cardiac, renal and hepatic function; and a negative pregnancy test. A diagnosis of invasive BC was made using clinical examination, mammography, ultrasonography and core biopsy. ",NA,during the first cycle of treatment,NA
15140550,NA,Combination,No,non-small cell lung cancer,"Chemotherapy-na¨ıve patients with histologically or cytologically confirmed unresectable stage IIIB or IV NSCLC were enrolled onto the study. Other inclusion criteria were: performance status (World Health Organization, WHO) 0—2; age δ 75 years; a life expectancy of τ 3 months; adequate renal (serum creatinine concentration δ 1.5 mg/dl), liver (total bilirubin level δ 1.5 mg/dl, transaminases δ 1.5 times the upper limit of normal or δ 3 times if hepatic metastases were present, and alkaline phosphatase δ 2.5 times the upper limit of normal) and bone marrow (absolute neutrophil count τ 1500 dl−1 and platelets τ 100,000 dl−1) function. Bidimensionally measurable disease was not mandatory for study enrollment.","Patients with prior radiation therapy to τ 25% of the bone marrow-containing bones, congestive heart failure, unstable angina pectoris or recent myocardial infraction were not eligible. In addition, patients with malnutrition (loss of more than 20% of body weight), active infection and symptomatic brain metastases, which failed to improve with radiotherapy, were also excluded from the study",during the first chemotherapy cycle,NA
15509491,NA,Combination,No,oral squamous cell carcinoma,"Patients with a resectable oral SCC (histologically proven and previously untreated) of late T2 (diameter more than 3 cm), T3, or T420 were registered for DOC and CDGP combination preoperative chemotherapy. Eligibility criteria for the chemotherapy were: (1) age between 20 and 75 years (patients aged >76 years were allowed if major organs functions was preserved), (2) Eastern Cooperative Oncology Group performance status (PS) score of 2 or less, (3) adequate bone marrow function (white blood cell count from 4,000 to 12,000/ll, neutrophil count of 2,000/ll or more, platelet count of 100,000/ll or more, and hemoglobin level of 10.0 g/dl or more), (4) adequate hepatic function (total serum bilirubin level less than or equal to 1.5 mg/dl, aspartate aminotransferase and alanine aminotransferase less than or equal to twice the upper limit of the normal ranges), (5) adequate renal function (serum creatinine less than or equal to 1.5 mg/dl and creatinine clearance rate more than or equal to 60 ml/min)","Patients were excluded if they had active infections, active second malignancy, severe heart diseases, interstitial pneumonia or lung fibrosis, severe pleural effusion or pericardial effusion that required drainage, fever more than or equal to 38 C, symptomatic brain metastasis, severe psychological disease, and possible pregnancy.",during the first treatment cycle,NA
15809878,NA,Combination,No,advanced cancer for which prior therapy had failed or for which there was no effective therapy available,"Patients eligible for this study required histological evidence of advanced cancer for which prior therapy had failed or for which there was no effective therapy available. Other eligibility criteria included: age >= 18 years; Southwest Oncology Group (SWOG) performance status 0–2; recovery from acute toxicities of chemotherapy, radiation or surgery; adequate bone marrow (absolute neutrophil count, ANC, >= 1500 cells/mm3, platelet count >= 100,000 cells/mm3) and liver function tests [bilirubin not more than the upper limit of normal (ULN) and transaminases not more than 2.5 times the ULN if alkaline phosphatase was not more than the ULN or alkaline phosphatase not more than four times the ULN if transaminases were not more than the ULN).",Patients with moderate (grade 2 or worse) peripheral neuropathy were excluded from study entry.,the first cycle of treatment,NA
16379039,NA,Combination,No,patients with advanced solid tumors,"Patients were eligible if they had an advanced or refractory malignant solid tumor for which no standard therapy was available. Other eligibility criteria included the following: age ≥18 years; Southwest Oncology Group (SWOG) performance status ≤2; fully recovered from acute toxicities of prior therapy directed to the cancer, no previous radiotherapy to the pelvis, and adequate bone marrow reserve (absolute neutrophil count ≥ 1.5 × 109/1 and platelet count ≥100 × 1099/1), and hepatic function (total serum bilirubin level ≤ upper limit of normal [ULN] and transaminases (AST and/or ALT) ≤ 1.5 ULN. Prior use of sulindac within 3 months of study entry was not allowed. In addition, concomitant use of over-the-counter NSAIDs or salicylates (e.g. aspirin, mesalamine, azodisalyclate, salsalate and sulfaxalazine) was not allowed. Patients agreed to use an effective method of birth control during their participation in the study and negative pregnancy test was required for women of childbearing potential.",Patients previously treated with exisulind or weekly docetaxel and patients with ≥ grade 2 peripheral neuropathy were excluded from participating.,during the first cycle of chemotherapy,NA
16042786,NA,Combination,No,patients with advanced gastric cancer,"Patients enrolled into this study had to be at least 18 years of age and have a histologically confirmed diagnosis of metastatic or recurrent gastric adenocarcinoma that was previously treated with, though not necessarily resistant to, cytotoxic chemotherapy. The patients were required to have a Eastern Cooperative Oncology Group (ECOG) performance status ≤2, normal blood counts, normal renal and hepatic functions, no history of anaphylaxis and no peripheral neuropathy of any origin. Patients had to have received at least one chemotherapy regimen, either as adjuvant treatment or for metastatic disease. Patients could have received prior 5-FU, provided it was administered in intravenous bolus or in oral form, but not with paclitaxel or docetaxel. Patients had to have fully recovered from the toxic effects of previous chemotherapy except for alopecia",NA,the first cycle of treatment,NA
16969706,NA,Combination,No,patients with locally recurrent or metastatic breast cancer,"Trial 001: Women with histologically or cytologically confirmed metastatic breast cancer were eligible if they had received at least two prior regimens (one of which may have been hormonal) for metastatic disease. In addition patients were required to have a Karnofsky performance status ≥ 80 and adequate renal (creatinine <1.5 mg/dL), hepatic (total bilirubin <1.5 mg/dL; AST and ALT <2.5 times upper limit of normal) and hematologic (WBC >3000/mm3; platelets >100,000/mm3; INR ≤1.2 with normal PTT) function. Patients were excluded if they had any history or radiographic evidence of central nervous system disease; screening brain magnetic resonance image (MR) was required prior to entry. In addition patients may not have had any other primary malignancy within 5 years, major surgical procedure or chemotherapy within 21 days, active infection or clinically significant cardiovascular disease including myocardial infarction or unstable angina within 3 months. Women of reproductive potential were required to use an effective barrier means of contraception throughout the study.Trial 002: Eligibility criteria were identical to Trial 001 except patients were required to have an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 and could have received no more than one prior non-taxane containing chemotherapy regimen for advanced disease. Adjuvant taxane use was allowed if the disease-free interval was >12 months.",NA,within the first cycle of therapy,NA
15274365,NA,Combination,No,Advanced or Recurrent Gastric Cancer,"The subjects of the study comprised patients with histologically or cytologically proven metastatic or recurrent, or unresectable locally advanced gastric cancer. Prior chemotherapy or adjuvant chemotherapy was permitted, provided it had been completed at least 4 weeks or 2 weeks, respectively, prior to the patient’s entry into this study. The inclusion criteria were: age 20 to 75 years, performance status (World Health Organization: WHO) 0 to 2 and an estimated life expectancy of more than 3 months. Other eligibility criteria included a white blood cell count between 4,000/mm3 and 12,000/mm3, absolute neutrophil count of over 2,000/mm3, platelet count of over 100,000/mm3, Hb over 9.5g/dl, serum bilirubin level under 1.5 mg/dl, AST and ALT within two times the upper limit of normal for the institution, BUN under 25mg/dl, serum creatinine within the upper limit of normal for the institution and the measured 24-hour creatinine clearance over 50 ml/min. Written informed consent was obtained from all the patients and the protocol was approved by the institutional ethics committees of the participating centers","Patients were excluded from the trial if any of the following exclusion criteria were present: symptomatic infectious disease, pulmonary fibrosis, interstitial pneumonia, bleeding tendency, preexisting symptomatic peripheral neuropathy or edema of more than grade 2 severity according to the common toxicity criteria of the National Cancer Institute (NCI-CTC), active double cancer, symptomatic pleural effusion or ascites, past history of allergic reaction to polysorbate 80, pregnancy or breast feeding, obstructive bowel disease, other concomitant anticancer therapy drug administration, including flucytocine and a past history of drug allergy. Patients were not permitted to receive corticosteroids or granulocyte colony-stimulating factor (G-CSF) during the study period, except as outlined later",during the first cycle ,NA
16525670,NA,Combination,No,advanced and recurrent gastric cancer,"Patients with advanced or recurrent gastric cancer were eligible for this study. This study started after obtaining approval from the institutional review board. Disease characteristics included the following criteria: i) histologically or cytologically proved gastric cancer, ii) measurable or evaluable lesions, iii) no prior chemotherapy (history of postoperative adjuvant chemotherapy was allowed), and iv) adjuvant therapy (including chemotherapy and immunotherapy) must be finished at least four weeks before the combination therapy starts. Patient characteristics included the following criteria: i) age of ≥20 and <75 years, ii) an Eastern Cooperative Oncology Group performance status of ≤2, iii) adequate hematopoietic function (4000/mm3≤ white blood cell ≤12000/mm3, neutrocyte, ≥2000/ mm3, platelet ≥10x104/mm3, hemoglobin ≥9.0 g/dl), iv) adequate hepatic function [total bilirubin ≤1.5 mg/dl, transaminase ≤2 times institutional normal upper limit (if caused by liver metastases, transaminase ≥2 times may be allowed based on the doctor's judgement)], v) serum creatinine ≤ institutional normal upper limit, blood urea nitrogen ≤25 mg/dl, vi) adequate cardiac function, vii) neither brain metastases nor history of brain metastases, and viii) before treatment, written informed consent must be obtained from the patients.",NA,NA,NA
16127289,NA,Combination,No,Advanced Solid Tumors,"Patients with histologically or cytologically confi rmed advanced-stage solid tumors were enrolled in the study. Prior radiotherapy (to less than 20% of bone-marrow-containing bones) or chemotherapy were allowed, but a treatment-free interval of at least 4 weeks was required before entering into the study. Other inclusion criteria were: age 18–75 years, performance status (World Health Organization; WHO) 0–2, life expectancy of at least 3 months, adequate bone marrow (absolute neutrophil count >=  1,500 x 10 6 cells/l, platelets >= 100,000 x 10 6 cells/l), renal (serum creatinine <= 1.5 mg/dl), liver [aspartate aminotransferase (SGOT), alanine aminotransferase (SGPT), alkaline phosphatase, bilirubin <= 2 times the upper normal limit] and cardiac function, and absence of active infection or severe malnutrition (loss of more than 20% of the body weight). Patients who had previously received doxorubicin-based chemotherapy had to have a left-ventricular ejection fraction > 50% evaluated by multigated (MUGA) scan or cardiac ultrasound. The presence of measurable disease was not required.",NA,during the first chemotherapy cycle,NA
15221599,NA,Combination,No,patients with locally advanced squamous cell carcinoma of the head and neck,"Eligible patients had histologically or cytologically confirmed SCCHN with at least one measurable lesion, stage III or IV disease without evidence of distant metastasis, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, life expectancy more than 3 months, WBC count of 4000 or more cells/µl, absolute neutrophil count of 2000 or more cells/µl, platelet count of 100000 or more µl, levels of hemoglobin (Hb) of 9.5g/dl or more, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 times the upper limit of normal (ULN), total bilirubin less than or equal to 1.5 times the ULN, alkaline phosphatase less than or equal to 2.5 times the ULN, blood urea nitrogen less than or equal to the ULN, creatinine less than or equal to 1.5 times the ULN, and a creatinine clearance rate (Ccr) of 60ml or more min. Patients were also required to be between 20 and 75 years of age and to be able to tolerate 3l of intravenous normal saline per day. In patients who had received previous chemotherapy or radiation, in principle at least 4 weeks had passed since they had discontinued that treatment","Patients were excluded if they had had progression of disease within 6 months of having received previous chemotherapy. Additional exclusion criteria included current or past history of another serious medical condition, such as chronic obstructive pulmonary disease, myocardial infarction, angina pectoris, arrhythmias, uncontrolled hypertension or diabetes mellitus, serious neurogenic or psychiatric disorder, active peptic ulcer disease, or active infection; pregnancy was also a criterion for exclusion.",during the 1st cycle,NA
16809732,NA,Single Drug,No,Superficial Bladder Cancer Refractory to Standard Intravesical Therapy,"All patients had a histologically confirmed diagnosis of superficial transitional cell carcinoma of the urinary bladder (Ta, T1, or Tis) at Columbia University Medical Center and were deemed medically unable to undergo radical cystectomy or had refused cystectomy. Demonstrated evidence of recurrent superficial bladder cancer refractory to standard intravesical therapy, including Bacillus Calmette-Guerin (BCG), mitomycin, interferon, or any combination thereof, was required. All grossly visible disease was fully resected before the study. Other eligibility criteria included the following: age >= 18 years; Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2; no previous intravesical therapy for 6 weeks; no history of prior radiation to the pelvis; peripheral neuropathy <= grade 1; and adequate hematopoietic and hepatic parameters.","Specific exclusion criteria included muscleinvasive disease (T2-T4), prior treatment with docetaxel, concomitant treatment with any chemotherapeutic agent, history of severe hypersensitivity reaction to docetaxel or other drugsformulated with polysorbate 80, history of vesicoureteral reflux or an indwelling urinary stent, any other malignancy diagnosed within 2 years of study entry (except basal or squamous cell skin cancers or noninvasive cancer of the cervix), participation in any other research protocol involving administration of an investigational agent within 3 months before study entry, and any contraindication to prescribed immunosuppressive medications because of a confounding medical condition. Female patients who were pregnant or lactating also were excluded",NA,NA
15849219,NA,Combination,No,advanced breast cancer patients,"Patients age 18 years or older with histologically confirmed breast cancer, evidence of metastatic disease, and no prior chemotherapy for metastases were eligible. Patients who had received prior adjuvant taxanes and/or doxorubicin were eligible if the chemotherapy was completed more than 6 months prior to study entry, and the total cumulative dose of adjuvant doxorubicin was limited to <_ 300 mg/M2. Hormone therapy in the adjuvant or metastatic setting was permitted provided it was discontinued at least 3 weeks before study entry. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status <= 2, and the following organ function: platelets >_ 100 000 cells/mm3; absolute neutrophil count >= 1500 cells/mm3; hemoglobin >= 10 g/dl; serum creatinine <2.0 mg/dl; and pretreatment left ventricular ejection fraction (LVEF) >= 50%. Due to the increased risk of side-effects of docetaxel with impaired liver function, the total bilirubin was required to be less than or equal to the upper limit of normal (ULN); AST and ALT <=  2.5 times ULN if alkaline phosphatase was normal; or alkaline phosphatase <= 4 times ULN if AST and ALT were normal.","Patients were excluded for a known hypersensitivity to taxanes, anthracyclines, polysorbate 80, eggs or eggs products; prior radiotherapy to mediastinal area or internal mammary lymph node exceeding 3500 cGy, or if they received radiation therapy to more than 25% of the bone marrow. Patients with untreated brain metastases were excluded. However, patients with previously treated brain metastases were eligible if they were stable for at least 3 months after surgery and/or radiation and were off steroids. Patients were not required to have bi-dimensionally measurable disease; if measurable disease was present, it was evaluated using standard response criteria (see below). ",occurring in cycle 1,NA
15143084,NA,Combination,No,Unfavorable Localized Adenocarcinoma of the Prostate,"The eligibility criteria included men with biopsy proven adenocarcinoma of the prostate and unfavorable localized disease defined as follows: T3N0M0 or T4N0M0, T1B/T1C/T2N0M0 and Gleason Score  8, or T1C/T2N0M0 with Gleason Score 5 to 7 and PSA >= 10 ng/mL. Other major eligibility criteria also included Karnofsky Performance Status >= 70, no history of prior chemotherapy or pelvic irradiation, adequate bone marrow/liver function, and no history of prior invasive malignant cancer(s) within the last 5 years except adequately treated or controlled basal cell or squamous cell carcinoma of the skin. ","Neoadjuvant or adjuvant hormonal therapy could be given, but concurrent hormonal therapy was not allowed. ",NA,NA
16773074,NA,Combination,No,patients with advanced gastric cancer,"Patients were eligible if they signed informed consent and met all the following criteria: histologically- or cytologically confirmed unresectable or recurrent GC; at least one measurable lesion (patients without a measurable lesion, but evaluable nonmeasurable lesions were permitted in the phase I part of this study); Eastern Cooperative Oncology Group performance status of 0– 1; good recovery from surgery (at least 28 days after the operation); up to one prior chemotherapy regimen except for prior taxane (paclitaxel or docetaxel) or S-1 (other fluoropyrimidines were allowed if at least 28 days elapsed after the last treatment); >= 20 years of age; estimated life expectancy of at least 3 months; haemoglobin >= 8.0 g dl-1; white blood cell count between 4000 and 12 000 mm-3; neutrophil count >= 2000 mm-3; platelet count >= 100 000 mm-3; serum bilirubin <= 1.5 mg dl-1; aspartate aminotransferase and alanine aminotransferase <= 2.5 times the upper limit of normal (ULN); and serum creatinine less than or equal to ULN.","Exclusion criteria were as follows: pregnant female or sexually active males/females unwilling to use contraception during the study; infection or suspected infection with fever; congestive heart failure; uncontrolled angina pectoris or arrhythmia; a history of myocardial infarction within the previous 3 months; uncontrolled diabetes or hypertension; interstitial pneumonia or lung fibrosis; peripheral neuropathy grade 2 or higher; pleural, peritoneal, or pericardial effusion that required treatment; gastrointestinal haemorrhage; symptomatic brain metastasis; diarrhoea; and active concomitant malignancy.",in the first treatment cycle,NA
16943532,NA,Combination,No,Locally Advanced Squamous Cell Cancer of the Head and Neck,"Patients were required to have untreated HNSCC (oral cavity, oropharynx, hypopharynx, or larynx); T3-4 and/or N2-3 M0 disease; Karnofsky performance status 70% or lower; life expectancy 6 months or longer, adequate bone marrow and hepatic function, normal coagulation parameters, normal serum calcium, and creatinine clearance higher than 50 mL/min. Patients were not eligible if they had: prior cancer history more recent than 5 years (except nonmelanoma skin cancer), synchronous primary cancer, pre-existing grades 2 to 4 peripheral neuropathy (National Cancer Institute Common Toxicity Criteria, version 2.0), or hypersensitivity to polysorbate 80 or docetaxel.",NA,NA,NA
16791410,NA,Combination,No,"advanced, recurrent, or metastatic soft tissue sarcoma (STS)","Patients 18 years and older were eligible if they had measurable, pathologically confirmed soft tissue or osteogenic sarcoma. All patients were required to have histologic, cytologic, or strong clinical or radiographic evidence of distantly metastatic, locally advanced, or recurrent disease (UICC Stages IIIB-IV or recurrent). Patients were required to have no prior chemotherapy for advanced, recurrent, or metastatic sarcoma. Prior adjuvant or neoadjuvant chemotherapy was allowed, provided the cumulative dose of doxorubicin was ≤360 mg/m2. Prior radiation therapy was allowed, as long as the last radiation dose was administered a minimum of three weeks prior to enrollment on trial. At least one site of evaluable or bidimensionally measurable disease was required. A performance status of Eastern Cooperative Oncology Group (ECOG) 0–2 was mandated. Adequate organ function was necessary, defined as leukocyte count >3,500/µL or absolute neutrophil count (ANC) >1750/µL, platelets >100,000/µL, serum creatinine <1.4 mg/dL or 24-h urine creatinine clearance >60 ml/min, bilirubin <1.5 mg/dL, liver enzymes (alanine transaminase or aspartine transaminase) <2.5 × normal if the alkaline phosphatase was within normal limits, and left ventricular ejection fraction (LVEF) >50% by multiple gated acquisition (MUGA) scan or echocardiogram.","Patients of reproductive potential could not participate unless they agreed to practice precautions to prevent pregnancy during treatment. Exclusion criteria included patients with a life expectancy of less than three months, pregnant or lactating women, a history of prior malignancy (except for adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer, or other cancer from which the patient had been disease-free for at least five years), patients who were physically, mentally, or emotionally unable to give informed consent, or history of cardiac disease of New York Heart Association Class II or greater. Patient could not receive concurrent radiation therapy, hormonal therapy for malignancy, or other chemotherapy while on this protocol. The following histologies were excluded: reticulum cell sarcoma, Kaposi’s sarcoma, and mesothelioma.",within the first three weeks of therapy,NA
16416334,NA,Combination,No,locally advanced non-small cell lung cancer,"Previously untreated patients with histologically or cytologically documented inoperable stage IIIA or IIIB NSCLC were eligible for this study. Other eligibility criteria included: (1) age less than 75, (2) Eastern Cooperative Oncology Group performance status equal to or less than 2, (3) evaluable or measurable disease, (4) no prior therapy, (5) adequate bone marrow function (leukocyte count >=4,000/mm3, platelet count >= 100,000/mm3, hemoglobin >=9.5 g/dl), renal function (serum creatinine <= 2.0 mg/dl), hepatic function (AST/ALT <= 2.5 times upper limit of normal, serum bilirubin <= 1.5 mg/dl), and pulmonary function (arterial blood gases PaO2 >=70 mmHg), (6) absence of active infection, heart failure, or acute myocardial infarction within 3 months before study entry, no serious medical or psychiatric illness. ",Patients with malignant pleural effusion or any disease that required irradiation of more than half of the hemithorax were ineligible.,NA,NA
16565832,NA,Combination,No,stage III non-small-cell lung cancer,"Patients with pathologically conWrmed, unresectable stage IIIA or IIIB NSCLC were eligible for study. Patients with stage T3N1 disease, malignant pleural eVusion, pericardial eVusion, or pleural dissemination were excluded. Other eligibility criteria included the following: (1) no previous treatment, including radiotherapy, chemotherapy, and surgery; (2) lesions that could be measured or assessed; (3) an age of 18–75 years; (4) an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and (5) a life expectancy of 3 months or longer. Patients also had to have an absolute granulocyte count of >= 2,000 per ul, a hemoglobin concentration of >= 10 g/dl, a platelet count of >= 100,000, and a serum creatine level of <= the upper limit of normal or a 24-h creatinine clearance of at least 50 ml/min. In addition, the results of liver function tests had to be <= 2.0 times the upper limit of normal, the PaO2 in a sample of arterial blood >= 70 torr, and the cardiac function normal. Pulmonary function tests of vital capacity, FEV1, and carbon monoxide diVusing capacity of the lung were also required.","Patients were excluded if they had apparent evidence of pulmonary fibrosis on computed tomography (CT) or were women who were pregnant. This study was approved by our institutional review board, and all patients provided their informed consent before enrollment.",NA,NA
15838660,NA,Combination,No,patients with advanced malignancies,"1. histologically confirmed, non-hematologic tumors resistant to standard chemotherapy or for which no effective therapy existed; 2. measurable or evaluable disease; 3. age greater than 18 years; 4. a median survival of at least 3 months; 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of <= 2; and 6. adequate hematopoietic function (hemoglobin >9.0 g dL-1; total leucocyte count >3,000 lL-1; platelet count >100,000 lL-1), hepatic function [bilirubin <2.0 g dL-1; transaminases or alkaline phosphatase levels <4 times upper limit of normal (ULN)] and renal function (serum creatinine <2.0 g dL1).","1. central nervous system metastasis; 2. any woman pregnant or breast feeding; 3. major surgery, cytotoxic chemotherapy, or radiotherapy within the previous 4 weeks; 4. clinically significant cardiac disease; 5. inability to comply with or understand informed consent; and 6. serologic evidence of hepatitis or HIV infections.",during cycle 1,NA
15310776,NA,Combination,No,Androgen-Independent Prostate Cancer,"Men with progressive AIPC and bone metastases were eligible for this study. All patients had progressive disease by clinical, radiological or PSA-based criteria. PSA progression was defined as two consecutive rises in the PSA level of at least 1 ng/mL over 4 weeks. When relevant, withdrawal of antiandrogen therapy was required. Patients had an Eastern Cooperative Oncology Group performance status of 2 or better, a serum testosterone level <= 30 ng/dL, and were maintained on luteinizing hormone-releasing hormone (LHRH) agonist therapy. Adequate organ functions were required and were defined as an absolute neutrophil count >= 1,500/mm3, platelet count >= 100,000/mm3, serum bilirubin <= 1.5 mg/dL, AST and ALT <= 2 the upper limit of normal, serum creatinine clearance >= 40 mL/min, or serum creatinine less than 1.5 the upper limit of normal.","Patients with comorbidities including symptomatic congestive heart failure, unstable angina or recent myocardial infarction, and oxygen-dependent lung disease were excluded. Chemotherapy or radiation therapy within the last 30 days and systemic radioisotope therapy within the last 90 days were not permitted.",during the imatinib lead-in module and cycle 1 of combination therapy ,NA
15567941,NA,Combination,No,advanced breast cancer,"Patients were eligible if they had a histologically confirmed locally advanced or metastatic breast cancer. Patients were required to have age >= 18 and <= 70 years, measurable disease, no prior systemic chemotherapy for advanced disease, no concurrent radiotherapy and/or hormone therapy and a Karnofsky performance status >= 50%. Previous adjuvant therapy with anthracyclines was allowed up to a total dose of doxorubicin <=300 mg/m2 or epirubicin <= 450 mg/m2. Other requirements included normal organ function (absolute granulocyte count >= 2000/mm3, platelet count >= 150,000/ mm3, hemoglobin >= 10.0 gr/dl, normal serum bilirubin and creatinine, AST and ALT <= 2.5-fold the upper limits of normal); normal left ventricular ejection fraction (LVEF) as measured by echography; no symptomatic brain metastases; no previous history of other tumors than basocellular carcinoma of the skin or adequately treated in situ carcinoma of cervix uteri.","Patients were excluded if they had a recurrent disease within the first year after completion of adjuvant therapy with anthracyclines, definite contraindications for the use of corticosteroids, acute infections, history of active angina or myocardial infarction within 6 months or significant arhythmia. Pregnant or lactating women were ineligible. ",during the first three cycles of chemotherapy,NA
15581049,NA,Combination,No,Metastatic Pancreatic Adenocarcinoma,"Patients aged 18 to 75 years with histologically or cytologically confirmed diagnosis of metastatic pancreatic adenocarcinoma were eligible for the study. Inclusion criteria comprised: Karnofsky performance status (KPS) >60; at least one previous line of chemotherapy, gemcitabine-containing, adequate bone marrow (absolute neutrophil count (ANC) > 1500 cells/mm3; platelet count > 100,000 cells/mm3 and hemoglobin > 10 g/dL); kidney function (serum creatinine <l.5 mg/dL) and liver function (serum total bilirubin < 1.5 mg/dL and serum transaminases <2 upper limit of normal). Patients with at least one bidimensionally measurable indicator lesion were assessable for response evaluation. All participating patients were required to give written informed consent.","Patients with prior malignancy were ineligible for the study, with the exception of those who had had basal cell carcinoma of the skin, carcinoma in situ of the cervix, or other cancer for which the patient had been disease free for at least 5 years. Patients with ampullary tumors or other histologic variants of pancreatic carcinoma were ineligible for the study. ",during the first cycle of chemotherapy,NA
17327701,NA,Combination,No,patients with pretreated hormone refractory prostate cancer,"Patients with HRPC, who had been previously treated with docetaxel-chemotherapy as first line, with disease progression and adequate major organ function were considered. Continued use of luteinizing hormone-releasing hormone agonist was required for those who had not undergone bilateral orchiectomy. Second-line chemotherapy (mitoxantrone, vinorelbine or other chemotherapeutic agents), analgesic drugs and biphosphonates (zoledronic acid, pamidronate, clodronate, etc) were permitted. Previous radiometabolic therapy was also permitted.",NA,in the first cycle of the treatment,NA
16020963,NA,Single Drug,No,Pretreated Metastatic Breast Cancer Patients,"All patients gave informed consent. Eligibility criteria included: histologic proof of primary breast cancer with at least one bidimen sionally measurable or evaluable metastatic lesion, life expectancy >= 3 months, age between 18 and 70 years, performance status (Eastern Cooperative Oncology Group, ECOG scale) <= 2. Other requirements were: adequate bone marrow function [absolute neutrophil count (ANC) >= 2.0 x 103 /dl; platelet count >=  100 x 103 /dl; hemoglobin >= 9 g/l], adequate liver function (bilirubin concentration <= 1.5 times the upper normal limit, aspartate aminotransferase and alanine aminotransferase <= 1.5 times the upper normal limit), adequate renal function (creatinine concentration <= 1.5 mg/dl; BUN < 50 mg/dl) and cardiac function. All patients had to have received prior chemotherapy with at least one anthracycline-containing regimen in either an adjuvant or metastatic setting, completed at least 4 weeks before beginning the new treatment. Previous treatment with paclitaxel was allowed. ","Patients with brain metastases, pulmonary, carcinomatous lymphangitis, neoplastic and/or pleural effusion as the only site of disease were considered not eligible. Other exclusion criteria included inadequate bone marrow reserve and renal or cardiac insuffi ciency. Biphosphonate administration for bone metastases was not allowed.",24 weeks of treatment,NA
15111343,NA,Combination,No,advanced gastric carcinoma,"Patients with metastatic or locally advanced adenocarcinoma of the stomach not previously treated palliatively by systemic therapy and not amenable to curative resection were enrolled in this trial. The patients were required to have a World Health Organization (WHO) performance status ≤1, normal blood counts, creatinine clearance ≥60 ml/min, adequate liver function tests [bilirubin <1× upper limit of normal (ULN), AST/ALT <2.5× ULN], no history of anaphylaxis and no peripheral neuropathy of any origin greater than grade 1. Patients with bidimensionally measurable or simply evaluable disease were eligible (elevated tumor markers or unidimensionally measurable disease).",NA,in cycle one,NA
15075667,NA,Combination,No,patients with metastatic solid tumors,"After approval by the Institutional Research Committee of the New York University School of Medicine, accrual was initiated in January 1998. Eligibility criteria included metastatic solid tumors with measurable or evaluable disease. Prior doxorubicin exposure (maximum 300 mg/m2 as an adjuvant therapy) was permitted, but patients could not have received prior taxane therapy. A maximum of two prior chemotherapy regimens, either both for metastatic disease in the absence of any adjuvant chemotherapy or only one prior regimen for metastatic disease after failing adjuvant chemotherapy, was allowed. Adequate organ function defined as platelets >= 100 000/ml, granulocyte count >= 1500/ml, hemoglobin level >= 8.0g/dl, creatinine level <= 2 mg/dl and bilirubin <= 1.5 mg/dl was required. Also, the baseline left ventricular ejection fraction by MUGA scan had to be >= 50% (lower limit of normal for the institution). All patients were expected to have an ECOG performance status of <= 2. Prior radiotherapy was allowed provided it was discontinued at least 4 weeks prior to entry and it had not been delivered to the whole pelvis or > 20% of bone marrow producing areas. Protocol treatment had to await recovery from any radiation therapy toxicity.","Patients were excluded if they presented with active brain metastasis, unstable angina pectoris, ventricular arrhythmias or myocardial infarction within the last 6 months of entry onto trial.",During the first treatment,NA
12702535,NA,Combination,No,patients with solid tumours,"Patients with solid tumours, but without brain or meningeal metastases, were eligible. Age was 18–75 years and WHO (World Health Organization) performance status (PS) was up to 2. Baseline neurosensory changes were required to be grade ≤1, neutrophils ≥1.5 × 109/l, platelets ≥100 × 109/l, haemoglobin ≥10 g/dl and serum creatinine <1.5× upper normal limit (UNL). The eligibility criteria for hepatic function were as follows: total bilirubin ≤1× UNL or ≤1.5× UNL if aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were normal; AST and ALT ≤2.5× UNL; ALP ≤5× UNL (except in the absence of liver metastases and presence of bone disease). Patients must not have received high-dose chemotherapy. Prior therapy with chemotherapy, hormonal therapy or radiotherapy must have been completed at least 4 weeks previously and total radiotherapy must have been to ≤30% of marrow-bearing areas. No more than one prior chemotherapy regimen for advanced disease, in addition to any adjuvant chemotherapy, was allowed. Patients gave written informed consent and the study was approved by the Institutional Ethics Committees of participating hospitals.",Patients with both ALP >2.5 × UNL and AST or ALT >1.5× UNL were not eligible. Patients with significant psychiatric or medical illnesses were not eligible.,"during cycle 1, or during subsequent cycles if particularly severe",NA
12901280,NA,Combination,No,Advanced Stage Solid Tumors,"Patients were entered on study from January 1998 to November 1999. Primary tumors included cancer of the head and neck, esophagus, stomach, hepatobiliary system, and sarcoma. Patients who had received prior chemotherapy or radiation therapy were eligible after a 4-week waiting period before starting the study. All patients were older than 18 years of age with a performance status of ECOG 0-2, white blood count >= 4000=uL; platelet count >= 100,000/uL; serum creatinine <= 1.5 mg/dL; and bilirubin <= 2.0 mg/dL: All patients were staged with physical examination and radiologic tests that included chest x-ray, computed tomography, and/or magnetic resonance imaging. All patients were evaluated for toxicity with each cycle and underwent response evaluation with physical examination and appropriate radiologic imaging after every two cycles of therapy. This study was approved by the Institutional Review Board at the University of North Carolina School of Medicine. All patients provided written informed consent.",NA,in the first cycle,NA
12381903,NA,Combination,No,Advanced Gastric Cancer,"Patients with histology-confirmed, unresectable, recurrent and/or metastasized, adenocarcinoma of the stomach were eligible for inclusion in this study. Inclusion criteria were: age between 18 and 75 years; ECOG performance status <= 2; adequate bone marrow (absolute neutrophil count and platelet count >= 1,500/ul and 100,000/ul, respectively), renal function (calculated creatinine clearance >= 60 ml/min) and hepatic function (bilirubin <= 1.5 mg/dl, transaminases <= 1.5 times upper normal limit). Bi-dimensionally measurable disease was not mandatory for study enrollment","Patients who had previously received chemotherapy were not eligible. Additional exclusion criteria were: preexisting motor or sensory neurotoxicity of grade 2 or above; congestive heart failure or history of ischemic heart diseases; active infection, and brain metastases.",the first chemotherapy cycle,NA
12138236,NA,Combination,No,Advanced Cancer,"The study was approved by the Institutional Review Board at Indiana University and all patients signed an informed consent form. Patients were required to have a biopsy-proven incurable malignancy with an Eastern Cooperative Oncology Group (ECOG) performance status of < 2. Patients were also required to have adequate hematologic (white blood cell count > 4,000/mm3 and platelet count > 100,000 mm/m3), hepatic (normal bilirubin; aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN) with a normal alkaline phosphatase (AP); or AP < 4 x ULN with a normal AST), and renal function (creatinine <= 1.5 x ULN).",NA,during their first cycle,NA
14725740,NA,Combination,No,Stage III Unresectable Non–Small-Cell Lung Cancer,"Previously untreated patients with histologically documented stage IIIA or stage IIIB NSCLC that was medically inoperable due to chronic obstructive pulmonary disease (COPD), cardiac, or comorbid disease were eligible for this study. Patients with direct vertebral body invasion or a malignant or exudative pleural effusion were not eligible. All patients had measurable or assessable disease. Further eligibility criteria included: age > 18 years; Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2; weight loss < 15% during the 3 months preceding diagnosis; no prior chemotherapy; no prior lung radiation therapy; platelet count ≥ 100,000/μL; absolute neutrophil count (ANC) ≥ 1800/μL; hemoglobin ≥ 9 g/dL; blood urea nitrogen (BUN) < 1.5 times normal; creatinine level < 1.5 mg/dL; bilirubin < 1.5 times the upper limit of normal (ULN); transaminases (serum glutamic-oxaloacetic transaminase [SGOT] and/or serum glutamic-pyruvic transaminase [SGPT]) may be up to 2.5 times institutional ULN if alkaline phosphatase was ≤ ULN, or alkaline phosphatase up to 4 x ULN if transaminases were ≤ ULN. All patients signed an informed consent.","However, patients who had both transaminase elevation > 1.5 x ULN and alkaline phosphatase > 2.5 x ULN were not eligible for this study (due to decreased clearance of docetaxel and increased risk of toxicity); oxygen partial pressure (PO2) > 50 mm Hg, carbon dioxide partial pressure (PCO2) < 50 mm Hg in a sample of arterial blood; forced expiratory volume in 1 second (FEV1) > 800 mL; and no other serious medical or psychiatric illness",NA,NA
11857398,NA,Combination,No,ADVANCED NONSMALL CELL LUNG CANCER,"Patients with histologically confirmed advanced NSCLC, stage IIIA (bulky), IIIB and IV were candidates for our study. Eligibility included (i) histologically confirmed NSCLC not curable by surgery and/or radiotherapy; (ii) WHO performance status <=2; (iii) life expectancy >= 3 months; (iv) adequate hematopoietic (ANC > 1,500/l, PLT > 100,000/l), liver [bilirubin  1.5 mg/dl, AST/ ALT < 2 x upper normal limit (nl), unless caused by tumor and serum albumin > 3.0 g/dl] and renal function (BUN and creatinine < 1.5 nl; nl = 1.5 mg/dl in our laboratory or creatinine clearance > 50 ml/min); (v) no previous chemotherapy; (vi) absence of active coronary artery disease (in the form of unstable angina or myocardial infarction over the last 12 months), unstable diabetes mellitus or peripheral neuropathy >= grade 2 by the NCICommon Toxicity Criteria (CTC); (vii) no prior irradiation to areas encompassing >20% of marrow-bearing bone, apart from emergency radiotherapy for superior vena cava obstruction, imminent vertebral or weight-bearing long bone fracture as a result of metastatic involvement or symptomatic rapidly progressive brain metastases; and (viii) presence of bidimensionally measurable disease outside a previously irradiated field, unless there was definite evidence of progression at this site.",NA,the first cycle,NA
11551421,NA,Combination,No,advanced or recurrent non-small cell lung cancer,"Patients with pathologically documented, advanced (clinical stage IV or IIIB with pleural dissemination) NSCLC without a history of prior chemotherapy or extensive radiotherapy were eligible for entry into the study. Each patient was required to satisfy the following criteria: Eastern Cooperative Oncology Group performance status (PS)  0 or 1; 15–70 years of age; measurable disease; estimated life expectancy >3 months; adequate renal and liver function, i.e. normal serum creatinine and total bilirubin levels, serum AST and ALT levels less than twice the upper limit of normal, a creatinine clearance of 60 ml/min or more, and an adequate bone marrow reserve, i.e. WBC count >4000/ul and < 12 000/ul, neutrophil count >2000/ul, platelet count > 100 000/ul, and hemoglobin level > 9.5 g/dl.","Patients with active infection, severe heart disease, or a past history of hypersensitivity were excluded. Patients with peripheral neuropathy, symptomatic brain metastases, active central nervous system disease, pleural effusion requiring drainage, pericardial effusion, or active concomitant malignancy were also excluded. ",during the first cycle of chemotherapy,NA
12237916,NA,Combination,No,Patients with Poor Prognosis Squamous Cell Carcinoma of the Head and Neck,"The patients who were included in this trial had biopsy-proven, locally advanced, Stage III or IV SCCHN. Prior to their diagnosis, patients had not received chemotherapy or radiation for SCCHN. Patients were required to receive one to three cycles of an induction chemotherapy regimen as initial treatment; the patients who actually enrolled received a minimum of two cycles of chemotherapy. Acceptable chemotherapy regimens consisted of cisplatin, 5-FU, and leucovorin (PFL), as described previously, or cisplatin and 5-FU, with a minimum cisplatin dose of 80 mg/m2 and a minimum 5-FU dose of 1000 mg/m2 per day for 4 days.32 Patients were offered enrollment in this study if they 1) achieved a PR or a nonresponse (NR) to induction chemotherapy; 2) achieved a clinical CR to induction chemotherapy but had a positive postinduction biopsy; or 3) had a tumor that indicated a very poor prognosis ( < 30% 2-year survival) based on pretreatment clinical factors, in the judgment of the treating physicians. Prior taxane treatment was not allowed, and patients were required to start concurrent docetaxel-radiation therapy within 13 weeks of the start of their induction chemotherapy. Furthermore, patients were required to be age >= 18 years, have an Eastern Cooperative Oncology Group performance status >= 2, and have adequate nutritional intake. A normal bilirubin level, levels of aspartate aminotransferase or alanine aminotransferase  1.5 times the upper limit of normal, and an alkaline phosphatase level < 2.5 times the upper limit of normal were required for enrollment.",Patients were excluded if they required intravenous alimentation to maintain their nutritional status.,NA,NA
14520528,NA,Combination,No,patients with inoperable or recurrent gastric cancer,"Patients with histologically confirmed inoperable or recurrent gastric cancer with measurable or evaluable lesions who had been administered less than one regimen as previous chemotherapy, except for adjuvant therapy, were eligible to participate in this study. Other eligibility criteria included an Eastern Clinical Oncology Group (ECOG) scale performance status of 2 or less; age between 20 and 75 years; life expectancy of at least 3 months; provision of written informed consent in accordance with government and institutional guidelines; and adequate organ function (defined by a WBC count of >= 4000/mm3 and <= 12000/mm3, an absolute neutrophil count of >= 2000/mm3, a platelet count of >= 10 x 104/mm3; hemoglobin, >= 9.0g/dl; total bilirubin, 1.5mg/dl; GOT and GPT levels <= 1.5 times the upper limit of normal or 3 times the upper limit of normal if liver metastases were present; alkaline phosphatase 2.5 times the upper limit of normal except in the presence of bone metastases; and serum creatinine and blood urea nitrogen levels <= the upper limits of normal).","Exclusion criteria included the following: chemotherapy within 4 weeks before study entry (2 weeks for oral antimetabolic and biological response modifiers (BRM) agents); prior chemotherapy with TXT, TXL, or CPT11; past history of allergic reactions to agents including polysorbate 80; peritoneal dissemination with unresolved bowel obstruction/subobstruction or a large amount of ascites; concomitant uncontrolled, nonmalignant disease (malignant hypertension, cardiac, pulmonary, renal, or hepatic disease; active infection); motor paralysis or peripheral neuropathy; the retention of pleural effusion or pericardial effusion that should be treated; diarrhea more than four times per day; active double cancer; pregnancy; brain metastases with any symptoms; steroid usage; or a prior history of the treatment of psychiatric diseases. Patients with obvious interstitial pneumonitis or pulmonary fibrosis on chest X-rays or computed tomographic (CT) scans were also excluded.",during the first cycle of therapy,NA
12581570,NA,Combination,No,locally advanced non-small cell lung cancer,"Patients with clinical Stages IIIA or IIIB NSCLC, defined by the New International Staging System , were recruited from the outpatient Oncology clinics of Tulane University Health Sciences Center and affiliated institutions. Determination of tumor resectability was performed by the treating physicians. Pathologic confirmation of mediastinal involvement was not routinely required. Inclusion criteria included adequate organ function and an ECOG performance status of 0/2. Pre-menopausal women must have had a negative pregnancy test prior to enrollment and were required to use adequate contraception during therapy.","Patients with a malignant pleural effusion were excluded. No prior therapy for lung cancer was allowed. Known hypersensitivity to docetaxel, acquired immunodeficiency syndrome, clinically significant peripheral neuropathy and symptomatic fluid overload were exclusion criteria",NA,NA
14584067,NA,Combination,No,Advanced HormoneRefractory Prostate Carcinoma,"Patients with histologically proven adenocarcinoma of the prostate, nonsmall cell lung carcinoma, breast carcinoma, or other solid tumor malignancies for which no effective alternative therapy exists were eligible to participate in this study. Other eligibility criteria for patients with prostate carcinoma included hormonerefractory disease, as evidenced by measurable soft tissue metastases; new bone scan abnormalities; or a rise in 3 consecutive PSA measurements at least 1 week apart. Patients with other solid tumor malignancies must have failed at least one previous chemotherapy regimen. Patients with prostate carcinoma must have failed antiandrogen withdrawal, as evidenced by the discontinuation of the antiandrogen of at least 28 days for flutamide or at least 42 days for bicalutamide. At least 8 weeks had to have passed since strontium-89 therapy, and at least 4 weeks had to have passed since any prior chemotherapy or radiotherapy. Patients were required to have an Eastern Cooperative Oncology Group performance status of 0 –2. Patients with a preexisting peripheral neuropathy >= Grade 2 were ineligible. All patients must have had measurable or evaluable disease, and all measurable/evaluable lesions must have been assessed within 28 days prior to registration by physical examination, X-ray, computed tomography (CT) scan, or magnetic resonance image.","Patients were ineligible if they had received prior therapy with docetaxel, although they could have received prior ketoconazole provided they had not received it for at least 90 days. Patients were required to have serum creatinine levels <= 2.0 mg/dL. Prior to receiving any dose of docetaxel, patients were required to have an absolute neutrophil count > 1000/mm3 and a platelet count > 100,000/mm3. Patients with a baseline bilirubin levels elevated above the institutional upper limit of normal (ULN) were excluded. Liver aspartate aminotransferase and alanine aminotransferase levels were required to be < 2.5 times the institutional ULN. Patients who had both transaminase elevations > 1.5 times the ULN and alkaline phosphatase elevations > 2.5 x ULN were not eligible for this study due to a potential for a decreased clearance of docetaxel and an increased risk of toxicity. Patients receiving concurrent warfarin were eligible but required monitoring of their International Normalized Ratio (INR) on a weekly basis. Patients were excluded from the study if they had any unstable, preexisting medical condition; and all patients with reproductive potential were required to use an effective contraceptive method if they were sexually active.",the first two cycles,NA
14508124,NA,Combination,No,Pancreatic Cancer,"Between March 2000 and June 2001, 13 patients with histologically proven adenocarcinoma of the pancreas, were included in this phase 1 trial. All patients were treated either at the Institut Paoli-Calmettes or at the Centre Val d’Aurelle, 2 regional comprehensive cancer centers. Patients were enrolled into this study if they met the following criteria: a histologic diagnosis of adenocarcinoma of pancreas, a tumor locally advanced and surgically unresectable, a performance status <= 2 on the Eastern Cooperative Oncology Group (ECOG) scale; a measurable lesion or assessable lesion, no prior therapy except an endoscopic drainage of the biliary tract (by stent) in case of obstructive jaundice due to tumor mass at the head of the pancreas, age between 18 and 75 years, adequate bone marrow function (leukocyte count >=2 ×109/l, platelet count >= 100 × 109/l and hemoglobin level >= 10g/dl), adequate hepatic function (AST and ALT levels >= 3.0 times the upper limit of normal and bilirubin up to the upper limit of normal), adequate renal function (creatinine level up to the upper limit of normal). All patients had to give written informed consent; the protocol was approved by the Marseille Ethic Committee (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale, CCPPRB 2).","Patients were ineligible if they had any of the following: visceral metastases, active concurrent malignancies, a history of a drug allergy or were lactating or pregnant",at cycle 1,NA
11583191,NA,Combination,No,in advanced breast cancer patients,"Eligible patients were women aged 18-75 years with documented locally advanced (stage III) or metastatic breast cancer (stage IV), and performance status (PS) <2 They were required to have adequate bone marrow, renal, hepatic, and cardiac function, defined respectively as: Absolute Neutrophyle Count (ANC) > 2000/ul. Platelet count (PLT) > 100,000/ul. and Hemoglobin (Hb) > 10 g/dl, creatinine < 1.6mg/dl; total bihrubin < I 5 time the upper-normal limits (UNL) of the Institutional normal values. SGPTand SGOT $ 2 5 UNL. and alkaline phosphatase < 5 UNL (unless bone metastases were present in the absence of any liver disorders), left ventricular ejection fraction (LVEF) > 50 as measured by radionuclide angiocardiography (MUGA) or by echocardiography. Prior adjuvant or neoadjuvant chemotherapy was allowed, provided that a cumulative dose of no more than 360 mg/m2 of epirubicin or 200 mg/m2 of doxorubicin had been given, and that there had been a therapy-free interval of at least 12 months Criteria for exclusion were any prior therapy with docetaxel or paclitaxel or any prior chemotherapy for metastatic disease.",NA,during the first cycle of chemotherapy,NA
11598413,NA,Combination,No,Non-Small-Cell Lung Cancer,"Patients with histologically or cytologically proven recurrent or metastatic NSCLC were eligible for this study. Patients were required to be 118 years old, have an Eastern Cooperative Oncology Group (ECOG) performance status ^2, adequate hematologic parameters, and normal kidney and liver function tests.",NA,during cycle 1,NA
12665678,NA,Combination,No,Advanced Solid Tumors,"Eligible patients were ≥ 18 yr of age and had a histologically confirmed diagnosis of locally advanced or metastatic cancer. All patients had either failed standard treatment or were those for whom no standard treatment existed. Patients were eligible if they had less than or two prior chemotherapy regimens. Prior paclitaxel but not docetaxel therapy was allowed. CALGB performance status ≤ 1 was required. Baseline laboratory requirements were as follows: white blood cell count ≥ 3000/µL, platelets ≥ 100,000/µL, total bilirubin less than or equal to the institutional upper limit of normal, serum creatinine ≤ 1.5 mg/dL, SGOT and SGPT ≤ 2.5 times the upper limit of normal (if alkaline phosphatase was less than or equal to upper limit of normal, or alkaline phosphatase up to 4 times the upper limit of normal if SGOT and SGPT were less than or equal to normal).","Patients were ineligible if they had received radiotherapy to both the thoracic and lumbar vertebrae or had prior pelvic radiation. Patients were ineligible if they had symptomatic peripheral neuropathy greater than grade 1 by CALGB toxicity criteria. No chemotherapy or radiotherapy was allowed within 4 wk of initiation of chemotherapy, and prior high-dose chemotherapy with stem cell transplant was not allowed. Pregnant women or those of childbearing potential not practicing birth control were ineligible, as were patients with symptomatic or medically uncontrolled ascites, pleural effusion, or edema.",during the first cycle,NA
12419756,NA,Combination,No,advanced cancer,"Patients were required to have histologically proven cancer, but patients with hematological malignancies, non-small-cell lung cancer and squamous cell carcinoma of the head and neck were excluded. Patients may have received up to one prior chemotherapy regimen. No prior taxane chemotherapy was permitted. Prior anthracycline dose had to be ≤300 mg/m2 of doxorubicin or ≤540 mg/m2 epirubicin. Prior radiotherapy to <30% of the marrow bearing areas was permitted. Prior chemotherapy or radiotherapy must have been completed at least 4 weeks prior to study entry. With regard to hepatic function, bilirubin had to be within normal limits, transaminases ≤2.5 × upper limit of normal (ULN) and alkaline phosphatase ≤5 × ULN (if liver disease present). However, if the level of alkaline phosphatase was >2.5 × ULN, transaminases had to be ≤1.5 × ULN. Other eligibility criteria were as follows: age from 18 to 75 years, Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2, absolute neutrophil count ≥2.0 × 109/l, platelet count ≥100 × 109/l, serum creatinine ≤1.5 × normal and left ventricular ejection fraction measured by radionuclide ventriculography ≥ lower limit of normal. Written informed consent was obtained from all patients and the protocol was approved by the Institutional Ethics Committee.","Patients were excluded from the trial for any of the following: uncontrolled angina, hypertension, arrhythmias, cardiac failure, myocardial infarction within the preceding 12 months, active infection, any contraindication for the use of dexamethasone, brain metastases as the only known site of disease or if uncontrolled, pre-existing peripheral neuropathy grade ≥2 by the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), and pregnancy or lactation.",during the first cycle,NA
11561784,NA,Combination,No,advanced cancer,"Patients were required to have a histologically confirmed advanced cancer that was refractory to standard therapy or for which no standard therapy was available, and to have measurable or evaluable disease or an elevated tumor marker. Other eligibility criteria included: age >= 18 years, Eastern Cooperative Oncology Group performance status of 0 to 2; adequate bone marrow (keukocytes >= 3000/mm3, absolute neutrophil count >= 1500/mm3 and platelet count >= 100,000/mm3), hepatic (bilirubin , 1.5 mg/dl, AST and ALT less than 1.5 times the upper limit of normal, and alkaline phosphatase less than 2.5 times the upper limit of normal), and rental function (serum creatinine , 1.5 mg/dl, or creatinine clearnce > 60 ml/min); recovery from the toxicities of previous anticancer therapy; and a life expectancy of at least 8 weeks. Women of childbearing age were required to have a negative pregnancy test and use effective means of contraception during study participation.","Patients with clinically active brain metastases, uncontrolled seizures or congestive heart failure not adequately controlled with medication were not eligible for treatment.",in the first 3 weeks of treatment,NA
12879480,NA,Combination,No,Patients with Advanced Malignancies,"All patients were required to have histologically documented resistant malignancy, measurable or evaluable disease, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 –2, life expectancy of 2 months or longer, age 18 years or older, and nonpregnant status. The following laboratory values were required: hemoglobin (>= 9 g/dL), absolute neutrophil count (ANC; >= 1500/mm3), platelet count (>= 100,000/mm3), creatinine (<= 2.0 mg/dL), bilirubin (<= 1.5 x the institutional normal), aspartate aminotransferase (<= 2 x the institutional normal), and no preexisting clinically significant hepatic or renal disease.","No chemotherapy or radiotherapy administration within 3 weeks of registration was allowed. No previous exposure to PEG-LD or docetaxel was allowed. Previous exposure to paclitaxel was allowed, as was previous exposure to doxorubicin if the cumulative dose was less than 350 mg/m2. Other exclusion criteria included clinically significant cardiac disease, uncontrolled central nervous system metastasis, active/uncontrolled infection, and concurrent malignancies.",during any cycle,NA
11521794,NA,Combination,No,metastatic breast cancer,"Thirty-four women with metastatic breast cancer were accrued into this phase I, dose-finding, single-center study. Eligible patients had histologically proven breast cancer with measurable and/or evaluable metastatic disease. Patients were excluded if they had received prior chemotherapy or > 2 hormonal therapy regimens for metastatic disease. Prior neoadjuvant and /or adjuvant chemotherapy, with or without anthracyclines, was permitted provided that at least 12 months had elapsed before study entry. Other eligibility criteria were WHO performance status <= 2, absolute neutrophil count (ANC) >= 2 x IO9/1, platelet count >= 100 x 109/l, hemoglobin >= 10 g/1, serum creatinine <= 140 umol/dl, ASAT/ALAT <= 2 x upper normal limit (UNL), and bilirubin <= 1.25 x UNL.","Exclusion criteria included: history of other malignancies (excluding non-melanoma skin cancer or well-excised cervical carcinoma), known CNS metastases, symptomatic peripheral neuropathy grade >= 2, any poorly controlled coexisting medical conditions, prior therapy with taxanes or vinorelbine, concurrent treatment with other anticancer or experimental drugs",during the first treatment cycle,NA
15139070,NA,Combination,No,Advanced Solid Tumors,"Patients were eligible for the current study if they met the following criteria: age  18 years, histologic diagnosis of a malignant solid tumor, a measurable or assessable lesion, <= 1 previous chemotherapy regimen for metastatic disease, a performance status of <= 2 on the Zubrod performance scale, life expectancy of >= 3 months, adequate bone marrow function (absolute granulocyte count >= 1500/L and a platelet count >= 140,000/L), adequate renal function (serum creatinine level <= 1.5 mg/dL or calculated or actual creatinine clearance >= 50 mL/min), and adequate hepatic function (serum bilirubin level <= 1.0 mg/dL and aspartate aminotransferase [AST] level <= 2.5 times the upper limit of normal [ULN] if the alkaline phosphatase [AP] level was <= the ULN; the AP level could be no more than 4 times the ULN; otherwise, the AST level had to be < 1.5 times the ULN and the AP level had to be < 2.5 times the ULN). Although previous radiation treatment was permitted, all chemotherapy or radiation was required to be completed >= 4 weeks before study entry. All patients entering the current study were informed of the investigational nature of the treatment and its potential adverse effects and were required to provide written informed consent.","Patients were ineligible for this trial if they had previous exposure to docetaxel or topotecan, symptomatic brain metastasis, serious infectious diseases, or active concurrent malignancies. They were also ineligible if they were lactating, pregnant, or wished to become pregnant, or if they had a history of drug allergy or psychiatric or medical problems severe enough to prevent compliance with the protocol. Patients with no history of previous therapy were eligible for this trial only if they were not eligible for protocols of higher priority.",in the first cycle,NA
12736567,NA,Combination,No,Advanced or Recurrent Breast Cancer ,"1) A histologically or cytologically confirmed primary lesion, or for metastatic or recurrent lesions, a histologic, cytologic or clinical diagnosis of the malignancy. 2) The neoplastic lesion (s) were measurable or assessable. 3) Patients failed to respond to prior chemotherapy regimens. 4) A washout period of >= 4 weeks since previous anticancer therapy was required. 5) JSCT (Japan Society for Cancer Therapy) performance status (PS) of 0 to 2. 6) A life expectancy of more than 3 months. 7) Adequate function of principal organs (bone marrow, heart, liver, lungs, kidneys, etc.), with leukocyte count 4,000-10,000/ram 3, neutrophil count >= 2,000/mm3, platelet count >= 100,000/mm3, hemoglobin >=  9.5 mg/dl, s-GOT and s-GPT <= twice the respective upper normal limits for the hospital (except for patients with liver metastasis), total bilirubin <= 1.5mg/dl, serum albumin >= 3.0g/dl, and serum creatinine and BUN within the normal range. 8) Age 15-74 years. 9) Written informed consent.","Patients were excluded from the study for any of the following: 1) known history of hypersensitivity to any drugs, 2) severe cardiac, infectious or hemorrhagic disorders, 3) peripheral neuropathy, 4) brain metastasis, 5) hypercalcemia, 6) concomitant malignancy, 7) prior intensive radiotherapy or chemotherapy with bone marrow transplantation, 8) pregnancy and lactation, 9) ongoing corticosteroid medication, 10) hepatic, renal or bone marrow dysfunction, and 11) varicella infection",During the First Cycle,NA
12373597,NA,Combination,No,advanced cancer,"Patients were enrolled onto this study if they met the following criteria: histologically confirmed advanced cancer, for which other forms of therapy had failed or were considered inappropriate; no more than one previous line of chemotherapy, > 4 weeks prior to enrollment; no prior exposure to a taxane or ifosfamide. Other eligibility criteria included age >= 17 years; ECOG performance status <= 2; expected survival duration of >= 3 months; adequate bone marrow function (absolute neutrophil count >= 2.0 x 109/l, platelets >= 100 x 109/l and Hb >= 100 g/l); adequate hepatic function (total bilirubin 516upper limit of normal (ULN); AST and ALT <= 2.5 x ULN, ALP <= 5 x ULN (except in presence of bone only metastases and other liver function tests normal, if both AST and/or ALT >= 1.5 x ULN and ALP >= 2.5 x ULN patients were excluded)); adequate renal function (serum creatinine <= 1.5 x ULN). ",Patients were excluded with significant co-morbid medical conditions; symptomatic peripheral neuropathy 4grade 2 according to NCIC Common Toxicity Criteria; and presence of CNS disease. ,in cycle 1,NA
11852999,NA,Combination,No,Metastatic Breast Cancer,"Patients were eligible for this study if they had a histologically confirmed carcinoma of the breast with metastasis. Patients were permitted to have received one prior chemotherapy regimen for metastatic disease. Patients who had prior exposure to taxanes for the treatment of metastatic disease were excluded; however, patients who received taxane-based adjuvant therapy with a disease-free interval longer than 6 months were considered eligible. Patients who had received vinblastine were not excluded. Patients were required to have a Zubrod performance status of 2 or less and a life expectancy of more than 12 weeks. Stable peripheral neuropathy of grade 1 or less was permissible. Laboratory requirements for eligibility included an absolute granulocyte count (AGC) of at least 1,500/mm3, platelet count of at least 100,000/mm3, a serum bilirubin level no greater than the upper limit of normal (ULN), and an aspartate aminotransferase and/or alanine aminotransferase value no greater than 1.5 times the ULN, concomitant with an alkaline phosphatase level less than 2.5 times the ULN. If only the aspartate or alanine aminotransferase value or the alkaline phosphatase value was abnormal, then patients with abnormal values up to three times the ULN were accepted. Patients with normal renal function as reflected by a normal blood-urea nitrogen level and creatinine level or a calculated creatinine clearance greater than 60 mg/min, adjusted for age, were eligible. At least 3 weeks had to have elapsed since each patient’s most recent administration of radiation therapy or chemotherapy.",NA,NA,NA
12140145,NA,Combination,No,advanced solid tumors,"Patients were eligible if they had advanced or metastatic solid tumors refractory to conventional therapy treated with at least one previous chemotherapy regimen. Eligibility criteria also included: age > 18 years; Karnofsky index > 60%; life expectancy of at least 12 weeks; and adequate bone marrow (platelets > 100x109 cells/l, absolute neutrophil count (ANC) > 1.5x109 cells/l), hepatic (total bilirubin within normal limits, aspartate transaminase < 2.0 times normal), and renal (serum creatinine < 1.5 times the upper limit of normal) functions. Patients had to have discontinued previous chemotherapy for at least 4 weeks. Prior radiotherapy to pelvis or abdomen was not allowed because of the increased risk of diarrhea induced by CPT-11. No major clinical neuropathy > grade 1, according to National Cancer Institute criteria, was allowed.",NA,during the first cycle,NA
11777624,NA,Combination,No,STAGE III NON– SMALL-CELL LUNG CANCER,"All patients had histologically proven and unresectable Stage III NSCLC. Inclusion criteria were as follows: performance status of 0 or 1 by the Eastern Cooperative Oncology Group (ECOG) scale; weight loss of < 10% within the past 6 months of diagnosis; age > 18 but < 70 years; forced expiratory volume in 1 second >= 1.5 L or > 50% of the predictive value; serum creatinine level <= 1.5 mg/dL; granulocyte count >= 2000/mL; platelet count >= 100,000/mL; serum bilirubin level <= 1.5 x the normal value; serum glutamic-oxaloacetic transaminase level <= 2.5 x the normal value; and alkaline phosphatase level <= 5 x the normal value. ","Exclusion criteria were as follows: supraclavicular lymph node involvement; malignant pleural effusion and/or pericardial effusion; recurrent disease after previous treatment; history of another malignancy (except for superficial skin cancer other than melanoma); history of anticancer chemotherapy or RT; recent history of myocardial infarction, angina pectoris, congestive heart failure, or uncontrolled arrhythmia within 6 months of diagnosis; and pregnancy",during the 7-week treatment,NA
12913084,NA,Combination,No,Head and Neck Cancer,"The eligibility criteria included 20–70 years of age, Eastern Cooperative Oncology Group (ECOG) performance status 0–2, serum creatinine <= 2.0 mg/dl, total bilirubin <= 1.5 mg/dl, GOT <= 80 IU/l, GPT <= 70 IU/l, white blood cell count >= 4000/mm3, hemoglobin >= 9.5 g/dl and platelets 100 000. ",Patients previously treated with radiotherapy or chemotherapy were excluded. Pregnant women or patients with major heart or infectious disease or uncontrolled diabetes mellitus were also excluded.,during the 6- or 7-week course of concurrent radiotherapy,NA
14977829,NA,Combination,No,High-Risk Localized Prostate Cancer,"Eligibility criteria included the following criteria: histologically confirmed adenocarcinoma of the prostate; prostatectomy planned as primary therapy; >= 10 years life expectancy; and any of the following high risk features: clinical stage T2c or surgically resectable T3a, or PSA >= 15 ng/ml, or Gleason grade >= 4 + 3 (4 + 3, 4 + 4, or any 5 elements).","Patients could not have bone metastases on radionuclide bone scan, lymph nodes >= 2 cm in diameter on pelvic computed tomography scan (scan required only in patients with a PSA >= 40 ng/ml), Eastern Cooperative Oncology Group performance status > 2, and left ventricular ejection fraction <= 50% by multiple gated acquisition technetium scan. Patients were also excluded for the following: any prior therapy for prostate cancer; significant active medical illness; second malignancy other than nonmelanoma skin cancer within 5 years; >= grade 2 peripheral neuropathy; hypersensitivity to drugs formulated with polysorbate-80; significant contraindications to corticosteroids; WBC count < 3000/mm3 ; neutrophil count < 1500/mm3; platelet count < 100,000/mm3; or conjugated bilirubin  upper limit of normal (ULN), alkaline phosphatase > 4.0 x ULN, alanine transaminase (ALT) > 2.0 x ULN, or ALT > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 xULN",during the first cycle of therapy,NA
14735175,NA,Combination,No,locally advanced squamous cell carcinoma of the head and neck (SCCHN),"Patients were selected if they had histologically or cytologically confirmed SCCHN, at least one unidimensionally measurable lesion, and stage III or IV disease without evidence of distant metastases. Patients with primary sites in the nasopharynx, mesopharynx, hypopharynx, larynx, oral cavity or paranasal sinus were eligible. Patients were required to be from 20 to 75 years of age and have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, life expectancy of at least 3 months, a WBC count of >= 4000 cells ul -1, an absolute neutrophil count (ANC) of >= 2000 cells ul -1, a platelet count of >= 100 000 ul-1, a haemoglobin level of >= 9.5 g dl-1, AST, ALT and alkaline phosphatase levels below 2.5 times the upper limit of normal (ULN), total bilirubin and creatinine levels below than 1.5 times ULN, a BUN level below the ULN and a 24-h creatinine clearance rate of more than 60 ml min-1","Patients who had received previous chemotherapy, radiotherapy or surgery were excluded. Patients were ineligible if they had another cancer.  Patients with significant cardiac arrhythmia or heart failure were ineligible",during the first treatment cycle,NA
14676112,NA,Single Drug,No,patients with peritoneal carcinomatosis,"Patients were required to have chemotherapeutically unresponsive malignancies, to have relapsed after previous chemotherapeutic regimens, or to have malignancies for which no defined “standard” chemotherapeutic regimen exists. Patients included in the study had a Karnofsky performance status >= 60%, age >=18 years, an expected survival >= 3 months, a serum creatinine <= 1.5 mg/dl or a 24-h creatinine clearance >= 50 ml/min, a total WBC >= 3,500/ul or absolute neutrophil count >= 2,000/ul, and platelet count >= 150,000/ul. Adequate hepatic function was defined as a serum bilirubin <= 1.5 mg/dl and aspartate aminotransferase and alanine aminotransferase within twice the institutional upper limit of normal. Previous radiation or chemotherapy must have been completed at least 4 weeks before beginning treatment on this protocol. There was no limit on the number of previous courses or types of chemotherapy. Female patients could not be pregnant. Patients must have been willing to undergo the necessary surgical procedure for insertion and removal of an i.p. catheter. All patients gave their voluntary informed consent and signed a consent document that had been reviewed and approved by the City of Hope National Medical Center Clinical Protocol Review and Monitoring Committee and Institutional Review Board.",during the first cycle,NA,NA
12491518,NA,Combination,No,Refractory Malignancies,"Patients with histologically or cytologically proven malignant disease that was refractory to standard therapy and who were treated with only one or two previous chemotherapy regimens were enrolled into the study. Other eligibility criteria included age 18–75 years, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, adequate hepatic function (total bilirubin <= 1.5 mg/dL, transaminases <= 2.5 times the institutional upper limit of normal [ULN], and alkaline phosphatase [ALP] <= 4 times ULN), adequate renal function (serum creatinine <= 1.5 mg/dL or measured/calculated creatinine clearance <= 60 mL/minute), adequate hematologic status (white blood cell count >= 3000/L, absolute neutrophil count (ANC) >= 1000/L, hemoglobin >= 9.0 gm/ dL, and platelet count >= 100,000/L), and measurable or evaluable disease.","Exclusion criteria included prior therapy with gemcitabine or docetaxel; radiotherapy to major bone marrow areas within 4 weeks of entry; prior bone marrow transplantation or stem cell support; therapy with investigational drugs within 4 weeks of study entry; pregnant or currently lactating; refusal to use effective contraception while on study if female of child-bearing potential; inability to give informed consent; medically unstable; psychological, social, and/or geographic issues not permitting weekly medical follow-up or compliance with the study protocol; and history of hypersensitivity reaction to products containing polysorbate 80 (Tween 80).",during Cycle I,NA
11557122,NA,Combination,No,non-small cell lung cancer,"Patients were eligible if they had histologically or cytologically proven unresectable locally advanced and metastatic NSCLC (clinical stage IIIb or IV). Other criteria included the following: (1) age >20 and < 75 years; (2) World Health Organization (WHO) performance status 0–1; (3) no other previous anticancer therapy; (4) adequate bone marrow (neutrophil counts > 2×103/ul, hemoglobin > 10 mg/dl, platelets counts > 100×10 3/ul), normal hepatic (total bilirubin level < 1.5 times and AST two times the upper normal limits), and renal (creatinine 1.5 mg/dl, creatinine clearance > 60 ml/min) functions. All patients gave written informed consent to participate in this study.",Patients were excluded from the trial for any of the following reasons: (1) active infection; (2) severe heart disease; (3) past history of hypersensitivity to drugs (for example; aspirin or antibiotics); (4) pleural or pericardial effusion that required drainage; (5) active brain metastasis; (6) pregnancy. Patients with concomitant active malignancy were also excluded. Other concomitant anticancer therapy or experimental drug administration of any type was not permitted.,at the two cycles of this chemotherapy,NA
12602908,NA,Single Drug,No,refractory metastatic breast carcinoma,"Before entry into the study all patients had to fulfil the following eligibility criteria: written informed consent; histologically proven MBC; age ≥18 but ≤70 years; ECOG performance status of 0– 2; life expectancy of at least 3 months; adequate bone marrow function (WBC ≥4,000/mmc, PTL ≥120,000/mmc, Hb ≥9 gr%); adequate liver (serum bilirubin ≤1.2 mg%, serum transaminases less than 2 times the normal value), and renal functions (serum creatinine ≤1.2 mg%, BUN ≤50 mg%); normal cardiac function as evaluated by EKG and echocardiography; no signs of CNS metastases; and absence of severe, uncontrolled metabolic, respiratory, cardiovascular, or neurological diseases. Other pre-requisites necessary for eligibility included: absence of second malignancy with the exception of adequately managed in situ uterine carcinoma or cutaneous basal cell carcinoma; and geographical accessibility to the oncological centers in order to guarantee a correct follow-up. Patients had not to have previously received a taxane drug for any reason. Previous hormonal therapy (HT) and radiotherapy (RT) were allowed. All antineoplastic therapies had to be withdrawn at least 3 weeks before entry into the study to avoid overlapping toxicity.",NA,during the first six 15-day cycles of CT,NA
12698179,NA,Combination,No,anthracycline pretreated advanced breast cancer,"Patients with histologically confirmed stage IV breast cancer pretreated with anthracycline-based chemotherapy were enrolled; patients progressing on anthracycline-based therapy or within 4 months after the end of such a treatment or patients treated with neoadjuvant and adjuvant anthracyclines that progressed within 12 months after the end of adjuvant chemotherapy were deemed anthracycline-refractory, while all other patients were considered potentially anthracycline-sensitive. Patients had to have bidimensionally measurable lesions with at least one outside a previously irradiated field, unless definite evidence of progression at this site was observed during a minimum 3-month period. No prior taxanes or ifosfamide were allowed. Other inclusion criteria were as follows: age 18– 72 years; a World Health Organization (WHO) performance status (PS) of 0 –2; life expectancy of at least 3 months; adequate haematopoietic (ANC >= 1500 ul-1, PLT >= 100 000 ul-1), liver (bilirubin < 1.5 mg dl-1, AST/ALT < 2 x upper normal limit, unless caused by tumour and serum albumin > 3.0 g dl-1) and renal function (BUN and creatinine < 1.5 x upper normal limit; and creatinine clearance > 50 ml min-1), and cardiac function (left ventricular ejection fraction (LVEF) >= 50%). Patients with brain metastases were eligible provided that they had been irradiated and had clinical and radiological improvement and were off steroids or receiving tapering doses of steroids.","Other exclusion criteria were radiation therapy within 4 weeks from treatment initiation, irradiation of more than 25% of the bone marrow-bearing skeleton, severe infection or malnutrition",during the first chemotherapy cycle ,NA
12942107,NA,Combination,No,locally advanced non-small-cell lung cancer,"Patients with histologically or cytologically confirmed NSCLC, unresectable stage IIIA or IIIB disease, were eligible for the study; however, those with T3N1 disease, malignant pleural effusion, pericardial effusion, or pleural dissemination were excluded. Other entry criteria included previously untreated disease, measurable lesion, Eastern Cooperative Oncology Group (ECOG) performance status (PS) (Oken et al, 1982) p1, age p75 years, and no history of malignancy within 5 years of study. Before enrolment, each patient had a complete medical history and physical, laboratory, and staging assessments. The laboratory examinations consisted of complete blood cell count (CBC), serum chemistry and tumour marker analyses, 24-h creatinine clearance evaluation, arterial blood gas analysis, urinalysis, electrocardiogram, and pulmonary function tests. Staging work-up included chest plain radiographs, computed tomography (CT) scan of the chest and abdomen (ultrasonography of the abdomen could be substituted), magnetic resonance imaging of the brain, radionuclide bone scan, and bronchofiberscopy. Mediastinoscopy was not included in the staging work-up. A mediastinal lymph node X10 mm along the short axis by CT scan was defined as a metastatic lymph node (N2- 3). Patients were required to have a white blood cell (WBC) count >= 4000 ul-1, platelet (PLT) count >= 100,000 ul-1, haemoglobin level >= 9 g dl-1, serum bilirubin level <= 1.5 mg dl-1, serum aspartate aminotransferase and alanine aminotransferase levels <= 2.5 times the upper normal limit, serum creatinine level <= 1.5 mg dl-1, 24-h creatinine clearance level >= 60 ml min-1, and arterial oxygen pressure (PaO2) >= 60 mmHg. ","Patients were excluded if they had markedly diminished vital capacity and/or forced expiratory volume in 1 s, any serious underlying diseases or complications, or were women who were pregnant, breast feeding, or of childbearing age",NA,NA
15122076,NA,Combination,No,advanced non small cell lung cancer (NSCLC),"All patients must have had a histologic or unequivocal cytologic diagnosis of non-small cell lung carcinoma and a SWOG performance status of 0–2. Eligible patients had stage IIIB, defined by a pleural effusion, unsuitability for irradiation, refusal to undergo radiation therapy, or stage IV disease. Patients with brain metastases were eligible if they completed radiotherapy or surgical resection 2 weeks before beginning therapy with objective evidence of stable disease or significant improvement in brain lesions on follow-up CT or MRI scan. Measurable or evaluable disease was allowed. All x-rays and scans to assess response and fulfill staging requirements were completed within 28 days prior to registration; bone scans are required only if clinically indicated and within 42 days of treatment. Brain MRI or CT scans were required only if clinically indicated and within 42 days of treatment. No prior chemotherapy was allowed and no prior radiation therapy to the measurable or evaluable site(s) to be followed for response was allowed. Completion of radiation therapy was required 2 weeks before starting the trial. All patients must have had an expected life expectancy of at least 3 months to be entered on the trial. Adequate renal, hepatic, and hematologic functions as defined by the following laboratory values obtained within 7 days of registration: Hematologic: WBC >3500/mm3, absolute granulocyte count >1500/mm3, platelet count >100,000/mm3; Serum bilirubin ≤ institutional upper limits of normal, AST and ALT ≤2.5 × institutional upper limits of normal (IULN), if alkaline phosphatase is ≤IULN.: Alkaline phosphatase may be up to 4 × IULN, if AST and/or ALT are ≤IUNL. However, patients with both increased transaminases >1.5 IULN and ALP >2.5 IULN were not eligible for this study; Renal function: Serum creatinine < institutional upper limits of normal, or a measured or calculated creatinine clearance of >50 ml/min. All patients were over 18 years old. Signed informed consent according to institutional and federal guidelines was required","Patients with a past or current history of another neoplasm, except for non-metastatic, non-melanoma skin cancers, carcinoma in situ of the cervix, or cancer cured by surgery or small field radiotherapy ≥5 years prior to registration. Patients with a significant history of cardiovascular disease, i.e. inadequately controlled hypertension, angina, myocardial infarction within the last 6 months, history or treatment for congestive heart failure unless resting MUGA scan ejection fraction is ≥50% were ineligible. Evidence of grade >2 peripheral neuropathy disqualified patients from the study. Females who were pregnant or nursing were not allowed to enroll.",NA,NA
11943893,NA,Combination,No,Squamous Cell Carcinoma of the Head and Neck (SCCHN),"Patients with locally advanced nonmetastatic SCCHN were enrolled in an institutional review board–approved phase I/II study of opTPFL followed by definitive radiation therapy. All patients signed institutional review board–approved informed consent documents before enrollment. Patients with American Joint Committee on Cancer stage III or IV (M0) SCCHN, with the exception of those with T1N1 or exophytic T3N0 lesions, were eligible. All subjects were required to have an Eastern Cooperative Oncology Group performance status of 2 or less, adequate and balanced enteral intake of food, life expectancy of more than 3 months, leukocytes 4,000 cells/mm3 or more or normal neutrophil count, platelets 100,000/mm3 or more, hemoglobin 10 g/dl or more, aspartate transaminase less than 1.5 x upper limit of normal, alkaline phosphatase less than 2.5 upper limit of normal, total bilirubin less than or equal to 2 x upper limit of normal, creatinine less than or equal to 1.5 mg/dl or 24-hour creatinine clearance greater than 50 ml/min, peripheral neuropathy less than grade II by National Cancer Institute Common Toxicity Criteria, and be able to tolerate 3 l of intravenous normal saline per day.",Patients with previous SCCHN were ineligible except for patients who were treated with surgery as the sole modality. Patients with other invasive malignancies within 3 years of trial enrollment were ineligible. Pregnant or breastfeeding patients were not eligible for this study,during cycle 1,NA
15108042,NA,Combination,No,squamous cell carcinoma of the head and neck,"Patients with histologically proven measurable HNSCC were entered in this study. The stages of disease were III or IV for the phase I study, and stage II, III, or IV for the phase II study. Patients without prior treatment, or those who had completed prior treatment more than 4 weeks earlier, were enrolled, whereas patients who had received radiotherapy as prior treatment were excluded. All patients were free of distant metastasis, with a performance status of 0 or 1, and were 20–75 years of age. Laboratory measurements required at study registration included the following: white blood cells >= 4000/mm3; neutrophils >= 2000/mm3; platelets >= 100000/mm3; hemoglobin >= 9.5g/dl; GOT and GPT, <= 1.5 times the institutional upper limit of normal; total bilirubin, <= 1.5mg/dl; serum creatinine, <= 1.2mg/dl; and serum alkaline phosphatase, <= 2.5 times the institutional upper limit of normal. All the patients were estimated to survive for more than 3 months. Written informed consent was obtained from all patients before registration.",Patients with thyroid carcinoma were excluded. ,during radiotherapy,NA
12172503,NA,Combination,No,advanced solid tumors,"Patients were considered eligible if they fulfilled the following criteria: (i) histologically or cytologically confirmed cancer, for which no treatment with greater potential than docetaxel or gemcitabine was available; (ii) locally advanced or metastatic disease; (iii) age >= 18 years; (iv) WHO performance status <= 2; (v) estimated life expectancy >= 12 weeks; (vi) adequate bone marrow function (absolute neutrophil count >= 2.0 x 109 cells/l, platelet count >= 100 x 109 cells/l); (vii) normal renal function [creatinine <= pupper normal limit (UNL) or creatinine clearance >= 60 ml/min]; (viii) adequate liver function (total bilirubin <= 1 x UNL, alanine transaminase (ALAT) and aspartate transaminase (ASAT) <= 2 x UNL, alkaline phosphatases <= 5 x UNL); (ix) no radiation therapy for at least 4 weeks (8 weeks in the case of extensive prior therapy); for the 4-week schedule, no more than two prior chemotherapy treatments for advanced disease, at least 4 weeks previously (6 weeks for nitrosureas, mitomycin C and carboplatin; 8 weeks if concomitant use of granulocyte colony stimulating factor or granulocyte macrophage colony stimulating factor was necessary); for the 3-week schedule, no more than one prior chemotherapy treatment for advanced disease, which must NOT have included mitomycin C, carboplatin or high-dose therapy; and (x) written informed consent according to institutional guidelines","Exclusion criteria included the following: (i) hematological malignancies; (ii) symptomatic brain metastases or leptomeningeal involvement; (iii) peripheral neuropathy grade >= 2 according to NCI common toxicity criteria (CTC version 1); (iv) pre-existing ascites and/or pleural effusions; and (v) prior taxoids, gemcitabine or other nucleoside analogs.",in the first cycle,NA
11810041,NA,Combination,No,Advanced Breast Cancer,"We enrolled patients 118 and ^75 years of age with histologically proven MBC and a World Health Organization (WHO) performance status score of 0–2. Bidimensionally measurable disease was not a prerequisite, but each patient received a complete [by X-ray, ultrasound, computed tomography (CT) scan] evaluation of their site of lesion and every measurable lesion was accurately recorded. All patients were pretreated with anthracyclines and may have received one prior taxane-based chemotherapy regimen (excluding gemcitabine) for metastatic disease. Prior radiotherapy or chemotherapy must have been completed >= 2 months before study entry. Other eligibility criteria were: adequate hepatic function (bilirubin < 2.0 mg/dl, transaminases < 2 times the upper limit of normal and alkaline phosphatase < 5 times the upper limit of normal), adequate renal function (creatinine < 1.2 mg/dl), normal cardiac function [documented by electrocardiogram (ECG) and a bidimensional echocardiography showing a left ventricular ejection fraction > 50%] and adequate bone marrow function [white blood cell (WBC) count > 3.0 x 109/l and platelet count > 100 x 109/l].","Exclusion criteria included: presence of brain metastases as the only site of disease, a history of other malignancies (other than skin cancer or in situ carcinoma of the cervix), active infections and psychological or geographic difficulties.",NA,NA
14663635,NA,Single Drug,No,patients with relapsed ovarian cancer after the administration of platinum/paclitaxel/irinotecan,"In principle, patients who satisfied the following inclusion criteria were selected for enrollment in the study: (1) histologically confirmed ovarian cancer, (2) currently undergoing treatment with platinum/paclitaxel/irinotecan, (3) presence of measurable or evaluable lesion(s), or diagnosis of relapse on the basis of an elevated serum carbohydrate antigen (CA) 125 value, (4) at least 20 years of age, (5) a performance status (PS) of 0–2, (6) absence of severe dysfunction of major organs (i.e., WBC count, >= 3000/mm3; neutrophil count, >= 1500/mm3; platelet count, >= 100000/mm3; hemoglobin, >= 9.0g/dl; GOT and GPT values two fold or less than the upper normal limit in the institution; serum total bilirubin 1.5-fold or less than the upper normal limit in the institution), and (7) provision of informed consent.","Patients were excluded from the study if any of the following criteria applied: (1) presence of an infection; (2) presence of an active double cancer; (3) presence of serious complications in the heart, lung, kidney, etc.; (4) presence of ascites, pleural effusion, or pericardial effusion requiring treatment; (5) poorly controlled diabetes; (6) presence of peripheral neuropathy of grade 3 or more; (7) pregnancy or the possibility of pregnancy; (8) a history of drug allergy; or (9) any other reason for which the investigator judged the patient to be unsuited for inclusion in the study.",NA,NA
25947565,NCT01624441,Combination,No,metastatic triple negative breast cancer,"Eligibility was based on the following criteria: histologically confirmed metastatic TNBC or considered incurable with standard chemotherapy and/or surgery, performance status of ECOG ≤2, Karnofsky >60 %, ≥ than 18 years old, life expectancy≥3 months, adequate electrolyte, organ function and hematologic parameters, ≤ 2 prior chemotherapy regimens for metastatic disease, and had at least one site of objective measurable disease. No prior dinaciclib was allowed; however, bisphosphonate therapy was allowed if started≥2 weeks prior to protocol therapy.",Patients with cumulative doses of anthracycline equivalent to≥360 mg/m2 of doxorubicin were excluded as were those with LVEF below normal by cardiac imaging,the first cycle ,NA
25312684, NCT01337505,Single drug,No,Soft Tissue Sarcoma,"Patients were aged 18 to 70 years with malignant solid tumors that had recurred or were refractory to standard therapy; had stable brain metastases, if present on computed tomography or magnetic resonance imaging scans during screening; had an Eastern Cooperative Oncology Group performance status of 0 to 2; had a life expectancy >12 weeks; were not pregnant or lactating (women patients only); had received no palliative surgery, chemotherapy, immunotherapy, and/or radiotherapy within 4 weeks of the screening visit, and had no exposure to any investigational agent within 30 days of the screening visit; had adequate liver and bone marrow function; had no clinically evident congestive heart failure worse than New York Heart Association functional class II; had no serious, clinically significant cardiac arrhythmias, no history or signs of active coronary artery disease, and no serious myocardial dysfunction or left ventricular ejection fraction <45% of predicted; had no active, clinically significant, serious infection, including human immunodeficiency virus, that required treatment; and had undergone no major surgery within 3 weeks of the first dose of the study drug. All patients provided written informed consent.","Palliative surgery, chemotherapy, immunotherapy and/or radiation less than 4 weeks prior to the Screening Visit. Exposure to any investigational agent within 30 days of the Screening Visit. Laboratory values: Screening serum creatinine greater than or equal to 1.5 mg/dL, alanine aminotransferase (ALT) greater than 3 times the upper limit of normal, total bilirubin greater than 3 times the upper limit of normal, white blood cell (WBC) count < 3500/mm3, absolute neutrophil count < 2000/mm3, platelet concentration < 100,000/mm3, hematocrit level < 33% for females or < 35% for males, or coagulation tests (PT,PTT) >1.5 times the upper limit or normal. Clinically evident congestive heart failure > class II of the New York Heart Association (NYHA) guidelines. Serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V. History or signs of active coronary artery disease with or without angina pectoris. Serious myocardial dysfunction defined scintigraphically (MUGA, myocardial scintigram)or ultrasound determined absolute left ventricular ejection fraction (LVEF) < 45% of predicted. History of HIV infection. Active, clinically significant serious infection requiring treatment with antibiotics, antivirals or antifungals. Major surgery within 3 weeks prior to treatment. Substance abuse or any condition that might interfere with the subject's participation in the study or in the evaluation of the study results. Any condition that is unstable and could jeopardize the subject's participation in the study.",cycle 1,NA
24807889,NA,Combination,No,The most prevalent tumor types were colorectal (n ¼ 9; 27.3%) and pancreatic cancer (n ¼ 5; 15.2%). ,"Eligible subjects were adult patients who had received a diagnosis of histologically or cytologically confirmed solid tumors or lymphoma, with locally advanced or metastatic disease for which there were no further treatment options known to provide clinical benefit. Subjects had a life expectancy of >= 16 weeks and an Eastern Cooperative Oncology Group performance status of 0 or 1. Subjects also had acceptable physical examinations, including ophthalmologic exams and acceptable bone marrow, renal, and hepatic function based upon screening laboratory tests. ","Patients were not eligible if they had received treatment with an anticancer therapy or corticosteroids (previous 2 weeks), required ongoing systemic immunosuppressive therapy, or were known to have brain metastases (unless stable for >= 28 days), active autoimmune disease, or insulin-dependent diabetes. Additional exclusion criteria included clinically significant cardiac or ophthalmologic disease, corrected QT (QTc) interval > 450 msec on baseline electrocardiogram, uncontrolled intercurrent illness, infection requiring antibiotic therapy or causing fever (previous week), lack of acceptable methods of birth control, and pregnancy.",during the first cycle,NA
24585045,NA,Combination,No,recurrent ovarian cancer,"(1) ovarian cancer confirmed by histological or cytological diagnosis, (2) recurrence less than 6 months after previous chemotherapy, (3) containing a measurable or evaluable lesion (including CA-125 level), (4) ECOG performance status (PS) 0–2, (5) 20–75-year old, (6) expected survival time of at least 2 months, (7) major organs remained functional (white blood cell count ≥3,000/mm3, neutrophil count ≥1,500/mm3, platelet count ≥10,0000/mm3, total bilirubin ≤1.5 mg/dL), and (8) informed consent provided. ","Exclusion criteria were (1) serious complication(s), (2) evident pulmonary fibrosis or interstitial pneumonitis, (3) pleural or cardiac effusion necessitating prompt local treatment, (4) brain metastasis requiring prompt treatment, (5) diarrhea (watery stool), (6) intestinal paralysis or intestinal obstruction, (7) active infection requiring treatment with antimicrobial agents, and (8) patients considered inappropriate as subjects by the physician in charge for any other reason",during the first course,NA
25958319,NA,Combination,No,endometrial cancer patients at high risk for peritoneal failure,"Eligible patients had a GOG performance status (PS) of 0-2 and adequate organ function including an absolute neutrophil count (ANC) ≥1,500/mm3, platelets (PLT) ≥100,000/mm3, hemoglobin ≥10 g/dl,creatinine ≤2 mg/% or 24 hour creatinine clearance ≥50 ml/min, bilirubin ≤1.5 x upper limit of normal (ULN), SGOT and alkaline phosphatase ≤2.5 x ULN. Patients were required to have a normal left ventricular ejection fraction at study entry. All patients were enrolled within 8 weeks of initial surgery. The initial surgery included a hysterectomy, bilateral salpingo-oophorectomy, and pelvic and para-aortic nodal dissection was encouraged but not required. Intraperitoneal and bulky nodal disease, if present, was to be debulked to ≤ 2 cm residual. Eligible and enrolled patients were centrally registered and provided signed informed consent consistent with all regulatory requirements",Patients were not allowed to have received prior radiation or chemotherapy for endometrial cancer.,based on AEs reported on cycles 3 and 4,"All pts received cycle 1–2 with IV TAP, and cycles 3–6 with IV/IP therapy, on a 21 day schedule. "
21625179,NA,Combination,No,Advanced Soft Tissue Sarcoma,"The study was approved by the institutional review board at all sites. All patients signed an informed consent document. Patients over the age of 18 years with an Eastern Cooperative Oncology Group performance status of 0 or 1, and the following unresectable or metastatic intermediate or high-grade STS subtypes, were eligible: synovial sarcoma, fibrosarcoma, liposarcoma, angiosarcoma, pleomorphic sarcoma, leiomyosarcoma, and unclassified, undifferentiated sarcoma. A central pathology review was not conducted. Patients were required to have adequate hematologic (ANC >= 1,500 cells/ul, platelet count >= 100,000/ul and hemoglobin >= 9.0 g/dl), hepatic [bilirubin <= 1.5 times upper limit of normal (ULN), AST (SGOT) and ALT (SGPT) <= 2.5 ULN] and renal function (serum creatinine < ULN). All patients had normal left ventricular ejection fraction, as assessed by a multiple-gated acquisition scan or transthoracic echocardiogram. Patients were allowed to have up to two prior chemotherapeutic regimens, although those previously treated with anthracyclines including doxorubicin, anthracenediones, ifosfamide or cyclophosphamide were excluded to eliminate prior therapeutic exposure to chemotherapies with similar mechanisms of action as doxorubicin and TH-302",NA,during cycle 1,NA
25189481,NCT01100944,Combination,No,Thymic Epithelial Tumors,"Eligible patients were those more than 18 years of age with histologically confirmed advanced (Masaoka stage III or IV) TETs who had not received prior systemic therapy for advanced disease with Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1, life expectancy more than 3 months, and adequate organ function.","Patients at increased cardiac risk were excluded, including those with unstable angina, myocardial infarction within the previous 12 months, baseline prolongation of QT/QTc interval as demonstrated by repeated QTc interval > 500 ms and long QT syndrome. Other exclusion criteria included: resectable disease, untreated brain metastases, radiotherapy or chemotherapy within 3 weeks before study drug administration, or positive serology for HIV.",during the first cycle of therapy,NA
25858498,NCT00789633,Combination,No,soft tissue sarcoma,"Eligible patients were 16 years and older with histologically confirmed, measurable, advanced STS excluding pediatric rhabdomyosarcoma, GIST, alveolar soft part sarcoma, and clear cell sarcoma. Inclusion Criteria:; Histologically or cytologically confirmed soft tissue sarcoma; Unresectable disease; Locally advanced or metastatic disease; The following tumor types are not allowed: Embryonal and alveolar rhabdomyosarcoma; Gastrointestinal stromal tumor; Alveolar soft part sarcoma; Clear cell sarcoma; Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan; No more than 1 prior therapy for sarcoma; No known brain metastases; ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%; ANC ≥ 1,500/µL; Platelet count ≥ 100,000/µL; Leukocytes ≥ 3,000/µL; Total bilirubin ≤ upper limit of normal(ULN); AST and ALT ≤ 2.5 times ULN; Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min; Fasting serum glucose < 120 mg/dL OR below ULN; LVEF ≥ 50% by MUGA scan; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception during and for 3 months after the last dose of anti-IGF-1R recombinant monoclonal antibody IMC-A12; No history of allergic reactions attributed to compounds of similar chemical or biological composition to anti-IGF-1R recombinant monoclonal antibody IMC-A12; No poorly controlled diabetes mellitus; Patients with a history of diabetes mellitus are eligible provided their blood glucose is within normal range and they are on a stable dietary or therapeutic regimen for this condition","No concurrent uncontrolled illness including, but not limited to, any of the following: Ongoing or active infection; Symptomatic congestive heart failure; Unstable angina pectoris; Cardiac arrhythmia; Psychiatric illness or social situation that would preclude compliance with study requirements; No other concurrent investigational or commercial agents or therapies; Recovered from all prior therapy; More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C); More than 4 weeks since prior major surgery, hormonal therapy (other than replacement), or hormonal therapy; No prior radiotherapy to the heart, mediastinum, or chest wall; No prior anthracycline therapy or anti-IGF-1R therapy",within the first two cycles ,NA
25615852,NA,Combination,No,Relapsed/Refractory Epithelial Ovarian Cancer,"Eligible patients had histologically confirmed, advanced epithelial ovarian carcinoma, primary peritoneal carcinoma, or fallopian tube carcinoma. All patients had received either one or two previous chemotherapy regimens for advanced ovarian cancer, with at least one of these regimens containing a platinum agent. Patients who were platinum resistant (relapse <6 months after completing a platinum-containing regimen) or platinum sensitive (relapse ≥6 months after a platinum-containing regimen) were eligible. Additional eligibility criteria included measurable disease (RECIST version 1.1) or evaluable disease with elevated serum CA-125 level; ECOG performance status 0 or 1; normal left ventricular ejection fraction; adequate bone marrow, renal, and liver function; and ≥18 years of age. In addition, all patients were required to sign written informed consent prior to entering the study.","Patient who had received previous liposomal doxorubicin or previous angiogenesis inhibitors were excluded. Additional exclusion criteria included untreated brain metastases; impaired cardiac function; concurrent treatment with CYP3A4 inhibitors; inability to swallow tablets; impaired gastrointestinal function preventing absorption of oral agents; other significant concurrent illnesses that would impair the ability to participate in the study and/or to tolerate study treatment. In addition, patients with known risk factors for treatment with angiogenesis inhibitors were excluded (uncontrolled hypertension, symptomatic ischemic heart disease or history of cerebral vascular accident; significant symptoms of bowel obstruction or recent bowel resection).",during the first cycle (28 days) of therapy,NA
24141374,NA,Combination,No,early recurrent ovarian carcinoma,"Eligible patients were adult women aged 18–70 years, with histologically confirmed ovarian, fallopian tube or primary peritoneal adenocarcinoma with evident clinical relapse within 12 months of the completion of platinum/taxane first-line chemotherapy. Other inclusion criteria were Eastern Cooperative Oncology Group (ECOG) performance status ≤1; life expectancy >3 months; at least one measurable lesion according to response evaluation criteria in solid tumours (RECIST) 1.0 criteria  and/or CA-125 elevation ; normal left ventricular ejection fraction (LVEF) and no exposure to chemo-, radiation-, endocrine- nor immunotherapy within 30 days before inclusion. Patients had polynuclear neutrophils (PNN) >1.5 G/L, platelets >100 G/L, creatinine clearance >50 mL/mn, total bilirubin <1.5 upper limit of normal (ULN), transaminases and alkaline phosphatase <2 ULN or <3 ULN in the case of hepatic metastases.","Patients with non-epithelial or borderline tumours, with symptomatic cerebral or meningeal metastasis, who had bowel obstruction, symptomatic cardiac failure, previous or concomitant experimental treatment and psychological or psychiatric disorders were excluded. Patients with no previous cancer, except basocellular and squamous skin cancer, and completely resected carcinoma in situ of the uterine cervix, were eligible. ",over the first two cycles,NA
25536954,NCT01027910,Combination,No,Metastatic Sarcoma,"Participants must have histologically confirmed metastatic or unresectable sarcoma; All participants must have received no more than a lifetime cumulative maximum dose of 300 mg/m2 or less of prior doxorubicin and no other anthracycline therapy. Participants must have measurable disease, defined as at least one unirradiated lesion that can be accurately measured in at least one dimension as 20mm or greater with conventional techniques or as 10mm or greater with spiral CT scan. ECOG performance status of 2 or less. Ability to swallow oral capsules without difficulty. Participants must have normal organ and marrow function as outlined in the protocol. Women of childbearing potential must have a negative serum/urine pregnancy test within 7 days prior to receiving the first dose of PCI-24781. An ECHO or MUGA demonstrating EF > 50% is required within 4 weeks prior to study drug administration. 18 years of age or older","Participants who have had immunotherapy, chemotherapy, experimental therapy or radiotherapy within 4 weeks before first day of study drug dosing or those who have not recovered to grade 1 or baseline from adverse events due to agents administered more than 4 weeks earlier. Participants who have previously received > 300 mg/m2 cumulative lifetime dose of doxorubicin, or who have received any other anthracycline chemotherapy. Major surgery within 4 weeks before first day of study drug dosing. Participants with known central nervous system/brain metastases. Participants receiving chronic corticosteroids > 20 mg prednisone equivalent per day for > 7 consecutive days (Topical, inhaled or nasal corticosteroids are permitted). Participants with any documented malabsorption syndromes or other conditions that may impair the absorption of PCI-24781 capsules. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Participants requiring concurrent therapeutic anticoagulation or have received therapeutic anticoagulation within 2 weeks of the first day of dosing. Risk factors for Torsades de Pointes, or use, within 4 weeks of starting study drug administration, of medications known to prolong QTc interval or that may be associated with Torsades de Pointes. QTc prolongation or other significant ECG abnormalities defined as 2nd degree AV block type II, 3rd degree AV block, or bradycardia. History of myocardial infarction, acute coronary syndromes, coronary angioplasty and/or coronary artery stenting within the past 6 months. For patients with history of major coronary artery disease in the judgement of the responsible physician, a cardiac stress test that demonstrates clinically significant abnormalities when performed within 28 days of first dose of study drug. Pregnant or breastfeeding women. Women of childbearing potential, or sexually active men unwilling to use adequate contraceptive protection during the course of the study. HIV-positive individuals. Other medical or psychiatric illness or organ dysfunction that, in the opinion of the investigator, would either compromise the patient's safety or interfere with the evaluation of the safety of PCI-24781",during cycle 1,NA
20629034,NA,Combination,No,Advanced Hepatocellular Carcinoma,"Advanced HCC patients who were not suitable for surgery or various locoregional therapies at the Queen Mary Hospital, Hong Kong were enrolled. HCC was diagnosed either by cytohistological confirmation or by noninvasive criteria according to European Association for the Study of the Liver criteria: cirrhotic patients either with focal lesion >2 cm with arterial hypervascularization demonstrated by 2 coincident imaging techniques or with focal lesion >2 cm with arterial hypervascularization demonstrated by 1 imaging technique and associated with alpha fetoprotein (AFP) level > 400 ng/mL.14 Staging was by both American Joint Committee on Cancer (AJCC) and Cancer of the Liver Italian Program score. The eligibility criteria included adult patients aged 18 to 75 years, patients with Child-Pugh class A or B cirrhosis, Karnofsky performance status >= 70%, expected life expectancy of >= 12 weeks and with adequate organ function, and complete blood picture (absolute neutrophil count >1.5 x 109/L, platelet count >100 x 109/L) and biochemistry (total bilirubin of <=  2 x upper limit of normal, serum creatinine <= 2 x upper limit of normal, serum aspartate aminotransferase and alanine aminotransferase <= 5 x upper limit of normal). Moreover, the disease must be measurable with at least 1 lesion, which was at least 1 cm in 1 dimension either on computed tomography (CT) or magnetic resonance imaging (MRI) scan.",during the first cycle of therapy,NA,NA
25698442,NCT00710125,Single Drug,No,"3 uterine leiomyosarcomas, 1 non-uterine leiomyosarcoma, 1 high grade malignant mesenchymal neoplasm, 1 malignant high grade sarcomatous neoplasm of the ovary, 1 desmoid, and 1 high grade sarcoma","Individuals (age≥18 years) with advanced metastatic cancer with progressive disease for whom no effective standard therapy was available, and who gave informed written consent according to Food and Drug Administration and institutional guidelines, were eligible. Patients had to have a performance status of at least 70 % on the Karnofsky scale. Patients must not have received any cytotoxic chemotherapy, hormonal therapy, other investigational agents, or palliative radiation within 4 weeks of the first treatment on study. Patients were required to have adequate bone marrow function (ANC count ≥1500/mm3, hemoglobin≥9.0 g/dL, and platelet count ≥100,000/mm3), renal function (serum creatinine ≤2.0 mg/dl or estimated creatinine clearance≥50 ml/min), and hepatic function (bilirubin ≤1.5×ULN, AST and ALT< 2.5×ULN (<5.0×ULN with liver involvement)). Patients were required to have an ejection fraction of 110 % of the lower limit of the institutional normal as determined by resting MUGA and have a baseline oxygen saturation by pulse oximetry of at least 90 %.","Exclusion criteria included: pregnancy or breast feeding; history of hypersensitivity to anthracyclines; having received a cumulative dose of doxorubicin exceeding 300 mg/m2 or a cumulative dose of epirubicin exceeding 450 mg/m2; having received an anthracycline within 6 months prior to study entry; brain metastases unless asymptomatic and stable off glucocorticoids; prior history of congestive heart failure (CHF); myocardial infarction within 6 months prior to enrollment, active ischemic heart disease, or uncontrolled hypertension; requiring active medical therapy for CHF or arrhythmia; > grade 1 motor neuropathy or>grade 2 sensory neuropathy; or lymphoma.",during the first cycle,NA
25058346,NA,Combination,No,early HER-2-negative breast cancer,"Women aged > 18 years with histologically confirmed HER-2-negative resectable breast cancer were eligible. Key inclusion criteria included: (1) signed informed consent form; (2) primary tumour over 2 cm on its longer diameter (measured by MRI; any nodal status and multicentricity were allowed, as long as the disease was deemed resectable by a multidisciplinary committee); (3) HER-2-negative disease; (4) ECOG 0–1; (5) adequate liver, haematologic and renal function defined by usual phase I criteria. ","Patients with previous treatment of any kind for breast cancer (excluding patients adequately treated > 5 years ago from a previous breast cancer), undergoing hormonal replacement or contraceptives, concurrent or previous malignancy of any kind up to 5 years before diagnosis (except from nonmelanoma skin cancer or in situ carcinoma of the breast or cervix), concurrent serious medical conditions, or patients undergoing anticoagulation/antiplatelet therapy (except low-dose heparin or <325 mg per day aspirin) or with a history of haemorrhagic/ thromboembolic event clinically significant in the last 6 months were excluded. Patients with recent major surgery (4 weeks) were not candidates for this trial.",during the first 3-week cycle,"Patients received oral nintedanib twice per day during the 12 courses of weekly paclitaxel. The morning dose of nintedanib of the paclitaxel days was omitted due to previous preclinical pharmacokinetic interaction observations. One week after the last nintedanib dose (2 weeks after the last paclitaxel infusion), adriamycin plus cyclophosphamide was started, every 21 days. Surgery was programmed a minimum of 4 weeks after the last chemotherapy dose, and in any case, 5 weeks since the last nintedanib dose. "
22752217,NA,Combination,No,previously untreated advanced gastric cancer,"All patients enrolled in this study were between 18 and 75 years old and had histologically or cytologically confirmed unresectable or metastatic gastric adenocarcinoma. Eligibility criteria for participation also included an estimated life expectancy >= 12 weeks, adequate bone marrow function (absolute neutrophil count [ANC] >= 1.5 x 109/L and platelet count >= 100 x 109/L), adequate renal function (serum creatinine < 1.5 mg/dL or calculated creatinine clearance >= 60 mL/min by the Cockcroft and Gault formula), adequate hepatic function (total bilirubin level <= 2 times institutional upper limit of normal [ULN], and serum transaminases levels <= 3 times institutional ULN). Patient’s performance status was assessed using the Eastern Cooperative Oncology Group (ECOG) criteria, and those with a performance status <= 2 were considered eligible. Eligibility also included the ability to reliably tolerate and comply with oral medication.","Patients who had received prior chemotherapy for advanced disease were excluded from participation in the study.  Patients with gastro-intestinal obstruction, or evidence of ongoing serious gastro-intestinal bleeding, were excluded from the study. Patients were also excluded if there was evidence of central nervous system metastasis, peripheral neuropathy >= grade 2, serious uncontrolled concomitant disease, or if they had another primary malignancy (except squamous or basal cell skin cancer or cervical carcinoma, in situ) within the past 5 years, or if they were pregnant or breastfeeding. ",during the first two cycles of treatment,NA
22178041,NA,Single Drug,No,Hepatic Malignancies,"Patients with unresectable primary or metastatic liver neoplasms, with no more than four lesions each with diameters no greater than 7 cm, were eligible. Systemic therapy for extrahepatic disease was not allowed 21 days before enrollment or 28 days after treatment. All patients were required to have a left ventricular ejection fraction greater than 50%, total bilirubin level lower than 2.0 mg/dL (34 μmol/L), serum creatinine level lower than 2.5 mg/dL (221 μmol/L), prothrombin time or partial thromboplastin time lower than 1.5 times the institution's upper normal limit, platelet count greater than 75,000/mm3, white blood cell (WBC) count greater than 1,500/mm3; and hemoglobin level greater than 10 g/dL.  ","Exclusion criteria included serious comorbid medical illnesses within the previous 6 months, uncorrectable coagulopathy, or any of the following medications: cyclosporine, phenobarbital, phenytoin, streptozocin, or live vaccines. ",NA,NA
26115930,NA,Single Drug,No,children with recurrent/refractory high‑grade glioma,"Patients older than 3 years and younger than 18 years at the time of inclusion with histologically documented malignant glioma, refractory or relapsing after surgery or biopsy, radiotherapy and at least one line of chemotherapy, with a life expectancy of more than 8 weeks were eligible for the study, provided they satisfied the following eligibility criteria: Lansky play scale >50 %, adequate haematological status (neutrophils >1000/mm3, platelets >100,000/mm3), normal liver function (bilirubin <1.5 × the upper limit of normal (ULN), AST and ALT <2.5 × ULN, fibrinogen >200 mg/dL and prothrombin level >70 %), adequate renal function (creatinine <1.5 × the normal values for age or creatinine clearance >70 mL/min/1.73 m2), normal electrocardiogram and echocardiography (ejection fraction >60 % and shortening fraction >30 %), and no organtoxicity with WHO grade >2. No other anticancer treatment was allowed during the study; the time interval between previous treatments and administration of Myocet® had to be at least 3 weeks for chemotherapy and 6 weeks in the case of previous use of nitrosoureas. ","A patient could not be included in the case of severe infection, previous large-field irradiation (such as craniospinal irradiation), previous use of high-dose chemotherapy with haematopoietic stem cell transplantation, known heart disease, and previous neurological toxicity grade >2. ",during the first two courses,NA
20352294,NA,Combination,No,"refractory breast, ovarian, primary peritoneal, or fallopian tube cancer","Patients with pathologically confirmed, locally advanced, unresectable or metastatic breast, ovarian, primary peritoneal, or fallopian tube cancer that was refractory to conventional treatment were enrolled after meeting the following inclusion criteria: Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1; >18 years of age; life expectancy of >3 months; normal laboratory values including absolute neutrophil count (ANC) ≥1.5×109/L, platelets >100×109/L, hemoglobin ≥9 g/dL, serum bilirubin < 1.2 mg/dL, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase <2× upper limit of normal (ULN) of the institution without liver involvement (<3× ULN of the institution with liver involvement); calculated creatinine clearance ≥45 mL/min; and, left ventricular ejection fraction (LVEF), by multiple gated acquisition scan (MUGA) or echocardiogram ≥50%. Male breast cancer patients were eligible for study participation.","Patients were excluded if they had received: more than 3 prior cytotoxic regimens, more than 300 mg/m2 prior cumulative treatment with doxorubicin or 540 mg/m2 cumulative treatment with epirubicin, treatment with any investigational agent within the 30 days prior to registration, prior treatment with either study drug for any reason, or prior radiation to more than 25% of bone marrow or to the mediastinal area. Patients were also excluded if they were pregnant or lactating, had a history of hypersensitivity to either study drug, were currently receiving any other cancer treatment (immunologic, biologic, or hormonal therapy), were unable to tolerate any required premedications, had prior myocardial infarction or active cardiac disease, had a history or evidence of central nervous system involvement, had serious, uncontrolled concurrent medical or psychiatric illness (including an infections requiring oral antibiotics, antiviral, or antifungal treatment), or were unable to interrupt the use of aspirin and/or other nonsteroidal anti-inflammatory agents for 2 days before, the day of, and 2 days after the dose of pemetrexed (5 days prior for long-acting agents such as piroxicam; low dose aspirin 100 mg/day or less was allowed).",occurring in cycle 1,NA
20405155,NA,Combination,No,refractory gynecological malignancies or metastatic breast cancer,"Eligible patients were accrued between 2004 and 2006 from two participating institutions, the Dana Farber Cancer Center and the Massachusetts General Hospital. Patients with histologically confirmed tumors consistent with recurrent ovarian cancer, peritoneal cancer, fallopian tube carcinoma, papillary serous carcinoma of the uterus, or metastatic breast cancer were eligible. Patients were allowed to have nonmeasurable or measurable disease and were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2. Acceptable hematological [absolute neutrophil count (ANC) > 1,250/mm3, platelet count > 150,000/mm3], hepatic (liver function tests < 2.5 times the upper limit of normal and bilirubin < 1.5 times the upper limit of normal), and renal (serum creatinine < 2 mg/dl) parameters were required. Additional eligibility criteria included: (1) a cumulative anthracycline dose that did not exceed 360 mg/m2 at study entry; (2) 3 weeks since prior therapy (cytotoxic and biologic); (3) an ejection fraction of >= 50% within 30 days prior to the first dose of the study drug; and (4) absence of brain and/or leptomeningeal metastases.",No greater than four prior chemotherapeutic regimens were allowed.,within the first two cycles of treatment,NA
25278449,NCT01240629,Single Drug,No,Castration- and Taxane-Resistant Prostate Cancer,"Participation was limited to men with prostate cancer who had documented progression with at least one prior hormone treatment, which must have included LHRH agonist therapy, and at least one prior chemotherapy regimen, which must have included taxane therapy. Men were eligible if they had an Eastern Cooperative Oncology Group performance status of 0–2, had recovered from the acute and late effects of prior therapy, and had adequate hematologic and organ function.","Patients with brain metastases, prior anthracycline or anthracenedione therapy, or an impaired left ventricular ejection fraction (LVEF < 50%) were excluded. Because of the possibility of receptor competition with AEZS-108, patients were required to discontinue any LHRH agonist therapy and eligibility began 2 weeks after their first missed scheduled dose to permit an adequate wash-out",during the first cycle,NA
23763920,NCT00271063,Single Drug,No,Adult Patients With Relapsed/ Refractory Acute Lymphoblastic Leukemia,"Patients aged 15 years or older, with relapsed/refractory ALL, free of previous therapy within 2 weeks before the first dose of study drug with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 were eligible. Other eligibility criteria included adequate hepatic (bilirubin < 2 the upper limit of normal [ULN] and serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase, and alkaline phosphatase < 3 times the ULN) and renal (creatinine < 2 times the ULN) functions; absence of uncontrolled intercurrent illnesses, including, but not limited to, infections and myocardial infarction, or other organ dysfunction (eg, left ventricular ejection fraction [LVEF] > 40%). All patients signed informed consent according to institutional guidelines and in compliance with the Declaration of Helsinki.","Concommitant therapy that includes other chemotherapy that is or may be active against ALL (except central nervous system [CNS] therapy). Any condition which in the opinion of the investigator, places the subject at unacceptable risk if he/she were to participate in the study. Cardiac ejection fraction less than 40%. Clinically relevant serious co-morbid medical conditions. Pregnant, lactating or not using adequate contraception. Known allergy to doxorubicin or anthracyclines.",during the first 21 days,NA
24455463,NA,Combination,No,aggressive Non- Hodgkin Lymphoma,"All patients gave written informed consent. Patients were eligible if they had previously untreated, biopsy-confirmed, aggressive non-Hodgkin lymphoma according to the definition of the World Health Organization [WHO] classification (Jaffe et al. 2001). Young patients < = 60 years with low risk aggressive lymphoma (as defined by normal pretreatment LDH) and elderly patients aged 61–75 years with aggressive lymphoma of all risk groups were eligible.","Exclusion criteria included previous therapy including radiotherapy, bone marrow involvement > 25%, age < 18 or > 75 years, previously treated other malignancy, platelet counts (plt) < 100 000/mm3, white blood counts (WBC) < 3000/mm3, major organ dysfunction, known human immunodeficiency or active hepatitis B or C infection, WHO Performance status = 4, pregnancy and lactation. Patients with primary CNS lymphoma, mucosa associated lymphoid tissue lymphoma, lymphoblastic or Burkitt lymphomas were not included. ",averaged over the cycles 1–5,NA
20495918,NA,Combination,No,locally advanced upper gastrointestinal adenocarcinomas,"Patients were eligible for these two studies if they had histologically conWrmed adenocarcinoma of the esophagus, stomach (including gastroesophageal junction), pancreas, and biliary tract, with locally advanced unresectable disease or in whom postsurgery pathology showed positive margins or with gross regional residual disease. Patients with adenocarcinoma of the esophagus, pancreas, and biliary tract status postresection and who were considered to have a high risk of recurrence (T3, T4, and/or lymph node metastases) were also acceptable, if they would have been treated with CIFU and radiation oV-protocol. Patients must have been older than 18 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, and adequate organ function deWned as white blood cell count >= 3,000/mm3, absolute neutrophil count >= 1,500/mm3, platelet count >= 100,000/mm3, serum creatinine <= 2.0 mg/dl, total bilirubin <= 2.0 mg/dl, and AST/ALT <= 2.5 x ULN, and a left ventricular ejection fraction of at least 50%. ",Patients who had previous chemotherapy or radiation treatment were excluded from the trials. Pregnant or lactating women were also excluded. ,during the radiation threatment,NA
17551496,NA,Combination,No,"9 breast cancer, 2 lung cancer, 3 bladder cancer, 2 ovarian cancer, 1 cancer of unknown primary, 5 other solid tumor.","Patients with histologically or cytologically confirmed advancedstage solid tumours, for which there is no effective therapy or who had relapsed after receiving the ‘standard’ first-line treatment, were enrolled onto the study. Prior surgery, radiotherapy (to o20% of bone marrow containing bones) or chemotherapy (maximum two prior regimens) were allowed, but a treatmentfree interval of at least 4 weeks was required before entering the study. Other inclusion criteria were: age 418 years, a World Health Organization (WHO) performance status of 0 –2, a life expectancy of at least 3 months, an adequate bone marrow (absolute neutrophil count > 1500 dl-1, Hb > 10 g dl-1 , platelets > 100 000 dl-1), renal (serum creatinine <1.5 mg dl-1), liver (total bilirubin <1.5 mg dl-1 and SGOT/SGPT < 2 times the upper normal values) and cardiac (normal baseline LVEF by multiple gated acquisition (MUGA) scan or echocardiogram) function and pre-existing peripheral neuropathy pgrade (WHO) 1. Additional inclusion criteria were: absence of an active infection or severe malnutrition (loss > 20% of the body weight during the last 3 months) and absence of any psychological or social condition potentially hampering compliance with the study protocol.","Patients with brain metastases were allowed to participate if they had been irradiated with clinical and/or radiographical improvement, while patients with prior history of congestive heart failure or active and uncontrolled coronary disease were not eligible. The presence of measurable disease was not required.",during the first chemotherapy cycle,NA
17960381,NA,Combination,No,"Breast cancer (6), Adenocarcinoma of unknown primary (6), Endometrial carcinoma (5), Ovarian carcinoma (4), Transitional cell carcinoma (3), Non-small cell lung cancer (3), Gastric adenocarcinoma (2), Head and neck carcinoma (2), Other (8) ","Prior surgery, radiotherapy (to less than 25% of bone marrow containing bones) and chemotherapy were allowed but with a treatment-free interval of at least 4 weeks before entering the study. Other inclusion criteria were as follows: age > 18 years; a World Health Organization (WHO) performance status (PS) of 0–2; a life expectancy of at least 3 months; adequate hematologic parameters, including an absolute neutrophil count (ANC) of more than 1,500/dl, a hemoglobin level of more than 10 g/dl, and a platelet count of more than 100,000/dl; adequate hepatic (serum bilirubin < 1.5 mg/dl, SGPT/SGOT < three times normal values), renal (serum creatinine < 1.5 mg/dl), and cardiac (left ventricular ejection fraction [LVEF] ¸ 50%) function. Patients with brain metastases were eligible if they had been irradiated, the brain lesions were radiographically stable, and clinical improvement was evident.",Patients with active infection or malnutrition (>20% weight loss during the last 3 months) or prior history of congestive heart failure or coronary artery disease were not eligible. Patients with more than NCI-CTC grade 1 peripheral neuropathy were not eligible. The presence of bidimensionally measurable disease was not required.,during the first chemotherapy cycle (Wrst 4 weeks of treatment = 2 treatment administrations),NA
17641537,NA,Combination,No,"Breast carcinoma (13), Ovarian carcinoma (7), NSCLC (6), Endometrial carcinoma (5), Head and neck cancer (4), Transitional cell carcinoma (2), Gastric carcinoma (2), Prostatic carcinoma (2), Adenocarcinoma of unknown primary origin (2), Cervical carcinoma (1), Thyroid carcinoma (1)","Patients were eligible if they were > 18 years old and had histologically or cytologically confirmed, locally advanced or metastatic solid tumors relapsing following conventional therapy. Chemonaive patients with advanced tumors, for which no standard effective treatment existed, were also eligible. Prior surgery, radiotherapy (to less than 25% of marrow-containing bones), or chemotherapy (maximum 2 prior regimens) was allowed, but a treatment-free interval of at least 4 weeks was required before study entry. Other inclusion criteria were as follows: performance status <= 2 (World Health Organization, WHO), adequate blood counts (absolute neutrophil count > 1,500/ul, hemoglobin > 10 g/dl, and platelets > 100,000/ul), adequate renal function (serum creatinine < 2 mg/dl), adequate hepatic function (total bilirubin < 1.5 mg/dl and SGPT/SGOT < 3 times upper normal limit for patients with liver involvement), adequate cardiac function (baseline LVEF > 55% by MUGA scan or echocardiogram), preexisting peripheral neuropathy up to National Cancer Institute (NCI CTC Version 2.0) grade 1, and a life expectancy of at least 3 months. All patients gave written informed consent before study entry. ",NA,during the first chemotherapy cycle,NA
16880787,NA,Combination,No,"paediatric patients with relapsed or resistant solid tumours: Arm A inculded Osteosarcoma 5, Rhabdomyosarcoma 2, PNET 2, Glioma 5, Ewings 1, Astrocytoma 2, Ependymoma 2, NHL 1, Neurosarcoma 1, Hodgkins 1, Undiff nasopharngeal ca 1, Hepatocellular carcinoma 1, Malignant germinal tumour 1, Malignant adrenal cortical carcinoma 1, Choroid plexus carcinoma 1. Arm B without G-CSF:  Neuroblastoma 4, Synovial sarcoma 2, Medulloblastoma 1, Spinal PNET 1, Osteosarcoma 1, Ewings 1, PPNET 1, Hodgkins 1, Anaplastic Ependymoma 1. Arm B with G-CSF: Neuroblastoma 4, Clear cell sarcoma 1, Rhabdomyosarcoma 1, Medulloblastoma 1, Nephroblastoma 1","Patients with recurrent or resistant malignant disease, aged between 1 and 18 years, with a predicted life expectancy of more than 8 weeks, and a performance status score (Karnofsky 430 or Lansky 43) were eligible for entry",NA,during the 21 days after the first dose of DaunoXome,NA
18497430,NA,Combination,No,"advanced malignancies: Sarcoma 16, Ovarian 4, head and neck (n = 2), pancreatic (n = 2), bladder (n = 1), breast (n = 1), gastric (n = 1), non-small-cell lung cancer (n = 1), small-cell lung cancer (n = 1) and other (not specified; n = 7)","Eligibility criteria included the ability to provide informed consent, patient age >= 18, and histologically documented cancer either refractory to standard therapy or appropriate for treatment with an anthracycline. Eastern Cooperative Oncology Group (ECOG) performance status of zero or one, normal liver and renal function, and normal cardiac function as determined by a left ventricular ejection fraction (LVEF) >50% without history of signs and symptoms of cardiac disease were required. All patients with reproductive potential had to agree to practice adequate contraception. ","Exclusion criteria included prior exposure to trabectedin, prior anthracycline exposure >= 250 mg/m2, hypersensitivity to dexamethasone, peripheral neuropathy >= grade 2, or known central nervous system metastasis.",during cycle 1,NA
19082825,NA,Combination,No,"Melanoma 3, Prostate 3, Cholangiocarcinoma 2, Colon 2, Esophageal 2, Unknown primary 2, Breast 1, Transitional cell 1, Gastric 1, Small cell lung 1, Hepatocellular 1, Gallbladder 1","Eligible patients were over 18 years of age and had a histologically documented, advanced stage, primary or metastatic solid tumor, that was refractory to standard therapy or for which no curative standard therapy was available. Other inclusion criteria included: Eastern Cooperative Oncology Group performance status of 0–2; adequate bone marrow (WBC >= 3,000/ul, absolute neutrophil count >= 1,500/ul, platelet >= 100,000/ul); adequate hepatic function (total bilirubin within institutional normal limit and alanine aminotransferase, <=2.5 x the institutional upper limit of normal); adequate renal function (creatinine <= 1.5 mg/dl or measured creatinine clearance >= 60 ml/min/1.73 m2 for patients with creatinine levels about institutional normal); an LVEF >45%; and life expectancy greater than 12 weeks. All patients had to practice eVective birth control and give written informed consent indicating that they were aware of the investigational nature of the study. Before entering the study, each patient gave written informed consent, according to institutional and federal guidelines.",Exclusion criteria included the following: untreated brain metastasis; <= 4 weeks since prior chemotherapy or radiation therapy; prior treatment with an anthracycline; G6PD deWciency; major surgery within 4 weeks; active infection; and any serious concomitant conditions that would place the patient at excessive or unacceptable risk of toxicity.,during the first cycle,NA
16126736,NA,Combination,No,"patients with a variety of advanced cancers were entered into the trial: lung (n = 8), gastric (n = 4), sarcoma (n =3), gallbladder (n = 2), ovarian (n = 2), esophageal (n = 2) and one each for gastrointestinal stromal and mesothelioma.",Patients were eligible for this study if they had an incurable malignancy; measurable disease; no chemotherapy for 3 weeks prior to study entry; no radiation therapy 4 weeks prior to study entry; Eastern Cooperative Oncology Group (ECOG) performance status 0–2; anticipated survival >3 months; serum creatinine <1.5 mg/dl; bilirubin <1 mg%; serum aspartate aminotransferase <3· normal; white blood cell count >3500/mm3; platelet count >100 000/mm3. Prior doxorubicin treatment could not exceed a cumulative 300 mg/m2. Left ventricular ejection fraction (LVEF) was required to be >45% at rest. ,NA,during the first cycles of DP or DPV,NA
17609947,NA,Combination,No,metastatic breast cancer previously treated with anthracycline,"This multicenter phase-I study was conducted in patients with MBC who had prior chemotherapy with anthracycline-containing regimens either in an adjuvant setting or for metastatic disease. The patients included had not received treatment for a minimum of 4 weeks prior to commencing this trial. Other eligibility criteria included: bi-dimensionally measurable disease, age 18–70 years, Eastern Cooperative Oncology Group (ECOG) performance status <= 2, left ventricular ejection fraction (LVEF) >=45% with normal ventricular contractility, adequate bone marrow (white blood cells >3,500 per ul, neutrophils >1,500 per ul, and platelets >100,000 per ul), serum creatinine <1.5 mg/dl, serum bilirubin less than upper limit of normal (ULN), AST and ALT <3 x ULN, and absence of clinically relevant neuropathy, psychiatric illness, pregnancy or lactation. ","Patients were excluded if they had brain metastases, a positive history for other types of cancer, with the exception of in situ cervical cancer radically resected and non-melanoma skin cancer.",during the Wrst two cycles of chemotherapy,NA
15466828,NA,Combination,No,Advanced Ovarian Cancer,"The subjects of this study were untreated patients with stage IIIC or IV epithelial ovarian cancer. The histology of tumors included serous, mucinous, endometrioid, clear cell, mixed epithelial, undifferentiated, malignant Brenner, transitional cell and unclassified types. Other eligible criteria for entry into this study were as follows: (a) Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; (b) age 16–75 years; (c) adequate bone marrow function [white blood cell count (WBC) >=3000/ mm3 or absolute neutrophil count (ANC) >=1500/mm3 and platelet count >100 000/mm3], adequate hepatic function [total serum bilirubin <=1.5 mg/dl and serum aspartate aminotransferase (AST) <=2.5 times the upper limit of normal], adequate renal function (serum creatinine <1.5 mg/dl and creatinine clearance >50 ml/min) and adequate cardiac function (normal or minor deviation in electrocardiogram); and (d) written informed consent.","Patients with low potential malignancies were not included. Patients were ineligible if they had (a) severe mental disorders; (b) uncontrolled hypertension; (c) history of cardiac failure, unstable angina, myocardial infarction within 6 months prior to the study; (d) liver cirrhosis; (e) diabetes mellitus, controlled with insulin; (f) history of severe hypersensitivity or hypersensitivity to drugs formulated with polyoxyethylated castor oil (Cremophor EL) as an ingredient (e.g. cyclosporine or vitamin K); (g) hepatitis B e antigen (HBeAg) or antibody against hepatitis C virus (HCV); or (h) if they were pregnant.",in the first course of chemotherapy,NA
17852117,NA,Combination,No,Advanced Pancreatic Adenocarcinoma,"Patients aged 18–75 years with histologically or cytologically confirmed diagnosis of Stage III or metastatic pancreatic adenocarcinoma (14) were eligible for the study. Eligibility criteria included: Karnofsky performance status (PS) >50; no previous chemotherapy, adequate bone marrow (absolute neutrophil count (ANC) ≥1500 cells/mm3; platelet count ≥100,000 cells/mm3 and hemoglobin ≥10 g/dl); kidney (serum creatinine ≤1.5 mg/dL) and liver function (serum total bilirubin ≤1.5 mg/dL and serum transaminases ≤3 upper limit of laboratory normal).","Patients with prior malignancy were ineligible for the study, with the exception of those who had had basal cell carcinoma of the skin, carcinoma in situ of the cervix, or other cancer for which the patient had been disease free for at least 5 years.  Patients with ampullary tumors, or other histologic variants of pancreatic carcinoma were ineligible for the study. Patients with at least one bidimensionally measurable indicator lesion were assessable for response evaluation. ",during the first cycle of chemotherapy,NA
16107496,NA,Combination,No,metastatic breast cancer,"Patients were eligible if they were >=18 and <=75 years of age, had histologically confirmed breast cancer, Karnofsky performance status score of >= 70, measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), stage IV disease progressive after single-agent taxane or combined chemotherapy not containing a free anthracycline. Previous first-line chemotherapy with a liposomal doxorubicin for not more than six courses was allowed in presence of normal cardiac function tests. Other requirements included: normal organ functions, absolute granulocyte count >=1.5 x 109/l, hemoglobin >= 8 g/dl, platelets >= 100/l, serum bilirubin <= 1.25 times the upper limit of reference range, serum creatinine <= 2 mg/dl, normal left ventricular ejection fraction (LVEF) and life expectancy of at least 12 weeks.","Patients were excluded if they had previous adjuvant/neoadjuvant chemotherapy with anthracyclines at doses exceeding 400 mg/m2, radiation therapy to any site within 4 weeks before the study, serious cardiac disease as defined by New York Heart Association, any motor or sensory neurotoxicity grade >= 2, symptomatic brain metastases, other co-existing malignancies with the exception of basal cell carcinoma or cervical cancer in situ, pregnancy or lactating women.",during the first cycle of treatment,NA
17045160,NA,Combination,No,metastatic breast cancer,"Women with histologically confirmed, stage IV MBC (as per the American Joint Committee on Cancer Staging) with lesions not amenable to surgery or radiation of curative intent, and who met the following criteria, were eligible for the study: age 18–70 years, World Health Organization (WHO) performance status 0–2, an estimated life expectancy of at least 12 weeks, and adequate bone marrow reserve and cardiac function. Prior cancerrelated hormonal treatments were permitted, but concurrent hormonal treatment was not allowed. Patients in phase I study could have had measurable or evaluable lesions, while patients in phase II study had to have at least one bidimensionally measurable lesion. Radiation treatment within 1 week of study entry was permitted if the irradiated site was not the only site of measurable disease. Phase I patients may have received up to one prior chemotherapy regimen (adjuvant, neoadjuvant, or in the metastatic setting) if completed at least 1 month before study entry.","Patients were excluded for: 1. Prior gemcitabine therapy. 2. Cumulative epirubicin doses of 450 mg/m2 or doxorubicin doses of 300 mg/m2 during a previous regimen. 3. Abnormal bilirubin, liver transaminase, creatinine, and calcium levels. 4. Congestive heart failure (gradeX3). 5. Acute myocardial infarction and previous myocardial infarction that led to New York Heart Association grade 3 or 4 congestive heart failure. 6. Acute inflammatory cardiac disease or cardiac arrhythmias with severe impairment of hemodynamics. 7. Pregnancy or breast-feeding. 8. Active infection or serious systemic disorder considered incompatible with the study. 9. Any central nervous system metastases. 10. Previous cancer within 5 years of enrollment. 11. Secondary primary malignancy excluding cervical carcinoma in situ or basal cell carcinoma. 12. Previous high-dose chemotherapy with autologous stem cell rescue. 13. Bone metastases as the only site of disease.",during the first treatment cycle,NA
16980599,NA,Combination,No,relapsed or refractory multiple myeloma,"Eligible patients must have been older than 18 years of age, had active relapsed or refractory multiple myeloma with a measurable serum or urine paraprotein, and must have been able to understand and sign an informed consent document. Patients must have had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of zero to two, a serum bilirubin less than two times the upper limits of normal, serum transaminases (alanine aminotransferase/aspartate aminotransferase) less than three times the upper limits of normal, adequate bone marrow function [absolute neutrophil count (ANC) >1000 per ul, platelet count >100 000 per ul, and hemoglobin >8 g/dl], a serum creatinine <= 2.5 mg/dl, and a left ventricular ejection fraction >50% by echocardiogram. Patients with ECOG PS of three and four were allowed if the decline in PS was related to bony disease. Patients were considered to have refractory disease if they demonstrated progression on active myeloma therapy. Relapsed multiple myeloma was defined as the evidence of progression (increased monoclonal protein and end organ damage) after the end of active therapy. Patients with >50% plasma cells in the bone marrow were allowed to have baseline ANC <1000 per ul and baseline platelet count <100 000 per ll (i.e. no particular minimum low count mandated). Women of childbearing potential must have had a negative serum or urine pregnancy test within 1 week of receiving the study drug and must have agreed to use an adequate contraceptive method and be subjected to monthly pregnancy testing","Exclusion criteria included the presence of a severe ongoing infection requiring i.v. antibiotics, a life expectancy of <3 months, a history of prior malignancy, a history of cardiac dysfunction with New York Heart Association classification II or greater, and patients who have received >500 mg/m2 of DOX alone, Doxil (Sequus Pharmaceuticals Inc., Menlo Park, CA) alone, or DOX plus Doxil. In addition, patients with uncontrolled medical problems or conditions that would have placed the subject at an unacceptable risk from study participation were excluded. Pregnant or lactating females at screening, and patients who had developed grade 2 or greater [National Cancer Institute, Common Toxicity Criteria (NCI CTC)] allergic reaction/hypersensitivity, or grade 3 or greater (NCI CTC) rash or any desquamation during prior thalidomide therapy were excluded as well. Patients who had previously received lenalidomide were excluded. A history of prior malignancy with the exception of adequately treated basal cell carcinoma of the skin and cervical in situ carcinoma  was only allowed if the patient has been disease free for at least 5 years. Patients with solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma-cell dyscrasias were excluded.",within the first cycle of DVd-R therapy,NA
19182205,NCT00306813,Combination,No,patients with relapsed and refractory multiple myeloma,"Patients at least 18 years of age with histologically confirmed relapsed or relapsed-refractory MM were eligible after no more than 3 previous lines of antineoplastic therapy. Relapse was defined as evidence of progressive disease (PD) after at least a partial remission (PR) achieved by any preceding therapy, whereas relapsed-refractory disease was defined as progression during administration of any therapeutic regimen or within 60 days after its completion. Patients had to have measurable disease parameters and were required to have an 0 to 2 Eastern Cooperative Oncology Group (ECOG) performance status, a left ventricular ejection fraction of 55% or greater on a 2-dimensional echocardiogram, a life expectancy of at least 3 months, and (if applicable) a negative serum pregnancy test. At baseline evaluation, the following laboratory values had to be met: absolute neutrophil count (ANC) of 1.5 x 109/L or greater; platelet count (PLT) of 100 x 109/L or greater; serum creatinine below 221 uM (2.5 mg/dL); and aspartate and alanine aminotransferase levels less than or equal to 3 times the upper limit of normal (ULN).","Previous treatment with lenalidomide was not permitted. Further exclusion criteria were any antimyeloma drug therapy 4 weeks or less before study entry and anthracycline-containing regimens 3 months or less before study entry, any thromboembolic events in the patient’s history, congestive heart failure more than or equal to New York Heart Association (NYHA) class II, sensory and/or motor neuropathy of grade 2 or higher; cumulative dose of doxorubicin greater than 300 mg/m2 or equivalent, and active, uncontrolled infection",during cycle 1,NA
15675483,NA,Combination,No,"Advanced Soft Tissue Limb Sarcoma: malignant fibrous histocytoma 7 patients, liposarcoma 3 patients, synovialsarcoma 2 patients, angiosarcoma 1 patient, alveolar soft part sarcoma 1 patient.","Patients between 18-70 years of age who met all of the following criteria were eligible for entry into the study: a) histologic documentation of the disease; b) advanced soft tissue sarcoma because of extracompartmental or multicompartmental lesions, tumors with gross bone or nerve infiltration, or multiple lesions in the same limb; c) performance status (ECOG): 0; and d) informed consent.","Patients were excluded if any of the following criteria existed: a) severe cardiovascular, hepatic, or renal disease; b) severe vascular disease of the involved limb; or c) limb tumor located in the proximal third of the thigh, too close to the inguinal ligament or gluteus.",NA,NA
17095524,NA,Single Drug,No,"Ovary 6, Non-small cell lung 6, Breast 1, Esophagus 1, Thymic cancer 1","Patients with malignant solid tumors were eligible if they met the following criteria: (i) histologic or cytologic confirmation of malignant solid tumor; (ii) tumors resistant to standard therapies or for which there was no effective treatment; (iii) >= 20 years and <= 74 years of age; (iv) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2; (v) life expectancy of at least 3 months; (vi) no chemotherapy, hormonal therapy, radiation therapy, or surgery within 4 weeks prior to the registration (in case of nitrosoureas or mitomycin for previous treatment: 6 weeks); (vii) adequate bone marrow activity (white blood cell count >= 4000/ul and <= 12 000/ul, absolute neutrophil count >= 2000/ul, platelet count >= 100 000/ul, and hemoglobin level >= 9.0 g/dl), adequate hepatic function (serum total bilirubin [Tbil] level <= 1.5 times the normal upper limit, transaminase <= 2.5 times the normal upper limit), adequate renal function (serum creatinine [Cr] level <= 1.5 times the normal upper limit), and adequate cardiac function (left ventricular ejection fraction [LVEF] >= 55%) by echocardiography; (viii) no severe complications such as uncontrollable infections, heart disease, diabetes and psychogenic disorders; (ix) written informed consent given.","Patients with any one of the following conditions were excluded from the study: pregnancy or lactation; symptomatic brain metastasis; doxorubicin dose given prior to study >= 300 mg/m2; a history of hypersensitivity reactions to doxorubicin or ingredients of PLD; hepatic B or C virus or human immunodeficiency virus infection; prior extensive radiation therapy (>30% of bone marrow reserves), and others.",during the 1st cycle,NA
16891112,NA,Combination,No,previously untreated adult patients with advanced or metastatic soft tissue sarcomas,"Patients with histologically confirmed soft tissue sarcoma and with measurable lesions with evidence of progression within 6 weeks prior to treatment were eligible for the study. GIST and embryonal rhabdomyosarcomas were not included. Patient age was between 18 and 70 years. Patients with prior malignant disease or other serious medical conditions were excluded. Patients were required to have normal haematological function (white blood cell count (WBC) >= 4 x 109/1 and platelets >= 100 x 109/1), serum creatinine <= 120 umol/l or calculated clearance (Cockroft and Gault method) >65 ml/min, bilirubin <30 umol/l, albumin >=25 g/l, cardiac ejection fraction >= 50% as determined by echocardiograhic or isotopic methods. Further inclusion criteria were: World Health Organisation (WHO) performance status 0 or 1, no radiotherapy to the sole index lesion, and no previous chemotherapy for advanced disease. The study was performed in accordance with the Declaration of Helsinki and local ethics regulations. Written informed consent was obtained.",NA,NA,NA
15477860,NA,Combination,No,"Pancreas 7,  Colorectal 7, Oesophagus 3, Gall bladder 3, Stomach 2, Leiomyosarcoma 1","Patients with metastatic or recurrent solid tumours refractory to conventional chemotherapy and for whom no effective therapy was available were eligible for enrolment in this study, provided that the following criteria were met: a histologically confirmed malignant tumour; a performance status of <= 2; an age of >= 20 and < 75 years; a normal haematological profile (neutrophil count >= 2000 ul-1, platelet count >= 100 000 ul-1, haemoglobin >= 8 g dl-1); normal hepatic function (total bilirubin level <= 1.5 mg dl-1, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 times the upper normal limit); normal renal function (serum creatinine <= 1.5 mg dl-1); normal cardiac function (New York Heart Association (NYHA) classification of <= 1); normal pulmonary function (PaO2 >= 60 mgHg); no chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin C chemotherapy) of the administration of NK911; and a life expectancy of more than 2 months.","Patients with any serious infection (including hepatitis B, hepatitis C, or HIV), symptomatic brain metastasis, and pre-existing cardiac disease (including congestive heart failure, myocardial infarction, or angina pectoris within 3 months) were ineligible for enrolment in the study. Patients were also excluded if they were pregnant or lactating or showed signs of gastrointestinal bleeding. Additionally, any patients whom the investigators considered ineligible were excluded.",during cycle 1,NA
20204368,NA,Combination,No,"patients with advanced cancer (The most common diagnoses were breast cancer (n = 11), colorectal cancer (n = 8) and ocular melanoma (n = 4). One patient had each of one of the following diagnoses: melanoma, gastric cancer, hepatocellular carcinoma, pancreatic cancer, neuroendocrine cancer, adenocystic head and neck cancer and leiomyosarcoma) and dominant liver involvement  ","Eligibility criteria included a histologically conWrmed diagnosis of malignancy and liver involvement as the dominant site of metastasis, deWned as hepatic metastases constituting >=50% of all tumor burden; Karnofsky performance status ¸60%; and adequate renal (serum creatinine <= 1.5 mg/dL or a calculated creatinine clearance >50 mL/min), hepatic (total bilirubin <=1.5 mg/dL, AST <=5 times upper normal reference value, or ALT <= 5 times upper normal reference value) and bone marrow function (ANC >= 1.5 x 109/L; PLT >= 100 x 109/L). Female patients with childbearing potential were eligible if they had a negative urine or serum HCG test. Pediatric patients were eligible at the discretion of the primary investigator. Patients were eligible to start therapy if >21 days from day 1 of prior therapy had elapsed, and they had complete recovery from all associated toxicities","Exclusion criteria included clinical or radiographic evidence of ascites, pregnancy, hypersensitivity to platinum compounds or anthracyclins, inability to complete an informed consent process and adhere to the protocol treatment plan and follow-up requirements, prothrombin time >20 s or INR >2.0, portal vein thrombosis, Grade 2 peripheral neuropathy, or medical history or clinical evidence of congestive heart failure.",during the Wrst cycle,NA
16377584,NA,Combination,No,"Ovary 27, Fallopian tube 1, Head and neck 2, Esophagus 1, Unknown primary 1 ","Eligible patients had an advanced or refractory malignant solid tumor for which no standard therapy was available. Other eligibility criteria included age 18 to 70 years, Southwest Oncology Group (SWOG) performance status ≤2, fully recovered from acute toxicities of prior therapy directed to the cancer, no previous radiotherapy to the pelvis, adequate bone marrow reserve (absolute neutrophil count ≥1.5 × 109/L and platelet count ≥100 × 109/L), and adequate renal (serum creatinine concentration ≤1.5 mg/mL or creatinine clearance ≥50 mL/min) and hepatic (total serum bilirubin level ≤2× upper limit of normal [ULN] and serum AST levels ≤3× ULN) function. In addition, in patients at risk for anthracycline-induced cardiac toxicity (prior cumulative dose of doxorubicin ≥450 mg/m2, age >60 years, pre existing heart disease, hypertension, or prior radiation to the chest) baseline left ventricular ejection fraction (LVEF) ≥50 percent was required. All patients gave written informed consent before enrollment in the study.",NA,during the first cycle of chemotherapy,NA
18927308,NA,Combination,No,Patients with Soft-Tissue Sarcoma,"Patients were eligible if they were ages >= 18 years with a diagnosis of STS (any histology, metastatic disease, or recurrent/ persistent disease after initial therapy), an Eastern Cooperative Oncology Group performance status of 0-1, a left ventricular ejection fraction within normal limits, and adequate organ function. To continue treatment, patients had to meet the following criteria on day 1 of each cycle: platelets z100,000/AL; absolute neutrophil count >= 1,500/uL; direct bilirubin <= upper limit of normal; transaminase elevation grade <= 2; and alkaline phosphatase elevation, other nonhematologic drug-related effects, and creatinine phosphokinase elevation grade <= 1","Patients were excluded if they had received >1 prior chemotherapy regimen (including adjuvant), were pregnant or lactating or planning to become pregnant during or for 1 year after therapy, had been exposed previously to anthracyclines or trabectedin, had received radiation therapy <4 weeks from study entry or had radiotherapy to >20% of the bone marrow, or had known central nervous system metastasis.",during cycle 1,NA
17317836,NA,Combination,No,"Patients with MetastaticTumors to the Lungs: Primary diagnoses Sarcoma 19, Lung 16, Colorectal 6, Osteosarcoma 4, Thyroid 3, Miscellaneous 5 (One each from mesothelioma, hepatocellular carcinoma, retinoblastoma, endometrial carcinoma, and unknown primary","Patients had cancer metastatic to the lung, age >=18 years, and Karnofsky performance status >=70%. In addition to adequate bone marrow, hepatic, and renal function, patients were required to have adequate pulmonary function: diffusing capacity for carbon monoxide, forced vital capacity, and forced expiratory volume in 1s >=50% predicted; resting oxygen saturation >=90%; exercise oxygen saturation >=85%. No therapy for 3 weeks before entry was allowed, and patients must have recovered from the toxicity of prior therapy and could not have received any radiation therapy to the lungs. Chest wall or breast irradiation was allowed provided there was no pulmonary damage attributed to radiation therapy. Left ventricular ejection fraction at or above the lower limit of normal was required. Prior anthracycline use was allowed but could not be associated with cardiac toxicity or exceed a total cumulative dose of 450 mg/m2","Women could not be pregnant or breast-feeding; patients were required to use an effective contraceptive method during and for 6 months after completing therapy. Patients who had prior therapy with mitomycin (>25 mg/m2), bleomycin or nitrosoureas (>200 mg/m2), or with any pulmonary toxicity from prior chemotherapy were excluded. Similarly, patients with asthma, complete atelectasis, and pneumonectomy were excluded from participation.",NA,NA
19582371,NA,Combination,No,adult patients with metastatic soft tissue sarcomas,"Eligibility criteria were the following: histologically − proven metastatic STS or relapse within 6 months from a previous chemotherapy, with an Eastern Cooperative Oncology Group (ECOG) performance status score≤2 and life expectancy more than three months. All patients had measurable disease. Patients were required to be older than 18 years and to have absolute neutrophils ≥1.5×10 9/L and platelets ≥ 100× 10 9/L; a serum creatinine concentration ≤1.6 mg/ dL or a creatinine clearance (estimated using the Cockroft-Gault formula)≥60 mL /min; a serum bilirubin concentration≤ 1.5 mg/ dL ; serum alkaline phosphatase , AST and ALT≤ 2.5 X the upper limit of the normal (in case of hepatic metastasis≤the upper limit of the normal); cardiac ejection fraction≥50% as determined by echocardiography; no radiotherapy within 4 weeks of study entry. ",Patients were excluded if they had had prior cumulative doxorubicin exposure more than 300 mg/m2 or epirubicin exposure more than 450 mg/m2; symptomatic cerebral metastases; previous or concomitant malignancies (with the exception of cervical carcinoma in situ and cutaneous spinocellular carcinoma); active severe infections; if they were women of fertile age without effective contraception and if they had been treated with the regimen in study within 4 weeks of enrolment,until dose limiting toxicity (DLT) in at least one patient,NA
15942626,NA,Combination,No,"Breast 4, Colorectal 3, Sarcoma (leiomyosarcoma, Kaposi’s sarcoma) 2, Other (hepatoma, ovarian, head and neck, primary peritoneal, renal cell carcinoma) 5","This study was initially written and approved for treatment of patients with AIDS-related Kaposi’s sarcoma. However, given the decline in Kaposi’s sarcoma with the use of highly active antiretroviral therapy (HAART) therapy and the known activity of PEG-LD in breast and ovarian malignancies, this protocol was amended to include patients with a histologically documented resistant or recurrent malignancies. A life expectancy >4 months, age >=18 years, and laboratory parameters (haemoglobin >= 8 g dl-1, absolute neutrophil count >=1000 cells ml -1, platelet count >=75 000 cells ml-1, creatinine <=2.0 mg dl-1, SGOT <=2 x the institutional upper limit of normal (ULN), and bilirubin <1.5 x the institutional ULN) were required. Prior cytotoxic or radiation therapy had to be completed 4 weeks prior to enrollment. Prior chemotherapy with PEG-LD and doxorubicin was permitted.","Patients with congestive heart failure or neuropathy (motor or sensory), or with a history of prior PEG-LD or cyclosporine A hypersensitivity were excluded. Any patient receiving medications that are metabolised by the cytochrome P450 system including calcium channel blockers, imidazole antifungal agents, anticonvulsants, or macrolide antibiotics had to discontinue these medications 48 h prior to valspodar therapy, during valspodar administration and up to 48 h after the last dose of valspodar in a cycle. ",during the second cycle,NA
16891870,NA,Combination,No,Pretreated Ovarian Cancer Patients,"Patients included in this study presented with histologically proven ovarian carcinoma treated by one or several lines of prior chemotherapy, including at least 1 platinum salt based regimen. Patients were to be over 18 years of age with a life expectancy of at least 3 months, World Health Organization (WHO) performance status of <=2, a left ventricular ejection fraction (LVEF) >= 50%, creatinine clearance >= 60 mL/min, serum total bilirubin <1.25 Upper Limit of Normal (ULN), transaminases and alkaline phosphatase 2ULN (or 3ULN if hepatic metastases present), absolute neutrophil count (ANC) > 1.5 x 109/L, platelet count >100 x 109/L, hemoglobin >9 g/dL. Patients were to present with measurable or evaluable disease and/or a CA 125 level > 40 U/mL. In the case of pretreatment with anthracyclines, the total prior dose of epirubicin or doxorubicin was to be lower than 750 mg/m2 and 450 mg/m2, respectively. A delay of 4 weeks between the end of previous treatment and inclusion in this study was enforced. The protocol was approved by the Ethics Committee of the Poitou-Charentes region. Informed written consent was to be obtained before the inclusion of each patient",NA,during the first 2 cycles,NA
15528980,NA,Combination,No,"locally advanced, inoperable or metastatic cancer with 1) Malignancy type: Gastric 20, Head and neck 1, Other malignancy 3, Unknown primary 1; 2) Sites of evaluable metastatic disease: Abdomen/pelvis 13, Adrenal 2, Bone 1, Liver 10, Lung 4, Nodes 10, Ovary 1","Inclusion criteria included: histological or cytological proof of inoperable locally advanced or metastatic cancer, ECOG performance status less than or equal to 2, life expectancy of more than 12 weeks, age ≥18 years and ≤75 years, no prior chemotherapy for advanced disease, no radiation therapy for 4 weeks prior to starting therapy, creatinine ≤ upper normal limit (UNL) unless creatinine clearance >65 mL/min, bilirubin ≤ UNL, AST or ALT ≤2× UNL or ≤3 × UNL if liver metastases, absolute granulocytes ≥1.5 × 109/L, platelets ≥100 × 109/L, patients accessible for treatment and follow-up. Patients who had received prior anthracycline therapy were eligible only if they had not received more than 50% of the recommended total cumulative dose (i.e. <240 mg/m2 doxorubicin).","Ineligibility criteria included: previous malignancy other than localized basal or squamous cell skin carcinoma or non-invasive cervix cancer, pregnant or lactating women, brain or meningeal metastases, active or uncontrolled infection, evidence of congestive heart failure or myocardial infarction within 6 months or LVEF <50%, concurrent therapy with other experimental drugs or anticancer therapy, other serious illness not permitting patients to be managed according to protocol.",during the first cycle of therapy,NA
19997959,NA,Combination,No,"advanced malignancies: Primary tumor type Esophagus 3, Sarcoma 1, Breast 1, Pancreas 1, Non-small cell lung 1, Renal 1, Thyroid, differentiated 1, Adenoid cystic carcinoma 1, Bladder 1, Hepatocellular 1, Prostate 1, Stomach 1, Colon 1","Eligible patients were at least 18 years of age and had a histologically documented, advanced stage solid tumor that was refractory to standard therapy or for which no curative standard therapy was available. Other inclusion criteria included: Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; absolute neutrophil count ≥1,500/mm3, platelet count ≥100,000/μL; total bilirubin <1.5 mg/dL; aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤2 x the institutional upper limit of normal; serum creatinine ≤2.0 mg/dL; adequate left ventricular function (> 45% at rest); and willingness and ability to provide written informed consent.","Exclusion criteria included: lifetime cumulative doxorubicin exposure >300 mg/m2; history of myocardial infarction, congestive heart failure, or clinically significant ventricular arrhythmias; ≤4 weeks since prior chemotherapy or radiation therapy; enrollment in a clinical trial using another anti-neoplastic or investigational agent given during the planned course of doxorubicin and MGd; pregnant or lactating women; history of porphyria (testing not required at screening); history of glucose-6-phosphate dehydrogenase (G6PD) deficiency (testing required at screening unless a prior test result was available); ≤14 days since ingesting multidrug resistant modulating drugs, such as cyclosporine; or an inability to complete specified follow-up assessments.","period through cycle 1 day 29 for Group A patients, and cycle 2 day 22 for Group B patients",NA
16755180,NA,Combination,No,Metastatic Breast Cancer,"Women included in this study had MBC with at least one measurable target lesion. For patients with only one target lesion, histologic or cytologic confirmation was required. Patients should not have received chemotherapy for advanced MBC, were to be aged 18 or over and have a performance status <=2. In the case of prior adjuvant or neoadjuvant chemotherapy, the interval between the end of chemotherapy and inclusion should have been >6 months. The cumulative prior anthracycline dose was to be <300 mg/m2 doxorubicin or <600 mg/m2 epirubicin. Hormone therapy was to be discontinued before initiation of study treatment. Patients were to have an isotopic left ventricular ejection fraction (LVEF) >50%, and a biologic profile compatible with treatment (absolute neutrophil count >=1500/uL; platelet count >=100,000/uL; creatinemia <=1.5 N; bilirubinemia <=1.5 N; transaminases <=2.5 N; alkaline phosphatases <=2.5N). Each patient gave written informed consent before inclusion in the study.","Patients were ineligible for inclusion if they presented  inflammatory breast cancer; were pregnant or breast-feeding; were not using effective contraception for premenopausal patients; presented severe uncontrolled infection, unstable cardiac pathology, cerebral metastasis, peripheral neuropathy >= grade 2, or allergy to cremophor EL; or had received prior radiotherapy to more than 30% of bone marrow.",during the first cycle,NA
18502128,NA,Combination,No,Asian women with metastatic breast cancer,"Patients were eligible for the study if they had metastatic breast cancer with clinically measurable disease as defined by at least one bidimensionally measurable lesion (WHO criteria); performance status 0-2 and had no prior chemotherapy for metastatic disease. Prior adjuvant chemotherapy was allowed if completed at least 12 months ago and cumulative anthracycline dose did not exceed 240 mg/m2. Patients were required to have left ventricular ejection fraction of at least 50% and adequate bone marrow, hepatic and renal functions.","The exclusion criteria were inflammatory breast cancer; active cardiac disease, clinical evidence of central nervous system metastases or serious concomitant systemic disorders including active infection.",the first 3 cycles,NA
16520906,NA,Combination,No,Advanced Uterine Cervix Carcinoma ,"Patients with histologically documented FIGO stage IIB–IVA cervical carcinoma with no prior RT or chemotherapy were eligible for the study. Other inclusion criteria were age 40–80 years, performance status (ECOG) 0–2, hemoglobin (Hb) > 12.5 g/dl, white blood count > 4,000/µl, absolute neutrophil count (ANC) > 2,200/µl, platelets (PLT) > 120,000/µl, normal liver, renal and cardiac function, measurable disease on CT/MRI scan or by clinical examination, as well as absence of a second primary tumor.","Patients with major heart, lung, psychiatric and allergic disease, or with active infection and malnutrition were excluded from the trial.",during the whole duration of CCRT and for the following 4 weeks after treatment completion,NA
18525299,NA,Combination,No,"advanced solid tumors: Lung 19, Gastrointestine 13, Head and neck 6, Miscellaneous 11","Eligibility criteria for patients in this study included: a biopsy-proven diagnosis of advanced solid cancers not curable by surgery, radiation therapy, or standard chemotherapy; measurable disease; Zubrod performance status of 0 to 2; age of older than 18 years; life expectancy of greater than 12 weeks; adequate hematologic (absolute neutrophil count >1500/mm3 and platelets >100,000/mm3), hepatic (total bilirubin and aspartate transferase <2 x upper limit of normal), and renal (serum creatinine <1.5 mg/dL) functions. Prior chemotherapy was allowed excluding irinotecan and anthracyclines. Patients were stratified by prior chemotherapy status for subsequent analysis. All patients signed informed consent and the study was conducted in accordance with the guidelines of the Institutional Review Board.",NA,until reaching DLT,NA
16503137,NA,Combination,No,"gemcitabine and imatinib: Desmoid tumour (n=1), Neuroendocrine carcinoma (n=1), Metastatic angiosarcoma (n=1), Adrenocortical carcinoma (n=2), Leiomyosarcoma (n=1), Non-small cell lung carcinoma (n=1)doxorubicin and imatinib:  Poorly differentiated carcinoma (n=1), Adenocarcinoma – pancreas (n=1), Leiomyosarcoma (n=4), Adenoid cystic carcinoma (n=1), Metastatic angiosarcoma (n=1), Adenocarcinoma – gastric (n=1)","The following eligibility criteria were required: patients with solid tumour malignancies for which there were no standard effective therapies; Eastern Cooperative Oncology Group performance status 0–2; estimated life expectancy of at least 3 months; no prior radiation therapy or systemic cancer therapy within 4 months; no major surgery within 2 weeks; full recovery from any toxic effects of prior treatments; no other active primary malignancy; no other severe and/or life-threatening medical condition including, symptomatic congestive cardiac failure within 6 months of study entry , acute or chronic liver disease or HIV infection; absence of pregnancy or lactation and willingness to use contraception. All patients gave written informed consent prior to study entry as per federal and institutional guidelines. Patients were required to have adequate end-organ function. Specific eligibility criteria for the doxorubicin and imatinib combination included a lifetime cumulative doxorubicin dose of <300 mg/m2; absence of prior cardiac irradiation; left ventricular ejection fraction within normal limits.","In the study of each combination, the study rules were amended after the first dose cohort was treated to exclude patients who had received more than one prior chemotherapy regimen, or who had received prior pelvic irradiation (see Section 3 for further detail about the toxicities that led to this amendment).",during cycle 1,NA
15367419,NA,Combination,No,"tumor types: Unknown primary 12, NSCLC 5, Ovarian 3, Thyroid 2, Breast 9, SCLC 3, Sarcoma 2, Mesothelioma 2, Renal, head and neck, melanoma, bladder,, lachrymal gland, hepatoma 1","Eligibility criteria for all patients included age >17 years, World Health Organization (WHO) performance status 0–2, life expectancy of at least 12 weeks, sufficient cardiac function defined by absence of symptoms and a left ventricular ejection fraction (LVEF) of at least 60%, adequate bone marrow [white blood cell count (WBC) >3.5 x 109, absolute neutrophil count (ANC) >1.5 x 109, platelet count >100 x 109), renal (serum creatinine _<150umol/l) and hepatic [serum bilirubin <1.25 x upper limit of normal (ULN), serum transaminases <2 x ULN or <5 x ULN in the presence of liver metastases] functions, and absence of clinically relevant neuropathy, psychiatric illness, pregnancy or lactation. All patients were required to have histologically or cytologically proven locally advanced or metastatic solid tumors. Any previous chemotherapy should have been discontinued at least 4 weeks (6 weeks for nitrosoureas, melphalan, mitomycin C) before enrollment. Extended-field radiotherapy should have been stopped at least 6 weeks prior to study entry, whereas concurrent limited field radiotherapy was allowed.",NA,during all cycles of chemotherapy,NA
10942057,NA,Combination,No,advanced nonHodgkin's indolent lymphoma,"Patients with the following histologies were eligible: follicular center-cell lymphoma (grades I—III), B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma, mantle-cell lymphoma, and marginal zone lymphoma (including nodal monocytoid B-cell lymphoma and low-grade MALT lymphoma). Patients were men or non-pregnant women (the latter confirmed by negative serum pregnancy test) at least 18 years of age. and if of child-bearing potential, practicing an effective means of contraception. Patients with recurrent disease could have received any number of prior therapies (radiotherapy or chemotherapy), which was to have been discontinued at least 30 days prior to enrollment. Patients who had not received prior therapy who had greater than stage IIA contiguous disease were also eligible. Patients were to be free of active infection, have adequate renal function (serum creatinine <= 2.0 mg/dl), hepatic function (AST, ALT, total bilirubin, and alkaline phosphatase <= 3 times upper limit of normal except when due to lymphoma). They were to have adequate hematologic function (absolute neutrophil count [ANC] >= 1500/mm3, platelet count >= 75 x 109/l, hemoglobin >=10 mg/dl). Cardiac function needed to be adequate (left ventricular ejection fraction [LVEF] >= 45% by multiple-gated acquisition [MUGA] scan or normal echocardiogram), an Eastern Cooperative Oncology Group (ECOG) performance status <= 3, and an expected survival >= 12 weeks. Patients must have had bi-dimensionally measurable lymphomatous lesions (not previously irradiated) or pathologic involvement of an accessible site of disease that could be re-biopsied over the course of the study (e.g., bone marrow involvement) or a site that was evaluable but not bi-dimensionally measurable (e.g., pleural or peritoneal effusion).",Patients with other malignancies (except non-melanoma skin cancer or carcinoma in situ of the cervix) and those previously treated with anthracyclines were excluded.,NA,NA
10850343,NA,Combination,No,"Tumor type: Breast 13, Sarcoma 4, Non-small cell lung cancer 4, Colon 4, Ovarian 2, Non-Hodgkin's Lyrnphoma 3, Hodgkin's Disease 1, Acute Myeloid Leukemia 1, Bladder (transitional cell) 1, Mesothelioma 1","Patients with advanced solid tumors who were not curable by standard treatment and had failed chemotherapy, usually a doxorubicin-containing regimen, were eligible. Patients were required to have a projected life expectancy of > 12 weeks and a Karnofsky performance status of at least 60%. Normal liver and adequate kidney function (creaturine clearance >= 50cc per min), normal clotting and stable bone marrow function (white blood count >= 3000/mm3, platelet count >= 100,000/mm3) and normal EKGs and an ejection fraction > 45% were required.","Women of childbearing age were excluded or had to be on an effective birth control method. Patients with significant coronary artery disease, cardiac arrhythmias or other active cardiac disease were not eligible. Patients were excluded ifradiation therapy had been given within one week of entering study or ifchemotherapy or other forms of systemic therapy were used within four weeks of entry.",NA,NA
10870069,NA,Combination,No,Neuroblastoma,"Patients ages birth to 21 years with neuroblastoma were eligible for this study if they had Evans Stage III or IV disease that had failed to respond or was resistant to initial chemotherapy, or had Stage I, II, or IV-S disease at the time of initial diagnosis with subsequent progression to Stage IV. Children with peripheral neuroepithelioma (primitive neuroectodermal tumor [PNET]) were eligible if they had residual unresectable tumor or metastatic disease at diagnosis or if they had developed disease recurrence during or after other chemotherapy. Other eligibility criteria were a life expectancy of at least 2 months, Karnofsky performance status of >= 70, and full recovery from the toxic effects of any previous therapy.","Exclusion criteria were a total lifetime doxorubicin dose > 250 mg/m2 or 150 mg/m2 with mediastinal or total body irradiation (TBI) of > 1000 centigrays; total cisplatin dose > 500 mg/m2; administration of the same 4 drugs in a similar format within 6 months of entry on this study; and prior bone marrow transplantation, TBI, or radiotherapy to > 50% of the bone marrow space.",the first course of therapy,NA
10907958,NA,Combination,No,platinum-resistant or refractory advanced ovarian cancer,"Eligibility criteria were a cytologically or histologically proven epithelial ovarian cancer resistant (i.e., relapsed more than one year after completion of platinum-based treatment) or refractory (i.e., progressed during platinum-based treatment or relapsed within one year of completion of platinum-based treatment) to prior platinumpaclitaxel containing chemotherapy, age < 70 years, performance status <3 according to the ECOG classification, white blood count >4000/mm3, platelet counts > 100,000/mm3, serum creatinine < 1.5 mg/dl, SGOTand SGPT < 1.25 x upper normal value, bilirubin < 1.25 x upper normal value. Informed consent was provided by each patient",Patients previously treated with anthracyclines were not eligible.,during cycles 1-4 ,NA
10343189,NA,Combination,No,Platinum-Resistant Advanced Ovarian Cancer,"Eligibility criteria were a cytologically or histologically proven epithelial ovarian cancer resistant (i.e. relapsed within 1 year from completion of platinum based treatment) or refractory (i.e. progressed during platinum-based treatment) to prior platinum containing chemotherapy, age <=70 years, performance status <3 according to the ECOG classification, white blood count >4000/mm3, platelet counts >100,000/mm3, serum creatinine <1.5 mg/dl. SGOT and SGPT <1.25 x upper normal value, bilirubin <1.25 x upper normal value. Informed consent was provided by each patient.",Patients previously treated with paclitaxel or anthracyclines were not ineligible.,during cycles 1 to 4,NA
9887248,NA,Combination,No,Previously Untreated Epithelial Ovarian Cancer,"Patients with histologically documented advanced ovarian cancer requiring chemotherapy were eligible for enrollment in the protocol. Other eligibility criteria included adequate hematologic, renal, and hepatic function. All patients were initially evaluated by echocardiogram or MUGA scan to evaluate for cardiac dysfunction prior to administering doxorubicin. In addition, all patients had to have a GOG performance score of less than or equal to 2. Informed consent was obtained prior to beginning the regimen","Patients were ineligible if they were less than 18 years old, pregnant or lactating at the time of diagnosis, or if they had a history of other malignancies (other than basal cell carcinoma of the skin).",NA,NA
10321510,NA,Combination,No,metastatic breast cancer,"Eligible patients had histologically documented breast cancer which was metastatic and included at least one measurable or evaluable lesion. Patients had not received prior chemotherapy for metastatic disease, but adjuvant chemotherapy or hormonal therapy was permitted. Eligible patients had either estrogen receptornegative tumors or estrogen receptor-positive tumors which had relapsed or progressed through at least one endocrine therapy. Other inclusion criteria were as follows: less than 250 mg/m2 lifetime doxorubicin treatment, prior radiation therapy to no more than 25% of the marrow-containing bones, age over 18 years, Eastern Cooperative Oncology Group (ECOG) performance status <=2, white blood cell count (WBC) >3500/mm3, platelet count >125 000/mm3, creatinine <1.5 mg%, bilirubin <1.5 mg% and aspartate aminotransferase (AST) <60 iu/ml, unless the abnormalities were due to metastatic involvement. Patients were also required to have adequate cardiac function, as demonstrated by a left ventricular ejection fraction >= 45% by gated blood pool imaging. Adequate pulmonary function with diffusing capacity for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), and forced vital capacity (FVC) at least 60% of predicted values was required due to one incidence of allergic pneumonitis in the pilot study.","Exclusion criteria were active cardiac illnesses such as congestive heart failure, angina pectoris, arrhythmia, or myocardial infarction within the preceding 12 months; other major medical illnesses such as uncontrolled diabetes mellitus; and pregnancy",in course one,NA
10573115,NA,Combination,No,advanced breast cancer,"Candidates for this study were women with histologically/cytologically proven locally advanced (T4 or N2 M0) or with metastatic breast cancer who had not received prior chemotherapy (except adjuvant). Previous radiotherapy or hormonal therapy was allowed; radiotherapy had to have involved less than 50% of the bone marrow, and had to have terminated at least four weeks before study entry. Other eligibility criteria included clinically or radiologically measurable or evaluable disease, age between 18 and 75 years, Zubrod performance status of 0–2, life expectancy of at least 12 weeks, no previous or concurrent malignancy except for inactive nonmelanoma skin cancer and in situ carcinoma of the cervix, or other cancer if the patient had been diseasefree for more than five years. Adequate bone marrow (absolute neutrophil count ≥ ×109/l, platelet count ≥ 100 × 109/l, and hemoglobin level ≥ 100 g/l), liver function (bilirubin level < two times the upper normal limit, AST and/or ALT < three times the upper normal limit, prothrombin time < 1.5 times control), and renal function (creatinine clearance ≥ 60 ml/min) were also required.","The presence of CNS metastases, severe cardiac arrhythmia or heart failure, second or third degree heart block, or acute myocardial infarction within four months prior to study entry were considered as exclusion criteria. ",in the first six treatment cycles,NA
11106111,NA,Combination,No,aggressive non-Hodgkin's lymphoma,"Eligibility criteria were as follows: patients with intermediate- and high-grade non-Hodgkin's lymphoma (NHL), according to the Working Formulation ; clinical stage of II, III or IV, by the Ann Arbor system; aged 15-65 years; and a good performance status (PS 0-2) by the Eastern Cooperative Oncology Group (ECOG) criteria. Patients whose lymphoma had been treated with radiotherapy alone were eligible for the study, but prior chemotherapy was not allowed. Other eligibility criteria included neutrophil count >= 1500/ul, platelet count >= 100,000/ul, aspartate amino-transferase (AST) and alanine amino-transferase (ALT) levels <=2.0 times the upper limit of the normal range, BUN and serum creatinine level within the normal limit, PaO2 level >=70 mmHg and normal cardiac left ventricular ejection fraction (>=50%). Pre-treatment staging procedures included a physical examination, complete blood cell counts with differential and platelet counts, biochemical examination, bone marrow aspiration and biopsy, chest X-ray, computed tomography scanning of the chest and abdomen, and gallium scincigraphy","Patients with lymphoma involving the central nervous system were ineligible. Patients with mycosis fungoides, Sezary's syndrome, adult T-cell leukemia/lymphoma and lymphoblastic lymphoma were excluded. Patients with diabetes mellitus requiring insulin therapy were ineligible.",in the first cycle of therapy,NA
9215819,NA,Combination,No,Advanced Breast Cancer,"Patients with hystologically confirmed breast cancer and metastatic disease with at least one bidimensionally measurable lesion were eligible for the study. Other eligibility criteria included age less than 70 years; Eastern Cooperative Oncology Group (ECOG) performance status <= 1; absolute neutrophil count (ANC) greater than 1,500/uL and platelet count greater than 100,000/u/L; normal function tests for liver (bilirubin < two times upper normal limit) and kidneys (creatinine concentration < two times upper normal limit); and left ventricular ejection fraction (LVEF) greater than 50% at bidimensional ultrasonography. Prior adjuvant therapy was allowed if stopped at least 6 months before study entry. Adjuvant anthracycline-based therapy was allowed if the total cumulative dose was less than 180 or 360 mg/m2 in case of doxorubicin or epirubicin, respectively. Patients must have received no prior chemotherapy for metastatic disease, while prior endocrine therapy was permitted.",NA,during the first two courses ,NA
9848577,NA,Combination,No,advanced breast cancer,"The following inclusion/exclusion criteria determined patient eligibility: histologic or cytological diagnosis of stage IV breast adenocarcinoma; age ≥ 18 years; Karnofsky performance status of ≥ 60; life expectancy ≥ 12 weeks; adequate bone marrow reserve with leucocytes > 3.5 × 109/L, platelets > 100 × 109/L and hemoglobin > 10 g/dl; no previous or current CNS metastases (or prior radiation for CNS metastases); no second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin); adequate liver, renal and blood-clotting function; calcium within normal limits; no serious concomitant systemic disorders (e.g, congestive heart failure) or active infection; childbearing potential terminated or use of contraceptive methods. Inclusion criteria relating to previous treatment were as follows: prior radiotherapy was allowed, provided radiation was finished 4 weeks before study entry; no prior chemotherapy for stage IV breast cancer (patients with adjuvant chemotherapy were admissible although therapy had to have been completed 1 year prior to enrollment); no previous gemcitabine treatment; prior treatment with anthracyclines was allowed provided the doses did not exceed 420 mg/m2 of epirubicin or 240 mg/m2 of doxorubicin; no other investigational agent within 4 weeks of enrollment.",NA,during the first cycle of therapy,NA
10949988,NA,Combination,No,Advanced Breast Cancer,"Pre and postmenopausal women with histologically confirmed breast cancer and metastatic disease with at least one bi-dimensionally measurable lesion, were eligible for the study. Other eligibility criteria included: age lower than 75 years; life expectancy over 3 months; ECOG performance status 0-2; absolute neutrophil count (ANC) greater than 1,500/mm3; normal function tests for liver (bilirubin < two times upper normal limit); left ventricular ejection fraction (LVEF) greater than 50% and bi-dimensional ultrasonography",NA,NA,NA
9193334,NA,Combination,No,"Advanced Soft Tissue Sarcomas:Malignant fibrous istiocytoma 9, Leiomyosarcoma 10, Sinovial sarcoma 3, Liposarcoma 2, Other 13","Consecutive patients with histologically verified, locally advanced inoperable and/or measurable metastatic soft tissue sarcomas of any site were considered eligible for this study. The protocol was approved by the ethical committee and patients were requested to give oral informed consent according to the rules of our institution. Patients were required to have adequate hematologic (WBC count > 4,000/uL and platelet count > 100,000/uL). renal (creatinine concentration < 1.2 mg/dL), hepatic (alkaline phosphatase, AST, and ALT < two times upper limts of normal function), and cardiac (normal ECG and echography with a left ventricular ejection fraction > 60%) functions. Furthermore, only adult patients (>= 18 and <= 65 years) with a performance status <= 2 and a life expectancy of more than 3 months were enrolled onto the study","Exclusion criteria were previous chemotherapeutic treatment, prior radiotherapy on parameter lesions, previous or concurrent malignancies, uncontrolled infections, and pregnancy.",the first three consecutive cycles,NA
9150898,NA,Combination,No,women with metastatic breast cancer,"This trial involved women with histologically confirmed breast cancer which was metastatic. There must have been histologic or cytologic proof of metastatic disease except in the case of multiple pulmonary nodules or multiple areas of bone metastasis documented radiographically which were known to be new or progressive. Patients could have received prior adjuvant systemic therapy and could have received no more than one prior chemotherapeutic regimen for metastatic disease. Prior doxorubicin was allowed so long as the cumulative dose was no more than 250 mg/m2. Patients could have disease that was measurable, evaluable, or nonevaluable. To be considered measurable, a lesion on physical examination or chest radiograph must have had clearly measurable perpendicular diameters with a diameter of at least 1.0 cm, or in the case of hepatomegaly, a liver edge palpable 5 cm or more below a costal margin or a xiphoid. When a CT scan, MRI or ultrasound was utilized, a diameter must have been at least 3.0 cm; and when a radioisotope liver scan was employed, a diameter must have been at least 5.0 cm. The evaluable disease designation required lesions that could clearly be evaluated but that were not bidi-mensionally measurable. A nonevaluable designation required that disease be present that did not fulfill criteria for either measurable or evaluable. Examples of nonevaluable disease are malignant pleural effusions or ascites and blastic or mixed lytic/blastic osseous metastases. The Eastern Cooperative Oncology Group (ECOG) performance score must have been 2 or better. Patients could not have received radiation to more than 15% of the marrow. The white blood cell (WBC) count must have been at least 3500/µL or absolute neutrophil count (ANC) at least 1800/µL, and the platelet count at least 100,000/µL. Serum calcium must have been less than 10%, serum total bilirubin less than 0.8 mg/dL, and serum creatinine < 0.8 mg/dL above the upper limit of institutional normal. Patients must not have had a history of congestive heart failure, angina pectoris, myocardial infarction within 4 months, bilateral bundle branch block, cardiac arrhythmia requiring digitalis or other cardiac medication, and the cardiac ejection fraction, as determined by MUGA or echocardiogram, must have been at least 50%. This trial was performed after approval by local institutional review boards and in accord with assurances filed with and approved by the Department of Health and Human Services (DHHS). Written informed consent was provided by each patient before entry on study",NA,in cycle one ,NA
9402167,NA,Combination,No,patients with metastatic breast cancer,"Patients were eligible if they had MBC, with at least one measurable or evaluable lesion according to World Health Organisation (WHO) criteria , and were without brain metastasis and/or meningeal disease. Age below 55 years, and a WHO performance status =S 2 were additional entry criteria. Prior chemotherapy was not allowed, except for non-anthracycline containing adjuvant chemotherapy at least one year before study entry. Pre-treatment assessment included a medical history and physical examination, chest X-ray, bone scan, abdominal CT scan, ECG, left ventricular ejection fraction (LVEF) and baseline laboratory investigations. Adequate bone marrow function (white blood cell count (WBQ >=4.0 x 1O9/1, platelets >= 100 x 1O9/1), renal function (creatinine clearance >=60 ml/min) and hepatic function (bilirubin <=25 um/1, AF, SGOTand SGPT <=2x normal value) wererequired. ",Patients with a LVEF <= 50% were excluded,in the 3 cycles,chemotherapy was given for three cycles with G-CSF mobilised peripheral blood progenitor cell (PBPC) reinfusion 
10370782,NA,Combination,No,metastatic breast cancer,"Patients with histologically proven breast cancer with measurable or evaluable metastatic disease who had not received any prior chemotherapy for metastatic disease were eligible for this study. Evaluable disease was defined as lytic bone disease measuring >= 1 cm. Patients who had received adjuvant chemotherapy were eligible if they had not received doxorubicin or if they had adequate cardiac function and had relapsed > 6 months after completion of a doxorubicin-containing regimen with a cumulative total dose of < 301 mg/m2 for doxorubicin administered by intravenous bolus or < 401 mg/m2  for doxorubicin given by 48-hour or longer infusion. Adequate cardiac function for patients who had received prior anthracyclines or anthracenediones was specified as a left ventricular ejection fraction (LVEF) >=65% without wall motion abnormalities or a LVEF of 50%-64% but an endomyocardial biopsy score of grade < 1 . Patients without prior exposure to cardiotoxic agents were required to have a LVEF of >= 60%. All patients were required to have a functioning central venous catheter. Other eligibility criteria were the standard criteria for a phase I study. No other simultaneous chemotherapy, hormonal therapy, immunotherapy, or radiotherapy could be administered. Patients were required to have sufficient physiologic reserve to tolerate the toxic effects of therapy. This included life expectancy of >= 12 weeks, Zubrod  performance status of <3, adequate hematologic reserve (absolute granulocyte count of >= 1,500 cells/ul and a platelet count of >= 100,000/ul); adequate hepatic function (serum bilirubin level <1.5 mg/ml); and adequate renal function (serum creatinine level <1.4 mg/ml). Before treatment, all patients gave written informed consent according to institutional and federal guidelines. All patients were","Because of the risk of anaphylactoid reactions following the administration of paclitaxel, patients were not eligible if they had a history of significant cardiac disease, such as serious arrhythmias requiring antiarrhythmic medication, a history of myocardial infarction within the past six months, or Mobitz type II or third-degree atrioventricular conduction system abnormalities uncorrected by cardiac pacemaker. ",NA,NA
11244325,NA,Combination,No,"patients with advanced refractory solid tumors.  For Paclitaxel-ifosfamide, Primary tumor site: Ovary 7,  Breast 7, Bladder 1, Testis 1; For Paclitaxel-epirubicin, Primary tumor site: Ovary 4,  Breast 6","Patients aged 18 years or older with histologically confirmed breast or ovary carcinoma who had failed at least one frontline chemotherapy for metastatic disease and had either measurable or evaluable disease were eligible. Prior treatment with adjuvant chemotherapy was allowed. Other requirements included: (1) ECOG performance status of 0–1, (2) normal organ function with absolute neutrophil count >= 1,500/Ìl, platelet count >= 100,000/Ìl, serum creatinine concentration <= 1.5 mg/dl, and serum bilirubin level <= 1.5 mg/dl, (3) no prior taxane treatment in both phase I studies was allowed, (4) no prior anthracycline treatment for patients assigned to the taxol-epirubicin combination, (5) no symptomatic heart disease or previous history of cardiac arrhythmias or myocardial infarction, (6) normal LVEF (greater than 50%) as measured by radionuclide angiography or echocardiography within 4 weeks of registration, (7) no obvious neurotoxicity in patients previously treated with platinum-based regimens, and (8) written informed consent.",NA,during the first cycle of therapy,NA
10509151,NA,Combination,No,"Patients with non-Hodgkin's lymphoma and advanced solid tumors. Tumor type: Breast 13, Lung 6, Oesophagus 1, Kidney 3, Liver 2, Uterus 2, Stomach 1, Germ cell 1,  Prostate 1, Unknown 5","All patients in stages I and II had a histological diagnosis of advanced cancer for which epirubicin may be indicated. Patients in stage III of the study had intermediate or high grade NHL and had received no prior cytotoxic therapy. Protocol patients were required to have an ECOG performance status <= 2 and were aged between 18 and 70 years. Adequate baseline organ function was necessary, documented by creatinine < 176 umol/l (2.0 mg/dl), bilirubin <35 umol/l (2.0 mg/dl) and AST (SGOT) < 3 x upper normal limit, normal bone marrow function with granulocytes > 2.0 x 109/l and platelets > 100 x 109/l, and a normal baseline left ventricular ejection fraction (LVEF) on multiple gated acquisition scan (MUGA). Patients may have received prior radiotherapy, provided it did not involve > 35% of red bone marrow and they had recovered from any acute radiationinduced toxicities. Patients were required to be able to comply with scheduled follow-up visits.","Patients were excluded if they had any significant cardiac history or ECG changes, a history of other malignancy other than localised basal or squamous cell carcinoma of the skin or non-invasive cervical cancer, clinical or radiological evidence of brain metastases, evidence of an active infectious process, evidence of myeloid malignancy, psychiatric disorders compromising informed consent, or if they were either pregnant or currently breast feeding",within cycle 1,NA
9488597,NA,Combination,No,"patients with advanced solid tumors. Primary tumors: colon 9, kidney 3, synovial sarcoma 1, rectum 2, colorectum 3, breast 4, secondary sarcoma 1, hemangiopericytoma 1, renal calix/urothelium 1, unknown 1","Patients included in the present study had a histologically or cytologically con®rmed malignant solid tumor for which no potential curative therapy was available. Patients with kidney or colon cancer were preferably chosen due to more frequent intrinsic MDR in these situations. Eligibility criteria included the following: an age of between 18 and 75 years; no chemotherapy or radiotherapy within 4 weeks of entry; in case of prior doxorubicin therapy, a cumulative doxorubicin dose of < 400 mg/m2; an ECOG/WHO performance status of <= 2; evidence of progression within the last 2 months; the possibility of repeated blood sampling; adequate hematologic, kidney, liver, and heart function, de®ned as a WBC count of >= 4,000/ul, a platelet count of >= 100,000/ul, a hemoglobin value of >= 10 g/dl, total bilirubin, transaminase, alkaline phosphatase, and creatinine levels of <= 1.25 times the upper limit of normal, and a left ventricular ejection fraction (LVEF) of >40% as determined by ultrasonography; and, finally, written informed consent.","Ineligibility criteria included recent myocardial infarction, arrhythmia, angina pectoris, or cardiac failure; sequelae of prior abdominal radiotherapy; concomitant uncontrolled infection or severe pathology; and pregnancy or lactation. ",NA,NA
10501914,NA,Single Drug,No,"solid tumors: Colon 5, Pancreas 2, Other 1","Adult patients, aged 18 to 75 years, with microscopically con®rmed diagnoses of solid tumors not amenable to conventional local or systemic treatments, were eligible for the study. Patients must have recovered from all acute toxic effects of prior therapy and a minimum of 4 weeks must have elapsed from the end of their last chemotherapy or radiotherapy (6 weeks in case of nitrosoureas and mitomycin C). Eligibility criteria included: an ECOG performance status (PS) of 2 or less; life expectancy of 3 months or more; a maximum cumulative dose of prior anthracyclines of 250 mg/m2 of Dx equivalents; a left ventricular ejection fraction (LVEF) as assessed by echo or MUGA scan above the lower limit of normal; adequate bone marrow (neutrophil count >= 2.0 x 103/ul, platelet count >= 100 x 103/ul), liver (bilirubin, ALT/AST within normal limits) and renal function (serum creatinine within normal limits); alkaline phosphatase not more than 2.5 times the upper limit of normal (unless secondary to malignancy, for which a value not more than 2.5 times the upper limit of normal of ALT/AST was acceptable); feasibility and willingness to participate in pharmacokinetic studies; and the provision of written informed consent",Criteria for exclusion were: previous high-dose chemotherapy requiring bone marrow transplantation or blood stem cell rescue; myocardial infarction within the last year; uncontrolled hypertension; irreversible arrhythmia; serious concomitant medical disease; GI disorders likely to hamper drug absorption; and concomitant chronic treatment with corticosteroids.,NA,NA
10673526,NA,Combination,No,Unresectable or Metastatic Transitional-Cell Carcinoma of the Urothelial Tract,"To be eligible for this study, all patients were required to have pathologic confirmation of unresectable or metastatic TCC of the urothelial tract. Metastatic lesions were required to be bidimensionally measurable. Examination under anesthesia, cystoscopy, and needle biopsies of pelvic nodes (when indicated) were performed to assess and stage patients with unresectable primary bladder tumors. All patients were required to be a minimum of 18 years old and to have a minimum Karnofsky performance status (KPS) of 60%. Other eligibility criteria included: neutrophil count >= 1,500 cells/uL; platelet count >= 150,000 cells/uL; serum creatinine <= 1.5 mg/dL or creatinine clearance >= 60 mL/min/1.73m2; bilirubin <= 1.5 times normal; and AST less than two times normal. Normal cardiac function, as judged by chest radiography, ECG, and nuclear medicine gated cardiac scan, was required.","Patients who had evidence of New York Heart Association functional class III or IV heart disease or severe arrhythmias, including first-, second-, or third-degree heart block, were excluded. Patients were not eligible if they had received any prior systemic chemotherapy or irradiation within 3 weeks of the start of protocol therapy. Patients with evidence of another active cancer were excluded",NA,NA
9789611,NA,Combination,No,"advanced sarcomas. Tumor location (one or more per patient): Local recurrence 9, Lung 14, Pleura 2, Lymph nodes 8, Liver 8, Bone 4, Other location (muscle pelvis, retroperitoneum and mediastinum) 10","Patients were required to have histologically proven advanced softtissue, bone or gynecological sarcoma. They were 18-70 years old and had a performance status ^ 2 according to the Eastern Cooperative Oncology Group (ECOG) criteria . All had normal hematological, renal and hepatic function. Cardiac function was tested by echocardiography or multigated nuclear scan and had to be within the normal range. ",Previous chemotherapy and CNS metastases were exclusion criteria.,during the first cycle of chemotherapy,NA
9443614,NA,Combination,No,advanced breast cancer,"Inclusion criteria for both the FAN and SUPERFAN regimens were: histological or cytological proof of measurable or evaluable anthracycline-naive metastatic breast cancer; prior hormone therapy allowable; previous irradiation allowable to <40% of red bone marrow; life expectancy >= 12weeks; Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2; age ³ 18 years; absolute granulocyte count of >= 2.5 x 109/l, a platelet count of >= 100 x 109/l and a hemoglobin of >= 100 g/l; normal bilirubin AST (SGOT) not more than three times normal; serum creatinine not more than 1.3 times normal; pretreatment resting MUGA LVEF >= 50% (normal)","Exclusion criteria were: prior anthracycline-containing adjuvant chemotherapy and prior chemotherapy for metastatic disease; uncontrolled systolic BP>180 and/or a diastolic BP of >100 mmHg; myocardial infarction within 12 months; congestive heart failure; unstable angina; cardiomyopathy; atrial or ventricular arrhythmias (even if controlled medically); active infection; previous cancer except in situ cervix cancer or curatively treated nonmelanomatous skin cancer, or carcinomas of the colon, cervix or uterus treated (and the patient disease free) more than 5 years prior to the diagnosis of breast cancer; unstable hypercalcemia; severe psychiatric or mental disability; signi®cant neuropathy or brain metastases.",NA,NA
10811502,NA,Single Drug,No,in recurrent or metastatic head and neck cancer,"Eligibility criteria for study entry included recurrent after first line chemo/radiotherapy, or metastatic, head and neck cancer, Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, adequate baseline organ function defined as WBC counts >= 3000/ul, platelets >= 100,000/ul, bilinibin =g 1.5 mg/dl, serum transaminases <= 2 x upper limit of normal, creatinine clearance >= 50 ml/min, life expectancy of at least three months.","Patients were ineligible if they had received more than one line of prior chemotherapy or had completed prior antitumor treatment less than a month before inclusion. Patients with a history of congestive heart failure, severe coronary heart disease were also ineligible. In addition, pregnancy, uncontrolled infection, cerebral metastases, concurrent or previous malignancy, severe neurologic disease also constituted exclusion criteria.",first cycle,NA
11187897,NA,Combination,No,"relapsed and refractory lymphoproliferative syndromes. Histological diagnosis:  Multiple myeloma 15, Non-Hodgkin’s lymphoma 9, Chronic lymphocytic leukemia 7, Hodgkin’s disease 3","Patients eligible for the study were those older than 17 and younger than 76 years of age with a histologically established diagnosis of malignant lymphoid disease, including non-Hodgkin and Hodgkin lymphoma, chronic lymphocytic leukemia and multiple myeloma. These patients were refractory to conventional chemotherapy including anthracyclines, or in relapse after having received at least one chemotherapeutic regimen including anthracyclines.","Patients likely to be cured or to have prolonged response to conventional therapy were excluded. Those with limited life expectancy (<1 month), abnormal kidney function (creatinine >150 mmol/l), abnormal hepatic functions (serum bilirubine >35 mmol/l, transaminases or alkaline phosphatases >4 × N), bone marrow dysfunction unrelated to the disease or electrolyte disorder were ineligible. Other exclusion criteria included known hypersensitivity to quinine and related molecules, previous history of hemorrhagic cystitis after cyclophosphamide administration and abnormal cardiac function, including decreased isotopic left ventricular ejection fraction (<50%), arrhythmia requiring treatment and untreated atrio-ventricular heart block.",NA,NA
10037175,NA,Combination,No,Metastatic Breast Cancer,"All patients were required to have histologically proven metastatic breast cancer. Patients were allowed to have received only one prior regimen for the treatment of their metastatic cancer, with no history of prior taxane therapy. Prior methotrexate as an adjuvant treatment was allowed. Patients were required to have adequate bone marrow (total WBC count > 3,000/mm3 and platelet count > 150,000/mm3), hepatic (bilirubin < 1.0 mg/dl), and renal function (creatinine level < 1.2 mg/dl or creatinine clearance > 50 ml/min) with a Karnofsky performance status of > 70%. No radiation or chemotherapy was to be given for at least 3 weeks (6 weeks for nitrosoureas) before starting this study, and patients were to have recovered from the major toxic effects of prior therapy. No clinical congestive heart failure, active angina, or unstable heart rhythms were allowed. ","Patients were ineligible if they had clinically significant edema, ascites, or pleural effusions. Pregnant or lactating women were excluded; patients were required to be at least 18 years of age, and all patients were counseled to practice effective contraception during this Phase I study",NA,NA
10394119,NA,Single Drug,No,Platinum-Pretreated Patients with Ovarian Carcinoma,"Patients were considered eligible if they had measurable or evaluable disease, were younger than 75 years, had a WHO performance status of 1 or less and gave informed consent. They had to have an adequate bone marrow, hepatic and renal function as indicated by a leukocyte and platelet count of 4.0 x 109/l or more and 100 x 109/l or more, respectively, a serum bilirubin < 25 Ìmol/l and a serum creatinine < 150 umol/l.","Patients were not allowed to enter the study if: prior radiotherapy, hormone therapy or chemotherapy was given within 4 weeks of start of protocol treatment and/or relevant toxic manifestations of prior treatment had not been resolved, there were signs or symptoms of brain involvement or leptomeningeal disease, there was active cardiac disease (congestive heart failure, significant arrhythmia, bilateral bundle branch block) or a history of a recent myocardial infarction",during the treatment,NA
11127949,NA,Single Drug,No,"relapsed solid tumors: breast carcinoma 14, NSCLC 6, SCLC 1, colon carcinoma 5, sarcoma 3, melanoma 2, other 5","All patients had a Zubrod performance status of 2 or better and a life expectancy of at least 12 weeks. Other eligibility criteria included the presence of measurable or evaluable tumors and adequate bone marrow, hepatic, and renal function as evidenced by an absolute granulocyte count of >=1500/mm3, platelet count of >=100,000/mm3, bilirubin level of <=1.5 umol/l, and creatinine level of <=1.5 umol/l. Patients were required to have undergone at least one chemotherapy regimen that was completed at least 3 weeks earlier. Those with reasonable standard second-line treatment options had to have received at least two different regiments of treatment for metastatic disease to be eligible for this phase I study. Those with cancer that was potentially responsive to anthracycline drugs had to have received a standard anthracycline or anthraquinone but were not required to have anthracycline-resistant disease, as defined by a relapse during or within 6 months after anthracycline treatment. ","An ejection fraction of >=55 %, as shown by two-dimensional echocardiography, was required, and patients with a history of heart failure were excluded.",NA,NA
9164225,NA,Combination,No,"Advanced Sarcoma: Angiosarcoma 5, Leiomyosarcoma 5, Liposarcoma 3, MFH 3, MPNT 3, Synovial sarcoma 3, Chondrosarcoma 2, GIST 2, Epithelioid sarcoma 1, Hemangiopericytoma 1, Carcinoma 1","The trial was limited to patients who had not previously been treated with an anthracycline and had not received more than one previous chemotherapy regimen. A Karnofsky performance status >= 60% was required, as was a WBC count >= 4000/uL, platelet count >= 150,000/uL, serum creatinine concentration less than 1.5 mg/dL, and serum bilirubin level less than 1.5 mg/dL. All patients had pretreatment radionuclide cineangiography or echocardiography that demonstrated a left ventricular ejection fraction >= 50%.","Patients with a history of arrythmia that required treatment or myocardial infarction within the preceding 6 months were excluded from the study, as were patients who had received therapeutic radiation within the 3 weeks that preceded the start of treatment. In addition, patients known to be allergic to eggs or egg products were excluded. ",NA,NA
9037361,NA,Combination,No,HFV-related non-Hodgkin's lymphoma,"HTV seropositive patients with a histologically confirmed diagnosis of NHL were eligible for the trial with additional inclusion criteria - written informed consent obtained, ECOG performance status 0-2, current treatment with one or more licensed antiretroviral agents (zidovudine, didanosine or zalcitabine). Laboratory parameters for inclusion into the study were platelets >=80 x 109/l, creatinine level <222 umol/1, bilirubin <34.2 umol/1 and ALT or AST <5 x upper limit of normal. Prior to receiving the first cycle of chemotherapy, the total neutrophil count needed to be >=1.2 x 10/1.","Exclusion criteria were: primary cerebral lymphoma, prior chemotherapy for NHL, any current active opportunistic infection, current treatment with other investigational agents and female patients who were pregnant or laclating.",in cycle 1 ,NA
10445421,NA,Combination,No,metastatic breast cancer,"Eligibility criteria included histologic documentation of metastatic breast carcinoma, measurable or assessable disease, no more than one previous chemotherapy regimen for metastatic disease, and no previous exposure to anthracyclines. Patients were also required to have a Zubrod performance status ≤ 2 and adequate organ function, which was defined as a serum creatinine level ≤ 1.2 mg/dl, a serum bilirubin level ≤ 1.5 mg/dl, an absolute granulocyte count ≥ 1,500/µl, a platelet count ≥ 100,000/µl, and a resting cardiac ejection fraction (EF) ≤ 0.60 with normal wall motion in a patients who did not have a history of cardiac failure.",NA,NA,NA
29719113,NCT02171260,Combination,No,"children with refractory or recurrent solid tumors: Ewing sarcoma 4 (17), Hepatoblastoma 2 (8.7), Malignant peripheral nerve sheath tumor 1 (4.3), Nephroblastoma 1 (4.3), Neuroblastoma 1 (4.3), Osteosarcoma 9 (39), Soft tissue sarcoma, nonrhabdomyosarcoma 5 (22)","Patients >6 months and <18 years of age with measurable or evaluable recurrent or refractory solid tumors, including lymphomas, were eligible. Histologic verification of malignancy from the time of the original diagnosis or relapse was required. Performance score (Lansky or Karnofsky) of ≥50 was required. Subjects were required to have recovered from the acute toxic effects of prior therapy and be at least 21 days from prior myelosuppressive therapy, 14 days from growth factor support, and 42 days from prior immunotherapy. Three half-lives must have elapsed since prior monoclonal antibody administration, 84 days since a stem cell transplant, and at least 150 days since total body, craniospinal, or hemipelvic irradiation. Other eligibility criteria included adequate bone marrow function (peripheral absolute neutrophil count [ANC] ≥ 1,000/mm3, platelets ≥ 100,000/mm3 [transfusion independent], and hemoglobin ≥ 8 g/dl); adequate renal function (age-adjusted normal serum creatinine or glomerular filtration rate ≥ 70 ml/min/1.73m2); adequate liver function (total bilirubin 1.5× the institutional upper limit of normal for age, alanine transaminase ≤ 110 U/l, aspartate transaminase ≤ 125 U/l, and albumin ≥ 2 g/dl); and adequate cardiac function (shortening fraction ≥ 27% or ejection fraction ≥ 50% and corrected QT interval [QTc] ≤ 480 msec). A separate cohort was included for children 6–12 months of age, with age-specific organ function criteria, definitions of toxicity, and modification of required blood sampling for research studies (however, this cohort failed to enroll any patients and was subsequently closed for lack of accrual).","Secondary to eribulin being a strong P-gp substrate with poor central nervous system (CNS) penetration being noted in preclinical studies,24 patients with CNS tumors or tumors with CNS metastases were excluded; as were patients with bone marrow metastasis, uncontrolled infections, viral hepatitis, or patients with ≥grade 1 peripheral sensory or motor neuropathy graded according to the modified (“Balis”) Pediatric Scale of Peripheral Neuropathies.2",during cycle 1 of therapy,NA
34773474,NCT02206763,Combination,No,"EGFR‑mutated, tyrosine kinase inhibitor‑naive metastatic non‑small cell lung cancer","Eligible patients had a pathologically confrmed diagnosis of metastatic NSCLC with a documented EGFR exon 19 deletion or exon 21 L858R substitution mutation. Patients were EGFR TKI-treatment–naive, except to erlotinib, in which stable doses for ≥11 days and ≤45 days were required; had an Eastern Cooperative Oncology Group performance status of 0, 1, or 2; and had measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria . Patients with treated or asymptomatic untreated brain metastases were eligible, whereas patients with active infection or carriers of hepatitis B or C were ineligible.",NA,during the frst 28 days of combined erlotinib and momelotinib treatment,NA
6957420,NA,Single Drug,No,"Primary tumor: Colon adenocarcinoma 4, Bronchogenic carcinoma 3, Breast adenocarcinoma 5, Renal adenocarcinoma 3, Epidermoid carcinoma & head and neck 2, Soft tissue sarcoma 4, Ovarian cystadenocarcinoma 1","Twenty-two patients with advanced solid tumors were studied. All had failed prior therapeutic attempts, and all gave informed consent for participation. All patients had creatinine clearance greater than 60 ml/min and bilirubin less than 3.0 mg/dl. In addition, patients were prospectively evaluated with radionuclide ventriculography. While no specific limits for inclusion in the study on the basis of left ventricular ejection fraction were set a priori, those with resting ejection fractions less than 50 per cent were evaluated individually and were included only at the discretion of the investigators. Patients who had received more than 75 per cent of allowable cumulative doses of other anthracyclines were admitted only if their ejection fractions were normal (at least 50 per cent) and no other evidence of cardiac impairment was present.",NA,NA,NA
26554651,NCT00410553,Combination,No,"advanced solid tumours: NSCLC 4, Ovarian 3, Head/neck 3, Colon 2, Endometrial 3, Gastric 3, Breast 1, Carcinoid 1, Unknown 1","Adult patients (>18 years) with histologically confirmed metastatic or unresectable malignancy with no curative treatment options were eligible. Other eligibility criteria included the following: measurable disease, ECOG performance status 0 to 2, maximum of two prior chemotherapy regimens for metastatic disease, prior therapy completed at least 4 weeks prior to registration, adequate bone marrow and organ function (leukocytes >3 x 109 l-1, absolute neutrophil count (ANC) >=1.5 x 109 l-1, platelets >=100 x 109 l-1, total bilirubin within normal institutional limits, AST/ALT <=2.5 x institutional upper limit of normal, creatinine clearance >=60 ml min-1 1.73 m-2). Prior treatment with gemcitabine or eribulin was not allowed. Prior radiation could not have encompassed more than 40% of a patient’s bone marrow. Patients had to have recovered from any toxicity related to prior therapy at the time of registration. As CYP3A4 appears to be the major enzyme responsible for hepatic metabolism of eribulin, the concurrent use of inhibitors and inducers of CYP3A4 were prohibited. All patients gave informed written consent.",NA,cycle 1,NA
25654665,"UMIN-CTR, UMIN 000009716",Combination,No,metastatic breast cancer,"Eligible patients were 20–74 years of age with a confirmed diagnosis of MBC. They were required to have an Eastern Cooperative Oncology Group performance status of 0 or 1 and adequate organ function. Previous treatments, including chemotherapy, radiotherapy, and surgery, were allowed if they had been completed at least 4 weeks before registration. However, previous administration of both anthracycline and taxanes was required","Patients with other serious illnesses or medical conditions, such as uncontrolled infection, other malignancies, or central nervous system metastases that were still symptomatic, were also not eligible for participation",during the first cycle of chemotherapy,NA
19509177,NA,Single Drug,No,"Advanced Solid Malignancies. Primary disease site: Colon/rectum 8, Ovary 6, Breast 2, Cervix 2, Uterus 2, Liver 2, Lung 2, Other primary disease sites (one patient each): parotid gland, gallbladder, appendix, pancreas, prostate, sarcoma (left limb), non-Hodgkin’s lymphoma, peritoneum, head and neck.","Patients enrolled in the study were at least 18 y of age and had histologically or cytologically confirmed advanced solid malignancies that had either progressed following standard therapy or for which no standard therapy existed. Patients were permitted to have received prior chemotherapy and were required to have a Karnofsky Performance Status of at least 70%, a life expectancy of at least 3 mo, and were also required to have adequate renal and hepatic function. All patients provided written informed consent before any study procedure. ","Patients who had received chemotherapy or investigational drug therapy within 3 wk (6 wk for nitrosoureas) before study initiation were excluded from participation as were those who required therapeutic doses of anticoagulant therapy, women who were pregnant or breast-feeding, and patients who had not successfully completed local therapy for central nervous system metastases. Additional exclusion criteria included a positive HIV test, any medically uncontrolled cardiovascular illness or receipt of an organ allograft, or a history of hypersensitivity to the study drug.",during cycle 1,NA
34468905,NCT02942095,Combination,No,"advanced solid tumors: Sarcoma N=6, Colorectal cancer N=5, Endometrial cancer N=2, Lung cancer N=2, Squamous cell carcinoma of head and neck N=1, Cervical cancer N=1, Pancreatic cancer N=1, Duodenal cancer N=1","Patients were eligible for the study if they had a pathologically confrmed advanced or metastatic cancer that was refractory to standard therapy, had relapsed after standard therapy, or for which there is no standard therapy that increases survival by at least three months. Other inclusion criteria were as follows: age≥18 years, absolute neutrophil count ≥ 1.5 × 109 cells/L, hemoglobin ≥ 8.0 g/dL, platelets≥75 × 109/L, creatinine≤1.5 × upper limit of normal (ULN) with calculated creatinine clearance greater than 30 ml/min, total bilirubin≤1.5× ULN, AST (SGOT) and/ or ALT (SGPT)≤3× ULN. Patients had to have been of prior therapies>2 weeks for investigational or cytotoxic agents or>5 half-lives for biological targeted agents.","Patients were excluded if they had received radiotherapy within 2 weeks prior to treatment initiation, were on ongoing chemotherapy, had severe or uncontrolled medical diseases (e.g., active infections, cardiovascular disease), had symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression, had major surgery within 14 days of enrollment, were diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease, had ≥ Grade 2 peripheral neuropathy, or Grade 1 with pain on clinical examination during screening, or were previously treated with ixazomib.",in the frst cycle,NA
12477447,NA,Combination,No,Previously Treated Epithelial Ovarian Carcinoma Patients,"Patients with histologically confirmed epithelial ovarian cancer, including those with clear-cell adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, serous adenocarcinoma, mixed epithelial carcinoma, and undifferentiated carcinoma were eligible for the study. Patients with extraovarian serous carcinoma were also eligible. All patients had measurable disease and/or elevated CA-125 levels. Lesions that could be measured on two dimensions by physical examination or by any means of medical imaging were defined as measurable disease. Sonography was acceptable if the lesions were clearly defined on initial examination and measurable in two dimensions. Ascites and pleural effusion were not considered measurable disease. Patients with CA-125 > 100 U/ml that was increasing on two separate measurements with or without measurable disease were eligible. All patients had received previous first-line or second-line chemotherapy for ovarian carcinoma. Platinum-sensitive patients who had not received treatment for at least 6 months were eligible, as were platinum-resistant patients whose disease had progressed during therapy or within 6 months after therapy. Eligible patients were required to have adequate bone marrow function (white blood cells >= 3 x 109 cells/L, neutrophils >= 1.5 x 109 cells/L, platelets >= 100 x 109/L) and a Gynecologic Oncology Group (GOG) performance status  2 at study entry.",Newly diagnosed patients and those with borderline ovarian carcinoma were ineligible. Patients who had previously received  2 chemotherapy regimens or topotecan treatment were ineligible. Patients were also ineligible if they had received radiation therapy primarily for ovarian cancer or had concomitant malignancy.,NA,NA
30703739,UMIN00009498,Combination,No,Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes,"1)	Female patients ≥18 years at the time of consent. 2) Performance status (Eastern Cooperative Oncology Group) of 0–1. 3)	Patients with confirmed progressive disease in the most recent treatment. 4) Previous treatment of breast cancer (metastatic, recurrent, preoperative, or postoperative) with anthracyclines (doxorubicin, epirubicin, etc.) and taxane agents (paclitaxel, docetaxel, albumin-bound paclitaxel, etc.). The combination and order of agents were irrelevant. 5)	Patients with organ function as assessed by laboratory tests* as indicated in the table below. Neutrophil count	≥1,500/mm3; Hemoglobin (No transfusion in the last 28 days)	≥9.0 g/dL; Platelet count	≥100,000/mm3; Total bilirubin	≤1.5 mg/dL; Serum AST/ALT (≤150 IU/L for patients with liver metastasis)	≤100 IU/L; Serum creatinine	≤1.2 mg/dL; Electrocardiography	Normal, or changes not requiring treatment, QTc interval <450 msec. 6) Patients whose toxicity was associated with previous treatment had recovered to grade ≤1. However, patients with Grade 2 sensory neuropathy with stable symptoms, alopecia, and onychomadesis were eligible. For patients with hypokalemia or hypomagnesemia requiring clinical correction, the correction had to be performed prior to enrollment. 7)	Patients predicted to have a chance of survival ≥3 months. 8) Patients who provided written consent. If the patient was a minor (age <20 years), consent was required from their legal guardian.","1)	Patients who were pregnant, nursing, might have been pregnant, or wished to become pregnant (women whose last menstrual period was less than one year earlier and women who may be menopausal due to drug therapy had to undergo a thorough diagnostic interview and pregnancy testing (via blood or urine)). 2)	Patients whose last therapy was radiotherapy, surgery, or immunotherapy, and patients whose most recent therapy session was within the last 2 weeks. Patients whose last therapy was with anti-cancer drugs, and were scheduled to begin their next cycle within 1 week counting from the start date of their previous cycle.  3)	Patients with active infections. 4) Patients with respiratory failure requiring oxygen inhalation therapy. 5)	Patients who required a therapeutic dose of warfarin or related drugs (however, heparin infusion for blood coagulation prevention was permitted). 6)	Patients with clinical symptoms or imaging findings of interstitial pneumonia or pulmonary fibrosis. 7)	Patients who were HBs antigen-positive, HCV antibody-positive (if positive, HCV-RNA was measured), HIV antibody-positive, HBV-DNA-positive, or HCV-RNA-positive. If a patient was HBs antigen-negative but was also found to be HBs antibody-positive or HBc antibody-positive, HBV-DNA was measured. Patients with prior infections that had healed (HBV-DNA-negative or HCV-RNA-negative) were eligible. 8)	Patients with prior unstable angina, prior myocardial infarction, or serious arrhythmia. 9)	Patients with diabetes under poor control or who were receiving insulin therapy. 10)	Patients with brain metastasis (however, such patients were eligible if they had completed local therapy and discontinued glucocorticoids for brain metastasis at least 4 weeks prior to enrollment, provided that symptoms and imaging results (contrast-enhanced cranial CT or contrast-enhanced cranial MRI) were stable. Stability in imaging results was assessed by comparing images taken at least 4 weeks prior to enrollment, to the most recent images). 11)	Patients with massive pleural effusion or ascites requiring drainage or aspiration. 12)	Patients with meningeal carcinomatosis. 13)	Patients who would have had difficulty participating in the trial due to psychiatric diseases or symptoms. 14)	Patients with difficulty in oral administration of drugs due to gastrointestinal obstruction or related symptoms. 15)Patients with prior treatment with, or allergies to eribulin mesylate or PARP inhibitors. 16)	Patients with synchronous double cancer in phase I*. However, double cancer did not include intraepithelial carcinoma (carcinoma in situ) judged to have been healed by local therapy, nor did it include lesions corresponding to intramucosal carcinoma. *The clinical trial coordinating center (the coordinating investigator) determined the patient’s eligibility based on factors such as history of breast cancer treatment. This did not include cases of prior malignancy other than breast cancer in phase II (intraepithelial carcinoma or intramucosal carcinoma), or cases in which curative resection was performed at least 5 years prior. 17)	Patients with findings indicative of myelodysplastic syndromes or acute myelogenous leukemia in peripheral blood smear samples. 18)	Patients unable to cooperate with the treatments, tests, and hospital visits scheduled in the trial period. 19)	Patients using the following CYP3A4 inhibitors or inducers: CYP3A4 inhibitors: azole antifungals, macrolide antibiotics, protease inhibitors CYP314 inducers: phenytoin, rifampicin, carbamazepine, barbiturates 20)	Patients deemed ineligible for the present trial for any other reason by the principal investigator/coordinating investigator.",21 days in cycle 1,NA
26943987,EudraCT number: 2014-000135-17,Combination,No,Triple-Negative Breast Cancers,"Patient eligibility should be reviewed and documented by an appropriately qualified member of the investigator’s study team before patients are included in the study. Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study: histological confirmed diagnosis of metastatic TNBC; Eastern Cooperative Oncology Group performance status of <= 2, adequate hematological, hepatic, renal, and an adequate cardiac function; age >= 18 years; at least 1 prior line of chemotherapy in metastatic setting; a written informed consent dated and signed by both patients and investigator; and a negative pregnancy test","The exclusion criteria were: radiotherapy within 4 weeks prior to start of this trial; a major surgery within 2 weeks of study enrollment; brain metastases or leptomeningeal disease; history of other cancers except curatively treated carcinoma of the cervix in situ or non-melanomatous skin cancer; a pre-existing peripheral neuropathy of grade > 2; a history of interstitial pneumonia or pulmonary insufficiency; a severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: diabetes mellitus, uncontrolled hypertension, severe malnutrition, unstable angina, or congestive heart failure.",in the first cycle of treatment (21 days),NA
3367191,NA,Combination,No,"Doxorubicin Resistant solid tumors. Acquired resistance: sarcoma 2, ovarian cancer 2, NHL 3, gastric cancer 2, breast cancer 4, carcinoid 1, SCBC 2, unknown 1, AUL 1, bladder cancer 1, myeloma 1, germ cell cancer 1. Intrinsic resistance: sarcoma 4, ovarian cancer 2, NSCBC 1, plasmacytoma 1, multiple primaries 1, schwannoma 2, bladder cancer 1, osteogenic sarcoma 1, acute lymphocytic leukemia 2","Only patients with prior objectively documented clinical doxorubicin resistance were eligible. Resistance could be either intrinsic, defined as no response to prior doxorubicin treatment, or acquired, defined as an initial response to doxorubicin followed by progressive disease while on treatment. Patients may have had prior doxorubicin as a single agent or as part of a combination chemotherapy regimen. Patients with histologically confirmed resistant solid tumors, lymphomas, or leukemias were eligible if they had measurable disease, a Southwest Oncology Group (SWOG) performance status of 0 to 3, and a life expectancy of >= 6 weeks. Prior radiation therapy and prior treatment with non-doxorubicincontaining regimens were permitted. Other eligibility criteria included a resting left ventricular ejection fraction (radionuclide ventriculography) of >= 45%, WBC count >= 3,000/uL, platelet count >= 100,000/uL, bilirubin <= 3 mg/dL, and an SGOT less than or equal to three times the institutional normal.",NA,NA,NA
32943461,NCT02207504,Combination,No,Metastatic Castration-resistant Prostate Cancer,"Eligible patients were 18 years of age or older, had histologically confirmed prostate adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status <2, radiographic evidence of  metastatic disease, serum testosterone levels <50 ng/dL, and evidence of disease progression based on rising PSA per the Prostate Cancer Working Group 2 (PCWG2) criteria or radiographic progression according to the RECIST 1.1 criteria (20, 21). There was no limit on the number of prior lines of therapy, and patients could have received docetaxel, ketoconazole, estrogens, abiraterone, or other antiandrogens, including prior enzalutamide, for CRPC. Patients with a small cell component on pathologic evaluation, brain metastases, or prior history of seizures or any medical or neurologic conditions that may predispose to seizures were excluded from the study. Patients were maintained on gonadotropin-releasing hormone agonist or antagonist therapy unless prior orchiectomy or intolerant. Concomitant use of strong CYP3A or CYP2C8 inhibitors, strong or moderate CYP3A inducers, or CYP2C8, CYP3A4, CYP2C9, and CYP2C19 substrates with narrow therapeutic indices was prohibited.","Pathology consistent with small cell carcinoma of the prostate. Prior treatment with c-Met inhibitors. Participants who have received any other investigational systemic agents in the last 2 weeks. Persistent grade >1 (NCI CTCAE v4.0) AEs due to investigational drugs that were administered more than 14 days before study enrollment with the exception of alocepia. Participants with known brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction or seizures that would confound the evaluation of neurologic and other adverse events. History of allergic reactions attributed to compounds of similar chemical or biologic composition to crizotinib or enzalutamide. History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma, history of loss of consciousness or transient ischemic attack within 12 months of study entry). Concomitant medications that would lower seizure threshold. Concomitant use of medications that may alter pharmacokinetics of crizotinib or enzalutamide. See section 5.5, but would exclude the use of strong CYP3A or CYP2C8 inhibitors, strong or moderate CYP3A inducers, CYP2C8, CYP3A4, CYP2C9 and CYP2C19 substrates with narrow therapeutic indice. -- Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as: http://medicine.iupui.edu/clinpharm/ddis/table.aspx. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Clinically significant heart disease defined as: Myocardial infarction within 6 months of Screening visit. Uncontrolled angina within 3 months of Screening visit. Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or subjects with history of congestive heart failure NYHA class 3 or 4 in the past, or history of anthracycline or anthracenedione (mitoxantrone) treatment, unless a screening echocardiogram or multi-gated acquisition scan (MUGA) performed within three months of the Screening visit results in a left ventricular ejection fraction that is ≥45%. History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsade de pointes). Prolonged corrected QT interval by the Fridericia correction formula (QTcF) on the screening electrocardiogram (ECG) > 470 msec. History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place. Hypotension (systolic blood pressure <86 mmHg) or bradycardia with a heart rate of <50 beats per minute on the Screening ECG, unless pharmaceutically induced and thus reversible (i.e. beta blockers) or known, chronic asymptomatic baseline heart rate. Uncontrolled hypertension as indicated by a resting systolic blood pressure >170 mmHg or diastolic blood pressure >105 mmHg at the Screening visit. No medications known to prolong the QT interval as crizotinib may increase the risk for QT prolongation Thrombosis or vascular ischemic events within the last six months, such as deep venous thrombosis, pulmonary embolism, transient ischemic attack, cerebral infarction, or myocardial infarction No medications known to prolong the QT interval as crizotinib may increase the risk for QT prolongation. Pregnant women are excluded from this study because women do not get prostate cancer, as they have no prostate. No defined washout period from major or minor surgery is required but incisions must be fully healed. HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with crizotinib or enzalutamide. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated. Inability to comply with study and/or follow-up procedures",in the first 28 days on crizotinib and enzalutamide,NA
21887501,NCT00326950,Single Drug,No,"Japanese patients with refractory cancers. Tumor type, n (%): NSCLC 3 (20.0), Breast 2 (13.3), Colorectal 3 (20.0), Biliary 2 (13.3), Other 5 (33.3) include cervical, head and neck, liposarcoma, melanoma, and renal","This was a single-center, non-randomized, open-label, doseescalation Phase I study of eribulin in Japanese patients with advanced solid tumors. Eligibility criteria included: 20–74 years of age; histologically or cytologically confirmed locally advanced solid malignancies that had either failed to respond or had progressed following standard therapy, or for whom no other treatment options were available; an Eastern Cooperative Oncology Group performance status of 0 or 1; a life expectancy of at least 3 months; no ongoing adverse drug reactions (ADRs) (excluding alopecia) to prior therapy, and adequate function of all major organs (including bone marrow, liver, kidney, and lungs).","Patients were excluded from the study if they had received chemotherapy or investigational drug therapy within 4 weeks prior to study initiation (exceptions to this were 6 weeks for nitrosoureas or 2 weeks for radio-, endocrine-, or immunotherapy). Additional exclusion criteria included: women who were pregnant or breastfeeding; those who required continuous systemic steroid therapy or extensive radiotherapy; patients who tested positive for HIV, hepatitis C virus antibody, or hepatitis B virus surface antigen; the presence of systemic infection (fever ≥38°C); pleural effusion or ascites; brain metastases; serious complications, which included medically uncontrolled cardiovascular illness, hepatic cirrhosis, interstitial pneumonia or pulmonary fibrosis, or a history of bleeding disorders.",during the first cycle,NA
33926914,NCT03386942,Combination,No,"Patients with Folate Receptor-a–Positive Advanced Solid Tumors. Cancer types included breast, endometrial, NSCLC, ovarian, and fallopian tube cancer; ovarian cancer was the most frequent, accounting for 12 (55%) of 22 patients. ","Participants who have provided voluntary written consent for participation in this clinical study. Participants to whom the rules for complying with this clinical study have been adequately explained, and who intend to and can comply with those rules. Male or female participants age >=20 years at the time of informed consent of screening 1 (or screening 2, in case of participants who enter this clinical study from screening 2). Part 1 only: Participants with FRA-positive solid tumor confirmed by immunohistochemistry (IHC) assay at the central laboratory using their available tumor samples from resected specimen (i.e., surgical or excisional/incisional biopsy samples) or core needle biopsy (<=18-gauge), or participants with a histological and/or cytological diagnosis of any serous ovarian carcinoma, fallopian tube carcinoma, endometrial carcinoma, or adenocarcinoma of Non-Small Cell Lung Cancer (NSCLC), whose archival resected tumor samples (that is, surgical or excisional/incisional biopsy sample). Part 1 only: At informed consent of screening 2, participants who failed standard therapies, or for which no appropriate treatment is available. Participants with adequate function of major organs within 2 weeks prior to the first administration of the study drug as follows. Hemoglobin >=9.0 grams per deciliter (g/dL). Neutrophil count >=1.5 × 10^3/microliters (μL). Platelet count >=10 × 10^4/μL. Total bilirubin <=1.5 × upper limit of normal (ULN) in the facility. Alanine aminotransferase and aspartate aminotransferase <=3.0 × ULN in the facility (in the case of liver metastases <=5*ULN). Serum creatinine <=1.5 × ULN in the facility. Albumin >=3 g/dL. Participants with Performance Status score of 0-1 established by Eastern Cooperative Oncology Group. Participants who are expected to survive for 3 months or longer after the first administration of the study drug. Washout period required from the end of prior treatment to the first administration of the study drug will be as follows: a. Anticancer therapy:  Antibody and other study drugs: >4 weeks (however, in the case where the half-life of other study drugs is known and 5 × half-lives of that study drug is less than or equal to 4 weeks, participants can be eligible after >=5 × half-lives of that study drug has passed). Prior chemotherapy (except small-molecule targeted therapy), surgical therapy, radiation therapy: >3 weeks. Endocrine therapy, immunotherapy except antibody, small-molecule targeted therapy: >2 weeks. Supportive therapies • Blood/platelet transfusion, hematopoietic stimulating agent including granulocyte colony-stimulating factor formulation: > 2 weeks. Participants whose formalin fixed, paraffin-embedded unstained slides of tumor sample are available for IHC test at central laboratory. If applicable biopsy will be performed by excisional, incisional or needle puncture (<=18-gauge as far as possible).","Medical history of clinically significant cardiovascular impairment: Congestive heart failure greater than or equal to New York Heart Association Class III. Unstable angina pectoris, myocardial infarction or stroke within 6 months before of the first administration of the study drug. Prolongation of corrected QT (QTc) interval to > 480 milliseconds (ms) (Fridericia method). Arrhythmias associated with hemodynamic instability. Concomitant systemic infection requiring medical treatment. Participants who test positive for human immunodeficiency virus (HIV antibody). Active viral hepatitis (B or C) (*) as demonstrated by positive serology or requiring treatment. (*) hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs)/hepatitis B core antibody (HBcAb), and anti-hepatitis C virus (HCV) antibody test. Participants who are anti-HBs/HBcAb (+) without detectable hepatitis B virus (HBV)-deoxyribonucleic acid (DNA)/HCV- ribonucleic acid (RNA) are eligible. Effusion requiring drainage continually. Participants whose toxicity of previous treatment has not recovered to Grade 1 or lower (except for alopecia and hemoglobin). Participants who have received a previous monoclonal antibody therapy and have evidence of an immune or allergic serious reaction. Participants who had previous treatment with other folate receptor targeting agents. Participants who have medical history of discontinuing prior eribulin due to toxicity. Has an active pneumonitis/interstitial lung disease (ILD), a history of pneumonitis/ILD that required systemic steroids, received radiotherapy to lung field within 12 months before the first dose of study intervention, or current clinically relevant lung disease (example, Chronic Obstructive Pulmonary Disease). Other active malignancy (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 24 months prior to the first administration of the study drug. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin or human chorionic gonadotropin). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 3 days before the first administration of the study drug (breastfeeding participants are not eligible even if they discontinue breastfeeding). Women of childbearing potential or man of impregnate potential who don't agree that both the participant and his/her partner will use a medically effective method for contraception (as below) during the study and after study drug discontinuation (male; 90 days, female; 60 days). Note: Condom*, contraceptive sponge**, foam**, jelly**, diaphragm*, intrauterine device*, or use of oral contraception* from at least 4 weeks before starting the study treatment (*Approved drugs or certified medical devices in Japan, **Non-approved drugs or certified medical devices in Japan). Known intolerance to the study drug or any of the excipients. Any medical or other condition that in the opinion of the investigator(s) would preclude the participant's participation in the study. Scheduled for surgery during the study. Diagnosed with meningeal carcinomatosis. Participants with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (e.g., radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment. Use of illegal recreational drugs.",during cycle 1 (days 1 to 21),NA
26362045,NA,Single Drug,No,patients with advanced solid tumors,"Forty patients with advanced, histologically confirmed solid tumors were entered on this trial. Patients were required to have chemotherapeutically unresponsive malignancies, to have relapsed following previous chemotherapeutic regimens, or to have malignancies for which no “standard” chemotherapeutic regimen exists. Eligibility requirements included a Karnofsky performance status (KPS) of at least 60 %, age ≥18 years, and an expected survival of at least 2 months. Adequate renal (24-h creatinine clearance of ≥60 mL/min), bone marrow (absolute neutrophil count ≥1500/dL and platelet count ≥100,000/ µL), and hepatic (serum bilirubin ≤1.5 mg/dL, and SGOT and SGPT within 2.5 times the institutional upper limit of normal) were required. Prior chemotherapy must have been completed at least 4 weeks prior to beginning treatment on this protocol [6 weeks for nitrosoureas and 8 weeks for 7-hydroxystaurosporine (UCN-01)], and patients must have recovered from side effects of prior therapy. There was no limit on the number of prior courses or types of chemotherapy. All patients of childbearing potential, both male and female, were advised to practice adequate contraception. Premenopausal women must have had a negative pregnancy test prior to entry on this study. All patients were required to have evaluable disease. The presence of measurable disease was not required for this phase I study. ","Patients with brain metastases were ineligible for this study. Because the safety of E7389 to the unborn fetus has not been established, pregnant patients and patients who were breast feeding were ineligible. Due to concerns regarding possible drug interactions, patients with HIV taking antiretroviral medications were ineligible. Patients with any nonmalignant intercurrent illness which was poorly controlled were ineligible. Patients may not have received concurrent therapy with any other antineoplastic therapy",in the first cycle,NA
9402745,NA,Single Drug,No,metastatic breast cancer,"All the patients were pretreated with anthracyclines (cumulative dose was 530 mg and 264 mg, respectively, for epirubicin and DOX) and had at admittance a PS ≤ 2 and a left ventricular ejection fraction >50%. ",NA,NA,NA
25242374,NCT01432886,Combination,No,advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer,"Key inclusion criteria included: 20–74 years of age; histologically or cytologically confirmed advanced or recurrent breast cancer; HER2+ tumor score of 3+ by immunohistochemistry staining or gene amplification by fluorescence in situ hybridization (FISH); and any of the following, 1) evidence of recurrence during adjuvant chemotherapy with trastuzumab and taxane, 2) evidence of recurrence within 6 months after adjuvant chemotherapy with trastuzumab and taxane or 3) prior chemotherapy including trastuzumab and taxane for advanced or recurrent breast cancer; normal function in major organs; left ventricular ejection fraction (LVEF) ≥60 % by multigated acquisition scan or echocardiogram (B or M mode); and Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.","Key exclusion criteria included: brain metastasis accompanied by clinical symptoms or requiring treatment; severe active infection requiring treatment; pleural effusions, ascites or pericardial effusions requiring drainage; pregnancy or breastfeeding; and refusal of supportive therapy by blood transfusion",in the first cycle,NA
30679780,NA,Single Drug,No,"patients with solid tumours. Tumour type, n (%):  Breast 10 (17.2), Cholangiocarcinoma 2 (3.4), Colorectala 11 (19.0), Endometrial 7 (12.1), Gall bladder 2 (3.4), NSCLC 3 (5.2), Ovarian 10 (17.2), Pancreatic 3 (5.2), Pleural mesothelioma 3 (5.2), Uterine cervix 3 (5.2), Other Includes adrenal glands, duodenal, oesophageal and laryngeal cancers 4 (6.9)","Patients aged ≥ 18 years with histologically or cytologically proven advanced solid tumours refractory to standard therapies were enroled. In the doseexpansion phase, the following tumours were permitted: endometrial cancer after failure of prior chemotherapy for recurrent, metastatic or high-risk disease; ovarian cancer after failure of prior chemotherapy or intolerance of platinum agents (including patients with platinum-sensitive and platinum-refractory disease); and breast cancer (HER2-negative subtype) after failure of previous standard (anthracycline and taxane) chemotherapy treatments. Patients were required to have had ≥1 measurable lesion based on Response Evaluation Criteria In Solid Tumours (RECIST) version (v) 1.1 (dose-expansion phase), an Eastern Cooperative Oncology Group performance status ≤ 1, and adequate liver, renal and bone marrow function.","Key exclusion criteria included patients having had any anticancer therapy within 21 days prior to study entry for cytotoxic agents and targeted agents, or within 30 days for an investigational agent, patients with pre-existing peripheral neuropathy of National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grade > 1, patients who had previously been treated with eribulin, and patients who had not recovered (to grade < 2) from acute toxicities associated with prior anticancer therapy or had received radiation therapy encompassing > 30% of the bone marrow.",during the first treatment cycle,NA
29468456,NCT01585870,Combination,No,"patients with advanced, metastatic, or refractory solid tumors. The most common tumor types (≥ 1 patient) included breast (n = 25; 62.5%), endometrial (n = 3; 7.5%), and cervical (n = 2; 5.0%).","Adult patients aged ≥ 18 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and advanced, metastatic, or refractory solid tumors who were not candidates for standard therapy were eligible for the study. Additional inclusion criteria were adequate bone marrow function (absolute neutrophil count [ANC] ≥ 1500/mm3, platelet count ≥ 100,000/mm3, and hemoglobin concentration ≥ 9.0 g/dL), adequate liver function (total bilirubin concentration < 1.5 × the upper limit of normal [ULN], and alanine aminotransferase [ALT] and aspartate aminotransferase [AST] levels < 2.5 × ULN [≤ 5.0 × ULN in patients with liver metastasis]), adequate renal function (serum creatinine concentration < 1.5 × ULN and glomerular filtration rate ≥ 50 mL/min/1.73 m2, as calculated using the Cockcroft–Gault formula), adequate pancreatic function (amylase and lipase levels < 1.5 × ULN), an international normalized ratio ≤ 1.5 × ULN, and a partial thromboplastin time or activated partial thromboplastin time ≤ 1.5 × ULN.","Patients were excluded if they were infected with human immunodeficiency virus or hepatitis B or C viruses; had uncontrolled hypertension, cardiac disease, ventricular arrhythmias requiring antiarrhythmic therapy, or a clinically significant abnormal electrocardiogram (ECG; including congenital long QT syndrome, QT interval corrected for heart rate [HR] according to Fridericia’s formula [QTcF] > 450 ms at screening, PR interval > 240 ms or ≤ 110 ms, evidence of second- or third-degree atrioventricular block, Q-wave > 40 ms or depth > 0.4–0.5 mV, evidence of ventricular pre-excitation, evidence of complete left bundle branch block, complete or incomplete right bundle branch block) or HR (persistent HR < 45 bpm or > 100 bpm); had a Child–Pugh score ≥ 6; or had received chemotherapy, hormonal therapy, investigational drugs, or radiotherapy within 28 days and/or had not recovered (grade ≥ 1) from prior therapy",in Cycle 2 when study drugs were coadministered,NA
31703728,NCT02120469.,Combination,No,patients with metastatic triple-negative breast cancer,"Informed consent forms were signed by all patients prior to study entry. Main patient eligibility criteria included the following: age ≥ 18 years; life expectancy of ≥ 3 months; ECOG performance status 0–2; histologically confirmed TNBC (ER < 10%, PR < 10%, HER-2neunegative defined by IHC 0 or 1, or FISH-negative); 0–3 lines of prior chemotherapy for metastases; prior treatment with anthracycline and/or taxane therapy including (neo) adjuvant setting; adequate bone marrow reserve (hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥ 1500/mm3, platelet count ≥ 100,000/mm3); adequate renal function defined by creatinine ≤ 1.5× the upper limit of normal (ULN); adequate liver function defined by total bilirubin ≤ 1.5× ULN, alanine transaminase (ALT), and aspartate transaminase (AST) ≤ 2.5× ULN (≤ 5× ULN in patients with liver metastases); able to obtain baseline computed tomography (CT), bone scan, or positron emission tomography (PET)/CT; and able to provide written informed consent. The mandatory use of dexamethasone mouthwash (alcohol-free 0.5 mg/5 mL dexamethasone solution) was amended at time of dose level B1 to reduce oral mucositis based on SWISH study results .","The main exclusion criteria included the following: chemotherapy or radiotherapy within 2 weeks prior to study entry; persisting ≥ grade 2 AE defined by NCI CTCAE v4.0 at screening visit except alopecia; untreated or unstable brain metastases; prior eribulin or everolimus use; HIV; chronic hepatitis B or C (known from the existing medical record); concomitant use with strong or moderate CPY3A4/PgP inhibitors and CPY3A4/PgP inducers; uncontrolled current illness including, but not limited to, ongoing or active infection (≥ grade 2 based on the NCI CTCAE v4.0); symptomatic congestive heart failure, unstable angina pectoris, or myocardial infarction within the past 6 months; cardiac ventricular arrhythmias requiring anti-arrhythmic therapy; unable to take oral medication; history of non-compliance to medical regimens; and psychiatric illness or social situations that would limit compliance with study requirements.",during the first cycle of therapy,NA
6590530,NA,Single Drug,No,advanced malignant neoplasms,"All patients selected for Phase I study had clinically and histologically documented advanced malignant neoplasms. Patients either had become resistant to conventional treatments or were known to be poorly responsive to standard drugs. All study patients had a life expectancy greater than 6 to 8 weeks and a performance status > 50 (Karnofsky scale). The age ranged from 4 to 71 years. Prior to starting 4-dm DNR, patients had recovered from toxicity of prior chemotherapy and/or radiotherapy. An acceptable hematologic status (leukocyte count > 4,000/mm 3 and platelet count > ll0,000/mm3), adequate hepatic and renal function (serum bilirubin and creatinine < 1.5 mg/dl) were required. ",No patient had a history of congestive heart failure or clinical and electrocardiographic evidence of severe cardiovascular disease. Patients suffering from gastrointestinal disturbances that could influence drug absorption were excluded from the oral administration of 4-dm DNR. ,NA,NA
19509146,NA,Single Drug,No,"Patients with Advanced Solid Tumors. Tumor type: NSCLC (1 unspecified) 6, Renal cell carcinoma 4, Gallbladder adenocarcinoma 2, Other* 9 (tumors include pancreatic adenocarcinoma, bladder carcinoma, papillary carcinoma of the thyroid, colorectal carcinoma, esophageal adenocarcinoma, endometrial stromal sarcoma, intestinal adenocarcinoma, giant cell carcinoma, and oral cancer (one of each))","Patients ages >=18 y were eligible if they had a histologically or cytologically confirmed diagnosis of an advanced solid tumor, measurable disease, progression following standard therapy (or a tumor for which no standard therapy exists), received no more than two prior chemotherapy regimens for metastatic disease, a Karnofsky Performance Status of >= 70%, and a life expectancy of >= 3 months. Requirements for adequate organ function included an absolute neutrophil count of >= 1,500/uL, platelets >= 100,000/uL, creatinine V1.5 mg/dL, total bilirubin <= 1.5 mg/dL, and aspartate transaminase and alanine transaminase <= 2 times the upper limit of normal. Patients were not permitted to use medications metabolized by CYP3A4 or potent inhibitors or inducers of CYP3A4 (eribulin is a CYP3A4 substrate; ref. 12), or therapeutic doses of anticoagulants. Prophylactic use of antiemetics, antidiarrheals, and antiallergic measures, such as corticosteroids and antihistamines, were permitted. Prophylactic use of filgrastim, pegfilgrastim, and erythropoietin were permitted after the first treatment cycle.",Patients were excluded if they had received chemotherapy within 3 wk of eribulin treatment (6 wk for nitrosoureas) or significant comorbid conditions. ,during cycle 1 (and cycle 2 if the patient had undergone intrapatient dose escalation),NA
25349975,NA,Combination,No,"advanced solid tumors. Primary sites of disease: Non-small cell lung 6, Small cell lung 3, Breast 4, Colon/gastric/oesophagus/stomach/bile duct 5, Pancreas 5, Head/neck (squamous) 6, Adrenal 2, Other: renal/bladder/ovary/liver/sarcoma 5 (1 of each)","Eligible patients enroled in the study were at least 18 years old and had histologically confirmed malignancy that was metastatic or unresectable and for which standard curative or palliative measures did not exist. Patients were allowed two or fewer prior chemotherapy regimens for advanced disease. Prior neoadjuvant or adjuvant chemotherapy was allowed if received >= 6 months before. Patients were required to have Eastern Cooperative Oncology Group (ECOG) performance status <= 2, life expectancy > 3 months, and adequate function of all major organs (including bone marrow, liver, kidney, and lungs). ","Exclusion criteria included having received chemotherapy or investigational therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) before study initiation, prior cumulative dose of cisplatin greater than 300 mg m-2, failure to successfully complete local therapy for brain metastasis and women who were pregnant or breast-feeding. Additional exclusion criteria included a positive human immune virus test, any medically uncontrolled cardiovascular illness, and preexisting grade 2 or higher neuropathy",during the first cycle,NA
1963273,NA,Combination,No,small-cell lung cancer,"Patients with histologically proven untreated small-cell lung cancer. Age <70 years (the biological age, e.g., performance status is relevant). Performance status: WHO grade 0, 1, 2; life expectancy at least 12 weeks. Normal cardiac function by cardiac scan with an ejection fraction>= 55%; no myocardial infarction within the previous 12 months, no persistent angina, no arrhythmia. Measurable or evaluable tumor parameters. Blood picture compensated (white blood cells > 4,000/ul, platelet count higher than 100,000.ul). No brain metastases. Informed consent.",NA,NA,NA
6511241,NA,Single Drug,No,"various solid tumors. Tumor types, Colon 12, Lung 5, Ovary 1, Brain 1, Bladder 1, Stomach 1, Head and neck 1, Breast 1, Melanoma 1, Soft tissue sarcoma 1, Kidney 1","All patients selected for this trial had histologically confirmed solid malignancies refractory to conventional therapy or for which no treatment of established effectiveness existed. They had completely recovered from major toxic effects induced by prior therapy. All patients had white blood cell counts (WBC) >= 4000/u1 and platelet counts >= 100,000/u1, maximum serum creatinine and bilirubin levels of 1.5 mg%. None of the patients had an overt heart failure or significant arrhythmia. Expected survival upon entry into the trial was longer than 6 weeks. ",NA,NA,NA
15886476,NA,Combination,No,"Patients with Advanced Solid Tumors. Tumor primaries: Small-cell lung cancer 18, Ovarian 19, Cancer of unknown primary 14, Head and neck, 14, Non-small-cell lung cancer 12, Bladder 11, Non-Hodgkin’s lymphoma 11, Mesothelioma 11","Eligibility criteria for all patients included age 16–75 years, performance status 0–2 at the ECOG (Eastern Cooperative Oncology Group) scale, life expectancy of at least 12 weeks, absence of clinically severe (worse than grade 1) neuropathy, psychiatric illness, pregnancy or lactation. All patients had adequate bone marrow (white blood cell count (WBC) > 3.5 x 10 9 /l, absolute neutrophil count (ANC) > 1.5 x 10 9 /l, platelet count > 100 x 10 9 /l), renal (serum creatinine > 1.5 x upper limit of normal (ULN) and glomerular fi ltration rate 1 50 ml/min as assessed by the Cockcroft-Gault formula) and hepatic (serum bilirubin ! 1.25 ! ULN, serum transaminases < 2 x ULN or < 5 x ULN in the presence of liver metastases) function. All patients should have histologically or cytologically proven locally advanced or metastatic unresectable solid tumors and discontinuation of previous chemotherapy at least 4 weeks (6 weeks for nitrosoureas, melphalan, mitomycin C) before enrollment. Extended fi eld radiotherapy should have been stopped at least 6 weeks prior to study entry. Prior administration of platinum compounds was allowed. Before enrollment in the trial, all patients provided written informed consent.",NA,the first 2 cycles of chemotherapy,NA
24132922,NA,Combination,No,"patients with high-risk (intermediate/high grade, >5 cm) extremity soft tissue sarcoma undergoing limb salvage surgery","Eligible patients were > 15 years of age with histologically confirmed intermediate or high grade (grade 2–3 on a 3- point scale or grade 2–4 on a 4-point scale) soft tissue sarcoma of the extremities or body wall. Patients had no contraindications to limb sparing surgery. Patients with metastatic disease (excluding brain metastases) were allowed, if they were appropriate candidates for resection of the primary tumor. No prior chemotherapy, radiation, or biotherapy was permitted. Patients had Eastern Cooperative Group performance status of 0 or 1, adequate organ function, and left ventricular ejection fraction (LVEF) >= 50%.","Excluded histologies were rhabdomyosarcoma (patients with pleomorphic rhabdomyosarcoma were eligible), Ewing sarcoma, primitive neuroectodermal tumor, osteosarcoma, or gastrointestinal stromal tumor. Tumors were superficial or deep and >5 cm in greatest dimension. Patients with systolic blood pressure >150 mmHg or diastolic pressure >90 mmHg despite optimal medical management, serious bleeding or major surgery within the previous 4 weeks, coagulopathy, severe peripheral vascular disease, or malabsorption problems were excluded.",the first 8 weeks of therapy,NA
34036220,NCT01911507,Combination,Yes,Patients With MET-Positive Non–Small-Cell Lung Cancer,"Key eligibility criteria included advanced/metastatic NSCLC with measurable disease, age ≥ 18 years, Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2, MET increased copy number by fluorescence in situ hybridization (FISH; CNG or MET/CEN7 ratio outside of normal range), MET IHC 2-3+, positive reverse transcriptase polymerase chain reaction (RT-PCR) value, or an exon 14 splice site mutation (Data Supplement). Patients in cohort A must have an EGFR activating mutation and a biopsy at the time of progression that shows evidence of MET positivity.",NA,in cycle 1,NA
33235994,NA,Combination,No,recurrent glioblastoma,"Adult patients ≥18  years of age with histologically confirmed intracranial GBM or gliosarcoma and unequivocal tumor progression determined by MRI were eligible. Baseline imaging was required to be within 14 days prior to trial registration, and steroid dose was required to be stable for at least 5 days. Patients were required to have recovered from toxic effects of prior drug therapy: 28 days from any investigational agent, 28  days from prior cytotoxic therapy, 14  days from vincristine, 42  days from nitrosoureas, 21  days from procarbazine administration, and 7 days from noncytotoxic agents. Patients who underwent recent resection of recurrent or progressive tumor were eligible as long as they had recovered from the effects of surgery, regardless of presence of postsurgical residual disease. Patients were required to have failed radiation therapy 42  days or more prior to registration. Furthermore, patients were required to meet the following criteria: Karnofsky performance status (KPS) ≥ 60, adequate bone marrow function (WBC ≥3000/mcl, ANC ≥1500/mm3, platelet count ≥100,000/mm3, and hemoglobin ≥10 gm/dL), total bilirubin within normal limits, liver transaminases (AST/ALT) ≤2.5× upper limit of normal, creatinine < 1.5 mg/ dL, INR <1.5 (or < 3.0 for patients on chronic anticoagulation therapy). ","Patients receiving enzyme inducing antiepileptic drugs (EIAEDs) or any other CYP3A4 inducers (except dexamethasone) were excluded. For women of child-bearing age, contraception was required for trial participation, and pregnant patients were excluded",during cycle 1,NA
32548867,NCT02642913,Combination,No,Patients with Advanced Hepatocellular Carcinoma,"Histologic proof of HCC reviewed and confirmed at per the local standard of care. Advanced unresectable or metastatic disease. Measurable disease as defined by RECIST version 1.1. Tissue available for the evaluation of AR by IHC on pretreatment HCC samples. If tissue is not available, a pretreatment biopsy will not be necessary for eligibility. Age ≥ 18 years-old. ECOG performance status ≤ 2. Child-Pugh category A. Adequate hepatic function defined by: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5.0 x upper limit of normal (ULN), Total Bilirubin ≤ 1.5 x ULN. Adequate hematologic function defined by: Absolute neutrophil count (ANC) ≥ 1200/mm3 (≥ 1.2 x 10^9/L), Platelets ≥ 75,000/mm3 (≥ 75 x 10^9/L), Hemoglobin ≥ 8 g/dL (≥ 80 g/L). Adequate renal function defined by: Serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance ≥ 40 mL/min (using the Cockcroft-Gault equation). Patients must be on antiviral therapy per the local standard of care if active or occult hepatitis B (HBV) infection. Patients with active hepatitis C (HCV) may not be antiviral therapy. Patients with a history of hypertension should be well controlled (BP ≤ 140/90) on a regimen of antihypertensive therapy. Gastrointestinal disorders in the opinion of the treating physician that would impair absorption. Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study. Patients with history of liver transplantation may be eligible for the dose expansion cohorts (Parts 2A and 2B) of this study provided all eligibility criteria are met and provided the subject has not had any episodes of acute rejection or serious opportunistic infection within 3 months from enrollment. Female subjects of childbearing potential must not be pregnant or lactating at screening. Participants must be capable of understanding and complying with the protocol requirements and signing informed consent. Certain immunosuppressive agents such as tacrolimus and sirolimus are prohibited due to drug interaction risk thus liver transplant patients who require these medications for immunosuppression are not eligible. Patients receiving everolimus at immunosuppressive dosages are eligible since the everolimus doses used are lower than standard anti-neoplastic dosages and this agent does not demonstrate anti-cancer activity in HCC. Everolimus does not interact adversely like other immunosuppressive agents.","Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma. For patients who will receive enzalutamide monotherapy, failure or intolerance of prior sorafenib is required for enrollment. For patients who will receive combination therapy, prior sorafenib is excluded. Patients may not have received cytotoxic, biologic or small molecule kinase inhibitor systemic therapy f or at least 3 weeks prior to the first dose of study treatment. Patients must not have received prior regional therapy such as ablation, embolization, or radiation therapy for at least 2 weeks prior to the first dose of study treatment. Patients who receive such therapy should have evidence of radiologic progression at this site or other progressing measurable disease. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 3 months before study enrollment. Eligible subjects must be without corticosteroid treatment at the time of study enrollment. History of seizure including febrile seizure or any condition that may predispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization). Also, current or prior treatment with antiepileptic medications for the treatment of seizures or history of loss of consciousness or transient ischemic attack within 12 months of enrollment. Clinically significant cardiovascular disease including: Myocardial infarction within six months prior to Screening; Uncontrolled angina within three months prior to Screening; Congestive heart failure NYHA class 3 or 4, or subjects with history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or MUGA scan; performed within 3 months results in a left ventricular ejection fraction that is ≥ 45%; History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes); History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place; Anticoagulation with warfarin. Inability to swallow tablets. Subjects with history of another primary cancer, with the exception of: curatively resected non-melanoma skin cancer; curatively treated cervical carcinoma in situ; other primary solid tumor with no known active disease present in the opinion of the investigator will not affect patient outcome in the setting of current HCC. Patients who are on strong inhibitors of CYP2C8, strong or moderate inducers of CY3A4 and CYP2C8 should discontinue these medications 2 weeks prior to the start of treatment",in cycle 1,NA
31822498,NCT02457910,Combination,No,Patients with AR+ Metastatic Triple-Negative Breast Cancer,"Eligible patients were >= 18 years old, with metastatic invasive mammary carcinoma. All participants were required to (i) provide informed written consent; (ii) have tumors demonstrating AR positivity (defined as >= 10% of tumor cell nuclei positive for AR by IHC) after central review at Vanderbilt University Medical Center; (iii) have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and (iv) an adequate hematologic, hepatic, and renal function. Patients were eligible for enrollment into the phase Ib portion regardless of tumor ER/PGR status (negative or positive), whereas phase II patients were required to be triple negative; defined as ER and PGR-negative (ER/PGR expression <1% cells by IHC) and HER2- negative [acceptable methods of HER2 analysis included IHC (0, 1þ), fluorescence in situ hybridization (FISH) with HER2/centromere on chromosome 17 (CEN17) ratio < 2, and/or chromogenic in situ hybridization with HER2/CEN-17 ratio <2 and average HER2 copy number < 4, and/or chromogenic in situ hybridization with HER2/CEN-17 ratio < 2 and average HER2 copy number < 4; by local assessment]. Patients with any number of prior therapies including prior antiandrogen therapy, other than enzalutamide, were allowed as long as they had adequate performance status and met all other eligibility criteria. Patients were also required to have measurable or bone-only evaluable disease; measurable disease was defined as at least one lesion that could be accurately measured in at least one dimension by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1, with radiology scans within 21 days of day 1, cycle 1.","Any kind of malabsorption syndrome significantly affecting gastrointestinal function, including history of Crohn's disease or inflammatory bowel disease. Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, biologic therapy) other than the ones specified in the protocol; patients must have discontinued the above cancer therapies for 1 week prior to the first dose of study medication, as well as recovered to baseline from toxicity induced by previous treatments; any investigational drugs should be discontinued 2 weeks prior to the first dose of study medication and radiotherapy must have been completed >= 2 weeks prior to initiation of study drug (cycle 1, day 1). Prior use of PI3K or Akt inhibitors in the metastatic setting for the treatment of cancer; these include, but are not limited to: taselisib, GDC-0941, GDC-0980, BEZ235, BKM120, LY294002, PIK-75, TGX-221, XL147, XL765, SF1126, PX-866, D-87503, D-106669, GSK615, CAL101; patients who have received PI3K/Akt inhibitors previously for < 4 weeks will be eligible. Prior treatment with enzalutamide. Current or previously treated brain metastasis or active leptomeningeal disease; head imaging is required during screening in all patients to exclude the presence of central nervous system (CNS) metastatic disease. History of seizure or any condition that may predispose to seizure; history of loss of consciousness or transient ischemic attack within 12 months before day 1. Pregnant or lactating women. Insulin-dependent diabetes; patients with type II diabetes must meet the inclusion criteria outlined above. Uncontrolled intercurrent illness including, but not limited to: Ongoing or active infection requiring parenteral antibiotics; Impairment of lung function (chronic obstructive pulmonary disease [COPD] > grade 2, lung conditions requiring oxygen therapy) or current dyspnea at rest; Symptomatic congestive heart failure (class III or IV of the New York Heart Association classification for heart disease); Known left ventricular ejection fraction (LVEF) < 50%; Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months; Uncontrolled hypertension (systolic blood pressure > 160 mm Hg or diastolic blood pressure > 100 mm Hg, found on two consecutive measurements separated by a 1 or 2-week period despite adequate medical support); Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment [National Cancer Institute-Common Terminology Criteria for Adverse Events, version 4.0, grade 3]); Corrected QT using the Fridericia correction formula (QTcF) >= 480 msec on screening electrocardiogram (EKG); Known history of QT/correct QT (QTc) prolongation or Torsades de Pointes (TdP); ST depression or elevation of >= 1.5 mm in 2 or more leads; Diarrhea of any cause >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2; Active autoimmune disease that is not controlled by nonsteroidal or steroidal (< 10 mg of prednisone per day) anti-inflammatory drugs or active inflammatory disease, including small or large intestine inflammation such as active Crohn's disease or ulcerative colitis, which requires immunosuppressive therapy; Psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance/pill diary; Known history of chronic liver disease including cirrhosis, current alcohol abuse, or infection with hepatitis B virus or hepatitis C virus (active or carrier) or renal failure; Known history of chronic pancreatitis; Conditions that affect lymphocyte counts, such as human immunodeficiency virus (HIV) infection or immunosuppressive therapy. Use of prohibited drugs",during cycle 1 (first 4 weeks),NA
18465342,NA,Combination,No,advanced breast cancer,"Eligible patients were women aged 18-74 years with histologically verified and locally advanced or metastatic breast cancer either progressing during treatment or relapsing after an antracycline-containing regime administered either as first-line chemotherapy for metastatic disease or in the adjuvant setting. Patients were required to have WHO performance status <= 2 and at least one measurable or evaluable lesion, and adequate haematological parameters (WCC > 3 x 09/, platelets > 100 x 109/l) and biochemical measures of hepatic and renal function (ASAT/ALAT <= 120 iu/l, bilirubin <= 35 mmol/l, creatinine <= 140 mmol/l).","Exclusion criteria were prior or concomitant malignant disease except appropriately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix, clinical symptoms suggesting peripheral neuropathy or brain metastases, prior irradiation of 25% or more of the red bone marrow, and more than one prior cytotoxic treatment for locally recurrent or metastatic disease",the first cycle,NA
25985977,NCT01642251,Combination,No,in extensive stage small cell lung cancer,"Salient eligibility criteria included: age of 18 years or above with pathologically confirmed SCLC or large cell neuroendocrine NSCLC, not pregnant and not breastfeeding if a female of childbearing potential, extensive stage SCLC or stage IV (AJCC 7th edition) if large cell neuroendocrine NSCLC; measurable disease by RECIST 1.1 criteria, ECOG performance status 0 or 1; and acceptable organ function.","Due to a suspected increased risk of seizures in patients with brain metastasis enrolled on other ongoing studies of veliparib at the time of study initiation, patients with CNS metastases were excluded from this study. Also, patients who had received prior chemotherapy for their diagnosis of SCLC were not eligible. T",during cycle 1,NA
29980894,NCT00858377,Single Drug,No,"adult patients with advanced solid tumors. Tumor types included ovarian (n = 4), breast (n = 6), prostate (n = 2), colon (n = 9), rectal (n = 2), and small-cell lung cancers (n = 3), and other (n = 24)","Patients were ≥ 18 years old with advanced solid tumors refractory to standard treatment, for which no standard therapy was available, or for which the patient refused standard therapy. Patients had to have an Eastern Cooperative Oncology Group (ECOG) performance status ≤2; life expectancy >3 months; measurable disease by RECIST; and adequate hematologic, renal, and hepatic functions. In the doseexpansion phase, patients with three tumor types were enrolled: (1) platinum-resistant and taxane-resistant epithelial ovarian cancer (measureable per RECIST or GCIG criteria if nonmeasurable per RECIST); (2) taxane-resistant TNBC with ≥1 previous therapy for metastatic disease (measureable per RECIST); and (3) castration-resistant and taxane- or cisplatin/ etoposide–resistant stage 4 prostate cancer (measureable per RECIST) with high-grade neuroendocrine or anaplastic clinical or pathological features. These tumor types were selected based on high unmet need after chemotherapy failure, association of AURKA amplification or Aurora kinase overexpression with advanced clinical stage and poor prognosis, and evidence of clinical activity with Aurora kinase inhibitors in preclinical and clinical models ","Patients were excluded if they had active parenchymal brain metastases, prior bone marrow transplant, history or presence of hematologic malignancies, history of bleeding diathesis, or active peptic ulcer disease. Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication. Active peptic ulcer disease. Gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (eg, Crohn's disease, ulcerative colitis). Active infection requiring intravenous (IV) antibiotics within 2 weeks of study enrollment (day 1). Known positive test for HIV. Active or chronic hepatitis B or hepatitis C infection, determined by serologic tests. Unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of alopecia. Anti-tumor therapy within 28 days of study day 1; concurrent use of hormone deprivation therapy for hormone-refractory prostate cancer or breast cancer is permitted. Treatment with immune modulators including, but not limited to, corticosteroids, cyclosporine and tacrolimus within two weeks prior to enrollment. Therapeutic or palliative radiation therapy within two weeks of study day 1. Systemic anticoagulation therapy, including warfarin, within 28 days of day 1. Prior treatment with aurora inhibitors. Prior participation in an investigational study (drug or device) within 28 days of study day 1. Major surgery within 28 days of study day 1. Any co-morbid medical disorder that may increase the risk of toxicity, in the opinion of the investigator or sponsor",in the first two treatment cycles (days 1– 28),NA
19956953,NA,Single Drug,No,patients with advanced solid tumors of epithelial origin with the most common tumor type being esophageal (n = 4),"The study population comprised adult patients with advanced and/or metastatic solid tumors of epithelial origin either refractory to previous therapy, or not deemed candidates for further cytotoxic chemotherapy. It was considered appropriate to permit enrollment to a broad patient population and not restrict to the approved indication for single agent erlotinib of patients with previously treated NSCLC. Patients must have had a minimum of 21 days from last chemotherapy, and recovered from treatment-related toxicities. Patients had an ECOG PS <= 2, a predicted life expectancy of at least 12 weeks, and adequate hematopoietic, hepatic, and renal function. An entry criterion of patients refraining from smoking for 25 days (14 days prestudy and 11 days on study) was imposed to reduce the inter-patient variability of erlotinib pharmacokinetics given the known impact of smoking on erlotinib plasma clearance",NA,within the Wrst 7 days of treatment,NA
23860642,NA,Combination,No,extensive-stage small cell lung cancer,"Patients with histologically documented, advanced solid malignancy refractory to standard therapy or for which no curative standard therapy was available were considered eligible for the dose escalation cohort. In the expanded cohort, patients with histologically or cytologically confirmed extensive-stage small cell lung cancer without any prior treatment were enrolled. Patients with a history of limited stage-SCLC were permitted to have prior definitive chemoradiotherapy and prophylactic cranial irradiation if recurrence was >6 month from definitive therapy. Other key eligibility criteria included: ≥18 years, Eastern Cooperative Oncology Group performance status of 0 to 2, adequate hematologic, hepatic and renal functions (WBC≥3000/ml, absolute neutrophil count≥1500/ml, platelets≥100,000/ml, total bilirubin <1.5 mg/dL, AST/ALT≤2.5 x the institutional upper limit of normal, creatinine <1.5x institutional upper limit of normal or measured creatinine clearance≥45 ml/min/1.73 m2 for patients with creatinine levels above institutional normal); and life expectancy greater than 12 weeks.","Patients were excluded if they had untreated brain metastasis, were treated within 4 weeks with chemotherapy or radiation therapy, received prior racemic gossypol or AT101 or BH3 mimetic or had a history of allergic reactions attributed to compounds of similar chemical or biologic composition to AT-101.",during the first 21 days of treatment,NA
26376115,NCT01279096,Combination,No,Childhood High Risk Relapse of Acute Lymphoblastic Leukemia,"1 to 21 years old at the date of acute lymphoblastic leukemia initial diagnosis. Very early medullary first relapse occurring during the first 18th months after complete remission OR patients with second relapse OR a relapse occurring 6 months or more after myeloablative stem cell transplantation will be eligible. Have a Karnofsky Performance Status (KPS) of ≥70 for patients >10 years of age or a Lansky Performance Status (LPS) of ≥60 for patients ≤10 years of age. No concomitant malignant disease. No active uncontrolled infection. Have adequate renal and hepatic functions. absence of concomitant severe cardiovascular disease, i.e. congestive heart failure. Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment. Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.","Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol. Use of any investigational agent within 30 days. Known hypersensitivity to clofarabine or excipients. Known hypersensitivity to mitoxantrone, etoposide or excipients. Allergy to both E Coli-Asparaginase and Erwinia Asparaginase. Prior transplant less than 6 months ago. Trisomy 21. Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment. Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment). Pregnant or lactating patients. Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.",during the first course of treatment,NA
17878176,NA,Combination,No,"locally advanced, non-operable pancreatic adenocarcinoma","Patients with histologically confirmed, newly diagnosed, locally advanced nonmetastatic adenocarcinoma of the pancreas were eligible for entry onto this study. Metastases were required to be excluded by diagnostic laparoscopy or exploratory laparotomy in all patients. Additional inclusion criteria were as follows: No prior chemotherapy or radiation for pancreas cancer; Age >18 years; ECOG performance status (PS) zero to two; Life expectancy of >12 weeks; Adequate organ and marrow function; Patients of child-bearing potential were required to use adequate contraception (hormonal or barrier method of birth control) before study entry and for the duration of study participation; Ability to understand and willingness to sign a written informed consent document; Measurable or assessable disease was required.","Patients were excluded if they had received prior chemotherapy or radiotherapy for pancreas cancer, had an active intercurrent illness or gastrointestinal disease or pathology that limited absorption of oral medication.",minimum of 8 weeks,NA
29119643,NCT01681537,Combination,No,patients with acute myeloid leukemia,"All patients signed an informed consent, and the study was conducted in accordance with the Declaration of Helsinki. The study included adult patients aged 18 to 70 with a diagnosis of AML according to the 2008 WHO criteria, and included patients who had either relapsed after or were refractory to one or more cycles of remission induction chemotherapy, according to standard International Working Group criteria.30 Patients with secondary AML were eligible, as well as patients with biphenotypic leukemia. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and intact organ function including a left ventricular ejection fraction >= 50%, creatinine< 2 mg/dL with an estimated glomerular filtration rate >= 60 ml/min, a total bilirubin less than 1.5 times the upper limit of normal (ULN) and an aspartate aminotransferase and alanine aminotransferase <= 3 times the ULN. Patients could receive hydroxyurea, steroids, or leukapheresis as needed until day 5 of the protocol treatment, but were required to be at least 14 days from prior treatment with cytotoxic chemotherapy or investigational agent and, if previously transplanted, at least 90 days from an allogeneic stem cell transplant, 60 days from any donor lymphocyte infusion, and without active graft versus host disease (GVHD) requiring immunosuppressive therapy.",Pregnant or breastfeeding Known hypersensitivity to thalidomide or lenalidomide Known seropositive for HIV Have had myocardial infarction within 6 months of enrollment or NYHA Class III or IV heart failure Other serious medical conditions or psychiatric conditions Major surgery within 28 days prior to treatment Received investigational agent or cytotoxic chemotherapy (except hydroxyurea) within 2 weeks of study Acute promyelocytic leukemia,during the first 28 days of treatment,NA
12544260,NA,Combination,No,"advanced malignancies. Diagnosis: prostate cancer 7, cervical cancer 2, melanoma 1, colon cancer 1, NSCLC and prostate cancer 1","The inclusion criteria for this study stipulated that patients have advanced cancer that had failed standard treatment or cancer that was not amenable to therapy with standard approaches. Patients had to be 18 years or older and give signed informed consent. It was required that subjects have adequate organ function: neutrophils > 1.5 x 109/l, platelets > 100 x 109/l, hemoglobin > 9 g/dl, serum creatinine <2 mg/dl, AST and ALT < 4 x upper limit of normal, and bilirubin < 2 mg/dl. Patients had to have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2 and measurable or evaluable disease. Female subjects of childbearing potential were required to have a negative pregnancy test and were counseled to avoid pregnancy. ","Breast-feeding was not allowed. The protocol specifically excluded patients with prior neuropathy of any grade because a previous study had shown an unacceptably high neurotoxicity rate with vinorelbine and paclitaxel in patients with pre-existing neuropathy . Subjects who had previously received vinorelbine or paclitaxel could not be included. Radiotherapy to more than 25% of the bone marrow, radiotherapy within 21 days of study entry or chemotherapy within 14 days of study entry was not allowed. Also ineligible were patients who had suffered a myocardial infarct within one year of enrollment, had congestive heart failure (New York Heart Association class 2 or greater), uncontrolled cardiac dysrhythmias, angina pectoris, uncontrolled hypertension or cardiomyopathy.",in the first two cyles of treatment,NA
23370364,NCT00537511,Combination,No,Patients with Extensive-Stage Small-Cell Lung Cancer,"signature of informed consent. Age >= 18. histologically or cytologically confirmed small cell lung cancer (SCLC). extensive stage SCLC. Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2. brain metastases that are asymptomatic and do not require steroid control. females of child bearing potential must use two forms of birth control","pregnant or lactating females; prior use of cytotoxic chemotherapy; surgery within 14 days of study; radiation within 14 days of study; prior therapy with CC-4047 (pomalidomide), lenalidomide or thalidomide; concurrent use or anticipated use of anti-cancer agents; absolute neutrophil count (ANC) < 1500/mm^3; platelets < 100 x 10^3/µL; serum creatinine >2.5 mg/dL; serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) > 3.0 x upper limit of normal (ULN); serum total bilirubin > 1.8 mg/dL; uncontrolled hypercalcemia; creatinine clearance <50 mL/min; uncontrolled hypertension; neuropathy >= grade 2; body mass index (BMI) >= 40; any other active invasive malignancy requiring treatment; known chronic infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); inability or unwillingness to comply with birth control requirements",during cycle 1,NA
26920889,NCT01411267,Combination,No,Childhood Leukemia & Lymphoma ,"Patients were required to be between >1 month and 21 years of age. Eligible patients were required to have ALL in first relapse (>25% bone marrow blasts) with MLL-r or hyperdiploidy or to have AML in  first relapse with  5% bone marrow blasts. Children with relapsed AML were included regardless of FLT3-ITD status due to quizartinib activity against overexpression of WT-FLT3, c-KIT overexpression and mutations, single-agent clinical activity in adult FLT3-WT patients, and the combination of intensive AML reinduction therapy used in this study. Other requirements included adequate liver [serum bilirubin <1.5 times upper limit of normal (ULN) for age, ALT < 5 times ULN for age], renal (derived from the Schwartz formula), cardiac (echocardiogram with shortening fraction  27%), and adequate performance status (Karnofsky or Lansky >50%).","Exclusion criteria included uncontrolled systemic infection, significant cardiovascular disease, and active central nervous system involvement (CNS3). Children with prolonged QT, using the Fridericia's formula to correct for heart rate (QTcF  450 ms) at study entry were not eligible",in the first course,NA
31876107,NCT01331135,Combination,No,children with recurrent or refractory solid and brain tumors,"Patients ≤ 30 years of age with recurrent or refractory solid tumors, including brain tumors, and patients with tumors that had no known curative therapy were eligible. Histologic verification of malignancy was required except for patients with intrinsic brain stem and optic pathway tumors, or pineal tumors with elevated alpha-fetoprotein or beta-HCG. Measurable or evaluable disease was not required for enrollment. Patients were required to have a Karnofsky or Lansky performance score of ≥50; adequate renal and liver function; blood glucose within normal limits, serum triglyceride level ≤ 300 mg/dL, serum cholesterol ≤ 300 mg/dL, and adequate pulmonary function. Adequate bone marrow function, defined as absolute neutrophil count (ANC) ≥ 750/mm3 and transfusion-independent platelet count ≥ 75 000/mm3, was also required for patients without bone marrow involvement. Patients with bone marrow disease were not considered evaluable for hematologic toxicity and had hematologic function requirements waived.","Exclusion criteria included uncontrolled infection, concurrent use of other investigational agents, anticancer agents, cytochrome P450 enzyme-inducing anticonvulsants, or potent CYP3A4 active agents. Patients on stable or decreasing doses of corticosteroids for seven days prior to enrollment were eligible.",during cycle 1,NA
20150371,NA,Single Drug,No,"patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas","Patients were 18 years old and with a life expectancy of .8 weeks. Patients must have a Karnofsky performance status of 60. All patients were required to have a histologically confirmed MG (GBM, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic mixed oligoastrocytoma) or meningioma with unequivocal evidence of tumor progression or recurrence on cranial imaging; patients with GBM post-RT were not allowed to have tumor progression. Patients with low-grade gliomas were eligible if their tumor had undergone malignant transformation confirmed by histologic analysis. Patients having undergone resection of their tumor at recurrence or progression were eligible after they recovered from surgery; evaluable or measurable disease was not required. All patients were required to have pretreatment brain CT or MRI within 14 days of starting therapy and to be on a stable steroid dosage for >= 5 days. The same type of brain imaging was required throughout treatment. All patients had to be on EIAEDs (phenytoin, carbamazepine, oxcarbazepine, phenobarbital, and primidone) to be eligible for enrollment. Patients with radiographic progression of disease within 12 weeks of completion of radiation were required to have clear evidence of disease progression prior to starting erlotinib. If there was a question of radiation changes or necrosis, or for patients treated with interstitial brachytherapy or stereotactic radiosurgery, confirmation of true progressive disease was required, based either on brain imaging (PET, SPECT, MRS or MR perfusion) or tumor-tissue based pathological confirmation. Patients with recurrent MG and meningiomas were limited to 3 prior relapses and 2 prior treatments with chemotherapy or biologic agents. They must have recovered from the toxic effects of these therapies to grade 1 or less and as follows: 4 weeks from prior cytotoxic therapy but 2 weeks from vincristine, 6 weeks from nitrosoureas, 3 weeks from procarbazine administration, 1 week for noncytotoxic agents, for example, cis-retinoic acid and 4 weeks for other experimental biologic agents. For the cohort of patients with stable GBM, no prior chemotherapy (including gliadel wafers) was allowed and treatment would begin within 6 weeks of the completion of radiation. All patients were required to have adequate bone marrow function (WBC >= 3000/ml, ANC >= 1500/mm3, platelet count of 100 000/mm3, and hemoglobin >= 10 mg/dL), adequate liver function (SGOT and bilirubin <1.5 times ULN), and adequate renal function (creatinine <1.5 mg/dL) within 14 days prior to registration","Patients with abnormalities of the cornea based on history, congenital abnormality, abnormal slit-lamp examination, or dry-eye syndrome were ineligible. Patients could not have any significant medical illnesses that would compromise their ability to tolerate this therapy. Known HIV-positive patients receiving combination antiretroviral therapy were excluded from the study due to potential drug interactions. Patients with a history of any other cancer (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off of all for that disease for 3 years, were ineligible. Patients could not be pregnant or breast-feeding. Women of childbearing potential and men agreed to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation and then 12 weeks after study completion.",during the first 28 days of treatment only,NA
20965266,NA,Combination,No,Patients with Primary Refractory and Relapsed and Refractory Non-Hodgkin Lymphoma,"Patients were eligible if they had primary refractory or relapsed and refractory diffuse large B cell (DLBCL), mediastinal B cell, mantle cell lymphoma (MCL), or diffuse large cell transformation of an indolent lymphoma, or relapsed or refractory follicular lymphoma (FL) with high FL International Prognostic Index (FLIPI) . Refractory disease was defined as failure to achieve at least a partial response to either first-line chemotherapy (primary refractory) or the last chemotherapy regimen if given for relapsed disease (relapsed and refractory). Patients were also required to be 18 to 70 years old, have a Karnofsky performance status of >= 70%, and have adequate organ function defined by a left ventricular ejection fraction > 45%, corrected gas transfer (DLCO) >50%, estimated creatinine clearance >60 mL/min/1.73 m2, and serum bilirubin, aminotranferease (AST), and aspartate aminotransferase (ALT) levels <2 x upper limits of normal.","Patients were excluded if they had a prior autologous or allogeneic transplant, active central nervous system lymphoma, uncontrolled infection, or if they were seropositive for human immunodeficiency virus (HIV). ",by day +30 after transplantation,clofarabine in combination with high-dose etoposide and cyclophosphamide followed by autologous peripheral blood stem cell transplantation
27565909,NCT01579929,Combination,No,extensive stage small cell lung cancer,"Patients eligible for inclusion in this study must meet all of the following criteria: SCLC pathologically confirmed at MSKCC. Untreated ES- SCLC, defined as those patients with extrathoracic metastatic disease, malignant pleural effusion, bilateral or contralateral supraclavicular lymphadenopathy, or contralateral hilar adenopathy. Age 18 years or older. Karnofsky Performance Status ≥ 70. Presence of at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). Adequate bone marrow, liver and renal function, as specified below: Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L. Hemoglobin (Hgb) ≥ 9 g/dL. Platelets ≥ 100 x 109/L. Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN ). AST and ALT ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present. Plasma creatine phosphokinase (CK) < 1.5 x ULN. Serum creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal. Patients with asymptomatic CNS metastases will be eligible. For patients that have undergone radiation therapy for their CNS metastases, a minimum of 14 days must elapse prior to study registration, and patients must have recovered from any adverse events related to radiotherapy with the exception of alopecia and grade 1 neuropathy.","Patients eligible for this study must not meet any of the following criteria: Patients who have had major surgery within 4 weeks of initiation of study medication. Patients who are unable to take oral drugs. Patients who have previously been treated with systemic LDE225 or with other Hh pathway inhibitors. Patients who have taken part in an experimental drug study within 4 weeks of initiating treatment with LDE225. Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy, or radiotherapy) concurrently or within 2 weeks of starting treatment. Patients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy). Patients who are on concomitant treatment with drugs that are contraindicated in this study and that cannot be discontinued within the time frames as listed. Patients who are planning on embarking on a new strenuous exercise regimen that can result in significant increases in plasma CK levels. Patients who are receiving treatment with medications known to be moderate and strong inhibitors or inducers of CYP3A4/5 or with drugs metabolized by CYP2B6 or CYP2C9 that have narrow therapeutic index that cannot be discontinued before starting treatment with LDE225. Medications that are strong CYP3A4/5 inhibitors should be discontinued at least 7 days and strong CYP3A/5 inducers should be discontinued for at least 14 days prior to starting treatment with LDE225 Some of these medications are recognized to cause rhabdomyolysis.)。 Patients who are receiving treatment with statins that are known to cause rhabdomyolysis and that cannot be discontinued at least 2 days prior to starting LDE225 treatment. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements. Impaired cardiac function or clinically significant heart disease, including any one of the following: congestive heart failure, angina pectoris within 3 months, acute myocardial infarction within 3 months, QTcF > 450 msec for males and > 470 msec for females on the screening ECG, history of clinically significant ECG abnormalities, family history of prolonged QT-interval syndrome, or other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen). Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL). Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and 4 months after the last study treatment. Highly effective contraception methods include the following: Total abstinence or Male or female sterilization or Combination of any two of the following (a+b or a+c, or b+c): Use of oral, injected, or implanted hormonal methods of contraception. Placement of an intrauterine device (IUD) or intrauterine system (IUS). Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to initiation of the study. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential. Sexually active males must use a condom during intercourse while taking the drug and for 6 months after stopping treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.","throughout the first 2 cycles (42 days following the first dose on cycle 1, day 1)",NA
11391583,NA,Combination,No,Patients with Hormone-Refractory Prostate Carcinoma,"Eligible patients had a histologic diagnosis of adenocarcinoma of the prostate with progressive systemic disease despite at least two endocrine manipulations. One of the manipulations included either orchiectomy, a luteinizing hormone-releasing hormone (LHRH) analogue with or without antiandrogens, megesterol acetate, or diethylstilbestrol. For patients on an antiandrogen, discontinuation of the agent was required as a second hormonal manipulation for a minimum of 4 weeks with evidence of subsequent rising PSA level or progressive, measurable disease. Patients were required to have a minimum life expectancy of 3 months and an Eastern Cooperative Oncology Group performance score <= 2. Additional requirements were adequate hepatic and renal function, granulocyte count >= 1500/uL and platelet count >= 100,000/uL. Patients were required to be at least 3 weeks beyond surgery, recovered from infectious process, and have no significant active medical illness that would preclude protocol treatment or survival. Prior radiation to a symptomatic metastatic site that was not the only measurable or evaluable lesion was allowed. Radiation therapy and corticosteroids had to be completed at least 2 weeks before therapy. Hydronephrosis with impaired renal function had to be adequately decompressed. ","Patients with central nervous system metastasis, unstable angina, uncontrolled congestive heart failure, or arrhythmia were excluded.",NA,NA
24368401,NCT00466466,Combination,No,patients with extensive-stage small-cell lung cancer,"Inclusion criteria: Patients with histologically or cytologically confirmed diagnosis of extensive disease small-cell lung cancer (ED SCLC). Age ≥ 18 years. WHO Performance Status Grade ≤ 1 (ie. ability to perform normal daily functions). Adequate bone marrow, liver and renal function","Chronic steroid treatment. Prior treatment with chemotherapy for advanced lung cancer. Prior treatment with mTOR inhibitors. Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers, eye conditions, chronic liver or kidney disorders, uncontrolled diabetes, infections or other severe medical conditions. Symptomatic or uncontrolled brain metastases. Other cancers within the past 5 years. Pregnant or breastfeeding women",within their first treatment cycle,NA
20922800,NCT00569114,Combination,No,Advanced Nonsmall Cell Lung Cancer,"Adult (>=18 years of age) patients with histologically confirmed stage IIIB (pleural effusion) or stage IV NSCLC that was measurable or evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) were eligible. Patients with central nervous system (CNS) metastases were eligible if their CNS disease was asymptomatic and stable after radiotherapy for >=2 weeks and they did not require corticosteroids for >=1 week. Patients must have failed at least 1 prior chemotherapy regimen or refused chemotherapy. Prior treatment with an EGFR TKI or ongoing treatment with erlotinib (150 mg/day) at study entry was allowed, but patients with disease progression at study entry while actively receiving an EGFR inhibitor were excluded. No patient entered the study on erlotinib. Of the 8 patients with prior erlotinib or gefitinib treatment, 2 had a partial response, 3 had stable disease (SD), and 2 had progressive disease as their best response to prior EGFR TKI therapy. In 1 patient, the previous response to erlotinib was unknown. Patients must have had an Eastern Cooperative Oncology Group performance status of 0, 1, or 2 and adequate organ function","Patients were ineligible if they had received prior treatment with a COX-2 inhibitor for metastatic NSCLC, radiation therapy <2 weeks prior to study entry, or chemotherapy, noncytotoxic investigational agents, or highdose corticosteroids within 3 weeks of initiating study treatment. Patients were excluded if they had a history of myocardial infarction, stroke, or cardiac intervention within 12 months; a history of gastrointestinal bleeding, ulceration, or perforation; or hypersensitivity to apricoxib, erlotinib, aspirin, or other nonsteroidal anti-inflammatory drugs (NSAIDs). Concurrent use of COX-2 inhibitors or other NSAIDs (within 2 days) or aspirin (within 7 days) of the first dose of study drug, antiplatelet drugs, or anticoagulants was not permitted. Low-dose aspirin was not allowed. Use of potent CYP3A4 inhibitors or inducers was prohibited during administration of erlotinib. Standard treatments for erlotinib-related rash and diarrhea were recommended. Use of proton pump inhibitors (PPIs) was not allowed initially; however, after the occurrence of a perforated duodenal ulcer in 1 patient in cohort 2, it was suggested that patients be placed on PPIs after the pharmacokinetics (PK) blood draws for apricoxib and erlotinib were completed. Repeat PK analysis of erlotinib following initiation of a PPI was not performed. Solubility of apricoxib is not affected by pH, and therefore absorption would not be expected to change in the presence of PPIs. T",during cycle 1,NA
33230647,"UMIN-CTR (ID, 000015373)",Combination,No,Janpanese adult relapsed/refractory acute lymphoblastic leukemia,"Patients aged 15–60 years with relapsed/refractory ALL (B-ALL, T-ALL, and Philadelphia chromosome-positive ALL) were enrolled in this study. Relapse was defned using the standard criteria as reappearance of disease after previous achievement of CR, and primary refractory disease was defned as persistent disease after standard induction therapy. Other inclusion criteria were Eastern Cooperative Oncology Group performance status 0–2, SpO2>94%, creatinine clearance level>60 mL/min, serum direct bilirubin level<2.0 mg/dL, and normal electrocardiogram results. Patients with prior allo-HSCT were also included","The key exclusion criteria were presence of other active cancers, central nervous system involvement, uncontrolled systemic infection, positivity for hepatitis B or C infection, and presence of serious organ dysfunction after prior allo-HSCT.",in the frst cycle,NA
17440682,NA,Combination,No,"advanced malignant solid tumors. Tumor types, NSCLC 7, Head and neck 2, Mesothelioma 2, Basal cell carcinoma of the skin 1, Esophageal 1, Hepatocellular carcinoma 1, Pancreatic adenocarcinoma 1, Renal cell carcinoma 1","Patients with histologically or cytologically confirmed advanced solid tumors were eligible. Other eligibility criteria included: age>18 years; life expectancy of greater than 12 weeks; and performance status 0–2. Patients may have only had one prior chemotherapy regimen and prior chemotherapy and/or radiotherapy must have been completed at least 4 weeks before study entry and all significant previous treatment-related toxicities had to be resolved. Adequate hematologic (absolute neutrophil count ≥ 1,500/ul, platelet count ≥ 100,000/ul), renal (serum creatinine ≤ 1.6 mg/dl or a calculated creatinine clearance ≥ 40 ml/min) and hepatic (serum bilirubin ≤ 1.5 mg/dl and aspartate aminotransferase [AST] within three times the institutional upper limit of normal) function were required. Patients with asymptomatic treated brain metastasis (surgical resection or radiotherapy) were eligible for this trial if they were neurologically stable and had been off steroids for at least 4 weeks. ","Because of possible vinorelbine-related neurotoxicity, patients with pre-existing neuropathy ≥ grade 2 were not eligible. Patients who had previously received EGFR targeted therapy or vinorelbine were excluded. Patients who were pregnant or who had unstable medical conditions (such as uncontrolled congestive heart failure), or other uncontrolled intercurrent illnesses were also excluded. Patients of childbearing potential were required to use a medically acceptable contraceptive. ",within the first cycle of treatment,NA
28531881,NCT02094560,Combination,No,"adults with refractory solid tumours: Basaloid, Squamous-cell carcinoma, Sarcomatoides thymus carcinoma, Unknown, Liver/adenosquamous, CUP, Lymph-node/squamous, Mixed tumour from seminoma and non-seminoma, Adenous, Merkel cell carcinoma, Oesophagus/Siewert-type I-II adenous, Other, Bone/adenosquamous, Sertoli-Leydig cell tumour, Cholangiocarcinoma, adenosquamous, Oesophagus/squamous, Adenosquamous ","Histologically- or cytologically-confirmed, advanced disease with documented progression (RECIST1.1.) after one or several chemotherapy line. Patients may also have received molecular targeted therapy and progressed while on therapy or after completion. Must have recovered from the acute reversible effects of previous anti-cancer chemotherapy, usually 3-4 weeks after myelosuppressive chemotherapy","Serious concurrent medical condition, which could affect compliance with the protocol or interpretation of results. Patients with uncontrolled infection and patients known to be infected with the human immunodeficiency virus (HIV) or hepatitis infection are not eligible for the study. Pregnancy or breast-feeding",during the first cycle,NA
29427728,NCT02028949,Single Drug,No,hepatocellular carcinoma,"Eligibility criteria included a confirmed diagnosis of HCC according to the European Association for the Study of the Liver (EASL) criteria;18 Child-Pugh liver function of A–B7 without ascites or jaundice; Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1; platelet count >50,000/mm3; absolute neutrophil count >1,000/mm3; serum creatinine <150 lmol/L; and a left ventricular ejection fraction (LVEF) >50%. ",Exclusion criteria were extrahepatic metastases; lobar/main portal tumour thrombosis; known gastrointestinal bleeding up to 30 days before study entry; anticoagulant therapy; pregnancy; and allergy or any other contra-indication to anthracyclines or iodine-containing agents.,within the month after the second session of the previous patient (day 1 to day 49),NA
19164205,NA,Single Drug,No,in advanced non–small-cell lung cancer (NSCLC) patients who smoke,"Eligible patients were current cigarette smokers (ie, smoking >= 10 cigarettes per day for >= 1 year despite advice and support to quit) with stage IIIB/IV NSCLC after failure of 1 or 2 prior chemotherapy regimens, ECOG PSof 0/1, adequate organ function (bilirubin <= 1.5 upper normal limit [ULN], ALT <= 2.5 ULN ( <= 5 x if liver metastases) and serum creatinine <= 1.5 x ULN), no prior EGFR inhibitors, no CYP3A4 or other CYP1A2 inducers and/or inhibitors, concurrently or 14 days before study, and no concurrent anticancer therapy",NA,the initial 14-day treatment period,NA
18794549,NA,Single Drug,No,"children with refractory solid tumors. CNS tumors (n  20): Brainstem glioma 5, Medulloblastoma 6, Supratentorial PNET 2, Ependymoma 4, Glioblastoma 1, Neurocytoma 1, Gliomatosis cerebri 1. Non-CNS tumors (n  26): Rhabdomyosarcoma 8, Soft tissue sarcoma 5, Neuroblastoma 5, Osteosarcoma 6, Germ cell 1, Rhabdoid 1","Eligible patients were younger than 22 years with a recurrent or refractory CNS tumor, osteogenic sarcoma, rhabdomyosarcoma, soft tissue sarcoma, neuroblastoma, or germ cell tumor. Patients were required to have a Karnofsky or Lansky performance score of at least 50 for those older than or 10 years old and younger, respectively, and a life expectancy of more than 8 weeks. Adequate bone marrow (absolute neutrophil count >= 1000/L, platelet count >= 100,000/L, hemoglobin >= 8 gm/dL), renal (normal serum creatinine for age) and hepatic (total bilirubin < 1.5 x normal and ALT < 2.5 x upper limit of normal) function was required. Patients were required to have recovered from the acute toxic effects of all prior treatment and could not have received myelosuppressive chemotherapy within 2 weeks of study entry; palliative radiation within 2 weeks or radiation to more than 50% of the pelvis or craniospinal axis within 6 months; or biologic therapy or growth factors within 7 days or stem-cell transplantation within 3 months","Exclusion criteria included uncontrolled infection, pregnancy or lactation, any previous erlotinib exposure, concurrent administration of an enzyme-inducing anticonvulsant, use of a proton pump inhibitor within 5 days or H2 blocker within 2 days of study entry, and use of a CYP3A4 inducer within 4 weeks or a CYP3A4 inhibitor within 1 week of study entry.",during the first course of treatment,NA
19117350,NA,Combination,No,"Pediatric Patients With Recurrent Solid Tumors: Ependymoma 5, Neuroblastoma 3, Medulloblastoma/supratentorial PNET 3, Atypical teratoid rhabdoid tumor 1, Osteosarcoma 1, Pineoblastoma 1, Malignant peripheral nerve sheath tumor 1, Wilms tumor 1 ","Patients <= 21 years of age with a histologically verified solid tumor that was refractory to conventional therapy, a Karnofsky or Lansky performance score 50%, and life expectancy >8 weeks were eligible for enrollment if they had recovered from the acute toxic effects of prior therapy; had no evidence of active graft-versus-host disease; and had not received 1) myelosuppressive therapy within 3 weeks (nitrosourea within 6 weeks); 2) hematopoietic growth factors or biologic (antineoplastic) agents within 1 week; 3) small-port palliative radiotherapy within 2 weeks; 4) total body, craniospinal, or whole-pelvis radiation within 3 months; 5) other substantial bone marrow radiation within 6 weeks; 6) allogeneic stem cell transplantation within 6 months; or 7) previous oxaliplatin exposure. Organ function requirements were as follows: for bone marrow, an absolute neutrophil count (ANC) >= 1000/uL, a platelet count >= 100,000/uL (transfusion-independent), and a hemoglobin >= 8 g/dL (bone marrow involvement with tumor allowed if criteria met); for renal function, a normal serum creatinine level for age or a glomerular filtration rate >= 80 mL/min/1.73 m2, serum potassium and sodium abnormalities <= grade 1 (supplementation allowed), and normal serum magnesium and calcium values (supplementation allowed); for hepatic function, hyperbilirubinemia <=  grade 1, hypoalbuminemia <=  grade 2, and alanine aminotransferase elevation <=  grade 2; for cardiac function, a normal electrocardiogram and shortening fraction >= 27% by echocardiography; for pulmonary function, no dyspnea at rest, no exercise intolerance, and oxygen saturation >94% on room air; and for the nervous system, seizure disorders absent or well controlled and peripheral neurotoxicity <= grade 1. Pregnant or breastfeeding patients were excluded, and agreement to use effective contraception was required if patients were of reproductive age","Patients receiving other investigational agents, anticancer agents, or anticonvulsants that interact with CYP3A (ie, phenytoin, carbamazepine, oxcarbazepine, phenobarbital) were excluded. Additional exclusion criteria were uncontrolled infection and life-threatening hypersensitivity to platinum-containing agents.",in the first course,NA
34543383,NCT02306291,Combination,No,patients with relapsed or refractory acute myeloid leukemia,"Patients enrolled in the R/R AML cohort in both the doseescalation and expansion phases were age $18 years with evidence of active leukemia as documented by a morphologically detectable bone marrow blast count of >= 5% and a peripheral absolute blast count of <= 20 000/mm3. After evaluation of the first 2 dose cohorts, the allowable peripheral absolute blast count was changed to <= 40 000/mm3. Patients were required to either have primary refractory AML after receiving at least 1, but not > 2, prior induction regimens (>= 1 containing an anthracycline) or be in their first or second relapse. Patients had to have been eligible to receive an intensive induction regimen including MEC (mitoxantrone, etoposide, and cytarabine; Figure 1). Two cycles of induction therapy using a standard anthracycline/cytarabine regimen (eg, 7 + 3 followed by 5 + 2) were counted as a single induction. Prior stem cell transplantation was allowed. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, with adequate baseline renal and hepatic function. Antileukemic treatment was prohibited within 14 days of starting study treatment, except for hydroxyurea and FLT-3 or other tyrosine kinase inhibitors, which were allowed up to 5 days before protocol treatment.","Patients with central nervous system leukemia were ineligible. No prior G-CSF, GM-CSF or plerixafor within 14 days of study drug dosing. Known history or evidence of active hepatitis A, B, or C or HIV. Uncontrolled acute life threatening bacterial, viral or fungal infection. Active graft versus host disease (GVHD) ≥ Grade 2 or extensive chronic GVHD requiring immunosuppressive therapy. Hematopoietic stem cell transplantation ≤ 4 months of dosing. Clinically significant cardiovascular disease",by day 42,NA
17255274,NA,Combination,No,"Patients with Advanced Solid Tumors:colorectal 23, penis carcinoma (two), NSCLC (one), melanoma (one), endometrial carcinoma (one), nasal adenocarcinoma (one), parotid gland carcinoma (one) urethral carcinoma (one), and unknown (one)","Patients with advanced solid tumors, such as colorectal cancer, with measurable or nonmeasurable disease, >= 18 years of age, an Eastern Cooperative Oncology Group performance status of 0 to 1, and a life expectancy >= 12 weeks were eligible for the trial. A minimum of 4 weeks (6 weeks for nitrosurea or mitomycin) since previous chemotherapy and/or radiotherapy was required.","Exclusion criteria included the following: any previous treatment with HER-targeted therapy or 5-FU/oxaliplatin; more than one previous chemotherapy regimen for metastatic disease, previous severe reaction to fluoropyrimidine therapy, or known dihydropyrimidine dehydrogenase deficiency; and peripheral neuropathy grade 2 or higher on the National Cancer Institute-Common Toxicity Criteria scale version 2.0. Patients with significant abnormalities of the surface of the eye and central nervous system metastases were also excluded.",in the first two treatment cycles,NA
19147777,NA,Combination,No,"Children, Adolescents, and Young Adults with High-Grade Glioma","Patients between ages 3 and 25 y with newly diagnosed high-grade glioma were eligible for this study. Additional eligibility criteria consisted of (a) interval between surgery and start of therapy <=42 d; (b) performance score of >= 40; (c) adequate hematologic (absolute neutrophil count of >=1,000/AL, platelet count of >=100,000/AL, and hemoglobin concentration of >=8 g/dL), renal (serum creatinine concentration of less than twice the institutional normal values for age), and hepatic (total bilirubin concentration of <1.5 times the institutional upper limit of normal, ALT of <5 times the institutional upper limit of normal, and albumin of >=2 g/dL) function. ","Exclusion criteria consisted of (a) diagnosis of diffuse brainstem glioma, (b) diagnosis of secondary high-grade glioma, (c) presence of leptomeningeal metastatic disease, (d) use of enzyme-inducing anticonvulsants (EIAC), (e) use of other concomitant anticancer therapy, (f) presence of other significant concomitant medical problems, and (g) pregnant or lactating patients. Female patients of childbearing age and male patients of child-fathering potential had to agree to use safe contraceptive methods. For patients who were weaned off EIACs, at least 7 d were required between discontinuation of EIACs and start of erlotinib. ",the first 8 weeks of therapy,NA
17634483,NA,Combination,No,"Solid Tumors in Patients With Hepatic or Renal Dysfunction: Colorectal 22, Hepatobiliary 6, Non–small-cell lung 5, Breast 3, Pancreatic 3, Bladder 3, Renal 2, Esophageal 2, Cervical 2, One patient each with prostate, testicular, ovarian, anal, and laryngeal cancer and one patient with malignant thymoma","Patients were eligible if they had tumors commonly expressing EGFR, including glioma, mesothelioma, hepatocellular cancer, and epithelial malignancies such as non–small-cell lung, breast, head and neck, esophageal, pancreatic, bladder, prostate, ovarian, cervical, colorectal, and anal carcinomas. Patients with other tumors were eligible only if there was documentation of EGFR expression in the tumor tissue. The protocol required that patients had disease for which standard curative or palliative measures did not exist. Prior treatments were allowed under the following circumstances: >= 4 weeks must have elapsed since major surgery or since completion of radiation or chemotherapy (except >= 6 weeks for melphalan or mitomycin and >= 3 months for suramin); no prior nitrosoureas; and no prior EGFR-targeting therapies. Patients had to be >= 18 years of age with an Eastern Cooperative Oncology Group performance status of 0 to 2. Required laboratory values at entry included an absolute neutrophil count >= 1,500/L and platelet count >= 100,000/L. The study had to be approved by the institutional review board of each participating institution, and all patients gave written informed consent.","Patients who were pregnant or lactating were excluded. Concomitant medications known to cause hepatic or renal toxicity were not allowed on study. Other exclusion criteria included abnormalities of the cornea, GI tract disease resulting in an inability to take oral medication, HIV-positive patients on antiretroviral therapy, ingestion of potent CYP3A4 inhibitors within 7 days of protocol therapy, and evidence of biliary or renal obstruction.",in the first 4 weeks of treatment,"the initial cohort definitions were as follows: cohort 1, AST >= 3 x upper limit of normal (ULN; normal direct bilirubin and normal creatinine); cohort 2, direct bilirubin of 1.0 to 7.0 mg/dL with any AST (normal creatinine); and cohort 3, creatinine of 1.6 to 5.0 mg/dL (AST <3 x ULN and direct bilirubin < 1.0 mg/dL). The amended cohort definitions were as follows: cohort 1a, albumin less than 2.5 g/dL (direct bilirubin < 1.0 mg/dL, any AST, and normal creatinine); cohort 2, direct bilirubin of 1.0 to 7.0 mg/dL with any AST (normal creatinine); and cohort 3a, creatinine of 2.5 to 5.0 mg/dL(albumin >= 2.5 g/dL, AST < 3 x ULN, and direct bilirubin < 1.0 mg/dL)."
23666235,NA,Combination,No,children with malignant glial tumors,"Patients aged between 3 and 18 years with a relapsed or refractory malignant glial tumor (grade III or IV, WHO criteria) and brainstem glioma at diagnosis documented on the basis of histology and/or radiological features were eligible for this study. Additional eligibility criteria included: life expectancy of at least 8 weeks; adequate performance status (Karnofsky or Lansky score >30); ability to swallow capsules; measurable disease; adequate laboratory values, including an absolute neutrophil count >=1 x 109/l, a platelet count >= 100 x 109/l, liver enzymes (aspartate aminotransferase and alanine aminotransferase levels) <= 2.5 times the normal laboratory upper limit, and urea, serum creatinine, and total bilirubin <1.5 times normal laboratory upper limit. An interval of at least 6 weeks from radiotherapy, and at least 4 weeks from chemotherapy, was necessary prior to entering the study (6 weeks since nitrosoureas). Patients were also required to have been on stable or decreasing corticosteroid therapy for at least 7 days before treatment initiation.","Pregnant or lactating females, patients with severe or threatening infection and children previously treated with single TMZ or oral VP-16 were excluded from the study.",during cycle 1,NA
20538454,NA,Combination,No,children with recurrent or progressive medulloblastoma,"Patients aged between 3 and 18 years with histologically confirmed supratentorial PNET/MB, including patients with metastatic disease, were eligible for this study. Metastatic disease was defined as unequivocal evidence on magnetic resonance imaging (MRI) scan of supratentorial metastases and/or spinal metastases. Patients were required to have a recurrent or progressive disease refractory to conventional therapy. Other eligibility criteria included disease measurable by conventional MRI criteria; life expectancy of at least 8 weeks; adequate performance status (Karnofsky or Lansky score > 30); ability to swallow capsules; a minimum of 6 weeks from prior RT and a minimum of 4 weeks after any CT (6 weeks since nitrosoureas); adequate laboratory values, including an absolute neutrophil count >= 1 x 109/l, a platelet count >= 100 x 109/l, total bilirubin levels <= 1.5 x the upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels <=2.5 x the upper normal limit. A clinically appropriate daily dose of steroids was determined for each patient before beginning the first cycle of therapy. The dose was required to have been stable for at least 7 d before treatment initiation, and efforts were made to maintain the same dose until the radiographic tumour measurement was performed after completing the second cycle. ",Patients with the following conditions were excluded from the study: previous treatment with single TMZ or oral VP-16; concomitant investigation of treatment for PNET/MB; severe or threatening infection; pregnant or lactating females.,the first course,NA
22028494,NA,Combination,No,"Refractory Cancer. Primary tumor type: Breast cancer 29, NHL 8, Ovarian cancer 7, Testicular cancer 1 ","Patients 18 to 64 years of age with histologically confirmed cancer and an Eastern Cooperative Oncology Group performance status of less than 2 were eligible. Patients were required to have adequate organ function and to have had no prior treatment with topotecan. Patients with breast cancer were required to have metastatic disease that had failed to respond to an anthracyclinecontaining regimen and 1 other salvage regimen. Patients with intermediate or high-grade non-Hodgkin lymphoma (NHL) who had relapsed and failed to respond to more than 2 salvage chemotherapy regimens or had failed to achieve a complete remission after first-line induction chemotherapy and failed to respond to more than 1 salvage regimen were eligible. Patients with Hodgkin lymphoma were eligible if they had failed at least 3 chemotherapy regimens. Patients with other malignancies were considered if they had failed standard therapy for their disease. Patients who were less than 55 years of age were eligible for the expanded MTD cohort if they had (i) intermediate or high-grade NHL and if they had relapsed and/or failed to respond to at least 2 chemotherapy regimens or had failed to achieve a complete remission after first-line induction chemotherapy and failed to respond to 1 or more salvage regimen, or (ii) low-grade or indolent histologies and had relapsed or failed to achieve a complete remission after first-line induction chemotherapy and had failed to respond to less than 2 salvage chemotherapy regimens, or (iii) had Hodgkin lymphoma and had received 2 or more salvage regimens. Patients who were 55 years of age or more were eligible if they had NHL with any histology or Hodgkin lymphoma if they had relapsed and/or failed to achieve a complete remission after first-line induction chemotherapy","Patients who had active infections, major metabolic disease (e.g., insulin-dependent diabetes or uncompensated adrenal or thyroid dysfunction), a positive antibody test for HIV, or leptomeningeal involvement were not eligible.",HCT on day 0,NA
20209646,NA,Combination,No,Refractory and Relapsed Pediatric Acute Leukemia,"Patients with relapsed or refractory leukemia <22 years of age at the time of diagnosis were eligible. Patients with AML were eligible if they met one of the following criteria: (1) duration of first bone marrow remission <6 months, (2) refractory to standard AML induction, (3) secondary AML or AML evolving from myelodysplastic syndrome, or (4) bone marrow relapse following bone marrow transplantation (BMT). Patients with ALL were eligible if they had: (1) second or subsequent bone marrow relapse or (2) bone marrow relapse following BMT. All patients with prior BMT were required to have had trilineage engraftment and be at least 6 months from transplant. Other eligibility criteria included: (1) recovery from prior therapy; (2) no therapy, with the exception of hydroxyurea, in the 4 weeks prior to enrollment; (3) adequate performance status (Lansky >40% if <12 years or Karnofsky >=50% or ECOG <= 2); (4) life expectancy >8 weeks; (5) adequate renal (normal creatinine or glomerular filtration rate for age) and hepatic function [bilirubin <1.5 x normal, alanine aminotransferase (ALT) < 2 x normal, albumin >3 g/dl]; and (6) cardiac ejection fraction >50% or shortening fraction >= 27% with less than 360 mg/m2 cumulative prior anthracycline exposure.","Exclusion criteria included history of etoposide allergy, pregnancy or breast feeding, use of anticonvulsant medication, uncontrolled infection, and isolated central nervous system or extramedullary relapse.",in first course,NA
16626884,NA,Combination,No,PATIENTS WITH GLIOBLASTOMA MULTIFORME,"All patients provided written informed consent. The protocol was approved by the institutional review board of each participating institution. Patients with newly diagnosed glioblastoma multiforme (Grade IV astrocytoma) by the World Health Organization criteria at central review by a North Central Cancer Treatment Group (NCCTG) study neuropathologist before study registration were eligible. Patients were enrolled at least 1 week after but not more than 4 weeks after maximal surgical resection (biopsy, subtotal resection. or gross total resection). No prior chemotherapy for brain tumors or prior cranial radiation therapy for any reason was allowed. Other inclusion criteria were age 18 years or older, Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2, absolute neutrophil count 1,500/uL or higher, platelet count 100,000/uL or higher, total bilirubin no higher than 1.5 times the institutional upper limit of normal (ULN), aspartate aminotransferase no higher than 2.5 times ULN, and creatinine no higher than 1.5 times ULN. ","Exclusion criteria included pregnancy, nursing, or refusal to use contraception if the patient or partner was of childbearing age. In addition, patients who were receiving other investigational agents, antiretroviral therapy, or coumadin were excluded. Patients with major surgery (excluding neurosurgical biopsy or resection of brain tumor) or significant traumatic injury that occurred 21 days or less before treatment, uncontrolled intercurrent illness (infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia), or psychiatric illness/social situations that would limit compliance with study requirements were also excluded. Patients with abnormalities of the cornea based on history (e.g., dry-eye syndrome, Sjogren’s syndrome), congenital abnormality (e.g., Fuch’s dystrophy), abnormal slit-lamp examination by use of a vital dye (e.g., fluorescein, Bengal-Rose), or an abnormal corneal sensitivity test (Schirmer test or similar tear-production test) were excluded.",NA,NA
23445779,NA,Combination,No,head and neck squamous cell carcinoma ,"Before being enrolled in the study, written informed consent was obtained from each patient. The main eligibility criteria were: T1-T4 N0-N3 corresponding to stage III or IV (UICC 2002) or T0 only if N2-N3, oropharynx, hypopharynx, larynx or oral cavity non-operated histologically proved squamous cell carcinoma; Age more than 20 years; Karnofsky performance status > = 70; not amenable to a combined radiation and surgery because of the loco-regional extension and / or general medical state; Laboratory tests compatible with the chemotherapy (platelet count >150 000/μl, neutrophiles > 2000/μl, creatinine serum level < 130 μmol/l and SGOT, SGPT, alkaline phosphatase, bilirubin less than two and a half times normal). All patients were required to sign the informed consent document that was approved by each Institutional Review Board before initiating protocol therapy.","A patient was considered unsuitable for inclusion in case of: previous RT or chemotherapy; infection; bulky lymph node (> 6 cm, N3) is not recommended, but will be left to the discretion of each investigator.",NA,NA
19495755,NA,Single Drug,No,patients with unresectable hepatocellular carcinoma,"HCC patients were considered eligible for the study if they possessed all the following characteristics: unresectable HCC conWrmed histologically or clinical diagnostic imaging such as computed tomography (CT); measurable lesions conWned in the liver without extra-hepatic metastasis, and in principle, no thrombosis of the portal trunk, a prominent A-V shunt, or a prominent A-P shunt; no lingering eVects of previous therapy (in principle, a 2-week interval was established for 5-Xuorouracil (5-FU) drugs and biological response modiWers, and a 4-week interval for other anticancer agents and radiation therapy); performance status of Eastern cooperative Oncology Group of 0-2; Child–Pugh classiWcation A or B; maintenance of adequate bone marrow, kidney, and cardiac functions, and meeting the following clinical laboratory test criteria (white blood cell counts >= 3,000/mm3, platelet count >= 5 x 104/mm3, hemoglobin concentration >= 9.5 g/dl, Serum creatinine value <= the upper limit of normal range, blood urea nitrogen <= 25 mg/dl, and prothrombin activity >= 50%); age >= 20; and predictive survival time >= 3 months","HCC patients were considered ineligible if they possessed one of the following characteristics: serious complications other than chronic hepatitis or liver cirrhosis; ¸1 active cancer; a history of serious hypersensitivity to drugs; pregnant or possibly pregnant women; breastfeeding; and any other reason that, as per the judgment of the attending physician, made the patient an unsuitable candidate for this study.",NA,NA
25316653,NCT00667615,Combination,No,elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation,"MSKCC or Weill Cornell biopsy confirmation of relapsed/refractory diffuse large B-cell lymphoma.Patients with large cell transformation of a low-grade B-cell lymphoma will be eligible. One or two prior chemotherapy regimens not including autologous stem cell transplantation. Age ≥ 60 years. Not a candidate for autologous stem cell transplantation. Patient must have performance status of ≤2 on the ECOG Performance Scale. Measurable disease. Adequate organ and bone marrow function: ANC ≥ 1000/mm3, platelet count ≥ 50,000/mm3, total bilirubin ≤ 1.5 ULN (with exception of Gilbert's disease), AST/ALT ≤ 2.5 ULN, creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 50 ml/min, potassium and magnesium within normal limits. Male patients agree to use an adequate method of contraception for the duration of the study. Patient is available for periodic blood sampling, study related assessments, and management at the treating institution for the duration of the study.","Patient who has had chemotherapy, radiotherapy, or biological therapy [including growth factors], within 30 days (42 days for nitrosoureas or mitomycin C) prior to initial dosing with study drug(s) or who has not recovered from adverse events due to agents administered more than 30 days earlier. Patients on a stable dose of steroids for at least 4 weeks prior to onset of study therapy may be included. Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drug(s). Patient had prior treatment with an HDAC inhibitor (e.g., romidespin (Depsipeptide),NSC-630176, MS 275, LAQ-824, belinostat (PXD-101), LBH589, MGCD0103,CRA024781, etc). Patients who have received compounds with HDAC inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not enroll in this study. Patients who have received such compounds for other indications, e.g. valproic acid for epilepsy, may enroll after a 30-day washout period. Patients with active CNS lymphoma and/or lymphomatous meningitis are excluded. However, patients with a history of CNS lymphoma and/or lymphomatous meningitis who have been stable without evidence of CNS and/or leptomeningeal recurrence would be eligible. They must be off steroids or on a stable dose of steroids. Patient with a primary central nervous system lymphoma. Patient has known hypersensitivity to the components of study drug or its analogs. Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. Patient is, at the time of signing informed consent, a regular user (including ""recreational use"") of any illicit drugs, substance abuse or had a recent history (within the last year) of drug or alcohol abuse. Patient is expecting to father children within the projected duration of the study. Patient has uncontrolled intercurrent illness or circumstances that could limit compliance with the study, including, but not limited to the following: active infection, acute or chronic graft versus host disease, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric conditions. Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study or is not in the best interest of the patient to participate. Patient has a history of a gastrointestinal surgery or other procedures that might, in the opinion of the investigator, interfere with the absorption or swallowing of the study drugs. Patient with a ""currently active"" second malignancy, other than non-melanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled. Patients are not considered to have a ""currently active"" malignancy if they have completed therapy for a prior malignancy, are disease free from prior malignancies for >5 years or are considered by their physician to be at less than 30% risk of relapse. Patient is HIV +. Patient has active hepatitis B or C.",NA,NA
23403629,NCT00357305,Combination,No,"Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia","Histologically or cytologically confirmed diagnosis of 1 of the following: Relapsed or refractory acute myeloid leukemia (AML); Patients with acute promyelocytic leukemia t(15;17) must have failed prior tretinoin and arsenic trioxide-containing regimen; Must be refractory to both agents with absence of durable hematologic response OR relapsed after a complete response duration of < 6 months; Relapsed or refractory acute lymphoblastic leukemia; Chronic myelogenous leukemia in accelerated or blastic phase; Must be refractory to treatment with imatinib mesylate or dasatinib; Disease progression despite continued treatment with imatinib mesylate or dasatinib; Patients in accelerated or blastic phase are eligible if unable to tolerate imatinib mesylate provided their disease has progressed on dasatinib or if unable to tolerate dasatinib; AML arising in the setting of underlying myelodysplastic syndromes (MDS) and/or myeloproliferative disorders (MPD); Secondary or therapy-related AML. No active CNS leukemia. Leukostasis OR leukemic blast count > 50,000/mm³ allowed provided patient is treated with emergency leukapheresis or hydroxyurea to reduce leukemic blast count to < 30,000/mm³. ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%. Bilirubin ≤ 1.5 times upper limit of normal (ULN). AST and ALT ≤ 2.5 times ULN. Creatinine ≤ 2.0 mg/dL. Not pregnant or nursing. Negative pregnancy test. Fertile patients must use effective contraception. No history of cytarabine-related neurotoxicity. No history of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat (SAHA) or other agents used in the study. No other uncontrolled illness, including, but not limited to, any of the following: Symptomatic congestive heart failure; Unstable angina pectoris; Cardiac arrhythmia; Psychiatric illness or social situation that would preclude compliance with study requirements. Infection allowed provided patient is receiving active treatment. No HIV positivity. See Disease Characteristics. Recovered from prior therapy: Persistent alopecia, fingernail discoloration, or hematologic abnormalities (primarily related to underlying disease) > 4 weeks after last course of chemotherapy or radiotherapy does not exclude patient. At least 2 weeks since prior valproic acid or any other histone deacetylase inhibitor. No more than 3 prior courses of induction/reinduction chemotherapy, including induction and consolidation therapy or induction therapy after any bone marrow transplantation or similar procedure: Prior low-dose azacitidine, growth factors, cytokines, thalidomide, interferon, or imatinib mesylate for treatment of preceding MDS/MPD do not count as prior induction/reinduction therapy. At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas [e.g., carmustine] or mitomycin C) or radiotherapy. At least 24 hours since prior hydroxyurea. At least 2 weeks since prior imatinib mesylate, hematopoietic growth factors, and biological agents. At least 4 weeks since prior autologous stem cell transplantation. Prior allogeneic stem cell transplantation allowed if all of the following criteria are met: At least 90 days since prior transplant; No evidence of graft-vs-host disease; At least 2 weeks since prior immunosuppressive therapy. No other concurrent anticancer agents or therapies. No other concurrent investigational agents. Concurrent hydroxyurea or leukapheresis allowed on days 1-10 of study treatment to control rising leukemic blasts (blasts > 30,000/mm³) or leukostasis",NA,first-cycle,NA
12506184,NA,Single Drug,No,"Patients With Advanced Solid Malignancies. Tumor types: Colorectal 15, Non–small-cell lung 4, Pancreas 3, Unknown primary 3, Melanoma 2, Leiomyosarcoma 2, Stomach 2, Small-cell lung, esophagus, parotid gland, breast, lymphoma, osteosarcoma 1 each","Patients with solid malignancies who failed to respond to standard therapy or for whom adequate therapy was not available were eligible for this study. The following eligibility criteria were also included: age of 18 years or older; an Eastern Cooperative Oncology Group (ECOG) performance status <= 2; no prior chemotherapy, investigational agents, or wide-field radiation therapy within 4 weeks (6 weeks for nitrosourea and mitomycin); adequate hematopoietic (absolute neutrophil count [ANC] 1,500/L, hemoglobin >= 8.5 g/dL, platelets >= 100,000/uL), hepatic (total bilirubin <= 1.5 mg/dL, transaminase <= 2.5 times institutional normal upper limit [<= 5 times if caused by liver metastasis]), and renal (creatinine <= 1.5 mg/dL) functions; no enteropathy or recent onset of diarrhea, defined as an excess of two to three stools above the normal rate within 4 weeks; no evidence of microscopic hematuria (>= 10 RBCs/high power field), unless caused by a nonurothelial etiology; no active brain metastases; and no coexisting medical problem of sufficient severity to limit compliance with the study. Before treatment, patients gave written informed consent according to federal and institutional guidelines",NA,during the first course,NA
15661261,NA,Combination,No,patients with refractory leukemia,"Patients over 18 years of age with established refractory acute leukemia defined as AML primary induction failure, relapsed AML, newly diagnosed high risk AML with poor prognosis (treatment related AML, or AML evolving from myelodysplastic syndromes), chronic myelogenous leukemia in blast crisis (CML-BC), or relapsed acute lymphoblastic leukemia were eligible. Patients with failure of primary induction therapy or who relapsed following CR were eligible if they underwent no more than two prior courses of induction therapy/reinduction therapy (no more than two relapses). Patients’ eligibility also included: ECOG performance status 0–2, serum creatinine less than 1.5 mg/dl or creatinine clearance greater than 60 ml/min, serum bilirubin less than 1.5 mg/dl, serum transaminases less than two times the upper limit of normal, and adequate left ventricular function as defined by either echocardiogram or MUGA. Prior chemotherapy (except hydroxyurea or interferon for CML) must have been terminated at least 3 weeks before entering the protocol, and patients had to have recovered from any toxic effects of such treatments. All medications known to increase or decrease cyclosporine-A concentrations were prohibited throughout the course of the study","Patients with leukostasis, active disseminated intravascular coagulation and active CNS leukemia, or those who had previously undergone prior allogenic bone marrow transplantation were ineligible for the study. Patients were also excluded if they had prior treatment with PSC-833, a history of neurotoxicity with ara-C, active untreated infectious illness, and impaired cardiac status. Pregnant and lactating women were also considered ineligible.",NA,NA
10867130,NA,Combination,No,older patients with newly diagnosed acute myeloid leukemia (AML),"Eligibility was limited to patients 56 years of age or older with AML, French–American–British (FAB) class M0 –M7, that was morphologically confirmed by bone marrow aspiration, biopsy, and cytochemical staining. Patients with secondary AML defined as a previous diagnosis of myelodysplastic syndrome (MDS) or after prior chemotherapy or radiotherapy for another malignancy were eligible. A history of prior treatment of MDS with low-dose cytosine arabinoside or other non-ablative therapies was permitted, if 30 days had elapsed from prior treatment. Patients had acceptable liver, renal, and cardiac function as indicated by  bilirubin less than two times the institutional upper limits of normal (IULN),  serum transaminase levels less than four times IULN,  serum creatinine less than 1.3 times the IULN, or creatinine clearance >= 50 cc/min, and  and ejection fraction >= 50% as measured by multigated cardiac blood pool (MUGA) scan or two-channel echocardiogram.","Patients with acute promyelocytic leukemia, AML M3, and blastic transformation of chronic myelogenous leukemia were excluded. Patients who received prior chemotherapy for acute leukemia were not eligible, although administration of hydroxyurea to control high cell counts was permitted. Patients with unstable cardiac arrhythmia or unstable angina and pregnant or lactating women were not eligible.",NA,NA
9493138,NA,Combination,No,patients with stage IIIB/IV non-small cell lung cancer (NSCLC),"To be eligible for this clinical trial, patients had to have histological or cytological confirmation of stage IIIB/IV NSCLC. Patients also were required to be aged <75 years, to have objective measurable disease, a minimum life expectancy of 12 weeks, a Karnofsky performance status of at least 70%, adequate bone marrow function (neutrophil count >1500/ul, leukocyte count >4000/ul, platelet count of >100 000/ul), adequate liver function (serum bilirubin <= 1.25× upper limit of normal, aspartate aminotransferase, alanine aminotransferase, gglutamyltransferase <= 3× upper limit of normal), and adequate renal function (serum creatinine <=1.25× upper limit of normal, creatinine clearance >=60 ml/min).","Patients displaying one or more of the following criteria were not eligible for the study: past or current history of neoplasm other than lung carcinoma, except for curatively treated nonmelanoma skin cancer, basal cell carcinoma or carcinoma in situ of the cervix; previous treatment with chemotherapy and/or radiotherapy; congestive heart failure or myocardial infarction in the past 6 months; HIV infection; pre-existing motor or sensory neurotoxicity >2 according to WHO criteria; administration of other chemotherapeutic drugs or hormonal therapy during the study period; proven or suspected brain metastases; fertile patients without use of contraceptive; pregnant or breast-feeding women.",the first cycle ,NA
11822756,NA,Combination,No,in lung cancer patients,"Patients with histologically or cytologically documented lung cancer progressive on or relapsing after previous chemotherapy were eligible for this study One patienl with mesothelioma was included Entry criteria included age range 18 to 70 years, WHO performance status 0-2 and a life expectancy of at least three months Adequate hematological, renal and liver functions were required, defined as WBC >= 30 x 109/l. ANC > 15 x 109/l, platelets >= 100 x IO9/1. hemoglobin >= 60 mmol/l, serum creatinine 140 umol/1 and bilirubin <35 umol/1, respectively Prior cytotoxic treatment and radiotherapy had to be ended more than four weeks before study entry, with full recovery of effects of previous therapy except alopecia",Patients with symptomatic brain metastases and signs of cardiac failure or active infection were excluded,during the first course,NA
8882988,NA,Combination,No,extensive small cell lung cancer,"Patients with histologically or cytologically confirmed extensive SCLC who had received no previous chemotherapy or radiotherapy (other than treatment for symptomatic cerebral metastases) were eligible for the study. Extensive disease was defined as tumor not confined to a lung, mediastinum, contralateral hilar nodes, or ipsi- or contralateral supraclavicular nodes. Malignant pleural effusions were considered extensive disease. Measurable disease (defined as any mass reproducibly measurable in two perpendicular diameters by physical examination, X-ray, or computerized tomography) was required as well as a CALGB performance score of 2 or better (ambulatory status), a life expectancy of at least 2 months, weight loss of less than 10% in the previous 6 months, no previous or concomitant malignancy, and no other serious medical or psychiatric illness which would have limited survival to less than 2 years or impair giving informed consent. ",NA,NA,NA
10561292,NA,Combination,No,Patients With Extensive Small-Cell Lung Carcinoma,"Eligibility criteria included histologically or cytologically documented SCLC and extensive disease, defined as disease beyond the hemithorax of origin and regional lymph nodes and demonstrated by staging that included chest x-ray, computed tomography of chest, abdomen, and brain, and bone scan. Bone marrow aspiration and biopsy were performed only if all other tests were negative for metastasis. Patients with a cytologically positive pleural effusion as the only evidence of extensive disease were eligible, as were patients with clinically silent brain metastasis. Adequate organ function was required, including absolute granulocyte count >=  1,500/µL, platelet count >= 100,000/µL, bilirubin level <= 1.5 mg/dL, creatinine level <= 1.5 mg/dL, and creatinine clearance >= 60 mL/min. A performance statusof 0 to 2 (Zubrod scale), no previous chemotherapy or radiotherapy, no recent (< 5 years) history of malignancy other than nonmelanoma skin cancer, and ability to provide informed consent were also required. ","Patients with serious intercurrent medical illness and those with severe chronic obstructive pulmonary disease (partial pressure of oxygen, <=50 and/or partial pressure of carbon dioxide, >= 50 on room air) were excluded.",NA,NA
9445186,NA,Combination,No,extensive small cell lung carcinoma,"Eligibility criteria included histologically or cytologically documented SCLC and ED, defined as disease beyond the hemithorax of origin and regional lymph nodes and demonstrated by staging, which included chest X-ray; computed tomography (CT) of chest, abdomen, and brain; and bone scan. Bone marrow aspiration and biopsy were performed only if all other tests were negative for metastasis. Patients with a cytologically positive pleural effusion as the only evidence of ED were eligible, as were patients with clinically silent brain metastasis. Adequate organ function was required, including absolute granulocytes ≥1500/mm , platelets ≥100,000/mm , bilirubin ≤1.5 mg/dL, creatinine ≤1.5 mg/dL, and creatinine clearance ≥60 mL/minute. A performance status of 0-2 (Zubrod scale), no prior chemotherapy or radiation, no recent history (within the last 5 years) of malignancy other than nonmelanoma skin cancer, and ability to provide informed consent were also required.",Patients with serious intercurrent medical illness and those with severe chronic obstructive pulmonary disease with pO ≤50 and/or pCO ≥50 in room air were excluded.,in Cycle 1 ,NA
11233806,NA,Combination,No,Advanced Non-Small Cell Lung Cancer,"The eligibility criteria were as follows: patients previously treated neither with chemotherapy nor with radiotherapy, histologically confirmed NSCLC, stage IIIB-IV with measurable and/or evaluable lesions, aged 18 to 75 years, Karnofsky Performance Status ≥70%, anticipated survival of at least 3 months, adequate hepatic, renal and hematologic function.","Patients were excluded if they had clinical signs of cerebral metastasis, other malignancies, acute heart failure or important arrhythmias and polyneuropathies. ",N/A,NA
8683232,NA,Combination,No,"Tumor type: Head and neck 12, Gynecologic 5, Pleura 4, Esophagus 2, Breast 1, Sarcoma 1, Colon 1, Unknown primary 3","Patient eligibility criteria were those of standard phase I trial, eg, microscopically confirmed diagnosis of a solid tumor not amenable to established form of treatment; age between 18 and 75 years; World Health Organization (WHO) performance status <= 2; life expectancy >= 2 months; no prior chemotherapy, immunotherapy, or radiotherapy for at least 4 weeks before study entry; WBC count more than 4,000/uL; platelet count more than 100,000/uL; normal hepatic and renal functions; no obvious absorption problems; and provision of a signed informed consent form according to French regulatory requirements.",NA,NA,NA
9457817,NA,Combination,No,LIMITED SMALL CELL LUNG CANCER: ,"Eligibility criteria included histologically or cytologically documented small cell lung cancer whose extent was limited as documented by chest X-ray, computed tomography (CT) of chest, brain, abdomen; radionuclide bone scan; bone marrow aspiration and biopsy; and physical examination. Patients with N3 disease manifested by ipsilateral supraclavicular or contralateral mediastinal lymphadenopathy were eligible. Bone marrow, renal, hepatic, cardiac, and pulmonary functions considered adequate by protocol-defined criteria were required. A performance status 12 (Zubrod scale), no prior chemotherapy or radiation, no history of malignancy other than nonmelanoma skin cancer, and ability to provide informed consent were also required. ",Patients with contralateral hilar or contralateral supraclavicular lymphadenopathy or with T4 disease indicated by pleural effusion visible on chest X-ray were excluded. ,in the first course,NA
10694563,NA,Combination,No,Limited-Stage Small-Cell Lung Carcinoma,"All patients had histologically confirmed, limited-stage disease and were previously untreated with chemotherapy or radiation therapy. Limited-stage disease is defined as disease confined to one hemithorax and adjacent nodes and which is treatable by radiotherapy field sizes (portals) tolerated by normal tissues. Additional eligibility criteria included the following: measurable or assessable disease; an ECOG performance status of 0, 1, or 2; life expectancy of 12 weeks or longer; age of 18 years or older; adequate hepatic, renal, and cardiac function (left ventricular ejection fraction of 45% or greater); no prior history of malignancy other than basal cell or squamous cell skin cancer or carcinoma in situ of the cervix with a disease-free interval of greater than 5 years.",Patients with supraclavicular node involvement or pleural effusion with positive cytology were considered to have extensive-stage disease and were ineligible,cycles 1 and 2,NA
8652278,NA,Single Drug,No,advanced solid tumour ,"Eligibility criteria for entry on to this study were histologically documented advanced solid tumour resistant to standard chemotherapy, age 18-75 years, performance status (WHO) G2, a life expectancy of 3 months, normal haematological status, hepatic and renal function. Written informed consent was obtained and the protocol approved by the institutional Ethics Committee.",NA,NA,NA
9053503,NA,Single Drug,No,"Advanced Cancer. Primary tumor site: Colon and rectum 14, Lung (non-small-cell) 3, Anal canal (squamous cell) 1, Gall bladder 1, Liver 1, Pancreas 1, Paranasal sinuses 1, Unknown 1","Patients with unresectable, locally recurrent or metastatic cancer for which there was no effective standard therapy or who had experienced failure of standard therapy were eligible. Other eligibility criteria were age >= 18 years, Eastern Cooperative Oncology Group (ECOG) performance status <= 2 (ambulatory at least 50% of the time), and life expectancy >= 3 months. Previous treatment included no more than two prior chemotherapy regimens, prior radiotherapy limited to a radiation field encompassing no more than 25% of the marrow-producing areas, and no chemotherapy in the preceding 4 weeks (8 weeks for nitrosoureas or mitomycin). In addition, patients were required to have a leukocyte count greater than 4,000/uL or a neutrophil count greater than 1,500/uL, platelet count greater than 150,000/uL, hemoglobin level greater than 10 g/dL, total bilirubin level less than 3.0 mg/dL, serum creatinine level <= 1.5 mg/dL, and a measured creatinine clearance of >= 75 mL/min. ","Exclusion criteria were pregnancy or lactation, and uncontrolled infection.",within 42 days of initiating treatment.,NA
10378670,NA,Combination,No,patients with non-small cell lung cancer,"Patients with histologically confirmed advanced or locally recurrent or metastatic NSCLC (stages IIIb and IV) for whom no therapies with greater potential benefit than cisplatin/VP-16 (and Ro 40-8757) existed were candidates for this stud. Additional eligibility criteria were: age 18-75 years; Karnofsky performance status >=70;life expectancy of at least 3 months; no previous systemic anticancer therapy; no radiation therapy for at least 4 weeks; no previous treatment with Ro 40-8757 or with other retinoids; adequate bone marrow function (hemoglobin >6 mmol/l, white blood cell (WBC) count >4 x 109/l and platelet count >100 x 109/l), liver function (total bilirubin level < 1.5 times upper limit of normal and AST <2.5 times upper limit of normal, or <5 times upper limit of normal if liver metastases were present), and renal function (serum creatinine <1.25 times upper limit of normal); serum calcium <2.6 mmol/l, cholesterol and triglycerides <1.25 times upper limit of normal. Written informed consent was required.",NA,NA,NA
9400949,NA,Combination,No,"Tumour sites: Ovary 14, Colorectal 7, Colorectal 1, Lung (SCLC) 1, Gall bladder 1, Stomach 1, Pancreas 1, Sarcoma 1, Head/neck 1, Fallopian tube 1, Unknown origin 1","Patients were eligible if they had a histologically confirmed diagnosis of a solid malignant tumour that was not amenable to established forms of effective therapy. Other eligibility criteria included a Zubrod-ECOG-WHO performance status <= 2, anticipated life expectancy of >= 3 months and age >= 18 years. Previous anti-cancer chemotherapy had to be discontinued for at least 4 weeks before entry into the study or 6 weeks in cases of pretreatment with a nitrosourea or mitomycin C. All patients had acceptable bone marrow function white blood cell (WBC) >= 4 x 109 1-1 and platelets >= 100 x 109 11; normal hepatic function, serum bilirubin <= 1.5 mg dl-' (25 pmol 1-1) and other liver function tests <= twice the normal upper limit or <= five times when related to liver metastases, prothrombin or thrombotest within normal limits; normal renal function, serum creatinine <= 1.4 mg dl-1 (120 gmol 1-1).",NA,NA,NA
7799021,NA,Combination,No,"Tumor type: Non small-cell lung cancer 25, Lymphoma 6, Other 8, Unknown origin 1","Adult patients with a histologically/cytologically confirmed diagnosis of solid tumor or lymphoma were eligible for this trial. Patients must have recovered from the toxic effects of prior therapy before they received etoposide phosphate. The eligibility criteria also included a performance status <= 2 on the World Health Organization (WHO) scale, a life expectancy of >=2 months, a WBC count of >= 4.0 x 103/uL and a platelet count >= 100 X 103/uL, normal hepatic function (bilirubin level <= 25 umo/L and other liver function tests within twice the normal upper limit unless related to liver metastases), normal renal function (serum creatinine level <= 120 umo/L and creatinine clearance >= 60 mL/min), adequate gastric absorption as evaluated by D-xylose test, feasibility and willingness of the patients to perform pharmacokinetic studies, and provision of written informed consent.",NA,NA,NA
12448655,NA,Combination,No,"gynecologic malignancies: Ovarian carcinoma 5, Primary peritoneal carcinoma 1","Eligibility criteria included histologically proven recurrent epithelial ovarian cancer, primary papillary peritoneal carcinoma, and fallopian tube carcinoma. All patients were to have received prior treatment with a platinum and paclitaxel-based chemotherapy regimen and at least three weeks had elapsed since any prior therapy. Participating patients were required to have adequate bone marrow (absolute granulocytes ≥1500/µl and platelets ≥100,000/µl),renal (serum creatinine ≤2.0 mg/dl), and hepatic (bilirubin ≤1.5 times the upper limit of normal, SGOT and alkaline phosphatase ≤3 times the upper limit of normal, and albumin >3g/dl) functions. Patients were to have a GOG performance status (PS) of 0–2 and provided written informed consent consistent with current institutional, state and federal regulations prior to study entry.",Patients with prior radiation to >10% of bone marrow were ineligible.,during the first cycle,NA
8083713,NA,Single Drug,No,"Patients With Solid Tumors: 11 colon, 10 non-small-cell lung, three sarcoma, two ovarian, one melanoma, one hepatoma, one breast cancer, one lymphoepithelioma, one salivary gland, one unknown primary, one carcinoid, one renal cell, one pancreatic, and one Kaposi's sarcoma","Patients treated as part of this trial had to meet the following criteria: age greater than 18 years, histologically documented malignancy that failed to respond to conventional therapy or that was potentially responsive to etoposide at the dose of etoposide phosphate being tested, Cancer and Leukemia Group B performance status of 0 to 1, normal renal function (creatinine level < 1.5 mg/dL), normal hepatic function (bilirubin level < 2.0 mg/dL), total WBC count >= 4 ,000/pL, and platelet count >= 100,000/pL. Informed, written consent as per institutional guidelines was obtained from all study subjects. ",NA,NA,NA
11155918,NA,Combination,No,LUNG CANCER,"The eligibility criteria for this study were as follows: histologically or cytologically proven advanced lung cancer; chemotherapy-naive or pretreated state in NSCLC or pretreaeted stage in SCLC; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2; age <75 years; having measurable or evaluable lesions; adequate organ functions [hematological function (WBC>=4000/mm3, Hb >=9.0 g/dl, platelet count >=100000/mm3), renal function (serum creatine <1.5 mg/dl, creatinine clearance >=50 ml/min), hepatic function (total bilirubin <2.0 mg/dl, serum transaminases <2 x upper limit of normal range) and pulmonary function (PaO2 >= 70 Torr)]; mp evidence of bone marrow infiltration confirmed by bone marrow aspiration; no medical problems sufficiently severe to prevent compliance with the study requirements; and written informed consent of patients.",Patients were not eligible if drug allergies for CPT-11 or etoposide existed. ,All the courses performed,NA
8636778,NA,Combination,No,"Non-small-cell lung 10, Ovary 5, Adenocarcinoma unknown primary 4, Colon 3, Small-cell lung 2, Breast 2, Other 9","Patients were eligible if they had a microscopically confirmed diagnosis of a solid tumor, not amenable to established forms of treatment. Patients were required to be between 18 and 75 years of age, with a performance status of <= 2 (World Health Organization [WHO] scale), and a life expectancy >= 3 months. Patients must have given informed consent. No chemotherapy, immunotherapy, or radiotherapy was allowed for at least 4 weeks before study entry (6 weeks for nitrosoureas, mitomycin C, and extensive radiotherapy). Patients were required to have normal renal function (serum creatinine concentration < 120 umol/L), hepatic function bilirubinn level < 25 umol/L, and ALT < two times upper limit of normal), and bone marrow function (WBC count >= 4.0 x 109/L and platelet count > 100 x 109/L). ",Patients with evidence of brain involvement or leptomeningeal disease were ineligible,NA,NA
15959778,NA,Combination,No,patients with advanced-stage small-cell lung cancer,"Patients with histologically or cytologically proven ASSCLC were considered eligible for this study if they fulfilled the following criteria: age greater than 17 years, performance status 0–2 on the World Health Organization (WHO) scale, no prior chemotherapy, life expectancy of at least 12 weeks, adequate bone marrow function (white blood cell count WBC >3.5x109/l, absolute neutrophil count ANC >1.5x109/l, platelet count >100x109/l), renal function [serum creatinine 140 umol/l (1.4 mg/dl)] and hepatic function (serum bilirubin less than 1.25 times the ULN, serum transaminases less then twice the ULN or less than five times the ULN in the presence of liver metastases), and absence of clinically relevant neuropathy, psychiatric illness, and pregnancy, lactation or inadequate contraception in female patients. Before the start of treatment, all patients had to sign written informed consent.",NA,during the first four cycles of treatment,NA
8021737,NA,Single Drug,No,"Children With Refractory Solid Tumors: Neuroblastoma 6, Ewing's sarcoma 4, Thymic carcinoma 2, Primitive neuroepithelioma 2, Osteosarcoma 2, Colon carcinoma 1, Germ cell tumor 1, Non-Hodgkin's lymphoma 1, Fibrosarcoma 1","Patients with solid tumors who were unresponsive to conventional therapy were potentially eligible for this phase I study. The study was approved by the hospital's institutional review board, and informed consent was obtained from the patients, parents, or legal guardians. Eligibility criteria were as follows: (1) age less than 21 years at initial diagnosis; (2) recovery from nonhematologic toxicities of prior chemotherapy, with a minimum of 3 weeks since the last treatment; (3) adequate liver function (bilirubin < 2 mg/dL, ALT < three times normal, normal prothrombin time), renal function (creatinine < 2 mg/dL or creatinine clearance > 80 mL/min/1.73 m2), and metabolic function (serum electrolytes, calcium, phosphorus, blood glucose); (4) good nutritional status (weight > 5th percentile for age, serum albumin > 3 g/dL); (5) a performance status of 0 to 2 on the Eastern Cooperative Oncology Group scale, or Karnofsky score greater than 50; (6) life expectancy of at least 8 weeks; and (7) absence of severe concomitant medical problems or history of allergy to VP-16.",NA,during or in the 7 days after the first course ,NA
9537196,NA,Combination,No,"Metastatic or Recurrent Malignancies: NSCLC 17, sarcoma 9, SCLC 4, colorectal 3, mesothelioma 2, head and neck 1, esophageal 1, pancreatic carcinoma 1, germ-cell tumor 1","Patients with solid tumors refractory to standard therapy or for which no standard therapy exists were eligible if they were 18 years of age or older; had a performance status of 0 to 2; a life expectancy of at least 2 months; adequate marrow (granulocytes ≥ 1,800/μL, platelets ≥ 100,000/μL, hemoglobin ≥ 10 g/dL); renal (serum creatinine ≥ 1.5 mg/dL or creatinine clearance ≥ 60 mg/min) and hepatic (bilirubin ≤ 1.5 × normal) functions; and no cytotoxic chemotherapy for the preceding 4 weeks (6 weeks for mitomycin or nitrosourea). ","Patients with known bone-marrow metastasis, cardiac arrhythmias, or congestive heart failure requiring medical therapy, uncontrolled infection, prior radiation therapy to more than 30% of the marrow-containing skeleton, any concurrent active malignancies, comorbid conditions limiting survival to less than 2 years or preventing full informed consent, and pregnant women, were not eligible for this study.",during the first treatment cycle ,NA
12673724,NA,Combination,No,Adults with Recurrent Malignant Glioma,"Patients were eligible for the study if they were age >= 18 years and had recurrence or progression of glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, or mixed anaplastic oligoastrocytoma. Disease recurrence was defined as an increase in tumor size as documented on an MRI scan, biopsy-prone recurrence, or the presence of tumor cells in the cerebral spinal fluid (CSF). Patients were also required to have a World Health Organization (WHO) performance score of <= 2 and a life expectancy of >= 12 weeks. Chemotherapy and/or radiotherapy were allowed up to 4 weeks before enrollment. Patients were required to have an absolute neutrophil count (ANC)  1000 neutrophils per mm3, a platelet count >= 100,000 platelets per mm3, a hemoglobin level >= 10 g/dL, creatinine and bilirubin levels <= 1.5 times the upper limit of normal (ULN), levels of aspartate and alanine aminotransferase <= three times the ULN, and alkaline phosphatase <= two times the ULN","Patients were ineligible if they had other systemic diseases, frequent vomiting which could interfere with the ability to take oral medications, previous or concurrent malignancies (except basal or squamous cell carcinoma of the skin), or human immunodeficiency virus infection. ",NA,NA
14596703,NA,Combination,No,PATIENTS WITH SMALL-CELL LUNG CANCER,"To be eligible for this study, adult patients had to have all of the following characteristics: histologic or unequivocal cytologic proof of SCLC, Eastern Cooperative Oncology Group performance status of 0-2, no prior chemotherapy or radiation therapy, no serious intercurrent medical illness, and adequate hematologic, renal, and hepatic function. All patients were required to give informed consent after education about the experimental nature of the study and to use contraception if appropriate. Patients with asymptomatic brain metastasis were eligible.",NA,during weeks 1-4 ,NA
10512128,NA,Combination,No,stage III non-small cell lung cancer,"Nineteen patients were entered onto the study between November 1993 and January 1995. Eligibility criteria included: histologic or cytologic diagnosis of NSCLC; stage IIIA or IIIB disease excluding patients with malignant pleural effusion or superior vena cava compression; Zubrod performance status 0–2; no prior invasive malignancy within 5 years other than non-melanoma skin cancer or cervical CIS; no prior chemotherapy or thoracic radiotherapy; WBC > 3500/mm3; platelets > 100 000/mm3; serum creatinine < 1.5 mg/dl; total bilirubin <= 2.0 mg/dl; and serum aspartate aminotransferase and alanine aminotransferase of less than two times the upper limit of normal. Pretreatment evaluation in all patients included a bone scan and CT scans of the chest, abdomen and brain. All patients signed a written informed consent form approved by the local Institutional Review Board.",NA,NA,NA
7916039,NA,Combination,No,Patients With Lymphoma and Multiple Myeloma,"Patients between 17 and 66 years of age with a histologically confirmed diagnosis of relapsed or refractory HD, NHL, or multiple myeloma were eligible for the study. Patients with NHL of lowgrade (LG), intermediate-grade (IG), or high-grade (HG) histology by the Working Formulation1 5 were eligible. Patients with lymphomatous involvement of bone marrow at the time of prestudy evaluation were eligible for entry onto the study, but received only peripheral-blood stem cells (PBSC) at transplantation. Patients with multiple myeloma must have had <= 10% plasma cells in the bone marrow, based on a differential count of 500 nucleated cells, at the time of prestudy evaluation. The prestudy evaluation was performed within 4 weeks of hospital admission for the transplant and included a history and physical examination, complete blood cell count, electrolytes, urinalysis, bone marrow aspirate and biopsy, chest x-ray, and other appropriate radiologic evaluation to define the extent of disease. Serum and urine protein electrophoresis and immunofixation, serum quantitative immunoglobulins, and 02-microglobulin were determined in patients with multiple myeloma","Patients were excluded if they had a performance status of >= 2 (Southwest Oncology Group criteria), abnormal liver function tests with bilirubin >+ 2 mg/dL and AST  >=100 U/L, abnormal renal function with a creatinine level more than 2.0 mg/dL or creatinine clearance less than 50 mL/min, abnormal cardiac function with left ventricular ejection fraction less than 45% by nuclear scan, or abnormal pulmonary function with forced expiratory volume in 1 second or diffusing capacity of the lung for carbon monoxide less than 50% predicted. Patients with human immunodeficiency virus-associated malignancies were excluded. ",NA,Autologous Stem-Cell Transplantation on day 0
10086724,NA,Combination,No,adults with myeloid leukemia,"Patients were eligible for this trial if they had relapsed or refractory acute myeloid leukemia and had received one or two prior regimens. Patients with chronic myeloid leukemia (CML) in blast phase and patients with secondary acute myeloid leukemia following a diagnosis of myelodysplasia (MDS) who were previously untreated or had received one prior regimen were also eligible. Additional eligibility criteria included an ECOG performance status <2, serum creatinine <1.5 times the upper limit of normal, normal serum bilirubin and a left ventricular ejection fraction measured by a MUGA scan >40%. ",Those who had previously received an autologous or allogeneic bone marrow transplant were excluded. Those with active or uncontrolled infection or with treatment-related acute myeloid leukemia were excluded.,in the first cycle,NA
8270989,NA,Combination,No,Patients With Advanced Non-Small-Cell Lung Cancer,"Each patient met the following criteria: Eastern Cooperative Oncology Group performance status (PS)' 9 of 0, 1, or 2; 15 to 74 years of age; measurable disease; estimated life expectancy of at least 3 months; adequate renal and liver function, ie, normal serum creatinine and blood urea nitrogen, creatinine clearance >= 60 mL/min, total bilirubin level <= 1.5 mg/dL, and serum AST and ALT less than two times the upper limit of normal; and adequate bone marrow reserve, ie, WBC count >= 4,000/uL, platelet count >= 100,000/uL, and hemoglobin level >= 10 g/dL. All patients were required to provide signedinformed consent before entry",NA,NA,NA
16649219,NA,Combination,No,"Metastatic Urothelial Carcinoma. Four patients had mixed histology withtransitional cell carcinoma and squamous cell carcinoma, whereas the other patients had pure transitional cell carcinoma","Patients with metastatic transitional cell carcinoma (N2-N3/M1) of the urothelium (renal pelvis, ureter, or bladder) who had bidimensionally measurable lesions were enrolled in the study. All patients were age 75 years or younger with a life expectancy >= 3 months, and all patients had an Eastern Cooperative Oncology Group (ECOG) performance status <= 2. No patients received chemotherapy within 6 weeks of enrollment in the study. Additional enrollment requirements included an absolute neutrophil count (ANC) >= 2000/uL, a platelet count >= 100,000/uL, a serum bilirubin level <= 2.0 mg/dL, an aspartate aminotransferase level <= 2 times the upper limit of normal, and a creatininenclearance >= 50 mL per minute.","Patients who had other active malignancies, irritable bowel disease, or a history of myocardial infarction within 3 months of the study were excluded.",the first cycle of treatment,NA
15756278,NA,Combination,No,platinum-pretreated patients with advanced ovarian cancer,"Women between the ages of 18 and less than 75 years with histologically proven epithelial ovarian cancer and measurable progressive disease or relapse were eligible for entry into this phase I/II study. Patients must have received only one previous chemotherapeutic regimen containing either cisplatin or carboplatin; previous additional treatment with a taxane also was permitted. Further eligibility criteria included adequate bone marrow function (platelets > 100 000 ul-1, haemoglobin >10 g dl-1, leucocytes > 3.500 ul-1), normal renal function (serum creatinineo < 1.3 mg dl-1 and/or creatinine clearance > 60 ml min-1), normal liver function (transaminases < 2 x the normal value, bilirubin < 1.5 g dl-1), Karnofsky performance status >= 70%, and freedom from other malignancies for 5 years or more (except successfully treated basal cell and squamous cell carcinoma of the skin or carcinoma in situ of the cervix).","Patients were excluded if their expected survival was less than 3 months, had an uncontrolled systemic infection, had received an investigational drug within the last 30 days, had received chemotherapy within 30 days of the first cycle of etoposide, or had been pretreated with etoposide. ",at the first treatment cycle,NA
12609572,NA,Combination,No,small-cell lung cancer,"Eligibility criteria included histologically or cytologically proven and measurable SCLC, limited- or extensive-stage disease, age 18/75 years, World Health Organization (WHO) performance status <= 2, no prior chemotherapy, and no previously irradiated disease except for emergency radiotherapy. Limited-stage disease was defined as disease confined to one hemithorax, and included patients with involvement of mediastinal, hilar, or supraclavicular lymph nodes (ipsilateral or bilateral). Patients with ispilateral pleural effusion were also considered to have limited stage disease. Patients not satisfying these criteria were considered to have extensive-stage disease. In addition, patients were required to have adequate hemopoietic function (absolute neutrophil count [ANC]] >= 1.5x109/l, hemoglobin]>= 10 g/dl, and platelet count] >= 100 x 109/l), liver function (bilirubin level <= 1.5 mg/dl, aspartate/alanine aminotransferase concentrations <= 2 times the upper limit of normal, and serum albumin level] >= 3 g/dl), and renal function (serum creatinine <= 1.5 mg/dl or creatinine clearance >= 50 ml/min). ",Patients with active coronary artery disease (in the form of unstable angina or myocardial infarction over the last 12 months) and/or unstable diabetes mellitus were excluded. Patients with asymptomatic brain metastases controlled with corticosteroids or prior radiotherapy were allowed to participate.,the first cycle of treatment,NA
12394265,NA,Combination,No,advanced non-small cell lung cancer,"Patients with microscopically confirmed diagnosis of NSCLC and clinical stages IIIB and IV were included in this study. Southwest Oncology Group performance status of 0–2 was required, in addition to adequate pulmonary, hepatic, renal and bone marrow function.",Patients with central nervous system involvement or patients who received prior chemotherapy or radiotherapy treatment were excluded.,NA,NA
8194024,NA,Single Drug,No,"Patients with Advanced Malignancies. Non-Hodgkin’s lymphoma 10, Small cell lung cancer 5, Breast cancer 4, Colon cancer 4, Carcinoma unknown primary 3, Non-small cell lung cancer 3, Soft tissue sarcoma 3, Germ cell neoplasm 2, Gastrinoma 1, Neuroendocrine carcinoma of unknown primary 1, Cervical cancer 1, Mesothelioma 1, Anal cancer 1","Eligibility requirements included histologic diagnosis of advanced cancer; tumors refractory to standard therapy; an Eastern Cooperative Oncology Group performance status of 0, 1, or 2; a life expectancy of at least 12 weeks; and no treatment with chemotherapy in the preceding 3 weeks. In addition, patients were required to have a leukocyte count of greater than 3,000/mm3, platelet count greater than 100,000/mm3, serum creatinine level less than 2 mg/dl, and serum bilirubin level less than 2 mg/dl unless directly attributable to liver metastases. All patients required an indwelling central access catheter.",NA,NA,NA
16412499,NA,Combination,No,ovarian or peritoneal carcinoma,"To be eligible for this study, patients had a histologic diagnosis of adenocarcinoma of the ovary, peritoneum, or fallopian tube, persistent or recurrent disease (measurable or non-measurable), after receiving at least one platinum- and paclitaxel-based regimen and a GOG performance status 2. Patients could not be eligible for any higher priority GOG phase II protocol or have a history of other malignancy within the last 5 years or radiation therapy to more than 10% of the bone marrow. Because of oral dosing, patients were required to have adequate intestinal function (defined as not requiring intravenous hydration or nutrition). Additionally, because of fixed dose formulations, patients were required to have a BSA of at least 1 m2.","Excluded were patients with tumors of low malignant potential (borderline tumors), active infection, hepatitis, gastrointestinal bleeding, or chronic treatment with H2 antagonists, proton pump inhibitors or antacids, or other conditions which would affect gastrointestinal absorption or motility. Patients previously treated with either of these agents were also excluded. ",on the first cycle of therapy,NA
15719439,NA,Combination,No,Recurrent Ovarian Carcinoma Pretreated with Platinum-Taxane,"Eligible patients had a histologic diagnosis of epithelial ovarian carcinoma and either 1) treatment failure or recurrent disease  < 12 months after platinum-taxane-containing, first-line chemotherapy (primary failure) or 2) treatment failure or recurrent disease > 12 months after platinum-based, first-line chemotherapy and then received taxane-based, second-line chemotherapy and developed recurrent disease again < 12 months after end of the second-line chemotherapy (secondary failure). Inclusion criteria were 1) age 18 –75 years; 2) an Eastern Cooperative Oncology Group (ECOG) performance status <= 2; 3) life expectancy >= 3 months; 4) at least 1 tumor lesion measuring >= 2 cm in greatest dimension (as defined by imaging methods: computed tomography [CT] scan, magnetic resonance image, ultrasonography, or chest X-ray) or elevated CA125 levels (> 70 U/mL; Phase II study only); 5) adequate bone marrow function (white blood cell count [(WBC] >= 3.0 x 109, absolute neutrophil count [ANC] >= 1.5 x 109, platelets >= 100 x 109, and hemoglobin > 6.0 mmol/L); 6) adequate liver function (alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels <= 2 times the upper limit of the normal range in patients with no liver metastases and <= 3 times the normal range in patients with liver metastases present); 7) adequate renal function (serum creatinine <= 150 u 150 umol/L); 8) no concomitant malignancies with the exception of basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix; and 9) informed consent.",NA,during the first 2 cycles of treatment,NA
16757061,NA,Combination,No,limited disease small cell lung cancer,"Limited disease SCLC according to the definition of the Veterans Administration Lung Cancer Study Group (VALG): primary tumor, localisized at one hemithorax region, with or without involved ipsilateral or/and contralateral mediastinal lymph nodes, with or without involved supracavicular lymph nodes, with or without pleural effusion; Karnofsky performance status of 70% or higher; adequate liver (bilirubin <1.25 times normal, GOT and GPT <3 times normal), kidney (creatinine <1.25 times normal, creatinine clearance >60 ml/min), lung (diffusion capacity >60%, FEV1 >1.4l) and bone marrow function (Hb >11 g/dl, leukocytes >3000 (mm3)−1, platelets >100,000 (mm3)−1). CT scans of the chest and abdomen, bone scintigraphy, and MRI of the neurocranium were carried out for tumor staging.","Prior chemotherapy, secondary malignancy and contraindications to irinoteca and cisplatin or to chemotherapy and radiotherapy in general. Of the 12 cases treated, 2 were classified stage cT2, 2 stage cT3, and 8 stage cT4. Ipsilateral lymph nodes were involved in seven patients (cN2), and both ipsi- and contralateral nodes were affected in the remaining five cases (cN3). The tumors were moderately differentiated (G2) in 3/12 cases, and poorly differentiated (G3) in 9/12 cases. Neuron-specific enolase (NSE) levels were elevated in all cases. The mean time between histological confirmation and the start of treatment was 13 days. The necessary diagnostic examinations and treatment planning measures, including radiotherapy planning and determination of the patient’s suitability for chemotherapy, were carried out during this period.",during RCT,NA
9137533,NA,Combination,No,recurrent malignant gliomas,"Patients aged 18– 75 years with recurrent malignant brain tumors (glioblastoma or anaplastic astrocytoma) and Karnofsky performance >= 50% were eligible. Recurrence was defined as > 25% increase in the cross-sectional area of the contrast-enhancing tumor on serial MRI or CT scans. All patients had adequate bone marrow function, defined by a white blood cell count (WBC) > 4000 cells/mm3, hemoglobin (Hb) > 10 g/dl and platelet count (PLT) > 150 000/mm3, adequate liver function (bilirubin < 1.5 mg/dl, normal transaminases), and normal renal function (creatinine < 1.8 mg/dl and creatinine clearance > 60 ml/min per 1.7 m2 body surface area).","Exclusion criteria was as follows: radiation therapy within 4 weeks and chemotherapy within 6 weeks of study entry, and pregnancy or lactation. Toxicity was graded according to NCI toxicity criteria",the first cycle,NA
21387258,NA,Combination,No,Metastatic Clear Cell Renal Cell Carcinoma,"Patients with metastatic, histologically confirmed RCC with a clear cell component were eligible for inclusion into the current study. Patients were aged >18 years, had Response Evaluation Criteria In Solid Tumors (RECIST)-defined measurable disease, were using effective contraception, and had an Eastern Cooperative Oncology Group performance status of <= 1. Adequate bone marrow, liver, and renal function was required (hemoglobin >= 9.0 g/dL, an absolute neutrophil count >= 1500/uL, platelet count >= 100,000/uL, total bilirubin <= 1.5 times the upper limit of normal [ULN], aspartate aminotransferase [serum glutamic oxaloacetic transaminase] <= 2.5 times the ULN, alanine aminotransferase [serum glutamic pyruvic transaminase] <= 2.5 times the ULN, and measured or calculated [using the Cockcroft-Gault equation] creatinine clearance >= 40 mL/min or serum creatinine <= 1.5 times the ULN), and total cholesterol was required to be <=300 mg/dL. Resolution of any pre-existing toxicity from prior therapy to below National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE; version 3.0) grade 1 was required.","Patients were excluded for any of the following: collecting duct, papillary, or chromophobe-type histology without a clear cell component; >2 prior systemic regimens for RCC; prior everolimus or sorafenib therapy; surgery, radiotherapy, or systemic therapy for RCC administered within 4 weeks of the initiation of study therapy; known brain metastasis, spinal cord compression, or carcinomatous meningitis; or evidence of brain or leptomeningeal disease on screening computed tomography or magnetic resonance imaging scan. Patients were also excluded for prior myocardial infarction; unstable or severe angina; coronary or peripheral artery bypass graft; New York Heart Association class II, III, or IV congestive heart failure; cerebrovascular accident or transient ischemic attack; or pulmonary embolism occurring within 12 months before study entry. In addition, hypertension that could not be controlled with medication was an exclusion criterion, as was the need for chronic treatment with systemic steroids or other immunosuppressive agents or a history of human immunodeficiency virus infection. Patients with an active bleeding diathesis or those requiring systemic anticoagulation with warfarin were excluded. Patients receiving low-dose warfarin for maintenance of venous access devices and patients receiving other forms of systemic anticoagulation were eligible",during cycle 1,NA
24190702,NCT01136733,Combination,No,metastatic renal cell carcinoma (RCC),"Patients were aged ≥18 years, with histologically confirmed and documented evidence of unresectable advanced or mRCC and disease progression after prior therapy targeting the VEGF domain. Two patients who had received no prior regimens were enrolled prior to a protocol amendment. Eligible patients had an Eastern Cooperative Oncology Group performance status of 0 or 1, adequately controlled blood pressure, adequate hematologic, hepatic, renal, and blood coagulation function, and internationalized normalized ratio (INR) of ≤1.5. There was no upper limit on prior therapies.","Key exclusion criteria included prior exposure to lenvatinib, discontinuation of prior TKI due to toxicity, known intolerance to rapamycins, therapy with an anticancer agent or major surgery within 21 days, or treatment with any investigational agent within 30 days. Patients with significant cardiovascular impairment, bleeding or thrombotic disorders requiring anticoagulant therapy and therapeutic INR monitoring, prolongation of QTc interval (>480 ms), untreated or unstable metastases to the central nervous system, urine protein ≥1 g/24 h, uncontrolled diabetes [fasting glucose >1.5 × upper limit of normal (ULN)], fasting total cholesterol >7.75 mmol/L, and fasting triglyceride levels >2.5 × ULN were also excluded.",during the first treatment cycle ,NA
33547201,NCT03387020,Combination,No,Children with Recurrent or Refractory Malignant Brain Tumors,"Common eligibility criteria for the phase I and surgical study included patients ≥1 but ≤21 years of age with recurrent, progressive, or refractory brain tumors. All tumors, except radiographically typical DIPG (defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons), were required to have histologic verification of HGG, medulloblastoma, central nervous system (CNS) embryonal tumor [not otherwise specified (NOS)], ependymoma, or atypical teratoid rhabdoid tumor (39). Patients with low-grade gliomas were excluded. Pretrial tumor tissue from all patients (except typical DIPGs) was screened for intact Rb by IHC in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. Molecular genomics were not required for eligibility. For the surgical study, eligible patients included those for whom surgical resection was clinically indicated and were amenable to receiving 7–10 days of ribociclib before surgery. Surgical patients who met treatment initiation criteria for the phase I component postsurgical recovery were enrolled on the current dose level of enrolled nonsurgical patients. Additional eligibility criteria for both phase I and surgical studies included: Lansky (≤16 years) or Karnofsky (>16 years) performance scores at least 50%; recovery from acute toxicities of all prior therapies; ≥3 months since craniospinal radiotherapy (>24 Gy), ≥2 weeks since local palliative radiotherapy, and ≥3 months since autologous stem cell transplantation; and adequate laboratory data, including bone marrow function (hemoglobin ≥ 8 g/dL, absolute neutrophil count ≥ 1,000 mm3, and platelets ≥ 100,000/mm3 transfusion independent, defined as no platelet transfusion within a 7-day period prior to enrollment), renal function (age-adjusted normal serum creatinine or glomerular filtration > 70 mL/minute/1.73 m2), liver function [total bilirubin < 1.5 times institutional upper limit of normal for age, ALT (SGPT) and aspartate aminotransferase (AST; SGOT) ≤3  institutional upper limit of normal for age, and albumin ≥ 2 g/dL], and on stable or decreasing steroid dosing for at least 1 week prior to enrollment. Neurologic deficits must have been stable for a minimum of 1 week prior to enrollment. Patients with controlled seizures on nonenzyme-inducing anticonvulsants were eligible. Patients of childbearing or child fathering potential must have agreed to use medically acceptable form of birth control while on study.","Patients were excluded for the following reasons: pregnancy; concurrent illness that would compromise the patient’s ability to tolerate therapy, other current malignancy, and investigational agent; on potent CYP3A4 inducers/inhibitors; significant active cardiac disease, hypertension, uncontrolled heart disease, history of cardiac dysfunction, cardiomyopathy, left ventricular ejection fraction < 50%, and QTc >450 milliseconds; and on warfarin or other coumadin-derived anticoagulant.",during the first cycle ,NA
27206639,NCT01217177,Combination,No,locally advanced cervix cancer,"Patients with pathologically confirmed squamous cell carcinoma of the uterine cervix were eligible if they were older than 18 years old, had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2, an International Federation of Gynecology and Obstetrics (FIGO) stage of IIB, IIIA or IIIB, a measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1, an adequate renal, hepatic, and bone marrow function, and a normal lipid profile. For women at reproductive age, a serum-negative β-human chorionic gonadotropin assay was required and a contraceptive method along the entire study was recommended.","Exclusion criteria included a previous malignancy in the last 5 years, positive para-aortic lymph nodes in the imaging evaluation, uncontrolled diabetes, pulmonary and cardiovascular disease, psychiatric disorders, and known HIV, hepatitis B and C infection.",up for 14 weeks (10 weeks of treatment plus 4 weeks of observation,NA
32005746,NCT01470209,Combination,No,"Advanced Solid Tumors. Primary tumor site, N (%) Lung 16 (37.2), Colon/rectal 7 (16.3), Salivary 5 (11.6), Breast 3 (7.0), Soft tissue sarcoma 3 (7.0), Thymus 2 (4.7), Bladder 2 (4.7), Thyroid 2 (4.7), Ovarian 2 (4.7), Pancreatic NET 1 (2.3)","Participants with histologic confirmation of a solid malignancy who have exhausted standard treatment options were eligible for the study if ≥18 years of age at the time of enrollment, and with at least one measurable lesion in accord with the RECIST 1.1 criteria. Additional eligibility criteria included Eastern Cooperative Oncology Group performance status of 0–2; adequate organ function indicated by: absolute neutrophil count ≥1,500 cell/mm3, hemoglobin ≥9 g/dL, platelets ≥100,000 cells/mm3; serum creatinine ≤1.5 x upper limit of normal (ULN); 24-hour clearance ≥50 mL/minute or calculated GFR of 60 cc/mL using the formula of Cockcroft and Gault; aspartate aminotransferase (AST) and alanine aminotransferase <2.5 x ULN or <5 x ULN in the presence of hepatic metastases and fasting plasma glucose ≤120 mg/dL (6.7 mmol/L).","Salient exclusion criteria included inability to swallow pills, prior treatment with a P13K inhibitor or discontinuation of prior everolimus treatment due to toxicity, and known psychiatric diagnosis or suspected diagnosis of mood disorder based on validated GAD-7 and PHQ-9 screening questionnaires.",during the DLT window in cycle 1,NA
24819684,NCT00610948,Combination,No,"patients with refractory solid tumors. Tumor type: Colorectal 24 (KRAS wild type 9, KRAS mutant 11, Unknown 4), Esophagogastric 3, Pancreas 3, Appendiceal adenocarcinoma 1, Small bowel adenocarcinoma 1, Cholangiocarcinoma 3, Adrenal cortical carcinoma 1","Eligible patients for this study had histologically confirmed metastatic solid malignancies with no clearly effective standard therapeutic options available based either on prior therapy or on disease type. Patients with tumor histologies potentially sensitive to EGFR-targeted therapy were recruited preferentially. The study was amended to restrict enrollment of patients with mCRC receiving panitumumab to those with KRAS wild-type tumors after data by Amado et al.  were published which reported a requirement of KRAS wild-type status for panitumumab efficacy. Other inclusion criteria included the following: age ≥18 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST); and a minimum of 3 weeks since major surgery and completion of radiation or completion of all prior systemic anticancer therapy. Patients were required to have adequate organ function, including an absolute neutrophil count (ANC) ≥1,500 cells/mm3, a platelet count ≥100,000/mm3, creatinine clearance ≥60 ml/min as calculated by the Cockcroft–Gault formula, total bilirubin ≤1.2 mg/dl, transaminases ≤2.5 × ULN (or ≤5 × ULN in cases of known liver metastases or primary liver cancer) and magnesium greater than or equal to the lower limits of normal. Patients enrolled on study were required to discontinue all medications that are known inducers or inhibitors of cytochrome P450 3A4 (CYP3A4).","Additional exclusion criteria included the presence of grade 2 or greater neuropathy at the time of study entry; pregnancy, breastfeeding or unwilling to use contraception; impairment of gastrointestinal function leading to altered absorption; active bleeding; and any concurrent lifethreatening acute medical problem at the discretion of the investigator.",during the first cycle of treatment (28 days),NA
25788492,NA,Combination,No,Metastatic Renal Cell Carcinoma,"For both the phase I and phase II components of the study, patients were required to have histologically confirmed RCC with a clear cell component. Notably, any proportion of clear cell disease was allowed. Patients were further required to have metastatic disease, a Karnofsky performance status (KPS) of 70, adequate organ function and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. ","Key exclusion criteria included collecting duct or medullary histology, active brain metastasis, significant cardiovascular events within 6 months, congestive heart failure (left ventricular ejection fraction < 50%), and full-dose anticoagulation. Patients may have received any number of prior VEGF-tyrosine kinase inhibitors (VEGF-TKI)  enrollment in the phase I component of the study, but may have received only one to two prior VEGF-TKIs before enrollment in the phase II component. ",during cycle 1,NA
34903452,NCT01149356,Combination,No,Patients with ER + Metastatic reast Cancer (MBC),"The study was a Phase Ib trial in patients with ER+/ HER2- MBC, who had the following characteristics: (1) disease that relapsed during treatment or within 6 months of discontinuation of an adjuvant nonsteroidal aromatase inhibitor or Tamoxifen, or (2) MBC that progressed during treatment with first or second line endocrine therapy. Previous chemotherapy was allowed (without limit on lines). An interval of at least 4 weeks since discontinuation of chemotherapy (6 weeks for nitrosoureas or mitomycin C) or at least 2 weeks since discontinuation of radiotherapy was required prior to entering the study. At the time this study was opened, CDK4/6 inhibitors, mTOR inhibitors and PI3KCA inhibitors were , hence no patients was pre-treated with these agents. Patients with visceral and non-visceral metastatic disease were eligible for enrollment, and CNS metastases were not an exclusion criterion. All premenopausal patients were to receive Goserelin (3.6 mg q28 days Sub-Q).",NA,during Cycle 1,NA
24908540,NCT01714765,Combination,No,vascular endothelial growth factor refractory clear cell renal cancer,"Patients with metastatic clear cell RCC were eligible for this study. Patients were required to have had progressive disease while taking VEGF targeted therapy and enrolled within 6 months of failing previous targeted therapy (VEGF or mTOR therapy). Patients were required to have a performance status of 0 or 1, over 3 months life expectancy, no evidence of cardiac disease within the last 6 months, adequate organ function (bilirubin <= 1.5 x upper limit of normal (ULN), transaminases <= 3 x ULN, creatinine <= 2 x ULN, absolute neutrophil count >= 1.5 x 109/L, platelets >= 100 x 109/L) and no contraindications for dovitinib or everolimus.","Patients with brain metastasis, established pulmonary fibrosis or uncontrolled blood pressure were excluded from the study as were those who had previously received dovitinib",during the first 4 weeks of therapy,NA
24685058,NA,Combination,No,Patients With Advanced Renal CellCarcinoma,"Patients eligible for this study included adults (≥ 18 years) with histologically confirmed nonhematologic malignancy and radiographically measurable metastatic disease for which there is no standard therapy. For patients with prostate cancer, biochemical evidence of disease (ie, elevated prostate-specific antigen [PSA]) in the setting of nonmeasurable bone metastases was allowed. Patients were required to have good performance status (Karnofsky performance status ≥ 70) and acceptable bone marrow, kidney, and liver function (absolute neutrophil count ≥ 1500/mm3, platelet count ≥ 100,000/mm3, hemoglobin value ≥ 9 g/dL, creatinine clearance > 40 mL/min, bilirubin level ≤ 1.5 times the upper limit of normal, and aspartate aminotransferase and alanine aminotransferase levels ≤ 2.5 times the upper limit of normal). Total cholesterol was required to be < 300 mg/dL and triglyceride levels < 350 mg/dL. Previous chemotherapy (> 4 weeks; > 6 weeks for mitomycin C, nitrosureas, or antibody therapy), radiotherapy, biological/immunotherapy or surgery (> 4 weeks) were permitted provided that there was resolution of all toxicities of Common Terminology Criteria for Adverse Events grade ≤ 1.","Exclusion criteria included concurrent malignancies other than superficial nonmelanomatous skin cancer, superficial bladder cancer, or nonmetastatic prostate cancer. After the US Food and Drug Administration's approval of sorafenib and sunitinib for the treatment of advanced RCC in January 2006, the study was amended to allow previous treatment with these agents as well as bevacizumab. Additional exclusion criteria included active central nervous system disease, liver disease, pleural effusion, ascites, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen. Patients with uncontrolled cardiac disease (angina, congestive heart failure, arrhythmia) or myocardial infarction (≤ 6 months); uncontrolled diabetes, infections, or hyperlipidemia; interstitial pneumonia or extensive symptomatic interstitial lung fibrosis; chronic renal disease; or gastrointestinal disease that could affect absorption of the study drug were also excluded. In addition, participants were excluded if they had received other investigational drugs ≤ 4 weeks before starting study treatment. Use of warfarin or oral anticoagulants metabolized by the cytochrome P450 system was not permitted, whereas heparin and low-molecular-weight heparin were allowed. Patients with human immunodeficiency virus infection and other severe acute or chronic medical or psychiatric conditions were also excluded.",within the first 42 days of treatment (28 days of combined treatment),NA
28616837,NA,Combination,No,"patients with advanced cancer: colorectal cancer, colon cancer, pancreatic cancer 2,","Eligible patients were aged ≥18 years with histological or cytological confirmed solid malignancies that were refractory to standard therapies, or for which no standard treatment option was available. Other eligibility criteria included WHO performance status ≤2, estimated life expectancy of ≥3 months, adequate bone marrow (white blood cell count ≥3.0 × 109/l, platelets ≥100 × 109/l), hepatic (serum bilirubin ≤1.5 × upper limit of normal (ULN), ALAT/ASAT ≤2.5 × ULN or in case of liver metastases ≤5 × ULN) and renal function (serum creatinine ≤150 μmol/l). Patients also had to be mentally, physically and geographically able to undergo the study treatment and follow-up.","Patients were ineligible if they were known with a serious concomitant medical condition, such as unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within the last 6 months before screening, serious uncontrolled cardiac arrhythmia, uncontrolled diabetes (fasting serum glucose >2 × ULN), severe infection, cirrhosis, chronic active/persistent hepatitis or severly impaired lung function. Furthermore, patients were ineligible when they had a known hypersensitivity to either study drug, if they had used either study drug in the previous 6 months or when they were concomitantly treated with strong CYP3A4/3A5/2C8 inhibitors/ inducers. Women were ineligible when they were pregnant or lactating.",during the first treatment cycle,NA
25335932,NCT01154335,Combination,No,patients with refractory metastatic colorectal cancer,"Eligible adult patients had histologically confirmed adenocarcinoma of the colon or rectum, and had progressed on, were intolerant to, or were not a candidate for treatment with fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab, cetuximab or panitumumab. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 , and the ability to swallow whole pills. Baseline laboratory values for eligibility included: absolute neutrophil count (ANC) ≥1,500/mm3; platelets ≥100,000/mm3; hemoglobin ≥9 g/dL; aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase ≤2.5 times the institutional upper limit of normal (ULN), or ≤5 times ULN in patients with known liver metastases; total bilirubin ≤1.5 times ULN; fasting serum glucose <150 mg/dL; fasting serum cholesterol ≤300 mg/dL and fasting triglycerides ≤2.5 times ULN.","Patients who have received any cancer therapies <4 weeks or 5 half lives (whichever is shorter) of initiating study therapy. Treatment with any investigational drug ≤ 4 weeks, or 5 half-lives of the drug, whichever is shorter. Patients who require coumadin for anticoagulation. Patients who have had major surgery or significant traumatic injury ≤4 weeks of the of study treatment. Minor surgery (with the exception of port placement) must be completed ≤ 7days prior to study therapy. Previous treatment with an IGFR inhibitor or MTOR Inhibitor. Chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Patients with QTc interval >450ms. Patients who require drugs that can prolong QTc.. Patients with congenital long QT syndrome, history of ventricular tachycardia, or ventricular fibrillation, or Torsades de Pointes with bradycardia.. Immunization with attenuated live vaccines within 1 week of beginning study therapy or during study period;Close contact to anyone that has received live virus vaccine should be avoided. Meningeal or brain metastasis. Other malignancies < 3 years, with the exception of adequately treated basal or squamous cell carcinomas of the skin, or carcinoma in situ of the cervix. Patients with known HIV. Patients with positive testing for hepatitis B or C",during the first cycle (28 days) of treatment,NA
33451345,NCT02123823,Combination,No,"hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer","Briefly, eligible patients were postmenopausal women aged ≥ 18 years, with histologically confirmed, locally advanced or MBC that was not amenable to curative therapy, and had recurred or progressed on/after the last line of systemic therapy for breast cancer. Patients were required to have hormone receptorpositive, HER2-negative tumours per local testing, and adequate archival tumour tissue. Patients had tumours that were resistant to non-steroidal AIs (defined as recurrence during/within 12 months after adjuvant treatment or progression during/within 1 month after treatment for locally advanced or MBC). Additional inclusion criteria included the following: life expectancy of ≥ 6 months, adequate organ function, a measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 or bone lesions (lytic or mixed) in the absence of a measurable lesion, and Eastern Cooperative Oncology Group performance status ≤ 2.","Exclusion criteria included the following: previous treatment with agents targeting the IGF, PI3K, AKT, or mTOR pathways; prior exemestane treatment; brain or central nervous system metastases; and > 2 previous lines of chemotherapy for locally advanced/MBC (> 1 previous line in phase II).",the first treatment cycle,NA
23963141,NCT01079481,Combination,No,patients with small-cell lung cancer,"Eligible patients were adults at least 18 years of age with pathologically confirmed limited or extensive staged SCLC, whose cancer had progressed after at least two prior chemotherapy regimens including at least one platinum-containing regimen. Other eligibility criteria were an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2, at least one measurable lesion by Response Evaluation Criteria in Solid Tumours (RECIST 1.1), which had not been radiated previously, absolute neutrophil count >=1500 per ul, platelet count >=1 00 000 per ul, serum total bilirubin <=1.5 x institutional upper limit of normal, serum transaminases <= 5 x upper limit of normal, and creatinine clearance >= 50 ml min -1. Patients must have terminated prior chemotherapy or radiotherapy 4 weeks before enrolment, and had to have recovered from toxicities related to prior therapies to grade 0–1.","Patients were ineligible if they had received prior therapy with known mTOR inhibitors, had diseases that might alter the absorption of everolimus, or had untreated or symptomatic brain metastases. Patients were also excluded if they had hypercholesterolemia of grade 3 or higher, uncontrolled diabetes with fasting glucose level >165 mg dl-1, uncontrolled infection, liver cirrhosis, or active viral hepatitis. Women who were pregnant, breast-feeding, or able to conceive but unwilling to practice effective contraception and patients with a known Cremophor allergy were also excluded.",within the first cycle of treatment,NA
33964572,NCT02077933,Combination,No,"solid tumours. Primary site of cancer n : Kidney 24, Breast 23, Pancreas 20, Rectum 3, Cervix 1, Lung 1, Other 2, Ovary 1, Parotid lymph nodes 1, Stomach 2, Small intestine 1, Uterus 1","Inclusion Criteria For entire trial: Adult > or = 18 years old; has signed the Informed Consent Form; has tumor tissue available for the analysis as described in the protocol; has an Eastern Cooperative Oncology Group performance status ≤2; has adequate bone marrow and organ function as defined in the protocol is able to swallow and retain oral medication; has either measurable or non-measurable disease as per RECIST 1.1. Inclusion Criteria for the BYL719+ Everolimus combination - escalation phase - all above plus has a histologically/cytologically confirmed metastatic and/or recurrent solid tumors for whom no standard therapy exists. Inclusion Criteria for the BYL719+ Everolimus combination - expansion phase, renal cell carcinoma cohort - all of above first 7 criteria plus has an histologically/cytologically confirmed Renal Cell Cancer as detailed in the protocol. Inclusion Criteria for the BYL719+ Everolimus combination - expansion phase, pancreatic NeuroEndocrine Tumor cohort. - all of above first 7 criteria plus has an histologically/cytologically confirmed pancreatic NeuroEndocrine Tumor as detailed in the protocol. Inclusion Criteria for the BYL719+ Everolimus combination - expansion phase, mTOR inhibitor-pretreated patients' cohort - all of above first 7 criteria plus has a histologically and/or cytologically confirmed solid malignancy as described in the protocol. Inclusion Criteria for the breast cancer cohorts in escalation and expansion phases, - all of above first 7 criteria plus is post-menopausal and has a histologically and/or cytologically confirmed diagnosis of breast cancer as described in the protocol. Specific Inclusion Criteria at the time of cross-over (breast cancer, expansion phase), - Patient randomized to the alpelisib and exemestane combination who has a radiologically documented progressive disease as detailed in the protocol","Patient has received previous treatment with a PI3K and/or AKT and/or mTOR inhibitor (mTOR inhibitor is allowed in expansion cohorts where patients should have areceived a prior mTOR inhibitor). Known intolerance or hypersensitivity to Everolimus or other rapamycin analogs. Patient with primary central nervous system (CNS) tumor or CNS tumor involvement as detailed in the protocol. Patient with diabetes mellitus, or documented steroid-induced diabetes mellitus. Patient has a history of another malignancy within 2 years prior to starting study treatment as described in the protocol. Patient who has not recovered to grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapy as detailed in the protocol. Patient who has had systemic therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to starting study treatment. Patient who has received radiotherapy ≤ 4 weeks prior to starting study drugs, with exception of palliative radiotherapy (≤ 2 weeks prior to starting study drugs), who has not recovered from side effects of such therapy to baseline or Grade ≤ 1 and/or from whom ≥ 30% of the bone marrow was irradiated. Patient who has undergone major surgery ≤ 4 weeks prior to starting study treatment or who has not recovered from side effects of such procedure. Patient has a clinically significant cardiac disease or impaired cardiac function or any severe and/or uncontrolled medical conditions as detailed in the protocol. Patient who is currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatment. Patient who has participated in a prior investigational study within 30 days prior to enrollment as described in the protocol. Patient who is currently receiving treatment with drugs known to be moderate or strong inhibitors or inducers of isoenzymes CYP34A or CYP2C8 as described in the protocol. Switching to a different medication prior to start of treatment is allowed. Patient with impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral alpelisib, everolimus, exemestane. Patient with known positive serology for human immunodeficiency virus. Patients who have received live attenuated vaccines within 1 week of start of study drug and during the study as specified in the protocol. Pregnant or nursing (lactating) woman as detailed in the protocol. Patient who does not apply highly effective contraception during the study and through the duration as defined in the protocol. Patients in the mTOR inhibitor-pretreated cohorts: all of above first 19 criteria plus have discontinued prior mTOR inhibitor therapy due to non-tolerable toxicity",in the first 35 days for patients in the dose-determining analysis set,NA
30635337,NA,Combination,No,Patients with Previously Treated Renal Cell Carcinoma,"For the phase I portion of the trial, patients could have any number of prior therapies and any RCC histology, but in the phase II portion, patients were required to have RCC with some clear-cell features and have previously received 1–3 prior regimens, including a VEGF receptor–TKI (VEGF-TKI). This study was conducted in accordance with the U.S. Common Rule and received institutional review board approval at each respective center with informed written consent obtained from each subject. All patients had at least one measurable site of disease per RECIST 1.1 criteria (10), as well as normal organ function and an ECOG performance status of 0–2. Also patients had fasting serum cholesterol <= 300 mg/dL or <[= 7.75 mmol/L and fasting triglycerides <= 2.5 x ULN, due to anticipated disruption of the glucose and lipid axis from everolimus.",during the first 5 weeks of this study,NA,NA
21177764,NCT00927966,Combination,No,Patients with Advanced Sarcomas and Other Solid Tumors. Nonsarcoma patients included 1 patient with colon cancer and 1 patient with adrenal cortical carcinoma.,"Key eligibility criteria included: histologically proven advanced sarcoma or other malignant solid tumor without any curative therapy; at least 2 lines of established therapy, if such treatment exists or refusal of such treatment; age >= 18 years, Eastern Cooperative Oncology Group performance status of 0 or 1, adequate bone marrow, renal, and hepatic function (absolute neutrophil count >= 1,500/mm3 unsupported by growth factors, platelets >= 100,000/mm3, creatinine <= 1.5 times institutional upper limit of normal (ULN), total bilirubin 1.5 times ULN, aspartate aminotransferase/alanine aminotransferase <= 2.5 times ULN, fasting serum cholesterol <= 7.75 mmol/L, and fasting triglycerides <= 2.5 times ULN); recovery from toxicities of prior anticancer therapy to grade 1 or less or returned to baseline; and use of adequate contraception in patients with reproductive potential.","Key exclusion criteria included prior systemic anticancer therapy within 3 weeks of study drug administration, kinase inhibitors within 2 weeks for patients with gastrointestinal stromal tumor (GIST), prior radiotherapy or major surgery within 2 weeks concurrent use of any anticancer therapies; symptomatic or uncontrolled brain or central nervous system metastases; pregnant or nursing women; concomitant use of chronic high dose corticosteroids (>100 mg of prednisone or >40 mg dexamethasone per day) within 2 weeks of study entry or any inhibitors or inducers of CYP3A; uncontrolled diabetes mellitus as defined by fasting serum glucose >1.5 times ULN; significant active cardiac disease, serious active infection, other uncontrolled significant medical illness, psychiatric illness, or social situation that would preclude study participation.","in cycle 1, days 1 to 21",NA
25029236,NCT00560963,Combination,No,locally advanced and/or metastatic pancreatic cancer,"Adult patients with histologically confirmed locally advanced or metastatic pancreatic adenocarcinoma were eligible for study enrollment. Further key inclusion criteria were as follows: adequate bone marrow, liver, and renal function on RAD001 treatment; at least one measurable lesion [longest diameter ≥20 mm on conventional computed tomography (CT) or MRI scan; ≥10 mm on spiral CT] according to the RECIST criteria (version 1.0) that has not been irradiated previously; at least 4 or 2 weeks’ time since previous major/minor surgery and recovery, completion of radiation, or completion of all previous systemic anticancer therapy. Eligible patients must have an ECOG performance status of 0–2.","Individuals were not eligible for study enrollment if there was documented intolerance to everolimus or gemcitabine, a history of another malignancy within 5 years before study enrollment, or if patients had a marked impairment in gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001. Furthermore, previous treatment with an mTOR inhibitor or with gemcitabine was not allowed (except adjuvant treatment with gemcitabine, which had to be completed ≥ 3 months before study entry). ",NA,NA
18332469,NA,Single Drug,No,"Patients With Advanced Solid Tumors. Primary diagnosis: Breast 19, Colorectal 16, Pancreas 4, NET 2, Renal 2, NSCLC 2, Gallbladder 2, Melanoma 2, Other 6 ","Main inclusion criteria were histologically confirmed advanced tumors, unresponsive to standard therapy; presence of disease accessible to repetitive biopsies; age >= 18 years; life expectancy >= 12weeks;WHO performance status of 0 to 2; and adequate bone marrow, hepatic, and renal function. All patients gaveinformed consent, and approvalwas obtainedfrom the ethics committees at the participating institutions and regulatory authorities",NA,in the first 28 days of treatment,NA
21984222,NA,Combination,No,patients with glioblastoma,"This phase IB/II, open-label, multicenter, 2-arm doseescalation study enrolled patients (C18 years) with histologically confirmed glioblastoma at first or second recurrence or relapse who were not receiving an EIACD and had (1) a Karnofsky Performance Status (KPS) C70, (2) acceptable laboratory values, and (3) a life expectancy C12 weeks",The study excluded patients with Common Terminology Criteria for Adverse Events (CTCAE) (version 3.0) grade-2 or greater peripheral neuropathy or unresolved diarrhea or any concurrent severe and/or uncontrolled medical conditions that could compromise study participation.,during the first 28 days after the initiation of study therapy,NA
32704173,NCT01218555,Combination,No,patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma,"Eligible adult patients were required to be ≥18 years of age, able and willing to provide informed consent and with histologic confirmation of a progressive solid malignancy. Patients were required to have at least one measurable site of disease according to the RECIST 1.1 criteria and must have discontinued anti-cancer therapy at least 4 weeks prior to initiation of treatment. Other eligibility criteria included Eastern Cooperative Oncology Group performance status of 0–2; adequate organ function indicated by: absolute neutrophil count ≥1500 cell/mm3, haemoglobin ≥9 g/dl,platelets ≥100,000 cells/mm3); serum creatinine within normal limits or creatinine clearance ≥60 ml/min/m2 if elevated; aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase (ALT) (SGPT) <2 × upper limit of the normal range (ULN) or <5 × ULN in the presence of hepatic metastases.",Salient exclusion criteria included inability to swallow pills; pregnancy or breast-feeding; prior exposure or known hypersensitivity to lenalidomide or everolimus; chronic treatment with systemic steroids or other immunosuppressive agent; and active therapy for HIV or infectious hepatitis type B or C.,in cycle 1 ,NA
34819039,NCT02623751,Combination,No,Japanese patients with hormone receptorpositive advanced breast cancer,"Postmenopausal women aged ≥ 20 and < 75 years at the time of consent; Estrogen receptor positive and/or progesterone receptors positive; HER2-negative; Nonresectable advanced or recurrent breast cancer previously treated with nonsteroidal aromatase inhibitor (AI), and planning to be treated with exemestane","Radiation therapy or immuno therapy within 14 days before the first dose of investigational product; Chemotherapy, biological medicines, other pharmacotherapy or major surgery within 21 days before the first dose of the investigational product; Prior chemotherapies of ≥ 3 regimens for advanced or recurrent breast cancer; Ongoing treatment with other investigational product","The dose-limiting toxicities (DLTs) of ENT monotherapy (3 mg or 5 mg once weekly or 10 mg as a single dose) in Cohorts 1–3 and ENT 5 mg weekly in combination with EXE 25 mg/d in Cohort 4 were assessed for 7 days (cycle 0) and 28 days (cycle 1), respectively",NA
21898375,NA,Combination,No,Patients With Metastatic Renal Cell Carcinoma,"Eligible patients had progressive metastatic RCC of any histological subtype, and could have received <=3 prior regimens for metastatic RCC, with the exception of sunitinib or an mTOR inhibitor. All were required to have Eastern Cooperative Oncology Group performance status 0 or 1 as well as adequate organ function defined by the following criteria: serum aspartate aminotransferase and alanine aminotransferase <= 2.5 x upper limit of normal (ULN) or <5 x ULN in the presence of liver metastases, serum bilirubin <= 1.5 mg/dL, leukocyte count >= 3000 cells/uL, absolute neutrophil count >= 1500/uL, platelets >= 100,000/uL, hemoglobin >= 9.0 g/dL, prothrombin time <= 1.5 x ULN, serum calcium <= 12.0 mg/dL, and serum creatinine <= 2.0 x ULN.","Patients were excluded for any of the following: poorly controlled blood pressure (>150/100 mm Hg); cardiac dysrhythmias or QTc prolongation (>450 ms for males and >470 ms for females); severe vascular disease in the past year, including cardiovascular, cerebrovascular, or peripheral vascular disease; uncontrolled brain metastases; chronic systemic steroids or other immunosuppressive agent; history of bleeding diathesis, coagulopathy, or therapy with full-dose warfarin; surgery; radiation therapy; systemic therapy; or grade 3 hemorrhage within 4 weeks. Prior gastrointestinal perforation, intra-abdominal abscess within 6 months, or impairment of gastrointestinal function that could limit drug absorption were also reasons for exclusion from enrollment. ",in the first 6-week cycle,NA
32335374,NCT02577458,Combination,No,patients with advanced clear-cell renal cell carcinoma,"Patients aged 18 to 70 years with a histologically or cytologically confirmed diagnosis of advanced ccRCC, disease progression after targeted therapy, an ECOG performance status of 0-1, and an expected survival time of more than 3 months were eligible for the study. Additionally, eligible patients were required to have adequate hematologic, hepatic, and renal function (hemoglobin >= 9.0 g/dL, ALT/AST <= 1.5 x ULN or <= 5 x ULN when having liver metastases, total bilirubin <= 1.5 x ULN, and serum creatinine <= 1.5 x ULN); and measurable disease according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1, and should not have received any chemotherapy, radiotherapy, biotherapy or endocrine therapy within 4 weeks before study treatment","Patients were excluded if they have poorly controlled blood pressure (150/90 mm Hg or higher with or without antihypertensive drugs); severe vascular disease including cardiovascular, cerebrovascular, or peripheral vascular disease; cardiac dysrhythmias or QTc prolongation (>450 ms); or brain metastases.",during the first 28-day cycle,NA
25902899,NA,Combination,No,"patients with advanced solid tumors refractory to standard therapy. Cancer diagnosis, n (%): Soft tissue sarcoma 13 (25), Breast 8 (15), Gynecological 8 (15), Gastrointestinal 6 (12), Lung 4 (7), Hepatocellular 3 (6), Neuroendocrine 3 (6), Genitourinary 3 (6), Head and neck 2 (4), Others 2 (4)","Patients had to be≥16 years old, have histologically-or cytologically proven refractory solid tumors, Eastern Cooperative Oncology Group (ECOG) performance status≤2 and have evaluable disease by RECIST criteria 1.1. Adequate organ function for therapy was determined by the following criteria: neutrophil count≥1.5 x 109/L; platelets≥ 100 x 109/L; creatinine≤1.5 X upper limit of normal (ULN); total bilirubin ≤ 1.5 X ULN; AST(SGOT) and/or ALT(SGPT)≤2.5 X ULN, and urine protein/creatinine <1.","Patients were excluded if they had untreated central nervous system (CNS) metastases; significant risk for gastrointestinal (GI) bleeding or GI abnormalities that affected drug absorption; corrected QT (QTc)>480 msecs; cardiovascular condition diagnosis within the past 6 months; uncontrolled systemic vascular hypertension; major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any nonhealing wound, fracture, or ulcer; evidence of active bleeding or bleeding diathesis; pulmonary lesions with increased risk of bleeding; unstable pre-existing medical, psychiatric, or other condition that could interfere with subject’s safety, provision of informed consent, or compliance to study procedures; use of any investigational drug within 30 days of therapy initiation; any ongoing toxicity from prior anticancer therapy that is>Grade 1 and/or that is progressing in severity, except alopecia. Patients with prior malignancies were eligible if they were disease-free for 2 years, and/ or had completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma. Patients of reproductive capacity who refused to use appropriate pregnancy-prevention methods during the study were also excluded.",during cycle one (4 weeks),NA
24057042,NCT00352443,Combination,No,patients with advanced cancers,"Patients with advanced solid tumors for whom there was no effective therapy were eligible. Patients were required to have a Zubrod performance status of 0–2 (similar to ECOG performance status 0–2) and adequate hematologic, renal and hepatic function. Patients were also required to have a normal cardiac ejection fraction, assessed either with multi-gated acquisition (MUGA) scan or echocardiography",NA,during the first cycle,NA
23928403,NCT00828594,Combination,No,patients with advanced hepatocellular carcinoma,"Eligible patients were aged P18 years and had advanced HCC according to the American Association for the Study of Liver Disease guidelines ; Barcelona Clinic Liver Cancer (BCLC) stage B or C disease ; no previous systemic therapy for HCC except tamoxifen; measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 , with a target lesion not previously treated with local therapy or that progressed since the last local treatment; Eastern Cooperative Oncology Group (ECOG) performance status 0–1; Child-Pugh class A liver disease with no encephalopathy or ascites; and adequate bone marrow, renal, and hepatic function. Patients positive for hepatitis B virus (HBV)-DNA or hepatitis B surface antigen received prophylactic antiviral therapy for P1 week before receiving study drug.",Exclusion criteria included current anticancer therapy or local anticancer therapy within 4 weeks of baseline tumor imaging; active bleeding within the previous 30 days; known human immunodeficiency virus seropositivity; any severe or uncontrolled medical condition; long-term treatment with corticosteroids or another immunosuppressive agent; and surgery within 2 weeks of enrollment.,"within the first treatment cycle (i.e., the first 28 days of therapy)",NA
7692002,NA,Combination,No,"Patients With Refractory Solid Tumors. Disease site: Lung, NSCLC:SCLC, Head and neck, Colon, Genitalia, Orbitat, Primary-unknown adenocarcinoma","Patients eligible for this study had histologically or cytologically diagnosed malignant solid tumors and had exhausted the standard therapeutic options for their disease or had a malignant disease for which no established therapy exists. They were 75 years of age or younger, had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2, and had received no chemotherapy or radiotherapy within 4 weeks of entering this study. They all had adequate kidney (serum creatinine < 1.5 mg/mL, creatinine clearance > 30 mL/min), liver (total bilirubin < 1.5 mg/dL, transaminase levels< two times the upper limits of normal), and bone marrow (leukocyte count > 3,000/uL, platelet count > 100,000/uL, hemoglobin concentration > 9.0 g/dL) functions. All voluntarily gave written informed consent before receiving treatment.",NA,during the first course,NA
23930209,NCT01042782,Combination,No,patients with metastatic esophagogastric adenocarcinoma,"Main eligibility criteria were patients 18 years of age with histologically confirmed diagnosis of metastatic gastric cancer or adenocarcinoma of the EGJ; CT or MRI scan had to demonstrate measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST)-criteria; and at least one prior chemotherapy in the palliative setting or progressive disease under adjuvant or neoadjuvant therapy within 6 months of treatment start date. Further criteria were Eastern Cooperative Oncology Group performance status (ECOG) 1, Life expectancy >4 months, sufficient renal, hepatic and bone marrow function. Participants gave written informed consent before they entered the study, which was approved by the responsible ethics committee.","Anticancer therapy within 3 weeks of enrollment including chemotherapy, hormonal therapy, immunotherapy, or radiotherapy. Patients with rapidly progressive tumors (upon the decision of the investigator) can be treated <4 weeks since last chemotherapy, if they fully recovered from all side effects. Prior therapy with RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus). Patients treated with Mitomycin C. No neurotoxicity >= grade 2 CTC. No gastric or intestinal obstruction. Patients taking drugs known to inhibit or induce isoenzyme CYP3A. Patients with any concurrent major medical condition liable to compromise the patient's participation in the study (e.g known HIV infection, uncontrolled diabetes, serious cardiac dysrhythmia or condition, New York Heart Association classification of III or IV, congestive cardiac failure, myocardial infarction within 6 months, unstable angina, chronic or acute renal or liver disease, uncontrolled serious infections including abscess or fistulae, etc.). Patients with a history of another malignancy prior to study entry, except curatively treated non-melanotic skin cancer or carcinoma in-situ cervical cancer unless in complete remission or no evidence of disease and off all therapy for that disease for a minimum of 5 years. No symptomatic brain metastasis. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer. Female patients who are pregnant or breast feeding. History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures. History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin",first cycle of treatment,NA
17947729,NA,Single Drug,No,"Pediatric Patients With Refractory Solid Tumors. Disease type at diagnosis: Astrocytoma, low grade 2, Astrocytoma, high grade (AA, GBM) 5, Brainstem glioma 3, Atypical teratoid rhabdoid tumor 1, Ependymoma 4, Ganglioglioma 1, Neuroblastoma 1, Oligoastrocytoma 1, Osteosarcoma 2, Primitive neuroectodermal tumor/medulloblastoma 3, Rhabdomyosarcoma 1, Sarcoma, clear cell 1","Patients had to be >=3 and younger than 22 years old with a histologically verified solid tumor refractory to conventional therapy; a Lansky or Karnofsky performance score >= 50; and a life expectancy of >= 8 weeks. Patients had to have a body-surface area of more than 1.0, and 0.8, and 0.5 m2 for dose level 0, and 1, and higher, respectively. Patients must have recovered from the acute toxic effects of prior therapy and must not have received growth factors within 1 week of study entry, myelosuppressive chemotherapy within 3 weeks (4 weeks if prior nitrosourea, temozolomide, or mitomycin), craniospinal or total-body irradiation within 3 months, local palliative radiotherapy within 8 weeks to the primary tumor, or focal irradiation to symptomatic metastatic sites within 2 weeks. Corticosteroids, at stable or decreasing dose for >= 1 week before start of therapy, were only permitted for the treatment of increased intracranial pressure or cord compression. Other requirements included adequate bone marrow function (peripheral absolute neutrophil count >= 750/uL, platelet count >= 75,000/uL [transfusion independent], and hemoglobin >= 8.0 g/dL), adequate renal function (age-adjusted normal serum creatinine or glomerular filtration rate >= 70 mL/min/1.73 m2), adequate liver function (total bilirubin <= 1.5 x institutional upper limit of normal for age and ALT <= 3 x institutional upper limit of normal for age), adequate cardiac function (shortening fraction >= 27% by echocardiogram or left ventricular ejection fraction > 50% by gated radionuclide study, normal ECG), stable neurologic deficits for >= 1 week, adequate pulmonary function, and normal serum sodium, calcium, magnesium, and potassium. Informed consent was obtained from patients, parents, or guardians, and assent was obtained as appropriate, at the time of protocol enrollment.","Patients on cyclosporine or tacrolimus, H2 antagonists or proton pump inhibitors (unless on corticosteroids), enzyme-inducing anticonvulsants, or other potent cytochrome P450 3A4 inhibitors were excluded, as were pregnant or lactating women or patients with uncontrolled infections",NA,NA
20975068,NA,Combination,No,Patients With Metastatic Breast Cancer Pretreated With Trastuzumab,"Patients were >= 18 years old; had histologically confirmed metastatic breast cancer with demonstrated HER2 overexpression, defined as a score of 3 + by immunohistochemistry and/or amplification by fluorescence in situ hybridization; and were previously treated with trastuzumab. Additional inclusion criteria were World Health Organization performance status of 0 or 1; left ventricular ejectionfraction greater than 50%; and adequate bonemarrow, hepatic, and renal functions.","Patients on chronic treatment with corticosteroids or another immunosuppressive agent, uncontrolled or symptomatic CNS metastases, or significantly decreased lung function were excluded from study participation.",within the first cycle of treatment,NA
33115815,NCT02152943,Combination,No,"Patients with Hormone Receptorpositive Metastatic Breast Cancer or Other Solid Tumors (Ovarian, Cervical cancer, endometrial cancer, and gastroesophageal junction cancer)","Eligible patients had a histologically confirmed diagnosis of an advanced solid tumor with hormone receptor positivity (i.e., estrogen receptor positivity with or without progesterone receptor positivity), defined as >1% expression on IHC, and with HER2 positivity [defined in accordance with the American Society of Clinical Oncology/CAP 2013 guidelines as 3þ expression on IHC, or HER2 amplification detected by FISH (overall ratio ≥ 2 with an average HER2 copy number >4 signals/cell; overall ratio ≥ 2 with an average HER2 copy number <4; or average ratio < 2 with an average HER2 copy number ≥6 signals/cell) or by next-generation sequencing (NGS, ≥4 copies), or HER2 mutation detected by NGS]; had measurable or evaluable disease according to RECIST 1.1 (27); and had been off prior chemotherapy at least 4 weeks; off therapies with delayed toxicity (e.g., nitrosoureas, mitomycin-C, and liposomal doxorubicin) at least 6 weeks; off biologic/targeted therapies at least 4 weeks or five half-lives (whichever was shorter); and/or off hormone therapy at least 2 weeks. Patients who received palliative low-dose radiotherapy 1 week before treatment, provided that it was not given to only the targeted lesions, were eligible for the study. Patients had to have adequate organ function and an Eastern Cooperative Oncology Group performance status score of 0 or 1. Female patients had to be either premenopausal and receiving a gonadotropin-releasing hormone agonist or postmenopausal (defined as age ≥ 60 years or as age < 60 years with prior bilateral oophorectomy or at least 12 months of spontaneous amenorrhea and postmenopausal follicle-stimulating hormone and estradiol levels).",NA,during the first 21 days of therapy,NA
23475104,NCT00942682,Combination,No,"patients with advanced neuroendocrine tumors. Tumor subtype: Carcinoid 18 (86), Small bowel 11 (52), Bronchus 3 (14), Other or unknown primarya 4 (19) (Other primary sites of disease included: stomach (1), duodenum (1), thymus (1), unknown primary (1)), Pancreatic neuroendocrine tumor 3 (14)","All patients were required to be 18 years of age or older and have histologically documented, locally unresectable or metastatic carcinoid or pancreatic neuroendocrine tumors of low-or intermediate-grade histology. Treatment with prior chemotherapy was allowed, as was prior chemoembolization, cryotherapy, or radiofrequency ablation if measurable disease was not affected. Prior bevacizumab was permitted if last dose was greater than 6 weeks from initiation of protocol therapy. Mandated laboratory requirements included: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.5 times the upper limit of normal (ULN) (<=5 times ULN if liver metastasis was present), total bilirubin <=1.5 times ULN, serum creatinine B1.5 times ULN, absolute neutrophil count (ANC) >=1,500/mm3, and platelet count >= 100,000/mm3. All patients were required to have Eastern Cooperative Oncology Group (ECOG) performance status <= 1.","Patients with poorly differentiated or high-grade neuroendocrine carcinomas were not eligible. Patients were excluded if they had received prior treatment with everolimus or sorafenib. Patients with a history of congestive heart failure, myocardial infarction, or unstable angina pectoris within 6 months preceding enrollment were excluded. Patients on chronic steroids or immunosuppressive therapy or with active or suspected chronic infections, including a history of chronic hepatitis B, were excluded.",within the first cycle (28 days) of treatment,NA
25900182,NCT01204476,Combination,No,"advanced well-differentiated neuroendocrine tumors. NET origin: Pancreatic 4, Small bowel 6, Lung 4, Kidney 1, Other/unknown 4","Eligible patients had progressive advanced or metastatic low- or intermediate-grade neuroendocrine cancers (carcinoid of any site or pNET) refractory to or without standard therapy options and evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse et al. 2000) and Eastern Cooperative Oncology Group performance status of 0–1. Patients may have received prior therapy (except mTOR inhibitors or agents that targeted IGF1R) with no limitation on the number of prior regimens. Patients also had to be aged 18 years or older with adequate hematopoietic, hepatic, and kidney function, fasting serum glucose <= 132 mg/dl, fasting serum cholesterol <= 300 mg/dl, and fasting triglycerides <= 375 mg/dl.",Exclusion criteria included: women who were pregnant or nursing; treatment with radiotherapy or chemotherapy within the past 4 weeks; major surgery within the past 3 weeks; known CNS metastasis requiring anticonvulsants or steroids; patients on therapeutic anticoagulation not on stable dosages; uncontrolled severe cardiac disease or diabetes mellitus; any medical condition that would impair the administration of an oral medication; prior mTOR and/or IGF1R therapies; and uncontrolled serious medical or psychiatric illness.,during thefirst cycle,NA
31654285,NCT01582009,Combination,No,patients with advanced clear cell renal cell carcinoma,"Patients were required to have histologically confirmed metastatic or unresectable renal cell carcinoma with a predominant clear cell phenotype that progressed on or within 6 months of stopping treatment with VEGFR TKIs. All patients were > 18- years of age, had an Eastern Cooperative Oncology Group (ECOG) Performance Status of <2, and had measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients should not have received anticancer therapies (including chemotherapy, radiation therapy, and immunotherapy) within 2 weeks of the start of study drug administration. All patients had adequate bone marrow, liver, kidney, and cardiac function (absolute neutrophil count >1500/mm3, platelets >100,000/mm3, total bilirubin <1.5 x laboratory upper limit of normal (ULN), AST/ALT ≤2.5 x laboratory ULN, creatinine <1.5 x laboratory ULN, PT/INR < 1.3 (or < 3 on warfarin therapy), and LVEF > institutional lower limit of normal (LLN)).","Patients were excluded if they were treated with an mTOR or HDAC inhibitor prior. Other key exclusion criteria included symptomatic diastolic heart failure, myocardial infarction within 6 months of the start of the study, uncontrolled diabetes mellitus or hyperlipidemia, active bleeding diathesis, impairment of gastrointestinal function that may alter absorption of study drugs, uncontrolled brain or leptomeningeal metastases, active or uncontrolled severe infections, HIV seropositivity, and chronic, systemic treatment with corticosteroids or other immunosuppressive agents",within the first treatment cycle,NA
1403040,NA,Combination,No,"patients with cancer. Tumor type: Ovarian, Colon, Lymphoma, Breast, Lung, Sarcoma, Other","Patients were eligible for participation if they had a histologically confirmed diagnosis of malignancy for which there was no known curative treatment. Patients were required to have measurable disease and a Karnofsky performance status of 50% or more. All patients had been off chemotherapy and radiotherapy for a minimum of 4 weeks before the start of protocol treatment. Patients were required to have adequate renal function (creatinine clearance > 40 mL/min), hepatic function (total bilirubin < 1.6 mg/dL and serum aspartate aminotransferase < three times the upper limit of normal), and bone marrow function (WBC count > 3,400/mm 3 and platelet count > 100,000/mmm 3). All patients gave informed consent to participate in the study.",Patients with known uncontrolled brain metastases were ineligible.,in a minimum of three treatment courses,NA
25701455,NA,Combination,No,non-small-cell lung cancer,"Patients (≥18 years) were eligible for inclusion if they had histologically confirmed unresectable non-pretreated stage III NSCLC. Stage IV NSCLC patients with symptomatic primary tumors requiring radiotherapy and with limited extrathoracic lesions (n < 3) were eligible after an amendment. Thesepatients did not present with widespread metastasis and responded to the definition of the oligometastatic status . Additional inclusion criteria were: measurable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST version 1.0); Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1 at trial entry; adequate hematologic, hepatic, and renal function","Exclusion criteria included: prior treatment with an mTOR inhibitor or radiotherapy; for stage IV NSCLC: diffuse and/or non-locally symptomatic (cough, dyspnea or pain) or with extrathoracic lesions requiring a systemic treatment; venous thromboembolism within the past 6 months; pulmonary fibrosis; concurrent treatment with CYP3A4 modulators, agents otherwise used in the treatment of cancer, immunosuppressant, corticoids for more than 6 months, or oral anticoagulants; severe coexisting or uncontrolled condition; impaired digestive function that could alter the absorption of the experimental molecule.",during treatment until the end of week 11,NA
22169794,NA,Combination,No,Patients with Advanced Renal Cell Cancer,"Patients with histologically confirmed predominant cRCC were eligible for participation in the study. Eligibility criteria included age >= 18 years, Zubrod performance status >= 70%, up to 3 previous systemic and/or investigative therapies for mRCC, which may have included previous single-agent exposure to everolimus or sorafenib, and 4 weeks since last previous therapy. Because of the unknown but potential risk for adverse events in nursing infants secondary to the treatment of the mother, any nursing mothers were required to agree to discontinue breastfeeding before treatment. Patients admitted into the study had to have the following laboratory values: granulocyte count >= 1500/uL, platelet count >= 100,000/uL, aspartate aminotransferase/alanine transaminase level <= 2.5 times the upper limit of normal (ULN), alkaline phosphatase level <= 1.5 x ULN, serum bilirubin level  <= 1.5 x ULN, amylase/lipase level within normal range, and urinalysis results <= 1 + protein.","Exclusion criteria included ongoing hemoptysis or cerebrovascular accident within the past 12 months; peripheral vascular disease with claudication on > 1 block; history of clinically significant bleeding, deep venous thrombosis, or pulmonary embolus within 1 year; ongoing need for full-dose oral or parenteral anticoagulation; evidence of current central nervous system metastases; significant cardiovascular disease, including congestive heart failure, angina pectoris requiring nitrate therapy, or myocardial infraction within the past 6 months; uncontrolled hypertension; ongoing requirement for systemic corticosteroid or immunosuppressant therapy; preexisting thyroid function that cannot be maintained in normal range by medication; uncontrolled psychiatric disorder; delayed healing of wounds, ulcers, and/or bone fractures; and a currently active second malignancy other than nonmelanoma skin cancer; and pregnancy.",NA,NA
24740268,NA,Combination,No,patients with solid tumors,"To enroll in Cohort I or Cohort II, patients required histologic proof of malignancy that was unresectable and was not amenable to all standard treatment for the disease with the exception of cancers in which gemcitabine was considered an appropriate initial treatment option. For Cohort III, patients required histologic proof of advanced intrahepatic or extrahepatic cholangiocarcinoma, or gallbladder carcinoma. They were not allowed to have received previous treatment for metastatic disease; though, patients were allowed to enroll who received gemcitabine ≥ 6 months prior as part of adjuvant therapy. Patients were required to be at least 18 years of age, have a life expectancy of ≥12 weeks, and have an Eastern Cooperative Oncology Group (ECOG) performance score of 0–2. Key serum study parameters included an absolute neutrophil count ≥1,500/μL, platelets ≥100,000/μL, hemoglobin ≥9.0 g/dL, creatinine ≤1.5 × the upper limit of normal (ULN), and ALT and AST ≤2.5 × ULN.","Exclusion criteria for this study included uncontrolled intercurrent illness, and current active other malignancy except non melanoma skin cancer and carcinoma in situ of the cervix. Patients who received everolimus previously were excluded, though there was no limit as to the number of other prior therapies. Prior chemotherapy, radiation therapy, immunotherapy, and biologic therapy were required to be completed greater than 4 weeks prior to registration. Mitomycin-C and nitrosoureas were required to be completed greater than 6 weeks prior to registration. Prior radiation of greater than 25 % of the bone marrow was not allowed. Brain and central nervous system metastases were allowed but were required to be treated and stable for at least 4 weeks prior to registration without the ongoing use of steroids. Exclusion criteria also included severe hepatic impairment or cirrhosis (Child-Pugh class C), severely impaired lung function with an FEV1 <1 liter, and known HIV positivity. Female patients were not eligible if pregnant or nursing, and men or women of childbearing potential were not eligible if unwilling to use adequate contraception during therapy.",in cycle 1,NA
21107682,NCT00426530,Combination,No,patients with HER2-overexpressing metastatic breast cancer,"Patients were C18 years of age with HER2-overexpressing metastatic breast cancer, verified by immunohistochemistry (score of 3?) or fluorescence in situ hybridization (for most patients, based on analyses of the primary tumor) who progressed during or after treatment with trastuzumab alone or in combination with other anticancer agents; had a World Health Organization performance status score of 0 or 1; had a left ventricular ejection fraction[50%; and had adequate bone marrow, cardiac, hepatic, and renal functions. Any previous anticancer treatment, except trastuzumab, had to be completed at least 4 weeks before enrollment. No immunosuppressants were permitted during the study",Patients with any severe or uncontrolled medical condition and those who previously had received vinorelbine or an mTOR inhibitor were excluded from the study.,in cycle 1,NA
34562750,NCT02432274,Single Drug,No,children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma ,"In addition to confirmed diagnosis of relapsed or refractory solid malignant tumors, eligible patients had evaluable or measurable disease per RECIST v1.1, adequate organ function, life expectancy of ≥3 months, Lansky Play score or Karnofsky Performance status score ≥50%, and adequate blood pressure control. Patients with osteosarcoma had to be in relapse.","Patients were excluded if they had any active infections or infectious illness, organ toxicity due to prior anticancer therapy, were currently on any other antitumor therapy, had previously been treated with lenvatinib outside of the current study, had received ≥2 previous VEGF/VEGFR-targeted therapies, were currently or within the 30 days preceding informed consent enrolled in another clinical trial, or for any electrocardiogram abnormality, gastrointestinal malabsorption or bleeding or any active second malignancy within 2 years before enrollment (in addition to the primary tumor types, but not including superficial melanoma, in situ, basal or squamous cell carcinoma of the skin). ",during cycle 1,NA
32998962,NCT01857193,Combination,No,"Postmenopausal Women with HRþ, HER2 Advanced Breast Cancer","Key inclusion criteria included postmenopausal and adult women (≥18 years of age) with HER2 locally advanced or metastatic breast cancer not amenable to curative treatment by surgery or radiotherapy who experienced recurrence during, or within 12 months of ending, adjuvant treatment with letrozole or anastrozole; or progression during, or within 1 month of stopping, letrozole or anastrozole treatment for ABC, with radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to enrollment. Local histologic or cytologic confirmation of ERþ breast cancer (dose escalation) and HRþ breast cancer (dose expansion) was required. A representative tumor specimen available for exploratory biomarker analysis from patients in both phases of the study was requested (not mandatory) and analyzed, when available. In the doseescalation groups, patients were required to have measurable or only nonmeasurable lesions (e.g., pleural effusion, ascites, any bone lesions; RECIST; ref. 19), whereas in the dose-expansion groups, patients were required to have ≥1 measurable lesion or lytic/mixed bone lesions in the absence of measurable disease. Prior treatment with chemotherapy for ABC was permitted but was restricted to ≤2 lines in the doseescalation phase and ≤1 line in the dose-expansion phase. Additional eligibility criteria included an Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1 and a representative tumor sample (archival or newly obtained) for molecular testing.","Patients were ineligible if they had HER2 overexpression (confirmed via IHC 3þ staining or in situ hybridization-positivity), a history of any brain or other central nervous system metastases; clinically significant, uncontrolled heart disease; and/or recent cardiac repolarization abnormalities. In the dose-expansion phase, patients previously treated with exemestane or an mTOR inhibitor, or who were intolerant to CDK4/6is, AIs, mTOR inhibitors, or any component of them, were not eligible for the study. In the dose-escalation phase, patients previously treated with CDK4/6is, mTOR inhibitors, or exemestane were eligible, unless they had shown intolerance to any of these drugs previously. Patients previously treated with a PI3K inhibitor were eligible for both phases.",in cycle 1,NA
27093189,NA,Combination,No,Patients with Metastatic Gastroesophageal Adenocarcinoma ,"This single-arm phase Ib study enrolled patients with histologically confirmed metastatic gastric, esophageal or gastroesophageal junction adenocarcinoma. Patients could not have received any prior treatment for metastatic disease but adjuvant chemotherapy was allowed if recurrent disease occurred after 6 months of its completion. Prior radiation therapy was allowed if progression after treatment is documented. Only patients with an ECOG (Eastern Cooperative Oncology Group) score of 0–1 and adequate organ function were eligible. Patients were required to have a fasting serum cholesterol ≤ 300 mg/dl OR ≤ 7.75 mmol/l AND fasting triglycerides ≤ 2.5 mmol/l × institutional upper limit of normal. In case one or both of these thresholds were exceeded, the patient would need to initiate appropriate lipid-lowering medication prior to beginning treatment on trial. Also, patients with a history of diabetes were required to have controlled diabetes, as evidenced by an HbA1C ≤ 8%.",NA,the first 2 cycles of treatment,NA
29739790,NA,Combination,No,KRAS Wild-Type Metastatic Colorectal Cancer,"Eligible patients had KRAS exon 2 WT (local laboratory testing) mCRC and must have failed first-line fluoropyrimidine-based chemotherapy (radiologic progression, development of metastatic disease within 6 months of completing adjuvant therapy, or toxicity to first-line therapy limiting further treatment). Patients were required to be over 18 years old, able to give informed consent, and have Eastern Cooperative Oncology Group (ECOG) of 0 to 1 for the phase Ib group, with ECOG of 0 to 2 allowed for the phase II component. Patients were required to have adequate bone marrow, renal, and hepatic function, fasting cholesterol <= 7.75 mmol/L, and fasting triglycerides <= 2.5 x upper limit of normal (ULN).","Patients who had received first-line anti-EGFR therapy were excluded. Patients with poorly controlled diabetes mellitus, untreated or symptomatic CNS metastases, or other severe and/or uncontrolled medical conditions were excluded. Patients who had received prior pelvic radiotherapy were excluded from the phase Ib study.",within 28 days of beginning therapy,NA
23725999,NA,Combination,No,Patients with Newly Diagnosed Glioblastoma,"Eligibility criteria were as follows: 18 years of age or older; Karnofsky performance status >= 70; centrally reviewed newly diagnosed, unifocal, supratentorial glioblastoma; no prior chemotherapy, treatment with an mTOR inhibitor, or radiation to the head or neck area (except T1 glottic tumors); standard hematologic and metabolic panel within normal limits (absolute neutrophil count ≥ 1800 cells/mm3, platelets ≥ 100,000 cells/m3, hemoglobin ≥ 10 g/dl, PT/INR ≤ 1.5, BUN ≤ 30 mg/dl, creatinine ≤ 1.5 × normal range, bilirubin ≤ 1.5 × normal range, and ALT/AST ≤ 2.5 normal range); fasting cholesterol ≤ 300 mg/dL or ≤ 7.75 mmol/L; triglycerides ≤ 2.5 × the upper limit of normal; no concurrent use of enzymeinducing anti-epileptic drugs (EIAEDs); no severe active co-morbidity; no history of deep vein thrombosis or pulmonary embolism; no malignancy (within 3 years) except nonmelanomatous skin cancer or carcinoma in situ of the cervix or bladder; no pregnancy or lactation; radiation must have been initiated within 5 weeks after surgery.",NA,during the first 8 weeks of treatment with everolimus and concurrent radiation/ temozolomide,NA
33721621,NCT01582191,Combination,No,"patients with advanced solid tumors. Disease type: Sarcoma 21 (26); Renal cell carcinoma (RCC) 14 (18); Thyroid 9 (11); Medullary, papillary, follicular, anaplastic, poorly differentiated 3, 1, 3, 1, 1; Breast 5 (6); Neuroendocrine 4 (5); Othersa 27 (34)","Patients with advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or who have no standard therapy available that improves survival by at least three months. Patients must be at least 3 weeks beyond their previous cytotoxic chemotherapy; patient must be at least 5 half-lives or 3 weeks, whichever is shorter, from their previous targeted or biologic therapy; in addition, patients must be at least 3 weeks beyond the last session of radiation therapy; local palliative radiation therapy that is not delivered to all target lesions is allowed immediately before or during treatment. Eastern Cooperative Oncology Group (ECOG) performance status should be less or equal to 3. Absolute neutrophil count more or equal to 750/mL. Platelets more or equal to 50,000/mL. Creatinine less or equal to 3 x upper limit of normal (ULN). Total bilirubin less than or equal to 3.0. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence)","Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, uncontrolled asthma, need for hemodialysis, need for ventilatory support. Pregnant or lactating women. History of hypersensitivity to vandetanib, lactose, murine products, or any component of the formulation. History of hypersensitivity to sirolimus, temsirolimus, everolimus. History of hypersensitivity to any component of the formulation. Patients unwilling or unable to sign informed consent document. Presence of cardiac disease that, in the opinion of the investigator, increases the risk of ventricular arrhythmia. History (within the last 3 months) or presence of stroke/cerebrovascular accident. Congenital long QT syndrome. Corrected QT for Fridericia (QTcF) interval greater than 500 ms that is not correctable to less than 500 ms such as with cessation of a causative medication, etc. History of myocardial infarction within 6 months with a residual arrhythmia that in the opinion of the investigator, increases the risk of ventricular arrhythmia. Presence of a symptomatic bradyarrhythmia or uncompensated heart failure",during the first 28 days,NA
18039566,NA,Combination,No,patients with advanced breast cancer,"Eligible patients were postmenopausal women or men (>= 18 years) with histologically confirmed metastatic or locoregionally recurrent advanced breast cancer who had received firstor second-line endocrine therapy with letrozole (2.5 mg/day) for >= 4 months without objective response (i.e. stable or progressive disease), excluding patients with bulky or symptomatic disease considered an urgent indication for chemotherapy. Other inclusion requirements were a life expectancy of >= 4 months, World Health Organization (WHO) performance status of 0 or 1, hypercholesterolaemia/hypertriglyceridaemia grade <=1 (with lipid-lowering drugs permitted), adequate bone marrow function (absolute neutrophil count [ANC] >= 1.5 x 109/L, platelets >= 100 x 109/L, haemoglobin >=10 g/dL), and normal liver and renal function (serum albumin within reference range, serum bilirubin <= 1.5 x upper limit of normal [ULN], serum transaminase <= 3 x ULN, serum creatinine <= 130 umol/L or creatinine clearance >= 60 mL/min by Cockcroft-Gault formula)","Exclusion criteria included treatment with strong CYP3A inhibitors or inducers, known central nervous system metastases, uncontrolled infection, known human immunodeficiency virus infection, anticoagulant medication, lactose intolerance, antineoplastic therapy within 4–6 weeks, radiation therapy within 3 weeks or surgery within 2 weeks prior to the study. Individuals with an active bleeding diathesis were also excluded. Patients with any other concurrent severe and/or uncontrolled medical disease (e.g. diabetes, hypertension, congestive heart failure, ventricular arrhythmias, active ischaemic heart disease, myocardial infarction within 6 months, chronic liver or renal disease, active ulceration of the upper gastrointestinal [GI] tract), impairment of GI function or GI disease that might significantly alter absorption of RAD001 were ineligible.",within the first 28 days,NA
26699397,NCT00935792,Combination,No,relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma ,"All sequential eligible and consenting patients were enrolled into this clinical trial. Inclusion criteria included a diagnosis of CLL (including the small lymphocytic lymphoma (SLL) variant) using modified National Cancer Institute-Sponsored Working Group 1996 (NCI-WG 1996) criteria as previously described, previous treatment for progressive CLL, and progressive disease based on NCI-WG 1996 criteria. Patients were required to have adequate organ function (creatinine < 1.5 x upper limit of normal (UNL), bilirubin < 3.0 x UNL) and ECOG performance status of 0–2 or 3 only if due to the effects of their CLL. Exclusion criteria included New York Heart Association Class III or IV heart disease, recent myocardial infarction (< 6 months) or major surgery (< 4 weeks), pregnancy, uncontrolled infection, human immunodeficiency virus infection, serological evidence of active hepatitis B or C infection, active autoimmune complications of CLL, other active primary malignancy requiring treatment or limiting survival to52 years, concomitant use of CYP3A4 inhibitors, known bleeding diathesis or ongoing anticoagulant therapy, and impaired lung function (DLCO < 50% of normal or PaO2 < 88% at rest).",NA,9 weeks,NA
33738668,NCT01784861,Combination,No,"Primary Tumor Type: Combined ICC/HCC, Glioblastoma, Neuroendocrine tumor, Lung, Pancreatic, Small Intestine, Thymus, Renal cell carcinoma","Patients with a history of solid malignancy for whom no other standard treatments were eligible to participate. Additionally, they had to be over 18 years of age, have measurable disease per RECIST v1.1 criteria, ECOG performance status 0–1, >1500/mcL absolute neutrophil count, >100,000/mcL platelets, hemoglobin >9 g/dL, creatinine <1.5, bilirubin <1.5, AST and  ALT <2.5x the upper limit of normal (ULN; <5x ULN if liver metastases were present), urine protein <1+, Fridericia’s corrected QT interval (QTcF) <450 ms, normal left ventricular ejection fraction, recovery from surgical procedures, and ability to swallow and retain oral medication.","Exclusion criteria included active or severe liver disease, currently receiving other anti-cancer therapy (chemotherapy [within 4 weeks], immunotherapy, radiation, surgery, hormonal therapy, biologic therapy, or other interventional procedure) or having received any other investigational agent within 21 days, vaccination with a live-attenuated vaccine within 1 week of registration, concurrent immune compromise (i.e. corticosteroid, other immunosuppressive agents), history of allergic reactions to similar drug compounds, fasting serum cholesterol >300 mg/dL (7.75 mmol/L) and fasting triglycerides >2.5x ULN requiring initiation of lipid-lowering medications, concomitant QTc prolonging drugs, patients at risk for Torsades de Pointes, concomitant use of herbal medications <7 days prior to trial participation and lasting for duration of study participation, concomitant use of moderate- or strong CYP3A4 inhibitors/inducers, known CNS metastases unless treated and stable off of steroids, treatment with therapeutic coumarin-like anticoagulants, uncontrolled intercurrent illness, presence of active GI disease or other condition, pregnant or breastfeeding, and known HIV positivity on combination antiretroviral therapy.",during cycle 1,NA
20953860,NA,Combination,No,"The cancers treated and patient numbers were colorectal (31), pancreas (7), melanoma (6), bladder (4), gastric (4), breast (3), cholangiocarcinoma (2), GE junction (2), lung (2), small bowel (2), and others (11). ","Male and female patients >=18 years of age with a diagnosis of pathologically conWrmed measurable or evaluable advanced solid tumor, with disease that was refractory to standard therapy or for which there was no standard therapy, were eligible. Patients had to have a Karnofsky performance status >=60%, total WBC count >=3,500/mm3, absolute neutrophil count >=1,500/mm3, platelet count >=100,000/mm3, and adequate hepatic, renal and cardiac function. Patients could have received prior chemotherapy (including irinotecan and 5-FU), immunotherapy, hormonal therapy, or radiotherapy for their disease, but 4 weeks from last dose had to elapse before study entry (6 weeks for nitrosoureas and mitomycin C). ",Patients with central nervous system metastasis or a primary central nervous system neoplasm were not eligible.,during the first cycle (One cycle consisted of 3 treatments in 6 weeks),NA
20461440,NA,Combination,No,"Solid tumor. Primary Sites of Disease: Colorectal 10, Sarcoma 7, Prostate 3, Biliary 2, Anal 1, Bladder 1, Adenoid Cystic 1, Esophageal 1, GIST 1, Laryngeal 1, Mesothelioma 1, Pancreatic 1, Small Bowel 1, Sweat Gland 1, Thyroid 1","Patients ≥18 years of age with a diagnosis of pathologically confirmed measurable or evaluable advanced solid tumor, with disease that was refractory to standard therapy or for which there was no standard therapy, were eligible. Patients had to have an Eastern Cooperative Oncology Group (ECOG) Performance Status score of ≤ 2, a total white blood cell count ≥3,000/mm3, an absolute neutrophil count ≥1,500/mm3, a platelet count of ≥100,000/mm3, and adequate hepatic and renal function. Patients may have received prior chemotherapy (including HDAC inhibitors), immunotherapy, hormonal therapy, or radiotherapy, but 2 weeks from last dose had to elapse before study entry (6 weeks for nitrosoureas and mitomycin C). ",Patients with central nervous system metastases or a primary central nervous system neoplasm were not eligible.,in the first 3 weeks of a cycle,NA
9790795,NA,Single Drug,No,Refractory Epithelial Ovarian Cancer,"Patients entered onto this study were required to have histologically confirmed metastatic epithelial ovarian cancer. The tumors had to be platinum resistant, as defined by (a) disease progression while on a first-line platinum-based regimen or (b) tumor progression within 6 months of completion of platinumbased chemotherapy. Patients may have failed no more than two prior chemotherapy regimens, at least one of which contained a platinum drug. For purposes of this study, in cases of reinduction with platinum-based chemotherapy for patients who developed a recurrence more than 6 months after discontinuing first-line platinum-based chemotherapy, the two regimens were counted as one. All patients were to have measurable disease, defined as lesions which could be measured by physical examination or by imaging techniques. Ascites and pleural effusions were not considered to be measurable disease. An elevated serum CA-125 level without associated measurable tumor was also not considered to be measurable disease. Other eligibility criteria were as follows: adequate bone marrow function (white blood count >=3000/mL, granulocyte count >=1500/mL, and platelet count >=100,000/mL); adequate renal function (serum creatinine <=1.4 mg%); adequate hepatic function (serum bilirubin and SGOT <= twice normal); a life expectancy of at least 12 weeks; a Zubrod performance status of 0–2; and age older than 18 years and younger than physiologic 65 years.","Exclusion criteria were as follows: no evidence of measurable disease, a diagnosis of borderline (low malignant potential) ovarian tumor, more than two prior chemotherapy regimens, Zubrod performance status of <= 3, another malignancy (prior or concomitant, with the exception of nonmelanoma skin cancer), prior treatment with vinorelbine, serious intercurrent medical illness, and the presence of brain metastases.",on the first cycle,NA
33423090,NCT00387504,Single Drug,No,patients with malignant solid tumors,"Patients aged ≥ 18 years were included if they had a histologically or cytologically confrmed solid tumor that was metastatic or unresectable, and for which standard therapies do not exist or were no longer efective. Other eligibility criteria included measurable disease by RECIST 1.0 criteria, Eastern Cooperative Oncology Group score of 0, 1, or 2, adequate organ function including hepatic (total bilirubin≤1.5×institutional upper limit of normal (ULN), AST/ALT≤2.5×ULN or ≤5×ULN for patients with liver metastases), hematologic (absolute neutrophil count≥1500/mcL, platelets≥75,000/mcL) and renal (creatinine clearance ≥ 60 mL/min/1.73m2). ","Exclusion criteria included patients with allergy to egg or history of allergic reactions to compounds of similar chemical or biologic composition to fenretinide, presence of untreated brain metastases, HIV infection, known hypertriglyceridemia requiring medication, poorly controlled diabetes mellitus with fasting serum glucose>200 mg/dl or hemoglobin A1C over 7.5%.",during the frst cycle,NA
23515411,NA,Combination,No,"Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2","Eligible patients were at least 18 years of age with an Eastern Cooperative Oncology Group performance status 2 or less and a diagnosis of relapsed or primary refractory AML, ALL, acute leukemia following prior MDS, CML-BC following prior imatinib therapy, RAEB-2, or acute leukemia in patients 60 years or older (no requirement for prior therapy). Additional eligibility criteria included normal to near-normal kidney and liver function; no prior autologous or allogeneic bone marrow/stem cell transplantation; and a baseline white blood cell count (WBC) < 50,000/mL. Hydroxyurea and/or leukapheresis was permitted to reduce the WBC, but hydroxyurea must have been discontinued 24 hours before study initiation.",NA,during the first cycle of therapy,NA
9681085,NA,Combination,No,advanced non-small-cell lung cancer,"Eligibility criteria included a CALGB performance status 0-2, histologically or cytologically proven NSCLC staged 1MB or IV, and measurable or evaluable disease. Prior treatment with a single experimental chemotherapy agent was allowed, provided it did not include any of the drugs in this combination regimen.",NA,during cycle 1,NA
29392425,NCT01435343,Combination,No,patients with the first early-relapsed or refractory acute myeloid leukemia,"This phase I–II multicenter, observational, single-arm trial was performed in ten institutions from the PETHEMA and CETLAM groups. The key inclusion criteria were as follows: (1) age equal or younger than 65 years, (2) AML (except acute promyelocytic leukemia (APL)) in the first relapse with duration of the first remission less than 1 year after the first line using standard intensive therapy (based on anthracycline and cytarabine 3 + 7 schedule), and (3) primary refractory disease (≥ 5% of blasts in the BM) after one induction cycle consisting of a anthracycline and cytarabine 3 + 7 schedule. ","Patients were excluded if they had the following: (1) Eastern Cooperative Oncology Group (ECOG) PS at screening of 3 or 4; (2) hepatic, renal, cardiac, infectious, or any other concomitant severe comorbidities contraindicating the administration of chemotherapy; (3) prior allo-SCT; (4) demonstrated central nervous system disease; (5) antecedents of myelodysplastic syndrome treated with AML-like chemotherapy; and (6) PB blast cell count > 50 × 109/L.",in the first 28 days after induction,"a treatment cycle is defined as the first day of the study drug administration regimens (Day 1) up to and including the day before the first day of the treatment cycle immediately afterwards. The treatment cycles will begin after Day 28 but no later than Day 85, counting from Day 1 of the treatment cycle immediately before."
27655665,NCT01096992,Combination,No,previously treated patients with CLL,Patients must have a diagnosis of CLL/Small Lymphocytic Lymphoma (SLL) and be previously treated. Patients must have an indication for treatment by 2008 IWCLL Criteria. Age >/= 16 years. Zubrod performance status </= 2. Adequate renal and hepatic function as indicated by all the following: a. serum creatinine </= 2 mg/dL AND; b. alanine aminotransferase (ALT) </= 2.5 times upper limit of normal AND; c. total bilirubin </= 2.5 times upper limit of normal. Patients must give written informed consent. Patients of childbearing potential must be willing to practice birth control during the study,"Pregnant or breast-feeding females. Significant co-morbidity indicated by major organ system dysfunction. Active, uncontrolled infection, including active hepatitis. Uncontrolled autoimmune hemolytic anemia (AIHA) or immune thrombocytopenia purpura (ITP). Treatment including chemotherapy, chemoimmunotherapy, monoclonal antibody therapy, radiotherapy, high-dose corticosteroid therapy (Prednisone >/ 60 mg daily or equivalent), or immunotherapy within 21 days prior to enrollment or concurrent with this trial",on the first course of the FBR regimen,NA
9256828,NA,Combination,No,Refractory or Recurrent Pediatric Acute Myeloid Leukemia (AML),"Patients younger than 21 years of age with confirmed bone marrow or central nervous system (CNS) involvement with refractory or recurrent AML were eligible if they had normal cardiac (defined as a normal electrocardiogram and shortening fraction of ≥ 29%), renal (defined as serum creatinine ≤ 1.5 × normal or a creatinine clearance of ≥ 70 ml/minute/1.73 m2), and hepatic (defined as a total bilirubin ≤ 1.5 × normal and serum alanine transferase ≤ 2.5 × normal) function. Patients were excluded if they had received more than 400 mg/m2 of prior anthracycline, whole brain irradiation > 2,400 cGy, had clinical or radiographic signs of leukoencephalopathy, or documented allergy/neurotoxicity to ara-C. Two weeks were required to have elapsed since their last chemotherapy.",NA,NA,NA
23228986,NCT00559624,Single Drug,No,patients with relapsed/refractory chronic lymphocytic leukemia (CLL),"A total of 24 patients were enrolled in the study. All of them provided written informed consent, prior to any study related procedure not part of the patient’s normal medical care. Eligible patients had a diagnosis of CLL according to National Cancer Institute (NCI) Working Group Criteria , with refractory or relapsed disease, Eastern Cooperative Oncology Group (ECOG) Performance Status <=2, and a life expectancy of at least 3 months. They had received one or more prior lines of treatment which must have included either a fludarabine- or cladribine-based regimen or an alkylator-based regimen. Refractoriness was defined as any patient who had failed to achieve a complete response (CR), nodular partial response (nPR), or partial response (PR) according to the NCI Working Group Guidelines for CLL . Fludarabine refractoriness also included patients who achieved a CR, nPR, or PR of <= 6 months duration. Other inclusion criteria were adequate renal function, defined by serum creatinine <= 1.5 x upper limit of normal (ULN) and a calculated creatinine clearance of >= 60 mL/min.","Patients who, in the opinion of the Investigator, need immediate treatment with proven chemotherapy and/or immunotherapy, and/or transplantation. Have B-CLL with central nervous system involvement. Have participated in any other investigational drug study or have undergone an experimental therapeutic procedure considered to potentially interfere with the study in the 30 days preceding Day 1. Have received chemotherapy or radiotherapy treatment in the 30 days preceding Day 1. Require oral or parenteral steroids with the exception of inhaled steroids or low-dose oral steroids (<10mg prednisolone per day or equivalent) for an indication other than B-CLL. Have a serious medical or psychiatric condition that could, in the Investigator's opinion, potentially interfere with their treatment and/or participation in the study. Have uncontrolled diabetes mellitus. Have a history of gout. Have a serious concomitant disease including: Significant cardiac disease - New York Heart Association Classes III or IV or have suffered a myocardial infarction in the last 6 months. Chronic pulmonary obstructive disease with hypoxemia. Clinically active auto-immune disease. Active infection such as tuberculosis, CMV (Cytomegalovirus). Any secondary malignancy requiring active treatment (except hormonal therapy). Have inadequate bone marrow reserve: neutrophils < 1.0 x 109/L, platelet count < 50 x 109/L (unsupported by transfusion), or coagulation abnormalities. Have inadequate liver function: total bilirubin > 1.5 x upper limit of normal values (ULN), AST, ALT, or alkaline phosphatase > 2.5 x ULN. Have inadequate renal function, defined by serum creatinine ≥ 1.5 x ULN, unless creatinine clearance is measured and found to be at least 60 mL/min. Have serum uric acid levels outside the normal range. Females of childbearing potential who are unwilling to employ adequate means of contraception (hormonal contraceptive, intrauterine device, diaphragm with spermicide or condom with spermicide) for the duration of the study and 30 days after the last acadesine administration. Pregnant or lactating females. Male patients who are not surgically sterile and who are unwilling to use a condom with spermicide for the duration of the study and for 3 months after the last acadesine administration. Abuse of alcohol or other recreational drugs. Known HIV or Hepatitis B (unless clearly due to vaccination) or C positive. Known allergy to acadesine or any of its excipients. Have undergone previous allogeneic stem cell transplant. Transformation to Richter's syndrome or other aggressive B-cell malignancy",within 21 days of dosing,NA
27862308,NA,Combination,No,chronic lymphocytic leukaemia,Patients (18–65 yr) with CLL in second remission (CR or PR according to NCI working group criteria (17)) after F/ FC/FCR/B/BR were eligible. Alemtuzumab consolidation had to be started at the earliest 90 d and at 150 d latest after last dose of chemotherapy.,"Patients with more than two prior chemotherapies, a clinically apparent autoimmune cytopenia, severe infections during prior chemotherapy or medical conditions requiring long-term use of corticosteroids could not enter the trial.",during or within 4 wk after the end of alemtuzumab therapy,NA
25684345,NCT00462358,Single Drug,No,patients with advanced solid tumors,"Patients were≥18 years of age with histologically or cytologically confirmed advanced solid tumors refractory to, or ineligible for, standard therapy. Patients were required to have evaluable disease that recurred or progressed following standard therapy, and had to have a predicted life expectancy of at least 12 weeks upon entering the study. Radiotherapy and treatment with investigational products or devices or any anti-neoplastic therapy was not allowed within 28 days prior to study drug administration, with the exceptions of local radiotherapy including<5 % of the bone marrow and hormone therapy that continued on a stable dose throughout the course of the study. Required laboratory values included absolute neutrophil count (ANC)≥2.0×109/L, hemoglobin (Hb)≥9 g/dL, platelet count≥100×109/L, aspartate transaminase (AST)/alanine transaminase (ALT)≤2.5×upper limit of normal (ULN), bilirubin≤1.5×ULN unless Gilbert’s Syndrome, serum creatinine≤1.25×ULN and International Normalized Ratio (INR)≤1.5. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status≤2. Patients enrolled in the expansion cohort were required to have a tumor accessible for biopsy.","Treatment with an investigational product or device, or anti-neoplastic therapy (with the exclusion of hormone therapy where the therapy will continue at a standard dose throughout the study) within 28 days prior to the first dose of study drug. Major surgery within 28 days prior to the first dose of study drug. Radiotherapy (RT) within 28 days prior to the first dose of study drug (except if local RT to <5% of the bone marrow). Known positive serology for the human immunodeficiency virus (HIV), hepatitis C, and/or active hepatitis B. Additional criteria exist.",the first 3-week treatment cycle,NA
23959599,NA,Single Drug,No,relapsed and refractory non-Hodgkin’s lymphoma,"Patients were enrolled on this National Cancer Institute (NCI)-sponsored clinical study following approval by The Ohio State University Institutional Review Board. All patients provided written informed consent. Patients with a confirmed diagnosis of NHL were accrued to one of four cohorts defined by the World Health Organization criteria: indolent B-cell (Cohort 1), mantle cell (Cohort 2), intermediate-grade B-cell including transformed lymphoma (Cohort 3), and T-/NK-cell excluding primary cutaneous disease (Cohort 4). All patients were required to have received at least one prior therapy. Patients with indolent B-cell NHL must have received at least two prior regimens, one of which must have included rituximab. Patients with diffuse large B-cell NHL could not be candidates for aggressive salvage chemotherapy and/or potentially curative autologous stem cell transplant. Further enrollment requirements included the following: age >= 18 years, Eastern Cooperative Oncology Group performance status 0–2, creatinine <= 1.5 mg/dL (or estimated creatinine clearance >= 70 mL/min), transaminases <= 3 times the upper limit of normal (ULN), bilirubin <= 2 times the ULN, hemoglobin >= 9 g/dL, absolute neutrophil count >= 1,500/mm3, and platelets >= 50,000/mm3 unless attributable to marrow involvement by the patient’s underlying lymphoma. Patients should not have received therapy within 4 weeks of enrollment.",Pregnant women and patients with HIV infection were excluded.,during the first cycle of treatment,NA
22402597,NA,Combination,No,locally advanced NSCLC lung carcinoma,"Eligibility was as follows: age C18 years; histologically confirmed advanced NSCLC classified as inoperable stage IIIA or stage IIIB by the UICC System, a Karnofsky performance score (KPS) of >=70 %, and no previous therapy.",Patients were excluded if they had postoperative thoracic recurrence or a history of any prior or concurrent cancer (except that of the skin) within the past 5 years. Patients with malignant pleural effusion were also excluded.,NA,NA
9923543,NA,Combination,No,in patients with metastatic breast cancer,"The two trials reported here together were conducted in patients with histologically con®rmed breast cancer and evidence of metastatic disease. Patients were enrolled in separate studies at Duke University Medical Center (DUMC) and the Dana-Farber Cancer Institute (DFCI). Because the studies and results were similar, we combined them in the same report. In the DUMC study, patients could receive up to two prior chemotherapy regimens in the metastatic setting, but no chemotherapy was permissible within 4 weeks of study entry (see Table 1). Hormonal therapy had to be  4 weeks prior to study entry unless there was de®nite evidence of disease progression on therapy. Radiation therapy must have been completed 2 weeks prior to entry, and patients could not have received radiation to >25% of the bone marrow. Other eligibility criteria were as follows: ECOG performance status 0±1, expected survival >=12 weeks, adequate bone marrow reserve (ANC >1500 mm3, PLT >100 000/mm3), adequate renal (serum creatinine <2.0 mg/dl) and hepatic function (bilirubin <2.0 mg/dl, SGOT less than three times normal), and measurable or evaluable disease. With the exception of several minor differences, eligibility and exclusion criteria were comparable at DFCI. At DFCI, patients were required to have metastatic breast carcinoma refractory to one or more prior chemotherapy regimens and an ECOG performance status of 2 or better. Measurable or evaluable disease was not required, and there was no stipulation regarding prior hormonal therapy. Other eligibility criteria included a total WBC >=3000/mm3, PLT >=100 000/mm3, and hemoglobin >=8 g/dl. The creatinine and total bilirubin were required to be <=2.0 mg/dl, and the SGOT and alkaline phosphatase not more than four times the upper limits of normal. Patients were not to have received radiotherapy or chemotherapy for 3 weeks prior to entering the study.","Exclusion criteria included the following: age less than 18 years, metastatic CNS disease, previous high-dose therapy with autologous bone marrow rescue, and preexisting grade III peripheral neuropathy, except for abnormalities related to cancer. Patients with a history of any other malignancy within the past 5 years other than super®cial nonmelanomatous skin cancer and in situ carcinoma of the cervix were also excluded.",NA,NA
9626219,NA,Single Drug,No,"Patients With Advanced Cancer. Tumor type: Non-small-cell lung, Carcinoma of unknown primary tumor, Melanoma, High-grade glioma, Small-cell lung, Colorectal cancer, Mesothelioma, Renal cancer, biliary tree (3), stomach (2), soft tissue sarcoma (2), hepatoma, thyroid, cervix, and bladder","Eligible patients had histologically proven advanced solid tumors, which included high-grade glioma. Patients may have received prior chemotherapy, with the exception of anthracyclines, and radiotherapy to less than 25% of red marrow. Radiotherapy and chemotherapy must have been completed 6 weeks before study drug administration. Other eligibility criteria included Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, age older than 18 years, neutrophil count greater than 1.5 x 109/L, platelet count greater than 100 X 109/L, hemoglobin level greater than 10 g/dL, bilirubin level less than two times and liver enzyme level less than three times the upper limit of normal, creatinine level less than 0.2 mmol/L, normal cardiac function as measured by baseline left ventricular ejection fraction (LVEF) on a resting nuclear gated heart pool scan, no history of myocardial infarction or current history of angina, and no other major coexisting medical problems.",NA,during the first cycle of treatment.,NA
8622024,NA,Combination,No,Women With Previously Treated Metastatic Breast Cancer,"Women with histologically documented metastatic breast cancer were eligible for this study. Eligibility criteria included the following: (1) age greater than 18 years; (2) Eastern Cooperative Oncology Group (ECOG) performance status <= 2; (3) life expectancy >= 3 months; (4) no surgery or radiation therapy within 14 days or chemotherapy within 28 days; (5) adequate hematopoietic (absolute neutrophil count [ANC] >= 1,500/gL and platelet count >= 100,000//L), hepatic (total bilirubin level <= 1.5 mg/dL), and renal (creatinine <= 1.5 mg/dL) functions; and (6) no other coexisting medical problems of sufficient severity to prevent completion of the study. With respect to prior anthracyclines, eligible patients had to have received a cumulative lifetime doxorubicin dose of at least 250 mg/m2 or an equivalent dose of another anthracycline, anthrapyrazole, or anthracene; have progressed while receiving doxorubicin for metastatic disease; or have relapsed within 6 months of completing adjuvant doxorubicin. ",NA,NA,NA
12073049,NA,Combination,No,"patients with progressive or relapsed solid tumors: Breast, Sarcoma, Pancreas, Colon, Rectum, Sarcoma,  Mesothelioma, Gastric, Head/neck, SCLC","Between August 1998 and May 1999, 12 eligible patients with histologically or cytologically proven, progressive malignant disease (carcinoma, sarcoma) with at least one bidimensionally measurable lesion were enrolled in this study. All patients but one had received at least one regimen of systemic chemotherapy. The only chemotherapy naive patient suffering from advanced squamous cell cancer of the esophagus refused a platinum-containing protocol. Prior therapy with one of the both substances was not allowed if progress occurred during this treatment. ECOG performance <3, age between 18 and 75 years(women and men), and life expectancy of >3 monthswere required for entry. Sufficient bone marrow function wasdefined asfollows: • white blood cell count (WBC) >= 4.0x109/l • absolute neutrophil count (ANC) >=2.0x109/l • platelets >=100x109/l • hemoglobin >=9 g/dl (after transfusion, if required) Sufficient renal function wasdefined asserum creatinine <= 1.5 mg % or calculated creatinine-clearance >=60 ml/min. The following conditionsprecluded patient enrolment: other treatment options with reasonable efficacy, stable remission after individual pretreatment, pregnancy and breast feeding, and active or uncontrolled infection. Patientshaving a required dose reduction of more than 50% during prior standard treatment due to toxicity were not eligible. Prior allogenic or autologousmarrow- or stem-cell transplantation or high-dose chemotherapy were not permitted.",NA,during the first cycle of treatment,NA
12351605,NA,Single Drug,No,"Patients With Advanced Neoplasms. Tumor type: Colorectal 13, Melanoma 10, Kidney 9, Non-Hodgkin’s lymphoma 5, Mantle-cell lymphoma 2, Breast 2, Hodgkin’s disease 2, Head and neck 2, Esophageal 2, Other 8","Patients were eligible if they had refractory tumors for which no standard therapy was available, were >= 18 years old, and had an Eastern Cooperative Oncology Group performance status of <= 2. The requirements for adequate organ function included an absolute granulocyte count >= 1,000/uL, platelets >= 75,000/uL, total bilirubin  1.5 times the upper limit of normal, AST and ALT <= 2.5 times the upper limit of normal, and creatinine <= 1.5 mg/dL. No prior chemotherapy or radiotherapy was allowed within 4 weeks of study entry (6 weeks for prior nitrosourea or mitomycin and 8 weeks for prior UCN-01).","Patients were excluded if they had brain metastasis, a myocardial infarction during the previous 6 months, New York Heart Association class II to IV heart disease, unstable or newly diagnosed angina pectoris, or coagulopathy requiring anticoagulation",during the first cycle of flavopiridol,NA
12451473,NA,Single Drug,No,"Patients with microscopic confirmation of malignancy (solid tumor or lymphoma). Tumor type: Prostate 10, Breast 4, Renal 4, Colon 3, Ovary 3, Gallbladder 3, Stomach 2, Esophagus 2, Lung 1, Melanoma 1, Sarcoma 1, Liver 1, Cervix 1, Head and neck 1, Unknown primary 1","The study was approved by the Human Subjects Committee at the University of Wisconsin Hospital. Patients with microscopic confirmation of malignancy (solid tumor or lymphoma) were eligible for enrollment. Other eligibility requirements included: ECOG performance status of 0 or 1, life expectancy of >12 weeks, age >18 years, and ability to provide informed consent. Patients must not have received chemotherapy and/or radiation therapy in the 4 weeks prior to enrollment and must have recovered completely from any toxicity. Adequate organ function was required, defined as: WBC >4000/mm3, platelets >100,000/mm3, ANC >1500/mm3 , serum bilirubin <1.5 mg/dl, AST less than twice normal, serum creatinine <1.5 mg/dl, and calcium <11.0 mg%.","Patients were ineligible if they had a previous history of brain metastasis, or seizure disorder. Pregnant or nursing females were ineligible.",during the first two courses of flavopiridol,NA
9164208,NA,Combination,No,Patients With 5Advanced Ovarian Cancer,"Patients with newly diagnosed stage II (bulky residual), 111I, or IV epithelial ovarian cancer and patients with primary peritoneal neoplasia were eligible. Inclusion criteria included the following: age 18 to 75 years, Zubrod score <= 2, and adequate hematologic function (hematocrit > 25%, WBC count > 3,000/uL, absolute neutrophil count [ANC] > 1,500/uL, and platelet count > 100,000/uL). All patients were required to have undergone prior cytoreductive surgery before chemotherapy was started. ","Exclusion criteria included prior chemotherapy, prior radiation to greater than 35% of the patient's bone marrow, impaired pulmonary function (forced expiratory volume [FEV] < 50% predicted or diffusion capacity of carbon monoxide [DLCO] < 50% predicted in patients with pulmonary disease), and renal (creatinine concentration > 2 mg/dL) or hepatic (total bilirubin level > 3.5 mg/dL) abnormalities. Patients with significant cardiac disease or metastatic disease in the CNS were also ineligible. ",in cycle 1,NA
11822765,NA,Combination,No,"Tumor type: Colorectal, Small- or non-small cell lung, Breast, Gastric, Unknown primary, Other (One patient each with esophageal. hepatocellular. renal cell, and small bowel carcinomas, and one patient with sarcoma)","Eligible patients had a histologically confirmed diagnosis of a solid tumor malignancy for which no curative or more effective therapy existed, life expectancy >= 12 weeks, Southwest Oncology Group (SWOG) performance status <= 2. measurable or evaluable disease, prior treatment with <=3 chemotherapy regimens, no prior chemotherapy with a camptolhecin analog, no myelosuppressive chemotherapy within the previous four weeks before study entry (six weeks for mitomycin C or nitrosoureas), full recovery from any toxic effects of prior treatment, no radiation therapy within six weeks before study entry, baseline absolute neutrophil count (ANC) >= 1500/mm3, platelet count >=125.000/mm\ hemoglobin >90/dl, creatinine <=2 0 mg/dl. bihrubin <=2 0 mg/dl. and aspartate dminotransferase (AST/SGOT) <= 3 times institutional upper limit of normal (IULN) (unless there was evidence of liver involvement, in which case it could be up to five times the IULN)","Patients were excluded if they had an active or uncontrolled infection, a history of myocardial infarction within the preceding six months, clinical evidence of New York Heart Association Functional Class III or IV heart disease, known central nervous system metastases or carcinomatous meningitis, interstitial pneumonias or interstitial fibrosis of the lung, clinically significant pleural effusion or ascites causing respiratory compromise, psychiatric conditions that would place the patient at poor risk for participation in this investigational drug trial, or known sensitivity to E co//-denved proteins (for patients scheduled to receive filgrastim [G-CSF]) Pregnant or lactating women were also excluded ",first-cycle,NA
18766965,NA,Combination,No,patients with relapsed or refractory acute myeloid leukemia,"Patients of 18 years age or older were eligible if they had histological confirmation of relapsed or refractory AML with at least 5% blasts in the bone marrow or peripheral blood unrelated to recovery of normal hematopoiesis from prior chemotherapy. Patients all had an alanine transaminase, aspartate transaminase, alkaline phosphatase and total bilirubin less than three times the upper limit of normal. Because this study included refractory relapsed AML patients who were heavily pre-treated, we set no criteria for time from last/previous treatment. However, in patients who had been recently treated we required count recovery with peripheral hematologic cell counts of WBC at least 2.00/mL, platelets at least 80,000/mL and hematocrit at least 25%, unless due to bone marrow involvement. In addition, an estimated creatinine clearance >= 40 mg/mL was required, as well as a cancer and leukemia Group B performance status of 0–2. Patients with central nervous system involvement  were eligible if they met other criteria and the CNS involvement had been treated prior to entry on study. ",Pregnant or lactating women were not eligible. Patients were not eligible if they had any other concurrent myelotoxic chemotherapy for 48 h prior to initiation of chemotherapy or if they were HIV positive.,NA,NA
34196874,NCT02833155,Combination,No,Chinese Postmenopausal Women with Hormone Receptor‑Positive Metastatic Breast Cancer,"Patients were eligible for enrollment based on the following criteria: (1) postmenopausal women aged ≤ 65 years; (2) estrogen receptor- and/or progesterone receptor-positive (> 1%) breast cancer, confrmed by pathology; (3) previously treated with a non-steroidal aromatase inhibitor (letrozole/anastrozole), with disease progression or relapse afterwards; (4) Eastern Cooperative Oncology Group Performance Status 0–1; (5) a life expectancy of > 3 months; and (6) adequate organ and bone marrow functions. ",Patients were excluded if they had received prior treatment with an HDACI.,4 treatment cycles (4 weeks for each cycle),NA
32998965,NCT03298984,Combination,No,Newly Diagnosed Acute Myeloid Leukemia,"Be between the ages of ≥18 and ≤65 years. Have an established, pathologically confirmed diagnoses of AML by World Health Organization (WHO) criteria with ≥20% bone marrow blasts based on histology or flow cytometry. Be newly diagnosed and previously untreated. Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2. Have a serum creatinine level ≤1.8 mg/dL. Have an alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level ≤5 times upper limit of normal (ULN). Have a total bilirubin level ≤2.0 mg/dL (unless secondary to Gilbert syndrome, hemolysis, or leukemia). Have a left ventricular ejection fraction (LVEF) >45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan. Be nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate prior to study entry, for the duration of study participation, and for at least 6 months after the last dose of study drug.. Be able to comply with the requirements of the entire study.. Provide written informed consent prior to any study related procedure. (In the event that the patient is re-screened for study participation or a protocol amendment alters the care of an ongoing patient, a new informed consent form must be signed.)","Received any previous treatment for AML. Diagnosed with APL-M3 or CBF-AML. Require concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within 12 hours) of starting Induction therapy.. Received >200 mg/m2 equivalents of daunorubicin. Have a peripheral blast count of >30,000/mm3 (may use hydroxyurea as in #3 above). Have active central nervous system (CNS) leukemia. Have evidence of uncontrolled disseminated intravascular coagulation. Have an active, uncontrolled infection. Have other life-threatening illness. Have other active malignancies or diagnosed with other malignancies within the last 6 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia. Have mental deficits and/or psychiatric history that may compromise the ability to give written informed consent or to comply with the study protocol. Are pregnant and/or nursing",during Cycle 1,NA
9250790,NA,Combination,No,Low-Grade Non-Hodgkin's Lymphoma,"Patients with histologically confirmed recurrent lowgrade NHL were eligible if they were younger than 75 years old and had a performance status of >= 60% (Karnofsky scale), a platelet count >= lOO,OOO/uL, a neutrophil count >= l,OOO/uL, a serum bilirubin level <=1.5 mg/dL, and a serum creatinine level <= 1.6 mg/dL.","Patients were excluded if they had a life expectancy of less than 12 weeks, had received anti-lymphoma therapy within 4 weeks of starting this study, had an HIV infection, or had a history of serious cardiac disease. ",NA,NA
7545219,NA,Combination,No,"Patients With Advanced Tumors. Tumor type, Colorectal 9, NSCLC 7, Unknown primary 5, Esophageal 3, Head and neck 3, Breast 3, SCLC 3, Melanoma 2, Soft tissue sarcoma 2, Gastric carcinoma 2, Hepatocarcinoma 1, Cholangiocarcinoma 1, Pancreatic carcinoma 1, Adenocarcinomo of the ileum 1, Neuroblastoma 1, Mesothelioma 1","Patients with pathologically confirmed solid tumors refractory to standard therapy or for which no standard therapy exists were eligible if they had measurable or assessable disease. A maximum of one prior chemotherapy regimen for metastatic disease was allowed. Other eligibility criteria included age greater than 16 years, Cancer and Leukemia Group B (CALGB) performance status 0 to 1, life expectancy of at least 2 months, and at least four weeks since prior chemotherapy or radiotherapy. The following laboratory entry criteria were required: granulocyte count >= 1,500/uL, platelet count >= 100,000//uL, hemoglobin level >= 10 g/dL, serum creatinine concentration <= 1.5 mg/dL or creatinine clearance >= 60 mL/min, and bilirubin level <= 1.5 mg/dL. All patients provided signed, informed consent.","Patients were ineligible if they had received prior therapy with taxanes or camptothecin compounds, or if they had received prior pelvic irradiation. Patients with a history of congestive heart failure, coronary heart disease, cardiac arrhythmias, or on medications known to affect cardiac conduction, such as beta-blockers, calcium channel blockers, or digoxin, were also ineligible. In addition, pregnancy, known bone marrow metastases, uncontrolled infection, concurrent active malignancy, or other serious medical or psychiatric illness also constituted exclusion criteria.",in the first treatment cycle ,NA
7527456,NA,Combination,No,"Patients With Advanced Solid Tumors. Cancer diagnosis: Non-small-cell lung, Colorectal, Unknown primary, Breast, Gastric, Renal, Adenoid cystic salivary gland","Patients with solid tumors that were refractory to standard treatment or for which no standard therapy existed were eligible if they had measurable or assessable disease. Other eligibility criteria included age greater than 18 years, Cancer and Leukemia Group B (CALGB) performance status of 0 to 2, life expectancy of at least 3 months, and at least 4 weeks from prior cytotoxic chemotherapy. Written, informed consent was required. The following laboratory entry criteria were required: granulocyte count > 1,500/uL, platelet count >=100,000/uL, hemoglobin level >= 10 g/dL, serum creatinine level <=1.5 mg/dL or creatinine clearance >= 60 mL/min, and bilirubin level <= 1.5 times normal.","Patients were ineligible if they had received prior treatment with cisplatin, carboplatin, nitrosoureas, or mitomycin, or if they had received radiation therapy to a port size greater than 12 x 12 cm or pelvic irradiation. Patients were also ineligible if the following existed: pregnancy; bone marrow metastasis; history of congestive heart failure or cardiac arrhythmias requiring medical therapy; uncontrolled bacterial, viral, or fungal infection; concurrent active malignancy; or other serious medical or psychiatric illness",in the first treatment course,NA
9508177,NA,Combination,No,"Patients With Malignant Solid Tumors. Diagnosis and response: Osteosarcoma, Neuroblastoma, Wilms' tumor, Rhabdomyosarcoma, Ewing's sarcoma/PNET, Malignant fibrous histiocytoma, Unknown primary, Round cell tumor, Pulmonary blastoma, Malignant schwannoma, Alveolar soft-part sarcoma, Hepatoblastoma ","After obtaining approval from the institutional review board and written informed consent from the responsible parent and/or guardian, 33 patients with histologically confirmed recurrent or refractory solid tumors were entered onto this phase I trial (Table 1). All patients were younger than 21 years of age, and had a life expectancy of at least 6 weeks, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and adequate nutritional status as assessed by weight over the third percentile for height and normal total serum protein. An absolute neutrophil count (ANC) greater than 1,500/pL and platelet count greater than 150,000/pL were required as evidence of full bone marrow recovery from prior chemotherapy. Other requirements were adequate hepatic function (bilirubin level <= 1.5 mg/dL and AST <= twice normal) and normal renal function (serum creatinine concentration < 1.5 mg/dL). Patients previously treated with bone marrow transplantation, with or without total-body irradiation, were eligible provided they met all other eligibility requirements and at least 6 months had elapsed since the bone marrow transplant.","Patients who were pregnant or breastfeeding, human immunodeficiency virus (HIV)-positive, or less than 6 weeks from the administration of extensive radiation therapy or nitrosourea therapy were excluded.",NA,NA
16186597,NA,Single Drug,No,Patients With Advanced Chronic Lymphocytic Leukemia,"Patients with a known prior diagnosis of CLL were eligible for this study if they required therapy and had relapsed or refractory symptomatic disease and had received at least one prior chemotherapy regimen that contained a purine analog. Other inclusion criteria were age >= 18 years; Eastern Cooperative Oncology Group status of 0, 1, or 2; adequate organ function; and written informed consent. ","Exclusion criteria included the following: another type of cancer or antecedent hematologic disorder before onset of CLL, HIV infection, significant comorbidity, prior allogeneic stemcell transplantation or organ allograft, major surgery or therapy for CLL within 3 weeks preceding study entry, pregnancy, lactation, hypersensitivity to phosphorothioate-containing oligonucleotides, or requirement for concurrent corticosteroid therapy.",during cycle 1 and cycle 2,NA
21745173,NA,Combination,No,"chronic lymphocytic leukemia. Nine patients had a diagnosis of CLL/small lymphocytic lymphoma (SLL), two had mantle cell lymphoma (MCL), six had follicular lymphoma (FL), and one had lymphoplasmacytic lymphoma (LPL).","Eligibility required confirmation of the presence of a relapsed lymphoma or CLL, adequate organ function as evidenced by an absolute neutrophil count (ANC) > 1000 per μL and a platelet count of > 50 000 per μL, the need for systemic treatment, and informed consent. ",NA,NA,NA
9773805,NA,Combination,No,"refractory solid tumor patients. Tumor types: nun-small cell lung, small cell renal, melanoma, esophageal, hepatoma, head/neck","Patients were eligible if they were regractory to standard first-line therapy or had a solid tumor for which there was no accepted standard first-line therapy. All patients were required to have a tissue diagnosis of malignancy and only one prior treatment regimen was allowed. Patients could have either measurable or evaluable disease. Entry criteria for this study also included: performance status 0 or 1 (ECOG), age 18 or higher, absolute neutrophil count (ANC)>=1500/ml, platelets>=100 000/ml, hemoglobin above 9.9 g/dl, creatinine less than twice institutional normal, bilirubin less than 1.5 mg/dl, AST and ALT less than 1.5 times institutional normal, alkaline phosphatase less than twice institutional normal, and at least 4 weeks from any prior cytotoxic chemotherapy or radiation therapy. ",Patients were ineligible if they had significant co-morbid conditions (including pregnancy) or a psychiatric illness that prevented informed consent. ,during cycle 1,NA
9738567,NA,Single Drug,No,"Patients With Refractory Neoplasms. Tumor type: Renal, Colon, Prostate, Non-Hodgkin's lymphoma, Breast, non-small-cell lung cancer (n =3), mesothelioma (n = 3), head and neck (n = 2), pancreas (n = 2), melanoma (n = 2), soft-tissue sarcoma (n = 2), Hodgkin's disease (n = 2), testicular (n =1), thymoma (n = 1), and esophageal carcinoma (n = 1)","Adult patients (> 18 years of age) with histologically confirmnned metastatic or locally recurrent cancer were eligible for this study if they had exhausted conventional effective therapeutic options. Patients with metastatic cancer for whom there was no effective first-line conventional chemotherapy were also eligible. Patients were required to have recent clinical evidence of disease progression. Patients with primary or secondary CNS malignancy or leukemia were not eligible. Eligibility criteria included Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, life expectancy of greater than 12 weeks, and at least 4 weeks from prior radiation or chemotherapy and recovery from toxic effects. At least 6 weeks were required since prior treatment with nitrosoureas, mitomycin, or bone-seeking radioisotopes, and at least 12 weeks from prior suramin, with suramin levels less than 100 pg/mL. Patients with prostate cancer had to have tumor progression after blockade of both testicular and adrenal androgens, without evidence of antiandrogen withdrawal response for at least 4 weeks before entry. All nonorchiectomized patients with prostate cancer continued to receive gonadotropin-releasing hormone analogues. Required laboratory parameters included adequate pretreatment blood counts (hemoglobin level > 9.0 g/dL, platelet count > 100,000/uL, and absolute granulocyte count > 2,000/uL) and prothrombin time and partial thromboplastin time results within normal range. A measured creatinine clearance of at least 60 mL/min, total bilirubin level less than 1.5 mg/dL, AST and ALT levels less than two times the upper normal limits, and liver tumor replacement less than 50% of total liver surface were also required before entry.","Patients with unstable or newly diagnosed angina pectoris, myocardial infarction (within 6 months of enrollment), New York Heart Association classes II to IV heart disease, severe chronic obstructive lung disease (forced vital capacity < 1,000 mL), uncontrolled seizure activity, active infection, positive serology for HIV, coagulopathy, or active renal disease were excluded. Patients who received steroids for other than physiologic replacement, or those in need of therapeutic anticoagulation with either coumadin or heparin were not eligible. However, patients who developed a thrombotic event while they received flavopiridol continued therapy while they underwent anticoagulation therapy, if otherwise eligible.",NA,NA
23813912,NCT00295919,Single Drug,No,Patients with Relapsed/Refractory Neuroblastoma,"Patients ≤ 30 years of age diagnosed with high-risk neuroblastoma with relapse at any time, refractory disease (less than partial response to frontline therapy based on International Neuroblastoma Response Criteria (INRC) ), or biopsy-documented neuroblastoma or ganglioneuroblastoma after a partial response to frontline therapy, were eligible. Patients were required to have at least one of the following: minimum of one centimeter soft tissue disease on CT/MRI scan, metaiodobenzylguanidine (MIBG) avid site(s), any amount of tumor in the bone marrow by standard histology. Specific organ function requirements included absolute neutrophil count (ANC) ≥ 750/μl, platelets ≥ 50,000/μl, creatinine < 1.5 × institutional upper limit of normal for age, and ALT/AST < 3 × institutional upper limit of normal for age. Postmenarchal females were required to have a negative beta-human chorionic gonadotropin and to utilize contraception. Morphological evidence of neuroblastoma in bone marrow was assessed by routine hematoxylin and eosin staining (i.e. routine morphology). ",Patients with intraparenchymal brain or meningeal metastases were excluded. ,in Course 1,NA
8823338,NA,Combination,No,Patients With Advanced Breast Carcinoma,"Patients were required to have recurrent, metastatic, or locally adenocarcinoma of the breast and to have received no more than I prior chemotherapy regimen for the treatment of metastatic disease. Other requirements included measurable and/or assessable disease, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and adequate bone marrow (leukocyte count >= 3,500/uL and platelet count >=100,000/uL), hepatic (total bilirubin level <= 1.5 mg/dL), renal (serum creatinine concentration <=1.5 mg/dL), and cardiac (left ventricular ejection fraction [LVEF] >= 50%) function, and informed consent. ","Patients were ineligible if (1) more than 300 mg/m2 of doxorubicin had been previously given; (2) if the mediastinum, whole pelvis, or more than 30% of the bone marrow was previously irradiated; (3) there was a history of left chest-wall irradiation and prior doxorubicin; (4) there was a history of significant cardiovascular disease or other poorly controlled medical illness; and (5) there were brain metastases or carcinomatous meningitis",during the first cycle only,NA
16849757,NA,Single Drug,No,"Children With HighRisk Solid Tumors. Diagnosis: Neuroblastoma, Ewing sarcoma, Osteosarcoma, Hepatoblastoma, Wilms’ tumor, Medulloblastoma, Glioma, Lung sarcoma, Melanoma","Patients who were 21 years of age or younger when diagnosed with a malignant solid tumor with either recurrent or refractory disease or recurrent neuroblastoma treated with myeloablative therapy and autologous stem-cell transplantation with any disease status were eligible. Informed consent approved by a local human investigations committee was obtained.Specific disease sites were reviewed only in patients reporting a response or stable disease for eight courses or more. Normal organ function, absolute neutrophil count 750/uL or greater, and platelets 50,000/uL or higher were required. Hematologic criteria were waived for patients with marrow metastases. Postmenarchal females were required to have a negative serum beta-human chorionic gonadotropin and to utilize contraception.",NA,NA,NA
12151959,NA,Combination,No,"Patients With Refractory Malignancies. Disease: NSCLC, cholangio, Merkel cell, Melanoma, bladder Cancer.","Eligible patients had measurable recurrent or residual cancer for which there was no standard curative treatment. Patients had not received more than one prior chemotherapy regimen for metastatic disease and were not previously treated with topotecan or vinorelbine. Eligible patients had adequate renal (serum creatinine <= 1.5 mg/dl), hepatic (aspartate aminotransferase <= 3 times the upper limits of normal, and bilirubin <= 1.5mg/dl) and bone marrow function (granulocytes >= 1,500 cells/mm3 and platelets >= 100,000/mm3), an Eastern Cooperative Oncology Group performance status (PS) of 0 to 1, no evidence of active brain metastasis, and an expected survival of at least 3 months. Written informed consent was obtained before entry onto study",cycle 1 ,NA,NA
18182662,NA,Combination,No,Patients With Richter’s Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia,"Signed informed consent explaining the investigational nature of the trial was obtained in accordance with institutional policy. Eligibility criteria included histologically or cytologically confirmed Richter’s transformation or fludarabine-refractory CLL, age >=18 years, Zubrod performance status of 0 to 2, and absence of uncontrolled life-threatening infections. Fludarabinerefractory CLL was defined as disease that failed to respond to fludarabinebased treatment or progressive disease within 6 months of response to a fludarabine-based regimen. Platelet counts >= 20,000/uL were required, unless lower counts were a result of disease involvement or autoimmune disorders. Adequate hepatic function (bilirubin <= 2 mg/dL, AST or ALT <=3 x the upper limit of normal) and renal function (serum creatinine ,= 2 mg/dL or creatinine clearance > 30 mL/min) were also required unless abnormalities were a result of disease involvement","Patients were excluded if they were pregnant; had a history of oxaliplatin, fludarabine, cytarabine, or rituximab intolerance; had received chemotherapy and/or radiation therapy within the previous 4 weeks; or had any other medical condition deemed by the investigator to be likely to interfere with a patient’s ability to give informed consent or cooperate/participate in the study or interfere with the interpretation of the result",NA,NA
32401633,NCT02642965,Combination,No,Children With Relapsed Acute Myeloid Leukemia,"AAML1421 enrolled children >1 and <= 21 years of age with relapsed/refractory AML in the dose-finding phase; the efficacy phase was restricted to first relapse with no prior reinduction attempt. A minimum of 5% leukemic burden in the marrow or a peripheral blood absolute blast count > 1,000/uL was required. Patients were required to have adequate renal and liver function. The intent was to include children who received maximal cumulative anthracyclines on COG de novo AML trials, which used a conversion multiplier of 3 daunorubicin equivalents for mitoxantrone. Patients were required to have adequate cardiac function, defined as shortening fraction (SF) of >= 27%, ejection fraction (EF) >= 50%, and corrected QT interval <500 milliseconds. ","Patients who received more than the maximal cumulative anthracyclines delivered with de novo therapy (> 450 mg/m2) were excluded. Patients with . 5 blasts/mL from a nontraumatic lumbar puncture or with overt signs of CNS involvement were not eligible. Patients with acute promyelocytic leukemia, bone marrow failure syndromes, Down syndrome, or Wilson disease were ineligible.",in cycle 1,NA
9256119,NA,Combination,No,Children With Acute Leukemia:,"Patients were required to be less than 21 years of age with histologically verified leukemia in bone marrow relapse. All patients must have fully recovered from the toxic effects of any prior therapy. At least 2 weeks were to have elapsed since the last dose of chemotherapy (4 weeks in the case of nitrosourea-containing therapy). Adequate organ function (renal: creatinine concentration <= 1.5 times normal, creatinine clearance or glomerular filtration rate >= 70 mL/min/1.73 m2; hepatic: bilirubin level <= 1.5 times normal and AST and ALT <= 2.5 times normal; cardiac: fractional shortening >= 29% or left ventricular ejection fraction >= 55% and cumulative anthracycline exposure <= 350 mg/m2 ) was required. All patients or their parents or legal guardians must have provided written informed consent and all institutional, Food and Drug Administration, and National Cancer Institute requirements for human studies must have been met",NA,the first course,NA
16292542,NA,Single Drug,No,pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C),"This open-label, single-centre phase I/II study was conducted from March 2001 to September 2002 in Sofia, Bulgaria. Fifteen pre-treated CLL-patients (3 female, 12 male, 47–72 years old, 61 years on average) were included who required treatment according to ‘‘need-totreat criteria’’ (Cheson et al. 1988). Maximally £ 3 previous chemotherapeutic treatments, including chlorambucil, were allowed per protocol, and patients were fludarabine-naı¨ve. Eleven patients fulfilled all required in- and exclusion criteria. Four patients had received more than three previous therapies, which meant violation of an inclusion criterion. At study entry, the CLL of 11 patients was classified as Binet stage B and four patients as Binet stage C. At baseline, 12 patients had a WHO performance status 0 and 3 patients a WHO performance status 1.",NA,the first treatment course,NA
20479064,NA,Combination,No,Patients with Advanced Breast Cancer,"Postmenopausal women with histologically or cytologically documented estrogen receptor+ and/or progesterone receptor+ breast carcinoma who had relapsed after previous treatment for metastatic disease were eligible. Patients with metastatic breast cancer of unknown receptor status who had previously demonstrated an objective response to hormonal therapy were also eligible. Patients were allowed to have either measurable or nonmeasurable disease. Eligible patients had an Eastern Cooperative Oncology Group performance status of ≤1; life expectancy of >6 months; and adequate bone marrow, hepatic, and renal function [absolute neutrophil count of ≥1.5 × 109/L, platelets of ≥100 × 109/L, hemoglobin of ≥10 g/dL, total bilirubin of ≤1.5 × upper limit of normal (ULN), aspartate transaminase and alanine aminotransferase of ≤2.5 × ULN or ≤5 × ULN if liver metastases were present, serum creatinine of ≤1.5 × ULN, and serum alkaline phosphatase of ≤2.5 × ULN] ≤2 weeks before treatment","Patients who had received immunotherapy for cancer within 4 weeks before screening or who had received prior doses of any anti-CTLA4 compound were excluded. In addition, patients were excluded if they had a history of chronic inflammatory or autoimmune disease, had chronic or acute viral hepatitis (B or C), required or had potential requirement for systemic corticosteroids, had a bleeding disorder or active infection, or had a history within the last 5 years of autoimmune colitis or other chronic gastrointestinal condition associated with diarrhea or bleeding. Patients with any coexisting malignancies, except for basal or squamous cell carcinoma of the skin or other solid tumors curatively treated with no evidence of disease for ≥ 5 years, were also excluded from study participation.",during the first 6 weeks of the first treatment cycle,NA
23104721,NA,Single Drug,No,patients with recurrent head and neck cancer,"Patients were aged ≥18 years with previously irradiated, unresectable, recurrent HNC (squamous cell carcinomas or other HNC histologies). Patients with distant metastases of low volume with a need for locoregional palliation were also eligible. Prior radiotherapy had to be completed ≥4 months and/or chemotherapy ≥1 month ago and patients had to have recovered from previous side-effects to grade ≤1. Patients needed to have tumor amenable to injection as assessed by an otolaryngologist. Expected life expectancy of >12 weeks, Eastern Cooperative Oncology Group (ECOG) ≤1, and normal organ function were required.","Patients with significant infection, immune deficiency, involvement of major vessels, and history of a bleeding diathesis/thrombosis were excluded",during cycles one or two,NA
25612635,NCT01227239,Combination,No,patients with locally advanced rectal cancer ,"Patients between 20 and 75 years of age who had histologically confirmed, non-metastatic, primary adenocarcinoma (well or moderately differentiated adenocarcinoma) of the middle or lower rectum (cT3-T4, any N, M0) were eligible for enrollment. Disease was staged according to the staging system of the American Joint Committee on Cancer, sixth edition. Additional eligibility criteria included a T stage of T3 or T4 on computed tomography (CT) plus magnetic resonance imaging (MRI); a resectable tumor as prospectively defined by the surgeon in charge; good general condition enabling major surgery (Eastern Cooperative Oncology Group performance status 0 or 1); normal liver, renal, and bone marrow functions; and written informed consent from the patient. ","Exclusion criteria were as follows: prior chemotherapy for rectal cancer or any prior pelvic irradiation; a history of malignant disease; severe heart disease, uncontrolled infection, or metabolic disorders; or severe neurologic impairment or inflammatory bowel disease",up to 28 days after termination of CRT,NA
21567184,NA,Combination,No,metastatic colorectal cancer patients previously treated with chemotherapy,"Patients with histologically confirmed colorectal cancer, who previously treated to the chemotherapy, were included in the study. Eligibility criteria are as follows: an age of 18–75 years, a life expectancy of at least 12 weeks, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, histologically or cytologically confirmed colorectal adenocarcinoma and measurable disease, adequate bone marrow function (neutrophils ≥1.5×109 cells/L, platelets ≥100×109 cells/L and hemoglobin ≥9 g/dL), serum creatinine <1.5 mg/dL, total bilirubin <1.5 mg/dL, AST <2 X the upper normal limit (< 5 X the upper normal limit in the presence of liver metastases), and no prolongation of the prothrombin time or activated partial thromboplastin time.","Patients were excluded from the study if they had (a) chemotherapy, including molecular target agents for at least 3 weeks before the start of study treatment, (b) radiotherapy treatment or major surgery for at least four weeks before the start of study treatment, (c) severe cardiovascular disorder, and (d) clinical evidence of CNS metastases",during the first cycle,NA
21290246,NA,Combination,No,patients with previously untreated metastatic or recurrent colorectal cancer,"All eligible patients had histologically or cytologically documented metastatic or recurrent colorectal adenocarcinoma after curative resection, as well as measurable or evaluable disease. Other eligibility criteria included age 18–70 years, Eastern Cooperative Oncology Group performance status (ECOG PS) <= 2 and adequate bone marrow function (absolute neutrophil count [ANC] >2 x 109/L, hemoglobin >9.0 g/dL, and platelets >100 x 109/L), renal function (creatinine <1.0 upper normal limit [UNL] or creatinine clearance >= 60 ml/min), and hepatic function (bilirubin <1.0 UNL, aspartate aminotransferase [AST]/ alanine aminotransferase [ALT]/alkaline phosphatase [ALP] <2.5 UNL [<5 UNL for patients with liver metastases])","Patients who had received prior chemotherapy or radiotherapy were excluded; however, those who had finished adjuvant chemotherapy at least 6 months before enrollment or had received prior adjuvant radiotherapy for rectal cancer could be included. T",during the first cycle,NA
22508373,UMIN000000883,Combination,No,"Japanese Patients with Advanced Colorectal Cancer Who Harbor UGT1A1 * 1/ * 1 , * 1/ * 6 or * 1/ * 28","Enrolled patients were required to meet the following eligibility criteria: histologically confirmed adenocarcinoma of the colon or rectum, unresectable recurrent or metastatic disease, age 20–70 years, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, measurable disease according to the Response Evaluation Criteria in Solid Tumors, version 1.0  , leukocyte count >= 3,500/mm 3 , neutrophil count >= 1,500/mm 3 , platelet count >= 100,000/mm 3 , serum creatinine <= 1.5 mg/dl, serum bilirubin <= 1.2 mg/dl and serum aspartate aminotransferase and alanine aminotransferase <= 5 times the respective upper limits of normal. Previous adjuvant or palliative chemotherapy with 5-FU with or without LV was allowed.","Exclusion criteria were previous chemotherapy with irinotecan or oxaliplatin, symptomatic cardiac disease, myocardial infarction, uncontrolled arrhythmias, active infections and inflammatory bowel disease. Patients with UGT1A1 * 6 / * 6, * 28 / * 28 or * 6 / * 28 genotypes were excluded. ",in the first cycle of treatment,NA
21152917,NA,Combination,No,previously treated advanced non-small cell lung cancer patients,"Patients with histologically or cytologically confirmed advanced NSCLC who were previously treated with one chemotherapy regimen except EGFR-TKIs were eligible for enrollment in the study. Additional eligibility criteria included measurable lesions with Response Evaluation Criteria In Solid Tumors (RECIST) ; a minimum age of 20; a maximum age of 75; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; adequate organ functions defined as white blood cell (WBC) count >=4,000 and <=12,000/mm3, absolute neutrophil count (ANC) >=2,000 mm3, platelet count >=100,000/mm3, hemoglobin >=9.5 g/dl, aspartate aminotransferase (AST) <=100 IU/l, alanine aminotransferase (ALT) <=100 IU/l, bilirubin <=1.5 mg/dl, creatinine <=1.2 mg/dl, and a partial pressure of arterial oxygen >=70 torr (if the reason of hypoxemia is the primary disease, >=60 torr); and life expectancy more than 3 months. ","Main exclusion criteria included patients with active infections, massive pleural or pericardial effusion or ascites, which require drainage, obvious interstitial pneumonia, diarrhea, intestinal paralysis or intestinal obstruction, clinically significant heart disease, other significant complications, pregnancy or lactation, active concomitant malignancy, symptomatic brain metastasis, administration of flucytosine or atazanavir sulfate, drug allergy and clinically significant mental disease",NA,NA
22623210,NA,Combination,No,"patients with advanced solid tumors. Primary tumor type: Breast, CRC, Gastric, Head and neck, Hepatobiliary, Melanoma, NSCLC, Ovarian, Pancreatic, Other","Patients with histologically or cytologically documented solid malignancies not amenable to treatment with curative intent were eligible. Other key eligibility criteria included: age >= 18 years; Eastern Cooperative Oncology Group performance status <= 1; and adequate hematopoietic, hepatic, and renal function","Exclusion criteria included: previous treatment with high-dose chemotherapy requiring stem-cell rescue, grade C 2 peripheral neuropathy; known hypersensitivity reaction to 5-FU; known brain metastases; grade 3 hemorrhage within 4 weeks of enrollment; uncontrolled hypertension (blood pressure [150/100 mmHg despite optimal therapy); ongoing cardiac dysrhythmias of grade C 2, atrial fibrillation, or increased QTc interval ([450 ms for males or[470 ms for females); and myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident, or pulmonary embolus\12 months before starting study treatment","during the first two cycles (4-week cycles) on the 2/2 and CDD schedules, and during the first three cycles (6-week cycles) on Schedule 4/2",NA
21447616,NA,Combination,No,patients with untreated metastatic colorectal cancer,"Eligibility criteria included age >=18 years; metastatic, inoperable histologically confirmed adenocarcinoma of the colon or rectum; measurable disease by RECIST ; Eastern Cooperative Oncology Group performance status of one or less; >6 months since completion of adjuvant 5-FU (+-oxaliplatin) treatment and adequate renal, liver and haematologic function","Exclusion criteria included prior chemotherapy for metastatic disease, prior irradiation to >25% of bone marrow, surgery or radiotherapy within 4 weeks of commencing study drug, known brain metastases, myocardial infarction or other significant coronary artery/thromboembolic disease in the past 12 months, uncontrolled hypertension and bleeding diathesis/therapeutic doses of warfarin/low-molecular-weight heparin",in the first three FOLFIRI (+sunitinib) cycles,NA
21968516,NA,Combination,No,Metastatic Breast Cancer,"Patients with a confirmed histological or cytological initial diagnosis of breast cancer were eligible for the study. The following criteria were required for inclusion: aged between 18 and 75 years, World Health Organization (WHO) Performance Status <= 2, and evidence of breast cancer metastases. In case of a single metastasis, histological or cytological proof was required for eligibility. The disease had to be measurable according to WHO criteria, with progression occurring after a first anthracycline/ taxane-based chemotherapy. Adjuvant and/or first-line metastatic hormone therapy was authorized with a washout period of at least 4 weeks prior to study entry (except for disease progression under hormone therapy). Patients had to have recovered from toxicities of prior treatment. Inclusion criteria also included: neuropathy < grade 2, no known cerebral or meningeal dissemination, no other history of cancer, life expectancy > 4 months, adequate hematopoietic function (absolute neutrophil count >= 2 x 10 9 /l, platelets >= 100 x 10 9 /l, hemoglobin level >= 10 g/dl), adequate hepatic function (total serum bilirubin <= 1.25 institutional upper limit of normal, aspartate aminotransferase <= 2 x upper limit of normal, serum creatinine <= 140 umol/l) as well as absence of clinically significant cardiac disease, history of seizure, central nervous system or psychiatric disorder, uncontrolled infection, peptic ulcer, uncontrolled diabetes mellitus, and uncontrolled hypercalcemia. Chronic use of bisphosphonates was authorized. Women with childbearing potential had to use a contraceptive method throughout the trial course and for at least 3 months after the last drug intake. ",Pregnant or breastfeeding patients were excluded. ,at the first treatment cycle (28 days),NA
25427841,NCT01183494,Combination,No,Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI ,"Eligible patients for this study were required to (1) have histologically confirmed adenocarcinomas of the colon or rectum; (2) have advanced or metastatic diseases that were not amenable to curative surgeries and had at least one measurable or evaluable lesion according to the Response Evaluation Criteria in Solid Tumor (RECIST, version 1.0) guidelines; (3) have Eastern Cooperative Oncology Group (ECOG) performance statuses in the range of 0–1; (4) be ≥ 20 years old; (5) have life expectancies of ≥ 3 months; (6) have not received prior chemotherapies or immunotherapies in metastatic settings, and (7) have adequate hematologic, hepatic and renal functions. Adjuvant chemotherapies or radiotherapies were allowed if they had been completed at least 6 months before enrolment. All of the patients provided written informed consent prior to their participation, and the Institutional Review Boards of the Asan Medical Center approved the study.","Prior irinotecan or bevacizumab treatment. Inflammatory bowel disease (Crohn's disease, ulcerative colitis). Diarrhea greater than grade 1. Bowel obstruction. Documented brain metastases. Serious active infectious disease. Active uncontrolled bleeding or fistulas. Pregnancy. Radiotherapy or major surgery within 4 weeks. Previous or concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer for which the patient has been disease-free for five years.",during the first cycle,NA
25143299,UMIN000007556,Combination,No,advanced pancreatic cancer,"Eligibility criteria were as follows: (1) histologically or cytologically proven pancreatic adenocarcinoma; (2) locally advanced or metastatic disease; (3) no prior treatment for pancreatic cancer; (4) ECOG performance status of 0–2; (5) age >20 years; (6) adequate organ function, as indicated by white blood cell count <10,000/mm3, absolute neutrophil count >1,500/mm3, platelet count >100,000/mm3, hemoglobin >9.0 g/dl, total bilirubin <3 times the upper limit of normal, aspartate aminotransferase and alanine aminotransferase levels <5 times the upper limit of normal, and serum creatinine level < 1.5 times the upper limit of normal; (7) expected life expectancy >2 months. ","The exclusion criteria were as follows: (1) severe complications, such as active infection, cardiac or renal disease, marked pleural effusion, or ascites; (2) active gastrointestinal bleeding; (3) active intestinal pneumonitis; (4) severe drug hypersensitivity; (5) active concomitant malignancy; and (6) pregnant or lactating women.",during the first two treatment cycles,NA
23575907,NCT00557557,Combination,No,Patients with Unresectable Isolated Liver Metastases from Colorectal Cancer,"Subjects who had isolated unresectable liver metastases from CRC and were scheduled for HAI with FUDR were eligible for enrollment in this phase I trial. Limited resectable extrahepatic disease was acceptable if the liver was felt to be the dominant site of life-threatening disease. Additional important inclusion criteria included: adequate hepatic function as evidenced by bilirubin <2.0 mg/dL, PT <2 s greater than the upper limit of normal, serum total bilirubin <1.5 mg/dL. ","Alkaline phosphatase <5 x the upper limit of normal (ULN), SGOT/SGPT <5 x the ULN, and patients with significant history of underlying hepatic disease were excluded.",in the first 6 weeks,NA
24839048,UMIN_CTR00002845,Combination,No,lower rectal cancer with T4 and lateral pelvic lymph node metastasis,"Tumor staging was based on the TNM classification . For the N staging, metastasis to lateral pelvic lymph nodes, which include the common iliac node, internal iliac node, external iliac node and obturator node, was defined as N3 in this study according to the Japanese classification . Patients entering the study had histologically confirmed rectal adenocarcinoma with the lower tumor margin below the peritoneal reflection. The tumors had evidence of invasion to adjacent organs (cT4) and lateral pelvic lymph node enlargement [i.e., lymph nodes with a short-axis diameter of more than 10 mm as shown by magnetic resonance imaging (MRI), with sections of 5 mm or less]. Patients were aged between 20 and 75 years, with a performance status of 0 or 1, and no history of chemotherapy, pelvic surgery or irradiation, We included patients with leukocytes >=3,000/L and <=12,000/uL, platelets >=100 x 103/uL, total bilirubin <=1.5 mg/dL, aspartate aminotransferase or alanine aminotransferase <=100 IU/L, creatinine <=1.2 md/dL and creatinine clearance >=60 mL/min/body.",NA,during or up to 14 days after the completion of chemoradiation,NA
22318782,NA,Single Drug,No,locally recurrent rectal cancer,"Patients with unresectable recurrent tumors or who declined to undergo surgery for recurrent tumors in the pelvis after radical surgery for primary rectal adenocarcinoma and for whom no distant metastases were apparent at the time of local recurrence were eligible for this study. We diagnosed locally recurrent rectal cancer without distant metastasis on the basis of findings from computed tomography or magnetic resonance imaging. Other eligibility criteria were: age, 20–74 years; Eastern Cooperative Oncology Group performance status (PS), 0 or 1; no previous pelvic irradiation; presence of measurable lesions; no severe disturbance of blood biochemistry (leukocyte count 3,500–12,000/mm3; neutrophil count >=2,000/mm3; platelet count >=100,000/mm3; hemoglobin >=9 g/dL) or main organ functions (serum bilirubin level <=1.5 mg/dL; serum aspartate aminotransferase and alanine aminotransferase levels less than twice upper limits of normal at each participating hospital; serum creatinine level less than the upper limit of normal at each hospital; and 24-h endogenous creatinine clearance >=50 mL/min), and the ability to take foods and drugs orally. ","Patients were excluded if they had a concomitant malignancy, acute infection, active gastroduodenal ulcer, viral hepatitis, serious mental disorder, or other serious concomitant disease of the lung, heart, or central nervous system, or if they were pregnant or lactating women. ",NA,NA
22615059,NA,Combination,No,patients with advanced gastric cancer,"Men and women, ≥18 years of age were eligible for inclusion in this study if they had stage IV gastric or gastroesophageal junction adenocarcinoma (type II or type III tumors ) measurable using Response Evaluation Criteria in Solid Tumors (RECIST version 1.0; ) for which curative therapy was not possible. Patients must not have received prior systemic therapy for metastatic disease, and were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ function.","Exclusion criteria included chemotherapy, radiation therapy, or surgery ≤4 weeks prior to enrollment. Palliative radiotherapy to non-target lesions was not allowed if it occurred ≤2 weeks prior to enrollment. Progressive disease while receiving adjuvant therapy, or a progression-free interval <6 months after the completion of adjuvant therapy were also exclusion criteria",first cycle,NA
20463088,NA,Combination,No,Patients with Refractory Solid Tumors. Primary tumor: Colorectal 38Gastric 1Esophagus 2Anal 1Cholangiocarcinoma,"Patients with advanced solid tumors who had failed standard chemotherapy or for whom no standard chemotherapy existed were eligible for enrollment. Treatment failure was defined as progression on, or within 3 months from last treatment. In addition, patients had to be ≥18 years of age, have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, have an expected survival ≥12 weeks, and have acceptable organ function defined as: WBC count ≥3,000/μL, absolute neutrophil count ≥1,500/μL, serum creatinine equal to or less than the upper institutional normal level, total bilirubin equal to or less than upper institutional normal level, and serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × upper institutional normal. Patients could not have received any chemotherapy within 3 weeks from initiation of study treatment with the exception of nitrosureas or mitomycin C, which required a 6-week interval before study treatment.","Patients with brain metastases, grade ≥2 neuropathy, or other severe intercurrent illnesses were excluded. Patients who were HIV positive and taking antiretroviral medicines were excluded because of potential drug-drug interactions. No other HDAC inhibitors (such as valproic acid) or other investigational agents were allowed while patients were on study. Patients taking drugs with major inhibitory or stimulatory effects on CYP450 enzymes were not eligible nor were pregnant or lactating females.",in cycle 1,NA
24599799,UMIN000002590,Combination,No,patients with advanced hepatocellular carcinoma,"Eligibility criteria for study entry were: Patients who had been diagnosed with HCC by histological examination or typical diagnostic images; no indication for surgical resection and local therapy (percutaneous ethanol injection, radiofrequency ablation, microwave coagulation therapy, transcatheter arterial chemoembolization, radiation therapy); systemic chemotherapy-naive; measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria (ver. 1.1) of at least one untreated target lesion; ECOG (Eastern Cooperative Oncology Group) performance status 0–1; age ≥20 years age; neutrophil count ≥1,500/μL; hemoglobin ≥9.0 g/dl; platelets ≥50,000/μL; total bilirubin <3.0 mg/dL; aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) < five times the upper limit of normal (ULN); albumin ≥2.8 g/dL, serum creatinine < within the ULN; prothrombin time ≥40 %; Child-Pugh score A; patients could take food and drugs orally; and life expectancy ≥12 weeks.","Exclusion  criteria for study entry were: Previous therapy for HCC within 30 days before study entry; major surgery within 30 days before study entry or surgery within 15 days before study entry; portal vein tumor thrombus in the primary trunk; uncontrollable hypertension; pleural effusion, ascites and pericardial fluid requiring drainage or affecting the respiratory and circulating dynamics; patients who received an albumin preparation or a blood transfusion within 30 days before study entry; hepatic encephalopathy or brain lesions with clinical symptoms; central nervous system tumor (including brain metastasis); bone metastasis with clinical symptoms; active infection [except hepatitis B virus and hepatitis C virus (HCV) infection]; evidence of serious gastrointestinal bleeding within 30 days before study entry; gastro-esophageal varices requiring preventive treatment; pregnant or lactating woman; no consent to use contraception during study treatment; second primary malignancy (except in situ carcinoma or prior malignancy treated >5 years ago without recurrence).",during the first cycle,NA
20062993,NA,Combination,No,patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy,"Patients with histologically or cytologically confirmed advanced mCRC who had failed treatment with 5-FU, oxaliplatin and irinotecan are eligible for the study. Prior treatment with bevacizumab and/or cetuximab/panitumumab is allowed. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as [20 mm with conventional techniques or as [10 mm with spiral CT scan. Tumor must be accessible for core biopsy at the beginning of treatment and demonstrate a high intratumoral TS expression level (TS/bactin[4.1 9 10-3) as previously reported  prior to the beginning of treatment. Patients have to be C18 years of age, have an adequate Karnofsky performance status ([50%) and a life expectancy of [12 weeks. In addition, patients must have acceptable organ function as defined by: leukocytes[3,000/ll, absolute neutrophil count [1,500/ll, platelets[100,000/ll, total bilirubin within 1.5 9 normal institutional limits, aspartate aminotransferase/alanine aminotransferase B2.5 9 institutional upper limit of normal (ULN), creatinine B 1.5 9 institutional ULN. Patients could not have received any systemic therapy within 4 weeks from initiation of study treatment. ","Patients with known brain metastases, uncontrolled intercurrent illness or HIV-positive patients receiving combination anti-retroviral therapy were excluded from the study because of possible pharmacokinetic interactions with vorinostat. ",in cycle 1,NA
25591799,NCT00660153,Combination,No,"Patients With Advanced Gastrointestinal Malignancies. Tumor Type, n (%): Gastric/esophageal adenocarcinoma 13 (43), Colorectal carcinoma 5 (17), Pancreatic adenocarcinoma 10 (33), Small bowel adenocarcinoma 2 (7)","Patients with a histologically or cytologically confirmed metastatic gastrointestinal malignancy for whom mFOLFOX-6 was considered an appropriate treatment were eligible. Other inclusion criteria: documented progressive disease, age >= 18 years, measurable or evaluable disease, no more than 2 previous chemotherapy regimens for metastatic disease, at least 3 weeks since previous systemic anticancer treatment, resolution of toxicities from previous treatment to <= Grade 1, Eastern Cooperative Oncology Group performance status <= 2, and a life expectancy >= 3 months.","Key exclusion criteria included: central nervous system metastases, second malignancies, inadequate hematologic, hepatic, or renal function, significant cardiovascular disease, uncontrolled hypertension, or myocardial infarction within 3 months, active infection, surgery in the previous 6 weeks, unhealed wounds, ulcers, or bone fractures, bleeding disorders, deep venous thrombosis, pulmonary embolus, or cerebrovascular accident within 12 months before the start of treatment, need for anticoagulation treatment, or local radiotherapy within 2 weeks before the start of cycle 1.",during the first cycle of treatment,NA
20103995,NA,Combination,No,Advanced colorectal cancer,"The criteria for eligibility were histological findings of colorectal carcinoma indicating nonresectable metastatic or recurrent disease, no prior chemotherapy, no major surgery or radiation therapy within 2 weeks of beginning treatment, measurable tumors with at least one lesion having dimensions ≧10 mm in longest diameter, a life expectancy of ≧3 months and a performance status (PS) according to the Eastern Cooperative Oncology Group (ECOG) criteria of 0-1, adequate bone marrow function (leucocytes ≧4000 per mm3, platelets ≧100000 per mm3), adequate liver function (bilirubin ≦1.5 mg/dl), adequate renal function (creatinine ≦1.1 mg/dl), no serious or uncontrolled concurrent medical illness, and no active other malignancy. Postoperative adjuvant chemotherapy excluding regimens including CPT-11 or S-1 was allowed. Patients were required to be ≧20 years and <75 years of age, and non-pregnant. All patients were informed of the investigative nature of this treatment, and gave their fully-informed written consent.",NA,during the first cycle of treatment,NA
25572362,NCT01310478 ,Combination,No,advanced colorectal cancer patients,"Provision of written informed consent. Histological or cytological confirmed adenocarcinoma of the colon or rectum. Age between 18 and 70 years. Patients must have received no prior systemic therapy for metastatic disease. Anyadjuvant/neoadjuvant oxaliplatin therapy must have been received >12 months prior to study entry and adjuvant/neoadjuvant 5-FU must have been received >6 months prior to study entry. Patients who have previously been disease free following a neoadjuvant chemotherapy regimen and resection of all primary tumour and metastatic disease are eligible. ECOG Performance Status of 0 or1. Life expectancy of at least 12 weeks. The required evidence of measurable lesions should be at least 10 mm in the longest diameter by spiral computed tomography scan or 20 mm with conventional techniques (RECIST criteria). Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening: Hemoglobin > 9.0 g/dl; Absolute neutrophil count (ANC) >1,500/mm3; Platelet count 100,000/μl; Total bilirubin < 1.5 times the upper limit of normal ALT and AST < 2.5 x ULN(< 5 x ULN for patients with liver involvement of their cancer); ALP< 4 x ULN; PT-INR/PTT < 1.5 x upper limit of normal; Serum creatinine < 1.5 x ULN","History of cardiac disease: congestive heart failure >NYHA class 2; with a history of symptomatic coronary artery disease(including angina and myocardial infarction) or other ischemic heart disease; cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension. History of HIV infection or chronic hepatitis B or C (high copy number of HBV). Active clinically serious infections (> grade 2 NCI-CTC version 3.0). Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry). Patients with seizure disorder requiring medication (such as steroids or anti-epileptics). Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma within 5 years. Recent (<28 days) major thoracic or abdominal surgery prior to entry into the studyor a surgical incision that is not fully healed. Known hypersensitivity to recombinant human endostatin, oxaliplatin, 5-FU, leucovorin, capecitabine or any of the excipients of these products. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results. Peripheral neuropathy ≥CTC grade 2. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study. Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial (and men for at least 3 months after last administration of study medication).",during cycle 1,NA
21344302,NA,Combination,No,patients with advanced hepatocellular carcinoma,"Patients had to be 18 years of age or older (21 for Singapore) and had to provide signed written informed consent. Other inclusion criteria included as follows: non-resectable, locally advanced, recurrent, or metastatic HCC that was either histologically proven OR a radiologically documented liver mass with Alpha-fetoprotein (AFP) [4,000 ng/mL, Hepatitis B surface antigen positive OR Alpha-fetoprotein (AFP)[400 ng/mL with Hepatitis B surface antigen negative. All patients had to have radiologically documented measurable disease and an ECOG performance status of 0–1 at study entry. Adequate hepatic function, as assessed by Child–Turcotte–Pugh score of 8 or better (Class A or well compensated B) and serum or alanine aminotransferase and serum bilirubin within normal levels as well as an adequate bone marrow, renal, and other end-organ function. Women of childbearing potential had to have a negative serum pregnancy test within 7 days before study entry and had to use effective contraception throughout the course of the study (contraception was also required for male subject). Enrolled patients also had to be willing not to receive fluoropyrimidine-containing chemotherapy for 8 weeks after the last dose of EU received in this study","Patients were excluded if they received chemotherapy, radiotherapy, or any other investigational drug within 28 days prior to study entry; if they had 2 or more previous treatment with systemic chemotherapy (chemotherapy administered as part of a chemo-embolization procedure was not considered systemic chemotherapy); portal hypertension with bleeding esophageal or gastric varices within the past 3 months; ascites that was refractory to conservative management; any gastrointestinal tract disease resulting in the inability to take oral medication; active peptic ulcer disease; known hypersensitivity to 5-FU or EU; history of primary brain tumors or brain metastases, unless any lesions had completely resolved following appropriate treatment and there had been no recurrence for at least 6 months; previous or concurrent malignancy at another site within the last 5 years, other than basal or squamous cell carcinoma of the skin, or curatively treated carcinoma in situ of the uterine cervix, prostate cancer, or superficial bladder cancer; stroke, major surgery, or other major tissue injury within 30 days before study entry; history of myocardial infarction within 6 months or significant congestive heart failure, angina, arrhythmias, or ECG abnormalities; other serious chronic disease or uncontrolled metabolic disorders that, in the investigator’s opinion, could render compliance or follow-up in the protocol problematic; breast-feeding or lactating; legal incapacity or limited legal capacity, unless authorization was granted by a legal guardian.",during Cycle 1,NA
21372498,NA,Combination,No,peritoneal metastasis of advanced gastric cancer.,"Patients aged 20-75 years, had to have histologically or cytologically confirmed peritoneal metasstasis of gastric cancer using laparoscopy under general anesthesia, who had not received abdominal surgery and any prior chemotherapy regimens","Patients with ischemic heart disease that needed medication, liver cirrhosis, lung fibrosis, pneumonia, intestinal bleeding or other severe complications wwere excluded. ",NA,NA
24097815,NA,Combination,No,incurable symptomatic rectal cancer,"Patient eligibility criteria were as follows: (i) diagnosis of recurrent or inoperable rectal cancer; (ii) no indication for resection; (iii) apparent increase in tumor size for at least 3 months after radiation therapy or systemic chemotherapy; (iv) performance status of 0–3 based on the Eastern Cooperative Oncology Group (ECOG) score; (v) acceptable renal function (serum creatinine concentration 1.2 mg/dL); and (vi) acceptable bone marrow function (leukocyte count >2500 cells/mm3, platelet count >50,000 cells/mm3). Written informed consent was obtained from all patients, and the study protocol was approved by the institutional review board of our institution.",NA,the first 4 weeks,NA
23674135,NA,Combination,No,Locally Advanced Anal Canal Carcinoma,"Patients with pathologically confirmed SCC of the anal canal were eligible if they were 18 to 70 years old, had a Karnofsky performance score of at least 70%, had category T3 to T4 tumors or were node-positive (defined by the AJCC Cancer Staging Manual13) and adequate renal, hepatic, and bone marrow function. For patients presenting with palpable inguinal nodes felt to be clinically positive and/or with inguinal nodes on imagery, inguinal node status was assessed by needle aspiration cytology or biopsy confirmation. Enlarged inguinal, perirectal, or pelvic nodes on computed tomography (CT) scan, >= 1.0 cm were considered to be clinically positive. ","Exclusion criteria included T1 or M1 tumor, severe comorbidities (uncontrolled infection, psychiatric disorders, cardiovascular disease, collagenosis, and known human immunodeficiency virus infection), or major malignancy (unless successfully treated and disease-free for at least 5 years). Pregnancy or women with childbearing potential who lacked effective contraception were also excluded.",12 weeks (8 weeks of treatment plus 4 weeks of toxicity observation),NA
23982118,NA,Combination,No,metastatic colorectal or gastric cancer,"Patients were eligible for the study if they were ≥18 years old with histologically confirmed gastric or colorectal adenocarcinoma, metastatic disease, measurable disease by the response evaluation criteria in solid tumors (RECIST) 1.0 , or non-measurable but evaluable disease; Eastern Cooperative Oncology Group (ECOG) performance status 0–2; and adequate baseline hematological function [absolute neutrophil count (ANC) ≥1,500/μL, platelet count ≥100,000/μL], hepatic function [serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × the upper limit of normal (ULN) (≤5 × ULN in the presence of liver metastases), serum bilirubin ≤1.5 mg/dL] and renal function (serum creatinine ≤ULN). Prior adjuvant or palliative chemotherapy including S-1, irinotecan, or oxaliplatin was allowed if at least 4 weeks had elapsed between the completion of previous therapy and enrollment in the study","Patients were excluded if they had uncontrolled, intercurrent illness or were receiving drugs with potential interactions with S-1.",during cycle 1,NA
21611734,NA,Combination,No,Japanese patients with metastatic colorectal cancer,"Eligible patients were aged ≥18 years, with histological or cytological confirmation of carcinoma of the colon or rectum. Patients required chemotherapy for stage IV (metastatic) disease and had a World Health Organization (WHO) performance score of 0 or 1, and adequate hematology and organ function. RECIST-measurable lesions were not mandatory for this part of the study. Any adjuvant oxaliplatin or 5-FU therapy must have been completed (or terminated) >12 and >6 months, respectively, prior to study entry. Patients could be hospitalized if required. Patients with brain or meningeal metastases were eligible if they were clinically stable and had not required corticosteroid treatment for ≥10 days","Exclusion criteria included: history of poorly controlled hypertension, significant proteinuria, hemorrhage, hemoptysis or thrombotic event; prior systemic therapy for metastatic disease; and prior therapy with monoclonal antibodies or small-molecule inhibitors against VEGF or VEGF receptors.",during the first 28 days,NA
25074036,NCT01291615,Combination,No,biliary tract cancers undergoing major hepatectomy,"Patients who underwent major hepatectomy (hemihepatectomy, trisectionectomy, or more ) due to BTC, underwent no therapy other than surgery, and met the following criteria were eligible for inclusion: histologically confirmed BTC (intrahepatic or extrahepatic bile duct cancer, gallbladder cancer, or ampulla of Vater cancer); UICC-Stage IB disease or higher; complete macroscopic (R0 or R1) resection; age >20 years; Eastern Cooperative Oncology Group performance status 0–1; adequate marrow function (neutrophil count >1,500/mm3, platelet count >100,000/mm3); adequate liver function (total serum bilirubin <3× the upper limit of normal [ULN] and aspartate aminotransferase and alanine aminotransferase levels <5× ULN); adequate renal function (serum creatinine concentration <1.2 mg/dl and creatinine clearance >60 ml/min); and adequate oral intake. Patients satisfying these criteria started the regimen between 4 and 12 weeks after surgical resection.","Exclusion criteria were the presence of pulmonary fibrosis or intestinal pneumonia, severe heart disease, uncontrolled diabetes mellitus, active infection, pregnancy or lactation, women of childbearing age unless using effective contraception, severe drug hypersensitivity, mental disorder, concurrent double cancer, or other serious medical conditions.",during the first two cycles,NA
25877225,UMIN000006123,Combination,No,untreated advanced biliary tract cancer,"Eligibility criteria were as follows: pathologically confirmed ABTC including extrahepatic cholangiocarcinoma (EHCC), intrahepatic cholangiocarcinoma (IHCC), or gallbladder carcinoma (GBC); age ≥20 years; Eastern Cooperative Oncology Group performance status 0–2; no prior chemotherapy; presence of measurable or evaluable lesion; adequate bone marrow function (peripheral absolute neutropenia count ≥1,500/mm3, platelet count ≥100,000/mm3, and hemoglobin ≥8.0 g/dL); adequate hepatic and renal functions (total serum bilirubin ≤3.0 mg/dL; this was set so that the patients with the bile drainage for obstructive jaundice can receive treatment as soon as possible, serum transaminases ≤2.5 times upper limit of normal [ULN] or ≤5 times ULN in case of liver metastasis, and serum creatinine within ULN or creatinine clearance ≥50 mL/min). ","The main exclusion criteria included inability of oral intake, infection with fever, massive ascites or pleural effusion, and uncontrolled intercurrent illness.",during the first two cycles,NA
21786211,NA,Combination,No,metastatic colorectal cancer,"Inclusion criteria were as follows: (1) patients with histologically proven colorectal cancer; (2) patients with measurable or assessable lesions; (3) patients whose major organ functions were maintained adequately (white blood cells >= 4,000/mm3; neutrophils >= 2,000/mm3; platelets >= 100,000/mm3; hemoglobin >= 9.5 g/dl; AST/ALT <= 2.5 x institutional upper limit of normal AST/ALT; total serum bilirubin <= 2.0 mg/dl; BUN <= 25 mg/dl; serum creatinine <= 1.5 mg/dl; creatinine clearance >= 50 ml/min; and normal ECG, excluding cardiac arrhythmias and ischemic changes); (4) patients whose performance status (ECOG) was 0–2; (5) patients who were free from carryover effects or adverse reactions from prior treatment; (6) life expectancy >= 3 months; (7) age >= 15 years and <= 75 years; and (8) patients who gave written informed consent.","Exclusion criteria were as follows: (1) severe fluid retention (pleural effusion or ascites); (2) metastasis to the central nervous system (CNS); (3) fresh bleeding from gastrointestinal tract; (4) diarrhea (watery stool); (5) infections; (6) intestinal paralysis or intestinal obstruction; (7) interstitial pneumonia or pulmonary fibrosis; (8) uncontrolled diabetes; (9) cardiac failure, renal failure, or hepatic failure; (10) active double cancer; (11) active psychiatric disorder; (12) previous abdominal irradiation; (13) pregnant women, nursing mothers, or women of childbearing potential; and (14) any patients who were judged to be inappropriate for the study by the investigator.",during the first course of treatment,NA
22763610,NA,Combination,No,advanced gastric and esophagogastric adenocarcinomas,"Patients were eligible for inclusion if they were between 18 and 72 years of age, had histologically confirmed, EGFRexpressing (determined by immunohistochemistry), advanced, recurrent or metastatic gastric or gastroesophageal adenocarcinoma, a life expectancy >12 weeks, a Karnofsky Performance Status (KPS) of at least 60, and at least one evaluable lesion, according to Response Evaluation Criteria In Solid Tumors (RECIST) . Patients also had to have adequate liver (bilirubin <2 x upper limit of normal [ULN], ALT/AST <2 x ULN or tumor-related ALT/AST <5 x ULN) and bone marrow (WBC >3,000/ul, platelets >100,000/ul, hemoglobin >9 g/dl) function, a creatinine clearance rate of 60 ml/minute or better, complete recovery from any relevant side effects of previous treatments and be practicing effective contraception throughout study participation if appropriate",Patients with relevant cardiac disorders were excluded from the study as were those who had received radiotherapy or major surgery within the 4 weeks prior to the start of the study and those who had received previous EGFR or vascular endothelial growth factor (VEGF)- targeted therapy.,during the first cycle ,NA
24480865,NA,Combination,No,Locally Advanced Head and Neck Squamous Cell Carcinoma ,"Patients eligible for this study were required to have histologically proven HNSCC (other than thyroid cancer) and measurable or evaluable lesions. Patients were required to have unresectable lesions with no previous history of treatment for head and neck cancer or recurrent cancer for which only radiotherapy had been administered; prior radiotherapy was permitted if the treatment had been completed at least 4 weeks before patient selection.  However, a history of prior chemotherapy was not permitted. The criteria for unresectability were as follows: >180° encasement of the carotid artery; fixation to the prevertebral fascia; massive fixed soft tissue disease, and gross extension along the pharyngeal wall. The other eligibility criteria were as follows: a patient age of 20–75 years; an Eastern Cooperative Oncology Group performance status of 0 or 1; a life expectancy of at least 3 months; the ability to receive oral treatment, and adequate organ functions, including a leukocyte count of 4,000–12,000/mm 3, a platelet count of 100,000/mm 3 , a hemoglobin level of 9.0 g/dl, serum transaminase (aspartate aminotransferase and alanine aminotransferase) and alkaline phosphatase levels within twice the upper limit of normal, a serum bilirubin level of 1.5 mg/dl, a serum creatinine level within the upper limit of normal and an estimated creatinine clearance according to the method of Cockcroft-Gault of 80 ml/min. The ethics committee of our hospital approved the study and written informed consent was obtained from each of the patients.",NA,during the first cycle of treatment,NA
23292146,NA,Single Drug,No,head and neck cancer,"Patients with histopathologically proven squamous cell carcinoma of the head and neck were eligible for this study. They were required to be at least 20 years old, to have an Eastern Cooperative Oncology Group performance status of 2 or less, and to have adequate organ function (leukocytes ≥ 3500/mm3, platelets ≥ 100 000/mm3, hemoglobin ≥ 9.0 g/dl, normal serum creatinine and blood urea nitrogen, serum glutamic oxaloacetic transaminase (GOT) ≤ 100 U/l, serum glutaminic pyruvic transaminase (GPT) ≤ 100 U/l, and serum albumin ≥ 3.0 g/dl).","Patients were excluded if they had received prior systemic therapy or radiotherapy, had another active malignancy, active infection, active gastric/duodenal ulcer, severe concurrent disease, or mental disorder.",during the chemoradiotherapy,NA
23208490,NCT00220649,Combination,No,"Patients with Metastatic Solid Tumors Including Adenocarcinoma of the Pancreas. Primary cancer site: Pancreas 9 36, Gastroesophageal 7 28, Hepatobiliary 2 8, Gallbladder 1 4, Duodenum 1 4, Oropharynx 1 4, Unknown primary","Inclusion criteria required all patients to have a pathologically confirmed diagnosis of a solid tumor, either metastatic or advanced inoperable stage that was refractory to conventional treatment or for which no standard therapy existed. Patients were 18 years or older with a life expectancy of at least 12 weeks and a Karnofsky performance score (KPS) of ≥60, absolute granulocyte count ≥1,500/mm3, platelet count ≥100,000/mm3, bilirubin ≤2.0 mg/dL, and creatinine of ≤1.5 mg/dL. In addition, all patients had measurable or evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) and did not receive any chemotherapy, immunotherapy, or radiotherapy for at least 4 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C). No additional concurrent chemotherapy, radiotherapy, immunotherapy, or other investigational drugs were permitted while participating in this study.","Important exclusion criteria included brain metastases or leptomeningeal disease; progressive sensory neuropathy or hearing loss; tinnitus; pregnancy or lactation; uncontrolled medical conditions such as diabetes, hypertension, arrhythmias, congestive heart failure, angina pectoris, and myocardial infarction within 1 year of entry; active infections; and history of prior invasive malignancies within 5 years of entry with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.",during the first two cycles (28 days),NA
20934959,NA,Combination,No,unresectable / recurrent gastric cancer,"Criteria for enrollment were as follows: (1) unoperated cases of histologically confirmed gastric cancer that was judged to have no indication for surgery by clinical findings, including image-based diagnosis; (2) cases that had undergone noncurable non-curative gastrectomy (including exploratory laparotomy); and (3) cases of postoperative recurrence. The presence or absence of measurable or evaluable lesions were not taken into account. Inclusion criteria were as follows: (1) no history of previous treatment by CDDP or taxanes; (2) no influence by previous treatment (chemotherapy or radiation therapy) and four weeks or longer since the end of the last treatment; (3) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 – 2; (4) 20 years of age or older; (5) sufficiently preserved functions of major organs: white blood cell count ≥ 4,000/μL; neutrophil count ≥ 2,000/μL; platelet count ≥ 10,000/μL; hemoglobin ≥ 8.0 g/dL; serum total bilirubin ≤ 1.5 mg/dL; AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ≤ double the upper normal limit (triple the upper normal limit in cases of liver metastasis); serum creatinine ≤ 1.5 mg/dL; creatinine clearance ≥ 50 ml/min; and electrocardiogram (ECG) showing no severe arrhythmia or ischemic changes; (6) expected survival of three months or longer; and (7) written informed consent prior to the trial. ","Exclusion criteria were as follows: (1) severe complications (heart diseases such as ischemic heart disease and arrhythmia requiring treatment, a history of myocardial infarction occurring within six months, liver cirrhosis, dyspnea requiring oxygen inhalation, psychiatric disease requiring treatment, and uncontrollable diabetes); (2) severe allergy; (3) allergy to the drugs used in this trial and those containing polyoxyethylene castor oil (such as cyclosporine solution); (4) allergy to alcohol; (5) multiple primary cancers (acceptable in patients with metachronous multiple primary cancers with a diseasefree period of five years or longer); (6) pregnant women, breast-feeding women, and potentially pregnant women; (7) peripheral nerve injury and brain metastasis with associated symptoms; and (9) others judged to be inappropriate by the physician in charge. ",during the first course,NA
21868555,NA,Combination,No,HER2-positive Metastatic Breast Cancer,"Patients aged ≥20 years old with a histological or cytological diagnosis of HER2-positive (IHC 3+ or IHC 2+/FISH+) MBC were eligible. Eligibility required measurable cancer by RECIST criteria(18); baseline left ventricular ejection fraction (LVEF) >55%; an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2; expected survival >6 months; adequate organ function defined as hemoglobin >9 g/dl, leukocyte count 3000-12,000/mm3, neutrophil count >1500 /mm3, platelet count >100,000/mm3, serum total bilirubin level less than the upper limit of normal in each institution ×1.5, and serum creatinine level less than the upper limit of normal. Treatment with one prior chemotherapeutic regimen was permitted for those with metastatic disease.",Patients with any of the following were excluded: lung metastasis with dyspnea; brain metastasis with symptoms; a second primary cancer; serious concomitant illness; cardiac abnormalities; or cases with possible infection.,within the first treatment cycle,NA
23665950,NCT00553696,Combination,No,japanese patients with advanced or metastatic gastric cancer,"Patients (male or female) eligible for inclusion in this study were aged ≥20 years, had an Eastern Cooperative Oncology Group performance status of 0 or 1, adequate organ function, and histologically or cytologically confirmed Stage IV gastric adenocarcinoma or gastroesophageal junction adenocarcinoma not amenable to surgery or radiation. Prior adjuvant therapy was permitted with a recurrence-free interval of >3 months after the completion of adjuvant therapy. Prior chemotherapy in the advanced/metastatic setting was not permitted; one regimen of chemotherapy, such as S-1 monotherapy, without progressive disease was allowed if the duration of treatment was less than 4 weeks.","Exclusion criteria included central nervous system (CNS) metastases, carcinomatous meningitis, or uncontrolled hypertension (blood pressure >150/100 mmHg). Patients with severe/unstable angina, myocardial infarction, coronary artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, including transient ischemic attack, or pulmonary embolism within 12 months prior to starting study treatment were also excluded.",in cycle 1,NA
24829073,NA,Combination,No,advanced hepatocellular carcinoma,"(1) patients with confirmed HCC according to histological studies or diagnostic imaging; (2) patients classified as having advanced disease if they were not eligible for or showed disease progression after surgery, PEI, RFA, or TACE; (3) patients with a minimum age of 20 years; (4) patients with an Eastern Cooperative Oncology Group performance status scale score of 0 or 1; (5) patients with measurable disease based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.0; and (6) patients with a white blood cell count of ≥3,000 cells/mm3 or neutrophil count of ≥1,500 cells/mm3, hemoglobin level of ≥9.0 g/dL, platelet count of ≥7.5×104 cells/mm3, total bilirubin level of 2.0 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels≤upper limit of normal×5, albumin level of ≥3.0 mg/dL, prothrombin timeinternational normalized ratio of ≤2.0, and creatinine level≤ upper limit of normal.","Patients were not eligible if they had received surgery, PEI, RFA, TACE, chemotherapy, or radiotherapy within 30 days before the start of this study. Patients were excluded if there was clinical evidence of central nervous system metastasis, severe cardiovascular disorder, hepatic encephalopathy, uncontrollable pleural effusion or ascites, or a serious infection. Patients requiring prophylactic variceal ligation or sclerotherapy were also excluded.",during the 1st cycle,NA
21134076,NA,Combination,No,patients with unresectable locally advanced squamous cell carcinoma of the head and neck,"Eligibility for the present study required a histologically or cytologically confirmed diagnosis of SCCHN with unresectable locally advanced disease, including postoperative local recurrence. Careful evaluation for unresectability was required from a multidisciplinary conference, which included head and neck surgeons, radiation oncologists and medical oncologists. Criteria for unresectability were carefully defined as follows: (i) technical unresectability, considered to mean tumors fixed to the carotid artery, mastoid, base of the skull or cervical spine; and (ii) physician determination of low surgical curability based on neck lymph node metastases such as N2c-3. Medical unsuitability for resection was not sufficient for patient eligibility; eligibility also required an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, age 20– 75 years and adequate organ function. Written informed consent was required from all patients before the start of any therapy",Patients were excluded if they had any of the following conditions: previous chemotherapy or radiotherapy; concurrent active malignancy except excised intramucosal gastric or esophageal cancer that could be removed by endoscopic mucosal resection; pharyngeal fistula; active bleeding from the GI tract; active infection; serious medical problem that might interfere with the achievement of study objectives; pregnancy or lactation; or expected survival <3 months.,during the chemoradiotherapy,NA
25217393,NA,Combination,No,Chinese patients with unresectable liver metastases from colorectal cancer,"All patients had histologically confirmed colorectal adenocarcinoma with unresectable hepatic metastases. Nonresectability was defined as meeting any of the following criteria: no ability to obtain a complete resection; no ability to preserve an adequate liver remnant; no ability to preserve two contiguous hepatic segments or adequate vascular inflow and outflow as well as biliary drainage. Patients with more than five hepatic metastases were also considered unresectable. Patients with hepatic metastases who also had concurrent extrahepatic metastases (pulmonary or lymph node) with a small tumor burden (≤3 lesions and ≤2 cm diameter) were included. Patients who completed prior adjuvant chemotherapy with Oxa/5-FU/LV ≥12 months before study entry and without chemotherapy-related toxicities were included. Prior surgery and radiotherapy for a primary tumor and/or prior palliative chemotherapy (with the exception of Oxa), resection and radiofrequency (RF) ablation for liver metastases were also permitted.","Patients were excluded from this study for any of the following reasons: younger than 18 years or older than 75 years, Karnofsky performance status (KPS) ≤70, concurrent malignancy (within 5 years), serious or treatment-resistant cardiovascular and cerebrovascular disease or neurological disease, white blood cell (WBC) count ≤3.0 × 109 U/L, absolute neutrophil count (ANC) ≤1.5 × 109 U/L, platelet count ≤90 × 109 U/L and direct bilirubin ≥1.5 times the upper normal limit (UNL), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥5 times the UNL. Patients with ascites, liver function Child Pugh grade B or C or a life expectancy shorter than 3 months were also excluded. All patients signed informed consent forms.",during the first two cycles,NA
22237958,NCT01284413,Combination,No,advanced biliary tract cancer ,"Patients with advanced biliary tract cancer that was not amenable to potentially curative surgery or that had recurred after surgery were eligible for inclusion if they met the following criteria: presence of histologically or cytologically confirmed biliary tract cancer (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer); Eastern Cooperative Oncology Group performance status of 0–1; age >=20 years; adequate bone marrow function (neutrophil count >=1,500/mm3, platelet count >=100,000/mm3), liver function (total bilirubin <=3.0 mg/dL, aspartate aminotransferase [AST]/alanine aminotransferase [ALT] <=150 IU/L), and renal function (creatinine clearance >=60 ml/min); and adequate oral intake. All patients provided written informed consent","The exclusion criteria were as follows: pulmonary fibrosis or interstitial pneumonia; severe heart disease; uncontrollable diabetes mellitus; active infection; pregnancy or lactation; women of childbearing age, unless using effective contraception; severe drug hypersensitivity; mental disorder; watery diarrhea; moderate or marked pleural effusion or ascites; and other serious medical conditions.",during the first two cycles (or one cycle at level 3),NA
25687990,UMIN000003803,Combination,No,unresectable biliary tract cancer,"Patients with inoperable BTC or recurrent liver tumors after BTC surgery who met the following inclusion criteria were considered eligible for the study: (1) the presence of histologically or cytologically confirmed BTC including intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma, and GBC; (2) no previous chemotherapy or radiation therapy; (3) Eastern Cooperative Oncology Group performance status of 0–2; (4) age between 20 and 79 years; (5) adequate bone marrow function (absolute neutrophil count [ANC] ≥1500/mm3, platelet count ≥100,000/mm3, and hemoglobin ≥9.0 g/dL), liver function (total bilirubin ≤3.0 mg/dL and aspartate aminotransferase [AST]/alanine aminotransferase [ALT] ≤150 IU/L), and renal function (creatinine clearance ≥60 mL/min); and (6) adequate oral intake. Patients who met the above criteria but had preexisting obstructive jaundice were allowed to participate in the study after their total bilirubin levels were reduced to ≤3.0 mg/dL by biliary stent insertion or percutaneous biliary drainage","The exclusion criteria were (1) hepatomesenteric or celiacomesenteric variation in the celiac trunk, (2) simultaneous or metachronous (within 5 years) second primary cancers with the exception of intramucosal tumors curable with local therapy, (3) pulmonary fibrosis or interstitial pneumonia, (4) severe heart disease, (5) uncontrollable diabetes mellitus, (6) active infection, (7) pregnancy or lactation, (8) severe drug hypersensitivity, (9) allergy to iodine-based contrast media, (10) mental disorder, (11) watery diarrhea, (12) moderate or marked pleural effusion or ascites, and (13) other serious medical conditions.",during the first two treatment cycles,NA
25422155,UMIN000008415,Combination,No,inoperable biliary tract cancer,"Patients had been diagnosed with unresectable or postoperative recurrent biliary tract cancer, histologically or radiologically. Any prior treatments for this disease were allowed. Additional inclusion criteria included age ≥20 and <80 years, Eastern Cooperative Oncology Group (ECOG) performance status <2, estimated life expectancy of ≥3 months, absolute neutrophil count ≥2,000/μL, white cell count ≥3,500 /μL <12,000 /μL, platelet ≥100,000/μL, serum AST/ALT ≤100 U/L, total bilirubin ≤2.0 mg/dL, serum creatinine ≤2.0 mg/dL, and 24-h creatinine clearance ≥60 mL/min.",NA,during the first one course,NA
21077997,NA,Combination,No,patients with advanced colorectal cancer,"The main eligibility criteria included the following: a histologically or cytologically confirmed, unresectable, locally advanced or metastatic colorectal cancer; age, 20 to <75 years; Eastern Cooperative Oncology Group (ECOG) performance status (PS), 2 or less; measurable disease; leukocyte count 3000 ⁄mm3 or more; platelet count 100 000 ⁄mm3 or more; hemoglobin 9.0 g ⁄ dL or more; serum creatinine 1.2 mg ⁄ dL or less; serum bilirubin 1.5 mg ⁄ dL or less; aspartate aminotransferase (AST) 100 IU ⁄L or less; alanine aminotransferase (ALT) 100 IU ⁄ L or less; and a life expectancy of 3 months or more. Patients who had received prior chemotherapy or radiotherapy were excluded; however, those who had received adjuvant chemotherapy completed at least 1 month before the entry were eligible. ","The exclusion criteria were: a serious pre-existing medical condition such as infection, severe heart disease, uncontrolled diabetes mellitus, interstitial pneumonia or pulmonary fibrosis; pericardial or pleural effusion requiring drainage; symptomatic brain metastasis; pregnancy; or lactation.",during cycles 1 and 2,NA
21540865,NCT00705016,Combination,No,recurrent and/or metastatic squamous cell cancer of the head and neck,Inclusion criteria for the study included: (i) adults aged X18 years; (ii) a histologically or cytologically confirmed diagnosis of recurrent and/or metastatic SCCHN that was not suitable for local therapy; (iii) patients with >=1 measurable lesion by either computerised tomography (CT) or magnetic resonance imaging (MRI); (iv) performance status >=70 on the Karnofsky performance status scale; and (v) 0 –1 on the Eastern Cooperative Oncology Group scale.,"Key exclusion criteria were (i) prior systemic chemotherapy (unless as part of multimodal treatment for locally advanced disease completed >6 months before study entry); (ii) surgery (excluding diagnostic biopsy) or irradiation <=4 weeks before study entry; (iii) nasopharyngeal carcinoma; (iv) active infection, uncontrolled hypertension, abnormal haematology or liver function; (v) pregnancy; (vi) other concomitant anticancer therapies or previous treatment with EGFR targeting therapy or signal transduction inhibitors; (vii) brain metastases; and (viii) known drug abuse.",during the first 3-week cycle of therapy,NA
23397499,NA,Combination,No,patients with recurrent/metastatic squamous cell carcinoma of the head and neck,"Adult patients aged ≥18 years were eligible if they had a histologically or cytologically confirmed diagnosis of R/M SCCHN not suitable for local therapy, with ≥1 lesion measurable either by computed tomography scan or magnetic resonance imaging, and a Karnofsky performance status (KPS) of ≥70 or Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at trial entry","Key exclusion criteria were as follows: prior systemic chemotherapy (first-line palliative treatment), except if given as part of a multimodal treatment for locally advanced disease and completed >2 months prior to trial entry; nasopharyngeal carcinoma, medical history of interstitial lung disease, or brain metastasis; relevant cardiovascular comorbidities; and previous treatment with EGFRtargeting therapy. ",in cycle 1,NA
16203658,NA,Combination,No,"Patients with Advanced Solid Tumors. Primary tumor: Colon, Pancreas, Stomach, Kidney, Billary tract, Head and neck, Urothelial, Hepatoma, Unknown primary","Patients with histologically or cytologically confirmed solid tumors, who were chemotherapy-naı¨ve or had received up to two chemotherapy regimens were eligible for the study. Other eligibility criteria were: an age range of 18–75 years; a performance status (ECOG) of 0–2; adequate bone marrow (absolute neutrophil count >=1.5 x 109/L and platelets >= 100 x 109/L), renal (creatinine <= 1.5 mg/dL), and liver (total bilirubin <= 1.25 times the upper limit of normal, aspartate, and alanine aminotransferase <= 3.0 times the upper limit of normal) function; absence of uncontrolled angina pectoris or a myocardial infraction 6 months prior to enrollment; absence of active infection or malnutrition (loss of more than 20 percent of the body weight).","Patients with severe cardiac dysfunction, chronic diarrhea, and more than Grade I peripheral neuropathy were excluded from the study.",during the first 6 weeks,NA
22510347,NA,Combination,No,Patients with Recurrent Gynecologic Cancer: ovarian cancer and endometrial cancer,"Eligible patients included women aged 19 years or older with histologically proven recurrent epithelial ovarian, primary peritoneal, fallopian tube, or endometrial cancer, who had been previously treated with conventional surgical procedures and standard adjuvant therapies. Patients were required to have adequate organ laboratory function as defined by a white blood cell (WBC) count >3,000 mL, granulocyte count >1,500 uL, platelets >100,000, creatinine clearance >80 mg/dL, creatinine <2.0, aspartate aminotransferase or alanine aminotransferase <2.5 x the upper limit of the normal reference range, bilirubin <2.0, and a prothrombin time/international normalized ratio/partial thromboplastin time (PT/INR/PTT) <1.5 x the upper limit of normal reference range. Patients were also required to have an ejection fraction of >55% on echocardiogram, oxygen saturation >92% on room air, a Gynecologic Oncology Group (GOG) performance status 0 to 2 and a life expectancy >3 months.","Those patients found to have tumors of low malignant potential, germ cell or sex cord/ stromal tumors, active cardiac or pulmonary disease, or coagulation disorders were excluded.",NA,NA
16163539,NA,Combination,No,patients with advanced gastric cancer,"The eligible patients included patients with unresectable advanced disease, metastatic disease, or relapsed disease after resection. Patients who had been previously treated with chemotherapy were also eligible if they had a treatment-free period of at least 4 weeks prior to initiation of the trial, and had recovered from all reversible toxicities. Patients whose survival duration was expected to be less than 3 months were not eligible. All patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of two or less. Other eligibility criteria included: age between 20 and 74 years, adequate hematological results (4.0 x 109 <= total leukocyte count <= 12.0 x 109/L, neutrophils >= 2.0·109/L, Hemoglobin >= 9.5 g/dl, platelets >= 100.0 x 109/L), adequate hepatic function (total serum bilirubin <= 1.5 mg/dl, liver transaminase AST/ALT less than 2.0 times the upper limit of normal values), and adequate renal function (serum creatinine <= 1.5 mg/dl).","Patients were excluded when they were pregnant, lactating, or of childbearing age. Patients were not eligible for the study if they had a previous serious medical illness, particularly cardiac disease or prior reactions to drugs containing Cremophor EL.",within the first cycle of the treatment,NA
16319514,NA,Combination,No,Advanced Pancreatic Cancer,"Patients were considered eligible if they met the following criteria: histologically or cytologically proven pancreatic adenocarcinoma, unresectable locally advanced or metastatic disease, naive to chemotherapy, Eastern Cooperative Oncology Group performance status of 0–2, age between 20 and 74 years, life expectancy of >= 8 weeks, and adequate organ function defi ned as white blood cell count >= 4,000/mm 3 , neutrophil count >= 2,000/mm 3 , platelet count >= 100,000/mm 3 , hemoglobin >= 9.0 g/dl, serum creatinine <= the upper limit of normal, serum albumin >= 3.0 g/dl, total bilirubin <= 2.0 mg/dl, and aspartate aminotansferase and alanine aminotransferase levels <= 2.5 times the upper limit of normal or <= 5 times the upper limit of normal if liver metastases or biliary drainage were present.","The exclusion criteria were severe complications, such as infection, heart disease and renal disease (in this study we did not defi ne in detail the exclusion criteria in relation to severe complications), metastasis to the central nervous system, marked pleural effusion or ascites, and watery diarrhea. Pregnant or lactating women were also excluded. ",during the fi rst two cycles of treatment,NA
16466986,NA,Combination,No,Potentially Resectable and/or Unresectable Cancer of the Pancreas and Distal Biliary Tract,"Patients eligible for this study included those with histologically proven pancreatic/periampullary cancers, including potentially resectable, unresectable, or metastatic tumors. Recurrent or residual tumors where radiation was previously administered to the upper abdomen or where significant portions of the stomach or small bowel had been resected were not eligible. Other eligibility criteria included: age ≥18; Karnofsky performance status ≥70 percent; ANC ≥2,000/mm3, platelets ≥100,000/mm3, Hg >9.0; SGOT, SGPT, Alk Phos ≤3x upper normal limit (UNL); ≤5× UNL if known hepatic metastases; bilirubin ≤1.5 × UNL; creatinine Clest ≥ 50 mL/min and no clinical indication of compromised function of the nonirradiated or least irradiated kidney; ability to adequately swallow and digest the eniluracil/5- FU tablets with no conditions that would significantly compromise intestinal absorption of the study drugs (such as resection of stomach or small bowel, active inflammatory bowel disease, etc.). ","Patients with any of the following prior therapies were excluded: prior radiation therapy that would compromise further radiation delivery; more than two prior cytotoxic regimens for advanced pancreatic or periampullary cancer; prior chemotherapy, radiation, hormonal, or biological therapy within the 28 days prior to study enrollment; prior nitrosourea or mitomycin C therapy within 42 days. Those with serious or poorly controlled medical conditions that could be exacerbated by the treatment or would seriously complicate compliance with the protocol were excluded as were pregnant patients. Patients must not have been taking any of the following medications that could interact with the metabolism or disposition of 5-FU or eniluracil: dipyridamole, folinic acid, allopurinol, trimethoprim, misonidazole, flucytosine, or cimetidine",from the start until 14 days after the completion of radiation,NA
15473585,NA,Combination,No,rectal cance,"Eligible for this study were patients aged 18 or more with histologically confirmed rectal adenocarcinoma, clinical stage T3-4 up to 12 cm from the anal verge or with low T2 tumors up to 6 cm from the anal verge, and with no evidence of distant metastases. Also required were ECOG performance status 0-1, ability to undergo surgical resection and adequate hematologic function (granulocytes >1,500/ml, platelets >100,000/ml), hepatic function (serum bilirubin and transaminases <1.5 times upper limit of normal) and renal function (serum creatinine <1.5 mg/dl). Patients with hemoglobin <12 g/dl were eligible after receiving blood transfusion before treatment. ","Patients who had received prior chemotherapy or pelvic radiotherapy, patients with another malignancy in the preceding 5 years, and patients with a history of ulcerative colitis or Crohn's disease were not eligible. ",during the chemoradiation and 4 weeks after completing chemoradiation,NA
26783290,NCT01344031,Combination,No,PostmenopausalWomen with Estrogen Receptor– Positive Metastatic Breast Cancer,"Eligible patients were postmenopausal females ages >=18 years, with stage IV, measurable or evaluable ERþ breast cancer, Eastern Cooperative Oncology Group performance status <=1, adequate organ and marrow function, total bilirubin not above the institutional upper limit of normal (ULN), AST(SGOT)/ALT(SGPT) <2.5 x institutional ULN, and normal creatinine), fasting glucose <= 120 mg/dL, and HbA1c <= 8%. Patients were allowed any number of prior regimens for the treatment of breast cancer. Patients with known brain metastases were eligible if stable >=3 months after local therapy and were off steroid. Measurable or evaluable disease by RECIST was allowed. ","Patients with prior AKT inhibitor, disease progression on anastrozole (MK-2206 plus anastrozole cohort), fulvestrant (MK-2206 plus fulvestrant cohort), or both anastrozole and fulvestrant (MK-2207 plus anastrozole and fulvestrant cohort) or baseline QTcF >470 msec, uncontrolled intercurrent illness, medications, or substances that are strong inhibitors or inducers of CYP 450 3A4, or chemotherapy or radiotherapy within 4 weeks were excluded. Medications that may cause QTc interval prolongation were avoided.",in the first 3 cycles,NA
14605864,NA,Combination,No,"The most frequently observed tumor site was the rectum anad all of these tumours were characterized as adenocarcinomas. Histopathological tumour types for other primary sites were adenocarcinoma (small bowel, colon, oesophagus, breast, cervis and unknown site), glioblastoma (brain), poorly differentiated serous carcinoma (ovary), leiomyosarcoma (pelvis) and transitional cell carcinoma (bladder). The primary tumour site was unknown for one patient. ","Patients were eligible for inclusion in this study if they were aged >=18 years, of adequate performance status (<= 1 on the WHO scale) and had a life expectancy of >3 months. Patients must have recovered from all acute toxicities from prior therapy exept alopecia anad grade 1 or less peripheral neurophathy. Adequate bone marrow, hepatic and renal function was required (haemoglobin>9 g/dl, neutrophil count >1.5x109/l, platelet count >100x109/l, serum bilirubin less than 1.5 times the upper normal imit (UNL), aspartate transaminase (AST) or alanine transaminase (ALT) and alkaline phosphatase (ALP) less than twice UNL (or less than five times UNL in the presence of liver metastase) and calculated creatinine clearance >50 ml/min. Patients with primary brain tumours or brain metastases were eligible provided they had stable symptoms and had received a stable dose of steroid for 1 month prior to receiving study drug and were able to give informed consent. ","Patients were ineligible in the event of : pregnancy or lactation; previous chemotherapy with BBR 3464; previous treatment with PVI 5-FU in the 6 months prior to study enrollment; tadiotherapy, nitrosoureas, mitomycin C or melphalan within 6 weeks of the start of treatment; other cytotoxic chemotherapy within 4 weeks of the start of treatment; full anticoagulation therapy with warfarin (eligible if an alternative anticoagulant could be used). Patients were also excluded if they had clinically significant cardiovascular disease (including myocardial infraction within the prior 6 months, severe arrhythmia or uncontrolled hypertension); symptomatic motor or sensory neurotoxicity NCI CIC (National Cancer Institute Common Toxicity Criteria) grade 2 or more; psychiatric disabilities, seizures or CNS disorders thought to be clinically significant; known chronic obstructive airways disease or interstitial lung disease (dyspnoea NCI CTC grade 3 or more); carbon monoxide diffusion capacity <50% of predicted value; prior disposition to diarrhoea (e.g. inflammatory bowel disease).",in courses 1 and 2,NA
14739662,NA,Combination,No,"Patients with advanced solid malignancies. Primary tumor site: colorectal, head and neck, lung, ovary, pancereas, renal, other.","Patients had a histologically documented metastatic or inoperable advanced solid malignancy for which there was no known curative or standard palliative therapy. Patients were at least 18-years old with a minimum life expectancy of 3 months and a WHO performance status <=2. Adequate hepatic, renal, and hematologic function as indicated by the following laboratory values was required: neutrophil count >=1500/ul; platelet count >=75,000/ul; hemoglobin >=10.0g/dl; serum creatinine <=1.5-times the upper limit of normal (ULN); total bilirubin <1.5-times ULN; and serum transaminase activities ,=2.5-times ULN. Patients had to be fully recovered from the effects of any prior intervention. The time from prior major surgery and entry into the study ahd to be at least 4 weeks, from prior chemotherapy 3 weeks (6 weeks for mitomycin C), and 4 weeks from radiotherapy.","Exclusion criteria included evidence of a primary or metastatic lesion in the central nervous system, cardiac disease, an abnormal electrocardiogram (ECG), and pregnancy or lactation. ",the first 28-day treatment,NA
15818508,NA,Combination,No,"adult patients with advanced solid tumours. Tumour types: gastrointestinal, colorectal, head and neck, others. ","The inclusion criteria for the present study were: written informed consent, signed and dated; histologically proven advanced solid tumour; adults (18-70 years of age) who had previously fialed standard treatment or for whom no established curative therapy existed; life expectancy >3 months; WHO performance status <=2; polymorphonuclear neutrophil count >2000 mm-3, platelets count >100,000 mm-3, haemoglobin >10 mg/dl; satisfactory renal function: creatinine <125 umol/l; prothrombin time >0.5 normal time; bilirubin <1.5 times the upper limi of the normal range (UNL) and serum transaminase <3 time UNL or, in the presence of hepatic metastases, bilirubin <1.5 times UNL and serum transaminases ,5 time UNL; prior theraoy without limitation for the first dose levels and for the final steps near the MTD and recommended dose, a maximum of one previous chemotherapy regimen; a washout period since previous chemotherapy of 4 weeks (6 weeks for previous mitomycin C, nitrosourea or extended-field radiation therapy); absence of previous exposure to topoisomerase I inhibiors; absence of severe concomitant infections, major organ failure, angina prectoris, bowel obstruction or inflammatory intestinal disease and symptomatic brain metastases or carcinomatous leptomeningitisl no prior severe toxicity with the same schedule of 5-FU; and absence of history of other cancer except curatively resected in situ cervical carcinoma or basal/spindle cell carcinoma of the skin.",Pregnant woman or patients with preproductive potential and no effective contraception were exclude.,at cycle 1,NA
16199307,NA,Combination,No,ADVANCED T-STAGE NASOPHARYNGEAL CARCINOMA,"Patients with histologically proven NPC Stage T3– 4, any N, or M0 disease were eligible for this study. All patients were staged according to the American Joint Committee on Cancer (AJCC) staging system from 1992 (9). Criteria for inclusion in the study included at least 1 bidimensionally measurable lesion, no prior chemotherapy, age >= 18 years, a performance status of <=2 (Zubrod), an absolute granulocyte count of >=1500/uL, a platelet count of >=100,000/uL, a serum creatinine level of <=1.5 mg/dL, and a creatinine clearance of >=60 mL/min.","Patients were excluded for any prior malignancy except for adequately treated basal or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient had been disease-free for more than 5 years. Pregnant or breast-feeding women were excluded. Patients who had received previous radiation therapy to the head and neck, except for treatment of nonmelanoma skin cancers outside of the current radiation therapy treatment volumes, were not eligible.",NA,NA
16249791,NA,Combination,No,locally advanced rectal cancer,"Eligibility criteria included histologically confirmed adenocarcinoma, WHO performance status 0–2 and no evidence of metastatic disease using chest X-ray and abdominopelvic CT. Acceptable haematological and renal function was required: neutrophils >1.5 × 109 l−1, platelets ⩾100 × 109 l−1, and serum creatinine <1.25 × the institutions upper limit of normal range.","Patients were excluded from the study because of prior chemotherapy or pelvic radiation, lack of efficient contraception or pregnancy, inflammatory bowel disease and cardiac conditions that would deter the safe delivery of 5FU. Patients having six episodes of stool per day or who were incontinent of faeces were also excluded.",up to and including week 10,NA
15729600,NA,Combination,No,advanced gastric cancer,"All patients had histologically proven unresectable or recurrent gastric cancer, and had not received prior chemotherapy, although adjuvant chemotherapy was allowed if it had been completed more than 30 days prior to entry. Other eligibility criteria included the following: 20–75 years of age, Eastern Cooperative Oncology Group performance status (PS) of at least 2; measurable disease; white blood cell count, 4000/ml or more; absolute neutrophil count, more than 2000/ml; hemoglobin level, more than 9.0g/dl; platelet count, more than 100000/ml; serum bilirubin level, less than 1.5mg/dl, aspartate transaminase and alanine transaminase levels, within three times the upper limit; serum blood urea nitrogen, less than 25mg/dl; creatinine, less than 1.5mg/dl; creatinine clearance, less than 50ml/min. All patients gave their written informed consent; the institutional review board of Tonan hospital approved this study.",NA,during the first course,NA
30684019,NCT02109016,Combination,No,patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer,"Eligible patients for this study were menopausal women, ≥ 18  years old with an estimated life expectancy > 12 weeks with histologically confirmed, stage IV, ER positive, HER2 negative breast adenocarcinoma that have progressed during or after treatment with fulvestrant. Patients also have to had ECOG performance status < 2 and adequate haematological, hepatic and renal functions. The presence of an accessible metastatic lesion for biopsy was required for participation (expansion cohorts only). ","Patients with more than three chemotherapy regimens in the metastatic/advanced setting were not eligible for this study, as were patients with active central nervous system metastases, as indicated by clinical symptoms, cerebral oedema, and/or progressive growth.",between C1D15 and C2D15 (first 28 days of administration of the combination lucitanib+fulvestrant,NA
30543347,NCT01219699,Combination,No,PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer,"Patients with histologically-confirmed, advanced unresectable solid tumors who have progressed within three months before screening/baseline visit Only patients who have confirmed PIK3CA status (wild type, mutation or amplification) will be allowed for screening (patients participating in the combination arm must be eligible for treatment with fulvestrant). Availability of a representative formalin fixed paraffin embedded tumor tissue sample. At least one measurable or non-measurable lesion. Age ≥ 18 years. World Health Organization (WHO) Performance Status ≤ 2. Good organ (hepatic, kidney, BM) function at screening/baseline vis","Brain metastasis unless treated and free of signs/symptoms attributable to brain metastasis in the absence of corticosteroid therapy (anti-epileptic therapy is allowed). Prior treatment with PI3K, AKT or mTOR inhibitor and failure to benefit. Patient with peripheral neuropathy NCI-CTC Grade ≥ 3. Patient with diarrhea NCI-CTC Grade ≥ 2. Patient with acute or chronic pancreatitis. Impaired cardiac function or clinically significant cardiac disease incl. unstable angina pectoris ≤ 3 months prior to starting study drug and Acute Myocardial Infarction (AMI) ≤ 3 months prior to starting study drug. Patients with clinically manifest diabetes mellitus, history of gestational diabetes mellitus or documented steroid-induced diabetes mellitus. Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control",in cycle 1,NA
16297614,NA,Combination,No,in advanced rectal cance,"All the patients included in the study presented with rectal adenocarcinoma that had been histologically docu- mented. The tumours were either locally advanced (clin- ical stage T3–T4 and with radiological (ultrasound or CT) evidence of perirectal fat infiltration) and/or meta- static tumours of the rectum requiring local treatment, or tumour recurrence; no magnetic resonance imaging was used during this study. The tumours were located below the peritoneal reflection in all cases. The other inclusion criteria were performance status (Eastern Cooperative Oncology Group) 0–2, age >18 years, satisfactory hematological, liver function and other laboratory parameters (neutrophils >=2 x 109/L, platelets 130 · 109/L, hemoglobin >100 g/L, creatinine <130 lmol/L, bilirubin <1.5 times the upper limit of the normal range (ULN), transaminases, alkaline phosphatase <2 ULN). Women of child-bearing potential were to have a negative pregnancy test. Patients were required to use effective contraception throughout the duration of treatment. ","Patients having received chemotherapy and/or pel- vic radiotherapy were also excluded. Patients presenting with acute occlusion without colostomy and those pre- senting with rectovesical fistula, inflammatory disease of the bowel, a contra-indication to 5FU (uncontrolled ischemic heart disease or cardiac toxicities experienced while on 5FU therapy) and/or to oxaliplatin (known peripheral neuropathy), an uncontrolled serious systemic disease, or psychiatric or psychological disorders interfer- ing with reliable follow-up could not be included in the study.",NA,NA
15205598,NA,Combination,No,metastatic colon cancer,"Patients with stage IV colon cancer who were newly diagnosed or had progressed on 5-FU-based chemotherapy were eligible for this study. The protocol was initiated in September 1999 and closed to accrual in August 2001, with a total of 11 evaluable and eligible patients enrolled. Patients were eligible if they had histologically defined metastatic colon cancer, bidimensionally measurable disease, normal white blood cell and platelet counts, normal creatinine, and SWOG/ECOG performance status 2 or less. ","Pregnant patients and patients who had received prior therapy with, or had known hypersensitivity to, a topoisomerase I inhibitor were ineligible.",NA,NA
28854070,NCT01327781,Combination,No,Women With Endocrine-Refractory Metastatic Breast Cancer,"This study enrolled women age ≥ 18 years with histologically confirmed ER-positive (> 1% nuclear staining) MBC or locally recurrent breast cancer that was either measurable or evaluable. Additional eligibility criteria included: Eastern Cooperative Oncology Group performance status of 0 to 1, adequate blood chemistries (absolute neutrophil count ≥ 1,000/μL; platelet count ≥ 75,000/μL; total bilirubin ≤ 1.5 × institutional upper limit of normal [ULN]; total AST and ALT ≤ 2.5 × ULN [5 × ULN if liver function test elevations resulted from live metastases]; and creatinine ≤ 1.5 × ULN).","Exclusion criteria included: uncontrolled brain metastases or tumors involving the spinal cord or heart; systemic anticancer therapy or radiation therapy within 3 weeks before registration; prior endoxifen treatment, clinically symptomatic cataracts requiring imminent surgery, or bisphosphonate or denosumab use < 90 days before registration; active deep venous thrombosis and/or pulmonary embolus requiring anticoagulant therapy or history of coagulopathy; uncontrolled intercurrent illnesses; and other invasive malignancy diagnosed or recurring < 2 years before registration. Women who were pregnant or breastfeeding were not eligible.",during the first cycle of treatment,NA
15274409,NA,Combination,No,Locally Advanced and Metastatic Pancreatic Cancer,"Patients included in the study, between 18 and 75 years of age, had to have a histological or cytological diagnosis of pancreatic adenocarcinoma, locally advanced or metastatic, not amenable to surgery of curative intent and had to be chemonaive with a performance status of 60 or higher. They had to have an estimated life expectancy of at least 12 weeks and adequate bone marrow reserve. Lesions serving as measurable disease had to have been at least one cm by one cm as defined by imaging techniques (CT or MRI) or physical examination. Patients had not to have central nervous metastases, serious concomitant systemic disorders, second primary malignancy, ascites or third space fluid. Informed consent was obtained from all patients.",NA,during the first course,NA
16596209,NA,Combination,No,advanced colorectal cancer,"Inclusion criteria were: histologically confirmed diagnosis of CRC with clinical evidence of metastatic disease; age between 18 and 75 years; World Health Organization (WHO) performance status 2 (3x103/mm3 WBC count, 1.5x103/mm3 neutrophils, 100x103/mm3 platelets, 10 g/dl hemoglobin, 1.3 mg/dl serum creatinine, 1.5 mg/dl serum bilirubin, AST and ALT (2.5-fold the normal value; life expectancy of more than 3 months.","Pregnant and breast-feeding women were excluded from the study, as were patients with a history of myocardial infarction.",the entire treatment,NA
15596912,NA,Combination,No,Patients With Advanced Gastrointestinal Carcinomas,"Patients with histologically proven inoperable carcinoma of the GI tract (apart from colorectal carcinoma) could enter the study. They should have Eastern Cooperative Oncology Group performance status of 0–2, normal serum creatinine, absolute neutrophil count (ANC) ≥1500/μL, platelets (PLT) ≥100.000/μL, bilirubin ≤2× upper normal limit, and serum transaminases ≤2.5× upper normal limit. Patients with brain metastases, heart failure, uncontrolled infection, pregnancy, neuropathy, or concurrent or previous malignancies were not allowed. Only 1 line of previous chemotherapy, not containing cisplatin or infusional 5FU, was allowed. All patients gave their informed consent before entering the study.",NA,NA,NA
16319513,NA,Combination,No,Patients with Advanced Gastric Cancer,"Tumor assessment was performed within 4 weeks before entry, and a complete blood cell count, liver and renal function tests were done within 2 weeks prior to entry. Patients enrolled in this study were required to fulfi ll the following criteria: (1) histologically proven unresectable locally advanced or metastatic gastric adenocarcinoma with assessable lesions, (2) performance status of 2 or less on the Eastern Cooperative Oncology Group scale, (3) life expectancy of at least 3 months, (4) age of 75 years or younger, (5) any prior chemotherapy except for taxanes completed 4 weeks or more before entry, (6) adequate bone marrow function (white blood cell count 4,000–12,000/mm 3 , platelet count >= 100,000/mm 3 and hemoglobin >= 8.0 g/dl), hepatic function (total bilirubin <= 1.5 mg/dl, serum transaminases <= 100 u/l) and renal function (serum creatinine <= the upper institutional limit), (7) tolerance of oral feeding, (8) no other severe medical conditions, (9) no other concurrent active malignancy, and (10) provision of written informed consent. This study was approved by the institutional review board of each hospital involved.",NA,during the fi rst 2 courses,NA
14581279,NA,Combination,No,"patients with solid tumors. Primary site: Colorectal 21, Pancreas 8, Gastric 5, Other gastointestinal (esophageal (one), cholangiocarcinoma (two) and primary peritoneal carcinoma (one)), Other 7 (breast (one), ovarian (one), renal (one), adenocarcinoma of unknown primary (one), uterine (one), mesothelioma (one) and tonsil (one))","Eligible patients were required to have histologically confirmed advanced solid malignancy, age ≥18 years, measurable or evaluable disease, Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2, and adequate organ function as defined by absolute neutrophil count (ANC) ≥1500/μl, platelet count ≥100 000/μl, and bilirubin and creatinine within insti- tutional normal limits.","Patients were excluded if they had brain metastases, allergy to platinum compounds or clinical neuropathy, as were pregnant or nursing women. Patients of childbearing age were required to practice contraception.",cycle 1 ,NA
23260601,NA,Combination,No,Children With Endemic Burkitt Lymphoma in Malawi,"Children aged 3 to 15 years with expanding maxillary or mandib- ular masses, no previous history of cancer treatment, and a Lansky performance score35 of 50 or greater were eligible for the study. Although pathologic specimens were sent for histologic confirmation of BL, treatment was initiated presumptively per standard of care, as pathologic confirmation can take 6 to 8 weeks. Minimum laboratory requirements for study inclusion were a hemoglobin level of 7 g/dL (after 10 mL/kg of whole blood transfusion if needed), white blood cell count of 2000 cells/uL, absolute neutrophil count (ANC) of 1000 cells/uL, and platelet count of 50,000 cells/uL. The maximum creatinine level allowed was 2.0 mg/dL.","Subjects were excluded for CNS symptoms (facial weakness, nonreactive pupil, marked visual changes), known intolerance to study medications, or if they were receiving other investigational drugs.",through days 35 to 38,NA
15613903,NA,Combination,No,patients with advanced gastric cancer,"The inclusion criteria included histologic or cytologic documentation of gastric adenocarcinoma, metastatic disease, no history of palliative chemotherapy, presence of at least one measurable lesion and age 18–75 years. Measurable lesions were defined as those lesions that could be measured in at least one dimension as >= 20 mm with conventional techniques or >= 10 mm with spiral computed tomography (CT). Previously irradiated lesions were not considered as measurable target lesions. Other criteria included an Eastern Cooperative Oncology Group (ECOG) performance status score <= 2, absolute neutrophil count (ANC) >= 1.5 x 109/l, platelets >= 100 x 109/l, serum creatinine <= 1.5 x upper limit of normal (ULN), total bilirubin <= 1.5 x ULN, and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN ( <= 5.0 x ULN with hepatic metastasis). Patients must have recovered from the effects of recent surgery (at least 2 weeks apart) and radiotherapy (at least 4 weeks apart). Patients with previous adjuvant or neoadjuvant chemotherapy were included if they had not been treated for more than 6 months between the end of adjuvant chemotherapy and first relapse. Patients could complete the initial work-up within 2 weeks of the first therapy for imaging studies, and within 14 days of the first therapy for clinical evaluation and biological work-up. CT scans and radiographs were mandatory for disease assessment. Imaging studies were conducted every 2 months. Complete blood count was checked before each OXA infusion. Biochemical analyses were performed every month. All patients must sign informed consent before beginning of the protocol procedure. This study was approved by the Scientific and Research Ethics Committees of the participating institutions.","Patients with the following were excluded: life expectancy < 3 months; central nervous system (CNS) metastasis (including clinical suspicion); bone metastasis only; pregnancy or breast-feeding; clinically detectable peripheral neuropathy > 2 on the Oxaliplatin Specific Neurological Scale; concomitant illness that might be aggravated by chemotherapy; active cardiac disease (e.g. angina or myocardial disease) within the 6-month period preceding entry into the study; active infection and history of other malignancy, except curatively treated non-melanoma skin cancer or cervical carcinoma in situ; unfit mental status; hypersensitivity to any component of the chemotherapeutic regimen; intestinal obstruction, malabsorption or any condition that would prevent oral intake of the study drugs.",during the first cycle of treatment,NA
15014353,NA,Combination,No,"patients with advanced pancreatic cancer or other solid tumors. Primary site: pancreas, gallbladder, hepatocellular, head and neck, gastric, melanoma, breast","Patients with a histologically or cytologically confirmed diagnosis of a solid tumor refractory to conventional treatment or for which no standard therapy existed were eligible for this phase I study. Other eligibility criteria included the following: age >= 18 years, Karnofsky performance status (KPS) of >= 60, life expectancy of at least 12 weeks; no chemotherapy, immunotherapy or radiotherapy for at least 4 weeks prior to entry into the study (6 weeks for nitrosureas or mitomycin C); no concurrent therapy including chemotherapy, immunotherapy, radiotherapy or any other investigational drug; no prior therapy with a topoisomerase I inhibitor; measurable or evaluable disease; adequate hematopoietic (absolute granulocyte count of >= 1500/mm3 and platelet count >= 100 x 109/l), renal (creatinine of <= 1.5 mg/dl) and hepatic function (bilirubin <= 2.0 mg/dl); negative pregnancy test documented prior to study entry for premenopausal women; men and women who were fertile must have used adequate contraception. ","Exclusion criteria included patients with brain involvement or leptomeningeal disease; progressive sensory neuropathy or hearing loss; serious illnesses or medical conditions including uncontrolled diabetes, hypertension or arrhythmias, congestive heart failure or unstable angina, active infection, prior invasive malignancies within 5 years with an exception of curatively treated basal or squamous cell carcinoma of skin or carcinoma in situ of the cervix.",the first 4 weeks (2 biweekly cycles),NA
15961435,NA,Combination,No,Patients with Advanced or Recurrent Gastric Cancer,"Patients in this study had histologically proven metastatic gastric cancer with/without measurable lesions. Other inclusion criteria were: age 20–75 years, Eastern Cooperative Oncology Group (ECOG) performance status <2, life expectancy >2 months, adequate bone marrow function (white cell count >4000/mm3, platelet count >100 000/mm3 and hemoglobin level >9.0 g/dl), adequate renal function (creatinine clearance >50 ml/min), adequate hepatic function (bilirubin level <1.5 mg/dl, and GOT and GPT less than twice the upper limit of normal), >1 month interval since prior chemotherapy, and no active cancer in other organs. All patients gave written informed consent conforming to institutional guidelines indicating that they were aware of the investigational nature of the study. ",NA,NA,NA
16145066,NA,Combination,No,Patients With Advanced Gastric Carcinoma,"All patients with advanced, unresectable, histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction were eligible if they were >= 18 years of age and had a Karnofsky performance score of >= 70, a life expectancy of >= 12 weeks, an absolute granulocyte count of more than 1,500/L, a platelet count of more than 100,000/L, a hemoglobin level of more than 9.0 g/dL, a serum bilirubin level of less than 1.5 x the upper limit of normal (ULN), and a normal creatinine level. Patients also were required to have transaminases less than 2.5 x the ULN (< 5 x the ULN in case of liver metastases). Presence of measurable cancer was not a requirement. Only patients who could swallow tablets were eligible. All patients were told to practice medically effective contraception. A written informed consent was required","Patients were excluded if they had brain metastases, had severe comorbid conditions, or lacked the ability to comply. Patients receiving concurrent inducers or inhibitors of enzyme CYP2A6 were excluded.",during the first cycle,NA
15719490,NA,Single Drug,No,locally advanced head and neck cancer,"Patients were eligible for the study if they had stage III or IV squamous cell carcinoma of the head and neck, if the tumour was considered non-resectable by a team consisting of head and neck surgeons and radiothera- pists, or if patients refused hospital admission or were considered unfit for more intensive chemotherapy regimens. Further entry criteria were: age > 18 years, World Health Organisation (WHO) Performance Status of <2, adequate bone marrow function (haemoglobin > 7mmol/l, white blood cell count (WBC) > 3.0 x 109 cells/l and platelets > 100 x 109 cells/l) adequate renal function (serum creatinine < 1.25 x the upper limit of normal (ULN) and a calculated creatinine clearance >1.08 ml/s) and adequate hepatic function (bilirubin < 1.25 x ULN,aspartate amino-transferase (ASAT)/alanine aminotransferase (ALAT) < 2.5 ULN).",Excluded were patients at risk for renal impairment (e.g. patients with known hydronephrosis or with one kidney) as were patients with a systemic or psychiatric disorder considered to have a contraindication to enter the study. Concomitant use of folic acid or folinic acid as a nutrition supplement was not allowed,the full treatment,NA
15297392,NA,Combination,No,Patients with Poor-Prognosis Cancer of the Head and Neck,"Patients were discussed in a multidisciplinary conference (at each individual institution), with a pathologist and medical, radiation, and surgical oncologists, to determine stage, optimal management and protocol eligibility. Patients were eligible if they had histological or cytological documentation of a malignant neoplasm located in the head and neck that required locoregional radiotherapy. Measurable disease was not required. Prior radiation therapy, chemotherapy (including 5-fluorouracil and/or paclitaxel), and/or surgery did not preclude enrollment. Patients presenting with new primary head and neck cancer were eligible if they had unresectable disease or an expected 2-year survival of <20%. Patients with metastatic disease or coexisting malignancies were eligible if the predominant site of head and neck cancer and associated symptoms required local treatment with radiation therapy. A Cancer and Leukemia Group B (CALGB) performance status <=2 was required. ","Patients were excluded if they had a white blood cell (WBC) count <=3,000/ul, absolute neutrophil count (ANC) <=1,500/ul, platelet count <=100,000/ul, creatinine >2.0 mg/dl, total bilirubin >1.5 mg/dl, or transaminase concentrations >2.5 times the upper limit of normal. Pregnancy was an absolute contraindication",in cycles in which gemcitabine was delivered,NA
15108040,NA,Combination,No,patients with metastatic colorectal cancer,"The main eligibility criteria included a histologically confirmed diagnosis of CRC with metastatic disease; age, 20 to less than 75 years; Eastern Cooperative Oncology Group (ECOG) performance status, 2 or less; measurable disease; leukocyte count, 3500/mm3 or more; neutrophil count, 1500/mm3 or more; platelet count, 100000/mm3 or more; serum creatinine 1.5mg/dl or less; serum bilirubin 2.0mg/dl or less and aspartate aminotransferase (AST) 100IU/l or less, alanine aminotransferase (ALT), 100IU/l or less; and a life expectancy of 3 months or more. Previous use of fluoropyrimidine derivatives was allowed. This study was approved by the local ethics committee, and patients were informed of the investigational nature of the study and provided their written informed consent before registration in the study","Patients with the following criteria were not eligible: central nervous system metastasis, unresolved bowel obstruction or diarrhea, and known contraindications to fluorouracil (angina pectoris, myocardial infarction in the past 6 months).",during cycles 1 and 2,NA
16141295,NA,Combination,No,Patients with Advanced Gastric Cancer ,"Before entry, tumor size was determined by chest or gastrointestinal X-ray film, endoscopic examination of the upper gastrointestinal tract, computed tomographic (CT) scan of the abdomen, barium enema and bone scintigram. A complete blood cell count, liver and renal function test, and urinalysis were performed within 7 days before entry. The eligibility criteria were as follows: age 20–75 years; histologically proven unresectable locally advanced or metastatic gastric adenocarcinoma; no previous chemotherapy, except adjuvant chemotherapy >30 days before entry; adequate organ function, defined as hemoglobin >8 g/dl, leukocyte count >4000–12 000/mm3, platelet count >100 000/mm3, serum bilirubin level <1.5mg/dl, serum transaminase (aspartate aminotransferase and alanine aminotransferase) <100/UI, alkaline phosphatase < twice the upperlimit of the normal range (ULN) of each hospital, serum creatinine level less than the ULN of each hospital; Eastern Cooperative Oncology performance status 0–1; expected survival period >3 months; and written informed consent from the patients. ",Patients with symptomatic brain metastases were not eligible.,during the first course,NA
15028404,NA,Combination,No,"patients with inextirpable non-rectal gastrointestinal cancer. Tumour sites included pancreas, biliary tract, duodenum and colon.","Eligible patients had histologically confirmed surgically inextirpable GI adenocarcinoma in which all known disease could be incorporated within a radiation target. Tumour sites included pancreas, biliary tract, duodenum and colon. Further adenocarcinomas in the abdomen with unknown primary site could be included (Table 1). Patients with inextirpable lesions and patients with residual disease after surgery could be included. Other eligibility criteria were age between 18 and 80 years, ECOG/WHO performance score 0 –2, life expectancy of at least 3 months, absolute neutrophils (ANC) count > 2.0 x 109/l, platelet count > 100 x 109/l, total bilirubin level < 1.25 x upper normal limit, S-ASAT < 2.0 x upper limit, S-ALAT < 2.0 x upper limit, alkaline phosphat- ase < 2.0 x upper limit, serum creatinine < 1.25 x upper limit and informed consent. The trial was approved by the regional ethics committees. ",Patients with distant metastasis or prior malignancies (excluding localised epithelial skin or cervical cancer) or prior non-surgical anti-neoplastic treatment were excluded. ,the entire chemoradiation course,NA
15122078,NA,Combination,No,patients with metastatic colorectal cancer,"Eligible patients were at least 18 years old, had pathologically confirmed metastatic adenocarcinoma of the colon or rectum, and had an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. In addition, they had adequate organ function, as indicated by absolute neutrophil count (ANC) ≥1,500/µL, platelet count ≥100,000/µL, serum creatinine ≤2.0 mg/dL, serum bilirubin ≤1.5 mg/dL, and serum alanine aminotransferase ≤2.5 times higher than the upper limit of normal (except in cases with liver involvement, when a value ≤5 times the upper limit of normal was accepted). Other eligibility criteria were full recovery from previous surgery (at least 2 weeks) or radiation therapy (at least 4 weeks), evaluable disease or at least one bidimensionally measurable lesion larger than 2.0 × 2.0 cm and not previously irradiated, and no more than one prior chemotherapy regimen for locally advanced or metastatic disease. Patients whose disease had progressed while they were undergoing adjuvant chemotherapy or within 6 months of its completion were considered to have received treatment for metastatic disease.","Patients who had previously been treated with irinotecan or oxaliplatin or with radiation therapy to the pelvis were excluded from the study, as were pregnant or breast-feeding women. Other exclusion criteria were clinically apparent brain or leptomeningeal metastases, prior malignancies other than nonmelanoma skin cancer or in situ cervical cancer within the previous 5 years, uncontrolled infection or diabetes mellitus, serious psychiatric disorders, myocardial infarction within the previous 6 months, heart failure, and history of epilepsy or use of anticonvulsant medications. Patients with known Gilbert’s syndrome were also excluded from participation because of reports of excessive irinotecan toxicity in such patients ",within the first course of treatment,NA
15942632,NA,Combination,No,metastatic pancreatic cancer,"Patients with histopathologically proven APC with distant metastasis were eligible for the study. Other eligibility criteria included: 20 –74 years of age, Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less (ambulatory and capable of self-care), estimated life expectancy of more than 2 months, adequate renal function (normal serum creatinine and blood urea nitrogen levels), liver function (total bilirubin level <=2.5 times upper normal limit (UNL) or <=3 times UNL after biliary drainage if the patient had obstructive jaundice and serum transaminases (GOT, GPT) levels <=2.5 times UNL or <=3 times UNL), bone marrow reserve (white blood cell count between 4000 and 12 000 mm-3, neutrophil count >=2000 mm-3, platelet count >=100 000 mm-3 and haemoglobin level >=9.5 g dl-1) and pulmonary function (PaO2>=70 mmHg). If the patients had a previous history of cancer treatment, that treatment (tumour resection, chemotherapy, immunotherapy, or radiotherapy) had to have been discontinued for at least 4 weeks before entry into the study. All subjects provided written informed consent.","The exclusion criteria were as follows: pulmonary fibrosis or interstitial pneumonia, marked pleural or pericardial effusion or marked peripheral oedema, severe heart disease, difficult to control diabetes mellitus, active infection, pregnant or lactating females, women of childbearing age unless using effective contraception, severe drug hypersensitivity, metastases to the central nervous system, severe neurological impairment or mental disorder, active concomitant malignancy and other serious medical conditions.",during the first treatment cycle,NA
15014354,NA,Combination,No,patients with advanced colorectal cancer (aCRC) andappendiceal adenocarcinoma,"Male or non-pregnant female patients with aCRC and appendiceal adenocarcinomas were eligible for the study if they were aged >= 18 years, had a WHO performance status <= 2 and >= 4 weeks had elapsed since the last administration of chemotherapy ( >= 8 weeks if treated with nitrosoureas or mitomycin C). Patients may have received prior adjuvant therapy or treatment for metastatic disease (5-FU-based regimen and/or irinotecan).","Exclusion criteria included severe recurrent infection or recent surgery (<4 weeks), inadequate renalfunction (serum creatinine clearance < 65 ml/min), insufficient hepatic function [bilirubin > 1.5 mg/dl, or serum glutamic-oxaloacetic transaminase (SGOT) > 2.5  upper limit of normal (ULN), or > 5  ULN for subjects with known liver metastases], impaired hematologic function [absolute neutrophil count (ANC) < 2000/mm3, platelets < 100 000/mm3]; concomitant anticancer therapy or folate supplements, brain metastases or prior radiotherapy to > 30% of bone marrow.",within the first cycle,NA
16009951,NA,Combination,No,Patients With Unresectable Liver Metastases From Colorectal Cancer,All patients had histologically confirmed colorectal adenocarcinoma with unresectable hepatic metastases.  Prior treatment for metastatic disease was permitted if the last dose had been administered at least 1 month before the date of pump placement. All patients provided written informed consent. ,"Patients were excluded from the study for any of the following reasons: extrahepatic disease, prior hepatic radiation, previous FUDR treatment, a Karnofsky performance score of less than 60, symptomatic peripheral sensory neuropathy, a WBC count of less than 3,000 cells/uL, a platelet count of less than 100,000 cells/uL, a serum total bilirubin level of >= 2.0 mg/dL (34.2 umol/L), and a previous or concurrent malignancy besides colorectal carcinoma (patients free of this disease for at least 5 years were considered eligible).",during the first two cycles of treatment,NA
14962716,NA,Combination,No,"patients with advanced cancer. Tumour type: Oesophagus 1, GE junction 1, Colon 10, Rectum 2, Pancreas 1, Cholangiocarcinoma 1, Lung 15","Eligible patients were at least 18 years of age with histologically-confirmed solid tumours that were refractory to standard therapy or for which no effective therapy was available. An Eastern Cooperative Oncology Group (ECOG) performance status <=2 and a life expectancy >=3 months were required. Patients had adequate bone marrow (neutrophils >= 1.5 x 109 cells/l and platelets >= 100 x 109 cells/l), kidney (serum creati- nine <= 176.8 ummol/l), and hepatic (serum bilirubin <= 25.65 ummol/l, and aspartale aminotransferase/alanine aminotransferase (AST/ALT) <=2.5 times the upper limit of normal) function. All patients had recovered from prior treatment and had received no cytotoxic chemotherapy in the previous 3 weeks (6 weeks for nitrosoureas and mitomycin C). All patients received information on the purpose and conduct of this study, and signed a written informed consent form.",NA,cycle 1,NA
29289986,NA,Combination,No,"women with endocrine‑resistant, ER+ metastatic breast cancer","Eligible patients were postmenopausal women age ≥ 18 years who had histologically confrmed metastatic or locally advanced, unresectable breast cancer that was estrogen and/or progesterone receptor positive and had progressed on at least one prior line of endocrine therapy. Unlimited prior endocrine therapies were allowed. Prior fulvestrant was not mandated. One prior line of chemotherapy was required in either the (neo)adjuvant or metastatic setting, and no more than 2 prior lines of chemotherapy were allowed in the metastatic setting. An Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1, life expectancy of ≥ 4 months, and adequate hematologic, hepatic, and renal function were required. Measurable or non-measurable disease per RECIST criteria (v.1.1) and stable treated CNS metastases were allowed. ","Patients necessitating routine use of proton pump inhibitors, H2-blockers, or pancreatic enzymes were ineligible as concurrent administration of these medications with alisertib has been associated with increased alisertib exposure",during the frst cycle of treatment,NA
15549585,NA,Combination,No,patients with metastatic colorectal cancer,"Eligible patients had histologically confirmed metastatic colorectal adenocarcinoma with measurable disease, defined as the presence of at least one index lesion able to be measured on computed tomographic (CT) scans. Other eligibility criteria included age between 20 and 75 years; Eastern Cooperative Group (ECOG) performance status of 0–2; adequate baseline bone marrow (white blood cell (WBC) count between 4000 and 12000/µl and platelets more than 100000/µl), suitable hepatic function (serum bilirubin level, 1.1mg/dl or less, and serum aspartate aminotransferase and alanine aminotransferase 100U/l or less), and suitable renal function (serum creatinine level, 1.2mg/ dl or less); and the ability to orally ingest food and liquids.","Patients who had received prior irinotecan, bolus 5-FU therapy, or pelvic radiotherapy were excluded. Patients could have previously received adjuvant fluoropyrimidinebased chemotherapy, provided that such therapy had been terminated at least 4 weeks before study entry. Patients were also excluded if they had severe pleural effusion, ascites, diarrhea, uncontrolled infection, symptomatic brain metastases, bowel obstruction, or a high risk of a poor outcome because of concomitant uncontrollable nonmalignant disease, such as diabetes, cardiac failure, or renal failure. Pregnant or breast-feeding women were also excluded",during cycle 1 or 2,NA
14676796,NA,Combination,No,patients with advanced gastric cancer,"The eligibility criteria were as follows: aged 20 –74 years; histologically proven unresectable locally advanced or metastatic gastric adenocarcinoma; no prior chemotherapy except adjuvant chemotherapy more than 30 days prior to entry; adequate organ function, defined as haemoglobin >8.0 g dl-1, leucocyte count >4 000 –12 000 mm-3, platelet count >100 000 mm-3, serum bilirubin level <1.5 mg dl-1 , serum transaminase (aspartate aminotransferase and alanine aminotransferase) <100 U l-1, alkaline phosphatase (ALP) < twice the upper limit of the normal range (ULN) of each hospital, serum creatinine level less than the ULN of each hospital, creatinine clearance >50 ml min-1; Eastern Cooperative Oncology performance status (PS) 0 –2; expected survival period more than 3 months; and written informed consent from the patients.",Patients with symptomatic brain metastases were not eligible.,during the first course,NA
16570038,NA,Combination,No,metastatic advanced gastric cancer,"Before entry, tumour size was determined by chest or gastrointestinal X-ray film, endoscopic examination of the upper gastrointestinal tract, computed tomographic (CT) scan of the abdomen, barium enema, and bone scintigram. Measurable lesions were selected according to response evaluation criteria in solid tumours (RECIST). A complete blood cell count, liver and renal function test, and urinalysis were performed within 7 days before entry. The eligibility criteria were as follows: age 20–80 years; histologically proven unresectable locally advanced or metastatic gastric adenocarcinoma; no previous chemotherapy or radiotherapy, adequate organ function, defined as haemoglobin >8 g dl-1, leucocyte count >4000–12 000 mm-3, platelet count >100 000 mm-3, serum bilirubin level <1.5 mg dl-1, serum transaminase (aspartate aminotransferase and alanine aminotransferase) <100 UI-1 , alkaline phosphatase otwice the upper limit of the normal range (ULN), serum creatinine level less than the ULN; Eastern Cooperative Oncology performance status 0– 1; expected survival period >3 months; oral intake of medicines is possible; and written informed consent from the patients. ","Patients with symptomatic brain metastases, large ascites, or pleural effusion were not eligible.",during the first course,NA
15033659,NA,Combination,No,advanced colorectal cancer,"The phase I cohort included patients with histologically confirmed solid tumors not curable with surgery or radiotherapy, or unresponsive to standard chemotherapy (maximum of one previous palliative line). Common inclusion criteria for phases I and II were as follows: age between 18 and 70 years; an Eastern Cooperative Oncology Group (ECOG) performance status (PS)≤2; a life expectancy ≥12 weeks; and adequate bone marrow function (neutrophil count ≥2000/mm3, platelet count ≥100 000/mm3, hemoglobin ≥10 g/dl), renal function (serum creatinine ≤125 μmol/l) and liver function [bilirubin level ≤1.25 × upper normal limit (ULN), serum transaminases ≤3 × ULN and prothrombin time ≥50%]. If liver metastases were present, bilirubin levels could be ≤1.5 × ULN and serum transaminases ≤5 × ULN.","The exclusion criteria for both phases were as follows: prior treatment with irinotecan or any other topoisomerase I inhibitor; severe toxicity with the same 5-FU schedule; symptomatic metastases in the central nervous system or carcinomatous leptomeningitis; previous cancer history (except for resolved cervical carcinoma or basal cutaneous carcinoma); a high risk of poor outcome due to concomitant nonmalignant disease (uncontrolled severe infection, major organic failure, ischemic cardiopathy, chronic inflammatory intestinal disease or chronic diarrhea syndrome); bowel obstruction or subobstruction; extensive pelvic radiotherapy; and lactating, pregnant women or patients with reproductive potential not implementing adequate contraceptive measures.",during the 6 weekly infusions and for 2 weeks after the last infusion,NA
16601426,NA,Combination,No,Patients With Metastatic Colorectal Cancer,"Entry onto this phase I/II trial required histologically proven, metastatic colorectal adenocarcinoma; no prior therapy for metastatic disease; Eastern Cooperative Oncology Group (ECOG) performance status <=1; age >=18 years old; and the ability to provide informed consent and comply with study related activities.","Patients were ineligible if they had an absolute neutrophil count (ANC) of less than 1500/mm3, hemoglobin less than 9 g/dL, platelet count less than 100,000/mm3; serum creatinine greater than 1.8 mg/dL or a creatinine clearance less than 60 mL/min; total bilirubin more than 1.5 times the upper limit of normal (ULN), AST greater than 3 times ULN for patients without liver metastases and greater than 5 times ULN in patients with liver metastases. Other exclusion criteria were: major surgery within 4 weeks before drug administration; treatment with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor within 2 weeks before study entry; previous treatment with any angiogenesis inhibitor; life expectancy of less than 12 weeks; contraindications to systemic 5-FU, leucovorin or irinotecan or known allergy to polyoxyl 35 castor oil (Cremophor); documented myocardial infarction or unstable angina within 12 months of study entry; New York Heart Association class 3 or 4 heart disease or atherosclerotic coronary artery disease requiring coronary artery bypass surgery within the preceding 2 years; insulin-dependent diabetes mellitus or noninsulin-dependent diabetes mellitus with clinical evidence of severe peripheral vascular disease or diabetic ulcers; colonic or small bowel disorders with uncontrolled symptoms; known central nervous system (CNS) metastases; other active malignancies, except basal cell carcinoma of the skin or in situ cervical carcinoma; or the presence of another chronic medical or psychiatric disorder, or laboratory abnormality that could result in unacceptable risks of study participation, study drug administration or interference with the interpretation of study results.",the first cycle,NA
33641211,NCT02384746,Combination,No,Advanced ER+ Breast Cancer,"Eligibility criteria: Patients were required to be postmenopausal with histologically confirmed ER‐positive, HER2‐negative metastatic or locally advanced breast cancer. Patients were required to have a favorable performance status (ECOG 0–1) without significant hematologic, hepatic, and renal impairment as measured by laboratory measurements, as well as cancer that was progressing by RECIST 1.1 criteria while taking fulvestrant for ≥56 days as the most recent line of treatment.",NA,during cycle 1 ,NA
14647137,NA,Combination,No,patients with previously treatedcolorectal and gastric cancer,"Patients eligible for this study had advanced disease of a histologically confirmed gastrointestinal adenocarcinoma. In the phase I part of this study, patients were allowed to be pretreated with any palliative chemotherapy. Objective evidence of tumour progression must have occurred while the patient was receiving chemotherapy or within 6 months from receiving the last dose of prior chemotherapy. Disease must have been bidimensional measurable in X-ray, ultrasound or computed tomography. Patients must have been between 18 and 75 years, have a performance status of 0–2 according to the ECOG criteria and a life expectancy of at least 3 months. Other inclusion criteria consisted of pretreatment neutrophile count ⩾2000 μl−1, platelet count ⩾150000 ul-1, serum creatinine concentration ⩽2.0 mg dl−1 and total bilirubin levels ⩽2.0 mg dl−1.","Exclusion criteria were known incompatibility to 5-FU or MMC, the presence of central nervous metastases, serious or uncontrolled concurrent medical illness or secondary malignancies except for basal cell carcinoma of the skin or carcinoma in situ of cervix uteri.",the first cycle,NA
15947933,NA,Combination,No,"Their median age was 59 years (range 43–69 years), and they had the following cancer diagnoses: non-small-cell lung carcinoma (five patients), colorectal carcinoma (four patients), esophageal carcinoma (two patients), and miscellaneous (four patients).","Patients with histologically or cytologically documented advanced solid malignancies refractory to conventional therapy were candidates. An accessible, biopsiable tumor was required for the CPT-11/5-FU study and was optional for the CPT-11/GEM study. Additional entry criteria included age >18 years, performance status (ECOG) 0–2 for the CPT-11/5-FU study, 0–1 for the CPT-11/GEM study, life expectancy greater than 12 weeks, no treatment with antineoplastic agents in the previous 3 weeks (6 weeks for nitrosoureas or mitomycin C), no radiotherapy in the previous 6 weeks, adequate bone marrow function defined as a white blood cell count >=3000/mm3, neutrophil count >=1500/mm3, hemoglobin >=10 g/dl, platelet count >100,000/mm3, adequate renal function defined as serum creatinine <1.6 mg/dl or creatinine clearance ‡50 ml/min, adequate liver function defined as hepatic enzymes (AST, ALT) not more than 1.5 times the upper limit of normal, bilirubin <= 1.5 mg/dl, normal cardiac function with no history of uncontrolled heart disease, and a negative pregnancy test for patients for whom pregnancy could be a possibility. Prior CPT-11 was allowed but prior 5-FU (CPT-11/5-FU study) or prior GEM (CPT-11/GEM study) was not allowed. All patients were required to give written informed consent.","Patients were ineligible if they were lactating, had had a myocardial infarction within the previous 3 months, had congestive heart failure, unstable angina, active infection requiring systemic therapy, history of a second malignancy within the past 5 years other than non-melanoma skin cancer, or carcinoma in situ of the cervix.",the first cycle only,NA
16549999,NA,Combination,No,"patients with advanced or metastatic solid tumors. Tumor types: Colorectal 13, Gastric adenocarcinoma 5, Pancreatic adenocarcinoma 2, Head and neck squamous cell 2, Others 5","Patients enrolled onto the study had histologically proven advanced solid tumor having previously failed standard treatment or for whom no established curative therapy exists; age > 18 years old; life expectancy of at least 12 weeks; ECOG performance status (PS) 0–1; adequate bone marrow reserve (absolute neutrophil count > 2000/mm3, platelet count > 100 000/mm3); adequate renal and hepatic function [serum creatinine < 1.5 upper limit of normal range (ULN), serum bilirubin < 1.5 ULN and serum transaminases < 2.5 ULN]. A washout period since previous chemotherapy or radiotherapy of 4 weeks was required.",Exclusion criteria included previous exposure to oxaliplatin or any fluoropyrimide derivate; known hypersensitivity to platinum derivates; presence of central nervous system metastases; serious or non-controlled concurrent medical illness; peripheral neuropathy WHO grade > 2 at the study entry and history of other malignancies except in situ cervical carcinoma or basal/spindle cell carcinoma of the skin.,the first cycle,NA
34417914,NA,Combination,No,pancreatic adenocarcinoma,"Patients recruited were age 18 years and older, had cytologic or histologic confrmed diagnosis of PC and received no prior treatment for metastatic pancreatic adenocarcinoma and had an Eastern Cooperative Oncology Group (ECOG) performance of status of 0 or 1. Patients who had received gemcitabine in the neoadjuvant or adjuvant setting were considered. Patients were required to have measurable disease by RECIST version 1.1, adequate blood and organ function, and ability to swallow capsules.","Patients were excluded if they have had primary brain tumors, clinical evidence of active brain metastasis, major surgery within 4 weeks of the start of the study, secondary malignancy within the past 3 years, active infection with of hepatitis B or C or human immunodefciency virus, or high-risk cardiovascular disease including congestive heart failure (New York Heart Association class III or IV), cardiac arrhythmia, or coronary artery disease",cycle 1,NA
30635165,NCT01908478,Combination,No,locally advanced pancreatic cancer,"Patients with histopathological or cytological diagnosis of adenocarcinoma of the pancreas, as well as those with high clinical suspicion of adenocarcinoma, which is deemed locally advanced unresectable or borderline resectable as determined by a pancreatic cancer surgeon and/or following evaluation by a GI oncology tumor board. Age 18 years or older","Patients who have had prior anti-cancer treatment for their disease. Patients who are currently receiving any other investigational agents. Metastatic disease. History of allergic reactions attributed to compounds of similar chemical or biologic composition to PARP [Poly (ADP-ribosome) polymerase] inhibitors or gemcitabine. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",within first 6 weeks,NA
17119113,NA,Combination,No,patients with Epstein-Barr virus–associated lymphoid malignancies,"ligibility for this combination therapy included the following criteria: (1) a microscopically documented neoplasm, which was EBV+ as determined by immunohistochemistry (EBNA-2+ and/or LMP-1+); (2) presence of evaluable disease; (3) patients with lymphoma must have been refractory to at least one combination chemotherapy regimen, which could include high-dose chemotherapy and marrow or stem-cell rescue or stem-cell transplantation, or immunotherapy, and were deemed incurable by standard therapy; (4) patients must have recovered from prior chemotherapy or radiotherapy and at least 3 weeks must have elapsed since the last course of chemotherapy; (5) adequate bone marrow function (absolute neutrophil count [ANC] > 1.0 × 109/L, platelet count > 50 × 109/L); (6) adequate hepatic function (total bilirubin level < 25.65 μmol/L [< 1.5 mg/dL], serum aminotransferases < 2 times the upper limit of normal); (7) adequate renal function (serum creatinine 265.2 μmol/L [< 3.0 mg/dL]), and calculated creatinine clearance 0.5 mL/second (> 30 mL/minute). There were no limitations on functional status for eligibility. Male or female patients at least 3 years of age were eligible. The study was conducted under an IND from the US Food and Drug Administration.",NA,NA,NA
31338636,NA,Combination,No,patients with previously untreated metastatic pancreatic cancer,"Patients with histologically documented stage IV ductal adenocarcinoma of the pancreas who had not received prior therapy for the treatment of this disease were eligible to participate. Patients were required to be >18 years old, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, have measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, and adequate hematologic, hepatic and renal function.","Given the target of vantictumab and the anticipated adverse effects associated with this drug related to bone fracture risk, the following patients were excluded: those with osteoporosis by DEXA scan, bone metastases and prior pathologic fracture or lytic lesion requiring impending orthopedic intervention, treatment with thiazolidinedione PPAR gamma inhibitor or long-term glucocorticoid, fasting B-C-terminal telopeptide (B-CTX, a bone turnover marker) of >1000 pg/mL, and history of metabolic bone disease.",in the first cycle (28 days) of treatment,NA
20708924,NA,Combination,No,children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas,"Patients >=3 and <=21 years of age with a newly diagnosed non-disseminated BSG or incompletely resected STMG were eligible. Other eligibility criteria included Kamofsky or Lansky performance score >= 50%, no prior chemotherapy (except corticosteroids) or radiotherapy, adequate bone marrow, renal and hepatic function. ",Patients who could not be pregnant have an uncontrolled infection or a history of deep venous or arterial thrombosis.,courses 1 and 2,NA
32772340,jRCTs 031180095,Combination,No,pancreatic cancer with peritoneal metastasis,"This study enrolled patients with peritoneal metastasis irrespective of the primary and extraperitoneal tumor status. The inclusion criteria were as follows: 1) histologically or cytologically-proven pancreatic adenocarcinoma; 2) no previous history of antitumor treatment other than surgery and adjuvant chemotherapy; 3) peritoneal metastasis confirmed by diagnostic imaging, staging laparoscopy or laparotomy; 4) age of ≥20 years and < 75 years; 5) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1; 6) adequate bone marrow function (white blood count ≥3000/mm3 and ≤ 12,000/mm3, neutrophil count ≥1500/mm3, hemoglobin ≥9.0 g/dl and platelet count ≥100,000/mm3), liver function (total bilirubin ≤2.0 mg/dL and aspartate/alanine transaminases ≤2.5 times ULN) and renal function (creatinine clearance ≤50 ml/min); 7) oral intake.","The exclusion criteria were as follows: 1) contraindication for GEM, nab-PTX or PTX; 2) active concomitant malignancies; 3) a history of drug hypersensitivity to iodine or gadolinium contrast agent; 4) blood transfusion or granulocytecolony stimulating factor usage within 7 days before enrollment; 5) concurrent severe diseases such as active infection, cardiac or respiratory disease; 6) pregnancy or lactation.",during cycle 1,NA
15744591,NA,Single Drug,No,"patients with solid tumors. The most common tumor types were NSCLC (5 patients), colon cancer (4 patients), breast and endometrial cancer (3 patients each)","Patients were selected based on the following eligibility criteria: histologically and/or cytologically documented advanced or metastatic solid tumors known to be associated with EGFR overexpression (testing for receptor status prior to entry was not required) for which no curative therapy existed, clinical or radiological assessable disease, tumor biopsy within 2 days of registration, age ≥ 18 years, ECOG performance status 0 to 2, 28 days must have elapsed since prior anti-cancer therapy, recovery from treatment related toxicities. All patients had absolute neutrophil count ≥ 1.5 × 109/L, platelets ≥100 × 109/L, bilirubin ≤ 1.25 × upper limit of normal (UNL), AST/ALT/alkaline phosphatase ≤ 2.5 × UNL (≤5 × UNL if documented liver metastases or bone metastases (alkaline phosphatase)), serum creatinine ≤ 1.25 × UNL and creatinine clearance >50 ml/min, PT/INR, PTT within normal limits. Patients had baseline ophthalmologic examination, left ventricular ejection fraction>50% and an unremarkable ECG (significant cardiac history), negative pregnancy test (if applicable) and were using adequate birth control measures.","Patients were excluded if they: had a history of previous or concurrent malignancies within 5 years (excluding curatively treated basal or squamous cell carcinoma of the skin or cervical cancer), were pregnant or lactating; had untreated or symptomatic brain or meningeal metastases, had infections, significant medical or corneal or skin conditions, arrhythmias, liver disease (excluding liver metastases), were receiving concurrent treatment with other experimental drugs or anti-cancer therapy, or had had ocular radiation.",NA,NA
23261229,NA,Combination,No,patients with advanced non-small cell lung cancer,"Patients with histologically confirmed unresectable NSCLC pretreated with a first-line platinum based doublet regimen were eligible for the study. Further inclusion criteria included age ≥18 years, an Eastern Cooperative Oncology Group (ECOG) performance status score of 0–2, at least once unidimensionally measurable lesion, and completion of prior treatment at least 2 weeks prior to study entry. ","Patients with ≥3 prior chemotherapy, prior anti-EGFR herapy, uncontrolled or symptomatic central nervous system metastases, active pulmonary fibrosis, uncontrolled heart disease, and inadequate hematologic, hepatic, or renal function were excluded",during the first cycle,NA
25784657,NCT00372515,Combination,No,patients with leptomeningeal metastases from non-small cell lung cancer,"Eligible patients were ≥ 18 years of age with histologically or cytologically confirmed non-small-cell lung cancer; a previously documented somatic EGFR mutation or documented partial or complete response to prior therapy with an EGFR-TKI; ECOG performance status 0–3; and cytologically confirmed leptomeningeal metastases. Other eligibility criteria included white blood cell count ≥ 3,000/mL; hemoglobin ≥ 9.0 g/dL; platelet count ≥ 80,000/ mL; creatinine ≤ 1.5 mg/dL; AST, ALT, and total bilirubin ≤ 1.5 times the institutional upper limit of normal; international normalized ratio ≤ 1.5; and activated thromboplastin time < 50 seconds. At least 2 weeks must have passed since prior radiation therapy, and at least 3 weeks must have passed since prior major surgery.","Patients were excluded for a history of prior gefitinib- or erlotinib-related toxicity that had led to a dose reduction or interruption; uncontrolled brain metastases that were associated with mass effect that would contraindicate lumbar puncture; history of other malignancy within the past five years, except for definitively treated non-melanomatous skin cancers or carcinoma in situ of the uterine cervix; a gastrointestinal disorder that might compromise absorption of gefitinib; any condition requiring concurrent or ongoing use of anticoagulation; pregnancy or breastfeeding; or any severe or unstable medical condition.",cycle 1,NA
33523334,NCT02624492,Combination,No,patients with relapsed/refractory diffuse large B-cell lymphoma,"Eligible patients were aged 18 years or older and had histologically confirmed relapsed/refractory DLBCL (including transformed follicular lymphoma). ‘Relapsed’ was defined as the appearance of any new lesion after attainment of an initial complete response (CR) and ‘refractory’ was defined as < 50% decrease in lesion size with prior anti-lymphoma treatment in the absence of new lesion development. All patients had previously been treated with an anti-CD20 monoclonal antibody in combination with anthracycline-containing chemotherapy and were either ineligible for high dose therapy and ASCT or had relapsed/progressed after an autologous/allogeneic stem cell transplant. Allogeneic stem cell transplant performed at least 6 months prior to study entry was permitted if patients did not require immunosuppressive treatment and had no evidence of active graft-versus-host disease. Patients were required to have Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, acceptable organ function, and a screening CT scan with involvement of at least one bi-dimensional lesion/node of > 1.5 cm.","Key exclusion criteria were: prior history of malignancy other than DLBCL; known central nervous system involvement; and receipt of anti-lymphoma treatment either within 14 days or, in the case of an investigational agent, less than five half-lives of the investigational drug, prior to the first dose of the current trial medication",during the MTD evaluation period (cycle 1),NA
34066784,NCT02109341,Combination,No,metastatic Pancreatic Cancer,"Eligibility criteria included age ≥18 and ≤75; a histological or cytological diagnosis of mPC with measurable disease defined according to the Response Evaluation Criteria in Solid Tumor (RECIST version 1.1 guidelines)  and no previous treatment for metastatic disease; an Eastern Cooperative Oncology Group (ECOG) PS score of 0 or 1, absence of previous abdominal radiotherapy on target lesions, absence of heart failure or unstable angina, or infarction within 12 months previous to inclusion; adequate organ function, including hematologic (absolute neutrophil count (ANC) ≥1.5 × 109/L, platelets ≥100 × 109/L), hepatic (bilirubin ≤1.5 times upper limits of normal (ULN), and renal (creatinine within normal limits ≤1.5 times (ULN)) values. Patients could have endoscopic or radiologic stenting to treat biliary obstructions.","Patients were not eligible if they had endocrine or acinar pancreatic carcinoma, known dihydropyrimidine dehydrogenase (DPD) deficiency, central nervous system metastases, other concomitant cancer, or history of cancer outside of carcinoma in situ of the cervix, basal, or squamous cell cancer; current active infections, serious pre-existing medical conditions or serious concomitant systemic disorders, a history of chronic diarrhea or inflammatory disease of the colon or rectum, or sub-occlusion or occlusion not resolved under symptomatic treatment; females who were pregnant or lactating were also excluded; and all subjects deprived of liberty or under guardianship or patients unable to undergo medical tests for geographical, social, or psychological reasons. Prior adjuvant treatment was allowed with tumor recurrence occurred ≥6 months after the last treatment.",during the first cycle ,NA
30068505,NCT01582776,Combination,No,in relapsed/refractory follicular B-cell lymphoma,"Eligible patients were >=18 years of age with a histopathologically confirmed diagnosis of CD20+ FL (World Health Organization grade 1, 2, or 3a) who had R/R disease after >=1 systemic treatment containing rituximab and life expectancy >=3 months. Additional inclusion criteria were an Eastern Cooperative Oncology Group performance status score of 0 to 2; adequate bone marrow, liver, and kidney function; and >=1 bidimensionally measurable lesion on computed tomography (CT) scan (greatest transverse diameter >15 mm and short axis >=10 mm). All patients were required to fulfill the lenalidomide requirements for pregnancy prevention.","The main exclusion criteria were central nervous system or leptomeningeal involvement by lymphoma, prior treatment with obinutuzumab or lenalidomide, and known CD20- status at relapse/progression. Patients were excluded if they had known infection with HIV, positive serology for hepatitis B or C, any serious active disease or comorbid medical condition (eg, severe cardiac disease), or any laboratory abnormalities not due to underlying lymphoma (eg, absolute neutrophil count <1.5 x 109/L, platelet count <=100 x 109/L, aspartate aminotransferase or alanine aminotransferase >=3.0 x upper limit of normal, serum total bilirubin >34 umol/L, or calculated creatinine clearance <50 mL/min). Patients were excluded if they had a history of other malignancies within 5 years (except for nonmelanoma skin tumors), any anticancer drug therapy within 28 days of initiation, or any corticosteroids within 4 weeks (except prednisone <=10 mg/d).",during cycle 1,NA
32758434,NCT02417285 ,Combination,No,patients with relapsed or refractory B-cell non-Hodgkin lymphoma,"Eligible patients were aged 18 years or older with measurable disease more than 1·5 cm in the longest diameter and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Eligibility criteria for the dose escalation phase included CD20-positive, histologically or cytologically confirmed diffuse large B-cell lymphoma (including transformed low-grade lymphoma or indolent non-Hodgkin lymphoma, follicular lymphoma, or marginal zone lymphoma). Patients with diffuse large B-cell lymphoma were required to have relapsed or refractory disease after two or more previous standard treatment regimens (eg, rituximab plus cyclo - phosphamide, doxorubicin, vincristine, and prednisone or similar first-line regimen and one or more salvage regimen) or autologous stem-cell transplantation in chemotherapy-sensitive patients.15 Since the primary objective of the study was to assess the safety of the combination, data on the presence of germinal centre B-cell subtype for patients with diffuse large B-cell lymphoma enrolled in the dose escalation were not collected. Patients with indolent non-Hodgkin lymphoma had to have relapsed or refractory disease after one or more previous standard systemic treatment regimens, including chemotherapy, immunotherapy, or chemoim- munotherapy. Eligibility criteria for the dose expansion phase included patients with CD20-positive, histologically confirmed follicular lymphoma (grade 1, 2, or 3a) with relapsed or refractory disease after one or more previous standard systemic treatment regimens, including chemo - therapy, immunotherapy, or chemo immunotherapy.15 Patients must also have had adequate haematological, hepatic, and renal function measured by the following: absolute neutrophil count at least 1·5 × 10⁹ cells per L without growth factor support for 7 days, haemoglobin at least 8 g/dL, aspartate aminotransferase and alanine aminotransferase 2·5 × upper limit of normal (ULN) or less or 5·0 × ULN or less if a liver tumour was present, serum bilirubin 1·5 × ULN or less or an estimated serum creatinine clearance of at least 60 mL/min by means of the Cockcroft-Gault equation. Lenalidomide-exposed (FL-1) patients were previously treated with two or more cycles of a lenalidomide-containing regimen, as either mono - therapy or in a combination. Patients with relapsed or refractory follicular lymphoma included patients who were lenalidomide-naive (FL-2) and had received one or more standard systemic treatments, without previous exposure to lenalidomide. Early relapse was defined as having disease progression within 24 months of the start of treatment. 7 Double-refractory patients were refractory to both rituximab and alkylating agents, as reported in previous studies. 16,17 For efficacy analyses, patients with relapsed or refractory follicular lymphoma were examined according to their risk status; relapsed or refractory follicular lymphoma that was neither early relapse nor double-refractory was considered standard risk, whereas all other patients were considered high risk.",Exclusion criteria included previous treatment with avadomide; previous systemic cancer treatments or radio- therapy 1 month before starting study drugs; previous autologous stem-cell transplantation within 3 months before first dose; symptomatic CNS involvement; persistent diarrhoea or at least grade 2 malabsorption; at least grade 2 peripheral neuropathy; symptomatic acute or chronic pancreatitis; impaired cardiac function; treatment-related myelodysplastic syn drome; and a history of malignancies (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the patient had been disease-free for at least 1 year before starting study treatment.,during cycle 1,NA
30563938,NCT01828034,Combination,No,Patients with Advanced Biliary Cancers,"Patients (age >=18 years), ECOG 0-1 with metastatic BTC, and measurable disease per RECIST (version 1.1) were enrolled (5). No prior systemic therapy for metastatic BTC was permitted. Patients who received prior chemotherapy in the adjuvant setting were eligible if more than 6 months had passed since completion of the adjuvant treatment. Patients were required to have adequate bone marrow (hemoglobin >= 8 g/dL, absolute neutrophil count >= 1,500/mcL, platelets >= 100,000/mcL), renal (serum creatinine < 1.6 mg/dL and/or measured creatinine clearance from 24-hour urine collection of > 60 mL/minute), and hepatic functions (total bilirubin <= 2 mg/dL, ALT/AST <= 5 x ULN).",Patients with biliary obstruction could join if bilirubin was corrected to required limit after adequate biliary drainage. Patients with symptomatic uncontrolled brain metastases or gastrointestinal malabsorption were excluded.,during the first cycle (21 days) ,NA
33387490,NCT03214250 ,Combination,No,metastatic pancreatic adenocarcinoma,"Subject has histologically or cytologically documented diagnosis of pancreatic adenocarcinoma with metastatic disease. Locally advanced subjects are not eligible. Subject must have measureable disease by RECIST 1.1. Subjects must be age 18 years or older. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Subjects must have the following laboratory values at screening within 2 weeks of the first dose of investigational agents: Absolute neutrophil count (ANC) ≥1.5 x 109/L (in absence of growth factor support); Platelet count ≥150 x 109/L; Hemoglobin ≥9 g/dL(without transfusion support); Serum creatinine ≤1.5 mg/dL, and creatinine clearance ≥ 50 ml/min as measured by Cockcroft and Gault formula; Aspartate aminotransferase (AST) and ALT ≤2.5 x upper limit of normal (ULN); Total bilirubin ≤1.5 x ULN, except in subjects with documented Gilbert's Syndrome, who must have a total bilirubin ≤3 x ULN. Women of childbearing potential (WOCBP) must have a negative pregnancy test (serum or urine) within the 7 days prior to study drug administration, and within the 3 days before the first study drug administration, or a negative pregnancy test within the 24 hours before the first study drug administration. WOCBP and male subjects who are sexually active with WOCBP must agree to use 2 highly effective methods of contraception (including a physical barrier) before the first dose of study drugs, during the study, and for 5 months for women and 7 months for men following the last dose of study drug. Subjects must have the ability to understand and willingness to sign a written informed consent document.","Patients meeting any of the following criteria are ineligible to participate in this study: 1. Patient must not have received any prior treatment, including chemotherapy, biological therapy, or targeted therapy for metastatic pancreatic adenocarcinoma, with the following exceptions and notes: a. Patients who have received prior adjuvant therapy for pancreatic adenocarcinoma are eligible if neoadjuvant and adjuvant therapy (including chemotherapy and/or radiotherapy) was fully completed more than 4 months before the start of study treatment. In this case, prior Gem and/or NP is allowable. b. Prior resection surgery is allowable. c. Patients initially diagnosed with locally advanced PC who have undergone chemotherapy then resection and were with no evidence of disease are eligible if metastatic relapse of disease has occurred and if the last dose of chemotherapy was more than 4 months before the date of study entry. 2. Patients must not have another active invasive malignancy, with the following exceptions and notes: a. History of a non-invasive malignancy, such as cervical cancer in situ, nonmelanomatous carcinoma of the skin, in situ melanoma, or ductal carcinoma in situ of the breast, is allowed. b. History of malignancy that is in complete remission after treatment with curative intent is allowed. c. No current or history of a hematologic malignancy is allowed, including patients who have undergone a bone marrow transplant. 3. History of clinically significant sensitivity or allergy to mAbs, their excipients, or intravenous gamma globulin. 4. Previous exposure to CD40, PD-1, PD-L1, CTLA-4 antibodies or any other immunomodulatory agent. 5. History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis, or history of interstitial lung disease. 6. Patients must not have a known or suspected history of an autoimmune disorder, including but not limited to inflammatory bowel disease, celiac disease, Wegner syndrome, Hashimoto syndrome, systemic lupus erythematosus, scleroderma, sarcoidosis, or autoimmune hepatitis, within 3 years of the first dose of investigational agent, except for the following. a. Patients with Type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders such as vitiligo, or alopecia not requiring systemic therapy, or conditions not expected to recur in the absence of an external trigger are eligible. b. Patients with a history of Hashimoto syndrome within 3 years of the first dose of investigational agent, which resolved to hypothyroidism alone. 7. Patients must not have an uncontrolled intercurrent illness, including an ongoing or active infection, current pneumonitis, symptomatic congestive heart failure (New York Heart Association class III or IV), unstable angina, uncontrolled hypertension, cardiac arrhythmia, interstitial lung disease, active coagulopathy, or uncontrolled diabetes. 8. Patients must not have a history of myocardial infarction within 6 months or a history of arterial thromboembolic event within 3 months of the first dose of investigational agent. 9. Patients must not have a history of human immunodeficiency virus, hepatitis B virus (HBV), or hepatitis C virus (HCV), except for the following: a. Patients with anti-hepatitis B core antibody but with undetectable HBV DNA and negative for hepatitis B surface antigen (HBsAg) b. Patients with resolved or treated HCV (i.e., HCV antibody positive but undetectable HCV RNA) 10. Patients must not have a history of primary immunodeficiency. 11. Patients must not receive concurrent or prior use of an immunosuppressive agent within 14 days of the first dose of investigational agent, with the following exceptions and notes: a. Systemic steroids at physiologic doses (equivalent to dose of oral prednisone 10 mg) are permitted. Steroids as anti-emetics for chemotherapy are not allowed. b. Intranasal, inhaled, topical, intra-articular, and ocular corticosteroids with minimal systemic absorption are permitted. c. Patients with a condition with anticipated use of systemic steroids above the equivalent of 10 mg prednisone are excluded. d. Transient courses of steroids may be approved by the Medical Monitor on a case by case basis, dependent on dose and reason. 12. Patients must not have a history of clinically manifested central nervous system (CNS) metastases. a. Patients with known or suspected leptomeningeal disease or cord compression are not eligible. 13. Patients must not have had major surgery as determined by the PI within 4 weeks before the first dose of investigational agent. 14. Patients must not have received another investigational agent within the shorter of 4 weeks or 5 half-lives before the first dose of investigational agent. 15. Patients must not have received a live attenuated vaccine within 28 days before the first dose of investigational agent, and patients, if enrolled, should not receive live vaccines during the study or for 180 days after the last dose of investigational agent.16. Females who are pregnant or lactating or who intend to become pregnant during participation in the study are not eligible to participate. 17. Patients who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient’s risk, interfere with protocol adherence, or affect the patient’s ability to give informed consent are ineligible to participate in the study.",during cycle 1,NA
18317068,NA,Combination,No,Patients with Refractory Non-small Cell Lung Cancer (NSCLC),"Patients with histologically or cytologically confirmed advanced/metastatic NSCLC were eligible. Other inclusion criteria: age >18 years; at least one prior platinum-based chemotherapy regimen; ECOG performance status 0 to 1 and a life expectancy of >=3 months; one bidimensionally mea- surable lesion, and adequate bone marrow, renal, and hepatic function.",Patients with prior anti-EGFR therapy or with history of prior hypersensitivity to chimerized or murine antibodies were ineligible,during the first treatment cycle (4 weeks),NA
17237473,NA,Combination,No,"patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer","Eligibility criteria included: histologically proven colorectal adenocarcinoma not amenable to curative surgery or radiotherapy; age ‡18 years; World Health Organisation performance status zero, one or two; unidimensionally measurable disease outside previously irradiated field as assessed by computed tomography (CT) according to the response evaluation criteria in solid tumors (RECIST) guidelines ; documented evidence of disease progression by CT within 12 weeks of the previous fluoropyrimidine or thymidylate synthase inhibitor-based chemotherapy; adequate organ function including bone marrow (white blood cells >3 x 109/l, neutrophil >1.5 · 109/l, platelet >100 · 109/l), liver [serum bilirubin <35 lmol/l, alanine transferase or aspartate transferase <2.5 x upper limit of normal range (ULN) if no demonstrable liver metastasis or <5 x ULN in the presence of liver metastasis] and kidneys (calculated creatinine clearance >60 ml/min).","exclusion criteria included prior treatment with irinotecan or other topoisomerase I inhibitors, prior treatment with EGFR-targeted agents, central nervous system metastasis, other malignancies within past 5 years, inability to take or absorb oral medications and systemic anticancer therapy within 4 weeks of study entry.",the first treatment cycle,NA
34953624,NCT02040064,Combination,No,refractory non-small cell lung cancer patients harbouring EGFR mutations,"Eligibility criteria included patients aged ≥ 18 years, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, histologically/cytologically confirmed stage IIIB-IV NSCLC with a sensitizing EGFR mutation as determined locally using a well-validated methodology, progression to prior therapy with first-generation EGFR- TKI without National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03) grade 2 or higher toxicity and proven clinical benefit (defined by either complete, partial response or stable disease (SD) lasting ≥ 4 months). Additionally, prior chemo- therapy given both upfront or between EGFR-TKI and inclusion in the study was allowed if systemic progression was documented, as well as surgery/radiotherapy if completed ≥ 6 months before the start of the study treatment (palliative radiotherapy ≥ 2 weeks). Adequate bone marrow, hepatic and renal function, and negative serology screening tests were required.","Exclusion criteria included prior treatment with any ICI, past medical history of inflammatory bowel disease or other gastrointestinal dis- orders, interstitial lung disease (ILD)/pneumonitis, autoimmune diseases or any other chronic disorder requiring systemic corticosteroids or immunosuppressors, as well as brain metastases unless asymptomatic and stable after treatment without requiring steroids.",within the first 42 days of the combination therapy initiation,NA
30488350,ACTRN12611000643976,Combination,No,Patients with Locally Advanced or Metastatic Pancreatic Cancer,"Chemotherapy-naïve, adult patients with a confirmed histological diagnosis of inoperable locally advanced or metastatic pancreatic carcinoma, were included in the current study. All patients had to have a performance status (PS) of 50-100% on the Karnofsky scale and a life expectancy of greater than 12 weeks. Patients should have had measurable or evaluable disease at screening according to Response Evaluation Criteria in Solid Tumors (RECIST) . Adequate hematological function [white blood cell count (WBC) >4000/μL, platelets (PLT) >100,000/μL, and hemoglobin (Hgb) >9.5 g/dL], liver function [total bilirubin level < 2 mg/dL, ALT and AST <2.5 x upper limits of normal (ULN)], and renal function (serum creatinine ≤1.5 mg/dL or calculated creatinine clearance >60 mL/min) were mandatory for study entry. In the presence of liver metastases, transaminase levels could be up to five times the upper limits of normal. Patients should also have had normal cardiac function (left ventricular ejection fraction within institutional normal range) and no serious cardiac illness or medical conditions in the last 6 months.","Patients with ampullary, periampullary, bile duct cancers, or endocrine tumors of the pancreas were also excluded. Other major exclusion criteria were any evidence of clinically active interstitial lung disease, pre-existing motor or sensory grade 2 neurotoxicity according to the WHO criteria, history of previous chemotherapy, and known hypersensitivity to gemcitabine. Concomitant use of CYP3A inducers (phenytoin, carbamazepine, rifampicin, barbiturates, or St John’s Wort) had to be avoided and so should treatment with strong CYP3A inhibitors. All female patients of childbearing potential should have had a negative serum or urine pregnancy test obtained within 2 days prior to the initiation of treatment and pregnant or nursing women were excluded.",during the first cycle of treatment,NA
33181832,NCT02558816,Combination,No,in relapsed and untreated patients with mantle cell lymphoma,"Age ≥18for French patients, Age ≥16 for English patients • Cohort A and B : Relapsed / refractory disease after at least one line of treatment. The relapse diagnosis (within 3 months before baseline), needs to be histologically confirmed (tumor biopsy or bone marrow biopsy) or confirmed by the presence (immunuphenotype) of circulating tumor cells on peripheral blood and/or bone marrow aspirate • Cohort C: Untreated patients with histologically confirmed mantle cell lymphoma (within 3 months before baseline). The initial diagnosis has to be confirmed according to WHO classification. • Stage II-IV in need of treatment (see Appendix 12 : Ann Arbor Staging) • ECOG performance status of 0 – 2. • Hematology values must be within the following limits: a. Absolute neutrophil count (ANC) ≥1000/mm3 independent of growth factor support; b. Platelets≥75,000/mm3 or ≥ 50,000/mm3 if bone marrow involvement and independent of transfusion support in either situation • Biochemical values within the following limits: a. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN); b. Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert’s syndrome or of non-hepatic origin; c. Serum creatinine ≤ 2 x ULN or estimated Glomerular Filtration Rate (Cockroft Gault11) ≥ 50 mL/min/1.73m2 • HIV, anti-HBc, HbsAg test negative • Life expectancy of more than 3 months. • Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with nlocal regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for at least 30 days after the last dose of venetoclax or 18 months after the last dose of obinutuzumab, whichever is longer. For males, these restrictions apply for 6 months after the last dose of study drug. • Women of childbearing potential must have a negative serum or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study. • Written signed informed consent form.","• Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification. • Major surgery within 4 weeks of inclusion. • Known central nervous system lymphoma. • History of stroke or intracranial hemorrhage within 6 months prior to inclusion. • Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon).). • Impaired liver, renal (GFR<50ml/min) or other organ function which will interfere with the treatment. • Requires treatment with strong CYP3A inhibitors. • Vaccinated with live, attenuated vaccines within 4 weeks of inclusion. • Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or active Hepatitis B Virus infection or any uncontrolled active systemic infection requiring intravenous (IV) antibiotics. (patients HbsAg+and/or antiHBc+ and/or HIV+ are excluded). • Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk. • Known hypersensitivity to study treatment (OBINUTUZUMAB, Ibrutinib, VENETOCLAX0199) or to any of the excipients. • Known allergy to xanthine oxidase inhibitors and rasburicase • Severe prior reactions to monoclonal antibodies or with prior significant toxicity (other than thrombocytopenia) from Bcl-2 inhibitor • History of prior other malignancy with the exception of: Curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study • Other cancers not specified above which have been curatively treated and from which subject is disease-free for <5 years. • Allografted patients • Psychiatric illness or condition which could interfere with their ability to understand the requirements of the study. • Pregnancy/lactation • Men or women of reproductive potential not agreeing to use acceptable method of birth control during treatment and for 18 months after completion of treatment for the women and 6 months for the men. • Use of any standard or experimental anti-cancer drug therapy within 28 days prior to the first dose of study drug.",during the first cycle for cohort A and during cycle 2 for cohorts B and C,NA
31740568,NCT01473940,Combination,No,Advanced Pancreatic Cancer,"Patients aged 18 years or older with confirmed advanced or metastatic pancreatic adenocarcinoma were included. Patients were required to have an Eastern Cooperative Oncology Group performance status of ≤1 and adequate liver, renal, and bone marrow function. Prior gemcitabine given concurrently with radiotherapy for localized cancer was permitted. Prior gemcitabine as adjuvant therapy was allowed if ≥3 months had elapsed between the last dose of gemcitabine and detection of recurrent disease.","Patients previously treated with ipilimumab, CD137 agonists, CTLA-4 inhibitors or agonists, or anti–PD-1 therapies were excluded. Prior systemic therapy for advanced pancreatic cancer with gemcitabine was prohibited. Other major exclusion criteria included central nervous system metastatic disease, active autoimmune disease, active infections including human immunodeficiency virus, hepatitis B or C infection, recent vaccine use, or significant comorbid conditions.",at the end of week 12,NA
19879702,NA,Combination,No,locally advanced head-and-neck cancer,"This study was institutional review board approved and carried out in accordance with the 1975 Declaration of Helsinki as re- vised in 2000. Patient eligibility included untreated Stage III, IVA, or IVB HNSCC, or a stage-equivalent recurrence after surgery. Patients with potentially resectable tumors were informed of surgical options and were required to indicate a preference for nonsurgical treatment. Other requirements included the following: measurable tumor by Response Evaluation Criteria In Solid Tu- mors (RECIST) (28), age >=18 years, hemoglobin >=10 g/dl, gran- ulocytes >=1,500/ul, platelets >=100,000/ul, serum creatinine <=1.5 times the upper limit of normal (ULN), total bilirubin <=2 times the ULN, and hepatic transaminases <=2.5 times the ULN. Pa- tients were required to provide informed consent. Separate consents were obtained for all biopsies.","Exclusions included previous radiation, chemotherapy, or EGFR-inhibitor therapy; other invasive malignancy within 5-years; pregnancy; or serious unrelated illness.",during the radiation therapy,NA
32334034,NCT01554410,Combination,No,Locoregionally Advanced Cervical Carcinoma,"Eligible patients were aged 18 years and had pathologi- cally confirmed, International Federation of Gynecology and Obstetrics 2009 stage IB-IVA squamous cell carcinoma or adenocarcinoma of the cervix, with either an intact cervix or posthysterectomy with residual gross pelvic dis- ease, or biopsy-proven paraortic nodal involvement (either resected or unresected). Patients with recurrent disease confined to the pelvis after hysterectomy alone were eligible. Pretreatment diagnostic evaluation included a history/physical examination, cervical biopsy, chest x-ray or chest computed tomography (CT), and pelvic CT or magnetic resonance imaging in all patients. 18F-fluo-rodeoxyglucose positron emission tomography/CT (PET/ CT), cystoscopy, and sigmoidoscopy were used if indicated. All patients had a Karnofsky performance status >=60, ab- solute neutrophil count >=1500/uL, platelet count >=100,000/uL, hemoglobin count >=8.0 gm/dL, serum creatinine <=1.5 mg/dL, and aminotransferases <1.5 times the upper limit of normal for age.","Patients were ineligible if they had prior invasive ma- lignancy (except nonmelanomatous skin cancer) with active disease within the past 3 years; were pregnant/lactating; received growth factors or erythropoietic drugs within 7 days of registration; or had active uncontrolled infection, paraortic nodal disease only, distant metastases, chemo- therapy within 3 years of registration, prior radiation ther- apy to the pelvis or abdomen, or a history of hematologic disease.",occurring from protocol registration until 30 days after the completion of all therapy,NA
16467100,NA,Combination,No,Adults with Recurrent Malignant Glioma,"Patients were required to have histologically confirmed malignant glioma (glioblastoma multiforme, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma) that was radiographically progressive following prior radiation or chemotherapy. Additional enrollment criteria included age at least 18 years, Karnofsky performance status z70%, stable corticosteroid dose for at least 1 week before therapy initiation, hematocrit >29%; absolute neutrophil count >1,000 cells/AL; platelet count >100,000 cells/AL, serum creatinine and bilirubin <1.5 times the institutional upper limit of normal, serum aspartate aminotransferase <2.5 times the institutional upper limit of normal, and carbon monoxide diffusing capacity of >75% predicted. Patients were required to be at least 3 weeks from prior surgical resection and to have recovered from all toxicities associated with any prior therapy. All patients were informed of the investigational nature of the study and provided informed consent as approved by the Duke University Medical Center Institutional Review Board.","Patients were excluded for any of the following: more that three prior episodes of progressive disease, pregnancy or nursing, refusal to use effective contraception if of reproductive potential, progressive disease following prior treatment directed against either EGFR or mTOR, and acute infection requiring i.v. antibiotics. In addition, patients were not eligible if they received prior stereotactic radiosurgery, radiation implants, or radiolabeled monoclonal antibody therapy, due to the difficulty distinguishing progressive tumor from radionecrosis on magnetic resonance imaging following such therapies. However, patients who had received these therapies were eligible if they had either biopsy confirmation of recurrent tumor, or if they had a new or progressive distant lesion on magnetic resonance imaging.",during the first cycle of therapy,NA
31297636,NCT02732938,Combination,No,metastatic pancreatic ductal adenocarcinoma,"Eligible patients were males and females ≥18 years of age, with histologically or cytologically proven diagnosis of mPDAC who had provided a baseline tumor sample at registration. Patients had not received previous radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease and had a life expectancy ≥12 weeks. Patients with Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1 and adequate bone marrow, renal, and liver function were included. ",Patients with known symptomatic brain metastases requiring steroids or who had prior therapy with modulators of monocyte or TAM function in metastatic setting were ineligible to participate.,drug in the first 28-day cycle,NA
30862645,NCT01685892,Combination,No,previously untreated and relapsed/refractory chronic lymphocytic leukemia,"Diagnosis of relapsing/refractory or previously untreated chronic lymphocytic leukemia. Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to (</=) 1. Adequate bone marrow function Adequate coagulation, renal and hepatic function. For all participants, agreement to remain abstinent or use contraceptive methods that result in a failure rate of less than (<) 1% per year during the treatment period and for at least 90 days (30 days for women) after the last dose of venetoclax or 18 months after the last dose of obinutuzumab, whichever is longer","Participants who have undergone allogenic stem cell transplant are ineligible unless they meet the following criteria, a) participants who are off all immunosuppressive therapy, b) participants who have no signs and/or symptoms of acute or chronic graft versus host disease, or c) participants must have appropriate hematology counts. Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. Uncontrolled autoimmune hemolytic anemia or thrombocytopenia. Investigational or anti-cancer therapy within 5 half-lives prior to the first dose of study drug. History of significant renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease",in cycle 1,NA
32973176,NCT03307148,Combination,Yes,pancreatic cancer,"STARPAC was an open-label, multicenter, phase Ib study of ATRA administered with gemcitabine and nab-paclitaxel in patients with locally advanced or metastatic pancreatic cancer, who had not received prior systemic therapy for their disease. Additional eligibility criteria included World Health Organization (WHO) performance status 0 or 1, life expectancy ≥12 weeks, and adequate hematologic and end-organ function within 14 days prior to the first study treatment. ","Major exclusion criteria were known brain metastases, pre-existing sensory neuropathy (>grade 1) and serious medical risk factors involving any major organ systems, or serious psychiatric disorders, which could compromise the patient’s safety or the study data integrity.",during the first 28 days of treatment,NA
12796031,NA,Combination,No,"Japanese patients with solid malignant tumors. Tumor type: Non-small-cell lung 23, Adenocarcinoma 18, Squamous 4, Poorly differentiated adenocarcinoma 1, Colorectal 5, Head and neck 2, Breast 1","We enrolled patients with solid malignant tumors that were resistant to stand- ard therapies or for which the investigator believed no appropriate treatment was available. Tumors were among those known to commonly express or overexpress EGFR, but patients were not selected on the basis of individual EGFR status. Patients aged 20–74 years with a life expectancy of ≥3 months and World Health Organization (WHO) performance status of ≤2 were eligible for inclusion.","Patients were excluded if their serum bilirubin was greater than the upper limit of reference range (ULRR); ALT or AST was more than 2.5 times the ULRR in the absence of demonstrable liver metastases or was more than five times the ULRR in the presence of liver metastases; serum creatinine was more than the ULRR; there was greater than a trace of blood or protein on urinalysis; or the total WBC count was less than 3.5 x 109/L, the neutrophil count was less than 2 x 109/L, or the platelet count was less than 100 x 109/L. In addition, patients were ineligible if they had a PR interval of more than 217 ms (because prolongation of the PR interval was noted in preclinical animal toxicity studies); had a history of clinically significant cardiac dysrhythmia; had any degree of atrioventricular block or other severe cardiac disease; had active dermatoses; had any ocular surface abnormalities; were receiving drugs associated with corneal toxicology; or were currently wearing contact lenses. Pending results of clinical pharmacology studies, patients who were receiving concurrent treatment with known cytochrome P450 3A4 inhibitors (such as ketoconazole and erythromycin) were also excluded, because these drugs were considered possibly to alter the pharmacokinetics of ZD1839",during the first treatment period,NA
28955007,NCT02151721,Combination,No,BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer,"Prior to enrollment in the study, patients must fulfill all of the following criteria : histologically or cytologically diagnosed NSCLC (excluding squamous cell carcinoma) ; NSCLC of clinicopathologic stage IIIB or IV for which radical radiation therapy is impractical or there is a recurrence after surgery ; EGFR mutations (deletion of exon 19 and L858R mutation of exon 21) for which the clinical benefits of an EGFR-TKI (gefitinib or erlotinib) are recognized by testing methods that are listed by the national health insurance ; having a history of treatment with an EGFR-TKI (gefitinib or erlotinib) and a history of pathologic deterioration during treatment ; having a history of treatment with cytotoxic anticancer agents (not including pre- or postoperative chemotherapy in the previous 1 or more years from the day of final administration) ; confirmed BIM polymorphism by the PCR fragment analytical method and the sequence method at the central laboratory ; having a lesion measureable according to the RECIST guidelines version 1.1 ; confirmed progression of pathology at the site of irradiation after irradiation in a patient who only has an irradiated lesion ; age 20 years and older ; Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 at the time of consent acquisition ; an estimated life expectancy of 12 or more weeks ; a patient whose acute toxicities in response to prior treatments have recovered to the baseline level in the most recent prior treatment, excepting adverse events considered not to be a safety concern at the discretion of the investigator ; acquisition of written informed consent to participate in the present study ; and adequate hematological, liver, renal and respiratory function within 14 days before entry as shown below. i) Neutrophil count of>=1,500/μL. ii) Platelet count of>=100,000/μL. iii) Total bilirubin level of<=1.5-fold of the upper limit of reference value at each institution. iv) Creatinine level of<=1.5mg/dL. v) PaO2 of>=70 Torr or SpO2 of>=94%.","Patients will be excluded for any of the following reasons : they received the final administration of a cytotoxic anticancer agent within the past 4 weeks, they received the final administration of an EGFR-TKI within the past 7 days, or they received surgery or radiotherapy for a primary tumor or mediastinum within the past 6 months ; radiotherapy considered necessary ; having an interstitial lung disease or history thereof, radiation pneumonitis treated with corticosteroids or having a history thereof, a large volume of or uncontrollable pleural effusion, ascites, or pericardial effusion, or a serious infection and other serious complications ; detection of known resistance mutations of the EGFR, e.g., T790M ; suffering from a severe or poorly controlled systemic disease ; having an active or poorly controlled or symptomatic metastasis to the central nervous system, or an active double cancer ; verified hepatitis B virus antigen or C virus antibody positivity.",during the first two cycles (14 days per cycle) of therapy,NA
31782583,NCT02151721,Combination,No,BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer,"Prior to enrolment in the study, patients had to fulfil all of the following criteria: histologically or cytologically diagnosed NSCLC (excluding squamous cell carcinoma); NSCLC of clinicopathological stage IIIB or IV for which radical radiation therapy was impractical or there was a recurrence after surgery; EGFR mutations (deletion of exon 19 and L858R mutation of exon 21) for which the clini-cal benefits of an EGFR-TKI (gefitinib, erlotinib, or afatinib) were recognized  by  testing  methods  that  were  listed  by  the  national  health insurance; history of treatment with an EGFR-TKI (gefitinib, erlotinib, or afatinib) and a history of pathological deterioration during treatment; history of treatment with cytotoxic anticancer agents (not including pre- or postoperative chemotherapy in the previous 1 year or more from the day of final dose); confirmed BIM polymorphism by the PCR fragment analytical method and the sequence method at the central laboratory; a lesion measur-able according to the RECIST guidelines version 1.1; 20 years of age and older; ECOG Performance Status (PS) 0 or 1; estimated life expectancy of 12 or more weeks; provision of written informed consent to participate in the present study; and adequate hemato-logical, liver, renal, and respiratory function within 14 days before entry.","Patients were excluded for any of the following reasons: received a cytotoxic anticancer agent within the past 4 weeks, received an EGFR-TKI within the past 7 days, or surgery or radiotherapy for a primary tumor or mediastinum within the past 6 months; interstitial lung disease or history thereof, radiation pneumonitis treated with corticosteroids or a history thereof; detection of known resistance mutations of EGFR (eg, T790M).",during the first two cycles (14  days per cycle) of therapy,NA
31910346,NA,Single Drug,No,"Patients with Advanced Carcinoembryonic Antigen Producing Malignancies. Diagnosis site, n (%): Colon, Lung, Rectum, Breast, Thyroid","Patients with advanced chemotherapy refractory metastatic CEA producing malignancies for which no standard therapies were available were eligible. Patients were required to have at least one measurable site of disease. Patients with untreated brain metastases were excluded. CEA expression was documented by either an elevated serum CEA level or positive immunohistochemistry. Other eligibility criteria included measurable disease; Karnofsky performance status of ≥60%; no therapy in the 4 weeks before study entry; adequate bone marrow function as defined by WBC ≥4000/μL, absolute neutrophil count ≥1500/μL, and platelet count ≥125,000/μL; creatinine <1.5 mg/dL or creatinine clearance >60 cc/min; bilirubin ≤1.5 mg/dL; and liver transaminases no greater than two times the upper limit of normal.",NA,the first course of treatment,NA
25552401,NCT01027676,Combination,No,previously treated patients with advanced non-small cell lung cancer,"The main eligibility criteria were histologic confirmation of advanced NSCLC, previous chemotherapy with at least one platinum-containing regimen, age ≥ 18 years, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of less or equal to 2, and a measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST). Adequate hematologic (WBC count ≥4,000/mm3, platelet count ≥150,000/mm3), hepatic (bilirubin level ≤1.5 mg/dL, AST/ALT ≤80 IU/L), and renal (creatinine concentration ≤1.5 mg/dL) function was required. Patients with brain metastases were enrolled if they were clinically stable without steroid treatment.","The exclusion criteria included serious concomitant systemic diseases or a history of uncontrolled cardiac dysfunction, or any previous treatment with EGFR signaling inhibitors or HDAC inhibitors.",during the first cycle,NA
20142724,NCT00113529,Combination,No,patients with metastatic renal cell carcinoma,"The study population comprised patients with metastatic RCC and a component of clear-cell carcinoma aged 18 years with unidimensionally measurable disease. Patients with one or no prior systemic therapy were enrolled. Other eligibility criteria included an Eastern Cooperative Oncology Group performance status of 0 or 1, adequate organ function including left ventricular ejection fraction (LVEF) 50%, and signed informed consent. ","Patients were ineligible if they had a history of or known brain metastases, clinically significant cardiovascular events or disease in the previous 12 months, ongoing cardiac dysrhythmias (National Cancer Institute Common Terminology Criteria for Adverse Events grade >= 2), atrial fibrillation or prolongation of the QTc interval (>450 milliseconds for males and >470 milliseconds for females), or uncontrolled hypertension",in cycle 1,NA
17694310,NA,Combination,No,patients with malignant glioma,"Patients aged ¸18 years with histologically proven supratentorial malignant glioma, including GBM, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, and malignant astrocytoma not otherwise speciWed, were eligible for inclusion. A life expectancy of >8 weeks and a KPS of ¸60 were required.  Patients with either stable or progressive disease were eligible for treatment. Adequate bone marrow (white blood cells >3,000/ul, absolute neutrophil count >1,500/ul, platelet count >120,000/ul, hemoglobin >10 g%), liver (serum glutamic–oxaloacetic transaminase and bilirubin <1.5 times the upper limit of normal) and renal function (creatinine <1.5 mg/dl or estimated creatinine clearance > 60 ml/min) were required within 14 days before entering the study. Patients must have recovered from toxic eVects of prior therapy with a minimum of 2 weeks after receiving vincristine, 6 weeks for nitrosoureas, 4 weeks for temozolomide, 3 weeks for procarbazine and 1 week for non-cytotoxic agents. Radiation had to be completed at least 3 weeks before study entry. Patients had to be at least 7-day post-tumor resection, if done, and recovered from the eVects of surgery or radiation. Measurable disease following recent resection of a recurrent tumor was not required for study entry. No more than three prior chemotherapeutic regimens were permitted. Patients also had to be on stable doses of concomitant medication, especially those aVecting the cytochrome P450 pathway (a minimum of 2 weeks), before entering the study. Growth factors or other investigational drugs was not permitted nor was previous use of geWtinib or erlotinib or any other anti-EGFR directed therapies.","Exclusion criteria included patients with major illness inadequately controlled with therapy or disease that would compromise their ability to tolerate study treatment; signiWcant gastrointestinal risk factors within the past 6 months; other cancers (except non-melanoma skin cancer or carcinoma in situ of the cervix) unless in complete remission and oV therapy for a minimum of 3 years; active infection, or pregnancy.",during the Wrst 35 days of treatment only (cycle 1),NA
23182702,NA,Combination,No,newly diagnosed glioblastoma patients,"Eligibility criteria were as follows: 18 years or older; Zubrod Performance Scale 0-1; histopathologically confirmed, newly diagnosed, unifocal supratentorial GBM; estimated survival of at least 8 weeks; no prior chemotherapy or RT to the head or neck area (except T1 glottic tumors); no active inflammatory disorders; no major medical/psychiatric illnesses; no malignancy (within 3 years) except nonmelanomatous skin cancer or carcinoma in situ of the cervix or bladder; and no pregnancy or lactation. RT must have been initiated within 5 weeks after surgery, with gefitinib initiated 1 week before RT.",NA,during RT,NA
34837745,NCT01964287,Combination,No,metastatic pancreatic adenocarcinoma,The main inclusion criteria were: histologically or cytologically confirmed and measurable MPC; initial definitive diagnosis of metastatic disease made <=6 weeks before inclusion; no previous treatment of metastatic disease; radiation sensitizer in adjuvant setting with fluorouracil or gemcitabine allowed if the last dose was completed at least 6 months earlier and no persistent toxicity was present; age between 18 and 75 years; and ECOG/World Health Organization (WHO) performance status <=1. ,The main exclusion criteria were: known brain metastases; history of other malignancy in the last 5 years (except in situ basal or squamous cell skin cancer or other cancers if disease free for at least 5 years); previous cytotoxic doses of any chemotherapy drug other than gemcitabine or fluorouracil in adjuvant setting; and >=grade 2 peripheral sensory neuropathy at the beginning of the study.,during the first two cycles,NA
19687340,NA,Combination,No,"pediatric patients with refractory solid tumors. Diagnosis: Neuroblastoma 6, Osteosarcoma 6, Wilms’ tumor 4, Brain tumor 3, Ewing sarcoma family of tumors 3, Other (*Hepatoblastoma, hepatocellular carcinoma (n = 2), adrenocortical carcinoma (n = 2), undifferentiated sarcoma, polyphenotypic sarcoma","Patients younger than 22 years old with recurrent or refractory solid tumors for which conventional treatment had failed were eligible. Also required were: life expectancy >= 8 weeks, performance status (Eastern Cooperative Oncology Group [ECOG])  2, recovery from toxicity of prior chemotherapy, hemoglobin >= 8 g/dL, absolute neutrophil count (ANC) >=750/uL, platelet count >=50,000/uLin the absence ofmarrowinfiltration by tumor, adequate liver function (bilirubin <= 1.5 x normal, ALT <= 3 x normal), and adequate renal function (serum creatinine <= 2 x normal for age).","Exclusion criteria included active infection, incomplete healing from major surgery, evidence of clinically active interstitial lung disease, or current use of known CYP3A4 inhibitors such as phenytoin, carbamazepine, barbiturates, rifampin, or St John’s wort.",the first course of treatment (21 days),NA
33121235,NCT01671904,Combination,No,chronic lymphocytic leukemia,"Diagnosis of relapsing/refractory or previously untreated CLL. Eastern Cooperative Oncology Group (ECOG) performance score of less than equal to (</=) 1. Adequate bone marrow function. Adequate coagulation, renal and hepatic function. Hematological values within the limits independent of growth factor support or transfusion unless cytopenia is caused by the underlying disease, i.e., no evidence of additional bone marrow dysfunction (e.g., myelodysplastic syndrome, hypoplastic bone marrow)","Participants received an allogeneic stem cell transplant. Known human immunodeficiency virus (HIV) positivity. Uncontrolled autoimmune hemolytic anemia or thrombocytopenia. Positive test results for chronic hepatitis B infection and hepatitis C virus (HCV). Received any anti-cancer therapy including chemotherapy or radiotherapy, steroid therapy for anti-neoplastic intent, and investigational therapy, including targeted small molecule agents within 28 days prior to the first dose of study drug or has not recovered to less than Grade 2 clinically significant adverse effect(s)/toxicity(s) of the previous therapy. Significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease",during the 1st cycle of the combination therapy,NA
26289594,NA,Single Drug,No,"patients with advanced solid tumours. Tumour type [n (%)]: Pancreatic 9 (20.9 %), Colon 7 (16.3 %), Rectal 6 (14.0 %), Ovarian 4 (9.5 %), Hepatocellular 3 (7.0 %), Oesophageal 2 (4.7 %), Cholangiocarcinoma 2 (4.7 %), Malignant melanoma 2 (4.7 %), Gastric 2 (4.7 %), Gall bladder 1 (2.3 %), Uterine sarcoma 1 (2.3 %), Malignant mesothelioma 1 (2.3 %), Neuroendocrine tumour of epiglottis 1 (2.3 %), Lung cancer (unspecified) 1 (2.3 %), Haemangiopericytoma 1 (2.3 %)","Eligible patients were aged ≥18 years with histologically or cytologically confirmed advanced solid tumours refractory to standard therapies, with Eastern Cooperative Oncology Group (ECOG) performance status ≤2; life expectancy >3 months; and adequate haematological, hepatic and renal function. Previous treatment with gemcitabine was allowed. Exclusion criteria included: symptomatic brain metastases; grade ≥2 neuropathy [National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0]; allergy to gemcitabine or egg yolk; positive serology for hepatitis B, C or human immunodeficiency virus; radiotherapy within 1 week of study entry or to >30 % of the bone marrow; and chemotherapy, hormone therapy or immunotherapy within 30 days (6 weeks for mitomycin C or nitrosoureas) before CP-4126 administration","Patients who were pregnant or lactating, and fertile male patients who were unable or unwilling to use adequate contraception were excluded. Patients with uncontrolled inter-current illness or any significant central nervous system or psychiatric disorders were also excluded.",during the first 28-day treatment cycle,NA
28832976,NA,Combination,No,patients with advanced pancreatic adenocarcinoma,Patients (age>=18 years) who had an Eastern CooperativeOncology Group performance status of 0 to 1 andadvanced pancreatic adenocarcinoma were enrolled. Oneor no prior treatment regimens for pancreatic adenocarci-noma were permitted for this cohort,"Patients were excluded for the following reasons:receipt of systemic chemotherapy or radiotherapy within 3weeks of the study, persistent therapy-related toxicities,inadequate organ or marrow function, and symptomatic,uncontrolled brain metastases.",during thefirst cycle (28 days),NA
26912134,NCT01242605,Combination,No,advanced or metastatic biliary tract cancer,"Patients were eligible if they had a histopathological or cytological diagnosis of non-resectable, recurrent or metastatic biliary tract (intra- or extra-hepatic), gallbladder or ampullary carcinoma for which no prior systemic chemotherapy had been given. Patients were required to have World Health Organisation (WHO) performance status ≤ 2, be aged ≥ 18, have an estimated life expectancy >3 months, and have adequate biliary drainage and major organ function. Patients had to be able to swallow selumetinib capsules and be capable of giving written informed consent.","Patients were not eligible if they had had any prior exposure to MEK, RAS, or RAF inhibitors, had not fully recovered from previous surgery, had had a prior malignancy (except curatively treated in-situ carcinoma of the cervix, non-metastatic basal and/or squamous cell carcinomas of the skin, or any early stage (stage I) malignancy adequately resected for cure greater than 5 years previously), had evidence of a severe or uncontrolled systemic disease, if the patient was pregnant or breast-feeding, or had any of the following cardiac conditions: uncontrolled hypertension (blood pressure ≥150/95 despite optimal therapy), heart failure (New York Heart Association Class II or above), prior or current cardiomyopathy, baseline left ventricular ejection fraction ≤ 50 %, atrial fibrillation with heart rate >100 beats per minute, unstable ischaemic heart disease (myocardial infarction within 6 months prior to starting treatment, or angina requiring use of nitrates more than once weekly).",during the first cycle of treatment,NA
23583440,NA,Combination,No,"advanced solid tumours. Primary tumour type, n (%): Pancreas 11 (35), Breast 6 (19), Non-small cell lung 4 (13), Bladder 2 (6), Endometrium/uterus 2 (6), Other includes cancer of the mouth, ovary, bile duct, salivary glands, small cell lung and cholangiocarcinoma (n = 1 for each)","Eligibility criteria included adults aged P18 years, histologically/cytologically confirmed diagnosis of solid tumours and an Eastern Co-operative Oncology Group performance status (ECOG PS) of 0 or 1 with adequate organ system function (haematologic, hepatic, renal, cardiac systems). Once the RP2D had been established, patients with ECOG PS of 2 could also be enrolled. In the pancreatic expansion cohort, patients could have not received prior systemic therapy for metastatic disease.","Patients were excluded if they had primary brain tumours or malignancies related to human immunodefi- ciency virus (HIV), or solid organ transplants; symp- tomatic or untreated leptomeningeal or brain metastases, or spinal cord compression; or ocular risks (history or risk of retinal vein occlusion [RVO], or central serous retinopathy [CSR]; glaucoma diagnosed within 1 month prior to study Day 1; intraocular pres- sure >21 mmHg as measured by tonography).",during the first 28 days after administration of the first dose ,NA
24916770,NCT00887757,Combination,No,"patients with solid tumors. Breast cancer, Colorectal carcinoma, Lung carcinoma, Melanoma, Mesothelioma, Non–small-cell lung cancer, Ovarian carcinoma, Pancreatic carcinoma, Renal carcinoma, Head and neck, Small-cell lung cancer, Testicular","Eligible patients were required to have a histologically documented cancer type for which gemcitabine was considered an appropriate indication therapy by the treating physician. Patients were required to have measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 , Eastern Cooperative Oncology Group Performance Status (ECOG PS ) ≤1, and adequate function of the bone marrow (absolute neutrophil count ≥1,500/μL; platelets ≥150,000/mm3; hemoglobin ≥9.0 g/dL), kidney (serum creatinine ≤2.0 mg/dL or calculated creatinine clearance ≥50 mL/min), and liver (aspartate aminotransferase [AST], alkaline phosphatase [ALP], and alanine aminotransferase [ALT] ≤3.0×the upper limit of normal [ULN]; bilirubin ≤1.5×ULN). Patients with bone metastasis could have ALP ≤5.0×ULN; patients with liver metastasis could have AST, ALP, and ALT ≤5.0×ULN. Coagulation parameters (activated partial thromboplastin time and prothrombin time) were required to be below 1.2×ULN.","Due to the known effects of navitoclax on platelet counts, patients were excluded who had active bleeding or thrombocytopenia-associated bleeding within 1 year, active peptic ulcer disease or potentially hemorrhagic esophagitis or gastritis, a requirement for concurrent therapeutic anticoagulants, or a history of immune thrombocytopenic purpura, autoimmune hemolytic anemia, or refractoriness to platelet transfusions. Patients were prohibited from using aspirin within 7 days of starting navitoclax. Grapefruit products and inhibitors of cytochrome P450 3A4 were also prohibited within 3 and 7 days, respectively, before the first dose of navitoclax. Patients were not to have anticancer or experimental therapies within the past 14 days before beginning study treatment. Women of child-bearing potential and nonsterilized men were required to use double–barrier contraception.",in cycle 1,NA
24737778,NCT00874042,Combination,No,"patients with solid tumors. Cancer type: Breast cancer 12 (16.2), Cholangiocarcinoma 8 (10.8), Endometrial cancer 4 (5.4), NSCLC 6 (8.1), Ovarian cancer 14 (18.9), Pancreatic adenocarcinoma 21 (28.4), Other 9 (12.2)","Key eligibility criteria were histologically or cytologically confirmed advanced-stage solid tumors, age ≥18 years, Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1, measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines, adequate bone marrow (Hgb ≥10 or ≥9 g/dl for expanded cohort, ANC ≥1.5 × 109/l, Platelets ≥100/l), hepatic (aspar- tate aminotransferase, alanine aminotransferase ≤2.5× upper limit of normal (ULN) or ≤5× ULN with metastatic liver disease) and renal function (serum creatinine ≤1.5× ULN).","Other cancer within the last three years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin. Previous anti-cancer chemotherapy, radiotherapy, major surgery, immunotherapy or investigational agents within 4 weeks prior to the first day of study defined treatment. History of cardiac disease: congestive heart failure defined as Class II to IV per New York Heart Association (NYHA) classification; active coronary artery disease (CAD); previously diagnosed bradycardia or other cardiac arrhythmia defined as ≥ Grade 2 according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) (version 3.0), or uncontrolled hypertension; myocardial infarction occurred within 6 months prior to study entry (myocardial infarction occurred > 6 months prior to study entry is permitted). Active clinically serious infections defined as ≥ Grade 2 according to NCI CTCAE, version 3.0. Substance abuse, medical, psychological or social conditions that may, in the opinion of the Investigator, interfere with the patient's participation in the study or evaluation of the study results. Any condition that is unstable or which could jeopardize the safety of the patient and his/her protocol compliance Known human immunodeficiency virus (HIV) infection. Pregnancy or breast-feeding. Inability to swallow oral medications. Significant gastrointestinal disorder, in the opinion of the Investigator, could interfere with the absorption of ARQ 197 and/or gemcitabine (e.g. significant, uncontrolled inflammatory bowel disease or extensive small bowel resection). Central nervous system metastases",during the first 28-day cycle of therapy,NA
27234064, EudraCT No. 2010-019214-25,Combination,No,chemotherapy-naive patients with unresectable pancreatic cancer,"Eligible patients had histologically/cytologically confirmed metastatic or locally advanced pancreatic cancer and had not received prior treatment with chemotherapy or radiotherapy. Pa- tients were aged 18 years or older with a Karnofsky Performance Status >=70 and adequate hematology, blood chemistry, and renal, liver, cardiac and pulmonary function. All patients signed informed consent forms.",Patients with chronic in- flammatory or autoimmune disease were excluded and no immu- notherapy within six weeks was allowed.,NA,NA
29362902,NCT02207465,Combination,No,patients with unresectable or borderline resectable pancreatic cancer,"Eligible patients were required to have pathologically proven pancreatic adenocarcinoma with either borderline resectable or unresectable disease. Criteria defining unresectable and borderline resectable patients was based on the National Comprehensive Cancer Network (NCCN) Guidelines (v 1.2014) . Other relevant inclusion criteria included, age≥18 years, ECOG performance status of ≤1, adequate organ function defined as follows: absolute neutrophil count of ≥ 1500/mm3, platelets ≥ 100,000/mm3, serum creatinine≤2 mg/dl, total bilirubin≤3, and AST<5 times the upper limit of normal.","Distant metastatic disease. Prior history of abdominal radiation therapy. Prior systemic therapy for pancreatic cancer. Prior or simultaneous malignancy within the past 2 years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ, thyroid carcinoma, or low-risk prostate cancer). In-situ carcinoma is allowed. Serious uncontrolled concomitant systemic disorders or psychiatric condition that would interfere with the safe delivery of protocol therapy. Treatment with an investigational anti-cancer agent within 4 weeks prior to enrollment into the study. Pregnant women, women planning to become pregnant and women that are nursing",up to 65 days after completion of chemoradiotherapy,NA
24907635,NCT00556023,Combination,No,chemotherapy-naive patients with metastatic pancreatic cancer,"Eligible patients had histologically/cytologically confirmed metastatic pan- creatic cancer and had not received prior systemic treatment with chemotherapy. Patients were aged 18 years or older with an Eastern Cooperative Oncology Group performance status 0 or 1 and adequate hematology, blood chemistry, and renal and liver function. ",Patients were excluded if they had received previous treatment with an anti-CTLA4 agent or radiotherapy for locally advanced disease within 4 weeks before randomization. Patients with inflammatory bowel disease or diarrhea at baseline; history of diverticulitis; or current (or active in the last 3 years) chronic inflammatory or autoimmune (except vitiligo) were excluded.,during the first 6 weeks following the first administration of tremelimumab (DLT observation window),NA
25837499,NCT01547260,Combination,No,patients with advanced pancreatic cancer,"Eligible patients had histologically or cytologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the pancreas. No prior chemotherapy for metastatic disease or locally advanced disease was allowed. Participants may have been previously treated with gemcitabine, fluorouracil, or capecitabine in the adjuvant setting. Patients should also be able to receive daily low molecular weight heparin (LMWH) (e.g. dalteparin 5000 IU subcutaneously daily) as prophylactic anticoagulant. Female subjects of childbearing potential should agree to use effective contraception without interruption, 4 weeks before starting study drug, throughout the study and for 4 weeks after end of study drug therapy. A negative urine pregnancy test in women of child-bearing potential before the start of treatment was required. Male subjects must agree to use condoms throughout study drug therapy and for one week after cessation of study therapy. Other eligibility criteria included: age >18 years, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, life expectancy > 12 weeks, adequate bone marrow function (defined as absolute neutrophil count (ANC) >1.5 x 109/L, platelet count >100 x 109/L), adequate renal and hepatic function (defined as serum creatinine <2,0 mg/dL (< 177 μmol/L) and total bilirubin < 3 x the institutional upper limit of normal (ULN), AST/SGOT and ALT/SGPT <3 x ULN or < 5 x ULN for patients with liver metastases.","Exclusion criteria included prior systemic therapy for adenocarcinoma of the pancreas (except in the adjuvant setting, see above), use of any other experimental therapies within 28 days prior to Cycle 1 Day 1, a history of or active deep vein thrombosis (DVT) or pulmonary embolism (PE) that were not managed on a stable dose of appropriate anticoagulant, known brain metastases, prior history of malignancy within 5 years (except basal or squamous cell carcinoma or carcinoma in situ of the cervix or breast, localized prostate cancer with PSA < 1.0 mg/dL) or pregnant or lactating females. An independent data and safety monitoring board (DSMB) monitored data throughout the study with respect to the occurrence of secondary primary malignancies (SPMs).",during the first treatment cycle,NA
30022224,NCT00078962,Combination,No,patients with solid tumors,"Male or female patients with a pathologically confirmed metastatic (or inoperable) solid tumor for whom no standard curative/palliative treatment existed or was no longer effective were eligible to participate. Other eligibility criteria included: signed informed consent; age≥18 years; Eastern Cooperative Oncology Group (EGOG) performance status of <2; life expectancy of at least 3 months; measurable disease according to RECIST version 1.0; recovery from any prior surgery and any AEs related to the previous therapy, the previous radiotherapy or chemotherapy>4 weeks before the first dose (>6 weeks for mitomycin C or BCNU); adequate bone marrow, hepatic, and renal function; and established central venous access for the administration of GTI2040 continuous infusion. Patients were permitted to have had prior chemotherapy, gemcitabine exposure or biological therapy","Patients with progressive brain metastases or primary brain tumors, unstable angina or cardiac arrhythmia, active infection and psychiatric illness were excluded. Patients on long-term oral anticoagulants and pregnant women were also excluded.",the first cycle of therapy ,NA
23539344,NA,Combination,No,"patients with solid tumors. Tumor type: Colorectal, Pancreas, NSCLC, Liver, Biliary tract/cholangio, Bladder, Stomach, Chondrosarcoma, Other(Breast and prostate cancer, squamous cell cancer of the skin, mesothelioma, and parotid cylindroma in schedule 1; head and neck cancer (2 cases), chondroblastic sarcoma, chondrosarcoma, desmoplastic small round cell tumor of the peritoneum, mesothelioma, and esophageal carcinoma in schedule 2)","Eligible patients had a histologically or cytologically confirmed diagnosis of a solid tumor, for which gemcitabine is either approved or considered the standard of care, or a tumor for which there was no standard treatment available. All patients had measurable or assessable disease. Patients were required to be older than 18 years of age, with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of less than 2, and adequate renal, hepatic, and bone marrow function. Prior treatment with gemcitabine was permitted. Other inclusion and exclusion criteria routinely used in phase I studies were also applied.",NA,during the first cycle,NA
23983255,NA,Combination,No,patients with advanced pancreatic ductal adenocarcinoma,"Inclusion criteria were age >18 years, Eastern Cooperative Oncology Group performance status of 0 to 1, and adequate end organ function","Exclusion criteria included previous systemic treatment for pancreatic cancer or radiotherapy within 4 weeks before randomization, autoimmune disorder, coagulopathy, major illness, and pregnancy or lactation",during cycle 1 of treatment,NA
22864469,NA,Combination,No,patients with advanced pancreatic adenocarcinoma,"Patients with newly diagnosed histologically or cytologically confirmed unresectable pancreatic adenocarcinoma were eligible for this study. The eligibility criteria were defined as follows: measurable or evaluable disease defined by RECIST criteria; >18 years old; Karnofsky Performance Status (KPS) ≥70; life expectancy >12 weeks; adequate bone marrow functions defined as an absolute neutrophil count >1,500/mm3, platelet count >100,000/mm3 and hemoglobin >10 g/dL; adequate renal function defined as serum creatinine ≤ 2.0 mg/dL or creatinine clearance ≥60 mg/min/1.73 m2; adequate hepatic function defined as total bilirubin ≤ 1.5 X the institutional upper limit normal value (ULN) and aspartate aminotransferase (AST) ≤ 2X the ULN. Patients must have signed the informed consent form. ","Patients with prior history of chemotherapy for pancreatic cancer, or active autoimmune disease requiring management with immunosuppressive drugs were excluded from this study",the first treatment cycle,NA
29748012,NA,Combination,No,advanced squamous non-small cell lung cancer,Confirmed squamous cell histology of Stage IIIB/IV or recurrent NSCLC. Measurable disease according to RECIST 1.1. Patient ECOG PS of 0 or 1. Male or female patients aged ≥18 years. Life expectancy of ≥3 months. Written informed consent in accordance with ICH-GCP guidelines,"Prior therapy for advanced, metastatic or recurrent NSCLC. Previous therapy with other VEGFR inhibitors or VEGF ligand inhibitors other than bevacizumab. Weight loss (>10%) within 6 weeks prior to starting treatment. Pre-existing interstitial lung disease. History of clinically significant hemoptysis within the past 3 months and history of major thrombotic or clinically relevant major bleeding events in the past 6 months. Tumor-specific exclusion criteria were: significant cardiovascular disease, active brain metastases, and radiographic evidence of cavitating or necrotic tumors. Patients with centrally located tumors with radiographic evidence (on computed tomography or magnetic resonance imaging) of local invasion of major blood vessels",during the first 21-day treatment cycle,NA
22847785,NA,Combination,No,"patients with advanced solid tumors. Slightly over half of the patients (19 patients) had lung, pancreas or bladder primary cancers; and 14 patients (39 %) had 3 or more metastatic organ sites.","Patients were required to be ≥18 years old with histologically or cytologically confirmed advanced solid tumor with no curable treatment option available. The lapse time between the last dose of prior treatment and enrolment on the study was 3 weeks for radiation therapy and 4 weeks for chemotherapy (6 weeks for nitrosoureas or mitomycin C). Prior treatment with gemcitabine was allowed, if given as a standard (30 min) infusion. Prior exposure to triapine or gemcitabine given at a fixed-dose-rate was not allowed. Patients had Eastern Cooperative Oncology Group performance status (ECOG PS) ≤2; life expectancy >12 weeks; leukocytes >3,000/μl; absolute neutrophil count >1,500/μl; platelets >100,000/μl; total bilirubin < institutional upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) <2.5 x ULN; serum creatinine within normal institutional limits, or creatinine clearance >60 mL/min, for patients with creatinine levels above institutional normal.","Patients with high risk for glucose-6-phosphate dehydrogenase (G6PD) deficiency were screened and those with this diagnosis were excluded, because of the potential risk for severe methemoglobinemia with triapine. Initially, there were no limitations for number of prior treatments (Arm A), but because of higher than expected myelosuppression, the protocol was amended (Arm B) and no more than 2 lines of systemic chemotherapy (not hormonal or targeted therapies), in the metastatic setting, was allowed. Patients with uncontrolled intercurrent illness, pregnant or breast-feeding females and HIV-positive patients receiving combination anti-retroviral therapy were excluded from the study.",in the first cycle of treatment,NA
29438372,NCT01098344,Combination,No,patients with pancreatic ductal adenocarcinoma,"Patients with histologically or cytologically proven stage III (inoperable) and IV PDAC were eligible for the trial. Previous chemotherapy for advanced disease was permitted. If gemcitabine treatment had been given previously, the patient must have tolerated a dose of at least 800 mg m-2. Patients were required to have radiologically assessable disease and tissue that was accessible to biopsy. Other inclusion criteria included a life expectancy of at least 12 weeks, World Health Organisation (WHO) performance status of 0 or 1 and the following haematological and biochemical parameters; haemoglobin >=9 gdl-1; absolute neutrophil count >=1.5 x 109 l-1; platelet count >= 100 x 109 l-1; serum bilirubin <=1.5 x upper limit of normal (ULN); alanine amino-transferase (ALT) <=2.5 x ULN (unless raised due to liver metastases in which case up to 5 x ULN was permissible); prothrombin time (PT) <=1.5 x ULN and calculated creatinine clearance >=50 ml min-1.",during the first cycle of a patient’s treatment,NA,NA
28748343,EudraCT 2009-016080-11,Combination,No,children with newly diagnosed diffuse intrinsic pontine glioma,"Children aged 3–18  years with newly diagnosed DIPG were eligible for this study. Inclusion criteria were: (i) diagnosis of a typical DIPG: symptoms <6 months and MRIconfirmed (≥50% involvement of the transverse area of the pons, T1 hypointensity, T2 hyperintensity, with a clear origin in the pons), (ii) written informed consent, (iii) transfusion-independent platelet count ≥75×109/L, peripheral absolute neutrophil count (ANC) ≥0.75×109/L, (iv) adequate liver function, defined as direct bilirubin ≤1.5×upper limit of normal (ULN) for age and alanine aminotransferase (ALAT) <5×upper limit of normal (ULN) for age, (v) adequate renal function, defined as serum creatinine ≤1.5×upper limit of normal (ULN) for age, (vi) willingness to perform a pregnancy test and apply contraceptives in females of child-bearing age. Biopsy was offered as an option, but was not mandatory for the diagnosis of a DIPG. ","Exclusion criteria were: (i) clinically-diagnosed neurofibromatosis (NF) type I (DNA-diagnostics not mandatory), (ii) patients who received prior therapeutic treatment for DIPG (except corticosteroids), (iii) presence of diffuse leptomeningeal disease, (iv) performance status (Lansky or Karnofsky score) of 40 or less (v) contra-indications for chemotherapy.",during the 6 weeks treatment period,NA
22543215,NA,Combination,No,patients with unresectable pancreatic cancer,"Patients had to have a pathologic diagnosis of adenocarcinoma of the pancreas, unresectable by radiographic criteria (>180 degree involvement of the superior mesenteric artery or celiac trunk or unreconstructable SMV/portal vein impingement) without distant metastasis. Resectability was determined by a multidisciplinary panel of surgeons, radiologists, and medical and radiation oncologists. Borderline resectable tumors were not allowed on this study. Additional criteria included a performance status of 0-2, absolute neutrophil count (ANC) of >=1500/mm3, platelets >=100,000/mm3, creatinine <2 mg/dL, bilirubin <3 mg/dL, alanine aminotrans- ferase/aspartate aminotransferase <=2.5 x upper limit of normal, and informed consent. ",NA,during IMRT or in the 13 weeks following completion of IMRT,NA
30082474,NCT02079636,Combination,No,Patients with Stage IV Non-Small Cell Lung Cancer,"Key eligibility criteria included previously treated advanced/ metastatic NSCLC, age >=18 years, Eastern Cooperative Oncology Group performance status 1, and adequate hematologic and end organ function. Eligibility was not restricted on the basis of molecular features; however, all patients with EGFR-activating mutations or ALK alterations should have progressed on or after an EGFR or ALK tyrosine kinase inhibitor prior to enrollment. Part A required nonsquamous histology and one to three prior therapies, including one platinum-based chemotherapy for advanced/metastatic NSCLC. Pemetrexed received as first-line or maintenance therapy must have been completed >=3 months prior to study entry. Part B allowed any histologic subtype and required one to three prior therapies for advanced/metastatic NSCLC. Part C allowed any histologic subtype and required two to three prior therapies for advanced/metastatic NSCLC. Study allowed patients with measureable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors v1.1. ",NA,during the first 21 days of treatment,NA
30206366,NCT01621854,Single Drug,No,"patients with advanced cancer. Overall, there were 19 primary cancer types, the most frequent being ovarian (n = 10, 15%), pancreas (n = 9, 13%), biliary (n = 7, 10%) and colorectal (n = 7, 10%)","Patients ≥18 years of age with a diagnosis of cancer refractory (or not amenable) to standard therapy were eligible for the study. Other inclusion criteria included a life expectancy of at least 12 weeks, Eastern Cooperative Oncology Group (ECOG) performance status15 of 0–2 and the following haematological and biochemical parameters: adequate bone marrow (leukocytes ≥ 3 × 109/L, neutrophils ≥ 1.5 × 109/L, platelets ≥ 100 × 109/L, haemoglobin ≥ 9 g/dL), liver function (total bilirubin ≤ 1.5 × upper limit of normal [ULN]), aspartate amino transferase (AST)/alanine amino transferase (ALT ≤ 2.5 × ULN (or ≤ 5 × ULN if liver metastases) and renal function (serum creatinine ≤ 1.5 × ULN). All patients provided written informed consent. ","History of allergic reactions attributed to previous gemcitabine treatment. Symptomatic CNS or leptomeningeal metastases. Prior chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy for bone pain), or immunotherapy within 28 days of first receipt of the IMP (within 6 weeks for nitrosoureas and mitomycin C). Hormone or biological therapy within 14 days of first receipt of IMP. Prior toxicities from chemotherapy or radiotherapy which have not regressed to Grade ≤ 1 severity (NCI-CTCAE version 4.0) apart from neuropathy and alopecia. Another active cancer (excluding basal cell carcinoma or cervical intraepithelial neoplasia (CIN/cervical in situ or melanoma in situ; part II only). Participants with uncontrolled concomitant illness, active infection requiring i.v. antibiotics. Participants will serious illnesses, medical conditions, or other medical history, including laboratory results, which, in the CI or delegates opinion would be likely to interfere with a participant's participation in the study, or with the interpretation of the results. Known HIV or known active Hepatitis B or C. Any condition (e.g., known or suspected poor compliance, psychological instability, geographical location, etc.) that, in the judgment of the CI or delegates may affect the participant's ability to sign the informed consent and undergo study procedures.",occurring through to the last scheduled day of Cycle 1,NA
25591040,NCT01426633,Combination,No,"advanced soft tissue sarcomas. There were four patients with a leiomyosarcoma, three of them of uterine origin, one in the gluteal region; and one patient with a retroperitoneal liposarcoma. ","Patients ≥18 years of age with a histological confirmed leiomyosarcoma or liposarcoma were eligible for enrollment. Any prior treatment was possible except adjuvant chemotherapy. Patients with evidence of newly diagnosed metastatic disease or disease progression during prior chemotherapy within the last six months in computed tomography or magnetic resonance imaging could be included. Patients were required to have a World Health Organisation (WHO) performance status of 0 or 1, an adequate haematological function (haemoglobin ≥9 g/dL, absolute neutrophil count (ANC) ≥ 1.5 × 103/mm3, platelets ≥100.000/mm3), an adequate hepatic function (serum total bilirubin ≤·upper limit of normal (ULN), serum total ALP ≤ 2.5 × ULN, serum AST and ALT ≤ 2.5 × ULN), and an adequate renal function (glomerular filtration rate (calculated by Cockroft-Gault) ≥ 60 mL/min).",NA,N/A,NA
24368064,NCT00556621,Combination,No,in muscle-invasive bladder cancer,"Inclusion criteria were as follows: pT2-pT4a MIBC with microscopically complete resection after the first or second TURBT; no macroscopically visible lesions in the pelvic nodes (N0) or distant metastases (M0); absence of carcinoma in situ; no hydronephrosis; Karnofsky performance score >=70%; life expectancy >=6 months; adequate bone marrow reserve (defined as follows: pretreatment absolute neutrophil count >=1500/uL, hemo- globin level >=10 g/dL, and platelet count >= 100,000/uL); creatinine clearance >=60 mL/min; bilirubin and aspartate aminotransferase <=3 and 4 times the institutional upper limits of normal, respectively; age >=18 years; signed informed consent form","Pregnant or breastfeeding patients were excluded, as were patients with previous radiation therapy or chemotherapy treat- ments (except anterior intrabladder treatment for localized carcinoma in situ) or history of malignancies other than adequately treated basal cell or squamous cell skin cancer or in situ cervical carcinoma.",During the chemoradiation therapy,NA
24936582,NA,Combination,No,patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery,"Eligible patients had histologically or cytologically confirmed muscle- invasive BC in clinical stages T2-4, N0-1 and M0. Inclusion criteria were in- operability due to tumor extent (locally advanced disease), evaluated by a multidisciplinary team or due to co-morbidity. Patients were also eligible when they refused surgery, or in case of a low performance status (PS) and/ or a high age >80 years which were the reasons for refusing surgery by the urologists. Further (selected) inclusion criteria were glomerular filtration rate (GFR) ≥30 ml/min (Cockcroft & Gault formula); PS 0-2 (WHO scale); before patient registration, written informed consent had to be given. ",NA,during the chemoradiotherapy,NA
28224231,NA,Combination,No,"advanced solid tumors. Tumor type: Carcinoma, Lymphoma,  Other","Japanese patients with treatment-refractory solid tumors were recruited. Inclusion criteria were as follows: (1) age between 20 and 75 years, (2) histologically or cytologically confirmed cancer, (3) evaluable tumor lesions according to the Response Evaluation Criteria in Solid Tumors guideline (Version 1.1), (4) Eastern Cooperative Oncology Group performance status 0 to 2, and (5) adequate bone marrow reserve at screening.","The exclusion criteria were as follows: (1) known hypersensitivity to platinum compounds or gemcitabine; (2) previous therapy with more than two different platinumbased regimens, or a regimen with a cumulative dose exceeding 480 mg/m2 for cisplatin, 1040 mg/m2 for oxaliplatin, or 42  mg/mL/min for carboplatin (cumulative area under the curve); (3) previous chemotherapy or radiotherapy within 28 days before the study treatment; (4) a history of symptomatic pulmonary fibrosis or interstitial pneumonia, with obvious evidence on a plain X-ray of the chest; (5) previous chest radiotherapy; (6) diagnosed chronic kidney disease defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2; and (7) greater than grade 2 auditory toxicity by pure tone audiometry or greater than grade 2 neurotoxicity.",during the first 2 cycles,NA
26177983,NCT02046304,Combination,No,patients with high-risk extremity and trunk soft tissue sarcoma,"To be eligible for the trial, patients had to have re-sectable (measurable or nonmeasurable), grade 2 or 3 (in-termediate- to high-grade) STS of an extremity or trunkwith histologic verification at The University of TexasMD Anderson Cancer Center. At the time of study enroll-ment, patients were also required to have a Zubrod per-formance status of 0 or 1, an absolute neutrophilcount>1500 cells/lL, a platelet count >=100,000/mL, a serum creatinine level <=1.8 mg/dL, liver transaminaselevels <= 3 times the upper limit of normal, and a total bili-rubin level <= 1.5 mg/dL.","Patients were excluded if theyhad received prior radiation therapy in the area of the pri-mary tumor or if the anticipated radiation field wouldhave included the perineum, scrotum, or vaginal introitus.Prior systemic chemotherapy was allowed with a washoutperiod of at least 3 weeks and confirmed normal bloodcounts before enrollment in the study.",NA,NA
30105668,NCT02101021,Combination,No,patients with previously untreated metastatic pancreatic ductal adenocarcinoma,"Patients were ≥ 18 years of age with previously untreated metastatic PDAC (measurable per Response Evaluation Criteria in Solid Tumors [RECIST] v 1.1); and an Eastern Cooperative Oncology Group (ECOG) performance status ≤1 and adequate hematologic, renal, and hepatic function","Patients wereexcluded for any current or previous treatment with biologic, small-molecule, immunotherapy, chemotherapy, or other agents for metastatic pancreatic carcinoma; uncontrolled intercurrent illness; recent major or minor surgery; certain prior or secondary malignancies; human immunodeficiency virus infection; hepatitis A, B, or C infection; peripheral neuropathy ≥Grade 2; central nervous system metastases; histology other than pancreatic adenocarcinoma; external biliary drain; myocardial infarction or unstable/uncontrolled cardiac disease; uncontrolled hypertension; and use of strong CYP3A4 inducers within 2 weeks prior to first dose of study medication.",during the first 28 days of treatment,NA
29338080,NCT01585805,Combination,No,Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma,"Patients with untreated, inoperable stage III or IV PDACwho were known carriers of a germlineBRCA1/2 orPALB2 mutation (BRCA1) and patients with a familyhistory who were susceptible for such mutations (eg, apersonal/family history of breast, pancreatic, ovarian,endometrial, prostate, or another related malignancy)were eligible. Other key eligibility criteria included thefollowing: measurable or evaluable disease (ResponseEvaluation Criteria in Solid Tumors [RECIST], version1.1), no prior platinum or PARPi therapy, an EasternCooperative Oncology Group score of 0 to 1, an age >=18 years, a life expectancy >= 3 months, and normal organand bone marrow function. The last criterion was definedas follows: an absolute neutrophil count >= 1500/lL, ahemoglobin level >= 9.0 mg/dL, a platelet count >= 100,000/lL, a total bilirubin level <= 2 times the institu-tional upper limit of normal [ULN], and aspartate amino-transferase/alanine aminotransferase levels <= 2.5 timesthe institutional ULN (unless there was evidence of livermetastases, in which case the aspartate aminotransferase/alanine aminotransferase levels had to be <= 5 times theinstitutional ULN and the creatinine level had to be <= 1.5times the ULN). Females of child-bearing potentialrequired a negative pregnancy test. Patients with a knownactive infection (eg, hepatitis B/C) and human immuno-deficiency virus–positive patients who did not have evi-dence of significant immunocompromise were eligible.","Patients were excluded if they had received prioradjuvant therapy with a platinum drug and if PDAC hadrecurred within 6 months of adjuvant therapy or if centralnervous system metastases were stable for3months.Patients who had contraindications to platinum agents orwere  receiving  any  other investigational agents  wereexcluded. Patients with a history of seizures or allergic reac-tions attributed to compounds with a composition similarto that of veliparib or other agents were also excluded. Inaddition, patients with uncontrolled infections, cardiovas-cular disease, or psychiatric illness were ineligible",the first cycle of treatment (21 days),NA
27873130,NCT01970553,Combination,No,"patients with advanced solid tumors. Primary tumor: NSCLC, Non-squamous, Squamous, Pancreatic adenocarcinoma, Breast, Triple negative, Hormone receptor-positive and HER2-negative, Ovarian carcinoma, Platinum resistant/refractory, Platinum sensitive, Other (Biliary tract adenocarcinoma (n = 3), mesothelioma (n = 2) and endometrial adenocarcinoma (n = 1))","Selection criteria included: age 18–75 years; histologically/ cytologically confirmed diagnosis of advanced malignant disease; ≤2 prior lines of cytotoxic-containing chemotherapy for advanced disease; life expectancy ≥3 months; recovery from previous toxicities to grade ≤ 1 (grade ≤ 2 for alopecia, cutaneous toxicity peripheral sensory neuropathy, fatigue); Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1; normal left ventricular ejection fraction(LVEF); and adequate bone marrow, hepatic, renal, and metabolic function.","Criteria for exclusion were: prior treatment with PM01183 or with gemcitabine-containing therapy for advanced disease (adjuvant therapy was allowed if ≤6 cycles were administered and relapse occurred at >6 months); symptomatic progressive or corticosteroid-requiring brain metastases or leptomeningeal involvement; pregnancy or lactation; radiotherapy to >35% of bone marrow; concomitant conditions such as unstable angina, myocardial infarction, congestive heart failure, or clinically significant valvular heart disease, symptomatic or uncontrolled arrhythmia requiring treatment, chronic hepatopathy, active uncontrolled infection, known human immunodeficiency virus (HIV) infection; and a history of prior bone marrow or stem cell transplantation.",in Cycle 1,NA
26056353,NCT01175733,Combination,No,Locally Advanced Pancreatic Cancer,"Adult patients with untreated LAPC were eligible for this phase I trial. Encasement >270 of the superior mesenteric or portal vein or >90 tumor contact with the superior mesenteric artery, celiac trunk, or common hepatic artery in the absence of distant metastasis was considered in a multidisciplinary team as LAPC. Histologic or cytologic confirmation of pancreatic cancer was required. Inclusion criteria also included measurable or evaluable disease as defined by response evaluation criteria in solid tumors (RECIST) 1.1 criteria, an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1, adequate hematological, hepatic (2.5 upper limit of normal, ULN) and renal function (estimated glomerular filtration rate >50 mL/min), normal calcium and magnesium levels.","Patients with imminent bowel obstruction, active bleeding, uncontrolled infection, or a second current malignant disease (except basal cell carcinoma of the skin) were not eligible. Patients with a history of allergic reactions to antibody treatment, impossibility of adequate radiation therapy, for example, due to tumor size, and patient suffering from any serious concomitant systemic disorders incompatible with the clinical study were considered not eligible.",during the first 43 days from start of combination treatment and attributable to combination therapy,NA
26377590,NA,Single Drug,No,"patients with advanced solid tumors. Location of tumor: Colorectal, Pancreas, Prostate, Sarcoma, Head and neck, Kidney, Lung, Liver, Bladder, Melanoma, Other","Key eligibility criteria included pathologically or cytologically proven advanced and/or metastatic solid tumor, no standard therapeutic option, age ≥18 years, performance status 0–2 (Eastern Cooperative Oncology Group [ECOG]), estimated life expectancy ≥12 weeks. Previous cancer treatments had to be discontinued for at least 30 days before study entry. Patients had to have adequate bone marrow function (hemoglobin ≥9.0 g/dL, neutrophil count ≥1.5×109/L, platelet count ≥100×109/L), adequate renal function (serum creatinine ≤1.5× the upper limit of normal [ULN]), and adequate hepatic function (aspartate transaminase [AST] and alanine transaminase [ALT] ≤2.5×ULN, bilirubin ≤1.5×ULN). ","Patients with liver cirrhosis, chronic hepatitis, history of excessive alcohol consumption, and patients positive for hepatitis B antigen, hepatitis C virus, or human immunodeficiency virus antibodies were excluded. Patients with gastrointestinal disease that might interfere with oral study drug absorption and patients with a history of severe hypersensitivity to dFdC were also excluded. ",during Cycle 1,NA
29348486,NCT01460537,Combination,No,"patients with advanced cancer. Cancer diagnosis: Breast cancer, Gallbladder cancer, Intrahepatic bile duct cancer, Non-small-cell lung cancer, Pancreatic adenocarcinoma, Small-cell lung cancer, Other","Patients were eligible if they were aged >=18 years with histologically or cytologically confirmed, advanced or refractory solid tumours, and if gemcitabine and cisplatin were medically appropriate. Patients were eligible for the expansion cohort if they had a histologically confirmed diagnosis of BTC (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma or gallbladder cancer). Patients were required to have at least one measurable lesion or evaluable disease, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Further inclusion criteria included: a life expectancy of ≥12 weeks; alanine aminotransferase and aspartate aminotransferase each ≤3 × ULN (≤5 × ULN for patients with liver involvement with cancer); total bilirubin ≤2 × ULN; serum creatinine ≤1.5 × ULN; prothrombin time <1.5 × ULN; and adequate bone marrow function as assessed by haemoglobin ≥9 g/dL (transfusion permitted), absolute neutrophil count ≥1500/mm3 and platelet count ≥100,000/mm3.","Exclusion criteria included: a prior diagnosis of type 1 or 2 diabetes mellitus; hyperglycaemia (defined as consistent fasting blood or plasma glucose >125 mg/dL) or glycated haemoglobin ≥7%; or poorly controlled hypertension, defined as systolic blood pressure >150 mmHg or diastolic pressure >90 mmHg, despite optimal medical management.",NA,NA
25003665,NCT01684449,Combination,No,"patients with advanced solid tumours. Tumour: Colorectal, Gastric, Cervix, NSCLC, Poorly differentiated chondrosarcoma, Eccrine gland adeno, Renal clear cell, Thymoma, Adrenal carcinoma, Urothelial carcinoma, Anaplastic thyroidal","To be enrolled in this study, patients had to meet the following eligibility criteria: diagnosis of advanced solid tumour that have progressed or are ineligible for standard treatment, no prior treatment with mTOR inhibitors or gemcitabine, Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1, either measurable or evaluable disease and age >=18 and <=70 years. The upper limit of age was established due to the increased risk of toxicity often seen in some elderly patients. Adequate bone marrow, hepatic and renal function were mandatory and were defined as: absolute neutrophil count >=1.5 x 109 l-1, platelets >= 100 x 109 l-1, bilirubin, aspartate aminotranferase (AST), alanine aminotransferase and creatinine <=1.5 x upper limit of normal and creatinine clearance >=60 ml min-1.","Patients with a history of other previous malignancies diagnosed or treated in the past 5 years (except basal cell skin carcinoma, adenocarcinoma in situ of the uterine cervix and superficial bladder cancer) and known central nervous system metastases were considered ineligible. Other exclusion criteria were treatment with experimental drugs within 30 days prior, pregnancy or lactancy, presence of active infection or any concomitant serious disease",within 3 weeks after the administration of the first cycle,NA
24614947,NCT01297998,Combination,No,patients with biliary tract cancer undergoing curative resection without major hepatectomy,"Patients with BTC who met the following criteria were eligible: histologically confirmed BTC (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer or ampullary cancer); Stage IB disease or higher; complete macroscopic (R0 or R1) resection without major hepatectomy (resection of more than three segments defined according to Couinaud’s classification); age over 20 years; Eastern Cooperative Oncology Group performance status of 0–1; adequate marrow function (neutrophil count ≥1,500/mm3, platelet count ≥100,000/mm3); adequate liver function [total serum bilirubin ≤3 times the upper limit of normal (ULN); aspartate aminotransferase and alanine aminotransferase levels ≤5 times the ULN]; adequate renal function (serum creatinine concentration ≤1.2 mg/dl and creatinine clearance ≥50 ml/min); adequate oral intake; and written informed consent. Patients satisfying these criteria started the regimen within 4–12 weeks after surgical resection.","Exclusion criteria were the presence of pulmonary fibrosis or interstitial pneumonia, severe heart disease, uncontrolled diabetes mellitus, and active infection; pregnancy or lactation; women of childbearing age, unless using effective contraception; severe drug hypersensitivity; mental disorder; concurrent double cancer; and other serious medical conditions.",during the first 6 weeks,NA
29502139,UMIN000012254,Combination,No,unresectable locally advanced pancreatic cancer,"The eligibility criteria for patients in this phase I study were as follows: (1) UR-LA pancreatic cancer with resectability assessed based on the 2015 NCCN guidelines version 2 ; (2) age between 20 and 75 years; (3) Eastern Cooperative Oncology Group (ECOG) PS of 0–1; (4) no previous antitumor treatment; (5) within 10×10 cm radiation field for the primary lesion and regional lymph node; (6) adequate biliary drainage if obstructive jaundice is present; (7) no direct invasion into the gastrointestinal tract; (8) no simultaneous cancer in other organs; (9) adequate oral intake; (10) expected survival of more than 3 months after treatment initiation; and (11) adequate major organ functions based on leukocyte count≥3500 and <12,000/ mm3, neutrophil count ≥ 2,000/mm3, hemoglobin level≥9.0 g/dL, platelet count≥100,000/mm3, total bilirubin level ≤ 2.0 mg/dL, aspartate aminotransferase and alanine aminotransferase levels≤150 U/L, serum creatinine level≤1.2 mg/dL, and creatinine clearance≥50 mL/min.",NA,during the two cycles of chemoradiotherapy using the GnP regimen,NA
27815358,NCT01359696,Combination,No,"Patients with Refractory Solid Tumors. Triple-negative breast cancer (TNBC) made up the highest proportion of malignancies (20% of all patients), followed by non–small cell lung cancer (NSCLC) and cancers of unknown primary origin (CUP).",Eligible patients age  18 years had locally advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable. Eastern Cooperative Oncology group (ECOG) performance status of 0 to 1 and adequate hematologic and end organ function and evaluable disease or measurable disease per RECIST v1.1 were required.,"Patients with more than 2 prior chemotherapy regimens for locally advanced or metastatic cancer, more than 6 cycles of an alkylating or platinum agent, or history of symptomatic congestive heart failure, myocardial infarction, or serious cardiac arrhythmia were excluded.",during either cycle 0 or 1,NA
23616084,NA,Combination,No,"Japanese patients with advanced solid tumors. Type of tumor: Lung adenocarcinoma, Small cell lung carcinoma, Colon carcinoma, Neuroendocrine carcinoma, Thymus carcinoma, Thyroid carcinoma","Male and female patients with histological or cytological evidence of solid tumor for which standard treatment had not been effective or established standard treatment options were not available were eligible to participate in the study. Other important eligibility criteria included: age >=18 years, performance status 0–2 (Eastern Cooperative Oncology Group [ECOG]), estimated life expectancy >=12 weeks. Previous cancer treatments had to be discontinued for at least 30 days before study entry. Patients had to have adequate bone marrow function (hemoglobin >=9.0 g/dL, neutrophil count >=1.5 x 109/L, platelet count >=100 x9 109/L), adequate renal function (serum creatinine <=1.5 x the upper limit of normal [ULN]), and adequate hepatic function (aspartate transaminase [AST] and alanine transaminase [ALT] - <= 2.5 x ULN, bilirubin <=1.5 x ULN). ","Patients with liver cirrhosis, chronic hepatitis, history of excessive alcohol consumption, and patients positive for HBs antigen, HCV or HIV antibodies were excluded. Patients with gastrointestinal disease that might interfere with oral study drug absorption and patients with a history of severe hypersensitivity to dFdC were also excluded.",during Cycle 1,NA
29788155,NCT01564251,Combination,No,"patients with refractory solid tumors. Most common tumor types: Breastc, Soft tissue sarcoma, NSCLC, Ovarian, SCLC, Colorectal, Endometrial, Pancreatic , Melanoma","Patients age >=18 years had histologically or cytologically documented, lo- cally advanced, or metastatic solid tumors for which standard therapy ei- ther does not exist or has proven ineffective or intolerable, Eastern Cooperative Oncology Group performance status of 0–1, and evaluable disease or measurable disease per RECIST v1.1. . Patients were required to have adequate bone marrow and organ function including neutrophil count >=1500/ull, platelet count >=100, 000/ul, hemoglobin >=10 g/dl, total bilirubin <=1.5 x the upper limit of normal, and AST and ALT <=3 x the upper limit of normal. ","Excluded patients had severe uncontrolled systemic disease or serious cardiac dysfunction, including left ventricular ejection fraction <55%, or contraindication to anti-Chk1 or gemcitabine therapy. For expansion cohorts, prior gemcitabine was not allowed",within the first 21 (arms 1 and 2a) or 28 (arm 2b) days,NA
28770300,NCT01154426,Combination,No,"The median age of the patients was 57 years (range 39–73), patients had good performance status (84% ECOG ≤ 1), and predominant cancer types being lung (29%), breast (26%), and pancreas (19%).","Study eligibility required patients with histologically documented solid tumors, progressed on standard therapy or without acceptable standard therapeutic options. Patients had to be ≥18 years, provide written informed consent, have an ECOG PS ≤2, and have a life expectancy of ≥3 months. Eligibility required adequate marrow, renal, and hepatic function, and a washout period of 4 weeks (6 weeks for mitomycin C or nitrosoureas)",NA,during cycle 1 ,NA
27685612,UMIN000005787,Single Drug,No,advanced pancreatic cancer refractory to gemcitabine,"Patients eligible for study entry had unresectableadvanced PC refractory to GEM. The eligibility criteria wereas follows: (i) cytologically or histologically proven invasiveductal   adenocarcinoma   or   adenosquamous   carcinoma; (ii) refractory to GEM-based chemotherapy as determined byradiologically or clinically confirmed PD, recurrence during orwithin 12 weeks of completion of adjuvant chemotherapy, orappearance of unacceptable toxicities; (iii) age≥20 years;(iv) Eastern Cooperative Oncology Group performance status0–2; (v) at least one measurable lesion according to RECISTversion 1.1;(8)(vi) adequate oral intake; (vii)>14 days’ inter-val from prior chemotherapy; (viii) satisfactory hematologicalfunctions (hemoglobin≥8.5 g/dL, leukocytes≥3000/mm3, neu-trophils≥1500/mm3, platelets≥75 000/mm3); (ix) adequatehepatic function (serum total bilirubin≤2.0 or≤3.0 mg/dLwith biliary drainage, serum AST and ALT≤100 or≤150 U/Lwith biliary drainage); and (x) adequate renal function (serumcreatinine≤1.5 mg/dL).  Written  informed  consent  wasobtained from all patients.","The exclusion criteria were: (i) moderate or massive pleuraleffusion or ascites; (ii) symptomatic brain metastasis or a his-tory of brain metastasis; (iii) synchronous or asynchronousother cancer within 3 years except carcinomain situor intra-mucosal carcinoma; (iv) active infection; (v) psychiatric disor-der; (vi) serious medical condition such as intestinal paralysis;(vii) intestinal obstruction; (viii) poorly controlled diabetes;(ix) heart failure, renal failure, hepatic failure, or active gas-trointestinal ulcer; and (x) pregnant or breast-feeding",within 28 days of initia-tion of GBS-01 treatment,NA
22515232,UMIN000002152,Combination,No,patients with advanced pancreatic cancer,"The eligibility criteria were: (i) histologically orcytologically proven pancreatic adenocarcinoma; (ii) locallyadvanced or metastatic disease; (iii) no prior treatment for pan-creatic cancer; (iv) ECOG performance status of 0–2; (v) age>20 years; and (vi) adequate organ function, as indicated bywhite blood cell count>3000/mm3, platelet count>100 000/mm3, hemoglobin>9.0 g/dl, serum creatinine within the upperlimit of normal, serum potassium within the upper limit of nor-mal, total bilirubin<3 times the upper limit of normal, andaspartate aminotransferase and alanine aminotransferase levels<5 times the upper limit of normal. ","he exclusion criteriawere: (i) systolic blood pressure<100 mmHg or>150 mmHg;(ii) any treatment for hypertension; (iii) use of ACEIs, ARBs,or renin inhibitors; (iv) severe complications, such as activeinfection, cardiac or renal disease, marked pleural effusion, orascites; (v) active gastrointestinal bleeding; (vi) active intesti-nal pneumonitis; (vii) severe drug hypersensitivity; (viii) activeconcomitant malignancy; or (ix) pregnant or lactating women.",during the firsttreatment cycle,NA
23483298,NA,Combination,No,Chinese patients with advanced pancreatic cancer,"The eligibility criteria included an age of 18–74 years and histologically or cytologically confirmed metastatic PDA with measurable lesions. Patients had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and an expected life expectancy of more than 60 days. The eligibility criteria also included adequate hematologic function (whole white blood cell count <=12,000/mm3, absolute neutrophil count >=2,000/mm3, hemoglobin >=9.0 g/dl, and platelets >=100,000/mm3), hepatic function (aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=100 IU/l, serum total bilirubin (TB) <=1.5 mg/dl, serum albumin >=3.0 g/dl), and renal function (serum creatinine (Cr) <=1.5 mg/dl). If patients had received prior adjuvant treatment, the diseasefree interval between the previous treatment and the time of tumor recurrence must have been at least 6 months. Prior adjuvant chemotherapy with fluorouracil or gemcitabine or radiation therapy was allowed. Patients must have had no previous antitumor treatment for the metastatic disease. ","The key exclusion criteria included surgery within 4 weeks before enrollment, pre-existing sensory neuropathy Cgrade 2, serious pre-existing medical conditions, such as severe heart disease, pulmonary fibrosis, uncontrolled infections and psychogenic disorders, human immunodeficiency virus infection, and active hepatitis B or C virus infection.",during the first treatment cycle,NA
29238851,NCT00372437,Combination,No,"patients with advanced pancreatic cancer and other advanced solid tumors.  Primary tumor site: Pancreas, Head and neck, Lung, Colorectal, Cervix, Ovarian, Other (granulosa cell tumor, T-cell lymphoma, and unknown primary tumor)","Individuals≥18 years with solid tumors were enrolled in the Phase I portion of the study if gemcitabine was considered the standard of care, or if they had refractory tumors or tumors for which no standard therapies exist. For the Phase 2 portion, patients with locally advanced non-resectable or metastatic pancreatic adenocarcinoma were recruited. All patients had adequate hematologic, hepatic and renal function and Karnofsky performance status ≥ 70. ","Key exclusion criteria included > 2 prior chemotherapy regimens, current infection or uncontrolled concomitant disease, medical conditions which may affect study participation, and exposure to investigational drugs or anti-cancer therapy≤28 days prior to study initiation. Pregnant or lactating women were also excluded. Additionally, individuals were excluded from the Phase II study if they had received prior treatment with gemcitabine or had any other form of active cancer (basal cell carcinoma, cervical intraepithelial neoplasia and melanoma in situ were permitted)",during the first cycle of treatment,NA
29756206,NCT01016483,Combination,No,patients with metastatic pancreatic cancer,For both parts of the study eligible patients were aged18years with histologically or cytologically confirmed adenocar-cinoma of the pancreas with documented distant metastases.All patients had to have evidence of disease and have givenwritten informed consent. Female patients needed to have anegative blood pregnancy test at screening and avoid preg-nancy during the trial.,"Exclusion criteria included: Eastern Cooperative OncologyGroup performance status (ECOG PS)>1; prior chemother-apy for metastatic disease; locally advanced disease (unresect-able, M0); bone marrow impairment (haemoglobin<9.0 g/dL,neutrophil count<1.5 x 109/L, platelets<100 x 109/L); renalimpairment (creatinine clearance<60 ml/min); liver functionabnormality (total bilirubin>1.5 x upper limit of normal[ULN], or aspartate transaminase/alanine transaminase [AST/ALT]>2.5 x ULN [or>5 x ULN for patients with liverinvolvement])  and  serum  calcium  above  ULN.  Patientsenrolled in the phase I safety run-in part of the trial did notparticipate in the phase II part.",in the first 28 days of treatment,NA
29030354,NCT02043288,Combination,No,"Patients with Advanced Solid Tumors. Tumor type: Lung cancer, Squamous cell head and neck cancer, Endocrine cancer, Sarcoma, Colorectal cancer, Gastro/esophageal cancer, Breast cancer","Patients 18 years or older with advanced solid tumors that relapsed or were refractory to standard curative or palliative therapy or had a contraindication to therapy were eligible for enrollment. In addition, patients were required to have measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST), performance status [Eastern Cooperative Oncology Group (ECOG) 0–1], adequate bone marrow reserve (absolute neutrophil count >=1.5 x 109/L, platelet count >100 X109/L, and hemoglobin 10 g/dL), and met organ function criteria [total serum bilirubin <1.5 x upper limit of normal (ULN), alanine transaminase, aspartate transaminase <2.5 x ULN or in patients with documented hepatic metastases <=5.0 x ULN, serum creatinine <1.5 mg/dL].","Patients were excluded from enrolling in the trial if they received platinum therapy 3 months prior to screening, cisplatin and gemcitabine concomitantly 6 months prior or were unable to receive platinum-based therapy due to previous toxicity. Those with uncontrolled comorbidities (diabetes, hypertension, and liver disease) and cardiovascular related events within the 6-month period prior to screening were also excluded.",in the first cycle of treatment,NA
26468947,NA,Combination,No,Advanced or Metastatic Bladder Cancer,"Patients with WHO performance status 0 or 1, 18 years or older, with normal hematological, kidney, liver and cardiac function and histologically proven advanced or metastatic TCC of the urothelial tract were eligible for the trial. Adequate tumor specimens from archived or resected tissue had to be available for immunohistochemistry and or fluorescence in situ hybridization evaluation of epidermal growth factor receptor and HER2 expression and subsequent biomarker analysis, even if positive results from the HER1/2 testing were not mandatory for inclusion. Patients with metastatic disease had to be chemotherapy naïve. Patients who had received intravesical therapy for superficial disease or who had received neoadjuvant or adjuvant chemotherapy with a minimum interval of 6 months between the completion of chemotherapy and the diagnosis of metastatic disease were eligible. Given the dependence of lapatinib elimination on CYP3A4 metabolism, drugs which were strong inducers or inhibitors of CYP3A4 were prohibited during treatment.",NA,at cycle 1,NA
29158367,NCT01621243,Combination,No,Patients with Metastatic Pancreatic Cancer,"Age of 18 years or older. Confirmed pancreatic ductal adenocarcinoma. Metastatic disease as documented by CT scan or MRI (locally advanced disease only NOT eligible). At least 1 site of disease measurable by RECIST ver1.1. ECOG performance status of 0 to 1. Adequate bone marrow, renal capacity and hepatic function. Willing to administer daily subcutaneous injections at home","Any prior radiotherapy, chemotherapy, surgery, or investigational therapy for adjuvant or metastatic pancreatic cancer. History of suspected history, or presence of heparin induced toxicity (w/ or w/o thrombosis). History of unexplained bleeding episodes within 3 months of M402 dosing. Received thrombolytic agents w/in the previous month. Had full-dose anticoagulation with heparin, enoxaparin, dalteparin, other LMWH, a/or other anticoagulants w/in 90 days before first dose of M402. High cardiovascular risk, including but not limited to, recent coronary stenting or myocardial infarction in the past year. Major trauma or surgery w/in prior 4 weeks",in cycle 1,NA
28750271,NCT02018874,Combination,No,"patients with advanced or metastatic cancer. Tumour types: Breast, Uterus (endometrium/cervix), Biliary tract, Stomach, Ovary, Kidney, Other (Various head and neck (n = 3), various genitourinary (prostate, testis and bladder; n = 1 each), colorectal)","Patients were aged >=18 years with histologic or cytologic evidence of advanced and/or metastatic solid tu- mours harbouring documented molecular alterations of the PI3K/AKT/mTOR pathway, including PTEN inac- tivation. All patients had an Eastern Cooperative Oncology Group performance status <=1 and adequate organ function. Patients must have had an estimated life expectancy >=12 weeks and discontinued all previous cancer therapies >=2 weeks before study enrolment, with all prior treatment-related toxicities grade <=I (except alopecia). ","Patients with any serious and/or unstable pre- existing medical conditions, symptomatic central nervous system malignancy or brain metastases or uncon- trolled cardiovascular disease were excluded",during the first 4 weeks of study treatment,NA
23511559,NCT00615446,Combination,No,"advanced solid tumours. Primary tumour types: RCC, Clear cell, Non-clear cell, Pancreatic cancer, Adenocarcinoma, Ductal adenocarcinoma, Other tumour type, Adenocarcinoma, Carcinoma, Dedifferentiated, Soft tissue and lung, Mesothelioma, Unknown","The population comprised patients aged X18 years with life expectancy X12 weeks and Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. All patients had histologically proven advanced solid tumours for which curative therapy was not available, had received p1 prior chemotherapy regimen, and were considered eligible for treatment with standard doses of single-agent gemcitabine. Other inclusion criteria included adequate organ function and haematological parameters without transfusion requirement (erythropoietin or darbepoietin permitted).","Patients were excluded if previously treated with gemcitabine or sunitinib; had severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, cerebrovascular accident, or transient ischaemic attack within the previous 12 months; National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0) grade 3 haemorrhage within 4 weeks of study entry; uncontrolled hypertension; uncontrolled brain metastases; and a second malignancy diagnosis within the last 5 years",during cycle 1,NA
19415279,NA,Combination,No,"patients with advanced solid tumors. Primary tumor: Non-small cell lung cancer, Bile duct, Breast, Urothelial, Unknown primary, Kidney, Mesothelioma, Ovaries, Melanoma, Endometrium, Non-Hodgkin lymphoma, Pancreas","Patients with histologically or cytologically conWrmed advanced stage solid tumors, for whom there was no other proven eVective treatment, were eligible for the study. Prior radiotherapy (to less than 25% of bone marrow containing bones) and chemotherapy were allowed but with a treatmentfree interval of at least 4 weeks before entering the study. Other eligibility criteria were as follows: age 18–75 years, performance status (WHO) 0–2, life expectancy of at least 3 months, adequate bone marrow (absolute neutrophil count >=1.5 x 109 l-1 and platelets >=100 x 109 l-1), renal (creatinine <=1.25 times the upper limit of normal and creatinine clearance >50 ml/min) and liver (total bilirubin <1.25 times and aspartate and alanine aminotransferases <=3.0 times the upper limit of normal) function, absence of active infection and malnutrition (loss of more than 20% of the body weight). Patients with brain metastases were eligible if they had been irradiated, the brain lesions were radiologically stable and clinical improvement was evident.",Patients with severe cardiac dysfunction and NCI-CTC peripheral neuropathy grade 1 or more were excluded from the study. The presence of measurable disease was not required,during the Wrst cycle of chemotherapy,NA
17641541,NA,Combination,No,"in patients with solid tumors. Tumor type: Non-small cell lung cancer, Breast cancer, Renal cell carcinoma, Transitional cell carcinoma, Malignant mesothelioma, Others","Patients were eligible if they were 6 18 years of age and had histologically or cytologically confirmed advanced or metastatic solid tumors refractory to standard treatments; in addition, chemotherapy-naïve patients with advanced tumors, for whom no standard and effective treatment existed, were also eligible. Prior surgery, radiotherapy (to less than 25% of marrow-containing bones) or chemotherapy were allowed, but a treatment-free interval of at least 4 weeks was required before study entry. Other eligibility criteria included: WHO performance status <= 2; life expectancy of at least 3 months; adequate bone marrow (platelets >= 100,000/dl, absolute neutrophil count > 1,500/dl and hemoglobin >= 9g/dl), hepatic (total billirubin < 1.5 mg/dl and alanine aminotransferase/aspartate aminotransferase < 3 x upper normal limit) and renal (serum creatinine < 2 mg/dl) function; absence of > 15% weight loss during the last 3 months; absence of any active infection, uncontrolled coronary artery disease or recent myocardial infraction, or other conditions which could influence the compliance of the patient to the protocol. All patients gave written informed consent before study enrollment",NA,during the first cycle (2 biweekly administrations) ,NA
16328413,NA,Combination,No,"patients with solid tumors. Mesothelioma 7 (33%), Colorectal cancer 3 (14%), Pancreatic cancer 2 (10%), Soft tissue sarcoma 2 (10%), Renal cell cancer 2 (10%), Non-small cell lung cancer 2 (10%), Other","Eligible patients were aged at least 18 years, with histological or cytological evidence of solid malignancy for which there was no standard treatment. Up to two prior chemotherapy regimens were allowed but chemotherapy must have been completed at least 4 weeks prior to enrolment (6 weeks for mitomycin or nitrosureas). Prior radiotherapy was allowed to <= 30% of bone marrow but must have been completed at least 2 weeks prior to enrolment. Other eligibility requirements were ECOG performance status 0–2, life expectancy >=12 weeks, adequate hematological function (absolute neutrophil count (ANC) >=1.5x109/l, platelet count >=100x109/l and hemoglobin >=90 g/l), adequate renal function (serum creatinine <= 0.16 mmol/l), adequate liver function (bilirubin <= 1.5 times upper limit of normal (xULN); alkaline phosphatase (ALP), aspartate transaminase (AST) and alanine transaminase (ALT) <= 3xULN; in the presence of liver metastases, ALP, AST and ALT <= 5xULN was acceptable), baseline neurosensory toxicity <= NCI-CTC grade 1, and written informed consent. Measurable disease was not required for study entry.",Patients with controlled brain metastases were eligible but patients with meningeal metastases were excluded,during cycle 1,NA
17932893,NA,Combination,No,patients with advanced pancreatic and biliary cancer,"Patients with histologically confirmed and clinicallymetastatic pancreatic or advanced unresectable/met-astatic biliary adenocarcinoma were eligible for thecurrent study. The response to the combination wasassessed  for  patients  with  measurable  disease.Patients had to be age>18 years with an Eastern Co-operative Oncology Group (ECOG) performance sta-tus of 0 to 2, and adequate organ function (definedas a white blood cell count >= 3000/mm3, an absoluteneutrophil count [ANC] >= 1500/mm3, a platelet count >= 100,000/mm3, serum creatinine <= 2.0 mg/dL, totalbilirubin <= 2.0 mg/dL, and aspartate aminotransfer-ase/alanine aminotransferase <= 2.5 times the upperlimit of normal [ULN] or <=5.0 times the ULN in thepresence  of  hepatic  metastases).  There  was  norestriction in the number of prior chemotherapy regi-mens received. Patients who previously had receivedeither gemcitabine as a standard infusion or irinote-can were eligible to be enrolled on the study; how-ever, patients who were previously treated with bothdrugs would not qualify for the trial. Patients mustnot have received any chemotherapy or radiotherapyfor 4 weeks before entering the study, and must havebeen fully recovered from the acute effects of anyprior chemotherapy or radiotherapy. ","Patients withbrain metastases, active infection, or other seriouscomorbid disease were excluded from this study.Pregnant or lactating women also were excluded.Written informed consent was obtained from allpatients. ",during the first and sec-ond treatment cycles,NA
19556122,NA,Single Drug,No,NA,"Patients with a pathologically confirmed solid tumour metastatic to the liver that was not amenable to surgery were eli- gible for inclusion. The presence of minimal extrahepatic sites of disease was only allowed if the bulk of the disease was in the liver. Patients had to be between 18 and 70 years of age, have a World Health Organisation (WHO) performance status <=2 and have a life expectancy >=3 months. The anatomy of the liver arterial supply, evaluated by angiography, had to allow adequate liver perfusion by HAI through an implantable arterial access device. In addition, patients were required to have a white blood cell (WBC) count >=3.0 x 109/L, a platelet count >=100 x 109/L, serum bilirubin 625 lmol/L, serum transaminases <2 times the upper limit of normal, a prothrombin time <=1.5 x the upper limit of normal, a serum creatinine <=120 umol/L and/or a creatinine clearance >=60 ml/min. Previous radiotherapy or chemotherapy had to be discontinued at least 4 weeks before study entry. ","Patients were excluded if any of the following applied: prior therapy with gemcitabine, symptomatic central nervous system metastases, severe infection and uncontrolled non-malignant systemic disease. Women were ineligible if they were preg- nant or were breast feeding. ",during any cycle of therapy,NA
22371451,NCT00678132,Combination,No,"adults with solid tumors. Tumor type: Non–small cell lung cancer 8 (35), Ovarian 3 (13), Pancreatic 3 (13), Esophageal 2 (9), Thymic carcinoma 2 (9), Others (include head and neck, adrenocortical, sarcoma, mesothelioma, and small-cell lung cancers)","Eligibility criteria included histologically confirmed advanced solid tumors for which standard curative treatments do not exist; completion of chemotherapy, radiotherapy, or surgery >=4 weeks before study enrollment; age >18 years; Eastern Cooperative Oncology Group (ECOG) performance status <=2; life expectancy 3 months or more; adequate organ and bone marrow function; and signed informed consent","Exclusion criteria included uncontrolled intercurrent illness, unstable brain metastases, primary CNS malignancies, and known deleterious BRCA1 and BRCA2 mutations (protocol was later amended to delete this exclusion criterion).",during the first cycle of treatment,NA
18058098,NA,Combination,No,"patients with advanced solid tumors. Tumor type: Colorectal 6, Breast 3, Cholangiocarcinoma 2, Sarcoma 2, Others (Includes one patient each with unknown primary carcinoma, melanoma, mesothelioma, renal cell carcinoma, mucoepidermoid carcinoma of the parotid gland, thymoma/thymic carcinoma, ovarian carcinoma, adenocarcinoma of the pancreas, and non-small cell lung cancer)","Patients with histologically conWrmed advanced solid malignancies refractory to standard therapy or for whom no eVective therapy was available were eligible for this study, including clinically stable patients with treated intracranial metastases, not requiring steroids and without carcinomatous meningitis. Additional eligibility criteria included: age >=18 years; Southwestern cooperative oncology group (SWOG) performance status of <=2; adequate oral/enteral intake with normal gastrointestinal absorption, and adequate hematopoietic, hepatic, and renal function. Patients were excluded if they had major surgery, radiotherapy, chemotherapy, or investigational agents within 4 weeks of study entry, concurrent anti-tumor therapy, previous FTI therapy, concurrent CYP3A4 inhibitors or inducers, or baseline QTc prolongation (>440 ms).","Patients who had prior high-dose chemotherapy requiring hematopoietic stem-cell rescue, prior therapy with nitrosoureas and mitomycin C, and radiation to >30% of bone-marrow containing areas were excluded",through cycle 2/day 1 (Cohort 1) or cycle 2/day 8 (cohorts 2 and 3),NA
17345085,NA,Combination,No,"in patients with solid tumors. Diagnosis: Colorectal 7, Pancreatic 7, Bile duct 2, Neuroendocrine of stomach 1, Renal cell 1, Unknown primary 2, Lung 1, Ovarian 1, Paraganglioma 1, Prostate 1","Patients with histologically conWrmed advanced solid tumors that had failed to respond to standard therapy or for which no standard therapy was available were eligible to participate in this study. Other eligibility criteria included measurable or assessable disease by computed tomography; age at least 19 years; ECOG performance status of <=2; absolute neutrophil count (ANC) of at least 1,500/ul; platelet count of at least 100,000/ul; serum creatinine level less than 1.3 mg/dl; total bilirubin less than 1.0 mg/dl; and AST and ALT levels less than 2.5 times the upper limit of normal; and >4 weeks since any prior therapy and recovery from any side eVects. Prior therapy with irinotecan (60–90 min) or gemcitabine (30 min) given as a short-infusion was allowed. All patients gave written informed consent according to federal and institutional guidelines.",NA,during the Wrst cycle of therapy,NA
17688925,NA,Combination,No,locally advanced cervical cancer,"Eligible patients had previously untreated, histologically confirmed, primary invasive carcinoma of the uterine cervix (any cell type). Clinical stages were IB2, IIA, IIB, IIIB, and IVA with negative para-aortic lymph nodes by radiologic evaluation or biopsy-negative para-aortic nodes if CT scan suspicious for adenopathy. Patients must have had adequate bone marrow, renal and hepatic function defined as absolute neutrophil count ≥1500/mcl; platelet count ≥100,000/mcl; creatinine b2.0 mg%; bilirubin ≤1.5 times normal; and SGOT ≤3 times normal. Patients with ureteral obstruction must be treated with stent or nephrostomy tube to maximize renal function. Additionally, patients were required to have a GOG performance status of 0, 1, or 2, no history of prior malignancy evident within the last 5 years and no prior chemotherapy or radiation therapy. Lastly, patients had to sign an appropriate written informed consent consistent with all federal, state and local institution requirements prior to receiving protocol therapy and be entered on study within 8 weeks of diagnosis.","Ineligible patients had disease that was less extensive than stage IB2 or had clinical evidence of disease outside the pelvis. Also ineligible were patients with severe infection, patients who were pregnant and did not wish pregnancy termination prior to initiation of treatment, patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of radiation fields, and patients whose circumstances did not permit completion of this study or the required follow-up",acute toxicity occurring within 30 days of radiation therapy completion and late toxicity occurring more than 30 days after radiation therapy completion,NA
18305938,NA,Combination,No,advanced lung cancer,"Eligibility criteria included age >=18 years; documented progressive or recurrent carcinoma of the lung requiring a course of palliative radiation therapy; Eastern Cooperative Oncology Group (ECOG) performance status <=2; disease outside any previous radiotherapy port; adequate bone marrow function (hemoglobin >=9.0 g/dl; WBC >=3,500/mm3; neutrophils >=1,500/mm3; platelets >=100,000/mm3); adequate renal function (creatinine <=1.5 mg/dl); adequate hepatic function (serum bilirubin <=2.0 mg/dl; SGOT/AST, SPGT/ALT, and alkaline phosphatase <=2 times the upper limit of normal); and written informed consent. ","Exclusion criteria were concurrent brain irradiation (patients with clinically stable brain metastases were eligible if not receiving corticosteroids); signiWcant, uncontrolled infection; active second malignancy; concurrent severe medical problems unrelated to the malignancy, which would signiWcantly limit full compliance with the study or expose the patient to extreme risk of decreased life expectancy; active peptic ulcer disease, esophageal reXux, or hiatal hernia; concurrent chemotherapy with other agents, immunotherapy, or investigational therapy (RT to other sites was allowed unless the investigator deemed the mucosal toxicity to be intolerable, and prior chemotherapy was also allowed); pregnancy or lactation; patients should not have received more than 60 Gy external beam RT to the thorax at the end of protocol therapy",NA,NA
19855966,NA,Combination,No,advanced pancreatic cancer,"Patients eligible for this clinical trial had locally advanced or metastatic adenocarcinoma of the pancreas with no prior chemotherapy and at least one measurable lesion. Additional eligibility criteria included: ECOG performance status 0–1, age >=18, ANC >=1,500 per mm3, WBC >=3,500 per mm3, platelets >=100,000 per mm3, hemoglobin >9.0 g/dL, serum creatinine <=2.0 mg/dL, ALT and AST <=3 times the upper limit of normal, and total bilirubin <=2.0 mg/dL. A negative pregnancy test for women of childbearing potential was required and patients needed a G6PD level >= the lower limit of normal.","Patients were excluded if they had received prior chemotherapy for advanced pancreatic cancer (adjuvant therapy was permitted), had brain metastases, life expectancy of less than 2 months, congestive heart failure, unstable angina or myocardial infarction during the prior 3 months, or respiratory insufficiency requiring oxygen therapy.",during the first cycle,NA
17051371,NA,Combination,No,"patients with advanced solid tumors. Diagnosis: Colorecta L23, Stomach 4, Pancreatobiliary 2, Melanoma 2, Unknown primary 2, Other 10","Adult patients 18 years of age and older with histologically conWrmed incurable malignancies were eligible. Three or fewer previous chemotherapy regimens and radiation to no more than 30% of bone marrow were allowed . Karnofsky performance status >=60%, leukocytes >=3,000/ul, absolute neutrophil count >=1,500/ul, platelets >=100,000/ul, total bilirubin within institutional normal limits, and alanine and aspartate transferase levels <=2.5 x institutional upper limits of normal were required as was a normal serum creatinine or a measured creatinine clearance >=60 ml/min.","Patients with clinically signiWcant peripheral neuropathy were excluded, as were patients with brain metastasis, platinum allergies, HIV patients on anti-retroviral treatment, and patients with pulmonary Wbrosis.",Course 1 ,NA
21106728,NA,Combination,No,"patients with advanced cancer. Primary tumor site: NSCLC 1, Colorectal 3, Breast 1, Cervical 2, Squamous cell carcinoma 3, Undifferentiated carcinoma 1, Poorly differentiated carcinoma 1, Cholangiocarcinoma 1, Oesophageal adenocarcinoma 2, Fibrosarcoma 1",Supplementary Methods not available,Supplementary Methods not available,during the first cycle of treatment,NA
18217204,NA,Combination,No,patients with advanced adenocarcinoma of the pancreas,"Initially, patients with locally advanced or metastatic pancreas or non-small cell lung cancer (NSCLC) were eligible if they had not received prior gemcitabine chemotherapy. Prior therapy (e.g., radiation, non-gemcitabinecontaining chemotherapy regimens) was allowed provided that the last dose was >30 days prior to start of treatment (6 weeks for mitomycin C and nitrosoureas), and patients had recovered from side effects of the previous therapy. A later amendment restricted the trial to patients with pancreatic cancer and no further patients with NSCLC were enrolled after that point. The restriction was designed to create a more uniform patient population and was also a reflection of pre-clinical data for the efficacy of the study drug in pancreatic cancer cells. Patients also had to have adequate organ function, defined as: WBC≥3,000/mm3, ANC≥1,500/mm3, platelet count≥100,000/mm3, creatinine≤1.5 mg/dl (or calculated glomerular filtration rate≥ 60 ml/min), bilirubin≤1.5×ULN (upper limits of normal), AST, ALT, and alkaline phosphatase≤5×ULN (subsequently reduced to ≤3×ULN) (in the absence of known liver and/or bone metastases). Patients were required to have an ECOG performance status of 0–2. Patients had to have lost no more than 10% of body weight in the 4 weeks prior to study entry. Patients had to be able to understand and provide written, informed consent before starting protocol therapy. Concomitant use of mega-dose vitamins or herbal supplements were not allowed. Use of a daily multivitamin or a nutritional supplement to maintain caloric intake was permitted. CEP701 is a known inhibitor of several cytochrome P450 (CYP) enzymes, including CYP 1A2, CYP 2C9, CYP 3A4/5 and CYP 2C19. Use of other medications that are substrates of these CYP enzymes was not forbidden, but caution was recommended. Patients were forbidden from drinking grapefruit juice while on study due to the fact that CEP701 is metabolized by the CYP 3A4/5 pathway, and grapefruit juice is a potent CYP 3A4/5 inhibitor",Pregnant or lactating females were not eligible.,in cycle 1 ,NA
18829514,NA,Combination,No,"in solid tumor malignancies (Invasive ductal carcinoma-breast, Head and neck carcinoma,  Neuroendocrine carcinoma of the vulva, Soft-tissue sarcoma of the thigh-pleomorphic liposarcoma, Non-small cell lung cancer,  Renal cell carcinoma-clear cell, Colon cancer, Nasopharyngeal carcinoma, Rectal cancer-squamous cell carcinoma, Atypical carcinoid arising from the trachea, Thyroid cancer, Carcinosarcoma of the ovary, Endometrial adenocarcinoma, Uterine carcinosarcoma) or advanced epithelial ovarian cancer","Patients were accrued in two independent cohorts: patients with ovarian cancer and patients with other solid tumors. Patients were eligible if they met the following criteria: histologic or cytologic diagnosis of solid tumor malignancy or ovarian cancer not considered curable by standard treatments; no prior treatment with pemetrexed or gemcitabine; age z18 years; Zubrod performance status 0 or 1; at least 2 weeks from prior radiation and recovered from toxicities of prior treatment; absolute neutrophil count z1,500/AL; platelet count >=100,000/uL; hemoglobin >=9 g/dL; bilirubin <=1.5 x upper limit of normal; alkaline phosphatase, aspartate transaminase, and alanine transaminase <=3 x upper limit of normal, unless there was liver involvement by tumor, in which case >=5 x upper limit of normal was acceptable; calculated creatinine clearance >=45 mL/min using Cockroft and Gault formula; negative pregnancy test for patients of child-bearing potential; and estimated life expectancy of >=12 weeks. Patients with prior radiation to <25% of the bone marrow were eligible, but patients with prior whole-pelvic or whole-brain radiation were excluded. Patients with ovarian cancer were permitted to have an unlimited number of prior cytotoxic chemotherapy regimens. Patients with advanced solid tumors were initially permitted to have an unlimited number of prior chemotherapies, but after two dose-limiting toxicities (DLT) were observed in solid tumor dosing cohort 2, this eligibility criterion was amended to permit only up to two prior cytotoxic regimens for patients in the solid tumor group. ","Patients were excluded for prior experimental therapy in the 30 days before enrollment, pregnancy, or breast-feeding, serious systemic disorder or active infection, history of brain metastases, and inability to take B12 and folate supplementation or dexamethasone.",within the first four cycles of treatment (8 weeks),NA
21051221,NCT00540579,Combination,No,metastatic pancreas cancer,"Eligible patients had histologically documented metastatic adenocarcinoma of the pancreas. No prior chemotherapy for metastatic disease or for primary treatment of locally ad- vanced disease was allowed. Participants may have been previously treated with adjuvant radiation therapy; concurrent 5-fluorouracil or gemcitabine may have been used as a radio- sensitizer in this setting. Following radiation therapy, no further adjuvant treatment with gemcitabine or 5-fluorouracil was allowed. All patients had measurable disease per Response Evaluation Criteria in Solid tumours (RECIST 1.0).14 Patients also had to be able to take daily aspirin (81 or 325 mg) as a prophylactic anticoagulation agent (patients intolerant of aspirin were able to use low dose warfarin or low molecular weight heparin). Patients with a history of, or active, venous thromboembolic events (VTE) were eligible as long as they were therapeutically managed on a stable dose of an appro- priate anticoagulant. Other eligibility criteria included: age >= 18 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; negative serum pregnancy test; ability to swallow intact capsules of pomalidomide; adequate organ function [defined as absolute neutrophil count (ANC) >= 1.5 x 109/L, platelet count >= 100 x 109/L, serum bilirubin <= 2.0 mg/dL (34 umol/L), serum SGOT/AST or SGPT/ALT 3 x the upper limit of normal (ULN) or 5 x ULN in the case of liver metastases and serum creatinine <=2.5 mg/dL (221 umol/L)]","The study excluded: patients with known brain or leptomeningeal metastases; clinically significant cardiovascular disease; or a history of an- other malignancy (except basal cell or squamous cell carci- noma or carcinoma in situ of the cervix or breast, localised prostate cancer with PSA < 1.0 mg/dL) unless free of disease for >>3 years, or pregnant or lactating females.",during cycle 1,NA
21170669,NCT00265876,Combination,No,advanced pancreatic cancer,"Patients were required to be ≥18 years of age, Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2; absolute granulocyte count ≥1.5×109/L, platelet count ≥100×109/L, and normal serum creatinine and bilirubin. Aspartate aminotransferase (AST) and alanine transaminase (ALT) were required to be ≤2.0 × the upper limit of normal (ULN), unless liver metastases were present (≤5 × ULN). Patients enrolled to the phase II portion of the study were required to have measurable disease (by Response Evaluation Criteria in Solid Tumors [RECIST]).","Exclusion criteria included concurrent other malignancies, any serious underlying medical conditions that would impair the ability of the patient to receive protocol treatment, or a gastrointestinal tract disease resulting in an ability to take oral medication.",cycle 1,NA
20589760,NA,Combination,No,nonsmall cell lung cancer,"Eligible patients had histologically proven NSCLC stages IIIA or IIIB, a Karnofsky score >=70, normal renal function, andadequate hematopoiesis. All patients underwent bronchoscopy, mediastinoscopy, computed tomography (CT) exam of chest and abdomen, bone scan, lung function and bloodtests.",NA,at least 6 weeks after treatment,NA
18608594,NA,Combination,No,"Patients with chemotherapy-resistant metastatic cancers (Pancreas, Neuroendocrine, Gastric, Lung, Colon, Breast, Prostate, Esophagus, AUP, Sarcoma, Liver, Hear & Neck, Kidney, Bladder, Mesothelioma)","Patients with chemotherapy-resistant metastatic cancers; i.e. tumors that progressed on chemotherapy were eligible for the protocol. Subjects had to have a Karnofsky performance status  of 50% or greater, and cardiac, pulmonary, renal, hematological and hepatic functional requirements as described below. Other eligibility criteria included age greater than 18 years and a life expectancy greater than 2 months. There was no upper age limit. As many as 5 prior chemotherapy regimens were allowed, as well as prior therapy with cisplatin and/or gemcitabine. However, chemotherapy could not be given within four weeks of protocol treatment. Radiation therapy could not be given within six weeks of protocol treatment. A protocol candidate was required to demonstrate comprehension of the informed consent and also to understand other available therapeutic options.",during the first 2 courses of therapy,NA,NA
17987263,NA,Combination,No,newly diagnosed glioblastoma,"Patients with a pathological diagnosis of supratentorial GBM (based on WHO classification ) have beenadmitted to the study after first line surgical procedure, either stereotactic biopsy or subtotal resection. Other eligibility criteria included age between 18 and 75 years, Karnofsky Performance status (KPS) >=70, life expectancy >=3 months, adequate bone marrow reserve (absolute neutrophils count—ANC >= 1.5 x 109/l, platelet count >= 100 x 109/l, hemoglobin >= 10.0 g/dl), normal renal (serum creatinine <= 1.5 mg/dl) and hepatic function (total bilirubin <= 1 g/dl x UNL, SGOT/SGPT <= 2.5 x UNL).","Patients were not eligible if they had received prior brain irradiation, and/or prior systemic chemotherapy, and/or any experimental agent for GBM, or if they had been diagnosed with malignancies within 5 years from study enrollment, with the exception of in situ carcinoma of the cervix, and/or carcinoma nonmelanoma of the skin. Other exclusion criteria were considered the presence of active concomitant illness, such as uncontrolled infections, diabetes, and severe cardiovascular or pulmonary disease. Patients with psychiatric disorders were not eligible. Pregnant or nursing women and those with reproductive potential not using an effective contraceptive method were also excluded from the study. Concomitant treatment with steroids and antiepileptic drugs was allowed.",during the radiotherapy,NA
16673059,NA,Combination,No,locally advanced non-small cell lung cancer,"All patients had histologically proven and unresectable stage III NSCLC. The detailed patient characteristics are listed in Table 1. Inclusion criteria were as follows: Karnofsky performance status of 80–100; age > 18 years; forced expiratory volume in 1 s (FEV1) ≥ 1.5 l; serum creatinine level ≤ 1.5 mg/dl; granulocyte count ≥ 2,000/µl; platelet count ≥ 100,000/µl; serum bilirubin level ≤ 1.5 × the normal value; serum glutamic-oxaloacetic transaminase level ≤ 2.5 × the normal value; and alkaline phosphatase level ≤ 5 × the normal value.","Exclusion criteria were as follows: malignant pleural effusion and/or pericardial effusion; recurrent disease after previous treatment; history of another malignancy; history of anticancer chemotherapy or radiotherapy; recent history of myocardial infarction, angina pectoris, congestive heart failure, or uncontrolled arrhythmia within 6 months of diagnosis; and pregnancy.",during concomitant radiochemotherapy,NA
21969517,NA,Combination,No,patients with advanced pancreatic cancer,"Written informed consent was obtainedfromallpatients before entering the study.Eligibility criteriaincludedage >= 18 years and histologically or cytologically confirmed metastatic PDA with measurable disease by computed tomography scan as defined by the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.0 guidelines.18 Patients had no previous treatment for metastatic disease. Prior adjuvant treatment with fluorouracilorgemcitabineadministeredasa radiation sensitizerduringandup to4weeks after radiation therapy was allowed. If a patient received adjuvant therapy, tumor recurrence must have occurred >= 6 months after the last treatment. Patients had an Eastern Cooperative Oncology Group performance status of 0 or 1 and had adequate hematologic, hepatic, and renal function.",NA,during cycle 1,NA
19023677,NA,Combination,No,biliary tract and gallbladder carcinomas,"Patients with a histologic diagnosis of carcinoma of the biliary tract (intrahepatic, extrahepatic, ampulla of Vater) or gallbladder with either locally advanced unresectable or metastatic disease that was not amenable to combined chemotherapy and radiation were potentially eligible for enrollment in this trial. Patients were required to be at least 18 years and to have an Eastern Cooperative Oncology Group (ECOG) performance score of 0–2. Hematologic and chemistry parameters were to be in the following ranges: absolute neutrophil count≥1.5×109 per liter, platelets≥ 100×109 per liter, total bilirubin≤3.0 times the institutional upper normal limit (UNL), AST≤5.0 times the UNL, and creatinine≤1.5 times the UNL. Prior embolization, chemoembolization, or radiofrequency ablation was permitted if completed at least 4 weeks prior to enrollment and new tumor growth was present. Adjuvant chemoradiotherapy or chemoradiotherapy for locally advanced disease using a drug other than gemcitabine was permitted if at least 6 months prior to enrollment.","Prior radiation to ≥25% of bone marrow was not allowed. Patients were not eligible if pregnant or lactating and were required to use adequate contraception methods to prevent pregnancy during treatment. Other contraindications included a history of brain or other central nervous system metastases not amenable to local therapy. Any history of prior malignancy diagnosed within 5 years was not allowed, with the exception of basal or squamous cell carcinoma of the skin and cervical carcinoma in situ.",NA,NA
18823054,NA,Combination,No,patients with nonsmall cell lung carcinoma,"Between July 2004 and September 2006, 13 patients with histologically proven, recurrent or refractory,advanced NSCLC were included in the study (Table 1).Inclusion criteria were the presence of measurable orevaluable disease; =2 previous chemotherapy regi-mens with at least 1 containing a platinum com-pound; prior chemotherapy that ended at least 4weeks previously; age>=18 years; an Eastern Coopera-tive Oncology Group (ECOG) performance status of<=2; adequate bone marrow reserve (neutrophil count>=1500mm-3 and a platelet count>=120,000mm-3); adequate renal and hepatic function; absent or stable brain metastases; and an estimated life expectancy>=12 weeks.",NA,NA,NA
19117344,NA,Combination,No,pretreated metastatic urothelial bladder cancer patients,"Eligible patients had to have histologically confirmed uro-thelial bladder cancer and to have received 1 prior line ofchemotherapy for metastatic disease including platinumcompounds/gemcitabine. Adjuvant chemotherapy waspermitted. Patients were required to have measurable dis-ease. All patients had to have adequate hematologic, renal,and hepatic functions (hemoglobin>9 g/dL, an absoluteneutrophil count [ANC]>1.5 x 109/L, platelet count>100 x 109/L, serum bilirubin level<1.5 upper limit ofnormal, and serum creatinine level <= 2 mg/dL), a WorldHealth Organization (WHO) performance status<3,and an estimated life expectancy >=12 weeks. Writteninformed consent was required before enrolment.","Exclusion criteria included brain metastases, bone me-tastases as the only site of metastases, radiotherapy within4 weeks before study entry, a history of other prior malignan-cies (except for treated nonmelanoma skin cancer or carcinoma in situ of the cervix), significant cardiac disease, or anyother serious medical conditions that would impair the abil-ity of the patient to receive the protocol treatment.",during Cycle 1.,NA
20044630,NA,Combination,No,"advanced solid tumors. Primary tumor type: Pancreatic adenocarcinoma, NSCLC, Gastro-esophageal, Colorectal, Renal, SCLC, Ovarian, Mesothelioma, Melanoma, Unknown primary","Patients with histologically proven solid tumor malignancies for which there is no standard effective therapy were eligible for enrollment. Additional eligibility criteria included: age ≥18 years; Karnofsky performance status ≥70%; absolute neutrophil count (ANC) ≥2000/mm3, platelets ≥100,000/mm3, hemoglobin ≥9.0; serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), alkaline phosphatase (AP) ≤3X upper normal limit (ULN); ≤5X UNL if known hepatic metastasis; bilirubin ≤1.5X UNL; creatinine clearance estimated ≥50 ml/min; no prior chemotherapy, radiation therapy, hormonal or biological therapy within 28 days prior to day 1 of study drug; no prior nitrosourea or mitomycin C within 42 days prior to day 1 of study drug; no prior pelvic radiation to more than 30% of the bone marrow; previous treatment-related toxicities should be fully resolved; no serious or poorly controlled medical condition which could be exacerbated or that would seriously complicate compliance with the protocol. Women of child-bearing potential were required to practice contraception and could not be pregnant or lactating",NA,during cycle one,NA
20978761,NA,Combination,No,"patients with advanced solid tumors. Disease site––pathology type: Gastric adenocarcinoma, Pancreatic adenocarcinoma, Cholangiocarcinoma, Colon adenocarcinoma, Non-small-cell lung cancer, Hepatocellular carcinoma, Bladder carcinoma, Other ","Enrolled patients were >=18 years of age with histologically or cytologically conWrmed advanced or metastatic solid tumors refractory to standard treatments, had received not more than 2 prior chemotherapy regimens, and had an estimated life expectancy of >=12 weeks. All patients were eligible regardless of measurability of disease, but response was assessed only in those with measurable disease as deWned by Response Evaluation Criteria in Solid Tumors(RECIST) . Patients were required to have an ECOG performance status of 0 or 1, adequate hematologic (deWned as absolute neutrophil count [ANC] >=1,500/mm3, platelet count >=100,000/mm3, hemoglobin >=9 g/dL), hepatic (bilirubin <1.5 times the upper limit of normal [xULN], aspartate transaminase (AST) and alanine transaminase (ALT) <3.0 x ULN if liver metastases were not present or <5 £ ULN if liver metastases were present), and renal (creatinine clearance [CrCl] >=45 mL/min) functions. Prior surgery or radiotherapy to <25% of bone marrow was allowed. Patients could not have received radiotherapy <=1–2 weeks before entering the study, and must have recovered from the acute toxic eVects of any previous chemotherapy or radiotherapy prior to enrollment.","Patients were excluded if they met any of the following criteria: received treatment <=30 days before study entry with any investigational drug; previously treated with pemetrexed or gemcitabine; pregnant or breast-feeding; serious concomitant systemic disorders that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient’s ability to complete the study; inability to interrupt aspirin or other non-steroidal anti-inXammatory drugs (NSAIDs) for more than 5 days; symptomatic brain metastases; presence of clinically relevant third-space Xuid collection that could not be controlled by drainage or other procedures prior to study entry; and inability or unwillingness to take folic acid, vitamin B12 supplementation, or dexamethasone.",during cycle 1,NA
21921646,NA,Combination,No,locally advanced unresectable or metastatic pancreatic adenocarcinoma,"Eligible patients were adults with a histologically or cytologically confirmed diagnosis of unresectable, locally advanced or metastatic PAC. All patients had measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.0), an Eastern Cooperative Oncology Group (ECOG) performance status of <= 2, and had not received any prior chemotherapy for locally advanced or metastatic disease (except for adjuvant therapy if completed > 6 months ago).",NA,during the first 28-day treatment cycle,NA
20082116,NA,Combination,No,"patients with refractory solid tumors. A variety of tumor types were treated, the most common were ovarian (n=7) and lung (n=5). Other tumor types (n=28) include bladder, breast, cholangiocarcinoma, colon, esophagus, kidney, melanoma, neuroendocrine, primary peritoneal, pancreas, prostate, sarcoma, thyroid and uterine.","Patients with a histologically confirmed malignancy considered unresectable and for which no other curative or lifeextending therapy was available were eligible for the trial. Patients were ≥18 years of age, had a life expectancy of ≥12 weeks, an Eastern Cooperative Oncology Group performance status ≤2, and were willing to provide all biologic specimens required by the protocol.","Exclusion criteria included any chemotherapy, immunotherapy, biologic therapy, or radiation therapy ≤4 weeks prior to study registration (≤6 weeks with mitomycin or nitrosoureas). Prior treatment with cisplatin and gemcitabine was allowed. Patients who failed to recover from toxic effects of prior treatment, received radiopharmaceuticals, or who received radiation therapy to the chest, potentially the heart or >25% of the bone marrow were also excluded. Patients were required to have the following laboratory values: hemoglobin ≥9.0 g/dL, absolute neutrophil count ≥1,500/μL, platelet count ≥100,000/μL, total bilirubin ≤2 × the upper limit of normal (ULN), AST≤2.5×ULN, alkaline phosphatase ≤2×ULN or ≤5×ULN if liver involvement, creatinine ≤1.5×ULN. Patients who received prior anthracycline therapy had to have a normal ejection fraction on MUGA. Other exclusion criteria included uncontrolled infection; pregnancy, lactation or unwillingness to use adequate contraception; significant cardiac disease; CNS metastases or seizure disorder; ≥ grade 2 peripheral neuropathy, as defined by the NCI Common Toxicity Criteria Version 2.0; history of serious allergic reactions to eggs; and concurrent use of drugs that inhibit the CYP450 3A4 enzyme or that may prolong the QTc interval ",during the first cycle,NA
18236006,NA,Combination,No,patients with metastatic transitional cell carcinoma of the urothelium,"Patients with a histologic or cytologic diagnosis of Stage IV TCC of the urothelium with clinical evidence or biopsy proof of metastases (T4b, N1–3, M1) were eligible for the study. All patients had measurable disease as defined by RECIST . Patients were not eligible if they had prior chemotherapy for metastatic disease, although adjuvant or neoadjuvant chemotherapy completed at least 6 months before enrollment was permitted. Prior radiation therapy was allowed as long as the irradiated area was not the only source of measurable disease and therapy was completed at least 3 weeks before enrollment. (Prior radiation to the whole pelvis was not allowed.) All patients scored 70–100 on the Karnofsky Performance Status (PS) Scale and had an estimated life expectancy of ≥12 weeks. Patients were required to have adequate bone marrow reserve, with an absolute neutrophil count (ANC)≥1.5×109/L, a platelet count of >100×109/L, and hemoglobin of >9.0 g/dL; and adequate hepatic and renal function (bilirubin<1.5 × the upper limit of normal [ULN], alkaline phosphatase [ALP], aspartate transaminase [AST], alanine transaminase [ALT]<3.0 × ULN [ALP, AST, and ALT <5 × ULN was acceptable with metastasis], and calculated creatinine clearance [ClCr]>45 mL/min using the standard Cockcroft and Gault formula ).","Patients were excluded if they were unable to discontinue aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) for 2 days before, on the day of, and 2 days after the dose of pemetrexed; had symptomatic brain metastases; or clinically relevant (by physical exam) third-space fluid collections (e.g., ascites, pleural effusions) uncontrolled by drainage or other procedures before study entry. Patients had to be willing and able to take oral or IV (intravenous) dexamethasone, an oral folic acid preparation, and intramuscular (IM) injections of vitamin B12 according to protocol specifications.",in the first cycle,NA
17925553,NA,Combination,No,in pancreatic cancer,"Patients with pathologic confirmation of pancreatic carcinoma with resectable, unresectable, or low-volumemetastatic diseasewere eligiblefor this study. Resectability was determined based on a multidetector computed tomography (CT) scan using a biphasic technique and surgical consultation per National Comprehensive Cancer Network guidelines.12 Pretreatment evaluation included a complete history and physical examination, and baseline assessment of organ function. Eligibility criteria included life expectancy more than 12 weeks; Zubrod performance status of <= 2; and adequate hematologic, renal, and hepatic function. Biliary obstruction, if present, required stenting before treatment initiation. ",Patients with prior history of abdominal irradiation or chemotherapy for pancreatic cancer were ineligible. ,during the first 9 week,NA
19556811,NA,Combination,No,patients with metastatic carcinoma of the breast,"Patients were eligible for the study if they had confirmed breast cancer with metastasis. Patients may have received previous hormonal therapy at any time but no more than 2 chemotherapy regimens for their metastatic disease. Patients were required to be older than 18 years and to have a life expectancy of more than 12 weeks, an Eastern Cooperative Oncology Group performance status of 2 or less, and adequate bone marrow, liver and kidney functions, defined as follows: absolute neutrophil count >= 1.5 x 10 9 /l, platelet count > 100.0 x 10 9 /l, hemoglobin level > 9.0 g/dl, total bilirubin level within the upper limits of normal range, aspartate aminotransferase and alanine aminotransferase both < 1.5 times the upper limit of normal range and serum creatinine < 2.0 mg/dl. Patients were required to have a therapy-free interval of at least 3 weeks since receiving their last radiation therapy or chemotherapy","All patients with childbearing potential who were not using adequate contraceptive measures were excluded from the study, as were those with metastatic central nervous system disease, a history of other invasive malignancy, concurrent active infection or a concurrent medical condition not well controlled by medication. ",NA,NA
20332663,NA,Combination,No,patients with locally advanced pancreatic cancer,"Patients with cytologically, histologically, or clinically confirmed locally advanced unresectable pancreatic cancer were enrolled in the trial. Determination of resectability was based on helical computed tomography (CT) scan, magnetic resonance im- aging, and positron emission tomography. Tumors without distant metastases were considered nonresectable if they involved vascular structures such as the superior mesenteric artery or the celiac trunk, or if a portal or superior mesenteric-portal venous confluent thrombosis was present. Eligibility criteria included life expectancy of >12 weeks, an Eastern Cooperative Oncology Group performance status of <=2, age between 20 and 75 years, and adequate hematologic, renal, and hepatic function. Biliary obstruction, if present, required stenting before treatment initiation. Patients with tumors in the head, uncinate process, and body or tail of the pancreas were eligible.","Patients with neuroendocrine tumors or clinical or radiographic evidence of distance metastasis, or previous treatment for pancreatic cancer were excluded.",During the CRT,NA
18449006,NA,Combination,No,"patients with thoracic malignancies: Non-small cell lung cancer, Small cell lung cancer, Esophageal cancer","1. Histologically or cytologically documented solid tumors. 2. Measurable disease by RECIST. 3. Patients must have progressed on standard therapy, not be a candidate for standard therapy, or have a disease or disease status for which there is no defined standard therapy. 4. Age >=18 yr. 5. Eastern Cooperative Oncology Group (ECOG) functional status of 0–2. 6. Adequate organ function defined as: Renal: serum creatinine <=1.5 x ULN or Cockcraft calculated creatinine clearance of >=60 ml/min; Hepatic: transaminases <=2.5 x ULN and total bilirubin in normal range; Bone marrow: ANC >=1.5 x 106/l, platelet count >=100,000 x 106/l. 7. Life expectancy of at least 8 wk","1. Previous anaphylactic reaction or severe allergic reaction to paclitaxel and/or docetaxel; 2. Previous anaphylactic reaction or severe allergic reaction to gemcitabine; 3. Symptomatic brain metastases; 4. Inability to sign informed consent; 5. Pregnant or lactating women; 6. Active infectious process that will require treatment with antibiotics for greater than 4 wk; 7. Uncontrolled congestive heart failure; 8. Symptomatic coronary artery disease or heart block; 9. Myocardial infarction within the last 3 months; 10. Chemotherapy, radiation therapy or any other treatment for malignancy within the last 3 wk; 11. Grade >=2 peripheral neuropathy at baseline assessment from any cause; 12. Irradiation of >25% of bone marrow; 13. Prior exposure to nitrosureas; 14. Prior exposure to >6 cycles of alkylating agents; 15. Prior exposure to >2 cycles of mitomycin; 16. Treatment with >3 previous lines of cytotoxic therapy for metastatic disease",on first cycle ,NA
20349264,NA,Combination,No,refractory and advanced malignancies,"Patients were recruited at the Stanford Cancer Center in Stanford, CA. The initial eligibility criteria for this trial were: histologically confirmed malignancy, metastatic or unresectable, for which standard curative or palliative measures did not exist or were no longer effective; age ≥18 years; Eastern Cooperative Oncology Group performance status ≤2; life expectancy >3 months; ≤3 prior chemotherapy regimens; no prior pelvic or whole abdominal radiotherapy; no prior chemotherapy, radiotherapy, or major surgery <4 weeks prior (<6 weeks for mitomycin C and nitrosureas); fully recovered from adverse events from prior treatments; absolute neutrophil count ≥1,500/mm3; platelet count ≥100,000/mm3; total bilirubin ≤1.5 mg/dL; normal aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels within 2.5 times the upper limit of normal; creatinine within normal limits or creatinine clearance ≥60 mL/min/1.73 m2 for patients with elevated creatinine; barrier contraception required for sexually active male patients; no pregnancy; no other investigational agents concurrently; no brain metastases; no history of allergic reaction to oblimersen or gemcitabine; no HIV-positive patients on combination antiretroviral therapy; no portal hypertension, history of cirrhosis/ hepatitis, or radiographic evidence of cirrhosis and/or varices.",NA,during the first 2 cycles of treatment,NA
19194117,NA,Combination,No,"patients with solid tumors. Histological diagnosis: Head and neck squamous cell carcinoma, Nasopharynx carcinoma, Small cell lung cancer, Nonsmall cell lung cancer, Thymoma, Mesothelioma ","Eligible patients had a histologically confirmed diagnosis of a solid tumor not eligible for a curative treatment, and measurable disease. Additionally, patients had to be >=18-year-old, have a Zubrod performance status <= 2, life expectancy >=12 weeks, and provide written informed consent","Main exclusion criteria were defined as follows: absolute granulocyte count < 1500/mm3, platelet count < 100,000/mm3, hemoglobin < 8 g/dL, aspartate aminotransferase and alanine aminotransferase > 2 x upper normal limit, bilirubin >1.5 x upper normal limit, creatinine >1.5 mg/dL, concurrent severe medical problems, pregnancy, chemotherapy received within prior 4 weeks, and prior treatment with topotecan, irinotecan, or gemcitabine.",the first treatment course,NA
18379785,NA,Combination,No,"patients with advanced solid tumors: Sarcoma 5, Leiomyosarcoma 3, Other 2, NSCLC 3, Colorectal 2, Renal 2, Anal 1, Salivary gland 1, Endometrial 1","Patients >=18 years of age with histologically conWrmed advanced solid tumor malignancies refractory to standard treatment options and/or for whom a gemcitabine-based regimen was appropriate were eligible for enrollment. Patients were required to have: an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; adequate hematologic function (hemoglobin >= 9 g/dL, absolute neutrophil count [ANC] >= 1,500/uL, platelets .= 100,000/uL); adequate hepatic function (serum total bilirubin <= upper limit of normal [ULN], serum total ALP <= ULN [or if elevated, ALP liver fraction or 5' nucleotidase <= ULN], serum AST and ALT <= ULN, serum albumin >= 2.5 g/dL); and adequate renal function (serum creatinine <= ULN). ","Patients were excluded if they had prior exposure to trabectedin; known hypersensitivity to dexamethasone or components of trabectedin or gemcitabine; known central nervous system metastasis; peripheral neuropathy >= grade 2; were pregnant or breastfeeding or of reproductive potential (males or females) and not employing adequate contraception; had other serious concomitant illness; were using concomitant medications that decrease hepatic blood Xow, such as somatostatin and its analogs, octreotide and lanreotide and non-cardioselective betablockers.",the Wrst cycle,NA
16566993,NA,Combination,No,"patients with recurrent cervix cancer: Squamous 19, Adenocarcinoma 5, Adenosquamous 3","Patients were eligible if they had recurrent cervical cancer following definitive radiation therapy. Eligible histologies included squamous cell, adenocarcinoma, or adenosquamous cell cancer of the cervix. Patients needed to have measurable disease by radiographic studies (plain X-ray, CT or MRI scans), adequate hematologic parameters (neutrophil count >1500/mm3, platelets >100,000/mm3), adequate renal function (serum creatinine <1.5mg/dl), adequate hepatic function (SGOT and total bilirubin <2× upper limit of normal (ULN)), ECOG performance status of 0 to 2, no serious active underlying medical issues, <grade 2 proteinuria, and no previous chemotherapy (except radiation-sensitizing doses of cisplatin (40 mg/m2/week)).",NA,during the first cycle of therapy,NA
20153912,NA,Combination,No,patients with advanced non-small cell lung cancer,"Patients were registered at the central data center when the following eligibility criteria were confirmed: cytologically or histologically confirmed NSCLC; stage IIIB disease without any indications for radiotherapy or stage IV disease; no prior treatment; age 70 years of age or older; and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. The criteria for organ function included: neutrophil count ≥2000/uL; platelet count ≥100,000/uL; hemoglobin level ≥9.5 g/dL; serum bilirubin concentration ≤1.5 mg/dL; serum aspartate aminotrans- ferase and alanine aminotransferase concentrations ≤100 IU/L; creatinine level ≤1.3 mg/dL; creatinine clearance rate ≥30 mL/min (≥60 mL/min for the phase II portion); and arterial oxygen saturation ≥90%","Patients were excluded from the study if they had either inter- stitial pneumonia or pulmonary fibrosis on chest X-ray films, any severe concomitant disease (severe cardiac disease, uncontrolled diabetes mellitus, severe infection), concomitant malignancy, pleural effusion necessitating treatment, or symptomatic cerebral involvement.",dur-ing the first cycle of chemotherapy,NA
20197102,NA,Combination,No,recurrent and refractory hodgkin lymphoma,"Eligibility criteria included histologically proven, recurrent or refractory HL confirmed at Stanford University; aged <=70 years; ECOG performance status 0-2. Adverse risk factors have been previously defined  as: (1) stage IV disease at relapse, (2) constitutional ‘‘B’’ symptoms at relapse, and (3) failure to achieve minimal disease (single lymph nodes <=2 cm or >75% reduction in a bulky tumor mass or bone marrow [BM] involvement <=10%) at transplant. High-risk HL patients were defined as those who had 1 or more of the above risk factors. All patients signed informed consent for the study approved by the institutional review board at Stanford University School of Medicine. Pretransplant testing included routine staging with medical history, physical examination, computed tomography (CT) with or without positron emission tomography (PET), BM aspiration, and biopsy with cytogenetics, baseline assessment of cardiac ejection fraction, and pulmonary function tests (PFTs). ",Patients with ejection fraction <40% and diffusion capacity corrected for hemoglobin <5% were not eligible for the study.,NA,NA
20188433,NA,Combination,No,advanced non-small cell lung cancer,Patients ≥18 years with an ECOG performance status of 0 or 1 and histologically proven stage IIIB or stage IV NSCLC not amenable to curative surgery or radiation therapy and who provided informed consents were recruited. Eligible patients had no prior immunotherapy or treatment with antiangiogenesis agents or chemotherapy (except adjuvant therapy completed >6 months prior to start of study treatment); life expectancy of ≥12 weeks; resolution of all acute toxic effects of prior radiotherapy or surgical procedures to National Cancer Institute (NCI) Common Terminol- ogy Criteria for Adverse Events (CTCAE) grade ≤1 (except alopecia); and adequate organ function,"Patients receiving treatment with anticonvulsant agents or coumarin-derivative anticoagulants within 2 weeks of starting study treatment were ineligible for inclusion in the trial. Patients were also excluded if they had grade 3 hemorrhage or evidence of hemoptysis <4 weeks before starting treatment; uncontrolled hypertension; history of or known brain metastases, spinal cord compression or carcinomatous meningitis or new evidence of brain or leptomeningeal disease; prior irradiation to >25% of the bone marrow (pelvic irradiation to 25%); history of cardiac disease, cerebrovascular disease or pulmonary embolism in the 12 months prior to start of study treatment; or ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2, atrial fibrillation of any grade, prolongation of the QTc interval or history of torsade de pointes",during the first treatment cycle,NA
16337995,NA,Combination,No,cervical cancer,"Eligible patients were at least 18 years old with pathological confirmation of cervix cancer with adenocarcinoma, adenosquamous carcinoma, clear cell carcinoma, squamous cell carcinoma, or poorly differentiated carcinoma, not otherwise specified and were International Federation of Obstetrics and Gynecology (FIGO) stage IB2 – IVA or stage IB1 with pathologically documented positive pelvic lymph node. Patients must be eligible to receive primary chemoradiation with curative intent and could not have undergone previous hysterectomy. Patients could not have evidence of tumor metastases in para-aortic lymph nodes either by surgical staging or diagnostic imaging. Paraaortic lymph nodes greater or equal to 1.5 cm in diameter on imaging studies must have been biopsy-proven negative for cancer. Required pretreatment evaluation included: history and physical examination (including pelvic examination), evaluation of performance status, clinical tumor measurements, laboratory testing (including complete blood count and comprehensive metabolic panel), and para-aortic lymph node evaluation by surgery, CT, or MRI. Eligibility required a Karnofsky performance status >60, and documentation of adequate bone marrow function (absolute granulocyte count >1500 cells/Al, platelet count >150,000 cells/Al), renal function (serum creatinine <2.0 mg/dl), and liver function: bilirubin <2 times the institutional upper limit of normal and SGOT <3 times the upper limit of normal.","Exclusion criteria included: a previous malignancy within 5 years exclusive of non-melanoma skin cancer, prior pelvic radiation, prior systemic chemo- therapy for malignancy, previous hysterectomy, evidence of distant metastases, active serious infection, pregnancy, breast-feeding, or documented HIV infection",within 30 days of completing protocol therapy,NA
21570216,NA,Combination,No,Patients With Locally Advanced Head-and-Neck Cancer,"Patients with histologically confirmed Stage III, IVA, or IVB LAHN cancer who were suitable for definitive chemoradiother- apy were eligible. Inclusion criteria specified that patients should be aged 20 to 75 years; have a definitive pathologic diag- nosis of cancer of the head and neck, an Eastern Cooperative Oncology Group performance status of 0 or 1, no previous radiotherapy, lesion(s) evaluated by imaging, and a life expectancy of at least 3 months; and have provided informed consent. They also had to have adequate hematologic function (white blood cell count >4,000/mm3, neutrophil count >2,000/mm3, platelet count >100,000/mm3, and hemoglobin level >9.5 g/dL); adequate hepatic function (aspartate aminotransferase and alanine aminotransferase levels <1.5 x normal upper limit, total bilirubin level <1.5 mg/dL, and alkaline phosphatase level <2.5 x normal upper limit); and adequate renal function (creatinine serum level <1.2 mg/dL).","Excluded patients were those with a history of hypersensitivity to the test drug or serious concurrent disease or apparent infection with fever, pregnant or lactating women or women who may possibly be pregnant, and other patients considered by the attending physician to be unsuitable for participation in the study. Criteria for discontinuation of therapy were defined as apparent exacerbation of the disease or a serious complication, a serious adverse event making continuation of treatment difficult, interruption of radiation for 2 consecutive weeks, refusal of the patient to continue therapy, or any other condition judged by the attending physician to contraindicate continued therapy.",NA,NA
17439736,NA,Combination,No,brain metastases in patients with non-small cell lung cancer,"The inclusion criteria are as follows: (1) Patients with histologically or cytologically confirmed NSCLC. (2) Patients with BM confirmed by MRI. (3)The number of BM is 3 or more than 3. (4) No previous radiotherapy or surgery to the brain of any form was allowed. (5) Agree to receive radiotherapy. (6) Patients with symptoms of BM need radiotherapy immediately or the extra cranial disease has been controlled. (7) Patients have recovered from previous treatment. (8) Eastern Cooperative Oncology Group performance status of 0-2 (2 includes patients whose status can be improved by radiotherapy and age ≥ 18 years). (9) Adequate haematologic function was required: white blood count ≥3.50×109/L, platelet count >100×109/L, and a haemoglobin level ≥ 100 g/L. (10) Adequate hepatic function was required: serum bilirubin needed to be below two times the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) below three times ULN-ALT and AST could be elevated to five times ULN in patients with known metastatic disease in the liver and creatinine below two times ULN. (11) Written informed consent.",The following patients were excluded from the study: (1) Patients with seizures who were not stable on antiepileptic medication. (2) Female patients of childbearing potential without adequate contraception (3 months). (3) Patients allergic to contrast material. (4) Patients without written informed consent. ,the first post-treatment month,NA
10690391,NA,Combination,No,"advanced previously treated malignancies. Primary tumor site: Pancreas, Head and Neck, Thyroid, Chest(Including mesothehoma), Ovary, Sarcoma, Bladder, Kidney, Stomach, Rectum, Carcinoma of unknown primary","Eligibility criteria also included : 1) Karnofsky performance status >= 6 0 ; 2) age 18-75 years; 3) life-expectancy > 3 months (enabling the completion of at least two courses of treatment); 4) no radiotherapy within three weeks prior entering onto the study; 5) adequate bone marrow reserve: white blood cell count 3.5 x 1O9/1, platelets 100 x 1O9/I. hematocrit > 30%. adequate liver function : bilirubin <1.5 upper normal limit (UNL). alanine transaminase (ALAT) or aspartate trans- aminase (ASAT) < 3 UNL or < 5 UNL in the presence of liver metastasis, and normal renal function: (creatinine < 1.5 UNL); 6) no serious concomitant disease: 7) no known brain or leptomeningeal metastasis; 8) a normal calcemia: 9) no use of any investigational agent within four weeks prior the study",NA,the first cycle ,NA
25052698,NA,Combination,No,untreated elderly patients with primary central nervous system lymphoma,"Previously untreated (except for a limited number of days of steroid treatment)patients, from 60 to 70 years with confirmed PCNSL were included. There was nolower limit of Karnofsky performance status (KPS). Central pathologist review haspreviously been reported .Normal granulocyte count (>23109/l), normal platelet count, serum creatininelevel and hepatic enzymes less than two times the normal upper limit were alsorequired. All patients were HIV-negative and had normal whole-body CT scan, bonemarrow biopsy, and cardiac function. Patients were ineligible in cases of other malig-nancies (except basocellular cutaneous cancer and in situ cervix uterine cancer) oractive infectious disease",NA,at cycle 1,NA
28869617,NCT00477815,Combination,No,multiple myeloma,"Patients ⩾18 years old, with a diagnosis of MM and candidates for HDM and ASCT were considered eligible for this trial. Patients were required to have an Eastern Cooperative Oncology Group performance status of 0, 1 or 2; ANC of ⩾1500/mm3, platelet count ⩾ 100 000/mm3, serum creatinine ⩽twice the upper limit of normal, bilirubin ⩽2 mg/dL, aspartate aminotransferase and alkaline phosphatase ⩽thrice the upper limit of normal, left ventricular ejection fraction ⩾ 45%, corrected pulmonary diffusion capacity ⩾50%, in the absence of uncontrolled infection, pregnancy or active nursing, HIV infection and other active malignancy requiring therapy. Prior therapy for MM was required to have been completed more than 3 weeks before registration; cyclophosphamide pulsing for stem cell collection was permitted.",Patients were not eligible if they were on other cancer therapy or chronic corticosteroids at doses of prednisone420 mg/day. ,during day − 22 to day − 2,NA
22149206,NA,Combination,No,patients with refractory or relapsed acute myeloid leukemia,"Eligible patients were adults with CD33-expressing AML refractory to two or more induction regimens or with CD33- expressing AML that had relapsed within 1 year of cytarabine containing therapy. In order to examine the safety of this regimen in transplant-eligible patients, enrollment was restricted to patients aged 18 – 60 years with adequate hepatic function (total bilirubin <= 1.5 x upper limit of normal and with aspartate aminotransferase [AST] and alanine aminotransferase [ALT] <= 2 x upper limit of normal). Patients were also required to have adequate renal function as defi ned by a glomerular fi ltration rate (GFR) of 60 mL/min/1.73 m 2 , no active uncontrolled infection and Eastern Cooperative Oncology Group (ECOG) performance status of 0 – 2. Patients who had undergone prior stem cell transplant were eligible, provided that the transplant was performed over 100 days prior to study enrollment and that no graft-versus-host disease was evident. All patients provided informed consent to participate in the trial, which was conducted in accordance with the Declaration of Helsinki.",NA,NA,NA
16847470,NA,Combination,No,patients with advanced acute myeloid leukaemia,"The study was approved by the Local Ethics Committee at the Hoˆtel Dieu Hospital. Adult patients (>18 and <80 years old) with a WHO performance status <=3 and with documented advanced myeloid malignancies were eligible for the study, that is, either (i) AML refractory to one (age >60 years) or two (<=60 years) induction courses of chemotherapy or in first relapse or more; relapse after autologous stem cell transplantation or allogeneic stem cell transplantation without possibility of allogeneic lymphocytes re-injection; (ii) accelerated or acute myeloproliferative disorders not responding to conventional treatments; (iii) MDS refractory to chemotherapy or in relapse after treatment (chemotherapy or stem cell transplantation); (iv) CML in accelerated or acute phase or refractory to interferon a. Patients provided signed, informed consent","Those patients who received chemotherapy within 4 weeks of study entry, with active severe infection, and with cardiac, renal or liver dysfunctions, were excluded. Pregnant and lactating women were excluded.",NA,NA
8695365,NA,Combination,No,patients with inoperable non-small-cell lung cancer,"Patients with inoperable TNM stage IIIa, IIlb or IV (Mountain, 1986) adenocarcinoma or squamous cell carcinoma of the bronchus, aged 18-75 years were entered into the study after giving informed consent. Criteria for entry into the study included no prior chemotherapy, measurable or evaluable disease, WHO performance status of 0-2, a life expectancy of 12+ weeks, no radiotherapy or steroid therapy within 3 weeks of study entry, a leucocyte count of >4.0 x 109 1-', platelets > 100 x 109 1 - and haemoglobin >10 g 1-'. ","Exclusion criteria included active infection, brain metastases, hypercalcaemia, second malignancy, serum creatinine > 0.15 mmol 1-1, serum bilirubin > twice upper limit of normal, aspartate transaminase > 3 x normal and prothrombin time > 1.5 x normal.",NA,NA
10426665,NA,Combination,No,"patients with advanced, recurrent, and/or metastatic solid tumors. Tumor types: pancreas, breast, biliary tract, non-small cell lung, stomach, ovary, unknown primary, colorectal, esophagus, bladder","Standard phase I eligibility was employed , including: microscopically confirmed advanced, refractory, or recurrent solid tumor; ECOG performance status of 0-2, age at least 18 years, ability to understand and give informed consent and adequate organ function consisting of: WBC >= 4,000/mm3, platelets >= 100,000/mm3, ANC >= 2,000/mm3, ALT and AST <= 3 x normal (or <= 5x normal in patients with liver metastases), creatinine <= 1.5 mg/dl and calcium <= 11 mg/dl.","Patients were ineligible if they: had received other chemotherapy or radiation therapy < 4 weeks prior to enrollment, had received prior gemcitabine therapy, had evidence of central nervous system metastases, or other serious, underlying medical illnesses, or were pregnant. ",the first cycle,NA
32777116,NCT01132586,Combination,No,relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome,"Eligible patients were adults aged 18 to 65 with a confirmed pathologic diagnosis of AML or high-risk MDS which had recurred or was refractory to at least one prior line of therapy. Patients who could not attain CR after one round of induction therapy containing anthracycline plus cytarabine (100-200 mg/m2 every 24 hours for 7 days) were considered to have refractory disease and were eligible for this study. High-risk MDS was defined as International Prognostic Scoring System (IPSS) score of 1.5 or higher.22 Cytogenetic risk for AML patients was defined per European LeukemiaNet 2017 criteria.23 Patients with secondary AML and therapy-related myeloid neoplasms were eligible. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of zero to two, and adequate organ function including a ventricular ejection fraction ≥40%, creatinine <2 mg/dL and calculated creatinine clearance ≥50 mL/min. Patients who had previously received lenalidomide, cytarabine and/or idarubicin were eligible provided that the combination of the three agents had never been administered, and that no lenalidomide had been administered for at least 6 months","Patients were excluded if they had active central nervous system disease, uncontrolled systemic infections, and if any chemotherapy or radiotherapy within 2 weeks prior to enrollment. All participants had to agree to practice appropriate contraception. Hydroxyurea was permitted until day 5 if necessary to maintain white blood cell count (WBC) <40 000/μL.",during cycle one of therapy,NA
10683085,NA,Combination,No,"patients with refractory solid tumors. Tumor types: NSCLC, kidney, head & neck, melanoma, colon, breast, ovary, gastric bladder, sarcoma","Eligibility criteria included: (1) histologic evidence of solid tumors refractory to conventional therapy; (2) at least 18 years of age; (3) ECOG performance status ≤2; (4) life expectancy ≥12 weeks; (5) off previous anticancer therapy for at least 3 weeks (at least 6 weeks for nitrosoureas or mitomycin C); (6) adequate bone marrow function (WBC ≥ 3,500/mm3 or granulocytes ≥ 1500/mm3, platelets ≥ 100,000/mm3, Hgb ≥ 9 gm%), hepatic function (bilirubin ≤ 1.5 times the upper limit of normal), aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 3.0 times normal (AST or ALT ≤ 5 times normal if due to malignancy), renal function (creatinine ≤ 2.0 mg/dl or Clcreat ≥ 60 ml/min); and (5) written, informed consent. ","Exclusion criteria included: (1) clinical evidence of active brain metastases (2) serious preexisting medical conditions that would prevent full compliance with the study, (3) pregnancy, and (4) prior GEM treatment.",NA,NA
33914097,NCT03661515,Combination,No,refractory/relapsed adult acute myeloid leukemia patients,"1. Written informed consent in accordance with national, local and institutional legal requirements. Patients must give their informed consent before the first screening. 2. Age ≥ 18 and ≤ 65 years. 3. ECOG (Eastern Cooperative Oncology Group) functional status ≤ 2. 4. Diagnosis of AML (defined according to WHO criteria) of any type, except acute promyelocytic leukemia (APL; AML M3). 5. Diagnosis of R / R AML defined as: disease recurrence; failure to achieve CR or CRi after 1 or 2 identical induction cycles based on anthracycline and cytarabine; not achieving CR / RCi after salvage therapy. 6. Have no contraindications to receiving intensive chemotherapy. 7. Female patients of childbearing potential must have a negative serum pregnancy test at diagnosis and agree to use two reliable methods of contraception for three months after the last dose of medication. Male patients should use reliable contraception (if sexually active with a woman of childbearing potential). 8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.","1. Patients with APL; LMA M3. 2. Pregnant or lactating patients. 3. Patients treated with radiotherapy, chemotherapy, immunotherapy or any other anticancer therapy ≤ 2 weeks before the start of the trial, or radioimmunotherapy 4 weeks. Hydroxyurea is allowed up to one day at the start of the test. 4. Pretreatment with a SINE compound. 5. Major surgery in the 2 weeks prior to first dose of study drug. 6. Any life-threatening disease, medical condition, or organ dysfunction that, in the opinion of the investigator, could compromise patient safety. 7. Unstable cardiovascular function, including: symptomatic ischemia, uncontrolled clinically significant conduction abnormalities, NYHA Class ≥ 3 congestive heart failure (CHF), or myocardial infarction (MI) in the previous 3 months. 8. Uncontrolled infection (ie clinically unstable) requiring parenteral, antiviral, or antifungal antibiotics one week prior to the first dose; however, the prophylactic use of these agents is acceptable even if it is intravenous. 9. Active hepatitis B or hepatitis C infection. 10. Known human immunodeficiency virus (HIV) infection. 11. Patients unable to swallow tablets, patients with malabsorption syndrome or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with the absorption of study treatment. 12. Any of the following laboratory abnormalities unless due to the AML itself: a) liver dysfunction: bilirubin> 2 times the upper limit of normal (ULN) (except patients with Gilbert syndrome: total bilirubin> 3 x ULN), alanine aminotransferase (ALT) and aspartic aminotransferase (AST)> 2.5 times ULN or in the case of liver metastases (AST and ALT> 5 x ULN); b) severe renal dysfunction: estimated creatinine clearance <30 ml / min, measured in 24-hour urine or calculated using the Cockroft and Gault formula: (140 years) x Mass (kg) / [72 x creatinine (mg / dL)]; multiply by 0.85 if you are a woman.  ",the first cycle of treatment w,NA
9547676,NA,Combination,No,"patients with pancreatic cancer and other solid tumors. There were 21 patients with pancreatic cancer, 3 patients with hepatoma, 2 patients with adenocarcinoma of unknown primary and one patient with a neuroendocrine tumor. ",All patients with a histologic or cytologic diagnosis of advanced or metastatic cancer who were not candidates for treatments of higher priority or efficacy and fulfilled the following criteria were eligible for the study: >=18 years of age; Zubrod performance status of 0 or 1; estimated life expectancy of >=12 weeks; patient compliance and geographic proximity permitting adequate follow up; no prior treatment with gemcitabine; no previous chemotherapy treatments except for 5-fluorouracil given in combination with radiation; and no other forms of therapy such as local radiation or steroids for at least three weeks prior to protocol entry. Patients may have had prior irradiation treatment if the treatment ports did not include extensive pelvic or vertebral areas.,"Exclusion criteria included: patients with leukemia and/or a second primary cancer (except those patients who have had resected basal cell carcinoma, stage I or less curatively resected cervical carcinoma, or were >5 years disease free from any prior malignancy); active infection; prior central nervous system metastases or patients who had prior brain radiation for central nervous system metastases; creatinine >1.5 mg/dl; total bilirubin >1.5 mg/dl and/or transaminases >3 times normal; calcium >10.5 mg/dl; WBC <3500/mm3, platelets <100,000/mm3, hemoglobin <10 gm%, and hematocrit <30%; pregnancy; breastfeeding; active cardiac disease requiring therapy for failure, angina, arrhythmias and/or infarctions in the preceding 6 months; severe pulmonary disease or significant peripheral vascular disorders; or significant neurological or psychiatric disorders.",NA,NA
27342239,NCT01040559,Single Drug,No,hepatocellular carcinoma,"Hepatocellular carcinoma cytologically or histologically proved or diagnosed according the criteria of the American Association for the Study of Liver Diseases(AASLD 2005). Three nodules maximum (unilobar disease without limitation in the number of nodules; 3 maximum nodules if bilobar disease [satellite nodules <1cm not included in the total sum]). Child-Pugh score A or B7. ECOG Performance Status < 2. Platelet count > 50,000/µl and absolute neutrophil count (ANC) >1,000/µl. Serum creatinine < 150 µmol/l. Resting ejection fraction > 50% (echocardiography or isotopic method). Age > 18 years. Signed written informed consent",Patients eligible for surgical resection or hepatic transplantation or radiofrequency ablation. Extrahepatic metastases. Known gastrointestinal bleeding up to 30 days before study entry. Patients with anticoagulant treatment. Evidence of portal vein thrombosis. Pregnancy. Clinically serious infection. Known hypersensitivity to anthracyclines. Known hypersensitivity to contrast medium,Within the first month after chemoembolization,NA
17158228,NA,Combination,No,AML,"Patients were eligible for inclusion if they had a diagnosis of AML and had not yet been treated, or had been deemed primary refractory, or in first or second relapse. To more cleanly assess the effect of cholesterol blockade in AML samples that were naive to cholesterol modification, patients were not eligible if they were receiving any cholesterol-lowering agent, including any HMG-CoAR inhibitor, fibric acid agents, bile acid sequestration agents, or niacin. Eligibility requirements included a Zubrod performance status of no more than 2, a cardiac ejection fraction at least 45% by echocardiography or multiple gated acquisition (MUGA) scan, a serum bilirubin level less than 34.2 uM (2.0 mg/dL), and a serum creatinine level less than 1.5 x normal unless felt to be secondary to the leukemia. ","Patients could not have any uncontrolled life-threatening infection, be pregnant, be HIV positive, or have evidence of acute or chronic hepatic impairment.",NA,NA
10561293,NA,Combination,No,locally advanced or metastatic non-small-cell lung cancer,"Chemotherapy-naive or pretreated patients <= 75 years of age were eligible if they had histologically or cytologically confirmed locally advanced (stage IIIB) or metastatic NSCLC. Patients who had received previous treatment with gemcitabine or paclitaxel were not eligible. Patients were also required to have adequate bone marrow function (absolute neutrophil count >= 2 x 109/L, platelet count >= 100 x 109/L, and hemoglobin level >= 100 g/L), adequate liver function (bilirubin level < two times the upper limit of normal, AST and/or ALT levels < three times the upper limit of normal, prothrombin time , 1.5 times control), and a creatinine clearance rate >= 60 mL/min. A performance status <= 2 on the World Health Organization (WHO) scale and a life expectancy of at least 12 weeks were also required. All patients gave their written informed consents, and the protocol was approved by the Ethical Committee for the Biologic Research of the National Tumor Institute of Naples.","The presence of severe cardiac arrhythmia or heart failure, second- or third-degree heart block, or acute myocardial infarction within 4 months before entry onto the study were considered exclusion criteria. The presence of CNS metastases was not considered as an exclusion criterion, provided that a good control of the symptoms had been obtained with corticosteroids.",treatment cycle 1,NA
9818075,NA,Single Drug,No,"patients with solid tumors: Pancreas, Colorectal, Cholangiocarcinoma, Gastric, Hepatoma, Mesothelioma","All patients had histologic proof of an advanced solid tumor malignancy refractory to conventional treatment, no more than one prior chemotherapy regimen (single agent or combination), a performance status $ 2 (Zubrod scale) and an anticipated life expectancy of at least 12 weeks. Eligibility criteria included a blood hemoglobin level of > 10 g/100 ml, an absolute granulocyte count > 1500 cells per cubic millimeter, plate- let count > 100,000 cells per cubic millimeter, creatinine < 1.5 mg/100 ml and bilirubin <1.5 mg/100 ml. The study was reviewed and approved by the institutional review board. All patients were informed as to the experimental nature of this program and signed an informed consent document in accordance with institutional policies",NA,The first-course,NA
18756533,NA,Combination,No,Acute Myeloid Leukemia,"Eligible were adults (age,.=18 years) with 1) AML infirst relapse or with primary refractory disease, whowere receiving the study drugs as first salvage ther-apy;  and  2)  high-risk  myelodysplastic  syndrome(>=10% marrow blasts) and not more than 1 priorchemotherapy regimen. Patients could have receivedadditional therapy with biological or targeted thera-pies (eg, hypomethylating agents, tyrosine kinaseinhibitors, or monoclonal antibodies such as gemtu-zumab  ozogamicin).  Additional  eligibility  criteriaincluded adequate hepatic (serum total bilirubin,<=2mg/dL;  serum  glutamic  pyruvic  transaminase[SGPT],<= 4 x upper limit of normal), renal (serumcreatinine, <=2 mg/dL), and cardiac (ejection fraction>30% by echocardiography or gated cardiac scan)function, and a performance status of at least 2(Eastern Cooperative Oncology Group).","Patients wereexcluded if they had received previous treatmentwith clofarabine, had symptomatic central nervoussystem (CNS) involvement, or had an active uncon-trolled systemic infection.",within the first treatment cycle,NA
20485286,NA,Combination,No,"patients with advanced solid malignancies. Tumour type: Sarcoma 15 (47): Chondrosarcoma 2 (6), Leiomyosarcoma 2 (6), Liposarcoma 2 (6), Ewing sarcoma 2 (6), Pleomorphic sarcoma 2 (6), Other sarcoma types 5 (16); Carcinoma of unknown primary tumour 3 (9); Neuroendocrine carcinoma 2 (6); Non-small-cell lung cancer 2 (6); Melanoma (uveal and mucosal) 2 (6); Miscellaneousa 8 (26) (Bile duct carcinoma, breast cancer, adenoid cystic carcinoma, endometrial cancer, urothelial cancer, pancreatic cancer, chordoma and cervical carcinoma; for all the cases n = 1.)","Patients with histologically or cytologically confirmed advanced or metastatic solid tumours, for whom no standard therapy was available, with an Eastern Cooperative Oncology Group (ECOG) performance status <2, were eligible. Other inclusion criteria were evaluable or measurable disease according to RECIST version 1 (Therasse et al, 2000), age >=18 years, life expectancy >=12 weeks, adequate bone marrow (neutrophil count <=1.5 x 109 cells per l; platelets >=100 x 109 cells per l; and haemoglobin >=6.0 mmol -1), liver (serum bilirubin <=1.5 x upper limit of normal (ULN) and serum ASAT and ALAT <= 2.5x  ULN or, if liver metastases were present, <=5 x ULN), and renal function (serum creatinin <=1.5 x ULN and creatinine clearance >=60 ml min1), two functioning kidneys, systolic blood pressure <150 mm Hg, and diastolic blood pressure <90 mm Hg (treatment with two anti-hypertensive drugs was allowed). ","Main exclusion criteria were history of cardiovascular disease, known HIV seropositivity, and signs or symptoms of CNS metastases",during the first treatment cycle,NA
11013279,NA,Combination,No,patients with locally advanced pancreas cancer,"Patients had locally advanced and unresectable biopsy-proven adenocarcinoma of the pancreas. Computed tomography (CT) criteria for unresectability included posterior infiltration into retroperitoneal soft tissues, portal vein thrombosis, encasement of the superior mesenteric artery or hepatic artery, and bulky regional adenopathy. Patients could not have evidence of distant metastases. Patients undergoing surgical exploration but found to be unresectable because of operative findings consistent with the criteria described above were eligible. Patients needed an ECOG performance status of 0 to 2. Initial laboratory requirements included WBC count >= 4,000/uL, platelet count >= 100,000/uL, bilirubin <= 3.0 mg/dL, and a serum creatinine <= 2.0 mg/dL. Patients had to maintain adequate oral intake of 1,500 calories per day and adequate hydration or had the placement of a supplemental feeding tube. Patients could not have received prior radiation therapy or chemotherapy. All patients had a tumor that could be adequately encompassed in a radiation treatment portal with acceptable doses to liver and kidney. The institutional Review board of participating institutions approved the study, and all patients signed informed consent.",NA,during treatment or within 4 weeks after completing treatment,NA
11094306,NA,Combination,No,non-small cell lung cancer,"All patients had to have a histologically or cytologically conÆrmed diagnosis of NSCLC and be chemo- therapy-naıve to be considered for inclusion in the study. Patients with relapsing disease following radio- therapy or surgery were considered eligible. Palliative radiotherapy was permitted up to 4 weeks prior to entry to the study provided it was administered to areas out- side the lung and was not being used for response evaluation. Additional requirements were age >=18 years, unidimensionally or bi-dimensionally measurable disease, Eastern Cooperative Oncology Group (ECOG) performance status <=2, life expectancy >=12 weeks, and no signiÆcant medical disorder or condition which would compromise study completion. All patients had to have an absolute neutrophil count (ANC) >= 1.5x109/l, platelet count >=100 x 109/l, haemoglobin >=9.0 g/l, serum creatinine within normal limits, bilirubin <1.5 x upper normal limit (UNL), asparate aminotransferase (AST) or alanine aminotransferase (ALT)<3 x UNL (or AST or ALT <5UNL if documented liver metastases).","Patients were excluded from the study if they were pregnant or breast feeding, had had another primary cancer within 5 years or had received an anticancer or investigational agent within 2 weeks of starting treatment. Patients were not permitted to receive any concurrent chemotherapy or immunotherapy while on the study",NA,NA
24738629,NCT01040559,Single Drug,No,hepatocellular carcinoma,Patients (age≥18 years) with HCC unsuitable for cura-tive treatments (resection or percutaneous ablation) wereevaluated for the study. Eligibility criteria included aconfirmed diagnosis of HCC according to the EuropeanAssociation for the Study of the Liver (EASL) criteria;19a maximum of 3 nodules in cases of bilobar disease;Child-Pugh liver function of A to B7 without ascites orjaundice; Eastern Cooperative Oncology Group perfor-mance status (ECOG PS) of 0 or 1; platelet count>50 000 per mmc; absolute neutrophil count>1000 permmc; serum creatinine<150lmol/L and a left ventricu-lar ejection fraction (LVEF)>50%,Exclusion criteriawere  extrahepatic  metastases;  known  gastrointestinalbleeding up to 30 days before study entry; anti-coagulanttherapy; thrombus within the main portal vein; hepatofu-gal bloodflow; portosystemic shunts; pregnancy andallergy to anthracyclines or iodine-containing agents,within  the  month  afterDEB-TACE,NA
10673977,NA,Combination,No,advanced non-small cell lung cancer,"Chemotherapy-naı»ve patients with histologically or cytologically conÆrmed stage IIIB or IV NSCLC were entered in this phase I study. Other eligibility criteria included: bidimensionally measurable or assessable disease, age 75 years, performance status 3 (ECOG scale) and an anticipated life expectancy of at least 3 months. The patients were required to have an adequate haematological, hepatic, renal and cardiac function. No prior chemotherapy or thoracic radiotherapy was permitted. Patients with a performance status of 3, untreated brain metastases and a life expectancy longer than 3 months were included in this trial, in order to make results of the trial more applicable to a broader population of lung cancer patients . The study was approved by the local ethical committee and written informed consent was obtained from each patient.","Patients with additional malignancies, other than curatively treated skin and cervical cancer, or with active cardiovascular disease were excluded.",in the first treatment cycle,NA
11099327,NA,Combination,No,"patients with advanced cancer. Tumor type: Breast 10, Lung, non–small-cell 6, Prostate 3, Carcinoma of unknown primary 2, Bladder 2, Lung, small-cell 1, Pancreas 1, Osteosarcoma 1","Patients with histologically confirmed solid malignancies, in whom no effective therapy existed, were candidates for this study. Eligibility criteria also included (1) age of 18 years or older; (2) Eastern Cooperative Oncology Group performance status of 2 or less (ambulatory and capable of self-care); (3) a minimum life expectancy of 12 weeks; (4) no major surgery or treatment with chemotherapy within 21 days (42 days for mitomycin or nitrosoureas); (5) measurable or nonmeasurable but assessable disease; (6) adequate hematopoietic (WBC count of >= 3,000/uL, absolute neutrophil count [ANC] of >= 1,500/uL, platelet count of >= 100,000/uL, and hemoglobin >= 9.0 g/dL), hepatic (total bilirubin less than 1.6 mg/dL; AST and ALT levels < two times the upper limit of normal, unless the elevation was caused by hepatic metastases, in which case elevations of five times the upper normal limits were permitted), and renal (serum creatinine level of < 2.0 mg/dL) functions; (7) no severe gastrointestinal disturbance that could preclude oral administration or gastrointestinal absorption; (8) no active neoplastic involvement of the CNS; (9) discontinuation of hematopoietic growth factors at least 3 weeks before study entry; (10) no concomitant use of drugs capable of inhibiting or inducing hepatic cytochrome p450 enzyme (CYP3A and CYP 2E1) metabolism within 2 weeks of study entry; (11) no prior treatment with doxorubicin or daunorubicin at cumulative doses exceeding 350 mg/m2 or mitoxantrone exceeding 140 mg/m2 unless left ventricular ejection fraction >= 40%; (12) QTc interval less than 450 ms on pretreatment ECG; (13) no clinically significant atrial or ventricular arrhythmia; and (14) no coexisting cardiac or medical problems of sufficient severity to limit compliance with the study. All patients gave informed written consent before treatment.",NA,during their first course,NA
10997809,NA,Combination,No,chemo-naïve patients with advanced non-small-cell lung cancer,"Chemo-nai've patients with histologically or cytologically proven stage Illb-IV NSCLC were eligible for this study. Additional eligibility criteria were adequate bone marrow (WBC >= 35OO/ul and platelet count >= 100,000/ul), hepatic (AST, ALT <= 2 times and total bilirubin <= 1.25 times upper limits of normal) and renal (serum creatinine <= 1.25 times upper limits of normal) functions, 18-65 years of age, performance status (ECOG) <=2, >=3 months of life expectancy, written informed consent.","Exclusion criteria were a prior radiotherapy to more than 30% of bone marrow reserve, absolute contraindication to steroids, previous or concurrent malignancies, uncontrolled infections.",during the first cycle,NA
11032598,NA,Combination,No,"patients with solid tumor malignancies. Carcinoma: Colon 18, Rectum 3, Lung 1, Breast 1, Ovary 1, Cholangio duct 1, Double primary (breast and pancreas) 1, Unknown primary 1, Small intestine 1","Patients with advanced metastatic carcinoma who did not respond to primary treatment and/or had no other effective treatment available were eligible for the study. Chemotherapy-naive patients with metastatic colorectal carcinoma were allowed to enter the protocol. The chemotherapy schema was believed to be at least as effective as combination of FA/5-FU for that particular group of patients. Participants were required to have an Eastern Cooperative Oncology Group performance status of 0 to 3, with an estimated life expectancy of at least 12 weeks. Previous chemotherapy had to be discontinued for 3 weeks before entering the study and for 6 weeks in the case of treatment with mitomycin or nitrosourea or extended radiation therapy. Patients had to have acceptable bone marrow function, defined as a neutrophil count >= 1,500/uL, platelet count >= 100,000/uL, serum creatinine less than 2 mg/dL, and bilirubin less than 1.5 mg/dL or less than 3.0 mg/dL in patients with known liver metastasis. Liver enzymes had to be less than three times the upper limit of normal in patients with known liver metastasis. Laboratory results had to be obtained within 2 weeks of registration to the study. Patients had to be older than 18 years of age and signed, informed consent was required.",Pregnant or lactating females were excluded from the study,NA,NA
11005695,NA,Combination,No,previously treated patients with advanced breast and ovarian cancer,"The eligibility criteria for study entry included: histologically or cytologically confirmed advanced breast or ovarian cancer; age 18±75 years; progression or relapse after first line treatment; a minimum interval of 4 weeks since prior chemotherapy; an Eastern Cooperative Oncology Group performance status of 0±2; adequate baseline organ function defined as a white blood cell count of >=3 x 109/l, a platelet count of >=100 x 109/l, a bilirubin level of <1.5 mg/dl, serum transaminase levels of less than twice the upper limit of normal, and a creatinine value of <1.4 mg/dl; and a life expectancy of at least 12 weeks. Prior palliative radiotherapy to symptomatic metastases was allowed, provided these lesions were not monitored for tumour response. The study was approved by the ethics committees of the participating centres and written informed consent was required from each patient",NA,the first cycle,NA
8622085,NA,Combination,No,advanced non-small-cell lung cancer,"Chemotherapy-naive patients - 75 years of age were eligible if they had histologically or cytologically confirmed inoperable NSCLC (stage IIIA, IIIB, or IV). They could have received prior radiotherapy provided that the measurable and assessable lesions were outside the radiotherapy treatment field. They were required to have adequate bone marrow function (absolute granulocyte count >= 2 x 109/L, platelet count >= 100 x 109/L, and hemoglobin level >= 100 g/L), and adequate liver function (bilirubin level < two times the upper limit of normal, AST and/or ALT < three times the upper limit of normal, prothrombin time < 1.5 times control), and creatinine concentration < 130 pmol/L). They were required to have a performance status <= 2 on the World Health Organization (WHO) scale, and life expectancy of at least 12 weeks. All patients gave informed consent.",NA,in the first four treatment cycles,NA
21519855,NA,Single Drug,No,adult patients with relapsed/refractory acute myeloid leukemia,"Adult patients with refractory or relapsed AML expressing the CD33 antigen were eligible for these studies. Other main criteria for eligibility in these studies were: ECOG performance score ≤2; adequate renal and liver function; no anti-leukemia therapy within 3 weeks prior to inclusion, except for hydroxyurea, which could be used up to 24 h prior to the first drug infusion. Prior therapy with gemtuzumab ozogamicin (Mylotarg®) or prior allogeneic stem cell transplantation was allowed only in the Day 1/4/7 study, with a washout period of 6 months prior to inclusion. All patients signed informed consent. The procedures were in accordance with the Helsinki Declaration.",NA,during the first cycle,NA
9400947,NA,Single Drug,No,"Tumour types: Head and neck, Colorectal, Breast, Non-small-cell lung, Ovary, Soft tissue sarcoma, Stomach, Bladder, Cervix, Melanoma, Mesothelioma, Oesophagus, Uterus, Unknown primary, Others","Patients with solid tumours had to have advanced refractory disease that was not amenable to conventional therapy or investigational therapy of higher potential efficacy or advanced disease for which no standard therapy existed. Patients had to have recovered from the toxic effects of any previous therapy. Patients had to be aged 18-75 years with a WHO performance status of 0-2. They had to have adequate organ function and normal prothrombin and partial thromboplastin times. Patients with haematological malignancies and those who had received previous therapy with fluorinated nucleotides, apart from 5-fluorouracil and its derivatives, were excluded. Patients receiving > 10 mg day-1 of prednisone (or equivalent) were excluded, unless this dose had been established more than 1 month before entry. All patients had to give written informed consent before entering the study, which was approved by local ethics committees.",NA,NA,NA
26750985,NCT01518556,Combination,No,acute myeloid leukemia,"Inclusion criteria were previously untreated de novo or secondary AML, or mixed phenotype acute leukemia, according to World Health Organization 2008 criteria. Patients were between ages 20 and 65 years, gave voluntary written informed consent, had an ECOG performance status score of 0–2. Patients should have adequate major organ functions unless these abnormalities are attributable to leukemia itself: left ventricular ejection fraction 445%, serum creatinine <1.5 x upper limit of normal (ULN), serum total bilirubin <1.5 x ULN, serum alanine transferase (ALT) and aspartate transferase (AST) <2.5 x ULN or ALT and AST <5 x ULN if liver function abnormality was attributable to underlying leukemia. ","Exclusion criteria were hypersensitivity to the study drug, any other malignancy within three years before the study enrollment, New York Heart Association class III or IV heart failure or myocardial infarction within the previous six months prior to consent, pregnant or breastfeeding women, acute promyelocytic leukemia, or HIV infection.",Within 2 months after induction therapy in the phase I study,NA
10955861,NA,Combination,No,"patients with solid malignancies. Primary tumor: colon, lung(non-small-cell), pancreatic, esophagus, bladder, unknown primary","All patients met the following conditions: age ≥18 years; Karnofsky Performance Status of ≥60%; a histologically confirmed solid tumor that had progressed after standard treatment regimens or for which no standard treatment regimen existed; no prior therapy with either paclitaxel or gemcitabine; no more than two previous chemotherapy regimens for metastatic disease; no symptomatic brain metastases or other medical or psychiatric conditions that, in the opinion of the principal investigator or designees, would have compromised the ability of the patient to tolerate this treatment safely; a total white blood cell count of ≥3,500/μl; absolute neutrophil count (ANC) ≥1,500/μl; platelets ≥100,000/μl; serum creatinine <1.5 mg/dl; total bilirubin <1.5 mg/dl (unless owing to Gilbert’s disease); serum transaminases <3× upper limits of normal; female patients of childbearing potential were required to have a negative pregnancy test before starting treatment and agreed to use adequate contraception.",NA,NA,NA
22404399,NA,Combination,No,advanced non-small cell lung cancer,"Chemotherapy-naive patients less than 75 years of age were eligible for this trial if they had histologically or cytologically confirmed inoperable NSCLC (Stage IIIa, IIIb, or IV) of any sub-type. They could have received prior radiotherapy provided that the measurable and evaluable lesions were outside the radiotherapy treatment field. They were required to have adequate bone marrow function (absolute granulocyte count > 2 x 109/1,platelets > 100 x 109/1, and haemoglobin 1 100 g/I), and adequate liver function (bilirubin < 2 times the upper limit of normal, AST and/or ALT < 3 times the upper limit of normal, prothrombin time < 1.5 times control) and normal renal function (creatinine < 130 pmol/l). They were required to have an adequate performance status, >=2 on the World Health Organization (WHO) scale, and a life expectancy of at least 12 weeks. All patients gave informed consent.",NA,in treatment cycle 1,NA
21585619, UMIN000001141 and UMIN000001142,Combination,No,Japan Adult with relapsed or refractory adult acute myeloid leukemia,"Between January 2007 and December2009, 19 eligible patients with relapsed and refractory AML were enrolled in the present study. The inclusion criteria were asfollows: (i) diagnosed as CD33+AML (excluding acute promyelocytic  leukemia);  (ii)  relapsed >=6 months after the first CR(CR1) or were refractory to initial standard induction therapy;(iii) age: 20–64 years old; (iv) 0–2 by the Eastern CooperativeOncology Group (ECOG) performance status; (v) no active double cancer; (vi) adequate cardiac, renal and hepatic function withleft ventricular ejection fraction >=50%, creatinine <=2.0 mg⁄dL,bilirubin <=1.5 mg⁄dL; (vii) no uncontrolled infection; and (viii)no human  immunodeficiency virus (HIV) infection. Patientswho received more than 500 mg⁄m2of daunorubicin (DNR) ina prior therapy were ineligible to DNR-including protocol. Cytogenetic abnormalities were grouped by standard criteria  andclassified according to the UK Medical Research Council(MRC) classification.",NA,NA,NA
9739439,NA,Combination,No,"patients with refractory solid tumors. Tumor types: Lung 7, Non-small cell 6, Small cell 1, Pancreas 6, Adenocarcinoma of unknown primary 5, Colorectal 4, Bladder/renal pelvis (transitional cell) 4, Renal cell 3, Others(Includes two each of melanoma and soft tissue sarcoma, and one each of head and neck and gastric cancers, Hodgkin's disease, and adenocarcinoma of esophagus)","Patients with histologically or cytologically confirmed solid tumors refractory to conventional therapy were enrolled in the study. Eligibil- ity criteria included the following: (1) age >=18 years; (2) estimated life expectancy >= 12 weeks; (3) Zubrod performance status of 0-2; (4) no surgery, radiation or chemotherapy within four weeks prior to enrollment; (S) no prior paclitaxel or gemcitabine therapy; (6) adequate hematopoietic reserve (absolute neutrophil count (ANC) >= 1500/ul and platelet count 2= 100,000/ul); (7) adequate hepatic and renal function (normal serum creatinine and bilirubin, serum aspartate aminotransferase (AST) < 3 times upper limit of normal); (8) normal prothrombin time (PT) and activated partial thromboplastin time (aPTT); and (9) presence of bidimensionally measurable and/or evaluable disease.",All patients with central nervous system (CNS) metastases and medical conditions that were deemed incompatible with safe participation in the trial were excluded. ,first-cycle,NA
23801301,NA,Combination,No,"patients with advanced sarcoma. Primary tumor site: Lower limb 4, Retroperitoneum 2, Head/neck 1, Chest wall 1, Other 4","To be enrolled in this study, patients had to meet the following eligibility criteria: diagnosis of advanced soft tissue or bone sarcoma previously treated with anthracyclines (or ineligibles for that treatment), no prior treatment with ifosfamide, age ≥18 and <72 years, Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1 and either measurable or evaluable disease. Adequate bone marrow, renal and hepatic function were mandatory and were defined as: absolute neutrophil count≥1.5×109/L, platelets≥100×109/L, hemoglobine≥ 9 g/dl, bilirubin≤1.5×upper limit of normal (ULN), aspartate transaminase and alanine transaminase≤2.5×ULN, creatinine≤1.5×ULN, creatinine clearance≥50 mL/min and INR≤1.5. ","Patients with uncontrolled hypertension, history of coagulopathy, thrombotic or embolic events were considered ineligibles. Other exclusion criteria were treatment with chemotherapy or radiotherapy within 3 weeks prior, pregnancy, life expectancy<12 weeks, other tumors treated with curative intention in the last 3 years and known central nervous system metastasis.",during cycle 1 of treatment,NA
10080603,NA,Combination,No,patients with pancreatic cancer,"Patients with histologically or cytologically proven carcinoma of the pancreas with locally advanced unresectable or metastatic bidimensionally measurable disease were eligible for this protocol. Other eligibility criteria included the following: (a) age 18 years or older; (b) Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower (ambulatory and capable of self-care); (c) no prior chemotherapy or hormone therapy (prior radiation therapy for symptom palliation was allowed, but patients could not have received radiation therapy within 4 weeks prior to entering the study, and measurable disease outside the radiation port was required); and (d) adequate bone marrow (WBCs >= 4,000/µL, absolute neutrophil count [ANC] >= 1,500/µL, and platelets >= 100,000/µL), kidney (creatinine <= 1.5 mg/dL), and liver (bilirubin <= 2 mg/dL and transaminases levels <= three times the upper normal limit [five times for patients with liver metastasis]) function.",Patients were excluded from the trial if they had brain or meningeal metastasis or any preexisting medical condition of sufficient severity to prevent full compliance with the study.,the first cycle,NA
11137206,NA,Combination,No,pretreated patients with stage IIIB-IV non-small cell lung cancer,"Eligibility criteria for study entry included histologically or cytologically confirmed stage IIIB or IV NSCLC; age 18–75 years; progression or relapse after first-line treatment; a minimum interval of 4 weeks since prior chemotherapy; an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; adequate baseline organ function defined as a WBC of >= 3000/ul, a platelet count of >= 100 000/ul, a bilirubin level of < 1.5 mg/dl, serum transaminase levels of less than two times of the upper limit of normal, and a creatinine value of < 1.4 mg/dl; life expectancy of at least 12 weeks. Prior palliative radiotherapy to symptomatic metastases was allowed, provided these lesions were not monitored for tumor re- sponse. The study was approved by the Ethics Committees of participating centers and written informed consent was required from each patient.",NA,the first cycle,NA
17154172,NA,Single Drug,No,patients with chronic myeloid leukemia who have failed prior therapy,"Patients age 12 years or older with Philadelphia chro-mosome (Ph)-positive CML in CP, accelerated (AP), orblast phase (BP) were eligible. Patients in early CPCML (time from diagnosis to therapy less than 12months) were not eligible and those in late CP wereeligible only after the maximal tolerated dose (MTD)or level 3 (whichever came first) was reached. In addi-tion, patients in late CP were eligible only if they hadfailed imatinib therapy, whereas these prior treatmentrestrictions did not apply to patients in AP or BP.Other eligibility criteria included: 1) life expectancy sufficiently long to fully evaluate the effects of at least2 courses of chemotherapy; 2) performance status 2or less by the Zubrod scale; 3) adequate hepatic andrenal function (ie, bilirubin and creatinine<2.0 mg/dL); and 4) adequate cardiac status (New York HeartAssociation class<II). ",Women who were pregnant orbreast-feeding were excluded because of potentialharmful effects of HHT on developing fetuses andnewborns,NA,NA
30378121,EudraCT 2010-021719-18,Combination,No,newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure,"Patients aged 18 years or olderwith newly diagnosed AML, as defined by the 2008 WorldHealth Organization classification (Vardimanet al, 2009),with high risk of induction failure and adequate organfunction were eligible for entry into the trial. High risk ofinduction failure was defined as absence of translocations t(15;17), t(8;21) and inv(16)/t(16;16), absence of the fusiontranscriptsPML-RARA,RUNX1-RUNX1T1,CBFB-MYH11,and  absence  ofNPM1mutations.","Patients  withFLT3-mutated AML were excluded due to a competing trial withan FLT3 inhibitor (Stoneet al, 2017). Patients with a con-comitant uncontrolled infection were not eligible. ",within 14 days after the start of the first induction cycle,NA
12942571,NA,Combination,No,Primary central nervous system lymphoma,"Requirements for inclusion in the trial included a his-tologically confirmed diagnosis of PCNSL, absence ofevidence of systemic lymphoma, age >16 years, lifeexpectancy of >4 weeks, normal liver function (ala-nine aminotransferase and alkaline phosphatase <= 2 times institutional normal and a bilirubin level <= 2.0mg/dL), a creatinine level <=2.0 mg/dL, a normal he-mogram (absolute neutrophil count [ANC] >=1500/uLand platelet count >=100,000 /uL), and a Zubrod per-formance status <3.","In this Phase I study, bidimen-sionally measurable disease was not an eligibility re-quirement. Any of the following made a patientineligible for the study: an active infection, pregnancyor not practicing adequate contraception, serious in-tercurrent medical illness, age > 75 years, cardiacejection fraction <55%, and positive human immu-nodeficiency virus (HIV) serolog",NA,NA
9220290,NA,Combination,No,"Maligancy: pancreas, lung, bladder, melanoma, uterus, gastric, breast, Other ( including ovarian, colon, anal and head & neck cancer, cancer of unknown origin and soft tissue sarcoma)","Patients with histologically confirmed advanced or metastatic solid tumors, 18–75 years old, performance status (WHO) <= 2 and life expectancy >= 12 weeks were considered eligible if they had normal hematologic parameters (WBC >= 3,500/uL, AGC >= 1,900/uL, platelet count x>=100,000/uL, and Hb >= 10 g/dL), adequate renal (creatinine <= 1,5 mg/dL) and liver functions (bilirubin <= 3 mg/dL, AST/ALT <= 111/120 U/L) and presented bidimensionally measurable disease not amenable to conventional treatment. The study was approved by the Regina Elena Institute Ethical Committee. Written informed consent was obtained from all the patients.",NA,NA,NA
10885899,NA,Single Drug,No,stage IV breast cancer,"Women with histologically confirmed locally advanced (stage III B) or metastatic breast cancer (stage IV) were eligible for this study. Other eligibility criteria included: age 18-75 years; Karnofsky performance status >60%; a life expectancy of at least 12 weeks; at least 6 months beyond adjuvant chemotherapy; adequate bone marrow function (white blood count (WBC)>=3500 ul, absolute granulocyte count (ANC) >=1500/ul, platelets >= 100000/ul, and hemoglobin >=10 g/dl), renal function (creatinine <= 1.5 mg/dl) and hepatic function (bilirubin <= 1.5 mg/dl, ALAT/ASAT <= 3 times the upper limit of normal and prothrombin time within the normal range of the institution). Patients eligible for the response evaluation required bidimensionally measurable or assessable disease.","Patients were ineligible if they had received previous treatment with gemcitabine or extensive radiotherapy (more than 30% of bone marrow involved). Patients with previous radiotherapy were eligible if there was measurable disease outside the radiation area. Further exclusion criteria included brain metastases, a history of prior malignancy, severe concurrent medical conditions or acute infection.",in course 1,NA
12637470,NA,Combination,No,patients with refractory myeloid leukemias,"Patients who had failed prior therapy for MDS refractory anemia with excess blasts (RAEB); RAEB in transformation (RAEB-T), chronic myelomonocytic leukemia (CMML), AML, or myeloid CML-BP were eligible. Other eligibility criteria included Eastern Cooperative Oncology Group performance score of <= 2; serum bilirubin of <= 2.0 mg/dL; AST (serum glutamic-oxaloacetic transaminase) or ALT (serum glutamate pyruvate transaminase) levels less than three times the upper limit of normal (ULN) or less than five times the ULN if considered to be the result of leukemia; and serum creatinine <= 1.5 mg/dL. For the dose-finding portion of the study, patients with AML included either those receiving first salvage therapy with first CR duration less than 12 months or patients receiving second or subsequent salvage therapy. Once DLT for a combination was established, those patients with AML whose first CR duration was 12 months or greater were eligible. Patients with active controlled infection were eligible.",NA,NA,NA
11150903,NA,Combination,No,platinum/paclitaxel-resistant ovarian cancer,Patients with histologically proven epithelial ovarian cancer progressing/recurring within 12 months from primary platinum/paclitaxel-containing chemotherapy were eligible for the study. Further entry criteria were: evidence of measurable lesions (as defined by CT scan); age >18 years; Eastern Cooperative Oncology Group (ECOG) performance status <3; life expectancy >12 weeks; patient informed consent; white blood cells count (>3.5 x 109/l; platelet count >150 x 109/l; bilirubin and creatinine levels less than 1.5 times the upper limit of normal.,"Patients were ineligible in the case of: Brenner’s or borderline ovarian tumors, prior malignancy except for adequately treated nonmelanoma skin cancer or in situ cervical carcinoma; other cytotoxic drug given within 30 days prior to entry into the study; uncontrolled severe infection and/or medical problems unrelated to malignancy which would limit full compliance with the study, or expose the patient to extreme risk.",The first course,NA
7860227,NA,Single Drug,No,"advanced or metastatic solid tumors. Malignancy: bladder 15, melanoma 9, head & neck 4, breast 3, renal 2, sarcoma 2, other (bincluding colon, pancreatic, NSCLC and epithelial thymom) 4","Adult patients aged 18-75 years old with histologically confirmed advanced or metastatic solid tumor, not amenable to conventional treatment, performance status (WHO) <= 2 and life expectancy >= 12 weeks were considered eligible if they had normal hematologic parameters (WBC > 3,500/gL, absolute granulocyte count >= 1,900/gL, platelet count >= 100,000/uL and Hb >= 10 g/dL), adequate renal (creatinine <= 1.5 mg/dL) and liver functions (Bilirubin <= 3 mg/dL, AST/ALT <= 111/120 U/L). Patients should have been free of prior chemotherapy for >= 3 weeks (6 for nitrosourea or mitomycin-C). ","Patients with hematologic malignancies, significant neurologic illness (including brain metastasis) and serious concomitant disease, incompatible with the study, were excluded. Approved contraceptive precautions were requested for patients who entered the study. ",the first course,NA
27677906,NCT00392691,Combination,No,elderly patients with lymphoma in relapse or resistant to chemotherapy,"Exclusion criteria were as follows: prior high‐dose chemotherapy,prior  therapy  with  radiolabelled  antibodies,  prior  radiotherapyincluding ≥25% of the bone marrow, bone marrow infiltration ≥25%,significant cardiac disease ejection fraction (EF≤50%, unstable anginapectoris, significant arrhythmia, history of myocardial infarction in thelast 3 months), major hepatic (bilirubin, AP, ASAT >2× ULN) or renalimpairment (creatinine clearance≤50 mL/min, using the Cockcroft‐Gault formula), urinary tract obstruction, significant pulmonary disease,and central nervous system involvement. Furthermore, any seriousmedical condition that could impair the patient's participation in thetrial, malignancies other than lymphomas with signs of relapse or thelast treatment for that malignancy less than 5 years ago or treatmentwithin another trial within 30 days prior to registration, were otherstandard exclusion criteria.",Elderly patients≥65 years in good clinical conditions (WHOperformance status 0‐1) with CD20‐positive lymphoma in relapse orrefractory to chemotherapy as an indication for ASCT were eligible.They had to have achieved at least a PR after salvage therapy,occurring within 8 weeksafter application of melphalan,NA
29610115,NCT02200848,Combination,No,relapsed and refractory CLL,"Patients had previously treated, pathologically confirmed CLL or SLL that required treatment per the 2008 International Workshop on CLL National Cancer Institute Working Group Guidelines.11 Other inclusion criteria included age >18 years, life expectancy >60 days, Eastern Cooperative Oncology Group performance status <2, and measurable disease by imaging or physical examination. Required initial laboratory values included an absolute neutrophil count >0.75 x 109/L and platelet count >50 x 109/L unless attributable to CLL, hemoglobin >8.0 g/dL, total bilirubin <=1.5 times the upper limit of normal (ULN) unless the patient had disease infiltration of the liver or Gilbert syndrome, aspartate aminotransferase and alanine transaminase <3 times institutional ULN, glomerular filtration rate >=30 mL/min per 1.73 m2 (CockcroftGault), and prothrombin time/international normalized ratio and partial thromboplastin time <1.5 times ULN.","Exclusion criteria included prior systemic therapy for CLL or SLL including chemotherapy, immunotherapy, immunosuppression, radiation therapy, or surgery within 4 weeks of enrollment. Corticosteroids could not have been administered within 2 weeks before study entry, except as maintenance therapy for a nonmalignant disease. Prior lenalidomide was permitted if it had been >2 years since exposure and the patient did not experience a progression while receiving the drug. Any prior Bruton tyrosine kinase inhibitor, strong CYP3A inhibitor within 7 days of enrollment, concomitant strong CYP3A inhibitors, and concomitant vitamin K antagonists were not permitted. Other exclusion criteria were allogeneic stem cell transplantation, central nervous system involvement, Richter transformation, uncontrolled autoimmune hemolytic anemia or immune-mediated thrombocytopenia, and known bleeding disorders. Patients with uncontrolled, intercurrent illness including, but not limited to, infection, cardiac, or psychiatric disease were excluded. Patients with prior malignancies were excluded unless they were treated with curative intent >3 years prior or had adequately treated nonmelanomatous skin cancer, lentigo maligna melanoma, or cervical carcinoma in situ.",Patients enrolled at DL1 were assessed for dose-limiting toxicity (DLT) during cycle 1. Patients enrolled at DL2 or DL3 were assessed for DLT in cycles 1 and 2. ,NA
33828254,NCT03332498,Combination,No,patients with mismatch repair proficient metastatic colorectal cancer,"Pertinent eligibility criteria were as follows: histologically confirmed MSS or pMMR metastatic colorectal adenocarcinoma, refractory or intolerant to fluoropyrimidine, oxaliplatin and irinotecan, and if RAS wild type, cetuximab or panitumumab containing therapies, age ≥18 years, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and adequate organ function.",NA,during the first 42 days on the study,NA
31230047,NCT02401048,Combination,No,"Patients with Pretreated Solid Tumors: Pancreatic adenocarcinoma, HER2-positive breast cancer, Triple-negative breast cancer, NSCLC (adenocarcinoma), NSCLC (squamous cell carcinoma)",Pathologically documented relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). Measurable disease sites on CT scan (>1.5 cm in longest dimension). Adequate hematologic function: Absolute Neutrophil Count >1500 cells/mm3; Platelets >50000 cells/mm3; Hemoglobin >8.0 g/dL. Adequate hepatic and renal function: AST or ALT ≤2.5 x ULN; Bilirubin ≤1.5 x ULN; Estimated creatinine clearance (Cockcroft-Gault) >40 mL/min. ECOG 0 or 1,"Received prior therapies: ibrutinib, or other BTK inhibitor and/or anti-PD1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA-4 antibody. Requires treatment or prophylaxis with a strong cytochrome P450 (CYP) 3A inhibitor. Primary CNS lymphoma or evidence of CNS involvement by lymphoma",The DLT observation period included cycle 1 and laboratory assessments on day 1 of cycle 2.,NA
17505827,NA,Combination,No,"Tumor type: Colorectal 2, Gastrointestinal stromal tumor 2, Neuroendocrine 2, Thyroid 2, Other (angiosarcoma, larynx, hepatocellular, pancreas)","Adult patients with histologically conWrmed advanced solid malignancies refractory to standard therapy or for whom no eVective therapy existed were candidates for this study. Other eligibility criteria included: (a) Karnofsky performance status (KPS) ¸70% (able to care for self); (b) adequate hematopoietic [absolute neutrophil count >=1,000/ul, platelets >=50,000/ul, hemoglobin (Hb) >=8 g/dl], hepatic [total serum bilirubin <=2 times the upper limit of normal (ULN), transaminases <=2.5 times ULN or <=5 times ULN in the presence of liver metastases], renal (serum creatinine <1.5 times ULN, or calculated creatinine clearance >40 ml/ min), and adrenal [normal adrenocorticotropic hormone (ACTH) stimulation test] function; (c) adequate cardiac function [left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan and serum cardiac troponin T (cTnT) and/or serum cardiac troponin I (cTnI) <= ULN] function; (d) no cardiovascular, cerebrovascular, or thromboembolic event within the previous 12 months; (e) no symptomatic congestive heart failure within the previous 12 months; (f) no ongoing cardiac dysrhythmias of National Cancer Institute (NCI) Common Toxicity Criteria (CTC) grade >= 2, atrial Wbrillation of any grade, or prolongation of the corrected QT interval to >450 ms for males or >470 ms for females within the previous 12 months; (g) no chemotherapy, radiotherapy, or biologic therapy within the previous 3 weeks; (h) no nitrosoureas or mitomycin C within the previous 6 weeks; (i) no investigational agents within the previous 4 weeks; and (j) no known central nervous system metastases. Females of childbearing age were required to be practicing eVective contraceptive measures and to have had a negative serum pregnancy test before study entry. Written informed consent was obtained according to federal and institutional guidelines.",NA,course 1,NA
21469980,NA,Combination,No,"patients with advanced malignancies. Tumor type: NSCLC 9 patients, Sarcoma 6 patients, Pancreas 4 patients, Renal 4 patients, Neuroendocrine 3 patients, Carcinoma of unknown primary 3 patients, Bladder 2 patients, Breast 2 patients, Colorectal 2 patients, Head and neck 2 patients, SCLC 2 patients, Other (cervix, esophagus, prostate, 1 patient each, thyroid, melanoma, GIST) 1 patient each","Patients ≥18 years of age with evaluable histologically proven advanced solid tumors refractory to conventional therapy or for whom no standard therapy exists, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and a life expectancy of at least 3 months were enrolled. Patients must have completed previous radiotherapy at least 2 weeks prior, previous chemotherapy at least 3 weeks prior, and previous investigational treatment at least 4 weeks prior to treatment. Patients were not allowed to receive any prior anti-VEGF therapy. The following baseline laboratory values were required: absolute neutrophil count (ANC) ≥ 1500/µL; platelets ≥100,000/µL; hemoglobin ≥9 g/dL; serum creatinine and serum bilirubin ≤1.5 times the upper limit of normal; SGOT and/or SGPT ≤2.5 times the upper limit of normal. Patients were also required to have negative or trace protein by urine dipstick. If a reading of 1+ was obtained at baseline, then patients were required to have a 24-hr urine collection with a total urine protein ≤ 500 mg. Patients with a history or presence of brain metastases were eligible, but only if they had received previous treatment for the metastases and the metastases were inactive and asymptomatic at the time of enrollment.","Patients who had major surgery within 4 weeks of treatment were excluded. Patients with any of the following concurrent severe and/or uncontrolled medical conditions were also excluded: uncontrolled hypertension; clinically significant cardiovascular disease; myocardial infarction within the previous 6 months; serious uncontrolled cardiac arrhythmia; active infection; impaired gastrointestinal function (due to oral medications); nonhealing wound; coagulopathy; or grade 4 thromboembolic event (patients with grade 3 thromboembolic events were eligible if on a stable dose of low molecular weight heparin). Patients were also excluded if they were taking therapeutic warfarin doses, phenytoin, carbamazepine, barbiturates, rifampin, phenobarbital, systemic retinoids, or St. John’s Wort. Female patients who were pregnant or lactating were ineligible. ",during the first cycle of therapy,NA
24093213,NA,Combination,No,"patients with refractory or advanced solid tumours. Type of cancer: Colon 3, Melanoma 3, Pancreas 2, Thyroid 2, Renal cell 2, Adrenal 1, Carcinoma of the penis 1, Head and neck 1, Sarcoma 1, Bladder 1, Meningioma 1, Glioma 1","Eligible patients needed to have: (1) histologically proven, advanced solid tumours refractory to conventional therapy or chemo-naive patients with advanced cancers (including patients with brain metastases); (2) a Karnofsky Performance score of >= 70; and (3) adequate physiologic organ function as evidenced by an absolute neutrophil count > 1500/ul, platelet count > 100 000/ul, aspartate transaminase or alanine transaminase levels < three times the upper limit of normal, serum creatinine < 2.5 times the upper limit of normal.","Patients were excluded if they had (1) prior stem cell transplant or heavy pretreatment (four or more chemotherapy regimens); (2) hypersensitivity to imidazotetrazine, or IFN-alpha-2b or any excipient in the formulations; (3) a preexisting, severe psychiatric condition or a history of suicidal ideation; (4) a life-threatening condition or severe pre-existing conditions such as severe coronary artery disease, and severe chronic obstructive pulmonary disease; (5) hypo- or hyperthyroidism; and (6) disease that made them unable to ingest/tolerate oral medications.",during the first 28-day cycle of therapy ,NA
30101387,NCT02257541,Combination,No,patients with advanced gastrointestinal stromal tumor,"Patients must have pathologically confirmed GIST. In the Phase Ib portion, must have locally advanced or metastatic GIST and have progressed on imatinib. In the Phase II portion, patients must be newly diagnosed or imatinib treatment naïve in the advanced/metastatic setting. Prior adjuvant imatinib therapy is allowed as long as disease recurrence was documented ≥90 days after last dose of imatinib and imatinib has not yet been restarted. Patients must be at least 18 years of age. Disease must be measurable by RECIST 1.1. ECOG Performance Status 0 or 1. Adequate renal, hepatic, and hematologic function as the following: Serum Creatinine ≤ 1.5 mg/dL, Total Serum Bilirubin ≤ 1.5 x upper limit of normal (ULN) unless due to Gilbert's Disease, Serum AST (SGOT) and/or ALT (SGPT) ≤ 2.5 x ULN (or ≤ 5.0 x ULN if considered due to tumor), ANC ≥ 1500/mm3, Platelets ≥ 100,000/mm3, and hemoglobin ≥ 10g/dL. Patients of childbearing potential must have a negative blood pregnancy test within 14 days of treatment. Patients must agree to use a reliable barrier method of birth control during and for 3 months following the last dose of study drug. Patient must have adequate cardiac function (left ventricular ejection fraction (LVEF) ≥50% as determined by a multigated acquisition (MUGA) scan or echocardiogram; and QTc interval ≤480 ms by Fridericia's formula (QTcF). Patient must be able to take oral medications. Patients must sign an informed consent document.","For phase I, prior intolerance to imatinib at a dose of 400 mg daily. For phase II, any receipt of cytotoxic, biologic, or immune therapy aimed to treat GIST except for adjuvant imatinib systemic therapy that concluded at least 90 days prior to registration. For Phase I, patients are eligible regardless of prior therapy. Chronic liver disease (e.g., cirrhosis). Known positive serology for HIV, active Hepatitis B, and/or active Hepatitis C infection. Patients have a history or current evidence of Central Serous Retinopathy (CSR) or retinal vein occlusion (RVO) or major predisposing factors to CSR or RVO (e.g. uncontrolled glaucoma or ocular hypertension) in the opinion of the study ophthalmologist. History of retinal degenerative disease. Active corneal disorder or keratopathy (e.g. corneal abrasion, bullous keratopathy). Severe and/or uncontrolled medical disease, including: Uncontrolled diabetes mellitus (A1c >8); Chronic Kidney Disease Stage III or higher (Creatinine Clearance <60mL/min/m2 by Modified Diet in Renal Disease (MDRD) calculation); Active, uncontrolled infection Known active brain metastasis unless they have been treated and shown documented radiographic stability for 28 days. Known other active malignancy (other than malignancies which the investigator determines are unlikely to interfere with treatment and safety analysis). Patients have clinically significant cardiovascular disease, including any of the following: Any history of acute coronary syndrome including myocardial infarction, stable or unstable angina, CABG, coronary angioplasty or stenting or known obstructive coronary artery disease; Symptomatic chronic heart failure (New York Heart Association Criteria, Class II-IV); Evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities < 6 months prior to screening except atrial fibrillation (AF) and paroxysmal supraventricular tachycardia (PSVT). Any history of thrombotic cerebrovascular accident or other arterial thrombosis. Uncontrolled arterial hypertension (systolic blood pressure >155 mmHg or diastolic >95 mmHg) despite appropriate medical therapy. History and/or current evidence of uncontrolled endocrine alterations of calcium/phosphate homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis, etc. Impairment of gastrointestinal function or gastrointestinal disease (e.g., uncontrolled ulcerative disease; uncontrolled nausea, vomiting, diarrhea; chronic malabsorption syndrome). Patients with major surgery within 3 weeks prior to study entry or who have not recovered from side effects of such procedure. Women who are pregnant or lactating. Sexually active males, unless they use a condom during intercourse while taking the drug and for 15 days after stopping treatment. They should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.Patients with any significant history of non-adherence to medical regimens or with inability to grant reliable informed consent.",occurred ≤28 days (first cycle) ,NA
33683501,NA,Combination,No,patients with relapsed/refractory chronic lymphocytic leukemia,"Eligible patients were ≤ 18 years old with relapsed/refractory CLL according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria . All patients had received at least one prior line of systemic treatment. Prior BTK inhibitors were not allowed. Other eligibility criteria included Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0–2; clinically quantifiable disease burden (absolute lymphocyte count > 10,000/µL, measurable lymphadenopathy, or quantifiable bone marrow infiltration); adequate organ function; and residual nonhematological toxicity from prior treatment of grade ≤ 1.","Key exclusion criteria were: any CD37-targeting antibody or CD37 antibody-drug conjugate; allogeneic stem cell transplant within 1 year or active graft-versus-host disease; known transformation of CLL to an aggressive B-cell malignancy at the time of screening; history of non-CLL malignancy except for adequately treated in-situ, stage I or II carcinoma in complete response (CR) or any other cancer that had been in CR for ≥ 2 years after the end of cancer treatment; and active uncontrolled autoimmune cytopenia.",Cycle 1,NA
7540421,NA,Combination,No,advanced solid tumours,"We enrolled patients with histologically confirmed diagnoses of solid malignancy, an ECOG performance status <2 and normal haematological, renal and hepatic function. ",NA,NA,NA
23045577,NCT00849654,Single Drug,No,Patients With Relapsed/Refractory B-Cell Malignancies,"Patients with relapsed or refractory, histologically confirmed NHL, CLL, or Waldenstro¨m macroglobulinemia (WM) who had failed at least one previous therapy were eligible. Inclusion criteria included: Eastern Cooperative Oncology Group performance status<= 1, age>=18 years,measureable disease (NHL: atleast one lymph node 2 cm in any axis; CLL: >= 5,000 leukemia cells/uL; WM: IgM level >=1,000mg/dLwith bonemarrowinfiltration), absolute neutrophil count >= 1,500/uL, platelet count >= 75,000/uL (unless CLL with cytopenia secondary to marrow involvement), and adequate renal and hepatic function.","Major exclusion criteria included: more than four previous systemic therapies; previous allogeneic stem-cell transplantation; immunotherapy, chemotherapy, radiotherapy, or experimental therapywithin 4weeks of study; major surgery within 4 weeks of study; active infection within 4 weeks of cycle one, day 1; CNS involvement by lymphoma; history of previous cancer < 2 years before study (except skin basal or squamous cell carcinomas, cervical cancer in situ, or other in situ carcinomas); and significant comorbidities",in cycle one,NA
25336693,NCT00878423,Single Drug,No,patients with advanced solid tumors,"Patients included in the study were 18 years of age, with an Eastern Cooperative Oncology Group (ECOG) performance status 0–2, and histologic or cytologic evidence of a metastatic solid tumor, including lymphoma that was refractory to standard therapy. Patients had to have adequate bone marrow function (hemoglobin > 9 g/dL, neutrophils > 1.4 x 109/L and platelets 100  109/L), hepatic function [serum bilirubin < 2.5 times the upper limit of reference range (ULRR); alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase < 2.5 times ULRR, unless due to the presence of liver metastases, when ALT and AST could have been up to 5 times the ULRR or bone metastases, when an isolated alkaline phosphatase < 5 times ULRR was acceptable], renal function (serum creatinine <= 1.5 times ULRR, without evidence of more than 1þ proteinuria on 2 occasions), and cardiac function (left ventricular ejection fraction > 50% on echocardiogram or multigated acquisition scan and QTc <= 460 msec according to Fridericia correction). ","Main exclusion criteria were pregnant or lactating females, ongoing central nervous system metastases, treatment with any anticancer therapies, or with known cytochrome P450 inducers, within 4 weeks of the start of AT13387, history of ischemic cardiac event, myocardial infarction or unstable cardiac disease within 3 months of study entry, prior history of infection with HIV or known active HBV or HCV infection, and any evidence of severe or uncontrolled systemic conditions.",during the first cycle of treatment,NA
23403628,NA,Single Drug,No,"Cancer type, Breast, Cervix, Colorectal, Endometrial, GIST, Melanoma, Mesothelioma, Ovarian, Prostate, Sarcoma, Other(include 1 patient of each tumor type of renal, desmoplastic small round cell, neuroendocrine, frontal-parietal hemangiopericytoma, unresectable duodenal adenocarcinoma, germ cell carcinoma, diffuse type giant cell, cholangiocarcinoma, and gastric adenocarcinoma.)","Patients with histologically confirmed advanced solid tumors that were not amenable to established forms of therapy were eligible for the study. Key inclusion criteria included the following: age 18 years or older; written informed consent; Eastern Cooperative Oncology Group Performance Status (ref. 15; ECOG PS) 0–2, predicted life expectancy of at least 12 weeks; and adequate hematopoietic, hepatic, and renal function. Patients with GIST were permitted to have had prior TKI therapy (e.g., imatinib or sunitinib) and because of the risk of symptom flare that may occur with TKI withdrawal in patients with GIST, these patients were only required to have a minimum period of 7 days off other TKI therapy.","Exclusion criteria included the following: patients with significant comorbidities including severe cardiac disease or uncontrolled hypertension; pregnancy, breast-feeding; residual drug-related toxicities of prior treatments (except alopecia, fatigue, and grade 1 neurotoxicity); concurrent CYP3A4 inducers or inhibitors within 14 days of the first dose of OSI-930; and anticancer chemotherapy or radiotherapy less than 3 weeks before study entry (4 weeks for carboplatin or investigational anticancer agents and 6 weeks for nitrosoureas and mitomycin C)",in the first treatment period,NA
31331917,NA,Combination,No,relapsed/refractory non–germinal center B-cell–like DLBCL,"Eligible patients were at least 18 years of age with relapsed/refractory pathologically confirmed DLBCL with 1 or more measurable disease sites larger than 1.5 cm in the longest dimension on a computed tomography scan. Relapsed/refractory status was defined as recurrence of disease after complete response (CR) or partial response (PR), stable disease, or PD at completion of the preceding regimen (including autologous transplantation). Patients without prior transplant must have been transplant-ineligible at study entry, defined as 1 or more criterion: age at least 70 years, diffuse lung capacity for carbon monoxide lower than 50%, left ventricular ejection fraction lower than 50%, organ dysfunction or comorbidities precluding transplantation, failure to achieve CR or PR with salvage therapy, or patient refusal. Patients were required to have the ability to swallow capsules; an Eastern Cooperative Oncology Group performance status lower than 2; life expectancy higher than 3 months; adequate hematologic, hepatic, and renal function; and both a prothrombin time/international normalized ratio and activated partial thromboplastin time of less than 1.5 × the upper limit of normal.","Key exclusion criteria included unresolved toxicities from prior anticancer therapy; medically apparent central nervous system lymphoma/leptomeningeal disease; prior allogeneic transplantation, other malignancies (except adequately treated nonmelanoma skin cancer), or HIV or hepatitis B or C infection; recent infection requiring IV anti-infective treatment completed within 14 days of study drug; known bleeding diathesis or hemophilia; clinically significant cardiovascular disease; and known hypersensitivity to study drug. Patients must not have received any chemotherapy, external beam radiation therapy, or anticancer antibodies within 2 weeks of study drug; radio- or toxin-immunoconjugates within 10 weeks of study drug; systemic immunosuppressant therapy within 28 days of study drug; or major surgery within 4 weeks of study drug.",NA,NA
7625371,NA,Combination,No,patients with non-small cell lung cancer previously treated with chemotherapy,"From June 1990 to February 1993, 23 patients with stage III or IV non-small cell lung caner were enrolled. Individuals studied had received one prior chemotherapy regimen ont containing either study drug. Patients were required to have a Karnofsky performance status >= 60%, keukocyte count >= 4,000/mm3, platelet count >= 160,000/mm3, serum bilirubin <= 1.5 mg/dl, and creatinine clearance >= 65 ml/min/1.7 m2. Measurable or evaluable indicator lesions were required.","Patients with unstable cardiac disease, hearing loss, or peripheral neuropathy were excluded. ",NA,NA
8740798,NA,Combination,No,advanced non-small-cell lung cancer,"Eligibility criteria included histologically or cytologically documented stage IIIB (e.g., malignant pleural effusion) or stage IV non-small-cell lung cancer, measurable or evaluable disease in a nonirradiated field, a life expectancy exceeding two months, and a Cancer and Leukemia Group B (CALGB) performance status of 0 to 2. No prior chemotherapy was permitted, and prior radiotherapy was limited to patients whose condition relapsed after primary surgery or radiotherapy, and to those who received radiotherapy for brain metastases or for palliation of other metastases when less than 40% of the marrow-bearing bone was the field. Finally, patients reviewd and signed a detailed informed consent document.","Patients with active brain metastase (i.e, untreated or with worsening symptoms) were not eligible. Initial laboratory requirements included a leukocyte count greater than 3500/mcl, platelet count greater than 100,000/mcl, hemoglobin greater than 10 g/ldk, and blood urea nitrogen, creatinine, bilirubin and aspartate aminotransferase levels less than 1.5 times normal. Patients were ineligible if they had active cardiac disease, were taking medication affecting cardic conduction, or on electrocardiogram had a conduction abnormality or arrhythmia worse than first-degree heart block. ",NA,NA
32147671,NCT01468688,Combination,No,patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib,"Adult patients with histologically confirmed unresectable or metastatic GIST who had failed prior therapy with both imatinib and sunitinib were enrolled. Patients were required to have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), a World Health Organisation performance status of 0–2 and adequate bone marrow and organ function. For the dose-expansion part, radiological confirmation of disease progression during previous therapy was required, and up to three lines of prior therapy were permitted.","Patients with previous treatment with PI3K inhibitors, any ongoing condition of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥2 related to previous imatinib and/or sunitinib and poorly controlled diabetes mellitus (defined as glycosylated haemoglobin >8%), were excluded from the study. Since buparlisib is known to be associated with psychiatric disorders, including mood disorders, anxiety and depression, patients with a medically documented history of active major psychiatric disorders were not eligible. At screening, patients who had a cut-off score of ≥10 in the 9-item depression scale of the Patient Health Questionnaire-9 (PHQ-9) or a cut-off score of ≥15 in the Generalized Anxiety Disorder Assessment-7 (GAD-7) mood scale, or selected a positive response to question numbers 1, 2 and 3 to question number 9 regarding potential for suicidal thoughts or ideation in the PHQ-9 (independent of the total score of the PHQ-9) were excluded from the study",during the first cycle (28 days) of therapy,NA
9635927,NA,Combination,No,advanced ovarian cancer,"Patients in this study had to have cisplatin or carboplatin pretreatment as frontline therapy for advanced ovarian carcinoma. Other inclusion criteria were: progressive measureable or evaluable disease, age <=70 years, WHO performance staus <=2, life expectancy of >=3 months, and adequate renal, liver and bone marrow function (creatinine, bilirubin <=1.5 x upper normal limit and ANC >=2.0 x 109/l, platelet count >=100 x 109/l). All patients gave their informed consent prior to study entry.",NA,NA,NA
21263099,NA,Single Drug,No,"pediatric patients with refractory solid tumors or imatinib-refractory. Diagnosis: Chronic myelogenous leukemia 9, Osteosarcoma, NOS, Hepatoblastoma 3, Acute lymphoblastic leukemia 2, Alveolar rhabdomyosarcoma 2, Synovial sarcoma, NOS 2, Ewing sarcoma 2, Neuroblastoma, NOS 2, Carcinoma, NOS 1, Adenocarcinoma, metastatic, NOS 1, Neuroendocrine carcinoma, NOS 1, Renal cell carcinoma, NOS (C64.9) 1, Paraganglioma, NOS 1, Desmoplastic small round cell tumor 1, Leiomyosarcoma, NOS 1, Rhabdomyosarcoma, NOS 1, Nephroblastoma, NOS 1, Malignant rhabdoid tumor 1, Malignant myoepithelioma 1, Epithelioid hemangioendothelioma, malignant 1, Telangiectatic osteosarcoma 1","Patients with solid tumors refractory to standard therapy or imatinibresistant, Ph-positive leukemia were eligible for the trial. Eligibility criteria included the following: age 1 to 21 years (inclusive); Karnofsky or Lanksy performance score of more than 50; recovery from the acute toxic effects of prior chemotherapy, radiotherapy, or immunotherapy with a minimum elapsed period of at least 7 days since the last dose of corticosteroids or hematopoietic growth factors; at least 3 months since stem-cell transplantation; at least 3 months since prior craniospinal radiation, pelvic radiation, or total-body irradiation; at least 2 weeks since local palliative radiation; and at least 6 weeks since other substantial radiation. Patients could not have evidence of active graft-versus-host disease. Patients were required to have adequate renal function (serum creatinine < the upper limit of normal for age or a glomerular filtration rate > 70 mL/min/1.73 m2), adequate liver function (serum bilirubin < 1.5 mg/dL x the upper limit of normal for age, ALT < 110U/L, and albumin > 2 g/dL), adequate cardiac function, and adequate pulmonary function. Patients with solid tumors were required to have an absolute neutrophil count more than 1,000/uL, a platelet count more than 100,000/uL, and a hemoglobin level more than 8 g/dL. Patients with leukemia were required to have platelet count more than 20,000/L and a hemoglobin level more than 8 g/dL. If necessary, platelet and RBC transfusions were allowed to meet these parameters on both treatment strata. One patient per cohort with bone marrow metastatic disease was permitted on protocol provided that the patient was not refractory to transfusion therapy. Administration of hydroxyurea was permitted up to 24 hours before the start of therapy if needed for cytoreduction of leukemia. Intrathecal therapy was permitted for patients with CNS leukemia.","Exclusion criteria included pregnancy or lactation in women of childbearing age; uncontrolled infection; receipt of concomitant enzyme-inducing anticonvulsant, antithrombotic, or antiplatelet agents; several CYP3A inhibitors (itraconazole, ketoconazole); HIV-positive patients whose highly active antiretroviral therapy regimen might interact with dasatinib; or concomitant use of other experimental agents.",during the first cycle of treatment,NA
12228203,NA,Combination,No,"patients with solid tumors. Primary diagnosis: Renal cell carcinoma, Melanoma, Gastric cancer, Other carcinomas (adrenal, bladder, myoepithelial, tongue, thyroid/adrenal)","Patients were eligible if they had a measurable, histologically documented solid tumor, including metastatic melanoma and RCC, that was unresponsive to initial treatment. Prior surgical excision was acceptable but was not required. Eligibility included an Eastern Cooperative Oncology Group performance status of 0 or 1; age 18 to 70 years; more than a 12-week life expectancy; and adequate hepatic, renal, and hematologic function (including absolute neutrophil count >= 3,000 cells/uL, platelet count >= 100,000/uL, hemoglobin  9.0 g/dL, serum creatinine <= 2.0 mg/dL or calculated creatinine clearance of >= 50 mL/min, serum bilirubin <= 1.5 times the upper limit of normal [ULN] unless due to disease infiltration, ratio of serum ALT to serum AST <= 1.5 times ULN unless due to disease infiltration, and normal serum calcium). Patients who had received prior IFN- or interleukin2–containing regimens were eligible","Patients were ineligible if they had received more than two prior systemic treatments, including chemotherapy or immunotherapy, or if they had evidence of CNS metastases, a history of hypersensitivity or intolerance to IFNa, a history of hospitalization because of neuropsychiatric disorders, severe cardiovascular disease, refractory thyroid dysfunction, uncontrolled diabetes, active hepatitis, or a life-threatening second active malignancy.",NA,NA
19541476,NA,Single Drug,No,"advanced and/or metastatic solid cancers. Primary cancer: GIST, Cortico-suprarenal cancer, Mesothelioma, Thyroid cancer, Bladder cancer, Cancer not differentiated, Colorectal cancer, Prostatic adenocarcinoma, Thymoma, Non-small cell lung cancer, Neuroendocrine tumour, Cystic adenoid carcinoma, Duodenum adenocarcinoma","Patients with histologically proven advanced solid malignancies for which no standard alternative curative therapy could be proposed were eligible. All patients were required to have at least one measurable target site. Other eligibility criteria included the following: age P18 years, an Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 2 and the absence of serious concomitant medical disorders. Additionally, patients had to exhibit adequate renal function (serum creatinine <1.5 times the upper limit of normal (ULN) or a calculated creatinine clearance >40 ml/min, adequate bone marrow function (WBC count >3500/mm,3 absolute neutrophil count [ANC] >2000 mm3, platelet count >105/mm3 and haemoglobin >11 g/dl), and adequate liver function (total bilirubin value <1.5 times ULN, ALAT level <2.5 times ULN and ASAT <2.5 times ULN). An effective con- traceptive method was requested for women of childbearing age and a negative pregnancy test was required prior to treatment administration","Patients were excluded if they were pregnant or nursing, had a known history of brain metastases, myocardial infarction or coronary disease, or had a history of gastro-intestinal (GI) disorder that could interfere with drug absorption. Patients with a history of any other malignancy, apart from in situ carcinoma of the cervix or basal cell carcinoma of the skin within five years prior to entry to the study, were also excluded. Patients could not have undergone surgery within the last six weeks and should not have been treated within the preceding four weeks to enrolment with any investigational drug, chemotherapy, radiotherapy, immunotherapy or hormonal therapy. The exclusion period was extended to six weeks for previous treatments with nitrosureas or mitomycin C. ",from the first dose of masitinib until 28 days after the last dose (7 days for the DLT,NA
20310049,NA,Single Drug,No,in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance,"Patients with Ph-positive leukemias, including CML-CP,CML-AP, CML-BP, and Ph-positive ALL, who haddeveloped  imatinib  resistance or intolerance  wereincluded in the trial. To be enrolled in the study, patients had to be aged18 years, to have an Eastern Cooperative OncologyGroup score of 0 to 2, and to have normal cardiac, hepatic, and renal functions. Women who were enrolledin the study could not be pregnant or lactating. Patientswere not allowed to have received chemotherapy within1 week or imatinib within 3 days before the start of thetrial. Exceptions included hydroxyurea administration asindicated clinically before and during the first 21 days oftreatment and corticosteroids up to 48 hours before thefirst study dose. ","Patients with comorbid states, such asopportunistic and/or uncontrolled systemic infections,impaired gastrointestinal function, psychiatric disorders,and/or sustained toxicity from prior therapies, wereexcluded from the study along with patients who had ahistory of another primary malignancy of clinical signifi-cance that required intervention",NA,NA
11535501,NA,Single Drug,No,Philadelphia chromosome-positive chronic myelogenous leukemia,"Adults aged 18 years or older referred to or treated at our institution with a diagnosis of Ph1 CML were eligible. Entry criteria required (1) failure on prior IFN-a therapy; (2) adequate performance status (ECOG performance 0-2), adequate liver (bilirubin, aspartate aminotransferase [AST], alanine aminotrasnferase [ALT] <= 2 x normal) and renal functions (creatinine <= 2 mg/100 mL) and cardiac status; and (3) absence of serious neuropsychiatric complications, unless directly related to prior IFN-a therapy.","Patients in blastic phase of CML were not eligible. Patients in accelerated phase of CML, as previously defined,37 were not eligible to be treated, except if they had clonal evolution as the only accelerated phase criterion.",NA,NA
18235116,NA,Single Drug,No,"patients with advanced malignancies and varying degrees of renal dysfunction. Tumor type: c-kit (CD117), status unknown: Renal, Colorectal, Lung, Ovarian cancer, Sarcoma, Melanoma, Other; c-kit (CD117)-positive: GIST, Endometrial stromal tumor, Other (thymus, Ewing’s sarcoma, colon, pancreas) ","Eligible patients were required to meet the following criteria: pathologically confirmed malignancy that was no longer curable by standard surgical or medical therapy, age >=16 years; Eastern Cooperative Oncology Group performance status <= 2; life expectancy >= 3 months; leukocytes >= 3,000/uL or absolute granulocytes >= 1,500/uL; platelets >= 100,000/uL; total bilirubin within institutional normal limits; and AST/ALT <= 1.5 x the institutional upper limit of normal. ","Because imatinib is metabolized by CYP3A, patients requiring therapeutic anticoagulation with warfarin were excluded. ",the first cycle of therapy,Group A (normal renal function) had CrCL >= 60 mL/min; group B (mild dysfunction) had CrCL 40 to 59 mL/min; group C (moderate dysfunction) had CrCL 20 to 39 mL/min; and group D (severe dysfunction) had CrCL less than 20mL/min.
15150579,NA,Combination,No,"Primary tumour site: Colon, Cervix, Melanoma, Ovarian, Gastric, Pancreas, Renal, Oropharynx, Non-small-cell lung cancer, Urogenital","The eligibility criteria were histologically confirmed metastatic or locally advanced cancer, no proven benefit of existing anticancer therapy, age between 18 and 75 years, World Health Organisation (WHO, 1979) performance status <=2, adequate bone marrow function (white blood cells (WBC) >=3.5 x 109 l-1, granulocytes >=1.5 x 109 l-1, platelets >=100 x 109 l-1, haemoglobin >=6 mmol l-1), adequate hepatic function (serum bilirubin <=20 umol l-1, alanine-aminotransferase (ALAT), aspartate-aminotransferase (ASAT), and alkaline phosphatase (AP) <=2 x the upper limit of the reference range or <=5 x the upper limit of the reference range if the elevation was directly contributed to the presence of metastatic disease), adequate renal function (serum creatinine <=120 mmol l-1 or creatinine clearance (CL) >=60 ml min-1), evaluable disease, and a life expectancy >=3 months.","The exclusion criteria were breast feeding, pregnancy or inadequate contraceptive protection, drug, medication or alcohol abuse, treatment with an investigational drug <=1 month prior to the study entry, surgery, radiotherapy (except for analgesic indications) or chemotherapy (mitomycin C or nitrosoureas <=1.5) <=1 month prior to the study entry, other diseases altering procedures of the trial, history of seizures or central nervous system disorders, severe intercurrent infection, serious uncontrolled concurrent medical or psychiatric disease, known hypersensitivity to IF or topotecan, and prior treatment with IF or topotecan. ",during the first treatment cycle,NA
28428884,NCT01738139,Combination,Yes,"patients with advanced malignancies. Malignancy: Melanoma, RCC (clear cell), NSCLC, GIST, Other (Prostate, Mesothelioma, Osteosarcoma, Germ-cell tumor, Salivary duct, Renal medullary, Anal)","Major inclusion criteria were metastatic or unresectable solid tumor refractory to standard therapies, age ≥15 years, ECOG ≤2, and normal organ and bone marrow function. For expansion cohorts, patients were required to have a metastatic or unresectable GIST, melanoma, or uncategorized tumors with tumor biopsies testing positive for KIT mutations or c-KIT expression on immunohistochemical analysis. Notably, all expansion cohort patients had KIT mutations confirmed by molecular testing prior to inclusion.","Major exclusion criteria included active autoimmune disease, human immunodeficiency virus (HIV), hepatitis B, hepatitis C, current immunodeficiency disease, and pregnancy. Concurrent immune or vaccine therapies were not allowed.",first two cycles,NA
16144928,NA,Combination,No,patients with chronic myelogenous leukemia,"All patients enrolled in the trial were over 18 years of age and had a confirmed diagnosis of chronic phase CML (Ph+ or bcr-abl+). Additional requirements included a diagnosis of CML of >6 months duration and resistance to IFN-a therapy as defined by at least one of the following conditions: (a) loss of cytogenetic response (Ph+ increases by >=30%), (b) a best response of minor or no cytogenetic response (Ph+, >=35%), (c) hematologic response in the absence of a cytogenetic response, or (d) hematologic resistance defined by persistent elevation of WBC >20 x 109/L despite treatment with IFN-a. Patients had to have a Karnofsky performance status score of >=80%. Patients deemed to be IFN-a intolerant were allowed to be included in the study.",Patients were excluded from the trial if they had accelerated or blastic phase CML as previously defined or if they had been screened for and expected to an allogeneic bone marrow transplant within the next 3 months.,within the first 28 days of therapy,NA
9457812,NA,Combination,No,patients with high-grade glioma,"All patients had histological confirmation of supratentorial diffuse infiltrating anaplastic astrocytoma, glioblastoma multiforme, anaplastic oligoastrocytoma, or gliosarcoma according to WHO criteria (16), within 3 weeks of study registration. All had no prior chemotherapy, radiotherapy, or immunotherapy for their brain tumor. Patients who were less than 18 years old, or had leukocytes < 4000/u1, plate- lets < 130,000/u1, creatinine greater than 1.5 mg/dl, aspartate transaminase (AST) > twice normal, elevated direct bilirubin, calcium > 12.0 mg/dl, uncontrolled infection, coexistent malignant disease, pregnancy or lactation, ECOG performance score of 4, or New York Heart Association Class III or IV were excluded from study participation. All patients provided written informed consent prior to study enrollment.",NA,NA,NA
19248046,NA,Combination,No,malignant glioma,"Patients were required to have a histologically confirmed diagnosis of grade 3 or 4 MG that was recurrent. Patients with prior low-grade glioma were eligible if histologic transformation to MG prior to enrollment was confirmed. Patients were also required to: be ≥18 years of age; have a Karnofsky performance status (KPS) ≥ 60%; be on a stable corticosteroid dose for ≥1 week; have satisfactory hematologic (hemoglobin >9 g/dl; absolute neutrophil count >1000 cells/μl; platelet count >100,000 cells/μl) and biochemical results (serum creatinine, BUN, AST and bilirubin < 2.0 times the upper limit of normal); have recovered from all expected toxicity related to previous therapy; and provide written informed consent. At least 4 weeks had to have elapsed since prior surgical resection, radiotherapy, or chemotherapy (6 weeks for nitrosoureas).","Exclusion criteria were: treatment with prior PDGFR- or VEGFR-directed agents; >three episodes of progressive disease; pregnancy or nursing; intra-tumoral hemorrhage (except post-operative grade 1); significant concurrent medical illness; prior malignancy; concurrent warfarin use; ≥ grade 2 peripheral edema, pulmonary or pericardial effusion or ascites; and prior stereotactic radiosurgery or radioimmunotherapy unless there was obvious radiographic disease progression or biopsy-proven recurrence",during cycle one (28 days),NA
22805325,NCT 00424385,Combination,No,patients with refractory castration-resistant prostate cancer,"Men with histologically confirmed CRPC, regardless of their original Gleason score, who had failed one or more lines of systemic chemotherapy, were eligible as long as their last treatment was >=4 weeks prior. Progression on the last chemotherapy had to be confirmed radiographically and/or biochemically. Patients had to have measurable disease by bone scan and/or computed tomography (CT), an ECOG (Eastern Cooperative Oncology Group) performance status <=2, and adequate organ function (total bilirubin <1.5 x upper normal limit, AST/ALT <2.5 upper normal limit, creatinine <1.5 upper normal limit, platelets >75 x 109 per l, and absolute neutrophil counts >1.0 x 109 per l). Patients were mandated to continue ADT while on study and were allowed to continue bisphosphonates for bone metastases. Continuing ADT and bisphosphonates in these patients was recommended based on common standard practice in CRPC patients and based on the NCCN guidelines in this setting (Mohler et al, 2010). ","Patients with prior malignancies (except for non-melanoma skin cancers) were excluded unless any active therapy for such malignancy was >3 years from study entry. Patients with known HIV status or brain metastases were excluded. Other major exclusion parameters included New York Heart Association class III/IV, uncontrolled hypertension defined as systolic >150 mm Hg and/or diastolic >90 mm Hg despite optimal therapy, active infectious or psychiatric illness, thrombotic or embolic events within 6 months from enrolment, pulmonary haemorrhage, bleeding event >grade 3 both within 4 weeks from study entry, use of St John’s Wort or rifampin, known cirrhosis or active hepatitis, prior radiotherapy to >25% of the bone marrow, and major surgery within 2 weeks of study entry.",in cycle 1,NA
10410530,NA,Combination,No,advanced primary lung cancer,"Eligibility criteria included: 1) histologically diagnosed advanced SCLC or NSCLC, except for untreated limited-stage SCLC, which is not evaluated in phase I studies because of the existence of established therapy; 2) 75 years of age or less; 3) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2; 4) no chemotherapy or radiotherapy administered within the 4 weeks prior to study entry; 5) had not received CPT-11 and/or ifosfamide prior to study; 6) adequate hepatic function (bilirubin level<=1.5 mg/dL, and transaminase levels <=2 x the upper limit of normal), adequate renal function (creatinine level <=1.4 mg/dL), and adequate bone marrow function (as documented by a leukocyte count >=4,000/uL and <=12,000/uL, but a leukocyte count>=3,000/uL on days 8,15 and on the day of CPT-11 infusion during first 2 cycles; platelet count >=100,000/uL, and hemoglobin concentration >= 9.0 g/dL).",NA,during the first 2 cycles,NA
18284451,NA,Combination,No,advanced squamous cell carcinoma of the uterine cervix,"The present study was initiated after receiving approval from the institutional review board of Okayama University Hospital and obtaining written informed consent from the patients prior to their participation. Patients with histologically documented advanced SCC of the uterine cervix were enrolled in the present study. Other eligibility criteria were as follows: age less than 70 years; an Eastern Cooperative Oncology Group performance status of 0 or 1; and documentation of adequate bone marrow function (absolute neutrophil count [ANC] >= 2000/mm3, platelet count >= 100,000/mm3), renal function (creatinine clearance >= 60 mL/min), and liver function (bilirubin <= 1.5 mg/dL, aspartate aminotransferase and alanine aminotransferase <= 2 times the upper normal limit).",Patients with a concurrent malignancy or a previous history of radiotherapy or chemotherapy were excluded from the study.,NA,NA
10343194,NA,Combination,No,advanced non-small cell lung cancer,"Patients were enrolled in the study if they met the following eligibility criteria and did not meet any of the exclusion criteria: (1) histologically or cytologically confirmed advanced NSCLC (stage III or IV), (2) no prior chemotherapy or no therapy for at least 4 weeks before study entry, (3) a life expectancy of at least 3 months, (4) a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale, (5) between 15 and 75 years of age, (6) adequate bone marrow function (hemoglobin >=9 g/dl, leukocyte count >=4,000/mm3, platelet count >=100,000/mm3), adequate renal function (serum creatinine <1.5 mg/dl), adequate liver function (SGOT and SGPT <2 times the upper limit of normal), and (7) informed consent for participation.","Exclusion criteria were as follows: (1) severe concurrent medical conditions, (2) pregnant or nursing mothers, (3) active concomitant malignancy, (4) active uncontrolled infection, (5) intestinal paralysis and obstruction, (6) interstitial pneumonia or pulmonary fibrosis, and (7) large amount of ascites and/or pleural effusion",during the first three courses of therapy,NA
18989889,NA,Combination,No,"children with refractory solid tumors. Histology: Neuroblastoma, Ewing sarcoma, Synovial cell sarcoma, Alveolar soft part sarcoma, Osteosarcoma, Neurofibrosarcoma, Adrenocortical carcinoma, Anaplastic ependymoma, Mesothelioma (omental), Hepatoblastoma, Wilm’s tumor","Eligible patients were <=21 years of age with a histologicaldiagnosis of cancer (solid tumor or leukemia) refractory toconventional therapy or for which no effective therapy was known. Patients were tobe stratified as (1) leukemia or(2) solid tumor. Othereligibility criteria included: (a) Karnofsky performance score of >=50 (ECOG 0-2), (b) adequate nutritional status (>3rd percentilefor weight with respect to height, normal total serum protein andalbumin/globulin ratio), (c) recovery from the acute toxic effects ofprior chemotherapy, radiotherapy, or immunotherapy, (d) at least 3 months since stem cell transplants with limited or no radiation, (e)at least 6 months since transplants employing total body irradiation,and (f) at least 6 weeks since the administration of a nitrosourea.Study exclusion criteria included: severe or uncontrolled infection,active graft versus host disease, or a history of craniospinal orextensive pelvic, abdominal, or mantle and Yport radiation. Patientswere required to have adequate renal function (serum creatinine below the upper limits of normal for age or a creatinine clearance orradioisotope glomerular filtration rate >=70 ml/min/1.73 m2 and no history of renal disease); adequate liver function (serum bilirubin <=1.5 mg/dl, and alanine aminotransferase <=2 times the institutionalupper limit of normal for age). Patients without malignantinfiltration of the bone marrow were required to have an absoluteneutrophil count >=1,500/ul and a platelet count >=100,000/ul. Additional anticancer therapies and enrollment on any other study were prohibited while patients were taking part in this investigation. Informed consent from the patient or their parent(s) and assent, asappropriate, were obtained in accordance with the U.S. NationalCancer Institute, Children’s Oncology Group, and individualInstitutional Review Board policies prior to study entry",NA,in the first cycle of therapy,NA
24434430,EudraCT number: 2009-011417-24,Combination,No,patients with treatment-refractory metastatic gastrointestinal stromal tumors,"Patients with metastatic GIST (aged 18 years and older) refractory to IM and sunitinib were enrolled in the trial following written informed consent. Additional main inclusion criteria were Eastern Cooperative Oncology Group performance score 2 or lower, absolute neutrophil count 1500 per litre, platelets 100 000 per litre, serum transaminase activity <2.5 x ULN, total bilirubin <1.5 x ULN, serum creatinine <1.5 x ULN or a creatinine clearance of >=60 ml min-1, fasting serum cholesterol <=350 mg dl-1, triglycerides <=300 mg dl-1, proteinuria <=1 g in 24 h, no prior thromboembolic disease, no history of haematemesis or haemoptysis. There was no limit on the number of previous anticancer regimens. ","Patients with a history of cardiac disease (congestive heart failure (4 New York Heart Association class 2), active coronary artery disease, cardiac arrhythmias requiring antiarrhythmic therapy other than beta blockers or digoxin, uncontrolled hypertension; myocardial infarction less than 6 month before study entry) were excluded.",cycle 1,NA
31471313,NCT02164240,Combination,No,Refractory Gastrointestinal Stromal Tumors,"1.1. At least 18 years of age at the time of study entry. 1.2. Histologically confirmed metastatic and/or unresectable GIST. Patients must demonstrate prior failure to at least imatinib, sunitinib and regorafenib (4th line and beyond). Any number of previous therapies for GIST is allowed.  Failure of imatinib is defined as either prior progression of disease on imatinib in the metastatic setting or progression during adjuvant imatinib, or within 3 months of completing adjuvant imatinib. Failure of sunitinib and regorafenib is defined only as prior progression of disease on sunitinib or on regorafenib as assessed by the investigator. 1.3. Measurable disease per modified RECIST 1.1. A lesion in a previously irradiated area is ineligible to be considered as measurable disease unless there is objective evidence of progression of the lesion prior to study enrollment. 1.4. ECOG performance status 0 or 1 (see Appendix A). 1.5. Participants must have adequate organ and marrow function as defined below (within 7 days prior to enrollment): a. Hemoglobin ≥ 9.0 g/dL (90 g/L). Previous transfusion is allowed. b. Absolute neutrophil count ≥ 1500/mm3. c. Platelets ≥ 100,000 /mm3. Previous transfusion is allowed. d. International normalized ratio (INR), and prothrombin time (PT) ≤1.5 x ULN (patients who are being prophylactically anticoagulated with an agent such as coumadin or low molecular weight heparin (LMWH) or therapeutically anticoagulated with LMWH will be allowed to participate provided they are stable and monitored at appropriate intervals per institutional guidelines throughout study). e. Alanine aminotransferanse (ALT) and aspartate aminotransferanse (AST) ≤ 2.5 x upper limit of normal (ULN), or ≤ 5.0 x ULN if liver metastases are present. f. Alkaline phosphatase (ALP) limit < 2.5 x ULN or ≤ 5.0 x ULN if liver metastases are present. g. Total serum bilirubin ≤ 1.5 x ULN. Patients with Gilbert’s syndrome with baseline serum bilirubin exceeding this limit are allowed to participate. h. Serum sodium within normal limits. i. Glomerular filtration rate (GFR) ≥ 30 ml/min/1.73 m2 according to the MDRD (modified diet in renal disease) abbreviated formula (see Appendix B). j. Serum phosphate levels ≥ 2.5 mg/dL or ≥ 0.8 mmol/L. 1.6. Patients must be able to swallow oral medication. 1.7. Willingness to use effective means of birth control throughout the duration of clinical study and for at least 3 months after completion of study drug. 1.8. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of study drug administration. 1.9. Ability to understand and the willingness to sign a written informed consent document.","2.1. Use of any approved tyrosine kinase inhibitors or investigational agents within 2 weeks or 6 half-lives of the agent, whichever is shorter, prior to receiving study drugs. 2.2. Patients with intolerance to sunitinib and/or regorafenib. 2.3. Participants who have had radiotherapy within 4 weeks prior to study entry.  2.4. Major surgery, or significant traumatic injury within 4 weeks prior to study entry. 2.5. Presence of symptomatic or uncontrolled brain or central nervous system metastases. 2.6. Known or suspected allergy to the investigational agent or any agent given in association with this trial. 2.7. Individuals with a history of a different malignancy, other than cervical cancer in situ, basal cell or squamous cell carcinoma of the skin, are ineligible, except if they have been disease-free for at least 5 years, and are deemed by the investigator to be at low risk for recurrence of that malignancy OR other primary malignancy is neither currently clinically significant nor requiring active intervention. 2.8. Clinically significant cardiac arrhythmias and/or patients who require anti-arrhythmic therapy (excluding beta blockers or digoxin). Patients with controlled atrial fibrillation are not exluded. 2.9. History of clinically significant cardiac disease or congestive heart failure > NYHA class 2. Patients must not have unstable angina (anginal symptoms at rest) or new-onset angina within the last 3 months or myocardial infarction within the past 6 months. 2.10. Hypertension as defined by systolic blood pressure >140 mmHg or diastolic blood pressure > 90 mmH despite optimal medical management. 2.11. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than 1 month before the start of study medication). 2.12. Patients with evidence or history of any bleeding diathesis, irrespective of severity. 2.13. Ongoing infection > Grade 2. 2.14. Patients with any seizure disorder requiring medication. 2.15. Non-healing wound, ulcer, or bone fracture. 2.16. Persistent proteinuria Grade 2 or higher measured by urine protein:creatinine ratio on a urine sample or during 24-hour assessment. 2.17. HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with sunitinib and regorafenib.  2.18. Patients with active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy, because of potential risk of lethal liver toxicity. 2.19. Interstitial lung disease with ongoing signs and symptoms at the time of informed consent. 2.20. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, clinically significant cardiac and pulmonary disease; liver diseases such as cirrhosis, chronic active or persistent hepatitis; or acute/ chronic medical/ psychiatric illness/ social situations or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or limit compliance with study requirements, or interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study. 2.21. Pregnant or lactating females. 2.22. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. 2.23. Strong CYP3A4 inhibitors (e.g. clarithromycin, indinavir, itraconazole, ketoconazole , nefazodone , nelfinavir , posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifampin, St. John’s Wort) within 28 days or 5 drug half-lives (if drug half-life in patients is known), whichever is longer, before start of study treatment.",during cycle 1 (28 days) ,NA
9060524,NA,Combination,No,advanced non-small-cell lung cancer,"Eligibility criteria included histologically or cytologically documented NSCLC stage IIIB or IV as defined by the American Joint Committee on Cancer criteria,with measurable or assessable disease. Patients were required to have an estimated life expectancy greater than 8 weeks, with a CALGB performance status of 0 to 2. Prior chemotherapy was not permitted. Prior radiation therapy was permitted only under the following conditions: (1) palliative brain irradiation for cerebral metastasis, (2) previous adjuvant radiation therapy with subsequent local or distant relapse, or (3) a history of definitive radiation therapy with subsequent progression of the radiated lesions or new measurable lesions outside of the field of radiation. No more than 40% of the total bone marrow space could have been incorporated in the prior radiation field. Normal laboratory parameters, including a WBC count greater than 3,500/uL, platelet count greater than 100,000/uL, hemoglobin level greater than 10 g/ dL, blood urea nitrogen (BUN) less than 1.5 times normal, creatinine concentration <= 1.5 mg/dL or creatinine clearance greater than 50mL/min, bilirubin level <= 1.5 times normal, and AST less than two times normal were required. Previously treated brain metastases were not an exclusion, but no active CNS disease was allowed. Pregnancy was an absolute contraindication to enrollment in this study. Finally, signed, witnessed, and dated informed consent was required for all patients.",NA,during cycle I of therapy ,NA
9363862,NA,Combination,No,pediatric patients with refractory cancer,"Patients <= 21 years of age with histologically confirmed cancer refractory to conventional therapy were eligible for this trial. Patients must have recovered from the toxic effects of prior therapy. All patients had adequate hepatic and renal function as defined by a serum bilirubin level less than 1.5 mg/dL, serum transaminases less than two times the upper limit of normal, and a serum creatinine concentration less than 1.5 times normal for age. Patients assessable for hematologic toxicity were required to have a granulocyte count greater than 1,500/pL and a platelet count greater than 100,000/pL.","Patients with CNS tumors, seizure disorder, hydrocephalus, or pseudotumor cerebri were excluded from the study. ",in cycle 1,NA
11032596,NA,Single Drug,No,"Primary tumor sites: Colorectal, Lung, Breast, Unknown, Bladder, Hypopharynx, Kidney, Melanoma, Sarcoma, Pancreas, Stomach, Urachus","All patients had a histologically or cytologically confirmed diagnosis of a solid tumor not amenable to established forms of treatment, gave written informed consent, and fulfilled the established inclusion criteria for this phase I study. The inclusion criteria were as follows: (a) age >= 18 years; (b) performance status <= 2 on the World Health Organization scale; (c) life expectancy >= 3 months; (d) no prior chemotherapy, immunotherapy, or radiotherapy for at least 4 weeks before entry onto the study, and no prior nitrosourea, mitomycin, high-dose carboplatin, or extensive radiotherapy for 6 weeks; (e) WBC count >= 3.0 x 109/L and platelet count >= 100 x 109/L; (f) adequate hepatic function, characterized by a bilirubin level less than 25 mmol/L (1.5 mg/dL) and transaminase (AST and ALT) levels  <= 2.5 times the upper normal limit (unless related to liver metastases, in which case < five times the upper normal limit was allowed); and (g) adequate renal function, defined by creatinine levels <= 140 mmol/L (1.6 mg/dL).","Exclusion criteria were (a) concomitant treatment with other investigational agents, (b) breastfeeding, pregnancy, or inadequate contraception in female patients, (c) any noncompensated or uncontrolled nonmalignant condition, (d) history of alcoholism, drug addiction, or psychotic disorders, and (e) brain involvement or leptomeningeal disease or prior irradiation to the brain.",during the first course,NA
24492162,NA,Combination,No,chemonaive patients with unresectable malignant pleural mesothelioma,"Eligible patients had unresectable MPM (any histologic type), were chemonaive, and had an ECOG PS of 0 to 2. The primary end point was maximum tolerated dose (MTD); secondary end points included response rate, progression-free survival (PFS), overall survival (OS), safety/toxicity, and tumor biomarker results.",NA,NA,NA
17293590,NA,Combination,No,children with newly diagnosed brainstem and recurrent malignant gliomas,"Patients 3 to 21 years of age with newly diagnosed malignant brainstem gliomas and recurrent malignant gliomas were eligible for this study (Pediatric Brain Tumor Consortium study PBTC006). Stratum 1 consisted of patients with newly diagnosed nonmetastatic diffuse intrinsic brainstem gliomas. A histopathological diagnosis was not required in the setting of a characteristic imaging appearance and clinical history (Albright et al., 1993; Jennings et al., 2002). Eligibility criteria were later amended to exclude patients with imaging evidence of intratumoral hemorrhage (ITH) at diagnosis. Stratum 2 consisted of patients with recurrent anaplastic astrocytoma, glioblastoma multiforme, or other high-grade glioma, as well as recurrent diffuse brainstem glioma. A histopathological diagnosis from either the initial presentation or the time of progression was required for all but malignant brainstem gliomas in this stratum. The eligibility criteria were later amended to exclude patients with an ITH not related to a previous surgical procedure. Other eligibility criteria included an adequate performance status (Karnofsky or Lansky score >= 50); absolute neutrophil count > 1000/ul, platelets > 100,000/ul (transfusion independent), and hemoglobin > 8 g/dl (with or without transfusion); adequate renal function as assessed by creatinine < 1.5 times the institutional normal for age or glomerular filtration rate . 70 ml/min/1.73 m2; and adequate hepatic function as assessed by bilirubin <= 1.5 times the institutional normal for age, serum glutamate-pyruvate transaminase (SGPT) (alanine aminotransferase) < 3 times the institutional normal for age, and albumin >= 2 g/dl. For patients in stratum 1, no prior therapy was allowed except routine corticosteroids. Concomitant anticonvulsant use was not permitted on this stratum. Furthermore, after the amendment, patients with evidence of hemorrhage after irradiation were off study and did not receive imatinib. For patients in stratum 2, at least three months must have elapsed prior to study entry for those who had previously received craniospinal irradiation; longer than eight weeks for local radiation to the primary tumor; and longer than two weeks for focal irradiation to symptomatic metastatic sites.","Patients who had previously received chemotherapy must have fully recovered from the acute toxic effects of therapy and, for those who had undergone stem cell transplantation, at least three months must have elapsed following treatment. In addition, neurological deficits, if present, had to be stable for a minimum of one week prior to study entry. Patients were also ineligible if they were pregnant or breastfeeding, had an uncontrolled infection, or were receiving another investigational or anticancer agent. Patients with deep venous or arterial thrombosis within six weeks of registration were also ineligible, as were those receiving warfarin",the DLT monitering periond was the first two 28-day courses (eight weeks) of imatinib treatment.,children with newly diagnosed intrinsic brainstem gliomas (stratum 1) and those with recurrent intracranial malignant gliomas (stratum 2)
17909807,NA,Combination,No,patients with metastatic renal cell carcinoma,"Patients were eligible if they had histologically proven RCC with clinical or biopsy proven metastases. All patients were older than 18 years of age, had bi-dimensionally measurable or evaluable disease, had a life expectancy of >=3 months; had a performance status Eastern Co-operative Oncology Group (ECOG) of <=1; had complete recovery from toxicity related to prior hormonal, radiation, or biologic therapy; had pretreatment laboratory values above stated minimum values (WBC >= 3.0 x 109/l, platelets >= 100 x 109/l, hemoglobin >= 9.5 g/dl, serum creatinine <= 1.5 mg/dl, bilirubin (total) <= 1.5 ml/dl, calcium <= 12 mg/dl and DLCO .= 50% predicted); had absence of signiWcant effusions or ascites; had no major surgery requiring general anesthesia within the preceding 28 days; and, had received <= 1 prior systemic regimens for metastatic RCC. Informed consent was obtained from all patients in accordance with institutional and federal guidelines.","Exclusion criteria included the following conditions: a history of a serious cardiac arrhythmia, congestive heart failure, angina pectoris, or other severe cardiovascular disease producing limitations of physical activity (i.e. New York Heart Association Class III or IV); active peptic ulcer disease, autoimmune disease, or inXammatory bowel disease; local or systemic infections requiring intravenous antibiotics within the past 28 days; pregnant or lactating women, and fertile women or men unless surgically sterile or using eVective contraception; known CNS metastases or known seizure disorder; positive for HIV, HBsAg, or HCAg; history of a malignancy other than a renal cell carcinoma or melanoma (exceptions basal or squamous cell carcinomas of the skin, carcinoma in situ of the uterine cervix, and any malignancy treated with curative intent and in complete remission for >=3 years); and patients with organ allograft.",during cycle one,NA
21242495,NCT00253474,Single Drug,No,young patients with plexiform neurofibromas,"Patients ≥18 months of age with unresectable progressive, symptomatic, or life-threatening PN were eligible. Initially there was no upper age limit, but the study was amended to limit enrollment to patients <21 years after untoward toxicity was encountered in adult patients enrolled on dose levels (DL) 1 and 2. Patients who met the diagnostic criteria for NF1 as defined by the NIH Consensus Conference13 were not required to have biopsy proof of a PN. Evidence of radiographic progression was not necessary. Patients had to have recovered from all toxic effects of previous therapy for their PN, a life expectancy of at least 12 months, and an Eastern Cooperative Oncology Group performance score of 0, 1, or 2. Adequate bone marrow (absolute neutrophil count ≥1,500/μL, Hb >10 g/dL, platelet count ≥100,000/μL), renal (normal serum creatinine for age or a creatinine clearance ≥70 mL/min/1.73 m2), and hepatic (total bilirubin <1.5 × normal and serum glutamic pyruvic transaminase <2 × upper limit of normal) function was required. Baseline studies had to be obtained within 28 days of study entry.","Exclusion criteria included any clinically significant unrelated systemic illness, cardiovascular disease, or severe psychiatric condition, pregnancy or lactation, exposure to an investigational chemotherapy agent within 30 days, a visual pathway glioma requiring treatment with chemotherapy, or a history of any malignancy.",during the first 8 weeks of treatment,NA
10755315,NA,Combination,No,patients with stage IIIB and IV non-small-cell lung cancer,"Patients were enrolled in the study if they met all of the following eligibility criteria and did not meet any of the exclusion criteria: (1) histologically or cytologically con®rmed advanced NSCLC (stage IIIB or IV), (2) no prior chemotherapy, (3) a life expectancy of at least 3 months, (4) a performance status (PS) of 0±2 on the ECOG scale, but at the cisplatin dose level of more than 70 mg/m2 restricted to a PS of 0 or 1, (5) between 15 and 75 years of age, (6) adequate bone marrow function (hemoglobin >=9 g/dl, leukocyte count >=4000/mm3, platelet count >=100,000/mm3), renal function (serum creatinine <1.5 mg/dl) and liver function (S-GOT and S-GPT less than twice the upper limit of normal), and (7) the provision of informed consent for participation.","Exclusion criteria were as follows: (1) severe concurrent medical conditions, (2) pregnant or nursing mothers, (3) active concomitant malignancy, (4) active uncontrolled infection, (5) intestinal paralysis and obstruction, (6) interstitial pneumonia or pulmonary fibrosis, and (7) large amount of ascites and/or pleural effusion.",during 3 course,NA
18359865,NA,Combination,No,adults with malignant glioma ,"Patients were required to have a histologically confirmed diagnosis of MG (GBM, anaplastic astrocytoma [AA], anaplastic oligodendroglioma [AO], or anaplastic oligoastrocytoma) and to have received prior XRT. Patients were eligible to enroll with either stable or recurrent disease, but patients with prior imatinib therapy, as well as those with either prior progression or prior >grade 3 toxicity on TMZ, were excluded. Patients with prior low-grade glioma were eligible as long as histologic transformation to MG before enrollment was confirmed. Patients were also required to be at least 18 years of age, to have a KPS score >=60%, to be on a stable corticosteroid dose for >=1 week, to have satisfactory hematologic results (hemoglobin >9 g/dl, absolute neutrophil count >1,000 cells/ul, platelet count >100,000 cells/ul) and biochemical results (serum creatinine, blood urea nitrogen [BUN], aspartate aminotransferase, and bilirubin <2.0 times the upper limit of normal), to have recovered from all expected toxicity related to previous therapy, and to provide written informed consent. No restriction was placed on the number of prior recurrences or treatments. At least 2 weeks between prior surgical resection, XRT, chemotherapy (6 weeks for nitrosoureas), or investigational agents and enrollment was also required.","Patients were excluded for pregnancy or nursing; lack of effective, appropriate contraception; acute infection requiring intravenous antibiotics; intratumoral hemorrhage (except postoperative grade 1); significant concurrent medical illness or prior malignancy; concurrent warfarin use; >= grade 2 peripheral edema, pulmonary or pericardial effusions, or ascites; and prior stereotactic radiosurgery or radioimmunotherapy unless there was obvious radiographic disease progression or biopsyproven recurrent tumor",during the first and second cycles of study therapy,NA
17322542,NA,Single Drug,No,"patients with advanced solid tumours. Tumour type: Colorectal, Renal, ACUP, Melanoma, Gastric, Other (Oesophageal, cervical, ovarian, urothelial, non-small cell, head and neck carcinoma, mesothelioma and leiomyosarcoma)","Patients with cytologically or histologically confirmed diagnosis of a malignant solid tumour, either refractory to conventional chemotherapy or for whom no effective therapy existed were eligible. Other eligibility criteria included: age >=18 years; World Health Organisation performance status zero to two; estimated life expectancy of >=12 weeks; no previous anticancer therapy for at least 4 weeks (6 weeks for nitrosourea, mitomycin C or carboplatin) and adequate haematopoietic (absolute neutrophil count >=1.5 x 109/l, platelet count ‡100 · 109/l and haemoglobin >=10.0 g/dl), hepatic {serum total bilirubin <1.25 x the institutional upper normal limit [UNL, with serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) <=2.5 x UNL or <=5.0 x UNL in case of liver metastases]} and renal function (serum creatinine concentration £1.5 UNL or creatinine clearance >60 ml/min.). Prior systemic treatment, including investigational drugs, surgery or radiation therapy was acceptable providedit had been completed at least 4 weeks before study registration. ","Specific exclusion criteria included hypersensitivity to any of the test materials or related compounds, previous bone marrow transplantation, pregnant or lactating women, clinical evidence of serious intercurrent disease, active or uncontrolled infection, brain metastases or major organ failure",during the first cycle ,NA
18927314,NA,Combination,No,"patients with solid tumors. Primary disease sites: Colorectal, Pancreatic/ampullary, Breast, Gastric, Adrenocortical, Sarcoma, Gall bladder, Anal, Carcinoid, Germ cell, Head and neck, High-grade neuroendocrine, Liver, Non – small cell lung, Carcinoma of unknown primary ","Patients with histologically confirmed solid tumors refractory to standard treatment, or for which no standard therapy exists, were considered. Other eligibility criteria included: age >=18 y; Karnofsky performance status >=60 y; WBC count >=3,000/mm3; absolute neutrophil count >=1,500/mm3; platelet count >=100,000/mm3; creatinine <=1.5 mg/dL; total bilirubin <=1.5 mg/dL; aspartate aminotransferase and alanine aminotransferase levels <=3 x upper limit of normal (or <=5 x upper limit of normal if there were known liver metastases); and normal serum potassium, magnesium, and calcium (or ionized calcium). Prior treatment with irinotecan but not 17AAG was allowed.","Patients were excluded if they were pregnant or lactating, had new untreated central nervous system metastases, primary brain tumor, HIV infection, severe egg allergy, or were taking potent CYP3A4 inducers or inhibitors. Because of supraventricular arrhythmias and pulmonary toxicity associated with 17AAG, patients at risk for cardiopulmonary toxicities were excluded, including those with a history of prior chest radiation, active ischemic heart disease or cardiac arrhythmias, left bundle branch block, heart failure, prolonged QTc, baseline diffusion-limited carbon monoxide <= 80%, baseline ejection fraction <50%, and debilitating pulmonary diseases",during first 2 cycles,NA
16328416,NA,Single Drug,No,"patients with advanced solid tumors. Tumor type: Colorectal, Upper gastrointestinal, Lung, Pancreas, Unknown, Other (appendix, melanoma, hepatocellular)","All patients participating in this study had histologic confirmation of a nonlymphoid, nonleukemic malignancy for which there was no known standard therapy that was either curative or capable of extending life expectancy. Additional eligibility criteria at study entry consisted of: Eastern Cooperative Oncology Group performance status <= 2, age >=18 years, absolute neutrophil count >=2,000/mm3, platelet count >=150,000/mm3, hemoglobin level >=9.0 gm/dl, serum creatinine within the institutional limits of normal, direct bilirubin within the institutional limits of normal, aspartate aminotransferase (SGOT) <= 3.0 times the institutional upper limit of normal (may be <= 5.0 times if liver involved with tumor), oral intake >=1,200 calories/day, and predicted life expectancy >12 weeks. Written informed consent was obtained from all patients prior to the study entry. The study was approved by the Mayo Foundation Institutional Review Board.","Patient exclusion criteria included: prior chemo or biological therapies within 4 weeks of study entry; any prior mitomycin C or nitrosourea chemotherapy; prior high-dose chemotherapy and progenitor cell transplant; prior radiation therapy to >10% of the bone marrow; active inflammatory bowel disease, significant bowel obstruction, chronic malabsorption or other major abdominal surgery resulting in alteration in transit or absorption of oral medication; ingestion of antacids, H2 antagonists, proton pump inhibitors, sucralfate, or anticonvulsants within the previous week; pregnancy or lactation; unwillingness to practice adequate contraception by men or women of child-bearing age; uncontrolled hypertension or cardiac arrhythmia; unstable angina; symptomatic congestive heart failure; myocardial infarction within the previous 6 months; central nervous system metastases or leptomeningeal disease; known HIV positivity or AIDS-related illness; active infections; or other severe nonmalignant systemic diseases which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.",the first cycle ,NA
16489079,NA,Combination,No,"Solid Tumors. Primary tumor:  Colorectal, Non-small lung cancer, Small cell lung cancer, Pancreatic, Gastric, Peritoneal mesothelioma","Patients with a histologically or cytologically confirmed solid tumor that was metastatic or unresectable and for which standard curative or palliative measures did not exist or for whom single-agent irinotecan constituted a reasonable treatment option were eligible for the trial. The last chemotherapeutic or radiation treatment was at least 4 weeks (6 weeks for nitrosureas or mitomycin C) before trial enrollment. Other criteria included age >=18 years of age,Eastern Cooperative Oncology Group performance status of <=1,estimated life expectancy of >12 weeks,no central nervous system involvement,adequate bone marrow function (neutrophils >=1,500/AL,hemoglobin >=8.0 g/dL, platelets >=100,000/AL),adequate hepatic function (serum bilirubin less than or equal to the upper limit of reference range,serum aspartate aminotransferase and alanine aminotransferase <= 2.5 x upper limitof reference range),and adequate renal function (creatinine <= 1.5 upper limit of reference range or creatinine clearance >= 60 mL/min). Patients with reproductive potential had to agree to use adequate contraception before study entry and for the duration of study participation.","The study excluded patients unable to receive oral medications,patients with brain metastases,patients with a history of Gilbert’s syndrome, and patients with active inflammatory bowel disease or chronic diarrhea. HIV-positive patients were not eligible because of possible pharmacokinetic interaction with antiretroviral drugs. Patients with grade >=2 neuropathy were not eligible,as no safety data were available regarding selenomethionine effects in this patient population and because of concern about possible exacerbation of neurotoxicity.",cycle 1,NA
15196737,NA,Combination,No,patients with advanced non-small cell lung cancer,"Patients were required to fulfill the following eligibility criteria: pathologically proven, advanced and inoperable NSCLC; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; age ≤ 75 years; no prior chemotherapy; presence of evaluable lesions; adequate reserves of hema- tologic function (WBC count ≥ 4000/ul, neutrophil count ≥ 2000/ul, hemoglobin level ≥ 9.5 g/dl, platelet count ≥ 10 × 104/ul), renal function (serumcreatinine ≤ 1.5 mg/dl), hepatic function (total bilirubin ≤ 1.5 mg/dl, serum transaminases ≤ 2.5 × upper limit of normal range) and pulmonary function (PaO2 ≥ 60 mmHg); acquisition of written informed consent.",Patients with symptomatic brain metastasis were excluded from the study. ,All treatment cycles,NA
16449240,NA,Combination,No,patients with advanced colorectal carcinoma,"This Phase I trial was conducted entirely at the University of Texas M. D. Anderson Cancer Center and included patients with histologically-proven, metastatic colorectal cancer whose disease had progressed after at least one, but no more than two, fluoropyrimidine-based chemotherapy regimens. Progression while on or within 6 months of adjuvant therapy was considered to qualify patients as failing a regimen for metastatic disease. Other eligibility criteria included are as follows: age above 18 years; ECOG performance status of 0–2; adequate organ function as evidenced by ANC of 1500/ul or better; platelet count of at least 100 000/ul; serum creatinine <=1.5 mg/dl or a calculated creatinine clearance of at least 60 ml/min; and SGOT less than three times the institutional upper limit of normal. Patients had to be fully recovered from any previous treatment, and a 4 week wait period was required after surgery or radiotherapy. Both measurable and evaluable disease were acceptable; measurable disease was defined as one bidimensionally measurable lesion of at least 10 mm outside the field of any prior radiation therapy","Patients previously treated with semaxanib, irinotecan or other topoisomerase I inhibitors were excluded from the study as were pregnant or breast-feeding women. Other exclusion criteria included are as follows: uncompensated coronary artery disease; uncontrolled diabetes; severe peripheral vascular disease; deep venous thrombosis within 3 months of entry; uncontrolled infection; serious psychiatric disorder; allergy to Cremophor or Cremophor-based drug products; active or uncontrolled infection; central nervous system or leptomeningeal metastasis; and history of seizure disorder or known Gilbert’s disease",in the first cycle,NA
15768380,NA,Single Drug,No,"Patients between the ages of 1 and 21 with a solid tumorrefractory to conventional therapeutic modalities. Diagnoses: 1) Non-CNS tumors: Hepatoblastoma, Synovial sarcoma soft tissue sarcomas, Hepatic sarcoma, Neuroblastoma, Rhabdomyosarcoma; 2) CNS tumors: Ependymoma, Optic glioma, Pontine glioma","Patients between the ages of 1 and 21 with a solid tumorrefractory to conventional therapeutic modalities, or forwhich no effective therapy was known were eligible forthis study. Other eligibility criteria included the fol-lowing: (a) Karnofsky or Lansky performance status of >=50%; (b) life expectancy of >=8 weeks; (c) recovery fromall acute toxic effects of prior therapy; (d) a stable or de-creasing dose of dexamethasone for at least 2 weeks forCNS tumor patients receiving this agent; (e) adequatebone marrow function (absolute neutrophil count >=1,500,hemoglobin >=8 g/dl,and aplatelet count >=100,000/mm3);(f) adequate hepatic function (bilirubin <1.5 mg/dl, SGPT<5xnormal); (g) adequate renal function (serum creatinine normalfor age or GFR >=70ml/min/1.73m2).",Patientswere excluded if they: (a) had previously receivedirinotecan; (b) had uncontrolled infection; (c) were re-ceiving other chemotherapeutic or investigational drugs;(d) had bone marrow involvement with disease; (e) hada prior bone marrow transplant that included TBI orallogeneic transplantation; or (f) were pregnant or lactat-ing. Initially there was no limitation on the number ofchemotherapy regimens that the patient could havereceived prior to entry onto this trial.,during cycle 1,NA
14551303,NA,Combination,No,"children with refractory or recurrent solid tumors. Brain tumors: Medulloblastoma, Ependymoma, High-grade glioma; Other tumors: Neuroblastoma, Ewing’s tumor and peripheral PNET, Rhabdomyosarcoma, Hepatoblastoma, Wilms’ tumor, Other (Included malignant Schwannoma, Burkitt’s lymphoma, osteosarcoma, and others)","Eligible patients were required to have cytologically and/or histologically confirmed diagnosis of malignant solid tumor (except for brainstem tumors, with clinical and radiological diagnosis), be refractory or in relapse after standard treatment, and/or be among those for whom no effective treatment was available. Two separate cohorts included less heavily pretreated (cohort 1) and heavily pretreated (cohort 2) patients, as defined by prior craniospinal irradiation and/or high-dose chemotherapy with stem cell rescue. Patients with bone marrow involvement were eligible for the study and assessable for hematotoxicity. Patients were to be between 6 months and 18 years of age, with a National Cancer Institute (NCI) performance status of 2 or less and a life expectancy greater than 6 weeks. Patients were required to have adequate blood cell counts (ie, polynuclear neutrophils > 1,500/mm3 [cohort 1], or > 1,000/mm3 [cohort 2]; and platelets > 100,000/mm3 [cohort 1], or > 75,000/mm3 [cohort 2]) except in case of bone marrow involvement, satisfactory hepatic function (ie, bilirubin <= 1.5 x the upper limit of normal [ULN] in the presence of hepatic metastases, or otherwise <= 1.25 x ULN; transaminases <= 2.5 x ULN), normal renal function, and no radiotherapy or chemotherapy within the last 4 weeks before study entry (6 weeks for nitrosoureas).","Exclusion criteria comprised severe gastrointestinal pathology, symptomatic or evolutive intracranial hypertension, and prior abdominal or bowel irradiation exceeding 20 Gy. ",on first cycle,NA
16821636,NA,Combination,No,advanced lung cancer patients,"Patients with histological or cytological confirmation of locally advanced or metastatic NSCLC or ED-SCLC, who had received either no prior chemotherapy or one previous chemotherapy regimen, were eligible. The eligibility criteria were as follows; (a) ≥20 but <75 years old; (b) Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1; (c) adequate organ function [white blood cell count (WBC) ≥4000 ul–1, neutrophil count ≥2000 ul–1, platelet count ≥100,000 ul–1, hemoglobin concentration ≥9.5 gdl–1, serum total bilirubin ≤1.5 mgdl–1, serum transaminase ≤2.5 x upper normal limits, serum creatinine ≤ upper normal limits, PaO2 ≥ 60 mmHg]. At least 4 weeks had to have passed after the completion of prior therapy and the patients had to have recovered from any toxic effects of such therapy","The exclusion criteria comprised pulmonary fibrosis or interstitial pneumonitis with symptoms or apparent abnormalities on chest X-ray, massive pleural effusion, pericardial effusion, or ascites, pregnancy, lactation, symptomatic brain metastases, active concurrent malignancies, severe drug allergies, severe heart disease, cerebrovascular disease, uncontrollable diabetes mellitus, severe infection or active peptic ulcer. ",during the first cycle,NA
17146732,NA,Combination,No,"patients with solid tumours. Malignancy type: Biliary tract, Bladder, Colon, Gallbladder, Gastric, Hepatocellular, Ovarian, Pancreas, Small cell lung cancer, Merkel cell, Unknown primary","Eligible patients were adults ( ≥ 18 years old) who had incurable advanced or metastatic solid tumours for which there was no standard treatment option. The presence of measurable or non-measurable disease was required. The patient may have had up to a maximum of 2 prior regimens of chemotherapy. Other eligibility requirements included: the ability to take oral medication, prior radiation treatment to an area representing ≤ 25% of bone marrow stores, no prior radical pelvic irradiation. Prior hormone or investigational agents was permitted but must have been discontinued at least four weeks prior to registration. Irinotecan may have been received only in the adjuvant setting with a treatment free interval of at least 12 months. An Eastern Cooperative Oncology Group (ECOG) performance status of 0–2 was required. Required laboratory tests included an absolute granulocyte count of ≥ 1.5 × 109/L, a platelet count of ≥ 100 × 109/L, serum creatinine of ≤ 1.5 × the institutional upper limit of normal (ULN), total bilirubin of ≤ 1.5 × ULN and AST or ALT levels of ≤ 2.5 × ULN.","Patients were excluded from participation in the study for any of the following reasons: presence of serious or uncontrolled infection, CNS metastases, pregnancy or lactating or concurrent treatment with other experimental drugs or anticancer therapy.",within the first 21 days of treatment,NA
12377659,NA,Combination,No,"Patients with histologic evidence of metastatic or locally advanced cancer. Primary tumor type: Colon, Rectum, Unknown primary, Breast, Gastric, Pancreas, Cholangiocarcinoma, Liver, Lung, Appendix, Larynx, Renal, Small bowel","Patients with histologic evidence of metastatic or locally advanced cancer for which there was no established curative or life-prolonging therapy were eligible for this study. Eligibility criteria included: (i) age ≥18 years; (ii) ECOG performance status ≤2; (iii) measurable or evaluable disease; (iv) life expectancy ≥12 weeks; and (v) informed consent. Exclusion criteria included: (i) history of lymphoma or leukemia; (ii) less than two prior chemotherapy regimens; (iii) prior treatment with CPT-11 or another camptothecin analog; (iv) prior chemotherapy in the last 4 weeks; (v) prior exposure to nitrosourea or mitomycin C; (vi) prior abdominal or pelvic radiation therapy to >25% of bone marrow (except in a separate cohort of patients with prior pelvic irradiation); (vii) other active medical problems such as known central nervous system metastases, interstitial lung disease, pleural effusions or ascites causing more than grade 2 dyspnea; (viii) less than four loose stools per day; and (ix) severe comorbid disease. Prior to study enrollment, patients were required to sign a Mayo Clinic Institutional Review Board-approved informed consent form.",NA,during the first cycle of therapy,NA
20039040,NA,Combination,No,metastatic colorectal cancer,"Individuals over the age of 18 with stage 4 histologically conWrmed colorectal cancer deemed to have the potential for clinical beneWt from treatment and with a life expectancy of at least 12 weeks were eligible for the study, designated PAT103. ECOG performance status of 2 or better, adequate hepatic (AST or ALT levels <=2.5 x upper normal limit (ULN) and total bilirubin levels <=1.5 x ULN), renal (serum creatinine <=1.5 x ULN) and bone marrow function (absolute neutrophil count >=1,500/mm3 and platelet count of >=100,000/mm3 ) were required.","Patients were excluded if they had recent major thoracic or abdominal surgery; chemotherapeutic or investigational agents, or radiotherapy in the preceding 4 weeks; mitomycin C or nitrosureas within previous 6 weeks; an active infection or signiWcant non-malignant intercurrent illness; known central nervous system metastases; a history of seizures; unresolved gastrointestinal symptoms; were pregnant or lactating; were serologically positive for hepatitis B, hepatitis C or HIV; were unable to swallow capsules; or were receiving concurrent antacid medication. A negative serum pregnancy test was required in women with childbearing potential, and all patients were required to use medically approved contraceptive precautions during the study and for 4 weeks afterwards.",during cycle 1,NA
12881390,NA,Combination,No,patients with advanced colorectal cancer,"All patients entered into this study had histologically or cytologically con- firmed advanced or metastatic colorectal adenocarcinoma. Eligibility criteria included life expectancy ≥12 weeks, Eastern Cooperative Oncology Group (ECOG) performance status ≤2, and adequate haematological (absolute neutrophil count ≥2 × 109/l, platelets ≥100 × 109/l), hepatic (bilirubin ≤1.5 × upper limit of normal) and renal (serum creatinine ≤1.5 × upper limit of normal) function, with at least one measurable site of disease (≥1 cm in at least one dimension). Patients could not have received prior chemotherapy, except adjuvant chemotherapy completed >6 months before study entry, and had disease for which treatment with fluoropyrimidines or topoisomerase I inhibitors was appropriate. Written informed consent was obtained from all patients","Patients were excluded from the study if they had bowel obstruction, any condition that might effect absorption of UFT or LV, had received prior radio- therapy (except palliative radiotherapy for control of locally symptomatic disease and adjuvant therapy for rectal carcinoma), experienced life-threatening toxicities as result of fluoropyrimidine, required therapy with a halogenated antiviral agent or who had a history of ulcerative colitis or Crohn’s disease.",during the first cycle of treatment ,NA
12598357,NA,Combination,No,"patients with advanced solid tumors. Site of primary tumor: Colorectal, Pancreas, Gastric, Esophagus, Cholangiocarcinoma, Kidney, Breast, Lung, Unknown primary site, Others (One pleural mesothelioma, one thyroid cancer, one carcinoid tumor of bowel and one retroperitoneal sarcoma)","Patients were eligible if they had histologically proven non-resectable metastatic solid tumors, or advanced or metastatic disease refractory to conventional therapy and for which no effective therapy was available. Eligibility criteria also included: age between 18 and 75 years; a WHO PS of two or less; adequate hematological, hepatic and renal functions defined by hemoglobin ≥10 g/dl, absolute neutrophil count ≥2 × 109/l, platelets count ≥100 × 109/l, total bilirubin ≤1.25 × the upper normal limit (UNL) of the institution, serum transaminases (aspartate aminotransferase, alanine amino- transferase) and alkaline phosphatase ≤3 × UNL (or in cases of liver meta- stasis, bilirubin ≤1.5 × UNL and serum transaminases ≤5 × UNL) and serum creatinine level ≤125 μmol/l. Patients must have discontinued previous antitumor treatment for at least 4 weeks (6 weeks in the case of aplasing chemotherapy such as nitrosourea, mitomycin C and carboplatin).",Exclusion criteria included: prior chemotherapy regimens with irinotecan or oxaliplatin; symptomatic brain metastasis or carcinomatous leptomeningitis; prior abdomino–pelvic radiation therapy; prior history of severe toxicity with 5-FU; unresolved bowel obstruction or partial bowel obstruction; current uncontrolled infection or serious illness or medical condition (including contraindication to 5-FU); prior history of peripheral neuropathy; concomitant treatment with another anticancer therapy or with another experimental drug; pregnancy or patients with reproductive potential without contraception.,during the first cycle,NA
16446328,NA,Combination,No,"pediatric patients with refractory solid tumors. Diagnosis: Neuroblastoma, Rhabdomyosarcoma, Brain tumor, Ewing sarcoma family of tumors, Other (Two renal cell carcinomas and one each of hemangiopericytoma, germ cell tumor, hepatoblastoma, alveolar soft-part sarcoma, undifferentiated sarcoma, osteosarcoma, malignant schwannoma, and chordoma.)","Eligible patientswereless than 21 years of agewith recurrent solid tumors for which conventional treatment had failed. Other eligibility criteria included the following: a life expectancy of at least 8 weeks, Eastern Cooperative Oncology Group performance status score of <= 2, recovery from the toxic effects of prior chemotherapy, hemoglobin concentration more than 8 g/dL, absolute neutrophil count more than 1,000u/L, platelet count more than 50,000u/L (unless marrow was infiltrated with tumor), adequate liverfunction (bilirubin < 1.5 xnormal and ALT <= 3 x normal), adequate renal function (serum creatinine <= 3 x normal for age), and normal metabolic parameters (serum electrolytes, glucose, calcium, and phosphorus).","Patients were ineligible if they had active infection, peptic ulcer disease, any GI condition that could alter motility or absorption, or allergy to cefixime or cefpodoxime or were receiving phenytoin, carbamazepine, or phenobarbital.",the first course of treatment,NA
11839656,NA,Single Drug,No,"Primary tumor: Colorectal, Pancreas, Other (Biliary duct; liver; leiomyosarcoma testis; unknown primary)","Patients were eligible if they had a histologically or cytologically documented solid tumor metastatic to the liver not amenable to surgery. The presence of minimal extrahepatic sites of disease was allowed only if the bulk of the disease was in the liver. The performance status had to be <=2 (WHO criteria), the life expectancy >= 3 months, and the age <=70 years. The anatomy of the liver arterial supply was assessed by angiography, and it had to allow placement of a catheter into the hepatic artery for adequate liver perfusion. Other criteria for eligibility were: a WBC count >= 4 x 109/liter; a platelet count >=100 x 109/liter; serum transaminases <=2 times the upper limit of normal, a prothrombin time <=1.25 the upper limit of normal, serum bilirubin <=20 uM, and serum creatinine <=110 uM or a creatinine clearance >=60 ml/min. No more than two prior chemotherapy regimens were allowed, and the last chemotherapy or prior radiotherapy had to be discontinued at least 4 weeks before study entry, or 6 weeks for nitrosoureas and mitomycin C.",Exclusion criteria were: prior treatment with topoisomerase I inhibitors; a history of inflammatory bowel disease or extensive intestinal resection; central nervous system metastases; uncontrolled infection; and a history of other cancer except adequately treated in situ carcinoma of the cervix or basal or squamous cell carcinoma of the skin,during the first course,NA
15138360,NA,Combination,No,patients with advanced non-small cell lung cancer,"Patients with histologically or cytologically proven unresectable NSCLC were registered for Pac and CPT combination chemotherapy. Eligibility criteria were an expected survival of at least 6 weeks, age <70 years, Eastern Cooperative Oncology Group performance score (PS) <=1, leukocyte count >=4,000/ul, hemoglobin >=10 g/dl, platelet count >=100,000/ul, total serum bilirubin <=1.5 mg/dl, aspartate aminotransferase and alanine aminotransferase <=90 IU/l, serum creatinine <=1.5 mg/dl, and creatinine clearance >=50 ml/min. Patients who had experienced postoperative recurrence were eligible for this study, but a period of rest of 4 or more weeks was required after surgery",Patients who had received chemotherapy or radiotherapy were excluded from this study.,during the first 4 courses ,NA
18179842,RCTN75771514,Combination,No,patients with limited-disease small-cell lung cancer,"Major inclusion criteria were cytologically or histologically proven SCLC, disease confined to one hemithorax according to IASLC criteria without evidence of cytologically proven malignant pleural effusion, no prior chemotherapy and/or radiotherapy, age 18 years or older, ECOG performance score 0 or 1, adequate organ functions, and absence of diarrhoea, bowel obstruction, inflammatory bowel disease or other serious medical conditions.",NA,cycles 2 and 3,NA
12187070,NA,Combination,No,patients with 5-fluorouracil-refractory advanced colorectal cancer,"Inclusion criteria were: histologically confirmed ACC, not amenable for surgical resection (i.e., metastatectomy); disease progression while on first-line palliative 5-FU-based chemotherapy or relapse within 6 months after adjuvant 5-FU-based chemotherapy; WHO performance status (PS) 0–2 and life expectancy of at least 3 months; age 18–75 years; satisfactory renal, hepatic, and bone marrow function; wash-out time of 4 weeks after the last chemotherapy infusion, and written informed consent.","Exclusion criteria were: more than two prior chemotherapeutic schedules (including one adjuvant and one palliative); prior exposure to CPT-11 or raltitrexed; chronic enteropathy on unresolved bowel obstruction; pregnancy; previous malignant disease other than carcinoma in situ of the cervix or basal cell carcinoma of the skin; cerebral metastases or leptomeningeal carcinomatosis, and severe or uncompensated concomitant medical conditions.",during the two first courses,NA
20176476,NA,Single Drug,No,paediatric oncology,"Eighty patients with malignant solid tumours were enrolled in this study. Two groups were considered separately including ‘less heavily pretreated’ (n = 48, group L) and ‘heavily pretreated’ (n = 32, group H) patients, as defined by prior craniospinal irradiation and/or high-dose chemotherapy with stem cell rescue. Patients were required to have adequate blood cell counts (i.e. neutrophils > 1500 mm-3 [group L], or >1000 mm-3 [group 2]; and platelets > 100,000 mm)3 [group L], or >75,000 mm-3 [group H]) except in the case of bone marrow involvement, satisfactory liver function, normal renal function and no radiotherapy or chemotherapy within the last 4 weeks before study entry (or 6 weeks if NU)",NA,the first cycle,NA
12453855,NA,Combination,No,patients with advanced gastrointestinal malignancies,"Patients with histologically proven recurrent or metastatic carcinoma of the gastrointestinal tract were candidates for this study. All patients should have received at least one 5-FU-based regimen. Other eligibility criteria were: age between 18 and 75 years; performance status (PS) <2 on the Eastern Cooperative Oncology Group scale; life expectancy >3 months; discontinuation of any previous chemotherapy for at least 1 month; normal bone marrow reserve, with absolute neutrophil count (ANC) ≥2000/μl, and platelet (PLT) count ≥100 000/μl; and adequate hepatic (bilirubin serum level <1.5 mg/dl; aspartate aminotransferase and alanine aminotransferase <2 × upper normal limit), and renal function (creatinine clearance >60 ml/min). All patients were informed of the investigational nature of this study, and each patient provided written consent before registration.",NA,the first cycle,NA
19402172,NA,Combination,No,adults with recurrent malignant glioma,"Eligible patients had a histologically confirmed diagnosisof progressive or recurrent primary MG (glioblastomamultiforme, gliosarcoma, anaplastic astrocytoma, ana-plastic oligodendroglioma, and anaplastic mixed oligoas-trocytoma). Patients were aged >= 18 years and required tohave Karnofsky performance score >= 60%. Patients musthave had measurable disease on contrast-enhanced mag-netic resonance imaging (MRI). An interval of at least 2weeks since prior surgical resection or 6 weeks since priorchemotherapy or radiotherapy had to have elapsed for thepatient to be enrolled into the clinical trial. Additionalenrollment criteria included adequate pretreatment bonemarrow function (hemoglobin >=10 g/dL, total granulo-cyte count >=1500 cells/uL, and platelet count >=100,000 cells/uL), renal function (blood urea nitrogen and serumcreatinine<1.5 times the upper limit of normal [ULN]),and hepatic function (total serum bilirubin<1.5 timesULN, aspartate aminotransferase and alanine aminotrans-ferase<2.5 times ULN, and alkaline phosphatase<2times ULN). Patients of reproductive potential wererequired to take effective contraceptive measures for theduration of the study. Each patient signed an informedconsent form.","The following patients were excluded from thestudy: patients who had previously failed CPT-11, nurs-ing or pregnant women, potentially fertile women or menwho were not using an effective contraception method,patients with a previous active malignancy treated withinthe past year, patients taking immunosuppressive agentsother than corticosteroids, patients with active infectionrequiring intravenous antibiotics, patients with knownhuman immunodeficiency virus infection, or those expe-riencing frequent vomiting or a medical condition thatcould interfere with oral medication intake.",NA,NA
19770383,NA,Combination,No,"children with refractory solid tumors, including primary CNS tumors and nonHodgkin’s lymphoma","Children (group A, ages 1 to 12 years) or adolescents (group B, ages 13 to 18 years) with solid tumors, including primary CNS tumors and nonHodgkin’s lymphoma, and with progressive disease after standard therapy or without standard therapy were eligible. Although the overall goal of the trial was to study a pediatric population younger than 18 years, the separate subgroup of patients younger than 12 years was created in response to the specific information request on this age group by regulatory agencies. Other key inclusion criteria were Karnofsky performance score of >= 50 for patients older than 10 years or a Lansky play scale of >= 50 for patients 10 years of age or younger; life expectancy of >= 8 weeks; no immunotherapy, radiotherapy, or chemotherapy within 2 weeks of first cetuximab dose (4 weeks from any prior investigational therapy, 6 weeks from prior nitrosoureas, mitomycin, or liposomal doxorubicin) and resolution or recovery to baseline from all previous therapy-related toxicities. Adequate bone marrow function (absolute neutrophil count >= 1,000/uL, platelet count >= 75,000/uL), hepatic function (total serum bilirubin  <= 1.5 x the upper limit of normal [ULN], alkaline phosphatase, AST, and ALT levels <= 2.5 x the ULN), and renal function (serum creatine <= 1.5 times the ULN) were required.","Key exclusion criteria included autologous bone marrow or peripheralblood stem-cell transplantation <= 3 months before study entry or allogeneic hematopoietic stem-cell transplantation <= 6 months before study entry; evidence of acute or chronic graft-versus-host disease; radiation therapy to >= 25% of bone marrow; brain metastases from non-CNS primary tumors (at the request of regulatory authorities); use of phenytoin, phenobarbital, primidone, carbamazepine, or valproic acid; and prior therapy with an anti-EGFR monoclonal antibody (prior EGFR-targeting small-molecule tyrosine kinase inhibitor treatment was acceptable).",during cycle 1,27 children in group A and 21 adolescent patients in group B
15083177,NA,Combination,No,"Patients with solid malignancy. Primary site: Cervical, Colorectal, Oesophageal, Pancreatic, Papilla of vater, Small intestinal, Unknown","Patients with a histologically or cytologically confirmed diagnosis of a solid malignancy refractory to standard therapy or for whom other treatment options were not available (e.g., pancreatic cancer), were eligible for the present study. Additional eligibility criteria included: (i) age at least 18 years; (ii) Eastern Cooperative Oncology Group performance status <=1; (iii) no previous treatment with antineoplastic agents for at least 4 weeks (or 6 weeks in case of nitrosoureas or mitomycin C), and no more than one prior chemotherapy regimen for advanced disease; (iv) no prior treatment with topoisomerase I inhibitors; (v) no known diagnosis of Gilbert’s syndrome or any other important contraindication for treatment with the normal prescribed dose of irinotecan; (vi) no prior extensive (>25%) radiotherapy of the bone marrow region; and (vii) adequate hematopoietic (WBC count, >3.5 x 109 l-1, and platelet count, >100 x 109 l-1), renal (serum creatinine concentration, <=1.5 x upper limit of institutional normal (ULN)), and hepatic function (total serum bilirubin, <= 1.5 x ULN; aspartate aminotransferase and alanine aminotransferase, <=2.5 x ULN or <=5 ULN in case of liver metastases).",NA,in the first cycle,NA
12357298,NA,Combination,No,"Patients with advanced solid tumors. Tumor type: Colorectal, Pancreatic, Cholangiocarcinoma, Other","Eligible patients had histologic proof of a malignant solid tumor and had either failed conventional chemotherapy or had a disease for which no standard therapy exists. Patients with recurrent or metastatic gastrointestinal adenocarcinoma with no prior treatment were eligible. A maximum of one prior adjuvant and one prior chemotherapy regimen for metastatic disease were allowed. Patients could not have had prior chemotherapy or radiotherapy within 4 weeks of entry into the study and must have recovered from all toxicities from prior treatments. Prior radiotherapy was limited to 25% or less of the bone marrow-bearing skeleton. Patients could not have received prior irinotecan or raltitrexed therapy. Patients were at least 18 years of age, with a life expectancy of at least 3 months and an ECOG performance status of 0 or 1. Eligibility criteria for bone marrow function included a WBC count of 3.5x106/l and a platelet count of 100x109/l. A serum creatinine level of less than or equal to 1.8 mg/dl or a creatinine clearance of greater than or equal to 60 ml/min was required. Serum bilirubin levels had to be less than or equal to 1.8 mg/dl. Liver enzyme levels of less than three times the upper limit of normal (ULN) and alkaline phosphatase levels of less than three times the ULN (unless due to metastatic disease, in which case, less than five times ULN) were required.","Pregnant or lactating patients, and patients with other serious medical illnesses, central nervous system metastases or clinically significant ascites or pleural effusions were excluded.",during cycle 1,NA
12204669,NA,Combination,No,patients with advanced non-small cell lung cancer,"Patients with histologically- or cytologically-documented NSCLC were candidates for this study. Other eligibility criteria included the following: stage IIIB (without indication of radiation therapy) or IV; age <=75 years; Eastern Cooperative Oncology Group (ECOG) performance status (PS) <=2; no prior chemo- or radio-therapy within 4 weeks of study entry; adequate haematopoietic function (leucocyte count >= 4x109/l, haemoglobin count >=90 g/l, platelet count >=100x109/l), hepatic function (total serum bilirubin level <=25.65 umol/l, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels <=twice the upper limit of normal value), and renal function (serum creatinine levels <=normal value); and no coexisting severe medical problems. ","Specific exclusion criteria included massive pleural or pericardial effusion, interstitial pneumonia, uncontrolled brain metastasis, and unresolved bowel obstruction",during the first cycle of treatment ,NA
14760509,NA,Combination,No,"patients with advanced cancer. Primary cancer: Colorectal, Pancreas, GE junction, Hepatoma, Leiomyosarcoma, Cholangiocarcinoma","Patients enrolled onto this study were at least 18 years of age and had a pathologically confirmed malignancy for which no standard therapy existed. Additional inclusion criteria included: life expectancy of at least 3 months, at least 4 weeks elapsed since prior chemotherapy or radiotherapy (6 weeks for nitrosoureas or mitomycin C), Eastern Cooperative Oncology Group (ECOG) performance status <= 2 (ambulatory at least 50% of waking hours), adequate hematologic function (absolute neutrophil count (ANC) >1500/ul, platelets >100,000/ul, hemoglobin >9.0/dl), adequate renal function (serum creatinine within normal limits), adequate hepatic function (ALT and AST not more than two times the upper limit of normal), and negative pregnancy test for women of child bearing potential. Prior irinotecan was allowed. Patients provided written informed consent as per institutional and federal requirements, and the protocol was approved by the Institutional Review Board of Fox Chase Cancer Center.","Exclusion criteria included prior bone marrow transplantation or high-dose chemotherapy, extensive prior radiation therapy (‡25% of bone marrow reserve), participation in another investigational treatment protocol within 30 days, known allergy to azole class of drugs or irinotecan, and concomitant use of proton pump inhibitors. ",during their first cycle of therapy,NA
12963697,NA,Combination,No,"patients with solid tumors. Disease Site: Colorectal, Small bowel, Hepatobiliary, Esophagus, Paranasal, Head and neck, Unknown","Patients with histologic or cytologic confirmed measurable or assessable metastatic or locally advanced cancer for which no established life-prolonging therapy was available or patients who were unresponsive to conventional therapy were eligible for this study. Other eligibility criteria included the following: age >= 18 years; Eastern Cooperative Oncology Group performance status <= 2; estimated life expectancy of >= 12 weeks; chemotherapy, biologic therapy, or immunotherapy for more than 4 weeks (6 weeks in patients treated with mitomycin or nitrosoureas) and recovery from any toxic effects of prior treatment; <= three prior chemotherapy regimens; completion of radiation therapy >= 4 weeks before enrollment; no pelvic radiation therapy; radiation therapy to <= 25% of bone marrow; neutrophil count >= 1,500/uL; platelet count >= 150,000/uL; hemoglobin >= 9.0 g/dL; serum creatinine within institutional normals or actual or estimated creatinine clearance >= 60 mL/min (using the Cockcroft-Gault formula); direct bilirubin <= 1.5 x and AST <= 5 x the upper limit of normal; no active or uncontrolled infection; absence of pregnancy or lactation and willingness to use adequate contraception; no known CNS metastases or uncontrolled seizure disorder; no uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure (New York Heart Association classification III or IV), unstable angina pectoris, or cardiac arrhythmia; no evident peripheral neuropathy >= grade 2; absence of any history of allergy to platinum compounds, CPT-11, or to antiemetics or antidiarrheals appropriate for administration in conjunction with chemotherapy as directed by this protocol; and absence of concomitant antiretroviral therapy. For patients in cohort 2 at the MTD, willingness to provide blood specimens for pharmacokinetic analysis and to undergo neurologic evaluations was required per protocol. All patients gave written informed consent according to institutional and federal guidelines.",NA,Cycle 1,NA
17429623,NA,Combination,No,"patients with solid tumors. Primary tumor site: Colorectal, Pancreas (adenocarcinoma), Pancreas (neuroendocrine), Biliary, Duodenal, Hepatocellular, Base of tongue (adenocystic carcinoma), Mesothelioma, Thyroid (medullary), Ovary, Skin (merkel cell), Unknown primary (adenocarcinoma) ","Patients were required to have histologically conWrmed malignancy that was metastatic or unresectable and for which standard curative or palliative measures did not exist, age >=18, ECOG performance status ,=2, life expectancy of 12 weeks or longer. Eligibility criteria also included adequate bone marrow, hepatic, and renal function [leukocytes >=3,000/ul, absolute neutrophil count (ANC) >=1.500/ul, platelet count >=100,000/ul, glucose lower than 200 mg/dl, normal bilirubin level, AST or ALT levels <2.5 x the upper limit of normal (ULN), creatinine within normal limits or creatinine clearance >=60 ml/min/1.73 m2 for patients with creatinine levels above institutional normal limits], and amylase levels <2.0 x the ULN. FEV1 > 75% of predicted, and adequate respiratory function tests (including a DLCO > 75% of predicted) were also required. Patients could have received any prior chemotherapy or radiation therapy, as long as it was terminated 28 days prior to study initiation. A special focus was put on patients with diabetes mellitus, symptomatic coronary artery disease, or pulmonary dysfunction. Patients were required to provide written informed consent prior to enrollment into the study.",Patients who had not recovered from adverse events due to agents administered more than 4 weeks earlier and those with clinically signiWcant and/or uncontrolled medical conditions were excluded.,during the first cycle,NA
16832665,NA,Combination,No,advanced non-small cell lung cancer,"Patients were enrolled in this study if they met the following criteria: a histologic or cytologic diagnosis of NSCLC; a stage IV disease, or stage IIIB disease that was not a candidate for curative radiation therapy; a measurable lesion; no prior chemotherapy; a performance status of 0 or 1 on the Eastern cooperative oncology group (ECOG) scale; a life expectancy of at least 3 months; adequate bone marrow function (leukocyte count >= 4,000/ul, platelet count >= 100,000/ul, and hemoglobin >= 10.0 g/dl), adequate hepatic function [aspartate amino-transferase (AST) and alanin aminotransferase (ALT) levels of <= 100 IU/l, and bilirubin <= 2.0 mg/dl ( <= 2 x the upper limit of normal)], adequate renal function (creatinine < the upper limit of normal) and arterial oxygen partial pressure (PaO2 >= 60 torr); electrocardiogram Wndings within the normal range; between 20 and 69 years of age; written informed consent to the study.","Patients were ineligible if they had serious infectious diseases or other severe complications (heart diseases, interstitial pneumonia, or uncontrollable diabetes); had watery diarrhea, paralytic ileus, or intestinal obstruction; had massive pleural or pericardial eVusion, or ascitic Xuid; had symptomatic brain metastases; had active concurrent malignancies; were lactating or pregnant women, or those willing to be pregnant; had a history of a drug allergy; had a history of acute myocardial infarction within the previous 12 months; had superior vena caval syndrome, which requires urgent radiotherapy; had other medical problems severe enough to prevent compliance with the protocol. ",during the Wrst cycle of treatment,NA
12912940,NA,Combination,No,adults with recurrent malignant glioma,"Adult patients (age >= 18 years) were required to have documented progressive or recurrent malignant gliomas, including the histological diagnosis of glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic mixed oligoastrocytoma. All of the following conditions were required for entry into the study: (a) measurable disease by contrast-enhanced MRI or CT scans; (b) a Karnofsky performance status of >=60%; (c) receiving a stable or decreasing dose of corticosteroids for >=1 week; (d) a stable or improving neurological examination; and (e) previous treatment with not more than one chemotherapy regimen. The minimum time intervals between previous treatment of the malignancy and entry into this study were 3 months for radiation and 3 weeks for chemotherapy, unless the regimen included a chloroethylnitrosourea, in which case the interval was 6 weeks. Full recovery from the effects of any earlier intervention was required. Eligibility also required demonstrating adequate results from hematological studies (absolute neutrophil count >= 1,500/ul; platelet count >= 100,000/ul), renal function assessment (serum creatinine <= 1.7 mg/dl), and the analysis of hepatic function (total bilirubin < 1.5 mg/dl; aspartate aminotransferase and alanine aminotransferase less than four times the upper limit of normal).","Factors resulting in exclusion from the study included: (a) a concurrent malignancy, except for basal cell carcinoma of the skin or cervical carcinoma in situ; (b) previous treatment with a topo I inhibitor; or (c) pregnancy or nursing, because of the risk of exposing the fetus or infant to the effects of chemotherapy",the first cycle of treatment,NA
15746053,NA,Single Drug,No,"patients with solid tumors. Tumor types: Lung, Melanoma, Gastrointestinal tract (including: esophageal, duodenal, colorectal 1 each), Gastric, Gynecologic, Unknown primary tumor, Genitourinary, Miscellaneous",Patients with a histologically confirmed diagnosis of a malignant solid tumor refractory to conventional chemotherapy or for whom no effective therapy existed were eligible. Other eligibility criteria were similar to those described previously (20). ,"Specific exclusion criteria included prior treatment with irinotecan, concomitant treatment with CYP3A4 inhibitors or inducers (wash-out period of at least 7 days since last intake), symptomatic brain metastases or leptomeningeal involvement, active inflammatory bowel disease, bowel (sub-)obstruction, chronic diarrhea, known chronic malabsorption or total colectomy, or other major abdominal surgery that might result in substantial alteration in transit or absorption of oral medication.",during the first cycle,NA
15592838,NA,Combination,No,"patients with advanced solid tumours. Primary tumour: Colorectum, Small intestine, Oesophagus/stomach, Pancreas, Lung, Ovaries, Breast","Patients with solid tumours with measurable or assessable disease refractory to standard therapy were eligible. Other eligibility criteria were age >18 years, a World Health Organisation (WHO) performance status <=2 and an estimated life expectancy >=12 weeks. Previous chemotherapy had to have been discontinued for at least 4 weeks before study entry, or for at least 6 weeks in those treated with mitomycin or nitrosourea. Patients had to have adequate haematological function defined as haemoglobin >=10 g/dl, neutrophil count >=2.0 x 109 cells/l, platelet count >= 150 x 109 cells/l; adequate hepatic function defined as serum bilirubin level less than the upper normal limit (UNL), transaminase levels less than three times UNL or less than five times UNL when related to liver metastasis, and adequate renal function defined as a serum creatinine level <1.5 mg/dl. Patients had to be able to swallow normally and had to be willing to comply with the intake of capsules. ","Exclusion criteria included: leukaemia, a history of treatment with high-dose chemotherapy with progenitor blood cell transplantation or with irinotecan, previous pelvic irradiation, chronic enteropathy (e.g. active inflammatory bowel disease, extensive intestinal resection, or chronic diarrhoea), bowel obstruction or subobstruction, symptomatic brain metastasis or carcinomatous leptomeningitis, concomitant severe infection (including prior documentation of HIV positivity), major organ failure, and evidence of active alcoholism or drug addiction. Pregnant or lactating women were excluded from the study.",during the first treatment cycle,NA
20213078,NA,Single Drug,No,patients with gastric adenocarcinoma with peritoneal seeding,"Eligible patients were at least 18 years of age with histologically proven gastric adenocarcinoma and received no previous chemotherapy, immunotherapy, or radiotherapy. All patients had performance status of ECOG 0-1, adequate hematologic (WBC count >= 4,000/mm3, platelet count¸>=150,000/mm3), hepatic (bilirubin level <= 1.5 mg/dL), and renal (creatinine concentration <= 1.5 mg/dL) functions. Childbearing potentials were controlled, if female, either by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine device [IUD], birth control pills, or barrier device) and if male, by use of an approved contraceptive method during the study and 3 months afterward. Patients were required to have resectable disease during preoperative evaluation such as endoscopic Wndings suggestive of advanced gastric cancer, radiologic Wnding of T3 or T4 disease with or without suspicious peritoneal seeding. The surgical Wnding and biopsy of suspected peritoneum must have demonstrated peritoneal involvement of adenocarcinoma. All patients provided written informed consent. ","Exclusion criteria included patients with myocardial infarction within 6 months or symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmia, serious concomitant infection, second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin or prior malignancy treated more than 5 years ago without recurrence), and history of signiWcant neurologic or psychiatric disorders. Pregnant or lactating women were also excluded. ",NA,NA
16080470,NA,Combination,No,patients with advanced non-small-cell lung cancer,"Patients were required to fulfil the following eligibility criteria: pathologically proven, advanced and inoperable NSCLC; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2; age ≤75 years; presence of evaluable lesions; adequate reserves of haematological function (white blood cell (WBC) count >4000 /uL, neutrophil count >2000 /uL, haemoglobin level >9.5 g/dL, platelet count >10x104 /uL), renal function (serum creatinine <1.5 mg/dL), hepatic function (total bilirubin <1.5 mg/dL, serum transaminases <2.5x upper limit of normal range) and pulmonary function (PaO2 ≥60 Torr); and acquisition of written informed consent. Both patients with and without prior chemotherapy were included. ",Patients with symptomatic brain metastasis were excluded from the study. ,in the first course,NA
12376204,NA,Combination,No,limited-disease small-cell lung cancer,"Eligibility criteria included the following: histologically- or cytologically-confirmed SCLC; no previous chemotherapy; measurable or assessable disease; age < 75 years with 0-2 performance status (PS) of Eastern Cooperative Oncology Group (ECOG); adequate haematological (leucocyte >= 4x109 cells/l, haemoglobin >=100 g/l, platelet count >= 100x109 #/l), hepatic (total bilirubin <=25.65 umol/l, alanine aminotransferase (ALT) and asparate aminotransferase (AST) levels <=double the normal upper limit) and renal function (serum creatinine <=105 mmol/l); no serious cardiac or pulmonary dysfunction (PaO2 >=70 torr); no other serious illnesses; no concomitant malignancies; no pregnancy; no stage I disease; the ability to provide informed consent",NA,duirng the four chemotherapy cycles,NA
20028383,NA,Combination,No,patients with metastatic colorectal cancer carrying the UGT1A1 allele *28,"Patients were eligible for this study if they met thefollowing criteria: proven unresectable or recurrent colorectalcancer; aged between 20 and 75 years; no major surgery, radio-therapy, or chemotherapy within 4 weeks prior to the study; anEastern Cooperative Oncology Group performance status of 0–2; predicted life expectancy of at least 3 months; adequate base-line organ functions, defined as a leukocyte count of at least4000⁄uL, neutrophil count of at least 2000⁄uL, platelet count ofat least 100 000⁄uL, hemoglobin of at least 9 g⁄dL, and aspartate aminotransferase and alanine aminotransferase levels threetimes or less than the upper limit of the institutional referencerange; total bilirubin below 1.5 mg⁄dL; and serum creatininebelow 1.5 mg⁄dL. ","Patients were ineligible if they had any of thefollowing conditions: serious infectious disease or other severecomplications (e.g. pulmonary fibrosis⁄interstitial pneumonia,uncontrollable diabetes); watery diarrhea, paralytic ileus, orintestinal obstruction; massive pleural effusion or ascitic fluid;symptomatic brain metastases; active concurrent malignancies;pregnancy or lactation, or trying to get pregnant; a history ofdrug allergy; and prior treatment with irinotecan.",during six courses of treatment,NA
16001174,NA,Combination,No,"children with refractory solid tumors. Predominant diagnoses were neuroblastoma (n=5), and osteosarcoma (n=2).","Patients 21 years old or younger with recurrent solid tumors unresponsive to conventional treatment, or with newly diagnosed solid tumors for which no conventional treatment was available, were eligible for this protocol. Other eligibility criteria included a life expectancy of at least 8 weeks; Eastern Cooperative Oncology Group performance status <= 2; recovery from the toxic effects of prior chemotherapy; hemoglobin level greater than 8 g/dl, absolute neutrophil count greater than 1,000/cu.mm, and platelet count greater than 75,000/cu.mm (unless bone marrow was infiltrated by tumor); adequate liver function (bilirubin level <= three times normal, ALT <= three times normal); adequate renal function (serum creatinine concentration £ three times normal for age); and normal metabolic parameters (serum electrolytes, glucose, calcium, and phosphorus); absence of prior craniospinal irradiation, total body irradiation, or irradiation to >20% of bone marrow volume with >25 Gy. Patients with recurring tumors after stem cell transplant (SCT) were also eligible for the study.","Patients were ineligible for study entry if they had an active infection, or if they were pregnant or lactating.",NA,NA
17717667,NA,Combination,No,previously untreated patients with advanced non-small cell lung cancer,"Written informed consent was obtained from all patients prior to treatment. The protocol and informed consent procedures were reviewed and approved by the Institutional Review Board of each participating institute. Eligibility criteria were as follows: histologically or cytologically conWrmed NSCLC; stage IIIB or IV disease; no prior chemoor radiotherapy; no massive pleural eVusion or ascites; age <=75 years; Eastern Cooperative Oncology Group performance status 0–1; life expectancy of at least 12 weeks; adequate bone marrow function (leukocyte count >=4,000/ul, platelet count >=100,000/ul, and hemoglobin level >=10.0 g/dl); serum bilirubin levels below the upper limit of normal; alanine aminotransferase (AST) and aspartate aminotransferase (ALT) levels <2 times the upper limit of normal; and serum creatinine below the upper limit of normal.","The major exclusion criteria were: superior vena cava syndrome; symptomatic central nervous system metastasis; concomitant malignancies; major surgery, cytotoxic chemo- or radiotherapy within the previous 4 weeks; clinically signiWcant cardiac diseases; infectious diseases; watery diarrhea; paralytic ileus; and intestinal obstruction. Pregnant or breast-feeding women were also excluded.",during cycle 1,NA
12885811,NA,Combination,No,locally advanced esophageal cancer,"All patients had histologically confirmed squamous cell carcinoma, adenocarcinoma, or poorly differentiated non–small-cell carcinoma of the esophagus, which was locally advanced, included clinical stages II to III disease (T1 N1 M0, T2– 4 N0–1 M0), and was staged by computed tomography (CT) scan and endoscopic ultrasound (EUS). For tumors of the gastroesophageal junction, at least 50% of the tumor had to involve the distal esophagus. Participants were required to be at least 18 years of age and to provide written informed consent before treatment. Patients were required to have a Karnofsky performance status of 70% or greater (Eastern Cooperative Oncology Group performance status <= 2) and adequate hematologic, renal, and hepatic function as defined by an absolute neutrophil count >= 1.5 x 109/L, platelets >= 100 x 109/L, hemoglobin >= 9.0 gm/dL, serum creatinine <= 1.5mg/dL, and total serum bilirubin <= 1.5 mg/dL. No prior chemotherapy or radiotherapy was permitted. ","Patients with T1N0 disease were excluded. Metastatic disease to supraclavicular or celiac lymph nodes or metastatic disease with biopsy-proven tumor invasion of the tracheobronchial tree or with tracheoesophageal fistula was not permitted. Severe comorbid conditions, including cardiac disease graded as New York Heart Association class 3 or 4, or myocardial infarction within the last 6 months also resulted in patient exclusion. Patients with a history of prior malignancy, other than basal cell carcinoma of the skin or in situ cervical carcinoma, diagnosed or treated within 3 years of entrance onto the study were ineligible. Patients with known Gilbert’s syndrome or with a history of seizure disorder who were receiving antiepileptic medication were also ineligible.",during combined chemoradiotherapy. Combined chemoradiotherapy was begun during week 8,NA
16088964,NA,Combination,No,adults with recurrent malignant glioma,"Patients were required to have a histologically con-firmed diagnosis of MG (GBM, anaplastic astrocytoma[AA], anaplastic oligodendroglioma [AO], or anaplasticoligoastrocytoma) that was recurrent as defined byclear-cut radiographic evidence of progressive disease(PD) after receipt of previous radiotherapy (RT) orchemotherapy. Eligible patients were also required tobe >= 18 years of age, have measurable tumor on acontrast-enhanced  magnetic  resonance  imaging(MRI) scan obtained within 2 weeks of study initiation,have a Karnofsky performance status score (KPS)>=60%, and be receiving a stable corticosteroid dosefor >=1 week before therapy initiation. Additional en-rollment criteria included the following: hematocritlevel >29%; absolute neutrophil count (ANC) >1000cells/uL; platelet count >100,000 cells/uL; and serumcreatinine level (mg/dL), blood urea nitrogen (BUN),serum aspartate aminotransferase (AST), and bilirubinlevels <2.0 times the institutional upper limit of nor-mal. At least 3 weeks between previous surgical resec-tion and >=6 weeks between previous RT or chemo-therapy, and enrollment were required unless therewas unequivocal PD. All patients were informed of theinvestigational nature of the study and informed con-sent was obtained from all patients as approved by theDuke University Medical Center institutional reviewboard.","The following patients were excluded from study:pregnant or nursing women; those with reproductivepotential and not using an effective contraceptivemethod; patients with PD after receipt of previoustreatment with either TMZ or CPT-11; acute infectionrequiring intravenous antibiotics; and patients whounderwent previous stereotactic radiosurgery, radia-tion implants, or radiolabeled monoclonal antibodytherapy unless there was obvious radiographic PD(such as a new or distant lesion) or biopsy-provenconfirmation of recurrent tumor.",during the first course,patients were accrued independently into 2 sep-arate  strata:  Stratum  A—patients  not  receivingEIAEDs;  Stratum  B—patients  receiving  EIAEDs.
19171709,NA,Combination,No,children with relapsed high-risk neuroblastoma,"Patients with high-risk neuroblastoma <= 30 years of age at diagnosis were eligible if they had either recurrent/progressive disease or residual tumor documented by histology afterfront-line therapy. All patientswere required to have measurable or nonmeasurable but assessable tumor documented by computed tomography (CT), magnetic resonance imaging (MRI), metaiodobenzylguanidine (MIBG) scanning, or bone marrow morphology. Other eligibility criteria included Eastern Cooperative Oncology Group performance status score of <= 2, hemoglobin >= 8.0 g/dL, absolute neutrophil count >=1,000/uL, platelet count >= 100,000/uL, and adequate renal and hepatic function. Patients with bone marrow disease were eligible if they met hematologic criteria. Prior treatment with autologous stem-cell transplantation was allowed. ","Exclusion criteria included use of enzyme-inducing anticonvulsants, cephalosporin allergy, active infection, or >= grade 2 diarrhea.",during first-course,NA
14871959,NA,Combination,No,pediatric patients with refractory solid tumors. Predominant diagnoses were Ewing’s sarcoma (n = 7) and neuroblastoma (n = 2).,"Patients being treated at Primary Children’s Medical Center (Salt Lake City, UT) for recurrent solid tumors or brain tumors for which conventional therapies had failed were eligible for this protocol. Eligibility requirements included a life expectancy of at least 8 weeks, Eastern Cooperative Oncology Group performance status of 0–2, recovery from the toxic effects of prior therapy, and adequate bone marrow function as determined by a hemoglobin level  8 g/dl, absolute neutrophil count > 1000/ul, and a platelet count >75,000/ul. In addition, patients were required to have adequate liver function (bilirubin < 1.5 x normal and alanine aminotransferase < 2.5 x normal) and renal function (serum creatinine < 3 x normal for age). ","Patients were ineligible if they had prior treatment with temozolomide or had active diarrhea or other gastrointestinal conditions that could affect drug absorption or confound observation of drug toxicity. Patients were also ineligible if they had prior craniospinal irradiation because previous Phase I trials had identified a separate, lower MTD for temozolomide for such patients (22). Because enzyme-inducing anticonvulsants have been documented to affect irinotecan clearance (26), patients were ineligible if they were taking these medications.",during course 1,NA
20049936,NA,Combination,No,"children with relapsed or refractory solid tumors. Diagnosis: Sarcoma (Ewing sarcoma, Osteosarcoma, Rhabdomyosarcoma, Synovial sarcoma, Spindle cell sarcoma, Undifferentiated sarcoma, Alveolar soft parts sarcoma), Neuroblastoma, Hepatolastoma, Wilms tumor, Brain tumor (Ependymoma, Medulloblastoma, Malignant glioma, Fibrillary astrocytoma, Atypical teratoid rhabdoid tumor), Paraganglioma, Pleuropulmonary blastoma","Patients older than 12 months and <=21 years with solid tumorsrefractory to standard therapy and no other curative option wereeligible.  All patients had measurable or evaluable disease, and Karnofsky (age>10 years) or Lansky (age <=10 years) performancescores of >=50. Required organ function included an absoluteneutrophil count >=1,000/ul, hemoglobin >=8.0 g/dl, transfusion-independent platelet count of >=100,000/ul, glomerular filtrationrate or creatinine clearance >=70 ml/min/1.73 m2or normal serumcreatinine for age, total bilirubin <=1.5 x upper limit of normal, AST of <=110 U/L (~2.5 x upper limit of normal), and serum albumin >=2 g/dl.","Exclusion  criteria  included  myelosuppressive  chemo-therapy within 3 weeks of enrollment, anticancer biologic therapy or hematopoietic growth factors within 7 days, local palliativeradiotherapy within 2 weeks, craniospinal  or extensive pelvicradiotherapy within 6 months, other substantial bone marrowradiotherapy within 6 weeks, known metastatic marrow disease, allergy to dacarbazine or cephalosporins, treatment with increasingdoses of  dexamethasone, treatment with agents known to affect irinotecan metabolism (e.g., enzyme-inducing anticonvulsants),uncontrolled infection, concurrent treatment for C difficile enteritis, or administration of other  investigational or anticancer agents.Patients were also excluded if they had previous treatment with temozolomide + irinotecan, or prior progression with either agent.",first-course ,NA
18956138,NA,Combination,No,"patients with advanced gastrointestinal cancer. All patients had either a gastrointestinal or hepatobiliary cancer—16 patients (54%) with adenocarcinoma of the esophagus, GE junction or stomach; two patients (7%) with squamous cell carcinoma of the esophagus; seven patients (23%) with pancreatic cancer; and one patient (3%) with hepatocellular carcinoma. Adenocarcinoma of unknown origin was diagnosed in 4 patients (13%), although all four were suspected to be pancreaticobiliary primaries. The predominant site of measurable disease was the liver (67%) and lymph nodes (60%).","To be eligible for this trial, all patients had to meet the following criteria: (1) histologic proof of a locally advanced (unresectable or recurrent) or metastatic solid tumor malignancy; (2) bi-dimensionally measurable or evaluable disease was preferable but not required; (3) one prior chemotherapy regimen was allowed in the first cohort (the protocol was amended after cohort 2 to exclude any patients with prior chemotherapy); (4) prior radiation was allowed, provided at least 4 weeks had elapsed and the radiation portal did not include the pelvis; (5) ≥18 years of age; (6) Karnofsky performance status [KPS] of ≥70%; (7) signed consent; and (8) adequate organ function as documented by laboratory studies (white blood count ≥3,000/μL, neutrophils ≥1,500/μL, platelets ≥100,000/μL, serum bilirubin ≤1.5 mg/dL, serum creatinine ≤1.5 mg/dL, and AST (SGOT) ≤3× upper reference value, except when abnormal value was due to liver metastases, in which case ≤5× upper reference value was acceptable).",Patients were excluded from this trial for the following criteria: (1) active or uncontrolled infection; (2) brain metastases or carcinomatous meningitis; (3) interstitial pulmonary fibrosis; (4) unstable angina or grade III/IV NYHA cardiac disease; (5) uncontrolled diabetes mellitus (blood glucose ≥250 mg/dL); (6) hypercalcemia (serum Ca ≥12.0 mg/dL); (7) pregnant or lactating women; (8) history of Gilbert’s disease; (9) history of a seizure disorder and on antiepileptic medications; or (9) unable to comply with the protocol or to undergo the specified follow-up for safety or effectiveness.,in the first cycle of treatment,NA
11843251,NA,Combination,No,patients with advanced gastric cancer,"Patients enrolled in this study were required to fulfill the following eligibility criteria- (1) histological confirmation of gastric cancer; (2) unresectable or metastatic disease, or recurrence after gastrectomy, (3) measurable lesion: (4) age <= 75 years; (5) performance status (PS) <= 2 on the Eastern Cooperative Oncology Group (ECOG) scale; (6) no prior chemotherapy or prior-treated with less than two regimens not including MMC, although prior use of CPT-11 was allowed, (7) no chemotherapy within four weeks before entry, (8) adequate bone marrow function (WBC >= 4000 cells/mm' and platelet >= 100,000 cells/mm1) (9) adequate liver function (serum bililbin level < 1.5 mg/dl and serum transaminase level < 2.5-fold the upper limit of normal): (10) adequate renal function (serum creatinine level <= 1 5 mg/dl. blood urea nitrogen level <=25 mg/dl); (II) no other serious medical condition; (11) no other active malignancies; (12) written informed consent ",NA,in the first cycle,NA
12750839,NA,Combination,No,advanced non-small-cell lung cancer,"Patients with histologically or cytologically proven unresectable NSCLC were registered for NDP and irinotecan combination chemotherapy. Eligibility criteria for the chemotherapy were: an expected survival of at least 6 weeks, age <70 years, Eastern Cooperative Oncology Group performance status (PS) score not more than 1, white blood cell count at least 4000/ul, hemoglobin at least 10 g/dl, platelet count at least 100,000/ul, total serum bilirubin not more than 1.5 mg/dl, aspartate aminotransferase and alanine aminotransferase not more than 90 IU/l, serum creatinine not more than 1.5 mg/dl, and creatinine clearance more than 40 ml/min. Patients experiencing postoperative recurrence and patients who had received radiotherapy or chemotherapy were eligible for the present study, but only one regimen of chemotherapy was allowed and 4 weeks or more rest was required after prior chemotherapy or radiation therapy. Written informed consent was obtained from every patient.",NA,in the first two courses,NA
12947066,NA,Combination,No,Patients who undergo resection of hepatic metastases from colorectal cancer,"All patients had histologically confirmed colorectal adenocarcinoma with completely resectable hepatic metastases. Patients were excluded from the study for any of the following reasons: extrahepatic disease, prior hepatic radiation, infection, Karnofsky performance status less than 60, previous or concurrent malignancy (unless patient had been free of disease for at least 5 years), WBC count less than 3,000 cells/uL, platelet count less than 100,000 cells/μL, or total bilirubin ≥ 1.5 mg/dL. Prior chemotherapy was permitted if the last dose was given 1 month before the date of hepatic resection. Computed tomography scans of the abdomen and pelvis and a chest radiograph had to be performed within 6 weeks before surgery. All patients signed informed consent forms. ",NA,during the first two cycles of treatment,NA
20127092,NA,Combination,No,patients with refractory solid tumors. The majority of patients had gastrointestinal (particularly pancreatic) or lung primary tumors.,"All patients gave informed consent prior to being enrolled in the study. Patients were required to have a histologically conWrmed, measurable or evaluable solid tumor malignancy that was metastatic or unresectable and for which standard chemotherapy measures do not exist or were no longer effective. All patients were at least 18 years of age, had Eastern Cooperative Oncology Group performance status 2 or less, and had life expectancy of greater than 12 weeks. Prior irinotecan was not allowed. Patients were required to have normal organ and bone marrow function deWned as follows: leukocytes >=3,000/ul; absolute neutrophil count >=1,500/ul; platelets >=100,000/ul; total bilirubin within normal limits; AST/ALT <=2.5 x upper limit of normal; and creatinine <=1.5 mg/dl or creatinine clearance >=50 ml/min per 1.73 m2. Patients could not have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosureas or mitomycin C) prior to entering the study. Toxicity from prior agents had to be resolved to grade 1 or less.","Women of child-bearing potential and all men agreed to practice adequate contraception, and pregnant or breast-feeding women were excluded. All patients were screened for glucose-6-phosphate dehydrogenase (G6PD) deWciency and excluded if G6PD was below the lower limit of normal, as 3-AP can induce hemolysis and methemoglobinemia in patients with G6PD deWciency . The protocol was later amended so that patients were also required to have a baseline screening test for UGT1A1 and excluded if homozygous for UGT1A1*28, which is known to increase irinotecan toxicity . Patients with HIV receiving combination antiretroviral therapy, prior myocardial infarction, or severe pulmonary disease requiring oxygen were excluded. Patients could not have uncontrolled intercurrent illness including, but not limited to, active infection, congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness. Patients were not allowed to be on enzymeinducing anticonvulsant agents. Patients with central nervous system metastasis were excluded unless the subject was more than 6 months from deWnitive therapy, radiographically and clinically stable, and not receiving acute steroid therapy or taper.",NA,NA
24252402,NCT00963547,Combination,No,"patients with HER2-positive solid tumors. Cancer type: Breast, Gastric","Patients 18 years of age or older with Eastern Cooperative Oncology Group performance status 0 to 1 and adequate hematologic, kidney, and liver function, and with histologically or cytologically confirmed locally advanced or metastatic HER2+ solid tumors, were eligible for the trial. Patients who were receiving trastuzumab and/or lapatinib prior to screening had to be off both drugs for 1 week prior to enrollment if trastuzumab was administered at 2 mg/kg per week, or for 3 weeks if trastuzumab was administered at 6 mg/kg per week; other chemotherapeutic or experimental agents were not allowed within 30 days of entering the trial. Since MK-2206 is metabolized by cytochrome p450 3A4, patients using potent cytochrome p450 3A4 inhibitors or inducers had to be off the medication for at least 14 days before the first dose of the study medications.","Patients with significant cardiac disease or known active central nervous system metastases and/or carcinomatous meningitis were not eligible – unless they had completed radiation or were clinically stable for 1 month prior to entry without evidence of new or enlarging central nervous system metastasis, and were no longer taking steroids for brain edema. Pregnant or lactating women were not eligible for enrollment",within the first 21 days of cycle 1,NA
25641763,NA,Combination,No,"patients with advanced solid tumor malignancies. Patients had colorectal (n58), nonsmall cell lung (n58), headand neck (n54), or anal (n52) cancers.","Adult patients who had refractory solid tumors that weretreatable with cetuximab at the time of the study (Kras wild-typecolorectal,nonsmallcelllung,headandneck,andanalsquamous cell cancers) were enrolled in a single-institution, open-label, dose-escalation, sequential cohort, phase 1 clinicalstudy at the Lombardi Comprehensive Cancer Center ofGeorgetown University (Washington, DC). Patients wererequired to have measurable disease, adequate organ func-tion, an Eastern Cooperative Oncology Group performancestatus from 0 to 2, a normal ventricular ejection fraction, alife expectancy >3 months, and resolution of reversible toxicities related to prior therapy to grade <=1.",NA,through the first 2 cycles oftreatment for a total of 6 weeks,NA
26210681,NA,Combination,No,"patients with solid tumors. Tumor types: Nonsmall cell lung cancer, Bladder, Sarcoma, GE junction, Head and neck, Melanoma, Hepatocellular, Others (pancreatic, breast, ovarian, adenoid cystic and carcinoma of unknown primary)","Patients aged 18 years or older with histologically or cytologically confirmed advanced solid tumors were enrolled in an open-label, phase 1 dose-escalation trial. Patients were required to have at least one target lesion, which could be used to assess response as defined by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 . Other eligibility criteria included an Eastern Cooperative Oncology Group (ECOG)  performance status ≤2, and adequate bone marrow [absolute neutrophil count ≥1.5 × 109/L, platelet count ≥100 × 109/L, renal (creatinine ≤2.0 mg/dL) and hepatic (total bilirubin ≤2.0 mg/dL)] function. Additional eligibility criteria for the expansion cohort only were that patients had either HER2 amplification, HER2 mutation, c-Met amplification, c-Met mutation, or an EGFR mutation. Written informed consent was obtained from all patients prior to their participation on the trial.",NA,during the initial 28 days of receiving the first dose of the study medications,NA
11205914,NA,Single Drug,No,"children with refractory solid tumors. Non-CNS tumors: Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma, Wilms’ tumor, Ewing’s sarcoma, Other (One each of the following diagnoses: hepatoblastoma, rhabdoid tumor, hepatocellular carcinoma, adrenocortical carcinoma, carcinoma of the colon,non-Hodgkin’s lymphoma, and clear cell sarcoma); CNS tumors: Brain stem glioma, Glioblastoma multiforme, Other (One each of the following diagnoses: rhabdoid, ependymoma, and pinealoblastoma)","The eligibility criteria initially limited enrollment to children ≥6 year and ≤21 years of age with a histologically confirmed solid tumor refractory to standard therapy. After preliminary experience in older children treated at the first two dose levels demonstrated that irinotecan-induced diarrhea was readily managed with supportive care,the patient eligibility criteria were expanded to include patients ≥1 and <6 years of age. Patients in this younger age group were enrolled in a separate stratum (stratum 3) at one dose level below the dose level for older children until the DLT and MTD were defined. Other eligibility criteria included the following: (a) an ECOG performance status ≤2; (b) a life expectancy>8 weeks; (c) adequate bone marrow function (an absolute neutrophil count >1500/mm3, a hemoglobin >9.0 g/dl, and a platelet count >100,000/mm3);(d) adequate liver function (serum bilirubin <1.5 mg/100 ml; alanine aminotransferase <2× normal); (e)adequate renal function (serum creatinine <1.5 mg/100 ml or creatinine clearance >60 ml/min/1.73m2); (f)recovery from the toxicity of prior therapy; (g) no other chemotherapy within 2 weeks (6 weeks for prior nitrosourea therapy) of entering onto this protocol; and (h) no prior extensive radiotherapy (e.g., pelvic or craniospinal) or bone marrow transplantation with total body irradiation. Initially, there was no limitation on the number of chemotherapy regimens that the patient could have received before entry onto this trial. After determination of the MTD in this heavily pretreated patient population (stratum 1), the eligibility criteria were revised to study a less-heavily pretreated patient population (stratum 2). The revised eligibility criteria excluded patients who had received >2 prior chemotherapy treatment regimens and patients who had received any prior central axis radiation (skull, spine, pelvis, or ribs) or a bone marrow transplant. The definition of the less-heavily pretreated group was designed to closely mirror pediatric patient populations in classic Phase II trials. Informed consent was obtained from the patient or his/her legal guardian before entry on this study in accordance with federal and individual institutional policies.",NA,during the first course of therapy,NA
24197661,NA,Combination,No,patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases,"Patients with histologically confirmed, HER2-positive breast cancer (3? staining by immunohistochemistry or gene amplification by fluorescence in situ hybridization) and new or progressive parenchymal CNS metastasis were eligible. Measurable CNS disease was not required but patients with leptomeningeal carcinomatosis only were excluded. Prior stereotactic radiosurgery (SRS) but not WBRT was allowed. Other key eligibility criteria included age >=18, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–2, life expectancy >12 weeks, adequate organ function; left ventricular ejection fraction (LVEF) >=50 %, and provision of informed consent. A 2 week washout from prior treatments was required with exception of trastuzumab. ",NA,"study entry until 1 month after WBRT completion, ~8 weeks",NA
23292205,ACTRN12611000418976,Combination,No,patients with recurrent high-grade gliomas,"Adult patients with confirmed histological diagnosis of grade IV glioblastoma multiforme or grade III anaplastic astrocytoma, who relapsed after optimal treatment and for whom there were no other standard treatments available, were included. All patients were required to have a WHO performance status of <=2 and be >18 years old with measurable disease at screening, according to RANO criteria . Adequate hematological function (absolute neutrophil count [ULN] >=1.5 x 109/L, platelet count >=100 x 109/L and hemoglobin >=9 g/dL), liver function (total bilirubin <1.5 x upper limit of normal [ULN], AST, ALT <2.5 x ULN) and renal function (serum creatinine <=1.25 x ULN or calculated creatinine clearance >=50 mL/min) were mandatory for study entry. Patients were also required to have normal cardiac function (left ventricular ejection fraction within institutional normal range) and in the past 6 months have had no serious cardiac illness or medical condition, including but not confined to: history of documented congestive heart failure, high-risk uncontrolled arrhythmias, angina pectoris requiring antianginal medication, clinically significant valvular heart disease, evidence of transmural infarction on ECG and poorly controlled hypertension (e.g., systolic >180 mmHg or diastolic greater than 100 mmHg). If a patient required anticoagulant therapy, the patient was allowed to remain on study provided that he/she was carefully monitored. Drugs and several herbal constituents (e.g., bergamontin and glabridin), which are inducers or inhibitors of CYP3A4, were prohibited during and 10 days prior to the initiation of the treatment. Available archived tumor tissue for subsequent translational research studies was mandatory for study entry",NA,during the first cycle of treatment,NA
12440223,NA,Single Drug,No,"patients with advanced cancer. Diagnosis: Colorectal, Breast, Bladder, Sarcoma, Other","Patients with advanced, incurable cancers were eligible for this phase I study. Eligibility criteria included adequate bone marrow reserve, normal liver function tests, and normal PT/PTT. Patients must have had an ECOG performance status of 0 or 1,expected to live at least 12 weeks, negative pregnancy test when indicated, and able to give informed consent. In addition, all patients were required to have a baseline ECG and resting RVG and their ejection fraction had to be equal to or greater than 50%. Because of concern of potential skin toxicity,all patients were required to have central venous vascu- lar access which had been placed no sooner than 5 days prior to beginning therapy with Depsipeptide.",NA,"during the first cycle. The 3 week on, 1 week off period defined a single cycle. ",NA
29315394,NCT00912275,Combination,No,HER2-positive metastatic breast cancer,"HER2-positive metastatic breast cancer female patients, regardless of hormone receptor (HR) status, were eligible. HER2-positive was defined as a 3+ by immunohistochemical (IHC) stain or a 2+ IHC stain accompanied by ≥2.2 ratio of HER2/CEP17 or absolute HER2 copy number >6 by fluorescent in situ hybridization (FISH). Other noticeable inclusion criteria included: age ≥ 20, ECOG performance status 0–2, at least one measurable lesion, no active brain metastases, and normal cardiac function with a left ventricular ejection fraction (LVEF) >50%. For HR-positive patients, hormonal therapy was not allowed during study.","Pregnant or lactating women. Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment). Prior therapy with lapatinib. CNS metastases. Ongoing anticancer treatment. Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, serious non-healing wound/ulcer/bone fracture, or psychiatric illness/social situations that would limit compliance with study requirements. Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).",during the first cycle,NA
31097774, NCT01434303,Combination,No,patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment,"Both male and female adult patients with metastatic HER2+ breast cancer were eligible. HER2 overexpression was defined either by immunohistochemical staining intensity (3+) or fluorescence in situ hybridisation (FISH) testing (HER2/CEP17 ratio >2.0).14 An ECOG performance status of 0–1, normal organ function, and prior exposure to trastuzumab were required, but it was not mandated that trastuzumab to be the immediately preceding regimen. If the patient had had progression to metastatic disease within 6 months of a previous trastuzumab regimen given during treatment of local disease (e.g., adjuvant therapy), the patient was eligible. Patients had to be able to swallow and retain oral medication. Measurable disease by Response Evaluation Criteria in Solid Tumours (RECIST) v 1.1,15 left ventricular ejection fraction equal to or greater than 50% were required. ",Lactating or pregnant patients were excluded.,within 28 days after the first dose,NA
28464908,NA,Combination,No,human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer,"There was no limit on the number of prior systemic therapies (hormonal or chemotherapy) or number of prior anti-HER-2-targeted therapies (including lapatinib) delivered prior to study entry. Patients were to have a baseline performance status of 0–2, and adequate hematological, hepatic and renal function. Specifically, the eligibility criteria were creatinine ≤1.2 times the upper limit of normal (ULN), total bilirubin ≤1.2 times the ULN and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤2 times the ULN. A baseline left ventricular ejection fraction of ≥50% was also required for study entry. Measurable disease was not a requirement for the dose escalation phase of the study. Last, tumor specimens were required from all enrolled patients, comprising at minimum a formalin-fixed paraffinembedded (FFPE) sample from the primary tumor.","Exclusion criteria included prior exposure to a c-Met inhibitor or to a VEGFR inhibitor; previous history of thromboembolic disease within 6 months prior to study entry; uncontrolled hypertension, active infection, untreated brain metastasis or leptomeningeal disease or serious cardiovascular disease.",during the first cycle of therapy,NA
23632474,NCT00445458,Combination,No,patients with HER2-positive metastatic breast cancer,"Aged >=18 years. Signed and dated informed consent form prior to protocol-specific screening procedures. Part 1: confirmed pathologic diagnosis of a solid tumor not curable with available standard therapy. Part 2: confirmed pathologic diagnosis of HER2-positive breast cancer (current stage IV disease); Prior treatment (neoadjuvant, adjuvant, or metastatic) with a trastuzumab-containing regimen (unless trastuzumab was contraindicated or unavailable); no other prior HER2-targeted agents were allowed, except lapatinib in Group B; Documented HER2 gene-amplified tumor (by FISH) or HER2 overexpression (by IHC, score of >=3). At least 1 measurable lesion as defined by modified RECIST guidelines. ECOG Performance Status of 0 or 1 for chronic phase patients. Left ventricular ejection fraction within institutional normal limits. Able to take daily oral capsules or tablets reliably. Normal hematologic laboratory parameters (ANC >= 1.5 × 109/L; platelets >=75 × 109/L; hemoglobin >=9.0 g/dL). Adequate hepatic function (AST/ALT <=2.5 × ULN or <=5 x ULN if attributable to liver metastases; total bilirubin <=1.5 × ULN). Adequate renal function (serum creatinine <=1.5 × ULN). For women of childbearing potential, a negative urine or serum pregnancy test.  Willingness to use reliable birth control (if applicable) throughout the study and for 28 days after the last dose",">1 prior cytotoxic chemotherapy regimen for metastatic disease (Part 2, Group A only), or >3 prior cytotoxic chemotherapy regimens for metastatic disease (Part 2, Group B only). Prior treatment with anthracyclines with a cumulative dose of doxorubicin of >800 mg/m2, or the equivalent dose for other anthracyclines or derivatives. Taxanes within 3 months of study treatment initiation. Major surgery, chemotherapy, radical (curative intent) radiotherapy, investigational agents, or other cancer therapy within 2 weeks of study treatment initiation, with recovery from any toxicities of prior anticancer treatment (excluding alopecia). Any other cancer within 5 years prior to screening, with the exception of contralateral breast carcinoma, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin. Skin as the only site of disease. Active central nervous system metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth. QTc interval >470 msec or known history of QTc prolongation or Torsade de Pointes. Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom (eg, Crohn’s disease). Pre-existing grade 2 motor or sensory neuropathy. Presence of clinically significant or uncontrolled cardiac disease. Known hypersensitivity to paclitaxel or Cremophor EL (polyoxyethylated castor oil)",during the first 28 days of therapy,NA
10509152,NA,Combination,No,advanced colorectal carcinoma,"Patients were required to have histologically proven diagnoses of locally advanced or metastatic colorectal carcinoma. Other eligibility criteria were: age from 18 to 75 years; performance status < 2 of the Eastern Cooperative Oncology Group (ECOG) scale; presence of measurable or evaluable indicator lesion(s); no previous chemotherapy for the advanced disease (adjuvant chemotherapy was allowed provided that it had been discontinued for at least six months); white blood cell count ^3500/mmc and neutrophil count (ANC) >2000/mmc, platelet (PLT) count > 100,000/mmc, haemoglobin (Hb) level > 10 g/dl; bilirubin <1.25x upper normal limit (UNL), ALT and AST ^ 2.5 x UNL in absence of liver metastases, or bilirubin < 1.5 x UNL, ALT and AST ^ 5 x UNL in presence of liver metas- tases; normal renal function (creatinine clearance < 60 ml/min). All eligible patients gave their informed consent for participation in this study which had been approved by the Ethics Committee for Biological Research of the National Tumour Institute of Naples, and carried out according to the Good Clinical Practice guidelines",Exclusion criteria were: inflammatory bowel diseases or significant diarrhoea in recent weeks (or during prior adjuvant 5-FU administration); total colectomy or ileostomy; bowel obstruction; uncontrolled metabolic disorders or active infections; severe ischaemic disease or acute myocardial infarction in the last six months.,the first cycle,NA
10561220,NA,Single Drug,No,"Patients 21 years old or younger with recurrent solid tumors. Diagnosis: Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Brain tumor, Peripheral neuroepithelioma, Other","Patients 21 years old or younger with recurrent solid tumors for which conventional modes of treatment had failed were eligible for this protocol. Other eligibility requirements included a life expectancy of at least 8 weeks; Eastern Cooperative Oncology Group performance status <= 2; recovery from the toxic effects of prior chemotherapy; hemoglobin level greater than 8 g/dL, absolute neutrophil count greater than 1,000/µL, and platelet count greater than 100,000/µL (unless marrow was infiltrated with tumor); adequate liver function (bilirubin level <= three times normal, ALT <= three times normal); adequate renal function (serum creatinine concentration <= three times normal for age); and normal metabolic parameters (serum electrolytes, glucose, calcium, and phosphorous). The study was approved by the institutional review board, and informed written consent was obtained from patients, parents, or guardians as appropriate, according to institutional guidelines.",Patients were ineligible for study entry if they had an active infection or were receiving antibiotics (other than prophylactic trimethoprim-sulfamethoxazole),the first course of treatment ((qd x 5) x 2 every 21 days),NA
24097864,NA,Combination,No,patients included in the Phase Ib portion of this study presented with histologically-documented locally advanced or metastatic HER2-positive breast cancer,"Patient inclusion criteria: patients included in the Phase Ib portion of this study presented with histologically-documented locally advanced or metastatic HER2-positive breast cancer, determined as fluorescence in situ hybridization (FISH)-positive, chromogenic in situ hybridization (CISH)-positive or immunohistochemical (IHC) score of 3+ by local laboratory assessment and were required to have measurable disease. All patients were required to have received prior HER2-directed therapy (trastuzumab, lapatinib) but no prior T-DM1 or pertuzumab therapy. Patients were required to have adequate organ function (serum aspartate transaminase and alanine transaminase ≤ 2.5 x upper limit of normal (ULN) except in the case of liver metastases when both transaminases must have been ≤5 x ULN, total bilirubin ≤ 1.5 x ULN, creatinine ≤ 1.5 g/dL or creatinine clearance ≥ 50 mL/min, absolute neutrophil count ≥ 1500/mm3, platelet count ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL) and cardiac ejection fraction > 55% as assessed by either echocardiogram (ECHO) or multiple gated acquisition (MUGA).","Exclusion criteria included: peripheral neuropathy ≥ Grade 3, history of exposure to cumulative doses of anthracyclines > 500 mg/m2, or a history of cardiac dysfunction. ",during the first 3 cycles,NA
10963644,NA,Single Drug,No,"patients with advanced solid malignancies. Tumor types: Colorectal, Pancreas, Sarcoma, Lung, non–small-cell, Prostate, Liver, Stomach, Bladder (transitional cell), bladder (small-cell), thymus, peritoneum (serous papillary carcinoma), breast, ovary, head and neck, cholangiocarcinoma, uterine, appendix","Patients with histologically confirmed advanced solid malignancies that failed to respond to standard therapy or for whom adequate therapy was not available were eligible for this study. Eligibility criteria also included age >= 18 years; a World Health Organization (WHO) performance status <= 2 (ambulatory and capable of self-care); life expectancy >= 12 weeks; no prior chemotherapy or wide-field radiation therapy within 4 weeks of treatment (6 weeks for nitrosoureas and mitomycin); adequate hematopoietic (absolute neutrophil count [ANC] >= 1,500/uL, hemoglobin level >= 8.5 g/dL, and platelet count >= 100,000/uL), hepatic (total bilirubin <= 1.5 mg/dL, AST and ALT <= 2.5 times institutional upper limit of normal[< five times institutional upper limit of normal for patients with liver metastasis]), and renal (creatinine <= 2.0 mg/dL) functions; measurable or assessable disease; prothrombin time <= 1.5 times institutional upper limit of normal; no chronic enteropathy nor recent onset of diarrhea defined as an excess of two to three stools/d above the normal frequency in the past 4 weeks; and no coexisting medical problem of sufficient severity to limit compliance with the study. Because preclinical studies had suggested that DX-8951 is metabolized by CYP3A P450 enzymes, patients were instructed to avoid a list of medications, foods, and beverages that could potentially modulate this enzyme system. These medications, foods, and beverages were discontinued if they were determined to not be absolutely necessary and/or if substitutions were available. All medications were recorded in the case report form. Patients gave written informed consent according to federal and institutional guidelines before treatment.",NA,during the first treatment course,NA
9619758,NA,Combination,No,non-small-cell lung cancer,"Prior to their participation in the study, patients admitted to the International Medical Center of Japan and Nippon Medical School Main Hospital were examined to ensure that they met the following criteria: (1) histologic diagnosis of NSCLC; (2) stage IIIB or IV disease; (3) no effects of prior treatment (more than 3 months after the previous treatment); (4) life expectancy of at least 8 weeks; (5) age <75 years; (6) performance status of 2 or better on the Eastern Cooperative Oncology Group (ECOG) scale; (7) adequate bone marrow function (leukocyte count >4000=ml, platelet count >100 000=ml, hemoglobin concentration >9 g/dl), hepatic function (bilirubin <1:5 mg/dl, transaminases less than twice the upper limit of normal), and renal function (creatinine <1:5 mg=dl, creatinine clearance >40 ml/min); (8) no medical problems severe enough to prevent compliance with the study requirements; and (9) informed consent of the patient.",NA,the first course,NA
11241238,NA,Combination,No,patients with advanced colorectal carcinom,"The eligibility criteria were as follows: histologically confirmed diagnosis of locally advanced or metastatic colorectal adenocarcinoma; age between 18 years and 70 years; life expectancy > 3 months; Eastern Cooperative Oncology Group (ECOG) performance status (PS) <= 1; measurable or evaluable disease; and prior therapy, including patients with at least one previous 5-FU-containing regimen (as adjuvant or palliative) and no more than two 5-FU-containing regimens (with adjuvant and/or palliative intent). The following blood parameters were validated before treatment: white blood cells (WBC) >= 3.5 x 109/L, neutrophils >= 2 x 109/L, platelets >= 100 x 109/L, hemoglobin >= 10 g/dL; bilirubin <= 1.25 x upper normal limit (UNL), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x UNL, PT (prothrombin time) >= 70% in the absence of liver metastases, or bilirubin <= 1.5 x UNL, ALT and AST <= 5 x UNL in patients with liver metastases; serum albumin >= 3 g/L; and normal renal function, with creatinine clearance of at least 60 mL/minute.",Patients were excluded for one of the following reasons: no prior 5-FU-containing regimen given as either as an adjuvant or palliative treatment; more than two prior lines of 5-FU-containing chemotherapy given as adjuvant and/or palliative treatment; metastatic lesions suitable for surgical resection or elective radiotherapy; previous treatment with CPT-11; inflammatory bowel diseases or chronic diarrhea (requiring therapy); total colectomy or ileostomy; bowel obstruction and/or subobstruction; severe diarrhea (World Health Organization [WHO] Grade 3– 4) during prior 5-FU administration; uncontrolled metabolic disorders or active infections; uncontrolled cardiac arrythmias; uncontrolled congestive cardiac failure or severe ischemic heart disease; acute myocardial infarction in the last 6 months; history of significant neurologic or psychiatric disorders; pregnancy or breast feeding; symptomatic cerebral metastases; or ongoing treatment with other anticancer agents or radiotherapy. ,during the first course,NA
11244327,NA,Combination,No,5-fluorouracil-refractory colorectal cancer patients,"Candidates for this study were patients with histologically proven metastatic carcinoma of the colon or rectum. These patients should have had a disease progression during or recurring within 3 months from previous standard 5FU-based chemotherapy used in either the adjuvant setting or for treating the advanced disease. No patient had been treated with CPT-11 or MMC. Patients should have had at least one bidimensional measurable indicator lesion. Other eligibility criteria included age more than 18 years, discontinuation of previous chemotherapy for at least 4 weeks, adequate bone marrow reserve [absolute neutrophil count (ANC) >=1,500/mm3, platelet (Plt) count >=100,000/mm3, hemoglobin level >=9.5 g/dl], bilirubin serum level <=1.25 x upper normal limit, ASAT and ALAT <=2.5 x upper normal limit. Informed consent was obtained from each patient before admission to this trial which was approved by the Ethical Committee for Biological Research of the National Tumour Institute of Naples.","Exclusion criteria were performance status 63 of the World Health Organization (WHO) scale, presence of brain metastases, life expectancy !12 weeks, uncontrolled metabolic disorders or active infections. ",the first cycle,NA
31471376,NCT01998035,Combination,No,patients with PTCL (peripheral T-cell lymphomas),"To be eligible for this multicenter phase 1 trial, patients were required to be >=18 years of age, have an Eastern Cooperative Oncology Group performance status of <=2, and have histologically confirmed R/R non-Hodgkin lymphoma or Hodgkin lymphoma, with no curative options. There was no limit to the number of prior therapies, and autologous (ASCT) and allogeneic (alloSCT) stem cell transplantations were allowed. Additional inclusion criteria included liver function tests (ie, aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) <=2 times the institutional upper limit of normal, total bilirubin <=1.5 times the upper limit of normal, a creatinine clearance >=50 mL/min, an absolute neutrophil count >=1000 cells/uL, and a platelet count >=75 000/uL.","Exclusion criteria included exposure to chemotherapy or radiotherapy within 2 weeks of study entry or lack of recovery from adverse events (AEs), caused by to therapy administered more than 2 weeks earlier. Other exclusionary criteria included: concomitant investigational therapy, systemic steroids not stabilized (at least 5 days in advance) to an equivalent of <=10 mg/day of prednisone at the time of study entry; active malignancy; HIV; hepatitis A, B, or C infection; pregnancy or nursing; or uncontrolled intercurrent illness.",during cycle 1 ,NA
25434923,EudraCT Number: 2009-017817-3,Single Drug,No,"patients with solid tumours. Primary cancer: Oesophageal/gastric, Non-small cell lung, Pancreatic, Renal, Breast, Other","Eligible patients had histologically confirmed solid tumours not amenable to established treatments, expressing EGFR (1+ to 3+ by immunohistochemistry) and/or overexpressing HER2 (3+ or 2+ using immunohisto- chemistry, or amplification by FISH). Breast and gastric cancer patients had HER2-positive tumours (3+ using immunohistochemistry, or 2+ and amplified HER2 by FISH). Colorectal cancer patients with KRAS mutation were excluded. Other eligibility criteria included written informed consent; Eastern Cooperative Oncology Group (ECOG) performance status 0–1; recovery from all previous therapy-related toxicities to Common Terminology Criteria for Adverse Events v4.0 (CTCAE) Grade 61; and adequate bone marrow, renal, hepatic and left ventricular function.",NA,during the first 28-day cycle,NA
7786821,NA,Single Drug,No,"patients with advanced solid tumors. Tumor typrs: Colon, Head and neck, Breast, Ovary, Pancreas, Kidney, Liver, Miscellaneous","Eligibility criteria included the following: 1) age between 18 and 75 years; 2) life expectancy of at least 3 months; 3) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; 4) no chemotherapy or radiotherapy within 4 weeks before entry (6 weeks for nitrosoureas or mitomycin C); 5) adequate baseline organ functions, defined as: WBC count >= 4,000/ul; platelet count >= 100,000/ul; hemoglobin >= 10 g/dl; total bilirubin <= 1.25 times the upper limit of normal; transaminases and alkaline phosphatases <= 2 times the upper limits of normal; creatinine <= 120 umol/1; serum electrolytes, prothrombin time, activated partial thromboplastin time and fibrinogen within normal limits; 6) no evidence of cardiac or respiratory insufficiency; 7) no history of chronic enteropathy; 8) no previous anaphylactic reaction; 9) negative pregnancy test for women of childbearing age; 10) written informed consent",NA,during the first cycle of treatment,NA
32816943,NCT01638533,Single Drug,No,Patients with Cancer and Hepatic Dysfunction,"Patients equal to or older than 18 years with histologic or cytologic confirmed lymphoma, chronic lymphocytic lymphoma, or select solid tumor malignancies were eligible even if a prior treatment included romidepsin. Patients with relapsed or refractory PTCL or CTCL were eligible without the requirement of having relapsed within 6 months of last treatment, consistent with labeling. Patients with solid tumors must have had recurrent or metastatic, disease, for which standard curative measures were unavailable. ","Patients with neuroendocrine tumors were excluded because of efficacy and safety concerns (11). Patients with prostate cancer, renal cell cancer, lung cancer, colorectal cancers, soft-tissue sarcomas (NCT00112463), glioma, and thyroid cancer were excluded in the normal and mild cohorts due to a lack of efficacy but were permitted to enroll in the moderate and severe cohorts (13–18).",during the first cycle,NA
10080615,NA,Combination,No,"Patients With Solid Tumors. Disease site: Colon/rectum, Unknown primary tumor, Endometrium, Renal cell","Patients with histologically documented, assessable, or measurable solid tumors refractory to conventional chemotherapy or for whom no effective therapy existed were candidates for this study. Eligibility criteria included the following: age >= 18 years, Southwest Oncology Group performance status 0 to 2, absolute neutrophil count >= 1,500/μL, hemoglobin level >= 9 g/dL, platelet count >= 100,000/μL, serum creatinine level <= 2.0 mg/dL, creatinine clearance >= 60 mL/min, serum bilirubin level # 2 mg/dL, AST and ALT levels no more than three times the institutional upper limits of normal, normal serum electrolyte counts, blood glucose level <= 250 mg/dL, and serum albumin level >= 3g/dL. Prior chemotherapy was acceptable as long as the last dose had been administered at least 3 weeks before enrollment (at least 6 weeks for nitrosoureas or mitomycin). Prior radiation therapy was acceptable as long as it had been completed at least 4 weeks before study registration. All patients gave written informed consent according to federal and institutional guidelines before initiation of treatment.",NA,first cycle,NA
8229134,NA,Combination,No,"patients with solid malignancies. Tumor types: Colorectal, Uterine cervix, Breast, Kidney, Liver, Non-small-cell lung, Ovary, Prostate, Stomach","All patients entered onto this trial had histologically proven solid malignancies for which no curative therapy was available. Eligibility criteria included the following: (1) age >= 18 years; (2) measurable or assessable tumor; (3) predicted life expectancy of >= 12 weeks; (4) Southwest Oncology Group (SWOG) performance status of 0, 1, or 2; (5) no surgery, radiation, or chemotherapy within 4 weeks before entry (6 weeks for previous treatment with nitrosoureas or mitomycin); (6) adequate baseline organ function, defined as WBC count >= 3,500/uL, platelet count >= 100,000/uL, hemoglobin >= 9.5g/dL, total bilirubin < 2.0 mg/dL, AST < 3.0-fold upper limit of normal, prothrombin time within normal limits, serum creatinine <= 2.0 mg/ dL or creatinine clearance Ž 60 mL/min, serum electrolytes within 10% of normal, and serum glucose <= 200 mg/dL; (7) negative skin test for hypersensitivity to CPT-1 1; (8) negative pregnancy test (for women of childbearing potential) and agreement to use contraception while on study; (9) no concurrent use of commercial or investigational antineoplastic therapy; (10) no acute atrial fibrillation or myocardial infarction in the previous 6 months; and ( 1) signed informed consent. Before initiation of this trial, institutional review board-approval was obtained at each of the participating centers.",NA,during cycle no. I of CPT- 11 treatment,NA
8918493,NA,Combination,No,"patients with advanced solid tumors. Primary tumor site: Colorectal, Unknown primary, Esophogeal, Carcinoid nonfunctional ","Eligibility criteria included documentation of incurable solid tumor malignancy with histologic confirmation of diagnosis at Memorial Sloan-Kettering Cancer Center. All patients were required to have essentially normal hepatic, renal, and bone marrow function, with a WBC count >= 4 x 109/L, platelet count >= 150 x 10 9/L, serum creatinine concentration <= 1.5 mg/dL, total bilirubin level <= 1.5 mg/dL, and AST level <= three times the upper limit of normal (or five times the upper limit of normal if hepatic metastases were present). A Karnofsky performance status of 70% or better was required. Prior 5FU-based therapy was permitted; however, because we anticipated giving substantial doses of 5FU, patients were excluded if prior 5FU had been discontinued solely due to intolerable toxicity. Patients were permitted to have received up to two prior chemotherapy regimens (with 5FU given on two different schedules counting as two different regimens); however, patients who had received prior mitomycin, carboplatin, or nitrosoureas were excluded. Based on concerns that patients who had undergone pelvic radiotherapy might be at greater risk for CPT-I I -induced neutropenia, prior pelvic irradiation was adopted as an exclusion criterion for this study.",NA,during the first 6 weeks of study,NA
9850031,NA,Combination,No,"patients with advanced solid tumors. Tumor type: Unknown primary, Gastric, Gallbladder, Pancreatic, Biliary tract, Lung, Colon, Small bowel, Sarcoma, Esophagus","Eligibility criteria included documentation of incurable solid tumor malignancy with histologic confirmation of diagnosis at Memorial Sloan-Kettering Cancer Center. All patients were required to have essentially normal hepatic, renal, and bone marrow function, with a WBC count >= 4 x 109 /L, platelet count >= 150 X 109/L, serum creatinine concentration <= 1.5 mg/dL, total bilirubin level <= 1.5 mg/dL, and AST <= three times the upper limit of normal (or five times the upper limit of normal if hepatic metastases were present). A Kamofsky performance status >= 70% was required. Prior chemotherapy was initially permitted; however, patients must not have received cytotoxic therapy for at least 3 weeks before initiation of treatment (at least 6 weeks if a patient had received prior mitomycin or nitrosoureas) and they must have fully recovered from toxicity of the previous therapy. All patients were fully informed of the investigational nature of this protocol and all gave written informed consent before initiation of treatment",NA,first-course,NA
11474256,NA,Combination,No,"The tumor types included non–small-cell lung cancer (13 patients), gastric cancer (1), ovarian sarcoma (2), renal cell (1), prostate (1), colon (1), melanoma (1), unknown primary (1), and breast cancer (1).","Eligible patients were required to have a life expectancy of more than 8 weeks and to have normal hematologic parameters including a leukocyte count of more than 4,000 cells/ul and a platelet count of more than 140,000. Liver function test abnormalities were acceptable if aspartate transaminase and alanine transaminase were less than three times the normal values and the bilirubin level was normal. Creatinine level more than 1.4 mg/dl was the major exclusion criteria. Performance status must have been 2 or less on the Eastern Cooperative Oncology Group scale. Patients must have had a clinical diagnosis of advanced malignancy and have received standard systemic chemotherapy and have established resistance to such therapy. Patients were not required to have measurable disease.",NA,NA,NA
24711549,NCT00544804,Single Drug,No,patients with human epidermal growth factor receptor 2-overexpressing breast cancer,"DISEASE CHARACTERISTICS: Histologically confirmed breast cancer, Advanced or metastatic disease, No effective curative therapy available, Bone-only disease allowed, Tumor HER2 overexpression, HER2 3+ expression by immunohistochemistry OR > 2-fold (HER2 2+) gene amplification by fluorescence in situ hybridization, Evaluable disease, Measurable disease is not required, No progressive brain metastases, Hormone receptor status not specified. PATIENT CHARACTERISTICS: Inclusion criteria: ECOG performance status 0-2; Life expectancy > 3 months; Female; Menopausal status not specified; Absolute neutrophil count ≥ 1,000 cells/mm^3; Hemoglobin ≥ 9 g/dL; Platelet count ≥ 75,000 cells/mm^3; Total bilirubin normal; AST and ALT ≤ 3 x upper limits of normal (ULN) (≤ 5 x ULN with liver metastases); Creatinine normal OR creatinine clearance ≥ 40 mL/min; INR ≤ 1.5; Potassium normal; Magnesium normal; Not pregnant; Negative pregnancy test; Fertile patients must use effective contraception prior to and during study therapy; Cardiac ejection fraction ≥ 50%; Consents to 2 tumor fine needle aspiration biopsies for biomarker analysis, Lung-only disease or sites otherwise deemed high-risk for biopsy, the requirement for biopsy will be waived","History of significant cardiac disease including any of the following: Congestive heart failure; Symptomatic cardiac arrhythmias; Unstable angina. Uncontrolled prior lapatinib ditosylate therapy toxicity ≥ grade 2;nAllergic reactions to IV contrast dye despite standard prophylaxis; History of malabsorption syndrome or disease significantly affecting gastrointestinal function or major resection of the stomach or small bowel that could affect absorption, distribution, metabolism, or excretion of study drug; Conditions that would impair the patient's ability to swallow and retain oral medication; Concurrent disease or condition that would make the patient inappropriate for study participation or would interfere with the patient's safety; Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol",during the first cycle (14 days) of therapy,NA
10873073,NA,Combination,No,"patients with advanced solid tumor malignancy. Tumor type: Colorectal, Esophageal, Gallbladder","Patients entered had histologically confirmed solid tumor malignancy that was not curable by surgery, radiation therapy, or standard chemotherapy. Eligibility criteria included the following: (a) measurable or evaluable disease; (b) age >= 18 years; (c) an ECOG performance status of <=2; (d) a life expectancy of at least 12 weeks; (e) no prior chemotherapy within the previous 4 weeks (6 weeks in patients treated with mitomycin C or nitrosoureas) and recovery from any toxic effects of prior treatment; (f) no more than two prior chemotherapy regimens; (g) no prior treatment with CPT-11 or other camptothecins; (h) no prior radiation therapy for at least 6 weeks and measurable lesions present outside the radiation field; (i) radiation therapy to <=25% of bone marrow; (j) adequate hematopoiesis (neutrophil count >= 1,500/mm3, platelet count >= 150,000/mm3, and hemoglobin level of >=9.0 g/dl), renal function (serum creatinine <= 2.0 mg/dl), and liver function (aspartate aminotransferase <=3 x institutional upper limit of normal or <= 5 x institutional upper limit of normal if liver involved with metastatic disease, and serum bilirubin within institutional upper limit of normal); (k) no active or uncontrolled infection; (l) absence of pregnancy or lactation; (m) no known central nervous system metastases or carcinomatous meningitis; (n) no interstitial pneumonia or extensive/symptomatic interstitial fibrosis of the lung causing greater than or equal to grade 2 dyspnea; and (o) no medical (uncontrolled high blood pressure, unstable angina, active congestive heart failure, myocardial infarction within the previous 6 months, or serious uncontrolled cardiac arrhythmia) or psychiatric conditions that might place patients at risk for participation in investigational treatment. All patients gave written informed consent according to institutional and federal guidelines before treatment.",NA,NA,NA
10071283,NA,Combination,No,patients with advanced colorectal cancer,"The eligibility criteria were as follows: age between 18 and 70 years; measurable, metastatic colorectal cancer; no prior chemotherapy or radiotherapy for metastatic colorectal cancer; interval between the end of prior adjuvant radiotherapy and/or chemotherapy and study entry at least 6 months; predicted life expectancy at least 3 months; World Health Organization (WHO) performance status 2 or lower; adequate baseline organ functions, defined as neutrophil count at least 2,000/µL, platelet count at least 100,000/µL, hemoglobin at least 10.0 g/dL; serum bilirubin level 1.25 or less times the upper limit and AST and ALT 3 or less times the upper limit of the institutional reference range; serum creatinine 140 µmol/L or less or a creatinine clearance of at least 60mL/min; no chronic diarrhea or unresolved bowel obstruction; no severe uncontrolled comorbidities or medical conditions (eg, myocardial infarction within the last 12 months); no brain metastases; no concurrent treatment with other commercial or experimental antineoplastic drugs; no second malignancies; and signed informed consent. ",NA,during the first cycle,NA
27026198,NA,Combination,No,"Adult Solid Tumors. Primary cancer site:  GI: colorectal, esophageal; Lung; Breast; Gyn: uterine, ovarian; Other (n = 1 each of adrenal, nasopharyngeal, chondrosarcoma, peritoneal, and salivary cancer)","The study included a dose escalation cohort followed by a dose expansion cohort. Participants were 18 years or older and had Eastern Cooperative Oncology Group performance status 0–2 with adequate hematologic, renal, hepatic, and cardiac function. In addition, the study required evaluable or measurable disease from histologically or cytologically confirmed advanced or metastatic solid tumor for which no standard curative measure existed. Participants with any advanced and incurable solid malignancy were eligible for the dose escalation cohort. Participants with HER2þ breast cancer deemed to be locally advanced (unresectable and incurable) or metastatic were eligible for the dose expansion cohort. HER2+ was defined as 3 + by IHC or ISH ratio >= 2.2. Participants who previously progressed on lapatinib were eligible as long as they did not demonstrate prior serious or life-threatening intolerance to doses of lapatinib exceeding 1,000 mg daily. Participants with treated, stable brain metastases or progressive but asymptomatic brain metastases who were not candidates for further local therapy were eligible. All participants were required to have normal baseline QTc; diabetes mellitus was allowed if well controlled.","Prior chemotherapy, radiotherapy, trastuzumab, and other targeted therapies excluding endocrine therapies were not allowed within 4 weeks of study drug. Tamoxifen was not allowed within 2 weeks and aromatase inhibitors within one day. In addition, participants were required to stop any strong/moderate inhibitors or inducers of CYP3A4; sensitive substrates of CYP3A4 with a narrow therapeutic index were disallowed. Medications prolonging QTc were not allowed. Pregnant or lactating women and individuals with HIV were not eligible.",during cycle 1,NA
11352961,NA,Combination,No,unresectable hepatic metastases from colorectal cancer,"All patients had histologically confirmed colorectal carcinoma with unresectable liver metastases comprising less than 70% of the liver parenchyma and no evidence of extrahepatic disease. To be eligible, patients were required to have disease measurable by computed tomography (CT) and meet the following laboratory conditions: leukocyte count greater than 3,500 cells per cubic millimeter, platelet count greater than 150,000 cells per cubic millimeter, albumin greater than 2.0 g/dL, and total bilirubin less than 2.0 mg/dL. Prior radiation to the liver was not permitted. Other criteria included performance status 60% or greater and the absence of infection or ascites. Prior treatment with systemic chemotherapy was required. The protocol for this study was approved by our institutional review board. Each patient submitted written informed consent before surgery (for pump placement and cryosurgery, if possible). All patients had a preoperative chest radiograph (posteroanterior and lateral views), CT of the abdomen and pelvis, baseline complete blood cell count, carcinoembryonic antigen (CEA), lactate dehydrogenase (LDH), alkaline phosphatase, AST, total bilirubin, albumin, and creatinine. CT was used to determine the percentage of liver involvement by tumor and to assess response. Cryosurgery candidates underwent preoperative PET scans.",Patients with significant arterial anomalies that would preclude complete liver perfusion were excluded. ,first two cycles,NA
11435065,NA,Combination,No,unresectable and locally advanced non-small cell lung cancer,"Eligibility criteria included the following: a histologically confirmed diagnosis of NSCLC; age <=75 years; Eastern Cooperative Oncology Group (ECOG) performance status (PS) <=2; life expectancy >12 weeks; adequate bone marrow function (leucocyte count >= 4x109/l platelet count >= 100x109/l and haemoglobin >=100 g/l); serum bilirubin <=25 mmol/l; alanine aminotransferase (ALT) and asparate aminotransferase (AST) levels <= double the normal upper limit; serum creatinine <=105 mmol/l and PaO2 >=70 torr; no medical problems severe enough to prevent compliance with the protocol, and provision of written informed consent.","Patients with previously untreated, unresectable and locally advanced stage III NSCLC were enrolled, but patients with pleural effusion were excluded. ",during two cycles of treatment,NA
10901362,NA,Combination,No,"patients with advanced gastrointestinal tract adenocarcinoma. Primary site: Colon, Rectum, Oesophagus, Stomach",Eligibility criteria were as follows: histologically confirmed advanced GI tract adenocarcinoma; life expectancy ≥ 12 weeks; WHO performance status (PS) ≤ 2; age 18–70 years; satisfactory renal and hepatic function; written informed consent.,Exclusion criteria were: previous treatment with topoisomerase I inhibitor; chronic enteropathy; symptomatic cerebral metastasis or leptomeningeal carcinomatosis; unresolved bowel obstruction; pregnancy; previous malignant disease (except adequately treated carcinoma in situ of the cervix uteri or basal cell carcinoma of the skin).,cycle 1,NA
27902470,NCT01931943,Combination,No,pre-treated patients with HER2-overexpressing advanced breast cancer,"Eligible women were 18 to 65 years old with ECOG PS of 0-1, and histologically/cytologically conﬁrmed advanced breast cancer. As determined by a local laboratory, HER2 overexpression was identified as IHC 3+ or ﬂuorescence in situ hybridization (FISH) positive. Prior treatment with trastuzumab was permitted but not required. Additional eligibility criteria are as follows: At least one measurable disease site defined by Response Evaluation Criteria in Solid Tumors (RECIST v.1.1), life expectancy of at least 3 months and adequate hematology (white blood count of ≥3.5×109/L, absolute neutrophil count of ≥1.5×109/L, platelet count of ≥100×109/L, hemoglobin of≥90 g/L), adequate hepatic function (serum bilirubin≤1.5 times upper limit of normal (ULN)), aspartate aminotransferase and alanine aminotransferase ≤1.5 × ULN, adequate renal function (creatinine and urea nitrogen≤1.5 × ULN), and adequate cardiac function (normal electrocardiography (ECG) and baseline left ventricular ejection fraction (LVEF) higher than 50%). Patients must be able to swallow and have normal gastrointestinal function. Patients must be recovered from any previous treatments. The interval must be more than six weeks since administration of nitroso or mitomycin. The interval of last radiotherapy treatment, other cytotoxic drugs or surgery should be more than 4 weeks. Patients should agree to take contraceptives during the study and for 6 months after the study (such as an intrauterine device [IUD], contraceptive drugs or condoms); Seven days before entering the study, serum or human chorionic gonadotropin should be negative, and must be in the non-lactation period.","Exclusion criteria for this study are as follows: patients currently receiving small molecule targeted drug therapy of inhibition of HER-2 or EGFR, uncontrolled or significant cardiovascular disease, a left ventricular ejection fraction (LVEF) <45%, known interstitial lung disease or active brain metastases. Any patients who are pregnant or breast feeding, any clinically significant gastrointestinal abnormalities that can influence oral administration, patients with a history of symptomatic brain metastases, active serious infection, uncontrolled large pleural effusion and ascites, requirement for the therapeutic drugs prolonging QT interval (such as anti-arrhythmia drugs), any medical history of small molecule targeted drug therapy of inhibition of HER-2 or EGFR.",until day 21 of the first cycle ,NA
8382970,NA,Single Drug,No,patients with refractory or relapsed acute leukemia,"Adults with a diagnosisof acute leukemia who were refractoryor had relapsedfollowingfrontlineinduction or salvage chemotherapy were entered into this study. All patients signed an informed consent to participate in the study accordingto institutional guidelines.Eligibility required: (1) a performance status of 2 or better on Zubrod scale, and (2) a bilirubin level of 1.5 mg% or less and a creatinine level of 1.5 mg% or less",NA,first course of treatment,NA
24013582,NCT00614978,Combination,No,brain metastases in patients with HER2-positive metastatic breast cancer,"Patients were eligible if they had recurrent or progressive brain metastases and HER2-positive BC (defined as 3+ immunohistochemistry or evidence of gene amplification as assessed by fluorescence in situ hybridization). Previous systemic chemotherapy, trastuzumab, lapatinib, WBRT, surgical excision or SRS were allowed. At least one measurable brain lesion, defined as >5 mm in its longest axial diameter by 3D-Gd magnetic resonance imaging (MRI), was required. Additional inclusion criteria included age ranging from 18 to 80 years old; expected life expectancy of > 3 months; ECOG performance status ≤2; adequate organ functions; and left ventricular ejection fraction (LVEF) > 50% as assessed by either echocardiography (ECHO) or multigated acquisition (MUGA) scan. Because of low accrual, the study protocol was amended to allow the inclusion of patients with newly diagnosed brain metastases, for whom 1 cycle of the study treatment would be administered before the planned standard treatment (surgery, radiosurgery, or radiotherapy). The concurrent administration of agents acting as inducers or inhibitors of CYP3A4 was not allowed. Concomitant treatment with corticosteroids for symptomatic brain metastases was allowed. All patients gave written informed consent before study enrollment.",NA,NA,NA
11895901,NA,Single Drug,No,"patients with refractory neoplasms. Tumor type: Sarcoma, Leiomyosarcoma, Colorectal, Renal, Breast, Non-small cell lung, Melanoma, Head and neck, Adenoid cystic","Patients with histologically confirmed evidence of malignancy for whom no known standard therapy was available that was either curative or definitely capable of extending life expectancy were eligible. Other eligibility criteria included age >=18 years, ECOG performance status <=2, and estimated life expectancy >12 weeks. Previous chemotherapy or biological therapy had to be discontinued for at least 4 weeks. Previous radiotherapy had to be completed 3 weeks before study entry and could not have encompassed >25% of the bone marrow. Patients were required to have the following laboratory values, obtained within 14 days of study participation: neutrophils >=1,000/ul, platelets >=100,000/ul, creatinine <=1.5 x upper normal limit, bilirubin <=1.5 x upper normal limit, aspartate aminotransferase/alanine aminotransferase (AST/ALT) <=3 x upper normal limit, prothrombin time/ partial thromboplastin time <=1.1 x upper normal limit.","Patients were not eligible if they had an uncontrolled infection, central nervous system metastasis, or recent major surgery (within 21 days). Pregnant or lactating patients were not allowed on study.",in the first cycle,NA
11720832,NA,Combination,No,advanced colorectal cancer,"Inclusion criteria were: age older than 18 years; advanced colorectal carcinoma not amenable to surgical resection; bi-dimensionally measurable disease in a nonirradiated area; one prior chemotherapy regimen for advanced disease (prior treatment with 5-FU or UFT, but not CPT-11 was allowed); patients were not refractory to the first-line of chemotherapy (just pretreated); life expectancy more than 12 weeks; World Health Organization (WHO) performance status 0-2; adequate renal function, defined as serum creatinine < 140 mmol/l; adequate hepatic function, defined as serum bilirubin less than 1.25 times the upper normal limit, transaminases (aspartate aminotransferase (AST) and alanine aminotransferase (ALT)) 3 times or less the upper normal limit or 5 times or less above the upper limit in the presence of liver metastases; adequate haematological function, defined as absolute neutrophil count of 2000 x106 cells/l or higher and platelets of 100x109 cells/l or higher. All the patients gave fully-informed consent prior to recruitment into the study.",Exclusion criteria were: chronic diarrhoea; bowel obstruction; uncontrolled severe disease; brain metastases; pregnancy or lactation; concomitant treatment with other anti-neoplastic drugs; secondary neoplasias.,the first treatment course,NA
9060529,NA,Combination,No,patients with advanced gastric cancer,"Patients were entered onto the study if they fulfilled the following eligibility criteria: (1) histologic confirmation of gastric cancer; (2) inoperable disease or recurrence after gastrectomy; (3) measurable lesion; (4) age <=75 years; (5) performance status (PS) <=2 on the Eastern Cooperative Oncology Group (ECOG) scale; (6) no chemotherapy within 4 weeks before entry; (7) adequate bone marrow function (WBC count >= 4,000/uL and platelet count >= 100,000//uL); (8) adequate liver function (serum bilirubin level <= 1.5 mg/dL and serum transaminase levels <= three times the upper limit of normal); (9) adequate renal function (serum creatinine level <= 1.5 mg/dL, blood urea nitrogen level <= 25 mg/dL, and creatinine clearance >= 50 mL/min); (10) no other severe medical conditions; (11) no other active malignancies; (12) no allergic reactions to skin prick test with CPT-11; and (13) provision of written informed consent in accordance with government guidelines (Good Clinical Practice, by the Ministry of Health and Welfare of Japan) and institutional guidelines.",NA,during the first course,NA
28950146,NCT01589861,Combination,No,trastuzumab-resistant HER2-positive advanced breast cancer,"Patients aged >=18 years with a locally advanced, recurrent or metastatic, histologically confirmed HER2-positive breast cancer and trastuzumab-resistant disease could be included. Other key inclusion criteria were World Health Organisation performance status <=1, appropriate haematological, liver, renal functions, no fasting plasma glucose >120 mg/dl, baseline left ventricular ejection fraction (LVEF) >50% and no history of major mood alterations. ","Previous treatment with lapatinib, neratinib or a PI3K inhibitor. untreated brain metastases. acute or chronic liver, renal disease or pancreatitis. any peripheral neuropathy ≥ CTCAE grade 2. any of the following mood disorders, or meets the cut-off score of ≥ 10 in the PHQ-9 or a cut-off of ≥ 15 in the GAD-7 mood scale, respectively, or selects a positive response of '1, 2, or 3' to question number 9 regarding potential for suicidal thoughts ideation in the PHQ-9 (independent of the total score of the PHQ-9): Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others); ≥ CTCAE grade 3 anxiety. diarrhea ≥ CTCAE grade 2. active cardiac disease. history of cardiac dysfunction. poorly controlled diabetes mellitus (HbA1c > 8 %). Other severe and/or uncontrolled concomitant medical conditions. Impairment of gastrointestinal function that may significantly alter the absorption of BKM120 been treated with any hematopoietic colony-stimulating growth factors ≤ 2 weeks prior to starting study drug. currently receiving treatment with medication with a known risk prolong the QT interval or inducing Torsades de Pointes. currently being treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A. receiving chronic treatment with steroids or another immunosuppressive agent. have received chemotherapy or targeted anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, antibodies [other than trastuzumab] or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy. have received small molecule therapeutics (excluding monoclonal antibodies) ≤ 5 effective half lives prior to starting study drug or who have not recovered from side effects of such therapy. have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy. have undergone major surgery ≤ 28 days prior to starting study drug or who have not recovered from side effects of such therapy. Known diagnosis of HIV infection. History of another malignancy within 3 years. Patient is unable or unwilling to abide by the study protocol. pregnant or breast feeding women",NA,NA
25082342,NCT00466895,Single Drug,No,"symptomatic, relapsed chronic lymphocytic leukemia","Adult patients, ≥18 years of age with CLL were enrolled on one of two cohorts (A or B) between May 2007 and July 2010. Cohort A included relapsed and refractory CLL patients, whereas Cohort B also included relapsed and refractory CLL patients having achieved a complete or partial response (CR/PR) to therapy and not considered candidates for stem cell transplantation. Patients had to be within 12 months of achieving a CR or PR and at least 60 days from the last dose of chemotherapy, with those patients in CR required to have minimal residual disease by flow cytometry. Other criteria for both cohorts included an absolute lymphocyte count less than 200,000 × 109 L–1, a platelet count of at least 50 × 109 L–1 or 100,000 × 109 L–1 for Cohorts A and B respectively, an absolute neutrophil count of at least 1 × 109 L–1, total bilirubin ≤2× upper limit of normal, serum creatinine ≤ 2.0 mg/dL, ALT/AST ≤ 5× the upper limit of normal, and absence of infection. Only patients with an Eastern Cooperative Oncology Group performance status ≤2 were included.","Patients with acute promyelocytic leukemia are excluded unless patient has failed salvage therapy with arsenic. Patients with HIV are excluded due to increased risk of infectious complications, marrow suppression, and potential interactions with antiviral therapy. CLL patients who have had chemotherapy (with the exception of hydroxyurea) or radiotherapy within 4 weeks prior to entering the study are excluded. CLL patients receiving corticosteroids (within 2 weeks) for treatment of disease (other than autoimmune manifestations of CLL) are not eligible. Patients who have received mitomycin C or nitrosourea require a six weeks recovery period before they can be enrolled on the current study. Patients with the following abnormal clinical values are excluded (unless abnormalities in these parameters are directly attributable to malignancy): Serum creatinine >2.0 mg/dl Total bilirubin > 2 x upper limit of normal (unless due to Gilbert's syndrome) ALT and AST > 5 x upper limit of normal",during the first cycle of lenalidomide,relapsed CLL patients (Cohort A) and patients achieving a partial response (PR) or better to recent therapy (Cohort B)
22426640,NCT01092091,Single Drug,No,patients with advanced hepatocellular carcinoma,"Advanced HCC patients not suitable for surgery or various loco-regional therapies at the Queen Mary Hospital, Hong Kong, were recruited. HCC was diagnosed either by cytohistological confirmation or by non-invasive criteria according to the European Association for Study of Liver disease (EASL) criteria: cirrhotic patients with either two coincident imaging techniques demonstrating focal lesion >2 cm with arterial hypervascularization or one imaging technique showing focal lesion >2 cm with arterial hypervascularization and associated with alpha fetal protein (AFP) level >400 ng/ml . Staging was by American Joint Committee on Cancer (AJCC) and Barcelona Clinic Liver Cancer (BCLC) score. The eligibility criteria included adult patients 18–75 years old; patients with Child-Pugh class A or B cirrhosis; Karnofsky performance status (KPS)≥80%; expected life expectancy of ≥12 weeks and with adequate organ function: complete blood picture (absolute neutrophil count (ANC) >1.0×109/L, platelet count >100×109/L) and biochemistry (total bilirubin of ≤2×upper limit of normal, serum AST and ALT≤5×upper limit of normal). The disease must be measurable with at least one lesion, which was at least 2 cm in one dimension either on CT or MRI scan. All the enrolled patients had clear progressive disease with their last treatment modalities prior to study entry","Advancing liver failure indicated by uncontrolled ascites, pleural effusions, encephalopathy, or a Child-Pugh score of C. Significant hepatic, renal or bone marrow dysfunction indicated by total bilirubin >40 µmol/L, evidence of bile duct obstruction, serum albumin <30 g/L, serum SGOT >5 x upper limit of normal, ANC <1.0 x 10^9/L, platelets <100 x 10^9/L, or INR >2.0. Significant cardiac or pulmonary disease defined by New York Heart Association (NYHA) Class III or IV, VEF <50% by echo or MUGA, or a history of myocardial infarction within the past 6 months, significant unstable arrhythmia or evidence of ischemia on ECG. Pregnant or nursing women. NOTE: Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Significant active infection including HIV requiring oral or parenteral anti-infective therapies; Use of investigational drug(s) within 4 weeks of enrollment; or, Prior treatment with arginine depleting agent.",NA,NA
34735674,NCT02089633,Combination,No,advanced hepatocellular carcinoma patients,"Eligible patients (age≥18 years) were required to have histological or radiological (based on European Association for the Study of the Liver non-invasive criteria) diagnosis of advanced HCC not amenable to surgery or locoregional therapy. Other eligibility criteria included Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, Child–Pugh class A or B, adequate bone marrow, liver and kidney function and normal electrocardiogram. Patients with clinically stable brain metastases for at least six months after defnitive therapy were also eligible.","Exclusion criteria included main portal vein tumour thrombosis, ascites uncontrolled by medication, prior treatment with systemic therapeutic agents other than targeted therapy, history of liver transplantation, history of allergic reactions to compounds of similar chemical or biological composition to capecitabine and oxaliplatin. Other exclusion criteria included dihydropyrimidine dehydrogenase defciency, pregnancy, lactation, history of seizure disorder, infection with human immunodefciency virus or severe concurrent infections or illness.",during the first 21-day treatment cycle ,NA
28483761,NCT01749969,Combination,No,relapsed/refractory multiple myeloma,"For the isatuximab Q2W cohorts, patients had a confirmed diagnosis of MM, had progressed or were refractory to the immediate prior therapy, and had received $2 prior anti-MM regimens. For the isatuximab QW/Q2W cohorts, eligibility criteria were amended so that only patients who had received >=2 lines of antiMM therapy (line defined as >=1 planned cycle of single-agent or combination therapy, or a sequence of treatments in a planned manner26) and were LENexposed were included. RRMM was defined according to the International Myeloma Workshop guidelines26; a regimen was defined as a distinct singleagent or combination therapy used for >1 cycle of anti-MM treatment. Eligible patients were aged >=18 years, with Karnofsky performance status >=60%; absolute neutrophil count >=1.0 x 109/L; platelet count >=75 x 109/L (>30 x 109/L in patients with >=50% bone marrow plasma cells); hemoglobin >=10 g/dL; alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and bilirubin <=1.5 x upper limit of normal; creatinine clearance >=30 mL/min; and fasting glucose <=150 mg/dL. Patients had measurable disease, with serum M-protein >=0.5 g/dL, urine M-protein >=200 mg per 24 hours, or involved serum free light chain assay >=10 mg/dL and an abnormal serum free light chain ratio (<0.26 or >1.65), or biopsy-proven plasmacytoma.","Key exclusion criteria included prior autologous transplantation within 12 weeks; prior anticancer treatment within 21 days; prior active malignancy; daily requirement for corticosteroids (>10 mg/d of prednisone); history of active bleeding or a severe underlying medical condition; prior major surgery within 4 weeks; active hepatitis B, C, or known HIV infection; baseline neuropathy grade >=3 or painful neuropathy grade >=2; pregnancy or breast-feeding; or hypersensitivity to any components of study therapy.",NA,NA
28853315,NCT01368757,Single Drug,No,patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1,"For study inclusion patients required a diagnosis of CMML according to the 2008 WHO criteria. Patients of all risk groups according to the MD Anderson Prognostic Scoring System (MDAPSS) could be included in the study, if they needed treatment. The treatment decision was at the discretion of the treating physician. Other inclusion criteria were: age >=18 years, Eastern Cooperative Oncology Group Performance Status of <=2 at study entry, platelets >50 G/l, creatinine clearance >30ml/min, transaminase levels <=2.5 ULN. Prior therapy with hydroxyurea or other drugs were permitted, but treatment had to be stopped at least four weeks before study entry. Patients had to be disease free of prior malignancies for at least five years (except treated basal cell or squamous cell carcinoma of the skin, and ‘in situ’ carcinoma of the cervix or breast). Female subjects at childbearing age had to agree to use a combination of two effective contraception methods due to a potential teratogenic risk of lenalidomide. Male subjects had to agree to use condoms if their female partner with childbearing potential had no contraception.","Patients were excluded if they were not able to sign the informed consent form, were pregnant or breast feeding females, had any condition including laboratory abnormalities associated with an unacceptable risk when participating in the study, had known hypersensitivity to thalidomide, had HIV positivity or infectious hepatitis A, B, C or any prior use of lenalidomide.",during the first cycle of lenalidomide,NA
33040274,NCT01222754,Combination,No,children with diffuse intrinsic pontine gliomas or high-grade gliomas,"Inclusion criteria included age<22 years, newly diagnosed HGG (histologic confrmation required) or DIPG (histologic confrmation not required if considered typical, i.e. hypoor iso-intense lesion on T1-weighted imaging, hyperintense on FLAIR/T2-weighted sequences, epicenter in the pons, involving>50% of pons), and no prior radiation therapy or chemotherapy. Patients with HGG were required to have inoperable disease or residual disease after initial resection. Patients were required to have a performance score (Lansky or Karnofsky)≥60, ability to swallow capsules, and adequate bone marrow function with absolute neutrophil count (ANC)≥1000/μl and platelets≥100,000/μl. Females of child-bearing potential and sexually active males were required to commit to abstinence from heterosexual intercourse or utilize two methods of birth control prior to study entry and for the duration of study participation.","Patients with overt renal, hepatic, cardiac or pulmonary disease, known/suspected coagulation disorder, history of Toxic Epidermal Necrosis or Stevens-Johnson syndrome, need for spinal radiation therapy (e.g. cord compression), and those pregnant or breastfeeding were excluded.",the time from the frst dose of lenalidomide through 2 weeks post-radiation completion,NA
24914044,NCT00975806,Combination,No,patients with advanced or metastatic renal cell carcinoma,"Patients aged ≥18 years with histologically confirmed unresectable or metastatic RCC were eligible to participate. RCC of any histological subtype was allowed in phase I, whereas the phase II portion would include patients with clear-cell component RCC only. Documented clinical or radiographic evidence of unresectable or metastatic disease was mandatory. Patients were required to have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of ≤1 and to be chemotherapy-naive. In phase I, patients were allowed prior treatment with tyrosine kinase inhibitors or bevacizumab, as long as treatment was completed 14 or 28 days before study entry, respectively. Furthermore, patients were required to have no active brain metastases and adequate organ function defined as: absolute neutrophil count ≥1.5 × 103/mm3; hemoglobin ≥9 g/dl; platelet count ≥100 × 103/μl; serum creatinine ≤2.5 mg/dl; aspartate transaminase and alanine transaminase ≤3× ECOG PS (ULN) or ≤5× ULN in patients with liver metastases; and total bilirubin ≤2.0 mg/dl. ","Any patient with, or with a history of, uncontrolled hypertension (blood pressure >160/90 mmHg), venous thromboembolism, arterial thrombotic events, unstable angina, myocardial infarction, clinically significant peripheral artery disease, congestive heart failure, ≤50% left ventricular ejection fraction, or peripheral neuropathy was excluded.",during the first cycle of therapy,NA
19499221,NA,Single Drug,No,recurrent glioblastoma multiforme,"Patients were eligible for study enrollment if they were >=18 years of age with a histologically-conWrmed diagnosis of GBM in Wrst relapse following either radiotherapy (RT) alone or RT with concurrent/adjuvant chemotherapy. Patients were required to be at least 6 weeks since their last RT and/or chemotherapy treatment and at least 2 weeks since surgery for recurrent tumor. Residual disease measuring at least 1 x 1 cm on contrast-enhanced CT or MRI was required. Eligible patients had an ECOG status of 0–2 and adequate cardiac, renal, liver and hematologic function [absolute neutrophil count >=1.5 x 109 L-1, platelet count >=100 x 109 L-1, serum creatinine <1.5 x upper limit of normal (ULN), AST and ALT <=2.5 x ULN, serum total bilirubin <ULN, and LVEF >=50%].",Patients were excluded for other underlying signiWcant medical problems or pregnancy.,during cycle 1 of therapy,NA
28622959,NCT01460940,Combination,No,Patients With Relapsed or Refractory Hodgkin Lymphoma,"Patients 18 years of age and older with classical or LP HL ac- cording to World Health Organization criteria13 previously treated with (at least) 1 previous cytotoxic chemotherapy were eligible. Previous autologous or allogeneic stem cell transplantation was permitted. Patients were permitted to have received previous panobinostat or lenalidomide. Additional eligibility criteria included measurable disease > 1 cm, left ventricular ejection fraction >= 45%, Eastern Cooperative Oncology Group performance status of 0 to 2, absolute neutrophil count >= 1200/uL, platelets > 100,000/uL, aspartate transaminase and alanine transaminase <= 2.5 times the upper limit of normal (ULN), bilirubin <= 1.5 times the ULN, and creatinine clearance >= 60 mL/minute using the Cockcroft-Gault calculation","Patients with any of the following conditions: pregnancy or nursing, HIV or hepatitis B or C, central nervous system lymphoma, preexisting gastrointestinal disease that could impair drug absorption, history of cardiac arrhythmia, or QTc on screening electrocardiogram > 450 ms were not eligible",during cycle 1,NA
27126994,NCT01791478,Combination,No,ER+/HER2- Metastatic Breast Cancer,"The patient population included postmenopausal patients with histologically confirmed ERþ/HER2 metastatic breast cancer refractory to at least one line of endocrine therapy in the metastatic setting, or diagnosed with metastatic breast cancer during or within 1 year of adjuvant endocrine therapy; evaluable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST); age >=18 years; life expectancy >=6 months; ECOG performance status <=1; adequate bone marrow, hepatic, and renal function; and fasting plasma glucose levels <=140 mg/dL (7.8 mmol/L). A tumor specimen (primary or metastatic) from archival material or a fresh biopsy was required for study enrollment.","Key exclusion criteria were CYP3A4 modifier drug treatment <=2 weeks before starting alpelisib, clinically manifested diabetes mellitus, and prior treatment with PI3K inhibitors. Prior treatment with everolimus was allowed.",in the first treatment cycle,NA
21556801,NA,Combination,No,women with advanced epithelial ovarian carcinoma,"After providing informed consent, women with histologically or cytologically confirmed advanced ovarian or primary peritoneal carcinoma with radiographic or clinical evidence of measurable disease (>=2 cm in diameter) were enrolled. To be eligible, women had to have disease progression or recurrence following first-line therapy with a platinum agent and paclitaxel plus an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.","Patients were ineligible if they had any of the following: inadequate hematological counts [absolute neutrophil count (ANC) <1,500 cells/mm3 or platelet count <100,000 cells/mm3]; abnormal renal or hepatic function [serum creatinine >1.5 mg/dl, serum aspartate transaminase (AST) or alanine transaminase (ALT) >3.0 times the upper limit of normal, or serum total bilirubin >2.0 mg/dl]; more than one prior chemotherapy regimen (with the exception of patients with platinum-sensitive disease who were retreated with a platinum-containing regimen); prior grade >=3 rash or any desquamating rash while taking thalidomide; prior grade >=3 allergic reaction/hypersensitivity to thalidomide; use of any standard or experimental anticancer drug therapy within 28 days of the initiation of study drug; or known active hepatitis C.",during cycle 1,NA
12569301,NA,Combination,No,pretreated patients with advanced colorectal cancer,"Enrolled patients were required to have unresectable local advanced or metastatic colorectal cancer. The eligibility criteria for patients included histologically confirmed colorectal adenocarcinoma, age >=18 and <=75 years, bidimensionally measurable (at least 1.5 x 1.5 cm2) disease, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2. Additional criteria included adequate bone marrow (neutrophils >=1500/mm3; platelets >=100 000/mm3), liver and renal functions (GOT and GPT <=5 x upper normal limit, serum bilirubin <=2.0 mg/dl and serum creatinine <=2.0 mg/dl). Progression during or within 6 months of 5-FU/LV chemotherapy for advanced disease or during 5-FU-based adjuvant therapy must have been documented. Patients who had been treated using the 5-FU/irinotecan regimens as first- or second-line chemotherapy were also eligible. Prior radiotherapy was allowed, provided the indicator lesion was outside the radiation port and at least 3 weeks had elapsed since completion of radiotherapy.","Patients with active infection, concurrent major systemic disease or history of any other malignancy (except appropriately treated, localized cervical or epithelial skin cancer) were excluded.",during the first two treatment cycles,NA
22451423,NCT01042704,Combination,No,patients with relapsed or refractory multiple myeloma,"Eligible patients had relapsed or refractory MM, were 18 years of age or older, had an Eastern Cooperative Oncology Group performance status of 0 to 2, and had an expected survival greater than 6 months. All patients had symptomatic MM and had previously been treated with at least 1 line of therapy, after which the patient had progressive or refractory disease. Prior lenalidomide and/or autologous SCT were permissible. Patients had to have a total white blood cell count of at least 2 x 109/L with an absolute neutrophil count of at least 1 x 109/L, hemoglobin of at least 9 g/dL, platelet count of at least 75 x 109/L, international normalized ratio 2 or 3 if on anticoagulation, total bilirubin less than or equal to 2.5 mg/dL, aspartate aminotransferase and alanine aminotransferase less than or equal to 5 times the institutional upper limit of normal, and creatinine less than 2.5 mg/dL. All patients gave written, informed consent before enrollment in the study.","Patients were excluded if they had nonsecretory MM, central nervous system involvement, other malignancy within 2 years before enrollment (excluding squamous/basal cell carcinoma of the skin or carcinoma in situ of the cervix), myocardial infarction within 6 months before enrollment or New York Heart Association class III or IV heart failure, prior allogeneic SCT, or allergic reaction to compounds of similar chemical or biologic composition to bendamustine or lenalidomide. In addition, patients were excluded if they received chemotherapy, radiotherapy (except in cases of severe bone pain or impending pathologic fracture), or investigational agents within one month of starting BLD. ",during the first cycle of therapy,NA
20956622,NA,Single Drug,No,relapsed or refractory acute leukemias,"Egibility Criteria and Study Design This study enrolled adult patients ( >=18 years old) with relapsed/refractory non-M3 AML or acute lymphoblastic leukemia (ALL). Patients were required to have total bilirubin <= 2 x upper limit of normal, creatinine <= 2.0mg/dL, ALT/AST <= 5 x upper limit of normal, left ventricular ejection fraction at least 40%, and Eastern Cooperative Oncology Group performance status <= 2. Active infection was permitted if controlled. Informed written consent approved by The Ohio State University Human Studies Committee was obtained for all patients before study entry",NA,cycle 1 of therapy,NA
15060739,NA,Single Drug,No,"patients with solid tumors. Disease: Colon adenocarcinoma, Rectal adenocarcinoma; Other major sites of disease: Liver, Lung","Patients with histologically (or cytologically) confirmed solid tumors (excluding primary CNS neoplasms) refractory to conventional therapy or for which no conventional treatment existed were eligible for the study. Detailed eligibility criteria also included age >=18 years; ECOG performance status (PS) of 2 or better; life expectancy greater than 3 months; adequate hematologic, hepatic, and renal functions determined by an absolute neutrophil count >=1.5x109/l, platelets >=100x109/l, total bilirubin not more than 1.5 times normal, SGOT and SGPT not more than 2.0 times normal (or not more than 5.0 times normal with hepatic metastases), and serum creatinine <= 2.0 mg/dl. Measurable or evaluable disease was required. Signed informed consent was obtained prior to enrollment",NA,NA,NA
12384400,NA,Single Drug,No,patients with relapsed multiple myeloma,"Patients with relapsed and/or refractory MM were eligible and must havefailed to respond to at least 2 prior regimens of treatment. Patients were considered refractory if they had progressive disease by Southwest Oncology Group (SWOG) criteria (an increase by more than 100% of the lowest level of protein production). Relapse following a remission was defined by SWOG criteria as any of the following: (1) more than 25% increase in M protein from baseline levels, (2) reappearance of M paraprotein, or (3) a definite increase in the size and number of lytic bone lesions recognized on radiographs (compression fractures per se did not constitute a relapse). Prior therapy with Thal was allowed, provided that it was tolerated.",Exclusion criteria included a prolonged QT interval (> 430 ms); predisposition to cardiac arrythmias; concomitant medications known to prolong the QT segment; at least grade 3 peripheral neuropathy; inadequate renal function (serum creatinine > 1.5 mg/dL); evidence of mucosal or internal bleeding; thrombocytopenia (platelets < 50 x 109/L [50 000/uL]); neutropenia (absolute neutrophil count < 1 x 109/L [1000/ uL]); pregnant or lactating women; and women of childbearing potential who were not using adequate contraception.,during the first 28 days,NA
25617965,NCT01093183,Combination,No,"patients with metastatic, castration-resistant prostate cancer","The inclusion criteria were as follows: Men with histologically confirmed prostate cancer who progressed after optimal, first-line, androgen-deprivation therapy with luteinizing hormone releasing hormone (LHRH)-agonist drugs, total androgen-blockade therapy, or orchiectomy and at least one-line chemotherapy docetaxel, were eligible for the trial. Patients were required to have adequate renal, hepatic, and hematological parameters defined as creatinine clearance >45 mL/min by Cockcroft-Gault formula; total bilirubin < upper limits of normal (ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), and hepatic alkaline phosphatase (ALP) <2 x ULN (<5.0 x ULN for subjects with known bone metastases); absolute neutrophil count greater than 1,500/mm3; platelets greater than 100,000/mm3; and, a hemoglobin >=9.0 g/dL.","Treatment with a cytotoxic chemotherapy or investigational drug within 30 days before day 1 of study treatment; palliative radiation therapy is allowed, as long as a radiated lesion is not used to assess response rate, and the radiation occurred greater than 4 weeks prior to enrollment. Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C or active hepatitis. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. Known hypersensitivity to thalidomide, lenalidomide or cyclophosphamide. Active infection at the start of lenalidomide. Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any EKG abnormality at screening has to be documented by the investigator as not medically relevant. History of life threatening or recurrent thrombosis/embolism; patients may participate if they are adequately anti-coagulated during the treatment. Patient has > grade 2 peripheral neuropathy within 14 days before enrollment. Any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease). Any unresolved chronic toxicity greater than Common Terminology Criteria (CTC) grade 2 from previous anticancer therapy (except alopecia). Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the trial",in the first cycle,NA
20724537,NCT00621400,Combination,No,patients with newly diagnosed AL amyloidosis,"Patients from 18 to 70 years with a diagnosis of de novo AL amyloidosis, including measurable hematologic and amyloid-related end-organ involvement, were eligible. The diagnosis of AL-amyloidosis required a histologic tissue diagnosis of amyloid deposition proven by Congo red staining of a tissue biopsy, plus proof of plasma cell dyscrasia (measurable M-protein in serum or urine by immunofixation or electrophoresis, and/or elevated free light chain [FLC] higher than 100 mg/L and an abnormal FLC ratio). Adequate organ function defined as absolute neutrophil count > 1.0 x 109/L, platelet count > 100 x 109/L, aspartate transaminase (AST) and alanine transaminase (ALT) < 2 x upper normal limit, total bilirubin < 1.5 mg/dL, creatinin serum level < 150 uM, and ECOG performance status of < 2 at study entry were required. For females of childbearing potential a negative serum or urine pregnancy test at screening visit, as well as within 24 hours of starting lenalidomide, was mandatory. All patients were counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure due to lenalidomide therapy. Patients had to be disease free from any prior malignancies for > 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.","Patients were excluded if they had symptomatic multiple myeloma, if they had received prior treatment with lenalidomide or any other experimental drug within 28 days of baseline, or any prior treatment for amyloidosis, if they were known positive for HIV or infectious hepatitis, type A, B, or C. Pregnant or breast feeding females were excluded. There was no eligibility restriction for any degree of cardiac involvement.",during the first cycle of lenalidomide,NA
26284823,NCT02302469,Single Drug,No,Waldenström macroglobulinemia,"Age >=18 years. Patients must have received prior therapy (any number of therapies) for WM and have relapsed or refractory WM. Eastern Cooperative Oncology Group performance score of 0 - 2. Hemoglobin >= 10g/dL or hematocrit >= 30%. Absolute neutrophil count (ANC) >1000/mm3 and platelet count >75,000/mm3. Adequate organ function defined as: serum glutamate pyruvate transaminase and serum glutamate oxaloacetate transaminase < 2 x International Unit/l, Total bilirubin >= 1.5 mg/dL, Clearance creatinin > 50 ml/mn. Evaluable immunochemical abnormalities including abnormal electrophoresis and serum free light chain assay with an increase of either kappa or lambda light chain lev -","Any other uncontrolled medical condition or comorbidity that might interfere with subject's participation. Patients treated or requiring corticosteroids >30mg/day. Pregnant or breast feeding females (Lactating females must agree not to breast feed while taking lenalidomide). Use of any other experimental drug or therapy within 28 days of baseline. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. Known positive for HIV or infectious hepatitis, type A, B or C -",NA,NA
27354719,NCT00963534,Combination,No,patients older than 65 years with untreated mantle cell lymphoma,"Patients were eligible if they were >65 years or <=65 years but unable to tolerate high-dose chemotherapy, with a confirmed diagnosis of MCL stage II to IV and World Health Organization Performance status 0-3, requiring treatment as a result of at least one of the following symptoms: bulky disease, nodal or extra nodal mass >7 cm, B– symptoms, elevated serum lactate dehydrogenase, involvement of >=3 nodal sites (each with a diameter >3 cm), symptomatic splenic enlargement, compressive syndrome, or pleural/peritoneal effusion. Further, patients should not have received any previous treatment (1 cycle of chemotherapy and/or radiotherapy was accepted).","Impaired liver function. ANC less than 1.0 x 10 9, unless caused by bone marrow infiltration by lymphoma. Platelet count less than 60 x 10 9, unless caused by bone marrow infiltration by lymphoma. Creatinine clearance below 50 ml/min (cockcroft formula)). Known HIV positivity. Known seropositivity for HCV, HBsAG, anti-HBc, or other active infection uncontrolled by treatment. Psychiatric illness or condition which could interfere with the subject´s ability to understand the requirements of the study. Requirement of corticosteroid therapy at a dose over 10 mg prednisolone/day. Pregnant or lactating females",within the first 2 cycles of LBR,NA
23692564,NA,Combination,No,relapsed or refractory multiple myeloma,"Patients with relapsed (first or second relapse only) or refrac-tory MM were entered into the study provided that they wereaged above 18 years, had an Eastern Cooperative OncologyGroup performance status of 0–2, and an expected survival ofat least 3 months. Relapse was defined as evidence of progres-sive disease (PD) after at least a PR achieved by any precedingtherapy, whereas refractory disease was defined as progressionwhile on treatment or within 60 d after its completion. Allpatients had histologically or cytologically proven stage II orIII MM according to the Durie–Salmon criteria (Durie &Salmon,  1975),  with  quantitatively  measurable  myelomaproteins in the serum and/or urine using protein electropho-resis. Patients also had to have a total neutrophil count of atleast 1. 5 x 109/l and a platelet count of at least 100 x 109/l.Further eligibility criteria were creatinine clearance >=50 ml/min [estimated Glomerular Filtration Rate (eGFR) using theModification of Diet in Renal Disease (MDRD) formula (Leveyet al, 1999)], total bilirubin 25-65umol/l and aspartate amino-transferase (AST) and alanine aminotransferase (ALT) <= x2the upper limit of normal. While in the study, women of childbearing ageand men had to consent to follow adequate birth controlmeasures and women had to abstain from breastfeeding. Allpatients gave written, informed consent before enrolmentinto the study, and were free to withdraw from the study atany time. ","Patients were excluded from the study if they had uncon-trolled or severe cardiovascular disease, including myocardialinfarction within 6 months before entry into the study, New York Heart Association Class III or IV heart failure, uncon-trolled angina pectoris or severe uncontrolled ventriculararrhythmias (>=Lown 3) and contraindications for treatmentwith lenalidomide, bendamustine or prednisolone.Patients who tested positive for human immunodeficiencyvirus or hepatitis B surface antigen or had a history ofanother malignancy diagnosed within 5 years prior to enrol-ment (excluding squamous/basal cell carcinoma of the skinor carcinomain situof the cervix or breast) were also con-sidered ineligible. In addition, pre-treatment with bendamus-tine or lenalidomide in the previous 6 months and knownhypersensitivity to thalidomide were also part of the exclu-sion criteria.",during thefirst two cycle,NA
31126332,NCT02619162,Combination,No,early breast cancer,"Females ≥ 18 years old were eligible for enrollment if they had a hormone receptor-positive breast tumor (defined as positivity for the ER and/or PR in > 5% of tumor cells tested at the local pathology department) > 1 cm in size that had been adequately treated within less than 6 months prior to registration and were amenable to receiving the aromatase inhibitor letrozole as a part of their adjuvant treatment. Patients had to be post-menopausal according to any of the following criteria: (1) women of any age who had a bilateral oophorectomy (including radiation castration and confirmed by subsequent amenorrhea for > 3 months) and were amenorrheic for > 3 months, (2) women that had spontaneous cessation of menses for ≥ 12 consecutive months, (3) women that had FSH, LH, and 17-B-estradiol levels in postmenopausal ranges without an alternative cause. A minimum of 4 weeks and a maximum of 24 weeks between the last treatment procedure (chemotherapy and/or radiation therapy; 6 weeks from major surgery) and registration were allowed. Patients had to have been taking letrozole for at least 4 weeks prior to registration. Other inclusion criteria included the following: an ECOG performance status of 0–1; adequate liver, renal, and hematologic function (defined as serum bilirubin < 1.25-fold the upper limit of normal [ULN], AST/ALT < 1.25-fold the ULN, serum creatinine < 1.5-fold the ULN or creatinine clearance < 50 mL/min, hemoglobin > 10 g/dL, a platelet count > 100 × 109/L, and a granulocyte count > 1.5 × 109/L), and LVEF > 50%.","Patients who had not recovered from previous toxicity to a tolerable grade of ≤ 2, who had bilateral tumors, who had concurrent severe conditions, who were taking anticoagulants, or with a history of clinically significant bleeding or thromboembolic events within 6 months of study entry were excluded from the study.",during the first treatment cycle,NA
22640031,NCT00415064,Combination,No,relapsed and relapsed/refractory multiple myeloma,"Eligible  patients  were >=18 years  old  with  relapsed  orrelapsed/refractory, measurable MM that required a second-or third-line of therapy. Patients with refractory disease weredefined as progressing on treatment or within 60 d of lasttreatment; patients refractory to thalidomide or thalidomide–dexamethasone were eligible. Patients who had been treatedpreviously with either lenalidomide or dexamethasone werealso eligible, unless they were refractory to lenalidomide–dexamethasone. Additional eligibility criteria included anEastern Cooperative Oncology Group (ECOG) performancestatus of 0–2, adequate liver function (defined as aspartateaminotransferase,  alanine  aminotransferase,  and  alkalinephosphatase <=3 times upper limit of normal, and bilirubin <=upper limit of normal) and renal function (serumcreatinine <=51·3lmol/l),   an   absolute   neutrophilcount>=1·0x109/l,  and  a  platelet  count>=75x109/lwithin 14 d prior to enrolment.",NA,NA,NA
31074316,NCT01400685,Combination,No,previously untreated patients with chronic lymphocytic leukemia,"Inclusion criteria for this phase I dose-escalation study included: age 18 years, Eastern Cooperative Oncology Group (ECOG) performance status <=2, life expectancy >=3 months, confirmed CLL/SLL based on standard histologic/immunophenotypic criteria described in the WHO classification of lymphoid malignancies, measurable disease (defined as lymphocytosis 5000 cells/ll, palpable or CT measurable lymphadenopathy >=2 cm, or bone marrow involvement >= 30%), and no prior systemic therapy for CLL/SLL (radiation or prior participation in investigational studies of immune modulation or vaccination was permissible if completed >=3 months prior to initiation of protocolbased therapy). All patients had to meet criteria for initiation of treatment based on IWCLL 2008 guidelines, be able to take prophylactic aspirin 81 mg daily (aspirin 325 mg daily, warfarin, or low molecular weight heparin permitted as alternative), and have adequate organ function (creatinine <=2 mg/dl or creatinine clearance >50 ml/min/1.73 m2, total bilirubin <=2 x ULN, and transaminases <=3 x ULN) and bone marrow function (absolute neutrophil count >= 500/ml and platelet count >=50,000/ml). ","We excluded patients with concurrent pregnancy or breastfeeding, evidence of laboratory TLS by Cairo–Bishop definition unless corrected prior to enrollment, HIV infection, uncontrolled concurrent medical problems, any prior use of lenalidomide or of any experimental drug or therapy within 28 d, known hypersensitivity to thalidomide, and unrelated prior malignancies unless disease free for at least 2 years (non-melanoma skin cancer or in situ cervical or breast cancer was eligible).",during cycles 1 and 2,NA
33674736,NCT01665183,Combination,No,"patients with pretreated metastatic melanoma or other advanced solid malignancies. Tumour history: Hepatocellular, HCC + biliary tract carcinoma, Ovarian carcinoma, Cutaneous melanoma, Uveal Melanoma, Others","Patients 18 years of age or older were eligible for the study if they had a histologically confirmed advanced solid tumour. Additional criteria included an Eastern Cooperative Oncology Group performance status of 0 or 1 and adequate haematological, hepatic and renal function, defined by creatinine clearance of at least 55 mL/min, AST and ALT less than 2.5 × the upper limit of normal, total bilirubin ≤1.2 mg/dl, serum uric acid ≤8 mg/dL, platelets greater than 75,000 cells/mm3, and absolute neutrophil count of 1500 cells/mm3. Specific criteria for patients with HCC alone or with coexistent BTC included intact hepatic function with a Child-Pugh score of A-B7. ","Exclusion criteria included systemic anticancer therapy within 4 weeks of study entry, active bleeding within the prior 3 months, uncontrolled or progressing brain or spinal cord metastases, significant concomitant or uncontrolled intercurrent illness, allergy to platinum or to pegylated or Escherichia coli products, and previous ADI-PEG20-based therapy.",within the initial 28 days of study entry,NA
27531679,NCT01615029,Combination,No,relapsed multiple myeloma,"In the dose-escalation phase (part 1), eligible patients had relapsed MM after 2 to 4 prior lines of therapy, were 18 years of age or older, had an Eastern Cooperative Oncology Group performance status of 2 or less, and had measurable levels of M-component (serum M-component >=1.0 g/dL or urine M-component >=200 mg/24-hour sample). In the dose-expansion cohort (part 2), patients had received at least 1 line of MM therapy, achieved a partial response (PR) or better to at least 1 regimen, and had documented evidence of progressive disease as defined by International Myeloma Working Group criteria on or after their last regimen","Patients were excluded if they had previously received an allogeneic stem cell transplantation (SCT) at any time or autologous SCT within 12 weeks of the first infusion, or antimyeloma treatment, radiotherapy, or any experimental drug or therapy within 2 weeks of the first infusion. Patients with clinical signs of meningeal involvement of MM or who had experienced prior grade 3 or higher deep vein thrombosis or pulmonary embolism were ineligible. Severe chronic obstructive pulmonary disease (forced expiratory volume in 1 second < 60% of predicted normal) or persistent asthma were exclusionary.",NA,NA
12853359,NA,Combination,No,"patients with organ dysfunction. Diagnosis: Pancreatic, Hepatocellular, Colorectal, Renal, Bladder, Unknown primary, Cholangiocarcinoma, Ovarian, Breast, Other ","Adult patients (≥18 years) with a histologically confirmed solid tumor that had not responded to standard treatment, for which no standard treatment existed, or for which treatment had been withheld due to elevated bilirubin or creatinine levels, were eligible for this study. Other eligibility criteria included WHO performance status 0–2, life expectancy ≥2 months and measurable or evaluable disease. At least 4 weeks were to have elapsed since prior antineoplastic chemotherapy, hormonal therapy, or radiation therapy, and at least 8 weeks since administration of mitomycin or nitrosoureas. Other eligibility criteria were absolute neutrophil count ≥500/μl, platelet count ≥100000/μl and hemoglobin ≥8 g/dl. Patients had to fit into one of three organ dysfunction groups: cohort I, creatinine >1.5 mg/dl (133 μmol/l) but ≤3.0 mg/dl (265 μmol/l), and normalbilirubin (high creatinine group); cohort II, bilirubin >1.5 mg/dl (26 μmol/l) but <5.0 mg/dl (86 μmol/l), with normal creatinine (intermediate bilirubin group); or cohort III, bilirubin ≥5.0 mg/dl (86 μmol/l) with normal creatinine (high bilirubin group). An implanted or tunneled central venous catheter was required. The University of Chicago Institutional Review Board approved the protocol. Written informed consent was obtained from all patients enrolled in the study.","Exclusion criteria included concomitant use of steroids or dipyridamole, significant cerebellar dysfunction or uncontrolled angina, and brain metastases, unless the patient was asymptomatic and off all therapy.",in cycle one,NA
12796032,NA,Combination,No,"patients with advanced solid tumors. Diagnosis: Colorectal cancer, Gastric cancer, Esophageal cancer, Head and neck cancer, Gallbladder cancer, Other","Eligibility criteria included histological evidence of advanced solid tumor, refractory to standard therapy or no standard therapy available; or a tumor type for which 5-FU/LV was appropriate therapy; at least 4 weeks since any previous antitumor therapy; age ≥18 years; neutrophil count ≥1.5 × 109/l; platelets ≥100 × 109/l; hemoglobin ≥5.6 mmol/l; serum creatinine <200 μmol/l; bilirubin <26 μmol/l; aspartate aminotransferase and alanine aminotransferase <3 × upper limit of normal (or <5 × in case of liver metastases); cholesterol <9 mmol/l; triglycerides <3.4 mmol/l; Eastern Cooperative Oncology Group (ECOG) performance status 0–2; and written informed consent.","Patients with symptomatic brain metastases, serious concomitant conditions, or pregnant/ nursing females were excluded. ",at least a total of 9 weeks of completed treatment with all three drugs,NA
11948111,NA,Combination,No,"patients with advanced cancer. The majority of patients (eight patients) had colorectal cancer; however, other tumor types included unknown primary adenocarcinoma (two patients) and gallbladder (one patient), ovarian (one patient), breast (one patient), pancreatic (one patient), and esophageal tumors (one patient). ","Patients eligible for this study included those with a histological diagnosis of cancer for which no effective therapy was available or that was unresponsive to conventional therapy. Patients were >=18 years of age with an ECOG performance status of <=2 and a life expectancy of >=12 weeks. Patients with measurable or evaluable disease were eligible. All patients were required to have fully recovered from toxicity of prior therapies and could not have received chemotherapy <=28 days before study entry. Organ function and laboratory requirements included the following: ANC > 1500 cells/mm3; platelet count > 100,000 cells/mm3; hemoglobin concentration > 9.0 g/dl; normal blood coagulation as assessed by PT, International normalized ratio, and aPTT; serum creatinine <=1.5 mg/dl; serum bilirubin <= 1.5 mg/dl; and serum AST and ALT < 2.5 times the upper limit of normal (or <5 times normal in the presence of hepatic metastases).",Patients were specifically excluded if they (a) had an underlying disease state associated with active bleeding or (b) had a history of coagulopathy or complement abnormality or were receiving therapeutic doses of anticoagulants such as heparin or warfarin.,the first cycle,NA
29237802,NCT01750983,Combination,No,"Patients with Advanced Cancers. The most frequently treated tumor types were Hodgkins lymphoma (n = 7, 19%), melanoma (n = 5, 14%), Thyroid cancer, Adrenocortical cancer, Adenoid cystic cancer, Renal cancer, leiomyosarcoma (n = 4, 11%), and other (cervical, colorectal, peritoneal, ovarian, triple-negative breast, squamous cell head and neck, chondrosarcoma, osteosarcoma, carcinosarcoma, and teratoma).","Patients with advanced or metastatic cancers with no available standard therapy are eligible to enter the Phase 1 portion of this study. Patients must be >/= 18 years. Patients must be >/= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery. A confirmation (written or verbal) that there is no risk of surgical complications from a patient's surgeon has to be obtained prior to starting therapy in patients with a history of major surgery within past 6 weeks. Patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol. For biologic/targeted agents patients must be >/= 5 half-lives or >/= 3 weeks form the last dose (whichever comes first). ECOG performance status </= 2. Patients must have adequate organ and marrow function defined as: absolute neutrophil count >/= 1,000/mL platelets >/=50,000/mL; CrCl >/=60mL/min by Cockcroft -Gault calculation; total bilirubin </= 2x ULN (exceptions may apply to benign non-malignant indirect hyperbilirubinemia such as Gilbert syndrome); ALT(SGPT) </= 5X ULN; willingness to participate in the RevAssist® program. Females: two effective contraceptive methods should be used during therapy, during therapy interruptions, and for at least 4 weeks after completing therapy. Males: must always use a latex condom during any sexual contact with females of childbearing potential, even if they have undergone a successful vasectomy. Patients must be able to understand and be willing to sign a written informed consent document.","Uncontrolled intercurrent illness, including, but not limited to, uncontrolled infection, uncontrolled asthma, need for hemodialysis, need for ventilatory support. Pregnant or lactating women. History of hypersensitivity to ipilimumab. History of hypersensitivity to lenalidomide. Patients unwilling or unable to sign informed consent document. Patients on hemodialysis. History of organ transplantation. History of autoimmune disease, including inflammatory bowel disease. History of severe motor or sensory neuropathy, or any other autoimmune disorder which is deemed to be significant. Patients with a prior history of Grade 4 rash associated with thalidomide treatment. History of Angioedema.",during the first cycle (28 days) of therapy,NA
20859231,NA,Combination,No,patients with metastatic melanoma previously untreated with systemic chemotherapy,"Patients ( >= 18 years of age) with histologically confirmed, measurable, unresectable stage III or IV melanoma (according to the 2002 American Joint Committee on Cancer staging criteria) were enrolled. Eligible patients were required to have an Eastern Cooperative Oncology Group performance status of 0–2; absolute neutrophil count >= 1500 cells/ml; platelet count >= 100 000/ml; serum total bilirubin and creatinine <= 1.5 mg/dl; and serum glutamic-oxaloacetic transaminase and glutamicpyruvic transaminase less than or equal to 2 times the upper limit of normal. All the patients had undergone MRI or computed tomography (CT) of the brain, and patients with evidence of brain metastases were excluded.","The patients were excluded if they had a history of cardiac disease or had other concurrent malignancy with the exception of nonmelanoma skin or insitu cervical cancer. The patients were also excluded if they had received earlier treatment with systemic chemotherapy. Earlier treatment with immunotherapy, thalidomide, or radiotherapy for metastatic melanoma was allowed but must have been completed at least 2 weeks before study treatment, with resolution of any toxic effects. The patients who had a history of a grade 2 or higher allergic reaction to thalidomide or desquamating rash while taking thalidomide were ineligible. Pregnant or lactating women were ineligible, and a negative pregnancy test was required immediately before treatment and every 4 weeks for all women capable of becoming pregnant.",during the first two cycles,NA
11432626,NA,Combination,No,pretreated patients with advanced colorectal cancer,"The elegibility criteria included, age <= 75 years, histologically proven MCRC, progressive disease while treated with fluoropyrimidines, bidimensionally measurable disease, performance status <=2 (ECOG scale); predicted life expectancy at least three months: adequate hematological, hepatic, renal and cardiac function; no brain metas- tases or second malignancies or uncontrolled metabolic disorders and active infections. The study was approved by the local ethical committee and written informed consent was obtained from each patient",NA,during the first treatment cycle,NA
22240778,NA,Combination,No,patients with locally advanced or metastatic breast cancer overexpressing HER2,"Patients eligible to this phase-I dose-escalation multicentre trial were women 418-year-old with histologically confirmed HER2- overexpressing locally advanced or metastatic breast cancer. HER2 overexpression was defined by a 3 + immunohistochemistry score, or a 2+ score with positive fluorescence in-situ hybridisation. Patients were to have received one or two lines of chemotherapy with trastuzumab, in adjuvant or metastatic setting. Trastuzumab was to be stopped at least 3 weeks before study entry. Additional inclusion criteria were a WHO performance status ranging from 0 to 2, adequate hematological, hepatic, cardiac and renal functions.","Ineligibility criteria included concomitant treatment by cytochrome P450 3A4 modulators (inhibitors or inducers) or pH modifying agents, significant gastrointestinal troubles affecting oral intake and prior treatment with VNR. ",during cycle 1 ,NA
21307147,NA,Combination,No,refractory solid tumors,Patients 18 years of age or older with advanced solid tumors not amenable to any clinical improvement by current standard therapies and suitable for cisplatin were enrolled. Additional eligibility requirements included: ECOG performance status of 0 to 1; absolute neutrophil count >1.5  109/L; platelet count >100  109/L; total bilirubin <1.5  upper limit of normal (ULN); aspartate and alanine aminotransferase <2.5  ULN in absence of liver metastasis or <5  ULN in presence of liver metastasis; serum creatinine <1.5  ULN. ,"Patients with significant cardiac, infectious, or peripheral vascular diseases were excluded, and patients completing systemic therapy within 4 weeks or having surgery or receiving corticosteroids within 2 weeks before treatment start. Patients with brain metastases were cautiously excluded because at the time of study design the risk of tumor-associated hemorrhage using an antivascular agent was unknown (23). ",during the first cycle,NA
12439334,NA,Combination,No,patients with recurrent rectal cancer,"Patients, 18 years and older, with recurrent rectal cancer were eligible for the study, if histologically proven relapsing tumor was inoperable and provided for primary radio-chemotherapy. Further eligibility requirements included: a performance status <= 2 according ECOG criteria, a projected life expectancy >=3 months, adequate renal and liver organ function, adequate hematological function with a white blood count >4000/ul, and a platelet count of >100 000/ul, no prior radiotherapy, no previous treatment with 5-FU and/or 5-FU analogs within the last 6 months, localized disease without dissemination, and no previous history of malignant disease within 5 years of study entry other than skin or cervical cancer.",Patients suffering from any known cardiac disease were excluded.,during treatment period,NA
29427149,NA,Combination,No,children with relapsed or refractory central nervous system tumors,"Children aged 1–21 years with refractory or progressive primary CNS tumors for which there were no standard treatment options were eligible. Histological confirmation was required, except for patients with brainstem or optic pathway glioma. Inclusion criteria included performance status >50 (Karnofsky or Lansky for patients>or ≤16 years, respectively), life expectancy ≥8 weeks, and adequate bone marrow function (absolute neutrophil count ≥1000/µL, platelet count≥100 000/µL, hemoglobin ≥8.0 g/dL), renal function (age-adjusted normal serum creatinine or glomerular filtration rate ≥70 mL/min/1.73 m2), and liver function (total bilirubin ≤2x and aspartate and alanine aminotransferase ≤3x institutional upper limit of normal for age). Patient must not have received marrow suppressive chemotherapy within 4 weeks (6 weeks for nitrosureas), biologic agents within 2 weeks, focal irradiation within 1 month, and craniospinal irradiation or autologous hematopoietic cell transplantation within 3 months prior to enrollment.","Exclusion criteria included concurrent use of enzyme-inducing anticonvulsants or anticoagulant therapy, evidence of intratumoral hemorrhage, gastrointestinal bleeding, pregnancy or lactation, and a history of coronary artery disease.",4 weeks (1 cycle),NA
20713864,NA,Combination,No,children with refractory CNS malignancies,"Eligible patients were age <= 21 years with a histologically verified malignant CNS tumor (histology was not required for diffuse intrinsic pontine gliomas) that was refractory to conventional therapy and had a Lansky or Karnofsky performance score >= 50. Patients were required to have recovered from the acute toxic effects of prior therapy and not to have received any of the following: growth factors within 2 weeks of study entry, myelosuppressive chemotherapy within 3 weeks (6 weeks if prior nitrosourea or mitomycin therapy), craniospinal or total-body irradiation within 3 months, local radiotherapy to the primary tumor within 4 weeks, or focal irradiation to symptomatic metastatic sites within 2 weeks. Patients who were receiving enzyme-inducing anticonvulsants at the time of registration were excluded, as were pregnant or lactating women or patients with uncontrolled infections. Patients who had received CYP3A4 inducers within 7 days or CYP3A4 inhibitors (with the exception of steroids) within 14 days before registration were excluded from the study. Patients in stratum II who were taking corticosteroids must have had a stable or decreasing dose for >= 1 week before registration. Other requirements included adequate bone marrow (peripheral absolute neutrophil count >= 1,000/uL, platelet count  >= 100,000/uL, transfusion independent hemoglobin >= 8.0 g/dL), renal (serum creatinine <= 1.5 x upper limit of normal [ULN] for age, or glomerular filtration rate  70mL/min/1.73 m2), liver (total bilirubin <= 1.5 x institutional ULN for age, ALT <= 2.5 x institutional ULN for age, and albumin >= 2 g/dL), cardiac (shortening fraction >= 27% by echocardiogram or left ventricular ejection fraction > 50% by gated radionuclide study), and pulmonary (no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry  94% if there was clinical indication for determination) function. Patients had to have displayed stable neurologic deficits for at least 1 week. Informed consent was obtained from patients, parents, or guardians, and assent was obtained as appropriate at the time of protocol enrollment. ",NA,Courses 1 and 2,NA
21825263,NA,Combination,No,patients with relapsed multiple myeloma,"Patients were required to have relapsed myeloma after at least one prior therapy (which could have contained CCI-779 or lenalidomide but not both), Eastern Cooperative Oncology Group performance status of 2 or greater, neutrophil count greater than 1.5x109/L, platelet count greater than 100 x 10^12/L, creatinine less than 2 mg/dL, bilirubin less than 1.5 x the upper limit of normal, AST/ALT less than 3 x the upper limit of normal, fasting serum cholesterol less than 350 mg/dL, fasting serum triglycerides less than 400 mg/dL, and all of the following: immunofixation positive serum and/or urine or an abnormal serum free light chain ratio, clonal plasma cells on bone marrow aspirate or core biopsy, and any sign of related organ or tissue impairment attributable to myeloma",Patients with active infections and a history of recurrent venous thromboembolism (VTE) or VTE occurring while receiving therapeutic levels of anticoagulation were excluded.,during cycle one,NA
21149652,NA,Single Drug,No,"pediatric patients with recurrent, refractory, or progressive primary CNS tumors","Patients <= 21 years old with recurrent, refractory, or progressive primary CNS tumors were eligible. Patients were required to have a performance score (Lansky or Karnofsky) of >= 60; be able to swallow capsules; and have adequate bone marrow function with absolute neutrophil count (ANC) >= 1,000/uL, hemoglobin >= 8 g/dL, and platelets >= 100,000/uL.","Patients with overt renal, hepatic, or pulmonary disease; patients at risk for thromboembolic events (ie, history of thromboembolic event unrelated to central line or family history of thrombophilia); and patients who were pregnant or breast-feeding were excluded.",the first treatment course,NA
25666183,NA,Combination,No,"patients with advanced cancer. Diagnosis: Adenoid cystic carcinoma, Melanoma, Other (Renal cell carcinoma, non-small cell lung cancer, breast cancer, colorectal cancer, parathyroid carcinoma, carcinoid tumor, transitional cell carcinoma of bladder)","To enroll in the study, patients had to have an advanced solid tumor for which there is no established standard-of-care therapy or that had not responded to one or more prior therapies. Patients were required to have an eastern cooperative oncology group performance status of 0–2 and the following threshold levels: platelets >50,000/mL, creatinine clearance >20 mL/min, and total bilirubin <5 mg/dL.","Patients were excluded from the study if they had a history of hypertensive crisis or hypertensive encephalopathy; significant vascular disease; evidence of bleeding diathesis or coagulopathy; a history of allergic reactions to the study drugs or their analogs; uncontrolled intercurrent illness, including ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), unstable angina pectoris, symptomatic cardiac arrhythmia, active bleeding, or active thrombosis; psychiatric illness or social situations that might affect compliance with study requirements; failure to recover from any prior surgery within 28 days of study entry; a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or a minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment; or a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment. ",during treatment cycle 1,NA
33075165,NCT02509039 ,Single Drug,No,"adult Japanese patients with advanced malignancies. 14 with NHL (5 DLBCL, 5 FL, 3 PTCL NOS, and 1 AITL) and one with a solid tumor (esophageal carcinoma. AITL, angioimmunoblastic T-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; NHL, non-Hodgkin lymphoma; PTCL-NOS, peripheral T-cell lymphoma not otherwise specified.","All patients provided written informed consent before any study-related procedures were carried out. Patients were ≥  20  years old and had histologi-cal or cytological confirmation of advanced solid tumors or NHL. Patients who had progressed on, or were unable to tolerate, standard anticancer therapy were included, as well as those for whom no other conventional therapy existed. ECOG PS was ≤  2 for  all  patients.  Required  initial  laboratory  values  included Funding informationBristol Myers Squibb Company, Princeton, NJ, USAof avadomide, with an acceptable toxicity profile and clinically meaningful efficacy in Japanese patients with previously treated NHL.KEYWORDSavadomide, CC-122, cereblon, dose-escalation, non-Hodgkin lymphoma, phase I absolute neutrophil count ≥  1.5 ×  109/L, hemoglobin ≥  9  g/dL, platelets ≥  100 × 109/L, AST and ALT ≤  3 × ULN or ≤  5.0 × ULN if liver tumors were present, serum bilirubin ≤  1.5 × ULN, and serum creatinine ≤  ULN or 24-hour clearance ≥  50   mL/m","Key exclusion criteria included primary CNS malignancies or symp-tomatic CNS metastases (patients with previously treated brain metastases and were stable for 6 weeks were allowed); acute or chronic pancreatitis; peripheral neuropathy grade ≥ 2 according to NCI CTCAE version 4.03; persistent diarrhea or malabsorp-tion NCI CTCAE grade ≥  2; impaired cardiac function or clini-cally significant cardiac diseases; prior systemic cancer–directed treatments or investigational modalities ≤  5 half-lives or 4 weeks (whichever was shorter), prior to starting avadomide, or contin-ued side effects of such therapy; and major surgery ≤  2  weeks prior  to  starting  avadomide  or  continued  postoperative  side effects",Cycle 1,NA
34955443,NCT01578954,Single Drug,Yes,older adults with acute myeloid leukemia,"Eligible patients for enrollment were of age ≥ 60 years with AML that had been treated with 1–2 prior courses of initial chemotherapy and were in CR, complete remission with incom- plete hematologic recovery (CRi), partial remission (PR), or had residual AML with ≤1 × 109/L circulating blasts. Initial therapies could include cytarabine plus an anthracycline, DNA methyltransferase inhibitors, or nucleoside analogs. Eastern Cooperative Oncology Group (ECOG) perfor- mance status ranged from 0 to 2. Eligibility included one of the following: patient preference to forego further cytotoxic chemotherapy, therapy re- lated AML, prior myelodysplastic syndrome or myeloproliferative neoplasm, European LeukemiaNet (ELN) intermediate or adverse risk genetic profile, or experience of grade 3 or higher non-hematologic toxicity during initial therapy.","Notable exclusion criteria were prior treatment with lenalidomide, acute promyelocytic leukemia, active or uncontrolled infection, or gastrointestinal disease or prior surgery that may affect the absorption of oral lenalidomide. ",The length of follow-up for DLT was 35 days,NA
23592273,NA,Combination,No,patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy,"Patients with aggressive B cell NHL relapsed/refractory disease not suitable for intensive salvage regimens or for anthracycline-based first-line chemotherapy were eligible. No specific criteria were predefined for ineligibility for intensive salvage therapy or anthracycline-based standard first-line therapy. The decision on whether patients were not considered fit enough to receive intensive salvage therapy or anthracycline-based first-line therapy was left to the treating physician. DLBCL and subtypes of DLBCL according to WHO 2008, follicular lymphoma grade 3b (FL3b) and transformed follicular lymphoma (tFL), were included. Further patient requirements were as follows: WHO performance status of 0–2, cardiac function with ejection fraction of more than 40 %, calculated creatinine clearance >50 mL/min, and adequate liver function and blood values","Patients with immunohistological evidence of bone marrow involvement ≥25 %, known CNS involvement, and unstable cardiovascular disease were excluded.",during the first cycle,NA
22967996,NCT00706030,Combination,No,patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy,"Eligible patients were either adults with a confirmed diagnosis of a solid tumor not curable with available therapies ( phase I) or females with a confirmed diagnosis of stage IV HER2-positive breast cancer (defined as an amplification ratio of 2.0 or more by fluorescent or chromogenic in situ hybridization), for which vinorelbine plus neratinib was a reasonable treatment option ( phase II). Patients eligible for phase II also must have received at least one prior antineoplastic treatment of metastatic disease or relapse during adjuvant treatment, including at least one prior trastuzumab-containing regimen for 6 weeks or longer. All patients were required to have at least one measurable lesion by modified Response Evaluation Criteria In Solid Tumors (RECIST) guidelines, version 1.0; an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2; and screening laboratory values and LVEF within normal limits. ","Key exclusion criteria included active central nervous system (CNS) metastases; any cancer therapy within 2 weeks before study start. For phase II only, additional exclusion criteria included having more than two prior cytotoxic chemotherapy treatment regimens for metastatic disease; prior treatment with vinorelbine for metastatic disease or with any HER2-targeted agents except trastuzumab; and taking greater than pre-specified cumulative prior doses of anthracyclines",from day 1 to day 21 of study drug,NA
21149673,NA,Combination,No,"children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome. Diagnosis: Nonrhabdomyosarcoma soft tissue sarcoma, Osteosarcoma, Ewing’s sarcoma, Carcinoma, Rhabdomyosarcoma, Malignant peripheral nerve sheath tumor, Myelodysplastic syndrome, Hepatoblastoma, Nephroblastoma, Alveolar soft part sarcoma, Atypical teratoid/rhabdoid tumor, Hepatocellular carcinoma, Hodgkin’s disease, Neuroblastoma, Pleuropulmonary blastoma","Eligible subjects were older than 12 months and <= 21 years of age at the time of study entry with: body-surface area higher than 0.4 m2 (due to lenalidomide capsule size); diagnosis of solid tumor (excluding primary brain tumor) or MDS; no known curative therapy or therapy proven to prolong survival with an acceptable quality of life; Karnofsky or Lansky performance score >= 50; and recovery from toxicity of prior therapy. Adequate organ function was required (peripheral absolute neutrophil count >= 1,000/uL; platelet count >= 100,000/uL; hemoglobin >= 8.0 g/dL; creatinine normal for age or creatinine clearance or glomerular filtration rate >= 70 mL/min/1.73 m2; total bilirubin <= 1.5 x upper limit of normal for age; ALT <= 110 U/L; serum albumin >= 2 g/dL). Patients with MDS were required to have transfusion supported platelet count >=30,000/uL and hemoglobin >= 8.0 g/dL.",NA,in the first course of therapy,NA
20553268,NA,Combination,No,multiply relapsed/refractory myeloma patients,"Patients diagnosed as relapsed myeloma, at first orsubsequent relapse, were eligible for the study but were excluded if they had received chemotherapy, including corticosteroids, within 28 d of the start of treatment. Localradiotherapy for symptom relief for previously recognizedmyeloma deposits was allowed before starting treatment butnot to new sites of disease if they developed during thestudy, which was classified as disease progression. Patients were eligible if they had adequate renal function (serumcreatinine <176.8 umol/l) and bone marrow reserve (base-line platelet count >20x109/l or absolute neutrophil count>1.0 x 109/l). ","In addition, patients with grade 3 peripheral neuropathy or a history of other malignancy within 3 yearswere excluded.",during  cycle  1,NA
29938772,NCT01383928,Combination,No,patients with newly diagnosed multiple myeloma,"Male or female patients 18 years or older. Symptomatic multiple myeloma with myeloma-related organ damage diagnosed according to standard criteria. Measurable disease defined by at least one of the following measurements: Serum M-protein ≥1 g/dL (≥10 g/L); Urine M-protein ≥200 mg/24 hours; Serum free light chain assay: involved free light chain level ≥10 mg/dL (≥100 mg/L) provided the serum free light chain ratio is abnormal. Patients must meet the following clinical laboratory criteria as specified below within 3 days before the first dose of study treatment to be enrolled in the study: ANC ≥1000/mm3 and platelet count ≥75,000/mm3 (platelet transfusions to help patients meet eligibility criteria not allowed within 3 days prior to study drug dosing); Total bilirubin ≤1·5 × ULN; ALT and AST ≤3 × ULN; o	Calculated creatinine clearance ≥30 mL/min. ECOG performance status of 0 to 2. Female patients who: are postmenopausal for at least 1 year before the screening visit, or; are surgically sterile, or; if they are of childbearing potential, agree to practice two effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study treatment, or agree to completely abstain from heterosexual intercourse, and; must also adhere to the guidelines of the lenalidomide pregnancy prevention programme. Male patients, even if surgically sterilized (i.e., status post-vasectomy), who: agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study treatment, or agree to completely abstain from heterosexual intercourse, and must also adhere to the guidelines of the lenalidomide pregnancy prevention programme. Must be able to take concurrent aspirin 81 to 325 mg daily (or enoxaparin 40 mg subcutaneously daily [or its equivalent] if allergic to aspirin) as prophylactic anticoagulation. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care","Peripheral neuropathy NEC grade ≥2 on clinical examination during the screening period.	Female patients who are lactating or pregnant. Major surgery within 14 days before the first dose of study drug. Infection requiring systemic antibiotic therapy or other serious infection within 14 days before the first dose of study drug. Diarrhoea grade >1, based on the NCI CTCAE grading, in the absence of antidiarrheals. Prior systemic therapy for multiple myeloma, including investigational proteasome inhibitors and IMiDs. Prior treatment with corticosteroids or localized radiation therapy does not disqualify the patient (the maximum dose of corticosteroids should not exceed the equivalent of 160 mg of dexamethasone, a total of which can be given in a 2-week period). Radiotherapy within 14 days before the first dose of study treatment. Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, ciprofloxacin, enoxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John’s wort within 14 days before the first dose of study treatment. Central nervous system involvement. Diagnosis of smouldering multiple myeloma, Waldenstrőm’s macroglobulinaemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS) syndrome, plasma cell leukaemia, primary amyloidosis, myelodysplastic syndrome or myeloproliferative syndrome. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina or myocardial infarction within the past 6 months. Prior or concurrent deep-vein thrombosis or pulmonary embolism. Rate-corrected QT interval of ECG (QTc) >470 ms on a 12-lead ECG obtained during the screening period; if a machine reading is above this value, the ECG should be reviewed by a qualified reader and confirmed on a subsequent ECG. Known human immunodeficiency virus positive. Known hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection. Any serious medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with the completion of treatment according to this protocol. Known allergy to any of the study medications. Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of study drug, including difficulty swallowing. Diagnosed or treated for another malignancy within 2 years before the first dose or previously diagnosed with another malignancy and any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection",in cycle 1,NA
9932161,NA,Combination,No,patients with advanced colorectal cancer,"To be entered in this trial, patients were required to have histologically or cytologically-confirmed metastatic and/or recurrent colorectal adenocarcinoma that was not amenable to curative surgical resection. They were required to have bidimensionally measurable disease, to be 75 years of age or younger, and to have an anticipated life expectancy of at least three months. Furthermore, patients were required to have a World Health Organisation (WHO) performance status of 3 or less, and to have adequate renal (serum creatinine concentration < 1.0 mg/dl), liver (total bilirubin level < 1.5 mg/dl and transaminase levels less than two times the upper limit of normal) and bone marrow (leukocyte count > 4,000/ul platelet count > 100.000/ul) functions. ","Patients with serious or uncontrolled concurrent medical illness or with central nervous system metastases were not eligible for treatment, nor were those who had undergone any prior palliative systemic therapy",NA,NA
10656432,NA,Combination,No,"patients with advanced malignancies. Primary tumorsL Osteosarcoma, Unknown primary, Ovary, Non-small cell lung cancer, Myeloma, Others","Twenty-one patients, ages 18–74 years, with histologically documented malignancies, admitted to the Medical Oncology Service of Anticancer Center (Montpellier, France), were considered eligible for this study. They had a performance status of 0–2 on the ECOG scale. Each patient underwent an initial evaluation, including (a) history and physical examination; (b) histopathological review; (c) chest X-ray; (d) pulmonary function test; (e) computerized tomodensitometry of the brain, thorax and abdomen; (f) and bone scan. Laboratory tests included: (a) complete hematology; (b) liver function (serum bilirubin, aminotransferases, g-glutamyl-aminotransferase, alkaline phosphatase, and serum proteins); (c) renal function (serum urea, serum creatinine, creatinine clearance calculated according to Cockcroft and Gault; Ref. 18); and (d) serology (HIV, hepatitis B and C virus, and cytomegalovirus). All of the subjects were negative for HIV virus and hepatitis B and C","Patients with granulocytes <1500/mm3, platelets < 100,000/mm3, significant renal dysfunction (creatinine clearance < 50 ml/min), significant hepatic dysfunction (serum bilirubin > 2.5 times normal or alanine aminotransferase, aspartate aminotransferase > four times normal), significant pulmonary dysfunction (forced expiratory volume in 1 s, forced vital capacity, or transfer factor for carbon monoxide < 65% of the predicted values), or significant cardiac dysfunction (isotopic left ventricular ejection fraction < 50%) were excluded from the study.",the first course,NA
14970856,NA,Combination,No,"patients with solid tumours. Primary tumour site:Carcinoma (not otherwise specified), Cervical cancer, Colorectal cancer, Lung cancer, Ovarian cancer","Patients were eligible for the study if they had a histologically proven diagnosis of a solid tumour for which no satisfactory treatment exists or against which established treatments had failed. Patients over the age of 18 were required to be of ECOG performance status 0, 1 or 2, and to have a predicted survival of at least 3 months. All patients had satisfactory haematological function, as defined by a haemoglobin level >+10 g dl-1, neutrophil count >=1.5 x 109 l-1 and a platelet count >=100 x 109 l-1. They also had to have satisfactory renal and hepatic function, with a serum creatinine within the normal range (<=110 umol l-1) and/or calculated creatinine clearance >=60 ml min-1, serum bilirubin <=17 mmol l-1 and other liver function tests less than twice the upper limit of the normal.","Patients with upper gastrointestinal cancers were excluded, as it was felt that this may alter the pharmacokinetics of an orally administered drug. Patients with recent ocular surgery were also excluded. In premenopausal women, pregnancy was excluded and adequate contraception was required for the duration of treatment and follow-up.",by day 28,NA
22892551,NCT00482846,Combination,No,patients with multiple myeloma with normal renal function,"Patients were eligible if they qualified for ASCT per institutional criteria and had at least 2.0 x 106 CD34þ cells/kg cryopreserved. Other requirements included an Eastern Cooperative Oncology Group performance status of <=2, MM stage 2/3, age >=18 years, creatinine clearance >60 mL/min/1.73 m2, total bilirubin <1.5 x institutional upper limit of normal, alanine aminotransferase and aspartate aminotransferase <3 x institutional upper limit of normal. ","Patients with baseline oral lesions, history of allergic reactions to melphalan, or prior exposure to palifermin were ineligible",by day +30,Patients undergo autologous peripheral blood stem cell transplantation on day 0.
22549288,NA,Combination,No,in-transit melanoma of the extremity,"Major inclusion criteria included: age 18 years or older, histologically confirmed recurrent American Joint Commission on Cancer (AJCC) stage IIIB or IIIC melanoma limited to a single extremity or stage IV melanoma limited to a single extremity, tumor tissue available for pre-ILI biopsy, measurable cutaneous disease distal to the location of tourniquet placement, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. We did not mandate that patients have their tumors tested for the Braf mutation as our preclinical data suggested that sorafenib may augment the efficacy of melphalan independent of tumor mutational status","Patients previously exposed to sorafenib were excluded, though patients having undergone prior ILI-M or HILP were allowed.",within 30 days from the last dose of sorafenib,NA
10863063,NA,Combination,No,pancreatic cancer,"Patients with resected pancreatic adenocarcinoma were eligible if they had the following features: tumor greater than 2 cm in greatest dimension; extension into duodenum, bile duct, or peripancreatic tissues; extension into stomach, spleen, colon, or large vessels; or the patient had positive lymph nodes pathologically. Patients with unresectable pan- creatic adenocarcinoma were eligible if the disease was considered fixed to the portal vein, superior mesenteric vessel, or other retroperitoneal structure; disease was con- sidered to be confined to the pancreas, contiguous organs, regional lymph nodes, and adjacent peritoneum by direct extension; or the disease was unresectable due to other medical conditions or the patient refused surgery. The MD Anderson clinicoradiographic system (Table 1) was used to stage the patients as Stage I (resectable) or Stage II (unresectable) (16). No patient with distant metastatic disease (MD Anderson Stage III) was allowed to enter the study. Patients were not allowed to have received prior radiotherapy or chemotherapy. Patients had no serious concurrent uncontrolled medical disorders present. Patients had an ECOG performance status of 2 or better with age equal to or greater than 18 years. Patients must have pathologic and/or cytologic diagnosis. Patients were required to have adequate organ function with an ANC of greater than 1500 per microliter, platelet count of greater than 100,000 per microliter, creatinine less than 1.5 mg per deciliter, bilirubin less than 2, SGOT less than 1.5 x normal, and alkaline phos- phatase less than 1.5 x normal.",NA,NA,NA
19034580,NA,Single Drug,No,unresectable liver metastases from colorectal cancer,"Patients who had isolated unresectable liver metastases from colorectal cancer and were scheduled for HAI with 5- fluorodeoxyuridine (FUDR) were eligible for enrollment. Patients were required to have histologically or cytologically proven measurable metastatic colorectal cancer that was limited to the parenchyma of the liver, although limited resectable extrahepatic disease was acceptable. Unresectable disease was defined as multiple bilobar tumors which would make anatomic resection with preservation of liver function impossible. Additional eligibility criteria included: (1) age >=18 years and weight >30 kg; (2) no chemotherapy, radiotherapy or biologic therapy in the 4 weeks prior to the liver perfusion; (3) recovery from all side-effects of prior therapy; (4) an Eastern Cooperative Oncology Group (ECOG) performance status <=2; and (5) adequate organ function as evidenced by serum bilirubin <2.0 mg/dl, prothrombin time <2 s greater than the upper limit of normal, platelet count >100,000/ul, hematocrit >27, white blood cell count >3,000/ul, and serum creatinine <=1.5 mg/dl or creatinine clearance >60 ml/min. Patients with elevated hepatic transaminases secondary to the presence of metastatic disease in the liver were ineligible.",Exclusion criteria were: (1) biopsy-proven cirrhosis; (2) portal hypertension; (3) pregnancy; and (4) uncorrectable coronary artery or pulmonary disease.,NA,NA
9389936,NA,Combination,No,"advanced gastric cancer. Sites of primary tumour: Gastro-oesophageal junction, Proximal stomach, Body, Distal stomach","Patients with histologically proven metastatic gastric carcinoma were included in this study. Admission criteria included: patients refractory (stable or progressive disease) to the PELF regimen (5-FU, leucovorin, cisplatin, epidoxorubicin); age < 70 years; Eastern Cooperative Oncology Group (ECOG) performance status O-2; presence of measurable disease; absence of concomitant disease and life expectancy > 3 months. Furthermore, patients had to present adequate organ function (serum creatinine < 1.5 mg/dL; BUN < 50 mg/dL, bilirubin < 1.5 mg/dL; GOT, GPT, alka- line phosphatase < three times the upper limit of normal; WBC (white blood cell) count > 4000/mm3; platelet count > 100 000/mm3). Prior chemotherapy was allowed if treatment had been stopped at least 2 months previously.",NA,the first two cycles of treatment,NA
9389916,NA,Combination,No,patients with metastatic colorectal cancer,"Admission criteria included biopsy-proven carcinoma, measurable recurrent or metastatic adenocarcinoma of the colon or rectum and a life expectancy of more than 1 month. Exclusion criteria were: age above 75 years, a per- formance status (PS) greater than 2 (WHO); surgically resectable metastases and more than one chemotherapy line for metastatic disease. Previous radiotherapy was not an exclusion criteria. Patients with inadequate bone marrow reserve (HB < 8 g/d1 or leukocyte count ~3000 mm3, platelet count 100000 mm3) and liver function tests (transaminases >I .5 normal) as well as renal dysfunction (creatinine > 1.5 mg/dl) were also excluded. Eligible patients underwent a complete clinical history and physical examination and surgical placement of a totally implanted double-venous access port (Port-A-Cath, Pharmacia, Sweden). Weight and height, complete blood cell counts and serum bilirubin, creatinine, ionogram, calcium, magnesium, total protein, alkaline phosphatase, serum liver transaminase, CEA and CA19-9 levels were also determined. The patients were submitted to chest x-rays, abdominopelvic computed tomographic (CT) scanning and colonoscopy one month before beginning the treatment.",NA,in the first three courses of therapy ,NA
18497327,NA,Combination,No,newly diagnosed high-grade gliomas of childhood,"Patients >=3 and <22 years of age at the time of diagnosis of a nonbrainstem, non–spinal cord, nondisseminated, histologically confirmed HGG with measurable postoperative residual were eligible. All specimens were centrally reviewed by a neuropathologist blinded to the outcome or response data (A.Y.). Patients could not have received prior treatment other than surgery or corticosteroids. Other eligibility criteria included enrollment within 31 days of surgery, a Karnofsky or Lansky score >=50%, and adequate bone marrow, renal, hepatic, and pulmonary function. ","Patients could not be receiving phenobarbital or cimetidine because of the potential interaction with lomustine. Other exclusion criteria included pregnancy and uncontrolled infection. Informed consent was obtained from patients, parents, or guardians at the time of enrollment",during course 1,NA
17146474,NA,Combination,No,patients with cerebral metastases from malignant melanoma,"Patients were eligible for enrolment if they had histologically confirmed primary or secondary malignant melanoma with radiological evidence of brain metastases. In the phase II section of the study, eligible patients had bi-dimensionally measurable brain metastases of at least 2 cm in size on either contrastenhanced CT or MRI. Previous systemic therapy was permitted for the treatment of melanoma and patients must have recovered from the effects of major surgery. Steroid therapy was permitted provided the dose was stable for at least 1 week before the administration of the trial treatment. Other inclusion criteria were: age of at least 18 years, WHO performance status of 0 to 2, life expectancy of 12 weeks or greater, adequate bone marrow function (haemoglobin >10 g dl – 1, absolute neutrophil count >1.5 x 109 l– 1 and platelet count >100 x 109 l-1), adequate renal function (plasma creatinine <120 umol l – 1 or calculated creatinine clearance >50 ml min– 1 and urea less than twice the laboratory upper limit of normal (ULN)) and adequate hepatic function (total and direct serum bilirubin <1.5 times laboratory ULN, alanine aminotransferase , aspartate aminotransferase and alkaline phosphatase o2 times the laboratory ULN). All patients provided written informed consent.","Exclusion criteria were systemic anticancer therapy within 4 weeks of study entry, prior fotemustine, lomustine or temozolomide therapy, prior whole-brain irradiation, radiation therapy given to 30% or more of the bone marrow, unresolved toxicities from previous therapies, acute infection or other uncontrolled medical co-morbidity, inability to take oral medication, poor respiratory reserve due to either a large volume of pulmonary metastases or coexisting medical conditions, previous or concurrent malignancies at other sites with the exception of surgically treated carcinoma-in-situ of the uterine cervix and basal or squamous cell carcinoma of the skin, pregnant or breastfeeding females and potentially fertile subjects not using effective contraception.",first two cycles of temozolomide,NA
15256243,NA,Combination,No,locally advanced pancreatic cancer,"In a phase I – II trial, of 21 patients with histo- logically proven locally advanced carcinoma of the pancreas were included.  In order to be amenable for inclusion, age had to be between 18 and 75 years and the Karnofsky performance status had to be above 80%. Further criteria were a leukocyte count > 2.5 x 10.9, no haemorrhage or active bleeding disorder, and no infections not controlled by antibiotics. Patients were not to have liver disease, although in the phase-I study patients with hepatic metastases were included. Patients were not to have a concurrent malignancy-determining prognosis. ","Patients with significant cardiovascular disease (New York Heart Association Class II/III/IV), insufficient renal function, or pregnancy were excluded. Patients having received radiation within 3 months prior to HAP, or chemotherapy within 6 weeks prior to entry into the study were excluded.",NA,NA
10907951,NA,Combination,No,locally advanced or metastatic squamous cell carcinoma of the head and neck,"Eligibility criteria for study entry included pathologically confirmed, unresectable, locally advanced or metastatic squamous-cell carcinoma of the head and neck, Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, adequate baseline organ function defined as WBC counts >=3000/ul, platelets >=100,000/ul, bilirubin <=1.5 mg/dl, serum transaminases <= 2 x upper limit of normal, creatinine clearance >= 60 ml/min, life expectancy of at least three months. Atumor was defined as unresectable if it was fixed to either a bone structure or lymph nodes, or if it was too invasive to allow for a radical surgical remova","Patients were ineligible if they had received prior radiotherapy or chemotherapy. Patients with a history of congestive heart failure or severe coronary heart disease were also ineligible. In addition, pregnancy, uncontrolled infection, cerebral metastases, concurrent or previous malignancy, severe neurologic disease also constituted exclusion criteria. ",the first cycle,NA
9554592,NA,Combination,No,"patients with advanced cancer. Diagnosis: Colon (4), pancreas (4), unknown (3), gastric (3), bile duct (3), miscellaneous (3)","Patients selected for this study had histologically confirmed, unresectable, advanced cancer, ECOG performance status <= 1, a white blood cell (WBC) count >= 4000/mm3 and a platelet count >= 100 000/mm3. ","Patients were excluded if they had received prior chemotherapy for unresectable disease or radiation therapy or had experienced recurrence while on 5-FU and levamisole therapy or within the 6 months of completion of the treatment. Patients were also excluded if they had an active infection, frequent vomiting, severe anorexia or recent major surgery.",NA,NA
8418223,NA,Combination,No,"The tumor types in the advanced-disease group included carcinomas of the colon (n = 4), breast (n = 2), kidney (n =2), melanoma (n = 11), and a malignant chordoma (n =1). ","Patients were divided into two groups: those with advanced malignancies refractory to standard therapy, and those with malignant melanoma or renal cell carcinoma who had been rendered diseasefree by surgery, but who were at high risk for relapse (adjuvant arm). Patients with completely resected stage IIA (Breslow depth > 1.5 mm), IIB (Breslow depth > 4.0 mm), or III (lymph node metastases) melanoma, and patients with stage II (tumor > 2.5 cm with invasion of perinephric fat) or III (lymph node metastases or extension into veins or Gerota's fascia) renal cell cancer were eligible for adjuvant therapy. Staging was according to the American Joint Committee on Cancer. These patients were enrolled within 6 weeks of surgical resection. The pathologic diagnosis of cancer was confirmed by the National Institutes of Health (NIH) Pathology Department before initiation of treatment. Eligibility criteria included Karnofsky performance status of 70% or greater, life expectancy untreated of at least 3 months, creatinine clearance greater than 50 mL/min, serum bilirubin less than 1.5 mg/dL, WBC count greater than 3,000/L, granulocyte count greater than 1,500/ML, platelet count greater than 100,000/uL, calcium less than 11 mg/dL, albumin greater than 3.0 g/dL, prothrombin time (PT) less than 13 seconds, and partial thromboplastin time (PTT) less than 35 seconds. Previous chemotherapy, hormonal therapy, immunotherapy, or radiation therapy must have been completed 4 weeks before study entry.","Patients with a history of myocardial infarction, coronary artery disease, congestive heart failure, or ventricular arrhythmias were excluded. Exclusion criteria also included CNS metastases, rheumatoid arthritis, inflammatory polyarthritis, systemic lupus erythematosus, and serum positive for antibodies to human immunodeficiency virus or hepatitis B surface antigen. Patients requiring therapy with aspirin or other nonsteroidal antiinflammatory drugs, corticosteroids, H2 blockers, or calcium channel blockers were excluded, as were patients with a history of a second malignancy, and pregnant or lactating women. ",NA,NA
23090987,NCT00948389,Combination,No,patients with recurrent glioblastoma,"Patients eligible for this study had histologically verified glioblastoma according to the WHO 2007 classification, recurrent after standard RT with concomitant and adjuvant temozolomide. Prior exposure to other agents as part of initial therapy was allowed if at least 4 weeks had elapsed since the end of treatment and if patients had recovered from all toxicity. Other than reoperation, no prior therapy for recurrent disease was allowed. In case of reoperation, a postsurgery MRI within 48 h after surgery must have been available, but presence of residual disease was not required because the primary endpoint for the phase II part of the study was progression-free survival (PFS) at 6 months (PFS6). In patients without residual disease or with nonmeasurable disease after a second surgery, PFS was calculated from enrollment to disease progression at MRI. For non-operated patients, documentation was needed (within 2 weeks prior to enrollment) of at least 1 bidimensionally contrast-enhancing lesion (diameter ≥2 cm). In order to exclude pseudoprogression11–13 or radiation necrosis, RT must have been completed at least 3 months prior to enrollment. Patients having received prior high-dose RT (≥65 Gy) were not eligible unless the recurrence was histologically confirmed. Other inclusion criteria were age ≥18 years, WHO performance status 0–2, stable or decreasing dose of corticosteroids for at least 1 week prior to treatment start, neutrophils ≥1.5 × 109 cells/L, platelets ≥100 × 109 cells/L, bilirubin >=1.5 × upper limit of the normal range (ULN), alkaline phosphatase and transaminases <2.5 × ULN, and serum creatinine <1.5 × ULN. Patients requiring anticonvulsant therapy must have been switched to a non-enzyme-inducing antiepileptic drug (non-EIAED) ≥2 weeks prior to study entry. Adequate pulmonary function was required, including diffusion lung capacity of carbon monoxide (DLCO) ≥60% of the predicted value. Clinically normal cardiac function was required, without cardiac insufficiency (New York Heart Association grades III and IV), unstable angina, or arrhythmia. Patients with ischemic heart disease in the prior 12 months must have been stable (eg, prior angina under appropriate therapy). Written informed consent from all patients and approval from the institutional review boards of participating centers were obtained.",NA,the first 2 cycles,NA
26553306,NA,Single Drug,No,"patients with advanced solid tumor malignancies. Cancer types: Ovarian, Lung (NSCLC), Gastrointestinal, Breast, Other: Neuroendocrine, Merkel cell, Bladder, Tubal","This was a prospective, single-armed, open-label, dose finding phase I/IIa study in adult patients (≥18 years) with histologically proven advanced solid tumors for whom there was no standard treatment available. Patients had to have a central intravenous line for infusion available and to have adequate organ function and laboratory parameters. Patients must not have received any systemic antitumor treatment within 4 weeks prior to the start of treatment with melflufen (6 weeks for nitrosurea or mitomycin C), or radiotherapy within 1 week prior to entry. ","Patients were excluded if Karnofsky performance status was below 70 %, if they were participating in any other interventional clinical study, or if they had ongoing infection or other major recent or ongoing disease that, according to the investigator, posed an unacceptable risk to the patient. Female patients of fertile age were required to use an adequate contraception device. Female patients were excluded if they were pregnant or lactating. The phase I part of the study was performed in Sweden (one center), and the phase IIa part in Sweden (two centers) and Russia (two centers). Patients in Sweden were required to have measurable breast cancer, ovarian cancer, lymphoma, lung cancer (nonsmall cell lung cancer (NSCLC), small cell lung cancer (SCLC) or mesothelioma), or bladder cancer. In Russia, only patients with ovarian cancer or NSCLC were included (based on one responding ovarian carcinoma, and one persistently stable lung cancer patient in Sweden). Furthermore, verified diabetes or fasting blood glucose level >7 mmol/L at screening were added as exclusion criteria in Russia (based on glucose content of infusate).",all treatment cycles,NA
8622018,NA,Combination,No,previously untreated metastatic colorectal cancer patients,"Eligibility criteria included histologically confirmed diagnosis of colorectal adenocarcinoma with metastatic disease previously untreated with chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status <= 2, life expectancy greater than 3 months, measurable disease, serum creatinine level less than 1.6 mg/dL, serum bilirubin level less than 1.6 mg/dL, AST/ALT less than 2.5 times normal values, leukocyte count greater than 3,500/uL, and platelet count greater than 100,000/uL.","Patients with a history of other malignant tumor (except in situ carcinoma of the cervix or nonmelanoma skin cancer), symptomatic cardiac disease or recent history of myocardial infarction or arrhythmia, active infections, and cerebral metastases were excluded",4 weeks of treatment,NA
25125340,NA,Combination,No,patients with metastases confined to the liver,"All patients had measurable, unresectable metastases confined to the liver. Unresectability was based on the decision made by the HPB multidisciplinary team. Often this was because the tumour is multifocal, too large or positioned close to central vascular structures. Standard staging studies were performed including CT scan of the chest and abdomen. Additional MRI or PET scans were performed if clinically indicated. Eligibility criteria included a WHO performance status of 0 or 1, leukocyte count >=3.0 x 109/L, platelet count >=100 x 109/L, minimum creatinine clearance level of 40 ml/min and maximum bilirubin level 17 umol/L.","Exclusion criteria were age over 65 years, more than 60% hepatic replacement by tumour tissue as estimated from the preoperative abdominal CT scan, evidence of extrahepatic metastatic disease or coagulation disorders (disorders affecting APTT, PT and/or INR). ",NA,NA
9816300,NA,Combination,No,"Patients with histological or cytological confirmation of unresect- able or recurrent GI adenocarcinoma originating from the stom- ach, pancreas, gallbladder, biliary tree, colon, or rectum were entered onto protocol. ","Eligible patients were required to be >=18 years old with normal renal (creatinine, <=2.0 mg/dl) and hepatic (bilirubin, <=1.5 mg/dl) function, adequate bone marrow reserve (hematocrit, >=25%; WBC, >=4000/mm3; and platelets, >=l00,000/mm3), expected survival >6 months and Eastern Cooperative Oncology Group performance status of <=2. Patients who received prior systemic chemotherapy were eligible if they received no chemotherapy for 1 month prior to entry",Patients who received prior radiotherapy to involved sites of disease were not eligible. Metastases beyond the planned irra- diation field were not considered in determining eligibility.,NA,NA
20478715,NA,Single Drug,No,"resectable lung metastases. The primary tumour was a colorectal carcinoma in 10 patients, a renal cell carcinoma in eight, a sarcoma in four and a salivary gland tumour in one.","Patient characteristics from the phase I and extension trials were previously reported [10,11]. In summary, patients with melphalan-sensitive tumours were included if all metastatic disease assessed by radiologic examination was resectable, metastatic disease was confined to the lungs, patients had adequate cardiac and pulmonary reserve to undergo surgery as well as metastasectomy and no co-morbid conditions that prevent an operation were present.",NA,NA,NA
22453252,NCT00482846,Combination,No,multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection,"Patients were eligible for the study if they qualified for ASCT per institutional criteria and had at least 2.0 x 106 CD341 cells/kg cryopreserved for ASCT. They also had to have an Eastern Cooperative Oncology Group performance status of <=2, stage 2 to 3 MM, age >=18 years, creatinine clearance <=60mL/minute/1.73 m2, total bilirubin <1.5 x institutional upper limit of normal, and an aspartate aminotransferase/alanine aminotransferase <3 x in- stitutional upper limit of normal. ","Patients with baseline oral lesions, a history of allergic reactions to melphalan, dependence on dialysis, and prior exposure to palifermin were deemed ineligible",by day 30 after ASCT,NA
10442367,NA,Combination,No,pretreated metastatic breast cancer,"Patients in this study had to have histologically proven breast cancer and a failure to respond to previous chemotherapy for breast cancer either adjuvant, metastatic, or both. Other inclusion criteria were progressive measurable or evaluable disease, age >= 18 years, World Health Organization (WHO) performance status <= 2, life expectancy of >= 3 months, and adequate renal, liver, and bone marrow function (creatinine, bilirubin <= 1.5 × upper limit of normal and absolute neutrophil count [ANC] >= 2.0 × 109/L, platelet count >= 100 × 109/L). All patients gave informed consent prior to study entry.",NA,during the first course of treatment,NA
8004761,NA,Combination,No,"Diagnosis: Carcinoma: Lung 9, Small-cell 3, Large-cell 1, Adeno- 3, Squamous 2, Colon 7, Stomach 4, Soft-tissue sarcoma 2, Miscellaneous 8","All patients were required to have histologically verified recurrent or metastatic malignant disease not amenable to standard therapy; an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2; a WBC of >=4 x 109/1; a platelet count of >=10^11/1; a serum bilirubin level of < 2.0 mg/dl; and a serum creatinine value of <2.0 mg/dl. ","Patients were excluded from the study if they had an active, uncontrolled infection or a severe intercurrent nonmalignant systemic disease or were pregnant or lactating.",NA,NA
11432616,NA,Combination,No,patients with hepatic metastases from colorectal cancer,"Consecutive patients at ages 18 or older with surgically removed colorectal cancer and metastatic disease confined to the liver with or without prior systemic or regional chemotherapy who were admitted to the university hospital GroBhadern, Munich, between November 1998 and March 2000 were eligible for the study.","Patients with metastases outside the liver or prior therapy with oxaliplatin were excluded from the study. Further exclusion criteria comprized coronary heart disease; heart failure, cardiomyopathy, severe arterial hypertension, abnormal liver function tests (total bihrubin >4.0 mg/dl), impaired renal function (serum creatinine > 2.0 mg/dl), impaired hematopoiesis (WBC count < 1500 G/l, platelet count < 100 G/l), severe infections, or pregnancy",During the first and second cycle of chemotherapy,NA
12203099,NA,Combination,No,"patients with advanced solid tumors, refractory to standard therapy. The largest group by tumor type was colorectal (18 patients) with a wide distribution of other tumor types","Patients were eligible if they met the following criteria: (1) histologically confirmed malignancy that was refractory to standard therapy; (2) aged 18 years or older; (3) measurable or evaluable disease; (4) ECOG performance status 0-2; (5) life expectancy >12 weeks; (6) WBC >3500/ul; (7) platelet count >90,000/ul; (8) serum bilirubin <2.0 mg/dl; (9) AST less than six times the upper limit of normal; and (10) serum creatinine <2.0 mg/dl. Recovery from prior anticancer treatment was required. No chemotherapy or radiation treatment was permitted for at least 4 weeks before enrollment, and in the case of nitrosoureas and mitomycin-C, that period was 6 weeks. Patients could have previously received treatment with either megestrol acetate or vinblastine.","Exclusion criteria included metastases to the central nervous system, symptomatic neuropathy and pregnancy. Women of childbearing age were required to have a negative pregnancy test at study entry. Patients with a history of deep venous thrombosis or pulmonary embolus were also excluded. Concurrent use of other progestins or any calcium channel blocker was not permitted.",NA,NA
10999043,NA,Combination,No,"Adults with unresectable, locally recurrent, or metastatic malignancies. Primary tumor types: Colorectal, Unknown primary, Hepatobiliary, Bladder, Anal canal, Melanoma","Adults (>= 18 years) with unresectable, locally recurrent, or metastatic malignancies for which effective standard therapy did not exist were eligible. An Eastern Cooperative Oncology Group Performance Status of 0-2 (ambulatory at least 50% of the time) and life expectancy of >=3 months were required. Previous radiotherapy (<=25% of marrow-producing areas) and chemotherapy (1 regimen) were permitted, provided that 4 weeks had elapsed since treatment (8 weeks for nitrosoureas or mitomycin C). Acceptable organ function was required, defined as white blood count >4000/u1, granulocyte count > 150O/ul, platelet count > lOO,OOO/u1, hemoglobin > 10 g/dl, serum bilirubin <3.0 mg/dl, and serum creatinine <=2.0 mg/dl.","Patients with chronic diarrhea or uncontrolled infection, or pregnant or breast feeding women were ineligible",NA,NA
9552052,NA,Combination,No,"patients with refractory malignancies. Diagnosis: Osteogenic sarcoma 6, Nasopharyngeal carcinoma 2, Ewings/PNET 2, AML 2, Other(One patient each with ALL, brain stem glioma, choroid plexus carcinoma, colorectal carcinoma, endometrial carcinoma, malignant peripheral nerve sheath tumor, neuroblastoma, and synovial cell carcinoma.)","The initial trial was restricted to patients less than 21 years of age; however, because of slow accrual, the age limit was increased to include all patients less than or equal to 70 years of age. Patients were eligible if they had refractory acute leukemia or a histologically or cytologically documented solid malignant tumor that was refractory to conventional therapeutic modalities or for which no effective therapy was known. Patients were required to have a predicted life expectancy of 6 weeks or greater, no severe, uncontrolled infection, and could not be pregnant or breast feeding. In addition, patients were required to have adequate nutritional status (>= third percentile for weight, normal total serum protein and albumin-globulin ratio), a performance status of 50% or greater on a Karnofsky scale, and normal hepatic function (bilirubin level <= 1.5 mg/dL, ALT level <= 2.5 times the upper limit of normal) and renal function (creatinine level normal for age). Patients with uninvolved bone marrow were required to have adequate bone marrow function, (absolute neutrophil count [ANC] >= 1,000/uL, platelet count >= 100/uL, hemoglobin >= 10 g/dL). Patients must have recovered from any previous acute toxicity and were not allowed to receive any other anticancer agents concomitantly. Patients who had previously undergone a bone marrow transplant were required to be at least 3 months from the procedure. Dexamethasone or other steroids as an antiemetic agent were prohibited, but patients with CNS tumors could be on chronic steroids. No patient with significant prior MTX neurotoxicity or evidence of third-space fluid was eligible. The protocol met institutional review board approval. Written informed consent was obtained from the patients and/or the parents before treatment was initiated.",NA,NA,NA
9552051,NA,Combination,No,"patients with advanced cancer. Tumor type: Colon or rectum 37, Breast 8, Pancreas 7, Unknown primary tumor 4, Kidney 3, Periampullary 3, Soft tissue sarcoma 1, Melanoma 1, Hepatoma 1","Patients with histologically confirmed advanced solid tumors that had failed to respond to standard therapy or for which no standard therapy was available were eligible to participate in this study. Other eligibility criteria included bidimensionally measurable or assessable disease by computed tomography, magnetic resonance imaging, radiograph, or physical examination; age of at least 18 years; Karnofsky performance status of at least 70% (ambulatory and capable of self-care); life expectancy of at least 12 weeks; and adequate organ function defined as an absolute neutrophil count (ANC) of at least 1,500/uL, platelet count of at least 100,000/uL, hemoglobin at least 10 g/dL, serum creatinine level less than 1.5 mg/dL or estimated creatinine clearance using the Cockcroft-Gault formula of at least 60 mL/min, total bilirubin level less than 2.0 mg/dL, and AST level less than two times the upper limit of normal. Patients must have been off previous anticancer therapy, which included radiation to greater than 10% of the bone marrow, for at least 3 weeks (6 weeks if the previous therapy included a nitrosourea or mitomycin), and must have recovered from the toxic effects of any previous therapy.","Patients were excluded from the study if they had any unstable, preexisting medical condition, previous significant surgical resection of the stomach or small bowel, malabsorption syndrome, or any disease that significantly affected gastrointestinal tract function. Pregnant and lactating women were also excluded from participation, and all patients with reproductive potential were required to use an effective contraceptive method if they were sexually active. Patients with significant psychological, social, or transportation problems that prohibited weekly medical follow-up and full protocol compliance were excluded from participation.","in Period 3, Cycle 1",NA
8269603,NA,Combination,No,"metastatic adenocarcinoma patients. Primary tumor sites: Colorectal 3, Pancreas 2, Kidney 5, Breast 2, Endometrium 1, Lung 1","Inclusion criteria included biopsy-proven advanced or metastatic adenocarcinoma, an age of between 18 and 75 years, an ECOG performance status of <=2, a life expectancy of >8 weeks, no radiation therapy in the preceding 4 weeks, a serum creatinine level of <150 uM, a serum bilirubin value of <= 1.5 times normal, an aspartate transferase value of <= 3 times normal, a granulocyte count of >= 1.5 x 109/1, and a platelet count of >= 100 x 109/1. The presence of measurable disease was not required","Pregnant women, nursing mothers, and patients with cerebral metastases were excluded.",NA,NA
8558227,NA,Combination,No,"metastatic breast cancer patients. disease sites: Soft tissue 34, Lung 25, Liver 19, Bone 32","Patients aged - 18 years with histologically or cytologically confirmed metastatic breast cancer who had been treated with - two prior chemotherapy regimens (adjuvant or one adjuvant and one metastatic only) were eligible for this study. Written informed consent was obtained before treatment according to National Cancer Institute (NCI) Investigational Review Board guidelines. All patients were required to have a normal baseline cardiac left ventricular ejection fraction and an Eastern Cooperative Oncology Group performance status of 0, 1, or 2 at study entry. Patients were excluded if they had CNS metastases or a history of cardiac disease or had undergone ,-ior paclitaxel therapy, autologous bone marrow transplantation, or treatment within 6 months with nitrosoureas, melphalan, or mitomycin. Prior irradiation to greater than 25% of the bone marrow was not allowed. Laboratory requirements included a WBC count >= 4,000/uL, platelet count >= 100,000/uL, serum bilirubin level less than 1.8 mg/dL, AST and ALT levels < three times the upper limit of normal, and serum creatinine level less than 1.5 mg/dL. Prestudy evaluation included medical history and physical examination with tumor measurements; chest x-ray; ECG; complete blood cell count with differential, serum chemistries, and liver function tests; staging studies appropriate to define the extent of metastatic disease, which included computed tomographic scans of chest and abdomen, ultrasounds of liver, bone scans, and plain radiographs of suspicious areas seen on bone scan, as indicated by clinical or laboratory examination; and determination of resting baseline cardiac left ventricular ejection fraction by radionuclide ventriculography. Restaging studies were performed after the second cycle of therapy and then after every third subsequent cycle in responding patients or those with stable disease. ",NA,the first cycle of therapy,NA
11032595,NA,Combination,No,rectal cancer,"Eligible patients had histologically confirmed rectal cancer and evidence of a T3 or T4 lesion or nodal involvement by endoscopic ultrasonography or computed tomography (CT). Other eligibility criteria were the ability to tolerate major surgery, age over 18 years, Zubrod performance status of 0 to 2, life expectancy of at least 3 months, absolute granulocyte count >= 1,500/mL, platelet count >= 100,000/mL, total bilirubin level <= 1.5 mg/dL, ALT level <= 70 IU/L, and serum creatinine level <= 1.5 mg/dL. ","Patients with distant metastasis or prior malignancies (excluding localized epithelial skin or cervical cancer), major surgery within 3 weeks, or prior chemotherapy or pelvic irradiation were excluded. Pregnant or breast-feeding women were not eligible, and sexually active fertile patients had to practice contraception. ",the entire chemoradiation course ,NA
16146748,NA,Combination,No,"high grade malignant glioma. Histopathological diagnosis: Glioblastoma multiforme, Anaplastic Astrocytoma","Eligibility criteria included a histopathology diagnosis of GBM, AA, age > 18 years, patients in recurrent or progressive disease. Disease recurrence or progression was defined with McDonald criteria, with an increase in tumour size on MRI scan or axial tomography. Patients with a life expectancy of less than three months and ECOG performance status > 1 were excluded. At least one month from last treatment (surgery and radiation therapy) was required before starting the TMZ treatment. Patients were required to have absolute neutrophil count >= 1000 neutrophil/mm3, platelet count >= 100.000 platelet/ mm3, haemoglobin levels >= 10 gr/dL, serum creatinine and bilirubin levels <= 1,5 times the upper limit of normal (ULN), serum levels of aspartate and alanine aminotransferase <= 3 times the ULN, and serum alkaline phosphatase <= 3 times the ULN.",Concurrent malignancies (except basal or squamous cell carcinoma of the skin) and severe co-morbidities were reasons of ineligibility,NA,NA
9661893,NA,Combination,No,advanced malignancies primarily confined to the peritoneal cavity. The predominant tumor types included: adenocarcinoma of the colon or rectum and other gastrointestinal primaries (20); ovarian or Fallopian tube cancer (15); and abdominal sarcomas (3),"Between February 1991 and June 1995. 39 patients with advanced malignancies, primarily confined to the peritoneal cavity, were entered into this Phase I trial. The diagnosis must have been histologically proven, the tumor must have been unresponsive to previous chcmotherapeutic regimens, or have no defined ""standard"" chemotherapeutic regimen. Patients were required to have a Karnofsky performance status of >=60%, age >= 18 years, and expected survival of at least 3 months. Adequate renal function was defined as serum creatinine <=1.5 mg/dl or 24-h creatinine clearance of >=60 ml/min. Adequate bone marrow function was defined as a total WBC >=4000/ul and platelet count >=150,000/ul. Adequate hepatic function was defined as serum bilirubin <= 1.5 mg/dl and aspartate aminotransferase and alanine aminotransferase within twice the upper limit of normal. Prior radiation or chemotherapy must have been completed at least 4 weeks before beginning treatment on this protocol. There was no limit on the number of prior courses of chemotherapy. Female patients could not be pregnant. Patients must have been willing to undergo the necessary surgical procedure for insertion and removal of i.p. catheters. All patients gave their voluntary informed consent and signed a consent document that had been reviewed and approved by the City of Hope National Medical Center Institutional Review Board",NA,the first cycle of i.p. chemotherapy,NA
9626215,NA,Combination,No,"patients with advanced lung cancer. Malignancy: NSCLC, SCLC, Unknown primary",All patients enrolled onto the study were treated previously with at least one type of diseaseappropriate therapy. All patients were staged within 4 weeks before enrollment onto the study with computed tomographic (CT) scans or chest x-rays. These tests were then performed bimonthly to assess responses to therapy. CT scans of the head were also performed before the start of the study to rule out CNS metastases. All of the patients underwent physical examination before administration of the study drug and were monitored for at least 1 month after discontinuation of therapy.,Patients were removed from study for progressive disease (defined as a > 25% increase in the sum of products of largest tumor diameters measured on radiologic studies) or unacceptable toxicity. ,during the initial 8 weeks of treatment,NA
9193347,NA,Combination,No,"patients with advanced cancer. Primary site: Pancreas, Adenocarcinoma, unknown primary, Bile duct, Appendix, Gastric, Sarcoma",Not reported,Not reported,NA,NA
15084615,NA,Combination,No,"children with refractory solid tumors. Diagnosis: Neuroblastoma 5, CNS tumors 4, Rhabdomyosarcoma 3, Soft-tissue sarcoma 3, Hepatoblastoma 2, Osteosarcoma 2, Adrenocortical carcinoma 1, Ewing sarcoma 1, PNET 1, Wilms tumor","Patients were eligible for enrollment if they were 21 years of age or younger and had histologically or cytologically documented diagnoses of solid tumors refractory to conventional chemotherapy or for which no effective therapy was known. Other eligibility criteria included life expectancy of 6 weeks or greater, adequate nutritional status, Karnofsky performance score of >= 50 (or Lansky play scale >= 50 in younger children), adequate bone marrow function (absolute neutrophil count >= 1,500/uL; platelet count >= 75,000/uL), and adequate hepatic and renal function (bilirubin level <= 1.5 mg/dL; ALT < five x upper limit of normal; normal serum creatinine for age or glomerular filtration rate>= 70 mL/min/1.73 m2).","Patients were ineligible if they were receiving any other antineoplastic therapy, had not recovered from toxicities of previous chemotherapies, had severe, uncontrolled infections, or were pregnant or lactating. ",during the first course,NA
9720737,NA,Single Drug,No,patients with multiple myeloma,"All patients met Durie and Salmon criteria for initial diagnosis of multiple myeloma, were <66 years of age, had an ECOG performance status of 0–1 and had adequate renal, hepatic and cardiac function. All patients signed a protocol-specific informed consent form approved by the institutional review board of the hospital where the treatment was administered.",NA,2 cycles of melphalan treatment (twice within 90 days),NA
9358936,NA,Combination,No,metastatic breast cancer,"Patients with histologically proven, measurable or evaluable progressive metastatic breast cancer, who had not received chemotherapy for metastatic disease, were eligible for this study. The other eligibility criteria were an age of more than 18 years; an ECOG performance status of 0-2; an expected survival >=3 months; reasonable bone marrow function (absolute granulocyte count >=4000/mm3, platelet count >= 100.000 /mm3, and hemoglobin level >=11 g/dl); adequate hepatic and renal function, including AST, ALT, bilirubin, alkaline phosphatase and serum creatinine values <= 1.25 times the upper limit of normal; no severe uncontrolled co-morbidities and no second malignancies. Informed consent was obtained before entry.",NA,all treatment cycles,NA
9713314,NA,Combination,No,advanced colorectal cancer,"Eligibility criteria included a histological diagnosis of a malignancy that was either resistant to standard therapy or without alternative standard therapies available. Life expectancy had to be at least 8 weeks with a performance status of not greater than 2 by the ECOG score. A total white blood cell count of >= 3500/mm3 and a platelet count of >= 100 000/mm3 were mandatory, in addition to adequate renal and liver function as deÆned by a normal serum creatinine and a serum bilirubin level of less than 1.5 mg%. A minimum interval of 4 weeks had to elapse from prior chemotherapy or 2 weeks from prior radiation therapy. All patients provided written informed consent",NA,NA,NA
32400117,CTRI/2018/01/011542,Combination,No,recurrent high-grade glioma,"Eligible patients had recurrent GBM, the diagnosis of re-currence was based on either histopathological confirmation or on unequivocal clinico-radiological features. The confirmation of clinico-radiological features was done in  a neurooncology multidisciplinary board. There was no upper limit on the episode of recurrence, any recurrence postcompletion of primary treatment was included. The other eligibility criteria were age > 18 years, an Eastern  Cooperative Oncology Group performance status (ECOG PS) score of 0, 1, 2, or 3 (on a scale from  0 to 5, with 0 indicating that the  atient is fully active and higher scores indicating greater disability), normal organ and bone marrow functions ( Leukocytes ≥ 2000/mcL or absolute neutrophil count ≥ 1500/mcL, platelets ≥ 100 000/mcL, Total bilirubin < 1.5 × institutional upper limit of normal, serum glutamic-oxaloacetic transaminase (SGO)/serum glutamic-pyruvic transaminase (SGPT)≤2.5 × institutional upper limit of normal and calculated creatinine clearance > 30 mL/min).","Exclusion criteria included administration of any benzimi-dazole (albendazole, flubendazole, thiabendazole, fenbenda-zole,  triclabendazole,  etc) within the last 3 months, failure within 3 months of stopping temozolomide, presence of any uncontrolled comorbidities, presence of any medical or psychiatric condition which would have increased the risks associated with the study participation, interfered with in-vestigational product administration, or interfered with the interpretation of the results. Pregnant -lactating females and patients with a history of previous life-threatening complications with temozolomide were also excluded.  ","the first cycle (over 1 week in arm A1, over 6 weeks in arm B1, and over 4 weeks in arm C1)",NA
7977165,NA,Combination,No,metastatic gastrointestinal adenocarcinomas,"Eligibility criteria were histologically confirmed gastrointestinal carcinoma; age <= 75 years: performance status, according to the Karnofsky Index, >= 60: life expectancy > 2 months: measurable disease according to WHO criteria ( 17): absence of brain metastases: absence of a second malignancy other than cutaneous basaloma or in situ uterine carcinoma: white blood cells >= 4.000/mm3; platelet count >= 120.000/mm3); blood urea nitrogen s 50 mg%. serum creatinine <= 1.2 mg%: serum bilirubin <= 1.2 mg%: more than a 3-week interval since the last potentially myelosuppressive therapy: no major cardiovascular, neurologic, respiratory, or metabolic disease: and geographic accessibility in order to assure a correct follow-up. ",NA,NA,NA
12381899,NA,Combination,No,"patients with advanced solid tumors. Type of tumor: NSCLC 6 (16), Ovarian cancer 17 (45), Breast cancer 15 (39)","All patients had to have a histologically confirmed metastatic NSCLC, breast and ovarian cancer and should have been off previous anticancer therapy for at least 4 weeks. Other eligibility criteria were performance status (WHO) 0–2, age <75 years, a life expectancy of at least 3 months, adequate hematologic parameters (absolute granulocyte count >1,500/ul, hemoglobin level >9 g/dl and platelet count >100,000/ul), adequate hepatic (serum bilirubin <1.5 mg/dl, transaminases <2 x the upper limit of normal) and renal function (serum creatinine <1.5 mg/dl), preexisting peripheral neuropathy up to National Cancer Institute grade 1 and no other medical problems severe enough to affect patients’ compliance with the protocol. Patients with brain metastases were eligible if they had been irradiated, the brain lesions were radiographically stable, and clinical improvement was evident.","Patients with malnutrition (>20% loss of body weight), active infection or a second primary tumor other than skin squamous cell carcinoma or in situ cervical carcinoma were not eligible.",in the first chemotherapy cycle,NA
33021083,EudraCT2010-021525-13,Combination,No,"Patients With Advanced Solid Tumors. Primary tumor type, n (%): NSCLC 9(24), Ovarian cancer 3(8), Mesothelioma 3(8), Urothelial cell carcinoma 3(8), Salivary gland carcinoma 3(8), Renal cell carcinoma 2(5), Anal carcinoma 2(5), Neuroendocrine carcinoma 2(5), Others (Squamous cell carcinoma of the head and neck (N=1; colorectalcancer (N=1); esophageal cancer (N=1); adenocarcinoma of un-known primary site (N=1); squamous cell carcinoma of the skin(N=1); duodenal carcinoma (N=1); cholangiocarcinoma (N=1);leiomyosarcoma of the uterus (N=1); osteosarcoma (N=1); thymiccarcinoma (N=1))","Patients with metastatic solid tumors, aged ≥18 years,with no systemic therapy of proven benefit availableand with a World Health Organization PerformanceStatus ≤2 were included. Other inclusion criteria wereacceptable bone marrow (absolute neutrophil count ≥1.5×109/L and platelet count ≥100×109/L), hep-atic (serum bilirubin ≤1.5×upper limit of normal[ULN], alanine aminotransferase and aspartate amino-transferase ≤2.5×ULN), and renal (serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min byCockcroft-Gault formula) functions. Red blood cell orplatelet infusions were allowed before screening andstart. No radio- or chemotherapy was allowed withinthe 4 weeks before the start of the study treatment.","Patients with bowel obstructions or motility disorders thatcould influence the oral absorption of drugs were ex-cluded. Moreover, patients using CYP3A4-modulatingdrugs were not enrolled in the study, as well as patientswith symptomatic cerebral or leptomeningeal metas-tases. Patients who had preexisting treatment-relatedtoxicities of grade>1, had an active infectious disease,or were HIV infected were also excluded from the trial.",during the first cycle of the treatment,NA
30077789,NA,Combination,No,High-Risk Chordoma,"Adults aged 18 years or older with histologically confirmed, nonmetastatic chordoma were eligible to participate in this study. Patients were required to have high-risk disease as defined by (1) local recurrence after surgery alone, (2) pre- vious intralesional resections, (3) unplanned incomplete re- sections, (4) tumors that are unresectable or at best marginally resectable based on locally advanced stage, or (5) refusal of surgery because of excessive morbidity and would otherwise receive nonoperative treatment with radiation and/ or medical management. Patients additionally were required to meet the following eligibility criteria: measurable disease by Response Evaluation Criteria in Solid Tumors 1.0 criteria, Eastern Cooperative Oncology Group performance status of 0 to 2, life expectancy >3 months, adequate organ function and laboratory values, and ability to swallow pills.","Patients were excluded if they had previous tyrosine kinase inhibitor therapy, previous RT, impaired cardiac function, impaired gastrointestinal function that could alter study agent ab- sorption, acute or chronic pancreatic disease, known infiltration of the central nervous system, a concurrent second malignancy, a history of a congenital or acquired bleeding disorder unrelated to the cancer, surgery within 4 weeks of day 1 of the study, or treatment with other investigational agents within 30 days of day 1 of the study. Women who were pregnant, breast-feeding, or of childbearing potential without a negative pregnancy test result before baseline were also excluded",occurred within days 1 to 56 of study,NA
15539916,NA,Single Drug,No,"advanced solid malignancies refractory to conventional therapy. Malignancy: Colorectal, Pancreas, Leiomyosarcoma, Head and neck, Mesothelioma, Skin, Ovarian, Lung","Patients with histologically or cytologically documented advanced solid malignancies refractory to conventional therapy were candidates. Additional entry criteria included: age >18 years; Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0–2; life expectancy >=12 weeks; measurable disease; no treatment with antineoplastic agents in the previous 3 weeks (6 weeks for nitrosoureas or mitomycin C); no radiotherapy in the previous 6 weeks; adequate bone marrow function defined as WBC >=3,000/mm3; ANC >=1,500/mm3; platelets 6100,000/mm3; Hgb >=10.0 g/dl; adequate renal function defined as serum creatinine <1.6 mg/dl or creatinine clearance >=50 ml/min; adequate liver function defined as hepatic enzymes (AST, ALT) <=1.5 x normal, bilirubin <=1.5 mg%; normal cardiac function with no history of uncontrolled heart disease, and a negative pregnancy test for patients for whom pregnancy could be a possibility","Patients were ineligible if they were pregnant or lactating, had had a myocardial infarction within the previous 3 months, had congestive heart failure, unstable angina, active infection requiring systemic therapy, a history of a second malignancy other than nonmelanoma skin cancer or CIS of the cervix within the past 5 years, symptomatic brain metastases, greater than grade 1 residual neurotoxicity from prior therapy, history of anaphylaxis to prior taxane therapy or inability to understand the investigational nature of the study. After grade 2 neurotoxicity of paresthesias was noted in a patient treated at a dose of 30 mg/m2, who had been previously treated with oxaliplatin, prior use of oxaliplatin was added as an exclusion criterion.",the first 2 cycles,NA
33039812,NCT03294252,Combination,No,advanced peritoneal metastases of gastrointestinal tract cancers,"The inclusion criteria were as follows: histologically confirmed PC from gastrointestinal tract cancer; at least 3 months of systemic chemotherapy; isolated advanced PC with peritoneal cancer index (PCI)  greater than 5, 13 and 15 for gastric, small bowel and colorectal primary cancer, respectively; age >= 18 years; life expectancy > 3 months; Eastern Cooperative Oncology Group performance status of 0 or 1; adequate organ function (detailed in supplement). Patients with pe- ripheral neuropathy grade >I, known hypersensitivity to oxaliplatin, complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency, active uncontrolled infection or any other cancer were excluded from the study.","Patients who received bevacizumab (Avastin®) less than 4 weeks ago can not be included. Extra-peritoneal metastases, except for less than 3 pulmonary nodules (each size <5mm). Known hypersensitivity to Oxaliplatin. Known complete dihydropyrimidine dehydrogenase (i.e. DPD) deficiency. Peripheral neuropathy Grade >1 due to or not with Oxaliplatin previously used. Active or other serious underlying disease that may prevent the patient from receiving treatment. Intracranial or intraocular hypertension (ongoing at the time of inclusion). Severe or Severe Heart Failure (ongoing at the time of inclusion). Complete intestinal obstruction (ongoing at the time of inclusion). Other concurrent cancer or history of cancer other than in situ cancer of treated cervix or basal cell carcinoma or squamous cell carcinoma. Pregnant or nursing women. Persons deprived of their liberty or under guardianship or unable to give their consent. Inability to submit to medical follow-up of the trial for geographical, social or psychological reasons. Long-term corticosteroids (duration> 3 months), except for weaning for at least 3 months",during two consecutives PIPAC sessions separated by 4e6 weeks,NA
34518310,NCT02366949,Combination,No,"patients with advanced solid tumors. Cancer type:Breast cancer 25 (33.3), Ovarian cancer 6 (8.0), Prostate cancer 4 (5.3), Pancreatic adenocarcinoma 4 (5.3), Cholangiocarcinoma 3 (4.0), Gastric cancer 3 (4.0), SCLC 2 (2.7), NSCLC 2 (2.7), Other","Male or female subjects aged ≥18 years. For the dose-escalation cohorts: patients with histologically or cytologically confirmed advanced malignancies (solid tumors), refractory to any standard therapy, with no standard therapy available. For the expansion cohort: patients with advanced, histologically or cytologically confirmed triple-negative breast cancer, relapsed on a paclitaxel-containing regimen within 12 months prior to enrolment and refractory to any standard therapy, have no standard therapy available. Other malignancies where paclitaxel was part of the standard of could be considered upon agreement of the investigator and the sponsor. Patients had to have evaluable or measurable disease (as per RECIST 1.1). Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Life expectancy of at least 12 weeks. Adequate bone marrow, liver, and renal functions assessed within 7 days before the first dose of study drug: Hemoglobin ≥9.0 g/dL; subjects with chronic erythropoietin treatment consistent with institutional guidelines can be included; Absolute neutrophil count (ANC) ≥1.5. 109/L; Platelet count ≥100. 109/L; Total bilirubin ≤1.5 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 times ULN (≤5 times ULN for subjects with malignant liver involvement); International normalized ratio (INR) and partial thromboplastin time (PTT) ≤1.5 times ULN; Note: patients on anticoagulation with an agent such as heparin, including enoxaparin, were allowed to participate. Low-dose aspirin was permitted (≤100 mg daily); Serum creatinine (mg/dL) ≤1.5 times ULN or if serum creatinine was increased to 1.5 times ULN, estimated glomerular filtration rate (eGFR) >35 mL/min per1.73 m2 calculated consistent with the Modification of Diet in Renal Disease Study Group (MDRD) formula. Negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test obtained within 7 days before the first dose of study drug in women of reproductive potential. Agreement, by women of reproductive potential or men with female partners of reproductive potential, to use highly effective contraception consistently before study entry and for the duration of study participation, including the 30-day period after the last dose of study drug . Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained before any study-specific procedures","Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study. Evidence of peripheral neuropathy of Grade >2. History of cardiac disease: congestive heart failure New York Heart Association (NYHA) class >II, unstable angina (anginal symptoms at rest), new-onset angina (within the past 3 months before study entry), myocardial infarction within the past 3 months before study entry, or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers, calcium channel blockers, and digoxin were permitted). Uncontrolled hypertension defined as systolic blood pressure>150 mmHg or diastolic blood pressure >90 mmHg, despite optimal medical management. Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C . History of human immunodeficiency virus, hepatitis B, or hepatitis C infection. Active clinically serious infections of Grade >2. Symptomatic metastatic brain or meningeal tumors unless the subject was >6 months from definitive therapy, had a negative imaging study within 4 weeks prior to the first dose of study drug and is clinically stable with respect to the tumor at the time of study entry. Patients with asymptomatic brain metastases on steroid therapy were excluded. Uncontrolled seizure disorder requiring therapy (e.g. strong CYP3A4 inducers such as carbamazepine and phenytoin). History of organ allograft transplantation. Evidence or history of bleeding disorder, i.e. any hemorrhage / bleeding event of grade >2 within 4 weeks before the first dose of study drug. Serious, non-healing wound, ulcer, or bone fracture. Ongoing renal dialysis. For expansion cohort only: Previous or coexisting cancer that is distinct in primary site or histology from the cancer evaluated during this study except for cervical cancer in-situ, treated basal cell carcinoma, or any cancer curatively treated >3 years before study entry. Any clinical condition that is considered unstable or might jeopardize the safety of the patient and his / her compliance in the study. Inability to swallow oral medications. Any malabsorption condition. Unresolved specific chronic toxicity of grade >2 (excluding alopecia). -	Prior treatments, concomitant medications, and special behavioral issues. Patients with a history of any prior grade ≥3 toxicity associated with taxane treatment, except haematological toxicities were excluded. Prior treatment with anticancer chemotherapy or immunotherapy other than paclitaxel during the study or within 4 weeks before the first dose of study drug. For small molecule drugs, a period of at least 5 half-lives before the first dose of study drug was acceptable. Mitomycin C or nitrosoureas should not be given within 6 weeks before the first dose of study drug. Acute toxic effects of previous anticancer chemotherapy or immunotherapy, which were not recovered to grade ≤1 (excluding alopecia). Radiotherapy to target lesions during study or within 3 weeks before the first dose of study drug. Palliative radiotherapy was allowed to non-target lesions. Major surgery or significant trauma within 4 weeks before the first dose of study drug. Investigational drug treatment outside this study during or within 4 weeks before the first dose of study drug. For small-molecule drugs, a period of at least 5 half-lives before the first dose of study drug is acceptable. Toxic effects of previous investigational drug treatment have to recover to grade ≤1. Prior enrolment into the study with exposure to BAY 1217389 . Substance abuse, medical, psychological, or social conditions that may interfere with. The patients´participation in the study or evaluation of the study results. Use of strong inhibitors of CYP3A4 and strong inducers of CYP3A4 was prohibited for 14 days before the first dose of BAY 1217389 or paclitaxel and for the duration of the Study. Use of strong inhibitors of CYP2C8 was prohibited for 14 days before the first dose of paclitaxel and for the duration of the study. -	Use of narrow therapeutic index drugs that are CYP3A4 substrates (e.g. alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus) was prohibited for the duration of the study. Use of narrow therapeutic index drugs that are CYP2C9 substrates (e.g. warfarin and phenytoin) was prohibited for the duration of the study. Clinically relevant findings in the ECG such as a second- or third-degree atrioventricular block, prolongation of the QTc interval (Fridericia) over 450 ms unless agreed otherwise between the investigator and the sponsor’s medically responsible person ",in cycle 1,NA
29437791,NA,Combination,No,Relapsed or Refractory Acute Myeloid Leukemia,"Patients must have histologically or cytologic documented relapsed and/or refractory acute myeloid leukemia, be >=18 years old, fit for intensive salvage therapy, Eastern Cooperative Oncology Group (ECOG) performance status of <= 3, and an expected survival of >3 months. Patients could not have received radiotherapy, treatment with cytotoxic agents, treatment with biologic agents or any anticancer therapy within the 2 weeks prior to enrolment on study. In addition, patients were required to have adequate hepatic function [aspartate aminotransferase (AST/SGOT) <= 3 x upper normal limit (UNL), alanine aminotransferase (ALT/SGPT)<= 3 x UNL ( <=5 x ULN if leukemic liver infiltration was present), bilirubin <=1.5 x UNL)] and renal function (serum creatinine <=1.5 mg/dL or 133 mmol/L).",NA,NA,NA
20445979,NA,Combination,No,"patients with advanced solid tumors potentially responsive to mitoxantrone. Primary tumor: Prostate, Breast, Bladder, Testicular","Patients were eligible for this study if they met all of the following inclusion criteria: histologically documented solid tumor (measurable or non-measurable) potentially responsive to mitoxantrone and for which no effective therapy was available; age >=18 years; ECOG performance status 0–2; predicted life expectancy >=12 weeks. Patients may have had any number of prior chemotherapy or radiation therapy regimens, but a minimum of 4 weeks must have elapsed between the end of previous therapy and entry into the protocol. Patients previously exposed to anthracyclines may not have exceeded a cumulative anthracycline dose of 250 mg/m2 of Adriamycin. Patients were required to have adequate bone marrow, hepatic and renal function as defined by the following: neutrophil count >=1.5 9 109/L; platelets 100 x 109/L; total bilirubin B upper limit of normal; ALT and AST <=2.5 x upper limit of normal; and serum creatinine <=2.0 mg/dL. Patients were also required to have adequate cardiac function with an estimated left ventricular ejection fraction of >=50%. ","Patients were excluded if they had a history of previous myocardial infarction, cerebrovascular accident or uncontrolled atrial fibrillation within 1 year of screening. Concurrent use of prednisone or luteinizing hormone-releasing hormone (LHRH) was permissible.",during the first cycle of therapy,NA
19774342,NA,Combination,No,"patients with refractory solid tumors. Tumor Types: Esophagus, Pancreas, Gallbladder/Cholangiocarcinoma, Renal, Small Cell Lung, Unknown Primary, Prostate","Enrolled patients were required to have a histologically confirmed solid tumor that was not amenable to conventional surgical, radiation, or chemotherapy treatment programs. Prior chemotherapy and/or radiation were allowed, however, at least 4 weeks must have elapsed since prior large-field radiation therapy, and at least 3 weeks for any previous anticancer therapy. Eligibility criteria included (1) age ≥18; (2) Eastern Cooperative Oncology Group performance status ≤2; (3) life expectancy ≥12 weeks; (4) adequate hematopoietic function (ANC ≥1500/µL, platelet count ≥100,000/µL, hemoglobin ≥9.0 g/dL), hepatic function (total bilirubin <1.5 mg/dL, AST<2.5 times the upper limit of normal), and renal function (creatinine <1.5 mg/dL or calculated creatinine clearance ≥60 mL/min/1.73 m2). A central line was required for drug administration. All patients gave informed written consent prior to treatment according to federal and institutional guidelines.",NA,during cycle one,NA
9849448,NA,Combination,No,metastatic breast cancer,"Eligibility criteria included: age 18-55 years, no previous chemotherapy for metastatic disease; adjuvant chemotherapy, if received, had to be completed at least 6 months prior to metastatic disease. Patients needed to have evaluable or measurable disease. Performance status according to Karnofsky was 60% or more. Cardiopulmonary, liver, kidney and haematopoietic functions were normal. ",NA,NA,"Induction chemotherapy consisting of 5-Øuorouracil (5-FU) 750 mg/m2 body surface area, epirubicin (EPI) 100 mg/m2 body surface area, CTX 750 mg/m2 body surface area, all delivered on day 1 as an i.v. infusion. Starting on day 4, recombinant human granulocyte colony-stimulating factor (rhG-CSF; Neupogen1, Amgen Canada Inc., Mississauga, Ontario, Canada) at a dose of 10 mg/kg body weight subcutaneously (s.c.), was administered daily for approximately 10-11 days until the total white blood cell count reached more than 2,500 ml. The ABSCs were cryopreserved in 10% dime- thylsulphoxide (DMSO) as previously described by Ho and colleagues  and on the day of re-infusion, the cells were thawed, and washed to avoid DMSO-related toxicity . After the Ærst cycle of chemotherapy, the patients received a further two or three cycles of induction chemotherapy consisting of 5-FU 600 mg/m2 body surface area, EPI 60 mg/m2 body surface area, CTX 600 mg/m2 body surface area all administered i.v. The treatment without haematopoietic growth factor support was delivered every 3 weeks if the absolute neutrophil count (ANC) was >= 1.5x109/l and platelets >= 100x109/l. "
18493824,NA,Single Drug,No,patients with stage IV peritoneal carcinomatosis from colorectal and appendiceal cancers,"All patients were older than 18 years with histologically confirmed colorectal or appendiceal cancer and had an Eastern Cooperative Group performance status of 0–2. Acceptable bone marrow (absolute neutrophil count >=1,500/uL, platelet count >= 100,000/uL), renal (serum creatinine <=1.5), and hepatic function (serum total bilirubin <=1.5 mg/dL, alkaline phosphatase £3· the upper limit of normal, and serum oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase (SGPT) <=3 x the upper limit of normal) were required for enrollment in this trial.","Ineligibility criteria included an active infection or a fever >=38.5C within 3 days of the scheduled day of protocol treatment, central nervous system metastases, known hypersensitivity to any of the components of oxaliplatin, receipt of investigational therapy within 30 days of IPHC (investigational therapy was defined as treatment for which there is currently no regulatory authority approved indication), peripheral neuropathy >= grade 2, history of allogeneic transplant, and known HIV or hepatitis B or C infection. Patients with prior malignancy within the past 5 years were considered to be ineligible except for curatively treated basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, or localized prostate cancer with a current prostate specific antigen (PSA) of <1.0 mg/dL on two successive evaluations.",at least 10 days elapsed since the completion of the first cohort,patients underwent cytoreductive surgery followed by a 2-h IPHC with escalating doses of oxaliplatin at a target outflow temperature of 40C
32816079,NA,Combination,No,primary CNS lymphoma,"Adult patients (aged 18–85 years) with histologically confirmed PCNSL, an Eastern Cooperative Oncology Group (ECOG) performance status < 4, and no extra-CNS involvement were enrolled, from July 2007 to January 2012, at 2 Italian radiotherapy centers (Catholic University of Rome and Perugia University). All of the patients had previously received 2 cycles of HD-MTX (3.5 g/m2). The baseline evaluations included a physical examination, ophthalmology examination, liquor cytology, cerebrospinal fluid cytology, and magnetic resonance imaging (MRI).","All patients underwent laboratory evaluations, and those whose values did not meet the following criteria were excluded: platelets > 100 × 109/L; hemoglobin (Hb) concentration > 11 g/L; white blood cells >4000/mm3; neutrophils > 1900/mm3; and aminotransferase, total bilirubin, and alkaline phosphatase concentrations <1.25 times the normal reference values. Patients were also excluded if they exhibit any of the following: immunosuppression (including positive HIV serology); concomitant malignancy other than basaloid carcinoma or cervical carcinoma in situ; degenerative neurological disease or neuropsychiatric disorder; preexisting PCNSL diagnosis; pregnancy; heart failure; respiratory failure; or kidney failure.",The DLT was evaluated following 3 months of post-treatment follow-up in each 3-patient cohort,NA
33602685,NCT2379247,Combination,No,HER2-Negative Metastatic Breast Cancer,"Eligible patients were females aged ≥18 years with locally advanced or metastatic HER2-negative (per 2013 ASCO/CAP guidelines; ref. 8) breast cancer who had received at least one line of chemotherapy in either the advanced or neo/adjuvant setting, had measurable disease (per RECIST version 1.1), Eastern Cooperative Oncology Group performance status ≤2, and adequate organ and marrow function. Previous endocrine therapy was allowed (no limit on number of prior endocrine therapies), and previous taxanes (except nabpaclitaxel) were allowed if >6 months since exposure. Participants with treated brain metastases were eligible if free from central nervous system symptoms and at least 3 months had passed since brain metastasis treatment.",Participants were excluded for uncontrolled diabetes mellitus [fasting plasma glucose (FPG) level >140 mg/dL (7.8 mmol/L) or glycosylated hemoglobin (HbA1C) >8%] or prior treatment with PI3Ki,during the first treatment cycle,NA
18394816,NA,Combination,No,advanced unresectable carcinoma of the head and neck,"The inclusion criteria comprised locally and/or regionally inoperable and histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx, without distant metastases. The criterion for inoperability was technical unresect- ability (1) as determined at the joint multidisciplinary head-and- neck tumor board conference. Patients had to be >=18 years old with expected survival of >6 months, with World Health Organization performance status <=2 and adequate hematologic, renal, and liver function, and had to provide written informed consent. ","Patients with a previous history of cancer in the last 5 years (except for cured non-melanoma skin cancer or in situ carcinoma of the uterine cervix), cardiac disease, clinically evident hearing impairment, peripheral neuropathy of Grade $1, or any other medical condition precluding safe administration of the planned therapy were considered ineligible for the study",NA,NA
32037195,NCT01952249,Combination,No,"platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer","Eligible participants were age 21 years or older with cytologically or histologically confirmed EOC. Inclusion criteria were platinum-resistant disease (defined as disease progression <6 months after receiving a minimum of four cycles of a platinum-containing regimen) or platinum-refractory disease (defined as disease progression while receiving a platinum-containing regimen); life expectancy of >3 months; RECIST v. 1.1 measurable disease ; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; and adequate bone marrow, hepatic, and renal function. ","Exclusion criteria were non-epithelial ovarian carcinoma; carcino- sarcoma; greater than four prior chemotherapy regimens; prior therapy with weekly paclitaxel for recurrent disease (administration of weekly paclitaxel as part of an upfront treatment strategy was acceptable if the patient had not had disease progression during or recurrence within 4 months of receipt); any other current anticancer therapy; prior radio- therapy to the pelvis or abdomen; current use of heparin, warfarin, or other similar anticoagulants (low-dose aspirin and/or nonsteroidal anti-inflammatory agents were allowed); and luminal tumors involving the gastrointestinal tract (owing to the increased risk of bleeding and integumentary disruption). Targeting DLL4 has been associated with pulmonary hypertension and heart failure, so specific cardiac exclusion- ary criteria were cardiac ischemia or heart failure within the last 6 months or use of any medications for cardiac ischemia; B-type natri- uretic peptide value of >100 pg/mL; left ventricular ejection fraction <50%; peak tricuspid velocity >3.0 m/s according to Doppler echocardiogram; and total cumulative dose of greater than or equal to 400 mg/m2 doxorubicin or an equivalent amount of liposomal doxorubicin. ",from days 0 through 28,NA
11281378,NA,Combination,No,"in high-risk and advanced solid tumors. Sites of metastasisL Solitary, Lung, Bone, Liver, Nodal, Bone Marrow, Multiple, Ovarian cancer, Ewing sarcoma","Patients were included from the following diagnostic groups: metastatic cancer in complete or partial response after standard chemotherapy, or with no evidence of disease after surgery or radiotherapy (stage IV NED), and high-risk breast cancer (five or more positive axillary nodes) after conventional adjuvant treatment. Additional inclusion criteria were: age 18 to 60 years, ECOG performance status 0 or 1, life expectancy greater than 12 weeks, absence of previous cardiovascular disease or other poorly controlled medical illness, adequate cardiac, renal, hepatic and hematological function (left ventricular ejection fraction (LVEF) >=50% measured by resting multigated nuclear scans (MUGA), creatinine ,1.2 mg/dl; total bilirubin <1.5mg/dl; absolute neutrophil count (ANC) >1.5 x 109/l; and platelets >100 x 109/l), informed consent prior to initiating therapy and adequate access to hospital (within 1 h).",Exclusion criteria were: confirmed central nervous system metastases or carcinomatous lymphangitis; treatment with chemotherapy or radiotherapy within 3 weeks prior to study entry; more than one previous regimen of prior chemotherapy (including adjuvant or neoadjuvant therapy); treatment with more than 350 mg/m2 of doxorubicin or 525 mg/m2 of 4-epirubicin; and previous treatment with radiotherapy through a left chest port.,during each cycle ,NA
16619562,NA,Combination,No,"advanced cancer. Primary tumor: Colorectal, Pancreas, Stomach, Biliary, Liver","All patients were required to meet the following criteria: confirmed histological or cytological diagnosis of cancer, at least 1 bidimensionally measurable or evaluable disease, WHO performance status 0-2, a life expectancy greater than 3 months, previous treatment by standard chemotherapy at the time of entry and refractory to any prior cytotoxic treatment. Patients were eligible if they had had 2 or 3 previous courses, provided that they had been off treatment for at least 3 weeks.",NA,NA,NA
7544169,NA,Combination,No,Forty-three women with locally advanced (11) or metastatic (32) breast cancer entered this study,"All patients studied had histologically proven locally advanced or metastatic adenocarcinoma of the breast. Eligibility criteria were as follows: age from 18 to 75 years, WHO performance status <= 2, estimated life expectancy >= 8 weeks, leukocyte count >= 3,000/L, platelet count >= 100,000/L, serum creatinine <= 1.5 mg/dl, serum bilirubin <= 2.0 mg/dl, and no antineoplastic treatment during the 8 weeks before entry.","Patients with active angina pectoris, congestive heart failure, myocardial infarction within the last six months, or impaired left ventricular ejection fraction were excluded.",at first course,NA
11283925,NCT01810718,Combination,No,patients with advanced colorectal carcinoma,"Patients with histologically confirmed, nonresectable metastatic or locally recurrent colorectal cancer (Stage IV; American Joint Committee on Cancer/International Union Against Cancer) and bidimensionally measurable disease (defined as the presence of at least one index lesion capable of two-dimensional measurement by computed tomographic [CT] scan outside any irradiated zone and >2 cm in greatest dimension) were considered candidates for this study. Eligibility criteria also included age between 19 years and 75 years, a World Health Organization (WHO) performance status of 0 –2, a life expectancy of at least 3 months, adequate bone marrow reserve (leucocyte count > 3500/uL, platelet count > 100,000/uL), and adequate renal function (serum creatinine concentration < 132 mmol), and hepatic function (serum bilirubin level < 34 umol/L and serum transaminase level < 2 times the upper limits of normal). Patients may have received adjuvant fluoropyrimidine-based chemotherapy and/or radiation therapy, which must have been completed at least 6 months before study entry. Similarly, palliative radiotherapy was allowed if <= 20% of the bone marrow was involved, there was the presence of a target lesion outside the radiation port, and there was full resolution of toxicities.","Exclusion criteria included the presence of central nervous system metastases, serious or uncontrolled concurrent medical illness, peripheral neuropathy, and a history of other malignancies with the exception of excised cervical or basal skin/squamous cell carcinoma",the first two treatment cycles,NA
17681103,NA,Combination,No,Metastatic Colorectal Cancer,"Patients with a histologic diagnosis of adenocarcinoma of the colon or rectum with locally advanced unresectable or stage IV CRC that was not amenable to curative therapy were potentially eligible for enrollment in this trial. Patients were required to be aged >= 18 years and to have an Eastern Cooperative Oncology Group performance score of 0-2. Hematologic and chemistry parameters were to be in the following ranges: absolute neutrophil count >= 1.5 x 109/L, platelet count >= 100 x 109/L, total bilirubin level <= 1.5 times the institutional upper limit of normal (ULN), aspartate aminotransferase level <= 2.5 X ULN, and creatinine level <= 1.5 x ULN.","Only 1 previous adjuvant therapy including CPT-11, 5-FU/leucovorin, or capecitabine (but not oxaliplatin) was allowed, if that recurrent disease was diagnosed >= 6 months after the last adjuvant chemotherapy treatment. In addition, patients could have received 1 advanced disease regimen that did not include pemetrexed or oxaliplatin. Previous radiation therapy to > 25% of bone marrow was not allowed. Patients were not eligible if pregnant or lactating and were required to use adequate contraception methods to prevent pregnancy during treatment. Other contraindications included a history of brain or other central nervous system metastases not amenable to local therapy. Any history of previous malignancy diagnosed within 5 years was not allowed, with the exception of basal or squamous cell carcinoma of the skin and cervical carcinoma in situ.",cycle 1,NA
32520407,NCT00916630,Single Drug,No,Recurrent or Progressive Central Nervous System Lymphoma,Disease state (5 categories of patients with these extremely rare disease are eligible: 1) Patients intolerant of Methotrexate-must have a diagnosis of B cell non-Hodgkin's lymphoma 2) Patients unable to receive methotrexate due to lack of drug availability-must have a diagnosis of B cell non-Hodgkin's lymphoma 3) Patients who fail to achieve a complete response to initial therapy for primary CNS lymphoma-must have a diagnosis of B cell non-Hodgkin's lymphoma 4) Recurrent Primary CNS lymphoma-If in the judgement of the treating physician therapy would be initiated without a repeat biopsy then the original biopsy with a diagnosis of B cell non-Hodgkin's lymphoma will suffice 5) Secondary CNS lymphoma-If in the judgement of the treating physician therapy would be initiated without a repeat biopsy then the original biopsy with a histologic diagnosis of B cell non-Hodgkin's lymphoma will suffice. Histologic diagnosis of B cell non-Hodgkin's lymphoma with measurable disease OR cytologic diagnosis of B cell non-Hodgkin's lymphoma with measurable disease OR immunohistochemical diagnosis of monoclonality (CDF) with or without measurable intracranial disease OR molecular diagnostic diagnosis of monoclonality CSF) with or without measurable intracranial disease OR Ocular-patients may have a combination of histologic confirmation of ocular lymphoma and measurable intracranial tumor. Slit-lamp examination and vitreal or retinal biopsy will be done to confirm ocular lymphoma OR neurolymphomatosis-evidence of measurable disease as nerve seeking lymphoma on MRI imaging with histologic diagnosis at any site. Karnofsky score of 60 or greater. Must be able to undergo MRI scanning. 18 years of age or older. Life expectancy of at least 2 months. Laboratory values as outlined in protocol. Must be willing to practice an effective method of birth control during participation in the study whether male or female.,"Definitive histologic diagnosis of low grade lymphoma without substantive clinical suspicion of transformation to an aggressive lymphoma. Renal dysfunction defined as creatinine clearance < 45 ml/min or serum creatinine > 2mg/dL. Transaminases > 3 times above the upper limits of the institutional normal. Acute infection, granulocytopenia or medical condition precluding surgery as judged by the caring physician and review team. Pregnant or lactating females. Patients must not have pre-existing immunosuppression, concurrent immunosuppressive treatment (with the exception of dexamethasone) or be a transplant recipient. Patients must not have received prior whole brain irradiation. They can have received prior focal irradiation. Prior participation in chemotherapy, cytotoxic therapy, immunotherapy or therapeutic protocols within 4 weeks fo enrollment. Patients unable to stop NSAIDS or Cox 2 inhibitors for two day before and after treatment as well as the day of treatment. No other active systemic malignancy with the exception of basal cell carcinoma of the skin and cervical carcinoma in situ. Patients with a remote history (5 years or more) of malignancy are eligible for the protocol in the absence of active disease. Clinically relevant third space fluid collection refractory to drainage. Patient refusal to participate in the pK study",within the first two cycles (28 days) of therapy or the 14-day observation period between each dose level cohort,NA
34256279,NCT01677559,Combination,No,"patients with advanced solid malignancies. Tumour type: Lung small cell, GI NET(high grade Pancreatic neuroendocrine carcinoma, Small bowel neuroendocrine carcinoma, high grade Esophageal neuroendocrine carcinoma), Non-GI NET(Neuroendocrine tumor of lung, Nasopharyngeal neuroendocrine carcinoma, Large cell neuroendocrine carcinoma, Lung neuroendocrine carcinoma), Other (Distal esophageal adenocarcinoma, Renal cell carcinoma, Lung adenocarcinoma, Pancreatic ductal adenocarcinoma, Gastro-esophageal junction adenocarcinoma, Hilar cholangiocarcinoma, Chondrosarcoma)","InPart A, patients with histologically confirmed metastatic or unresectable solid tumours for which standard curative or palliative measures did not exist or were no longer effective were enrolled. In Part B, patients with histologically or cytologically confirmed diagnosis of pancreatic cancer or poorly differentiated or high-grade NETs, including gastroenteropancreatic NETs (GEP-NET), who had progressed on at least one line of standard regimen were enrolled. All histologic grade was determined with by Ki-67 and/or morphology by pathologists at Washington University. Patients were required to have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 . Other inclusion criteria included age >=18 years old, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0e1, adequate bone marrow and organ function, as well as the ability to understand and willingness to sign a Human Research Protection Office (HRPO) approved written informed consent document.","Exclusion criteria included having received prior chemotherapy or radiotherapy within 4 weeks or 5 half-lives before study treatment, presence of another active malignancy within the previous 2 years that could alter the course of cancers being treated, known brain metastases, prior radiation to >25% of bone marrow, prior exposure to nab-paclitaxel  or Aurora kinase inhibitors, constant use of proton-pump inhibitors, H2 blockers or pancreatic enzymes, presence of uncontrolled intercurrent illness, pregnant and/or breastfeeding and antiretroviral therapy for HIV.",cycle 1,NA
29720734,NCT02044796,Combination,No,newly diagnosed AML or other high-grade myeloid neoplasms,"Adults aged ≥18 years with untreated AML  (acute promyelocytic leukemia excepted) or other myeloid neoplasms with ≥10% blasts in blood and/or marrow were eligible if they had a treatment-related mortality (TRM) score of ≤6.9. This score (online calculator: https://cstaging. fhcrc-research.org/TRM/) is composed of weighted information from 8 covariates (age, performance status, white blood cell [WBC] count, peripheral blood blast percentage, type of AML [de novo vs. secondary], platelet count, albumin, and creatinine) and corresponds to a ≤6.9% probability of death within 28 days (“TRM”) of receipt of intensive chemotherapy for newly-diagnosed AML . Patients had to have a left ventricular ejection fraction ≥45%, creatinine ≤2.0 mg/dL, and bilirubin ≤2.5 times the upper limit of normal, no uncontrolled infection, and an expected survival of >1 year absent AML. Disease risk was assessed according to MRC/NCRI criteria , and, when molecular data was available, 2017 European LeukemiaNet (ELN) criteria . Best responses, defined according to standard criteria [19, 20], were measured after 1–2 cycles of therapy. Measurable residual disease (MRD) was assessed by multiparametric flow cytometry (MFC). The sensitivity of the MFC MRD assay varies with the type of phenotypic aberrancy and immunophenotypes of normal cells in the background populations. Therefore, the assay does not have uniform sensitivity across all cases but is able to detect MRD when present in the large majority of cases down to a level of 0.1% and in progressively smaller subsets of patients as the level of residual disease decreases below that level. When identified, the abnormal population was quantified as a percentage of the total CD45+ white cell events","Myeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not considered candidate for tyrosine kinase inhibitor treatment. Concomitant illness associated with a likely survival of < 1 year. Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24 hours; patients with fever thought to be likely secondary to leukemia are eligible. Known hypersensitivity to any study drug. Pregnancy or lactation. Treatment with any other investigational agent",Up to day 45 after start of induction chemotherapy,NA
15205208,NA,Combination,No,"patients with advanced solid tumors. Tumor type: Sarcoma 5, Adenocarcinoma, unknown primary 3, Head and neck 3, Esophagus 3, Colon 3, Ovary 3, Stomach 2, Non-small-cell lung cancer 2, Pancreas 2, Uterine corpus and cervix 2, Rectum 2, Miscellaneous (Small intestine, prostate, breast, cholangiocarcinoma, renal, adrenal)","Patients with a histologically or cytologically confirmed diagnosis of locally advanced or metastatic malignant solid tumor not amenable to curative therapy were eligible. Other eligibility criteria included age >= 18 years, World Health Organization (WHO) performance status <= 2, an estimated life expectancy of at least 12 weeks, and adequate bone marrow [platelets >= 100 x 109/L, hemoglobin >_ 9 g/dL, absolute granulocyte count (AGC) >2.0 x 109/L], hepatic [bilirubin <= 1.5 x upper limit of normal, aspartate transaminase (AST) and alanine transaminase (ALT) <= 3.0 x normal (AST and ALT <= 5.0 x normal is acceptable if due to liver metastases), and albumin >= 2.5 g/dL] and renal function (calculated creatinine clearance >= 45 mL/min). Up to two previous chemotherapeutic regimens were allowed, but not within 4 weeks of enrollment (6 weeks for nitrosoureas or mitomycin). Previous radiotherapy was allowed if patients recovered from its toxic effects before study entry","Patients were excluded from the study for: plasma homocysteine >= 12 mmol/l; active infection; symptomatic brain metastasis; previous treatment with pemetrexed or previous oxaliplatin within 6 months of enrollment; previous high-dose chemotherapy with autologous stem-cell rescue; evidence of peripheral neuropathy grade >1 according to the National Cancer Institute common toxicity criteria (NCI-CTC); inability to discontinue administration of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) 2 days before (5 days for long half-life NSAIDs) the day of, and 2 days after, therapy; or clinically significant effusions (pleural or peritoneal)",during the first cycle,NA
17308894,NA,Single Drug,No,advanced solid tumor patients,"Patients were to have histologically or cytologically conWrmed advanced solid tumors that had failed all therapy of established merit, and meet all the following criteria: age >=18 years, WHO performance status <=2, life expectancy >=3 months, discontinuation of all previous anticancer treatments for at least 4 weeks before first dose of study drug (6 weeks for nitrosoureas, melphalan and mitomycin C), discontinuation of all prior radiotherapy (8 weeks for extensive prior radiotherapy), use of eVective contraceptive methods, adequate bone marrow function (absolute neutrophil count >=1.5 x 109/l, platelet counts >=100 x 109/l), hepatic function (serum bilirubin <=1.5 x the upper limit of normal (ULN); aspartate aminotransferase and alanine aminotransferase <3 x ULN), renal function (serum creatinine and blood urea to be within normal limits and creatinine clearance, calculated according to the Cockroft–Gault formula, >50 ml/min). ","Patients were ineligible in the event of clinical signs of brain metastases and/or leptomeningeal involvement by tumor, prior nephrectomy, National Cancer Institute—Common Toxicity Criteria (NCI-CTC version 2) grade 2-4 neuropathy or hearing loss >= grade 2, or patients with active uncontrolled infection or other serious illness.",during the Wrst cycle ,NA
17538173,NA,Single Drug,No,"in children and adolescents with refractory solid tumors. The most common diagnoses were neuroblastoma/ganglioneuroblastoma (n = 7) and medulloblastoma (n = 5), Hepatocellular carcinoma 3, Colorectal carcinoma 2, Ewing’s family of tumors 1, Rhabdomyosarcoma 1, Wilms’ tumor (diffuse anaplasia)] 1, Chondrosarcoma 1, Ependymoma (anaplastic), Hepatoblastoma, Desmoplastic small round cell tumor 1, Epithelioid sarcoma 1, Gliomatosis cerebri 1","Age < 21 years. Solid tumor refractory to conventional therapy or for which no standard treatment exists. Histologic confirmation of the diagnosis except for tumors originating in the brainstem. Eastern Cooperative Oncology Group performance status <= 2 or Lansky Play performance scale >= 50%. >= 3 weeks since prior chemotherapy ( 6 weeks for nitrosoureas). >=1 week since hematopoietic growth factors. >=6 weeks since irradiation of any significant marrow-containing compartment. >=3 months since bone marrow or stem cell transplantation. >=6 months since craniospinal (>24 Gy); total abdominal, pelvic, or lung irradiation; or mantle and inverted Y port radiation. No evidence of graft-versus-host disease and not receiving therapy for this condition. Hemoglobin >= 8 g/dL. Absolute neutrophil count >= 1,000/mm3. Platelet count >= 100,000/mm3. Normal serum electrolytes, calcium, phosphorous, and glucose. ALT and AST activity < 3 times normal. Serum creatinine within normal limits for age or Technetium99 diethylene triamine pentacetic acid clearance rate > 50 mL/min/m2","Peripheral neuropathy. History of allergy to platinum compounds or appropriate antiemetics. Uncontrolled intercurrent illness. Need for concomitant medications other than analgesics, magnesium, antiemetics, seizure medication, and antibiotic Pneumocystis carinii pneumonia prophylaxis. Antiretroviral therapy for HIV infection. Pregnancy or lactation",during the first course of treatment ,NA
30889492,NCT02848443,Combination,No,patients with metastatic colorectal cancer,"Eligible patients were aged >=18 years with histologically confirmed mCRC pre-treated with at least one line of standard chemotherapy for metastatic disease. In addition, patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, a life expectancy of >3 months, adequate bone marrow, liver and kidney function and at least 1 evaluable or measurable metastatic lesion per revised Response Evaluation Criteria In Solid Tumours (RECIST), version 1.1.","Key exclusion criteria included grade >=2 peripheral neuropathy and prior treatment with trifluridine/tipiracil. There was no upper limit to the number of prior anti-neoplastic regimens received, and prior exposure to oxaliplatin was permitted, provided the treatment was not discontinued for toxicity due to oxaliplatin and the patient had not experienced grade >=3 hypersensitivity (or grade 1-2 not controlled with pre-medication) due to oxaliplatin. ",within the first 28 days of therapy (2 treatment cycles),NA
34272090,NCT02788708,Combination,No,"patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer","Women were eligible if they were > 18 years old, had recurrent histologically confirmed endometrial cancer, platinum resistant (progression <6 months after completion of a platinum containing regimen) epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (all histological subtypes), and ECOG performance status ≤1. Patients had to have measurable disease by RECIST v1.1 criteria, were required to have received prior treatment with a platinum containing regimen, and allowed to have received an unlimited number of prior regimens (including prior taxanes and targeted therapy such as bevacizumab). Patients had to have normal organ function, and needed to be able to take and absorb oral medications.","Patients with significant cardiovascular disease, recent venous or arterial thromboembolism and recent major surgery or non-healing wounds were excluded",the first cycle of treatment,NA
15908652,NA,Single Drug,No,"children and adults with refractory hematologic malignancies. Fifty-nine patients were adults and 34 patients were children. Of the patients enrolled, 66% had T-cell malignancies, 22% had B-cell malignancies, and 13% had myeloid or other hematologic malignancies.","Patients were selected based on the following eligibility criteria: age younger than 75 years; histologically or cytogenetically documented diagnosis of a refractory hematologic malignancy in relapse; adequate organ system function as evidenced by serum creatinine <= 2.0 mg/dL, hepatic transaminases <= 3 x the upper limit of normal, serum bilirubin <= 3.0 mg/dL, and normal cortical and cerebellar neurologic function; life expectancy of >= 2 months; no active infection at the time of treatment; adequate nutritional status (> third percentile for weight, normal total serum protein, and albumin/globulin ratio) and adequate performance status (Karnofsky performance status > 30 or Eastern Cooperative Oncology Group performance status of 0 to 3); not receiving any other anticancer agents or enrolled onto any other investigational study during the course of the study; recovery from acute toxicity of all previous chemotherapy; and no history of a seizure disorder or significant neurologic toxicity with prior chemotherapy or radiation therapy. In patients who had experienced relapse after allogeneic or autologous bone marrow transplantation, cardiac and pulmonary function studies were obtained. These patients were required to meet the following criteria: cardiac ejection fraction by echocardiogram or radionuclide scan of greater than 45% for patients <= 18 years of age and >= 35% for patients older than 18 years; pulmonary function tests demonstrative forced vital capacity and forced expiratory volume in 1 second of >= 75% of predicted for age or diffusing capacity of lung for carbon monoxide >= 60%. All patients (or patient’s legal guardians) were enrolled onto the study after the approval of each institution’s institutional review board and were required to give written informed consent according to institutional and federal guidelines before study enrollment.",NA,during the first course of therapy,NA
33975862,NCT02630199,Combination,No,"Refractory Cancer. Tumor types:Gastric cancer 15 (26.3), Colon cancer 3 (5.3), Sarcoma 4 (7.0), Hepatocellular carcinoma 1 (1.7), Neuroendocrine carcinoma 1 (1.7), Melanoma 33 (57.9)","Eligible patients were ages >19 years with metastatic solid cancer and measurable disease according to RECIST version 1.1 (21). Patients must have received standard-of-care chemotherapy, be Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and have adequate hematologic parameters (hemoglobin ≥9 g/dL, ANC ≥1,500 per mL, and platelets ≥75,000 per mL), hepatic (ALT and AST ≤2.5  institutional upper limit of normal unless liver metastases are present in which case it must be ≤5x ULN), and renal functions (estimated creatinine clearance ≥45 mL/min). Although it was not a requirement for study entry, all patients with metastatic melanoma undergoing palliative immune-chemotherapy received annual brain MRI as a screening for asymptomatic brain metastases. ","Key exclusion criteria were prior receipt of more than four chemotherapy regimens or previous treatment with an ATR inhibitor or paclitaxel. Patients must not have received any palliative chemotherapy or investigational therapies within 14 days of the first administration of study drugs, and were excluded if they had symptomatic brain metastases requiring local therapy",during the first cycle of treatment,NA
31810960,UMIN 000010945,Combination,No,in Metastatic Breast Cancer Patients,"The eligibility criteria were female patients age 20-75 years with invasive, metastatic or recurrent, pathologically-confirmed adenocarcinoma of the breast that was human epidermal growth factor receptor type 2 (HER2)-negative by immunohistochemistry or in situ hybridization, regardless of hormone receptor status, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1, and at least one measurable lesion. Laboratory value requirements included normal renal function (serum creatinine, ≤1.2 g/dl), normal hepatic function (aspartate aminotransferase (AST) and alanine aminotransferase (ALT), <100 IU/l and total bilirubin, ≤1.5 mg/dl) and normal hematologic function (white blood cells, ≥4,000/mm3: neutrophils, ≥2,000/mm3: platelets, ≥100,000 mm3: and hemoglobin, ≥9.0 g/dl). Patients who had received adjuvant paclitaxel or docetaxel were included, if 6 months had passed since completion of that therapy.","Patients were excluded if they had severe complications in other organs,had undergone any surgery within 4 weeks prior to enrollment, had received more than two regimens for MBC, had received first-line paclitaxel or docetaxel or nab-paclitaxel for MBC, or had grade ≤2 sensory neuropathy. Inclusion was not dependent on the presence or absence of measurable lesions.",in the first cycle,NA
16142489,NA,Combination,No,"primary inoperable advanced head and neck cancer. All the patients had histologically proven inoperable advanced squamous cell carcinoma (17 histologic grades 2 and 4 grade 3). Seventeen patients were stage IVA and four patients were stage IVB. Tumours were located as follows: oral cavity (3), oropharynx (14), hypopharynx (3), and larynx (1)","All the patients were required to have a histologically proven inoperable advanced squamous cell carcinoma (oral cavity, oropharynx, hypopharynx, larynx; stages IVA and IVB). The other eligibility criteria were: 18–70 years of age, no prior radiotherapy, WHO performance status <= 2, normal hematologic values (leucocytes >3.0x109/l, platelets >100x109/l, hemoglobin >10 g/dl), normal renal and liver function, and adequate contraception in the case of female patients. The local committee on ethical issues had approved the treatment protocol, and signed informed consent was obtained from all the patients before their entry into the study.","Patients with nasopharynx, para-nasal sinus, and salivary gland tumours or distant metastases were excluded.",NA,NA
33585999,NCT02041429,Combination,No,HER2-negative metastatic breast cancer,Patients were required to have histologically confrmed metastatic or unresectable HER2-negative breast cancer. Eligibility criteria included either measurable or evaluable disease; ≤3 prior chemotherapies for advanced disease; age ≥18 years; life-expectancy>3 months; Eastern Cooperative Oncology Group (ECOG) performance status≤2; and adequate end organ function.,Both men and women were allowed to participate and those who were pregnant were excluded.,2 cycles of therapy,NA
31273010,NCT02316171,Combination,No,Non Muscle-Invasive Bladder Cancer,"1.	Clinical diagnosis of NMIBC based on cystoscopic appearance. 2.	Age > 18 years. 3. Able to read, understand and provide written informed consent to participate in the study. 4. Performance Status (PS): Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. 5.	No intravesical therapy within 6 weeks of study entry. 6. No prior radiation to the pelvis. 7. Adequate hematologic function, defined as: Absolute neutrophil count (ANC) > 1,500/mm3; Haemoglobin >9.0 g/dl; Platelet count > 100,000/mm3. 8. Adequate renal function, defined as: Serum creatinine ≤ 1.5 mg/dL. 9. Adequate hepatic function, defined as: Total bilirubin within normal limits; Aspartate transaminase (AST) ≤ 2.5 x upper limits of normal (ULN); Alanine transaminase (ALT) ≤ 2.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN, unless bone metastasis was present in the absence of liver metastasis.","1. Prior local or systemic treatments for NMIBC. 2.	Concurrent treatment with any chemotherapeutic agent. 3. Subjects not deemed acceptable to receive general anaesthesia. 4. Women who were pregnant or lactating. 5.	History of vesicoureteric reflux or an indwelling urinary stent. 6. Participation in any other research protocol involving administration of an investigational agent within 3 months prior to study entry. 7. Active cardiac disease. 8.	Known infection with HIV, hepatitis B or hepatitis C. 9. Active uncontrolled infection",from the time of first administration to 7 days later,NA
10213209,NA,Single Drug,No,"cancer patients. Tumor distribution: Colorectal cancer 6, Renal cell carcinoma 4, Breast cancer 2, Prostatic cancer 2, Cervical carcinoma 1, Mesothelioma 1, Neurofibrosarcoma 1","All patients were required to have histologically proven cancer that was no longer amenable to standard treatment. Eligibility criteria were as follows: (a) performance status, WHO grades 0–3; (b) age, 18–75 years; (c) life expectancy, at least 3 months; (d) adequate bone marrow, liver, and renal function; (e) no chemotherapy or radiotherapy for at least 4 weeks; and (f) informed consent. ",Patients with brain metastases or with known contraindications for MTX treatment were excluded.,during the first three administrations,NA
8157471,NA,Combination,No,"patients with advanced solid malignancies. The following primary tumor sites were observed: non-small cell lung (10 patients), pancreas (2 patients), colon (2 patients), unknown (3 patients) and kidney, pleura, gastroesophageal junction, appendix, uterus, and sarcoma of the left leg (observed in one patient each). ","Patients with histologically proven tumors for which there are no standard therapies were entered into the study. Patients who were over 18 years of age, had an Eastern Cooperative Oncology Group (ECOG) performance status of grade 0 to 2, and had a life expectancy of at least 2 months were eligible. Patients having stable brain metastases were also eligible. Acceptable cardiac function was required; this was documented by a left ventricular ejection fraction (LVEF) > 45% as measured by a multiple gated acquisition (MUGA) scan. Other requirements for eligibility consisted of a serum bilirubin < 2 mg/dl, an SGOT less than twice the upper limit of normal, a serum creatinine < 2.0 mg/dl, a white blood cell (WBC) count > 4000 mm 3, an absolute neutrophil count (ANC) of > 1500 mm 3, and a platelet count of > 125 000/mm 3. Each participant was informed of the investigational nature of the study and gave informed consent before enrollment.","Patients were excluded if they had received chemotherapy or radiation therapy < 4 weeks before study entry, received more than two previous chemotherapeutic regimens, received previous therapy with mitoxantrone or more than 180 mg/m 2 of doxorubicin, required corticosteroids, or were pregnant or lactating women",course 1,NA
18463792,NA,Combination,No,patients with metastatic cancer,"Standard eligibility criteria for phase I studies were applied. These included histologically or cytologically confirmed solid tumors refractory to conventional therapy or for which no curative therapy exists, measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria , no anticancer therapy within 30 days prior to study entry, Eastern Cooperative Oncology Group performance status of 0 to 2 , adequate hematopoietic reserve: absolute neutrophil count ≥1,500 per microliter, platelets count ≥100,000 per microliter, and hemoglobin ≥9 g/dL, adequate hepatic function: bilirubin ≤1.5 times the upper limit of normal (ULN), serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤3×ULN (AST and ALT ≤5×ULN if liver had tumor involvement), adequate renal function defined as calculated creatinine clearance ≥45 mL/min, age ≥18 years, barrier contraception for participants of child-bearing age, and signed informed consent.",NA,during the first cycle,NA
10829050,NA,Combination,No,"patients with advanced cancer. Seventeen patients (35%) had malignant mesothelioma, and 11 (23%) had colorectal cancer","Patients with histologically-proven solid neoplasms without viable therapeutic alternative were eligible for this study. Measurable disease was not required. All patients were required to have World Health Organization (WHO) performance status of <= 2, age between 18 and 75 years, life expectancy greater than 12 weeks, WBC count >= 4 x 109 cells/L, absolute neutrophil count of >= 2.0 x 109 neutrophils/L, platelet count >= 100 x 109 platelets/L, hemoglobin level >= 10 g/dL, serum creatinine level within normal values, total bilirubin level <= 1.5 times the upper limit of normal (ULN), alkaline phosphatases less than five times ULN, AST and ALT <= 1.5 times ULN (or < three x ULN if hepatic metastases were present). ","Exclusion criteria included the following: prior radiotherapy that involved more than 35% of the bone marrow, chemotherapy or radiotherapy within 4 weeks before study entry (6 weeks for nitrosoureas or mitomycin C), prior chemotherapy with raltitrexed or oxaliplatin, history of other malignancies (except excised in situ cervical carcinoma or basal/squamous cell skin carcinoma), concomitant use of folinic acid and vitamin supplement containing folic acid, and peripheral neuropathy of National Cancer Institute grade >= 2. Patients with prior high-dose chemotherapy and stem-cell support, symptomatic brain metastases, or corrected hypercalcemia greater than 3 mmol/L were also excluded.",During the First Two Cycles,NA
32918791,UMIN000012531,Combination,No,Patients with Locally Advanced Non-Small Cell Lung Cancer,"First screening registration entry: 1 Patients with advanced malignant tumors; 2 Opioid non daily use patients. Secondary screening registration entry: 1 Cancer pain,that is targeted for the opioid treatment,taking NSAIDs or acetaminophen; 2 NRS is 3 or more; 3 Opioid treatment naive within 30 hours; 4 Patients who have no influence on previous chemotherapy, radiation therapy; 5 Written informed consent","1) patients with chronic renal failure (glomerular filtration rate, 30 mL/min), 2) patients with severe hepatic or respiratory failure, 3) patients deemed ineligible for the study by the study coordinator or a collaborative investigator",during the concurrent chemoradiotherapy period,NA
11208839,NA,Combination,No,patients with advanced non-small-cell lung cancer,"Patients with histologically proven NSCLC not suitable for primary surgical treatment were enrolled onto this study. Other eligibility criteria were (1) no previous chemo- and/or radiotherapy, (2) presence of at least one bidimensionally measurable lesion, (3) age >= 18 and <= 75 years, (4) estimated life expectancy >= 12 weeks, (5) Eastern Cooperative Oncology Group performance status <= 2, (6) adequate hematopoietic reserve (absolute neutrophil count [ANC] >= 2,000/uL, platelet count [PLT] >= 100,000/uL, adequate hepatic and renal function including serum creatinine <= 1.5 x the upper limit of normal and creatinine clearance >= 60 mL/min, and serum bilirubin and AST <= 1.5 x the upper limit of normal.",Patients with symptomatic brain metastases were not eligible. ,at the first treatment cycle,NA
8656247,NA,Single Drug,No,patients with advanced colon cancer,"Histologic slides from all patients in this study were reviewed in the Department of Pathology, Memorial Hospital for Cancer and Allied Diseases. The diagnosis of colon cancer was confirmed in all cases. Eligibility criteria included advanced unresectable disease, failed conventional chemotherapy, no chemotherapy for at least 6 weeks, serum creatinine concentration less than 2 mg/100 mL, bilirubin level less than 2 mg/100 mL, granulocyte count greater than 3,500/uL, platelet count greater than 100,000/uL, prothrombin time less than 1.3 times control, and Karnofsky performance status >=60.  As the A33 antigen does not survive routine tissue fixation and more than 95% of colon cancers express the A33 antigen, documentation of antigen expression by immunohistochemistry was not a requirement for patient entry. ","Patients with serious cardiac disease (New York State Heart Association Class III to IV) were excluded, as were those with pulmonary disease, infectious disease that required antibiotic therapy, brain metastases, prior radiotherapy, prior exposure to mouse Igs, pregnancy or lactation, or an expected survival duration less than 6 weeks. ",NA,NA
10506618,NA,Combination,No,stage IIIB or IV non-small-cell lung cancer,"Patients had to fulfill the following criteria to be eligible for the phase I study: age more than 15 years and less than 75 years; histologically or cytologically proven diagnosis of NSCLC; measurable lesions; Eastern Cooperative Oncology Group performance status of 0, 1, or 2; stage IIIB or IV disease; no prior treatment; no symptoms of brain metastasis; no pregnant/nursing women; no active concomitant malignancy; no disseminated bone metastasis requiring radiotherapy; massive pleural effusion requiring tube drainage; adequate blood cell counts (hemoglobin level >= 9.5 g/dL, WBC count >= 4,000 to 12,000/µL, and platelet [PLT] count >= 100,000 µL); adequate renal and liver functions (serum creatinine level less than the upper limit of normal, blood urea nitrogen level <= 25 mg/dL, bilirubin level <= 1.5 mg/dL); and no severe heart or pulmonary diseases. Written informed consent was obtained. ",NA,during the first two courses,NA
32803633,NCT01973309,Combination,No,patients with locally advanced or metastatic HER2-negative breast cancer,"Eligible patients had locally recurrent or metastatic HER2- negative breast cancer treated with ≤2 prior lines of chemotherapy for locally recurrent or metastatic disease. Patients had evaluable or measurable disease by RECIST v1.1 (Response Evaluation Criteria in Solid Tumors)  and an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1. Patients were ≥18 years old with adequate hematopoietic, hepatic and kidney function. ","Key exclusion criteria included: dose delays during prior taxane treatment; pregnant or breastfeeding; anti-cancer therapy within 3 weeks or 5 half-lives; bone radiation<2 weeks; untreated brain metastasis or leptomeningeal disease; HIV; bleeding diathesis or therapeutic warfarin; osteoporosis; bone metastases with pathologic fracture, planned orthopedic intervention or unable to receive bisphosphonate or denosumab; chronic glucocorticoid steroids; ß-C-terminal telopeptide (ß-CTX)>1000 pg/mL and metabolic bone disease. Additional bone-specific exclusions were added for cohorts 4–7: prior radiation to the spine or pelvis; gastric bypass; fragility fracture; moderate morphometric fracture identifed on imaging; and risk of major osteoporotic fracture>20% or hip fracture>3% by FRAX. Normal calcium, 25-OH-vitamin D and TSH were required.","The DLT window was 28 and 31 days in cohorts 1–6 and 7, respectively.",NA
34781168,NCT01980277,Combination,No,HER2-negative advanced breast cancer patients,"This trial involved patients with HER2-negative advanced breast cancer (ABC, i.e. inoperable locally advanced or metastatic breast cancer), with (phase IB part) or without (phase II part) previous cytotoxic treatment for advanced disease. Patients aged ≥18 years, and with histologically confirmed HR+ or HR- breast cancer, measurable (Phase II part) or measurable and non-measurable (phase IB part) disease according to RECIST 1.1, WHO/ECOG performance status ≤ 1 (phase IB part), < 2 (phase II part) were eligible","Patients with bone metastases only, symptomatic cerebral metastases, previous AKT and PI3K inhibitors, and inadequate bone marrow and organ functions were excluded. ",during cycle 1 ,NA
22781384,NCCCTS-09-387,Single Drug,No,leptomeningeal carcinomatosis,"To be enrolled in this study, the patient must have had a positive CSF cytology result and one of the following LMCrelated conditions; (1) symptoms of hydrocephalus, such as headache with nausea and vomiting, altered mentality and/or gait disturbance; (2) increased ICP (> 15 cm H2O) measured at the subgaleal reservoir; and (3) either cauda equina symptoms or signs of cranial neuropathy, other than mass effects. Wholespine magnetic resonance imaging was performed in all patients before the VLP therapy, to ensure the free CSF flow without disruption. If any suspicious intradural metastasis obstructing the CSF flow was detected, radioisotope cisternography was performed. In case of any block of the CSF pathway, the VLP was deferred.","Exclusion criteria were, as follows: (1) space-occupying brain lesion that might cause herniation; (2) hemorrhagic metastases; (3) equal or more than grade 3 leukopenia or thrombocytopenia; and (4) altered mentality worse than stuporous state, which was expected to interfere with the evaluation of the VLP chemotherapy side effects.",NA,NA
25504632,NCT00866528,Combination,No,patients with Stage IIIBwet/IV Non-small Cell Lung Cancer,"Patients with previously untreated advanced solid tumors for whom paclitaxel-based therapy was considered appropriate; age 18 years; Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1; measurable disease per RECIST (version 1.0; ref. 26); adequate bone marrow, hepatic, and renal function; and life expectancy >= 12 weeks were eligible.","Exclusion criteria included clinically significant gastrointestinal abnormalities; poorly controlled hypertension; a history of cerebrovascular accident, including transient ischemic attack, pulmonary embolism or untreated deep venous thrombosis, and cardiac dysfunction within the past 6 months; evidence of active bleeding or bleeding diathesis; recent hemoptysis; and known endobronchial lesions. Coadministration of pazopanib plus paclitaxel with strong CYP3A4 inhibitors was prohibited beginning 14 days before the first dose of study drug until the end of study treatment.",within cycle 1,NA
20091169,NA,Combination,No,"patients with advanced solid tumors. Tumor type: Transitional cell, Ovarian, Esophageal, Prostate, Non-small cell lung, Small cell lung, Adrenocortical, Neuroendocrine, Urethral clear cell, Unkown primary.","Adult patients of at least 18 years of age were eligible if they had a histological diagnosis of advanced solid tumors refractory to standard therapy, an Eastern Cooperative Oncology Group Performance Status <= 2, adequate hematopoietic function, alanine aminotransferase (ALT)<3 x ULN, creatinine <= 1.5 x ULN, and urine protein/creatinine ratio <= 1.","Patients may have received but not progressed on taxane-based therapy, and were excluded if they had prior treatment with anti-VEGF agents. Other exclusion criteria were active cardiovascular disease within the prior 6 months, a history of brain metastases, concomitant use of warfarin or heparin, and grade >= 2 neuropathy.",in both cycles 1 and 2,NA
22832803,NA,Combination,No,patients with EGFR-expressing advanced non-small cell lung cancer,"Eligibility criteria, EGFR expression analysis and details of pretreatment evaluations and follow-up have previously been reported in full . Briefly, the main inclusion criteria were age ≥18 years, histologically confirmed, EGFR-expressing NSCLC, stage IIIB or IV, radiologically measurable disease, life expectancy >12 weeks, Karnofsky performance status ≥60 %, adequate organ function, and no chemotherapy or radiotherapy within 4 weeks before the first infusion of matuzumab and paclitaxel. Following a protocol amendment, tumors were scored EGFR-expressing by immunohistochemistry if a faint/barely perceptible membrane staining was detected in any of the tumor cells. The study was approved by local ethics committees and was carried out in accordance with the Declaration of Helsinki and good clinical practice guidelines. All patients gave informed consent prior to inclusion.",NA,during the first two cycles,NA
26433959,ChiECRCT2014025,Combination,No,cervical cancer patients with high risk factors,"Patients were enrolled in this phase I study based on the following eligibility criteria: 18–70 years old; histologically confirmed cervical carcinomas, have no prior history of chemotherapy or radiotherapy; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; underwent radical hysterectomy and pelvic lymph node dissection without residual disease for clinical stage IB–IIA according to the guidelines of the International Federation of Gynecology and Obstetrics (FIGO) ; at least one of the following pathologic high risk factors were present following resection: deep stromal invasion (defined as invasion into greater than half the thickness of the cervical wall), positive pelvic lymph nodes, lymphovascular space invasion, tumor size >4 cm. Further inclusion criteria were (1) adequate bone marrow parameters (white blood cell count >=4.0 x 109/l, hemoglobin >=12 g/dl, and platelet count >=100 x 109/l), (2) alanine and aspartate aminotransferase levels <=2.5 times of the upper limit of normal value, (3) total bilirubin and creatinine levels <=1.0 times of the upper limit of normal value, and (4) enrollment within 3 months from the date of surgery.","Exclusion criteria were: with metastases, positive paraaortic lymph nodes, involved surgical margin, a second primary tumor, or who were unable to tolerate chemoradiotherapy because of other systemic illnesses.",during the concurrent chemoradiotherapy,NA
28477227,NA,Combination,No,"patients with advanced solid tumors. Over half of the patients had either breast (n = 4) or esophageal cancer (n = 3), andthe remaining 5 patients had other distinct solid tumormalignancies (lung, thyroid, bladder, neuroendocrinepancreas, sarcoma)","Eligible patients were aged ≥18 years and had histologically confrmed metastatic, unresectable, solid tumor malignancy (excluding lymphoma) that had progressed on standard therapy; an Eastern Cooperative Oncology Group (ECOG) performance status ≤1; life expectancy of ≥12 weeks; and adequate hematologic, hepatic and renal function. All patients provided written informed consent.",NA,during cycle 1,NA
25073954,UMIN000009046,Combination,No,patients with metastatic or recurrent breast cancer,"The eligibility criteria were (1) patients for whom invasive breast cancer was histologically confirmed; (2) patients for whom metastatic/recurrent breast cancer was clinically confirmed; (3) patients with no history of chemotherapy for their metastatic/recurrent breast cancer, or patients with a history of one regimen of preoperative or postoperative chemotherapy (for their metastatic/recurrent breast cancer) which was completed at least 6 months before participation in the present study; (4) patients for whom an immunohistochemistry (IHC) assay or a fluorescence in situ hybridization (FISH) assay did not show an overexpression of human epidermal growth factor receptor-2 (HER2) (i.e., IHC <30 % or FISH <2.2); (5) patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1; (6) patients with no clinically significant electrocardiographic abnormalities; (7) patients for whom each laboratory test value within 21 days before enrollment was within the following ranges (white blood cell count >=4,000 cells/mm3, neutrophil count >=2,000 cells/mm3, hemoglobin level >=9.0 g/dL, platelet count >=100,000 cells/mm3, total bilirubin <=1.5 mg/dL, AST/ALT B150 IU/L, and creatinine <=1.5 mg/dL; (8) patients aged >=20 years; (9) patients whose survival was expected to be at least months from the start of treatment; and (10) patients who submitted their own written consent.",NA,during Cycle 1 ,NA
21406471,NA,Combination,No,metastatic breast cancer,"Patients with MBC; Eastern Cooperative Oncology Group performance status of zero to one; normal hepatic, renal and marrow function were eligible. Prior taxane therapy, stable brain metastases and baseline neuropathy grade 1 or less were allowed.","Due to the risk of fluid retention from dasatinib, patients with pleural or pericardial effusions were excluded.",during cycle 1,NA
22695940,NA,Single Drug,No,"patients with advanced solid tumors.  Of these 34 patients, 25 (73.5 %) had colorectal cancers, 2 (5.9 %) had stomach cancer, 1 each (2.9 %) had pancreatic, neuroendocrine and urinary bladder cancer, and 4 (11.8 %) had unidentified primary sites","Patients eligible for enrollment were ≥18 years of age; histologically confirmed unresectable or metastatic solid tumors with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 or lower; failed all standard chemotherapeutic regimens; one or more measurable lesions as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0; and adequate hematologic, hepatic and renal functions.","Major exclusion criteria were prior exposure to taxanes; concurrent use of P-glycoprotein inhibitors; chronic use of proton pump inhibitors or H2-receptor antagonists; and prior cholecystectomy or total gastrectomy which could cause abnormal bile acid secretion. Additional exclusion criteria were any unresolved toxicity from previous treatment, including peripheral neuropathy higher than grade 2.",the first cycle of treatment,NA
19738417,NA,Combination,No,"patients with refractory solid tumors. Tumor types: Ovary 11, Cervix 4, Renal cell carcinoma 5, Stomach 1, Sarcoma NOS 1, Leiomyosarcoma 3, Melanoma 1, Pancreas 1, Hepatobiliary 1, Prostate 1","Patients were eligible for trial if they fulfilled the following criteria: histologically proven solid tumors; ECOG performance status of 0–2; failure of prior therapy or untreated metastatic melanoma, renal cell cancer or non-small cell lung cancer (this trial was initiated prior to standard initial therapy of these cancers); adequate end organ function: white blood count ≥3,000/mm,3  hematocrit ≥27% without transfusion support, platelet count ≥100,000/mm, serum creatinine ≤1.5 mg/dL or measured creatinine clearance ≥45 mL/min, liver function tests ≤2x ULN; PT and PTT ≤1.25x ULN, no therapeutic anticoagulant use and no evidence of bleeding; no concurrent infections; no evidence of myocardial damage or ischemia within the preceding 6 mo, no current cardiac conduction defects; no brain metastases (computed tomography or magnetic resonance imaging required for melanoma or lung cancer patients); evaluable or measurable disease, PSA-only disease in refractory hormone-independent prostate cancer patients; and a life expectancy of ≥3 mo. Patients were to be at least 4 w from prior chemotherapy, hormonal, radiation or biological therapy with 6-w requirement for patients who had received mitomycin C or carboplatin.","Patients who had progressed within 6 mo of prior paclitaxel administration were excluded as were patients who had received CAI. All patients of child-bearing capability were required to use contraception during and for 2 mo after therapy, and pregnant or lactating patients were excluded.",within the first 28 d of therapy,NA
30623229,NCT00825201,Single Drug,No,advanced malignancies primarily confined to the peritoneal cavity. Twenty-seven patients with peritoneal carcinomatosis secondary to gynecologic (n=14) and gastrointestinal (n=12) malignancies and peritoneal mesothelioma (n = 1) were enrolled on this study. ,"The following patients were eligible for this study: adults with histologically confirmed advanced cancer primarily confined to the peritoneal cavity for which no “standard” chemotherapy regimens existed, with an Eastern Cooperative Group (ECOG) performance status (PS) of 0–2, adequate hematological, hepatic (total bilirubin within normal institutional limits, liver enzymes<2.5×upper limit of normal, ULN), and renal function (estimated creatinine clearance>60 mL/min/1.73 m2). Prior IP chemotherapy was allowed. Patients with ovarian cancer having residual disease at second-look laparotomy or following secondary debulking were also eligible and were enrolled>4 weeks after surgery. There was no limit on the number of prior lines of chemotherapy, but the protocol required a 4-week washout from previous chemotherapy or radiotherapy (6 weeks for nitrosoureas or mitomycin C). Prior taxane exposure was allowed if pre-existing sensory neuropathy was ≤grade 1.","The following patients were not eligible: patients with ongoing abdominal infections, bowel obstruction, and peritoneal adhesions that precluded the placement of an IP catheter; patients with known brain metastases; pregnant or breastfeeding women; patients with a history of allergic reactions to compounds similar to nab-paclitaxel; and patients with serious or uncontrolled intercurrent illness.",during the first cycle of treatment,NA
27998970,NCT01281852,Combination,No,"persistent or recurrent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix","Patients >=18 years of age with a histologic diagnosis of recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy and a GOG performance status of 0–2 were eligible. Patients had received prior definitive chemotherapy and radiation therapy and could have received consolidation therapy up to four cycles of paclitaxel and carboplatin. Measurable disease was not required. Patients had to have adequate bone mar-row, renal, hepatic, cardiac, and neurologic functions. ","Exclusion criteria included prior PARPi therapy, inability to swallow pills, previous history of other invasive malignancies, and any uncontrolled inter-current illness that would preclude compliance with study requirements. ",during the first cycle of therapy,NA
30876442, NCT02429622,Combination,No,unresectable esophageal Cancer,"Patients (18 ≤ age<70) with histologically or cytologically confirmed primary squamous cell carcinoma (SCC) of the esophagus were eligible for the study. All patients were required to be unsuitable for surgery according to the assessment prior to or during chemoradiation by thoracic surgeons or a multi-disciplinary team (MDT). All patients enrolled were required to be candidates for potential curative treatment, with a Karnofsky performance score (KPS) ≥ 70 and had no distant visceral metastasis or prior treatment history. Patients with a history of a prior malignancy were considered eligible if disease-free for 5 or more years. Patients enrolled must have adequate bone marrow, liver and kidney function. The protocol was reviewed and approved by the Institutional Review Board. Written informed consent was obtained from each patient.","Known drug allergy. Insufficient hepatorenal function. Severe cardiovascular diseases, diabetes with uncontrolled blood sugar, mental disorders, uncontrolled severe infection, active ulceration which need intervention.",NA,NA
19010522,NA,Combination,No,patients with cervical carcinoma metastatic to the para-aortic lymph nodes,"Patients with clinical stages IB, II, IIIB and IVA invasive carcinoma of the cervix with histologically positive para-aortic nodes were eligible. Acceptable modes of evaluation for para- aortic adenopathy included fine needle aspiration and extra- peritoneal or laparoscopic lymph node sampling. Lymphadenectomy was not required. Additional eligibility criteria included an absolute neutrophil count (ANC) of ≥ 1500/μl, platelets ≥ 100,000/μl, creatinine b 2 mg%, bilirubin ≤ 1.5 times the upper limit of normal, SGOT (serum glutamic oxaloacetic transaminase) ≤3 times the upper limit of normal, and a GOG performance status of 0–2. Entry onto the study was required to be within eight weeks of diagnosis. Patients with obstructive uropathy must have been treated with ureteral stenting or percutaneous nephrostomy. CT (computed tomography) scan of the chest, abdomen and pelvis were required to exclude patients with metastatic cancer outside of the radiation treatment field","Patients were excluded who had received previous pelvic or abdominal radiation or cytotoxic chemotherapy, or who had evidence of any cancer within the preceding three years.",30 days following completion of therapy,NA
30945121,NA,Combination,No,patients with HER2-positive advanced gastric cancer,"Key eligibility criteria included: patients aged≥19 years; histopathologically confrmed locally advanced unresectable, relapsed or metastatic gastric adenocarcinoma (including adenocarcinoma of the esophagogastric junction); HER2 immunohistochemistry (IHC) 3 + or HER2 IHC 2 + and HER2 fluorescence in situ hybridization (FISH) + ; the presence of one or more measurable lesions by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) ; one previous line of chemotherapy, including fuoropyrimidine or platinum, regardless of trastuzumab exposure; and adequate bone marrow and hepatic functions.","Key exclusion criteria included: a history of hypersensitivity to drugs containing Cremophor® EL and trastuzumab; previous exposure to taxanes, and symptomatic central nervous system metastasis",the frst cycle,NA
28196905, NCT02890511,Single Drug,No,"Patients with Advanced Solid Tumors or Gastric Cancer. Site of primary tumor: Stomach, Colon or rectum, Parotid gland, Salivary gland","Patients between 18 and 70 years old. Patients prognosed with advanced or metastatic solid cancer by histopathology or cytology analysis who have no available standard therapy or who have failed at least once with the standard therapy. Adequate bone marrow function, liver function and adequate kidney function. Eastern Cooperative Oncology Group performance status ≤ 2. Life expectancy of 3 month or more. Written informed consent","Major infectious or neurological disease and bowel obstruction. Brain metastasis or hematologic malignancy. Patients who underwent surgery, radiation therapy, hormone or chemotherapy within 4 weeks prior to the beginning of investigational drug administration. Patients with the history of failure to the taxane line of chemotherapy (with the exception of when it was used before 6 month as adjuvant therapy or when the treatment was discontinued due to docetaxel related side effect). Patients who are required to continuously take P-gp (P-glycoprotein) suppressor, immune suppressor, proton-pump inhibitor or H2-receptor antagonist during clinical trial period. Patients deemed by the investigator to suffer from severe heart disease (myocardial infarction, congestive heart failure, arrythmia accompanying drastic changes on ECG, severe or unstable angina pectoris, or other severe heart disease) or accompanying other severe internal diseases (such as uncontrollable diabetes, chronic obstructive pulmonary disease). Patients with prior history of participating in a clinical trial within 30 days from registration for current clinical trial. Patient with history of alcohol or drug abuse in the recent 3 months. Pregnant women, nursing mothers, or patients of childbearing age who did not agree to contraception (both men and women). Patients with (or suspected to have) abnormality in bile acid secretion (e.g.,. patients with resected gallbladder). Patients who had a history of serious gastrointestinal bleeding, or with diseases that could affect the absorption of oral medication (malabsorption syndrome, active peptic ulcer). Patients with history of severe hypersensitive reaction to active ingredient and excipient of the investigational drug. Patient who are in a state that is deemed inappropriate to participate in the clinical trial by the investigator",First cycle of treatment,NA
20877350,NA,Combination,No,"patients with advanced solid tumours. Tumour type: Sarcoma 4, Bladder cancer 3, Gastric cancer 3, Colorectal cancer 2, NSCLC 2, Miscellaneous 8","Eligible patients were aged X18 years, and had histologically or cytologically confirmed advanced solid malignancies, refractory to conventional treatment. Patients were also required to have life expectancy >=12 weeks, Eastern Cooperative Oncology Group (ECOG) performance status X2, adequate haematopoietic (absolute neutrophil count >=1.5 x 109 l-1; platelets >=100 x 109 l-1), hepatic (bilirubin <=1.5 x upper normal limit (ULN), aspartate transaminase/alanine transaminase <=2.5 C ULN) and renal (creatinine >=1.5 x ULN) function. ","Patients with previous anticancer therapy within 4 weeks of study entry (6 weeks for mitomycin and nitrosureas), known brain tumours or brain metastases and patients who failed to recover from acute adverse effects of previous therapies or who had received more than four previous chemotherapy regimens were excluded. ",during the first 21 days of treatment,NA
30635336,NCT01320592,Combination,No,Advanced Breast Cancer,"Eligible patients had histologically confirmed stage IV breast cancer, with any combination of ER, progesterone receptor (PR), or HER2 expression, measurable disease defined by RECIST 1.1 (12), <=3 prior cytotoxic chemotherapies in the metastatic setting, adequate organ function, and Eastern Cooperative Oncology Group performance status (ECOG PS) <2. Prior taxane (including paclitaxel) for early-stage and/or advanced breast cancer was allowed, although there had to be at least 365 days from the last dose of paclitaxel. Patients with both ER+ and PR- disease were required to have expression of Rb protein immunohistochemically in either the primary or metastatic tumor; Rb testing was not required for those with ER+ and/or PR+ disease, as these tumors are nearly universally Rb+ (13). Patients with a history of brain metastases were allowed if they had received treatment for known lesions, were off steroids to control symptoms, and had no new or progressing central nervous system (CNS) lesions. Washout from previous therapy was required: 21 days from cytotoxic therapy or radiation, 28 days for an investigational agent, and 24 hours for endocrine therapy.","Patient who has had chemotherapy, radiotherapy or hormonal therapy within 3 weeks (6 weeks for nitrosoureas, mitomycin C or bevacizumab), or who has not recovered from the adverse events due to previous agents administered more than 4 weeks prior to Study Day 1. If the patient has residual toxicity from prior treatment, toxicity must be < Grade 1. patients less than 4 weeks post major surgical procedure (all surgical wounds must be fully healed). For the purpose of this criterion, a major surgical procedure is defined as one requiring the administration of general anesthesia. Patient has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. However, patients with CNS metastases (including brain metastases) who have completed a course of radiotherapy are eligible for the study provided they are clinically stable. Oral corticosteroids for control of CNS symptoms are allowed. Patient has known hypersensitivity to the components of study drug or its analogs. The subject has uncontrolled intercurrent illness including, but not limited to Ongoing or active infection.  Diabetes mellitus. Hypertension. Symptomatic congestive heart failure, unstable angina pectoris, stroke or myocardial infarction within 3 months. Patient has baseline neuropathy of > grade 2. Patients who have known allergic reactions to Paclitaxel or IV Contrast Dye despite standard prophylaxis. The subject is pregnant or breastfeeding. The subject is known to be positive for the human immunodeficiency virus (HIV). Note: baseline HIV screening is not required. The subject is unable eor unwilling to abide by the study protocol or cooperate fully with the investigator or designee.",in the first cycle,NA
19386478,NA,Combination,No,Patients with histologically proven diagnosis of carcinoma of the uterine cervix,"Patients with histologically proven diagnosis of carcinoma of the uterine cervix, International Federation of Gynecology and Obstetrics stage IB to IIIB, were included in the study. Inclusion criteria were: (1) age <= 70 years, (2) ECOG <= 2, (3) haemoglobin >= 9 gm%, platelet >= 100 000/mm3 and leukocyte count > 4000/mm3, (4) normal hepatic, renal and cardiac function.","Patients with a previous history of malignancy, radiation therapy or chemotherapy were excluded.",during the treatment of concurrent radiation and combination chemotherapy,NA
18956139,NA,Combination,No,"Solid tumors. Most common tumor types were follicular/papillary thyroid carcinoma (15.8%), mesothelioma (12.6%) and head and neck (9.5%).","Patients (≥18 years old) with histological or cytological diagnosis of locally advanced or metastatic solid tumors for which no life-prolonging therapy existed and with evidence of measurable or evaluable disease  were eligible. Other criteria were: life expectancy ≥12 weeks; World Health Organization (WHO) performance status ≤2; adequate hematopoietic, hepatic, and renal function; discontinuation of prior chemotherapy ≥4 weeks prior to study entry, completion of prior radiation two weeks before enrollment and recovery from its acute toxic effects.","Exclusion criteria were: taxane therapy within 6 months of enrollment; prior pemetrexed therapy; inability to take folic acid and vitamin B12 supplementation; inability to stop taking aspirin or nonsteroidal anti-inflammatory medications for 2 days before, the day of, and 2 days after dosing with pemetrexed; active infection; symptomatic central nervous system metastases; significant cardiovascular disease or serious concomitant systemic disorders; peripheral neuropathy >grade 1; clinically significant pleural or peritoneal effusions or albumin <25 g/L.",during cycle 1,NA
18794097,NA,Single Drug,No,"patients with locally advanced or metastatic carcinoma. Tumor type: Breast, Ovary, Colon, Leiomyosarcoma, Non-small cell lung cancer, Other","Patients were eligible if they had histologically confirmed, locally advanced or metastatic carcinoma, an Eastern Cooperative Oncology Group performance status of <=2, and were >=18 years old. Requirements for adequate organ function included an absolute neutrophil count (ANC) of >=1,500/uL, platelets >=100,000/uL, hemoglobin >=9.0 g/dL, creatinine <=2.0 mg/dL, total bilirubin <=1.5 times the upper limit of normal, and alanine aminotransferase and aspartate aminotransferase <=2.5 times the upper limit of normal. Other eligibility criteria included no prior chemotherapy or radiotherapy within 3 weeks of treatment. Patients with prior exposure to taxanes were eligible","Patients were excluded if they had grade z2 neuropathy, symptomatic brain metastases, or hypersensitivity to paclitaxel or liposomes. ",during cycle 1,NA
21853310,NA,Single Drug,No,Japanese patients with solid tumors and metastatic breast cancer,"Eligible patients included men and non-pregnant women with adequate birth control with biopsy-proven diagnoses of solid tumors for which standard therapy had failed and who had not received any chemotherapy and any radiotherapy for at least 3 weeks before enrollment. The other requirements were as follows: age between 20 and 75 years; ECOG performance status (PS) 0–2; life expectancy >=60 days; adequate bone marrow function (white blood cell count <= 12 000/mm3, absolute neutrophil count (ANC) >= 2 000/mm3, hemoglobin >= 9.0 g/dL, and platelet count >=100 000/mm3); adequate liver function (total bilirubin <= 1.5 mg/dL and liver transaminases [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)] < 100 IU/L); adequate renal function (serum creatinine <= 1.5 mg/dL); serum albumin >=3.0 g/dL; and written informed consent. Patients with prior history of taxane administration were allowed.","The exclusion criteria were as follows: (1) any surgery within 4 weeks before enrollment; (2) history of radiotherapy with >30% of hematopoietic bone marrow; (3) pre-existing neuropathy >=grade 2; pleural eVusion or ascites requiring drainage; (4) brain metastases with any symptoms or required treatment; (5) chronic steroid treatment; (6) serious pre-existing medical conditions such as infections, pulmonary Wbrosis, diabetes, or heart disease; and (7) hepatitis B or C virus or human immunodeWciency virus infection.",in the Wrst cycle,NA
24658629,NA,Single Drug,No,adult Chinese patients with advanced solid tumors,"Patients were eligible if they had histologically or cytologically confirmed advanced solid malignancies refractory to conventional treatment or for whom no effective therapy existed. The inclusion criteria included the following: age 18–70 years; Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less; adequate hematological, renal, and hepatic function; life expectancy of at least 3 months; and no prior chemotherapy, immunotherapy, or radiation therapy within 4 weeks.","Exclusion criteria included the following: active bacterial infection requiring antibiotic treatment; presence of psychiatric disease, uncontrolled brain metastasis, or seizure disorder; presence of grade 2 or more severe peripheral neuropathy; and women who were pregnant or lactating.",in the first cycle,NA
20406837,NA,Combination,No,"patients with advanced solid tumors. Primary tumor type: STS, Breast, Other","Eligibility requirements included the following: age of ≥18 years, a histologic confirmation of cancer not amenable to conventional treatment, an Eastern Cooperative Oncology Group performance status of ≤2, life expectancy of ≥3 months, and either measurable or evaluable disease. The following laboratory values were required within 14 days of study treatment: an absolute neutrophil count (ANC) of ≥1.5 × 109/L, platelets of ≥100 × 109/L, hemoglobin of ≥8.5 g/dl, albumin of ≥2.5 g/dl, calculated creatinine clearance of ≥50 mL/min, bilirubin of less than or equal to the upper limit of normal (ULN), aspartate aminotransferase and alanine aminotransferase of ≤3× ULN, and alkaline phosphatase (AP) ≤1.5× ULN (if total AP is >1.5× ULN, the AP liver fraction and/or 5′-nucleotidase and/or γ glutamyltransferase were required to be within normal limits). Patients with a history of central nervous system metastases were eligible provided that a radiographic study showed no progression from previous treatments and no evidence of peritumoral edema, there was no requirement for corticosteroids, and there was no evidence of progressive central nervous system symptoms. ","Patients with primary central nervous system malignancies were not eligible. Patients were excluded if they had serious nonmalignant systemic disease, e.g., active uncontrolled infection, uncontrolled diabetes mellitus, recent (within 6 months before study entry) myocardial infarction, unstable angina pectoris, or life-threatening ventricular arrhythmia requiring treatment. Chemotherapy, radiotherapy (wide-field with >25% bone marrow reserve), or biological therapy within 4 weeks before administration of trabectedin (mitomycin C or nitrosurea therapy within 6 weeks) were not allowed. Immunocompromised patients, including patients known to be HIV positive, were not eligible. Patients with peripheral neuropathy exceeding the National Cancer Institute Common Toxicity Criteria grade 2 in severity were also excluded from enrollment. Patients were also excluded if they were pregnant or breastfeeding women, or if they were not using appropriate contraceptive measures.",during the first two cycles,NA
20941597,NA,Single Drug,No,"patients with advanced cancer and dominant liver involvement. The most common diagnoses were colorectal cancer (n = 10) and breast cancer (n = 7). One patient had each of the following cancers: gastric, hepatocellular, prostate, bladder, thyroid, small-cell lung, ovarian, melanoma, and cholangiocarcinoma.","Eligibility criteria included a histologically confirmed diagnosis of malignancy and liver involvement as the dominant site of metastasis; ECOG performance status <= 2; and adequate renal (serum creatinine <= 2.0 mg/dL), hepatic (total bilirubin <2.0 mg/dL or ALT <= 5 x upper normal reference value), and bone marrow function (ANC >= 1.5 cells/uL; PLT >= 100,000 cells/uL). Female patients of childbearing potential were eligible if they had a negative urine or human chorionic gonadotropin serum test. Pediatric patients were eligible at the discretion of the primary investigator. Patients were eligible to start therapy if >21 days had elapsed since prior therapy and they had complete recovery (to Grade 1) from all associated toxicities.","Exclusion criteria included clinical or radiographic evidence of ascites, pregnancy, hypersensitivity to paclitaxel or products containing polyoxyethylated castor oil or cremophor, inability to complete an informed consent process and adhere to the protocol treatment plan and follow-up requirements, untreatable bleeding diathesis, portal vein thrombosis, Grade 2 peripheral neuropathy, or untreated brain metastases.",during the first cycle,NA
28868573,NCT02667743,Combination,No,"patients with advanced solid malignancies. Tumor type, n (%): Non-small cell lung cancer 17 (94), Breast cancer 1 (6)","Eligible patients had histopathologically and/or cytologically confirmed advanced solid malignancies recurrent to failed standard treatments. The inclusion criteria included the following: (a) aged 18–70 years; (b) Eastern Cooperative Oncology Group performance status of ≤2; (c) life expectancy of more than 3 months; (d) measurable lesion (longest diameter, ≥20 mm by conventional measurement means or ≥10 mm by spiral CT); (e) adequate hematological, renal, and hepatic functions; and (f) no prior chemotherapy, immunotherapy, or radiation therapy for a period of 4 weeks.","The main exclusion criteria included the following: (a) uncontrolled brain metastases, grade ≥ 2 lesion of peripheral neuropathy (National Cancer Institute’s Common Terminology Criteria for Adverse Events, NCI CTCAE version 3.0); (b) severe neurologic or mental disorders; (c) grade ≥ 2 active bacterial infections (NCI CTCAE version 3.0); (d) other diseases with bronchial asthma, uncontrolled diabetes, severe epilepsy, uncontrolled cardiac disease, or myocardial infarction; (e) history of other malignancies within 5 years (except for cured cervical cancer or basal cell carcinoma); (f) pregnant or lactating women; and (g) allergic constitution or allergies known to any component of the drug.",during the first 21-day treatment cycle,NA
26266640,NA,Combination,No,previously treated advanced non-small cell lung cancer,"Eligible patients were required to have histologically and/ or cytologically proven NSCLC, recurrent or refractory disease after one or two previous chemotherapy regimens, an Eastern Cooperative Oncology Group performance status (PS) of 0–2, aged ≥20 years, a life expectancy of ≥8 weeks, adequate bone marrow reserve (leukocyte count ≥3,000 mm−3, absolute neutrophil count ≥1,500 mm−3, platelet count ≥100,000 mm−3, and hemoglobin ≥9 g dL−1), adequate function (total serum bilirubin ≤1.5 mg dL−1, aspartate transaminase [AST], alanine transaminase [ALT] less than twice the upper limit of the normal range and serum creatinine ≤1.5 mg dL−1), ECG findings within the normal range, a left ventricular ejection fraction ≥50 %, and arterial oxygen partial pressure ≥60 torr. ","Patients with concomitant malignancy, central nervous system metastases, active infectious diseases or other serious medical problems were ineligible.",during the first cycle of chemotherapy,NA
21820161,NA,Combination,No,"untreated ovarian, fallopian tube, and primary peritoneal carcinoma","Patients with a histologic diagnosis of epithelial ovarian carcinoma, fallopian tube adenocarcinoma, peritoneal primary carcinoma or carcinosarcoma, as verified by submission of the local institutional pathology report, were eligible. International Federation of Gynecology and Obstetrics (FIGO, 1985 Staging System) Stages IIB, IIC, III or IV were included, and patients could have had either optimal or suboptimal residual disease. All patients must have undergone an appropriate debulking surgery and enrolled within 12 weeks of surgery. All patients were required to have a GOG performance status of 0, 1, or 2, and measurable disease was not required. Laboratory criteria for eligibility included an absolute neutrophil count (ANC) ≥ 1500/μL, platelet count ≥ 100,000/μL, creatinine ≤ 1.5 times upper limit of normal (ULN), bilirubin ≤ 1.5 times ULN, alkaline phosphatase and aspartate aminotransferase (SGOT) ≤ 2.5 times ULN using the National Cancer Institute Common Toxicity Criteria version 3.0 (NCI CTCAE v3). Patients with baseline hearing loss were allowed to participate provided they had a baseline audiogram; repeat evaluation was recommended after cycles three and six or with complaints of tinnitus or hearing loss. All patients gave written informed consent and authorization to release personal health information before study entry in compliance with institutional, state, and federal regulations.",NA,during the first four cycles of treatment,NA
19633055,NA,Combination,No,"Asian cancer patients with solid tumors. Primary site: Breast, Head and neck, Lung, Nasopharyngeal, Others","Patients were eligible for the trial if they satisfied the following inclusion criteria: (i) cytologically or histologically confirmed solid tumors that were advanced and incurable; (ii) age between 21 and 70 years; (iii) Eastern Cooperative Oncology Group performance status of zero to two; (iv) life expectancy of at least 3 months; (v) adequate bone marrow function with absolute neutrophil count >=1.5 x 103/ml, hemoglobin >=9 g/dl and platelet count >=100 x 103/ml; (vi) adequate hepatic function with serum total bilirubin level <=2.0 mg/dl (34 mmol/l) and alanine transaminase and aspartate transaminase <=2 x the upper limit of normal; (vii) adequate renal function with serum creatinine <=141 umol/l; (viii) no chemotherapy or radiotherapy within 4 weeks before entry into the study. Previously irradiated patients with marker lesions not within the irradiated field were eligible for the study. Patients with controlled or asymptomatic brain metastases not requiring dexamethasone were eligible. Patients who had previous paclitaxel treatment were excluded but prior docetaxel (Taxotere, Aventis Pharma, UK) treatment was allowed","Exclusion criteria included the following: (i) active or uncontrolled infection; (ii) preexisting cardiac disease, including congestive heart failure, arrhythmias requiring treatment or myocardial infarction within the preceding 3 months and (iii) pneumonitis or uncontrolled large pleural effusions, uncontrolled diabetes mellitus (random blood glucose >11.0 mmol/l) and pregnancy, lactation or refusal to use effective contraception.",during the first cycle (28-day period),NA
29936064,NCT01962103,Single Drug,No,"paediatric patients with recurrent/refractory solid tumours. Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor, Sarcoma, Ewing's, Sarcomas, Epitheliod, Sarcoma, Soft Tissue, Sarcoma, Spindle Cell, Melanoma, Malignant Melanoma, Clinical Oncology, Oncology, Medical, Pediatrics, Osteosarcoma, Osteogenic Sarcoma, Osteosarcoma Tumor, Sarcoma, Osteogenic, Tumors, Cancer, Neoplasia, Neoplasm, Histiocytoma, Fibrosarcoma, Dermatofibrosarcoma","Paediatric patients aged >= 6 months to <18 years with recurrent/refractory solid tumours were enrolled. The study included patients whose disease progressed on standard therapy or for whom no standard therapy ex- ists. Key eligibility criteria included a Lansky/Karnofsky performance status of >=70, adequate bone marrow function (absolute neutrophil count >=1.0 x 109/L, platelets >=80 x 109/L, haemoglobin >=8 g/dL) and adequate organ function (ie, aspartate aminotransferase, alanine aminotransferase <=2.5 x upper limit of normal range [ULN], total bilirubin <=1.5 x ULN, creatinine <=1.5 x ULN).","Patients with primary brain tumours, active/untreated brain metastasis or baseline peripheral neuropathy grade >=2 were excluded",within the first cycle of treatment,NA
21372602,NA,Combination,No,gastric cancer with peritoneal metastasis,"The eligibility criteria were as follows: histologically proven unresectable or recurrent gastric adenocarcinoma; progression of peritoneal metastasis after S-1-based chemotherapy; age more than 20 years; Eastern Cooperative Oncology Group performance status 0–2; adequate bone marrow function (leukocyte count 3,000–12,000/mm 3, hemoglobin >= 8.0 g/dl, platelets >= 100,000/mm 3); adequate liver function; adequate renal function and an expected survival period of more than 3 months.","Patients were excluded if they had metastasis to distant organ sites (such as the liver, lungs or bone), other active concomitant malignancies, or other severe medical conditions. ",during the first course,NA
19509578,NA,Combination,No,locally advanced cervical carcinoma in Japanese women,"Inclusion criteria for patients in this study were as follows: aged 20 to 70 years, clinical stages Ib2 to IVa invasive cervical carcinoma, and the presence of negative paraaortic nodes. Acceptable modes of evaluation for paraaortic adenopathy included magnetic resonance imaging and computed tomography. Additional inclusion criteria included an absolute neutrophil count of greater than 3000/uL, platelets greater than 150,000/uL, hemoglobin level greater than 10 g/dL, bilirubin level less than 1.5 mg/dL, glutamicoxaloacetic transaminase and glutamic-pyruvic transaminase less than 2 times the upper limit of normal levels, creatinine level less than 1.5 mg/dL, and an Eastern Cooperative Oncology Group performance status of 0 to 2.",NA,during the radiotherapy,NA
23349317,NA,Single Drug,No,recurrent malignant glioma,"Eligibility included histologically confirmed World Health Organization (WHO) grades 2 to 4 glioma with unequivocal radiographic progression, informed consent, age >= 18 years, measurable disease, Eastern Cooperative Oncology Group (ECOG) performance status score <= 2; MRI <= 21 days of registration on a stable steroid dose; life expectancy >= 3 months; adequate bone marrow function (neutrophils >= 1,500/mL; platelets >= 100,000/mL), adequate hepatic and renal function [alanine aminotransferase (ALT)/alkaline phosphatase < 2.5 x normal; bilirubin < 1.5 x normal, creatinine clearance > 60 mL/min]; >=2 weeks from cytochrome P450 enzyme–inducing anti-epileptic drugs (EIAED), >=28 days from cytotoxic or investigational agents; and >=6 weeks from bevacizumab. ","Patients who were pregnant or nursing, had severe concurrent illness, prior malignancy, or >=grade 2 pre-existing neuropathy were excluded.",in the first 21-day cycle,NA
23053259,NA,Combination,No,Her2/neu overexpressing breast cancer,Patients with histologically/cytologically confirmed diagnosis of Her2-positive (IHC 3+ or ICH2+ with positive FISH) MBC were eligible. Other important eligibility criteria were as follows: patients for whom paclitaxel/trastuzumab might be an appropriate treatment and for whom an anthracycline was not suitable; prior treatment with chemotherapy and/or radiation completed for at least 4 weeks prior to study enrollment and hormonal therapy discontinued at least 1 day prior to treatment start; no previous therapy with trastuzumab and/or paclitaxel within the last year and no clinical signs of central nervous system (CNS) involvement; normal cardiac ejection fraction assessed by MUGA scan and QTc interval B440 ms; and effective contraception.,NA,During cycle 2,NA
27595901,"JapicCTI-101,233",Combination,No,"patients with solid tumors. Primary tumor: Gastric, Esophageal, Esophageal, oral floor, Renal pelvis, Prostate, Bladder, Breast, Occult primary","Patients with histologically or cytologically diagnosed solid tumors refractory to standard treatment or for whom no effective treatment was available were eligible for Part I of this study, provided that they met the following criteria: age 20–75 years; ECOG performance status of 0 to 2; maintenance of adequate organ function; normal hematopoietic (WBC 4000–10,000/mm3, ANC ≥2000/mm3, platelet count ≥100,000/mm3, hemoglobin ≥9.0 g/dL), hepatic (AST and ALT ≤2.5 times the upper limit of normal, or ≤5 times the upper limit of normal in the presence of hepatic involvement, total bilirubin ≤1.5 mg/dL) and renal functions (serum creatinine ≤1.5 mg/dL).","Key exclusion criteria included grade ≥ 2 peripheral sensory neuropathy. To enter Part II of this study, patients had to meet these criteria as well as to have advanced or recurrent breast cancer diagnosed histologically or cytologically and at least one measurable tumor lesion as outlined by the New Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1. Patients were not considered for enrollment in Part II if they had received any taxane against advanced breast cancer or postoperative adjuvant therapy during the previous 6 months.",during the first cycle,NA
19034451,NA,Single Drug,No,"patients with advanced solid malignancies. Primary tumor types: Colon 5; Breast 3; Prostate 3; Lung NSCLC, unknown, ovarian, esophagus 2 Each; Lung SCLC, pancreas, carcinoid, hepatocellular, renal, melanoma, head and neck 1 Each","Inclusion criteria included a histologically proven diagnosis of solid malignancy refractory to treatment, or for which no conventional therapy was available; an Eastern Cooperative Oncology Group performance status of 0–1; at least 18 years of age; a life expectancy greater than 16 weeks; a hemoglobin level equal or greater than 9 g/dl, an absolute neutrophil count equal or greater than 1.5 £ 109/l, a platelet count equal or greater than 100 £ 109/l, a bilirubin less than 1.5 times the upper limit of normal (ULN); alanine or aspartate aminotransferases less than 2.5 times the ULN in the absence of liver metastases, (or up to 5 times the ULN in the presence of liver metastases), and a serum creatinine less than 1.5 times the ULN. Patients had to sign a written informed consent.","Patients were excluded if they had received radiotherapy, endocrine therapy, immunotherapy, or chemotherapy within 4 weeks before starting PPX. Exclusion criteria included cancer treatment within 4 weeks of enrollment, treatment with more than two alkylating regimens or a stem cell transplant, persistent neuropathy grade 2 or higher, and comorbid conditions precluding safe PPX administration.",in cycle 1,NA
24496920,NCT00736619,Combination,No,patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC),"Eligible patients were ≥18 years of age with histologically or cytologically confirmed stage IIII/IVB HNSCC, Karnofsky performance status (KPS) of at least 70%, and adequate organ function. Demonstration of adequate bone marrow (absolute neutrophil count ≥ 1500/µL, platelets ≥ 100,000/µL, hemoglobin ≥ 9 gm/dL), renal (serum creatinine ≤ 1.5 mg/dL or estimated creatinine clearance of ≥ 45 ml/min by Cockcroft and Gault method) and hepatic (total bilirubin ≤ 1.0 mg/dL; aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase value within range of table in eligibility sheet) function was required.  ","Key exclusion criteria were prior radiation therapy for head and neck cancer, presence of multifocal peripheral sensory alterations or paresthesias interfering with activities of daily living, or history of severe infusion reaction to a monoclonal antibody.   Patients with nasopharyngeal carcinoma were not eligible","included at least 4 weekly cetuximab infusions (after loading `dose) and  4 nab-paclitaxel infusions (at the prescribed dose level) concurrently with at least 30 radiation treatments, and the 2 week (14 calendar day) period after the final radiation treatment",NA
22421191,NA,Combination,No,optimally debulked ovarian cancer,"Patients who had a histologically or pathologically confirmed diagnosis of stage III carcinoma of the ovary, primary peritoneum, or fallopian tube were eligible if they (1) had no prior treatment and were optimally debulked at primary surgery to individual tumor plaques of less than 1 cm or (2) had received up to 4 cycles of i.v. carboplatin/taxane as neoadjuvant chemotherapy for advanced, unresectable disease and at interval surgery were optimally debulked to less than 1 cm. Additional inclusion criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, adequate hepatic function [defined as serum bilirubin 2 times the upper limit of normal (ULN) and alanine and aspartate transaminases <=2.5 times the ULN], and adequate renal function, as defined by a creatinine clearance rate of >=45 mL/min. Eligible patients were required to have a hemoglobin level of >=9 g/dL, white blood cell count >=3,500/uL, and platelets >=100,000/uL. Patients with mild to moderate renal insufficiency (defined as a creatinine clearance between 45 and 79 mL/min) needed to be able to interrupt nonsteroidal antiinflammatory treatment for at least 2 days before, the day of, and at least 2 days after the administration of pemetrexed. Finally, patients must have been able to receive folic acid, vitamin B12, and dexamethasone treatments.","Exclusion criteria included life-threatening complications of their malignancies, severe, and/or uncontrolled concurrent medical disease (e.g., uncontrolled diabetes or heart disease, uncontrolled chronic renal or liver disease, or active uncontrolled infection). Additional exclusion criteria included presence of third space fluid not controllable by drainage, evidence of uncontrollable nausea, history of abdominal fistula, intraabdominal abscess or other contraindication to i.p. therapy, preexisting history of significant hearing loss, or known hypersensitivity to any component of pemetrexed, cisplatin, or paclitaxel. Eligible patients must not have a prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient was in complete remission, or any other cancer from which the patient had been disease-free for 5 years.",the first cycle of therapy,NA
28317088,NCT01954355,Combination,No,"patients with advanced solid tumors. Tumor type: Ovarian 9, Breast 2, Pancreas 2, NSCLC 1, Anal canal 1, Cervix uteri 1, Myxofibrosarcoma 1, Klatskin cancer 1","Patients were eligible for the dose-escalation phase if they had a histologically or cytologically documented advanced solid malignancy, refractory to standard therapy or for which no standard therapy existed, previously treated with ≤2 lines of chemotherapy for advanced disease. Patients were eligible for the dose-expansion phase if they had a histologically or cytologically confirmed diagnosis of advanced ovarian cancer previously treated with platinum and taxane chemotherapy (previous taxane could have been administered either on a 3-weekly, or on a weekly, schedule), were refractory (progressive disease during chemotherapy) or resistant (progressive disease within 6 months of completing chemotherapy) to their last platinum-containing chemotherapy regimen and had received ≤2 prior lines of chemotherapy for advanced disease. Other key eligibility criteria for both phases included: Eastern Cooperative Oncology Group performance status 0 to 1; adequate hematologic, hepatic, and renal function (absolute neutrophil count ≥1.5 × 109/L, platelets ≥100 × 109/L, AST/ALT ≤2.5 times upper limit of normal [ULN], or ≤5.0x ULN if liver metastases were present, bilirubin ≤1.5 x ULN and creatinine clearance >50 mL/min, according to the formula of Cockcroft-Gault); a ≥ 4-week interval (6-week interval if prior nitrosoureas or mitomycin C) between trial treatment and any prior treatment with chemotherapy, radiotherapy or targeted agents; no concomitant treatment with strong CYP3A4/5 inhibitors or inducers, drugs metabolized by CYP2B6 or CYP2C9, or drugs with potential to cause rhabdomyolysis (such as 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitors, clofibrate, gemfibrozil); and no treatment with warfarin sodium. ","Patients with symptomatic brain metastases, prior therapy with Hh inhibitor, or known hypersensitivity to taxanes, and those positive for hepatitis B, C or HIV, were excluded.",during the first cycle of treatment,NA
18962846,NA,Combination,No,women with high-risk endometrial cancer,"All patients underwent hysterectomy and bilateral salpingo-oophorectomy by laparotomy or laparoscopy. The abdomen was inspected to identify extra-uterine disease if present, and gross disease had to be cytoreduced to less than 2 cm in order to be eligible for the study. Patients with positive para-aortic lymph nodes were eligible for the study, but surgical assessment was not a formal requirement of this phase I trial. Following surgery, patients found to have surgical stage III–IV endometrial carcinoma (all histologic types), or any stage (I–IV) clear cell or serous endometrial cancer were eligible. Central pathology review was not performed. Patients were enrolled within 8 weeks of surgery. The study received local institutional review board (IRB) review, and following approval, all patients signed an IRB approved informed consent prior to enrollment. Pre-entry requirements included a GOG performance status of 0–2, and adequate bone marrow, renal, and hepatic function (defined as absolute neutrophil count (ANC) N 2000/mm3, platelet count (PLT) ≥ 100,000/mm3, creatinine within institutional normal limits, bilirubin ≤ 1.5 × laboratory normal, and serum glutamic oxaloacetic transaminase (SGOT) ≤ 3 × laboratory normal).","Patients were not eligible if they had received prior therapy with radiation or chemotherapy for any prior malignancy, had recurrent endometrial cancer, or metastatic disease involving lung or liver parenchyma, or inguinal or scalene lymph nodes. Patients with other invasive malignancies (except non-mela- noma skin cancer) present within the last five years were also excluded.",within and greater than 30 days of completion of radiation therapy,NA
27411683,NCT01735409,Combination,No,Metastatic Nasopharyngeal Carcinoma,"Patients aged ≥ 18 years with a histologically proven diagnosis of NPC and evidence of metastatic disease were enrolled. Principal inclusion criteria were: previous failure or intolerance of standard treatment (prior chemotherapy or radiotherapy up to one line) for advanced NPC, or ineligibility for standard therapy (intermediate radiotherapy for local disease); an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–2; at least 1 measurable evaluable lesion; life expectancy of ≥ 12 weeks; adequate hematologic (ANC > 1.5 × 109/L, platelet count >100 × 109/L, and hemoglobin ≥ 90 g/L), hepatic (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] < 2.5 × upper limit of normal [ULN], and bilirubin < 1.0 × ULN), and renal (serum creatinine < 1.5 × ULN or estimated creatinine clearance ≥ 60 mL/min [calculated using the Cockcroft-Gault formula]; ) function; and willingness to provide a biopsy sample for assessment of SPARC expression","Exclusion criteria included: treatment with either more than 2 prior lines of anticancer therapy for metastatic disease, or any chemotherapy, radiotherapy, or other anticancer therapies within 3 weeks before enrollment; central nervous system metastases; pre-existing peripheral neuropathy of NCI-CTCAE grade ≥ 2; any active, clinically serious infection requiring or likely to require antibiotics for > 4 weeks; a life-threatening medical condition (e.g., congestive heart failure, symptomatic coronary artery disease, or heart block); a history of myocardial infarction within 3 months before enrollment; prior or current immunodeficiency; a history of allergy to paclitaxel or docetaxel; or a previous or concurrent malignancy other than NPC (except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis, T1], or any cancer curatively treated > 3 years prior to study entry).",during all treatment cycles,NA
25537644,NCT01042925,Combination,No,trastuzumab-refractory HER2-positive metastatic breast cancer,"Eligible patients were female and aged >=18 years, and had pathologically and radiologically confirmed metastatic, HER2-positive (by local testing) breast cancer that had progressed on at least one trastuzumab-containing regimen for metastatic disease. Patients were required to have measurable disease, an Eastern Cooperative Oncology Group performance status of <=2, and adequate organ and marrow function, including absolute neutrophil count (ANC) >=1,500/mm3, platelets >=100,000/mm3, and hemoglobin >=9 g/dL. Patients receiving pilaralisib plus trastuzumab and paclitaxel (Arm 2) were required to have received at least one prior taxane regimen for adjuvant treatment or treatment of metastatic disease. ",Patients were excluded if they had received previous treatment with a PI3K and/or AKT inhibitor.,during Cycle 1,NA
31792036,NCT02810418,Combination,No,Patients with Advanced Pancreatic Adenocarcinoma,"Eligible patients were 18 years old and had a histologically confirmed diagnosis of PDAC. Advanced or recurrent disease previously treated with at least one line of standard chemotherapy was required. Prior nab-paclitaxel was permitted if >4 months since last administration. Other requirements included: measurable disease per RECIST version 1.1, Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1, adequate organ function including baseline documentation of left ventricular ejection fraction >= 50% by echocardiogram, and ambulatory oxygen saturation > 88%.","Exclusion criteria for all study arms: Known or clinically suspected central nervous system (CNS) 2.1.2.1 primary tumors or metastases including leptomeningeal metastases. History or clinical evidence of CNS metastases unless they have been previously treated, are asymptomatic, and have had no requirement for steroids or enzyme-inducing anticonvulsants in the last 14 days. Evidence of significant, uncontrolled concomitant diseases which could affect compliance with the protocol or interpretation of results, including significant pulmonary disease other than that related to the primary cancer, uncontrolled diabetes mellitus, and/or significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, unstable angina, or clinically significant pericardial effusion) Any known diagnoses, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition (other than pancreatic adenocarcinoma) that would contraindicate the use of an investigational drug, interfere with tumor measurement or lead to an expected life expectancy of less than 6 months as judged by the investigator Active or uncontrolled infections. Live attenuated vaccinations within 14 days prior to treatment. Dementia or altered mental status that would prohibit informed consent. Pregnant women are excluded from this study because the effects of LMB-100 on the developing fetus are unknown and may have the potential to cause teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with LMB-100, breastfeeding should be discontinued if the mother is treated with LMB-100. These potential risks may also apply to other agents used in this study. Known hypersensitivity to any of the components of LMB-100. Baseline corrected QT interval by Fridericia (QTcF) interval of > 470 ms, participants with baseline resting bradycardia < 45 beats per minute, or baseline resting tachycardia> 100 beats per minute. Exclusion criteria specific to patients who will be receiving nab-paclitaxel (all arms except Arm B1 Single Agent Lead-in): Participants with contra-indication and/or history of severe hypersensitivity reactions to nab-paclitaxel. Participants with baseline peripheral neuropathy greater than grade 2. Human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection due to risk of progression while receiving immunosuppressive chemotherapy",within 21 days of the first LMB-100 administration,NA
26112004,NCT01491217,Combination,No,Patients With Metastatic or Recurrent Gastric Cancer,"Patients must histologically or cytologically be diagnosed to have an advanced solid cancer. (phaseI) Advanced/metastatic/recurred gastric cancer(PhaseII). ECOG performance status ≤ 2. Patients have proper bone marrow, kidney, liver function and patients do not have remarkable dysfunction of heart and lung: WBC≥4000/mm3; Platelet ≥100,000/mm3; Hemoglobin≥9.0g/dL; ANC≥ 1,500 /mm3; Creatinine ≤ 1.5mg/dL; AST/ALT/ALP ≤ 3 X the upper limit of normal; Total bilirubin ≤2.0mg/dL *AST/ALT/ALP ≤ 3 X the upper limit of normal but <5 if liver or bone metastasis is present","Patients with blood tumor (ex, leukemia), uncontrolled infectious disease, neurologic disorders, metastasis to CNS or ileus (patients requiring non-oral administration of anti-biotics to treat active bacterial infection are nor eligible, but patients can participate in the trial after complete eradication or control of the infection). Patients who have received bone marrow transplant or are to receive bone marrow transplant. Patients who had the medical history of atrial or ventricular arrhythmia or congestive heart failure or received medical treatment for myocardial infarction within 6 months.",on 28 days of 1 cycle,NA
24013936,NA,Combination,No,advanced solid tumor patients with emphasis on non-small cell lung cancer,"For the phase I component, patients with cytologically or histologically proven advanced solid tumors, any number of prior chemotherapy regimens and performance status (PS) 0–2 were eligible. For the phase II component, patients with cytologically or histologically proven stage IIIB (pleural effusion)/ IV NSCLC by AJCC 6th Ed. and patients that progressed or recurred after first-line therapy were eligible. Patients must have received platinum-based therapy and no more than 2 previous chemotherapy regimens for advanced NSCLC (for patients with recurrent stage III disease up to 2 prior treatments including prior adjuvant or concurrent chemoradiotherapy were allowed), have measurable disease by RECIST 1.016 and PS 0–1. Other eligibility criteria included: age ≥ 18 years, life expectancy ≥ 12 weeks, adequate renal function (creatinine clearance of ≥ 45 ml/min), adequate liver function (AST and ALT≤2.5 X upper limit of normal (ULN) and bilirubin ≤ ULN), adequate bone marrow function (platelets ≥100,000 cells/mm3 and ANC≥1,500 cells/mm3). Prior chemotherapy must have been completed ≥ 4 weeks and radiation must have been completed ≥ 2 weeks prior to start of therapy and all significant treatment related toxicities had to be resolved. Patients with asymptomatic treated brain metastasis (surgical resection or radiotherapy) were permitted if they were neurologically stable and off steroids and anticonvulsants for at least 4 weeks.","Exclusion criteria included: pregnancy or breast-feeding, other active malignancy, uncontrolled inter-current illness, presence of third space fluid which cannot be controlled by drainage, pre-existing peripheral neuropathy grade ≥ 2 (NCI CTCAE Version 3.0)  or prior treatment with pemetrexed or nab-paclitaxel (prior sb-paclitaxel was allowed). ",during the first cycle,NA
29844129,NCT01649336,Combination,No,Patients with Platinum-Resistant Ovarian Cancer,"Eligible patients were women with EOC, including fallopian tube or primary peritoneal cancer, who had platinum-resistant or platinum-refractory disease or disease no longer amenable to further platinum therapy (e.g., those with platinum hypersensitivity) as determined by the treating physician. Patients had to have measurable or evaluable (nonmeasurable) disease per RECIST version 1.1 criteria and an Eastern Cooperative Oncology Group (ECOG) performance status of 2. Furthermore, patients had to have adequate hematopoietic, hepatic, and renal function at baseline, as well as normal cardiac ejection fraction per institutional standards.","History or concurrent evidence of retinal vein occlusion (RVO) or current risk factors for RVO. Prior therapy with a MEK inhibitor. History of hypersensitivity to taxanes or drug formulations containing Cremophor®. History of acute coronary syndromes. Uncontrolled or symptomatic brain metastases that are not stable, require steroids, are potentially life-threatening or that have required radiation within 28 days prior to first dose of study treatment. Concomitant malignancies or previous malignancies with less than a 5-year disease-free interval at the time of enrollment; patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or ductal carcinoma in situ may enroll irrespective of the time of diagnosis. Known positive serology for the human immunodeficiency virus (HIV), active hepatitis C, and/or active hepatitis B. Treatment with ritonavir at the time of first dose of study treatment. Treatment with continuous or intermittent small molecular therapeutics, biologic therapy or hormonal therapy within 28 days prior to first dose of study treatment. Treatment with a cyclical chemotherapy within a period of time that is less than the cycle length used for that treatment prior to first dose of study treatment. Treatment with any other investigational agents within a period of time that is less than the cycle length used for the treatment or within 28 days (whichever is shorter) prior to first dose of study treatment. Treatment with prior radiotherapy within 21 days prior to first dose of study treatment; however, if the radiation portal covered ≤ 10% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy. Additional criteria exist.",during cycle 1 of treatment,NA
22203732,NA,Single Drug,No,"patients with advanced solid tumors. Primary tumor site, n (%): Breast 14 (25), Melanoma 13 (23), Lung (NSCLC) 8 (14.5), Lung (SCLC) 8 (14.5), Head and neck 7 (12.5), Other includes hepatocellular carcinoma (n = 2), colorectal (n = 2), cervical (n = 1), and ovarian (n = 1)","To be eligible, patients had to be 18 years or more of age and have progressing and measurable metastatic or advanced solid tumor not amenable to established forms of therapy, an Eastern Cooperative Oncology Group performance status 0 to 2, and adequate hematologic, hepatic, and renal function; patients enrolled into the expanded maximum tolerated dose (MTD) cohort were required to show evidence of progressing brain metastases by computed tomography (CT) or MRI scan before study entry. Patients with symptomatic brain metastases were not excluded from the study.","Patients with unstable or uncompensated organ system dysfunction, known severe hypersensitivity to paclitaxel, severe toxicity with previous taxane treatment, and/or persistent >= grade 2 neurotoxicity were excluded. Treatment with P450, CYP3A4, and 2C8 enzyme-inducing anticonvulsant drugs during the study and within 14 days of day 1, and chemotherapy, immunotherapy, radiotherapy, and investigational agents during the study and within 4 weeks of day 1 were prohibited.",during cycle 1,NA
25103625,NA,Combination,No,"Patients with advanced solid malignancy. Tumor type: Lung 1 (9%), Breast 1 (9%), Pancreas 1 (9%), Uterine carcinosarcoma 1 (9%), Adenoid cystic carcinoma 1 (9%), Epithelioid hemangioendothelioma 1 (9%), Colorectal 5 (46%)","Patients were eligible for this phase I trial if they had a histo-logically documented advanced solid malignancy for whichno standard therapy existed. Other eligibility criteria included:signed informed consent; evaluable disease according toRECIST 1.1 criteria (Eisenhauer et al., 2009); recovery to any oxicity to less than grade 2 according to the NCI CTCAE V4.0and adequate organ function, defined as follows (must complyall of them): ECOG 0-2, life expectancy higher than 3 months,adequate hematologic function (absolute neutrophil counthigher than 1500/mm3; platelet count higher than 75,000/mm3; hemoglobin higher than 8 g/dl); serum creatinine below1.5 x upper limit of normal; adequate liver function (serumbilirubine below 1.5 x upper limit of normal, GOT and GPTbelow 2.5 x upper limit of normal in presence or absence ofliver metastasis); potassium between 3 and 5.5 mmol/L andsodium between 130 and 150 mmol/L","Exclusion criteria included: LVEF<50%, long QTc or othersignificant heart conditions; active significant endocrine con-ditions including diabetes; and concurrent treatment with CYP inducers or QTc-prolonging drugs.",from the first adminis-tration of dovitinib to the end of the first cycle (42 days),NA
25688104,NCT01263145,Combination,No,"advanced solid tumors and metastatic breast cancer. Primary site: Colorectal, Breast, Ovary, Ocular melanoma, Head and neck, Endometrial","Eligible patients had histologically confirmed metastatic tumors that had failed at least two therapy lines (escalation) and metastatic breast cancer that had progressed after maximum three therapy lines (expansion). Patients had measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 or evaluable disease (14), were age 18 years or older, had adequate organ function including HgbA1c under 8%, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–2. Prior treatment with PI3K pathway inhibitors and paclitaxel for early disease was permitted.","Patients were excluded if pregnant, breastfeeding, or taking CYP3A4 inducers or inhibitors. Washout period was 21 days. ",during the first cycle,NA
30016392,NCT02193633,Combination,No,patients with high-grade serous ovarian and squamous non-small-cell lung cancer,"Histologically- or cytologically-proven solid tumour refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient, or where treatment with paclitaxel is an appropriate treatment option. Patients will be enrolled into two cohorts on the expansion phase. One cohort of the patients must have recurrent high grade serous ovarian cancer. Patients with clear cell ovarian are excluded. The other cohort of patients at expansion must have squamous cell lung cancer. Patients who have had conventional treatment and where paclitaxel is appropriate. In instances where paclitaxel is appropriate but the patient has not already received it the patient may be enrolled after discussion between the referring oncologist and Principal Investigator. Life expectancy of at least 12 weeks. ECOG performance status of 0-1 (Appendix 1). Females should be using adequate contraceptive measures (see restrictions below), should not be breast-feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening: Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments; Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation. Male patients should be willing to use barrier contraception i.e., condoms. Measurable or evaluable disease. Patients enrolled in the expansion phase should have measurable disease by RECIST v1.1 criteria (Appendix 3). Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week (Day -7 to Day 1) before the patient goes in the trial. Laboratory Test	Value required: Haemoglobin (Hb) ≥ 9.0 g/dL; Absolute neutrophil count	≥ 1.5 x 109/L; Platelet count ≥ 100 x 109/L; Serum bilirubin 	≤ 1.5 x upper limit of normal (ULN); Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 x (ULN) if no demonstrable liver metastases or ≤ 5 times ULN in the presence of liver metastases; Alkaline phosphatase (ALP)	< 5 x ULN; Creatinine clearance OR Serum creatinine	≥ 50 mL/min (uncorrected value) ≤ 1.5 x ULN; Fasting glucose <= 125 mg/dL (7 mmol/L); Erythrocyte-HbA1c <= 59 mmol/mol. 18 years or over. Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up.","Radiotherapy (except for palliative reasons), chemotherapy, endocrine therapy, or immunotherapy during the previous 3 weeks (4 weeks for investigational medicinal products and 6 weeks for nitrosoureas and Mitomycin-C) before treatment. N.B. Exceptions to this are patients receiving weekly Taxol as standard of care who have not had a partial or complete response after 6 to 12 weekly doses. Those patients should discontinue their weekly Taxol treatment and may be enrolled to the dose expansion phase without a wash out period. Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 1 toxicities, which in the opinion of the Investigator and the DDU should not exclude the patient. Known leptomeningeal involvement, brain metastases or spinal cord compression. Known  hypersensitivity (>Grade 2) to taxanes, drugs containing Cremophor, AZD2014 or structurally/chemically similar drugs. Unresolved bowel obstruction. Current refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow formulated product or previous significant bowel resection that would preclude adequate absorption of AZD2014. Patients with Diabetes Type I or uncontrolled Type II (HbA1c >59 mmol/mol assessed locally) as judged by the investigator. Major surgery within 4 weeks prior to entry to the study (excluding placement of vascular access), or minor surgery within 2 weeks of entry into the study and from which the patient has not yet recovered. Treatment with warfarin. Patients on warfarin for DVT/PE can be converted to LMWH. Exposure to potent or moderate inhibitors or inducers of CYP3A4/5 if taken within the stated washout periods before the first dose of study treatment: Inhibitors (competitive): ketoconazole, itraconazole, indinavir, saquinovir, nelfinavir, atazanavir, amprenavir, fosamprenavir, troleandomycin, telithromycin, fluconazole, nefazodone, cimetidine, aprepitant, miconazole, fluvoxamine, P-glycoprotein, grapefruit juice, or Seville oragnes (1 week minimum wash-out period), amiodarone (27 week minimum wash-out period); Inhibitors (time dependent): erythromycin, clarithromycin, verapamil, ritonavir, diltiazem (2 week minimum wash-out period); Inducers: phenytoin, rifampicin, St. John's Wort, carbamazepine, primidone, griseofulvin, carbamazepine, barbiturates, troglitazone, pioglitazone, oxcarbazepine, nevirapine, efavirenz, rifabutin (3 week minimum wash-out period) and phenobarbitone (5 week minimum washout period). Exposure to potent or moderate inhibitors or inducers of CYP2C8 if taken within the stated washout periods before the first dose of study treatment: Inhibitors: Gemfibrozil, trimethoprim, glitazones, montelukast, quercetin (1 week minimum wash-out period); Inducers: Rifampicin (3 week minimum wash-out period). At high medical risk because of non-malignant systemic disease including active uncontrolled infection e.g. interstitial lung disease, severe hepatic impairment, uncontrolled chronic renal disease. Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV). Patients who have experienced any of the following procedures or conditions: currently or in the preceding 12 months: coronary artery bypass graft; angioplasty; vascular stent; myocardial infarction (MI); uncontrolled angina pectoris; congestive heart failure NYHA Grade 2; ventricular arrhythmias requiring continuous therapy; supraventricular arrhythmias including AF, which are uncontrolled; Torsades de Pointes; haemorrhagic or thrombotic stroke, including transient ischaemic attacks or any other central nervous system bleeding. Resting ECG with measurable QTc interval of >470ms msec at 2 or more time points within a 24 hour period. Concomitant medications known to prolong QT interval, or with factors that increase the risk of QTc prolongation or risk of arrhythmic events (such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome), or unexplained sudden death under 40 years of age. Inability to discontinue medication with agents designated as having a risk of Torsades de Pointes due to QT prolongation (see Appendix 5). Left ventricular (LV) dysfunction (LVEF outside institutional range of normal) by MUGA or echocardiogram. Current malignancies of other types, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.  Cancer survivors, who have undergone potentially curative therapy for a prior malignancy who have no evidence of that disease currently are eligible for the trial. Prior bone marrow transplant or have had extensive radiotherapy to greater than 25% of bone marrow within eight weeks of starting trial. Patients participating in or planning to participate in another interventional clinical trial whilst on this study. Participation in an observational trial is acceptable. Any other condition which in the Investigator’s opinion would not make the patient a good candidate for the clinical trial.",First cycle of treamtent (7 weeks),NA
15865080,NA,Combination,No,advanced gastric cancer patients,"Patients with histologically confirmed non-resectable or recurrent gastric cancer were candidates for this study. The eligibility criteria also included: i) a performance status of 0-2; ii) an age of 20-75 years; iii) a life expectancy of longer than 3 months; iv) no major surgery, radiotherapy, or chemotherapy within 28 days of study entry; v) adequate bone marrow, renal and liver functions as defined by WBC ≥3,500, Hb ≥8.0, PLT ≥80,000, AST/ALT ≤2 times institutional upper normal limits, and total bilirubin <2 times institutional upper normal limits; vi) no significant cardiac disease evident by ECG; and vii) no limitations from prior regimens. Patients gave written informed consent before treatment, according to institutional guidelines.",NA,during the first cycle of treatment,NA
11474274,NA,Combination,No,"patients with advanced solid tumors. Primary tumor: Breast 11, Ovarian 4, NSCLC 2, SCLC 1, Kidney 2, Other (colon, cervix, endometrium, prostate, sarcoma, NHL) 6","Patients with histologically or cytologically confirmed carcinomas and disease progression after at least one chemotherapy regimen were enrolled. Other inclusion criteria were: a World Health Organization performance status less than or equal to 2; age 75 years or less; a life expectancy of 3 months or greater; adequate renal (serum creatinine concentration < 1.5 mg/dl) and liver (total bilirubin < 1.25 mg/dl) function tests; adequate hematologic parameters (neutrophils >=1,500/dl and platelets >=100,000/dl); no prior chemotherapy or radiation therapy for at least 4 weeks before study entry and no radiation therapy to more than 25% of the bone marrow–containing bones.","Patients with malnutrition (loss of more than 20% of body weight), active infection, brain metastases that failed to improve with radiotherapy, preexisting motor or sensory neurotoxicity grade II or greater, congestive heart failure, or unstable angina pectoris were not eligible.",during the first chemotherapy cycle,NA
17668866,NA,Combination,No,refractory leukemia in children,"Patients <=21 years of age at the time of original diagnosis with ahistologically  confirmed  diagnosis  of  ALL,  AML,  or  chronicmyelogenous  leukemia  (CML)  (>25%  leukemia  blast  involve-ment), refractory to standard therapy, were eligible for this trial. Additional eligibility requirements included an ECOG performancestatus of 0, 1, or 2; life expectancy >=2 months; full recovery from theacute toxic effects of prior chemotherapy and radiotherapy, with atleast 2 weeks since prior chemotherapy excluding steroids (4 weeksfrom  prior  nitrosourea  therapy),  and  no  prior  treatment  withpaclitaxel;  normal  renal  function;  adequate  liver  function  (totalbilirubin <=2  times the upper limit  of normal (ULN), AST, andALT<2.5 times ULN)); and adequate cardiac function (normal EKG and either shortening fraction >=27% by echocardiogram orejection fraction >=50% by gated radionuclide study). All patients ortheir legal guardians provided written informed consent inaccordance with institutional, FDA, and NCI policies.",NA,during thefirst cycle of therapy,NA
11345652,NA,Single Drug,No,"Primary tumor types included breast (3), ovarian (3), non-small-cell lung cancer (3), adenocarcinomas of unknown primary site (3), colon (2), and pancreas (1) tumors","Patients with histological proof of cancer for whom no standard therapy of proven benefit existed were eligible for the study. Pre- vious radiotherapy or chemotherapy other than taxoid therapy was allowed, provided that the last treatment was at least 4 weeks prior to study entry and any resulting toxicities were resolved. Patients had to have acceptable bone marrow (white blood cells >3.0 x 109/l, platelets >100 x 109/l), liver function (serum bilirubin <= 25 µmol/l, serum albumin >=25 g/l), renal function (serum creatinine <= 160 µmol/l or clearance >= 50 ml/min), and a World Health Organization (WHO) performance status <= 2.","Patients were not eligible if they suffered from uncontrolled infectious disease, neurological disease, bowel obstruction, or symptomatic brain metastases. Other exclusion criteria were concomitant use of known P-gp inhibitors and chronic use of H2 receptor antagonists or proton pump inhibitors. ",the first two cycles,NA
18682950,NA,Combination,No,"patients with advanced solid tumors. Primary tumor type: Sarcoma 14, Ovarian 7, Lung 7, Mesothelioma 3, Thyroid 3, Breast 2, Salivary 2, Endometrial 1, Thymoma 1, Bladder 1, Melanoma 1, Neuroendocrine 1",All patients gave written informed consent. Inclusion criteria included a histologically proven solid tumor refractory to treatment or for which no conventional treatment was available; performance status of 0 to 2; >18 years of age; life expectancy >=12 weeks; hemoglobin >=10 g/dL; ANC >= 1.5 x 109/L; platelets >=00 x 109/L; bilirubin <=1.5 x upper limit of normal (ULN); alkaline phosphatase <=2.5 x ULN; alanine aminotransferase/aspartate aminotransferase <=2.5 x ULN if no liver metastases (or 5 x ULN in the presence of liver metastases); and plasma creatinine <=1.5 x ULN.,"Patients were excluded if they had received radiotherapy, endocrine therapy, immunotherapy, or chemotherapy <4 weeks before treatment. Exclusion criteria used were typical of any phase I clinical trial. Patients with preexisting drug-related neuropathy were also excluded.",in cycle 1,NA
15297186,NA,Single Drug,No,patients with platinum- and paclitaxel-resistant epithelial ovarian cancer,"Eligible patients were those with histologically confirmed metastatic epithelial ovarian cancer that was both platinum- and paclitaxel-resistant. Resistance was defined as: (1) progression of disease while on a first-line regimen containing a platinum drug or paclitaxel or (2) tumor progression within 6 months of completion of platinum- or paclitaxel-based therapy administered as either first- or second-line treatment. Patients could have failed an unlimited number of prior chemotherapy regimens. Patients with nonmeasurable dis- ease were eligible if they had an elevated CA-125 level. All patients had to have adequate bone marrow; renal and liver function; a Zubrod performance status of 0, 1, or 2; and a life expectancy of more than 12 weeks.","Patients with tumors of low malignant potential, previous abdominal or pelvic irradiation, or a positive HIV test were excluded from the study.",the first treatment,NA
16533873,NA,Combination,No,patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC),"Inclusion criteria were as follows: age ‡18 years, histologically confirmed NSCLC stage IIIB or IV, measurable disease either by computed tomography (CT) or magnetic resonance imaging (MRI), immunohistochemical evidence of EGFR expression in tumor tissue (as defined in the next section), predicted life expectancy >3 months, Karnofsky performance status ‡60%, no chemotherapy or radiotherapy within 4 weeks before the first infusion of matuzumab and paclitaxel, adequate baseline organ functions [creatinine level <1.5 x upper limit of normal (ULN); bilirubin level <2 x ULN, alanine aminotransferase/aspartate aminotransferase (ALT/AST) <5 x ULN], adequate bone marrow function (white blood count >3000/ul; platelet count >100 000/ul; hemoglobin level >9 mg/dl), no severe uncontrolled comorbidities, and signed informed consent.",NA,The first 6-week period (the first two treatment cycles),NA
12827291,NA,Combination,No,"Patients with solid malignancies. Primary tumour: NSCLC 15, SCLC 2, Mesothelioma 4, Ovarian 1, Cervical 1","Patients with refractory solid tumours for which no effective treatment exists were eligible. All were a minimum of 18 years of age, with a life expectancy of at least 12 weeks and a World Health Organization (WHO) performance status of 0 or 1. Other eligibility criteria included absolute neutrophil count (ANC) >=1.5x109/l, platelets >=100x109/l and haemoglobin >=9 g/dl; creatinine clearance >=60 ml/min (calculated using the Cockcroft-Gault formula); serum bilirubin not more than 1.25 times the upper limit of the reference range (ULRR); alanine and aspartate aminotransferases less than 2.5 times the ULRR in the absence of liver metastases and less than 5 times the ULRR if liver metastases were present. ",Patients were excluded if they had received more than one prior line of platinumbased therapy or more than six cycles of carboplatin as were those in whom more than 30% of the bone marrow had been irradiated.,during the first cycle,NA
16626792,NA,Combination,No,recurrent ovarian cancer,"Patients with recurrent or persistent ovarian or primary peritoneal carcinoma were eligible. Patients were required to be candidates for IP therapy based on adequate potential IP fluid distribution with no gross fluid loculations or adhesions that would significantly affect IP drug distribution. This determination could be made based on clinical assessment or by imaging. Measurable disease was not required. Patients were required to have a Gynecologic Oncology Group (GOG) Performance Grade of 0, 1 or 2 (capable of self-care), a life expectancy of at least 6 months and to be at least 21 years of age. Prior chemotherapy, investigational therapy or radiation to the major bone marrow-bearing areas must have been completed at least 4 weeks before study entry (6 weeks for prior nitrosurea or mitomycin). Additional eligibility criteria included a WBC count ≥3000 per mcl, absolute neutrophil count ≥1500 per mcl, platelet count ≥100,000 per mcl, serum creatinine ≤2.0 mg/dL and bilirubin ≤1.5× institutional normal.",Patients with medical problems of sufficient severity to limit full compliance with the study or which would expose them to undue risks were ineligible as were patients with a prior history of unmanageable reaction to paclitaxel. ,The first two 8-week cycles,NA
12401907,NA,Combination,No,"patients with refractory malignancies. Tumor Types: Colorectal 13, Breast 13, Lung 4, Upper Aerodigestive 3, Other (bladder, gastric, uterine, and 4, cholangiocarcinoma) (1 each)","Patients aged ≥18 years with a life expectancy of at least 3 months and an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 were enrolled. All patients were required to have a pathologic diagnosis of an advanced malignancy that was unresponsive to currently available therapy or for which there was no known effective treatment. Patients could have received no more than two prior chemotherapy regimens in the metastatic setting (one additional adjuvant treatment was allowed) and must have recovered from the toxicities of previous regimens prior to enrollment. At least 3 weeks must have elapsed since previous chemotherapy and 2 weeks since previous radiation therapy. Patients who had received previous treatment with paclitaxel or 5-FU were not excluded from the study. The following laboratory parameters were required for study eligibility: WBC ≥3,000/µl; platelet count ≥100,000/µl; total bilirubin ≤1.5 mg/dl; serum creatinine <2.0 mg/dl, and estimated creatinine clearance ≥50 ml/minute. Patients with a history of brain metastases were eligible, but only if the metastases had been treated and were inactive and asymptomatic at the time of enrollment","Patients with symptoms of malabsorption or who were unable to swallow the study medication were excluded, as well as any patients with active concurrent infections or serious underlying medical conditions. Female patients who were pregnant or lactating also were excluded from the study.",cycle 1 only,NA
12768320,NA,Combination,No,"patients with prostate cancer and other advanced malignancies. Tumor origin: Breast 1, Prostate 5, Lung 1, Gastric 1, Cervical 3, Ovary 1, Bladder 2","Enrolled in this trial were 14 patients with prostate cancer or refractory metastatic malignancy. One patient decided not to start therapy after registration. Eligibility criteria included histologically confirmed metastatic solid tumors that had failed to respond to standard treatment, Eastern Cooperative Oncology Group (ECOG) performance status 0–2, and a life expectancy of at least 8 weeks. Requirements also included age greater than 18 years, adequate bone marrow function, granulocytes greater than 2000/mm3, platelets greater than or equal to 100,000/mm3, hemoglobin greater than or equal to 9 g/dl, adequate renal function, serum creatinine level less than or equal to 1.5 mg/dl, adequate hepatic function, bilirubin level less than or equal to 1.5 mg/dl, and serum glutamic oxaloacetic transferase (SGOT) less than or equal to twice the upper limit of normal. All patients were required to give written informed consent, which was approved by the Institutional Review Board of Robert Wood Johnson University Hospital.",NA,during the first cycle,NA
14566475,NA,Combination,No,locally advanced head and neck tumors,"Inoperable, locally advanced squamous cell cancer of the head and neck region. Sites: oral cavity, oropharynx, hypopharynx. Age 18–75 years. Karnofsky index ≥ 70%. Measurable tumor. No severe comorbidity with contraindications to scheduled chemotherapy. Adequate compliance. Informed consent.",Severe comorbidity (especially impaired renal or cardiac function). Secondary cancers. Distant metastases at diagnosis. Pregnancy or breast-feeding. ,over the whole Simultaneous radiochemotherapy time,NA
12140142,NA,Combination,No,locally advanced non-small cell lung cancer,"Selection criteria included the following: (1) histologically or cytologically documented NSCLC; (2) medi- cally inoperable or unresectable stage II, IIIa or IIIb ; (3) measurable or evaluable tumor parameters; (4) no previous chemotherapy or radiotherapy; (5) performance status ECOG 0-2; (6) adequate hematologic, renal and liver function; and (7) all patients signed informed consent in accordance with guidelines of the institutional review board. Patients were not excluded from this trial if they had lost more than 5% of their body weight during the preceding 3 months, and/or if they had small ipsilateral pleural effusion detected by a computed tomographic (CT) scan of the chest. A diagnostic thoracocentesis was not required",NA,during the chemoradiotherapy phase (cycles 1 and 2),"Based on known prognostic factors, patients were grouped into a good risk and poor risk category. Those with good risk features were defined as having a performance status of 0/1, no pleural effusion and <5% weight loss in the preceding 3 months. Poor risk factors included a performance status of two, pretreatment weight of >=5%, or ipsilateral pleural effusion"
11710824,NA,Combination,No,patients with recurrent ovarian cancer,"Patients with progressive or recurrent ovarian cancer were eligible for this phase I study. In case of prior treatment with a weekly cisplatin-based regimen, a minimal progression-free interval of 3 months after the completion of the weekly cisplatin schedule, was mandatory. Other eligibility criteria included: WHO performance status 0–2, evaluable disease, no more than 2 prior chemotherapy regimens, no chemotherapy, hormonal or radiotherapy for at least 4 weeks prior to entry in the study, no signs of bowel obstruction, neutrophils ≥ 1.5 × 109 l–1, platelet count ≥ 100 × 109 l–1, total bilirubin < 1.25 times the upper limit of normal, creatinine clearance > 60 ml min–1, peripheral neurotoxicity ≤ grade 1, no condition precluding adequate intake of oral topotecan, and no prior therapy with a topoisomerase I inhibitor. ",NA,NA,NA
15216957,NA,Combination,No,Stage IV (M0)Unresectable Head and Neck Squamous Cell Carcinoma,"Patients who were enrolled in this study were required to have histological confirmation of HNSCC and unresectable primary tumor and/ornodal disease.  Other inclusion criteria were stage IV (M0) unre-sectable disease, an ECOG performance score ≤2,normal liver and renal function, fitness for inductionchemotherapy. Patients were evaluated and treatment recommendations were made at a multidiscipli-nary  university hospital that included head and  necksurgeons, radiation oncologists and medical oncolo-gists. ",Patients with nasopharynx carcinomaand unknown primary site tumor were excluded as well as patients with previous history of cancer.,during chemo-radiation,patients were submitted to a course of paclitaxel 175 mg/m2 day 1 and cisplatin 75 mg/m2 day 2 given every 3 weeks for three courses. Curative radiotherapy (RT) started 3 weeks after the last cycle of chemotherapy 
11603001,NA,Combination,No,ovarian cancer,"Eligibility requirements included: histologically confirmed, TAG-72 positive ovarian adenocarcinoma or papillary serous carcinoma consistent with ovarian origin; persistent or recurrent disease after a primary platinum-based  chemotherapy program; disease confined to the peritoneal cavity (including involvement of retroperitoneal lymph nodes) and no tumor nodule >5 cm. Measurements were from CT scans or from description at laparotomy for those patients who had nodetectable disease by CT scan. No history of another invasive malignancy, prior intraperitonealor antibody treatment or whole abdomen radiation was allowed. Patients had to be >18 years old, have a Karnofsky performance status >60, have adequate organ function, and receive noconcurrent non-study chemotherapy, radiation or immunotherapy. ",NA,NA,NA
17021821,NA,Combination,No,metastatic breast cancer,"The criteria for enrolment in the trial included histologically or cytologically proven breast cancer at Wrst diagnosis, evidence of progressive metastatic disease, age between 18 and 75, karnofsky performance status >=70, life expectancy >=12 weeks, adequate bone marrow, hepatic and renal functions characterized as follows: neutrophils >=2.0 x 109 per l, platelets >=100 x 109 per l, haemoglobin >=10 g/dl or 6.2 mmol/l, total bilirubin <=1.25 x ULN, transaminases (ALAT, ASAT) <=1.5 ULN, and serum creatinine <= 1.5 x ULN. For evaluation of anti-tumor eYcacy, the patients had to present with at least one bidimensionally measurable target lesion, by World Health Organization criteria, measured by appropriate imaging procedures within 21 days prior to entry into the study. Regarding previous cancer therapy, surgery had to have taken place 2 weeks or more prior to entry into the study, while hormonal therapy could be continued until study entry but had been discontinued then. If the patient had received any adjuvant or neoadjuvant chemotherapy, 12 months or more should have elapsed since the end of that therapy. To be eligible, patients must have not received palliative chemotherapy for metastatic breast cancer. Radiation therapy was allowed been given provided it did not aVect the proposed measurable lesion(s) and was stopped at least 4 weeks prior to study entry.","Exclusion criteria included prior adjuvant chemotherapy with vinca derivatives or taxanes, concurrent treatment with any other cancer chemotherapy, participation in any other clinical trial within 30 days prior to study screening, poorly controlled medical disorder (diabetes, hypertension, infection), clinical signs of CNS disorder and brain or leptomeningeal metastasis.",in the firrst treatment cycle,NA
16891865,NA,Combination,No,esophageal and gastric cancer,"Patients with a histologically confirmed diagnosis of esophageal adenocarcinoma or squamous cell carcinoma, or gastric adenocarcinoma were enrolled between January 2004 and May 2005. PPX/RT could be administered as definitive loco-regional or adjuvant therapy. Patients with metastatic disease with dysphagia were also eligible. Required laboratory parameters included absolute neutrophil count >1,500 uL hemoglobin>10 g/dL, platelets >100,000 uL, creatinine <1.5 mg/dL, bilirubin <1.5 mg/dL, alanine aminotransferase, and alkaline phosphatase <2.5 x upper limit of normal, and calcium <12 mg/dL. A complete history and physical examination were performed on all patients before treatment. Height, weight, performance status, and tumor stage were recorded. Required staging studies included a computed tomography (CT) scan of the chest, abdomen, and pelvis. Pre- and post-treatment endoscopies were required only in patients with loco-regional disease. ","Patients with previous irradiation, Eastern Cooperative Oncology Group (ECOG) performance status >1, life expectancy <12 weeks, tracheobronchial invasion, tracheoesophageal fistula, unstable cardiac disease within 6 months, active infection, brain metastasis, laryngeal or phrenic nerve paralysis, unstable neurologic symptoms, sensory or motor neuropathy greater than grade 1, or other concurrent malignancy, were excluded.",during the chemoradiation,NA
18414864,NA,Single Drug,No,"resistant solid tumor malignancies. Diagnosis: Colorectal 5, Lung 4, Breast 2, Other (cervical, esophageal, melanoma, mesothelioma, osteosarcoma, ovarian, pancreatic, prostate, renal cell, unknown primary carcinomas) 10","Patients ¸18 years of age were eligible for enrollment onto the study if they had a histologically or cytologically conWrmed malignant solid tumor, failed all conventional chemotherapy options available, and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0¡2. Laboratory criteria for eligibility included absolute neutrophil count (ANC) >=1.5 x 109 cells/L, platelet count >=100 x 109 cells/L, bilirubin <= upper limit of normal, creatinine · upper limit of normal, and alanine transaminase and aspartate transaminase <=1.5 times the upper limit of normal. No chemotherapy or radiation therapy was permitted within 4 weeks of study entry, and no major surgery was permitted within 2 weeks of study entry. ","Patients with the following conditions were ineligible: active central nervous system metastases, baseline peripheral neuropathy >= grade 2 (National Cancer Institute Common Toxicity Criteria v.2), serious concurrent medical illness, or a known hypersensitivity to Cremophor®. Women who were either pregnant or breast feeding were ineligible.",during cycle 1,NA
12006516,NA,Single Drug,No,"patients with advanced solid tumor. Malignancy: Breast cancer 13 (68), Melanoma 6 (32)","Eligible patients included those with a diagnosis of an advanced solid tumor, having failed standard therapy. Requirements included a Zubrod performance status of 0–3, an expected survival of >6 weeks, hemoglobin >= 9 g/dl, ANC >= 1,500/mm3, platelet count >= 100,000/mm3, serum creatinine < 2 mg/dl, and serum bilirubin < 1.5 mg/dl. Patients with prior exposure to taxanes were eligible for the study",NA,NA,NA
12231518,NA,Single Drug,No,"patients with advanced malignancies. Tumor type: Breast 17, Colon 5, NSCLC 12, Ovary 4, Unknown primary 3, Gastric 1, Kidney 1, Soft tissue sarcoma 2, Melanoma 1, Mesothelioma 2, Pleura 1, Small cell lung carcinoma 2, Cervix 1","Patients with advanced nonhematologic malignancies who had progressed on standard therapy or for whom no standard chemotherapy was available were recruited into the study. Before entry each patient underwent assessment with a full history, clinical examination, radiological staging, and laboratory evaluation, informed written consent having been obtained. Eligibility criteria included histological/cytological confirmation of a nonhematological malignancy; Eastern Cooperative Oncology Group performance status <=2; age >18 years; life expectancy >= 3 months; and written informed consent. Patients must have adequate bone marrow (ANC >= 2.0 X 109/liter, platelet count >=100  X 109/liter), hepatic (total bilirubin <=1.5 mg/dl, liver transaminases <=2.5 X upper limit of normal), and renal (serum creatinine <=1.5 upper limit of normal) function. At least 4 weeks must have elapsed since prior chemotherapy (6 weeks for nitrosoureas, mitomycin C, or carboplatin), immunotherapy, or wide-field radiotherapy. Fertile patients were requested to use effective methods of contraception. Approval from the relevant local ethical committees was obtained for each center before recruitment into the trial.","Major exclusion criteria included any evidence of severe or uncontrolled medical disorder or an active infection, which would impair the ability to receive study medication, including prior known hypersensitivity to Cremophor EL, pre-existing neurological toxicity (>= grade 2 according to the National Cancer Institute CTC Version 2.0), dementia or altered mental status that would prohibit understanding of the informed consent, active brain metastases including evidence of cerebral edema by computed tomography scan or magnetic resonance imaging, or progression from prior imaging study, clinical symptoms of/ from brain metastases, or any requirements for steroids. Pregnant or breastfeeding patients were not recruited.",during the first course of treatment,NA
16258082,NA,Single Drug,No,"patients with advanced nonhematologic malignancies. Tumor type: Melanoma, Breast, Non–small-cell lung, Ovarian, Renal, Unknown primary, Colorectal, Prostate, Small-cell lung, Peritoneal ","Eligible patients included males and nonpregnant females practicing adequate birth control who were at least 18 years of age, had a life expectancy of at least 2 months, and had not received any chemotherapy (inclusive of investigational therapies) for at least 3 weeks before study drug administration. Patients had biopsyproven diagnoses of advanced malignancy or solid tumors for which standard therapy had failed. Patients had a Southwest Oncology Group performance status of 0 to 2, hemoglobin >= 9 g/dL, WBC count >= 3.0 x 109/L with an absolute neutrophil count (ANC) >= 1.5 x 109/L, platelet count >= 100 x 109/L, serum creatinine less than 2 mg/dL, serum bilirubin less than 1.5 mg/dL, and hepatic transaminases less than 3 x the upper limit of normal. Prior taxane therapy was permitted.","Patients were excluded from the trial if they had a history of allergy or hypersensitivity to the study drug or its excipients, had symptomatic brain metastases, had a serious concurrent illness that was likely to limit full compliance with the study, had a pre-existing peripheral neuropathy (grade 1 or higher), were unlikely to complete the study with appropriate follow-up visits, or were currently taking any anticancer medication or protease inhibitor. A washout period of 30 days was required before initiation of therapy.",during the first cycle of treatment ,"patients were enrolled onto two cohorts at each dose level based on the amount of prior cytotoxic chemotherapy they had received (ie, lightly pretreated [LP] or heavily pretreated [HP] patients"
12460783,NA,Single Drug,No,"patients with advanced solid tumours. Tumour type: Sarcoma, Colorectal, Ovary, Kidney, Other ","Adult patients aged 18 years or more with histologically- or cytologically-confirmed diagnoses of advanced solid tumours for which no proven effective therapy exists were eligible for this study. Eligibility criteria also included a performance status (PS) of <=2 on the Zubrod scale,no prior chemo- or radiotherapy for at least 4 weeks (6 weeks for mitomycin or nitrosoureas), adequate bone marrow reserve [absolute neutrophil count (ANC) >=1.5x109/l,platelet count >=100x109/l], hepatic [bilirubin <=1.3 x upper limit of normal (ULN) and alanine transaminase/aspartate trans- aminase (ALAT/ASAT) <=2.5 x ULN] renal function [creatinine <=1.5 x ULN] and written informed consent of patients. ","Serious pre-existing medical conditions,pre- existing 5grade 1 peripheral neuropathy,known significant hypersensitivity to Cremophor El1 vehicle or polysorbate 80,symptomatic brain metastases were criteria for exclusion.",during the first cycle,NA
12176795,NA,Combination,No,"patients with advanced solid tumors. Tumor types: NSCLC, SCLC, Soft tissue sarcoma, Gastric, Renal, Head and neck, Other","Adult patients aged 18 to 75 years old, with histologically/cytologically confirmed diagnoses of solid tumors not amenable to conventional local or systemic treatments, were eligible for this trial. Patients had to have recovered from the toxic effects of prior therapies, with a treatment-free period of at least 4 weeks (6 weeks for those given nitrosoureas, mitomycin C or extensive radiotherapy). Inclusion criteria also included a WHO performance status (PS) of ≤2, a life expectancy of ≥3 months, an adequate bone marrow function [absolute neutrophil count (ANC) ≥1.5 × 109/l, platelet count ≥100 × 109/l], normal liver (bilirubin within normal limits and ALAT/ASAT/AP ≤2.5× normal) and renal function (creatinine ≤120 μmol/l), and written informed consent. ","Serious concomitant medical disease, clinically uncontrolled brain metastases, grade 2 or above pre-existent peripheral neuropathy, concomitant steroids at daily doses of >20 mg of methylprednisolone or equivalent, uncontrolled hypertension or arrhythmias, more than three previous chemotherapy regimens for study 1 and more than two for study 2, were criteria for exclusion",the first cycle,NA
16248762,NA,Combination,No,patients with advanced (TAG-72  positive) non-small cell lung cancer,"Patients  with  stage  IIIB  (N3)  or  pleural  effusion(not candidates for surgery or combined modalitytherapy) and stage IV NSCLC, who relapsed afteror were refractory to standard therapies were eli-gible for this study. Eligibility criteria included tumor TAG-72 reactivity by immunoperoxidasestaining (at least 10% of the cells), objectively measurable disease, an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2,and   adequate hematologic (neutrophil count >=1500 cells/uL, platelet count >=150,000/uL, he-moglobin >=10 g/dL), renal (serum creatinine <=1.5mg/dL) and liver function (serum bilirubin <=1.5mg/dL, AST/ALT  <=2 times upper  normal limit). All patients were required to give written, in-formed consent prior to enrollment.","Patients were excluded for radiation to at least 25% of the active marrow; other invasive malignanciesor infection with HIV or hepatitis B; more than one prior chemotherapy regimen; or previous useof paclitaxel or monoclonal  antibody therapy. Concurrent chemotherapy different than paclitaxel, radiation therapy, or immunotherapy were not allowed. ",a  weekly  follow-up  (6  weeks)  after  infusionof 90Y-mCC49,NA
12110496,NA,Combination,No,patients with advanced oesophageal cancer,"Eligibility included patients with metastatic or unresectable histologically-proven squamous cell-, adeno-, or undifferentiated carcinoma of the oesophagus or oesophageal-gastric junction area, a Performance Status (World Health Organisation (WHO)) of 0–2, a life expectancy of more than 12 weeks, adequate haematological, renal and hepatic function defined as white blood cell count (WBC) >=3.0x109 cells/l, platelets >=100x109 cells/l, creatinine <=120 umol/l and total bilirubin <=1.5xupper normal limit. Patients with neurotoxicity > Common Toxicity Criteria (CTC) grade 1 were not eligible. Prior radiation for primary or meta- static disease was allowed, but not in the 4 weeks prior o study entry and not involving more than 30% of the bone marrow. ",Patients previously treated with chemotherapy were not eligible,during the first 4 weeks of treatment,NA
17452427,NA,Combination,No,unresectable stage III non-small cell lung cancer,"The eligibility criteria were: histologically or cytologically proven NSCLC; unresectable stage IIIA or IIIB disease indicated for curative radiotherapy; no previous treatment; measurable disease; the percentage of the normal lung volume receiving 20 Gy or more (V20) (13) expected to be 30% or less; age between 20 years and 74 years; Eastern Cooperative Oncology Group (ECOG) performance status (14) 0 or 1; adequate bone marrow function (12.0 x 109/L white blood cell (WBC) count >= 4.0 x 109/L, neutrophil count >= 2.0 x 109/L, hemoglobin >= 10.0 g/dL and platelet count >= 100 x 109/L), liver function (total bilirubin <= 1.5 mg/dL and transaminase < twice the upper limit of the normal value), and renal function (serum creatinine <= 1.5 mg/dL and creatinine clearance >= 60 mL/min); and a PaO2 of 70 torr or more.","Patients were excluded if they had malignant pleural or pericardial effusion, active double cancer, a concomitant serious illness, such as uncontrolled angina pectoris, myocardial infarction in the previous 3 months, heart failure, uncontrolled diabetes mellitus, uncontrolled hypertension, interstitial pneumonitis or lung fibrosis identified by a chest X-ray, chronic obstructive lung disease, infection or other diseases contraindicating chemotherapy or radiotherapy, pregnancy, or breast-feeding.",during the first and second cycles of chemotherapy and thoracic radiation,NA
17589845,NA,Combination,No,"Patients with previously untreated NSCLC, either stage IIIB with pleural eVusion or stage IV","The criteria for study entry were: (1) histologically or cytologically conWrmed NSCLC; (2) stage IIIB disease with pleural eVusion or IV disease; (3) age between 20 and 75 years; (4) Eastern Cooperative Oncology Group (ECOG) performance status of two or less; (5) a measurable lesion; (6) life expectancy of 3 months or more; (7) adequate bone marrow function (white blood cell [WBC] count from 4,000 to 12,000 ul-1, neutrophil count of 2,000 ul-1 or more, platelet count of 100,000 ul-1 or more, and hemoglobin level of 9.0 g dl-1 or more), renal function (serum creatinine levels less than 1.5 mg dl-1 and creatinine clearance rate of 50 ml min-1 or more), and hepatic function (total serum bilirubin level less than the upper limit of the normal range, levels of aspartate aminotransferease and alanine aminotransferase less than or equal to twice the upper limits of the normal ranges), and arterial oxygen pressure of 70 mmHg or more; and (8) written informed consent. ","Patients who had previously received chemotherapy were not eligible for this study, but previous radiotherapy was permitted if it was not given to the target lesion used to assess response. Patients were excluded if they had active infections, severe heart disease, interstitial pneumonia, lung Wbrosis, peripheral neuropathy, symptomatic brain metastasis, or an active second malignancy.",during the first course of chemotherapy,NA
15711828,NA,Single Drug,No,"patients with advanced solid tumors. Tumor type: Melanoma 1, Ovary 2, Pancreas 2, Lung (small-cell) 1, Bladder 1","Eligible patients were at least 18 years of age with histologically confirmed solid tumors that were refractory to standard therapy or for which no effective therapy was available. An ECOG performance status of 0 or 1 and a life expectancy >=16 weeks were required. Patients had adequate bone marrow (neutrophils >=1500 mm-3 and platelets >=100,000 mm-3), renal (serum creatinine not more than 1.5 times the upper limit of normal) and hepatic (serum bilirubin not more than 1.5 times the upper limit of normal, and AST/ALT not more than 2.5 times the upper limit of normal) function. All patients had recovered from prior treatment and had received no chemotherapy, immunotherapy, or radiotherapy in the previous 4 weeks (6 weeks for nitrosoureas and mitomycin C).","The exclusion criteria included: no treatment with more than two regimens containing an alkylating agent with stem cell toxicity (melphalan, nitrosourea, busulfan, mitomycin C, and carboplatin); no preexisting neurotoxicity from previous treatment equal to or greater than National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade 2; no active brain metastasis; and no serious uncontrolled medical disorder or active infection that would impair the ability of the patient to receive the study treatment. Because of excessive neurotoxicity, beginning with patient 7, exclusion criteria were subsequently modified to: no more than four cycles of a neurotoxic agent (taxane, vinca alkaloid, epothilone, platinum, or any experimental agent with neurotoxicity as a known side effect); and no preexisting neurotoxicity from previous treatment greater than NCI-CTC grade 1.",during the first cycle of treatment ,NA
17519083,NA,Combination,No,stage III non-small cell lung cancer,"Patients qualifying for this study had the following characteristics: male or female, 18–70 years, stages IIIa or IIIb NSCLC UICC 1997), measurable tumour, no prior thoracic radiotherapy or no chemotherapy in the past month, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, serum creatinine of  less  than  2mg/dL,  white  blood  cell  ≥4000/mm3, haemoglobin ≥10g/dL, platelet count ≥100000/mm3, forced expiratory volume in  one second ≥1.5 litre or >50% of predicted value, creatinine and total bilirubin levels ≤1.5 times the upper limit of normal, and aspartate and alanine aminotransferase levels ≤2.0 times the upper limit of normal","Patients who were excluded included pregnant or lactating women, women of childbearing age who lacked a reliable contraceptive method, patients with significant cardiac disease or uncontrolled diabetes, and patients with a second primary tumour other than non-melanoma skin cancer or in situ cervical carcinoma. Patients were also excluded if they had serious, uncontrolled infections, were hypersensitive to paclitaxel, or had participated in another clinical trial within 4 weeks of the start of treatment.",during the concurrent chemoradiotherapy ,"The continual three-dimensional (3D) conformal radiotherapy (60Gy in 30 fractions for 6 weeks) delivered concurrently with paclitaxel  after 2-3 cycles of induction chemotherapy. The Induction chemotherapy regimen included cisplatin (40mg/m2) on days 1 and 2, and vinorelbine (25mg/m2) on days 1 and 8 every 3 weeks for 2 or 3 cycles. "
14701767,NA,Combination,No,localized esophageal cancer,"Patients (age >= 18 years) with histologically confirmed primary or recurrent epidermoid carcinoma or adenocarcinoma of the esophagus (including the gastroesophageal junction) were eligible for the study. Eligible patients included patients with primary disease clinically limited to the esophagus or nodal metastases only (T1-4, N0-1, M0-1A), patients with locoregional failure only, and patients that underwent resection with positive microscopic margins. Patients had to be candidates for curative radiation therapy, with a Karnofsky performance status  60%, and could not have received any prior chemotherapy or radiotherapy. Required laboratory tests included a total WBC count >= 4,000/uL, a platelet count >= 150,000/uL, a serum creatinine <= 1.5 mg/dL and/or creatinine clearance of >= 65 mL/min/L, and a total serum bilirubin <= 1.5 mg/dL. ","Patients were excluded from participation in the study for the presence of any of the following: positive cytology of the pleura, pericardium, or peritoneum; metastases to distant organs; biopsy-proven invasion of the tracheobronchial tree; tracheoesophageal fistula; general medical condition preventing combined-modality treatment (eg, New York Heart Association grade >= 3 congestive heart failure); or active cancer arising at another primary site other than basal cell carcinoma of skin or in situ cervical carcinoma.",the entire chemoradiotherapy program and to be followed for 4 weeks afterwards ,NA
16537186,NA,Combination,No,"patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy. Twenty-six out of 31 were diagnosed with squamous cellcarcinoma of the head and neck; 22 had measurable, previouslyirradiated disease. Three patients had primary lung cancers.","Enrollees were required to have treatment-na ̈ıve, locally ad-vanced, or recurrent carcinoma of the upper aerodigestive tract,not amenable to conventional “curative” radiation or surgey .The predominant burden of disease had to be local or regional.Primary sites included squamous cell carcinoma of the head andneck, salivary gland tumors, and lung cancers. Eligibility stipu-lated minimum age of 18, Eastern Cooperative Oncology Group(ECOG) performance status 0–2, completion of radiation≥3months prior to enrollment, and chemotherapy≥4weeks priorto study entry. Eligibility also mandated adequate physiologicindices, including serum creatinine ≤1.5 mg/dl, absolute neu-trophil count ≥1,800/ml, platelets ≥100,000/ml, bilirubin≤1.5mg/dl, and transaminases≤3times the upper limit of normal. A minimum baseline intake of 1,000 calories/day was required,and patients had to agree to placement of a gastrostomy tube ifrecommended.","Exclusions included systemic bone, brain or leptomeningealmetastasis; significant co-existing medical or psychiatric illnesses precluding aggressive chemoradiation; active, uncontrolled congestive heart failure, or significant arrhythmias within the previous 6 months; and pre-existing Grade ≥2 neuropathy. ",during the chemoradiation therapy,NA
17091249,NA,Single Drug,No,"subjects with advanced malignant solid tumors. Tumor site: Colorectal 5, Pancreas 2, Renal 2, Prostate 1, NSCLC 1, Others 1 each (Gastric, Adenocarcinoma unknown primary, Chondrosarcoma, Esophagus, Mesothelioma, Small cell undifferentiated carcinoma, Spindle cell carcinoma)","Subject inclusion criteria included histologically confirmed malignant solid tumors that had failed to respond to conventional therapy for cancer or a malignancy for which no conventional therapy existed. Subjects must have recovered from all acute adverse effects from prior therapies excluding alopecia and to an Eastern Cooperative Oncology Group performance status of 0, 1 or 2. Subjects had to have measurable disease defined as at least one measurable lesion as specified by the modified RECIST criteria and adequate bone marrow function (a white blood cell count >=3,000/mm3, absolute neutrophil count >=1,500/mm3, and platelet count >=100,000 cells/uL); adequate hepatic function (total bilirubin <=1.5 x the upper limit of normal, and alanine aminotransferase and aspartate aminotransferase <=2.5 x the upper limit of normal); adequate renal function (serum creatinine < 2.0 mg/dL); and a signed IRB approved consent form.","Exclusion criteria included subjects with primary central nervous system metastases or symptomatic brain metastases; subjects known to be HIV-seropositive or having acute or chronic hepatitis B or C infections, subjects with concurrent serious infections requiring intravenous antibiotic or antiviral treatment, or subjects with chronic immunosuppression. Additionally, subjects were excluded if they had a known hypersensitivity to ethanol-cremophor, raspberry flavoring, lipid emulsions, egg or egg products. Subjects with a history of unstable angina or recent myocardial infarction (within the previous 6 months), or any other major illness that, in the investigator’s judgment, could potentially compromise the subject’s safety were also excluded. Because MAC-321 was being administered orally, any condition that could potentially inhibit the oral absorption of MAC-321 also resulted in subject exclusion. Finally, subjects with prior exposure to MAC-321, previous pelvic radiation, grade 2 or greater peripheral neuropathy, and recent major surgery were also excluded. Subjects were discouraged to take concurrent medications known to be cytochrome P450 inhibitors or inducers.",NA,NA
17510207,NA,Combination,No,"patients with advanced solid tumors. Tumor types: Pancreatic 4, Sarcoma 4, Ovarian 3, Colorectal 3, Prostate 2, Esophageal 2, Head and neck 1, Gastric 1, Appendiceal 1, Endometrial 1, Non – small cell lung 1, Melanoma 1, Bladder 1, Adrenal 1","Individuals with advanced and/or metastatic solid tumor (measurable or evaluable) for whom no standard effective therapy was available and who gave informed consent according to institutional and Food and Drug Administration guidelines were eligible, provided that the following criteria were met: adequate bone marrow (absolute neutrophil count, >=1,500 cells/mm3; platelet count, >=100,000 cells/mm3); adequate hepatic function (total bilirubin, <=1.5 mg/dL; alanine aminotransferase, <=1.5 x the institutional upper limit of normal); and adequate renal function defined as a calculated (Cockcroft-Gault formula) or measured creatinine clearance >=50 mL/min.","Patients were ineligible under the following conditions: <18 years old; life expectancy <3 months; Eastern Cooperative Oncology Group performance status >1; chemotherapy (6 weeks for nitrosourea, mitomycin C, and carboplatin), radiotherapy, immunotherapy, or hormonal therapy <4 weeks from study entry; lack of adequate birth control or of a negative pregnancy test if a fertile female; any ongoing significant pulmonary or cardiac disease or history of significant cardiac arrhythmia; evidence of prolonged QTc interval on electrocardiogram or taking medications known to prolong the QTc interval; a history of receiving more than three prior cytotoxic chemotherapy regimens or irradiation to >30% of bone marrow containing skeleton; ongoing peripheral neuropathy > grade 1; a prior history of >=grade 3 cremaphor or taxane hypersensitivity reaction; and inability to discontinue within 7 days of study entry medications known to be substrates of cytochrome P450-3A4 or potentially nephrotoxic medications.",during cycle 1,NA
16551860,NA,Single Drug,No,"Adult patients with solid tumor. Tumor type: NSCLC 19 (40), Colon 10 (21), ACUP 3 (6), Melanoma 3 (6), Cholangiocarcinoma 2 (4), Prostate carcinoma* 2 (4), PNET 1 (2), Sarcoma (undifferentiated, high grade) 1 (2), Other 7 (15)","Adult patients with histologically or cytologically confirmed diagnosis of a solid tumor not amenable to standard therapy were eligible for this study. They had to have an Eastern Cooperative Oncology Group performance status of <=2, a life expectancy of at least 3 months and adequate renal, liver, and bone marrow function, defined as creatinine <1.5 times the upper limits of normal, bilirubin <1.5 times the upper limits of normal, alanineaminotransferase <2.5 times the upper limits of normal, absolute neutrophil count >1.5 x 109/L and platelets >100 x 109/L. An adequate method of birth control had to be used, and women of child-bearing potential had to have a negative serum or urine pregnancy test. At least 4 weeks had to have elapsed from prior anticancer treatment (including taxanes) and toxicities (except alopecia) had to be recovered to <=grade 1 (according to the National Cancer Institute Common Toxicity Criteria version 2.0, NCI-CTCv2.0; ref. 18).","Exclusion criteria for patients were serious uncontrolled medical disease, active infection, significant pulmonary or cardiovascular disorder, QTc interval >450 ms, sensory or motor neuropathy >=grade 2, active brain metastasis, inability to swallow capsules, history of gastrointestinal disease (surgery or malabsorption that could affect the absorption of BMS-275183), concomitant use of known inducers or inhibitors of cytochrome P450 isoform CYP 3A4, and any psychiatric or other disorders such as dementia that would impair compliance. Concomitant radiotherapy or systemic anticancer therapy was not allowed.",during the first cycle,NA
16557435,NA,Combination,No,"advanced gastric cancer. Histologically, 11 patients had intestinal-type adenocarcinoma, and 8 patients had the diffuse type.","The criteria for eligibility included the following: (1) prior chemotherapy regimen completed 4 weeks before entry; (2) adequate bone marrow function (white blood cell [WBC] count ≥ 4000/mm3, platelet count ≥ 100 000/mm3, hemoglobin ≥ 9.0g/dl), adequate liver function (serum bilirubin level ≤ 1.5 mg/dl and serum transaminase level ≤ twice the upper limit of the normal range; if hepatic metastasis had been documented, then serum transaminase level ≤ three times normal range) and adequate renal function (serum creatinine level ≤ 1.5mg/dl, 24-h creatinine clearance ≥ 60ml/min), normal electrocardiogram (ECG); (3) Eastern Clinical Oncology Group (ECOG) performance status (PS) of 2 or less; (4) age between 20 and 79 years; (5) absence of any other serious medical conditions; (6) absence of any other active malignancy; (7) life expectancy greater than 2 months.",NA,the first cycle of this therapy,NA
15026799,NA,Combination,No,patients with advanced non-small-cell lung cancer,"In the phase I study, patients were enrolled if they met the following criteria: (1) age p75 years, (2) histological or cytological diagnosis of NSCLC; (3) unresectable stage IIIB or IV disease; (4) performance status (PS) of 0, 1, or 2 on the ECOG scale with a predicted life expectancy of at least 12 weeks; (5) measurable or evaluable disease, (6) no prior or only one regimen of chemotherapy; (7) any previous chemotherapy or radiation therapy had been completed more than 4 weeks before enrollment and patients had recovered from any adverse effects; (8) adequate major organ function as documented by a WBC count >=4000 ul-1, platelet count >=100 000 ul-1, haemoglobin >=9.5 g dl-1; total serum bilirubin <=1.5 mg dl-1, AST and ALT <=2 x the institutional upper limit of normal, serum creatinine <=1.1 mg dl-1, PaO2 >=70 Torr, and normal ECG. Written informed consent was obtained from all patients.","Patients were not eligible for study enrollment in any of the following cases: (1) recent (within the past 3 months) myocardial infarction, uncontrolled angina pectoris, or arrythmia, (2) uncontrolled hypertension or diabetes, (3) active infection, (4) pulmonary fibrosis, (5) massive pleural effusion or ascites, or (6) cerebrovascular disease",during the first treatment cycle,NA
18235124,NA,Combination,No,patients with stage IV non-small-cell lung cancer,"Patients with stage IV or recurrent NSCLC who had received no prior chemotherapy for advanced NSCLC were eligible. Patients may have received chemotherapy in the adjuvant or neoadjuvant setting. Prior treatment with gefitinib or erlotinib for advanced disease was allowed. Any patients who had received prior radiotherapy must have completed radiation more than 3 weeks before study entry. Laboratory requirements for eligibility were AST and ALT <= 2.5 x the upper limit of normal range, total bilirubin within the normal range, creatinine <= 1.5 mg/dL, absolute neutrophil count >= 1.5 x 109 cells/L, platelets >= 100 x 109 cells/L, and hemoglobin >= 9 g/dL.",Patients with peripheral neuropathy grade more than 1 were excluded. ,in cycle 1,NA
15596915,NA,Combination,No,locoregionally advanced nasopharyngeal carcinoma,"Patients 18 to 65 years of age were eligible if they had histologically proved, stage IIB–VIB (UICC 1997) squamous cell carcinoma",Patients were excluded if they had histories of any prior or concurrent malignant tumor. Prior radiotherapy or chemotherapy rendered patients ineligible as did a pregnancy or lactating female,during therapy,NA
16889823,NA,Combination,No,cervical carcinoma limited to the pelvi,"Patients with clinical stages IB2, IIA, IIB, IIIB and IVA invasive carcinoma of the cervix with radiologically negative para-aortic nodes were eligible. Acceptable modes of evaluation for para-aortic adenopathy included magnetic resonance imaging, computed tomography or lymphangiogram. Any suspicious nodes identified in the para-aortic region were required to be proven negative by biopsy. Additional eligibility criteria included an absolute neutrophil count (ANC) of ≥1500/μl, platelets ≥ 100,000/μl, creatinine <2 mg%, bilirubin ≤1.5 times the upper limit of normal, SGOT ≤3 times the upper limit of normal and a GOG performance status of 0–2. Entry onto the study was required to be within 8 weeks of diagnosis. Patients with obstructive uropathy must have been treated with ureteral stenting or percutaneous nephrostomy.","Patients with metastases to para-aortic or scalene nodes, or organs outside the radiation treatment field, were ineligible as were those who had received previous pelvic or abdominal radiation or cytotoxic chemotherapy or who had evidence of any cancer within the preceding 3 years.",in any of the six planned cycles,NA
15010068,NA,Single Drug,No,"patients with solid tumours. Tumour types: Colorectal 3; Gastro-intestinal tract, including: Esophageal 1, Gastric 2, Gallbladder 1, Pancreatic 2; Unknown primary tumour 2; Miscellaneous 3","Patients with a histologically-confirmed diagnosis of a malignant solid tumour refractory to conventional chemotherapy or for whom no effective therapy existed were eligible. Other eligibility criteria included the fol- lowing: age >=18 years; Eastern Cooperative Oncology Group performance status <=1; no previous anticancer therapy for at least 4 weeks (6 weeks for nitrosourea or mitomycin-C); and adequate haematopoietic (absolute neutrophil count (ANC) >=1.5 x109 cells/l, platelet count >=100 x 109 cells/l and haemoglobin 5100 g/l (or 6.2 mmol/l), hepatic (serum total bilirubin <=25.65 umol/l, and serum aspartate transaminase (AST), alanine transaminase (ALT) <=2.5 times the institutional upper normal limit (UNL) (<=5.0 times UNL in case of liver metastases), and renal function (serum creatinine con- centration <=132.6 mmol/l). Prior surgery or radiation therapy (irradiation field encompassing < 25% of bone marrow) was acceptable as long as it had been com- pleted at least 4 weeks before study registration. ","Specific exclusion criteria included known hypersensitivity to Cremophor EL and/or paclitaxel-containing regimens, known brain metastases, spinal cord compression, and/ or carcinomatous meningitis",during the first cycle,NA
33928486,NCT02613221,Combination,No,"pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS","Major inclusion criteria were patients aged 20–74 years; histologically confrmed unresectable, metastatic colorectal adenocarcinoma; refractory or intolerant to fuoropyrimidines, irinotecan, oxaliplatin, and angiogenesis inhibitors (e.g. bevacizumab, ziv-afibercept, or ramucirumab); measurable lesions based on the Response Evaluation Criteria in Solid Tumours (RECIST version 1.1); Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1; and presence of wild-type KRAS/NRAS.","Major exclusion criteria were history of treatment with any anti-EGFR drugs (cetuximab or panitumumab), regorafenib, or FTD/TPI and presence of known v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation.",NA,NA
15127231,NA,Combination,No,"pretreated advanced cancer patients. Histology, primary site (n, %): Small-cell lung cancer 20 38.46, Ovarian cancer 19 36.54, Non-small-cell lung cancer","All patients were required to meet the following criteria: confirmed histologic or cytologic diagnosis of cancer, at least one bidimensionally measurable or evaluable disease, WHO performance status 0–2, a life expectancy greater than 3 months, previous treatment by standard or first-line chemotherapy, and at the time of entry to have been refractory to any prior cytotoxic treatment. Patients were eligible if they had had two or three previous courses, provided they had been off treatment for at least 3 weeks. Eligible patients were required to have adequate hematologic, renal and hepatic functions as defined by WBC count 3.5x109/l, absolute neutrophil count 1.5x109/l, platelet count 100x109/l, hemoglobin level 9 g/dl, total bilirubin level 1.5 mg/dl, ALT and AST twice the upper normal limit in the absence of liver metastases or five times the upper normal limit in case of documented liver metastasis and creatinine level 1.5 mg/dl. Informed consent was required and obtained from all patients according to local regulatory requirements.",NA,NA,NA
15613553,NA,Combination,No,locally advanced non-small-cell lung cancer,"Patients with histologically or cytologically documented locally advanced NSCLC were enrolled into this study. Other eligibility criteria included the following: (i) age <75 years; (ii) Eastern Cooperative Oncology Group (ECOG) performance status <2; (iii) measurable or assessable tumor; (iv) adequate bone marrow function (granulocytes >2000/ml, hemoglobin level >10 g/dl, platelet count >100 000/ml), renal function (creatinine clearance >60 ml/min) and pulmonary function (arterial oxygen partial pressure PaO2 >65 Torr); (v) acceptable cardiac function as determined by electrocardiogram and echocardiogram; (vi) absence of central nervous system metastases, polyneuropathy and active infection; (vii) life expectancy >8 weeks; (viii) absence of previous chemotherapy or thoracic RT; and (ix) no serious medical or psychiatric illness that would preclude informed consent. All patients gave written informed consent before enrollment.",NA,during the therapy,NA
23054206,NCT00692159,Combination,No,"patients with advanced solid tumors. Tumor type: Epithelial ovarian cancer, Non-squamous NSCLC, Squamous NSCLC, Pancreatic cancer, Colorectal cancer, Sarcoma, Other (adenoid cystic, bladder, breast, cholangiocarcinoma, esophageal, head and neck, prostate, peritoneal and uterine)","Eligible patients had histologically proven advanced or metastatic solid cancer for which curative therapy was unavailable, an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate organ function as demonstrated by an absolute neutrophil count ≥1,500 cells/μL, hemoglobin ≥10 g/dL, platelets ≥100,000/μL, prothrombin time or international normalized ratio ≤1.5 times the institutional upper limit of normal (ULN), creatinine ≤1.5 times the ULN, bilirubin ≤1.5 mg/dL, and aspartate and alanine transaminases ≤2.5 times the ULN (or ≤5 times the ULN in patients with liver metastases). ","Patients were excluded if they had a known history of central nervous system disease, thromboembolic disease, clinically significant malignant effusions, or had received cancer therapy within 4 weeks prior to study entry. Patients were also excluded if they had received prior high dose chemotherapy associated with stem cell rescue, had a known disorder associated with hemolysis, or were pregnant or lactating.",occurring in cycles 1 and 2,NA
26386124,ACTRN12609000294257,Combination,No,malignant pleural mesothelioma,"Eligible patients had confirmed MPM, Eastern Co-operative Oncology Group (ECOG) performance status (PS) 0–1, and were planned for first-line cisplatin/pemetrexed. All had adequate haematological, renal, and hepatic function and measureable disease (defined by Modified RECIST) . Patients were ineligible if they had previous therapy for MPM, radiotherapy to all measurable lesions, symptomatic central nervous system involvement, or previous malignancy within 10 years.",Exclusions specific to study drug were: history of venous thromboem- bolism or severe autoimmunity.,NA,NA
21989766,NCT00528619,Combination,No,"patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer","Male or female patients, 18 years or older, with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 were considered for study entry into the original cohort. Patients were eligible if they had a diagnosis of a solid malignancy that was histologically or cytopathologically confirmed and refractory to standard therapy, or for which no standard therapy existed. Eligibility criteria included adequate organ function (including bone marrow, kidney, and liver), and a life expectancy of >=12 weeks. In the NSCLC expansion cohort, previously treated and/or platinum refractory/intolerant patients with recurrent or advanced NSCLC of all histological subtypes were eligible for enrollment.","Patients were excluded if they had uncontrolled or symptomatic brain metastases, gross hemoptysis (>=5 mL per episode or >=10 mL per day) within 4 weeks of study start, uncontrolled hypertension (>150/100 mmHg) despite standard antihypertensive agents, or cardiac disease, cerebrovascular accident or pulmonary embolism within 12 months of starting on study. Other exclusion criteria included National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 3.0) grade 3 hemorrhage within 4 weeks of treatment, ongoing cardiac dysrhythmias of grade >=2, atrial fibrillation of any grade, prolongation of the QTc interval (>450 ms for men or >470 ms for women), or prior treatment with pemetrexed or sunitinib.",during cycle 1 ,NA
10501910,NA,Combination,No,"Patients with advanced solid tumors. Tumor type: Colorectal 25, Pancreas 3, Others (one each)","All patients underwent a complete history, physical examination, chest radiography, and laboratory evaluation. Eligibility criteria included: (1) histologic evidence of solid tumors refractory to conventional therapy and other investigational agents of higher priority; (2) at least 18 years of age; (3) WHO performance status <= 2; (4) life expectancy >= 12 weeks; (5) off previous anticancer therapy for at least 3 weeks (at least 6 weeks for nitrosoureas or mitomycin C); (6) adequate bone marrow function (WBC >= 3000/mm3 or granulocytes >= 1500/mm3, platelets >= 100 000/mm3, Hgb >= 9 g%), hepatic function (bilirubin <= 1.5 mg%, AST not more than twice the upper limit of normal, albumin >= 2.5 g/dl, normal PT/PTT), renal function (creatinine <= 1.5 mg/dl or Clcreat >= 60 ml/min), cardiac function (no dysrhythmias requiring therapy, no myocardial infarction in the previous 6 months), and metabolic function (electrolytes within normal limits unless due to cancer, blood glucose < 200 mg/dl); and (7) the provision of written, informed consent.",Exclusion criteria included: (1) clinical evidence of brain metastases; (2) serious preexisting medical conditions which would prevent full compliance with the study; (3) pregnancy; (4) concomitant anticancer therapy; (5) the use of aspirin; and (6) the presence of pleural or peritoneal effusions. Patients requiring chronic aspirin therapy and those with eusions were excluded due to the potential for excess drug accumulation based on structural similarities of MTA and methotrexate.,during course 1 ,NA
22658814,NA,Combination,No,previously treated patients with non-small-cell lung cancer,"Adult patients, with a life expectancy of at least 3 months and an ECOG (Eastern Cooperative Oncology Group) performance status of 0-2, were enrolled. The patients were required to have a patholog-ically or cytologically confirmed diagnosis of recurrent, advanced, or metastatic NSCLC that had progressed after 1 prior platinum-based chemotherapy regimen for advanced disease. All histologic subtypes were eligible for inclusion, because this was the standard of care when the study commenced. The patients could have received prior adjuvant chemotherapy as long as the disease-free interval was longer than 1 year. The patients were required to have measurable disease by one or more techniques (computerized tomography,1 magnetic resonance imaging) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0.20 The patients also were required to have adequate liver and renal function, and be able to take folic acid and vitamin B12 supplementation","The patients with active brain metastases or concomitant intercurrent illnesses, including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social situation that would have limited compliance with trial requirements, were excluded. Additional exclusion criteria included patients who had previously received pemetrexed or more than one prior chemotherapy regimen for advanced disease or who had been treated with an- other investigational drug or anticancer therapy for NSCLC within the 28 days before the start of therapy. Previous treatment with epidermal growth factor receptor tyrosine kinase inhibitors in the advanced setting was permitted.",during the first treatment cycle,NA
27717315,ChiCTR-OPN-16008316,Combination,No,inoperable stage III lung adenocarcinoma,"Patients with histologically or cytologically confirmed adenocarcinoma stage IIIA/IIIB, deemed unresectable by the Lung Cancer International Staging System, were eligible. Each patient was a candidate for definitive radiotherapy. Other eligibility criteria included the following: measurable or assessable disease as defined by the response evaluation criteria in solid tumours (RECIST) criteria, performance status (PS) of 0 or 1, absolute neutrophil ≥2000 cells/μL, and platelet count ≥100,000/μL; hemoglobin level ≥9 g/dL; calculated creatinine clearance ≥60 mL/min; bilirubin level ≤2.0 mg/dL; transaminase less than or equal to twice the upper limit of the normal value; forced expiratory volume in 1 s >1.0 L.","Exclusion criteria comprised previous surgery, radiation or chemotherapy; >5 % weight loss; clinically significant medical or psychiatric disorders.",during chemoradiation and up to 5 weeks after consolidation completion,"Consolidation consisted of three pemetrexed/nedaplatin (500 mg/m2, 60 mg/m2) cycles every 3 weeks after concurrent therapy."
17145830,NA,Combination,No,"patients with locally advanced or metastatic breast cancer. More than three quarters of patients had at least two sites of metastatic disease at baseline. Liver, lung, and bone metastases were each present in about half of the patients.","Major eligibility criteria included histologic or cytologic diagnosis of locally advanced or metastatic breast cancer, performance status 0 to 2 on the WHO scale, and an estimated life expectancy of at least 12 weeks. Patients were not allowed to receive other forms of treatment for at least 4 weeks before study enrollment with the exception of radiotherapy (to <25% of the bone marrow) and endocrine therapy (except luteinizing hormone-releasing hormone analogues). Patients were required to have adequate bone marrow function (absolute neutrophil count >=1.5 x 109/L, platelet count >=100 x 109/L, and hemoglobin >=9 g/dL), adequate liver function [bilirubin <=1.5 times the upper limit of normal, alkaline phosphatase, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) <=3.0 times the upper limit of normal], and normal renal function (calculated creatinine clearance >=45 mL/min).","Patients were excluded from the study for the following reasons: chemotherapy within 4 weeks before study enrollment, treatment with any drug within the last 30 days that had not received regulatory approval at the time of study entry; previous participation in a clinical study involving pemetrexed; serious concomitant systemic disorders, including active infection, second primary malignancy, and symptomatic central nervous system metastases; inability to take folic acid or vitamin B12 supplementation or dexamethasone (or an equivalent corticosteroid); and inability to stop treatment with nonsteroidal antiinflammatory drugs. In addition, patients were excluded from the study for pregnancy, breast-feeding, and/or childbearing potential without adequate contraception.",during cycle 1,NA
16940981,NA,Combination,No,"Japanese patients with solid tumours. The majority of patients were male (65%), had an ECOG performance status of 1 (84%), were diagnosed with NSCLC (61%), and received prior chemotherapy (94%) ","Eligible patients had histologic or cytologic diagnosis of solid cancer that was incurable by standard treatments. Patients also must have been between 20 and 75 years of age, have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 –2, and have an estimated life expectancy of at least 3 months. Adequate organ function was required, which included bone marrow reserve (white blood cell count 4.0 –12.0 x 103 mm-3, platelets >=100  103 mm-3, haemoglobin >=9.0 g dl-1, and absolute granulocyte count >=2.0 x 103 mm-3), hepatic function (bilirubin <=1.5 x upper limit of normal, aspartate/alanine transaminase (AST/ALT) <=2.5 x upper limit of normal, and serum albumin >=2.5 g dl-1), renal function (serum creatinine <= upper limit of normal and Cockcroft and Gault creatinine clearance >=60 ml min-1), and lung function (PaO2 >=60 torr). Prior chemotherapy or hormone therapy was allowed if it was carried out >=14 days before study entry (>=35 days for nitrosourea or mitomycin-C). Previous radiotherapy was also allowed, but only if <=25% of marrow was irradiated and if it was completed >=21 days before study entry. Pretreated patients must have recovered from all toxicities before study entry. Prior surgery was allowed if patients recovered from the effect of the operation.","Patients were excluded from this study for active infection, symptomatic brain metastasis, interstitial pneumonitis, or pulmonary fibrosis diagnosed by chest X-ray, serious concomitant systemic disorders incompatible with the study, clinically significant effusions, or the inability to discontinue aspirin and other nonsteroidal anti-inflammatory agents during the study.",during cycle 1,NA
20091088,NA,Combination,No,patients with relapsed or refractory acute leukemia,"Patients who were at least 15 years of age, with a diagnosis of relapsed or refractory acute leukemia, were eligible for this study. The first patient was enrolled on 25 March 2005 and the last patient visit was on 10 October 2006. This study was conducted at one study center (MD Anderson Cancer Center) in the United States. The protocol was approved by the institutional review board prior to enrolling any patient, and all patients provided written informed consent according to regulatory guidelines prior to undergoing any study procedure or receiving any study therapy. Other eligibility criteria included: Eastern Cooperative Oncology Group performance score 0 to 2; serum bilirubin <1.5 mg/dL; aspartate transaminase (AST) and alanine transaminase (ALT) levels <3–5 times upper limit of normal (ULN); creatinine <1.5 mg/dl or calculated creatinine clearance (CrCl) ≥45 mL/min based on the standard Cockcroft and Gault formula; estimated life expectancy ≥16 weeks; use of adequate contraception; and negative pregnancy test in women of childbearing potential.","Exclusion criteria were: treatment within the last 30 days with an investigational anti-leukemia drug; cytotoxic chemotherapy (other than imatinib, corticosteroids, or hydroxyurea) or radiotherapy within the last 7 days; known central nervous system (CNS) disease; history of allergic reactions attributed to compounds of similar chemical or biologic composition to pemetrexed; uncontrolled intercurrent illness including active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social disorders that would limit compliance with study requirements; clinically relevant third-space fluid collections that could not be controlled by drainage or other procedures prior to study entry; and second primary malignancy (except in situ carcinoma of the cervix or adequately treated non-melanomatous carcinoma of the skin or other malignancy treated ≥5 years previously with no evidence of recurrence; prior low grade [Gleason score ≤6] localized prostate cancer was allowed). Additional exclusion criteria were inability or unwillingness to take folic acid, vitamin B12 supplementation, or dexamethasone and inability to interrupt aspirin or other nonsteroidal antiinflammatory agents for a 5-day period (8-day period for long-acting agents such as piroxicam.",in the first cycle of treatment,NA
34724131,NCT04012619,Combination,No,untreated nonsquamous non-small-cell lung cancer,Eligible patients had histologically or cytologically confrmed stage IIIB/IIIC/IV nonsquamous NSCLC; were negative for mutations of EGFR\ALK\ROS1; were aged 18 to 70; never received any systematic treatment (including immunotherapy); had an Eastern Cooperative Oncology Group (ECOG) performance status 0–1; had an expected survival time ≥3 months; and presented no major organ dysfunction.,"Patients were excluded if they had active brain metastases, uncontrolled hypertension, severe cardiovascular diseases, or coagulation abnormalities.",in cycle 1,NA
30382439,NA,Combination,No,patients with advanced solid tumors,"Patients older than 18 years with confirmed advanced solid tumors refractory to or failing standard treatment were eligible for the study. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower and adequate bone marrow, renal, and liver function. In addition, patients should have no contraindications to the intake of folic acid, vitamin B12 or dexamethasone and be able to permanently discontinue aspirin doses of ≥1.3 g/day ≥10 days before through ≥10 days after pemetrexed disodium treatment. ","Patients with symptomatic, untreated, or uncontrolled CNS metastases or seizure disorder, symptomatic serosal effusion, concurrent severe and/or uncontrolled medical disease, acute or chronic liver disease or severe impairment of gastrointestinal absorption were excluded. Other exclusion criteria included uncontrolled infection; inadequate recovery from previous therapies including surgery, radiation, chemotherapy, biologic therapy, hormonal therapy or immunotherapy, and prior treatment with mitomycin C, nitrosoureas, or bevacizumab within 6 weeks of study entry. Concurrent intake of CYP3A4-inducing agents was not allowed.",in the first three weeks of combination therapy ,NA
25920360,NCT01985295,Combination,No,patients with locally advanced soft tissue sarcoma of the extremities,"Eligible patients were age >=18 years, Eastern Cooperative Oncology Group (ECOG) performance status 0 – 2, with pathologically confi rmed intermedi-ate or high grade ESTS, >=5 cm in maximal dimen-sion,  without  evidence  of  metastases. Routinely, a magnetic resonance imaging (MRI) of the tumor mass and a computed tomography (CT) scan of the chest were performed. Prior to entry, patients were evaluated for adequate hematological-, coagulation-, hepatic-,  renal-,  cardiac-  and thyroid function. In young females a negative pregnancy test just prior to start of pazopanib was obligatory and adequate con-traceptive measures were mandatory for both sexes. Patients were checked for prohibited co-medication as per protocol defined.","Prior malignancies; except subjects who have had another malignancy and have been disease-free for 5 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible. Patients with recurrent sarcomas (even without prior radiotherapy). Ewing sarcoma and other PNET family tumours, rhabdomyosarcomas (both pediatric and adult), osteosarcomas. Clinically significant gastrointestinal abnormalities which might interfere with oral dosing diagnosed as: Active peptic ulcer disease. Known intraluminal metastatic lesions with suspected bleeding. Inflammatory bowel disease, ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation. History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment. Major resection of the stomach or small bowel. Uncontrolled hypertension. Unstable or serious concurrent condition (e.g., active infection requiring systemic therapy). Prolongation of corrected QT interval (QTc) >480 msecs. History of any one of more of the following cardiovascular conditions within the past 6 months: Cardiac angioplasty or stenting. Myocardial infarction. Unstable angina. Symptomatic peripheral vascular disease. Coronary artery by-pass graft surgery. Class II, III or IV congestive heart failure as defined by the New York Heart Association (NYHA). History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. Macroscopic hematuria. Haemoptysis that is clinically relevant within 4 weeks of first dose of study drug. Evidence of active bleeding or bleeding diathesis. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer. Chemotherapy or radiation therapy within 2 weeks prior to the first dose of study drug. Biological therapy or treatment with an investigational agent within 28 days or 5 half-lives, whichever is longer prior to the first dose of study drug. Prohibited medications listed in the protocol for 14 days or five half-lives of a drug (whichever is longer) prior to Visit 1 and for the duration of the study should not be taken. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib. Pregnancy or lactating. Hypothyroidism.",during the six-week chemoradiotherapy period within the radiation portals until day of surgery (designated as DLT-I) and those occurring perioperatively until Day 21 after surgery (DLT-II),NA
31186313,NCT01438554,Combination,No,"Advanced Solid Tumors and Differentiated Thyroid Cancers. Tumor histology (%): Thyroid subtype, Papillary 2 (8), Follicular 1 (4), Poorly differentiated 1 (4), Carcinoma 1 (4), Basal cell carcinoma 1 (4), Cholangiocarcinoma 2 (8), Colorectal cancer 2 (8), Endometrial cancer 1 (4), Maxillary sinus cancer 1 (4), Melanoma 4 (15), Merkel cell carcinoma 1 (4), Ovarian cancer 3 (12), Pancreatic ductal adenocarcinoma 1 (4), Pancreatic islet cell tumor 1 (4), Sarcoma 2 (8), Serous papillary cystadenocarcinoma 1 (4), Squamous cell base of tongue cancer 1 (4)","This was an open-label, multicenter [Sidney Kimmel Comprehensive Cancer Center (SKCCC) at John Hopkins University (JHU, Baltimore, MD) and The University of Texas MD Anderson Comprehensive Cancer Center (MDACC, Houston, TX)] trial funded by the National Comprehensive Cancer Network. Patients older than 18 years with advanced solid tumors that were refractory to standard-of-care treatment options were eligible for the dose-finding cohort of the study, and expansion cohorts for DTC, cholangiocarcinoma, and soft-tissue sarcoma were subsequently enrolled at the MTD; here, we report the dose-finding and DTC expansion cohorts. Subjects enrolling in the DTC expansion cohort must have had progressive disease within 6 months of enrolling in the study as assessed by successive imaging and disease that was also amenable to biopsy. Patients with DTC must have had radioiodine nonavid lesions or radioiodine avid lesions that have not responded to treatment with radioactive iodine [defined as >=600 millicuries (mCi), last dose at least 6 months prior to enrollment]. Other eligibility criteria included the presence of RECIST criteria 1.1 measurable disease, an Eastern Cooperative Oncology Group performance status <=1 (or Karnofsky performance status 60%) and adequate organ function as defined by absolute neutrophil count >=1,500 cells/uL, platelet count >= 100,000 cells/uL, international normalized ratio <=1.2 x upper limit of normal (unless stabilized with anticoagulation therapy and within the recommended range for the desired level of anticoagulation), total bilirubin <=1.5 x upper limit of normal (or, in patients with Gilbert syndrome, total bilirubin >1.5 x as long as direct bilirubin is normal), and serum creatinine <=1.5 x upper limit of normal or creatinine clearance >=45 mL/minute and urine protein to creatinine ratio <1, or, if >1, 24-hour urine protein <1 g (17).","Chemotherapy, radiotherapy, other investigational therapy, or major surgery within 4 weeks. Sarcoma and cholangiocarcinoma ONLY: Prior VEGF-targeted TKI therapy. Pregnant or currently breastfeeding. Unresolved toxicity greater than grade 1. Evidence of active hepatitis or HIV. Significant cardiovascular disease. Taking medications known to be strong inducers or inhibitors of CYP3A enzymes. Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding. History of gastrointestinal condition causing malabsorption or obstruction. Cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep vein thrombosis (DVT) within past 6 months. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase risk of pulmonary hemorrhage. Hemoptysis within 6 months of starting treatment. History of retinal vein occlusion (RVO) or central serous retinopathy (CSR), or predisposing factors to RVO or CSR as assessed by ophthalmic exam. Known brain mets that are not stable for at least 8 weeks prior to treatment, or patient is on glucocorticoids for brain mets.",in cycle 1,NA
15923057,NA,Combination,No,patients with non-small cell lung cancer,"Patients with histologically or cytologically diagnosed solid tumors for phase I and patients with bidimensionally measurable, stage IIIB/IV ad- vanced NSCLC for phase II were assessed for el- igibility. Common inclusion criteria included: at least aged 18 years with minimum estimated 12 weeks life expectancy; good bone marrow reserve (platelets ≥100 × 109/L, hemoglobin ≥90 g/L, absolute granulocyte count (AGC) >2.0 × 109/L); adequate hepatic function (bilirubin ≤1.5 × upper limit of normal (ULN), transaminase ≤3.0 × ULN (unless liver metastases present)); and good renal function (creatinine clearance ≥0.75 mL/s, albumin ≥25 g/L). Eastern Cooperative Oncology Group (ECOG) performance status 0—2 was allowed for phase I, while phase II were 0—1. Phase I pa- tients could receive other cancer therapy up to 4 weeks before enrolment, while phase II patients were allowed prior adjuvant therapy if more than 1 year since completion.",Common exclusion criteria included: symptomatic brain metastases; un- controlled pleural or peritoneal effusions; National Cancer Institute-Common Toxicity Criteria (NCI-CTC)  grade 2—4 sensory neuropathy; or in- ability to interrupt non-steroidal anti-inflammatory drugs,cycle 1 ,NA
31506897,NCT01591421,Combination,No,patients with KRAS wild-type advanced colorectal cancer,"Patients had histologically confirmed locally recurrent or metastatic, incurable colorectal cancer and were eligible to receive standard panitumumab treatment as per local guidelines (i.e. must have failed, or have been unable to receive prior irinotecan, oxaliplatin and thymidylate synthase inhibitor therapy). Patients were not allowed prior EGFR inhibitors. Archival tissue samples were collected for translational studies in all patients. KRAS wild type tumours were eligible, as defined by standard local laboratory testing which was restricted to KRAS testing in codons 12 and 13 during the time of the study. Non-measurable disease was allowed for the phase I portion of the trial, all patients in the phase II portion required measurable disease(RECIST 1.1) . Patients needed to have a baseline ECOG performance status of 0–2, and adequate hematological, hepatic and renal function (creatinine of ≤1.5 times upper limit of normal (ULN), total bilirubin ≤ULN, and AST/ALT ≤3 times ULN). ","Patients were screened for mood disorders and if significant anxiety (≥ CTCAE grade 3 anxiety or score ≥ 12 in Patient Health Questionnaire, PHQ-9) or depression (≥ 15 in Generalized Anxiety Disorder, GAD-7 mood scale or suicidal ideation) was found the patient was ineligible. Initially, diabetic patients were not eligible but the protocol was amended to allow this once safety was established",during cycle 1,NA
31065954,NCT01868022,Combination,No,patients with malignant pleural mesothelioma,"Histological or cytological confirmation of unresectable measurable; malignant pleural mesothelioma for which no prior systemic therapy was administered or after recurrence after local therapy; Measurable lesions according to Response Evaluation Criteria in Solid; Tumors (RECIST) version 1.1.; 18 years and older; Archival material available; Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2. Hematologic values: hemoglobin ≥ 10 g/dL, neutrophils ≥ 1.5x109/L, platelets ≥ 100x109/L, partial thromboplastin time ≤ 1.25x upper limit of normal (ULN)). Hepatic function: albumin ≥ 2.5 g/dL, total bilirubin ≤ 1.25x ULN , aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5x ULN. Renal function serum creatinine ≤ 1.5x ULN or creatinine clearance ≥ 45 mL/min. Cardiac function: Left ventricular ejection fraction ≥ lower limit of normal by echocardiography","Previous treatment with any FGFR inhibitor.Any biological therapy within six weeks prior to the first dose of GSK3052230. Any unresolved toxicity from anticancer therapy ≥ grade 2, except alopecia, active malignancy, symptomatic leptomeningeal or brain metastases. Uncontrolled infections, prior trauma or surgery within 28 days before the first dose of study drug, cardiac abnormalities, human immunodeficiency positivity. Conditions likely to increase the potential for abdominal perforation or fistula formation such as ulcers, pelvic radiation or intra-abdominal abscesses in the recent history.",within the first 21 days of period on study ,NA
34740922,NCT02535325,Combination,No,Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer,"Patients aged ≥18 years with histologically confirmed adenocarcinoma of the lung with stage III or oligometastatic stage IV disease were eligible. Patients must have pathologic diagnosis of adenocarcinoma or large cell carcinoma of the lung with confirmation by immunohistochemistry (e.g., transcription termination factor 1 [TTF-1] positivity) (histologic tissue diagnosis is recommended, but cytology is acceptable); stage IIIA/IIIB or oligometastatic stage IV in which the patient is still considered an appropriate candidate for aggressive chemoradiotherapy for the primary tumor; oligometastatic disease is defined as =< 5 metastatic sites (=< 3 lesions per organ); for intracranial metastasis, the patient should have asymptomatic disease that is stable on steroids or 1 to 3 symptomatic metastatic lesions treated with stereotactic radiosurgery (SRS). Eastern Cooperative Oncology Group (ECOG) performance status < 2. Life expectancy of greater than 12 months. Ability to swallow and retain orally-administered medication and does not have any clinically significant gastro-intestinal abnormalities (e.g., malabsorption syndrome or major resection of the stomach or bowel). Leukocytes >= 3,000/mcL. Absolute neutrophil count >= 1,500/mcL. Platelets >= 100,000/mcL. Total bilirubin within normal institutional limits. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x institutional upper limit of normal. Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal. Creatinine within normal institutional limits OR Creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal. Hemoglobin >= 9 g/dL without transfusion within 7 days prior to enrollment. The effects of methoxyamine (TRC102) on the developing human fetus are unknown; for this reason and because methoxyamine as well as other therapeutic agents used in this trial are known to be teratogenic. women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men and women treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of methoxyamine administration. Ability to understand and the willingness to sign a written informed consent document","Patients who have had prior chemotherapy or any other investigational drug within 30 days of registration or prior radiotherapy to the study treatment volume; prior surgery is allowed; there must be at least 6 weeks between mitomycin or nitrosoureas and any new therapy. Patients who are receiving any other investigational agents. Patients with a history of any active malignancy requiring on-going treatment, except basal cell carcinoma or squamous cell carcinoma of the skin. History of allergic reactions attributed to compounds of similar chemical or biologic composition to methoxyamine or to pemetrexed or cisplatin. Undetectable haptoglobin or evidence of glucose-6-phophate dehydrogenase (G6PD) deficiency, pyruvate kinase deficiency, hemoglobinopathy, hereditary spherocytosis, thalassemia or other disorder associated with hemolysis. Patients receiving any medications or substances that are inhibitors or inducers of nonsteroidal anti-inflammatory drugs (NSAIDS), probenecid, salicylates, sulfonamides are ineligible; concomitant drugs that are sensitive CYP450 substrates or strong and moderate CYP450 inducers and inhibitors should be avoided; because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list; medical reference texts such as the Physicians' Desk Reference may also provide this information; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Pregnant women are excluded from this study because methoxyamine is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with methoxyamine, breastfeeding should be discontinued if the mother is treated with methoxyamine; these potential risks may also apply to other agents used in this study. Patients who are known to be human immunodeficiency positive (HIV)-positive and are on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with methoxyamine, pemetrexed or cisplatin; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated",two cycles of chemotherapy during concurrent chemoradiotherapy,NA
33933896,NCT02964689,Combination,No,patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations,"Eligible pts had locally advanced, metastatic, or recurrent non-squamous NSCLC with KRAS exon 2 or 3 (codon 12, 13 or 61) mutations by local testing with measurable disease according to RECIST version 1.1. Pts had to be eligible for cisplatin-based chemotherapy with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 with no prior systemic treatment for metastatic NSCLC. Previous adjuvant or neo-adjuvant chemotherapy was allowed provided that at least 6 months had elapsed since the last dose. Additional eligibility criteria included adequate bone marrow and organ function.",Pts were excluded if they had persistent blood pressure of greater than or equal to 150/100 mmHg despite medical treatment; leptomeningeal carcinomatosis or symptomatic/untreated CNS metastases; evidence of retinal vein occlusion (RVO) by mandatory ophthalmic examination or predisposing factors to RVO; history of retinal degenerative disease; peripheral neuropathy of greater than grade 1,during the first cycle of therapy,NA
10506594,NA,Combination,No,"The most common tumor types were mesothelioma, head and neck cancer, and non—smallcell lung cancer.","Major eligibility criteria included the following: (1) histologic or cytologic diagnosis of cancer for which no proven therapeutic option was available; (2) World Health Organization performance status <=2; (3) estimated life expectancy of >= 12 weeks; (4) adequate bone marrow function (granulocyte value >= 1.5 x 109/L, white blood cell count >= 3.0 x 109/L, platelet count >= 100 x 109/L, hemoglobin value >= 9.0 g/dL); (5) adequate liver function (serum bilirubin concentration <= 1.5 mg/dL, alanine transaminase or aspartate transaminase value <= three times the upper normal value [<= five times normal in case of known disease metastatic to the liver]); (6) prothrombin time and PT and activated partial thromboplastin time within normal range; (7) normal renal function (creatinine level <= 1.5 mg/dL or calculated creatinine clearance rate >= 60 mg/min); and (8) provision of written informed consent according to institutional guidelines.","Exclusion criteria included the following: (1) hematologic malignancy; (2) prior therapy (platinum-based therapy within 6 months before entry onto the study, chemotherapy within 3 weeks before entry onto the study [6 weeks in case of nitrosoureas or mitomycin C therapy]); (3) clinical evidence of brain metastasis; (4) active heart disease and/or myocardial infarction within 6 months before entry onto the study; (5) pregnancy, current breast-feeding, and/or childbearing potential without adequate contraception; (6) active infection; and (7) serum calcium concentration above the upper limit of normal.",the first cycle,NA
34180036,NCT01468922,Combination,No,"patients with refractory solid tumors. Synovial sarcoma, Alveolar soft part sarcoma, Hurthle cell thyroid carcinoma, Metastatic colon adenocarcinoma, Hemangiopericytoma, Pleural mesothelioma,  Chondrosarcoma, Malignant mesothelioma, Alveolar soft part sarcoma, Myxoid liposarcoma, Adenocarcinoma, Hepatocellular carcinoma, Granular cell tumor, Alveolar rhabdomyosarcoma, Adenocystic carcinoma,  Metastatic renal cell carcinoma,  Papillary serous adenocarcinoma - ovary, Non-small cell lung carcinoma, Prostatic adenocarcinoma, Neuroendocrine tumor, Metastatic granulosa cell tumor, Malignant chondrosarcoma, Myoepithelial adenocarcinoma - parotid gland, Renal cell carcinoma, Unspecified carcinoma, Leiomyosarcoma, Ovarian carcinoma, Non-small cell lung carcinoma, Esophageal carcinoma, Colonic adenocarcinoma","Patients ≥18 years old were eligible if they had a pathologically confrmed solid tumor that had progressed following at least one line of prior therapy or had no acceptable standard therapies. Patients enrolled in the expansion cohort were required to have malignancies where prior reports suggested a potential oncogenic role for c-MET signaling , to have disease amenable to biopsy, and to be willing to undergo pre-and post-treatment biopsies. All previous anticancer therapies should have been completed at least 4 weeks prior to enrollment. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status≤1 and adequate organ and marrow function defned as an absolute neutrophil count ≥1,500/μL, platelets ≥100,000/μL, total bilirubin≤1.5×the upper limit of normal (ULN), aspartate aminotransferase and/or alanine aminotransferase <2.5×ULN, and creatinine <1.5×ULN, and urine protein/creatinine ratio < 1 or 24-h urine protein <1 g. Well-controlled blood pressure (BP), defned as a BP not greater than 140 mm Hg (systolic) and 90 mm Hg (diastolic) was also required for eligibility. Initiation or adjustment of BP medication was permitted prior to study entry if the average of 3 BP readings at a visit prior to enrollment was more than 140/90 mm Hg. ","Patients were excluded if they had an uncontrolled intercurrent illness, were pregnant or lactating, or had received treatment for brain metastases within the past 3 months. Prior c-MET inhibitor therapy or anti-angiogenic therapy was allowed in the escalation cohort but not in the expansion cohort; prior anti-angiogenic therapy should have been completed at least 3 months prior to enrollment. ",in the frst cycle,NA
29081023,Eudract no. 2014–002415-41,Combination,No,patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy,"Patients between 18 and 80 years with histologically or cytological documented diagnosis of inoperable, locally advanced or metastatic UCC were eligible for the study. ECOG performance status of 0–1 was mandatory. Further, progressive disease not suited for re-induction with platinum-based chemotherapy, defined as progression during or less than 6 months after initial chemotherapy for locally advanced or metastatic disease or relapsed/progressing less than 6 months after neoadjuvant/adjuvant chemotherapy had to be present. Prior treatment with only one platinum containing chemotherapy regimen was required. Measurable disease according to RECIST 1.1 criteria had to be present and verified by a CT-scan performed no later than 2 weeks prior to inclusion. Progressing tumors occurring in tissue previously radiated were considered evaluable if radiotherapy was terminated at least 3 months before inclusion. Sufficient renal function defined as glomerular filtration rate (GFR) >45 ml/min was required. GFR should be calculated directly from CrEDTA / iohexolclearance or creatinine clearance ≥4 weeks since prior surgery or radiotherapy. Fertile men and women of childbearing potential was required to use sufficient contraception from before entering the study until 6 months after.","No prior treatment with study drugs was allowed. Additional exclusion criteria were: any other systemic disease or co-morbid condition which, according to the investigator, contraindicated the use of the study drug by rendering the subject at increased risk of treatment complications, impaired liver function defined as serum bilirubin ≥1.5 upper limit of normal (ULN) or AST and/or ALT ≥3 x ULN, impaired bonemarrow function defined as platelets < 100,000/mm3 and ANC < 1500/mm3, presence of brain metastasis or other central nervous system disease involvement, any other malignancy within 5 years. Nursing mothers or pregnant women could not enter the study. Hypersensitivity to pemetrexed, vinflunine, other vincaalcaloids, mannitol, hydrochloric acid, sodium hydroxide, as well as concomitant yellow fever vaccination were considered exclusion criteria.",during cycle 1,NA
28528917,NCT01238770,Combination,No,"patients with platinum-resistant, recurrent, pre-treated ovarian cancer ","Written informed consent. Female subjects ≥18 years of age. Histologically or cytologically confirmed diagnosis of: epithelial ovarian cancer which is platinum resistant or platinum refractory,cancer of the fallopian tube, peritoneal cancer. Patients must have failed available standard chemotherapy regimen. Prior treatment with at least 2 chemotherapy regimens in advanced tumor setting. Performance status ECOG 0 - 2. Adequate contraception. Adequate organ function. Measurable disease according to RECIST criteria. Able to swallow and retain oral medication. Life expectancy of at least 12 weeks.","Any second malignancy within the last 5 years, with the exception of basal cell or squamous cell skin cancer or in situ carcinoma of the cervix uteri. History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug. Clinically significant gastrointestinal abnormalities which might interfere with oral dosing. Any unstable or serious concurrent condition (e.g., active infection requiring systemic therapy). Prolongation of corrected QT interval (QTc) >480 msecs. History of any one or more of the following cardiovascular conditions within the past 6 months: Cardiac angioplasty or stenting; Myocardial infarction; Unstable angina; Symptomatic peripheral vascular disease; Coronary artery by-pass graft surgery; Class II, III or IV congestive heart failure as defined by the New York Heart Association (NYHA); History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. Macroscopic hematuria. Hemoptysis that is clinically relevant within 4 weeks of first dose of study drug. Evidence of active bleeding or bleeding diathesis. Known endobronchial lesions or involvement of large pulmonary vessels by tumor. Prior major surgery or trauma within 14 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer.. Chemotherapy or radiation therapy within 2 weeks prior to the first dose of study drug.. Biological therapy, hormonal therapy or treatment with an investigational agent within 28 days or 5 half-lives. Prior antiangiogenic therapy.. Is unable or unwilling to discontinue predefined prohibited medications listed in the protocol for 14 days or five half-lives of a drug (whichever is longer) prior to Visit 1 and for the duration of the study. Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol. Pregnancy. More than 3 different chemotherapy regimens in advanced tumor setting. Uncontrolled hypertension. History of ischemic event (stroke, myocardial infarction, unstable angina, TIA, symptomatic peripheral vascular disease). History or clinical evidence of thrombo-embolic event. History of haemoptysis, cerebral, or clinically significant gastrointestinal haemorrhage in the past 6 months. Active bleeding. Signs/Suspicion of intestinal obstruction",NA,NA
20096951,NA,Combination,No,locally advanced non-small cell and limited disease small cell lung cancer,"No prior chemo- or radiotherapy. ECOG 0 or 1. ANC ≥ 1.5 × 109/L, platelets ≥100 × 109/L and hemoglobin ≥9.6 g/dL. Measurable disease (RECIST). Calculated creatinin clearance ≥60 mL/min (Cockroft and Gault). FEV1 > 30% predicted normal value. Diffusion capacity >40% predicted normal value V20 ≤ 36%. Able to drain third space fluids",Pleural effusion with positive cytology. Stage III NSCLC with supraclavicular lymph node involvement and lower lobe tumors. Uncontrolled vena cava superior syndrome. Serious concomitant systemic disorder. Myocardial infarction <6 months or symptomatic heart disease. Significant weight loss (>10%) over previous 6 weeks before study entry. Inability to take folic acid or vitamin B12 supplementation. Inability to take corticosteroids,the complete chemo-radiation period up to 6 weeks after the last fraction of radiotherapy administration,"Treatment naïve patients received 1 cycle of cisplatin 80 mg/m2 in study I (stage III NSCLC), 75 mg/m2 in study II (LD-SCLC) and pemetrexed 500 mg/m2 before the phase I part"
19701110,NA,Combination,No,patients with recurrent non-small cell lung cancer (NSCLC),"Eligibility criteria included age more than or equal to 18 years, histologic or cytologic diagnosis of NSCLC (any histology), previous therapy with at least one platinum con- taining regimen for either locally advanced or metastatic disease, Eastern Cooperative Oncology Group PS of 0 to 1, and measurable disease by RECIST group response criteria. Adequate hematologic (absolute neutrophil count >=1500/mm3, platelets >=100,000/mm3), renal (creatinine clearance >=45 ml/min), and liver function at baseline (bilirubin <= upper limit of normal, aspartate transaminase <=1.5 x upper limit of normal, alkaline phosphatase <=5 x upper limit of normal) were required. Patients with previous brain metastases were allowed if they had been adequately treated for their brain metastases and were asymptomatic and off steroids. Patients must not have received radiation or chemotherapy within 3 weeks of registration or any investigational drugs within 30 days of registration","Patients were excluded if they had serious concomitant systemic disorders or history of uncontrolled cardiac disease. They were also excluded if they had received previous therapy with pemetrexed or cetuximab, were pregnant, or breast-feeding.",NA,NA
24989332,NCT01445392,Combination,No,chemotherapy-naive  patients  with  advanced  malignant  pleural  mesothelioma  (MPM),"Eligible patients were men and nonpregnant women withhistologically confirmed MPM of an epithelial or biphasicsubtype (those who had biphasic tumors with a predomi-nantly sarcomatoid component were excluded); aged >=18years; a Karnofsky performance status >=70; and adequatebone marrow, lung, liver, and renal functions (the latterwas defined as a serum creatinine clearance >=60 mL/mi-nute estimated according to the Cockroft-Gault formula).Patients must have had measurable stage III or IV diseasethat was not amenable to potentially curative surgical resec-tion. ","Patients who had received prior radiotherapy (withthe exception of palliative, extrathoracic, localized radiother-apy within 4 weeks), biologic therapy (within 4 weeks), orsystemic chemotherapy for pleural mesothelioma were excluded. Tumor mesothelin expression was not an eligibil-ity criterion, because nearly all epithelial mesotheliomas andthe epithelial component of the biphasic mesotheliomaexpress mesothelin.",NA,NA
26291057,NCT00732420,Combination,No,patients with advanced solid tumours,"Eligible patients were those with histologically or cytologically confirmed diagnosis of a progressive advanced solid tumour that was resistant to standard therapy or for whom there was no established therapy. Other inclusion criteria were: written informed consent; >=18 years; Eastern Cooperative Oncology Group performance status of <=1; able to swallow and retain oral medications; adequate haematological (neutrophils >=1.5 x 109 per litre; haemoglobin >=6.2 mmoll-1; platelets X100  109 per litre), hepatic (bilirubin <=1.5 x upper limit of normal (ULN); AST and ALT <=3 x ULN or <=5 x ULN in case of liver metastases) and renal function (Cockroft-Gault creatinine CL >=50 ml min-1 and urine protein creatinine ratio and partial thromboplastin time <=1.2 x ULN).","Exclusion criteria were: less than 4 weeks since last chemo, radio or biologic therapy or surgery or less than 6 weeks since last prior nitrosurea or mitomycin C chemotherapy; administration of investigational drugs within 30 days or 5 elimination half-lives; prior treatment with pazopanib or investigational anti-angiogenic compounds; uncontrolled infection; pregnancy or lactating (all patients with child-bearing potential had to use adequate contraceptive protection); poorly controlled hypertension (systolic X140 mm Hg or diastolic blood pressure X90 mm Hg); prolonged QTc interval; class III or IV heart failure; vascular events within 6 months; therapeutic heparin or warfarin use; leptomeningeal or brain metastases; and any other condition that would interfere with the patient’s ability to comply with the dosing schedule and protocol-specified evaluations.",cycle 1,NA
30496584,NA,Combination,No,elderly patients with non-squamous non-small-cell lung cancer,"Eligible patients were required to meet the following criteria: histologically or cytologically proven unresectable Stage IIIA or IIIB NSCLC; no previous chemotherapy or radiotherapy; a performance status of 0 to 1 as per the Eastern Cooperative Oncology Group (ECOG) scale; aged >70 years; life expectancy of 3 months or more; adequate bone marrow reserves (leukocyte count ≥4000 mm−3, neutrophil count ≥2000 mm−3, platelet count ≥100 000 mm−3, and hemoglobin ≥9.0 g/dl); normal liver function (total serum bilirubin ≤1.5 mg/dl; aspartate transaminase [AST] and alanine transaminase [ALT] <2.5 times the upper limit of the normal range); normal renal function (normal serum creatinine and blood urea nitrogen levels); arterial oxygen pressure ≥70 torr. ",Patients were excluded if they met any of the following criteria: malignant pericardial or pleural effusions; active double cancer; a concomitant serious illness such as myocardial infarction in the previous 3 months; uncontrolled angina pectoris; heart failure; uncontrolled diabetes mellitus; uncontrolled hypertension; interstitial pneumonia or lung disease; infection or other diseases contraindicating chemotherapy or radiotherapy; pregnancy or breast-feeding. ,during concurrent chemotherapy and thoracic radiation,NA
21831954,NCT00370513,Combination,No,hepatocellular carcinoma,"Eligible patients were at least 18 years of age, satisfied European Association for the Study of the Liver diagnostic criteria for diagnosis of HCC (14), and had advanced (local unresectable and/or metastatic) disease not amenable to surgery or local therapy. Prior systemic or local therapy was permitted, provided it was completed within the protocolspecified time frame as follows: >4 weeks since prior systemic therapy, radiotherapy, or major surgery; >6 weeks since administration of nitrosoureas, mitomycin, or prior local-ablative therapy; >60 days since completion of prior radiofrequency ablation. Patients who received prior therapy had to show evidence of disease progression and must have fully recovered from previous therapy. Additional eligibility criteria included an Eastern Cooperative Oncology Group performance status of 0 or 1; at least 1 target lesion according to Response Evaluation Criteria for Solid Tumors (RECIST; ref. 15); adequate hematologic and renal function; and Child–Pugh class A cirrhosis with adequate hepatic parameters [serum albumin >= 2.8 g/dL, serum bilirubin < 2.0 mg/mL; aspartate aminotransferase (AST) <= 2.0 x upper limit of normal; and alanine aminotransferase [ALT] <= 2.0 x upper limit of normal].","Major exclusion criteria included underlying malabsorption syndrome, any condition that interfered with oral administration of the study drug, Child–Pugh class B or C cirrhosis, previous therapy with any VEGF-directed angiogenesis inhibitor, and previous history of portal vein thrombosis or bleeding esophageal varices. Additional exclusion criteria included poorly controlled hypertension; QTc prolongation (defined as a QTc interval > 470 msec); previous class III or IV heart failure; history of cerebrovascular events within 6 months; history of myocardial infarction, hospitalization for unstable angina, or cardiac angioplasty or stenting within 6 months; or untreated venous thrombosis.",cycle 1,NA
20460487,NA,Combination,No,pretreated non-small cell lung cancer patients,"Adult patients with a life expectancy of at least 3 months and an Eastern Cooperative Oncology Group performance score of 0 to 2 were included in the study. Patients were required to have pathologically confirmed metastatic, unresectable, or locally advanced NSCLC of any histology and had to have relapsed during or following one prior platinum-based chemotherapy regimen. At the time of study conduct, there was no label restriction for pemetrexed treatment in patients with nonsquamous cell histology. All patients were required to have bidimensionallymeasurable disease by one or more techniques (computerized tomography, magnetic resonance imaging, or X-ray). Patients with gastrointestinal abnormalities that would interfere with the intake or absorption of study drug or patients with symptomatic brain metastases or brain metastases requiring therapy were excluded from the trial. Patients were also required to have adequate renal and hepatic functions. Prior treatment with an EGFR tyrosine kinase inhibitor or anti-EGFR monoclonal antibody was permitted; however, prior treatment with pemetrexed or another agent targeting the VEGF pathway was not permitted.","Patients with centrally located tumors with radiologic evidence (computerized tomography or magnetic resonance imaging) of local invasion of major blood vessels were excluded. Patients with a history of hemorrhagic or thrombotic events in the past 12 months, clinically significant hemoptysis in the past 3 months, or significant cardiovascular diseases were also excluded.",during the first treatment cycle,NA
23857966,NCT00929903,Single Drug,No,"children with soft tissue sarcoma and other refractory solid tumors. Sarcoma 28, Brain tumor 17 (High-grade glioma, Ependymoma, Low-grade glioma, Germ cell, Medulloblastoma/PNET, Atypical teratoid/rhabdoid), Embryonal 3 (Hepatoblastoma, Wilms tumor), Other 3 (Melanoma, Renal cell)","Patients >= 2 and less than 22 years of age with recurrent or refractory solid or primary CNS tumors were eligible. Patients with CNS involvement could not have new or >= three foci of punctate hemorrhage on baseline MRI. Patients in part 2b (DCE-MRI cohort) had a diagnosis of STS, did not require anesthesia for imaging, and were younger than age 25 years. Other eligibility criteria included the following: recovery from prior therapy; performance status >= 50; adequate baseline renal, hepatic, and hematologic function; normal blood pressure (BP) without antihypertensive agents; adequate cardiac function; QTc less than 450 milliseconds; and stable thyroxine supplementation if hypothyroid","Exclusion criteria included the following: active bleeding, intratumoral hemorrhage, or bleeding diathesis; history of thromboembolic events; treatment with antiplatelet or antithrombotic agents; recent or planned major surgery; impaired wound healing; abdominal fistula, perforation, or abscess; uncontrolled infection; pregnancy or lactation; treatment with strong CYP3A4 inhibitors or QTc-prolonging drugs; and concurrent use of other investigational or anticancer agents.",during cycle 1,NA
26810581,NA,Combination,No,Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas,"Inclusion criteria included: 1. Patients with stage IIIor IV esophageal/GEJ carcinoma where chemoradia-tion therapy is considered appropriate, 2. Age 18 yearsold and older, 3. No prior systemic therapy regimens,4. Eastern Cooperative Oncology Group performancestatus of 0–2, 5. Measurable or evaluable disease onradiographic imaging, 6. Adequate bone marrow func-tion: WBC>=2500 cells/mL, ANC>=1500 cells/mL,Hemoglobin >=9 mg/dL, platelets >=100,000/mL, 7.Adequate liver function tests (LFT): Total Bilirubin<=ULN, Transaminases (aspartate aminotransferase[AST] and alanine aminotransferase [ALT])<=2.5×ULN (<=5.0×ULN if due to metastatic disease in theliver),8.Renalfunction:creatinineclearance of >=45 mL/min using the standard Cockcroft and Gault for-mula","Exclusion criteria included: 1.Inability to interruptaspirin or other NSAIDs pre and post twice monthlydrug dosing, 2. Inability to take folic acid, vitamin B12,or corticosteroids, 3. Pre-existing peripheral neuropa-thy>grade I, 4. Significant cardiac disease includ-ing: uncontrolled blood pressure, unstable angina,congestive heart failure within 6 months (M), myocar-dial infarction within the previous year, or serious car-diac arrhythmia requiring treatment, 5. Need for pro-longed colony-stimulating factor in order to maintainWBC and ANC eligibility values, 6. Prior RT to gastricor esophageal fields, 7. History of receiving PEM and CDDP",observed for a period of 30 days from the end of study treatment prior to next cohort dose escalation,NA
21353323,NA,Combination,No,patients with unresectable stage III non-small cell lung cancer,"Patients eligible for this study were required to have histologically or cytologically documented stage IIIA/IIIB NSCLC deemed unresectable. Additional inclusion criteria were patient age >18 years, Eastern Cooperative Group Performance Status 0–1, mea- surable or evaluable disease as defined by the response evaluation criteria in solid tumours (RECIST) criteria, adequate bone mar- row function (hemoglobin >9 mg/dL, absolute neutrophil count >1500/uL, platelets >100,000/uL), adequate kidney function (creatinine clearance ≥45 mL/min according to the Cockroft and Gault formula), adequate liver function (total bilirubin <1.25 × upper limit of normal [ULN]), aspartate aminotransferase and alanine aminotransferase <3 × ULN), and adequate lung function (forced expiratory volume in 1 s ≥1000 mL and lung diffusion test for carbon monoxide [DLCO] >30%). ","Patients were excluded from the study if maximum planned treated volume (PTV) >2000 cm3 and V20 (percentage healthy lung volume minus PTV, which receives 20 Gy) >35%. Patients who had received chemotherapy during the last 5 years or thoracic radiation therapy at any time were not eligible. Patients with currently active malignancy other than non- melanoma skin cancer were not eligible, except if they had been considered disease-free for the last 2 years. Patients with history of acute myocardial infarction, uncontrolled heart failure or cardiac arrhythmias within the last 6 months were also excluded. Patients with any other significant clinical disorder were excluded. Patients should have been able to take supplements of folic acid and vitamin B12, and to suspend aspirin or other non-steroidal anti- inflammatory drugs (NSAIDs) during a period of 5 days (8 days in the case of long-acting drugs such as piroxicam).",during any of the 3 cycles of chemoradiation,NA
21073623,NA,Combination,No,locally advanced esophageal squamous cell carcinoma,"Patients were 18 to 70 years old with previously untreated histologically confirmed SCC of thoracic esophagus, for which chemotherapy and RT were indicated. They were required to have bidimensionally measurable disease, Karnofsky performance status of 70 or higher, and life expectancy of 3 months or longer. The minimum laboratory requirements were as follows: hemoglobin (Hb) >= 10 g/dL or greater, absolute white blood cell count (WBC) of 4000/mL or greater, platelets count (PLT) of 100 000/mL or greater, total bilirubin level of 1.5 mg/dL or less, serum creatinine level 1.5 times the upper limit of normal or less, and aspartate/alanine aminotransferase levels 2.5 times the upper limit of normal or less.","Exclusion criteria were patients with distant metastases, radiographic or bronchoscopic evidence of esophageal perforation, and some other serious underlying medical conditions (significant cardiac disease or uncontrolled diabetes, central nervous system disorders or psychological disability thought) that might impair the ability to receive protocoled treatment, or previous evidence of chemotherapy or RT. Patients were also excluded if they had serious, uncontrolled infections, or had participated in another clinical trial before the start of treatment.",during or up to 8 weeks after completion of CCRT,NA
26560486,NCT00979576,Combination,No,Japanese patients with advanced non-small cell lung cancer,"Japanese male or female patients aged ≥20 and ≤74 years with histologically confirmed Stage IIIB/IV or recurrent NSCLC (all histologies) and relapse after or failure of prior first-line chemotherapy were eligible for enrollment. The minimum time allowed to elapse between the last anticancer therapy and the first administration of trial drug was 4 weeks. In the case of recurrent disease, one additional prior regimen was allowed for adjuvant, neoadjuvant or neoadjuvant plus adjuvant therapy. All patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, a life expectancy of at least 3 months and adequate organ function. The presence of measurable lesions, according to response evaluation criteria in solid tumors (RECIST), was not a prerequisite for inclusion.","Further exclusion criteria included previous therapy with other VEGFR inhibitors or VEGF ligand inhibitors for the treatment of NSCLC (other than bevacizumab), previous therapy with nintedanib and/or pemetrexed for the treatment of NSCLC, active brain metastases, leptomeningeal disease,history or presence of distinct or suspected pulmonary fibrosis or interstitial lung disease (ILD), radiographic evidence of cavitary or necrotic tumors, centrally located tumors with radiographic evidence of local invasion of major blood vessels, history of clinically significant hemoptysis within the past 3 months, and history of major thrombotic or a clinically relevant major bleeding event in the past 6 months.",during treatment Cycle 1,NA
23653147,NA,Single Durg,No,"patients with advanced solid tumors and hepatic dysfunction. Type of primary tumor/hematologic malignancy: Bile duct, Breast, Colon/rectum, Liver, Lung, Pancreas, Other. Colorectal cancer and liver cancer were the 2 most common types of primary tumor. ","Eligible patients were 18 years or more of age with a life expectancy of more than 3 months and a Karnofsky Performance Status of 60% or more. All patients must have had a histologically or cytologically confirmed solid tumor or lymphoma except patients with hepatocellular carcinoma diagnosed by an elevated a-fetoprotein level (>=500 ng/mL) and positive serology for hepatitis. Other eligibility criteria included: absolute neutrophil count (ANC) of >=1.5 x 109/L, platelet >= 100109/L; serum creatinine<=ULN; or a calculated or measured level of >=60 mL/min/1.73 m2 for creatinine levels above the institutional normal. For patients with gliomas or brain metastases, only those patients receiving a stable dose of corticosteroids and who were seizure-free for at least 1 month before enrollment were eligible. Patients taking CYP 450 enzyme-inducing anticonvulsant drugs were switched to other medications at least 7 days before the first dose of pazopanib. Patients requiring anticoagulation were required to be on a stabilized dose of low molecular weight heparin. Therapeutic anticoagulation with warfarin was not permitted. Patients with biliary obstruction were eligible if the stent had been in place for at least 10 days before study initiation and liver function was stable for at least 2 days without any categorical change in hepatic dysfunction stratum. Radiotherapy was required to be completed 4 weeks or more before entering the study; chemotherapy, targeted therapy, or biotherapy for 3 weeks or more; and nitrosoureas or mitomycin C for 6 weeks or more. Agents with longer halflives (such as suramin and bevacizumab) required longer elimination periods","Patients were not eligible if they had received prior therapy with pazopanib, had major surgery within 28 days before treatment, or were receiving any other concurrent investigational agents. Pregnant patients and patients with human immunodeficiency virus, or uncontrolled intercurrent illness were also excluded. The following patients were not eligible for this study: patients with a serious or nonhealing wound, ulcer, or bone fracture; history of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 28 days of treatment; a cerebrovascular accident, myocardial infarction, baseline QT >= 480 msec, recent admission for unstable angina, cardiac angioplasty, or stenting within 6 months of entry.",the first cycle,"Patients were stratified into 4 groups [A (normal), B (mild), C (moderate), and D (severe)], using the NCIODWG categories of liver dysfunction for trials involving anticancer therapeutics"
28238078,NCT01485042,Combination,No,"adult patients with advanced solid tumors. Sarcoma represented 40% of all enrolled patients, followed by genitourinary (13%), colorectal (10%), and neuroendocrine (10%).","All patients were enrolled at Duke University Medical Center (Durham, NC). Patients with histologically and/or cytologically confirmed malignant solid tumor refractory to standard therapies, or for which no standard therapies exist, or for whom pazopanib would be considered a therapeutic option were eligible for enrollment. Additional inclusion criteria included: measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, age ≥18 years, Karnofsky performance status (KPS) ≥80%, life expectancy of at least 3 months, and adequate renal, cardiac, hepatic and bone marrow function. Erythropoietin and transfusion support was permitted provided treatments were not required more than every 8 weeks. Women of childbearing potential (WOCBP) were required to have a negative serum pregnancy test within 7 days of study drug initiation. Both men and women were required to use two methods of contraception for the duration of the study, and for 6 months after last study drug administration.","Patients were excluded if they received anticancer therapies, including investigational agents, chemotherapy, radiation therapy, antibody based therapy, etc., within 4 weeks from day 1 of study drug initiation or if they had major surgery or significant traumatic injury within 4 weeks from day 1 of study drug.",during the first 28-day cycle of treatment,NA
28771961,NA,Combination,No,previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer,"The patient eligibility criteria for this study were as follows:aged≥75; histologically and/or cytologically confirmedstage IIIA or IIIB NSqNSCLC, inoperable disease, no his-tory of chemotherapy or RT, an Eastern CooperativeOncology Group performance status (PS) of 0 or 1, a lifeexpectancy of 12 weeks or longer, adequate organ function(a leukocyte count of≥4000/μL, a neutrophil count of≥2000/μL, a hemoglobin level of≥10 g/dL, a platelet countof≥100 000/μL, a serum bilirubin level of≤1.5 mg/dL,serum alanine aminotransferase and aspartate aminotrans-ferase levels≤2 times higher than the upper limit of nor-mal, and a serum creatinine level of≤1.5 mg/dL), and anoxyhemoglobin saturation (SpO2) level (as measured bypulse oximetry) of≥95% (in room air); no other form ofcancer; and determined by a radiologist as able to undergoRT safely (V20≤35%)","The exclusion criteriawere  as  follows:  T3N1  disease;  having  suffered  a myocardial infarction within the previous three months;uncontrolled diabetes mellitus, an active infection, intersti-tial pneumonia (confirmed by chest X-ray), cerebrovascu-lar disease, symptomatic pericardial effusion, symptomaticsuperior vena cava syndrome, or a history of significantneurological or psychiatric disorders; severe heart disease,such as uncontrolled angina pectoris, heart failure, hyper-tension, or arrhythmia; positivity for the hepatitis B surfaceantigen; or any other complications that made the subjectunsuitable for this trial.",during treatment,NA
27213589,NA,Combination,No,patients with advanced solid tumors,"Patients must have had a diagnosis of advanced solid tumor malignancy with no potential curative treatment. Any number of prior lines of therapy was allowed. Ineligible patients included those with uncontrolled brain metastases, contraindication to antiangiogenic agents, arterial thromboembolic or embolic events within the past 6 months, major cardiac dysfunction, systolic blood pressure greater than 160 mm Hg or diastolic pressure greater than 100 mm Hg despite optimal medical management, inability to interrupt aspirin or non-steroidal anti-inflammatory agents for a 5-day period, serious uncontrolled infection (Common Terminology Criteria for Adverse Events [CTCAE] v 4; grade > 2), or known or presumed intolerance to pemetrexed or sorafenib. Patients unwilling or unable to take folic acid, vitamin B12, or dexamethasone, or with an inability to swallow or suspected malabsorption were also ineligible. Prior treatment with pemetrexed or sorafenib was allowed. Eligible patients had to meet the following criteria: at least 18 years of age; aspartate transaminase (AST) or alanine transaminase (ALT) less than or equal to 3 times the upper institutional limit of normal (ULN); total bilirubin of less than or equal to 1.5 times the upper institutional limit; creatinine clearance of at least 45 mL/min by standard Crockcroft-Gault equation; INR less than or equal to 1.5, unless due to anticoagulants; hemoglobin levels of at least 8.5 g/dL; total white count of at least 3.0 × 109/L; an absolute neutrophil count of at least 1.5 × 109/L; and a platelet count of at least 80 × 109/L for cohort A and at least 100 × 109/L for cohort B. Initially, an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less was required. A protocol amendment effective for cohort B modified the ECOG performance status inclusion criteria to a score of 1 or less for cohort B and further defined eligibility criteria by excluding any patients with grade 2 or greater neuropathy, low serum B12/folate levels, or platelets of less than 100 × 102/L. Prior chemotherapy toxicities were allowed as long as they were stable and did not interfere with study drug toxicity assessment. Patients were required to have measurable or evaluable disease by RECIST v1.",NA,The first 28 days of treatment ,NA
23698253,NCT01072890,Combination,No,patients with several advanced solid tumors,"Eligible patients were aged 18 years and older with refractory solid tumors and a Zubrod Performance Status of 0–2. Any number of previous treatments was allowed as long as treatment was completed at least 2 weeks before registration and all toxicities had resolved to grade 1 or less. Further inclusion criteria included the ability to provide informed consent, the ability to take oral medication, and acceptable end-organ function defined by an absolute neutrophil count >= 1500/mm3, platelet count >= 100 000/mm3, total bilirubin within institutional normal limits, alanine aminotransferase and aspartate aminotransferase <= 2.5 times the upper limit of normal (ULN) or <= 5 times ULN for patients with liver involvement, and creatinine <= 1.5 times ULN.","Exclusion criteria included any previous treatment with temsirolimus, everolimus, rapamycin, or pazopanib and the need for ongoing treatment with warfarin or low-molecularweight heparin. Patients were excluded for significant cardiac comorbidities including New York Heart Association class II or greater congestive heart failure, myocardial infarction within the past 6 months, new onset of angina within the previous 3 months, corrected QT interval >480 ms, and systolic blood pressure >160 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management. Further exclusion criteria included thrombotic or embolic events within the past 6 months, evidence of bleeding diathesis or coagulopathy, fasting cholesterol >350 mg/dl, and fasting triglycerides >400 mg/dl. Patients with major surgery, open biopsy, or significant traumatic injury within the previous 4 weeks were also excluded, as were patients with nonhealing wound, ulcer, or bone fracture or clinically serious active infection.",during the first cycle of therapy,NA
17442992,NA,Single Drug,No,"children with refractory solid tumors. Diagnosis: Osteosarcoma 12, Ewing sarcoma 3, Brainstem tumor 3, Hepatoblastoma 2, Renal cell carcinoma 2, Anaplastic astrocytoma or glioblastoma multiforme 2, Glioma 1, Ependymoma 1, Medulloblastoma 1, Pilocytic astrocytoma 1, Nasopharyngeal adenocarcinoma 1, Rhabdomyosarcoma 1, Wilms’ tumor 1, Liposarcoma 1, GI stromal tumor 1","Patients older than 12 months and <= 21 years of age with solid tumors for which no curative or life-prolonging therapies exist were eligible for the study. Histologic verification at initial diagnosis was required except for intrinsic brainstem tumors. Additional eligibility criteria were Karnofsky (age > 10 years) or Lansky (age <=10 years) performance score of >=50; life expectancy of at least 8 weeks; no myelosuppressive chemotherapy within 3 weeks of study entry; at least 7 days from completion of any antineoplastic biologic agent; at least 2 weeks from local palliative radiation, 6 months from craniospinal or 50% radiation of pelvis, and 6 weeks from other substantial bone marrow radiation; no allogeneic stem-cell transplantation within 6 months of study entry and no acute graft-versus-host disease; no hematopoietic growth factors within 1 week of study entry; stable or decreasing dexamethasone dose for patients with CNS tumors; an absolute neutrophil count >= 1,000/uL, transfusion-independent platelet count  100,000/L, and hemoglobin >=8.0 g/dL; glomerular filtration rate or creatinine clearance >= 70 mL/min/ 1.73 m2 or normal serum creatinine for age; total bilirubin <= 1.5 and ALT <= 2.5 x upper limit of normal for age; serum albumin >= 2.0 g/dL; no dyspnea at rest, no exercise intolerance, and pulse oximetry more than 94%. Seizure disorder was allowed only if well controlled with anticonvulsants. ","Patients who were pregnant or breast-feeding were excluded, as were patients with uncontrolled infections, pleural effusions, or ascites. Receipt of other investigational or anticancer agents and previous exposure to pemetrexed was not allowed.",During the First Course,NA
19830387,NA,Combination,No,"patients with refractory solid tumors.  Eight patients had colorectal cancer, 3 breast, 2 each had lung, cholangiocarcinoma, and pancreas cancer, and one patient sarcoma.","Patients aged 18 or older with histologically confirmed solid tumors refractory to standard therapies, or for which no standard therapy exists, were eligible for enrollment on this phase I trial. Patients were also required to meet the following criteria: >3 month life expectancy; Eastern Cooperative Oncology Group (ECOG) performance status 0–2; measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST); at least 4 weeks from chemotherapy, investigational agent, or surgery; and adequate organ function (bilirubin ≤1.5 mg/dL; transaminases ≤3 times upper limit of normal (ULN), or ≤5 times ULN if known liver metastasis; creatinine clearance ≥60 ml/min by Cockcroft-Gault; platelet≥ 100,000/µL; absolute neutrophil count ≥ 1500/µL). Patients with creatinine clearance between 45 and 80 mg/min were instructed to hold NSAID therapy. Patients with brain metastases were permitted only if they had undergone CNS directed therapy at least 3 months earlier and had both clinically and radiographically stable disease for at least 8 weeks.","Because of potential interaction with vinflunine, P450 CYP3A4 inducing or inhibiting drugs had to be discontinued or patients had to be on stable doses for a minimum of 2 weeks prior to enrollment; strong inhibitors of P450 CPY3A4 (e.g. ketoconazole, ritonovir) were not permitted. To ensure safety with pemetrexed, patients with clinically significant pleural effusion or ascites not amenable to drainage were excluded. Other exclusion criteria included: prior allergic reaction to a vinca alkaloid; New York Heart Association class III or IV heart failure, unstable angina, or myocardial infarction within 6 months; poorly controlled hypertension; uncontrolled infection or severe illness; pregnancy, refusal to use contraception, or breastfeeding",during cycle one of treatment,NA
23179337,NCT00619424,Combination,No,"patients with advanced solid tumors. Primary tumor type, n (%): Non-small-cell lung 13 (52), Non-squamous 7 (28), Squamousa 6 (24), Small-cell lung 2 (8), Breast 2 (8), Unknown primary 3 (12), Esophagus 1 (4), Head and neck 1 (4), Bladder 1 (4), Renal cell 1 (4), Malignant thymoma 1 (4)","Eligible patients were at least 18 years of age with a histologically or cytologically confirmed diagnosis of advanced solid tumor that had failed standard therapy, for which no standard therapy existed, or for which pemetrexed was considered standard therapy. Additional eligibility criteria included Eastern Cooperative Oncology Group performance status 0 or 1; adequate hematologic, hepatic, and renal function; and measurable disease based on a computed tomography scan. Prior treatment with bevacizumab was allowed. Patients with squamous cell lung cancer were also eligible because enrollment into the study was initiated before pemetrexed use was restricted to patients with nonsquamous histology.","Exclusion criteria included central nervous system metastases (unless treated and stable without medication); hypertension (≥140/90 mmHg); evidence of active bleeding, including hemoptysis or bleeding diathesis; gastrointestinal abnormalities that might interfere with oral dosing; any surgery or trauma within the 4 weeks before study treatment initiation; and cardiovascular or cerebrovascular events in the 6 months before enrollment in the study. ",within the first 21 consecutive days of observation during combination therapy,NA
24919569,NCT00788957,Combination,No,patients with wild-type KRAS metastatic colorectal cancer,"Eligible patients were >=18 years of age, had an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1, and had histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum. Radiographic evidence of disease progression during or following prior treatment with irinotecan- and/or oxaliplatin-based chemotherapy for mCRC was required. At least 1 unidimensionally measurable lesion per modified RECIST 1.0 was required. Archival tumor tissue was confirmed by a central laboratory to be WT KRAS using a validated test method.","Patients were excluded if they received prior treatment with an anti-EGFR inhibitor (e.g., panitumumab, cetuximab, erlotinib, and/or gefitinib) unless treatment was received in the adjuvant setting >=6 months before enrollment. Prior treatment with MET or IGF1R inhibitors was not allowed. Additional exclusion criteria included the use of systemic chemotherapy or radiotherapy <= 21 days before enrollment and the use of any targeted therapies 30 days before enrollment (including bevacizumab)",within the first 4 weeks (28 days) on study,NA
23108697,NCT00528619,Combination,No,non-small cell lung cancer and mesothelioma,"Patients aged >=18 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 were recruited. In the dose-escalation cohorts, patients had a histological or cytopathological diagnosis of solid malignancy refractory to standard therapy, or for which no standard therapy existed, or for which the chemotherapy backbone would have been an acceptable choice as an earlier line of treatment. Patients also had to have adequate organ function and a life expectancy of >=12 weeks. In the expansion cohort, patients with recurrent or advanced NSCLC of any histological subtype and patients with advanced unresectable mesothelioma (pleural or peritoneal; stage 3 or 4) were eligible. ","Patients were excluded if they had: uncontrolled or symptomatic brain metastases; hemoptysis (>=5 mL per episode or >=10 mL/day) within 4 weeks prior to the start of the study; uncontrolled hypertension (>150/100 mmHg); or cardiac disease, cerebrovascular accident, or pulmonary embolism in the previous 12 months. Other key exclusion criteria included: National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 3 hemorrhage within 4 weeks of treatment; ongoing cardiac dysrhythmias of grade >=2 or prolongation of the QTc interval (>450 ms for males or >470 ms for females); chemotherapy, surgery, or radiation therapy <4 weeks before study start (except palliative radiotherapy to non-target lesions).",during the first 22 days of treatment,NA
33715996,NCT01642017,Single Drug,No,"unfit older patients with metastatic cancer among renal cell carcinoma, non small cell lung cancer, pancreatic neuroendocrine cancer, sarcoma , ovarian cancer , thyroid cancer, bladder cancer or breast cancers, who cannot receive any treatment with curative intent.","Patients ≥75 years, defined as unfit according to geriatric assessment, with metastatic disease (renal cell carcinoma, non-small cell lung cancer, pancreatic neuroendocrine cancer, sarcoma, ovarian can- cer, thyroid cancer, bladder cancer or breast cancer) who could not receive treatment with curative intent were eligible. Additional entry criteria included WHO performance status ≤2, life expectancy ≥3 months, adequate organ system function (further details in supplementary material). To be defined as unfit and eligible, patients had to present at least one abnormal geriatric test with none of the following items (dementia [according to DSM-IV], malnutrition [MNA ≤ 17], severe depression [suspected if GDS ≥ 6], fall [≥1 in the last three months], delirium [≥3 criteria of CAM], and at least two grade 3 or one grade 4 comorbidities [according to CIRS-G]",Other main exclusion criteria were contraindication for pazopanib and symptomatic central nervous system metastasis.,during the first month of treatment,NA
30958892,NCT01973868,Combination,No,"patients with advanced solid tumors. Cancer type: Colorectal cancer, Pancreatic adenocarcinoma1, Hepatocellular carcinoma, Non-small cell lung cancer, Breast cancer, Bladder cancer, Other (includes adenoid cystic carcinoma, high-grade neuroendocrine tumor, submandibular gland adenoid cystic carcinoma, cholangiocarcinoma, primary malignant neuroendocrinetumor of the pancreas, anal adenocarcinoma, metastatic basal cell carcinoma, prostate cancer, adenocarcinoma of the rectum, adenocarcinoma of thegastroesophageal junction and adenocarcinomaof the distal esophagus)","Patients≥18 years of age with a histologically or cytologicallyconfirmed locally advanced or metastatic solid tumors who wereunsuitable for, or no longer responding to standard therapy, orfor whom regorafenib or cetuximab was considered as a standardtreatment, were eligible for inclusion. Other key inclusion criteriaincluded an Eastern Cooperative Oncology Group performancestatus of 0 or 1, noKRASmutation in patients with mCRC, a lifeexpectancy of ≥3 months and adequate bone marrow (platelet ≥100,000/mm3, absolute neutrophil count ≥1,000/mm3), liver(aspartate aminotransferase ≤2.5×upper limit of normal) andrenal function (creatinine clearance ≥30 ml/min).","Patients wereexcluded if they had received prior treatment with regorafenib;previously discontinued cetuximab due to toxicity or intolerance;had known metastatic brain or meningeal tumors; a history oforgan allograft or cardiac disease; or were diagnosed with humanimmunodeficiency virus or active hepatitis B/C. Further exclusioncriteria included major surgery within 4 weeks of start of studytreatment; a nonhealing wound, ulcer, or bone fracture; uncon-trolled hypertension or significant acute gastrointestinal disorderswith diarrhea as a major symptom; arterial or venous thromboticor embolic events; and pregnancy or breastfeeding. In addition,other anticancer treatments were not permitted during the study.",in Cycle 1,NA
29438091,NCT00338494,Combination,No,Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma,"Eligible patients were over the age of 18 and had a histologically confirmed low-grade or intermediate-grade B-cell or T-cell lymphoma with measurable disease defined by the Cheson lymphoma criteria . All enrolled patients must have failed at least one standard chemotherapy regimen, excluding single-agent rituximab. Patients had to demonstrate an adequate Eastern Cooperative Oncology Group (ECOG) performance status of <2 and have a life expectancy of >12 weeks, normal cardiac function (ejection fraction >45%), and appropriate organ function (absolute neutrophil count >1000 x 109/L, white blood cell count >2.5 x 109/L, platelet count >75 x 109/L, hemoglobin >9.0 g/dL, total bilirubin <2.0 mg/dL, aspartate and alanine transaminase <3 3 upper limit of normal, and creatinine <2.0 mg/dL).","Exclusion criteria included a previously untreated B-cell or T-cell lymphoma, previous treatment with clofarabine, chronic use of oral high-dose corticosteroids greater than 20 mg/day prednisone for any medical condition, and prior radiotherapy to the only site of measurable disease. Additional standard exclusion criteria were implemented, including known AIDS-related or human immunodeficiency virus-positive lymphoma, active or untreated central nervous system lymphoma, autologous bone marrow or stem cell transplant (within the previous 6 months), and autoimmune thrombocytopenia. Patients were also ineligible if they used an investigational agent within 30 days or any anticancer therapy 3 weeks before study entry, had an active systemic infection, an active secondary malignancy, or were pregnant or lactating.",N/A,NA
22893631,NCT00347971,Combination,No,patients with indolent B-cell malignancies,"Eligible patients had indolent CD20þ B-cell lymphomas, either SLL/CLL, FL, or marginal zone lymphoma (MZL), measurable by CT scans, relapsed after previous therapy (including rituximab for patients with FL); age >=18 years; ECOG performance status 0 or 1; life expectancy 6 months; hemoglobin >10 g/dL; neutrophil count >1,500 cells/mm3; platelet count >75,000/mm3; and adequate hepatic and renal function. ","Patients with a history of central nervous system involvement, peripheral white blood cell count >50,000/mm3, systemic corticosteroids within 1 month of enrollment, or previous autologous or allogeneic hematopoietic stem cell transplant were excluded.",during the first treatment cycle,NA
11332149,NA,Combination,No,patients with locally advanced or metastatic squamous cell carcinoma of the head and neck,"Patients with histologically confirmed advanced or metastatic squamous cell carcinoma of the head and neck region (SCCHN) were included in the study. They all underwent a complete history, physical examination, chest X-ray, CT-scan and laboratory evaluation. Inclusion criteria were as follows: 1) no prior chemotherapy except in an adjuvant setting, more than nine months earlier; 2) World Health Organization (WHO) performance status of 0 to 2; 3) life expectancy more than three months; 4) adequate haematopoietic reserve (white blood cells > 4.0 x |09/l and platelets > 100 x 1O9/1); 5) creatinine clearance > 65 ml/min; 6) bilirubin and transaminases < 2.0 x upper limit of normal range; 7) age of at least 18 years; 8) patients should be mentally, physically, and geographically able to undergo treatment and follow-up.",Exclusion criteria: 1) systemic treatment for cancer except adjuvant as mentioned in inclusion criteria; 2) other invasive malignancy within the last five years; 3) serious active or uncontrolled infection; 4) antibiotics interfering with cisplatin excretion; 5) pregnancy or breast feeding; 6) patients with bone metastases only; 7) prior radiotherapy ended within four weeks prior to entering this study; 8) unresolved toxicity from prior anticancer therapy; 9) patients taking vitamin supplements containing folic acid.,during these two complete cycles,NA
19894051,NA,Combination,No,"patients with refractory solid tumors (Melanoma 2, Nasopharyngeal cancer 1, Thymoma 1, Metastatic adenocarcinoma 5, Colorectal adenocarcinoma 1, Squamous cell cancer of the head and neck 1) and lymphomas 4(Anaplastic large cell lymphoma 1, Peripheral T cell lymphoma 1, Small lymphocytic lymphoma 1, Hodgkin’s lymphoma 1)","Patients (age >= 18 years) were eligible for this study if they had pathologically confirmed metastatic or unresectable malignancy for which there were no acceptable standard therapies; an Eastern Cooperative Oncology Group performance status <=2; adequate organ and bone marrow function defined as absolute neutrophil count >=1,000/uL, platelets >=100,000/uL, total bilirubin <=1.5 x the upper limit of normal (ULN), aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) <=2.5 x ULN, and creatinine <=1.5 x ULN; and 12-h fasting glucose <=110 mg/dL or between 110 and 140 mg/dL with hemoglobin A1C <=6.5 mg/dL. Prior anticancer therapy must have been completed at least 4 weeks (6 weeks for nitrosoureas and mitomycin C) before starting the study drug; toxicities were required to have recovered to eligibility levels.","Patients were excluded if they had an uncontrolled intercurrent illness; were pregnant or lactating; had brain metastases within the past 6 months; or had a history of diabetes, hyperglycemia, or interstitial lung disease within the last year. Other exclusion criteria included a history of duodenal or gastric ulcer or severe gastritis within the past 6 months (due to the risk of exacerbation by prednisone), symptomatic congestive heart failure, or unstable angina pectoris.",during cycle 1,NA
28735378,NCT01610570,Single Drug,No,children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript,"Patients ≥12  months ≤17  years of age with evaluable refractory or recurrent extracranial solid tumors (phase 1) or ≥18 years of age with refractory, histologically confrmed Ewing sarcoma with documented EWS–FLI1 translocation and measurable disease (phase 2) were eligible. After determination of the recommended phase II dose for children, the phase II Ewing sarcoma cohort was to be expanded to include children ≥12 months ≤17. Other eligibility criteria included recovery from acute toxic efects of prior therapy, Karnofsky/Lansky performance score ≥50% or ECOG 1 or 2 (adults); interval from prior therapy ≥21 days for myelosuppressive chemotherapy or monoclonal antibody treatment; ≥7 days for hematopoietic growth factors; ≥2 weeks for local palliative radiation; ≥3 months from total body, craniospinal, or ≥50% radiation to the pelvis; ≥6  weeks from other substantial bone marrow radiation; ≥3 months from a stem cell transplant or rescue; and no evidence of active graft versus host disease; adequate renal function [age-adjusted normal serum creatinine, or GFR ≥70  mL/min/1.73m2]; and adequate liver function (total bilirubin ≤1.5  ×  institutional upper limit of normal (ULN), albumin ≥2  g/dL, and alanine aminotransferase (ALT) ≤110  U/L). Adequate bone marrow function was required and defned as an absolute neutrophil count (ANC) ≥1000/μL and hemoglobin ≥8.0 g/dL and transfusion independent platelet count of ≥75,000/μL.","Clinically significant systemic illness (e.g. serious active infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the judgment of the PI would compromise the patient s ability to tolerate protocol therapy or significantly increase the risk of complications. Patients with a history intracranial Ewing sarcoma including cerebral metastases. Patients with evidence of active bleeding, intratumoral hemorrhage or history of bleeding diatheses. Patients who are receiving anticoagulants other than prophylactic anticoagulation of venous or arterial access devices, provided that requirements for PT, PTT and fibrinogen are met, as described. Investigational Drugs: Patients who are currently receiving another investigational drug. Patients who are concurrently receiving agents, which may increase the risk for mithramycin related toxicities, such as hemorrhage including: Thrombolytic agents, Anti-inflammatory drugs, nonsteroidal (nonsteroidal anti-inflammatory drugs (NSAIDs)) or aspirin or salicylate containing products, which may increase risk of hemorrhage, Dextran, Dipyridamole, Sulfinpyrazone, Valproic acid, Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents. Lactating or pregnant females (due to risk to fetus or newborn, and lack of testing for excretion in breast milk). Patients with history of human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) due to potentially increased risk of mithramycin toxicity in this population.. Hypersensitivity to plicamycin (mithramycin). Requirement for any of the contraindicated medications: nonsteroidal anti-inflammatory drugs, aspirin, dextran or other iron containing solutions (due to incompatibility), dipyridamole, sulfinpyrazone or valproic acid. Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study. Patients receiving concurrently other therapies directed at their cancer.",during cycle 1,NA
23799873,NCT01653067,Combination,No,patients with relapsed or refractory diffuse large cell B-Cell lymphoma,"To be included into the STORM trial, patients must be at least 18 years old and have a histologically confirmed diagnosis of DLBCL according to the World Health Organization classification. There must be a documented relapse or progression after at least one prior treatment but a maximum of two prior treatments. Prior treatment must have included at least three cycles of anthracyclinecontaining chemotherapy (e.g. CHOP-like). The histology has to be confirmed by a reference pathologist. Evaluation of CD20 status is compulsory. At least one measurable tumor mass (>1.5 cm x >1.0 cm), involvement of any organ or bone marrow infiltration must be present. In addition, adequate organ function and a Eastern Cooperative Oncology Group [ECOG] performance Status of less than 3 are essential for inclusion into the trial. Patients are required to use adequate contraception before entry and throughout the study, if appropriate. Naturally, patients must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.","Patients with lymphoma other than DLBCL or active central nervous system lymphoma are not eligible. Other exclusion criteria are severe concomitant diseases, active uncontrolled infections including HIV, active hepatitis B or C or other malignant disease (except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, DCIS of the breast, or other solid tumors curatively treated with no evidence of disease for >5 years). Prior treatment with temsirolimus, known CD20 negativity, disease refractory to DHAP in a prior treatment line, severe psychiatric illness, peripheral neuropathy or neuropathic pain grade 2 or worse, prior autologous or allogeneic stem cell or bone marrow transplantation, concurrent treatment with another investigational agent during the conduct of the trial or known intolerance to sirolimus or derivates, cytarabine, cisplatine or rituximab will prohibit inclusion, as well as pregnancy or breast feeding",NA,NA
31420468,NCT02649686,Combination,No,HER2-Positive Metastatic Breast Cancer ,"Eligibility criteria for trial enrollment required patients to have HER2-positive (immunohistochemistry [IHC] 3+ and/or fluorescence in situ hybridization amplified as assessed locally and by their laboratory standards) advanced breast cancer for which no curative therapy exists. Patients must have had prior exposure to a taxane, trastuzumab, and pertuzumab (although exceptions to the requirement for prior pertuzumab could be waived) and preferably also prior exposure to T-DM1. Other prior treatment inclusion criteria included not being eligible for further trastuzumab treatment as per provincial or formulary guidelines and at least two lines of anti-HER2 regimens in the setting of metastatic breast cancer (MBC). All patients were required to be at least 18 years of age and to have measurable disease, Eastern Cooperative Oncology Group performance status of 0 to 2, and standard baseline organ function measurements. There was no limit to the number of prior cytotoxic or other systemic therapy regimens, but patients could not have had previous treatment with PD-1 or PD-L1 inhibitors or other immune-based therapy. Patients enrolled to the RP2D/expansion cohort must have had accessible disease suitable for biopsy and consent to a biopsy prior to treatment and at the end of cycle 1. Paired biopsies were also strongly recommended in the dose-finding stage of the study. All patients consented to release of archival tissue (if patients did not have archival tissue, then a biopsy prior to treatment was acceptable).","Patients could not have had active or prior documented autoimmune or inflammatory disorders. Live attenuated vaccination was not allowed within 30 days prior to registration or within 30 days of receiving durvalumab. Patients with active infections or untreated, uncontrolled, or symptomatic cardiovascular conditions were not eligible. ",during the first cycle of therapy,NA
28402581,NCT01369849,Combination,No,relapsed or refractory chronic lymphocytic leukemia,"Age ≥18 years. Diagnosis of: CLL according to the NCI criteria (Cheson, Bennett et al. 1996) (Hallek 2008)  or SLL according to the WHO criteria (Harris, 1999). This includes previous documentation of: Biopsy-proven small lymphocytic lymphoma (Harris, 1999) or Diagnosis of CLL according to NCI working group criteria (Cheson, 1996 and Hallek 2008) as evidenced by all of the following: Peripheral blood B cell count of >5 x 109/L consisting of small to moderate size lymphocytes; Immunophenotyping consistent with CLL defined as: The predominant population of lymphocytes share both B-cell antigens [CD19, CD20 (typically dim expression), or CD23] as well as CD5 in the absence of other pan-T-cell markers (CD3, CD2, etc.); Clonality as evidenced by k or lamda light chain expression (typically dim immunoglobulin expression) or other genetic method (e.g. IGHV analysis). NOTE: Splenomegaly, hepatomegaly, or lymphadenopathy are not required for the diagnosis of CLL. Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded by demonstrating a negative FISH analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy or negative immunohistochemical stains for cyclin D1 on involved tissue biopsy. Demonstrated progression after one or two prior lines of CLL therapy. Note:  Rituximab monotherapy does not count as a prior line of therapy. Progressive disease with any one of the following characteristics based on standard criteria for treatment as defined by the NCI-WG 1996 (Cheson, 1996 and Hallek, 2008). 1.	Symptomatic CLL characterized by any one of the following: a.	Weight loss ≥10% within the previous 6 months; b.	Extreme fatigue attributed to CLL; c.	Fevers >100.5° F for 2 weeks without evidence of infection; d.	Drenching night sweats without evidence of infection. 2.	Evidence of progressive bone marrow failure with hemoglobin <11 g/dL or platelet count <100 x 109/L. 3.	Massive or rapidly progressive splenomegaly (>6 cm below left costal margin). 4.  Massive (>10 cm) or rapidly progressive lymphadenopathy. Life expectancy >=12 months. ECOG Performance Status (PS) 0, 1, or 2.  This form is available on the NCCTG website https://ncctg.mayo.edu/ncctg/forms/Non Protocol SpecificForms. The following laboratory values obtained <=14 days prior to registration. Total bilirubin ≤1.5 x Institutional Upper Limit of Normal (ULN) unless due to Gilbert’s disease. If total bilirubin is >1.5 x ULN, a direct bilirubin should be performed and must be <1.5 mg/dL for Gilbert’s to be diagnosed; SGOT (AST) <=2.5 x ULN; SGPT (ALT) <=2.5 x ULN; Creatinine <=1.5 x ULN OR creatinine clearance >=60 mL/min/1.73 m2 for patients with creatinine levels >1.5 x ULN.; Adequate bone marrow function as defined by: A non-transfused platelet count ≥30 X109/L; Neutrophil count (ANC) ≥1 X109/L\; Hemoglobin (Hgb) ≥8g/dL. Note:  Cytopenias due to bone marrow failure are common in patients with relapsed CLL requiring treatment.  Accordingly, normal bone marrow function is NOT required for participation. Negative pregnancy test done ≤7 days prior to registration, for women of childbearing potential only. Ability to complete patient diaries and questionnaire(s) by themselves or with assistance. Provide informed written consent. Willing to return to NCCTG enrolling institution for follow-up. Willing to provide blood samples for correlative research purposes (see Sections 6.31 and 14.11). Willing to provide bone marrow aspirate (body fluid) for correlative research purposes. Mayo Rochester ONLY: Willing to provide bone marrow core biopsy tissue for correlative research purposes (see Sections 17.11 and 17.4). All patients: Willing to provide bone marrow biopsy for central pathology review (all patients) (see Section 17.11). Able to swallow whole tablets. NOTE: Nasogastric or G tube administration is not allowed.  Tablets must not be crushed or chewed.","Prior treatment with bendamustine. Prior treatment with any experimental Akt inhibitors. More than 2 previous purine nucleoside based-therapy (i.e. fludarabine, pentostatin, or cladribine). More than 2 previous alkylating agent based-therapy (i.e. cyclophosphamide, chlorambucil). More than 3 total prior lines of therapy for CLL. Primary refractory disease as defined by progression while receiving or within 6 months of completion of a chemoimmunotherapy regimen such as fludarabine, cyclophosphamide and rituximab (FCR) or pentostatin, cyclophosphamide and rituximab (PCR). Phase II ONLY:  FISH abnormality of 17P deletions. (Note: Patients with 17P deletions will be included in Phase I but will be excluded in Phase II unless enough activity is found in the Phase I). Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown •	Pregnant women • Nursing women • Men or women of childbearing potential who are unwilling to employ adequate contraception. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.  Including but not limited to the following: •	New York Heart Association Class III or IV heart disease (Located on the NCCTG website at https://ncctg.mayo.edu/ncctg/forms/NonProtocolSpecificForms/ ) •	Recent myocardial infarction (<1 month) •	Uncontrolled infection •	Known infection with the human immunodeficiency virus (HIV/AIDS) and/or patients taking HAART as further severe immunosuppression with this regimen may occur. •	Infection with known chronic, active Hepatitis C •	Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded. •	Uncontrolled diabetes defined as HbA1c 8 or fasting blood glucose >=140 mg/dL. Any of the following: •	History of significant ventricular arrhythmia in the last 5 years including: ventricular tachycardia or ventricular fibrillation. •	QTc prolongation on baseline ECG (defined as a QTc interval >450 msec for males and QTc interval > 470 msec for females). •	Currently using a medication known to cause prolonged QTc (See Appendix III) which cannot be discontinued. Note: Other medications with possible risk of prolonged QTc are allowed but should be used with caution.  Patients using these medications should be monitored accordingly.  See Appendix IV. •	Ventricular arrhythmia on baseline ECG (ventricular tachycardia or ventricular fibrillation>=3 beats in a row).  •	Second or third degree heart block. NOTE: Because QTc prolongation has been reported in patients taking MK-2206, individuals with the above characteristics may not be enrolled in this study. Receiving any other investigational agent concurrently  which would be considered as a treatment for the primary neoplasm. Other active primary malignancy requiring treatment or which limits survival to <24 months. Any major surgery <=28 days prior to registration. Any radiation therapy <=4 weeks prior to registration. Current use of corticosteroids. EXCEPTION:  Low doses of steroids (<10 mg of prednisone or equivalent dose of other steroid) used for treatment of non-hematologic medical conditions. NOTE: Previous use of corticosteroids is allowed. Active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment. NOTE: Patients who have a positive Coombs test but no evidence of hemolysis are NOT excluded from participation. Receiving any medications or substances that are strong or moderate inhibitors of CYP450 3A4. Use of the following strong or moderate inhibitors are prohibited ≤7 days prior to registration. Strong Inhibitors of CYP3A4: Indinavir, Nelfinavir, Ritonavir, Clarithromycin, Itraconazole, Ketoconazole, Nefazodone, Saquinavir, Telithromycin. Moderate Inhibitors of CYP3A4; Aprepitant, Erythromycin, Fluconazole, Grapefruit juice, Verapamil, Diltiazem. Receiving any medications or substances that are inducers of CYP450 3A4. Use of the following inducers is prohibited ≤12 days prior to registration. Inducers of CYP3A4: Efavirenz, Nevirapine, Carbamazepine, Modafinil, Phenobarbital, Phenytoin, Pioglitazone, Rifabutin, Rifampin, St. John’s wort",during cycle 1,NA
21425150,NCT00156013,Single Drug,No,"relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients","Eligible patients were aged >=18 years and had histologi-cally confirmed NHL of B-cell or T-cell lineage withmeasurable disease on a computed tomography scan and/or evaluable on a positron emission tomography scan. Allenrolled patients must have failed on a previous standardchemotherapy regimen with or without monoclonalantibody-based therapy. Patients had to demonstrateadequate Eastern Cooperative Oncology Group, perform-ance status (<=2), were required to have a life expectancy >=12 weeks, and had to have appropriate organ function(creatinine <=2 mg/dL; aspartate and alanine aminotrans-ferase levels <=3 times the upper limit of normal, total bilirubin <=2 mg/dL, neutrophils >=1500/mm3, and platelets >=100,000/mm3). Cytopenia, if present, had to be relatedto bone marrow involvement with disease.","Standard  exclusion  criteria  were  implemented,including active or untreated central nervous system lym-phoma, human immunodeficiency virus-positive–relatedlymphoma, autologous HSCT (within the previous 3months), a history of allogeneic bone marrow or organtransplantation, and autoimmune thrombocytopenia.Those with bulky disease (any lymph node>10 cm) orwith circulating malignant lymphocytes>24,000 cells/lL were excluded. Ineligibility also included chronictreatment with high-dose corticosteroids (>1 mg/kgdaily) and any anticancer therapy in the 3 weeksbefore study entry. Short-term, low-dose corticosteroid administration and analgesic, antiemetic, antidiarrheal,and anti-infective therapies were permitted.",during the first cycle,NA
32144134,NCT01307267,Combination,No,Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas,"Patients ≥18 or ≥20 years of age (if required by local, regulatory authorities) were eligible if they had histologically confirmed, relapsed/refractory CD20þ NHL or small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) with nodal disease and ≤10,000 lymphocytes/mL, with no available, effective therapy. Patients were enrolled into the expansion cohort if they had FL refractory to previous rituximab therapy or relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients were required to have measurable disease with at least one extranodal tumor mass >1 cm in the greatest transverse diameter (GTD) or malignant lymph nodes >1.5 cm in the GTD, and the product of the diameters >2.25 cm2; Eastern Cooperative OncologyGroup (ECOG) performance status ≤1; absolute neutrophil count ≥1.0 x 109/L; platelet count ≥75 x 109/L; hemoglobin ≥8.0 g/dL; and adequate renal, hepatic, and cardiac functions.","Exclusion criteria included prior allogeneic hematopoietic stem cell transplant, any anticancer therapy or hematopoietic growth factors within 28 days or systemic corticosteroid therapy or radiation therapy within 14 days prior to the first dose of study treatment, prior treatment with a 4-1BB/CD137 agonist, an autoimmune disorder or an active clinically significant infection, a severe allergic or anaphylactic reaction to antibodies or infused therapeutic proteins, and known utomilumab and/or rituximab antidrug antibodies (ADA). Furthermore, patients were not included if they had symptomatic brain metastases requiring steroid therapy. Patients were eligible if they had completed treatment for their brain metastases and recovered from the acute effects of radiation therapy or surgery, had discontinued corticosteroids for ≥4 weeks, and were neurologically stable.",within the first two treatment cycles ,NA
11508814,NA,Combination,No,"patients with recurrent malignant gliomas, including glioblastoma multiforme, anaplastic astrocytoma, and anaplastic oligodendroglioma","Patients eligible for the study had (1) histologically documented malignant glioma, including glioblastoma multiforme, anaplastic astrocytoma, and anaplastic oligodendroglioma, (2) inoperable relapse or tumor progression confirmed by cerebral computerized tomography (CT) of previously irradiated supratentorial malignant glioma, and (3) at least one bidimensionally measurable cerebral lesion. Patients were between 18 and 65 years of age with a Karnofsky performance status ≥60%, a life expectancy greater than 3 months, adequate hematological function (white blood cells ≥4 000/mm3 and polynuclear neutrophils ≥2 000/mm3, haemoglobin ≥10 g/dl, and platelets ≥150 000/mm3) and adequate hepatic and renal functions (creatinine ≤130 µmol/l and/or creatinine clearance ≥60 ml/min, transaminases, alkaline phosphatase and bilirubin ≤2× upper limit of normal). Patients were to be available for follow-up, and were not to have received any chemotherapy or radiotherapy for at least 4 weeks prior to study entry (6 weeks for nitrosourea pretreatment). All patients provided written informed consent.",NA,during the induction cycle,NA
23568716,NA,Combination,No,patients with cetuximab-resistant KRAS wild type metastatic CRC,"Eligible subjects were at least 18 years of age with histologically-confirmed adenocarcinoma of the colon or rectum who had failed at least one prior line of therapy for metastatic disease. All subjects must have previously received 5-fluorouracil (5-FU) or capecitabine, irinotecan or oxaliplatin, and cetuximab, and must have demonstrated radiographic progression of disease on a cetuximab-containing regimen. Eastern Cooperative Oncology Group (ECOG) performance status had to be 0–1, with adequate bone marrow and organ function and measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.0 (RECIST)","Exclusion criteria included subjects whose tumors harbored KRAS mutations; subjects who were pregnant or breastfeeding; brain metastases; or presence of serious medical conditions that would impose excessive risk to the patient. Because pertuzumab led to mild decreases in left ventricular ejection fraction (LVEF) in early-phase trials , subjects with LVEF <50 %, wall motion abnormalities, or a history of congestive heart failure were also excluded. ",during the first cycle,NA
34157616,NCT02085148,Single Drug,No,"paediatric patients with recurrent or refractory solid malignancies. Histology at diagnosis: extracranial tumours, Ewing sarcoma family of tumours, Carcinoma (colon adenocarcinoma, adrenal, NOS, epithelialemyoepithelial), Osteosarcoma, Rhabdomyosarcoma, Nephroblastoma, Other sarcomas (undifferentiated, desmoplastic small round cell), Neuroblastoma, Epithelioid hemangioendothelioma","Eligible paediatric patients (aged 6 months to <18 years) had malignant solid or central nervous system (CNS) tumours recurrent or refractory to standard therapy, with no known effective treatment. Additional inclusion criteria included life expectancy >=12 weeks; >=1 measurable or evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Karnofsky (>12 years of age) or Lansky (<=12 years of age) performance status >=70%; and adequate organ function.",Key exclusion criteria included prior exposure to regorafenib and known hypersensitivity to the study agent or formulation excipients. Other anticancer treatments or radiotherapy were not permitted 4 weeks before the start of the study.,in cycle 1,NA
32697348,NCT00943943,Combination,No,"relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients",Eligibility: Patients with relapsed or refractory AML with FLT3-ITD mutation were eligible. Eligibility included 1) Eastern Cooperative Oncology Group performance status ≤ 3; 2) age ≥ 18 years; 3) adequate organ function (total bilirubin ≤1.5 mg/dl; ALT ≤2.5 times the institutional upper limit of normal; creatinine ≤1.5 mg/dl 4) no chemotherapy except hydroxyurea within 2 weeks of study drug treatment (hydroxyurea had to be discontinued at least 24 hours prior to start of study drug); 5) absence of  proliferative disease (absolute blast count >20 x 109/L); 6) cardiac ejection fraction ≥50%; 7) not receiving standard or investigational treatment. ,"Patients with uncontrolled hypertension or congestive heart failure), ventricular arrhythmias, human immunodeficiency virus (HIV) infection or active hepatitis B or C were excluded. Additional exclusions were transient ischemic attacks, significant bleeding event within 4 weeks.",during the first 4 weeks of treatment ,NA
30262659,NCT01722305,Combination,No,relapsed/refractory primary CNS or vitreoretinal lymphoma,"We enrolled relapsed/refractory PCNSL or PVRL patients with at least 1 prior line of systemic therapy, 18 years of age or older, with pathologic features consistent with DLBCL. Eligible patients had a CNS lesion, positive CSF (cerebrospinal fluid) cytology, or positive ocular tissue biopsy. All patients had biopsy-proven PCNSL or PVRL. Other inclusion criteria included an Eastern Cooperative Oncology Group (ECOG) performance status <=3, absolute neutrophil count >= 1 x 109/L, platelets >= 100 x 109/L, total bilirubin <=1.5x upper limit of normal (ULN) or if total bilirubin is >1.5 x ULN, the direct bilirubin must be <=1.5 x ULN (<= 0.45 mg/dL), AST (aspartate aminotransferase) <=3 x ULN, and creatinine <=2.5 x ULN. For thromboprophylaxis, all patients took an aspirin (81 or 325 mg orally daily) or an anticoagulant. Patients were required to follow standard guidelines with respect to fertility for the IMiD class of drugs. Females of childbearing potential (FCBP) were required to have a negative serum or urine pregnancy test within 10 to 14 days prior to and again within 24 hours of starting POM. They had to either commit to continued abstinence from heterosexual intercourse or begin 2 acceptable methods of birth control, 1 highly effective method and 1 additional effective method. Men were required to agree to use a latex condom during sexual contact with a FCBP even if they had had a vasectomy. All patients were counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. ","Pregnant or nursing women, and men or women of childbearing potential who were unwilling to use adequate contraception, were excluded. Other exclusion criteria included uncontrolled infection, previous development of erythema nodosum while on thalidomide or similar drugs, therapy with myelosuppressive chemotherapy or biologic therapy within 21 days prior to registration, history of thromboembolic episodes within 3 months prior to registration, immunodeficiency states including HIV infection, inability to swallow or absorb treatment medications, major surgery within 4 weeks of registration, uncontrolled active hepatitis B or C, or New York Heart Association classification of III or IV.",the first cycle of treatment,NA
33025730,NCT03257631,Single Drug,No,"children with recurrent, refractory, and progressive central nervous system tumors","Patients between 3 and 21 years of age with a recurrent, progressive, or refractory CNS tumor were eligible. Refractory disease was specifically defined as the presence of persistent abnormality on conventional MRI imaging that is further distinguished by histology (tissue sample) or advanced imaging, or as determined by the treating physician and discussed with the principal investigator prior to enrollment. Patients were required to have a performance score (Lanskyor Karnofsy) greater than or equal to 60. Patients were required to be able to swallow capsules, and due to capsule size and dosing requirements, have a body surface area (BSA) ≥0.55 m2. Laboratory parameters required for eligibility at enrollment required the following: absolute neutrophil count ≥1000/mm3, platelet ≥100000/mm3 (unsupported), hemoglobin ≥8 g/dL, total bilirubin ≤1.5 times theinstitutional upper limit of normal (ULN), ALT ≤3 times the institutional ULN, albumin ≥3g/dL, serum creatinine with anormal range based on age and gender, and oxygen saturation of ≥ 93% on room air.","Patients with significant concurrent illness, including pulmonary, renal, hepatic, or cardiac disease were excluded. Patients who were pregnant or breast feeding and those patients with a history of thromboembolic events were excluded. Concomitant steroid use was allowable during the dose escalation phase.",the first course of therapy,NA
34581757,NCT03255096,Combination,No,patients with diffuse large B-cell lymphoma,"Patients eligible for study inclusion had DLBCL and/or HGBL-DH/TH, R/R to first-line or subsequent therapies, who had received at least 1 prior chemotherapy regimen that included an anti-CD20 targeting agent, with no curative option.  Patients were relapsed or refractory to >=1 course of chemotherapy, including an anti-CD20 monoclonal antibody, and were not eligible for ASCT (including those with chemorefractory disease). Patients with transformed follicular lymphoma (FL) were eligible, provided DLBCL or HGBL-DH/TH histology was biopsy confirmed before study entry and a treatment regimen as described had been administered. All patients were >=18 years of age, had an Eastern Cooperative Oncology Group (ECOG) performance status <=1, and had acceptable organ function. Life expectancy was at least 3 months.","Current central nervous system (CNS) lymphoma or leptomeningeal infiltration. New York Heart Association (NYHA) Class III or IV cardiac disease, myocardial infarction, within the past 6 months, unstable arrhythmia, or known pericardial disease. Fredericia-corrected QT interval (QTcF) >470 msec (female) or >450 msec (male), or history of congenital long QT syndrome. Any electrocardiogram (ECG) abnormality, which in the opinion of the Investigator would preclude safe participation in the study. Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study entry requiring systemic therapy. Clinically important respiratory impairment. Grade ≥ 3 sensory or motor neuropathy. Any Grade >1 (according to the NCI CTCAE 4.03) adverse reaction unresolved from previous treatments and not readily managed and controlled with supportive care. Serious non-malignant disease that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor. History of progressive multifocal leukoencephalopathy (PML). History of other malignancy within 2 years prior to screening, except for ductal carcinoma in situ not requiring chemotherapy, appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, low-grade, localized prostate cancer (Gleason score ≤ 7) not requiring treatment or appropriately treated Stage I uterine cancer. Completion of ASCT within 100 days prior to Day 1 of Cycle1. Prior standard or investigational anti-cancer therapy, as specified below: Radio-immunoconjugate 4 weeks or 5 half-lives, whichever is longer prior to Day 1 of Cycle 1; Monoclonal antibody or antibody-drug conjugate (ADC) therapy within 3 weeks prior to Day 1 of Cycle 1; Radiotherapy, chemotherapy, or targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1; CAR T-cell therapy 30 days prior to Day 1 of Cycle 1. History of major solid organ transplant (i.e., heart, lungs, liver and kidney). History of an allogeneic bone marrow transplant. Major surgical procedure within 28 days prior to Day 1 of Cycle 1. Treatment with systemic corticosteroids ≥ 20 mg/day prednisone or equivalent, for non-lymphoma treatment reasons. For lower acceptable doses, documentation of a stable dose for at least 4 weeks prior to Day 1 of Cycle 1 is required. Treatment with strong to moderate CYP3A inhibitors or moderate CYP3A inducers within 7 days prior to the first dose of study treatment. Treatment with strong CYP3A inducers within 14 days prior to the first dose of study treatment of RO6870810/venetoclax. Consumption of grapefruits, grapefruit products, Seville oranges (including marmalade that contains Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax. Participants who are currently receiving any other investigational agent ((other than anti-cancer therapy as specified in exclusion criteria number 13) or have received an investigational agent within 30 days or 5 half-lives prior to Day 1 of Cycle 1, whichever is longer. Prior treatment with small molecule bromodomain and extra terminal (BET) family inhibitor. Known to be human immunodeficiency virus (HIV) positive. Presence of positive test results for hepatitis B surface antigen (HBsAg) or hepatitis C antibodies (HcAb) (for participants receiving regimen including rituximab) Pregnant or breastfeeding female. Significant allergy to a biological pharmaceutical therapy that, in the opinion of the Investigator, poses an increased risk to the participant. Uncontrolled cancer pain. Participants requiring pain medication must be on a stable regimen at study entry. Symptomatic lesions amenable to palliative radiotherapy should be treated prior to enrollment. History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies (for participants receiving regimen including rituximab). Known sensitivity or allergy to murine products or any component of RO6870810, venetoclax, or rituximab.",during cycle 1,NA
19261664,NA,Single Drug,No,"Japanese patients with solid tumors. Tumor type: NSCLC 7, Rectum 3, Stomach 2, Ovary 2, Breast 1, Esophagus 1, Germ cell 1, Primary unknown 1","Patients were eligible if they had histologically or cytologically confirmed malignant solid tumors that were resistant to standard therapies, or for which there was no effective treatment. HER2 status was not used in the selection process, except for those patients with breast cancer. Eligibility criteria were: age 20 – 74 years; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1; life expectancy >12 weeks; no previous chemotherapy, radiation therapy or surgery within 4 weeks before treatment with pertuzumab (6 weeks for previous treatment with nitrosoureas or mitomycin); adequate bone marrow (absolute neutrophil count >=1500/mm3, platelet count >=75 000/mm3 and hemoglobin level >=9.0 g/dl), hepatic [serum total bilirubin <=1.5 mg/dl, aspartate amino transferase (AST) <=80 IU/l, alanine amine transferase (ALT) <=80 IU/l and alkaline phosphatase (ALP) <=1400 IU/l], renal (serum creatinine <=1.3 mg/dl), coagulation [ prothrombin time international normalized ratio (PT-INR) <1.3, activated partial thromboplastin time (APTT) <60 s], pulmonary [arterial oxygen pressure (PaO2) >=70 torr], and cardiac [left ventricular ejection fraction (LVEF) >= 50% by echocardiography] functions.","Exclusion criteria included: pregnancy or lactation; symptomatic brain metastasis; HER2-positive breast cancer by fluorescence in situ hybridization; previous treatment with antibody agents for HER receptors; a history of hypersensitivity reactions to any drug; pleural effusion and ascites that required drainage; cumulative doxorubicin dose of >= 360 mg/m2 given prior to study; hepatitis B or C or HIV; and serious pre-existing medical conditions such as uncontrolled infections, hypertension, hypercalcemia, diabetes, severe heart disease or psychogenic disorders.",NA,NA
11955653,NA,Combination,No,"patients with previously untreated, metastatic non-small cell lung cancer (NSCLC)","Patients with histologically proven metastatic NSCLC were eligible for the study providing they were >= 18 years of age, had a life expectancy of .=12 weeks and a WHO performance status <=2. In addition, each patient had to have >= 1 evaluable and/or measurable lesion. Measurable lesions were those that could be measured in two perpendicular axes with at least one dimension >=2.5 cm or both dimensions >=1.0 cm. An evaluable but non-measurable lesion was defined as a lesion that could be measured in two perpendicular axes but with one dimension < 1.0 cm or both dimensions < 2.5 cm; lesions that could be measured in one axis only; and visible but non-measurable lesions that could be photographed, or radiologically assessable lesions.","Principal exclusion criteria were: previous or con- comitant systemic chemotherapy or radiotherapy; previous or current malignancies at other sites; clinical evidence of intracerebral metastases; concomitant use of folic acid or complex-forming drugs, such as penicillamine or dimethylaminophenol; abnormal blood cell counts (white blood cell count < 4× 109/l, platelet count < 100× 109/l) or biochemistry (bilirubin 1.5 times the upper limit of normal range [ULN]; aspartate aminotransferase or alanine aminotransferase >1.5× ULN, unless due to hepatic metastases; abnormal crea- tinine or creatinine clearance < 65 ml/min (calculated using the Cockcroft formula)); and other serious medical conditions.",2 cycles of treatments,NA
22753910,NCT00539682,Single Drug,No,patients with relapsed/refractory B-cell lymphoma,"Adult patients with refractory or relapsed B-cell non-Hodgkin’s lymphoma (NHL) expressing the CD19 antigen were enrolled onto this study. Other main criteria for eligibility included: Eastern Cooperative Oncology Group performance score <= 2, absolute neutrophil count >= 1,500/uL, and platelets >=100, 000/uL; adequate renal and liver function; measurable disease; no chemotherapy or radiotherapy within 4 weeks before enrollment and no radioimmunotherapy within 12 weeks before enrollment. There was no limit on the number of prior regimens, and patients with prior autologous and allogeneic stem-cell transplantation were eligible. ","However, patients with Burkitt’s lymphoma, lymphoblastic lymphoma, chronic lymphocytic leukemia, CNS lymphoma, known HIV infection or active viral hepatitis were not eligible for inclusion.","Although dose escalation was primarily based on the incidence of DLTs during cycle 1, toxicities that met the criteria for DLTs and were observed during cycle 2 or subsequent cycles were also taken into consideration for the dose definition",NA
22921184,NA,Single Drug,No,"patients with advanced solid tumours and B-cell malignancies. The most common tumour types enrolled were colorectal cancer [23%], gastrointestinal stromal tumour [16%] and epithelial ovarian cancer [11%]","Patients were >=18 years with advanced solid malignancies refractory to standard treatments. The main inclusion criteria were: life expectancy >=12 weeks; ECOG performance status 0–1; women of non-childbearing potential (post-menopausal or history of bilateral oophorectomy or hysterectomy) or not pregnant or willing to use contraception; left ven- tricular ejection fraction (LVEF) >45% [ECHO or MUGA]. The protocol was amended and IRB approved to treat patients with CD20+ B-cell malignancies with SF1126 alone and/or in combination with rituximab at the maximum administered dose (MAD). The inclusion criteria were relapsed or refractory B-cell malignancy in patients, >=18 years, relapsed/refractory to purine analogues or alkylating agents or not amenable to first line therapy.","Exclusion criteria included: chemotherapy or radiotherapy within 4 weeks of study start; inadequate haematologic (neutrophils <=1.5 x 109/L, platelets <=100 x 109/L, haemoglobin <=9 g/dL), hepatic (serum bilirubin >ULN of reference range or ALT or AST or ALKP >2.5 ULN of reference range or >5 times ULN of reference range with liver metastases) or renal function (serum creatinine >ULN of reference range or CrCl of <50 mL/min or >+2 proteinuria on 2 consecutive dipsticks within 24 h); history of ischaemic heart disease or myocardial infarction within 3 months of the study; severe or uncontrolled systemic conditions or current unstable or uncompensated respiratory or cardiac conditions.",during the 1st cycle,NA
15249589,NA,Combination,No,patients with relapsed or refractory myeloma,"Patients diagnosed with MM and who were considered refractory to treatment after at least two cycles of treatment or who relapsed after previous treatment were eligible for entry. Bisphosphonates were allowed, but corticosteroids or other chemotherapy, including investigational agents, had to be discontinued for at least 30 days before entry onto study.","Patients were not eligible if they had serum creatinine levels greater than 1.5 mg/dL or grade 3 peripheral neuropathy as assessed by the clinician-assessed Neuropathy Targeted Symptom Questionnaire, were unable to maintain a platelet count >= 20,000 cells/uL, or had an absolute neutrophil count of less than 1,000 cells/uL. Patients were also excluded if they had a history of malignancy within the last 3 years or had other clinically relevant active comorbid medical conditions within 6 months or less that were uncontrolled by appropriate medication. ",during the first 4 weeks of treatment,NA
27154915,NCT01055496,Combination,No,patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma (NHL),"Eligible patients were aged >= 18 years, with a diagnosis of CD22þ B-cell NHL (Table 1). Patients were required to have an Eastern Cooperative Oncology Group performance status of <=2; total bilirubin <=upper limit of normal (ULN; in patients without Gilbert disease); aspartate and alanine aminotransferase (AST and ALT) <=2.5 x ULN; serum creatinine <=2 x ULN and a urine protein/creatinine ratio of <= 0.5; an absolute neutrophil count >=1.0 x 109/L (1,000/uL) and a platelet count >=100 x 109/L; and >=1 measurable disease lesion >1 cm in diameter (product diameter >= 2.25 cm2 by CT or MRI). Patients in the dose-escalation cohorts had >=1 prior anticancer treatment, including prior rituximab and chemotherapy. Enrollment of previously untreated patients in the MTD confirmation and preliminary efficacy cohorts was permitted if they were not considered candidates for anthracycline-based therapy.","Key exclusion criteria included the following: >3 previous chemotherapy regimens containing >=2 cytotoxic agents; treatment with anti-CD22 antibodies, radioimmunotherapy or autologous transplant within 6 months of the first dose of study drugs; chemotherapy, cancer-immunosuppressive therapy, radiotherapy, growth factors (except for erythropoietin), or investigational agents within 28 days of first dose of study drugs. Also excluded were candidates for hematopoietic stem cell transplant; patients with a Fridericia corrected QT interval >470 msec at screening, symptomatic central nervous system disease, or a history of venoocclusive disease/sinusoidal obstruction syndrome or chronic liver disease",during cycle 1,NA
27601593,NCT01209130,Combination,No,"patients with relapsed/refractory (r/r) diffuse DLBCL, iNHL (including follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma), mantle cell lymphoma (MCL), and CLL","Eligibility criteria included: age >=18 years; Eastern Cooperative Oncology Group (ECOG) performance status <= 2; measurable disease; adequate end-organ function as assessed by standard laboratory chemistries and hematology tests; no prior antibody or ADC within 4 weeks; no radiotherapy, chemotherapy, or investigational treatment within two weeks prior to the first dose of pinatuzumab vedotin; no prior allogeneic stem cell transplant; no autologous stem cell transplant within 100 days of first study treatment administration; no history of central nervous system lymphoma; grade 1 peripheral neuropathy","Prior use of any monoclonal antibody or antibody-drug conjugate within 4 weeks prior to study treatment. Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other investigational anti-cancer agent within 2 weeks prior to of study treatment. Completion of autologous stem cell transplant within 100 days prior to study treatment. Prior allogeneic stem cell transplant",during the first cycle,NA
33451977,NCT02663518,Single Drug,No,Patients with Relapsed or Refractory Hematologic Malignancies,"Adults (aged ≥18 years) recruited in the study had documented advanced malignancies that progressed following treatment with standard anticancer therapy, or for which there were no approved conventional therapies; Eastern Cooperative Oncology Group performance status ≤2; adequate coagulation, hepatic, and renal function; and had recovered from prior anticancer drug or radiotherapy toxicities. Patients in the dose-escalation group had documented advanced lymphoma following ≥2 prior therapies, including anti-CD20 therapy for B-NHL, and adequate hematologic status [absolute neutrophil count (ANC) ≥ 1.5  109/L, platelets ≥75 x 109/L, and hemoglobin ≥ 100 g/L] without transfusion or growth factor support. Additional patients in the initial doseexpansion group had advanced small-cell lung cancer (SCLC); multiple myeloma treated with ≥3 prior therapies, including an immunomodulatory drug or proteasome inhibitor; AML; myelodysplastic syndrome (MDS); BCR/ABL1-negative myeloproliferative neoplasm (MPN); chronic lymphocytic leukemia (CLL); indolent or aggressive B-NHL, Hodgkin lymphoma, or T-cell NHL (TNHL) treated with ≥2 prior therapies, including anti-CD20 antibodies for B-NHL; ANC ≥ 1 x 109/L (not applicable for AML, MDS, or MPN); platelets ≥ 50 x 109/L; and hemoglobin ≥ 8 g/L.",Exclusion criteria included irreversible antiplatelet/anticoagulant or investigational or anticancer therapy within 14 days (excluding hydroxyurea in myeloid malignancies); allogeneic transplant within 30 days or active graft-versus-host disease (except grade 1 skin involvement); prior anti-CD47 therapy (except prior TTI-621); history of hemolytic anemia or bleeding diathesis; prior grade 4 rituximab infusion–related reaction (rituximab combination arm); or prior or active autoimmune disease or treatment with anti–PD-1/PD-L1 or anti-CTLA4 (nivolumab combination arm).,during the 3-week observation period,NA
30082475,NCT01397825,Combination,No,Relapsed/Refractory Aggressive B-cell Lymphoma,"Adults diagnosed with histologically confirmed DLBCL/TFL, MCL, or Burkitt lymphoma (with neoplastic cells expressing CD20), who had relapsed/refractory disease after 1 to 4 prior systemic therapies, and had relapsed following autologous stem cell transplantation (ASCT) or were not eligible for ASCT, were enrolled. Patients with transformed DLBCL/TFL from a previous indolent NHL or the concomitant presence of a component of low-grade lymphoma were not excluded from participation. Additional requirements included measurable disease (>=2 cm in the longest diameter), an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and adequate bone marrow [absolute neutrophil count (ANC) >=1,250 cells/mm3; platelet count >=75,000/mm3], hepatic [total bilirubin <=1.5 times upper limit of normal (ULN); serum alanine or aspartate aminotransferase (ALT/AST) <=3 times ULN], and renal (calculated creatinine clearance >=30 mL/minute) function. ","Patients were excluded if they had prior treatment with AAK inhibitors, diagnosis or treatment for a malignancy other than lymphoma within 2 years prior to first dose, evidence of active malignancy other than lymphoma, ASCT <=3 months prior to enrollment or allogeneic stem cell transplantation at any time, or grade 2 peripheral neuropathy",in cycle 1,NA
22875080,NA,Single Drug,No,"patients with advanced solid tumors. The most common tumor types included colon (8), sarcoma (5), prostate (4), and 2 each of adrenal, breast, head and neck, hepatocellular, melanoma, ovarian, and thyroid.","Patients with histologically confirmed solid tumors not amenable to standard therapy were eligible. Other inclusion criteria included age C18 years, life expectancy of at least three months, and radiographic or clinical evidence of measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria . Initially at the study opening patients with an Eastern Cooperative Oncology Group performance status 0–2 were eligible. However, due to myelosuppression observed the protocol was amended to allow only patients with ECOG performance status of 0–1. Patients with tumors involving their central nervous system tumors must be on a stable or decreasing dose of systemic steroids prior to enrolling onto study. Since there is a concern about thrombo-embolic events while on IMiDs patients with central nervous system disease must agree to a low dose aspirin or similar antiplatelet medication while receiving study drug. Collection and analysis of pharmacokinetic data was not performed in this study. Females of child-bearing potential must use two reliable forms of contraception simultaneously or practice abstinence from heterosexual intercourse for at least 28 days prior to starting study medication, during treatment, and for at least 28 days after study medication ends. Females of child-bearing potential with regular menstrual cycles must have two negative pregnancy tests prior to enrolling and every 28 days until completion of study. Women with irregular menstrual cycles the pregnancy test is weekly for the first 28 days and then every 14 days while until study discontinuation. If a pregnancy test becomes positive the study drug would immediately be discontinued. Male patients agreed to use a latex condom during sexual contact with females of child-bearing potential.","Study exclusion criteria included any serious medical or psychiatric illness that would place the patient at unacceptable risk or prevent the subject from signing the informed consent. At least 28 days must have elapsed since prior cytotoxic chemotherapy, and at least 14 days from the use of prior radiation therapy or thalidomide, lenalidomide, or structurally related compounds. Patients who experienced a desquamating rash from thalidomide, lenalidomide, or structurally related compounds were ineligible. Exclusion criteria also included absolute neutrophil count <1,500/mm3, platelet <75,000/mm3, hemoglobin <9 gm/dl, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >=3 times the upper limit of normal, peripheral neuropathy >=2, or ongoing infection. Patients with uncontrolled hypercalcemia, hypocalcemia, glycosemia, or thyroid disorders were also ineligible.",during cycle 1,NA
25057177, NCT00787969,Combination,No,mantle cell lymphoma,"Mantle cell lymphoma was confirmed by central pathology review. Patients were eligible if they had measurable disease as defined by at least one mass ≥2 cm, or based on splenomegaly extending at least 3 cm below the left costal margin. Patients were also eligible for study entry if they had assessable disease based on diffuse organ infiltration, though, in this case, response criteria did not include the possibility of partial response (PR). Additional eligibility criteria included: age ≥18 years; ECOG PS 0, 1, 2 or 3; platelets ≥100 000 × 109/l; neutrophils ≥1.500 × 109/l; and adequate renal and hepatic function.","Exclusion criteria included: prior therapy for lymphoma; central nervous system involvement by lymphoma, HIV positive; prior mTOR in- hibitor treatment; concurrent malignancy; or stem-cell transplant planned.",during the first cycle of therapy,NA
11432631,NA,Combination,No,"Patients with metastatic or locally advanced cancer. Tumor types: Colorectal, Small bowel, Upper GI, Melanoma, Liver, Unknown primary","Patients with histologic or cytologic evidence of metastatic or locally advanced cancer for which there was no therapy capable of cure or likely to prolong survival were eligible for this study Eligibility criteria also included age > 18 years, ECOG performance score =£2, adequate bone marrow reserve (platelets >200,000/ul, absolute neutrophil count > 1500/ul), adequate hepatic function (direct bilirubin within normal limits, alkaline phosphatase and AST ;£3 times the upper limit of normal) and normal creatinine. Patients were required to have an estimated life expectancy of at least 12 weeks. ","Patients were ineligible if they had uncontrolled infection or radiation to more than 25% of the bone marrow. Chemotherapy, immunotherapy, biologic therapy, or radiation therapy within the prior four weeks was not permitted. In addition, patients with clinically significant ascites or pleural effusion and > 2 prior chemotherapy regimens were excluded. ",during the first treatment cycle,NA
8622063,NA,Single Drug,No,"patients with solid tumors. Tumor types: Colon, Ovary, Head and neck, Mesothelioma, Melanoma, Sarcoma, Breast, Other",Inclusion criteria for the protocol were as follows: (1) histologically confirmed malignancy that was progressive and not amenable to cure by existing treatment modalities; (2) World Health Organization (WHO) performance status of 0 to 2; (3) age between 18 and 75 years; and (4) life expectancy of at least 15 weeks,"Exclusion criteria were as follows: (1) systemic anticancer therapy within the previous 4 weeks (6 weeks for nitrosoureas and mitomycin); (2) extensive radiotherapy within the previous 8 weeks; (3) prior chemotherapy for more than 6 months with chlorambucil, mitomycin, or nitrosoureas; (4) irradiation of more than 30% of total bone marrow; (5) unresolved toxicity from prior anticancer therapy; (6) intracerebral metastases; (7) treatment with corticosteroids for reasons other than antiemetic or replacement purpose; (8) total WBC count less than 3 x 109/L, platelet count less than 100 x 109/L, and hemoglobin less than 10 g/dL; (9) chromium 51-EDTA ( 51Cr-EDTA) clearance less than 70 mL/min, plasma bilirubin level more than 25 umol/L, ALT more than 50 IU/L, and alkaline phosphatase more than 200 IU/L unless known to be due to demonstrable (by computed tomographic [CT] scan or hepatic ultrasound) hepatic secondaries; (10) treatment with folic acid supplements; (11) serious active or uncontrolled infection; (12) pregnancy or breast feeding; and (13) previous or concurrent malignancy other than adequately treated skin malignancies or cervical carcinoma-in-situ.",NA,NA
27293194,NCT01410513,Combination,No,patients with relapsed or refractory B-cell malignancies,"Eligible patients were >18 years old with histologically orcytologically and phenotypically confirmed iNHL, MCL or CLL. Patients had measurable disease and had relapsed after,or were refractory to, at least one standard therapy. Refrac-tory disease was defined as unresponsive to or progressingwithin 6 months of completing a standard therapeutic regi-men. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status≤2, and ade-quate organ and haematological function with absolute neu-trophil count (ANC)≥1 x 109/l, platelet count≥75 x 109/l and haemoglobin ≥80 g/l. ","Patients were ineligible if theyhad active central nervous system metastases; had receivedprior therapy with a PI3K, mTOR or dual PI3K/mTOR inhi-bitor resulting in AEs necessitating treatment discontinua-tion; had received cytotoxic chemotherapy, small moleculecancer therapy, biological cancer therapies other than ritux-imab, hormonal therapy, radio- or immuno- conjugates orimmunosuppressants to treat malignancy within 4 weeks, orradiation therapy within 2 weeks prior to start of study treat-ment; had an autologous stem cell transplantation within 16 weeks prior to start of study treatment or had any historyof allogeneic stem cell transplantation. ",during the first cycle (4 weeks),NA
19652067,NA,Single Drug,No,"patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. Overall, the study was comprised of patients with diffuse large B-cell lymphoma, T-cell lymphoma, and HL.","Patients were required to have histologically confirmed NHL by using the WHO classification or to have HL. Eligibility required the following: measurable disease in the phase II study and evaluable disease in the phase I study; disease that was relapsed/refractory to prior therapy with no limit on prior therapy; no prior chemotherapy for at least 4 weeks; time period of at least 3 months since the last administration of any monoclonal antibody, unless there was objective evidence of disease progression within that time (phase II studies only); 18 years of age or older; life expectancy of 3 months or greater; a Karnofsky performance status  60%; and no signs of congestive heartfailure. Patientswere not excludedforfebrile episodes aslong as therewas no evidence of active infection. Prior MTX exposure was not exclusionary. All patients were required to sign an institutional review board–approved informed consent and Health Insurance Portability and Accountability Act consent. Within 2 days of study drug administration, patients had to meet the following criteria: absolute neutrophil count greater than 1,000/uL; platelet count >= 50,000/uL; total bilirubin <= 1.5 times upper institutional limit of normal (ULN); AST/ALT <= 2.5 times ULN (or four times ULN if liver involvement); and creatinine less than 1.5 times ULN or a creatinine clearance of >=50mL/min.","Patientswere excludedif theywere pregnant; had evidence of intracranial disease; had major surgery within 4 weeks; had uncontrolled illness, including active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, a myocardial infarction, or cerebrovascular accident within 6 months of study enrollment; known HIV disease; or psychiatric illness/social situations that would limit compliance with study requirements.",in cycle 1,NA
27381904,NCT01570387,Combination,No,patients with AL amyloidosis,"This clinical trial was approved by the institutional review board in accordance with federal regulations andtheDeclaration ofHelsinki. Eligibilityincludedthe following: a diagnosis of AL amyloidosis, a difference between involved and uninvolved serum freelight chainlevels >=50mg/L, >=1 line of priortreatment, a platelet count >=100 x3 109/L, an absolute neutrophil count >=1.5 x 109/L, a total bilirubin <=1.5 mg/dL, aspartate aminotransferase/alanine aminotransferase <=2 x upper limit of normal, a serum creatinine <=3.0 mg/dL, and a performance status <=2. All eligible patients were enrolled in the Risk Evaluation and Mitigation Strategies program.","Secondary or familial amyloidosis. Multiple myeloma (≥30% plasma cells in a bone marrow biopsy specimen or lytic bone lesions). Cytotoxic chemo or radiation therapy ≤4 weeks of study entry or following baseline evaluation. Symptomatic cardiac arrhythmias or O2-dependent restrictive cardiomyopathy. Dialysis-dependent. Untreated or uncontrolled infections.. Serious medical conditions, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. Pregnant or breast feeding females (lactating females must agree not to breast feed while taking pomalidomide). Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. Use of any other experimental drug or therapy within 28 days of baseline. Known intolerance to steroids. Known hypersensitivity to thalidomide or lenalidomide. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. Concurrent use of other anti-cancer agents or treatments. Known HIV positivity is not an exclusion, unless cluster of differentiation 4 (CD4) counts <200/microliter and/or patient has multi-drug resistant HIV infections and/or other concurrent AIDS-defining conditions. HIV b-DNA < 75 copies/mL.",during cycle 1,NA
11597383,NA,Combination,No,chemonaive patients with stage II/III T2/N+ and T3/N+ rectal cancer ,"Eligibility criteria included: histologically confirmed primary adenocarcinoma of the middle and low rectum; clinical stage  T3N0-2M0 or T2N1-2M0; age >18 years; Karnofsky performance status >60; non-preg- nant, non-lactating; no prior chemotherapy, immu- notherapy or radiotherapy to the pelvis. The following laboratory entry criteria were required: leucocyte count >=4000x106 cells/l granulocyte count >=1500x106 cells/l; haemoglobin level >=100 g/l; platelet count >=100x109 cells/l; serum creatinine <=132.6 mmol/l; bilirubin level <=25.65 mmol/l. All patients were required to provide signed, informed consent prior to study entry. ",NA,during radiotherapy treatmen,NA
23572496,NA,Combination,No,"patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas","Patients with histologically confirmed relapsed or refractory CD20-positive B-cell lymphoma (follicular lymphoma with or without transformation, mantle and marginal zone lymphoma, or other indolent lymphomas) were included provided they fulfilled the following criteria: age greater than 18 y with a life expectancy of more than 3 mo, not pregnant or lactating, and performance status of 2 or better according to the World Health Organization scale. Within 1 wk of the start of treatment, patients were required to have an absolute neutrophil count above 1.5 x 109/L, a circulating lymphocyte count below 5 x 109/L, a platelet count above 100 x 109/L, a total bilirubin level of no more than 20 mmol/L, an alanine aminotransferase level below 2.5 times normal, and a serum creatinine clearance level above 60 mL/min. A bone marrow biopsy specimen showing less than 25% infiltration by tumor cells was required.","Patients who had previously undergone radiation therapy to the pelvis, femora, or lumbar spine or high-dose treatment with stem cell transplantation were excluded.",NA,NA
11038040,NA,Combination,No,Patients with resected Dukes' stage B or C rectal cancer ,"Eligible patients were at least 18 >ears of age. had microscopically confirmed Dukes"" Stage B or C adenocarcinoma of the rectum which had been curatively resected, a WHO performance status <= 2, a life expectancy of at least 12 weeks, and were considered appropriate to receive systemic adjuvant chemotherapy and radiotherapy","Principal exclusion criteria were previous systemic chemotherapy for colorectal cancer: previous radiotherapy to the planned exposure area; extensive metastatic disease; abnormal blood cell counts (white blood cells < 4 0 x 1O9/1, unless neutrophil count >=2.0 x 1O9/1, or platelet count < 100 x 109/l) or biochemistry (serum creatinine > upper limit normal [ULN], serum bilirubin >= 1.25 x ULN or aspartate aminotransferase or alanine aminotransferase >2.5 x ULN); other serious medical conditions.",NA,NA
10645208,NA,Combination,No,patients with advanced colorectal cancer,N/A,N/A,N/A,NA
32343640,NCT03406871,Combination,Yes,Patients With Advanced Gastric or Colorectal Cancer,"The main inclusion criteria for the study were: (1) histologically or cytologically confirmed advanced or metastatic solid tumors refractory to or intolerant of standard chemotherapy, (2) an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, (3) adequate bone marrow reserve, and (4) adequate hepatic and renal function (Appendix, online only). Patients who had previously received immune checkpoint inhibitors, such as antiPD-1 or anti-PD-L1 mAbs, were eligible. ","Major exclusion criteria included: (1) history of a previous treatment with regorafenib, (2) active or history of chronic or recurrent autoimmune disease, or (3) the presence of a serious comorbidity. ",during the first 4 weeks ,NA
23295790,NCT00299494,Combination,No,Patients with relapsed/refractory CD20(+)/CD22(+) B-cell non-Hodgkin lymphoma (NHL),"Main eligibility criteria included age ≥ 18 years; Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2; life expectancy ≥ 12 weeks; absolute neutrophil count ≥ 1,500/μL; platelets ≥ 75,000/μL; serum creatinine and total bilirubin ≤ 1.5× upper limit of normal; AST and ALT ≤ 2.5× upper limit of normal; one or more disease lesion ≥ 1.5 × 1.5 cm; and no prior allogeneic hematopoietic stem-cell transplantation, radioimmunotherapy, or anti-CD22 antibody treatment. ",Subjects who are candidates for other potentially curative therapies. Subjects must not have received previous radioimmunotherapy. Subjects who have undergone a prior bone marrow transplantation within the last 6 months.,during the first 28 days after the first administration of inotuzumab ozogamicin + rituximab,NA
28314788,NCT01326702,Combination,No,"patients with relapsed/refractory lymphoma, multiple myeloma, and solid malignancies. Ten patients had gynecologic malignancies, 8 had lymphoma, 5 had gastrointestinal malignancies, 4 had sarcoma, 2 had breast malignancies, and 1 each had melanoma, urothelial carcinoma, carcinoid tumor, adenocarcinoma of the maxillary sinus, and multiple myeloma","Inclusion criteria for the phase Ib dose-escalation cohort included: age > 18 years, Eastern Cooperative Oncology Group (ECOG) performance status <= 2, life expectancy >= 3 months, histologically confirmed solid malignancy, lymphoma, or multiple myeloma (relapsed or refractory to at least 1 prior chemotherapeutic regimen or biologic agent and ineligible for or having refused curative options for treatment, including stem cell transplant when applicable), and adequate organ [creatinine <= 2 x upper limit of normal (ULN) or creatinine clearance > 60 mL/min, total bilirubin <= 2 x ULN, and transaminases <= 2.5 x ULN] and marrow function (absolute neutrophil count >= 1,000/mL, platelet count >= 100,000/mL, and hemoglobin >= 8.0 g/dL unsupported by transfusion within 2 weeks). ","We excluded patients with active infection, HIV with a CD4 count < 300, uncontrolled concurrent medical problems, history of allergic reactions to veliparib, bendamustine, or mannitol, intolerance of repeated doses of rituximab (for expansion cohort), concurrent pregnancy or breastfeeding, history of seizure, uncontrolled central nervous system metastases, unrelated prior malignancies within 3 years of enrollment, or any unrelated prior malignancies that have not undergone potentially curative therapy (non-melanoma skin cancer or melanoma in situ that was completely excised was eligible).",during cycle 1,NA
12451472,NA,Combination,No,advanced breast cancer,"Eligibility criteria included documentation of histologically proven advanced metastatic breast cancer following prior chemotherapy. Of 12 patients entered, 11 had one or two metastatic sites. All patients had initially been treated with anthracycline and/or taxane chemotherapy regimens, and seven (58%) were responsive to anthracyclines and three (37%) were responsive to taxanes. In addition, eight patients with estrogen-positive receptors had received prior hormone therapy. The main inclusion criteria were performance status (WHO) <= 2, life expectancy greater than 12 weeks and normal hepatic, renal and bone marrow function defined by WBC count <=4x109/l, absolute neutrophil count <= 1.5x109/l, platelet count >=100x109/l, hemoglobin >=10 g/dl, serum creatinine not more than 1.5 times the upper limit of normal (ULN), total bilirubin level not more than 1.25 times the ULN, and AST, ALT, and alkaline phosphatase less than 2.5 times the ULN or less than 5 times the ULN if hepatic metastases were present.","Exclusion criteria included chemotherapy or radiotherapy within 4 weeks of study entry prior to chemotherapy with vinorelbine or raltitrexed, previous malignancy, concomitant uncontrolled nonmalignant disease (cardiac, pulmonary, renal or hepatic disease, or active infection), and brain or meningeal involvement of the disease. The protocol was approved by the Local Ethics Committee (CCPPRB) and signed informed consent was obtained from all patients",during the first two treatment cycles,NA
32052473,NCT01471210 (CA186-011) & NCT01775631 (CA186-017),Combination,No,patients with relapsed or refractory B-cell lymphoma,"In CA186-011, eligible patients with B-cell NHL had R/R disease after ≥1 prior line of standard therapy per IWG Response Criteria for NHL.23 In CA186-017, eligible patients had CD20+ B-cell NHL with measurable disease per IWG Response Criteria for NHL23 that was refractory to or had relapsed after ≥1 prior line of standard therapy. Patients in the expansion phase must have received ≥1 prior multiagent chemotherapy regimen and must have had R/R disease after prior rituximab alone or in combination with chemotherapy. In both studies, patients had to be aged ≥18 years with an ECOG performance status of 0 or 1 and were required to provide pre- and ontreatment biopsies or fine-needle aspirates. Anticancer therapy, nononcology live viral vaccine therapy (for the prevention of infectious diseases), surgery (unless minor [ie, biopsies]), radiotherapy, or the use of immunosuppressive medications or immunosuppressive doses of systemic corticosteroids (doses >10 mg/day of prednisone or equivalent) or growth-factor treatments were not permitted within 28 days of dosing in either study. Prior treatment with agents targeting immune checkpoints (eg, programmed death [PD]-1, programmed death ligand 1 [PD-L1], PD-L2, lymphocyte-activation gene 3, or cytotoxic T lymphocyte antigen-4) was permitted after a washout period of >100 days from the last dose in a subset of patients treated in CA186-011. And, it was permitted only during the early portion of CA186-017 after a washout period of >28 days; in the final CA186-017 protocol, prior treatment with checkpoint pathway inhibitors was prohibited. Prior treatment with agents targeting T-cell costimulatory pathways (eg, CD137, glucocorticoidinduced TNFR-related protein, OX40) was not permitted in either study.","Patients with central nervous system lymphoma, active autoimmune disease (or a documented history of autoimmune disease or a syndrome that required systemic steroids or immunosuppressive medications), known or suspected HIV or hepatitis (or history of hepatitis), evidence of active infection, or history of clinically significant cardiac disease were not eligible for enrollment in either study.","during the first 9 weeks of therapy in CA186-011, during the first 43 days of therapy in CA186-017",NA
30060083,NCT01594229,Combination,No,patients with relapsed or refractory NHL,"Patients were required to have an Eastern Cooperative Oncology Group performance status of 0 or 1, adequate bone marrow (independent of growth factor support), including absolute neutrophil count (ANC) ≥1000/µl, platelets ≥75,000/mm3, and hemoglobin ≥9.0g/dL, and adequate coagulation, renal, and hepatic function. Patients were excluded if they had posttransplant lymphoproliferative disease, Burkitt's or Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, or MCL","Patients with refractory DLBCL that was unresponsive to or had progressed in ≤3 months of first-line R-CHOP or equivalent, or who had progressed within ≤2 months of last chemotherapy were also excluded.",during cycle 1,NA
29563636,NCT01004003,Combination,No,European patients with advanced hepatocellular carcinoma,Key inclusion criteria included patients aged ≥18 years with advanced HCC not amenable to curative/locoregional therapy and with ≥1 measurable lesion by Response Evaluation Criteria in Solid Tumours (RECIST) v1.0 (for phase-II); Eastern Cooperative Oncology Group (ECOG) performance score (PS) ≤2; Child–Pugh score 5–6 (for phase-II) and alanine/aspartate aminotransferase (ALT/AST) levels ≤2 times upper limit of normal (ULN) (for phase-II and phase-I group I; phase-I group II had ALT or AST >2–≤5 times ULN or Child–Pugh score 7); >4 weeks since most recent local therapy; no prior systemic therapy for HCC; no history of other malignancy within the past 3 years; and life expectancy ≥12 weeks. Additional inclusion criteria are listed in the protocol. ,"Prior systemic therapy for HCC. Fibrolamellar hepatocellular carcinoma (HCC). Bilirubin greater than 1.5 times ULN. AST or ALT greater than 2 times ULN. Uncontrolled or refractory ascites to adequate medical therapy. Hepatic encephalopathy more than grade 1 according to Child-Pugh criteria. Prothrombin time international normalized ratio greater than 2.3, or prothrombin time more than 6 seconds prolonged than control. Absolute neutrophil count less than 1000 /µL. Platelet count less than 60000 /µL. Hemoglobin less than 9 g/dL. Serum creatinine greater than 1.5 times Upper Limit of Normal (ULN). Proteinuria of Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or greater. Variceal bleeding within last 6 months prior to start of study treatment. History of major thrombotic (except portal vein thrombosis) or clinically relevant major bleeding event in the past 6 months. Known inherited predisposition to bleeding or thrombosis. Significant cardiovascular diseases (i.e. hypertension not controlled by medical therapy, blood pressure > 150/90 mmHg), unstable angina, history of myocardial infarction within the past 6 months, congestive heart failure > class II according to New York Heart Association (NYHA), serious cardiac arrhythmia, pericardial effusion). Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid =< 325mg per day). Major surgery within 4 weeks prior to start of study treatment. Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug). Known serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study. Patients who are sexually active and unwilling to use a medically acceptable method of contraception (e.g. such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner for participating females, condoms for participating males) during the trial and for at least twelve months after end of active therapy. Current alcohol abuse or drug abuse that would limit pt ability to comply with protocol.  Symptomatic central nervous system (CNS) metastasis. Life expectancy less than 12 weeks. Patient unable to take oral medication",within the first 28 days of therapy,NA
25976292,NA,Single Drug,No,"children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms","Patients >12 months and <22 years of age with recurrent orrefractory solid tumors (STs; part A), including lymphomas, wereeligible. In addition, patients with hematologic malignancies(HMs), including relapsed or refractory ALL or acute myeloidleukemia (AML), and patients with chronic MPNs (polycythemiavera [PV], essential thrombocythemia, juvenile myelomonocyticleukemia [JMML]) without known curative therapies (part B) wereeligible to enroll at one dose level below that at which patients withSTs were enrolling. Other eligibility criteria included a Lansky orKarnofsky score >= 50, recovery from acute toxic effects of prior totherapy, and >= 7 days from prior to growth factor therapy (if shortacting or 14 days if long acting). Patients with STs had to be >= 3 weeks from receipt of myelosuppressive chemotherapy. Patientswith HMs had to be >=2 weeks from prior to cytotoxic therapy withthe exception of maintenance-type ALL therapy for which therewas no washout period. Patients had to be>3 months from prior tostem cell transplant and without evidence of graft-versus-hostdisease. At least 2 weeks from local radiation had to have elapsed.Patients who were on corticosteroids must have been taking a stableor decreasing dose for 7 days prior to enrollment. Hydroxyurea usewas permitted until 24 hr prior to the first dose of ruxolitinib.Other requirements for patients with STs without known bonemarrow involvement included adequate bone marrow function(peripheral absolute neutrophil count>1,000/ml, platelet count>100,000/ml, hemoglobin>8.0 g/dl, and transfusion indepen-dence). Patients with STs with marrow involvement and transfu-sion-dependent hematologic malignancies patients could enroll on study, but did not contribute data for the assessment of hematologicDLTs. Other standard organ function requirements included an age-adjusted normal serum creatinine or glomerular filtration rate(GFR) >=70 ml/min/1.73 m2and normal liver function (total bilirubin <= 1.5x the institutional upper limit of normal for age, ALT <=110 U/l, and albumin >=2 g/dl).",NA,the first cycle of therapy,NA
25248753,NA,Combination,No,Patients with advanced hepatocellular carcinoma,"Patients were eligible for study enrollment if they had histologically or cytologically confirmed advanced HCC and had progressed on or were intolerant of sorafenib. Other eligibility criteria included: measurable disease by RECIST version 1.1 criteria, Child Pugh Class A, ECOG performance status≤1, Cancer of the Liver Italian Program (CLIP) score≤3, Barcelona Clinic Liver Cancer (BCLC) stage C or BCLC stage B who cannot tolerate or failed TACE, WBC ≥1,500/μL, platelets ≥75,000/μL, hemoglobin ≥9.0 g/dL, creatinine ≤2.0 mg/dL, total bilirubin ≤3× the upper limit of normal (ULN), ALT and AST ≤5× ULN.","Exclusion criteria included QTc >450 milliseconds (msec) or history of QT prolongation with previous medications; ventricular ejection fraction ≤55 %; chemoembolization, radiation, or systemic therapy within 4 weeks of starting treatment; serious medical comorbidities including but not limited to symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia; concurrent investigational agents; untreated brain metastases; HIV positivity on combination antiretroviral therapy due to potential drug interactions with the study drug; and pregnancy or lactation.",within the first cycle (28 days) of therapy,NA
21045832,NA,Combination,No,"patients with advanced solid cancer. Tumour type: Sarcoma 8 (42%), Colorectal cancer 3 (16%), Melanoma 2 (11%), Non-small cell lung cancer 2 (11%), Hepatocellular carcinoma 2 (11%), Thyroid cancer 1 (5%), Breast cancer 1 (5%)","Patients aged >=18 years, with histologically or cytologically confirmed advanced solid malignancies refractory to conventional treatment or without any regular therapy option were enrolled. Eligibility criteria included life expectancy >=12 weeks, Eastern Cooperative Oncology Group performance status <=1, no previous anti-cancer therapy within 4 weeks of study entry, no previous treatment with sorafenib or sirolimus, adequate hematopoietic (absolute neutrophil count >=1.5 x 109 l-1; platelets >=100 x 109 l-1), hepatic (bilirubin <=1.5 x upper limit of normal (ULN), aspartate transaminase/alanine transaminase <=2.5 x ULN, in case of liver metastases <=5 x ULN,) and renal function (creatinine <=2 x ULN).",Patients with clinically symptomatic brain tumours or brain metastases and patients with uncontrolled comorbidity were excluded.,during the first 50 days of treatment,NA
22415798,NA,Combination,No,"patients with advanced solid tumors. The most common tumor types were 15 NSCLC 13 adenocarcinoma including 3 in dose escalation phase and 2 bronchoalveloar carcinoma (BAC) both in NSCLC cohort), 8 RCC, 8 (all clear cell type including 2 in dose escalation phase), 2 CRC, renal sarcoma and 1 each leiomyosarcoma.","Patients with age ≥18 and histologically or cytologically documented locally advanced or metastatic solid tumors refractory to established forms of therapy or for which sorafenib alone would be considered as appropriate therapy were eligible for the dose escalation phase. Other criteria included Eastern Cooperative Oncology Group performance status ≤2; life expectancy ≥3 months; and adequate hematopoietic, hepatic, and renal function as demonstrated by neutrophil count ≥1.5×109/L, platelet count ≥75×109/L; bilirubin ≤1.5×upper limits of normal (ULN); AST and or ALT≤2.5×ULN or ≤5×ULN if documented liver metastases; serum creatinine ≤1.5×ULN","Exclusion criteria included previous exposure to other anticancer or investigational agent within 5 half-lives of the agent when known, or within 2 weeks (for agents dosed daily) or 3 weeks (for agents dosed less frequently) of last dose when the half-life was not known; radiotherapy within 7 days to non-target lesions or within 28 days to target lesions; allergy to study drugs; exposure to other HDAC inhibitors within 30 days; ongoing previous treatment related side effects/adverse events except alopecia (any grade acceptable) that were ≥ grade 2; pregnancy; symptomatic brain metastases; preexisting cardiac dysfunction or myocardial dysfunction / thromboembolic events within prior 6 months, other uncontrolled intercurrent illness or an inability to comply with the study requirements. Previous exposure to HDAC inhibitors or sorafenib was allowed in all cohorts within the restrictions already specified unless the patient received both in combination and/or experienced grade ≥3 toxicities with these drugs. In addition, for the RCC and NSCLC cohorts, patients were required to have the corresponding tumor type that was measurable by RECIST (version 1.0)",during the first cycle,NA
25371323,NA,Combination,No,"patients with advanced solid tumors. Tumor Type: Colorectal cancer 10 (32), NSCLC 4 (13), Sarcoma 5 (16), Esophageal/GE junction cancer 2 (6), Thyroid cancer 2 (6), Melanoma 2 (6), Others 6 (19)","Patients with histologically or cytologically confirmed locally advanced, inoperable or metastatic solid tumors were eligible for the study. Other inclusion criteria included age ≥18 years; Eastern Cooperative Oncology Group (ECOG) performance status 0–1; adequate bone marrow (absolute neutrophil count ≥1.5 × 109/L; Platelet ≥100 × 109/L; Hgb ≥10 g/dL), liver (total bilirubin ≤1.5 x upper limit of normal (ULN), ALT and AST ≤3x ULN, but allowed ≤5 × ULN if liver metastasis was present), and renal (creatinine clearance >40 ml/min) functions.","The study excluded patients who previously were unable to tolerate sorafenib 400 mg/day; received anti-cancer chemotherapy, immunotherapy or investigational agents, or had major surgery <4 weeks prior to starting treatment. Also excluded were patients with a history of significant cardiac disease; left ventricular ejection fraction <40 % on MUGA scan; untreated brain metastasis or uncontrolled medical conditions. Concurrent intake of strong CYP3A4 inducers or inhibitors was not allowed.",within the first cycle (28 days) of treatment,NA
26644411,NCT00785226,Combination,No,"Patients with Advanced Cancer. Tumor type: Colorectal, Esophageal, Head and neck, Lung, Melanoma, Ovarian, Pancreatic, Prostate, Small-bowel adenocarcinoma, Hepatocellular carcinoma","All patients gave written, informed consent. Patients were eligible if they: were aged 18 years or older; had an Eastern Cooperative Oncology Group performance status of 0 or 1; had cardiac function within normal range (as measured by echocardiogram or multigated acquisition scan); and had a histologically or cytologically confirmed advanced solid malignancy. Patients in the MTD expansion cohort had to have an unresectable tumor, either HCC (Child–Pugh A status) or melanoma, head and neck, colorectal, breast, or thyroid, amenable to biopsy (optional for HCC patients). Other inclusion criteria for all cohorts were: amylase and lipase <=2 x upper limit of normal (ULN); hemoglobin >=8.5 g/L; absolute neutrophil count >=1500/mm3; platelet count >=75,000/mm3; total bilirubin <= 1.5 x ULN; aspartate aminotransferase/alanine aminotransferase <=2.5 x ULN (or <=5 x ULN for patients with liver involvement); pro-thrombin time international normalized ratio/partial thromboplastin time <= 1.5 x ULN; and creatinine <=1.5 x ULN. ",Exclusion criteria were: a prior or concurrent distinct cancer in a primary site other than the one being evaluated in the study; swallowing dysfunction or malabsorption syndrome that may impair treatment with the study drug; cytotoxicity from chemotherapy or adverse events (AE) from administration of other treatments 4 or more weeks prior; major surgery within 4 weeks; cardiac disease; or HIV infection. The use of inhibitors and inducers of CYP3A4 and CYP2C19 (enzymes known to metabolize refametinib) was to be discussed with the study sponsor.,within the first cycle,NA
22962440,NA,Single Drug,No,"children with refractory solid tumors or leukemias. Diagnosis:Osteosarcoma (solid tumor 10, AML 8), Ewing's sarcoma (solid tumor 4, ALL 3), Alveolar rhabdomyosarcoma 4, Synovial sarcoma 3, Alveolar soft part sarcoma 2, MPNST 2, Sarcoma, other 7, Hepatoblastoma 4, Wilms tumor 4, Adrenocortical carcinoma 3, Renal cell carcinoma 2, Other 4 (solid tumor)","Patients >=24 months and <=21 years of age with treatmentrefractory, histologically confirmed measurable, or evaluable solid extracranial tumors (part A) or with refractory leukemias with >25% leukemic blasts in the bone marrow (part B) were eligible. Other eligibility criteria included ability to swallow intact tablets; recovery from toxic effects of prior therapy; Karnofsky/Lansky performance score >= 50; interval from prior therapy >=21 days for myelosuppressive chemotherapy or monoclonal antibody treatment; 7 days for hematopoietic growth factors, >=2 weeks for local palliative radiation; 3 months from total body, craniospinal, or 50% radiation to the pelvis; 6 weeks from other substantial bone marrow radiation; >= 3 months from a stem cell transplant or rescue; and no evidence of active graft versus host disease; adequate renal function [age-adjusted normal serum creatinine, or GFR >= 70 mL/min/1.73 m2); and adequate liver function [total bilirubin <=1.5 x institutional upper limit of normal (ULN), albumin >= 2 g/dL, and alanine aminotransferase (ALT) <= 110 U/L]. Adequate bone marrow function was required and defined as an absolute neutrophil count (ANC) >= 1,000/uL, transfusion-independent platelet count >=75,000/uL, and hemoglobin >=8.0 g/dL for part A; and platelet count >= 20,000/uL and hemoglobin >= 8.0 g/dL for part B. After dose-limiting serum, ALT/aspartate aminotransferase (AST) elevation was observed at the starting dose level in one patient with hepatic metastases and preexisting grade 1 elevation in AST/ALT, the eligibility criteria were revised to require a normal ALT (<=45 U/L) at enrollment. Eligibility criteria were re-revised in part B due to allow for mild elevation in the ALT (<=225 U/L) as many patients with leukemia have disease-related baseline elevations in serum. Additional eligibility criteria included normal serum lipase and amylase; diastolic blood pressure within the 95th percentile for age and gender and not receiving anti-hypertensive medication.","Exclusion criteria included pregnancy or lactation; uncontrolled infection; concurrent use of other investigational agents, anticancer agents, agents to prevent organ rejection posttransplant, cytochrome P450 enzyme-inducing antiepileptic drugs, rifampin, grapefruit juice, St. Johns Wort, or therapeutic anticoagulants; evidence of bleeding diathesis; leptomeningeal disease; and Gilbert syndrome.",during cycle 1 ,NA
28488066,NCT01276210,Combination,No,"adults had 1–4 brain metastases from solid malignancies. Primary: Lung 13 (57%), Breast 5 (22%), Renal cell 2 (9%), Esophagus 1 (4%), Bladder 1 (4%), Colon 1 (4%)",Eligible patients were ≥18 years old with histologically confirmed solid tumors (except for lymphomas and small cell lung cancer) who had 1–4 brain metastases less than 4 cm in size for which the treating radiation oncologist recommended treatment with SRS. Patients who had prior radiation or surgery for CNS metastatic disease were eligible as long as 1 month had elapsed prior to enrollment. Patients were required to have an Eastern Cooperative Oncology Group performance status of ≤1 with adequate metabolic function. Prior treatment with sorafenib or other tyrosine kinase inhibitors was allowed as long it had been discontinued either more than 28 days or five half-lives prior to enrollment.,"Exclusion criteria included concurrent chemotherapy, grade 3 hemorrhage within 4 weeks of enrollment, concurrent medications that could potentially affect hepatic metabolism, uncontrolled hypertension, heart failure>New York Heart Association class II, angina, ventricular arrhythmias or thromboembolic event within the previous 6 months.",for 1 month after SRS (stereotactic radiosurgery),NA
29520435,NCT01008566,Combination,No,advanced hepatocellular carcinoma,"Eligible patients were aged 18 years and older with unresectable or metastatic HCC and a Zubrod performance status of 0–1. The diagnosis of HCC was based on standard imaging criteria of arterial phase enhancement and venous or delayed phase wash out in the setting of liver cirrhosis or hepatitis, or on histologic confirmation (which was not mandatory if the imaging criteria were satisfied). No prior systemic treatment for HCC was allowed; however, patients may have had prior embolization, chemoembolization, intra-arterial chemotherapy infusion, ethanol injection, radiofrequency ablation or cryosurgery. Further inclusion criteria included the ability to give informed consent, assent to adequate contraception, no evidence of hepatic encephalopathy in the preceding 6 months and acceptable end-organ function defined by an absolute neutrophil count>1000/mm3, platelet count>65,000/mm3, total bilirubin≤2 times the institutional upper limit of normal (ULN), ALT and AST<5 times the ULN, prothrombin time<4 s of prolongation above the ULN, and creatinine<1.5 mg/dL or calculated creatinine clearance>50 mL/min using the Cockcroft–Gault formula.","Exclusion criteria included Child–Pugh C cirrhosis or Child–Pugh B cirrhosis with more than seven points, local therapy for HCC within 4 weeks prior to treatment on this study or those who have not recovered from adverse events related to therapy administered more than 4 weeks earlier, receipt of other investigational agents, inability to swallow sorafenib whole and any component of fibrolamellar histology. Patients were also excluded for brain metastases, fasting blood glucose>160 mg/dL, esophageal or gastric variceal bleeding within the last 6 months, clinically evident ascites (minimal, medically controlled ascites detectable on imaging studies only was allowed). Further exclusion criteria included cardiac comorbidities including clinically significant and uncontrolled cardiac dysrhythmia, New York Heart Association class II or greater congestive heart failure, unstable angina, myocardial infarction within the past 6 months, and systolic blood pressure>150 mmHg or diastolic blood pressure>100 mmHg on two occasions within 2 weeks of beginning therapy. Patients with active hepatitis B infection were required to be on appropriate antiviral therapy.",First 1 month of therapy,NA
34109515,NCT01724606  ,Combination,No,breast cancer patients with brain metastases,"The study included patients with histologically confrmed BC and new or progressive brain metastases (BM) (≥10 mm in longest dimension) by MRI of the brain. Patients were required to have planned WBRT based on number or size as assessed by the treating investigator. The protocol specifed WBRT (1 fraction /day×10 fractions) to be administered. No patient received hippocampal avoidance. Patients with leptomeningeal metastases were allowed if confned to the WBRT feld only (additional MRI spine was required to demonstrate no other area of involvement within 4 weeks of enrollment). Other key eligibility criteria included Karnofsky Performance Status (KPS)≥70, a non-escalating dose of steroid (not exceeding more than 16 mg daily of oral dexamethasone) for≥5 days, and no prior exposure to an anti-VEGF agent except bevacizumab. Patients must have had adequate organ function.","Leptomeningeal metastases, hemorrhagic metastases, presence of midline shift Please note: leptomeningeal metastases may be allowed if it is limited to cranial metastasis (MRI spine should be completed, within 4 weeks of enrollment, to show that no other leptomeningeal metastases is present) and is not the only metastasis present in the brain.'Contraindications to sorafenib. Prior treatment with any agent that targets vascular endothelial growth factor (VEGF) or VEGF receptors (VEGFR) (licensed or investigational including sorafenib), except bevacizumab. Craniotomy or any other major surgery, open biopsy, or significant traumatic injury within 4 weeks of enrollment. Serious, non-healing wound, ulcer, or bone fracture. Uncontrolled seizures. Use of cytochrome P450 enzyme-inducing anti-epileptic drugs (such as phenytoin, carbamazepine, or phenobarbital) is not allowed. Cardiac disease: Congestive heart failure >class II New York Heart Association (NYHA) (See Appendix B, or Unstable angina (anginal symptoms at rest), or new-onset angina (begun within the last 3 months), or myocardial infarction within the 6 months prior to enrollment, or Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. Congenital long QT syndrome or taking drugs known to prolong the QT interval ( See Appendix D or http://www. Azcert.org ) Subjects taking any drugs with a known risk of causing torsades de pointes. Grade 3 hypertension ( SBP ≥ 160 mm Hg and/or DBP ≥ 100 mm Hg despite maximal medical therapy) ≥ Grade 2 Lipase increased (>1.5 x ULN), Thrombolic, embolic, venous, or arterial events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months. Evidence or history of bleeding diathesis or coagulopathy at the time of enrollment. Pulmonary hemorrhage/bleeding event >National Cancer Institute Common Terminology for Adverse Events (NCI-CTCAE, version 4.0) Grade 2 within 4 weeks of enrollment. Any other hemorrhage/bleeding event ≥NCI-CTCAE Grade 3 within 4 weeks of enrollment. Therapeutic anticoagulation with Vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids. However, prophylactic anticoagulation as described below is allowed: Low dose warfarin (1 mg orally, once daily) with PT-INR ≤ 1.5 x ULN is permitted. Infrequent bleeding or elevations in PT-INR have been reported in some subjects taking warfarin while on sorafenib or capecitabine therapy. Therefore, subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes. Low dose aspirin (≤ 100 mg daily). Active clinically serious infection >NCI-CTCAE Grade 2. Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C (the safety and effectiveness of sorafenib in this patient population have not been studied). Previous or concurrent cancer that is distinct in primary site or histology from breast cancer within 5 years prior to enrollment EXCEPT cervical cancer in situ, treated basal cell carcinoma, squamous cell carcinoma (SCC), as long as it is other than SCC involving skin of the head and/or neck, and superficial bladder tumors [Ta and Tis]. Subjects who have used strong CYP3A4 inducers (eg, phenytoin, carbamazepine, phenobarbital, St. John's Wort [Hypericum perforatum], dexamethasone at a dose of greater than 16 mg daily for more than one day, or rifampin [rifampicin], and/or rifabutin) within 28 days before randomization. Concurrent anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy (other than that specified by the protocol), surgery, immunotherapy, biologic therapy including trastuzumab, lapatinib, bevacizumab, tyrosine kinase inhibitors other than sorafenib or tumor embolization Women who are pregnant or breast-feeding. Use of any investigational drug within 28 days or 5 half-lives, whichever is longer, preceding enrollment. For the purposes of this study, bevacizumab will not be considered investigational therapy. Inability to comply with protocol and /or not willing or not available for follow-up assessments. Any condition which in the investigator's opinion makes the patient unsuitable for the study participation.",during the WBRT and 2 weeks after WBRT,NA
23061485,NA,Combination,No,elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome,"Patients were eligible if they had AML or high-risk MDS (International Prognostic Scoring System [IPSS] score >=1.5), were at least 60 years of age, and were considered by their treating physi-cian to be unsuitable for standard induction therapy (at high risk of treatment failure or toxicity), or if they refused such therapy. No prior chemotherapy regimen was permissible (except hydroxyurea, provided it was  discontinued >48 h prior to the start of protocol therapy). Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status 0-2, adequate renal and hepatic function (creatinine  <=1.2 x upper limit of normal [UNL], aspartate aminotransferase [AST] and alanine aminotransferase [ALT] <=2 x UNL, bilirubin x UN).","Patients were excluded if they had documented central nervous system (CNS) involvement, were receiving or were planned for other cytotoxic therapy, had upper gastrointestinal or other conditions that would preclude compliance  with oral medication, had active uncontrolled infection, had recent or uncontrolled cardiac disease or uncontrolled blood pressure, were on therapeutic doses of anticoagulants, had pre-existing neuropathy >=grade 2, or if informed consent could not be obtained. ",in cycle 1,NA
25818407,NCT00783653,Combination,No,patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations,Patients  with  untreated  newly  diagnosed  AML  aged60 years or older with presence ofFLT3-ITD orFLT3-TKDcould be included in the trial. Determination ofFLT3muta-tional status was carried out within 48 h in the reference lab-oratories at Hannover and Ulm (Germany). Patients wererequired to have an Eastern Cooperative Group (ECOG) per-formance score of 3 or better and adequate organ functions,"Main exclusion criteria were central nervous system leukae-mia, human immunodeficiency virus infection, major cardio-vascular events in the preceding 12 months, uncontrolledhypertension or long QT syndrome",NA,NA
27681866,NCT01029418,Combination,No,patients with advanced hepatocellular carcinoma,"Patients with unresectable BCLC Stage B/C hepatocellular carcinoma that is biopsy-proven ( histology or cytology from prior tumor biopsy specimen is acceptable). Patients without prior systemic treatment ( chemotherapy or molecular targeted therapy) except prior adjuvant therapy, if given more than 6 months ago. Patients who had prior local therapy ( TACE; PEI; RFA) more than 4 weeks prior to study entry. No radiotherapy within 4 weeks before entry. Child-Pugh class A only ( Appendix A). Age 21 years and older. ECOG performance status 0 or 1 ( Appendix A). Life expectancy > 3 months. Patients must have normal organ and marrow function as defined below: Absolute neutrophil count > 1.5 x 109/L;Platelets> 75 x 109/L; Haemoglobin > 9.0g/dl;Total bilirubin < 51umol/L ( 3 mg /dL); AST(SGOT)/ALT(SGPT) < 5 X institutional ULN; Creatinine 1.5 ULN; INR <1.7 or prothrombin time ( PT) <4 seconds above ULN; Left ventricular ejection fraction (LVEF) >50%. Measurable disease according to RECIST. A lesion which has previously been locally treated (including TACE or RFA) is eligible as long as there is evidence of disease progression. Suitable for oral administration of drug. Ability to understand and the willingness to sign a written informed consent document","Prior systemic therapy including sorafenib or a MEK inhibitor or sunitinib or other investigational drugs. Any prior local therapy ( surgery, radiation therapy, hepatic arterial embolization, or cryoablation) within 4 weeks of study entry. Prior liver transplant. NCI CTCAE grade > 3 hemorrhage within 4 weeks of starting study treatment, or documented variceal hemorrhage of any grade within 12 months of study entry (as documented on endoscopy). Presence of esophageal varices (> Grade 2) at risk of bleeding and/or serious or non-healing wound/ulcer ( as documented by endoscopy). History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of study entry. Patients with underlying inflammatory bowel disease, partial or complete bowel obstruction or chronic diarrhea. Any of the following within the 12 months prior to study drug administration: severe/unstable angina, myocardial infarction, coronary artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, including transient ischemic attack, or pulmonary embolism. History of cardiac disease: active congestive heart failure; cardiac arrythmias of NCI CTCAE grade >2 or requiring pacemaker; uncontrolled hypertension; cardiomyopathy; atrial fibrillation rate >100bpm. Patients with factors that increase the risk of QT prolongation or arrhythmic events ( hypokalemia, family history of long QT interval syndrome) or QTc interval of > 450ms for males or > 470ms for females on screening",during the first 28 days of combination therapy,NA
30352941,NCT02024087,Combination,No,Patients with hepatocellular carcinoma (HCC),"Histologically confirmed, locally advanced or metastatic HCC. Child-Pugh Score A (5-6). At least one target lesion that has not been treated with local therapy and is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Life expectancy of at least 12 weeks. Able to tolerate oral therapy. Appropriate clinical laboratory values within 72 hours prior to study day 1: Females of child bearing potential (defined as sexually mature women who have not undergone hysterectomy or bilateral oophorectomy, or are not naturally postmenopausal ≥ 24 consecutive months) must have negative urine or blood pregnancy test prior to enrollment and use adequate birth control methods (abstinence, oral contraceptives, barrier method with spermicide, or surgical sterilization) during study participation. Males must agree to use a latex condom during any sexual contact with females of child bearing potential while participating in the study and for 12 weeks following the last dose of dalantercept, even if he has undergone a successful vasectomy. Patients must be counseled concerning measures to be used to prevent pregnancy and potential toxicities prior to the first dose of dalantercept.","Mixed tumor histology. Prior systemic therapy for metastatic disease. Adjuvant therapy < 6 months prior to study day 1. Prior treatment with dalantercept or other agent targeting the ALK1 pathway. Prior treatment with sorafenib or other RAF/VEGF targeted therapies. Hepatic radiation, chemoembolization, and radiofrequency ablation < 4 weeks prior to study day 1. Palliative radiation therapy to metastatic sites of disease < 2 weeks prior to study day 1. Interferon therapy < 4 weeks prior to study day 1. Uncontrolled Hepatitis B despite appropriate therapy. Clinically significant pulmonary, endocrine, neurologic, hematologic, gastrointestinal (GI), autoimmune, psychiatric or genitourinary disease unrelated to HCC that in the judgment of the investigator should preclude treatment with dalantercept or sorafenib. Known HIV infection. Clinically significant cardiovascular risk. Clinically significant active pulmonary risk. Known active gastrointestinal (GI) bleeding. Known bleeding diathesis Known history of hereditary hemorrhagic telangiectasia (HHT). History of another primary cancer, with the exception of: Curatively resected non melanoma skin cancer. Curatively treated cervical carcinoma in situ. Other primary solid tumor with no known active disease in the opinion of the investigator that will not affect patient outcome in the setting of current HCC diagnosis. Major surgery within 4 weeks prior to study day 1 Active infection Anti-coagulation therapy Concomitant treatment with potent CYP3A4 inducers Peripheral edema ≥ grade 2 within 2 weeks prior to study day 1. History of recurrent ascites requiring paracentesis within 4 weeks of study day 1. History of severe (using the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 4.0 [NCI-CTCAE] v4 current minor version ≥ grade 3) allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients",NA,NA
20109071,NA,Single Drug,No,patients with myelodysplastic syndrome or acute myeloid leukemia,"Patients were eligible if they had AML or MDS (chronic myelomonocytic leukemia orrefractory anemia with excess blasts). One prior chemotherapy regimen (induction with or without consolidation) was permissible, although elderly patients (age >65) or those considered at high-riskof treatment failure or toxicity with standard induction could have had no prior therapy. Eligible patients were age >=18 years, had an Eastern Cooperative Oncology Group (ECOG) performancestatus 0–2, had no requirement for urgent cytoreduction, had adequate renal and hepatic function (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] <=2 times the upper limit ofnormal (UNL), bilirubin <= UNL, creatinine <= UNL).","Patients were excluded if they had documented central nervous system (CNS) involvement, were receiving or were planned for cytotoxic therapy, hadupper gastrointestinal or other conditions that would preclude compliance with   oral medication, wereunable to discontinue drugs known to inhibit cyto-chrome 3A4, had active uncontrolled infection, or if informed consent could not be ensured. ",during the first cycle of treatment,NA
26714427,NA,Combination,No,"refractory or recurrent pediatric solid malignancies. Diagnosis: Embryonal rhabdomyosarcoma 1 (8.3), Ewing sarcoma 3 (25), Fibromatosis 2 (16.7), Neuroblastoma 1 (8.3), Neuroendocrine carcinoma 1 (8.3), Osteosarcoma 4 (33.3)","Patients aged 3–18 years with relapsed or refractory solid tumor malignancies; including central nervous system malignancies and fibromatosis and previously treated with chemotherapy were eligible. Patients needed to have radiologic evidence of disease and were preferred, but not required, to have measurable disease using RECIST 1.1, a life expectancy of at least 12 weeks, no known curative therapy, a Karnofsky or Lansky score ≥50, recovered  from prior therapy, no previous sorafenib therapy, >6 months since prior topotecan, >3 weeks since last myelosuppressive therapy, >7 days since filgrastim and >14 days since pegfilgrastim, >21 days or 4 halflives (whichever is greater) since biologic agent, ≥4 weeks since completion of local palliative irradiation, ≥3 months from prior Total Body Irradiation, craniospinal irradiation, or ≥50 Gy radiation of pelvis, ≥6 weeks for substantial  bone marrow radiation, ≥3 months since Stem Cell Transplant and no evidence of active graft versus host disease along with transfusion and growth factor independence, adequate bone marrow function (absolute neutrophil count ≥1500/μL, platelet count≥100,000/μL, and hemoglobin ≥10 gm/dL), normal serum creatinine for age or a glomerular filtration rate ≥60 mL/min/1.73 m2, bilirubin ≤ upper limit of normal (ULN), alanine transaminase ≤ULN, and all clinically sig-nificant chemistries grade 1 or less with the exclusion of alkaline phosphatase, uric acid, aspartate transaminase, and lactate dehydrogenase, prothrombin time and partial thromboplastin time ≤1.5 X ULN, 12-  lead electrocardiogram with corrected QTc <450 msec, either shortening fraction ≥28% or left ventricular ejection fraction ≥50%, systolic and diastolic blood pressure ≤95% for age and gender (antihypertensive management allowed), no ongoing cardiac dysrhythmias ≥grade 2, atrial fibrillation of any grade, unstable angina, symptomatic congestive heart failure, or myocardial infarction, resting pulse oximetry of ≥92% and no dyspnea at rest. Patients with known bone marrow metastatic disease were eligible but could not be refractory to red blood cell or platelet transfusion. ","Women who were pregnant or lactating, patients with nonhealing wounds/ulcers or bone fractures, and patients with a history of organ allograft were excluded.  ",during cycle 1,NA
26867886,NA,Combination,No,Hepatocellular Carcinoma,"Eligible patients had advanced HCC not suitable for transplant, resection, transcatheter arterial chemo- embolization, radiofrequency ablation, or alcohol ablation, with Child-Pugh class A liver function. The HCC diagnosis was established with biopsy or with typical imaging characteristics in the setting of cirrhosis or chronic hepatitis B or C. Patients had to have >800 mL of uninvolved liver (total liver volume minus gross tumor volume [GTV]) and an Eastern Cooperative Oncology Group performance score <=1. Bilirubin was <1.5 x upper limit of normal (ULN), aspartate aminotransferase or alanine aminotransferase <5 x ULN, international normalized ratio (INR) < 1.3, platelets >=80 x 109/L, neutrophils >=1.5 x 109/L, creatinine <1.5 x ULN or creatinine clearance 60 mL/min/ 1.73 m2, with no bleeding within 2 months of registration","Exclusion criteria included myocardial infarction <6 months, congestive heart failure, unstable angina, active cardiomyopathy, unstable ventricular arrhythmia, previous stroke <12 months, human immunodeficiency virus, anti- coagulant therapy, other active malignancies, bleeding or clotting disorder, and extrahepatic metastases >2 cm.",3 months after SBRT,NA
25294187,NA,Combination,No,"adult patients with advanced solid tumors (RCC, HCC, melanoma, NSCLC, breast cancer, and other: adenocarcinoma of rectum (1), adenocarcinoma of colon (2), adenocarcinoma of esophagus (1), mesothelioma (2) )","Patients were enrolled if they met the following criteria: were 18 years of age or older; had advanced or metastatic solid tumors for which no effective treatment was available; signed informed consent; had Eastern Cooperative Oncology group (ECOG) performance status (PS) ≤1 ; had adequate bone marrow, liver and renal functions; received no previous anticancer therapy within 4 weeks prior to the first day of study drug; had no history of congestive heart failure defined as Class II to IV per New York Heart Association classification or active coronary heart disease; had no previously diagnosed clinically significant bradycardia, other uncontrolled cardiac arrhythmia defined as≥Grade 2 according to CTCAE v. 4.0. 3.0 , uncontrolled hypertension or myocardial infarction within 6 months of first dose of study drugs; had no other significant comorbidities. Patients who were on sorafenib monotherapy treatment could be enrolled at the discretion of the investigators.",NA,within the first cycle,NA
29313954,NCT00329719,Combination,No,patients with recurrent glioblastoma,"Eligible patients had glioblastoma confirmed on cen-tral pathology review before enrollment to the treatmenttrial; one of us (C.G.) performed the central pathologyreview. Patients were aged>=18 years with<=2 prior sys-temic chemotherapy regimens, had radiographically con-firmed tumor progression with an Eastern CooperativeOncology Group performance status <=2, were >=12 weeksfrom the completion of radiotherapy and >=4weeksfromprior cytotoxic chemotherapy (>=6 weeks for nitrosoureas),and had stable or decreasing corticosteroid dose. Patientswere required to have adequate bone marrow function(white blood cell count >=3000/mm3,anabsoluteneutro-phil count >=1500/mm3, platelet count >=100,000/mm3,and hemoglobin>=10/dL), adequate liver function (aspartate aminotransferase <=2.5 and bilirubin<2.0 times theupper limit of normal), adequate renal function (creatinine <=2 times the upper limit of normal), fasting cholesterol<350 mg/dL (9.0 mmol/L), and fasting trigly-cerides<400 mg/dL (4.56 mmol/L). ","Prior intratumoraltherapy was excluded unless there was unequivocal remotetumor progression, as was a history of coagulopathy; useof enzyme-inducing antiepileptic drugs; and any history ofsignificant intratumoral, intracerebral, or subarachnoidhemorrhage. Pregnant women and patients with seriousintercurrent medical illnesses and conditions that couldalter drug metabolism were excluded. Due to the potentialteratogenicity of sorafenib and temsirolimus, all patientsof childbearing potential were required to use adequatebirth control. ",during the first 28 days of treatment,NA
33824476,NCT02115373,Single Drug,No,pretreated advanced hepatocellular carcinoma with MET overexpression,"1.	Histologically confirmed HCC. 2. Child–Pugh Class A liver function score. 3. MET overexpression status, as determined by the central laboratory (in Phase II prospectively for patient selection), defined as MET protein overexpression (moderate [2+] or strong [3+] staining intensity for MET on IHC in the majority [≥50%] of tumour cells). 4.	Availability of a pretreatment tumour biopsy (excluding fine needle aspiration and cytology samples) taken after the patient had discontinued sorafenib and within 28 days before the day of first dosing with tepotinib. 5.	Male or female, 18 years of age or older. 6.	Measurable disease in accordance with RECIST Version 1.1. 7.	ECOG PS 0 to 1 (inclusive). 8.	Previously treated with sorafenib for ≥4 weeks and discontinued sorafenib treatment at least 14 days prior to day 1 due to either intolerance or radiographic progression. 9.	Signed and dated informed consent indicating that the patient had been informed of all the pertinent aspects of the study prior to enrollment. 10.	Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures. 11.	Life expectancy of at least 3 months as judged by the investigator","1.	Prior systemic anticancer treatment for aHCC (except for sorafenib as described in the inclusion criteria). 2.	Prior treatment with any agent targeting the HGF/MET pathway. 3.	Local regional therapy within 4 weeks before day 1 (e.g. surgery, radiation therapy, hepatic arterial embolisation, transcatheter arterial chemoembolisation, chemoembolisation, radiofrequency ablation, percutaneous ethanol injection and cryoablation). 4.	Laboratory index at baseline: haemoglobin ≤8.5 g/dL; neutrophils <1.5 × 109/L; platelets <60 × 109/L; TBL >3 mg/dL; AST or ALT >5 × ULN; serum creatinine ≥1.5 × ULN; calculated CrCl <60 mL/min according to the Cockcroft–Gault formula; international normalised ratio >2.3. 5.	Past or current history of neoplasm other than HCC, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at least 5 years. 6.	Known central nervous system or brain metastasis that was either symptomatic or untreated. 7.	Medical history of difficulty in swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may have hampered compliance and/or absorption of the tested products. 8.	Clinically significant gastrointestinal bleeding within 4 weeks before study entry. 9.	Peripheral neuropathy grade ≥2 (CTCAE Version 4.0). 10.	Impaired cardiac function evidenced by any of the following conditions: left ventricular ejection fraction <45% defined by echocardiograph (screening assessment was not required for patients without a history of congestive heart failure unless clinically indicated); serious arrhythmia; unstable angina pectoris; myocardial infarction within the last 12 months prior to study entry, or pericardial effusion; QTc prolongation >470 ms, risk factors for Torsades de Pointes (Heart Insufficiency NYHA II–IV); hypokalaemia, family history of long QT syndrome. 11.	Uncontrolled hypertension by standard medication (not stabilised to 150/90 mmHg or below).12.	 Known HIV infection. 13.	Known or suspected drug hypersensitivity to any ingredients of tepotinib. 14.	Pregnancy, lactation or patients not of childbearing potential due to being postmenopausal (female patients only), or patients of reproductive potential not willing or able to employ a highly effective method of birth control/contraception to prevent pregnancy from screening until 3 months after receiving the last dose of study drug. A highly effective method of contraception was defined as having a low failure rate (<1% per year) when used consistently and correctly. 15.	Concurrent treatment with non-permitted drug. 16.	Substance abuse, other acute or chronic medical or psychiatric condition or laboratory abnormalities that might have increased the risk associated with study participation at the discretion of investigators. 17.	Prior treatment with tepotinib or other c-Met inhibitors. 18.	 Participation in another interventional clinical study within the 28 days prior to day 1. 19.	Previous anticancer treatment-related toxicities not recovered to grade 0 to 1 or baseline (except alopecia, peripheral neuropathy, and elevated liver enzymes). 20.	History of liver transplant. 21.	Active or uncontrolled infections except chronic HBV, chronic HCV, or both. 22.	Any concurrent medical condition or disease that would potentially compromise the conduct of the study (at the discretion of the investigators)",during the first treatment course ,NA
28465443,NCT01306058,Combination,No,Hepatocellular Carcinoma,"Eligible patients were at least 18 years old with histopathologic confirmation of HCC by the Laboratory of Pathology of the NCI. Other eligibility criteria included: Eastern Cooperative Oncology Group performance status score 0–2; adequate bone marrow, liver, and renal function; disease not amenable to potentially curative liver transplantation, resection or ablative techniques, and progression following or not be amenable to transhepatic arterial chemoembolization (TACE). If liver cirrhosis was present, patients must have had a Child–Pugh A or B (7 points) classification. In addition, patients with cirrhosis were required to have had esophagogastric endoscopy within 6 months prior to study entry for the assessment of varices. Concomitant treatment of underlying cancer was prohibited.",Prior progressive disease on sorafenib was excluded. ,within the first 28 days of treatment,NA
28668472,NA,Combination,No,NA,"Patients had incurable cancer, with a measurable, symptomatic and/or progressive soft tissue lesion in the thorax, abdomen or pelvis. Patients were >=18 years old with prognosis >=3 months, Eastern Cooperative Oncology Group performance status 0–1 and adequate organ and marrow function (Supplementary Material). Organ and Marrow function requirements for inclusion: Leukocytes >=3,000/mcL, Neutrophils >=1,500/mcL, Platelets >=100,000/mcL, Hemoglobin >10 g/dL, Total bilirubin within institutional upper limit of normal (ULN), AST/ALT <=5 times ULN, Creatinine ≤ULN or creatinine clearance >=45mL/min/1.73 m2 if creatinine >ULN, PT-INR/PTT <1.5 times ULN","Exclusion criteria included overlap of planned radiation with previously irradiated volumes, inability to meet RT dose constraints, prior sorafenib, uncontrolled brain metastases and anticancer therapy within 4 weeks of sorafenib. Given potential sorafenib toxicities, patients with poorly controlled hypertension, bleeding disorders and cardiac dysfunction were excluded. Bone-only lesions were excluded, as these were considered non-measurable",during combination therapy or within 8 weeks post-RT,NA
33649501,NCT01128998,Combination,No,"advanced solid tumors. Primary cancer types were colon cancer (4 patients; including one rectal cancer), pancreatic cancer (3 patients), and gastric cancer, gall bladder cancer, cholangiocarcinoma, thymic adenosquamous cell carcinoma, pancreatic neuroendocrine tumor (pNET), and ampulla Vater cancer (one patient each). ","Patients histologically or cytologically proven to have metastatic or locally advanced malignant solid tumors and failed to respond to standard therapy were eligible to participate in this study. Eligible patients were≥20 and≤75 years old, with adequate performance status (ECOG 0–2) and normal hematologic (absolute neutrophil count≥1500/μl, hemoglobin≥9  g/dl, Platelet≥100,000/μl), hepatic (total bilirubin<1.5 times of upper limit of normal (ULN;≤3 X ULN in patients treated by drainage of obstructive jaundice), ALT and AST ≤2.5 X ULN (≤5 X ULN for patients with liver involvement of cancer)), and renal (serum creatinine ≤1 X ULN) functions. Teir life expectancy should also be≥12 weeks. ","Patients who were pregnant, lactating, or presented severe comorbidities (e.g., infection, heart failure, myocardial infarction) within 12 months or known hypersensitivity to any drug component of the treatment regimen were ineligible. ",during the frst and second cycles ,NA
29898591,NCT01942083,Combination,No,Patients with Advanced Hepatocellular Carcinoma,"Patients with HCC, confirmed by a pathological or noninvasive assessment according to the American Association for the Study of Liver Diseases criteria for patients with confirmed cirrhosis, were eligible for inclusion in this study if they met the following criteria: age between 20 and 75 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; extrahepatic metastasis or locally advanced disease not amenable to surgical resection or loco-regional therapies; Child-Pugh classification A or B (except 9); documented evidence of unresponsiveness to, intolerance to, or ineligibility for sorafenib; and estimated life expectancy of 12 weeks or greater.","Past liver transplantation. Uncontrollable hepatic encephalopathy or ascites. Presence of brain metastases. Clinically significant gastrointestinal bleeding in past 6 months or current active gastrointestinal bleeding. Primary malignancy other than HCC. Human immunodeficiency virus (HIV) infection. Severe or poorly controlled complication that may affect the conduct or results of the study. Use of Interferon preparation within 4 weeks (28 days) before start of study treatment in the present study. Pregnant, nursing, or possibly pregnant women, or women desiring to become pregnant during the study period. Other cases judged by the Investigator to be ineligible for participation in the study.",in cycle 1 ,NA
33785364,NCT02046291,Combination,No,"patients >= 18 years old who underwent myeloablative (MA) or nonmyeloablative (NMA) single or double UCBT and did not achieve platelet engraftment by day +28. With respect to underlying diagnosis or disease, 10 patients/controls had AML, five had ALL, three had MDS, one had NHL, and one had MM.",Any patient who has undergone a single or double umbilical cord blood transplant (UCBT) except those with primary myelofibrosis. Those with acute leukemia must be in remission at the time of transplant. Must have achieved neutrophil engraftment (defined as an ANC >500 for three consecutive days) and be off daily G-CSF prior to starting romiplostim. Intermittent G-CSF is allowed. Failure to achieve platelet engraftment (defined as platelet count ≥20x10^9/L on 3 consecutive measurements without transfusion for 7 days) by day +28 post UCBT. Between day +28 and day +42 status post myeloablative or nonmyeloablative UCBT (single or double cord blood transplant). Age ≥ 18 years. Adequate organ function within 7 days of enrollment defined as: Creatinine: ≤ 2.0 mg/dL; Hepatic: SGOT and SGPT < 5 x upper limit of institutional normal (ULN). Women of child bearing potential agree to use effective contraception during therapy and for 4 months after completion of therapy. Voluntary written consent,Known pregnancy - Pregnancy Category C: there are no adequate and well-controlled studies of romiplostim in pregnancy. Recurrence of AML or myelodysplastic syndrome on bone marrow evaluation done within 21 days of enrollment. Presence of clinically significant bone marrow fibrosis on the bone marrow examination immediately prior to UCBT. Patients requiring more than one platelet transfusion per day. History of an allergy to romiplostim,NA,NA
15870716,NA,Single Drug,No,"patients with advanced, refractory solid tumours. The most common forms of cancer werecolon carcinoma (34%), breast cancer (16%), and kidney carcinoma (16%)","A total of 44 patients with advanced, refractory solid tumours were enrolled between December 2000 and December 2002. Eligible patients were at least 18 years of age and had failed curative measures, an Eastern Cooperative Oncology Group (ECOG) performance status of <=2 and a life expectancy of >=12 weeks. These patients also had adequate bone marrow (haemoglobin >=10 mg dl-1, platelets >100 000 mm-3, neutrophils >=2000 mm-3), hepatic (bilirubin <=1.5 x upper limit of normal (ULN), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <=5 x ULN), and renal (serum creatinine <=1.5 x ULN or calculated creatinine clearance >60 ml min-1 function.","Patients with primary or metastatic brain or meningeal tumours were excluded from the study, as were patients with clinically evident congestive heart failure, serious cardiac arrhythmias, or symptoms of coronary heart disease or ischaemia. Patients with serious active infections, and pregnant or lactating women were also excluded from the study. Enrolled patients had not received immunotherapy or chemotherapy within 4 weeks of study entry, or  within 3 weeks of study entry",within the first 28 days,NA
15073100,NA,Combination,No,relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL),"Patients with stage III or IV histologically confirmed CD20+ B-cell NHL in relapse or refractory to prior therapy were eligible for enrollment. Patients with primary central nervous system lymphoma or lymphomatous meningitis were ineligible. Patients had to be at least 18 years of age, have a Karnofsky Performance Score of at least 70%, and provide written informed consent in accordance with Institutional Review Board guidelines. The patient or a personal assistant had to have been willing and able to administer IL-2 by s.c. injection in an outpatient setting. Within 2 weeks before treatment initiation, patients were required to have laboratory values as follows: absolute neutrophil count of >= 1,000/ul, platelet count of >= 75,000/ul, lymphocyte count <= 20,000/ul, serum creatinine <= 1.5 mg/dl, total bilirubin <= 3 mg/dl, and alanine aminotransferase and aspartate aminotransferase levels <	2.5 times institutional upper limits of normal. Women of childbearing age were required to have a negative pregnancy test within 2 weeks of treatment initiation, and all of the patients were to use appropriate contraception while on study. Previous treatment with rituximab was allowed provided it was completed at least 3 months before study entry.","Patients were excluded if they had received prior radioimmunotherapy with ibritumomab tiuxetan or tositumomab, had received IL-2 previously, had a contraindication to receiving rituximab, had a history of type I hypersensitivity to murine proteins, had a previous or concurrent malignancy (except for inactive nonmelanoma skin cancer, cervical carcinoma in situ, or other solid tumor treated curatively and without evidence of recurrence for at least 2 years before study entry), had symptomatic thyroid disease requiring medical intervention other than replacement therapy for hypothyroidism, a history of autoimmune disease, human immunodeficiency virus, clinically significant cardiac, pulmonary, or hepatic disease, or serious active infection, had undergone organ transplantation, allogeneic bone marrow transplant, or had who required cyclosporine or other immunosuppressive medication. Patients could not have had chemotherapy, radiation therapy, or major surgery in the 30 days before treatment.",the 5-week treatment course,NA
27103123,NA,Combination,No,"patients with refractory solid malignancies. Among eighteen patients, five had kidney cancers including one clear cell renal cell carcinoma (RCC), one papillary RCC, one medullary RCC, one mixed cell type RCC (60 % of sarcomatoid component and 40 % clear cell component), and one metastatic kidney angiomyolipoma","Patients of equal or more than 18 years of age, with histologically confirmed malignancy that was metastatic or unresectable and for which standard measures do not exist or no longer effective, with measurable disease by RECIST criteria, adequate hematopoietic with Hgb ≥ 9 g/dl, ANC ≥ 1000/μl, platelet >100,000/μl; liver functions with total bilirubin <1.5 × upper limit normal (ULN), AST/ALT < 3 × ULN; and renal function with serum creatinine ≤2 × ULN, ECOG performance status of 0–1, were enrolled in the study. All subjects had normal cardiac ejection fraction as assessed by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan prior to treatment.",Sexually active men and women with child-bearing potential used acceptable contraceptive methods. Pregnant and nursing patients were excluded from the study.,NA,NA
28988377,NA,Combination,No,recurrent glioblastoma,"Eligible patients were ≥18 years of age with recurrent histologically confirmed WHO grade IV GBM or gliosarcoma. Patients must have unequivocal radiographic evidence of disease recurrence on either MRI or CT. A baseline MRI was obtained within 14 days of treatment on no or stable steroid dosage of at least 5 days. There were no restrictions on the number of recurrences or treatments, but patients must have progressed following prior radiotherapy and be at least 42 days from completion of radiotherapy. Eligibility criteria included Karnofsky performance score (KPS)≥60 and adequate hematologic and organ function.","Patients were excluded if they had received prior sorafenib, vatalanib, AEE-788, or any farnesyl transferase inhibitors, were receiving EIADs, had grade 2 or higher peripheral neuropathy, had histories of allergy to imidazoles, or were pregnant or breastfeeding. Patients were also excluded if they had significant medical illness or any disease that may obscure toxicity or dangerously alter drug metabolism. ",the first 28 days of treatment (cycle 1),NA
31305287,NCT01075113,Combination,No,patients with unresectable hepatocellular carcinoma,"Patients had a diagnosis of HCC by histopathologic or clinical criteria. Eligible patients had a history of cirrhosis or chronic hepatitis B infection and imaging abnormalities > 1 cm in size with classic enhancement by magnetic resonance imaging or triple-phase computed tomography scan. If patients did not have a history of cirrhosis or chronic hepatitis B infection then in addition to imaging abnormalities, elevated alpha-fetoprotein (AFP) (> 20 mg/dL) was required for eligibility. Prior therapies such as surgery, chemoembolization, radiofrequency ablation, and alcohol injection were allowed as long as toxicity from prior therapy was grade (gr) ≤1. Prior treatment with sorafenib was allowed as long as toxicity from ongoing treatment was gr ≤2. Patients were required to have measurable or evaluable disease by response evaluation criteria in solid tumors (RECIST) version 1.1, modified RECIST, or elevated AFP. Eligible patients had to meet the following criteria: age 18 years and above; Eastern Cooperative Oncology Group performance status score ≤1; Child-Pugh classification A; total bilirubin ≤ 3.0 mg/dL; creatinine ≤1.5× the institutional upper limit of normal; hemoglobin levels of ≥8.5 g/dL without transfusion or erythroid-stimulating agents before baseline evaluation; and an absolute neutrophil count of ≥ 1.5×109/L. As the trial progressed, eligibility criteria were modified with the following updates: (1) the hepatic function inclusion criteria were made less stringent for patients with cirrhosis and included patients with Child-Pugh A or B; (2) a platelet count of ≥60×109/L was modified to a platelet count of ≥80×109/L; (3) acceptable international normalized ratio was increased from ≤1.5 to ≤1.7, unless because of anticoagulants; (4) baseline parameters for alkaline phosphatase and alanine aminotransferase/aspartate aminotransferase were removed; (5) baseline minimum leukocyte count requirement was removed; (6) allowing patients with human immunodeficiency virus (unless on highly active antiretroviral therapy); and (7) clarification that hepatic portal vein thrombus was not an exclusion criterion.","Ineligible patients included those who were candidates for curative therapy including surgical resection or orthotopic liver transplantation, known central nervous system metastasis, receipt of any investigational agent within 4 weeks of the first dose of study treatment, known intolerance of vorinostat, inability to swallow medication, suspected malabsorption, active alcohol abuse, contraindication to antiangiogenic agents, thromboembolic or embolic events within the past 6 months, major cardiac dysfunction, systolic blood pressure ≥160 mm Hg or diastolic pressure ≥90 mm Hg despite optimal medical management, significant lung disease (defined as O2 saturation <88% in room air), serious uncontrolled infection, or medical/ psychological/social conditions that, in the opinion of the investigator, would increase the risk to the patient, interfere with the patient’s participation in the study, or hinder evaluation of the study results",during the initial 4-week treatment period,"The patients accrued to date in Cohort B were unable to tolerate therapy, and it has been determined that dose intensification of vorinostat is not possible, despite reducing the dose of sorafenib."
24786603,NCT00884416,Combination,No,patients with newly diagnosed high-grade glioma,"Patients with newly diagnosed high-grade glioma (WHO grade III or GBM) for whom treatment with RT and TMZ was considered medically reasonable were eligible for inclusion in this study. Eligibility criteria further included age >=18 years, ECOG performance status 0–2 and a life expectancy of at least 3 months. Patients were also required to have adequate renal, hepatic, cardiac and bone marrow function and to be on stable or decreasing dose of steroids in the 2 weeks prior to enrolment. All patients with reproductive potential were required to use effective birth control. Patients on stable anticoagulation therapy were allowed to enter the study. Given the primary aim of this phase I study, O6-methylguanine DNA-methyltransferase gene (MGMT) determination was performed in all patients but was not used as the selection or stratification criterion.","Exclusion criteria included having previous or current malignancies at other sites (with the exception of cervical carcinoma in situ, non melanoma carcinoma of the skin, superficial bladder tumour (Ta, Tis and T1) or any cancer curatively treated .3 years prior to study entry), serious medical or psychiatric illness that might interfere with the prescribed treatment, history of HIV infection, chronic hepatitis C or B, having had organ allograft, renal dialysis, as well as prior exposure to Ras pathway inhibitors. Of note, in our institution, all brain tumour patients are treated exclusively with non-enzyme-inducing anti-seizure medication.",until the end of week 10 (completion of RT and a 4 week break period),NA
25711511,NCT01656265,Single Drug,No,Japanese patients with advanced hepatocellular carcinoma,"Patients with advanced HCC who were refractoryto or intolerant to the previous sorafenib treatment and, also,patients who had refused to start a sorafenib treatment wereeligible for the present study. Other inclusion criteria were:age≥20 years, Eastern Cooperative Oncology Group perfor-mance status of 0 or 1, Child-Pugh class A, adequate organfunctions (i.e. neutrophils≥1500⁄lL, platelets ≥60 000⁄lL,hemoglobin ≥9.0 g⁄dL, total bilirubin ≥2.0 mg⁄dL, aspartateaminotransferase and alanine aminotransferase≤5 times theinstitutional upper limit of normal (ULN), serum creatinine≤1.5 times the ULN, prothrombin time⁄international normalized ratio ≥0.8 times to ≤ULN and albumin ≥2.8 g⁄dL) and alife expectancy of ≥3 months.","Exclusion criteria were as fol-lows: prior treatment with a c-Met inhibitor, treatment withanticancer  agents  (including  investigational  drugs)  within2 weeks before enrollment (within 4 weeks before enrollmentif the anticancer agents were antibodies), locoregional thera-pies such as transcatheter arterial chemoembolization or hepa-tic  arterial  infusion  chemotherapy  within  4 weeks  beforeenrollment, a history of liver transplantation, clinically seriousinfection of ≥Grade 3 according to Common Terminology Cri-teria for Adverse Events (CTCAE) version 4.0 (excluding hep-atitis B virus [HBV] and hepatitis C virus [HCV] infection),gastrointestinal disorders potentially affecting the absorption oftivantinib, positive tests for antibodies to human immunodefi-ciency virus, human T-cell lymphotropic virus type I, or both,ongoing interferon therapy for HBV⁄HCV, known symptom-atic brain metastases and pregnancy",during the DLT-observa-tion  period  (Day 1–29),"Patients with either the*2(G681A)or*3(G636A) allele were defined as PM, and others weredefined as EM."
16006586,NA,Single Drug,No,"patients with advanced, refractory solid tumors. Primary tumor type: Colon 17 (41), Ovary 10 (24), Peritoneum 3 (7), Pancreas 3 (7), Kidney 2 (5), Cervix 2 (5), Breast 1 (2), Uterus 1 (2), Pharynx 1 (2), Unknown primary 1 (2)","Patients with documented evidence of incurable advanced, metastatic or recurrent solid tumors refractory to available therapy were enrolled. All patients were heavily pretreated, and met the following criteria: age ‡16 years; Eastern Cooperative Oncology Group performance status £2; life expectancy of at least 12 weeks; presence of clinically and/or radiologically assessable disease; and adequate bone marrow, liver and renal function. All patients gave written informed consent. Additional consent was obtained for biopsies and tumor samples. This study received institutional ethical ap- proval, and was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines.",Individuals who fulfilled any of the following criteria were not eligible for admission to the study: pregnant or lactating women; patients receiving concurrent treatment or treatment within 30 days of screening with other experimental drugs or anticancer therapy; symptomatic or untreated brain metastases; serious illness or medical condition that would not permit the patient to be managed according to the protocol; immunotherapy or chemo- therapy within 4 weeks of study entry; radiotherapy within 3 weeks of study entry; and previous exposure to Raf kinase inhibitors or similar compounds,within the first 28 days,NA
22961690,NA,Single Drug,No,children with neurofibromatosis type I and plexiform neurofibromas,"Patients age >=3 and <=18 years with a clinical diagnosis ofNF1 based on NIH consensus criteria  and presence of aninoperable measurable PN defined as a lesion of >=3 cm measuredin one-dimension that has the potential to cause significantmorbidity  were eligible. Adequate organ function and priortherapy similar to previously published criteria were required. Diastolic blood pressure within 95th percentile for age andgender, no anti-hypertensive medication, and ability to swallowwhole tablets were required. ",NA,during cycles 1–3 ,NA
25239228,NCT01398501,Combination,No,patients with acute myeloid leukemia (AML),"Patients were between the ages of 18 and 75, had a diagnosis of AML with a FLT3-ITD mutation, underwent first allogeneic HSCT, and had an Eastern Cooperative Oncology Group performance status score of 0 to 2. Any conditioning regimen and graft-versus- host disease (GVHD) prophylaxis regimen was allowed and left at the discretion of the treating physician. Donors were 7/8 or 8/8 HLA-matched related or unrelated, double umbilical cord blood, or haploidentical. Stem cell sources were peripheral blood or bone marrow grafts. No pre-HSCT disease status was specified, but patients were only eligible if they were in morphological complete remission by bone marrow biopsy assessment after day +30 and if they had all cell peripheral blood chimerism >= 70% of donor origin. Participants had recovered hematopoietic function defined by absolute neutrophil count >= 1000/mL without growth factor support in the previous 7 days and platelet count >= 50,000/mL without transfusion support in the previous 7 days. ","Patients with recent significant bleeding events, uncontrolled hypertension, serious nonhealing wounds, and active GVHD requiring >= .5 mg/kg/day of prednisone (or equivalent) or therapy beyond systemic corticosteroids were excluded. Use of sorafenib or other FLT3 inhibitors before HSCT was allowed.",the first 28-day cycle,NA
24554062,NCT00805727,Combination,No,patients with locally advanced soft tissue sarcoma of the extremity,"1.	Histologically confirmed soft-tissue sarcoma located on the extremity. a. Intermediate or High grade (NCI grade 2 or 3/3-tier system), > 5 cm in maximal dimension. b. Low grade (NCI grade 1/3-tier system), > 8 cm in maximal dimension. c.	No evidence of regional or distant metastatic disease. 2. Patient must be 18 years of age or older. 3.	Patient must have an ECOG performance status of ≤ 2. 4.	Patient must have adequate bone marrow, liver, and renal function as assessed by the following: a.	Hemoglobin ≥ 8.5 g/dl; b. Absolute neutrophil count (ANC) ≥ 1,500/mm3; c. Platelets ≥ 100,000/mm3; d. Total bilirubin ≤ 1.5 mg/dL. NOTE: Patients with elevated bilirubin secondary to Gilbert’s syndrome are eligible to participate in the study; e. AST and ALT ≤ 2.5 times the institution upper limit of normal (ULN); f. Creatinine ≤ 1.5 times ULN. 5.	Females of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to the start of treatment . NOTE: Postmenopausal women must be amenorrheic for at least 12 months to be deemed not of reproductive potential. 6. Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation.  Men should use adequate birth control for at least three months after the last administration of sorafenib. 7.	Ability to understand and the willingness to sign a written informed consent.  A signed informed consent must be obtained prior to any study specific procedures. 8. INR < 1.5 or a PT/PTT within normal limits. Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate.  For patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable. 9. If patient is a cancer survivor, ALL of the following criteria must apply: a. Patient has undergone potentially curative therapy for all prior malignancies. b. No evidence of any prior malignancies for at least 5 years with no evidence of recurrence (except for effectively treated basal cell or squamous cell carcinoma of the skin, carcinoma-in-situ of the cervix treated by surgery alone, or carcinoma-in-situ of the breast treated by surgery alone). c. Patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies.","1.	Patient is receiving additional cancer-directed therapy at time of entry into trial. 2.	Any prior systemic therapy for sarcoma. 3.	Patient has received or is receiving preoperative investigational treatment. 4.	Patient has congestive heart failure > class II NYHA.  Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months. 5.	Patient has history of cardiac ventricular arrhythmia requiring ongoing anti-arrhythmic therapy. 6.	Patient with a histologic diagnosis of alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, or Ewing’s sarcoma. 7. Patient has uncontrolled hypertension, defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management. 8. Patient has known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C. 9. Patient has active clinically serious infection > CTCAE Grade 2. 10. Patient has thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months. 11.	Patient has history of pulmonary hemorrhage/bleeding event >  CTCAE Grade 2 within 4 weeks of first dose of study drug. 12.	Patient has history of any other hemorrhage/bleeding event  > CTCAE Grade 3 within 4 weeks of first dose of study drug. 13. Patient has history of clinical or laboratory evidence of bleeding diathesis or coagulopathy. 14. Patient has history of major surgery or significant traumatic injury within 4 weeks of first study drug. 15. Patient has concomitant use of St. John’s Wort or rifampin (rifampicin). 16. Previous use or current use of Sorafenib. 17.	Patient has known or suspected allergy to sorafenib or any agent given in the course of this trial. 18. Patient has any condition that impairs his or her ability to swallow whole pills. 19. Patient has active malabsorption problem not controlled with medical therapy. 20.	Indwelling metal that would preclude patient from undergoing DCE-MRI.",from the start of treatment until the date of surgery,Surgical resection occurred day 50–90 of the study
28202227,NCT00892424,Combination,No,patients with liver metastases,"Histologically confirmed liver metastases or histological confirmation of primary cancer with liver lesion(s) consistent with metastases; metastases unsuitable for liver resection; Child-Pugh class (CP) A; no prior upper abdominal radiotherapy or sorafenib; no systemic therapy within 2 weeks; no major surgery within 4 weeks; Karnofsky performance status (KPS) >= 60; bilirubin <= 1.5 times upper limit of normal (ULN), alanine aminotrans- ferase (ALT)/aspartate aminotransferase (AST) <= 5.0 times ULN, platelets >= 100 x 109/L; informed consent.","Patients receiving anti-retroviral/anti-coagulant therapy, or with serious medical comorbidities were excluded. Concurrent use of CYP3A4 inducers was not allowed. No maximal number or size of liver metastases was specified",with a minimum of 3 months follow-up,NA
21246251,NA,Combination,No,Japanese patients with unresectable or metastatic renal cell carcinoma,"Patients with histologically or cytologically confirmed unresectable and/or metastatic RCC or malignant melanoma, refractory to standard treatment, were eligible for inclusion. Additional inclusion criteria included age z18 years; Eastern Cooperative Oncology Group performance status of 0 or 1; life expectancy z12 weeks; and adequate bone marrow, liver, and renal function.","Exclusion criteria included cardiac disease; congestive heart failure or uncontrolled hypertension; cerebral disease; serious infections; cirrhosis; brain tumors; seizure disorder; history of organ allograft; anticancer chemotherapy or hormonal therapy 4 weeks before initiating IFN (i.e., day 14); radiotherapy within 3 weeks of study entry; major surgery within 4 weeks of study entry; or prior exposure to Ras, MEK, or VEGF pathway inhibitors.",in Cycle 1,NA
21954442,NA,Single Drug,No,patients with recurrent or progressive malignant glioma,"Criteria required for entry into the study included: age ≥18 years; histologically proven malignant glioma (glioblastoma multiforme, anaplastic astrocytoma, or anaplastic oligodendroglioma); progressive or recurrent tumor after radiation therapy with or without chemotherapy; measurable tumor by MRI or CT imaging; complete recovery from toxicity of previous therapies; 3 months from completion of radiation therapy to study entry; ≤2 prior chemotherapy regimens; KPS ≥60%; and Mini Mental State Exam score ≥15. Eligibility also required demonstrating acceptable hematological parameters (absolute neutrophil count ≥1500/mL; platelet count ≥100 000/mL; normal coagulation tests), renal function (serum creatinine ≤1.7 mg/dL), and hepatic function (total bilirubin ≤1.5 mg/dL; serum levels of aspartate aminotransferase and alanine aminotransferase ≤4 times the upper limit of normal). Agreement to practice adequate birth control methods was required for fertile patients. Each patient was required to sign a written informed consent document, satisfying all federal and institutional policies and regulations, as a condition of registering for participation in the study. ","Conditions resulting in exclusion from the study included: a serious concurrent infection, illness, or medical condition; females who were pregnant or nursing; any concurrent cancer therapy except for corticosteroids; a concurrent malignancy or a prior neoplasm that had been curatively treated with a disease-free interval ,5 years; evidence of bleeding diathesis; or requirement for therapeutic anticoagulation.",during the initial 28-day cycle of therapy,NA
30478190, NCT01296581,Single Drug,No,"Patients with Advanced Solid Tumors. Cancer Types or Histologic Subtypes Breast, 1 (2%), Lung, non-small cell, 1 (2%), Lung, small cell, 2 (4%), Ovarian - platinum sensitive, 3 (6%), Ovarian - primary platinum resistant, 2 (4%), Ovarian - secondary platinum resistant, 2 (4%), Ovarian - platinum refractory, 3 (6%), Pancreatic, 1 (2%), Endometrial, 6 (12%), Colorectal, 8 (15%), Sarcoma, 2 (4%), Renal, 3 (6%), Gastrointestinal stroma, 1 (2%), Other*, (Carcinoid (3, 6%); cervical (2, 4%); clear cell ovary; gastric, Hurthle cell carcinoma of right thyroid; liver; melanoma; neuroendocrine carcinoid tumor; parotid gland; squamous cell carcinoma of the vulva; thyroid; unknown primary; uterine; and vagina (1 patient each, 2%))","Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy that is not responsive to standard therapies or for which there is no effective therapy. Expansion Cohort Phase: Histologically or cytologically confirmed recurrent serous or clear cell epithelial ovarian adenocarcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma for which there is no available curative standard therapy, in the investigator's opinion. Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1. Life expectancy of at least 12 weeks. Ability to swallow and retain oral medication. Adequate organ system function. Male patients willing to use adequate contraceptive measures. Female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures and who have a negative serum or urine pregnancy test within 24 hours prior to initial trial treatment. Patients must have measurable or evaluable disease. Expansion Cohort Phase: Patients with serous histology must have a CA 125 level ≥ 2x ULN within 14 days prior to the start of X-82. Patients with elevated CA 125 levels at baseline are not required to have measurable disease by RECIST criteria. Patients with clear cell histology that do not have an elevated CA 125 level must have measurable disease. Patients must be ≥ 18 years of age. Patients entering this study must be willing to provide tissue from a previous tumor biopsy (if available) for correlative testing. If tissue is not available, a patient will still be eligible for enrollment into the study. For the expansion cohort, patients will also be requested, but not required, to undergo a pre-treatment biopsy. Willingness and ability to comply with trial and follow-up procedures. Ability to understand the nature of this trial and give written informed consent.","Patients currently receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy [with the exception of LHRH agonists for prostate cancer], surgery and/or tumor embolization). Use of an investigational drug within 21 days or 5 half-lives (whichever is shorter) prior to the first dose of X-82. A minimum of 10 days between termination of the investigational drug and administration of X-82 is required. In addition, any drug-related toxicity should have recovered to grade 1 or less. Any major surgery, radiotherapy, or immunotherapy within the last 21 days (limited palliative radiation is allowed ≥2 weeks). Chemotherapy regimens with delayed toxicity within the last 4 weeks (or within the last 6 weeks for prior nitrosourea or mitomycin C). Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks. Patients with a known allergy or delayed hypersensitivity reaction to drugs chemically related to X-82 (sunitinib, sorafenib or pazopanib) or to the active ingredient of X-82. Concomitant use of drugs with a risk of causing prolonged QTc and/or Torsades de Pointes. Concomitant use of herbal medications (i.e. St. John's wort, Kava, ephedra (ma huang), ginko biloba) at least 7 days prior to the first dose of study drug and throughout participation in the trial. Patients with known CNS metastases, unless metastases are treated and stable and the patients do not require systemic steroids. Treatment with therapeutic doses of coumarin-type anticoagulants (maximum daily dose of 1mg allowed for port line patency permitted). Low molecular weight heparin (LMWH) will be allowed. Females who are pregnant or breastfeeding. Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of X-82. Decreased left ventricular function at study entry defined as LVEF <50% by either Echocardiogram or MUGA scan. Patients who have previously experienced myocardial infarction, severe/unstable angina, coronary/peripheral arterial bypass, symptomatic congestive heart failure (New York Heart Association [NYHA] Class 3 or 4), arterial thrombosis, cerebrovascular accident, or transient ischemia, in the 60 days prior to Day 1 of Cycle 1. Patients with inadequately controlled hypertension (defined as BP > 150/100) with or without current antihypertensive medications. Patients with a history of additional risk factors for Torsades de Pointes (e.g. familial long QT syndrome, heart failure, left ventricular hypertrophy, slow heart rate (<45 bpm). Patient with a QTcF interval ≥450 msecs or other significant ECG abnormalities as determined the investigator. A serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol. Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol. Patients with a history of intolerance to, or significant toxicity with, VEGFR tyrosine kinase inhibitor(s) (TKI). Patients entering the expansion after the determination of MTD are limited to previous treatment with one anti-VEGFR TKI",during Cycle 1,NA
23099651,NA,Combination,No,recurrent glioblastoma or gliosarcoma,"Adults (≥18 y old) with histologically confirmed GBM or gliosarcoma with unequivocal tumor recurrence by MRI scan were eligible. A baseline MRI was performed within 14 days of registration on a stable steroid dosage for ≥5 days. Patients must have had progressive disease following prior radiotherapy and have had an interval of ≥42 days from the completion of radiotherapy to study entry. Phase I patients may have had any number of prior relapses; phase II patients may have had treatment for no more than 2 prior relapses. Additional eligibility criteria included Karnofsky performance score ≥60, life expectancy ≥8 weeks, adequate bone marrow function (absolute neutrophil count ≥1500/mm3, platelet count ≥100 000/mm3, hemoglobin ≥10/dL), adequate liver function (alanine aminotransferase and alkaline phosphatase ≤2 times the upper limit of normal; bilirubin <1.5 mg/dL), adequate renal function (blood urea nitrogen or creatinine ≤1.5 times the upper limit of normal), fasting cholesterol <350 mg/dL (9.0 mmol/L), and fasting triglycerides <400 mg/dL (4.56 mmol/L). Due to potential teratogenicity of sorafenib and temsirolimus, all patients of childbearing potential were required to use adequate birth control.",Patients receiving any enzyme-inducing antiepileptic drugs were excluded. Pregnant women and patients with serious intercurrent medical illnesses and conditions that could alter drug metabolism were excluded.,during the first 28 days of treatment,NA
27992451, NCT00764972,Combination,Yes,patients with Metastatic Breast Cancer,"Women at least 18 years of age with histologically proven metastatic breast cancer and a life expectancy over 6 months were eligible for the study. Inclusion criteria included: HER-2 negative disease as defined by local testing, measurable disease by RECIST 1.0 criteria; ECOG performance status of 0–1, adequate bone marrow reserve, as well as normal heart, kidney and liver functions (creatinine <=1.5 UNL, bilirubin <=1.5 UNL, AST/ALT <=2 UNL and a baseline left ventricular ejection fraction (LVEF) of at least 50%).","Patients were excluded if they received previous chemotherapy for metastatic disease, any previous therapy with vinorelbine or any anti-angiogenic therapy, any breast cancer treatment in 4 weeks preceding enrolment, known central nervous system metastases, previous history of ischemic cardiovascular disease or thromboembolic events, and other uncontrolled relevant medical conditions.",NA,NA
33646489,NA,Combination,No,patients with advanced hepatocellular and renal cell carcinomas,"Patients recruited were age 18 years and older, had cytological or histological confirmed diagnosis of advanced hepatocellular or renal cell carcinoma with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. HCC patients had Child Pugh A or B7 liver disease and were not amenable to surgery or orthotopic liver transplant. Patients with prior first-line treatment with sorafenib were allowed. RCC patients had received standard approved first-line therapy only. Adequate blood and organ function, as well as measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 were required for inclusion.","Patients were excluded if they had active malignancy within 3 years prior to registration, were pregnant or nursing women, had inadequately controlled hypertension, prolonged QTc >500 msec on baseline electrocardiogram, fibrolamellar histology HCC or mixed hepatocholangiocarcinoma, hepatic sarcomas and other non-HCC primary liver tumors (See S2 for full protocol).",in cycle 1 ,NA
21594722,NA,Combination,No,patients with advanced hepatocellular carcinoma,"Men and women C18 years of age, of any racial or ethnic background with advanced-stage, histologically confirmed HCC with at least one measurable lesion by RECIST 1.1 , that was suitable for treatment with sorafenib, but had not received any prior systemic therapy were eligible. Patients were required to have an ECOG performance status of 0 or 1; a Child-Pugh score A; adequate hematologic function (ANC >= 1.5 z 109/L; platelet count >= 100 z 109/L; hemoglobin >= 8.5 g/dL maintained in the absence of red blood cell transfusions; and international normalized ratio <=1.7; or prothrombin time <=2 s above control); adequate hepatic function (albumin >= 2.8 g/dL; total bilirubin <= 2 mg/dL; and alanine aminotransferase and aspartate aminotransferase <=5 times the upper limit of the normal range); and adequate renal function (serum creatinine <=1.5 times the upper limit of the normal range or creatinine clearance >=60 mL/min).",Patients with serious inter-current illnesses were excluded.,during the first cycle of PR-104,NA
33972742,NCT01988493,Single Drug,No,Asian patients with advanced hepatocellular carcinoma with MET overexpression,"Histologically or cytologically confirmed HCC. Intermediate HCC of BCLC stage B, who were not eligible for surgical and/or local-regional therapies* or who had PD after surgical and/or local-regional therapies*, or advanced HCC of BCLC stage C. A tumor biopsy (excluding fine-needle aspiration and cytology samples) was required for determining MET status (a fresh pretreatment tumor biopsy was recommended but an archived tumor sample was acceptable). Child–Pugh class A with no encephalopathy at screening. Asian male or female patients ≥18 years of age. ECOG PS of 0 or 1. Signed and dated informed consent indicating that the patient had been informed of all the pertinent aspects of the study before enrollment. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. Life expectancy of ≥3 months as judged by the investigator. PD or intolerance to prior standard treatment for advanced HCC (Korean patients only)","Prior treatment with any agent targeting the HGF/MET pathway. Prior local-regional therapy within 4 weeks prior to day 1 of study treatment (e.g. major surgery, radiation therapy (with the exception of palliative bone-directed radiotherapy† and radiotherapy administered to superficial lesions), hepatic arterial embolization, transcatheter arterial chemoembolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation). History of liver transplant. Laboratory index at baseline: Hemoglobin ≤8.5 g/dL (without transfusion or growth factor support in the preceding 14 days); Neutrophils <1.5 × 109/L; Platelets <60 × 109/L (without transfusion or growth factor support in the preceding 7 days); Total bilirubin >3 mg/dL; Aspartate aminotransferase/alanine aminotransferase >5 × ULN; Renal impairment as evidenced by serum creatinine ≥1.5 × ULN, or calculated CrCl <60 mL/min by Cockroft–Gault formula (24-hour CrCl could be requested by the investigator for confirmation, if calculated CrCl was <60 mL/min. In such cases, patients with 24-hour CrCl <60 mL/min were to be excluded) CrCl (〖ml∙min〗^(–1) )=  (140-age (years)  ×weight (kg))/(72 ×serum creatinine (mg∙ 〖dL〗^(–1)))  [×0.85 for women]; International normalized ratio >2.3 (in accordance with the guidance that was modified for Child–Pugh classification); Albumin <28 g/L (without transfusion in the preceding 14 days). Past or current history of neoplasm other than HCC, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for ≥5 years. Known central nervous system or brain metastasis that was either symptomatic or untreated. •	Medical history of difficulty swallowing, malabsorption, or other chronic GI disease, or conditions that could have hampered compliance and/or absorption of the tested products. Clinically significant GI bleeding within 4 weeks before day 1 of study treatment. Impaired cardiac function: Left ventricular ejection fraction <45% on recent echocardiography; Serious arrhythmia; Unstable angina pectoris; Congestive heart failure New York Heart Association III and IV; Myocardial infarction within the 12 months before day 1 of study treatment; Pericardial effusion. Hypertension uncontrolled by standard therapies (not stabilized to ≤150/90 mmHg). Family history of long QT syndrome, or treatment with any agent known to prolong QT/QTc interval, or with a marked prolongation of QT/QTc interval (e.g. repeated demonstration of a QTc interval >450 ms). Known human immunodeficiency virus infection. Acute pancreatitis and/or chronic pancreatitis, with elevated lipase and/or amylase, clinical symptoms, and/or imaging studies indicative of the diagnosis (mainland Chinese patients only). Known or suspected drug hypersensitivity to any ingredients of tepotinib. Pregnancy or lactation (female patients only), or patients of reproductive potential not willing or able to employ a highly effective method of birth control/contraception to prevent pregnancy from 2 weeks before receiving study drug until 3 months after receiving the last dose of study drug. A highly effective method of contraception was defined as having a low failure rate (<1% per year) when used consistently and correctly. Concurrent treatment with a non-permitted drug. Substance abuse, other acute or chronic medical or psychiatric condition, or laboratory abnormalities that could have increased the risk associated with study participation in the opinion of the investigator. Participation in another interventional clinical study within the 28 days before day 1 of study treatment or within a time period that was less than the cycle length for the investigational treatment (whichever was shorter), or if the patient had any adverse event caused by the investigational treatment that was not recovered to grade 1 or less. •	Previous anticancer treatment-related toxicities not recovered to baseline or grade 0 to 1 (except alopecia). Any concurrent medical condition or disease that would potentially compromise the conduct of the study (at the discretion of the investigators). Clinically significant third space fluid accumulation despite the use of diuretics (e.g. moderate-to-large ascites that required tapping, or pleural effusion that either required tapping or resulted in shortness of breath). Complete occlusion of the major portal vein or vena cava due to HCC (the major portal vein was defined as the part of portal vein between the union of the splenic and superior mesenteric veins and the first bifurcation into the left and right vein)",during Cycle 1,NA
11304768,NA,Single Drug,No,chronic lymphocytic leukemia.  patients with either CLL (n = 40) or other mature B-cell leukemias (n = 10),"Entry criteria required the following: (1) confirmation of the diagnosis, (2) normal renal (creatinine < 2.0 mg/100 mL) and hepatic (bilirubin < 2.0 mg/100 mL) function, and (3) a performance status <= 3 (Zubrod scale). Patients with CLL in Rai stages III to IV were eligible. Patients with stages 0 to II disease were eligible if they had evidence of active disease as indicated by an increase in symptoms related to leukemia including weight loss of >= 10% over a 6-month period, temperature of 38°C or greater without evidence of infection, extreme fatigue, massive or progressive hepatosplenomegaly, or massive or progressive lymphadenopathy.",NA,NA,NA
32634234,NCT01787552,Combination,No,JAK inhibitor-naive patients with myelofibrosis (MF),"Patients were 18 years or older diagnosed with primary myelofibrosis (PMF), postpolycythemia vera (PV) MF, or post- essential thrombocythemia (ET) MF, per the 2008 World Health Organization criteria for PMF and the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria for post-PV MF and post-ET MF. Patients were ineligible or unwilling to undergo stem cell transplantation; the assessment was made by the treating physician as significant proportion of patients were either not in the transplant age group or ineligible due to associated medical conditions or not interested in transplant based on their preferences. Platelet count ≥75 x 109/L not achieved with aided transfusions. Absolute neutrophil count >1.5 x 109/L. International normalized ratio <1.5.  Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 2. Palpable splenomegaly defined as ≥ 5 cm below the left costal margin. Patients were classified as intermediate risk level 1, intermediate risk level 2, or high risk","Previous therapy with Janus kinase (JAK) inhibitors and smoothened (SMO) inhibitors. Patients with inadequate organ function including encephalopathy (≥grade 1), hepatocellular disease, total bilirubin ≥2 x upper limit of normal (ULN), alanine aminotransferase >3 x ULN, Modification of Diet in Renal Disease estimated glomerular filtration rate <30 mL/min/1.73 m2 or on dialysis, creatine phosphokinase >1.5 x ULN. Patients with impaired cardiac function, active malignancy, and acute bacterial infections ",in the first 6 weeks of treatment,NA
16061863,NA,Single Drug,No,"patients with advanced, refractory solid tumors","Patients ages >=18 years were eligible for enrollment in this study if they had documented evidence of incurable, advanced, metastatic, or recurrent solid tumors that are refractory to available therapy. Additional enrollment criteria included Eastern Cooperative Oncology Group performance status of 0, 1, or 2; life expectancy of at least 12 weeks; and adequate bone marrow (hemoglobin >9.0 g/d, neutrophils >1,500/mm3, platelets >75 000/mm3), hepatic (bilirubin <1.5 x upper limit of normal, alanine aminotransferase, and aspartate aminotransferase <2.5 x upper limit of normal), and renal (serum creatinine <1.5 x upper limit of normal) function. All patients gave written informed consent. Patients were eligible if they had received prior adjuvant chemotherapy, or had up to three prior chemotherapy regimens for metastatic disease.","Exclusion criteria included the following: treatment within 4 weeks of study entry with other chemotherapy or immunotherapy; radiotherapy within 3 weeks of study entry; biological response modifiers within 3 weeks of study entry; bone marrow transplant or stem cell rescue within 4 months of study entry; investigational drug therapy within 4 weeks of study entry; use of ketoconazole, itraconazole, ritonavir, or grapefruit juice; previous exposure to Ras pathway inhibitors; pregnant or lactating women; or substance abuse. Individuals who had any of the following medical conditions were also excluded: clinically evident congestive heart failure; serious cardiac arrhythmias; symptoms of coronary heart disease or ischemia on a cardiac stress test, present either at screening or by history; history of HIV, or chronic hepatitis B or C; active infections; brain metastases; history of seizure disorder; or history of organ allograft.",NA,NA
23519998,NA,Combination,No,hepatocellular carcinoma,"Patients were recruited and treated at the UCSF Helen Diller Family Comprehensive Cancer Center and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The principal inclusion criteria were: radiographic  or histologic diagnosis of American Joint Committee on Cancer (AJCC) stage II, III, or IV HCC not eligible for curative therapies; no prior systemic therapy; Child Pugh A or B with ≤7 points; Eastern Cooperative Oncology Group (ECOG) performance status ≤2; measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; ≥6 weeks since prior liver-directed therapy or resection; co-treatment with antiviral therapy if active HBV; and adequate organ function (absolute neutrophil count ≥1500/mcl, platelet count ≥75 000/mcl, total bilirubin ≤1.5 times upper limits of normal (ULN), AST/ALT less than five times ULN, INR ≤1.5 times ULN, albumin ≥2.8 g/dl).","The exclusion criteria included mixed histology, transplantation, HIV, and uncontrolled blood pressure, diabetes, or hyperlipidemia",during cycle 1,NA
25145500,NA,Combination,No,patients with advanced extremity melanoma ,"Patients were eligible for study if they were C18 years of age, had histologically confirmed recurrent American Joint Committee on Cancer stage IIIB, IIIC, or IV extremity melanoma, experienced treatment failure or disease recurrence after a previous LPAM-based regional chemotherapy (ILI or HILP), had directly measurable cutaneous disease distal to planned tourniquet placement, had an Eastern Cooperative Oncology Group performance status of 0 or 1, and had a palpable pulse in the affected extremity. All patients underwent whole-body positron emission tomography/computed tomography within 6 weeks of ILI to evaluate the presence of macroscopic disease, which would make the patient ineligible for the study. ",NA,up to 15 days after ILI (isolated limb infusion),NA
23554030,NCT01076530,Combination,No,children with refractory or recurrent CNS malignancies,"Patients older than 12 months and <=21 years with refractory orrecurrent primary brain or spinal cord tumors for which therewas noknown curative therapy were eligible for this trial. Tumors had tomeasurable or evaluable by imaging and histological verification ofmalignancy was required except for patients with diffuse intrinsicbrain stem tumors, optic pathway gliomas, or patients with pinealtumors and elevations of CSF or serum tumor markers includingalpha-fetoprotein or beta-HCG. Other eligibility criteria included: aLansky or Karnofsky score >=50; recovery from the acute toxiceffects of prior therapy; and at least 7 days from prior growth factortherapy; 3 weeks from myelosuppressive chemotherapy (6 weeks ifprior nitrosourea), 6 months from craniospinal or total bodyirradiation, 2 weeks sinc local palliative radiotherapy, and 2 weekssince prior therapy with valproic acid (another HDAC inhibitor). Patients who were on corticosteroids mustbe taking a stable or decreasing dose for 7 days prior to enrollment.Prior treatment with TEM was allowed, provided there was nodisease progression during or within 1 month after that treatment. Other requirements included adequate bone marrow function(peripheral absolute neutrophil count >=1,000/ul, platelet count >=100,000/ul, transfusion independent, and hemoglobin >=8.0 g/dl),renal function (age-adjusted normal serum creatinine or GFR >=70 ml/min/1.73 m2),  liver  function  (total  bilirubin <=1.5 x institutional upper limit of normal for age, ALT <=110 U/L, andalbumin >=2 g/dl).","Patients were excluded if they were pregnant, lactating women, hadan uncontrolled infection, were receiving enzyme-inducing anti-convulsants, had a QTc >450 milliseconds or were previously treated with vorinistat. ",the first cycle of therapy,NA
28295182,NCT01403415,Combination,No,children and adolescents with second or greater relapse of ALL,"Patients≥1 and<22 years of age in second or greater relapseof ALL were eligible. Relapsed leukaemia was defined as>25% blasts in bone marrow (M3) or 5–25% blasts in bonemarrow  (M2)  with  evidence  of  extramedullary  disease. Eligibility criteria included a Lansky/Karnofsky performance score ≥50, recovery from acute toxic effects of priortherapy and lack of active infections. Patients had to be≥2 weeks from prior cytotoxic therapy with the exception ofmaintenance-type ALL therapy for which there was no wash-out period or a single intrathecal methotrexate within 72 hof systemic therapy initiation. Patients had to be≥7 daysfrom short-acting growth factor therapy or≥14 days if long-acting,≥7 days from biological  therapy, >42 days fromimmunotherapy and >3 half-lives from prior therapy with amonoclonal antibody. Patients had to be ≥3 months from prior HSCT and without evidence of graft-versus-host dis-ease. At least 2 weeks from local radiation had to haveelapsed. Patients receiving corticosteroids must have beentaking a stable or decreasing dose for 7 days prior to enrol-ment. Hydroxycarbamide (hydroxyurea) use was permitteduntil 24 h prior to the first dose of study chemotherapy.Other eligibility requirements included a normal age-adjusted serum creatinine or glomerular filtration rate ≥70 ml/min/1.73 m2, normal cardiac function defined byshortening fraction ≥27% or ejection fraction ≥50%, ade-quate pulmonary function with a baseline oxygen saturation>94% on room air, and adequate liver function defined astotal bilirubin≤1.5 x the institutional upper limit of normalfor age, normal gamma-glutamyltransferase (GGT) for age, alanine aminotransferase ≤22 u/l and albumin ≥20 g/l. Serumtriglyceride and cholesterol were required to be ≤3.89 and 7.77 mmol/l, respectively, and a fasting glucose had to bewithin normal limits for age.",Patients with an isolated central nervous system relapse orextramedullary disease requiring immediate radiation therapywere not eligible.,cycle 1,NA
26235333,NA,Single Drug,No,Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma,"Patients>12 months of age and diagnosed before the age of 21with histologically proven neuroblastoma and confirmation ofrefractory or recurrent disease or medulloblastoma with histologicconfirmation at diagnosis or at the time of recurrence/progressionwere eligible for this study. Residual abnormal tissue at a primary ormetastatic site must have measured more than 1 cm in any dimensionby standardized imaging (CT or MRI) for measurable disease or forpatients with only skeletal disease neuroblastoma, there must havebeen at least two persisting skeletal foci on123meta-iodobenzylgua-nidine (MIBG) follow-up scans. Patients without bone marrowmetastases were requiredto have an ANC >750/ul and platelet count >50,000/ul. Patients had to demonstrate adequate liver function asdefined by total bilirubin <=1.5 x upper limit of normal (ULN) for ageand SGPT (ALT) <10 xupper limit of normal for age and a bilirubin <1.5 mg/dl ULN for age and no other significant organ toxicitydefined as >Grade 2 by National Cancer Institute Common ToxicityCriteria for Adverse Events version 3 (NCI-CTCAE v3.0)",NA,within 30 days of taking study drug,NA
25467181,NA,Combination,No,"Children with Recurrent Solid Tumors. Diagnosis: Rhabdomyosarcoma 9, Osteosarcoma 6, Ewing sarcoma 5, Malignant glioma (including GBM) 4, Medulloblastoma 2, Wilms tumor 2, Desmoplastic small round cell tumor 2, Astrocytoma NOS 1, Choroid plexus papilloma 1, Neuroblastoma 1, Neurilemmoma 1, Ganglioneuroblastoma 1, Gastrointestinal stromal tumor 1, Hepatocellular carcinoma 1, Atypical teratoid rhabdoid tumor 1, Epithelioid sarcoma 1","Patients >12 months and <22 years with measurable or evaluable solid tumors refractory to therapy were eligible. Histologic verification of malignancy was required except for patients with intrinsic brainstem glioma. Other eligibility criteria included Lansky or Karnofsky score >=50; recovery from the acute toxic effects of prior therapy; >=3 months since total body irradiation, craniospinal or hemi-pelvic radiation, and >=2 months since a stem cell transplant; adequate bone marrow function [peripheral absolute neutrophil count (ANC) >= 1,000/uL, platelets >= 100,000/uL (transfusion independent), hemoglobin >= 8.0 g/dL]; adequate renal function (age-adjusted normal serum creatinine or a glomerular filtration rate >= 70 mL/min/1.73 m2); adequate liver function [total bilirubin <= 1.5 x institutional upper limit of normal for age, SGPT (alanine aminotransferase, ALT) <= 5 x institutional upper limit of normal for age and albumin >= 2 g/ dL]; prothrombin time and international normalized ratio < 1.2 x upper limit of normal. Patients receiving corticosteroids had to be on a stable or decreasing dose for >=7 days before study enrollment.","Patients were excluded if they had known bone marrow involvement; had received prior temsirolimus or monoclonal antibody therapy targeting IGFIR; were pregnant or lactating; had an uncontrolled infection; were receiving enzyme inducing anticonvulsants (EIACD), insulin, growth hormone therapy, or any of the following CYP3A4 inducers or inhibitors: erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice, or St. John's wort or other noncytotoxic anticancer agents. Also excluded were patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to cixutumumab or temsirolimus, or patients who had undergone major surgery within 6 weeks before study enrollment.",during the first 28-day cycle,NA
24194293,NA,Combination,No,patients with glioblastoma multiforme,"Patients were required to have adequate bone marrow (absolute neutrophil count >=1,500 per mm3, platelet count >=100,000 per mm3), renal (serum creatinine <1.5 times the upper limit of normal) and hepatic function (serum AST or ALT <2 times the upper limit of normal, serum bilirubin <1.5 mg/dl). Patients who were receiving corticosteroids had to be receiving a stable or decreasing dose for at least 14 days before randomization. All patients with reproductive potential must have been using effective contraception","Exclusion criteria included infection with HIV, any prior cranial radiotherapy, pregnant or lactating women, or having received any other investigation agents during or within 1 month prior to treatment. Patients receiving the following drugs that are contraindicated with NFV were excluded: antiarrhythmics (amiodarone, quinidine), antimycobacterial (rifampin), ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), herbal products (St. John’s wort), HMG-CoA reductase inhibitors (lovastatin, simvastatin), neuroleptic (pimozide), and sedatives/hypnotics (midazolam, triazolam). Patients receiving the following drugs were clinically evaluated as to whether dosage/medication could be changed to permit the patient on study: anti-convulsants (carbamazepine, phenobarbital, phenytoin), anti-mycobacterial (rifabutin), erectile dysfunction agent (sildenafil), HMG-CoA reductase inhibitor (atorvastatin), immunosuppressants (cyclosporine, tacrolimus, sirolimus), narcotic analgesic (methadone), oral contraceptive (ethinyl estradiol), and macrolide antibiotic (azithromycin).",within 1 month of chemoradiotherapy,NA
28004284,NA,Combination,No,"patients with advanced solid tumors. Colorectal 9 (31), Ovarian 6 (21), Non-small cell lung 3 (10), Renal 2 (7), Pancreatic 2 (7), Cholangiocarcinoma, bladder, endometrial, tongue, esophageal, liposarcoma, carcinosarcoma 1 each (24).","Eligible patients were at least 18 years old with histologically confirmed advanced solid malignancy for which standard curative or palliative systemic therapies did not exist or were no longer effective. All patients were required to have measurable or evaluable disease, Eastern Cooperative Oncology Group performance status of 0–2, life expectancy of at least 12 weeks as well as adequate renal, liver and bone marrow reserve [defined as serum creatinine within institutional normal limit or creatinine clearance ≥60 mL/min/1.73 m2; aspartate transaminase/alanine transaminase <2.5 x upper limit of normal (ULN) and total bilirubin <1.5 x ULN that was later updated as per package insert (version 8/2014) to allow patients with mild hepatic impairment (bilirubin >1–1.5 x ULN or aspartate transaminase > ULN but bilirubin ≤ ULN) to receive temsirolimus at a reduced dose of 15 mg/week; hemoglobin ≥9 g/dL, total white blood count ≥3.000/μL, absolute neutrophil count ≥1.500/μL and platelet count ≥100.000/μL]. In addition, patients were required to have normal phosphorus levels and a metabolic profile within normal limits (defined as fasting glucose ≤150 mg/dL, fasting cholesterol ≤350 mg/dL and fasting triglycerides ≤300 mg/dL). Patients with brain metastasis were allowed to enroll as long as their brain disease was treated and under control. Women of child-bearing potential were required to use adequate contraception.","Key exclusion criteria included recent treatment with chemotherapy, radiotherapy or endocrine therapy, incompletely resolved adverse events due to agents administered more than 4 weeks prior to study entry, previous anticancer therapy with mTOR or c-Met inhibitors, HIV infection, uncontrolled diabetes, clinically symptomatic hypothyroidism as well as history of allergic reactions attributed to compounds of similar chemical or biologic composition to tivantinib or temsirolimus. Concurrent use of CYP2C19 sensitive substrates, inducers or moderate/strong inhibitors as well as CYP3A4/5 inducers or moderate/strong inhibitors was prohibited.",between the first dose and the first day of cycle 2,NA
11302252,NA,Combination,No,Glioblastoma,"Eligibility requirements for this study included a histologic diagnosis of cancer (excluding leukemia) that was considered refractory to standard therapy. Prior radiotherapy must have been completed at least 6 weeks before registration, and prior chemotherapy must have been administered at least 4 weeks before registration. All toxicities from prior treatment must have resolved. No more than one prior chemotherapy regimen was permitted, and no prior treatment with nitrosoureas was permitted. At registration, patients must have had a performance status of 0–2 by Southwest Oncology Group criteria, adequate bone marrow reserve (absolute neutrophil count >1799/liter, platelets >124,000/liter, and hemoglobin >8.9 g%), a serum creatinine of <1.5 mg/dl (or a creatinine clearance of >70 ml/min), a serum bilirubin of <1.5 mg/dl, and a serum SGOT of <2 times the institutional upper limit of normal. All blood studies pertaining to eligibility must have been done within 14 days of registration. In addition, patients with other medical illnesses that, in the opinion of the investigator, would compromise the patient’s ability to tolerate the therapy and patients who were pregnant or nursing were excluded. Finally, there must have been evidence of evaluable or measurable disease at the time of registration. Patients with primary or metastatic CNS tumors must have had a baseline imaging study (enhanced CT or MRI) performed within 21 days of registration while the patient was taking a stable dose of corticosteroids.",NA,in firrst cycle,NA
26686201,NA,Combination,No,"advanced solid tumors. Primary tumor type Ovary: Colon, Lung, Neuroendocrine, Others (include one of each of breast cancer, gastric cancer, gallbladder cancer, thyroid cancer, bladder cancer, renal cell carcinoma, endometrial mixed carcinoma, bone chordoma, and endometrial sarcoma) ","Inclusion criteria included age of 18 years or older with histologically or cytologically confirmed advanced solid tumors, and for which standard anticancer treatment did not exist or were no longer effective; Eastern Cooperative Oncology Group (ECOG) performance status of 0–1; life expectancy ≥12 weeks; Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 measurable disease; well-controlled blood pressure; adequate bone marrow, renal, liver functions and lipid profile","Key exclusion criteria included central nervous system metastasis; coagulopathy or history of clinically significant bleeding within 6 months; venous or arterial thromboembolism within 12 months; unresolved toxicities from prior systemic therapy ≥ grade 2 by CTCAE version 4.0; prior treatment by trebananib or medication targeting ANG or Tie2 receptor; clinically significant cardiovascular disease within 12 months; major surgery within 28 days; treatment within strong immune modulators within 30 days; non-healing wound, ulcer, or fracture; chemotherapy or radiotherapy within 4 weeks or other investigational drug within 21 days; concomitant administration of strong CYP3A4 inhibitors or inducers. ",during cycle 1,NA
16134182,NA,Combination,No,"Tumor type: Colorectal 18, Melanoma 9, Lung (NSCLC/SCLC) 5 (3/2), Brain 3, Head and neck 2, Liver 2, other (esophageal, gallbladder, gastric, leiomyosarcoma, pancreatic, prostate, and carcinoma of anunknown primary site (one patient each))","Patients >=18 years of age with a life expectancy of >=3months and an Eastern Cooperative Oncology Groupperformance status score of 0, 1, or 2 were enrolled. Allpatients were required to have pathologic evidence ofan advanced, incurable cancer that was unresponsiveto available therapy or for which there was no knowneffective regimen. Patients could have received nomore than three previous chemotherapy regimens (in-cluding adjuvant treatment) and must have recoveredfrom the toxicities of previous regimens before enroll-ment. At least 4 weeks must have elapsed since previ-ous chemotherapy (6 wks for previous mitomycin or nitrosoureas), and 2 weeks since RT. The followinglaboratory values were required: absolute neutrophilcount (ANC) >=1500/uL; platelet count >=100,000/uL;serum bilirubin level <=1.5 times the upper limit ofnormal (ULN); transaminase levels <5 times the ULN; and a serum creatinine level <2.0 mg/dL. Patientswith a history of brain metastases were eligible, butonly if the metastases had been treated and wereinactive and the patients were asymptomatic.",Patients with symptoms of malabsorption or who were unable to swallow the study medication were excluded. Female patients who were pregnant or lactating were ineligible.,during the first treatment cycle ,NA
21735117,NA,Combination,No,patients with malignant glioma,"Study patients were >=18 years of age with histologically confirmed WHO grade III or IV malignant glioma (glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, and/or anaplastic oligoastrocytoma) previously treated with conventional external beam radiation therapy. Initially, only patients with recurrent disease, on a therapy other than temozolomide, were enrolled, however, the study was amended to allow patients with stable disease on temozolomide, once temozolomide administered during and after radiation therapy became standard of care. Additional eligibility criteria included: Karnofsky performance status >=60; stable corticosteroid dose for >=2 weeks; adequate hematologic (absolute neutrophil count >1,500 cells/ul; platelet count >100,000 cells/ul; hemoglobin >10 g/dl), and biochemical results (serum creatinine, blood urea nitrogen (BUN), and bilirubin <1.5 times the upper limit of normal; and aspartate aminotransferase (AST) <2.5 times the upper limit of normal); recovery from all expected toxicity related to previous therapy; life expectancy greater than 12 weeks; and written informed consent per Duke IRB. At least 3 weeks had to have elapsed since prior surgical resection, 2 weeks since prior radiotherapy, or 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and 1 week for daily therapy). For patients enrolling on study after completion of radiotherapy and temozolomide, imaging had to demonstrate clear disease stability. If there was any concern for possible disease progression and/or pseudoprogression, patients had to receive one or two cycles of 5-day temozolomide prior to enrollment. Imaging had to be stable or improved after one or two cycles of 5-day temozolomide before the patient could be eligible on study.","Exclusion criteria included: prior treatment with farnesyl transferase inhibitors; prior disease progression, grade 4 hematologic toxicity, or grade 3 or 4 non-hematologic toxicity on temozolomide; pregnancy or nursing; significant medical illness; less than 5 years free of another primary malignancy; and significant QTc prolongation (>500 ms) on electrocardiogram (EKG).",during cycle 1,stratum A included patients on non-EIAEDs or not on any antiepileptic drug; stratum B included patients receiving EIAEDs
23605083,NA,Combination,No,patients with metastatic breast cancer,"This study enrolled women 18 years of age or older with a histologically confirmed diagnosis of metastatic or locally recurrent breast cancer that was either measurable or evaluable. Any number of prior therapies was acceptable. Additional eligibility criteria included Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0–1, fasting serum glucose <120 mg/dL, and adequate organ function.","Exclusion criteria included diabetes requiring oral hypoglycemics or insulin, uncontrolled brain metastases, current use of hormonal therapy, investigational agents, herbal preparations, enzyme-inducing anti-epileptic drugs or CYP3A4 inducers, systemic anticancer therapy within 3 weeks or radiation within 2 weeks before registration; prior treatment with agents targeting IGF-1R/IGF or PI3K/ Akt/mTOR pathway, known hypersensitivity reactions to macrolide antibiotics, known HIV positivity, and uncontrolled intercurrent illnesses. Women who were pregnant or breast feeding were not eligible.",during the first cycle of treatment,NA
20934264,NA,Combination,No,patients with newly diagnosed glioblastoma,"Eligible patients were $18 years of age with pathologically confirmed newly diagnosed GBM. Other than surgery, patients were not allowed any additional therapeutic intervention before enrollment. Eligibility criteria also included Karnofsky Performance Status $60 and adequate hematologic and organ function. ","Patients were excluded from the study if they had significant existing medical problems, were pregnant, or were breastfeeding. ",the first 10 weeks of treatment ,NA
24908656,NA,Combination,No,children with recurrent CNS tumors,"Children <21 years of age with refractory or recurrent primary CNS malignancy for whom no curative therapy existed were eligible. Patients were required to have a Karnofsky (age >16 y) or Lansky (age ≤16 y) performance status ≥50. Patients had to be able to swallow medications. Patients were required to have adequate baseline renal, hepatic, and hematologic functions, and standard prior therapy criteria were applied as previously described.27 Patients who received TMZ previously were eligible if they met all criteria.","Patients were excluded if they were receiving other anticancer or experimental therapy; had systemic illness, uncontrolled infection, or seizures; were pregnant or lactating; or were receiving hematopoietic growth factors. Following an unanticipated episode of hypertensive encephalopathy (see Results), our study was amended to exclude patients with poorly controlled hypertension, prior history of hypertensive crisis or encephalopathy, or documented CNS ischemia or infarction.",the first cycle,NA
23860641,NCT 01198184,Combination,No,"patients with advanced solid tumors. Type of tumor: Sarcoma 6 (35), Neuroendocrine tumor 2 (12), SCCHN 2 (12), Other 7 (41) (included ovarian, lung cancer(non-small cell carcinoma), gastrointestinal stromal tumor, melanoma, hepatocellular carcinoma, endometrial cancer, cholangiocarcinoma)","Patients were required to have a histologically confirmed advanced, incurable solid malignancy that was refractory to conventional therapy or for which no standard therapy existed, age ≥18 years, life expectancy ≥12 weeks, an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤1, with adequate hematological, hepatic, and renal function. Prior therapy with a γ-secretase inhibitor, or any inhibitor of the PI3K/AKT/mTOR pathway was prohibited.","Key exclusion criteria included: a) concomitant use of medications that were strong inducers/inhibitors or substrates of CYP3A4; b) patients with malabsorption syndrome or other condition that would interfere with intestinal absorption; c) uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia or hypokalemia despite adequate electrolyte supplementation; d) a QTc interval ≥470 mSec as measured by Bazett’s formula; e) pre-existing significant pulmonary infiltrates of unknown origin",the first 2 cycles,NA
15014015,NA,Combination,No,"patients with advanced solid neoplasms. Primary tumor types: Sarcoma 20, Melanoma 11, Colorectal 12, Brain (GBM) 6, Endometrium 2, Mesothelioma 2, Ovary 2, Other [pancreas, bladder, breast, brain (astrocytoma), stomach, head and neck, liver, kidney] 1 each","Patients with histologically confirmed advanced solid malignancies refractory to conventional therapy or for whom no effective therapy existed were candidates for this study. Eligibility criteria also included: age >=18 years; a Southwestern Oncology Group (SWOG) performance status <=2; lifeexpectancy >=3 months; no surgery or chemotherapy within 4 weeks of treatment; radiation therapy <=20% of the bone marrow; no prior nitrosourea or mitomycin C; adequate hematopoietic [absolute neutrophil count (ANC) >=1500/uL, platelet count >=100,000/uL, hemoglobin >=9.0 g/dl], hepatic (total bilirubin within normal limits, aspartate amino transaminase <= 2 times institutional normal upper limits), and renal (serum creatinine within normal limits or calculated creatinine clearance >=70 ml/min according to the method of Cockcroft and Gault; Ref. 38) functions; no prior resection of the stomach or small intestines; and no medical condition that could potentially interfere with oral drug administration or limit full compliance with the study. ",NA,during the first course,NA
20156802,NA,Combination,No,patients with glioblastoma multiforme,"Eligibility criteria included patients >=18 years of age; estimated survival of >12 weeks; Karnofsky performance status >=60; and a histologically confirmed, newly diagnosed GBM or GS with a biopsy or resection <=5 weeks prior to treatment. Patients must have recovered from the effects of surgery and had adequate organ function. All patients practiced birth control during and for 3 months after treatment.","Exclusion criteria included prior cranial RT, chemotherapy, or carmustine wafers; any anticoagulant therapy (permitted, if required, after starting treatment with careful monitoring); history of any other cancer (except nonmelanoma skin cancer or carcinoma in situ of the cervix) unless in complete remission without therapy for a minimum of 3 years; any significant medical illnesses that could not be adequately controlled or would compromise the patient’s ability to tolerate the treatment; and an electrocardiogram demonstrating clinically significant arrhythmia that was symptomatic or required treatment. Patients must have discontinued enzyme-inducing antiepileptic drugs 2 weeks prior to treatment.",during RT + enzastaurin + temozolomide or during the first adjuvant cycle,NA
24880570,"Primary cancer: Breast, Ovarian, Colorectal,Other ( includes 1 each: abdominal/pelvic sarcoma, adenocarcinoma of the jejunum, atypical carcinoid cancer, cervix uteri cancer, cholangiocarcinoma, external ear cancer, gallbladder cancer, esophageal cancer, lung cancer, melanoma, prostate cancer, stomach cancer, and urothelial",NA,NA,NA,NA,NA,NA,NA
23633392,NA,Combination,No,patients with recurrent or temozolomide refractory glioblastoma,"The study enrolled adult patients (>=18 years), with aKarnofsky performance status (KPS) score of >=60, whohad histologically confirmed supratentorial glioblastomaor gliosarcoma. Patients were required to have unequivo-cal radiographic evidence of tumor progression orrecurrence, as determined by magnetic resonance imagingor computed tomography scan, after radiation therapy.Additional eligibility criteria included adequate bonemarrow, renal, and liver function. Patients might havehad as many as 2 prior chemotherapy regimens for recur-rent or progressive tumor but could not have had prior treatment with an FTI (lonafarnib or tipifarnib). Patientsin phase 1b expansion were required to have a treatmenthistory of a minimum of 2 cycles of adjuvant TMZ. Animaging study, to serve as baseline, had to be performedwithin 14 days prior to registration and on a steroid dosethat has been stable or decreasing for at least 5 days.Patients must have recovered from the toxic effects ofprior therapy. Patients who had undergone recent resec-tion of recurrent or progressive tumor were eligible even ifthey did not have radiologically measurable disease, pro-vided they had completely recovered from surgery.Patients were not permitted to use enzyme-inducing anti-epileptic drugs (EIAEDs) because of well-establisheddrug-drug interactions that lead to alterations in the phar-macokinetics of lonafarnib. Patients changing fromEIAEDs to non-EIAEDs had to be off EIAEDs for at least72 hours prior to the initiation of treatment.",Patients witha history of any other cancer (except nonmelanoma skincancer or carcinoma in situ of the cervix) were ineligibleunless in complete remission and off of all therapy for thatdisease for a minimum of 3 years. Subjects deemed tohave progressed immediately after completing concurrentTMZ and radiation therapy were not considered for entryin order to reduce possibility of “pseudo-progression.” ,during their first cycle of therapy,NA
25832688,NA,Combination,No,newly diagnosed supratentorial glioblastoma multiforme,"Adults 18 years of age or older with adequate performance status (Zubrod 0-1) were eligible for enrollment following biopsy results or resective surgery for newly diagnosed, supratentorial, histologically confirmed GBM or gliosarcoma. Pretreatment characteristics, including extent of resection and location of lesion, are summarized in Table E1 (available online at www.redjournal.com). With the exception of non-melanoma skin cancer or noninvasive bladder or cervix lesions, no malignancy was allowed within 3 years prior to GBM diagnosis.","With the exception of non-melanoma skin cancer or noninvasive bladder or cervix lesions, no malignancy was allowed within 3 years prior to GBM diagnosis. Additional exclusions included pregnancy, breast feeding, prior chemotherapy, RT to the head or neck area, contraindication for MRI with gadolinium, history of porphyria or G6PD deficiency, active inflammatory disorders, or major medical or psychiatric illness.",within 21 days of conclusion of RT,NA
26503473,NCT00121680,Combination,No,patients with stage 4 or unresectable stage 3 melanoma,"Patients with a histologically and/or cytologically confirmed solid tumor or lymphoma who are resistant/refractory to approved therapies or for whom no curative therapies are available All previous treatment (including surgery and radiotherapy) must have been completed at least four weeks prior to study entry and any acute toxicities must have resolved Aged 18 years. Because of the potential additional risk to children suggested by preclinical models of dysplasia in growing epiphyseal growth plates, enrollment will be limited to adult patients ECOG performance status score of 0 or 1 Written informed consent prior to any study specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice Willing and able to comply with the protocol guidelines for the duration of the study For patients in the Schedule 2 Expanded Melanoma Cohort only: histologically and/or cytologically confirmed advanced and/or metastatic melanoma who are resistant/refractory to approved therapies or for whom no curative therapies are available. In addition, patients must have melanoma lesions amenable to tissue biopsy and must agree to undergo biopsies of malignant and adjacent non-malignant tissue pretreatment and at the end of Cycle 1 of treatment For patients in the Melanoma Combination Cohort only: histologically and/or cytologically confirmed melanoma that is advanced and/or metastatic","Untreated or unstable metastases to the central nervous system (CNS) tumors. Patients who have completed local therapy and have discontinued the use of steroids for this indication at least 4 weeks prior to commencing treatment and in whom stability has been proven by at least 2 CT or MRI scans obtained at least 4 weeks apart are permitted Any of the following laboratory parameters: hemoglobin < 9 g/dL (5.6 mmol/L); neutrophils <1.5 x 109/L; platelets <100 x 109/L; serum bilirubin >25 mol/L (1.5 mg/dL); liver function tests with values >3 x upper limit of normal (ULN); renal function with serum creatinine >1.5 ULN or creatinine clearance < 60 mL/min Positive history of HIV, active hepatitis B or active hepatitis C or severe/uncontrolled intercurrent illness or infection Patients with centrally located non-small cell lung cancers and squamous cell lung cancers Clinically significant cardiac impairment or unstable ischemic heart disease including a myocardial infarction within six months of study start Patients with marked Baseline prolongation of QT/QTc interval (QTc interval > 450 msec for males or > 470 msec for females) using the Fridericia method for QTc analysis Bleeding or thrombotic disorders, or using therapeutic dosages of anticoagulants, such as warfarin. Occasional use of NSAIDs and antiplatelet agents such as aspirin, clopidogrel, aggrenox and dipyridamole are not considered exclusionary if taken <7 days per 28 days. However, if the patient requires chronic use (>/=7 days out of 28 days) of full doses of aspirin or NSAIDs then the patient is excluded. Concomitant antiplatelet agents and NSAIDs should be used with caution Requirement for chronic use of full dose aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) Poorly controlled hypertension (defined as requiring changes in any hypertensive regimen within 1 week three months of study entry) or patients diagnosed with hypertension based on repeat blood pressure measurements of >160/90 mmHg at Screening >1+ proteinuria on urine dipstick testing or 30 mg/dL A history of gastrointestinal malabsorption or having undergone surgery requiring gastrointestinal anastomoses within four weeks of starting therapy or who have not recovered from major surgery within three weeks of starting therapy History of alcoholism, drug addiction, or any psychiatric or psychological condition which, in the opinion of the Investigator, would impair study compliance Any treatment with investigational drugs within 30 days before the start of the study Previous treatment with E7080 Known intolerance to temozolomide (or any of the excipients) Women who are pregnant or breast-feeding; women of childbearing potential with a positive pregnancy test at Screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception (including two forms of contraception, one of which must be a barrier method) in the opinion of the Investigator (revised per Amendment 04). Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential Fertile males with female partners who are not willing to use contraception or whose female partners are not using adequate contraceptive protection Legal incapacity",cycle 1,NA
10561328,NA,Single Drug,No,"patients with advanced solid malignancies. Tumor types: Colon, Non–small-cell lung, Soft tissue sarcoma, Melanoma, Mesothelioma, Breast, Endometrial, Adenoid cystic cancer, Head and neck","Patients with histologically documented solid malignancies refractory to conventional therapy or for whom no effective therapy existed were candidates for this study. Eligibility criteria also included: (1) age >= 18 years; (2) a Southwestern Oncology Group performance status >= 2 (ambulatory and capable of self-care); (3) a life expectancy of at least 12 weeks; (4) no surgery, wide-field radiation therapy and/or chemotherapy within 4 weeks of treatment (6 weeks for those previously treated with a nitrosourea or mitomycin); (5) adequate hematopoietic (absolute neutrophil count [ANC] >= 1,500/µL, platelets >= 130,000/µL, and hemoglobin >= 9 gm/dL), hepatic (total bilirubin >= 1.0 mg/dL,AST and ALT >= 2.0 times the upper normal limit), and renal (serum creatinine >= 1.3 mg/dL or estimated creatinine clearance >= 60 mL/min according to the method of Cockcroft and Gault22) functions; (6) no prior resection of the stomach or small intestine; (7) no frequent vomiting or medical condition that could potentially interfere with oral drug administration; and (8) no coexisting medical problem of sufficient severity to limit full compliance with the study.",NA,in the first cycle of treatment,NA
32293798,NCT01051557,Combination,No,patients with with glioblastoma,"Patients must have unstained slides or tissue blocks available from at least one prior surgery; frozen tissue is also requested if available. Patients must have received prior radiotherapy and temozolomide; there is otherwise no limit on the number of prior recurrences/therapies. At least 6 weeks (42 days) must have elapsed since completion of radiation therapy to initiation of study treatment. At least 4 weeks (28 days) must have elapsed since most recent temozolomide and initiation of study treatment. Patients must have recovered from the toxic effects of other prior direct inhibitors of vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR): 4 weeks from prior therapy with agents such as bevacizumab (Avastin), aflibercept (VEGF-Trap), cediranib (AZD2171), or XL-184 (BMS 907351); any questions regarding the definition of a direct anti-VEGF/VEGFR therapy must be discussed with the principal investigator (PI) or co-PI; patients must have recovered from the toxic effects of other prior therapy including: 4 weeks (28 days) from any investigational agent, two weeks (14 days) from vincristine, 6 weeks (42 days) from nitrosoureas, 3 weeks (21 days) from procarbazine administration, and 1 week (7 days) for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count), and 4 weeks (28 days) from any other prior cytotoxic therapy; any questions related to the definition of non-cytotoxic agents should be directed to the co-PI. Patients must have shown unequivocal evidence for tumor progression by magnetic resonance imaging (MRI)/computed tomography (CT) on the baseline MRI/CT in comparison to a prior scan OR have recently undergone resection for recurrent/progressive disease; the baseline brain MRI/CT must be performed 14 days or fewer prior to treatment; the same type of scan, i.e., MRI (or CT for patients who cannot undergo MRI) must be used throughout the period of protocol treatment for tumor measurement; criteria for progression on this study are not mandatory if the disease progression is obvious in the opinion of the investigator; any questions should be addressed to the PI. Patients must be on a stable or decreasing dose of corticosteroids for a minimum of 5 days before the baseline MRI/CT (and positron emission tomography [PET] scans for patients on the phase II study) except patients undergoing surgery on the surgical substudy of phase II; if the corticosteroid dose is increased between the date of imaging and registration a new baseline MR/CT is required. Karnofsky performance status >= 60%. Life expectancy of greater than 8 weeks. White blood cell (WBC) >= 2,000/ul. Absolute neutrophil count (ANC) >= 1,500/mm^3. Platelet count of >= 100,000/mm^3; Platelet count of at least 100,000/mm^3 on at least 2 consecutive blood draws, at least 1 week apart, with results stable/trending upward; any question regarding the definition of stable/trending upward must be discussed with the PI. Hemoglobin >= 10 gm/dl; eligibility level for hemoglobin may be reached by transfusion. Serum glutamic oxaloacetic transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT) < 2 times upper limit of normal (ULN). Bilirubin < 2 times ULN. Creatinine < 1.5 mg/dL. Calcium levels at or above the lower limit of normal. Phosphorus levels at or above the lower limit of normal. Cholesterol level =< 350 mg/dl. Triglycerides level =< 400 mg/dl. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Women of childbearing potential must have a negative beta-human chorionic gonadotropin (B-HCG) pregnancy test documented within 7 days prior to treatment. Women must agree not to breast feed. Patients must have the ability to understand and the willingness to sign a written informed consent document. Measurable disease is not required for eligibility in patients who recently underwent resection as long as progressive disease led to the surgery, and the histology of the most recent surgery documented recurrent/progressive/persistent malignant glioma. If cytoreductive surgery is planned for tumor recurrence at the time of enrollment, such patients may be eligible for the surgical substudy (Phase II only), taking temsirolimus + perifosine pre-operatively and then re-initiating such therapy after recovering from the effects of surgery. PHASE I: Patients must have a EITHER: Histologically confirmed intracranial malignant glioma of the following types: glioblastoma, anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic oligo-astrocytoma (AOA) also called anaplastic mixed gliomas, malignant glioma NOS (not otherwise specified); patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of a high grade (malignant) glioma is made; OR Histologically confirmed low grade (World Health Organization [WHO] grade II) gliomas (such as low grade astrocytoma, low grade oligodendroglioma, low grade oligo-astrocytoma (mixed gliomas), or low grade glioma NOS) IF there is radiographic evidence by MRI or CT of malignant transformation but histologic confirmation of high grade (malignant) transformation would not be otherwise undertaken for routine clinical care; inclusion of patients in this group will allow increased accrual rapidity by enrolling patients who are otherwise ineligible for almost all malignant glioma trials yet whom are treated presumptively for malignant glioma. PHASE II: Patients must have a histologically confirmed intracranial malignant glioma of the following types: glioblastoma, anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic oligo-astrocytoma (AOA) also called anaplastic mixed gliomas, malignant glioma NOS (not otherwise specified); patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of a high grade (malignant) glioma is made","Patients may not be receiving any other investigational agents.Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temsirolimus or perifosine. Patients must not be taking EIAED; if previously on an EIAED, the patient must be off of it for at least two weeks prior to treatment on study. Patients must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with temsirolimus and perifosine. Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible",during thefirst 4-week cycle of treatment,NA
25374407,NA,Combination,No,"patients with advanced or refractory solid tumors. Tumor types included lung (5), prostate (2), pancreas(1), bladder (2), uterus (3), cervix (4), and vagina (2).","Patients were eligible if they had histologically confirmed metastatic or unresectable solid tumors for which standard curative measures did not exist or were no longer effective. The histology subtypes included in the trial were limited to those tumors for which temsirolimus or vinorelbine have reported clinical activity: lung, breast, ovary, cervix, vagina, prostate, uterus, renal, bladder, and NETs. Other eligibility criteria included the following: age ≥18 years; Eastern Cooperative Oncology Group (ECOG) performance status ≤2; projected life expectancy >3 months, full recovery from acute toxicities of prior cancer directed therapy (chemotherapy, surgery, or radiation); peripheral neuropathy grade 0–1; and adequate organ function. Adequate organ function was defined by the following: absolute neutrophil count (ANC) >1,500 cells/mm3, platelet count ≥100,000 cells/mm3, hemoglobin ≥9.0 g/dL, serum creatinine <1.5 mg/dL, AST or ALT <2.5 upper limit of normal (ULN), alkaline phosphatase <2.5 ULN, and serum bilirubin <1.0 mg/dL. In patients with bone metastasis who had no evidence of liver metastasis and normal bilirubin, an alkaline phosphatase <5 ULN was allowed.","No other concomitant therapy directed toward cancer was allowed during study enrollment. Additional exclusion criteria included prior therapy with vinorelbine or an mTOR inhibitor; receipt of chemotherapy or radiation within 4 weeks prior to starting study treatment; any unresolved toxicity greater than Common Toxicity Criteria (CTC) grade 1 from previous anticancer therapy (excluding alopecia); ongoing long term use of steroids for chronic conditions; and concurrent use of strong inhibitors of CYP3A4. Women who were pregnant, had a positive pregnancy test, or were breast-feeding were excluded. For women of childbearing age, a negative pregnancy test was documented 7 days prior to the administration of therapy. Patients agreed to use an effective form of contraception for the duration of the study",during the first cycle,NA
10576660,NA,Single Drug,No,"For refractory or relapsing malignacies. The most common diagnosis was glioma (10/30); the second most common was sarcoma (7/30).  Other tumour types, in order of incidence, included mesothelioma (3/30), ovarian carcinoma (3/30), lung carcinoma (3/30), melanoma (2/30), adenocarcinoma (1/30) and bladder carcinoma (1/30).","All patients enrolled in this study were adults with a life expectancy of at least 12 weeks, a histologically confirmed malignancy and measurable or evaluable disease refractory to standard therapy. Additional criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of > 2; white blood cell count of ≥ 4.0 × 109 l–1; platelet count of ≥ 130 × 109 l–1; haemoglobin of ≥ 10 g dl–1; and serum creatinine and bilirubin levels within the upper limit of normal.","Patients with central nervous system (CNS) metastases, uncontrolled infection, multiple myeloma, chronic leukaemia or bone marrow involvement, as well as those who were pregnant or nursing, were excluded from the study. Also excluded were patients who had received chemotherapy, biological therapy or radiation within 4 weeks before study initiation, patients who had received nitrosourea or mitomycin C within 6 weeks before study initiation or those who experienced frequent vomiting or conditions that would prevent administration of oral capsules.",during the first course of treatment,NA
26285766,NA,Combination,No,patients with newly diagnosed malignant gliomas,"Patients eligible for enrollment met the following criteria: >= 18 years old, histologically proven newly diagnosed MG (AA, AO, GBM), completion of >=80 % of prescribed RT/TMZ without grade 3 or 4 toxicity. Additional enrollment requirements included: absolute neutrophil count >=1500/uL; platelet count >=100,000/uL; serum creatinine <=1.7-mg/dL; total bilirubin <=1.5-mg/dL; aspartate and alanine aminotransferase <=4 times the upper limit of normal; stable dexamethasone dose for >=5 days prior to enrollment; Karnofsky Performance Status (KPS) >=60 %; and a Mini Mental State Examination (MMSE) score >=15.",Exclusion criteria included: enzyme inducing anti-epileptic medications; malignancy within 5 years; pregnant or nursing women; serious concurrent medical condition or other condition that would compromise safety or compliance. ,two treatment cycles (56 days) for mTMZ patients and 10 weeks for the cTMZ group,NA
24323026,NCT00838539,Combination,No,"patients with human epidermal growth factor receptor 2-dependent and other solid tumors. Primary cancer diagnosis: Breast, Colorectal, Gynecologic, Non–small-cell lung, Pancreatic, Thymic, Other","Eligible patients included adults with metastatic solid tumors and progression through at least one standard regimen of therapy. Patients were required to have an Eastern Cooperative Oncology Group performance status of 0 to 2 and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.0). Normal cardiac function (by echocardiogram or multigated acquisition scan) and serum calcium as defined by local laboratory limits were required. In addition, adequate bone marrow and organ function, a negative pregnancy test, and the use of prophylactic contraceptives for female and male patients with partners of childbearing age were required.","Patients were ineligible if they had clinically significant cardiac disease, chronic corticosteroid use, symptomatic or clinically active CNS metastasis, grade 2 or greater diarrhea of any etiology (or active GI disease with potential diarrhea), QTc of more than 470 milliseconds, major surgery within 4 weeks, or serious active infection.",during the first 28 days,NA
16234526,NA,Combination,No,"pediatric patients with solid tumors. Diagnosis: Sarcoma 10, CNS tumor 31, High-grade glioma 8, Low-grade glioma 5, Brainstem glioma 10, Medulloblastoma/PNET 5, Ependymoma 3","Pediatric patients <= 21 years old with a histologically confirmed solid tumor refractory to standard treatment were eligible for this study. Histologic confirmation was not required for brainstem or optic pathway gliomas. Patients must have recovered from the toxic effects of prior therapy, have an Eastern Cooperative Oncology Group performance score of <= 2 and a life expectancy of at least 8 weeks.8 Patients had to be able to swallow capsules. Patients must have had their last fraction of limited-field radiation therapy at least 4 weeks before study entry and their last fraction of extensive radiation (eg, craniospinal radiation) at least 4 months before study entry. Patients must have received their last dose of chemotherapy at least 3 weeks before study entry (4 weeks for nitrosoureas), their last investigational therapy at least 4 weeks before study entry, and be off colony-stimulating factors for at least 1 week before study entry. Prior TMZ use was allowed if it was more than 3 months since the last dose and prior use was not associated with significant toxicity. Patients with brain tumors receiving corticosteroids for the control of tumor-associated edema had to be on a stable or decreasing dose for at least 1 week before study enrollment. Patients were required to have adequate bone marrow function (absolute neutrophil count of > 1,500/uL, hemoglobin > 8 gm/dL, and platelet count > 100,000/uL), adequate liver function, (bilirubin within normal limits and ALT < 2 x the upper limit of normal), and an age-adjusted normal serum creatinine or a creatinine clearance >= 60 mL/min/1.73 m2.","Patients currently receiving other investigational chemotherapeutic agents were excluded, as were patients with a history of myeloablative therapy requiring bone marrow or stem cell transplantation within the previous 4 months, pregnant or breastfeeding females and patients with clinically significant unrelated systemic illness that would compromise the patient’s ability to tolerate this therapy or interfere with the study procedures or results. ",the first treatment cycle,NA
20511167,NA,Combination,No,patients with relapsed or refractory leukemia,"Eligible patients were aged ≥ 18 years and had relapsed/refractory leukemias for which no current therapies were anticipated to result in a durable remission. Relapsed/refractory leukemias included acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myeloid leukemia (CML) in blast crisis. Those with central nervous system leukemia were allowed to participate as well. In the absence of rapidly progressing disease, the interval from previous treatment must have been > 2 weeks for myelosuppressive cytotoxic agents. Persistent chronic toxicities from previous chemotherapy must not have been grade > 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 3.0. Other eligibility criteria included Eastern Cooperative Oncology Group performance score of ≤ 2, serum creatinine ≤ 2.0 mg/dL, total bilirubin ≤ 1.5 × the upper limit of normal (ULN), and alanine aminotransferase or aspartate aminotransferase ≤ 3 × the ULN at trial entry. Women who were not postmenopausal or surgically sterile required a negative pregnancy test within 2 weeks before beginning treatment. Both women and sexually active men were required to use an effective contraceptive method for the duration of the trial","Ineligibility criteria included uncontrolled active infection of any kind; active heart disease, including myocardial infarction within the previous 3 months; symptomatic coronary artery disease; arrhythmias not controlled by medication or uncontrolled congestive heart failure; treatment with other standard or investigational agents for leukemia; and treatment with disulfiram (Antabuse), as the formulation of laromustine contains 30% ethanol.",the first-cycle,NA
9738573,NA,Combination,No,"children and adolescents with recurrent solid tumors. Diagnosis:  Astrocytoma/glioma, Ependymoma, Brain stem, Cerebral PNET/medulloblastoma, Other brain tumors includes I pineal tumor and I meningioma, Osteosarcoma, Rhabdomyosarcoma, All other tumors (Includes 1 neurofibroma, 1 neuroblastoma, 1 retinoblastoma (prior CSI), 1 clear-cell carcinoma of the kidney, 1 hepatocellular carcinoma, and 1 embryonal carcinoma of the ovary) ","Eligible patients were required to have a recurrent or progressive solid tumor refractory to standard therapy that had been histologically confirmed at the time of initial diagnosis (except brain stem tumors) and to be aged 21 years or younger at the time of study entry. Other eligibility criteria included full recovery from all prior therapies, with at least 3 weeks since the last dose of chemotherapy and/or radiotherapy (6 weeks since nitrosoureas); adequate bone marrow (platelet count >= 100,000/uL, neutrophil count >= 1,000/uL), renal (serum creatinine level <= 1.5 times normal), hepatic (serum AST or ALT levels <= 2.5 times normal, bilirubin level <= 1.5 times normal), and CNS function (seizures under good control and no preexisting toxicity greater than grade 2); a life expectancy of at least 2 months; and an Eastern Cooperative Oncology Group performance status of 0 to 2. Patients with medulloblastoma or other primitive neuroectodermal tumors (PNETs) and neuroblastoma were required to have a negative bone marrow examination. Informed consent by the patient or legal guardian was required before enrollment, and local institutional review board approval was required at all participating centers. In addition, participants must have been able to swallow capsules. Exceptions for this last criteria were made for two patients who received temozolomide through a nasogastric tube.","Patients were not excluded because of the number of prior therapies received; however, patients who had received prior total-body irradiation were excluded.",during the first course of temozolomide. ,NA
9744506,NA,Single Drug,No,"paediatric patients with advanced cancer. Diagnoss: Brain stem glioma, High-grade astrocytoma, Haemangiopeitcoma, Rhabdomyosarcoma, Chondrosarcoma, Osteogenic sarcoma, Pancreatic neuroendocrie tumour, Primitive neuroectodermal tumour, Ependymoma ",Patients aged less than 18 years. with histologically proven malignancy. for whom no conventional therapies were available to offer a reasonable hope of cure or significant palliation were eligible. Neuroradiological imaging alone was accepted for diffuse intrinsic brain stem gliomas. Patients were required to have a Common Toxicity Criteria (CTC) performance status of 0. 1 or 2 (except for patients with brain stem tumours who were allowed a performance status of 3). One patient with a brain stem glioma and performance status of 4 was entered and was not evaluable because of death due to disease progression in the first cycle. No nitrosourea or mitomycin C therapy was allowed within 6 weeks. and no other chemotherapy or radiotherapy was to have been received within 4 weeks of the first dose of temozolomide. ,The following patients were not eligible to enter the study: patients who had a malignancy that involved the bone marrow: those who were a poor medical risk because of systemic disease: HIV-positive patients: those who had received prior allogeneic or autologous bone marrow transplantation: those who had received a prior peripheral stem cell transplantation and those with previous or concurrent malignancies.,during the first 28 days after the first daily dose of SCH 52365,Eligible patients were stratified according to whether they had not (Arn A) or had (Arm B) received prior CSI or nitrosourea therapy.
21881915,NA,Combination,No,patients with advanced solid tumors,"Patients over 18 years of age with histologic proof of cancer that was unresectable were eligible for this study. Patients had to be able to provide informed consent, have an estimated life expectancy ≥12 weeks, an ECOG performance status (PS) ≤2, and had to be willing to return to Mayo Clinic for follow–up. Adequate organ function was defined based on laboratory values obtained ≤14 days prior to registration: (1) ANC ≥1500/μL; (2) PLT ≥100,000/μL; (3) total bilirubin ≤upper limit of normal (ULN); (4) AST ≤3× ULN or AST ≤5× ULN if liver involvement; (5) creatinine ≤1.5×ULN; (6) fasting cholesterol <350 mg/dL; (7) fasting triglycerides <400 mg/dL; (8) Hgb ≥10 g/dL. Women of childbearing potential only were required to have a negative serum pregnancy test done ≤7 days prior to registration.","Patients were excluded if they had used any of CYP3A4 inducing drugs ≤7 days prior to registration, if there was known standard therapy for the patient’s disease that was potentially curative or definitely capable of extending life expectancy, if they had any uncontrolled infection, or HIV positive patients on antiretroviral agents that undergo CYP3A4 metabolism. Further exclusion criteria included prior therapies with any agent targeting EGFR or mTOR, chemotherapy ≤4 weeks prior to study entry, mitomycin C/nitrosoureas ≤6 weeks prior to study entry, immunotherapy ≤4 weeks prior to study entry, biologic therapy ≤4 weeks prior to study entry, radiation therapy ≤4 weeks prior to study entry, and radiation to >30% of bone marrow, failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment, New York Heart Association classification III or IV, CNS metastases or seizure disorder, other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational, concurrent use of warfarin or oral contraceptives or any of the following: (1) pregnant women; (2) nursing women; (3) men or women of childbearing potential who are unwilling to employ adequate contraception.",first cycle,NA
30393943,NA,Combination,No,"pediatric patients with recurrent or refractory solid tumors. Four patients had CNS tumors, including ependymoma (n=2) and medulloblastoma (n=2); other diagnoses(n=1each):neuroblastoma, osteosarcoma, and malignant granular cell tumor","Children and adolescents ≥1 year and ≤18 years with relapsed or refractory solid tumors, including CNS malignancies (excluding DIPG) and lymphoma, with histologic verification of malignancyat diagnosis (except optic pathway glioma and pineal tumors with elevated tumor markers) were included. Soft-tissue sarcomas were excluded due to the positive results of temsirolimus in combination with vinorbine and cyclophosphamide for children with rhabdomyosarcoma. Patients were required to have measurable or evaluable disease and must have received at least one prior treatment regimen. Eligibility also required Lanskyor Karnofsky ≥50%, adequate bone marrow (absolute neutrophil count [ANC] ≥1.0×109/L, platelets ≥100×109/L without transfusion, and hemoglobin ≥80g/L [may receive transfusions]). Patients with marrow involvement were included if they met marrow function criteria and were evaluable for hematologic toxicity. Patients had adequate renal function (GFR ≥70mL/min/1.72m2 or serum creatinine ≤1.5×upper limit of normal [ULN]) for age,liver (total bilirubin ≤1.5×ULN, ALT, and AST≤1.5×ULN and serum albumin ≥20 g/L), metabolic (serum triglyceride and cholesterol≤300 mg/dL, blood glucose≤ULN, electrolytes ≤grade 1),and pulmonary function (no dyspnea at rest, O2 saturation ≥92% on room air). Patients must have recovered from prior treatment-related toxicity and be ≥3 weeks from myelosuppressive chemotherapy, ≥28 days from major surgery (or ≥7 days from minor surgery), ≥90 days from total body irradiation, craniospinal radiotherapy or ≥50% pelvic radiation, ≥6 weeks from other substantial marrow irradiation, ≥2 weeks from local, small port palliative radiotherapy, ≥8 weeks from 131I-MIBG therapy for neuroblastoma, ≥60 days from stem cell transplant/rescue with no graft-versus-host disease (GVHD), ≥7 days from hematopoietic growth factors and ≥3 half-lives from last administration of monoclonal antibodies. Prior therapy with vinblastine or mTOR inhibitors was allowed if no progression on therapy or severe adverse events","Patients with uncontrolled infection, diabetes, bleeding disorders, risk of QTc prolongation, or baseline QTc >470ms were excluded. Patients with a history of allergic reaction or hypersensitivity to the study drugs and those with untreated brain metastases, spinal cord compression, or meningeal metastases were not eligible. Patients receiving other investigational agents, other anticancer agents or radiation therapy, angiotensin-converting enzyme inhibitors, QTc prolonging drugs, anticoagulants, anti-GVHD agents, or potent CYP3A4/5 substrates/inhibitors/inducers were excluded",cycle 1,NA
22923449,NCT00268385,Combination,No,Patients with High-Grade Gliomas,"Patients were eligible for the study if they had histologically proven intracranial HGG (glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, and malignant astrocytoma not otherwise specified), were 18 years or older, and had a Karnofsky performance status (KPS) 60 or more, adequate bone marrow function (WBC >= 3,000/uL, ANC >= 1,500/mm3, platelet count >= 100,000/mm3, and hemoglobin >= 10 gm/dL), adequate liver function (SGOT and bilirubin < 2 times the upper limit of normal), adequate renal function (creatinine < 1.5 mg/dL), and were 3 or more weeks from completion of radiotherapy. For part 1, patients with either stable disease after radiotherapy (with or without concurrent TMZ) or following progression on radiotherapy alone (i.e., no concurrent TMZ) were eligible. Any number of prior relapses was allowed. For part 2, only patients with stable disease after radiotherapy were eligible and the only prior therapies permitted were concomitant TMZ with radiotherapy or radiotherapy alone.",Patients who had previously progressed on TMZ as well as patients who were taking valproic acid (another HDAC inhibitor) within 2 weeks before enrollment were excluded.,during the first 28 days of treatment,NA
21750201,NA,Combination,No,"patients with advanced cancer. Adrenocortical carcinoma 10 (24%), Breast cancer 9 (21%), Ewing's sarcoma 3 (7%), Desmoplastic small-round-cell tumor 3 (7%), Ovarian cancer 2 (5%), Colorectal cancer 2 (5%), Neuroendocrine cancer 2 (5%), Other (n = 1 each: Nasopharynx, non–small cell lung cancer, small-cell lung cancer, myxoid sarcoma, rhabdomyosarcoma, uterine leiomyosarcoma, endometrial, histiocytoma, melanoma, prostate, and gastroesophageal junction)","Eligible patients had advanced or metastatic, histologically proven malignant tumors, and patients enrolled in the maximum tolerated dose (MTD) expansion cohort must have disease that is accessible to biopsy. Further requirements were age 16 years or older, ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1, and life expectancy of more than 12 weeks. Patients must have absolute neutrophil count >=1500/mL; platelets >=100,000/mL; creatinine <= 2X upper limit of normal (ULN); bilirubin <= 1.5X ULN; AST(SGOT) and/or ALT (SGPT) <= 5X ULN. There was no limit to prior numbers of treatment, including IGF-1R inhibitors or mTOR inhibitors. Treatment with radiotherapy (except palliative radiation to control symptoms), endocrine therapy, or chemotherapy must have ceased at least 4 weeks before starting treatment","Patients with well-controlled diabetes and hyperlipidemia were allowed in the dose expansion cohort, but were excluded in the dose escalation portion. Further patient exclusions were treatment with concurrent strong CYP3A modifiers, major surgery within 4 weeks, significant comorbidity, brain metastases, and pregnant or nursing females.",NA,NA
28194539,NCT01378377,Combination,No,"patients with advanced solid tumors. Type of tumor at diagnosis: Breast, Colorectal, Renal cell, Gastric, Melanoma, Thyroid, Non-small cell lung, Ovarian, Endometrial, Other","Subjects with histologically or cytologically confirmed solid tumors, either refractory to standard therapy or for which no effective standard therapy is available. Measurable or evaluable disease at baseline by RECIST 1.0. Age >= 18 years. Subject has read and understands the informed consent form and is willing and able to give informed consent. Performance Status score of less than or equal to (<=) 1 according to the Eastern Cooperative Oncology Group (ECOG) scale. Women of childbearing potential must have a negative blood pregnancy test at the screening visit. Female subjects of childbearing potential and male subjects with female partners of childbearing potential must be willing to avoid pregnancy by using an adequate method of contraception for 2 weeks prior to screening, during the trial and for 3 months after the last dose of trial medication.","The subject has previously been treated with mammalian target of rapamycin (mTOR) inhibitor or a mitogen-activated protein kinase (MEK) inhibitor and taken off treatment due to drug-related AEs. The subject has received any of the following: Chemotherapy, immunotherapy, hormonal therapy, biologic therapy, any investigational agent or any other anti-cancer therapy within 28 days (6 weeks for nitrosoureas or mitomycin C) of Day 1 of trial treatment; non-cytotoxic chemotherapy or investigational agent with limited potential for delayed toxicity is permitted if terminated at least 5 half-lives prior to Day 1 of trial treatment. Extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation. The subject has not recovered from toxicity due to prior therapy to baseline or CTCAE v4.0 of Grade 1 or less (except alopecia). The subject has poor organ or marrow function as defined in protocol. History of central nervous system (CNS) metastases or primary CNS tumor, unless subject has been previously treated for these conditions, is asymptomatic and has had no requirement for anticonvulsants or high dose corticosteroids for a minimum of 2 weeks prior to entry into the trial. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of Day 1 of trial drug treatment. Recent major surgery or trauma (within the last 28 days), unhealing/open wounds, diabetic ulcers, recent drainage of significant volume of ascites or pleural effusion. History of congestive heart failure, unstable angina, myocardial infarction, symptomatic cardiac conduction abnormality, pacemaker, or other clinically significant cardiac disease or history of a stroke within 3 months prior to entering the trial. Baseline corrected QT interval on screening electrocardiogram (ECG) (QTc) >= 460 ms or left ventricular ejection fraction (LVEF) < 40% on screening echocardiogram. Other uncontrolled intercurrent diseases Retinal degenerative disease (hereditary retinal degeneration or age-related macular degeneration), history of uveitis or history of retinal vein occlusion, or medically relevant abnormal ophthalmology assessments at screening. Known or suspected allergy to pimasertib, temsirolimus, other rapamycins (sirolimus, everolimus, etc.), their excipients, or any agent given in the course of this trial. Immunization with attenuated live vaccines within one week of trial entry (examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG, etc.). Concomitant use of any medications or substances that are strong inhibitors or inducers of CYP3A enzyme, including, but not limited to, phenytoin, carbamazepine, barbiturates, azoles, rifampin, phenobarbital, or St. John's Wort. Pregnant or lactating female. Legal incapacity or limited legal capacity.",in the first treatment cycle ,NA
18006772,NA,Combination,No,children with brain tumors,"Patients <=21 years of age with recurrent or refractory brain tumors were eligible for this study. Histologic confirmation at diagnosis or at the time of recurrence/progression was required for all patients except those with brainstem tumors. Other inclusion criteria consisted of (a) performance score >=60 and life expectancy >8 weeks; (b) stable neurologic deficits and stable doses of dexamethasone for >=1 week; (c) no more than two previous therapy regimens; (d) interval from previous chemotherapy >3 weeks (6 weeks if nitrosourea was used) and >6 months from myeloablative chemotherapy; (e) interval from previous craniospinal radiotherapy (dose >=18 Gy), local radiotherapy, and local radiotherapy for symptomatic metastatic sites >=3 months, >=4weeks, and >=2 weeks, respectively; (f) no growth factors for >2 weeks; (g) adequate organ function, particularly hematopoietic (absolute neutrophil count [ANC] >1,000/uL, platelet count >100,000/uL [transfusion independent], hemoglobin >8 g/dL), renal (serum creatinine <=1.5 times upper levels of institutional normal or glomerular filtration rate >70 mL/min/1.73 m2 ), and hepatic [serum bilirubin <= upper limit of normal for age, alanine aminotransferase and aspartate aminotransferase (AST) <2.5 times upper levels of institutional normal]","Exclusion criteria consisted of pregnant and lactating patients, unwillingness to use acceptable forms of contraception when applicable, use of other anticancer or experimental therapy, presence of uncontrolled infections, and previous hypersensitivity to dacarbazine, temozolomide, or polyethylene glycol. Patients who had previously received temozolomide were eligible for this study if they had not received this medication for >=3 months and had not experienced any grade 3/4nonhematologic toxicity",the first 4 weeks from the start of therapy,Patients were stratified into two strata according to previous therapy: stratum 1 for patients who received only local or no radiotherapy and stratum 2 for patients who underwent craniospinal radiotherapy at doses >18 Gy or myeloablative chemotherapy
19289491,NA,Combination,No,patients who had recurrent or progressive malignant glioma (MG) ,"Eligible patients had a histologically confirmed diagnosis of progressive or recurrent MG. They must have had measurable disease on contrast-enhanced MRI or CT scan (for patients when MRI was medically contraindicated) performed within 2 weeks of study drug administration. Patients were >18 years old and required to have a Karnofsky performance scale (KPS) score of >70%. An interval of at least 2 weeks since prior surgical resection, 4 weeks since prior chemotherapy (6 weeks for a nitrosourea-based regimen), or 12 weeks from prior radiotherapy had to have elapsed for the patient to be enrolled into the clinical trial. Additional enrollment criteria included adequate pretreatment bone marrow function (total granulocyte count >2,000 cells/ul, platelets >125,000 cells/ul), renal function (serum creatinine <1.5 upper limit of normal), and hepatic function (serum glutamic oxalacetic transaminase and bilirubin <2.5 times upper limit of normal). Patients of reproductive potential were required to take effective contraceptive measures for the duration of the study and for 2 months after completing therapy. All patients were informed of the investigational nature of the study and were required to sign an informed consent form as approved by the Duke University Health System Institutional Review Board.","The following patients were excluded from the study: pregnant or breast-feeding women, potentially fertile women or men who were not using an effective contraception method, patients treated in the past with the combination of TMZ plus O6-BG, patients with active infection requiring intravenous antibiotics, patients with a concurrently active primary malignancy, patients with known human immunodeficiency virus infection, and patients who received investigational drugs <2 weeks prior to starting on the study drug or who had not recovered from side effects of such therapy.",during the first cycle of therapy,NA
16192602,NA,Combination,No,patients with recurrent or progressive malignant glioma,"For entry into the study, patients were required to have a histologically confirmed diagnosis of primary intracranial, infratentorial, or supratentorial WHO grade 3 or greater astrocytic, oligodendroglial, or mixed glial tumor. In the first phase of the study, patients with either newly diagnosed or recurrent/progressive disease were eligible. However, in the second phase of the study, patients were required to have recurrent/progressive disease. All patients were required to have residual disease on contrast-enhanced magnetic resonance imaging (MRI) study or computed tomography (CT) scan when MRI was medically contraindicated. Patients were required to be at least 18 years of age,have a Karnofsky performance status >= 60%, and have a life expectancy of greater than 12 weeks at study entry. Patients must have recovered from toxicity of prior treatment, and an interval of at least 4 weeks since prior chemotherapy (6 weeks for a nitrosourea-based regimen) had to have have elapsed for the patient to be enrolled into the clinical trial. The number or type of prior chemotherapy treatments or failures did not limit eligibility. Prior failure of temozolomide was not a requirement. Additional enrollment criteria included adequate pretreatment bone marrow function (total granulocyte count >= 1,500/uL; platelet count >= 100,000/uL), renal function (serum creatinine <= 1.5 mg/dL or creatinine clearance greater than 60 mL/dL and serum urea nitrogen <= 25 mg/dL), and hepatic function (serum glutamic oxalacetic transaminase <= 2.5 x the upper limit of normal, and total serum bilirubin within normal limits). For patients on corticosteroids, a stable dose for 2 weeks before entry into the study was required, if clinically possible. Patients of reproductive potential were required to take effective contraceptive measures for the duration of the study and for 2 months after completing the study. All patients were informed of the investigational nature of the study and were required to provide signed informed consent as approved by the institutional review board","The following patients were excluded from the study: pregnant women, nursing women, potentially fertile women or men who were not using an effective contraception method and patients recovering from surgery.",during the first cycle,NA
20821342,NA,Single Drug,No,patients with newly diagnosed glioblastoma a treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide,"Inclusion criteria for patients included pathological diagnosis of GBM; age >=18 years; Karnofsky Performance Score (KPS) >= 60; Mini-Mental Status Examination (MMSE) score >=15; adequate bone marrow function (absolute neutrophil count >=1500/mm3; hemoglobin >= 8 g/dl; platelet count >=100,000/mm3); serum creatinine and bilirubin <=1.5 x institutional upper normal limit; and liver transaminases <=3.0 x institutional upper normal limit","Exclusion criteria included concurrent use of anti-coagulants; prolonged mean corrected QT interval or patients with a history of familial prolonged QT syndrome; pregnancy or breast feeding; history of uncontrolled hypertension or other serious medical illnesses including, but not limited to, unstable angina, arrhythmia, symptomatic congestive heart failure, active infection; infection with the human immunodeficiency virus; imaging evidence of intratumoral or intracerebral hemorrhage deemed significant by the treating physician; chronic proton pump inhibitor or H2 antagonist use.",7 weeks,NA
25962426,NCT00321594,Single Drug,No,patients with unresectable Hepatocellular Carcinoma (HCC),"Eligibility criteria included: Histologically/cytologically confirmed unresectable HCC; ECOG ≤2; measurable disease; life expectancy > 12 weeks; absolute neutrophil count ≥ 1.5 × 109/L, platelets ≥ 80 × 109/l, serum creatinine ≤ 150 μmol/L, total bilirubin ≤ 30 umol/l, albumin ≥28 g/l, alanine transaminases ≤ 5.0 × UNL (institutional upper normal limit), alkaline phosphatase ≤ 6 × UNL, prothrombin time ≤ 4 sec of ULN, and absence of clinical ascites.","The main exclusion criteria were Child’s B or C cirrhosis, use of other systemic treatments within 3 weeks prior to study entry; prior use of mTORI; significant cardiovascular disease; severe impairment of lung function; poorly controlled diabetes mellitus; and ≥ grade 2 preexisting neuropathy.",during cycle 1,NA
23726267,NA,Combination,No,patients with renal cell carcinoma,"Aged 》=18 years. Histologically confirmed RCC with a clear cell component. Documented PD. Measurable disease by RECIST criteria. <=1 prior VEGFR-targeted therapy; no prior treatment with mTOR-targeted drugs. Karnofsky performance status 70%, life expectancy >=3 months. Ability to give written informed consent","Known hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or any other component of the temsirolimus formulation. Primary CNS malignancies or active CNS metastases. Hematologic malignancies (ie, leukemia, lymphoma, and multiple myeloma). Hematologic abnormalities (hemoglobin <9.0 g/dL; ANC <1500/mm3; platelets <100,000/mm3). Serum chemistry abnormalities (fasting serum cholesterol >350 mg/dL; fasting triglycerides >400 mg/dL; total bilirubin >1.5 × ULN; AST or ALT >2.5 × ULN (or >5 × ULN in patients with liver metastasis); serum albumin <3.0 g/dL; creatinine 1.5 × ULN [or calculated creatinine clearance  < 50 mL/m/1.73 m2]; proteinuria > 2.5 g/24-h or 3+ with urine dipstick). Significant cardiovascular disease (ie, active clinically symptomatic left ventricular failure, active hypertension [diastolic blood pressure >100 mmHg; patients with a history of hypertension must have been stable on antihypertensive drugs for >=4 weeks], uncontrolled hypertension [blood pressure >140/90 mmHg on >=2 antihypertensive medications], and myocardial infarction <=3 months prior to first dose of study drug). Patients with delayed healing of wounds, ulcers, and/or bone fractures. Pulmonary hypertension or pneumonitis. Serious/active infection; infection requiring parenteral antibiotics. Inadequate recovery from any prior surgical procedure; major surgical procedure within 6 weeks prior to study entry. Uncontrolled psychiatric disorder, altered mental status precluding informed consent or necessary testing. Inability to comply with protocol requirements. Ongoing hemoptysis or history of clinically significant bleeding. Cerebrovascular accident 12 months of study entry, or peripheral vascular disease with claudication on walking <1 block. Deep venous thrombosis or pulmonary embolus. 6 months of study entry and/or ongoing need for full-dose oral or parenteral anticoagulation. Patients with a “currently active” second primary malignancy other than non-melanoma skin cancers. Patients are not considered to have a “currently active” malignancy if they have completed anticancer therapy and are considered by their physician to be 30% risk of relapse. Pregnant or lactating women; all male and female fertile patients must use adequate contraception (barrier method) while on study and for 3 months thereafter. Known concomitant genetic or acquired immune suppression disease, such as HIV",cycle 1,NA
16899365,NA,Single Drug,No,children with recurrent/ refractory brain tumours,"Patients had to be less than 18 years of age, with a recurrent or progressive brain tumour that was refractory to standard therapy, or for which there was no standard salvage treatment. The Karnofsky performance status had to be greater or equal to 60. Subjects had to be on a stable dose of steroids for at least 1 week prior to enrolment, and have a life expectancy of more than 12 weeks. Patients also had to have recovered from any toxic effects of previous chemotherapy, and be off growth factors for at least 1 week. A haemoglobin count greater than 100 g/l, a platelet count higher than 100 x 109/l and a neutrophil count greater than 1.5 x 109/l were mandatory, as was creatinine, urea, total and direct bilirubin lower than 1.5 times the upper limit of laboratory normal and AST and ALT lower than 3 times normal. Patients were not eligible if they had undergone bone marrow transplantation within the prior 6 months. Females of reproductive potential had to have a negative pregnancy test","Exclusion criteria included previous treatment with dacarbazine (DTIC) or TMZ. Also excluded were patients with fre- quent vomiting or any other medical condition interfering with oral intake that would prevent the patient from swallowing TMZ capsules. Patients requiring a dose delay of more than 4 weeks between courses or a dose reduction to less than 50 mg/m2 were taken off the study. Patients were allowed to resume a subsequent cycle at the same dosage if laboratory values were returned to the level of study entry criteria; a dose reduction schema was established according to Common Toxicity Criteria (CTC) version 2.0, NCI, April 30th, 1999.",the first course ,NA
16614943,NA,Combination,No,Patients with recurrent or progressive brain metastases ,"Adult patients with single or multiple parenchymal brain metastasis from solid tumors, recurrent or progressive after standard treatment, were eligible for this study. Other inclusion criteria were Karnofsky Performance Score >=60, absolute neutrophil count >=1500, platelet >=100,000, hemoglobin >=10 g/dl, and normal renal and hepatic function. Patients who had received prior radiosurgery were allowed to participate if: (1) they had new brain metastases not previously treated with SRS, (2) PET or MRS imaging confirmed the presence of active tumor, or (3) there was surgical resection demonstrating active tumor pathologically. ","Exclusion criteria included any chemotherapy within 4 weeks prior to study, prior treatment with TMZ, dacarbazine or vinorelbine, and serious non-oncologic systemic disease. Patients with concomitant leptomeningeal carcinomatosis were not formally excluded.",cycle 1,NA
11606103,NA,Single Drug,No,previously treated ovarian cancer patients,"Patients with a histologically confirmed diagnosis of epithelial ovarian cancer, including those with serous adenocarcinoma, mucinous adenocarcinoma, endometrioid adenocarcinoma, clear-cell adenocarcinoma, mixed epithelial carcinoma, and undifferentiated carcinoma, were enrolled in the study. Patients with extraovarian serous carcinoma were also en- rolled. All patients had measurable disease by bidimensional measurements or elevated cancer antigen (CA) 125 levels. Measurable disease was defined as lesions that could be mea- sured on physical examination or by any means of medical imaging. Ascites and pleural effusion were not considered measurable disease. Sonography was acceptable if the lesions were clearly defined on initial examination and measurable in two dimensions. Patients with CA 125 > 100 U/mL that was increasing on two separate measurements with or without measurable disease were eligible. Eligible patients demonstrated adequate bone marrow function (white blood cells >=3000/uL, granulocytes >=1500/uL, platelets >=100,000/uL) and a Gynecologic Oncology Group (GOG) performance status <=2 at study entry. All patients had received previous chemotherapy treatment in first-line and, in many cases, second-line ovarian carcinoma. Platinum-sensitive patients who had been treatment free for >=6 months were eligible, as were platinum-resistant patients whose disease had progressed during therapy or within 6 months after therapy.","Newly diagnosed ovarian cancer patients and those with borderline ovarian carcinoma were ineligible. Patients who had prior treatment with topotecan were ineligible, as were those who had previously received more than two chemotherapy treatment regimens. Patients were ineligible if they had re-ceived radiation therapy primarily for ovarian cancer and had no evidence of recurrence from another malignancy for <5 years. Patients with a concomitant malignancy were ineligible",NA,NA
21063221,NA,Combination,No,patients with relapsed/refractory neuroblastoma,"Patients below 21 years of age with refractory or relapsed neuroblastoma and measurable disease were eligible for this study. The extent of disease was determined by radiographic scan [computed tomography or magnetic resonance imaging and 123I-metaiodobenzylguanidine (MIBG)], urinary catecholamine levels, and bone marrow biopsy. Current disease state must have been one for which there was currently no known curative therapy. A negative urine pregnancy test was required for female participants above 13 years of age. Patients had to demonstrate adequate liver function as defined by aspartate aminotransferase (AST) or alanine aminotransferase (ALT) less than 10 x normal and a bilirubin less than 1.5 mg/dL, as well as recovery from the acute toxic effects of prior chemotherapy. Patients currently receiving another investigational or anticancer drug were excluded from this study, as were patients with severe or uncontrolled infection, or a life expectancy of less than 3 months as judged by clinical examination with Lansky score and degree of organ involvement.",NA,during cycles 1 and 2,NA
11742479,NA,Single Drug,No,patients with recurrent ovarian cancer,"Eligible patients were between 18 and 75 years of age with advanced recurrent ovarian cancer and with a life expectancy of > 12 weeks. In the absence of histological evidence of disease progression, patients could be entered into this trial on the basis of repeated elevated CA125 levels. Patients had received at least one prior treatment with platinum- and paclitaxel containing chemotherapy, but no topotecan or other topo-isomerase inhibitors. All patients had a performance status of 0–2, according to WHO criteria, normal blood counts (leucocytes 3.0 × 109/L, platelets 100 × 109/L) and adequate renal-(serum creatinine 1.5 × upper normal limit) or liver function (bilirubin 1.5 × upper normal limit).","Exclusion criteria included patients with borderline ovarian tumours or germ cell tumours, complete bowel obstruction, a history of atrial or ventricular arrhythmias, congestive heart failure, or documented myocardial infarction within the previous 6 months. Patients with active infection or other serious medical conditions were also excluded. Finally, patients with peritoneal adhesions which preclude homogenous distribution of peritoneal fluid were excluded. ",NA,NA
29138343,NCT01012817,Combination,No,"Patients with Solid Tumors. the majority of evaluable patients enrolled in the study had ovarian, fallopian tube, or primary peritoneal cancer (45 patients), all of whom had platinum-resistant disease.","Patients 18 years or older with any histologically confirmed solid tumor with measurable disease (longest diameter 2 cm with conventional CT) that was metastatic or unresectable who had relapsed less than a year from their prior platinum treatment were eligible. In addition patients had to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, adequate bone marrow (as defined by an absolute neutrophil count >= 1,500/mcL, hemoglobin >= 9.0 g/dL, and platelets >= 100,00/mcL), renal [Cr <= 1.5  the upper limit of normal (ULN)] and hepatic function (total bilirubin <= 1.5 x ULN, ALT and AST <= 2.5 x ULN in the absence of hepatic metastasis or ALT <= 3 x ULN and AST <= 5 x ULN in the presence of hepatic metastasis), as well as the ability to swallow and absorb oral medication. Initially there was no limit on the number of prior regimens, but this was amended at dose level 4 due to impact of prior therapies on marrow reserve. For women of child-bearing potential, a negative serum or urine pregnancy test was required.","Exclusion criteria included treatment with chemotherapy, radiation, or immunotherapy within 4 weeks prior to receiving treatment (6 weeks if prior treatment was mitomycin C or a nitrosourea); prior treatment with a PARP inhibitor; prior radiation therapy to >25% of the bone marrow; uncontrolled intercurrent illness; immunocompromise (other than related to the use of glucocorticoids); known CNS metastases or seizure disorder; New York Heart Association class II or III heart disease or history of MI within 6 months; and other active malignancy other than nonmelanoma skin cancer and carcinoma in situ of the cervix.",during the first treatment cycle,NA
11721172,NA,Single Drug,No,"patients with refractory solid tumors. Tumour type: Ovary 7, SCLC 11, Non-SCLC 4, Melanoma 2, Cervix 2","All patients had a pathologically confirmed diagnosis of metastatic solid tumors refractory to all known forms of effective therapy as well as other investigational agents of higher potential efficacy. Patients must have been off previous anticancer therapy for at least 4 weeks (6 weeks in case of carboplatin, nitrosourea or mitomycin C). Other eligibility criteria were: performance status (WHO) 0–2; age < 75 years; a life expectancy of at least 3 months; inoperable disease; adequate hematologic parameters (absolute granulocyte count >1,500/ul, hemoglobin level >9 g/dl, and platelet count >100,000/ul), adequate hepatic (serum bilirubin <1.5 mg/dl, transaminases < twice the upper limit of normal) and renal (serum creatinine <1.5 mg/dl) function, and no other medical problems which might affect patient compliance to the protocol. Patients with brain metastases were eligible if they had been irradiated, the brain lesions were radiographically stable, and clinical improvement was evident. ","Patients with malnutrition (more than 20% loss of body weight), active infection, or a second primary tumor other than squamous skin carcinoma or in situ cervical carcinoma were excluded from the study.",during the 1st chemotherapy cycle ,NA
23604531,NA,Single Drug,No,patients with relapsed small cell lung cancer (SCLC),"Patients with histologically or cytologically confirmed SCLC pretreated with at least one prior regimen were included in the present study. Patients with both sensitive (>60 days after first-line chemotherapy) and refractory (<=60 days after first-line chemotherapy) relapse were allowed. Additional eligibility criteria included age >=18 years, life expectancy of at least 3 months, and a World Health Organization (WHO) performance status of <=2. Patients had to have adequate liver [serum bilirubin <=1.5 times the upper normal limit (UNL); aspartate transaminase (AST) and alanine transaminase (ALT) <=2.5 UNL in the absence of demonstrable liver metastases, or <=5 UNL in the presence of liver metastases], renal (serum creatinine <=1.5 times the UNL), and bone marrow (neutrophils >=1.5 x 109/l and platelets >=100 x 109/l) function. Prior radiotherapy to <25 % of marrow-containing bones was allowed. Patients with asymptomatic brain metastases were enrolled, provided that they had been treated with whole-brain irradiation and were clinically and radiologically stable. At least 4 weeks had to have elapsed since the last chemotherapy or radiotherapy course.","Patients with active infection, history of clinically significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, and ventricular arrhythmias), or a second primary tumor other than squamous cell carcinoma of the skin or in situ cervical carcinoma were not eligible. Previous treatment with intravenous or oral topotecan was not allowed. ",during the first chemotherapy cycle,NA
16208519,NA,Combination,No,elderly patients with small-cell lung cancer,"The eligibility criteria for entry into this study were as follows: (1) pathologically proven SCLC, (2) age of 76 years or more, (3) no prior anticancer therapy,(4) PS of 0–2 on the Eastern Cooperative Oncology Group (ECOG) scale , (5) presence of evaluable lesions, (6) adequate reserves of hematological function (white blood cell [WBC] count >= 4,000/ul, neutrophil count >= 2,000/ul, hemoglobin level >= 9.5 g/dl, platelet count >= 10x104/ul), renal function (serum creatinine <= 1.5 mg/dl), hepatic function (total bilirubin £ 1.5 mg/dl, serum transaminases < 2.5 x upper limit of normal range) and pulmonary function (PaO2 >= 60 Torr at rest), and (7) acquisition of a written informed consent.",Patients with symptomatic brain metastasis were excluded from the study.,in the first cycle,NA
22198338,NA,Combination,No,patients with locally advanced cervical cancer,"Patients ≥18 years of age were eligible if they had primary, previously untreated, histologically confirmed by original institution, invasive carcinoma of the uterine cervix. Patients were required to have a Clinical Stage IB2, IIA, IIB, IIIB, or IVA cancer with negative para-aortic lymph nodes by radiologic evaluation or biopsy. Patients must have had adequate bone marrow, renal and hepatic function defined as; absolute neutrophil count ≥ 1500/mcl; platelet count≥ 100,000/mcl; creatinine≤ 1.5 times upper institutional normal; bilirubin ≤ 1.5 times upper limit of normal; and SGOT and alkaline phosphatase ≤ 2.5 times upper limit of normal. Patients with ureteral obstruction must have been treated with stent or nephrostomy tube to maximize renal function before enrollment. Additionally, patients were required to have a GOG Performance Status of 0, 1, or 2 and no history of prior malignancy evident within the last 5 years. ","Patients with severe infection, pregnant patients who did not wish pregnancy termination prior to treatment, patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplantation, that would require modification of radiation fields, and patients whose circumstances would not permit completion of this study or the required follow-up were ineligible.",during any of the six treatment cycles or within four weeks following completion of treatment.,NA
20165849,NA,Combination,No,"patients with solid tumor malignancies. The most common tumor type was SCLC (n = 8), followed by extrapulmonary small cell (n = 3), pulmonary carcinoid (n = 1), Merkel cell (n = 1), and melanoma (n = 1).","Men and women >=18 years of age with a Karnofsky performance status of >=70% and with histologically or cytologically conWrmed solid tumors for which topotecan was an appropriate treatment were eligible. Patients with progressive brain metastases, leptomeningeal involvement, and neurologic dysfunction other than peripheral neuropathy were excluded given the need to accurately assess neurologic adverse events associated with obatoclax mesylate. Any number of prior chemotherapy or radiation treatments was allowed, with the last treatment given >=4 weeks prior. Normal organ and bone marrow function was required, deWned as a leukocyte count >=3,000/uL, absolute neutrophil count >=1,500/uL, platelets >=100,000/uL, total bilirubin within institutional normal limits, AST and ALT <=2.5 times institutional upper limit of normal, and a creatinine clearance >=60 mL/min/1.73 m2. While obatoclax mesylate has a low potential to inhibit drugs metabolized by CYP1A2, CYP2C19, and CYP3A4/5, eVorts were made to change enzyme-inducing medications to non-inducing drugs. A list of commonly prescribed CYP1A2, CYP2C19, and CYP3A4/5 substrates, inhibitors, and inducers was provided as an appendix to the study protocol for crossreferencing patient medication lists during the eligibility review process. A suitable non-interacting replacement drug was substituted when available","Pregnant patients were excluded, as were patients with uncontrolled comorbid conditions",NA,NA
12626128,NA,Combination,No,patients with intrinsic pontine glioma of childhood,"Eligibility criteria included clinical and radiographic (MRI) evidence of tumors that intrinsically (greater than 50% intra-axial) involved the pons, the pons and medulla, the pons and midbrain, the entire brainstem, or tumors that contiguously involved the thalamus or upper cervical cord. Histologic verification was not required. Patients were required to be less than 21 years of age at enrollment, have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and have a life expectancy of more than 8 weeks. History, physical exam, and contrast-enhanced MRI of the brain, as well as adequate hematologic, renal, and liver function, were required for enrollment. Other eligibility requirements were adequate bone marrow function including peripheral absolute neutrophil count >1000/mm3, platelet count >100,000/mm3 (transfusion independent), and hemoglobin >10.0 g/dl (transfusion allowed); adequate renal function including serum creatinine <1.5 x normal, creatinine clearance, or radioisotope glomerular filtration rate >70 ml/min/1.73 m2; and adequate liver function including total bilirubin <1.5 x normal and aspartate transaminase or alanine transaminase <2.5 x normal. All patients and/or their parents or legal guardians were required to sign an informed consent according to Children’s Cancer Group guidelines.",Patients with neurofibromatosis or pregnant patients were not eligible for the study,during the radiotherapy,NA
15013589,NA,Combination,No,"Patients with advanced thoracic malignancies. Primary diagnosis (number of patients): Non-small-cell lung cancer 22, Esophageal cancer 1, Connective tissue malignancy","Eligibility criteria included age ≥ 18 years; histologically confirmed thoracic malignancy; scheduled to received 60 Gy radiation to the thorax; Eastern Cooperative Oncology Group performance status of 0 or 1; ≥4 weeks from their most recent chemotherapy and/or radiation and have fully recovered from toxicity (except nitrosurea and mitomycin C which required = 6 weeks from most recent treatment); adequate bone marrow function (WBC = 4000/mm3; platelets = 100,000/mm3; ANC = 1500/mm3); adequate hepatic function (total bilirubin = 1.5 mg/dl); adequate renal function (creatinine = 1.5 mg/dl with calcium and electrolytes within normal limits); and written informed consent obtained per institutional and NIH guidelines.",Exclusion parameters were prior radiotherapy to areas of the thorax to be irradiated during this study; a history of brain metastasis; pregnant or nursing patients; and patients with potentially curable disease by conventional surgery.,during the thoracic radiotherapy ,NA
11104627,NA,Combination,No,"Patients with recurrent epithelial ovary, tubal, or peritoneal carcinoma","Patients with recurrent (documented either histologically or CA 125 >100 U/ml) epithelial cancers of the ovary, fallopian tube, or peritoneum following treatment with paclitaxel and a platinum analogue were eligible for participation. Patients may have received no more than two prior regimens. Standard phase II inclusion criteria were employed: adequate bone marrow, hepatic, and renal function was necessary, no evidence of infection, GOG performance status #2, low-malignant-potential tumors were excluded, and no other history of malignancy other than skin (excluding melanoma). Creatinine clearance was calculated by the method of Jelliffe . All patients signed an IRB approved informed consent",NA,cycle 1,NA
19885837,NA,Combination,No,pediatric patients with recurrent/refractory AML,"Eligible patients with recurrent or refractory AML whowere aged <21 years were treated at St. Jude Children’sResearch Hospital and at the University of MichiganComprehensive Cancer Center from 1998 to 2003. Theyhad a life expectancy >=6 weeks, an Eastern CooperativeOncology Group performance status <=3, and adequaterenal (creatinine <2 x normal) and hepatic (bilirubin <= 3mg/dL, alanine aminotransferase and aspartate amino-transferase <=500 U/dL) function. Three patients previ-ously treated in a pilot study at St. Jude Children’sResearch Hospital with the same combination wereincluded. Patients were grouped for analysis as those whohad not previously undergone allogeneic HSCT (Stratum1) and those who had (Stratum 2). This study and theinclusion of the 3 additional patients were approved byinstitutional review board. Signed informed consent wasobtained from patients, parents, or legal guardians, withassent from the patients, if appropriate",NA,NA,Patients were grouped for analysis as those whohad not previously undergone allogeneic HSCT (Stratum1) and those who had (Stratum 2)
18752593,NA,Combination,No,patients with multiple myeloma that was refractory or that had relapsed after conventional chemotherapy or high-dose therapy with stem-cell support,"Patients with relapsed or refractory MM were entered into thestudy provided that they were aged between 18 and 80 years, had an Eastern Cooperative Oncology Group performancestatus of 0–2, and an expected survival of at least 3 months. Allpatients had histologically or cytologically proven stage II or IIIMM  according to the Durie & Salmon (1975) criteria,  with quantitatively measurable myeloma proteins in the serum and/or urine using protein electrophoresis. Patients also had to have a total white blood cell count of at least 3 x 109/l and a platelet count of at least 75 x 109/l.","Patients were excluded from the study if they had non-secretory or local plasmacytoma, human immunodeficiency virus or hepatitis B surface antigen-positive secondary malignancy or active hepatitis, any other secondary malignancy, hadundergone pretreatment with bendamustine or thalidomide inthe last 6 months, or had serious concomitant diseases, such asovertheartinsufficiency,myocardial infarction within 3 months prior to the trial, dysrhythmias >= Lown 4b, chronicrespiratory disease with hypoxaemia, bilirubin > 3.0 x upper limit of normal, serum  creatinine  clearance > 0.33 ml/s, anautoimmune disease or  allogeneic transplant, a severe diseaseof the central nervous system, pheochromocytoma, glaucoma,or severe poorly controlled diabetes mellitus. In addition, patients were excluded if they had participated in a clinical study within 1 month of the current study. Women of childbearing  age who were unwilling to use a dual methodof contraception and men unwilling to use a condom were alsonot allowed to participate in the study. ",during the first two cycles,Patients were stratified into two groups:group A (four to six patients for each thalidomide dose level) comprised patients who had relapsed after conventional chemotherapy; group B (four to six  patients for  each thalidomide dose level) comprised those who had relapsed after high-dose therapy with stem-cell support. 
9849451,NA,Single Drug,No,"adult patients with solid tumours. Tumour types: Colorectal 10, Ovarian 3, Hepatocellular 2, Breast 2, Non-small cell lung cancer 2, Small cell lung cancer 2, Miscellaneous 8","Patients with a histologically conÆrmed diagnosis of malignant solid tumour refractory to standard forms of therapy were eligible. Other eligibility criteria included: age >= 18 years; WHO performance status <= 2; an estimated life expectancy of >= 12 weeks; no previous anticancer therapy >= 4 weeks (6 weeks for nitrosoureas or mitomycin C); adequate haematopoietic (white blood cell (WBC) >= 4 x 109/l and platelets >= 100 x 109/l), hepatic (bilirubin within normal limits, aspartate amino transferase (AST), alanine amine transferase (ALT) and/or alkaline phosphatase <= 2 x normal), and renal function (serum creatinine <= 133 mmol/l (2.0 mg/dl)). All patients gave written informed consent before entry into the study.",Specific exclusion criteria included: active peptic ulcer or any gastrointestinal condition (including prior upper gastrointestinal resection) which could alter absorption or motility; patients taking H2-antagonists or proton pump inhibitors.,during the first course,NA
9607572,NA,Single Drug,No,"adult patients with solid tumors. Tumor types: Colorectal, Ovarian, SCLC, NSCLC, Miscellaneous ","Patients with a histologically confirmed diagnosis of a malignant solid tumor that was refractory to standard forms of therapy were eligible. Other eligibility criteria included: age of >=18 years; WHO performance score of <=2; an estimated life expectancy of >=12 weeks; no anticancer therapy in the preceding 4 weeks (6 weeks for nitrosoureas or mitomycin C); adequate hematopoetic (WBC, >=4 X lO9/liter; platelets, >=100 x l09/liter), hepatic (bilirubin within normal limits; aspartate aminotransferase, alanine aminotransferase, and/or alkaline phosphatase, <=2 X upper limit of normal), and renal [serum creatinine, <=l33 umol/liter (2.0 mg/dl)] function.","Specific exclusion criteria included: active peptic ulcer or any gastrointestinal condition that could alter absorption or motility or patients taking H, antagonists or proton pump inhibitors. ",during the first course,NA
25677219,NCT00483860,Single Drug,No,"patients with advanced solid tumours and impaired renal function. Thes tudy population consisted most frequently of patients with primary tumours of the ovary, the prostate (both12%) and non-small lung (NSCLC, 10%).","Patients with histologically or cytologically confirmed advanced solid tumours, for whom no standard treat-ment was available or for whom single agent topotecan therapy was considered suitable, were eligible. Other inclusion criteria were ability to provide written informed consent,≥18 years, Eastern Cooperative Oncology Group(ECOG)  performance status≤2 and stable renal func-tion, defined as <10% change in estimated CLcr for morethan 4 weeks prior to start.","In addition to standard exclusion criteria, the following were included current dialysis,participation in another clinical study within 30 days or five elimination half-lives of the drug under investigation,uncontrolled emesis, bilirubin >1.5 times the upper limitof normal (ULN) alanine aminotransferase, aspartate aminotransferase or alkaline phosphatase >two timesULN, in case of liver metastases<five times ULN,haemoglobin <5.6 mmol l-1 or <9gdl-1, white blood cellcount<3.5 × 109l-1, absolute neutrophil count <1.5 ×109l-1 or platelets <100 × 109l-1, active infection, lessthan 4 weeks since last chemo-, radio-biologic-therapy orsurgical procedure, failure to recover from any prior chemo-therapy toxicity at baseline with the exception of grade 1neuropathy or any grade alopecia, impaired gastro-intestinal absorption or motility, concurrent ciclosporin A treatment, concurrent severe medical problems unre-lated to the malignancy significantly limiting compliancewith protocol/study events, history of allergic reactionsto topotecan or chemically related compounds. Patients were not allowed to receive drugs known to inhibit orinduce human breast cancer resistance protein (BCRP, ABCG2), P-glycoprotein (P-gp,ABCB1) and multidrug resistance protein (MRP1,ABCC1) during pharmacokinetic sampling. The study protocol was approved bythe Medical Ethics committee and all patients had to give written informed consent prior to entry into the study.The study was conducted in accordance with the ICH guidelines of good clinical practice (GCP).",NA,"Patients were assigned to one offive groups (Table 1) according to measuredCLcrat baseline based on the amount of creatinineexcreted in a 24 h urine collection and prior platinumtreatments: CLcr >80 ml min-1 and limited prior PBchemotherapy (group A), CLcr >80 ml min-1 and prior PB chemotherapy (group B), mild renal impairment(CLcr =50–79 ml min-1, group C), moderate renal impairment (CLcr =30–49 ml min-1, group D) and severe renal impairment (CLcr <30 ml min-1,  group E)."
27793021,NCT01670175,Combination,No,"children and young adults with relapsed and refractory solid tumors. Diagnosis: Osteosarcoma 7, Ewing sarcoma 3, Rhabdomyosarcoma 3, Brain Tumor 2a, Neuroblastoma 1, Other 5 (One patient each with alveolar soft part sarcoma, desmosplastic small round cell tumor, esthesioneuroblastoma, myxofibrosarcoma, and undifferentiated sarcoma)","Patients were eligible for participation if they were 12 months to 30 years of age, had histologic diagnosis of solid tumor (including brain tumors) with measurable or evaluable disease, and had no known curative options. Patients were required to have a Karnofsky (age > 16 years) or Lansky (age < 16 years) performance score of 50 or more and to have recovered from previous therapy. Patients previously treated with sirolimus, topotecan, or cyclophosphamide as single agents were eligible. Patients previously treated with two of the three drugs were eligible, though patients previously treated with all three agents in combination were excluded. Patients previously treated with sirolimus analogues (e.g. temsirolimus, everolimus, or ridaforolimus) were also eligible. Patients were required to have adequate baseline bone marrow (absolute neutrophil count > 750/μL; platelet count >75,000/μL for patients without bone marrow involvement or platelet count > 25,000/μL for those with known bone marrow metastatic disease), renal, hepatic, pulmonary, and central nervous system function according to defined protocol criteria. Patients were required to have serum fasting triglyceride and cholesterol levels both < 300 mg/dL.","Exclusion criteria included: pregnancy or breastfeeding; concurrent use of strong CYP3A4 inducers or inhibitors; concurrent use of enzyme-inducing anticonvulsants; concurrent use of corticosteroids not on a stable or decreasing dose for 7 days prior to enrollment; uncontrolled infections; or history of allergic reaction to compounds of similar composition to sirolimus, topotecan, or cyclophosphamide.",During the first 28-day Cycle,NA
7949242,NA,Single Drug,No,"patients with refractory malignancies. Primary tumors； colorectal, lung (non-small cell), ovarian, carcinoid, unknown primary, pancreas, renal cell, prostate, breast, gastric, esophageal, skin","All patients had a pathologically confirmed diagnosisof metastatic solid tumors refractory to all known forms of effective therapy as well as other investigational agents of higher potential efficacy. They also had a Southwest Oncology Group (SWOG) performance status of 》= 2 and an anticipated life expectancy of at least 12 weeks. Additional eligibility criteria included: white blood cell count of >=3000 cells/µl) (granulocytes  =>=1500 cells/µl), platelets 100000/µ1, hemoglobin 10 g/dl, seNm creatinine <= 1.5 mg/dl and bilirubin <=1.5 mg/di. ","Patients with a prior history of hemorrhagic cystitis, prior pelvic irradiation or urinalysis indicating greater than five red blood cells per high power fteld on microscopic examination were excluded. Patients must have been off previous anticancer therapy for at least 3 weeks (6 weeks if a nitrosourea or mitomycin C were used).",NA,NA
16520988,NA,Single Drug,No,patients with advanced hepatocellular carcinoma,"Patients with measurable, metastatic or locally advanced HCC whose tumors had failed to have definitive local therapy [including surgical resection, percutaneous ethanol or alcohol injection (PEI or PAI), transcatheter arterial chemoembolization (TACE), or in combination) or whose tumor was too advanced; 18–75 years of age; and an Eastern Cooperative Oncology Group (ECOG) performance score of 0–2 were eligible. The diagnosis of HCC had to be established by cytology or histopathology. Patients were required to have a Child-Pugh’s Score <= 8 with a serum total bilirubin <= 3 mg/dL, a prothrombin times <= 5 s above normal control, a platelet count >= 7.5x104/mm3, a white cell count >=3,000/mm3, and a serum creatinine <1.5 mg/dL. Female of childbearing age should show a negative pregnant test. Sexually active patients, in conjunction with their partners, had to agree to practice birth control measure during and for at least 2 months after thalidomide therapy. ",NA,In first week,NA
11099328,NA,Single Drug,No,"patients with advanced cancer. Tumor types: Lung (NSCLC) 1, Colorectal 2, Stomach 2, Cervix 3, Pancreas 1, Leiomyosarcoma 1, Kidney 1, Unknown primary 1","Patients entered onto this study met the following criteria: (1) histologically confirmed solid tumor, unresponsive to standard therapy; (2) age >= 18 years; (3) minimum life expectancy of 3 months; (4) Southwest Oncology Group (SWOG) performance status <= 2; (5) no chemotherapy or radiotherapy within 4 weeks before treatment with DX-8951f (6 weeks for previous treatment with nitrosoureas, mitomycin, carboplatin, or extensive radiotherapy); (6) normal liver function, defined as bilirubin level <= 17 umol/L, transaminase concentrations <= 2.5 times the upper limit of normal (ULN) (<= five times ULN in cases of liver metastases), and alkaline phosphatase concentration <= 1.5 times ULN (unless due to bone metastases); (7) adequate bone marrow function, defined as leukocyte count >= 3,000/uL, neutrophil count >= 1,500/uL, platelet count >= 100,000/uL, and hemoglobin level >= 8.5 g/dL; (8) prothrombin time and activated partial thromboplastin time within normal limits; (9) psychosocial state compatible with the participation in the study; (10) signed informed consent according to institutional and national guidelines; (11) no kidney or liver failure; (12) no history of myocardial infarction within 6 months; (13) no history of chronic enteropathy, including ulcerative colitis and Crohn’s disease; (14) no uncontrolled systemic infection; (15) use of a reliable contraception for women of child-bearing age; (16) no known history of severe or life-threatening drug allergy or hypersensitivity to camptothecin derivatives; (17) absence of diarrhea or excess of two to three stools daily over normal frequency in the previous month; and (18) no symptomatic brain metastases.",NA,cycle 1,NA
8637048,NA,Combination,No,"patients who had refractory, malignant, solid tumors and who either had or lacked hepatic injury. Primary tumor sites: Colorectal, Pancreas, Other (Includes one each of ovarian, urinary, bladder, breast, renal, and hepatocellular carcinomas and melanoma)","Patients with histologically documented, malignant, solid tumors refractory to conventional therapy or for which no effective therapy currently exists were candidates for this study. Since serum bilirubin level (reflecting the clearance of bilirubin) is related to the sufficiency of hepatic function and not to liver damage per se, patients were assigned on this basis to either a control group (total serum bilirubin level £1.2 mg/dL; seven patients) or a hepatic dysfunction group (serum total bilirubin level >l.2 mg/dL; 14 patients). Eligibility criteria for the study included the following: 1) 18 years of age or older, 2) an Eastern Cooperative Oncology Group performance status of 3 or better, 3) a life expectancy of at least 6 weeks (determined by an experienced oncologist), which would allow the completion of preliminary pharmacologic studies and at least one course of therapy; 4) no major surgery within 14 days or wide-field radiotherapy and/or chemotherapy within 28 days of entering the study protocol (or within at least 6 weeks for those treated with either a nitrosourea or mitomycin); 5) adequate hematopoietic functions (white blood cell [WBC] count >4000/uL and platelet count >100 000/uL); 6) no history of hemorrhagic cystitis and fewer than five red blood cells per high-power field on urine microscopy examination; 7) normal renal function (creatinine level <1.3 mg/dL); 8) no biliary stem or nephrostomy tube placement within 7 days of study entry; 9) no deficiency in the enzyme glucose 6-phosphate dehydrogenase; and 10) no concurrent medications that could potentially affect cytochrome P450 enzyme systems, such as amobarbital, carbamazepine, chlorimipramine, cimetidine, tetrahydro-cannabinol, disulfiram, ethanol, ethinyl estradiol/d/-norgesterol, halofenate, L-dopa, methaqualone, diphenhydramine, phenobarbital, quinine, rifampicin, spironolactone, amitriptyline, vitamin C. or allopurinol. All patients gave written, informed consent according to institutional and federal guidelines before treatment.",NA,NA,NA
9779705,NA,Combination,No,"patients with advanced cancer. Tumor type; Colorectal 13, Unknown primary 4, Esophageal 3, Melanoma 2, Renal cell 2, Breast 1, Small cell 1, Hepatocarcinoma 1, Duodenal 1, Cholangiocarcinoma 1, Peritoneal 1","Patients with pathologically confirmed solid tumors refractory to standard therapy or for which no standard therapy existed were eligible if they had measurable or assessable disease and had received a maximum of one prior chemotherapy regimen for metastatic disease. Other eligibility criteria included age greater than 16 years, CALGB performance status 0 or 1, life expectancy of at least 2 months, and at least 4 weeks since prior chemotherapy or radiotherapy. The following laboratory entry criteria were required: granulocyte count >= 1,500/uL, platelet count >= 100,000/uL, hemoglobin level >= 10 g/dL, serum creatinine 5 1.5 mg/dL, and bilirubin level 5 1.5 mg/dL. All patients provided signed, informed consent.","Patients were ineligible if they had received prior whole pelvic irradiation or prior therapy with camptothecins or platinum compounds. In addition. pregnancy, concurrent active malignancy, known bone marrow metastases, or any contraindication to an indwelling central venous catheter also constituted exclusion criteria.",in the first treatment cycle,NA
8648378,NA,Combination,No,patients with solid tumors,"Only patients with solid tumors refractory to conventional therapy or for whom no effective therapy existed were candidates for this study. Eligibility criteria included the following: (1) age >= 18 years; (2) Eastern Cooperative Oncology (ECOG) performance status <= 2 (ambulatory and capable of self-care); (3) life expectancy enabling the completion of at least two courses of therapy; (4) no major surgery within 14 days or radiotherapy and/or chemotherapy within 28 days; (5) adequate hematopoietic (absolute neutrophil count [ANC] >= 1,500/uL and platelet count >= 100,000/uL), hepatic (total bilirubin level <= 1.5 mg/dL), and renal (creatinine concentration <=1.5 mg/dL) functions; (6) no history of hemorrhagic cystitis and less than five RBCs per high-power field in urine; and (7) no other coexisting medical problems of sufficient severity to prevent full compliance with the study. ","Since the principal objective of the studywas to determine the toxicities and optimal TPT doses for subsequent trials of untreated or minimally pretreated patients, patients were ineligible if they had (1) received wide-field radiation to the pelvis or more than 20% of bone marrow-bearing bones; (2) received more than four courses of chemotherapy that contained an alkylating agent; (3) received any nitrosourea or mitomycin; or (3) widespread metastases to bones or bone marrow.",All courses,NA
9060549,NA,Single Drug,No,"adult patients with solid tumors. Tumor type: Colorectal, Oropharynx, Ovarian, Lung (non-small-cell), Melanoma, Breast, Carcinoma, unknown primary, Soft tissue sarcoma, Gastric, Kidney, Cervix","Patients with a histologically confirmed diagnosis of a malignant solid tumor refractory to standard forms of therapy were eligible. Other eligibility criteria included the following: age 18 to 75 years; Eastern Cooperative Oncology Group (ECOG) performance status <= 2; estimated life expectancy >= 12 weeks; no previous anticancer therapy for >=4 weeks (6 weeks for nitrosoureas or mitomycin); and adequate hematopoietic (WBC count >= 4 x 109/L and platelet count >= 100 x 109 /L), hepatic (bilirubin within normal limits, and AST, ALT, and/or alkaline phosphatase <= two times normal), and renal (serum creatinine concentration <=132.6 lamol/L) function","Specific exclusion criteria included active peptic ulcer or any gastrointestinal condition that could alter absorption or motility, and patients taking H2 -antagonists or proton pump inhibitors. ",NA,NA
7738619,NA,Combination,No,women with responsive metastatic breast cancer ,"Women between the ages of 18 and 60 with metastatic or locally advanced inoperable breast cancer with a complete or partial response to therapy as defined by standard Eastern Cooperative Oncology Group criteria were eligible for this study.23 Patients could have tumor with any estrogen or progesterone receptor level, and had to have adequate renal, hepatic, cardiac, pulmonary, and hematopoietic reserves to undergo high-dose alkylator therapy. All patients had bone marrow biopsies negative for tumor by routine histologic examination.",NA,NA,NA
10071262,NA,Combination,No,patients with advanced ovarian cancer,"Patients with histologically confirmed stage III advanced epithelial ovarian carcinoma who had undergone cytoreductive surgery and were left with residual disease (> 1 cm residual mass) or stage IV disease and who had not received any previous chemotherapy, immunotherapy, or hormonal therapy for ovarian carcinoma were eligible for the study. Patients had to have measurable or assessable disease. At a later stage, patients with successfully debulked tumor status could also be entered after amendment of the protocol in agreement with the medical ethics committee. Other eligibility criteria included age at least 18 years; Eastern Cooperative Oncology Group performance status 2 or lower; estimated life expectancy at least 12 weeks; adequate bone marrow function, defined as WBC count at least 4,000/µL, absolute neutrophil count at least 1,500/µL, hemoglobin at least 6.2 mmol/L (9.0 g/dL), and platelet count at least 100,000/µL; adequate hepatic function, defined as serum bilirubin not more than 34 µmol/L (2.0 mg/dL) and AST and alkaline phosphatase not more than twice the normal upper limit or not more than three times the normal upper limit when related to liver metastases; and adequate renal function, defined as serum creatinine not more than 133 µmol/L (1.5 mg/dL) or calculated creatinine clearance at least 60 mL/min ","Ineligibility criteria included a histologic diagnosis of borderline epithelial carcinoma, gross ascites, uncontrolled infection, concomitant ketoconazole treatment, history of allergic reactions to polyoxyethylated castor oil or compounds chemically related to topotecan, cisplatin, or paclitaxel, or pre-existing cardiac disease.",during the first treatment cycle,NA
20630830,NA,Single Drug,No,patients with advanced non-small-cell lung cancer,"Patients who met the following criteria were enrolled in this study: a histologic or cytologic diagnosis of stage IV NSCLC or stage III disease that was not a candidate for curative radiation therapy; no therapy within 4 weeks before entry (within 6 weeks for nitrosourea or mitomycin C); a measurable or evaluable lesion; a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale; a life ex- pectancy of at least 3 months; adequate bone marrow function (leukocyte count, 4000-12,000/μL; neutrophil count ≥ 2000/μL; platelet count, ≥ 100,000/μL; and hemoglobin concentration, ≥ 9.5 g/dL), normal hepatic function (bilirubin, ≤ 1.5 mg/dL; aspartate aminotransferase and alanine aminotransferase levels ≤ 2.5 × the upper limit of normal [ULN]), and normal renal function (creatinine, ≤ the ULN and creatinine clearance ≥ 50 mL/min; aged between 20 and 74 years; and gave written informed consent to participation in the study obtained.","Patients were ineligible if they had a serious infectious disease or any other serious complication (eg, heart disease, interstitial pneumonia, or uncontrollable diabetes); gastrointestinal bleeding or paralytic ileus; massive pleural or pericardial effusion, or ascites; symptomatic brain metastases; an active concurrent malignancy; were lactating or pregnant, or might become pregnant; unwilling to use contraception (for men); had a history of bone marrow transplantation; had a history of drug allergy; had been treated with topotecan; or had any other severe medical problem that might compromise compliance with the protocol.",during the first cycle of treatment,NA
7602366,NA,Single Drug,No,"patients with solid malignant tumors. Tumor sites: Colorectal, Ovary, Lung (NSCLC), Unknown origin, Gallbladder, Stomach, Kidney, Pancreas, Melanoma, Cervical","Eligibility criteria included a histologically confirmed diagnosis of a solid malignant tumor no longer amenable to established forms of effective therapy. All patients had acceptable bone marrow function (WBC count > 4 x 109/L and platelet count >= 100 x 109/L), serum bilirubin level 2 25 imol/L and serum creatinine concentration <= 120 umol/L World Health Organization (WHO) performance status <= 2, anticipated life expectancy >= 12 weeks, and age between 18 and 75 years. The study protocol was approved by the Medical Ethical Committee of the hospital, and all patients gave written, informed consent","Patients with a prior history of hemorrhagic cystitis, urinalysis that indicated more than five RBCs per high-power field on microscopic examination, or prior pelvic irradiation were excluded. Previous anticancer chemotherapy had to be discontinued for at least 4 weeks before study entry or for 6 weeks in case of pretreatment with a nitrosourea or mitomycin C.",NA,NA
12506183,NA,Single Drug,No,"patients 3 years and older with neoplastic meningitis. Non-CNS tumors: Acute lymphoblasic leukemia 3, Retinoblastoma 3, Breast cancer 2, Lung cancer 2; CNS tumors: Medulloblastoma/PNET 9, Gliomatosis 2, Ependymoma 1, Pineoblastoma 1","Patients were eligible for this trial if they were 3 years of age or older and were diagnosed with leukemia, lymphoma, or other solid tumors and overt meningeal tumor involvement that was refractory to conventional therapy. Patients with leukemia/lymphoma were required to have a CSF WBC count >= 5/uL and evidence of blasts on cytospin preparation or by cytology. Patients with solid tumors had a positive CSF cytology examination or unequivocal evidence of leptomeningeal disease on computed tomography (CT) or magnetic resonance imaging (MRI) scans. Other eligibility criteria included (1) an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less; (2) a life expectancy of > 8 weeks; (3) adequate liver function (serum bilirubin < 2.0 mg/100 mL and ALT < three times the upper limit of normal); (4) adequate renal function (serum creatinine < 1.5 mg/100 mL); (5) normal metabolic parameters (serum electrolytes, calcium, and phosphorus); (6) recovery from the toxic effects of prior therapy; and (7) no prior IT therapy within 1 week of starting treatment on this study. Patients could not receive other therapy targeted specifically at their leptomeningeal disease but could receive concomitant chemotherapy to control systemicdisease or bulk CNS disease provided that the systemic chemotherapy was not an investigational agent or an agent with significant penetration into the CNS (eg, high-dose methotrexate, thiotepa, high-dose cytarabine, fluorouracil, intravenous mercaptopurine). ","Study exclusion criteria included clinical evidence of obstructive hydrocephalus or compartmentalization of CSF flow, as documented by a radioisotope CSF flow study, and women of childbearing age who were pregnant or lactating",NA,NA
18096059,NCT00287963,Combination,No,patients with recurrent lung cancer,"Patients were recruited based upon the following eligibility criteria: pathologically proven lung cancer, all histologic types of lung cancer were eligible (both small cell and non-small cell lung cancer); recurrent or progressive disease after at least one prior chemotherapy +/- radiotherapy regimen; at least 2 weeks after completion of prior radiotherapy; no prior therapy with topotecan or vinorelbine; age ≥ 18 years; ECOG performance status ≤ 2; adequate organ and marrow function defined as: absolute neutrophil count ≥ 1,500/mm3, platelets ≥ 100,000/mm3, total bilirubin ≤ 1.5 mg/dl, creatinine ≤ 1.5 mg/dl; non-pregnant and nonlactating; no active concurrent invasive malignancy; ability to understand and the willingness to sign a written informed consent document.","Patients were excluded if they: had chemotherapy within 4 weeks prior to entering study; were currently receiving other investigational agents; had a history of allergic reactions attributed to compounds of similar chemical or biologic composition to topotecan or vinorelbine; had uncontrolled intercurrent illness including active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness.",during cycle 1,NA
12109520,NA,Single Drug,No,"patients with various solid tumors in Japan. Cancer class Lung cancer (SCLC, NSCLC), Colorectal cancer, Rectal cancer, Colon cancer, Ovarian cancer, Cervical cancer, Uterine cancer, Breast cancer, Pharyngeal cancer, Pleural mesothelioma, Submandibular cancer","Patients who met the following criteria were selected: (1) patients with histologically or cytologically confirmed malignant solid tumors; (2) patients who did not respond to the standard treatment or for whom there was no appropriate treatment; (3) patients who had adequate organ function to evaluate the adverse reactions of nogitecan hydrochloride (4000/mm3 <= WBC count <= 12000/mm3; platelet count, >= 100000/mm3; hemoglobin, >=9.5 g/dl; GOT, GPT, and alkaline phosphatase [ALP], 2 times the upper limit of their respective normal ranges at each medical institution; total bilirubin, <=1.5 mg/dl; serum creatinine, <= the upper limit of the normal range at each medical institution); (4) patients with a performance status (PS) of 0–2; (5) patients who had a predicted life expectancy of 3 or more months; (6) patients who had been off the previous therapy, with at least 2 weeks having passed for biological response modifiers (BRMs), hormone preparations, and metabolic inhibitors, and 4 weeks for other therapies; (7) patients aged from 15 to 75 years; (8) inpatients; (9) patients who had given their consent to participate in the investigation; (10) patients with no history of drug hypersensitivity; (11) patients with no symptoms associated with metastasis in the brain, no ascites, no subileus, and no severe complication; and (12) patients who were not pregnant or nursing or who would not be come pregnants.",Others whom the investigator considered ineligible were excluded.,NA,NA
16501591,NA,Single Drug,No,ovarian carcinomas,"Inclusion criteria were as follows: histologically proven ovarian, fallopian tube or primary peritoneal carcinoma, age between 18 and 65 years, ECOG performance index <=2, creatinine clearance >=60 ml/min, bilirubin <1.25 normal value, transaminases and alkaline phosphatases <2 normal values (three times if hepatic metastases were present), normal cardiac function, normal blood count and, negative viral serologies. Patients were enrolled either after a single line of CT including a platinum salt (cisplatin or carboplatin) and a taxane if they had experienced progressive or stable disease on CT, or had macroscopically positive second look, initial stage FIGO IV disease, or relapse before 6 months after the end of the initial treatment, or relapse after two lines of CT including a platinum salt and a taxane, and with a first relapse occurring more than 6 months after the end of the initial treatment and whose disease was primarily or secondarily refractory to a second-line treatment with a platinum salt and/or a taxane. As it was a phase I study to determine the MTD of topotecan, measurable disease was not required. Patients had to have signed an informed consent","Exclusion criteria were as follows: expected survival <3 months, previous pelvic radiotherapy, previous treatment with topoisomerase I inhibitors, intestinal occlusion, grade >=2 platinum-induced neuropathy, clinical evidence of cerebral metastases, serious psychiatric disease, uncontrolled serious infection, previous HDCT or more than two lines of prior CT.",the first HD cycle,NA
14752800,NA,Combination,No,"children with recurrent or refractory solid tumors. Most patients hadeither a CNS tumor or neuroblastoma. Diagnosis and response: Pontine glioma, Medulloblastoma/PNET, Neuroblastoma, Osteosarcoma, CNS neuroglial neoplasm, Glioblastoma multiforme, Hepatocellular carcinoma, Peripheral nerve sheath tumor, Low-grade glioma, Ependymoma","Eligibility criteria included a histologically confirmed diagnosis of a solid tumor for which there was no availablestandard therapy. Tumor biopsies were not required forpatients with intrinsic brainstem gliomas. Patients wererequired to be less than 21-years old at the time of studyentry, not pregnant or lactating, have a life expectancy ofgreater than 8 weeks, and have no severe uncontrolled infections. Patients were required to have fully recoveredfrom the effects of prior therapy, defined as at least 21 days since completion of radiation therapy, chemotherapy, o rother investigational agent, 8 weeks since craniospinal irradiation, and 16 weeks since high-dose chemotherapyand stem cell rescue. All patients were required to have adequate bone marrow function (absolute neutrophil count: >=1,500/mm3; platelet count: >=100,000/mm3), hepatic function (total bilirubin: <=2.0 mg/dl; ALT: <=5 x normal) and renal function (creatinine: <=1.5 x normalfor age). Patients who had received prior therapy with topotecan and cyclophosphamide were eligible for enrollment.",NA,over two courses ,NA
14519630,NA,Single Drug,No,"patients with hematological malignancies. Disease: MDS 13, CMML 7, AML 3, Ph-negativeb CML 2, CML in BP 1","Patients with primary refractory or relapsing AML after a first remission of < 6 months in duration or relapsing disease after second or higher salvage therapy were eligible for the study. Previously untreated or treated patients with primary refractory or relapsed CML in accelerated phase or BP were eligible, as were previously untreated patients with Philadelphia chromosome-negative CML who were ineligible for other therapies. Also included were patients with primary refractory or relapsing high-risk MDS (RAEB or RAEB in transformation) or CMML and previously untreated patients who had high-risk MDS or CMML who were >=70 years of age and/or had an Eastern Cooperative Oncology Group performance status of >2. To be eligible, patients were required to be >16 years of age and to have an estimated life expectancy of >= 12 weeks. Adequate hepatic (total bilirubin <= 2 mg/dl) and renal function (creatinine <= 1.5 mg/dl) were required, unless organ dysfunction was directly caused by hematological disorder.","Patients with active serious infections, clinically active peptic ulcer, chronic malabsorption syndrome, diarrhea of infectious origin, irritable bowel syndrome, or documented central nervous system disease were ineligible. Pregnant female patients were ineligible, and female patients were required to use effective contraception if they were of childbearing age. Patients had to be off investigational drugs for >=30 days or 5 half-lives, whichever was longer. Patients were required to be off hematopoietic growth factors for at least 2 weeks. ",the first course ,NA
21795476,NCT00553189,Combination,No,"adults with refractory solid tumors and lymphomas. Tumor types: Colorectal 5, Ovarian 5, Melanoma 2, Pancreas 1, Endometrial cancer 2, Hurthle cell thyroid 1, Other 8 (Pleural mesothelioma, hepatocellular, non-Hodgkin's lymphoma (low grade), external ear adenocarcinoma, bile duct adenocarcinoma, small cell lung cancer, esophageal adenocarcinoma, and chondrosarcoma)","Patients eligible for this trial had histologically documented solid tumors and low-grade lymphoid malignancies that were refractory to standard therapy; an Eastern Cooperative Oncology Group performance status <=2; and adequate organ and marrow function defined as leukocytes >=3,000/uL, absolute neutrophil count >=1,500/uL, platelets >=100,000/uL, total bilirubin <=1.5 x the upper limit of normal (ULN), aspartate aminotransferase and/or alanine aminotransferase <2.5 x ULN, and creatinine <1.5 x ULN. Prior anticancer therapy must have been completed at least 4 weeks prior to enrollment. Prior therapy with a PARP inhibitor was allowed.",Patients were excluded if they had an uncontrolled intercurrent illness or were pregnant or lactating.,in the first 2 cycles ,NA
21690471,NA,Single Drug,No,"pediatric patients with recurrent/refractory solid tumors. Disease type: Solid tumors 11 (Rhabdomyosarcoma 3, Osteosarcoma 3, Neuroblastoma 2, Wilms tumor 1, Germ cell tumor 1, Adrenocortical carcinoma 1), Brain tumors 8 (Medulloblastoma 2, Ependymoma 2, Primitive neuroectodermal tumor 1, Atypical teratoid rhabdoid tumor 1, Glioblastoma multiforme 1, Pontine glioma 1)","Age 1 to 21 years. Solid tumor recurrent or refractory to standard therapy or for which no standard treatment is available. Evaluable disease: >= 3 months since autologous or allogeneic bone marrow or stem-cell transplantation. >= 2 weeks since local radiotherapy. >= 3 months since craniospinal radiotherapy. >= 6 months since radiotherapy to whole abdomen or pelvis, whole lungs, > 25% of bone marrow reserve. >=6 months since total-body irradiation. >= 3 weeks since chemotherapy (>= 6 weeks for nitrosoureas). >= 3 weeks since immunotherapy.  >= 3 weeks since any prior investigational therapy (defined as treatment not approved for any indication). >= 7 days since growth factors. Lansky (age 1 to 10 years) or Karnofsky (age 11 to 21 years) performance status >= 60%. Absolute neutrophil count >= 1,000/uL. Platelet count >= 75,000/uL (>= 50,000/uL for patients with bone marrow involvement by tumor). Hemoglobin >= 8 g/dL (red blood cell transfusion permitted if bone marrow involved by tumor). Creatinine clearance (estimated by the Schwartz formula) >= lower limit for age or serum creatinine <= 2 x normal for age. Bilirubin <= 1.5 x institutional ULN. AST and ALT <= 3 x institutional ULN. Life expectancy >= 2 months. Among patients of childbearing potential or with partners of childbearing potential, willingness to use a reliable birth control method during the study and for 12 weeks after its completion","Known hepatitis B, hepatitis C, or HIV infection. Active infection or serious intercurrent illness. Pulmonary hypertension or pneumonitis. Any other major illness that, in the investigator’s judgment, would substantially increase the risk associated with the patient’s participation in the study. Concomitant therapy with any other investigational agent. Receiving enzyme-inducing anticonvulsants. Major surgery within 6 weeks before study entry. Pregnancy or lactation. Known hypersensitivity to any components in the temsirolimus infusion. Medical reasons for being unable to receive protocol-required premedication. Unwillingness or inability to comply with protocol guidelines",during the first course of treatment,NA
11925142,NA,Combination,No,patients with advanced squamous cell carcinoma of the cervix,"Patients were included in the study if they had Stage IIB or greater squamous cell carcinoma of the cervix and other poor prognostic factors. These prognostic factors included bilateral parametrial in- volvement, tumor diameter greater than 6 cm, and known positive lymph nodes. All patients underwent examination under anesthesia, cystoscopy, and proctoscopy. CT scanning of the abdomen and pelvis was performed. Needle aspiration of suspicious lymph nodes was performed. ",NA,NA,NA
18202794,NA,Combination,No,adults with glioblastoma multiforme of the brain,"Patients with histologically documented GM after surgery or stereotactic biopsy, with no prior RT or CT were eligible for the study. Other inclusion criteria were age 21-76 years, performance status (WHO) 0-2, hemoglobin (Hb) >12.5 g/dl, white blood count (WBC) >4,000/μl, absolute neutrophilcount (ANC) >2,200/μl, platelets (PTL) >120,000/μl, normal liver, renal and cardiac function, measurable disease on MRI scan, absence of a second primary tumor, and a written informed consent.","Patients with major heart, lung, renal or psychiatric disease were excluded.",during the whole duration of CCRT and for the following 4 weeks after treatment completion,NA
8888741,NA,Combination,No,"children with refractory solid tumors. Rhabdomyo-sarcoma, Wilms tumor, Renal cell carcinoma, Neuroblastoma, Brain tumor, Ewing/PNET Soft tissue sarcoma, Osteosarcoma","Children and adolescents up to the age of 21 years were eligible for this study if they had a histologically documented solid tumor refractory to conventional ther apy or a tumor for which no effective curative therapy was known. The patients were required to have a life expectancy of at least 6 weeks, a Karnofsky performance status of >50%, and an adequate nutritional status as reflected by a weight above the third percentile for height and a normal total scrum protein and albumin/globulin ratio. Eligibility requirements included an absolute neutrophil count (ANC) of> 1,500/µl and a platelet count of> 100,000/µl ( increased to 150,000/µl atkr analysis of the toxicity data from the first dose level), an SGPT less than twice normal. a bilirubin of <l .6 mg/dl, and a creatininc of< 1.6 mg/dl. Patients with marrow disease were not required to meet the ANC and platelet count requirements. Patients must have recovered from the acute toxicity of prior therapy and must not have re­ ceived a nitrosourca in the preceding 6 weeks. No other anticancer agents were to be administered during the course of the study.",NA,NA,NA
11990712,NA,Combination,No,"children with recurrent solid tumors. Diagnosis: NHL-histiocytic, Undifferentiated lymphoma, Burkitt, Astrocytoma, Ependymoma, Brain stem, PNET, Medulloblastoma, Neuroblastoma, Retinoblastoma-bilateral, Wilms tumor, Hepatoblastoma, Osteosarcoma, Ewing sarcoma, Bone NOS, Rhabdomyosarcoma, Synovial sarcoma, Extraosseous Ewing/PNET, Soft tissue sarcoma NOS, Nasopharyngeal CA, Other NOS","All patients were considered to have disease refractory to conventional therapy and had histologic verification of the malignancy (except patients with brain stem glioma). They had a life expectancy of >2 months and adequate bone marrow (absolute neutrophil count 1,000/uL, platelets 100,000/uL), renal (creatinine normal for age or creatinine clearance >70 mL/min per 1.73 m2), and liver (transaminase <2.5-times and bilirubin <1.5-times laboratory normals) function. The patient’s performance status was required to be near normal (out of bed >12 h/d and only slight decrease in “normal” activity level). Patients might have received previous therapy with topotecan or cisplatin (but total dose <500 mg/m2) but not a combination of cisplatin and topotecan.",NA,NA,Patients were stratified based on the presence of bone marrow metastases and/or previous history of extensive radiation therapy to the bone marrow (craniospinal or pelvic).. patients with extensive previous radiation therapy to bone marrow sites such as craniospinal radiation or bone marrow involvement (stratum I) and patients who had neither extensive bone marrow radiation nor bone marrow involvement (stratum II).
8120553,NA,Combination,No,"patients with cancer. Primary tumor site: Colon, Ovarian, Gastric, NSCLC, Sarcoma, Renal, Pancreatic, Breast, Melanoma, H&N, anal, lymphoma","Forty-four patients were entered onto this study, and all met standard phase I eligibility criteria, including the following: (1) histologically confirmed malignant solid tumor refractory to standard therapy or for which no established therapy existed; (2) measurable or assessable disease; (3) Eastern Cooperative Oncology Group performance status grade 0, 1, or 2; (4) adequate organ function with a WBC count greater than 3,000/uL, platelets greater than 100,000/uL, bilirubin <= 2.0 mg/dL, liver functions (AST and alkaline phosphatase) less than three times the upper limits of normal, and creatinine <= 2.0 mg/mL; (5) resolution of side effects of prior chemotherapy or radiotherapy and at least 4 weeks since last administration (6 weeks for nitrosoureas and mitomycin); and (6) estimated life expectancy of at least 12 weeks. ",NA,NA,NA
16683075,NA,Combination,No,patients with metastatic renal cell carcinoma,"Between December 8, 2000 and December 20, 2003, 33 eligible patients with a histologic diagnosis of unresectable/metastatic renal cell carcinoma were enrolled. All histologic subtypes of renal cell carcinoma with measurable or evaluable disease were eligible for this study. An ECOG performance status of 0 to 2, age of ≥18 years and a life expectancy of ≥3 months were required for entry. Adequate hematologic, renal, hepatic and pulmonary function were required and were defined as follows: hemoglobin of ≥9.5 gm/100 ml, white blood cell count of ≥3.0 × 109/L, platelets ≥100 × 109/L, creatinine ≤1.5 mg/dl (≤2.0 mg/dl in post—nephrectomy patients), serum calcium ≤12 mg/dl, and DLCO ≥50% of predicted. All female patients of child bearing age must have had a negative pregnancy test, with a sensitivity of at least 50 MIU/ml, within 24 h prior to beginning therapy. Additionally all female patients of child bearing potential needed to abstain from heterosexual intercourse or use 2 approved methods of birth control and all male patients needed to abstain from heterosexual intercourse or use latex condoms. In patients with brain metastasis, definitive therapy consisting of surgical resection, whole brain radiotherapy or gamma knife therapy was required. A repeat brain MRI or CT demonstrating at least stable disease, with the patient off steroids, was needed four weeks later.","Patients receiving ≥3 prior treatment regimens were not eligible. Prior radiotherapy for control of painful skeletal lesions, hormonal therapy or major surgery were allowed, but must have been completed ≥28 days from the start of treatment. Additionally, the following conditions precluded patient enrollment: requirement for more than physiologic doses of corticosteroids, HIV, HbsAg or Hepatitis C antibody positive status, history of another malignancy within the past three years (except basal cell carcinoma or carcinoma in situ of the uterine cervix), active infection within the past 28 days requiring intravenous antibiotics, or prior organ allografts.",During cycle 1,NA
16284058,NA,Combination,No,"patients with advanced solid cancers. Ovarian neoplasm NOS 20, Ovarian epithelial cancer 1, Colorectal cancer 3, Peritoneal neoplasm 2, Salivary gland cancer 2, Cervical carcinoma 1, Endometrial cancer 1, Transitional cell cancer of renal pelvis 1, Solid tumor NOS 1, Squamous cell carcinoma of the cervix 1","Patients 18 years of age or older with malignant solid tumors refractory to conventional therapy or for whom no effective therapy exists were eligible. Patients with ovarian cancer had to have received at least one course of platinum-based therapy. Each platinum course was counted as one line of therapy. No restrictions were put on the number of previous chemotherapy regimens but patients could not have received prior topotecan. Patients must have completed any prior radiotherapy or surgery at least 4 weeks before study entry and patients must have recovered from the toxic effects of any prior therapy. Patients had no more than 40% of their bone marrow irradiated and had either progressive or evaluable disease outside the field or progression post-radiation therapy Patients had adequate performance status of ECOG 0, 1 or 2; life expectancy of at least 12 weeks; normal bone marrow and organ function defined as absolute neutrophil count of >1500/ul, platelets > 100 000/ul, total bilirubin equal to or below the upper limit of normal (ULN), AST and/or ALT <2.5 times ULN, creatinine no higher than ULN or creatinine clearance >50 ml/min/1.73 m2.","Patients were excluded if they had known brain metastases; a history of other active malignancy in the past 5 years with the exception of adequately treated cervical carcinoma in situ and non-melanomatous skin cancers; or a serious medical condition. Because of the effects of UCN-01 on serum glucose levels, patients with insulin-dependent diabetes mellitus were excluded. Pregnant or breastfeeding women were also excluded",during cycle 1,NA
17848737,NA,Combination,No,"patients with brain metastases. Of these nine patients, four had melanoma as their primary cancer, two had breast cancer, and one each had small cell lung cancer, non-small cell lung cancer, and renal cell carcinoma","Eligibility criteria included patient age at least 18 yr and non-pregnant, with pathologically confirmed solid tumors and radiologically detectable and measurable evidence of brain metastases by CT or MRI. Potential study subjects were made ineligible by any of the following: a prior history of topotecan therapy; cranial or whole pelvic irradiation; the presence of uncontrolled bacterial, viral, or invasive fungal infections; or a history of significant CHF (NYHA class 3 or 4), unstable angina, or MI within 6 mo of study entry. Informed consent was obtained. Additional eligibility requirements included ECOG performance status of 0–2, ANC at least 1500/µL; platelet count of at least 100,000; serum bilirubin < 2.1 mg/dL; serum creatinine < 2.1 mg/dL, and creatinine clearance > 40 mL/min. The use of steroids was allowed per investigator discretion, but patients with CNS lymphomas were excluded due to a potential response to steroids alone. All patients received a complete history and physical including neurologic exam; brain CT/MRI; CBC with differential, serum electrolytes, renal, and hepatic function tests; and urine pregnancy test (if appropriate) prior to study entry.",NA,within 4 mo from Start of RT,NA
28283779,NA,Combination,No,"patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers","Eligible patients in Part 1 had locally advanced or metastatic SCLC, ovarian cancer or cervical cancer. Patients with SCLC or ovarian cancer must have failed initial therapy and received up to 4 prior regimens of therapy. Patients with cervical cancer had advanced disease not amenable to curative surgery and/or radiation therapy and received up to 4 prior regimens of therapy. In Part 2, enrollment was restricted to SCLC and ovarian cancer. Patients had evaluable or measurable disease by RECIST (Response Evaluation Criteria in Solid Tumors) , a minimum life expectancy of 12 weeks, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1. Patients also had to be age 18 years or older with adequate hematopoietic, hepatic and kidney function.","Exclusion criteria included: previous treatment with irinotecan, topotecan or other topoisomerase I inhibitors; women who were pregnant or nursing; treatment with radiotherapy or immunotherapy or major surgery within 3 weeks; chemotherapy regimens, biologic or targeted therapies within 2 weeks; known central nervous system metastasis except for SCLC patients with previously treated CNS lesions stable for at least 4 weeks; uncontrolled infection or systemic disease; clinically significant cardiac disease not well controlled with medication or myocardial infarction within the last 12 months; neuropathy > grade 1; known hypersensitivity to any components of ME-344 or topotecan; known human immunodeficiency virus (HIV) or hepatitis B or C; history of solid organ transplant; and psychiatric disorder or social or geographic situation that would preclude study participation.",the first 28-day cycle ,NA
11896112,NA,Single Drug,No,children with refractory acute leukemia,"Patients eligible for these protocols (POG 9275 and 9575) were younger than 21 years at study entry and had leukemias unresponsive to conventional therapy. Other eligibility requirements included life expectancy of at least 6 weeks, recovery from toxicities of previously received chemotherapies, no severe or uncontrolled infections, and adequate liver function (bilirubin <= 1.5 mg/dL, AST <= two times normal), renal function (creatinine < 1.5 mg/dL), nutritional status (weight > third percentile for age, albumin >= 3 g/dL), and performance status (Eastern Cooperative Oncology Group status, 0 to 2), as well as more than 3 months since bone marrow transplantation or 6 or more months since total-body irradiation and bone marrow transplantation. ",NA,NA,NA
21590367,NCT00516438,Combination,No,"patients with advanced solid tumors. Tumor type, n: Colorectal 8, Pancreatic 3, Esophageal 2, Gastric 1, Thymus 1, Lung 1, Mediastinal carcinoid 1, Uterine leiomyosarcoma 1, Adrenal carcinoma 1","Patients aged ≥18 years with histologically or cytologically diagnosed advanced solid tumors for whom no suitable effective therapy exists were included. Patients were also required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, an estimated life expectancy of ≥12 weeks, adequate bone marrow function (absolute neutrophil count [ANC] ≥1.5×109/L, platelet count ≥100×109/L, hemoglobin ≥10 g/dL) renal function (serum creatinine ≤1.5×upper limit of normal [ULN]), hepatic function (total bilirubin ≤1.5×ULN, aspartate aminotransferase [AST] ≤2.5×ULN, and alanine aminotransferase [ALT] ≤2.5×ULN).","Patients who had received any chemotherapy, radiotherapy (except for palliative reasons), endocrine therapy or immunotherapy within 4 weeks of study entry, or patients who had received >2 previous chemotherapy regimens for metastatic disease were excluded. Additional exclusion criteria included known brain or leptomeningeal metastases; current or past hematological malignancy; persistent toxic effects of Common Terminology Criteria for Adverse Events (CTCAE version 3.0) grade ≥2 from any cause except alopecia; and gastrointestinal disorders likely to interfere with the absorption of the study drugs.",during cycle 1,NA
8955652,NA,Combination,No,"adults with solid tumors. Disease site: Lung (non-small-cell) 10, Pancreas 3, Primitive neuroectodermal tumor 1, Head and neck 1, Parotid 1, Sinus (adenoid cystic) 1","Patients with solid tumors refractory to conventional therapy or for whom no effective therapy existed were candidates for this study. Eligibility criteria included (1) age - 18 years; (2) an Eastern Cooperative Oncology Group (ECOG) performance status <2 (ambulatory and capable of self-care); (3) a life expectancy that would enable the completion of at least two courses; (4) no major surgery within 14 days; (5) no wide-field radiotherapy and/or chemotherapy within 28 days; (6) adequate hematopoietic (absolute neutrophil count [ANC] >= 1,500/uL and platelet count >= 100,000/uL), hepatic (total bilirubin level < 1.5 mg/dL), and renal (creatinine concentration <= 1.5 mg/dL) functions; (7) no history of hemorrhagic cystitis and less than five RBCs per high-power field in the urine; (8) no clinically significant peripheral neuropathy; and (9) no coexisting medical problems of sufficient severity to prevent full compliance with the study. ","Since the principal objective of the study was to determine the toxicities and optimal doses of the combination of TPT and CDDP for subsequent trials involving untreated or minimally pretreated patients, patients were ineligible if they had (1) received large-field radiation to the pelvis or more than 20% of bone marrowcontaining bones; (2) received more than four courses of chemotherapy that contained an alkylating agent or any nitrosourea or mitomycin; or (3) widespread metastases to bone",during all courses,NA
29051322,NA,Combination,No,Patients with Advanced BRAF V600-Mutant Solid Tumors. 23 patients with advanced melanoma and one patient with a confirmed BRAF V600E–mutant gastrointestinal stromal tumor (GIST) were enrolled.,"Patients were eligible for the study if they were 18 years or older with pathologically confirmed advanced (unresectable stage IIIC or IV) BRAF V600–mutant (V600E or V600K) solid tumors, including melanoma. There were no restrictions placed on prior therapy received including the use of prior BRAF- and MEKdirected therapies. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and adequate organ and marrow function. ","Patients with active untreated central nervous system (CNS) disease were excluded. Patients with previously treated CNS disease were required to be stable for 8 weeks prior to enrollment. Patients were also excluded if their corrected QT interval was greater than 480 milliseconds, had uncontrolled diabetes mellitus, or if they were known to be human immunodeficiency virus positive.",during cycle 1,NA
15701855,NA,Single Drug,No,"children with refractory solid tumors. Diagnosis: Osteosarcoma 4, Ewing sarcoma 3, Wilms tumor 2, Hepatoblastoma 1, Rhabdomyosarcoma 1, Synovial sarcoma 1","Patients were considered eligible if they were younger than 18 years, had histologically confirmed extracranial solid tumors that were refractory to conventional treatment, life expectancy of at least 8 weeks, and Karnofsky or Lansky performance of at least 50%. Patients must have had adequate bone marrow function (absolute neutrophil count >1,500/mm3, platelet count >100,000/mm3, and hemoglobin >8 g/dL), adequate liver function [total bilirubin <1.5 times normal, alanine aminotransferase (ALT) < 2.5 times normal, g-glutamyl transpeptidase (GGT) <2.5 times normal, albumin >=2 g/dL, and normal hepatic fraction alkaline phosphatase (ALP)], adequate renal function (serum creatinine level <1.5 times normal for age), and creatinine phosphokinase (CPK) <2 times normal. In addition, patients had to have recovered from toxicities of all prior therapy: more than 4 weeks since myelosuppressive chemotherapy (6 weeks if prior nitrosourea), at least 2 weeks from local palliative radiotherapy, at least 6 months from substantial bone marrow radiation (craniospinal radiation, total body irradiation, total abdominal/pelvic/chest irradiation, mantle and hemipelvic irradiation), at least 6 months from stem cell transplantation with no evidence of graft-versus-host disease, and at least 1 week from receiving growth factors. ","Patients were excluded if they were pregnant or lactating, had severe uncontrolled infection, or were receiving any other anticancer agents.",during the first course of therapy,NA
20809205,NA,Single Drug,No,"patients with advanced solid tumor. Diagnosis: Head and neck 10, Breast 4, Gastrointestinal (Esophagus (1), jejunum (1), and rectum (1)) 3, Sarcoma 2, Liver 2, Melanoma 1","Eligible subjects were at least 18 years of age with histologically or cytologically confirmed nonoperable solid tumors for which there are no effective therapy or refractory to conventional treatment. Additional inclusion criteria included a performance status ≤2 (ECOGZubrod scale), life expectancy greater than 3 months, and at least 1 measurable disease site. Adequate organ and marrow function required for eligibility was defined by leukocytes ≥3,000/mm3, platelets ≥100,000/mm3, total bilirubin within the institutional limit of normal, aspartate aminotransferase and alanine aminotransferase ≤5 times the institutional upper limit of normal (ULN), and creatinine <1.5 times the institutional ULN. Female subjects with reproductive potential were required to have a negative pregnancy test (urine and/or serum β-human chorionic gonadotropin) and agree to use an effective (>90% reliability) form of birth control during the study. Patients were required to be able to understand and sign a written informed consent document.","Subjects with an acute infection or fever over 38.5°C within 3 days prior to study entry, chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C), radiotherapy within 4 weeks, treatment with any investigational agent within 4 weeks, uncontrolled brain metastasis, cardiovascular disease, lactation, or history of allergic reactions attributed to compounds of similar chemical or biologic composition to PEGylated nanoliposomal vinorelbine were not eligible for the study. ",during the first course of treatment,NA
1330081,NA,Single Drug,No,"patients with metastatic solid tumors.  Primary tumors: non-small cell lung	16, colorectal 11, pancreas	2, renal cell 2, ovarian 2, adenocarcinoma-unknown 2, small cell lung 1, prostate 1, head and neck 1, melanoma 1, squamous cell of skin 1, cholangiocarcinoma 1, ampulla of vater 1","All patients had a microscopically confirmed diagnosis of metastatic solid tumors refractory to all known forms of effective therapy, a SWOG performance status of 2 or less and an anticipated life expectancy of at least 12 weeks. Additional eligibility criteria included: white blood cell count of at least 3000 cells/µl (granulocytes greater than or equal to 1500 cells/µl), platelets greater than 100 000/µl, hemoglobin greater than 10 g/dl, serum creatinine 1.5 mg/dl or less and bilirubin 1.5 mg/dl or less. Patients must have been off previous anticancer therapy for at least 3 weeks (6 weeks if a nitrosourea or mitomycin C were used). ","Patients with a prior history of hemorrhagic cystitis, prior pelvic irradiation or urinalysis indicat­ ing greater than five red blood cells per high power field on microscopic examination were excluded. ",NA,NA
17409986,NA,Single Drug,No,"Japanese patients with solid, malignant tumors. Primary tumor diagnosis (n): NSCLC, Colorectal, Breast, Stomach, Other","Adult patients between 20 and 74 years of age with solid, malignant tumors refractory to standard therapies, or for which no appropriate therapy exists, were eligible for inclusion. Patients were required to have a life expectancy >=3 months and a World Health Organization performance status of 0 or 1.","The main exclusion criteria were significant cardiac, hematopoietic, hepatic or renal dysfunction; severe complications (including active double cancers); any gastro- intestinal disease that would affect drug bioavailability; poorly controlled hypertension; CNS tumors and metastases; systemic anticancer therapy or radiotherapy within the previous 4 weeks; unresolved adverse effects from prior anti- cancer therapy or radiotherapy; and incomplete recovery from prior surgery. ",during cycle 1,NA
22781552,NA,Combination,No,Patients with advanced solid tumors. Tumor types: Breast and ovarian ,"Patients were eligible if they were >=18 years of age with histologically confirmed advanced solid tumor malignancy (irrespective of the HER2 expression) not curable with standard therapies, negative pregnancy test, Karnofsky performance status (KPS) of >=70%, 2 weeks from prior radiation or chemotherapy (6 weeks for nitrosoureas), hemoglobin of at least 8.5 g/dL, absolute neutrophil count (ANC) of at least 1.5 x 109 cells/L, platelet count of at least 75 x 109/L, serum bilirubin no more than 2 x the upper limit of normal (ULN), AST and ALT no more than 2.5 x ULN, and serum creatinine no more than 2 x ULN; patients were required to have either measurable or evaluable disease, assessed with scans 4 weeks before initiation of treatment on the trial.","Patients were excluded if they were pregnant or lactating, had a prior severe hypersensitivity reaction to trastuzumab, active central nervous system metastases, moderate dyspnea at rest or the need for supportive oxygen, New York Heart Association class III/IV congestive heart failure, left ventricular ejection fraction (LVEF) of <50%, a history of prior radiation including the heart in the field, myocardial infarction or active ischemia within 12 months, history of uncontrolled dysrhythmias, requirement for antiarrhythmics, left bundle branch block, baseline QTcF interval of >450 msec for men and 470 msec for women in the absence of a correctable electrolyte imbalance, congenital QTc prolongation, and prior malignancies except basal cell carcinoma of the skin and carcinoma in situ of either the uterine cervix or urinary bladder",during cycle 1,NA
33947692,NCT02167854,Combination,No,Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer,"Eligible patients were women 18 years of age or older who had a histologically or cytologically confirmed diagnosis of metastatic HER2+ breast cancer (defined in accordance with American Society of Clinical Oncology/College of American Pathologists guidelines; ref. 22) with a documented PIK3CA mutation by tumor tissue analysis with next-generation sequencing. Patients were also required to have Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, measurable or nonmeasurable disease, adequate end organ function, and fasting plasma glucose < 140 mg/dL. All patients must have received prior pertuzumab and T-DM1 unless they were deemed ineligible for these treatments. Any number of prior lines of chemotherapy in the metastatic setting was allowed. ","Patients were excluded if they had prior grade 3 hypersensitivity to cremophor or trastuzumab, had active central nervous system metastases, clinically significant cardiac disease or impaired cardiac function (ejection fraction <50%), diabetes that was suboptimally controlled, or a history of prior treatment with a PI3K or AKT inhibitor. ",during cycle 1 (≤ 28 days following the first dose of alpelisib),NA
23429330,NCT01220284,Combination,No,"patients with advanced solid malignancies. Tumor type: Prostate 7, Ovarian 3, reast 4, Bladder 2, Kidney 2, Pancreas 4, Others 5 ( 1 cervical, 1 endometrial, 1 melanoma, 2 of unknown origin)","Eligibility criteria included a diagnosis of advanced solid tumors for which treatment with oral V or platinum-containing regimens could be of benefit, ≤ 2 previous lines of chemotherapy for advanced disease, ECOG PS (Eastern Cooperative Oncology Group Performance Status) < 2, adequate hematological (absolute neutrophil count (ANC) ≥ 1,500/μl, platelet ≥ 100,000/μl), renal (serum creatinine ≤ 1.5 mg/dl) and liver function (total bilirubin ≤ upper limit of normal (ULN); aspartate aminotrans ferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (AP) ≤ 5× ULN). If the AP value was between 2.5× and 5× ULN, the hepatic isoenzyme of AP had to be ≤ 2.5× ULN.","Exclusion criteria were: resistance to vinca alkaloids or platinum compounds defined as disease progression < 6 months from the last treatment with each agent, prior radiotherapy to > 30% of bone marrow, persisting toxicity of > grade (G) 1 due to previous treatment, > G1 neuropathy, > G1 hearing loss and > G2 tinnitus, impaired oral intake or abnormal absorption, symptomatic brain metastases, uncontrolled intercurrent illness, congestive heart failure, unstable angina pectoris, or psychiatric illness. The concurrent use of cytochrome P450 3A4 inhibitors was not allowed.",during the first cycle,NA
22847981,NA,Single Drug,No,"children and adolescents with relapsed or refractory solid tumors. Desmoplastic smallround cell tumor, Embryonal liver sarcoma, Synovial sarcoma, Neuroendocrine carcinoma, Nasopharyngeal carcinoma, Osteosarcoma, Ewing’s sarcoma, Malignant peripheral nerve sheath tumor, Diffuse intrinsic pontine glioma, Mesenchymal chondrosarcoma","Patients were eligible if they were between 4 and 16 years ofage, had a measurable or evaluable solid tumor that relapsed afteror was refractory to standard therapy, had a Lansky (<=10 years)or Karnofsky (>10 years) performance status >=60%, wererecovered to grade <=1 toxicity from prior therapy and were >=3weeks from prior myelosuppressive chemotherapy, >=1 week fromgrowth factors (e.g., filgrastim and epoetin), >=2 weeks frompegfilgrastim, >=30 days from an investigational agent, >=7 daysfrom a biologic agent, >=4 weeks from radiation therapy to greaterthan 25% marrow-containing bones, >=2 weeks from palliativeradiation, and >=2 months from autologous transplant, and hadan absolute neutrophil count (ANC) >=1,500 mcL-1, plateletcount >=75,000 mcL-1(transfusion independent), hemoglobin >=8 g/dl (transfusion permitted), AST/ALT <=2.5 x upper limitof normal (ULN), bilirubin <= ULN, alkaline phosphatase <= ULN(or if above ULN, 5'nucleotidase <= ULN or gamma-glutamyltranspeptidase (GGT) <=2.5 xULN), normal age-adjusted serumcreatinine or creatinine clearance >=60 ml/minute/1.73 m2, andcreatine kinase <=2.5 x ULN","Exclusion criteria included a history of xeroderma pigmento-sum or other diseases with impaired DNA repair, pregnancy orbreast-feeding, severe or uncontrolled infections, other investiga-tional agents, and allogeneic stem cell transplants or prior therapy with trabectedin. ",during cycle 1 ,NA
28623430,NCT00258349,Combination,No,patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer,"Patients with histologically confirmed HER2-overexpressing breast cancer, defined locally by immunohistochemical analysis (with 3? indicating positive status), fluorescence in situ hybridization (with an amplification ratio >=2.0 indicating positive status), or both. Efficacy analysis was performed only for those subjects with centrally confirmed HER2-overexpressing breast cancer. Evidence of measurable metastatic disease and/or chest wall recurrence was required for inclusion in the study. Patients may have received prior radiation therapy; however, the only site of measurable disease must not have been irradiated, except in the case of chest wall recurrence previously treated with adjuvant radiation therapy. Eligible patients must have had documented disease recurrence or progression while receiving trastuzumab or must have had relapsed within 3 months of completing the last dose of adjuvant trastuzumab or trastuzumab for metastatic disease. Patients must have had adequate organ and marrow function, defined as (1) CBC values (obtained within 14 days prior to registration) of ANC >=1500/uL, platelet count >=100,000/mm3 , and hemoglobin >=9 g/dL; and (2) prestudy chemistry values (obtained within 4 weeks prior to registration) of serum creatinine <=1.5 g/dL, ALT <=2 x ULN, AST <=2 x ULN, and total bilirubin <=1.5 mg/dL. Eligible patients must have had adequate cardiac function as defined by left ventricular ejection fraction less than or equal to the lower limit of institutional normal obtained within 6 weeks prior to registration, as assessed by an echocardiogram and nuclear scan and no evidence of PR prolongation or AV block on ECG performed within 4 weeks prior to registration. CYP450 inducers or inhibitors must have been discontinued 1 week prior to initiating protocol treatment. Patients must not have had chemotherapy or radiotherapy within 3 weeks prior to entering the study. Patients must have recovered from all adverse events related to prior chemotherapy or radiation. Patients must not have been receiving any other investigational agents, nor might they have received any other investigational agents within 4 weeks prior to entering the study. Patients must not have had a history of untreated brain metastasis or brain metastasis currently undergoing radiation. Patients with brain metastasis representing the sole site of disease were not eligible. Patients with previously treated brain metastasis who had responded to brain radiotherapy and/or surgery and had continued in response were eligible, provided the brain was not the only site of measurable disease. Patients must not have had a history of allergic reactions attributed to compounds of similar chemical or biologic composition to SAHA or other agents used in study. Patients must not have had taken valproic acid, another histone deacetylase inhibitor, for at least 2 weeks prior to registration.",during the first cycle of therapy,NA,NA
23099652,NCT 00272350,Single Drug,No,patients with recurrent malignant glioma,"Eligibility criteria included age ≥18 and histologically confirmed GBM, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, malignant glioma/astrocytoma not otherwise specified, progressive low-grade gliomas, or infiltrative brainstem gliomas, diagnosed radiographically. There were no restrictions regarding the number of prior relapses. All patients had progression after radiation therapy that was completed at least 4 weeks prior to study enrollment. Other criteria for study entry included Karnofsky Performance Status ≥60, normal echocardiogram, and normal organ function as measured by white blood cell count ≥3000/mL, absolute neutrophil count ≥1500/mm3, platelet count ≥100 000/mm3, hemoglobin ≥10 g/dL, serum glutamic oxaloacetic transaminase and bilirubin ≤2 times upper limit of normal, and creatinine ≤1.5 mg/dL or creatinine clearance ≥60 cc/min. Subjects must have recovered from toxic effects of prior therapy and not received vincristine within 2 weeks, nitrosureas or radiation therapy within 6 weeks, procarbazine within 3 weeks, other prior cytotoxic therapy or surgery within 4 weeks, any noncytotoxic investigational agent within 2 weeks, or other noncytotoxic agents within 1 week of study entry. A stable daily dose of corticosteroids for ≥5 days was required before obtaining the baseline MRI scan. Patients may have received prior therapy with VEGF-directed agents. All patients in the phase I study were on EIAEDs. Patients were eligible after signing informed consent for participation in this National Cancer Institute Institutional Review Board – approved trial (NCT 00272350).","Exclusion criteria for participation were other concurrent tumor therapy, active malignancy, active infection, pregnancy, breast feeding, QTc >460 ms, poorly controlled hypertension (systolic blood pressure > 160 or diastolic blood pressure > 100), active gastrointestinal disease with diarrhea, severe or uncontrolled systemic disease, and clinically significant dysrhythmia or cardiac disease.",in the first cycle,NA
27450049,NCT01248858,Combination,No,"patients with advanced solid tumors. The study included a range of tumor types with more than half being KRAS-mutant colorectal, breast, KRAS-mutant NSCLC, or pancreatic cancer. ","Patient age ≥ 18 years with relapsed or refractory solid tumors who provided written consent, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate hematologic and organ function were enrolled. To enrich for patients with increased likelihood to derive clinical benefit, the study was amended to specifically enroll KRAS-mutant colorectal cancer (CRC), KRAS-mutant nonsmall cell lung cancer (NSCLC), BRAF-mutant melanoma previously treated with a BRAF inhibitor, pancreatic, endometrial, ovarian, bladder, triple negative breast cancer, and other cancers with a rationale for co-treatment with PI3K and MEK inhibitors. Prior therapy with PI3K and MEK pathway inhibitors was permitted.","Key exclusion criteria were: treatment with anti-cancer therapy within 28 days, history of retinal vein occlusion or central serous retinopathy or visible retinal pathology, diabetes (type 1 or 2), uncontrolled systemic diseases, unstable brain metastases, history of major cardiovascular disease, and/or pregnant/lactating females. ",in the first 28-day treatment period,NA
25500057,NCT01155453,Combination,No,"Patients with Selected Advanced Solid Tumors. adult patients with advanced solid tumors harboring RAS or BRAF mutations such as colorectal cancer, melanoma, NSCLC, triple-negative breast cancer (TNBC),  pancreatic cancer, and other (Includes 1 patient with thyroid cancer, 1 patient with ampullary cancer, 1 patient with choroid melanoma of the eye, and 1 patient with endocervical cancer.)","Dose-escalation part enrolled adult patients with advanced solid tumors harboring RAS or BRAF mutations such as colorectal cancer, melanoma, NSCLC, triple-negative breast cancer (TNBC), or pancreatic cancer. When MTD was defined, dose-expansion part was conducted in adult patients with measurable and evaluable (by RECIST version 1.0) advanced NSCLC, ovarian, or pancreatic cancer with RAS or BRAF mutations. Patients had baseline World Health Organization (WHO) performance status (PS) 0 to 2, and adequate organ function. ","Patients with anxiety assessed as grade >= 3 [National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4] or ocular/retinal comorbidities associated with increased risk of central serous retinopathy or retinal vein occlusion were excluded. ",in cycle 1,NA
30992546,NCT01938443,Combination,No,patients with advanced solid tumours,"Subjects were eligible for the study if they were aged ≥18 years, had mesothelioma or solid tumours with a high likelihood of MAPK pathway activation, and had received ≥1 prior course of chemotherapy. Other key eligibility criteria included Eastern Cooperative Oncology Group (ECOG) performance status 0–1; adequate haematologic, hepatic, and renal function; ability to swallow oral medication; and left ventricular ejection fraction (LVEF) at or above the lower limit of normal. Female patients with childbearing potential were asked to comply with protocol-specified contraceptive measures, and male patients with female partners of childbearing potential needed to have had a prior vasectomy or agree to use effective contraception.","Patients with symptomatic leptomeningeal or brain metastases were excluded, as were patients with active interstitial lung disease or pneumonitis; a history of retinal vein occlusion or central serous retinopathy; current use of warfarin; history or evidence of cardiovascular risk; and presence of active gastrointestinal disease or other condition that may interfere with the pharmacokinetics of the drugs",within the first 28 days,NA
29350463,NCT01519323,Single Drug,No,"pediatric patients with surgically incurable, BRAF mutation-positive melanoma","Pediatric patients (aged 12–17 years) with histologically confirmed,surgically incurable and unresectable stage IIIc or IV melanoma that tested positive for the BRAF V600 mutation (CobasR 4800 BRAF V600 Mutation Test, Roche Molecular Systems,Inc., Branchburg, NJ) were enrolled. Other key inclusion criteria included a Karnofsky Performance Score of > 50 (patients aged ≥ 16 years) or a Lansky scoreof≥60 (patients aged < 16 years), a life expectancy > 3 months, and adequate hematologic, hepatic, and renal function. Patients with asymptomatic, previously treated, radiographically stable central nervous system(CN) lesions were eligible if the patient had not required CNS-directed therapy for at least 3 months prior to starting treatment, and had not required glucocorticoids or anticonvulsants for at least 21 days prior to starting treatment.","Patients were excluded if they had any of the following: active or untreated CNS lesions, a history of spinal cord compression or carcinomatous meningitis, prior treatment with selective/specific BRAF or MEK inhibitors or vemurafenib, were pregnant or lactating, acorrected QT(QTc) ≥450msec, or a history o fcongenital long QT syndrome.",during the first 28 days of study treatment,NA
15905307,NA,Single Drug,No,"patients with solid, malignant tumors. Colorectal, Renal, Prostate, Melanoma, Liver, Head and neck, Mesothelioma, Other","Adult patients with malignant tumors refractory to standard treatments, or for whom no standard treatment exists, were recruited from six centers in the USA and Australia. Subjects were required to have a WHO perform- ance status of 0, 1 or 2, and a life expectancy of more than 12 weeks.","The main exclusion criteria were significant cardiac, hematopoietic, hepatic or renal dysfunction; any gastrointestinal pathology that would affect drug bioavailability; a history of coagulopathy, central nervous system (CNS) tumors or metastases; and other anticancer therapy within the previous 4 weeks. Concomitant use of amiodarone, chlorpromazine, ketoconazole, itraconazole, troleandomycin, erythromycin, diltiazem, verapamil, phenytoin, carbamazepine, barbiturates, rifampicin or warfarin was not permitted",occurring during the first 35 days of treatment (cycles 0 and 1),NA
11984084,NA,Combination,No,"patients with solid tumors. Primary tumor site: colon, lung, esophagus, gastric, kidney, ovarium, uterus, rectum, unknown, others","Eligibility criteria included a histologically or cytologically confirmed diagnosis of a solid tumor not amenable to established forms of treatment. Previous chemotherapy and/or radiotherapy was allowed provided that the last treatment was at least 4 weeks before study entry or 6 weeks in case of nitrosoureas, mitomycin C and high-dose carboplatin. All patients had acceptable bone marrow function [absolute neutrophil count (ANC) >= 2.0 x 109/l, platelets >= 100 x 109/l, hemoglobin (Hb) >= 10 g/100 ml], adequate hepatic function [defined as serum bilirubin <25 uM, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (AP) <3 x upper normal limit or <2.5 x upper normal limit when due to liver metastases] and adequate renal function (serum creatinine <=120 uM and creatinine clearance >=60 ml/min). Other eligibility criteria were a performance status (PS) <=2 on the ECOG (Eastern Cooperative Oncology Group) scale, age between 18 and 75 years, and a life expectancy of >= 3 months. The patients had to have a normal ECG and had to be recovered from any prior surgery.",NA,during the first treatment cycle,NA
18048823,NA,Combination,No,"Patients with an advanced solid tumor. Tumor types: the majority of patients (n = 15) had HER-2 metastatic breast cancer, Prostate 2, Gynecologic (ovarian, uterine) 2, Renal 1, Colorectal 1 Thymus 1","Eligibility requirements included age at least 18 years, histologic documentation of a nonhematologic malignancy (irrespective of HER-2 expression) with evidence of progression during treatment with standard therapy, Karnofsky performance status of at least 70%, negative pregnancy test, 2 weeks’ removal from prior radiation or chemotherapy (6 weeks for nitrosoureas), hemoglobin of at least 8.5 g/dL, absolute neutrophil count (ANC) of at least 1.5 x 109 cells/L, platelet count of at least 75 x 109/L, serum bilirubin no more than 2 the upper limit of normal (ULN), AST and ALT no more than 2 x ULN, and creatinine no more than 2 x ULN. Patients continuing on weekly trastuzumab were permitted to continue without break.","Patients were excluded for prior severe hypersensitivity reaction to Cremophor-containing therapy or trastuzumab, active CNS metastases, severe dyspnea at rest, or a need for supportive oxygen; New York Heart Association class III/IV congestive heart failure, left ventricular ejection fraction less than 50%, a history of prior radiation including the heart in the field, myocardial infarction or active ischemia within 12 months, history of uncontrolled dysrhythmias, requirement for antiarrhythmics, or left bundle branch block. Additionally, on the basis of two reports from ongoing trials with tanespimycin showing QTc prolongation, this study was amended to exclude patients with QTcF more than 450 ms (males) or 470 ms (females), congenital long QTc syndrome, or medications causing QTc prolongation.",during cycle 1,NA
17325895,NA,Combination,No,patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement,"Eligible subjects had a histologic diagnosis of recurrent low-grade or transformed NHL according to the International Working Formulation, which was commonly in use at the time of study develop-ment . Using current (WHO) criteria, all subjectswere required to have CD20+ small lymphocytic lymphoma, follicle center grade I or II lymphoma, ora transformation to diffuse large B cell lymphoma[14 – 20]. Additional key eligibility requirements included stage IV disease with greater than 25% of the intratrabecular marrow space involved (either by bilateral bone marrow biopsies with an average estimated involvement of 25% or a unilateral bone marrow biopsy   demonstrating greater than 50% involvement). Other requirements were Karnofsky performance status of at least 60%, absolute neutrophil count (ANC) of at least 1500 cells/mm3 and aminimum platelet count of 150 000 cells/mm3 within 14 days of study entry, adequate renal and hepatic function, age 18 years or greater, and bidimensionally measurable disease. There was no restriction onthe number of circulating peripheral blood lymphocytes as study entry.","Patients with de novo aggressive NHL were excluded, as were patients with documented HIV positivity or evidence of central nervous system involvement with lymphoma. Subjects who had undergone either a stem cell or bone marrow transplant were also excluded from study enrollment, as were those with documented human antimurine antibody positivity, prior RIT, or cytotoxic chemotherapy, immunosuppressants, or cytokine therapy within 4 weeks prior to  study entry. Colony stimulating factors were allowed in accordance with the American Society of Clinical Oncology guidelines. ",NA,NA
28119295,NCT01148849,Single Drug,No,"patients with HER2-positive advanced solid tumors. Tumor type, n (%): Breast 27 (41%), Gastroesophageal 20 (30%), Colorectal 5 (8%), Gall Bladder 2 (3%), Lung 2 (3%), Other (include rectal, sigmoid colon, ampulla of Vater, bladder, endometrial cancer, esophageal-squamous cell carcinoma, malignant tumor of lacrimal gland, salivary duct cancer, submandibular gland cancer, and transitional cell carcinoma of the renal pelvis)","Enrolled patients had histologically or cytologically confirmed carcinoma with documented HER2 overexpression by immunohistochemistry (IHC) (2þ or 3þ) and disease progression during or following the last treatment regimen. Eligibility included age >=18 years; life expectancy >=3 months; Eastern Cooperative Oncology Group performance status <=1; measurable disease by Response Criteria for Solid Tumors (RECIST) v1.1; adequate bone marrow, renal, and hepatic function; and left ventricular ejection fraction (LVEF) >=50%. ",Key exclusion criteria included class III or IV New York Heart Association heart disease; significant pulmonary compromise; significant prior anthracycline exposure,during Cycle 1,NA
24954229,NA,Combination,No,patients with stage III non-small-cell lung cancer,"Eligibility criteria included (1) age between 18 and 70 years; (2) histologically confirmed and previously untreated NSCLC stage IIIA (only N2) and stage IIIB disease (supraclavicular lymph node involvement and malignant pleural effusion excluded); (3) Karnof- sky performance status (KPS) >= 80%; (4) life expectancy >= 12 weeks; (5) adequate bone marrow, hepatic, and renal functions; (6) presence of at least one bidimensionally measurable lesion (SWOG [Southwest Oncology Group] criteria); (7) absence of any psychological, familial, sociologic, or geographic conditions potentially hampering compliance with the study protocol; and (8) signed informed consent before any protocol-specific procedure.","Patients presenting with contraindication to vinca alkaloids were excluded from the trial. Excluded from the second part of the study were patients with hearing impairment grade 2 or worse based on the National Cancer Institute Common Toxicity Criteria (NCICTC), version 2.0, and patients with any other contraindication to the administration of CDDP. ",NA,NA
8439950,NA,Single Drug,No,"pediatric patients with refractory malignancies. Patient diagnoses: Osteosarcoma, Ewing's sarcoma, Rhabdomyosarcoma, Leydig cell tumor, Hepatoblastoma, Wilms' tumor, Lymphoma, Acute nonlymphocytic leukemia, Mixed lineage leukemia","Patients, 25 years or younger, with histologically confirmed cancer refractory to standard therapy were eligible for this trial. Other eligibility criteria included: (a) an Eastern Oncology Cooperative Group performance status of <=2; (b) a life expectancy of >8 weeks; (c) adequate liver function (serum bilirubin < 2.0 mg%); (d) adequate renal function (serum creatinine <1.5 mg% or creatinine clearance >60 ml/min/l .73 m2); (e) recovery from the toxic effects of prior therapy; (/) no prior chemotherapy within 2 weeks (6 weeks if a nitrosourea) of entering onto this protocol; (g) no prior extensive radiother apy (e.g., pelvic or craniospinal) or bone marrow transplantation with total body irradiation; and (h) no prior history of grade 2 or greater hemorrhagic cystitis (gross hematuria, no clots) and fewer than 5 RBCs/high-power field by urinalysis. Patients with solid tumors had adequate bone marrow function defined as a peripheral absolute granulocyte count > 1500/mm3. a hemoglobin >10.0 g/dl. and a platelet count >100,000/mm3.",NA,NA,NA
29882016,NCT00620594,Combination,No,"patients with advanced solid tumors including patients with advanced breast cancer. Primary sites of tumor: Breast, Colon,  Lung, Rectum, Ovary, Kidneys, Skin melanoma, Uterus, Soft tissue sarcoma, Prostate, Cervix, Bone sarcoma,  Salivary gland,  Stomach, Bladder, Small intestine,  Other (adrenal, pleural, choroid, gallbladder, para renal, tongue, Axillary gland, Endometrial, ileum and liver, thorax, unknown)","Patients with histologically confirmed advanced unresectable solid tumors failing standard therapy or for whom no standard therapy existed were eligible for the single-agent dose-escalation part of the study. Archival or fresh tumor biopsies for prescreening of molecular alterations affecting PIK3CA and/or PTEN expression were required for the single-agent safety expansion. For the combination part of the study, patients with histologically confirmed metastatic HER2+ aBC after failure of trastuzumab treatment (disease progression during trastuzumab maintenance given as adjuvant treatment or for metastatic disease) and with tumors carrying molecular alterations of PIK3CA and/or PTEN were eligible. For all the study arms, patients were required to have ≥1 lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 ; age ≥18 years; World Health Organization (WHO) performance status ≤2; life expectancy ≥12 weeks. Adequate bone marrow, cardiac, hepatic, and renal functions were required.","Key exclusion criteria included treatment with corticosteroids≤2 weeks prior to starting study drug, diagnosis of diabetes mellitus or history of gestational diabetes, and prior treatment with a PI3K inhibitor.",in cycle 1,NA
30087028,NCT02258607,Combination,No,"patients with platinum-treated, refractory, metastatic, KRAS-mutated NSCLC","Adult patients with KRAS-mutated metastatic NSCLC were eligible if they had disease progression after receiving >=1 platinum-based chemotherapy regimen, or if disease progression occurred >=6 months after completion of adjuvant therapy for stage I to IIIA disease including >=1 platinum-based regimen; had measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST)10; and Eastern Cooperative Oncology Group performance status of 0 or 1. ","Patients were excluded if they had received previous treatment or immunotherapy for NSCLC within 21 and 28 days, respectively, of study enrollment, or had been exposed previously to JAK inhibitors, MEK inhibitors, or other agents thought to have activity against the TBK1 pathway.",during the first 28-day cycle,NA
31253596,NCT02016729,Combination,No,patients with relapsed/refractory acute myeloid leukemia (AML),"Patients aged >=18 years with pathologically documented, treatment-refractory or relapsed AML, Eastern Cooperative Oncology Group performance status <=2, life expectancy >3 months, and adequate renal (serum creatinine <2.0 mg/dL or estimated glomerular filtration rate >40 mL/min/1.73m2), hepatic (aspartate aminotransferase and alanine aminotransferase <= 3.0 x upper limit of normal [ULN], alkaline phosphatase ,2.03 ULN, and bilirubin <=1.5 x ULN), and cardiac (left ventricular ejection fraction of at least the lower limit of normal) function were eligible for the study.","Patients with 17p deletion based on cytogenetics or with TP53- mutant (P53MT) AML when TP53 mutational status was known were excluded from the study. Patients with complex karyotype (defined as AML exhibiting >3 cytogenetic abnormalities in bone marrow, not including inv(16), t(16;16), t(8;21), t(15;17), and t(9;11)) were excluded, as AMLs with complex karyotypes have high rates of TP53 mutation.22-25 Patients with complex karyotype with known P53WT status were allowed. Other exclusion criteria included acute promyelocytic leukemia or active central nervous system leukemia; history of interstitial lung disease, pneumonitis (arm 2); history or risk of retinal vein occlusion (arm 2 only); allogeneic stem cell transplantation within 8 weeks before study entry; ongoing immunosuppressive therapy or graft-versus-host disease; immune modulators or corticosteroids within 2 weeks before study entry; unresolved toxicities from prior anticancer therapy, excluding alopecia; antitumor therapy within 14 days before study entry; or prior treatment with an MDM2 inhibitor (arms 1 and 2) or MEK inhibitor (arm 2)",first 28 days,NA
27129177,NCT01271920,Combination,No,metastatic HER2-positive breast cancer patients ,"Female patients, who were aged ≥ 18 years with confirmed HER2-positive, nonoperable, locally advanced or metastatic breast cancer who progressed on prior anti–HER2-based regimens including at least 1 regimen containing trastuzumab, were eligible. HER2 overexpression was based on either immunohistochemistry at the 3+ level or immunohistochemistry 2+ level confirmed by fluorescence in situ hybridization. Patients who developed metastases while receiving adjuvant trastuzumab were eligible, and their adjuvant therapy was considered as 1 prior regimen. Patients who received lapatinib as a last line of treatment were eligible. Other key inclusion criteria were ≥ 1 measurable lesion as defined by Response Evaluation Criteria In Solid Tumors version 1.0 (RECIST), documented progressive disease following the last line of therapy, and Eastern Cooperative Oncology Group performance status of ≤ 1.","Patients were excluded if they had the following: known symptomatic central nervous system metastases requiring treatment (for symptom control and/or growing); impaired cardiac function; received prior treatment with any HSP90 or histone deacetylase inhibitor; systemic anticancer treatment prior to AUY922 dosing (radiotherapy, chemotherapy, hormonotherapy, investigational drugs, and monoclonal antibodies other than trastuzumab within 4 weeks; palliative radiotherapy within 2 weeks; and nitrosoureas and mitomycin within 6 weeks); unresolved diarrhea > Common Toxicity Criteria for Adverse Events version 4.0 (CTCAE) grade 1; not recovered from the reversible side effects of previous systemic anticancer therapy (except for alopecia) < CTCAE grade 2 prior to the first dose; therapeutic doses of sodium warfarin; acute or chronic liver or renal disease; other concurrent severe and/or uncontrolled medical conditions that could cause unacceptable safety risks; known hypersensitivity to any study medication; and history of another primary malignancy that was currently clinically significant or currently required active intervention.",in the first cycle of treatment (28 days),NA
11234874,NA,Single Drug,No,"patients with solid malignancies. Primary tumor site (n): Colorectal 5, Leiomyosarcoma 4, Gastrointestinal stromal 2, Melanoma 2, Mesothelioma 2, Ovarian 2 Renal cell 2, Lung, non-small cell 1, Esophageal 1","The study was restricted to patients with a histologically or cytologically confirmed solid tumor that was either refractory to conventional therapy or for which no standard treatment existed. Patients had to be at least 18 years of age with a minimum life expectancy of 3 months. The interval between major surgery or any other prior treatment of the malignancy and entry into this study had to be at least 6 weeks, with full recovery from the effects of the earlier intervention. Minimum eligibility requirements included the following: (a) Eastern Cooperative Oncology Group performance status <=2; (b) neutrophil count >=1,500/ul; (c) platelet count >=100,000/ul; (d) hemoglobin >=9.0 g/dl; (e) serum creatinine <=2.0 mg/dl; (f) total bilirubin <1.5 mg/dl; and (g) SGOT, SGPT, and alkaline phosphatase activities <= 3 x the upper limit of normal. Serum transaminase and alkaline phosphatase activities had to be <= 5 x the upper limit of normal for patients with documented liver metastases","The study excluded patients with: (a) evidence of a primary or metastatic lesion in the central nervous system; (b) baseline neurotoxicity greater than or equal to grade 2 (National Cancer Institute CTC); (c) prior bone marrow transplantation, required for stem cell support; (d) history of chronic active liver disease; or (e) pregnancy or breast feeding.",during the first cycle of therapy,NA
11230466,NA,Single Drug,No,"patients with solid tumors. Tumor type: Colon/rectum 13, Sarcoma 14, Breast 8, Ovary 6, Renal 3, Stomach 2, Unknown primary 2, Larynx 1, Bladder 1, Melanoma 1, Urothelial carcinoma 1","Patients were eligible for inclusion if they had a histologically or cytologically confirmed advanced solid tumor that was not amenable to established forms of treatment. Patients had to be aged between 18 and 75 years and have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) <= 2. In addition, patients were required to have a neutrophil count >= 2.5 x 109/L, a platelet count >= 100 x 109/L, hemoglobin levels of >= 10 g per 100 mL, normal hepatic function (bilirubin < 25 mmol/L [1.5 mg/dL], transaminases and alkaline phosphatase [AP] <= the upper normal limit), and normal renal function (serum creatinine <= 120 mmol/L [1.4 mg/dL]).","Patients were ineligible for the study if they had received any radiotherapy, chemotherapy, immunotherapy, or growth factor administration in the 4 weeks before study entry, a bone marrow transplant, or intensive chemotherapy with stem-cell support. Pregnant or breastfeeding women were also ineligible, as were patients with a previous history of liver disease (eg, chronic active hepatitis or cirrhosis) and patients with clinical signs or evidence of brain involvement or leptomeningeal disease.",four assessable cycles,NA
22996801,NA,Single Drug,No,"cancer patients with liver dysfunction. Tumor types: Hepatocellular carcinoma, Colorectal cancer, Prostate cancer, Renal cancer, Breast cancer, Neuroendocrine cancer, Corpus uteri, Non small cell lung cancer, Pancreatic cancer","Cancer patients aged between 18 and 75 years old presenting at least one evaluable lesion from histologically proven solid tumors, and for which therapy did not exist or failed (treatment discontinued for at least 4 weeks before study entry), were eligible. In addition, they had to have an estimated life expectancy of more than 12 weeks, a Performance status (WHO classification) between 0 and 2, and adequate hematological and renal functions (ANC ≥2×109/L, platelets ≥100×109/L, Hemoglobin≥10 g/dL, creatinine ≤ ULN; Cockcroft-Gault calculated creatinine clearance≥50 mL/min). Eligible patients had to exhibit clinical and biochemical signs of chronic, mild to severe liver dysfunction.",The main ineligibility criteria were Child–Pugh grade C cirrhotic patients; any medical condition that might have been aggravated by the treatment or that cannot be controlled; patients with brain and/or leptomeningeal metastases; concomitant anticancer therapy or experimental drug administration within 30 days prior to VFL dosing.,the first cycle,"3 groups of increasing degrees of liver dysfunction (LD). Cohorts were initiated in a chronological order, starting with group 1, the lowest level of LD. As the hepatic characteristics of this group were close to those of “normal” cancer patients previously treated with vinflunine. Results from group 1 served as a basis for the selection of a starting dose in group 2. Once group 2 was explored, patients with a higher level of LD were enrolled in group 3 with a starting dose based on the results of group 2."
21660618,NA,Combination,No,"patients with advanced cancer and alteration of hepatic function. Primary tumor type: Ovary, Soft tissue sarcoma, Colorectal, Cholangiocarcinoma, Pancreas, Other (Liver, melanoma, non-small cell lung cancer, Endometrium, esophagus, testicular, Stomach)","Eligibility requirements included: age .=18 years and <=70 years, a histological or cytological confirmation of malignant tumor not amenable to conventional treatment, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) <=2, life expectancy >=3 months, and either measurable or evaluable disease. The following laboratory values were required within 3 days of study drug treatment: absolute neutrophil count (ANC) >=1.5 x 109/l; platelets >=100 x 109/l; hemoglobin >=9 g/dl; creatinine <=132 lmol/l (1.5 mg/dl) or creatinine clearance >=40 ml/min; and ALT/AST <2.5 ULN. As above mentioned, baseline AP and bilirubin values defined the strata in which the patient was to be included.","Patients were excluded if they had symptomatic cerebral involvement, bone metastasis or Paget disease, Gilbert syndrome or clinically significant hemolysis, acute or chronic leukemia, multiple myeloma, or serious nonmalignant systemic disease: e.g., active uncontrolled infection, myocardial infarction in the previous year, angina pectoris, congestive heart failure, or significant advanced hepatic diseases (e.g., cirrhosis or active chronic hepatitis). Chemotherapy, radiotherapy or biologic therapy within 4 prior weeks (mitomycin C, nitrosurea therapy or temozolamide within 6 prior weeks) were not allowed. Patients were also excluded if they were pregnant or breastfeeding women, or if they were not using appropriate contraceptive measures",during the first treatment cycle,"Patients were to be stratified into 3 different strata: stratum I (ULN \ AP B1.5 9 ULN), stratum II (1.5 9 ULN \ AP B2.5 9 ULN), and stratum III (AP [2.5 9 ULN). "
19417019,NA,Single Drug,No,"patients with advanced solid malignancies. Primary tumor type: Soft tissue sarcoma, Ovary, Breast, Melanoma, Other (Bone, brain, right adrenal, Abdominal and pelvic metastases (10))","Eligibility requirements included: age ≥18 y, a histologic or cytologic confirmation of cancer not amenable to conventional treatment, an Eastern Cooperative Oncology Group performance status ≤2, and either measurable or evaluable disease. The following laboratory values were required within 14 prior days: an absolute neutrophil count of ≥1.5 × 109/l; platelets ≥100 × 109/l; hemoglobin ≥ 9 g/dL; albumin ≥2.5 g/dL; creatinine clearance and bilirubin ≤ upper limit of normal (ULN); aspartate aminotransferase and alanine aminotransferase of ≤3 × ULN (≤ 5 × ULN, in case of documented liver metastases), and alkaline phosphatase ≤ 1.5 × ULN (if total alkaline phosphatase > 1.5 × ULN, the alkaline phosphatase liver fraction and 5′-nucleotidase were required to be within normal limits). Patients with a history of centra nervous system metastases were eligible provided there was no progression from previous treatments, no requirement for corticosteroids, no evidence of peritumoral edema, and no evidence of progressive central nervous system symptoms. ","Patients with primary central nervous system malignancies were not eligible. Patients were excluded if they had acute or chronic leukemia, multiple myeloma, or serious nonmalignant systemic disease, e.g. active uncontrolled infection, myocardial infarction, unstable angina pectoris, or uncompensated congestive heart failure within the prios 6 mo. Chemotherapy, radiotherapy, or biologic therapy within 4 prior wk(mitomycin C or nitrosurea therapy, temozolamide, other minor groove binders within 6 prior wk) or prior allogenic, syngenic, or autologous bone marrow or stem cell transplantation were not allowed. Pregnant or breast-feeding women, or patients not using appropriate contraceptive measures, were excluded.",in the first two cycles,NA
12932661,NA,Combination,No,"patients with solid tumours. Primary tumour site: Gastrointestinal tract, Lung, Kidney, Ovary, Oesophagus, Cervix, Gastrointestinal stromal tumor, Uterine sarcoma, Sarcomatoid bladder cancer, Other (Breast, melanoma, pancreas, peritoneum, Bladder, breast, liver, melanoma, pancreas), Unknown","Patients aged 18 years or above with a histologically- or cytologically-confirmed diagnosis of solid tumour were eligible, if they were not amenable to established forms of treatment. Further inclusion criteria were: performance status (PS) <=2 Eastern Cooperative Oncology Group (ECOG) scale, life expectancy >=3 months, neutrophil count >=2.0 x 109/l, platelet count >= 100 x 109/l, haemoglobin >= 10 g/100 ml, normal hepatic function except for patients with liver meta- stases (who were eligible if aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x the upper limit of normal (UNL), normal renal function, normal electrocardiogram (ECG) and negative serology for hepatitis.",Exclusion criteria were those routinely employed in phase I studies of cytotoxic agents with the potential to induce bone marrow suppression. ,in the first cycle,NA
19419856,NA,Combination,No,"adult patients with advanced solid tumours. Tumour type: Ovary, Uterine leiomyosarcoma, Endometrium, NSCLC, Other ","The study consisted of two parts; in the first part (dose finding-DFP), which aimed to define the maximum tolerated dose (MTD) and the recommended dose (RD) of the combination of T and C, were entered patients with advanced solid tumours, who had failed a maximum of 2 prior lines of chemotherapy (3 in the case of breast cancer) and for whom treatment with C was indicated; in the second part (expansion of the RD – ERD) were entered patients with a diagnosis of non-small cell lung cancer (NSCLC) or ovarian cancer (OC) and no prior treatment. Other eligibility criteria were <70 years of age, expected survival of P3 months, ECOG Performance Status (PS) <= 1, adequate haematological, renal and liver function (alkaline phosphatase (AP) <= 1.5 x upper normal limits (UNL), aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT) within normal limits, <= 2.5 x UNL in the case of liver metastases, normal total serum bilirubin, albumin >= 2.5 g/dl","Exclusion criteria were a pre-existing symptomatic hearing impairment, peripheral neuropathy > grade 1, significant liver disease, >500 mg/m2 prior cumulative dose of C or platinum equivalent, prior radiotherapy to >30% bone marrow reserve. At least one measurable lesion according to RECIST11 was requested in the ERD",at cycle 1,NA
23299791,NA,Single Drug,No,"patients with advanced/metastatic solid tumours. Tumour types included genitourinary (n = 15) including 6 patients with prostate carcinoma, lung (n = 5), head and neck (n = 3), breast (n = 1), gynaecologic (n = 1), musculoskeletal (n = 1) and unknown primary (n = 1) cancers.","Eligible patients were >=18 years of age, with a life expectancy of at least 3 months, histologically confirmed solid tumour with a maximum of two lines of prior chemotherapy for locally advanced or metastatic disease, which was refractory to standard treatment or without standard therapeutic options. Patients had to have Karnofsky performance score >=70 % and had fully recovered from toxic effects of previous therapies. Prior treatment with vinflunine or another vinca alkaloid was allowed, except in the metastatic setting. Other eligibility criteria included the following:  adequate haematopoietic function (absolute neutrophils count (ANC) >=1,500 ul-1, platelet count >=100,000 ul-1 and haemoglobin >10.0 g/dl), total bilirubin <= upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.5 times ULN in absence of liver metastasis, <=5 times ULN if liver metastasis; serum creatinine <ULN, creatinine clearance >=50 ml/min; no clinically relevant comorbidity such as uncontrolled cardiovascular diseases, significant neurologic or psychiatric disorders, grade >1 peripheral neuropathy, any alteration of the gastrointestinal tract likely to impact on absorption and elimination of oral drugs; no progressive or symptomatic brain metastases. ",NA,during the first cycle,NA
22382883,NA,Combination,No,"patients with advanced/metastatic solid tumors. Primary cancer: Non-small-cell lung cancer 5, Melanoma 4, Digestive cancer (Esophagus 2, Anus 1, Hepatocarcinoma 1, Cholangiocarcinoma 1), Gynaecological cancer (Cervix 2, Endometrium 1), Mesothelioma 2, Gastro intestinal stromal tumor 1, Thyroı¨d 2, Breast 3, Bladder 2, Small-cell lung cancer 1, Prostate 2, Penile cancer 1, Chondrosarcoma 1, Head and neck 3, Carcinoma of unknown origin 1","Patients, between 18 and 75 years old, were eligible for the, study if they had an histologically confirmed solid tumor for, which effective standard therapy was not available, or if they, had progressive disease after standard therapeutic modalities, with a maximum of two lines of prior chemotherapy for, locally advanced or metastatic disease (targeted therapy and, hormone therapy were not included in chemotherapy lines)., The interval between completion of the last chemotherapy or, radiotherapy and enrolment in the trial had to be at least, 6 weeks for nitrosoureas and mitomycin C based therapy, and 3 weeks for all the other treatments. Patients had to have, a Karnofsky performance status >=70%, with an estimated, life expectancy of at least 3 months. The biological criteria, for eligibility were defined by laboratory tests of adequate, bone marrow function: haemoglobin[10 g/dl, neutrophils >1.5 x 109/L, platelets >100 x 109/L and adequate liver and kidney functions: total bilirubin B Upper Limit of Normal (ULN), aspartate aminotransferase and alanine aminotransferase <=2.5 x ULN in absence of liver metastases and <=5 x ULN if liver metastases, alkaline phosphatase <=5 x ULN (except in patients with documented bone or liver metastases), creatinine \ULN and creatinine clearance C50 mL/min according to Cockroft and Gault formula.","Patients were excluded if they had Central Nervous System (CNS) metastases (unless they have been previously treated for these metastases and were stable by CT scan without cerebral oedema); history of significant neurologic or psychiatric disorders precluding understanding and giving consent; peripheral neuropathy grade >1 (according to the NCI-CTC: National Cancer Institute Common Toxicity Criteria version 3.0); dysphagia grade >=2, malabsorption syndrome, extensive surgery of the stomach or the small bowel, major alterations of gastro intestinal transit such as subocclusive syndrome; or uncontrolled comorbidity such as active serious infection, uncontrolled diabetes or unstable cardiovascular conditions. Some previous treatments were forbidden: high dose chemotherapy with hematopoietic stem cell rescue; extensive radiotherapy up to more than 25% of bone marrow reserve; treatment with vinflunine or a vinca alkaloid in the metastatic setting. Participation in another clinical trial within 28 days before study entry and any other concurrent anti-cancer therapy were not permitted",during the first cycle,NA
29635147,NCT01373710 ,Combination,No,patients with HER2 positive breast carcinomatous meningitis,"Men or women >= 18 years of age with HER2-BC (3+ overexpression of HER2 by immunohistochemistry or HER2 gene amplification by in situ hybridisation)  and MC diagnosed by CSF cytology and/or clinical symptoms of MC and MC evident on magnetic resonance imaging (MRI) were eligible. Other eligibility criteria included life expectancy 2 months, adequate bone marrow, liver and kidney function and good baseline left ventricular ejection fraction. Prior treatment with trastuzumab was permitted. The presence of brain metastases was permitted without prior treatment if they were asymptomatic and without threat of cerebral herniation. Patients with symptomatic brain metastases could be included if (1) surgery and/or radiotherapy was performed;(2) the cerebral localisation did not contrain- dicate IT or intraventricular administration and (3) a period of at least 3 weeks had passed since the last session of radiotherapy or surgery. With the exception of lapatinib, all systemic treatments (chemotherapy, hormone therapy and/or trastuzumab i.v.) could be initiated, maintained or modified during the study","Principal non-inclusion criteria were defined by suspicion of disorder of CSF circulation, recent administration of lapatinib (wash-out period >2 weeks required), allergy to trastuzumab, pre-existing cardiac dysfunction, severe pre-existing cerebrovascular dysfunction, pregnancy and inability to give informed consent. Concurrent radiotherapy was contraindicated during IT trastuzumab therapy",during the first 4 weeks of IT trastuzumab,NA
25417902,NCT01476137,Combination,No,"patients with solid tumors and multiple myeloma. Primary Tumor Type: Breast, Pancreas, Colon/rectum, Melanoma, Non-small cell lung, Head and neck, Ovary, Other","Patients aged 18 years or older with advanced solid tumor malignancies that were not responsive to standard therapies or for which there was no approved or curative therapy or standard therapy was refused were eligible for enrollment in this two phase study. In Phase II, patients with proteasome-refractory multiple myeloma and relapsed refractory triple negative breast or endometrial cancer were to be enrolled once the MTD was reached and the RP2D was determined in Phase I. Other key inclusion criteria included: availability of archived or fresh tumor tissue, adequate organ function, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. ","Type 1 diabetes, active GI disease, recent major surgery or undergoing other anti-cancer treatments, presence of leptomeningeal disease, and clinically significant cardiovascular disease or current evidence/risk of retinal venous occlusion or central serous retinopathy were criteria for exclusion.",during the first 28 days of combination therapy,NA
20921456,NA,Combination,No,children with diffuse intrinsic pontine glioma,"Eligibility criteria consisted of: performance score ≥ 40; adequate hematologic (absolute neutrophil count ≥ 1,000/μL, platelet count ≥ 100,000/μL, and hemoglobin concentration ≥ 8 g/dL), renal (serum creatinine concentration < 2× the institutional normal values for age), and hepatic (total bilirubin concentration < 1.5× the institutional upper limit of normal, ALT < 5× the institutional upper limit of normal, and albumin ≥ 2 g/dL) function; use of safe contraceptive methods for females of childbearing age and males with child-fathering potential; QTc interval in ECG less than 450 ms.","Exclusion criteria consisted of patients with intratumoral hemorrhage detected by T1- or T2-weighted magnetic resonance imaging (MRI) sequences with largest diameter ≥ 1 cm; patients receiving other anticancer or experimental therapies; patients with other medical conditions that could not be adequately controlled, or that would impair the evaluation of toxicities related to this therapy, or alter drug metabolism or tolerance to treatment; patients with cardiac problems, including a history of arrhythmias and QTc interval prolongation; use of other medications associated with a significant risk of prolonging QTc interval; significant hypertension defined as blood pressure of greater than the 95th percentile for age, height, and sex; and use of enzyme-inducing anticonvulsants or other medications that could affect the function of CYP3A4, with the exception of dexamethasone and fluconazole.",the first 6 weeks of therapy,NA
25352401,NCT00450138,Combination,No,Patients with previously untreated HNSCC ,"Eligible patients were aged >=18  years with histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or arynx that was not previously treated or resected (stage  III–IV with noproven hematogenous metastatic disease). Patients were included if they had a World Health Organization (WHO) performance status (PS) 0–1, life expectancy >=12 weeks and normal cardiac, hematopoietic, hepatic, and renal function. Patients with a history of non-melanoma skin cancer, or other previous malignancies treated >=3 years before the current tumor from which thepatient had remained continually disease-free and patients with in situ   carcinoma of the cervix and adequately treated basal cell or squamous cell carcinoma of the skin were eligible for inclusion","Patients were excluded if they had received any previous anticancer therapy for treatment of their current diagnosis, other investigational drugs within the past 30 days, or any concomitant medications that may affect  quantum tunneling composite (QTc) or induce CYP3A4 function and could not be discontinued. Other exclusion criteria included the presence of simultaneous primary tumors or major surgery in the 4 weeks before screening, or  an incompletely healed surgical incision. For regimen 2, additional exclusion criteria included preexisting neuropathy Common Terminology Criteria for Adverse Events(CTCAE) grade >=2, known severe hyper sensitivity to cisplatin,  and evidence of preexisting moderate to severe decline of hearing capacity. ",Treatment was continued for 8 to 9 weeks unless the patients experienced a DLT or met another criterion for discontinuation,NA
26801247,NCT0110429,Combination,No,patients with triple-negative breast cancer (TNBC) and BRCA mutation-associated breast cancer,"Adequate organ function is defined as absolute neutrophil count (ANC) > 1,500/mm3 , platelets > 100,000/mm3,  hemoglobin > 9.0 g/dL, serum creatinine < 1.5 × upper limit of normal (ULN), AST and/or ALT < 2.5 × ULN, except patients with liver metastases, may have AST and/or ALT<5 × ULN, bilirubin <1.5 × ULN,  PTT ≤ 1.5 × ULN, and INR < 1.5. Systemic therapies must have been completed within either 28 days or 5 half lives of a targeted therapy (whichever is shorter), prior to study drug administration.  Radiation therapy must have been completed at least 2 weeks prior to the enrollment date.  ","Patients were excluded if they had baseline peripheral neuropathy that exceeded grade 1, clinically significant and uncontrolled major medical conditions, or were pregnant or lactating. ",in the first cycle,NA
21373895,NA,Single Drug,No,"patients with advanced cancer. The most common cancer types included carcinoma of the prostate (N = 6), breast (N = 4), lung (N = 3), endometrium (N = 3), kidney (N = 2), and cervix (N = 1)","Inclusion criteria included histologically documented advanced carcinoma that was refractory to standard treatment or for whom no curative therapy was available, age of 18 years or older, Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2, and adequate hematologic (neutrophils >= 1000/uL and platelets >= 100,000/uL), renal (serum creatinine < 1.5 mg/DL), and hepatic function (total bilirubin within normal limits and aspirate transaminase level <= 3-fold the upper limits of normal). Patients were required to be willing and able to attend clinic 3 times weekly for directly observed administration of oral vinorelbine",Patients with functional or mechanical gastrointestinal obstruction or chronic nausea/vomiting that would make it difficult to comply with oral drug administration were not eligible.,during cycle 1,NA
23536435,NA,Combination,No,children with newly diagnosed diffuse intrinsic pontine glioma,"Patients between 18 months and 20 years old with newly diagnosed nonmetastatic DIPG or other brainstem highgrade gliomas were eligible for this study. Other eligibility criteria consisted of: (i) performance score 40 or more; (ii) adequate hematologic [absolute neutrophil count >=1,000/uL, platelet count >=100,000/uL (transfusion independent), and hemoglobin concentration >=8 g/dL], renal (serum creatinine concentration <2 times the institutional normal values for age), and hepatic (total bilirubin concentration <1.5 times the institutional upper limit of normal, SGPT <5 times the institutional upper limit of normal, and albumin >=2 g/dL) function; (iii) use of safe contraceptive methods for females of childbearing age and males of child fathering potential; and (iv) QTc interval in electrocardiogram <450 msec","Exclusion criteria consisted of: (i) patients receiving other anticancer or experimental therapies; (ii) patients with other medical conditions that could not be adequately controlled or that would impair the evaluation of toxicities related to this therapy or alter drug metabolism or tolerance to treatment; (iii) use of enzyme-inducing anticonvulsants or other medications that could affect the function of CYP3A4, except for dexamethasone and fluconazole; (iv) patients with cardiac problems, including a history of arrhythmias and QTc interval prolongation; (v) use of other medications associated with significant risk of prolonging QTc interval; (vi) significant hypertension defined as blood pressure more than 95th percentile for age, height, and sex; and (vii) body surface area more than 1.8 m2 for dosage levels in which the dose of dasatinib was 85 mg/m2.",the first 6 weeks of therapy,NA
33947696,NCT02202200,Combination,No,Patients with BRAF V600E/KMUT metastatic melanoma harboring CDKN2A loss and RB1 expression ,"Patients with unresectable stage III or stage IV BRAFV600E/K metastatic melanoma were enrolled from 2014 to 2018. The inclusion criteria were as follows: CDKN2A loss (defined as either low p16 protein/mRNA expression, mutation, or loss of the CDKN2A gene) and Rb expression in a recent metastatic sample (<6 months); age >18 years; Eastern Cooperative Oncology Group performance status <2; life expectancy >3 months; no previous monotherapy against the AKT/ PIK3 pathway; and no previous therapy with MEKis unless associated with BRAFis. BRAFV600 mutation screening was performed using two different technologies: allelic discrimination real-time PCR and pyrosequencing. The CDKN2A gene status was determined by sequencing exons 1a and 2, gene-specific copy number analysis and quantitative reverse transcription PCR (RT-PCR). p16 expression was assessed by IHC (Clone E6H45, Roche-Ventana). Total Rb expression was assessed by IHC (Clone EPR17512, ab181616, Abcam) and quantitative RT-PCR using specific primers. ","The exclusion criteria were as follows: inadequate renal function (serum creatinine >2.0 mg/dl and/or creatinine clearance <60 ml/min); inadequate hepatic function (serum bilirubin >25 μmol/l, transaminases >3.0 times the upper limit of normal (ULN) or 5ULN in liver metastasis cases); inadequate bone marrow function (absolute neutrophil count <1500/mcl, platelets <150000/mcl and hemoglobin<8 g/dL); myocardial infarction or unstable angina within the past 6 months; congenital long QT syndrome or screening QTc > 470 ms; malabsorption syndrome or other condition that would interfere with enteral absorption; HIV and/or hepatitis (B and C) positive before inclusion; chemotherapy or immunotherapy within 4 weeks; drugs interfering with palbociclib and vemurafenib metabolism; requirement for chronic corticosteroid therapy ≥10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant; fertile women who do not want or cannot use effective contraception (hormonal contraception unauthorized) during the study and up to 6 months after the end of study; pregnant or lactating women; fertile and sexually active men whose partners are fertile women who do not use effective contraception.",during the first 2 cycles,The patients were stratified into two distinct strata according to the previous BRAFi treatment status (no previous BRAFi treatment: strata 1; previous BRAFi treatment: strata 2).
24470511,NA,Combination,No,patients with HER2-positive advanced or metastatic breast cancer ,"Patients aged >= 18 years with HER2+ metastatic breast cancer and evidence of disease progression as per Response Evaluation Criteria In Solid Tumors version 1.0 (RECIST v1.0) and resistance to trastuzumab were included. Resistance to trastuzumab was defined as recurrence while on or within 4 weeks since the most recent infusion for patients who received trastuzumab for metastatic disease (or within 12 months for patients who received trastuzumab as adjuvant therapy). Resistance to T-DM1 was considered as equivalent to trastuzumab for the purpose of defining study eligibility. Other key inclusion criteria included World Health Organization (WHO) performance status <=2; provision of a representative tumor sample for the determination of tumor molecular status; >= 1 but <=4 prior lines of HER2-directed therapy (trastuzumab, lapatinib, and/or T-DM1); <=4 lines of prior cytotoxic chemotherapy.","Patients were excluded if they had received previous treatment with a PI3K inhibitor or had a contraindication to trastuzumab treatment. Patients with untreated brain metastases were also excluded; however, patients were eligible if the brain metastases were previously treated, they had completed therapy (including radiation and/or surgery) >4 weeks earlier, and were clinically stable (as determined by the investigator) with respect to the tumor at the time of study entry. Other exclusion criteria included a medically documented history of, or active, major mood or psychiatric disorder; Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxiety; poorly controlled diabetes mellitus (HbA1c >8%); and fasting plasma glucose >140 mg/dL or >7.8 mmol/L.",during the first cycle of treatment,NA
22082325,NA,Combination,No,patients with advanced cancer,"Patients were adults with a confirmed histological diagnosis of a solid tumour and an ECOG performance status 1, and adequate hematologic, hepatic and renal functions. ","Patients were excluded if they had active central nervous system metastases, known hypersensitivity to the study drugs, known psychiatric or substance abuse disorders, pre-existing grade 2 or higher neuropathy, and had received radiotherapy to more than 30% of the bone marrow surface. ",during the first cycle of treatment,NA
25503302,NCT00821080,Combination,No,adults with recurrent glioblastoma,"Patients were eligible for the present study if they were adults (age 18 or greater) with recurrent GBM on no CYP3A4-inducing drugs, previously treated with standard therapy including resection if feasible, radiation and temozolomide, no more than three prior chemotherapies, naı¨ve to prior anti-VEGF, anti-EGF therapy or mTOR inhibitors and had a Karnofsky performance status (KPS) >=60 % and mini-mental status examination (MMSE) score [15. Patients must have been at least 3 months from the completion of radiation or radiosurgery and must have been maintained on a stable or decreasing corticosteroid regimen for at least 3 days prior to the start of treatment. Laboratory prerequisites included: normal ANC and platelets, renal, liver, and cardiac function.","The patient could not be taking any concomitant medication that might cause QTc prolongation, induce Torsades de Pointes or induce CYP3A4 function. Uncontrolled hypertension and hyperlipidemia were also exclusions to enrollment.",the first cycle,NA
19184020,NA,Combination,No,patients with advanced colorectal adenocarcinoma,"Patient eligibility included histologically conWrmed metastatic colorectal adenocarcinoma (stage IV); suitability for first- or second-line chemotherapy; age >=18 years; a WHO performance status of 0 or 1; and adequate cardiac, haematopoietic, hepatic and renal function. Patients with brain metastases were eligible if treated at least 4 weeks before the start of study treatment and if clinically stable without steroid treatment for >=1 week. ",Patients were ineligible if they had received chemotherapy and/or radiotherapy less than 4 weeks before the start of study therapy; or had received any second-line or subsequent chemotherapy,NA,NA
30569244,NCT01810016,Combination,No,"patients had pathologically confirmed Stage III, IVa, IVb HNSCC. The primary tumor sites included tonsil (n = 12),base of tongue (n = 9), posterior pharyngeal wall (n = 1),supraglottic larynx (n = 2), glottic larynx (n = 2) and hypopharynx (n = 3).","All eligible patients had: 1) pathologically confirmed HNSCC, 2) Stage III, Stage IVa or Stage IVb disease, 3) unresectable or borderline resectable disease involving the larynx, hypopharynx, nasopharynx and oropharynx. Patients were deemed unresectable if they have clinically confirmed carotid artery encasement, skull base involvement, trismus or deep neck musculature invasion at the time of diagnosis. Borderline resectability was defined as those patients in which surgery was unlikely to result in excision of all macroscopic disease or would result in a total glossectomy, total laryngopharyngectomy, skull base resection or carotid resection. All patients were required to be >18 years of age, be able to provide written consent, have an ECOG performance status of 0–2 and have adequate hematologic, renal and hepatic function. ","Ineligibility criteria included: 1) major surgery or trauma within 28 days of enrollment 2) prior radiation to any of the planned radiation field, 3) history of hypersensitivity to HDACi or any other drug used in this study 4) active peptic ulcer disease 5) pregnant or lactating women 6) uncontrolled co-morbid conditions that would limit compliance with the treatment regimen and 7) patients with active viral hepatitis or known HIV infection.",during the entire course of chemoradiation,NA
11745237,NA,Combination,No,"patients with advanced malignant disease. Disease: RCC 60, Adrenocortical carcinoma 5, Breast carcinoma 8, NHL 2, Sarcoma 2, Bladder carcinoma 1, Ovarian carcinoma 1","Seventy-nine patients were enrolled on the trial: Informed consent was obtained from all patients. Enrollment criteria included age >18 years, a Karnofsky performance status >= 70%, and a life expectancy of > 3 months. Patients were ineligible if they had received chemotherapy, immunotherapy, or radiation therapy in the 4 weeks prior to study entry. Patients were required to have normal hepatic function (alanine and aspartate aminotransferase levels <= twice the upper limit of normal), normal renal function (creatinine clearance >= 75 mL per minute), and normal hematologic parameters (white blood cell count >= 4000, absolute neutrophil count >= 2000, and platelet count $ 100,000). During the study, patients could not be treated simultaneously with PSC 833, other P450-interactive compounds, or other drugs known to interact with cyclosporine A. ",NA,in cycle 2,NA
10811501,NA,Single Drug,No,"patients with advanced solid tumors. Primary tumor site: colorectal 4, Breast 3, Small bowel 2, Sarcoma 2, Melanoma 2, Mesothelioma 1, kidney 1, lun(small-cell) 1, ovary 1, primary unknown 1, salivary gland 1","Patients with histologically or cytologically confirmed solid malignancies refractory to standard therapies or for whom no standard therapy existed were eligible. Patient entry criteria also included: (1) age >=18 years, (2) life-expectancy of at least 12 weeks, (3) Southwest Oncology Group (SWOG) performance status of 0-2, (4) no treatment with chemotherapy in the preceding 4 weeks (6 weeks for prior mitomycin C or nitrososureas), (5) measurable or evaluable disease, and (6) adequate hematopoeitic (hemoglobin >=9 g/dl, absolute neutrophil count (ANC) >=1500/mm3, platelet count >=100,000/mm3, hepatic (bilirubin <=1.5 mg/dl, aspartate serum transferase (AST) <=3 times upper limit of normal), and renal (creatinine <=1.5 mg/dl) functions.","Patients were excluded if they had evidence of an active infection, congestive heart failure, unstable angina, or a myocardial infarction within six months of study entry.",during cycle 1,NA
8194022,NA,Combination,No,patients with metastatic RCC,"Entry criteria included (1) histologic documentation of metastatic RCC, (2) an estimated life expectancy of at least 2 months, (3) evaluable disease, and (4) a Kamofsky performance status of at least 70%. Prior chemotherapy and immunotherapy were allowed; however, those who had received prior fluoropyrimidine or vinca alkaloid therapy were excluded. Before enrollment of a patient, the therapy was explained and informed written consent was obtained. ",NA,NA,NA
23639470,JapicCTI-101264,Single Drug,No,patients with ALK-rearranged advanced non-small-cell lung cancer,"Patients were eligible if they were aged 20 years or older; had histologically or cytologically confirmed advanced or metastatic ALK- rearranged stage IIIB, IV, or recurrent NSCLC; had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1; had measurable lesions as defi ned by Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) (for the phase 2 portion only); received two or more (phase 1 portion) or one or more (phase 2 portion) previous chemotherapy regimens; and had adequate haematological, hepatic, and renal function.","We excluded patients who had received previous treatment with any ALK inhibitor. Other exclusion criteria included symptomatic brain metastases or brain metastases requiring treatment, history of serious cardiac dysfunction, clinically significant gastrointestinal abnormality that would affect the absorption of the study drug, and pregnant or lactating women",from day 1 to day 3 in cycle 0 and from day 1 to day 21 in cycle 1,NA
9157072,NA,Single Drug,No,"patients (pts) with solid tumors (non-small-cell lung [3 pts], unknown primary [3 pts], mesothelioma [2 pts], colon/rectum, sarcoma, thyroid, head/neck and cervix [1 pt each])","All patients had histologic evidence of solid tumors for which there was no other proven treatment (chemotherapy, radiotherapy or surgery) available. Patients had an age between 18 and 70 years, an estimated survival of at least three months and a WHO performance status of <= 2. Previous chemotherapy, radiotherapy or biological response modifier therapy must have had been completed more than 4 weeks prior to study entry (in case of mitomycin C or nitrosourea >= 6 weeks). Other eligibility criteria included: granulocytes >= 2000//ul, platelets >= 100000//ul; serum bilirubin < 1.5 mg/dl and creatinine < 1.2 mg/dl; written informed consent.","Patients who had received previous therapy containing vinca alkaloids, patients with cerebral metastasis or patients with neurologic disorders which could interfere with the evaluation of neurologic toxicities (except pre-existing grade 1 peripheral neuropathy) were not eligible. Also, patients with active infectious disease, pregnant patients, patients for whom lung radiation was planned and mentally incapacitated patients were ineligible. ",NA,NA
29221762,NCT01118676,Combination,No,Patients With Stage III Non-Small-cell Lung Cancer,"Eligible patients had to satisfy the following criteria: age > 18 years, inoperable stage IIIA or IIIB NSCLC (American Joint Committee on Cancer, 7th edition),28 World Health Organization performance status of 0 to 1, and combined modality therapy deemed appropriate by a multidisciplinary tumor board. Initial staging included chest computed tomography (CT), 2-deoxy-2- [fluorine-18]fluoro-D-glucose (18F-FDG) positron emission to- mography (PET), and brain magnetic resonance imaging. Other requirements included an absolute neutrophil count of >= 1500/mm3, platelet count of >= 100,000/mL, serum creatinine < 1.5 times the upper limit of normal (ULN), serum aspartate amino-transferase and alanine aminotransferase < 2 times the ULN, and serum bilirubin at or less than the ULN. The patients had no contraindications to the use of antiangiogenic treatment (uncontrolled hypertension, need for therapeutic anticoagulation).","Patients previously treated for a malignancy by means of chemotherapy, radiotherapy or surgery. Uncontrolled hypertension. Uncontrolled bleeding within the last 3 months. Patients under anti-coagulation with anti-vitamin K or therapeutic dose heparin ; low-molecular heparins for prophylaxis are permitted and are not considered an exclusion criterion. Presence of cerebral metastases. Participation in a clinical trial within the last 8 weeks. Any other specific concomitant anti-tumor treatment (such as chemotherapy, radiotherapy …). Patients with a history of myocardial infarction or a cerebral vascular accident within the last 12 months. Continued use of aspirin (>325mg/day). Major surgery whiting the last 28 days or planned. Major non-healing wound, ulcer. Pregnant or breastfeeding women cannot participate in this trial. Women of reproductive potential must have a negative pregnancy test (blood) within 72 hours before the start of treatment. Men and women of reproductive potential must use an efficient contraceptive method when entering the trial and until one months after the end of treatment. History of a thrombo-embolic or hemorrhagic event. Patients put under tutelage. Patients not able to follow the procedures visits, exams foreseen by the trial. Any other severe medical or psychiatric condition or biological anomaly - acute or chronic - that, in the investigator's opinion - may render the inclusion of the patient inappropriate.",during the combined treatment and until 1 month after completion.,NA
34301808,NCT03013491,Combination,No,"patients with advanced solid tumors. Patients with 21 different solid tumor types (cervical carcinoma n=3; 2 each of pancreatic and uterine carcinoma; all others of a single tumor type (anal squamous cell carcinoma, estrogen receptor–positive breast cancer, colon carcinoma, gastric cancer, glioblastoma, leiomyosarcoma, mesothelioma, neuroendocrine cancer, osteosarcoma, ovarian carcinoma, prostate nonadenocarcinoma, rectal carcinoma, squamous cell carcinoma of the head and neck, small cell lung cancer, salivary gland carcinoma, triple-negative breast cancer and testicular carcinoma.)) were enrolled.","Eligible patients were aged ≥18 years with Eastern Cooperative Oncology Group performance status 0 or 1 and had an anticipated life expectancy of ≥3 months. Patients were required to have metastatic or advanced unresectable solid tumors (excluding thymic epithelial tumor, thymoma, and thymic carcinoma) naive to prior PD-1/PD-L1 and CTLA-4 inhibitor therapy and to be ineligible for standard-of-care therapy. Patients were eligible regardless of PD-L1 status. Patients with treated stable brain metastases were eligible for the study if their treatment did not require radiation therapy or steroids. Active screening for brain metastases was not required.","Exclusion criteria included prior chimeric antigen receptor T-cell therapy; chemotherapy or immunotherapy within 14 days, live vaccine within 30 days, or radiation therapy within 3 months prior to study drug; HIV-related illness, hepatitis B or C; age-related macular degeneration; solid organ or bone marrow transplant; prior or current autoimmune disease; history of a medical condition requiring treatment with >10mg daily prednisone equivalents or immunosuppressants; and women who were pregnant or breastfeeding. ",28 days,NA
32819972,NCT01557114,Combination,No,patients with metastatic melanoma,"Eligible patients had unresectable locally advanced or metastatic melanoma with at least one measurable metastasis accessible to radiotherapy. Subcutaneous nodules and lymph nodes were considered as targets for irradiation. Tumor lesions located within vital organs or gastrointestinal tract were not considered as target for radiotherapy. All patients had measurable and non-measurable disease evaluable according to irRC. Patients were ≥18 years of age, were able to give written informed consent, had Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 and had normal renal and liver functions on blood tests. ","Patients were excluded if they had one of the following criteria: (1) suspected or known central nervous system tumors including brain metastasis, (2) any other malignancy with a disease-free for less than 5 years, (3) an autoimmune disease, (4) a history of prior treatment with ipilimumab, (5) prior radiotherapy within the same body area or (6) radiotherapy in fields containing flat bones (volume >35%). If chemotherapy or immunotherapy were previously used, a wash-out period of 2 weeks at least was required before the first administration of ipilimumab.",during the first combination treatment cycle (from week 4 to week 10),NA
31778074,NCT00585195,Single Drug,No,"patients with advanced cancer. Primary tumor type, n (%): Colorectal 6 (17), Soft tissue sarcoma 5 (14), NSCLC 3 (8), Bladder 2 (6), Esophageal 2 (6), Inflammatory myofibroblastic tumor 2 (6),  Pancreas 2 (6),  Prostate 2 (6),  Ovarian 2 (6), Other 10 (28)","1. Histologically confirmed advanced malignancies (except for leukemia) refractory to standard-ofcare therapy or for whom no standard of care therapy was available o Solid tumors: measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) V.1.0. Target lesions that had been previously irradiated were not considered measurable (lesion) unless an increase in size was observed following completion of radiation therapy. 2. Able, in the investigator’s opinion, to receive at least two cycles of treatment. 3. Female or male, 18 years of age or older. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 5. Resolution of all acute toxic effects of prior therapy or surgical procedures to grade ≤1 (except alopecia). 6. Adequate organ function as defined by the following criteria: o Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN), or AST and ALT ≤5 × ULN if liver function abnormalities were due to underlying malignancy o Total serum bilirubin ≤1.5 × ULN (except for patients with documented Gilbert syndrome) o Absolute neutrophil count ≥1500/µL o Platelets ≥100,000/µL o Hemoglobin ≥9.0 g/dL o Serum creatinine ≤2.0 × ULN. 7. Signed and dated informed consent document indicating that the patient (or legal representative) had been informed of all the pertinent aspects of the study before enrollment. 8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures","Patients presenting with any of the following were not to be included in the study: 1. Major surgery, radiation therapy or systemic anticancer therapy within 4 weeks of starting study treatment; within 2 weeks of starting study treatment for patients in the recommended phase II dose (RP2D)-enriched population or anaplastic lymphoma kinase (ALK)-negative cohorts. 2. Prior high-dose chemotherapy requiring haematopoietic stem cell rescue except for patients with lymphoma or myeloma. 3. For c-Met-dependent tumors, prior therapy specifically directed against c-Met or hepatocyte growth factor; for ALK-dependent tumors, prior therapy specifically directed against ALK. 4. Current treatment on another clinical study. 5. Brain metastases, spinal cord compression, carcinomatous meningitis or leptomeningeal disease unless appropriately treated and neurologically stable for at least 4 weeks and not taking medications contraindicated to Exclusion Criteria #12–15. 6. Any of the following within the 12 months before starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure or cerebrovascular accident including transient ischaemic attack; within 6 months before starting study treatment for pulmonary embolus. However, upon agreement between the investigator and sponsor, the requirement for the 6-month post-event period for pulmonary embolus could be waived if the event was considered to be due to advanced cancer. Appropriate treatment with anticoagulants was permitted. 7. Ongoing cardiac dysrhythmias of National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE V.3.0) grade ≥2, uncontrolled atrial fibrillation of any grade, or QT interval, corrected QT interval >470 msec. 8. Hypertension that could not be controlled by medications (>150/100 mm Hg despite optimal medical therapy). 9. Known human immunodeficiency virus (HIV) infection. 10. Pregnant or breastfeeding. Female patients must have been surgically sterile or postmenopausal, or must have agreed to the use of effective contraception during the period of therapy. All female patients with reproductive potential must have had a negative pregnancy test (serum or urine) before enrollment. Male patients must have been surgically sterile or must have agreed to use effective contraception during the period of therapy. The definition of effective contraception was based on the judgment of the principal investigator or a designated associate. 11. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would have imparted, in the judgment of the investigator or sponsor, excess risk associated with study participation or study drug administration, which would have made the patient inappropriate for entry into this study. 12. Use of drugs that were known potent cytochrome P450 (CYP) 3A4 inhibitors within 7 days before the first dose of crizotinib, including but not limited to, ketoconazole, itraconazole, miconazole, clarithromycin, erythromycin, ritonavir, indinavir, nelfinavir, saquinavir, amprenavir, delavirdine, nefazodone, diltiazem, verapamil and grapefruit juice. All concomitant medication must have been approved by the sponsor. 13. Use of drugs that are known potent CYP3A4 inducers within 12 days before the first dose of crizotinib, including, but not limited to, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, tipranavir, ritonavir and St. John’s wort. All concomitant medication must have been approved by the sponsor. 14. Concurrent use of drugs that were CYP3A4 substrates with narrow therapeutic indices including, but not limited to, pimozide, aripiprazole, triazolam, ergotamine and halofantrine. All concomitant medication must have been approved by the sponsor.  15. Patients who participated in the midazolam interaction substudy must not: (1) have had any contraindications to midazolam administration according to the current package insert for midazolam; (2) taken any midazolam dose that was not specified in the protocol within 7 days of the first dose of midazolam; and (3) taken any medications or herbal supplements known to be CYP3A inhibitors or inducers for 7 days (for CYP3A inhibitors) or 12 days (for CYP3A inducers) before the first dose of midazolam. All concomitant medication must have been approved by the sponsor. 16. Patients with known interstitial fibrosis or interstitial lung disease",during cycle 1,NA
29563138,NCT01625234,Single Drug,No,"patients with advanced solid tumors and advanced ALK-positive NSCLC. Tumor type, n (%): NSCLC 89 (92), Head and neck 4 (4), Colorectal 2 (2), Small cell 1 (1), Breast 1 (1)","Eligible patients in dose escalation had advanced solid tumors. Dose expansion was limited to patients with advanced NSCLC whose tumors were positive for ALK as determined by fluores cence in situ hybridization (FISH) or immunohistochemistry (IHC) from local testing. ALK FISH-positive was defined as the FDA-cleared recommended threshold of 15% cells showing split signal; a second confirmatory test was required if the positive signal was between 10% and 15%. For ALK positivity by IHC, strong granular cytoplasmic staining (3þ) was required. ALK rearrangements were confirmed centrally via FISH for all patients. Additional eligibility criteria included age 18 years, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, adequate organ function and, in dose expansion, measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), v1.1. Prior therapy with crizotinib and/or secondgeneration ALK tyrosine kinase inhibitors (TKI) was allowed without a limit on prior therapies. A minimum washout period of 10 days was required between termination of treatment and administration of ensartinib. However, in the case of ALK TKIs, a 5-day window was allowed. Patients with asymptomatic CNS lesions were allowed. CNS lesions with evidence of tumor growth at least 1 month post whole brain radiation therapy (WBRT) can be target lesions as evidenced by gadolinium-enhanced MRI. Target lesions may not have been treated with stereotactic radiosurgery (SRS). Additional inclusion criteria included: Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1; adequate organ function; ability to swallow and retain oral medication; measurable or evaluable disease for dose escalation and measurable disease for dose expansion (except patients in the CNS metastases cohort whose lesions do not meet RECIST criteria must have at least one CNS target lesion).","Additional exclusion criteria included: pregnant or lactating females; gastrointestinal disease or other condition that would interfere significantly with the absorption, distribution, metabolism, or excretion of ensartinib; prior stem cell transplant; known allergy or delayed hypersensitivity reaction to drugs that are chemically related to ensartinib (e.g., crizotinib) or to the active ingredient of ensartinib; clinically significant cardiovascular disease, including QTcF interval ≥ 450ms or other significant ECG abnormalities, and clinically uncontrolled hypertension; New York Heart Association class III/IV congestive heart failure, cardiomyopathy, arrhythmia or conduction abnormality requiring medication, severe/unstable angina, coronary artery/peripheral bypass graft, or myocardial infarction, or a cerebrovascular accident or transient ischemia within 12 months of start of dosing; patients who are immunosuppressed (including known HIV infection) or who have an active infection, known hepatitis C, or any serious underlying medical condition that would impair the ability of the patient to receive protocol treatment; psychological, familial, sociological, or geographical conditions that would prevent them from complying with protocol requirements; or concurrent condition that in the investigator’s opinion might interfere with protocol compliance or would impart an excessive risk associated with study participation.	",during the first treatment cycle,NA
22234637,NA,Single Drug,No,"gastrointestinal (GI) cancer. Disease type: Gastric cancer, Colon cancer, Rectal cancer ","Patients who were eligible to enroll in this study includedthose with a histologically or cytologically diagnosed solid tumor with no standard therapy available or those who had failed to respond to standard therapy, with ECOG performance status of 0–2, whose life expectancy was >=3 months after enrollment, and who were >=20 years of age.","Patients were not eligible for enrollment if they had adverse events (AEs) from previous anti-cancer treatments that were National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grade 2 or more severe (with the exception of alopecia); were positive for HIV, HBV, or HCV; had a brain tumor or brain metastasis; had any concurrent malignancy (unless they had tumors localized in mucosa/epithelium or those who had been in remission for >=5 years); had anemia requiring blood transfusions within 2 weeks before enrollment; had bone marrow, hepatic, or renal dysfunction beyond predefined criteria; had peritoneal or pleural effusion requiring treatment; or had any uncontrolled concomitant illness (arrhythmias, unstable angina, congestive heart failure, uncontrolled hypertension, infections requiring systemic treatment, or continuous use of steroids). Additionally, patients were excluded if they required immunotherapy, radiotherapy, surgery, or chemotherapy or if they underwent these procedures within 4 weeks before enrollment; had hematopoietic cytokine treatment (e.g., G-CSF) within 2 weeks before enrollment; had mitomycin C or nitrosoureas within 6 weeks before enrollment; had a history of radiotherapy directed toward >25% of hematopoietic marrow cells; or had previously participated in a clinical trial of an HDAC inhibitor. The use of prophylactic concomitant use of colony stimulating factors, antibiotics, or antiemetics was prohibited during the 1st cycle",during the first cycle,NA
28032129,NCT00939770,Combination,No,"children with solid tumors or anaplastic large-cell lymphoma (ALCL). Solid tumours (Ewing’s sarcoma, Inflammatory myofibroblastic tumour, Osteosarcoma, Neuroblastoma, Non-small-cell lung, Other(Hepatocellular carcinoma (n=2); Wilms’ tumour (n=1); malignant schwannoma (n=1); fusiform malignancy (n=1)), Rhabdomyosarcoma, Soft-tissue sarcoma), Lymphomas (Anaplastic large-cell lymphoma), CNS tumours (Glioma, Ependymoma)","Patients older than 12 months and younger than 22 years with measurable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy and for whom there was no known curative treatment were eligible. To be included in part A2 of the study, patients had to have confirmed ALK translocations, activating mutations, or amplification (defined as greater than four-fold increase in the ALK signal number as compared with reference signal number on chromosome 2q) performed as a Clinical Laboratory Improvement Amendments (CLIA) certified assay. ALK immunohisto- chemistry could be used as a surrogate for FISH in patients with anaplastic large-cell lymphoma, or infl ammatory myofibroblastic tumours. To be included in part A3 of the study, patients had to have neuroblastoma, with or without bone marrow involvement. Patients in all three parts of the study could not have received previous cytotoxic chemotherapy within 3 weeks before enrolment and had to have recovered from the acute toxic eff ects of previous therapy before initiation of crizotinib. Patients were required to have a Karnofsky (those older than 16 years) or Lansky (those younger than 16 years) performance score of at least 50. Patients had to have adequate bone marrow (patients in the dose escalation group without bone marrow involvement had to have absolute neutrophil count ≥1000 cells per μL, platelet count ≥75 000 cells per μL, and haemoglobin ≥80 g/L; patients with bone marrow metastatic disease, as well as patients in the other two groups, had to have absolute neutrophil count ≥750 cells per μL, platelet count ≥25 000 cells per μL, and haemoglobin ≥80 g/L), renal (normal serum creatinine for age), hepatic (total bilirubin ≤1·5×normal and alanine aminotransferase ≤5·0×upper limit of normal (ULN—for this study, the ULN was 45 U/L), and cardiac (QTc ≤480 ms) function. Patients also could not have received palliative radiation within 2 weeks or radiation to more than 50% of the pelvis or craniospinal axis within 6 months; or biological therapy or growth factors within 7 days or autologous stem-cell transplantation within 3 months (previous allogeneic transplantation was an exclusion criteria) of enrolment. ","Patients with CNS tumours or known CNS metastases were excluded af ter two patients in part A1 had intratumoral haemorrhage. Exclusion criteria also included uncontrolled infection, pregnancy or lactation, and concurrent administration of some P-glycoprotein substrates. ",during cycle 1,NA
26966027,NCT01284192,Combination,No,patients with advanced solid tumors,"Adult patients (≥18 years of age) with histologically or cytologically confirmed diagnosis of relapsed/refractory tumor were included in the dose-escalation study. Patients had to have Eastern Cooperative Oncology Group (ECOG) performance status ≤2, adequate life expectancy >12 weeks, be non-child bearing (or be using protocol-specified contraceptive measures), and be able to swallow oral medications. Additional criteria for patients with ALK abnormalities in the dose-escalation phase included patients to be positive for ALK abnormalities (by any molecular method including, but not limited to, polymerase chain reaction, direct sequencing, in situ hybridization, or be previously confirmed by fluorescence in situ hybridization), to not have symptomatic brain metastases, to not to be taking >5 mg prednisone daily, or to not require hepatic enzyme-inducing anti-seizure medication. Inclusion into the dose-expansion cohort required patients to have ALK-positive tumors that had progressed on crizotinib.","Key exclusion criteria for the doseescalation cohort included patients with leptomeningeal involvement (as assessed through medical history review or through physical examination), inadequate bone marrow, renal and/or hepatic function, and a known history of long QT syndrome. ",in cycle 1,NA
14597873,NA,Combination,No,multiple myeloma patients ,"Diagnosis of multiple myeloma, stage II or III according to Durie and Salmon, previous treatment: relapsed or primary refractory disease or first-line treatment before high-dose chemotherapy, age 18–75, Karnofsky index > 60%.","Neutropenia < 500/ml or thrombocytopenia < 100 000/ml, active infection, heart failure (NYHA III or IV) or myocardial infarction in the last 3 months, impaired liver function with bilirubin > 2.0 mg/dl or ASAT or ALAT > 3  normal range, impaired renal function with creatinine > 3.0 mg/dl, uncontrolled diabetes mellitus.",the first cycle,NA
31898184,NA,Combination,No,patients with advanced renal cell carcinoma,"Eligibility criteria for enrollment included adults, aged ≥21 years, with histologically confirmed advanced or metastatic RCC and disease progression on two or more prior treatments. All patients were required to have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 as well as adequate hematologic, hepatic, and renal function. There was no upper limit on prior therapies.","Key exclusion criteria included chemotherapy or radiotherapy within 4 weeks, concurrent investigational agents, valproic acid or other retinoid, known active brain metastases, known intolerance to vorinostat, uncontrolled intercurrent illness including but not limited to, ongoing or active infection or significant cardiovascular impairment.",during the first treatment cycle,NA
33148673,NCT02737475,Combination,No,"Patients With Advanced Solid Tumors. Patients with the following tumors were enrolled in the dose-escalation and -exploration cohorts (parts 1A, 2A, 3A, 4, and 5): melanoma, non-small cell lung cancer (NSCLC), head and neck cancer (restricted to squamous cell carcinoma), transitional cell carcinoma of the genitourinary tract, RCC, pancreatic adenocarcinoma, colorectal cancer (CRC), cervical cancer, triple-negative breast cancer (TNBC), adenocarcinoma of the endometrium, ovarian cancer (OC), prostate adenocarcinoma, hepatocellular cancer (Child-Pugh A only), small cell lung cancer, gastric and gastroesophageal junction cancer, and thyroid cancer. ","Eligible patients were aged ≥18 years, had confirmed advanced solid tumors (metastatic, recurrent, refractory, and/or unresectable) and ≥1 lesion with measurable disease per RECIST version 1.1, and had progressed on or been intolerant of ≥1 standard treatment regimen in the advanced or metastatic setting (parts 1A, 2A, 2E, 3A, 4, 5, 6A, 7A). However, in patients with bladder cancer (parts 2C, 8) or cervical cancer (part 2D), patients must have been offered and/or received or refused ≥1 prior platinum-based therapy. In part 6A, patients with RCC must have progressed on or been intolerant of ≥1 standard treatment regimen in the advanced/metastatic setting. In part 6B, no prior therapy was allowed for patients with RCC, with the exception of 1 prior adjuvant or neoadjuvant therapy for completely resectable disease that did not include an agent targeting VEGF or VEGFRs. In part 7B, no prior systemic therapy was allowed for patients with stage IV or recurrent NSCLC and if recurrence occurred ≥6 months after the last dose. Other key eligibility criteria included Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were required to provide pretreatment and on-treatment tumor biopsies (core needle, excisional, or incisional). Prior immune checkpoint inhibitor therapy was permitted following a washout period >4 weeks after the last treatment. In the safety cohort (part 6A), patients with histologically confirmed RCC with clear-cell component who received ≥ 1 prior systemic treatment in the advanced or metastatic setting were enrolled. In the safety cohort (part 7A), eligible patients had histological or cytological confirmation of NSCLC with advanced squamous or nonsquamous histology with ≥ 1 prior systemic treatment for NSCLC. Patients enrolled in the dose-exploration cohort (part 8) had histologically or cytologically confirmed bladder cancer. Patients were required to be immunotherapy treatment naive, have received or refused 1 prior platinum-based therapy for metastatic or locally advanced unresectable disease, and be within 12 months of perioperative treatment with a platinum agent in the setting of cystectomy. In the dose-expansion cohorts, eligible patients had histologically or cytologically confirmed bladder cancer (part 2C). Patients must have been offered and/or received or refused 1 prior platinum-based therapy for the treatment of metastatic or locally advanced unresectable disease and had < 2 prior systemic therapies. In part 6B, patients with histologically confirmed advanced or metastasized RCC with a clear-cell component were enrolled. No prior systemic therapy for RCC was permitted, with the following exception: 1 prior adjuvant or neoadjuvant therapy for completely resectable RCC if such therapy did not include an agent that targets VEGF or VEGF receptors and if recurrence occurred ≥ 6 months after the last dose of adjuvant or neoadjuvant therapy. In part 7B, prior adjuvant or neoadjuvant chemotherapy (last administration ≥ 6 months prior to enrollment) and prior definitive chemoradiation for locally advanced disease (last administration ≥ 6 months prior to enrollment) were permitted. ","Patients were excluded if they had metastases in the central nervous system or it was the only site of disease, carcinomatous meningitis, autoimmune disease, interstitial lung disease that was symptomatic and required systemic treatment with either corticosteroids (prednisone equivalents >10 mg daily) or other immunosuppressive medications within 14 days of study drug administration, uncontrolled or significant cardiovascular disease, or history of chronic hepatitis. Patients were also excluded if they had been treated previously with T-cell costimulation agents; had a history of life-threatening toxicity related to prior immune therapy; had evidence of active infection, positive HIV test history, or known AIDS; or had any major surgery within 4 weeks of study drug administration.",From first dose to 28 days after first dose,"monotherapy; part 1A); BMS-986178 (monotherapy escalation doses) plus nivolumab 240 mg i.v. every 2 weeks (part 2A); BMS-986178 (monotherapy escalation doses) plus ipilimumab 1 mg/kg i.v. every 3 weeks (part 3A); In the dose-expansion phase, patients with advanced bladder cancer received BMS-986178 80 mg plus nivolumab 240 mg every 2 weeks (part 2C), patients with RCC received BMS-986178 40 mg plus nivolumab 240 mg plus ipilimumab 1 mg/kg every 3 weeks for four cycles followed by maintenance BMS-986178 and nivolumab 480 mg every 4 weeks (part 6B), and patients with NSCLC received BMS-986178 40 mg plus nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks (part 7B). The doseexpansion cohorts evaluating the combination of BMS-986178 plus nivolumab and ipilimumab were preceded by safety lead-in cohorts (parts 6A and 7A). In additional dose-exploration cohorts, patients were treated withBMS-986178 80 mg every 2 weeks plus nivolumab 480 mg every 4 weeks (part 4), BMS-986178 80 mg every 3 weeks plus ipilimumab 3 mg/kg every 3 weeks (part 5), or BMS-986178 20/40/80 mg every 12 weeks plus nivolumab 480 mg every 4 weeks or nivolumab monotherapy 480 mg every 4 weeks (part 8). "
20606092,NA,Combination,No,"children with with recurrent or refractory solid tumor (parts A, D); leukemia with more than 25% blasts in the bone marrow (part B). Diagnosis part A: CNS tumors (Malignant glioma, Medulloblastoma, Astrocytoma, mixed glioma, Ependymoma, NOS, Atypical teratoid/rhabdoid tumor), Non-CNS tumors (Soft tissue sarcomas, Ewing’s sarcoma, Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma). Diagnosis part B: Acute lymphoblastic leukemia, Acute promyelocytic leukemia, Acute lmyeloid leukemia FAB M1). Diagnosis part C: CNS tumor (Medulloblastoma, Primitive neuroectodermal tumor, Pineoblastoma, Atypical teratoid rhabdoid tumor), Non-CNS tumor (Neuroblastoma). Diagnotic part D: CNS tumor (Malignant glioma, Ependymoma, Medulloblastoma, Pineoblastoma), Non-CNS tumor (Rhabdomyosarcoma, Endodermal sinus tumor, Osteosarcoma)","Patients older than 12 months and younger than 22 years with measurable or evaluable tumors refractory to therapy were eligible. Histologic verification of malignancy was required except for patients with intrinsic brainstem glioma. Eligible diagnoses included patients with recurrent or refractory solid tumor (parts A, D); leukemia with more than 25% blasts in the bone marrow (part B); neuroblastoma, medulloblastoma, CNS PNET or ATRT (part C). Other eligibility criteria included: Lansky or Karnofsky score >= 60; bodysurface area of >= 0.5 m2; recovery from the acute toxic effects of prior therapy; >=3 months since total-body irradiation, craniospinal or hemi-pelvic radiation and >= 2 months since a stem-cell transplant; adequate bone marrow function for patients with solid tumors (peripheral absolute neutrophil count >= 1,000/uL, platelets >= 100,000/uL [transfusion independent], hemoglobin >= 8.0 g/dL), for patients with leukemia (part B) platelets >= 20,000/uL, hemoglobin >= 8.0 g/dL; adequate renal function (age-adjusted normal serum creatinine or a glomular filtration rate >= 70 mL/min/1.73 m2), adequate liver function (total bilirubin <= 1.5 x institutional upper limit of normal for age, ALT <= 5 x institutional upper limit of normal for age and albumin >= 2 g/dL). Patients who were to receive 13cRA (part C) had to have <= grade 1 skin toxicity, serum triglycerides lower than 300 mg/dL, a negative urine dipstick for protein, or lower than 1,000 mg/24 hour urine collection, and no gross hematuria. ","Patients were excluded if they had received valproic acid in the previous 2 weeks, were on enzyme-inducing anticonvulsants, or other noncytotoxic anticancer agents, were pregnant or lactating or had uncontrolled infections. Patients with solid tumor with bone marrow involvement and patients with active CNS leukemia were excluded. Patients with CNS malignancies receiving dexamethasone had to be on a stable or decreasing dose for >= 7 days before study enrollment.",the first course,NA
22080430,NA,Combination,No,"patients with melanoma, pancreatic and lung cancer ","Patients with histologically-confirmed NSCLC, metastatic pancreatic adenocarcinoma or melanoma (lymphoma and multiple myeloma were allowed in a later amendment) for which a standard, approved therapy was not available and ≥18 years old were eligible. Patients were required to have Karnofsky Performance Status (KPS) ≥70% and adequate hematopoietic, electrolyte, hepatic, renal, and cardiac laboratory results","Patients were excluded if they had received chemotherapy, biologic agents, immunotherapy, major surgery or other investigational agents within 28 days or if they had received radioimmunotherapies or intrathecal therapy in the prior 12 weeks. Additionally, patients were excluded if they had known brain metastases, significant cardiac disease, prior treatment with other HDACi or proteasome inhibitors, previous hypersensitivity reaction to vorinostat, propylene glycol or ethanol, had an active secondary malignancy, significant proteinuria, urinary tract infection, active urine sediment, kidney disease or were pregnant or breast-feeding. Patients who required systemic therapy; parenteral antibiotics or were HIV positive or had active Hepatitis A, B, or C infections, or any altered mental status or psychiatric condition were also excluded from the study",cycle 1,NA
19708032,NA,Combination,No,adults with relapsed or refractory acute lymphoblastic leukemia,"Patients who had previously treated ALL, including thelymphoblastic lymphoma and Burkitt leukemia/lym-phoma (BLL) subtypes, were eligible if they had an East-ern Cooperative Oncology Group performance status >=3, if they had total bilirubin and creatinine levels <= 2 times the upper limit of normal, and if serious activeinfections were controlled. At least 21 days must haveelapsed since the previous antileukemia therapy except inpatients who had rapidly progressive disease if they had recovered from previous toxicity. Previous stem cell trans-plantation (SCT) was allowed as long as the other eligibil-ity criteria were met.","Patients could not have known CNSdisease that required active intrathecal (IT) chemotherapyor craniospinal radiation therapy, although asymptom-atic, controlled CNS disease was allowed. Patients werealso excluded on the basis of other neurologic criteria,including a history of grade 3/4 sensory or motor neurop-athy with previous chemotherapy, persistent grade >= 2 active neuropathy, or active neurologic disorders unre-lated to chemotherapy (eg, familial neurologic disordersor acquired demyelinating disorders). Pregnant womenwere not eligible. ",cycle 1,NA
31617432,NCT01567709,Combination,No,patients with relapsed/refractory lymphoid malignancies,"Eligible patients were >=18 years, with a diagnosis ofrelapsed or refractory lymphoid malignancy (classical HL, B- and T-cell non-HLs) that was histologically orcytologically confirmed, and had measurable disease.Patients were required to have an Eastern CooperativeOncology Group performance status of2, adequateorgan and hematologic function (including an abso-lute  neutrophil  count >=1500/uL and platelets >=100,000/uL) and to have recovered from toxicity ofprior treatments. Prior hematopoietic stem cell trans-plant patients were allowed if they were past dayþ100 of transplant, had no active graft-versus-hostdisease and had been off immunosuppressants for atleast 4 weeks.","Exclusion criteria included administra-tion of chemotherapy or radiotherapy within 4 weeks(6 weeks for nitrosoureas or mitomycin C) prior toentering the study, known brain metastases, and prioruse of valproic acid or any other HDAC inhibitor forlymphoma treatment.",during the first cycle (21 days),NA
17962510,NA,Single Drug,No,patients with advanced leukemias and myelodysplastic syndromes,"Patients with relapsed or refractory acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or MDS, or chronic myelocytic leukemia (CML) in accelerated phase or blast crisis that had progressed after treatment with imatinib mesylate were eligible for enrollment. Patients with AML, ALL, CLL, CML (accelerated phase or blast crisis), or MDS who refused or were not candidates for conventional chemotherapy were also eligible. Other eligibility criteria included age of at least 18 years, Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or less, adequate hepatic (bilirubin no more than 25.7 umol/L [1.5 mg/dL]; aspartate aminotransferase/alanine aminotransferase no more than 2.5 times the upper limit of normal), and renal (creatinine no more than 176.8 umol/L [2.0 mg/dL] or creatinine clearance more than mL/s [60 mL/min]) function, and a life expectancy greater than 3 months. Patients must have discontinued prior therapy for at least 2 weeks and recovered from prior toxicities.","Patients with central nervous system involvement by leukemia, HIV infection, or clinically significant illness (including active infection, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled cardiac arrhythmia) were excluded. Patients who planned to undergo allogeneic bone marrow transplantation within 4 weeks, or who were pregnant, lactating, or receiving concurrent complementary or alternative medicines were also excluded.",during the first treatment cycle,NA
29512900,NA,Combination,No,children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma,"Patients between the ages of 2 and 21 years old with clinically and/or radiologically recurrent or progressive HGG or DIPG were eligible for this study. Other inclusion criteria consisted of the following: (1) performance score≥50; (2) adequate hematologic (hemoglobin ≥8g/dl [irrespective of previous transfusions], absolute neutrophil count ≥1,000/mm3, and platelet count ≥100,000/mm3 [transfusion independent]), renal(normal serum creatinine for age), and hepatic (transaminases and bilirubin <3× and <1.5× the institutional upper limit of normal, respectively, and albumin ≥2 g/dl) functions; (3) stable neurologic deficits on a fixed or decreasing dose of dexamethasone for≥1 week; (4) no more than a grade 1 toxicity attributed to previous therapies; (5) interval from previous local, craniospinal, and palliative RT of ≥3 months, ≥6 months, and≥ 2 weeks, respectively; (6) interval ≥4 weeks from previous chemotherapy (6 weeks if nitrosourea); (7) interval ≥1 week from previous small-molecule inhibitors with short half-lives; (8) interval ≥ 3 half-lives fromp revious monoclonal antibodies; (9) interval ≥3 months from previous high-dose chemotherapy with stem-cell rescue; (10) interval ≥1 week and ≥2 weeks from the use of filgrastim and pegfilgrastim, respectively; and (11) effective con-traception for females of childbearing age and males of child fathering potential.",Exclusion criteria consisted of the following: (1) use of other anticancer therapies; (2) use of enzyme-inducing anticonvulsants less than 10 days before start of protocol therapy; (3) previous treatment with a PDGFR or c-Met inhibitor; (4) presence of other medical conditions that could interfere with the study procedures or tolerance to therapy; and (5) pregnant or lactating patients.,Dasatinib and crizotinib were initially administered twice daily and the DLT evaluation period lasted for 6 weeks. Drug administration was switched to once daily and the DLT-evaluation period to 4 weeks,NA
14676117,NA,Combination,No,patients with refractory B-cell malignancies other than acute leukemias,"Patients with biopsy proven B-cell malignancies, including CLL, NHL, and MM were eligible. Patients with CLL required failure of an alkylating agentcontaining regimen as well as fludarabine-based therapy. Patients with NHL were enrolled only after failure of all possible therapy with curative intent. Patients with MM must have received at least one prior chemotherapy regimen and not be eligible for a dose intensification treatment approach. Prior vincristine therapy was allowed. Prior stem cell or BM transplantation was permitted. Patients with HIV-related lymphoma were ineligible. Other eligibility criteria included an Eastern Cooperative Oncology Group performance status of 0, 1, or 2 and a life expectancy of >12 weeks. Eligibility organ function criteria included: hematological function (WBC >= 3000/ul, absolute neutrophil count >= 1500/ul, platelets >= 50,000/ul, hemoglobin > 8.5 g/dl); hepatic function (bilirubin <= 1.5 mg/dl, aspartate aminotransferase/alanine aminotransferase <= 2 x upper limit of normal); and renal function (creatinine <= 2.0 mg/dl and/or actual creatinine clearance >= 40 ml/min/1.73 m2). Normal coagulation parameters were not required, however, patients were not to have any clinical evidence of a bleeding diathesis. ",NA,during cycle 1,NA
22506596,NCT00771472,Single Drug,No,Japanese patients with relapsed or refractory cutaneous T-cell lymphoma,"All the patients were required tohave histologically confirmed CTCLdocumented as stage IIB or higher within 1 year prior to study treat-ment and to have progressive, persistent or recurrent disease. Thepatients were also required to have received at least one prior sys-temic therapy. Other inclusion criteriawereasfollows:aged20yearsor older; Eastern Cooperative Oncology Group Performance Status(ECOG PS) of 0–2; life expectancy of longer than 3 months; and ade-quate hematological, hepatic and renal function. Patients wererequired to agree to practice effective contraception unless infertilitywas documented. ","The exclusion criteria included prior HDAC inhibitor therapy given concurrently or within 30 days of baseline, or anyother anticancer therapy given concurrently or within 3 weeks beforeregistration. Only patients receiving stable doses of topical steroidsor SS patients receiving stable doses of systemic steroids (<=10 mgprednisone⁄day) for 3 months or longer before study entry wereallowed to continue receiving these medications during the study.Supportive treatments, such as antihistamines, anti-emetics or anti-diarrhea agents, were also permitted. Patients who were pregnant orlactating, had an acute infection requiring i.v. antibiotics, a knownHIV infection, an active hepatitisBorCvirusinfection,orotheruncontrolled underlying illnesses were also excluded.",during the 28 days of the first cycle,NA
11843245,NA,Single Drug,No,patients with advanced breast cancer (ABC),"All enrolled patients had histologically confirmed locally advanced or metastatic breast cancer and had received no more than two prior chemotherapy regimens for ABC. Other eligibility criteria included age over 18 years; Karnofsky performance status of 70% or greater; life expectancy of at least three months; a three-week minimum interval between the end of previous chemotherapy and study entry (six weeks for prior nitrosourea and mitomycin C); adequate haematopoietic function (haemoglobin >= 9 g/dl, neutrophil count >= 2000/mmJ, and platelet count >= lOO.OOO/mm3); adequate liver function tests (total bilirubin < 2 mg/dl. transaminases < 2 x upper normal limit (UNL)); serum creatinine <= 2.5 mg/dl and written informed consent.","Exclusion criteria included previous therapy with vinca-alkaloids, any unstable pre-existing major medical condition; previous radio- therapy involving > 25% of bone marrow; pregnant or lactating women; evidence of central nervous system metastases; pre-existing clinically significant peripheral neuropathy; malabsorption syndrome or disease affecting the gastrointestinal tract function, previous surgical resection of stomach or small bowel; or any psychological, family, sociological or geographical conditions hampering medical follow-up or compliance with the study protocol.",the first four weeks,NA
27589687,NCT01087554,Combination,No,"patients with advanced malignancy. Disease type, N (%): Colorectal cancer 11 (16%), Sarcoma 9 (13%), Melanoma 8 (11%), Hepatocellular carcinoma 6 (9%), Neuroendocrine carcinoma 5 (7%), Non-small cell lung cancer 4 (6%), Kidney cancer 3 (4%), Thyroid cancer 3 (4%), Appendiceal cancer 2 (3%), Bladder cancer 2 (3%), Endometrial cancer 2 (3%), Hodgkin lymphoma 2 (3%), Mesothelioma 2 (3%), Ovarian cancer 2 (3%), Pancreatic or ampullary carcinoma 2 (3%), Salivary gland cancer 2 (3%), Breast cancer 1 (1%), Cervical cancer 1 (1%), Gastric cancer 1 (1%), Prostate cancer 1 (1%), Carcinoma of unknown primary 1 (1%)","Among those who presented to the Clinical Center for Targeted Therapy, patients who met all the eligibility criteria were selected. All patients had disease that had failed to respond to standard therapy, had progressed despite standard therapy, or for which there was no available therapy that would prolong survival by at least 3 months. Patients were required to be off systemic therapy for at least 3 weeks before starting the protocol (or 5 half-lives in the case of biologics or targeted agents). Other inclusion criteria included an Eastern Cooperative Oncology Group performance status of 0, 1, 2, or 3; adequate organ and bone marrow function, as defined by an absolute neutrophil count of 1,000/µL or greater, a platelet count of 50,000/µL or greater, a total bilirubin level less than twice the institutional upper limits of normal (in the absence of Gilbert syndrome), an alanine aminotransferase level less than 2.5 times (less than 5 times for patients with liver involvement) the institutional upper limits of normal, and a creatinine level of 2.0 mg/dL or less; and the use of contraception during the study period.","Patients were excluded if they had a history of myocardial infarction within 3 months prior to starting treatment, were pregnant or breastfeeding, or had undergone a major surgical procedure within 28 days before starting therapy. Palliative radiation therapy was allowed during the study treatment. The use of other standard or investigational anticancer agents was not allowed. ",during the first four weeks of therapy,NA
10080616,NA,Single Drug,No,"patients with advanced carcinoma. Tumor types: Renal cell 8, Pancreas 3, Colon 2, Non–small-cell lung cancer 2, Mesothelioma 2, Melanoma 1, Nasopharyngeal carcinoma 1, Breast cancer 1, Primary unknown 1, Medullary carcinoma of thyroid 1, Small cleaved cell lymphoma 1, Adrenocorticocarcinoma 1, Prostate carcinoma 1","Patients were eligible if they had a histologically confirmed malignancy that was refractory to conventional forms of cancer therapy or a malignancy for which there was no effective standard chemotherapy. Inclusion criteria also included the following: age greater or equal to 18 years; a life expectancy of at least 12 weeks; an Eastern Cooperative Oncology Group performance status of 0 to 2; adequate bone marrow function, as defined by an absolute granulocyte count of more than 1,500/dL, a platelet count of more than 100,000/dL, and a hemoglobin count of more than 8.0 g/L; adequate hepatic function, as defined by a total bilirubin concentration of less than 1.25 times normal; and adequate renal function, as defined by a serum creatinine concentration of less than 1.25 times normal. Patients were not permitted to have evidence of preexisting neurologic dysfunction. Patients were required to be available for frequent visits and treatment at the Vancouver Clinic of the British Columbia Cancer Agency. All patients gave written informed consent to the study, including the pharmacokinetic sampling.",NA,NA,NA
11165410,NA,Combination,No,patients with untreated stage IIIb and IV non-small cell lung cancer,"This phase I–II, open-label, multicentre, dose- finding study of paclitaxel combined with vinorel- bine was conducted in patients with histologically proven NSCLC (stage IIIb or IV) not previously treated. The main eligibility criteria were age of 18 – 75 years inclusive, presence of at least one clinically and/or radiologically measurable lesion, a WHO performance status <=2, a life expectancy of 12 weeks or greater, adequate bone marrow, adequate liver and renal function, no history of neoplasm (except cured basal cell carcinoma or carcinoma in-situ of the cervix). ","The main exclusion criteria were a history of unstable cardiac disease, motor or sensory neuropathy, active infection, or allergic reaction to preparations con- taining cremophor.",during the first two cycles,NA
29047029,NCT01744652,Combination,No,"patients with advanced cancer. Among the 61 patients enrolled, the most common diagnosis was sarcoma (13/61; 21%), followed by prostate cancer (10/61; 16%) and colorectal cancer (5/61; 8%).","Patients were eligible for the study when they had a pathologically confirmed solid malignancy that was metastatic or unresectable and for which standard curative or palliative measures that improve survival by at least 3 months did not exist. Other eligibility criteria were as follows: age ≥ 16 years, Eastern Cooperative Oncology Group performance status of 0 to 2, absolute neutrophil count ≥1000/μL, platelet count ≥75,000/μL, total bilirubin ≤2.0 mg/dL, and aspartate aminotransferase/alanine aminotransferase ≤2.5× upper limit of normal (if liver metastasis was present, then ≤5.0× upper limit of normal).","Patients were excluded if they were receiving any concurrent chemotherapy or experiencing any severe or uncontrolled medical disease (e.g., active infection, cardiovascular issues), symptomatic congestive heart failure (New York Heart Association class III or IV) or unstable angina pectoris, known pulmonary hypertension, or inability to swallow oral medication. Patient had been off previous investigational or cytotoxic therapies for at least 3 weeks or within 5 half-lives of biological targeted agents.",during the first cycle (first four weeks),NA
26091915,NCT01169532,Combination,No,"patients with advanced solid tumors. Thirteen patients (87 %) had RCC, three of which had papillary RCC and ten that had clear cell RCC (ccRCC). There was one patient with esophageal carcinoma and one with a small bowel carcinoid tumor","Eligible patients were initially considered for the study if they had metastatic RCC refractory to prior systemic therapy. However due to emerging data suggesting efficacy of this approach in other tumor types,[22–24] the protocol was amended to include patients with all solid tumors and lymphomas. Enrollment was limited to patients whose disease was refractory to at least one line of therapy but who had received no more than one prior cytotoxic chemotherapy. There was no limit on the number of prior targeted or immunotherapies. Patients were > 18 years of age, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, had adequate organ function, and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Female patients of childbearing age were required to have a negative serum or urine pregnancy test≤5 days prior to study registration and agree to use an effective method of contraception. Restrictions on timing of prior therapies included cytotoxic chemotherapy, radiotherapy or immunotherapy ≤3 weeks before starting treatment, the use of bevacizumab ≤6 weeks prior to day 1 of treatment, or a lack of recovery from previous treatment-related acute adverse events (AEs). For patients who had received prior targeted therapies, treatment must have been discontinued at least five half-lives prior to initiation of study treatment. ","Key exclusion criteria included an active infection requiring antibiotics, uncontrolled diabetes or hyperlipidemia, and a known diagnosis of HIV. Stable brain metastases were permitted. ",during the first 3 weeks of treatment,NA
11241232,NA,Combination,No,patients with advanced breast carcinoma,"Patients were considered eligible if they had microscopically confirmed carcinoma of the breast, with no prior chemotherapy for their metastatic disease. Hormonal therapy or adjuvant chemotherapy was admissible. Patients who were receiving hormonal therapy for metastatic disease were required to wait 4 weeks after completion of the last dose of hormonal treatment before entering this study; no waiting period was required for patients with rapidly progressive visceral disease. All patients were required to have bidimensionally measurable disease, performance status of 0 –2, and a life expectancy greater than 16 weeks. Laboratory requirements for eligibility included an absolute granulocyte count greater than 1500 cells/mm3 and a platelet count greater than 100,000 cells/mm3, a serum creatinine less than 2.5 mg/dL, a serum total bilirubin less than 1.3 mg/dL, and a serum glutamic pyruvic transaminase less than 3 times the upper limit of normal. ","Patients were excluded if they were considered medically unstable or had uncontrolled cardiac disease, a history of congestive heart failure, or unstable angina or arrhythmia that required medications, were pregnant or lactating, or were not using adequate contraception. Patients who had metastatic disease to the central nervous system or a history of other malignancy within the past 5 years, except for basal cell carcinoma of the skin or carcinoma in situ of the cervix, were excluded from this study. Patients with preexisting clinically significant peripheral neuropathy were excluded except when it was considered to be resulting from the cancer process.",NA,NA
9626216,NA,Combination,No,patients with advanced chest malignancies. Most patients had NSCLC (n = 35) and were nearly equally divided between adenocarcinoma (n = 15) and squamous cell carcinoma (n = 12). One patient each had squamous cell carcinoma of the esophagus and follicular thyroid cancer. ,"Eligibility for this University of Chicago Institutional Review Board-approved study included cytologic or histologic documentation of an advanced intrathoracic neoplasm that required palliative or definitive RT to the chest. Patients with metastatic disease who required chest RT for relief of locoregional symptoms were eligible, as were patients who had undergone surgical resection who were recommended to receive adjuvant RT due to a high risk of local relapse. All patients were required to have a Cancer and Leukemia Group B (CALGB) performance status <= 2 and adequate hepatic (total bilirubin level <= two times normal and AST < three times normal), renal (blood urea nitrogen [BUN] level < 1.5 times normal and creatinine clearance >= 50mL/min), and bone marrow (WBC count > 3,500/uL, absolute neutrophil count [ANC] > 1,500/uL, hemoglobin [Hgb] > 10 g/dL, and platelets > 100,000/uL3 ) function. Signed informed consent was required for all patients. Prior chemotherapy was permitted, but no prior thoracic RT was allowed. ",NA,NA,NA
25695691,NCT01019850,Combination,No,Patients with Relapsed or Refractory Neuroblastoma,"Patients were eligible if they were 2 to 30 years of age at time of enrollment, had relapsed or refractory high-risk neuroblastoma, and had MIBG-avid bone and/or soft tissue disease based upon MIBG diagnostic scan obtained within 4 weeks of study enrollment. All patients were required to have >= 2.0 x 106 CD34+ autologous hematopoietic stem cells (PBSC)/kg available. Patients were required to have adequate performance score (Lansky or Karnofsky score >= 50) and life expectancy >= 6 weeks. Patients were required to be a minimum of 2 weeks from last systemic therapy, 12 weeks from prior stem cell transplant, 2 weeks from prior small port radiation, and 3 months from large field radiation. Patients previously treated with 131I-MIBG, vorinostat, other HDACi, whole abdominal or total body radiation, or allogeneic transplant were excluded. Patients were required to meet standard laboratory criteria before enrollment: absolute neutrophil count (ANC) >= 750/mm3; unsupported platelet count >= 50,000/mm3; hemoglobin >= 8 g/dL; creatinine <= 1.5 times the upper limit of age-adjusted normal value or estimated creatinine clearance  60 mL/minute/1.73 m2; total bilirubin <= 1.5 times upper limit of normal (ULN); and ALT and AST < 3 times ULN. Patients were also required to have adequate cardiac and pulmonary function as follows: cardiac ejection fraction >= 55% or shortening fraction >= 27%; corrected QT interval <= 450 msec; and lack of dyspnea at rest, exercise intolerance, pleural effusion, or oxygen requirement. With the finding of one patient at dose level 5 with grade 5 central nervous system (CNS) hemorrhage in the setting of expected thrombocytopenia and unexpected prolonged prothrombin and partial thromboplastin times (PT and PTT), the protocol was amended to also require baseline International Normalized Ratio (INR) <= 1.5 and PTT <= 1.5 ULN for the remaining 11 patients.","Patients were excluded if they were pregnant, breastfeeding, unable to tolerate radiation isolation, and/or receiving selected drugs known to prolong the QT interval. Patients with other serious concomitant medical illness or with a history of noncatheter-related deep venous thrombosis were also excluded.",during the first course (From day 1 of vorinostat therapy to 56 days after stem cell re-infusion),NA
29603591,NA,Combination,No,patients with refractory/recurrent neuroblastoma,"Age ≤21 years at the time of enrollment. High-risk neuroblastoma and had measurable disease by computed tomography, magnetic resonance imaging and/or evaluable disease by bone marrow (BM) morphology, and/or metaiodobenzylguanidine (MIBG) scans obtained within 4 weeks of enrollment. Patients were required to be classified in one of the following disease categories: relapse or progression; refractory to initial therapy (less than a partial response [PR] by International Neuroblastoma Response Criteria [INRC] after at least four cycles of chemotherapy); persistent biopsy-proven disease after initial therapy (an INRC PR after at least four cycles of chemotherapy). Patients had adequate performance scores (Lansky or Karnofsky performance score > 50). Minimum of 3 weeks from last systemic therapy. 7 days from last biologic therapy (or 3 half-lives for monoclonal antibodies, whichever was longer). 12 weeks from previous myeloablative therapy. 2 weeks from previous small-port radiation. 6 weeks from previous iodine-131-MIBG therapy. 12 weeks from large-field radiation. Organ Function Requirements: Absolute neutrophil count ≥750/mL (>500/mL for patients with marrow metastases); unsupported platelet count ≥50,000/mL; serum creatinine ≤1.5 times the upper limit of age-adjusted normal value; total bilirubin ≤1.5 times upper limit of normal; AST/ALT ≤3 times upper limit of normal; alkaline phosphatase ≤2.5 times upper limit of normal; normal ejection fraction (≥55%) or shortening fraction (≥27%); a corrected QT interval ≤450 msec; serum triglycerides ≤300 mg/dL and a <grade 2 serum calcium.","Patients were excluded if they were pregnant, breastfeeding, or had active infection. Patients who required scheduled specific strong inducers of hepaticc ytochrome enzymes (enzyme inducing anticonvulsants, pentamadine, or azole antifungals) were excluded. Patients previously treated with vorinostat or isotretinoin were eligible, provided the two drugs had not been previously used incombination.",during the first cycle,NA
18297527,NCT00109109,Single Drug,No,patients with advanced multiple myeloma,"Patients at least 18 years of age with relapsed and/orrefractory multiple myeloma, measurable serum or urine  M-protein, Eastern Cooperative Oncology Group (ECOG) performance status 0–2, and adequate hematologic, hepatic, and  renal function were eligible. All patients must have had a life expectancy of greater than 3 months and have agreed to practice effective contraception throughout the entire study unless infertility was documented. At least 3 weeks must have passed since prior therapy with recovery from all prior toxicities.","Patients planning to undergo autologous or allogeneic stem cell transplantation within 4 weeks of therapy, who had prior HDAC inhibitor treatment, were concurrently using complementary or alternative medicines, or had a  clinically significant illness (including active systemic infection, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or   uncontrolled cardiac arrhythmia) at the investigator’s discretion were ineligible. Other exclusion criteria included: psychiatric illness that would limit compliance, pregnancy, lactation, known HIV infection,  active hepatitis B or C infection, prior malignancy within the last 3 years (except adequately treated basal cell or squamous cell skin cancer, in situ cervical canceror other malignancies for which the patient had beendisease   free for at least 3 years), nonsecretory myeloma, plasma cell leukemia, hypercalcemia, or impaired renal function requiring dialysis.",NA,NA
7747714,NA,Combination,No,patients with metastatic renal cell cancer (RCC),"Patients were eligible for participation if they had histologically confirmed adenocarcinoma of the kidney with either measurable or evaluable metastatic disease that was not previously irradiated, and an ECOG (Eastern Cooperative Oncology Group) performance status of <=2. Chemotherapy was not allowed. Patients were required to have adequate renal function (normal serum potassium, creatinine clearance >= 1.3 ml/s), hepatic function (aspartate aminotransferases <=2 times the upper limit of normal, normal bilirubin, and prothrombin time < 15 seconds), and bone marrow function (absolute granulocyte count >=2.0 X 109/L, platelet count > 100 X 109/L).","Patients were excluded if they had a history of a previous malignancy, active infectious process, uncontrolled hypertension, brain metastases, or a history of seizures. Concomitant therapy with other potentially nephrotoxic drugs (nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, and aminoglycosides) or drugs that affect cyclosporine metabolism (isoniazid, rifampin, erythromycin, ketoconazole, diltiazem, verapamil) was not allowed. ",the first treatment course,NA
31409616,NCT02638090,Combination,No,Advanced/Metastatic Non-Small Cell Lung Cancer,"Eligible patients had histologically confirmed advanced or metastatic NSCLC with progression. Patients in phase I may or may not have received prior therapy with an ICI, whereas patients in phase Ib were required to have received prior ICI therapy. Eligible patients also had an Eastern Cooperative Oncology Group performance status of 0 to 1, adequate organ function, and measureable disease according to Response Evaluation Criteria in Solid Tumor (RECIST) guidelines version 1.1.","Exclusion criteria included untreated, progressive, and symptomatic brain metastases; active uncontrolled autoimmune disorders; and chronic systemic steroid use equivalent to  10 mg of prednisone. ICI-relapsed patients were defined as those who had achieved stable disease (SD) or better for at least 3 months of prior ICI treatment, and ICI-refractory patients were those who experienced disease progression within 3 months of prior ICI treatment. Patients were enrolled regardless of their PD-L1 status.",NA,NA
31823832,NCT01422499,Single Drug,No,"children with relapsed solid tumor, lymphoma, or leukemia. Brain tumors (High-grade glioma, Medulloblastoma, Ependymoma, Low grade glioma, PNET, Malignant pleomorphic neuroepithelial tumor), Extracranial solid tumors (Ewing sarcoma, Osteosarcoma, Neuroblastoma, DSRCT, Soft tissue sarcoma, Wilms tumor, SETTLE tumor), Leukemia (AML)","Children and adolescents (3–18 years) with relapsed or therapy-refractory solid tumors (including brain tumors), lymphoma, or leukemia following standard first-line or relapse protocols in pediatric oncology were eligible. Reference-confirmed diagnosis by one of the pathological, radiological, or study reference centers recognized by the Society for Pediatric Oncology und Hematology (GPOH) in Germany was required. No other simultaneous anti-neoplastic treatment or radiotherapy during the study and 2 weeks before enrolment was allowed. Other eligibility criteria included adequate general condition (Lansky Score > 50%) and life expectancy > 3 months, liver enzymes (ALT or AST) < ×5 upper limit of normal reference value, bilirubin and creatinine < ×3 upper limit of normal reference value, solid tumors: leukocytes > 2000/μl, thrombocytes > 50.000/μl and adequate bone marrow function to permit evaluations of hematopoietic toxicity, no CTCAE grade 3 or 4 toxicity from previous treatments (no persistent CTCAE ≥ grade 3 toxicity from previous treatments), normal ECG. For solid tumors (including brain tumors), measurable disease activity according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was required. Written informed consent of the legal representatives and the patient (if the patient was able to understand the study situation and to give consent) was mandatory. Women with childbearing potential had to agree to use adequate contraception or to abstain from heterosexual activity throughout the study, starting with Visit 1, and sexually active male patients had to agree to use an adequate method of contraception for the duration of the study.","Patients were excluded if they had a history of deep vein thrombosis or pulmonary embolism, were pregnant or lactating, and used concomitant treatments and/or anti-neoplastic treatment such as chemotherapy, immune therapy, and differentiation therapy, other targeted therapy, or received radiotherapy. The use of valproic acid as prior antiepileptic therapy was allowed with a 14-day washout period. Other exclusion criteria included prior exposure to HDACi, known active HBV, HCV, or HIV infection, the use of concomitant treatments such as amber (Hypericum perforatum), plant extracts, vitamins, and other anti-oxidative compounds, participation in other clinical trials or observation period of competing trials, respectively, unable to swallow vorinostat suspension or capsules, and use of coumarin-derivative anticoagulants and any other medication which could accentuate known dose-dependent adverse effects of the study drug, for instance bone marrow depression or QT-prolongation",1 month,NA
7931480,NA,Single Drug,No,advanced breast carcinoma (ABC) patients ,"Patients entered onto this study were required to have histologically proven advanced and metastatic adenocarcinoma of the breast, and to be proposed for VRL as first-line treatment for metastatic disease or as second- or third-line therapy. Patients should have completed prior adjuvant chemotherapy at least 12 months before trial entry, and should have been off palliative chemotherapy or hormonal therapy for a minimum of 4 weeks. All patients were to have measurable-disease target lesions either on physical examination, x-rays, ultrasound, or computed tomographic (CT) scan. Other eligibility criteria were as follows: World Health Organization (WHO) performance status less than 2, expected survival of greater than 3 months, adequate bone marrow reserve (absolute granulocyte count > 2,000/uL, platelet count > 100,000/uL, and hemoglobin level > 11 g/dL), as well as adequate renal and hepatic functions (serum creatinine AST, ALT, bilirubin, and alkaline phosphatase levels < 1.25 times upper limit of normal value). ","Exclusion criteria were as follows: age greater than 70 years, radiation therapy to the only measurable site of disease, presence of other concomitant cancers, brain metastases, or leptomeningeal disease. ",NA,NA
34347089,NCT01189266,Combination,No,children with diffuse intrinsic pontine glioma,"Children age 3 to 21 years with newly diagnosed DIPG, radiographically defined as tumors with a pontine epicenter and diffuse involvement of at least two-thirds of the pons, were eligible without histological confirmation. Patients with brainstem tumors that did not meet the above definition of “typical” DIPG were only eligible if tumors were biopsied and proven to be an anaplastic astrocytoma, glioblastoma, gliosarcoma, or anaplastic mixed glioma. Other eligibility criteria included: a Lansky or Karnofsky performance score of 50 or higher, no prior therapy except for surgery and/or dexamethasone, adequate bone marrow functions (peripheral absolute neutrophil count ≥ 1,000/µl, platelet count ≥ 100,000/µl [transfusion independent],and hemoglobin ≥ 8  g/dl), adequate renal function (ageadjusted normal serum creatinine or a creatinine clearance or glomerular filtration rate 70 ml/min/1.73 m2 or higher), adequate liver function (total bilirubin less than 1.5 times the institutional upper limit of normal; ALT ≤ 110 unit/L, and albumin ≥ 2 gm/dl), ability to swallow capsules or liquid, and enrollment within 28 days of diagnosis.","Patients with disseminated DIPG were not eligible. Pregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. Growth factors that support platelet or white cell number or function must not have been administered within the 7 days prior to enrollment. Patients who are currently receiving another investigational drug are not eligible. Patients who are currently receiving other anti-cancer agents are not eligible. Patients must not currently be receiving enzyme inducing anticonvulsants. Patients on valproic acid must discontinue valproic acid for at least 2 weeks before starting protocol therapy. Patients receiving coumadin, heparin, low-molecular weight heparin, or any other anti-coagulants are not eligible for study entry. Patients receiving acetylsalicylic acid (ASA) (> 81 mg/day), non-steroidal anti-inflammatory drugs, clopidogrel (Plavix), dipyridamole (Persantine), or any other drug that inhibits platelet function are not eligible for study entry. Patients who have an uncontrolled infection are not eligible. Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible",During concurrent radiation therapy and vorinostat,NA
19817748,NCT00127140,Single Drug,No,Japanese patients with malignant lymphoma,"Patients with ML who had received one to four prior regimens and had relapsed after complete response or partial response or were refractory to previous chemotherapies were eligible. Patients must have been >=20 years, but <=75 years in age, with Eastern Cooperative Oncology Group performance status of 0–1 and adequate hepatic (total bilirubin <= 1.5xthe upper limit of normal [ULN]; aspartate aminotransferase andalanine aminotransferase <= 2.5xULN), hematologic (neutrophilcount >=1500⁄uL; platelet count >=100 000⁄uL; hemoglobin >=9.0 g⁄dL, prothrombin and activated partial thromboplastin time <=1.5 x ULN), and renal function (creatinine <= 1.5xULN and creatinine   clearance >=50 mL⁄min). ","Exclusion criteria included: prior HDAC inhibitor treatment or allogeneic stem cell transplantation, prior therapy within 4 weeks of study, central nervous system involvement, uncontrolled concomitant illness, pregnancy, lactation, or concurrent malignancies. ",during the first cycle,NA
34896762,NCT02521051,Combination,No,patients with advanced ALK-rearranged non-small-cell lung cancer,"Eligible patients had locally advanced or metastatic non-squamous NSCLC with ALK rearrangements as established using ALK FISH, immunohistochemistry, or next-generation sequencing. ALK FISH was considered positive if >15% of tumor cells demonstrated abnormal signals. Patients who were treatment-naive in the advanced setting, as well as those who had disease progression on previous treatments including ALK TKI(s), were permitted to enroll; however, prior alectinib or anti-angiogenic therapy was not permitted. While patients were initially required to have at least one measurable CNS lesion per modified RECIST version 1.1 in addition to measurable extracranial disease by RECIST version 1.1, the protocol was later amended to allow enrollment with or without measurable CNS disease. Other key eligibility criteria included age 18 years or older, Eastern Cooperative Oncology Group performance status of 0-2, and adequate end-organ function. Patients who had clinically stable or asymptomatic untreated, non- hemorrhagic CNS metastases were eligible.","Key exclusion criteria included: squamous cell or mixed, predominantly squamous adenosquamous histology; history of hemoptysis; tumor infiltrating into large vessels or proximal tracheobronchial network; intracranial hemor- rhage; history of or genetic predisposition to a bleeding diathesis or coagulopathy; arterial or venous thromboembolic events within 6 months of enrollment; and poorly controlled arterial hypertension (systolic >150 mm Hg and/or diastolic > 100 mm Hg).",within the first cycle of treatment (21 days),NA
32181989,NA,Single Drug,No,"Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. A total of 12 patients (92%)had lung adenocarcinoma, and one patient (8%) hadmalignant pleural mesothelioma.","Adult patients (aged 18–65) with a locally advanced or metastatic malignancy harboring a genetic alteration inALK, who had disease progression despite underlying standard chemotherapy or had no effective standard therapy, were included in this study. Patients had at least one measurable lesion (according to RECIST 1.1), and the tumorhad to be ALK-positive (ALK rearrangement was detected in more than 15% of cells, which was measured by theVentana ALK IHC test or FISH using the Vysis break-apart ALK probe). Partial ALK-positive results, such as alymph node needle biopsy, were also considered acceptable. The Eastern Cooperative Oncology Group (ECOG) score was less than two, the survival time was expected tobe no less than 12 weeks, and patients had to have a rela-tively sufficient organ reserve function for treatment","The main exclusion criteria were: (i) patients with symptomatic central nervous system (CNS) metastases who were neurologically unstable or required increasing doses of steroids or local CNS-directed therapy to control their CNS symptoms; (ii) patients with impaired cardiac function orany clinically significant cardiac disease; (iii) patients withabnormal laboratory values that appeared during screeningand on day 1 of predose; (iv) patients with an impairment in gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CT-707, and (v) patients with a history of pancreatitis or history of increased serum amylase or lipase that was due to pancreatic disease.",during the first cycle of medication,NA
10963843,NA,Combination,No,locally advanced non small cell lung cancer,"Patients with histologically or cytologically documented locally advanced NSCLC were enrolled in the study. Other eligibility criteria were: age less than 70 years; Eastern Cooperative Oncology Group (ECOG) performance status less than 3; measurable tumor; adequate bone marrow function (granulocyte count >= 2000/mm3; platelet count >= 100 000/mm3; hemoglobin > 10 g/dl); adequate hepatic function (bilirubin levelB 1.5 times normal and ASTB twice normal) and pulmonary function with PO2 > 50, PCO2 < 50 and forced expiratory volume in 1 s (FEV1) > 800 ml; absence of brain metastases, active infection and heart disease contraindicating treatment; no previous chemotherapy or radiotherapy; no previous or concurrent malignancy, except non melanoma skin cancer or in situ carcinoma of the cervix adequately treated. Informed consent was required.",NA,NA,NA
26891067,NCT01222780,Single Drug,No,"Children, Adolescents, and Young Adults With Refractory Solid Tumors (Ewing sarcoma, desmoplastic small round cell tumor, alveolar rhabdomyosarcoma) or Leukemias","Pediatric patients (age 2–20 years) with relapsed or chemotherapy refractory malignancies with measurable orevaluable disease were eligible. Eligibility criteria required thatsubjects enroll a minimum of 7 days following chemotherapy and 30 days following investigational or monoclonal antibodytherapy. Subjects with a prior history of stem cell transplantation were eligible in the absence of active graft-versus-hostdisease and without immunosuppressive therapy for at least 4 weeks. Other inclusion criteria included performance status of >=50, adequate liver function with bilirubin < 2 × the upper limit of normal and aspartate aminotransferase (AST) and alanineaminotransferase (ALT) < 5 × the upper limit of normal, andnormal serum creatinine for age. A neutrophil count >=1,000/μl and platelet count >= 50,000/μl were required unless due tomarrow involvement by disease.","Subjects with preexisting >=grade 2 sensory or motor neuropathies, history of persistent >= grade 2 active neurologic disorders unrelated to chemotherapy, active central nervous system leukemia or lymphoma, or systemic uncontrolled infection were excluded. The use of azole-based antifungal agents was prohibited due to drug interactions.",during the first treatment cycle,NA
28816142,NCT00946673,Combination,No,patients with 1 to 4 NSCLC brain metastases,"All patients age 18 years and older with histologically proven non-small cell lung cancer and 1-4 brain metastases, each measuring less than 2 cm will be eligible. Prior surgery or radiation is allowed as long as the target metastatic lesion(s) has not been treated with previous radiation. Adequate organ function (section 3.1.10). ECOG performance status 0-2. Life expectancy of >=12 weeks. Systemic chemotherapy washout period >=7 days.","Patients who have previously been treated with whole brain irradiation, pediatric patients (age <18), pregnant women, and patients who are unable to give informed consent.",30 days following Stereotactic Radiosurgery,NA
20564083,NA,Combination,No,patients with unresectable metastatic melanoma,"Eligible patients were chemotherapy naive, aged 18 yearsor older, with inoperable, histologically confirmed stageIII or IV melanoma, measurable disease, an Eastern Co-operative Oncology Group (ECOG) performance status of 0-1, a projected life expectancy of 4 months, no serious concomitant diseases, no other concurrent cancers or cancer treatments, and no brain metastases. Also required were a normal cardiac ejection fraction and no history of recent anginaor myocardial infarction in the prior 3 months. Laboratory values were required to be within acceptable protocol-defined ranges. The patientswere required to have completed any other cancer therapy at least 4 weeks before the start of protocol therapy, andnot to be receiving parenteral antibiotics or systemic steroid therapy.",Pregnant or nurs-ing women were excluded. Patients with respiratory insufficiency requiring oxygen therapy were excluded.,Cycle 1,NA
23320927,NCT00132522,Combination,No,"patients with EpCAM-positive advanced solid tumors. Tumor type: Ovarian carcinoma, Lung carcinoma, Colon,  Prostate, Other (includes 1 patient each of melanoma, acinic cell carcinoma, and adenocarcinoma of unknown origin)","Patients (age ≥ 18 years) with advanced or recurrent solid tumors were eligible after failing standard therapy. Tumor tissue had to demonstrate EpCAM expression by immunohistochemistry on ≥ 25% of the tumor cells, as centrally assessed. Other eligibility criteria included: Karnofsky Performance Status score ≥ 70%, adequate baseline organ function, as defined by aspartate transaminase, alanine transaminase ≤ 2.5 × the upper limit of normal (ULN), bilirubin ≤ 1.5 × ULN, no history of significant renal impairment or chronic kidney disease, normal creatinine, or creatinine clearance ≥ 60 mL/min, adequate pulmonary function (≥ 70% of predicted values for forced vital capacity and forced expiratory volume in 1 second, O2 saturation ≥ 90%) unless due to malignant disease to be treated, no significant impairment of hematopoietic and cardiac functions, and blood sodium, potassium, and phosphorus within normal limits. Patients had to be able to safely discontinue concomitant antihypertensive therapy for at least 48 hours, and to tolerate concomitant treatment with indomethacin or other nonsteroidal anti-inflammatory drugs.","The major study exclusion criteria were known brain metastases, immediate need for palliative radiotherapy or systemic corticosteroid therapy, immunosuppression, autoimmune disease (except autoimmune thyroiditis and vitiligo). Pregnancy or lactation, known serious uncontrolled medical condition, known hypersensitivity to study drugs or excipients, or prior exposure to huKS-IL2, were also exclusion criteria.",during the first cycle,NA
31506385,NCT01677741,Single Drug,No,"Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors. Fifteen patients had been diagnosed with pLGG and the rest of them had HGG (n = 8), LCH (n = 2), neuroblastoma (n = 1), or papillary thyroid cancer (n = 1)","The study population consisted of patients ages 1 to 18 years with recurrent, refractory, or progressive BRAF V600–mutant solid tumors who had received at least 1 prior therapy. BRAF V600 mutations were determined locally by a Clinical Laboratory Improvement Amendments–approved laboratory (or equivalent local certification). Patients with advanced melanoma could be enrolled and receive dabrafenib as first-line treatment. Additional eligibility requirements included adequate organ function (absolute neutrophil count >=1,000/uL; hemoglobin >=8.0 g/dL; platelets >=75,000/uL; estimated or radioisotopic determination of glomerular filtration rate >=60 mL/min/1.73 m2 or serum creatinine within normal ranges for age/sex; adequate liver function defined by bilirubin <= 1.5 times the upper limit of normal [ULN] and both aspartate aminotransferase and alanine aminotransferase <=2.5 times ULN; and adequate cardiac function defined by a left ventricular ejection fraction of >=50% and a corrected QT interval of <450 milliseconds) and a Karnofsky or Lansky performance status of >=50%. ","Patients were not eligible if they had received chemotherapy or radiotherapy within 3 weeks (or 6 weeks for nitrosoureas or mitomycin C) or an investigational agent within 28 days (or 5 half-lives or twice the duration of the biological effect) prior to the first dose of dabrafenib; a history of leukemia or another malignancy; a history of myocardial infarction, unstable angina, peripheral vascular disease, familial QTc prolongation, abnormal cardiac valve morphology, or other cardiac issues; or other uncontrolled medical conditions.",within the first 28 days of treatment with dabrafenib,NA
22918078,NA,Combination,No,patients with advanced solid tumours,"All patients gave written informed consent. Eligible patients were >=18 years, with Eastern Cooperative Oncology Group performance status of <=1, adequate organ function, histologically/cytologically proven solid tumours or B-cell non-Hodgkin’s lymphoma after failure of standard therapy. ","Patients requiring treatment with immunosuppressive agents, or having autoimmune disease, inflammatory bowel disease, chronic viral infections or significant cardiovascular or pulmonary disease, were ineligible",in cycle 1,NA
22307137,NCT00810966,Combination,No,"adults with refractory solid tumors and lymphomas. Tumor types: Ovarian 11, Carcinoid 1, Breast 12,Colon 1, Pancreas 1, Urothelial 2, Melanoma 1, Sarcoma 1, Endometrial 2, Lymphoma 2, Unknown primary","Patients (age  18 years) were eligible if they had pathologically confirmed metastatic solid tumor or low-grade lymphoma for which there was no acceptable standard therapy; a Karnofsky performance status of 60% or more; and adequate liver, kidney, and marrow function defined as absolute neutrophil count of 1,500/uL or more, platelets of 100,000/uL or more, total bilirubin of 1.5 x the upper limit of normal (ULN), aspartate aminotransferase and/or alanine aminotransferase less than 2.5 x ULN, creatinine less than 1.5 x ULN. Prior exposure to PARP inhibitors or cyclophosphamide was allowed. Previous anticancer therapy or surgery must have been completed at least 4 weeks before enrollment; patients were required to have evidence of disease progression on previous therapy by staging scans.","Patients unable toswallow pills or those with uncontrolled intercurrent illness, brain metastases within the past 3 months, history of seizures (high-dose veliparib caused seizures in a preclinical model), or gastrointestinal conditions that might predispose to drug intolerability or poor drug absorption were excluded.",in the first cycle,NA
25728527,NCT01240538,Single Drug,No,"children with relapsed or refractory extracranial solid tumors. Diagnosis: Alveolar rhabdomyosarcoma 2 (7.1), Chondroblastic osteosarcoma 1 (3.6), Clear cell sarcoma 1 (3.6), Desmoplastic small round cell tumor 1 (3.6), Embryonal rhabdomyosarcoma 3 (10.7), Ewing sarcoma 3 (10.7), Germ cell tumor 1 (3.6), Hemangiosarcoma/angiosarcoma 1 (3.6), Hepatoblastoma 2 (7.1), Neoplasm, malignant/Tumor, malignant, NOS 1 (3.6), Wilms tumor 3 (10.7), Neuroblastoma 2 (7.1), Osteosarcoma 3 (10.7), Retinoblastoma 1 (3.6), Rhabdomyosarcoma 1 (3.6), Synovial sarcoma 2 (7.1)","Patients >=3 and <=21 years with recurrent or refractory solidtumors, excluding tumors originating in or metastatic to the centralnervous system or lymphomas, were eligible. Patients wererequired to have a Karnofsky (age >15) or Lansky (age <16)performance score of >=50. Organ function requirements included:adequate bone marrow function (absolute neutrophil count greater >=1,000/ml,  and a transfusion-independent platelet count >=100,000/ml); adequate renal function (normal serum creatininefor age or a creatinine clearance or radioisotope GFR >=70 ml/min/1.73 m2), and adequate hepatic function (total bilirubin <=1.5 timesthe upper limit of normal for age, ALT <=110 U/L and serumalbumin greater >=2 g/dl). Patients must have recovered from theacute toxic effects of prior therapy, including a 3 week interval sincethe last myelosuppressive therapy, 2 weeks since radiation therapy,6 weeks since immunotherapy, and 1 week since biotherapy.","Viral immunizations were not permitted within 7 days of enrollment orduring the on-study treatment period. Patients with known germlinemutations affecting Ras activation (e.g., neurofibromatosis type 1,cardio-facial-cutaneous syndrome, Noonan syndrome, and Costellosyndrome) were excluded from enrollment. Patients requiringongoing immunosuppression or a history of known viral infectionswith HIV or hepatitis B or C were also excluded.",during cycle 1 of therapy,NA
8751547,NA,Combination,No,patients with FIGO III/IV epithelial ovarian cancer,All patients with newly diagnosed FIGO stage III/IV epithelial ovarian cancer were eligible if they fit the following criteria: epithelial histology confirmed at the National Cancer Institute without borderline or mixed histology; initiation of therapy within 6 weeks of staging laparotomy; measured creatinine clearance of §60 ml/min; hepatic enzymes within three times the upper limit of normal; no prior treatment; no other history of invasive cancer; and ability to give informed consent. Patients had electromy-elography and nerve conduction studies and audiograms before or within the first cycle of chemotherapy. All patients had CAT scans and CA-125 levels obtained prior to initiation Dose Escalation Schema of chemotherapy,NA,for cycles 1–6,NA
25139740,NCT00741377,Combination,No,patients with relapsed or refractory multiple myeloma and prior skeletal-related events,"Patients with relapsed or refractory MM requiring treatmentwith a non-bortezomib-containing regimen (bortezomib wasnot allowed on study due to its anabolic effect on bonemarkers; however, prior treatment with bortezomib was per-mitted) and current or planned treatment with zoledronicacid were eligible for the study. Diagnosis of symptomaticMM was defined by the International Myeloma WorkingGroup (Durieet al, 2003), which included the followingparameters: M-protein in serum or plasma, clonal bone mar-row plasma cells or plasmocytoma and related-organ or tis-sue impairment. Patients had to have≥1 prior SRE, defined as: pathologicalfracture, spinal cord compression or a requirement for eitherradiation or surgery due to pain, prevention of imminentfracture or stabilization of a fracture. Patients also had tohave stable renal function, defined as two serum creatininedeterminations of<123.76lmol/l  or  calculated  creatineclearance>60 ml/min using the Cockcroft–Gault formula(Cockcroft & Gault, 1976). Additional inclusion criteria included no current active den-tal problems, including osteonecrosis of the jaw (patients wererequired to undergo a detailed dental examination to exludepatients at high risk of osteonecrosis of the jaw); no symptomsof  hyperviscosity, no amyloidosis or recurrent  infection;corrected serum calcium <3.0 mmol/l or ionized calcium<1.635 mmol/l within 14 d prior to registration; life expec-tancy of ≥12 months; Eastern Cooperative Oncology Groupperformance status ≤2; absolute neutrophil count ≥1.5x109/l;platelet count ≥75x109/l; haemoglobin ≥90 g/l; aspartatetransaminase and alanine transaminase ≤2.5xupper limit ofnormal (ULN); and serum bilirubin ≤1.5xULN.","Known concomitant disease(s) known to influence calcium metabolism including hyperparathyroidism, hyperthyroidism and/or Paget's disease of bone. Current active dental problems including: Ongoing infection of the teeth or jawbone (maxilla or mandibula); Current exposed bone in the mouth; Dental or fixture trauma; Current or previous osteonecrosis of the jaw; Slow healing after dental procedures; Recent (within 6 weeks) or planned dental or jaw surgery during the study (extraction, implants). Patients who are allergic to/ intolerant of bisphosphonate therapy. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. uncontrolled diabetes, active or uncontrolled infection, uncontrolled diarrhea) that could cause unacceptable safety risks or compromise compliance with the protocol. Other clinically significant heart disease (e.g. symptomatic congestive heart failure, uncontrolled arrhythmia, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen). Other protocol-defined inclusion/exclusion criteria may apply",during Cycle 1,NA
7607931,NA,Combination,No,"patients with advanced lymphoid malignancies, including acute lymphoblastic leukemia (ALL) (n = 24) and non-Hodgkin’s lymphoma (NHL) (n= 20) ","Forty-four patients, 6-48 (median 28) years of age, with advanced lymphoid malignancies (primary refractory disease,chemoresistant first relapse, secondrelapse, or beyond) including acute lymphoblastic leukemia (ALL) (n = 24) and non-Hodgkin’s lymphoma (NHL) (n = 20) were entered into this study. Classification of pa- tients into advanced and less advanced categories has been previously described (1). Twenty-two patients with ALL and 19patients with NHL had failed primary therapy or were beyond first untreated relapse, and 1 with ALL and 2 with NHL were in third remission. Patients with active hepatitis or abnormal renal function were excluded. In addition, patients receiving mediastinal radiotherapy to a dose of 20 Gy or more before transplant were ex-cluded to decreasethe incidence of fatal interstitial pneumonia syndrome (IPS). Marrow wasobtained from HLA-identical siblings as previously described",NA,NA,NA
9213323,NA,Combination,No,"patients with advanced solid tumors. 26 with breast cancer, 6 withsarcoma, 3 with colon cancer, and 4 with other solid tumors, includinglung and head and neck carcinomas","To be eligible, patients had to have a histologically confirmed advancedsolid malignancy (any type) and measurable or evaluable disease. Othercriteria included a life expectancy 3 months or more and Karnofsky performancestatus 60% or more, no prior chemotherapy or radiation within the previous4 weeks, and normal or only mildly impaired liver function.",NA,NA,NA
24958809,NCT00880321,Single Drug,No,patients with BRAFV600 mutation–positive melanoma ,"A patient was eligible for inclusion in this study only if all of the following criteria applied. Written informed consent provided. Aged 18 years or older. Histologically or cytologically confirmed diagnosis of a solid tumor that is not responsive to standard therapies or for which there is no approved or curative therapy. Presence of a BRAF mutation was initially optional in the dose-escalation cohorts but later required in both the dose-escalation and -expansion cohorts due to absence of activity in BRAF wild-type tumors. Performance status score of 0 or 1 according to the Eastern Cooperative Oncology Group scale. Patients with performance status of 2 may be enrolled with approval of the GSK Medical Monitor. Ability to swallow and retain oral medication. Male patients must agree to use acceptable contraception methods. This criterion must be followed from the time of the first dose of study medication until 16 weeks after the last dose of study medication. A female patient was eligible to participate if she was of: –	Non-childbearing potential, defined as premenopausal females with a documented tubal ligation or hysterectomy; or postmenopausal, defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle-stimulating hormone > 40 MlU/mL and estradiol < 40 pg/mL [< 140 pmol/L] is confirmatory). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use acceptable contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status prior to study enrollment. For most forms of HRT, at least 2 to 4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their postmenopausal status, patients can resume use of HRT during the study without use of a contraceptive method; –	Childbearing potential and agrees to use acceptable contraception methods for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female patients must agree to use contraception until 4 weeks after the last dose of study medication. Adequate organ system function, defined as: –	Absolute neutrophil count ≥ 1.2 × 109/L; –	Hemoglobin ≥ 9 g/dL (patients with chronic hemolysis or similar conditions requiring continuous red blood cell replacement will not be considered to have met this criteria); –	Platelets ≥ 75 × 109/L; –	Prothrombin time/international normalized ratio (PT/INR) and partial thromboplastin time (PTT) ≤ 1.3 × ULN; –	Total bilirubin ≤ 1.5 × ULN; –	Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (if liver metastases are present, ALT and AST levels of ≤ 5 × ULN are allowed). Approval of the GSK Medical Monitor is required; –	Creatinine ≤ ULN, or calculated creatinine clearance ≥ 50 mL/min (as calculated by the Cockcroft–Gault formula), or 24-hour urine creatinine clearance ≥ 50 mL/min; –	Troponin ≤ ULN or ≤ 10% CV level; –	Cardiac ejection fraction ≥ LLN. Additional inclusion criteria for the RP2D expansion cohorts: –	Presence of radiologically and/or clinically documented disease with ≥ 1 measurable lesion as defined by Response Evaluation Criteria In Solid Tumors (RECIST) v1.0 (i.e., ≥ 2 cm in diameter by conventional technique or ≥ 1 cm in diameter by computed tomography). NOTE: Patients will be ineligible if the only measurable site of disease is located in a previously irradiated site. A cutaneous or subcutaneous lesion identified as a target lesion will be acceptable if ≥ 1 cm in diameter in 1 dimension.","A patient was not eligible for inclusion in this study if any of the following criteria applied. Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, biological therapy, hormonal therapy, surgery, and/or tumor embolization). Use of an investigational anticancer drug within 28 days preceding the first dose of dabrafenib. Current use of a prohibited medication or requirement of any of these medications during treatment with dabrafenib. Current use of therapeutic warfarin. Low-molecular-weight heparin and prophylactic low-dose warfarin are permitted. PT/PTT must meet the inclusion criteria. Patients taking warfarin must have their INR followed closely. Any major surgery, radiotherapy, or immunotherapy within the last 4 weeks. Limited radiotherapy within the last 2 weeks. Use of chemotherapy regimens with delayed toxicity within the last 4 weeks (6 weeks for prior nitrosourea or mitomycin C). Use of chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks. Unresolved toxicity higher than grade 1 from previous anticancer therapy, except alopecia, unless agreed to by the GSK Medical Monitor and the investigator. Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs. A history of known HIV infection. Primary malignancy of the central nervous system. Symptomatic or untreated leptomeningeal or brain metastases, or spinal cord compression. Patients previously treated for these conditions who are asymptomatic and off corticosteroids for ≥ 1 month are permitted. Brain metastases must be stable for ≥ 2 months, with verification by imaging (brain magnetic resonance imaging [MRI] completed at screening). A computed tomography scan with and without contrast may be performed if an MRI is contraindicated. Patients are not permitted to receive enzyme-inducing anti-epileptic drugs. In the RP2D expansions, patients with asymptomatic, untreated brain metastases who have not been stable for 2 months may be enrolled with approval of the GSK Medical Monitor. These patients can be on a stable dose of corticosteroids . History of alcohol or drug abuse within 6 months prior to the screening visit. Psychological, familial, sociologic, or geographic conditions that do not permit compliance with the protocol. Concurrent condition that, in the investigator’s opinion, would jeopardize compliance with the protocol. QTc interval ≥ 480 ms. History of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks. Class II, III, or IV heart failure as defined by the New York Heart Association functional classification system. Abnormal cardiac valve morphology (patients with minimal abnormalities can be entered on study with approval from the GSK Medical Monitor). Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug, or excipients (to date, there are no known US Food and Drug Administration-approved drugs chemically related to dabrafenib). Pregnant or lactating female. Unwillingness or inability to follow the procedures outlined in the protocol. Known glucose-6-phosphate dehydrogenase deficiency. Positive test result for human papillomavirus (HPV). Entry on study allowed only at the discretion of the patient and investigator after informed consent regarding discussion of the risk of HPV infection. If enrolled, these patients must use condoms for sexual activity, regardless of the use of other contraceptive measures and childbearing status. Prior treatment with a BRAF or MEK inhibitor unless approved by the GSK Medical Monitor.",during the first cycle,NA
31811016,NCT01677741,Single Drug,No,Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma,"Eligible patients with LGG were aged 1 to <18 years and had at least one evaluable BRAF V600 mutation–positive tumor according to Response Assessment in Neuro-Oncology (RANO) criteria, determined locally by a Clinical Laboratory Improvement Amendments–approved laboratory (or equivalent), adequate organ function, and a Karnofsky (for >=16 years of age) or Lansky (for <16 years of age) performance score of >=50. Baseline evaluable (but not measurable) disease was required. Patients were required to have recurrent, refractory, or progressive disease following receipt of >=1 prior standard therapy. Patients could not have received chemotherapy or radiotherapy within 3 weeks (or 6 weeks for nitrosoureas or mitomycin C) or an investigational agent within 28 days (or five half-lives or twice the duration of the biological effect) prior to the first dose of dabrafenib.","Only in part 2, patients were excluded if they had received previous treatment with a RAF inhibitor (including dabrafenib) or a MEK inhibitor; previous treatment with sorafenib was permitted.",NA,NA
31796520,NCT02383212,Combination,No,"Patients with Advanced Malignancies. The most common tumor types were colorectal (n = 7; 11.7%), head and neck (n = 6; 10.0%), and breast, non-melanoma skin cancer, and soft-tissue sarcoma (each n = 5; 8.3%).","Patients were eligible if they were >=18 years, had histologically or cytologically confirmed diagnosis of advanced solid tumors, had no alternative standard-of-care therapeutic option, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients were required to have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) (8), and for those receiving hfRT, at least one measurable nonirradiated lesion. Additional inclusion criteria are as follows: Hepatic function: - Total bilirubin ≤1.5 x upper limit of normal (ULN); - Transaminases ≤3 x ULN; - Alkaline phosphatase ≤2.5 x ULN; - For patients with hepatic metastases or hepatic malignancies, exclude patients with concomitant 3 x ULN ≤ aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤5 x ULN and 1.5 x ULN ≤ total bilirubin ≤3 x ULN. Renal function: serum creatinine ≤1.5 x ULN or creatinine clearance (CrCl) >50 ml/min. Bone marrow function: Hemoglobin ≥9.0 g/dL; Absolute neutrophil count ≥1.5 x 109/L; Platelet count ≥75 x 109/L.","Select exclusion criteria included any prior treatment with an anti–PD-1/anti–PD-L1 agent, prior treatment with other immune-modulating agents within 4 weeks of initiation of cemiplimab, ongoing or recent (within 5 years) autoimmune disease requiring systemic immunosuppression, or active brain metastasis. Additional exclusion criteria are as follows: History of invasive malignancies within 5 years of enrollment. Treatment with immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks of initiation of cemiplimab. Active infection requiring therapy, including known infection with human immunodeficiency virus, or active infection with hepatitis B or hepatitis C virus History of pneumonitis within 5 years prior to enrollment. Any investigational or antitumor systemic treatment within 4 weeks prior to the initial administration of cemiplimab. Patients on gonadotropin-releasing hormone agonists are not excluded. Patients receiving bisphosphonates or denosumab are not excluded. History of documented allergic reactions or acute hypersensitivity reaction attributed to treatment with antibody therapies in general, or to agents specifically used in the study. Known allergy to doxycycline or tetracycline (precaution due to presence of trace components in cemiplimab). Known hypersensitivity to cyclophosphamide for patients enrolled in cohorts receiving cyclophosphamide. Breast-feeding. Positive serum pregnancy test. History within the last 5 years of an invasive malignancy other than the one treated in the study. Acute or chronic psychiatric problems that, under the evaluation of the investigator, make the patient ineligible for participation. Patients with a history of solid organ transplant (patients with prior corneal transplant may be allowed to enroll following discussion and approval from the medical monitor).",during the first cycle,NA
32741971,NCT02597036,Combination,No,patients with advanced solid tumours,"The study included adult patients with histologically or cytologically confirmed advanced/metastatic solid tumours who were appropriate candidates for experimental therapy in the absence of a standard therapy or for whom available standard therapies had failed to provide clinical benefit for their disease, who refused standard therapies, or who were not a candidate for those therapies, and had progressive disease prior to study entry. Study patients were required to have measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;16 life expectancy that would allow completion of at least two treatment cycles; adequate hematologic, hepatic, renal, and coagulation functions; Eastern Cooperative Oncology Group performance status of ≤1; to have discontinued receiving any anticancer therapy for the last 28 days or five halflives of the previous treatment before enrolment, whichever was shorter, and recovered from the acute effects of therapy.","Patients were excluded if they had any contraindication to LY3127804 or other MAbs, were previously treated with Ang-2 inhibitors, had any second primary active malignancy, or had any bleeding disorder or thromboembolic event. Patients with active/ known fungal/bacterial/viral infection, history of major surgery within 28 days prior to randomisation, or placement of a central venous access device within 7 days before receiving treatment, or any planned major surgery during the trial, and patients (with non-small cell lung cancer only) with gross haemoptysis or major blood vessel encasement were also excluded",the first 28 days after first dosing (cycle 1),NA
8622060,NA,Combination,No,"patients with poor-prognosis breast cancer, non-Hodgkin's lymphoma (NHL), or ovarian cancer ","All patients had Oncology Group (SWOG) performance status less than 2 and acceptable organ function pretransplant (creatinine clearance > 60 mLmin, left ventricular ejection fraction > 45%, diffusion capacity of carbon monoxide and forced expiratory volume 1.0 > 60% of predicted, and bilirubin/AST/ALT < two times the upper limit of normal). ",Taxane treatment within the past three months was required as an exclusion criteria by reviewers from the National CANCER iNSTItute who supplied paclitaxel for this study. A history OF alcohol abuse and/or active neuromuscular disease were also exclusion criteria. Patients previously treated with CPA and/or cDDP were not excluded.,NA,NA
21811257,NA,Combination,No,"patients with advanced melanoma and other solid tumours. The majority of patients (88%) had melanoma, either of cutaneous, uveal, or mucocutaneous origin. Two patients had colorectal carcinoma, and one patient each had oesophageal, small bowel, and small-cell lung cancer.",All patients were X18 years of age with histologically confirmed metastatic solid tumours refractory to standard therapy or for which no effective therapy was available. ,Patients were excluded from the study if they previously received therapy with dacarbazine.,NA,NA
27649551,NCT02239900,Combination,No,"NSCLC, Colorectal, Sarcoma, RCC, Cholangiocarcinoma,  Unknown primary,  Squamous HNC, Cervical, Gastric, Neuroendocrine, Adrenocortical, Salivary, Anaplastic thyroid, Uveal melanoma , Pancreatic, Papillary thyroid, Gastroesophageal, Prostate, other","Patients must have histological confirmation of metastatic cancer with at least one metastatic or primary lesion in the liver, lung, or adrenal gland. Patients who have completed previous systemic therapies 5 drug half-lives or 4-weeks prior to enrollment on study, whichever is shorter. Note: patients with anaplastic thyroid will be waived from this inclusion criteria given the rapid trajectory of their disease. All patients must have at least one metastatic or primary lesion within the lung or liver located in an anatomical location amenable to SBRT treatment with 50 Gy in 4 fractions, or if not, with either a lung, liver, or adrenal lesion treatable to 60 Gy in 10 fractions. Repeat radiation in fields previously radiated will be allowed at the discretion of the treating physician. Age >/= 18 years. ECOG performance status </=2 (Karnofsky >60%). Patients must have normal organ and marrow function as defined below: * Total bilirubin </= 2.0 mg/dL. (Does NOT apply to patients with Gilbert's Syndrome) * Aminotransferase (AST) Serum Glutamic Oxaloacetic Transaminase (SGOT)/ Alanine Aminotransferase (ALT) Serum Glutamic-Pyruvic Transaminase (SGPT) <2.5 X institutional upper limit of normal (patients with liver involvement will be allowed </= 5.0 X institutional upper normal limit) *WBC >/= 2500/uL, ANC >/= 1000/uL *Platelets >/= 75K *Hemoglobin >/= 9g/dL *Creatinine </= 2.0 x ULN. Patients must be willing and able to review, understand, and provide written consent before starting therapy. Patients with brain metastasis will be included as long as they are free of neurologic symptoms related to metastatic brain lesions and who do not require or receive systemic corticosteroid therapy in the 14 days prior to beginning ipilimumab therapy. Patients that have previously progressed on immunotherapy such as ipilimumab will be eligible.","Serious autoimmune disease at the discretion of the treating attending: Patients with a history of active serious inflammatory bowel disease (including Crohn's disease and ulcerative colitis) and autoimmune disorders such as rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus or autoimmune vasculitis [e.g., Wegener's Granulomatosis] are excluded from this study. Active diverticulitis, intra-abdominal abscess, Gastrointestinal (GI) obstruction, abdominal carcinomatosis or other known risk factors for bowel perforation. Any underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of Adverse Events: (AE's) e.g. a condition associated with frequent diarrhea or chronic skin conditions, recent surgery or colonic biopsy from which the patient has not recovered, or partial endocrine organ deficiencies. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, history of congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Known active HIV, Hepatitis B, or Hepatitis C that has not been documented to be cured. Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to one month prior to or after any dose of ipilimumab). Concomitant therapy with any of the following: IL-2, interferon or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigational therapies; or chronic use of systemic corticosteroids while receiving ipilimumab (as long as steroid replacement is significantly greater than what is required for physiologic replacement, i.e. in hypothyroidism). Pregnant women are excluded from this study. Women of child-bearing potential and men must agree to use contraception prior to study entry and for the duration of study participation. Acceptable forms of birth control include: Birth control pills plus a barrier method, such as a condom or diaphragm, Intrauterine devices (IUD) plus a barrier method, Implantable or injectable birth control (such as NorplantR or epo-ProveraR) started at least 3 months before joining the study, plus a barrier method, or Double-barrier method, such as a condom when used in combination with a diaphragm. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician. History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician. Prior allogeneic stem cell transplantation",NA,NA
11840607,NA,Combination,No,metastatic breast cancer,"Fifteen patients with hormone refractory or estrogen receptor negative metastatic breast cancer were enrolled. Eligibility criteria included metastatic breast cancer in patients who had not received doxorubicin either as part of adjuvant treatment or in metastatic disease. All patients 18 years or older, with ECOG performance status of 2 or less, with normal hematologic, hepatic and renal profile were eligible for the protocol. A complete history and physical examination was performed on all patients entering the trial. Metastatic workup included mammography, bone scan, abdominal and pelvic ultrasound and liver scan. CT scans were done when indicated.",Echocardiography was performed on all patients and patients with ejection fraction of less than 50% were excluded. Patients who had central nervous system metastasis documented on MRI or CT scan were also excluded.,the first course,NA
30655615,ANZCTRN: 12613000924752,Combination,No,"Patients had BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer","Eligible patients with recurrent or metastatic disease after standard therapies had measurable (Response Evaluation Criteria in Solid Tumors [RECIST] v1.1) or non-measurable HGSOC with an elevated CA125 evaluable using Gynecologic Cancer InterGroup (GCIG) CA125 response criteria,21 an Eastern Cooperative Organization Group performance status of ≤2, and adequate bone marrow, liver, and kidney function.","Documentation of gBRCAm status was not required. Prior exposure to a PARP inhibitor was not allowed. Patients who were unable to swallow pills or those with uncontrolled intercurrent illness, including brain metastases or gastrointestinal conditions that might predispose to drug intolerance or poor drug absorption were also excluded.",during the first two cycles,NA
33811482,NCT01246986,Combination,No,patients with advanced hepatocellular carcinoma,"Eligible patients were ≥18 years of age with a histologic diagnosis of HCC, were not amenable to curative surgical resection, and had adequate organ function as indicated by Child-Pugh A (CP-A) score. All patients had measurable disease per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST v 1.1). 21 Patients were required to have had progression of disease on, intolerance to, or declined prior sorafenib, the only front- line standard of care at the time of study conduct. Any number of prior systemic therapies were allowed.","Key exclusion criteria included: other histologies including mixed HCC-cholangiocarcinoma and fibrolamellar carcinoma, clinically relevant ascites or encephalopathy, prior liver transplant, uncontrolled hypertension (≥150/90 mmHg despite standard medical management), moderate or severe cardiac disease; severe proteinuria (≥1000 mg in 24-h period), major surgery within 28 days, gastrointestinal hemor-rhage within 3 months, thrombotic event within 6 months of enrollment, and therapeutic anticoagulation.",during cycle 1,NA
24440659,NA,Combination,No,patients with relapsed/refractory acute lymphoblastic leukemia,"Patients aged 21 years and older with a diagnosis of previously treated ALL (including Burkitt leukemia/lymphoma and lympho- blastic lymphoma) whose disease had either relapsed or who were refractory to induction therapy were eligible for the study. The study was later amended so that the duration of the first remission of patients who were in first relapse had to be < 12 months. Patients were required to have discontinued previous therapy for at least 2 weeks by the time of study enrollment. Concurrent treatment for relapse in the central nervous system (CNS) or CNS prophylaxis with intrathecal chemotherapy was permitted. Other eligibility criteria included (1) performance status of at least 3 (Eastern Cooperative Oncology Group scale), (2) adequate organ function (serum total bilirubin level <= 2.5 mg/dL, alanine aminotransferase [ALT] or aspartate aminotransferase [AST] levels <= 3 x the upper limit of normal, and glomerular filtration rate >= 60 mL/min), (3) absence of active heart disease (New York Heart Association class 3 or greater) based on history and physical ex- amination, and (4) a cardiac ejection fraction that was at least 45% (based on multigated acquisition scan [MUGA] or echo- cardiogram)",NA,within the first 14 days after start of treatment,NA
21159616,NA,Single Drug,No,"patients with advanced cancer. Type/site of primary cancer: Lung 8 (17%), Melanoma 7 (15%), Colon 6 (13%), Breast 4 (8%), Ovarian 3 (6%), Pancreas 3 (6%), Prostate 3 (6%), Renal cell 2 (4%), Other (Adenoid cystic (n = 1), bronchoalveolar (n = 1), endometrial (n = 1), follicular dendritic (n = 1), large cell (n = 1), Merkel cell (n = 1), mucoepidermoid (n = 1), parathyroid (n = 1), and tonsillar cancer (n = 1), gastroesophageal adenocarcinoma (n = 1), thymoma (n = 1), and mesothelioma (n = 1)) 12 (25%)","Patients were eligible to enroll if they had advanced or metastatic cancer, documented pathologic evidence of malignancy, and measurable or evaluable neoplastic disease; were at least 18 years of age; had a Karnofsky performance score of 70 or greater and a predicted life expectancy of 12 weeks or greater; and had aspartate aminotransferase and alanine aminotransferase levels 3 times or less the upper limit of normal, bilirubin within normal limits, an absolute neutrophil count of 1.5 x 109/L or greater, platelet count of 100 x 109/L or greater, hemoglobin level 9 g/dL or greater, and serum creatinine level 1.5 times or less than the upper limit of normal. Patients were eligible after recovery from prior chemotherapy, surgery, or radiotherapy and if they had grade 1 or less baseline peripheral neuropathy. Patients with brain metastases were also eligible. ","Patients were excluded if they had a prior serious, uncontrolled hypersensitivity reaction to polyoxyethylated castor oil, were pregnant or lactating, had received anticancer treatment within the previous 28 days, had spinal cord compression, a history of other malignancies within the past 5 years, symptoms of heart failure of class III or higher according to New York Heart Association criteria, or had primary brain cancer. ",during the first 28 days of treatment ,NA
34433633,NCT00562640,Combination,No,patients with recurrent ovarian cancer,"Eligible patients had recurrent or persistent, pathologically confirmed WT1+ ovarian, primary peritoneal, or fallopian tube carcinomas. Tumors were tested for WT1 positivity by immunohistochemistry as previously described,21 with positive expression graded according to an adaption of the German Immunoreactive Score (IRS, range 4–12 was considered positive).30 Patients were required to have Karnofsky Performance Status (KPS)≥70 and normal hematologic and biochemical parameters. Prior chemotherapy must have been completed at least 3 weeks prior to leukapheresis and prior to initiation of study therapy. Patient’s disease was required to be evaluable radiologically by RECIST V.1.1.",NA,NA,NA
22887831,NCT00293410,Combination,No,children with relapsed or refractory acute leukemias,"Male and female patients, between 1 and 21 years of age andof all ethnic and racial groups were eligible for this study. Thestudy required histologically confirmed R/R acute leukemia in-cluding all AML subtypes, AML evolving from myelodysplasticsyndrome (MDS) or myeloproliferative disorders (MPD), all ALLsubtypes, acute promyelocytic leukemia (APL) refractory to arse-nic or retinoic acid, any R/R acute leukemia showing progressionsince last treatment, chronic myelogenous leukemia (CML) inaccelerated phase or blast crisis refractory to imatinib, andhigh-risk MPD with myelofibrosis, chronic myelomonocytic leukemia (CMML) with 5–19% blasts, and R/R juvenile myelomo-nocytic leukemia (JMML). Patients who had relapsed >=3 monthsafter allogeneic or autologous hematopoietic stem cell transplan-tation (SCT) were initially eligible, although subsequently exclud-ed based on toxicities observed in this and other studies withCLO. Eastern Cooperative Oncology Group (ECOG) performancestatus of 0–2 for adolescent/young adult patients and Lansky PlayScale >=50 for pediatric patients less than age 10 years wererequired. Laboratory values obtained <=7 days before receivingstudy treatment had to meet the following criteria: total bilirubin <=1.5 mg/dl, aspartate transaminase (AST) and alanine transaminase (ALT) <=2.5 x upper limit of normal (ULN), adequate renalfunction for age or glomerular filtration rate (GFR)>60 ml/min/1.73 m2as calculated by the Modification of Diet in Renal Diseaseequation . Normal cardiac function by echocardiogram within 30 days of study entry was required . Subjects could not havehad chemotherapy, radiation, or major surgery within 2 weeks oftrial entry, with the exceptions of patients who received 5-azacyti-dine, thalidomide, hydroxyurea , imatinib, or interferon.Patients must have discontinued all growth factors, except erythroidstimulating agents, 1 week before study","Exclusion criteria included patients with known HIV or AIDS,active infection, progressive infection of the lungs, sinuses, orabdomen, activeGrade 2 graft-versus-host disease (GVHD),pregnancy or active lactation and female patients who refusedto use contraception methods",during the first treatment cycle,NA
20048182,NA,Combination,No,"Patients with advanced solid malignancies. Primary malignancy: Colorectal, Head and neck, Hepatocellular, Pancreas, Carcinoid, esophagus, neuroendocrine, ovary,prostate, melanoma, stomach, uterine (leiomyosarcoma), Bladder, breast, thyroid (medullary), thyroid (papillary), biliary tract ","Patients with advanced solid malignancies refractory to treatment or lacking standard therapeutic options were eligible. Other eligibility criteria included the following: age >= 18 years; adequate hematologic, hepatic, and renal function; and an Eastern Cooperative Oncology Group performance status <= 2.","Key exclusion criteria were as follows: centrally located pulmonary lesions adjacent to or invading large blood vessels as assessed by the investigator; serious nonhealing active wound, ulcer, or bone fracture; deep venous thrombosis (DVT) within 6 months of entry; proteinuria >= 1+; prior left chest wall radiotherapy; anthracycline dose >= 300 mg/m2 with abnormal left ventricular ejection fraction; prior treatment with VEGF or VEGFR inhibitors or anyMAb (amended to within 6 weeks of entry); hypersensitivity reaction to a therapeutic protein; and use of thrombolytic agents, full-dose heparin or warfarin, aspirin, and nonsteroidal anti-inflammatory drugs",during cycle 1,NA
33046516,NCT02789345,Combination,No,patients with EGFR T790M-positive NSCLC,"Eligible patients were at least 18 years old with locally advanced or metastatic NSCLC; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1; measurable disease as defined by the RECIST Version 1.1 (RECIST 1.1; ref. 40); disease progression immediately following first-line EGFR TKI treatment regardless of prior chemotherapy; documented evidence of lung cancer with one of the two common EGFR mutations known to be associated with EGFR TKI sensitivity (Exon 19 deletion or Exon 21 L858R mutation), and T790M-positive status using a validated test, including but not limited to those approved by the FDA (e.g., Cobas EGFR Mutation Test Version 2) in the United States or recommended in the Summary of Product Characteristics for osimertinib in the European Union, performed locally after disease progression on EGFR TKI treatment. Patients who had CNS metastases were eligible if the disease was asymptomatic and stable, requiring no steroids or anticonvulsants for ≥2 weeks prior to receiving treatment; patients receiving radiotherapy needed to have completed ≥4 weeks prior to receiving treatment. ","Patients were not eligible if they had received prior treatment with osimertinib or another third-generation EGFR TKI or had a recent clinically significant illness or medical condition, including clinically active interstitial lung disease, inadequate organ function (hepatic, hematologic, coagulation, renal), or unresolved toxicity from prior systemic cancer therapy, surgery, or radiotherapy.",during the first two cycles (4 weeks) of treatment,NA
25307519,NCT01048892,Combination,No,"children with relapsed/refractory solid tumors. Diagnosis: Carcinoid tumor 1 (4.5), Adrenal cortical carcinoma 3 (13.6), Embryonal rhabdomyosarcoma 1 (4.5), Alveolar rhabdomyosarcoma 2 (9.1), Wilms’ tumor 3 (13.6), Ganglioneuroblastoma 1 (4.5), Neuroblastoma 11 (50.0)","Patients >=3 years and <=21 years with measurable or evaluablerefractory incurable disease and histologic confirmation of neuroblas-toma, rhabdomyosarcoma, Wilms tumor, retinoblastoma, and adreno-cortical carcinoma or carcinoid tumorwere eligible. Other eligibility criteria included Karnofsky or Lansky score >50%; recovery fromacute toxic effects of prior therapy; >3 weeks since myelosuppressive chemotherapy; >3 half-lives of the antibody since last monoclonalantibody administration; >2 weeks since local palliative irradiation; >6 weeks since treatment with therapeutic doses of MIBG; >6 weeks since total-body irradiation; >3 months since transplant or stem cellinfusion; >42 days since immunotherapy; adequate bone marrow function (peripheral absolute neutrophil count (ANC) >1,000/mm3,platelet count >100,000/mm3 (transfusion independent), hemoglobin >8.0 g/dl); adequate renal function (age-adjusted normal serumcreatinine or a glomular filtration rate >70 ml/min/1.73 m2); adequate liver function (bilirubin <1.5 x institutional upper limit of normal forage, ALT <110 U/L, serum albumin >2 g/dl) and adequate pulmonary function (oxygen saturation >92% on room air)","Patients were excluded if pregnant or breast feeding. Patients were also excluded if: requiring steroids and not on a stable or decreasing dose for the prior 7 days; receiving another investigational agent/anti-cancer agent; viral immunizations administered <7 days from enrollment; chronic diarrhea (>7days), urinary incontinence during day/night, or uncontrolled infection. Patients with a primary CNS tumor or known metastatic CNS disease; known pulmonary tumors or metastases >5 cm, as evaluated bychest CT; having an indwelling urinary catheter or not completely toilet trained; or known pregnant member in their household.",at least 28 days for part A (single dose of NTX-010),NA
28439108,NCT00450814,Combination,No,patients with recurrent or refractory multiple myeloma,"Patients were eligible if they had relapsed or refractory myeloma, aged 18 years or older, at least two or more prior non-overlapping chemotherapeutic combinations but did not have known standard therapy known to extend life expectancy, ECOG performance status 0, 1 or 2, life expectancy of greater than 12 weeks, adequate bone marrow reserve (neutrophil count ⩾1 × 109/l, platelets ⩾50 × 109/l and hemoglobin ⩾8.5 g/dl), adequate organ reserve (AST ⩽2 times upper limit of normal, creatinine o2 times upper limit of normal, total bilirubin ⩽1.5 × upper limit of normal and an international normalized ratio ⩽1.4 × upper limit of normal), a negative serum pregnancy test done ⩽7 days prior to registration for women of childbearing potential, ability to provide written informed consent.","Patients were excluded if they had prior allogeneic stem cell transplantation, uncontrolled infection, chemotherapy within 3 weeks prior to registration, or immunotherapy or biologic therapy within 4 weeks of study registration, New York Heart Association classification III or IV, known symptomatic coronary artery disease, or known atrial fibrillation or superventricular tachycardia, active central nervous system disorders, HIVpositive test result, allergy to oral iodine, previous exposure to heatinactivated measles virus vaccine, pregnant or nursing women, men or woman with reproductive capacity not willing to use contraception and exposure to household contacts ⩽15 months old or household contact with known immunodeficiency",the first 6 weeks,NA
10865980,NA,Combination,No,patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma,"Patients with relapsing and/or refractory B-CLL or indolent NHL were eligible. Other eligibility criteria were: Eastern Cooperative Oncology Group performance status 2; life expectancy 3 months; age 18 years; appropriate contraception; no prior chemo-, immuno- or radiotherapy for at least 4 weeks before entry; complete recovery from toxic effects of previous antitumor therapy; absence of active infection; satisfactory hematologic parameters (neutrophil count 1.0 × 109/l, platelet count 50 × 109/l) unless due to disease infiltration; absence of autoimmune cytopenia; AST and ALT within 2.5 times the normal upper limit; bilirubin and creatinine levels within the normal range. Written informed consent was obtained from all the patients. ",NA,during the first course,NA
31895753,EudraCT: 2011-004200-38,Single Drug,No,patients with uveal melanoma develop distant metastasis underwent RFA,"Eligible patients were aged 18  years or older and had histological or cytological confirmed unresectable metastatic uveal melanoma (as confirmed by multidisciplinary tumor board). All patients needed to have at least two liver metastasis (both >1 cm) and one of them should be feasible for RFA. Patients were not allowed to have been treated with previous systemic therapy for metastatic disease. A WHO performance status of 0 or 1, normal organ function and lactate dehydrogenase (LDH) levels less than two times the upper limit of normal were required.",Exclusion criteria included cerebral metastasis and history of autoimmune disease requiring immunosuppressive medication.,from day 1 (the day that the patient underwent RFA) until 12  weeks after the first infusion of ipilimumab,NA
33229456,NCT02791334,Combination,No,"patients with advanced, refractory solid tumors.  Tumor type: Breast (n=10), Colorectal (n=8), Endometrial (n=5), Esophageal, Gastro-intestinal or GIST, Lung, Melanoma, Ovarian, Pancreatic, Other (Includes prostate adenocarcinoma (n=2), choriocarcinoma, squamous cell carcinoma (unknown origin), cholangiocarcinoma, vaginal adenocarcinoma, squamous cell carcinoma of the anus, adrenal carcinoma, squamous cell carcinoma of the esophagus, malignant neoplasm of thyroid, renal carcinoma, malignant neoplasm of extrahepatic bile duct, squamous cell carcinoma of the skin, squamous cell carcinoma of tongue, urothelial carcinoma, chondrosarcoma, soft tissue sarcoma, carcinoma of oropharynx, epithelial carcinoma (unknown origin), cervical carcinoma (n=1 for each) )","Patients were eligible if they were ≥18 years of age and had histologically or cytologically confirmed advanced cancer, at least one measurable lesion accessible according to RECIST v1.1, an ECOG performance status of 0–1, discontinued all previous treatments for cancer for ≥14 days, and an estimated life expectancy of ≥12 weeks. Subjects could not have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease; received a live vaccine within 30 days of starting the study; or have history of any other condition, therapy, or abnormality that could interfere with the study. Patients scheduled to receive ramucirumab could not have a Child-Pugh score of ≥7, intratumor cavitation, tumor invasion or encasement of a major blood vessel, an elective surgery during the trial or major surgery within 28 days of enrollment, or have had central venous access device placement within 7 days of enrollment. For the phase Ia dose escalation, the protocol was amended so that patients scheduled to receive abemaciclib + PD-L1 inhibitor concurrent combination therapy could not have liver metastases and had to have normal serum liver enzyme levels. Patients enrolled into the monotherapy phase Ib expansion cohort had to have confirmed diagnosis of metastatic cutaneous melanoma with advanced unresectable disease and could not have received more than two lines of prior systemic therapy. Patients enrolled into the LY3300054 + merestinib phase Ib expansion cohort had to have confirmed diagnosis of metastatic or locally advanced, unresectable pancreatic adenocarcinoma and could not have received more than two lines of prior systemic therapy. Women could not be breastfeeding, pregnant, or planning to become pregnant.",NA,"the first treatment cycle (28 days for Q2W and Q4W dosing, 21 days for Q3W dosing)",NA
28879519,NCT01582997,Single Drug,No,Japanese patients with BRAF V600 mutation-positive solid tumors: Melanoma and Thyroid,"Men and women (of non-childbearing potential or childbearing potential with a negative serum pregnancy test 7 days prior to the first dose of medication and using adequate contraception until 4 weeks after the last dose of study medication) were included in the study. The patients had to be aged ≥20 years with a histologically or cytologically confirmed diagnosis of BRAFV600E/K mutation-positive advanced solid tumor not responsive to standard therapy or for which there was no approved or curative therapy. Other inclusion criteria included patients negative for hepatitis B or C virus test, and had an Eastern Cooperative Oncology Group performance status (ECOG-PS) score of 0 or 1, and had adequate organ functions.","Patients were excluded if they had a history of other malignancy within the past 5 years; were required to receive concomitant cancer therapy; had received treatment with an investigational anti-cancer drug within 28 days or its 5 halflives, whichever was longer, preceding the first dose of the study drug; had received prior treatment with a BRAF or MEK inhibitor; had a history of acute coronary syndromes, coronary angioplasty, or stenting within the past 24 weeks, had QTc interval ≥ 480 msecs; had grade 2 or greater valvular heart disease as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0; or had Class II, III, or IV heart failure, as defined by the New York Heart Association (NYHA) functional classification system.","the period from the first 28 days after administration of the first dose (i.e., during 7 days after a single administration and 21 days after starting continuous BID administration)",NA
27166393,NCT00566618,Combination,No,"patients with bone predominant, HER2-negative breast cancer metastases","Patients were consented and enrolled in the trial if they met the following eligibility criteria: had a confirmed pathologic diagnosis of invasive carcinoma of the breast that was HER2-negative (0–1+ by IHC or 2+ and nonamplified by FISH), who carried a diagnosis of metastatic disease with predominant bone involvement defined as bone metastases detected on imaging studies in the presence or absence of visceral involvement (if visceral involvement was present, patients had to be asymptomatic from visceral disease and have no metastases in visceral organs that measured >3 cm in size). Patients had to be >=18 years of age and have a performance status ECOG <=2 and could have received one prior line of chemotherapy. Patients were required to have adequate hematologic, renal, and hepatic function prior to enrollment. Patients with HR-positive breast cancer were also required to have had one prior hormonal therapy for metastatic disease, and have documented progression of disease on hormonal therapy prior to enrolment. Patients had to have completed previous radiotherapy at least 2 weeks (8 weeks for brain radiation) prior to study enrollment. All patients had to have recovered to grade <=1 from all acute toxicity of previous therapy.","Patients with irradiated tumor as the only site of evaluable disease were not eligible for protocol therapy unless there was documented disease progression within the previously radiated site. Patients were excluded if they required concurrent radiation, had an active infection requiring the use of intravenous antibiotics, had another malignancy (other than breast cancer) that required radiotherapy or systemic treatment within the past 5 years, had active cardiac disease, had concurrent medical conditions which may increase the risk of toxicity (pleural or pericardial effusion, bleeding diathesis), were unwilling or unable to use an acceptable method of contraception for the entire study period and for at least 4 weeks after cessation of study drug, were pregnant or breastfeeding, or had untreated or uncontrolled brain metastasis. Patients were also excluded if they had active dental problems, recent or planned dental or jaw surgery within 8 weeks of enrollment, and known hypersensitivity to zoledronic acid or aspirin. Patients were not allowed to receive any concurrent bisphosphonate therapy other than that prescribed by the study.",during cycle 1,NA
16675578,NA,Combination,No,"patients with refractory solid tumors. Tumor type: Colorectal, Glioma, Pancreatic, Hepatocellular, Renal, Melanoma, Chondrosarcoma, Adrenocortical carcinoma, Adenoid squamous, NSCLC, Cervical, Prostate, Bladder, Thymic carcinoid, Insulin-secreting, Leiomyosarcoma","Study eligibility included the following criteria: (a) patients with a solid tumor malignancy (leukemias and lymphomas excluded) documented by radiographic and histologic evaluation, refractory to standard therapy or for which no effective therapy is available, (b) age >=18 years, (c) estimated life expectancy >=3 months, (d) Eastern Cooperative Oncology Group performance status 0 to 2, (e) no chemotherapy, radiation therapy, immunotherapy, or hormonal therapy within 4 weeks of study start, (f) body weight >=45 kg, (g) adequate bone marrow, renal, and hepatic function defined by WBC >=3,000/mm3, absolute neutrophil count >=1,500/mm3, platelets >=100,000/mm3, hemoglobin >=9 g/dL, creatinine clearance >=50 mL/min, aspartate aminotransferase and alanine aminotransferase <=2.5 x upper limit of the laboratory normal, bilirubin <1.5 x upper limit of normal, and (h) a willingness to participate in this investigational study as indicated by signing an Institutional Review Board – approved informed consent. ","Patients were ineligible for study if any of the following exclusion criteria were present: (a) pregnant or lactating females, (b) > grade 1 neurologic abnormality, (c) HIV-positive status, (d) known allergy to sulfa medications, and (e) New York Heart Association class 3 to 4 cardiovascular disability status.",during the first cycle of therapy,NA
24916771,NA,Combination,No,patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck,"Inclusion criteria included patients with: metastatic KRAS codon 12 and 13 wild-type CRC or recurrent/metastatic HNSCC; measurable disease per RECIST 1.1; life expectancy>3 months; adequate hepatic, hematologic, and renal function; magnesium≥lower limit of normal; Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1; completed previous treatment (chemotherapy, surgery, or radiation) >4 weeks prior. Prior treatment with cetuximab or other EGFR-targeted therapies (e.g., panitumumab) was allowed.",Exclusion criteria included: presence of any medical/social factors affecting patient safety; pregnancy or breastfeeding; previous treatment with a PI3K inhibitor; known human immunodeficiency virus; known or suspected clinically active brain metastases; poorly controlled diabetes mellitus; and/or history of hypersensitivity reactions to cetuximab.,cycle 1,NA
33713742,NCT01674842,Combination,No,Patients with triple-negative breast cancer (TNBC) ,"Key eligibility criteria included TNBC (estrogen receptor nuclear staining positive of <10%, progesterone receptor nuclear staining positive of <10%; and HER2 0 or 1+ by immunohistochemical staining, or <2.0 by fluorescent in situ hybridization), and surgical excision of all gross disease with negative surgical margins. Any prior systemic therapy was allowed, either in the adjuvant or preoperative setting, excluding cisplatin or carboplatin. Patients receiving preoperative systemic therapy were required to have American Joint Committee on Cancer seventh edition clinical stage II or III disease at presentation and have residual invasive disease at the time of surgery. Patients receiving upfront surgery were required to have stage II or III disease",Pregnant or breastfeeding. Prior radiation to breast or ipsilateral regional nodes. Ongoing therapy with other investigational agents. Hormonal therapy. Significant co-morbidity. Pathologic complete response following preoperative chemotherapy. Biopsy proven metastatic disease,the 8-week observation period,NA
33135391,NCT02429466,Combination,No,Patients with metastatic GCTs,"Patients 18 years and older who had histologically or serologically confirmed recurrent, metastatic GCTs were eligible. Patients had measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) or  had increased and clearly rising GCT biomarkers (hCG or AFP). Patients had acceptable liver and kidney function and an Eastern Cooperative  ncology Group (ECOG)  performance status of at least 2.29 Patients also needed to be chemotherapy naïve for 3 weeks and have active disease that was platinum refractory. Platinum refractory disease was defined as progression while on cisplatin-based chemotherapy or within 6 weeks after completing  chemotherapy or after high-dose chemotherapy (HDCT). The criteria for refractory disease in our study were increased to 6 weeks from the typical 4 weeks to increase rate of recruitment","Exclusion criteria included active, symptomatic central nervous system metastasis, Grade 2 or greater neuropathy, and Tx with investigational agent within 30 days",weeks 1-18,NA
19169687,NA,Single Drug,No,Japanese patients with solid tumors. Twenty-nine patients were suVering from adenocarcinoma of the colon or rectum and the remaining patient had adenocarcinoma of the lung. ,"Only Japanese patients, aged between 20 and 74 years, with a histologically or cytologically conWrmed advanced solid EGFR-expressing tumor, refractory to a standard therapy or for which no standard therapy existed, were eligible. They required an Eastern Cooperative Oncology Group performance status of 0–2; a life expectancy of at least 3 months after the start of study; adequate hematological (leukocyte count: >=3,000 and <12,000 mm-3; neutrophil count: >=1,500 mm-3; platelet count: >=100,000 mm-3; hemoglobin: >=9 g/dL), hepatic (aspartate aminotransferase and alanine aminotransferase: <=2.5 times the upper limit of the reference range; serum total bilirubin: <=1.5 times the upper limit of the reference range), and renal (serum creatinine: <=1.5 times the upper limit of the reference range) function. Patients were required to be available for hospitalization until day 22 of the study, to have no carry-over eVect from prior therapy and to not have received treatment with blood transfusions, blood products or blood cell factors such as granulocyte colony stimulating factor during 2 weeks prior to enrollment. All patients gave their written informed consent prior to study entry","Patients were excluded if they had: symptomatic brain metastasis, a previous history of cancerous meningitis, poorly controlled epileptic seizures or clinically signiWcant mental or central nervous system disorders or if they had previously received monoclonal antibody therapy (including cetuximab). They were also ineligible if they had serious cardiac or cardiovascular disease, diabetes mellitus, hypertension, active infection or symptomatic blood coagulation disorder, acute pulmonary disorder, interstitial pneumonia, or pulmonary Wbrosis; active, double cancers; a previous history of malignant tumors (other than nonmelanoma skin cancer, uterine cervical carcinoma or gastrointestinal intramucosal carcinoma) with a sign of recurrence within the last 5 years; a large volume of pleural eVusion or ascites or were positive for hepatitis B virus, hepatitis C virus or human immunodeWciency virus. Patients were also excluded if they required chronic treatment with systemic steroids; were pregnant or lactating; if they wished to have a child; or if they had an alcohol or drug addiction or a previous history of drug allergy or anaphylactic symptoms.",6 weeks from the Wrst administration until 1 week after the Wfth administration,NA
22960004,NA,Combination,No,women with newly diagnosed locally advanced cervical cancer,"Patients with a histologic diagnosis of International Federation of Gynecology and Obstetrics (FIGO) clinical Stage IB–IVA with positive or negative pelvic and/or para-aortic lymph nodes by radiological eval- uation and GOG performance status of 0 or 1 were eligible. Patients with positive lymph nodes were enrolled to the extended field radiation cohort. Para-aortic lymph node involvement was confirmed with biop- sy or sampling. Standard laboratory criteria were met. Patients could not have received any prior treatment for their cervical cancer. All patients gave written informed consent before study entry in compli- ance with institutional, state, and federal regulations",NA,NA,NA
31486872,NA,Combination,No,patients with extensive-disease (ED)-small cell lung cancer (SCLC),"The patient eligibility criteria for this study were as follows: (1) a histologically and/or cytologically confrmed diagnosis of SCLC; (2) not having received any prior treatment for SCLC; (3) having LD, which was defned as disease limited in scope to one hemithorax according to positron emission tomography, with or without regional metastases, including ipsilateral hilar, bilateral mediastinal, or bilateral supraclavicular lymph node metastases; (4) not having any synchronous active malignancies; (5) being aged≤75 years; (6) having an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1; (7) exhibiting adequate organ function (a leukocyte count of ≥4000/µl, a hemoglobin level of ≥10.0 g/dl, a platelet count ≥10.0×104/µl, a serum total bilirubin of ≤1.5 mg/dl, hepatic transaminase levels of ≤2× the upper normal limit, and a serum creatinine level of ≤the upper normal limit); (8) having consulted with radiotherapy physicians and having been judged to have appropriate lung function levels that can be maintained even after radiotherapy prior to registration; and (9) providing written informed consent. ","The exclusion criteria were as follows: (1) being classifed with stage IA disease that was eligible for lobectomy; (2) exhibiting pericardial efusion with subjective symptoms; (3) displaying pleural efusion or malignant pleural efusion that was confrmed on a chest X-ray; (4) requiring emergency radiotherapy due to symptoms of superior vena cava syndrome; (5) having severe heart disease; i.e., (i) a history of uncontrolled angina, (ii) having sufered a myocardial infarction in the previous 3 months, or (iii) sufering heart failure; (6) having uncontrolled hypertension or diabetes mellitus; (7) having a severe infection; (8) being pregnant; or (9) experiencing complications that it was considered would interfere with the implementation of therapy.",during the frst 28 days of treatment,NA
20148348,NA,Single Drug,No,"Twenty seven patients with solid tumors were enrolled: five head and neck, three pancreas, four gall bladder, two each of prostate, breast, colorectal, lung, and esophagus, and five others.","Eligibility included patients with histologically or cytologically confirmed advanced solid tumors; age greater than 18 years; life expectancy of greater than 12 weeks; and performance status 0–2. Prior chemotherapy and/or radiotherapy must have been completed at least 4 weeks and 2 weeks respectively before study entry and all significant previous treatment-related toxicities had to be resolved. Patients with asymptomatic treated brain metastasis (surgical resection or radiotherapy) were eligible for this trial if they were neurologically stable and had been off steroids for at least 4 weeks. Required laboratory tests included adequate hematologic (absolute neutrophil count ≥1,500/uL, platelet count ≥100,000/uL), renal (serum creatinine ≤1.6 mg/dl or a calculated creatinine clearance ≥40 mL/min) and hepatic (serum bilirubin ≤2 mg/dL and aspartate aminotransferase [AST] within three times the institutional upper limit of normal) function",Patients who had previously received EGFR targeted therapy were excluded.,within the first cycle of treatment,NA
17203757,NA,Single Drug,No,"patients with soft tissue limb sarcomas. The tumor histology was: malignant fibrous histiocytoma (10 patients), liposarcoma (5), synovialsarcoma (2), angiosarcoma (1), alveolar soft part sarcoma (1) and leiomyosarcoma (1)","Patients between 18-70 years of age who met all of the following criteria were eligible for entry into the study: a) histologic documentation of the disease; b) advanced soft tissue sarcoma because of extracompartmental or  multicompartmental lesions, tumors with gross bone or nerve infiltration, or multiple lesions in the same limb; c) performance status(ECOG): 0; and d) informed consent.","Patients were excluded if any of the following criteria existed: a) severe cardiovascular, hepatic, orrenal disease; b) severe vascular disease of the involved limb; or c) limb tumor located in the proximal third of the thigh, too close to the inguinal ligament or gluteus.",NA,NA
29567334,UMIN000010369,Combination,No,head and neck squamous cell carcinoma in Japan,"Patients were eligible for inclusion if they had head and neck SCC that was treated with radical CCRT comprising whole- neck irradiation of the primary lesion and level II–IV lymph nodes on both sides. Additional criteria were age 20–75 years, an Eastern Cooperative Oncology Group performance status (PS) of 0 or 1, no previous chemotherapy, no complications or other cancer that might affect treatment of head and neck cancer, sufficient bone marrow function, no liver abnormalities, and creatinine clearance or estimated glomerular filtration rate (eGFR) >= 60 ml/min",NA,NA,NA
12460785,NA,Single Drug,No,"patients with advanced solid tumours. Tumour type: NSCLC 12, Colorectal 11, Gastric 8, Renal 7, Head and neck 6, Miscellaneous 25","Patients with a cytologically- or histologically-con- firmed diagnosis of a malignant solid tumour refractory to standard forms of therapy were eligible for thes studies provided that they met the following criteria: age 18–75 years; Eastern Cooperative Oncology Group (ECOG) performance status <=2; estimated life expectancy >=12 weeks; no previous anticancer therapy for at least 4 weeks (6 weeks for nitrosoureas, carboplatin or mitomycin C); no previous intensive ablative regimens; no more than two prior chemotherapeutic regimens for metastatic disease; and adequate haematopoietic (hae- moglobin >=6.2 mmol/l, absolute peripheral granulocyte count >=2.0x109/l and platelet count >=100x109/l), hepatic (bilirubin within normal limits, and serum aspartate aminotransferase and alanine aminotransfer- as <=42.5 times the upper normal limit) and renal (serum creatinine concentration < 133 mmol/l or creatinine clearance > 1 ml/s) functions. The left ventricle ejection fraction (LVEF), measured by either echo or multigated acquisition (MUGA) scan, should be within the limits of normal. All patients gave written informed consent before study entry.",NA,during course 1,NA
33262140,NCT01562210,Combination,No,patients with non-small cell lung cancer (NSCLC),"Patients with pathologically proven stage II/III inoperable NSCLC were eligible. To increase patient accrual, a protocol amendment allowed the enrollment of oligometastatic patients with a good response to induction chemotherapy and radical treatment of the oligometastasis (32) in the (SC)RT arm. Further inclusion criteria included World Health Organization (WHO) performance state 0–1, acceptable pulmonary function [forced expiratory volume in the first second (FEV1) ≥ 30% and diffusing capacity for carbon monoxide (DLCO) ≥ 40%], and signed written informed consent.",NA,until 1 year posttreatment,NA
19789325,NA,Combination,No,"patients with advanced solid tumors. Tumor type: GIST, Colon, Sarcoma, Melanoma, Rectum, Gastric, Mesothelioma, MPN sheath tumor, Ovary, Other (desmoid tumor, biliary tract, and small bowel (5D2) and adenoid cystic carcinoma, myoepithelioma, chordoma, squamous cell carcinoma of left pinna, meningioma, chromophobe renal cell carcinoma, medullary thyroid, and endometrial and breast (CDD))","All patients who entered into this study had a verified advanced solid malignancy, refractory to conventional therapy or for which there was no effective therapy. Eligible patients were ages ≥18 y with an Eastern Cooperative Oncology Group performance status of 0 to 1. They should not have received chemotherapy, immunotherapy, or radiotherapy within 4 wk of entering the study (6 wk for nitrosoureas, mitomycin C, and liposomal doxorubicin) and at least 2 wk must have elapsed since exposure to other kinase inhibitors. Eligibility criteria also included adequate hematologic, hepatic, and renal function6; serum potassium and magnesium within the institution's reference range; corrected serum calcium above the institution's lower limit of normal; and either a bleeding time that was less than the institution's upper limit of normal or a platelet aggregometry test within normal limits.","Patients were excluded if they had received prior radiotherapy to ≥25% of the bone marrow–containing skeleton or if they had uncontrolled or significant cardiovascular disease, known brain metastasis, prolonged QT syndrome or QTc >450 ms, history of a significant bleeding disorder, vasculitis, or a significant bleeding episode from the gastrointestinal tract in the preceding 6 mo. Patients who were pregnant or breast-feeding or who were of childbearing potential but unwilling or unable to use adequate contraception were also excluded. Prohibited medications included those known to increase the risk of Torsades de Pointes, irreversible inhibitors of platelet function, and anticoagulants",the first 28 d of drug administration,NA
33607477,NCT01946867,Combination,No,elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx,"This study was conducted at five sites in France and Spain. Eligible patients were >=65 years old, ineligible for cisplatin either because of age or contraindications as per the investigator’s opinion. The 65-year-old age limit was selected because it is unclear whether cetuximab improves outcomes in this population. Patients had to have histologically or cytologically confirmed LA- HNSCC of the oral cavity or oropharynx (independent of human papillomavirus (HPV) status), stage III or IVA disease as per AJCC guidelines (7th Edition, 2010), with no evidence of metastasis, as determined by positron-emission tomography. Patients had to have accessible tumour for injection, a Karnofsky performance status >=70 and adequate bone marrow, kidney, and liver functions.","The key exclusion criteria included prior RT to any area within the planned RT field, tumour-related dyspnoea, tumour ulceration which implies vascular risk or non-measurable disease as defined by RECIST 1.1 criteria.",NA,NA
21781226,NCT00339144,Single Drug,No,"Japanese patients with solid tumors. The primarytumors were breast cancer in four, colon or rectal cancer in six,soft tissue sarcoma in two (one gastrointestinal stromal tumor),renal cell carcinoma (RCC) in one, head and neck cancer in one,thymoma in one and ovarian cancer in one","Eligible patients were aged 20 years or older with an EasternCooperative Oncology Group performance status (ECOG PS) of0–2, and had a solid cancer, verified cytologically or histologi-cally, that was refractory to conventional therapy, or for whichthere was no established therapy. Patients were eligible if they had adequate bone marrow function (neutrophil  count >=2000⁄mm3, platelets >=125 000⁄mm3, hemoglobin >=9.0 g⁄dL),liver function (total bilirubin, aspartate aminotransferase [AST],alanine aminotransferase [ALT] <=two times the upper limit ofnormal), renal function (creatinine <=1.5 times the upper limit ofnormal) and serum potassium, magnesium and corrected cal-cium within the range of grade 0–1 of the National Cancer Institute Common Terminology Criteria for Adverse Events(CTCAE) v3.0. Patients should not have received chemotherapy, immunotherapy or radiotherapy within 4 weeks before the startof therapy (6 weeks if nitrosourea or mitomycin C and 2 weeksif endocrine therapy).","Patients were excluded if they had symptomatic brain metas-tasis, pleural effusion, prolonged QT syndrome or QTc prolon-gation of more than 450 ms, grade II or III atrioventricularblock, heart rate of <50 b.p.m., uncontrolled hypertension, history of a significant bleeding disorder, vasculitis, gastrointestinal bleeding within 6 months, recent ischemic heart disease or drug allergy. Patients who were pregnant or breastfeeding or those who were of childbearing potential but unwilling or unable touse adequate contraception were also excluded. Prohibited medications included those known to increase the risk of Torsades de Pointes, irreversible inhibitors of platelet function and drugsthat increase intra-gastric pH",during the first course ,NA
32464516,NCT02537223,Combination,No,patients with locoregionally advanced squamous cell carcinoma of the head and neck,"Eligible patients had untreated locoregionally advanced, non-me- tastatic SCCHN and were candidates for radical cisplatin-based CRT. Additional eligibility criteria included age ≥18 years, adequate organ function, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 and ability to swallow oral medication.","Exclusion criteria included prior chemotherapy or RT for SCCHN; tumors arising from the nasopharynx, skin or unknown site; prior treatment with agents tar- geting the PI3K pathway; and insulin-requiring or symptomatic diabetes mellitus or fasting glucose > 7.8 mmol/L. ",from the start of CRT until eight weeks after completion (total DLT period 15 weeks),NA
32994295,NCT02022098,Combination,No,Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck,"Patients aged 18–75 years with histologically confirmed, previously untreated LA-SCCHN [stage III, IVA, or IVB, per 7th Union for International Cancer Control/American Joint Committee on Cancer/ tumor–node–metastasis (TNM) classification] of the oral cavity, oropharynx (HPV negative by p16 IHC), hypopharynx, and/or larynx were eligible. Other inclusion criteria included smoking history of >10 pack-years, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and adequate hematologic, renal, hepatic, and cardiac function.","Key exclusion criteria included history of hepatitis B virus or hepatitis C virus infection, Child-Pugh class C, nasopharyngeal, paranasal sinus, nasal cavity, or unknown primary site, distant metastatic disease (M1), grade ≥2 peripheral neuropathy, or clinical hearing loss.",during the 9-week treatment period,NA
28679776,NCT01584284,Combination,No,Patients with Locoregionally Advanced Head and Neck Carcinoma,"Patients were eligible for enrollment if they had newly diagnosed, biopsy-proven, unresected stage III–IVB primary head and neck carcinoma, excluding p16-positive stage III–IVA (AJCC 7th edition) oropharyngeal cancer. Patients with p16-positive nonoropharyngeal cancer or stage IVB oropharyngeal cancer (p16 positive or p16 negative) were eligible. All patients were treated with definitive intent, not postoperatively. All patients with primaries of the salivary gland, paranasal sinus, and oral cavity had unresectable disease based on skull base or base of tongue involvement. Patients were required to be 18 years or older and have an Eastern Cooperative Oncology Group (ECOG) performance status <=2. Laboratory requirements for enrollment included absolute neutrophil count >= 1,800 cells/mm3; platelets >=100,000 cells/mm3; hemoglobin >= 8.0 g/dL; bilirubin <= 1.5 mg/dL; liver enzymes <= twice the upper limit of normal; serum creatinine <= 1.5 mg/dL; and international normalized ratio < 1.5.","Patients were ineligible if they had evidence of metastatic disease, any prior anticancer treatments (e.g., chemotherapy, radiation, or surgery), or any active immunosuppressive systemic infection, including HIV, AIDS, and hepatitis B or C. In addition, patients were excluded if they were on immunosuppressive therapy or had immune disorders, such as autoimmune disease, including clinically significant dermatologic disorders (e.g., eczema or psoriasis). Prior splenectomy, previous organ transplantation, and prior gene therapy or virus treatments were also grounds for exclusion",during treatment ,NA
21765046,NA,Combination,No,"patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck","Eligible patients had histologically confirmed NSCLC, prostate adenocarcinoma, and SCCHN. NSCLC patients were ineligible for resection with stage III and IV disease and, were unsuitable for radical radiotherapy and planned to be treated with palliative radiotherapy alone. Prostate cancer patients were locally advanced, as defined by a prostate- specific antigen (PSA) level >20, Gleason score of ‡7, or stage T3 or T4. Patients with head and neck squamous cell cancers had locally advanced tumours, stage III or IV. Inclusion criteria included age ‡18 years, World Health Organization performance status of zero to two, life expectancy of >12 weeks, minimum 4-week interval between prior chemotherapy, immunotherapy, and radiotherapy and receiving CA4P, and adequate renal, hepatic, and haematological function.","Patients were excluded if they had major surgery in the preceding 4 weeks, active brain metastases, grade 2 or greater peripheral neuropathy, clinically significant cardiac abnormality including uncontrolled hypertension, history of angina or myocardial infarction, arrhythmias, prolongation of QTc interval, symptomatic peripheral vascular disease or cerebrovascular disease.",NA,NA
16683074,NA,Combination,No,"patients with advanced solid tumors. Primary tumor: Prostate cancer, Soft tissue sarcoma, Renal carcinoma, Bone sarcoma, Ovarian adenocarcinoma, Other","Patients with histologically or cytologically confirmed advanced or metastatic malignant solid tumors were eligible for inclusion if, in the investigator’s opinion, they could benefit from irofulven/cisplatin combination therapy (e.g., chemotherapy naive patients with mesothelioma, or renal cell, prostate, unknown primary or hepatocellular carcinoma; platinum-naive patients with soft tissue sarcomas or breast, gastric, pancreas, biliary tract, hepatocellular or prostate carcinomas; platinum pre-treated patients (≥12 months platinum free interval) with bone sarcomas, ovarian, head and neck, bladder or esophageal cancer, SCLC, NSCLC). Patients were also required to have age ≥18 years; Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1; life expectancy >3 months; previous anticancer treatment discontinued at least 4 weeks prior to treatment initiation (6 weeks for mitomycin C); adequate organ function (white blood cell count (WBC) ≥3.0 × 109/L, absolute neutrophil count (ANC) ≥1.5 × 109/L, platelet count ≥150 × 109/L, hemoglobin ≥9 g/dL; bilirubin ≤1.25 times the upper limit of normal (ULN), aspartate transaminases (AST) and alanine transaminases (ALT) ≤2.5 ULN, prothrombin time ≥50% of control, serum albumin >25 g/L; creatinine clearance (calculated according to the Cockroft and Gault formula ) ≥60 mL/min); patients of reproductive age had to be using effective contraceptive methods and have a negative pregnancy test. ","Patients were ineligible in the following cases: prior radiation therapy to more than 35% of the bone marrow; prior therapy with nitrosoureas, high dose carboplatin (AUC >6), bone marrow transplant or intensive chemotherapy with stem cell support; prior mitomycin C cumulative dose ≥25 mg/m2; presence of any serious concomitant systemic disorders incompatible with the study (e.g., uncontrolled congestive heart failure, active infection); presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient’s compliance; history of another malignancy (other than cured basal cell carcinoma of the skin or cured insitu carcinoma of the cervix) within 5 years of study entry; treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to the study entry; pregnant or breastfeeding patients.",during the first 2 cycles,NA
17947485,NA,Combination,No,patients with previously untreated extensive-stage disease small cell lung cancer,"Eligible patients had histologically or cytologically confirmed SCLC and evidence of extensive-stage disease defined as either disease not encompassed in a reasonable radiation port or extrathoracic disease. Patients had to meet the following criteria: age of 18 to 70 years; Eastern Cooperative Oncology Group performance status of 0 to 2; no prior chemotherapy; bidimensionally measurable disease(s); total WBC count >=4,000/mm3; absolute neutrophil count >=1,500/mm3; hemoglobin >=9 g/dL; platelet count >=100,000/mm3; total bilirubin <=1.5 mg/dL; aspartate aminotransferase/alanine aminotransferase each <=2 times the upper limits of normal; and serum creatinine <=1.5 mg/dL or calculated (i.e.,Cockcroft-Gault equation) creatinine clearance >=60 mL/min.","Exclusion criteria were as follows: previous or concurrent malignancy (except nonmelanoma skin cancer, in situ carcinoma of the cervix or breast,or other cancer if the patient has been disease-free for 5 years),a serious medical or psychiatric illness preventing informed consent,or survival limited to <2 months. ",during the first cycle ,NA
21285987,NA,Single Drug,No,"patients with solid tumours. Primary tumor: Lung, Colon, Mesothelioma, Oesophagus, Pancreas, GIST, Melanoma, Renal cell","Patients with histologically confirmed advanced solid tumours, for which no standard therapy exists or has failed therapy, were eligible for enrolment in this study, provided that the following criteria were met: Eastern Cooperative Oncology Group performance status of <=2; age of >=18 years; life expectancy of at least 12 weeks; a normal haematological profile, renal function, hepatic function, and serum calcium level, no more than one previous course of Pt therapy, with maximum cumulative doses of 480 mg m-2 of cisplatin, 1040 mg m-2 of oxaliplatin, or 42 mg m-1 min-1 (min = minutes) cumulative area under the concentrationtime curve (AUC) of carboplatin, and no chemotherapy, no radiotherapy (except palliative radiation delivered to <20% of bone marrow), no immunotherapy, or no corticosteroids (greater than 10 mg per day of prednisone or equivalent) within 4 weeks before entering the study or patients who have not recovered from adverse events because of agents administered more than 4 weeks earlier.","Patients who had severe hypersensitivity to Pt compounds, ototoxicity assessed by audiometry (except senile hearing loss at high frequency) or other neurotoxicity X grade 2 were ineligible for enrolment in the study. Patients were excluded if they were pregnant or lactating.",in cycle 1,NA
21257722,NA,Combination,No,"Patients with advanced solid tumors. The cancers treated and patient numbers were colorectal (11), adrenal cortical (7), sarcoma (6), pancreas (4), melanoma (3), hepatocellular (3), gastric (3), Head & Neck 2, Cholangiocarcinoma 2, Ovarian 1, Bladder 1","Eligible patients were 18 years of age or more with a diagnosis of pathologically confirmed measurable or evaluable advanced solid tumor, with disease that was refractory to standard therapy or for which there was no standard therapy. Eligible patients had Karnofsky performance status of 70% or more, total white blood cell count 3,500/mm3 or more, absolute neutrophil count 1,500/mm3 or more, platelet count of 100,000/mm3 or more, hemoglobin of 9.5 g/dL or more, haptoglobin 30 mg/dL or more, and adequate hepatic and renal function. Patients may have received prior chemotherapy (including cisplatin) but 4 weeks from last dose had to elapse before study entry (6 weeks for nitrosoureas and mitomycin C). ",Patients with central nervous system metastases or a primary central nervous system neoplasm were not eligible.,during the first cycle (4 weeks),NA
16884375,NA,Combination,No,South African patients with cervical carcinoma,"The eligibility criteria were as follows. 1. Biopsy-proven untreated invasive carcinoma of the cervix. 2. FIGO stage IB2 through to IIIB without hydronephrosis undergoing radical pelvic radiotherapy. 3. Eastern Cooperative Oncology Group performance status 0–2. 4. Over 18 years of age. 5. Adequate renal function (calculated creatinine clearance of >=60 mL/min according to the Cockroft and Gault formula). 6. Reliability as regards follow-up procedures. 7. Hgb >= 10 g/dL, WBC >= 3.0 x 109/L, platelets >= 100 3 x 109/L and absolute neutrophil count >= 1.8 x 109/L. 8. Human immunodeficiency virus negative. 9. Signed consent.",1. Prior invasive cancer. 2. Medical contraindications to chemotherapy. 3. Prior pelvic irradiation and prior systemic chemotherapy.,during all treatment cycles,NA
25573383,NA,Combination,No,Patients with Head and Neck Squamous Cell Carcinoma,"This was a multi-institutional phase I single arm dose-escalation trial. It was approved and activated by the Institutional Review Boards of all participating centers. Eligibility included patients with stage III/IV locally advanced HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx and either (i) stage IV p16-positive tumor and >10 pack years smoking history, or (ii) stage III/IV p-16–negative tumor with evaluable disease by RECIST (version 1.1) criteria; no prior systemic therapy for the index cancer; age 18 years or greater; ECOG PS of 0–2; and adequate bone marrow function as denoted by absolute neutrophil count (ANC) >= 1,800/uL, platelets >= 100,000 uL, hemoglobin >= 8.0 g/dL, creatinine <= 1.5 x upper limit of normal (ULN), total bilirubin <= 1.5 x ULN, aspartate aminotransferase/alanine aminotransferase (AST/ALT) <= 2 x ULN.","Exclusion criteria included tumors of the nasopharynx and paranasal sinuses, and prior therapy targeted at EGFR, HER2, or HDAC for any indication. HPV status was determined by p16 immunohistochemistry (IHC). Patients were defined as HPV-positive in the setting of strong and diffuse nuclear and cytoplasmic staining of p16 in >=70% of tumor cells",the 7 weeks of combined modality therapy,NA
16619579,NA,Combination,No,"patients with advanced gastric cancer. Six patients had locally advanced gastric carcinomas. Of these, 4 had disseminations within the peritoneal cavity with ascites. Fourteen patients had measurable metastatic lesions. Abdominal lymph node metastases were seen in 8 of these patients, liver metastases were observed in 6 patients, lung metastases were seen in 3 patients and superficial lymph node metastases were found in 2 patients.","Patients with histologically verified gastric carcinoma, either locally advanced or metastatic, were eligible for the study. Other eligibility criteria were: age between 20-74 years, Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2, no chemotherapy treatment within 4 weeks prior to entry, adequate organ function (defined by white blood count (WBC) ≥4,000/ul, absolute neutrophil count ≥2,000/ul, platelet count ≥100,000/ul, hemoglobin ≥9.0 g/dl, serum bilirubin ≤1.5 mg/dl, serum transaminase no greater than 3 times the normal upper limit, serum creatinine ≤1.5 mg/dL), expected survival of greater than 3 months and written informed consent.",NA,during the first course of treatment,NA
21176985,NA,Combination,No,patients with locally advanced head and neck squamous cell carcinoma,"Before being included in the study, written informed consent was obtained from each patient. The main eligibility criteria were T2–T4 (UICC 2002), oropharynx, nasopharynx, hypopharynx, larynx or oral cavity non-operated squamous cell carcinoma, 18 year old or over, WHO performance status 0 or 1, weight loss less than 10% of body weight in the last two months, and laboratory tests compatible with the use of cisplatin (platelet count > 100 000/ll, neutrophiles > 2500/ll, hemoglobin level > 10 g/100 ml, creatinine serum level < 110 lmol/l). Patient should be able to swallow capsules. ","A patient was considered unsuitable for inclusion in case of prior treatment with cisplatin within five weeks of study start, having symptomatic hearing loss, mal-absorption disease and history (within one year) of ongoing gastroduodenal ulcer",throughout the course of radiotherapy and during the follow-up period (2 weeks after completion of radiotherapy). ,NA
9740093,NA,Combination,No,patients with peritoneal carcinomatosis. The most common histology was colon carcinoma (41%). Five retroperitoneal and intraperitoneal sarcoma patients were included.,N/A,N/A,NA,NA
11020576,NA,Combination,No,women with locally advanced cervical cancer,"Patients eligible for inclusion on this trial included the following: cervix cancer patients with bulky Stage IB and IIA, all Stages IIB–IVA, Stage IVB (PA nodes only), life expect- ancy of greater than 6 months, nonpregnant, performance status of 3 or less (ECOG), signed informed consent, and no contraindication to RT, cisplatin, or TPZ",NA,NA,NA
27110950,UMIN000005585,Combination,No,patients with inoperable stage III non-small cell lung cancer (NSCLC),"Eligible patients were required to have histologically or cyto-logically proven inoperable stage IIIA or IIIB NSCLC asdefined in the TNM Classification of Malignant Tumors (6thedition), no previous chemotherapy or radiation therapy, a per-formance status of 0–1 on the Eastern Cooperative OncologyGroup scale, adequate bone marrow reserves, as well as nor-mal liver and renal function.","Patients were excluded if theyhad malignant pleural or pericardial effusion, supraclavicularlymphnode metastasis, active secondary cancer, or a concomi-tant serious illness that contraindicated chemotherapy or PBT.",within 1–90 days from the start ofradiotherapy,NA
20801016,NA,Single Drug,No,"patients with solid tumours. Tumour type: Breast 2 (11), Melanoma 2 (11), Oesophagus 2 (11), Prostate 2 (11), Parotic carcinoma 2 (11), Oro-/hypopharyngeal cancer 2 (11), Urothelial carcinoma 2 (11), Other 4 (22)(Adenoid cystic carcinoma, cancer of unknown primary, non-small-cell lung cancer, sarcoma)","Eligibility included a histological- or cytological- documented locally advanced or metastatic solid tumour refractory to standard therapy or for which no effective therapy existed and ECOG performance status 0–2. Required laboratory values included: absolute neutrophil count >=1.5 x 109/L, platelet count >=100 x 109/L, haemoglobin >=9 g/dL, total bilirubin <=1.5 x ULN, alkaline phosphatase <=2.5 x ULN, creatinine and blood urea within normal limits, unless creatinine clearance was >=60 mL/min calculated according to Cockcroft–Gault formula, aspartate aminotransferase and alanine aminotransferase <=2.5 x ULN, or <=5 x ULN in case of liver metastases.",NA,NA,NA
20855460,NA,Combination,No,Patients with platinum-refractory or platinum-resistant epithelial ovarian cancer,"Patients were ≥18 years of age with histologically confirmed epithelial ovarian, fallopian, or primary peritoneal carcinoma, and measurable disease evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) or clinical signs/symptoms and an elevated CA-125. Eligible patients must have experienced disease progression within 6 months of last platinum therapy. A Karnofsky performance status of ≥70%, life expectancy of ≥3 months, and adequate hematologic, renal, pulmonary, and hepatic function were required. The protocol received Institutional Review Board approval at Memorial Sloan-Kettering Cancer Center, and all patients were required to provide written informed consent.","Patients were ineligible if they had central nervous system tumor involvement, evidence of other active malignancy, or ascites of ≥500 mL. Patients with active serious systemic disease, including asthma or heart disease, were excluded. Chemotherapy, biological therapy, or immunotherapy within 3 weeks before enrollment, or a history of immune or allergic reaction or documented human antihuman antibodies were also exclusion criteria.",within 5 weeks of initiating therapy,NA
16937305,NA,Combination,No,Japanese patients with cancer of the uterine cervix,NA,NA,NA,"Primary CCRT was indicated in 2 patients with stage IIb cancer, 19 patients with stage IIIb cancer, and 4 patients with stage IVa cancer, postoperative adjuvant CCRT was indicated in patients with the following conditions: positive pelvic lymph-node metastasis, positive parametrial invasion, positive peritoneal cytology, positive lymph-vascular invasion, and positive surgical margin. "
10427950,NA,Combination,No,patients with squamous cell carcinomas and transitional cell carcinomas of the urogenital tract ,"Patients had to have histopathologically proven squamous cell carcinoma of any origin or transitional carcinoma of the urogenital tract which was not amenable to curative therapy with measurable disease, a Zubrod  performance status of <=2, 20 to 75 years of age, no concomitant anticoagulation, bilirubin <=25umol/l, ASAT and ALAT <=2 x the normal upper limit, serum creatinin <=120 umol/l, normal cholesterol and triglyceride levels, granulocyte count >=1 500/mm3 and platelets >=100 000/mm3. Patients should neither have active CNS metastasis, nor havereceived IFN-a or have been given any other retinoid previously. Written informed consent was also required",NA,the first cycle,NA
16754599,NA,Combination,No,"patients with advanced, recurrent or progressive ovarian carcinoma","Patient eligibility included those with either measurable or assessable disease Stage III or IVepithelial ovarian cancer with recurrent disease or disease which was initially refractory tostandard cisplatin-based therapy. Patients were required to have macroscopic disease >=1 cma nd were stratified with respect to being 1–2 cm vs >2 cm. Patients were also requiredto have no serious underlying co-morbid diseases likely to limit survival or prevent protocoltreatment such as pneumonia, sepsis or other serious infection. They were required to havenormal renal, cardiac, hepatic and pulmonary functions and a GOG performance statusof 0, 1 or 2. ",NA,NA,NA
18600301,NA,Combination,No,"patients with refractory solid tumors. Type of cancer Pancreatic, Lung NSCLC, Lung SCLC, Ovary, Breast, Cervix, Sarcoma, Melanoma, Renal, Unknown, Colon, Bladder, Nasopharynx, Gall bladder, Esophagus, Uterus ","Patients 18 years of age or older, with histologically proven cancer not amenable to curative therapy or who had failed standard chemotherapy regimens were eligible for the study if the following criteria were met: (1) performance status of 0 to 2 according to the Eastern Cooperative Oncology Group Performance Status Scale; (2) expected survival of greater than 12 weeks; (3) adequate bone marrow function (granulocyte count of 1,500/mm3 or more, platelet count of 100,000/mm3 or more, and absence of a regular red blood cell transfusion requirement; normal renal and hepatic functions (serum bilirubin concentration lower than 2 mg/dl; and SGPT lower than twice the upper limit of normal); (4) no known allergy to camptothecins; (5) evaluable or measurable disease; and (6) signed informed consent. ","Patients were excluded if their disease was amenable to attempted curative therapy; if they had known symptomatic central nervous system metastases, other serious illness, or psychiatric condition; if they received concurrent treatment with other experimental drugs or other anti-cancer therapy; or if they were pregnant, lactating, or not using effective contraception.",during the first course of therapy,"patients in arm 1 were treated with at the single agent recommended dose of cisplatin (50 mg/m2), and increasing doses of 9NC and in arm 2 with the single agent recommended dose of 9NC (1.5 mg/day) and increasing dose of cisplatin"
28466360,UMIN000015595,Combination,No,patients with advanced CD44v-positive gastric cancer (AGC),"Main inclusion criteria included (1) the presence of histopathologically proven unresectable or recurrent gastric adenocarcinoma, (2) the presence of an archival tumor specimen with CD44v-positive cells, (3) the presence of a biopsiable tumor before and after one cycle of treatment, (4) disease progression during or within 3 months after previous treatment with cisplatin for AGC, and (5) adequate general status or organ function, as in our previous study",Patients with a history of severe adverse events with cisplatin were excluded. ,cycle 1,NA
20606530,NA,Combination,No,patients with locally advanced cervical cancer,"Patients were required to have histologically proven squamous cell carcinoma or adenocarcinoma of the cervix, stages IB2, IIA, IIB, III, or IVA, no prior treatment of an invasive cervical cancer, no prior chemotherapy, and no prior pelvic or abdominal radiotherapy. The other eligibility criteria were the following: Eastern Cooperative Oncology Group (ECOG) performance status, zero to 2; absolute neutrophil count, 1.5 x 109/L or more; platelet count, 100 x 109/L or more; total bilirubin level, less than 1.25 times the upper limit of the reference range; aspartate amino transferase (AST)/alanine amino transferase (ALT), <=3 times the upper limit of the reference range; calculated creatinine clearance (using the Cockcroft-Gault formula19), >=60 mL/min. Written informed consent was obtained from all patients, and the institutional ethics committees approved the protocol.","Patients were excluded from the trial for any of the following reasons: other invasive malignancies in the last 5 years; evidence of involvement of para-aortic nodes (but not common iliac nodes) based on computed tomography (CT), magnetic resonance imaging (MRI), 2-deoxy-2-[18F]fluoroD-glucose positron emission tomography (FDG-PET), or lymphadenectomy; symptomatic peripheral neuropathy, grade 2 or higher; significant cardiac disease resulting in an inability to tolerate the intravenous fluid load as required for the administration of cisplatin; clinically significant sensorineural hearing impairment that interfered with activities of daily living or required a hearing aid; and any uncontrolled intercurrent illness.",during weeks 1 to 5,NA
20480279,NA,Combination,No,"patients with advanced solid tumors. Primary diagnosis: SCCHN 11, Cervical cancer 5, Endometrial cancer 2, Leiomyosarcoma 2, UndiVerentiated hypopharynx 1","Inclusion criteria common to both parts of the study were: age of at least l8 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; life expectancy of at least 3 months; adequate baseline organ function deWned as absolute neutrophil count (ANC) >= 1,500 x 109/L, platelets >= 100,000 x 109/L, hemoglobin >= 10 g/dL, liver transaminases <= 3 x upper limits of normal (ULN) (in case of liver metastasis <=5.0 x ULN), total serum bilirubin <= 1.5 x ULN, serum albumin >= 3 g/dL, serum creatinine <= 1.25 x ULN, alkaline phosphatase <= 2.5 x ULN; negative serum pregnancy test; signed written informed consent and adequate treatment compliance.","The main speciWc inclusion criteria in the dose escalation part of the study included histologic or cytologic conWrmation of any squamous cell carcinoma subsequently amended to all tumors; recurrent/metastatic disease after failure of one or more standard therapy lines and a cumulative dose of cisplatin not higher than 475 mg/m2, prior to enrollment. ",during cycle 1,NA
26414837,NA,Combination,No,Patients With Advanced Esophageal Carcinoma,"Patients aged 20 to 75 years with a measurable target lesion pathologically confirmed as squamous cell carcinoma (SCC) or adenocarcinoma, which was surgically unresectable or recurrent, were eligible. They also had to have an ECOG performance status of 0, 1, or 2, a life expectancy of >12 weeks, and adequate liver, bone marrow, renal, and cardiovascular function (serum bilirubin <=1.5 mg/dL; neutrophil count, 2000/mm3; serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=1.5 times the upper limit of normal; alkaline phosphatase (ALP) 2.5 times the upper limitof normal, platelet count >10 x 104/mm3; hemoglobin 9.5 g/dL; and creatinine 1.2 mg/dL. The last chemotherapeutic treatment had to be at least 4 weeks before trial enrollment.","Patients were excluded for the following reasons: known sensitivity to DOC, CDDP, 5-FU, or polysorbate 80; presence of other severe diseases, including malignant hypertension, severe heart failure, liver failure, and liver cirrhosis; inadequately controlled diabetes mellitus or bleeding disorders; current infectious disease with fever; presence of motor paralysis, peripheral neuropathy, or severe edema; pleural effusion or cardiac effusion needing treatment; presence of multiple primary cancers; pregnancy, or breast feeding; presence of interstitial pneumonia on chest X-rays or CT, or pulmonary fibrosis; known psychosis or neurologic manifestations, or patients considered unlikely to fully cooperate in the study; and patients deemed inappropriate for the study by the investigator for any other reason.",the first 2 treatment cycles,NA
21220472,NA,Combination,No,"patients with advanced solid tumors. Primary tumor: Ovarian, Pancreas/biliary, Mesothelioma, NSCLC, Colorectal, Prostate, Endometrial, Gastric, Breast, Sarcoma, Kidney, Melanoma, Neuroendocrine, Esophageal, Salivary gland, Cervix","Inclusion criteria included: pathologically confirmed, locally advanced, or metastatic solid tumors, refractory to standard therapy or for which conventional therapy is not reliably effective; age 18 or more years; Eastern Cooperative Oncology Group Performance Score (ECOG PS) 0 to 2 (0–1 for the combination study); life expectancy more than 3 months; adequate organ function [hematological (absolute neutrophil count >=1.5 x 109 cells/L, platelets >=100 x 109/L, hemoglobin >=9 g/dL, INR <=1.5 x ULN); hepatic (bilirubin <=1.5 x ULN, ALT-AST <=2.5 x ULN); renal (serum creatinine <1.5 mg/dL, creatinine clearance >= 60 mL/min); metabolic (serum potassium, calcium, and magnesium >=LLN); and cardiac (CPK-MB, CPK-MM <=ULN, and troponin I within normal values)]; signed informed consent. ","Exclusion criteria included: previous anticancer treatment less than 4 weeks prior to first dose of study treatment (6 weeks for mitomycin C and antiandrogen therapy, 8 weeks for bicalutamide); patients with active central nervous system metastasis, patients with evidence of peripheral neuropathy of greater than grade 1 severity (combination study only).",during the first 2 cycles ,NA
16418184,NA,Combination,No,patients previously treated for advanced non-small cell lung cancer,"Patients with either cytologically or histologically confirmed advanced NSCLC who demonstrated disease progression either during or after a prior chemotherapy were eligible. The eligibility criteria also included the following factors: an age ranging from 20 to 75 years; an Eastern Cooperative Oncology Group performance status <=1; a life-expectancy of >=3 months; no chemotherapy or radiation therapy within 4 weeks of treatment; an adequate hematopoietic status [absolute neutrophil count (ANC) >=2000/ul, hemoglobin level >=10 g/dl, platelet count >=100 000/ul], hepatic (transaminases <=2 x institutional normal upper limit, total bilirubin <=1.5 x institutional normal upper limit) and renal(creatinine <= institutional normal upper limit) functions; either measurable or evaluable but nonmeasurable disease such as numerous small sized pulmonary metastases, PaO2 >= 60 torr; and left ventricle ejection fraction of 60% or more based on ultrasound cardiogram. Patients gave their written informed consent before treatment.",NA,during the first course of the treatment,NA
12695856,NA,Combination,No,"patients with advanced malignancies. the tumor types included: lung cancer (13), adenocarcinoma of unknown primary (5), gastrointestinal or hepatobiliary tract cancer (21), gynecologic cancer (4), breast cancer (6), head and neck cancer (7), kidney/adrenal cancer (2) and soft tissue sarcomas (3).","Entered into this phase I study were 61 patients. Eligibility requirements included: advanced inoperable malignancy which was histologically confirmed and unresponsive to previous chemotherapy regimens, or for which no ‘‘standard’’ chemotherapeutic regimen existed. Previous treatment with platinum compounds did not disqualify patients from treatment on this protocol if they had recovered from toxicity attributable to previous therapy. The presence of CNS metastases, either previously treated or asymptomatic, also did not exclude a patient from entry. Patients were required to be at least 18 years of age.","Pregnant women were ineligible. Patients with any nonmalignant intercurrent illnesses (e.g., cardiovascular, pulmonary, or neurologic) which was either poorly controlled with currently available treatment or of such severity that the investigators deemed it unwise to enter the patient into this study were ineligible. Patients currently being treated for severe infection, or who were recovering from major surgery, were ineligible until recovery was complete",one complete course with a 14-day follow-up,NA
26891913,NA,Combination,No,pateints with the locally advanced oesophageal squamous-cell carcinoma (ESCC),"Eligibility criteria included patients with ESCC confirmed byhistopathology who had received CCRT and RT, from Stage IIA toIVA with bidimensionally measurable sites. They were required tobe 18–70 years of age, with Karnofsky performance status >=70 and weight loss <=5%. The minimum laboratory requirementswere as follows: absolute white blood cell count >=4000 ml-1 or greater, haemoglobin >=10 g dl-1 or greater, platelet count >=1,00,000 per ml, total bilirubin level <=1.5 mg dl-1, serum creatinine level <=1.5 times the upper limit of normal or less and aspartate/alanine aminotransferase levels <= 2.5 times the upperlimit of normal or less. ","Exclusion criteria included patients with metastatic sites, imaging or bronchoscopic evidence of oesophageal perforation andsome other serious underlying medical conditions which might potentially interrupt the planned treatments; for instance, severecardiac diseases or uncontrolled diabetes, serious uncontrolled infections, central nervous system disorders or psychological disability. Patients were also excluded if they had previously received chemotherapy or RT.",during CCRT,NA
15589600,NA,Combination,No,patients with cervical carcinoma,"Eligibility criteria for postoperative radiation included the presence of at least one of the following: positive pelvic lymph node metastasis, a positive surgical margin, deep stromal invasion, and parametrium invasion. The following were the other inclusion criteria: (1) aged <= 75 years; (2) ECOG performance status <= 2; (3) no previous chemotherapy or radiotherapy; (4) leukocytes >= 3000/mm3; (5) neutrophils >=2000/mm3; (6) platelets >= 100,000/mm3; (7) serum crea- tinine <= 1.5 mg/dl; (8) normal chest radiograph and electrocardiogram; and (9) informed consent.",Patients with either disease outside the pelvis or para-aortic lymph node swelling were not eligible. ,during the RT,NA
22994941,UMIN-CTR 000003541,Combination,No,patients with hepatocellular carcinoma,"Patients with HCC were considered eligible for the study if they fulfilled the following criteria: 20–80 years of age; at least one measurable tumour blush on angiography; histologically and/or clinically diagnosed HCC; no other therapeutic treatment was found to be effective or appropriate to their condition, according to the Japanese guidelines for HCC treatment; an Eastern Cooperative Oncology performance status of 0–2; adequate hepatic function (Child–Pugh, score ≤7; total bilirubin, ≤3.0 mg/dl; albumin, ≥3.0 g/dl); adequate haematological function (neutrophils, ≥1,500/mm3; platelets, ≥50,000/mm3; haemoglobin, ≥8.0 g/dl); adequate renal function (creatinine clearance, ≥50 ml/min adjusted for 1.73 m2 of body surface area); serum amylase, ≤324 IU/dl and an interval of 4 weeks or more since previous therapy. All nodules were radiologically diagnosed as HCC when they satisfied at least one of the following criteria based on CT or MRI: typical haemodynamics of classical HCC (substantial enhancement during arterial phase followed by a washout with ‘corona-like’ peripheral enhancement in equilibrium phase) and similar characteristics of coexisting nodules that had been diagnosed as HCC. All eligible HCC cases were recurrent with a history of CDDP administration in eight patients.",Patients with the following characteristics were considered ineligible: massive pleural effusion and/or ascites refractory to treatment; active cancer other than HCC; active infectious disease; active haemorrhagic state; severe mental disorder; hepatic encephalopathy; history of allergic reaction to iodine phase contrast and/or platinum agents; ongoing interferon therapy and difficulty with oral food intake. ,NA,NA
10847466,NA,Combination,No,patients with carcinoma of the cervix uteri,"Women with a histologically proven diagnosis of carcinoma of the uterine cervix, FIGO stage IIB to IVA or with pelvic disease recurrent after surgery were eligible, if they fulfilled the following criteria: aged <= 70 years, ECOG performance status <= 2, no previous chemotherapy or radiotherapy, leukocytes >=4000/mm3, platelets >= 100,000/mm3, serum creatinine <1.5 mg/dl. All patients were evaluated by clinical examination and hematological and biochemical assessment and were staged with two-view chest X-rays, magnetic resonance or computed tomography of the pelvis, cystoscopy and rectosigmoidoscopy, bone scan and X-ray details of the hot-spots",NA,during the treatment (6 weeks),NA
16575008,NA,Combination,No,patients undergoing pleurectomy for malignant pleural mesothelioma (MPM),"Eligible patients had a diagnosis of MPM confirmed by immunohistochemistry and electron microscopy on an open pleural biopsy. All pathology was examined by a mesothelioma review panel at a single institution. All patients were evaluated with a complete medical history, physical examination, computed tomography of the chest and upper abdomen, magnetic resonance imaging of the chest, serum chemistry and hematology, pulmonary function testing, and doppler echocardiography.19Patientswere enrolled onto this study if surgical cytoreduction was determined to be tolerable and technically feasible.","Patients with clinical or radiographic evidence of Brigham stage III or IV MPM were ineligible. Eligible patients were offered enrollment onto the study, andinformed consentwas obtainedin anintent-to-treat design",within 30 days of the procedure,NA
27878356,NCT00024323,Combination,No,patients with advanced-stage solid tumor malignancies,"The trial was open to women and men 18 years of age or older who had a diagnosis of a measurable advanced-stage malignancy refractory to standard therapy or for which no curative therapy existed. Patients must have had an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; a life expectancy greater than three months; adequate kidney, liver, and bone marrow capacity as determined by laboratory assessment; and be practicing adequate contraception or abstinence. Female patients of childbearing potential must have had a negative pregnancy test within two weeks before study drug administration. Patients must not have had active infections, severe hearing impairment, active central nervous system metastases, presence of any other life-threatening illnesses, prior severe allergic reaction to cisplatin, or poor nutrition (i.e., albumin < 2.5 g/dL). Participants must have had prior treatment for their malignancy, meaning at least 3 weeks of convalescence after prior surgery, last dose of chemotherapy, and/or last dose of radiation therapy. This also included at least 2-week recovery from hormonal therapy or biologic anticancer therapy. Persistent toxicities from prior therapies must not have been greater than grade 1. Patients must not have had cisplatin or platinum analog within three months of starting study drug administration. Patients whose prior therapy included triapine were not re-challenged with a triapine–cisplatin treatment. All patients must have provided written informed consent prior to initiating trial treatment",NA,at cycle 1,NA
15653702,NA,Combination,No,previously untreated patients with extensive-stage small-cell lung cancer,"Patients with histologically and/or cytologically documented SCLC were eligible for this study. Each patient was required to meet the following criteria: extensive-stage disease ; no prior therapy for primary lesion; measurable lesion; Eastern Cooperative Oncology Group (ECOG) per- formance status (PS) 0–2; expected survival time >2 months; age 20 –74 years; adequate hematological function [white blood cell (WBC) count 4000– 12 000/mm3, neutrophils >= 2000/mm3, platelets >= 100 000/mm3, hemoglobin >= 10 g/dl]; adequate hepatic function [total bilirubin within 1.5 x the upper limit of normal; aspartate aminotransferase (AST) and ala- nine aminotransferase (ALT) within 2.5 x the upper limit of normal]; adequate renal function (creatinine within the upper limit of normal); partial pressure of arterial oxygen 60 torr; no abnormality requiring treatment on electrocardiogram; left ventricle ejection fraction >60%; written informed consent","Patients with symptomatic brain metastasis, pleural effusion that required drainage, non-steroidal anti-inflammatory drug or glucocorticoid use for >50 days, pericarditis carcinomatous, active infection, varicella, superior vena cava syndrome, syndrome of inappropriate secretion of anti- diuretic hormone (SIADH), gastric and/or duodenal ulcer, severe heart disease, severe renal disease, active concomitant malignancy, symptomatic pneumonitis and/or pulmonary fibrosis and pregnant/nursing women were excluded.",the first course of chemotherapy,NA
22922041,NA,Single Drug,No,Patients with Unresectable Hepatocellular Carcinoma,"Patients were considered for enrollment if they had (i) unresectable bilobar multifocal HCC (or multifocal recurrent HCC in the remnant liver after surgery) confirmed by histologic examination or diagnostic imaging; (ii) measurable hypervascular lesions confined to the liver that showed early enhancement on contrast-enhanced dynamic computed tomography (CT); (iii) no tumor thrombus in the first branch or main trunk of the portal vein; (iv) no extrahepatic metastases; (v) Eastern Cooperative Oncology Group performance status of 0, 1, or 2; (vi) Child–Pugh classification of A or B; (vii) no lingering effect of any previous treatment (at least a 4-wk interval from most recent treatment); (viii) adequate bone marrow, renal, and cardiac function demonstrated by laboratory test results obtained within 2 weeks of signing the study consent (ie, leukocyte count >= 3,000 mm2, platelet count >= 50,000/mm3, hemoglobin level >= 9.5 g/dL, serum creatinine level no greater than the upper limit of normal range, blood urea nitrogen level <= 25 mg/dL, and no abnormality on electrocardiogram); (ix) age at least 20 years and younger than 75 years; and (x) life expectancy of at least 8 weeks.","Patients were excluded from the study if they had (i) previous transarterial chemoembolization with a platinum-containing drug; (ii) an extrahepatic collateral tumor supply suspected or confirmed by contrast-enhanced CT or previous angiography; (iii) previous surgical bile duct reconstruction or endoscopic sphincterotomy; (iv) lymph node or other distant metastases; (v) severe comorbidity including cardiac failure, myocardial infarction, pulmonary fibrosis, interstitial pneumonia, intractable diabetes mellitus, or renal failure; (vi) an active infection except for viral hepatitis; (vii) another concurrent malignancy; (viii) a known allergy to iodinated contrast media, platinum-containing drugs, or gelatin-containing drugs or foods; (ix) pregnancy or lactation; or (x) any condition judged by the investigators to potentially jeopardize patient safety or compliance with the study protocol",NA,NA
10561301,NA,Combination,No,patients with advanced squamous cell carcinomas of the head and neck,"Patients were required to have histologic evidence of squamous cell carcinoma from a mucosal head and neck site. Nasopharyngeal primary tumors were excluded. Only patients with stage III or IV disease were eligible, and patients with distant metastases were excluded. Patients were required to have a Zubrod performance status score of less than or equal to 2, and those with a prior history of cancer, excluding early skin cancer (defined as stage I or II basal or squamous cell carcinomas of the skin), were ineligible. Minimum laboratory criteria required included an absolute granulocyte count of more than or equal to 1,500 cell/mL, a platelet count of more than or equal to 100,000 cells/mL, a bilirubin count of less than or equal to 1.5 mg/dL, an AST level no more than four times the upper limit of normal, and a serum creatinine level of less than or equal to 1.5 mg/dL",NA,NA,NA
19723113,NA,Combination,No,patients with recurrent epithelial ovarian cancer,"Patients were enrolled into the current study if they were ≥18 and ≤70 years old;had histopathological confirmation of epithelial ovarian cancer; had received first-linechemotherapy with platinum-based regimensbut had been treated with ≤2 regimens; had recurrent disease after the completion of chemotherapy or progressive disease during treatment, as measured radiologically by com-puted tomography scan or by serum CA-125 level (i.e.,>50 U/mL on two previous occasions at least 1 week apart); had an Eastern Co-operative Oncology Group performance status≤1; and had anticipated survival≥3months.The time since the last chemotherapy, surgery,hormonal  therapy,  immunotherapy, or radia-tion therapy had to be at least 4 weeks. Laboratory criteria included white bloodcell (WBC) count≥3500/mm3, absolute neutrophil count (ANC) ≥1500/mm3, plateletcount ≥100,000/mm3, hemoglobin level ≥9.0g/dL, serum total bilirubin level ≤1.5 mg/dL,serum transaminase level less than three timesthe upper limit of normal (ULN), alkaline phosphatase level less than three times ULN, serumcreatinine level ≤1.5 mg/dL, and creatinine clearance ≥60 mL/min.",NA,from day 1 to 14,NA
23692812,NCT00359359,Combination,No,chemotherapy-naive patients with metastasised small-cell lung cancer,"Eligibility criteria included histologically confirmed, metastasised SCLC including at least one unidimensionally measurable lesion. Patients were chemotherapy-naive and radiotherapy was allowed only for brain metastases, but completed at least 3 weeks before study entry. Other eligibility criteria included age >=18, Eastern Cooperative Oncology Group (ECOG) performance status of 0/1, no surgical resection within 4 weeks prior inclusion and estimated life expectancy >=12 weeks. Laboratory requirements were haemoglobin >=10 g/dl, WBC-count >=3000/mm3, absolute neutrophil count =1500/mm3, platelets >100,000/mm3, serum bilirubin <=1.5x the institutional upper limit, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.5x the institutional upper limit or 5x in case of liver metastases and creatinine clearance >=60 ml/min. Patients with brain metastases had to be asymptomatic or stable following surgery or/and radiotherapy.","Patients were excluded, if baseline neuropathy was >=grade 2, with any history of uncontrolled intercurrent illness (e.g. infection, cardiovascular events or mental disorders) or if pregnant, breast feeding or without agreement for adequate birth control measures.",during the first treatment cycle,NA
11821794,NA,Single Drug,No,patients with locally advanced gastric cancer ,"Patients who were eligible for entry into this trial had histologically confirmed gastric adenocarcinoma with macroscopic serosal invasion that was resectable at first operation. Additional eligibility criteria included an age of less than 75 years, an Eastern Cooperative Oncology Group performance status of 2 or lower (ambulatory and capable of self-care), an estimated life expectancy of 6 months or more, no concomitant severe cardiovascular disease or second malignancy, a white blood cell count greater than 3000/mL, a platelet count greater than 100,000/mL, a serum creatinine concentration of 1.5 mg/dL or less, and a total bilirubin level of less than 2 mg/dL. In addition, patients had no prior abdominal radiotherapy and no systemic or intraperitoneal chemotherapy before operation. Informed consent was obtained from each patient",NA,NA,NA
7911736,NA,Single Drug,No,"patients with solid tumors. Seven patients with colon cancer, three with lung, two with rectal, and one each with chondrosarcoma, pancreatic adenocarcinoma, renal cell cancer, gastric cancer, small bowel adenocarcinoma, and anaplastic astrocytoma were treated","All patients were required to have a solid tumor that was refractory to standard therapy or one for which no standard therapy existed. All patients were required to have adequate bone marrow function, as manifested by a leukocyte count of more than 3500/u1 and a platelet count of at least 100,000 cells/ul; an Eastern Cooperative Oncology Group performance status of 0, 1 or 2; a serum bilirubin concentration of less than 1.6 mg/dl; a serum creatinine concentration of no more than 2.0 mg/dl; a serum glutamic oxaloacetic transaminase concentration of no more than three times the normal value (unless caused by hepatic metastases); and a serum calcium concentration of no more than 12 mg/dl. Patients were required to be free of significant local or systemic infection at the onset of the study, off cytotoxic therapy for 4 weeks (6 weeks for mitomycin C, nitrosoureas, or melphalan) before starting cladribine, and were required to have no evidence of central nervous system (CNS) metastatic disease. Patients had to be at least 18 years of age. Women could not be pregnant and were advised to practice birth control if they were fertile. Written informed consent was obtained from all patients according to federal and institutional guidelines.",NA,during Cycle 1,NA
34787778,NCT00977431,Combination,No,patients with newly diagnosed glioblastoma,"Eligible patients were aged ≥18 and<70 years, with newly-diagnosed, histologically-confrmed World Health Organization grade 4 malignant glioma and proven MGMT gene promoter methylation status (or tumor material available for testing).","Exclusion criteria included: surgery within 2 weeks prior to the start of treatment or planned during the trial; placement of a Giladel® wafer at surgery, prior radiotherapy of the cranium (including brachytherapy and/ or radiosurgery for GBM); and treatment with other investigational drugs concomitantly with the study.",during the 6-week RT phase,NA
32866424,NCT02378532,Combination,No,patients with a newly diagnosed glioblastoma,"The main inclusion criteria were histologically confirmed newly diagnosed GBM, age 18–70 y/o and a World Health Organization (WHO) performance status ≥ 2. The blood samples of these patients required a neutrophil count of ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, a serum creatinine ≤1.5 x upper limit of normal, total bilirubin ≤ 1.5 x upper limit of normal and GPT/alanine transaminase or GOT1/aspartate aminotransferase and ALPL/alkaline phosphatase ≤3 x upper limit of normal.","The main exclusion criteria included prior radio- or chemotherapy, recent severe cardiac disease, a history of cardiac arrhythmia, cardiac conduction distur-bances or medication potentially causing them, retinal or visual field changes unrelated to the tumor location and the use of concurrent CYP/cytochrome P450 enzyme-inducing drugs",NA,NA
14551141,NA,Single Drug,No,pediatric patients with advanced leukemia,"Patients younger than 21 years of age with relapsed or refractory leukemia who were not candidates for treatments of higher efficacy or priority were eligible for study. Informed consent indicating that patients, guardians, or both were aware of the investigational nature of this study was signed according to institutional guidelines. Other eligibility criteria required the absence of chemotherapy in the 2 weeks before study entry and the resolution of any toxic effects of prior therapy; adequate liver and renal function values (bilirubin 2 mg/dL or lower and creatinine 1.5 mg/dL or lower), and good performance status (Zubrod 0-2)",NA,NA,NA
11920222,NA,Combination,No,elderly patients with previously untreated acute myeloid leukemia,"The study population consisted of previously untreated patients >=60 years of age, who had a cytopathologically con®rmed diagnosis of primary or secondary AML (M0 to M7) according to the FrenchAmerican-British (FAB) classi®cation. Patients who had progressed from myelodysplastic syndrome (MDS) were eligible if they had received no previous chemotherapy. Other eligibility criteria included World Health Organization (WHO) performance status <=2, life expectancy >=12 weeks, and suitability for intensive chemotherapy in the opinion of the treating physician. ","Patients with a prior history of polycythemia rubra vera or primary myelo®brosis, or in blast cell crisis of chronic myeloid leukemia, were excluded. Documented central nervous system involvement, left ventricular ejection fraction of <50% as measured by cardiac radionuclide-gated blood pool scan, serum creatinine >=175 mmol/l, serum bilirubin >=2.5-fold the institutional upper limit of normal, positive hepatitis B surface antigen or a known history of hepatitis C or human immunode®ciency virus infection, known hypersensitivity to CsA, or prior treatment with cytotoxic agents and/or radiotherapy were all causes for exclusion.",T during the first induction cycle,NA
28039367,NCT01800695,Combination,No,Participants With newly diagnosed glioblastoma,"Eligible patients (≥18 y of age) had newly diagnosed supratentorial glioblastoma or subvariants, Karnofsky performance status score of 70 or above, and no significant postoperative hemorrhage. They also had adequate bone marrow, renal, and hepatic function, as follows: neutrophil count ≥1500/mm3; platelets ≥100000/mm3; hemoglobin ≥9.0  g/dL; serum creatinine ≤1.5 times the upper limit of the normal range (ULN); bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ≤2.5 times ULN; prothrombin time/international normalized ratio ≤1.5. Women of childbearing potential and men who had agreed to use adequate contraception prior to, during, and 6 months after completion of therapy were allowed.","Patients were considered ineligible if they had received any anticancer therapy within 28 days before the treatment, or had any medical history of major immunologic reaction to any IgG-containing agent or any component of TMZ or to dacarbazine (DTIC). Lactating or pregnant females were not allowed in the study.","~10 wk, from day 1 of ABT-414 until 4 wk after the last dose of RT","Four weeks following completion of concurrent RT and TMZ, patients received adjuvant TMZ (150–200 mg/m2, days 1–5 of 28-day cycle) plus ABT-414 (days 1 and 15 of 28-day cycle)."
29374809,NCT01907165,Combination,No,newly diagnosed glioblastoma patients,"Diagnosis of histologically confirmed GBM (WHO grade IV). At least 18 years of age. ECOG performance status of at least 2. Has received or is in the process of completing a course of definitive radiotherapy of at least 45 Gy with concurrent temozolomide (patient may be registered before completing radiotherapy as long as it is anticipated that s/he will complete at least 45 Gy). Eligible for and planning to receive maintenance temozolomide after completion of definitive radiotherapy plus temozolomide. Willing to remain abstinent from consuming alcohol while on disulfiram. Meets the following laboratory criteria: Absolute neutrophil count ≥ 1,500/mcL; Platelets ≥ 100,000/mcL; Hemoglobin > 9.0 g/dL (transfusion and/or ESA allowed); Total bilirubin ≤ 2x institutional upper limit of normal (ULN); AST and ALT < 3 x ULN; Calculated creatinine clearance must be > 60 mL/min (by Cockcroft-Gault). Females of childbearing potential (defined as a female who is non-menopausal or surgically sterilized) must be willing to use an acceptable method of birth control (i.e., hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Able to take oral medication. Able to understand and willing to sign an IRB-approved written informed consent document (legally authorized representative permitted).","Receipt of any other investigational agents within 14 days prior to study enrollment. Enrolled on another clinical trial testing a novel therapy or drug. History of allergic reaction to disulfiram. Treatment with clinically significant cytochromes P450 enzyme inducers, such as phenytoin, phenobarbital, chlordiazepoxide, diazepam, isoniazid, metronidazole, warfarin, amitriptyline within 14 days prior to the first dose of disulfiram. Of note, lorazepam and oxazepam are not affected by the P450 system and are not contraindicated with disulfiram. Active or severe hepatic, cardiovascular, or cerebrovascular disease, including myocardial infarction within 6 months prior to enrollment, have New York Heart Association (NYHA) Class III or IV heart failure (Appendix B), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. History of idiopathic seizure disorder, psychosis or schizophrenia. Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of initiation of treatment.",within the first 28 days of starting DSF,NA
21282541,NA,Single Drug,No,Adults with advanced AML or acute lymphoblastic leukemia (ALL),"Adults with advanced AML or acute lymphoblastic leukemia (ALL) based onWHO classification or high-riskmyelodysplasia (International Prognostic Scoring System [IPSS] intermediate-2 or higher) were eligible. Patients had Eastern Cooperative Oncology Group (ECOG) performance status <= 2, creatinine < 1.5 mg/dL, bilirubin < 1.5 mg/dL, AST/ALT < 150 U/L, and left ventricular ejection fraction (LVEF) by echocardiogram or multiple gated acquisition > 50%. Hydroxyurea was allowed up to 24 hours before CPX-351. Bone marrow karyotype was generally available but was not required for study entry.","Patients with CNS leukemia and active infections (fungal, HIV, or hepatitis C) were excluded. Prior chemotherapy was permitted up to 2 weeks before study start.",during the first induction course,NA
18607882,NA,Single Drug,No,"patients with solid tumours. Nineteen patients had malignant melanoma, 8 ovarian cancer, and 7 patients NSCLC.   ","Patients with a histological confirmed diagnosis of advanced malignant melanoma, ovarian cancer or NSCLC who had failed standard therapy, were enrolled between November 2003 and May 2005. Further eligibility criteria were ECOG-WHO performance status 0-2, age >=18 years, adequate bonemarrow function (absolute neutrophil count >=1.5x109/L, platelets >=100x109/L, and haemoglobin >=9 g/dL), hepatic function (transaminases <=2.5xupper normal   laboratory value (UNL) or <5xUNL if documented liver metastases; bilirubin andalkaline phosphatase <=1.5xUNL), renal function (creatinine <=1.6 mg/dL), and no significant reduction in heart function, life expectancy >3  months, no chemo-, radio-, or immunotherapy within 6 weeks prior to study and measurable lesions on computed tomography (CT) scans or magneticresonance imaging (MRI). Major surgery, excluding biopsy, was not permitted  within 4 weeks prior tostudy start. ","Pregnant or breast feeding women, andpatients with previous or current malignancies atother sites (with the exception of adequately treated in situ carcinoma of the cervix uteri or basal or squamous cell carcinomas of the skin), known brainand/or leptomeningeal tumour involvement and history of allergic reactions to ara-C or eggs, uncontrolled intercurrent illnesses (including active infection, symptomatic congestive heart failure, unstable angina  pectoris, cardiac arrhythmia, or ahistory of significant neurological or psychiatric disorders) were also excluded",in the first treatment cycle,NA
32347934,NCT01390571,Combination,No,Adult patients with recurrent glioblastoma,"Eligibility criteria included age ≥18, histological diagnosis of GBM, radiological evidence of recurrence (RANO criteria) after primary treatment with chemoradiotherapy and adjuvant chemotherapy, WHO performance status 0-2 and life expectancy >12 weeks. Laboratory crtieria included hemoglobin ≥10.0 g/dL, neutrophils ≥1.5 x 109/L, platelets ≥100 x 109/L, creatinine clearance ≥50mL/min, bilirubin ≤1.5 upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 ULN. ","Exclusion criteria included previous chemotherapy for recurrent GBM; radiotherapy, endocrine therapy, or immunotherapy within 12 weeks, or chemotherapy or biological therapy within 4 weeks.",during the first treatment cycle,NA
20922784,NCT00372853 ,Combination,No,patients with metastatic renal cell carcinoma,"Adult patients with histologically documented mRCCwho had received no more than 1 previous systemic therapy regimen were eligible. All patients had good EasternCooperative Oncology Group (ECOG) performance sta-tus (0 or 1). Any treatment-related toxicities from a previ-ous therapy or surgical procedure must have resolved to grade 0 or 1 according to version 3.0 of the National Can-cer Institute Common Terminology Criteria for AdverseEvents. Patients were required to have evidence ofadequate organ function determined within 21 days ofenrollment (serum aspartate aminotransferase and serumalanine aminotransferase levels <=2.5 times the upper limit of normal [ULN] or <=5 times the ULN with liver metastases, total serum bilirubin <=1.5 times the ULN, absoluteneutrophil count >=1.5x109 cells/L, platelets >=100x109cells/L, hemoglobin >=8 g/dL without the support ofgrowth factors, serum calcium <=12.0 mg/dL, serum creatinine <=1.5 times the ULN, and left ventricular ejectionfraction >= the lower limit of normal as assessed by multi-gated acquisition scan). Any major surgery, radiation therapy, or systemic  therapy (including  chemotherapy,dendritic cell-based immunotherapy, vaccines, or otherbiologic therapy) must have been completed >= 4 weeksbefore screening. Prior treatment with sunitinib or temsir-olimus was not allowed.","Patients with brain metastases orleptomeningeal disease were excluded. Patients also wereexcluded if they fell under the following categories:received treatment on another clinical trial within 21 daysof enrollment; any grade 3 hemorrhage within 4 weeks ofenrollment; concurrent malignancy that might requiretreatment during study; uncontrolled hypertension; his-tory of chronic autoimmune disease; treatment with warfarin within 5 days of enrollment; ongoing cardiacdysrhythmia grade >=2; atrial fibrillation; a QTc interval >450 msec for men or >470 msec for women; myocar-dial infarction, severe/unstable angina, coronary/periph-eral artery bypass graft, congestive heart  failure,cerebrovascular accident, transient ischemic attack, orpulmonary embolism within 12 months before enroll-ment; concomitant treatment with a cytochrome P4503A4 inhibitor or inducer or with any drug that has proar-rhythmic potential; a history of chronic inflammatorybowel disease, celiac disease, acute colitis, diverticulitis, orany chronic gastrointestinal condition associated with di-arrhea; received treatment with immunosuppressantswithin 4 weeks of enrollment; known acquired immuno-deficiency syndrome-related illness; or currently pregnantor lactating",during the first 6weeks after the first dose of tremelimumab ,NA
30359477,NCT01430351,Combination,No,Adults with newly diagnosed glioblastoma ,"Eligible patients were aged ≥18 years and had histologically confirmed supratentorial GBM or gliosarcoma; a Karnofsky performance status ≥60; and adequate bone marrow, liver, and renal function. Patients were required to have  completed standard radiation with concurrent TMZ and to be enrolled within 5 weeks after completion of chemoradiation. All patients underwent a baseline post-treatment gadolinium-diethylenetriamine-pentacetate–enhanced    magnetic resonance imaging (GD-DPTA MRI) scan within 14 days before registration on a stable or decreasing dose of steroids. Patients were required to have no evidence of progressive disease according to Response  Assessment in Neuro-Oncology (R ANO) criteria, although pseudoprogression defined according to R ANO criteria was allowed. Patients who were enrolled on the mefloquine treatment arms were re-quired to have no prolonged QTc interval >450 msec or no evidence of clinically significant arrhythmia within 14 days before registration; no concurrent cardiac disease requiring β-blocker treatment (unable to change medication to another class); no concurrent  treatment with an antimalarial drug, quinine, or quinidine; no history of psychosis/schizophrenia; and were not allowed to take an enzyme-inducing anticonvulsant (which required a 2-week wash-out period before starting  treatment with mefloquine). All patients were required to provide informed consent indicating that they were aware of the investigational nature of this study, in keeping with the policies of The University of Texas MD Anderson Cancer Center Institutional Review Board, which approved the protocol as consistent with the principles set forth in the Declaration of Helsinki and other ethics standards.","Patients must not have any significant medical illnesses that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy. For mefloquine arm, patients with evidence of QTc interval > 450 ms or clinically significant arrhythmia on baseline EKG obtained within 14 days of registration will be ineligible for protocol enrollment. Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off of all therapy for that disease for a minimum of 3 years, are ineligible. Patients must not have active infection or serious intercurrent medical illness. Patients must not be pregnant/breast feeding and must agree to practice adequate contraception (acceptable forms of birth control include condom with spermicide and/or diaphragm with spermicide, and non-barrier contraception such as tubal ligation, vasectomy, oral contraceptives, implanted levonorgestrel, vaginal hormonal contraceptive ring). Patients must not have any disease that will obscure toxicity or dangerously alter drug metabolism; patients with a history of psychosis/schizophrenia or cardiac disease requiring beta-blocker treatment (unable to change medication to non-beta blocker), anti-malarial drugs, or quinine or quinidine will not be eligible for enrollment to a mefloquine containing arm; patients who are on active treatment with one of the study drugs at the time of evaluation will not be eligible for enrollment to an arm containing that study drug. For mefloquine arm, patients must not be on enzyme inducing anticonvulsants (EIAED); if the treating physician elects to change the medication to a non-enzyme inducing agent, a 2-week wash out period will be required after stopping EIAED prior to initiation of treatment",the first 28-day cycle ,NA
19536893,NA,Combination,No,"patients with oligometastases. Treatment site: Bone 14, Liver 9, Lung 6, Lymph node 4, Soft tissue 2. Primary sites (histology): Head and neck squamous cell carcinoma 4, Prostate adenocarcinoma 3, Hepatocellular carcinoma 3, Colorectal adenocarcinoma 2, Nonsmall cell lung cancer 2, Pancreatic adenocarcinoma 2, Renal cell carcinoma 2, Breast adenocarcinoma 1, Cutaneous melanoma 1, Pulmonary leiomyosarcoma 1","Patients were eligible if they had histologically or cytologically documented advanced solid tumor malignancy with radiographic evidence of 1 to 5 sites of active metastatic disease on whole body imaging (Positron emission to-mography [PET] or computed tomography [CT] chest,abdomen, pelvis and bone scan) measuring <=6 cm in maximum dimension.  Other  key  eligibility  criteria included age >=18 years, Eastern Cooperative OncologyGroup (ECOG) performance status of 0 to 2, and adequate hematologic, hepatic, and renal function. Adequate hematologic, hepatic, and renal function was defined as hemoglobin greater than 9.0 g/dl, absolute neutrophil count (ANC) greater than 1500/mL, platelet count greater than 100,000/mL, serum creatinine and bilirubin within institutional limits, serum albumin greater than 2.9 g/dl, serum alkaline phosphatase less than 2.5 times the upper limit of normal, and serum AST and ALTless than 2.5 times the upper limit of normal. Eligibility required prior chemotherapy or radiation to be discontin-ued for at least 2 weeks before study entry. Three patients received chemotherapy within 3 months of starting radiation and all had evidence of progression before starting sunitinib. ","Patients were excluded if they had uncontrolled brain metastases, malignant pleural or pericardial effusion,life expectancy <3 months, prior radiation to volume encompassed by planning target volume (PTV), or uncontrolled inter current illness defined as on going active infection, symptomatic congestive heart failure, unstable anginapectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",NA,NA
31724813,NCT02116777,Combination,No,children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma,"The study was conducted by the Children’s Oncology Group Phase 1/Pilot Consortium. Patients aged 1 to 21 years with recurrent or refractory solid tumors were eligible for the dose-finding (phase 1) component. Patients < 30 years old with measurable recurrent or refractory EWS/PNET were eligible for the phase 2 component. It should be noted that patients who carried a diagnosis of “Ewinglike” tumors—a small round blue cell tumor that shares many clinical, morphological, and molecular characteristics with EWS but lacks the pathognomonic EWS-ETS fusions14—were excluded from this cohort as the lack of these fusions eliminated a major theoretical mechanism of PARPi activity. Subjects were required to be recovered from the acute toxic effects of prior therapy, have a performance score (Lansky/Karnofsky) of ≥ 50, have an absolute neutrophil count ≥ 1000/mm3 and platelets ≥ 100 000/mm3, adequate renal and hepatic function based on age, and cardiac function (shortening fraction ≥ 27% or ejection fraction ≥ 50%).","Patients were excluded if they had a history of total body or craniospinal irradiation or radiation to ≥ 50% of the pelvis, uncontrolled infections, or, for the phase 1 component, a history of disease progression after exposure to a PARPi plus TMZ; they were excluded from the phase 2 if they had prior exposure to any PARPi. ",during cycle 1,NA
21690570,NA,Single Drug,No,"pediatric patients with refractory solid tumors. Diagnosis: Brain tumor, Soft tissue sarcoma, Ewing sarcoma, Neuroblastoma, Osteosarcoma, Other (Includes 1 patient each with desmoplastic small round cell tumor; renal cell carcinoma; spindle epithelial tumor with thymus like differentiation; GIST; and malignant meningioma)","Patients were eligible for participation if they were 2 to 21 years of age, had histologic diagnosis of solid malignancy with measurable or evaluable disease, and had no known curative options. Patients were required to have a Karnofsky (age >10 years) or Lansky (age 10 years) performance score 50 or more and to have recovered from previous therapy. Patients were required to have adequate baseline bone marrow, renal, hepatic, pancreatic, and cardiac function according to defined protocol criteria. Patients with preexisting hyper- or hypothyroidism were required to have stable thyroid function. Patients could not be receiving concomitant antihypertensive medications and had to have blood pressure less than 95th percentile for age, height, and gender","Exclusion criteria included: inability to swallow capsules; body surface area less than 0.5 m2 (due to available capsule sizes); concurrent use of strong CYP3A4 inducers or inhibitors; treatment with agents that might increase the risk of bleeding complications; presence of pleural-based tumors; or uncontrolled infection. An amendment to the eligibility criteria was made after enrollment of the first 12 patients (part A) because of cardiac and hematologic toxicity. In the amended protocol (part B), patients with previous anthracycline treatment or cardiac radiation exposure were excluded. Patients with known bone marrow metastases were also excluded from part B to provide a clear assessment of the hematologic toxicity of sunitinib after a patient in part A developed dose-limiting neutropenia. This amendment also allowed enrollment of patients with central nervous system tumors. These patients were excluded from part A because experience with the use of antiangiogenic agents in children with central nervous system tumors was limited at the time of study initiation.",in cycle 1,Part A: patients with previous anthracycline treatment or cardiac radiation exposure. Part B:  pediatric patients without previous anthracycline exposure or previous cardiac radiation
19933907,NA,Single Drug,No,patients with acute leukemia and myelodysplastic syndrome,"Adults with relapsed or refractory acute leukemia, MDS, or untreated diseasewhowere unwilling to proceedwith conventional systemic chemotherapy were eligible. Other eligibility criteria included age of 18 years or older; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; adequate hepatic (ie, bilirubin <= 1.5 mg/dL; ALT <= 2.5 x upper limit of normal [ULN] or <= five times ULN if hepatic abnormality related to leukemia) and renal functions (ie, creatinine <= 2.0 mg/dL or creatinine clearance > 60 mL/min); no prior chemotherapy, radiation therapy, or investigational anticancer therapy in the previous 2 weeks; absence of CNS involvement by leukemia; and absence of uncontrolled intercurrent illnesses, including infections, cardiac conditions, or other organ dysfunctions.",NA,during the first treatment cycle,NA
12637486,NA,Single Drug,No,"patients with solid and hematologic cancers. Tumor type: Breast, Colon/gastric, Lung, CLL (other lymphoproliferative), AML, ALL, CML blastic phase","Adult patients 18 years or older with solid tumors, chronic leukemia, lymphoma, myeloma, or acute leukemia who were not candidates for treatments of higher efficacy or priority were eligible for the study. Informed consent indicating that patients were aware of the investigational nature of this study was signed according to institutional guidelines. Other eligibility criteria required the following: (1) no prior chemotherapy in the 2 weeks before entering this study and resolution of toxic effects of prior therapy; (2) adequate liver (bilirubin <= 2 mg %) and renal functions (creatinine <= 1.5 mg %); (3) good performance status (Zubrod 0 to 2); and (4) normal granulocyte count ( 109/L) and normal platelet count ( 100  109/L), except for patients with leukemia",Pregnant and lactating women were not eligible.,the first 2 cycles,NA
21353747,NA,Combination,No,patients with high-grade gliomas,"Patients >18 years of age with newly diagnosed and histologically confirmed World Health Organization Grade 3 or 4 HGG were eligible for the present study. Eligible patients had a Karnofsky performance status of >=60 and adequate hematologic and kidney function (hemoglobin >9 g, absolute neutrophils >1,500/mm3, platelets >100,000/mm3, blood urea nitrogen <=30, creatinine <=1.5). In addition, the patients had to have no clinical heart disease, no evidence of thrombophlebitis, and an absence of moderate or severe neuropathy",NA,NA,NA
11352969,NA,Combination,No,breast cancer patients,"All patients had metastatic breast cancer. Eligible patients had histologically confirmed diagnosis of breast cancer; age greater than 18 years; Zubrod performance status of 0, 1, or 2; absolute neutrophil count >= 1,500/mm3; platelet count >= 90,000/mm3; fasting triglycerides less than three times the upper limits of normal; serum creatinine <= 1.5 mg/dL or creatinine clearance <= 60 mL/min; and liver function tests (ALT, AST, and total bilirubin) <= two times the upper limit of normal. ","Patients with the following characteristics were excluded: cytotoxic chemotherapy within the previous 3 weeks, CNS metastasis, or a seizure disorder. There was no limit to the number of previous chemotherapy or hormone therapy regimens.",in the first 8 weeks,NA
31636097,NCT02403310,Combination,No,patients with poor-risk AML,"1. Patients must have newly diagnosed, previously untreated acute myeloid leukemia (AML) (excluding M3).  2. Patients must have adverse-risk AML defined as poor-risk karyotype (complex, monosomal or other known poor-risk cytogenetic abnormality), poor-risk mutations/fusion genes or known history of antecedent hematologic disorder, or treatment related AML, or be ≥60 years of age. 3. Cytogenetics, FISH, or mutational analysis confirming adverse risk features must have been done within 90 days prior to enrollment. 4. Patients may not have undergone any prior therapy for their AML other than hydroxyurea. However, if patients had an antecedent myelodysplastic syndrome (MDS), prior treatment with a hypomethylating agent or any other therapy (with the exception of allogeneic stem cell transplant) used to treat their MDS is allowed. 5. Age >18 years. Because no dosing or adverse event data are currently available on the use of selinexor in patients <18 years of age, children are excluded from this study. 6. ECOG performance status <2. 7. Life expectancy of greater than 2 months. 8. Patients must have normal organ function as defined: • Total bilirubin within normal institutional limits. AST(SGOT)/ALT(SGPT)  <2.5 × institutional upper limit of normal. •	Creatinine ≤2 mg/dL or creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. 9.	Be able and willing to adhere to the study visit schedule and other protocol requirements. 10.	Baseline left ventricular ejection fraction (LVEF) ≥ 50%. 11.	The effects of selinexor on the developing human fetus are unknown.  For this reason and because XPO1 inhibitors are potentially teratogenic, women of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 days and again within 24 hours prior to beginning study treatment. 12.	Patients of childbearing potential must practice contraception. Females of childbearing potential:  Recommendation is for 2 effective contraceptive methods during the study. Adequate forms of contraception are double barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation. Male patients with female partners who are of childbearing potential: Recommendation is for male and partner to use at least 2 effective contraceptive methods, as described above, during the study.  Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with selinexor, breastfeeding mothers must agree to discontinue nursing if the mother is treated with selinexor. 13. Ability to understand and the willingness to sign a written informed consent document. 14. Must be able to swallow capsules and have no evidence of GI tract abnormality that would alter the absorption of oral medications. 15.Prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 1.5 x ULN.","1.	Patients may not be receiving any other investigational agents. 2. Patients with documented central nervous system involvement of AML. 3. AML with favorable risk cytogenetic abnormalities including t(15;17), t(8;21) or inv(16). 4. Patients who are in the blast phase of chronic myeloid leukemia. 5. Major surgery within 2 weeks of first dose of study drug. Patients must have recovered from the effects of any surgery performed greater than 2 weeks prior. 6.	WBC count ≥50,000 on hydroxyurea. 7. Predicted inability to tolerate standard induction chemotherapy with daunorubicin and cytarabine. 8. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 9. Patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy.  Therefore, HIV-positive patients receiving combination antiretroviral therapy are excluded from the study because of possible pharmacokinetic interactions with selinexor.  Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated. 10.	No other malignancies in addition to AML that are currently requiring treatment with the exception of basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast. 11. Patients with a history of allogeneic stem cell transplant for MDS or any other antecedent hematologic disorder are not eligible.",a minimum of 28 days,NA
23763917, NCT00926731,Combination,No,elderly patients with AML,"Eligible patients had newly diagnosed de novo or secondary AML, or chronic myelomonocytic leukemia, according to World Health Organization (WHO) pathological classification17; were aged 60 years or older, judged unsuitable for intensive induction chemotherapy, and were considered likely to be able to complete 12 weeks (3 cycles) of treatment. Cytogenetic risk groups were assigned according to Medical Research Council criteria.18 Patients were required to have a WHO performance status (PS) of 0 to 3 (PS of 3 was acceptable if solely attributed to the underlying AML) and considered likely to complete 3 cycles (12 weeks) of treatment. Patients with asymptomatic central nervous system disease were eligible if symptom-free for > 10 days.","Exclusion criteria included: diagnosis of acute promyelocytic leukemia or blast crisis of chronic myeloid leukemia; chemotherapy, radiotherapy, or an investigational anticancer agent within 2 weeks of the start of study treatment; persistent clinically significant toxicities from any previous anticancer therapy of National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE) grade > 1 (except alopecia); serum creatinine > 1.5 times the upper limit of normal (ULN) or 24-hour creatinine clearance < 50 mL/min (Cockcroft-Gault); serum bilirubin > 1.5 times the ULN; aspartate aminotransferase or alanine aminotransferase > 2.5 times the ULN (unless considered because of leukemic organ involvement); and QTc interval >= 470 milliseconds.",the first treatment cycle,NA
24415560,NCT00727766,Combination,No,adults aged 60 and older with acute myeloid leukemia,"Patients aged 60 years or older with a diagnosis of non-M3 AML according to WHO criteria in morphologic complete remission (CR) following intensive induction chemotherapy (such as anthracyclines plus cytarabine or cladribine plus cytarabine ± mitoxantrone) were eligible. Up to one cycle of consolidation therapy was permitted prior to enrollment. Other eligibility criteria included: Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; adequate hepatic (serum total bilirubin ≤1.5X upper limit of normal [ULN], AST/ALT≤2.5 ULN, and alkaline phosphatase ≤2.5 ULN ) and renal function (creatinine ≤1.0 or estimated glomerular filtration rate (GFR) >60 mL/min/1.73 m2); absence of concomitant chemotherapy, radiation, or immunotherapy; absence of severe concurrent disease, organ dysfunction, or uncontrolled active infection; or absence of active gastrointestinal disease that may affect the ability to absorb oral clofarabine. Tre","Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol. The diagnosis of AML-M3 (acute promyelocytic leukemia) characterized by translocations involving the retinoic acid receptor-alpha (RAR-alpha) gene. Use of investigational agents within 2 weeks or any anticancer therapy within 2 weeks before study entry. The patient must have recovered from all acute toxicities from any previous therapy. Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment. Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment). Have currently active gastrointestinal disease, or prior surgery that may affect the ability of the patient to absorb oral clofarabine.",during the first cycle of treatment,NA
25465491,NA,Combination,No,patients with advanced renal cell carcinoma,"Eligible patients were required to have mRCC of any histologic type with evaluable disease defined according to the initial Response Evaluation Criteria in Solid Tumors (RECIST) criteria.14 Patients were required to be at least 18 years of age; have an Eastern Cooperative Oncology Group performance status <= 1; and to have adequate organ and marrow function within 14 days before study enrollment, defined as an absolute neutrophil count >= 1500/uL, platelet count >= 100,000/uL, hemoglobin >= 9.0 g/dL, total bilirubin <= 2.0 mg/dL, albumin <= 2.5 g/dL, serum creatinine <= 2.0 mg/dL, and aspartate aminotransferase and alanine aminotransferase <= 2.5 times the upper limit of normal and without evidence of liver metastasis or <= 5 times the upper limit of normal with evidence of liver metastasis. Patients were required to be able to swallow pills and sign informed consent; women were required to have a pregnancy test to ensure that they were not pregnant; and men and women were required to use an acceptable form of birth control during their participation in the study.","Exclusion criteria included previous malignancy, with the exception of nonmelanoma skin cancer, carcinoma in situ, or malignancy that had been definitively treated and monitored with no evidence of disease for at least 2 years. Other exclusion criteria included uncontrolled brain metastasis; current administration of alternative anticancer therapy, with the exception of bisphosphonates or megestrol acetate; stroke or transient ischemic attack in the previous 6 months; uncontrolled infection; myocardial infarction or unstable angina in the previous 6 months; New York Heart Association Grade >= II congestive heart failure; serious cardiac dysrhythmia refractory to medical management; peripheral vascular disease (Grade >= III); uncontrolled hypertension defined as > 140/90 mm Hg (antihypertensive medications were allowed); pregnancy; immune deficiency, including HIV and highly active antiretroviral therapy; history of coagulopathy or serious bleeding diathesis; concomitant treatment with rifampin, St John’s wort, or cytochrome p450 enzymeeinducing drugs or cytochrome P450 3A4 inhibitors; significant baseline proteinuria, defined as a urinary protein to creatinine ratio > 2; major surgical procedure, including open biopsy or trauma, in the previous 28 days; core biopsy or other minor surgical procedure in the previous 7 days; history of abdominal fistula, gastrointestinal perforation, or intra- abdominal abscess in the previous 6 months; nonhealing wound, ulcer, or bone fracture; or known hypersensitivity to S or T.",within the first 3 weeks,NA
29016887,NCT00731731,Combination,No,patients with newly diagnosed glioblastoma,"Patients were eligible who were age ≥18  years with histologically confirmed GBM, gliosarcoma, or other World Health Organization grade IV astrocytoma variants, as determined by pre-registration central pathology review. Patients’ disease had to be measurable or evaluable by gadolinium MRI or contrast CT scan. All patients were required to begin involved brain RT on the same day that treatment with vorinostat and TMZ commenced. In addition, eligible patients were required to have a KPS of ≥60 or Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; life expectancy ≥12 weeks; adequate hematologic, liver, and renal function; and ability to begin treatment ≥2 weeks to ≤5 weeks after surgery","Patients who met any of the following criteria were excluded: prior cytotoxic or noncytotoxic drug therapy, or experimental drug therapy for brain tumors; prior cranial RT; prior Gliadel wafers; use of valproic acid or another HDAC inhibitor ≤2 weeks prior to registration and during treatment; other active malignancy ≤3  years prior to registration; history of myocardial infarction or unstable angina ≤6  months prior to registration or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias; New York Heart Association Class ≥II congestive heart failure; congenital long QT syndrome; prolonged QTc interval (>450 msec); or use of any Category I drugs associated with a risk of torsades de pointes ≤7 days prior to registration.",during the first 10 weeks of treatment,NA
29077941,NCT01800695,Combination,No,patients with glioblastoma,"Eligible patients (≥18 y of age) had newly diagnosed supratentorial glioblastoma or subvariants, Karnofsky performance status score of 70 or above, and no significant postoperative hemorrhage. They also had adequate bone marrow, renal, and hepatic function, as follows: neutrophil count ≥1500/mm3; platelets ≥100000/mm3; hemoglobin ≥9.0  g/dL; serum creatinine ≤1.5 times the upper limit of the normal range (ULN); bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ≤2.5 times ULN; prothrombin time/international normalized ratio ≤1.5. Women of childbearing potential and men who had agreed to use adequate contraception prior to, during, and 6 months after completion of therapy were allowed. Importantly, eligible patients were adults who had newly diagnosed or recurrent supratentorial glioblastoma or subvariants, Karnofsky Performance Status (KPS) ≥70, and no significant postoperative hemorrhage. They also had adequate bone marrow, renal, and hepatic functions. For arm B, the eligible patients with newly diagnosed glioblastoma had completed postoperative RT and concurrent TMZ but had not progressed; depatux-m was added to standard adjuvant TMZ. Recurrent glioblastoma patients in arms B and C had disease progression and a gap of at least 12 weeks after RT. ","Patients were considered ineligible if they had received any anticancer therapy within 28 days before the treatment, or had any medical history of major immunologic reaction to any IgG-containing agent or any component of TMZ or to dacarbazine (DTIC). Lactating or pregnant females were not allowed in the study. Prior treatments with head and neck RT (arm B newly diagnosed), Gliadel wafers or other intratumoral therapies, bevacizumab, and/or nitrosoureas (arm B recurrent disease) were exclusionary",first 4 weeks of treatment with either depatux-m plus TMZ or depatux-m monotherapy,NA
20858843,NA,Combination,No,patients with newly diagnosed or relaosed/refractory AML,"Patients with previously untreated AML age >60 years or those who were unable to receive intensive chemotherapy due to comorbid conditions, such as cardiovascular disease, were eligible. Patients with relapsed or primary refractory AML were also included. More than 25% of the patients' bone marrow blasts were required to express CD33. No antileukemic therapy was administered for 3 weeks before study entry except for hydroxyurea, which was discontinued before treatment. Concurrent use of either oral or intravenous antibiotics was allowed. Entry criteria included creatinine <2 mg/dL or creatinine clearance >60 mL/min, bilirubin ≤2 mg/dL, and alkaline phosphatase and aspartate aminotransferase ≤2.5 times normal. Patients could not have detectable antibodies to lintuzumab or active central nervous system involvement by leukemia.",NA,NA,NA
28371832,NCT01480050,Combination,No,patients with recurrent high-grade gliomas,"Patients provided written informed consent prior to participating in this study. Eligibility criteria included: age ≥18  years, histologically proven HGG (World Health Organization [WHO] grade III or IV) that was progressive or recurrent following standard upfront radiation and TMZ. Patients needed evidence of measurable contrast-enhancing disease. Patients must have had an interval of at least 3  months after completion of their most recent therapy, including after the most recent TMZ treatment. No prior cytotoxic therapies other than TMZ and carmustine wafers were allowed. Additional requirements included an absolute neutrophil count of ≥1500/μL; platelet count of ≥100000/μL; bilirubin and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of ≤3 times the upper institutional limit; creatinine clearance of ≥50 mL/min for subjects with creatinine levels above the institutional normal; and Karnofsky performance status (KPS) ≥60%.",NA,NA,NA
30589027,NA,Combination,No,patients with high‑grade gliomas,"Postoperative Grades III and IV glioma patients were confirmed by pathology (patients with restricted lesions and nondiffuse growth). They received cranial magnetic resonance (MR) examination after 48 h of surgery, and radiotherapy was performed after 2–4 weeks of surgery. The age of patients was between 18 and 70 years, KSP scores were ≥60, blood routine and liver and kidney functions were normal, expected survival period was ≥3 months, maximum diameter of the residual tumor, surgical cavity, and primary tumor bed was ≥6 cm,[16,20] and lesions were not in the brain stem and thalamus. All patients had not received chemotherapy or brain radiotherapy previously.","The exclusion criteria included pregnant and lactating women, secondary primary malignant tumor, severe pulmonary infection, and combination with mental illness or other diseases that required hospitalization",NA,NA
16924496,NA,Combination,No,Patients with Advanced Gastric Cancer,"The patients enrolled in this study had histologically confirmed non-resectable or recurrent gastric cancers.(1) Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, (2) up to one regimen of prior chemo- therapy (completed 1 month previously), (3) adequate bone marrow, liver, and renal functions as defined by WBC >4,000, <12,000/mm3, PLT >100,000/mm3, Hb >8.0 g/dl, AST/ALT <2 times institutional upper limits, total bilirubin <1.5 mg/dl, creatinine <1.5 mg/dl, and creatinine clearance >60 ml/min, (4) no significant cardiac disease evident on electrocardiogram (ECG), (5) expected survival period >3 months, (6) no active cancer in other organs, and (7) age at least 20 years.","Patients who showed severe organ dysfunction, history of hypersensitivity, inflammatory disease, mas- sive ascites and/or pleural effusion, or brain metastasis were excluded from the study. ",NA,NA
20041339,NA,Single Drug,No,advanced biliary cancer Asian patients with or without hepatic dysfunction,"Patients were considered eligible for participation in the study if they had advanced biliary tract cancer that is metastatic or unresectable; were at least 18 years of age; and had an Eastern Cooperative Oncology Group perfor- mance status (PS) of 0 to 2 or a Karnofsky PS ≥60%, with a life expectancy greater than 3 months. Acceptable renal function (i.e., serum creatinine levels within normal institutional limits) and bone marrow function (i.e., abso- lute neutrophil count (ANC) >1.5 × 109/L and platelets >100 × 109/L) were required. Patients with abnormal liver function were eligible for the study and were grouped according to National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) HD criteria. No distinction was made between HD due to metastases and other causes. Liver function tests were repeated within 24 h of starting initial therapy. Patients who received a shunt to alleviate biliary obstruction were eligible for the study, provided the shunt had been in place for at least 10 days prior to the first dose of S-1 and provided that liver function had been stabilized.","Exclusion criteria included previous radiotherapy and chemotherapy (i.e., with the exception of adjuvant chemo- therapy administered more than 6 months ago), therapeutic doses of warfarin, history of allergic reactions to 5-FU or its derivatives, uncontrolled intercurrent illness and pregnant women",Only DLT events that occurred during the first cycle of treatment were used to guide dose escalation.,NA
19103671,NA,Combination,No,Japanese Patients with Stage II/III Esophageal Cancer,"Eligibility criteria included the following: histologically proved squamous cell, adenosquamous cell or adenocarcinoma of the thoracic esophagus, excluding the esophagogastric junc- tion; UICC clinical stage II/III disease, excluding T4 tumors; no prior treatment for esophageal cancer; an age of 20–70 years; an Eastern Cooperative Group performance status (PS) of 0 or 1 and written informed consent. Eligible patients also had to have a white blood cell count of >= 4000/mm3, a platelet count of >=100 000/mm3, a hemoglobin concentration of >=10 g/dl, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels of <=2.5 times the upper limit of normal; a total serum bilirubin concentration of <=1.5 mg/ dl; a serum creatinine concentration of <=1.2 mg/dl, a 24-h creatinine clearance of >=50 ml/min, a PaO2 of >= 70 torr while breathing room air and no electocardiographic abnormalities.","Patients were excluded if they had any of the following: esophageal fistula; massive pleural effusion, pericardial effu- sion or ascites; evidence of interstitial pneumonia or pul- monary fibrosis on chest X-ray film; active gastrointestinal bleeding; a history of other malignancies, except for mucosal carcinoma or a cancer from which the patient had not remained disease free for 5 years; prior thoracic radi- ation; a history of severe cardiovascular disease or severe diabetic mellitus; active infection; pregnancy; nursing infants or psychiatric illness.",NA,NA
17533388,NA,Single Drug,No,Patients eligible for study entry had histologically or cytologically confirmed locally advanced nonresectable pancreatic cancer,"Eligibility criteria were age 20 – 74 years; Karnofsky performance status 70 – 100 points; no evidence of distant metastasis; adequate oral intake; estimated life expectancy >= 12 weeks after study entry; no earlier treatment for PC; adequate haematological function (haemoglobin >= 10 g dl^-1, leucocytes >= 4000 mm^-3, neutrophils >= 2000 mm^-3 and platelets >= 100000mm^-3); adequate hepatic function (serum total bilirubin p2.0 times upper normal limit (UNL); serum albumin >= 3.0 g dl^-1 and serum transaminases (aspartate aminotransferase (AST)/alanine aminotransferase (ALT)) p2.5 times UNL or p5 times UNL if biliary drainage present); adequate renal function (serum creatinine <= 1.0 mg dl^-1); written informed consent.",The exclusion criteria were watery diarrhoea; pleural effusion or ascites; active infection; active gastroduodenal ulcer; severe complication such as heart disease or renal disease; mental disorder; history of drug hypersensitivity; active concomitant malignancy; pregnant and lactating females; females of child- bearing age unless using effective contraception.,NA,NA
17262086,NA,Combination,No,patients administered 􏰎􏰎􏰎 as a 5-day schedule synchronously with 5-fluorouracil,"Eligibility criteria included histologically confirmed adenocarci- noma, WHO performance status 0 – 2 and no evidence of metastatic disease using chest X-ray and abdomino-pelvic CT. Acceptable haematological and renal function was required: neutrophils > 1.5 x 10^9 l^-1, platelets >= 100 x 10^9 l^-1 and serum creatinine ?<1.25 x the institutions upper limit of normal range. Patients with locally advanced, biopsy proven carcinoma of the rectum were included either on the basis of fixity on digital rectal examination (DRE), T4 stage on pelvic CT or when MRI demonstrated a high risk of involvement of the circumferential resection margin. ","Patients were excluded from the study because of prior chemotherapy or pelvic radiation, lack of efficient contraception or pregnancy and bowel or cardiac conditions that would deter the safe delivery of 5FU. Patients having six episodes of stool per day or who were incontinent of faeces were also excluded.",NA,NA
17053988,NA,Combination,No,patients with locally advanced oesophageal cancer,"(1) histologically proven squamous cell or adenocarcinoma of the oesophagus or gastro-oesophageal junction (stage T3−4 N0−1 M0 ), (2) untreated locally advanced disease or locally recurrent disease following surgery, (3) measurable disease by computerised tomog- raphy (CT) scan, (4) ECOG performance status ≤1, (5) no non-steroidal anti-inflammatory drug (NSAID) use for > 3 months, (6) life expectancy > 3 months, (7) adequate end-organ function, and (8) ability to provide written informed consent. ","(1) previous radiotherapy or chemotherapy, (2) previous asthma or allergic reaction to celecoxib, aspirin or other NSAIDs, (3) pregnant or lactating women, (4) concurrent or prior malignancy within 5 years, (5) significant comorbid medical conditions; (i) symptomatic peptic ulcer disease or oesophagitis in the last 3 months not related to cancer, (ii) cardiac history requiring aspirin, (iii) uncontrolled coronary artery disease or myocardial infarction in the last 6 months, (iv) symptomatic congestive cardiac failure, (v) uncontrolled infection or poorly controlled diabetes mellitus, and (vi) other medical conditions considered pro- hibitive by the treating physician. ",NA,NA
17218488,NA,Combination,No,"patients with advanced colorectal cancer","Patients eligible for the study were ‡18 years of age with histologically confirmed inoperable locally advanced or metastatic CRC.  life expectancy of ‡3 months, World Health Organization performance status (PS) of two or less, measurable disease, and laboratory parameters within the following ranges: absolute neutrophil count (ANC) >1.5 * 10^9 /l, hemoglobin >9 g/dl, platelets >= 100 * 10^9 /l, aspartate aminotransferase £3.0 · upper limit of normal (ULN), serum <= 1.5 * ULN, serum creatinine <=1.5 * ULN, 24-h creatinine clearance >= 50 ml/min, and total 24-h urinary protein <= 500 mg.","While previous surgical resection and adjuvant chemotherapy were permitted, patients could not have received prior treatment of advanced disease. Concurrent severe or uncontrolled medical disease, pregnant or breast-feeding women, and use of warfarin were all exclusion criteria",NA,NA
17976948,NA,Combination,No,Acute respiratory disease syndrome with preoperative chronomodulated chemoradiotherapy in patients with esophageal cancer.,"Untreated patients up to 70 years old with histologically proven SCC or adenocarcinoma of the esophagus qualified for the study. Patients had to be operative candidates and should not have involvement of the tracheobronchial tree or other structures that would preclude a complete resection. Further eligibility criteria were localised disease (i.e., UICC stage I and II: T1e3, N0, M0 and T1e2, N1, M0) according to clinical means, tomography scan and endoscopic ultrasound; less than 4 nodes seen at tomography scan or endoscopic ultrasound; good clinical condition (ECOG performance status grade <2); adequate nutritional intakes (daily intakes >1500 kcal, less than 15% of weight loss); normal liver, renal, respiratory, cardiac and bone marrow function. ",NA,NA,NA
18682717,NA,Combination,No,"Patients with metastatic colorectal cancer","patientswere aged X18 years, had no prior chemotherapy for metastatic disease and a World Health Organization performance status of 0 –2. All patients had adequate organ and haematological function.",NA,NA,NA
19940007,NA,Single Drug,No,patients with metastatic colorectal cancer,"Patients were eligible for inclusion if they were at least 18 years of age with histologically confirmed EGFR-expressing mCRC. EGFR expression was evaluated using a DakoCytomation pharmDxä immunohistochemistry kit (Dako, Glostrup, Denmark), with one tumour cell staining to any intensity being the minimum criterion required to confirm expression. Patients were required to have at least one tumour site accessible for biopsy and at least one bi-dimensionally measurable lesion, not in an irradiated area. They also had to have an Eastern Cooperative Oncology Group performance status of two or less, a life expectancy of ‡12 weeks and adequate bone marrow, liver, and renal function.","Principal exclusion criteria were previous exposure to EGFR-targeting therapy, previous chemotherapy for mCRC, previous adjuvant treatment within 6 months of study entry, surgery or irradiation within 30 days of study entry, or known or suspected brain metastases.",DLT observed during the first 6 weeks of treatment.,NA
20038727,NA,Combination,No,Patients undergoing first-line treatment for metastatic colorectal cancer (CRC),"Eligibility criteria included UGT1A1*1/*1 and *1/*28 genotypes, no prior chemotherapy for metastatic disease, age >= 18 or <= 75 years, absolute neutrophil count >= 2,000/muL, platelets >= 100,000/muL, performance status (Eastern Cooperative Oncology Group) of 0 to 2, life expectancy more than 3 months, creatinine clearance more than 65 mL/min (Cockcroft-Gault formula), ALT and AST less than 2x the upper limit of normal, and total serum bilirubin less than 1.25x the upper limit of normal.",Patients with either *28/*28 or genotypes containing the *36 (TA5) and *37 (TA8) UGT1A1 alleles were not eligible.,cycle 1,NA
17377918,NA,Combination,No,"Patients With Refractory Pancreatic, Bile Duct, Colorectal, or Gastric Cancer","Patients with histologically confirmed, measurable metastatic gastric, pancreatic, colorectal, or bile duct cancer who were refractory to standard therapy (defined as having disease progression during or within 6 weeks of previous chemotherapy documented by 2 subsequent computed tomography [CT] scans using World Health Organization [WHO] criteria) or for whom no effective therapy existed were eligible for the study. Age >18 years; an Eastern Cooperative Oncology Group (ECOG) performance status <= 3; sufficient renal, hepatic, and bone marrow function (defined as the following: total bilirubin <1.5 times the upper limit of normal [ULN], aspartate and alanine aminotransferase levels <2.5 times the ULN, creatinine <1.5 times the ULN, absolute neutrophil count >1.5 3 109/L, and platelets >100 3 109/L); complete resolution of all side effects caused by previous treatment; no concurrent, uncontrolled medical illness; and no other current or previous malignancy within the past 5 years (with the exception basal cell skin cancer or a cervical carcinoma in situ treated by surgery).","Patients were excluded from the study if they had brain metastases, inflammatory bowel disease, coronary heart disease, cardiac insufficiency (New York Heart Association II-IV), known hypersensitivity to any of the study drugs, or if they were pregnant or breast-feeding. Women of child-bearing potential were advised to take adequate precautions to prevent pregnancy. Participants gave their written informed consent before they entered the study, which was approved by the responsible ethics committee. After a high drop-out rate (patients who did not complete 2 cycles of treatment for reasons other than toxicity) was observed in the first cohort, the protocol was amended to include only patients with an ECOG performance status <=2.",NA,NA
18395356,NA,Combination,No,"Eligibility criteria included the following: histologically proven, resectable rectal carcinoma; clinical stages cT2N1-2M0 cT3N02M0 as assessed by digital examination, pelvic computed tomographic scan or magnetic resonance imaging (MRI), liver ultrasonography, chest X-rays, and barium enema; absence of positive lymph nodes outside the mesorectum and distant metastases; age >= 18 years; and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.","Exclusion criteria were other malignancies either coexisting or diagnosed within the last 5 years, and contraindications to chemoradiation. All patients provided written informed consent.",NA,NA,NA
18797462,NA,Combination,No,Patients with locally advanced oesophageal squamous cell carcinoma,"atients (aged 18 – 70 years) with histologically confirmed, locally advanced, non-metastatic OSCC (cT2 – 4 N0 – N þ M0) were eligible. All were candidates for curative surgery, with a Bartel score < 21 (Bartels et al, 1998), no prior chemotherapy or radiotherapy and adequate organ function.","oesophageal stent implantation, tracheobronchial tree invasion, tracheobronchial fistula, a second malignancy, uncontrolled infection, neuropathy grade >1 or congestive heart failure of New York Heart Association grade >=2.",NA,NA
19002384,NA,Combination,No,patients with advanced colorectal cancer,"Patients with histologically confirmed locally advanced, recurrent or metastatic CRC, who were not felt to be amenable to curative resection or radiation therapy, and were eligible for first- or second-line chemotherapy, were enrolled in this study. Patients were required to have a WHO performance status of 0 or 1, be 18 years or older and have normal cardiac, haematopoietic, hepatic and renal function.","Patients were excluded if they had received firstline chemotherapy and/or radiotherapy less than 4 weeks before the start of study therapy, or any second-line chemotherapy; or had brain metastases or spinal cord compression (unless treated at least 4 weeks before trial entry and if clinically stable without steroid treatment for ≥1 week).",NA,NA
16786333,NA,Single Drug,No,patients with advanced upper gastrointestinal cancer,"Eligibility criteria for this trial included histologically conWrmed, advanced upper gastrointestinal malignancies, including esophageal, gastric, pancreatic and biliary tract cancers that were refractory to conventional treatment or for which no standard therapy exists. Patients at least 18 years of age with Karnofsky Performance Status  >= 50% and life expectance  >= 12 weeks were included in the study. In addition, all patients had adequate bone marrow function (absolute neutrophil count  ̧ 1,500 cells/mul, hemoglobin > 9.0 g/dL, and platelet count  >= 100,000 cells/mul); adequate hepatic function (total bilirubin <= 1.5 x the upper limit of normal, and alanine aminotransferase/aspartate aminotransferase <= 2.5 x the upper limit of normal [ULN] or <= 5 x the ULN if liver metastasis present); and, adequate renal function (serum creatinine <= 1.25 x the ULN). Prior chemotherapy for advanced disease, including prior therapy with Xuoropyrimidines, was allowed.","known brain metastasis, history of DPD deWciency, any serious uncontrolled medical disorder or active infection, uncontrolled or clinically signiWcant cardiovascular disease (as indicated by a myocardial infarction within 6 months, atrial or ventricular arrhythmias), congestive heart failure, gastrointestinal disorders that would interfere with absorption, and females who were either pregnant or lactating.",first cycle of treatment,NA
19194126,NA,Combination,No,Patients With Advanced Colorectal Cancer,"All patients had histologically or cytologically confirmed advanced or metastatic colorectal adenocarcinoma. Patients had received no prior chemotherapy or only one regimen of previous chemotherapy (with a washout period >4 weeks after the final day of the previous therapy). Adjuvant chemotherapy performed more than 6 months previously was not counted as previous therapy. Further eligibility criteria included: (1) age 20 to 75 years; (2) Eastern Cooperative Oncology Group performance status of 0 or 1; (3) life expectancy >=3 months; (4) adequate hematological (absolute leukocyte count >=4000/mm3 and <=12,000/mm3, neutrophil count >=2000/mm3, platelets >=100,000/ mm3), hepatic (transaminases <=2.5 times the upper limit of normal, serum bilirubin <=2.0 mg/dL) and renal (serum creatinine <= the upper limit of normal) function; and (5) the ability to take oral medication.","Patients were excluded if they had brain metastases, a history of other neoplasms (except cured nonmelanoma, skin carcinoma, or cured carcinoma in situ), a history of severe drug allergy, interstitial pneumonitis or pulmonary fibrosis, severe pleural effusion or ascites, active infection, bowel obstruction, diarrhea, and serious uncontrolled comorbidity or medical conditions. Pregnant or lactating women or women not using effective contraception were also excluded.",first cycle,NA
19299904,NA,Combination,No,Patients with advanced Gastric Cancer,"The eligibility criteria were as follows: histologically proven unresectable or recurrent gastric adenocarcinoma; peritoneal metastasis and/or cancer cells on peritoneal cytology; age more than 20 years; Eastern Cooperative Oncology Group performance status 0–2; adequate bone marrow function (leukocyte count 3,000–12,000/mm3, hemoglobin >=8.0 g/dl, platelets >=100,000/ mm3); adequate liver function; adequate renal function, and an expected survival period of more than 3 months.","Patients were excluded if they had metastasis to distant organ sites, such as the liver, lungs or bone, other active concomitant malignancies, or other severe medical conditions. Written informed consent was obtained from all patients.",NA,NA
16704539,NA,Combination,No,Patients with advanced pancreatic cancer,"Patients with histologically and/or cytologically proven, metastatic or locally advanced pancreatic cancer not amenable to curative surgery were eligible to take part in the present study. The inclusion criteria included age ≤75 years, Eastern Cooperative Oncology Group (ECOG) performance scores ≤2, white blood cells ≥3000/μL, absolute neutrophil count ≥1500/μL, platelet count ≥105/μL, bilirubin ≤2.0 mg/dL, aspartate aminotransferase and alkaline phosphatase levels ≤5 times the institutional upper limits of normal, creatinine ≤1.5 mg/dL, and negative pregnancy test for women of childbearing age.","Exclusion criteria included prior chemotherapy, uncontrolled infections, severe cardiopulmonary debilitating illness (including past history of ischemic heart diseases; sensory neuropathy of grade 1 or higher of any etiology) and central nervous system metastases. A minimum of 4 weeks after prior surgery or radiotherapy was required.",the first cycle,NA
19225923,NA,Combination,No,patients with advanced non-small cell lung cancer,"The study population consisted of patients between 20 and 75 years of age with cytologically or histologically confirmed stage IIIB NSCLC with pleural effusion and stage IV NSCLC with measurable lesions. Previous chemotherapy or radiotherapy was permitted. Other eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, and at least 3 months of life expectancy. Laboratory requirements included hemoglobin more than 9.0 g/dl, white blood cell count more than 4000/mm3, neutrophils more than 2000/mm3, platelets more than 100 000/mm3, total bilirubin less than 1.5 mg/dl, transaminase less than 2× the institutional upper limit of the normal value, serum creatinine less than the institutional upper limit of the normal value, creatinine clearance more than 60 ml/min, and PaO2 more than 60 mmHg.","Patients were ineligible if they had symptomatic brain metastases, active double cancer, or a severe comorbidity contraindicating chemotherapy, including symptomatic cardiovascular disease, uncontrolled diabetes, pulmonary fibrosis obvious in a chest X-ray, diarrhea, and infectious diseases. Women who were pregnant, intending to become pregnant, or breast-feeding; patients with a history of drug allergy; those previously treated with S-1, CPT-11, other fluoropyrimidines, or flucytosine; and those unable to take oral medications, were also excluded.",during cycle 1,NA
18929446,NA,Combination,No,"Eligible patients were required to have: histologically or cytologically proven unresectable Stage IIIA or IIIB NSCLC; no previous chemotherapy or radiotherapy; a performance status of 0-1 on the Eastern Cooperative Oncology Group scale; an age between 20 years and 74 years; a life expectancy of 12 weeks or more; adequate bone marrow reserve (leukocyte count $4,000 mm^-3, neutrophil count >=2,000 mm^-3, platelet count >=100,000 mm^-3, and hemoglobin >=10 g/dL^-1); normal liver function (total serum bilirubin <=1.5 mg/dL^-1, and aspartate transaminase and alanine transaminase less than twice the upper limit of the normal range), normal renal function (normal serum creatinine and blood urea nitrogen levels), and pulmonary function (PaO2 >=70 torr).","Patients were excluded if they had malignant pleural or pericardial effusion; active double cancer; a concomitant serious illness, such as uncontrolled angina pectoris; myocardial infarction in the previous 3 months; heart failure; uncontrolled diabetes mellitus; uncontrolled hypertension; interstitial pneumonia or lung disease; infection or other diseases contraindicating chemotherapy or radiotherapy; pregnancy; or breastfeeding.",NA,NA,NA
18004083,NA,Combination,No,females with histologically and/or cytologically confirmed stage IV breast cancer,"Eligibility criteria were as follows: females with histologically and/or cytologically confirmed stage IV breast cancer; age older than 18 years; Eastern Cooperative Oncology Group (ECOG) Performance Status 0–2; life expectancy > 12 weeks; adequate cardiac function (left-ventricular ejection fraction >=50% by echocardiogram); adequate hepatic and renal function: creatinine and total bilirubin <= 1.5 x upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3 x upper limit of normal (<= 5 in patients with liver metastases); adequate bone marrow reserve: absolute neutrophil count >= 1.5 x 10^9/l, platelet count >= 100 x 10^9/l, hemoglobin 69 g/dl. Patients were enrolled irrespective of hormone receptor or menopausal status and HER2/neu expression. An interval of at least 4 weeks between the last dose of chemotherapy (1 or more lines) for metastatic disease and recovery from all (except alopecia) prior treatment-related side effects was required before entering the study.","Serious active infections or other serious underlying medical conditions which would impair the ability of the patient to receive protocol treatment (at the discretion of the investigator); unstable angina, myocardial infarction or congestive heart failure in the previous 6 months; known central nervous system tumors, including metastatic brain disease; previous or concurrent malignancy other than breast cancer, except for non-melanoma skin cancer or curatively treated carcinoma in situ of the uterine cervix; prior severe hypersensitivity reactions to agents containing Cremophor EL; pregnancy or breast-feeding females or patients not using adequate methods of birth control; other concomitant chemical, hormonal or radiation therapy or experimental anticancer medications.",during the first month of treatment,NA
16821599,NA,Combination,No,Patients with Recurrence of Head and Neck Cancer,"Patients with histologically confirmed head and neck cancer, excluding thyroid cancer, were enrolled in this trial. Written informed consent was obtained from each patient before enrollment. All patients were diagnosed as having recurrence with a measurable region after their initial treatment. Previous treatments, including chemotherapy, radiotherapy and surgery, were allowed if the treatment had finished at least one month prior to registration for the present study. The specific eligibility criteria were: patients were required to be within 20 to 75 years of age; to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; to have adequate hematological, hepatic and renal function (WBCs >3,500/Ìl, neutrophil count >2,000/Ìl, platelet count >100,000/Ìl and hemoglobin level >9 g/dL; AST and ALT <three times normal values, total bilirubin <1.5 mg/dl and creatinine clearance >60 ml/min, respectively); and to have a life expectancy of at least three months. The patients also had to be able to comply with the oral administration of S-1.",NA,NA,NA
18323870,NA,Combination,No,Chinese Patients with Esophageal Cancer,"Patients (aged ≧18 years and ≦70 years) with primary esophageal squamous cell carcinoma proven by histology and staged by thoracoabdominal helical computed tomography (CT) (T2-4, N0-1, M0-1) were eligible for this study. Due to the fact that endoscopic ultrasound was not available in our center, we evaluated clinical staging based on CT scans . The T stage was defined by the maximal transverse diameter of the esophageal tumor: T1 ≦2 cm, T2 ＞2 cm and ≦4cm, T3＞4 cm. Tumors indicating an invasion of any adjacent structures were classified as T4. If the minimal transverse diameter of the lymph nodes, in mediastinal and celiac, was larger than 1 cm, the lymph nodes were classified as N1; otherwise, they were classified as N0. Patients should not have received any prior radiotherapy or chemotherapy. All patients were requested to have a Karnofsky performance status ≧ 60. The required laboratory tests included a neutrophil count ≧2.0 ×10^9/L, a platelet count ≧100 ×10^9/L, a hemoglobin count ≧100 g/L, and serum creatinine, aspartate aminotransferase, alanine aminotransferase, and a total serum bilirubin ≦ the upper limits of normal.","The exclusion criteria consisted of any of the following: pregnancy; lactation; tracheoesophageal fistula; a history of other malignancies, with the exception of carcinoma in situ of the cervix, nonmelanomatous skin cancer, and cancer from which the patient had not been disease-free for 5 years; a general medical condition preventing combined modality therapy; and a known hypersensitivity to CDDP or 5-FU; as well as any use of a concurrent antineoplastic therapy.",NA,NA
27628195,NA,Combination,No,patients with metastatic or recurrent gastrointestinal cancer,"Patients were eligible for this study if they fulfilled all of the following criteria: (1) histologically confirmed unresectable or metastatic GI or biliary tract adenocarcinoma; (2) age of ≥18 years; (3) Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; (4) at least one measurable lesion, as defined using version 1.1 of the Response Evaluation Criteria In Solid Tumors (RECIST) ; (5) prior adjuvant chemotherapy without oxaliplatin, irinotecan, and S-1 that had been completed >4 weeks before enrollment; (6) adequate hematological, renal, and hepatic functions, as defined using an absolute neutrophil count (ANC) of ≥1.5 × 109/L, a platelet count of ≥100 × 10^9/L, serum creatinine levels of ≤1.4 mg/dL, serum total bilirubin of ≤twofold above the upper limit of normal (ULN), or aspartate aminotransferase and alanine aminotransferase levels of ≤2.5-fold above the ULN (or ≤fivefold above the ULN in the presence of hepatic metastasis); and (7) willing to provide informed consent to participate in this study.","The exclusion criteria were: (1) a history of chemotherapy, with the exception of adjuvant chemotherapy; (2) contraindication for any drug in the OIS regimen; (3) serious GI bleeding or obvious bowel obstruction; (4) central nervous system metastasis; (5) other previous or concurrent malignancies within the last 5 years, with the exception of cured basal cell carcinoma of the skin or carcinoma in situ of the uterine cervix; (6) pregnant or lactating; (7)sexually active and the partner being unwilling to practice contraception during the study; and (8) other clinically significant comorbid conditions, such as active infection or severe cardiopulmonary dysfunction.",during the first cycle,NA
17855009,NA,Combination,No,PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER,"Eligible patients had previously untreated T3 or T4 and N0–N3 and M0 locally advanced rectal cancer, histopathologically confirmed before surgery, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Other eligibility criteria were as follows: age 20–80 years (completed years) at enrollment; no severe disturbance of main organ functions (including bone marrow, heart, lung, liver, and kidney) or blood biochemistry (leukocyte count, 4000–12,000/mm^3; neutrophil count, >= 2000/mm3; platelet count, $100 x 10^3/mL; hemoglobin concentration, $9.0 g/dL; total bilirubin concentration, <= 1.5 mg/dL; serum aspartate aminotransferase and alanine aminotransferase levels, less than twice the upper limit of normal at our hospital; serum creatinine concentration, less than the upper limit of the normal at the hospital; and normal electrocardiographic findings); and the ability to ingest solid foods and drugs orally.",NA,Dose-limiting toxicity was evaluated on the basis of adverse events occurring within 1 week after the completion of chemoradiotherapy.,NA
18510175,NA,Combination,No,elderly patients with nonsmall cell lung cancer,"Eligible patients were required to have histologically and/ or cytologically proven unresectable stage IIIB or IV NSCLC; no previous chemotherapy or radiotherapy; a PS of 0–1 on the Eastern Cooperative Oncology Group; an age more than 70 years; a life expectancy of 12 weeks or more; adequate bone marrow reserve (leukocyte count >= 4000/mm3, neutrophil count >= 2000/mm3, platelet count >= 100 000/mm3, and hemoglobin >= 10 g/dl); normal liver function (total serum bilirubin <= 1.5 mg/ dl, and aspartate transaminase, alanine transaminase less than twice the upper limit of the normal range), normal renal function (normal serum creatinine and blood urea nitrogen levels), and pulmonary function (PaO2 Z 60 Torr).","Patients with concomitant malignancy, central nervous system metastases, active infectious diseases, or other serious medical problems were ineligible.",during the first one cycle,NA
27317556,NA,Combination,No,Patients with locally advanced lower rectal cancer (SAMRAI-1),"Eligible patients had to satisfy all of the following criteria: (1) a histologically confirmed diagnosis of rectal cancer (adenocarcinoma); (2) resectable clinical stage T3 or T4, N0-2 disease with the primary tumor located either above or below the peritoneal reflection, the inferior tumor margin located distally to the peritoneal reflection, and no enlarged nodules measuring >= 10 mm in diameter suggesting extramesorectal metastasis on computed tomography (slice width, <= 5 mm) (i.e., no distinct metastasis to lateral lymph nodes), as confirmed by imaging studies performed within 4 weeks before enrollment; (3) no hepatic, peritoneal, or distant metastasis; (4) an age of 20–80 years at enrollment; (5) no previous treatment; and (6) no severe compromise of main organ functions, with a white cell count of 4000/lL or more and less than 12,000/lL, a platelet count of 100 x 10^3/lL or more, a hemoglobin level of 9.0 g/dL or more, a total bilirubin level of 1.5 mg/dL or less, aspartate aminotransferase and alanine aminotransferase levels of less than twice the institutional upper limit of normal, a serum creatinine level of less than the institutional upper limit of normal, and an creatinine clearance rate of 50 mL/min or more. Patients also had to have ECOG performance status of 0 or 1 and to be able to orally receive drugs. Written informed consent was obtained from all patients before enrollment.","Patients were excluded from the study if they had any of the following conditions: a history of serious drug hypersensitivity; active double cancer or multiple colorectal cancers; a genotype of UGT1A1*6/*6, UGT1A1*28/*28, or were heterozygous for both (UGT1A1*6/*28); active infection (fever of 38.0 °C or higher); serious complications (e.g., intestinal paralysis or intestinal obstruction); a history of interstitial pneumonia; diarrhea (watery stool); or positive test results for HBs antigen. In patients with a genotype of UGT1A1*6/*6 or UGT1A1*28/*28 or who were heterozygous for both UGT1A1*6/*28, treatment with irinotecan has been reported to possibly cause serious adverse events, especially neutropenia. Therefore, patients with these genotypes were excluded from the present study.",DLT was defined as any of the following events or conditions occurring within 28 days after the completion of chemoradiotherapy,NA
18841161,NA,Combination,No,Patients with inoperable/metastatic oesophageal squamous cell carcinoma or adenocarcinoma.,"Eligible patients were required to meet all of the following criteria: locally advanced (tumour length >= 5 cm) or metastatic adenocarcinoma, squamous cell or adenosquamous carcinoma of the oesophagus; aged 18– 75 years; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2; not suitable for oesophageal resection according to a multidisciplinary team; no prior chemotherapy or chest irradiation; length of radiotherapy field <= 30 cm; peripheral neuropathy <= grade 1 NCI common terminology criteria (CTC) version 2.0 (NCI); sufficient calorific intake; adequate bone marrow function (absolute neutrophil count (ANC) >= 2 x 10^9 l^-1, platelet count X100 >= 10^9 l^-1), normal renal and liver function.","Patients were excluded if they were presenting small cell or undifferentiated carcinoma of the oesophagus, complete dysphagia, weight loss 420% of normal body weight, history of prior malignancies (other than cured non-melanoma skin cancer, cured cervical carcinoma in situ or stage I or II node-negative head-and neck cancer cured more than 3 years ago), prior neck radiotherapy with field overlapping the proposed oesophageal radiotherapy field, brain or leptomeningeal metastases, tracheo – oesophageal fistula or biopsy-proven invasion of the tracheo – bronchial tree.",NA,NA
16638094,NA,Combination,No,Patients with advanced pancreatic cancer,"Patients with newly histopathologically proven unresectable, locally advanced or metastatic adenocarcinoma of exocrine pancreas were enrolled into the study. The eligibility criteria included chemonaive patients with at least one measurable lesion; Eastern Cooperative Oncology Group (ECOG) performance status ≤3; age ≥15 years; white cell count ≥3000/μL; platelet count ≥100 000/μL; total bilirubin <3.0 mg/dL; serum creatinine level ≤1.6 mg/dL; and transaminases <4 times the upper limit of normal.","Patients with central nervous system metastases, concurrent second primary malignancies, pregnancy, uncontrolled active infection or other concomitant serious disease were excluded.",First cycle,NA
31765987,NA,Combination,No,Patients with metastatic pancreatic adenocarcinoma,"The inclusion criteria were as follows: (1) histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas with at least one measurable lesion; (2) aged between 20 and 75 years; (3) Eastern Cooperative Oncology Group Performance status of 0 or 1; (4) adequate organ functions (detail in supplement); (5) no history of prior chemotherapy, except adjuvant therapy that was completed at least 6 months before enrolment and (6) prior radiotherapy if the source of the measurable lesions was not included in the previous radiation filed.","The exclusion criteria were as follows: (1) major abdominal surgery, radiotherapy or other investigating agents within 4 weeks; (2) known or suspicious brain tumours; (3) uncontrolled active infection or active cardiopulmonary disease; (4) pregnancy or breastfeeding and (5) concurrent malignancy except for adequately treated in situ carcinoma of the cervix, adequately treated basal cell carcinoma of the skin or any malignancy that remains disease-free for 3 or more years.",during the first 2 cycles,NA
19551382,NA,Combination,No,Patients with previously untreated advanced gastric cancer,"Patients aged from 18 to 70 years with histologically conWrmed unresectable or metastatic adenocarcinoma of the stomach, with the following inclusion criteria, were eligible: Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; no prior palliative chemotherapy or radiotherapy; adequate bone marrow, renal, and liver functions; and written informed consent. Prior to adjuvant chemotherapy that did not contain 5-FU derivatives or platinum was allowed if it was completed at least 6 months before enrollment. In phase II study, measurable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) were required.","Patients were excluded if they had brain metastasis, obvious gastrointestinal obstruction, signiWcant gastrointestinal bleeding, serious comorbid medical illness, or peripheral neuropathy  >= grade 2.",first treatment cycle,NA
17579864,NA,Combination,No,patients with metastatic or recurrent gastric cancer,"All patients with advanced, histologically conWrmed adenocarcinoma of stomach were eligible if they met the following inclusion criteria: age 18–70 years; ECOG performance status 0–2; no previous palliative chemotherapy or radiotherapy; ability for suYcient oral intake; adequate bone marrow, renal, and hepatic function; and written informed consent. The presence of measurable lesions by the response evaluation criteria in solid tumors group (RECIST) criteria was required for enrollment in the phase II study.","Patients were excluded if they had brain metastases, signiWcant gastrointestinal bleeding, had serious comorbid condition, or the use of concomitant drugs which have potential interaction with S-1.",The Wrst two treatment cycles,NA
29971467,NCT02102022,Combination,No,patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies,"Patients 18 years of age or older, with histologically proven advanced gastrointestinal cancers for the dose escalation (Cohort 1 and 2) and HCC for the dose expansion were eligible. Patients had evaluable disease assessed by an radiologist blinded to the clinical care of patients by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1) . HCC patients were required to have progressed or have had intolerable toxicity on sorafenib, the sole standard of care at that time. Patients with pancreatic ductal adenocarcinoma (PDAC) were required to have progressed on a gemcitabinebased regimen, while other gastrointestinal malignancies could be treatment-naïve or had progressive disease on any form of prior systemic therapies. Any number of prior treatments was allowed for all patients. Additional criteria included Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, adequate hematologic, hepatic, and renal function. Specific criteria for HCC included intact hepatic function with a Child Pugh A score. Patients with hepatitis B viremia (HBV) were required to be maintained on antiviral therapy. All patients were required to have archival tissue for ASS1 determination, and if unavailable, the investigator could opt to obtain a pretreatment biopsy.","Exclusion criteria included anticancer therapy within 4 weeks of entering the study, except radiation therapy for symptomatic treatment within 2 weeks of study entry which was then amended to 2 weeks for any anticancer treatment, ongoing toxic manifestations of previous treatments, ≥ grade 2 peripheral sensory neuropathy, symptomatic brain or spinal cord metastases, significant concomitant or uncontrolled intercurrent illness, recent major surgery, history of another primary cancer (unless treated curatively or unlikely to affect patient outcome), allergy to platinum or pegylated or Escherichia coli products, pregnancy, history of seizure disorder, and previous therapy with ADI-PEG 20.",cycle one,NA
18176087,NA,Combination,No,Patients with Advanced or Recurrent Gastric Cancer,"All patients enrolled in this study attended the Osaka University Hospital (Osaka, Japan) or Toyonaka Municipal Hospital (Osaka, Japan) between January 2004 and March 2007. The inclusion criteria were (1) histopathologically confirmed advanced or recurrent gastric cancer; (2) presence of measurable lesions; (3) no prior chemotherapy except for adjuvant chemotherapy using neither taxanes nor S-1 more than 4 weeks prior to entry; (4) performance status 0–1 on the Eastern Cooperative Oncology Group Scale; (5) age 20–75 years; (6) estimated life expectancy of at least 3 months; (7) adequate organ functions, defined as leukocyte count >3,000/mm3, neutrophil count >1,500/mm3, platelet count >100,000/mm3, hemoglobin >8.0 g/dl, serum transaminase (aspartate aminotransferase and alanine aminotransferase) level below twice the upper limit of the normal range of each hospital, serum bilirubin level <1.5 mg/dl, serum creatinine level below the upper limit of the normal range of each hospital;(8) no other active malignancies, and (9) provision of a written informed consent. ","Patients were excluded if they had severe comorbid conditions, infectious diseases, severe pleural or peritoneal effusion, brain metastasis, peripheral neuropathy and a past history of drug allergy. Pregnant and breast-feeding women were also excluded.",during the first treatment course,NA
17720738,NA,Single Drug,No,Patients with Advanced/ Recurrent Colorectal Cancer,"Patients enrolled in this study were required to have histologically proven adenocarcinoma of the colon or rectum that was considered to be inoperable and to have at least one measurable metastasis (RECIST criteria). Patients also had to be older than 18 years and aged under 75 years, be expected to survive for more than 3 months after starting chemotherapy, have a performance status of 0 –1 on the Eastern Cooperative Oncology Study Group (ECOG) scale, and have no problems with oral intake. Other eligibility criteria included a white blood cell count of 4000 – 12 000/mm3, a neutrophil count >2000/mm3,a platelet count >100 000/mm3, a hemoglobin >8.9 g/dl, AST and ALT <2.5 times the institutional upper limit of normal (ULN) total bilirubin <1.5 mg/dl, and creatinine , the ULN.","Exclusion criteria included the following: previous CPT-11 treatment; concomitant treatment with other chemotherapy agents or radiation within the previous 2 weeks or failure to recover from adverse effects; interstitial pneumonia or pulmonary fibrosis causing chest X-ray changes or symptoms (or a history of these diseases); a fluid collection in a body cavity that needed treatment; concurrent active cancer originating from a site other than the colorectum or metachronous cancer that was untreated or had a disease free period ,5 years (except carcinoma in situ or surgically treated skin cancer); infectious disease or intestinal paresis or obstruction; watery diarrhea; poorly controlled diabetes mellitus; uncontrolled medical conditions such as cardiac failure, hepatic failure, or renal failure; symptomatic brain metastasis; actual or potential pregnancy, breast-feeding status, or the intention to become pregnant in the near future; a past history of serious drug allergy; or any other condition that was judged to make the patient ineligible for this study by the responsible physician.",NA,NA
28293715,UMIN000016630,Combination,No,patients with locally advanced pancreatic adenocarcinoma,"Patients eligible for study entry had LAPC which was classified into borderline resectable or unresectable pancreatic cancer without distant metastasis based on the resectability status of the National Comprehensive Cancer Network (NCCN) 2016, version 2. Eligibility criteria were as follows: (1) a histologically or cytologically proven diagnosis of adenocarcinoma or adenosquamous carcinoma; (2) tumor with contact with the major arteries including the superior mesenteric artery, celiac artery, or common hepatic artery on pretreatment computed tomography (CT); (3) no previous antitumor treatment except for biliary drainage; (4) age between 20 and 79; (5) Eastern Cooperative Oncology Group (ECOG) performance status of 0–1; (6) adequate hematological, hepatic, and renal functions by hemoglobin ≥8.0 g/dL, leucocytes ≥3000/ mm3 and ≤12,000/mm3, neutrophils ≥1500/mm3, platelets ≥100,000/mm3, total bilirubin ≤2.0 mg/dL, aspartate aminotransferase and alanine aminotransferase ≤100 U/L, serum creatinine ≤1.2mg//dL, and albumin ≤3.0 g/dL; and (7) adequate oral intake.",NA,DLTs were determined during the 6 cycles of neoadjuvant chemotherapy.,NA
16684860,NA,Combination,No,Patients with Colorectal Cancer,"Patients with histologically confirmed colorectal cancer who had measurable metastatic disease were eligible for the study. Prior chemotherapy and radiotherapy for metastatic disease were not permitted. Patients who had received adjuvant oral fluorouracil-based therapy were eligible if they had remained free of disease for at least 6 months after the completion of such therapy. Other eligibility criteria included an age of 20–75 years; an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; adequate baseline bone marrow function (white blood cell [WBC] count more than the lower limit of normal at each hospital and <12 000/ml, neutrophil count >2000/ml and platelet count >100 000/ml), hepatic function (serum bilirubin level 1.5 times the upper limit of normal or less, and serum aspartate aminotransferase and alanine aminotransferase 2.5 times the upper limit of normal or less) and renal function (serum creatinine level 1.5 times the upper limit of normal or less); and a life expectancy of at least 12 weeks. All patients gave written informed consent.","Patients were excluded if they had symptomatic brain metastasis; pre-existing watery diarrhea; concomitant nonmalignant disease, such as cardiac, pulmonary, renal or hepatic disease; or uncontrolled infection. This study was approved by the institutional review board of each center. Before enrollment,all patients underwent a physical examination (including documentation of measurable disease), a complete blood cell count with differential count, serum chemical analysis, chest radiography, electrocardiography, and computed tomographic (CT) scanning or magnetic resonance imaging (MRI).",during cycle 1,NA
16636336,NA,Combination,No,Patients With Locally Advanced Rectal Cancer: Cancer and Leukemia Group B 89901,"Patients entering the study had histologically confirmed rectal adenocarcinoma beginning within 12 cm of the anal verge, as determined by endoscopy. The tumor had to be fixed on physical examination or have evidence of T3 or T4 disease by endoscopic ultrasound or magnetic resonance imaging. In addition, patients could have no evidence of metastatic disease by abdominal computed tomography scan and could have no history of neuropathy. We included patients with granulocytes >= 1,500/uL, platelets >= 1,500/uL, bilirubin <= the upper limit of normal, AST or ALT <= 2.5 x the upper limit of normal, and creatinine <= 1.5 mg/dL or creatinine clearance >= 60 mL/min/ 1.73 m2.",NA,First cycle,NA
17133268,NA,Combination,No,patients with unresectable and/or recurrent advanced gastric cancer,"Eligible patients had histologically proved unresectable or recurrent gastric cancer. Up to one regimen of prior chemotherapy was allowed (adjuvant chemotherapy was allowed provided that at least 28 days had elapsed since the last treatment), except for prior treatment with taxanes (paclitaxel or docetaxel). Other inclusion criteria were as follows: an age of 20 – 75 years; a performance status of 0 – 1 (Eastern Clinical Oncology Group); an estimated life expectancy of more than 3 months; a white blood cell count between 4000 and 12 000 mm-3; an absolute neutrophil count of over 2000 mm-3, a platelet count of over 100 000 mm-3,a haemoglobin level of over 8.0 g dl-1; aspartate aminotransferase and alanine aminotransferase levels within two times the upper limit of normal for the institution; a serum bilirubin level of less than 1.5 mg dl-1; a serum creatinine level within the upper limit of the normal value for the institution; a 24-h creatinine clearance of more than 50 ml min-1; and a normal electrocardiogram. Only patients who could swallow tablets were eligible.","Patients were excluded if they had brain metastases, severe comorbid conditions, active double cancers, a past history of drug allergy, or were unable to comply with the protocol requirements. Pregnant women were also excluded.",NA,NA
19934112,NA,Combination,No,Patients with Advanced/Recurrent Head and Neck Cancer,"histologically or cytological confirmed HNC (excluding thyroid cancer), unresectable locally advanced (Stage III/IV disease) and recurrent or distant metastasis, at least measurable disease after prior treatment. If the patients had received prior treatment, radiotherapy more than 28 days, surgery and chemotherapy or adjuvant chemotherapy more than 14 days was required before registration. Other eligibility criteria included the following: age 20 – 80 years, Eastern Cooperative Oncology Group (ECOG) performance status 0 – 1, life expectancy > 3 months, adequate bone marrow, hepatic and renal functions (reflected by an absolute hemoglobin level of .9.0 g/dl, leukocyte count . lower limit of normal, platelet count >100 x 10^-9 cells/l, normal bilirubin level of < 1.5 mg/dl, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels <2.5 times the upper limit of normal, serum creatinine level , upper limit of normal and creatinine clearance > 70 ml/min). Within 14 days before registration, all patients underwent a complete physical examination that included their medical history, blood count,serum biochemistry tests (hepatic and renal function tests and electrolytes), urinalysis and echocardiography; a chest radiograph (X-ray) and computed tomography (CT) or magnetic resonance imaging scans of all disease sites were obtained during the 28 days before registration. Patients who had undergone induction chemotherapy with CDDP/5-FU or platinum-based chemotherapy were excluded from the Phase II study unless it used a lower dose as a sensitizer of CCRT.","The exclusion criteria were as follows (summary): severe drug hypersensitivity, pulmonary fibrosis or interstitial pneumonia, severe heart disease, difficult-to-control diabetes, active infection or acute inflammation, active concomitant malignancy, and other serious medical conditions. Patients were required to give written informed consent before admission to the study.",NA,NA
18379784,NA,Combination,No,patients with unresectable or recurrent gastric cancer,"Patients were eligible for this study if they had a histopathologically or cytologically conWrmed diagnosis of unresectable or recurrent gastric cancer, irrespective of whether they had received previous treatment; if they were at least 20 and younger than 75 years; if they had a performance status of 0 to 1; and if they were expected to survive for at least 3 months. Other eligible criteria were no severe dysfunction of major organs such as the marrow, heart, lung, liver, and kidney; a leukocyte count of 4,000–12,000 per uL, a neutrophil count of  ̧2,000 per uL, a platelet count of >=̧1000 £ 10^3 per uL, a hemoglobin level of >= ̧8.0 g/dL, serum aspartate aminotransferase and alanine aminotransferase levels not exceeding twice the upper limits of normal, a serum total bilirubin level of <=1.5 mg/dL, a serum creatinine level not exceeding the upper limit of normal, a creatinine clearance of at least 50 mL/min, a clinically normal electrocardiogram (clinically irrelevant abnormalities allowed); and the ability to take oral medications. All patients gave written informed consent to participate in the study.",NA,during the Wrst course of treatment,NA
17437021,NA,Combination,No,patients with unresectable pancreatic cancer,"Patients with histologically or cytologically confirmed adenocarcinoma of the pancreas were enrolled onto this study from July 2004 to December 2005 at the Kagoshima University Hospital. Eligible patients were clinically or surgically staged and considered unresectable for cure. Patients with metastatic disease were eligible if the principal symptom associated with their primary disease was pain and if they had an estimated life expectancy greater than 6 months. Eligibility criteria also included the following: age >= 20 years; Eastern Cooperative Oncology Group performance status of 0 – 2; measurable or assessable disease; life expectancy of > 3 months; adequate organ function defined as granulocyte count of >= 1500 ul –1, haemoglobin >= 8 gdl–1, platelet count >= 100 000 ml –1, bilirubin <=1.5 mg dl –1, and creatinine <= 2.5 mg dl –1. If the patients had any previous chemotherapy, radiotherapy or combinedmodality treatment for either advanced disease or postoperative adjuvant therapy, that treatment had to have been discontinued for at least 4 weeks before entry into the study.","The exclusion criteria were as follows: active infection, severe heart disease, interstitial pneumonitis or pulmonary fibrosis, pleural effusion or ascites, active gastroduodenal ulcer, pregnant or lactating females, severe mental disorder, active concomitant malignancy, and other serious medical conditions. The patients who did not have sufficient integrity of the gastrointestinal tract or who had malabsorption syndrome were also excluded.",NA,NA
20694727,NA,Combination,No,patients with resistant solid tumor malignancies,"Patients at least 18 years of age were eligible for enrollment into the study if they had a histologically confirmed malig- nant solid tumor for which standard curative treatment did not exist or was no longer effective, measurable or evaluable disease, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2. Laboratory criteria included absolute neutrophil count >= 1,500/ul, platelet counts >= 100,000/ll, serum creatinine <= 1.5 x upper limit of normal (ULN), aspartate aminotransferase and alanine aminotransferase <= 3 x ULN, and total bilirubin <= 1.5 x ULN. Prior chemotherapy or radiotherapy must have been completed at least 4 weeks prior to treatment. Patients with brain metastasis, known sensitivity to UCN-01 or irinotecan, insulin-dependant diabetes mellitus or uncontrolled inter- current illness, diagnosis of Gilbert’s disease, or chronic unconjugated hyperbilirubinemia were excluded. Initially, all patients on this trial were required to have a DLCO >= 60% and oxygen saturation >=90% on room air at rest and after a 6-min walk. However, to increase eligibility, the requirement to obtain a DLCO was removed.",NA,NA,NA
28233053,NA,Single Drug,No,patients with recurrent high-grade glioma,"Eligibility criteria for this phase 1 clinical trial included unequivocal radiographic or pathologic confirmation of recurrent high-grade glioma (glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, or malignant astrocytoma NOS); age ≥18; Karnofsky Performance Status score of ≥60;adequate organ and bone marrow function; lack of other cancer, infection, or serious medical problem; and patients could not be on any enzyme-inducing drugs including enzyme-inducing anticonvulsants. There were no limits on number of prior recurrences or prior treatments aside from exclusion of patients who had previously been treated with irinotecan. Patients were stratified by UGT1A1 genotype; patients who were homozygous wild-type were enrolled in the wild-type (WT) cohort, while patients who were heterozygous wild-type/*28 were enrolled into the heterotype (HT) cohort.",Patients who were homozygous 7/7 *28 were not eligible for study enrollment.,The assessment period for dose-limiting toxicity was 1 cycle (21 days).,NA
27061418,NA,Combination,No,Patients with previously treated advanced solid tumors and acceptable organ function,The main eligible patient selection criteria are the following: histologically confirmed refractory solid tumors with no known regimen of higher efficacy available; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; normal organ and marrow function; no prior chemotherapy within 4 weeks; no history of brain metastases unless irradiated ≥4 weeks previously and off corticosteroids for >1 week;,"patients with a history of a serious ventricular arrhythmia, QTc prolongation, or left ventricular ejection fraction (LVEF) ≤40 % as well as patients who tested positive for anti-HbsAg, anti-HCV, anti-HIV, or antisyphilis antibodies were excluded.",during cycle 1,NA
8217238,NA,Combination,No,Patients with Gastrointestinal Malignancies,"Patients had to have fulfilled all the following criteria in order to be eligible for this study: I) primary diagnosis of histologically proven gastrointestinal cancer; 2) failure of any conventional therapy; 3) at least 18 years of age and have an ambulatory performance status above 60% on the Karnofsky scale; 4) normal cardiac function, preserved hepatic and renal functions, and normal blood counts; and 5) a minimum life expectancy of 3 months as well as the ability to understand and to sign a written informed consent.","Patients were excluded if they had undergone previous treatment with IFN-alpha-2a or had brain metastasis or a known seizure disorder. Treatment with chemotherapy, immunotherapy or radiotherapy less than 3 weeks prior to entry was not acceptable, nor was on-going treatment with corticosteroids. Patients needed to have evaluable or measurable disease.",NA,NA
7882458,NA,Combination,No,"15 patients were accrued between May 1990 and July 1991. Primary sites were unknown (3), colorectal (3), head and neck (2), lung (2), gynecologic (1), gallbladder (1), sarcoma (1), anal canal (1) and pancreas (1).","Patients must have fulfilled all the following criteria to be eligible for this study: 1. A primary diagnosis of histologically proven cancer for which standard therapy is not of proven benefit or for which the established standard therapy has proved unsuccessful in that patient 2. An age of 18 years or more and an ambulatory performance status of above 60% on the Karnofsky scale (KS). 3. Normal cardiac function, preserved hepatic and renal functions and normal blood counts. 4. A minimal life expectancy of 3 months was required as well as the ability to understand and sign a written informed consent form.","Patients were excluded if they had prior treatment with IFN, brain metastases or a known seizure disorder. Treatment with chemotherapy (6 weeks in the case of mitomycin C or the nitrosourea), immunotherapy or radiotherapy at less than 3 weeks prior to entry was not acceptable, nor was ongoing treatment with corticosteroids.",NA,NA
30838483,"UMIN-CTR, ID: 000015764",Combination,No,patients with refractory metastatic colorectal cancer,"Eligible patients had a histologically confirmed diagnosis of mCRC and had shown a response or stable disease (SD) before confirmed progression during previous oxaliplatin-based therapy at least 6 months before entering the study. Patients also met the following criteria: age over 20 but less than 80 years; Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1; has failed at least two previous chemotherapies that included 5-fluorouracil, oxaliplatin, irinotecan, bevacizumab, anti-EGFR antibody if KRAS exon2 wild-type; measurable or evaluable disease; life expectancy ≥12 weeks; neutrophil count ≥1500/mm3; platelet count ≥100,000/mm3; hemoglobin ≥9.0 g/dL; total bilirubin ≤1.5 mg/dL; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times the upper limit of normal (ULN) (≤5.0 if liver metastases were presents); serum creatinine ≤1.5 times the ULN, and signed informed consent.","Patients with any of the following conditions were excluded: treatment history of FTD/TPI; severe peripheral sensory neuropathy (PSN); a history of serious hypersensitivity to drugs; bleeding from tumor affecting hemodynamics; multiple primary cancers within the past 5 years; ascites, pleural or pericardial effusion requiring drainage; uncontrolled diabetes; uncontrolled hypertension; cirrhosis, liver failure, renal failure; paralytic or mechanical bowel obstruction; interstitial lung disease, severe emphysema or pulmonary fibrosis; active infection; history of myocardial infarction within the previous 6 months; uncontrolled angina pectoris or arrhythmia; cerebrovascular disorder or brain metastases; hemorrhagic ulcer requiring blood transfusion; clinically significant mental or psychological disease; and any other condition making a patient unsuitable for this study.",during the first treatment cycle,NA
25860347,NCT01136031,Combination,No,fluoropyrimidine- and platinum-pretreated patients with metastatic or recurrent gastric cancer.,"Patients over 18 years of age, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, histologically confirmed adenocarcinoma of the stomach and initially metastatic or recurrent gastric cancer refractory to a prior single-chemotherapy regimen including fluoropyrimidine and platinum were eligible. Patients also had to have at least one measurable lesion based on RECIST version 1.0 criteria. Patients had to have adequate hematologic, hepatic, and renal function (absolute neutrophil counts > 1.5 × 109/L, thrombocytes > 100 × 109/L, total bilirubin < 1.5 × upper limit of normal, aminotransferase < 2.5 × upper limit of normal, and alkaline phosphatase < 2.5 × upper limit of normal).","UGT1A1 polymorphisms were tested, and patients with homozygosity of the UGT1A1*28 allele (TA)7/7 was excluded. Patients with previous active or passive immunotherapy, allogeneic organ transplantation requiring immunosuppressive therapy, intestinal obstruction or impending obstruction, recent active upper gastrointestinal bleeding, pregnant or lactating patients, those with interstitial pneumonia or diffused symptomatic fibrosis of the lungs, clinically significant (i.e., active) heart disease (e.g., congestive heart failure, symptomatic coronary artery diseases, cardiacarrhythmias), or patients with grade 1 peripheral neuropathy according to the NCI CTCAE 3.0 caused by other factors (e.g., alcohol, diabetes) were excluded.",NA,NA
33611805,NA,Combination,No,Patients with Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy,"(a) age ≥3 years; (b) histologically confirmed recurrent or refractory unresectable EWS, but EWS-FLI 1 translocation by fluorescence in situ hybridization was not required in this study; (c) prior treatment consisted of standard EWS chemotherapy agents such as doxorubicin, vincristine, cyclophosphamide, ifosfamide, and etoposide; (d) adequate organ function; (e) an Eastern Cooperative Oncology Group performance status of 0 or 1; (f) an estimated life expectancy of ≥3 months; and (g) time elapsed from previous therapy must be ≥3 weeks for systemic therapy and ≥2 weeks for radiation therapy or major surgery. For the phase II portion, the existence of an evaluable lesion according to the RECIST version 1.1 was required in addition to the general criteria of phase Ib.","Patients were excluded if they had (a) poorly controlled hypertension; (b) metastasis to the central nervous system; (c) persistent clinically significant toxicities caused by previous cancer therapy; and/or (d) active hepatitis B, hepatitis C, or HIV.",NA,NA
8426214,NA,Combination,No,patients with Head and Neck Cancer,"eligible patients had histologically or cytologically confirmed squamous-cell or mucoepidermoid carcinoma or lymphoepithelioma ofthe head and neck. All patients were previously untreated and had stage IV disease; patients with stage III disease were eligible only if they had a location of the primary tumor in the base of tongue or hypopharynx. A performance status of _<2 (Cancer and Leukemia Group B), normal bone marrow and renal function, and signed informed consent were also required. There was no upper age limit. Initial evaluation included a history and physical examination, complete blood cell (CBC) count, serum chemistries, chest radiograph, bone scan, barium swallow, and a computed tomographic (CT) or magnetic resonance (MRI) scan of the head and neck. Local tumor extent and regional metastases were further assessed by triple endoscopy. Schematic tumor maps were drawn and the clinical stage determined at a multispecialty patient management conference according to the 1988 American Joint Committee for Cancer Staging.",NA,The toxicities observed following cycle 1,NA
21424369,NA,Combination,No,Patients with peritoneal carcinomatosis (PC),"The inclusion criteria were: (1) age between 18 and 65 years, (2) PC of colorectal or gastric origin, pseudomyxoma peritonei, peritoneal mesothelioma or primary peritoneal serous carcinoma, (3) PC considered resectable based on clinical and radiological investigations as previously described, and (4) signed informed consent","The exclusion criteria were: (1) World Health Organization (WHO) performance status[2, (2) cardiopulmonary failure: dyspnea class [1 (New York Heart Association classification), or PaO2 at rest \60 mmHg or left ventricular ejection fraction \60%, (3) renal failure: serum creatinine [120 lmol/l, (4) hepatic failure: prothrombin level \70%, (5) leukopenia \1,500/ll, (6) thrombocytopenia \100,000/ll, (7) central nervous system disease (vascular or neoplastic), (8) more than one isolated hepatic metastasis, and (9) pregnancy.",NA,NA
21509928,NCT00143533,Combination,No,Pediatric Patients With Refractory Solid Tumors,"Criteria included age <=21 years, histologically verified solid tumor refractory to conventional therapy, Karnofsky or Lansky score >=50%, life expectancy >8 weeks, recovery from the acute toxic effects of prior therapy, normal bone marrow without transfusion [(ANC) >= 1,000/ml, platelet count >= 75,000/ml, and hemoglobin >= 8 g/dL)]; renal (creatinine level <= 3x normal for age); and liver function (serum bilirubin <= 3x normal, and ALT elevation <= 3x normal).","For patients with CNS disease, any deficits must have been stable for at least 2 weeks with a stable or decreasing dexamethasone dosage. Pregnant or breastfeeding patients were excluded. Patients receiving anticonvulsants that interact with CYP3A (i.e., phenytoin, carbamazepine, oxcarbazepine, and phenobarbital) were excluded. Additional exclusion criteria were uncontrolled infection and previous allergic reaction to penicillin or cephalosporins.",Toxicity assessment during the first course was used to assess DLT,NA
24958824,NA,Combination,No,The UGT1A1 Genotype of Patients With Cancer,"Patients with histologically confirmed solid tumors or lymphoma refractory to standard therapy were enrolled. Eligibility criteria included UGT1A1 *1/*1,*1/*28, and *28/*28 genotypes。 astern Cooperative Oncology Group (ECOG) performance status of 0 to 1; measurable or assessable disease; life expectancy greater than 3 months, age 18 years or older; leukocyte count greater than 3,000/muL; absolute neutrophil count (ANC) at least 1,500/muL; platelet count at least 100,000/muL; total bilirubin within normal institutional limits; ALT and AST levels at less than 2.5 times the upper limit of normal; and a serum creatinine level within normal institutional limits or a glomerular filtration rate greater than 50 mL/min/1.73 m2 for patients with creatinine levels above institutional normal as calculated by the modified Modification of Diet in Renal Disease equation recommended by the National Kidney Disease Education Program.",patients carrying the rare UGT1A1*36 and UGT1A1*37 alleles captured by the assay were not eligible,at cycle 1,NA
7917927,NA,Combination,No,"Twenty-nine patients with adenocarcinomas of gastrointestinal or unknown primarv, and three with advanced neuroendocrine tumours,","Patients were eligible for the study if they had histologically confirmed adenocarcinoma of the gastrointestinal tract, adenocarcinoma of unknown primary or neuroendocrine tumour and had not previously been treated with chemotherapy. Two patients were treated adjuvantly following resection of stage C3 colonic carcinoma. For all others, the indication for chemotherapy was advanced disease not amenable to local treatment modalities, and all but one had measurable disease by CT scan. Life expectancy of > 3 months and Karnofsky performance status of > 60% were required, as were pretreatment WBC > 3.5 x 109 , neutrophils > 2 x 109  and platelets > 150 x 109 .",Patients with creatinine or EDTA clearance of <50 mlmin'- were excluded because of the likely effect on IFN-x pharmacokinetics,NA,NA
20405511,NA,Combination,No,Children With Refractory Solid Tumors,"Patients under age 22 years with relapsed and/or refractory malignant solid tumors without known effective therapy, including CNS tumors and lymphoma, were eligible. Patients were enrolled at least 3 weeks after their last myelosuppressive chemotherapy and at least 6 months after hematopoietic stem cell transplant. Patients were required to have adequate renal function (serum creatinine [Cr] < twice upper limit of normal for age), adequate hepatic function (serum bilirubin <1.5 mg/dl), and adequate peripheral blood counts (defined as absolute neutrophil count [ANC] > 750/ mm3 and platelets >75,000/mm3) unless bone marrow was involved with tumor.","Patients with leukemia, uncontrolled infection, or those that had received more than four prior chemotherapy regimens were not eligible. Additional exclusionary criteria included patients who were pregnant or breast-feeding and those who were receiving P450 enzyme inducing anticonvulsants (due to documentation of the effects of anticonvulsants on irinotecan clearance)",NA,NA
33289920,NCT02044120,Combination,No,Patients With Advanced Ewing Sarcoma,"Eligible patients had histologically confirmed advanced ES with EWS translocation by fluorescence in situ hybridization or reverse transcriptase–polymerase chain reaction. Requirements included an age ≥ 13 years, no known curative treatment, an Eastern Cooperative Oncology Group performance status of 0 to 2, 1 or more prior chemotherapy regimens, measurable disease according to RECIST (version 1.1), a life expectancy ≥ 3 months, and adequate hematologic (absolute neutrophil count ≥ 1.0 × 109/L, hemoglobin > 9 g/dL, and platelets > 150 × 109L) and renal function (serum creatinine ≤ 1.5 times the institutional upper limit of normal).","Patients who were previously treated with a PARP inhibitor or had a QTCF value > 480 milliseconds, a known history of myelodysplasia, or active central nervous system disease were excluded.",during the first cycle of treatment,NA
22674635,NCT00520637,Combination,No,Patients With Advanced Malignancies,"To be eligible, patients had to be aged >18 years; have measurable metastatic or advanced malignancies that were not amenable to established forms of therapy; be willing to be tested for uridine diphosphate glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) genotype; and have an Eastern Cooperative Oncology Group performance status of 0 to 210 and adequate hematologic, hepatic, and renal function.","Patients who were pregnant or had chronic enteropathies, symptomatic central nervous system tumor involvement, and unstable or uncompensated respiratory, cardiac, hepatic, or renal disease or any other organ system dysfunction were excluded.",during cycle 1,NA
30406838,NA,Single Drug,No,patients with solid tumors,"Patients with metastatic or unresectable solid tumors for whom no standard treatment options existed were eligible for inclusion. Patients were required to be in performance status 0–1 according to ECOG , have a life expectancy of ≥ 3 month and adequate organ and bone marrow function. ","patients with chronic enteropathy, bowel obstruction or sub-obstruction, prior history of malabsorption or symptomatic brain metastases were excluded",the first two cycles,NA
27920527,NA,Single Drug,No,patients with advanced malignancies,"Patients eligible for this study met the following criteria: histologically confirmed diagnosis of solid tumor refractory to standard therapy or for which no standard therapy existed; age .18 years; life expectancy $3 months; Eastern Cooperative Oncology Group performance status ,2; no chemotherapy, hormonal therapy, immunotherapy, or radiotherapy within 4 weeks before treatment with DTS-108 and no immunosuppressive agents within 3 weeks preceding study entry; and adequate renal function with creatinine clearance $60 mL/min/1.73 m2. Based on known toxicities of campthotecin derivatives, patients who entered into this trial were also required to have no chronic severe diarrhea at baseline and no history of inflammatory bowel disease.",NA,at cycle 1,NA
23921573,NCT00925015,Combination,No,Japanese patients with advanced colorectal cancer,"The main eligibility criteria were as follows: histologically (or cytologically) confirmed advanced colorectal cancer that had previously failed to respond to both irinotecan and oxaliplatin and had progressed on or within 3 months of the last therapy; a patient age of 20 years or older; an Eastern Cooperative Oncology Group performance status of 0 or 1; and adequate hematological, hepatic, and renal functions.","The exclusion criteria included the use of chemotherapy, radiotherapy, or biological therapy within 4 weeks prior to enrollment; primary or unstable central nervous system metastasis; and symptomatic ascites or pleural effusion requiring treatment.",Dose limiting toxicities (DLTs) were evaluated during a prespecified 4-week period,NA
26429709,NCT01009073,Combination,No,adults with advanced solid tumors,"Adult patients were eligible for the study if they had histologically and/or cytologically documented cancer for which irinotecan is an appropriate therapy, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤2, adequate renal and hepatic function (serum creatinine ≤2.0 mg/dL or calculated creatinine clearance ≥50 mL/min; aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ≤3.0× the upper limit of normal [ULN] of the institution’s normal range; and bilirubin ≤1.5× ULN), adequate bone marrow function (absolute neutrophil count [ANC] ≥1000 cells/μL and platelet count >150 × 109/L independent of platelet transfusions within 3 months before receiving study drug; hemoglobin ≥9.0 g/dL), and coagulation parameters of partial thromboplastin time (aPTT) and prothrombin time (PT) <1.2× ULN","Patients were excluded if they had undergone an allogeneic stem cell transplant, had a significant history of cardiovascular disease, or had active bleeding, thrombocytopeniaassociated bleeding within the previous year, or concurrent therapeutic anticoagulant use. Patients were also ineligible if they had active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis, a history of active immune thrombocytopenic purpura, or autoimmune hemolytic anemia, or were refractory to platelet transfusions. In addition, the protocol was amended after the study had commenced (in July 2010, after three patients experienced dose-limiting toxicities [DLTs]) to exclude patients who were UGT1A1*28 7/7 homozygous because of the known increased risk of irinotecan toxicities in this patient group",NA,NA
30859690,C000000314,Single Drug,No,Children aged 2–18 years with solid tumors who were either refractory to or relapsed after standard chemotherapy were enrolled.,"Patients aged 2–18 years with a relapsed/refractory disease including neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, retinoblastoma, nephroblastoma, hepatoblastoma, osteosarcoma, synovial sarcoma, leiomyosarcoma or any other solid tumor of non-epithelial origin were eligible. Patients on standard chemotherapy without relapse or refractory tumor were considered for enrollment if they were unable to continue chemotherapy due to adverse reactions. Performance status ≥ 50 points on the Karnofsky/Lansky scale and ≥3 months’ life-expectancy were required. Patients had to have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0.15 An interval > 28 days from the last date of therapy and adequate organ function including absolute neutrophil count ≥ 1,000/mm3, platelet count ≥ 50 000/mm3, hemoglobin ≥ 8.0 g/dL, serum aspartate aminotransferase, alanine aminotransferase <3-fold the upper limit of the normal range, serum total bilirubin ≤ 1.5 mg/dL, and serum creatinine ≤ 1.2 mg/dL were required. Hospitalization at least during the first course of chemotherapy was required for close observation. Informed consent was obtained according to the guidelines of the institutional review board (IRB).","Patients were excluded if they had concurrent active malignancy in a different site, symptomatic metastasis to the central nervous system or primary central nervous system tumor. Patients with serious complications such as infection, diarrhea, gastrointestinal obstruction, paralytic ileus, malignant fluid retention, interstitial pneumonia, pulmonary fibrosis, cardiac disease or other disease that might interfere with the trial were excluded. Patients were excluded if they were pregnant or breast-feeding or had a past history of serious drug allergy or IRI treatment. Transfusion of blood and blood-products and hematopoietic growth factors such as granulocyte colony-stimulating factor were prohibited in the 7 days prior to registration.",the first course of treatment,NA
30167847,18606,Combination,No,Patients with advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane,"Inclusion criteria were age ≥20 years; histologically confirmed unresectable or recurrent gastric or gastro-esophageal junction adenocarcinoma, previously treated with one or more chemotherapy regimens involving both fluoropyrimidine and taxanes with/without platinum; evaluable lesion according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; estimated life expectancy ≥ 3 months; and adequate organ function, as defined by hemoglobin (Hb) ≥ 8 g/dL, absolute neutrophil count (ANC) ≥1500/mm3, platelet count ≥ 100,000/mm3, total bilirubin ≤ 1.5 mg/dL, serum transaminase level ≤ 150 U/L, creatinine ≤ 2.0 mg/dL, and ≤ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grade 3 proteinuria. Exclusion criteria were brain metastasis, poorly controlled hypertension; any arterial thrombotic or thromboembolic events within 3 months before enrollment; > CTCAE grade 3 proteinuria;a grade 3–4 bleeding event; a history of bowel perforation; contraindication to irinotecan or ramucirumab, prior history of irinotecan administration; and synchronous or previous malignancy other than carcinoma in situ.","We excluded homozygosity for UGT1A1*28 (*28/*28), UGT1A1*6 (*6/*6) and heterozygosity for both UGT1A1*28 and *6 (*28/*6) in this study. The UGT1A1*28 and *6 genotype is associated with irinotecan-induced hematologic toxicity, diarrhea, or both . UGT1A1*28/*28, *6/*6 and *28/*6 are associated with severe irinotecan-related neutropenia in Japanese patients ; in addition, the association between UGT1A1*6/*6 and severe neutropenia in Asian populations has been verified in a meta-analysis. For patients with UGT1A1*28/*28 or *6/*6, the MTD of irinotecan is considered to be 150 mg/m2 , and recently published guidelines recommended that UGT1A1 phenotyping should be carried out in patients with a suspicion of UGT1A1 deficiency, as reflected by low conjugated bilirubin, and in patients receiving an irinotecan dose of > 180 mg/m2 per administration",NA,NA
30042150,NCT02188264,Combination,No,patients with Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer,"Patients with a histologic or cytopathologic diagnosis of an advanced solid cancer that is refractory to standard therapy or for which there is no standard therapy were included in the dose escalation cohort of the study. Once the MTD was identified, patients who had progressed on oxaliplatin- and irinotecanbased therapies with a histologic or cytopathologic diagnosis of advanced/metastatic unresectable colorectal cancer with known RAS mutational status, no known BRAF mutation and measurable disease were eligible for the expansion cohort. Patients were required to be >=18 years, Eastern Cooperative Oncology Group (ECOG) Performance Status 0–1, and have an estimated life expectancy >3 months. Adequate marrow function, renal function, hepatic function, and serum albumin >= 2.5 g/dL were required.","Study-specific exclusion criteria included chemotherapy or radiotherapy within 4 weeks, unstable brain metastases, less than 1 month from definitive therapy of brain metastases, uncontrolled inter-current illness, known ophthalmologic conditions especially current or past history of serious retinopathy or retinal vein occlusion, major surgical procedure within less than 3 weeks or minor surgical procedure within 1 week of first study drug administration, inability to swallow capsules, known history of HIV, hepatitis B, and/or hepatitis C, pregnancy, and electrolyte abnormalities that are refractory to therapy.",in the first28day,NA
34031756,NCT04088604,Single Drug,No,patients with advanced esophageal squamous cell carcinoma,"This is a phase I, open-label, non-randomized, dose escalation study of LY01610. Key inclusion criteria included: (i) having histologically confirmed solid tumors and have experienced disease progression or intolerance to standard systemic treatment; (ii) age ≥ 18 and≤ 70 years; (iii) Eastern Cooperative Oncology Group performance status score < 2; (iv) life expectancy≥ 3 months; (v) adequate bone marrow, liver and renal functions: absolute neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L and hemoglobin ≥ 90  g/L; total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (ALT and AST ≤ 5 × ULN for patients with liver metastasis); serum creatinine ≤ 1.5 × ULN or creatinine clearance rate ≥ 50 mL/ min (Cockcroft-Gault formula); (vi) no chemotherapy or radiotherapy within 4 weeks before treatment initiation.","The exclusion criteria included: (i) active systemic infections requiring intravenous antibiotics; (ii) significant cardiovascular diseases, such as myocardial infarction, unstable angina, congestive heart failure (New York Heart Association ≥ class II), or unstable arrhythmia within 6 months before screening; (iii) uncontrolled ascites or pleural effusions; (iv) pregnancy, lactating or refusal to use effective contraception; (v) a second malignancy within 5 years prior to screening; (vi) symptomatic brain metastasis; (vii) previous exposure to irinotecan; (viii) UGT1A1 *28 homozygous 7/7 variant.",the first cycle,NA
22415148,NA,Combination,No,patients with extensive-stage small-cell lung cancer,"Patients were enrolled in this study if they met the following criteria: a histologic or cytologic diagnosis of ED-SCLC; a measurable lesion; no prior chemotherapy; a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale; a life expectancy of at least 8 weeks; adequate bone marrow function (leukocyte count C 4,000/ll, platelet count C 100,000/ll, and hemoglobin C 10.0 g/dl); adequate hepatic function (aspartate amino-transferase and alanine amino-transferase levels B 100 IU/l, and bilirubin B 2.0 mg/dl); adequate renal function (creatinine B the upper limit of normal); adequate arterial oxygen partial pressure (PaO2 C 60 torr); electrocardiogram findings within the normal range; and between 20 and 74 years of age. Written informed consent was required for participation in the study.","Patients were ineligible if they had serious infectious diseases or other severe complications (heart diseases, pulmonary fibrosis/interstitial pneumonia, or uncontrollable diabetes); had watery diarrhea, paralytic ileus, or intestinal obstruction; had massive pleural or pericardial effusion, or ascitic fluid; had symptomatic brain metastases; had active concurrent malignancies; were lactating or pregnant women, or those willing to be pregnant; had a history of a drug allergy; had a history of acute myocardial infarction within the previous 6 months; had superior vena caval syndrome, requiring urgent radiotherapy; or had other medical problems severe enough to prevent compliance with the protocol.",NA,NA
33993383,NCT01923337,Combination,No,adult patients with refractory advanced solid tumors,"Eligible adult patients had histologically or cytologically confirmed metastatic or unresectable solid tumors for which standard curative or palliative measures did not exist or were no longer effective or a solid tumor for which irinotecan as monotherapy was considered standard. Patients could have been treated with any number of prior therapies as long as they were completed 2 weeks prior to study entry, the patient retained an ability to swallow oral medications and the Zubrod (ECOG) performance status remained between 0 and 2. Measurable or non-measurable disease was allowed but must have been assessed within 28 days of study entry. Laboratory criteria included adequate bone marrow function, normal serum total bilirubin, ALT and AST ≤ 1.5 times institutional upper limit of normal or ≤ 5.0 times institutional upper limit of normal in the presence of liver metastases, and a creatinine ≤ 1.5 times institutional upper limit of normal or creatinine clearance ≥ 60 mL/min/1.73m2 measured by 24-h urine collection.","exclusion criteria included a history of known Gilbert’s syndrome or homozygous presence of the uridine diphosphate glucuronosyltransferase (UGT) 1A1*28 allele on pre-treatment testing. Additional exclusion criteria included prior radiation to greater than 25% of the bone marrow, therapeutic anticoagulation, active infection, non-healing wound, recent major surgery and symptomatic or uncontrolled brain metastasis. Previously treated brain metastases were allowed as long as the patient was neurologically stable and off steroids and anticonvulsants at the time of registration. Due to the potential for drug interactions, known strong CYP3A4 inducers or inhibitors were prohibited. Cardiac exclusion included myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. An electrocardiogram was required prior to study entry.",DLT was based on the first course of treatment.,NA
34383370,NCT01518413,Combination,No,pediatric patients with relapsed or refractory solid tumors,Patients 2 to 22 years of age with relapsed or refractory solid tumors and measurable or evaluable disease were eligible for this nonrandomized dose-escalation study. Patients met standard eligibility requirements including performance status and organ function parameters,NA,first cycle,NA
24249672,NA,Combination,No,"Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors","Patients >12 months and <22 years of age with measurable or evaluable recurrent or refractory solid tumors, including CNS tumors or lymphomas, were eligible. Histologic verification of malignancy was required with the exception of patients with an intrinsic brain stem glioma, optic pathway glioma, or pineal tumor associated with elevated serum or cerebrospinal fluid tumor markers. Other eligibility criteria included a Karnofsky/Lansky performance score  >= 50; interval from prior therapy >21 days for myelosuppressive chemotherapy, >7 days for biologic agents, >6 weeks for immunotherapy, >3 half lives for monoclonal antibodies, >7 days for short-acting and >14 days for long-acting hematopoietic growth factors; >=2 weeks for local palliative radiation; >24 weeks from total body, craniospinal, or radiation to >=50% of the pelvis; >6 weeks from other substantial bone marrow radiation; >=12 weeks from a stem cell transplant or rescue and no evidence of active graft versus host disease; and no prior treatment with the combination of the three anticancer agents comprising this regimen. Adequate renal function (age-adjusted normal serum creatinine, or GFR >= 70 ml/minutes/1.73 m2); adequate liver function [total bilirubin <=1.5 x institutional upper limit of normal (ULN), albumin >2 g/dl, and alanine aminotransferase (ALT) <= 110 U/L]; a prothrombin time <1.2 <= ULN, blood glucose <=ULN, serum triglyceride level <=300 mg/dl, serum cholesterol <=300 mg/dl, and adequate pulmonary function were required. Adequate bone marrow function, defined as an absolute neutrophil count (ANC) >=1,000/mm3 and transfusion-independent platelet count >=100,000/mm3 were also required.","Exclusion criteria included pregnancy or lactation; uncontrolled infection; concurrent use of other investigational agents, anticancer agents, cytochrome P450 enzyme-inducing antiepileptic drugs, potent CYP3A4 inducers or inhibitors, therapeutic anticoagulants, angiotensin-converting enzyme inhibitors, agents to prevent organ rejection post-transplant, and chronic systemic corticosteroids. This trial was approved by the Institutional Review Boards of participating sites.",NA,NA
24691674,NCT00838578,Combination,No,patients with metastatic colorectal cancer,"Adult patients (≥18 years of age) with histologically confirmed, measurable mCRC (according to Response Evaluation Criteria in Solid Tumors version 1.0 criteria ) were eligible if they were not candidates for a surgically curative procedure. For the Phase 1 portion of the study, patients had to have disease recurrence or progression following FOLFOX/CapOx ± bevacizumab but no more than three prior chemotherapy or biologic regimens for mCRC. For Phase 2, patients had to have disease recurrence or progression within 12 months of the last cycle of a first-line metastatic or adjuvant FOLFOX/CapOx ± bevacizumab regimen for mCRC. Surgery, chemotherapy, radiotherapy, immunotherapy, biological therapy, or any other investigational drug must have been completed for ≥4weeks prior to study entry (≥6 weeks for nitrosoureas and mitomycin). Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 in the initial protocol but this was subsequently amended to ≤1. They were also required to have adequate bone marrow and organ function defined as: absolute neutrophil count ≥1,500/μl, platelet count ≥100,000/μl, hemoglobin of ≥9 g/dl; total bilirubin ≤1.5 times the institutional upper limit of normal (ULN); aspartate aminotransferase and alanine aminotransferase ≤2.5 times ULN or ≤5.0 times ULN in the presence of known hepatic metastases, and serum creatinine ≤1.5 times ULN or a calculated creatinine clearance of >60 mL/min (Cockcroft-Gault formula).","Exclusion criteria included: active, uncontrolled infection; known HIV-positive status; known or suspected CNS metastasis; history of myocardial infarction or cerebrovascular accident within 6 months; American Heart Association class III or IV congestive heart failure; medical condition requiring chronic use of high-dose corticosteroids or other chronic immunosuppressive therapy; history of Grade ≥2 allergic reaction or hypersensitivity following exposure to humanized or human monoclonal antibodies (but not chimeric antibodies); history of human anti-humanized or human antibody (HAHA) serum reactivity; prior use of anti-A33 monoclonal antibody therapy; pregnant or breast-feeding women and male or female patients who did not agree to use effective contraception during the study; and any significant concurrent disease or illness that would, in the opinion of the investigator, compromise patient safety or compliance, or interfere with the interpretation of the study results. In addition, for the Phase 2 study only, patients were excluded if they had a history of treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies and/or irinotecan.",during the 6-week treatment period,NA
31857431,NA,Combination,No,Children with Relapsed Solid Tumors,"Patients age 1 to 21 years with measurable or evaluable solid tumors, including central nervous system (CNS) tumors, refractory to standard treatment and for whom no known curative therapy existed, were eligible. Histologic verification of malignancy, at diagnosis or recurrence, was required with the exception of diffuse intrinsic brainstem tumors (DIPG). Other eligibility criteria included a Lansky or Karnofsky performance score of >= 50; recovery from the acute toxic effects of prior therapy including resolution of therapy related neurologic effects resolved to grade =< 2; adequate bone marrow function [absolute neutrophil count (ANC) >= 1,000/mm3 and platelet count >= 100,000/mm3], renal function (normal serum creatinine for age and gender, or creatinine clearance >= 70 mL/minute/1.73 m2), liver function [bilirubin 1.5 times upper limit of normal for age, ALT < 110 U/L, serum albumin >= 2 g/dL], QTc <= 480 msec, and ability to swallow capsules.","Patients receiving drugs known to be moderate or strong inhibitors or inducers of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range, were not eligible.",first cycle of protocol therapy,NA
22615057,NCT00134069,Combination,No,patients with advanced colorectal cancer,"Eligible patients had histologically confirmed advanced or metastatic CRC with progression after at least first line therapy, evaluable or measurable disease by RECIST (Response Evaluation Criteria in Solid Tumors)  and Eastern Cooperative Oncology Group (ECOG) performance status of 0–2. Patients also had to be 18 years or older with adequate hematopoietic, hepatic and kidney function. ",Exclusion criteria included: treatment with radiotherapy or chemotherapy within 4 weeks of study entry; prior therapy with targeted agents against the MAPK pathway; known central nervous system metastases; HIV positive patients on antiretroviral therapy; any medical condition that would impair administration of an oral medication; and clinically significant bleeding diathesis.,during the first cycle,NA
26842236,NCT00576654,Combination,No,Patients with Advanced Solid Tumors,"Eligible patients had histologically or cytologically confirmed metastatic or unresectable malignancy for which standard curative or palliative measures were nonexistent or ineffective or for which irinotecan was a viable treatment regimen; Eastern Cooperative Oncology Group (ECOG) performance status <= 2; measurable disease (per RECIST) accessible for biopsy; and adequate organ and marrow function defined as absolute neutrophil count >= 1,500/mL, platelets >=100,000/mL, aspartate aminotransferase and/or alanine aminotransferase <= 2.5 X upper limit of normal (ULN) or <= 5 X ULN if liver metastases present; bilirubin <= 1.5 X ULN; and creatinine <= 1.5 X ULN or calculated or measured creatinine clearance >= 60 mL/min/1.73 m2. Patients homozygous for the UGT1A1*28 allele (A(TA7)TAA) were ineligible due to the potential increased risk of toxicity associated with irinotecan","Prior chemotherapy, experimental therapy, or radiotherapy to >5% of bone marrow must have been completed at least 4 weeks prior to treatment initiation. Patients who received prior radiation to 50% of their total marrow volume were excluded. CYP3A4 isoform-inducing drugs had to be discontinued at least 2 weeks prior to the first administration of irinotecan. Patients were also excluded if they had an uncontrolled intercurrent illness, prior history of seizures (based on the ability of veliparib to lower the seizure threshold), known active brain metastases, or a requirement for chronic maintenance of growth factor support.",DLTs were based on toxicities observed during the first cycle.,NA
25577133,NA,Single Drug,No,advanced solid tumor patients,"This trial was a multi-center, first-in-human, open-label, phase I, dose-escalation study of PEP02 (liposomeencapsulated irinotecan, PharmaEngine, Inc., Taipei, Taiwan), in patients with advanced refractory solid tumors. Patients with histologically confirmed advanced solid tumors that were refractory to standard systemic chemotherapy were eligible. Further inclusion criteria were age ≥20 years, Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1, life expectancy of more than 12 weeks and adequate bone marrow, hepatic and renal functions within 1 week before commencing treatment (hemoglobin ≥ 10 g/dL, absolute neutrophil count ≥1.5 × 103/mL, platelets ≥ 100 × 103/mL, serum bilirubin within normal limit, ALT ≤ 2.5× upper limit of normal, creatinine within normal limit). All prior active treatments, including major surgery, chemotherapy, radiotherapy (except palliative) or endocrine therapy, had to be ceased at least 4 weeks, and all treatment-related toxicities had to be resolved to no greater than grade 1 before enrollment.","Patients with central nervous system metastases, pregnancy, uncontrolled active infection or other concomitant serious diseases and who had previously received irinotecan were excluded.",NA,NA
20943763,NA,Single Drug,No,Adult Patients with Solid Tumors,"Eligible patients had histologically or cytologically confirmed malignant tumors for which standard curative or palliative measures did not exist. Further requirements were as follows: age ≥20 and <75 years; Eastern Cooperative Oncology Group (ECOG) performance status ≤2; life expectancy ≥2 months; and adequate bone marrow, hepatic, renal, and pulmonary function within 1 week before commencing treatment [absolute neutrophil count ≥2,000/μL, platelet count ≥100,000/μL, hemoglobin ≥9 g/dL, total bilirubin ≤1.5 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times the upper limit of normal, creatinine ≤1.5 mg/dL, PaO2 ≥60 mmHg]. Treatment with radiotherapy, endocrine therapy, or chemotherapy must have ceased at least 4 weeks before commencing treatment.","Patients with severe, clinically significant, and/or uncontrolled medical conditions were excluded.",NA,NA
32537847,NCT02745769,Combination,No,Previously Treated Metastatic Colorectal Cancer,age ≥18 years; advanced or mCRC; measurable disease at the time of study enrollment; had received prior second-line treatment with oxaliplatin and/or irinotecan (no prior immune checkpoint inhibitors had been administered and patients with RAS wild-type CRC must also have received prior treatment with an epidermal growth factor receptor monoclonal antibody); Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; and adequate organ function.,The main exclusion criteria were significant gastrointestinal bleeding within 3 months and significant venous thromboembolic events or any arterial thromboembolic events within 6 months prior to enrollment; uncontrolled hypertension; treatment with chronic nonsteroidal anti-inflammatory drug or antiplatelet therapy at the time of enrollment; or other serious uncontrolled medical disorders.,NA,NA
8708712,NA,Combination,No,patients with advanced cancer of variable histology with good prognostic features,"Patients at least 18 years old with a histologically confirmed malignancy refractory to standard therapy were eligible for this trial. All patients were required to meet the following criteria before registration: measurable or assessable disease that was clearly progressive; Karnofsky performance status of 70% to 100%; a life expectancy of at least 12 weeks; ability to give informed consent; negative pregnancy test for females of reproductive age; granulocyte count greater than 1,500/gL; platelet count greater than 100,000/pZL; hemoglobin levels greater than 10 mg/dL; normal coagulation parameters; bilirubin levels less than 1.6 mg/dL; transaminases less than four times the upper limit of normal; creatinine levels less than 2.0 mg/ dL; calcium levels less than 12.0 mg/dL; a normal treadmill stress examination; and a normal computed tomography (CT) scan of the brain.",Patients were excluded for the following: any history of cardiac disease; seizure disorders; infection with human immunodeficiancy virus (HIV) or testing positive for hepatitis B surface antigen; an ongoing requirement for corticosteroids; prior treatment with the combination of IL-2 and IFN-a;,in the first cycle of therapy (4 weeks),NA
26884555,NA,Combination,No,patients with advanced neuroblastoma,"Patients were eligible if they were age 1 to 30 years at the time of enrollment, had high-risk neuroblastoma, and had evaluable disease by bone marrow (BM) morphology, computed tomography, magnetic resonance imaging, and/or metaiodobenzylguanidine (MIBG) scans obtained within 4 weeks of enrollment. Patients were required to be classified in one of the following disease categories: relapse or progression, refractory to initial therapy (less than a partial response [PR] by International Neuroblastoma Response Criteria [INRC] after at least four cycles of chemotherapy), or persistent biopsy-proven disease after initial therapy (an INRC PR after at least four cycles of chemotherapy). Patients previously treated with irinotecan and/or temozolomide were eligible if they did not have prior disease progression while being treated with a regimen containing those agents.","Patients previously treated with alisertib were excluded.Patients were excluded if they were pregnant, breastfeeding, unable to swallow intact pills, had a body surface area less than 0.38 m2, had undergone previous allogeneic stem-cell transplantation, required hemodialysis, had active infection, had known history of HIVor hepatitis B or C infection, or had known active intraparenchymal brain metastasis. Patients who required scheduled benzodiazepines, scheduled antacid medications, specific phosphoglycoprotein substrates, or specific strong inducers of hepatic cytochrome enzymes were excluded.",NA,NA
23170896,EU-CTR2006-001345-33,Single Drug,No,patients with advanced solid tumors,"ligible patients were ≥ 18 years old, with histologically or cytological confirmed advanced solid malignancies who were refractory to standard therapies or for whom there was no effective standard therapy, and with Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. Further criteria for inclusion included adequate bone marrow function (neutrophil count ≥ 1.5 x109, platelet count ≥ 1x109, and haemoglobin≥10.0 g/dL) and adequate hepatic (serum bilirubin ≤ 1.5 x upper limit of normal [ULN], alanine amino transferase (ALT) and aspartate amino transferase (AST) ≤ 2.0 x ULN) and renal (serum creatinine ≤ 1.5 x ULN) function.","Standard Phase I trial exclusion criteria included exposure to prior cytotoxic chemotherapy, extended field radiotherapy or surgery within 4–6 weeks before the start of the study; presence of severe concomitant medical illness; and the presence of symptomatic brain metastases. A history of severe or life-threatening drug allergy or hypersensitivity to camptothecin derivatives and diarrhoea (excess of 2–3 stools/day above normal frequency within 2 weeks prior to the start of the study) were additional exclusion criteria.",NA,NA
22421195,NA,Combination,No,Patients 1 to 30 years old with relapsed or refractory neuroblastoma and MIBGavid tumors,"Patients 1 to 30 years of age with relapsed or refractory neuroblastoma were eligible if they had MIBG-avid disease documented within 4 weeks of study enrollment. Patients were required to have a minimum of 2.0 x 10^6 CD34þ autologous hematopoietic stem cells per kilogram available for infusion, Lansky or Karnofsky performance score of 50 or more, and life expectancy of 6 or more weeks. Patients were eligible after a minimum of 3 weeks from last systemic therapy, 3 months from prior stem cell transplant, 2 weeks from prior small port radiation, and 3 months from large field radiation.Patients were required to meet the following organ function criteria: absolute neutrophil count (ANC) of 750/mm3 or more without growth factor support; platelet count of 50,000/mm3 or more without platelet transfusion; hemoglobin of 8 g/dL or more; estimated creatinine clearance of 60 mL/min/1.73 m2 or more or serum creatinine of 1.5 or less times the upper limit of age-adjusted normal value; total bilirubin of 1.5 or less times the upper limit of normal; aspartate aminotransferase (ALT) and alanine aminotransferase (AST) less than 3 times the upper limit of normal; cardiac ejection fraction of 55% or more or shortening fraction of 27% or more; and lack of dyspnea at rest, exercise intolerance, pleural effusion, or oxygen requirement.","Patients were excluded for prior whole abdominal or total body radiation, allogeneic transplant, or I-MIBG therapy. Prior vincristine and/or irinotecan were allowed. Additional exclusion criteria included: pregnancy, breast feeding, other major systemic disease, inability to tolerate radiation isolation, concomitant enzyme-inducing anticonvulsants, cephalosporin allergy, diarrhea of grade 2 or more, and active infection.",in the first course,NA
27871319,NCT02884128,Combination,No,Patients with advanced solid tumors,"The inclusion criteria were as follows: (1) histologically or cytologically confirmed advanced solid tumor refractory to standard systemic chemotherapy; (2) aged between 20 and 70 years; (3) Eastern Cooperative Oncology Group performance score (ECOG PS) of 0 or 1; (4) life expectancy ≥ 2 months; (5) adequate bone marrow, hepatic and renal functions: white blood cells ≥ 3,000/mm3,absoluteneutrophil count≥ 1,500/mm3,platelets≥ 100,000/mm3, hemoglobin ≥ 10 g/dL, serum total bilirubin within normal range, AST and ALT ≤ 3× upper limit of normal range, serum creatinine ≤ 1.5 mg/dL and blood urea nitrogen ≤ 25 mg/dL; (6) no prior treatment for at least 4 weeks before study initiation, including major surgery, chemotherapy, any investigational products or radiotherapy (6 weeks for nitrosoureas and mitomycin C); (7) recovered from all treatment-related toxicities or resolved to no greater than grade 1 before enrollment; and (8) written informed consent.","The exclusion criteria were as follows: (1) known or suspicious primary or secondary brain tumors; (2) HBsAg-positive or anti-HCV antibody-positive with splenomegaly (defined as spleen size > 11 cm measured in longest diameter by CT scan); (3) uncontrolled active infection or other concomitant serious disease; (4) pregnancy or breast-feeding; (5) previous exposure to irinotecan; (6) history of allergic reactions to compounds of similar chemical or biologic composition as PEP02, 5FU, or LV.",during the first cycle,NA
28573606,UMIN000004313,Combination,No,Patients with Advanced Hepatocellular Carcinoma,"The eligibility criteria for this study were as follows: (1) patients with advanced HCC confirmed histologically or clinically based on the American Association for the Study of Liver Diseases guidelines ; (2) unresectable and incurable with RFA or TACE; (3) age C20 years; (4) at least one measurable lesion on computed tomography (CT) or magnetic resonance imaging (MRI) scans (not including necrotic lesions caused by prior treatment); (5) other prior treatments without systemic chemotherapy permitted if such treatment performed at least 28 days before registration; (6) cirrhotic status of Child–Pugh A; (7) Eastern Cooperative Oncology Group performance status of 0 or 1; (8) hematological findings (neutrophil count of C1500 cells/mm3, platelet count of C50,000 cells/mm3, and hemoglobin of C10.0 g/dL), renal function (serum creatinine concentration of B1.5 9 ULN), and hepatic function (total bilirubin level of B2.0 mg/dL, aspartate and alanine transaminase levels of B5.0 9 ULN); and (9) written, informed consent from the patient.","Patients who previously received systemic anticancer therapy or molecular target therapy including sorafenib were excluded from this study. Other exclusion criteria were (1) uncontrollable ascites; (2) varices in the esophagus or stomach with a high risk of bleeding; (3) medical history of hepatic coma; (4) clinically evident congestive heart failure, serious cardiac arrhythmias, active or symptomatic coronary artery disease or ischemia; (5) primary and metastatic brain tumors; (6) history of organ allograft; (7) prior malignancy; (8) treatment with biologic-response modifiers or CYP3A4 inhibitors; or (9) medical/psychological/social problems that might affect study participation or evaluations.",NA,NA
27189323,NA,Combination,No,patients with unresectable or recurrent gastric cancer,"Patients with AGC who met all the following criteria were eligible to participate in the study: unresectable or recurrent gastric cancer histologically or cytologically diagnosed as adenocarcinoma; evaluable lesion(s) identified by imaging (e.g., CT), with or without measurable lesion(s) defined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; previously untreated with chemotherapy for AGC, except for preoperative or postoperative adjuvant chemotherapy, which was allowed for patients with recurrent gastric cancer who had evidence of recurrence on images 180 days or more after the completion of chemotherapy; Eastern Cooperative Oncology Group performance status of 0–1; and neutrophil count C2,000/mm3, hemoglobin C8.0 g/dl, platelet count C100,000/mm3, serum total bilirubin B1.5 times upper limit of normal (ULN), creatinine clearance C60 ml/min, and aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels B2.5 times ULN.",Patients who met any of the following criteria were excluded from the study: peripheral sensory neuropathy or peripheral motor neuropathy. HER2 status was not included in the eligibility criteria.,in the first cycle,NA
26490655,NCT01571024,Combination,No,patients with advanced refractory solid tumors,"Patients eligible for enrollment on this study had histologically confirmed advanced solid tumors refractory to standard therapy or for which no accepted standard therapy exists. Other inclusion criteria included: measurable or evaluable disease, Eastern Cooperative Oncology Group (ECOG) performance status ≤1, and complete recovery from all reversible toxicities related to their previous treatments. Patients were required to have an absolute neutrophil count (ANC) ≥1500 cells/mm3,plateletcount≥100,000/m3, and hemoglobin ≥9g/ dL. All patients had normal kidney function. For patients with liver metastases, total bilirubin ≤1.5 × the upper limit of normal (ULN) was required as well as an AST and ALT ≤3× ULN.","Pertinent exclusion criteria included prior treatment with a PI3K inhibitor, patients with known coagulopathies on coumarin-derived anticoagulants, chronic corticosteroid treatment, patients with documented mood disorders, and GI dysfunction resulting in impaired absorption. Initially, the protocol excluded patients solely based on a history of poorly controlled diabetes mellitus defined by fasting plasma glucose ≤120; the protocol was subsequently amended to only include patients with a fasting plasma glucose ≤120 and a hemoglobin A1c (HgA1c) ≤8.0 %.",during the first cycle of treatment (28 days),NA
34050586,UMIN000017002,Combination,No,Patients with Unresectable Pancreatic Cancer (HGCSG 1403),Patients who had not received prior therapy for unresectable PDAC were enrolled,NA,one cycle,NA
26220846,NA,Combination,No,patients with locally advanced pancreatic cancer,"Patients diagnosed with LAPC by histopathological or cytological confirmation were enrolled to this study. Eligibility criteria were age ≥20 years; Eastern Cooperative Oncology Group (ECOG) performance status ≤2; no evidence of distant metastasis; adequate oral intake; no earlier treatment for pancreatic cancer; adequate hematological function (hemoglobin ≥10 g/dl, leukocytes ≥3000/ mm3, platelets ≥100,000/mm3); adequate hepatic function (serum total bilirubin ≤2.0 mg/dl and serum transaminases (aspartate aminotransferase (AST) and alanine aminotransferase (ALT)) ≤2.5 times upper normal limit (UNL); adequate renal function (serum creatinine ≤1.0 mg/dl); written informed consent.",The exclusion criteria were watery diarrhea; pleural effusion or ascites; active infection; active gastroduodenal ulcer; severe complications such as heart disease or renal disease; mental disorder; history of drug hypersensitivity; active concomitant malignancy; pregnant and lactating females.,NA,NA
32669374,NCT01489865,Combination,No,Patients with Metastatic Pancreatic Cancer,"Patients with mPDAC with measurable disease [as per RECIST 1.1 (25)] were eligible. Patients were ages ≥18 years, had an Eastern Cooperative Oncology Group performance status score of ≤2, and had adequate organ and bone marrow function [hemoglobin ≥9.5 g/dL, absolute neutrophil count ≥1.5 x 10^9/L, platelet count ≥75 x 10^9/L, serum creatinine level <1.5 mg/dL, bilirubin level ≤2.5 x upper limit of normal (ULN), and ALT/AST levels ≤3 x ULN].","For the phase I portion of the study, patients were not selected on the basis of prior therapy, family history (FH), nor germline or tumor HR-DDR mutational status.",the first cycle of therapy,NA
29691300,NA,Combination,No,patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma,"Key inclusion criteria for all patients included age 18 years; Eastern Cooperative Oncology Group Performance Status of <=1; life expectancy of >3 months; adequate hematologic, hepatic, and coagulation function; serum creatinine <=1.5 x upper limit of normal; and willingness to follow adequate precautions to prevent pregnancy. For part A, patients were required to have histologically or cytologically confirmed advanced malignant solid tumors refractory to or intolerant of standard therapy, or for which no standard therapy was available. For the gastric/GEJ adenocarcinoma cohort of part B, patients were required to have histologically confirmed, HER2negative, inoperable advanced gastric/GEJ adenocarcinoma treatment-naive in the metastatic setting (prior systemic therapy in the nonmetastatic setting was allowed).","Key exclusion criteria for all patients included significant comorbid medical conditions that posed a risk to patient safety or limited study participation; pregnancy or lactation in women; untreated central nervous system metastases; and known HIV, HBV, or HCV infection.",during cycle 1,NA
31185328,NA,Combination,No,"patients with locally advanced tumour without metastases (Stage T2, T3 or T4, whatever N stage; Stage N1–N3 whatever T stage)","included adult males or females, with histologically proven squamous cell carcinoma of the anal canal, with locally advanced tumour without metastases (AJCC TNM Stage T2 > 3 cm or T3 or T4 , whatever N stage; Stage N1–N3 whatever T stage), WHO general health status 0 or 1, life expectancy above 3 months, and blood CD4+ 400 cells/mm3 in HIV positive individuals only.","Patients with previous anti-EGFR treatment, or previous pelvic RT, or other previous malignancy within 5 past years, or known or suspected central nervous system metastasis were not included",within 30 days after the end of the RT,NA
31558477,NA,Combination,No,Untreated Patients with Gastrointestinal Cancer Using,"This study enrolled patients with untreated locally advanced or metastatic pancreatic cancer, gastroesophageal adenocarcinoma, biliary tract cancers (including gallbladder adenocarcinoma, ampullary adenocarcinoma, and cholangiocarcinoma), adenocarcinoma of unclear primary (with a gastrointestinal primary suspected), or any other primary gastrointestinal malignancy felt to be appropriate by the treating physician. Age >=18 years and Eastern Cooperative Oncology Group (ECOG) performance status of 0–1 were required. Adequate organ function was required as defined by absolute neutrophil count >= 1,500/mL, hemoglobin > 9 g/dL, platelets > 100,000/mL, total bilirubin < 1.25 x upper limit of normal (ULN), creatinine <= 1.5 mg/dL, aspartate aminotransferase and alanine aminotransferase <= 2.5 x ULN, and alkaline phosphatase <= 2.5 x ULN unless bone metastasis was present in the absence of liver metastasis. Patients taking substrates, inhibitors, or inducers of CYP3A4 were encouraged to switch to alternative drugs if possible, given the potential for drug–drug interactions with irinotecan.","Patients were excluded if they had received prior chemotherapy or radiotherapy for any cancer; diarrhea >= grade 1; neuropathy >= grade2,aspertheNCICommonTerminology Criteria for Adverse Events version 4.0 (NCI-CTCAE; ref. 17); or any UGT1A1 polymorphism other than *1 or *28.",during cycle 1,NA
33985455,ChiCTR1900027833,Combination,No,patients with locally advanced or advanced pancreatic ductal adenocarcinoma,"Histologically or cytologically confirmed locally advanced or advanced PDAC; No previous antitumor treatment (including chemotherapy, radiotherapy, surgery or other investigational therapy); Aged 18 to 75 years old; Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 2; Life expectancy of greater than 3 months; Adequate organ function as below: Absolute neutrophil count ≥1500/mm3, platelet count ≥80,000/mm3, hemoglobin ≥8.0 g/dL; Total bilirubin, alanine aminotransferase, and aspartate aminotransferase ≤2.5 × upper limit of normal; Serum creatinine ≤1.8 mg/dL, uric acid < 500 μmol/L, creatinine clearance ≥60 mL/min, proteinuria≤2 g/24 h; Child-Pugh score<7; No abnormalities in the ECG; Patients of both genders must be willing to practice reliable contraception during the trial; Must be able to participate the study voluntarily and sign the informed consent document.","Known severe hypersensitivity to any drugs of the study regimen; Synchronous or metachronous malignancies within 5 years (except for adequately treated basal cell carcinoma of the skin and carcinoma in situ of the cervix); Females who are pregnant or lactating; Patients with evidence of new known or suspected uncontrolled metastases to brain;Concurrent other kinds of chemotherapy, radiotherapy or clinical trials during the trial course;  Serious or uncontrolled infectious disease (HIV, active tuberculosis, or HBV DNA > 103/ml), obvious coagulation disorder, active bleeding and bleeding tendency or other major diseases of the cardiovascular, respiratory, digestive, or immune system;  Serious or uncontrolled pleural effusion or ascites;  Severe mental disorders; Unsuitable for enrollment in the opinion of the investigator.",the first cycle,NA
28489753,UMIN000005808,Combination,No,patients with metastatic pancreatic cancer after gemcitabine-based chemotherapy failure,"All patients were aged 18 years or more with histologically or cytologically confirmed metastatic pancreatic adenocarcinoma. Patients who were previously treated with GEM-based first-line chemotherapy were eligible for this study if they met the following inclusion criteria: Eastern Cooperative Oncology Group performance status (PS) of 0 or 1, aged 18 to 75 years, MPC with at least 1 measurable lesion based on the Response Evaluation Criteria in Solid Tumors (RECIST), and adequate hematological, liver, and renal functions (hemoglobin >9.0 g/dL, white blood cell count <10,000/mm3, neutrophil count >1,500/ mm3, platelet count >100,000/mm3, total bilirubin <1.5-fold higher than the upper normal limit, serum transaminase <threefold higher than the upper normal limit, creatinine <1.5-fold higher than the upper normal limit). All patients provided their written informed consent.","Patients were excluded if they had grade 2 or higher peripheral sensory neuropathy, received a blood transfusion, blood products, or hematopoietic growth factor preparations, such as granulocyte-colony stimulating factor (G-CSF) within 7 days before enrolment; had UGT genetic polymorphisms (homozygous UGT1A1∗28 or UGT1A1∗6 or heterozygous UGT1A1∗6 and UGT1A1∗28); apparent coelomic fluid (pleural effusion, ascites, or pericardial fluid) or peritoneal dissemination; poorly controlled diabetes; synchronous or metachronous double cancer; brain metastases; significant gastrointestinal bleeding or obstruction; or active infection.",the first 2 treatment cycles,NA
30511200,NA,Combination,No,Japanese patients with advanced solid tumors,"Patients aged ≥20 years with histologically or cytologically confirmed solid tumors in whom the standard or other standard-equivalent therapy was ineffective or inappropriate were eligible for the study. In Part 2, patients for whom 5-FU chemotherapy was indicated were also eligible based on discussions between the investigator and sponsor. Other inclusion criteria included a life expectancy of ≥3months,Eastern Cooperative Oncology Group performance status of 0 or 1, ability to receive medications orally, measurable or nonmeasurable lesions based on the Response Evaluation Criteria In Solid Tumors (RECIST version 1.1, 2009), and adequate hematologic, hepatic, and renal functions. Patient eligibility was confirmed by laboratory investigations within the 7 days before enrollment, which included aspartate aminotransferase or alanine aminotransferase concentrations, total bilirubin, absolute neutrophil count, platelet count, hemoglobin concentration, and creatinine clearance.","Patients were excluded from the study if they had a severe disease or clinical condition (e.g., brain metastasis, active infection, heart or gastrointestinal diseases, or HIV- or hepatitis C virus-positive status). Surgery, extended-field radiotherapy, chemotherapy within 28 days (35 days for mitomycin C), local radiotherapy within 14 days, or other investigational products within 30 days prior to enrollment were not permitted. Patients who were receiving treatment known to have interactions with S-1 were excluded.",in Cycle 1,NA
33957442,NA,Combination,No,Patients (aged >=18 years) had locally advanced/metastatic pancreatic ductal adenocarcinoma (mPDAC),"Eligible patients were >= 18 years of age, had histologically or cytologically confirmed pancreatic adenocarcinoma that was locally advanced or metastatic, and had not been treated previously in the advanced/metastatic setting. Patients also had measurable disease using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 ; adequate haematological, hepatic and renal function; and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1  (dose-exploration part) or a Karnofsky Performance Status score of >= 70 (dose-expansion part).","Exclusion criteria included any second malignancy in the previous 3 years and use of strong CYP3A4 inhibitors or inducers, or strong UGT1A1 inhibitors.",during cycle 1 (28-day DLT period).,NA
27979915,NCT01172964,Combination,No,Recurrent High-Grade Glioma Patients,"To be eligible to participate in this study, patients had to be at least 18 years old, have radiographic findings consistent with recurrent, supratentorial high-grade gliomas (including glioblastoma, anaplastic astrocytoma, gliosarcoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma), and be in need of tumor resection or biopsy. Other inclusion criteria were as follows: (i) Karnofsky performance status >= 60%; (ii) previous treatment with brain radiation and temozolomide; (iii) recovered from toxicity of prior therapy; (iv) adequate bone marrow (defined as an absolute neutrophil count of >= 1,500 cells/mm3 and platelet count >= 100,000 cells/mm3), hepatic [total bilirubin <=2.0 mg/dL and AST (SGOT) <=4 times the institutional upper limit of normal] and renal function (serum creatinine within normal limits); (v) a minimum of 4 weeks from previous chemotherapy (6 weeks from treatment with a nitrosourea); and (vi) no anticipated physical connection between the postresection tumor cavity and the cerebral ventricles.",Patients were excluded from study participation if they had (i) anti-HLA antibodies specific for class I or II HLA antigens expressed by the CD-NSCs; (ii) a chronic or active viral central nervous system infection; (iii) a coagulopathy or bleeding disorder; (iv) a serious medical or psychiatric illness that could interfere with the completion of protocol treatment; or were (v) currently receiving other ch,NA,NA
28058527,NA,Combination,No,Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure,"Patients with unresectable liver metastases from CRC after failure of standard systemic chemotherapy, including fluoropyrimidine, oxaliplatin, and irinotecan with/without molecular-targeted agents, were eligible. Additional eligibility criteria were as follows: (1) age, ≥20 years old; (2) Eastern Cooperative Oncology Group PS, 0–2; (3) presence of measurable metastatic disease, as defined by the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1); (4) adequate hematological function (white blood cell count, ≥3000/μL; platelet count, ≥7.5 × 104/μL); (5) adequate hepatic function [total bilirubin, ≤3.0 mg/dL; aspartate aminotransferase (AST); and alanine aminotransferase (ALT), ≤250 U/ L]; (6) adequate renal function (serum creatinine, ≤2.0 mg/ dL); and (7) normal cardiac function. All patients provided written informed consent to participate in this trial.",NA,during the first cycle.,NA
32877909,NA,Combination,No,Patients with Gastric Cancer with Peritoneal Metastasis,"Eligibility criteria were histologically proven adenocarcinoma of the gastric or gastroesophageal junction; positive peritoneal dissemination by staging laparoscopy; human epidermal growth factor receptor type 2 (HER2) negative (0, 1+ in immunohistochemistry or 2+ in immunohistochemistry and FISH negative) or untested; no noncurable factors except peritoneal dissemination; no prior chemotherapy or radiotherapy for gastric cancer; ≥20 years old and ≤75 years old; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; patients for whom oral intake may be possible; adequate organ function, as defined by neutrophil count ≥1,500/mm3, hemoglobin ≥8.0 g/dL, platelet count ≥100,000/mm3, total bilirubin ≤2.0 mg/dL, aspartate aminotransferase ≤100 U/L, alanine aminotransferase ≤100 U/L, serum creatinine ≤1.2 mg/dL, creatinine clearance ≥60 mL/min; and life expectancy of at least 3 months.","Exclusion criteria were as follows: history of hypersensitivity to nab-paclitaxel, S-1, oxaliplatin; severe infection; active hepatitis B; patients with serious complications, such as uncontrollable cardiovascular disease, angina or arrhythmia, myocardial infarction in the past 3 months, uncontrollable diabetes mellitus, and interstitial lung disease or pulmonary fibrosis; peripheral neuropathy ≥ grade 2; uncontrollable diarrhea; multiple primary cancers; pregnant or lactating patients, or with unknown or suspected pregnancy.",during cycle 1,NA
27155613,UMIN000006396,Combination,No,patients with colorectal liver metastases,"(1) histologically proven liver metastasis from colorectal adenocarcinoma after R0 resection; (2) primary lesion had been completely removed or resected simultaneously with the metastatic lesion; (3) irrespective of initial or repeat hepatic resection; (4) no extrahepatic metastases; (5) no previous local therapy, including radiofrequency ablation or cryoablation therapy; (6) age 20–80 years; (7) performance status of 0–2; (8) adequate organ function, including a leukocyte count between 3000 and 12,000 mm3, neutrophil count of ≥1500 mm3, platelet count of ≥100,000 mm3, hemoglobin concentration of ≥9.0 g/dl, aspartate aminotransferase and alanine aminotransferase levels of ≤100 IU/L, serum bilirubin level of ≤1.5 mg/dl, and creatinine clearance level of ≥60 mL/ min; (9) adequate gastrointestinal function with oral intake; and (10) ≤ 8 weeks after surgery.","Patients were excluded if they had another active cancer, serious postoperative complications, or history of S-1 or oxaliplatin administration. Patients with any of the following concurrent conditions were also excluded: receiving insulin treatment; poorly controlled diabetes mellitus or hypertension; severe peripheral neuropathy or diarrhea; a history of myocardial infarction within the past 6 months or unstable angina; interstitial pneumonia, pulmonary fibrosis, or pulmonary emphysema.",the first treatment cycle,NA
27745984,NCT00188266,Combination,No,patients had completely resected stage IB to IV (Union for International Cancer Control TNM 6th edition) nonmetastatic gastric adenocarcinoma.,"Eligibility criteria were as follows: completely resected adenocarcinoma of stomach or gastroesophageal junction with <=2 cm extension into esophagus, TNM disease stages according to the American Joint Committee on Cancer/ Union for International Cancer Control 6th edition (11) IB to IV without distant metastases, preoperative crosssectional imaging, no prior abdominal radiation therapy, Eastern Cooperative Oncology Group performance status 2, adequate baseline major organ function, pretreatment caloric intake >1500/day, treatment commenced within 90 days of surgery, and written informed consent. An upper age limit was not initially defined, but an amendment after the completion of dose level (DL) 3 specified maximum age 70 years.",NA,NA,NA
32642753,UMIN000012135,Combination,No,patients with sinonasal squamous cell carcinoma,"atients with histologically proven, grossly measurable sinonasal SCC were eligible. The other inclusion criteria were an Eastern Cooperative Oncology Group performance status of 0 or 1, age 20–75 years, ability to be immobilized using a standard head immobilization system for ∼30 min, sufficient oral intake, adequate organ function and no abnormal electrocardiogram within 28 days prior to registration.","atients were excluded from this study if they had a history of RT for the primary site, pulmonary fibrosis or interstitial pneumonia detected by chest radiographs within 28 days prior to registration, watery diarrhea, active infections except viral hepatitis, serious comorbidities (including heart failure, renal failure, liver failure, hemorrhagic peptic ulcer, paresis of the intestine, intestinal obstruction and severe diabetes), moderate or severe ascites or pleural effusion, central nervous system metastases, active synchronous or metachronous double cancers within the 3 years prior to registration (carcinoma in situ and intramucosal carcinoma were permitted), or were undergoing treatment with flucytosine, phenytoin or warfarin potassium. In addition, female patients who were/could be/wished to get pregnant or were breast-feeding, and male patients whose partners were planning to get pregnant, were excluded. Those with severe mental disorders, whom physicians judged to be ineligible for this study, were also excluded.",NA,NA
30191522,NCT02319018,Combination,No,patients with advanced gastrointestinal cancers,"Eligible patients were ≥ 18 years of age with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–1, had adequate organ and marrow function, were able to swallow oral medication, and did not have grade ≥ 2 peripheral neuropathy. Prior treatment with FOLFOX was allowed.",NA,NA,NA
26597443,NCT01621217.,Combination,No,patients with locally advanced anal cancer,"Eligible patients had a histologically confirmed untreated squamous cell carcinoma of the anus with stage T2 (>= 4 cm)e4N0e3 M0 or any T N2e3 M0 (TNMUICC 6th edition 2002), >=18 years of age, Eastern Clinical Oncology Group (ECOG) performance status 0e1, adequate bone marrow, hepatic and renal function.","Exclusion criteria included previous pelvic irradiation, severe comorbidities, prior malignancy within the last 5 years (other than non-melanoma skin cancer or in situ carcinoma of the cervix), or pregnancy.",NA,NA
25989270,NA,Combination,No,Patients with KRAS mutant mCRC,"Eligible patients were aged Z18 years with histologically confirmed KRAS mt mCRC with disease progressing during or following first-line treatment for metastatic disease with oxaliplatin plus fluoropyrimidine-based chemotherapy (with or without bevacizumab). Patients were required to have measurable metastatic disease according to Response Evaluation Criteria In Solid Tumours (RECIST v1.0), an Eastern Cooperative Oncology Group performance status of 1 or less and adequate hepatic (total bilirubin < 1.5 x upper limit of normal (ULN), or aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x ULN (for subjects with liver involvement, AST/ ALT < 5 x ULN)), renal (serum creatinine < 1.5 x ULN and/or calculated creatinine clearance (Cockroft–Gault formula) >50 ml min ^- 1) and marrow function (haemoglobin 49.0 g dl ^- 1, neutrophil count >1.5 x 10^9 l ^- 1 and/or platelet count > 100 x 10^9 l).",Main exclusion criteria comprised retinal degenerative disease and history of uveitis or retinal vein occlusion. Patients should have not received chemotherapy with any nvestigational drug or participated in another clinical trial within 4 weeks before study treatment. Enrolled patients were not allowed to have received radiotherapy on more than 30% of bone marrow reserves or bone marrow/stem cell transplantation before study treatment.,NA,NA
26025485,NA,Combination,No,patients with gastric cancer,"Patients were recruited in a single center based on the following eligibility criteria: age 18–75 years; histologically confirmed adenocarcinoma of stomach or gastroesophageal junction; underwent curative gastrectomy without residual disease (R0) with D1 or D2 lymph node dissection; postoperative classification of T4 and/or N ? M0 according to the 7th edition of American Joint Committee cancer TNM system; Eastern Cooperative Oncology Group performance status of 0 or 1; adequate organ function was also required: neutrophil count C 1,500/lL; platelet count C 100,000/lL; hemoglobin C 8.0 g/dL; serum total bilirubin and creatinine levels B 1.0 times the upper limit of the normal value (ULN); and enrollment within 8 weeks from the date of surgery.","Patients with definite evidence of distance metastases, history of prior chemotherapy or radiotherapy and with coexisting malignancies or who were unable to tolerate chemotherapy because of other systemic illnesses were excluded from this study.",NA,NA
26861740,NCT01376453,Combination,No,Patients with confirmed stage II or III rectal cancer,"The eligibility criteria included histologically confirmed adenocarcinoma of the rectum defined as being within 12 cm of the anal verge as determined by sigmoidoscopy and/or colonoscopy with no evidence of distant metastasis but with evidence of T3, T4, or positive perirectal lymph nodes by CT scan/MRI and transrectal ultrasound. Additional inclusion criteria were ECOG performance status of 0 or 1 with adequate bone marrow, liver, and renal function (hemoglobin >9.0 g/dL, absolute neutrophil count >1500/mm3, platelet count >100,000/mm3, total bilirubin <1.5 times ULN, ALT and AST <2.5 times the ULN, and creatinine <1.5 times ULN). Patients who were on anti-coagulation treatment with an agent such as warfarin were allowed to participate.",NA,NA,NA
29995287,"apicCTI-152,864",Combination,No,patients with pre-treated biliary tract or pancreatic cancer,"The main eligibility criteria were as follows: unresectable/ recurrent BTC or unresectable/recurrent PC; at least one prior systemic chemotherapy regimen; Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1; age of 20–79 years; life expectancy ≥3months;andadequateorganandbonemarrow function (neutrophil count ≥1500/mm3, platelet count ≥100,000/mm3, serum total bilirubin ≤2.0 mg/dL, aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x the institutional upper limit of normal (ULN), serum creatinine ≤1.5 mg/dL, creatinine clearance ≥60 mL/min, and QTcF interval < 460 msec).",The main exclusion criteria were as follows: prior treatment with an HDAC inhibitor; prior treatment with S-1 (only for regimens 2 and 3); use of any other investigational drug within 20 days before enrollment; use of any other drug within 13 days before enrollment; cardiovascular complications or a history of myocardial infarction within 6 months before enrollment; symptomatic brain metastasis or suspected brain metastasis; and double cancer (synchronous double cancer or metachronous double cancer with a disease-free interval < 5 years).,first cycle of therapy,NA
30121935,NA,Combination,No,elderly patients with advanced non-small cell lung cancer,"Patients who fulfilled the following eligibility criteria were registered: at least one measurable tumor lesion, cytologically or histologically confirmed NSCLC, stage IIIB disease without any indications for radiotherapy or stage IV disease, no prior chemotherapy, age of ≥70 years, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, adequate organ function and bone marrow activity (neutrophil count, ≥3000/μL; platelet count, ≥100,000/μL; hemoglobin level, ≥9.5 g/dL; serum bilirubin concentration, ≤1.5 mg/dL; serum aspartate aminotransferase and alanine aminotransferase concentrations, ≤twice the upper limit of the normal range; creatinine level, ≤upper limit of normal; and creatinine clearance rate, ≥60 mL/min), life expectancy of >2 months, and ability to take medications orally.","Patients were excluded from the study if they had interstitial pneumonia, a severe concomitant disease (e.g., severe cardiac disease, uncontrolled diabetes, or severe infection), an active concomitant malignancy, severe drug hypersensitivity, or alcohol hypersensitivity. In addition, patients were excluded if they had received flucytosine.",during the first cycle of chemotherapy,NA
26163340,JapicCTI-132099,Combination,No,patients with advanced colorectal cancer,"Key inclusion criteria were as follows: (1) Japanese patients with histologically confirmed unresectable metastatic or recurrent cancer of the colon or rectum, and confirmed progressive disease in one prior chemotherapy containing a fluoropyrimidine and oxaliplatin; (2) At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0; (3) No history of treatment with irinotecan; (4) Age from 20 to 74 years; (5) Eastern Cooperative Oncology Group Performance Status (PS) of 0 or 1; (6) Adequate bone marrow function (platelet counts ≥100,000/mm3, haemoglobin levels ≥9.0 g/dL, white blood cell counts ≥3000/mm3 and neutrophil counts ≥2000/mm3); (7) Adequate liver function (bilirubin ≤1.5 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times the upper limit of normal range (ULN) or ≤5-times the ULN if liver metastasis is present); (8) Adequate kidney function (creatinine levels ≤1.5 mg/dL); (9) Life expectancy of at least 12 weeks.","Patients were excluded from the study if they had a history of serious drug hypersensitivity; concurrent treatment with atazanavir sulphate; persistent≥grade 2 adverse reactions due to prior therapy except for alopecia and anaemia; anticancer treatment within the 3 weeks and/or extensive radiation therapy within the 6 weeks prior to the start of study treatment; other concurrent cancer; brain metastasis; or if they were pregnant or breast-feeding women. During the study, granulocyte colony stimulating factor (G-CSF) was allowed except for prophylactic use.",Cycle 1,NA
8120556,NA,Combination,No,patients with low-grade lymphoma (LGL),"Patients with recurrent LGL (diffuse small lymphocytic, follicular small cleaved, follicular mixed) and follicular large-cell lymphoma were eligible. All patients had adequate marrow function (granulocytes > 1,500/ML; platelets > 100,000/jL), liver function (bilirubin - 2.0 mg/dL), renal function (creatinine : 1.5 mg/dL), and cardiac function (ejection fraction --50%).","For this phase I study, patients were excluded if they were older than 65 years of age, had prior pelvic radiotherapy, had prior poor tolerance of chemotherapy, or were human immunodeficiency virus-positive.",NA,NA
27919976,UMIN 000016377,Combination,No,Patients with HER2-negative Metastatic Breast Cancer,"Patient eligibility. Patients were eligible for this study if they had histologically confirmed breast cancer; were aged 20-64 years; had an Eastern Cooperative Oncology Group performance status of 0 or 1; and had a survival expectancy of at least 6 months. Other eligibility criteria were: no severe dysfunction of major organs such as the bone marrow, heart, lung, liver, or kidney; leukocyte count of ≥4000/mm3; neutrophil count of ≥2000/mm3; hemoglobin concentration of ≥9.0 g/dl; platelet count of ≥10.0×104/mm3; serum total bilirubin concentration of ≤1.5 mg/dl; serum aspartate aminotransferase concentration of <100 IU/l; serum alanine aminotransferase of <100 IU/l; serum creatinine clearance of ≥60 ml/min as determined from 24-h urine collection, or predicted creatinine clearance calculated using the Cockcroft-Gault formula.",Patients with a history of taxane or S-1 chemotherapy for MBC and those who had experienced grade 2 or more peripheral neuropathy before enrolment were excluded.,during cycle 1,NA
26019463,NA,Combination,No,patients with advanced biliary tract cancer,"atients with histologically or cytologically confirmed biliary tract cancer were eligible for enrollment if they met the following criteria: unresectable or recurrent disease; no prior therapy (radiation or chemotherapy) other than surgery; 20-79 years of age; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and adequate bone marrow function (white blood cell count 3500-12000/mm3, neutrophil count ≥ 2000/mm3, platelet count ≥ 100000/mm3, and hemoglobin ≥ 10 g/dL), adequate liver function (aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ three times the upper limit of normal (ULN) (in patients with obstructive jaundice, ≤ five times the ULN after biliary drainage), and total bilirubin ≤ 2 mg/dL (in patients with obstructive jaundice, ≤ 3 mg/dL after biliary drainage), adequate renal function (creatinine clearance ≥ 60 mL/min; 24-h urine collection was recommended, or the CockcroftGault formula could be used if 24-h collection was not possible), and adequate heart function (practically normal); and adequate oral intake.","The exclusion criteria were as follows: the presence of another cancer; severe complications (for example, congestive heart disease, coronary artery disease, active arrhythmias, a history of cerebral infarction or hemorrhage, active gastrointestinal bleeding or ulcer, uncontrollable diabetes mellitus, renal failure, active hepatitis, liver cirrhosis, or liver failure); the presence of a fever with suspected infection; paresis, peripheral neuropathy, or edema unrelated to biliary tract cancer; severe pleural or pericardial effusion; moderate or severe ascites; pregnancy or nursing infants, women of childbearing age; pulmonary fibrosis or interstitial pneumonia; severe mental disorders; a history of severe allergy or allergies to the drugs used in this study; treatment with another fluoropyrimidine cytotoxic agent; and treatment with flucytosine.",NA,NA
26275531,NA,Combination,No,patients with advanced gastrointestinal malignancies,"Patients were ≥18 years of age with histological diagnosis of metastatic gastrointestinal malignancies for whom FOLFIRI could be considered standard of care treatment. Subjects must have received at least one prior therapy except for small bowel cancer. All patients had measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST), an Eastern Cooperative Oncology Group performance status (ECOG-PS) of ≤2, and adequate organ function as defined by neutrophil count ≥1.5×109/L; platelets 100×109/L; hemoglobin >9 g/dL; bilirubin ≤1.5×upper limit of normal (ULN); and aspartate transaminase/alanaine transaminase ≤3×ULN, creatinine ≤1.5×ULN. Women of childbearing potential must have had negative pregnancy test.","Patients were excluded if they had received prior treatment with irinotecan. Concurrent treatment with radiation and irinotecan was allowed if it was administered prior to> 4 weeks. Patients with serum cholesterol >300 mg/dL and fasting triglycerides >2.5×ULN, HbA1c >8 % or a fasting plasma glucose>1.5×ULN, antineoplastic therapy or major surgery within 4 weeks of starting the study drug, liver or biliary tract disease, alcohol abuse in last 12 months, pancreatitis, uncontrolled brain metastases, clinical significant cardiac arrhythmias, QTc >140 ms, risk factors for Torsades de Pointes, history of syncope, other active malignancy and any uncontrolled medical illness were excluded. Patients with hypersensitivity to any component of FOLFIRI or somatostatin analogues were not allowed to participate in the trial.",during first cycle: 1),NA
32253228,NA,Combination,No,Patients with Locally Advanced Rectal Cancer,"Patients with histologically confirmed, locally advanced, not otherwise pretreated stage II or III rectal adenocarcinoma, cT3/4 and/or cNþ, M0 (AJCC 7th edition) were recruited to two centers (The Ohio State University, Columbus, OH and Vanderbilt University, Nashville, TN). Investigators obtained informed written consent from each participant or participant's guardian prior to enrollment. The research was conducted in accordance with the recognized ethical guidelines of the Declaration of Helsinki, CIOMS, Belmont report, and U.S. Common Rule. Clinical study was performed after the approval by an institutional review board. Patients were aged ≥18 years and had adequate hepatic, bone marrow, and renal organ function and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Initially, the trial was open only to patients with a KRAS gene mutation (codon 12, 13, 61), NRAS mutation (codon 12, 13, 61), or BRAF gene mutation, but due to slow accrual and the nature of the phase I trial to determine the recommended phase II dose of trametinib, it was opened to all KRAS, NRAS, and BRAF wild-type patients as well (beginning with patient #6).",NA,8.5 weeks in this trial,NA
26117830,JapicCTI-090973,Combination,No,patients with metastatic renal cell carcinoma,"Patients were eligible if they were 20 years of age or older, and had: a history of nephrectomy; a histologically confirmed diagnosis of clear-cell or papillary RCC; received no previous treatment or only one regimen of cytokine therapy; an Eastern Cooperative Oncology Group performance status of 0 or 1; measurable lesions as defined by the Response Evaluation Criteria in Solid Tumours (RECIST; version 1.0); adequate hematological, hepatic, and renal function.","We excluded patients who had brain metastasis, a known hypersensitivity to S-1 or sorafenib, or severe complications, concurrent malignancy, marked pleural effusion or ascites, watery diarrhea or peptic ulcer. Written informed consent was obtained from all patients before enrollment.",during the first cycle,NA
32977220,NCT02504333,Combination,No,patients with untreated metastatic exocrine pancreatic cancer,"The main eligibility criteria were as follows: histologically or cytologically confirmed metastatic PDAC with measurable disease according to the RECIST (Response Evaluation Criteria In Solid Tumours) version 1.1 criteria, >= 18 years, Eastern Cooperative Oncology Group (ECOG) PS <= 1, no prior systemic treatment with chemotherapy (except adjuvant therapy), life expectancy >12 weeks, adequate haematology hepatic and renal function.","Main exclusion criteria were the presence of central nervous system metastases, pre-existing sensory neuropathy > Grade 1, surgery or radiotherapy during the previous 4 weeks, prior malignancy within the past 5 years (except for basal cell skin cancer and adequately treated stage I/II cervical cancer) or any other comorbid medical conditions.",the first two cycles of therapy (12 weeks),NA
32710148,UMIN000023277,Combination,No,patients with metastatic colorectal cancer,"The inclusion criteria were histologically or cytologically confirmed colorectal adenocarcinoma, clinically unresectable disease, age between 20 and 75 years, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (patients above 70 years of age were eligible if their ECOG PS was 0), wild-type or single-heterozygous UGT1A1 *28 or *6, no history of chemotherapy (previous adjuvant therapy with fluoropyrimidine monotherapy was allowed if it was completed more than 24 weeks before relapse), presence of measurable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), and adequate organ functions.","Exclusion criteria included the following serious comorbidities: central nervous system metastasis, other active malignancies, active infection, severe lung disease, uncontrolled hypertension or diabetes, bleeding disorders requiring blood transfusion, and peripheral neuropathy of grade 2 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, version 4.03). Patients who had major surgery within 4 weeks, or thromboembolic events of grade 3 or higher within 6 months before study entry were excluded.",in the first treatment cycle,NA
32694153,NA,Combination,No,Patients with Previously Untreated Stage IV Pancreatic Cancer,"Patients over the age of 18 years with histologically documented adenocarcinoma of the pancreas, Eastern Cooperative Oncology Group (ECOG) performance status 0–1, evaluable disease by RECIST, and adequate hematologic and end-organ function were enrolled. Because of previously established on-target toxicity of WNT antagonists demonstrating evidence of bone fragility fractures, patients required a normal calcium, vitamin D, and thyroid-stimulating hormone level at time of enrollment.","Patients with history of osteoporosis, or evidence of bone metastases with pathologic fractures were excluded. All patients provided signed written informed consent and the protocol was approved by the Institutional Review Boards at participating institutions.",28 days following the first administration of ipafricept,NA
7595747,NA,Single Drug,No,"Patients with advanced solid tumors. Tumor type: Colorectal, Gastric, Head and neck, Hepatoma, Renal, Sarcoma","All patients underwent a complete history, physical examination, chest x-ray, and laboratory evaluation. Eligibility criteria included the following: (1) histologic evidence of solid tumor refractory to conventional therapy and other investigational agents of higher priority; (2) at least 18 years of age; (3) World Health Organization (WHO) performance status <= 2; (4) life expectancy >= 12 weeks; (5) off previous anticancer therapy for at least 3 weeks (at least 6 weeks for nitrosoureas or mitomycin); (6) adequate bone marrow function (WBC count >= 3,000/uL or granulocyte count >= 1,500/uL, platelet count >= 100,000/uL, hemoglobin level >= 9 g/dL), hepatic function bilirubinn level < 1.5 mg/dL, AST <= two times the upper limit of normal, albumin level >= 2.5 g/dL, normal prothrombin/partial thromboplastin time), renal function (creatinine concentration <= 1.5 mg/dL or creatinine clearance - 60 mL/min), cardiac function (no dysrhythmias requiring therapy and no myocardial infarction in the previous 6 months), and metabolic function (electrolytes within normal limits unless due to cancer, blood glucose < 200 mg/dL); and (7) written, informed consent.","Exclusion criteria included the following: (1) clinical evidence of brain metastases, (2) serious preexisting medical conditions that would prevent full compliance with the study, (3) pregnancy, (4) concomitant anticancer therapy, (5) use of aspirin, or (6) presence of pleural or peritoneal effusions. Patients who required chronic aspirin therapy and those with effusions were excluded due to the structural similarities of LY231514 and MTX",course 1,NA
7664282,NA,Combination,No,"children with refractory cancer. Diagnoses: Osteosurcoma, Ewing's sarcoma, Primitive neurocclodermal tumor, Rhabdomvosarcoma, Primitive ssarcoma of bone, Synovial cell sarcoma, Untlifferenliated sarcoma, Lymphoma, Hepatohlastoma","Patients <25 years of age with histolugically confirmed cancer refractory to conventional therapy were eligible for this trial. Patients must have recovered from the toxic affects of prior therapy before receiving amifostine/melphalan. All patients had adequate hepatic and renal function as defined by a serum bilirubin <1.5 mg/dl, serum transaminases <2 times the upper limit of normal, and a serum creatinine level <1.5 times normal for a patient's age. Patients were required to have a granulocyte count >15000/mm3 and a platelet count >100,000/mm3",NA,NA,NA
8336196,NA,Single Drug,No,"Patients With Lung Cancer. Adenocarcinoma, Squamous cell carcinoma, Large-cell carcinoma, Small-cell carcinoma","All patients entered onto this study had histologically or cytologically proven lung cancers. The eligibility criteria were as follows: age from 18 to 79 years, World Health Organization (WHO) performance status' 8 < 3, estimated life expectancy > 4 weeks, leukocyte count > 3 X 10'/L, platelet count > 100 X 109/L, serum creatinine < 1.5 mg/dL, serum bilirubin < 2.0 mg/dL, and no antineoplastic treatment during the 4 weeks before entry (8 weeks for agents with delayed hematologic toxicity such as mitomycin). Patients with non-smallcell lung cancer had advanced (stage IIIB or IV) cancers or postoperative relapse. Untreated patients and patients previously treated with chemotherapy, radiotherapy, or both were eligible. Patients with small-cell lung cancer were eligible if they were refractory or resistant to standard chemotherapy and radiotherapy.",in cycle 1,NA,NA
8402670,NA,Combination,No,"patients with advanced or metastatic solid tumor. Primary site:  Breast, Colon, Kidney, Lung, Other","Eligibility criteria included histologically documented advanced or metastatic solid tumor refractory to standard therapy or for which no conventional therapy was available. 18 years or older, and Eastern Oncology Cooperative Group performance status 0, 1, or 2. Prior radiotherapy and chemotherapy had to be completed at least 3 weeks (6 weeks for nitrosoureas and mitomycin C) prior to entry into the trial, and recovery from toxicity of prior therapy had to be complete before study entry. Patients with adequate organ function were eligible. Adequate organ function was defined as: granulocytes, >=1.5 x 109/liter; platelets, >=lOO x lO9/liter; creatinine, <=1.5 x normal; normal bilirubin; AST, <=2 x normal; and left ventricular ejection fraction, >=50% as determined by MUGA scan. Written informed consent according to institutional and regulatory requirements was obtained prior to therapy","Ineligibility criteria included more than one prior anthracycline or intercalator; cumulative doses of >=200 mg/m2 dox, >=85mg/m2 mitoxantrone, or Â£350 mg/m2 epirubicin; a history of myocardial infarction within 1 year prior to entry; congestive heart failure; angina; uncontrolled hypertension; active cardiomyopathy or ventricular arrhythmias; prior therapy with a phase 1 agent; radiotherapy to the left hemithorax or mediastinum >=4000 cGy or to >=30% of the marrow bearing skeleton; surgery during the previous 14 days; more than one primary malignancy (except nonmelanoma skin cancer and in.tint carcinoma of the cervix); and pregnancy.",cycle 1,NA
8909321,NA,Combination,No,"patients iwth carcinoma. Primary sites of disease: Stomach: 38, Pancreas: 6, Unknown primary: 6, Gallbladder: 3, Duodenum: 2, Bile duct: 1, Esouhams: 1","Patients treated as part of this trial had to meet a series of eligibility criteria. All patients had to have been >= 18 years of age with histologically confirmed carcinoma by the Pathology Department of Memorial Hospital. Patients must have had an incurable cancer and a Karnofsky performance status (KPS) >= 60% with a life expectancy of at least 8 weeks. All patients must have had a leukocyte count >= 4000/uL and a platelet count >= 150,000/uL prior to starting therapy, serum bilirubin <= 1.5 mg/dL, serum creatinine <= 1.5 mg/dL, and normal heart function (New York Heart Association Class 1-11 with no prior history of congestive heart failure). Patients without measurable disease were allowed entry on this Phase I protocol although attempts were made to define measurable disease in all patients so that the therapeutic efficacy of the combination could be evaluated. Previously treated patients were accepted as long as they had received myelosuppressive chemotherapy within the previous 4 weeks (6 weeks for prior nitrosurea or mitomycin C). However, no patient who entered this study had received any prior treatment. The total dose of prior doxorubicin had to be less than 200 rnglm’. They may not have received radiation therapy to major bone marrow-containing areas within the prior 4 weeks",Patients with large pleural effusions or ascites were excluded from the study,NA,NA
9041168,NA,Combination,No,Metastatic Melanoma,"Patients were required to be 18 years or older and signed written informed consent had to be obtained. They had to have histologically documented metastatic melanoma with measurable or evaluable disease. Adequate renal, liver, and hematologic function was required with an Eastern Cooperative Oncology Group (ECOG) performance status of <=2.","Patients with central nervous system metastases, a history of deep venous thrombosis, or pulmonary embolism were excluded.",NA,NA
9436939,NA,Combination,No,patients with relapsed or refractory multiple myeloma,"Eligible patients had histologically confirmed MM with resistance to or relapse after at least one prior chemotherapy regimen. Only patients aged 18-75 years with Durie-Salmon stage II or III were enrolled. Patients were required to have a performance status not exceeding ECOG 3, no radio- or chemotherapy within the last 4 weeks before study entry, an adequate baseline organ function defined as WBC > 1500/ul, platelets > 75000/ul, creatinine clearance >50 ml/min or serum creatinine < 1.8 mg/dl, serum bilirubin < 2 mg/dl, serum GOT or serum GPT < 100 U/I.","Patients with severe pulmonary or cardiac disease, active infections, other concomitant malignant diseases, brain or psychiatric disorders were excluded.",NA,NA
9815746,NA,Combination,No,"patients with advanced malignancies. Diagnosis: Breast Cancer, Lung, Small cell, Non-small cell, Colorectal, Ovary, Gastric, Pancreas, Renal, Bladder, Thymus, Schwannoma, Sarcoma: Soft tissue, Primary unknown","Patients age 18 years and older with histologically or cytologically confirmed advanced cancer who had been treated previously with up to four prior chemotherapy regimens were eligible for this study. Patients must have failed all potentially curative therapy prior to this study. Written informed consent was obtained before treatment according to NCI2 and The Walter Reed Army Medical Center Investigational Review Board guidelines. All patients were required to have a normal baseline cardiac left ventricular ejection fraction and an Eastern Cooperative Oncology Group performance status of 0, 1, or 2 at study entry. Laboratory requirements included a WBC count >=3,500/ul, platelets >=100,000/ul, serum bilirubin less than 1.8 mg/dl, aspartate aminotransferase and alanine aminotransferase not to exceed three times the upper limit of normal, and serum creatinine less than 1 .5 mg/dl.","Patients were excluded if they had central nervous system metastases; a history of cardiac disease; had exceeded 360 mg/m2 of prior doxorubicin therapy; or had undergone prior camptothecin therapy, autologous bone marrow transplantation, or prior treatment within 6 months with nitrosoureas, melphalan, or mitomycin C. Concurrent irradiation and prior irradiation to the mediastinum were not allowed.",during the first cycle of therapy,NA
10389912,NA,Combination,No,Relapsed Epithelial Ovarian Cancer,"Women with histopathologically confirmed epithelial ovarian carcinoma and documented recurrent disease defined as new ascites with positive cytology, biopsy-proven relapse, or a rising CA-125 more than 1 month since previous treatment were eligible for this study. Other eligibility criteria included a prior platinum-containing chemotherapy, a GOG performance status <= 2, and a cardiac ejection fraction (LVEF) >= 45%.","Patients were excluded if they had a history of congestive heart failure, active angina pectoris or myocardial infarction within 6 months of treatment, an electrocardiogram with significant ischemia or conduction defect, a serum creatinine >1.5 mg/dl, or serum bilirubin (direct) and aspartate aminotransferase >1.5 times the upper limit of the normal range",on cycle 1 of chemotherapy,NA
10589753,NA,Combination,No,patients with untreated extensive stage small cell lung cancer (SCLC),"Adult patients (.18 years) with histologically or cytologically confirmed extensive stage SCLC were eligible to participate in this trial if they had measurable or evaluable disease. Patients with brain metastases were excluded. All patients were required to have normal organ function according to protocol guidelines, a performance status of <2, and an expected survival of >3 months.","Patients with any evidence of a cardiac conduction abnormality were ineligible, as were patients receiving b blockers, calcium channel blockers, digoxin, or antiarrhythmic medications. Patients with clinically evident hearing loss or symptomatic peripheral neuropathy were ineligible. Patients with a prior history of malignancy other than nonmelanoma skin cancer or cervical carcinoma in situ were excluded if their disease-free interval was ,5 years. Patients could not have received prior chemotherapy, but previous surgery or radiotherapy was allowed",during all the treatment cycles,NA
10590370,NA,Combination,No,patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma,"Patients entered onto this study were required to have one of the following: 1) histologically confirmed primary epithelial ovarian carcinoma, Grade 2 or 3 and Stage III or IV; or 2) histologically confirmed primary peritoneal carcinoma. All patients must have had appropriate initial surgery, suboptimal residual tumor (>2 cm) or disease beyond the peritoneal cavity, and no prior cytotoxic chemotherapy. Patients with either measurable disease (by physical examination or by imaging techniques) or nonmeasurable disease were evaluated. Other eligibility criteria were as follows: adequate bone marrow function (white blood count >= 3000/uL, granulocyte count >= 1500/uL, and platelet count >= 100,000/uL); adequate renal function (serum creatinine <= 1.4 mg%); adequate hepatic function (serum bilirubin and serum glutamic oxaloacetic transaminase [SGOT] levels = twice normal); a life expectancy of at least 12 weeks; a Zubrod performance status of 0 –2;23 and age >18 years and <65 years.","Exclusion criteria were as follows: a diagnosis of borderline (low malignant potential) or Grade 1 ovarian tumor; optimal (<=2 cm) residual disease after surgery (unless disease extended beyond the peritoneal cavity); prior chemotherapy or radiotherapy; evidence of severe infection or gastrointestinal bleeding; history of cardiac arrhythmia or current use of antiarrhythmic medication; history of congestive heart failure, unstable angina, or myocardial infarction within the past 6 months; unclassified ovarian carcinoma or carcinoma of questionable ovarian or peritoneal origin; Zubrod performance score >= 3; and another malignancy (prior or concomitant, with the exception of nonmelanoma skin carcinoma).",in each cycle of therapy,NA
11049969,NA,Combination,No,relapsed B-cell lymphomas,"Adults with relapsed NHL expressing the CD20 antigen were eligible if previous chemotherapy had failed and they had evaluable disease, normal renal and hepatic function, no systemic cytotoxic therapy for 4 weeks, and less than 25% involvement of their bone marrow (BM) with lymphoma. Patients with splenomegaly or tumor burdens greater than 500 cm3 on computed tomographic (CT) volumetric assessment were eligible only if they underwent tumor cytoreduction with chemotherapy or splenectomy before transplantation. All patients had autologous hematopoietic stem cells harvested and cryopreserved before study entry.","Patients with a life expectancy of less than 2 months or a serious coexistent medical condition, acquired immunodeficiency syndrome, chronic lympho- cytic leukemia, central nervous system lymphoma, or human antimouse antibodies (HAMAs) were excluded.",NA,NA
11051260,NA,Combination,No,Advanced Breast Cancer,"(a) metastatic or recurrent advanced breast cancer with histological or cytological confirmation; (b) no prior chemotherapy except adjuvant chemotherapy; (c) estrogen receptor negative or refractory to prior hormone therapy; (d) age, 20–75 years; and (e) good performance status (performance status of 0–2 by Eastern Cooperative Oncology Group criteria). Other eligibility criteria included a WBC count of >=4,000/ml, a neutrophil count of >=2,000/ml, a platelet count of >=100,000/ml, hemoglobin >=9.5 grams/dl, serum albumin >=3.0 grams/dl, total bilirubin level<= 1.5 mg/dl, AST and alanine aminotransferase levels<=2.0 times the upper limit of the normal range, blood urea nitrogen level within the normal limit, PaO2 level>=60 torr, normal electrocardiography, and normal cardiac LVEF (>=50%). For patients with liver metastasis of breast cancer, AST and alanine aminotransferase values were required to be less than 3 times the upper limit of the normal range. Written informed consent was obtained from all patients.",NA,first two cycles,NA
11335910,NA,Single Drug,No,"patients with solid tumors.Primary tumors included soft tissue sarcoma (7 patients), head and neck carcinoma (6 patients), gastrointestinal tract carcinoma (3 patients), carcinoma of the genitourinary tract (3 patients), lung carcinoma (2 patients), and other malignancies (2 patients).","Patients who had recurrent or metastatic solid tumors that were refractory to therapy or for whom no effective therapy was available were eligible for accrual if the following criteria were met: pathologically or cytologically confirmed diagnosis; measurable disease by physical examination or image study; an Eastern Cooperative Oncology Group (ECOG) performance status >= 2; no prior chemotherapy or radiotherapy in recent 4r weeks; adequate bone marrow reserve (WBC >= 3500/mm3 or ANC >= 1500/mm3 and platelets> 90,000/mm3 ); creatinine <= 1.5 times upper normal limit; bilirubin <= 1.5 times upper normal limit; serum alanine and aspartate aminotransferase levels <= 3.0 times upper normal limits; and signed informed consent.",NA,during the first dosing cycle,NA
11350887,NA,Combination,No,Tumor types:Ovarian 15;Lung 7;Sarcoma 3;Other 8,"Patients were eligible if they had a pathological confirmation of incurable malignancy and had measurable disease.No chemotherapy for 3 weeks prior to study entry (6 weeks for nitrosoureas) or no radiation therapy for 4 weeks prior to study entry was permitted. Patients were required to have an Eastern Cooperative Oncology Group performance status 0–2 and an anticipated survival of>3 months.Adequate renal function (creatinine , 1.5 mg/dl) and hepatic function (serum bilirubin, <1.0 mg/dL, serum aspartate amino transferase ,<3* upper limit of normal) was required.Normal bone marrow function was required as indicated by white blood count greater than 3,500 per mm3 and platelet count greater than 100,000 per mm3.Prior doxorubicin treatment was allowed but could not exceed a cumulative dose of 300 mg/m2. LVEF was required to be >=45% at rest by radionuclide ventriculogram.",Patients with active central nervous system metastases were excluded.,during the first cycle of DP or DPV,NA
11355147,NA,Single Drug,No,patients with metastatic renal carcinoma,"Patients were eligible if they had a measurable, histologically documented solid tumor, including metastatic melanoma and RCC, that was unresponsive to initial treatment. Prior surgical excision was acceptable but was not required. Eligibility included an Eastern Cooperative Oncology Group performance status of 0 or 1; age 18 to 70 years; more than a 12-week life expectancy; and adequate hepatic, renal, and hematologic function (including absolute neutrophil count > 3,000 cells/uL, platelet count > 100,000/uL, hemoglobin > 9.0 g/dL, serum creatinine < 2.0 mg/dL or calculated creatinine clearance of > 50 mL/min, serum bilirubin < 1.5 times the upper limit of normal [ULN] unless due to disease infiltration, ratio of serum ALT to serum AST < 1.5 times ULN unless due to disease infiltration, and normal serum calcium). Patients who had received prior IFN- or interleukin- 2– containing regimens were eligible.","Patients were ineligible if they had received more than two prior systemic treatments, including chemotherapy or immunotherapy, or if they had evidence of CNS metastases, a history of hypersensitivity or intolerance to IFNa, a history of hospitalization because of neuropsychiatric disorders, severe cardiovascular disease, refractory thyroid dysfunction, uncontrolled diabetes, active hepatitis, or a life-threatening second active malig- nancy.",first 4 weeks of therapy,NA
11768362,NA,Combination,No,large operable or locally advanced/inflammatory breast cancer,"Eligibility criteria included age ≤65 and histologically or cytologically proven (FNA, incisional biopsy or Trucut biopsy) LO primary BC (requiring either a mastectomy or a large tumorectomy whose cosmetic result could be anticipated to be unsatisfactory), LA BC (T4 any N, or any T, N2 or N3), or clinically I BC (defined as: redness over at least one-third of the breast)). Other requirements were WHO Performance Status 0–1, adequate marrow function (neutrophil count ≥1.5 × 109/l and platelet count ≥100×109/l), adequate renal function (serum creatinine <120µmol/l) and hepatic function (serum bilirubin <20µmol/l, ASAT(SGOT) <60IU/l) and normal left ventricular fraction (LVEF) measured either by echocardiography or by radionuclide angiocardiography (MUGA). D","Distant metastasis, other than ipsilateral supraclavicular nodes, previous chemotherapy or radiation therapy were exclusion criteria",The first 2 cycles,NA
11869937,NA,Combination,No,"Patients with refractory acute myeloid or lymphoid leukemia (AML, ALL)","Patients with a diagnosis of refractory AML and ALL and with a life expectancy >3 months were eligible for the study, provided they gave informed consent. Refractoriness was defined by primary resistance to the current induction regimen (onetwo courses) or a different salvage regimen; first relapse after a complete remission lasting <6 months; first relapse after a remission lasting >6 months if prior treatment included an allogeneic hematopoietic cell transplant (allo-BMT) or other high-dose therapy (HDAC or autograft regimen); and any subsequent relapse.",NA,NA,NA
11925132,NA,Combination,No,Advanced Ovarian Cancer,"Women with newly diagnosed, stage III or IV ovarian cancer; stage II ovarian cancer with bulky residual disease; or primary peritoneal carcinoma were eligible for entry into the study. Patients were required to be >18 years old, have a Gynecologic Oncology Group performance status 2, hematocrit >25%, white blood cell count >3000 cells/mm3, absolute neutrophil count (ANC) >1500 cells/mm3, and platelet count >100,000/mm3. Baseline serum creatinine and bilirubin were required to be within normal limits, with liver enzymes and alkaline phosphatase less than twice the upper limit of normal. Patients were required to have undergone primary debulking surgery within 2 months of study entry.","Patients with impaired hepatic or renal function and patients who had received prior chemotherapy, prior radiation of hematopoietic sites (>10%), or any radiation therapy within 1 month of entering the study were excluded.",during the first cycle of therapy,NA
12114412,NA,Combination,No,patients with refractory acute leukemia,"Patients with primary refractory or relapsed acute leukemia (AML or ALL), or refractory or relapsed lymphoblastic lymphoma were eligible for this study. In addition, patients with chronic myelogenous leukemia in myeloid blast crisis who were either treated previously or untreated were considered eligible for protocol entry. Eligibility criteria also included Karnosky performance status >=60; age >=18 years (patients receiving 3 g/m2 ara-C must have been <= 60 years of age); calculated or actual creatinine clearance >=40 ml/min (for patients receiving 3 g/m2 ara-C, the creatinine clearance must have been >=60 ml/min); total bilirubin <=2 mg/dl (excluding patients with Gilbert’s syndrome); aspartate aminotransferase/alkaline phosphatase <=2.5 x upper limit of normal; and patients must have recovered from the major toxic effects of previous therapy.","Patients were excluded for the following: systemic chemotherapy within 3 weeks before beginning study treatment (except for hydroxyurea, which needed to be discontinued 24 h before therapy); clinically significant pulmonary disease, previous significant ara-C-related cerebellar toxicity; poor medical risks because of nonmalignant systemic disease; active, uncontrolled, serious infection; pregnancy; and medical status that would make it difficult to interpret cortical or cerebellar neurological toxicity",NA,NA
12576438,NA,Combination,No,"refractory solid tumors. Non-CNS tumors: Ewing’s sarcoma, Osteogenic sarcoma, Rhabdomyosarcoma, Neuroblastoma, Chondrosarcoma, Hepatocellular carcinoma; CNS tumors: Ependymoma, Brain stem glioma, Medulloblastoma","Patients between 1 and 22 years of age with confirmed malignant solid tumors refractory to standard therapy were eligible for this trial. Other eligibility criteria included: (a) Karnofsky score >= 50% for patients > 10 years old and Lansky play scale >= 50% for patients <= 10 years old; (b) life expectancy >= 8 weeks; (c) >=3rd percentile weight for height; (d) serum albumin >= 2.5 grams %; (e) recovery from acute toxicity of previous therapy; (f) no significant systemic illness (e.g., uncontrolled infection); (g) no growth factors for >=1 week before entry; (h) stable or decreasing doses of dexamethasone for >=2 weeks before entry (for patients with CNS tumors); (i) no anticancer therapy for >=3 weeks before entry (6 weeks for nitrosoureas); (j) no local radiation for >=2 weeks before entry; (k) no craniospinal or >=50% pelvic radiation for >=6 months before entry; (l) no autologous or allogeneic bone marrow transplantation (without total body irradiation) for .=6 months before entry; (m) no graft-versus-host disease; (n) ANC >= 1,000/mm3; hemoglobin concentration >= 8 grams/dl; (o) Pt count >=100,000/mm3; (p) bilirubin <= 1.5 mg/dl; (q) SGPT less than or equal to twice the upper limit of normal; and (r) normal serum creatinine for age, or glomerular filtration rate","Specific exclusion criteria were pregnancy, breast feeding, and therapy with anticonvulsants. For less heavily pretreated patients, the exclusion criteria also included more than two previous chemotherapy regimens, central axis radiation, bone marrow involvement with cancer, and previous bone marrow transplantation","The DLTs were evaluated for all treatment cycles, although determination of MTD was performed based on toxicities during the first course only.",NA
12796372,NA,Combination,No,Patients with Limited Small Cell Lung Cancer,"Eligibility criteria included LD SCLC as documented by chest radiography; computed tomography of the chest, brain, and abdomen; radionuclide bone scan; bone marrow aspiration and biopsy; and physical examination. Patients with N3 disease as manifested by ipsilateral supraclavicular or contralateral mediastinal lymphadenopathy were eligible. Patients with contralateral hilar or contralateral supraclavicular lymphadenopathy were excluded to limit the size of the irradiation field and pulmonary toxicity.  Adequate organ function was required, including an absolute granulocyte count >= 1,500/l, platelets >= 150,000/l, total bilirubin <= 1.5mg/dl, and serum creatinine <= 1.5 mg/dl or creatinine clearance >= 40 ml/min. A performance status of <= 2 on the Zubrod scale, no previous chemotherapy or radiotherapy, no recent history of other malignancies (excluding nonmelanoma skin cancer or carcinoma in situ of the uterine cervix), and written informed consent were also required.",Patients with a pleural effusion visible on chest X-ray were excluded.,in the first two cycles of chemotherapy,NA
15341977,NA,Combination,No,uveal melanoma and other solid tumours,"Patients meeting the following criteria were selected for inclusion: patients with uveal melanoma were eligible when they had received no prior chemotherapy or only fotemustine or the BOLD combination. There is no standard chemotherapy regimen for renal cell cancer, therefore, first-line treatment within this protocol was allowed for these patients. Patients with other histologies were only eligible if they had failed at least one standard chemotherapy regimens. Further inclusion criteria were a Karnofsky performance status of at least 60% and adequate hepatic, renal, cardiac and bone marrow function.",NA,NA,NA
15736475,NA,Combination,No,pretreated patients with metastatic breast cancer,"Patients with histologically or cytologically confirmed MBC and measurable or assessable disease were enrolled. All patients had to have either progression during, or within 3 months after, the completion of an anthracycline- and taxane-based chemotherapy. Other eligibility criteria were: age 18-75 years; performance status (WHO) 0-2; life expectancy of at least 3 months, and at least 4 weeks from prior cytotoxic chemotherapy; adequate bone marrow (absolute neutrophil count ≥ 1500/dl, hemoglobin ≥ 10g/dl and platelets ≥ 100,000/dl), hepatic (serum bilirubin ≤ 1.5 times the upper limit of normal; aspartate aminotransferase and alanine aminotransferase ≤ 5.0 times the upper limit of normal) and renal (serum creatinine ≤ 1.5mg/dl) function. Patients with brain metastases were eligible provided that they had been irradiated and had clinical and radiological improvement","Patients with severe cardiac dysfuction or unstable agina pectoris, or prior irradiation affecting more than 30% of the bone marrow, were not eligible. Patients with active infection, malnutrition or a second primary tumour, apart from adequately treated in situ carcinoma of the cervix or a non-melanoma skin cancer, were ineligible",during the first cycle,NA
15865068,NA,Combination,No,Advanced Breast Cancer,"Women aged 18 to 60, with a histologically proven diagnosis of locally advanced breast cancer (LABC) (stages IIIA or IIIB) or recurrent MBC (stage IV), were eligible for the study. The following conditions were required: WHO performance status ≤2, life expectancy ≥3 months, no prior chemotherapy for MBC or LABC, no prior adjuvant high-dose intensified chemotherapy with autologous bone marrow or stem cell rescue, adjuvant chemotherapy stopped at least 6 months before the study entry, no concomitant hormonotherapy, adequate bone marrow (granulocytes ≥2, 000/mm3; platelets ≥150, 000/mm3), kidney (creatinine ≤16 mg/l) or liver functions (SGOT, SGTP, total bilirubins ≤1.5 and/or alkaline phosphatase ≤2.5 upper normal limits in absence of bone metastases). If patients had previously received an anthracycline or an anthracenedione as adjuvant treatment, a maximum cumulative dose of ≤300 mg/m2 doxorubicin, ≤480 mg/m2 epirubicin and ≤60 mg/m2 mitoxantrone was allowed. Prior radiotherapy was permitted provided it was not performed on measurable or evaluable lesions. Normal left ventricular ejection function (LVEF) (≥55% by isotopic or ultrasound testing) was required before starting the treatment. Patients had to present at least one measurable or evaluable lesion according to WHO as assessed by a work-up including a general biology with tumor markers (CEA, CA 15.3), a recent mammography, CT scans of thorax and abdomen and a bone scintigraphy","Patients with an active cardiac event within the previous 6 months, as well as patients suffering from an actual severe and/or active heart disease (class III or IV heart failure according to the New York heart association) or with active central nervous system (CNS) metastases, were excluded.",During the first course,NA
16062072,NA,Combination,No,Metastatic Esophagogastric Cancer,"Patients were required to have histologically confirmed metastatic squamous or adenocarcinoma of the esophagus, gastroesophageal junction, or stomach. Patients could not have received prior chemotherapy for metastatic disease; however, previous adjuvant or neoadjuvant therapy were allowed. A minimum of 28 days was required after prior adjuvant or neoadjuvant therapy. Patients were enrolled at 4 hospitals that participate within the Brown University Oncology Group in Providence, RI, and at the Beth Israel Deaconess Medical Center, Boston, MA. Patients were required to be at least 18 years of age with an Eastern Cooperative Oncology Group Performance Status (PS) of 0 to 2. There was no upper age limit. Required laboratory values included an absolute neutrophil count >= 1500 cells/L, platelets >= 100,000 cells/L, creatinine 1.5 mg/dL, normal total bilirubin, and transaminases 5 times the upper institutional limit of normal. Patients were required not to have significant infection or other coexistent medical condition that would preclude protocol therapy. Other major eligibility criteria included peripheral neuropathy less than grade 1. A complete history and physical examination were performed on all patients prior to study entry and prior to starting each treatment cycle. Blood counts were assessed weekly; chemistry and liver function tests were measured prior to the start of each cycle. Height, weight, PS, and tumor stage were recorded. Required staging studies included computed tomographic scans of the chest and abdomen",NA,during the first cycle of treatment,NA
16077976,NA,Combination,No,patients with NSCLC refractory for both platinum and docetaxel,"Eligibility criteria included pathologically or cytologically proven unresectable NSCLC, refractory for both platinum-based chemotherapy and docetaxel; Eastern Cooperative Oncology Group performance status (PS) <=1; age from 20 to 75 years; both a leukocyte count >4000/ul and a neutrophil count >2000/ul; hemoglobin >10 g/dl; platelet count >100000/ul; serum creatinine <=1.2 mg/dl; total serum bilirubin <=1.2 mg/dl; serum aspartate aminotransferase (GOT) <=2.5 x of the upper limit of normal; serum alanine aminotransferase (GPT) <=2.5 x of the upper limit of normal; alkaline phosphatase (ALP) <=2.5 x of the upper limit of normal; arterial oxygen concentration >70 mmHg or arterial oxygen saturation >93%; and written informed consent. Patients with postoperative recurrence were eligible. The cross-over administration of between vinorelbine or gemcitabine and first-line chemotherapy regimen was not prohibited in this phase I study. Patients who had received gefitinib on condition that its duration was short (4 weeks or less) were eligible, but if any adverse events developed, these events were regarded as toxicity in this study.","Patients with the following criteria were excluded from the study; active infection, interstitial pneumonitis or pulmonary fibrosis diagnosed by plain chest X-ray or chest computed tomography (CT), ileus, motor palsy or peripheral neuropathy, body cavity effusion requiring tube drainage, uncontrollable liver cirrhosis, diabetes mellitus, heart disease, myocardial infarction <3 months before the date of treatment, active multiple cancer, brain metastasis with clinical symptoms, past history of serious drug allergy, need of means of therapy other than chemotherapy, and pregnant or nursing women.",during the first 2 courses,NA
16463060,NA,Single Drug,No,"patients with advanced cancer. Tumor type: Kidney 2, Prostate 8, Melanoma 1, Head and neck 3, Pancreas 3, Breast 1, NSCLC 2, Leiomyosarcoma 1","Patients were eligible for the study if they had refused standard therapy or had failed at least one standard systemic treatment regimen for their malignancy, were >= 18 years of age, had Eastern Cooperative Group (ECOG) performance status of 0–2, and a life expectancy of at least 3 months. Adequate organ function was required, including ANC >=1.5 x 109 l -1, platelets >= 100 x 109 l-1, Hb >= 10.0 g/dl for men and >= 9.0 g/dl for women, serum creatinine <= 0.12 mmol/l, and AST/ALT levels <= 5 times the upper limit of normal.","Patients were ineligible if they had more than 25% of hemopoietic bone marrow previously irradiated, active infection, or active, untreated CNS metastases. No investigational agent or chemotherapy was allowed within at least 3 weeks of study entry (6 weeks for nitrosureas or mitomycin C), and patients must have recovered from previous side effects.",within the first 4 weeks of treatment,NA
16596187,NA,Combination,No,pretreated advanced pancreatic cancer patients,"Patients >18 years of age with histologically or cytologically confirmed adenocarcinoma of the pancreas and bidimensionally measurable disease, who had undergone chemotherapy pretreatment and had recurrent or non-responsive disease, were enrolled in the study. Other eligibility criteria included a World Health Organization (WHO) performance status (PS) of 0-2, life expectancy of at least 3 months, adequate bone marrow reserves (granulocyte count ≥1500/dl, platelet count ≥120000/dl) normal renal (serum creatine concentration <1.2 mg/dl) and liver function tests (total serum bilirubin concentration, <3 mg/dl, provided that serum transaminases and serum proteins were normal), normal cardiac function with no history of clinically unstable angina pectoris or myocardial infarction, or congestive heart failure within the 6 months prior, and no central nervous system involvement. Prior surgery was allowed provided that it had taken place at least 3 weeks before.","Patients with active infection, malnutrition or a second primary tumor (except for a non-melanoma skin epithelioma or in situ cervix carcinoma) were excluded from the study.",NA,NA
16763792,NA,Combination,No,advanced malignancies,"Patients with histologic proof of metastatic or locally advanced solid tumors were eligible for this study. Eligibility criteria included age >= 18 years; Eastern Cooperative Oncology Group performance status <= 2; adequate bone marrow (platelets >= 100 x 109 cells/l, absolute neutrophil count [ANC] <= 1.5 x 109 cells/l), hepatic (total bilirubin <= 1.5 x upper limit of normal and AST <= 1.5 x upper limit of normal) and renal (serum creatinine <= 1.5 times the upper limit of normal) functions; life expectancy ¸ 12 weeks; no chemotherapy, radiotherapy, immunotherapy, biologic, or investigational drug therapy within 4 weeks prior to study entry; no nitrosourea or mitomycin C chemotherapy within 6 weeks prior to study entry and no prior bone marrow transplant.","Excluded from this study were patients with radiation therapy to > 30% of the bone marrow; grade 2 or more peripheral neuropathy; uncontrolled infection; known HIV-positivity; brain metastasis, unless disease had been resected by surgery or radiosurgery and patient had been stable for at least 8 weeks.",during the first cyle,NA
17197129,NA,Combination,No,ESOPHAGEAL CARCINOMA,"Eligible patients were >= 18 years of age with previously untreated, histologically confirmed adenocarcinoma or squamous cell carcinoma of the thoracic esophagus or gastroesophageal junction, for which chemotherapy and radiation therapy was indicated. Patients were required to have bidimensionally measurable disease, a Karnofsky performance status >= 70, and a life expectancy >= 3 months. Baseline laboratory requirements were as follows: absolute neutrophil count >= 1,500/mm3, platelets >= 100,000/mm3, total bilirubin <= 1.5 mg/dL, serum creatinine <= 1.5 x upper limit of normal, and aspartate transaminase/alanine aminotransferase <= 2.5 x upper limit of normal.","Patients with distant metastases were eligible, with the exception of brain metastases, carcinomatous meningitis, or lymphangitic lung metastases. Other exclusion criteria included pa- tients with radiographic or bronchoscopic evidence of esophageal perforation, serious underlying medical conditions that would im- pair their ability to receive protocol treatment, tumor extension above the thoracic inlet or 4 cm distal to the gastroesophageal junction, or prior chemotherapy or radiation therapy",during or up to 2 weeks after completion of chemoradiotherapy,NA
17465237,NA,Combination,No,patients with malignant brain tumors,"Patients with relapsed malignant primitive brain tumors not eligible for further surgery and/or radiotherapy were enrolled into the study. Patients having had prior chemotherapy were admitted, including those treated with temozolomide if it had not been combined with other alkylating agents. Other inclusion criteria were: histological or radiological diagnosis of high grade malignant glioma, age between 18 and 75 years, ECOG performance status not worse than 3, more than 8 weeks of life expectancy, neutrophil count >2.0x109/L and platelets >100x109/L, serum creatinine and total bilirubin <1.5 x upper normal limit, possibility of regular follow-up.","Patients with relevant concomitant illnesses or active infection in progress were excluded. In fertile woman, those with pre-existing pregnancy were excluded and adequate contraception was strongly recommended",cycle 1,NA
17905421,NA,Combination,No,platinum- and taxane-resistant ovarian cancer,"Inclusion criteria for the study were the following: (1) histologically confirmed, advanced and/or metastatic ovarian cancer, primary peritoneal cancer, or fallopian tube cancer; (2) platinum- and taxane-resistant disease (defined as progression of disease during or recurrence of disease within 6 months of completing platinum and taxane chemotherapy or failure to achieve a CR [with persistent macroscopic disease] after six cycles of chemotherapy if the last two cycles had produced no measurable change in disease status); (3) patients may have had any number of prior chemotherapy regimens, except high-dose chemotherapy and/or peripheral blood stem cell transplantation; (4) measurable disease (defined as at least one lesion ≥20 mm that could be accurately measured in at least one dimension by conventional techniques, including palpation, plain X-ray, computed tomography, and magnetic resonance imaging, or at least one lesion ≥10 mm measurable by spiral computed tomography; (5) Zubrod performance status of ≤2; and (6) evidence of adequate liver, renal, and bone marrow function (absolute neutrophil count ≥1.5 × 109/L, platelets ≥100 × 109/L, total bilirubin ≤1.7 μmol/L, alanine transaminase, and aspartate transaminase ≤1.5 times the upper limit of normal [ULN], alkaline phosphatase ≤2.5 times the ULN, and serum creatinine ≤1.5 times the ULN).","Patients were excluded for the following reasons: (1) chemotherapy within 4 weeks of the start of the first cycle of bortezomib; (2) previous high-dose chemotherapy and/or peripheral blood stem cell transplantation; (3) radiotherapy within 4 weeks of study enrollment (except for palliative radiotherapy); (4) grade 2 or higher peripheral neuropathy; (5) surgery within 4 weeks of study enrollment; (6) a history of hypersensitivity reaction to carboplatin; (7) electrocardiographic evidence of acute ischemia or new conduction system abnormalities; (8) myocardial infarction within 6 months of enrollment; (9) brain metastases or central nervous system disease; (10) a history of another malignancy, except nonmelanoma skin cancer or carcinoma in situ of the cervix, unless the cancer was in complete remission and all therapy for it had been completed a minimum of 5 years earlier; (11) human immunodeficiency virus infection; (12) pregnancy or breast-feeding; (13) known hypersensitivity to bortezomib; and (14) previous therapy with a biologic agent",during the first cycle,NA
18689866,NA,Combination,No,"patients with advanced, aggressive T-cell or NK/T-cell lymphoma.","histologically confirmed PTCLs and NK/T-cell lymphomas excluding ALK-positive anaplastic large-cell T-cell lymphomas (ALCL)performance status (Eastern Cooperative Oncology Group) of three or less,age £65 yearsat least one or more unidimensionally measurable lesions (‡2 cm by conventional computerized tomography (CT) or ‡1 cm by spiral CT or skin lesions or a measurable lesion by physical examination)adequate renal function (serum creatinine £1.5 mg/dl or creatinine clearance ‡60 ml/min);adequate hepatic function (serum transaminases £3· upper normal limit, bilirubin <1.5 mg/dl)adequate bone marrow function (neutrophil count ‡1500/mm and platelets >=75 000/ll)no previous treatment of the disease;Ann Arbor stage III or IV.",Patients with any other malignancies within the past 5 years except skin basal cell carcinoma or carcinoma in situ of cervix were excluded from the study.Patients with central nervous system involvement and HIV positivity were also excluded from the study.,Evaluations were made after three and six cycles.,NA
19319526,NA,Combination,No,bone metastases,"Patients with histologically documented adenocarcinoma of the prostate, progressive hormone-refractory disease and more than one painful bone metastasis (99mTc-HDP scintigraphy within 8 weeks prior to screening) were included in this open-label prospective phase I study. Other inclusion criteria were a Karnofsky performance score of at least 60%, life expectancy of at least 3 months, age of at least 18 years and the ability to understand and willingness to sign an informed consent document. Patients receiving bisphosphonate therapy had to discontinue their treatment for at least 2 weeks prior to study entry, and patients under luteinizing hormone-releasing hormone (LH-RH) agonists (and/or antiandrogens) had to continue their treatment.","Patients with pathological long-bone fractures or clinically evident spinal cord compression and patients with known malignancies other than prostate cancer (not including basal cell carcinoma of the skin) were excluded. Other exclusion criteria were chemotherapy (including Estracyt®) within 6 weeks prior to screening; prior treatment with systemic radiotherapeutic bone agents within 3 months (6 months for 89Sr); receipt of any other investigational drug within 4 weeks of study entry; previous hemi-body external radiation therapy (for >25% of the bone marrow within 6 months); concomitant treatment with interferon-alfa, allopurinol, sorivudine and folinic acid; clinically significant bleeding disorders; disseminated intravascular coagulation; hypersensitivity to phosphonate compounds or 5-FU; known deficiency of dihydropyrimidine dehydrogenase; concurrent illnesses or treatments that might preclude study completion; active CNS or epidural brain metastasis; absolute neutrophil count (ANC) < 2×109/l; platelet count < 150×109/l; haemoglobin < 6.0 mmol/l; serum creatinine clearance < 50 ml/min (Cockroft and Gault); bilirubin > 1.5 upper limit of normal; aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 upper limit of normal; or total prostate-specific antigen (PSA) < 5 ng/ml",during the 8 weeks of follow-up,NA
19443394,NA,Combination,No,Patients with metastatic gastric cancer,"The main eligibility criteria included a histologically proven, unresectable, locally advanced or metastatic gastric adenocarcinoma; age, 20 to less than 75 years; Eastern Cooperative Oncology Group (ECOG) performance status, 2 or less; measurable disease; leukocyte count 3,500/mm3, or more; neutrophil count 1,500/mm3, or more; platelet count 100,000/mm3, or more; serum creatinine 1.5 mg/dl, or less; serum bilirubin 2.0 mg/dl, or less; aspartate aminotransferase (AST) 100 IU/l or less; alanine aminotransferase (ALT) 100 IU/l, or less; a life expectancy of 3 months or more; and no prior chemotherapy or radiotherapy except adjuvant chemotherapy more than 30 days prior to entry. This study was approved by the local Ethics Committee at each institution and patients were informed of the investigational nature of the study and provided their written informed consent before registration in the study.","Patients with the following criteria were not eligible: central nervous system metastasis with neurological symptoms, unresolved bowel obstruction or diarrhea, and known contraindication to fluorouracil (angina pectoris, myocardial infarction in the past 6 months).",during cycles 1 and 2.,NA
20530446,NA,Combination,No,non-small cell lung cancer,"All patients were required to meet the following criteria: confirmed histological or cytological diagnosis of cancer, at least one bi-dimensionally measurable or evaluable disease, World Health Organisation (WHO) performance status 0-2, a life expectancy greater than 3 months, previous treatment by standard or first-line chemotherapy, and at the time of entry into the study, to have been refractory to any prior cytotoxic treatment. Patients were eligible if they had two or three previous treatment courses, provided they had been off treatment for at least 3 weeks.",NA,NA,NA
20670085,NCT00350961,Combination,No,advanced cholangiocarcinomas,"Patients with solid malignancies with no other treatment option were eligible for the Phase I part of the trial. Only patients with histologically confi rmed CC (intra- and extra-hepatic bile duct carcinoma and carcinoma of the gall bladder) were eligible for the Phase II part of the trial. Other eligibility criteria included age 18 – 75 years; measurable or evaluable disease according to the RECIST criteria; WHO performance status 2; no severe, uncontrolled, concomitant illness; and no known defi ciency of dihydropyrimidine dehydrogenase. Laboratory requirements for eligibility were neutrophils count >= 1.5 X 10 9 cells/L, platelets >=100 X 10 9 cells/L, Cr-EDTA clearance > 50 mL/min, transaminases <= 3x the upper limit of normal range, billirubin <= 1.5x the normal range for the Phase I part and <= 3x the normal range for the Phase II part of the trial. Prior chemotherapy, radiotherapy or immunotherapy had to be completed at least four weeks prior to inclusion in the Phase I part, and prior chemotherapy or radiotherapy was not allowed in the Phase II part of the study. All patients gave signed informed consent.","Chemotherapy, radiotherapy or immunotherapy 4 weeks prior to inclusion. Experimental therapy < 8 weeks prior to inclusion. Uncontrolled, severe concurrent medical disease. Prior malignancy during the last 5 years, except for non-melanoma skin cancer and carcinoma in situ cervix uteri. Allergy to gemcitabine, oxaliplatin or capecitabine. Pregnancy or lactation",in cycle 1,NA
20712886,ISRCTN38983527,Combination,No,early breast cancer,"Eligible patients were aged 18-65 years with histologically confirmed stage II/IIIA breast cancer with four or more positive axillary lymph nodes. All patients had undergone surgery (complete surgical resection [R0] of breast tumour and axilla) before inclusion in the study. Other key inclusion criteria included Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, left ventricular ejection fraction within the normal institutional range, and adequate haematological, renal and hepatic function","Patients were excluded if they had inflammatory breast cancer or had received neoadjuvant endocrine therapy, chemotherapy or radiotherapy. Patients with known dihydropyrimidine dehydrogenase deficiency or creatinine clearance < 30 mL/min were excluded","As defined in the protocol, the safety analysis included all patients who received at least one cycle of chemotherapy.",NA
20837944,NCT 00618124,Combination,No,Advanced Solid Tumors,"Patients age  18 years with histologically proven advanced solid malignancies for which curative treatment was not available were enrolled. All patients were to have received two or fewer prior systemic chemotherapy regimens (excluding capecitabine), while any number of prior biologic (excluding antiangiogenic agents) or immunotherapeutic agents were permitted if completed  4 weeks before study entry. Given the possible effect of sunitinib and capecitabine on hematopoiesis, previous chemotherapy regimens were limited to two or fewer to exclude patients with impaired bone marrow reserve. Biologic/immunotherapeutic agents are less likely to cause long-term impairment of bone marrow reserve; their prior use was not excluded. Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, life expectancy of  12 weeks, and adequate organ function as defined by blood tests (criteria included AST and ALT <= 2.5  upper limit of normal [ULN], total serum bilirubin <= 1.5 ULN, absolute neutrophil count  1,500/mL without growth factor support, and serum creatinine <= 1.5  ULN). Patients with previously treated stable brain metastases were eligible.","Patients were excluded if they had unstable angina, congestive heart failure, cardiac dysrhythmias of grade >= 2, atrial fibrillation, or QTc interval prolongations; had a grade 3 hemorrhage within 4 weeks of starting study treatment; used coumarin-derivative anticoagulants; or had hypertension (blood pressure > 150/100 mmHg) uncontrolled with standard antihypertensive agents.",during cycle 1 of Schedule 4/2 (6 weeks) or Schedule 2/1 (3 weeks) or the first two cycles of the CDD schedule (6 weeks [each cycle being 3 weeks]).,NA
21174612,NA,Combination,No,patients with metastatic renal cell carcinoma (RCC),"Therapy-naive patients with mRCC with adequate organ function were eligible for the study. Histology was unrestricted and measurable disease was not mandatory. Key inclusion criteria consisted of age greater than 18 years, ECOG performance sta-tus of 0 or 1, 0-2 risk factors according to Memorial Sloan-Kettering Cancer Center (MSKCC) criteria and mandatory prior nephrectomy.","Key exclusion criteria consisted of CNS metastases, chronic infectious disease, prior or active auto-immune disease and cardiovascular events within the last 12 months.",during the first week,NA
21339064,NA,Combination,No,metastatic breast cancer,"Eligibility criteria included: age P 18 years, histologically proven breast cancer that was metastatic or locally recurrent and inoperable with curative intent, Eastern Cooperative Oncology Group performance status (PS) 0–2, and adequate haematologic, renal, and hepatic function. To enter into part II of the study, patients were required to have at least one measurable lesion according to RECIST.18 Prior exposure to taxane and anthracycline therapy was required for all patients, administered either in the neoadjuvant, adjuvant, or metastatic settings, either concurrently or sequentially, or in combination with other drugs",NA,during the first cycle,NA
21868563,NA,Combination,No,Resectable Advanced Gastric Cancer,Eligibility criteria included: histological confirmation of gastric adenocarcinoma; curable clinical Stage III or IV disease according to the criteria of the Japanese Research Society for Gastric Cancer (15); age >20 and <80 years; performance status (PS) 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Scale; no prior chemotherapy; adequate liver and renal function and the ability to take medications orally. All the eligible patients provided written informed consent to participate.,NA,during the first course,NA
21909644,NA,Single Drug,No,ovarian cancer resistant or refractory to platinum therapy,"he main inclusion criteria were as follows: histologically or cytologically documented advanced epithelial ovarian cancer (FIGO stages III and IV) measurable with CT and/or MRI, excluding mixed mullerian tumours (MMT) carcinosarcomas; prior chemotherapy regimen(s) for ovarian cancer at least one being a platinum-based therapy. The last dose of prior chemotherapy should have been given at least 6 weeks before the start of elacytarabine treatment; evidence of platinum-resistant or refractory disease (resistant defined as progression according to the Response Evaluation Criteria in Solid Tumors 1.0 (RECIST) or CA-125 within 6 months after completion of PBT (platinum-based therapy)); refractory defined as progression during first-line chemotherapy or progressing within 1 month); ECOG Performance Status 0–1; age 18 years or more.",NA,cycle 1,NA
22156765,NA,Combination,No,patients with platinum-resistant or heavily treated ovarian cancer,"Written informed consent was obtained from all patients or patients’ relatives to receiving protocol. Patients with recurrent or progressive ovarian cancer, who were histologically confirmed to have primary ovarian, fallopian tube, or primary peritoneal cancer, were eligible for this study. Patients were required to meet the following criteria: age of 18–70 years; Eastern Cooperative Oncology Group performance status 0–2; at least one tumor lesion measuring 1 cm or more in the greater dimension [computed tomography (CT)/MRI or chest X-ray] or pretreatment serum CA-125 > 2 x upper normal level (35 U/ml); at least 4 weeks’ treatment-free interval from the previous treatment; and free of clinical infection.","The exclusion criteria were as follows: patients previously treated with topoisomerase inhibitor, suitable candidates for curative treatment with surgery, those with a history of allergic reactions attributed to compounds of similar chemical structures or biologic composition to agents used in the study, pregnant or nursing women.",the first two cycles of treatment,Patients were defined as platinum-resistant if they had a platinum-free interval spanning less than 6 months. Patients were defined as heavily treated if they had two or more independent courses of chemotherapeutic treatment regardless of regimens.
22701615,NCT00436072,Combination,No,Patients with Previously Treated Metastastic Colorectal Cancer,"Patients were eligible if they had metastatic colorectal adenocarcinoma and had received 1–2 prior chemotherapy regimens for metastatic disease (prior adjuvant therapy completed within 12 months of enrollment was considered 1 prior regimen). At study onset (February 2007), data on treatment interaction between KRAS mutation status and cetuximab was not known and thus the first 7 patients were not selected by KRAS status; the protocol was amended on July 17, 2008 to restrict to only patients with KRAS wildtype tumors. Patients had to have measurable disease by Response Evaluation Criteria in Solid Tumors Group (RECIST),  an Eastern Cooperative Oncology Group (ECOG) performance status 0–2, and adequate hematological, hepatic and renal function. Patients could not have been previously treated with prior EGFR inhibitor (prior irinotecan was permitted).","Exclusion criteria included uncontrolled serious medical or psychiatric illness, other malignancy within past 3 years (except limited basal cell or squamous cell carcinoma of the skin or in situ cervix carcinoma), inadequately controlled hypertension (blood pressure .160/100 mmHg on antihypertensive medications), clinically significant cardiac event such as myocardial infarction or New York Heart Association classification of heart disease .2 within 3 months of study entry, history of ventricular arrhythmia that was either symptomatic or required treatment, potassium ,4.0 mEq/ L despite supplementation, serum calcium (ionized or adjusted for albumin) or magnesium out of normal range despite supplementation, previous history of QTc prolongation as a result from other medication that required discontinuation of that medication,congenital long QT syndrome, first degree relative with unexplained sudden death under 40 years of age, presence of left bundle branch block, QTc with Bazett’s correction that is unmeasurable or $480 msec on ECG, concomitant medication that may cause QTc prolongation induced Torsades de Pointes or induce CYP3A4 function, lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome, currently active diarrhea that may affect ability to absorb vandetanib or tolerate potential diarrhea from study drugs, pregnancy or active lactation, and incompletely healed surgical incisions.",the first 28 days,NA
22761464,NCT00150462,Single Drug,No,patients with relapsed or refractory multiple myeloma or lymphoma,"Patients 18 years or more of age with histologically confirmed multiple myeloma, non–Hodgkin lymphoma (NHL), Waldenstrom’s macroglobulinemia, or Hodgkin € lymphoma (HL), and treatment-refractory or relapsed disease after 2 or more prior therapies were eligible for the study. Other key eligibility criteria included Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2, expected survival more than 6 weeks, no radiation, chemotherapy, or immunotherapy less than 4 weeks before study screening, and no active infections. Baseline white blood cell counts must have been 2 x 109/L or more, absolute neutrophil count (ANC) of 1 x 109/L or more, hemoglobin level of 8 g/dL or more, and platelet count of 50 x 109/L or more. Patients with prior bortezomib treatment were eligible, as were patients with a history of peripheral neuropathy, provided the neuropathy was less than grade II at study entry. Other eligibility criteria included adequate cardiovascular, hepatic, and renal function (CrCL >= 30 mL/min).","Female subjects who are pregnant or lactating. Subjects who are transfusion dependent. Subjects with NHL or HL who have received steroid therapy in the previous seven days. Subjects with MM or Waldenström's Macroglobulinemia who have received steroid therapy in the previous three weeks, except for MM subjects in the Carfilzomib + DEX Expansion Cohort, where previous treatment with dexamethasone will be allowed. The dose and schedule of administration of dexamethasone will be adjusted to that used in the protocol. Radiation, chemotherapy, or immunotherapy in the previous four weeks, or subjects who, in the judgment of the Investigator, have not recovered from the effects of previous therapy. For the Dose Escalation period, subjects who have received prior radioimmunotherapy with anti-cluster of differentiation (CD)20 monoclonal antibodies such as Bexxar® or Zevalin®; subjects treated with these products will be allowed in the Dose Expansion period. Subjects who have received allogeneic stem cell transplant therapy. Subjects with NHL or HL who have received autologous stem cell transplant therapy and have relapsed within 100 days of therapy. Rituxan therapy within three months before Day 1 unless there is evidence of disease progression. Major surgery within three weeks before Day 1. Congestive heart failure (CHF) (New York Heart Association class III to IV). Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose. Subjects who are known or suspected of having human immunodeficiency virus (HIV) infection or who are HIV seropositive. Active hepatitis A, B, or C infection; or positive for Hepatitis C ribonucleic acid (RNA) or hepatitis B antigen. Non-hematologic malignancy within the past three years except a) adequately treated basal cell or squamous cell skin cancer, b) carcinoma in situ of the cervix, or c) prostate cancer with stable prostate specific antigen (PSA) levels for three years. Subjects with treatment-related myelodysplastic disorder. Subjects with known brain metastasis (active central nervous system [CNS] disease only). Serious psychiatric or medical conditions that could interfere with treatment. Participation in an investigational therapeutic study within one month prior to Day 1. Significant neurotoxicity (Grade 2 or higher with pain) at the time of study initiation. Concurrent therapy with approved or investigative anticancer therapeutics. Subjects with previous hypersensitivity to bortezomib injection. Subjects with contraindications to receiving allopurinol. Subjects in whom the required program of oral and intravenous fluid hydration is contraindicated, e.g., due to pre-existing pulmonary, cardiac, or renal impairment. Subjects with known or suspected amyloidosis. Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis",in the first 28 days,NA
22837181,NCT00672295,Combination,No,Patients with Advanced or Recurrent Ovarian Cancer,"Eligible patients must have had histologic or cytologic evidence of advanced (stage III or IV) or recurrent epithelial ovarian, peritoneal, or tubal cancer. Patients may have had prior cytotoxic chemotherapeutic regimens including prior treatment with carboplatin and paclitaxel. All patients must have had measurable disease; age  18 years; performance status of 0 to 2; absolute neutrophil count (ANC) >= 1500/mm3; platelets >= 100,000/mm3; creatinine <= 1.5 times the upper limit of normal (ULN); bilirubin <= 1.5 ULN; SGOT and alkaline phosphatase <= 2.5 ULN; and neuropathy < grade 1. Patients provided written informed consent","Patients with a prolonged QTc interval on pre-entry electrocardiogram (>450 ms), taking anticoagulants or medications that inhibit platelet function, serious concurrent medical illness, significant cardiac disease, pre-existing pleural effusions greater than one fourth of the lung field, or clinically significant ascites were excluded.",during the first cycle of treatment,NA
22977524,EudraCT 2005005548-21,Combination,No,metastatic colorectal cancer,"Patients with histologically confirmed mCRC, previously untreated for metastatic disease, ≥18 years of age, an ECOG performance status (PS) 0 to 1, with a life expectancy of ≥12 weeks and at least one measurable lesion according to RECIST criteria (19) were eligible. All patients had normal organ function defined as: neutrophils ≥1,500 and platelets ≥100,000; total bilirubin ≤1.5 x UNL, ASAT and ALAT ≤2.5 x UNL (≤5 in case of liver metastases), ALP ≤2.5 x UNL (<5 in case of liver metastases; ≤10 in case of bone metastases); creatinine ≤1.5 x UNL or creatinine clearance >50 ml/min; and urine dip-stick proteinuria <2+.","Main exclusion criteria included: radiotherapy administered within 4 weeks before the start of the study, the presence of brain metastases, prior adjuvant therapy containing oxaliplatin, history of inflammatory bowel disease and or acute occlusion/sub-occlusion, presence of non-healing ulcers or coagulopathies, uncontrolled hypertension or clinically active cardiovascular disease, current and ongoing treatment with anticoagulant drugs, receiving other investigational drugs within 30 days before the study entry, or subjected to major surgical procedures within 28 days before the study entry.",in the first cycle of treatment,NA
22993353,Eudract 2005-002658-23,Combination,No,Locally Advanced Esophageal Cancer,"Patients with histologically for confirmed non-resectable and locally advanced carcinoma of the esophagus or GEJ, Siewert type 1 and 2, were eligible. Operable patients who had declined surgery were also eligible treatment. Other inclusion criteria included measurable disease assessed by RECIST version 1.0, age between 18 and 75 years, life expectancy of more than three months, WHO performance status (PS) 0-2, and adequate bone marrow, hepatic, and renal functions.","Major exclusion criteria included peripheral neuropathy greater than grade 1, other malignancies in the last five years except non-melanoma skin cancer, known allergy to components of the treatment, known dihydropyrimidine dehydrogenase deficiency, previous treatment with oxaliplatin, cetuximab, or radiotherapy prohibiting the delivery of 59.4 Gy",during day 1-day 112,NA
23147218,NCT00735878,Combination,No,Previously Treated Non-Small Cell Lung Cancer Patients,"Adult patients (age 1 18) with histologically confirmed diagnosis of advanced stage NSCLC (IIIB with malignant pleural effusion or stage IV) with at least one, but not more than two prior chemotherapy regimens were eligible for enrollment if there were at least one measurable lesion for Response Evaluation Criteria in Solid Tumors (RECIST) tumor assessments and they had adequate hematologic, renal and hepatic function, with a Karnofsky Performance Score of 70–90. Prior treatment with a platinum agent was allowed.","Exclusion criteria included untreated central nervous system metastases, neuropathy, gastrointestinal abnormalities, concurrent colchicine therapy, and cytotoxic chemotherapy within 3 weeks of initiating the investigational treatment.",the first cycle,NA
23867058,NA,Combination,No,Patients with High-Risk Chronic Lymphocytic Leukemia,"Patients were enrolled on the National Cancer Institute (NCI)-sponsored and The Ohio State University institutional review board-approved study following written informed consent. Enrollment criteria included: age over 17 years, symptomatic CLL or SLL by NCI criteria  with poor-risk genetic or clinical risk factors [presence of del(17p13.1), del(11q22.3), unmutated IgVH (≥98% homology), age over 70 years and/or elevated B2M(≥4)], no prior therapy with purine analogs, Eastern Cooperative Oncology Group (ECOG)  performance status less than 3, no active infection, and adequate renal and hepatic function.",Patients with cytopenias were not excluded from participation,during the first two cycles of therapy,NA
23907406,NCT00529022,Combination,No,advanced malignancies:Ovarian; Melanoma; Colorectal; Breast; Endometrial; Nasopharyngeal; Cervical; Cholangiocarcinoma; Esophageal; Non-small cell lung carcinoma; Pancreatic; Prostate; Sebaceous Cell; Thymic; Squamous cell carcinoma larynx,"Patients were eligible if they had histologic proof of advanced cancer and progressed following standard therapy or for whom no standard effective therapy was available; measurable disease, as defined by Response Evaluation Criteria in Solid Tumors 1.0 (RECIST); Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less; adequate function of bone marrow (absolute neutrophil count ≥1,500/uL, platelet count ≥100,000/uL, hemoglobin ≥9.0 g/dL), liver (albumin ≥3.0 g/dL, bilirubin ≤2.0 mg/dL, alanine aminotransferase ≤3× upper limit of normal), and kidney (creatinine ≤2.0 mg/dL). Patients must have been off all previous chemotherapy or radiotherapy for 3 weeks (within 2 weeks if given weekly, 6 weeks for nitrosoureas or mitomycin C, and 30 days if previously treated with an investigational drug).","Any concurrent chemotherapy. Underlying medical condition that might be aggravated by treatment or that cannot be controlled, such as active uncontrolled serious infection and cardiac dysfunction. Medical and psychiatric problems of sufficient severity to limit full compliance with the study or expose patients to undue risk. Known hypersensitivity to azacitidine, valproic acid, carboplatin or their analogs. Failure to recover from any prior surgery within 4 weeks of study entry. Pregnant or lactating. Any treatment specific for tumor control within 3 weeks of dosing with study drugs (within 2 weeks if given weekly or within 6 weeks for nitrosoureas or mitomycin C) or failure to recover from the toxic effect of any of these therapies prior to study entry. Any investigational drug within 30 days of first day of dosing. Any signs of intestinal obstruction interfering with nutrition or oral intake. History of central nervous system (CNS) metastasis unless the patient has had surgery or radiation, and does not require oral or intravenous corticosteroids or anticonvulsants. Advanced malignant hepatic tumors that are defined as the total hepatic metastases more than 25% of hepatic parenchyma. History of high dose chemotherapy for ovarian cancer in phase 2 of the study, if Phase 2 of study needed. High dose chemotherapy is defined as the intensity and/or the density of a chemotherapeutic agent that are beyond standard of care for ovarian cancer treatment. History of prior malignancy except for adequately treated carcinoma in situ of the uterine cervix, basal cell or squamous cell skin cancer, or other cancer for which the patient has been disease free for at least two years in phase 2 study, if Phase 2 of study needed.",non-hematological toxicity occuring in cycle 1,NA
23954889,NCT01166113,Combination,No,relapsed/refractory myeloma patients,"Patients with MM who were 18 years of age or older, were relapsed or relapsed/refractory to lenalidomide, and who had received 1 to 3 prior lines of therapy were eligible. Relapse was defined as the reoccurrence of disease requiring the initiation of a salvage therapy, and refractory disease was defined as relapse while receiving salvage therapy or progression within 60 days of the most recent therapy. Patients were required to have measurable disease, a Karnofsky performance status 60% or higher, a platelet count 50 x 109/L or higher, a neutrophil count of 1.00 x 109/L or higher, a corrected serum calcium 3.5 mmol/L (14 mg/dL) or lower, serum hepatic aminotransferase levels 2.5-fold or less of the upper limit of normal, total bilirubin 1.5-fold or less of the upper limit of normal, and serum creatinine 2 mg/dL or less, and to agree to use contraception.",Patients with clinically relevant active comorbid medical or psychiatric conditions or history of malignancy within the last 5 years were excluded.,during the first cycle of therapy,NA
24535315,NA,Combination,No,patients with advanced solid tumors,"Eligible patients were ≥18 years old with histologically confirmed cancer not amenable to conventional treatment; with an Eastern Cooperative Oncology Group (ECOG) performance status score ≤2; with recovery from toxicities of previous treatments (except for alopecia or grade <2 peripheral neuropathy); and with adequate bone marrow, renal and hepatic function. The following laboratory values were required at 7 days before enrollment: platelet count≥100×109/l; hemoglobin≥9 g/dl, absolute neutrophil count (ANC)≥1.5×109/l; alkaline phosphatase (AP)≤2.5×the upper limit of normality (ULN) (≤5×ULN in case of bone metastases); aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤ 2.5×ULN (≤5×ULN in case of liver metastases); total bilirubin≤1.5×ULN, unless due to Gilbert’s syndrome; calculated creatinine clearance≥60 ml/min; albumin≥2.5 g/dl; partial thromboplastin time within normal limits, and left ventricular ejection fraction (LVEF)≥50 %. Prior platinum-based therapies were allowed. However, at least 3 weeks had to elapse since the last chemotherapy, biological or hormonal therapy (at least 6 weeks for nitrosoureas and mitomycin C, long-life monoclonal antibodies or bicalutamide). Radiotherapy was not allowed within 4 weeks before PM00104 administration (within 8 weeks for extensive radiotherapy).","Patients were excluded if they had any of the following: progressive or corticosteroid-requiring brain or leptomeningeal metastases; significant non-neoplastic liver or renal disease; increased cardiac risk (unstable angina, myocardial infarction within the last 6 months; significant valvular heart disease; congestive heart failure; symptomatic arrhythmia; abnormal electrocardiogram; uncontrolled arterial hypertension; previous mediastinal radiotherapy, or previous treatment with doxorubicin or epirubicin at cumulative doses >400 mg/m2 or >900 mg/m2, respectively); or other relevant clinical conditions (active infection or immunodeficiency). Patients were also excluded if they were pregnant or breast-feeding women, or if they were not using appropriate contraceptive measures. The eligibility criteria stated no limit to the number of prior chemotherapy lines.",during Cycle 1,NA
24682421,NCT00838240,Combination,No,patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS),"All previously untreated patients from three selected centers from EORTC-LG and GIMEMA (University Hospitals of Leiden and Nijmegen, The Netherlands, and “Sapienza” Rome, Italy) with AML according to the new criteria of the WHO  were eligible for entry onto the trial provided they met the following requirements: (1) age 18 to 60 years; (2) diagnosis of primary or secondary, intermediate or bad risk AML (including AML after MDS) or HR-MDS, i.e., bone marrow blasts 10–19 %; (3) no evidence of severe concurrent cardiac, pulmonary, neurological, and metabolic disorders or uncontrolled infections; and (4) adequate liver (AST/ALT/alkaline phosphatase level <2.5× upper normal limit) and renal (serum creatinine<upper normal limit) function tests.","Excluded were patients with good risk AML (i.e., AML-M3 with t(15;17), and AML with t(8;21) or inv(16), provided that they had less than 100×109/L WBCs). RT-PCR and/or ISH techniques were used in all three participating centers to allow exclusion of these good risk patients within 48 h of the morphological diagnosis. In addition, blast crisis of chronic myeloid leukemia and AML supervening after a chronic myeloproliferative disease or other progressive malignant diseases were excluded.",occurring during 8 weeks after the start of the remission induction,NA
24711126,NCT00849550,Combination,No,advanced solid tumors,"Eligible patients were required to have a histologically confirmed solid malignancy refractory to standard therapy or for which standard therapies did not exist or were no longer effective or for whom capecitabine, oxaliplatin, and/or bevacizumab would be considered a standard therapy or therapeutic option. Additional eligibility requirements included: age ≥18 years; Karnofsky performance status (KPS) ≥70 %; previous radiation therapy, hormonal therapy, biologic therapy or chemotherapy for cancer permitted ≥4 weeks prior to study drug; surgery permitted ≥4 weeks prior to study drug. Adequate organ and marrow function was defined as: absolute neutrophil count (ANC) ≥1,500/μl; platelets ≥100,000/μl; hemoglobin >9 g/dL; total bilirubin ≤1.5 times the upper limit of normal (ULN); aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤2.5 times ULN or ≤5 times ULN if known hepatic metastases; fasting serum cholesterol≤1.5 × ULN; fasting serum triglyceride≤2.5 × ULN; fasting blood sugar <160 mg/dL; creatinine clearance ≥50 mL/min/m2 ; left ventricular ejection fraction ≥50 % and proteinuria ≤1 g/24 h.","Additional exclusion criteria included: pregnancy, breastfeeding, central nervous system metastases, surgically resectable hepatic or pulmonary metastatic colorectal cancer, clinically significant cardiovascular disease with intervention within last 12 months, HIV or hepatitis B or C seropositivity, full dose anti-coagulation other than low molecular weight heparin, tumor invasion or encasement of a major artery, abdominal fistula or gastrointestinal perforation within 6 months of study drug, arterial thrombosis within past 12 months, bleeding diathesis or major bleed within 6 months of study drug, significant vascular or peripheral vascular disease, uncontrolled hypertension (blood pressure >140/90 mmHg) despite supportive care, history of hypertensive encephalopathy or crisis, chronic treatment with systemic steroids or another immunosuppressive agent, peripheral neuropathy of grade≥2, impairment of gastrointestinal function or gastrointestinal disease that may significantly alter drug absorption, evidence of interstitial lung disease, radiation to >25 % of bone marrow at any point. No history of hypersensitivity or intolerance with capecitabine, oxaliplatin, bevacizumab, or everolimus was permitted. Concurrent administration of medications with CYP3A4 or P-glycoprotein interactions (inhibitors, inducers or substrates) was not permitted. Serious medical conditions that might have significantly affected patient safety or toxicity assessment were prohibited.",in cycle 1,NA
24904120,NCT00963820,Single Drug,No,relapsed/refractory multiple myeloma,"Patients were eligible for the dose-escalation phase if they had relapsed orrefractory MM after at least 2 prior lines of therapy, which must have includedbortezomib, thalidomide or lenalidomide, and corticosteroids in any combination. Criteria for enrollment to the MTD expansion cohorts differed only interms of prior therapies and relapsed/refractory status (Figure 1). Patientscould be refractory to any regimen as most recent prior therapy, exceptwhere specified.Patients required measurable disease (serum M-protein $1 g/dL [$0.5 g/dLacceptable in dose-escalation phase] or urine M-protein $200 mg/24 hours),Eastern Cooperative Oncology Group performance status of 0-2, adequatehematologic (absolute neutrophil count $1,000/mm3, platelets $75 000/mm3),hepatic (total bilirubin #1.5 3 upper limit of normal, alanine/aspartateaminotransferase #2.5 3 upper limit of normal), and renal (creatinineclearance $20 mL per minute) function.","Patients with grade $2 PN(per other studies of PIs13,17,34,35) or grade .1 diarrhea, or who had majorsurgery, serious infection, radiotherapy, or systemic treatment with strongCYP1A2 inhibitors or strong inhibitors/inducers of CYP3A within 14 days, or any investigational products within 21 days of the first dose of ixazomib, wereexcluded. No prior exposure to investigational PIs was allowed, except forcarfilzomib. Concurrent corticosteroid therapy for coexisting conditions inexcess of 10 mg per day prednisone or equivalent was prohibited. Othercomorbidities or severe preexisting illness that in the treating physician’sopinion could interfere with oral absorption and/or tolerance of ixazomibexcluded patients from participation.",cycle 1 (18 days),NA
24991839,NA,Combination,No,"patients with advanced solid tumors and melanoma. Primary tumor site: NSCL 5 (14), head and neck 1 (3), Melanoma 27 (73), Colon 1 (3), Breast 1 (3), liposarcoma 1 (3, )esophageal (sCC) 1 (3), Brain metastasis 16 (43)","Patients ≥ 18 y, with histologically confirmed metastatic or unresectable solid tumor for which standard-of-care options were exhausted or there were no agreed upon standard-of-care options, measurable disease, an ECOG performance status of < 2, adequate hematological (White Blood Count ≥ 3,000/mm3, absolute neutrophil count ≥ 1,500 /mm3, platelets ≥ 100,000/mm3), renal (serum creatinine ≤ 2.0 × upper limit of normal [ULN]), hepatic  (bilirubin ≤ 1.5 × ULN transaminases ≤ 2.5 × ULN or ≤ 5.0 ULN in the presence of liver metastases), and coagulopathic (international normalized ratio ≤ 1.5 and partial thromboplastin time < ULN;) function were eligible. There was no limit on the number of prior therapies, except that prior TMZ was not allowed. Patients must have discontinued active immu-notherapy or chemotherapy ≥ 4 wk prior to entering the study and oral targeted  therapies ≥ 2 wk prior to starting the study treatment, and must have recovered from adverse events due to those agents. Patients with brain metastases were also eligible; however, the patients must have completed radiation therapy, if radiation was clinically indicated at the time of diagnosis, and discontinued steroids prior to enrollment.","Patients with active, clinically significant and/or uncontrolled medical conditions were excluded, including human immunodeficiency virus, psoriasis, and porphyria, the latter 2 due to the risk of disease exacerbation.",during the first 6 wk of this study,NA
24991840,NCT00486603,Combination,No,patients with newly diagnosed glioblastoma multiforme,"Patients ≥ 18 y of age with histologically confirmed supratentorial GB diagnosed < 3 mo prior to registration were eligible. Other criteria included no prior tumor-directed therapy other than surgery, KPS ≥ 60%, normal  hematological, adequate renal and liver function (transaminases ≤ 4 times the upper limits of the institutional normal), ability to provide written informed consent, and Mini Mental State Exam score of ≥ 15.","Exclusion  criteria  included  pregnancy  or  breast  feeding,  car-mustine (Gliadel®) wafers, or a history of macular degeneration, diabetic retinopathy, porphyria, or psoriasis. Patients requiring cytochrome P450 enzym-inducing  anticonvulsant drugs were not eligible.",the first 10 week cycle,NA
25062770,NCT00925132,Combination,No,recurrent or unresectable stage III or IV melanoma,"Eligible participants included male or female patients that were 18 years of age or older, with recurrent or unresectable stage III or IV melanoma of any site. Since we sought to evaluate enhancement of chemosensitivity by epigenetic drugs, this trial enrolled patients with inherently aggressive and resistant disease, including noncutaneous melanoma like ocular and mucosal; patients with brain metastases, after the brain disease was adequately addressed either by whole brain radiation, radiosurgery, or resection; and patients that had progressed during or after their most recent treatment. Eligibility criteria also included adequate liver, renal, cardiac and bone marrow function; normal electrolytes; normal thyroid function (or on adequate replacement doses); normal LVEF by MUGA or echocardiogram; measurable disease per RECIST 1.0 criteria; and Eastern Cooperative Oncology Group (ECOG) performance status of 0–2. Previously treated or treatment-naïve patients were both eligible, except those who had previously received valproic acid, HSP90 inhibitors, hypomethylating agents, or HDAC inhibitors. Female patients of childbearing potential were required to not be pregnant, breast-feeding, and to use double contraception during and 3 months after study completion.","Exclusion criteria included: uncontrolled hypertension; history of ventricular fibrillation, torsades de pointes, or sustained ventricular tachycardia; heart rate <50 beats/ min; congestive heart failure NYHA class III or IV; acute coronary syndrome within 6 months of study enrollment; ECG abnormalities of QTc prolongation (>450 ms), right bundle branch block or left anterior hemiblock; known HIV or hepatitis C positivity; unresolved diarrhea or significant gastrointestinal impairment potentially interfering with panobinostat or temozolomide absorption; and concomitant use of CYP3A4 inhibitors or drugs known to increase risk of torsades de pointes.",cycle 1,sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)
25117475,NCT00925743,Combination,No,advanced solid tumors,"Adult patients with a histologically or cytologically confirmed metastatic or unresectable advanced solid malignancy, for which standard curative measures did not exist, but for which cisplatin-based therapy was considered appropriate, were eligible for this study. Prior taxane therapy was permitted","Exclusion criteria included: Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2; prior cabazitaxel treatment within 2 years or cisplatin treatment within 6 months; history of hypersensitivity to taxanes, cisplatin, polysorbate-80 or derivatives; history of significant hearing impairment; any clinically significant toxic effect (excluding alopecia) of prior therapy that had not resolved to Grade ≤1; prior chemotherapy, biologic therapy, targeted noncytotoxic therapy, or radiotherapy within 3 weeks before registration; absolute neutrophil count <1,500/mm3, platelets < 75,000/mm3, hemoglobin <9.0 g/dL or prothrombin time/ international normalized ratio >1.5; estimated creatinine clearance <60 mL/min, or serum creatinine >1.0× upper limit of normal (ULN); total bilirubin > ULN, alkaline phosphatase >5.0× ULN, serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) >2.5× ULN if alkaline phosphatase is ≤2.5× ULN, or AST or ALT >1.5× ULN if alkaline phosphatase is >2.5× ULN and ≤5.0× ULN; or concurrent or planned treatment with a strong CYP3A4 inhibitor",during the first treatment cycle,NA
25225420,NCT00531284,Single Drug,No,patients with relapsed and/or refractory multiple myeloma,"Patients age >= 18 years with measurable relapsed and/or refractory MM and >= two prior lines of therapy were eligible. Other inclusion criteria included Eastern Cooperative Oncology Group performance status <= 2, adequate hepatic function, absolute neutrophil count >= 1,000/uL, platelet count >=30,000/uL, hemoglobin >= 7.0 g/dL, and creatinine clearance >= 20 mL/min.","Therapy with approved/investigational anticancer agents or radiotherapy within 3 weeks of study initiation was not permitted. Additionally, patients were excluded if they had clinically significant cardiovascular disease (congestive heart failure New York Heart Association class III to IV, symptomatic ischemia, uncontrolled conduction abnormalities, or myocardial infarction within 3 months), active infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks, or significant neuropathy (grade 3 to 4 or grade 2 with pain per National Cancer Institute Common Terminology Criteria for Adverse Events [AEs; version 3.0]14) at study initiation.",during the first cycle,NA
25290090,NCT00959946,Combination,No,"locally advanced/metastatic breast, pancreatic, or colorectal cancers; cholangiocarcinoma; or glioblastoma","Eligible patients were men and women aged >= 18 years with a confirmed pathologic diagnosis of locally advanced or metastatic breast cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, or glioblastoma that was not curable with approved regimens. Patients were also required to have at least one radiologically measurable lesion as defined by the Response Evaluation Criteria In Solid Tumors (RECIST), version 1.0, and an Eastern Cooperative Oncology Group Performance Status score of 0 to 2. Bone or skin could not be the only site of disease, and patients with clinically unstable primary or metastatic central nervous system tumours were ineligible. No prior treatment with Src inhibitors was permitted; however, prior treatment with capecitabine or 5-FU was allowed unless stopped for toxicity. No chemotherapy, investigational therapy, major surgery, or radiation therapy within 14 days of study treatment initiation was allowed.","Prior bosutinib, or any other prior Src inhibitor. Prior chemotherapy with capecitabine or 5-FU for the treatment of metastatic disease is allowed unless patient stopped therapy for toxicity.",during the first 21 days,NA
25483416,NA,Combination,No,advanced myeloid neoplasia,"Patients were eligible for the study if they were 18 years or older and had relapsed or refractory AML, secondary AML, or newly diagnosed AML if older than 60 years of age and not candidates for, or who had refused conventional chemotherapy. Patients with MDS, including chronic myelomonocytic leukemia (CMML), were eligible if they had intermediate or high risk IPSS scores or one or more of the following criteria: hemoglobin<10 g/dL or red cell transfusion dependence, platelets<50,000/uL, or absolute neutrophil count <1,000/uL. Patients with advanced phases of Philadelphia chromosome negative myeloproliferative diseases were also eligible.In the randomized phase of the study, eligibility was limited to those patients with AML in the categories defined above with dysplasia on bone marrow cytology, and the MDS/ CMML categories defined above. There was no limit to the number or types of prior regimens received. Prior therapy with azacitidine was permitted. Patients were required to have a Karnofsky performance status≥60 % and adequate hepatic and renal function.","The exception was hydroxyurea, which was permitted up to 24 h prior to starting therapy to control hyperleukocytosis. No cytotoxic therapy or radiation was permitted within 2 weeks prior to enrollment. Because a class effect of HDAC inhibitors is the induction of QT prolongation, patients with baseline prolongation of the QTc interval of >500 msec were excluded.",NA,NA
25577134,UMIN000005440,Combination,No,metastatic colorectal cancer,"enrolled patients were required to meet the following eligibility criteria: histologically confirmed colorectal cancer, clinically proven unresectable advanced/mCRC, 20–74 years of age, an Eastern Cooperative Oncology Group (ECOG) performance status 0–1, negative or heterozygous for UGT1A1*6 or UGT1A1*28, presence of a measurable lesion (Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1) , not pretreated for metastatic disease, leukocyte count ≥3,500 mm−3, neutrophil count ≥1,500 mm^-3, platelet count ≥100,000 mm^-3, serum creatinine ≤1.5 mg/dl, serum bilirubin ≤1.2 mg/ dl and serum aspartate aminotransferase and alanine aminotransferase ≤5 times the respective upper limits of normal, adequate organ functions, estimated life expectancy >3 months.",NA,the first two cycles of treatment,3-week cycle
25683772,NCT01057225,Combination,No,patients with newly diagnosed multiple myeloma (NDMM),"Adult transplant-eligible patients with previously untreatedsymptomatic MM were eligible for enrolment. Patients wererequired to have an Eastern Cooperative Oncology Group(ECOG) performance status (PS) of 0–2. An ECOG PS of 3 was allowed if considered secondary to pain. Minimum laboratory requirements included absolute neutrophil count ≥ 1x109/l, platelet count of ≥ 75x109/l,  haemoglobin ≥80 g/l and creatinine clearance ≥30 ml/min.","Patients with peripheral sensory neuropathy Grade≥2 or severe cardiaccomorbidity (including New York Heart Association Class IIIor IV heart failure, uncontrolled angina, or severe ventriculararrhythmia, cardiac amyloidosis with hypotension or recenthistory of myocardial infarction) were excluded",in the first or second cycle for patients enrolled to Dose Levels -1 and 0 and in the first cycle only for patients enrolled to Dose Levels 1 and 2,NA
25784682,NCT01279694,Combination,No,patients aged over 65 years with newly diagnosed multiple myeloma,"Patients aged >65 years with a diagnosis of symptomatic, measurable, newly diagnosedMM were eligible for enrollment. Adequate organ function (defined as absolute neutrophil count >1.0 x 109/L, platelet count >50 x 109/L, aspartate transaminase and alanine transaminase <3 times the upper limit of normal, total bilirubin less than twofold of the upper limit of normal, and creatinine clearance >30 mL/min), and Eastern Cooperative Oncology Group performance status of 0 to 2 at study entry were required","Exclusion criteria were the presence of another cancer, amyloidosis, severe ongoing infection, or any other serious medical condition or psychiatric disease.",in the first cycle of treatment,NA
25794535,NCT00969761,Combination,No,Advanced or metastatic solid tumors,"Patients aged ≥18 years with confirmed diagnosis of advanced, non-resectable or metastatic solid tumors, who had failed conventional treatment, or for whom no therapy of proven efficacy existed, or who were not amenable to established forms of treatment.indication for treatment with platinum therapy as judged by the investigator;Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤2.recovery from Common Terminology Criteria for Adverse Events (CTCAE) grade 2 to 4 therapy-related AEs from previous systemic anticancer therapies or radiotherapies (except alopecia of CTCAE grade 2).","Patients were excluded if they had clinical evidence of symecond malignancy currently requiring another anticancer therapy; absolute neutrophil count (ANC) <1,500/mm3; platelet count <100,000/mm3; serum creatinine >1.5 mg/dL (>132 μM/L, SI unit equivalent) or creatinine clearance <70 mL/min (as calculated according to Cockcroft–Gault formula for glomerular filtration rate [GFR] estimate); known history of relevant QT prolongation, (e.g., long QT syndrome); pre-existing clinically relevant hearing loss; treatment with other investigational drugs or participation in another clinical interventional trial within the 4 weeks prior to the start of therapy or concomitantly with this trial, or systemic anticancer therapy or radiotherapy within the 4 weeks prior to the start of therapy or concomitantly with this trial, with the exception of steroids and bisphosphonates.ptomatic progressive brain or leptomeningeal disease during the past 6 months;",first treatment cycle,NA
25806091,NCT01039155,Combination,No,advanced cancers that have relapsed or are refractory to any platinum therapy:CRC; Gynecological; Lung; Head and neck,"Eligible patients had a histologically confirmed advanced malignancy that was metastatic or unresectable and for which standard curative or palliative measures were not expected to increase survival by at least 3 months. In addition, the patients’ cancers were relapsed or refractory to any platinum compound. Platinum-refractory disease was defined as disease that did not respond to a platinum compound-containing regimen or that recurred after treatment with a platinum compound-containing regimen. At least one prior chemotherapy regimen was required, and patients had to be ≥6 weeks beyond treatment with a nitrosourea compound or mitomycin-C and ≥4 weeks beyond any other chemotherapy or radiotherapy and recovered to ≤ grade 1 toxicity after any treatment-limiting toxicity of prior therapy. Patients were required to have acceptable clinical functions, including an Eastern Cooperative Oncology Group performance status ≤2 (Karnofsky score >60%) and normal organ and marrow functions, as defined by leukocytes ≥4,000/μl, absolute neutrophil count ≥1,500/μl, platelets ≥100,000/μl, total bilirubin ≤1.0 mg/dl, aspartate transaminase/alanine transaminase ≤3× the institutional upper limit of normal, serum creatinine ≤2.0 mg/dl, and international normalized ratio (INR) ≤1.75 (per institutional guideline). All male and female subjects of childbearing potential were educated about practicing effective contraception during the study and were willing and able to continue contraception for 3 months after their last dose of study treatment.",NA,NA,NA
25924991,NCT01165216,Combination,No,Japanese patients with non-small-cell lung cancer,"Japanese patients of either sex were eligible to participate in this study if they had histologically- or cytologicallydocumented stage IIIB NSCLC and were not candidates for definitive thoracic radiotherapy, stage IV NSCLC, or recurrent disease following radiotherapy and/or surgery. Eligible patients were required to have adequate bone marrow function (hemoglobin≥9.0 g/dL, absolute neutrophil count [ANC]≥1500/mm3, and platelet count≥100,000/mm3), liver function (total bilirubin≤2.0 times the upper limit of normal [x ULN], aspartate aminotransferase [AST]≤2.5 × ULN, alanine aminotransferase [ALT]≤2.5 × ULN), and renal function (calculated creatinine clearance based on Cockcroft and Gault formula≥50 mL/min). Other inclusion criteria included age of at least 20 years; no prior chemotherapy, hormonal therapy, immunotherapy or targeted therapy for NSCLC; a life expectancy of at least 3 months; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and the ability and willingness to comply with visits and procedures as specified in the protocol (patients were admitted to the hospital from at least Day 1 to Day 22 of the third treatment cycle).","Patients were ineligible to participate in this study if they had symptomatic brain metastases or brain metastases requiring medication, a history of autoimmune disease or motor neuropathy of autoimmune origin, peripheral neuropathy of grade 2 or higher, diarrhea of grade 2 or higher, current or a history of gastrointestinal perforations, and chronic use of immunosuppressants and/or systemic corticosteroids.","during the first two cycles after ipilimumab treatment (i.e., from Day 1 at Cycle 3 to Day 21 at Cycle 4)",NA
26055299,NCT00986804,Single Drug,No,Acute Myelogenous Leukemia and Myelodysplastic Syndrome; after Allogeneic Stem Cell Transplantation,"Adults 18 years of age or older, with AML or MDS, who achieved a complete remission (CR) after alloHSCT were enrolled in the study between day +50 and +100 after alloHSCT. Exceptions were made for 3 patients who were enrolled shortly after day +100: for 2 patients, day +100 fell during the weekend/holiday, and for 1 patient, who was already consented, lived far away, and had transportation problems. CR was defined as < 5% blasts in the bone marrow with a count of at least 200 nucleated cells, no blasts with Auer rods, no extramedullary disease, absolute neutrophil count (ANC) >= 1500/uL, platelet count >= 50,000/uL, and no blasts in the peripheral blood. The higher threshold for ANC than that recommended by International Working Group (IWG), was chosen in anticipation of neutropenia secondary to decitabine and lower platelet threshold was allowed to facilitate enrollment. No platelet transfusion within 7 days of enrollment or growth factor support was allowed to meet those criteria. Other major eligibility criteria included Eastern Cooperative Oncology Group performance status <= 2, no grade 3 and 4 acute GVHD, no uncontrolled infection, creatinine < 1.5 * upper limit of normal (ULN), bilirubin <= 1.5 * ULN, and hepatic enzymes <= 2.5 * ULN. Both myeloablative and nonmyeloablative conditioning regimens were allowed, and both related and unrelated donors were permitted using either peripheral blood or bone marrow as a source of graft. Donors could be mismatched at a single antigen at HLA-A, -B, or -DR locus, plus a single antigen mismatch at HLA-C; 2-antigen mismatch at a single locus was not allowed. Acute GVHD prophylaxis was according to the treating physician.","Exceptions were made for 3 patients who were enrolled shortly after day +100: for 2 patients day +100 fell during the weekend/holiday and one patient, who was already consented, lived far away and had transportation problems.",cycle 1,NA
26384354,NCT01464034,Combination,No,relapsed or refractory myeloma,"Patients were required to have had a confirmed diagnosis of multiple myeloma that was relapsed after prior therapy or that was refractory to the most recently received therapy. All patients must have received prior lenalidomide therapy and must have been refractory to a regimen containing a full (25 mg) or maximum tolerated dose (MTD) of lenalidomide. Patients progressing on low-dose lenalidomide maintenance were not eligible to enroll. Key inclusion criteria included: age >=18 years; Eastern Cooperative Oncology Group performance status of 0 to 2; adequate hepatic function, with bilirubin <2 times the upper limit of normal, and aspartate aminotransferase and alanine aminotransferase <3 times the upper limit of normal; serum creatinine <=2 mg/dL or creatinine clearance >=50 mL per minute; and adequate bone marrow function as evidenced by an absolute neutrophil count >=1.0 x 109/L, a hemoglobin level >=8 g/dL, and a platelet count >=50 x 109/L. Patients must also have provided written informed consent. Patients had to commit to standard contraceptive guidelines during pomalidomide therapy.","Exclusion criteria included: congestive heart failure (CHF; New York Heart Association class III-IV), symptomatic ischemia, conduction system abnormalities uncontrolled by conventional intervention, myocardial infarction in the previous 6 months, or uncontrolled hypertension, and significant neuropathy (grade 3/4, or grade 2 with pain).",during cycle 1,NA
26588925,UMIN000006604,Combination,No,relapsed AL amyloidosis,"The present study included previously treated (less than three courses) patients with biopsy-confirmed AL aged between 20 and 65 years. Other criteria included an absolute neutrophil count ⩾ 2.0 × 109/L, a platelet count ≥75 × 109/L, hemoglobin ≥8 g/dL, an adequate liver function (aspartate aminotransferase and alanine aminotransferase ⩽2.5 × the upper limit of normal and total bilirubin ≤2 mg/dL), serum creatinine ≤2.5 mg/dL, no severe comorbidities including respiratory and neurologic disease, or severe diabetes mellitus, and not carriers of hepatitis, HTLV-1, or HIV virus.","Patients were excluded if they had received prior treatment with BOR, New York Heart Association (NYHA) classification III or IV, ejection fraction <40 %, continuous pleural effusion, supine systolic blood pressure less than 90 mmHg, N-terminal pro-brain natriuretic peptide (NT-proBNP) >332 pg/mL (BNP >50 pg/mL), saturation of oxygen level <95 %, symptomatic orthostatic hypotension, grade 3 or higher diarrhea not controllable with medication, grade 2 or higher neuropathy or painful peripheral neuropathy, pulmonary complications such as interstitial pneumonitis, pulmonary fibrosis, pulmonary amyloidosis, and computed tomography abnormality, KL-6 >500 U/mL, SP-D >110 ng/mL, SP-A >43.8 ng/mL, or were pregnant.",during cycle 1,NA
26616225,26616225,Combination,No,"recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer:","Eligible patients included those with a histologic diagnosis of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer documented by elevated CA 125, or clinically measurable disease, or non-measurable disease (defined as symptomatic ascites or pleural effusions, solid and/or cystic abnormalities on imaging that do not meet RECIST 1.1 criteria) . Patients must have had a platinum-free interval of at least 6 months following initial platinum-based chemotherapy. Patients that received maintenance therapy in front-line treatment with biologics, hormones, or taxanes were eligible for the study as long as at least 6 months had passed from the initial platinum-based chemotherapy. Additionally, a GOG performance status of 0 or 1 was required. Laboratory criteria for eligibility included an absolute neutrophil count (ANC) ≥ 1500/mcl, platelets ≥ 100,000/mcl, creatinine ≤ 1.5 times the institutional upper limit of normal (ULN), bilirubin b 1.2 times the ULN, alanine transaminase and aspartate transaminase ≤ 3.0 times the ULN, and alkaline phosphatase ≤ 2.5 times the ULN and left ventricular ejection fraction (LVEF) ≥ institutional lower limit of normal (LLN) as determined by gated cardiac radionucleotide scan (MUGA) or echocardiogram. Pretreatment neuropathy (sensory and motor) was also assessed and required to be ≤grade 1 using National Cancer Institute Common Toxicity Criteria version 4.0 (NCI CTCAE v4). Additional criteria for patients treating on the bevacizumab cohort included the requirement for a urine protein of < 2+ on urine analysis or b 1000 mg on 24-hour urine. In addition, patients receiving bevacizumab could not have a serious non-healing wound, ulcer or bone fracture, a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the last 6 months, or significant cardiovascular disease. Patients that had previously received bevacizumab in first-line therapy were not excluded from participation. This study was reviewed and approved by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute. All patients gave written informed consent before study entry in compliance with institutional, state, and federal regulations.","Patients were not eligible if they had received more than one prior chemotherapy regimen, a PARP inhibitor, or PLD.",in the first 4 cycles of treatment,NA
26632033,NA,Combination,No,Advanced Colorectal Cancer,"Patients with advanced, unresectable, histologically confirmed metastatic or locally advanced colorectal adenocarcinoma were eligible if they were untreated or had been treated with 1 prior non-irinotecancontaining regimen for advanced disease, were 18 years of age and had measurable disease, a Karnofsky performance score of 60, a life expectancy of 12 weeks, an absolute granulocyte count of more than 1500/μL, a platelet count of more than 100,000/μL, a serum bilirubin level of 2 mg/dL, normal renal function, transaminases less than 2.5 × the upper limit of normal (ULN), and ULN <5 × the ULN (in case of liver metastases).","Patients should not have had chemotherapy and/or radiotherapy in the 3 weeks prior to enrollment. Patients were excluded if they had brain metastases, peripheral neuropathy >grade 1, severe comorbid health conditions, or lacked the ability to comply",during the first cycle,NA
26847165,NCT02340936,Combination,No,patients with relapsed or refractory diffuse large B-cell lymphoma,"Eligible patients were aged 18–70 years, diagnosed with his-tologically confirmed DLBCL (Swerdlowet al, 2008) withrefractory or relapsed disease following first-line treatmentwith rituximab in combination with an anthracycline-con-taining regimen, and measurable disease, with baseline positron emission tomography (PET) scans demonstratingpositive lesions compatible with anatomical tumour sites identified by computerized tomography (CT). Patients were required to have an Eastern Cooperative Oncology Group performance status of 0–2, and be deemed eligible for ASCT.","Exclusion criteria were: pregnant or nursing women; human immunodeficiency virus infection; active hepatitis Bor C infection; presence of central nervous involvement;history of myocardial infarction within the past 6 months;any significant concurrent, uncontrolled medical condition;absolute neutrophil count<1.5 x 109/l; platelet count of <50 x 109/l; total bilirubin >2 x upper limit of normal(ULN), and/or alkaline phosphatase or aspartate amino-transferase>2.5 x ULN unless there was evidence of directliver involvement by lymphoma, and creatinine >1.5 x ULN",during the first cycle,NA
26924128,NCT01365559,Single Drug,No,"patients with advanced solid tumors. Patients with a broad range of tumor types were enrolled, including non–small cell lung cancer (eight patients, 18 %), colorectal cancer (seven patients, 16 %), Ovarian 3 (6.8), Kidney 2 (4.5), Breast 2 (4.5), Melanoma 2 (4.5), Unknown 2 (4.5), Other (includes one patient each with angiosarcoma of the scalp, cervical, chondrosarcoma, gastrointestinal stromal tumor, leiomyosarcoma, liposarcoma, liver, medulloblastoma, merkel cell carcinoma to right clavicle, neuroendocrine carcinoid tumor in ileum, neuroendocrine merkel cell, pelvic, prostate, pseudopapillary tumor of the pancreas, rectal squamous cell carcinoma, small cell of the uterus, small cell lung, and squamous cancer of the anus)","Adults with histologically confirmed advanced solid tumors that were refractory or recurrent after standard treatment were eligible. Patients were required to have adequate baseline hematologic, renal, and hepatic function, which was defined as absolute neutrophil count ≥1,500 cells/mm3, hemoglobin ≥8 g/dL, platelet count ≥100,000/mm3, creatinine clearance ≥30 mL/min, serum total bilirubin ≤1.5× the upper limit of normal (ULN), and alanine transaminase ≤3 × ULN or ≤5 × ULN in patients with liver involvement. An Eastern Cooperative Oncology Group performance status of ≤2, and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)  were also required for eligibility. Patients with previously treated brain metastases could be enrolled if there was no evidence of active central nervous system disease for at least 3 months prior to study drug administration","Although there was no limit to the number of prior therapies, patients who received prior treatment with a proteasome inhibitor were ineligible. Additional exclusion criteria included chemotherapy within 4 weeks or radiotherapy or immunotherapy within 3 weeks of receiving the first dose of oprozomib; New York Heart Association Class III or IV congestive heart failure, symptomatic ischemia, or conduction abnormalities warranting clinical intervention; myocardial infarction within 3 months prior to study entry; active infection requiring systemic treatment within 2 weeks; human immunodeficiency virus infection; active hepatitis A, B, or C infection; grade ≥3 peripheral neuropathy or grade 2 peripheral neuropathy with pain; pleural effusions or ascites requiring repeat thoracentesis or paracentesis; and pregnancy (lactating females were also excluded).",during the first 14 days (1 cycle) of treatment,NA
26966095,NCT01907165,Combination,No,newly diagnosed glioblastoma after chemoradiotherapy,"Eligible patients were required to be age >=18 years with newly diagnosed GBM and were eligible to receive adjuvant TMZ after completion of standard RT with concurrent TMZ. Additional eligibilities included: Zubrod performance score of 0–2, abstinence from alcohol consumption, adequate bone marrow, liver, and renal functions (absolute neutrophil count >=1500 per cubic millimeter; platelet >=100,000 per cubic millimeter; total bilirubin <= 2* upper limit of normal [ULN]; liver-function values <3* ULN; and creatinine clearance >60 mL/min).  All patients gave written informed consent.","Patients were excluded if they had idiopathic seizure disorder, psychosis, or schizophrenia. Medications with significant cytochromes P450 enzyme activity and interaction with DSF were not permitted.",within the first 28 days of starting DSF,NA
27009059,NCT00461045,Single Drug,No,relapsed or relapsed and refractorymultiple myeloma,"This study enrolled relapsed or RRMM patients age $18 years and withKarnofsky performance status $70%. Patients could have undergone priorautologous bone marrow transplantation.Dose-escalation cohorts enrolled patients with relapsed or RRMM diseasefor which no other approved treatment was available and clinically indicated.Relapsed or RRMM patients enrolled in RP2D cohorts were required to havereceived at least 2 prior treatment regimens, including at least 2 cycles oflenalidomide and at least 2 cycles of BZ (either separate or within the sameregimen), and also received a cytotoxic chemotherapy agent (eg, alkylatingagent). RelapsedMM patients were those who had progressive disease (PD) afterhaving achieved at least stable disease for at least 1 cycle during 1 prior regimen.Refractory MM patients were those with documented PD within 60 days ofcompleting the most recent regimenMeasurable disease was not required for dose-escalation patients (schedule Aor B). Measurable relapsed or relapsed and refractory disease34 was required forpatients enrolled at theRP2D for both schedules.Measurable disease was definedas serum M-protein $0.5 g/dL or urine M-protein $200 mg/24 hours orinvolved serum free light chain level $10 mg/dL, provided the serum free lightchain ratio was abnormal).Eligibility criteria required washout times prior to start of study treatment ofchemotherapy, biological immunotherapy, radiation therapy, transplantation,and investigational agents to account for possible ongoing activity or toxicity ofthese agents","Early eligibility criteria excluded concomitant oral prednisone .10 mg/dayor intrathecal therapy, ongoing coagulopathies and/or anticoagulants, evidence of mucosal or internal bleeding and/or platelet-refractory documented adrenocortical insufficiency or preexisting pancreatitis, untreated urinary tractinfection, abnormal urine sediment, and preexisting kidney disease (parameterswere imposed to exclude patients with substantial renal impairment includingcreatinine and creatinine clearance limits and protein level evaluations to detecturinary casts suggestive of glomerular nephritis). As more safety informationwas gained, protocol amendments allowed anticoagulants for treatment of priordeep vein thrombosis, mineralocorticocoid replacement therapy, bisphosphonates, and low-dose corticosteroids.Eligibility criteria also excluded significant cardiac disease, prior hypersensitivity reaction to therapy containing propylene glycol or ethanol; bacterial orfungal infection requiring systemic therapy; infection requiring parenteral antibiotics; known positivity for HIV, hepatitis A, B, or C; and any medical conditionsthat wouldimpose excessive risktothe patient. Pregnant or breast-feedingwomen were excluded, as were patients unwilling or unable to comply withprotocol procedures.",DLT was defined as the occurrence of the following drug-related toxicitiesobserved during cycle 1,"Part 1 comprised 5 stages: stage 1 was a 3+3 doseescalation to determine the schedule A (once-weekly) MTD or RP2D, stage 2comprised expansion of the RP2D up to 12 patients, stage 3 introduced a lyophileformulation; stage 4 was schedule B (twice-weekly) dose escalation, and stage 5was expansion of up to 24 patients treated at the schedule B RP2D."
27207788,NCT01677858,Combination,No,relapsed or refractory multiple myeloma,"Adult patients with relapsed, or relapsed and refractory MM, who had received1 to 3 prior regimens of therapy were eligible to enroll; additional eligibilitycriteria included Eastern Cooperative Oncology Group performance status 0 to 1,adequate hepatic function, left ventricular ejection fraction of $40%, absoluteneutrophil count of $1000/mm3, platelet count of $50 000/mm3, and creatinineclearance of $30 mL/min","Exclusion criteria included cytotoxic chemotherapywithin 28 days prior to enrollment, congestive heart failure (CHF) (in terms ofeligibility criteria, defined as active CHF by New York Heart Association criteria[classes III-IV], symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction within 6 monthsprior to enrollment), grade 3 to 4 neuropathy within 14 days prior to enrollment(or grade 2 neuropathy with pain), and prior carfilzomib therapy.",a treatment-related DLT during thefirst 28-day cycle of treatment in the phase 1 portion of the study,NA
27246305,NCT02217956,Combination,No,initially unresectable ovarian cancer,"Patients aged between 18 and 65 with a confirmed histologic diagnosis of epithelial ovarian cancer were screened for the study if their disease was deemed unresectable at diagnosis (stage-IIIC according to the International Federation of Gynecology and Obstetrics) . When the senior surgeon considered that a complete cytoreduction of the disease was impossible, patients received 6 cycles of neoadjuvant chemotherapy. They were included in the study if macroscopically CCRS was considered feasible (laparoscopy's and/or ct scan's results), providing all eligibility criteria were fulfilled. The main criteria were: 1) adequate renal function (creatinine b140 μmol/L, clearance N60 mL/min), bone marrow function (neutrophil count N1500/μL, platelets N150,000/μL), hepatic function (bilirubin ≤1.5×ULN, AST/ALT ≤1.5×ULN) and nutritional status (albumin N25 g/L); 2) No grade N 1 neuropathy (CTCAE-v4.0 classification); 3) No contraindication to bevacizumab administration","Incomplete cell kill surgery. Non-epithelial ovarian cancer. Borderline tumors. Non in complete remission previous cancer for more than 5 five years before inclusion. Uncontrolled high blood pressure (blood pressure > 150/100 mm Hg despite antihypertensive treatment). Previous abdominal or pelvic radiotherapy. Previous pathology of the central nervous system, except for well controlled pathology like epilepsy. Previous stroke, transient ischemic attacks or subarachnoid hemorrhage. Previous pulmonary embolism. Pregnant or breastfeeding women (Women in age must have a blood negative pregnancy test at least 15 days before going under surgery). Participation to an other clinical trial within 30 days before inclusion in the study. Known hypersensitivity to platin or bevacizumab. Not healed wound, ulcer or bone fracture. Previous haemorrhagic or thrombotic malfunction < 6 months. Significant CArdiovascular disorder including: Heart attack or unstable angina within the 6 months before inclusion; Grade > 1 congestive heart failure according to the NYHA classification. Uncontrolled cardiac arrhythmia despite of treatment (patients with atrial fibrillation for which the pace is under control can be include). Long term or recent (within 10 days before inclusion) medication using Aspirin at dosage > 325 mg/day. Long term or recent (within 10 days before inclusion) medication using anticoagulant per os or parenteral or thrombolytic given at full dosage for therapeutic purpose.. Grade > 1 previous sensory and motor neuropathies according to CTC AE V4.0. Previous abdominal fistula, GI perforation or intra-abdominal abscess within 6 months before first administration of bevacizumab. Proof of any other disease, metabolic malfunction, physical or laboratory exam showing any possibility of disease or condition contraindicating administration of the drug under trial or exsposing the patient to several complications related to the treatment. Persons deprived of liberty. Impossibility to comply with the medical following of the treatment for geographical, social or mental reason",within 30 days following CCRS + HIPEC,NA
27289242,NA,Combination,No,patients with locoregionally advanced squamous cell carcinoma of the head and neck,"Previously untreated patients with histologically- or cytologically-confirmed locally advanced SCCHN who were candidates for conventional chemoradiotherapy were eligible to enroll. Other eligibility criteria included age 18 years or older, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and adequate renal (estimated creatinine clearance of ≥50 mL/min), hematopoietic (absolute neutrophil count ≥1.5 x 10 /L, total leukocyte count ≥3.0 x 10 /L, hemoglobin ≥80 g/L, and platelet count ≥100 x 10 /L), liver (total bilirubin ≤ the upper normal limit, aspartate aminotransferase/AST and alanine aminotransferase/ALT levels ≤2.5 x the upper normal limit), and cardiac functions (no clinically significant changes on 12- lead electrocardiogram, QTc interval ≤ 480 msec, no history of Torsades de Pointes or other symptomatic QTc abnormality)","Patients with primary tumors of the nasopharynx, skin, or unknown primary site were excluded. Patients who had received any prior chemotherapy or radiotherapy for the current malignancy, or previous treatment with EGFR-targeting agents, were excluded from this trial",from the commencement of treatment to 8 weeks after completion of radiation,NA
27336466,NA,Combination,Yes,Unresectable Pancreatic Cancer,"ECOG performance status of 0 or 1; > 18 years of age (no upper age limit); Cytologic or histologic proof of adenocarcinoma of the pancreas; No radiographic or clinical evidence of metastatic disease at the time of study entry; Locally advanced, unresectable disease (Tumor extension to the superior mesenteric artery (SMA), celiac; axis, occlusion of the superior mesenteric vein (SMV) or portal venous confluence); Found to be unresectable at the time of laparotomy; Unresectability due to underlying medical problems; Patients may have received prior chemotherapy but not prior radiation therapy to the upper abdomen; Absolute neutrophil count (ANC) >1,500 cells/ul; Platelet count >100,000 cells/ul; Total bilirubin < 5mg/dL with adequate biliary decompression; Alanine aminotransferase (ALT) < 5 times the upper limit of normal. BUN < 30 mg/dl; Creatinine < 1.5 mg/dl and creatinine clearance > 30ml/min","Prior abdominal radiotherapy. Imaging (CT or MRI) or endoscopic evidence of direct duodenal invasion by tumor. Prior therapy with bevacizumab, cetuximab, or gefitinib. Prior therapy with erlotinib is permitted unless the patient was taken off erlotinib due to treatment failure. Prior severe infusion reaction (bronchospasm, stridor, urticaria and/or hypotension) to a monoclonal antibody. Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5–fluorouracil. Proteinuria at baseline or clinically significant impairment of renal function as demonstrated by urine dipstick for proteinuria > 2+. Prior history of cancer within the last five years except for basal cell carcinoma of the skin or carcinoma in situ of the cervix. Pregnant or lactating women. Serious, uncontrolled, concurrent infection(s) requiring IV antibiotics; Clinically significant cardiovascular disease, arrthymia or peripheral vascular disease within 6 months of study entry; Psychiatric disorders rendering patients incapable of complying with the requirements of the protocol. History or evidence upon physical examination of CNS disease; Prior history of pulmonary embolism or deep venous thrombosis. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study entry; Fine needle aspirations or core biopsies within 7 days prior to study entry; Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome or inability to swallow; Known, existing uncontrolled coagulopathy (INR > 1.5); Recent use of anti-coagulation other than low dose (1mg) coumadin, IV and LMW heparin; Current serious, nonhealing wound, ulcer, or bone fracture. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study entry; The presence of an organ allograft.",Weeks 1 through 6,NA
27390847,NCT00845884,Combination,No,Advanced Esophago-Gastric Cancer,Patients above 18 years of age at the time of enrollment. Histologically confirmed previously untreated metastatic or unresectable adenocarcinoma of the stomach. Patients must have at least one measurable lesion (measuring >10mm in standard CT or >5mm in spiral CT). Adequate organ function. Life expectancy of at least three months. Patients must have an ECOG Performance Status of 0 or 1. Signed written informed consent to participate in the study.,"Participation in an investigational trial within 30 days of the screening visit. Known allergy or any other adverse reaction to any of the study drugs or to any related compound. Prior anti-angiogenic treatment, chemotherapy or radiotherapy for advanced disease. Patients will be eligible if they had received adjuvant chemotherapy or radiotherapy more than 12 months prior to enrollment. Prior treatment with drugs included in the investigational regimen. Prior use of 5-fluorouracil in the adjuvant setting is allowed. Significant bleeding by the primary tumor (in unoperated patients). Clinically significant (i.e. active) cardiovascular disease. This includes, but is not limited to, the following examples: Cerebrovascular accidents (up to 6 months prior to randomization) Myocardial infarction (up to 1 year prior to randomization). Uncontrolled hypertension (above 150/100 mmHg) while receiving chronic medication Unstable angina New York Heart Association (NYHA) Grade II or greater congestive heart failure. Serious cardiac arrhythmia requiring medication. Clinically significant ECG findings. Patients who suffer from serious cardiac arrhythmia requiring medication can enter the study only if they are considered to be in a stable condition regarding both the arrhythmia and their medication. Patients with pacemakers are allowed to enter the study only if they are considered as being in a stable condition. In case of doubt, the investigator should obtain a consultation with a local cardiologist. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, not fully healed wounds, or anticipation of the need for major surgical procedure during the course of the study. Severe co-morbid conditions including uncontrolled diabetes or hypertension, cerebral vascular disease or uncontrolled infection. Fertile subjects who are not willing to use an acceptable method of contraception during the treatment period and for 28 days following completion of treatment For women of child-bearing potential: a positive pregnancy test at screening or breast-feeding. History of prior malignancy (other than non-melanoma skin cancer, in-situ cervical cancer, or superficial transitional cell bladder cancer) in the last 5 years prior to enrollment. Clinically significant hearing loss. Patients with a history of seizure disorder who are receiving phenytoin, phenobarbital, or other antiepileptic medication. Known peripheral neuropathy of CTCAE v 3.0 Grade 1 or more. Organ allografts requiring immunosuppressive therapy. Serious, non-healing wound, ulcer, or bone fracture.",during the first two cycles of treatment,NA
27502784,NA,Combination,No,recurrent  glioblastoma,"Eligible patients were ≥18 years of age with histologically proven WHO grade IV glioblastoma and evidence of progression or recurrence on MRI within 2 weeks prior to enrollment. Further inclusion criteria included: initial surgical resection (≥6 weeks prior), radiation therapy (≥3 months), and/or chemotherapy with regimens including nitrosurea agents (≥6 weeks) or not including nitrosurea agents (≥4 weeks), no history of bortezomib treatment, and no more than three prior biologic agents.","Exclusion criteria included the use of enzyme-inducing antiepileptic drugs (EIAEDs), standard systemic and hematologic parameters, a Karnofsky Performance Status (KPS) of at least 60, and no more than 3 previous episodes of GBM progression",NA,NA
27503200,NCT01139970,Combination,No,Acute Myeloid Leukemia,"Patients 18 years or older with relapsed or refractory AML; CMML-2 (>10% or >5%–19% blasts and promonocytes in the bone marrow or peripheral blood, respectively); newly diagnosed AML arising in the setting of prior MDS, MPN, or chemotherapy; or patients aged >= 60 years having untreated AML with adverse cytogenetic findings and/or not considered candidates for intensive induction chemotherapy were eligible for the study. Patients could have received any number of prior therapies, including allogeneic stem cell transplant (SCT, >=60 days previously, no GVHD, and off immune suppression for at least 2 weeks) or autologous SCT (>=4 weeks previously), provided that performance status (Eastern Cooperative Oncology Group 0–2) and standard organ function criteria (bilirubin < 2 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <5* upper limit of normal, serum creatinine < 2 mg/dL) were met.  A leukemic blast count <30 * 10^9/L was required at initiation of study treatment. Hydroxyurea (HU), corticosteroids, or leukapheresis had to be discontinued at least 24 hours prior to initiation of treatment; however, HU was allowed on treatment days 1 through 12 of cycle 1 if it became necessary to control a rising blast count (>=30 * 10^9/L). The study (NCT01139970) was conducted in accordance with the Declaration of Helsinki after approval by the ethics committee of each participating center. Informed consent was obtained from each participant.","Patients were excluded if they had active central nervous system leukemia, uncontrolled infection, or other life-threatening illnesses.",cycle 1,NA
27542211,NCT01193517,Combination,No,histologically confirmed colorectal adenocarcinoma,"Eligibility criteria required Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2, adequate organ function, measurable disease, peripheral neuropathy ≤ 2 grade 2, and refractory to fluoropyrimidine and oxaliplatin therapy (defined as either clinical or radiographic progression on or within 3 months of treatment).",NA,the first treatment cycle,NA
27544076,NCT01451437,Single Drug,No,patients with refractory/recurrent acute myelogenous leukemia,"Eligible patients were aged ≥18 years with a diagnosis of refractory or recurrent AML. They had to have an Eastern Cooperative Oncology Group (ECOG) performance status ≤2 with adequate organ function (creatinine <1.5 upper limit of normal [ULN] or calculated creatinine clearance ≥60 mL/min, total bilirubin <1.5 ULN aspartate aminotransferase/serum glutamic-oxalecetic transaminases(SGOT) and alanine aminotransferase/serum glutamicpyruvic transaminases (SGPT) <3x ULN) and were ineligible for standard therapy. Subjects enrolled in the 3 + 3 escalation portion of Part 1 were required to have a confirmed WT p53 status (as per Roche Molecular Systems AmpliChip p53 Assay).","Significant exclusion criteria included: active malignancy other than AML; history of leptomeningeal leukemia requiring intrathecal therapy; myelodysplasic syndrome (Part 1, only); isolated extramedullary leukemia without meeting bone marrow criteria for AML; diagnosis of AML blast crisis of chronic myelogenous leukemia; bone marrow transplant with active graft-versus-host disease or who received immunosuppressive therapy",Up to 28 days (Cycle 1) for non-hematologic toxicities and 42 days (Cycle 1) for hematologic toxicities,NA
27565810,JapicCTI-132162,Combination,No,Japanese patients with non-squamous non-small cell lung cancer,"Eligible patients for stage 1 met the following criteria: patients aged ≥20 years with histologically or cytologically confirmed solid tumors; had advanced/relapsing tumors refractory to standard treatment or for which no standard treatment had been established; had Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–1; had adequate hematological, hepatic, and renal function. Eligible patients for stage 2 met the following criteria: patients aged ≥20 years with histologically or cytologically confirmed non-Sq NSCLC of clinical stage IIIB/IV, or postoperative relapse; had never undertaken chemotherapy for advanced/relapsing NSCLC; had ECOG PS 0–1; had adequate hematological, hepatic, and renal function",The major exclusion criteria common for both stage 1 and 2 were as follows: central nervous system metastases that were either symptomatic or required treatment; complication of type 1 or type 2 diabetes mellitus that requires drug treatment; a history of treatment using drugs with PI3K inhibitory action; a complication or a history of interstitial lung disease diagnosed by imaging. The following additional exclusion criteria were defined for stage 2: a complication or a history of hemoptysis/bloody sputum; bleeding tendency; cavitation of pulmonary lesions diagnosed by imaging; grade ≥ 2 peripheral neuropathy.,cycle 0 and cycle 1 of stage 1(31-35 days); cycle 1 of stage 2 (22 days),NA
27716819,NCT01488344,Combination,No,Elderly Patients with Acute Myeloid Leukemia,"Elderly patients (>= 60 years) with de novo, secondary, or previously treated AML (except acute promyelocytic leukemia) according to the French-American-British (FAB) or World Health Organization (WHO) classification not considered fit to receive intensive induction or salvage chemotherapy were eligible for the study. Cytogenetics and NPM1, FLT3 and CEBPA mutational status and assignment to risk groups according to the European LeukemiaNet (ELN) classification were done according to standard procedures. In patients with 20–30% bone marrow blasts, the indication for 5-azacitidine had to be considered prior to inclusion into the trial. By amendment of March 2013, patients at risk for hollow organ perforation (i.e. patients with ulcerative colitis, Crohn`s disease, or diverticulitis) could only be enrolled if the potential benefit of the study participation outweighed the risk for perforation in the opinion of the investigator.","Exclusion criteria included: known central nervoussystem manifestation of AML; inadequate liver function (ALT and AST >= 2.5 x ULN) unless caused by leukemic infiltration; known chronically active hepatitis C infection or acute hepatitis; chronically impaired renal function (creatinine clearance < 30 ml/min); uncontrolled hypertension with a resting systolic blood pressure > 160 mmHg or diastolic blood pressure > 95 mmHg despite adequate treatment; severe trauma or surgerywithin 4 weeks of study entry;severe, non-healing wounds, ulcers or fractures; uncontrolled active infection; concurrent malignancies other than AML or other severe diseaseswhich in the opinion of the investigator were likely to influence the endpoint assessment; hypersensitivity to cytarabine (not including drug fever or exanthema); parallel participation in another clinical trial for the same indication; any severe concomitant condition, which made it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol.",in the first treatment cycle,NA
27810904,NCT01836029,Combination,No,in Patients with Recurrent orMetastatic SCCHN,"Patients eligible for this study were adults with recurrentSCCHN not amenable to curative surgery or radiation, or patientswith distant metastatic disease. Eligibility criteria also includedpatients previously treated with systemic therapy, but for whomplatinum-based therapy was no longer appropriate due to thepresence of platinum-intolerant/refractory disease, and/orpatients who had completed definitive chemoradiation less than3 months prior to study enrolment. Prior therapy with agents thattarget or block EGFR without a history of severe toxicity wasallowed. Additional eligibility criteria included life expectancy of12 weeks, Eastern Cooperative Oncology Group performancestatus (25) of 0 to 2, and adequate bone marrow, renal, hepatic,and cardiac function.","Patients were ineligible if they had beentreated with investigational therapy or had recent major surgery inthe previous 4 weeks or had received chemotherapy, palliativeradiotherapy, or oral or parenteral corticosteroids in the previous2 weeks. Patients who required systemic immunosuppressivetherapy and those with active central nervous system involvement, brain or meningeal metastases (unless stable for 28 days)were also ineligible. Additional exclusion criteria included activeautoimmune disease or infection, clinically significant cardiacdisease within 6 months, and current retinal vascular disorderand/or uveitis. Patients were also excluded if they had clinicallydetectable and actively progressing second primary malignancies",cycle 1 of the study,NA
27853996,NCT01451632,Combination,No,"Adult patients with metastatic solid tumors thought to beEGFR dependent were eligible for the trial. A tumor wasconsidered EGFR dependent if it had a somatic EGFR alteration or if there was literature supporting the EGFR dependence of that tumor type. Refractory, non-small cell lung cancer patients were required to have received prior treatmentwith EGFR tyrosine kinase inhibitors (gefitinib and erlotinib).In addition, these lung cancer patients were required to harboreither a somatic EGFR mutation associated with sensitivity toEGFR inhibitors or have demonstrated clinical benefit (either a documented partial responses or ≥6 months of stable disease) from an EGFR inhibitor [22]. Metastatic head and neckcancer patients were eligible if they had progressed on at leastone line of platinum-based therapy. Metastatic triple negativebreast cancer patients were eligible if they had failed at leastone standard chemotherapy regimen. In Part I of the trial,metastatic colon cancer patients were eligible if they had nostandard treatment options remaining.","The inclusion criteria mandated that patients have measurable disease per RECIST criteria (version 1.1) and an EasternCooperative Oncology Group (ECOG) performance status ≤1.Participants were required to have adequate bone marrow function defined as absolute neutrophil count ≥1500/μL, hemoglobin >9 g/dL, and platelets ≥100,000/μL. In Part I of the trial,patients were required to have aminotransferase (AST), alanineaminotransferase (ALT), and alkaline phosphatase (AlkPhos) ≤ 2.5 x upper limit of normal (ULN) or ≤5 x ULN ifliver metastases are present. In Part II of the trial, patients wererequired to have an AST, ALT, and Alk Phos ≤1.5 x upper limitof normal (ULN) or ≤2.5 x ULN if liver metastases are present.For both Part I and Part II of the trial, patients needed to have abilirubin ≤1.5 x ULN and creatinine ≤1.5 x ULN.Patients must have recovered from the effects of any priorsurgery, radiotherapy or other anti-neoplastic therapy. Patientswith ≤ Grade 2 peripheral neuropathy were eligible.","Patientswere excluded if they had a primary CNS tumor or any untreated brain metastasis. Patients with any active infection,recent cerebral vascular accident, New York HeartAssociation Class III or IV congestive heart failure, left ventricular ejection fraction <50 %, or another active malignancyin the last 3 years were ineligible.Radiation therapy or other standard systemic therapy within14 days prior to the initiation of study treatment was notallowed. Patients could not have received experimental therapywithin 4 weeks of study entry. Patients with a history of allergicreactions to cetuximab or irinotecan (Part II only) were alsoexcluded. For Part II of the trial, patients with Gilbert’sSyndrome, Crigler-Najar Syndrome or those possessing theUGT1A1*28 homozygous allele were excluded. Patients inthe expansion cohorts needed to be willing to undergo mandatory pre-treatment and post-treatment tumor biopsies.",during cycle 1,NA
28363909,NCT01719380,Combination,No,Patients with refractory BRAFV600-mutant metastatic CRC (mCRC),"Adult patients with mCRC were enrolled on the basis of documented wild-type KRAS and a BRAFV600 mutation. Eligibility criteria included ECOG PS of ≤2, either progression after ≥1 prior standardof-care regimen or intolerance to irinotecan-based regimens, and life expectancy of ≥3 months. All patients gave written informed consent per Declaration of Helsinki recommendations, and the protocol was reviewed and approved by a properly constituted Institutional Review Board prior to study start",Symptomatic or untreated leptomeningeal disease. Symptomatic brain metastasis. Patients with clinically manifested diabetes. Acute or chronic pancreatitis. Clinically significant cardiac disease,within the first 28 days of treatment,NA
28546581,NCT00946647,Combination,No,"International Prognostic Scoring System (IPSS) intermediate-2- or high-risk MDS, CMML or AML with multilineage dysplasia and ⩽30% bone marrow blasts who were not planning to undergo hematopoietic stem cell transplant","Adult patients (aged ⩾18 years) with International Prognostic Scoring System (IPSS) intermediate-2- or high-risk MDS, CMML or AML with multilineage dysplasia and ⩽30% bone marrow blasts who were not planning to undergo hematopoietic stem cell transplant were enrolled. Key inclusion criteria were an Eastern Cooperative Oncology Group performance status (ECOG PS) ⩽2 and adequate hepatic and renal function. Patients with therapy-related MDS or AML, relapsed/refractory AML, clinical symptoms of central nervous system leukemia, or impaired cardiac function were excluded.","patients who had received prior treatment with a DACi, AZA or decitabine, or who were currently receiving a drug known to prolong the QT interval that could not be terminated, were not eligible.",throughout the trial and up to 28 days after the last dose of study treatment,phase Ib
28555084,NCT01729845,Combination,No,adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms,"Adults aged ⩾ 18 years with relapsed/refractory AML (acute promyelocytic leukemia excepted) or other myeloid neoplasms with ⩾ 10% blasts in either peripheral blood and/or bone marrow were eligible if they had relapsed or refractory disease according to standard International Working Group Criteria and a treatment-related mortality (TRM) score of ⩽ 9.2.  Patients were also required to have a left ventricular ejection fraction ⩾ 40%, creatinine ⩽ 1.5 times the institutional upper limit of normal and bilirubin ⩽ 2.5 times the institutional upper limit of normal. Prior autologous or allogeneic hematopoietic cell transplantation (HCT) was permitted provided any graft-versus-host disease was well controlled with stable use of immunosuppressive agents, as was prior use of DNMT inhibitors or MEC (but not in combination).","An expected survival of <1 year from another illness, uncontrolled infection or treatment with other investigational agents (including treatment with tyrosine kinase (‘FLT3’) inhibitors) were exclusions.",NA,NA
28600476,NCT01482377,Combination,No,"Solid Tumor Patients:Tumor type, n (%);Colorectal 22 13;Head and neck 11 2;NSCLC 10 43;Carcinoma of unknown primary origin 2 1;Pancreatic cancer 0 3;Gastric cancer 0 2;Thymus cancer 0 2;Other 4a 5b","Patients had to have a histologically confirmed diagnosis of an advanced or metastatic HER3-expressing carcinoma that was refractory to standard treatment or for which no standard therapy existed. Eligible patients were >=18 years of age, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and had adequate hematology, blood chemistry, and renal and liver function. Patients eligible for enrollment underwent a fresh (pretreatment) tumor biopsy that was used to assess the level of HER3 protein expression by IHC using central pathology review.Discernible HER3 membrane staining in any neoplastic cell，provided that a minimum of 100 tumor cells were present in the biopsy specimen, was considered diagnostically positive for HER3 protein expression.For the extension phase of the cetuximab combination part, only patients with advanced HER3-expressing SCCHN, NSCLC, and colorectal cancer (proven to beKRASwild-type and expressing EGFR as per local assessment by the investigator) were recruited. For the extension phase of the erlotinib combination part, only patients with advanced HER3-expressing sqNSCLC and patients with nonsquamous lung carcinomas with a documented NRG1 somatic gene fusion (determined by local PCR and sequencing assays) were recruited to enrich for patients more likely to benefit from lumretuzumab.",NA,"first two cycles of treatment (i.e., 28 days)",NA
28618305,NA,Combination,No,patients with advanced solid tumours,"To be eligible, patients had to have solid tumours refractory to conventional treatment, a life expectancy ofmore than 12 weeks, an Eastern Cooperative OncologyGroup (ECOG) performance status  1. They were aged18 years with adequate haematological, hepatic andrenal functions. In the dose escalation part, any tumour typewas eligible for the study",Patients were excluded if they hadreceived previously a combination of mTOR and EGFRinhibitors.,4-week period from the start ofthe combination treatment.,NA
28881728,ACTRN12610001031055,Combination,No,"relapsed or refractory AML who had received up to two prior lines of intensive therapy, and untreated AML in patients aged ≥ 60 years unfit for intensive chemotherapy.","Over the age of 18 who have received up to 2 previous lines of intensive chemotherapy•  No prior failure to achieve at least a PR with Azacitidine or Everolimus•  Provision of written informed consent•  Secondary AML (including therapy-related) are included•  Life expectancy of greater than 3 months in relation to diseases other than AML/MDS•  ECOG performance status 0 – 3•  Electrolyte levels (potassium, calcium (albumin-adjusted), magnesium, phosphorous) within normal limits (WNL) oreasily correctable with supplements•  Adequate hepatic function as defined by bilirubin ≤ 1.5 × the upper limit of normal (ULN) and aspartate aminotransferase(AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN•  Adequate renal function, with serum creatinine ≤ 1.5 × ULN or GFR > 30 ml/minute•  Patients with no uncontrolled active infection•  Hydroxyurea ceased 48 hours prior to study therapy","Any serious medical or psychiatric conditions which the investigator feels may interfere with the patient’s ability to giveinformed consent or participate in the procedures or evaluations of the study•  History of major non-compliance to medication•  Evidence of CNS leukaemia•  Uncontrolled viral infection with known HIV or Hepatitis type B or C•  Currently active gastrointestinal disease (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea,malabsorption syndrome, or small bowel resection), or other disease, that prevents the patient from absorbing or takingoral medication•  Any other concurrent severe and/or uncontrolled medical conditions (e.g. acute or chronic liver disease, infection,pulmonary disease) that in the opinion of the investigator could potentiate unacceptable safety risks or jeopardizecompliance with the protocol•  Males with a female partner of childbearing potential do not agree to use at least 2 effective contraceptive methodsthroughout the study and for 6 months following the date of last dose",by day 42 of first cycle,NA
28881739,NCT00748553,Combination,No,advanced or metastatic solid tumors: Ovarian; Endometrial; Lung ;Breast; Non-Hodgkins Lymphoma ; SLL/CLL ; Sarcoma ; Pancreatic; Biliary tract ; Bladder,"Inclusion criteria for this phase I trial was any solid tumor, including lymphoma that had progressed on at least one prior therapy in the recurrent or metastatic setting. The criteria was subsequently modified after the first three patients, to no more than two prior therapies. Other criteria included an eastern cooperative oncology group (ECOG) performance status of ≤ 2, adequate hematological parameters, kidney and liver function. Patients agreed to use appropriate methods of contraception while on study medication during and up to three months post last treatment and were able to give a written informed consent. Exclusion criteria include any surgery, radiotherapy or chemotherapy within 4 weeks of day 1 of treatment, known brain metastasis, prior use of taxanes with in the past 6 months, active infection requiring treatment, grade 2 or greater motor or sensory neuropathy, known or suspected hypersensitivity to azacitidine or mannitol, pregnancy, breast feeding or any other condition in the investigator’s opinion that the patient was not eligible.","Inclusion criteria for this phase I trial was any solid tumor, including lymphoma that had progressed on at least one prior therapy in the recurrent or metastatic setting. The criteria was subsequently modified after the first three patients, to no more than two prior therapies. Other criteria included an eastern cooperative oncology group (ECOG) performance status of ≤ 2, adequate hematological parameters, kidney and liver function. Patients agreed to use appropriate methods of contraception while on study medication during and up to three months post last treatment and were able to give a written informed consent. Exclusion criteria include any surgery, radiotherapy or chemotherapy within 4 weeks of day 1 of treatment, known brain metastasis, prior use of taxanes with in the past 6 months, active infection requiring treatment, grade 2 or greater motor or sensory neuropathy, known or suspected hypersensitivity to azacitidine or mannitol, pregnancy, breast feeding or any other condition in the investigator’s opinion that the patient was not eligible.",first cycle,NA
28992562,NCT00974584,Combination,No,advanced nonesmall cell lung cancer,"Eligible patients were >=18 years with advanced NSCLC (stage IIIB ineligible for chemoradiotherapy, stage IV or recurrent), who were chemotherapy-naı̈ve or had received one line of chemotherapy, with an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 and baseline diffusing capacity of the lungs for carbon monoxide (DLCO) >=50% of predicted, corrected for haemoglobin and alveolar volume. Adequate haematological and end organ function and evaluable or measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST], version 1.0) were also the inclusion criteria. Patients with known central nervous system (CNS) metastases were eligible if they had evaluable/measurable disease outside the CNS. Any radiotherapy for CNS metastases must have been completed at least 8 weeks before screening and any neurosurgical resection or brain biopsy must have been performed more than 3 months before day 1.","Key exclusion criteria were type 1 or type 2 diabetes (glycosylated haemoglobin >=7%, fasting glucose >=he 22day assessment window in cycle 17.49 mmol/L and/or requiring regular medication), any adjuvant or neoadjuvant anti-cancer regimen for NSCLC within 4 weeks or >1 previous anti-cancer regimen for advanced NSCLC. Additional key exclusion criteria for patients in the bevacizumab arms included inadequately controlled hypertension, prior history of hypertensive crisis or encephalopathy, myocardial infarction or unstable angina, stroke or transient ischaemic attacks, vascular disease and haemoptysis. Patients with squamous cell NSCLC were not eligible for bevacizumab and pemetrexed combinations.",22 day assessment window in cycle 1,NA
29038850,UMIN 000009144,Combination,No,metastatic colorectal cancer,"Enrolled patients were required to meet the following eligibility criteria: histologically confirmed CRC, clinically proven KRAS wild-type unresectable advanced mCRC (they were enrolled during 2012–2014 and were selected for only KRAS wild-type mutation), 20–74 years of age, an Eastern Cooperative Oncology Group (ECOG) performance status 0–1, negative or heterozygous for UGT1A1*6 or UGT1A1*28 alleles, the presence of a measurable lesion (according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1), no previous treatment for metastatic disease, neutrophil count≥1.5×109/L, platelet count≥100×109/L, serum creatinine≤1.5 mg/dL, serum bilirubin≤1.2 mg/dL, serum aspartate aminotransferase and alanine aminotransferase≤5 times the respective upper limits of normal, adequate organ function, and an estimated life expectancy>3 months.",NA,in the first 2 treatment cycles,NA
29076150,NA,Combination,No,relapsed and refractory multiple myeloma,"Adults with RRMM with measurable disease in serum or urine and who had received ≥2 prior anti-myeloma therapies were eligible. All patients had received prior LEN and BTZ, given separately or in combination. Patients had to achieve at least stable disease or better for at least one cycle of prior anti-myeloma regimen before progressing, with refractoriness to last anti-myeloma therapy and have an Eastern Cooperative Oncology Group performance score ≤2.",Exclusion criteria included Grade ≥2 peripheral neuropathy; absolute neutrophil count <1.0 X 109/l; platelet count <50 X 109/l or <30 X 109/l for patients with ≥50% bone marrow plasmacytosis; creatinine clearance <35 ml/min; serum liver transaminase levels >3 X upper limit of normal (ULN); serum bilirubin >1.5 X ULN; congestive heart failure (New York Heart Association class III–IV); and prior exposure to POM and/or MRZ.,during Cycle 1,NA
29348128,NCT01814826,Combination,No,patients with AML,"Eligible patients were $60 years old with untreated AML who were considered unlikely to benefit from standard induction defined by $1 of the following: age $75 years, presence of antecedent MDS, adverse cytogenetic risk, and Eastern Cooperative Oncology Group performance status (ECOG PS) of 2. Other inclusion criteria included ECOG PS of 0 to 2, adequate renal function (calculated creatinine clearance > 50 mL/min), adequate hepatic function (bilirubin within normal range, AST and ALT <= 2.5 * upper limit of normal [ULN]), and adequate cardiac function (B-type natriuretic peptide <= 1.5 * ULN, left ventricular ejection fraction >= 50%, and pulmonary artery systolic pressure <= 1.5 * ULN).","Exclusion criteria included treatment with an investigational antileukemic agent within 14 days prior to entering study, uncontrolled intercurrent illness, and known infection with HIV and/or viral hepatitis B or C. Moderate and strong CYP3A inhibitors or chronic continuous use of CYP3A inducers were not permitted.",cycle 1,NA
29500276,NCT01696032,Combination,No,Recurrent Ovarian Cancer,"Participants who are women 18 years of age or older. Participants who have histologically or cytologically confirmed recurrent high-grade serous epithelial ovarian cancer (Grade 2 or 3), primary peritoneal carcinomatosis or fallopian tube cancer. Participants who have platinum-resistant disease (defined as having relapsed within 6 months of her last platinum-containing regimen). There is no limit on the number of prior treatment regimens in Part 1. In Part 2, participants may have had no more than 3 prior cytotoxic treatment regimens, excluding adjuvant or maintenance therapy. Participants must have had prior paclitaxel treatment. Participants who have measurable disease according to RECIST v1.1 or detectable disease. Participants with ECOG performance status of 0 or 1. Participants with acceptable organ function. Participants must be at least 3 weeks from last chemotherapy.","Participants who have hypersensitivity to SGI-110 and/or carboplatin or other components of these drug products. Participants who have received prior therapy with any hypomethylating agents. Participants who are refractory to platinum treatment i.e., progressed while on platinum treatment. Participants with abnormal left ventricular ejection fraction. Participants with Grade 2 or greater neuropathy. Participants with known brain metastases. Participants with known history of HIV, HCV or HBV.",during cycle 1 of therapy,NA
29559563,NCT01248949,Combination,No,ovarian cancer; bevacizumab-refractory recurrent malignant glioma;NSCLC; Colon/CRC;RCC;Esophageal/gastroesophageal;Endometrial;HCC;Glioblastoma;Prostate;Laryngeal;Pancreatic;Cervical;Thyroid; Melanoma,"Eligible patients were at least 18 years of age, had advanced solid tumors refractory to standard therapy or for which no standard therapy exists (monotherapy arm), and lacked curative options for whom chemotherapy and/or bevacizumab was standard of care (combination arms). Patients were also required to have a Karnofsky performance status of at least 60 for patients with recurrent malignant glioma or at least 70 for patients with other malignancies and adequate organ and marrow function (hemoglobin >=9 g/dL, absolute neutrophil count >=1,500/mm3, platelet count >=100,000/mm3, aspartate aminotransferase [AST] and alanine aminotransferase [ALT] levels <=2* upper limit of normal [ULN; no liver metastasis] or <=5*ULN [patients with liver metastasis], bilirubin <=1.5* ULN [except for patients with Gilbert's disease: <=5* ULN], and creatinine clearance >= 50 mL/min as determined by the Cockcroft-Gault equation). Prior radiotherapy was allowed if exposure was not estimated to have exceeded an area of 25% of marrow space. Patients in the MEDI3617 single-agent, dose-expansion arm in ovarian cancer were required to have recurrent or persistent epithelial ovarian, primary peritoneal, or fallopian tube carcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and at least 1 prior line of treatment, including at least 1 prior platinum-based therapy. Patients in the expansion cohorts were required to have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (v1.1) or MacDonald criteria in the case of malignant gliomas.",NA,"The time from the first dose of MEDI3617 to 21 or 28 days, depending on treatment arm (MEDI3617 administration every 3 weeks [Q3W] versus every 2 weeks [Q2W]), was defined as the dose-limiting toxicity (DLT) period.",NA
29693796,NCT01709435,Combination,No,children and adolescents with recurrent or refractory solid tumors,"Eligible patients were between the ages of 2 and 18 years (y), had a body surface area ≥ 0.35 m2; had a relapsed or refractory solid tumor including CNS tumors (Part A), or MTC (Part B); measurable or evaluable disease; no known curative therapy or therapy proven to ong survival with an acceptable quality of life; a Lansky (≤16 y) or Karnofsky (> 16 y) performance status ≥ 50%; and were recovered from the acute toxic effects of prior anticancer therapy. In addition, they were able to swallow intact tablets, had adequate organ function defined as: absolute neutrophil count (ANC)≥1000/mm3, platelet count ≥ 100,000/mm3, creatinine clearance or radioisotope GFR ≥ 70 ml/min/1.73 m2 or serum creatinine(Cr; mg/dl) based on age and gender; urine protein ≤ 30 mg/dl in urinalysis or ≤1+ on dipstick; total bilirubin ≤ 1.5 × upper limit of normal (ULN) for age, ALT ≤ 110 U/l, serum albumin ≥ 2.8 g/dL; PT and INR ≤ 1.5 × ULN; serum amylase and lipase ≤ 1.5 × ULN; blood pressure ≤ 95th percentile for age, height, and gender, and were not receiving medication for treatment of hypertension.","Patients were not eligible if they had a history of congenital prolonged QTc syndrome, QTc > 480 msec; significant cardiac arrhythmias, stroke, or myocardial infarction within 6 months prior to enrollment; were receiving potent CYP3A4 inducers or inhibitors, systemic treatment anticoagulation, enzyme-inducing anticonvulsants, escalating doses of corticosteroids, or drugs that prolong QTc; or had any active bleeding or major surgical procedure within 28 days of enrollment or minor procedures within 7 days of enrollment.",during Cycle 1,NA
29764853,NCT02269943,Combination,No,Relapsed or Refractory Solid Tumors,Age = or > 18 years Histological or cytological diagnosis of undifferentiated or poorly differentiated nasopharyngeal carcinoma that is locally advanced or metastatic. Disease progression either clinically or radiographically after 1-2 previous regimens. Patient has received a platinum containing regimen. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Radiographically-documented measureable disease. Adequate organ and bone marrow functions. Willingness to follow pregnancy precautions.,"History of, or current brain metastasis. Any other malignancy within 5 years prior to randomization with the exception of adequately treated in situ carcinoma of the cervix, uteri, or non-melanomatous skin cancer (all treatment of which should have been completed 6 months prior to enrollment), in situ squamous cell carcinoma of the breast, or incidental prostate cancer. Previous treatment with azacitidine (any formulation), decitabine, any other hypomethylating agent. History of gastrointestinal disorder or defect. Impaired ability to swallow oral medication. Persistent diarrhea or malabsorption. Active cardiac disease and human immunodeficiency virus (HIV) infection Active bleeding; pathological condition that carries a high risk of bleeding; risk of pseudoaneurysm of the internal carotid artery and carotid blowout syndrome. Major surgery within 14 days prior to starting Investigational Product or has not recovered from major side effects. Another investigational therapy within 28 days or 5 half lives of randomization/enrollment, whichever is shorter. Patient has not recovered from the acute toxic effects of prior anticancer therapy, radiation, or major surgery/significant trauma. Radiotherapy < or = 4 weeks or limited field radiation for palliation < or = 2 weeks prior to starting with the investigational product. Pregnancy/Breast feeding. Any condition that places the patient at unacceptable risk if he/she were to participate in the study or that confounds the ability to interpret data from the study.",in cycle 1,NA
29882250,NA,Combination,No,metastatic castration-resistant prostate cancer,"The study enrolled patients with mCRPC with symptomatic or radiographic progression from prior therapy. Patients may have received 0-2 prior chemotherapy regimens for CRPC; thus, patients could be docetaxel-naïve or refractory. Continuation of androgen deprivation therapy with a luteinizing hormone-releasing hormone agonist or antagonist was required in patients who were not surgically castrate. Patients were required to have an Eastern Cooperative Oncology Performance Status (ECOG PS) of two or less, and demonstrate no major organ dysfunction or uncontrolled hypertension (defined as systolic blood pressure greater than 140 mmHg, or diastolic blood pressure greater than 90 mmHg).","Patients who received prior Met or VEGFR inhibitors were excluded. While treatment with prior CYP17A1 inhibitors was exclusionary, prior ketoconazole was allowed if >120 days elapsed since discontinuation",during the first cycle,NA
29998365,NCT00925769,Combination,No,pancreatic adenocarcinoma,"The eligibility criteria included patients age 18 or older with histologically or cytologically confirmed locally advanced, unresectable and/or metastatic PAC according to the 6th Edition of the American Joint Commission on Cancer (AJCC) Staging System for Pancreatic Adenocarcinoma. Patients were required to have an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2, adequate bone marrow, liver and kidney function as well as an activated partial thromboplastin time ≤ 1.5 × ULN within 7 days prior to enrolment. The urine dipstick for proteinuria had to be <2+. Prior adjuvant radiochemotherapy was allowed.","Main exclusion criteria were resectable pancreatic cancer, previous therapy for metastatic or locally advanced disease (first-line treatment) and/or pre-exposition to one of the three drugs to be tested.",6 weeks,NA
30084837,NA,Combination,No,Heavy Smoker Patients with Locally Advanced Head and Neck Cancer,"Inclusion criteria included patients with: histologically/ cytologically confirmed AJCC 7th ed. III–IVB oropharynx, larynx, hypopharynx, and inoperable oral cavity; measurable disease per RECIST 1.1; age >=18 years, life expectancy >12 weeks; adequate hepatic, hematologic, and renal function; Eastern Cooperative Oncology Group Performance Status (ECOG PS) of <=2. Owing to the inferior survival of smoking-related HNSCC regardless of HPV status, both heavy smoker (>=10 pack-years) HPVþ and HPV patients were eligible. Upto two prior cycles of induction chemotherapy were allowed.",NA,"for approximately 10 weeks (~70 days), which spanned the entire treatment period and included approximately 4 weeks of observation following treatment",NA
30518523,ISRCTN (ISRCTN98335443) and ACTRN (ACTRN12615000702516),Combination,No,patients with ER and BCL2-Positive Metastatic Breast Cancer,"Patients ages >18 years with histologically confirmed ER-positive (defined as >1% positive stained carcinoma cells) and BCL2-positive metastatic breast cancer were enrolled. BCL2 status was determined by IHC on archival or fresh tumor biopsies and defined as positive if >10% cells stained positive with at least moderate cytoplasmic staining (intensity 2–3 on 0–3 scale). Of note, tumors from all patients recruited to mBEP exhibited BCL2-positive immunostaining in >50% of cells, with 2+ or 3+ intensity. Eligibility criteria included ECOG performance status of 0 to 1, evaluable disease as defined by RECIST v1.1, life expectancy of >6 months, and adequate end-organ function. Patients in the dose-expansion phase must not have received ≥3 lines of prior therapy in the metastatic setting and required measurable disease.","Exclusion criteria included tamoxifen use within the last 3 months, absolute contraindication to tamoxifen, and uncontrolled brain metastases.",in the first 4 weeks of treatment,NA
30895346,NA,Combination,No,"refractory solid tumors. Type of primary tumor, no. (%), Pancreatic adenocarcinoma 21 (84), Peritoneal mesothelioma 1 (4), Cervical carcinoma 1 (4), Ampullary adenocarcinoma 1 (4), Cancer of unknown primary 1 (4)","General inclusion criteria for all patients were age> 18 years, KPS>70%, life expectancy ≥3 mo, adequate organ and marrow function, capable of taking oral medications, willingness to use effective contraception, and negative pregnancy test. Specific inclusion criteria for the dose escalation phase include histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard therapy would include gemcitabine or for which standard curative or palliative measures do not exist or are no longer effective. Specific inclusion criteria for the dose expansion phase included histologically or cytologically documented adenocarcinoma of the pancreas, radiologic or surgical proof of metastatic disease, no prior chemotherapy for metastatic pancreatic disease (prior 5-fluorouracil orcapecitabine or other agents used as radiosensitizers with concurrent radiation therapy was permitted). Gemcitabine was only permitted if administered in the adjuvant setting with >6 months between last gemcitabine treatment and diagnosis of metastatic disease.","General exclusion criteria included any anti-cancer treatments (except for hormonal therapy for metastatic breast or prostate cancer) or major surgeries within 28 days of day 1; pregnancy or breastfeeding; impairment of gastrointestinal function that could alter drug absorption; significant cardiac disease or stroke; bleeding diathesis or medications that inhibit platelet function; fluid retention; known HIV, hepatitis C, acute or chronic active hepatitis B; serious chronic infection requiring ongoing treatment; drugs that increase the risk of Torsades de Pointes; CYP3A4 inhibitors or inducers; proton pump inhibitors or H2 antagonists; or prior severe infusion reaction to a monoclonal antibody",during cycle 1,NA
30952640,NCT01246063,Combination,No,Relapsed/Refractory Multiple Myeloma,"Eligible patients were 18 years of age or older with a diagnosis of RRMM post one or more lines of prior treatment and measurable disease in the blood (>= 0.5 g/dL by electrophoresis or >= 10 mg/dL difference in involved and uninvolved lightchains), urine (>=200 mg/dL/24 hours), bone marrow (>= 30% plasma cells), or extramedullary plasmacytoma.","Patients with poor hematologic reserve, liver function, or performance status, and those requiring hemodialysis were excluded, as were patients with a history of plasma cell leukemia, HIV, or active hepatitis. Patients with a left ventricular ejection fraction below 55%, electrocardiogram evidence of acute ischemia or significant conduction system abnormalities, or recent history of acute myocardial infarction, unstable angina, or arrhythmia were excluded because of the known cardiac toxicities of carfilzomib and PLD. Patients who had received prior carfilzomib, PLD or doxorubicin, and those refractory to bortezomib were not excluded.",during cycle 1,NA
31005227,NA,Combination,No,locally advanced esophageal squamous cell carcinoma,"Eligible patients had untreated histologically confirmed squamous cell carcinoma (SqCC) or adenocarcinoma (AC) of the middleor distal esophagus or gastro-esophageal junction (GEJ). Patientshad locally advanced tumors, defined as T2-3N0-1M0-1a accordingto the 1997 American Joint Committee on Cancer criteria (AJCC)7th edition. The extent of disease was evaluated by physical examination, upper endoscopy, Positron Emission Tomography withComputerized Tomography (PET-CT) scan and Endoscopic Ultrasound (EUS).Patients had to be surgical candidates, with an Eastern Cooperative Oncology Group (ECOG) performance status 1, intact hematological, cardiovascular, renal and liver functions, no severecomorbidities and no cancer within the preceding 5 years. Patientsprovided written informed consent prior to study enrollment.",NA,NA,NA
31053600,NCT02302495,Combination,No,Multiple Myeloma,"Eligible patients were 65 years of age or older and presented with symptomatic, measurable, previously untreated multiple myeloma. Additional eligibility criteria included: be able to understand and voluntarily sign an informed consent form and be able to adhere to the study visit schedule and other protocol requirements, Eastern Cooperative Oncology Group (ECOG) performance status score <= 2, absolute neutrophil count >= 1X109/L, spontaneous platelet count > 75 X 109/L, and hemoglobin >= 8.5 g/dL.","The main exclusion criteria included terminal renal failure that required dialysis or clearance creatinine < 30 mL/minute, history of other cancer, heart failure class 3 and 4 according to the NYHA criteria, past history of myocardial infarction within the last 6 months or uncontrolled cardiac conduction abnormalities, left ventricular ejection fraction below 45% (LVEF < 45%), patients known positive for HIV or active infectious type B or C hepatitis, and female of childbearing potential. Male subjects must understand the potential teratogen risk of melphalan and the potential genotoxic risk of carfilzomib if engaged in sexual activity with a pregnant female or a female of childbearing potential.",the first treatment cycle,NA
31164456,NCT02352571,Single Drug,No,Advanced cancer/solid tumor only,"In the dose escalation part, patients who met the following key criteria were enrolled: (a) histologically confirmed solid tumorsrefractory to standard therapy or for which there is no standard therapy; (b) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; (c) adequate organ functionIn the cohort expansion part, C1 recruited patients with metastatic CRC who received no prior EGFR antibody treatment andwho failed on 5-FU, oxaliplatin, and irinotecan treatment. C2 enrolled patients with metastatic CRC with resistance to priorEGFR antibody therapy. C3 enrolled patients with EGFR over-expressing (2+ or 3+ by immunohistochemistry [IHC]) metastaticgastric cancer (GC) who failed on standard treatment.","Key exclusion criteria were as follows: (a) central nervous system metastasis; (b) heart failure, coronary heart disease, orother clinically significant cardiac disease within 6 months prior to enrollment; (c) known KRAS mutation in the dose escalation part or known KRAS or BRAF mutation in the cohort expansion part.","DLT was evaluated during the first 6 weeks of treatment (4-week treatmentfollowed by a 2-week rest period).","Adaptive design, but no details of statistical design is provided"
31486207,NCT01816984,Combination,No,in recurrent and metastatic(R/M) head and neck squamous cell carcinoma (HNSCC),"Eligible patients were ≥18 years old with histologically orcytologically confirmed diagnosis of HNSCC not amenableto curative intent therapy who had demonstrated progressivedisease following exposure to a platinum agent or anothercytotoxic chemotherapy or radiation. Patients were requiredto have radiographically measurable disease assessed by thelocal investigator in accordance with the Response EvaluationCriteria in Solid Tumors (RECIST v1.1), an ECOG ≤2, normal organ and marrow function, and no active cardiac disease. Prior cetuximab treatment did not prevent enrollment.","Patients who had received prior treatment with a PI3K inhibitor or had greater than two prior lines of cytotoxic chemotherapy in the recurrent or metastatic setting were excluded.Patients who had received anticancer therapy within 4 weeksof treatment were excluded until they allowed for adequatewashout of their previous therapy and resolution of anyadverse effects from that treatment. Patients with acute orchronic liver or renal disease, patients with untreated brainmetastasis, or a history of a major depressive episode or othersignificant psychiatric history were excluded from the study",at agiven dose level after 4 weeks of active treatment,NA
31675952,NCT01661972,Combination,No,chemotherapy refractory metastatic colorectal cancer,"Eligibility for the dose escalation cohort included patients with a histologically or cytologically confirmed malignant solid tumor that was refractory to all standard therapies. Eligibility for the expansion cohort included patients with metastatic CRC who had progressed on, were intolerant of, or were inappropriate for all standard therapies. Subjects must have been treated with a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan and bevacizumab or have contraindication to such treatment. Prior epidermal growth factor receptor (EGFR)-targeting agent (cetuximab or panitumumab) was required for subjects with RAS wildtype tumors. Patients in the dose escalation cohort were not required to have measurable disease by RECIST version 1.1. Patients in the expansion cohort were required to have measurable disease by RECIST version 1.1. Inclusion criteria for all subjects in the dose escalation and the expansion cohorts included Karnofsky performance status (KPS) equal to or greater than 70%, life expectancy of at least 3 months, and adequate organ and marrow function.","Exclusion criteria for all subjects in the dose escalation and expansion cohorts included systolic blood pressure greater than 150 mmHg and/or diastolic blood pressure greater than 90 mmHg, history of arterial thromboembolic events or symptomatic pulmonary embolism within 6 months of study enrollment, anti-coagulation with warfarin, history of fistula, history of gastrointestinal perforation, and history of any major bleeding within 6 months of enrollment. Prior treatment with zivaflibercept was permitted.",in cycle 1,NA
31707687,NCT02619864,Combination,No,patients with previously treated glioblastoma multiforme,"Eligible patients had histologically confirmed GBM with documented radiographic evidence of recurrence/progression after primary treatment. Patients must have received one TMZ regimen as part of initial treatment, discontinued TMZ at least 16 weeks prior to registration, and had not progressed while receiving adjuvant TMZ or radiation. Measurable disease according to Revised Assessment in Neuro-Oncology (RANO) criteria was mandated for all patients enrolled from DL3 onwards. .",NA,"during Cycle 1 up to DL2, and during Cycle 1 or 2 for DL3",NA
32534811,NA,Combination,No,platinum-sensitive recurrent ovarian cancer,"PSOC patients (epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer) with documented radiographic progression or relapse according to RECIST v1.1  between 6 and 18 months of completion of most recent platinum-based chemotherapy were eligible. Other inclusion criteria were age ≥ 18 years, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, archival tumor sample, measurable disease, absolute neutrophil count ≥ 1500/μL, hemoglobin ≥ 9 g/dL, platelet count ≥ 100,000/μL, total bilirubin ≤ 1.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN, serum creatinine ≤ 1.5 × ULN, international normalized ratio (INR) ≤ 1.5 × ULN, and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN. Confirmed expression of NaPi2b in tumors was not a criteria for inclusion.","The exclusion criteria were: platinum-based chemotherapy within 6 months prior to day 1, or prior treatment with N2 platinum-based chemotherapy regimens or N4 anti-cancer regimens overall; prior treatment with NaPi2b or SCL34A2 targeted therapy; anti-tumor therapy (chemotherapy, biologic, experimental, or hormonal therapy) or major surgical procedure within 4 weeks prior to day 1; palliative radiation within 2 weeks prior to day 1; current grade N 1 toxicity (except alopecia and anorexia) from prior therapy or grade N 1 neuropathy from any cause; any significant, uncontrolled, concomitant disease; history of carboplatin-related toxicity requiring discontinuation; severe allergic or anaphylactic reactions to monoclonal antibody therapy. Additional exclusion criteria for patient eligibility for bevacizumab cohort included: hypersensitivity to prior bevacizumab, uncontrolled hypertension or hypertensive crisis, significant cardiac history (heart failure or ischemic heart disease), active central nervous system metastases, vascular disease (i.e. thromboses), coagulopathy, bleeding diatheses, recent surgery or non-healing wounds, and proteinuria.",during cycle 1,NA
32584367,NCT01702558,Combination,Yes,Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer,"All patients were age ≥18 years and had HER2-positive tumors, Eastern Cooperative Oncology Group (ECOG) performance status ≤2, adequate liver/renal function, left ventricular ejection fraction ≥50%, and life expectancy ≥12 weeks. Patients with mBC were eligible if they had HER2-positive tumors (locally scored as immunohistochemistry [IHC] 3+ or in situ hybridization [ISH]-positive based on ratio of ≥2 copies of the HER2 gene versus number of signals for CEP17) and had received at least one prior treatment for early or metastatic disease (including chemotherapy and trastuzumab, separately or in combination). Eligibility criteria were the same for phase I and II. Patients with LA/mGC were eligible if they had HER2-positive (IHC 2+, IHC 3+, or ISH-positive, centrally confirmed in the primary tumor or metastatic lesions), inoperable LA/mGC amenable to treatment with T-DM1 plus capecitabine, and had not received prior chemotherapy for advanced or metastatic disease. Prior (neo)adjuvant therapy was allowed if ≥6 months had elapsed between treatment completion and study enrollment.","Patients were excluded if they had previously received T-DM1 or if they received trastuzumab within 21 days, lapatinib within 14 days, hormonal therapy within 14 days, or an investigational therapy within 28 days (or five half -lives) before study drug initiation. Patients were also excluded with: symptomatic brain metastases; history of symptomatic congestive heart failure (CHF) (New York Heart Association Classes II−IV), or myocardial infarction or unstable angina within 6 months prior to study drug initiation; history of left ventricular ejection fraction decrease to <40% or symptomatic CHF with previous trastuzumab treatment.",Cycle 1,NA
32998961,NCT03303339,Combination,No,Patients with Relapsed or Refractory Acute Myeloid Leukemia,"Patients 18 years or older with a confirmed diagnosis of AML and Eastern Cooperative Oncology Group (ECOG) performance status of 0–2 were eligible. Patients were allowed up to three prior treatment regimens for their AML, including HMAs. Induction therapy and hematopoietic stem cell transplant were counted as one prior line of therapy. Treatment-na€ve patients who were unfit for intensive induction therapy were also eligible. Treatments for preexisting myelodysplastic syndrome (MDS) were allowed and not considered as prior treatment","Patients with treatment-related AML and acute promyelocytic leukemia were excluded, as were patients with aspartate aminotransferase and/or alanine aminotransferase ≥2.5  upper limit of normal, total bilirubin >2 mg/dL, or serum creatinine ≥2.0 mg/dL.",in the first cycle,NA
33095287,NCT01606878,Combination,No,children with refractory solid tumors and ALCL.,"Patients > 12 months or < 22 years of age with recurrent or refractory solid tumors, including lymphomas and excluding CNS tumors, were eligible. Histologic verification of malignancy was required and patients needed to have either measurable or evaluable disease. Other eligibility criteria included a Karnofsky/Lanksy performance score ≥ 50. Patients must have recovered from acute side effects of prior therapy. Intervals from prior therapy included: > 21 days for myelosuppressive chemotherapy, > 7 days for biologic agents, > 42 days for immunotherapy, and ≥ 21 days for monoclonal antibodies. Intervals from hematopoietic growth factor support were, > 7 days for short-acting and > 14 days for long-acting factors. For prior radiation, > 14  days were required for local palliative radiation, > 150 days for prior total body irradiation, craniospinal XRT or radiation to ≥ 50% of the pelvis, and > 42 days for other substantial bone marrow radiation or therapeutic 131I-MIBG.In addition, ≥ 84 days from stem cell transplant or rescue without evidence of active graft vs. host disease and ≥ 42 from autologous stem cell infusion after 131I-MIBG therapy was required. Patients must not have received prior therapy with crizotinib. Adequate renal function (age-adjusted normal serum creatinine, or GFR ≥ 70 mL/min/1.73 m2); adequate liver function (total bilirubin ≤ 1.5 X ULN, ALT≤ 110, serum albumin ≥ 2  g/dL); adequate cardiac function (QTc ≤ 480 ms); and BSA ≥ 1.07 m2 for patients receiving the formulated capsules and ≥ 0.43 m2 for patients receiving the microsphere formulation were required. Adequate bone marrow function, defined as absolute neutrophil count (ANC) ≥ 1000/mm3 and transfusion-independent platelet count ≥ 100,000 mm3 were also required.","Exclusion criteria included women who were pregnant or breastfeeding, uncontrolled infection, concurrent use of other investigational agents, anticancer agents, chronic use of CYP3A4 inducers, inhibitors or substrates with narrow therapeutic indices, agents to prevent organ rejection post-transplant and chronic systemic corticosteroids. Proton pump inhibitors (PPIs) were prohibited for patients enrolling on the crizotinib microsphere formulation (cMS) as this formulation requires an acidic environment for the microsphere’s to be released and absorbed.",during cycle 1 of therapy.,NA
33203645,NCT01960023,Combination,No,"Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab","Enrollment occurred between February 2014 and December 2015. Eligible patients, identified through the NSABP live tissue repository, were >18 years with ECOG PS ¼ 0–2, quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) by central Clinical Laboratory Improvement Amendments (CLIA) testing, and had measurable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Prior treatment with oxaliplatin and irinotecan as part of standard chemotherapy regimens and anti-EGFR therapy with either cetuximab or panitumumab was required. Patients were required to have archived tissue samples from their primary or treatment-naïve metastatic tumor. Upon enrollment, a research biopsy from a metastatic lesion was obtained. Acceptable laboratory parameters included an absolute  neutrophil count (ANC) of ≥1,000/mm, platelet count of >100,000/mm3, and hemoglobin of ≥9.0 g/dL, a total bilirubin of ≤1.5x ULN, and AST and ALT of ≤2.5x ULN or if liver metastases ≤5x ULN, and a serum creatinine of ≤1.5x ULN.","Patients were excluded if they could not swallow oral medications, had symptomatic brain metastases, active hepatitis B or C with abnormal liver function tests, intrinsic lung disease causing dyspnea, or symptomatic cardiac disease.",during cycle 1,NA
33386556,UMIN000015620,Combination,No,"patients with RAS wild‑type, metastatic colorectal cancer","Patients were included if they had histologically confirmed colorectal adenocarcinoma; presence of RAS wild-type tumor; measurable metastatic disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 ; age 20-to-74 years old; Eastern Cooperative Oncology Group performance status of 0 or 1; no prior chemotherapy for metastatic disease; previous adjuvant chemotherapy that ended more than 6 months before study entry; a life expectancy ≥ 12 weeks; and adequate hematologic, hepatic, and renal function, as defined by an absolute neutrophil count of ≥ 1500/mm3, platelet count of ≥ 10.0 × 104/mm3, total bilirubin ≤ 1.2 mg/dl, serum transaminase ≤ 2.5 times the respective upper limits of normal, and a serum creatinine level of ≤ 1.5 mg/dl","The exclusion criteria were the presence of: UGT1A1*28/*28, *6/*6 or *6/*28 genotypes; prior treatment with anti-EGFR antibody; clinically relevant coronary disease or myocardial infarction within 12 months before study entry; major surgery or radiotherapy within the last 4 weeks; known severe allergic reaction to any drugs; intestinal obstruction; uncontrolled active infection; symptomatic central nervous system metastases; severe lung disease (i.e., interstitial pneumonia, fibroid lung, or severe emphysema); concurrent active malignancy; peripheral sensory neuropathy and diarrhea ≥ grade 2 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0.; pregnancy or lactation.",The DLT evaluation took place in the period starting from drug administration on day 1 of the first course to before drug administration on day 1 of the third course.,NA
33469991,NCT02008383,Combination,No,KRAS Wild-Type Metastatic Colorectal Cancer,"For the Monotherapy MET Amplified cohort only: MET gene amplification by prospective screening assay from peripheral blood. Histologically and/or cytologically confirmed and radiographically measurable KRAS wild-type adenocarcinoma of the colon or rectum that is metastatic and/ or unresectable. Subjects must have been treated with a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan and bevacizumab or have contraindication to such treatment. In addition, for the monotherapy MET Amplified cohort, must have received prior treatment with anti-EGFR therapy (either panitumumab or cetuximab). At least one site of disease that is measurable by RECIST (version 1.1) criteria that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation. Age ≥ 18 years. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Life expectancy greater than 3 months. Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s). Women of childbearing potential must have a negative pregnancy test within 7 days before the first dose of study treatment. Capable of understanding and complying with the protocol requirements and has signed the informed consent document. Adequate organ and marrow function as defined by protocol.","Cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 3 weeks, or nitrosoureas/ mitomycin C within 6 weeks before the first dose of study treatment. Prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment. For Combination Dose Finding and Combination Expansion cohorts only: History of hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins. Hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the Lead PI. Radionuclide treatment, including yttrium-90 treatment, within 6 weeks of the first dose of study treatment. Radiation therapy: a. to the thoracic cavity, abdomen or pelvis within 3 months of the first dose of study treatment or has ongoing complications or is without complete recovery and healing from prior radiation therapy b. to bone metastases within 14 days of the first dose of study treatment c. to any other site(s) within 28 days of the first dose of study treatment. Any other type of investigational agent within 28 days before the first dose of study treatment. Not recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all prior therapies except alopecia, oxaliplatin-related neuropathy, and other non-clinically significant adverse events. Presence of or known history of brain/ CNS tumor or metastases. KRAS exon 2 (codons 12 or 13) mutation detected in tumor tissue specimen. Concurrent severe and/or uncontrolled medical conditions which may compromise participation in the study, including impaired heart function or clinically significant heart disease. Prothrombin time (PT) or partial thromboplastin time (PTT) test ≥ 1.3 x laboratory upper limit of normal (ULN) within 7 days before the first dose of study treatment. Concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel). Low dose aspirin (≤ 81 mg/day), low-dose warfarin (≤ 1 mg/day), and prophylactic LMWH are permitted. Chronic concomitant treatment of strong CYP3A4 inducers or CYP3A4 inhibitors. Previously experienced any of the following: clinically significant gastrointestinal bleeding within 6 months before the first dose of study treatment hemoptysis of ≥ 0.5 teaspoon (2.5ml) of red blood within 3 months before the first dose of study treatment any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment Radiographic evidence of cavitating pulmonary lesion(s). Tumor in contact with, invading or encasing any major blood vessels. Evidence of endotracheal or endobronchial tumor. Uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: Cardiovascular disorders including: i. Congestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening ii. Concurrent uncontrolled hypertension defined as sustained BP > 140 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment iii. Any history of congenital long QT syndrome iv. Any of the following within 6 months before the first dose of study treatment: unstable angina pectoris clinically-significant cardiac arrhythmias. stroke (including TIA, or other ischemic event) myocardial infarction thromboembolic event requiring therapeutic anticoagulation. Note: Subjects with a venous filter (e.g., vena cava filter) are not eligible for this study. b. Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including: i. Any of the following within 28 days before the first dose of study treatment active peptic ulcer disease active inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis malabsorption syndrome. ii. Any of the following within 6 months before the first dose of study treatment: abdominal fistula gastrointestinal perforation bowel obstruction or gastric outlet obstruction intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more that 6 months before the first dose of study treatment. c. Other disorders associated with a high risk of fistula formation or wound healing complications, including percutaneous endoscopic gastrostomy (PEG) tube placement within 3 months before the first dose of study therapy. d. History of chronic pancreatitis. e. Other clinically significant disorders such as: i. active infection requiring IV antibiotic within 28 days before the first dose of study treatment. ii. serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment. iii. history of organ transplant. iv. concurrent uncompensated hypothyroidism or thyroid dysfunction. Note: Patients with newly diagnosed thyroid conditions may participate if stable on a new regimen for at least 7 days before the first dose of study treatment. v. history of surgery as follows: major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications minor surgery, including dental procedures, within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery. 19. History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan. 20. Unable to swallow tablets. 21. Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms within 28 days before start of treatment. Note: At baseline (i.e. screening), three ECGs to be obtained within 30 minutes but approximately 2 minutes apart (i.e. triplicate). If the average of the three consecutive results for QTcF is ≤ 500 ms, the subject meets eligibility in this regard. 22. Pregnant or breastfeeding. 23. For the Combination Dose Finding and Combination Expansion cohorts only: Previously identified allergy or hypersensitivity to components of the study treatment formulation or panitumumab. 24. Unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee. 25. Evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment. 26. Known history of HIV seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment.",NA,NA
33472913,ISRCTN 16332228,Combination,Yes,"Solid Malignancies Including Urothelial Carcinoma. Primary tumor site: Urinary tract, Pleura, Ovary, Mediastinum, Testis, Unknown","Key inclusion criteria for both phases included Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, 16 years or older, glomerular filtration rate (GFR) estimation ≥60 mL/minute, hemoglobin ≥90 g/L, neutrophil count ≥1.5 x 109/L, platelets ≥100 x 109/L, bilirubin ≤ 1.5 x the institutional upper limit of normal (ULN), alanine transaminase and alkaline phosphatase ≤2.5 x ULN (ALP ≤ 5 x ULN if caused by liver or bone metastases), and life expectancy over 3 months.","Key exclusion criteria included unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) v4.03 grade 1 (except alopecia), prior radiotherapy to >30% of bone marrow and major surgery, or an investigational medicinal product within 30 days.",during cycle 1,NA
33577866,NA,Combination,No,patients with locally advanced head and neck squamous cell carcinoma,"Adults with a histologically proven diagnosis of Stage III, IVA, or IVB HNSCC, measurable/non-measurable disease at the primary site or nodal stations, adequate organ function, and Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, were included. All patients provided written informed consent","Patients who received prior systemic chemotherapy or RT to the head and neck region, or undergone curative-intent surgery, were excluded. Patients with distant metastatic disease, serious pre- existing medical conditions, ECG abnormalities, or serious cardiac conditions were excluded",The DLT period started at the initiation of study treatment and concluded 4 weeks after the end of treatment (approximately 11 weeks for Part A and 12 weeks for Part B).,NA
33741296,NCT03502681,Combination,No,Metastatic Urothelial Carcinoma,"We enrolled patients with stage IV disease (either locally advanced node-positive [N3] or metastatic urothelial cancer [M1] of the bladder and upper urinary tract). All patients had measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1. Enrolled patients were cisplatinineligible and treatment-naïve, or platinum-resistant or -intolerant.","Cisplatin ineligibility was defined as one of the following: GFR 30 but <60 ml/min, Eastern Cooperative Oncology Group (ECOG) performance status of 2, grade > 2 hearing loss, grade 2 peripheral neuropathy, or New York Heart Association class III–IV heart failure.",in the first cycle (28 d) of combination therapy,NA
34019214,NCT04097444,Combination,No,metastatic colorectal cancer,"1.	Provision of personally written informed consent after receiving full explanation of the study2.	Histologically confirmed colon or rectal adenocarcinoma (excluding appendix cancer and anal canal cancer)3.	Clinically unresectable tumor4.	≥20 years of age at enrollment5.	ECOG performance status (PS) score of 0 or 1 (≥71 years of age: PS score of 0)6.	Measurable lesion in accordance with RECIST version 1.1 criteria on contrast-enhanced computed tomography of the chest, abdominal, or pelvic (trunk) (required within 28 days of enrollment)7.	No previous chemotherapy for colon or rectal cancer (only patients with confirmed relapse ≥ 24 weeks after completion of postoperative adjuvant chemotherapy can be enrolled)8.	RAS/BRAF mutation analysis at enrollment identifies RAS/BRAF status as either the wild type or mutant type9.	Vital organ functions meet the following criteria within 14 days before enrollment. If multiple test results are available in that period, the results closest to the enrollment date will be used. No blood transfusions or hematopoietic factor administration will be permitted within 2 weeks before the measurement date.a.	Neutrophil count: ≥1500/mm3b.	Platelet count: ≥10.0 × 104/mm3c.	Hemoglobin concentration: ≥9.0 g/dLd.	Total bilirubin: ≤1.5-fold of the upper limit of normal (ULN)e.	AST, ALT, ALP: ≤2.5-fold of the ULN (≤5-fold of the ULN for liver metastases)f.	Serum creatinine: ≤1.5-fold of the ULN, or creatinine clearance: ≥30 mL/ming.	Urine protein: ≤2+ (if ≥3+, urine protein/creatinine ratio: <2.0)10.	UGT1A1 polymorphism is a wild type or a single heterozygous type","1.	Previous radiation therapy in which ≥20% of bone marrow was exposed to the radiation field2.	Untreated brain metastases, spinal cord compression, or primary brain tumor3.	History of central nervous system disease (excluding asymptomatic lacunar infarction)4.	Requirement of continuous systemic corticosteroid treatment5.	Inconsistently controlled oral or parenteral	anticoagulant (e.g., low-molecular-weight heparin) dose (≥14 days; oral anticoagulants: conditions with high bleeding risk, such as PT-INR ≥ 3 and clinically significant active bleeding [within 14 days of enrollment])6.	Arterial thrombosis or arterial thromboembolism such as myocardial infarction, transient ischemic attack, or cerebrovascular attack in the last year before enrollment7.	Previous treatment using an investigational drug within 28 days before enrollment, or participation in a study of an unapproved drug8.	Any of the following comorbidities:a.	Uncontrolled hypertensionb.	Uncontrolled diabetes mellitusc.	Uncontrolled diarrhead.	Peripheral sensory neuropathy (≥Grade 1)e.	Active peptic ulcerf.	Unhealed wound (except for suturing associated with implanted port placement)g.	Evidence of cardiovascular disease, cerebrovascular disorder (within 24 weeks), myocardial infarction (within 24 weeks), unstable angina pectoris, New York Hearth Association classification ≥Grade 2 congestive heart failure, serious arrhythmias requiring drug therapyh.	Uncontrolled venous thromboembolism (unless clinically stable, asymptomatic, or appropriately treated with an anticoagulant)i.	Systemic treatment required for, or evidence of, infectionsj.	Other clinically significant diseases (e.g., interstitial pneumonia or renal impairment)9.	Major surgical procedure within 28 days before study treatment initiation10.	Physical defects of the upper gastrointestinal tract; malabsorption syndrome or difficulty taking oral medication11.	Pregnant, breastfeeding, positive pregnancy test (women who have menstruated in the last year will be tested), or patients who are unwilling to use contraception during the study12.	Active hepatitis B or C, or evidence of HIV infection13.	Previous chemotherapy for other malignancies (excluding hormone therapy for breast cancer).14.	Other active malignancies (excluding malignancies that are expected to be completely cured, such as intramucosal carcinoma and carcinoma in situ)15.	Diseases such as intestinal paralysis, intestinal obstruction, or gastrointestinal perforation within 1 year before enrollment16.	Pleural effusion, ascites, or pericardial effusion requiring drainage17.	History of hypersensitivity to fluorouracil, levofolinate, oxaliplatin, irinotecan, bevacizumab, and their excipients or Chinese hamster ovary cell proteins18.	History of adverse reactions to fluoropyrimidine drugs indicative of dihydropyrimidine dehydrogenase (DPD) deficiency19.	Endoluminal stenting20.	Unsuitable for the study according to the opinion of the investigators",the first cycle,NA
34040175,NCT02157792,Combination,No,"patients with advanced solid tumours. Primary tumour: NSCLC, Pancreatic cancer, Breast cancer, Head and neck cancer, Colorectal cancer, Other (did not include small-cell lung cancer or ovarian cancer)","Eligible patients were ≥18 years of age with histologically or cytologically confirmed metastatic or unresectable solid tumours and measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1,20 for which standard curative or palliative therapy did not exist or was no longer effective at the time of study enrolment, or for whom treatment regimens containing gemcitabine and cisplatin might be considered. Patients for whom gemcitabine and/or cisplatin were appropriate treatment options were informed that, given the exploratory nature of this study, the doses of chemotherapy would be lower than those given in standard regimens, but were deemed clinically justified when administered in combination with berzosertib. Eligible patients had a World Health Organization performance status of 0–1, adequate bone marrow, liver and kidney function and a life expectancy of at least 12 weeks. In addition, patients were required to have received ≤6 cycles of prior chemotherapy with cisplatin and/or carboplatin (unless approved by the sponsor medical monitor).","Key exclusion criteria included radiotherapy (except palliative), endocrine therapy, immunotherapy or chemotherapy within the 4 weeks prior to receiving study therapy, more than six cycles of prior treatment with cisplatin, ongoing toxicity or recent major surgery (≤2 weeks of the first dose of study drug), active central nervous system disease or symptoms within 4 weeks prior to treatment, cardiac conditions within 6 months prior to treatment, prior bone marrow transplant or radiation to >15% of bone marrow and receiving medications that are known to be strong inhibitors or inducers of CYP3A4 that could not be discontinued at least one week before the start of treatment and for the duration of the study",cycle 1,NA
34319586,NCT02227940,Combination,No,"patients with advanced solid tumors. Disease site: Breast adenocarcinoma, Hepatocellular carcinoma, Cholangiocarcinoma, Head and neck cancer, Hepatic adenocarcinoma, Leiomyosarcoma, Pancreatic carcinoma, Small intestine carcinoma, Tumor of fibrous tissue, Cancer unknown primary","Arm 1: histologically or cytologically confirmed solid tumors that are advanced that gemcitabine-based treatment is considered a clinically appropriate option. Arm 2: histologically or cytologically confirmed adenocarcinoma of the pancreas that is locally advanced or metastatic. Arm 3: histologically or cytologically confirmed solid tumors that are advanced that gemcitabine plus cisplatin treatment is considered a clinically appropriate option. Arms 1E, 2E and 3E: solid tumor that demonstrate anaplastic lymphoma kinase (ALK) positivity; ALK positivity can be assessed using the assays below, and documentation of ALK positivity using one of the tests below is required: Fluorescence in situ hybridization (FISH) test for ALK positivity using the Food and Drug Administration (FDA)-approved FISH test (Abbott Molecular Inc), using Vysis breakapart probes (defined as 15% or more positive tumor cells); OR Harboring a confirmed ALK positivity, as determined by positivity to the Ventana immunohistochemistry (IHC) assay.Arms 1E: previously treated with and progressed on gemcitabine-containing therapy. Arms 1, 2, 3: patients should have clinically measurable or evaluable malignant disease. Arms 1E, 2E, 3E: patients with at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 that have not been previously irradiated. Eastern Cooperative Oncology Group (ECOG) performance status =< 1. Life expectancy >= 3 months. Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (system international [SI] units 1.5 x 10^9/L). Platelets >= 100,000 cells/mm^3 (SI units 100 x 10^9/L). Hemoglobin >= 9 g/dL (SI units 90 g/L) (in the absence of transfusion within 24 hours prior to dosing). Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) =< 3 x upper limit of normal (ULN); in patients with known hepatic involvement, AST and ALT =< 5 x ULN are allowed. Total bilirubin =< 1.5 x ULN. Calculated or measured creatinine clearance (CrCL) >= 60 mL/min using modified Cockcroft and Gault formula. Serum lipase =< 2 x ULN. Serum amylase =< 2 x ULN. International normalized ratio (INR) =< 1.5; (anticoagulation is allowed if target INR =< 1.5 on a stable dose of warfarin or on a stable dose of low molecular weight [LMW] heparin for > 2 weeks at the first dose of study agent). If urinalysis shows proteinuria, 24 hour urine collection is to be performed and the 24 hour urine protein is to be < 2 grams to be eligible. Willing and able to comply with scheduled visits, treatment plan and laboratory tests. Ability to understand and willingness to sign a written informed consent; a signed informed consent must be obtained prior to any study specific procedures. Patient must consent to the use of their archival tumor tissue for protocol use if available","Arms 2, 2E, 3, 3E: patients who previously received > 2 lines of systemic chemotherapy for advanced or metastatic disease. Previous pelvic radiation affecting >= 25% of the bone marrow; patients who received whole pelvic radiation are excluded. Patients who have received the last administration of an anti-cancer therapy including chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies (but excluding nitrosourea, mitomycin-C, targeted therapy and radiation) =< 4 weeks prior to starting study drug. Patients who have received the last administration of nitrosourea or mitomycin-C =< 6 weeks prior to starting study drug. Patients who have had radiotherapy =< 4 weeks prior to starting study drug, or =< 2 weeks prior to starting study drug in the case of localized radiotherapy (e.g., for analgesic purpose or for lytic lesions at risk of fracture). Patients who have received targeted therapy (e.g., sunitinib, sorafenib, pazopanib), except ALK inhibitors, =< 2 weeks prior to starting study drug. Patients who have residual toxicity(-ities) from previous anti-cancer treatment(s) that is/are clinically significant or > grade 1 are excluded; those whose toxicity(-ities) improved to grade 1 or better will be eligible. The patient is less than 5 half-lives from prior ALK inhibitor or targeted therapy (for adequate wash-out) without recovery from treatment toxicities to < grade 1 or to their pre-treatment levels. Patients with known history of extensive disseminated bilateral interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention). Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury =< 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device =< 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury. Known hypersensitivity or infusion reaction to cisplatin and gemcitabine. Patients with known hypersensitivity to any of the excipients of ceritinib (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate). Receiving medications that meet one of the following criteria and that cannot be discontinued at least 1 week prior to the start of treatment with ceritinib and for the duration of participation: Medication with a known risk of prolonging the QT interval or inducing torsades de pointes; Strong inhibitors or strong inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)/5; Medications with a low therapeutic index that are primarily metabolized by CYP3A4/5, cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8) and/or cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9); Therapeutic doses (defined as doses need to achieve target INR > 1.5) of warfarin sodium (Coumadin) or any other Coumadin-derived anti-coagulant; anticoagulants not derived from warfarin are allowed (e.g., dabigatran, rivaroxaban, apixaban); Unstable or increasing doses of corticosteroids; Enzyme-inducing anticonvulsive agents; Herbal supplements. Any of the following concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study; impaired cardiac function or clinically significant cardiac diseases, including any of the following: Unstable angina within 6 months prior to screening; Myocardial infarction within 6 months prior to screening; History of documented congestive heart failure (New York Heart Association functional classification III - IV); Uncontrolled hypertension defined by a systolic blood pressure (SBP) >= 160 mm Hg and/or diastolic blood pressure (DBP) >= 100 mm Hg, with or without antihypertensive medication; Initiation or adjustment of antihypertensive medication(s) is allowed prior to screening; Ventricular arrhythmias; supraventricular and nodal arrhythmias not controlled with medication; Other cardiac arrhythmia not controlled with medication; Corrected QT (QTc) > 450 msec using Fridericia correction on the screening electrocardiogram (ECG). Any active gastrointestinal (GI) impairment which, in the opinion of the investigator, would impair or alter the absorption of ceritinib (e.g., ulcerative colitis, or Crohn's disease). Ongoing GI adverse events > grade 2 (e.g., nausea, vomiting, or diarrhea) at the start of the study. History of alcoholism, drug addiction, or any psychiatric or psychological condition which, in the opinion of the investigator, would impair study compliance. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol. Pregnant or breast-feeding women. Women of child-bearing potential, defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (e.g., who has had menses any time in the preceding 12 consecutive months), must have a negative serum pregnancy test =< 3 days prior to starting study treatment. Women of child-bearing potential, who are biologically able to conceive, not employing 2 forms of highly effective contraception; male not using at least at least one form of highly effective contraception will be excluded; highly effective contraception (e.g. male condom with spermicide, diaphragm with spermicide, intra-uterine device) must be used by both sexes during the study and must be continued for 3 months after the end of study treatment; oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study. Patients with untreated brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases; patients with brain metastases that have been definitively treated and on stable or decreasing dose of steroid within 4 weeks of starting study treatment will be eligible","The DLT evaluation periodwas 28 days for Arms 1 and 2, and 21 days for Arm 3",NA
34322775,NCT02822482,Combination,No,patients with recurrent and/or metastatic head and neck squamous cell carcinoma,"Patients aged≥18 years with recurrent and/or metastatic histologically or cytologically confrmed HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx, defned as distant metastases and/or inoperable local and/or regional recurrence, were eligible. Eligible patients were required to have disease progression on or after cetuximab and platinum therapy. Patients had to have at least one evaluable lesion according to RECIST1.1, an Eastern Cooperative Oncology Group performance status of≤2, adequate bone marrow (absolute neutrophil count [ANC] ≥ 1.0× 109/L, platelets ≥ 75× 109/L), and organ functions (ALT/AST ≤ 2.5×upper limit of normal [ULN], bilirubin ≤ 1.5xULN, creatinine clearance ≥ 60 mL/min as measured or calculated by Cockcroft and Gault formula, or serum creatinine ≤ ULN).",Patients with uncontrolled diabetes mellitus were excluded,during Cycle 1,NA
34428285,NCT02343536,Combination,No,patients with previously untreated intermediate- to high-risk DLBCL or grade 3B/transformed follicular lymphoma,"Eligible patients were aged 18-80 years with histologically confirmed, previously untreated DLBCL, including high-grade B-cell lymphoma with BCL2 or BCL6 and/or MYC rearrangements, grade 3B FL, or transformed lymphoma. Patients were required to have measurable disease .1.5 cm in the longest diameter, Ann Arbor stage II-IV disease, an IPI score $2 or DLBCL double-positive for BCL2 and MYC by immunohistochemistry or fluorescent in situ hybridization (FISH) based on local pathology laboratory assessment, and an Eastern Cooperative Oncology Group performance status #2. Cell of origin (COO) was determined by immunohistochemistry using the Hans algorithm at the local institution and/or by RNA-sequencing algorithm in available cases.",NA,all 6 cycles of therapy,NA
34559360,NCT02124148,Combination,No,patients with advanced and/or metastatic cancer,"Key inclusion criteria were age ≥ 18 years, performance status of ≤ 1 on the Eastern Cooperative Oncology Group (ECOG) scale, and adequate organ function (hematologic, hepatic, and renal parameters). Patients were to have histological or cytological evidence of a diagnosis of cancer that was advanced or metastatic; to be an appropriate candidate for experimental therapy after available standard therapies had been used or if the patient refused standard therapy; and for whom treatment with cetuximab, cisplatin, pemetrexed, or 5-fluorouracil was a reasonable treatment option. In dose escalation, all patients must have had the presence of measurable and/or nonmeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1","Key exclusion criteria were symptomatic central nervous system malignancy or metastasis at the time of study entry; serious cardiac condition or QTc interval of >470 ms on screening and baseline electrocardiogram in repeated measurements; and for patients receiving cisplatin, pemetrexed, or 5-fluorouracil, no more than two previous lines of cytotoxic chemotherapy.",Cycle 1,NA
34668982,NA,Single Drug,No,patients older than 19 years of age with relapsed or refractory peripheral T-cell lymphoma (PTCL),"Eligible histologies included angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) ALK +/ALK-, adult T-cell leukemia/lymphoma (ATLL), NK-cell lymphoma (NKL), transformed mycosis fungoides (MF), and PTCL unspecifed (PTCL-U).KPS>70 Expected survival greater than or equal to 4 months ANC>700 cells/mm3a Platelet count>50 mm3a Hemoglobin>8 g/dla Liver function tests (AST, ALT, and bilirubin)<3×upper limits of normal (ULN)bSerum creatinine≥40 mL/mincLeft ventricular ejection fraction (LVEF)≥40",Pregnancy or breast feedingActive serious infection within 14 days of starting carflzomibUnstable angina or MI within 5 months prior to enrollmentUncontrolled hypertension or diabetesOther malignancies within the last 2 yearsdSignifcant peripheral neuropathy within 14 days of starting carflzomib,NA,NA